﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Machalinska, A
   Klos, P
   Safranow, K
   Dziedziejko, V
   Rudnicki, M
   Paczkowska, E
   Karczewicz, D
   Machalinski, B
AF Machalinska, Anna
   Klos, Patrycja
   Safranow, Krzysztof
   Dziedziejko, Violetta
   Rudnicki, Michal
   Paczkowska, Edyta
   Karczewicz, Danuta
   Machalinski, Boguslaw
TI Neural stem/progenitor cells circulating in peripheral blood of patients
   with neovascular form of AMD: a novel view on pathophysiology
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularisation;
   Tissue-committed stem cells
ID BONE-MARROW; MACULAR DEGENERATION; STEM-CELLS; RECEPTOR CXCR4;
   RISK-FACTORS; PROGENITOR; DISEASE; MUSCLE; ROLES; SDF-1
AB The neovascular form of age-related macular degeneration (AMD) manifested with choroidal neovascularization (CNV) is one of the leading causes of rapid and irreversible visual loss. Recent reports suggest that bone marrow-derived stem/progenitor cells (SPCs) play a crucial role in the development and progression of the disease. The purpose of this study was to investigate whether or not undifferentiated non-haematopoietic stem cells, including those capable of differentiating into neural phenotypes, play a role in the pathological state of CNV formation.
   Peripheral blood samples were collected from 46 patients diagnosed with CNV and from 46 controls. The CXCR4(+)Lin(-)CD45(-) stem cells were counted and analysed by flow cytometry. Using qRT-PCR and immunocytofluorescence, the expression of early neural and glial cell markers (beta-III-tubulin, nestin, and glial fibrillary acidic protein) in the sorted cells was analysed, and correlated with plasma concentrations of stromal cell-derived factor 1 (SDF-1) (enzyme-linked immunosorbent assay), which is a pivotal chemokine that regulates the trafficking of SPCs.
   We found that the number of circulating CXCR4(+)Lin(-)CD45(-) cells did not differ in patients with active CNV as compared to the controls. However, we noticed significant intracellular overexpression of beta-III-tubulin in the cells derived from AMD patients. Moreover, we observed significantly lower SDF-1 plasma levels in neovascular AMD patients compared to healthy individuals.
   Our findings suggest that neural progenitor cells, together with low SDF-1 concentrations, may play a considerable role in the process of AMD progression. Further investigations aimed at the precise elucidation of these issues may help with the future development of effective prevention against, and the treatment of, this disease.
C1 [Machalinska, Anna] Pomeranian Med Univ, Dept Histol & Embryol, PL-70111 Szczecin, Poland.
   [Machalinska, Anna; Karczewicz, Danuta] Pomeranian Med Univ, Dept Ophthalmol, PL-70111 Szczecin, Poland.
   [Klos, Patrycja; Rudnicki, Michal; Paczkowska, Edyta; Machalinski, Boguslaw] Pomeranian Med Univ, Dept Gen Pathol, PL-70111 Szczecin, Poland.
   [Safranow, Krzysztof; Dziedziejko, Violetta] Pomeranian Med Univ, Dept Biochem & Med Chem, PL-70111 Szczecin, Poland.
C3 Pomeranian Medical University; Pomeranian Medical University; Pomeranian
   Medical University; Pomeranian Medical University
RP Machalinska, A (通讯作者)，Pomeranian Med Univ, Dept Histol & Embryol, Powstancow Wlkp 72, PL-70111 Szczecin, Poland.
EM annam@sci.pam.szczecin.pl; machalin@sci.pam.szczecin.pl
RI Dziedziejko, Violetta V./A-7626-2015; Machalinska, Anna/P-6701-2014;
   Machaliński, Bogusław/P-3025-2014; Paczkowska, Edyta/AAX-2347-2021;
   Safranow, Krzysztof/B-5127-2015; Paczkowska, Edyta/N-1209-2014; Kłos,
   Patrycja/C-6205-2017
OI Dziedziejko, Violetta V./0000-0003-4809-415X; Safranow,
   Krzysztof/0000-0001-9415-2758; Paczkowska, Edyta/0000-0001-7052-9741;
   Kłos, Patrycja/0000-0002-0686-3953; Machalinski,
   Boguslaw/0000-0002-6013-0419
FU Polish Ministry of Science and Higher Education [N N402 172137]
FX This work was supported by the Polish Ministry of Science and Higher
   Education (grant number: N N402 172137 to AM).
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x
   Bhutto IA, 2006, BRIT J OPHTHALMOL, V90, P906, DOI 10.1136/bjo.2006.090357
   Caballero S, 2004, GRAEF ARCH CLIN EXP, V242, P85, DOI 10.1007/s00417-003-0813-7
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Egan CG, 2008, DIABETOLOGIA, V51, P1296, DOI 10.1007/s00125-008-0939-6
   Egan CG, 2011, HEART VESSELS, V26, P258, DOI 10.1007/s00380-010-0053-9
   Egan CG, 2009, THROMB HAEMOSTASIS, V101, P1138, DOI 10.1160/TH08-11-0723
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Kicic A, 2003, J NEUROSCI, V23, P7742
   Kucia M, 2007, LEUKEMIA, V21, P297, DOI 10.1038/sj.leu.2404470
   Kucia M, 2006, ARCH IMMUNOL THER EX, V54, P121, DOI 10.1007/s00005-006-0015-1
   Kucia M, 2004, J MOL HISTOL, V35, P233
   Kucia M, 2005, BIOL CELL, V97, P133, DOI 10.1042/BC20040069
   Kucia M, 2004, BLOOD CELL MOL DIS, V32, P52, DOI 10.1016/j.bcmd.2003.09.025
   Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Paczkowska E, 2009, STROKE, V40, P1237, DOI 10.1161/STROKEAHA.108.535062
   Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367
   Siqueira RC, 2010, ARQ BRAS OFTALMOL, V73, P474, DOI 10.1590/S0004-27492010000500019
   Stolzing A, 2006, AGING CELL, V5, P213, DOI 10.1111/j.1474-9726.2006.00213.x
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   van Weel V, 2007, ARTERIOSCL THROM VAS, V27, P1426, DOI 10.1161/ATVBAHA.107.139642
   Wang W, 2010, DISCOV MED, V9, P13
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
NR 28
TC 9
Z9 9
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2011
VL 249
IS 12
BP 1785
EP 1794
DI 10.1007/s00417-011-1767-9
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 857VK
UT WOS:000297751000008
PM 21847578
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Family, F
   Mazzitello, KI
   Arizmendi, CM
   Grossniklaus, HE
AF Family, Fereydoon
   Mazzitello, K. I.
   Arizmendi, C. M.
   Grossniklaus, H. E.
TI Dynamic Scaling of Lipofuscin Deposition in Aging Cells
SO JOURNAL OF STATISTICAL PHYSICS
LA English
DT Article
DE Computer simulation; Dynamic scaling; Cluster size distribution; Aging;
   Lipofuscin; Retina pigment epithelium; Age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE; MACULAR
   DEGENERATION; ACCUMULATION; GROWTH; AGGREGATION; MECHANISMS; MODEL
AB Lipofuscin is a membrane-bound cellular waste that can be neither degraded nor ejected from the cell but can only be diluted through cell division and subsequent growth. The fate of postmitotic (non-dividing) cells such as neurons, cardiac myocytes, skeletal muscle fibers, and retinal pigment epithelial cells (RPE) is to accumulate lipofuscin, which as an "aging pigment" has been considered a reliable biomarker for the age of cells. Environmental stress can accelerate the accumulation of lipofuscin. For example, accumulation in brain cells appears to be an important issue connected with heavy consumption of alcohol. Lipofuscin is made of free-radical-damaged protein and fat, whose abnormal accumulation is related to a range of disorders including Type IV mucolipidosis (ML4), Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, Parkinson disease, and age-related macular degeneration (AMD) which is the leading cause of blindness beyond the age of 50 years. The study of lipofuscin formation and growth is important, because of their association with cellular aging. We introduce a model of non-equilibrium cluster growth and aggregation that we have developed for studying the formation and growth of lipofuscin. As an example of lipofuscin deposit in a given kind of postmitotic cell, we study the kinetics of lipofuscin growth in a RPE cell. Our results agree with a linear growth of the number of lipofuscin granules with age. We apply the dynamic scaling approach to our model and find excellent data collapse for the cluster size distribution. An unusual feature of our model is that while small particles are removed from the cell the larger ones become fixed and grow by aggregation.
C1 [Mazzitello, K. I.; Arizmendi, C. M.] Univ Nacl Mar del Plata, Fac Ingn, RA-7600 Mar Del Plata, Argentina.
   [Family, Fereydoon] Emory Univ, Dept Phys, Atlanta, GA 30322 USA.
   [Grossniklaus, H. E.] Emory Univ, LF Montgomery Ophthalm Pathol Lab, Atlanta, GA 30322 USA.
C3 National University of Mar del Plata; Emory University; Emory University
RP Mazzitello, KI (通讯作者)，Univ Nacl Mar del Plata, Fac Ingn, RA-7600 Mar Del Plata, Argentina.
EM kmazzite@gmail.com
RI Arizmendi, Constancio Miguel/H-7497-2016
OI Arizmendi, Constancio Miguel/0000-0002-0954-9724; Family,
   Fereydoon/0000-0003-2046-2993
FU CONICET [PIP 5569]; Universidad Nacional de Mar del Plata; ANPCyT,
   Argentina [PICT 11-21409, PICTO 11-495]; Emory College of Arts and
   Sciences
FX This research was partially supported by a grant from the CONICET (PIP
   5569), Universidad Nacional de Mar del Plata and ANPCyT (PICT 11-21409
   and PICTO 11-495), Argentina, and by a Seed Grant from Emory College of
   Arts and Sciences.
CR Alberts B., 2002, GARLAND SCI
   BarabuYsi A.-L., 1995, FRACTAL CONCEPTS SUR, DOI [DOI 10.1017/CBO9780511599798, 10.1017/CBO9780511599798]
   BENJACOB E, 2009, SYSTEMS BIOL CHALLEN
   Berg HC, 2000, PHYS TODAY, V53, P24, DOI 10.1063/1.882934
   Bindewald-Wittich A, 2006, INVEST OPHTH VIS SCI, V47, P4553, DOI 10.1167/iovs.05-1562
   BISCARINI F, 1995, PHYS REV B, V52, P14868, DOI 10.1103/PhysRevB.52.14868
   BOULTON M, 1986, BRIT J OPHTHALMOL, V70, P808, DOI 10.1136/bjo.70.11.808
   Brinkmann M, 2000, PHYS REV B, V61, P16339, DOI 10.1103/PhysRevB.61.R16339
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Cavallotti CAP., 2008, AGE RELATED CHANGES, DOI 10.1007/978-1-59745-507-7
   Family F., 1984, KINETICS AGGREGATION
   Family F., 1991, DYNAMICS FRACTAL SUR
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Friedlander S.K., 1977, SMOKE DUST HAZE FUND
   Gray Douglas A, 2005, Sci Aging Knowledge Environ, V2005, pre1, DOI 10.1126/sageke.2005.5.re1
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hannover A., 1842, KGL DANSKE VIDENSK K, V10, P1
   Heringdorf FJMZ, 2001, NATURE, V412, P517, DOI 10.1038/35087532
   HERRMANN HJ, 2000, TRAFFIC GRANULAR FLO
   HOLLYFIELD JG, 2006, RETINAL DEGENERATIVE, V572
   Holtzman E, 1989, LYSOSOMES
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Howard J., 2001, MECH MOTOR PROTEINS
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   KONEFF H, 1886, MITT NATURFORSCH GES, V44, P13
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lim JI, 2007, AGE RELATED MACULAR
   LUBYPHELPS K, 1987, P NATL ACAD SCI USA, V84, P4910, DOI 10.1073/pnas.84.14.4910
   MARSHALL J, 1987, EYE-T OPHTH SOC UK, V1, P282, DOI 10.1038/eye.1987.47
   Mazzitello KI, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.051908
   Meakin P., 1998, FRACTAL SCALING GROW
   Merks RMH, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000163
   MUNNELL JF, 1968, J GERONTOL, V23, P154, DOI 10.1093/geronj/23.2.154
   NAKANO M, 1992, J GERONTOL, V47, pB126, DOI 10.1093/geronj/47.4.B126
   PIMPENELLI A, 1999, PHYS CRYSTAL GROWTH
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   SEIDEN PE, 1990, ADV PHYS, V39, P1, DOI 10.1080/00018739000101461
   SHEEHY MRJ, 1995, J GERONTOL A-BIOL, V50, pB327, DOI 10.1093/gerona/50A.6.B327
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   STANLEY HE, 1985, J POLYM SCI POL SYM, P19
   STREHLER BL, 1959, J GERONTOL, V14, P430, DOI 10.1093/geronj/14.4.430
   Szweda PA, 2003, AGEING RES REV, V2, P383, DOI 10.1016/S1568-1637(03)00028-X
   Terman A, 1998, APMIS, V106, P265, DOI 10.1111/j.1699-0463.1998.tb01346.x
   VICSEK T, 1985, PHYS REV A, V32, P1122, DOI 10.1103/PhysRevA.32.1122
   VICSEK T, 1984, PHYS REV LETT, V52, P1669, DOI 10.1103/PhysRevLett.52.1669
   Vicsek T., 1992, FRACTAL GROWTH PHENO, DOI DOI 10.1142/1407
   VISCSEK T, 2001, FLUCTUATIONS SCALING
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Zhang ZY, 1997, SCIENCE, V276, P377, DOI 10.1126/science.276.5311.377
NR 55
TC 3
Z9 3
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0022-4715
EI 1572-9613
J9 J STAT PHYS
JI J. Stat. Phys.
PD JUL
PY 2011
VL 144
IS 2
BP 332
EP 343
DI 10.1007/s10955-011-0178-y
PG 12
WC Physics, Mathematical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physics
GA 799QK
UT WOS:000293301000007
DA 2022-11-30
ER

PT J
AU Tezel, TH
   Geng, LJ
   Lato, EB
   Schaal, S
   Liu, YQ
   Dean, D
   Klein, JB
   Kaplan, HJ
AF Tezel, Tongalp H.
   Geng, Lijun
   Lato, Ewa Bodek
   Schaal, Shlomit
   Liu, Yongqing
   Dean, Douglas
   Klein, Jon B.
   Kaplan, Henry J.
TI Synthesis and Secretion of Hemoglobin by Retinal Pigment Epithelium
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR DEGENERATION; QUATERNARY STRUCTURE; NITRIC-OXIDE; CELLS;
   EXPRESSION; INDUCTION; PROTEINS; SYSTEM; OXYGEN; BLOOD
AB PURPOSE. To demonstrate the production of hemoglobin by human retinal pigment epithelium (RPE).
   METHODS. Proteomic analysis using 10 donor eyes identified hemoglobin as a major constituent of soluble human RPE proteome. Western blot analysis, RT-PCR, and immunocytochemistry were used to confirm the results. The presence of erythrocyte-specific proteins within primary human RPE cytosol was investigated to rule out phagocytosis as the source of hemoglobin. ELISA was used to determine the rate of hemoglobin secretion from human RPE cells. Globin mRNA expression of human RPE was studied in comparison with a human erythroblast cell line and a spontaneously transformed human RPE cell line (ARPE-19).
   RESULTS. Hemoglobin is a regular constituent of soluble human RPE proteome. RT-PCR and Western blot analysis confirmed the presence of hemoglobin in human RPE. No other erythrocyte-specific proteins were detected within human RPE cytosol. Hemoglobin expression persisted up to seven passages in vitro. Human RPE globin expression exceeded that in human erythroblast and ARPE-19 cells. Immunohistochemistry revealed the presence of hemoglobin within RPE and Bruch's membrane. The hemoglobin release rate was calculated to be 1.9 +/- 1.2 attomoles per cell per hour.
   CONCLUSIONS. Hemoglobin expression by human RPE brings a new perspective to the understanding of oxygen transport to the outer retina. Malfunction of RPE-hemoglobin production may underlie the pathophysiology of ocular diseases characterized by subfoveal hypoxia and VEGF upregulation, such as age-related macular degeneration and diabetic retinopathy. Pharmacologic modulations of local hemoglobin production in RPE cells will create new opportunities to interfere with the course of these diseases. (Invest Ophthalmol Vis Sci. 2009; 50: 1911-1919) DOI: 10.1167/iovs.07-1372
C1 [Tezel, Tongalp H.; Geng, Lijun; Lato, Ewa Bodek; Schaal, Shlomit; Liu, Yongqing; Dean, Douglas; Kaplan, Henry J.] Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, Louisville, KY 40202 USA.
   [Klein, Jon B.] Univ Louisville, Sch Med, Kidney Dis Program, Louisville, KY 40292 USA.
   [Klein, Jon B.] Univ Louisville, Sch Med, Prote Core Lab, Louisville, KY 40292 USA.
C3 University of Louisville; University of Louisville; University of
   Louisville
RP Tezel, TH (通讯作者)，Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Kentucky Lions Eye Ctr, 301 E Muhammad Ali Blvd, Louisville, KY 40202 USA.
EM tongalp.tezel@louisville.edu
FU National Institutes of Health [EY016120]; Research to Prevent Blindness,
   Inc.; Kentucky Research Challenge Trust Fund; NATIONAL EYE INSTITUTE
   [K08EY016120] Funding Source: NIH RePORTER
FX Supported in part by Grant EY016120 from the National Institutes of
   Health; Career Development Award from Research to Prevent Blindness,
   Inc. (THT); and the Kentucky Research Challenge Trust Fund (HJK).
CR Bhaskaran M, 2005, BIOCHEM BIOPH RES CO, V333, P1348, DOI 10.1016/j.bbrc.2005.06.042
   Breuer R, 1938, J BIOL CHEM, V126, P561
   Carmella SG, 2002, CARCINOGENESIS, V23, P1903, DOI 10.1093/carcin/23.11.1903
   CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532
   Daniel WW., 1995, BIOSTATISTICS FDN AN, P273
   Derwent JK, 2000, INVEST OPHTH VIS SCI, V41, P3634
   Epstein P, 2007, ANN INTERN MED, V146, P532, DOI 10.7326/0003-4819-146-7-200704030-00011
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Jena BP, 2004, J CELL MOL MED, V8, P1, DOI 10.1111/j.1582-4934.2004.tb00255.x
   Klein JB, 2005, J BIOL CHEM, V280, P31870, DOI 10.1074/jbc.M501802200
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Liu LM, 1999, P NATL ACAD SCI USA, V96, P6643, DOI 10.1073/pnas.96.12.6643
   Loureiro RMB, 2005, CYTOKINE GROWTH F R, V16, P77, DOI 10.1016/j.cytogfr.2005.01.005
   Marmor M, 1998, RETINAL PIGMENT EPIT, P3
   MARRS JA, 1995, J CELL BIOL, V129, P507, DOI 10.1083/jcb.129.2.507
   Moench T, 2004, JAIDS-J ACQ IMM DEF, V37, pS194, DOI 10.1097/00126334-200410013-00011
   Newton DA, 2006, J BIOL CHEM, V281, P5668, DOI 10.1074/jbc.M509314200
   NOE DA, 1984, CLIN CHEM, V30, P627
   Norwitz ER, 2005, AM J OBSTET GYNECOL, V193, P957, DOI 10.1016/j.ajog.2005.06.055
   Orchard GE, 1998, AM J DERMATOPATH, V20, P357, DOI 10.1097/00000372-199808000-00006
   Padnick-Silver L, 2002, VISUAL NEUROSCI, V19, P793, DOI 10.1017/S095252380219609X
   Pappin D J, 1997, Methods Mol Biol, V64, P165
   ROYER WEJ, 1992, ADV COMP ENV PHYSL, V87, P116
   Safo MK, 2005, BIOCHEMISTRY-US, V44, P8347, DOI 10.1021/bi050412q
   SILVA MM, 1992, J BIOL CHEM, V267, P17248
   Sorhaug S, 2006, TOXICOLOGY, V228, P280, DOI 10.1016/j.tox.2006.09.008
   Stepuro TL, 2006, J PHYSIOL PHARMACOL, V57, P29
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 1997, CURR EYE RES, V16, P802, DOI 10.1076/ceyr.16.8.802.8981
   Thongboonkerd V, 2004, J AM SOC NEPHROL, V15, P650, DOI 10.1097/01.ASN.0000115334.65095.9B
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Wang XD, 2004, P NATL ACAD SCI USA, V101, P11477, DOI 10.1073/pnas.0402201101
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   West KA, 2003, MOL CELL PROTEOMICS, V2, P37, DOI 10.1074/mcp.D200001-MCP200
   Witt O, 2003, BLOOD, V101, P2001, DOI 10.1182/blood-2002-08-2617
NR 38
TC 31
Z9 34
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2009
VL 50
IS 4
BP 1911
EP 1919
DI 10.1167/iovs.07-1372
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 424CP
UT WOS:000264543400058
PM 19060278
DA 2022-11-30
ER

PT J
AU Turkcuoglu, P
   Deniz, N
   Koc, M
   Kurt, J
   Celiker, U
AF Tuerkcueoglu, Peykan
   Deniz, Nurettin
   Koc, Mustafa
   Kurt, Julide
   Celiker, Uelku
TI The effect of photodynamic therapy on retrobulbar blood flow parameters
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE colour Doppler imaging; photodynamic therapy; retrobulbar blood flow
ID RENAL-ARTERY STENOSIS; CHOROIDAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; DOPPLER SONOGRAPHY; AGE; EYE; ORBIT; CIRCULATION; ANATOMY;
   DISEASE
AB Purpose: To investigate the effect of photodynamic therapy (PDT) on retrobulbar blood flow parameters.
   Methods :Twenty-four patients with choroidal neovascular membrane of at least four MPS disc area in one eye due to age-related macular degeneration scheduled for PDT were recruited. Peak systolic and end diastolic velocity of ophthalmic, central retinal and posterior ciliary artery of both eyes were measured with colour Doppler imaging and resistivity index were computed before, at the first and fourth weeks following PDT.
   Results: Following PDT, the mean peak systolic velocity of posterior ciliary artery increased significantly to a value of 31.90 +/- 13.44 at the first (P = 0001), then returned to an insignificant value of 29.95 +/- 13.03 at the fourth week (P = 0.360), when compared with pre-PDT mean measurement (30.16 +/- 13.15). Resistivity index of posterior ciliary artery also increased significantly to a value of 0.740 +/- 0.77 at the first (P = 0.046), then returned to an insignificant value of 0.666 +/- 0.14 at the fourth week (P = 0.407), when compared with pre-PDT mean measurement (0.709 +/- 0.90). All the other measured data (peak systolic velocity, end diastolic velocity, resistivity index of ophthalmic and central retinal artery; end diastolic velocity of posterior ciliary artery of the treated eyes; all colour Doppler imaging measurements of untreated eyes) did not show any significant change at the first and fourth week following PDT, when compared with the pre-PDT values.
   Conclusion: The peak systolic velocity and resistivity index of the posterior ciliary artery appear to increase in the first week and return to their baseline values at the fourth week following PDT.
C1 [Tuerkcueoglu, Peykan; Deniz, Nurettin; Kurt, Julide; Celiker, Uelku] Firat Univ, Sch Med, Dept Ophthalmol, Elazig, Turkey.
   [Koc, Mustafa] Firat Univ, Sch Med, Dept Neuroradiol, Elazig, Turkey.
C3 Firat University; Firat University
RP Turkcuoglu, P (通讯作者)，Firat Univ, Sch Med, Dept Ophthalmol, Elazig, Turkey.
EM peykan74@yahoo.com
RI turkcuoglu, peykan/GQB-2596-2022
OI turkcuoglu, peykan/0000-0002-9750-6213
CR ARCHER D, 1970, AM J OPHTHALMOL, V69, P543, DOI 10.1016/0002-9394(70)91619-3
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Conkbayir I, 2003, CLIN IMAG, V27, P256, DOI 10.1016/S0899-7071(02)00547-8
   Costa VP, 1997, OPHTHALMOLOGY, V104, P1994, DOI 10.1016/S0161-6420(97)30066-9
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   Flower RW, 1999, RETINA-J RET VIT DIS, V19, P365
   Hirata Y, 2006, PROG RETIN EYE RES, V25, P129, DOI 10.1016/j.preteyeres.2005.08.001
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Krammer B, 2001, ANTICANCER RES, V21, P4271
   Li JC, 2006, J ULTRAS MED, V25, P735, DOI 10.7863/jum.2006.25.6.735
   LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036
   Lieb WE, 1998, RADIOL CLIN N AM, V36, P1059, DOI 10.1016/S0033-8389(05)70231-1
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   RING HG, 1967, ARCH OPHTHALMOL-CHIC, V78, P431
   RUSKELL G L, 1961, Am J Ophthalmol, V52, P807
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9
   van den Bergh H, 2001, Semin Ophthalmol, V16, P181, DOI 10.1076/soph.16.4.181.10299
   Williamson TH, 1996, SURV OPHTHALMOL, V40, P255, DOI 10.1016/S0039-6257(96)82001-7
   WILLIAMSON TH, 1995, BRIT J OPHTHALMOL, V79, P17, DOI 10.1136/bjo.79.1.17
   YONEYA S, 1987, ARCH OPHTHALMOL-CHIC, V105, P681
NR 23
TC 4
Z9 4
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JAN-FEB
PY 2008
VL 36
IS 1
BP 39
EP 42
DI 10.1111/j.1442-9071.2007.01644.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 263YD
UT WOS:000253251500011
PM 18190598
DA 2022-11-30
ER

PT J
AU Reboul, E
   Thap, S
   Tourniaire, F
   Andre, M
   Juhel, C
   Morange, S
   Amiot, MJ
   Lairon, D
   Borel, P
AF Reboul, Emmanuelle
   Thap, Sinay
   Tourniaire, Franck
   Andre, Marc
   Juhel, Christine
   Morange, Sophie
   Amiot, Marie-Josephe
   Lairon, Denis
   Borel, Patrick
TI Differential effect of dietary antioxidant classes (carotenoids,
   polyphenols, vitamins C and E) on lutein absorption
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE bioavailability; uptake; enterocytes; naringenin; gallic acid; caffeic
   acid
ID INTESTINAL-CELL LINE; IN-VITRO DIGESTION; MACULAR PIGMENT; LIPID
   DROPLETS; CACO-2 CELLS; HUMAN RETINA; TC-7 CELLS; ZEAXANTHIN; HUMANS;
   BIOAVAILABILITY
AB Lutein is assumed to protect the human retina from blue light and oxidative stress and diminish the incidence of age-related macular degeneration. This antioxidant is commonly ingested with other dietary antioxidants. The aim of the present study was to assess whether the main dietary antioxidants, i.e. carotenoids, polyphenols and vitamins C and E, affect lutein absorption. We measured the effect of adding a mixture of antioxidants (500 mg vitamin C, 67 mg (100IU) vitamin E and 1 g polyphenols) to a lutein-containing meal (18 mg) on the postprandial lutein response in the chylomicron-rich fraction in eight healthy men. Lutein response was weakest (-23%; P=0.07) after ingestion of the meal containing antioxidants (21.9 (SEM 4-6) v. 28-4 (SEM 7-2) nmol X h/l). To assess the effect of each class of antioxidants and potential interactions, we subsequently evaluated the effect of various combinations of antioxidants on lutein uptake by human intestinal Caco-2 TC-7 cells. A full factorial design showed that both a mixture of polyphenols (gallic acid, caffeic acid, (+)-catechin and naringenin) and a mixture of carotenoids (lycopene plus (3-carotene) significantly(P < 0.05) impaired lutein uptake by (-10 to -30%), while vitamins C and E had no significant effect. Subsequent experiments showed that the aglycone flavanone naringenin was the only polyphenol responsible for the effect of the polyphenol mixture, and that the carotenoid effect was not carotenoid species-dependent. Taken together, the present results suggest that lutein absorption is not markedly affected by physiological concentrations of vitamins C and E but can be impaired by carotenoids and naringenin.
C1 INSERM, U476, F-13385 Marseille, France.
   INRA, UMR1260, F-13385 Marseille, France.
   Univ Aix Marseille 2, F-13385 Marseille, France.
   IPHM IFR 125, F-13385 Marseille, France.
   Avantage Nutr, F-13012 Marseille, France.
   Clin Invest Ctr, F-13009 Marseille, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   INRAE; UDICE-French Research Universities; Aix-Marseille Universite
RP Borel, P (通讯作者)，INSERM, U476, 27 Bd Jean Moulin, F-13385 Marseille, France.
EM Patrick.Borel@medecine.univ-mrs.fr
RI Amiot, Marie Josephe/M-1203-2017; Tourniaire, Franck/K-9131-2017;
   Reboul, Emmanuelle/K-6637-2017; Borel, Patrick/A-4057-2015; AMIOT, MARIE
   JOSEPHE/N-8894-2019; Amiot, Marie Josephe/C-4457-2015
OI Amiot, Marie Josephe/0000-0003-4563-4587; Tourniaire,
   Franck/0000-0002-6394-7045; Reboul, Emmanuelle/0000-0002-4576-1992;
   Borel, Patrick/0000-0001-9977-3238; AMIOT, MARIE
   JOSEPHE/0000-0003-4563-4587; Lairon, Denis/0000-0001-9941-3742
CR Blum S, 2006, ANN NUTR METAB, V50, P20, DOI 10.1159/000089560
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Borel P, 1996, J LIPID RES, V37, P250
   Cardinault N, 2003, EUR J NUTR, V42, P315, DOI 10.1007/s00394-003-0426-2
   Chan C, 1998, CURR EYE RES, V17, P890, DOI 10.1076/ceyr.17.9.890.5141
   CHUGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318, DOI 10.1016/0002-8223(93)91559-9
   Cooper DA, 1997, J NUTR, V127, pS1699, DOI 10.1093/jn/127.8.1699S
   During A, 2002, J LIPID RES, V43, P1086, DOI 10.1194/jlr.M200068-JLR200
   During A, 1998, BIOCHEM BIOPH RES CO, V249, P467, DOI 10.1006/bbrc.1998.9160
   Ferruzzi MG, 2001, J AGR FOOD CHEM, V49, P2082, DOI 10.1021/jf000775r
   FOSSATI P, 1982, CLIN CHEM, V28, P2077
   Garrett DA, 1999, J AGR FOOD CHEM, V47, P4301, DOI 10.1021/jf9903298
   George S, 2005, J AGR FOOD CHEM, V53, P1370, DOI 10.1021/jf048396b
   Gres MC, 1998, PHARMACEUT RES, V15, P726, DOI 10.1023/A:1011919003030
   HENDRICH S, 1994, J NUTR, V124, pS1789, DOI 10.1093/jn/124.suppl_9.1789S
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Krinsky NI, 2002, J NUTR, V132, p540S, DOI 10.1093/jn/132.3.540S
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Luchoomun J, 1999, J BIOL CHEM, V274, P19565, DOI 10.1074/jbc.274.28.19565
   Lyan B, 2001, J CHROMATOGR B, V751, P297, DOI 10.1016/S0378-4347(00)00488-6
   Nemeth K, 2003, EUR J NUTR, V42, P29, DOI 10.1007/s00394-003-0397-3
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554
   Reboul E, 2005, J NUTR, V135, P790, DOI 10.1093/jn/135.4.790
   REBOUL E, 2003, CLIN NUTR, V22, pS103
   Riso P, 2003, INT J VITAM NUTR RES, V73, P201, DOI 10.1024/0300-9831.73.3.201
   Salvini S, 2002, BRIT J NUTR, V87, P211, DOI 10.1079/BJN2001507
   SIEDEL J, 1983, CLIN CHEM, V29, P1075
   Siems WG, 1999, BIOFACTORS, V10, P105, DOI 10.1002/biof.5520100204
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Souci SW., 2000, FOOD COMPOSITION NUT
   Sugawara T, 2001, J NUTR, V131, P2921, DOI 10.1093/jn/131.11.2921
   Tachibana H, 2004, BIOFACTORS, V21, P383, DOI 10.1002/biof.552210174
   Tanumihardjo SA, 2005, J AM DIET ASSOC, V105, P114, DOI 10.1016/j.jada.2004.10.011
   Tesoriere L, 2004, AM J CLIN NUTR, V80, P941, DOI 10.1093/ajcn/80.4.941
   TRINDER P, 1969, J CLIN PATHOL, V22, P246, DOI 10.1136/jcp.22.2.246-b
   Tyssandier V, 2003, AM J PHYSIOL-GASTR L, V284, pG913, DOI 10.1152/ajpgi.00410.2002
   Tyssandier V, 2002, AM J CLIN NUTR, V75, P526, DOI 10.1093/ajcn/75.3.526
   Tyssandier V, 2001, BBA-MOL CELL BIOL L, V1533, P285, DOI 10.1016/S1388-1981(01)00163-9
   van den Berg H, 1999, NUTR REV, V57, P1, DOI 10.1111/j.1753-4887.1999.tb01769.x
   Walle T, 2005, J NUTR, V135, P48, DOI 10.1093/jn/135.1.48
NR 43
TC 72
Z9 73
U1 1
U2 21
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD MAR
PY 2007
VL 97
IS 3
BP 440
EP 446
DI 10.1017/S0007114507352604
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 148MQ
UT WOS:000245079700005
PM 17313704
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Sokolov, VS
   Sokolenko, EA
   Sokolov, AV
   Dontsov, AE
   Chizmadzhev, YA
   Ostrovsky, MA
AF Sokolov, V. S.
   Sokolenko, E. A.
   Sokolov, A. V.
   Dontsov, A. E.
   Chizmadzhev, Yu. A.
   Ostrovsky, M. A.
TI Interaction of pyridinium bis-retinoid (A2E) with bilayer lipid
   membranes
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE pyridinium bis-retinoid; A2E; photooxidation; singlet oxygen;
   photosensitizer; bilayer lipid membrane; adsorption; boundary potential;
   surface charge; lipid oxidation; gramicidin
ID AGE-RELATED MACULOPATHY; LIGHT-INDUCED DAMAGE; LIPOFUSCIN FLUOROPHORE;
   PHOTODYNAMIC INACTIVATION; MACULAR DEGENERATION; PIGMENT EPITHELIUM;
   BEAVER DAM; PHOTOOXIDATION; OXIDATION; GENERATION
AB The accumulation of lipofuscin granules within the retinal pigment epithelium (RPE) cells is correlated with the progression of age-related macular degeneration. One of the fluorophores contained in lipofiscin granules is pyriclinium bis-retinoid (A2E). To test its membrane-toxic effect, the interaction of A2E with bilayer lipid membranes (BLM) was studied. The incorporation of charged A2E molecules into the membranes has been detected as a change of either zeta-potential of multilayer liposomes or boundary potential of BLM. It was shown that the presence of up to 25 mol% of A2E did not destabilize the bilayers made of saturated phosphatidylcholine (PC). However, the destabilizing effect became very significant when BLM contained negatively charged lipids such as cardiolipin or phosphatidylserine. The electrical breakdown measurements revealed that the A2E-induced decrease of BLM stability was primarily associated with the growing probability of lipid pore formation.
   It was found from the measurements of boundary potential of BLM that exposure of A2E to light initiates its transformation into at least two products. One of them is epoxy-A2E, which, being hydrophilic, moves from the membrane into water solution. The other product is a non-identified hydrophobic substance. Illumination of A2E-containing BLM made from unsaturated PC by visible light caused the membrane damage presumably due to oxidation of these lipids by singlet oxygen generated by excited A2E molecules. However, this effect was very weak compared to the effect of known photosensitizers. The illumination of BLM with A2E also leads to the damage of gramicidin incorporated into the membrane, as was detected by measuring the conductance of channels formed by this peptide. (c) 2006 Elsevier B.V. All rights reserved.
C1 Russian Acad Sci, AN Frumkin Inst Phys Chem & Electrochem, Moscow 119071, Russia.
   Russian Acad Sci, NM Emanuel Inst Biochem Phys, Moscow, Russia.
C3 Russian Academy of Sciences; Frumkin Institute of Physical Chemistry &
   Electrochemistry; Russian Academy of Sciences; Emanuel Institute of
   Biochemical Physics
RP Sokolov, VS (通讯作者)，Russian Acad Sci, AN Frumkin Inst Phys Chem & Electrochem, Leninsky Prospect 31,Bldg 5, Moscow 119071, Russia.
EM sokolov@elchem.ac.ru
RI Chizmadzhev, Yuri A/L-1984-2013; Alexander, Dontsov/R-8069-2019;
   Sokolov, Valerij/S-2902-2016
OI Sokolov, Valerij/0000-0003-1376-2007
CR Albert AD, 1996, BBA-BIOMEMBRANES, V1285, P47, DOI 10.1016/S0005-2736(96)00145-9
   Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Chernomordik L. V., 1989, ELECTROPORATION ELEC, P83, DOI [10.1007/978- 1-4899-2528-2_5, DOI 10.1007/978-1-4899-2528-2_5]
   Darnell JE, 1986, MOL CELL BIOL
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   Dontsov AE, 1999, BIOFIZIKA+, V44, P880
   Ermakov YA, 2003, MEMBR SCI T, V7, P109, DOI 10.1016/S0927-5193(03)80027-X
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Gaillard ER, 2004, EXP EYE RES, V79, P313, DOI 10.1016/j.exer.2004.05.005
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Kanofsky JR, 2003, PHOTOCHEM PHOTOBIOL, V77, P235, DOI 10.1562/0031-8655(2003)077<0235:SOGFA>2.0.CO;2
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   KUNZ L, 1995, BIOCHEMISTRY-US, V34, P11895, DOI 10.1021/bi00037a030
   Ostrovskii M. A., 1992, Sensornye Sistemy, V6, P51
   Ostrovsky M. A., 2005, ADV BIOL CHEM, V45, P173
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pawlak A, 2002, INVEST OPHTH VIS SCI, V43, pU1301
   Rokitskaya TI, 1996, BBA-BIOENERGETICS, V1275, P221, DOI 10.1016/0005-2728(96)00025-4
   ROKITSKAYA TI, 1993, FEBS LETT, V329, P332, DOI 10.1016/0014-5793(93)80248-S
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Schutt F, 2001, INVEST OPHTH VIS SCI, V42, pS943
   SOKOLOV V S, 1980, Biophysics (English Translation of Biofizika), V25, P174
   SOKOLOV VS, 1990, BIOELECTROCH BIOENER, V23, P27, DOI 10.1016/0302-4598(90)80003-2
   SOKOLOV VS, 2004, ULTRATHIN ELECTROCHE, P255
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Stozhkova I N, 1997, Membr Cell Biol, V11, P381
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
NR 39
TC 16
Z9 20
U1 0
U2 3
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD FEB 1
PY 2007
VL 86
IS 2
BP 177
EP 185
DI 10.1016/j.jphotobiol.2006.09.006
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 135OS
UT WOS:000244163500011
PM 17070694
DA 2022-11-30
ER

PT J
AU Yin, XY
   Bose, D
   Kwon, A
   Hanks, SC
   Jackson, AU
   Stringham, HM
   Welch, R
   Oravilahti, A
   Silva, LF
   Locke, FAE
   Fuchsberger, C
   Service, SK
   Erdos, MR
   Bonnycastle, LL
   Kuusisto, J
   Stitziel, NO
   Hall, IM
   Morrison, J
   Ripatti, S
   Palotie, A
   Freimer, NB
   Collins, FS
   Mohlke, KL
   Scott, LJ
   Fauman, EB
   Burant, C
   Boehnke, M
   Laakso, M
   Wen, XQ
AF Yin, Xianyong
   Bose, Debraj
   Kwon, Annie
   Hanks, Sarah C.
   Jackson, Anne U.
   Stringham, Heather M.
   Welch, Ryan
   Oravilahti, Anniina
   Silva, Lilian Fernandes
   Locke, FinnGen Adam E.
   Fuchsberger, Christian
   Service, Susan K.
   Erdos, Michael R.
   Bonnycastle, Lori L.
   Kuusisto, Johanna
   Stitziel, Nathan O.
   Hall, Ira M.
   Morrison, Jean
   Ripatti, Samuli
   Palotie, Aarno
   Freimer, Nelson B.
   Collins, Francis S.
   Mohlke, Karen L.
   Scott, Laura J.
   Fauman, Eric B.
   Burant, Charles
   Boehnke, Michael
   Laakso, Markku
   Wen, Xiaoquan
TI Integrating transcriptomics, metabolomics, and GWAS helps reveal
   molecular mechanisms for metabolite levels and disease risk
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; MENDELIAN RANDOMIZATION; MACULAR DEGENERATION;
   GENETIC-VARIANTS; LARGE-SCALE; COLOCALIZATION; PREVALENCE; COMPLEX;
   LOCI; EQTL
AB Transcriptomics data have been integrated with genome-wide association studies (GWASs) to help understand disease/trait molecular mechanisms. The utility of metabolomics, integrated with transcriptomics and disease GWASs, to understand molecular mechanisms for metabolite levels or diseases has not been thoroughly evaluated. We performed probabilistic transcriptome-wide association and locus-level colocalization analyses to integrate transcriptomics results for 49 tissues in 706 individuals from the GTEx project, metabolomics results for 1,391 plasma metabolites in 6,136 Finnish men from the METSIM study, and GWAS results for 2,861 disease traits in 260,405 Finnish individuals from the FinnGen study. We found that genetic variants that regulate metabolite levels were more likely to influence gene expression and disease risk compared to the ones that do not. Integrating transcriptomics with metabolomics results prioritized 397 genes for 521 metabolites, including 496 previously identified gene-metabolite pairs with strong functional connections and suggested 33.3% of such gene-metabolite pairs shared the same causal variants with genetic associations of gene expression. Integrating transcriptomics and metabolomics individually with FinnGen GWAS results identified 1,597 genes for 790 disease traits. Integrating transcriptomics and metabolomics jointly with FinnGen GWAS results helped pinpoint metabolic pathways from genes to diseases. We identified putative causal effects of UGT1A1/UGT1A4 expression on gallbladder disorders through regulating plasma (E,E)-bilirubin levels, of SLC22A5 expression on nasal polyps and plasma carnitine levels through distinct pathways, and of LIPC expression on age-related macular degeneration through glycerophospholipid metabolic pathways. Our study highlights the power of integrating multiple sets of molecular traits and GWAS results to deepen understanding of disease pathophysiology.
C1 [Yin, Xianyong; Bose, Debraj; Kwon, Annie; Hanks, Sarah C.; Jackson, Anne U.; Stringham, Heather M.; Welch, Ryan; Fuchsberger, Christian; Morrison, Jean; Scott, Laura J.; Boehnke, Michael; Wen, Xiaoquan] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA.
   [Yin, Xianyong; Bose, Debraj; Kwon, Annie; Hanks, Sarah C.; Jackson, Anne U.; Stringham, Heather M.; Welch, Ryan; Fuchsberger, Christian; Morrison, Jean; Scott, Laura J.; Boehnke, Michael; Wen, Xiaoquan] Univ Michigan, Sch Publ Hlth, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Oravilahti, Anniina; Silva, Lilian Fernandes; Kuusisto, Johanna; Laakso, Markku] Univ Eastern Finland, Inst Clin Med, Internal Med, Kuopio, Finland.
   [Oravilahti, Anniina; Silva, Lilian Fernandes; Kuusisto, Johanna; Laakso, Markku] Kuopio Univ Hosp, Kuopio 70210, Finland.
   [Locke, FinnGen Adam E.; Stitziel, Nathan O.] Washington Univ, Sch Med, McDonnell Genome Inst, St Louis, MO 63108 USA.
   [Fuchsberger, Christian] Eurac Res, Inst Biomed, I-39100 Bolzano, Italy.
   [Service, Susan K.; Freimer, Nelson B.] Univ Calif Los Angeles, Ctr Neurobehav Genet, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
   [Erdos, Michael R.; Bonnycastle, Lori L.; Collins, Francis S.] Natl Human Genome Res Inst, Mol Genet Sect, Ctr Precis Hlth Res, NIH, Bethesda, MD 20892 USA.
   [Kuusisto, Johanna] Kuopio Univ Hosp, Ctr Med & Clin Res, Kuopio 70210, Finland.
   [Stitziel, Nathan O.] Washington Univ, Cardiovasc Div, Dept Med, St Louis, MO 63110 USA.
   [Stitziel, Nathan O.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
   [Hall, Ira M.] Yale Univ, Dept Genet, Ctr Genom Hlth, New Haven, CT 06510 USA.
   [Ripatti, Samuli; Palotie, Aarno] Univ Helsinki, Inst Mol Med Finland, FIMM, HiLIFE, Helsinki 00290, Finland.
   [Ripatti, Samuli; Palotie, Aarno] Univ Helsinki, Dept Publ Hlth, Helsinki 00014, Finland.
   [Ripatti, Samuli] Broad Inst & Harvard, Cambridge, MA 02142 USA.
   [Palotie, Aarno] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Dept Med, Dept Neurol, Boston, MA 02114 USA.
   [Palotie, Aarno] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
   [Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
   [Fauman, Eric B.] Pfizer Worldwide Res Dev & Med, Internal Med Res Unit, Cambridge, MA 02139 USA.
   [Burant, Charles] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Eastern Finland;
   Kuopio University Hospital; University of Eastern Finland; Washington
   University (WUSTL); European Academy of Bozen-Bolzano; University of
   California System; University of California Los Angeles; National
   Institutes of Health (NIH) - USA; NIH National Human Genome Research
   Institute (NHGRI); Kuopio University Hospital; University of Eastern
   Finland; Washington University (WUSTL); Washington University (WUSTL);
   Yale University; University of Helsinki; University of Helsinki; Harvard
   University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Harvard University; Massachusetts General Hospital; Harvard
   University; Massachusetts General Hospital; University of North
   Carolina; University of North Carolina Chapel Hill; Pfizer; University
   of Michigan System; University of Michigan
RP Wen, XQ (通讯作者)，Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA.; Wen, XQ (通讯作者)，Univ Michigan, Sch Publ Hlth, Ctr Stat Genet, Ann Arbor, MI 48109 USA.; Laakso, M (通讯作者)，Univ Eastern Finland, Inst Clin Med, Internal Med, Kuopio, Finland.; Laakso, M (通讯作者)，Kuopio Univ Hosp, Kuopio 70210, Finland.
EM markku.laakso@uef.fi; xwen@umich.edu
OI Burant, Charles/0000-0001-9189-5003; Oravilahti,
   Anniina/0000-0001-8866-4482; Yin, Xianyong/0000-0001-6454-2384
FU National Institutes of Health (NIH) [U01 DK062370, R35 GM138121, R01
   DK119380, P01 HL151328, R01 HL131961, UM1 HG008853, R01 DK093757, U01
   DK105561]; American Diabetes Association Postdoctoral Fellowship
   [1-19-PDF-061]; University of Michigan Precision Health Scholarship;
   Academy of Finland [321428]; Sigrid Juselius Foundation; Academy of
   Finland Center of Excellence in Complex Disease Genetics [312062,
   336820, 312074, 336824]; Finnish Foundation for Cardiovascular Research
   [101016775]; NIH Intramural Research Program of the National Human
   Genome Research Institute [ZIA HG000024]
FX We thank all the participants and investigators in the GTEx, METSIM, and
   FinnGen studies. This work was supported by National Institutes of
   Health (NIH) awards U01 DK062370 (M.B.), R35 GM138121 (X.Q.W.), R01
   DK119380 (X.Q.W.), P01 HL151328 (N.O.S.), R01 HL131961 (N.O.S.), UM1
   HG008853 (I.H., N.O.S., L.G., A.E.L.), R01 DK093757 (K.L.M.), and U01
   DK105561 (K.L.M.); an American Diabetes Association Postdoctoral
   Fellowship (1-19-PDF-061, X.Y.); a University of Michigan Precision
   Health Scholarship (X.Y.); Academy of Finland grant 321428 (M.L.); the
   Sigrid Juse ' lius Foundation (M.L., S.R.); Academy of Finland Center of
   Excellence in Complex Disease Genetics grants 312062 and 336820 (S.R.)
   and grants 312074 and 336824 (A.P.); the Finnish Foundation for
   Cardiovascular Research (S.R.); University of Helsinki HiLIFE Fellow and
   Grand Challenge grants (S.R.); and Horizon 2020 Research and Innovation
   Programme (grant 101016775 ``INTERVENE'', S.R.). F.S.C., M.R.E., and
   L.L.B. were supported by the NIH Intramural Research Program of the
   National Human Genome Research Institute (ZIA HG000024).
CR Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   Bartel J, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005274
   Benner C, 2016, BIOINFORMATICS, V32, P1493, DOI 10.1093/bioinformatics/btw018
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Cano-Gamez E, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00424
   Chen GJ, 2021, NPJ GENOM MED, V6, DOI 10.1038/s41525-021-00208-6
   Chu XJ, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02413-z
   Everhart JE, 1999, GASTROENTEROLOGY, V117, P632, DOI 10.1016/S0016-5085(99)70456-7
   Feofanova EV, 2020, AM J HUM GENET, V107, P849, DOI 10.1016/j.ajhg.2020.09.003
   Flitman RS, 2021, J PROTEOME RES, V20, P5103, DOI 10.1021/acs.jproteome.1c00585
   Foley CN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20885-8
   Frankish A, 2021, NUCLEIC ACIDS RES, V49, pD916, DOI 10.1093/nar/gkaa1087
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gamazon ER, 2015, NAT GENET, V47, P1091, DOI 10.1038/ng.3367
   Giambartolomei C, 2018, BIOINFORMATICS, V34, P2538, DOI 10.1093/bioinformatics/bty147
   Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383
   Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Hasham SN, 2006, CLIN CHIM ACTA, V372, P179, DOI 10.1016/j.cca.2006.04.020
   Hasin Y, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1215-1
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hollywood K, 2006, PROTEOMICS, V6, P4716, DOI 10.1002/pmic.200600106
   Hormozdiari F, 2016, AM J HUM GENET, V99, P1245, DOI 10.1016/j.ajhg.2016.10.003
   Hukku A, 2022, AM J HUM GENET, V109, P825, DOI 10.1016/j.ajhg.2022.04.005
   Hukku A, 2021, AM J HUM GENET, V108, P25, DOI 10.1016/j.ajhg.2020.11.012
   Hulse KE, 2015, CLIN EXP ALLERGY, V45, P328, DOI 10.1111/cea.12472
   Ivanisevic J, 2015, SCI REP-UK, V5, DOI 10.1038/srep12757
   Johnson AD, 2009, HUM MOL GENET, V18, P2700, DOI 10.1093/hmg/ddp202
   Julkunen H, 2021, ELIFE, V10, DOI 10.7554/eLife.63033
   Kastenmuller G, 2015, HUM MOL GENET, V24, pR93, DOI 10.1093/hmg/ddv263
   King CD, 2000, CURR DRUG METAB, V1, P143, DOI 10.2174/1389200003339171
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Kurki M.I., 2022, PREPRINT, DOI 10.1101/
   Laakso M, 2017, J LIPID RES, V58, P481, DOI 10.1194/jlr.O072629
   Lains Ines, 2021, Ophthalmol Sci, V1, DOI 10.1016/j.xops.2021.100017
   Lempp M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12474-1
   Li Binglan, 2021, Front Genet, V12, P713230, DOI 10.3389/fgene.2021.713230
   Li HP, 2022, FASEB J, V36, DOI 10.1096/fj.202101921RR
   Lim ET, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004494
   Loos RJF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19653-5
   Lotta LA, 2021, NAT GENET, V53, DOI 10.1038/s41588-020-00751-5
   Mamas M, 2011, ARCH TOXICOL, V85, P5, DOI 10.1007/s00204-010-0609-6
   Meneses MJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20164049
   Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312
   Mortezaei Z, 2021, HEREDITY, V127, P485, DOI 10.1038/s41437-021-00479-w
   Ndungu A, 2020, AM J HUM GENET, V106, P188, DOI 10.1016/j.ajhg.2020.01.003
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888
   RIP JW, 1992, BIOCHEM J, V288, P1005, DOI 10.1042/bj2881005
   Stender S, 2013, JAMA INTERN MED, V173, P1222, DOI 10.1001/jamainternmed.2013.6465
   Stephens M, 2017, BIOSTATISTICS, V18, P275, DOI 10.1093/biostatistics/kxw041
   Tanha HM, 2021, AM J HUM GENET, V108, P2086, DOI 10.1016/j.ajhg.2021.09.011
   Torres JM, 2020, AM J HUM GENET, V107, P1011, DOI 10.1016/j.ajhg.2020.10.009
   Valette K, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02227-6
   Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7
   Wainberg M, 2019, NAT GENET, V51, P592, DOI 10.1038/s41588-019-0385-z
   Wang G, 2020, J R STAT SOC B, V82, P1273, DOI 10.1111/rssb.12388
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wen XQ, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006646
   Yin XY, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-29143-5
   Zelezniak A, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003572
   Zhang AH, 2016, BIOMED CHROMATOGR, V30, P7, DOI 10.1002/bmc.3453
   Zhang YH, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02026-y
   Zhou W, 2018, NAT GENET, V50, P1335, DOI 10.1038/s41588-018-0184-y
   Zhu A, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009455
   Zhu ZH, 2016, NAT GENET, V48, P481, DOI 10.1038/ng.3538
NR 69
TC 0
Z9 0
U1 6
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT 6
PY 2022
VL 109
IS 10
BP 1727
EP 1741
DI 10.1016/j.ajhg.2022.08.007
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 6F6SL
UT WOS:000884188100001
PM 36055244
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Font, O
   Torrents-Barrena, J
   Royo, D
   Garcia, SB
   Zarranz-Ventura, J
   Bures, A
   Salinas, C
   Zapata, MA
AF Font, Octavi
   Torrents-Barrena, Jordina
   Royo, Didac
   Banderas Garcia, Sandra
   Zarranz-Ventura, Javier
   Bures, Anniken
   Salinas, Cecilia
   Angel Zapata, Miguel
TI Validation of an autonomous artificial intelligence-based diagnostic
   system for holistic maculopathy screening in a routine occupational
   health checkup context
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Artificial intelligence; Screening; Retinography; Diabetic retinopathy;
   Age-related macular degeneration
ID MAJOR RISK-FACTORS; DIABETIC-RETINOPATHY; GLOBAL PREVALENCE;
   TELEMEDICINE
AB Purpose This study aims to evaluate the ability of an autonomous artificial intelligence (AI) system for detection of the most common central retinal pathologies in fundus photography.
   Methods Retrospective diagnostic test evaluation on a raw dataset of 5918 images (2839 individuals) evaluated with non-mydriatic cameras during routine occupational health checkups. Three camera models were employed: Optomed Aurora (field of vieW-FOV 50 degrees, 88% of the dataset), ZEISS VISUSCOUT 100 (FOV 40 degrees, 9%), and Optomed SmartScope M5 (FOV 40 degrees, 3%) Image acquisition took 2 min per patient. Ground truth for each image of the dataset was determined by 2 masked retina specialists, and disagreements were resolved by a 3rd retina specialist. The specific pathologies considered for evaluation were "diabetic retinopathy" (DR), "Age-related macular degeneration" (AMD), "glaucomatous optic neuropathy" (GON), and "Nevus." Images with maculopathy signs that did not match the described taxonomy were classified as "Other."
   Results The combination of algorithms to detect any abnormalities had an area under the curve (AUC) of 0.963 with a sensitivity of 92.9% and a specificity of 86.8%. The algorithms individually obtained are as follows: AMD AUC 0.980 (sensitivity 93.8%; specificity 95.7%), DR AUC 0.950 (sensitivity 81.1%; specificity 94.8%), GON AUC 0.889 (sensitivity 53.6% specificity 95.7%), Nevus AUC 0.931 (sensitivity 86.7%; specificity 90.7%).
   Conclusion Our holistic AI approach reaches high diagnostic accuracy at simultaneous detection of DR, AMD, and Nevus. The integration of pathology-specific algorithms permits higher sensitivities with minimal impact on its specificity. It also reduces the risk of missing incidental findings. Deep learning may facilitate wider screenings of eye diseases.
C1 [Font, Octavi; Royo, Didac; Bures, Anniken; Salinas, Cecilia; Angel Zapata, Miguel] Optretina Image Reading Team, Barcelona, Spain.
   [Torrents-Barrena, Jordina] Univ Pompeu Fabra, Dept Informat & Commun Technol, BCN MedTech, Barcelona, Spain.
   [Banderas Garcia, Sandra] Univ Autonoma Barcelona UAB, Fac Cirurgia & Ciencies Morfol, Barcelona, Spain.
   [Banderas Garcia, Sandra; Angel Zapata, Miguel] Hosp Valle De Hebron, Ophthalmol Dept, Barcelona, Spain.
   [Zarranz-Ventura, Javier] Hosp Clin Barcelona, Inst Clin Ophthalmol ICOF, Barcelona, Spain.
   [Zarranz-Ventura, Javier] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain.
   [Bures, Anniken; Salinas, Cecilia] Inst Microcirugia Ocular IMO, Barcelona, Spain.
C3 Pompeu Fabra University; Autonomous University of Barcelona; Hospital
   Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron;
   University of Barcelona; Hospital Clinic de Barcelona; University of
   Barcelona; Hospital Clinic de Barcelona; IDIBAPS
RP Garcia, SB (通讯作者)，Univ Autonoma Barcelona UAB, Fac Cirurgia & Ciencies Morfol, Barcelona, Spain.; Garcia, SB (通讯作者)，Hosp Valle De Hebron, Ophthalmol Dept, Barcelona, Spain.
EM sandrabanderasgarcia@gmail.com
RI Zarranz-Ventura, Javier/AAB-5390-2021
OI Zarranz-Ventura, Javier/0000-0003-2338-8143; Banderas Garcia,
   Sandra/0000-0002-3641-3806; Zapata, Miguel Angel/0000-0002-0096-4569
FU Universitat Autonoma de Barcelona
FX Open Access Funding provided by Universitat Autonoma de Barcelona.
CR Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Ahmed J, 2006, DIABETES CARE, V29, P2205, DOI 10.2337/dc06-0295
   Ahn JM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207982
   Zapata MA, 2020, CLIN OPHTHALMOL, V14, P419, DOI 10.2147/OPTH.S235751
   Beynat J, 2009, DIABETES METAB, V35, P49, DOI 10.1016/j.diabet.2008.07.002
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Bujang MA, 2016, J CLIN DIAGN RES, V10, pYE1, DOI 10.7860/JCDR/2016/18129.8744
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   Chan CKW, 2015, OPHTHALMOLOGY, V122, P2278, DOI 10.1016/j.ophtha.2015.06.050
   Chew EY, 2015, OPHTHALMOLOGY, V122, P2155, DOI 10.1016/j.ophtha.2015.08.007
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   Farley TF, 2008, ANN FAM MED, V6, P428, DOI 10.1370/afm.857
   FERRIS FL, 1994, PREV MED, V23, P740, DOI 10.1006/pmed.1994.1127
   FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290
   Gonzalez-Gonzalo C, 2020, ACTA OPHTHALMOL, V98, P368, DOI 10.1111/aos.14306
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hamilton WS, 2007, LANCET, V370, P1480, DOI 10.1016/S0140-6736(07)61627-4
   Jonas JB, 2017, LANCET, V390, P2183, DOI 10.1016/S0140-6736(17)31469-1
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Krizhevsky A., 2021, ADV NEURAL INFORM PR, V25, P1
   Kumar S, 2006, J TELEMED TELECARE, V12, P19, DOI 10.1258/135763306775321399
   LAIRSON DR, 1992, DIABETES CARE, V15, P1369, DOI 10.2337/diacare.15.10.1369
   Lakhani P, 2017, RADIOLOGY, V284, P574, DOI 10.1148/radiol.2017162326
   Lecun Y., 2015, DEEP LEARNING, V521, DOI DOI 10.1038/NATURE14539
   Lee S J, 2001, Aust J Rural Health, V9, P186, DOI 10.1046/j.1038-5282.2001.00356.x
   Levy J., 2011, ISR MED ASSOC J, VJ13, P40
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu J, 2021, OPHTHALMOL RETINA, V5, P71, DOI 10.1016/j.oret.2020.06.016
   Massin P, 2003, DIABETIC MED, V20, P635, DOI 10.1046/j.1464-5491.2003.01002.x
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Nguyen HV, 2016, OPHTHALMOLOGY, V123, P2571, DOI 10.1016/j.ophtha.2016.08.021
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP66, DOI 10.1016/j.ophtha.2019.09.025
   Phu J, 2021, CLIN EXP OPTOM, V104, P367, DOI 10.1111/cxo.13114
   Romero-Aroca P., 2010, Arch Soc Esp Oftalmol, V85, P232, DOI 10.1016/j.oftal.2010.09.005
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Sharma Mohita, 2011, Community Eye Health, V24, P17
   Spurling GKP, 2010, AUST NZ J PUBL HEAL, V34, pS30, DOI 10.1111/j.1753-6405.2010.00549.x
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Szegedy C., 2016, 2016 IEEE C COMPUTER, P2818, DOI DOI 10.1109/CVPR.2016.308
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Ting DSW, 2016, CLIN EXP OPHTHALMOL, V44, P260, DOI 10.1111/ceo.12696
   Urban G, 2018, GASTROENTEROLOGY, V155, P1069, DOI 10.1053/j.gastro.2018.06.037
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ST, 2018, MULTIMED TOOLS APPL, V77, P10437, DOI 10.1007/s11042-017-4440-4
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zapata MA, 2021, GRAEF ARCH CLIN EXP, V259, P575, DOI 10.1007/s00417-020-04860-z
   Zapata MA, 2017, TELEMED E-HEALTH, V23, P31, DOI 10.1089/tmj.2016.0020
NR 53
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2022
VL 260
IS 10
BP 3255
EP 3265
DI 10.1007/s00417-022-05653-2
EA MAY 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4O6EP
UT WOS:000795627500001
PM 35567610
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Scondotto, G
   Sultana, J
   Vadala, M
   Avitabile, T
   Cillino, S
   Foti, SS
   Labbate, L
   Longo, A
   Mirabelli, E
   Puzo, MR
   Rapisarda, C
   Toro, PI
   Trombetta, CJ
   Trifiro, G
   Virgili, G
AF Scondotto, Giulia
   Sultana, Janet
   Vadala, Maria
   Avitabile, Teresio
   Cillino, Salvatore
   Foti, Saveria Serena
   Labbate, Luca
   Longo, Antonio
   Mirabelli, Eliana
   Puzo, Maria Rosalia
   Rapisarda, Carlo
   Toro, Patricia Ibanez
   Trombetta, Costantino J.
   Trifiro, Gianluca
   Virgili, Gianni
CA ITACA Intravitreal Therapy Adm Cli
TI Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal
   diseases in real world setting: A multi-centre prospective study from
   Southern Italy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Pharmacology < PHARMACOLOGY; diabetic macular edema < RETINA;
   epidemiology; biostatistics < LENS; CATARACT; pathologic myopia <
   RETINA; retina; medical therapies < RETINA
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; RANIBIZUMAB
AB Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on visual acuity and other ophthalmic parameters from baseline at different follow-up times for each indication. Data from 1327 patients was collected. Most patients were diagnosed with age-related macular degeneration (AMD) (660, 49.7%), followed by diabetic macular oedema (423, 31.9%), retinal vein occlusion (164, 12.3%), and myopic choroidal neovascularization (80, 6.0%). Patients were followed for a median of 10.3 months (interquartile range: 3.6 - 24.7 months). Mean patient age was 69.7 (+/- 10.9) years and 54.2% were males. Ranibizumab (55.4%) and aflibercept (27.5%) were the most commonly used drugs. Baseline visual acuity significantly improved by about 0.05 to 0.1 logMAR at all follow-up times for AMD and RVO but less consistently for the other diseases. Intravitreal ranibizumab use accounted for half of all treatment for retinal diseases in a Southern Italian out-patient setting. Patients treated with anti-VEGF drugs for AMD and RVO in Southern Italy experienced significant improvement in VA.
C1 [Scondotto, Giulia; Labbate, Luca; Mirabelli, Eliana; Trombetta, Costantino J.] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy.
   [Sultana, Janet] Mater Hosp, Pharm Dept, Msida, Malta.
   [Sultana, Janet] Univ Exeter, Coll Med & Hlth, Exeter, Malta.
   [Vadala, Maria] Inst European & Mediterranean Sci & Technol IEMES, Palermo, Italy.
   [Avitabile, Teresio; Longo, Antonio; Rapisarda, Carlo] AOU Policlin Vittorio Emanuele, Dept Ophthalmol, Catania, Italy.
   [Cillino, Salvatore] Univ Palermo, Dept Biomed Neurosci & Adv Diagnost, Ophthalmol Sect, Palermo, Italy.
   [Foti, Saveria Serena] Acad Spin Off INSPIRE Innovat Solut Med Predict &, Messina, Italy.
   [Puzo, Maria Rosalia; Toro, Patricia Ibanez] Basilicata Reg, Assistance & Pharmaceut Serv Off, Personal Policies Dept, Potenza, Italy.
   [Trifiro, Gianluca] Univ Verona, Dept Diagnost & Publ Hlth, Ple LA Scuro 10, I-37134 Verona, Italy.
   [Virgili, Gianni] Univ Florence, Dept Neurosci Psychol Drug Res & Clin Hlth, Florence, Italy.
   [Virgili, Gianni] Queens Univ Belfast UK, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
C3 University of Messina; Azienda Ospedaliera Universitaria Policlinico
   Vittorio Emanuele Presidio Ferraotto; University of Palermo; University
   of Verona; University of Florence
RP Trifiro, G (通讯作者)，Univ Verona, Dept Diagnost & Publ Hlth, Ple LA Scuro 10, I-37134 Verona, Italy.
EM gianluca.trifiro@unime.it
RI ; Virgili, Gianni/P-6607-2014
OI VADALA', Maria/0000-0002-2726-698X; Virgili, Gianni/0000-0002-9960-2989;
   L' Abbate, Luca/0000-0003-0232-6402
FU Italian Medicines Agency [CUP-H56D16000070005]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by the Italian Medicines Agency (grant number
   CUP-H56D16000070005).
CR Albrecht M, 2018, GLOB REG HEALTH TECH, DOI 10.1177/2284240318793905
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Ehlken C., GRAEFES ARCH CLIN EX, V258, P2077
   Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Giancipoli E, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5612342
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Kim YC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78954-3
   Kiss S, 2020, OPHTHALMOLOGY, V127, P1179, DOI 10.1016/j.ophtha.2020.02.027
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Miller DG, 2006, OPTOMETRY VISION SCI, V83, P316, DOI 10.1097/01.opx.0000216019.88256.eb
   Neri PG., 2014, COST EFFECTIVENESS I, P15, DOI [10.7175/fe.v15i4.976, DOI 10.7175/FE.V15I4.976]
   Papadopoulos Z, 2020, CURR MED SCI, V40, P851, DOI 10.1007/s11596-020-2253-6
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scondotto G, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7582763
   Virgili G, 2020, EUR J OPHTHALMOL, V30, P1440, DOI 10.1177/1120672119885045
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub6
   Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269
NR 23
TC 0
Z9 0
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2022
VL 32
IS 5
BP 3064
EP 3073
AR 11206721211073402
DI 10.1177/11206721211073402
EA JAN 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3S5GW
UT WOS:000751399000001
PM 35075918
DA 2022-11-30
ER

PT J
AU Lv, D
   Chen, DL
   Wang, ZJ
   Cui, ZK
   Ma, JH
   Ji, SL
   Chen, JS
   Tang, SB
AF Lv, Da
   Chen, Donglong
   Wang, Zhijie
   Cui, Zekai
   Ma, Jacey Hongjie
   Ji, Shangli
   Chen, Jiansu
   Tang, Shibo
TI COL10A1 is a novel factor in the development of choroidal
   neovascularization
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE Choroidal neovascularization (CNV); Age-related macular degeneration
   (AMD); RNA-sequence; Hypoxia
ID MACULAR DEGENERATION; COLLAGEN; ANGIOGENESIS; EXPRESSION;
   ANGIOPOIETIN-2; CELLS; MODEL
AB With the dramatic rise in the aging population, researching age-related macular degeneration (AMD), especially the severe form neovascular AMD (nAMD), has become more important than ever. In this study, we found that collagen type X was increased in retina-choroid tissue of mice with laser-induced choroidal neovascularization (CNV) based on immunohistofluorescence. RNA sequencing and bioinformatic analyses were performed to compare the retina-choroid tissue complex of the CNV mouse model to normal controls. Collagen type X alpha 1 chain (Col10a1) was among the most significantly upregulated genes, and the results were validated with an animal model at the mRNA and protein levels by quantitative real-time polymerase chain reaction (qPCR) and western blotting, respectively. COL10A1 was also upregulated in human retinal microvascular endothelial cells (HRMECs), human umbilical vein endothelial cells (HUVECs), RPE19 cells and RF/6A cells under hypoxic conditions. Next, in vitro and in vivo experiments were performed to study the effect of COL10A1 on neovascularization. siRNA knockdown of COL10A1 suppressed the proliferation and tube formation ability of HRMECs under hypoxic conditions. Snail family transcriptional repressor 1 (SNAIL1) and angiopoietin-2 (ANGPT2) were downregulated in COL10A1 knockdown HRMECs under hypoxic conditions and thus were potential downstream genes. Significant decreases in CNV leakage and CNV lesion area, as assessed by fundus fluorescein angiography (FFA) and immunofluorescence of choroidal flat mounts, respectively, were observed in a mouse model intravitreally injected with anti-collagen X monoclonal antibody (mAb) compared to the controls. In conclusion, COL10A1 promotes CNV formation and may represent a new candidate target for the treatment and diagnosis of nAMD and other neovascular diseases.
C1 [Lv, Da; Wang, Zhijie; Ma, Jacey Hongjie; Chen, Jiansu; Tang, Shibo] Cent South Univ, Aier Sch Ophthalmol, Changsha, Peoples R China.
   [Lv, Da; Chen, Donglong; Wang, Zhijie; Cui, Zekai; Ma, Jacey Hongjie; Ji, Shangli; Chen, Jiansu; Tang, Shibo] Aier Eye Inst, Changsha, Peoples R China.
   [Chen, Jiansu] Jinan Univ, Key Lab Regenerat Med, Minist Educ, Guangzhou, Peoples R China.
   [Chen, Jiansu] Jinan Univ, Med Coll, Inst Ophthalmol, Guangzhou, Peoples R China.
   [Tang, Shibo] Chinese Acad Sci, CAS Ctr Excellence Brain Sci & Intelligence Techn, Shanghai, Peoples R China.
C3 Central South University; Jinan University; Jinan University; Chinese
   Academy of Sciences
RP Chen, JS; Tang, SB (通讯作者)，Cent South Univ, Aier Sch Ophthalmol, Changsha, Peoples R China.
EM chenjiansu2000@163.com; tangshibo@vip.163.com
RI TANG, Shi/GXH-5719-2022
FU National Natural Science Foundation of China [81570876]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81570876) .
CR Abd AJ, 2017, DRUG DISCOV TODAY, V22, P1671, DOI 10.1016/j.drudis.2017.07.010
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Campbell K, 2016, DEVELOPMENT, V143, P4291, DOI 10.1242/dev.139071
   Campbell M, 2019, BIOCHEM PHARMACOL, V164, P321, DOI 10.1016/j.bcp.2019.04.029
   Chapman KB, 2012, FUTURE ONCOL, V8, P1031, DOI [10.2217/fon.12.79, 10.2217/FON.12.79]
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   Detaram HD, 2020, CLIN EXP OPHTHALMOL, V48, P61, DOI 10.1111/ceo.13644
   Eamegdool SS, 2020, FREE RADICAL BIO MED, V146, P357, DOI 10.1016/j.freeradbiomed.2019.11.018
   Ehlken C, 2019, OPHTHALMIC RES, V61, P174, DOI 10.1159/000481260
   Farnoodian M, 2017, CLIN SCI, V131, P1763, DOI 10.1042/CS20170066
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Hachana S, 2020, BRIT J PHARMACOL, V177, P1949, DOI 10.1111/bph.14962
   Hansen NUB, 2016, CLIN BIOCHEM, V49, P903, DOI 10.1016/j.clinbiochem.2016.05.023
   Heljasvaara R, 2017, MATRIX BIOL, V57-58, P55, DOI 10.1016/j.matbio.2016.10.002
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Huang HP, 2018, ONCOTARGETS THER, V11, P1571, DOI 10.2147/OTT.S160196
   Jo N, 2006, MOL VIS, V12, P1243
   Kim J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau6732
   Kimura K, 2016, INT J CLIN ONCOL, V21, P302, DOI 10.1007/s10147-015-0888-2
   Li TT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0877-2
   Li Y, 2014, REDOX BIOL, V2, P485, DOI 10.1016/j.redox.2014.01.023
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Makoukji J, 2016, SCI REP-UK, V6, DOI 10.1038/srep36639
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Necula L, 2020, WORLD J GASTROENTERO, V26, P3024, DOI 10.3748/wjg.v26.i22.3024
   Nicolini G, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.117080
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Park SM, 2019, MAT SCI ENG C-MATER, V104, DOI 10.1016/j.msec.2019.109964
   Lamas JR, 2010, ANN RHEUM DIS, V69, P1880, DOI 10.1136/ard.2009.122564
   Reale E, 2009, CELLS TISSUES ORGANS, V190, P170, DOI 10.1159/000187632
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   Scholz A, 2015, ANN NY ACAD SCI, V1347, P45, DOI 10.1111/nyas.12726
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Semkova I, 2014, EXP EYE RES, V118, P80, DOI 10.1016/j.exer.2013.11.006
   Sole X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106748
   Thurston G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006650
   Velazquez-Villoria A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162296
   Vilkeviciute A, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/5631083
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yu YT, 2019, FASEB J, V33, P3496, DOI 10.1096/fj.201801652R
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
NR 48
TC 0
Z9 0
U1 3
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD JAN
PY 2022
VL 139
AR 104239
DI 10.1016/j.mvr.2021.104239
EA SEP 2021
PG 10
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA WD5EQ
UT WOS:000704964100009
PM 34520774
DA 2022-11-30
ER

PT J
AU Sim, H
   Lee, W
   Choo, S
   Park, EK
   Baek, MC
   Lee, IK
   Park, DH
   Bae, JS
AF Sim, Hyunchae
   Lee, Wonhwa
   Choo, Samyeol
   Park, Eui Kyun
   Baek, Moon-Chang
   Lee, In-Kyu
   Park, Dong Ho
   Bae, Jong-Sup
TI Sulforaphane Alleviates Particulate Matter-Induced Oxidative Stress in
   Human Retinal Pigment Epithelial Cells
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium; oxidative
   stress; retina; choroid
ID IN-VITRO; MACULAR DEGENERATION; LUNG; INFLAMMATION; MECHANISMS;
   APOPTOSIS; DAMAGE; RESPONSES; PHASE; MODEL
AB Age-related macular degeneration (AMD) is a leading cause of blindness in the elderly, and oxidative damage to retinal pigment epithelial (RPE) cells plays a major role in the pathogenesis of AMD. Exposure to high levels of atmospheric particulate matter (PM) with an aerodynamic diameter of <2.5 mu m (PM2.5) causes respiratory injury, primarily due to oxidative stress. Recently, a large community-based cohort study in the UK reported a positive correlation between PM2.5 exposure and AMD. Sulforaphane (SFN), a natural isothiocyanate found in cruciferous vegetables, has known antioxidant effects. However, the protective effects of SNF in the eye, especially in the context of AMD, have not been evaluated. In the present study, we evaluated the effect of SFN against PM2.5-induced toxicity in human RPE cells (ARPE-19) and elucidated the molecular mechanism of action. Exposure to PM2.5 decreased cell viability in ARPE-19 cells in a time- and dose-dependent manner, potentially due to elevated intracellular reactive oxygen species (ROS). SFN treatment increased ARPE-19 cell viability and decreased PM2.5-induced oxidative stress in a dose-dependent manner. PM2.5-induced downregulation of serum- and glucocorticoid-inducible kinase 1 (SGK1), a cell survival factor, was recovered by SFN. PM2.5 treatment decreased the enzymatic activities of the antioxidant enzymes including superoxide dismutase and catalase, which were restored by SFN treatment. Taken together, these findings suggest that SFN effectively alleviates PM2.5-induced oxidative damage in human ARPE-19 cells via its antioxidant effects, and that SFN can potentially be used as a therapeutic agent for AMD, particularly in cases related to PM2.5 exposure.
C1 [Sim, Hyunchae; Lee, Wonhwa; Choo, Samyeol; Bae, Jong-Sup] Kyungpook Natl Univ, Coll Pharm, Daegu, South Korea.
   [Park, Eui Kyun] Kyungpook Natl Univ, Sch Dent, Dept Pathol & Regenerat Med, Daegu, South Korea.
   [Baek, Moon-Chang] Kyungpook Natl Univ, Sch Med, Dept Mol Med, Daegu, South Korea.
   [Lee, In-Kyu; Park, Dong Ho] Kyungpook Natl Univ Hosp, Leading Edge Res Ctr Drug Discovery & Dev Diabet, Daegu, South Korea.
   [Lee, In-Kyu] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea.
   [Lee, In-Kyu] Kyungpook Natl Univ, Res Inst Aging & Metab, Daegu, South Korea.
   [Park, Dong Ho] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Dept Ophthalmol, Sch Med, Daegu, South Korea.
C3 Kyungpook National University; Kyungpook National University; Kyungpook
   National University; Kyungpook National University; Kyungpook National
   University Hospital; Kyungpook National University; Kyungpook National
   University Hospital; Kyungpook National University; Kyungpook National
   University; Kyungpook National University Hospital
RP Bae, JS (通讯作者)，Kyungpook Natl Univ, Coll Pharm, Daegu, South Korea.; Park, DH (通讯作者)，Kyungpook Natl Univ Hosp, Leading Edge Res Ctr Drug Discovery & Dev Diabet, Daegu, South Korea.; Park, DH (通讯作者)，Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Dept Ophthalmol, Sch Med, Daegu, South Korea.
EM DongHo_Park@knu.ac.kr; baejs@knu.ac.kr
RI Lee, In-Kyu/AAR-6374-2021; Bae, Jong-Sup/AAU-9724-2020
FU KoreaHealth Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI15C0001]; National Research Foundation of Korea (NRF) -
   Korean government [2020R1A2C1004131, 2017M3A9G8083382,
   2017R1A5A2015391]; Basic Science Research Program of the National
   Research Foundation of Korea (NRF) - Korean government (Ministry of
   Science and ICT) [2019R1A2C1084371]; Ministry of Science and ICT (MSIT),
   Korea, under the Information Technology Research Center (ITRC) support
   program [IITP2021-2020-0-01808]; Korea Health technology R&D Project
   through the Korea Health Industry Development Institute (KHIDI) -
   Ministry of Health & Welfare, Republic of Korea [HI16C1501]
FX J-SB was supported by a grant fromthe KoreaHealth Technology R&D Project
   through the Korea Health Industry Development Institute (KHIDI), funded
   by the Ministry of Health & Welfare, Republic of Korea (grant number:
   HI15C0001) and by a National Research Foundation of Korea (NRF) grant
   funded by the Korean government (2020R1A2C1004131, 2017M3A9G8083382,
   2017R1A5A2015391). DP was financially supported by the Basic Science
   Research Program of the National Research Foundation of Korea (NRF),
   funded by the Korean government (Ministry of Science and ICT)
   (2019R1A2C1084371). DP was also supported by the Ministry of Science and
   ICT (MSIT), Korea, under the Information Technology Research Center
   (ITRC) support program (IITP2021-2020-0-01808) supervised by the
   Institute of Information & Communications Technology Planning &
   Evaluation (IITP). I-KL and DP were supported by a grant of the Korea
   Health technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI), funded by the Ministry of Health &
   Welfare, Republic of Korea (HI16C1501).
CR Amadi-Obi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045801
   Bergvall C, 2006, ANAL BIOANAL CHEM, V384, P438, DOI 10.1007/s00216-005-0192-5
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Bisig Ch., 2015, EMISS CONTROL SCI TE, V1, P237, DOI 10.1007/s40825-015-0019-6
   Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32
   Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8
   Chirino YI, 2010, TOXICOL LETT, V193, P209, DOI 10.1016/j.toxlet.2010.01.009
   Chua SYL, 2022, BRIT J OPHTHALMOL, V106, P705, DOI 10.1136/bjophthalmol-2020-316218
   Chua SYL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.32
   Dumax-Vorzet AF, 2015, MUTAGENESIS, V30, P621, DOI 10.1093/mutage/gev025
   Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geng H, 2006, TOXICOL IN VITRO, V20, P575, DOI 10.1016/j.tiv.2005.09.015
   Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004
   Huang WY, 2018, J AGR FOOD CHEM, V66, P1638, DOI 10.1021/acs.jafc.7b06135
   Ighodaro OM, 2018, ALEX J MED, V54, P287, DOI 10.1016/j.ajme.2017.09.001
   Jeong SY, 2020, BIOTECHNOL BIOPROC E, V25, P1, DOI 10.1007/s12257-019-0382-1
   Jia YY, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14030232
   Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997
   Kim KH, 2015, ENVIRON INT, V74, P136, DOI 10.1016/j.envint.2014.10.005
   Lee BS, 2019, BMB REP, V52, P271, DOI 10.5483/BMBRep.2019.52.4.175
   Lee H, 2020, ENVIRON POLLUT, V262, DOI 10.1016/j.envpol.2020.114301
   Lee W, 2020, PHYTOMEDICINE, V69, DOI 10.1016/j.phymed.2020.153200
   Lee W, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041462
   Lee W, 2019, AM J CHINESE MED, V47, P1237, DOI 10.1142/S0192415X19500630
   Lee W, 2019, BIOTECHNOL BIOPROC E, V24, P445, DOI 10.1007/s12257-019-0096-4
   Li J, 2018, BIOCHEM BIOPH RES CO, V496, P1291, DOI 10.1016/j.bbrc.2018.02.002
   Lin LY, 2019, INT J BIOL MACROMOL, V122, P64, DOI 10.1016/j.ijbiomac.2018.10.077
   Liu CW, 2018, PART FIBRE TOXICOL, V15, DOI 10.1186/s12989-018-0240-x
   Liu YX, 2016, J AGR FOOD CHEM, V64, P416, DOI 10.1021/acs.jafc.5b05436
   Lodovici M, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/487074
   Ma YH, 2019, BIOTECHNOL BIOPROC E, V24, P646, DOI 10.1007/s12257-019-0151-1
   Maier KL, 2008, INHAL TOXICOL, V20, P319, DOI [10.1080/08958370701866313, 10.1080/08958370701866313 ]
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Mikolka P, 2019, PHYSIOL RES, V68, pS253, DOI 10.33549/physiolres.934364
   Musat O, 2012, Oftalmologia, V56, P45
   Nguyen LTH, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/8847358
   Pang LL, 2019, INT J CLIN EXP PATHO, V12, P3700
   Pintea A, 2011, J FOOD COMPOS ANAL, V24, P830, DOI 10.1016/j.jfca.2011.03.007
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Sun NZ, 2018, CARDIOL J, V25, P268, DOI 10.5603/CJ.a2017.0105
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Valavanidis A, 2008, J ENVIRON SCI HEAL C, V26, P339, DOI 10.1080/10590500802494538
   Valavanidis A, 2013, INT J ENV RES PUB HE, V10, P3886, DOI 10.3390/ijerph10093886
   Wang YW, 2021, ACTA PHARMACOL SIN, V42, P726, DOI 10.1038/s41401-020-00502-6
   Winkler BS, 1999, MOL VIS, V5
   Yang B, 2013, EXPERT OPIN THER TAR, V17, P255, DOI 10.1517/14728222.2013.745513
   Zhang YY, 2019, RSC ADV, V9, P40736, DOI 10.1039/c9ra06002b
   Zwolak I, 2016, TOXICOL IND HEALTH, V32, P1013, DOI 10.1177/0748233714544190
NR 50
TC 4
Z9 4
U1 5
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUN 17
PY 2021
VL 8
AR 685032
DI 10.3389/fmed.2021.685032
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TC4XL
UT WOS:000668643300001
PM 34222291
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hanumunthadu, D
   Adan, K
   Tinkler, K
   Balaskas, K
   Hamilton, R
   Nicholson, L
   Addison, PKF
   Addison, PKF
   Sivaprasad, S
   Menon, D
   Sarma, B
   Dhillon, V
   Rahman, N
   Sawri-Rajan, R
   Finocchio, L
   Fotiou, P
   Fontenlos, RR
   Vermeirsch, S
   Agarwal, A
   Khalid, H
   Roth, J
   Trepatchayakom, S
   Martin-Gutierrez, MP
   Alves, MBD
   Hurtikova, K
   Ahnood, D
   Hirji, N
   Rasheed, R
   Agorogiannis, E
   Heng, LZ
   Ajamil, S
   Rozenberg, A
   Strong, S
   Demir, B
   Lara, CV
   Arpa, C
   Sadiq, S
   Bouras, K
   Hoeh, A
   Grimaldi, G
   Dias, KOM
   Shah, BJ
   Selvam, S
   Yang, EL
   Wong, KR
   Hennings, C
   Hussain, R
   Woronkowicz, M
AF Hanumunthadu, Daren
   Adan, Khadra
   Tinkler, Kerry
   Balaskas, Konstantinos
   Hamilton, Robin
   Nicholson, Luke
   Addison, Peter K. F.
   Addison, Peter K. F.
   Sivaprasad, Sobha
   Menon, Deepthy
   Sarma, Barsha
   Dhillon, Virinder
   Rahman, Najiha
   Sawri-Rajan, Rajasudha
   Finocchio, Lucia
   Fotiou, Panteleimon
   Fontenlos, Ricardo Romero
   Vermeirsch, Sandra
   Agarwal, Aditi
   Khalid, Hagar
   Roth, Janice
   Trepatchayakom, Supawat
   Martin-Gutierrez, Maria Pilar
   De Albuquerque Alves, Marcela Bohn
   Hurtikova, Katarina
   Ahnood, Dana
   Hirji, Nashila
   Rasheed, Rajna
   Agorogiannis, Eleftherios
   Heng, Ling Zhi
   Ajamil, Sofia
   Rozenberg, Assaf
   Strong, Stacey
   Demir, Bahar
   Lara, Carlos Valdes
   Arpa, Cristina
   Sadiq, Saqlain
   Bouras, Konstantinos
   Hoeh, Alexandra
   Grimaldi, Gabriela
   Dias, Karla Orsine Murta
   Shah, Bejal
   Selvam, Senthil
   Yang, Elizabeth
   Wong, Karen
   Hennings, Charles
   Hussain, Rohan
   Woronkowicz, Malgorzata
CA Moorfields Med Retina Virtual Ass
TI Outcomes following implementation of a high-volume medical retina
   virtual clinic utilising a diagnostic hub during COVID-19
SO EYE
LA English
DT Article
AB Background To describe the clinical outcomes following implementation of a high-volume medical retina virtual clinic utilising a diagnostic hub. Methods Retrospective consecutive case-series of all patients attending the medical retina virtual clinics at Moorfields Eye Hospital (City Road) for 6 weeks from September 21, 2020. Results In 6 weeks, 1006 patients attended the medical retina virtual clinics, which included an appointment in the diagnostic hub followed by an assessment asynchronously the following working day. The vast majority of patients were follow-up attendances (969, 96.3%) with much fewer new patient attendances (37, 3.7%). The most common diagnoses made overall were diabetic retinopathy (457, 45.4%), age-related macular degeneration (208, 20.7%) and retinal vein occlusion (80, 8.0%). The majority of patient (643, 63.9%) outcomes were follow-up in the medical retina virtual clinics including 313 (31.1%) with OCT-only pathway and 330 (32.8%) with OCT and widefield fundus imaging. Routine follow-up requested after virtual assessment included 320 (31.8%) with a 3-4 month review and 267 (26.5%) with a 6 months assessment. Only 62 patients (6.2%) were asked to return for face-to-face assessment within 2 weeks. Conclusions We describe a new high-volume medical retina virtual clinic utilising a diagnostic hub in which more than 1000 patients were seen and assessed asynchronously. Most patients were assessed as suitable for routine follow-up in this virtual pathway and only a small proportion required urgent reviews (within 2 weeks). In the COVID-19 era, this form of high-volume virtual clinic has the potential to review patients efficiently and safely.
C1 [Hanumunthadu, Daren; Adan, Khadra; Tinkler, Kerry; Balaskas, Konstantinos; Hamilton, Robin; Nicholson, Luke] Moorfields Eye Hosp NHS Fdn Trust, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Nicholson, L (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, London, England.
EM luke.nicholson3@nhs.net
RI Balaskas, Konstantinos/ABD-5979-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; Sivaprasad,
   Sobha/0000-0001-8952-0659; Rozenberg, Assaf/0000-0003-0339-5063
CR [Anonymous], 2021, EYE LOND, V35, P299
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Kern C, 2019, OPHTHALMOL RETINA, V3, P422, DOI 10.1016/j.oret.2019.01.011
   Kiss S, 2014, CURR DIABETES REP, V14, DOI 10.1007/s11892-014-0514-0
   Kortuem K, 2018, BRIT J OPHTHALMOL, V102, P1391, DOI 10.1136/bjophthalmol-2017-311494
   Kotecha A, 2017, EYE, V31, P899, DOI 10.1038/eye.2017.9
   Lee JX, 2018, CLIN OPHTHALMOL, V12, P2337, DOI 10.2147/OPTH.S181108
   Ratnarajan G, 2015, OPHTHAL PHYSL OPT, V35, P577, DOI 10.1111/opo.12224
   Royal College of Ophthalmologists, 2015, WAY FORWARD AGE RELA
   Royal College of Ophthalmologists, 2020, GUIDANCE RESTARTING
   Scanlon PH, 2017, ACTA DIABETOL, V54, P515, DOI 10.1007/s00592-017-0974-1
   Schmid MK, 2019, EYE, V33, P1584, DOI 10.1038/s41433-019-0455-6
   Tsaousis KT, 2016, ACTA OPHTHALMOL, V94, pe353, DOI 10.1111/aos.12832
   Ward E, 2021, EYE, V35, P592, DOI 10.1038/s41433-020-0910-4
   Zur D, 2018, OPHTHALMOLOGY, V125, P267, DOI 10.1016/j.ophtha.2017.08.031
NR 17
TC 2
Z9 2
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2022
VL 36
IS 3
BP 627
EP 633
DI 10.1038/s41433-021-01510-4
EA APR 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZH5FE
UT WOS:000637456600006
PM 33824508
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Vidal, KS
   Suemoto, CK
   Moreno, AB
   Viana, MC
   Lotufo, PA
   Bensenor, IM
   Brunoni, AR
AF Vidal, Kallene S.
   Suemoto, Claudia K.
   Moreno, Arlinda B.
   Viana, Maria C.
   Lotufo, Paulo A.
   Bensenor, Isabela M.
   Brunoni, Andre R.
TI Association Between Posterior Segment Eye Diseases, Common Mental
   Disorders, and Depression: Cross-Sectional and Longitudinal Analyses of
   Brazilian Longitudinal Study of Adult Health Cohort
SO JOURNAL OF THE ACADEMY OF CONSULTATION-LIAISON PSYCHIATRY
LA English
DT Article
DE cohort study; depressive disorders; anxiety disorders; glaucoma; macular
   degeneration; diabetic retinopathy
ID ILLUMINATION PUPIL RESPONSE; RETINAL GANGLION-CELLS; VISION LOSS;
   ANXIETY; PREVALENCE; PREDICTORS; SYMPTOMS; SCAN
AB Background: Posterior segment eye diseases, such as glaucoma and retinal diseases (such as diabetic retinopathy, age-related macular degeneration, and retinal detachment), are chronic diseases that are among the major causes of visual impairment. Objective: We investigated the prevalence of anxiety disorders, depressive disorders, and common mental disorders in these patients and also the incidence of depression. Methods: We examined baseline (2008-2010) and follow-up (2012-2014) data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). We used the Clinical Interview Schedule-Revised (CIS-R) to perform International Classification of Diseases-10-based diagnoses of anxiety and depressive disorders. Common mental disorder was defined as a Clinical Interview Schedule-Revised >11. We used multinomial logistic regression models to investigate associations between eye diseases and mental disorders, adjusted by age, gender, educational level, self-reported ethnicity, cardiovascular conditions, and self-reported quality of vision. Results: Out of 10,775 subjects, 249 (2.3%), 303 (2.8%), and 30 (0.3%) reported having retinal diseases, glaucoma, or both, respectively. Patients with retinal diseases and those with glaucoma and retinal diseases presented a higher prevalence of common mental disorders (relative-risk ratios of 1.7 and 3.7, respectively, P < 0.001). These patients also presented a higher incidence of depression at follow-up (relative-risk ratios of 3.0 and 5.9, respectively, P < 0.001). Patients with glaucoma presented neither a higher prevalence nor a higher incidence of mental disorders or depression. Conclusions: Retinal diseases but not glaucoma were associated with mental disorders, indicating that patients with posterior segment eye diseases require distinct management of psychiatric morbidity according to the underlying pathology.
C1 [Vidal, Kallene S.] Univ Sao Paulo, Inst Psychol, Lab Vis, Sao Paulo, Brazil.
   [Suemoto, Claudia K.] Univ Sao Paulo, Div Geriatr, Fac Med, Sao Paulo, Brazil.
   [Moreno, Arlinda B.] Fundacao Oswaldo Cruz, Dept Epidemiol & Quantitat Methods Hlth, Natl Sch Publ Hlth Sergio Arouca, Rio De Janeiro, Brazil.
   [Viana, Maria C.] Univ Fed Espirito Santo, Ctr Psychiat Epidemiol CEPEP, Dept Social Med, Postgrad Program Publ Hlth, Vitoria, ES, Brazil.
   [Lotufo, Paulo A.; Bensenor, Isabela M.; Brunoni, Andre R.] Univ Sao Paulo, Hosp Univ, Fac Med Univ Sao Paulo, Ctr Clin & Epidemiol Res, Sao Paulo, SP, Brazil.
   [Brunoni, Andre R.] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Brunoni, Andre R.] Univ Sao Paulo, Dept & Inst Psychiat, Lab Neurosci LIM 27, Fac Med, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Fundacao Oswaldo
   Cruz; Universidade Federal do Espirito Santo; Universidade de Sao Paulo;
   Universidade de Sao Paulo; Universidade de Sao Paulo
RP Brunoni, AR (通讯作者)，Hosp Univ HU USP, Av Prof Lineu Prestes 2565, Sao Paulo, Brazil.
EM brunoni@usp.br
RI Vidal, Kallene SM/N-8685-2014; Brunoni, Andre R./H-8394-2012; Suemoto,
   Claudia K/C-7218-2012
OI Brunoni, Andre R./0000-0002-6310-3571; Suemoto, Claudia
   K/0000-0002-5942-4778; Barbosa Moreno, Arlinda/0000-0002-8282-6521
FU Brazilian Ministry of Health; CNPq [01060010.00RS, 01060212.00BA,
   01060300.00ES, 01060278.00MG, 01060115.00SP, 01060071.00RJ]; Selo Paulo
   Research State Foundation [FAPESP 15/22227-2]; CNPq
FX The ELSABrasil study was supported by the Brazilian Ministry of Health
   and CNPq (grants 01060010.00RS, 01060212.00BA, 01060300.00ES,
   01060278.00MG, 01060115.00SP, 01060071.00RJ) . K.S.M.V. receives a
   fellowship from Selo Paulo Research State Foundation (FAPESP 15/22227-2)
   . A.R.B. receives a research productivity grant from CNPq (1B) .
CR Alonso J, 2018, DEPRESS ANXIETY, V35, P802, DOI 10.1002/da.22778
   Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
   Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brugha TS, 1999, PSYCHOL MED, V29, P1029, DOI 10.1017/S0033291799008892
   Brunoni AR, 2019, ACTA PSYCHIAT SCAND, V140, P552, DOI 10.1111/acps.13109
   Brunoni AR, 2020, J AFFECT DISORDERS, V263, P252, DOI 10.1016/j.jad.2019.11.155
   Brunoni AR, 2013, J AFFECT DISORDERS, V151, P71, DOI 10.1016/j.jad.2013.05.054
   Cigolle CT, 2018, J GERONTOL B-PSYCHOL, V73, P901, DOI 10.1093/geronb/gbw063
   Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Duque-Chica GL, 2018, J GLAUCOMA, V27, P723, DOI 10.1097/IJG.0000000000001003
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   Feigl B, 2012, ACTA OPHTHALMOL, V90, pe230, DOI 10.1111/j.1755-3768.2011.02226.x
   Frank CR, 2019, JAMA OPHTHALMOL, V137, P793, DOI 10.1001/jamaophthalmol.2019.1085
   Hassan B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216492
   Heesterbeek TJ, 2017, OPHTHAL PHYSL OPT, V37, P385, DOI 10.1111/opo.12388
   Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V319, P1429, DOI 10.1001/jama.2018.1536
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/s0140-6736(18)32279-7
   Jonas JB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202132
   Leasher JL, 2019, BRIT J OPHTHALMOL, V103, P885, DOI 10.1136/bjophthalmol-2017-311746
   LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415
   Lim NCS, 2016, J GLAUCOMA, V25, P605, DOI 10.1097/IJG.0000000000000393
   Maynard ML, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20659
   Maynard ML, 2015, INVEST OPHTH VIS SCI, V56, P6906, DOI 10.1167/iovs.15-17357
   Naimi TS, 2017, ADDICTION, V112, P207, DOI 10.1111/add.13451
   Nunes MA, 2011, REV HCPA, V31, P487
   Nunes MA, 2016, REV BRAS PSIQUIATR, V38, P91, DOI 10.1590/1516-4446-2015-1714
   Patton GC, 2014, LANCET, V383, P1404, DOI [10.1016/s0140-6736(13)62116-9, 10.1016/S0140-6736(13)62116-9]
   Rees G, 2016, JAMA OPHTHALMOL, V134, P1007, DOI 10.1001/jamaophthalmol.2016.2213
   Rezapour J, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0831-1
   Rosenblat JD, 2020, AUST NZ J PSYCHIAT, V54, P346, DOI 10.1177/0004867419888576
   Schmidt MI, 2013, REV SAUDE PUBL, V47, P105, DOI 10.1590/S0034-8910.2013047003889
   Pereira TSS, 2015, SAO PAULO MED J, V133, P510, DOI 10.1590/1516-3180.2015.01233108
   Szlejf C, 2019, INT J CARDIOL, V274, P358, DOI 10.1016/j.ijcard.2018.06.037
   van der Aa HPA, 2016, OPHTHALMOLOGY, V123, P1164, DOI 10.1016/j.ophtha.2015.11.028
   van der Aa HPA, 2015, QUAL LIFE RES, V24, P2885, DOI 10.1007/s11136-015-1032-5
   van Nispen RMA, 2016, ACTA OPHTHALMOL, V94, P76, DOI 10.1111/aos.12896
   Wang BS, 2018, BRIT J OPHTHALMOL, V102, P220, DOI 10.1136/bjophthalmol-2017-310333
   Wang ST, 2018, NEUROSCI LETT, V662, P368, DOI 10.1016/j.neulet.2017.10.055
   Wang SY, 2012, AM J OPHTHALMOL, V154, P436, DOI 10.1016/j.ajo.2012.03.039
   WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589
NR 43
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2667-2960
J9 J ACAD CONSULT-LIAIS
JI J. Acad. Consult.-Liaison Psychiat.
PD JAN-FEB
PY 2021
VL 62
IS 1
BP 70
EP 78
PG 9
WC Psychiatry; Psychology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry; Psychology
GA TH6WR
UT WOS:000672228200009
PM 32279886
OA Bronze
DA 2022-11-30
ER

PT J
AU Biasella, F
   Plossl, K
   Karl, C
   Weber, BHF
   Friedrich, U
AF Biasella, Fabiola
   Ploessl, Karolina
   Karl, Claudia
   Weber, Bernhard H. F.
   Friedrich, Ulrike
TI Altered Protein Function Caused by AMD-associated Variant rs704 Links
   Vitronectin to Disease Pathology
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; age-related macular degeneration; vitronectin; VTN; rs704
ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; PIGMENT EPITHELIUM-CELLS; PLURIPOTENT
   STEM-CELLS; MACULAR DEGENERATION; EXTRACELLULAR-MATRIX; UROKINASE
   RECEPTOR; GENE-EXPRESSION; HUMAN-PLASMA; IN-VITRO; INTEGRIN
   ALPHA(V)BETA(3)
AB PURPOSE. Vitronectin, a cell adhesion and spreading factor, is suspected to play a role in the pathogenesis of age-related macular degeneration (AMD), as it is a major component of AMD-specific extracellular deposits (e.g., soft drusen, subretinal drusenoid deposits). The present study addressed the impact of AMD-associated non-synonymous variant rs704 in the vitronectin-encoding gene VTN on vitronectin functionality.
   METHODS. Effects of rs704 on vitronectin expression and processing were analyzed by semi-quantitative sequencing of VTN transcripts from retinal pigment epithelium (RPE) cells generated from human induced pluripotent stem cells (hiPSCs) and from human neural retina, as well as by western blot analyses on heterologously expressed vitronectin isoforms. Binding of vitronectin isoforms to retinal and endothelial cells was analyzed by western blot. Immunofluorescence staining followed extracellular matrix (ECM) deposition in cultured RPE cells heterologously expressing the vitronectin isoforms. Adhesion of fluorescently labeled RPE or endothelial cells in dependence of recombinant vitronectin or vitronectin-containing ECM was investigated fluorometrically or microscopically. Tube formation and migration assays addressed effects of vitronectin on angiogenesis-related processes.
   RESULTS. Variant rs704 affected expression, secretion, and processing but not oligomerization of vitronectin. Cell binding and influence on RPE-mediated ECM deposition differed between AMD-risk-associated and non-AMD-risk-associated protein isoforms. Finally, vitronectin affected adhesion and endothelial tube formation.
   CONCLUSIONS. The AMD-risk-associated vitronectin isoform exhibits increased expression and altered functionality in cellular processes related to the sub-RPE aspects of AMD pathology. Although further research is required to address the subretinal disease aspects, this initial study supports an involvement of vitronectin in AMD pathogenesis.
C1 [Biasella, Fabiola; Ploessl, Karolina; Karl, Claudia; Weber, Bernhard H. F.; Friedrich, Ulrike] Univ Regensburg, Inst Human Genet, Bldg D3,Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
   [Weber, Bernhard H. F.] Univ Hosp Regensburg, Inst Clin Human Genet, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Friedrich, U (通讯作者)，Univ Regensburg, Inst Human Genet, Bldg D3,Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM ulrike.friedrich@klinik.uni-regensburg.de
FU Pro Retina Foundation, Aachen, Germany
FX Supported by a scholarship from the Pro Retina Foundation, Aachen,
   Germany.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   AKAMA T, 1986, J BIOCHEM-TOKYO, V100, P1343, DOI 10.1093/oxfordjournals.jbchem.a121840
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Anderson DH, 1999, INVEST OPHTH VIS SCI, V40, P3305
   BARTHA K, 1991, J BIOL CHEM, V266, P792
   Benson DA, 2005, NUCLEIC ACIDS RES, V33, pD34, DOI 10.1093/nar/gki063
   Birch DG, 2007, INT J NANOMED, V2, P65, DOI 10.2147/nano.2007.2.1.65
   Bird A, 2021, BRIT J OPHTHALMOL, V105, P1469, DOI 10.1136/bjophthalmol-2020-317447
   Brakenhielm E, 2007, CIRC RES, V101, P536, DOI 10.1161/CIRCRESAHA.107.160937
   Brandal S, 2011, NUCLEIC ACID THER, V21, P373, DOI 10.1089/nat.2011.0320
   Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8
   BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Cannarrozzi G, 2010, CELL, V141, P355, DOI 10.1016/j.cell.2010.02.036
   Carpentier G., ANGIOGENESIS ANAL IM
   CHAIN D, 1990, FEBS LETT, V269, P221, DOI 10.1016/0014-5793(90)81159-L
   CHAIN D, 1991, BIOCHEM J, V274, P387, DOI 10.1042/bj2740387
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chillakuri CR, 2010, FEBS LETT, V584, P3287, DOI 10.1016/j.febslet.2010.06.023
   Corydon TJ, 2016, CELL PHYSIOL BIOCHEM, V40, P1, DOI 10.1159/000452520
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Daniel AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145684
   Date K, 2019, FEBS OPEN BIO, V9, P755, DOI 10.1002/2211-5463.12616
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454
   Dejana E., 1989, VASCULAR ENDOTHELIUM, P141
   Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133
   Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Francois PP, 1999, J BIOL CHEM, V274, P37611, DOI 10.1074/jbc.274.53.37611
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Friedrich U, 2011, HUM MOL GENET, V20, P1132, DOI 10.1093/hmg/ddq557
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   GEBB C, 1986, J BIOL CHEM, V261, P6698
   Gibson AD, 2001, BBA-PROTEIN STRUCT M, V1545, P289, DOI 10.1016/S0167-4838(00)00290-9
   Gomez NM, 2013, PFLUG ARCH EUR J PHY, V465, P481, DOI 10.1007/s00424-012-1181-0
   Gong J, 2020, STEM CELL TRANSL MED, V9, P364, DOI 10.1002/sctm.19-0321
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9
   Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   HARUMIYA S, 1993, J BIOCHEM-TOKYO, V113, P710, DOI 10.1093/oxfordjournals.jbchem.a124108
   Hazawa M, 2016, VASC PHARMACOL, V87, P150, DOI 10.1016/j.vph.2016.09.006
   Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357-2725(96)00155-0
   HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425
   Isogai C, 2001, CANCER RES, V61, P5587
   Jang YC, 2000, SURGERY, V127, P696, DOI 10.1067/msy.2000.105858
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Katagiri Y, 2003, J BIOL CHEM, V278, P11897, DOI 10.1074/jbc.M212512200
   Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540
   Kleinman ME, 2009, RETINAL PHYS
   KONKLE BA, 1988, J CLIN INVEST, V82, P579, DOI 10.1172/JCI113635
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Leavesley DI, 2013, IUBMB LIFE, V65, P807, DOI 10.1002/iub.1203
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   LODISH HF, 1988, J BIOL CHEM, V263, P2107
   Luo Y, 2006, INVEST OPHTH VIS SCI, V47, P3644, DOI 10.1167/iovs.06-0166
   Madsen CD, 2007, J CELL BIOL, V177, P927, DOI 10.1083/jcb.200612058
   Mahabeleshwar GH, 2007, SEMIN ONCOL, V34, P555, DOI 10.1053/j.seminoncol.2007.09.009
   McLenachan Samuel, 2017, Biochem Biophys Rep, V10, P178, DOI 10.1016/j.bbrep.2017.03.008
   MILIS L, 1993, CLIN EXP IMMUNOL, V92, P114
   MIMURO J, 1989, J BIOL CHEM, V264, P936
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moreira EF, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.10
   Nachtigal AL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051597
   Nandrot EF, 2008, ADV EXP MED BIOL, V613, P369, DOI 10.1007/978-0-387-74904-4_43
   Okita K, 2013, STEM CELLS, V31, P458, DOI 10.1002/stem.1293
   Pal LR, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S8-S4
   Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075
   Pezzoli D, 2018, BIOMATERIALS, V180, P130, DOI 10.1016/j.biomaterials.2018.07.013
   Plossl K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216320
   Plossl K, 2018, EXP EYE RES, V177, P23, DOI 10.1016/j.exer.2018.07.021
   Plossl K, 2017, MOL BIOL CELL, V28, P2178, DOI 10.1091/mbc.E17-01-0064
   Plossl K, 2017, J CELL MOL MED, V21, P768, DOI 10.1111/jcmm.13019
   Ponce M. Lourdes, 2009, V467, P183, DOI 10.1007/978-1-59745-241-0_10
   Preissner KT, 2011, SEMIN THROMB HEMOST, V37, P408, DOI 10.1055/s-0031-1276590
   PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275
   Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sabatelli P, 2001, MATRIX BIOL, V20, P475, DOI 10.1016/S0945-053X(01)00160-3
   SALONEN EM, 1989, J BIOL CHEM, V264, P6339
   Salvi SM, 2006, POSTGRAD MED J, V82, P581, DOI 10.1136/pgmj.2005.040857
   Sambrook Joseph, 2006, CSH Protoc, V2006, DOI [10.1101/pdb.prot3966, 10.1101/pdb.prot4455, 10.1101/pdb.prot4022, 10.1101/pdb.prot4056, 10.1101/pdb.prot4044, 10.1101/pdb.prot4050, 10.1101/pdb.prot3871, 10.1101/pdb.prot3825, 10.1101/pdb.prot4027, 10.1101/pdb.prot4085, 10.1101/pdb.prot3723, 10.1101/pdb.prot4453, 10.1101/pdb.prot3972]
   Samuel W, 2017, MOL VIS, V23, P60
   Sano K, 2007, GLYCOBIOLOGY, V17, P784, DOI 10.1093/glycob/cwm031
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schmid V, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.1
   Schvartz I, 1999, INT J BIOCHEM CELL B, V31, P539, DOI 10.1016/S1357-2725(99)00005-9
   Seiffert D, 1997, HISTOL HISTOPATHOL, V12, P787
   Shin TM, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-16
   Shirinifard A, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002440
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sohn EH, 2015, RETINA-J RET VIT DIS, V35, P48, DOI 10.1097/IAE.0000000000000263
   Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spreghini E, 1999, J INFECT DIS, V180, P156, DOI 10.1086/314822
   Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0
   Stefansson S, 2007, J BIOL CHEM, V282, P15679, DOI 10.1074/jbc.M702125200
   STOCKMANN A, 1993, J BIOL CHEM, V268, P22874
   Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2
   Sveinbjornsson G, 2016, NAT GENET, V48, P314, DOI 10.1038/ng.3507
   TOLLEFSEN DM, 1990, J BIOL CHEM, V265, P9778
   Tomasini B R, 1991, Prog Hemost Thromb, V10, P269
   Tuller T, 2010, P NATL ACAD SCI USA, V107, P3645, DOI 10.1073/pnas.0909910107
   Vakonakis I, 2009, J BIOL CHEM, V284, P15668, DOI 10.1074/jbc.M109.003673
   Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang T, 2006, BRIT J OPHTHALMOL, V90, P81, DOI 10.1136/bjo.2005.078048
   Wasmuth S, 2009, INVEST OPHTH VIS SCI, V50, P5304, DOI 10.1167/iovs.08-3326
   WEI Y, 1994, J BIOL CHEM, V269, P32380
   Wu WWH, 2003, J BIOL CHEM, V278, P28139, DOI 10.1074/jbc.M302464200
   WUN TC, 1989, J BIOL CHEM, V264, P7862
   Yi M, 2003, P NATL ACAD SCI USA, V100, P11435, DOI 10.1073/pnas.1635112100
   Yoneda A, 1998, BIOCHEMISTRY-US, V37, P6351, DOI 10.1021/bi972247n
   Zheng XX, 1995, P NATL ACAD SCI USA, V92, P12426, DOI 10.1073/pnas.92.26.12426
NR 123
TC 7
Z9 7
U1 1
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2020
VL 61
IS 14
AR 2
DI 10.1167/iovs.61.14.2
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PN0YS
UT WOS:000604213900012
PM 33259607
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sahli, E
   Altinbay, D
   Kiziltunc, PB
   Idil, A
AF Sahli, Esra
   Altinbay, Deniz
   Kiziltunc, Pinar Bingol
   Idil, Aysun
TI Effectiveness of Low Vision Rehabilitation Using Microperimetric
   Acoustic Biofeedback Training in Patients with Central Scotoma
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Acoustic biofeedback training; central scotoma; microperimetry
ID PREFERRED RETINAL LOCUS; MACULAR DEGENERATION; ECCENTRIC FIXATION;
   LOCATION; PATTERNS; BEHAVIOR; ACUITY; FOVEA; EYES
AB Purpose To evaluate the efficacy of visual rehabilitation with microperimeter biofeedback in patients with central scotoma. Materials and Methods 35 consecutive patients with central scotoma (17 age-related macular degeneration (AMD), 14 Stargardt disease, and 4 cone dystrophy) were included in the study. Visual acuity, reading performance by Minnesota Low Vision Reading Test (MNREAD), quality of life by 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), and fixation analysis by MAIA microperimeter were evaluated before and 1 month after training. The rehabilitation program consisted of 10 training sessions of 10 minutes. Results The median best-corrected visual acuity (BCVA) was 0.80 logMAR (range 0.3 to 1.3 logMAR). Fifty-nine percent of patients with AMD developed a preferred retinal locus (PRL) nasal to the fovea, and 64% of the patients with Stargardt disease preferred a PRL superior to the fovea. The PRL location in 3 of 4 cone dystrophy patients was nasal to the fovea. The mean PRL distance from the fovea was 7.57 +/- 3.61 degrees. Fixation stability improved with P1 values of 22.34 +/- 11.81 versus 32.05 +/- 18.79 (p= .003) and 95% bivariate contour ellipse area (BCEA) values of 41.6 versus 23.6 (p= .018) before and after training, respectively. There was a significant difference in reading acuity between before and after training (p= 0.008). The overall score and near activities score of NEI VFQ-25 were found to be increased at the end of the rehabilitation (p< 0.001). Conclusion Rehabilitation with acoustic biofeedback in patients with central scotoma looks like a useful technique for improving fixation stability, reading performance and quality of life.
C1 [Sahli, Esra; Altinbay, Deniz; Kiziltunc, Pinar Bingol; Idil, Aysun] Ankara Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
   [Altinbay, Deniz] Niv Eye Ctr, Dept Ophthalmol, Adana, Turkey.
C3 Ankara University
RP Sahli, E (通讯作者)，Ankara Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
EM esracansizoglu@gmail.com
RI Kiziltunc, Pınar Bingol/W-8319-2018; Şahlı, Esra/AAW-4371-2021
OI Kiziltunc, Pınar Bingol/0000-0003-4394-7926; Altinbay,
   Deniz/0000-0002-3976-4361; Idil, Sefay Aysun/0000-0002-5979-9158
CR Amore FM, 2013, CAN J OPHTHALMOL, V48, P431, DOI 10.1016/j.jcjo.2013.07.013
   Barboni MTS, 2019, APPL PSYCHOPHYS BIOF, V44, P61, DOI 10.1007/s10484-018-9423-3
   Calabrese A, 2016, JAMA OPHTHALMOL, V134, P398, DOI 10.1001/jamaophthalmol.2015.6097
   Calkan D, 2009, TURK J OPHTHALMOL, V39
   Chiang WY, 2018, GRAEF ARCH CLIN EXP, V256, P1403, DOI 10.1007/s00417-018-4006-9
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Daibert-Nido M, 2019, CAN J OPHTHALMOL, V54, P328, DOI 10.1016/j.jcjo.2018.10.016
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Erbezci M, 2017, RETINA, V38
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Frennesson C, 2007, ACTA OPHTHALMOL SCAN, V85, P868, DOI 10.1111/j.1600-0420.2007.00984.x
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Kameda T, 2009, JPN J OPHTHALMOL, V53, P580, DOI 10.1007/s10384-009-0735-y
   Krishnan AK, 2018, GRAEF ARCH CLIN EXP, V256, P29, DOI 10.1007/s00417-017-3818-3
   LIN SJ, 2004, INVEST OPHTH VIS S2, V45
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 2000, NEI VFQ 25 SCORING A
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Messias A, 2007, INVEST OPHTH VIS SCI, V48, P5815, DOI 10.1167/iovs.06-0367
   Molina-Martin A, 2018, SEMIN OPHTHALMOL, V33, P620, DOI 10.1080/08820538.2017.1375125
   Mori F, 2001, AM J OPHTHALMOL, V132, P897, DOI 10.1016/S0002-9394(01)01216-8
   Murro V, 2017, EUR J OPHTHALMOL, V27, P740, DOI 10.5301/ejo.5000972
   Okada K, 2006, EYE, V20, P805, DOI 10.1038/sj.eye.6702014
   Petre KL, 2000, OPTOMETRY VISION SCI, V77, P34, DOI 10.1097/00006324-200001000-00011
   Ramirez Estudillo Juan Abel, 2017, Int J Retina Vitreous, V3, P21, DOI 10.1186/s40942-017-0071-1
   Ratra D, 2019, CLIN EXP OPTOM, V102, P172, DOI 10.1111/cxo.12834
   Rees AL, 2005, INT C SER, V1282, P694, DOI DOI 10.1016/J.ICS.2005.05.172
   Reinhard J, 2007, VISION RES, V47, P2076, DOI 10.1016/j.visres.2007.04.012
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   Rohrschneider K, 1997, OPHTHALMOLOGE, V94, P624, DOI 10.1007/s003470050171
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Shima N, 2010, CAN J OPHTHALMOL, V45, P62, DOI 10.3129/i09-236
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   Timberlake GT, 1987, INVEST OPHTHALMOL VI, V28
   Verdina T, 2013, EUR J OPHTHALMOL, V23, P723, DOI 10.5301/ejo.5000291
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Vingolo EM, 2009, APPL PSYCHOPHYS BIOF, V34, P127, DOI 10.1007/s10484-009-9083-4
   Vingolo Enzo Maria, 2018, Front Biosci (Schol Ed), V10, P48
NR 43
TC 7
Z9 7
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD MAY 4
PY 2021
VL 46
IS 5
BP 731
EP 738
DI 10.1080/02713683.2020.1833348
EA OCT 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RU3DD
UT WOS:000579197400001
PM 33073619
DA 2022-11-30
ER

PT J
AU Marie, M
   Forster, V
   Fouquet, S
   Berto, P
   Barrau, C
   Ehrismann, C
   Sahel, JA
   Tessier, G
   Picaud, S
AF Marie, Melanie
   Forster, Valerie
   Fouquet, Stephane
   Berto, Pascal
   Barrau, Coralie
   Ehrismann, Camille
   Sahel, Jose-Alain
   Tessier, Gilles
   Picaud, Serge
TI Phototoxic damage to cone photoreceptors can be independent of the
   visual pigment: the porphyrin hypothesis
SO CELL DEATH & DISEASE
LA English
DT Article
ID LIGHT; AUTOFLUORESCENCE; EXPOSURE; CELL; DEGENERATION; MECHANISMS;
   STRESS; DEATH
AB Lighting is rapidly changing with the introduction of light-emitting diodes (LEDs) in our homes, workplaces, and cities. This evolution of our optical landscape raises major concerns regarding phototoxicity to the retina since light exposure is an identified risk factor for the development of age-related macular degeneration (AMD). In this disease, cone photoreceptors degenerate while the retinal pigment epithelium (RPE) is accumulating lipofuscin containing phototoxic compounds such as A2E. Therefore, it remains unclear if the light-elicited degenerative process is initiated in cones or in the RPE. Using purified cone photoreceptors from pig retina, we here investigated the effect of light on cone survival from 390 to 510 nm in 10 nm steps, plus the 630 nm band. If at a given intensity (0.2 mW/cm(2)), the most toxic wavelengths are comprised in the visible-to-near-UV range, they shift to blue-violet light (425-445 nm) when exposing cells to a solar source filtered by the eye optics. In contrast to previous rodent studies, this cone photoreceptor phototoxicity is not related to light absorption by the visual pigment. Despite bright flavin autofluorescence of cone inner segment, excitation-emission matrix of this inner segment suggested that cone phototoxicity was instead caused by porphyrin. Toxic light intensities were lower than those previously defined for A2E-loaded RPE cells indicating cones are the first cells at risk for a direct light insult. These results are essential to normative regulations of new lighting but also for the prevention of human retinal pathologies since toxic solar light intensities are encountered even at high latitudes.
C1 [Marie, Melanie; Forster, Valerie; Fouquet, Stephane; Berto, Pascal; Sahel, Jose-Alain; Tessier, Gilles; Picaud, Serge] Sorbonne Univ, Inst Vis, INSERM, CNRS, 17 Rue Moreau, F-75012 Paris, France.
   [Berto, Pascal] Univ Paris, Campus St Germain,45 Rue St Peres, F-75006 Paris, France.
   [Barrau, Coralie; Ehrismann, Camille] Essilor Int R&D, 147 Rue Paris, F-94220 Charenton Le Pont, France.
   [Sahel, Jose-Alain] Univ Pittsburgh, Sch Med, 3550 Terrace St, Pittsburgh, PA 15213 USA.
   [Sahel, Jose-Alain] INSERM DGOS CIC 1423, CHNO Quinze Vingts, DHU Sight Restore, 28 Rue Charenton, F-75012 Paris, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French
   Research Universities; Universite Paris Cite; Essilor International;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; CHNO des Quinze-Vingts; UDICE-French Research
   Universities; Sorbonne Universite
RP Picaud, S (通讯作者)，Sorbonne Univ, Inst Vis, INSERM, CNRS, 17 Rue Moreau, F-75012 Paris, France.
EM serge.picaud@inserm.fr
RI ; Picaud, Serge/H-4012-2014
OI Tessier, Gilles/0000-0003-3558-925X; MARIE, Melanie/0000-0003-3516-3582;
   Picaud, Serge/0000-0002-0548-5145
FU Agence National pour la Recherche [ANR-12-TECS-0013]; Essilor
   International;  [ANR-15-RHU-0001];  [ANR-10-LABX-65]; 
   [ANR-18-IAHU-0001];  [ANR-11-IDEX-0004-02]
FX We thank Arthur Planul for artwork, Kate Grieve for carefully reading
   the manuscript, Anais Potey and Elisabeth Dubus for technical
   assistance. We thank the cell culture, imaging and HTS platforms at the
   Institut de la Vision. We thank the School of Surgery (Ecole de
   Chirurgie, Assistance Publique Hopitaux de Paris) for postmortem human
   ocular globes. We thank Cheryl Mae Craft (University of Southern
   California ROSKI Eye Institute, Los Angeles, CA) for providing the
   antibody (LUMIf-hCAR) for cone arrestin. This work was supported by
   French state funds managed by the Agence Nationale de la Recherche
   within the Investissements d'Avenir program, RHU LIGHT4DEAF
   [ANR-15-RHU-0001], LABEX LIFESENSES [ANR-10-LABX-65], IHU FOReSIGHT
   [ANR-18-IAHU-0001], [ANR-11-IDEX-0004-02]. It received a grant from the
   Agence National pour la Recherche for the CHRONOMOFOS project
   [ANR-12-TECS-0013] and a grant from Essilor International.
CR [Anonymous], **NON-TRADITIONAL**
   Arnault E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071398
   Balse E, 2005, INVEST OPHTH VIS SCI, V46, P367, DOI 10.1167/iovs.04-0695
   Behar-Cohen F, 2011, PROG RETIN EYE RES, V30, P239, DOI 10.1016/j.preteyeres.2011.04.002
   BENSON RC, 1979, J HISTOCHEM CYTOCHEM, V27, P44, DOI 10.1177/27.1.438504
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Chen Y, 2011, CIRC RES, V109, P1327, DOI 10.1161/CIRCRESAHA.111.258723
   Craft CM, 2014, ADV EXP MED BIOL, V801, P49, DOI 10.1007/978-1-4614-3209-8_7
   Croce AC, 2014, EUR J HISTOCHEM, V58, P320, DOI 10.4081/ejh.2014.2461
   dos Santos AF, 2019, J CANC METASTASIS TR, V5, P25, DOI DOI 10.20517/2394-4722.2018.83
   Fain GL, 1999, INVEST OPHTH VIS SCI, V40, P2770
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Kaido M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152936
   Kam JH, 2019, VISUAL NEUROSCI, V36, DOI 10.1017/S0952523819000063
   Kanan Y, 2007, INVEST OPHTH VIS SCI, V48, P40, DOI 10.1167/iovs.06-0592
   Kou JY, 2017, ONCOTARGET, V8, P81591, DOI 10.18632/oncotarget.20189
   Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734
   Lee JB, 2014, INVEST OPHTH VIS SCI, V55, P4119, DOI 10.1167/iovs.13-13441
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Monici M, 2005, BIOTECHNOL ANN REV, V11, P227, DOI 10.1016/S1387-2656(05)11007-2
   Narayan DS, 2016, ACTA OPHTHALMOL, V94, P748, DOI 10.1111/aos.13141
   Natoli R, 2016, CURR EYE RES, V41, P1473, DOI 10.3109/02713683.2016.1139725
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Papayan G, 2014, PHOTODIAGN PHOTODYN, V11, P400, DOI 10.1016/j.pdpdt.2014.05.003
   Pastuszka Miroslaw, 2013, Klin Oczna, V115, P296
   Rambhatla PV, 2015, CLIN DERMATOL, V33, P238, DOI 10.1016/j.clindermatol.2014.10.016
   Reme C, 2005, INVEST OPHTH VIS SCI, V46, P2672, DOI 10.1167/iovs.04-1095
   Sharma R, 2016, INVEST OPHTH VIS SCI, V57, P632, DOI 10.1167/iovs.15-17961
   Sliney DH, 2005, PHOTOCHEM PHOTOBIOL, V81, P483, DOI 10.1562/2005-02-14-RA-439.1
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SPERLING HG, 1991, VISION RES, V31, P1797, DOI 10.1016/0042-6989(91)90027-3
   Sternberg ED, 1998, TETRAHEDRON, V54, P4151, DOI 10.1016/S0040-4020(98)00015-5
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Vandersee S, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/579675
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
   Zhang Y, 2001, NEW INSIGHTS RETINAL, P309, DOI [10.1007/978-1-4615-1355-1_33, DOI 10.1007/978-1-4615-1355-1_33]
NR 37
TC 8
Z9 8
U1 4
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG 29
PY 2020
VL 11
IS 8
AR 711
DI 10.1038/s41419-020-02918-8
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA NF9UT
UT WOS:000563636400001
PM 32862199
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zinflou, C
   Rochette, PJ
AF Zinflou, Corinne
   Rochette, Patrick J.
TI Absorption of blue light by cigarette smoke components is highly toxic
   for retinal pigmented epithelial cells
SO ARCHIVES OF TOXICOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polycyclic aromatic hydrocarbons;
   Benzo[a]pyrene; Indeno[1; 2; 3-cd]pyrene; High energy visible blue
   light; Oxidative stress
ID POLYCYCLIC AROMATIC-HYDROCARBONS; EXPERIMENTAL ANIMAL-MODEL; MACULAR
   DEGENERATION; OXIDATIVE STRESS; MAINSTREAM SMOKE; MITOCHONDRIAL
   MORPHOLOGY; ALPHA-TOCOPHEROL; EXPOSURE; DAMAGE; KERATINOCYTES
AB Lesion to the retinal pigment epithelium (RPE) is a crucial event in the development of age-related macular degeneration (AMD), the leading cause of blindness in industrialized countries. Tobacco smoking and high-energy visible blue (HEV; 400-500nm) light exposure are major environmental risk factors for AMD. Individually, they have been shown to cause damage to the RPE. Tobacco smoke contains toxic polycyclic aromatic hydrocarbons (PAH) that can accumulate in RPE and which absorb HEV light. It can thus be postulated that the interaction between both factors in RPE cells can have a synergic toxic effect to the RPE. To test this hypothesis, cultured human RPE cells (ARPE19) were treated with nanomolar concentrations of benzo[a]pyrene (BaP) or indeno[1,2,3-cd]pyrene (IcdP), then exposed to HEV light using an irradiation system that mimics the solar spectrum normally transmitted to the retina through the human ocular media. Using mitochondrial network morphology changes and key features of AMD-related RPE defects such as apoptotic cell death and oxidative stress, we demonstrate that a synergistic phototoxicity is generated when nanomolar concentrations (500nM) of IcdP interact with sub-lethal amounts of HEV light. Indeed, we found IcdP to be at least 3000 times more toxic for RPE cells when irradiated with HEV light. This synergy translates into disruption of mitochondrial network, ROS enhanced accumulation and apoptosis of RPE cells. Our results underline an important interplay between two environmental risk factors involved in AMD progression and strongly indicate that IcdP, upon interaction with HEV light, may initiate the biological mechanisms underlying the association between cigarette smoking and AMD-related RPE degeneration.
C1 [Zinflou, Corinne; Rochette, Patrick J.] Univ Laval, CHU Quebec, Hop St Sacrement, Axe Med Regeneratr,Ctr Rech, Quebec City, PQ, Canada.
   [Zinflou, Corinne; Rochette, Patrick J.] Univ Laval, LOEX, Ctr Rech Organogenese Expt, Quebec City, PQ, Canada.
   [Rochette, Patrick J.] Univ Laval, Dept Ophtalmol & ORL Chirurg Cervicofaciale, Quebec City, PQ, Canada.
C3 Laval University; Laval University; Laval University
RP Rochette, PJ (通讯作者)，Univ Laval, CHU Quebec, Hop St Sacrement, Axe Med Regeneratr,Ctr Rech, Quebec City, PQ, Canada.; Rochette, PJ (通讯作者)，Univ Laval, LOEX, Ctr Rech Organogenese Expt, Quebec City, PQ, Canada.; Rochette, PJ (通讯作者)，Univ Laval, Dept Ophtalmol & ORL Chirurg Cervicofaciale, Quebec City, PQ, Canada.
EM Patrick.rochette@orlo.ulaval.ca
OI Rochette, Patrick/0000-0002-0678-8869
FU Canadian Institutes of Health Research (CIHR) [MOP-133719]
FX The authors are grateful to the Institut National d'Optique (INO)
   (Quebec, Canada) for technical support. This work was supported by a
   Grant from the Canadian Institutes of Health Research (CIHR, MOP-133719)
   to P.J.R. P.J.R. is a research scholar from the Fonds de Recherche du
   Quebec - Sante (FRQ-S).
CR Ali R, 2015, J BIOPHOTONICS, V8, P361, DOI 10.1002/jbio.201300170
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Botta C, 2009, ENVIRON TOXICOL, V24, P492, DOI 10.1002/tox.20455
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Burke KE, 2009, TOXICOL IND HEALTH, V25, P219, DOI 10.1177/0748233709106067
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Dabestani R, 1999, PHOTOCHEM PHOTOBIOL, V70, P10, DOI 10.1562/0031-8655(1999)070<0010:IRACOP>2.3.CO;2
   Ding YS, 2006, ENVIRON SCI TECHNOL, V40, P1133, DOI 10.1021/es0517320
   Ding YS, 2005, ENVIRON SCI TECHNOL, V39, P471, DOI 10.1021/es048690k
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ebrahimi KB, 2018, ANTIOXID REDOX SIGN, V29, P389, DOI 10.1089/ars.2017.7084
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hoffmann D, 2001, CHEM RES TOXICOL, V14, P767, DOI 10.1021/tx000260u
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kontush A, 1996, J LIPID RES, V37, P1436
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lerman S., 1980, RADIANT ENERGY EYE, P73
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lodovici M, 2004, J APPL TOXICOL, V24, P277, DOI 10.1002/jat.992
   Marrot L., 2017, CURR MED CHEM
   MAUTHE RJ, 1995, CARCINOGENESIS, V16, P133, DOI 10.1093/carcin/16.1.133
   Patton WP, 2002, EXP EYE RES, V74, P513, DOI 10.1006/exer.2001.1160
   Pleil JD, 2010, J CHROMATOGR B, V878, P1753, DOI 10.1016/j.jchromb.2010.04.035
   Poot M, 1996, J HISTOCHEM CYTOCHEM, V44, P1363, DOI 10.1177/44.12.8985128
   PUTTING BJ, 1994, EXP EYE RES, V58, P31, DOI 10.1006/exer.1994.1192
   Rabin DM, 2013, AGING-US, V5, P51
   Rivera-Figueroa AM, 2004, J CHEM EDUC, V81, P242, DOI 10.1021/ed081p242
   Roberto A, 1996, PHARMACOL TOXICOL, V79, P92, DOI 10.1111/j.1600-0773.1996.tb00248.x
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Schirmer K, 1998, TOXICOLOGY, V127, P143, DOI 10.1016/S0300-483X(98)00031-6
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Sharma A, 2008, INVEST OPHTH VIS SCI, V49, P5111, DOI 10.1167/iovs.08-2060
   Soeur J, 2017, J DERMATOL SCI, V86, P162, DOI 10.1016/j.jdermsci.2017.01.007
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   URANO S, 1990, J NUTR SCI VITAMINOL, V36, P513, DOI 10.3177/jnsv.36.513
   Vu AT, 2015, CHEM RES TOXICOL, V28, P1616, DOI 10.1021/acs.chemrestox.5b00190
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0
   Wang SG, 2007, ENVIRON TOXICOL, V22, P318, DOI 10.1002/tox.20241
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001
NR 58
TC 8
Z9 10
U1 0
U2 13
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5761
EI 1432-0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD FEB
PY 2019
VL 93
IS 2
BP 453
EP 465
DI 10.1007/s00204-018-2344-3
PG 13
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA HK3QV
UT WOS:000457833300014
PM 30426163
DA 2022-11-30
ER

PT J
AU Chen, L
   Liu, M
   Luan, Y
   Liu, YF
   Zhang, ZC
   Ma, B
   Liu, X
   Liu, Y
AF Chen, Li
   Liu, Ming
   Luan, Yan
   Liu, Yingfei
   Zhang, Zhichao
   Ma, Bo
   Liu, Xuan
   Liu, Yong
TI BMP-6 protects retinal pigment epithelial cells from oxidative
   stress-induced injury by inhibiting the MAPK signaling pathways
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE neovascular age-related macular degeneration; bone morphogenetic protein
   6; oxidative stress; retinal pigment epithelial cells; apoptosis
ID NEURAL STEM-CELLS; MACULAR DEGENERATION; INDUCED APOPTOSIS; IRON
   HOMEOSTASIS; MOUSE MODEL; EXPRESSION; ACTIVATION; KINASE;
   IDENTIFICATION; JNK
AB Worldwide, neovascular age-related macular degeneration (nAMD) is one of the most common causes of blindness in the elderly. In particular, degeneration of retinal pigment epithelial (RPE) cells represents the main pathological process in the development of nAMD, and oxidative stress serves a major role. The present study aimed to investigate the association between bone morphogenetic protein 6 (BMP-6) and nAMD. BMP-6 concentration was significantly reduced in patients with wet nAMD compared with in the control group. Furthermore, the present study investigated the protective effects of BMP-6 on RPE cells following oxidative stress-induced injury. Cell Counting Kit-8 assay and terminal deoxynucleotidyl transferase dUTP nick-end labeling staining demonstrated that BMP-6 increased RPE cell viability, which was decreased following treatment with hydrogen peroxide (H2O2), and reduced H2O2-induced apoptosis. In addition, western blotting revealed that BMP-6 reversed the decrease in pro-caspase-3 levels and the dysregulation of the B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X protein (Bax) balance caused by H2O2. In addition, alterations in c-Jun N-terminal protein kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) expression were examined, and pretreatment with BMP-6 was demonstrated to reduce H2O2-induced activation of JNK and p38 MAPK. Conversely, the effects of BMP-6 were attenuated by its inhibitor noggin. In conclusion, the present study demonstrated that BMP-6 may protect RPE cells from oxidative stress injury to a certain extent, which may be associated with alterations in the MAPK signaling pathway. However, the specific mechanism of action underlying this effect requires further investigation. Overall, the present study laid a foundation for exploring novel nAMD treatment methods.
C1 [Chen, Li; Ma, Bo; Liu, Xuan] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Ophthalmol, Xian 710061, Shaanxi, Peoples R China.
   [Chen, Li; Luan, Yan; Liu, Yingfei; Zhang, Zhichao; Liu, Yong] Xi An Jiao Tong Univ, Hlth Sci Ctr, Inst Neurobiol, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
   [Liu, Ming] First Hosp Xian, Dept Ophthalmol, Xian 710002, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University
RP Liu, Y (通讯作者)，Xi An Jiao Tong Univ, Hlth Sci Ctr, Inst Neurobiol, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
EM liuy5599@163.com
FU Science and Technology Development Project of Shaanxi Province
   [2012K16-11-01, 2016SF-257]; China postdoctoral science foundation
   [2017M623152]
FX The present study was supported by grants from the Science and
   Technology Development Project of Shaanxi Province (grant nos.
   2012K16-11-01 and 2016SF-257) and the China postdoctoral science
   foundation (grant no. 2017M623152).
CR Abell AN, 2007, J BIOL CHEM, V282, P30476, DOI 10.1074/jbc.M705783200
   Andriopoulos B, 2009, NAT GENET, V41, P482, DOI 10.1038/ng.335
   Arjunan P, 2016, INVEST OPHTH VIS SCI, V57, P1612, DOI 10.1167/iovs.15-17437
   Bandyopadhyay A, 2013, BIOCHEM PHARMACOL, V85, P857, DOI 10.1016/j.bcp.2013.01.004
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bokara KK, 2011, STEM CELLS DEV, V20, P527, DOI 10.1089/scd.2010.0312
   Canali S, 2017, BLOOD, V129, P405, DOI 10.1182/blood-2016-06-721571
   Cia D, 2014, CURR EYE RES, V39, P944, DOI 10.3109/02713683.2014.885532
   Feligioni M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028185
   Hadziahmetovic M, 2011, AM J PATHOL, V179, P335, DOI 10.1016/j.ajpath.2011.03.033
   Haudek VJ, 2008, J PROTEOME RES, V7, P5138, DOI 10.1021/pr800438f
   Haynes T, 2007, P NATL ACAD SCI USA, V104, P20380, DOI 10.1073/pnas.0708202104
   Hoshyar R, 2013, DNA CELL BIOL, V32, P50, DOI 10.1089/dna.2012.1866
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Ki YW, 2013, TOXICOL LETT, V218, P235, DOI 10.1016/j.toxlet.2013.02.003
   Kim JH, 2009, J MICROBIOL BIOTECHN, V19, P1355, DOI 10.4014/jmb.0906.06003
   Klettner Alexa, 2015, Med Monatsschr Pharm, V38, P258
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775
   Meynard D, 2009, NAT GENET, V41, P478, DOI 10.1038/ng.320
   Naderi J, 2003, APOPTOSIS, V8, P91, DOI 10.1023/A:1021657220843
   Paeng SH, 2015, INT J MOL MED, V35, P1419, DOI 10.3892/ijmm.2015.2116
   Piubelli C, 2017, AM J HEMATOL, V92, P562, DOI 10.1002/ajh.24730
   Rosen RB, 2012, MOL VIS, V18, P1640
   Savory J, 1999, NEUROTOXICOLOGY, V20, P805
   Sekine Y, 2006, CURR MOL MED, V6, P87, DOI 10.2174/156652406775574541
   Shepherd TG, 2008, GENE, V414, P95, DOI 10.1016/j.gene.2008.02.015
   Snigdha S, 2012, NEUROSCI BULL, V28, P14, DOI 10.1007/s12264-012-1057-5
   Song KN, 2010, J BIOL CHEM, V285, P12169, DOI 10.1074/jbc.M109.087197
   Sun GX, 2013, NEUROSCI LETT, V534, P205, DOI 10.1016/j.neulet.2012.12.019
   Tamm C, 2008, APOPTOSIS, V13, P354, DOI 10.1007/s10495-007-0172-7
   Tawfik A, 2014, INVEST OPHTH VIS SCI, V55, P3616, DOI 10.1167/iovs.13-13677
   Tu G, 2016, MOL MED REP, V13, P2320, DOI 10.3892/mmr.2016.4797
   Wang CH, 2017, MOL MED REP, V16, P922, DOI 10.3892/mmr.2017.6631
   Wang ZY, 2009, FREE RADICAL BIO MED, V46, P1032, DOI 10.1016/j.freeradbiomed.2008.11.027
   Yan JD, 2009, FREE RADICAL BIO MED, V46, P1275, DOI 10.1016/j.freeradbiomed.2009.02.007
   Yuen HF, 2012, CANCER SCI, V103, P1145, DOI 10.1111/j.1349-7006.2012.02252.x
   Zhang Y, 2016, VISUAL NEUROSCI, V33, DOI 10.1017/S0952523816000122
   Zhao LL, 2014, AM J PATHOL, V184, P2862, DOI 10.1016/j.ajpath.2014.07.008
   Zhu YJ, 2017, INT J MOL MED, V40, P281, DOI 10.3892/ijmm.2017.3022
NR 40
TC 12
Z9 12
U1 0
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD AUG
PY 2018
VL 42
IS 2
BP 1096
EP 1105
DI 10.3892/ijmm.2018.3675
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GP1MX
UT WOS:000440581300040
PM 29767257
OA Bronze
DA 2022-11-30
ER

PT J
AU Bennis, A
   ten Brink, JB
   Moerland, PD
   Heine, VM
   Bergen, AA
AF Bennis, Anna
   ten Brink, Jacoline B.
   Moerland, Perry D.
   Heine, Vivi M.
   Bergen, Arthur A.
TI Comparative gene expression study and pathway analysis of the human
   iris- and the retinal pigment epithelium
SO PLOS ONE
LA English
DT Article
ID ROD OUTER SEGMENTS; STEM-CELLS; MACULAR DEGENERATION;
   FUNCTIONAL-NEURONS; OXIDATIVE STRESS; MOUSE; PHAGOCYTOSIS;
   TRANSPLANTATION; FIBROBLASTS; ACTIVATION
AB Background The retinal pigment epithelium (RPE) is a neural monolayer lining the back of the eye. Degeneration of the RPE leads to severe vision loss in, so far incurable, diseases such as age-related macular degeneration and some forms of retinitis pigmentosa. A promising future replacement therapy may be autologous iris epithelial cell transdifferentiation into RPE in vitro and, subsequently, transplantation. In this study we compared the gene expression profiles of the iris epithelium (IE) and the RPE.
   Methods We collected both primary RPE- and IE cells from 5 freshly frozen human donor eyes, using respectively laser dissection microscopy and excision. We performed whole-genome expression profiling using 44k Agilent human microarrays. We investigated the gene expression profiles on both gene and functional network level, using R and the knowledge database Ingenuity.
   Results The major molecular pathways related to the RPE and IE were quite similar and yielded basic neuro-epithelial cell functions. Nonetheless, we also found major specific differences: For example, genes and molecular pathways, related to the visual cycle and retinol biosynthesis are significantly higher expressed in the RPE than in the IE. Interestingly, Wnt and aryl hydrocarbon receptor (AhR-) signaling pathways are much higher expressed in the IE than in the RPE, suggesting, respectively, a possible pluripotent and high detoxification state of the IE.
   Conclusions This study provides a valuation of the similarities and differences between the expression profiles of the RPE and IE. Our data combined with that of the literature, represent a most comprehensive perspective on transcriptional variation, which may support future research in the development of therapeutic transplantation of IE.
C1 [Bennis, Anna; ten Brink, Jacoline B.; Bergen, Arthur A.] Acad Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.
   [Bennis, Anna; Bergen, Arthur A.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci NIN KNAW, Amsterdam, Netherlands.
   [Moerland, Perry D.] Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Bioinformat Lab, Amsterdam, Netherlands.
   [Heine, Vivi M.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Child Neurol, Neuroscience Campus Amsterdam, Amsterdam, Netherlands.
   [Heine, Vivi M.] Vrije Univ Amsterdam, Ctr Neurogen & Cognit Res, Dept Complex Trait Genet, Neuroscience Campus Amsterdam, Amsterdam, Netherlands.
   [Bergen, Arthur A.] Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; Royal
   Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical
   Center Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit
   Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam
RP Bergen, AA (通讯作者)，Acad Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.; Bergen, AA (通讯作者)，Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci NIN KNAW, Amsterdam, Netherlands.; Bergen, AA (通讯作者)，Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
EM aabergen@amc.uva.nl
RI Heine, Vivi M/F-1741-2011; Moerland, Perry/AAG-1425-2020
OI Heine, Vivi M/0000-0003-4416-3875; Moerland, Perry/0000-0002-2357-3659;
   Bergen, Arthur/0000-0002-6333-9576
FU General Dutch Foundation Preventing Blindness; foundation
   Blinden-Penning; National Foundation for Blindness and Low Vision
   (LSBS); National Foundation of Macular Degeneration (MD); Netherlands
   Eye Foundation (Oogvereniging); Gelderse Foundation for the Blind;
   Retina Netherlands Foundation; Foundation Winckel-Sweep; Rotterdam
   Foundation for the Blind (RvB); Hague Foundation Care for the Blind
FX This study was supported by grants from the General Dutch Foundation
   Preventing Blindness, the foundation Blinden-Penning, the National
   Foundation for Blindness and Low Vision (LSBS); The National Foundation
   of Macular Degeneration (MD); The Netherlands Eye Foundation
   (Oogvereniging); The Gelderse Foundation for the Blind; Retina
   Netherlands Foundation; The Foundation Winckel-Sweep; The Rotterdam
   Foundation for the Blind (RvB); and The Hague Foundation Care for the
   Blind (all coordinated through the UitZicht platform, project 2011-6,
   http://www.uitzicht.nl/). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abe T, 2000, CURR EYE RES, V20, P268
   Abe T, 1999, CELL TRANSPLANT, V8, P501, DOI 10.1177/096368979900800505
   Abe T, 2007, PROG RETIN EYE RES, V26, P302, DOI 10.1016/j.preteyeres.2007.01.003
   [Anonymous], 2013, CELL REP, V4, P271
   Arnhold S, 2004, EXP NEUROL, V187, P410, DOI 10.1016/j.expneurol.2004.02.015
   Asami M, 2007, DEV BIOL, V304, P433, DOI 10.1016/j.ydbio.2006.12.047
   Bazan NG, 2006, ADV EXP MED BIOL, V572, P531
   Bennis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141597
   Booij Judith C, 2010, PLoS One, V5, pe9341, DOI 10.1371/journal.pone.0009341
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   Cai H, 2006, ARCH OPHTHALMOL-CHIC, V124, P1276, DOI 10.1001/archopht.124.9.1276
   Caiazzo M, 2011, NATURE, V476, P224, DOI 10.1038/nature10284
   Choudhary M, 2015, J PATHOL, V235, P101, DOI 10.1002/path.4433
   Dhamodaran K, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt445
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Finnemann SC, 2006, ADV EXP MED BIOL, V572, P499
   Guo ZY, 2014, CELL STEM CELL, V14, P188, DOI 10.1016/j.stem.2013.12.001
   Hagglund AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081158
   Heinrich C, 2015, NAT CELL BIOL, V17, P204, DOI 10.1038/ncb3108
   HU DN, 1992, INVEST OPHTH VIS SCI, V33, P2443
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Janssen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040168
   Janssen SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083345
   Jasty S, 2012, STEM CELL REV REP, V8, P1163, DOI 10.1007/s12015-012-9394-3
   Kim SY, 2014, INVEST OPHTH VIS SCI, V55, P6031, DOI 10.1167/iovs.14-15091
   Kuhl SJ, 2013, BBA-GEN SUBJECTS, V1830, P2297, DOI 10.1016/j.bbagen.2012.08.010
   Lanza R., 2013, ESSENTIALS STEM CELL
   Law AL, 2009, MOL BIOL CELL, V20, P3896, DOI 10.1091/mbc.E08-12-1204
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   Marson A, 2008, CELL STEM CELL, V3, P132, DOI 10.1016/j.stem.2008.06.019
   Michalopoulos GK, 2007, J CELL PHYSIOL, V213, P286, DOI 10.1002/jcp.21172
   Miki T, 2011, STEM CELL REV REP, V7, P836, DOI 10.1007/s12015-011-9275-1
   Philp NJ, 2001, AM J PHYSIOL-CELL PH, V280, pC1319, DOI 10.1152/ajpcell.2001.280.5.C1319
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P48, DOI 10.1007/BF01007837
   Ross J, 2014, CELL REP, V9, P1770, DOI 10.1016/j.celrep.2014.10.049
   RUIZ A, 1995, GENE, V155, P179, DOI 10.1016/0378-1119(94)00812-7
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Seko Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035611
   Shadrach KG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067983
   Sheridan CM, 2009, EYE, V23, P1910, DOI 10.1038/eye.2008.420
   Simo R, 2010, BIOMED RES INT BIOME, V2010
   Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006
   Smyth, 2004, STAT APPL GENET MOL, V3, P1, DOI DOI 10.2202/1544-6115.1027
   Song MJ, 2015, BRAIN RES
   Stamer WD, 2003, INVEST OPHTH VIS SCI, V44, P2803, DOI 10.1167/iovs.03-0001
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338
   Sun GW, 2006, DEV BIOL, V289, P243, DOI 10.1016/j.ydbio.2005.10.035
   Thompson DA, 2003, PROG RETIN EYE RES, V22, P683, DOI 10.1016/S1350-9462(03)00051-X
   Thumann G, 2004, OPHTHALMOLOGE, V101, P882, DOI 10.1007/s00347-004-1084-3
   Thumann G, 2010, GENE THER, V17, P181, DOI 10.1038/gt.2009.124
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   Thumann G, 2001, SURV OPHTHALMOL, V45, P345, DOI 10.1016/S0039-6257(00)00195-8
   van Soest SS, 2007, MOL VIS, V13, P1608
   vanMeurs JC, 2016, RETINAL PIGMENT EPIT
   Vierbuchen T, 2010, NATURE, V463, P1035, DOI 10.1038/nature08797
   Westenskow P, 2009, DEVELOPMENT, V136, P2505, DOI 10.1242/dev.032136
   Wiley LA, 2016, SCI REP-UK, V6, DOI 10.1038/srep30742
   Yoo AS, 2011, NATURE, V476, P228, DOI 10.1038/nature10323
   Zhang PL, 2014, J BIOL CHEM, V289, P9221, DOI 10.1074/jbc.M113.542845
NR 69
TC 5
Z9 7
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 21
PY 2017
VL 12
IS 8
AR e0182983
DI 10.1371/journal.pone.0182983
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FE2TT
UT WOS:000408069300011
PM 28827822
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Jensen, H
   Tubaek, G
AF Jensen, Hanne
   Tubaek, Gitte
TI Elderly people need an eye examination before entering nursing homes
SO DANISH MEDICAL JOURNAL
LA English
DT Article
ID BLUE MOUNTAINS EYE; VISUAL IMPAIRMENT; VISION IMPAIRMENT; OLDER
   AMERICANS; PREVALENCE; RESIDENTS; HEARING; ADULTS; HEALTH; FALLS
AB Introduction: It is well documented that eye diseases develop with ageing and thus more elderly people have a visual handicap. It is important that the elderly are examined well, that they have the correct prescription and optimal aids. This is especially applicable to those residing in nursing homes.
   Method: In this study, an eye examination was offered to all residents in 11 nursing homes. The examination was conducted by an optometrist who brought her own equipment. A medical history was recorded, an eye examination conducted, and the ophthalmologist assessed the records and evaluated the optical coherence tomography images. Personnel were given a questionnaire concerning their assessment of the residents' visual abilities.
   Results: Among 502 potential residents, 371 were examined, whereas 131 could not participate. A total of 22% were visually impaired, 13% socially blind and 13% were unable to cooperate. A total of 32% were well-described having correct optics, 15% were recommended glasses and 36% were referred to an ophthalmologist for further diagnostics or check-up. The most frequent cause of impaired vision was cataract and age-related macular degeneration. For many of the residents, no diagnosis was registered, and the staff had no knowledge of the cause of their resident's vision impairment. Furthermore, in one of every four cases, staff were unaware that the resident's vision was impaired.
   Conclusion: It is recommended that everyone who is referred to a retirement home receives an eye examination and that nursing home staff are given relevant knowledge that will allow them to assist the residents in a proper way due to vision-related issues.
C1 [Jensen, Hanne] Rigshosp, Kennedy Ctr, Eye Clin, Glostrup, Denmark.
   [Tubaek, Gitte] GenSyn Opt, Vejle, Denmark.
C3 Rigshospitalet
RP Jensen, H (通讯作者)，Rigshosp, Kennedy Ctr, Eye Clin, Glostrup, Denmark.
EM h.jensen@dadlnet.dk
FU Danish Association for the Blind; Dag Lenards Fond
FX The study was funded by the Danish Association for the Blind and by Dag
   Lenards Fond.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823
   Goldstein JE, 2015, JAMA OPHTHALMOL, V133, P762, DOI 10.1001/jamaophthalmol.2015.0693
   Gopinath B, 2016, AGE AGEING, V45, P409, DOI 10.1093/ageing/afw022
   Gupta P, 2016, INVEST OPHTH VIS SCI, V57, P2905, DOI 10.1167/iovs.15-18469
   Heine C, 2002, DISABIL REHABIL, V24, P763, DOI 10.1080/09638280210129162
   Holton H., 2009, OPTIKEREN, V6, P10
   Hong T, 2014, INVEST OPHTH VIS SCI, V55, P7589, DOI 10.1167/iovs.14-14262
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Krarup J C, 1980, Ugeskr Laeger, V142, P1897
   Labreche T, 2011, CAN GERIATR J, V14, P8
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   Thederan L, 2016, DTSCH ARZTEBL INT, V113, P323, DOI 10.3238/arztebl.2016.0323
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
NR 15
TC 2
Z9 2
U1 0
U2 2
PU DANISH MEDICAL ASSOC
PI COPENHAGEN
PA TRONDHJEMSGADE 9, DK-2100 COPENHAGEN, DENMARK
SN 2245-1919
J9 DAN MED J
JI Dan. Med. J.
PD FEB
PY 2017
VL 64
IS 2
AR A5325
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA EP0AC
UT WOS:000397048200003
PM 28157061
DA 2022-11-30
ER

PT J
AU Nishiguchi, KM
   Yokoyama, Y
   Fujii, Y
   Fujita, K
   Tomiyama, Y
   Kawasaki, R
   Furukawa, T
   Ono, F
   Shimozawa, N
   Togo, M
   Suzuki, M
   Nakazawa, T
AF Nishiguchi, Koji M.
   Yokoyama, Yu
   Fujii, Yusuke
   Fujita, Kosuke
   Tomiyama, Yusuke
   Kawasaki, Ryo
   Furukawa, Toshinori
   Ono, Fumiko
   Shimozawa, Nobuhiro
   Togo, Mutsumi
   Suzuki, Michihiro
   Nakazawa, Toru
TI Analysis of Macular Drusen and Blood Test Results in 945 Macaca
   fascicularis
SO PLoS One
LA English
DT Article
ID AGE-RELATED MACULOPATHY; FACTOR-H POLYMORPHISM; RHESUS-MONKEYS; BRUCHS
   MEMBRANE; HIGH-RISK; DEGENERATION; VARIANT; GENES; ASSOCIATION;
   PREVALENCE
AB Age-dependent formation of macular drusen caused by the focal accumulation of extracellular deposits beneath the retinal pigment epithelium precede the development of age related macular degeneration (AMD), one of the leading causes of blindness worldwide. It is established that inflammation contributes to the pathogenesis of drusen and AMD. However, development of a preemptive therapeutic strategy targeting macular drusen and AMD has been impeded by the lack of relevant animal models because most laboratory animals lack macula, an anatomic feature present only in humans and a subset of monkeys. Reportedly, macular drusen and macular degeneration develop in monkeys in an age-dependent manner. In this study, we analyzed blood test results from 945 Macaca fascicularis, 317 with and 628 without drusen. First, a trend test for drusen frequency (the Cochran-Armitage test) was applied to the quartile data for each parameter. We selected variables with an increasing or decreasing trend with higher quartiles at P < 0.05, to which multivariate logistic regression analysis was applied. This revealed a positive association of age (odds ratio [OR]: 1.10 per year, 95% confidence interval [CI]: 1.07-1.12) and white blood cell count (OR: 1.01 per 1 x 10(3)/mu l, 95% CI: 1.00-1.01) with drusen. When the monkeys were divided by age, the association between drusen and white blood cell count was only evident in younger monkeys (OR: 1.01 per 1 x 10(3)/mu l, 95% CI: 1.00-1.02). In conclusion, age and white blood cell count may be associated with drusen development in M. fascicularis. Systemic inflammation may contribute to drusen formation in monkeys.
C1 [Nishiguchi, Koji M.; Nakazawa, Toru] Tohoku Univ, Dept Adv Ophthalm Med, Grad Sch Med, Sendai, Miyagi, Japan.
   [Yokoyama, Yu; Fujii, Yusuke; Tomiyama, Yusuke; Nakazawa, Toru] Tohoku Univ, Dept Ophthalmol, Grad Sch Med, Sendai, Miyagi, Japan.
   [Fujita, Kosuke; Nakazawa, Toru] Tohoku Univ, Dept Retinal Dis Control, Grad Sch Med, Sendai, Miyagi, Japan.
   [Kawasaki, Ryo] Yamagata Univ, Dept Publ Hlth, Grad Sch Med Sci, Yamagata, Japan.
   [Furukawa, Toshinori] Kurashiki Univ Sci & Arts, Dept Comparat Anim Sci, Kurashiki, Okayama, Japan.
   [Ono, Fumiko] Chiba Inst Sci, Fac Risk Management, Choshi, Japan.
   [Ono, Fumiko] Chiba Inst Sci, Fac Crisis Management, Choshi, Japan.
   [Shimozawa, Nobuhiro] Natl Inst Biomed Innovat Hlth & Nutr, Tsukuba Primate Res Ctr, Tsukuba, Ibaraki, Japan.
   [Togo, Mutsumi; Suzuki, Michihiro] Corp Prod & Res Lab Primates, Tsukuba, Ibaraki, Japan.
C3 Tohoku University; Tohoku University; Tohoku University; Yamagata
   University
RP Nishiguchi, KM (通讯作者)，Tohoku Univ, Dept Adv Ophthalm Med, Grad Sch Med, Sendai, Miyagi, Japan.
EM nishiguchi@oph.med.tohoku.ac.jp
RI Kawasaki, Ryo/H-9716-2019; Kawasaki, Ryo/B-7266-2009
OI Kawasaki, Ryo/0000-0002-7492-6303
FU Japan Society for the Promotion of Science KAKENHI [TN 26293372, KMN
   16K11315]; SENJU Pharmaceutical Co., Ltd
FX This study was supported by Japan Society for the Promotion of Science
   KAKENHI Grants-in-Aid for Scientific Research B (TN 26293372) and Japan
   Society for the Promotion of Science KAKENHI Grants-in-Aid for
   Scientific Research Research C (KMN 16K11315). This study was also
   supported by SENJU Pharmaceutical Co., Ltd (KMN and TN). All the funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.; We thank Dr. Airi Takagi at
   the Clinical Research, Innovation and Education Center, Tohoku
   University Hospital for the constructive discussion and kindly providing
   advice for our statistical analysis. The manuscript was edited by a
   professional English editing service (Enago, Tokyo, Japan;
   www.enago.jp).
CR BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELMOFTY AAM, 1980, EXP EYE RES, V31, P147, DOI 10.1016/0014-4835(80)90075-5
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Gouras P, 2010, GRAEF ARCH CLIN EXP, V248, P973, DOI 10.1007/s00417-010-1325-x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kobayashi H, 2014, EXP ANIM TOKYO, V63, P305, DOI 10.1538/expanim.63.305
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011
   Nicolas MG, 1996, EXP EYE RES, V62, P211, DOI 10.1006/exer.1996.0026
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shankar A, 2007, AM J EPIDEMIOL, V165, P375, DOI 10.1093/aje/kwk022
   Suzuki MT, 2003, PRIMATES, V44, P291, DOI 10.1007/s10329-002-0016-6
   Tsuchida J, 2008, J AM ASSOC LAB ANIM, V47, P29
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 38
TC 3
Z9 3
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2016
VL 11
IS 10
AR e0164899
DI 10.1371/journal.pone.0164899
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ED7AX
UT WOS:000389009200027
PM 27776188
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Xiang, W
   Zhuang, WJ
   Chi, H
   Sheng, XL
   Zhang, W
   Xue, ZQ
   Pan, B
   Liu, Y
AF Xiang, Wei
   Zhuang, Wenjuan
   Chi, Hao
   Sheng, Xunlun
   Zhang, Wen
   Xue, Zhongqi
   Pan, Bo
   Liu, Yang
TI Evaluating VEGFR1 genetic polymorphisms as a predisposition to AMD in a
   cohort from northern China
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; genetic polymorphisms; VEGFR1 gene
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; EYE; ANGIOGENESIS;
   RANIBIZUMAB; POPULATION; PREVALENCE; EXPRESSION; BLINDNESS; RECEPTOR
AB Objective: The association among genetic variants in VEGFR1 and a predisposition to age-related macular degeneration (AMD) in a northern cohort from China was evaluated.Methods: A retrospective case-control correlation study was conducted on 432 cases and 906 gender-and ethnicity-matched controls. Whole DNA was isolated from peripheral blood samples after the individuals underwent detailed eye examinations. Eight single nucleotide polymorphisms (SNPs) in VEGFR1 genes were genotyped for all individuals using a MALDI-TOF technique. The distribution of genotypes was analyzed for Hardy-Weinberg equilibrium and the relationships among the genotype and allele frequencies with AMD were evaluated by age-adjusted logistic regression analysis. The measurement of linkage disequilibrium (LD) was carried out by Haploview 4.2. Bonferroni testing was employed to correct for multiple comparisons.Results: Among the SNPs genotyped, p values of six SNPs were less than 0.05 between AMD cases and unaffected controls. However, after Bonferroni correction, the genotype and allele distributions of only two SNPs, rs9554322 and rs9582036 differed significantly between the controls and AMD patients. Further, the rs9554322 CC genotype conferred strong susceptibility to AMD (OR = 6.057, 95% CI: 3.099-11.839). Rs9943922 was also found to be significantly associated with AMD in the distributions for the genotype and allele recessive model (p = 0.004). The specific haplotype CA of rs9582036 and rs9554320 was associated with AMD (p = 0.035), but the correlation did not remain after correction.Conclusions: The SNPs rs9554322, rs9582036 and rs9943922 were correlated with AMD. Gene variants in VEGFR1 were linked to a pronounced emerging risk for AMD in a population in northern China.
C1 [Xiang, Wei; Chi, Hao; Zhang, Wen; Xue, Zhongqi] Ningxia Med Univ, Dept Ophthalmol, Yinchuan, Peoples R China.
   [Zhuang, Wenjuan; Sheng, Xunlun; Pan, Bo; Liu, Yang] Peoples Hosp Ningxia Hui Autonomous Reg, Ningxia Eye Hosp, 936 Huang He East Rd, Yinchuan 750011, Peoples R China.
C3 Ningxia Medical University
RP Zhuang, WJ (通讯作者)，Peoples Hosp Ningxia Hui Autonomous Reg, Ningxia Eye Hosp, 936 Huang He East Rd, Yinchuan 750011, Peoples R China.
EM zh_wenj@163.com
FU National Natural Science Foundation of China (NSFC) [81460093]; External
   Scientific and Technological Cooperation Programs of NingXia Hui
   Autonomous Region [2014ZYH65]; National Basic Research Program of China
   (973 Program) [2011CB510200]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC, No. 81460093), the External Scientific and
   Technological Cooperation Programs of NingXia Hui Autonomous Region
   (2014ZYH65), and the National Basic Research Program of China (973
   Program; #2011CB510200).
CR Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cruz-Gonzalez F, 2014, GRAEF ARCH CLIN EXP, V252, P469, DOI 10.1007/s00417-014-2585-7
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Hampton BM, 2015, CLIN OPHTHALMOL, V9, P873, DOI 10.2147/OPTH.S84155
   Hiratsuka S, 2001, CANCER RES, V61, P1207
   Koh SP, 2014, BMC GENET, V15
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Lambrechts D, 2012, LANCET ONCOL, V13, P724, DOI 10.1016/S1470-2045(12)70231-0
   Liu ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059421
   Lu F, 2013, INVEST OPHTH VIS SCI, V54, P2911, DOI 10.1167/iovs.12-11381
   Luttun A, 2002, ANN NY ACAD SCI, V979, P80, DOI 10.1111/j.1749-6632.2002.tb04870.x
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Owen LA, 2014, INVEST OPHTH VIS SCI, V55, P3543, DOI 10.1167/iovs.14-14047
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   Zhao H, 2005, GENET RES, V86, P77, DOI 10.1017/S001667230500769X
NR 22
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2016
VL 37
IS 4
BP 388
EP 393
DI 10.3109/13816810.2015.1107597
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA EC0HQ
UT WOS:000387780700006
PM 26914796
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Silver, RE
   Kwong, M
   Rosner, B
AF Seddon, Johanna M.
   Silver, Rachel E.
   Kwong, Manlik
   Rosner, Bernard
TI Risk Prediction for Progression of Macular Degeneration: 10 Common and
   Rare Genetic Variants, Demographic, Environmental, and Macular
   Covariates
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; genetics; prediction; progression;
   risk modeling
ID BREAST-CANCER; MODELS; CFH; VALIDATION; C3
AB PURPOSE. To determine the association between genetic variants and transition to advanced age-related macular degeneration (AMD), and to develop a predictive model and online application to assist in clinical decision making.
   METHODS. Among 2951 subjects in the Age-Related Eye Disease Study, 834 progressed from no AMD, early AMD, or intermediate AMD to advanced disease. Survival analysis was used to assess which genetic, demographic, environmental, and macular covariates were independently associated with progression. Attributable risk, area under the curve statistics (AUCs), and reclassification odds ratios (ORs) were calculated. Split-sample validation was performed. An online risk calculator was developed and is available in the public domain at www.seddonamdriskscore.org.
   RESULTS. Ten genetic loci were independently associated with progression, including newly identified rare variant C3 K155Q (hazard ratio: 1.7, 95% confidence interval: 1.2-2.5, P = 0.002), three variants in CFH, and six variants in ARMS2/HTRA1, CFB, C3, C2, COL8A1, and RAD51B. Attributable risk calculations revealed that 80% of incident AMD is attributable to genetic factors, adjusting for demographic covariates and baseline macular phenotypes. In a model including 10 genetic loci, age, sex, education, body mass index, smoking, and baseline AMD status, the AUC for progression to advanced AMD over 10 years was 0.911. Split-sample validation showed a similar AUC (0.907). Reclassification analyses indicated that subjects were categorized into a more accurate risk category if genetic information was included (OR 3.2, P < 0.0001).
   CONCLUSIONS. Rare variant C3 K155Q was independently associated with AMD progression. The comprehensive model may be useful for identifying and monitoring high-risk patients, selecting appropriate therapies, and designing clinical trials.
C1 [Seddon, Johanna M.; Silver, Rachel E.] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
   [Kwong, Manlik] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA.
   [Rosner, Bernard] Harvard Univ, Sch Med, Channing Div Network Med, Boston, MA USA.
C3 Tufts Medical Center; Tufts University; Tufts University; Tufts Medical
   Center; Harvard University; Harvard Medical School
RP Seddon, JM (通讯作者)，Tufts Med Ctr, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
FU National Institutes of Health, Bethesda, Maryland, United States
   [RO1-EY11309, RO1-EY022445]; Massachusetts Lions Eye Research Fund,
   Inc., New Bedford, Massachusetts, United States; Research to Prevent
   Blindness, Inc., New York, New York, United States; Foundation Fighting
   Blindness, Columbia, Maryland, United States; American Macular
   Degeneration Foundation, Northampton, Massachusetts, United States;
   Age-Related Macular Degeneration Research Fund, Ophthalmic Epidemiology
   and Genetics Service, Tufts Medical Center, Tufts University School of
   Medicine, Boston, Massachusetts, United States; NATIONAL EYE INSTITUTE
   [R01EY011309, R01EY022445] Funding Source: NIH RePORTER
FX Supported by Grants RO1-EY11309 and RO1-EY022445 from the National
   Institutes of Health, Bethesda, Maryland, United States; the
   Massachusetts Lions Eye Research Fund, Inc., New Bedford, Massachusetts,
   United States; unrestricted grants from Research to Prevent Blindness,
   Inc., New York, New York, United States; Foundation Fighting Blindness,
   Columbia, Maryland, United States; the American Macular Degeneration
   Foundation, Northampton, Massachusetts, United States; and the
   Age-Related Macular Degeneration Research Fund, Ophthalmic Epidemiology
   and Genetics Service, Tufts Medical Center, Tufts University School of
   Medicine, Boston, Massachusetts, United States. The authors alone are
   responsible for the content and writing of the paper.
CR Age Related Eye Disease Study Research Group, 2011, ARCH OPHTHALMOL-CHIC, V119, P1417
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Arias Elizabeth, 2010, Natl Vital Stat Rep, V58, P1
   Centers for Disease Control and Prevention (CDC), 2009, NAT CTR HLTH STAT NC
   Cook NR, 2006, ANN INTERN MED, V145, P21, DOI 10.7326/0003-4819-145-1-200607040-00128
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879
   HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Rosner B, 2009, BIOMETRICS, V65, P188, DOI 10.1111/j.1541-0420.2008.01062.x
   Rosner B, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2110
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087047
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   SNEE RD, 1977, TECHNOMETRICS, V19, P415, DOI 10.2307/1267881
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 27
TC 67
Z9 70
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2015
VL 56
IS 4
BP 2192
EP 2202
DI 10.1167/iovs.14-15841
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ1NP
UT WOS:000355250700009
PM 25655794
OA Green Published
DA 2022-11-30
ER

PT J
AU Lu, B
   Lin, YH
   Tsai, YC
   Girman, S
   Adamus, G
   Jones, MK
   Shelley, B
   Svendsen, CN
   Wang, SM
AF Lu, Bin
   Lin, Yanhua
   Tsai, Yuchun
   Girman, Sergey
   Adamus, Grazyna
   Jones, Melissa K.
   Shelley, Brandon
   Svendsen, Clive N.
   Wang, Shaomei
TI A Subsequent Human Neural Progenitor Transplant into the Degenerate
   Retina Does Not Compromise Initial Graft Survival or Therapeutic
   Efficacy
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE retinal degeneration; visual function; human neural progenitor cells;
   transplantation; redosing; immune response
ID AMYOTROPHIC-LATERAL-SCLEROSIS; CENTRAL-NERVOUS-SYSTEM; EMBRYONIC
   STEM-CELLS; SUBRETINAL SPACE; RAT MODEL; MACULAR DEGENERATION;
   PARKINSONS-DISEASE; NEUROTROPHIC FACTOR; PIGMENT EPITHELIUM;
   IMMUNE-RESPONSE
AB Purpose: Stem and progenitor cell transplantation provides a promising clinical application for treating degenerative retinal diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Our previous studies have shown that a single subretinal injection of human cortical-derived neural progenitor cells (hNPC(ctx)) into cyclosporine-treated Royal College of Surgeons (RCS) rats preserved both photoreceptors and visual function. However, it is still unknown whether nonautologous progenitor cell readministration for sustained vision is efficacious and safe in terms of the initial graft initiating an immune response to a subsequent graft.
   Methods: A cell suspension containing 3x10(4) hNPC(ctx) into one eye of cyclosporinetreated RCS rats at postnatal day 21 (P21), followed by a second transplantation at P95 into the previously untreated fellow eye.
   Results: hNPC(ctx) delayed photoreceptor degeneration and preserved visual function, as measured by electroretinography (ERG), optokinetic response (OKR), and luminance threshold recordings (LTRs). Visual function and photoreceptors of the initially treated eye were still preserved 6 weeks after hNPC(ctx) were injected into the second eye. Antibodies against T-cell markers showed that CD3, CD4, and CD8 T cells were not detected at P90 and P140 in most cases. No detectable level of anti-nestin antibody was found in serum by enzyme-linked immunosorbent assay (ELISA).
   Conclusions: This xenograft study with cyclosporine-treated animals demonstrates that readministration of hNPC(ctx) into the fellow eye did not induce anti-graft immune responses or lower therapeutic efficacy of hNPC(ctx) in preserving vision. Thus, readministration of progenitor cells to sustain long-term efficacy may be an option for long-term therapies of retinal degeneration.
C1 [Lu, Bin; Lin, Yanhua; Tsai, Yuchun; Girman, Sergey; Jones, Melissa K.; Shelley, Brandon; Svendsen, Clive N.; Wang, Shaomei] Cedars Sinai Med Ctr, Board Governors Regenerat Med Inst, Los Angeles, CA 90048 USA.
   [Adamus, Grazyna] OHSU, Casey Eye Inst, Portland, OR USA.
C3 Cedars Sinai Medical Center; Oregon Health & Science University
RP Wang, SM (通讯作者)，Cedars Sinai Med Ctr, Board Governors Regenerat Med Inst, Los Angeles, CA 90048 USA.
EM shaomei.wang@cshs.org
FU NIH [R01EY020488]; Department of Defense [W81XWH-12-1-0617]; Foundation
   Fighting Blindness; Board of Governors Regenerative Medicine Institute
   at Cedars-Sinai Medical Center funding; NATIONAL EYE INSTITUTE
   [R01EY020488] Funding Source: NIH RePORTER
FX This work was supported by NIH (R01EY020488), Department of Defense
   (W81XWH-12-1-0617), Foundation Fighting Blindness, Board of Governors
   Regenerative Medicine Institute at Cedars-Sinai Medical Center funding.
CR Anosova NG, 2001, J CLIN INVEST, V108, P1175, DOI 10.1172/JCI12204
   Assadiasl S, 2014, IRAN J IMMUNOL, V11, P139, DOI IJIv11i3A1
   Behrstock S, 2006, GENE THER, V13, P379, DOI 10.1038/sj.gt.3302679
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boisgerault F, 2001, J IMMUNOL, V167, P1891, DOI 10.4049/jimmunol.167.4.1891
   Burrell BE, 2012, J IMMUNOL, V189, P4705, DOI 10.4049/jimmunol.1202027
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   Daiger SP, 2005, SCIENCE, V308, P362, DOI 10.1126/science.1111655
   Ebert AD, 2008, EXP NEUROL, V209, P213, DOI 10.1016/j.expneurol.2007.09.022
   Emborg ME, 2008, CELL TRANSPLANT, V17, P383
   Englund-Johansson U, 2010, EXP EYE RES, V90, P292, DOI 10.1016/j.exer.2009.11.005
   Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107
   Francis PJ, 2009, INVEST OPHTH VIS SCI, V50, P3425, DOI 10.1167/iovs.08-2908
   GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879
   Game DS, 2002, TRANSPL IMMUNOL, V10, P101, DOI 10.1016/S0966-3274(02)00055-2
   Gamm DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000338
   Ghosh F, 2000, OPHTHALMOLOGICA, V214, P54, DOI 10.1159/000027472
   Girman SV, 2005, VISUAL NEUROSCI, V22, P37, DOI 10.1017/S0952523805221041
   Glass JD, 2012, STEM CELLS, V30, P1144, DOI 10.1002/stem.1079
   Goldman S, 2005, NAT BIOTECHNOL, V23, P862, DOI 10.1038/nbt1119
   Gorantla VS, 2010, TRANSPLANT REV-ORLAN, V24, P147, DOI 10.1016/j.trre.2010.04.002
   Gould DS, 1999, IMMUNOL TODAY, V20, P77, DOI 10.1016/S0167-5699(98)01394-2
   Han XN, 2013, CELL STEM CELL, V12, P342, DOI 10.1016/j.stem.2012.12.015
   Hori J, 2003, STEM CELLS, V21, P405, DOI 10.1634/stemcells.21-4-405
   HUMPHRIES P, 1990, CLIN GENET, V38, P1
   JIANG LQ, 1993, INVEST OPHTH VIS SCI, V34, P3347
   Kim MK, 2011, CURR OPIN ORGAN TRAN, V16, P231, DOI 10.1097/MOT.0b013e328344870c
   Kim SU, 2009, J NEUROSCI RES, V87, P2183, DOI 10.1002/jnr.22054
   Kingsley CI, 2002, J IMMUNOL, V168, P1080, DOI 10.4049/jimmunol.168.3.1080
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Lescaudron L, 2012, CURR MED CHEM, V19, P6018
   McGill TJ, 2007, INVEST OPHTH VIS SCI, V48, P1906, DOI 10.1167/iovs.06-1117
   Nichols NL, 2013, AM J RESP CRIT CARE, V187, P535, DOI 10.1164/rccm.201206-1072OC
   Nussbaum J, 2007, FASEB J, V21, P1345, DOI 10.1096/fj.06-6769com
   Patel NK, 2005, ANN NEUROL, V57, P298, DOI 10.1002/ana.20374
   Petranyi GG, 2002, TRANSPL IMMUNOL, V10, P91, DOI 10.1016/S0966-3274(02)00054-0
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shelley BC, 2014, JOVE-J VIS EXP, V91, pe5511
   Stein-Streilein Joan, 2002, Int Rev Immunol, V21, P123, DOI 10.1080/08830180212066
   Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224
   Streilein JW, 2002, HUM IMMUNOL, V63, P435, DOI 10.1016/S0198-8859(02)00393-2
   Svendsen C, 2008, CELL STEM CELL, V2, P412, DOI 10.1016/j.stem.2008.04.010
   Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634
   Swijnenburg RJ, 2008, P NATL ACAD SCI USA, V105, P12991, DOI 10.1073/pnas.0805802105
   Tai YT, 2004, CURR OPIN PHARMACOL, V4, P98, DOI 10.1016/j.coph.2003.09.006
   Testa F, 2013, OPHTHALMOLOGY, V120, P1283, DOI 10.1016/j.ophtha.2012.11.048
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wenkel H, 1998, INVEST OPHTH VIS SCI, V39, P1823
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   Yang J, 2012, STEM CELLS INT, V2012
   Young MJ, 2000, MOL CELL NEUROSCI, V16, P197, DOI 10.1006/mcne.2000.0869
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
   Ziv Y, 2006, P NATL ACAD SCI USA, V103, P13174, DOI 10.1073/pnas.0603747103
NR 62
TC 11
Z9 10
U1 2
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2015
VL 4
IS 1
AR 7
DI 10.1167/tvst.4.1.7
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED0WE
UT WOS:000388562500007
PM 25694843
OA Green Published
DA 2022-11-30
ER

PT J
AU Lee, YM
   Kim, CS
   Sohn, E
   Jo, K
   Lim, HR
   Kim, SK
   Kim, JS
   Kim, J
AF Lee, Yun Mi
   Kim, Chan-Sik
   Sohn, Eunjin
   Jo, Kyuhyung
   Lim, Hye Ryeng
   Kim, Sun Ki
   Kim, Jin Sook
   Kim, Junghyun
TI Sipjeondaebo-Tang, a Traditional Herbal Formula, Inhibits Retinal
   Neovascularization in a Mouse Model of Oxygen-Induced Retinopathy
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE oxygen-induced retinopathy; platelet derived growth factor; retinal
   neovascularization; Sipjeondaebo-tang; vascular endothelial growth
   factor
ID ENDOTHELIAL GROWTH-FACTOR; JUZEN-TAIHO-TO; TARGETING ANGIOGENESIS;
   IN-VITRO; PDGF-B; MECHANISMS; CELLS; RATS; VEGF; PAEONIFLORIN
AB Retinal neovascularization is a common pathology in age-related macular degeneration, retinopathy of prematurity and proliferative diabetic retinopathy. Platelet derived growth factor (PDGF) is a vasoactive factor and has been implicated in proliferative retinopathies. Oxygen-induced retinopathy in the mouse is the standard experimental model of proliferative retinopathies. Sipjeondaebo-tang (SDT) is the most widely used traditional herbal formula in East Asia, also known as Shi-Quan-Da-Bu-Tang in Chinese and Juzen-taiho-to in Japanese. SDT has been known to exert anti-angiogenic activities in several tumor models, but the role of SDT in proliferative retinopathies remains unclear. Thus, the object of the present study is to examine the mechanism of action and efficacy of SDT on retinal neovascularization in oxygen-induced ischemic retinopathy (OIR) mice. Neonatal mice at postnatal day 7 (P7) were exposed to 75% concentration of oxygen for 5 days (P7-P12), and then returned to room air from P12 to P17 to induce retinal neovascularization. SDT were administered once per day for 5 consecutive days (P12-P16) by intraperitoneal injection. Retinal neovascularization was measured at P17. We used a protein array to evaluate the expression levels of angiogenic factors. Inhibitory activity of SDT on PDGF-BB/PDGFR beta interaction was evaluated in vitro. Retinal neovascularization in the OIR mice was significantly decreased by SDT. SDT decreased the expression levels of PDGF-BB protein and VEGF mRNA. Moreover, SOT dose-dependently inhibited PDGF-BB/PDGFR beta interaction (IC50 = 388.82 +/- 7.31 mu g/ml). In conclusion, SDT is a potent inhibitor of retinal neovascularization through inhibiting the pro-angiogenic effect of PDGF-BB.
C1 [Lee, Yun Mi; Kim, Chan-Sik; Sohn, Eunjin; Jo, Kyuhyung; Lim, Hye Ryeng; Kim, Sun Ki; Kim, Jin Sook; Kim, Junghyun] Korea Inst Oriental Med, Korean Med Based Herbal Drug Dev Grp, Herbal Med Res Div, Taejon 305811, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Kim, J (通讯作者)，Korea Inst Oriental Med, Korean Med Based Herbal Drug Dev Grp, Herbal Med Res Div, 1672 Yuseongdaero, Taejon 305811, South Korea.
EM dvmhyun@kiom.re.kr
FU Korea Institute of Oriental Medicine [K14302]
FX This work was supported by a grant [K14302] from the Korea Institute of
   Oriental Medicine.
CR Aiello LP, 1997, OPHTHALMIC RES, V29, P354, DOI 10.1159/000268033
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Alvarez RH, 2006, MAYO CLIN PROC, V81, P1241, DOI 10.4065/81.9.1241
   Appelmann I, 2010, RECENT RESULTS CANC, V180, P51, DOI 10.1007/978-3-540-78281-0_5
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Butchbach MER, 2007, J NEUROSCI METH, V161, P285, DOI 10.1016/j.jneumeth.2006.11.002
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cao LM, 2010, INVEST OPHTH VIS SCI, V51, P6658, DOI 10.1167/iovs.10-5524
   Castellon R, 2002, EXP EYE RES, V74, P523, DOI 10.1006/exer.2001.1161
   Giddabasappa A, 2012, INVEST OPHTH VIS SCI, V53, P5066, DOI 10.1167/iovs.12-9627
   Gupta SK, 2013, J OCUL PHARMACOL TH, V29, P419, DOI 10.1089/jop.2012.0089
   HARANAKA K, 1985, CANCER IMMUNOL IMMUN, V20, P1
   Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8
   Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283
   Hsiu SL, 2003, PLANTA MED, V69, P1113, DOI 10.1055/s-2003-45192
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Ji Bo, 2006, Zhong Xi Yi Jie He Xue Bao, V4, P30
   Kamiyama H, 2005, BIOL PHARM BULL, V28, P2111, DOI 10.1248/bpb.28.2111
   Kim KJ, 2013, PHYTOTHER RES, V27, P841, DOI 10.1002/ptr.4800
   Kiyohara H, 2004, EVID-BASED COMPL ALT, V1, P83, DOI 10.1093/ecam/neh004
   Kociok N, 2006, INVEST OPHTH VIS SCI, V47, P5057, DOI 10.1167/iovs.06-0407
   Kogure Toshiaki, 2005, Mod Rheumatol, V15, P445
   Lee HJ, 2006, CARCINOGENESIS, V27, P2455, DOI 10.1093/carcin/bgl104
   Lee JJ, 2012, MOL VIS, V18, P838
   Lee Y, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/245271
   McClain RM, 2001, TOXICOL PATHOL, V29, P128, DOI 10.1080/019262301753178537
   Miki K, 2009, OPHTHALMOLOGY, V116, P1748, DOI 10.1016/j.ophtha.2009.05.020
   Raines EW, 2004, CYTOKINE GROWTH F R, V15, P237, DOI 10.1016/j.cytogfr.2004.03.004
   ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207
   Ruma IMW, 2014, INT J ONCOL, V45, P209, DOI 10.3892/ijo.2014.2397
   Shin IS, 2011, REGUL TOXICOL PHARM, V59, P375, DOI 10.1016/j.yrtph.2010.09.018
   Tagami K, 2004, BIOL PHARM BULL, V27, P156, DOI 10.1248/bpb.27.156
   Tanaka J, 2012, PHYTOTHER RES, V26, P214, DOI 10.1002/ptr.3533
   VASSBOTN FS, 1994, J BIOL CHEM, V269, P13874
   Xie WK, 2011, MOL VIS, V17, P3512
   Yance DR, 2006, INTEGR CANCER THER, V5, P9, DOI 10.1177/1534735405285562
   Zehetner C, 2014, INVEST OPHTH VIS SCI, V55, P337, DOI 10.1167/iovs.13-12978
   Zheng YQ, 2007, INFLAMM RES, V56, P182, DOI 10.1007/s00011-006-6002-5
NR 38
TC 6
Z9 7
U1 0
U2 8
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD NOV
PY 2014
VL 234
IS 3
BP 229
EP 236
DI 10.1620/tjem.234.229
PG 8
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA AT8RL
UT WOS:000345199700008
PM 25365937
OA Bronze
DA 2022-11-30
ER

PT J
AU Plank, T
   Rosengarth, K
   Schmalhofer, C
   Goldhacker, M
   Brandl-Ruhle, S
   Greenlee, MW
AF Plank, Tina
   Rosengarth, Katharina
   Schmalhofer, Carolin
   Goldhacker, Markus
   Brandl-Ruehle, Sabine
   Greenlee, Mark W.
TI Perceptual learning in patients with macular degeneration
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE perceptual learning; fMRI BOLD; cortical plasticity; visual cortex;
   macular degeneration
ID CENTRAL SCOTOMA; VISUAL-ACUITY; TEXTURE-DISCRIMINATION;
   SPATIAL-FREQUENCY; BRAIN ACTIVATION; RETINAL LOCUS; READING SPEED; HUMAN
   ADULTS; VISION; FIXATION
AB Patients with age-related macular degeneration (AMD) or hereditary macular dystrophies (JMD) rely on an efficient use of their peripheral visual field. We trained eight AMD and five JMD patients to perform a texture-discrimination task (TDT) at their preferred retinal locus (PRL) used for fixation. Six training sessions of approximately one hour duration were conducted over a period of approximately 3 weeks. Before, during and after training twelve patients and twelve age-matched controls (the data from two controls had to be discarded later) took part in three functional magnetic resonance imaging (fMRI) sessions to assess training-related changes in the BOLD response in early visual cortex. Patients benefited from the training measurements as indexed by significant decrease (p = 0.001) in the stimulus onset asynchrony (SON between the presentation of the texture target on background and the visual mask, and in a significant location specific effect of the PRL with respect to hit rate (p = 0.014). The following trends were observed: (i) improvement in Vernier acuity for an eccentric line-bisection task; (ii) positive correlation between the development of BOLD signals in early visual cortex and initial fixation stability (r = 0.531); (iii) positive correlation between the increase in task performance and initial fixation stability (r = 0.730). The first two trends were non-significant, whereas the third trend was significant at p = 0.014, Bonferroni corrected. Consequently, our exploratory study suggests that training on the TDT can enhance eccentric vision in patients with central vision loss. This enhancement is accompanied by a modest alteration in the BOLD response in early visual cortex.
C1 [Plank, Tina; Rosengarth, Katharina; Schmalhofer, Carolin; Goldhacker, Markus; Greenlee, Mark W.] Univ Regensburg, Inst Expt Psychol, D-93053 Regensburg, Germany.
   [Brandl-Ruehle, Sabine] Univ Med Ctr Regensburg, Dept Ophthalmol, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Greenlee, MW (通讯作者)，Univ Regensburg, Inst Expt Psychol, Univ Str 31, D-93053 Regensburg, Germany.
EM mark.greenlee@psychologie.uni-regensburg.de
RI Greenlee, Mark/M-6414-2018
OI Greenlee, Mark/0000-0003-2305-9286; Goldhacker,
   Markus/0000-0002-4355-4017; Plank, Tina/0000-0001-5329-7037
CR Astle Andrew T, 2011, BMJ Case Rep, V2011, DOI 10.1136/bcr.07.2010.3143
   Astle AT, 2010, VISION RES, V50, P2445, DOI 10.1016/j.visres.2010.09.004
   Bach M, 1996, OPTOMETRY VISION SCI, V73, P49, DOI 10.1097/00006324-199601000-00008
   Backman O., 1979, LOW VISION TRAINING
   BALL K, 1982, SCIENCE, V218, P697, DOI 10.1126/science.7134968
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Brett M., 2002, NEUROIMAGE, V16, pS497, DOI DOI 10.1016/S1053-8119(02)90010-8
   Chung STL, 2004, VISION RES, V44, P695, DOI 10.1016/j.visres.2003.09.028
   Chung STL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035829
   Chung STL, 2011, INVEST OPHTH VIS SCI, V52, P1164, DOI 10.1167/iovs.10-6034
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Ding J, 2011, P NATL ACAD SCI USA, V108, pE733, DOI 10.1073/pnas.1105183108
   Fahle M., 2002, PERCEPTUAL LEARNING
   FIORENTINI A, 1981, VISION RES, V21, P1149, DOI 10.1016/0042-6989(81)90017-1
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Frank SM, 2014, HUM BRAIN MAPP, V35, P1201, DOI 10.1002/hbm.22245
   Ghose GM, 2002, J NEUROPHYSIOL, V87, P1867, DOI 10.1152/jn.00690.2001
   GIBSON EJ, 1963, ANNU REV PSYCHOL, V14, P29, DOI 10.1146/annurev.ps.14.020163.000333
   Goldhacker M, 2014, VISION RES, V99, P99, DOI 10.1016/j.visres.2013.11.010
   Goldstone RL, 1998, ANNU REV PSYCHOL, V49, P585, DOI 10.1146/annurev.psych.49.1.585
   Gori S, 2014, VISION RES, V99, P78, DOI 10.1016/j.visres.2013.11.011
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Hussain Z, 2012, J NEUROSCI, V32, P474, DOI 10.1523/JNEUROSCI.3845-11.2012
   Huurneman B, 2013, INVEST OPHTH VIS SCI, V54, P6208, DOI 10.1167/iovs.13-12220
   KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966
   Levi DM, 2012, OPTOMETRY VISION SCI, V89, P827, DOI 10.1097/OPX.0b013e318257a187
   Levi DM, 2009, VISION RES, V49, P2535, DOI 10.1016/j.visres.2009.02.010
   LEVITT H, 1971, J ACOUST SOC AM, V49, P467, DOI 10.1121/1.1912375
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   McGovern DP, 2012, J VISION, V12, DOI 10.1167/12.11.4
   Miles WR, 1930, J GEN PSYCHOL, V3, P412, DOI 10.1080/00221309.1930.9918218
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Plank T, 2013, HUM BRAIN MAPP, V34, P2607, DOI 10.1002/hbm.22088
   Plank T, 2011, NEUROIMAGE, V56, P1556, DOI 10.1016/j.neuroimage.2011.02.055
   POGGIO T, 1992, SCIENCE, V256, P1018, DOI 10.1126/science.1589770
   Polat U, 2004, P NATL ACAD SCI USA, V101, P6692, DOI 10.1073/pnas.0401200101
   Polat U, 2012, SCI REP-UK, V2, DOI 10.1038/srep00278
   Polat U, 2009, EXPERT REV OPHTHALMO, V4, P573, DOI 10.1586/EOP.09.54
   PORAC C, 1976, PSYCHOL BULL, V83, P880, DOI 10.1037/0033-2909.83.5.880
   Rosengarth K, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00428
   Rubin GS, 2009, NEURO-OPHTHALMOLOGY, V33, P120, DOI 10.1080/01658100902998732
   Sagi D, 2011, VISION RES, V51, P1552, DOI 10.1016/j.visres.2010.10.019
   Schoups A, 2001, NATURE, V412, P549, DOI 10.1038/35087601
   Schwartz S, 2002, P NATL ACAD SCI USA, V99, P17137, DOI 10.1073/pnas.242414599
   Seitz A, 2005, TRENDS COGN SCI, V9, P329, DOI 10.1016/j.tics.2005.05.010
   Siaudvytyte L, 2012, MEDICINA-LITHUANIA, V48, P109, DOI 10.3390/medicina48020015
   SIRETEANU R, 1995, VISION RES, V35, P2037, DOI 10.1016/0042-6989(94)00295-W
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TrauzettelKlosinski S, 1996, NEURO-OPHTHALMOLOGY, V16, P241, DOI 10.3109/01658109609044632
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   Yotsumoto Y, 2008, NEURON, V57, P827, DOI 10.1016/j.neuron.2008.02.034
   Yu DY, 2010, VISION RES, V50, P860, DOI 10.1016/j.visres.2010.02.006
   Yu DY, 2010, VISION RES, V50, P36, DOI 10.1016/j.visres.2009.10.005
   Zhou YF, 2006, VISION RES, V46, P739, DOI 10.1016/j.visres.2005.07.031
NR 56
TC 22
Z9 22
U1 1
U2 13
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD OCT 17
PY 2014
VL 5
AR 1189
DI 10.3389/fpsyg.2014.01189
PG 14
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA AR6UC
UT WOS:000343717600001
PM 25368597
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Campochiaro, PA
AF Campochiaro, Peter A.
TI Ocular neovascularization
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Review
DE Angiogenesis; Age-related macular degeneration; Diabetic retinopathy;
   Hypoxia-inducible factor-1; Vascular endothelial growth factor;
   Platelet-derived growth factor
ID ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA;
   EPITHELIUM-DERIVED FACTOR; CHOROIDAL NEOVASCULARIZATION; RETINAL
   NEOVASCULARIZATION; INCREASED EXPRESSION; STEM-CELLS; IN-VIVO;
   VASCULAR-PERMEABILITY; ANGIOGENESIS FACTOR
AB Retinal and choroidal vascular diseases constitute the most common causes of moderate and severe vision loss in developed countries. They can be divided into retinal vascular diseases, in which there is leakage and/or neovascularization (NV) from retinal vessels, and subretinal NV, in which new vessels grow into the normally avascular outer retina and subretinal space. The first category of diseases includes diabetic retinopathy, retinal vein occlusions, and retinopathy of prematurity, and the second category includes neovascular age-related macular degeneration (AMD), ocular histoplasmosis, pathologic myopia, and other related diseases. Retinal hypoxia is a key feature of the first category of diseases resulting in elevated levels of hypoxia-inducible factor-1 (HIF-1) which stimulates expression of vascular endothelial growth factor (VEGF), platelet-derived growth factor-B (PDGF-B), placental growth factor, stromal-derived growth factor-1 and their receptors, as well as other hypoxia-regulated gene products such as angiopoietin-2. Although hypoxia has not been demonstrated as part of the second category of diseases, HIF-1 is elevated and thus the same group of hypoxia-regulated gene products plays a role. Clinical trials have shown that VEGF antagonists provide major benefits for patients with subretinal NV due to AMD and even greater benefits are seen by combining antagonists of VEGF and PDGF-B. It is likely that addition of antagonists of other agents listed above will be tested in the future. Other appealing strategies are to directly target HIF-1 or to use gene transfer to express endogenous or engineered anti-angiogenic proteins. While substantial progress has been made, the future looks even brighter for patients with retinal and choroidal vascular diseases.
C1 [Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins University
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
FU Genzyme; Oxford BioMedica; NATIONAL EYE INSTITUTE [R01EY012609] Funding
   Source: NIH RePORTER
FX The author is consultant for Genentech, Regeneron, Allergan, and Aerpio
   for which Johns Hopkins University receives remuneration and receives
   research support for clinical trials from the above, Genzyme, and Oxford
   BioMedica.
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   BAIRD A, 1985, BIOCHEMISTRY-US, V24, P7855, DOI 10.1021/bi00348a001
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Boyer DS, 2009, INVEST OPHTHALMOL VI
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2012, GENE THER, V19, P121, DOI 10.1038/gt.2011.164
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Campochiaro PA, 2011, HUM GENE THER, V22, P523, DOI 10.1089/hum.2011.050
   Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200
   Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715
   Colorado PC, 2000, CANCER RES, V60, P2520
   Cousins SW, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002671
   Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7
   Diez H, 2007, EXP CELL RES, V313, P1, DOI 10.1016/j.yexcr.2006.09.009
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Grant MB, 2002, NAT MED, V8, P607, DOI 10.1038/nm0602-607
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7
   Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128
   Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Hofmann JJ, 2007, GENE EXPR PATTERNS, V7, P461, DOI 10.1016/j.modgep.2006.11.002
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lai CM, 2001, HUM GENE THER, V12, P1299, DOI 10.1089/104303401750270959
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   LANG RA, 1993, CELL, V74, P453, DOI 10.1016/0092-8674(93)80047-I
   Li C, 2007, ARCH OPHTHALMOL-CHIC, V125, P795, DOI 10.1001/archopht.125.6.795
   Lobov IB, 2005, NATURE, V437, P417, DOI 10.1038/nature03928
   Lu HS, 2005, J BIOL CHEM, V280, P41928, DOI 10.1074/jbc.M508718200
   Lu PR, 2009, CORNEA, V28, P562, DOI 10.1097/ICO.0b013e3181930bcd
   Luna J, 1996, LAB INVEST, V75, P563
   Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2001
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Nambu H, 2005, J CELL PHYSIOL, V204, P227, DOI 10.1002/jcp.20292
   Nambu H, 2004, GENE THER, V11, P865, DOI 10.1038/sj.gt.3302230
   Noda K, 2008, FASEB J, V22, P2928, DOI 10.1096/fj.07-105346
   Okamoto N, 1997, AM J PATHOL, V151, P281
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442
   Otani A, 2002, NAT MED, V8, P1004, DOI 10.1038/nm744
   Outtz HH, 2011, BLOOD, V118, P3436, DOI 10.1182/blood-2010-12-327015
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   PATZ A, 1984, CURR EYE RES, V3, P159, DOI 10.3109/02713688408997197
   Patz A, 1968, Trans Am Ophthalmol Soc, V66, P940
   PATZ A, 1953, AM J OPHTHALMOL, V36, P1511, DOI 10.1016/0002-9394(53)91779-6
   Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0
   Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3
   Shen JK, 2007, INVEST OPHTH VIS SCI, V48, P4335, DOI 10.1167/iovs.07-0113
   Shen JK, 2006, FASEB J, V20, P723, DOI 10.1096/fj.05-5046fje
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   Silva RLE, 2006, J CELL PHYSIOL, V208, P161, DOI 10.1002/jcp.20645
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Stefater JA, 2011, NATURE, V474, P511, DOI 10.1038/nature10085
   Takahashi K, 2003, FASEB J, V17, P896, DOI 10.1096/fj.02-0824fje
   Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Xie B, 2009, J CELL PHYSIOL, V218, P192, DOI 10.1002/jcp.21588
   Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105
NR 107
TC 256
Z9 274
U1 6
U2 109
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD MAR
PY 2013
VL 91
IS 3
BP 311
EP 321
DI 10.1007/s00109-013-0993-5
PG 11
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 097QB
UT WOS:000315487500004
PM 23329331
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Zhang, XZ
   Cotch, MF
   Ryskulova, A
   Primo, SA
   Nair, P
   Chou, CF
   Geiss, LS
   Barker, LE
   Elliott, AF
   Crews, JE
   Saaddine, JB
AF Zhang, Xinzhi
   Cotch, Mary Frances
   Ryskulova, Asel
   Primo, Susan A.
   Nair, Parvathy
   Chou, Chiu-Fang
   Geiss, Linda S.
   Barker, Lawrence E.
   Elliott, Amanda F.
   Crews, John E.
   Saaddine, Jinan B.
TI Vision Health Disparities in the United States by Race/Ethnicity,
   Education, and Economic Status: Findings From Two Nationally
   Representative Surveys
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; EYE CARE; OLDER-ADULTS; DIABETIC-RETINOPATHY; MACULAR
   DEGENERATION; RISK; POPULATION; PREVALENCE; COMMUNITY; DEPRESSION
AB PURPOSE: To assess vision health disparities in the United States by race/ethnicity, education, and economic status.
   DESIGN: Cross-sectional, nationally representative samples.
   METHODS: We used national survey data from the National Health and Nutrition Examination Survey (NHANES) and the National Health Interview Survey (NHIS). Main outcome measures included, from NHANES, age-related eye diseases (ie, age-related macular degeneration [AMD], cataract, diabetic retinopathy [DR], glaucoma) and from NHIS, eye care use (ie, eye doctor visits and cannot afford eyeglasses when needed) among those with self-reported visual impairment. The estimates were age- and sex-standardized to the 2000 US Census population. Linear trends in the estimates were assessed by weighted least squares regression.
   RESULTS: Non-Hispanic whites had a higher prevalence of AMD and cataract surgery than non-Hispanic blacks, but a lower prevalence of DR and glaucoma (all P < .001 in NHANES 2005-2008). From 1999 to 2008, individuals with less education (ie, <high school vs >high school) and lower income (poverty income ratio [PM] <1.00 vs >= 4.00) were consistently less likely to have had an eye care visit in the past 12 months compared with their counterparts (all P <.05). During this period, inability to afford needed eyeglasses increased among non-Hispanic whites and Hispanics (trend P = .004 and P = .007; respectively), those with high school education (trend P = .036), and those with PIR 1.00-1.99 (trend P < .001).
   CONCLUSIONS: Observed vision health disparities suggest a need for educational and innovative interventions among socioeconomically disadvantaged groups. (Am J Ophthalmol 2012;154:S53-S62. (c) 2012 Published by Elsevier Inc.)
C1 [Zhang, Xinzhi] Ctr Dis Control & Prevent, Vis Hlth Initiat, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Ryskulova, Asel] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
   [Primo, Susan A.] Emory Univ, Sch Med, Emory Eye Ctr, Atlanta, GA USA.
C3 Centers for Disease Control & Prevention - USA; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); Centers for
   Disease Control & Prevention - USA; CDC National Center for Health
   Statistics (NCHS); Emory University
RP Zhang, XZ (通讯作者)，Ctr Dis Control & Prevent, Vis Hlth Initiat, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,K-10, Atlanta, GA 30341 USA.
EM XZhang4@cdc.gov
OI Cotch, Mary Frances/0000-0002-2046-4350
FU National Center for Health Statistics (NCHS); Centers for Disease
   Control and Prevention (Atlanta, Georgia); Intra Agency from the
   Division of Diabetes Translation [05FED47304]; Centers for Disease
   Control and Prevention; National Eye Institute, National Institutes of
   Health, Intramural Research Program grant (Bethesda, Maryland)
   [ZIAEY000402]; NATIONAL EYE INSTITUTE [ZIAEY000402] Funding Source: NIH
   RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported. Publication
   of this article was supported by the National Center for Health
   Statistics (NCHS), Centers for Disease Control and Prevention (Atlanta,
   Georgia). Funding for the National Health and Nutrition Examination
   Survey (NHANES) ophthalmology component was provided by the Intra Agency
   Agreement 05FED47304 from the Division of Diabetes Translation, the
   Centers for Disease Control and Prevention. Funding for the vision
   component was provided by the National Eye Institute, National
   Institutes of Health, Intramural Research Program grant ZIAEY000402
   (Bethesda, Maryland). The NCHS was involved in the design and conduct of
   the NHANES and NHIS study and in data collection. The Division of
   Diabetes Translation provided funding support for the ophthalmology
   component and was involved in the design and conduct of the study, in
   the collection, analysis, and interpretation of the data, and in the
   preparation, review, and approval of this article before submission.
   Involved in design (X.Z., M.F.C., A.R., J.B.S.) and conduct of the study
   (X.Z., M.F.C., A.R., S.A.P., J.B.S.); collection, management, analysis
   (X.Z., P.N., C.F.C.), and interpretation of the data (X.Z., M.F.C.,
   A.R., S.A.P., P.N., C.F.C., L.S.G., L.E.B., A.F.E., J.E.C., J.B.S.); and
   preparation, review, or approval of the manuscript (X.Z., M.F.C., A.R.,
   S.A.P., P.N., C.F.C., L.S.G., L.E.B., A.F.E., J.E.C., J.B.S.). Drs
   Zhang, Chou, and Nair had full access to all the data in the study and
   take responsibility for the integrity of the data and the accuracy of
   the data analysis. The NHANES and NHIS surveys are publicly available
   data and their protocols were approved by a human subjects review board,
   and written informed consent was obtained from all participants. The
   authors thank the NHANES and NHIS participants, without whom this study
   Would not be possible. The findings and conclusions in this paper are
   those of the authors and do not necessarily represent the official
   position of the Centers for Disease Control and Prevention.
CR Bailey R. N., 2006, Morbidity and Mortality Weekly Report, V55, P1321
   Baker RS, 2005, OPHTHAL EPIDEMIOL, V12, P1, DOI 10.1080/09286580590921330
   BAZARGAN M, 1995, J GERONTOL B-PSYCHOL, V50, pS119, DOI 10.1093/geronb/50B.2.S119
   Calonge N, 2009, ANN INTERN MED, V151, P37, DOI 10.7326/0003-4819-151-1-200907070-00007
   Centers for Disease Control and Prevention, 2006, IMPR NAT VIS HLTH CO
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Department of Health Human Services Washington DC. Healthy People 2010 (Group) and United States Government Printing Office., 2000, HLTH PEOPL 2010
   Ellwein LB, 2002, ARCH OPHTHALMOL-CHIC, V120, P804
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202
   Harris MI, 1998, DIABETES CARE, V21, P1230, DOI 10.2337/diacare.21.8.1230
   Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017
   Kempen AH, 2004, ARCH OPHTHALMOL-CHIC, V122, P495
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein RJ., 2001, HLTH PEOPLE 2010 STA, DOI DOI 10.1037/E583772012-001
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Korn EL, 1999, ANAL HLTH SURVEYS
   Lee DJ, 2005, OPHTHAL EPIDEMIOL, V12, P13, DOI 10.1080/09286580490907751
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Mitchell P, 1997, MED J AUSTRALIA, V166, P73, DOI 10.5694/j.1326-5377.1997.tb138724.x
   Orr P, 1999, OPHTHALMOLOGY, V106, P904, DOI 10.1016/S0161-6420(99)00508-4
   Primo SA, 2009, J PUBLIC HEALTH MAN, V15, P529, DOI 10.1097/PHH.0b013e3181af63e0
   Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x
   Saaddine JB, 2003, OPHTHALMOLOGY, V110, P253, DOI 10.1016/S0161-6420(02)01839-0
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   SINGER DE, 1992, ANN INTERN MED, V116, P660, DOI 10.7326/0003-4819-116-8-660
   Terry AL, 2010, OPHTHAL EPIDEMIOL, V17, P411, DOI 10.3109/09286586.2010.528575
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   U.S. Census Bureau, CURR POP SURV DEF EX
   Unzueta M, 2004, ETHNIC DIS, V14, P285
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   West SK, 1998, AM J EPIDEMIOL, V148, P1033
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   World Health Organization, GLOB IN EL AV BLINDN
   Zhang XZ, 2007, ARCH OPHTHALMOL-CHIC, V125, P411, DOI 10.1001/archopht.125.3.411
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zhang XZ, 2008, OPHTHAL EPIDEMIOL, V15, P418, DOI 10.1080/09286580802399102
NR 43
TC 114
Z9 114
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2012
VL 154
IS 6
SU S
BP S53
EP S62
DI 10.1016/j.ajo.2011.08.045
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 047ZC
UT WOS:000311879000007
PM 23158224
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yu, BL
   Wang, J
   Suter, PM
   Russell, RM
   Grusak, MA
   Wang, Y
   Wang, ZX
   Yin, SA
   Tang, GW
AF Yu, Bolan
   Wang, Jie
   Suter, Paolo M.
   Russell, Robert M.
   Grusak, Michael A.
   Wang, Yin
   Wang, Zhixu
   Yin, Shian
   Tang, Guangwen
TI Spirulina is an effective dietary source of zeaxanthin to humans
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Zeaxanthin; Spirulina; Bioavailability; H-2 labelling
ID MACULAR PIGMENT; BETA-CAROTENE; VITAMIN-A; NATIONAL-HEALTH; LUTEIN;
   BIOAVAILABILITY; AGE; SERUM; PLASMA; EGG
AB Zeaxanthin is a predominant xanthophyll in human eyes and may reduce the risk of cataracts and age-related macular degeneration. Spirulina is an algal food that contains a high concentration of zeaxanthin. In order to determine the zeaxanthin bioavailability of spirulina for dietary supplementation in humans, spirulina was grown in nutrient solution with (H2O)-H-2 for carotenoid labelling. Single servings of 2 H-labelled spirulina (4.0-5.0 g) containing 2.6-3.7mg zeaxanthin were consumed by fourteen healthy male volunteers (four Americans and ten Chinese) with 12 g dietary fat. Blood samples were collected over a 45 d period. The serum concentrations of total zeaxanthin were measured using HPLC, and the enrichment of labelled zeaxanthin was determined using LC-atmospheric pressure chemical ionisation-MS (LC-APCI-MS). The results showed that intrinsically labelled spirulina zeaxanthin in the circulation was detected at levels as low as 10% of the total zeaxanthin for up to 45 d after intake of the algae. A single dose of spirulina can increase mean serum zeaxanthin concentration in humans from 0.06 to 0.15 mu mol/l, as shown in our study involving American and Chinese volunteers. The average 15 d area under the serum zeaxanthin response curve to the single dose of spirulina was 293 nmol x d/mu mol (range 254-335) in American subjects, and 197 nmol x d/mu mol (range 154-285) in Chinese subjects. It is concluded that the relative bioavailability of spirulina zeaxanthin can be studied with high sensitivity and specificity using 2 H labelling and LC-APCI-MS methodology. Spirulina can serve as a rich source of dietary zeaxanthin in humans.
C1 [Yu, Bolan; Russell, Robert M.; Tang, Guangwen] Tufts Univ, Jean Mayer US Dept Agr Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Yu, Bolan] Guangzhou Med Univ, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
   [Wang, Jie; Yin, Shian] Natl Inst Nutr & Food Safety, Beijing, Peoples R China.
   [Suter, Paolo M.] Nestle Fdn, Lausanne, Switzerland.
   [Suter, Paolo M.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
   [Grusak, Michael A.] Baylor Coll Med, Childrens Nutr Res Ctr, USDA, ARS, Houston, TX 77030 USA.
   [Wang, Yin] Zhejiang Acad Med Sci, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Zhixu] Nanjing Med Univ, Nanjing, Jiangsu, Peoples R China.
C3 Tufts University; Guangzhou Medical University; Nestle SA; University of
   Zurich; University Zurich Hospital; Baylor College of Medicine; United
   States Department of Agriculture (USDA); Zhejiang Academy of Medical
   Sciences; Nanjing Medical University
RP Tang, GW (通讯作者)，Tufts Univ, Jean Mayer US Dept Agr Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.
EM guangwen.tang@tufts.edu
FU Nestle Foundation, Lausanne, Switzerland; US Department of Agriculture
   [58-1950-7-707, 58-1950-9-001, 58-6250-6-001]
FX The authors thank David A. Dworak and Chee-Ming Li for their assistance
   with producing the <SUP>2</SUP>H-labelled spirulina. This work was
   supported by the Nestle Foundation, Lausanne, Switzerland and by the US
   Department of Agriculture, under Cooperative Agreements 58-1950-7-707,
   58-1950-9-001 and 58-6250-6-001. The authors' contributions were as
   follows: B. Y. conducted the sample and data analyses, and wrote the
   manuscript; R. M. R. and G. T. designed the study, conducted the US
   study and revised the manuscript; J. W., Y. W. and Z. W. conducted the
   human study and collected samples in China; P. M. S. was affiliated with
   the University Hospital and Nestle Foundation (Lausanne, Switzerland)
   and revised the manuscript; S. Y. supervised the human study in China;
   M. A. G. produced the labelled spirulina, provided the spirulina diets
   and revised the manuscript. None of the authors had any personal or
   financial conflicts of interest.
CR Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   ANNAPURNA VV, 1991, PLANT FOOD HUM NUTR, V41, P125, DOI 10.1007/BF02194081
   Castenmiller JJM, 1998, ANNU REV NUTR, V18, P19, DOI 10.1146/annurev.nutr.18.1.19
   CIFERRI O, 1983, MICROBIOL REV, V47, P551, DOI 10.1128/MMBR.47.4.551-578.1983
   Ford ES, 2000, ANN EPIDEMIOL, V10, P106, DOI 10.1016/S1047-2797(99)00038-1
   Gireesh T, 2004, BRIT J NUTR, V92, P241, DOI 10.1079/BJN20041175
   Goodrow EF, 2006, J NUTR, V136, P2519, DOI 10.1093/jn/136.10.2519
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HUDSON BJF, 1974, J SCI FOOD AGR, V25, P759, DOI 10.1002/jsfa.2740250703
   Johnson EJ, 2010, CURR OPIN CLIN NUTR, V13, P28, DOI 10.1097/MCO.0b013e32833308ff
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   Maiani G, 2009, MOL NUTR FOOD RES, V53, pS194, DOI 10.1002/mnfr.200800053
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Miranda MS, 1998, BRAZ J MED BIOL RES, V31, P1075, DOI 10.1590/S0100-879X1998000800007
   NIERENBERG DW, 1991, AM J CLIN NUTR, V53, P1443, DOI 10.1093/ajcn/53.6.1443
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Schweigert FJ, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-17
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Traber MG, 2000, AM J CLIN NUTR, V71, P1029
   Vishwanathan R, 2009, AM J CLIN NUTR, V90, P1272, DOI 10.3945/ajcn.2009.28013
   Wang J, 2008, AM J CLIN NUTR, V87, P1730, DOI 10.1093/ajcn/87.6.1730
   Wenzel AJ, 2006, J NUTR, V136, P2568, DOI 10.1093/jn/136.10.2568
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Yeum KJ, 2002, ANNU REV NUTR, V22, P483, DOI 10.1146/annurev.nutr.22.010402.102834
   Zaripheh S, 2002, J NUTR, V132, p531S, DOI 10.1093/jn/132.3.531S
NR 32
TC 19
Z9 20
U1 1
U2 47
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD AUG 28
PY 2012
VL 108
IS 4
BP 611
EP 619
DI 10.1017/S0007114511005885
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 000CT
UT WOS:000308364800008
PM 22313576
OA Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Qiu, HX
   Mao, YP
   Gu, Y
   Wang, Y
   Zhu, JG
   Zeng, J
AF Qiu, Haixia
   Mao, Yongping
   Gu, Ying
   Wang, Ying
   Zhu, Jianguo
   Zeng, Jing
TI Vascular targeted photodynamic therapy for bleeding gastrointestinal
   mucosal vascular lesions: A preliminary study
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Gastrointestinal; Vascular lesions; Photodynamic therapy;
   Vascular-targeted
ID PORT-WINE STAINS; ESOPHAGEAL-VARICES; MACULAR DEGENERATION; TUMOR;
   NEOVASCULARIZATION; VERTEPORFIN; VESSELS
AB Background: Vascular-targeted photodynamic therapy (V-PDT) has shown good selectivity and efficacy in the treatment of certain types of vascular disease, including port wine stains, age-related macular degeneration, and esophageal varices. This study was conducted to test the efficacy and safety of V-PDT in the treatment of gastrointestinal (GI) bleeding caused by the abnormal dilatation of capillaries.
   Methods: Patients with bleeding GI mucosal vascular lesions treated with V-PDT were included in this retrospective study. The efficiency of V-PDT was analyzed by comparing the documented endoscopy results, hemoglobin levels, and transfusion requirements before and at 6 months after the last V-PDT. Side effects during and after V-PDT and follow-up results were also analyzed.
   Results: Seven patients with bleeding GI mucosal vascular lesions were treated with V-PDT. After 1-4 V-PDT sessions, all patients no longer needed transfusions to maintain a stable hemoglobin level during the follow-up period of 6 months. The mean hemoglobin level of the seven patients improved from 6.21 +/- 1.48 g/dl to 11.66 +/- 1.21 g/dl (p < 0.001), and the GI bleeding and melena of all the patients disappeared. No perforations, strictures, scars, or episodes of photosensitization occurred in the seven patients, and there were no recurrences of GI bleeding during the 1-21 months of further follow-up.
   Conclusions: This preliminary study indicated that V-PDT is a highly selective, safe, well-tolerated, and effective treatment modality for bleeding GI mucosal vascular lesions. However, prospective studies with larger sample sizes are needed to confirm this finding. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Qiu, Haixia; Gu, Ying; Wang, Ying; Zhu, Jianguo; Zeng, Jing] Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing 100853, Peoples R China.
   [Mao, Yongping] Chinese Peoples Liberat Army Gen Hosp, Dept Gastroenterol & Hepatol, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Chinese People's
   Liberation Army General Hospital
RP Gu, Y (通讯作者)，Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM qiuhxref@126.com; maoyongping@yahoo.com.cn; guyinglaser@sina.com
FU National High Technology Research and Development Program of China
   [2008AA030117]; National Natural Science Foundation of China [60878055,
   61036014]
FX This work was supported by the National High Technology Research and
   Development Program of China (No. 2008AA030117), the National Natural
   Science Foundation of China (No. 60878055), and the Key Program of
   National Natural Science Foundation of China (No. 61036014).
CR Ben-Soussan E, 2004, EUR J GASTROEN HEPAT, V16, P1315, DOI 10.1097/00042737-200412000-00013
   Chen B, 2006, CRIT REV EUKAR GENE, V16, P279, DOI 10.1615/CritRevEukarGeneExpr.v16.i4.10
   DASILVA FAM, 1995, PHOTOCHEM PHOTOBIOL, V61, P414, DOI 10.1111/j.1751-1097.1995.tb08632.x
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   Gu Y, 2007, ANN DERMATOL VENER, V134, P241, DOI 10.1016/S0151-9638(07)91816-5
   Gu Y, 1992, CHINESE J LASER MED, V1, P6
   Hamblin MR, 1999, BRIT J CANCER, V81, P261, DOI 10.1038/sj.bjc.6690686
   Ido K, 1997, GASTROINTEST ENDOSC, V45, P420, DOI 10.1016/S0016-5107(97)70156-1
   Jensen DM, 1997, GASTROINTEST ENDOSC, V45, P20, DOI 10.1016/S0016-5107(97)70298-0
   Kurohane K, 2001, CANCER LETT, V167, P49, DOI 10.1016/S0304-3835(01)00475-X
   Li CZ, 2009, LASER MED SCI, V24, P167, DOI 10.1007/s10103-008-0542-6
   Li LB, 2009, LASER MED SCI, V24, P597, DOI 10.1007/s10103-008-0620-9
   LIBERSKI SM, 1994, GASTROINTEST ENDOSC, V40, P584, DOI 10.1016/S0016-5107(94)70258-6
   LIU FG, 2001, CHIN J LASER MED SUR, V10, P9
   Liu FG, 2001, CHINESE J LASER MED, V10, P69
   Naga Mazen, 2011, Arab J Gastroenterol, V12, P40, DOI 10.1016/j.ajg.2011.01.012
   Nagamine N, 2002, GASTROINTEST ENDOSC, V55, P420, DOI 10.1067/mge.2002.121599
   Pavey DA, 2004, GASTROINTEST ENDOSC, V59, P233, DOI 10.1016/S0016-5107(03)02539-2
   Qiu HX, 2011, DERMATOL SURG, V37, P1603, DOI 10.1111/j.1524-4725.2011.02129.x
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Seshadri M, 2005, CLIN CANCER RES, V11, P4241, DOI 10.1158/1078-0432.CCR-04-2703
   Sharman WM, 1999, DRUG DISCOV TODAY, V4, P507, DOI 10.1016/S1359-6446(99)01412-9
   Wang KK, 2010, TECH GASTROINTEST EN, V12, P35, DOI 10.1016/j.tgie.2010.01.009
   Xu D. Y., 1996, TUMOR PHOTODYNAMIC T, P149
   Xu DY, 2007, PHOTODIAGN PHOTODYN, V4, P13, DOI 10.1016/j.pdpdt.2006.09.003
   Xu YZ, 1986, ACAD J 2 MIL MED U, V7, P82
   [张丽 Zhang Li], 2004, [中国激光医学杂志, Chinese Journal of Laser Medicine and Surgery], V13, P208
   2001, AM J OPHTHALMOL, V131, P541
NR 29
TC 10
Z9 11
U1 1
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD JUN
PY 2012
VL 9
IS 2
BP 109
EP 117
DI 10.1016/j.pdpdt.2011.11.003
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 950ZL
UT WOS:000304690300003
PM 22594980
DA 2022-11-30
ER

PT J
AU Cousins, SW
   Espinosa-Heidmann, DG
   Miller, DM
   Pereira-Simon, S
   Hernandez, EP
   Chien, H
   Meier-Jewett, C
   Dix, RD
AF Cousins, Scott W.
   Espinosa-Heidmann, Diego G.
   Miller, Daniel M.
   Pereira-Simon, Simone
   Hernandez, Eleut P.
   Chien, Hsin
   Meier-Jewett, Courtney
   Dix, Richard D.
TI Macrophage Activation Associated with Chronic Murine Cytomegalovirus
   Infection Results in More Severe Experimental Choroidal
   Neovascularization
SO PLOS PATHOGENS
LA English
DT Article
ID COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; CHRONIC REJECTION;
   UP-REGULATION; EXPRESSION; DISEASE; ANGIOGENESIS; INCREASES; RISK; RAT
AB The neovascular (wet) form of age-related macular degeneration (AMD) leads to vision loss due to choroidal neovascularization (CNV). Since macrophages are important in CNV development, and cytomegalovirus (CMV)-specific IgG serum titers in patients with wet AMD are elevated, we hypothesized that chronic CMV infection contributes to wet AMD, possibly by pro-angiogenic macrophage activation. This hypothesis was tested using an established mouse model of experimental CNV. At 6 days, 6 weeks, or 12 weeks after infection with murine CMV (MCMV), laser-induced CNV was performed, and CNV severity was determined 4 weeks later by analysis of choroidal flatmounts. Although all MCMV-infected mice exhibited more severe CNV when compared with control mice, the most severe CNV developed in mice with chronic infection, a time when MCMV-specific gene sequences could not be detected within choroidal tissues. Splenic macrophages collected from mice with chronic MCMV infection, however, expressed significantly greater levels of TNF-alpha, COX-2, MMP-9, and, most significantly, VEGF transcripts by quantitative RT-PCR assay when compared to splenic macrophages from control mice. Direct MCMV infection of monolayers of IC-21 mouse macrophages confirmed significant stimulation of VEGF mRNA and VEGF protein as determined by quantitative RT-PCR assay, ELISA, and immunostaining. Stimulation of VEGF production in vivo and in vitro was sensitive to the antiviral ganciclovir. These studies suggest that chronic CMV infection may serve as a heretofore unrecognized risk factor in the pathogenesis of wet AMD. One mechanism by which chronic CMV infection might promote increased CNV severity is via stimulation of macrophages to make pro-angiogenic factors (VEGF), an outcome that requires active virus replication.
C1 [Cousins, Scott W.; Espinosa-Heidmann, Diego G.] Duke Univ, Ctr Eye, Dept Ophthalmol, Duke Ctr Macular Dis, Durham, NC 27710 USA.
   [Cousins, Scott W.; Espinosa-Heidmann, Diego G.; Miller, Daniel M.; Pereira-Simon, Simone; Hernandez, Eleut P.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Chien, Hsin; Meier-Jewett, Courtney; Dix, Richard D.] Georgia State Univ, Dept Biol, Viral Immunol Ctr, Atlanta, GA USA.
   [Dix, Richard D.] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
C3 Duke University; Bascom Palmer Eye Institute; University of Miami;
   University System of Georgia; Georgia State University; Emory University
RP Cousins, SW (通讯作者)，Duke Univ, Ctr Eye, Dept Ophthalmol, Duke Ctr Macular Dis, Durham, NC 27710 USA.
EM rdix@gsu.edu
FU NIH [EY/AI 013318, EY 010568, P30 EY06360]; Fight for Sight; NATIONAL
   EYE INSTITUTE [R01EY010568, P30EY006360, P30EY005722] Funding Source:
   NIH RePORTER
FX Supported by NIH Grant EY/AI 013318 (SWC), NIH Grant EY 010568 (RDD),
   Core Grant NIH P30 EY06360, and Fight for Sight. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Andel M, 2003, Vnitr Lek, V49, P960
   Armitage G C, 2000, Oral Dis, V6, P335, DOI 10.1111/j.1601-0825.2000.tb00126.x
   Blasi Claudio, 2004, Ann Ital Med Int, V19, P249
   Boyle J. J., 2005, Current Vascular Pharmacology, V3, P63, DOI 10.2174/1570161052773861
   Caposio P, 2011, VIRUS RES, V157, P204, DOI 10.1016/j.virusres.2010.09.011
   Chan G, 2008, J VIROL, V82, P1040, DOI 10.1128/JVI.00864-07
   Cousins S, 2005, AGE RELATED MACULAR, P26
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Dace DS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003381
   Dix RD, 2004, CURR EYE RES, V29, P91, DOI 10.1080/02713680490504641
   DIX RD, 1994, CURR EYE RES, V13, P587, DOI 10.3109/02713689408999892
   Dix RD, 1998, OPHTHALMIC RES, V30, P295, DOI 10.1159/000055488
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Fantin A, 2010, BLOOD, V116, P829, DOI 10.1182/blood-2009-12-257832
   Farrell HE, 2011, J VIROL, V85, P6091, DOI 10.1128/JVI.02113-10
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Grahame-Clarke C, 2003, CIRCULATION, V108, P678, DOI 10.1161/01.CIR.0000084505.54603.C7
   GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hagedorn CL, 2006, OPHTHAL RES, P3, DOI 10.1007/978-1-59745-047-8_1
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hanson LK, 1999, J VIROL, V73, P5970, DOI 10.1128/JVI.73.7.5970-5980.1999
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Hodson EM, 2005, LANCET, V365, P2105, DOI 10.1016/S0140-6736(05)66553-1
   Horvath R, 2000, J CLIN VIROL, V16, P17, DOI 10.1016/S1386-6532(99)00064-5
   Hsich E, 2001, ATHEROSCLEROSIS, V156, P23, DOI 10.1016/S0021-9150(00)00608-0
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Koffron AJ, 1998, J VIROL, V72, P95, DOI 10.1128/JVI.72.1.95-103.1998
   Kol Amir, 2004, Ital Heart J, V5, P350
   Krabbe KS, 2004, EXP GERONTOL, V39, P687, DOI 10.1016/j.exger.2004.01.009
   LaVerda D, 1999, Infect Dis Obstet Gynecol, V7, P64, DOI 10.1155/S1064744999000137
   Leinonen M, 2000, SCAND CARDIOVASC J, V34, P12
   Lenzo JC, 2001, ANTIMICROB AGENTS CH, V45, P1444, DOI 10.1128/AAC.45.5.1444-1449.2001
   Liliana S, 2011, VIRUS RES, V157, P193
   Lowe G D, 2001, Ann Periodontol, V6, P1, DOI 10.1902/annals.2001.6.1.1
   Lu M, 2006, OPHTHAL RES, P309, DOI 10.1007/978-1-59745-047-8_18
   Ludewig B, 2004, J LEUKOCYTE BIOL, V76, P300, DOI 10.1189/jlb.1203605
   Ma JX, 2006, OPHTHAL RES, P23, DOI 10.1007/978-1-59745-047-8_2
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   MAUEL J, 1971, J EXP MED, V134, P335, DOI 10.1084/jem.134.2.335
   Maussang D, 2009, CANCER RES, V69, P2861, DOI 10.1158/0008-5472.CAN-08-2487
   MELNICK JL, 1983, LANCET, V2, P644
   MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166
   Mocarski ES., 2007, FIELDS VIROLOGY, P2702
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325
   Muhlestein JB, 2000, CIRCULATION, V102, P1917, DOI 10.1161/01.CIR.102.16.1917
   Muhlestein Joseph B, 2002, Am J Cardiovasc Drugs, V2, P107, DOI 10.2165/00129784-200202020-00004
   Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298
   O'Connell S. R., 1999, VITREORETINAL DIS ES, P213
   Orloff SL, 2002, TRANSPLANTATION, V73, P679, DOI 10.1097/00007890-200203150-00005
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Prichard MN, 2011, VIRUS RES, V157, P212, DOI 10.1016/j.virusres.2010.11.004
   Qavi H B, 2000, Cent Eur J Public Health, V8, P71
   Randolph-Habecker J, 2002, CYTOKINE, V19, P37, DOI 10.1006/cyto.2002.0874
   Reddehase MJ, 2002, J CLIN VIROL, V25, pS23
   Reinhardt B, 2005, J GEN VIROL, V86, P23, DOI 10.1099/vir.0.80327-0
   Reinhardt B, 2006, J GEN VIROL, V87, P2849, DOI 10.1099/vir.0.81955-0
   RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Sinzger C, 1996, J INFECT DIS, V173, P240, DOI 10.1093/infdis/173.1.240
   Steinhoff G, 1995, SCAND J INFECT DIS, P58
   Streblow DN, 2008, CURR TOP MICROBIOL, V325, P397
   Streblow DN, 2003, J VIROL, V77, P2182, DOI 10.1128/JVI.77.3.2182-2194.2003
   Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1
   SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410
   Sweet C, 1999, FEMS MICROBIOL REV, V23, P457, DOI 10.1111/j.1574-6976.1999.tb00408.x
   Tielsch JA, 1995, VISION PROBLEMS US R, P1
   Tikkanen J, 2001, TRANSPLANT P, V33, P1801, DOI 10.1016/S0041-1345(00)02686-5
   Tombran-Tink J, 2006, OPHTHAL RES, P215, DOI 10.1007/978-1-59745-047-8_13
   Valantine HA, 1999, CIRCULATION, V100, P61, DOI 10.1161/01.CIR.100.1.61
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vliegen I, 2004, MICROBES INFECT, V6, P1056, DOI 10.1016/j.micinf.2004.05.020
   Vliegen I, 2004, MICROBES INFECT, V6, P17, DOI 10.1016/j.micinf.2003.09.024
   Vomaske J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000304
   WU TC, 1992, AM J PATHOL, V140, P739
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zeng HS, 2005, TRANSPLANTATION, V79, P17, DOI 10.1097/01.TP.0000137334.46155.94
NR 89
TC 23
Z9 23
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD APR
PY 2012
VL 8
IS 4
AR e1002671
DI 10.1371/journal.ppat.1002671
PG 16
WC Microbiology; Parasitology; Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microbiology; Parasitology; Virology
GA 934KY
UT WOS:000303444200055
PM 22570607
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Yu, M
   Benham, A
   Logan, S
   Brush, RS
   Mandal, MNA
   Anderson, RE
   Agbaga, MP
AF Yu, Man
   Benham, Aaron
   Logan, Sreemathi
   Brush, R. Steven
   Mandal, Md Nawajes A.
   Anderson, Robert E.
   Agbaga, Martin-Paul
TI ELOVL4 protein preferentially elongates 20:5n3 to very long chain PUFAs
   over 20:4n6 and 22:6n3
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE elongase of very long chain fatty acids; very long chain polyunsaturated
   fatty acids; chylomicrons; fatty acids/biosynthesis; juvenile autosomal
   dominant Stargardt-like macular dystrophy type 3 disease; arachidonic
   acid; fish oil
ID POLYUNSATURATED FATTY-ACIDS; DIETARY DOCOSAHEXAENOIC ACID; MACULAR
   DEGENERATION; RETINITIS-PIGMENTOSA; ELECTRICAL RESPONSE; FISH
   CONSUMPTION; GENE-TRANSFER; N-3; MICE; BIOSYNTHESIS
AB We hypothesized that reduction/loss of very long chain PUFAs (VLC-PUFAs) due to mutations in the ELOn-gase of very long chain fatty acid-4 (ELOVL4) protein contributes to retinal degeneration in autosomal dominant Stargardt-like macular dystrophy (STGD3) and age-related macular degeneration; hence, increasing VLC-PUFA in the retina of these patients could provide some therapeutic benefits. Thus, we tested the efficiency of elongation of C20-C22 PUFA by the ELOVL4 protein to determine which substrates are the best precursors for biosynthesis of VLC-PUFA. The ELOVL4 protein was expressed in pheochromocytoma cells, while green fluorescent protein-expressing and nontransduced cells served as controls. The cells were treated with 20:5n3, 22:6n3, and 20:4n6, either individually or in equal combinations. Both transduced and control cells internalized and elongated the supplemented FAs to C22-C26 precursors. Only ELOVL4-expressing cells synthesized C28-C38 VLC-PUFA from these precursors. In general, 20: 5n3 was more efficiently elongated to VLC-PUFA in the ELOVL4-expressing cells, regardless of whether it was in combination with 22: 6n3 or with 20: 4n6. In each FA treatment group, C34 and C36 VLC-PUFAs were the predominant VLC-PUFAs in the ELOVL4-expressing cells. In summary, 20: 5n3, followed by 20: 4n6, seems to be the best precursor for boosting the synthesis of VLC-PUFA by ELOVL4 protein.-Yu, M., A. Benham, S. Logan, R. S. Brush, M. N. A. Mandal, R. E. Anderson, and M-P. Agbaga. ELOVL4 protein preferentially elongates 20: 5n3 to very long chain PUFAs over 20: 4n6 and 22: 6n3. J. Lipid Res. 2012. 53: 494-504.
C1 [Benham, Aaron; Logan, Sreemathi; Brush, R. Steven; Mandal, Md Nawajes A.; Anderson, Robert E.; Agbaga, Martin-Paul] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK USA.
   [Yu, Man; Logan, Sreemathi; Anderson, Robert E.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK USA.
   [Benham, Aaron; Logan, Sreemathi; Brush, R. Steven; Mandal, Md Nawajes A.; Anderson, Robert E.; Agbaga, Martin-Paul] Dean McGee Eye Inst, Oklahoma City, OK USA.
   [Yu, Man] Sichuan Univ, W China Hosp, Ophthalm Labs, Chengdu, Peoples R China.
   [Yu, Man] Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center; Sichuan University; Sichuan University
RP Agbaga, MP (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK USA.
EM martin-paul-agbaga@ouhsc.edu
RI Logan, Sreemathi/AAV-1098-2021; Chen, Tianren/AAS-6018-2021
OI Logan, Sreemathi/0000-0001-9160-0383
FU National Institutes of Health, National Eye Institute [EY-04149,
   EY-00871, EY-12190]; National Center for Research Resources [RR-17703];
   Research to Prevent Blindness, Inc.; Foundation Fighting Blindness; Hope
   for Vision and Knights Templar Eye Foundation, Inc.; NATIONAL CENTER FOR
   RESEARCH RESOURCES [P20RR017703] Funding Source: NIH RePORTER; NATIONAL
   EYE INSTITUTE [P30EY012190, R01EY004149, R01EY000871] Funding Source:
   NIH RePORTER
FX This work was supported by National Institutes of Health, National Eye
   Institute, Grants EY-04149, EY-00871, and EY-12190 (R. E. A.); National
   Center for Research Resources Grant RR-17703 (R. E. A.); grants from
   Research to Prevent Blindness, Inc. and the Foundation Fighting
   Blindness (R. E. A.); and from the Hope for Vision and Knights Templar
   Eye Foundation, Inc. (M. P. A.). Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the National Institutes of Health.
CR Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105
   Agbaga MP, 2010, J LIPID RES, V51, P1624, DOI 10.1194/jlr.R005025
   Agbaga MP, 2010, ADV EXP MED BIOL, V664, P233, DOI 10.1007/978-1-4419-1399-9_27
   ANDERSON RE, 1992, ADV EXP MED BIOL, V318, P285
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   AVELDANO MI, 1992, ADV EXP MED BIOL, V318, P231
   AVELDANO MI, 1993, J BIOL CHEM, V268, P11663
   AVELDANO MI, 1988, BIOCHEMISTRY-US, V27, P1229, DOI 10.1021/bi00404a024
   AVELDANO MI, 1987, J BIOL CHEM, V262, P1172
   Bedell M, 2010, EXP EYE RES, V90, P476, DOI 10.1016/j.exer.2009.10.010
   BENOLKEN RM, 1973, SCIENCE, V182, P1253, DOI 10.1126/science.182.4118.1253
   Berdeaux O, 2010, J CHROMATOGR A, V1217, P7738, DOI 10.1016/j.chroma.2010.10.039
   Berson EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1306, DOI 10.1001/archopht.122.9.1306
   Bjerve K S, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P862
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Brush RS, 2010, INVEST OPHTH VIS SCI, V51, P4422, DOI 10.1167/iovs.09-5134
   BURR GO, 1973, NUTR REV, V31, P248
   Carmona-Antonanzas G, 2011, COMP BIOCHEM PHYS B, V159, P122, DOI 10.1016/j.cbpb.2011.02.007
   Catalan J, 2002, BEHAV NEUROSCI, V116, P1022, DOI 10.1037//0735-7044.116.6.1022
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   CONNOR WE, 1992, NUTR REV, V50, P21
   DeltonVandenbroucke I, 1997, J LIPID RES, V38, P147
   Demar JC, 2008, J LIPID RES, V49, P1963, DOI 10.1194/jlr.M800117-JLR200
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Furland NE, 2007, J BIOL CHEM, V282, P18151, DOI 10.1074/jbc.M700709200
   Furland NE, 2007, J BIOL CHEM, V282, P18141, DOI 10.1074/jbc.M700708200
   Garelli A, 2006, INVEST OPHTH VIS SCI, V47, P3017, DOI 10.1167/iovs.05-1659
   Ge YL, 2002, J NEUROCHEM, V82, P1360, DOI 10.1046/j.1471-4159.2002.01077.x
   German OL, 2006, J NEUROCHEM, V98, P1507, DOI 10.1111/j.1471-4159.2006.04061.x
   Greiner RS, 1999, LIPIDS, V34, pS239, DOI 10.1007/BF02562305
   Guillou H, 2010, PROG LIPID RES, V49, P186, DOI 10.1016/j.plipres.2009.12.002
   Hodge WG, 2006, CAN J OPHTHALMOL, V41, P481, DOI 10.1016/S0008-4182(06)80012-8
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   HOFFMAN DR, 1995, INVEST OPHTH VIS SCI, V36, P1009
   Hubbard AF, 2006, ARCH OPHTHALMOL-CHIC, V124, P257, DOI 10.1001/archopht.124.2.257
   Jakobsson A, 2006, PROG LIPID RES, V45, P237, DOI 10.1016/j.plipres.2006.01.004
   Jeffrey BG, 2002, LIPIDS, V37, P839, DOI 10.1007/s11745-002-0969-0
   Jung UJ, 2008, AM J CLIN NUTR, V87, p2003S, DOI 10.1093/ajcn/87.6.2003S
   Kang ZB, 2001, P NATL ACAD SCI USA, V98, P4050, DOI 10.1073/pnas.061040198
   Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7
   Li F, 2009, MOL VIS, V15, P1185
   Lin YH, 2005, J LIPID RES, V46, P1962, DOI 10.1194/jlr.M500127-JLR200
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Maharvi GM, 2010, TETRAHEDRON LETT, V51, P6426, DOI 10.1016/j.tetlet.2010.09.139
   Martin RE, 2005, INVEST OPHTH VIS SCI, V46, P1147, DOI 10.1167/iovs.04-1207
   Martin RE, 2000, NEUROCHEM RES, V25, P715, DOI 10.1023/A:1007575406896
   McMahon A, 2007, FEBS LETT, V581, P5459, DOI 10.1016/j.febslet.2007.10.050
   McMahon A, 2007, MOL VIS, V13, P258
   McMahon A, 2011, J LIPID RES, V52, P1128, DOI 10.1194/jlr.M014415
   Meyer A, 2004, J LIPID RES, V45, P1899, DOI 10.1194/jlr.M400181-JLR200
   Miyauchi O, 2001, OPHTHALMIC RES, V33, P191, DOI 10.1159/000055669
   Monroig O, 2010, BBA-MOL CELL BIOL L, V1801, P1145, DOI 10.1016/j.bbalip.2010.06.005
   Murayama K, 2002, EXP EYE RES, V74, P671, DOI 10.1006/exer.2002.1151
   Niu SL, 2004, J BIOL CHEM, V279, P31098, DOI 10.1074/jbc.M404376200
   Ofman R, 2010, EMBO MOL MED, V2, P90, DOI 10.1002/emmm.201000061
   Ohno Y, 2010, P NATL ACAD SCI USA, V107, P18439, DOI 10.1073/pnas.1005572107
   Okuda A, 2010, MOL VIS, V16, P2438
   PAWLOSKY RJ, 1992, J LIPID RES, V33, P1711
   POULOS A, 1988, BIOCHEM J, V253, P645, DOI 10.1042/bj2530645
   REZANKA T, 1989, PROG LIPID RES, V28, P147, DOI 10.1016/0163-7827(89)90011-8
   Rezanka T, 2009, PROG LIPID RES, V48, P206, DOI 10.1016/j.plipres.2009.03.003
   Richardson UI, 2007, BBA-MOL CELL BIOL L, V1771, P558, DOI 10.1016/j.bbalip.2007.01.016
   Rotstein NP, 1996, BIOCHEM J, V316, P859, DOI 10.1042/bj3160859
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Suh M, 2005, CURR EYE RES, V30, P959, DOI 10.1080/02713680500246957
   Suh M, 2009, INVEST OPHTH VIS SCI, V50, P4394, DOI 10.1167/iovs.08-2565
   Torrejon C, 2007, PROSTAG LEUKOTR ESS, V77, P319, DOI 10.1016/j.plefa.2007.10.014
   Vasireddy V, 2006, INVEST OPHTH VIS SCI, V47, P4558, DOI 10.1167/iovs.06-0353
   Vasireddy V, 2009, EXP EYE RES, V89, P905, DOI 10.1016/j.exer.2009.07.021
   Weisinger HS, 2002, LIPIDS, V37, P759, DOI 10.1007/s11745-002-0958-3
   WHEELER TG, 1975, SCIENCE, V188, P1312, DOI 10.1126/science.1145197
   Xiao JN, 2005, INVEST OPHTH VIS SCI, V46, P3777, DOI 10.1167/iovs.05-0724
NR 78
TC 37
Z9 39
U1 0
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD MAR
PY 2012
VL 53
IS 3
BP 494
EP 504
DI 10.1194/jlr.M021386
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 900IK
UT WOS:000300880200017
PM 22158834
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Zhou, T
   Zhou, KK
   Lee, K
   Gao, G
   Lyons, TJ
   Kowluru, R
   Ma, JX
AF Zhou, T.
   Zhou, K. K.
   Lee, K.
   Gao, G.
   Lyons, T. J.
   Kowluru, R.
   Ma, J-x.
TI The role of lipid peroxidation products and oxidative stress in
   activation of the canonical wingless-type MMTV integration site (WNT)
   pathway in a rat model of diabetic retinopathy
SO DIABETOLOGIA
LA English
DT Article
DE Diabetic retinopathy; Inflammation; LRP; Oxidation; Peroxidation;
   Retina; WNT
ID LOW-DENSITY-LIPOPROTEIN; FORKHEAD-BOX-O; T-CELL-FACTOR; BETA-CATENIN;
   PLASMINOGEN-ACTIVATOR; SIGNALING PATHWAY; N-ACETYLCYSTEINE; LDL;
   PROTEINS; RECEPTOR
AB Our recent studies suggest that activation of the wingless-type MMTV integration site (WNT) pathway plays pathogenic roles in diabetic retinopathy and age-related macular degeneration. Here we investigated the causative role of oxidative stress in retinal WNT pathway activation in an experimental model of diabetes.
   Cultured retinal pigment epithelial cells and retinal capillary endothelial cells were treated with a lipid peroxidation product, 4-hydroxynonenal (HNE), and an antioxidant, N-acetyl-cysteine (NAC). In vivo, rats with streptozotocin-induced diabetes were treated by NAC for 8 weeks. Activation of the canonical WNT pathway was measured by TOPFLASH assay and by western blot analysis of WNT pathway components and a WNT target gene, Ctgf. Oxidative stress in the retina was evaluated by immunostaining of HNE and 3-nitrotyrosine.
   Levels of phosphorylated and total LDL receptor-related protein (LRP)6, and cytosolic beta-catenin, as well as transcriptional activity of T cell factor (TCF)/beta-catenin were significantly increased by HNE. The production of connective tissue growth factor (CTGF) was also upregulated by HNE. NAC blocked the WNT pathway activation induced by HNE. Furthermore, LRP6 stability was increased by HNE and decreased by NAC. Retinal levels of HNE and 3-nitrotyrosine were significantly increased in diabetic rats, compared with those in non-diabetic rats. In the same diabetic rat retinas, levels of LRP6, cytosolic beta-catenin and CTGF were significantly increased. NAC treatment reduced HNE and 3-nitrotyrosine levels and attenuated the upregulation of LRP6, beta-catenin and CTGF in diabetic rat retina.
   Lipid peroxidation products activate the canonical WNT pathway through oxidative stress, which plays an important role in the development of retinal diseases.
C1 [Zhou, T.; Zhou, K. K.; Lee, K.; Lyons, T. J.; Ma, J-x.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
   [Zhou, T.; Gao, G.] Sun Yat Sen Univ, Dept Biochem, Zhongshan Med Sch, Guangzhou 510275, Guangdong, Peoples R China.
   [Lyons, T. J.; Ma, J-x.] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Oklahoma Diabet Ctr, Oklahoma City, OK 73104 USA.
   [Lyons, T. J.; Ma, J-x.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Sect Endocrinol & Diabet, Oklahoma City, OK 73104 USA.
   [Kowluru, R.] Wayne State Univ, Dept Ophthalmol, Detroit, MI USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; Sun Yat Sen University; University of Oklahoma System;
   University of Oklahoma Health Sciences Center; University of Oklahoma
   System; University of Oklahoma Health Sciences Center; Wayne State
   University
RP Ma, JX (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.
EM jian-xing-ma@ouhsc.edu
RI Zhou, Kelu/C-1322-2017
OI Zhou, Kelu/0000-0001-6751-942X; Lyons, Timothy/0000-0003-2106-1622
FU National Institutes of Health [EY018659, EY012231, EY019309,
   P20RR024215, EY17313]; Oklahoma Center for the Advancement of Science
   and Technology (OCAST); ADA; NATIONAL CENTER FOR RESEARCH RESOURCES
   [P20RR024215] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY018659, R01EY019309, R01EY012231, R01EY017313] Funding Source: NIH
   RePORTER
FX This study was supported by National Institutes of Health grants
   EY018659, EY012231, EY019309, P20RR024215, EY17313, a grant from the
   Oklahoma Center for the Advancement of Science and Technology (OCAST)
   and a research award from the ADA.
CR Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   Atkuri KR, 2007, CURR OPIN PHARMACOL, V7, P355, DOI 10.1016/j.coph.2007.04.005
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Y, 2009, AM J PATHOL, V175, P2676, DOI 10.2353/ajpath.2009.080945
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Dozza B, 2004, J NEUROCHEM, V89, P1224, DOI 10.1111/j.1471-4159.2004.02413.x
   Drake J, 2004, NEUROSCI LETT, V356, P155, DOI 10.1016/j.neulet.2003.11.047
   Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8
   Funato Y, 2006, NAT CELL BIOL, V8, P501, DOI 10.1038/ncb1405
   Gong SP, 2008, STEM CELLS DEV, V17, P695, DOI 10.1089/scd.2007.0168
   GRANT MB, 1991, INVEST OPHTH VIS SCI, V32, P53
   Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200
   Klein RL, 2005, ANN NY ACAD SCI, V1043, P379, DOI 10.1196/annals.1333.044
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Kuiper EJ, 2008, J HISTOCHEM CYTOCHEM, V56, P785, DOI 10.1369/jhc.2008.950980
   Lad N, 2008, STEM CELLS DEV, V18, P7
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Maiese K, 2008, PHARMACOL THERAPEUT, V118, P58, DOI 10.1016/j.pharmthera.2008.01.004
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007-0259
   Mattson MP, 2009, EXP GERONTOL, V44, P625, DOI 10.1016/j.exger.2009.07.003
   Munoz-Najar U, 2011, ANTIOXID REDOX SIGN, V14, P241, DOI 10.1089/ars.2010.3250
   Nagai N, 2009, INVEST OPHTH VIS SCI, V50, P1903, DOI 10.1167/iovs.08-2383
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821
   Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787
   Onorato JM, 1998, ANN NY ACAD SCI, V854, P277, DOI 10.1111/j.1749-6632.1998.tb09909.x
   Pan WJ, 2008, SCIENCE, V321, P1350, DOI 10.1126/science.1160741
   Polak Monika, 2004, Ann Univ Mariae Curie Sklodowska Med, V59, P434
   Poli G, 2008, MED RES REV, V28, P569, DOI 10.1002/med.20117
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Shin SY, 2004, CANCER LETT, V212, P225, DOI 10.1016/j.canlet.2004.03.003
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955-2964.2006
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   Tsai GY, 2009, CLIN EXP OPHTHALMOL, V37, P223, DOI 10.1111/j.1442-9071.2009.02000.x
   Usatyuk PV, 2006, J BIOL CHEM, V281, P35554, DOI 10.1074/jbc.M607305200
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59
   Wu MY, 2008, INVEST OPHTH VIS SCI, V49, P2679, DOI 10.1167/iovs.07-1440
   Yang YS, 2003, ACTA BIOCHIM POL, V50, P319
   Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540
   Zhou T, 2009, INVEST OPHTH VIS SCI, V51, P4371
NR 49
TC 59
Z9 61
U1 1
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD FEB
PY 2011
VL 54
IS 2
BP 459
EP 468
DI 10.1007/s00125-010-1943-1
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 703SO
UT WOS:000286001800032
PM 20978740
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wong, WT
   Kam, W
   Cunningham, D
   Harrington, M
   Hammel, K
   Meyerle, CB
   Cukras, C
   Chew, EY
   Sadda, SR
   Ferris, FL
AF Wong, Wai T.
   Kam, Waynekid
   Cunningham, Denise
   Harrington, Molly
   Hammel, Keri
   Meyerle, Catherine B.
   Cukras, Catherine
   Chew, Emily Y.
   Sadda, Srinivas R.
   Ferris, Frederick L.
TI Treatment of Geographic Atrophy by the Topical Administration of OT-551:
   Results of a Phase II Clinical Trial
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL-ACUITY LOSS; MACULAR DEGENERATION; NATURAL-HISTORY; OXIDATIVE
   DAMAGE; RISK-FACTORS; VITAMIN-E; AGE; DISEASE; AUTOFLUORESCENCE;
   PATHOGENESIS
AB PURPOSE. To investigate the safety and preliminary efficacy of OT-551, a disubstituted hydroxylamine with antioxidant properties, for the treatment of geographic atrophy (GA), the advanced atrophic form of age-related macular degeneration (AMD).
   METHODS. The study was a single-center, open-label phase II trial, enrolling 10 participants with bilateral GA. Topical 0.45% OT-551 was administered in one randomly assigned eye three times daily for 2 years. Safety measures were assessed by complete ophthalmic examination, fundus photography, and review of symptoms. The primary efficacy outcome measure was the change in best corrected visual acuity at 24 months. Secondary efficacy measures included changes in area of GA, contrast sensitivity, microperimetry measurements, and total drusen area from baseline.
   RESULTS. Study drug was well tolerated and was associated with few adverse events. The mean change in BCVA at 2 years was +0.2 +/- 13.3 letters in the study eyes and -11.3 +/- 7.6 letters in fellow eyes (P = 0.0259). However, no statistically significant differences were found between the study and fellow eyes for all other secondary outcome measures.
   CONCLUSIONS. OT-551 was well tolerated by study participants and was not associated with any serious adverse effects. Efficacy measurements in this small study indicate a possible effect in maintaining visual acuity. However, the absence of significant effects on other outcomes measures in this study suggests that OT-551, in the current concentration and mode of delivery, may have limited or no benefit as a treatment for GA (ClinicalTrials.gov number, NCT00306488). (Invest Ophthalmol Vis Sci. 2010;51:6131-6139) DOI:10.1167/iovs.10-5637
C1 [Wong, Wai T.; Meyerle, Catherine B.; Cukras, Catherine; Chew, Emily Y.; Ferris, Frederick L.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Wong, Wai T.; Kam, Waynekid] NEI, Off Sci Director, NIH, Bethesda, MD 20892 USA.
   [Cunningham, Denise] NEI, Off Clin Director, NIH, Bethesda, MD 20892 USA.
   [Harrington, Molly; Hammel, Keri] EMMES Corp, Rockville, MD USA.
   [Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); National Institutes of Health (NIH) - USA; NIH National
   Eye Institute (NEI); Emmes Corporation; Doheny Eye Institute; University
   of Southern California
RP Wong, WT (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, 7 Mem Dr,Bldg 7,Room 217, Bethesda, MD 20892 USA.
EM wongw@xnei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute; NATIONAL EYE INSTITUTE [ZIAEY000494,
   ZIEEY000487, ZIAEY000497, ZIAEY000495] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute Intramural Research Program.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   CUKRAS C, OPHTHALMOLOGY, V117, P489
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Liang QH, 2005, BIOCHEM PHARMACOL, V70, P1371, DOI 10.1016/j.bcp.2005.04.011
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Prahs P, 2010, GRAEF ARCH CLIN EXP, V248, P651, DOI 10.1007/s00417-009-1208-1
   SAMUNI A, 1991, BIOCHEMISTRY-US, V30, P555, DOI 10.1021/bi00216a033
   Samuni AM, 2001, BBA-GEN SUBJECTS, V1525, P70, DOI 10.1016/S0304-4165(00)00172-0
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Sibony P, 2008, J NEURO-OPHTHALMOL, V28, P114, DOI 10.1097/WNO.0b013e318175cd90
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Yamamoto Manabu, 2009, Osaka City Med J, V55, P19
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhou JL, 2008, PHOTOCHEM PHOTOBIOL, V84, P75, DOI 10.1111/j.1751-1097.2007.00205.x
NR 37
TC 79
Z9 82
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2010
VL 51
IS 12
BP 6131
EP 6139
DI 10.1167/iovs.10-5637
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 688GJ
UT WOS:000284837500007
PM 20574018
OA Green Published
DA 2022-11-30
ER

PT J
AU Canovas, R
   Lima, VC
   Garcia, P
   Morini, C
   Prata, TS
   Rosen, RB
AF Canovas, Renata
   Lima, Veronica Castro
   Garcia, Patricia
   Morini, Chiara
   Prata, Tiago S.
   Rosen, Richard B.
TI Comparison between Macular Pigment Optical Density Measurements Using
   Two-Wavelength Autofluorescence and Heterochromatic Flicker Photometry
   Techniques
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; SPATIAL-DISTRIBUTION; FUNDUS
   AUTOFLUORESCENCE; LUTEIN SUPPLEMENTATION; PRIMATE RETINAS; AGE;
   DEGENERATION; CAROTENOIDS; EYES; POPULATION
AB PURPOSE. The association of macular pigment (MP) with age-related macular degeneration has been extensively studied in recent years, and interest in a rapid, objective, and accurate technique to measure MP optical density (MPOD) has increased. The purpose of this study was to compare the MPOD values at specific loci around the fovea using the heterochromatic flicker photometry (HFP) and the two-wavelength autofluorescence (AF) methods in a young, healthy population.
   METHODS. Ten patients (20 eyes) were enrolled. Subjects with any ocular or systemic disease were excluded. All patients underwent HFP and AF examination. The AF examination was performed using a modified scanning laser ophthalmoscope. Values for both devices were measured at four eccentricities around the fovea (0.25 degrees, 0.5 degrees, 1.0 degrees, and 1.75 degrees). Each eye was tested three times with each method. Statistical analysis was based on paired t-test and linear regression analysis.
   RESULTS. At all retinal eccentricities, the HFP values were consistently lower than the HRA values (P < 0.001). There was, however, a significant correlation at almost all locations. The strongest correlation between two methods was found at 1.75 degrees from the center of the fovea (r = 0.73).
   CONCLUSIONS. The modified-HRA AF method for MPOD generated results that were highly correlated with the standard HPF method but consistently higher at all eccentricities. These findings suggest that HRA can be reliably used in patients unable to perform HPF, which is important for wider clinical application of MP testing. (Invest Ophthalmol Vis Sci. 2010;51:3152-3156) DOI:10.1167/iovs.09-3608
C1 [Canovas, Renata; Lima, Veronica Castro; Garcia, Patricia; Morini, Chiara; Rosen, Richard B.] New York Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, New York, NY 10003 USA.
   [Prata, Tiago S.] New York Eye & Ear Infirm, Einhorn Clin Res Ctr, New York, NY 10003 USA.
   [Garcia, Patricia; Rosen, Richard B.] New York Med Coll, Dept Ophthalmol, Valhalla, NY 10595 USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Eye & Ear
   Infirmary of Mount Sinai; New York Medical College
RP Rosen, RB (通讯作者)，New York Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, 310 E 14th St, New York, NY 10003 USA.
EM rrosen@nyee.edu
RI Prata, Tiago/AAV-6676-2020
OI Prata, Tiago/0000-0003-1830-3766
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2004, VISION RES, V44, P3045, DOI 10.1016/j.visres.2004.07.008
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Celentano JC, 2002, J NUTR, V132, p535S, DOI 10.1093/jn/132.3.535S
   Chen SF, 2001, CURR EYE RES, V23, P422, DOI 10.1076/ceyr.23.6.422.6963
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Duncan JL, 2002, EXP EYE RES, V74, P371, DOI 10.1006/exer.2001.1126
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   Haegerstrom-Portnoy G, 1999, OPTOMETRY VISION SCI, V76, P141, DOI 10.1097/00006324-199903000-00014
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Helb HM, 2008, RETINA-J RET VIT DIS, V28, P808, DOI 10.1097/IAE.0b013e31816d81aa
   KATZ J, 1994, INVEST OPHTH VIS SCI, V35, P2461
   KATZ J, 1988, OPHTHALMIC SURG LAS, V19, P585
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   PEASE PL, 1987, VISION RES, V27, P705, DOI 10.1016/0042-6989(87)90067-8
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Wooten BR, 2005, OPTOMETRY VISION SCI, V82, P378, DOI 10.1097/01.OPX.0000162654.32112.A1
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
NR 37
TC 19
Z9 20
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2010
VL 51
IS 6
BP 3152
EP 3156
DI 10.1167/iovs.09-3608
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 598OC
UT WOS:000277846500045
PM 19578017
DA 2022-11-30
ER

PT J
AU Henderson, BA
   Grimes, KJ
AF Henderson, Bonnie An
   Grimes, Kelly Jun
TI Blue-Blocking IOLs: A Complete Review of the Literature
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE blue blocking; circadian rhythm; color perception; contrast sensitivity;
   light blocking IOL; phototoxicity; scotopic vision; sleep disturbance;
   yellow IOLs
ID AGE-RELATED MACULOPATHY; FILTERING INTRAOCULAR LENSES; SHORT-WAVELENGTH
   LIGHT; BEAVER DAM EYE; MACULAR DEGENERATION; CONTRAST SENSITIVITY;
   MELATONIN SUPPRESSION; COLOR-VISION; RISK-FACTORS; CATARACT-SURGERY
AB Intraocular lenses (IOLs) that block both ultraviolet and blue wavelength light (<500 nm) were introduced in the 1990s. Since then, the potential benefits and harm from blocking blue light has been debated. We report the results of a complete review of all peer-reviewed published studies regarding the impact of blocking the transmission of blue light. Fifty-six published reports on subjects related to blue-blocking lenses including sleep disturbance, visual outcomes, cataract surgery, lens transmittance, sunlight exposure, and macular disease were found in peer reviewed journals from 1962 to 2009. Eleven reports specifically compared visual outcomes between blue-blocking IOLs and non-blue-locking IOLs. Of these, 10 independent studies (10/11, 91%) concluded that there are no significant effects of blue-blocking IOLs on various meters of visual performance including visual acuity, contrast sensitivity, color perception, and photopic, mesopic, and scotopic sensitivities. Only one group of authors reported that the use of blue-blocking IOLs may have detrimental effects on scotopic vision and circadian rhythms. However, the actual clinical significance of these potential negative effects on scotopic vision and on sleep patterns is uncertain. The benefits of blocking the transmission of blue light to the macula and the relationship between progression of age-related macular degeneration remain unclear. However, the published studies clearly state that the use of blue-blocking IOLs is not detrimental in visual acuity, color perception, and contrast sensitivity. The reported potential negative effects on scotopic vision and sleep disturbance appear to be minimal and may not be clinically relevant. (Surv Ophthalmol 55:284-289, 2010. (C) 2010 Elsevier Inc. All rights reserved.)
C1 Harvard Univ, Sch Med, Boston, MA USA.
   Ophthalm Consultants Boston, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Ophthalmic Consultants of
   Boston
RP Henderson, BA (通讯作者)，Ophthalm Consultants Boston, 52 2nd Ave,Suite 2500, Waltham, MA 02451 USA.
EM bahenderson@eyeboston.com
CR Asplund R, 2004, ARCH GERONTOL GERIAT, V38, P69, DOI 10.1016/j.archger.2003.08.001
   Asplund R, 2002, ARCH GERONTOL GERIAT, V35, P179, DOI 10.1016/S0167-4943(02)00022-5
   BADIA P, 1991, PHYSIOL BEHAV, V50, P583, DOI 10.1016/0031-9384(91)90549-4
   Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262
   Boivin DB, 1996, NATURE, V379, P540, DOI 10.1038/379540a0
   Brainard GC, 2001, J NEUROSCI, V21, P6405
   BROADWAY J, 1986, LANCET, V2, P813
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   BUYSSE DJ, 1992, J AM GERIATR SOC, V40, P779, DOI 10.1111/j.1532-5415.1992.tb01849.x
   Charman WN, 2003, OPHTHAL PHYSL OPT, V23, P181, DOI 10.1046/j.1475-1313.2003.00105.x
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   CZEISLER CA, 1986, SCIENCE, V233, P667, DOI 10.1126/science.3726555
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Hafezi F, 1997, EXP EYE RES, V64, P963, DOI 10.1006/exer.1997.0288
   HAM WT, 1980, VISION RES, V20, P1105, DOI 10.1016/0042-6989(80)90047-4
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Herljevic M, 2005, EXP GERONTOL, V40, P237, DOI 10.1016/j.exger.2004.12.001
   Kara N, 2006, J CATARACT REFR SURG, V32, P1328, DOI 10.1016/j.jcrs.2006.03.033
   KINNEY JAS, 1983, AM J OPTOM PHYS OPT, V60, P132
   Kiser AK, 2008, CLIN EXP OPHTHALMOL, V36, P514, DOI 10.1111/j.1442-9071.2008.01824.x
   Lamberg L, 1998, JAMA-J AM MED ASSOC, V280, P1123, DOI 10.1001/jama.280.13.1123
   LAMBERG L, 1998, JAMA-J AM MED ASSOC, V280, P1126
   Landers J, 2007, CLIN EXP OPHTHALMOL, V35, P152, DOI 10.1111/j.1442-9071.2006.01434.x
   Landers JA, 2009, J CATARACT REFR SURG, V35, P83, DOI 10.1016/j.jcrs.2008.10.015
   Leger D, 1999, ANN NEUROL, V46, P648, DOI 10.1002/1531-8249(199910)46:4<648::AID-ANA14>3.0.CO;2-X
   LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030
   LOCKLEY S, 1995, LANCET, V346, P1491, DOI 10.1016/S0140-6736(95)92508-2
   Lucas RJ, 2001, NAT NEUROSCI, V4, P621, DOI 10.1038/88443
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mainster M A, 1978, J Am Intraocul Implant Soc, V4, P84
   MAINSTER MA, 1978, AM J OPHTHALMOL, V85, P167, DOI 10.1016/S0002-9394(14)75943-4
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Mainster MA, 2003, BRIT J OPHTHALMOL, V87, P1523, DOI 10.1136/bjo.87.12.1523
   Marshall J, 2005, J CATARACT REFR SURG, V31, P2319, DOI 10.1016/j.jcrs.2004.11.061
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Moseley MJ, 1996, LANCET, V348, P1514, DOI 10.1016/S0140-6736(05)65928-4
   Raj SM, 2005, J CATARACT REFR SURG, V31, P2324, DOI 10.1016/j.jcrs.2005.08.052
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P2088, DOI 10.1016/j.jcrs.2005.04.029
   RUSHTON WA, 1962, SCI AM, V207, P190
   Schmidinger G, 2008, J CATARACT REFR SURG, V34, P769, DOI 10.1016/j.jcrs.2007.12.034
   Schwiegerling J, 2006, J CATARACT REFR SURG, V32, P141, DOI 10.1016/j.jcrs.2005.11.021
   Tabandeh H, 1998, AM J OPHTHALMOL, V126, P707, DOI 10.1016/S0002-9394(98)00133-0
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Thapan K, 2001, J PHYSIOL-LONDON, V535, P261, DOI 10.1111/j.1469-7793.2001.t01-1-00261.x
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   van de Kraats J, 2007, J CATARACT REFR SURG, V33, P879, DOI 10.1016/j.jcrs.2007.02.020
   van Norren D, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.117903
   vandenBerg TJTP, 1997, INVEST OPHTH VIS SCI, V38, P1321
   Vuori ML, 2006, ACTA OPHTHALMOL SCAN, V84, P92, DOI 10.1111/j.1600-0420.2005.00579.x
   Werner JS, 2005, BRIT J OPHTHALMOL, V89, P1518, DOI 10.1136/bjo.2005.073734
   Wirtitsch MG, 2009, OPHTHALMOLOGY, V116, P39, DOI 10.1016/j.ophtha.2008.08.035
   YAP M, 1984, OPHTHAL PHYSL OPT, V4, P227, DOI 10.1111/j.1475-1313.1984.tb00360.x
   Yuan ZX, 2004, AM J OPHTHALMOL, V138, P138, DOI 10.1016/j.ajo.2004.02.024
   1992, ARCH OPHTHALMOL, V110, P1701
NR 57
TC 39
Z9 41
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0039-6257
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD MAY-JUN
PY 2010
VL 55
IS 3
BP 284
EP 289
DI 10.1016/j.survophthal.2009.07.007
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 592HR
UT WOS:000277369700007
PM 20499436
DA 2022-11-30
ER

PT J
AU Chen, H
   Lukas, TJ
   Du, N
   Suyeoka, G
   Neufeld, AH
AF Chen, Huiyi
   Lukas, Thomas J.
   Du, Nga
   Suyeoka, Genn
   Neufeld, Arthur H.
TI Dysfunction of the Retinal Pigment Epithelium with Age: Increased Iron
   Decreases Phagocytosis and Lysosomal Activity
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR DEGENERATION; OXIDATIVE STRESS; CATHEPSIN-D; FERRIC
   NITRILOTRIACETATE; MOLECULAR CONTROL; SUBSTANTIA-NIGRA; POTENTIAL
   FACTOR; BRUCHS MEMBRANE; OUTER SEGMENTS; KNOCKOUT MICE
AB PURPOSE. Iron accumulation with age in the retinal pigment epithelium (RPE) may be one important source of oxidative stress that contributes to age-related macular degeneration (AMD). Young and old rodent RPE/choroid were compared to assess iron homeostasis during normal aging and the effects of increased iron on the functions of retinal pigment epithelial cells.
   METHODS. The iron level, mRNA expression, and protein level of iron-regulatory molecules in RPE/choroid were quantitatively compared between young and old animals. To test the effects of increased intracellular iron on the functions of retinal pigment epithelial cells, in vitro ARPE-19 cells were treated with high levels of iron and assessed for phagocytosis activity and lysosomal activity.
   RESULTS. Iron level was significantly increased in the aged RPE/choroid. Ferritin and ceruloplasmin mRNAs were significantly increased in the aged RPE/choroid, whereas transferrin, transferrin receptor, and ferroportin mRNAs did not change with age. At the protein level, decreased transferrin and transferrin receptor, increased ferritin and ceruloplasmin, and unchanged ferroportin were observed in the aged RPE/choroid. Exposure of ARPE-19 cells to increased iron markedly decreased phagocytosis activity, interrupted cathepsin D processing, and reduced cathepsin D activity in retinal pigment epithelial cells.
   CONCLUSIONS. The RPE/choroid of aged animals demonstrates iron accumulation and associated alterations in iron homeostasis. Iron accumulation with age may impair the phagocytosis and lysosomal functions of retinal pigment epithelial cells in the aged RPE/choroid. Therefore, age-related changes of iron homeostasis in the RPE could increase the susceptibility of the tissue to genetic mutations associated with AMD. (Invest Ophthalmol Vis Sci. 2009; 50: 1895-1902) DOI: 10.1167/iovs.082850
C1 [Chen, Huiyi; Lukas, Thomas J.; Du, Nga; Suyeoka, Genn; Neufeld, Arthur H.] Northwestern Univ, Sch Med, Dept Ophthalmol, Lab Invest Aging Retina, Chicago, IL 60611 USA.
C3 Northwestern University
RP Chen, H (通讯作者)，Northwestern Univ, Sch Med, Dept Ophthalmol, Lab Invest Aging Retina, Tarry 13-752,303 E Chicago Ave, Chicago, IL 60611 USA.
EM huiyi-chen@northwestern.edu
FU National Institutes of Health [EY12017]; Forsythe Foundation; Research
   to Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY012017] Funding
   Source: NIH RePORTER
FX Supported by National Institutes of Health Grant EY12017, a generous
   gift from the Forsythe Foundation, and an unrestricted grant from
   Research to Prevent Blindness.
CR Aguirre P, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-3
   Bartzokis G, 1997, MAGN RESON IMAGING, V15, P29, DOI 10.1016/S0730-725X(96)00234-2
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bishop GM, 2002, DEV NEUROSCI-BASEL, V24, P184, DOI 10.1159/000065696
   BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664
   Chen HY, 2009, NEUROBIOL AGING, V30, P1865, DOI 10.1016/j.neurobiolaging.2008.01.002
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Crichton R., 2001, INORGANIC BIOCH IRON
   Dentchev T, 2005, ARCH OPHTHALMOL-CHIC, V123, P1745, DOI 10.1001/archopht.123.12.1745
   Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Duncan JL, 2003, INVEST OPHTH VIS SCI, V44, P826, DOI 10.1167/iovs.02-0438
   Fischer R, 2006, CHEMBIOCHEM, V7, P1428, DOI 10.1002/cbic.200600209
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Hahn P, 2006, NEUROREPORT, V17, P1803, DOI 10.1097/WNR.0b013e3280107776
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5
   Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175
   HUNT RC, 1992, J CELL PHYSIOL, V152, P102, DOI 10.1002/jcp.1041520114
   JELLINGER KA, 1993, ADV NEUROL, V60, P267
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Laurent-Matha V, 2006, J BIOCHEM, V139, P363, DOI 10.1093/jb/mvj037
   Lockwood TD, 2004, ARCH BIOCHEM BIOPHYS, V432, P12, DOI 10.1016/j.abb.2004.09.011
   Lockwood TD, 2006, PARASITOL RES, V100, P175, DOI 10.1007/s00436-006-0239-3
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   NIAZI SB, 1993, ANALYST, V118, P821, DOI 10.1039/an9931800821
   Nunez MT, 2004, FREE RADICAL BIO MED, V37, P953, DOI 10.1016/j.freeradbiomed.2004.06.005
   Qin SF, 2008, J BIOL CHEM, V283, P6744, DOI 10.1074/jbc.M708848200
   Rakoczy PE, 1996, EXP EYE RES, V63, P159, DOI 10.1006/exer.1996.0104
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Rattner A, 2006, NAT REV NEUROSCI, V7, P860, DOI 10.1038/nrn2007
   REGAN CM, 1980, EXP EYE RES, V30, P183, DOI 10.1016/0014-4835(80)90112-8
   Rouault TA, 2005, NAT REV MOL CELL BIO, V6, P345, DOI 10.1038/nrm1620
   Rouault TA, 2002, BLOOD CELL MOL DIS, V29, P309, DOI 10.1006/bcmd.2002.0571
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Sergeant C, 2004, METAL IONS BIOL MED, V8, P491
   SOFIC E, 1991, J NEUROCHEM, V56, P978, DOI 10.1111/j.1471-4159.1991.tb02017.x
   SWAIMAN KF, 1989, NEUROCHEM RES, V14, P683, DOI 10.1007/BF00964879
   SWAIMAN KF, 1991, NEUROCHEM RES, V16, P1269, DOI 10.1007/BF00966657
   WILLIAMS DM, 1974, AM J PHYSIOL, V227, P1094, DOI 10.1152/ajplegacy.1974.227.5.1094
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Yamaoka Kiyonori, 2002, Physiological Chemistry and Physics and Medical NMR, V34, P119
   Yefimova MG, 2002, INVEST OPHTH VIS SCI, V43, P537
   Zaidi N, 2008, BIOCHEM BIOPH RES CO, V376, P5, DOI 10.1016/j.bbrc.2008.08.099
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zecca L, 2001, J NEUROCHEM, V76, P1766, DOI 10.1046/j.1471-4159.2001.00186.x
NR 52
TC 74
Z9 74
U1 1
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2009
VL 50
IS 4
BP 1895
EP 1902
DI 10.1167/iovs.08-2850
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 424CP
UT WOS:000264543400056
PM 19151392
DA 2022-11-30
ER

PT J
AU Klettner, A
   Roider, J
AF Klettner, Alexa
   Roider, Johann
TI Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro:
   Efficiency and possible additional pathways
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL INJECTION;
   MONOCLONAL-ANTIBODY; AVASTIN; THERAPY; CELLS; VEGF; FAB; NEUROPILIN-1
AB PURPOSE. Vascular endothelial growth factor (VEGF) antagonists are the therapy of choice for age-related macular degeneration. Ranibizumab and pegaptanib have been approved by the United States Food and Drug Administration, whereas bevacizumab is used off label. In this study, the authors compare these VEGF inhibitors directly regarding their efficiency to neutralize VEGF in a quantifiable in vitro system.
   METHODS. Porcine retina-retinal pigment epithelium-choroid organ culture and RPE cell culture were prepared from fresh eyes, cultivated in a perfusion chamber, and treated with clinically relevant concentrations of bevacizumab, ranibizumab and pegaptanib. VEGF content of the supernatant was analyzed with ELISA. Additionally, the influence of bevacizumab and ranibizumab on intracellular VEGF was analyzed with Western blot.
   RESULTS. At clinically significant doses, bevacizumab (0.25 mg/mL) and ranibizumab (0.125 mg/mL) neutralized VEGF completely for 6 hours, whereas pegaptanib (0.08 mg/mL) showed no effect. Bevacizumab and ranibizumab neutralized VEGF significantly up to 16 hours. When diluted, bevacizumab lost its inhibiting properties at a concentration of 975 ng/mL, and ranibizumab neutralized VEGF up to a concentration of 120 ng/mL. Both substances significantly diminished VEGF expression in Western blot.
   CONCLUSIONS. At clinical doses, bevacizumab and ranibizumab are equally potent in neutralizing VEGF. To neutralize VEGF completely in this system, a fraction of the clinical dose is needed. Ranibizumab is more efficient at neutralizing VEGF when diluted. Pegaptanib showed no effect in this system, which might help explain the clinical experience regarding this drug. A direct effect of ranibizumab and bevacizumab on VEGF protein expression indicates additional pathways of VEGF inhibitors.
C1 [Klettner, Alexa; Roider, Johann] Univ Kiel, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel
RP Klettner, A (通讯作者)，Univ Kiel, Dept Ophthalmol, UK S-H,Campus Keil,Hegewischstr 2, D-24105 Kiel, Germany.
EM aklettner@ophthalmol.uni-kiel.de
RI Klettner, Alexa Karina/M-8344-2018; Roider, Johann/E-4513-2010
OI Klettner, Alexa/0000-0002-2709-1059
FU Deutsch Ophthalmologische Gesellschaft Forschungsforderpreis
FX Supported by Deutsch Ophthalmologische Gesellschaft
   Forschungsforderpreis.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Campochiaro PA, 2007, DRUG TODAY, V43, P529, DOI 10.1358/dot.2007.43.8.1120868
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fuh G, 2006, J BIOL CHEM, V281, P6625, DOI 10.1074/jbc.M507783200
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   Klettner A, 2003, BRIT J PHARMACOL, V138, P1004, DOI 10.1038/sj.bjp.0705132
   Kobuch K, 2008, EXP EYE RES, V86, P661, DOI 10.1016/j.exer.2008.01.011
   Kramer I, 2007, J CLIN PHARM THER, V32, P1, DOI 10.1111/j.1365-2710.2007.00800.x
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Liu WB, 2005, CYTOKINE, V32, P206, DOI 10.1016/j.cyto.2005.09.009
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6
   Presta LG, 1997, CANCER RES, V57, P4593
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   THOMAS EL, 2008, 7 INT S OC PHARM THE, pA32
   Zhao B, 2006, BRIT J OPHTHALMOL, V90, P1052, DOI 10.1136/bjo.2006.091215
NR 24
TC 137
Z9 141
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2008
VL 49
IS 10
BP 4523
EP 4527
DI 10.1167/iovs.08-2055
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 355IZ
UT WOS:000259703900043
PM 18441313
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Li, B
   Yin, W
   Hong, X
   Shi, Y
   Wang, HS
   Lin, SF
   Tang, SB
AF Li, Bin
   Yin, Wei
   Hong, Xun
   Shi, Yu
   Wang, Hong-Sheng
   Lin, Shao-Fen
   Tang, Shi-Bo
TI Remodeling retinal neovascularization by ALK1 gene transfection in vitro
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; HEMORRHAGIC TELANGIECTASIA TYPE-2;
   RECEPTOR-LIKE KINASE-1; TGF-BETA; OCULAR NEOVASCULARIZATION; VASCULAR
   DEVELOPMENT; ANGIOGENESIS; CELLS; EXPRESSION; ANTIBODY
AB PURPOSE. To explore a novel strategy for balancing retinal neovascularization by assessing the role activin-like kinase receptor 1 (ALK1) plays in neovascularization in vascular endothelial growth factor (VEGF)-stimulated human retinal capillary endothelial cells (HRCECs).
   METHODS. HRCECs were transfected with an ALK1 gene-encoding plasmid or a pSIREN-ALK1 RNAi vector and stimulated with VEGF. The mRNA and protein expression levels of ALK1, occludin, ANG2, and ALK5 were evaluated by real-time PCR and/or Western blot analysis. Microscopy techniques and flow cytometry were used to assess the effects of enhanced levels of ALK1 on migration and proliferation and the formation of tubelike structures of HRCECs.
   RESULTS. The level of ALK1 in ALK1-transfected cells was significantly increased compared with that in control cells. ALK1-transfected cells exhibited increased expression of occludin and decreased expression of ANG2 and ALK5, compared with expression in the control cells. HRCECs transfected with pSI-REN-ALK1 RNAi exhibited decreased expression of ALK1 and occludin and increased expression of ANG2 and ALK5 compared with the control cells. Transfection with ALK1 affected the migration and proliferation of VEGF-stimulated HRCECs. ALK1 also inhibited the formation of endothelial tubelike structures, but did allow the formation of entire vessel structures.
   CONCLUSIONS. Overexpression of ALK1 promoted remodeling of newly formed blood vessels and prevented further angiogenesis. These findings provide insight into the control of retinal neovascularization and demonstrate a novel strategy for maintaining a stable phase of vessel formation, allowing for effective retinal neovascularization without the common adverse effects seen in patients with diabetic retinopathy, age-related macular degeneration, and retinal vein occlusion.
C1 [Li, Bin; Shi, Yu; Lin, Shao-Fen; Tang, Shi-Bo] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
   [Yin, Wei] Sun Yat Sen Univ, Dept Biochem, Zhongshan Sch Med, Guangzhou 510060, Guangdong, Peoples R China.
   [Hong, Xun] Sun Yat Sen Univ, Anim Ctr, Dept Pharmacol, Guangzhou 510060, Guangdong, Peoples R China.
   [Wang, Hong-Sheng] Sun Yat Sen Univ, Ctr Microbiol Biochem & Pharmacol, Sch Pharmaceut Sci, Guangzhou 510060, Guangdong, Peoples R China.
   [Li, Bin] Huazhong Univ Sci & Technol, Dept Ophthalmol, Tongji Med Coll, Wuhan 430074, Hubei, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University; Huazhong University of Science & Technology
RP Tang, SB (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
EM scotopsin@yahoo.com.cn; tangsb@mail.sysu.edu.cn
RI Wang, Hongsheng/N-1940-2019; TANG, Shi/GXH-5719-2022; Yin,
   Wei/O-7401-2016; WANG, Hongsheng/C-8965-2011
OI Wang, Hongsheng/0000-0002-0054-4820; Yin, Wei/0000-0001-8862-3197; 
FU National Nature Science Foundation in China [30471849, 30672278]; Tongji
   Hospital Initiation Research Fund [20070716]; Huazhong University of
   Science and Technology; Wuhan and Sun Yat-sen University, Guangzhou
FX Supported in part by Grants 30471849 and 30672278 from the National
   Nature Science Foundation in China and Grant No. 20070716 from the
   Tongji Hospital Initiation Research Fund, and by the Huazhong University
   of Science and Technology and the Wuhan and Sun Yat-sen University,
   Guangzhou (BL).
CR Aiello LP, 1997, INVEST OPHTH VIS SCI, V38, P1647
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Assis AM, 2007, J HUM GENET, V52, P237, DOI 10.1007/s10038-006-0104-3
   Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S
   Borgstrom P, 1998, PROSTATE, V35, P1
   Campochiaro PA, 2007, CURR GENE THER, V7, P25, DOI 10.2174/156652307779940252
   Candia AF, 1997, DEVELOPMENT, V124, P4467
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Castanares C, 2007, J CELL SCI, V120, P1256, DOI 10.1242/jcs.03419
   Chang CW, 1997, INVEST OPHTH VIS SCI, V38, P1082
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Deng WT, 2005, HUM GENE THER, V16, P1247, DOI 10.1089/hum.2005.16.1247
   Feng YY, 1999, INVEST OPHTH VIS SCI, V40, P157
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferris FL, 2004, NEW ENGL J MED, V351, P2863, DOI 10.1056/NEJMe048316
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743
   Goumans MJ, 2003, TRENDS CARDIOVAS MED, V13, P301, DOI 10.1016/S1050-1738(03)00142-7
   Goumans MJ, 1999, DEVELOPMENT, V126, P3473
   Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48
   Hong KH, 2007, LAB INVEST, V87, P670, DOI 10.1038/labinvest.3700560
   Jonson T, 2001, INT J ONCOL, V19, P71
   Kanda S, 2003, J BIOL CHEM, V278, P257, DOI 10.1074/jbc.M204771200
   Kim JH, 2008, MOL VIS, V14, P556
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lamouille S, 2002, BLOOD, V100, P4495, DOI 10.1182/blood.V100.13.4495
   [李斌 LI Bin], 2006, [中国病理生理杂志, Chinese Journal of Pathophysiology], V22, P904
   Li B, 2006, MICROVASC RES, V72, P146, DOI 10.1016/j.mvr.2006.07.002
   Lux Andreas, 2006, BMC Cardiovasc Disord, V6, P13, DOI 10.1186/1471-2261-6-13
   Mallet C, 2006, STEM CELLS, V24, P2120, DOI 10.1634/stemcells.2005-0494
   Noonan Douglas M., 2007, V174, P219
   Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626
   Ota T, 2002, J CELL PHYSIOL, V193, P299, DOI 10.1002/jcp.10170
   Park SO, 2008, BLOOD, V111, P633, DOI 10.1182/blood-2007-08-107359
   Presta LG, 1997, CANCER RES, V57, P4593
   Roviezzo F, 2005, J PHARMACOL EXP THER, V314, P738, DOI 10.1124/jpet.105.086553
   Russ PK, 1998, INVEST OPHTH VIS SCI, V39, P2479
   SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355
   Scharpfenecker M, 2007, J CELL SCI, V120, P964, DOI 10.1242/jcs.002949
   Seki T, 2006, LAB INVEST, V86, P116, DOI 10.1038/labinvest.3700376
   Seki T, 2003, CIRC RES, V93, P682, DOI 10.1161/01.RES.0000095246.40391.3B
   Thurston G, 2002, J ANAT, V200, P575, DOI 10.1046/j.1469-7580.2002.00061.x
   Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X
   Wu XP, 2006, MICROVASC RES, V71, P12, DOI 10.1016/j.mvr.2005.11.004
   Yao YC, 2007, CARDIOVASC RES, V74, P279, DOI 10.1016/j.cardiores.2006.09.014
   Yao YC, 2006, J BIOL CHEM, V281, P33921, DOI 10.1074/jbc.M604239200
NR 46
TC 9
Z9 9
U1 1
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2008
VL 49
IS 10
BP 4553
EP 4560
DI 10.1167/iovs.07-0995
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 355IZ
UT WOS:000259703900047
PM 18829861
DA 2022-11-30
ER

PT J
AU Sepp, T
   Khan, JC
   Thurlby, DA
   Shahid, H
   Clayton, DG
   Moore, AT
   Bird, AC
   Yates, JRW
AF Sepp, T
   Khan, JC
   Thurlby, DA
   Shahid, H
   Clayton, DG
   Moore, AT
   Bird, AC
   Yates, JRW
CA AMD Study Grp
TI Complement factor H variant Y402H is a major risk determinant for
   geographic atrophy and choroidal neovascularization in smokers and
   nonsmokers
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR DEGENERATION; DISEASE; DRUSEN; GLOMERULONEPHRITIS;
   SUSCEPTIBILITY; POLYMORPHISM; ASSOCIATION; SMOKING; COMMON
AB PURPOSE. The complement factor H (CFH) gene polymorphism Y402H ( 1277T -> C) has been associated with susceptibility to age-related macular degeneration (AMD). The purpose of this study was to confirm this association in a U. K. population, to determine whether the association holds for both geographic atrophy (GA) and choroidal neovascularization (CNV), and to investigate interactions with smoking.
   METHODS. A case-control study was undertaken in 443 cases of AMD, with 262 spouses as control subjects. All subjects completed a health and lifestyle questionnaire, had an ophthalmic assessment with fundus photography, and were genotyped.
   RESULTS. The frequencies of the C allele and CC genotype were significantly higher in cases than in controls. In comparison to the TT genotype, the odds ratios for AMD associated with the CT and CC genotypes were 3.1 (CI 2.0-4.6) and 6.3 ( CI 3.8-10.4), respectively. The results were similar in subgroup analyses confined to cases with GA or CNV. The findings were also similar for subgroup analyses restricted to subjects who had never smoked, moderate smokers, or heavier smokers (> 20 pack years of smoking). Heavier smokers with the CC genotype may be particularly at risk. The frequency of the CC genotype did not differ significantly between cases with and without a family history of AMD. There was no evidence that genotype had any influence on age at onset of disease.
   CONCLUSIONS. The CFH Y402H variant is strongly associated with both GA and CNV in the U. K. population. This association is similar in smokers and nonsmokers. Heavier smokers with the CC genotype may be at particular risk.
C1 Univ Cambridge, Dept Med Genet, Cambridge, England.
   UCL, Inst Ophthalmol, London, England.
   Moorfields Eye Hosp, London, England.
C3 University of Cambridge; University of London; University College
   London; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust
RP Yates, JRW (通讯作者)，Univ Cambridge, Dept Med Genet, Inst Med Res, Addenbrookes Hosp, Wellcome Trust MRC Bldg,Box 139, Cambridge CB2 2XY, England.
EM jrwy1@cam.ac.uk
RI Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X; Harding, Simon/0000-0003-4676-1158
FU MRC [G0000067] Funding Source: UKRI; Medical Research Council [G0000067]
   Funding Source: Medline; Wellcome Trust Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bernaards CM, 2001, ADDICTION, V96, P1653, DOI 10.1046/j.1360-0443.2001.9611165311.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith MR, 2003, ATHEROSCLEROSIS, V169, P331, DOI 10.1016/S0021-9150(03)00200-4
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 19
TC 144
Z9 159
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2006
VL 47
IS 2
BP 536
EP 540
DI 10.1167/iovs.05-1143
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 006UF
UT WOS:000234922100011
PM 16431947
DA 2022-11-30
ER

PT J
AU Arnold, JJ
   Blinder, KJ
   Bressler, M
   Bressler, SB
   Burdan, A
   Haynes, L
   Lim, JI
   Miller, JW
   Potter, MJ
   Reaves, A
   Rosenfeld, PJ
   Sickenberg, M
   Slakter, JS
   Soubrane, G
   Strong, HA
   Stur, M
AF Arnold, JJ
   Blinder, KJ
   Bressler, M
   Bressler, SB
   Burdan, A
   Haynes, L
   Lim, JI
   Miller, JW
   Potter, MJ
   Reaves, A
   Rosenfeld, PJ
   Sickenberg, M
   Slakter, JS
   Soubrane, G
   Strong, HA
   Stur, M
CA Treatment Age-Related Macular Dege
   Verteporfin Photodynamic Therapy S
TI Acute severe visual acuity decrease after photodynamic therapy with
   verteporfin: Case reports from randomized clinical trials - TAP and VIP
   report no. 3
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION
AB PURPOSE: To describe in detail occurrences of acute severe visual acuity decrease after photodynamic therapy (PDT) with verteporfin in the Treatment of Age,related macular degeneration with Photodynamic therapy (TAP) Investigation and the Verteporfin In Photodynamic therapy (VIP) Trial.
   DESIGN: Observational case series.
   METHODS: Retrospective review of all cases that developed acute severe visual acuity decrease after treatment.
   RESULTS: Of 15 acute severe visual acuity decrease events originally identified in 14 eyes of 14 patients, one event in one patient was judged unlikely to have been an acute severe visual acuity decrease event on retrospective review of these events in preparation of this report. Eleven events occurred after the first treatment. At follow,up, 10 improved by at least 1 line in visual acuity from the level noted at the time of the event. Of the nine patients returning for the month 24 examination, visual acuity decreased at least 3 lines from baseline in six, including at least 6 lines in four, and remained within 1 line in three. Associated abnormal morphology included three with a serous macular detachment and abnormal choroidal hypofluorescence, four with macular hemorrhage, three with a greenish subfoveal hemorrhage, and four with no abnormality. Events appeared to be more likely when patients had a visual acuity of 20/50 or better.
   CONCLUSIONS: Acute severe visual acuity decrease after PDT with verteporfin was an uncommon event; the risk did not outweigh the benefits of therapy previously reported. When considering verteporfin therapy, patients should be warned of the possibility of this serious adverse event. (C) 2004 by Elsevier Inc. All rights reserved.
RP Bressler, M (通讯作者)，Suite 115,550 N Broadway, Baltimore, MD 21205 USA.
EM nbressler@jhmi.edu
OI Miller, Joan/0000-0003-2046-3996
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   *TREATM AG REL MAC, 2003, 4 TAP VIP
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
NR 8
TC 111
Z9 118
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2004
VL 137
IS 4
BP 683
EP 696
DI 10.1016/j.ajo.2003.11.059
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 811HK
UT WOS:000220762800012
PM 15059708
DA 2022-11-30
ER

PT J
AU Rodriguez, J
   Sanchez, R
   Munoz, B
   West, SK
   Broman, A
   Snyder, RW
   Klein, R
   Quigley, H
AF Rodriguez, J
   Sanchez, R
   Munoz, B
   West, SK
   Broman, A
   Snyder, RW
   Klein, R
   Quigley, H
TI Causes of blindness and visual impairment in a population-based sample
   of US Hispanics
SO OPHTHALMOLOGY
LA English
DT Article
ID BALTIMORE EYE SURVEY; CAUSE-SPECIFIC PREVALENCE; ADULT-POPULATION;
   URBAN-POPULATION; OLDER AMERICANS; GLAUCOMA; INJURIES
AB Objective: To describe the causes of blindness and visual impairment in a population-based sample of Hispanics.
   Design: A cross-sectional study.
   Participants: A random sample of 4774 Hispanic residents of Santa Cruz and Pima Counties in Southern Arizona aged 40 years and older who participated in Proyecto VER (Vision Evaluation and Research).
   Testing. Subjects were interviewed and underwent a thorough ophthalmic examination. Presenting and best-corrected visual acuity was determined using the Early Treatment of Diabetic Retinopathy Study protocol, followed by a standardized ophthalmic examination to determine the causes of visual loss. Anterior and posterior segment specialists in ophthalmology confirmed the causes.
   Main Outcome Measures: Causes of visual loss (best-corrected acuity worse than 20/40).
   Results: The response rate of eligible participants was more than 70%. Best-corrected acuity in the better seeing eye worse than 20/40 increased from 0.3% in those aged 40 to 49 to 5.6% in those aged 65 and older. The leading cause was cataract, accounting for 42% of all visual loss, followed by age-related macular degeneration (15%), and diabetic retinopathy (13%). Among 14 people who were bilaterally blind, open-angle glaucoma was the leading cause. Women had higher age-adjusted prevalence of severe cataract compared with men and were more likely to be visually impaired from cataract, diabetic retinopathy, and open-angle glaucoma, although gender differences were not statistically significant.
   Conclusions. Causes of visual impairment differ from those reported in Caucasian populations, with open-angle glaucoma being the leading cause of blindness. Further work on gender-based obstacles to eye care in the Hispanic community may be warranted. (C) 2002 by the American Academy of Ophthalmology.
C1 Univ Arizona, Dept Ophthalmol, Tucson, AZ 85721 USA.
   Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr, Baltimore, MD USA.
   Univ Wisconsin, Madison, WI USA.
C3 University of Arizona; Johns Hopkins University; Johns Hopkins Medicine;
   University of Wisconsin System; University of Wisconsin Madison
RP West, SK (通讯作者)，Univ Arizona, Dept Ophthalmol, Tucson, AZ 85721 USA.
OI Klein, Ronald/0000-0002-4428-6237
FU NEI NIH HHS [EY 11283] Funding Source: Medline
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   DANA MR, 1990, JAMA-J AM MED ASSOC, V264, P2400, DOI 10.1001/jama.264.18.2400
   Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579
   Gasch AT, 2000, OPHTHALMOLOGY, V107, P303, DOI 10.1016/S0161-6420(99)00076-7
   KATZ J, 1993, ARCH OPHTHALMOL-CHIC, V111, P1564, DOI 10.1001/archopht.1993.01090110130038
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1487
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLOPFER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P838, DOI 10.1001/archopht.1992.01080180110037
   Li SZ, 1999, OPHTHALMOLOGY, V106, P1602, DOI 10.1016/S0161-6420(99)90459-1
   Munier A, 1998, BRIT J OPHTHALMOL, V82, P630, DOI 10.1136/bjo.82.6.630
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Quigley HA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1819, DOI 10.1001/archopht.119.12.1819
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Sundquist J, 2001, J AM GERIATR SOC, V49, P109, DOI 10.1046/j.1532-5415.2001.49030.x
   Taylor H, 1988, LENS RES, V5, P175
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   *US CENS BUR, 20033 US CENS BR POP
   *US CENS BUR, 2000, PROF GEN DEM CHAR 20, P1
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   West SK, 2001, DIABETES CARE, V24, P1204, DOI 10.2337/diacare.24.7.1204
   Wu SY, 1999, INVEST OPHTH VIS SCI, V40, P2179
NR 26
TC 100
Z9 109
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2002
VL 109
IS 4
BP 737
EP 743
AR PII S0161-6420(01)01008-9
DI 10.1016/S0161-6420(01)01008-9
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 535GC
UT WOS:000174636000033
PM 11927431
DA 2022-11-30
ER

PT J
AU Kumar, V
   Kumar, P
   Ravani, R
   Gupta, P
AF Kumar, Vinod
   Kumar, Pradeep
   Ravani, Raghav
   Gupta, Prasad
TI Macular telangiectasia type II with pachychoroid spectrum of macular
   disorders
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Macular telangiectasia type II; pachychoroid; multimodal imaging
ID CHOROIDAL THICKNESS; DISRUPTION
AB Purpose: To report the cases with features of macular telangiectasia type II and pachychoroid spectrum of macular disorders simultaneously. Methods: It is a retrospective case series from a tertiary eye care center. Multimodal imaging features of these eyes including color fundus photographs, red free imaging, short-wave autofluorescence, fundus fluorescein angiography, indocyanine green angiography, and optical coherence tomography were studied. Results: Six eyes of three patients having combination of macular telangiectasia type II and pachychoroid group of disorders were found. Three eyes showed features of central serous chorioretinopathy, one eye had polypoidal choroidal vasculopathy, one eye had pachychoroid pigment epitheliopathy and one had thickened choroid. Conclusion: This is the first report of macular telangiectasia type II in association with the pachychoroid spectrum of macular disorders and provides insight into possible common etiopathogenetic mechanisms.
C1 [Kumar, Vinod; Kumar, Pradeep; Ravani, Raghav; Gupta, Prasad] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences
RP Kumar, P (通讯作者)，All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
EM eyepradeep@yahoo.com
CR Akkaya S, 2018, INT OPHTHALMOL, V38, P2239, DOI 10.1007/s10792-017-0666-4
   Atmani K, 2013, OPHTHALMOLOGICA, V230, P126, DOI 10.1159/000354111
   Chhablani J, 2014, RETINA-J RET VIT DIS, V34, P1819, DOI 10.1097/IAE.0000000000000180
   Clemons TE, 2013, OPHTHAL EPIDEMIOL, V20, P109, DOI 10.3109/09286586.2013.766757
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   GASS JD, 1982, ARCH OPHTHALMOL-CHIC, V100, P769
   Issa PC, 2013, PROG RETIN EYE RES, V34, P49, DOI 10.1016/j.preteyeres.2012.11.002
   Liu B, 2016, RETINA-J RET VIT DIS, V36, P9, DOI 10.1097/IAE.0000000000000837
   Matet A, 2017, RETINA, V38, pS67
   Nunes RP, 2015, OSLI RETINA, V46, P162, DOI 10.3928/23258160-20150213-17
   Oh JH, 2014, RETINA-J RET VIT DIS, V34, P1123, DOI 10.1097/IAE.0000000000000038
   Powner MB, 2013, OPHTHALMOLOGY, V120, P2344, DOI 10.1016/j.ophtha.2013.04.013
   SPITZNAS M, 1986, GRAEF ARCH CLIN EXP, V224, P321, DOI 10.1007/BF02150023
   Thomas NR, 2017, INDIAN J OPHTHALMOL, V65, P516, DOI 10.4103/ijo.IJO_167_17
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
   Zhu MD, 2013, RETINA-J RET VIT DIS, V33, P1547, DOI 10.1097/IAE.0b013e318285cb9c
NR 16
TC 3
Z9 3
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2019
VL 29
IS 2
BP 216
EP 222
DI 10.1177/1120672118769527
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HQ0LP
UT WOS:000462086800014
PM 29676172
DA 2022-11-30
ER

PT J
AU Xi, YJ
   Miao, Y
   Zhou, R
   Wang, ML
   Zhang, FB
   Li, Y
   Zhang, Y
   Yang, HJ
   Guo, FF
AF Xi, Yujie
   Miao, Yan
   Zhou, Rui
   Wang, Maolin
   Zhang, Fangbo
   Li, Yu
   Zhang, Yi
   Yang, Hongjun
   Guo, Feifei
TI Exploration of the Specific Pathology of HXMM Tablet Against Retinal
   Injury Based on Drug Attack Model to Network Robustness
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE he xue ming mu tablet; age-related macular degeneration; diabetic
   retinopathy; oxidative stress; inflammation; network robustness; drug
   attack
ID MICROVASCULAR ENDOTHELIAL-CELLS; PIGMENT EPITHELIAL-CELLS; CAFFEIC
   ACID-DERIVATIVES; ACUTE LUNG INJURY; PROTOCATECHUIC ACID; IN-VITRO;
   ANTIINFLAMMATORY ACTIVITY; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   OXIDATIVE DAMAGE
AB Retinal degenerative diseases are related to retinal injury because of the activation of the complement cascade, oxidative stress-induced cell death mechanisms, dysfunctional mitochondria, chronic neuroinflammation, and production of the vascular endothelial growth factor. Anti-VEGF therapy demonstrates remarkable clinical effects and benefits in retinal degenerative disease patients. Hence, new drug development is necessary to treat patients with severe visual loss. He xue ming mu (HXMM) tablet is a CFDA-approved traditional Chinese medicine (TCM) for retinal degenerative diseases, which can alleviate the symptoms of age-related macular degeneration (AMD) and diabetic retinopathy (DR) alone or in combination with anti-VEGF agents. To elucidate the mechanisms of HXMM, a quantitative evaluation algorithm for the prediction of the effect of multi-target drugs on the disturbance of the disease network has been used for exploring the specific pathology of HXMM and TCM precision positioning. Compared with anti-VEGF agents, the drug disturbance of HXMM on the functional subnetwork shows that HXMM reduces the network robustness on the oxidative stress subnetwork and inflammatory subnetwork to exhibit the anti-oxidation and anti-inflammation activity. HXMM provides better protection to ARPE-19 cells against retinal injury after H2O2 treatment. HXMM can elevate GSH and reduce LDH levels to exhibit antioxidant activity and suppress the expression of IL-6 and TNF-alpha for anti-inflammatory activity, which is different from the anti-VEGF agent with strong anti-VEGF activity. The experimental result confirmed the accuracy of the computational prediction. The combination of bioinformatics prediction based on the drug attack on network robustness and experimental validation provides a new strategy for precision application of TCM.
C1 [Xi, Yujie; Zhou, Rui; Wang, Maolin; Zhang, Fangbo; Li, Yu; Zhang, Yi; Yang, Hongjun; Guo, Feifei] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.
   [Xi, Yujie; Li, Yu; Yang, Hongjun] Chinese Med Res Inst, Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China.
   [Miao, Yan] Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Pharmacol, Hlth Sci Ctr, Xian, Peoples R China.
   [Zhou, Rui] Guangzhou Univ Chinese Med, Coll Tradit Chinese Med, Guangzhou, Peoples R China.
   [Yang, Hongjun] China Acad Chinese Med Sci, Expt Res Ctr, Beijing Key Lab Tradit Chinese Med Basic Res Preve, Beijing, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Chinese Materia
   Medica, CACMS; Tianjin University of Traditional Chinese Medicine; Xi'an
   Jiaotong University; Guangzhou University of Chinese Medicine; China
   Academy of Chinese Medical Sciences; Experimental Research Center, CACMS
RP Yang, HJ; Guo, FF (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.; Yang, HJ (通讯作者)，Chinese Med Res Inst, Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China.; Yang, HJ (通讯作者)，China Acad Chinese Med Sci, Expt Res Ctr, Beijing Key Lab Tradit Chinese Med Basic Res Preve, Beijing, Peoples R China.
EM ffguo@icmm.ac.cn; hjyang@icmm.ac.cn
OI Xi, Yujie/0000-0002-0269-868X
CR Adisakwattana S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020163
   AKAMATSU H, 1991, ARCH DERMATOL RES, V283, P162, DOI 10.1007/BF00372056
   Alam MA, 2012, J PHARM PHARMACOL, V64, P326, DOI 10.1111/j.2042-7158.2011.01391.x
   Alrashdi B, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1622-1
   An JF, 2014, CELL MOL BIOL, V60, P8
   Baldassano SN, 2016, SCI REP-UK, V6, DOI 10.1038/srep26087
   Barben M, 2018, ADV EXP MED BIOL, V1074, P177, DOI 10.1007/978-3-319-75402-4_22
   Borgatti SP, 2005, SOC NETWORKS, V27, P55, DOI 10.1016/j.socnet.2004.11.008
   Campbell WA, 2021, GLIA, V69, P2503, DOI 10.1002/glia.24056
   Cao H, 2015, MOL MED REP, V11, P3593, DOI 10.3892/mmr.2015.3153
   Chen Qiong-Fang, 2017, Zhongguo Zhong Yao Za Zhi, V42, P3564, DOI 10.19540/j.cnki.cjcmm.20170731.006
   Chen TT, 2021, FOOD SCI NUTR, V9, P6596, DOI 10.1002/fsn3.2605
   Chen W., 2022, J TRADIT CHIN OPHTHA, V32, P77, DOI [10.13444/j.cnki.zgzyykzz.2022.01.019, DOI 10.13444/J.CNKI.ZGZYYKZZ.2022.01.019]
   Chen WP, 2021, PHYTOMEDICINE, V80, DOI 10.1016/j.phymed.2020.153375
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Choi DY, 2009, INT IMMUNOPHARMACOL, V9, P959, DOI 10.1016/j.intimp.2009.04.001
   Choi HG, 2018, ARCH PHARM RES, V41, P64, DOI 10.1007/s12272-017-0983-1
   Muller CMD, 2019, J ETHNOPHARMACOL, V242, DOI 10.1016/j.jep.2019.112040
   Digby JE, 2012, ARTERIOSCL THROM VAS, V32, P669, DOI 10.1161/ATVBAHA.111.241836
   Dinc E, 2017, CURR EYE RES, V42, P1659, DOI 10.1080/02713683.2017.1368085
   FREEMAN LC, 1979, SOC NETWORKS, V1, P215, DOI 10.1016/0378-8733(78)90021-7
   Gambhir D, 2012, INVEST OPHTH VIS SCI, V53, P2208, DOI 10.1167/iovs.11-8447
   Gao L., 2020, CHINA PHARM, V29, P133, DOI [10.3969/j.issn.1006-4931.2020.10.040, DOI 10.3969/J.ISSN.1006-4931.2020.10.040]
   Gil-Martinez M, 2020, CURR MED CHEM, V27, P583, DOI 10.2174/0929867326666190726121711
   Giridhar Pyda, 2002, Indian Journal of Ophthalmology, V50, P239
   GOLDSBOROUGH CE, 1960, LANCET, V2, P675
   Guo Fei-Fei, 2020, Zhongguo Zhong Yao Za Zhi, V45, P2257, DOI 10.19540/j.cnki.cjcmm.20200312.401
   Guo FF, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00049
   Hadjipavlou-Litina D, 2015, METHODS MOL BIOL, V1208, P361, DOI 10.1007/978-1-4939-1441-8_26
   Hage Per, 2022, ISL NETW COMM KINSH
   Haider N, 2010, MOLECULES, V15, P5079, DOI 10.3390/molecules15085079
   Hu JM, 2018, J AGR FOOD CHEM, V66, P6742, DOI 10.1021/acs.jafc.8b01534
   Huang H, 2021, ANN PALLIAT MED, V10, P10954, DOI 10.21037/apm-21-2563
   Jiang RW, 2005, CURR MED CHEM, V12, P237, DOI 10.2174/0929867053363397
   Jung JE, 2007, CARCINOGENESIS, V28, P1780, DOI 10.1093/carcin/bgm130
   Kabeya LM, 2013, CHEM-BIOL INTERACT, V206, P63, DOI 10.1016/j.cbi.2013.08.010
   Kamat JP, 1999, REDOX REP, V4, P179, DOI 10.1179/135100099101534882
   Keegan G, 2020, EXP EYE RES, V197, DOI 10.1016/j.exer.2020.108104
   Kitano H, 2007, NAT REV DRUG DISCOV, V6, P202, DOI 10.1038/nrd2195
   Kuenzi BM, 2017, NAT CHEM BIOL, V13, P1222, DOI [10.1038/NCHEMBIO.2489, 10.1038/nchembio.2489]
   Li Q, 2011, J PLANT PHYSIOL, V168, P927, DOI 10.1016/j.jplph.2010.11.025
   Li WX, 2014, J CHROMATOGR A, V1346, P49, DOI 10.1016/j.chroma.2014.04.042
   Li XC, 2009, MOLECULES, V14, P5349, DOI 10.3390/molecules14125349
   Li YL, 2022, J ETHNOPHARMACOL, V282, DOI 10.1016/j.jep.2021.114531
   Liang Jing, 2013, Zhongguo Zhong Yao Za Zhi, V38, P3970
   Liao QJ, 2013, ANTIVIR RES, V100, P578, DOI 10.1016/j.antiviral.2013.09.021
   Liu CL, 2002, FOOD CHEM TOXICOL, V40, P635, DOI 10.1016/S0278-6915(02)00002-9
   Liu JR, 2008, PHYTOMEDICINE, V15, P23, DOI 10.1016/j.phymed.2007.11.012
   Liu ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep21146
   Lu DY, 2011, J PHARM ANAL, V1, P203, DOI 10.1016/j.jpha.2011.05.001
   Ma SL, 2016, J ETHNOPHARMACOL, V188, P193, DOI 10.1016/j.jep.2016.05.018
   Ma Y, 2016, INFLAMMATION, V39, P1453, DOI 10.1007/s10753-016-0377-4
   Manchope MF, 2017, ONCOTARGET, V8, P3766, DOI 10.18632/oncotarget.14084
   Massengill MT, 2018, ADV EXP MED BIOL, V1074, P185, DOI 10.1007/978-3-319-75402-4_23
   Negishi H, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028423
   Nicolis E, 2008, INT IMMUNOPHARMACOL, V8, P1672, DOI 10.1016/j.intimp.2008.08.001
   Ozturk H, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-0977-x
   Paeng SH, 2015, INT J MOL MED, V35, P1419, DOI 10.3892/ijmm.2015.2116
   Pan L, 2017, ORGANOGENESIS, V13, P183, DOI 10.1080/15476278.2017.1364829
   PASSI S, 1991, FREE RADICAL RES COM, V15, P17, DOI 10.3109/10715769109049121
   Pinero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Pintatum A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050799
   Pontiki E, 2019, MOLECULES, V24, DOI 10.3390/molecules24010012
   Qi Y, 2017, AM J CHINESE MED, V45, P1157, DOI 10.1142/S0192415X1750063X
   Qian SH, 2011, J ETHNOPHARMACOL, V137, P985, DOI 10.1016/j.jep.2011.07.018
   Reifen R, 2015, J NUTR BIOCHEM, V26, P1632, DOI 10.1016/j.jnutbio.2015.08.006
   Riaz A, 2020, CURR DRUG METAB, V21, P1079, DOI 10.2174/1389200221999200728144801
   Rossi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082848
   Saberi M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81767-7
   Salem HA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07280-y
   Santos DF, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111402
   Sarikaya SBO, 2015, J ENZYM INHIB MED CH, V30, P761, DOI 10.3109/14756366.2014.965700
   Scott AW, 2016, JAMA OPHTHALMOL, V134, P1111, DOI 10.1001/jamaophthalmol.2016.2627
   Shen JH, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-90
   Shi JH, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/8205983
   Somasundaran S, 2020, CLIN EXP OPHTHALMOL, V48, P1043, DOI 10.1111/ceo.13834
   Sun X., 2008, FOOD RES DEV, V08, P127, DOI [10.3969/j.issn.1005-6521.2008.11.036, DOI 10.3969/J.ISSN.1005-6521.2008.11.036]
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Taner G, 2017, DRUG CHEM TOXICOL, V40, P183, DOI 10.1080/01480545.2016.1190740
   [陶益 Tao Yi], 2017, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V28, P88
   Timonen JM, 2011, EUR J MED CHEM, V46, P3845, DOI 10.1016/j.ejmech.2011.05.052
   USP, 2015, CHINESE PHARMACOPOEI
   Varpe SS, 2012, INDIAN J PHARMACOL, V44, P788, DOI 10.4103/0253-7613.103303
   von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005
   Wang KH, 2017, CLIN EXP PHARMACOL P, V44, P862, DOI 10.1111/1440-1681.12775
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Wang X, 2021, MOLECULES, V26, DOI 10.3390/molecules26237293
   Wang YM, 2015, INFLAMMATION, V38, P1080, DOI 10.1007/s10753-014-0073-1
   Wu TH, 2019, J CELL BIOCHEM, V120, P18901, DOI 10.1002/jcb.29210
   Wu WF, 2020, PHYTOMEDICINE, V69, DOI 10.1016/j.phymed.2020.153202
   Xie XS, 2009, J DIABETES COMPLICAT, V23, P360, DOI 10.1016/j.jdiacomp.2008.05.002
   Xu L, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101700
   Ya FL, 2021, THROMB HAEMOSTASIS, V121, P931, DOI 10.1055/s-0040-1722621
   Yan JF, 2014, CURR MICROBIOL, V69, P740, DOI 10.1007/s00284-014-0647-z
   [杨杰 Yang Jie], 2019, [华西药学杂志, West China Journal of Pharmaceutical Sciences], V34, P617
   Yang YY, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00376-0
   Zhang FB, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/802784
   Zhang LY, 2016, J PHARMACEUT BIOMED, V131, P107, DOI 10.1016/j.jpba.2016.08.031
   Zhang WX, 2019, EUR J MED CHEM, V183, DOI 10.1016/j.ejmech.2019.111695
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
   Zhu XJ, 2020, MICROB PATHOGENESIS, V142, DOI 10.1016/j.micpath.2020.104077
NR 101
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 25
PY 2022
VL 13
AR 826535
DI 10.3389/fphar.2022.826535
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 0Z9KW
UT WOS:000791389300001
PM 35401181
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kabanarou, SA
   Bontzos, G
   Xirou, TN
   Kapsala, Z
   Dimitriou, E
   Theodossiadis, P
   Chatziralli, I
AF Kabanarou, Stamatina A.
   Bontzos, Georgios
   Xirou, Tina
   Kapsala, Zoi
   Dimitriou, Eleni
   Theodossiadis, Panagiotis
   Chatziralli, Irini
TI Multimodal Imaging for the Assessment of Geographic Atrophy in Patients
   with "Foveal" and "No-Foveal" Sparing
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Geographic atrophy; OCTA; En-face OCT; Multimodal imaging; Foveal
   sparing
ID OPTICAL COHERENCE TOMOGRAPHY; NEAR-INFRARED AUTOFLUORESCENCE;
   AGE-RELATED MACULOPATHY; FUNDUS AUTOFLUORESCENCE; MACULAR DEGENERATION;
   LIGHT AUTOFLUORESCENCE; VISUAL-ACUITY; BLUE-LIGHT; PROGRESSION;
   ANGIOGRAPHY
AB Introduction: The aim of the study was to evaluate the applicability of optical coherence tomography (OCT) angiography (OCTA) for measuring geographic atrophy (GA) areas in age-related macular degeneration (AMD) patients with "foveal" and "no-foveal" sparing disease and compare it to other imaging modalities. Methods: A multimodal imaging protocol was applied, using infrared (IR) imaging, fundus autofluorescence (FAF), OCTA, and en-face OCT in 35 eyes of 23 AMD patients with GA. Patients were classified into 2 groups, with and without foveal sparing disease. GA area measurements for all imaging modalities were compared for each group separately. Results: The measured GA area was estimated to be 6.68 +/- 3.18 mm(2) using IR; 6.99 +/- 3.09 mm(2) using FAF; 6.56 +/- 3.11 mm(2) using OCTA, and 6.65 +/- 3.14 mm(2) using en-face OCT. There was no statistically significant difference in the GA area between different modalities (p = 0.977). When separate analysis was conducted for patients with "foveal" and "no-foveal" sparing disease, although GA measurements in FAF imaging displayed higher numerical values than the other modalities, especially in patients with foveal sparing, no statistically significant difference in the GA area was found between the different imaging modalities in either group (p = 0.816 for foveal sparing; p = 0.992 for no-foveal sparing group). Conclusions: OCTA can be reliably used in the assessment of GA in AMD patients with and without foveal sparing disease. For both groups, measurements are comparable to IR, en-face OCT, and FAF, despite the fact that the latter recorded larger area of GA, mainly in the foveal sparing cases.
C1 [Kabanarou, Stamatina A.; Bontzos, Georgios; Xirou, Tina] Korgialenio Benakio Hosp, Dept Ophthalmol, Athens, Greece.
   [Kapsala, Zoi] Hippokrateion Hosp, Dept Ophthalmol, Athens, Greece.
   [Dimitriou, Eleni; Theodossiadis, Panagiotis; Chatziralli, Irini] Natl & Kapodistrian Univ Athens, Dept Ophthalmol 2, Athens, Greece.
C3 Hippokration General Hospital; National & Kapodistrian University of
   Athens
RP Bontzos, G (通讯作者)，Korgialenio Benakio Hosp, Dept Ophthalmol, Athens, Greece.
EM gbontzos@hotmail.gr
RI Bontzos, Georgios/AAJ-1809-2020
OI Bontzos, Georgios/0000-0003-4970-9793
CR Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Borrelli E, 2019, BRIT J OPHTHALMOL, V103, P610, DOI 10.1136/bjophthalmol-2018-311849
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Heiferman MJ, 2016, RETINA-J RET VIT DIS, V36, pS137, DOI 10.1097/IAE.0000000000001254
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wolf-Schnurrbusch UEK, 2011, INVEST OPHTH VIS SCI, V52, P9497, DOI 10.1167/iovs.11-8346
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Yehoshua Z, 2010, OPHTHALMIC SURG LASE, V41, P6
NR 47
TC 0
Z9 0
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD AUG
PY 2021
VL 64
IS 4
BP 675
EP 683
DI 10.1159/000512103
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TZ2FF
UT WOS:000684290300016
PM 33027784
OA Bronze
DA 2022-11-30
ER

PT J
AU Zhang, JX
   Mao, K
   Gu, Q
   Wu, XW
AF Zhang, Junxiu
   Mao, Ke
   Gu, Qing
   Wu, Xingwei
TI The Antiangiogenic Effect of Sanguinarine Chloride on Experimental
   Choroidal Neovacularization in Mice via Inhibiting Vascular Endothelial
   Growth Factor
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE angiogeneisis; age-related macula degeneration (AMD); choroidal
   neovascluarization; sanguinarine chloride; vascular endthelial growth
   factor (VEGF)
AB Background: The purpose of this study is to investigate the antiangiogenic effect of Sanguinarine chloride (SC) on models of age-related macular degeneration (AMD) both in vivo and in vitro.
   Methods: Choroidal neovascularization (CNV) was conducted by laser photocoagulation in C57BL6/J mice. SC (2.5 mu M, 2 mu l/eye) was intravitreally injected immediately after laser injury. The control group received an equal amount of PBS. 7 days after laser injury, CNV severity was evaluated using fundus fluorescein angiography, hematoxylin and eosin (H&E) staining, and choroid flat-mount staining. Vascular endothelial growth factor (VEGF) expression in the retina/choroid complex was measured by western blot analysis and ELISA kit. In vitro, human retinal microvascular endothelial cells (HRMECs) were used to investigate the effects of SC on cell tube formation, migration, and cytotoxicity. The expression of VEGF-induced expression of extracellular signal-regulated kinase (ERK)1/2, protein kinase B (AKT), mitogen-activated protein kinases (p38-MAPK) in vitro and laser induced VEGF expression in vivo were also analyzed.
   Results: SC (<= 2.5 mu M) was safe both in vitro and in vivo. Intravitreal injection of SC restrained the formation of laser induced CNV in mice and decreased VEGF expression in the laser site of the retina/choroid complex. In vitro, SC inhibited VEGF-induced tube formation and endothelial cell migration by decreasing the phosphorylation of AKT, ERK1/2, and p38-MAPK in HRMECs.
   Conclusions: SC could inhibit laser-induced CNV formation via down-regulating VEGF expression and restrain the VEGF-induced tube formation and endothelial migration. Therefore, SC could be a potential candidate for the treatment of wet AMD.
C1 [Zhang, Junxiu; Gu, Qing; Wu, Xingwei] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Ocular Fundus Dis,Shanghai Gen H, Shanghai Engn Ctr Visual Sci & Photomed,Dept Opht, Shanghai, Peoples R China.
   [Mao, Ke] Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Renji Hosp, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Wu, XW (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Ocular Fundus Dis,Shanghai Gen H, Shanghai Engn Ctr Visual Sci & Photomed,Dept Opht, Shanghai, Peoples R China.
EM wxweye@sina.com
FU National Natural Science Foundation of China [81674027]; Three year
   action plan of Shanghai to further speed up the development of
   traditional Chinese Medicine [ZY(2018-2020)-FWTX-3010]
FX This study was supported by the National Natural Science Foundation of
   China (No.81674027) and the Three year action plan of Shanghai to
   further speed up the development of traditional Chinese Medicine
   (ZY(2018-2020)-FWTX-3010).
CR Achkar IW, 2017, FUTURE MED CHEM, V9, P933, DOI 10.4155/fmc-2017-0041
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Basini G, 2007, ANN NY ACAD SCI, V1095, P371, DOI 10.1196/annals.1397.040
   Basini G, 2007, BIOFACTORS, V29, P11, DOI 10.1002/biof.5520290102
   Basini G, 2007, J REPROD DEVELOP, V53, P573, DOI 10.1262/jrd.18126
   Basu P, 2016, ADV EXP MED BIOL, V928, P155, DOI 10.1007/978-3-319-41334-1_7
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cheng HW, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0495-3
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Cheung PW, 2017, AM J PHYSIOL-RENAL, V313, pF404, DOI 10.1152/ajprenal.00004.2017
   Eun JP, 2004, BIOCHEM BIOPH RES CO, V317, P618, DOI 10.1016/j.bbrc.2004.03.077
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fu CX, 2018, CURR PHARM DESIGN, V24, P2760, DOI 10.2174/1381612824666180829100601
   Galadari S, 2017, PHYTOMEDICINE, V34, P143, DOI 10.1016/j.phymed.2017.08.006
   Gaziano R, 2016, WORLD J GASTRO ONCOL, V8, P30, DOI 10.4251/wjgo.v8.i1.30
   Gheorghe Andreea, 2015, Rom J Ophthalmol, V59, P74
   Hellstrom A, 2013, LANCET, V382, P1445, DOI 10.1016/S0140-6736(13)60178-6
   Hennig R, 2015, EUR J PHARM BIOPHARM, V95, P294, DOI 10.1016/j.ejpb.2015.02.027
   Kang S, 2016, ACTA OPHTHALMOL, V94, DOI [10.1167/iovs.16-19754, 10.1111/j.1755-3768.2016.0252]
   LeBlanc ME, 2019, EXP EYE RES, V181, P120, DOI 10.1016/j.exer.2019.01.009
   Lechner J, 2017, VISION RES, V139, P7, DOI 10.1016/j.visres.2017.04.003
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Mackraj I, 2008, CARDIOVASC THER, V26, P75, DOI 10.1111/j.1527-3466.2007.00037.x
   Mao K, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6210694
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitra RN, 2017, ACS NANO, V11, P4669, DOI 10.1021/acsnano.7b00429
   Pal P, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0523-3
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Song JH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082842
   Wei X, 2018, EXP EYE RES, V168, P2, DOI 10.1016/j.exer.2017.12.009
   Xin XN, 2020, SAUDI J BIOL SCI, V27, P2491, DOI 10.1016/j.sjbs.2020.06.039
   Xu JY, 2013, MOL CLIN ONCOL, V1, P331, DOI 10.3892/mco.2012.41
   Zhang R, 2017, J CELL MOL MED, V21, P1117, DOI 10.1111/jcmm.13043
   Zhang Y, 2019, MOL MED REP, V19, P4449, DOI 10.3892/mmr.2019.10087
NR 37
TC 5
Z9 6
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 15
PY 2021
VL 12
AR 638215
DI 10.3389/fphar.2021.638215
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA RE4DE
UT WOS:000634106100001
PM 33790794
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tomita, Y
   Cakir, B
   Liu, CH
   Fu, ZJ
   Huang, S
   Cho, SS
   Britton, WR
   Sun, Y
   Puder, M
   Hellstrom, A
   Talukdar, S
   Smith, LEH
AF Tomita, Yohei
   Cakir, Bertan
   Liu, Chi-Hsiu
   Fu, Zhongjie
   Huang, Shuo
   Cho, Steve S.
   Britton, William R.
   Sun, Ye
   Puder, Mark
   Hellstrom, Ann
   Talukdar, Saswata
   Smith, Lois E. H.
TI Free fatty acid receptor 4 activation protects against choroidal
   neovascularization in mice
SO ANGIOGENESIS
LA English
DT Article
DE Free fatty acid receptor 4 (FFAR4); NF-& x138;b; IL-6; Laser-induced
   choroidal neovascularization (CNV); Age-related macular degeneration
   (AMD)
ID MACULAR DEGENERATION; INSULIN-RESISTANCE; AQUEOUS-HUMOR; GPR120;
   INFLAMMATION; BEVACIZUMAB; MACROPHAGES; PREVALENCE; CYTOKINES; AGONIST
AB To examine whether free fatty acid receptor 4 (FFAR4) activation can protect against choroidal neovascularization (CNV), which is a common cause of blindness, and to elucidate the mechanism underlying the inhibition, we used the mouse model of laser-induced CNV to mimic angiogenic aspects of age-related macular degeneration (AMD). Laser-induced CNV was compared between groups treated with an FFAR4 agonist or vehicle, and between FFAR4 wild-type (Ffar4(+/+)) and knock out (Ffar4(-/-)) mice on a C57BL/6J/6N background. The ex vivo choroid-sprouting assay, including primary retinal pigment epithelium (RPE) and choroid, without retina was used to investigate whether FFAR4 affects choroidal angiogenesis. Western blotting for pNF-& x138;B/NF-& x138;B and qRT-PCR forIl-6, Il-1 beta, Tnf-alpha, Vegf, and Nf-& x138;bwere used to examine the influence of FFAR4 on inflammation, known to influence CNV. RPE isolated fromFfar4(+/+)andFfar4(-/-)mice were used to assess RPE contribution to inflammation. The FFAR4 agonist suppressed laser-induced CNV in C57BL/6J mice, and CNV increased inFfar4(-/-)compared toFfar4(+/+)mice. We showed that the FFAR4 agonist acted through the FFAR4 receptor. The FFAR4 agonist suppressed mRNA expression of inflammation markers (Il-6, Il-1 beta) via the NF-& x138;B pathway in the retina, choroid, RPE complex. The FFAR4 agonist suppressed neovascularization in the choroid-sprouting ex vivo assay and FFAR4 deficiency exacerbated sprouting. Inflammation markers were increased in primary RPE cells ofFfar4(-/-)mice compared withFfar4(+/+)RPE. In this mouse model, the FFAR4 agonist suppressed CNV, suggesting FFAR4 to be a new molecular target to reduce pathological angiogenesis in CNV.
C1 [Tomita, Yohei; Cakir, Bertan; Liu, Chi-Hsiu; Fu, Zhongjie; Huang, Shuo; Cho, Steve S.; Britton, William R.; Sun, Ye; Smith, Lois E. H.] Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.
   [Puder, Mark] Boston Childrens Hosp, Vasc Biol Program, Boston, MA USA.
   [Puder, Mark] Boston Childrens Hosp, Dept Surg, Boston, MA USA.
   [Hellstrom, Ann] Sahlgrens Acad, Queen Silvia Childrens Hosp, Pediat Ophthalmol, Gothenburg, Sweden.
   [Talukdar, Saswata] Merck & Co Inc, San Francisco, CA USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   Harvard University; Boston Children's Hospital; Harvard University;
   Boston Children's Hospital; Queen Silvia Children's Hospital; University
   of Gothenburg; Merck & Company
RP Smith, LEH (通讯作者)，Harvard Med Sch, Boston Childrens Hosp, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.
EM Lois.Smith@childrens.harvard.edu
RI Tomita, Yohei/AAC-6968-2021; Tomita, Yohei/AGR-6793-2022
OI Sun, Ye/0000-0002-7674-9056; Tomita, Yohei/0000-0003-1013-5737; FU,
   ZHONGJIE/0000-0002-8182-2983
FU NEI NIH HHS [R01 EY030140, R01 EY030904, R01EY030140, R01 EY029238,
   R01EY029238, R01 EY017017] Funding Source: Medline; NICHD NIH HHS [U54
   HD090255] Funding Source: Medline; NIH HHS [R24EY024868,
   R01EY01717-13S1] Funding Source: Medline
CR Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Datilo MN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32553-5
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fu ZJ, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910473
   Fu ZJ, 2017, INVEST OPHTH VIS SCI, V58, P3862, DOI 10.1167/iovs.17-21796
   Garcia-Layana A, 2009, OPHTHALMIC RES, V42, P205, DOI 10.1159/000232946
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Huang JF, 2019, EBIOMEDICINE, V39, P540, DOI 10.1016/j.ebiom.2018.12.019
   Hudson BD, 2013, MOL PHARMACOL, V84, P710, DOI 10.1124/mol.113.087783
   Ichimura A, 2012, NATURE, V483, P350, DOI 10.1038/nature10798
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Janssen S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040168
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Li XZ, 2013, FASEB J, V27, P4987, DOI 10.1096/fj.13-235333
   Miao H, 2012, MOL VIS, V18, P574
   Moniri NH, 2016, BIOCHEM PHARMACOL, V110, P1, DOI 10.1016/j.bcp.2016.01.021
   Nakamoto K, 2019, YAKUGAKU ZASSHI, V139, P1169, DOI 10.1248/yakushi.19-00011-4
   Nobili V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088005
   Noel A, 2007, TRENDS MOL MED, V13, P345, DOI 10.1016/j.molmed.2007.06.005
   Oh DY, 2014, NAT MED, V20, P942, DOI 10.1038/nm.3614
   Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Raptis DA, 2014, J HEPATOL, V60, P625, DOI 10.1016/j.jhep.2013.11.006
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Schilperoort M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708047
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Talukdar S, 2011, TRENDS PHARMACOL SCI, V32, P543, DOI 10.1016/j.tips.2011.04.004
   Ulven T, 2015, ANNU REV NUTR, V35, P239, DOI 10.1146/annurev-nutr-071714-034410
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Williams-Bey Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097957
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yasukawa T, 2007, GRAEF ARCH CLIN EXP, V245, P1475, DOI 10.1007/s00417-007-0571-z
   Yasukawa T, 2009, EXPERT REV OPHTHALMO, V4, P107, DOI 10.1586/EOP.09.1
NR 41
TC 15
Z9 15
U1 1
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD AUG
PY 2020
VL 23
IS 3
BP 385
EP 394
DI 10.1007/s10456-020-09717-x
PG 10
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA MB2FO
UT WOS:000542420500010
PM 32140799
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yeo, JH
   Chung, H
   Kim, JT
AF Yeo, Joon Hyung
   Chung, Hum
   Kim, Jee Taek
TI Swept-Source Optical Coherence Tomography Angiography According to the
   Type of Choroidal Neovascularization
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE optical coherence tomography angiography; neovascular age-related
   macular degeneration; choroidal neovascularization
ID MACULAR DEGENERATION; OCT ANGIOGRAPHY; VASCULOPATHY; SECONDARY; SUBTYPES
AB We analyzed and compared the sensitivity of choroidal neovascularization (CNV) detection according to CNV type in patients with active neovascular age-related macular degeneration (AMD) using swept-source optical coherence tomography (OCT) angiography (OCTA). A retrospective chart review was performed in patients with neovascular AMD. OCTA images were classified into three groups: GroupA(well-circumscribed vascular complex); Group B (moderately circumscribed vascular complex); and Group C (poorly circumscribed vascular complex), according to CNV appearance. Demographic characteristics, OCT parameters, neovascularization subtypes, and OCTA image quality were analyzed to determine the effect on visualization of the neovascular complex. A total of 130 patients with CNV secondary to active neovascular AMD were analyzed. Among them, 52 eyes from 47 patients were included in the study. Eighteen eyes (34.6%) were classified into Group A, 24 (46.2%) into Group B, and 10 (19.2%) into Group C. Statistical analysis showed no significant differences in demographic characteristics or OCT parameters between the three groups. Overall sensitivity of active CNV detection was 80.7% (42/52 eyes). In 73.5% (25/34) of eyes with type 1 CNV (sub-retinal pigment epithelial type), 100.0% (9/9) of eyes with type 2 CNV (sub-retinal type), and 88.9% (8/9) of eyes with type 3 CNV (retinal angiomatous proliferation type), the vascular complex was well visualized on OCTA. OCTA provides adequate noninvasive imaging of CNV in patients with neovascular AMD, which may assist in CNV diagnosis and activity monitoring. In particular, type 2 CNV was well detected in OCTA in comparison with type 1 and type 3 CNV.
C1 [Yeo, Joon Hyung; Chung, Hum; Kim, Jee Taek] Chung Ang Univ, Coll Med, Dept Ophthalmol, Seoul 06973, South Korea.
C3 Chung Ang University; Chung Ang University Hospital
RP Kim, JT (通讯作者)，Chung Ang Univ, Coll Med, Dept Ophthalmol, Seoul 06973, South Korea.
EM jeetaek@cau.ac.kr
OI Kim, Jee Taek/0000-0002-0818-6159
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT, and Future Planning
   [NRF-2015R1C1A1A01054285, NRF-2019R1H1A1035593]
FX This study was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Science, ICT, and Future Planning (NRF-2015R1C1A1A01054285;
   NRF-2019R1H1A1035593).
CR de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, pOCT27, DOI 10.1167/iovs.15-19043
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kotsolis AI, 2010, BRIT J OPHTHALMOL, V94, P1506, DOI 10.1136/bjo.2009.159913
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Nagiel A, 2015, JAMA OPHTHALMOL, V133, P629, DOI 10.1001/jamaophthalmol.2015.0668
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Parravano M, 2017, ACTA OPHTHALMOL, V95, pE425, DOI 10.1111/aos.13180
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
NR 25
TC 11
Z9 11
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2019
VL 8
IS 9
AR 1272
DI 10.3390/jcm8091272
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA JC3NA
UT WOS:000489184200006
PM 31443399
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Abdolrahimzadeh, S
   Parisi, F
   Marcelli, M
   Giustolis, R
   Gharbiya, M
AF Abdolrahimzadeh, Solmaz
   Parisi, Francesco
   Marcelli, Michela
   Giustolis, Rosalia
   Gharbiya, Magda
TI Optical coherence tomography evidence of macular ganglion cell-inner
   plexiform layer thinning in eyes with subretinal drusenoid deposits
SO EYE
LA English
DT Article
ID NERVE-FIBER LAYER; RETICULAR PSEUDODRUSEN; CHOROIDAL THICKNESS; RETINAL
   LAYERS; AGE; DEGENERATION; PREVALENCE; SEGMENTATION; CONSUMPTION
AB Background/Objectives The purpose of this study was to evaluate macular ganglion cell layer-inner plexiform layer (GCL-IPL) and choroidal thickness in early age-related macular degeneration (AMD) in eyes with subretinal drusenoid deposits (SDD).
   Subjects/Methods Comprehensive ophthalmological examination was performed. Near infrared reflectance and raster images using enhanced depth imaging were acquired with spectral domain optical coherence tomography. Drusen and SDD were diagnosed based on raster scans and near infrared reflectance. GCL-IPL maps were generated with automated segmentation and choroidal thickness maps were obtained by manually delineating the choroid-scleral boundary.
   Results Forty-eight eyes from 48 patients (mean age 77.5 +/- 5.7, range 68-90 years) with a diagnosis of early AMD and 42 eyes of 42 age-matched control subjects (mean age 76.9 +/- 5.7, range 67-88 years) were included. Of these, 28 eyes (58.3%) had drusen alone, 4 eyes (8.3%) had SDD alone, and 16 eyes (33.3%) had drusen associated with SDD. Compared with controls, average choroidal thickness was significantly decreased in AMD eyes (P < 0.05). There was no significant difference in choroidal thickness in eyes with SDD with respect to those with drusen alone. GCL-IPL thickness was reduced in an annular pattern at the 3 and 6 mm macular areas in AMD patients with respect to controls (P < 0.05). GCL-IPL thickness at 3 mm was significantly reduced in eyes with SDD with respect to those with drusen alone (P = 0.03).
   Conclusions The GCL-IPL is reduced in thickness with an annular pattern in early AMD and is significantly thinner in eyes with SDD.
C1 [Abdolrahimzadeh, Solmaz] Sapienza Univ Rome, St Andrea Hosp, NESMOS Dept, Ophthalmol Unit, Rome, Italy.
   [Parisi, Francesco; Marcelli, Michela; Giustolis, Rosalia; Gharbiya, Magda] Sapienza Univ Rome, Dept Sense Organs, Ophthalmol Unit, Azienda Policlin Umberto I, Rome, Italy.
C3 Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Sapienza
   University Rome; University Hospital Sapienza Rome
RP Abdolrahimzadeh, S (通讯作者)，Sapienza Univ Rome, St Andrea Hosp, NESMOS Dept, Ophthalmol Unit, Rome, Italy.
EM solmaz.abdolrahimzadeh@uniromal.it
RI Gharbiya, Magda/AAS-1182-2021
OI Gharbiya, Magda/0000-0002-4991-9689
CR Abdolrahimzadeh S, 2017, CURR EYE RES, V42, P1468, DOI 10.1080/02713683.2017.1347692
   Abdolrahimzadeh S, 2016, RETINA-J RET VIT DIS, V36, P2329, DOI 10.1097/IAE.0000000000001097
   Abdolrahimzadeh S, 2016, RETINA-J RET VIT DIS, V36, P75, DOI 10.1097/IAE.0000000000000650
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   Cringle SJ, 2002, INVEST OPHTH VIS SCI, V43, P1922
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Shin IH, 2018, RETINA-J RET VIT DIS, V38, P253, DOI 10.1097/IAE.0000000000001535
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   SNODDERLY DM, 1992, J NEUROSCI, V12, P1169
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2017, JAMA OPHTHALMOL, V135, P259, DOI 10.1001/jamaophthalmol.2016.5327
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Vongkulsiri S, 2014, AM J OPHTHALMOL, V158, P710, DOI 10.1016/j.ajo.2014.07.009
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
   Zhou Q, 2017, ACTA OPHTHALMOL, V95, pE518, DOI 10.1111/aos.13398
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 30
TC 8
Z9 8
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2019
VL 33
IS 8
BP 1290
EP 1296
DI 10.1038/s41433-019-0405-3
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IP8ZQ
UT WOS:000480336800015
PM 30926911
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Vidal, PL
   de Moura, J
   Novo, J
   Penedo, MG
   Ortega, M
AF Vidal, Placido L.
   de Moura, Joaquim
   Novo, Jorge
   Penedo, Manuel G.
   Ortega, Marcos
TI Intraretinal fluid identification via enhanced maps using optical
   coherence tomography images
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID MACULAR EDEMA; RETINAL FLUID; OCT IMAGES; SEGMENTATION; QUANTIFICATION;
   CLASSIFICATION; CALIBER; LAYER
AB Nowadays, among the main causes of blindness in developed countries are age-related macular degeneration (AMD) and the diabetic macular edema (DME). Both diseases present, as a common symptom, the appearance of cystoid fluid regions inside the retinal layers. Optical coherence tomography (OCT) image modality was one of the main medical imaging techniques for the early diagnosis and monitoring of AMD and DME via this intraretinal fluid detection and characterization. We present a novel methodology to identify these fluid accumulations by means of generating binary maps (offering a direct representation of these areas) and heat maps (containing the region confidence). To achieve this, a set of 312 intensity and texture-based features were studied. The most relevant features were selected using the sequential forward selection (SFS) strategy and tested with three archetypal classifiers: LDC, SVM and Parzen window. Finally, the most proficient classifier is used to create the proposed maps. All of the tested classifiers returned satisfactory results, the best classifier achieving a mean test accuracy higher than 94% in all of the experiments. The suitability of the maps was evaluated in a context of a screening issue with three different datasets obtained with two different devices, testing the capabilities of the system to work independently of the used OCT device. The experiments with the map creation were performed using 323 OCT images. Using only the binary maps, more than 91.33% of the images were correctly classified. With only the heat maps, the proposed methodology correctly separated 93.50% of the images. (C) 2018 Optical Society of America under the terms of the OSA Open Access Publishing Agreement
C1 [Vidal, Placido L.; de Moura, Joaquim; Novo, Jorge; Penedo, Manuel G.; Ortega, Marcos] Univ A Coruna, Dept Comp Sci, La Coruna 15071, Spain.
   [Vidal, Placido L.; de Moura, Joaquim; Novo, Jorge; Penedo, Manuel G.; Ortega, Marcos] Univ A Coruna, CITIC Res Ctr Informat & Commun Technol, La Coruna 15071, Spain.
C3 Universidade da Coruna; Universidade da Coruna
RP Novo, J (通讯作者)，Univ A Coruna, Dept Comp Sci, La Coruna 15071, Spain.; Novo, J (通讯作者)，Univ A Coruna, CITIC Res Ctr Informat & Commun Technol, La Coruna 15071, Spain.
EM jnovo@udc.es
RI Hortas, Marcos Ortega/A-5955-2011; Penedo, Manuel F.
   González/N-7767-2015; Buján, Jorge Novo/N-3366-2014; de Moura Ramos,
   José Joaquim/H-4207-2017
OI Hortas, Marcos Ortega/0000-0002-2798-0788; Penedo, Manuel F.
   González/0000-0002-6881-0865; Buján, Jorge Novo/0000-0002-0125-3064; de
   Moura Ramos, José Joaquim/0000-0002-2050-3786; Lizancos Vidal, Placido
   Francisco/0000-0002-6009-4737
FU Instituto de Salud Carlos III (ISCIII) [PI14/02161, DTS15/00153];
   Ministerio de Economia, Industria y Competitividad, Gobierno de Espana
   [DPI2015-69948-R]; Conselleria de Cultura, Educacion e Ordenacion
   Universitaria, Xunta de Galicia [ED431C 2016-047, ED431G/01]
FX Instituto de Salud Carlos III (ISCIII) (PI14/02161, DTS15/00153);
   Ministerio de Economia, Industria y Competitividad, Gobierno de Espana
   (DPI2015-69948-R); Conselleria de Cultura, Educacion e Ordenacion
   Universitaria, Xunta de Galicia (ED431C 2016-047, ED431G/01).
CR Al-Kadi OS, 2008, IEEE T BIO-MED ENG, V55, P1822, DOI 10.1109/TBME.2008.919735
   Baamonde S, 2017, LECT NOTES COMPUT SC, V10305, P222, DOI 10.1007/978-3-319-59153-7_20
   Buczkowski S, 1998, PATTERN RECOGN, V31, P411, DOI 10.1016/S0031-3203(97)00054-X
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Dalal N, 2005, PROC CVPR IEEE, P886, DOI 10.1109/cvpr.2005.177
   de Moura J, 2017, LECT NOTES ARTIF INT, V10259, P305, DOI 10.1007/978-3-319-59758-4_35
   de Moura J, 2017, PROCEDIA COMPUT SCI, V112, P1369, DOI 10.1016/j.procs.2017.08.043
   de Sisternes L, 2017, BIOMED OPT EXPRESS, V8, P1926, DOI 10.1364/BOE.8.001926
   Dijkstra E. W., 1959, NUMER MATH, V1, P269, DOI [10.1007/BF01386390, DOI 10.1007/BF01386390]
   Esmaeili Mahdad, 2016, J Med Signals Sens, V6, P166
   Gabor D., 1946, Journal of the Institution of Electrical Engineers. III. Radio and Communication Engineering, V93, P429
   Girish GN, 2018, COMPUT METH PROG BIO, V153, P105, DOI 10.1016/j.cmpb.2017.10.010
   Girish GN, 2016, IEEE ENG MED BIO, P1292, DOI 10.1109/EMBC.2016.7590943
   Gonzalez A, 2013, COMP MED SY, P397, DOI 10.1109/CBMS.2013.6627825
   Gopinath K., 2018, IEEE J BIOMED HEALTH, P1
   Gordon-Lipkin E, 2007, NEUROLOGY, V69, P1603, DOI 10.1212/01.wnl.0000295995.46586.ae
   Haghighat M, 2015, EXPERT SYST APPL, V42, P7905, DOI 10.1016/j.eswa.2015.06.025
   HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jindahra P, 2010, CURR OPIN NEUROL, V23, P16, DOI 10.1097/WCO.0b013e328334e99b
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   LISSACK TSVI, 1976, IEEE T INFORM THEORY, V22, P34, DOI 10.1109/TIT.1976.1055512
   Montuoro A, 2017, BIOMED OPT EXPRESS, V8, P1874, DOI 10.1364/BOE.8.001874
   Moura J., 2016, LECT NOTES COMPUTER, V9730, P807
   Nguyen TT, 2008, DIABETES CARE, V31, P544, DOI 10.2337/dc07-1528
   Ojala T, 2002, IEEE T PATTERN ANAL, V24, P971, DOI 10.1109/TPAMI.2002.1017623
   Pose-Reino A, 2005, J HYPERTENS, V23, P843, DOI 10.1097/01.hjh.0000163154.35577.8e
   Rashno A., 2017, IEEE T BIOMED ENG, VPP
   Rashno A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186949
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roy A. G., 2017, ABS170402161 CORR
   Roychowdhury S, 2013, IEEE ENG MED BIO, P1426, DOI 10.1109/EMBC.2013.6609778
   Sabari Girish G., 2018, INT J AMBIENT ENERGY, P1
   Sahoo M, 2017, MEASUREMENT, V101, P138, DOI 10.1016/j.measurement.2017.01.027
   Sanchez-Tocino H, 2002, INVEST OPHTH VIS SCI, V43, P1588
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Tennakoon R, 2018, I S BIOMED IMAGING, P1436, DOI 10.1109/ISBI.2018.8363842
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Wang J, 2016, BIOMED OPT EXPRESS, V7, P1577, DOI 10.1364/BOE.7.001577
   Wang T, 2016, INFORM SCIENCES, V358, P92, DOI 10.1016/j.ins.2016.04.017
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P1153, DOI 10.1001/jama.287.9.1153
   Wu ML, 2018, IEEE T BIO-MED ENG, V65, P87, DOI 10.1109/TBME.2017.2695461
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
NR 47
TC 18
Z9 19
U1 0
U2 5
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD OCT 1
PY 2018
VL 9
IS 10
BP 4730
EP 4754
DI 10.1364/BOE.9.004730
PG 25
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA GV6AI
UT WOS:000446188200012
PM 30319899
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mewborn, CM
   Lindbergh, CA
   Robinson, TL
   Gogniat, MA
   Terry, DP
   Jean, KR
   Hammond, BR
   Renzi-Hammond, LM
   Miller, LS
AF Mewborn, Catherine M.
   Lindbergh, Cutter A.
   Robinson, Talia L.
   Gogniat, Marissa A.
   Terry, Douglas P.
   Jean, Kharine R.
   Hammond, Billy Randy
   Renzi-Hammond, Lisa M.
   Miller, Lloyd Stephen
TI Lutein and Zeaxanthin Are Positively Associated with Visual-Spatial
   Functioning in Older Adults: An fMRI Study
SO NUTRIENTS
LA English
DT Article
DE xanthophylls; visual-spatial reasoning; fMRI; older adults; cognition
ID PIGMENT OPTICAL-DENSITY; HETEROCHROMATIC FLICKER PHOTOMETRY;
   AGE-RELATED-CHANGES; MACULAR PIGMENT; COGNITIVE FUNCTION; NEURAL
   SPECIALIZATION; RETINAL CAROTENOIDS; PARKINSONS-DISEASE;
   ALZHEIMERS-DISEASE; BLOOD-FLOW
AB Lutein (L) and zeaxanthin (Z) are two xanthophyll carotenoids that have antioxidant and anti-inflammatory properties. Previous work has demonstrated their importance for eye health and preventing diseases such as age-related macular degeneration. An emerging literature base has also demonstrated the importance of L and Z in cognition, neural structure, and neural efficiency. The present study aimed to better understand the mechanisms by which L and Z relate to cognition, in particular, visual-spatial processing and decision-making in older adults. We hypothesized that markers of higher levels of L and Z would be associated with better neural efficiency during a visual-spatial processing task. L and Z were assessed via standard measurement of blood serum and retinal concentrations. Visual-spatial processing and decision-making were assessed via a judgment of line orientation task (JLO) completed during a functional magnetic resonance imaging (fMRI) scan. The results demonstrated that individuals with higher concentrations of L and Z showed a decreased blood-oxygen-level dependent (BOLD) signal during task performance (i.e., "neural efficiency") in key areas associated with visual-spatial perception, processing, decision-making, and motor coordination, including the lateral occipital cortex, occipital pole, superior and middle temporal gyri, superior parietal lobule, superior and middle frontal gyri, and pre- and post-central gyri. To our knowledge, this is the first investigation of the relationship of L and Z to visual-spatial processing at a neural level using in vivo methodology. Our findings suggest that L and Z may impact brain health and cognition in older adults by enhancing neurobiological efficiency in a variety of regions that support visual perception and decision-making.
C1 [Mewborn, Catherine M.; Lindbergh, Cutter A.; Robinson, Talia L.; Gogniat, Marissa A.; Jean, Kharine R.; Hammond, Billy Randy; Renzi-Hammond, Lisa M.; Miller, Lloyd Stephen] Univ Georgia, Dept Psychol, Athens, GA 30602 USA.
   [Terry, Douglas P.] Massachusetts Gen Hosp, Dept Psychiat, Dept Phys Med & Rehabil, Boston, MA 02114 USA.
   [Renzi-Hammond, Lisa M.] Univ Georgia, Coll Publ Hlth, Inst Gerontol, Dept Hlth Promot & Behav, Athens, GA 30602 USA.
C3 University System of Georgia; University of Georgia; Harvard University;
   Massachusetts General Hospital; University System of Georgia; University
   of Georgia
RP Miller, LS (通讯作者)，Univ Georgia, Dept Psychol, Athens, GA 30602 USA.
EM cmewborn@uga.edu; cal@uga.edu; talia.robinson25@uga.edu;
   marissa.gogniat25@uga.edu; douglasterry1@gmail.com; kjean@uga.edu;
   bhammond@uga.edu; lrenzi@uga.edu; lsmiller@uga.edu
RI Gogniat, Marissa/AAA-6761-2022
OI Hammond, Billy/0000-0002-5762-0206; Renzi-Hammond,
   Lisa/0000-0003-4334-8202
FU Abbott Nutrition, Columbus, OH, USA
FX The authors would like to acknowledge Joanne Curran-Celentano and Karen
   Semo for assistance with serum analysis. This work was supported by
   Abbott Nutrition, Columbus, OH, USA [research grant to LMRH, BRH, and
   LSM]; The University of Georgia's Bio-Imaging Research Center
   [administrative support to LSM]; and DSM Nutritional Products
   (Switzerland) who provided the supplements and placebos for the
   randomized-controlled trial from which the current data were derived.
CR Akbaraly NT, 2007, J GERONTOL A-BIOL, V62, P308, DOI 10.1093/gerona/62.3.308
   Ashburner J., 2021, SPM12 MANUAL
   Beatty S, 2004, ARCH BIOCHEM BIOPHYS, V430, P70, DOI 10.1016/j.abb.2004.03.015
   BENTON A, 1975, NEUROLOGY, V25, P907, DOI 10.1212/WNL.25.10.907
   BENTON AL, 1978, ARCH NEUROL-CHICAGO, V35, P364, DOI 10.1001/archneur.1978.00500300038006
   BENTON AL, 1967, CONFIN NEUROL, V29, P1
   Biesbroek JM, 2014, NEUROPSYCHOLOGIA, V62, P68, DOI 10.1016/j.neuropsychologia.2014.07.013
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Cabeza R, 1997, J NEUROSCI, V17, P391
   Caracciolo B, 2014, MECH AGEING DEV, V136, P59, DOI 10.1016/j.mad.2013.11.011
   Chee MWL, 2006, J COGNITIVE NEUROSCI, V18, P495, DOI 10.1162/jocn.2006.18.4.495
   Collins DW, 1997, BEHAV NEUROSCI, V111, P845, DOI 10.1037/0735-7044.111.4.845
   Craft N.E., 2004, EXP ANIM, V21, P22
   Davis SW, 2008, CEREB CORTEX, V18, P1201, DOI 10.1093/cercor/bhm155
   Duzel E, 2011, HIPPOCAMPUS, V21, P803, DOI 10.1002/hipo.20834
   Duverne S, 2008, NEUROBIOL AGING, V29, P1902, DOI 10.1016/j.neurobiolaging.2007.04.022
   Erdman JW, 2015, FOODS, V4, P547, DOI 10.3390/foods4040547
   Feeney J, 2013, NEUROBIOL AGING, V34, P2449, DOI 10.1016/j.neurobiolaging.2013.05.007
   Fink GR, 2000, NEUROLOGY, V54, P1324, DOI 10.1212/WNL.54.6.1324
   Ganis G, 2004, COGNITIVE BRAIN RES, V20, P226, DOI 10.1016/j.cogbrainres.2004.02.012
   Grady CL, 1999, CEREB CORTEX, V9, P805, DOI 10.1093/cercor/9.8.805
   GRADY CL, 1994, J NEUROSCI, V14, P1450, DOI 10.1523/JNEUROSCI.14-03-01450.1994
   GUR RC, 1987, ARCH GEN PSYCHIAT, V44, P617
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   HENDERSON VW, 1989, ARCH NEUROL-CHICAGO, V46, P391, DOI 10.1001/archneur.1989.00520400045018
   HOVESTADT A, 1987, NEUROLOGY, V37, P485, DOI 10.1212/WNL.37.3.485
   Hurst JW, 1990, CLIN METHODS HIST PH
   Johnson E.J., 2013, J AGING RES, V2013
   Johnson EJ, 2008, NUTR NEUROSCI, V11, P75, DOI 10.1179/147683008X301450
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Kesler SR, 2004, CEREB CORTEX, V14, P174, DOI 10.1093/cercor/bhg116
   Kosslyn S.M., 1996, IMAGE BRAIN RESOLUTI
   Lazar NA, 2008, STAT BIOL HEALTH, P1, DOI 10.1007/978-0-387-78191-4_1
   Lezak MD, 2012, NEUROPSYCHOLOGICAL A
   Lindbergh CA, 2018, J INT NEUROPSYCH SOC, V24, P77, DOI 10.1017/S1355617717000534
   Lindbergh CA, 2017, J INT NEUROPSYCH SOC, V23, P11, DOI 10.1017/S1355617716000850
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   Martin AD, 2009, EUR PHYS J C, V63, P189, DOI 10.1140/epjc/s10052-009-1072-5
   Mewborn C, 2015, ARCH CLIN NEUROPSYCH, V30, P605, DOI 10.1093/arclin/acv054
   Mewborn CM, 2018, ARCH CLIN NEUROPSYCH, V33, P861, DOI 10.1093/acn/acx109
   Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167
   Min JY, 2014, DEMENT GERIATR COGN, V37, P246, DOI 10.1159/000356486
   Morris JC, 1993, NEUROLOGY
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   NORTH AJ, 1981, J GERONTOL, V36, P576, DOI 10.1093/geronj/36.5.576
   Nyberg L, 2003, P NATL ACAD SCI USA, V100, P13728, DOI 10.1073/pnas.1735487100
   Park DC, 2004, P NATL ACAD SCI USA, V101, P13091, DOI 10.1073/pnas.0405148101
   Park DC, 2009, ANNU REV PSYCHOL, V60, P173, DOI 10.1146/annurev.psych.59.103006.093656
   Paterson A, 1944, BRAIN, V67, P331, DOI 10.1093/brain/67.4.331
   Payer D, 2006, NEUROREPORT, V17, P487, DOI 10.1097/01.wnr.0000209005.40481.31
   Possin KL, 2010, NEUROCASE, V16, P466, DOI 10.1080/13554791003730600
   Power R, 2018, J ALZHEIMERS DIS, V61, P947, DOI 10.3233/JAD-170713
   RASKIN SA, 1990, INT J NEUROSCI, V51, P9, DOI 10.3109/00207459009000503
   Renzi LM, 2014, NEUROBIOL AGING, V35, P1695, DOI 10.1016/j.neurobiolaging.2013.12.024
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Renzi LM, 2008, FASEB J, V22
   Reuter-Lorenz PA, 2000, J COGNITIVE NEUROSCI, V12, P174, DOI 10.1162/089892900561814
   Reuter-Lorenz PA, 2014, NEUROPSYCHOL REV, V24, P355, DOI 10.1007/s11065-014-9270-9
   Rorden C, 2007, DCM2NII VERSION 7 OC
   SALTHOUSE TA, 1992, HDB AGING COGNITION, P167
   SanGiovanni JP, 2012, AM J CLIN NUTR, V96, p1223S, DOI 10.3945/ajcn.112.038240
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   SKA B, 1990, J CLIN EXP NEUROPSYC, V12, P695, DOI 10.1080/01688639008401012
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Thiebaut de Schotten M, 2005, SCIENCE, V309, P2226, DOI 10.1126/science.1116251
   Tranel D, 2009, J CLIN EXP NEUROPSYC, V31, P219, DOI 10.1080/13803390802317542
   Vishwanathan R, 2014, AGE AGEING, V43, P271, DOI 10.1093/ageing/aft210
   Vishwanathan R, 2013, NUTR NEUROSCI, V16, P21, DOI 10.1179/1476830512Y.0000000024
   WAHLIN TBR, 1993, ARCH GERONTOL GERIAT, V17, P165, DOI 10.1016/0167-4943(93)90048-M
   Walk AM, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00183
   Wooten BR, 2005, OPTOMETRY VISION SCI, V82, P378, DOI 10.1097/01.OPX.0000162654.32112.A1
   Zamroziewicz MK, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00297
NR 72
TC 20
Z9 20
U1 0
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD APR
PY 2018
VL 10
IS 4
AR 458
DI 10.3390/nu10040458
PG 16
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA GJ3HN
UT WOS:000435182900074
PM 29642425
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Al-Kinani, AA
   Zidan, G
   Elsaid, N
   Seyfoddin, A
   Alani, AWG
   Alany, RG
AF Al-Kinani, Ali A.
   Zidan, Ghada
   Elsaid, Naba
   Seyfoddin, Ali
   Alani, Adam W. G.
   Alany, Raid G.
TI Ophthalmic gels: Past, present and future
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Ophthalmic gels; Gel-forming eye drops; In-situ gelling systems;
   Hydrogels; Ocular tolerability; Contact lenses; 3D bioprinting
ID OCULAR DRUG-DELIVERY; IN-SITU GEL; AMNIOTIC MEMBRANE TRANSPLANTATION;
   ENVIRONMENT-SENSITIVE HYDROGELS; CONTACT-LENSES; SILICONE-HYDROGEL;
   TRANSSCLERAL DELIVERY; SUSTAINED-RELEASE; POSTERIOR SEGMENT; GELLING
   SYSTEMS
AB Aqueous gels formulated using hydrophilic polymers (hydrogels) along with those based on stimuli responsive polymers (in situ gelling or gel forming systems) continue to attract increasing interest for various eye health related applications. They allow the incorporation of a variety of ophthalmic pharmaceuticals to achieve therapeutic levels of drugs and bioactives at target ocular sites. The integration of sophisticated drug delivery technologies such as nanotechnology-based ones with intelligent and environment responsive systems can extend current treatment duration to provide more clinically relevant time courses (weeks and months instead of hours and days) which will inevitably reduce dose frequency, increase patient compliance and improve clinical outcomes. Novel applications and design of contact lenses and intracanalicular delivery devices along with the move towards integrating gels into various drug delivery devices like intraocular pumps, injections and implants has the potential to reduce comorbidities caused by glaucoma, corneal keratopathy, cataract, diabetic retinopathies and age-related macular degeneration. This review describes ophthalmic gelling systems with emphasis on mechanism of gel formation and application in ophthalmology. It provides a critical appraisal of the techniques and methods used in the characterization of ophthalmic preformed gels and in situ gelling systems along with a thorough insight into the safety and biocompatibility of these systems. Newly developed ophthalmic gels, hydrogels, preformed gels and in situ gelling systems including the latest in the area of stimuli responsive gels, molecularly imprinted gels, nanogels, 3D printed hydrogels; 3D printed devices comprising ophthalmic gels are covered. Finally, new applications of gels in the production of artificial corneas, corneal wound healing and hydrogel contact lenses are described. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Al-Kinani, Ali A.; Alany, Raid G.] Kingston Univ London, Drug Discovery Delivery & Patient Care DDDPC Res, Sch Life Sci Pharm & Chem, Kingston Upon Thames KT1 2EE, Surrey, England.
   [Zidan, Ghada; Seyfoddin, Ali] Auckland Univ Technol, Sch Sci, Drug Delivery Res Grp, Auckland, New Zealand.
   [Elsaid, Naba] Anglia Ruskin Univ, Bishop Hall Lane, Chelmsford CM1 1SQ, Essex, England.
   [Seyfoddin, Ali] Auckland Univ Technol, Sch Interprofess Hlth Studies, Auckland, New Zealand.
   [Alani, Adam W. G.] Oregon State Univ, Dept Pharmaceut Sci, Coll Pharm, Portland, OR USA.
   [Alani, Adam W. G.] Oregon Hlth & Sci Univ, Sch Med, Dept Biomed Engn, Portland, OR 97201 USA.
   [Alany, Raid G.] Univ Auckland, Sch Pharm, Auckland, New Zealand.
C3 Kingston University; Auckland University of Technology; Anglia Ruskin
   University; Auckland University of Technology; Oregon State University;
   Oregon Health & Science University; University of Auckland
RP Alany, RG (通讯作者)，Kingston Univ London, Sch Life Sci Pharm & Chem, Kingston Upon Thames KT1 2EE, Surrey, England.
EM r.alany@kingston.ac.uk
RI Al-kinani, Ali Athab/M-7209-2019; Al-Kinani, Ali A./S-7073-2017
OI Al-kinani, Ali Athab/0000-0003-4940-7648; Al-Kinani, Ali
   A./0000-0003-4940-7648; Zidan, Ghada/0000-0003-2545-4052; Alani,
   Adam/0000-0002-9214-9317
CR Abdelkader H, 2015, BRIT MED BULL, V113, P59, DOI 10.1093/bmb/ldv002
   Abdelkader H, 2012, INT J PHARMACEUT, V432, P1, DOI 10.1016/j.ijpharm.2012.04.063
   Agarwal K., 2011, ASIAN J BIOMED PHARM, V1
   Ahearne M, 2005, J R SOC INTERFACE, V2, P455, DOI 10.1098/rsif.2005.0065
   Ahmed TAE, 2008, TISSUE ENG PART B-RE, V14, P199, DOI 10.1089/ten.teb.2007.0435
   Alany RG, 2006, J CONTROL RELEASE, V111, P145, DOI 10.1016/j.jconrel.2005.11.020
   Alexander A, 2014, EUR J PHARM BIOPHARM, V88, P575, DOI 10.1016/j.ejpb.2014.07.005
   Almeida H, 2013, EXPERT OPIN DRUG DEL, V10, P1223, DOI 10.1517/17425247.2013.796360
   Ambrosio L, 2011, WOODHEAD PUBL MATER, P25
   Andrade-Vivero P, 2007, J PHARM SCI-US, V96, P802, DOI 10.1002/jps.20761
   Ankareddi I, 2007, INT J PHARM, V336, P241, DOI 10.1016/j.ijpharm.2006.11.065
   Arvidson SA, 2013, MACROMOLECULES, V46, P300, DOI 10.1021/ma3019359
   Bae Y.H., 1997, CONTROLLED DRUG DELI, P147
   Bain MK, 2012, INT J BIOL MACROMOL, V51, P831, DOI 10.1016/j.ijbiomac.2012.07.028
   Barile FA, 2010, J PHARMACOL TOXICOL, V61, P136, DOI 10.1016/j.vascn.2010.01.001
   Bartok M, 2015, TOXICOL IN VITRO, V29, P72, DOI 10.1016/j.tiv.2014.09.005
   Beharry K.D., 2017, PROSTAGLANDINS OTHER
   Behl G, 2016, PHARM RES-DORDR, V33, P1638, DOI 10.1007/s11095-016-1903-7
   BenEzra D., 2006, BLEPHARITIS CONJUNCT, P204
   Bernhard JC, 2016, WORLD J UROL, V34, P337, DOI 10.1007/s00345-015-1632-2
   Bertassoni LE, 2014, LAB CHIP, V14, P2202, DOI 10.1039/c4lc00030g
   Bertassoni LE, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/2/024105
   Billiet T, 2014, BIOMATERIALS, V35, P49, DOI 10.1016/j.biomaterials.2013.09.078
   Boland Thomas, 2006, Biotechnology Journal, V1, P910, DOI 10.1002/biot.200600081
   Boone A, 2009, EYE CONTACT LENS, V35, P260, DOI 10.1097/ICL.0b013e3181b26c49
   Bose S, 2013, MATER TODAY, V16, P496, DOI 10.1016/j.mattod.2013.11.017
   Bromberg LE, 1998, ADV DRUG DELIVER REV, V31, P197, DOI 10.1016/S0169-409X(97)00121-X
   Burdick J.A., 2011, ADV MAT, V23
   Buwalda SJ, 2017, BIOMACROMOLECULES, V18, P316, DOI 10.1021/acs.biomac.6b01604
   Calixto G, 2015, PHARM DEV TECHNOL, V20, P490, DOI 10.3109/10837450.2014.882941
   Cao DF, 2017, MAT SCI ENG C-MATER, V70, P665, DOI 10.1016/j.msec.2016.09.042
   Cao F, 2010, DRUG DELIV, V17, P500, DOI 10.3109/10717544.2010.483255
   Cao YX, 2007, J CONTROL RELEASE, V120, P186, DOI 10.1016/j.jconrel.2007.05.009
   Catros S, 2011, BIOFABRICATION, V3, DOI 10.1088/1758-5082/3/2/025001
   Chae JJ, 2014, MIL MED, V179, P686, DOI 10.7205/MILMED-D-13-00360
   CHANDRASEKARAN R, 1990, CARBOHYD POLYM, V12, P431, DOI 10.1016/0144-8617(90)90092-7
   CHANDRASEKARAN R, 1988, CARBOHYD RES, V181, P23, DOI 10.1016/0008-6215(88)84020-5
   Phan CM, 2014, EXPERT OPIN DRUG DEL, V11, P537, DOI 10.1517/17425247.2014.882315
   Cheah CM, 2002, P I MECH ENG H, V216, P369, DOI 10.1243/095441102321032166
   Chen XW, 2012, J BIOMATER APPL, V27, P391, DOI 10.1177/0885328211406563
   Chirila TV, 2001, BIOMATERIALS, V22, P3311, DOI 10.1016/S0142-9612(01)00168-5
   Cho SH, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.40667
   Choi HG, 1998, INT J PHARM, V165, P33, DOI 10.1016/S0378-5173(97)00386-4
   Choonara YE, 2010, J PHARM SCI-US, V99, P2219, DOI 10.1002/jps.21987
   Ciolino JB, 2014, BIOMATERIALS, V35, P432, DOI 10.1016/j.biomaterials.2013.09.032
   Ciolino JB, 2011, INVEST OPHTH VIS SCI, V52, P6286, DOI 10.1167/iovs.10-6935
   Cohen S, 1997, J CONTROL RELEASE, V44, P201, DOI 10.1016/S0168-3659(96)01523-4
   Craig JP, 2000, EYE, V14, P635, DOI 10.1038/eye.2000.156
   Darwhekar G., 2011, ASIAN J PHARM ANAL, V1, P93
   de Lima G.G., 2014, 1 INT EL C MAT MULT
   Debellemaniere G, 2016, J REFRACT SURG, V32, P201, DOI 10.3928/1081597X-20160121-05
   Deen G.R., 2012, POLYMERS, V4
   Deshpande PB, 2010, PHARM DEV TECHNOL, V15, P369, DOI [10.3109/10837450903262017, 10.1080/10837450903262017]
   Dholakia M, 2012, J PHARM BIOALLIED SC, V4, pS42, DOI 10.4103/0975-7406.94138
   Draize JH, 1944, J PHARMACOL EXP THER, V82, P377
   Duan B, 2013, J BIOMED MATER RES A, V101, P1255, DOI 10.1002/jbm.a.34420
   Edsman K, 1998, EUR J PHARM SCI, V6, P105, DOI 10.1016/S0928-0987(97)00075-4
   Elsaid N, 2016, MOL PHARMACEUT, V13, P2923, DOI 10.1021/acs.molpharmaceut.6b00335
   Elsaid N, 2014, EXP EYE RES, V121, P121, DOI 10.1016/j.exer.2014.02.001
   Elsaid N, 2012, INVEST OPHTH VIS SCI, V53, P8105, DOI 10.1167/iovs.12-10717
   Eskes Chantra, 2005, Altern Lab Anim, V33 Suppl 1, P47
   Faccia P., 2015, EXPRESS POLYM LETT, V9
   Fathi M, 2015, BIOIMPACTS, V5, P159, DOI 10.15171/bi.2015.31
   Faulkner-Jones A, 2015, BIOFABRICATION, V7, DOI 10.1088/1758-5090/7/4/044102
   Feng YQ, 2014, CURR EYE RES, V39, P541, DOI 10.3109/02713683.2013.853803
   Florence A.T., 2010, INTRO CLIN PHARM, V35
   Fuongfuchat A, 1996, CARBOHYD RES, V284, P85, DOI 10.1016/0008-6215(95)00396-7
   Fusco S, 2014, EXPERT OPIN DRUG DEL, V11, P1815, DOI 10.1517/17425247.2014.938633
   Gan L, 2009, INT J PHARMACEUT, V365, P143, DOI 10.1016/j.ijpharm.2008.08.004
   Garg T., 2013, STIMULI SENSITIVE HY, V30
   Geethalakshmi A., 2013, TEMPERATURE TRIGGERE, V3, P153, DOI [10.7324/JAPS.2013.30227, DOI 10.7324/JAPS.2013.30227]
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   GRANT GT, 1973, FEBS LETT, V32, P195, DOI 10.1016/0014-5793(73)80770-7
   GRASDALEN H, 1987, CARBOHYD POLYM, V7, P371, DOI 10.1016/0144-8617(87)90004-X
   Gratieri T, 2011, EUR J PHARM BIOPHARM, V79, P320, DOI 10.1016/j.ejpb.2011.05.006
   GRIFFITH JF, 1980, TOXICOL APPL PHARM, V55, P501, DOI 10.1016/0041-008X(80)90052-6
   Grolik M, 2012, J MATER SCI-MATER M, V23, P1991, DOI 10.1007/s10856-012-4666-7
   Gulsen D, 2005, CURR EYE RES, V30, P1071, DOI 10.1080/02713680500346633
   Gulsen D, 2004, INVEST OPHTH VIS SCI, V45, P2342, DOI 10.1167/iovs.03-0959
   Gupta H, 2007, DRUG DELIV, V14, P507, DOI 10.1080/10717540701606426
   Gupta NV, 2012, IRAN J PHARM RES, V11, P481
   Gurny R., 1985, J CONTROL RELEASE, V2, P353, DOI DOI 10.1016/0168-3659(85)90057-4
   H. Food Drug Administration, 2009, FED REGISTER, P68068
   Harbell J, 2006, 45 ANN SOC TOX M SAN
   Harish NM, 2009, INDIAN J PHARM SCI, V71, P421, DOI 10.4103/0250-474X.57291
   Heskins M., 1968, J MACROMOL SCI CHEM, V2, P1441, DOI [DOI 10.1080/10601326808051910, 10.1080/10601326808051910]
   Highley CB, 2015, ADV MATER, V27, P5075, DOI 10.1002/adma.201501234
   Hoffman AS, 2002, POLYM ADVAN TECHNOL, V13, P992, DOI 10.1002/pat.232
   Hong SM, 2015, ADV MATER, V27, P4035, DOI [10.1002/adma.201570182, 10.1002/adma.201501099]
   Horkay F, 2008, J POLYM SCI POL PHYS, V46, P2803, DOI 10.1002/polb.21590
   Hsiue GH, 2002, BIOMATERIALS, V23, P457, DOI 10.1016/S0142-9612(01)00127-2
   Hsu KH, 2014, J DRUG DELIV SCI TEC, V24, P123, DOI 10.1016/S1773-2247(14)50021-4
   Hsu KH, 2013, EUR J PHARM BIOPHARM, V85, P531, DOI 10.1016/j.ejpb.2013.04.017
   Huang WB, 2014, INVEST OPHTH VIS SCI, V55, P5380, DOI 10.1167/iovs.14-15231
   Hui A, 2016, OPTOMETRY VISION SCI, V93, P367, DOI 10.1097/OPX.0000000000000809
   HUI HW, 1985, INT J PHARM, V26, P203, DOI 10.1016/0378-5173(85)90230-3
   Hutmacher DW, 2000, BIOMATERIALS, V21, P2529, DOI 10.1016/S0142-9612(00)00121-6
   I.H.T. Guideline, 2003, GUID STAB TEST NEW D, V4
   Jester JV, 2001, TOXICOL IN VITRO, V15, P115, DOI 10.1016/S0887-2333(00)00065-5
   Jin R, 2010, BIOMEDICAL APPLICATIONS OF HYDROGELS HANDBOOK, P203, DOI 10.1007/978-1-4419-5919-5_11
   Jung HJ, 2013, J CONTROL RELEASE, V165, P82, DOI 10.1016/j.jconrel.2012.10.010
   Jungst T, 2016, CHEM REV, V116, P1496, DOI 10.1021/acs.chemrev.5b00303
   Kant A, 2011, PHARMACOLOGYONLINE, V2, P28
   Kapoor Y, 2008, J COLLOID INTERF SCI, V322, P624, DOI 10.1016/j.jcis.2008.02.028
   Kaur IP, 2002, DRUG DEV IND PHARM, V28, P353, DOI 10.1081/DDC-120002997
   Kheirkhah A, 2008, AM J OPHTHALMOL, V145, P787, DOI 10.1016/j.ajo.2008.01.009
   Khurana V., 2014, RECENT PATENTS NANOM, V4, P57, DOI DOI 10.2174/1877912304999140930143244
   Khutoryanskaya OV, 2014, MACROMOL BIOSCI, V14, P225, DOI 10.1002/mabi.201300313
   Kim J, 2008, BIOMATERIALS, V29, P2259, DOI 10.1016/j.biomaterials.2008.01.030
   Kim J, 2010, J CONTROL RELEASE, V148, P110, DOI 10.1016/j.jconrel.2010.07.119
   Knowlton S, 2015, TRENDS BIOTECHNOL, V33, P504, DOI 10.1016/j.tibtech.2015.06.007
   Koch L, 2013, CURR PHARM BIOTECHNO, V14, P91
   Koch L, 2012, BIOTECHNOL BIOENG, V109, P1855, DOI 10.1002/bit.24455
   Kompella UB, 2013, PROG RETIN EYE RES, V36, P172, DOI 10.1016/j.preteyeres.2013.04.001
   Kumar A, 2007, PROG POLYM SCI, V32, P1205, DOI 10.1016/j.progpolymsci.2007.05.003
   Kumar M., 2011, INT J PHARM BIOL ARC, V2
   KUMAR S, 1994, J OCUL PHARMACOL, V10, P47, DOI 10.1089/jop.1994.10.47
   Kushwaha SKS, 2012, INT J PHARM INVESTIG, V2, P54, DOI 10.4103/2230-973X.100036
   Lam CXF, 2002, MAT SCI ENG C-BIO S, V20, P49, DOI 10.1016/S0928-4931(02)00012-7
   LANG JC, 1995, ADV DRUG DELIVER REV, V16, P39, DOI 10.1016/0169-409X(95)00012-V
   Le Bourlais C, 1998, PROG RETIN EYE RES, V17, P33, DOI 10.1016/S1350-9462(97)00002-5
   Lee CH, 2009, J CONTROL RELEASE, V136, P88, DOI 10.1016/j.jconrel.2009.02.013
   Lee JH, 2012, J DRUG DELIV, V2012, DOI 10.1155/2012/527516
   Lee JS, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/2/024103
   LEE KK, 1990, CHEM ENG SCI, V45, P766, DOI 10.1016/0009-2509(90)87019-O
   Lee SC, 2013, ADV DRUG DELIVER REV, V65, P17, DOI 10.1016/j.addr.2012.07.015
   Lee YB, 2010, EXP NEUROL, V223, P645, DOI 10.1016/j.expneurol.2010.02.014
   LEHR CM, 1992, INT J PHARM, V78, P43, DOI 10.1016/0378-5173(92)90353-4
   LEMP M A, 1973, International Ophthalmology Clinics, V13, P221, DOI 10.1097/00004397-197301310-00016
   Lewis W., 1994, RED BLOOD CELL LYSIS, P99
   Li CC, 2006, IND ENG CHEM RES, V45, P3718, DOI 10.1021/ie0507934
   Li YL, 2015, CHEM REV, V115, P8564, DOI 10.1021/cr500131f
   Li ZB, 2017, J MOL ENG MATER, V5, DOI 10.1142/S2251237317400032
   Lin HR, 2004, BIOMACROMOLECULES, V5, P2358, DOI 10.1021/bm0496965
   Lin T, 2013, DRUG DES DEV THER, V7, P361, DOI 10.2147/DDDT.S42624
   Lo R, 2009, BIOMED MICRODEVICES, V11, P959, DOI 10.1007/s10544-009-9313-9
   Lordo RA, 1999, TOXICOL IN VITRO, V13, P45, DOI 10.1016/S0887-2333(98)00062-9
   Lu CH, 2013, J PHARM SCI-US, V102, P627, DOI 10.1002/jps.23390
   Ma WD, 2008, DRUG DEV IND PHARM, V34, P258, DOI 10.1080/03639040701580622 
   Ma WD, 2008, INT J PHARMACEUT, V350, P247, DOI 10.1016/j.ijpharm.2007.09.005
   Mahajan HS, 2015, CARBOHYD POLYM, V122, P243, DOI 10.1016/j.carbpol.2015.01.018
   Mahato RI, 2011, PHARM DOSAGE FORMS D
   Makwana S B, 2016, Results Pharma Sci, V6, P1, DOI 10.1016/j.rinphs.2015.06.001
   Malik HH, 2015, J SURG RES, V199, P512, DOI 10.1016/j.jss.2015.06.051
   Mandal S, 2012, INT J PHARM INVESTIG, V2, P78, DOI 10.4103/2230-973X.100042
   Marsh J, 2014, J MED DEVICES, V8, DOI 10.1115/1.4026451
   MATSUMOTO T, 1990, BIOPOLYMERS, V29, P1707, DOI 10.1002/bip.360291404
   Maulvi FA, 2016, DRUG DELIV, V23, P3017, DOI 10.3109/10717544.2016.1138342
   MAURICE D M, 1955, Br J Ophthalmol, V39, P463, DOI 10.1136/bjo.39.8.463
   Meallet MA, 2003, OPHTHALMOLOGY, V110, P1585, DOI 10.1016/S0161-6420(03)00503-7
   Melchels FPW, 2012, PROG POLYM SCI, V37, P1079, DOI 10.1016/j.progpolymsci.2011.11.007
   Melchels FPW, 2010, BIOMATERIALS, V31, P6121, DOI 10.1016/j.biomaterials.2010.04.050
   Milne G.W.A., 2005, GARDNERS COMMERCIALL, P503
   Mimura T., 2008, TISSUE ENG CORNEAL S
   Mironov V, 2003, TRENDS BIOTECHNOL, V21, P157, DOI 10.1016/S0167-7799(03)00033-7
   Miyata T, 1999, NATURE, V399, P766, DOI 10.1038/21619
   Miyata T, 2002, ADV DRUG DELIVER REV, V54, P79, DOI 10.1016/S0169-409X(01)00241-1
   Miyazaki S, 2001, INT J PHARM, V229, P29, DOI 10.1016/S0378-5173(01)00825-0
   Miyazaki S, 1999, J CONTROL RELEASE, V60, P287, DOI 10.1016/S0168-3659(99)00084-X
   MORTAZAVI SA, 1993, INT J PHARM, V94, P195, DOI 10.1016/0378-5173(93)90024-A
   Muller M, 2015, BIOFABRICATION, V7, DOI 10.1088/1758-5090/7/3/035006
   Murphy SV, 2014, NAT BIOTECHNOL, V32, P773, DOI 10.1038/nbt.2958
   Ng WL, 2016, INT J BIOPRINTING, V2, P53, DOI 10.18063/IJB.2016.01.009
   Nocera A.D., 2015, IFMBE P, P136
   Norman J, 2017, ADV DRUG DELIVER REV, V108, P39, DOI 10.1016/j.addr.2016.03.001
   NORN MS, 1963, ACTA OPHTHALMOL, V41, P13
   Nyberg EL, 2017, ANN BIOMED ENG, V45, P45, DOI 10.1007/s10439-016-1668-5
   OECD, TEST NO 405 AC EYE I
   Oh SH, 2007, BIOMATERIALS, V28, P1664, DOI 10.1016/j.biomaterials.2006.11.024
   Osswald CR, 2015, ANN BIOMED ENG, V43, P2609, DOI 10.1007/s10439-015-1314-7
   Ouyang LL, 2015, BIOFABRICATION, V7, DOI 10.1088/1758-5090/7/4/044101
   Ozcelik B, 2013, ACTA BIOMATER, V9, P6594, DOI 10.1016/j.actbio.2013.01.020
   Pal K, 2009, MODERN BIOPOLYMER SCIENCE: BRIDGING THE DIVIDE BETWEEN FUNDAMENTAL TREATISE AND INDUSTRIAL APPLICATION, P519, DOI 10.1016/B978-0-12-374195-0.00016-1
   PAPE WJW, 1990, ARZNEIMITTEL-FORSCH, V40-1, P498
   Pataky K, 2012, ADV MATER, V24, P391, DOI 10.1002/adma.201102800
   Patchan MW, 2016, J BIOMATER APPL, V30, P1049, DOI 10.1177/0885328215616273
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Patel MM, 2003, BIOMACROMOLECULES, V4, P1184, DOI 10.1021/bm034028p
   Patel SP, 2015, AAPS PHARMSCITECH, V16, P327, DOI 10.1208/s12249-014-0196-6
   Pati F, 2016, ANGEW CHEM INT EDIT, V55, P4650, DOI 10.1002/anie.201505062
   Pati F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4935
   Peng CC, 2012, J CONTROL RELEASE, V162, P152, DOI 10.1016/j.jconrel.2012.06.017
   Peng CC, 2010, BIOMATERIALS, V31, P4032, DOI 10.1016/j.biomaterials.2010.01.113
   Peppas NA, 2000, EUR J PHARM BIOPHARM, V50, P27, DOI 10.1016/S0939-6411(00)00090-4
   Perez E P, 1995, Tissue Eng, V1, P263, DOI 10.1089/ten.1995.1.263
   Prasad LK, 2016, DRUG DEV IND PHARM, V42, P1019, DOI 10.3109/03639045.2015.1120743
   Pratoomsoot C, 2008, BIOMATERIALS, V29, P272, DOI 10.1016/j.biomaterials.2007.09.031
   Prina E., 2017, STEM CELL REV REP, P1
   Qi HY, 2007, INT J PHARM, V337, P178, DOI 10.1016/j.ijpharm.2006.12.038
   Qiu Y, 2001, ADV DRUG DELIVER REV, V53, P321, DOI 10.1016/S0169-409X(01)00203-4
   Rafat M, 2008, BIOMATERIALS, V29, P3960, DOI 10.1016/j.biomaterials.2008.06.017
   Rasool BKA, 2012, AAPS PHARMSCITECH, V13, P883, DOI 10.1208/s12249-012-9813-4
   Ratner BD, 2004, ANNU REV BIOMED ENG, V6, P41, DOI 10.1146/annurev.bioeng.6.040803.140027
   Ribeiro AM, 2015, J PHARM PHARM SCI, V18, P683, DOI 10.18433/J3H60P
   Oliveira GAR, 2015, TOXICOL IN VITRO, V29, P1283, DOI 10.1016/j.tiv.2015.05.007
   Salvador MR, 2016, J INTELL STUD BUS, V6, P59, DOI 10.37380/jisib.v6i1.154
   Ruel-Gariepy E, 2004, EUR J PHARM BIOPHARM, V58, P409, DOI 10.1016/j.ejpb.2004.03.019
   Rupenthal I.D., 2010, PHARM SCI ENCY DRUG, P14
   Rupenthal ID, 2011, MOL PHARMACEUT, V8, P2282, DOI 10.1021/mp200140e
   Rupenthal ID, 2011, INT J PHARMACEUT, V411, P78, DOI 10.1016/j.ijpharm.2011.03.043
   Rupenthal ID, 2011, INT J PHARMACEUT, V411, P69, DOI 10.1016/j.ijpharm.2011.03.042
   Rutz AL, 2015, ADV MATER, V27, P1607, DOI 10.1002/adma.201405076
   Sa-Lima H, 2011, J BIOMED MATER RES A, V98A, P596, DOI 10.1002/jbm.a.33140
   Sadeghi AMM, 2008, EUR J PHARM BIOPHARM, V70, P270, DOI 10.1016/j.ejpb.2008.03.004
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Sangwan Virender S., 2007, Indian Journal of Ophthalmology, V55, P251
   SARKAR N, 1979, J APPL POLYM SCI, V24, P1073, DOI 10.1002/app.1979.070240420
   Schmaljohann D, 2006, ADV DRUG DELIVER REV, V58, P1655, DOI 10.1016/j.addr.2006.09.020
   SCHMOLKA IR, 1972, J BIOMED MATER RES, V6, P571, DOI 10.1002/jbm.820060609
   Schneider HJ, 2003, ANGEW CHEM INT EDIT, V42, P3544, DOI 10.1002/anie.200219965
   Schneider HJ, 2006, EUR J ORG CHEM, V2006, P677, DOI 10.1002/ejoc.200500633
   Sepahvandi A, 2016, BIONANOSCIENCE, V6, P276, DOI 10.1007/s12668-016-0219-8
   Shastri DH, 2010, J YOUNG PHARM, V2, P116, DOI 10.4103/0975-1483.63144
   Shigemitsu H, 2016, NAT PROTOC, V11, P1744, DOI 10.1038/nprot.2016.099
   SIEGEL RA, 1993, ADV POLYM SCI, V109, P233
   Sivaram AJ, 2015, WIRES NANOMED NANOBI, V7, P509, DOI 10.1002/wnan.1328
   Song JK, 2013, INT IMMUNOPHARMACOL, V17, P99, DOI 10.1016/j.intimp.2013.05.020
   Souto E.B., 2012, PATENTING NANOMEDICI
   Srividya B, 2001, J CONTROL RELEASE, V73, P205, DOI 10.1016/S0168-3659(01)00279-6
   Sultana Y, 2006, PHARM DEV TECHNOL, V11, P313, DOI 10.1080/10837450600767698
   Swift T, 2016, SOFT MATTER, V12, P2542, DOI 10.1039/c5sm02693h
   Takata S, 2002, POLYMER, V43, P3101, DOI 10.1016/S0032-3861(02)00089-7
   Takeuchi H, 2005, ADV DRUG DELIVER REV, V57, P1583, DOI 10.1016/j.addr.2005.07.008
   Tanihara M, 1998, PEPTIDES, V19, P421, DOI 10.1016/S0196-9781(97)00420-8
   Thrimawithana TR, 2012, J DRUG DELIV SCI TEC, V22, P117, DOI 10.1016/S1773-2247(12)50015-8
   Thrimawithana TR, 2011, EUR J PHARM SCI, V44, P399, DOI 10.1016/j.ejps.2011.08.026
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Thrimawithana TR, 2011, DRUG DELIV LETT, V1, P40
   U.S. Department of Health and Human Services, 2016, 109931 ISO US DEP HL
   Upadhayay P, 2016, IRAN J PHARM RES, V15, P3
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Valmikinathan CM, 2012, BIOFABRICATION, V4, DOI 10.1088/1758-5082/4/3/035006
   van Tienen TG, 2002, BIOMATERIALS, V23, P1731, DOI 10.1016/S0142-9612(01)00280-0
   Vashist A, 2014, J MATER CHEM B, V2, P147, DOI 10.1039/c3tb21016b
   VYAS SP, 1992, J MICROENCAPSUL, V9, P347, DOI 10.3109/02652049209021249
   Waran V, 2014, J SURG EDUC, V71, P193, DOI 10.1016/j.jsurg.2013.08.010
   Wei G, 2002, J CONTROL RELEASE, V83, P65, DOI 10.1016/S0168-3659(02)00175-X
   WICHTERLE O, 1960, NATURE, V185, P117, DOI 10.1038/185117a0
   Wilde L, 2014, INT J PHARMACEUT, V461, P296, DOI 10.1016/j.ijpharm.2013.11.062
   Wilson CG, 2004, EXP EYE RES, V78, P737, DOI 10.1016/j.exer.2003.10.004
   Wilson SL, 2015, TOXICOLOGY, V327, P32, DOI 10.1016/j.tox.2014.11.003
   Wittmann K, 2015, TISSUE ENG PT A, V21, P1343, DOI [10.1089/ten.tea.2014.0299, 10.1089/ten.TEA.2014.0299]
   Wright B, 2013, DRUG DISCOV TODAY, V18, P79, DOI 10.1016/j.drudis.2012.07.012
   Wright B, 2012, REGEN MED, V7, P295, DOI [10.2217/RME.12.7, 10.2217/rme.12.7]
   Wu CJ, 2007, YAKUGAKU ZASSHI, V127, P183, DOI 10.1248/yakushi.127.183
   Wu ZD, 2016, SCI REP-UK, V6, DOI 10.1038/srep24809
   Xiao XH, 2014, J BIOMED MATER RES A, V102, P1782, DOI 10.1002/jbm.a.34848
   Xie P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109373
   Xinming Li, 2008, Cont Lens Anterior Eye, V31, P57, DOI 10.1016/j.clae.2007.09.002
   Xu JK, 2011, DRUG DELIV, V18, P150, DOI 10.3109/10717544.2010.522612
   Xu JK, 2010, ACTA BIOMATER, V6, P486, DOI 10.1016/j.actbio.2009.07.021
   Xu T, 2013, BIOMATERIALS, V34, P130, DOI 10.1016/j.biomaterials.2012.09.035
   Xu XD, 2007, J BIOMED MATER RES A, V81A, P418, DOI 10.1002/jbm.a.31063
   Xu X, 2017, INT J BIOL MACROMOL, V95, P294, DOI 10.1016/j.ijbiomac.2016.11.028
   Xu YR, 2004, LANGMUIR, V20, P6134, DOI 10.1021/la049907r
   YAMADA N, 1990, MAKROMOL CHEM-RAPID, V11, P571
   Yang XY, 2016, AAPS PHARMSCITECH, V17, P294, DOI 10.1208/s12249-015-0354-5
   Yang Y, 2010, ATLA-ALTERN LAB ANIM, V38, P303, DOI 10.1177/026119291003800413
   You Jin-Oh, 2010, J Biol Eng, V4, P15, DOI 10.1186/1754-1611-4-15
   Yu SH, 2017, CARBOHYD POLYM, V155, P208, DOI 10.1016/j.carbpol.2016.08.073
   Zhai DY, 2013, ACS NANO, V7, P3540, DOI 10.1021/nn400482d
   Zhang XZ, 2004, BIOMATERIALS, V25, P3793, DOI 10.1016/j.biomaterials.2003.10.065
   Zhang YS, 2017, ANN BIOMED ENG, V45, P148, DOI 10.1007/s10439-016-1612-8
   Zhong X, 1996, CHEM ENG SCI, V51, P3235, DOI 10.1016/0009-2509(95)00344-4
   Zidan G., 2017, PHARM DEV TECHNOL, P1
   ZIGNANI M, 1995, ADV DRUG DELIVER REV, V16, P51, DOI 10.1016/0169-409X(95)00015-Y
   Zou L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028720
NR 267
TC 86
Z9 88
U1 19
U2 175
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD FEB 15
PY 2018
VL 126
BP 113
EP 126
DI 10.1016/j.addr.2017.12.017
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GK5MY
UT WOS:000436220400008
PM 29288733
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Rudolf, M
   Sefat, AMM
   Miura, Y
   Tura, A
   Raasch, W
   Ranjbar, M
   Grisanti, S
   Aherrahrou, Z
   Wagner, A
   Messinger, JD
   Garber, DW
   Anantharamaiah, GM
   Curcio, CA
AF Rudolf, Martin
   Sefat, Armin Mir Mohi
   Miura, Yoko
   Tura, Aysegul
   Raasch, Walter
   Ranjbar, Mahdy
   Grisanti, Salvatore
   Aherrahrou, Zouhair
   Wagner, Anna
   Messinger, Jeffrey D.
   Garber, David W.
   Anantharamaiah, G. M.
   Curcio, Christine A.
TI ApoA-I Mimetic Peptide 4F Reduces Age-Related Lipid Deposition in Murine
   Bruch's Membrane and Causes Its Structural Remodeling
SO CURRENT EYE RESEARCH
LA English
DT Article
ID APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; BASAL LAMINAR DEPOSIT;
   MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   ULTRASTRUCTURAL-CHANGES; ESTERIFIED CHOLESTEROL; MOUSE MODEL; NULL MICE;
   DRUSEN
AB Purpose: Accumulation of lipoprotein-derived lipids including esterified and unesterified cholesterol in Bruch's membrane of human eyes is a major age-related change involved in initiating and sustaining soft drusen in age-related macular degeneration (AMD). The apolipoprotein (apo) A-I mimetic peptide 4F is a small anti-inflammatory and anti-atherogenic agent, and potent modifier of plasma membranes. We evaluated the effect of intravitreally-injected 4F on murine Bruch's membrane.
   Methods: We tested single intravitreal injections of 4F doses (0.6 mu g, 1.2 mu g, 2.4 mu g, and placebo scrambled peptide) in ApoE(null) mice >= 10 months of age. After 30 days, mice were euthanized. Eyes were processed for either direct immunofluorescence detection of esterified cholesterol (EC) in Bruch's membrane whole mounts via a perfringolysin O-based marker linked to green fluorescent protein or by transmission electron microscopic visualization of Bruch's membrane integrity. Fluorescein isothiocyanate-conjugated 4F was traced after injection.
   Results: All injected eyes showed a dose-dependent reduction of Bruch's membrane EC with a concomitant ultrastructural improvement compared to placebo treated eyes. At a 2.4 mu g dose of 4F, EC was reduced on average by similar to 60% and Bruch's membrane returned to a regular pentalaminar structure and thickness. Tracer studies confirmed that injected 4F reached intraocular targets.
   Conclusion: We demonstrated a highly effective pharmacological reduction of EC and restoration of Bruch's membrane ultrastructure. The apoA-I mimetic peptide 4F is a novel way to treat a critical AMD disease process and thus represents a new candidate for treating the underlying cause of AMD.
C1 [Rudolf, Martin; Sefat, Armin Mir Mohi; Miura, Yoko; Tura, Aysegul; Ranjbar, Mahdy; Grisanti, Salvatore; Wagner, Anna] Univ Lubeck, Dept Ophthalmol, Lubeck, Germany.
   [Raasch, Walter] Univ Lubeck, Dept Expt & Clin Pharmacol & Toxicol, Lubeck, Germany.
   [Ranjbar, Mahdy] Univ Lubeck, Lab Angiogenesis & Ocular Cell Transplantat, Lubeck, Germany.
   [Aherrahrou, Zouhair] Univ Lubeck, Inst Integrat & Expt Genom, Lubeck, Germany.
   [Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Garber, David W.; Anantharamaiah, G. M.] Univ Alabama Birmingham, Atherosclerosis Res Unit, Birmingham, AL USA.
   [Anantharamaiah, G. M.] Univ Alabama Birmingham, Dept Med Biochem & Mol Genet, Birmingham, AL USA.
C3 University of Lubeck; University of Lubeck; University of Lubeck;
   University of Lubeck; University of Alabama System; University of
   Alabama Birmingham; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham
RP Rudolf, M (通讯作者)，Univ Lubeck, Dept Ophthalmol UKSH, Ratzeburger Allee 160 Hs 29, D-23566 Lubeck, Germany.
EM mirudolf@aol.com
RI Miura, Yoko/B-5588-2015; Raasch, Walter/AAR-1165-2020
OI Aherrahrou, Zouhair/0000-0002-1241-8733
FU International Retinal Research Foundation (IRRF) USA; Euretina
   Innovation Award; AMD-Forderpreis der Deutschen Ophthalmologischen
   Gesellschaft; NIH [P01-34343, R01 EY06109]; Macula Vision Research
   Foundation; Research to Prevent Blindness; EyeSight Foundation of
   Alabama
FX This project was partly supported the International Retinal Research
   Foundation (IRRF) USA, the Euretina Innovation Award 2011, the
   AMD-Forderpreis der Deutschen Ophthalmologischen Gesellschaft 2009, by
   NIH grants P01-34343, R01 EY06109, Macula Vision Research Foundation and
   unrestricted funds from Research to Prevent Blindness and from the
   EyeSight Foundation of Alabama to the Department of Ophthalmology at
   UAB.
CR Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   Anantharamaiah GM, 2007, J LIPID RES, V48, P1915, DOI 10.1194/jlr.R700010-JLR200
   Anderson M, 2006, VET OPHTHALMOL, V9, P201, DOI 10.1111/j.1463-5224.2006.00463.x
   Apte RS, 2016, EBIOMEDICINE, V5, P26, DOI 10.1016/j.ebiom.2016.02.003
   Armstrong D, 1998, Angiogenesis, V2, P93, DOI 10.1023/A:1009010628371
   Averill MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109252
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Bloedon LT, 2008, J LIPID RES, V49, P1344, DOI 10.1194/jlr.P800003-JLR200
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Buga GM, 2008, J LIPID RES, V49, P192, DOI 10.1194/jlr.M700433-JLR200
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA., 2012, RETINA-J RET VIT DIS, V1, P466
   Curcio C, 2017, INVEST OPHTH VIS SCI, V58
   Curcio CA, 2015, AM J OPHTHALMOL, V160, P1024, DOI 10.1016/j.ajo.2015.08.001
   Curcio CA, 2014, INVEST OPHTH VIS SCI, V55, P7296, DOI 10.1167/iovs.14-15858
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Datta G, 2001, J LIPID RES, V42, P1096
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Gupta H, 2005, CIRC RES, V97, P236, DOI 10.1161/01.RES.0000176530.66400.48
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Jiang M, 2015, J CELL BIOL, V210, P595, DOI 10.1083/jcb.201410112
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kruth HS, 2011, CURR OPIN LIPIDOL, V22, P386, DOI 10.1097/MOL.0b013e32834adadb
   Leman LJ, 2014, J MED CHEM, V57, P2169, DOI 10.1021/jm4005847
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Li XR, 2004, CIRCULATION, V110, P3488, DOI 10.1161/01.CIR.0000149713.48317.27
   Lucocq JM, 2007, TRANSGENIC RES, V16, P133, DOI 10.1007/s11248-006-9048-9
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Navab M, 2005, ARTERIOSCL THROM VAS, V25, P1325, DOI 10.1161/01.ATV.0000165694.39518.95
   Navab M, 2004, CIRCULATION, V109, P3215, DOI 10.1161/01.CIR.0000134275.90823.87
   Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711
   Navab M, 2006, NAT CLIN PRACT CARD, V3, P540, DOI 10.1038/ncpcardio0661
   Navab M, 2015, J LIPID RES, V56, P871, DOI 10.1194/jlr.M056614
   Navab M, 2006, CURR OPIN LIPIDOL, V17, P440, DOI 10.1097/01.mol.0000236371.27508.d4
   Nguyen SD, 2015, J LIPID RES, V56, P1206, DOI 10.1194/jlr.M059485
   Ong JM, 2003, CURR EYE RES, V27, P15, DOI 10.1076/ceyr.27.2.15.15460
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Reddy ST, 2014, CURR OPIN LIPIDOL, V25, P304, DOI 10.1097/MOL.0000000000000092
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Rudolf M, 2014, INVEST OPHTH VIS SCI, V55, P4759, DOI 10.1167/iovs.14-14311
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schmidt-Erfurth U, 2008, INVEST OPHTH VIS SCI, V49, P390, DOI 10.1167/iovs.07-0227
   Sharifov OF, 2015, APOLIPOPROTEIN MIMET, P63
   Smith DD, 2010, J PHYSIOL PHARMACOL, V61, P309
   Smith JD, 2010, CURR OPIN INVEST DR, V11, P989
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Su F, 2010, P NATL ACAD SCI USA, V107, P19997, DOI 10.1073/pnas.1009010107
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Van Lenten BJ, 2008, J LIPID RES, V49, P2302, DOI 10.1194/jlr.M800075-JLR200
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Watson CE, 2011, J LIPID RES, V52, P361, DOI 10.1194/jlr.M011098
   Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538
   White C Roger, 2009, Vasc Dis Prev, V6, P122
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zeng GF, 2007, BLOOD, V109, P1345, DOI 10.1182/blood-2006-07-037952
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
NR 95
TC 16
Z9 16
U1 1
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2018
VL 43
IS 1
BP 135
EP 146
DI 10.1080/02713683.2017.1370118
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ1GE
UT WOS:000427324100019
PM 28972410
DA 2022-11-30
ER

PT J
AU Wang, L
   Cano, M
   Datta, S
   Wei, H
   Ebrahimi, KB
   Gorashi, Y
   Garlanda, C
   Handa, JT
AF Wang, Lei
   Cano, Marisol
   Datta, Sayantan
   Wei, Hong
   Ebrahimi, Katayoon B.
   Gorashi, Yara
   Garlanda, Cecilia
   Handa, James T.
TI Pentraxin 3 recruits complement factor H to protect against oxidative
   stress-induced complement and inflammasome overactivation
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE age-related macular degeneration; complement; inflammasome; innate
   immunity; pentraxin 3; retinal pigmented epithelium
ID RETINAL-PIGMENT EPITHELIUM; C-REACTIVE PROTEIN; HEPARIN-BINDING DOMAIN;
   AMYLOID-P COMPONENT; MACULAR DEGENERATION; NLRP3 INFLAMMASOME;
   REGULATORY DOMAINS; BRUCHS MEMBRANE; MYELOID CELLS; PTX3
AB The discovery that genetic abnormalities in complement factor H (FH) are associated with an increased risk for age-related macular degeneration (AMD), the most common cause of blindness among the elderly, raised hope of new treatments for this vision-threatening disease. Nonetheless, over a decade after the identification of this important association, how innate immunity contributes to AMD remains unresolved. Pentraxin 3 (PTX3), an essential component of the innate immunity system that plays a non-redundant role in controlling inflammation, regulates complement by interacting with complement components. Here, we show that PTX3 is induced by oxidative stress, a known cause of AMD, in the retinal pigmented epithelium (RPE). PTX3 deficiency in vitro and in vivo magnified complement activation induced by oxidative stress, leading to increased C3a, FB, and C3d, but not C5b-9 complex formation. Increased C3a levels, resulting from PTX3 deficiency, raised the levels of Il1b mRNA and secretion of activated interleukin (IL)-1 by interacting with C3aR. Importantly, PTX3 deficiency augmented NLRP3 inflammasome activation, resulting in enhanced IL-1, but not IL-18, production by the RPE. Thus, in the presence of PTX3 deficiency, the complement and inflammasome pathways worked in concert to produce IL-1 in sufficient abundance to, importantly, result in macrophages accumulating in the choroid. These results demonstrate that PTX3 acts as an essential brake for complement and inflammasome activation by regulating the abundance of FH in the RPE, and provide critical insights into the complex interplay between oxidative stress and innate immunity in the early stages of AMD development. Copyright (c) 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Wang, Lei; Cano, Marisol; Datta, Sayantan; Wei, Hong; Ebrahimi, Katayoon B.; Gorashi, Yara; Handa, James T.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
   [Garlanda, Cecilia] Humanitas Clin & Res Ctr, Ist Ricovero & Cura Carattere Sci, Milan, Italy.
C3 Johns Hopkins University; Johns Hopkins Medicine; IRCCS Ca Granda
   Ospedale Maggiore Policlinico
RP Handa, JT (通讯作者)，400 N Broadway,Smith Bldg,Rm 3015, Baltimore, MD 21287 USA.
EM jthanda@jhmi.edu
RI Wang, Lei/C-1902-2015; Garlanda, Cecilia/K-4601-2016
OI Wang, Lei/0000-0002-7957-1003; Garlanda, Cecilia/0000-0002-1510-7703
FU RPB Senior Scientist Award; Wilmer Core Grant [EY001765]; RPB; Merlau
   family;  [EY14005];  [EY019904]; NATIONAL EYE INSTITUTE [R01EY014005,
   P30EY001765, R01EY019904] Funding Source: NIH RePORTER
FX This work was supported by grants EY14005 (JTH) and EY019904 (JTH), an
   RPB Senior Scientist Award (JTH), Wilmer Core Grant EY001765, an
   Unrestricted Grant from RPB, and by the Merlau family and Aleda Wright.
   JTH is the Robert Bond Welch Professor.
CR Asgari E, 2013, BLOOD, V122, P3473, DOI 10.1182/blood-2013-05-502229
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Bottazzi B, 1997, J BIOL CHEM, V272, P32817, DOI 10.1074/jbc.272.52.32817
   Braunschweig A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023991
   BREVIARIO F, 1992, J BIOL CHEM, V267, P22190
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Csincsi AI, 2015, J IMMUNOL, V194, P4963, DOI 10.4049/jimmunol.1403121
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Franceschini A, 2015, FASEB J, V29, P2450, DOI 10.1096/fj.14-268714
   Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195
   Garlanda C, 2005, ANNU REV IMMUNOL, V23, P337, DOI 10.1146/annurev.immunol.23.021704.115756
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   GORDON DL, 1995, J IMMUNOL, V155, P348
   Gout E, 2011, J IMMUNOL, V186, P5815, DOI 10.4049/jimmunol.1100180
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hertle E, 2012, DIABETOLOGIA, V55, P881, DOI 10.1007/s00125-012-2462-z
   Hitzler I, 2012, J IMMUNOL, V188, P3594, DOI 10.4049/jimmunol.1103212
   Inforzato A, 2008, J BIOL CHEM, V283, P10147, DOI 10.1074/jbc.M708535200
   Inforzato A, 2013, SEMIN IMMUNOL, V25, P79, DOI 10.1016/j.smim.2013.05.002
   Kadl A, 2010, CIRC RES, V107, P737, DOI 10.1161/CIRCRESAHA.109.215715
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kopp A, 2012, J IMMUNOL, V189, P1858, DOI 10.4049/jimmunol.1200357
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lamkanfi M, 2012, ANNU REV CELL DEV BI, V28, P137, DOI 10.1146/annurev-cellbio-101011-155745
   Latini R, 2004, CIRCULATION, V110, P2349, DOI 10.1161/01.CIR.0000145167.30987.2E
   Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489
   Lee HW, 2011, MOVEMENT DISORD, V26, P2364, DOI 10.1002/mds.23871
   Ma YJ, 2009, J BIOL CHEM, V284, P28263, DOI 10.1074/jbc.M109.009225
   Ma YJ, 2011, J BIOL CHEM, V286, P3405, DOI 10.1074/jbc.M110.190637
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Meher AK, 2012, FREE RADICAL BIO MED, V52, P1708, DOI 10.1016/j.freeradbiomed.2012.02.022
   Nauta AJ, 2003, EUR J IMMUNOL, V33, P465, DOI 10.1002/immu.200310022
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Okamura H, 1998, CURR OPIN IMMUNOL, V10, P259, DOI 10.1016/S0952-7915(98)80163-5
   Onat A, 2011, CLIN CHIM ACTA, V412, P1171, DOI 10.1016/j.cca.2011.03.005
   Orsini F, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00380
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rider P, 2011, J IMMUNOL, V187, P4835, DOI 10.4049/jimmunol.1102048
   Rolph MS, 2002, ARTERIOSCL THROM VAS, V22, pE10, DOI 10.1161/01.ATV.0000015595.95497.2F
   Roumenina LT, 2006, BIOCHEMISTRY-US, V45, P4093, DOI 10.1021/bi052646f
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Wang L, 2014, BBA-MOL CELL RES, V1843, P1248, DOI 10.1016/j.bbamcr.2014.03.016
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   Wyatt MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068088
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yao GD, 2014, MOL CELL ENDOCRINOL, V382, P244, DOI 10.1016/j.mce.2013.10.014
   Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003
NR 64
TC 27
Z9 29
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD DEC
PY 2016
VL 240
IS 4
BP 495
EP 506
DI 10.1002/path.4811
PG 12
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EC0GX
UT WOS:000387778300012
PM 27659908
DA 2022-11-30
ER

PT J
AU Carnevali, A
   Cicinelli, MV
   Capuano, V
   Corvi, F
   Mazzaferro, A
   Querques, L
   Scorcia, V
   Souied, EH
   Bandello, F
   Querques, G
AF Carnevali, Adriano
   Cicinelli, Maria Vittoria
   Capuano, Vittorio
   Corvi, Federico
   Mazzaferro, Andrea
   Querques, Lea
   Scorcia, Vincenzo
   Souied, Eric H.
   Bandello, Francesco
   Querques, Giuseppe
TI Optical Coherence Tomography Angiography: A Useful Tool for Diagnosis of
   Treatment-Naive Quiescent Choroidal Neovascularization
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INDOCYANINE GREEN ANGIOGRAPHY; MACULAR DEGENERATION; FLUORESCEIN
   ANGIOGRAPHY
AB PURPOSE: To describe the optical coherence tomography angiography (OCT-A) features of treatment-naive quiescent choroidal neovascularization (CNV) secondary to age-related macular degeneration, and to estimate the detection rate for neovascularization by means of OCT-A.
   DESIGN: Diagnostic tool validity assessment.
   METHODS: Treatment-naive quiescent CNV were identified from a pool of patients at 2 retina referral centers. Patients underwent a complete ophthalmologic examination including fluorescein angiography, indocyanine green angiography, spectral-domain optical coherence tomography, and OCT-A. Detection rates of CNV by means of OCT-A were estimated with a second cohort of patients without CNV (negative controls).
   RESULTS: Twenty-two eyes of 20 consecutive patients with quiescent CNV were included. In 4 out of 22 eyes it was not possible to classify the CNV "shape," "core," "margin," and "location," either because the vascular network was not clearly shown (3 cases) or because it was not visible at all (1 case). CNV shape on OCT-A was rated as circular in 8 eyes and irregular in 10 eyes. CNV core was visible in 2 eyes. CNV margin was considered as well defined in 15 eyes and poorly defined in 3 eyes. CNV margin showed small loops in 9 eyes and large loops in the other 6 eyes. CNV location was fovealsparing in 12 eyes. Sensitivity and specificity of quiescent CNV detection by OCT-A turned out to be 81.8% and 100%, respectively.
   CONCLUSIONS: OCT-A allows the clinician to non-invasively identify treatment-naive quiescent CNV and may be considered as a useful tool to guide the frequency of return visits and, possibly, make treatment decisions. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Carnevali, Adriano; Cicinelli, Maria Vittoria; Corvi, Federico; Mazzaferro, Andrea; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
   [Carnevali, Adriano; Scorcia, Vincenzo] Magna Graecia Univ Catanzaro, Dept Ophthalmol, Catanzaro, Italy.
   [Capuano, Vittorio; Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, Creteil, France.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Magna
   Graecia University of Catanzaro; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI bandello, francesco/AAH-2405-2019; Corvi, Federico/AAD-7691-2021;
   cicinelli, maria vittoria/M-1611-2019
OI bandello, francesco/0000-0003-3238-9682; Corvi,
   Federico/0000-0002-2661-5500; cicinelli, maria
   vittoria/0000-0003-2938-0409; Querques, Giuseppe/0000-0002-3292-9581
CR An L, 2008, OPT EXPRESS, V16, P11438, DOI 10.1364/OE.16.011438
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P30, DOI 10.1159/000309489
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Nehemy MB, 2015, OSLI RETINA, V46, P1056, DOI 10.3928/23258160-20151027-13
   Pece A, 2005, EUR J OPHTHALMOL, V15, P759, DOI 10.1177/112067210501500616
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P2433, DOI 10.1097/IAE.0000000000000761
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083
   Wang RKK, 2010, IEEE J SEL TOP QUANT, V16, P545, DOI 10.1109/JSTQE.2009.2033609
NR 25
TC 103
Z9 107
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2016
VL 169
BP 189
EP 198
DI 10.1016/j.ajo.2016.06.042
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW4UA
UT WOS:000383637300020
PM 27394033
DA 2022-11-30
ER

PT J
AU Clemens, CR
   Bastian, N
   Alten, F
   Milojcic, C
   Heiduschka, P
   Eter, N
AF Clemens, Christoph R.
   Bastian, Nina
   Alten, Florian
   Milojcic, Carolin
   Heiduschka, Peter
   Eter, Nicole
TI Prediction of retinal pigment epithelial tear in serous vascularized
   pigment epithelium detachment
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; near-infrared; optical coherence
   tomography; pigment epithelium detachment; pigment epithelium tear
ID INTRAVITREAL BEVACIZUMAB INJECTION; THERAPY; PATHOGENESIS
AB Purpose: The aim of the study was to identify predictive factors for detection of impending retinal pigment epithelium (RPE) tears in patients under anti-VEGF therapy for treatment of retinal pigment epithelial detachment (PED) due to exudative age-related macular degeneration (AMD) using near-infrared reflectance imaging (NIR), spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FLA). Methods: We retrospectively evaluated NIR, SD-OCT and FLA images, number of intravitreal injections as well as demographical data of 103 eyes of 98 patients with vascularized PED [48.5% fibrovascular PED (fPED), 51.5% serous vascularized PED (svPED)] secondary to AMD. Results: Fifteen eyes with svPED of 103 included eyes (14.6%) developed an RPE tear under anti-VEGF therapy. Prior to RPE tear formation, we could identify radial hyperreflective lines spreading in a funnel-like pattern across the PED lesion in NIR images in 11 eyes correlating with folds in the RPE on corresponding SD-OCT scans (mean observation period: 115.466.6days; mean number of injections: 3.2 +/- 1.5; mean PED height 828.2 +/- 356.5m). In nine RPE tears (81.8%), the edge of the tear could be clearly localized on the opposite side of the PED lesion in relation to the origin of hyperreflective lines. None of the fPED patients showed the described signal. Conclusions: Patients under anti-VEGF therapy for treatment of svPED due to AMD frequently show radial hyperreflective lines in NIR images prior to RPE tear development that correspond to wrinkled changes in the RPE. Hyperreflective lines may serve as an indicator for an impending RPE tear in svPED patients.
C1 [Clemens, Christoph R.; Alten, Florian; Heiduschka, Peter; Eter, Nicole] Univ Munster, Dept Ophthalmol, Med Ctr, D-48149 Munster, Germany.
   [Bastian, Nina; Milojcic, Carolin] Univ Bonn, Dept Ophthalmol, Med Ctr, Bonn, Germany.
C3 University of Munster; University of Bonn
RP Clemens, CR (通讯作者)，Univ Munster, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM christoph.clemens@ukmuenster.de
RI Heiduschka, Peter/AAX-3882-2021
CR Bastian N, 2013, KLIN MONATSBL AUGENH, V230, P270, DOI 10.1055/s-0032-1328159
   Caramoy A, 2012, ACTA OPHTHALMOL, V90, pE328, DOI 10.1111/j.1755-3768.2011.02284.x
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Gelisken F, 2006, ACTA OPHTHALMOL SCAN, V84, P833, DOI 10.1111/j.1600-0420.2006.00765.x
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Hirano Y, 2012, ACTA OPHTHALMOL
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Sutter FK, 2007, KLIN MONATSBL AUGENH, V224, P297, DOI 10.1055/s-2007-962949
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 26
TC 26
Z9 31
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2014
VL 92
IS 1
BP E50
EP E56
DI 10.1111/aos.12234
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292TJ
UT WOS:000329925000014
PM 23819839
DA 2022-11-30
ER

PT J
AU Viiri, J
   Amadio, M
   Marchesi, N
   Hyttinen, JMT
   Kivinen, N
   Sironen, R
   Rilla, K
   Akhtar, S
   Provenzani, A
   D'Agostino, VG
   Govoni, S
   Pascale, A
   Agostini, H
   Petrovski, G
   Salminen, A
   Kaarniranta, K
AF Viiri, Johanna
   Amadio, Marialaura
   Marchesi, Nicoletta
   Hyttinen, Juha M. T.
   Kivinen, Niko
   Sironen, Reijo
   Rilla, Kirsi
   Akhtar, Saeed
   Provenzani, Alessandro
   D'Agostino, Vito Giuseppe
   Govoni, Stefano
   Pascale, Alessia
   Agostini, Hansjurgen
   Petrovski, Goran
   Salminen, Antero
   Kaarniranta, Kai
TI Autophagy Activation Clears ELAVL1/HuR-Mediated Accumulation of
   SQSTM1/p62 during Proteasomal Inhibition in Human Retinal Pigment
   Epithelial Cells
SO PLOS ONE
LA English
DT Article
ID BINDING PROTEIN P62; MACULAR DEGENERATION; ALZHEIMERS-DISEASE; MEDIATED
   PROTEOLYSIS; OXIDATIVE STRESS; BODY FORMATION; EXPRESSION; KINASE; HUR;
   DEGRADATION
AB Age-related macular degeneration (AMD) is the most common reason of visual impairment in the elderly in the Western countries. The degeneration of retinal pigment epithelial cells (RPE) causes secondarily adverse effects on neural retina leading to visual loss. The aging characteristics of the RPE involve lysosomal accumulation of lipofuscin and extracellular protein aggregates called "drusen". Molecular mechanisms behind protein aggregations are weakly understood. There is intriguing evidence suggesting that protein SQSTM1/p62, together with autophagy, has a role in the pathology of different degenerative diseases. It appears that SQSTM1/p62 is a connecting link between autophagy and proteasome mediated proteolysis, and expressed strongly under the exposure to various oxidative stimuli and proteasomal inhibition. ELAVL1/HuR protein is a post-transcriptional factor, which acts mainly as a positive regulator of gene expression by binding to specific mRNAs whose corresponding proteins are fundamental for key cellular functions. We here show that, under proteasomal inhibitor MG-132, ELAVL1/HuR is up-regulated at both mRNA and protein levels, and that this protein binds and post-transcriptionally regulates SQSTM1/p62 mRNA in ARPE-19 cell line. Furthermore, we observed that proteasomal inhibition caused accumulation of SQSTM1/p62 bound irreversibly to perinuclear protein aggregates. The addition of the AMPK activator AICAR was pro-survival and promoted cleansing by autophagy of the former complex, but not of the ELAVL1/HuR accumulation, indeed suggesting that SQSTM1/p62 is decreased through autophagy-mediated degradation, while ELAVL1/HuR through the proteasomal pathway. Interestingly, when compared to human controls, AMD donor samples show strong SQSTM1/p62 rather than ELAVL1/HuR accumulation in the drusen rich macular area suggesting impaired autophagy in the pathology of AMD.
C1 [Viiri, Johanna; Hyttinen, Juha M. T.; Kivinen, Niko; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Amadio, Marialaura; Marchesi, Nicoletta; Govoni, Stefano; Pascale, Alessia] Univ Pavia, Pharmacol Sect, Dept Drug Sci, I-27100 Pavia, Italy.
   [Sironen, Reijo] Univ Eastern Finland, Inst Clin Med Pathol & Forens Med, Kuopio, Finland.
   [Sironen, Reijo] Kuopio Univ Hosp, Dept Clin Pathol, SF-70210 Kuopio, Finland.
   [Sironen, Reijo] Univ Eastern Finland, Bioctr Kuopio, Kuopio, Finland.
   [Sironen, Reijo] Univ Eastern Finland, Canc Ctr Eastern Finland, Kuopio, Finland.
   [Rilla, Kirsi] Univ Eastern Finland, Inst Biomed, Sch Med, Dept Anat, Kuopio, Finland.
   [Akhtar, Saeed] King Saud Univ, Coll Appl Med Sci, Dept Optometry & Vis Sci, Riyadh, Saudi Arabia.
   [Provenzani, Alessandro; D'Agostino, Vito Giuseppe] Univ Trento, Ctr Integrat Biol, Lab Genom Screening, Trento, Italy.
   [Agostini, Hansjurgen] Univ Freiburg, Univ Eye Hosp, Dept Ophthalmol, D-79106 Freiburg, Germany.
   [Petrovski, Goran] Univ Debrecen, Med & Hlth Sci Ctr, Dept Ophthalmol, H-4012 Debrecen, Hungary.
   [Petrovski, Goran] Univ Debrecen, Med & Hlth Sci Ctr, Dept Biochem & Mol Biol, Stem Cells & Eye Res Lab, H-4012 Debrecen, Hungary.
   [Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, Kuopio, Finland.
   [Salminen, Antero] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; University of Pavia; University of
   Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland; University of Eastern Finland; University of Eastern Finland;
   University of Eastern Finland; King Saud University; University of
   Trento; University of Freiburg; University of Debrecen; University of
   Debrecen; University of Eastern Finland; Kuopio University Hospital;
   University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
EM kai.kaarniranta@uef.fi
RI Provenzani, Alessandro/I-9211-2012; Govoni, Stefano/K-2965-2015;
   D'Agostino, Vito/AAS-4260-2020; Akhtar, Saeed/AGY-3605-2022; Marchesi,
   Nicoletta/GQZ-7428-2022
OI Provenzani, Alessandro/0000-0003-1652-3415; Govoni,
   Stefano/0000-0002-7243-6837; D'Agostino, Vito/0000-0003-3379-2254;
   Marchesi, Nicoletta/0000-0001-6271-1420; Hyttinen,
   Juha/0000-0002-3414-4032; Kaarniranta, Kai/0000-0003-2600-8679; Rilla,
   Kirsi/0000-0002-7862-5727; Petrovski, Goran/0000-0003-2905-9252
FU Kuopio University Hospital EVO grant [5503726]; Academy of Finland;
   Finnish Cultural Foundation and its North Savo Fund; Finnish Eye
   Foundation; Evald and Hilda Nissi Foundation; Blind Friends Society
FX This work was supported by the Kuopio University Hospital EVO grant
   5503726, the Academy of Finland, the Finnish Cultural Foundation and its
   North Savo Fund, the Finnish Eye Foundation, Evald and Hilda Nissi
   Foundation and Blind Friends Society. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdelmohsen K, 2009, EMBO J, V28, P1271, DOI 10.1038/emboj.2009.67
   Abdelmohsen K, 2008, P NATL ACAD SCI USA, V105, P20297, DOI 10.1073/pnas.0809376106
   Amadio M, 2008, CURR PHARM DESIGN, V14, P2651, DOI 10.2174/138161208786264052
   Amadio M, 2009, J ALZHEIMERS DIS, V16, P409, DOI 10.3233/JAD-2009-0967
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bonelli MA, 2004, EXP GERONTOL, V39, P423, DOI 10.1016/j.exger.2003.12.004
   Braak H, 2011, J NEURAL TRANSM, V118, P809, DOI 10.1007/s00702-010-0508-2
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Geetha T, 2012, BIOMARKERS, V17, P99, DOI 10.3109/1354750X.2011.653986
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Gurskaya NG, 2006, NAT BIOTECHNOL, V24, P461, DOI 10.1038/nbt1191
   INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P
   Ishii T, 1997, BIOCHEM BIOPH RES CO, V232, P33, DOI 10.1006/bbrc.1997.6221
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Korolchuk VI, 2009, AUTOPHAGY, V5, P862, DOI 10.4161/auto.8840
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Krohne TU, 2010, INVEST OPHTH VIS SCI, V51, P553, DOI 10.1167/iovs.09-3755
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Kuusisto E, 2002, NEUROPATH APPL NEURO, V28, P228, DOI 10.1046/j.1365-2990.2002.00394.x
   Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009
   Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x
   Nakaso K, 2004, BRAIN RES, V1012, P42, DOI 10.1016/j.brainres.2004.03.029
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pankiv S, 2010, J BIOL CHEM, V285, P5941, DOI 10.1074/jbc.M109.039925
   Pascale A, 2012, CELL MOL LIFE SCI, V69, P501, DOI 10.1007/s00018-011-0810-7
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005
   Salminen A, 2012, PROG NEUROBIOL, V96, P87, DOI 10.1016/j.pneurobio.2011.11.005
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Samari HR, 1998, J BIOL CHEM, V273, P23758, DOI 10.1074/jbc.273.37.23758
   Sambrook J, 1990, MOL CLONING LAB MANU, P125
   Schaljo B, 2009, J IMMUNOL, V183, P1197, DOI 10.4049/jimmunol.0803883
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   SIN HP, 2012, ACTA OPHTHALMOL, DOI DOI 10.1111/J.1755-3768.2011.02357.X.EPUB
   Srikantan S, 2012, FRONT BIOSCI-LANDMRK, V17, P189, DOI 10.2741/3921
   Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Viana R, 2008, BIOCHEM BIOPH RES CO, V369, P964, DOI 10.1016/j.bbrc.2008.02.126
   Viiri J, 2010, MOL VIS, V16, P1399
   Wang AL, 2009, AUTOPHAGY, V5, P1190, DOI 10.4161/auto.5.8.10087
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
NR 66
TC 123
Z9 127
U1 2
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 29
PY 2013
VL 8
IS 7
AR e69563
DI 10.1371/journal.pone.0069563
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 204MP
UT WOS:000323369700043
PM 23922739
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Hamann, S
   Metrailler, S
   Schorderet, DF
   Cottet, S
AF Hamann, Severine
   Metrailler, Sylviane
   Schorderet, Daniel F.
   Cottet, Sandra
TI Analysis of the Cytoprotective Role of alpha-Crystallins in Cell
   Survival and Implication of the alpha A-Crystallin C-Terminal Extension
   Domain in Preventing Bax-Induced Apoptosis
SO PLOS ONE
LA English
DT Article
ID HEAT-SHOCK-PROTEIN; RETINAL-PIGMENT EPITHELIUM; LEBERS CONGENITAL
   AMAUROSIS; STAUROSPORINE-INDUCED APOPTOSIS; RPE65(-/-) MOUSE MODEL;
   B-CRYSTALLIN; IN-VIVO; MITOCHONDRIAL DYSFUNCTION; MACULAR DEGENERATION;
   MOLECULAR CHAPERONE
AB alpha-Crystallins, initially described as the major structural proteins of the lens, belong to the small heat shock protein family. Apart from their function as chaperones, alpha-crystallins are involved in the regulation of intracellular apoptotic signals. alpha A- and alpha B-crystallins have been shown to interfere with the mitochondrial apoptotic pathway triggering Bax pro-apoptotic activity and downstream activation of effector caspases. Differential regulation of alpha-crystallins has been observed in several eye diseases such as age-related macular degeneration and stress-induced and inherited retinal degenerations. Although the function of alpha-crystallins in healthy and diseased retina remains poorly understood, their altered expression in pathological conditions argue in favor of a role in cellular defensive response. In the Rpe65(-/-) mouse model of Leber's congenital amaurosis, we previously observed decreased expression of alpha A- and alpha B-crystallins during disease progression, which was correlated with Bax pro-death activity and photoreceptor apoptosis. In the present study, we demonstrated that alpha-crystallins interacted with pro-apoptotic Bax and displayed cytoprotective action against Bax-triggered apoptosis, as assessed by TUNEL and caspase assays. We further observed in staurosporine-treated photoreceptor-like 661W cells stably overexpressing alpha A- or alpha B-crystallin that Bax-dependent apoptosis and caspase activation were inhibited. Finally, we reported that the C-terminal extension domain of alpha A- crystallin was sufficient to provide protection against Bax-triggered apoptosis. Altogether, these data suggest that alpha-crystallins interfere with Bax-induced apoptosis in several cell types, including the cone-derived 661W cells. They further suggest that alpha A-crystallin-derived peptides might be sufficient to promote cytoprotective action in response to apoptotic cell death.
C1 [Hamann, Severine; Metrailler, Sylviane; Schorderet, Daniel F.; Cottet, Sandra] IRO, Sion, Switzerland.
   [Hamann, Severine; Schorderet, Daniel F.] Swiss Fed Inst Technol EPFL, Sch Life Sci, Lausanne, Switzerland.
   [Schorderet, Daniel F.; Cottet, Sandra] Univ Lausanne, Dept Ophthalmol, Lausanne, Switzerland.
C3 Swiss Federal Institutes of Technology Domain; Ecole Polytechnique
   Federale de Lausanne; University of Lausanne
RP Cottet, S (通讯作者)，IRO, Sion, Switzerland.
EM sandra.cottet@irovision.ch
FU Swiss National Science Foundation (SNSF) [31003A-138313]; Fondation
   Telethon Action Suisse (FTAS)
FX This research was supported by the Swiss National Science Foundation
   (SNSF) Grant 31003A-138313 (www.snf.ch) and the Fondation Telethon
   Action Suisse (FTAS) (www.telethon.ch). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681
   Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252
   Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200
   Asomugha CO, 2011, MOL VIS, V17, P2356
   Augusteyn Robert C, 2004, Clin Exp Optom, V87, P356
   Basha E, 2012, TRENDS BIOCHEM SCI, V37, P106, DOI 10.1016/j.tibs.2011.11.005
   Cavusoglu N, 2003, MOL CELL PROTEOMICS, V2, P494, DOI 10.1074/mcp.M300029-MCP200
   Cottet S, 2008, APOPTOSIS, V13, P329, DOI 10.1007/s10495-008-0180-2
   Cottet S, 2006, FASEB J, V20, P2036, DOI 10.1096/fj.06-6211com
   De S, 2007, ARCH OPHTHALMOL-CHIC, V125, P641, DOI 10.1001/archopht.125.5.641
   DEJONG WW, 1993, MOL BIOL EVOL, V10, P103
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Dufour EM, 2003, NEUROBIOL DIS, V14, P166, DOI 10.1016/S0969-9961(03)00102-5
   Ghosh JG, 2005, BIOCHEMISTRY-US, V44, P14854, DOI 10.1021/bi0503910
   Ghosh JG, 2007, BIOCHEMISTRY-US, V46, P6308, DOI 10.1021/bi700149h
   Hamann S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006616
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   Hu WF, 2012, CURR MOL MED, V12, P177, DOI 10.2174/156652412798889036
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Jones SE, 1998, NEUROREPORT, V9, P4161, DOI 10.1097/00001756-199812210-00030
   Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200
   Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200
   Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200
   Kannan R, 2012, PROG RETIN IN PRESS
   KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112
   Kapphahn RJ, 2003, BIOCHEMISTRY-US, V42, P15310, DOI 10.1021/bi034774e
   Kashkar H, 2002, CELL DEATH DIFFER, V9, P750, DOI 10.1038/sj.cdd.4401024
   KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652
   Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010
   Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471
   Liu JP, 2004, EXP EYE RES, V79, P393, DOI 10.1016/j.exer.2004.06.015
   Liu S, 2007, BIOCHEM BIOPH RES CO, V354, P109, DOI 10.1016/j.bbrc.2006.12.152
   Maeda A, 1999, INVEST OPHTH VIS SCI, V40, P2788
   Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384
   McGreal RS, 2012, BBA-GEN SUBJECTS, V1820, P921, DOI 10.1016/j.bbagen.2012.04.004
   Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510
   Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x
   Metrailler S, 2012, EXP EYE RES, V96, P70, DOI 10.1016/j.exer.2011.12.019
   Munemasa Y, 2009, INVEST OPHTH VIS SCI, V50, P3869, DOI 10.1167/iovs.08-3138
   Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Pasupuleti N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.3
   Rao NA, 2008, INVEST OPHTH VIS SCI, V49, P1161, DOI 10.1167/iovs.07-1259
   Rao NA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033582
   Reddy GB, 2006, IUBMB LIFE, V58, P632, DOI 10.1080/15216540601010096
   Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X
   Santhoshkumar P, 2004, MOL CELL BIOCHEM, V267, P147, DOI 10.1023/B:MCBI.0000049373.15558.b8
   Santhoshkumar P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019291
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   Vos MJ, 2008, BIOCHEMISTRY-US, V47, P7001, DOI 10.1021/bi800639z
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Xi JH, 2003, MOL VIS, V9, P410
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Yaung J, 2007, MOL VIS, V13, P566
   Ying X, 2008, J MOL NEUROSCI, V35, P253, DOI 10.1007/s12031-007-9010-1
   Yoshimura N, 2003, INVEST OPHTH VIS SCI, V44, P2211, DOI 10.1167/iovs.02-0704
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
NR 61
TC 26
Z9 28
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 1
PY 2013
VL 8
IS 2
AR e55372
DI 10.1371/journal.pone.0055372
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 085EU
UT WOS:000314597900034
PM 23383327
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Crooke, A
   Huete-Toral, F
   Martinez-Aguila, A
   Colligris, B
   Pintor, J
AF Crooke, Almudena
   Huete-Toral, Fernando
   Martinez-Aguila, Alejandro
   Colligris, Basilio
   Pintor, Jesus
TI Ocular disorders and the utility of animal models in the discovery of
   melatoninergic drugs with therapeutic potential
SO EXPERT OPINION ON DRUG DISCOVERY
LA English
DT Review
DE animal models; indoles; melatonin; melatonin analogsmelatonin actions;
   melatoninergic drugs; melatonin receptors; ocular diseases
ID NITRIC-OXIDE SYNTHASE; ELEVATED INTRAOCULAR-PRESSURE; AQUEOUS-HUMOR
   DYNAMICS; RETINAL GANGLION-CELLS; INDUCED DIABETIC-RATS; OPEN-ANGLE
   GLAUCOMA; OXIDATIVE STRESS; MACULAR DEGENERATION; VITAMIN-E;
   EXPERIMENTAL UVEITIS
AB Introduction: The pineal indole-derived hormone melatonin is a modulator of circadian and seasonal rhythms with an important role in ocular health and disease. This could be due to specific melatonin receptors that have been identified in structures such as cornea, lens, ciliary body, retina, choroid and sclera. In addition, a local synthesis of melatonin occurs in several of these ocular tissues.
   Areas covered: The authors review existing literature on the most common animal models where ocular melatonin actions have been tested. The therapeutic potential of melatonin in diabetic keratopathy and retinopathy, keratitis, cataracts, glaucoma, uveitis, age-related macular degeneration and retinitis pigmentosa is discussed. Furthermore, the authors comment on the usefulness of different animal models for the development of melatoninergic drugs with therapeutic potential.
   Expert opinion: The use of animals for the study of ocular diseases and the potentiality of melatonin and its analogs, as future therapeutic drugs, should be performed on the basis of a rationale study. It is important to note that melatonin receptors seem to be widespread all over the eye. This strongly suggests that, in order to modify the physiology and biochemistry of malfunctioning ocular tissue, the melatonin receptors which are present in that tissue must be first identified. Second there is the need to confirm that those receptors targeted perform the desirable responses, and as a third measure, to use selective agonists (or antagonists) instead of melatonin. However, although some animals mimic ocular pathologies relatively well, and these can be used in melatonin studies, there is still a long way to go till some of the results obtained in animal models could be used for human therapy.
C1 [Crooke, Almudena; Huete-Toral, Fernando; Martinez-Aguila, Alejandro; Colligris, Basilio; Pintor, Jesus] Univ Complutense Madrid, Dept Bioquim & Biol Mol 4, EU Opt, Madrid 28037, Spain.
C3 Complutense University of Madrid
RP Pintor, J (通讯作者)，Univ Complutense Madrid, Dept Bioquim & Biol Mol 4, EU Opt, C Arcos Jalon 118, Madrid 28037, Spain.
EM jpintor@vet.ucm.es
RI Martínez-Águila, Alejandro/ABD-9888-2020; Crooke, Almudena/Z-1516-2019
OI Martínez-Águila, Alejandro/0000-0001-8228-8180; Crooke,
   Almudena/0000-0003-4360-1896; Huete Toral, Fernando/0000-0003-3166-411X;
   Colligris, Basilio/0000-0001-6907-3636; Pintor,
   Jesus/0000-0002-9191-7679
FU Spanish Ministry of Economy and Competition [SAF2010-16024]; Ministry of
   Health Social Services and Equality RETICS [RD07/0062/0004]; Universidad
   Complutense de Madrid [GR35/10-A-920777]
FX We would like to thank the Spanish Ministry of Economy and Competition
   (Project SAF2010-16024), the Ministry of Health Social Services and
   Equality RETICS (Project RD07/0062/0004) and the Universidad Complutense
   de Madrid (Project GR35/10-A-920777) for their funding contribution to
   this publication.
CR Abe M, 1999, EXP EYE RES, V68, P255, DOI 10.1006/exer.1998.0601
   ABE M, 1994, J PINEAL RES, V17, P94, DOI 10.1111/j.1600-079X.1994.tb00119.x
   Agorastos A, 2011, J PINEAL RES, V50, P1, DOI 10.1111/j.1600-079X.2010.00816.x
   Alarma-Estrany P, 2008, J PINEAL RES, V45, P468, DOI 10.1111/j.1600-079X.2008.00618.x
   Alarma-Estrany P, 2007, PHARMACOL THERAPEUT, V113, P507, DOI 10.1016/j.pharmthera.2006.11.003
   Alarma-Estrany P, 2011, J PHARMACOL EXP THER, V337, P703, DOI 10.1124/jpet.110.178319
   Alarma-Estrany P, 2009, J PINEAL RES, V47, P201, DOI 10.1111/j.1600-079X.2009.00702.x
   Almasieh M, 2012, PROG RETIN EYE RES, V31, P152, DOI 10.1016/j.preteyeres.2011.11.002
   Anisimov SV, 2004, REV NEUROSCIENCE, V15, P209
   Anwar MM, 2003, COMP BIOCHEM PHYS A, V135, P539, DOI 10.1016/S1095-6433(03)00114-4
   Anwar MM, 2001, COMP BIOCHEM PHYS C, V129, P57, DOI 10.1016/S1532-0456(01)00180-6
   Baltmr A, 2010, EXP EYE RES, V91, P554, DOI 10.1016/j.exer.2010.08.009
   Bardak Y, 2000, CURR EYE RES, V20, P225, DOI 10.1076/0271-3683(200003)20:3;1-9;FT225
   Beforte N, 2007, INVEST OPHTH VIS SCI, V48, P2127, DOI 10.1167/iovs.06-1229
   Belforte N, 2010, INVEST OPHTH VIS SCI, V51, P5768, DOI 10.1167/iovs.10-5660
   Belforte NA, 2010, J PINEAL RES, V48, P353, DOI 10.1111/j.1600-079X.2010.00762.x
   Benozzi J, 2002, INVEST OPHTH VIS SCI, V43, P2196
   Berson DM, 2002, SCIENCE, V295, P1070, DOI 10.1126/science.1067262
   Brainard GC, 2001, J NEUROSCI, V21, P6405
   Buonfiglio DD, 2011, INVEST OPHTH VIS SCI, V52, P7416, DOI 10.1167/iovs.10-6756
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Camacho ME, 2012, MINI-REV MED CHEM, V12, P600
   CARDINAL.DP, 1971, ENDOCRINOLOGY, V89, P301, DOI 10.1210/endo-89-1-301
   CARDINALI DP, 1971, J NEUROCHEM, V18, P1769, DOI 10.1111/j.1471-4159.1971.tb03752.x
   Carta F, 2012, EXPERT OPIN THER PAT, V22, P79, DOI 10.1517/13543776.2012.649006
   Ciuffi M, 2003, J PHOTOCH PHOTOBIO B, V71, P59, DOI 10.1016/j.jphotobiol.2003.07.004
   Crawford TN, 2009, CURR DIABETES REV, V5, P8, DOI 10.2174/157339909787314149
   Crooke A, 2012, J PINEAL RES, V52, P265, DOI 10.1111/j.1600-079X.2011.00938.x
   Crooke A, 2011, PHARMACOGENET GENOM, V21, P587, DOI 10.1097/FPC.0b013e32834910d1
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   de Zavalia N, 2011, J NEUROCHEM, V117, P904, DOI 10.1111/j.1471-4159.2011.07260.x
   DeMuro RL, 2000, J CLIN PHARMACOL, V40, P781, DOI 10.1177/00912700022009422
   Do CW, 2004, J MEMBRANE BIOL, V200, P1, DOI 10.1007/s00232-004-0688-5
   Dubocovich ML, 2010, PHARMACOL REV, V62, P343, DOI 10.1124/pr.110.002832
   DUBOCOVICH ML, 1988, FASEB J, V2, P2765, DOI 10.1096/fasebj.2.12.2842214
   Er H, 2006, OPHTHALMOLOGICA, V220, P17, DOI 10.1159/000089270
   Gooneratne NS, 2012, J PINEAL RES, V52, P437, DOI 10.1111/j.1600-079X.2011.00958.x
   Gressens P, 2008, EUR J PHARMACOL, V588, P58, DOI 10.1016/j.ejphar.2008.04.016
   Grieshaber MC, 2010, PROG RETIN EYE RES, V29, P79, DOI 10.1016/j.preteyeres.2009.08.002
   Gul M, 2008, CORNEA, V27, P795, DOI 10.1097/ICO.0b013e318169d67c
   HAWLINA M, 1992, DOC OPHTHALMOL, V79, P141, DOI 10.1007/BF00156573
   Hikichi T, 2011, CLIN OPHTHALMOL, V5, P655, DOI 10.2147/OPTH.S19559
   Sande PH, 2008, AM J PATHOL, V173, P1702, DOI 10.2353/ajpath.2008.080518
   Iribarne M, 2007, INVEST OPHTH VIS SCI, V48, P1348, DOI 10.1167/iovs.06-0964
   Ismail SA, 2009, ANESTH ANALG, V108, P1146, DOI 10.1213/ane.0b013e3181907ebe
   Del Sole MJ, 2012, J PINEAL RES, V52, P29, DOI 10.1111/j.1600-079X.2011.00913.x
   Karslioglu I, 2005, J RADIAT RES, V46, P277, DOI 10.1269/jrr.46.277
   Kaur C, 2007, J PATHOL, V212, P429, DOI 10.1002/path.2195
   Kaur C, 2008, CLIN OPHTHALMOL, V2, P879, DOI 10.2147/opth.s3361
   Kaur C, 2009, INVEST OPHTH VIS SCI, V50, P5364, DOI 10.1167/iovs.09-3552
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kilic E, 2002, J PINEAL RES, V32, P106, DOI 10.1034/j.1600-079x.2002.1823.x
   Kroger RHH, 1996, J COMP PHYSIOL A, V179, P837
   Kukner A, 2006, ACTA OPHTHALMOL SCAN, V84, P54, DOI 10.1111/j.1600-0420.2005.00544.x
   Lax P, 2011, J PINEAL RES, V50, P183, DOI 10.1111/j.1600-079X.2010.00827.x
   Lee AJ, 2011, EXPERT OPIN EMERG DR, V16, P137, DOI 10.1517/14728214.2011.521631
   Li T, 2003, INVEST OPHTH VIS SCI, V44, P3692, DOI 10.1167/iovs.02-0990
   Li ZR, 1997, J PINEAL RES, V22, P117, DOI 10.1111/j.1600-079X.1997.tb00312.x
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liang FQ, 2001, NEUROREPORT, V12, P1011, DOI 10.1097/00001756-200104170-00029
   Liu G, 2011, MOL VIS, V17, P1405
   Liu H, 2011, ARCH OPHTHALMOL-CHIC, V129, P269, DOI 10.1001/archophthalmol.2011.4
   Lundmark PO, 2007, EXP EYE RES, V84, P1021, DOI 10.1016/j.exer.2006.10.018
   Markantonis SL, 2008, J CLIN PHARMACOL, V48, P240, DOI 10.1177/0091270007311112
   Martin X D, 1992, Eur J Ophthalmol, V2, P67
   Mistraletti G, 2010, J PINEAL RES, V48, P142, DOI 10.1111/j.1600-079X.2009.00737.x
   Mor M, 2004, J PINEAL RES, V36, P95, DOI 10.1046/j.1600-079X.2003.00102.x
   Mor M, 2010, EXPERT OPIN THER PAT, V20, P1059, DOI 10.1517/13543776.2010.496455
   Moreno MC, 2005, EXP EYE RES, V81, P71, DOI 10.1016/j.exer.2005.01.008
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184
   Neufeld AH, 2004, BRAIN RES BULL, V62, P455, DOI 10.1016/j.brainresbull.2003.07.005
   Neufeld AH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1050
   Nickla DL, 1998, EXP EYE RES, V66, P163, DOI 10.1006/exer.1997.0420
   Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200
   Osborne Neville N., 1994, Acta Neurobiologiae Experimentalis (Warsaw), V54, P57
   Osborne NN, 1998, INVEST OPHTH VIS SCI, V39, P2374
   Pandi-Perumal SR, 2006, FEBS J, V273, P2813, DOI 10.1111/j.1742-4658.2006.05322.x
   Papastergiou GI, 1998, EXP EYE RES, V66, P195, DOI 10.1006/exer.1997.0421
   Pattabiraman PP, 2012, AM J PHYSIOL-CELL PH, V302, pC979, DOI 10.1152/ajpcell.00396.2011
   Piccione G, 2010, EXP ANIM TOKYO, V59, P215, DOI 10.1538/expanim.59.215
   Pintor J, 2003, BRIT J PHARMACOL, V138, P831, DOI 10.1038/sj.bjp.0705118
   Pintor J, 2001, EUR J PHARMACOL, V416, P251, DOI 10.1016/S0014-2999(01)00864-0
   Pintor J, 2011, Patent No. [P201101173, 201101173]
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rada JAS, 2006, INVEST OPHTH VIS SCI, V47, P25, DOI 10.1167/iovs.05-0195
   Rastmanesh R, 2011, MED HYPOTHESES, V76, P79, DOI 10.1016/j.mehy.2010.08.036
   Rohde B H, 1985, J Ocul Pharmacol, V1, P235, DOI 10.1089/jop.1985.1.235
   Rosen R, 2009, MOL VIS, V15, P1673
   Rosenstein RE, 2010, J PINEAL RES, V49, P1, DOI 10.1111/j.1600-079X.2010.00764.x
   ROWLAND JM, 1981, CURR EYE RES, V1, P169, DOI 10.3109/02713688109001822
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   SAMPLES JR, 1988, CURR EYE RES, V7, P649, DOI 10.3109/02713688809033192
   Sawada A, 1999, EXP EYE RES, V69, P525, DOI 10.1006/exer.1999.0732
   SCHAEFFEL F, 1995, VISION RES, V35, P1247, DOI 10.1016/0042-6989(94)00221-7
   Serle JB, 2004, J GLAUCOMA, V13, P385, DOI 10.1097/01.ijg.0000133150.44686.0b
   Shareef S, 1999, INVEST OPHTH VIS SCI, V40, P2884
   SHAREEF SR, 1995, EXP EYE RES, V61, P379, DOI 10.1016/S0014-4835(05)80131-9
   Siu AW, 1999, J PINEAL RES, V27, P122, DOI 10.1111/j.1600-079X.1999.tb00606.x
   Siu AW, 2006, J PINEAL RES, V40, P101, DOI 10.1111/j.1600-079X.2005.00304.x
   Sampaio LDS, 2008, INT J DEV NEUROSCI, V26, P277, DOI 10.1016/j.ijdevneu.2008.02.001
   Sampaio LDS, 2009, INT J DEV NEUROSCI, V27, P511, DOI 10.1016/j.ijdevneu.2009.07.001
   Suzen S, 2012, CHEM BIOL DRUG DES, V79, P76, DOI 10.1111/j.1747-0285.2011.01216.x
   Taysi S, 2008, INT J RADIAT BIOL, V84, P803, DOI 10.1080/09553000802390932
   Tezel G, 2011, EXP EYE RES, V93, P178, DOI 10.1016/j.exer.2010.07.009
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Vincent L, 2010, J PINEAL RES, V48, P222, DOI 10.1111/j.1600-079X.2010.00746.x
   Wang F, 2011, CURR EYE RES, V36, P103, DOI 10.3109/02713683.2010.526750
   Webers CAB, 2008, DRUG AGING, V25, P729, DOI 10.2165/00002512-200825090-00002
   Wiechmann AF, 2008, EXP EYE RES, V86, P241, DOI 10.1016/j.exer.2007.10.015
   Yagci R, 2006, CURR EYE RES, V31, P845, DOI 10.1080/02713680600899663
   Yeleswaram K, 1997, J PINEAL RES, V22, P45, DOI 10.1111/j.1600-079X.1997.tb00302.x
   Yi CX, 2005, ANN NY ACAD SCI, V1057, P384, DOI 10.1196/annals.1356.029
   Yilmaz T, 2002, EUR J OPHTHALMOL, V12, P443, DOI 10.1177/112067210201200601
   Zhang RN, 2010, INT J BIOL MACROMOL, V47, P255, DOI 10.1016/j.ijbiomac.2010.04.013
   Zhao M, 2010, INVEST OPHTH VIS SCI, V51, P3145, DOI 10.1167/iovs.09-4415
NR 116
TC 9
Z9 11
U1 0
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1746-0441
EI 1746-045X
J9 EXPERT OPIN DRUG DIS
JI Expert. Opin. Drug Discov.
PD OCT
PY 2012
VL 7
IS 10
BP 989
EP 1001
DI 10.1517/17460441.2012.714769
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 015QK
UT WOS:000309460800008
PM 22860991
DA 2022-11-30
ER

PT J
AU Wang, YX
   Xu, L
   Sun, XY
   Zou, Y
   Zhang, HT
   Jonas, JB
AF Wang, Ya Xing
   Xu, Liang
   Sun, Xiu Ying
   Zou, Yang
   Zhang, Hai Tao
   Jonas, Jost B.
TI Five Year Incidence of Visual Field Loss in Adult Chinese. The Beijing
   Eye Study
SO PLOS ONE
LA English
DT Article
ID FREQUENCY-DOUBLING PERIMETRY; LOW-VISION; TECHNOLOGY PERIMETRY;
   PREVALENCE; POPULATION; IMPAIRMENT; GLAUCOMA; BLINDNESS; CHINA; URBAN
AB Purpose: To describe the cumulative 5 year incidence of visual field loss in adult Chinese in Greater Beijing.
   Methods: The Beijing Eye Study 2006 included 3251 subjects (mean age 60.4 +/- 10.1 years) who had participated in the Beijing Eye Study 2001 and returned for re-examination. All participants underwent a comprehensive eye examination, including visual field test by frequency doubling threshold perimetry. An abnormal visual field was defined as reduced sensitivity in at least one test location. Incident visual field loss was defined as a change in visual field from normal at baseline to abnormal at follow-up.
   Results: An incident visual field loss was detected in 273 eyes ( 4.3 +/- 0.5%) /235 subjects (7.3 +/- 0.5%). It was significantly associated with higher age (P = 0.001), higher intraocular pressure (P < 0.001), and higher fasting blood glucose concentration (P = 0.019). Considering only eyes (n = 140) with a detected cause for visual field loss, the most frequent causes were cataract (68 (48.6%) eyes) followed by glaucoma (23 (16.4%) eyes), diabetic retinopathy (13 (9.3%) eyes), age-related macular degeneration (10 (7.1%) eyes), and myopic degenerative retinopathy (9 (6.4%) eyes). For 133 (48.7%) eyes with a visual field loss, the cause for the VFL remained unclear.
   Conclusions: The 5-year incidence of visual field loss was 4.3 +/- 0.5% per eye or 7.3 +/- 0.5% per subject. It increased significantly with age, intraocular pressure, and fasting blood glucose level. Major causes for the incidence of visual field loss were cataract, glaucoma and diabetic retinopathy.
C1 [Wang, Ya Xing; Xu, Liang; Sun, Xiu Ying; Zou, Yang; Zhang, Hai Tao; Jonas, Jost B.] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Heidelberg, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Wang, YX (通讯作者)，Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China.
EM xlbio1@gmail.com; Jost.Jonas@augen.ma.uni-heidelberg.de
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
FU National Key Laboratory Fund, Beijing, China; Beijing Natural Science
   Foundation, Beijing, China
FX Supported by the National Key Laboratory Fund, Beijing, China, and the
   Beijing Natural Science Foundation, Beijing, China. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Czudowska MA, 2010, OPHTHALMOLOGY, V117, P1705, DOI 10.1016/j.ophtha.2010.01.034
   Dimitrov PN, 2003, INVEST OPHTH VIS SCI, V44, P5075, DOI 10.1167/iovs.02-0457
   Foran S, 2003, OPHTHALMOLOGY, V110, P41, DOI 10.1016/S0161-6420(02)01295-2
   Gunnlaugsdottir E, 2010, ACTA OPHTHALMOL, V88, P358, DOI 10.1111/j.1755-3768.2008.01445.x
   Hennis AJ, 2009, OPHTHALMOLOGY, V116, P1461, DOI 10.1016/j.ophtha.2009.02.017
   Huang SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1362, DOI 10.1001/archophthalmol.2009.138
   Hyman L, 2010, ARCH OPHTHALMOL-CHIC, V128, P601, DOI 10.1001/archophthalmol.2010.78
   Iester M, 2000, AM J OPHTHALMOL, V130, P160, DOI 10.1016/S0002-9394(00)00464-5
   Iwasaki A, 2002, AM J OPHTHALMOL, V134, P529, DOI 10.1016/S0002-9394(02)01684-7
   Iwase A, 2007, OPHTHALMOLOGY, V114, P27, DOI 10.1016/j.ophtha.2006.06.041
   JOHNSON CA, 1983, ARCH OPHTHALMOL-CHIC, V101, P371
   JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P2942
   JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P505, DOI 10.1007/BF00181769
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Kogure S, 2003, BRIT J OPHTHALMOL, V87, P604, DOI 10.1136/bjo.87.5.604
   Leske MC, 2007, OPHTHALMOLOGY, V114, P1058, DOI 10.1016/j.ophtha.2006.08.051
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Liu HH, 2010, OPHTHALMOLOGY, V117, P1763, DOI 10.1016/j.ophtha.2010.01.020
   Liu WW, 2007, OPHTHALMOLOGY, V114, P1795, DOI 10.1016/j.ophtha.2007.03.010
   Mansberger SL, 2007, J GLAUCOMA, V16, P73, DOI 10.1097/01.ijg.0000243481.75155.97
   McKean-Cowdin R, 2007, AM J OPHTHALMOL, V143, P1013, DOI 10.1016/j.ajo.2007.02.022
   PandaJonas S, 1996, AM J OPHTHALMOL, V121, P181, DOI 10.1016/S0002-9394(14)70583-5
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Realini T, 2004, OPHTHALMOLOGY, V111, P2133, DOI 10.1016/j.ophtha.2004.05.024
   Roy MS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1061, DOI 10.1001/archopht.125.8.1061
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Skenduli-Bala E, 2005, ARCH OPHTHALMOL-CHIC, V123, P233, DOI 10.1001/archopht.123.2.233
   Thomas D, 2001, AM J OPHTHALMOL, V131, P734, DOI 10.1016/S0002-9394(01)00837-6
   Topouzis F, 2004, AM J OPHTHALMOL, V137, P420, DOI 10.1016/j.ajo.2003.09.045
   Varma R, 2010, AM J OPHTHALMOL, V149, P713, DOI 10.1016/j.ajo.2009.12.011
   Wang YX, 2007, ARCH OPHTHALMOL-CHIC, V125, P1402, DOI 10.1001/archopht.125.10.1402
   Wang YX, 2010, AM J OPHTHALMOL, V150, P917, DOI 10.1016/j.ajo.2010.06.037
   Wang YX, 2006, AM J OPHTHALMOL, V141, P1078, DOI 10.1016/j.ajo.2006.01.023
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
   Xu L, 2006, AM J OPHTHALMOL, V141, P591, DOI 10.1016/j.ajo.2005.10.018
   Xu L, 2008, AM J OPHTHALMOL, V145, P929, DOI 10.1016/j.ajo.2008.01.004
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Zhang JS, 2011, OPHTHALMOLOGY, V118, P711, DOI 10.1016/j.ophtha.2010.08.021
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P409, DOI 10.1016/j.ophtha.2009.11.023
NR 44
TC 5
Z9 5
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 18
PY 2012
VL 7
IS 5
AR e37232
DI 10.1371/journal.pone.0037232
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 959VG
UT WOS:000305343500082
PM 22624000
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Querques, G
   Querques, L
   Forte, R
   Massamba, N
   Coscas, F
   Souied, EH
AF Querques, Giuseppe
   Querques, Lea
   Forte, Raimondo
   Massamba, Nathalie
   Coscas, Florence
   Souied, Eric H.
TI Choroidal Changes Associated with Reticular Pseudodrusen
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
AB PURPOSE. To analyze choroidal changes associated with reticular pseudodrusen by indocyanine green angiography (ICGA) and enhanced depth imaging spectral-domain optical coherence tomography (EDI SD-OCT).
   METHODS. Twenty-two consecutive patients (22 eyes) with reticular pseudodrusen, and without medium/large drusen, underwent ICGA and EDI OCT. Twenty-one age-and sex-matched subjects (21 eyes) with early age-related macular degeneration (AMD), and without pseudodrusen, also underwent EDI OCT.
   RESULTS. Mean age of patients with reticular pseudodrusen and with early AMD was 82.5 +/- 0.9 and 79.3 +/- 4.4 years of age, respectively (P = 0.9), and 59.0% and 76.2% were females, respectively (P = 0.7). On ICGA, reticular patterns appeared as hypofluorescent, not overlying the large choroidal vessels. Areas of iso/hyperfluorescence on ICGA, occurring adjacently to reticular patterns, appeared on OCT as subretinal deposits. The mean subfoveal choroidal thickness was significantly reduced in the group with reticular pseudodrusen compared with that in the control group (174.6 +/- 10.1 and +241.4 +/- 16.5, respectively; P < 0.001). At all measurement points, but the 3000 mu m superior to the fovea, the choroidal thickness of eyes with reticular pseudodrusen appeared thinner than that of the control group. Interestingly, the choroid of eyes with reticular pseudodrusen appeared thicker at 3000 mu m superior to the fovea compared with that at all other measurement points.
   CONCLUSIONS. It was shown that the reticular patterns appeared as hypofluorescent lesions on ICGA, closely abutting, but not overlying the large choroidal vessels. In eyes with reticular pseudodrusen, EDI OCT revealed an overall thinned choroid. (Invest Ophthalmol Vis Sci. 2012;53:1258-1263) DOI:10.1167/iovs.118907
C1 [Querques, Giuseppe; Querques, Lea; Forte, Raimondo; Massamba, Nathalie; Coscas, Florence; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, F-94000 Creteil, France.
   [Querques, Giuseppe; Querques, Lea] Univ Vita Salute San Raffaele, Hosp San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Flower RW, 1997, INDOCYANINE GREEN AN, P2
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P229, DOI 10.1097/IAE.0b013e3181f049bd
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 11
TC 132
Z9 135
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2012
VL 53
IS 3
BP 1258
EP 1263
DI 10.1167/iovs.11-8907
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 925VT
UT WOS:000302790700025
PM 22222508
DA 2022-11-30
ER

PT J
AU Zeng, SM
   Hernandez, J
   Mullins, RF
AF Zeng, Shemin
   Hernandez, Jasmine
   Mullins, Robert F.
TI Effects of Antioxidant Components of AREDS Vitamins and Zinc Ions on
   Endothelial Cell Activation: Implications for Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID C-REACTIVE PROTEIN; RETINAL-PIGMENT EPITHELIUM; ADHESION MOLECULE-1;
   ICAM-1 EXPRESSION; COMPLEMENT; CHORIOCAPILLARIS; PROGRESSION;
   PREVALENCE; MACROPHAGE; MEMBRANE
AB PURPOSE. To investigate whether the benefit of Age-Related Eye Disease Study (AREDS) formula multivitamins and zinc in the progression of age-related macular degeneration (AMD) may occur through inhibiting inflammatory events in the choroid.
   METHODS. Mouse C166 endothelial cells (ECs) and, for some experiments, human retinal pigment epithelium (RPE)-choroid organ cultures were treated with AREDS multivitamin solution (MVS) or ZnCl2. The cytotoxicity of MVS was evaluated using a lactate dehydrogenase colorimetric assay. Cell motility was assessed using a scratch assay. Macrophage adhesion to EC monolayers or ICAM-1 protein was determined after MVS and zinc treatment and with or without lipopolysaccharide (LPS). Quantitative reverse transcription PCR and Western blot analysis were used to determine the effects of MVS on the expression of proinflammatory molecules in treated and untreated cells.
   RESULTS. AREDS MVS and zinc did not affect C166 EC viability until the 56th hour after treatment. Scratch assays showed partial inhibition of MVS and zinc on EC migration. In cell adhesion assays, MVS and zinc decreased the number of macrophages bound to EC and to ICAM-1 protein. Quantitative PCR showed that LPS increased the expression of ICAM-1 in both C166 and human RPE-choroid cultures, which was partially offset by MVS and zinc. MVS and zinc also mitigated LPS-induced ICAM-1 protein expression on Western blot analysis.
   CONCLUSIONS. Treatment with AREDS MVS and zinc may affect both angiogenesis and endothelial-macrophage interactions. These results suggest that AREDS vitamins and zinc ions may slow the progression of AMD, in part through the attenuation of EC activation. (Invest Ophthalmol Vis Sci. 2012;53:1041-1047) DOI:10.1167/iovs.11-8531
C1 [Zeng, Shemin; Hernandez, Jasmine; Mullins, Robert F.] Univ Iowa, Dept Ophthalmol & Visual Sci, Inst Vis Res, Iowa City, IA USA.
C3 University of Iowa
RP Mullins, RF (通讯作者)，4135E MERF,375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Mullins, Robert/0000-0002-5006-0891
FU National Eye Institute [R01 EY017451]; Macula Vision Research
   Foundation; Hansjoerg EJW Kolder MD, PhD Professorship in Best Disease
   Research
FX Supported in part by National Eye Institute Grant R01 EY017451 (RFM),
   the Macula Vision Research Foundation, and the Hansjoerg EJW Kolder MD,
   PhD Professorship in Best Disease Research.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Chen JT, 2006, INVEST OPHTH VIS SCI, V47, P664, DOI 10.1167/iovs.05-1008
   Clapper JD, 2007, POLYMER, V48, P6554, DOI 10.1016/j.polymer.2007.08.023
   Cousins RJ, 2010, INT J VITAM NUTR RES, V80, P243, DOI 10.1024/0300-9831/a000030
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Ebrahimi KB, 2011, J LIPIDS, V2011, DOI 10.1155/2011/802059
   Evans J, 2008, EYE, V22, P751, DOI 10.1038/eye.2008.100
   Fahed DC, 2011, EUR J OPHTHALMOL, V21, P67, DOI 10.5301/EJO.2010.4138
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujihara M, 2003, PHARMACOL THERAPEUT, V100, P171, DOI 10.1016/j.pharmthera.2003.08.003
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kowluru RA, 2008, INVEST OPHTH VIS SCI, V49, P1645, DOI 10.1167/iovs.07-0764
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Lonnerdal B, 2000, J NUTR, V130, p1378S, DOI 10.1093/jn/130.5.1378S
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Mocchegiani E, 2010, P NUTR SOC, V69, P290, DOI 10.1017/S0029665110001862
   Mullins RF, 2006, MOL VIS, V12, P224
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nan R, 2008, J MOL BIOL, V384, P1341, DOI 10.1016/j.jmb.2008.10.030
   Pemp B, 2010, INVEST OPHTH VIS SCI, V51, P2, DOI 10.1167/iovs.09-3888
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seo M, 2010, FASEB J, V24, P464, DOI 10.1096/fj.09-137562
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Skeie JM, 2008, INVEST OPHTH VIS SCI, V49, P5574, DOI 10.1167/iovs.08-1984
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665
   WHO, 2009, PREV AV BLINDN VIS I
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 46
TC 28
Z9 28
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2012
VL 53
IS 2
BP 1041
EP 1047
DI 10.1167/iovs.11-8531
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 925VA
UT WOS:000302788600070
PM 22247465
OA Green Published
DA 2022-11-30
ER

PT J
AU Kim, P
   Brodbaker, E
   Lichtinger, A
   Yeung, SN
   Bahar, I
   Iovieno, A
   Amiran, MD
   Rootman, DS
AF Kim, Peter
   Brodbaker, Elliott
   Lichtinger, Alejandro
   Yeung, Sonia N.
   Bahar, Irit
   Iovieno, Alfonso
   Amiran, Maoz D.
   Rootman, David S.
TI Outcomes of Repeat Endothelial Keratoplasty in Patients With Failed Deep
   Lamellar Endothelial Keratoplasty
SO CORNEA
LA English
DT Article
DE endothelial keratoplasty; deep lamellar endothelial keratoplasty;
   Descemet stripping automated endothelial keratoplasty; endothelial
   failure
ID PENETRATING KERATOPLASTY; VISUAL-ACUITY; GRAFT; EYES
AB Purpose: To report the outcomes of repeat endothelial keratoplasty (EK) in patients with previous failed deep lamellar endothelial keratoplasty (DLEK).
   Methods: This retrospective interventional case series involved the review of clinical records of patients with failed DLEK surgery who underwent repeat EK surgery.
   Results: Ten eyes of 9 patients (2 men and 7 women) were included. The mean age at initial DLEK surgery was 71.2 +/- 8.0 years (range, 59-80 years), and the duration to repeat EK was 47 +/- 14.3 months (range, 16-63 months). Removal of the failed DLEK donor disc was performed in 7 eyes (70%); in 3 eyes (30%), repeat EK was performed without removal of the failed donor disc. The mean follow-up after repeat EK surgery was 21.7 months (range, 3-44 months). Improvements in corneal clarity and visual acuity were obtained in all eyes. Mean preoperative logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) was 1.46 (20/577; range, 20/100 to counting fingers) and improved to 0.64 (20/87; range, 20/30 to 20/300) at the final follow-up (P = 0.03). Four eyes had limited BCVA secondary to ocular comorbidites, including age-related macular degeneration, cystoid macular edema, and advanced glaucomatous optic neuropathy. No significant postoperative complications were noted after repeat EK surgeries.
   Conclusions: Repeat EK in patients with late DLEK failure is effective in improving corneal clarity and is a viable alternative to penetrating keratoplasty (PK). Surgery may be performed with or without removal of the failed donor disc. Visual outcomes may be limited by the existence of ocular comorbidities.
C1 [Kim, Peter; Brodbaker, Elliott; Lichtinger, Alejandro; Yeung, Sonia N.; Bahar, Irit; Iovieno, Alfonso; Amiran, Maoz D.; Rootman, David S.] Toronto Western Hosp, Dept Ophthalmol, Toronto, ON M5T 2S8, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto
RP Kim, P (通讯作者)，Toronto Western Hosp, Dept Ophthalmol, Toronto, ON M5T 2S8, Canada.
EM peterkim76@gmail.com
RI Yeung, Sonia/AAV-2660-2020; Iovieno, Alfonso/B-2939-2011
OI Yeung, Sonia/0000-0002-1197-8026
FU Canadian National Institute for the Blind
FX Dr. Yeung is supported by the E. A. Baker Fellowship Fund Grant from the
   Canadian National Institute for the Blind.
CR Bahar I, 2008, OPHTHALMOLOGY, V115, P1525, DOI 10.1016/j.ophtha.2008.02.010
   COVERT DJ, 2007, CORNEA, V26, P962
   Gorovoy MS, 2006, CORNEA, V25, P886, DOI 10.1097/01.ico.0000214224.90743.01
   Heidemann DG, 2008, CORNEA, V27, P161, DOI 10.1097/ICO.0b013e31815b8304
   Koenig SB, 2007, CORNEA, V26, P670, DOI 10.1097/ICO.0b013e3180544902
   Lee WB, 2009, OPHTHALMOLOGY, V116, P1818, DOI 10.1016/j.ophtha.2009.06.021
   Mashor RS, 2010, OPHTHALMOLOGY, V117, P680, DOI 10.1016/j.ophtha.2009.12.039
   Melles GRJ, 1998, CORNEA, V17, P618, DOI 10.1097/00003226-199811000-00010
   Melles GRJ, 1999, AM J OPHTHALMOL, V127, P340, DOI 10.1016/S0002-9394(98)00324-9
   Melles GRJ, 2004, CORNEA, V23, P286, DOI 10.1097/00003226-200404000-00011
   Price FW, 2006, CORNEA, V25, P895, DOI 10.1097/01.ico.0000227888.03877.22
   Price FW, 2006, J CATARACT REFR SURG, V32, P411, DOI 10.1016/j.jcrs.2005.12.078
   Price FWJ, 2005, J REFRACT SURG, V21, P886
   Price MO, 2008, OPHTHALMOLOGY, V115, P857, DOI 10.1016/j.ophtha.2007.06.033
   Price MO, 2006, OPHTHALMOLOGY, V113, P1936, DOI 10.1016/j.ophtha.2006.05.034
   Price MO, 2010, CLIN EXP OPHTHALMOL, V38, P128, DOI 10.1111/j.1442-9071.2010.02213.x
   Straiko MD, 2011, AM J OPHTHALMOL, V151, P233, DOI 10.1016/j.ajo.2010.08.017
   Suh LH, 2008, OPHTHALMOLOGY, V115, P1517, DOI 10.1016/j.ophtha.2008.01.024
   Terry MA, 2005, OPHTHALMOLOGY, V112, P1541, DOI 10.1016/j.ophtha.2005.03.026
   Terry MA, 2004, CORNEA, V23, P143, DOI 10.1097/00003226-200403000-00007
   Terry MA, 2001, CORNEA, V20, P239, DOI 10.1097/00003226-200104000-00001
   Terry MA, 2008, CORNEA, V27, P1131, DOI 10.1097/ICO.0b013e3181814cbc
   Yepes N, 2007, CORNEA, V26, P530, DOI 10.1097/ICO.0b013e318038d2ff
NR 23
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3740
J9 CORNEA
JI Cornea
PD NOV
PY 2011
VL 30
IS 11
BP 1183
EP 1186
DI 10.1097/ICO.0b013e31821522b4
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 832UM
UT WOS:000295834100001
PM 21918430
DA 2022-11-30
ER

PT J
AU Kunchithapautham, K
   Rohrer, B
AF Kunchithapautham, Kannan
   Rohrer, Baerbel
TI Sublytic Membrane-Attack-Complex (MAC) Activation Alters Regulated
   Rather than Constitutive Vascular Endothelial Growth Factor (VEGF)
   Secretion in Retinal Pigment Epithelium Monolayers
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MESSENGER-RNA DEGRADATION; AU-RICH ELEMENTS; MACULAR DEGENERATION;
   OXIDATIVE-STRESS; PROTEIN-KINASE; CELL-LINE; INDUCED EXPRESSION;
   SERPING1 GENE; PATHWAY; RAS
AB Uncontrolled activation of the alternative complement pathway and secretion of vascular endothelial growth factor (VEGF) are thought to be associated with age-related macular degeneration (AMD). Previously, we have shown that in RPE monolayers, oxidative-stress reduced complement inhibition on the cell surface. The resulting increased level of sublytic complement activation resulted in VEGF release, which disrupted the barrier facility of these cells as determined by transepithelial resistance (TER) measurements. Induced rather than basal VEGF release in RPE is thought to be controlled by different mechanisms, including voltage-dependent calcium channel (VDCC) activation and mitogen-activated protein kinases. Here we examined the potential intracellular links between sublytic complement activation and VEGF release in RPE cells challenged with H2O2 and complement-sufficient normal human serum (NHS). Disruption of barrier function by H2O2 + NHS rapidly increased Ras expression and Erk and Src phosphorylation, but had no effect on P38 phosphorylation. Either treatment alone had little effect. TER reduction could be attenuated by inhibiting Ras, Erk and Src activation, or blocking VDCC or VEGF-R2 activation, but not by inhibiting P38. Combinatorial analysis of inhibitor effects demonstrated that sublytic complement activation triggers VEGF secretion via two pathways, Src and Ras-Erk, with the latter being amplified by VEGF-R2 activation, but has no effect on constitutive VEGF secretion mediated via P38. Finally, effects on TER were directly correlated with release of VEGF; and sublytic MAC activation decreased levels of zfp36, a negative modulator of VEGF transcription, resulting in increased VEGF expression. Taken together, identifying how sublytic MAC induces VEGF expression and secretion might offer opportunities to selectively inhibit pathological VEGF release only.
C1 [Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   Med Univ S Carolina, Dept Neurosci, Div Res, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina
RP Rohrer, B (通讯作者)，Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave,SEI 511, Charleston, SC 29425 USA.
EM rohrer@musc.edu
FU National Institutes of Health [R01 EY019320, C06 RR015455]; Dept. of
   Veterans Affairs, Foundation Fighting Blindness [I01 RX000444]; Research
   to Prevent Blindness, Inc.; NATIONAL CENTER FOR RESEARCH RESOURCES
   [C06RR015455] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY019320] Funding Source: NIH RePORTER; Veterans Affairs
   [I01RX000444] Funding Source: NIH RePORTER
FX This work was supported, in whole or in part, by Grant R01 EY019320 from
   the National Institutes of Health, Grant I01 RX000444 from the Dept. of
   Veterans Affairs, Foundation Fighting Blindness, and an unrestricted
   grant to Medical University of South Carolina from Research to Prevent
   Blindness, Inc.; We thank Joshua Thurman (University of Colorado Denver
   School of Medicine, Denver, CO) for helpful discussions and Luanna
   Bartholomew for critical review (Medical University of South Carolina,
   Charleston, SC). Animal studies were conducted in a facility constructed
   with support from the National Institutes of Health (C06 RR015455).
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augustin AJ, 2009, CLIN OPHTHALMOL, V3, P175
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bohana-Kashtan O, 2004, MOL IMMUNOL, V41, P583, DOI 10.1016/j.molimm.2004.04.007
   Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238
   Caparros E, 2006, BLOOD, V107, P3950, DOI 10.1182/blood-2005-03-1252
   CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1
   Chen YW, 2007, EUR J IMMUNOL, V37, P167, DOI 10.1002/eji.200636285
   CHOI NH, 1990, INT IMMUNOL, V2, P413, DOI 10.1093/intimm/2.5.413
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Edwards MG, 2003, PHYSIOL GENOMICS, V13, P119, DOI 10.1152/physiolgenomics.00172.2002
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Essafi-Benkhadir K, 2007, MOL BIOL CELL, V18, P4648, DOI 10.1091/mbc.E07-06-0570
   Fearon DT, 1998, SEMIN IMMUNOL, V10, P355, DOI 10.1006/smim.1998.0137
   Fehrenbach H, 1999, ANAT REC, V254, P61
   Finnegan S, 2010, EUR J NEUROSCI, V32, P322, DOI 10.1111/j.1460-9568.2010.07301.x
   Giddings KS, 2004, NAT STRUCT MOL BIOL, V11, P1173, DOI 10.1038/nsmb862
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holers VM, 2003, CLIN IMMUNOL, V107, P140, DOI 10.1016/S1521-6616(03)00034-2
   Holers VM, 2000, IMMUNOPHARMACOLOGY, V49, P125, DOI 10.1016/S0162-3109(00)80298-2
   Ito S, 2006, ONCOGENE, V25, P2420, DOI 10.1038/sj.onc.1209263
   JACKSON MB, 1981, P NATL ACAD SCI-BIOL, V78, P6421, DOI 10.1073/pnas.78.10.6421
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kannan R, 2006, MOL VIS, V12, P1649
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Lai WS, 1998, J BIOL CHEM, V273, P506, DOI 10.1074/jbc.273.1.506
   Lohr HR, 2006, EXP EYE RES, V83, P380, DOI 10.1016/j.exer.2006.01.014
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P3248, DOI 10.1073/pnas.070049497
   Moskovich O, 2007, J BIOL CHEM, V282, P29977, DOI 10.1074/jbc.M703742200
   NICHOLSONWELLER A, 1993, IMMUNOL RES, V12, P244, DOI 10.1007/BF02918256
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Park KH, 2009, MOL VIS, V15, P200
   Peng HW, 2002, J IMMUNOL, V169, P2594, DOI 10.4049/jimmunol.169.5.2594
   PODACK ER, 1984, ACTA PATH MICRO IM C, V92, P89
   PODACK ER, 1984, MOL IMMUNOL, V21, P589, DOI 10.1016/0161-5890(84)90044-0
   Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3
   Rosenthal R, 2007, MOL VIS, V13, P443
   Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sala-Newby GB, 1998, IMMUNOLOGY, V93, P601
   Samuel W, 2008, J NEUROCHEM, V106, P591, DOI 10.1111/j.1471-4159.2008.05409.x
   SARMA JV, 2010, CELL TISSUE RES
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schneider-Merck T, 2009, EUR J CANCER, V45, P2050, DOI 10.1016/j.ejca.2009.04.014
   SCOLDING NJ, 1989, NATURE, V339, P620, DOI 10.1038/339620a0
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   STEPHENS CL, 1979, J IMMUNOL, V122, P455
   Susuki K, 2007, J NEUROSCI, V27, P3956, DOI 10.1523/JNEUROSCI.4401-06.2007
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   WOOD A, 1993, J NEUROSCI, V13, P3319
   Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116
   Yun HY, 1999, DIABETES RES CLIN PR, V45, P113, DOI 10.1016/S0168-8227(99)00039-X
   Zerbib J, 2010, MOL VIS, V16, P1324
NR 73
TC 56
Z9 63
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 8
PY 2011
VL 286
IS 27
BP 23717
EP 23724
DI 10.1074/jbc.M110.214593
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 786HO
UT WOS:000292294900013
PM 21566137
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Arimura, E
   Matsumoto, C
   Nomoto, H
   Hashimoto, S
   Takada, S
   Okuyama, S
   Shimomura, Y
AF Arimura, Eiko
   Matsumoto, Chota
   Nomoto, Hiroki
   Hashimoto, Shigeki
   Takada, Sonoko
   Okuyama, Sachiko
   Shimomura, Yoshikazu
TI Correlations between M-CHARTS and PHP Findings and Subjective Perception
   of Metamorphopsia in Patients with Macular Diseases
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID EPIRETINAL MEMBRANE; QUANTIFICATION; CATARACT; HOLE
AB PURPOSE. To assess the correlations between a patient's subjective perception of metamorphopsia and the clinical measurements of metamorphopsia by M-CHARTS and PreView PHP (PHP).
   METHODS. The authors designed a 10-item questionnaire focusing on the symptoms of metamorphopsia and verified its validity with a Rasch analysis. M-CHARTS measured the minimum visual angle of a dotted line needed to detect metamorphopsia, and PHP used the hyperacuity function for detection. Subjects were 39 patients with idiopathic epiretinal membrane (ERM), 22 patients with idiopathic macular hole (M-hole), 19 patients with age-related macular degeneration (AMD), and 51 healthy controls.
   RESULTS. Rasch analysis suggested the elimination of one question. The nine-item questionnaire score significantly correlated to the M-CHARTS score in ERM (r = 0.59; P = 0.0004) but not in M-hole and to the PHP result in AMD (r = -0.29; P = 0.04) but not in ERM. Eighty percent of ERM patients with greater horizontal M-CHARTS score subjectively perceived horizontal metamorphopsia more often. M-CHARTS showed better sensitivities than PHP in both ERM (89% vs. 42%) and AMD (74% vs. 68%) and better specificity (100% vs. 71%) in healthy controls. Rasch analysis indicated that the present form of the questionnaire is better suited for moderate to severe cases of metamorphopsia than for mild cases.
   CONCLUSIONS. The questionnaire appears to be a valid assessment of patient subjective perception of metamorphopsia and can be used to supplement the clinical measurements of metamorphopsia by M-CHARTS and PHP in patients with macular diseases. (Invest Ophthalmol Vis Sci. 2011; 52: 128-135) DOI: 10.1167/iovs.09-3535
C1 [Arimura, Eiko] Kinki Univ, Fac Med, Sakai Hosp, Dept Ophthalmol,Minami Ku, Sakai, Osaka 5900132, Japan.
   [Matsumoto, Chota; Nomoto, Hiroki; Hashimoto, Shigeki; Takada, Sonoko; Okuyama, Sachiko; Shimomura, Yoshikazu] Kinki Univ, Fac Med, Dept Ophthalmol, Osaka, Japan.
C3 Kindai University (Kinki University); Kindai University (Kinki
   University)
RP Arimura, E (通讯作者)，Kinki Univ, Fac Med, Sakai Hosp, Dept Ophthalmol,Minami Ku, Sakai, Osaka 5900132, Japan.
EM arimura@ganka.med.kindai.ac.jp
FU Ministry of Education of the Japanese Government [12671731]; Osaka
   Medical Research Foundation for Incurable Diseases
FX Supported by the Ministry of Education of the Japanese Government (Grant
   12671731, 2000) and the Osaka Medical Research Foundation for Incurable
   Diseases.
CR AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Arimura E, 2005, INVEST OPHTH VIS SCI, V46, P2961, DOI 10.1167/iovs.04-1104
   Arimura E, 2007, ACTA OPHTHALMOL SCAN, V85, P55, DOI 10.1111/j.1600-0420.2006.00729.x
   Azuma Noriyuki, 2000, Nippon Ganka Gakkai Zasshi, V104, P960
   BARALDI P, 1986, INT OPHTHALMOL, V9, P173, DOI 10.1007/BF00159846
   BERNTHPETERSEN P, 1982, ACTA OPHTHALMOL, V60, P243
   BERNTHPETERSEN P, 1981, ACTA OPHTHALMOL, V59, P198
   ENOCH JM, 1984, ARCH OPHTHALMOL-CHIC, V102, P1164, DOI 10.1001/archopht.1984.01040030942019
   FREISEN L, 1979, A VONGRAEFES ARCH KL, V210, P69
   GASS JDM, 1995, AM J OPHTHALMOL, V119, P752, DOI 10.1016/S0002-9394(14)72781-3
   HOLLINS M, 1977, VISION RES, V17, P403, DOI 10.1016/0042-6989(77)90031-1
   Hughe A, 1984, HDB SENSORY PHYSL, P613
   LAKSHMINARAYANAN V, 1991, OPTOMETRY VISION SCI, V68, P942, DOI 10.1097/00006324-199112000-00005
   LINBLOM B, 1987, CHIBRET INT J OPHTHA, P48
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Matsumoto C, 2003, INVEST OPHTH VIS SCI, V44, P4012, DOI 10.1167/iovs.03-0117
   MATSUMOTO C, 1985, GANKA RINSHO IHO, V79, P663
   Matsumoto Chota, 2000, Rinsho Ganka, V54, P373
   NAKAJIMA M, 1985, GANKA RINSHO IHO, V79, P633
   Shinoda K, 2000, JPN J OPHTHALMOL, V44, P424, DOI 10.1016/S0021-5155(00)00173-8
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
NR 21
TC 49
Z9 50
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2011
VL 52
IS 1
BP 128
EP 135
DI 10.1167/iovs.09-3535
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 702VW
UT WOS:000285925000018
PM 20739469
DA 2022-11-30
ER

PT J
AU Lowe, J
   Maia, M
   Wakshull, E
   Siguenza, P
   Liu, P
   Lakhani, S
   Rusit, J
   Elliott, R
   Quarmby, V
AF Lowe, John
   Maia, Mauricio
   Wakshull, Eric
   Siguenza, Patricia
   Liu, Patrick
   Lakhani, Saleem
   Rusit, Jeriza
   Elliott, Rebecca
   Quarmby, Valerie
TI Development of a novel homogenous electrochemiluminescence assay for
   quantitation of ranibizumab in human serum
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Ranibizumab; Electrochemiluminescence; Pharmacokinetics
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; ANTIBODIES;
   IMMUNOASSAYS; MACULOPATHY; VALIDATION; MEMBRANES; FAB
AB A solution-phase electrochemiluminescence assay (ECLA) was developed to quantify ranibizumab in serum from patients treated with this biotherapeutic for neovascular age-related macular degeneration Ranibizumab, a recombinant humanized Fab ("fragment, antigen binding"), binds with high affinity and specificity to vascular endothelial growth factor A (VEGF-A), inhibiting its activity Fab molecules contain the amino acid sequence that binds antigen and are composed of one constant and one variable domain from each heavy and light chain of the antibody High assay sensitivity was required to enable pharmacokinetic (PK) evaluation of ranibizumab-dosed patients in clinical trials. Our assay's lower limit of quantitation is 300 pg/ml. ranibizumab in neat set um, achieving a 67-fold improvement in sensitivity relative to a conventional ELISA-based PK method In this assay, ruthenium-labeled affinity-purified rabbit anti-rambizumab antibodies and biotinylated rhVEGF ale added to scrum samples During overnight incubation, these two labeled molecules bind to ranibizumab, and the resulting immune complex is then captured by streptavidin-coated paramagnetic beads and analyzed for electrochemiluminescence The ranibizumab PK ECLA has a reporting range of 300-24,000 pg/ml., based on accuracy and precision parameters It showed high precision for both intra- and inter-assay analyses Recovery of ranibizumab from 10 individual donors averaged between 100% and 119% of nominal concentration. There was no cross-reactivity observed in the assay to other recombinant humanized antibodies (whole molecules or monoclonal antibody fragments) or human IgG. To our knowledge, this report represents the first description of development and validation of an ECLA-based PK assay for a recombinant humanized Fab therapeutic agent (C) 2010 Elsevier B V All rights reserved
C1 [Lowe, John; Maia, Mauricio; Wakshull, Eric; Quarmby, Valerie] Genentech Inc, Dept BioAnalyt Res & Dev, San Francisco, CA 94080 USA.
   [Siguenza, Patricia; Liu, Patrick; Lakhani, Saleem; Rusit, Jeriza; Elliott, Rebecca] Genentech Inc, Dept BioAnalyt Assays, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech
RP Lowe, J (通讯作者)，Genentech Inc, Dept BioAnalyt Res & Dev, MS38,1 DNA Way, San Francisco, CA 94080 USA.
RI Lakhani, Sunil R/I-1970-2018
OI Lakhani, Sunil R/0000-0003-4067-2760
CR BIRDSALL HH, 1983, CLIN EXP IMMUNOL, V53, P497
   BLACKBURN GF, 1991, CLIN CHEM, V37, P1534
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   DeSilva B, 2003, PHARM RES-DORDR, V20, P1885, DOI 10.1023/B:PHAM.0000003390.51761.3d
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Findlay JWA, 2000, J PHARMACEUT BIOMED, V21, P1249, DOI 10.1016/S0731-7085(99)00244-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   HAUGHNEY PC, 2005, ARVO ANN M MAY 1 5 2
   Horninger D, 2005, J PHARMACEUT BIOMED, V38, P703, DOI 10.1016/j.jpba.2005.01.036
   Jelkmann W, 2001, CLIN CHEM, V47, P617
   Kaiser PK, 2007, INT J CLIN PRACT, V61, P501, DOI 10.1111/j.1742-1241.2007.01299.x
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Melnikova I, 2005, NAT REV DRUG DISCOV, V4, P711, DOI 10.1038/nrd1827
   Mock DM, 1997, J LAB CLIN MED, V129, P384, DOI 10.1016/S0022-2143(97)90187-6
   PERSSELIN JE, 1985, J CLIN INVEST, V76, P723, DOI 10.1172/JCI112027
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Shih T, 2006, CLIN THER, V28, P1779, DOI 10.1016/j.clinthera.2006.11.015
   Swanson S J, 1999, Dev Biol Stand, V97, P135
   Verschraegen I, 2007, CLIN CHIM ACTA, V380, P75, DOI 10.1016/j.cca.2006.12.031
   WALLER M, 1972, J INFECT DIS, V125, P45, DOI 10.1093/infdis/125.1.45
   Zimmermann R, 2005, CLIN CHEM, V51, P2365, DOI 10.1373/clinchem.2005.055558
NR 28
TC 10
Z9 11
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0731-7085
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD SEP 5
PY 2010
VL 52
IS 5
BP 680
EP 686
DI 10.1016/j.jpba.2010.01.048
PG 7
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 584WU
UT WOS:000276785400006
PM 20226615
DA 2022-11-30
ER

PT J
AU Kirschkamp, T
   Schmid-Schonbein, H
   Weinberger, A
   Smeets, R
AF Kirschkamp, Thomas
   Schmid-Schoenbein, Holger
   Weinberger, Andreas
   Smeets, Ralf
TI Effects of Fibrinogen and alpha(2)-Macroglobulin and Their Apheretic
   Elimination on General Blood Rheology and Rheological Characteristics of
   Red Blood Cell Aggregates
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Age-related maculopathy; Alpha-2-macroglobulin; Extracorporeal
   elimination; Rheology; Therapeutic apheresis
ID MEMBRANE DIFFERENTIAL FILTRATION; PERIPHERAL VENOUS-BLOOD; MACULAR
   DEGENERATION; FLOW VELOCITY; ADHESIVENESS/AGGREGATION; MICROCIRCULATION;
   MODEL; MACROCIRCULATION; RHEOPHERESIS; CAPILLARIES
AB Methods of therapeutic apheresis, such as plasma exchange or rheopheresis eliminate moderately aggregating macromolecules like fibrinogen, as well as strongly aggregating substances like alpha(2)-macroglobulin from blood. In order to examine the specific effect of eliminating a2-macroglobulin as a highly aggregating macromolecule, this study aimed to analyze the different rheological properties of: (i) moderately aggregating red blood cells (RBCs; inducible by fibrinogen); and (ii) strongly aggregating RBCs (inducible by (alpha(2)-macroglobulin). In vitro, RBC aggregate geometry was determined in the presence of strong and moderate aggregation inducing macromolecules. In vivo, flow behavior of RBC aggregates was analyzed by intravital microscopy. Using network scanning, the number of perfused and non-perfused microvessels was determined. In vitro, the higher adhesive forces of strongly aggregating RBCs led to both a higher packing density of single RBCs within aggregates, expressed as a significantly reduced thickness of individual RBCs, and greater deformation, expressed as a significantly diminished offset between RBCs and an increased curvature of RBCs at the ends of the aggregates. In vivo rheoscopy showed that only high aggregating RBCs persisted in the precapillary bed and led to the absence of RBCs in up to 40% of nutritive capillaries. These novel findings are of importance regarding recent developments in clinical hemorheology, specifically the clinical use of hemapheretic therapies for diseases in which impaired microcirculation plays a role in either their development or progression, such as age-related macular degeneration and complications of diabetes mellitus. Our data support that procedures reducing the concentration of alpha(2)-macroglobulin in blood by extracorporeal elimination might provide a more efficient improvement of overall blood fluidity in microcirculatory beds.
C1 [Kirschkamp, Thomas; Weinberger, Andreas] Rhein Westfal TH Aachen, Aachen Univ Hosp, Dept Ophthalmol, D-52072 Aachen, Germany.
   [Schmid-Schoenbein, Holger] Rhein Westfal TH Aachen, Dept Physiol, D-52072 Aachen, Germany.
   [Smeets, Ralf] Rhein Westfal TH Aachen, IZKF BIOMAT, Interdisciplinary Ctr Clin Res, D-52072 Aachen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen
   University; RWTH Aachen University
RP Kirschkamp, T (通讯作者)，Rhein Westfal TH Aachen, Aachen Univ Hosp, Dept Ophthalmol, Horbacher St 65, D-52072 Aachen, Germany.
EM thomas.kirschkamp@web.de
CR Ben-Ami R, 2003, AM J PHYSIOL-HEART C, V285, pH2663, DOI 10.1152/ajpheart.00128.2003
   Berliner S, 2001, ACTA CARDIOL, V56, P121, DOI 10.2143/AC.56.2.2005628
   Brunner R, 1999, OPHTHALMOLOGE, V96, P679, DOI 10.1007/s003470050474
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   BRUNNER R, 1993, HAMORHEOLOGISCHE THE
   Dati F, 1996, EUR J CLIN CHEM CLIN, V34, P517
   DRIESSEN G, 1985, MICROCIRC ENDOTH LYM, V2, P551
   DRIESSEN G, 1988, MICROVASC RES, V35, P73, DOI 10.1016/0026-2862(88)90051-9
   DRIESSEN G, 1990, INT J MICROCIRC, V9, P141
   DRIESSEN G, 1981, BIBL HAEMATOL, V47, P21
   DRIESSEN GK, 1980, PFLUG ARCH EUR J PHY, V388, P75, DOI 10.1007/BF00582631
   DRIESSEN GK, 1982, PFLUG ARCH EUR J PHY, V392, P261, DOI 10.1007/BF00584307
   DRIESSEN GK, 1979, PFLUG ARCH EUR J PHY, V380, P1, DOI 10.1007/BF00582604
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Klingel R, 2002, THER APHER, V6, P271, DOI 10.1046/j.1526-0968.2002.00418.x
   Lominadze D, 2002, FEBS LETT, V517, P41, DOI 10.1016/S0014-5793(02)02575-9
   Luke C, 2003, THER APHER DIAL, V7, P263, DOI 10.1046/j.1526-0968.2003.00027.x
   Marton Z, 2001, CLIN HEMORHEOL MICRO, V24, P75
   Pulanic D, 2005, COLLEGIUM ANTROPOL, V29, P341
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Pulido JS, 2005, J CLIN APHERESIS, V20, P168, DOI 10.1002/jca.20066
   Schechner V, 2003, EUR J CLIN INVEST, V33, P955, DOI 10.1046/j.1365-2362.2003.01260.x
   Schuff-Werner P, 2004, EUR J CLIN INVEST, V34, P378, DOI 10.1111/j.1365-2362.2004.01341.x
   SEEBODE D, 1994, MICROVASC RES, V47, P388, DOI 10.1006/mvre.1994.1031
   TAMAI M, 1982, INVEST OPHTH VIS SCI, V22, P439
   THOMAS L, 2007, LAB DIAGNOSIS
   Varlet-Marie E, 2003, CLIN HEMORHEOL MICRO, V28, P139
   Vaya A, 2004, THROMB HAEMOSTASIS, V91, P354, DOI 10.1160/TH03-08-0497
   Widder RA, 2002, INVEST OPHTH VIS SCI, V43, P2906
NR 31
TC 22
Z9 28
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-9979
EI 1744-9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD OCT
PY 2008
VL 12
IS 5
BP 360
EP 367
DI 10.1111/j.1744-9987.2008.00610.x
PG 8
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Urology & Nephrology
GA 405KP
UT WOS:000263223400004
PM 18937718
DA 2022-11-30
ER

PT J
AU Matsubara, A
   Nakazawa, T
   Noda, K
   She, HC
   Connolly, E
   Young, TA
   Ogura, Y
   Gragoudas, ES
   Miller, JW
AF Matsubara, Akihisa
   Nakazawa, Toru
   Noda, Kosuke
   She, Haicheng
   Connolly, Edward
   Young, Tara A.
   Ogura, Yuichiro
   Gragoudas, Evangelos S.
   Miller, Joan W.
TI Photodynamic therapy induces caspase-dependent apoptosis in rat CNV
   model
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   MACULAR DEGENERATION; INTRAVITREAL TRIAMCINOLONE; SIGNAL-TRANSDUCTION;
   CELL APOPTOSIS; CYTOCHROME-C; ACTIVATION; VERTEPORFIN; PATHWAY
AB PURPOSE. To investigate the mechanism of cell death in laser-induced choroidal neovascularization (CNV) after photodynamic therapy (PDT).
   METHODS. PDT was performed in Brown-Norway rats using laser light at a wavelength of 689 nm, irradiance of 600 mW/cm(2), and fluence of 25 J/cm(2) after intravenous injection of verteporfin at the doses of 3, 6, and 12 mg/m(2). Apoptotic cells in CNV were detected by TUNEL assay at 1, 3, 6, 15, 24, and 48 hours after PDT. Caspase activation at 1, 3, 6, 15, and 24 hours after PDT was determined by immunohistochemistry (IHC) with a cleaved caspase-3 or -9 antibody. Akt activity was determined by Western blot and IHC with a phosphorylated-Akt (pAkt) antibody. To investigate the roles of Akt in PDT-induced apoptosis, insulin-like growth factor (IGF)-1, an Akt activator, with or without wortmannin, an inhibitor of PI3K-Akt pathway, was injected into the vitreous before PDT.
   RESULTS. The number of TUNEL-positive cells in CNV increased at 3 hours after PDT and peaked at 6 hours, showing a dose dependence of verteporfin. Caspase activation was detected in TUNEL-positive cells. Dephosphorylation of Akt in CNV occurred within 1 hour. IGF-1 significantly activated Akt and suppressed the number of TUNEL-positive cells in CNV, and the effects of IGF-1 were diminished by wortmannin.
   CONCLUSIONS. PDT induced caspase-dependent apoptosis in CNV. These results suggest that PDT leads to dephosphorylation of Akt and subsequent activation of the caspase-dependent pathway. Understanding the intracellular signaling mechanisms of apoptosis in PDT may lead to more selective and effective treatment of CNV secondary to age-related macular degeneration.
C1 Harvard Univ, Massachusetts Eye & Ear Infirm, Retina Serv, Sch Med,Angiogenesis & Laser Labs, Boston, MA 02114 USA.
   Univ Calif Los Angeles, Jules Stein Eye Inst, Retina Div, Los Angeles, CA 90024 USA.
   Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; University of California System; University of California Los
   Angeles; Nagoya City University
RP Miller, JW (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Retina Serv, Sch Med,Angiogenesis & Laser Labs, 243 Charles St, Boston, MA 02114 USA.
EM joan_miller@meei.harvard.edu
OI Miller, Joan/0000-0003-2046-3996
FU NEI NIH HHS [P30 EY014104] Funding Source: Medline; NIAID NIH HHS
   [AI050775] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY014104]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASES [K08AI050775] Funding Source: NIH RePORTER
CR BERKOW JW, 1984, AM J OPHTHALMOL, V97, P143, DOI 10.1016/S0002-9394(14)76083-0
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Granville DJ, 1998, FEBS LETT, V422, P151, DOI 10.1016/S0014-5793(97)01616-5
   Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017
   Granville DJ, 2001, AM J PATHOL, V159, P305, DOI 10.1016/S0002-9440(10)61696-3
   Granville DJ, 1999, AM J PATHOL, V155, P1021, DOI 10.1016/S0002-9440(10)65202-9
   Granville DJ, 1997, CELL DEATH DIFFER, V4, P623, DOI 10.1038/sj.cdd.4400286
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Liu W, 2000, APOPTOSIS, V5, P323, DOI 10.1023/A:1009679307513
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Nakazawa T, 2005, MOL VIS, V11
   Nakazawa T, 2003, CURR EYE RES, V26, P55, DOI 10.1076/ceyr.26.1.55.14254
   Nakazawa T, 2002, J NEUROSCI RES, V68, P668, DOI 10.1002/jnr.10259
   Nakazawa T, 2002, INVEST OPHTH VIS SCI, V43, P3319
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Renno RZ, 2000, INVEST OPHTH VIS SCI, V41, P3963
   Solban N, 2006, CANCER RES, V66, P5633, DOI 10.1158/0008-5472.CAN-06-0604
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Stefanis L, 2005, NEUROSCIENTIST, V11, P50, DOI 10.1177/1073858404271087
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 30
TC 13
Z9 14
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2007
VL 48
IS 10
BP 4741
EP 4747
DI 10.1167/iovs.06-1534
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214SE
UT WOS:000249757600046
PM 17898299
DA 2022-11-30
ER

PT J
AU Thomson, LR
   Toyoda, Y
   Langner, A
   Delori, FC
   Garnett, KM
   Craft, N
   Nichols, CR
   Cheng, KM
   Dorey, CK
AF Thomson, LR
   Toyoda, Y
   Langner, A
   Delori, FC
   Garnett, KM
   Craft, N
   Nichols, CR
   Cheng, KM
   Dorey, CK
TI Elevated retinal zeaxanthin and prevention of light-induced
   photoreceptor cell death in quail
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Review
ID MACULAR PIGMENT CAROTENOIDS; NITRIC-OXIDE SYNTHASE; CONE OIL DROPLETS;
   VISUAL PIGMENTS; CIGARETTE-SMOKING; OXIDATIVE STRESS; ALPHA-TOCOPHEROL;
   BETA-CAROTENE; CATARACT-EXTRACTION; DIETARY CAROTENOIDS
AB PURPOSE. Inferential evidence indicates that macular pigments (lutein and zeaxanthin) protect photoreceptors and/or retard age-related macular degeneration. These experiments tested the hypothesis that retinal zeaxanthin prevents light-induced photoreceptor cell death.
   METHODS. Retinal damage was assessed in quail fed a carotenoid-deficient (C-) diet for 6 months. Groups of 16 birds (8 male, 8 female) were fed a C- diet supplemented with 35 mg 3R,3'R-zeaxanthin for 1, 3, or 7 days; one group was continued on C- diets. Half of each group was exposed to intermittent 3200-lux white light (10 1-hour intervals separated by 2 hours in dark). After 14 additional hours in the dark, one retina of each quail was collected for HPLC analysis, and the contralateral retina was embedded in paraffin for counts of apoptotic nuclei.
   RESULTS. After 7 days' supplementation, concentrations of zeaxanthin in serum, liver, and fat had increased by factors of 50.8, 43.2, and 6.5, respectively (all P < 0.001). In contrast, retinal zeaxanthin fluctuated significantly upward on day 3, but there was no net change on day 7. The number of apoptotic rods and cones in light-damaged eyes correlated significantly and inversely with zeaxanthin concentration in the contralateral retina (r = -0.61; P < 0.0001 and r = -0.54; P < 0.002), but not with serum zeaxanthin. Similar correlations were observed with retinal lutein, which correlated strongly with retinal zeaxanthin (r = 0.95; P < 0.0001).
   CONCLUSIONS. Retinal zeaxanthin dose dependently reduced light-induced photoreceptor apoptosis; elevated serum levels did not. These data provide the first experimental evidence that xanthophyll carotenoids protect photoreceptors in vivo.
C1 Schepens Eye Res Inst, Boston, MA USA.
   Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
   Columbia Univ, Sch Med, New York, NY USA.
   Univ Leipzig, Eye Clin, Dept Ophthalmol, Leipzig, Germany.
   Appl Food Biotechnol Inc, O Fallon, MO USA.
   Craft Technol Inc, Wilson, NC USA.
   Univ British Columbia, Dept Anim Sci, Vancouver, BC V6T 2A2, Canada.
C3 Harvard University; Schepens Eye Research Institute; Harvard University;
   Harvard Medical School; Columbia University; Leipzig University;
   University of British Columbia
RP Dorey, CK (通讯作者)，R&D Consulting, 15 Draper Ave, Arlington, MA 02474 USA.
EM kdorey@earthlink.net
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   BAUERFFEND JC, 1981, CAROTENOIDS COLORANT
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   BOWMAKER JK, 1993, VISION RES, V33, P571, DOI 10.1016/0042-6989(93)90180-5
   BOWMAKER JK, 1977, VISION RES, V17, P1129, DOI 10.1016/0042-6989(77)90147-X
   Bowmaker JK, 1997, VISION RES, V37, P2183, DOI 10.1016/S0042-6989(97)00026-6
   Brady WE, 1996, J NUTR, V126, P129, DOI 10.1093/jn/126.1.129
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   BUDNIK V, 1984, NEUROSCI LETT, V51, P145, DOI 10.1016/0304-3940(84)90276-3
   CANTILENA LR, 1992, AM J CLIN NUTR, V55, P659, DOI 10.1093/ajcn/55.3.659
   Carpenter KLH, 1997, FEBS LETT, V401, P262, DOI 10.1016/S0014-5793(96)01488-3
   Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   CHEN EP, 1993, GRAEF ARCH CLIN EXP, V231, P416, DOI 10.1007/BF00919652
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   CUADROS MA, 1992, NEUROSCI LETT, V148, P11, DOI 10.1016/0304-3940(92)90792-6
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DIETERLENLIEVRE F, 1988, J CELL SCI, P29
   Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200
   Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   FITE KV, 1994, EXP EYE RES, V59, P417, DOI 10.1006/exer.1994.1126
   FITE KV, 1989, CURR EYE RES, V8, P1039, DOI 10.3109/02713688908997396
   FITE KV, 1993, EXP EYE RES, V57, P449, DOI 10.1006/exer.1993.1147
   Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942
   Gale CR, 2001, OPHTHALMOLOGY, V108, P1992, DOI 10.1016/S0161-6420(01)00833-8
   Gartner C, 1996, INT J VITAM NUTR RES, V66, P119
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185
   GOLDSMITH TH, 1984, VISION RES, V24, P1661, DOI 10.1016/0042-6989(84)90324-9
   Goti D, 2000, J NEUROCHEM, V74, P1374, DOI 10.1046/j.1471-4159.2000.0741374.x
   Goulinet S, 1997, ARTERIOSCL THROM VAS, V17, P786, DOI 10.1161/01.ATV.17.4.786
   Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Grune T, 2000, BIOGERONTOLOGY, V1, P31, DOI 10.1023/A:1010037908060
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1997, OPTOMETRY VISION SCI, V74, P499, DOI 10.1097/00006324-199707000-00017
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   Hart NS, 2000, J COMP PHYSIOL A, V186, P681, DOI 10.1007/s003590000121
   Hart NS, 2000, J COMP PHYSIOL A, V186, P375, DOI 10.1007/s003590050437
   Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221
   HODOS W, 1991, VISION RES, V31, P669, DOI 10.1016/0042-6989(91)90008-S
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   King TJ, 1997, PURE APPL CHEM, V69, P2135, DOI 10.1351/pac199769102135
   Kohler KL, 2000, INVEST OPHTH VIS SCI, V41, pS601
   Kunert KS, 1999, CURR EYE RES, V18, P440, DOI 10.1076/ceyr.18.6.440.5265
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Lee JY, 1997, VISION RES, V37, P505, DOI 10.1016/S0042-6989(96)00159-9
   Leung IYF, 2001, INVEST OPHTH VIS SCI, V42, P466
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Marmor MF, 1996, AM J OPHTHALMOL, V122, P382, DOI 10.1016/S0002-9394(14)72065-3
   Martin KR, 1996, J NUTR, V126, P2098, DOI 10.1093/jn/126.9.2098
   MEYER DB, 1971, COMP BIOCHEM PHYSIOL, V40, P61, DOI 10.1016/0305-0491(71)90062-9
   MIETTINEN TA, 1980, ANN CLIN RES, V12, P295
   Mortimer BC, 1998, COMP BIOCHEM PHYS A, V120, P671, DOI 10.1016/S1095-6433(98)10085-5
   NAVASCUES J, 1994, J COMP NEUROL, V350, P171, DOI 10.1002/cne.903500203
   Nomura AMY, 1997, CANCER EPIDEM BIOMAR, V6, P487
   ORGANISCIAK DT, 1989, INVEST OPHTH VIS SCI, V30, P795
   Organisciak DT, 2000, INVEST OPHTH VIS SCI, V41, P3694
   Panasenko OM, 2000, ARCH BIOCHEM BIOPHYS, V373, P302, DOI 10.1006/abbi.1999.1424
   Park JS, 1998, J NUTR, V128, P1802, DOI 10.1093/jn/128.10.1802
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   ROMANCHIK JE, 1995, J NUTR, V125, P2610
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Scheidegger R, 1998, NITRIC OXIDE-BIOL CH, V2, P8, DOI 10.1006/niox.1997.0156
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SEDDON JM, 1995, JAMA-J AM MED ASSOC, V273, P622
   Shanmugaratnam J, 1997, MOL BRAIN RES, V50, P113, DOI 10.1016/S0169-328X(97)00176-9
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1366
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1228
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1499
   Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5
   Stewart JE, 1998, INT J BIOCHEM CELL B, V30, P407, DOI 10.1016/S1357-2725(97)00151-9
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Sumantran VN, 2000, CANCER EPIDEM BIOMAR, V9, P257
   SZANTO A, 1994, BBA-LIPID LIPID MET, V1214, P39, DOI 10.1016/0005-2760(94)90007-8
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   Thanos S, 1996, PROG RETIN EYE RES, V15, P331, DOI 10.1016/1350-9462(96)00006-7
   THOMSON LR, 1997, INVEST OPHTH VIS SCI, V38, P93
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   TOYODA Y, 1996, INVEST OPHTH VIS SCI, V36, pS802
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
   Werner JS, 2000, J OPT SOC AM A, V17, P1918, DOI 10.1364/JOSAA.17.001918
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   WILLIAMS TP, 1983, INVEST OPHTH VIS SCI, V24, P285
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Woodall AA, 1996, BRIT J NUTR, V76, P307, DOI 10.1079/BJN19960034
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG SR, 1984, VISION RES, V24, P129, DOI 10.1016/0042-6989(84)90098-1
NR 117
TC 114
Z9 123
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2002
VL 43
IS 11
BP 3538
EP 3549
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 609AB
UT WOS:000178879500024
PM 12407166
DA 2022-11-30
ER

PT J
AU Almogbil, HH
   Nasrallah, FP
   Zderic, V
AF Almogbil, Hanaa H.
   Nasrallah, Fadi P.
   Zderic, Vesna
TI Feasibility of Therapeutic Ultrasound Application in Topical Scleral
   Delivery of Avastin
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE anti-VEGF; bevacizumab; sclera; drug delivery; diabetic retinopathy;
   intravitreal injection; macromolecules; eye drug delivery
ID OCULAR DRUG-DELIVERY; MEDIATED TRANSSCLERAL DELIVERY; GROWTH-FACTOR
   THERAPY; ENHANCED PENETRATION; RECENT PERSPECTIVES; POSTERIOR SEGMENT;
   BEVACIZUMAB; EYE; COMPLICATIONS; SAFETY
AB Purpose: Macromolecules have been shown to be effective in vision-saving treatments for various ocular diseases, such as age-related macular degeneration and diabetic retinopathy. The current delivery of macromolecules requires frequent intraocular injections and carries a risk of serious adverse effects.
   Methods: We tested the application of therapeutic ultrasound as a minimally invasive approach for the delivery of Avastin into the diseased regions of the eye. Avastin (bevacizumab) is an anti-vascular endothelial growth factor (VEGF) antibody with a molecular weight of 149 kDa. We tested the effectiveness and safety of Avastin delivery through rabbit sclera in vitro using a standard diffusion cell model. Ultrasound at frequencies of 400 kHz or 3 MHz with an intensity of 1 W/cm(2) was applied for the first 5 minutes of 1-hour drug exposure. Sham treatments mimicked the ultrasound treatments, but ultrasound was not turned on. Absorbance measurements of the receiver compartment solution were performed at 280 nm using a spectrophotometer.
   Results: Absorbance measurements indicated no statistical difference between the sham (n = 13) and 400 kHz ultrasound group (n = 15) in the delivery of Avastin through the sclera. However, the absorbance values were statistically different (P < 0.01) between the 3 MHz ultrasound group (0.004, n = 8) and the matched sham group (0.002, n = 7). There was 2.3 times increase in drug delivery in the 3 MHz ultrasound when compared to the corresponding sham group. Histological studies indicated no significant damage in the ultrasound-treated sclera due to ultrasound application.
   Conclusions: Our preliminary results provided support that therapeutic ultrasound may be effective in the delivery of Avastin through the sclera.
C1 [Almogbil, Hanaa H.; Zderic, Vesna] George Washington Univ, Dept Biomed Engn, Washington, DC 20052 USA.
   [Nasrallah, Fadi P.] Retina Consultants, Washington, DC USA.
C3 George Washington University
RP Zderic, V (通讯作者)，George Washington Univ, Sch Engn & Appl Sci, Dept Biomed Engn, 800 22nd St NW,Rm 6670, Washington, DC 20052 USA.
EM zderic@gwu.edu
CR Agrahari V, 2016, DRUG DELIV TRANSL RE, V6, P735, DOI 10.1007/s13346-016-0339-2
   Almogbil HH, 2019, J ACOUST SOC AM, V145, P1894
   Ambati J, 2000, INVEST OPHTH VIS SCI, V41, P1181
   Arvinte T, 2019, J PHARMACEUT BIOMED, V175, DOI 10.1016/j.jpba.2019.06.039
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Boyer DS, 2013, THER ADV ENDOCRINOL, V4, P151, DOI 10.1177/2042018813512360
   Cambier D, 2001, J REHABIL MED, V33, P212
   Cao YS, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320933775
   Chau Y, 2017, EUR J PHARM SCI, V100, P273, DOI 10.1016/j.ejps.2017.01.016
   Cheung ACY, 2010, INT J PHARMACEUT, V401, P16, DOI 10.1016/j.ijpharm.2010.09.001
   Christensen D.A., 1988, ULTRASONIC BIOINSTRU
   Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12-6-713
   Quirino-Makarczyk LD, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00212-5
   Demetriades AM, 2008, J OCUL PHARMACOL TH, V24, P70, DOI 10.1089/jop.2007.0061
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Gualino V, 2019, RETINA-J RET VIT DIS, V39, P1664, DOI 10.1097/IAE.0000000000002220
   Gwon A, 2008, ANIMAL MODELS IN EYE RESEARCH, P184, DOI 10.1016/B978-0-12-374169-1.00013-8
   Hariharan P, 2017, ULTRASOUND MED BIOL, V43, P1223, DOI 10.1016/j.ultrasmedbio.2017.01.013
   Huang H, 2018, ADV DRUG DELIVER REV, V126, P96, DOI 10.1016/j.addr.2017.09.008
   Huang D, 2014, EUR J PHARM BIOPHARM, V88, P104, DOI 10.1016/j.ejpb.2014.04.011
   HYNYNEN K, 1989, MED PHYS, V16, P618, DOI 10.1118/1.596364
   Iglicki M, EYE LOND, DOI [10.1038/s41433-032-01722-8, DOI 10.1038/S41433-032-01722-8]
   Iglicki M, 2019, ACTA DIABETOL, V56, P1141, DOI 10.1007/s00592-019-01357-y
   Iglicki M, 2019, RETINA-J RET VIT DIS, V39, P2161, DOI 10.1097/IAE.0000000000002270
   Iglicki M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200365
   Iglicki M, 2018, ACTA DIABETOL, V55, P541, DOI 10.1007/s00592-018-1117-z
   Irimia T, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10111221
   Jegal U, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52069-w
   Joseph M, 2017, EXPERT OPIN DRUG DEL, V14, P631, DOI 10.1080/17425247.2016.1227783
   Karpinecz B, 2021, J ULTRAS MED, V40, P2561, DOI 10.1002/jum.15641
   Kazazi-Hyseni F, 2010, ONCOLOGIST, V15, P819, DOI 10.1634/theoncologist.2009-0317
   Kim HM, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13050655
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Kompella UB, 2010, THER DELIV, V1, P435, DOI 10.4155/TDE.10.40
   Lamy R, 2013, INVEST OPHTH VIS SCI, V54, P5908, DOI 10.1167/iovs.13-12133
   Lang Gabriele E, 2007, Dev Ophthalmol, V39, P31, DOI 10.1159/000098498
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Mello P, 2019, OPHTHALMOLOGICA, V241, P9, DOI 10.1159/000492132
   MITRAGOTRI S, 1995, SCIENCE, V269, P850, DOI 10.1126/science.7638603
   Moisseiev E, 2014, GRAEF ARCH CLIN EXP, V252, P331, DOI 10.1007/s00417-013-2495-0
   Molokhia SA, 2013, J OCUL PHARMACOL TH, V29, P92, DOI 10.1089/jop.2012.0241
   Moon BG, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/9810270
   Mulligan K, 2020, JAMA OPHTHALMOL, V138, P40, DOI 10.1001/jamaophthalmol.2019.4557
   Nabili M, 2015, MED PHYS, V42, P5604, DOI 10.1118/1.4929553
   Nabili Marjan, 2014, J Ther Ultrasound, V2, P6, DOI 10.1186/2050-5736-2-6
   Nabili M, 2013, ULTRASOUND MED BIOL, V39, P638, DOI 10.1016/j.ultrasmedbio.2012.11.010
   OLSEN TW, 1995, INVEST OPHTH VIS SCI, V36, P1893
   Palte HD, 2012, ANESTH ANALG, V115, P194, DOI 10.1213/ANE.0b013e318253622e
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Pescina S, 2010, J PHARM PHARMACOL, V62, P1189, DOI 10.1111/j.2042-7158.2010.01153.x
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Pradeep T, 2019, HISTOLOGY EYE
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P803, DOI 10.2147/OPTH.S133637
   Rem AI, 2001, EXP EYE RES, V72, P153, DOI 10.1006/exer.2000.0939
   Salz DA, 2015, MIDDLE EAST AFR J OP, V22, P145, DOI 10.4103/0974-9233.151887
   Seah I, 2020, EYE, V34, P1341, DOI 10.1038/s41433-020-0770-y
   Shikari H, 2014, SEMIN OPHTHALMOL, V29, P276, DOI 10.3109/08820538.2014.962167
   Shin Seong Hwan, 2018, Korean J Ophthalmol, V32, P196, DOI 10.3341/kjo.2017.0081
   Short BG, 2008, TOXICOL PATHOL, V36, P49, DOI 10.1177/0192623307310955
   Snell R, 1998, CLIN ANATOMY EYE, V2
   Soliman AZ, 2012, SEMIN OPHTHALMOL, V27, P221, DOI 10.3109/08820538.2012.708812
   Suen WLL, 2013, INVEST OPHTH VIS SCI, V54, P4358, DOI 10.1167/iovs.13-11978
   Suri R, 2020, J DRUG DELIV SCI TEC, V55, DOI 10.1016/j.jddst.2019.101389
   Tkacova M, MEASUREMENT
   Wallsh JO, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051049
   Wen H, 2013, J PHARM SCI-US, V102, P892, DOI 10.1002/jps.23387
   Zderic V, 2004, CORNEA, V23, P804, DOI 10.1097/01.ico.0000134189.33549.cc
   Zderic V, 2004, J ULTRAS MED, V23, P1349, DOI 10.7863/jum.2004.23.10.1349
   Zderic V, 2002, ULTRASOUND MED BIOL, V28, P823, DOI 10.1016/S0301-5629(02)00515-X
   Zhang H, 2014, INVEST OPHTH VIS SCI, V55
   Zur D, 2020, ACTA OPHTHALMOL, V98, pE217, DOI 10.1111/aos.14230
   Zur D, 2019, OPHTHALMIC RES, V62, P231, DOI 10.1159/000499540
NR 74
TC 1
Z9 1
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD DEC
PY 2021
VL 10
IS 14
AR 2
DI 10.1167/tvst.10.14.2
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XL5EJ
UT WOS:000728167300001
PM 34851358
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yang, XR
   Chen, H
   Zhang, TC
   Yin, XL
   Man, JY
   He, QF
   Lu, M
AF Yang, Xiaorong
   Chen, Hui
   Zhang, Tongchao
   Yin, Xiaolin
   Man, Jinyu
   He, Qiufeng
   Lu, Ming
TI Global, regional, and national burden of blindness and vision loss due
   to common eye diseases atone with its attributable risk factors from
   1990 to 2019: a systematic analysis from the global burden of disease
   study 2019
SO AGING-US
LA English
DT Article
DE blindness and vision loss; global burden; risk factors; temporal trends;
   prevention
ID MACULAR DEGENERATION; ATHEROSCLEROSIS RISK; VISUAL IMPAIRMENT; PEOPLE
   BLIND; PREVALENCE; SMOKING; TRENDS; METAANALYSIS; PROJECTIONS; MORTALITY
AB To map the magnitudes and temporal trends of blindness and vision loss (BVL) due to common eye diseases along with its attributable risk factors at the national, regional, and global levels. The annual burden of BVL in 204 countries and territories was extracted from the Global Burden of Disease Study 2019. The estimated annual percentage change (EAPC) and causes composition change were calculated to quantify the temporal trends of BVL-related disease burden by sex, region, and eye disease. The global disability-adjusted life years (DALYs) of BVL increased from 12.44 million in 1990 to 22.56 million in 2019, with a slightly decreased rate from 3.03 to 2.78 per 1000 population (EAPC = -0.30). About 29.6% of BVL-related DALYs worldwide were caused by cataract, followed by refraction disorders (29.1%), near vision loss (21.7%), other vision loss (13.7%), glaucoma (3.3%), and age-related macular degeneration (2.5%) in 2019. The age-standardized DALYs rates due to each eye disease type in most regions were decreased, especially in countries with high burden and high-middle socio-demographic index. Moreover, the contribution of smoking and air pollution from solid fuels to BVL burden decreased, however, the age-standardized burden of BVL attributed to high body-mass index and high fasting plasma glucose elevated gradually across almost all regions. The temporal trend of BVL burden due to specific eye diseases varies remarkably by region, sex and age. Understanding the real-time patterns of BVL burden is crucial for formulating more effective and targeted prevention and healthcare strategies to decrease the BVL burden.
C1 [Yang, Xiaorong; Chen, Hui; Lu, Ming] Shandong Univ, Clin Epidemiol Unit, Qilu Hosp, Jinan, Peoples R China.
   [Yang, Xiaorong; Chen, Hui; Lu, Ming] Shandong Univ, Clin Res Ctr, Qilu Hosp, Cheeloo Coll Med, Jinan, Peoples R China.
   [Zhang, Tongchao; Yin, Xiaolin; Man, Jinyu; He, Qiufeng; Lu, Ming] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Jinan, Peoples R China.
C3 Shandong University; Shandong University; Shandong University
RP Yang, XR; Lu, M (通讯作者)，Shandong Univ, Clin Epidemiol Unit, Qilu Hosp, Jinan, Peoples R China.; Yang, XR; Lu, M (通讯作者)，Shandong Univ, Clin Res Ctr, Qilu Hosp, Cheeloo Coll Med, Jinan, Peoples R China.; Lu, M (通讯作者)，Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Jinan, Peoples R China.
EM yangxiaorong@sdu.edu.cn; lvming@sdu.edu.cn
RI Yang, Xiaorong/AAI-3015-2020; Yang, Xiaorong/AGZ-9159-2022
OI Yang, Xiaorong/0000-0001-9866-3029; Zhang, Tongchao/0000-0001-5491-3882
FU National Key Research and Development Program of China [2019YFC0907003];
   Shandong Provincial Natural Science Foundation [ZR2020QH302]; National
   Natural Science Foundation of China [81973116]
FX This work was supported by the National Key Research and Development
   Program of China (grant number: 2019YFC0907003) , Shandong Provincial
   Natural Science Foundation (grant number: ZR2020QH302) , National
   Natural Science Foundation of China (grant numbers: 81973116) . The
   funders were not involved in the collection, analysis, or interpretation
   of data, or the writing or submitting of this report.
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Balmes JR, 2019, J ALLERGY CLIN IMMUN, V143, P1979, DOI 10.1016/j.jaci.2019.04.016
   Bilano V, 2015, LANCET, V385, P966, DOI 10.1016/S0140-6736(15)60264-1
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Casey C, 2019, EUR J CLIN NUTR, V73, P319, DOI 10.1038/s41430-018-0353-1
   Chakravarthy U, 2017, OPHTHAL EPIDEMIOL, V24, P239, DOI 10.1080/09286586.2017.1281426
   Choudhuri P, 2020, J CLEAN PROD, V265, DOI 10.1016/j.jclepro.2020.121487
   Courtright P, 2018, BRIT J OPHTHALMOL, V102, P1324, DOI 10.1136/bjophthalmol-2018-312476
   Cupples ME, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e542
   Detaram HD, 2020, BRIT J OPHTHALMOL, V104, P893, DOI 10.1136/bjophthalmol-2019-314849
   Dighe S, 2020, BRIT J OPHTHALMOL, V104, P1070, DOI 10.1136/bjophthalmol-2019-314813
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fricke TR, 2018, OPHTHALMOLOGY, V125, P1492, DOI 10.1016/j.ophtha.2018.04.013
   *GBD 2019 RISK FAC, 2019, LANCET, V0396
   Gravely S, 2017, LANCET PUBLIC HEALTH, V2, pE166, DOI 10.1016/S2468-2667(17)30045-2
   Han XT, 2017, OPHTHALMOLOGY, V124, P734, DOI 10.1016/j.ophtha.2017.01.020
   Hu Y, 2020, JAMA OPHTHALMOL, V138, P1129, DOI 10.1001/jamaophthalmol.2020.3451
   Khairallah M, 2015, INVEST OPHTH VIS SCI, V56, P6762, DOI 10.1167/iovs.15-17201
   Leasher JL, 2016, DIABETES CARE, V39, P1643, DOI 10.2337/dc15-2171
   Lietman TM, 2020, OPHTHALMOLOGY, V127, P11, DOI 10.1016/j.ophtha.2019.11.001
   Lin HL, 2019, SCI TOTAL ENVIRON, V655, P168, DOI 10.1016/j.scitotenv.2018.11.239
   Mansouri A, 2018, INT J HEALTH POLICY, V7, P59, DOI 10.15171/ijhpm.2017.48
   Millen AE, 2019, INVEST OPHTH VIS SCI, V60, P1362, DOI 10.1167/iovs.18-25945
   Mountjoy E, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2022
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Plotnikov D, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.7
   Puzzolo E, 2019, GEOHEALTH, V3, P370, DOI 10.1029/2019GH000208
   Puzzolo E, 2016, ENVIRON RES, V146, P218, DOI 10.1016/j.envres.2016.01.002
   Resnikoff S, 2008, B WORLD HEALTH ORGAN, V86, P63, DOI 10.2471/BLT.07.041210
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Vos T, 2020, LANCET, V396, P1562
   Wang YJ, 2020, ACTA OPHTHALMOL, V98, pE138, DOI 10.1111/aos.14198
   West SK, 2020, OPHTHAL PHYSL OPT, V40, P66, DOI 10.1111/opo.12666
   Wolffsohn JS, 2019, PROG RETIN EYE RES, V68, P124, DOI 10.1016/j.preteyeres.2018.09.004
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2019, WORLD REP VIS
   Yang XR, 2021, EPIDEMIOL PSYCH SCI, V30, DOI 10.1017/S2045796021000275
   Yang XR, 2021, LUNG CANCER, V152, P49, DOI 10.1016/j.lungcan.2020.12.007
   Ye LX, 2020, J DIABETES, V12, P807, DOI 10.1111/1753-0407.13072
   Ye X, 2020, ACTA OPHTHALMOL, V98, pE593, DOI 10.1111/aos.14330
   Yu JR, 2021, INT J CANCER, V149, P993, DOI 10.1002/ijc.33617
   Zebardast N, 2017, AM J OPHTHALMOL, V174, P134, DOI 10.1016/j.ajo.2016.11.004
   Zhang T, 2016, J EPIDEMIOL COMMUN H, V70, P836, DOI 10.1136/jech-2016-207331
NR 45
TC 11
Z9 11
U1 3
U2 16
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG 15
PY 2021
VL 13
IS 15
BP 19614
EP 19642
PG 29
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA UK2JU
UT WOS:000691802000014
PM 34371482
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Koirala, D
   Beranova-Giorgianni, S
   Giorgianni, F
AF Koirala, Diwa
   Beranova-Giorgianni, Sarka
   Giorgianni, Francesco
TI Early Transcriptomic Response to OxLDL in Human Retinal Pigment
   Epithelial Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE retinal pigment epithelium; oxidized LDL; transcriptome; oxidative
   stress; drusen
ID OXIDATION-SPECIFIC EPITOPES; MACULAR DEGENERATION; HEME OXYGENASE-1;
   MITOCHONDRIAL DYSFUNCTION; LIPOFUSCIN ACCUMULATION; RPE CELLS;
   INFLAMMATION; EXPRESSION; GENE; RECEPTOR
AB In the sub-retinal pigment epithelium (sub-RPE) space of the aging macula, deposits of oxidized phospholipids, oxidized derivatives of cholesterol and associated oxidized low-density lipoproteins (OxLDL) are considered contributors to the onset and development of age-related macular degeneration (AMD). We investigated the gene expression response of a human-derived RPE cell line exposed for short periods of time to non-cytotoxic levels of OxLDL or LDL. In our cell model, treatment with OxLDL, but not LDL, generated an early gene expression response which affected more than 400 genes. Gene pathway analysis unveiled gene networks involved in the regulation of various cellular functions, including acute response to oxidative stress via up-regulation of antioxidative gene transcripts controlled by nuclear factor erythroid-2 related factor 2 (NRF2), and up-regulation of aryl hydrocarbon receptor-controlled detoxifying gene transcripts. In contrast, circadian rhythm-controlling genes and genes involved in lipid metabolism were strongly down-regulated. Treatment with low-density lipoprotein (LDL) did not induce the regulation of these pathways. These findings show that RPE cells are able to selectively respond to the oxidized forms of LDL via the up-regulation of gene pathways involved in molecular mechanisms that minimize cellular oxidative damage, and the down-regulation of the expression of genes that regulate the intracellular levels of lipids and lipid derivatives. The effect on genes that control the cellular circadian rhythm suggests that OxLDL might also disrupt the circadian clock-dependent phagocytic activity of the RPE. The data reveal a complex cellular response to a highly heterogeneous oxidative stress-causing agent such as OxLDL commonly present in drusen formations.
C1 [Koirala, Diwa; Beranova-Giorgianni, Sarka; Giorgianni, Francesco] Dept Pharmaceut Sci, Memphis, TN 38163 USA.
   [Koirala, Diwa; Beranova-Giorgianni, Sarka; Giorgianni, Francesco] Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center
RP Beranova-Giorgianni, S; Giorgianni, F (通讯作者)，Dept Pharmaceut Sci, Memphis, TN 38163 USA.
EM koiraladiwa@gmail.com; sberanova@uthsc.edu; fgiorgia@uthsc.edu
FU Retina Research Foundation; BrightFocus Foundation [M2016068]
FX This research was funded by the Retina Research Foundation, and the
   BrightFocus Foundation (grant number M2016068).
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Bauer M, 2002, ANTIOXID REDOX SIGN, V4, P749, DOI 10.1089/152308602760598891
   Binder CJ, 2016, NAT REV IMMUNOL, V16, P485, DOI 10.1038/nri.2016.63
   Bucolo C, 2019, J CELL PHYSIOL, V234, P17295, DOI 10.1002/jcp.28347
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Dikic I, 2017, ANNU REV BIOCHEM, V86, P193, DOI 10.1146/annurev-biochem-061516-044908
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Duguay D, 2009, CHRONOBIOL INT, V26, P1479, DOI 10.3109/07420520903497575
   Finnemann S. C., 2008, VISUAL TRANSDUCTION, P67, DOI [10.1007/978-1-59745-374-5_4, DOI 10.1007/978-1-59745-374-5_4]
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Guido ME, 2010, PROG NEUROBIOL, V92, P484, DOI 10.1016/j.pneurobio.2010.08.005
   Guillaumond F, 2010, MOL CELL BIOL, V30, P3059, DOI 10.1128/MCB.01141-09
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jaeger C, 2016, ENVIRON HEALTH INSIG, V10, P133, DOI 10.4137/EHI.S38343
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jang KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.437
   Janowski BA, 2002, P NATL ACAD SCI USA, V99, P12675, DOI 10.1073/pnas.202471599
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207
   Ko GYP, 2020, EUR J NEUROSCI, V51, P194, DOI 10.1111/ejn.14185
   Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Kronke G, 2003, J BIOL CHEM, V278, P51006, DOI 10.1074/jbc.M304103200
   Kuda O, 2013, J BIOL CHEM, V288, P15547, DOI 10.1074/jbc.M113.473298
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240
   Leproult R, 2014, DIABETES, V63, P1860, DOI 10.2337/db13-1546
   Levitan I, 2010, ANTIOXID REDOX SIGN, V13, P39, DOI 10.1089/ars.2009.2733
   Lowrey PL, 2011, ADV GENET, V74, P175, DOI 10.1016/B978-0-12-387690-4.00006-4
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517
   Maury E, 2014, DIABETES METAB, V40, P338, DOI 10.1016/j.diabet.2013.12.005
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Neale Benjamin M, 2010, Proc Natl Acad Sci U S A, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Park S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057138
   Pittala V, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1420892
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Silverstein Roy L, 2010, Trans Am Clin Climatol Assoc, V121, P206
   SMITMCBRIDE Z, 2016, J OPHTHALMOL, V2016
   Sporl F, 2012, P NATL ACAD SCI USA, V109, P10903, DOI 10.1073/pnas.1118641109
   Synowiec E, 2012, MOL BIOL REP, V39, P2081, DOI 10.1007/s11033-011-0955-3
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tonelli C, 2018, ANTIOXID REDOX SIGN, V29, P1727, DOI 10.1089/ars.2017.7342
   Trammell RA, 2014, COMPARATIVE MED, V64, P13
   Viiri J, 2010, MOL VIS, V16, P1399
   Villegas-Pérez MP, 2005, Arch Soc Esp Oftalmol, V80, P565
   Wang LJ, 1998, AM J PATHOL, V152, P711
   Wang Q, 2014, INVEST OPHTH VIS SCI, V55, P3986, DOI 10.1167/iovs.13-13076
   Ward SM, 2010, J BIOL CHEM, V285, P38987, DOI 10.1074/jbc.M110.175182
   Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Willis D, 2000, J PATHOL, V190, P627
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yan GG, 2017, INT J CLIN EXP PATHO, V10, P1619
   Yin L, 2007, SCIENCE, V318, P1786, DOI 10.1126/science.1150179
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Zhang Y, 2016, INT J BIOL SCI, V12, P569, DOI 10.7150/ijbs.14027
NR 66
TC 5
Z9 5
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 22
AR 8818
DI 10.3390/ijms21228818
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OY3YC
UT WOS:000594184200001
PM 33233417
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Uyar, E
   Ulas, F
   Alkan, Y
AF Uyar, Enes
   Ulas, Fatih
   Alkan, Yunus
TI Can Vitreous Reflux Affect The Short-Term Treatment Response After
   Intravitreal Ranibizumab Injection?
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; diabetic macular edema; intravitreal
   ranibizumab; macular thickness; treatment response; vitreous reflux
ID INTRAOCULAR-PRESSURE; MACULAR DEGENERATION; AGE; DRUG
AB Purpose The aim of this study was to evaluate the effect of vitreous reflux (VR) on the short-term effect of intravitreal ranibizumab injection. Materials and Methods The study included 181 eyes of 81 age-related macular degeneration (AMD) and 100 diabetic macular edema (DME) patients. Treatment response was evaluated by measuring central macular thickness (CMT) as well as 1 mm and 3 mm central macular thicknesses (MT1 and MT3). Patients were grouped as; Group 1: no VR, Group 2: <3 mm VR, and Group 3: >3 mm VR according to conjunctival bleb diameters. The data were analyzed using variance, correlation and regression analyses. Results In AMD patients, reduction of CMT values following the treatment were 88.3 +/- 110.6 mu m in Group 1, 85.6 +/- 158.7 mu m in Group 2, and 93.1 +/- 92.2 mu m in Group 3. Likewise, in DME patients, it was 82.4 +/- 88.4 mu m, 72.9 +/- 109.9 mu m, and 73.7 +/- 113.7 mu m, respectively. Reduction of MT1 values after the treatment were 47.4 +/- 72.6 mu m, 36.0 +/- 131.9 mu m, and 36.7 +/- 114.4 mu m in AMD patients, and 33.3 +/- 72.5 mu m, 36.6 +/- 90.2 mu m, and 46.9 +/- 83.4 mu m in DME patients. In all comparisons among groups of VR, macular thickness (MT) change did not exhibit significant difference following an intravitreal ranibizumab treatment (p> .05). Conclusion We found that the increase in VR amount did not adversely affect the decrease in MT after intravitreal ranibizumab treatment in AMD and DME patients.
C1 [Uyar, Enes] Aksaray Univ, Aksaray Training & Res Hosp, Dept Ophthalmol, TR-68200 Aksaray, Turkey.
   [Ulas, Fatih; Alkan, Yunus] Abant Izzet Baysal Univ, Dept Ophthalmol, Fac Med, Bolu, Turkey.
C3 Aksaray University; Abant Izzet Baysal University
RP Uyar, E (通讯作者)，Aksaray Univ, Aksaray Training & Res Hosp, Dept Ophthalmol, TR-68200 Aksaray, Turkey.
EM enuyar@gmail.com
OI Ulas, Fatih/0000-0003-4468-3985; Uyar, Enes/0000-0003-2544-3580;
   /0000-0001-5454-3113
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Ashraf M, 2016, BRIT J OPHTHALMOL, V100, P1596, DOI 10.1136/bjophthalmol-2016-308388
   Bek T, 2018, CLIN OPHTHALMOL, V12, P473, DOI 10.2147/OPTH.S158760
   Benz MS, 2006, OPHTHALMOLOGY, V113, P1174, DOI 10.1016/j.ophtha.2005.10.061
   Boon CJF, 2008, OPHTHALMOLOGY, V115, P1268, DOI 10.1016/j.ophtha.2008.02.021
   Bressler SB, 2019, JAMA OPHTHALMOL, V137, P382, DOI 10.1001/jamaophthalmol.2018.6786
   Brodie FL, 2014, RETINA-J RET VIT DIS, V34, P1473, DOI 10.1097/IAE.0000000000000098
   Brodie FL, 2014, CURR EYE RES, V39, P752, DOI 10.3109/02713683.2013.864774
   Christoforidis JB, 2013, CLIN EXP OPHTHALMOL, V41, P614, DOI 10.1111/ceo.12074
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   Fong AHC, 2013, CLIN INTERV AGING, V8, P467, DOI 10.2147/CIA.S36811
   Hubschman JP, 2010, RETINA-J RET VIT DIS, V30, P167, DOI 10.1097/IAE.0b013e3181b094cf
   Knecht PB, 2009, RETINA-J RET VIT DIS, V29, P1175, DOI 10.1097/IAE.0b013e3181aade74
   Lee CY, 2013, BIOMED MICRODEVICES, V15, P841, DOI 10.1007/s10544-013-9771-y
   Lopez-Guajardo L, 2008, EYE, V22, P430, DOI 10.1038/sj.eye.6703054
   Nicholson L, 2017, EYE, V31, P1358, DOI 10.1038/eye.2017.69
   Ozkaya A, 2013, J OCUL PHARMACOL TH, V29, P325, DOI 10.1089/jop.2012.0144
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Rodrigues EB, 2007, AM J OPHTHALMOL, V143, P1035, DOI 10.1016/j.ajo.2007.01.035
   Rodrigues EB, 2011, J OCUL PHARMACOL TH, V27, P197, DOI 10.1089/jop.2010.0082
   Saeed MU, 2011, SEMIN OPHTHALMOL, V26, P61, DOI 10.3109/08820538.2011.559518
   Sato S, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006459
   Seddon JM, 2019, AM J OPHTHALMOL, V198, P223, DOI 10.1016/j.ajo.2018.10.022
   Singh RP, 2016, OPHTHALMOLOGY, V123, P1581, DOI 10.1016/j.ophtha.2016.03.038
   Turgut Burak, 2009, J Clin Med Res, V1, P280, DOI 10.4021/jocmr2009.12.1280
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   ZHANG X, 2018, BIOMED RES INT, V2018, DOI DOI 10.1155/2018/9640131
NR 29
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD FEB 1
PY 2021
VL 46
IS 2
BP 248
EP 254
DI 10.1080/02713683.2020.1789664
EA JUL 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PO7OH
UT WOS:000547658000001
PM 32635750
DA 2022-11-30
ER

PT J
AU Chittasupho, C
   Kengtrong, K
   Chalermnithiwong, S
   Sarisuta, N
AF Chittasupho, Chuda
   Kengtrong, Kantalada
   Chalermnithiwong, Supawan
   Sarisuta, Narong
TI Anti-angiogenesis by dual action of R5K peptide conjugated itraconazole
   nanoparticles
SO AAPS PHARMSCITECH
LA English
DT Article
DE angiogenesis; HUVEC; R5K; itraconazole; PLGA
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; TUMOR-GROWTH;
   INTRAVITREAL INJECTION; INHIBITS ANGIOGENESIS; RANIBIZUMAB; ANTIFUNGAL;
   EXPRESSION; PLGA; VERTEPORFIN
AB Neovascular age-related macular degeneration (AMD) is a leading cause of central vision loss and irreversible blindness. Vascular endothelial growth factor (VEGF) plays an important role in neovascularization under the retina and macula by promoting endothelial cell proliferation, migration, and angiogenesis. Although anti-VEGF drugs have shown their efficacy in visual improvement, long-term use of these drugs leads to ocular and systemic complications due to the non-selectivity of the drug. In this study, the dual-mode anti-angiogenic drug delivery system, which potentially inhibited VEGF in two different ways, was developed. The itraconazole encapsulated nanoparticles, conjugated with R5K peptide, were fabricated to allow multivalent binding interactions with VEGF. The R5K peptide blocked VEGF binding to its receptor, while itraconazole altered the signaling pathway of VEGF stimulation. The dual action of this novel drug delivery system aimed to enhance the anti-angiogenic effects of individual drugs. R5K-ITZ-NPs demonstrated potent, cell-type specific, and dose-dependent inhibition of vascular endothelial cell proliferation, migration, and tube formation in response to VEGF stimulation. The physical stability study showed that R5K-ITZ-NPs were stable when stored at 4 degrees C. However, the drug remaining in R5K-ITZ-NPs when stored at 4 degrees C for 28 days were only 17.2%. The chemical stability test revealed that the degradation of R5K-ITZ-NPs followed second-order kinetics. The release profile showed the burst release of ITZ followed by sustained release of the drug This novel drug delivery system may be an option for neovascular AMD patients who are resistant to ITZ and may represent a novel therapy for AMD.
C1 [Chittasupho, Chuda; Kengtrong, Kantalada; Chalermnithiwong, Supawan] Srinakharinwirot Univ, Fac Pharm, Dept Pharmaceut Technol, Ongkharak 26120, Nakhonnayok, Thailand.
   [Sarisuta, Narong] Thammasat Univ, Fac Pharm, Dept Pharmaceut Sci, Pathum Thani 12121, Thailand.
C3 Srinakharinwirot University; Thammasat University
RP Chittasupho, C (通讯作者)，Srinakharinwirot Univ, Fac Pharm, Dept Pharmaceut Technol, Ongkharak 26120, Nakhonnayok, Thailand.
EM chuda@g.swu.ac.th
RI Chittasupho, Chuda/ADC-2911-2022; Chittasupho, Chuda/ABA-5410-2020
OI Chittasupho, Chuda/0000-0002-0696-9969; 
FU Office of the Higher Education Commission; Thailand Research Fund
   [MRG6180064]
FX This work was supported by the Office of the Higher Education Commission
   and the Thailand Research Fund (MRG6180064).
CR Aftab BT, 2011, CANCER RES, V71, P6764, DOI 10.1158/0008-5472.CAN-11-0691
   Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   Alhowyan AA, 2019, J MICROBIOL METH, V161, P87, DOI 10.1016/j.mimet.2019.01.020
   Almalik A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10836-7
   Bae DG, 2000, J BIOL CHEM, V275, P13588, DOI 10.1074/jbc.275.18.13588
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478
   Chirila TV, 1998, PROG POLYM SCI, V23, P475, DOI 10.1016/S0079-6700(97)00045-2
   Chittasupho C, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-018-1256-0
   Choi CH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06510-7
   Chong CR, 2007, ACS CHEM BIOL, V2, P263, DOI 10.1021/cb600362d
   Chu LH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110871
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dinarvand R, 2011, INT J NANOMED, V6, P877, DOI 10.2147/IJN.S18905
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Favot L, 2003, THROMB HAEMOSTASIS, V90, P334, DOI 10.1160/TH03-02-0084
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Hao Q, 2009, J BIOL CHEM, V284, P799, DOI 10.1074/jbc.M807546200
   Head SA, 2015, P NATL ACAD SCI USA, V112, pE7276, DOI 10.1073/pnas.1512867112
   Herbst Roy S, 2006, Expert Opin Emerg Drugs, V11, P635, DOI 10.1517/14728214.11.4.635
   Izak-Nau E, 2015, RSC ADV, V5, P84172, DOI 10.1039/c5ra10187e
   Jahan ST, 2015, INT J NANOMED, V10, P7371, DOI 10.2147/IJN.S90866
   Khoee S, 2012, EUR J MED CHEM, V50, P416, DOI 10.1016/j.ejmech.2012.02.027
   Kim J, 2010, CANCER CELL, V17, P388, DOI 10.1016/j.ccr.2010.02.027
   Kim JW, 2010, EXP MOL MED, V42, P514, DOI 10.3858/emm.2010.42.7.052
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin SW, 2015, MAR DRUGS, V13, P861, DOI 10.3390/md13020861
   Liu CW, 2012, INT J NANOMED, V7, P4749, DOI 10.2147/IJN.S32830
   Lyu S, 2005, J POLYM SCI POL PHYS, V43, P383, DOI 10.1002/polb.20340
   Maiz-Fernandez S, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11040742
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nacev BA, 2011, J BIOL CHEM, V286, P44045, DOI 10.1074/jbc.M111.278754
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Okuyama H, 2006, J BIOL CHEM, V281, P15554, DOI 10.1074/jbc.M602003200
   Parikh Shalin K, 2011, Pharm Methods, V2, P88, DOI 10.4103/2229-4708.84442
   Parikh T, 2016, PHARM RES-DORDR, V33, P1456, DOI 10.1007/s11095-016-1890-8
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schlingemann RO, 1997, BRIT J OPHTHALMOL, V81, P501, DOI 10.1136/bjo.81.6.501
   Shim JS, 2016, CLIN CANCER RES, V22, P2709, DOI 10.1158/1078-0432.CCR-15-1888
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Varenne F, 2015, COLLOID SURFACE A, V486, P124, DOI 10.1016/j.colsurfa.2015.08.043
   Vey E, 2012, POLYM DEGRAD STABIL, V97, P358, DOI 10.1016/j.polymdegradstab.2011.12.010
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Xu J, 2010, P NATL ACAD SCI USA, V107, P4764, DOI 10.1073/pnas.0910872107
   Yang J, 2014, CELL MOL IMMUNOL, V11, P285, DOI 10.1038/cmi.2014.6
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yoo SA, 2005, J IMMUNOL, V174, P5846, DOI 10.4049/jimmunol.174.9.5846
   Yorston David, 2014, Community Eye Health, V27, P44
   Zhang N, 2008, BIOCONJUGATE CHEM, V19, P145, DOI 10.1021/bc700227z
   Zhao YY, 2011, J HISTOCHEM CYTOCHEM, V59, P474, DOI 10.1369/0022155411400871
NR 60
TC 10
Z9 10
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD JAN 21
PY 2020
VL 21
IS 3
AR 74
DI 10.1208/s12249-019-1568-8
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KM7JZ
UT WOS:000514317900002
PM 31965399
DA 2022-11-30
ER

PT J
AU Hellinen, L
   Pirskanen, L
   Tengvall-Unadike, U
   Urtti, A
   Reinisalo, M
AF Hellinen, Laura
   Pirskanen, Lea
   Tengvall-Unadike, Unni
   Urtti, Arto
   Reinisalo, Mika
TI Retinal Pigment Epithelial Cell Line with Fast Differentiation and
   Improved Barrier Properties
SO PHARMACEUTICS
LA English
DT Article
DE retinal pigment epithelium; outer blood-retinal barrier; cell line;
   ARPE19; differentiation; tight junctions; microvilli; drug permeation;
   beta-blockers
ID ARPE-19 CELLS; EXPRESSION; PERMEABILITY
AB Retinal pigment epithelium (RPE) acts as an outer blood-retinal barrier that limits the access of circulating xenobiotics to the eye. In addition, the RPE limits posterior elimination of intravitreally injected drugs to circulation. Thus, permeation in the RPE has a significant effect on ocular pharmacokinetics. The RPE is also a potentially important drug target in age-related macular degeneration. Therefore, the cell models of the RPE are important tools in ocular drug development, but poor availability and problems in reproducibility limit the use of primary RPE cell cultures. Furthermore, the best and widely used human cell line ARPE19 requires specialized culture conditions and a long time for cellular differentiation. In this paper, we describe a cell population arisen from the ARPE19 culture, with fast differentiation and improved barrier properties. This cell line, LEPI, forms clear microvilli and rapidly displays RPE-like cobblestone morphology after subculture in simple culture conditions. The LEPI cells show RPE-specific functions and expression of RPE65, ezrin, and BEST1 proteins. On filter, the LEPI cells develop tighter barrier than the ex vivo bovine RPE-choroid: permeability coefficients of beta-blockers (atenolol, nadolol, timolol, pindolol, metoprolol, betaxolol) ranged from 0.4 x 10(-6 )cm/sec to 2.3 x 10(-6) cm/sec depending on the drug lipophilicity. This rapidly differentiating cell line will be an asset in ocular studies since it is easily maintained, it grows and differentiates quickly and does not require specialized culture conditions for differentiation. Thus, this cell line is suitable for both small scale assays and high throughput screening in drug discovery and development.
C1 [Hellinen, Laura; Pirskanen, Lea; Tengvall-Unadike, Unni; Urtti, Arto; Reinisalo, Mika] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70210, Finland.
   [Urtti, Arto] Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, Drug Res Programme, POB 56, FI-00014 Helsinki, Finland.
   [Urtti, Arto] St Petersburg State Univ, Inst Chem, Lab Biohybrid Technol, St Petersburg 198504, Russia.
   [Reinisalo, Mika] Univ Eastern Finland, Fac Hlth Sci, Inst Clin Med, Dept Ophthalmol, Kuopio 70210, Finland.
C3 University of Eastern Finland; University of Helsinki; Saint Petersburg
   State University; University of Eastern Finland
RP Reinisalo, M (通讯作者)，Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70210, Finland.; Reinisalo, M (通讯作者)，Univ Eastern Finland, Fac Hlth Sci, Inst Clin Med, Dept Ophthalmol, Kuopio 70210, Finland.
EM mika.reinisalo@uef.fi
OI Tengvall-Unadike, Unni/0000-0002-3440-4383
FU Academy of Finland [311122]; Finnish Cultural Foundation; Government of
   Russian Federation Mega-Grant [14.W03.031.0025]
FX This research was funded by Academy of Finland, grant number 311122,
   Finnish Cultural Foundation (personal grant for L.H.) and Government of
   Russian Federation Mega-Grant, grant number 14.W03.031.0025 "Biohybrid
   technologies for modern biomedicine" (A.U.).
CR Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Capes-Davis A, 2013, INT J CANCER, V132, P2510, DOI 10.1002/ijc.27931
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Mannermaa E, 2010, EUR J PHARM SCI, V40, P289, DOI 10.1016/j.ejps.2010.04.001
   Oganesian A, 1997, INT OPHTHALMOL, V21, P165, DOI 10.1023/A:1026402031902
   Pavan B, 2018, DRUG DISCOV TODAY, V23, P1672, DOI 10.1016/j.drudis.2018.06.009
   Pelkonen L, 2017, EUR J PHARM SCI, V109, P162, DOI 10.1016/j.ejps.2017.07.027
   Pelkonen L, 2017, MOL PHARMACEUT, V14, P605, DOI 10.1021/acs.molpharmaceut.6b00782
   Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1716, DOI 10.1167/iovs.02-0287
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Ramsay E, 2017, J PHARM SCI-US, V106, P2463, DOI 10.1016/j.xphs.2017.04.061
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Samuel W, 2017, MOL VIS, V23, P60
   Shadforth AMA, 2017, J TISSUE ENG REGEN M, V11, P1915, DOI 10.1002/term.2089
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tian J, 2005, BRIT J OPHTHALMOL, V89, P1510, DOI 10.1136/bjo.2005.072108
   Westerhout J, 2014, EUR J PHARM SCI, V63, P167, DOI 10.1016/j.ejps.2014.07.003
   Zhou JH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/289360
NR 21
TC 11
Z9 11
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD AUG
PY 2019
VL 11
IS 8
AR 412
DI 10.3390/pharmaceutics11080412
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IV8KT
UT WOS:000484515100058
PM 31412689
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Siedlecki, J
   Wertheimer, C
   Wolf, A
   Liegl, R
   Priglinger, C
   Priglinger, S
   Eibl-Lindner, K
AF Siedlecki, Jakob
   Wertheimer, Christian
   Wolf, Armin
   Liegl, Raffael
   Priglinger, Claudia
   Priglinger, Siegfried
   Eibl-Lindner, Kirsten
TI Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic
   properties of axitinib on human endothelial cells and pericytes in vitro
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age related macular degeneration; Choroidal neovascularization; VEGF;
   PDGF
ID RECEPTOR TYROSINE KINASE; MACULAR DEGENERATION; GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB TREATMENT; VISUAL-ACUITY; EXPRESSION;
   SURVIVAL; MEMBRANES; BEVACIZUMAB
AB Purpose Drugs currently approved for neovascular age-related macular degeneration (nAMD) offer anti-VEGF monotherapy only. Platelet-derived growth factor (PDGF) signaling is pivotal to pericyte-induced stabilization of choroidal neovascularizations (CNV), and causes partial anti-VEGF resistance. No combination therapy for VEGF and PDGF has been approved yet. Axitinib is a tyrosine kinase inhibitor interfering with VEGF and PDGF signaling, and has been approved for the treatment of renal cell carcinoma. This study evaluates anti-angiogenic properties of axitinib in an in-vitro model of choroidal neovascularizations in nAMD.
   Methods Human endothelial cells (HUVEC) and human pericytes (hPC-PL) were treated with axitinib doses ranging from 1.0 ng/ml to 10 mu g/ml. Cellular viability and proliferation were assessed with a modified MTT assay. VEGF-and PDGF-stimulated migration was observed in modified Boyden chambers. Formation of capillary structures was evaluated on Cultrex basement membrane.
   Results Proliferation was significantly inhibited in both cell lines in a dose-dependent manner. VEGF and PDGF significantly induced, whereas simultaneous axitinib normalized cellular migration in HUVEC and pericytes. On growth-factor-reduced Cultrex, VEGF induced the formation of capillary structures, while axitinib significantly reverted this effect. Axitinib reduced the amount of vessel associated tissue on full growth factor Cultrex. All effects on both cell lines were observed in non-toxic concentrations of axitinib.
   Conclusions Axitinib inhibits angiogenesis in endothelial cells and pericytes via VEGFR and PDGFR modulation in vitro. Further studies are needed to elucidate whether axitinib may also improve therapy of CNV in AMD in vivo by interference with pericyte stabilization of pathological vessels.
C1 [Siedlecki, Jakob; Wertheimer, Christian; Wolf, Armin; Liegl, Raffael; Priglinger, Claudia; Priglinger, Siegfried; Eibl-Lindner, Kirsten] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Mathildenstr 8, D-80336 Munich, Germany.
C3 University of Munich
RP Siedlecki, J (通讯作者)，Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Mathildenstr 8, D-80336 Munich, Germany.
EM jakob.siedlecki@med.uni-muenchen.de
OI Wertheimer, Christian/0000-0002-7017-7560
CR Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549
   AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012
   Akiyama H, 2006, J CELL PHYSIOL, V207, P407, DOI 10.1002/jcp.20583
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006
   BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carneiro A, 2009, EXP EYE RES, V88, P522, DOI 10.1016/j.exer.2008.11.011
   Chang FC, 2012, J FORMOS MED ASSOC, V111, P589, DOI 10.1016/j.jfma.2012.09.008
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Franco M, 2011, BLOOD, V118, P2906, DOI 10.1182/blood-2011-01-331694
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gaengel K, 2009, ARTERIOSCL THROM VAS, V29, P630, DOI 10.1161/ATVBAHA.107.161521
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gerding H, 2014, KLIN MONATSBL AUGENH, V231, P427, DOI 10.1055/s-0034-1368241
   Giddabasappa A, 2016, EXP EYE RES, V145, P373, DOI 10.1016/j.exer.2016.02.010
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   GUYER DR, 1986, ARCH OPHTHALMOL-CHIC, V104, P702, DOI 10.1001/archopht.1986.01050170092029
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Hu-Lowe DD, 2008, CLIN CANCER RES, V14, P7272, DOI 10.1158/1078-0432.CCR-08-0652
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kang S, 2013, CURR EYE RES, V38, P119, DOI 10.3109/02713683.2012.727520
   Kelly RJ, 2010, RECENT RESULTS CANC, V184, P33, DOI 10.1007/978-3-642-01222-8_3
   Kernt M, 2012, GROWTH FACTORS, V30, P49, DOI 10.3109/08977194.2011.639300
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593
   Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Muether PS, 2013, RETINA-J RET VIT DIS, V33, P1809, DOI 10.1097/IAE.0b013e318285cd9e
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rini BI, 2011, CLIN CANCER RES, V17, P3841, DOI 10.1158/1078-0432.CCR-10-2806
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Thiele S, 2013, KLIN MONATSBL AUGENH, V230, P247, DOI 10.1055/s-0032-1328161
   WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0
   Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 66
TC 29
Z9 31
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2017
VL 255
IS 5
BP 963
EP 972
DI 10.1007/s00417-017-3595-z
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EV0ND
UT WOS:000401436500012
PM 28161830
DA 2022-11-30
ER

PT J
AU Chang, CH
   Chiu, HF
   Han, YC
   Chen, IH
   Shen, YC
   Venkatakrishnan, K
   Wang, CK
AF Chang, Chi-Huang
   Chiu, Hui-Fang
   Han, Yi-Chun
   Chen, I-Hsien
   Shen, You-Cheng
   Venkatakrishnan, Kamesh
   Wang, Chin-Kun
TI Photoprotective effects of cranberry juice and its various fractions
   against blue light-induced impairment in human retinal pigment
   epithelial cells
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article
DE Condensed tannin; ARPE-19 cell; antioxidation; macular degeneration
ID RADICAL SCAVENGING ACTIVITY; IN-VIVO EVIDENCE; MACULAR DEGENERATION;
   ARPE-19 CELLS; VACCINIUM-MACROCARPON; ANTIOXIDANT ACTIVITY; INDUCED
   DAMAGE; VISIBLE-LIGHT; INDUCED DEATH; ANTHOCYANINS
AB Context: Cranberry has numerous biological activities, including antioxidation, anticancer, cardioprotection, as well as treatment of urinary tract infection (UTI), attributed to abundant phenolic contents.
   Objective: The current study focused on the effect of cranberry juice (CJ) on blue light exposed human retinal pigment epithelial (ARPE-19) cells which mimic age-related macular degeneration (AMD).
   Materials and methods: Preliminary phytochemical and HPLC analysis, as well as total antioxidant capacity and scavenging activity of cranberry ethyl acetate extract and different CJ fractions (condensed tannins containing fraction), were evaluated. In cell line model, ARPE-19 were irradiated with blue light at 450 nm wavelength for 10 h (mimic AMD) and treated with different fractions of CJ extract at different doses (5-50 mu g/mL) by assessing the cell viability or proliferation rate using MTT assay (repairing efficacy).
   Results: Phytochemical and HPLC analysis reveals the presence of several phenolic compounds (flavonoids, proanthocyanidin, quercetin) in ethyl acetate extract and different fractions of CJ. However, the condensed tannin containing fraction of ethyl acetate extract of CJ displayed the greater (p < 0.05) scavenging activity especially at the dose of 1 mg/mL. Similarly, the condensed tannin containing fraction at 50 mu g/mL presented better (p < 0.05) repairing ability (increased cell viability). Furthermore, the oligomeric condensed tannin containing fraction display the best (p < 0.05) repairing efficiency at 50 mu g/mL.
   Discussion and conclusion: In conclusion, this study distinctly proved that condensed tannin containing fraction of CJ probably exhibits better free radicals scavenging activity and thereby effectively protected the ARPE-19 cells and thus, hampers the progress of AMD.
C1 [Chang, Chi-Huang] Chung Shan Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.
   [Chiu, Hui-Fang] Minist Hlth & Well Being, Taichung Hosp, Dept Chinese Med, Taichung, Taiwan.
   [Han, Yi-Chun; Chen, I-Hsien; Venkatakrishnan, Kamesh; Wang, Chin-Kun] Chung Shan Med Univ, Sch Nutr, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan.
   [Shen, You-Cheng] Chung Shan Med Univ, Sch Hlth Diet & Ind Management, Taichung, Taiwan.
C3 Chung Shan Medical University; Chung Shan Medical University Hospital;
   Chung Shan Medical University; Chung Shan Medical University
RP Wang, CK (通讯作者)，Chung Shan Med Univ, Sch Nutr, 110,Sec 1,Jianguo N Rd, Taichung 40201, Taiwan.
EM wck@csmu.edu.tw
RI Shen, You-Cheng/AAW-2665-2020; Wang, Chin-Kun/S-6253-2019
OI Shen, You-Cheng/0000-0002-3098-4712; Wang, Chin-Kun/0000-0003-1308-2909
FU National Science Council, Taiwan [NSC 92-2313-B-040-002]
FX This study was funded by National Science Council, Taiwan (NSC
   92-2313-B-040-002).
CR Aksoy L, 2013, SAUDI J BIOL SCI, V20, P235, DOI 10.1016/j.sjbs.2013.02.003
   ARNAO MB, 1990, ANAL BIOCHEM, V185, P335, DOI 10.1016/0003-2697(90)90304-R
   Buchert J, 2005, J SCI FOOD AGR, V85, P2548, DOI 10.1002/jsfa.2284
   Burger O, 2000, FEMS IMMUNOL MED MIC, V29, P295, DOI 10.1016/S0928-8244(00)00220-0
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Canter PH, 2004, SURV OPHTHALMOL, V49, P38, DOI 10.1016/j.survophthal.2003.10.006
   Connor AM, 2002, J AGR FOOD CHEM, V50, P893, DOI 10.1021/jf011212y
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U
   Howell AB, 2001, FASEB J, V15, pA284
   Johnson J, 2009, INVEST OPHTH VIS SCI, V50, P2398, DOI 10.1167/iovs.08-2088
   JULKUNENTIITTO R, 1985, J AGR FOOD CHEM, V33, P213, DOI 10.1021/jf00062a013
   Kalt W, 2008, J AGR FOOD CHEM, V56, P705, DOI 10.1021/jf071998l
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Lavigne JP, 2008, CLIN MICROBIOL INFEC, V14, P350, DOI 10.1111/j.1469-0691.2007.01917.x
   Lavola A, 2012, J AGR FOOD CHEM, V60, P1020, DOI 10.1021/jf204056s
   Liu YX, 2012, BRIT J NUTR, V108, P16, DOI 10.1017/S000711451100523X
   Matsumoto H, 2003, J AGR FOOD CHEM, V51, P3560, DOI 10.1021/jf034132y
   Matsumoto H, 2006, EXP EYE RES, V83, P348, DOI 10.1016/j.exer.2005.12.019
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Naczk M, 1994, J PHARM BIOMED ANAL, V41, P1523
   Neto CC, 2007, J NUTR, V137, p186S, DOI 10.1093/jn/137.1.186S
   OYAIZU M, 1986, Japanese Journal of Nutrition, V44, P307
   Peng ML, 2016, J FUNCT FOODS, V24, P122, DOI 10.1016/j.jff.2016.04.006
   Ruel G, 2008, BRIT J NUTR, V99, P352, DOI 10.1017/S0007114507811986
   Ruel G, 2007, MOL NUTR FOOD RES, V51, P692, DOI 10.1002/mnfr.200600286
   Said U, 2005, ISOTOPE RAD RES, V37, P395
   Sanchez-Moreno C, 2002, FOOD SCI TECHNOL INT, V8, P121, DOI [10.1177/1082013202008003770, 10.1106/108201302026770]
   Schieber A, 2001, J CHROMATOGR A, V910, P265, DOI 10.1016/S0021-9673(00)01217-6
   Schnebelen-Berthier C, 2015, INT J FOOD SCI NUTR, V66, P222, DOI 10.3109/09637486.2014.971227
   SHIMADA K, 1992, J AGR FOOD CHEM, V40, P945, DOI 10.1021/jf00018a005
   STRUMEYER DH, 1975, J AGR FOOD CHEM, V23, P909, DOI 10.1021/jf60201a019
   Sun BS, 1998, J AGR FOOD CHEM, V46, P1390, DOI 10.1021/jf970753d
   Szajdek A, 2008, PLANT FOOD HUM NUTR, V63, P147, DOI 10.1007/s11130-008-0097-5
   Tanaka J, 2013, FOOD CHEM, V139, P129, DOI 10.1016/j.foodchem.2013.01.036
   Tanito M, 2002, INVEST OPHTH VIS SCI, V43, P2392
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Wang Chin-Kun, 1993, Journal of the Chinese Agricultural Chemical Society, V31, P623
   Wang SY, 2000, J AGR FOOD CHEM, V48, P140, DOI 10.1021/jf9908345
   Wang Y, 2015, J SCI FOOD AGR, V95, P936, DOI 10.1002/jsfa.6765
   Wilson T, 1998, LIFE SCI, V62, pPL381
   Xie ZG, 2007, CURR EYE RES, V32, P471, DOI 10.1080/02713680701257621
   Yan XJ, 2002, J AGR FOOD CHEM, V50, P5844, DOI 10.1021/jf0202234
   Yang H, 2012, CURR EYE RES, V37, P339, DOI 10.3109/02713683.2011.645106
   Youn HY, 2009, J PHOTOCH PHOTOBIO B, V95, P64, DOI 10.1016/j.jphotobiol.2009.01.001
   Zhang L, 2005, HELICOBACTER, V10, P139, DOI 10.1111/j.1523-5378.2005.00301.x
NR 50
TC 10
Z9 12
U1 5
U2 27
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1388-0209
EI 1744-5116
J9 PHARM BIOL
JI Pharm. Biol.
PY 2017
VL 55
IS 1
BP 571
EP 580
DI 10.1080/13880209.2016.1263344
PG 10
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA EG2BE
UT WOS:000390846600069
PM 27937080
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Marakis, TP
   Koutsandrea, C
   Chatzistefanou, KI
   Tountas, Y
AF Marakis, Theodoros P.
   Koutsandrea, Chrysanthi
   Chatzistefanou, Klio I.
   Tountas, Yannis
TI Reliability, validity and responsiveness of the Greek MacDQoL
   individualized measure of the impact of macular degeneration on quality
   of life
SO QUALITY OF LIFE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Quality of life; Questionnaire;
   Psychometric properties; Rasch analysis; Greece
ID LETTER-CHART; PREVALENCE; EYE; RANIBIZUMAB; CRITERIA
AB To assess the psychometric properties of the Greek Macular Disease-Dependent Quality of Life Questionnaire (MacDQoL).
   The MacDQoL was translated in Greek and administered to 191 patients with neovascular age-related macular degeneration (AMD). To assess validity, all patients completed the Greek SF-12 health survey and underwent vision measurements. For test-retest reliability, a subset of twenty participants completed the MacDQoL twice, 2 weeks apart. Responsiveness was assessed on 102 patients who completed the MacDQoL at a follow-up visit, 1 year later. Rasch analysis was used to assess the Greek MacDQoL's response category functioning, precision, unidimensionality, targeting and differential item functioning.
   Internal and test-retest reliability of the average weighted impact (AWI) was 0.952 and 0.97, respectively. Test-retest reliability of MacDQoL items ranged from 0.78 to 0.99. Principal component analysis revealed three subscales (activities, embarrassment and family life), which were also confirmed by confirmatory factor analysis. Rasch analysis revealed poor functionality of response categories and that was resolved by collapsing response categories and using the impairment scores only. In terms of convergent validity, the AWI and revised MacDQoL scales showed significant correlations with SF-12 summary scales (rho = 0.21-0.30) and vision assessments (rho = 0.31-0.46). Poorer AMD-related QoL at 1-year follow-up was associated with deterioration in distance visual acuity and worse eye near visual acuity.
   The Greek MacDQoL is a reliable, valid and sensitive to change in vision instrument for assessing AMD patients' perceptions of QoL. However, Rasch analysis revealed that its multiplicative rating scale is flawed. Scientific measurement was restored with a number of revisions to the questionnaire.
C1 [Marakis, Theodoros P.; Koutsandrea, Chrysanthi; Chatzistefanou, Klio I.] Univ Athens, Sch Med, Dept Ophthalmol 1, Athens, Greece.
   [Tountas, Yannis] Univ Athens, Sch Med, Dept Hyg & Epidemiol, Ctr Hlth Serv Res, Athens, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   Athens Medical School; National & Kapodistrian University of Athens
RP Marakis, TP (通讯作者)，Univ Athens, Sch Med, Dept Ophthalmol 1, Athens, Greece.
EM theomarakis@yahoo.gr; ancode@otenet.gr; kliochat@med.uoa.gr;
   ytountas@med.uoa.gr
CR Abdelfattah NS, 2014, INT J OPHTHALMOL-CHI, V7, P891, DOI 10.3980/j.issn.2222-3959.2014.05.27
   ARDITI A, 1993, INVEST OPHTH VIS SCI, V34, P120
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Berdeaux G, 2011, VALUE HEALTH, V14, P110, DOI 10.1016/j.jval.2010.10.027
   Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572
   Bond T.G., 2015, APPLYING RASCH MODEL, V3rd ed., DOI DOI 10.4324/9781315814698
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chien TW, 2008, RASCH MEAS T, V22, P1171
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2012, OPHTHALMOLOGY, V119, P2351, DOI 10.1016/j.ophtha.2012.05.031
   Gothwal VK, 2011, CLIN EXP OPTOM, V94, P52, DOI 10.1111/j.1444-0938.2010.00554.x
   Horton JC, 1997, SURV OPHTHALMOL, V42, P169, DOI 10.1016/S0039-6257(97)00055-6
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Kontodimopoulos N, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-55
   Labiris G, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-4
   Mitchell J., 2006, HEALTH QUAL LIFE OUT, DOI [10.1186/1477-7525-4-97, DOI 10.1186/1477-7525-4-97.]
   Mitchell J., 2006, HEALTH QUAL LIFE OUT, DOI [10.1186/1477-7525-3-25, DOI 10.1186/1477-7525-3-25.]
   Mitchell J, 2008, AM J OPHTHALMOL, V146, P447, DOI 10.1016/j.ajo.2008.04.031
   Mollazadegan K, 2014, J CATARACT REFR SURG, V40, P774, DOI 10.1016/j.jcrs.2013.10.040
   Ord LM, 2015, J CLIN MED, V4, P1841, DOI 10.3390/jcm4091841
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rosseel Y, 2012, J STAT SOFTW, V48, P1, DOI 10.18637/jss.v048.i02
   Terwee CB, 2007, J CLIN EPIDEMIOL, V60, P34, DOI 10.1016/j.jclinepi.2006.03.012
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   Wild D, 2005, VALUE HEALTH, V8, P94, DOI 10.1111/j.1524-4733.2005.04054.x
NR 28
TC 4
Z9 4
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0962-9343
EI 1573-2649
J9 QUAL LIFE RES
JI Qual. Life Res.
PD JAN
PY 2017
VL 26
IS 1
BP 183
EP 191
DI 10.1007/s11136-016-1407-2
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
   Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA EJ9TZ
UT WOS:000393571300018
PM 27614659
DA 2022-11-30
ER

PT J
AU Jha, KA
   Nag, TC
   Wadhwa, S
   Roy, TS
AF Jha, Kumar Abhiram
   Nag, Tapas C.
   Wadhwa, Shashi
   Roy, Tara Sankar
TI Expressions of visual pigments and synaptic proteins in neonatal chick
   retina exposed to light of variable photoperiods
SO JOURNAL OF BIOSCIENCES
LA English
DT Article
DE Light damage; opsins; photoreceptors; PSD-95; synaptophysin
ID RAT RETINA; MACULAR DEGENERATION; DIFFERENTIAL EXPRESSION; LONG-TERM;
   DAMAGE; ILLUMINATION; ALBINO; SYNAPTOPHYSIN; RETINOPATHY; MECHANISMS
AB Light causes damage to the retina, which is one of the supposed factors for age-related macular degeneration in human. Some animal species show drastic retinal changes when exposed to intense light (e.g. albino rats). Although birds have a pigmented retina, few reports indicated its susceptibility to light damage. To know how light influences a cone-dominated retina (as is the case with human), we examined the effects of moderate light intensity on the retina of white Leghorn chicks (Gallus g. domesticus). The newly hatched chicks were initially acclimatized at 500 lux for 7 days in 12 h light: 12 h dark cycles (12L:12D). From posthatch day (PH) 8 until PH 30, they were exposed to 2000 lux at 12L:12D, 18L:6D (prolonged light) and 24L:0D (constant light) conditions. The retinas were processed for transmission electron microscopy and the level of expressions of rhodopsin, S- and L/M cone opsins, and synaptic proteins (Synaptophysin and PSD-95) were determined by immunohistochemistry and Western blotting. Rearing in 24L:0D condition caused disorganization of photoreceptor outer segments. Consequently, there were significantly decreased expressions of opsins and synaptic proteins, compared to those seen in 12L:12D and 18L:6D conditions. Also, there were ultrastructural changes in outer and inner plexiform layer (OPL, IPL) of the retinas exposed to 24L:0D condition. Our data indicate that the cone-dominated chick retina is affected in constant light condition, with changes (decreased) in opsin levels. Also, photoreceptor alterations lead to an overall decrease in synaptic protein expressions in OPL and IPL and death of degenerated axonal processes in IPL.
C1 [Jha, Kumar Abhiram; Nag, Tapas C.; Wadhwa, Shashi; Roy, Tara Sankar] All India Inst Med Sci, Dept Anat, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi
RP Nag, TC (通讯作者)，All India Inst Med Sci, Dept Anat, New Delhi 110029, India.
EM tapas_nag@yahoo.com
RI NAG, TAPAS CHANDRA/R-6285-2019; ROY, TARA SANKAR/J-3264-2019
OI NAG, TAPAS CHANDRA/0000-0002-6962-0844; ROY, TARA
   SANKAR/0000-0002-9852-2952
FU Science and Engineering Research Board, DST, New Delhi, India
   [AS-27/2012]; UGC (New Delhi)
FX The work was financially supported by Science and Engineering Research
   Board, DST, New Delhi, India (No. AS-27/2012, TCN). KAJ received
   fellowships from UGC (New Delhi). The TEM work was carried out at SAIF,
   AIIMS, New Delhi.
CR Ashby R, 2009, INVEST OPHTH VIS SCI, V50, P5348, DOI 10.1167/iovs.09-3419
   Basha AA, 2014, ANN ANAT, V196, P312, DOI 10.1016/j.aanat.2014.04.004
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cebulla CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044257
   Cohen Y, 2011, EXP EYE RES, V92, P40, DOI 10.1016/j.exer.2010.10.012
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dagar S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090250
   El-Hussein AE, 2000, SCIENCE, V290, P1364
   Gabilondo I, 2015, ANN NEUROL, V77, P517, DOI 10.1002/ana.24351
   Garcia-Martin E, 2014, AM J OPHTHALMOL, V157, P470, DOI 10.1016/j.ajo.2013.09.028
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   Hart NS, 2006, J EXP BIOL, V209, P4776, DOI 10.1242/jeb.02568
   Hart NS, 2001, PROG RETIN EYE RES, V20, P675, DOI 10.1016/S1350-9462(01)00009-X
   Hering H, 1996, J COMP NEUROL, V375, P393, DOI 10.1002/(SICI)1096-9861(19961118)375:3<393::AID-CNE4>3.0.CO;2-Y
   Jha KA, 2015, NEUROCHEM RES, V40, P2153, DOI 10.1007/s11064-015-1698-7
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Kihara AH, 2008, NEUROSCIENCE, V151, P995, DOI 10.1016/j.neuroscience.2007.09.088
   Koulen P, 1998, J NEUROSCI, V18, P10136
   Kumar V, 2014, NEUROSCIENCE, V269, P302, DOI 10.1016/j.neuroscience.2014.03.061
   Li F, 2001, EXP EYE RES, V73, P569, DOI 10.1006/exer.2001.1068
   Li T, 2000, VISION RES, V40, P2387, DOI 10.1016/S0042-6989(00)00098-5
   LI T, 1995, VISION RES, V35, P1203, DOI 10.1016/0042-6989(94)00231-A
   Linberg KA, 2002, VISUAL NEUROSCI, V19, P603, DOI 10.1017/S095252380219506X
   Marc RE, 2008, MOL VIS, V14, P782
   MARSHALL J, 1972, EXP EYE RES, V14, P164, DOI 10.1016/0014-4835(72)90063-2
   Montiani-Ferreira F, 2005, MOL VIS, V11, P11
   MORRIS VB, 1967, J COMP NEUROL, V129, P313, DOI 10.1002/cne.901290404
   Nag TC, 2012, MICRON, V43, P759, DOI 10.1016/j.micron.2012.01.011
   Nag TC, 2001, J BIOSCIENCES, V26, P179, DOI 10.1007/BF02703642
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Organisciak DT, 1998, INVEST OPHTH VIS SCI, V39, P1107
   PENN JS, 1989, EXP EYE RES, V49, P205, DOI 10.1016/0014-4835(89)90091-2
   PEREZ J, 1994, EXP TOXICOL PATHOL, V46, P229, DOI 10.1016/S0940-2993(11)80088-6
   Read SA, 2015, INVEST OPHTH VIS SCI, V56, P6779, DOI 10.1167/iovs.14-15978
   Reese CD, 2008, IND SAFETY HLTH ADM
   Sanyal T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067347
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Sze CI, 1997, J NEUROPATH EXP NEUR, V56, P933, DOI 10.1097/00005072-199708000-00011
   SZEL A, 1992, EXP EYE RES, V55, P47
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   VanGuilder HD, 2008, EUR J NEUROSCI, V28, P1, DOI 10.1111/j.1460-9568.2008.06322.x
   Wang X, 2002, HISTOL HISTOPATHOL, V17, P1043, DOI 10.14670/HH-17.1043
   Wasowicz M, 2002, INVEST OPHTH VIS SCI, V43, P813
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
NR 47
TC 1
Z9 2
U1 0
U2 11
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0250-5991
EI 0973-7138
J9 J BIOSCIENCES
JI J. Biosci.
PD DEC
PY 2016
VL 41
IS 4
BP 667
EP 676
DI 10.1007/s12038-016-9637-6
PG 10
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA EF1BP
UT WOS:000390060400009
PM 27966487
DA 2022-11-30
ER

PT J
AU Holz, FG
   Tadayoni, R
   Beatty, S
   Berger, AR
   Cereda, MG
   Hykin, P
   Staurenghi, G
   Wittrup-Jensen, K
   Nilsson, J
   Kim, K
   Sivaprasad, S
AF Holz, F. G.
   Tadayoni, R.
   Beatty, S.
   Berger, A. R.
   Cereda, M. G.
   Hykin, P.
   Staurenghi, G.
   Wittrup-Jensen, K.
   Nilsson, J.
   Kim, K.
   Sivaprasad, S.
TI Determinants of visual acuity outcomes in eyes with neovascular AMD
   treated with anti-VEGF agents: an instrumental variable analysis of the
   AURA study
SO EYE
LA English
DT Article
ID MACULAR DEGENERATION; WEAK INSTRUMENTS; RANIBIZUMAB; SAFETY; EFFICACY;
   RETINA
AB Purpose To identify the strongest variable(s) linked with the number of ranibizumab injections and outcomes in AURA, and to identify ways to improve outcomes using this association.
   Methods AURA was a large observational study that monitored visual acuity over a 2-year period in patients with neovascular age-related macular degeneration (AMD) who received ranibizumab injections. Baseline characteristics, resource use, and outcomes were analyzed using an instrumental variable approach and regression analysis.
   Results Data were analyzed from 2227 patients enrolled in AURA. Optical coherence tomography (OCT) and ophthalmoscopy were the most common diagnostic tests used, and this combination was the strongest instrumental variable. Use of OCT and ophthalmoscopy affected the number of injections given and resulted in an increase in visual acuity gains from baseline of 17.6 letters in year 1 and 2.5 letters in year 2. Regression models using the instrumental variable (OCT and ophthalmoscopy combined) showed that >= 5.1 (95% CI: 3.3-11.4) ranibizumab injections were needed to maintain visual acuity from baseline to year 1 and >= 8.3 (95% CI: 5.3-18.8) injections were needed to maintain visual acuity from year 1 to year 2. To gain >= 15 letters, >= 7.9 (95% CI: 5.1-17.5) ranibizumab injections would be needed in year 1 and >= 16.1 (95% CI: 10.3-36.4) injections would be needed over 2 years.
   Conclusions These findings highlight the role that regular monitoring plays in guiding neovascular AMD therapy and they showed that the number of ranibizumab injections needed to maintain visual acuity is higher than that administered in AURA.
C1 [Holz, F. G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Tadayoni, R.] Hop Lariboisiere, Dept Ophthalmol, Paris, France.
   [Beatty, S.] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland.
   [Berger, A. R.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Berger, A. R.] St Michaels Hosp, Toronto, ON, Canada.
   [Cereda, M. G.; Staurenghi, G.] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, Luigi Sacco Hosp, Milan, Italy.
   [Hykin, P.; Sivaprasad, S.] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England.
   [Wittrup-Jensen, K.] Bayer Pharmaceut, Berlin, Germany.
   [Nilsson, J.] Mapi Grp, Real World Strategy & Anal, Stockholm, Sweden.
   [Kim, K.] AstraZeneca Nord Balt, Hlth Econ, Sodertalje, Sweden.
   [Sivaprasad, S.] Kings Coll Hosp London, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
C3 University of Bonn; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research
   Universities; Universite Paris Cite; University of Toronto; University
   of Toronto; University Toronto Affiliates; Saint Michaels Hospital
   Toronto; University of Milan; Luigi Sacco Hospital; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; Bayer AG; Bayer Healthcare Pharmaceuticals;
   AstraZeneca; King's College Hospital NHS Foundation Trust; King's
   College Hospital
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015; Staurenghi, Giovanni/K-4388-2017
OI Sivaprasad, S./0000-0001-8952-0659; Staurenghi,
   Giovanni/0000-0002-2299-5251
FU Bayer Pharmaceuticals, Leverkusen, Germany; Bayer Pharmaceuticals
FX The AURA study was funded by Bayer Pharmaceuticals, Leverkusen, Germany.
   Medical writing assistance was provided by S Phillips, PhD, from
   PAREXEL, and was funded by Bayer Pharmaceuticals.
CR Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brookhart MA, 2010, PHARMACOEPIDEM DR S, V19, P537, DOI 10.1002/pds.1908
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burgess S, 2012, STAT MED, V31, P1582, DOI 10.1002/sim.4498
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Greenland S, 2000, INT J EPIDEMIOL, V29, P1102, DOI 10.1093/oxfordjournals.ije.a019909
   Hariprasad SM, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/690641
   Hassenstein A, 2009, OPHTHALMOLOGE, V106, P116, DOI 10.1007/s00347-008-1901-1
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Lin WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127454
   Little RJ, 2000, ANNU REV PUBL HEALTH, V21, P121, DOI 10.1146/annurev.publhealth.21.1.121
   Maeda JLK, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-378
   Martens EP, 2006, EPIDEMIOLOGY, V17, P260, DOI 10.1097/01.ede.0000215160.88317.cb
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Scientific Department The Royal College of Ophthalmologists, AG REL MAC DEG GUID
   Staiger D, 1997, ECONOMETRICA, V65, P557, DOI 10.2307/2171753
   Theil Henri., 1971, PRINCIPLES ECONOMETR, V1st
   Zohoori N, 1997, ANN EPIDEMIOL, V7, P251, DOI 10.1016/S1047-2797(97)00023-9
NR 26
TC 37
Z9 37
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2016
VL 30
IS 8
BP 1063
EP 1071
DI 10.1038/eye.2016.90
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DZ7EL
UT WOS:000386027400007
PM 27197868
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Luhmann, UFO
   Carvalho, LS
   Robbie, SJ
   Cowing, JA
   Duran, Y
   Munro, PMG
   Bainbridge, JWB
   Ali, RR
AF Luhmann, Ulrich F. O.
   Carvalho, Livia S.
   Robbie, Scott J.
   Cowing, Jill A.
   Duran, Yanai
   Munro, Peter M. G.
   Bainbridge, James W. B.
   Ali, Robin R.
TI Ccl2, Cx3cr1 and Ccl2/Cx3cr1 chemokine deficiencies are not sufficient
   to cause age-related retinal degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE chemokine knockout mice; Ccl2/Cx3cr1 double knockout mice; Ccl2; Cx3cr1;
   age-related macular degeneration; retinal degeneration; subretinal
   macrophages; genetic background
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; MICROGLIAL CELLS; TRANSENDOTHELIAL
   MIGRATION; DENDRITIC CELLS; MACROPHAGES; SUBSETS; ACCUMULATION;
   RECRUITMENT; EXPRESSION; MODEL
AB Monocytes, macrophages, dendritic cells and microglia play critical roles in the local immune response to acute and chronic tissue injury and have been implicated in the pathogenesis of age-related macular degeneration. Defects in Ccl2-Ccr2 and Cx3cl1-Cx3cr1 chemokine signalling cause enhanced accumulation of bloated subretinal microglia/macrophages in senescent mice and this phenomenon is reported to result in the acceleration of age-related retinal degeneration. The purpose of this study was to determine whether defects in CCL2-CCR2 and CX3CL1-CX3CR1 signalling pathways, alone or in combination, cause age-dependent retinal degeneration. We tested whether three chemokine knockout mouse lines, Ccl2(-/-), Cx3cr1(-/-) and Ccl2(-/-)/Cx3cr1(-/-), in comparison to age-matched C57Bl/6 control mice show differences in subretinal macrophage accumulation and loss of adjacent photoreceptor cells at 12-14 months of age. All mouse lines are derived from common parental strains and do not carry the homozygous rd8 mutation in the Crb1 gene that has been a major confounding factor in previous reports. We quantified subretinal macrophages by counting autofluorescent lesions in fundus images obtained by scanning laser ophthalmoscopy (AF-SLO) and by immunohistochemistry for Iba1 positive cells. The accumulation of subretinal macrophages was enhanced in Ccl2(-/-), but not in Cx3cr1(-/-) or Ccl2(-/-)/Cx3cr1(-/-) mice. We identified no evidence of retinal degeneration in any of these mouse lines by TUNEL staining or semithin histology. In conclusion, CCL2-CCR2 and/or CX3CL1-CX3CR1 signalling defects may differentially affect the trafficking of microglia and macrophages in the retina during ageing, but do not appear to cause age-related retinal degeneration in mice. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Luhmann, Ulrich F. O.; Carvalho, Livia S.; Robbie, Scott J.; Cowing, Jill A.; Duran, Yanai; Bainbridge, James W. B.; Ali, Robin R.] UCL Inst Ophthalmol, Dept Genet, London EC1V 9EL, England.
   [Munro, Peter M. G.] UCL Inst Ophthalmol, Imaging Unit, London EC1V 9EL, England.
   [Bainbridge, James W. B.; Ali, Robin R.] NIHR Biomed Res Ctr Ophthalmol, London, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London
RP Luhmann, UFO (通讯作者)，UCL Inst Ophthalmol, Dept Genet, 11-43 Bath St, London EC1V 9EL, England.
EM u.luhmann@ucl.ac.uk
RI Carvalho, Livia/B-4984-2013
OI Bainbridge, James/0000-0003-1318-8201; Carvalho,
   Livia/0000-0002-3909-5778; Ali, Robin/0000-0003-3126-6517
FU Wellcome Trust [WT074617]; National Institute for Health Research
   [NIHR-RP-011-003, NF-SI-0508-10130] Funding Source: researchfish
FX This project was supported by the Wellcome Trust (WT074617). The funders
   had no role in study design, data collection and analysis, decision to
   publish or preparation of the manuscript.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883
   Auffray C, 2009, ANNU REV IMMUNOL, V27, P669, DOI 10.1146/annurev.immunol.021908.132557
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715
   CASPI RR, 1992, J IMMUNOL, V148, P2384
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Duisit G, 2002, MOL THER, V6, P446, DOI 10.1006/mthe.2002.0690
   Dzenko KA, 2005, MICROVASC RES, V70, P53, DOI 10.1016/j.mvr.2005.04.005
   Eter N, 2008, INVEST OPHTH VIS SCI, V49, P3649, DOI 10.1167/iovs.07-1322
   Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Huang DR, 2002, J NEUROSCI, V22, P10633
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000
   Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Luhmann UFO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035551
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   McMenamin PG, 1999, BRIT J OPHTHALMOL, V83, P598, DOI 10.1136/bjo.83.5.598
   Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Paques M, 2010, GLIA, V58, P1663, DOI 10.1002/glia.21037
   RANDOLPH GJ, 1995, J IMMUNOL, V155, P3610
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-30
   Tacke F, 2006, IMMUNOBIOLOGY, V211, P609, DOI 10.1016/j.imbio.2006.05.025
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yona S, 2010, CURR OPIN HEMATOL, V17, P53, DOI 10.1097/MOH.0b013e3283324f80
NR 39
TC 37
Z9 37
U1 0
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2013
VL 107
BP 80
EP 87
DI 10.1016/j.exer.2012.11.015
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 082IJ
UT WOS:000314385200011
PM 23232206
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Wickremasinghe, SS
   Busija, L
   Guymer, RH
   Wong, TY
   Qureshi, S
AF Wickremasinghe, Sanjeewa S.
   Busija, Lucy
   Guymer, Robyn H.
   Wong, Tien Y.
   Qureshi, Salmaan
TI Retinal Venular Caliber Predicts Visual Outcome after Intravitreal
   Ranibizumab Injection Treatments for Neovascular AMD
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CARDIOVASCULAR RISK-FACTORS; MACULAR
   DEGENERATION; VASCULAR CALIBER; SUBGROUP ANALYSIS; VESSEL CALIBER;
   EXPRESSION
AB PURPOSE. To examine whether baseline retinal vascular caliber predicts visual response to intravitreal ranibizumab injections in patients with neovascular age-related macular degeneration (AMD).
   METHODS. In this prospective cohort study, patients with neovascular AMD received three monthly intravitreal injections of ranibizumab, followed by as needed dosing up to 1 year. Retinal vascular caliber was measured from digital fundus photographs at baseline and summarized as central retinal artery equivalent (CRAE) and venular equivalent (CRVE), representing average caliber of arterioles and venules, respectively. Visual outcome at 12 months was assessed and the relation to baseline retinal vascular caliber was determined.
   RESULTS. A total of 88 eyes were analyzed at baseline. After accounting for age, sex, size of choroidal neovascularization, and number of injections, patients who deteriorated in visual acuity at 12 months had significantly larger baseline CRVE, 243.10 mu m (95% confidence interval [CI], 227.01-259.19), compared with those who were stable, 214.30 mu m (95% CI, 205.79-222.81) and those who improved, 215.26 mu m (95% CI, 204.69-225.84; P = 0.007). Baseline CRAE did not differ significantly from eyes whose vision deteriorated, 150.12 mu m (95% CI, 140.67-159.57), compared with those remaining stable, 143.64 mu m (95% CI, 138.64-148.63), or gaining vision 142.92 mu m (95% CI, 136.71-149.13; P = 0.69).
   CONCLUSIONS. In eyes with neovascular AMD treated with intravitreal ranibizumab, larger baseline retinal venular caliber was significantly associated with a poorer response to treatment, possibly reflecting increased disease severity. (Invest Ophthalmol Vis Sci. 2012;53:37-41) DOI:10.1167/iovs.11-7689
C1 [Wickremasinghe, Sanjeewa S.; Busija, Lucy; Guymer, Robyn H.; Wong, Tien Y.; Qureshi, Salmaan] Univ Melbourne, Royal Victorian Eye & Ear Hosp Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
C3 Centre for Eye Research Australia; University of Melbourne; National
   University of Singapore; Singapore National Eye Center
RP Wong, TY (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020; Busija, Lucy/Y-6064-2019
OI Wong, Tien Yin/0000-0002-8448-1264; Busija, Lucy/0000-0001-7464-9089;
   Guymer, Robyn/0000-0002-9441-4356
FU Novartis; National Health and Medical Research Council [52993]
FX Supported in part by a Novartis fellowship (SSW), National Health and
   Medical Research Council Grant 52993, and Operational Infrastructure
   Support from the Victorian Government to the Centre for Eye Research
   Australia.
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   BENGTSSON B, 1992, GRAEF ARCH CLIN EXP, V230, P24, DOI 10.1007/BF00166758
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Bylsma G, 2006, CLIN EXP OPHTHALMOL, V34, P388, DOI 10.1111/j.1442-9071.2006.01231.x
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Knudtson MD, 2003, CURR EYE RES, V27, P143, DOI 10.1076/ceyr.27.3.143.16049
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   McGeechan K, 2009, AM J EPIDEMIOL, V170, P1323, DOI 10.1093/aje/kwp306
   McGeechan K, 2009, ANN INTERN MED, V151, P404, DOI 10.7326/0003-4819-151-6-200909150-00005
   Mendrinos E, 2011, INVEST OPHTHALM 1213
   Nguyen TT, 2010, STROKE, V41, P1343, DOI 10.1161/STROKEAHA.110.581017
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sun C, 2008, INVEST OPHTH VIS SCI, V49, P1784, DOI 10.1167/iovs.07-1450
   Sun C, 2009, SURV OPHTHALMOL, V54, P74, DOI 10.1016/j.survophthal.2008.10.003
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Wong TY, 2006, ARCH INTERN MED, V166, P2388, DOI 10.1001/archinte.166.21.2388
   Wong TY, 2006, INVEST OPHTH VIS SCI, V47, P2341, DOI 10.1167/iovs.05-1539
NR 28
TC 11
Z9 14
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2012
VL 53
IS 1
BP 37
EP 41
DI 10.1167/iovs.11-7689
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 924LY
UT WOS:000302694500005
PM 22110075
OA Green Published
DA 2022-11-30
ER

PT J
AU Sapieha, P
   Stahl, A
   Chen, J
   Seaward, MR
   Willett, KL
   Krah, NM
   Dennison, RJ
   Connor, KM
   Aderman, CM
   Liclican, E
   Carughi, A
   Perelman, D
   Kanaoka, Y
   SanGiovanni, JP
   Gronert, K
   Smith, LEH
AF Sapieha, Przemyslaw
   Stahl, Andreas
   Chen, Jing
   Seaward, Molly R.
   Willett, Keirnan L.
   Krah, Nathan M.
   Dennison, Roberta J.
   Connor, Kip M.
   Aderman, Christopher M.
   Liclican, Elvira
   Carughi, Arianna
   Perelman, Dalia
   Kanaoka, Yoshihide
   SanGiovanni, John Paul
   Gronert, Karsten
   Smith, Lois E. H.
TI 5-Lipoxygenase Metabolite 4-HDHA Is a Mediator of the Antiangiogenic
   Effect of omega-3 Polyunsaturated Fatty Acids
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID OXYGEN-INDUCED RETINOPATHY; ACTIVATED-RECEPTOR-GAMMA; LIPID MEDIATORS;
   RETINAL NEOVASCULARIZATION; DOCOSAHEXAENOIC ACID; ANTIINFLAMMATORY
   ACTIONS; MYOCARDIAL-INFARCTION; ANTI-INFLAMMATION; PROTECTIN D1;
   PPAR-GAMMA
AB Lipid signaling is dysregulated in many diseases with vascular pathology, including cancer, diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration. We have previously demonstrated that diets enriched in omega-3 polyunsaturated fatty acids (PUFAs) effectively reduce pathological retinal neovascularization in a mouse model of oxygen-induced retinopathy, in part through metabolic products that suppress microglialderived tumor necrosis factor-alpha. To better understand the protective effects of omega-3 PUFAs, we examined the relative importance of major lipid metabolic pathways and their products in contributing to this effect. omega-3 PUFA diets were fed to four lines of mice deficient in each key lipid-processing enzyme (cyclooxygenase 1 or 2, or lipoxygenase 5 or 12/15), retinopathy was induced by oxygen exposure; only loss of 5-lipoxygenase (5-LOX) abrogated the protection against retinopathy of dietary omega-3 PUFAs. This protective effect was due to 5-LOX oxidation of the omega-3 PUFA lipid docosahexaenoic acid to 4-hydroxy-docosahexaenoic acid (4-HDHA). 4-HDHA directly inhibited endothelial cell proliferation and sprouting angiogenesis via peroxisome proliferator-activated receptor gamma (PPAR gamma), independent of 4-HDHA's anti-inflammatory effects. Our study suggests that omega-3 PUFAs may be profitably used as an alternative or supplement to current anti-vascular endothelial growth factor (VEGF) treatment for proliferative retinopathy and points to the therapeutic potential of omega-3 PUFAs and metabolites in other diseases of vasoproliferation. It also suggests that cyclooxygenase inhibitors such as aspirin and ibuprofen (but not lipoxygenase inhibitors such as zileuton) might be used without losing the beneficial effect of dietary omega-3 PUFA.
C1 [Sapieha, Przemyslaw; Stahl, Andreas; Chen, Jing; Seaward, Molly R.; Willett, Keirnan L.; Krah, Nathan M.; Dennison, Roberta J.; Connor, Kip M.; Aderman, Christopher M.; Smith, Lois E. H.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Ophthalmol, Boston, MA 02115 USA.
   [Sapieha, Przemyslaw] Univ Montreal, Maisonneuve Rosemont Hosp Res Ctr, Dept Ophthalmol, Montreal, PQ H1T 2M4, Canada.
   [Stahl, Andreas] Univ Eye Hosp Freiburg, D-79106 Freiburg, Germany.
   [Liclican, Elvira; Gronert, Karsten] Univ Calif Berkeley, Sch Optometry, Vis Sci Program, Berkeley, CA 94720 USA.
   [Carughi, Arianna; Perelman, Dalia] Hlth Res & Studies Ctr, Los Altos, CA 94022 USA.
   [Carughi, Arianna; Perelman, Dalia] Palo Alto Med Fdn, Palo Alto, CA 94301 USA.
   [Kanaoka, Yoshihide] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
   [Kanaoka, Yoshihide] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [SanGiovanni, John Paul] NEI, Div Epidemiol & Clin Res, Bethesda, MD 20892 USA.
C3 Harvard University; Boston Children's Hospital; Harvard Medical School;
   Universite de Montreal; University of Freiburg; University of California
   System; University of California Berkeley; Palo Alto Medical Foundation
   Research Institute; Harvard University; Harvard Medical School; Harvard
   University; Brigham & Women's Hospital; National Institutes of Health
   (NIH) - USA; NIH National Eye Institute (NEI)
RP Smith, LEH (通讯作者)，Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.
EM lois.smith@childrens.harvard.edu
RI SanGiovanni, John Paul/AAU-3895-2020
OI Connor, Kip/0000-0002-2048-9080
FU NIH [EY017017, EY017017-04S1, EY016136]; Children's Hospital Boston
   Mental Retardation and Developmental Disabilities Research Center [P01
   HD18655]; Research to Prevent Blindness; Alcon Research Institute;
   MacTel Foundation; Roche Foundation for Anemia Research; V. Kann
   Rasmussen Foundation; Canadian Institutes of Health Research; Charles A.
   King Trust; Canadian National Institute for the Blind; Deutsche
   Forschungsgemeinschaft; Juvenile Diabetes Research Foundation
   International; William Randolph Hearst Award [F32 EY017789]; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT
   [P30HD018655] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY022275, F32EY017789, R01EY016136, R01EY017017] Funding Source: NIH
   RePORTER
FX This work was supported by NIH grants EY017017, EY017017-04S1 (L. E. H.
   S.), and EY016136 (K. G.); Children's Hospital Boston Mental Retardation
   and Developmental Disabilities Research Center grant P01 HD18655 (L. E.
   H. S.); Research to Prevent Blindness Senior Investigator Award (L. E.
   H. S.); Alcon Research Institute Award (L. E. H. S.); MacTel Foundation
   (L. E. H. S.); Roche Foundation for Anemia Research (L. E. H. S.); and
   V. Kann Rasmussen Foundation (L. E. H. S.). P. S. holds a Canada
   Research Chair in Retinal Cell Biology and is supported by grants from
   the Canadian Institutes of Health Research, the Charles A. King Trust
   Award, and the Canadian National Institute for the Blind. A. S. is
   funded by Deutsche Forschungsgemeinschaft. Additional support was
   provided by the Juvenile Diabetes Research Foundation International
   (J.C.), the William Randolph Hearst Award F32 EY017789 (K.M.C.).
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987
   Austen K Frank, 2005, Novartis Found Symp, V271, P166
   Bazan NG, 2009, PROSTAG LEUKOTR ESS, V81, P205, DOI 10.1016/j.plefa.2009.05.024
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   Brault S, 2007, AM J PHYSIOL-REG I, V292, pR1174, DOI 10.1152/ajpregu.00619.2006
   Chen Jing, 2007, Angiogenesis, V10, P133, DOI 10.1007/s10456-007-9066-0
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Diau GY, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-11
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Gonzalez-Periz A, 2006, FASEB J, V20, P2537, DOI 10.1096/fj.06-6250fje
   Gonzalez-Periz A, 2009, FASEB J, V23, P1946, DOI 10.1096/fj.08-125674
   Graham DJ, 2010, JAMA-J AM MED ASSOC, V304, P411, DOI 10.1001/jama.2010.920
   Gronert K, 1999, METH MOL B, V120, P119
   Gronert K, 2008, MOL INTERV, V8, P28, DOI 10.1124/mi.8.1.7
   Hardy P, 2005, PROSTAG LEUKOTR ESS, V72, P301, DOI 10.1016/j.plefa.2005.02.004
   Hassan IR, 2009, J IMMUNOL, V182, P3223, DOI 10.4049/jimmunol.0802064
   Holman RT, 1998, J NUTR, V128, p427S, DOI 10.1093/jn/128.2.427S
   Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200
   Itoh T, 2008, NAT STRUCT MOL BIOL, V15, P924, DOI 10.1038/nsmb.1474
   Itoh T, 2008, N-S ARCH PHARMACOL, V377, P541, DOI 10.1007/s00210-007-0251-x
   Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200
   Kang JX, 2004, NATURE, V427, P504, DOI 10.1038/427504a
   Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341
   Lee JH, 2009, NAT REV CARDIOL, V6, P753, DOI 10.1038/nrcardio.2009.188
   Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581
   LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953
   Letts L G, 1987, Cardiovasc Clin, V18, P101
   Liu D, 2005, INFLAMM RES, V54, P464, DOI 10.1007/s00011-005-1379-0
   Majos A, 2011, NEURORADIOLOGY, V53, P523, DOI 10.1007/s00234-010-0809-z
   Moriguchi T, 2004, J LIPID RES, V45, P1437, DOI 10.1194/jlr.M400087-JLR200
   Murata T, 2001, ARCH OPHTHALMOL-CHIC, V119, P709, DOI 10.1001/archopht.119.5.709
   Murphy RC, 2005, ANAL BIOCHEM, V346, P1, DOI 10.1016/j.ab.2005.04.042
   Murphy RC, 2007, BIOCHEM J, V405, P379, DOI 10.1042/BJ20070289
   Osher E, 2006, MOL CELL ENDOCRINOL, V252, P201, DOI 10.1016/j.mce.2006.03.038
   Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873
   Sapieha P, 2010, J CLIN INVEST, V120, P3022, DOI 10.1172/JCI42142
   Sapieha P, 2010, INT J BIOCHEM CELL B, V42, P5, DOI 10.1016/j.biocel.2009.10.006
   Schmitz G, 2008, PROG LIPID RES, V47, P147, DOI 10.1016/j.plipres.2007.12.004
   Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294
   Serhan CN, 2007, METHOD ENZYMOL, V432, P275, DOI 10.1016/S0076-6879(07)32012-0
   Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647
   Serhan CN, 2005, PROSTAG LEUKOTR ESS, V73, P141, DOI 10.1016/j.plefa.2005.05.002
   Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276
   Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760
   SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335
   Serhan CN, 2000, E SCHERING RES FDN W, V31, P143
   Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197
   Shen LQ, 2008, ARCH OPHTHALMOL-CHIC, V126, P793, DOI 10.1001/archopht.126.6.793
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith Lois E H, 2003, Semin Neonatol, V8, P469, DOI 10.1016/S1084-2756(03)00119-2
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Stahl A, 2009, ANGIOGENESIS, V12, P297, DOI 10.1007/s10456-009-9155-3
   Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176
   Tjonahen E, 2006, CHEM BIOL, V13, P1193, DOI 10.1016/j.chembiol.2006.09.011
   Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335
   Yli-Jama P, 2002, J INTERN MED, V251, P19, DOI 10.1046/j.1365-2796.2002.00922.x
NR 63
TC 187
Z9 194
U1 2
U2 22
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD FEB 9
PY 2011
VL 3
IS 69
AR 69ra12
DI 10.1126/scitranslmed.3001571
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 795JS
UT WOS:000292971100004
PM 21307302
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Steinle, JJ
   Lashbrook, BL
AF Steinle, Jena J.
   Lashbrook, Bethany L.
TI Cervical sympathectomy regulates expression of key angiogenic factors in
   the rat choroid
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE sympathetic nerves; adrenergic receptors; blood vessels; macular
   degeneration; vascular remodeling; choroid
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; BLOOD-FLOW;
   RECEPTOR; VEGF; ANGIOPOIETIN-1; STIMULATION; CONTRIBUTES; INHIBITOR
AB Age-related macular degeneration is the leading cause of blindness in people over the age of 55. In addition to an increased risk of vision loss due to macular degeneration, aging results in a substantial loss of sympathetic nerve activity. We have previously shown that loss of sympathetic nerve activity to the eye causes significant remodeling of the choroidal vasculature. The hypothesis of the present study was that the choroidal remodeling noted after sympathectomy was due to alterations in key angiogenic growth factors. To test this hypothesis, female Sprague-Dawley rats underwent superior cervical ganglionectomy, which eliminates all sympathetic innervation to the eye. Six weeks after surgery, eyes were removed, and the choroidal tissue was processed for real-time PCR to measure gene expression and western blot analysis to assess protein expression. Gene and protein expression were significantly increased for vascular endothelial growth factor (VEGF) and pigment epithelial-derived growth factor (PEDF) in the sympathectomized eye, as compared to the contralateral eye (P < 0.05). Protein expression was increased 4-fold for angiopoietin1, with no change in steady-state gene expression. For both p53 and placental growth factor, steady-state mRNA levels were significantly decreased, while protein expression was significantly increased. Protein expression for Flt-1 was decreased significantly, with reduced gene expression. These results suggest that the vascular remodeling noted in the choroidal blood vessels after sympathectomy is a complex process involving numerous growth factor families. Therefore, modulation of sympathetic nerve activity may be a suitable mechanism to prevent the vascular growth associated with macular degeneration. (c) 2006 Elsevier Ltd. All rights reserved.
C1 So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA.
C3 Southern Illinois University System; Southern Illinois University
RP Steinle, JJ (通讯作者)，So Illinois Univ, Sch Med, Dept Physiol, 1135 Lincoln Dr,LSIII,Room 2071, Carbondale, IL 62901 USA.
EM jsteinle@siumed.edu
OI Steinle, Jena/0000-0002-7539-2892
CR Apte RS, 2004, INVEST OPHTH VIS SCI, V45, P4491, DOI 10.1167/iovs.04-0172
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BURNSTOCK G, 1990, J AUTONOM NERV SYST, V30, pS25, DOI 10.1016/0165-1838(90)90096-2
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Castello R, 2002, CLIN CHEM, V48, P1288
   Chandrasekar B, 2004, BIOCHEM BIOPH RES CO, V319, P304, DOI 10.1016/j.bbrc.2004.04.185
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   Headley VV, 2004, MOL CELL BIOCHEM, V258, P109, DOI 10.1023/B:MCBI.0000012841.03400.42
   Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035
   Jiang YL, 2004, JPN J OPHTHALMOL, V48, P106, DOI 10.1007/s10384-003-0043-x
   Joussen AM, 2001, GRAEF ARCH CLIN EXP, V239, P972, DOI 10.1007/s004170100365
   KIEL JW, 1995, INVEST OPHTH VIS SCI, V36, P579
   Kumar R, 1998, INT J ONCOL, V12, P749
   Lashbrook BL, 2005, AUTON NEUROSCI-BASIC, V121, P33, DOI 10.1016/j.autneu.2005.05.006
   Lutty G, 1999, MOL VIS, V5
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Ottino P, 2002, EXP EYE RES, V74, P393, DOI 10.1006/exer.2001.1135
   Perrino C, 2005, J AM COLL CARDIOL, V45, P1862, DOI 10.1016/j.jacc.2005.02.062
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rechtman Ehud, 2002, Expert Opin Pharmacother, V3, P931, DOI 10.1517/14656566.3.7.931
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Steinle JJ, 2000, J PHARMACOL EXP THER, V294, P627
   Steinle JJ, 2000, AM J PHYSIOL-REG I, V279, pR202, DOI 10.1152/ajpregu.2000.279.1.R202
   Steinle JJ, 2002, EXP EYE RES, V74, P761, DOI 10.1006/exer.2002.1182
   Steinle JJ, 2002, BRIT J PHARMACOL, V136, P730, DOI 10.1038/sj.bjp.0704771
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9
   Thurston G, 2005, DEVELOPMENT, V132, P3317, DOI 10.1242/dev.01888
   Wiley LA, 2006, INVEST OPHTH VIS SCI, V47, P439, DOI 10.1167/iovs.05-0656
   Yao YG, 2005, FEBS LETT, V579, P1227, DOI 10.1016/j.febslet.2005.01.017
NR 34
TC 12
Z9 12
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2006
VL 83
IS 1
BP 16
EP 23
DI 10.1016/j.exer.2005.11.006
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 054WD
UT WOS:000238408400003
PM 16487969
DA 2022-11-30
ER

PT J
AU Maturi, RK
   Bleau, LA
   Wilson, DL
AF Maturi, Raj K.
   Bleau, Laura A.
   Wilson, Donald L.
TI Electrophysiologic findings after intravitreal bevacizumab (Avastin)
   treatment
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; Avastin; multifocal electroretinography; Ganzfeld
   electroretinography; monoclonal antibodies; macular degeneration
ID COHERENCE TOMOGRAPHY FINDINGS; ELECTRORETINOGRAM; INJECTION
AB Purpose: To evaluate the short-term electrophysiologic effects of intravitreal bevacizumab in the treatment of exudative age-related macular degeneration (AMD).
   Methods: Nine subjects with AMD who received treatment with intravitreal bevacizumab for exudative AMD underwent pretreatment testing with multifocal electroretinography (mf-ERG) or Ganzfeld electroretinography (G-ERG). All five G-ERG subjects underwent repeated testing at 1 week after intravitreal bevacizumab. All four mf-ERG subjects and four of the five G-ERG subjects underwent repeated testing with the same pretreatment protocol at 1 month after treatment. One G-ERG subject also received a second intravitreal injection of bevacizumab at 6 weeks after initial treatment and underwent repeated testing at 1 month after the second dose (3 months after initial treatment).
   Results: All four subjects undergoing mf-ERG had improvement of the macular response at 1 month of after treatment. The average improvement in response density of the central 15 degrees of macular response was 35% (range, 11-65%). Subjects undergoing G-ERG testing had no significant changes in electrophysiologic response, although some variation in amplitude and implicit time was noted at different testing times. Optical coherence tomography central subfield thickness decreased from 298 mu m at baseline to 274 mu m at 1 month after treatment. Visual acuity improved in a majority of subjects.
   Conclusion: In this study, the intravitreal use of bevacizumab resulted in improvement of mf-ERG macular function responses and relatively stable G-ERG responses. The macular electrophysiologic response suggests that macular function improves with treatment. G-ERG suggests that there is no significant measurable photoreceptor toxicity with the use of intravitreal bevacizumab over the short term.
C1 Midwest Eye Inst, Vitreo Retinal Serv, Indianapolis, IN 46280 USA.
RP Maturi, RK (通讯作者)，Midwest Eye Inst, Vitreo Retinal Serv, 201 Penn Pkwy, Indianapolis, IN 46280 USA.
EM rmaturi@indyretina.com
CR Grover S, 2003, OPHTHALMOLOGY, V110, P1159, DOI 10.1016/S0161-6420(03)00253-7
   Palmowski AM, 2002, OPHTHALMOLOGY, V109, P1788, DOI 10.1016/S0161-6420(02)01147-8
   Regillo CD, 2003, RETINA OPTIC NERVE I, P213
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Terasaki H, 2002, INVEST OPHTH VIS SCI, V43, P452
NR 6
TC 136
Z9 150
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2006
VL 26
IS 3
BP 270
EP 274
DI 10.1097/00006982-200603000-00003
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100QW
UT WOS:000241684700003
PM 16508425
DA 2022-11-30
ER

PT J
AU Lee, CJ
   Huie, P
   Leng, T
   Peterman, MC
   Marmor, MF
   Blumenkranz, MS
   Bent, SF
   Fishman, HA
AF Lee, CJ
   Huie, P
   Leng, T
   Peterman, MC
   Marmor, MF
   Blumenkranz, MS
   Bent, SF
   Fishman, HA
TI Microcontact printing on human tissue for retinal cell transplantation
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID IRIS PIGMENT-EPITHELIUM; ANTERIOR LENS CAPSULE; MEMBRANES; SUPPORT;
   CULTURE
AB Objectives: To demonstrate that microcontact printing, a modern materials fabrication technique, can be used to engineer the surface of human tissue and to show that inhibitory molecules can be used to pattern the growth of retinal pigment epithelial cells or iris pigment epithelial cells on human lens capsule for transplantation.
   Methods: Photolithographic techniques were used to fabricate photoresist-coated silicon substrates into molds. Poly(dimethylsiloxane)stamps for microcontact printing were made from these molds. The poly(dimethylsiloxane) stamps were then used to "wet-transfer" growth inhibitory molecules to the surface of prepared human lens capsules that were obtained during cataract surgery. Human retinal pigment epithelial and rabbit iris pigment epithelial cells were grown on a lens capsule substrate in the presence and absence of a patterned array of inhibitory factors.
   Results: We found that human lens capsule could be microprinted with a precision similar to that obtained on glass or synthetic polymers. Retinal pigment epithelial cells and iris pigment epithelial cells cultured onto an untreated lens capsule showed spreading and formed into fusiform-appearing cells. in contrast, cells cultured on a lens capsule with a hexagonal micropattern of growth inhibitory molecules retained an epithelioid form within the inhibitory hexagons.
   Conclusion: Inhibitory growth molecules can be micro-patterned onto human lens capsule, and these micropatterns can control the organization of retinal pigment epithelial cells or iris pigment epithelial cells cultured onto the lens capsule surface.
   Clinical Relevance: Microprinting on autologous human tissue may facilitate efforts to effectively organize cell cultures and transplantations for the replacement of vital ocular tissues such as the retinal pigment epithelium in age-related macular degeneration.
C1 Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA.
   Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.
   Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.
C3 Stanford University; Stanford University; Stanford University
RP Fishman, HA (通讯作者)，Stanford Univ, Sch Med, Dept Ophthalmol, 300 Pasteur Dr,Room A157, Stanford, CA 94305 USA.
RI Leng, Theodore/AAQ-7459-2020
OI Bent, Stacey/0000-0002-1084-5336; Leng, Theodore/0000-0002-8461-3562
CR Bron AJ., 1997, WOLFFS ANATOMY EYE O, V8
   Gouras P., 1998, RETINAL PIGMENT EPIT, P492
   Green WR, 1999, AGE RELATED MACULAR, P81
   Guymer R., 1998, RETINAL PIGMENT EPIT, P693
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   Hu DN, 1997, ARCH OPHTHALMOL-CHIC, V115, P89, DOI 10.1001/archopht.1997.01100150091015
   Ishida M, 1998, CURR EYE RES, V17, P392, DOI 10.1080/02713689808951220
   Kim KS, 1998, CURR EYE RES, V17, P962, DOI 10.1076/ceyr.17.10.962.5243
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Lu LC, 2001, BIOMATERIALS, V22, P291, DOI 10.1016/S0142-9612(00)00179-4
   McPherson J. M., 2000, PRINCIPLES TISSUE EN, P697
   MOHAN PS, 1986, J BIOL CHEM, V261, P4328
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   PARENTEAU NL, 2000, PRINCIPLES TISSUE EN, P879
   Takayama S., 2000, PRINCIPLES TISSUE EN, P209
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 2001, SURV OPHTHALMOL, V45, P345, DOI 10.1016/S0039-6257(00)00195-8
   Whitesides GM, 2001, ANNU REV BIOMED ENG, V3, P335, DOI 10.1146/annurev.bioeng.3.1.335
   WONGPICHEDCHAI S, 1992, INVEST OPHTH VIS SCI, V33, P3341
   Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73
   ZARBIN MA, 1999, AGE RELATED MACULAR, P363
NR 22
TC 48
Z9 51
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9950
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD DEC
PY 2002
VL 120
IS 12
BP 1714
EP 1718
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 624AV
UT WOS:000179737900014
PM 12470147
DA 2022-11-30
ER

PT J
AU Tang, H
   Du, H
   Kuang, XL
   Huang, H
   Zeng, JS
   Long, CD
   Zhu, BB
   Fu, LC
   Wang, H
   Zhang, QJ
   Lin, SB
   Yan, JH
   Shen, HX
AF Tang, Han
   Du, Han
   Kuang, Xielan
   Huang, Hao
   Zeng, Jingshu
   Long, Chongde
   Zhu, Binbin
   Fu, Licheng
   Wang, Hua
   Zhang, Qingjiong
   Lin, Shuibin
   Yan, Jianhua
   Shen, Huangxuan
TI Arbutin Protects Retinal Pigment Epithelium Against Oxidative Stress by
   Modulating SIRT1/FOXO3a/PGC-1 alpha/beta Pathway
SO FRONTIERS IN GENETICS
LA English
DT Article
DE age-related macular degeneration; oxidative stress; SIRT1 signaling
   pathway; mitochondrial health; cell senescence
ID DNA DAMAGE; CELLS; SIRT1; INFLAMMATION; APOPTOSIS; MITOCHONDRIAL;
   DEGENERATION; ACTIVATION; MECHANISM; CULTURE
AB Age-related macular degeneration (AMD), which is the leading cause of blindness among the elderly in western societies, is majorly accompanied by retinal pigment epithelium (RPE) degeneration. Because of the irreversible RPE cell loss among oxidative stress, it is crucial to search for available drugs for atrophic (dry) AMD. RNA-Seq analysis revealed that genes related to aging and mitochondrial health were differentially expressed under Arbutin treatment, whereas compared to oxidative injury, our study demonstrated that Arbutin substantially abrogated oxidative stress-induced cell senescence and apoptosis linked to intracellular antioxidant enzyme system homeostasis maintenance, restored mitochondrial membrane potential (MMP), and reduced the SA-beta-GAL accumulation in RPE. Furthermore, Arbutin alleviated oxidative stress-mediated cell apoptosis and senescence via activation of SIRT1, as evidenced by the increase of the downstream FoxO3a and PGC-1 alpha/beta that are related to mitochondrial biogenesis, and the suppression of NF-kappa B p65 inflammasome, whereas rehabilitation of oxidative stress by SIRT1 inhibitor attenuated the protective effect of Arbutin. In conclusion, we validated the results in an in vivo model constructed by NAIO(3)-injured mice. OCT and HE staining showed that Arbutin sustained retinal integrity in the case of oxidative damage in vivo, and the disorder of RPE cytochrome was alleviated through fundus observation. In summary, our findings identified that oxidative stress-induced mitochondrial malfunction and the subsequent senescence acceleration in RPE cells, whereas Arbutin inhibited TBHP-induced RPE degeneration via regulating the SIRT1/Foxo3a/PGC-1 alpha/beta signaling pathway. These findings suggested that Arbutin is a new agent with potential applications in the development of AMD diseases.
C1 [Tang, Han; Du, Han; Kuang, Xielan; Zeng, Jingshu; Long, Chongde; Zhu, Binbin; Fu, Licheng; Zhang, Qingjiong; Yan, Jianhua; Shen, Huangxuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.
   [Kuang, Xielan; Shen, Huangxuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Biobank Eye, Guangzhou, Peoples R China.
   [Huang, Hao] Guangzhou Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Guangzhou, Peoples R China.
   [Wang, Hua] Southern Med Univ, Zhujiang Hosp, Dept Intens Care, Guangzhou, Peoples R China.
   [Lin, Shuibin] Sun Yat Sen Univ, Affiliated Hosp 1, Precis Med Inst, Ctr Translat Med, Guangzhou, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical
   University; Southern Medical University - China; Sun Yat Sen University
RP Yan, JH; Shen, HX (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Peoples R China.; Shen, HX (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Biobank Eye, Guangzhou, Peoples R China.
EM yanjh2011@126.com; shenhx@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81670874, 81670885];
   Natural Science Foundation of Guangdong Province of China
   [2020A1515010144, 2021A1515010513]; Fundamental Research Funds of the
   State Key Laboratory of Ophthalmology; Open Research Funds of the State
   Key Laboratory of Ophthalmology
FX The work was supported by the National Natural Science Foundation of
   China (81670874 and 81670885), Natural Science Foundation of Guangdong
   Province of China (NO. 2020A1515010144 & NO.2021A1515010513), and the
   Fundamental Research Funds of the State Key Laboratory of Ophthalmology
   (NO. N/A) and the Open Research Funds of the State Key Laboratory of
   Ophthalmology (NO. N/A).
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Chen QQ, 2019, FREE RADICAL BIO MED, V130, P48, DOI 10.1016/j.freeradbiomed.2018.10.419
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chong CM, 2016, REDOX BIOL, V9, P50, DOI 10.1016/j.redox.2016.06.002
   D'Onofrio N, 2018, ANTIOXID REDOX SIGN, V28, P711, DOI 10.1089/ars.2017.7178
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Ding YQ, 2020, NEUROMOL MED, V22, P56, DOI 10.1007/s12017-019-08562-6
   Duan JL, 2022, HEPATOLOGY, V75, P584, DOI 10.1002/hep.32209
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Fan YT, 2018, ARCH BIOCHEM BIOPHYS, V650, P1, DOI 10.1016/j.abb.2018.05.008
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Gao Y, 2021, ANGEW CHEM INT EDIT, V60, P10756, DOI 10.1002/anie.202101278
   He J, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3681707
   Huang H, 2021, J MOL MED, V99, P383, DOI 10.1007/s00109-020-02017-3
   Hubbard BP, 2013, SCIENCE, V339, P1216, DOI 10.1126/science.1231097
   Jin YH, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121301
   Joshi PK, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00934-5
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu HJ, 2017, MOL MED REP, V16, P2069, DOI 10.3892/mmr.2017.6838
   Ma CT, 2021, ADV CLIN EXP MED, V30, P535, DOI 10.17219/acem/133493
   Rabin DM, 2013, AGING-US, V5, P51
   Rera M, 2011, CELL METAB, V14, P623, DOI 10.1016/j.cmet.2011.09.013
   Roy Anandita, 2012, Pathophysiology, V19, P137, DOI 10.1016/j.pathophys.2012.05.001
   Ryu DR, 2019, AGING CELL, V18, DOI 10.1111/acel.12904
   Saeedi M, 2021, PHYTOTHER RES, V35, P4136, DOI 10.1002/ptr.7076
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Steinmetz C, 2017, HEPATOLOGY, V65, P2074, DOI 10.1002/hep.29072
   Sun W, 2018, METABOLISM, V88, P61, DOI 10.1016/j.metabol.2018.06.006
   Yeh YC, 2020, INT J MED SCI, V17, P368, DOI 10.7150/ijms.40255
   Yu Q, 2018, CANCER LETT, V418, P20, DOI 10.1016/j.canlet.2017.12.035
   Zhang H, 2020, J CELL MOL MED, V24, P12368, DOI 10.1111/jcmm.15736
   Zhang WQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15997-0
   Zhou X, 2017, CURR MOL MED, V17, P312, DOI 10.2174/1566524017666171106115655
   Zhu Q, 2019, ARTIF CELL NANOMED B, V47, P2010, DOI 10.1080/21691401.2019.1608217
NR 37
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD AUG 16
PY 2022
VL 13
AR 922807
DI 10.3389/fgene.2022.922807
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 4E7UF
UT WOS:000848026400001
PM 36051689
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Boltz, A
   Radunsky, K
   Weingessel, B
   Vecsei-Marlovits, VP
AF Boltz, Agnes
   Radunsky, Katharina
   Weingessel, Birgit
   Vecsei-Marlovits, Veronika Pia
TI Brolucizumab for pre-treated patients with choroidal neovascularization
   and signs of tachyphylaxis to aflibercept and bevacizumab
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal neovascularization; Age-related macular degeneration;
   Brolucizumab; Tachyphylaxis; Anti-VEGF therapy
ID MACULAR DEGENERATION; RANIBIZUMAB; PREVALENCE
AB Purpose Treatment of choroidal neovascularization due to age-related macular degeneration is a challenging topic since an increasing number of patients show reduced morphological response to conventional treatment with intravitreal injections. The present study tested the hypothesis that the newly introduced anti-VEGF antibody brolucizumab does not only show promising results in pre-treated patients but is also a viable option in cases of tachyphylaxis to aflibercept or bevacizumab.
   Methods Thirty-six eyes of 34 patients with a history of at least 10 anti-VEGF injections as well as persistent retinal fluid following the past 5 monthly injections with aflibercept and bevacizumab prior to first treatment with brolucizumab were included in the study. Morphological and functional treatment response was compared before and after switching to brolucizumab.
   Results Mean best-corrected visual acuity did not significantly change after treatment with brolucizumab. In contrast, central retinal thickness significantly decreased 4 weeks after treatment with brolucizumab from 340.36 to 282.22 mu m (p < 0.001) as well as pigment epithelial detachment from 346.73 to 280.47 mu m (p < 0.001). In 24 eyes (66.67%), complete resolution of intra-and subretinal fluid was observed after a single dose of brolucizumab. No serious adverse events, such as intraocular inflammation and retinal vasculitis, were reported after a single injection of brolucizumab.
   Conclusion Brolucizumab is not only effective in treatment-naive patients as shown in the pivotal HAWK and Harrier trials, but also in pre-treated patients as seen in the present study. Our data also suggest that brolucizumab is potent in patients with signs of tachyphylaxis to other anti-VEGF agents and thus a viable treatment option.
C1 [Boltz, Agnes; Radunsky, Katharina; Weingessel, Birgit; Vecsei-Marlovits, Veronika Pia] Hietzing Hosp, Dept Ophthalmol, Wolkersbergenstr 1, A-1130 Vienna, Austria.
   [Boltz, Agnes; Radunsky, Katharina; Weingessel, Birgit; Vecsei-Marlovits, Veronika Pia] Karl Landsteiner Inst Proc Optimizat & Qual Manag, Vienna, Austria.
C3 Hietzing Hospital
RP Boltz, A (通讯作者)，Hietzing Hosp, Dept Ophthalmol, Wolkersbergenstr 1, A-1130 Vienna, Austria.; Boltz, A (通讯作者)，Karl Landsteiner Inst Proc Optimizat & Qual Manag, Vienna, Austria.
EM agnes.boltz@gesundheitsverbund.at
CR Avaylon J, 2020, INT MED CASE REP J, V13, P145, DOI 10.2147/IMCRJ.S252260
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Hara C, 2019, GRAEF ARCH CLIN EXP, V257, P2559, DOI 10.1007/s00417-019-04456-2
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Waizel M, 2016, EUR J OPHTHALMOL, V26, P469, DOI 10.5301/ejo.5000781
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zuber-Laskawiec K, 2019, J PHYSIOL PHARMACOL, V70, P779, DOI 10.26402/jpp.2019.5.13
NR 15
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2022
VL 260
IS 8
BP 2561
EP 2566
DI 10.1007/s00417-022-05634-5
EA MAR 2022
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3F5UF
UT WOS:000774697400001
PM 35348844
DA 2022-11-30
ER

PT J
AU Puell, MC
   Contreras, I
   Pinilla, I
   Escobar, JJ
   Soler-Garcia, A
   Blasco, AJ
   Lazaro, P
AF Puell, Maria Cinta
   Contreras, Ines
   Pinilla, Isabel
   Escobar, Jose Juan
   Soler-Garcia, Antonio
   Blasco, Antonio Javier
   Lazaro, Pablo
TI Beyond visual acuity: Patient-relevant assessment measures of visual
   function in retinal diseases
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; diabetic retinopathy;
   psychophysical testing; retinal pathology; research; practice
   management; socioeconomics and education in medicine; ophthalmology
ID APPROPRIATE USE CRITERIA; CORONARY REVASCULARIZATION; REPORTED OUTCOMES;
   UNDERUSE; OVERUSE; VALIDITY; QUALITY; REPRODUCIBILITY; IDENTIFY; CARE
AB Purpose: To identify patient-reported outcomes (PROs) and other clinical outcome measures (contrast sensitivity (CS), low-luminance visual acuity (LLVA) and reading acuity or reading speed (RA-RS)), relevant to patients with age-related macular degeneration (AMD) or diabetic retinopathy (DR), which would be recommended for use in clinical practice. Methods: The RAND/UCLA Appropriateness Method, based on the synthesis of the scientific evidence and the collective judgment of an expert panel using the two-round Delphi method, was applied. The evidence synthesis was performed by searching for articles on outcome measures for AMD and/or DR published between 2005 and 2018 in English or Spanish. The expert panel consisted of 14 Spanish ophthalmologists, who rated the recommendation degree for each outcome measure on a scale of 1 (extremely irrelevant) to 9 (maximum relevance). The recommended outcome measures were established according to the panel median score and the level of the panelists' agreement. Results: Through the evidence search, 33 PRO-specific questionnaires (21 for visual function, six for AMD, three for DR, one for AMD and DR) and two treatment satisfaction questionnaires (one on AMD and one on DR) were identified. In addition, 21 methods were found for measuring CS, five for LLVA, and nine for RA-RS. According to the panel ratings, 11 of the 64 outcome measures evaluated for AMD, and seven of the 61 evaluated for DR were recommended. Conclusion: The AMD and DR outcome measures recommended will help ophthalmologists choose the outcome measure most appropriate for their patients. Furthermore, the use of PROs will contribute to shifting clinical practice towards patient-centered medicine.
C1 [Puell, Maria Cinta] Univ Complutense Madrid, Sch Optic & Optometry, Madrid, Spain.
   [Contreras, Ines] Ramon Cajal Univ Hosp, Ramon Cajal Hlth Res Inst IRYCIS, Clin Rementeria, Madrid, Spain.
   [Pinilla, Isabel] Aragon Inst Hlth Res IIS Aragon, Zaragoza, Spain.
   [Escobar, Jose Juan] Hosp Clinico Univ, Dept Ophthalmol, Zaragoza, Spain.
   [Soler-Garcia, Antonio] Dos Maig Hosp, Barcelona, Spain.
   [Blasco, Antonio Javier] Virgen Victoria Univ Hosp, Malaga, Spain.
   [Blasco, Antonio Javier; Lazaro, Pablo] Independent Hlth Serv Researcher, C Dalia,2. P 10,Rivas Vaciamadrid, Madrid 28522, Spain.
C3 Complutense University of Madrid; Hospital Universitario Ramon y Cajal
RP Blasco, AJ (通讯作者)，Independent Hlth Serv Researcher, C Dalia,2. P 10,Rivas Vaciamadrid, Madrid 28522, Spain.
EM antoniojblasco@hotmail.com
RI Puell, MarÃa/ABE-2972-2021
OI Pinilla, Isabel/0000-0003-0349-9997; Contreras,
   Ines/0000-0003-3524-9335; Puell, Maria Cinta/0000-0002-9227-4927
FU Bayer Spain
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   research was funded by Bayer Spain. The funding organization had no role
   in the design and development of the study or the collection,
   management, analysis, and interpretation of the data.
CR Aguilar MD, 2000, RAND PUBLICATION, V1269
   [Anonymous], 2017, J AM COLL CARDIOL, DOI [DOI 10.1016/j.jtcvs.2007.10.042, DOI 10.1016/j.jacc.2016.10.034]
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Ayanian JZ, 1998, NEW ENGL J MED, V338, P1896, DOI 10.1056/NEJM199806253382608
   Byrne M, 2020, BRIT DENT J, V228, P83, DOI 10.1038/s41415-020-1200-z
   Calvert M, 2018, JAMA-J AM MED ASSOC, V319, P483, DOI 10.1001/jama.2017.21903
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Expert Panel on Gastrointestinal Imaging:, 2018, J Am Coll Radiol, V15, pS56, DOI 10.1016/j.jacr.2018.03.014
   Fitch K, 2000, EUR J CARDIO-THORAC, V18, P380, DOI 10.1016/S1010-7940(00)00530-3
   Garcia-Layana A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/595132
   GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009
   Harrington RA, 2015, JAMA-J AM MED ASSOC, V314, P2029, DOI 10.1001/jama.2015.15436
   Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906
   International Society for Quality of Life Research (prepared by Aaronson N Elliott T Greenhalgh J Halyard M Hess R Miller D Reeve B Santana M Snyder C), 2015, USERS GUIDE IMPLEMEN
   Khadka J, 2013, OPTOMETRY VISION SCI, V90, P720, DOI 10.1097/OPX.0000000000000001
   Ko DT, 2012, J AM COLL CARDIOL, V60, P1876, DOI 10.1016/j.jacc.2012.06.056
   Krezel AK, 2015, BRIT J OPHTHALMOL, V99, P1560, DOI 10.1136/bjophthalmol-2014-306544
   Lavallee DC, 2016, HEALTH AFFAIR, V35, P575, DOI 10.1377/hlthaff.2015.1362
   Lawson EH, 2012, J CLIN EPIDEMIOL, V65, P1133, DOI 10.1016/j.jclinepi.2012.07.002
   Lazaro P, 1998, REV ESP CARDIOL, V51, P689, DOI 10.1016/S0300-8932(98)74812-2
   LEE PP, 1993, CATARACT SURG LIT RE
   Lindsley KB, 2018, JAMA OPHTHALMOL, V136, P1217, DOI 10.1001/jamaophthalmol.2018.3456
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   National Quality Forum, 2013, PAT REP OUTC PROS PE
   Nelson EC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7818
   PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766
   Patel MR, 2012, J AM COLL CARDIOL, V60, P1885, DOI 10.1016/j.jacc.2012.07.044
   Patel Manesh R, 2012, J Am Coll Cardiol, V59, P857, DOI 10.1016/j.jacc.2011.12.001
   Pesudovs K, 2013, OPTOMETRY VISION SCI, V90, P717, DOI 10.1097/01.opx.0000432565.70467.75
   Quintana JM, 2009, OPHTHALMOLOGY, V116, P409, DOI 10.1016/j.ophtha.2008.07.017
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Senthil MP, 2017, SURV OPHTHALMOL, V62, P546, DOI 10.1016/j.survophthal.2016.12.011
   Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022
   Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607
   Shekelle PG, 2001, NEW ENGL J MED, V344, P677, DOI 10.1056/NEJM200103013440912
   Szende A, 2014, SELF REPORTED POPULA, P62, DOI DOI 10.1007/978-94-007-7596-1
   Terwee CB, 2018, QUAL LIFE RES, V27, P1159, DOI 10.1007/s11136-018-1829-0
   Tobacman JK, 1999, MED CARE, V37, P937, DOI 10.1097/00005650-199909000-00009
   U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health, 2009, PATIENT REPORTED OUT
   Vilagut Gemma, 2005, Gac Sanit, V19, P135, DOI 10.1157/13074370
NR 40
TC 1
Z9 1
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2021
VL 31
IS 6
BP 3149
EP 3156
AR 1120672121990624
DI 10.1177/1120672121990624
EA JAN 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA XA5GJ
UT WOS:000679159000001
PM 33482694
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhou, LB
   Zhou, YQ
   Zhang, YY
AF Zhou, Lin-Bin
   Zhou, Ye-Qi
   Zhang, Yin-Yu
TI Blocking VEGF signaling augments interleukin-8 secretion via MEK/ERK/1/2
   axis in human retinal pigment epithelial cells
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; vascular endothelial growth factor
   signaling; anti-vascular endothelial growth factor therapy; retinal
   pigment epithelial cells; interleukin-8
ID NF-KAPPA-B; MACULAR DEGENERATION; INDUCED INFLAMMATION; EXPRESSION;
   IL-8; ACTIVATION; PATHWAYS; DISEASE; RESISTANCE; SURVIVAL
AB AIM: To identify proangiogenic factors engaged in neovascular age-related macular degeneration (AMD) except vascular endothelial growth factor (VEGF) from human retinal pigment epithelial (hRPE) cells and investigate the underlying mechanisms.
   METHODS: VEGF receptor 2 (VEGFR2) in ARPE-19 cells was depleted by siRNA transfection or overexpressed through adenovirus infection. The mRNA and the protein levels of interleukin-8 (IL-8) in ARPE-19 cells were measured by quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay respectively. The protein levels of AKT, p-AKT, MEK, p-MEK, ERK1/2, p-ERK1/2, JNK, p-JNK, p38 and p-p38 were detected by Western blotting. A selective chemical inhibitor, LY3214996, was employed to inhibit phosphorylation of ERK1/2. Cell viability was determined by MTT assay.
   RESULTS: Knockdown of VEGFR2 in ARPE-19 cells robustly augmented IL-8 production at both the mRNA and the protein levels. Silencing VEGFR2 substantially enhanced phosphorylation of MEK and ERK1/2 while exerted no effects on phosphorylation of AKT, JNK and p38. Inhibiting ERK1/2 phosphorylation by LY3214996 reversed changes in VEGFR2 knockdown-induced IL-8 upregulation at the mRNA and the protein levels with no effects on cell viability. VEGFR2 overexpression significantly reduced IL-8 generation at the mRNA and the protein levels.
   CONCLUSION: Blockade of VEGF signaling augments IL-8 secretion via MEK/ERK1/2 axis and overactivation of VEGF pathway decreases IL-8 production in hRPE cells. Upregulated IL-8 expression after VEGF signaling inhibition in hRPE cells may be responsible for being incompletely responsive to anti-VEGF remedy in neovascular AMD, and IL-8 may serve as an alternative therapeutic target for neovascular AMD.
C1 [Zhou, Lin-Bin; Zhang, Yin-Yu] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, 7 Jinsui Rd, Guangzhou 510060, Guangdong, Peoples R China.
   [Zhou, Ye-Qi] Soochow Univ, Affiliated Childrens Hosp, Suzhou 215123, Jiangsu, Peoples R China.
C3 Sun Yat Sen University; Soochow University - China
RP Zhang, YY (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, 7 Jinsui Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM Zhangxy7@mail.sysu.edu.cn
FU National Natural Science Foundation of China [81200670]
FX Supported by the National Natural Science Foundation of China
   (No.81200670).
CR Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Busch M, 2018, OPHTHALMOLOGICA, V239, P215, DOI 10.1159/000486404
   Cabral T, 2018, OPHTHALMOL RETINA, V2, P31, DOI 10.1016/j.oret.2017.04.004
   Capozzi ME, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23601-1
   Catarino S, 2012, ACTA OPHTHALMOL, V90, pE255, DOI 10.1111/j.1755-3768.2011.02350.x
   Chen X, 2018, BIOMED PHARMACOTHER, V101, P87, DOI 10.1016/j.biopha.2018.02.054
   Cheng SC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122957
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Du Y, 2018, CURR MOL MED, V18, P273, DOI 10.2174/1566524018666181004115304
   Fu DX, 2016, INVEST OPHTH VIS SCI, V57, P3369, DOI 10.1167/iovs.16-19291
   Ghasemi H, 2011, OCUL IMMUNOL INFLAMM, V19, P401, DOI 10.3109/09273948.2011.618902
   Ha H, 2017, THERANOSTICS, V7, P1543, DOI 10.7150/thno.15625
   Hayashi H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38067-4
   Huang C, 2019, MOL THER-ONCOLYTICS, V14, P196, DOI 10.1016/j.omto.2019.05.005
   Jia X, 2017, THROMB HAEMOSTASIS, V117, P750, DOI 10.1160/TH16-11-0885
   Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009
   Kitanaka N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220262
   Korhonen E, 2019, CYTOKINE, V116, P70, DOI 10.1016/j.cyto.2018.12.015
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   Li L, 2020, J CELL PHYSIOL, V235, P1259, DOI 10.1002/jcp.29041
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200
   Paeng SH, 2015, INT J MOL MED, V36, P808, DOI 10.3892/ijmm.2015.2266
   Petreaca ML, 2007, MOL BIOL CELL, V18, P5014, DOI 10.1091/mbc.E07-01-0004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmeck B, 2007, EUR RESPIR J, V29, P25, DOI 10.1183/09031936.00141005
   Schmeck B, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-98
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tao LF, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0489-7
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Wang JJ, 2018, INT J OPHTHALMOL-CHI, V11, P1277, DOI 10.18240/ijo.2018.08.05
   Wang Y, 2010, EXP EYE RES, V91, P135, DOI 10.1016/j.exer.2010.02.008
   Wilkerson I, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0219-y
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhong HB, 2016, INFLAMM RES, V65, P709, DOI 10.1007/s00011-016-0952-z
NR 39
TC 1
Z9 1
U1 1
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUL 18
PY 2020
VL 13
IS 7
BP 1039
EP 1045
DI 10.18240/ijo.2020.07.04
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MG0GV
UT WOS:000545714700004
PM 32685389
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Meng, XD
   Zhou, W
   Sun, ZY
   Han, Q
   Zhang, JK
   Zhang, HW
   Wang, WJ
   Zhong, M
   Wang, MY
   Zhang, JL
   Hao, J
   Han, H
   Zhao, X
   Hu, XX
   Zhu, XL
   Li, JN
   Wang, T
   Huang, YL
   Liao, MY
   Song, YT
   Yan, H
AF Meng, Xiangda
   Zhou, Wei
   Sun, Zhuoyu
   Han, Qi
   Zhang, Jingkai
   Zhang, Hongwen
   Wang, Weijuan
   Zhong, Min
   Wang, Meiyan
   Zhang, Junlan
   Hao, Jing
   Han, Han
   Zhao, Xiao
   Hu, Xingxing
   Zhu, Xinlei
   Li, Jianan
   Wang, Tian
   Huang, Yunli
   Liao, Mengyu
   Song, Yinting
   Yan, Hua
TI Prevalence and causes of bilateral visual impairment in rural areas of
   Tianjin, China - The Tianjin Eye Study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE visual impairment; prevalence; cause; risk factor
ID VISION IMPAIRMENT; ADULT-POPULATION; BLINDNESS; DISTANCE; PROVINCE
AB Purpose To estimate the prevalence, causes and risk factors of bilateral visual impairment in rural areas of Tianjin, China. Methods A large population-based, cross-sectional study. A stratified random cluster sampling method was used to investigate 12 233 participants in all age groups living in rural Tianjin. Participants completed questionnaires and received professional ophthalmology examinations. Results According to World Health Organization best-corrected visual acuity (BCVA) criteria, the crude prevalence of bilateral visual impairment (BCVA < 20/63), bilateral low vision (BCVA < 20/63 to >= 20/400) and bilateral blindness (BCVA < 20/400) was 2.53%, 2.40% and 0.14% (age- and gender-standardized prevalence was 1.86%, 1.76% and 0.11%). The prevalence increased with age and was higher in women than men. The most common causes of bilateral visual impairment in the total population were cataract (48.39%), refractive error/amblyopia (17.74%), age-related macular degeneration (AMD) (10.00%), diabetic retinopathy (5.81%) and glaucoma (3.87%). For participants younger than 50 years, refractive error/amblyopia was the leading cause of low vision and blindness, while cataract was the major cause in the participants over 50. Female gender, older age and self-reported diabetes were associated with increased risks of visual impairment. Conclusion The age- and gender-standardized prevalence of low vision, especially in the older group (50+), was higher in this study compared with previous studies in China. Refractive error/amblyopia was the leading cause of bilateral visual impairment in younger group, while cataract was the primary cause in the older group. These findings will provide useful information for planning comprehensive eye healthcare programmes in China.
C1 [Meng, Xiangda; Zhou, Wei; Han, Qi; Zhang, Jingkai; Hao, Jing; Han, Han; Zhao, Xiao; Hu, Xingxing; Zhu, Xinlei; Li, Jianan; Wang, Tian; Huang, Yunli; Liao, Mengyu; Song, Yinting; Yan, Hua] Tianjin Med Univ, Gen Hosp, Dept Ophthalmol, 154 Anshan Rd, Tianjin 300052, Peoples R China.
   [Sun, Zhuoyu] Tianjin Med Univ, Sch Publ Hlth, Dept Epidemiol & Stat, Tianjin, Peoples R China.
   [Zhang, Hongwen] Peoples Hosp Jizhou Dist, Dept Ophthalmol, Tianjin, Peoples R China.
   [Wang, Weijuan] Tianjin Med Univ, Gen Hosp, Binhai Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
   [Zhong, Min] Jinghai Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
   [Wang, Meiyan] Tianjin Haibin Peoples Hosp, Dept Ophthalmol, Tianjin, Peoples R China.
   [Zhang, Junlan] Peoples Hosp Wuqing Dist, Dept Ophthalmol, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University
RP Yan, H (通讯作者)，Tianjin Med Univ, Gen Hosp, Dept Ophthalmol, 154 Anshan Rd, Tianjin 300052, Peoples R China.
EM zyyyanhua@tmu.edu.cn
RI han, han/HDL-7807-2022
FU National Natural Science Foundation of China [81830026, 81800815]
FX This study was supported by the National Natural Science Foundation of
   China (grants 81830026 and 81800815). The authors acknowledge all
   members of the Tianjin Eye study for their contributions to this study.
   The authors have stated that they do not have a significant financial
   interest or other relationship with any product manufacturer or provider
   of services discussed in this article. The authors also do not discuss
   the use of off-label products, which includes unlabelled, unapproved, or
   non-investigative products or devices. No potential conflicts of
   interest relevant to this article were reported.
CR Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Chen X, 2018, MED SCI MONITOR, V24, P317, DOI 10.12659/MSM.908218
   Cooper J, 2018, EYE CONTACT LENS, V44, P231, DOI 10.1097/ICL.0000000000000499
   Du X, 2012, TIANJIN STAT YB 2012
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foreman J, 2018, JAMA OPHTHALMOL, V136, P240, DOI 10.1001/jamaophthalmol.2017.6457
   Guo C, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14091034
   Hu JY, 2017, INT J OPHTHALMOL-CHI, V10, P140, DOI 10.18240/ijo.2017.01.23
   Huang Xiao-bo, 2009, Zhonghua Yan Ke Za Zhi, V45, P786
   Jia WP, 2014, LANCET DIABETES ENDO, V2, pE6, DOI 10.1016/S2213-8587(14)70027-0
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Li J, 2012, INVEST OPHTH VIS SCI, V53, P4498, DOI 10.1167/iovs.12-9429
   Li T, 2015, OPHTHAL EPIDEMIOL, V22, P239, DOI 10.3109/09286586.2015.1009119
   Li YP, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0705-6
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Tang YT, 2015, OPHTHALMOLOGY, V122, P1480, DOI 10.1016/j.ophtha.2015.03.022
   Wang LH, 2013, INVEST OPHTH VIS SCI, V54, P4117, DOI 10.1167/iovs.13-11911
   Wang XY, 2016, ASIA-PAC J OPHTHALMO, V5, P445, DOI 10.1097/APO.0000000000000235
   Weingessel B, 2018, ACTA OPHTHALMOL, V96, P88, DOI 10.1111/aos.13439
   Wu J, 2017, TIANJIN STAT YB 2017
   Yang WY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22590
   You QS, 2011, OPHTHALMOLOGY, V118, P1069, DOI 10.1016/j.ophtha.2010.09.032
   Zhang GS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004905
   Zhang YG, 2012, CLIN EXP OPHTHALMOL, V40, P484, DOI 10.1111/j.1442-9071.2011.02682.x
   Zhao JL, 2018, AM J OPHTHALMOL, V185, P81, DOI 10.1016/j.ajo.2017.10.016
NR 26
TC 5
Z9 5
U1 2
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2021
VL 99
IS 2
BP E136
EP E143
DI 10.1111/aos.14523
EA JUN 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QT2FQ
UT WOS:000545435600001
PM 32602247
DA 2022-11-30
ER

PT J
AU Zhang, YH
   Li, J
   Yang, WZ
   Xian, ZH
   Feng, QT
   Ruan, XC
AF Zhang, Yue-Hong
   Li, Juan
   Yang, Wei-Zhong
   Xian, Zhuan-Hua
   Feng, Qi-Ting
   Ruan, Xiang-Cai
TI Mitochondrial expression and activity of P-glycoprotein under oxidative
   stress in outer blood-retinal barrier
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE P-glycoprotein; retinal pigment epithelium; oxidative stress;
   mitochondria
ID EPITHELIAL-CELLS; RPE CELLS; LOCALIZATION; DAMAGE; STRATEGIES;
   TRANSPORTERS; DYSFUNCTION; MECHANISMS; RESISTANCE; LINE
AB AIM: To investigate the role of oxidative stress in regulating the functional expression of P-glycoprotein (P-gp) in mitochondria of D407 cells.
   METHODS: D407 cells were exposed to different ranges of concentrations of H2O2. The mitochondrial location of P-gp in the cells subjected to oxidative stress was detected by confocal analysis. Expression of P-gp in isolated mitochondria was assessed by Western blot. The pump activity of P-gp was evaluated by performing the efflux study on isolated mitochondria with Rhodamine 123 (Rho-123) alone and in the presence of P-gp inhibitor (Tariquidar) using flow cytometry analysis. The cells were pretreated with 10 mmol/L N-acetylcysteine (NAC) for 30min before exposing to H2O2, and analyzed the mitochondrial extracts by Western blot and flow cytometry.
   RESULTS: P-gp was co-localized in the mitochondria by confocal laser scanning microscopy, and it was also detected in the mitochondria of D407 cells using Western blot. Exposure to increasing concentrations of H2O2 led to gradually increased expression and location of P-gp in the mitochondria of cells. Rho-123 efflux assay showed higher uptake of Rho-123 on isolated mitochondria in the presence of Tariquidar both in normal and oxidative stress state. H2O2 up-regulated P-gp in D407 cells, which could be reversed by NAC treatment.
   CONCLUSION: H2O2 could up-regulate the functional expression of P-gp in mitochondria of D407 cells, while antioxidants might suppress oxidative-stress-induced over-expression of functional P-gp. It is indicative that limiting the mitochondrial P-gp transport in retinal pigment epithelium cells would be to improve the effect of mitochondria-targeted antioxidant therapy in age-related macular degeneration-like retinopathy.
C1 [Zhang, Yue-Hong; Yang, Wei-Zhong; Xian, Zhuan-Hua; Feng, Qi-Ting] Guangzhou Med Univ, Municipal Peoples Hosp Guangzhou 1, Dept Ophthalmol, Affiliated Hosp, Guangzhou 510080, Guangdong, Peoples R China.
   [Li, Juan] Xi An Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shaanxi Ophthalm Med Ctr,Xian Hosp 4,Affiliated G, Xian 710004, Shaanxi Provinc, Peoples R China.
   [Ruan, Xiang-Cai] Guangzhou Med Univ, Municipal Peoples Hosp Guangzhou 1, Dept Anesthesiol, Affiliated Hosp, Guangzhou 510080, Guangdong, Peoples R China.
C3 Guangzhou Medical University; Xi'an Jiaotong University; Guangzhou
   Medical University
RP Ruan, XC (通讯作者)，Guangzhou Med Univ, Municipal Peoples Hosp Guangzhou 1, Dept Anesthesiol, Affiliated Hosp, Guangzhou 510080, Guangdong, Peoples R China.
EM xc_ruan@hotmail.com
RI Ruan, Xiangcai/L-9904-2016
OI Ruan, Xiangcai/0000-0001-6112-7994
FU National Natural Science Foundation of China [81400424]; Guangdong
   Medical Science Foundation [A2015151]
FX Supported by National Natural Science Foundation of China (No.
   81400424); Guangdong Medical Science Foundation (No. A2015151).
CR Anand BS, 2002, EXPERT OPIN BIOL TH, V2, P607, DOI 10.1517/14712598.2.6.607
   Anders MW, 2006, EXPERT OPIN DRUG MET, V2, P71, DOI 10.1517/17425255.2.1.71
   Apostolova N, 2015, ANTIOXID REDOX SIGN, V22, P686, DOI 10.1089/ars.2014.5952
   Barot M, 2013, EXP EYE RES, V106, P47, DOI 10.1016/j.exer.2012.10.006
   Cai L, 2013, INT J OPHTHALMOL-CHI, V6, P772, DOI 10.3980/j.issn.2222-3959.2013.06.06
   Cano M, 2014, FREE RADICAL BIO MED, V69, P1, DOI 10.1016/j.freeradbiomed.2014.01.004
   Chen P, 2013, DRUG METAB DISPOS, V41, P1934, DOI 10.1124/dmd.113.052704
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Constable PA, 2006, EXP EYE RES, V83, P24, DOI 10.1016/j.exer.2005.10.029
   Dranka BP, 2014, NEUROSCI LETT, V583, P159, DOI 10.1016/j.neulet.2014.09.042
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Escobales N, 2014, J MOL CELL CARDIOL, V77, P136, DOI 10.1016/j.yjmcc.2014.10.009
   Fetisova EK, 2010, FEBS LETT, V584, P562, DOI 10.1016/j.febslet.2009.12.002
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Guenova ML, 2010, HEMATOLOGY, V15, P135, DOI 10.1179/102453309X12583347113690
   Han JY, 2014, ORG BIOMOL CHEM, V12, P9793, DOI 10.1039/c4ob01981d
   Hytti M, 2015, EXP EYE RES, V132, P208, DOI 10.1016/j.exer.2015.02.001
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Laberge RM, 2009, ARCH BIOCHEM BIOPHYS, V491, P53, DOI 10.1016/j.abb.2009.09.012
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Mannermaa E, 2009, PHARM RES-DORD, V26, P1785, DOI 10.1007/s11095-009-9890-6
   Mantovani I, 2006, J CELL PHYSIOL, V207, P836, DOI 10.1002/jcp.20628
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Markovets AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021682
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Munteanu E, 2006, BIOCHEM PHARMACOL, V71, P1162, DOI 10.1016/j.bcp.2006.01.006
   Nawa A, 2010, LIFE SCI, V86, P402, DOI 10.1016/j.lfs.2010.01.009
   Nowak JZ, 2014, ACTA POL PHARM, V71, P900
   Nwaozuzu OM, 2003, J NEUROCHEM, V87, P1043, DOI 10.1046/j.1471-4159.2003.02061.x
   Paterson JK, 2007, EXP CELL RES, V313, P3100, DOI 10.1016/j.yexcr.2007.04.019
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Porteous CM, 2013, BBA-GEN SUBJECTS, V1830, P3458, DOI 10.1016/j.bbagen.2013.02.005
   Robertson SJ, 2009, J NEUROCHEM, V111, P132, DOI 10.1111/j.1471-4159.2009.06306.x
   Saprunova VB, 2012, BIOCHEMISTRY-MOSCOW+, V77, P648, DOI 10.1134/S0006297912060120
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Shen Y, 2016, INT J OPHTHALMOL-CHI, V9, P363, DOI 10.18240/ijo.2016.03.06
   Shen Y, 2012, ONCOL REP, V27, P1535, DOI 10.3892/or.2012.1671
   Silva R, 2015, PHARMACOL THERAPEUT, V149, P1, DOI 10.1016/j.pharmthera.2014.11.013
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Solazzo M, 2006, EXP CELL RES, V312, P4070, DOI 10.1016/j.yexcr.2006.09.005
   Tainton KM, 2004, CELL DEATH DIFFER, V11, P1028, DOI 10.1038/sj.cdd.4401440
   Terada Y, 2014, J PHARM PHARM SCI, V17, P266, DOI 10.18433/J3JG7D
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Zhang YH, 2012, INVEST OPHTH VIS SCI, V53, P3508, DOI 10.1167/iovs.11-9337
   Zhang YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031631
NR 48
TC 6
Z9 6
U1 2
U2 10
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUL 18
PY 2017
VL 10
IS 7
BP 1055
EP 1063
DI 10.18240/ijo.2017.07.06
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FA7DH
UT WOS:000405604500006
PM 28730106
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Jain, P
   Sheth, J
   Anantharaman, G
   Gopalakrishnan, M
AF Jain, Prashant
   Sheth, Jay
   Anantharaman, Giridhar
   Gopalakrishnan, Mahesh
TI Real-world evidence of safety profile of intravitreal bevacizumab
   (Avastin) in an Indian scenario
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Endophthalmitis; intravitreal Avastin; intravitreal bevacizumab;
   off-label use; real world
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; VERTEPORFIN PHOTODYNAMIC
   THERAPY; MACULAR DEGENERATION; ADVERSE EVENTS; SHORT-TERM; RANIBIZUMAB;
   TRIAL; MULTICENTER; INJECTIONS; 6-MONTH
AB Purpose: The purpose of this study was to evaluate the safety profile of intravitreal bevacizumab (Avastin) as an off-label pharmacotherapeutic agent for various ocular conditions. Methods: Retrospective analysis was carried out on 3806 injections of 1761 patients that were administered with intravitreal bevacizumab injection at a tertiary eye care center in India. The injections were administered on a pro re nata basis for various indications such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Results: The mean age of the patients was 61.8 +/- 11.59 years. A total of 59.2% of the patients were men and 40.8% women. The most common indications for which the injection was administered were DME (27.5%), AMD (26%), and branch RVO (12.3%). Among the ocular side effects, endophthalmitis was seen in three eyes (0.08%), retinal breaks in none of the eyes whereas 35 eyes had a rise in intraocular pressure (IOP) >21 mmHg (0.9%). Preexisting glaucoma was present in four eyes while remaining 31 eyes did not have any history of glaucoma. IOP rise was significantly more in eyes with preexisting glaucoma as compared to nonglaucomatous eyes (P = 0.04). No systemic adverse events were noted in our study population. Conclusion: Our study provides real-world evidence regarding the safety profile of intravitreal bevacizumab (Avastin). These data suggest that bevacizumab is a safe and economical pharmacotherapeutic agent that can be administered for a variety of ocular disorders. Analyzing the safety of bevacizumab is necessary for a developing country like India as the majority of the population cannot afford the costly ranibizumab as compared to bevacizumab for ocular healthcare.
C1 [Jain, Prashant; Sheth, Jay; Anantharaman, Giridhar; Gopalakrishnan, Mahesh] Giridhar Eye Inst, Dept Vitreoretina, Ponneth Temple Rd, Kochi 682020, Kerala, India.
RP Jain, P (通讯作者)，Giridhar Eye Inst, Dept Vitreoretina, Ponneth Temple Rd, Kochi 682020, Kerala, India.
EM giridhareye@gmail.com
RI Sheth, Jay/AAZ-6612-2020
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   [Anonymous], 2014, NY TIMES
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Ehlers JP, 2013, BRIT J OPHTHALMOL, V97, P248, DOI 10.1136/bjophthalmol-2012-302489
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Kaiser PK, 2012, GRAEF ARCH CLIN EXP, V250, P1563, DOI 10.1007/s00417-012-2123-4
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 28
TC 13
Z9 13
U1 0
U2 2
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JUL
PY 2017
VL 65
IS 7
BP 596
EP 602
DI 10.4103/ijo.IJO_992_16
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FB8KJ
UT WOS:000406387600011
PM 28724817
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tarita-Nistor, L
   Gonzalez, EG
   Brin, T
   Mandelcorn, MS
   Scherlen, AC
   Mandelcorn, ED
   Steinbach, MJ
AF Tarita-Nistor, Luminita
   Gonzalez, Esther G.
   Brin, Taylor
   Mandelcorn, Mark S.
   Scherlen, Anne-Catherine
   Mandelcorn, Efrem D.
   Steinbach, Martin J.
TI Fixation Stability and Viewing Distance in Patients with AMD
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE central vision loss; binocular vision; AMD; binocular fixation; viewing
   distance
ID PREFERRED RETINAL LOCUS; MACULAR DISEASE; DEGENERATION
AB Purpose. People with normal vision perform activities of daily living binocularly, while changing viewing distance frequently and effortlessly. Typically, in patients with age-related macular degeneration (AMD), fixation stability is recorded with monocular instruments at a fixed viewing distance (i.e. optical infinity) to determine the location and precision of the preferred retinal loci (PRLs)-the part of the functional retina that fulfills the role of a pseudo-fovea. Fixation stability recorded with these instruments has been related to performance on visual tasks at shorter viewing distances, although it is not known how viewing distance affects the precision of ocular motor control in these patients. This study examined whether viewing distance affects fixation stability during binocular and monocular viewing.
   Methods. Thirty patients with bilateral AMD, 10 older controls, and 10 younger controls participated. Each patient's better eye (BE) and worse eye (WE) were identified based on their visual acuity. Fixation stability was recorded with a binocular eye-tracker at three viewing distances (40 cm, 1 m, 6 m) in binocular and monocular (with BE and with WE) viewing conditions. Fixation stability was evaluated with a bivariate contour ellipse area.
   Results. For the AMD group, there was no effect of viewing distance on fixation stability, regardless of viewing condition (i.e. binocular, monocular with the BE or with the WE). The same pattern of results was found for the two control groups.
   Conclusions. Viewing distance does not affect fixation stability in patients with AMD. Fixation stability data recorded with an instrument at a fixed viewing distance can be related to performance on visual tasks at other viewing distances.
C1 [Tarita-Nistor, Luminita; Gonzalez, Esther G.; Brin, Taylor; Steinbach, Martin J.] Toronto Western Hosp, Vis Sci Res Program, 399 Bathurst St,FP 6-212, Toronto, ON M5T 2S8, Canada.
   [Gonzalez, Esther G.; Mandelcorn, Mark S.; Mandelcorn, Efrem D.; Steinbach, Martin J.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON M5S 1A1, Canada.
   [Scherlen, Anne-Catherine] Essilor Inc Corp, Inst Vis, Paris, France.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; University of Toronto; Essilor International;
   UDICE-French Research Universities; Sorbonne Universite
RP Gonzalez, EG (通讯作者)，Toronto Western Hosp, Vis Sci Res Program, 399 Bathurst St,FP 6-212, Toronto, ON M5T 2S8, Canada.
EM esther.gonzalez@utoronto.ca
OI Brin, Taylor/0000-0001-7749-5759
CR Calabrese A, 2011, INVEST OPHTH VIS SCI, V52, P2417, DOI 10.1167/iovs.09-5056
   Castet E, 2012, SEEING PERCEIVING, V25, P449, DOI 10.1163/187847611X620955
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   DISCENNA AO, 1995, J NEUROSCI METH, V58, P89, DOI 10.1016/0165-0270(94)00162-A
   Frennesson C, 2007, ACTA OPHTHALMOL SCAN, V85, P868, DOI 10.1111/j.1600-0420.2007.00984.x
   Gonzalez EG, 2015, INVEST OPHTHALMOL VI, V56
   Gonzalez EG, 2006, CAN J OPHTHALMOL, V41, P333, DOI 10.1139/I06-019
   Kabanarou SA, 2006, OPHTHALMOLOGY, V113, P2251, DOI 10.1016/j.ophtha.2006.06.028
   Kumar G, 2014, INVEST OPHTH VIS SCI, V55, P5125, DOI 10.1167/iovs.14-14608
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   Petre KL, 2000, OPTOMETRY VISION SCI, V77, P34, DOI 10.1097/00006324-200001000-00011
   Reinhard J, 2007, VISION RES, V47, P2076, DOI 10.1016/j.visres.2007.04.012
   SCHOR CM, 1981, VISION RES, V21, P683, DOI 10.1016/0042-6989(81)90076-6
   Seiple WH., 2012, OPTOM REP, V2, P11
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tarita-Nistor L, 2015, OPTOMETRY VISION SCI, V92, P863, DOI 10.1097/OPX.0000000000000641
   Tarita-Nistor L, 2012, OPTOMETRY VISION SCI, V89, P277, DOI 10.1097/OPX.0b013e318244e8b1
   Tarita-Nistor L, 2011, INVEST OPHTH VIS SCI, V52, P1887, DOI 10.1167/iovs.10-6059
   Tarita-Nistor L, 2009, VISUAL NEUROSCI, V26, P487, DOI 10.1017/S0952523809990265
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   UKWADE MT, 1993, OPTOMETRY VISION SCI, V70, P123, DOI 10.1097/00006324-199302000-00007
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
NR 27
TC 7
Z9 7
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD FEB
PY 2017
VL 94
IS 2
BP 239
EP 245
DI 10.1097/OPX.0000000000001018
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ7QJ
UT WOS:000393417000012
PM 27811525
DA 2022-11-30
ER

PT J
AU Aboelnour, A
   Kam, JH
   Elnasharty, MA
   Sayed-Ahmed, A
   Jeffery, G
AF Aboelnour, Asmaa
   Kam, Jaimie Hoh
   Elnasharty, M. A.
   Sayed-Ahmed, Ahmed
   Jeffery, Glen
TI Amyloid beta deposition and phosphorylated tau accumulation are key
   features in aged choroidal vessels in the complement factor H knock out
   model of retinal degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Retina; Aging; Macular degeneration; Tau; Amyloid beta
ID BLOOD-VESSELS; A-BETA; ANGIOPATHY; PEPTIDE; DISEASE
AB Extra-cellular deposition including amyloid beta (A beta) is a feature of retinal ageing. It has been documented for Bruch's membrane (BM) where A beta is elevated in complement factor H knockout mice (Cfh(-/-)) proposed as a model for age related macular degeneration. However, arterial deposition in choroidal vessels prior to perfusion across BM has not been examined. A beta is associated with tau phosphorylation and these are linked in blood vessels in Alzheimers Disease where they can drive perivascular pathology. Here we ask if A beta, tau and phosphorylated tau are features of ageing in choroidal vessels in 12 month C57 BL/6 and Cfh(-/-) mice, using immune staining and Western blot analysis.
   Greater levels of A beta and phosphorylated tau are found in choroidal vessels in Cfn(-/-) mice. Western blot revealed a 40% increase in A beta in Cfh(-/-) over C57 BL/6 mice. A beta deposits coat around 55% of the luminal wall in Cfn(-/-) compared to only about 40% in C57 BL/6. Total tau was similar in both groups, but phosphorylated tau increased by >100% in Cfn(-/-) compared to C57 BL/6 and covered >75% of the luminal wall compared to 50% in C57 BL/6. Hence, phosphorylated tau is a marked choroidal feature in this mouse model. All deposition was clumped in Cfn(-/-) mice and likely to influence blood flow dynamics. Disturbed flow is associated with atherogenesis and may be related to the accumulation of membrane attack complex recently identified between choroidal vessels in those at high risk of macular degeneration due to complement factor H polymorphisms. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Aboelnour, Asmaa; Elnasharty, M. A.] Damanhour Univ, Fac Vet Med, Histol & Cytol Dept, Damanhour, Egypt.
   [Sayed-Ahmed, Ahmed] Damanhour Univ, Fac Vet Med, Dept Anat, Damanhour, Egypt.
   [Kam, Jaimie Hoh; Jeffery, Glen] UCL, Inst Ophthalmol, 11-43 Bath St, London, England.
C3 Egyptian Knowledge Bank (EKB); Damanhour University; Egyptian Knowledge
   Bank (EKB); Damanhour University; University of London; University
   College London
RP Jeffery, G (通讯作者)，UCL, Inst Ophthalmol, 11-43 Bath St, London, England.
EM g.jeffery@ucl.ac.uk
OI Aboelnour, Asmaa/0000-0003-2643-5216
FU Egyptian Government Mission; Faculty of Veterinary Medicine, Damanhour
   University, Egypt; Biotechnology and Biological Sciences Research
   Council [BB/N000250/1] Funding Source: researchfish; BBSRC
   [BB/N000250/1] Funding Source: UKRI
FX BBSRC BB/N000250/1. Asmaa S Aboelnour was supported by The Egyptian
   Government Mission and by a scholarship from the Faculty of Veterinary
   Medicine, Damanhour University, Egypt.
CR Armstrong RA, 2012, FOLIA NEUROPATHOL, V50, P240, DOI 10.5114/fn.2012.30524
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blanc EM, 1997, J NEUROCHEM, V68, P1870
   Calaza KC, 2015, NEUROBIOL AGING, V36, P2869, DOI 10.1016/j.neurobiolaging.2015.06.010
   Chirco K.R., 2015, EXP EYE RES, P30024
   Chiu JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/physrev.00047.2009
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Marchesi VT, 2011, FASEB J, V25, P5, DOI 10.1096/fj.11-0102ufm
   Mendel T, 2013, FOLIA NEUROPATHOL, V51, P120, DOI 10.5114/fn.2013.35954
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Niwa K, 2001, AM J PHYSIOL-HEART C, V281, pH2417, DOI 10.1152/ajpheart.2001.281.6.H2417
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Perez M, 2004, J ALZHEIMERS DIS, V6, P461
   Smith EE, 2009, STROKE, V40, P2601, DOI 10.1161/STROKEAHA.108.536839
   Stoothoff WH, 2005, BBA-MOL BASIS DIS, V1739, P280, DOI 10.1016/j.bbadis.2004.06.017
   Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0
   Townsend KP, 2002, ANN NY ACAD SCI, V977, P65, DOI 10.1111/j.1749-6632.2002.tb04799.x
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Weller RO, 1998, AM J PATHOL, V153, P725, DOI 10.1016/S0002-9440(10)65616-7
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Williams S, 2005, NEUROPATH APPL NEURO, V31, P414, DOI 10.1111/j.1365-2990.2005.00663.x
NR 30
TC 8
Z9 11
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2016
VL 147
BP 138
EP 143
DI 10.1016/j.exer.2016.05.015
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP0NP
UT WOS:000378186800016
PM 27181225
DA 2022-11-30
ER

PT J
AU Friedrich, U
   Datta, S
   Schubert, T
   Plossl, K
   Schneider, M
   Grassmann, F
   Fuchshofer, R
   Tiefenbach, KJ
   Langst, G
   Weber, BHF
AF Friedrich, Ulrike
   Datta, Shyamtanu
   Schubert, Thomas
   Ploessl, Karolina
   Schneider, Magdalena
   Grassmann, Felix
   Fuchshofer, Rudolf
   Tiefenbach, Klaus-Juergen
   Laengst, Gernot
   Weber, Bernhard H. F.
TI Synonymous variants in HTRA1 implicated in AMD susceptibility impair its
   capacity to regulate TGF-beta signaling
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HIGH-TEMPERATURE REQUIREMENT; SERINE-PROTEASE HTRA1; MACULAR
   DEGENERATION; GENE-EXPRESSION; UP-REGULATION; IN-VITRO; CHOROIDAL
   NEOVASCULARIZATION; MICROGLIAL ACTIVATION; PULSE PROTEOLYSIS; OXIDATIVE
   STRESS
AB High-temperature requirement A1 (HTRA1) is a secreted serine protease reported to play a role in the development of several cancers and neurodegenerative diseases. Still, the mechanism underlying the disease processes largely remains undetermined. In age-related macular degeneration (AMD), a common cause of vision impairment and blindness in industrialized societies, two synonymous polymorphisms (rs1049331:C>T, and rs2293870:G>T) in exon 1 of the HTRA1 genewere associated with a high risk to develop disease. Here, we show that the two polymorphisms result in a protein with altered thermophoretic properties upon heat-induced unfolding, trypsin accessibility and secretion behavior, suggesting unique structural features of the AMD-risk-associated HTRA1 protein. Applying MicroScale Thermophoresis and protease digestion analysis, we demonstrate direct binding and proteolysis of transforming growth factor beta 1 (TGF-beta 1) by normal HTRA1 but not the AMD-risk-associated isoform. As a consequence, both HTRA1 isoforms strongly differed in their ability to control TGF-beta mediated signaling, as revealed by reporter assays targeting the TGF-beta 1-induced serpin peptidase inhibitor (SERPINE1, alias PAI-1) promoter. In addition, structurally altered HTRA1 led to an impaired autocrine TGF-beta signaling in microglia, as measured by a strong down-regulation of downstream effectors of the TGF-beta cascade such as phosphorylated SMAD2 and PAI-1 expression. Taken together, our findings demonstrate the effects of two synonymous HTRA1 variants on protein structure and protein interaction with TGF-beta 1. As a consequence, this leads to an impairment of TGF-beta signaling and microglial regulation. Functional implications of the altered properties on AMD pathogenesis remain to be clarified.
C1 [Friedrich, Ulrike; Datta, Shyamtanu; Ploessl, Karolina; Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93053 Regensburg, Germany.
   [Schubert, Thomas; Laengst, Gernot] Univ Regensburg, Dept Biochem, D-93053 Regensburg, Germany.
   [Schneider, Magdalena; Fuchshofer, Rudolf] Univ Regensburg, Inst Human Anat & Embryol, D-93053 Regensburg, Germany.
   [Tiefenbach, Klaus-Juergen] Univ Regensburg, Inst Biophys & Phys Biochem, D-93053 Regensburg, Germany.
   [Schubert, Thomas] 2bind GmbH, D-93053 Regensburg, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg; University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Längst, Gernot/G-5287-2015; Fuchshofer, Rudolf/M-3712-2019; Fuchshofer,
   Rudolf/E-8221-2010
OI Längst, Gernot/0000-0002-8232-1179; Fuchshofer,
   Rudolf/0000-0002-0474-6980; Fuchshofer, Rudolf/0000-0002-0474-6980;
   Grassmann, Felix/0000-0003-1390-7528; Schubert,
   Thomas/0000-0002-9709-3287; Weber, Bernhard H.F./0000-0002-8808-7723
FU Deutsche Forschungsgemeinschaft (DFG) [WE1259/19-1, WE1259/19-2]
FX This work was supported in part by grants from the Deutsche
   Forschungsgemeinschaft (DFG) (WE1259/19-1 and WE1259/19-2 to B.H.F.W.).
CR ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042
   Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n
   Ajayi F, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.046
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Baaske P, 2010, ANGEW CHEM INT EDIT, V49, P2238, DOI 10.1002/anie.200903998
   Bai YJ, 2014, MOL VIS, V20, P1258
   Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   Bamberger ME, 2002, NEUROSCIENTIST, V8, P276, DOI 10.1177/1073858402008003013
   Bianchi S, 2014, NEUROLOGY, V82, P898, DOI 10.1212/WNL.0000000000000202
   Bowden MA, 2006, GYNECOL ONCOL, V103, P253, DOI 10.1016/j.ygyno.2006.03.006
   Brest P, 2011, NAT GENET, V43, P242, DOI 10.1038/ng.762
   Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599
   CAO HJ, 1995, INVEST OPHTH VIS SCI, V36, P1411
   Cekanaviciute E, 2014, GLIA, V62, P1227, DOI 10.1002/glia.22675
   Chamary JV, 2009, SCI AM, V300, P46, DOI 10.1038/scientificamerican0609-46
   Chamary JV, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r75
   Chamary JV, 2006, NAT REV GENET, V7, P98, DOI 10.1038/nrg1770
   Chamberland A, 2009, J BIOL CHEM, V284, P27352, DOI 10.1074/jbc.M109.037051
   Chen Y, 2013, J INT MED RES, V41, P1445, DOI 10.1177/0300060513480926
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   D'Andrea MR, 2004, NEUROBIOL AGING, V25, P675, DOI 10.1016/j.neurobiolaging.2003.12.026
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dickey SW, 2013, CELL, V155, P1270, DOI 10.1016/j.cell.2013.10.053
   Dong C, 2002, J HEART LUNG TRANSPL, V21, P999, DOI 10.1016/S1053-2498(02)00403-5
   Duan JB, 2003, J MOL EVOL, V57, P694, DOI 10.1007/s00239-003-2519-1
   Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055
   Duhr S, 2006, P NATL ACAD SCI USA, V103, P19678, DOI 10.1073/pnas.0603873103
   Ebert S, 2009, J NEUROCHEM, V110, P1863, DOI 10.1111/j.1471-4159.2009.06286.x
   Eigenbrot C, 2012, STRUCTURE, V20, P1040, DOI 10.1016/j.str.2012.03.021
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fung KL, 2014, CANCER RES, V74, P598, DOI 10.1158/0008-5472.CAN-13-2064
   Graham JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074094
   Grassmann F, 2015, NEUROMOL MED, V17, P111, DOI 10.1007/s12017-015-8342-1
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hadfield KD, 2008, J BIOL CHEM, V283, P5928, DOI 10.1074/jbc.M709299200
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   Huang WC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-28
   Hughes V, 2012, NATURE, V485, P570, DOI 10.1038/485570a
   Hunt RC, 2014, TRENDS GENET, V30, P308, DOI 10.1016/j.tig.2014.04.006
   Jacobo SMP, 2013, MOL CELL BIOL, V33, P1976, DOI 10.1128/MCB.01283-12
   Javelaud D, 2004, INT J BIOCHEM CELL B, V36, P1161, DOI 10.1016/S1357-2725(03)00255-3
   Javelaud D, 2004, PATHOL BIOL, V52, P50, DOI 10.1016/j.patbio.2003.10.002
   Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928
   Karlstetter M, 2014, ADV EXP MED BIOL, V801, P207, DOI 10.1007/978-1-4614-3209-8_27
   Karlstetter M, 2010, J IMMUNOL, V185, P3379, DOI 10.4049/jimmunol.0903300
   Karring H, 2013, MOL VIS, V19, P861
   Kim MS, 2009, PROTEIN SCI, V18, P1051, DOI 10.1002/pro.115
   Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308
   Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7
   Kutz SM, 2001, J CELL SCI, V114, P3905
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Latta CH, 2015, NEUROSCIENCE, V302, P103, DOI 10.1016/j.neuroscience.2014.09.061
   Launay S, 2008, CELL DEATH DIFFER, V15, P1408, DOI 10.1038/cdd.2008.82
   Li JJ, 2008, NEUROSCIENCE, V156, P662, DOI 10.1016/j.neuroscience.2008.07.061
   Lue LF, 2015, NEUROSCIENCE, V302, P138, DOI 10.1016/j.neuroscience.2014.09.050
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Madani F, 2009, J AM CHEM SOC, V131, P4613, DOI 10.1021/ja809315x
   Malet H, 2012, NAT STRUCT MOL BIOL, V19, P152, DOI 10.1038/nsmb.2210
   Mauney J, 2010, MATRIX BIOL, V29, P657, DOI 10.1016/j.matbio.2010.08.008
   Mendioroz M, 2010, NEUROLOGY, V75, P2033, DOI 10.1212/WNL.0b013e3181ff96ac
   Mullany SA, 2011, CLIN CANCER RES, V17, P427, DOI 10.1158/1078-0432.CCR-09-3069
   Na YR, 2009, PROTEIN SCI, V18, P268, DOI 10.1002/pro.29
   Nackley AG, 2006, SCIENCE, V314, P1930, DOI 10.1126/science.1131262
   Nakayama M, 2014, INVEST OPHTH VIS SCI, V55, P6514, DOI 10.1167/iovs.14-14453
   Nishimoto Y, 2011, NEUROLOGY, V76, P1353, DOI 10.1212/WNL.0b013e318215281d
   Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Paglinawan R, 2003, GLIA, V44, P219, DOI 10.1002/glia.10286
   Park CW, 2005, NAT METHODS, V2, P207, DOI 10.1038/NMETH740
   Polur I, 2010, HISTOL HISTOPATHOL, V25, P599, DOI 10.14670/HH-25.599
   Promsote W, 2014, MOL VIS, V20, P73
   Rozovsky I, 1998, NEUROBIOL AGING, V19, P97, DOI 10.1016/S0197-4580(97)00169-3
   Ruggiano A, 2014, J CELL BIOL, V204, P868, DOI 10.1083/jcb.201312042
   Schapansky J, 2015, NEUROSCIENCE, V302, P74, DOI 10.1016/j.neuroscience.2014.09.049
   Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063
   Shridhar V, 2002, CANCER RES, V62, P262
   Singh N, 2011, ARCH BIOCHEM BIOPHYS, V516, P85, DOI 10.1016/j.abb.2011.10.007
   Spittau B, 2015, GLIA, V63, P142, DOI 10.1002/glia.22740
   Streit WJ, 2008, FRONT BIOSCI-LANDMRK, V13, P3423
   Supanji, 2013, EXP EYE RES, V112, P79, DOI 10.1016/j.exer.2013.04.013
   SUZUMURA A, 1993, J IMMUNOL, V151, P2150
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tambuyzer BR, 2009, J LEUKOCYTE BIOL, V85, P352, DOI 10.1189/jlb.0608385
   Team RDC, 2010, R LANG ENV STAT COMP
   Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015
   Vidro-Kotchan E, 2011, CURR EYE RES, V36, P370, DOI 10.3109/02713683.2010.549601
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Vorwerk P, 2002, ENDOCRINOLOGY, V143, P1677, DOI 10.1210/en.143.5.1677
   Wang N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039446
   Wang XL, 2012, CNS NEUROSCI THER, V18, P867, DOI 10.1111/j.1755-5949.2012.00373.x
   Wong WT, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00022
   Yu AL, 2009, EXP EYE RES, V88, P495, DOI 10.1016/j.exer.2008.10.028
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Zhang FL, 2010, SCIENCE, V329, P1534, DOI 10.1126/science.1191701
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
NR 106
TC 34
Z9 35
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 15
PY 2015
VL 24
IS 22
BP 6361
EP 6373
DI 10.1093/hmg/ddv346
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DB2WK
UT WOS:000368371000008
PM 26310622
OA Bronze
DA 2022-11-30
ER

PT J
AU Channa, R
   Sophie, R
   Bagheri, S
   Shah, SM
   Wang, JX
   Adeyemo, O
   Sodhi, A
   Wenick, A
   Ying, HS
   Campochiaro, PA
AF Channa, Roomasa
   Sophie, Raafay
   Bagheri, Saghar
   Shah, Syed M.
   Wang, Jiangxia
   Adeyemo, Olukemi
   Sodhi, Akrit
   Wenick, Adam
   Ying, Howard S.
   Campochiaro, Peter A.
TI Regression of Choroidal Neovascularization Results in Macular Atrophy in
   Anti-Vascular Endothelial Growth Factor-Treated Eyes
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; GEOGRAPHIC ATROPHY; NATURAL-HISTORY;
   RANIBIZUMAB; DEGENERATION; VEGF
AB PURPOSE: To determine the incidence and progression of macular atrophy in patients with neovascular age-related macular degeneration (AMD) treated with vascular endothelial growth factor (VEGF) antagonists.
   DESIGN: Retrospective interventional case series.
   METHODS: All patients with neovascular AMD treated by the same physician during a 12-month period of ascertainment had all images from their entire follow-up period evaluated, and areas of retina that developed atrophy were compared to the same areas prior to the onset of anti-VEGF treatment. Longitudinal measurements of retinal atrophy were made.
   RESULTS: In 39 patients, 52 eyes with neovascular AMD were identified. We excluded 5 eyes from analysis (4 had retinal pigment epithelium tears, and 1 had a laser scar). Fundus photographs of the remaining eyes showed that 18/47 eyes (38%) contained hypopigmented areas suggestive of atrophy within the macula at some time during follow-up. Spectral-domain optical coherence tomography confirmed that these areas had loss of retinal pigmented epithelium and ellipsoids zones, with or without subretinal material suggestive of subretinal fibrosis. Comparison of fundus photographs with fluorescein angiograms showed that in 13/18 eyes (72%), atrophy developed in areas previously occupied by choroidal neovascularization, and the other 5 eyes had atrophy prior to the onset of anti-VEGF treatment. The mean ( standard deviation) rate of increase in pure atrophic areas (no subretinal material) was 0.7 +/- 0.8 mm(2) per year, with a range of 0.01-2.6 mm(2)/year.
   CONCLUSION: Treatment of neovascular AMD with a VEGF-neutralizing protein can result in regression of choroidal neovascularization, which is sometimes associated with atrophy of overlying retina. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Channa, Roomasa; Sophie, Raafay; Bagheri, Saghar; Shah, Syed M.; Adeyemo, Olukemi; Sodhi, Akrit; Wenick, Adam; Ying, Howard S.; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Wang, Jiangxia] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Biostat, Dept Biostat, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health
RP Campochiaro, PA (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, 815 Maumenee,600 N Wolfe St, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
RI C, Roomasa/AAK-5176-2020; Shah, Syed/K-2672-2018
OI Sophie, Raafay/0000-0003-3207-9094; Bagheri, MD, PhD,
   Saghar/0000-0002-5165-5811
FU NIH/NEI [EY01765]; Regeneron (Tarrytown, NY); ASIM and AREDS2/Forsight;
   Genentech; Regeneron Pharmaceuticals, Inc.; Aerpio; Allergan; Genzyme
   Oxford; Biomedica; Roche; Graybug; Wilmer Biostatistics Core Grant
   [EY01765]; NATIONAL EYE INSTITUTE [P30EY001765] Funding Source: NIH
   RePORTER
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICJME FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST, and the following were reported. Dr
   Wang received funding from NIH/NEI Wilmer Biostatistics Core Grant
   EY01765; Dr Ying received funding from Regeneron (Tarrytown, NY) for
   research, speaker fees and reimburkment for travel from ASIM and
   AREDS2/Forsight; Dr Wenick is a consultant for Bristol-Meyers-Squibb and
   received payment for lectures from Vindico Medical Education; Dr
   Campochiaro has a consultancy for which Johns Hopkins University
   receives remuneration with Genentech, Regeneron Pharmaceuticals, Inc and
   Aerpio; has consultancy for which there is personal remuneration with
   Abbvie Advanced Cell Technology, Alimera, Applied Genetic Technologies,
   Eleven, and Kala; receives research funding from Genentech, Regeneron
   Pharmaceuticals, Inc., Aerpio, Allergan, Genzyme Oxford, Biomedica, and
   Roche; and has equity in Graybug. Design and conduct of study (R.C.,
   R.S., S.B., S.S., O.A., A.S., A.W., H.Y., P.A.C.); Collection,
   management, analysis, and interpretation of data (R.C., R.S., S.B.,
   S.M.S., J.W., O.A., A.S., A.W., H.S.Y., P.A.C.); and Preparation,
   review, or approval of manuscript (R.C., R.S., S.B., S.M.S., j.W., O.A.,
   A.S., A.W., H.S.Y., P.A.C.). The authors acknowledge the Wilmer
   Biostatistics Core Grant EY01765 and thank Dr James T. Handa for
   critical review of the manuscript.
CR BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
NR 19
TC 35
Z9 37
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2015
VL 159
IS 1
BP 9
EP 19
DI 10.1016/j.ajo.2014.09.012
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AY7NU
UT WOS:000347747500003
PM 25217857
DA 2022-11-30
ER

PT J
AU Lyzogubov, VV
   Bora, NS
   Tytarenko, RG
   Bora, PS
AF Lyzogubov, Valeriy V.
   Bora, Nalini S.
   Tytarenko, Ruslana G.
   Bora, Puran S.
TI Polyethylene glycol induced mouse model of retinal degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; retinal degeneration; mouse model;
   pathology
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   PIGMENT EPITHELIUM; CELL-DEATH; PHOTORECEPTOR DEGENERATION;
   GENETIC-VARIANTS; BRUCHS MEMBRANE; UNITED-STATES; MICE
AB Age-related macular degeneration (AMD) is a leading cause of irreversible blindness. This study was done to characterize dry AMD-like changes in mouse retinal pigment epithelium (RPE) and retina after polyethylene glycol (PEG) treatment. We injected male C57BL/6 mice subretinally with PBS, 0.025, 0.25, 0.5 and 1.0 mg of PEG-400 and the animals were sacrificed on day 5. Eyes were harvested and processed for histological analysis. In all other experiments 0.5 mg PEG was injected and animals were sacrificed on days 1, 3, 5 or 14. Paraffin, 5 mu m and plastic, 1 pm and 80 nm sections were used for further analysis. Subretinal injection of 0.5 mg PEG induced a 32% reduction of outer nuclear layer (ONL) thickness, 61% decrease of photoreceptor outer and inner segment length, 49% decrease of nuclear density in the ONL and 31% increase of RPE cell density by day 5 after injection. The maximum level of TUNEL positive nuclei in the ONL (6.8 + 1.99%) was detected at day 5 after PEG injection and co-localized with Casp3act. Histological signs of apoptosis were observed in the ONL by light or electron microscopy. Degeneration of RPE cells was found in PEG injected eyes. Gene expression data identified several genes reported to be involved in human AMD. C3, Cfi, Serping1, Mmp9, Htra1 and Lpl were up-regulated in PEG injected eyes compared to PBS controls. PEG leads to morphological and gene expression changes in RPE and retina consistent with dry AMD. This model will be useful to investigate dry AMD pathogenesis and treatment. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Lyzogubov, Valeriy V.; Bora, Nalini S.; Tytarenko, Ruslana G.; Bora, Puran S.] Univ Arkansas Med Sci, Pat & Willard Walker Eye Res Ctr, Jones Eye Inst, Dept Ophthalmol, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences
RP Bora, PS (通讯作者)，Univ Arkansas Med Sci, Pat & Willard Walker Eye Res Ctr, Jones Eye Inst, Dept Ophthalmol, 4301 West Markham St,Slot 523-7, Little Rock, AR 72205 USA.
EM pbora@uams.edu
OI Bora, Puran/0000-0003-4781-1217
FU Department of Ophthalmology Research foundation; Pat & Willard Walker
   Eye Research Center, Jones Eye Institute, Little Rock, AR
FX This work was supported in part by Dr. Phil Palade and Department of
   Ophthalmology Research foundation, Pat & Willard Walker Eye Research
   Center, Jones Eye Institute, Little Rock, AR.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Chang B, 2005, VISUAL NEUROSCI, V22, P587, DOI 10.1017/S0952523805225075
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis SJ, 2012, RETINA-J RET VIT DIS, V32, P1171, DOI 10.1097/IAE.0b013e31823496b8
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Ebert SM, 2012, J BIOL CHEM, V287, P27290, DOI 10.1074/jbc.M112.374777
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Fu L, 2007, HUM MOL GENET, V16, P2411, DOI 10.1093/hmg/ddm198
   Galluzzi L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043249
   Gao H, 1996, EXP EYE RES, V62, P181, DOI 10.1006/exer.1996.0022
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hafezi F, 2000, BRIT J OPHTHALMOL, V84, P922, DOI 10.1136/bjo.84.8.922
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hussain AA, 2011, INVEST OPHTH VIS SCI, V52, P4459, DOI 10.1167/iovs.10-6678
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lee SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.266
   Loskutova E, 2013, NUTRIENTS, V5, P1962, DOI 10.3390/nu5061962
   Lucin KM, 2013, NEURON, V79, P873, DOI 10.1016/j.neuron.2013.06.046
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Lyzogubov VV, 2010, AM J PATHOL, V177, P1870, DOI 10.2353/ajpath.2010.091168
   Lyzogubov VV, 2009, CELL BIOL INT, V33, P765, DOI 10.1016/j.cellbi.2009.04.013
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rattner A, 2008, J NEUROSCI, V28, P9880, DOI 10.1523/JNEUROSCI.2401-08.2008
   Repnik U, 2012, BBA-PROTEINS PROTEOM, V1824, P22, DOI 10.1016/j.bbapap.2011.08.016
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Salomon RG, 2011, CHEM RES TOXICOL, V24, P1803, DOI 10.1021/tx200206v
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Seddon JM, 2013, FARADAY DISCUSS, V161, P9, DOI 10.1039/c2fd90045a
   Sun Q, 2013, J BIOL CHEM, V288, P15947, DOI 10.1074/jbc.M112.426791
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Templeton JP, 2013, INVEST OPHTH VIS SCI, V54, P2599, DOI 10.1167/iovs.12-11175
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Wang AL, 2010, VISION RES, V50, P638, DOI 10.1016/j.visres.2009.08.029
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Yamada H, 2001, AM J PATHOL, V159, P1113, DOI 10.1016/S0002-9440(10)61787-7
   Yao JY, 2014, INVEST OPHTH VIS SCI, V55, P3237, DOI 10.1167/iovs.13-13336
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
NR 56
TC 13
Z9 14
U1 1
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2014
VL 127
BP 143
EP 152
DI 10.1016/j.exer.2014.07.021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ1KI
UT WOS:000342539900017
PM 25088354
DA 2022-11-30
ER

PT J
AU Argun, M
   Tok, L
   Uguz, AC
   Celik, O
   Tok, OY
   Naziroglu, M
AF Argun, M.
   Tok, L.
   Uguz, A. C.
   Celik, O.
   Tok, O. Y.
   Naziroglu, M.
TI Melatonin and amfenac modulate calcium entry, apoptosis, and oxidative
   stress in ARPE-19 cell culture exposed to blue light irradiation (405
   nm)
SO EYE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; RETINAL ANGIOGENESIS; MACULAR DEGENERATION;
   VISIBLE-LIGHT; ANIMAL-MODEL; SELENIUM; RETINOPATHY; PREMATURITY;
   INHIBITION; RELEASE
AB Purpose Under conditions of oxidative stress, cell apoptosis is triggered through the mitochondrial intrinsic pathway. Increased levels of reactive oxygen species (ROS) are linked to excess cell loss and mediate the initiation of apoptosis in a diverse range of cell types. The aims of this study were to assess intracellular Ca2+ release, ROS production, and caspase-3, and -9 activation in ARPE-19 cells during the blue light-mediated cell death, and to examine a potential protective effect of melatonin and amfenac, in the apoptotic cascade.
   Methods ARPE-19 cells were cultured in their medium. First, MTT tests were performed to determine the protective effects of amfenac and melatonin. Cells were then exposed to blue light irradiation in an incubator. Intracellular Ca2+ release experiments, mitochondrial membrane depolarization, apoptosis assay, glutathione (GSH), glutathione peroxidase (GSH-Px), and ROS experiments were done according to the method stated in the Materials and methods section.
   Results Cell death was clearly associated with increased levels of ROS production, as measured by 2',7'-dichlorofluorescein fluorescence, and associated increase in Ca2+ levels, as measured by Fura-2-AM. Blue light-induced cell death was associated with an increased level of caspase-3 and 9, suggesting mediation via the apoptotic pathway. Cell death was also associated with mitochondrial depolarization. Melatonin was shown to delay these three steps.
   Conclusion Melatonin, amfenac, and their combination protect ARPE-19 cells against blue light-triggered ROS accumulation and caspase-3 and -9 activation. The antiapoptotic effect of melatonin and amfenac at doses inhibiting caspase synthesis modified Ca2+ release and prevented excessive ROS production, suggesting a new therapeutic approach to age-related macular degeneration.
C1 [Argun, M.; Tok, L.; Tok, O. Y.] Suleyman Demirel Univ, Fac Med, Dept Ophthalmol, TR-32260 Isparta, Turkey.
   [Uguz, A. C.; Celik, O.; Naziroglu, M.] Suleyman Demirel Univ, Fac Med, Dept Biophys, TR-32260 Isparta, Turkey.
   [Uguz, A. C.; Celik, O.; Naziroglu, M.] Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey.
C3 Suleyman Demirel University; Suleyman Demirel University; Suleyman
   Demirel University
RP Uguz, AC (通讯作者)，Suleyman Demirel Univ, Fac Med, Dept Biophys, Dogu Kampusu, TR-32260 Isparta, Turkey.
EM cihangiruguz@sdu.edu.tr
RI celik, omer/F-4300-2011; ARGUN, Mehmet/AAA-7547-2020; Uğuz, A.
   Cihangir/J-8531-2012
OI celik, omer/0000-0002-9262-996X; 
FU Scientific Research Unit of Suleyman Demirel University [3173-TU 2-12]
FX The study was partially supported by the Scientific Research Unit of
   Suleyman Demirel University (protocol 3173-TU 2-12). MN and LT
   formulated the present hypothesis. ACU and MA were responsible for
   writing the report. MA, OC, and ACU were also responsible for analyzing
   the data. OYT made critical revision of the manuscript. The authors wish
   to thank Dr Gemma Figtree (Sydney, Australia) for polishing the English.
CR Altinkilic S, 2010, J MEMBRANE BIOL, V235, P211, DOI 10.1007/s00232-010-9267-0
   Arcieri ES, 2005, ARCH OPHTHALMOL-CHIC, V123, P186, DOI 10.1001/archopht.123.2.186
   Baba K, 2009, P NATL ACAD SCI USA, V106, P15043, DOI 10.1073/pnas.0904400106
   Bennet D, 2013, ANAL BIOCHEM, V436, P84, DOI 10.1016/j.ab.2013.01.025
   Berridge MJ, 2006, CELL CALCIUM, V40, P405, DOI 10.1016/j.ceca.2006.09.002
   Brechard S, 2008, J LEUKOCYTE BIOL, V84, P1223, DOI 10.1189/jlb.0807553
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Espino J, 2011, AGE, V33, P497, DOI 10.1007/s11357-010-9194-0
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hajnoczky G, 2010, CURR BIOL, V20, pR888, DOI 10.1016/j.cub.2010.09.035
   Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x
   Ivanova TN, 2008, BRAIN RES, V1207, P111, DOI 10.1016/j.brainres.2008.02.025
   Juknat AA, 2005, J PINEAL RES, V38, P84, DOI 10.1111/j.1600-079X.2004.00166.x
   Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371
   Ki YW, 2013, TOXICOL LETT, V218, P235, DOI 10.1016/j.toxlet.2013.02.003
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   KREMER M, 1982, PROSTAGLANDINS, V23, P695, DOI 10.1016/S0090-6980(82)80007-5
   LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6
   Liang FQ, 2004, EXP EYE RES, V78, P1069, DOI 10.1016/j.exer.2004.02.003
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liang FQ, 2001, NEUROREPORT, V12, P1011, DOI 10.1097/00001756-200104170-00029
   Lipovsky A, 2013, PHOTOMED LASER SURG, V31, P526, DOI 10.1089/pho.2012.3339
   Liu CM, 2004, CELL TISSUE RES, V315, P197, DOI 10.1007/s00441-003-0822-1
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAINSTER MA, 1987, EYE-T OPHTH SOC UK, V1, P304, DOI 10.1038/eye.1987.49
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Masferrer JL, 2000, CANCER RES, V60, P1306
   Naziroglu M, 2007, NEUROCHEM RES, V32, P1990, DOI 10.1007/s11064-007-9386-x
   Naziroglu M, 2009, NEUROCHEM RES, V34, P2181, DOI 10.1007/s11064-009-0015-8
   Niesman MR, 1997, NEUROCHEM RES, V22, P597, DOI 10.1023/A:1022474120512
   Osborne NN, 1998, INVEST OPHTH VIS SCI, V39, P2374
   PLACER ZA, 1966, ANAL BIOCHEM, V16, P359, DOI 10.1016/0003-2697(66)90167-9
   Reiter RJ, 2003, CARDIOVASC RES, V58, P10, DOI 10.1016/S0008-6363(02)00827-1
   Saito Y, 2007, MOL VIS, V13, P840
   Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102
   SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tosini G, 2012, EXP EYE RES, V103, P82, DOI 10.1016/j.exer.2012.08.009
   Uguz AC, 2009, J MEMBRANE BIOL, V232, P15, DOI 10.1007/s00232-009-9212-2
   Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x
   Uguz AC, 2012, NEUROCHEM RES, V37, P1631, DOI 10.1007/s11064-012-0758-5
   Wiechmann AF, 2008, PROG RETIN EYE RES, V27, P137, DOI 10.1016/j.preteyeres.2007.10.001
   Wilkinson-Berka JL, 2003, INVEST OPHTH VIS SCI, V44, P974, DOI 10.1167/iovs.02-0392
   Wolf EJ, 2007, J CATARACT REFR SURG, V33, P1546, DOI 10.1016/j.jcrs.2007.05.018
   Yanni SE, 2010, BRAIN RES BULL, V81, P310, DOI 10.1016/j.brainresbull.2009.10.018
NR 47
TC 28
Z9 29
U1 1
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2014
VL 28
IS 6
BP 752
EP 760
DI 10.1038/eye.2014.50
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK3QQ
UT WOS:000338340200017
PM 24603419
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Wittchen, ES
   Hartnett, ME
AF Wittchen, Erika S.
   Hartnett, M. Elizabeth
TI The Small GTPase Rap1 Is a Novel Regulator of RPE Cell Barrier Function
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; ACTIN CYTOSKELETON; ADHERENS JUNCTIONS; FACTOR SECRETION;
   EXCHANGE FACTOR; RHO-GTPASES; ADHESION; ACTIVATION
AB PURPOSE. To determine whether the small GTPase Rap1 regulates the formation and maintenance of the retinal pigment epithelial (RPE) cell junctional barrier.
   METHODS. An in vitro model was used to study RPE barrier properties. To dissect the role of Rap1, two techniques were used to inhibit Rap1 function: overexpression of RapGAP, which acts as a negative regulator of endogenous Rap1 activity, and treatment with engineered, adenovirally-transduced microRNAs to knockdown Rap1 protein expression. Transepithelial electrical resistance (TER) and real-time cellular analysis (RTCA) of impedance were used as readouts for barrier properties. Immunofluorescence microscopy was used to visualize localization of cadherins under steady state conditions and also during junctional reassembly after calcium switch. Finally, choroidal endothelial cell (CEC) migration across RPE monolayers was quantified under conditions of Rap1 inhibition in RPE.
   RESULTS. Knockdown of Rap1 or inhibition of its activity in RPE reduces TER and electrical impedance of the RPE monolayers. The loss of barrier function is also reflected by the mislocalization of cadherins and formation of gaps within the monolayer. TER measurement and immunofluorescent staining of cadherins after a calcium switch indicate that junctional reassembly kinetics are also impaired. Furthermore, CEC transmigration is significantly higher in Rap1-knockdown RPE monolayers compared with control.
   CONCLUSIONS. Rap1 GTPase is an important regulator of RPE cell junctions, and is required for maintenance of barrier function. This observation that RPE monolayers lacking Rap1 allow greater transmigration of CECs suggests a possible role for potentiating choroidal neovascularization during the pathology of neovascular age-related macular degeneration. (Invest Ophthalmol Vis Sci. 2011;52:7455-7463) DOI:10.1167/iovs.117295
C1 [Hartnett, M. Elizabeth] Univ Utah, Moran Eye Ctr, Dept Ophthalmol, Salt Lake City, UT 84132 USA.
   [Wittchen, Erika S.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC USA.
C3 Utah System of Higher Education; University of Utah; University of North
   Carolina; University of North Carolina Chapel Hill
RP Hartnett, ME (通讯作者)，Univ Utah, Moran Eye Ctr, Dept Ophthalmol, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM me.hartnett@hsc.utah.edu
FU (NEI/NIH) (MEH) [R01 EY017011]; American Heart Association
   [10SDG3430042, R01-GM029860, ARRA 3-R01-GM029860-28S]; NATIONAL EYE
   INSTITUTE [P30EY014800, R01EY017011] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding
   Source: NIH RePORTER
FX Supported by R01 EY017011 (NEI/NIH) (MEH), American Heart Association
   Scientist Development Grant 10SDG3430042 (ESW), R01-GM029860, and ARRA
   3-R01-GM029860-28S.
CR Aghajanian A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008045
   Atienza JM, 2006, ASSAY DRUG DEV TECHN, V4, P597, DOI 10.1089/adt.2006.4.597
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Bhutto IA, 2008, ARCH OPHTHALMOL-CHIC, V126, P670, DOI 10.1001/archopht.126.5.670
   Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0
   CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853
   Chrzanowska-Wodnicka M, 2005, J CLIN INVEST, V115, P680, DOI 10.1172/JCI200522973
   Cullere X, 2005, BLOOD, V105, P1950, DOI 10.1182/blood-2004-05-1987
   Duchniewicz M, 2006, MOL CELL BIOL, V26, P643, DOI 10.1128/MCB.26.2.643-653.2006
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fukuhra S, 2006, J BIOCHEM MOL BIOL, V39, P132
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Gieser JP, 2001, ARCH OPHTHALMOL-CHIC, V119, P899
   Gloerich M, 2010, ANNU REV PHARMACOL, V50, P355, DOI 10.1146/annurev.pharmtox.010909.105714
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   Hogan C, 2004, MOL CELL BIOL, V24, P6690, DOI 10.1128/mcb.24.15.6690-6700.2004
   JANOUEIXLEROSEY I, 1992, BIOCHEM BIOPH RES CO, V189, P455, DOI 10.1016/0006-291X(92)91580-J
   Kooistra MRH, 2005, FEBS LETT, V579, P4966, DOI 10.1016/j.febslet.2005.07.080
   Lampugnani Maria Grazia, 2010, J Biol, V9, P16, DOI 10.1186/jbiol232
   Li Y, 2007, J IMMUNOL, V179, P8322, DOI 10.4049/jimmunol.179.12.8322
   MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4
   Peng SM, 2011, INVEST OPHTH VIS SCI, V52, P1392, DOI 10.1167/iovs.10-5984
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200
   Rizzolo LJ, 2007, INT REV CYTOL, V258, P195, DOI 10.1016/S0074-7696(07)58004-6
   RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D
   Sakurai A, 2006, MOL BIOL CELL, V17, P966, DOI 10.1091/mbc.E05-07-0647
   Scheffzek K, 2005, CELL MOL LIFE SCI, V62, P3014, DOI 10.1007/s00018-005-5136-x
   Sehrawat S, 2008, MOL BIOL CELL, V19, P1261, DOI 10.1091/mbc.E06-10-0972
   Solly K, 2004, ASSAY DRUG DEV TECHN, V2, P363, DOI 10.1089/adt.2004.2.363
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tian J, 2004, PHYSIOL GENOMICS, V17, P170, DOI 10.1152/physiolgenomics.00179.2003
   Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463
   VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
   Wittchen ES, 2008, METHOD ENZYMOL, V443, P285, DOI 10.1016/S0076-6879(08)02014-4
   Wittchen ES, 2005, J BIOL CHEM, V280, P11675, DOI 10.1074/jbc.M412595200
   Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9
NR 53
TC 24
Z9 25
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2011
VL 52
IS 10
BP 7455
EP 7463
DI 10.1167/iovs.11-7295
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 827YU
UT WOS:000295467200055
PM 21873678
OA Green Published
DA 2022-11-30
ER

PT J
AU Ahlers, C
   Golbaz, I
   Einwallner, E
   Dunavolgyi, R
   Malamos, P
   Stock, G
   Pruente, C
   Schmidt-Erfurth, U
AF Ahlers, Christian
   Golbaz, Isabelle
   Einwallner, Elisa
   Dunavoelgyi, Roman
   Malamos, Panagiotis
   Stock, Geraldine
   Pruente, Christian
   Schmidt-Erfurth, Ursula
TI Identification of Optical Density Ratios in Subretinal Fluid as a
   Clinically Relevant Biomarker in Exudative Macular Disease
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; AGE-RELATED MACULOPATHY; COHERENCE
   TOMOGRAPHY; ULTRAHIGH-RESOLUTION; DEGENERATION; RANIBIZUMAB; PREVALENCE;
   VERTEPORFIN; VEGF; EYE
AB PURPOSE. To investigate the potential role of optical density ratios (ODRs) obtained from subretinal fluid analysis in exudative macular disease and to identify the predictive role of ODRs under therapy in comparison to conventional morphometric measurements (CMMs).
   METHODS. Fifteen patients with neovascular age-related macular degeneration (nAMD) and 15 with acute central serous chorioretinopathy (CSC) were included in this prospective comparative and interventional case series. High-definition optical coherence tomography (SD-OCT) was performed according to a standardized protocol. nAMD patients received a standard treatment consisting of three monthly doses of intravitreous ranibizumab. Best corrected visual acuity (BCVA) was assessed at baseline (BSL) and weeks 2, 4, and 12. SD-OCT parameters were compared between CSC and nAMD at baseline. Predictive factors for functional recovery under ranibizumab treatment were identified in patients with nAMD.
   RESULTS. ODR showed highly significant differences between CSC and nAMD, whereas it was not possible to differentiate between these diseases on the basis of CMM. During follow-up, CMM correlated with BCVA at BSL only, whereas ODR showed a significant correlation with BCVA at week 4 and 12 during antiangiogenic therapy.
   CONCLUSIONS. Results suggest that CMM may correlate with BCVA at BSL, but has limited predictive value regarding recovery of visual function. Most interesting, ODR correlated with BCVA under therapy and was the only parameter that was pathognomic for nAMD in contrast to CSC in this study. ODR may reflect the status of the blood-retina barrier and may be used for pathophysiologic differentiation and prognostic purposes in exudative macular disease. (Invest Ophthalmol Vis Sci. 2009;50:3417-3424) DOI:10.1167/iovs.08-2759
C1 [Ahlers, Christian; Golbaz, Isabelle; Einwallner, Elisa; Dunavoelgyi, Roman; Malamos, Panagiotis; Stock, Geraldine; Pruente, Christian; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
C3 Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Dunavoelgyi, Roman/0000-0002-1842-240X; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311
FU Carl Zeiss Meditec
FX Supported by Carl Zeiss Meditec, which provided a high-definition OCT
   system.
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Barthelmes D, 2008, INVEST OPHTH VIS SCI, V49, P3529, DOI 10.1167/iovs.07-1320
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   KLEIN ML, 1974, ARCH OPHTHALMOL-CHIC, V91, P247
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Ojima Y, 2007, OPHTHALMOLOGY, V114, P2197, DOI 10.1016/j.ophtha.2007.02.015
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 20
TC 32
Z9 34
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2009
VL 50
IS 7
BP 3417
EP 3424
DI 10.1167/iovs.08-2759
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 461SP
UT WOS:000267292100050
PM 19168899
DA 2022-11-30
ER

PT J
AU Kaur, C
   Foulds, WS
   Ling, EA
AF Kaur, C.
   Foulds, W. S.
   Ling, E. A.
TI Blood-retinal barrier in hypoxic ischaemic conditions: Basic concepts,
   clinical features and management
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Blood retinal barrier; Hypoxia-ischaemia; Vascular endothelial growth
   factor; Anti-VEGF therapy
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA;
   INTERCELLULAR-ADHESION MOLECULE-1; FIBRILLARY ACIDIC PROTEIN; MULLER
   GLIAL-CELLS; KAPPA-B ACTIVATION; PIGMENT EPITHELIUM; BRAIN-BARRIER;
   NITRIC-OXIDE; TIGHT JUNCTIONS
AB The blood-retinal barrier (BRB) plays an important role in the homeostatic regulation of the micro-environment in the retina. It consists of inner and outer components, the inner BRB (iBRB) being formed by the tight junctions between neighbouring retinal capillary endothelial cells and the outer barrier (oBRB) by tight junctions between retinal pigment epithelial cells. Astrocytes. Muller cells and pericytes contribute to the proper functioning of the iBRB. In many clinically important conditions including diabetic retinopathy, ischaemic central retinal vein occlusion, and some respiratory diseases, retinal hypoxia results in a breakdown of the iBRB. Disruption of the iBRB associated with increased vascular permeability, results in vasogenic oedema and tissue damage, with consequent adverse effects upon vision. Factors such as enhanced production of vascular endothelial growth factor (VEGF), NO, oxidative stress and inflammation underlie the increased permeability of the iBRB and inhibition of these factors is beneficial. Experimental studies in our laboratory have shown melatonin to be a protective agent for the iBRB in hypoxic conditions.
   Although oBRB breakdown Can occur in conditions such as accelerated hypertension and the toxaemia of pregnancy, both of which are associated with choroidal ischaemia and in age-related macular degeneration (ARMD), and is a feature of exudative (serous) retinal detachment, our studies have shown that the oBRB remains intact in hypoxic/ischaemic conditions. Clinically, anti-VEGF therapy has been shown to improve vision in diabetic maculopathy and in neovascular ARMD. The visual benefit in both conditions appears to arise from the restoration of BRB integrity with a reduction of retinal oedema. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Kaur, C.; Ling, E. A.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore.
   [Kaur, C.; Foulds, W. S.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Foulds, W. S.] Natl Univ Singapore Hosp, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 119074, Singapore.
   [Foulds, W. S.] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland.
C3 National University of Singapore; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   University of Glasgow
RP Kaur, C (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Block MD10,4 Med Dr, Singapore 117597, Singapore.
EM antkaurc@nus.edu.sg
FU National University of Singapore and a research [R-181-000-098112];
   Singapore Biomedical Research Council [05/1/35/19/422]; Nature
   Publishing Group; Ophthaltnological Societies of the United Kingdom
FX This study was supported by a research grant (R-181-000-098112) from the
   National University of Singapore and a research grant (05/1/35/19/422)
   from the Singapore Biomedical Research Council. The help provided by Dr
   Viswanathan Sivakumar in the preparation of the manuscript is gratefully
   acknowledged. Figs. 3 and 7A are reproduced with permission of the
   Nature Publishing Group in respect of earlier publication in the
   Transactions of the Ophthaltnological Societies of the United Kingdom or
   in Eye. Fig. 9 is modified from an illustration in the Journal of
   Pathology and Bacteriology (nowJoumal of Pathology). Fig. 9D and 16 was
   provided by Professor W.R. Lee.
CR ABE Y, 1990, J IMMUNOL, V145, P2902
   Agrawal A, 2006, SURV OPHTHALMOL, V51, P129, DOI 10.1016/j.survophthal.2005.12.003
   Ahmadieh H, 2008, GRAEF ARCH CLIN EXP, V246, P483, DOI 10.1007/s00417-007-0688-0
   Aijaz S, 2006, INT REV CYTOL, V248, P261, DOI 10.1016/S0074-7696(06)48005-0
   Akopov S, 1996, CEREBROVAS BRAIN MET, V8, P11
   Alm A., 1992, ADLERS PHYSL EYE, P198
   ANDERSON DR, 1975, ARCH OPHTHALMOL-CHIC, V93, P267
   ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467
   Antcliff RJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P539
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Arend O, 1996, OPHTHALMOLOGY, V103, P80, DOI 10.1016/S0161-6420(96)30729-X
   ARMSTRONG D, 1991, FREE RADICAL BIO MED, V11, P433, DOI 10.1016/0891-5849(91)90161-U
   ASHTON N, 1963, J PATHOL BACTERIOL, V86, P453, DOI 10.1002/path.1700860220
   Ashton N, 1965, Trans Ophthalmol Soc U K, V85, P199
   AUGUSTIN AJ, 1993, GRAEF ARCH CLIN EXP, V231, P647, DOI 10.1007/BF00921959
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Balabanov R, 1998, J NEUROSCI RES, V53, P637, DOI 10.1002/(SICI)1097-4547(19980915)53:6<637::AID-JNR1>3.0.CO;2-6
   BALAZS EA, 1982, BIOMEDICAL F OPHTHAL, V1, P6
   BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420
   Bamforth SD, 1997, AM J PATHOL, V150, P329
   Bandopadhyay R, 2001, J NEUROCYTOL, V30, P35, DOI 10.1023/A:1011965307612
   Barber AJ, 2000, INVEST OPHTH VIS SCI, V41, P3561
   Behzadian MA, 2001, INVEST OPHTH VIS SCI, V42, P853
   BERNSTEIN M. H., 1965, INVEST OPHTHAL MOL, V4, P1016
   BERTRAM B, 1991, Fortschritte der Ophthalmologie, V88, P321
   BILL A, 1990, EYE, V4, P319, DOI 10.1038/eye.1990.43
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Bolanos JP, 1999, BBA-BIOENERGETICS, V1411, P415, DOI 10.1016/S0005-2728(99)00030-4
   Bringmann A, 2000, MICROSC RES TECHNIQ, V50, P384, DOI 10.1002/1097-0029(20000901)50:5<384::AID-JEMT7>3.0.CO;2-W
   Bringmann A, 2005, ACTA OPHTHALMOL SCAN, V83, P528, DOI 10.1111/j.1600-0420.2005.00565.x
   BROWN GC, 1988, INT OPHTHALMOL, V11, P239, DOI 10.1007/BF00131023
   Brown JC, 2004, ARCH OPHTHALMOL-CHIC, V122, P330, DOI 10.1001/archopht.122.3.330
   BUNTMILAM AH, 1985, INVEST OPHTH VIS SCI, V26, P1377
   Cahill MT, 2003, AM J OPHTHALMOL, V136, P1136, DOI 10.1016/S0002-9394(03)00571-3
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Campochiaro PA, 2007, CURR GENE THER, V7, P25, DOI 10.2174/156652307779940252
   CHADER GJ, 1989, INVEST OPHTH VIS SCI, V30, P7
   CHADER GJ, 1982, CELL BIOL EYE, P377
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chen Q, 1997, INVEST OPHTH VIS SCI, V38, P643
   Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4
   Clarkson JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P486
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1425
   COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014
   Cohen L., 1965, BIOCH EYE, P36
   COX SN, 1988, ARCH OPHTHALMOL-CHIC, V106, P1190
   Croll SD, 2004, EXP NEUROL, V187, P388, DOI 10.1016/j.expneurol.2004.02.010
   CUNHAVAZ JG, 1976, DOC OPHTHALMOL, V41, P287, DOI 10.1007/BF00146764
   CUNHAVAZ JG, 1978, AM J OPHTHALMOL, V86, P467, DOI 10.1016/0002-9394(78)90291-X
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   Cunningham MA, 2008, SURV OPHTHALMOL, V53, P139, DOI 10.1016/j.survophthal.2007.12.005
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dallasta LM, 1999, AM J PATHOL, V155, P1915, DOI 10.1016/S0002-9440(10)65511-3
   Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3
   DAMATO BE, 1990, EYE, V4, P382, DOI 10.1038/eye.1990.51
   De Venecia G, 1976, Arch Ophthalmol, V94, P1766
   DEUEL TF, 1981, P NATL ACAD SCI-BIOL, V78, P4584, DOI 10.1073/pnas.78.7.4584
   DEVENECIA G, 1984, ARCH OPHTHALMOL-CHIC, V102, P68, DOI 10.1001/archopht.1984.01040030052033
   DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289
   Distler C, 1996, VISION RES, V36, P2381, DOI 10.1016/0042-6989(96)00005-3
   DITZEL J, 1976, DIABETES, V25, P832
   DOBREE J H, 1970, British Journal of Ophthalmology, V54, P1, DOI 10.1136/bjo.54.1.1
   Dobrogowska DH, 1998, J NEUROCYTOL, V27, P163, DOI 10.1023/A:1006907608230
   DOWLING JE, 1961, AM J CLIN NUTR, V9, P23, DOI 10.1093/ajcn/9.4.23
   Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7
   Dubois-Dauphin M, 2000, NEUROSCIENCE, V95, P9
   Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487
   Duh EJ, 2002, INVEST OPHTH VIS SCI, V43, P821
   EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4
   Eichler W, 2000, NEUROREPORT, V11, P3533, DOI 10.1097/00001756-200011090-00026
   Eichler W, 2001, NEUROREPORT, V12, P4103, DOI 10.1097/00001756-200112210-00048
   EKSTROM P, 1988, INVEST OPHTH VIS SCI, V29, P1363
   El-Remessy AB, 2003, AM J PATHOL, V162, P1995, DOI 10.1016/S0002-9440(10)64332-5
   ELNER VM, 1990, AM J PATHOL, V136, P745
   Esser S, 1998, J CELL SCI, V111, P1853
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   *ETDRS, 1985, ARCH OPHTHALMOL-CHIC, V103, P1677
   FATT I, 1971, EXP EYE RES, V12, P218, DOI 10.1016/0014-4835(71)90094-7
   FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761
   FFYTCHE TJ, 1974, BRIT J OPHTHALMOL, V58, P514, DOI 10.1136/bjo.58.5.514
   Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367
   FISHMAN GA, 1989, ARCH OPHTHALMOL-CHIC, V107, P1445, DOI 10.1001/archopht.1989.01070020519031
   FONG ACO, 1993, SURV OPHTHALMOL, V37, P393, DOI 10.1016/0039-6257(93)90138-W
   FORBES MS, 1977, AM J ANAT, V149, P47, DOI 10.1002/aja.1001490105
   FOULDS W. S., 1966, INVEST OPHTHALHOL, V5, P93
   FOULDS WS, 1979, BRIT J OPHTHALMOL, V63, P71, DOI 10.1136/bjo.63.2.71
   FOULDS WS, 1975, T OPHTHAL SOC UK, V95, P118
   FOULDS WS, 1990, EYE, V4, P243, DOI 10.1038/eye.1990.35
   FOULDS WS, 1985, BRIT J OPHTHALMOL, V69, P529, DOI 10.1136/bjo.69.7.529
   FOULDS WS, 1985, BRIT J OPHTHALMOL, V69, P237, DOI 10.1136/bjo.69.4.237
   FOULDS WS, 1973, T OPHTHAL SOC UK, V93, P343
   FOULDS WS, 1964, THESIS U GLASGOW
   FOULDS WS, 1961, MOD PROBL OPHTHAL, V4, P233
   FRANK RN, 1990, INVEST OPHTH VIS SCI, V31, P999
   Fraser-Bell S, 2008, CURR OPIN OPHTHALMOL, V19, P185, DOI 10.1097/ICU.0b013e3282fb7c45
   Fraunfelder FW, 2005, DRUG TODAY, V41, P703, DOI 10.1358/dot.2005.41.11.917340
   Frenkel-Denkberg G, 1999, FEBS LETT, V462, P341, DOI 10.1016/S0014-5793(99)01552-5
   Fukumura D, 2001, CANCER RES, V61, P6020
   Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539
   Futter CE, 2006, PIGM CELL RES, V19, P104, DOI 10.1111/j.1600-0749.2006.00303.x
   Gardner T W, 1995, Trans Am Ophthalmol Soc, V93, P583
   Gardner TW, 1997, INVEST OPHTH VIS SCI, V38, P2423
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Grammas P, 2003, MICROVASC RES, V65, P18, DOI 10.1016/S0026-2862(02)00016-X
   GREGORY CY, 1988, T BIOCH SOC, V16, P319
   GRIERSON I, 1978, ACTA OPHTHALMOL, V56, P935
   GROSCHE J, 1995, NEUROSCI LETT, V185, P119, DOI 10.1016/0304-3940(94)11239-F
   Grover D, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005656.pub2
   GUNDERSEN D, 1993, J CELL BIOL, V121, P335, DOI 10.1083/jcb.121.2.335
   GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863
   Haefliger IO, 1997, INVEST OPHTH VIS SCI, V38, P1563
   HAEFLIGER IO, 1994, INVEST OPHTH VIS SCI, V35, P991
   HANSSON HA, 1970, EXP EYE RES, V9, P285, DOI 10.1016/S0014-4835(70)80086-0
   Harris A, 1996, BRIT J OPHTHALMOL, V80, P209, DOI 10.1136/bjo.80.3.209
   Hauser D, 2008, RETINA-J RET VIT DIS, V28, P825, DOI 10.1097/IAE.0b013e318165767e
   HAYREH SS, 1994, AM J OPHTHALMOL, V117, P429, DOI 10.1016/S0002-9394(14)70001-7
   Heath H, 1962, Br J Ophthalmol, V46, P385, DOI 10.1136/bjo.46.7.385
   HENKIND PAUL, 1967, INVEST OPHTHALMOL, V6, P103
   HIRANO A, 1994, MICROSC RES TECHNIQ, V27, P543, DOI 10.1002/jemt.1070270609
   Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6
   Hofman P, 2000, CURR EYE RES, V21, P637, DOI 10.1076/0271-3683(200008)21:2;1-V;FT637
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Hughes S, 2006, NEUROBIOL AGING, V27, P1838, DOI 10.1016/j.neurobiolaging.2005.10.021
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Jablonski MM, 2001, GLIA, V35, P14, DOI 10.1002/glia.1066
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Jiang SN, 2000, INVEST OPHTH VIS SCI, V41, P645
   Jin M, 2004, INVEST OPHTH VIS SCI, V45, P323, DOI 10.1167/iovs.03-0355
   Jin ML, 2002, INVEST OPHTH VIS SCI, V43, P2782
   Jo N, 2003, INVEST OPHTH VIS SCI, V44, P4054, DOI 10.1167/iovs.02-1308
   JOHNSON NF, 1975, EXP EYE RES, V20, P97, DOI 10.1016/0014-4835(75)90147-5
   JOHNSON NF, 1977, T OPHTHAL SOC UK, V97, P640
   JOHNSON NF, 1976, ACTA OPHTHALMOL, V54, P529
   JOHNSON NF, 1977, BRIT J OPHTHALMOL, V61, P564, DOI 10.1136/bjo.61.9.564
   JOHNSON NF, 1975, ACTA OPHTHALMOL, V53, P321
   JOHNSON NF, 1977, T OPHTHAL SOC UK, V97, P557
   JOHNSON NF, 1978, EXP EYE RES, V27, P45, DOI 10.1016/0014-4835(78)90052-0
   JOHNSON NF, 1976, VISION CIRCULATION, P79
   Josko J, 2004, MED SCI MONITOR, V10, pRA89
   Josko J, 2003, FOLIA NEUROPATHOL, V41, P161
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Joussen AM, 2003, OPHTHALMOLOGE, V100, P363, DOI 10.1007/s00347-003-0800-8
   Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   JUTTE A, 1980, KLIN MONATSBL AUGENH, V177, P1, DOI 10.1055/s-2008-1057601
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   Kaur C, 2007, J PATHOL, V212, P429, DOI 10.1002/path.2195
   Kaur C, 2006, INVEST OPHTH VIS SCI, V47, P1126, DOI 10.1167/iovs.05-0518
   KEEGAN WA, 1985, EXP EYE RES, V40, P619, DOI 10.1016/0014-4835(85)90084-3
   KEFALIDES NA, 1978, P 1 INT S BIOL CHEM, P215
   Kennedy BG, 2002, MOL VIS, V8, P422
   KERR C, 1986, THESIS U GLASGOW
   Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099
   Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200
   Kim JE, 2008, RETINA-J RET VIT DIS, V28, P735, DOI 10.1097/IAE.0b013e318163194c
   Koto T, 2007, AM J PATHOL, V170, P1389, DOI 10.2353/ajpath.2007.060693
   Krebs I, 2008, BRIT J OPHTHALMOL, V92, P933, DOI 10.1136/bjo.2007.128447
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   KROLL AJ, 1968, AM J OPHTHALMOL, V66, P410, DOI 10.1016/0002-9394(68)91524-9
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   KUWABARA T, 1963, ARCH OPHTHALMOL-CHIC, V69, P492, DOI 10.1001/archopht.1963.00960040498013
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Lossinsky AS, 2004, HISTOL HISTOPATHOL, V19, P535, DOI 10.14670/HH-19.535
   LOWE GD, 1986, DIABETES RES CLIN EX, V3, P67
   LOWE GDO, 1980, DIABETOLOGIA, V18, P359
   Lu M, 1999, INVEST OPHTH VIS SCI, V40, P1808
   Mark KS, 2004, AM J PHYSIOL-HEART C, V286, pH174, DOI 10.1152/ajpheart.00669.2002
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P893
   MARMOR MF, 2006, RETINA, P1891
   MARTINEY JA, 1990, AM J PATHOL, V137, P1411
   Mathews MK, 1997, INVEST OPHTH VIS SCI, V38, P2729
   Matsugi T, 1997, ARCH OPHTHALMOL-CHIC, V115, P1281, DOI 10.1001/archopht.1997.01100160451011
   MATSUGI T, 1976, INVEST OPHTH VIS SCI, V38, P2695
   Mayhan WG, 1999, AM J PHYSIOL-CELL PH, V276, pC1148, DOI 10.1152/ajpcell.1999.276.5.C1148
   MCKECHNIE NM, 1982, INVEST OPHTH VIS SCI, V22, P449
   MCNAUGHT EI, 1988, EYE, V2, P288, DOI 10.1038/eye.1988.55
   MCNAUGHT EI, 1977, T OPHTHAL SOC UK, V97, P634
   MCNAUGHT EI, 1981, BRIT J OPHTHALMOL, V65, P473, DOI 10.1136/bjo.65.7.473
   MELLI M, 1983, RES CLIN LAB, V13, P371
   MENDRINOS E, ACTA OPHTHA IN PRESS
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   MILLER S, 1976, EXP EYE RES, V23, P177, DOI 10.1016/0014-4835(76)90201-3
   MILLER SS, 1982, P NATL ACAD SCI-BIOL, V79, P2111, DOI 10.1073/pnas.79.6.2111
   Min JK, 2005, J IMMUNOL, V175, P531, DOI 10.4049/jimmunol.175.1.531
   Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121
   Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836
   MOLNAR I, 1985, INVEST OPHTH VIS SCI, V26, P1410
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   MOSELEY H, 1984, BRIT J OPHTHALMOL, V68, P145, DOI 10.1136/bjo.68.3.145
   MOSELEY H, 1981, DOC OPHTHALMOL, V25, P87
   MURATA T, 1995, OPHTHALMIC RES, V27, P48, DOI 10.1159/000267567
   Musch MW, 2006, AM J PHYSIOL-GASTR L, V290, pG222, DOI 10.1152/ajpgi.00301.2005
   NEGI A, 1986, INVEST OPHTH VIS SCI, V27, P1564
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Nishijima K, 2004, INVEST OPHTH VIS SCI, V45, P977, DOI 10.1167/iovs.03-0526
   OKADA M, 1990, GRAEF ARCH CLIN EXP, V228, P467, DOI 10.1007/BF00927264
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181
   Parodi MB, 2008, BRIT J OPHTHALMOL, V92, P1046, DOI 10.1136/bjo.2007.128025
   PEARSE AGE, 1961, STRUCTURE EYE, P53
   Pederson J.E., 2006, RETINA, P1909
   PEDUZZI M, 1984, INT OPHTHALMOL, V7, P15, DOI 10.1007/BF00138264
   PEER J, 1995, LAB INVEST, V72, P638
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Petty MA, 2002, PROG NEUROBIOL, V68, P311, DOI 10.1016/S0301-0082(02)00128-4
   Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1716, DOI 10.1167/iovs.02-0287
   POITRYYAMATE CL, 1995, J NEUROSCI, V15, P5179
   PORRELLO K, 1986, INVEST OPHTH VIS SCI, V27, P1577
   POURNARAS CJ, 1989, EXP EYE RES, V49, P347, DOI 10.1016/0014-4835(89)90045-6
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006
   Purtscher O., 1912, GRAEFES ARCH OPHTHAL, V82, P347
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   RAHI AHS, 1975, T OPHTHAL SOC UK, V95, P180
   Reichenbach A, 2007, GRAEF ARCH CLIN EXP, V245, P627, DOI 10.1007/s00417-006-0516-y
   REMPKY A, 1996, GRAEFES ARCH CLIN S1, V234, pS8
   RIVA CE, 1981, INVEST OPHTH VIS SCI, V21, P34
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   Roberts WG, 1997, CANCER RES, V57, P765
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   ROBINSON F, 1986, INVEST OPHTH VIS SCI, V27, P722
   RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330
   ROHLICH P, 1970, EXP EYE RES, V10, P80, DOI 10.1016/S0014-4835(70)80013-6
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rungger-Brandle E, 2000, INVEST OPHTH VIS SCI, V41, P1971
   Russ PK, 1998, INVEST OPHTH VIS SCI, V39, P2479
   SAGATIES MJ, 1987, INVEST OPHTH VIS SCI, V28, P2000
   Sakagami K, 1999, J PHYSIOL-LONDON, V521, P637, DOI 10.1111/j.1469-7793.1999.00637.x
   SAUGSTAD OD, 1988, PEDIATRICS, V81, P395
   SCHNITZER J, 1987, NEUROSCI LETT, V78, P29, DOI 10.1016/0304-3940(87)90556-8
   SCHNITZER J, 1988, GLIA, V1, P74, DOI 10.1002/glia.440010109
   SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399
   Schoch HJ, 2002, BRAIN, V125, P2549, DOI 10.1093/brain/awf257
   Schonfelder U, 1998, MICROVASC RES, V56, P22, DOI 10.1006/mvre.1998.2086
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   SEBAG J, 1989, VITREOUS STRUCTURE F, P47
   SHAKIB M, 1966, EXP EYE RES, V5, P229, DOI 10.1016/S0014-4835(66)80011-8
   SHALLAL A, 1990, EXP EYE RES, V50, P281, DOI 10.1016/0014-4835(90)90212-D
   SHELHAMER JH, 1985, ANN INTERN MED, V103, P121, DOI 10.7326/0003-4819-103-1-121
   SHEPRO D, 1993, FASEB J, V7, P1031, DOI 10.1096/fasebj.7.11.8370472
   Shibuya Masaubmi, 2006, Angiogenesis, V9, P225, DOI 10.1007/s10456-006-9055-8
   Shimura M, 2008, AM J OPHTHALMOL, V145, P854, DOI 10.1016/j.ajo.2007.12.031
   Shukla A, 1996, EXPERIENTIA, V52, P136, DOI 10.1007/BF01923358
   SIDMAN RL, 1958, ANN NY ACAD SCI, V74, P182, DOI 10.1111/j.1749-6632.1958.tb39543.x
   Simionescu M, 2002, MICROSC RES TECHNIQ, V57, P269, DOI 10.1002/jemt.10086
   SIMS DE, 1991, CAN J CARDIOL, V7, P431
   SINGERMAN LJ, BR J OPHTHA IN PRESS
   Sivakumar V, 2008, J NEUROSCI RES, V86, P702, DOI 10.1002/jnr.21519
   SLUITER W, 1993, J CARDIOVASC PHARM, V22, pS37, DOI 10.1097/00005344-199322004-00006
   SOHEILIAN M, 2008, RETINA, V27, P1187
   Soucek T, 2003, NEURON, V39, P43, DOI 10.1016/S0896-6273(03)00367-2
   Spoerri PE, 2006, MOL VIS, V12, P32
   Stamer WD, 2003, INVEST OPHTH VIS SCI, V44, P2803, DOI 10.1167/iovs.03-0001
   STARITA C, 1997, INVEST OPHTH VIS SCI, V38, P62
   Stefansson E, 2001, ACTA OPHTHALMOL SCAN, V79, P435, DOI 10.1034/j.1600-0420.2001.790502.x
   STEINBERG RH, 1977, PHILOS T ROY SOC B, V277, P459, DOI 10.1098/rstb.1977.0028
   Stepinac TK, 2005, INVEST OPHTH VIS SCI, V46, P956, DOI 10.1167/iovs.04-0500
   Strunnikova N, 2001, INVEST OPHTH VIS SCI, V42, P2130
   Sutter FKP, 2004, OPHTHALMOLOGY, V111, P2044, DOI 10.1016/j.ophtha.2004.05.025
   TAILOI CL, 1992, INVEST OPHTH VIS SCI, V33, P2148
   Takeda N, 2001, DIABETOLOGIA, V44, P1043, DOI 10.1007/s001250100588
   TAKEUCHI A, 1994, INVEST OPHTH VIS SCI, V35, P3792
   Thiel VE, 2001, ANTIOXID REDOX SIGN, V3, P273, DOI 10.1089/152308601300185223
   Torii H, 2007, PHARMACOL RES, V55, P104, DOI 10.1016/j.phrs.2006.10.010
   TORIS CB, 1990, INVEST OPHTH VIS SCI, V31, P43
   TOUT S, 1993, NEUROSCIENCE, V55, P291, DOI 10.1016/0306-4522(93)90473-S
   Tretiach M, 2005, NEUROSCI LETT, V378, P160, DOI 10.1016/j.neulet.2004.12.026
   TROPE GE, 1983, BRIT J OPHTHALMOL, V67, P137, DOI 10.1136/bjo.67.3.137
   TSACOPOULOS M, 1976, VISION CIRCULATION, P93
   Tserentsoodol N, 1998, HISTOCHEM CELL BIOL, V110, P543, DOI 10.1007/s004180050316
   TSUBOI S, 1987, INVEST OPHTH VIS SCI, V28, P92
   Tsujikawa A, 1999, INVEST OPHTH VIS SCI, V40, P1183
   Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088
   Usatyuk PV, 2004, J BIOL CHEM, V279, P11789, DOI 10.1074/jbc.M311184200
   VINORES SA, 1990, LAB INVEST, V62, P742
   Vinores SA, 1999, DOC OPHTHALMOL, V97, P217, DOI 10.1023/A:1002136712070
   Vinores SA, 2007, J NEUROIMMUNOL, V182, P73, DOI 10.1016/j.jneuroim.2006.09.015
   VLASSARA H, 1986, CLIN CHEM, V32, pB37
   WAKAKURA M, 1993, EXP EYE RES, V56, P17, DOI 10.1006/exer.1993.1004
   WAKAKURA M, 1989, EXP EYE RES, V48, P337, DOI 10.1016/S0014-4835(89)80003-X
   WALLOW IH, 1980, INVEST OPHTH VIS SCI, V19, P1433
   WALLOW IHL, 1977, INVEST OPHTH VIS SCI, V16, P447
   WALLOW IHL, 1980, INVEST OPHTH VIS SCI, V19, P1176
   Wang YL, 2007, EYE, V21, P1501, DOI 10.1038/sj.eye.6702716
   WATANABE T, 1988, NATURE, V332, P834, DOI 10.1038/332834a0
   WELLS RE, 1961, SCIENCE, V133, P763, DOI 10.1126/science.133.3455.763
   Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575
   Wilkinson-Berka JL, 2004, CURR PHARM DESIGN, V10, P3331, DOI 10.2174/1381612043383142
   Williams CD, 1997, ANAT RECORD, V249, P380, DOI 10.1002/(SICI)1097-0185(199711)249:3<380::AID-AR9>3.0.CO;2-Y
   Willis CL, 2004, GLIA, V48, P1, DOI 10.1002/glia.20049
   WILSON DJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P100, DOI 10.1001/archopht.1988.01060130106038
   WILSON TM, 1973, EXP EYE RES, V16, P421, DOI 10.1016/0014-4835(73)90099-7
   WILSON TM, 1977, INVEST OPHTH VIS SCI, V16, P576
   WILSON TM, 1976, VISION CIRCULATION, P45
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Winkler BS, 2004, NEUROCHEM INT, V45, P311, DOI 10.1016/j.neuint.2003.08.017
   Winkler BS, 1999, MOL VIS, V5
   Winkler BS, 2000, INVEST OPHTH VIS SCI, V41, P3183
   Witt KA, 2003, AM J PHYSIOL-HEART C, V285, pH2820, DOI 10.1152/ajpheart.00589.2003
   WU LZ, 1985, JPN J OPHTHALMOL, V29, P406
   Yang ZL, 2005, HUM MOL GENET, V14, P255, DOI 10.1093/hmg/ddi023
   Yannuzzi LA, 1996, ARCH OPHTHALMOL-CHIC, V114, P545
   Yoshida S, 2004, GRAEF ARCH CLIN EXP, V242, P409, DOI 10.1007/s00417-004-0874-2
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   ZAUBERMAN H, 1972, ARCH OPHTHALMOL-CHIC, V87, P549
   Zhang YF, 1997, INVEST OPHTH VIS SCI, V38, P1653
   Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002
   Zheng L, 2007, INVEST OPHTH VIS SCI, V48, P361, DOI 10.1167/iovs.06-0510
   ZIMMERMAN L E, 1958, Trans Am Acad Ophthalmol Otolaryngol, V62, P697
   Zinn KM, 1979, RETINAL PIGMENT EPIT, P3
NR 320
TC 272
Z9 292
U1 1
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2008
VL 27
IS 6
BP 622
EP 647
DI 10.1016/j.preteyeres.2008.09.003
PG 26
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 382RS
UT WOS:000261623700004
PM 18940262
DA 2022-11-30
ER

PT J
AU Simonelli, F
   Testa, F
   Zernant, J
   Nesti, A
   Rossi, S
   Rinaldi, E
   Allikmets, R
AF Simonelli, F
   Testa, F
   Zernant, J
   Nesti, A
   Rossi, S
   Rinaldi, E
   Allikmets, R
TI Association of a homozygous nonsense mutation in the ABCA4 (ABCR) gene
   with cone-rod dystrophy phenotype in an Italian family
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE cone-rod dystrophy; phenotype; ABCA4; Italian family; nonsense mutation
ID RECESSIVE RETINITIS-PIGMENTOSA; ARRAYED PRIMER EXTENSION;
   STARGARDT-DISEASE; MACULAR DEGENERATION; LOCUS; DEHYDROGENASE;
   LOCALIZATION; MICE
AB Genetic variation in the ABCA4 (ABCR) gene has been associated with several distinct retinal phenotypes, including Stargardt disease/fundus flavimaculatus (STGD/FFM), cone-rod dystrophy (CRD), retinitis pigmentosa (RP) and age-related macular degeneration. The current model of genotype/phenotype association suggests that patients harboring deleterious mutations in both ABCR alleles would develop RP-like retinal pathology. Here we describe ABCA4-associated phenotypes, including a proband with a homozygous nonsense mutation in a family from Southern Italy. The proband had been originally diagnosed with STGD. Ophthalmologic examination included kinetic perimetry, electrophysiological studies and fluorescein angiography. DNA of the affected individual and family members was analyzed for variants in all 50 exons of the ABCA4 gene by screening on the ABCR400 microarray. A homozygous nonsense mutation 2971G>T (G991X) was detected in a patient initially diagnosed with STGD based on funduscopic evidence, including bull's eye depigmentation of the fovea and flecks at the posterior pole extending to the mid-peripheral retina. Since this novel nucleotide substitution results in a truncated, nonfunctional, ABCA4 protein, the patient was examined in-depth for the severity of the disease phenotype. Indeed, subsequent electrophysiological studies determined severely reduced cone amplitude as compared to the rod amplitude, suggesting the diagnosis of CRD. ABCR400 microarray is an efficient tool for determining causal genetic variation, including new mutations. A homozygous protein-truncating mutation in ABCA4 can cause a phenotype ranging from STGD to CRD as diagnosed at an early stage of the disease. Only a combination of comprehensive genotype/phenotype correlation studies will determine the proper diagnosis and prognosis of ABCA4-associated pathology. Copyright (C) 2004 S. Karger AG, Basel.
C1 Second Univ Naples, Dept Ophthalmol, Naples, Italy.
   Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   Columbia Univ, Dept Pathol, New York, NY 10027 USA.
C3 Universita della Campania Vanvitelli; Columbia University; Columbia
   University
RP Simonelli, F (通讯作者)，Piazza Leonardo 14, IT-80129 Naples, Italy.
EM franctes@tin.it
RI Testa, Francesco/J-3185-2012; Rossi, Settimio/AHI-1119-2022; Simonelli,
   Francesca/AHE-7571-2022; Allikmets, Rando/ABD-4533-2021; Rossi,
   Settimio/J-4922-2012
OI Simonelli, Francesca/0000-0001-8520-6769; Testa,
   Francesco/0000-0002-1482-1577
FU NATIONAL EYE INSTITUTE [R01EY013435] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY13435] Funding Source: Medline
CR Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Assink J. J. M., 1998, IOVS, V39, pS295
   Birch DG, 2001, EXP EYE RES, V73, P877, DOI 10.1006/exer.2001.1093
   BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Briggs CE, 2001, INVEST OPHTH VIS SCI, V42, P2229
   Cideciyan AV, 2000, VISUAL NEUROSCI, V17, P667, DOI 10.1017/S0952523800175029
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   Danciger M, 2001, INVEST OPHTH VIS SCI, V42, P2458
   DEUTMAN AF, 2001, RETINA, P1210
   Fukui T, 2002, INVEST OPHTH VIS SCI, V43, P2819
   GERBER S, 1995, AM J HUM GENET, V56, P396
   Iida A, 2002, J HUM GENET, V47, P285, DOI 10.1007/s100380200041
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Khaliq S, 2000, INVEST OPHTH VIS SCI, V41, P3709
   Kurg A, 2000, GENET TEST, V4, P1, DOI 10.1089/109065700316408
   MARMOR MF, 1989, ARCH OPHTHALMOL-CHIC, V107, P816, DOI 10.1001/archopht.1989.01070010838024
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   MOORE AT, 1992, J MED GENET, V29, P289, DOI 10.1136/jmg.29.5.289
   Papaioannou M, 2000, INVEST OPHTH VIS SCI, V41, P16
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Payne AM, 1999, INVEST OPHTH VIS SCI, V40, pS603
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rozet JM, 1999, J MED GENET, V36, P447
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Shroyer NF, 2001, INVEST OPHTH VIS SCI, V42, P2757
   Simon A, 1996, GENOMICS, V36, P424, DOI 10.1006/geno.1996.0487
   Simonelli F, 2000, INVEST OPHTH VIS SCI, V41, P892
   SZYLYK JP, 1993, ARCH OPHTHALMOL-CHIC, V111, P781
   Tonisson N, 2002, P NATL ACAD SCI USA, V99, P5503, DOI 10.1073/pnas.082100599
   van Driel MA, 1998, OPHTHALMIC GENET, V19, P117, DOI 10.1076/opge.19.3.117.2187
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   YAGASAKI K, 1989, ARCH OPHTHALMOL-CHIC, V107, P701, DOI 10.1001/archopht.1989.01070010719034
NR 36
TC 16
Z9 18
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2004
VL 36
IS 2
BP 82
EP 88
DI 10.1159/000076886
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 802FK
UT WOS:000220149200003
PM 15017103
DA 2022-11-30
ER

PT J
AU Bowen, PE
   Espinosa, SM
   Hussain, EA
   Stacewicz-Sapuntzakis, M
AF Bowen, PE
   Espinosa, SM
   Hussain, EA
   Stacewicz-Sapuntzakis, M
TI Esterification does not impair lutein bioavailability in humans
SO JOURNAL OF NUTRITION
LA English
DT Article
DE lutein; lutein ester; bioavailability; humans
ID MACULAR DEGENERATION; BETA-CAROTENE; INTESTINAL-ABSORPTION; VITAMIN-E;
   SERUM; ZEAXANTHIN; SUPPLEMENTATION; VEGETABLES; PIGMENT; RISK
AB Age-related macular degeneration (ARMD) is inversely associated with the accumulation of lutein + zeaxanthin in the macula, but higher lutein intakes are inconsistently related to reduced risk of ARMD in epidemiologic studies. Resolution of efficacy awaits clinical trials designed with knowledge of lutein supplement pharmacokinetics. Lutein bioavailability was determined for lutein diester and unesterified lutein formulations as they might be incorporated into dietary supplements. Healthy subjects (n = 18) consumed a single dose of each formulation (either 0.5 or 0.67 mumol lutein/kg body, 10 and 8 subjects, respectively) in random order, and the appearance of free lutein + zeaxanthin was measured in serum from 0 to 408 h. Areas under the serum concentration X time curves (AUC), as a measure of bioavailability, were independent of gender, body mass index and lutein dose. The lutein diester formulation was 61.6% more bioavailable than the unesterified lutein formulation with higher mean AUC, maximum serum concentration and ascending slope (P < 0.05). The AUC was greater in 14 of 18 subjects when they consumed the lutein diester formulation. Comparison with data from previous studies suggested that dissolution was a greater limitation to bioavailability than lutein ester hydrolysis because an oil-solubilized unesterified lutein preparation, given at 0.5 mumol/kg body, resulted in greater mean peak concentrations and AUC compared with either the unesterified or lutein diester formulations used in our study. In conclusion, the lutein diester formulation poses no impediment to lutein bioavailability at the doses tested, but formulation dissolution is an important factor in lutein bioavailability and should be evaluated before a supplement and dose are selected for use in clinical trials.
C1 Univ Illinois, Dept Human Nutr, Chicago, IL 60680 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Bowen, PE (通讯作者)，Univ Illinois, Dept Human Nutr, Chicago, IL 60680 USA.
EM pbowen@uic.edu
OI Bowen, Phyllis/0000-0002-2950-3694
CR [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BERNDSCHOT TJM, 2000, INVESTIG OPHTHALMOL, V41, P3322
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Breithaupt DE, 2001, J AGR FOOD CHEM, V49, P2064, DOI 10.1021/jf001276t
   de Pee S, 1998, AM J CLIN NUTR, V68, P1058, DOI 10.1093/ajcn/68.5.1058
   Duewer DL, 2000, ANAL CHEM, V72, P3611, DOI 10.1021/ac991481b
   Furr HC, 1997, J NUTR BIOCHEM, V8, P364, DOI 10.1016/S0955-2863(97)00060-0
   Granado F, 1998, BRIT J NUTR, V80, P445, DOI 10.1017/S0007114598001512
   Gruszecki WI, 1999, ADV PHOTOSYNTH, V8, P363
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KHACHIK F, 1991, PURE APPL CHEM, V63, P71, DOI 10.1351/pac199163010071
   KOSTIC D, 1995, AM J CLIN NUTR, V62, P604, DOI 10.1093/ajcn/62.3.604
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   LEE DR, 1996, 1983 METROPOLITAN HE, P235
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Marzo A, 1998, PHARMACOL RES, V38, P401, DOI 10.1006/phrs.1998.0380
   Olmedilla B, 1997, CANCER LETT, V114, P179, DOI 10.1016/S0304-3835(97)04656-9
   Piccaglia R, 1998, IND CROP PROD, V8, P45, DOI 10.1016/S0926-6690(97)10005-X
   Roodenburg AJC, 2000, AM J CLIN NUTR, V71, P1187
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   STACEWICZSAPUNTZAKIS M, 1987, J MICRONUTR ANAL, V3, P27
   VANDEVEN M, 1984, BIOPHYS J, V45, P1203, DOI 10.1016/S0006-3495(84)84269-1
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   Wingerath T, 1995, ARCH BIOCHEM BIOPHYS, V324, P385, DOI 10.1006/abbi.1995.0052
   Zander E, 2000, BRIT J OPHTHALMOL, V84, P871, DOI 10.1136/bjo.84.8.871
NR 32
TC 135
Z9 151
U1 1
U2 26
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD DEC
PY 2002
VL 132
IS 12
BP 3668
EP 3673
DI 10.1093/jn/132.12.3668
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 625UB
UT WOS:000179833000017
PM 12468605
OA Bronze
DA 2022-11-30
ER

PT J
AU Munoz, B
   West, SK
AF Munoz, B
   West, SK
TI Blindness and visual impairment in the Americas and the Caribbean
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CATARACT-SURGERY; CHILDHOOD BLINDNESS; OLDER AMERICANS; SAO-PAULO;
   PREVALENCE; EYE; POPULATION; BARRIERS; CHILDREN; PROGRAMS
AB Aim: To summarise available data on the prevalence and causes of visual impairment and blindness in the Americas and the Caribbean.
   Methods: The published literature was searched in Medline and LILACS using the following key words: blindness, visual impairment, prevalence. Articles were reviewed, and the references a the articles were also searched for relevant articles, which were also reviewed.
   Results: Using the mortality in children under the age of 5 as an indicator, the overall prevalence of childhood blindness (in the under age 15 group) for the region was estimated at 0.45/1000, with the majority (67%) living in countries with mortality of children under age 5 above 30/1000 live births, Corneal opacities were more common in countries where the under 5 year mortality are above 30/1000 live births and retinopathy of prematurity (ROP) was an important cause in countries with intermediate death rates. For adults, overall blindness rates were not estimated because of the social, economic, and ethnic diversity in the region. The primary causes of visual loss in adults in the Americas were age related eye diseases, notably cataract and glaucoma in the African-American and Hispanic populations, and age related macular degeneration in the white population. Uncorrected refractive error was a significant cause of decreased vision across ages, ethnic groups, and countries.
   Conclusion: More data are needed on the magnitude and causes of visual loss for the Caribbean and Latin American countries. Rates of blindness and visual loss from available data within these countries are widely disparate. Prevention and control of avoidable blindness needs to be an ongoing focus in this region.
C1 Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Munoz, B (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr, Room 118,600 N Wolfe St, Baltimore, MD 21287 USA.
FU NATIONAL EYE INSTITUTE [U10EY011283] Funding Source: NIH RePORTER; NEI
   NIH HHS [EY11283] Funding Source: Medline
CR ALEMANYMARTOREL.J, 1994, REV CUB OFTALMOL, V7, P68
   Apple DJ, 2000, SURV OPHTHALMOL, V45, pS5
   Brian G, 2001, B WORLD HEALTH ORGAN, V79, P249
   BRILLIANT GE, 1991, ARCH OPHTHALMOL-CHIC, V109, P584, DOI 10.1001/archopht.1991.01080040152048
   Broman AT, 2001, INVEST OPHTH VIS SCI, V42, pS534
   CALIGARIS LSA, 1998, THESIS U SAO PAULO
   CAM CW, 1986, ARCH PERU OFTALMOL, V1, P11
   CAM CW, 1986, REV PERU OFTALMOL, V12, P14
   CARVALHO RC, 1997, ARQ BRAS OFTALMOL, V60, P243
   Choi T B, 1995, J Am Optom Assoc, V66, P484
   COURTRIGHT P, 1995, TROP GEOGR MED, V47, P15
   DANA MR, 1990, JAMA-J AM MED ASSOC, V264, P2400, DOI 10.1001/jama.264.18.2400
   DeCarlo D K, 1999, J Am Optom Assoc, V70, P647
   ESTEVES JF, 1996, ARQ BRAS OFTALMOL, V59, P244
   Fletcher AE, 1999, ARCH OPHTHALMOL-CHIC, V117, P1393, DOI 10.1001/archopht.117.10.1393
   FOSTER A, 1992, EYE, V6, P173, DOI 10.1038/eye.1992.34
   Foster A, 2001, BRIT J OPHTHALMOL, V85, P635, DOI 10.1136/bjo.85.6.635
   FRIEDERICH R, 1982, ANN OPHTHALMOL, V14, P38
   Garrido CMB., 1999, ARQ BRAS OFTALMOL, V62, P132
   GILBERT C, 1995, OPHTHALMIC GENET, V16, P1, DOI 10.3109/13816819509057847
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   GILBERT C, 1993, B WORLD HEALTH ORGAN, V71, P485
   Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227
   GILBERT CE, 1994, DEV MED CHILD NEUROL, V36, P326, DOI 10.1111/j.1469-8749.1994.tb11853.x
   Gilbert CE, 1998, EPIDEMIOLOGY EYE DIS, P181
   Hameed TK, 2001, CAN J OPHTHALMOL, V36, P175, DOI 10.1016/S0008-4182(01)80038-7
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   JOSE NK, 1990, INT OPHTHALMOL, V14, P155, DOI 10.1007/BF00158313
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Lam B L, 2000, Ophthalmic Epidemiol, V7, P73
   Lee DJ, 1998, OPHTHALMOLOGY, V105, P552, DOI 10.1016/S0161-6420(98)93042-1
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL S
   LEITE LA, REV BRAS OFALMOL, V57, P619
   LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046
   Leske MC, 2001, ARCH OPHTHALMOL-CHIC, V119, P89
   LUNA EJA, 1992, INT J EPIDEMIOL, V21, P169, DOI 10.1093/ije/21.1.169
   MASON RP, 1989, OPHTHALMOLOGY, V96, P1363
   Maul E, 2000, AM J OPHTHALMOL, V129, P445, DOI 10.1016/S0002-9394(99)00454-7
   MEDINA NH, 1992, TROP MED PARASITOL, V43, P121
   MEDINA NH, 1993, ARQ BRAS OFTALMOL, V56, P276
   Mets M B, 1999, Trans Am Ophthalmol Soc, V97, P653
   MORIARTY BJ, 1988, BRIT J OPHTHALMOL, V72, P65, DOI 10.1136/bjo.72.1.65
   Morschbacher R., 1996, ARQ BRAS OFTALMOL, V59, P83
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Munoz B, 2001, INVEST OPHTH VIS SCI, V42, pS710
   MUNOZ B, 2002, INVEST OPHTH VIS SCI, V43, P615
   NAEYAERT KM, 1990, J VIS IMP, P361
   NEWTONKARA J, 1990, INT OPHTHALMOL, V10, P156
   NOBREGA MJ, 1993, ARQ BRAS OFTALMOL, V53, P13
   Rabiu MM, 2001, BRIT J OPHTHALMOL, V85, P776, DOI 10.1136/bjo.85.7.776
   Rahi JS, 1999, BRIT J OPHTHALMOL, V83, P387, DOI 10.1136/bjo.83.4.387
   Rearwin D T, 1997, J Am Optom Assoc, V68, P511
   Resnikoff S, 2001, B WORLD HEALTH ORGAN, V79, P222
   Richards FO, 2001, AM J TROP MED HYG, V65, P108, DOI 10.4269/ajtmh.2001.65.108
   RODRIGUEZ J, IN PRESS OPHTHALMOLO
   Rodriguez M A, 1995, Bol Oficina Sanit Panam, V119, P11
   ROJAS JR, 1990, ANN OPHTHALMOL, V22, P423
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   SALIVE ME, 1992, OPHTHALMOLOGY, V99, P1840
   Scarpi MJ, 1990, ARQ BRAS OFTALMOL, V53, P171
   Scarpi MJ, 1989, ARQ BRAS OFTALMOL, V52, P177
   Snellingen T, 1998, BRIT J OPHTHALMOL, V82, P1424, DOI 10.1136/bjo.82.12.1424
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   *STAT DIV POP DIV, 2001, IND YOUNG ELD POP
   Steinkuller PG, 1999, J AAPOS, V3, P26, DOI 10.1016/S1091-8531(99)70091-1
   TAYLOR HR, 1985, B WORLD HEALTH ORGAN, V63, P559
   TAYLOR HR, 1983, REV INT TRACH PATHOL, V60, P19
   Tenorio A, 1987, ARCH PERU OFTALMOL, V2, P26
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Vaidyanathan K, 1999, B WORLD HEALTH ORGAN, V77, P104
   VICENCIO C, 1991, ARCHIVOS CHILENOS OF, V48, P56
   VICENCIO C, 1989, ARCH CHIL OFTAL, V2, P103
   VIET HH, 2001, BR J OPHTHALMOL, V85, P653
   West SK, 2001, DIABETES CARE, V24, P1204, DOI 10.2337/diacare.24.7.1204
   Whitcher JP, 2001, B WORLD HEALTH ORGAN, V79, P214
   Wilkinson M E, 1996, J Am Optom Assoc, V67, P397
   Wilson M, 1987, Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique, P159
   *WORLD BANK GROUP, 2001, WORLD DEV IND DAT BA
   2001, WEEKLY EPIDEMIO 0119, V76, P17
   [No title captured]
NR 80
TC 79
Z9 86
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2002
VL 86
IS 5
BP 498
EP 504
DI 10.1136/bjo.86.5.498
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 547BU
UT WOS:000175313400005
PM 11973241
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Simunovic, MP
   Shao, EH
   Osaadon, P
   Sasongko, MB
   Too, LK
AF Simunovic, Matthew P.
   Shao, Emily H.
   Osaadon, Perach
   Sasongko, Muhammad Bayu
   Too, Lay Khoon
TI Two-step versus 1-step subretinal injection to compare subretinal drug
   delivery: a randomised study protocol
SO BMJ OPEN
LA English
DT Article
DE vetreoretinal; medical retina; ophthalmology
ID TISSUE-PLASMINOGEN-ACTIVATOR; RETINAL THICKNESS; IN-VITRO; FLUORESCEIN;
   PEOPLE
AB Introduction There is increasing interest in subretinal injections as a surgical procedure, largely as a result of emerging treatments for ocular diseases which necessitate this manoeuvre. However, surgical variables in the efficacy of such treatments have to date been largely overlooked and the proportion of drug which reaches the intended compartment of the subretinal space remains unknown. Our aims are twofold: first, to determine the proportion of subretinally injected medication retained following surgical delivery and second, to compare two different techniques of injection ('1-step' vs '2-step'). Methods We outline a randomised controlled trial of subretinal injection of alteplase following vitrectomy for the management of submacular haemorrhage secondary to age-related macular degeneration. Patients will be randomised to receive either 1-step injection, where the therapeutic solution simultaneously defines the surgical plane or 2-step injection, where the surgical plane is first identified with balanced salt solution prior to injection of subretinal alteplase, as outlined below. Sodium fluorescein will be used as an optical label to track drug reflux into the vitreous cavity using quantitative protocols established in our laboratory. All patients will undergo fluid air exchange at the completion of surgery, with injection of bevacizumab 1.25 mg and 20% sulfahexafluoride gas as the vitreous substitute (both of which may help improve outcomes). Alteplase, sodium fluorescein and bevacizumab will all be used for off-label indications in the trial. Ethics and dissemination Ethical approval has been obtained from the South Eastern Sydney Local Health District's Human Research Ethics Committee (HREC 17/092). The results of this trial will be disseminated in peer-reviewed proceedings (associated with conference presentation) and in scholarly journals.
C1 [Simunovic, Matthew P.; Too, Lay Khoon] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Simunovic, Matthew P.; Shao, Emily H.; Osaadon, Perach; Sasongko, Muhammad Bayu] Sydney Eye Hosp, Retinal Unit, Sydney, NSW, Australia.
C3 University of Sydney
RP Simunovic, MP (通讯作者)，Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.; Simunovic, MP (通讯作者)，Sydney Eye Hosp, Retinal Unit, Sydney, NSW, Australia.
EM matthew.simunovic@sydney.edu.au
RI Sasongko, Muhammad Bayu/GNP-0074-2022
OI Sasongko, Muhammad Bayu/0000-0002-0366-8335; Simunovic,
   Matthew/0000-0003-0596-1356
FU Foundation Fighting Blindness, USA [CD-CL-0816-0710-SYD]
FX MPS is supported by a Career Development Award from the Foundation
   Fighting Blindness, USA CD-CL-0816-0710-SYD.
CR Bressler NM, 2008, AM J OPHTHALMOL, V145, P894, DOI 10.1016/j.ajo.2007.12.025
   Chalam KV, 2012, INVEST OPHTH VIS SCI, V53, P8154, DOI 10.1167/iovs.12-10290
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chao DL, 2019, GENEREVIEWS
   Davis JL, 2019, RETINA-J RET VIT DIS, V39, P2, DOI 10.1097/IAE.0000000000002609
   Edwards TL, 2016, NEW ENGL J MED, V374, P1996, DOI 10.1056/NEJMc1509501
   Hsu ST, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.19
   KATO S, 1983, DEV BRAIN RES, V11, P143, DOI 10.1016/0165-3806(83)90211-0
   Khan MA, 2017, RETINA-J RET VIT DIS, V37, P1203, DOI 10.1097/IAE.0000000000001349
   Kwan ASL, 2006, INVEST OPHTH VIS SCI, V47, P2662, DOI 10.1167/iovs.05-1019
   LEWIS H, 1991, AM J OPHTHALMOL, V111, P197, DOI 10.1016/S0002-9394(14)72259-7
   McGregor JE, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15317-6
   Novelli FJD, 2017, RETINA-J RET VIT DIS, V37, P1607, DOI 10.1097/IAE.0000000000001491
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Salvetti AP, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.4
   Scruggs BA, 2019, STEM CELL TRANSL MED, V8, P797, DOI 10.1002/sctm.18-0210
   Simunovic Matthew P, 2020, Retina, DOI 10.1097/IAE.0000000000002800
   Simunovic MP, 2017, JAMA OPHTHALMOL, V135, P234, DOI 10.1001/jamaophthalmol.2016.5630
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Takahashi K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209996
   Xue K, 2017, EYE, V31, P1308, DOI 10.1038/eye.2017.158
NR 21
TC 0
Z9 0
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD DEC
PY 2021
VL 11
IS 12
AR e049976
DI 10.1136/bmjopen-2021-049976
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XP8HR
UT WOS:000731101300017
PM 34911710
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chen, DD
   Peng, XY
   Wang, YX
   Jiang, MJ
   Xue, MJ
   Shane, GH
   Liu, XH
   Jia, XL
   Liu, BX
   Lu, YW
   Mu, HM
   Zhang, FY
   Hu, YZ
AF Chen, Dan-Dan
   Peng, Xuyan
   Wang, Yuxuan
   Jiang, Mingjun
   Xue, Mengjiao
   Shane, Guohui
   Liu, Xuhui
   Jia, Xiaolin
   Liu, Baixue
   Lu, Yingwei
   Mu, Hongmei
   Zhang, Fengyan
   Hu, Yanzhong
TI HSP90 acts as a senomorphic target in senescent retinal pigmental
   epithelial cells
SO AGING-US
LA English
DT Article
DE HSP90; senotheray; NF-kb; HIF1 alpha; beta-galactosidase
ID MACULAR DEGENERATION; RPE CELL; GELDANAMYCIN; DEGRADATION; HIF-1-ALPHA;
   EXPRESSION; INHIBITOR; THERAPIES; AMD
AB The senescence of retinal pigment epithelial (RPE) cells is associated with age-related macular degeneration (AMD), a leading cause of blindness in the world. HSP90 is a predominant chaperone that regulates cellular homeostasis under divergent physio-pathological conditions including senescence. However, the role of HSP90 in senescent RPE cells still remains unclear. Here, we reported that HSP90 acts as a senomorphic target of senescent RPE cells in vitro. Using H2O2-induced senescent ARPE-19 cells and replicative senescent primary RPE cells from rhesus monkey, we found that HSP90 upregulates the expression of IKK alpha, and HIF1 alpha in senescent ARPE-19 cells and subsequently controls the induction of distinct senescence-associated inflammatory factors. Senescent ARPE-19 cells are more resistant to the cytotoxic HSP90 inhibitor IPI504 (IC50 = 36.78 mu M) when compared to normal ARPE-19 cells (IC50 = 6.16 mu M). Administration of IPI504 at 0.5-5 mu M can significantly inhibit the induction of IL-1 beta, IL-6, IL-8, MCP-1 and VEGFA in senescent ARPE-19 and the senescence-mediated migration of retinal capillary endothelial cells in vitro. In addition, we found that inhibition of HSP90 by IPI504 reduces SA-beta-Gal's protein expression and enzyme activity in a dose-dependent manner. HSP90 interacts with and regulates SA -13-Gal protein stabilization in senescent ARPE-19 cells. Taken together, these results suggest that HSP90 regulates the SASP and SA-beta-Gal activity in senescent RPE cells through associating with distinctive mechanism including NF-KB, HIF1 alpha and lysosomal SA-beta-Gal. HSP90 inhibitors (e.g. IPI504) could be a promising senomorphic drug candidate for AMD intervention.
C1 [Chen, Dan-Dan; Peng, Xuyan; Wang, Yuxuan; Jiang, Mingjun; Xue, Mengjiao; Liu, Xuhui; Jia, Xiaolin; Liu, Baixue; Lu, Yingwei; Zhang, Fengyan; Hu, Yanzhong] Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Div Ophthalmol & Vis Sci, Zhengzhou, Peoples R China.
   [Hu, Yanzhong] Henan Univ, Dept Cell Biol & Genet, Jointed Natl Lab Antibody Drug Engn, Coll Basic Med Sci, Kaifeng, Peoples R China.
   [Mu, Hongmei; Hu, Yanzhong] Kaifeng Cent Hosp, Eye Dis Inst, Kaifeng Key Lab Cataracts & Myopia, Kaifeng, Peoples R China.
   [Shane, Guohui] Zhengzhou Univ, Sch Basic Med Sci, Dept Med Genet & Cell Biol, Zhengzhou 450001, Henan, Peoples R China.
C3 Zhengzhou University; Henan University; Zhengzhou University
RP Zhang, FY; Hu, YZ (通讯作者)，Zhengzhou Univ, Affiliated Hosp 1, Dept Ophthalmol, Div Ophthalmol & Vis Sci, Zhengzhou, Peoples R China.; Hu, YZ (通讯作者)，Henan Univ, Dept Cell Biol & Genet, Jointed Natl Lab Antibody Drug Engn, Coll Basic Med Sci, Kaifeng, Peoples R China.; Hu, YZ (通讯作者)，Kaifeng Cent Hosp, Eye Dis Inst, Kaifeng Key Lab Cataracts & Myopia, Kaifeng, Peoples R China.
EM fcczhangfy@zzu.edu.cn; hyz@henu.edu.cn
FU National Nature Science Foundation of China [81970785, 81570825,
   U1604171, 8170272, 81900843, 31802314]; Medical Science and Technology
   Development Project of Henan Health Commission [SBGJ202003055]
FX This work is supported by grants from the National Nature Science
   Foundation of China (No.81970785, 81570825, U1604171, 8170272, 81900843
   and 31802314), Medical Science and Technology Development Project of
   Henan Health Commission (No. SBGJ202003055).
CR Agarraberes FA, 2001, J CELL SCI, V114, P2491
   Aguila M, 2016, ADV EXP MED BIOL, V854, P161, DOI 10.1007/978-3-319-17121-0_22
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705
   Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711
   Cook C, 2013, J ALZHEIMERS DIS, V33, pS145, DOI 10.3233/JAD-2012-129008
   Coryell PR, 2021, NAT REV RHEUMATOL, V17, P47, DOI 10.1038/s41584-020-00533-7
   Cui XK, 2015, BBA-MOL CELL RES, V1853, P746, DOI 10.1016/j.bbamcr.2015.01.004
   Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020
   de Mera-Rodriguez JA, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.623175
   Feng L, 2016, DISCOV MED, V21, P149
   Fuhrmann-Stroissnigg H, 2018, CELL CYCLE, V17, P1048, DOI 10.1080/15384101.2018.1475828
   Fuhrmann-Stroissnigg H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00314-z
   Gomez-Pastor R, 2018, NAT REV MOL CELL BIO, V19, P4, DOI 10.1038/nrm.2017.73
   Han SY, 2017, CANCER RES, V77, P343, DOI 10.1158/0008-5472.CAN-16-0613
   He MY, 2019, AGING CELL, V18, DOI 10.1111/acel.13003
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kampik D, 2017, GENE THER, V24, P810, DOI 10.1038/gt.2017.89
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   Kelly UL, 2020, J BIOL CHEM, V295, P13601, DOI 10.1074/jbc.RA119.012305
   Komatsuda A, 1999, PATHOL INT, V49, P513, DOI 10.1046/j.1440-1827.1999.00901.x
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Lee BY, 2006, AGING CELL, V5, P187, DOI 10.1111/j.1474-9726.2006.00199.x
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001
   Maeda T, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081785
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Muraleva NA, 2014, CELL CYCLE, V13, P3499, DOI 10.4161/15384101.2014.958393
   Narita T, 2009, CLIN CANCER RES, V15, P6128, DOI 10.1158/1078-0432.CCR-08-3180
   Ovadya Y, 2018, J CLIN INVEST, V128, P1247, DOI 10.1172/JCI95149
   Piippo N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25123-2
   Qing GL, 2006, CELL RES, V16, P895, DOI 10.1038/sj.cr.7310109
   Rashid A, 2016, ADV EXP MED BIOL, V854, P757, DOI 10.1007/978-3-319-17121-0_101
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sarangi U, 2012, DRUG TARGET INSIGHT, V6, P19, DOI 10.4137/DTI.S9943
   Schopf FH, 2017, NAT REV MOL CELL BIO, V18, P345, DOI 10.1038/nrm.2017.20
   Somogyvari M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30592-6
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   van Deursen JM, 2019, SCIENCE, V364, P636, DOI 10.1126/science.aaw1299
   Wang W, 2010, DISCOV MED, V9, P13
   Wang YH, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw3172
   Westenskow PD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8470263
   Wu WC, 2007, EXP EYE RES, V85, P721, DOI 10.1016/j.exer.2007.08.005
   Wu WC, 2010, EXP EYE RES, V91, P211, DOI 10.1016/j.exer.2010.05.005
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zhang PS, 2019, NAT NEUROSCI, V22, P719, DOI 10.1038/s41593-019-0372-9
NR 50
TC 5
Z9 5
U1 1
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD SEP 15
PY 2021
VL 13
IS 17
BP 21547
EP 21570
PG 24
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA WC6XE
UT WOS:000704398100021
PM 34495872
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Lee, J
   Lee, J
   Cho, S
   Song, J
   Lee, M
   Kim, SH
   Lee, JY
   Shin, DH
   Kim, JM
   Bae, JH
   Song, SJ
   Sagong, M
   Park, D
AF Lee, JoonHo
   Lee, Joonseok
   Cho, Sooah
   Song, JiEun
   Lee, Minyoung
   Kim, Sung Ho
   Lee, Jin Young
   Shin, Dae Hwan
   Kim, Joon Mo
   Bae, Jung Hun
   Song, Su Jeong
   Sagong, Min
   Park, Donggeun
TI Development of Decision Support Software for Deep Learning-Based
   Automated Retinal Disease Screening Using Relatively Limited Fundus
   Photograph Data
SO ELECTRONICS
LA English
DT Article
DE deep learning; diagnosis; fundus
ID DIABETIC-RETINOPATHY; RISK-FACTORS; VALIDATION; SYSTEM
AB Purpose-This study was conducted to develop an automated detection algorithm for screening fundus abnormalities, including age-related macular degeneration (AMD), diabetic retinopathy (DR), epiretinal membrane (ERM), retinal vascular occlusion (RVO), and suspected glaucoma among health screening program participants. Methods-The development dataset consisted of 43,221 retinal fundus photographs (from 25,564 participants, mean age 53.38 +/- 10.97 years, female 39.0%) from a health screening program and patients of the Kangbuk Samsung Hospital Ophthalmology Department from 2006 to 2017. We evaluated our screening algorithm on independent validation datasets. Five separate one-versus-rest (OVR) classification algorithms based on deep convolutional neural networks (CNNs) were trained to detect AMD, ERM, DR, RVO, and suspected glaucoma. The ground truth for both development and validation datasets was graded at least two times by three ophthalmologists. The area under the receiver operating characteristic curve (AUC), sensitivity, and specificity were calculated for each disease, as well as their macro-averages. Results-For the internal validation dataset, the average sensitivity was 0.9098 (95% confidence interval (CI), 0.8660-0.9536), the average specificity was 0.9079 (95% CI, 0.8576-0.9582), and the overall accuracy was 0.9092 (95% CI, 0.8769-0.9415). For the external validation dataset consisting of 1698 images, the average of the AUCs was 0.9025 (95% CI, 0.8671-0.9379). Conclusions-Our algorithm had high sensitivity and specificity for detecting major fundus abnormalities. Our study will facilitate expansion of the applications of deep learning-based computer-aided diagnostic decision support tools in actual clinical settings. Further research is needed to improved generalization for this algorithm.
C1 [Lee, JoonHo; Lee, Joonseok; Cho, Sooah; Song, JiEun; Lee, Minyoung] Samsung SDS Artificial Intelligence Res Ctr, Seoul 05510, South Korea.
   [Kim, Sung Ho; Lee, Jin Young; Shin, Dae Hwan; Kim, Joon Mo; Bae, Jung Hun; Song, Su Jeong] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Ophthalmol, Sch Med, Seoul 03181, South Korea.
   [Sagong, Min; Park, Donggeun] Yeungnam Univ, Dept Ophthalmol, Yeungnam Univ Hosp, Coll Med, Daegu 42415, South Korea.
C3 Sungkyunkwan University (SKKU); Yeungnam University; Yeungnam University
   Hospital
RP Song, SJ (通讯作者)，Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Ophthalmol, Sch Med, Seoul 03181, South Korea.
EM js1985.lee@samsung.com; js1985.lee@samsung.com; sooah.cho@samsung.com;
   sooah.cho@samsung.com; miny.lee@samsung.com; n09072.kim@samsung.com;
   gnyoungee.lee@samsung.com; daehwan87.shin@samsung.com;
   kjoonmo1@gmail.com; jhbae94@hotmail.com; sjsong7@gmail.com;
   ophsgm@gmail.com; bluepdg@naver.com
OI Kim, Joon Mo/0000-0002-4543-043X; Park, Dong-Geun/0000-0001-8820-382X;
   Lee, JoonHo/0000-0002-6577-298X
FU Kangbuk Samsung Hospital medical research fund grant [HIY0180061]
FX This research was funded by Kangbuk Samsung Hospital medical research
   fund grant (HIY0180061).
CR Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Choi JY, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0187338, 10.1371/journal.pone.0187336]
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Hinton G., 2015, DISTILLING KNOWLEDGE
   Kim CS, 2011, OPHTHALMOLOGY, V118, P1024, DOI 10.1016/j.ophtha.2010.10.016
   Kim KE, 2016, OPHTHALMOLOGY, V123, P532, DOI 10.1016/j.ophtha.2015.11.004
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Park SJ, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e239
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Rhee EJ, 2016, MICROVASC RES, V108, P64, DOI 10.1016/j.mvr.2016.08.002
   Ro Y, 2019, AAAI CONF ARTIF INTE, P8859
   Saito K, 2018, PROC CVPR IEEE, P3723, DOI 10.1109/CVPR.2018.00392
   Selvaraju RR, 2017, IEEE I CONF COMP VIS, P618, DOI 10.1109/ICCV.2017.74
   Seong SC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016640
   Sermanet P., 2014, P ICLR
   Setiawan AW, 2013, INT CONF ICT SMART S, P215
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Szegedy C., 2016, 2016 IEEE C COMPUTER, P2818, DOI DOI 10.1109/CVPR.2016.308
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Vapnik V., 1998, STAT LEARNING THEORY
   염동주, 2009, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V50, P1645
   Zagoruyko Sergey, 2016, ARXIV160507146, DOI 10.5244/C.30.87
NR 28
TC 3
Z9 3
U1 4
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-9292
J9 ELECTRONICS-SWITZ
JI Electronics
PD JAN
PY 2021
VL 10
IS 2
AR 163
DI 10.3390/electronics10020163
PG 15
WC Computer Science, Information Systems; Engineering, Electrical &
   Electronic; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Physics
GA PX1BF
UT WOS:000611097900001
OA gold
DA 2022-11-30
ER

PT J
AU Grewal, MK
   Chandra, S
   Gurudas, S
   Bird, A
   Jeffery, G
   Sivaprasad, S
AF Grewal, Manjot K.
   Chandra, Shruti
   Gurudas, Sarega
   Bird, Alan
   Jeffery, Glen
   Sivaprasad, Sobha
TI Exploratory Study on Visual Acuity and Patient-Perceived Visual Function
   in Patients with Subretinal Drusenoid Deposits
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE subretinal drusenoid deposits; intermediate age related macular
   degeneration; retinal ageing; low-luminance questionnaire; low-luminance
   visual acuity; low-luminance deficit
ID LOW LUMINANCE QUESTIONNAIRE; MACULAR DEGENERATION; GEOGRAPHIC ATROPHY;
   RETICULAR PSEUDODRUSEN; ROD FUNCTION; EYES; PROGRESSION; VISION;
   ASSOCIATION; SCORES
AB Purpose: To investigate the value of visual acuity and patient-perceived visual function test when subretinal drusenoid deposits (SDD) are incorporated into the classification of age-related macular degeneration (AMD). A total of 50 participants were recruited into the study in these groups: healthy ageing (n = 11), intermediate AMD (iAMD) with no SDD (n = 17), iAMD with SDD (n = 11) and non-foveal atrophic AMD (n = 11) confirmed by two retinal imaging modalities. Best-corrected visual acuity (BCVA) and low luminance visual acuity (LLVA) were measured and low luminance deficit (LLD) was calculated. Participants were also interviewed with the low luminance questionnaire (LLQ). Linear regression was used to assess function-function relations. Compared with healthy participants, BCVA and LLVA scores were significantly reduced in the atrophic AMD group (p< 0.0001 andp= 0.00016, respectively) and in patients with SDD (p= 0.028 andp= 0.045, respectively). Participants with atrophy also had reduced BCVA (p= 0.001) and LLVA (p= 0.009) compared with the iAMD no SDD group. However, there were no differences in visual function tests between healthy aging and iAMD without SDD and between iAMD with SDD and atrophic AMD groups. The LLD score did not differ between groups. BCVA and LLVA correlated well. The LLQ did not correlate with visual function tests. This study shows that LLD is not a marker of disease severity as assessed clinically. Although LLQ is a good marker for disease severity using the current AMD classification, it does not differentiate between eyes with and without SDD. Eyes with non-macular geographic atrophy and SDD had lower function than eyes with no SDD and healthy controls.
C1 [Grewal, Manjot K.; Chandra, Shruti; Gurudas, Sarega; Bird, Alan; Jeffery, Glen; Sivaprasad, Sobha] UCL, Inst Ophthalmol, London EC1V 9EL, England.
   [Grewal, Manjot K.; Chandra, Shruti; Sivaprasad, Sobha] Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, London EC1V 2PD, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Sivaprasad, S (通讯作者)，UCL, Inst Ophthalmol, London EC1V 9EL, England.; Sivaprasad, S (通讯作者)，Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, London EC1V 2PD, England.
EM m.grewal@ucl.ac.uk; shruti.chandra.18@ucl.ac.uk;
   sarega.gurudas.17@ucl.ac.uk; alan.bird@ucl.ac.uk; g.jeffery@ucl.ac.uk;
   sobha.sivaprasad@nhs.net
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Chandra, Shruti/0000-0002-2634-9775
FU Fight for Sight [1905b]; Institute of Ophthalmology UCL [522031]
FX This research was funded by Fight for Sight grant number: 1905b,
   Institute of Ophthalmology UCL grant no: 522031.
CR Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Connolly DM, 2009, AVIAT SPACE ENVIR MD, V80, P933, DOI 10.3357/ASEM.2535.2009
   Eckmiller MS, 2004, PROG RETIN EYE RES, V23, P495, DOI 10.1016/j.preteyeres.2004.04.005
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Flynn OJ, 2018, INVEST OPHTH VIS SCI, V59, P2411, DOI 10.1167/iovs.17-22874
   Gao WH, 2008, OPT EXPRESS, V16, P6486, DOI 10.1364/OE.16.006486
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Rosser DA, 2003, INVEST OPHTH VIS SCI, V44, P3278, DOI 10.1167/iovs.02-1100
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Stockman A, 2006, OPHTHAL PHYSL OPT, V26, P225, DOI 10.1111/j.1475-1313.2006.00325.x
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59, P289, DOI 10.1167/iovs.17-22528
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
   Ying GS, 2008, OPHTHALMOLOGY, V115, P1876, DOI 10.1016/j.ophtha.2008.05.023
NR 27
TC 3
Z9 3
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2020
VL 9
IS 9
AR 2832
DI 10.3390/jcm9092832
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA OD8KD
UT WOS:000580094700001
PM 32882940
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wolff, B
   Macioce, V
   Vasseur, V
   Castelnovo, L
   Michel, G
   Nguyen, V
   Daien, V
   Mauget-Faysse, M
   Gillies, M
AF Wolff, Benjamin
   Macioce, Valerie
   Vasseur, Vivien
   Castelnovo, Laurent
   Michel, Guillaume
   Nguyen, Vuong
   Daien, Vincent
   Mauget-Faysse, Martine
   Gillies, Mark
TI Ten-year outcomes of anti-vascular endothelial growth factor treatment
   for neovascular age-related macular disease: A single-centre French
   study
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE anti-VEGF therapy; geographic atrophy; long-term follow-up; neovascular
   age-related macular degeneration
ID LONG-TERM OUTCOMES; DEGENERATION; THERAPY; ATROPHY; RANIBIZUMAB; ANCHOR;
   MARINA; RISK
AB Importance Long-term data of intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors are lacking. Background This study aims to assess visual and anatomic outcomes of eyes with neovascular age-related macular degeneration (nAMD) after 10 years of anti-VEGF therapy. Design Retrospective analysis of data from a prospectively designed database. Participants One hundred and sixteen eyes with nAMD (94 participants) that started anti-VEGF therapy at least 10 years earlier. Methods Eyes were tracked by the Fight Retinal Blindness! registry. Main Outcome Measures Mean change in visual acuity at 10 years vs baseline. Visual acuity was assessed by the number of letters read on a logarithm of the minimum angle of resolution chart. Results Eyes received a median of 27.5 injections over 10 years. Mean visual acuity was 57.5 letters (SD 17.5) at baseline. It increased slightly at 1 year, then dropped steadily by 18 letters (95% CI: 13.7; 22.3) at 10 years. Overall, 10% of eyes gained >= 10 letters, 64% lost >= 10 letters and 23% remained stable (+/- 5 letters from baseline). Geographic atrophy and subretinal fibrosis were found in 93% and 71%, respectively, after 10 years, both mostly affecting the centre of the fovea. Pre-treated eyes (47.5%) had significantly worse visual acuity than treatment-naive eyes at baseline and during follow-up and were significantly more likely to have atrophy and fibrosis. Conclusions and Relevance Despite short-term stabilization, long-term visual outcomes of nAMD eyes under anti-VEGF therapy may be poor. Development of atrophy and fibrosis, resulting from the natural progression of the disease, may partly explain this evolution.
C1 [Wolff, Benjamin; Vasseur, Vivien; Castelnovo, Laurent; Michel, Guillaume] Maison Rouge Ophthalmol Ctr, 6 Rue Eglise, Strasbourg, France.
   [Macioce, Valerie] Univ Montpellier, Clin Res & Epidemiol Unit, CHU Montpellier, Montpellier, France.
   [Vasseur, Vivien; Mauget-Faysse, Martine] Rothschild Fdn, Res Dept, Paris, France.
   [Daien, Vincent] Gui Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Daien, Vincent] Inserm, U1061, Montpellier, France.
   [Nguyen, Vuong; Gillies, Mark] Univ Sydney, Save Sight Inst, Sydney Med Sch, Sydney, NSW, Australia.
C3 Universite de Montpellier; CHU de Montpellier; Universite de
   Montpellier; CHU de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Montpellier; University of
   Sydney
RP Wolff, B (通讯作者)，Maison Rouge Ophthalmol Ctr, 6 Rue Eglise, Strasbourg, France.
EM bwolff@hotmail.fr
RI ; Daien, Vincent/Z-5516-2019
OI wolff, benjamin/0000-0003-4709-692X; Daien, Vincent/0000-0001-5675-0861;
   Nguyen, Vuong/0000-0001-9070-9803
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   CHANDRA S, 2020, EYE 0124, DOI DOI 10.1038/S41433-020-0764-9
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Elliott DB, 2016, OPHTHAL PHYSL OPT, V36, P355, DOI 10.1111/opo.12310
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Haddad WM, 2017, RETINA-J RET VIT DIS, V37, P951, DOI 10.1097/IAE.0000000000001282
   International Council of Ophthalmology, 2002, VISUAL STANDARDS ASP
   Invernizzi A, 2019, AM J OPHTHALMOL, V204, P105, DOI 10.1016/j.ajo.2019.03.001
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pedrosa AC, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4263017
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Varano M, 2014, OPHTHALMOLOGICA, V231, P204, DOI 10.1159/000357504
   Vaze A, 2014, ACTA OPHTHALMOL, V92, pe697, DOI 10.1111/aos.12417
   von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
NR 28
TC 16
Z9 16
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2020
VL 48
IS 5
BP 636
EP 643
DI 10.1111/ceo.13742
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MG8KJ
UT WOS:000546280000010
PM 32112667
DA 2022-11-30
ER

PT J
AU Carlsson, E
   Supharattanasitthi, W
   Jackson, M
   Paraoan, L
AF Carlsson, Emil
   Supharattanasitthi, Wasu
   Jackson, Malcolm
   Paraoan, Luminita
TI Increased Rate of Retinal Pigment Epithelial Cell Migration and
   Pro-Angiogenic Potential Ensuing From Reduced Cystatin C Expression
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Cell migration; retinal pigment epithelium; cystatin C; age-related
   macular degeneration
ID MACULAR DEGENERATION; CYSTEINE CATHEPSINS; GENETIC ASSOCIATION;
   CEREBROSPINAL-FLUID; G73A POLYMORPHISM; RISK-FACTOR; STEM-CELLS;
   DISEASE; GENOTYPE; QUANTIFICATION
AB PURPOSE. Variant B precursor cysteine protease inhibitor cystatin C, a known recessive risk factor for developing exudative age-related macular degeneration (AMD), presents altered intracellular trafficking and reduced secretion from retinal pigment epithelial (RPE) cells. Because cystatin C inhibits multiple extracellular matrix (ECM)-degrading cathepsins, this study evaluated the role of this mutation in inducing ECM-related functional changes in RPE cellular behavior.
   METHODS. Induced pluripotent stem cells gene-edited bi-allelically by CRISPR/Cas9 to express the AMD-linked cystatin C variant were differentiated to RPE cells and assayed for their ability to degrade fluorescently labeled ECM proteins. Cellular migration and adhesion on multiple ECM proteins, differences in transepithelial resistance and polarized protein secretion were tested. Vessel formation induced by gene edited cells-conditioned media was quantified using primary human dermal microvascular epithelial cells.
   RESULTS. Variant B cystatin C-expressing induced pluripotent stem cells-derived RPE cells displayed a significantly higher rate of laminin and fibronectin degradation 3 days after seeding on fluorescently labeled ECM (P < 0.05). Migration on matrigel, collagen IV and fibronectin was significantly faster for edited cells compared with wild-type (WT) cells. Both edited and WT cells displayed polarized secretion of cystatin C, but transepithelial resistance was lower in gene-edited cells after 6 weeks culture, with significantly lower expression of tight junction protein claudin-3. Media conditioned by gene-edited cells stimulated formation of significantly longer microvascular tubes (P < 0.05) compared with WT-conditioned media.
   CONCLUSIONs. Reduced levels of cystatin C lead to changes in the RPE ability to degrade, adhere, and migrate supporting increased invasiveness and angiogenesis relevant for AMD pathology.
C1 [Carlsson, Emil; Supharattanasitthi, Wasu; Paraoan, Luminita] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, William Duncan Bldg,6 West Derby St, Liverpool L7 8TX, Merseyside, England.
   [Supharattanasitthi, Wasu] Mahidol Univ, Fac Pharm, Dept Physiol, Bangkok, Thailand.
   [Jackson, Malcolm] Univ Liverpool, Inst Ageing & Chron Dis, Dept Musculoskeletal Biol, Liverpool, Merseyside, England.
C3 University of Liverpool; Mahidol University; University of Liverpool
RP Paraoan, L (通讯作者)，Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, William Duncan Bldg,6 West Derby St, Liverpool L7 8TX, Merseyside, England.
EM lparaoan@liverpool.ac.uk
RI Paraoan, Luminita/K-1066-2016
OI Paraoan, Luminita/0000-0001-7568-7116; Supharattanasitthi,
   Wasu/0000-0003-3789-8312
FU Macular Society
FX The authors thank the Macular Society for its support and also thank
   Michael Cross and Bettina Wilm for advice on angiogenesis assays and DNA
   Sequencing & Services (MRC I PPU, School of Life Sciences, University of
   Dundee, Scotland) for DNA sequencing.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441-009-0834-6
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Benussi L, 2003, NEUROBIOL DIS, V13, P15, DOI 10.1016/S0969-9961(03)00012-3
   Bertram L, 2007, NAT GENET, V39, P17, DOI 10.1038/ng1934
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bock C, 2011, CELL, V144, P439, DOI 10.1016/j.cell.2010.12.032
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Butler JM, 2015, HUM GENET, V134, P705, DOI 10.1007/s00439-015-1552-7
   CHAN BMC, 1992, J BIOL CHEM, V267, P8366
   Chlenski A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023880
   Crawford FC, 2000, NEUROLOGY, V55, P763, DOI 10.1212/WNL.55.6.763
   Donahue RP, 2007, DIABETES CARE, V30, P1724, DOI 10.2337/dc07-0040
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eriksson P, 2004, ARTERIOSCL THROM VAS, V24, P551, DOI 10.1161/01.ATV.0000117180.57731.36
   Finckh U, 2000, ARCH NEUROL-CHICAGO, V57, P1579, DOI 10.1001/archneur.57.11.1579
   Fonovic M, 2014, BBA-GEN SUBJECTS, V1840, P2560, DOI 10.1016/j.bbagen.2014.03.017
   Hetheridge C, 2011, BIOCHEM SOC T, V39, P1597, DOI 10.1042/BST20110738
   Hua Y, 2012, INT J NEUROSCI, V122, P431, DOI 10.3109/00207454.2012.672502
   Ida H, 2004, MOL VIS, V10, P439
   Kay P, 2014, INVEST OPHTH VIS SCI, V55, P926, DOI 10.1167/iovs.13-13239
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Klein R, 2009, ARCH OPHTHALMOL-CHIC, V127, P193, DOI 10.1001/archophthalmol.2008.551
   Kramer L, 2017, TRENDS PHARMACOL SCI, V38, P873, DOI 10.1016/j.tips.2017.06.003
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Loew M, 2005, ARTERIOSCL THROM VAS, V25, P1470, DOI 10.1161/01.ATV.0000168416.74206.62
   Maetzler W, 2010, J ALZHEIMERS DIS, V19, P937, DOI 10.3233/JAD-2010-1289
   Melander O, 2009, JAMA-J AM MED ASSOC, V302, P49, DOI 10.1001/jama.2009.943
   Nguyen A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147684
   Niemisto A, 2005, IEEE T MED IMAGING, V24, P549, DOI 10.1109/TMI.2004.837339
   Noto D, 2005, INT J CARDIOL, V101, P213, DOI 10.1016/j.ijcard.2004.03.018
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   OLAFSSON I, 1995, SCAND J CLIN LAB INV, V55, P597, DOI 10.3109/00365519509110259
   Paraoan L, 2004, TRAFFIC, V5, P884, DOI 10.1111/j.1600-0854.2004.00230.x
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Peng SM, 2011, INVEST OPHTH VIS SCI, V52, P1392, DOI 10.1167/iovs.10-5984
   Postovit LM, 2006, STEM CELLS, V24, P501, DOI 10.1634/stemcells.2005-0459
   Ratnayaka A, 2007, EXP EYE RES, V84, P1135, DOI 10.1016/j.exer.2006.01.030
   Reiser J, 2010, J CLIN INVEST, V120, P3421, DOI 10.1172/JCI42918
   Rossi A, 2004, BIOL CHEM, V385, P363, DOI 10.1515/BC.2004.040
   Sarnak MJ, 2005, ANN INTERN MED, V142, P497, DOI 10.7326/0003-4819-142-7-200504050-00008
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shi GP, 1999, J CLIN INVEST, V104, P1191, DOI 10.1172/JCI7709
   Stoka V, 2016, AGEING RES REV, V32, P22, DOI 10.1016/j.arr.2016.04.010
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sukhova GK, 2005, CIRC RES, V96, P368, DOI 10.1161/01.RES.0000155964.34150.F7
   Supharattanasitthi W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36740-2
   Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   Vizovisek M, 2019, MATRIX BIOL, V75-76, P141, DOI 10.1016/j.matbio.2018.01.024
   Weber CR, 2012, ANN NY ACAD SCI, V1257, P77, DOI 10.1111/j.1749-6632.2012.06528.x
   Wistow G, 2002, MOL VIS, V8, P205
   Yamamoto-Watanabe Y, 2010, BRAIN RES, V1361, P140, DOI 10.1016/j.brainres.2010.09.033
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 55
TC 5
Z9 6
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2020
VL 61
IS 2
AR 9
DI 10.1167/iovs.61.2.9
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KR6TJ
UT WOS:000517748100009
PM 32049341
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Streho, M
   Lavallee, G
   Aimadaly, M
   Perrenoud, F
   Puech, M
   Tadayoni, R
   Giocanti-Auregan, A
AF Streho, Mate
   Lavallee, Gwenaelle
   Aimadaly, Mourtaza
   Perrenoud, Francois
   Puech, Michel
   Tadayoni, Ramin
   Giocanti-Auregan, Audrey
TI Geographic Atrophy and OCT Angiography: Descriptive Study and
   Correlation With Autofluorescence
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE; MACULAR DEGENERATION
AB BACKGROUND AND OBJECTIVE: Geographic atrophy (GA) involves the progressive loss of retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris (CC). CC flow within a GA area is severely impaired in patients with atrophic age-related macular degeneration. The aim of this study was to compare GA area measured on optical coherence tomography angiography (OCTA) (CC nonperfusion area) and on fundus autofluorescence (FAF).
   PATIENTS AND METHODS: In this prospective, observalional, cross-sectional study, OCTA and FAF were performed in patients with GA. On OCTA (CC segmentation), the CC nonperfusion area was measured manually using calipers. On FAF, CA was manually delimited, and the total surface was obtained using Region Finder software. The primary endpoint was to compare the CC nonperfusion area measured on OCTA and on the gold standard method (FAF).
   RESULTS: Forty eyes of 34 patients with a mean age of 82.63 years +/- 9.21 years (range: 66 years to 100 years) were included. The mean GA area measured on FAF and OCTA was, respectively, 2.184 +/- 3.045 mm(2) and 2.349 +/- 3.237 mm(2) (P = .035). The mean difference was 0.165 +/- 0.290 mm(2). A strong correlation was found between both measurements (r = 0.97; P < .0001; confidence interval: 0.98-0.99), although the CC nonperfusion area was larger than the GA area on FAF (P = .035).
   CONCLUSIONS: In this study, the authors showed that in GA, the CC nonperfusion area correlates linearly with the CA area assessed by FAF. Also, the CC nonperfusion area is larger than the. CA area measured by FAF. suggesting that CC degeneration could occur before RPE degeneration in GA.
C1 [Streho, Mate; Lavallee, Gwenaelle; Aimadaly, Mourtaza; Perrenoud, Francois; Puech, Michel] Ctr Explore Vis, Paris, France.
   [Streho, Mate; Lavallee, Gwenaelle; Aimadaly, Mourtaza; Perrenoud, Francois; Puech, Michel] Ctr Explorat Vis, Rueil Malmaison, France.
   [Tadayoni, Ramin] Hop Lariboisiere, Ophthalmol Dept, Paris, France.
   [Giocanti-Auregan, Audrey] Avicenne Hosp, Ophthalmol Dept, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Avicenne - APHP
RP Giocanti-Auregan, A (通讯作者)，Paris XIII Univ, Avicenne Hosp, AP HP, Ophthalmol Dept,DHU Vis & Handicaps, Paris, France.
EM audrey.giocanti@aphp.fr
CR Choi W, 2017, RETINA-J RET VIT DIS, V37, P11, DOI 10.1097/IAE.0000000000001250
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Takasago Y, 2019, RETINA-J RET VIT DIS, V39, P296, DOI 10.1097/IAE.0000000000001980
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
NR 9
TC 1
Z9 1
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2019
VL 50
IS 9
BP E222
EP E228
DI 10.3928/23258160-20190905-13
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA JC5LI
UT WOS:000489323500001
PM 31589762
DA 2022-11-30
ER

PT J
AU Gao, Z
   Liao, Y
   Chen, C
   Liao, CY
   He, DX
   Chen, JM
   Ma, JX
   Liu, ZG
   Wu, YL
AF Gao, Zhan
   Liao, Yi
   Chen, Chao
   Liao, Chunyan
   He, Danxue
   Chen, Jingmeng
   Ma, Jianxing
   Liu, Zuguo
   Wu, Yalin
TI Conversion of all-trans-retinal into all-trans-retinal dimer reflects an
   alternative metabolic/antidotal pathway of all-trans-retinal in the
   retina
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE retinal metabolism; photoreceptor; retina; retinoid; phagocytosis;
   all-trans-retinal; all-trans-retinal dimer; metabolic; antidotal
   pathway; primary porcine RPE cells; retina
ID PIGMENT EPITHELIAL-CELLS; POTENTIAL THERAPEUTIC AGENTS; PHOTORECEPTOR
   OUTER SEGMENTS; RECESSIVE STARGARDT-DISEASE; VISUAL CYCLE; TRANSPORTER
   ABCA4; LIPOFUSCIN; RPE; A2E; IDENTIFICATION
AB Free all-trans-retinal (atRAL) and retinal pigment epithelium (RPE) lipofuscin are both considered to play etiological roles in Stargardt disease and age-related macular degeneration. A2E and all-trans-retinal dimer (atRAL-dimer) are two well characterized bisretinoid constituents of RPE lipofuscin. In this study, we found that, after treatment of primary porcine RPE (pRPE) cells with atRAL, atRAL-dimer readily formed and accumulated in a concentration- and time-dependent manner, but A2E was barely detected. Cell-based assays revealed that atRAL, the precursor of atRAL-dimer, significantly altered the morphology of primary pRPE cells and decreased cell viability at a concentration of 80 m regardless of light exposure. By contrast, atRAL-dimer was not cytotoxic and phototoxic to primary pRPE cells. Compared with atRAL and A2E, atRAL-dimer was more vulnerable to light, followed by the generation of its photocleaved products. Moreover, we observed the presence of atRAL-dimer in reaction mixtures of atRAL with porcine rod outer segments (ROS), RPE/choroid, or neural retina. Taken together, we here proposed an alternative metabolic/antidotal pathway of atRAL in the retina: atRAL that evades participation of the visual (retinoid) cycle undergoes a condensation reaction to yield atRAL-dimer in both ROS and RPE. Translocation of atRAL, all-trans N-retinylidene-phosphatidylethanolamine (NR-PE), atRAL-dimer, and photocleavage products of atRAL-dimer from ROS into RPE is accomplished by phagocytosing shed ROS on a daily basis. Without causing damage to RPE cells, light breaks up total atRAL-dimer within RPE cells to release low-molecular-weight photocleavage fragments. The latter, together with ROS-atRAL-dimer photocleavage products, may easily move across membranes and thereby be metabolically eliminated.
C1 [Gao, Zhan; Liao, Yi; Chen, Chao; Liao, Chunyan; He, Danxue; Liu, Zuguo; Wu, Yalin] Xiamen Univ, Coll Med, Eye Inst, Fujian Prov Key Lab Ophthalmol & Visual Sci, Xiangan South Rd, Xiamen 361102, Peoples R China.
   [Chen, Jingmeng] Xiamen Univ, Coll Med, Clin Skills Training Ctr, Xiamen 361102, Peoples R China.
   [Ma, Jianxing] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Dept Physiol, Oklahoma City, OK 73104 USA.
C3 Xiamen University; Xiamen University; University of Oklahoma System;
   University of Oklahoma Health Sciences Center
RP Wu, YL (通讯作者)，Xiamen Univ, Coll Med, Eye Inst, Fujian Prov Key Lab Ophthalmol & Visual Sci, Xiangan South Rd, Xiamen 361102, Peoples R China.
EM yalinw@xmu.edu.cn
FU China National Natural Science Foundation [81570857, 81700864]; Sanming
   Project of Medicine in Shenzhen [SZSM201612022]; Fundamental Research
   Funds for the Central Universities; Natural Science Foundation of Fujian
   Province [2017J01148, 2016J01412]; research grant for young and mid-aged
   teachers of Fujian Province [JAT160011]
FX This work was supported in part by grants from the China National
   Natural Science Foundation (81570857 to Y. W. and 81700864 to Y. L.),
   the Sanming Project of Medicine in Shenzhen (SZSM201612022 to Z. L. and
   Y. W.), the Fundamental Research Funds for the Central Universities (to
   Y. W. and Y. L.), and the Natural Science Foundation of Fujian Province
   (2017J01148 to Y. W. and 2016J01412 to Y. L.) and in part by a research
   grant for young and mid-aged teachers of Fujian Province (JAT160011 to
   Y. L.). The authors declare that they have no conflicts of interest with
   the contents of this article.
CR Chen CH, 2002, BIOPHYS J, V83, P1403, DOI 10.1016/S0006-3495(02)73911-8
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fishkin N, 2004, CHEM REC, V4, P120, DOI 10.1002/tcr.20000
   Fishkin NE, 2005, P NATL ACAD SCI USA, V102, P7091, DOI 10.1073/pnas.0501266102
   Li J, 2016, TOXICOLOGY, V371, P41, DOI 10.1016/j.tox.2016.10.005
   Li J, 2013, J BIOL CHEM, V288, P35671, DOI 10.1074/jbc.M113.511386
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Liu X, 2016, INVEST OPHTH VIS SCI, V57, P1017, DOI 10.1167/iovs.15-18429
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   Molday RS, 2007, J BIOENERG BIOMEMBR, V39, P507, DOI 10.1007/s10863-007-9118-6
   Molday RS, 2006, ADV EXP MED BIOL, V572, P465
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034
   Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sullivan JM, 2009, EXP EYE RES, V89, P602, DOI 10.1016/j.exer.2009.03.005
   Sun H, 2001, J BIOENERG BIOMEMBR, V33, P523, DOI 10.1023/A:1012883306823
   Tang PH, 2013, PROG RETIN EYE RES, V32, P48, DOI 10.1016/j.preteyeres.2012.09.002
   Travis GH, 2007, ANNU REV PHARMACOL, V47, P469, DOI 10.1146/annurev.pharmtox.47.120505.105225
   Tsybovsky Y, 2011, BIOCHEMISTRY-US, V50, P6855, DOI 10.1021/bi200774w
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Wielgus AR, 2010, PHOTOCHEM PHOTOBIOL, V86, P781, DOI 10.1111/j.1751-1097.2010.00750.x
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Zhao JL, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20734
NR 30
TC 5
Z9 5
U1 1
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 14
PY 2018
VL 293
IS 37
BP 14507
EP 14519
DI 10.1074/jbc.RA118.002447
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GT7AG
UT WOS:000444671500028
PM 30049796
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Jiang, C
   Xie, P
   Sun, RX
   Sun, XT
   Liu, GH
   Ding, SJ
   Zhu, MD
   Yan, B
   Liu, QH
   Chen, X
   Zhao, C
AF Jiang, Chao
   Xie, Ping
   Sun, Ruxu
   Sun, Xiantao
   Liu, Guohua
   Ding, Sijia
   Zhu, Meidong
   Yan, Biao
   Liu, Qinghuai
   Chen, Xue
   Zhao, Chen
TI c-Jun-mediated microRNA-302d-3p induces RPE dedifferentiation by
   targeting p21(Waf1/Cip1)
SO CELL DEATH & DISEASE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; CELLS; MICRORNAS;
   MIR-302; PROMOTES; DIFFERENTIATION; REPRESSION; EYE; NEOVASCULARIZATION
AB Dedifferentiation of retinal pigment epithelium (RPE) cells and choroidal neovascularization (CNV) contributes to the pathogenesis of age-related macular degeneration (AMD). MicroRNAs (miRNAs) have crucial roles in AMD onset and progression. We thus aim to investigate the effects of miRNAs on RPE dedifferentiation and endothelium cell (EC) behavior, and analyze its downstream pathways. We have previously identified miR-302d-3p as the most downregulated miRNA signature along with RPE differentiation. Herein, in vitro study supported that miR-302d-3p induces RPE dedifferentiation typified by reduction of RPE characteristic markers, interrupts its phagocytosis, and promotes its migration, proliferation, and cell-cycle progression. c-Jun was identified as a potential upstream transcript factor for MIR302D, which might modulate RPE function by regulating miR-302d-3p expression. P21(Waf1/Cip1), a cyclin-dependent kinase inhibitor encoded by the CDKN1A gene, was identified as a downstream target of miR-302d-3p. Our data suggested that p21(Waf1/Cip1) could promote RPE differentiation, and inhibit its proliferation, migration, and cell-cycle progression. We also demonstrated that miR-302d-3p suppresses RPE differentiation through directly targeting p21(Waf1/Cip1). In addition, the miR-302d-3p/CDKN1A axis was also involved in regulating tube formation of ECs, indicating its potential involvement in CNV formation. Taken together, our study implies that miR-302d-3p, regulated by c-Jun, contributes to the pathogenesis of both atrophic and exudative AMD. MiR-302d-3p promotes RPE dedifferentiation, migration, proliferation and cell-cycle progression, inhibits RPE phagocytosis, and induces abnormal EC behavior by targeting p21(Waf1/Cip1). Pharmacological miR-302d-3p inhibitors are prospective therapeutic options for prevention and treatment of AMD.
C1 [Jiang, Chao; Xie, Ping; Sun, Ruxu; Liu, Qinghuai; Chen, Xue; Zhao, Chen] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
   [Sun, Xiantao] Childrens Hosp Zhengzhou, Dept Ophthalmol, Zhengzhou 450053, Henan, Peoples R China.
   [Liu, Guohua] Shandong Univ, Qilu Childrens Hosp, Dept Ophthalmol, Jinan 250000, Shandong, Peoples R China.
   [Ding, Sijia] Nanjing Med Univ, Dept Sci & Technol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
   [Zhu, Meidong] Univ Sydney, Discipline Clin Ophthalmol & Eye Hlth, Save Sight Inst, Camperdown, NSW 2000, Australia.
   [Yan, Biao; Chen, Xue; Zhao, Chen] Fudan Univ, Shanghai Med Coll, Eye & ENT Hosp, Dept Ophthalmol & Vis Sci, Shanghai 200023, Peoples R China.
   [Yan, Biao; Chen, Xue; Zhao, Chen] Fudan Univ, State Hlth Minist, Key Lab Myopia, Shanghai 200023, Peoples R China.
   [Yan, Biao; Chen, Xue; Zhao, Chen] Shanghai Key Lab Visual Impairment & Restorat, Shanghai 200023, Peoples R China.
C3 Nanjing Medical University; Shandong University; Nanjing Medical
   University; University of Sydney; Fudan University; Fudan University
RP Chen, X; Zhao, C (通讯作者)，Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.; Chen, X; Zhao, C (通讯作者)，Childrens Hosp Zhengzhou, Dept Ophthalmol, Zhengzhou 450053, Henan, Peoples R China.
EM drcx1990@163.com; dr_zhaochen@163.com
FU National Natural Science Foundation of China [81700877, 81525006,
   81670864, 81730025]; Natural Science Foundation of Jiangsu Province
   [BK20171087]; Shanghai Outstanding Academic Leaders [2017BR013]; Open
   Foundation of State Key Laboratory of Reproductive Medicine (Nanjing
   Medical University) [SKLRM-KA201607]; Priority Academic Program
   Development (PAPD) of Jiangsu Higher Education Institutions
FX This study was supported by National Natural Science Foundation of China
   (81700877 to X.C., and 81525006, 81670864, and 81730025 to C.Z.);
   Natural Science Foundation of Jiangsu Province (BK20171087 to X.C.);
   Shanghai Outstanding Academic Leaders (2017BR013 to C.Z.); Open
   Foundation of State Key Laboratory of Reproductive Medicine (Nanjing
   Medical University, SKLRM-KA201607 to X.C.); and a project funded by the
   Priority Academic Program Development (PAPD) of Jiangsu Higher Education
   Institutions.
CR Adijanto J, 2012, J BIOL CHEM, V287, P20491, DOI 10.1074/jbc.M112.354761
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Askou AL, 2017, HUM GENE THER METHOD, V28, P222, DOI 10.1089/hgtb.2017.079
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Buccarello L, 2017, ONCOTARGET, V8, P83038, DOI 10.18632/oncotarget.19886
   Cai N, 2013, RNA, V19, P85, DOI 10.1261/rna.035295.112
   Chang HM, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1909
   Chen X., 2017, CELL DEATH DIS, V8, P3037
   Chen X, 2014, HUM MOL GENET, V23, P2926, DOI 10.1093/hmg/ddu005
   Corydon TJ, 2015, HUM GENE THER, V26, P525, DOI 10.1089/hum.2015.064
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Dolezalova D, 2012, STEM CELLS, V30, P1362, DOI 10.1002/stem.1108
   Du HJ, 2013, P NATL ACAD SCI USA, V110, P2377, DOI 10.1073/pnas.1221729110
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ehlken C, 2019, OPHTHALMIC RES, V61, P174, DOI 10.1159/000481260
   Emde A, 2014, EMBO J, V33, P1428, DOI 10.15252/embj.201488142
   Fareh M, 2012, CELL DEATH DIFFER, V19, P232, DOI 10.1038/cdd.2011.89
   Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605
   Frampton JE, 2013, DRUG AGING, V30, P331, DOI 10.1007/s40266-013-0077-9
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Haraguchi T, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp040
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho TT, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1198
   Hu SJ, 2013, STEM CELLS, V31, P259, DOI 10.1002/stem.1278
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Jiang C, 2016, ONCOTARGET, V7, P52340, DOI 10.18632/oncotarget.10566
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kim JE, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.331
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Li W, 2013, AGEING RES REV, V12, P1005, DOI 10.1016/j.arr.2013.05.006
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708
   Lin SL, 2011, NUCLEIC ACIDS RES, V39, P1054, DOI 10.1093/nar/gkq850
   Lin SL, 2010, CANCER RES, V70, P9473, DOI 10.1158/0008-5472.CAN-10-2746
   Lipchina I, 2011, GENE DEV, V25, P2173, DOI 10.1101/gad.17221311
   Liu YQ, 2010, INVEST OPHTH VIS SCI, V51, P3372, DOI 10.1167/iovs.09-4321
   Liu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep14867
   Marneros AG, 2016, EMBO MOL MED, V8, P208, DOI 10.15252/emmm.201505613
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Ohana R, 2015, DEVELOPMENT, V142, P2487, DOI 10.1242/dev.121533
   Parchem RJ, 2015, CELL REP, V12, P760, DOI 10.1016/j.celrep.2015.06.074
   Scheel AHJ, 2009, CELL CYCLE, V8, P1426, DOI 10.4161/cc.8.9.8324
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundermeier TR, 2017, J BIOL CHEM, V292, P3366, DOI 10.1074/jbc.M116.770024
   Sundermeier TR, 2016, FASEB J, V30, P23, DOI 10.1096/fj.15-279745
   Tian B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02407-7
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Wang LM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-448
   Wang Y, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-144
   Wormald R, 2007, COCHRANE DB SYST REV, V3
   Xiao M, 2017, RNA BIOL, V14, P1326, DOI 10.1080/15476286.2015.1112487
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   YANG ST, 2016, PLOS ONE, V11
   Zhang HJ, 2013, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00196
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhao C, 2009, AM J HUM GENET, V85, P617, DOI 10.1016/j.ajhg.2009.09.020
NR 61
TC 10
Z9 10
U1 2
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR 18
PY 2018
VL 9
AR 451
DI 10.1038/s41419-018-0481-5
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GF2OP
UT WOS:000431779800013
PM 29670082
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, X
   Zhou, DY
   Shen, J
   Wu, YB
   Sun, QZ
   Dong, JM
   Yu, JC
AF Chen, Xing
   Zhou, Danying
   Shen, Jian
   Wu, Yanbing
   Sun, Qingzhu
   Dong, Jianming
   Yu, Jianchun
TI Prevalence and Causes of Visual Impairment in Adults in Binhu District,
   Wuxi, China
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Blindness; Cataract; Root Cause Analysis; Vision Disorders; Vision, Low
ID BLINDNESS; POPULATION; EYE; STRATEGIES; PROVINCE
AB Background: Previously reported data has guided the treatment and prevention of blindness. This study aimed to evaluate the current prevalence and causes of visual impairment among adults who were 50 years old and older in the Binhu District of Wuxi City, China.
   Material/Methods: A randomized sample of stratified clusters was used to analyze individuals from 30 basic sampling units in Wuxi Binhu District. Visual impairment was defined according to World Health Organization (WHO) standards.
   Results: A total of 6725 people who were at least 50 years old participated in this study. According to WHO standards, bilateral low vision and blindness prevalence were both higher in women than in men (low vision: 6.5% vs. 5.2%; and blindness: 1.4% vs. 0.8%; P=0.022 and P=0.039, respectively). The incidence of bilateral visual impairment increased significantly with age (P<0.001 and P<0.001, respectively). Further studies showed that the main causes of bilateral low vision were cataract, high myopic macular degeneration (MMD), and age-related macular degeneration (AMD). The main causes of bilateral blindness were cataract, MMD, and eye loss/atrophy, while the main causes of monocular low vision were cataract, MD, and AMD. The main causes of monocular blindness were cataract, eye loss/atrophy, and AMD.
   Conclusions: The prevalence of low vision and blindness remains high in the Binhu District of Wuxi City in China, especially among older women. In our study, cataracts were the leading cause of visual impairment. Our study highlights that some efforts should be initiated to prevent and treat blindness and low vision. Additional causes of visual impairment were MMD, AMD, and eye loss/atrophy.
C1 [Chen, Xing; Zhou, Danying; Shen, Jian; Wu, Yanbing; Sun, Qingzhu; Dong, Jianming; Yu, Jianchun] Soochow Univ, Wuxi Peoples Hosp 9, Dept Ophthalmol, Wuxi, Jiangsu, Peoples R China.
C3 Soochow University - China
RP Yu, JC (通讯作者)，Soochow Univ, Wuxi Peoples Hosp 9, Dept Ophthalmol, Wuxi, Jiangsu, Peoples R China.
EM jiuyuanyanke@163.com
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 2014, ZHONGHUA YAN KE ZA Z, V50, P851
   Chen H, 2014, INT J OPHTHALMOL-CHI, V7, P139, DOI 10.3980/j.issn.2222-3959.2014.01.26
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Huang SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1362, DOI 10.1001/archophthalmol.2009.138
   Li EY, 2013, OPHTHALMOLOGY, V120, P2176, DOI 10.1016/j.ophtha.2013.04.003
   Li L, 2008, EYE, V22, P1069, DOI 10.1038/eye.2008.53
   Lu Hong, 2012, Zhonghua Yan Ke Za Zhi, V48, P205
   Maignan M, 2009, JAMA-J AM MED ASSOC, V302, P1270, DOI 10.1001/jama.2009.1353
   Munier A, 1998, BRIT J OPHTHALMOL, V82, P630, DOI 10.1136/bjo.82.6.630
   Nakamura Y, 2010, OPHTHALMOLOGY, V117, P2315, DOI 10.1016/j.ophtha.2010.03.043
   Pararajasegaram R, 1999, AM J OPHTHALMOL, V128, P359
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Tang YT, 2015, OPHTHALMOLOGY, V122, P1480, DOI 10.1016/j.ophtha.2015.03.022
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   Tong Xiao-wei, 2011, Zhonghua Yan Ke Za Zhi, V47, P785
   Wang Lanming, 2012, Zhongguo Yi Liao Qi Xie Za Zhi, V36, P426
   Wang Y, 2011, OPHTHALMOLOGY, V118, P279, DOI 10.1016/j.ophtha.2010.05.026
   Xu L, 2006, OPHTHALMOLOGY, V113
   Yao Y, 2013, PAK J MED SCI, V29, P1203
   Zhao J, 1999, Zhonghua Yan Ke Za Zhi, V35, P341
   Zhao Jia-liang, 2011, Zhonghua Yan Ke Za Zhi, V47, P779
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P409, DOI 10.1016/j.ophtha.2009.11.023
NR 23
TC 7
Z9 8
U1 0
U2 6
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JAN 16
PY 2018
VL 24
BP 317
EP 323
DI 10.12659/MSM.908218
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FT4WT
UT WOS:000423156600001
PM 29335399
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Hsiung, J
   Zhu, DH
   Hinton, DR
AF Hsiung, Jamie
   Zhu, Danhong
   Hinton, David R.
TI Polarized Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial
   Cell Monolayers Have Higher Resistance to Oxidative Stress-Induced Cell
   Death Than Nonpolarized Cultures
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE Age-related macular degeneration; Retinal pigment epithelial cell;
   Embryonic stem cells; Polarized retinal pigment epithelial cell;
   Oxidative stress; Apoptosis
ID HUMAN BRUCHS MEMBRANE; MACULAR DEGENERATION; HYDROGEN-PEROXIDE;
   AQUEOUS-HUMOR; BAX TRANSLOCATION; INDUCED APOPTOSIS; SUBRETINAL SPACE;
   RPE; TRANSPLANTATION; BCL-2
AB Oxidative stress-mediated injury to the retinal pigment epithelium (RPE) is a major factor involved in the pathogenesis of age-related macular degeneration (AMD), the leading cause of blindness in the elderly. Human embryonic stem cell (hESC)-derived RPE cells are currently being evaluated for their potential for cell therapy in AMD patients through subretinal injection of cells in suspension and subretinal placement as a polarized monolayer. To gain an understanding of how transplanted RPE cells will respond to the highly oxidatively stressed environment of an AMD patient eye, we compared the survival of polarized and nonpolarized RPE cultures following oxidative stress treatment. Polarized, nonpolarized/confluent, nonpolarized/subconfluent hESC-RPE cells were treated with H2O2. Terminal deoxynucleotidyl transferase dUTP nick end labeling stains revealed the highest amount of cell death in subconfluent hESC-RPE cells and little cell death in polarized hESC-RPE cells with H2O2 treatment. There were higher levels of proapoptotic factors (phosphorylated p38, phosphorylated c-Jun NH2-terminal kinase, Bax, and cleaved caspase 3 fragments) in treated nonpolarized RPE particularly subconfluent cells relative to polarized cells. On the other hand, polarized RPE cells had constitutively higher levels of cell survival and antiapoptotic signaling factors such as p-Akt and Bcl-2, as well as antioxidants superoxide dismutase 1 and catalase relative to nonpolarized cells, that possibly contributed to polarized cells' higher tolerance to oxidative stress compared with nonpolarized RPE cells. Subconfluent cells were particularly sensitive to oxidative stress-induced apoptosis. These results suggest that implantation of polarized hESC-RPE monolayers for treating AMD patients with geographic atrophy should have better survival than injections of hESC-RPE cells in suspension.
C1 [Hsiung, Jamie; Zhu, Danhong; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
   [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 University of Southern California; University of Southern California
RP Hinton, DR (通讯作者)，2011 Zonal Ave,HMR209, Los Angeles, CA 90089 USA.
EM dhinton@usc.edu
FU California Institute for Regenerative Medicine Grant [DR1-01444]; Arnold
   and Mabel Beckman Foundation to the Doheny Eye Institute,; National
   Cancer Institute [P30CA014089]; NATIONAL CANCER INSTITUTE [P30CA014089]
   Funding Source: NIH RePORTER
FX We thank Christine Spee for her help with cell preparation and Ernesto
   Barron and Eric Barron for their help with figure preparation and
   design. This work was supported by California Institute for Regenerative
   Medicine Grant DR1-01444, a grant from the Arnold and Mabel Beckman
   Foundation to the Doheny Eye Institute, and Award P30CA014089 from the
   National Cancer Institute. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   National Cancer Institute or the National Institutes of Health.
CR Aouacheria Abdel, 2007, Recent Pat DNA Gene Seq, V1, P43, DOI 10.2174/187221507779814434
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481
   Burke JM, 2011, MOL VIS, V17, P2864
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Ellerby LM, 1996, J NEUROCHEM, V67, P1259
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335
   Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Ho TC, 2006, APOPTOSIS, V11, P1899, DOI 10.1007/s10495-006-9403-6
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Jang JH, 2003, BIOCHEM PHARMACOL, V66, P1371, DOI 10.1016/S0006-2952(03)00487-8
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Li XH, 2002, BIPOLAR DISORD, V4, P137, DOI 10.1034/j.1399-5618.2002.40201.x
   Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Pan CK, 2013, EXPERT OPIN BIOL TH, V13, P1125, DOI 10.1517/14712598.2013.793304
   Papadopoulos MC, 1998, EUR J NEUROSCI, V10, P1252, DOI 10.1046/j.1460-9568.1998.00134.x
   Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761
   RAMACHANDRAN S, 1991, EXP EYE RES, V53, P503, DOI 10.1016/0014-4835(91)90167-D
   Richer SP, 1998, VISION RES, V38, P2881, DOI 10.1016/S0042-6989(98)00069-8
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004
   Schwartz SD, 2014, LANCET
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Spector A, 1998, INVEST OPHTH VIS SCI, V39, P1188
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Sugino IK, 2011, INVEST OPHTH VIS SCI, V52, P4979, DOI 10.1167/iovs.10-5386
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   WONGPICHEDCHAI S, 1992, INVEST OPHTH VIS SCI, V33, P3341
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Zhu DH, 2011, INVEST OPHTH VIS SCI, V52, P1573, DOI 10.1167/iovs.10-6413
NR 50
TC 40
Z9 42
U1 0
U2 4
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD JAN
PY 2015
VL 4
IS 1
BP 10
EP 20
DI 10.5966/sctm.2014-0205
PG 11
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AY6EL
UT WOS:000347660100012
PM 25411476
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Reyes, SV
   Silvestri, V
   Amore, F
   Markowitz, SN
AF Reyes, Sophia V.
   Silvestri, Valeria
   Amore, Filippo
   Markowitz, Samuel N.
TI Use of prisms for vision rehabilitation after macular function loss may
   impact oculomotor control
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
AB Objective: To determine the effect from using prisms for image relocation on fixation stability estimates in low-vision (LV) patients with age-related macular degeneration (AMD).
   Methods: The study was designed as a prospective, nonrandomized, observational case series. Inclusion criteria included documented AMD, LV with best corrected visual acuity of 20/50 to 20/400 in the better eye, and cases wearing distance glasses with prisms for image relocation incorporated in the glasses. Preferred retinal locus (PRL) and fixation stability were assessed using the Nidek MP1 and MAIA microperimeters. A control group was used to compare results.
   Results: We recruited 14 study subjects with AMD and 10 with no retinal pathology serving as a control group. On average, 6 (SD 2) prisms diopters were prescribed to all in distant viewing glasses. Fixation stability was better at 3-month interval from baseline (p = 0.021) in the AMD group and stayed the same for the following 9 months. No change in fixation stability was noticed in the control group. There was no statistically significant difference in PRL eccentricity between the 3- and 12-month intervals in the AMD group (p = 0.39). However, there was a positive correlation between PRL eccentricity and baseline bivariate contour ellipse area in the AMD group (p = 0.052).
   Conclusions: Patients with LV with AMD who are using prisms for image relocation toward the peripheral retinal exhibit better fixation stability than those who are not using prisms. Better fixation stability may impact on other visual outcomes. Use of prisms should be considered in any LV rehabilitation attempt and used in conjunction with other modern interventions in LV rehabilitation.
C1 [Reyes, Sophia V.; Markowitz, Samuel N.] Univ Toronto, Dept Ophthalmol & Vis Sci, Low Vis Serv Univ Hlth Network Hosp, Toronto, ON, Canada.
   [Silvestri, Valeria; Amore, Filippo] Int Agcy Prevent Blindness, Natl Ctr Serv & Res Prevent Blindness & Rehabilat, Rome, Italy.
C3 University of Toronto; University Health Network Toronto
RP Markowitz, SN (通讯作者)，1225 Davenport Rd, Toronto, ON M6H 2H1, Canada.
EM snm1@rogers.com
RI Silvestri, Valeria/AAB-9530-2022
OI Silvestri, Valeria/0000-0002-8451-8901
CR Al-Karmi R, 2006, CAN J OPHTHALMOL, V41, P313, DOI 10.1139/I06-016
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Gonzalez EG, 2011, INVEST OPHTH VIS SCI, V52, P4208, DOI 10.1167/iovs.10-7026
   MARKOWITZ SN, CAN J OPHTH IN PRESS
   MARKOWITZ SN, 2012, ACTA OPHTHALMOL
   Seiple W, 2011, INVEST OPHTH VIS SCI, V52, P2938, DOI 10.1167/iovs.10-6137
   Shima N, 2010, CAN J OPHTHALMOL, V45, P62, DOI 10.3129/i09-236
   Tarita-Nistor L, 2009, INVEST OPHTH VIS SCI, V50, P84, DOI 10.1167/iovs.08-2342
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
NR 11
TC 4
Z9 4
U1 0
U2 6
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2013
VL 48
IS 5
BP 427
EP 430
DI 10.1016/j.jcjo.2013.03.001
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5OM
UT WOS:000331149300029
PM 24093191
DA 2022-11-30
ER

PT J
AU Mantopoulos, D
   Murakami, Y
   Comander, J
   Thanos, A
   Roh, M
   Miller, JW
   Vavvas, DG
AF Mantopoulos, Dimosthenis
   Murakami, Yusuke
   Comander, Jason
   Thanos, Aristomenis
   Roh, Miin
   Miller, Joan W.
   Vavvas, Demetrios G.
TI Tauroursodeoxycholic Acid (TUDCA) Protects Photoreceptors from Cell
   Death after Experimental Retinal Detachment
SO PLOS ONE
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; BILE-ACID; INDUCED APOPTOSIS; RAT
   HEPATOCYTES; HUNTINGTONS-DISEASE; EXPERIMENTAL-MODEL; DEGENERATION;
   ACTIVATION; NECROSIS; CYTOLYSIS
AB Background: Detachment of photoreceptors from the underlying retinal pigment epithelium is seen in various retinal disorders such as retinal detachment and age-related macular degeneration and leads to loss of photoreceptors and vision. Pharmacologic inhibition of photoreceptor cell death may prevent this outcome. This study tests whether systemic administration of tauroursodeoxycholic acid (TUDCA) can protect photoreceptors from cell death after experimental retinal detachment in rodents.
   Methodology/Principal Findings: Retinal detachment was created in rats by subretinal injection of hyaluronic acid. The animals were treated daily with vehicle or TUDCA (500 mg/kg). TUNEL staining was used to evaluate cell death. Photoreceptor loss was evaluated by measuring the relative thickness of the outer nuclear layer (ONL). Macrophage recruitment, oxidative stress, cytokine levels, and caspase levels were also quantified. Three days after detachment, TUDCA decreased the number of TUNEL-positive cells compared to vehicle (651 +/- 68/mm(2) vs. 1314 +/- 68/mm(2), P = 0.001) and prevented the reduction of ONL thickness ratio (0.84 +/- 0.03 vs. 0.65 +/- 0.03, P = 0.002). Similar results were obtained after 5 days of retinal detachment. Macrophage recruitment and expression levels of TNF-a and MCP-1 after retinal detachment were not affected by TUDCA treatment, whereas increases in activity of caspases 3 and 9 as well as carbonyl-protein adducts were almost completely inhibited by TUDCA treatment.
   Conclusions/Significance: Systemic administration of TUDCA preserved photoreceptors after retinal detachment, and was associated with decreased oxidative stress and caspase activity. TUDCA may be used as a novel therapeutic agent for preventing vision loss in diseases that are characterized by photoreceptor detachment.
C1 [Mantopoulos, Dimosthenis; Murakami, Yusuke; Comander, Jason; Thanos, Aristomenis; Roh, Miin; Miller, Joan W.; Vavvas, Demetrios G.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Angiogenesis Lab,Dept Ophthalmol, Boston, MA USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Mantopoulos, D (通讯作者)，Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Angiogenesis Lab,Dept Ophthalmol, Boston, MA USA.
EM vavvas@meei.harvard.edu
OI Comander, Jason/0000-0002-4257-7145; Roh, Miin/0000-0003-3346-754X;
   Vavvas, Demetrios/0000-0002-8622-6478; Miller, Joan/0000-0003-2046-3996
FU Research to Prevent Blindness Foundation; Lions Eye Research Fund;
   Onassis Foundation; National Eye Institute [EY014104]; Yeatts Family
   Fund; NATIONAL EYE INSTITUTE [P30EY014104] Funding Source: NIH RePORTER
FX The Research to Prevent Blindness Foundation, the Lions Eye Research
   Fund (D. G. V.), the Onassis Foundation (D. G. V.), National Eye
   Institute Grant EY014104 (Massachusetts Eye and Ear Infirmary core
   grant), and Yeatts Family Fund (D. G. V. and J.W.M). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Arroyo JG, 2005, AM J OPHTHALMOL, V139, P605, DOI 10.1016/j.ajo.2004.11.046
   Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425
   Benz C, 1998, J HEPATOL, V28, P99, DOI 10.1016/S0168-8278(98)80208-0
   Benz C, 1998, EUR J CLIN INVEST, V28, P577
   Boatright JH, 2006, MOL VIS, V12, P1706
   Boatright Jeffrey H, 2009, J Ocul Biol Dis Infor, V2, P149
   Boisgerault F, 1996, P NATL ACAD SCI USA, V93, P3466, DOI 10.1073/pnas.93.8.3466
   Campo RV, 1999, OPHTHALMOLOGY, V106, P1811, DOI 10.1016/S0161-6420(99)90353-6
   Cardoso I, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-74
   CHANG CJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P880, DOI 10.1001/archopht.1995.01100070054025
   Colell A, 2001, HEPATOLOGY, V34, P964, DOI 10.1053/jhep.2001.28510
   COOK B, 1995, INVEST OPHTH VIS SCI, V36, P990
   Duan WM, 2002, CELL TRANSPLANT, V11, P195
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3
   HAIMANN MH, 1982, ARCH OPHTHALMOL-CHIC, V100, P289
   Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3
   Hisatomi T, 2008, J CLIN INVESTIGATION
   Keene CD, 2002, P NATL ACAD SCI USA, V99, P10671, DOI 10.1073/pnas.162362299
   Keene CD, 2001, EXP NEUROL, V171, P351, DOI 10.1006/exnr.2001.7755
   Lamireau T, 2003, LIFE SCI, V72, P1401, DOI 10.1016/S0024-3205(02)02408-6
   Lecleire-Collet A, 2005, RETINA-J RET VIT DIS, V25, P44, DOI 10.1097/00006982-200501000-00006
   Liu H, 2010, EYE, V24, P137, DOI 10.1038/eye.2009.20
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Nakazawa T, 2006, MOL VIS, V12, P867
   Nakazawa T, 2011, INVEST OPHTH VIS SCI, V52, P1384, DOI 10.1167/iovs.10-6509
   Oveson BC, 2011, J NEUROCHEM, V116, P144, DOI 10.1111/j.1471-4159.2010.07092.x
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Phillips MJ, 2008, INVEST OPHTH VIS SCI, V49, P2148, DOI 10.1167/iovs.07-1012
   Ramalho RM, 2006, J NEUROCHEM, V98, P1610, DOI 10.1111/j.1471-4159.2006.04007.x
   Rodrigues CMP, 1998, MOL MED, V4, P165, DOI 10.1007/BF03401914
   Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100
   Rodrigues TMP, 2002, J CEREBR BLOOD F MET, V22, P463, DOI 10.1097/00004647-200204000-00010
   Roh MMY, 2011, EDARAVONE ROS SCAVEN
   Schoemaker MH, 2004, HEPATOLOGY, V39, P1563, DOI 10.1002/hep.20246
   Sugata K, 1996, J GASTROEN HEPATOL, V11, P451, DOI 10.1111/j.1440-1746.1996.tb00290.x
   Trichonas G, 2010, P NATL ACAD SCI US
   Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255
   Wei H, 2008, HUM MOL GENET, V17, P469, DOI 10.1093/hmg/ddm324
   WILKES SR, 1982, AM J OPHTHALMOL, V94, P670, DOI 10.1016/0002-9394(82)90013-7
   Zacks DN, 2003, INVEST OPHTH VIS SCI, V44, P1262, DOI 10.1167/iovs.02-0492
   Zacks DN, 2004, INVEST OPHTH VIS SCI, V45, P4563, DOI 10.1167/iovs.04-0598
NR 42
TC 77
Z9 79
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 22
PY 2011
VL 6
IS 9
AR e24245
DI 10.1371/journal.pone.0024245
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 825IJ
UT WOS:000295265100006
PM 21961034
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Huang, LL
   Coleman, HR
   Kim, J
   de Monasterio, F
   Wong, WT
   Schleicher, RL
   Ferris, FL
   Chew, EY
AF Huang, Lynn L.
   Coleman, Hanna R.
   Kim, Jonghyeon
   de Monasterio, Francisco
   Wong, Wai T.
   Schleicher, Rosemary L.
   Ferris, Frederick L., III
   Chew, Emily Y.
TI Oral supplementation of lutein/zeaxanthin and omega-3 long chain
   polyunsaturated fatty acids in persons aged 60 years or older, with or
   without AMD
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR DEGENERATION; VITAMIN-E; LUTEIN SUPPLEMENTATION; ALPHA-CAROTENE;
   BETA-CAROTENE; UNITED-STATES; BIOAVAILABILITY; PREVALENCE; DISEASE;
   HEALTH
AB PURPOSE. Increased dietary intake of lutein/zeaxanthin and omega-long-chain polyunsaturated fatty acids (omega-3 LCPUFA) was found to be associated with reduced risk of advanced age-related macular degeneration (AMD). The purpose of the study was to examine the effect of oral supplementation of omega-3 LCPUFA on changes in serum levels of lutein/zeaxanthin during supplementation in persons 60 years of age and older, with or without AMD.
   METHODS. Forty participants with AMD of various degrees of severity received lutein (10 mg) and zeaxanthin (2 mg) daily and were equally randomized to receive omega-3 LCPUFA (350 mg docosahexaenoic acid [DHA] and 650 mg eicosapentaenoic acid [EPA]) or placebo for 6 months. Serum levels of lutein, zeaxanthin, and omega-3 LCPUFAs and macular pigment optical densities were measured at baseline, 1 week, and 1, 3, 6, and 9 months.
   RESULTS. By month 6, the median serum levels of lutein/zeaxanthin increased by two- to threefold compared with baseline. Increases in serum levels of lutein/zeaxanthin did not differ by omega-3 LCPUFA treatment (P > 0.5). After 1 month, in the omega-3 LCPUFA-treated group, the median levels of DHA and EPA increased and the placebo group had no changes. At month 6, participants with AMD had a lower increase in serum lutein concentration than did those without AMD (P < 0.05).
   CONCLUSIONS. The addition of omega-3 LCPUFA to oral supplementation of lutein/zeaxanthin did not change the serum levels of lutein and zeaxanthin. A long-term large clinical trial is necessary to investigate the benefits and adverse effects of these factors for the treatment of AMD.
C1 [Chew, Emily Y.] NEI, CRC, NIH, Div Epidemiol & Clin Res,Clin Trials Branch, Bethesda, MD 20892 USA.
   [de Monasterio, Francisco] NEI, NIH, Off Clin Director, Bethesda, MD 20892 USA.
   [Kim, Jonghyeon] EMMES Corp, Rockville, MD USA.
   [Schleicher, Rosemary L.] Ctr Dis Control & Prevent, Atlanta, GA USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Emmes Corporation; Centers for Disease Control &
   Prevention - USA
RP Chew, EY (通讯作者)，NEI, CRC, NIH, Div Epidemiol & Clin Res,Clin Trials Branch, Bldg 10,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Sanguansri, Luz/B-6630-2011; Wong, Wai/B-6118-2017
OI Sanguansri, Luz/0000-0003-1908-7604; Wong, Wai/0000-0003-0681-4016;
   Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute; Pfizer Pharmaceuticals Group, Bethesda; NIH;
   Pfizer; National Institutes of Health
FX Supported by the intramural funds of the National Eye Institute; and a
   grant to the Foundation for the NIH from Pfizer Pharmaceuticals Group,
   Bethesda, MD (LLH), with a public-private partnership supported jointly
   by the NIH and Pfizer. LLH is a Clinical Research Training Program
   Scholar at the National Institutes of Health.
CR Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Granado F, 1998, BRIT J NUTR, V80, P445, DOI 10.1017/S0007114598001512
   Lacher DA, 2005, CLIN CHEM, V51, P450, DOI 10.1373/clinchem.2004.039354
   Lagerstedt SA, 2001, MOL GENET METAB, V73, P38, DOI 10.1006/mgme.2001.3170
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   Roodenburg AJC, 2000, AM J CLIN NUTR, V71, P1187
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SOWELL AL, 1994, CLIN CHEM, V40, P411
   Tanumihardjo SA, 2005, J AM DIET ASSOC, V105, P114, DOI 10.1016/j.jada.2004.10.011
   Traber MG, 2000, AM J CLIN NUTR, V71, P1029
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
NR 19
TC 36
Z9 41
U1 1
U2 15
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2008
VL 49
IS 9
BP 3864
EP 3869
DI 10.1167/iovs.07-1420
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 344AB
UT WOS:000258896500017
PM 18450596
DA 2022-11-30
ER

PT J
AU Medici, V
   Sturniolo, GC
AF Medici, Valentina
   Sturniolo, Giacomo Carlo
TI Tetrathiomolybdate, a copper chelator for the treatment of Wilson
   disease, pulmonary fibrosis and other indications
SO IDRUGS
LA English
DT Article
ID NEUROLOGICALLY AFFECTED PATIENTS; SQUAMOUS-CELL CARCINOMA; ORAL ZINC
   THERAPY; PHASE-II TRIAL; AMMONIUM TETRATHIOMOLYBDATE; INITIAL THERAPY;
   MOUSE MODEL; FOLLOW-UP; ANIMAL-MODEL; CANCER
AB Tetrathiomolybdate (TTM) is a copper chelator that has also demonstrated antiangiogenic, antifibrogenic and anti-inflammatory actions in preclinical studies. The drug, from the University of Michigan was licensed to Pipex Pharmaceuticals Inc for development for several indications; development of the drug for cancer was later licensed to Attenuon LLC. In a phase III clinical trial, TTM stabilized neurological function in patients with Wilson disease, causing significant recovery in 81% of patients at 3 years post initiation of therapy; a second phase III trial was ongoing at the time of publication. A phase I/II clinical trial demonstrated the efficacy of TTM in patients with idiopathic pulmonary fibrosis, and led the FDA to grant TTM Orphan Drug status for this disease. Several phase II clinical trials had also been completed in patients with various cancers, and revealed mixed efficacy. TTM was also assessed in a phase I clinical trial for age-related macular degeneration, but the results reported from the trial were negative; no further development has occurred for this indication. TTM was assessed for the treatment of psoriasis in a phase II clinical trial, but no data have been reported. At the time of publication, phase II and phase III clinical trials were ongoing in patients with Alzheimer's disease and primary biliary cirrhosis, respectively. The most common clinical side effects observed for TTM over the range of indications have been anemia, neutropenia, leukopenia and transanimase elevations. These side effects were generally resolved with either a dose adjustment or temporary suspension of the dosing regimen. TTM is predicted to most likely find a niche in the therapy of Wilson disease, for which current treatment options are limited.
C1 [Medici, Valentina] Univ Calif Davis, Div Gastroenterol & Hepatol, Dept Internal Med, Davis, CA 95817 USA.
   [Sturniolo, Giacomo Carlo] Univ Hosp Padova, Gastroenterol Sect, Dept Surg & Gastroenterol Sci, I-35128 Padua, Italy.
C3 University of California System; University of California Davis;
   University of Padua; Azienda Ospedaliera - Universita di Padova
RP Medici, V (通讯作者)，Univ Calif Davis, Div Gastroenterol & Hepatol, Dept Internal Med, 4150 V St,Suite 3500, Davis, CA 95817 USA.
EM valentina.medici@ucdmc.ucdavis.edu
OI Medici, Valentina/0000-0001-5438-284X
CR Askari FK, 2003, J LAB CLIN MED, V142, P385, DOI 10.1016/S0022-2143(03)00157-4
   Askari FK, 2004, EXP BIOL MED, V229, P857, DOI 10.1177/153537020422900820
   BERENSON JP, 2006, BLOOD, V108
   BOTHA CJ, 1995, J S AFR VET ASSOC, V66, P6
   BREMNER I, 1982, J INORG BIOCHEM, V16, P109, DOI 10.1016/S0162-0134(00)80219-6
   BREWER G, 1994, ARCH NEUROL-CHICAGO, V51, P545, DOI 10.1001/archneur.1994.00540180023009
   Brewer GJ, 2006, J INORG BIOCHEM, V100, P927, DOI 10.1016/j.jinorgbio.2005.10.007
   Brewer GJ, 2006, ARCH NEUROL-CHICAGO, V63, P521, DOI 10.1001/archneur.63.4.521
   Brewer GJ, 2005, DRUG DISCOV TODAY, V10, P1103, DOI 10.1016/S1359-6446(05)03541-5
   Brewer GJ, 2000, CLIN CANCER RES, V6, P1
   BREWER GJ, 1991, ARCH NEUROL-CHICAGO, V48, P42, DOI 10.1001/archneur.1991.00530130050019
   Brewer GJ, 1996, ARCH NEUROL-CHICAGO, V53, P1017, DOI 10.1001/archneur.1996.00550100103019
   BREWER GJ, 1983, ANN INTERN MED, V99, P314, DOI 10.7326/0003-4819-99-3-314
   Brewer GJ, 2003, ARCH NEUROL-CHICAGO, V60, P379, DOI 10.1001/archneur.60.3.379
   Brewer GJ, 2003, J LAB CLIN MED, V141, P210, DOI 10.1067/mlc.2003.20
   Carlson MD, 2004, PEDIATR NEUROL, V30, P57, DOI 10.1016/S0887-8994(03)00422-3
   Cox C, 2003, ARCH OTOLARYNGOL, V129, P781, DOI 10.1001/archotol.129.7.781
   Elner SG, 2005, INVEST OPHTH VIS SCI, V46, P299, DOI 10.1167/iovs.04-0180
   FLAHERTY KR, 2007, ABS AM THORAC S 0521, pA497
   FROMMER DJ, 1981, DIGESTION, V21, P169, DOI 10.1159/000198559
   FRYDMAN M, 1990, J GASTROEN HEPATOL, V5, P483, DOI 10.1111/j.1440-1746.1990.tb01427.x
   GARTNER EM, 2003, P AM SOC CLIN ONCOL, V22
   GOONERATNE SR, 1981, BRIT J NUTR, V46, P469, DOI 10.1079/BJN19810055
   Hassouneh B, 2007, MOL CANCER THER, V6, P1039, DOI 10.1158/1535-7163.MCT-06-0524
   Haywood S, 2004, J COMP PATHOL, V130, P21, DOI 10.1016/S0021-9975(03)00065-3
   Henry NL, 2006, ONCOLOGY-BASEL, V71, P168, DOI 10.1159/000106066
   HILL GM, 1987, HEPATOLOGY, V7, P522, DOI 10.1002/hep.1840070318
   Hou GQ, 2005, J LAB CLIN MED, V146, P299, DOI 10.1016/j.lab.2005.07.004
   Hu GF, 1998, J CELL BIOCHEM, V69, P326, DOI 10.1002/(SICI)1097-4644(19980601)69:3<326::AID-JCB10>3.0.CO;2-A
   HUMPHRIES WR, 1988, VET REC, V123, P51, DOI 10.1136/vr.123.2.51
   HUMPHRIES WR, 1986, VET REC, V119, P596
   JOHNSON WD, 2004, P AM ASS CANC RES, V45
   JONES LK, 2007, AM ASS CANC RES ANN, V98
   Juarez JC, 2006, CLIN CANCER RES, V12, P4974, DOI 10.1158/1078-0432.CCR-06-0171
   Kent MS, 2004, J TRACE ELEM EXP MED, V17, P9, DOI 10.1002/jtra.10033
   Khan MK, 2006, ARCH OTOLARYNGOL, V132, P333, DOI 10.1001/archotol.132.3.333
   Khan MK, 2002, NEOPLASIA, V4, P164, DOI 10.1038/sj.neo.7900218
   KHAN MK, 2005, P AM ASS CANC RES, V46
   Klein D, 2004, J HEPATOL, V40, P409, DOI 10.1016/j.jhep.2003.11.034
   LOWNDES S, 2006, P AM SOC CLIN ONCOL, V25
   Lyubimov AV, 2004, REPROD TOXICOL, V19, P223, DOI 10.1016/j.reprotox.2004.07.006
   Ma S., 2004, J APPL RES CLIN EXP, V4, P419
   Mamou F, 2006, ANTICANCER RES, V26, P1753
   MARRERO JA, 2002, HEPATOLOGY 2 S4, V36
   McCubbin MD, 2006, J RHEUMATOL, V33, P2501
   Medici V, 2007, DIGEST LIVER DIS, V39, P601, DOI 10.1016/j.dld.2006.12.095
   Medici V, 2006, MOVEMENT DISORD, V21, P2030, DOI 10.1002/mds.21109
   MILLS CF, 1981, J INORG BIOCHEM, V14, P189, DOI 10.1016/S0162-0134(00)80000-8
   MILLS CF, 1981, J INORG BIOCHEM, V14, P163, DOI 10.1016/S0162-0134(00)80037-9
   MULLER A, 1981, ANGEW CHEM INT EDIT, V20, P934, DOI 10.1002/anie.198109341
   Omoto A, 2005, ARTHRITIS RES THER, V7, pR1174, DOI 10.1186/ar1801
   Pan Q, 2003, MOL CANCER THER, V2, P617
   Pan Q, 2002, CANCER RES, V62, P4854
   Pan QT, 2003, MOL CANCER RES, V1, P701
   PARKE A, 1988, AM J PATHOL, V130, P173
   PASS H, 2004, P AM SOC CLIN ONCOL, V23
   *PIP PHARM INC, 2006, COMP WORLD WID WEB S
   Redman BG, 2003, CLIN CANCER RES, V9, P1666
   SUZUKI KT, 1995, J TRACE ELEM MED BIO, V9, P170, DOI 10.1016/S0946-672X(11)80043-X
   *U MICH, CLIN TRIALS GOV 2006
   U MICH, 2008, COMP WORLD WOD WEB S
   *U MICH CANC CTR, 2007, CLIN TRIALS GOV 1213
   Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635
   van Golen KL, 2002, NEOPLASIA, V4, P373, DOI 10.1038/sj.neo.7900258
   Vine Andrew K, 2002, Trans Am Ophthalmol Soc, V100, P73
   *WEILL MED COLL CO, 2008, CLIN TRIALS GOV 0118
   WORDEN FP, 2008, AM SOC CLIN ONCOL AN, V44
   YARZE JC, 1992, AM J MED, V92, P643, DOI 10.1016/0002-9343(92)90783-8
   Zeng CH, 2008, EXP BIOL MED, V233, P1021, DOI 10.3181/0801-RM-10
   ZICHE M, 1982, JNCI-J NATL CANCER I, V69, P475
NR 70
TC 26
Z9 27
U1 1
U2 10
PU THOMSON REUTERS (SCIENTIFIC) LTD
PI LONDON
PA 77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND
SN 1369-7056
J9 IDRUGS
JI IDrugs
PD AUG
PY 2008
VL 11
IS 8
BP 592
EP 606
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 333EG
UT WOS:000258134700014
PM 18683094
DA 2022-11-30
ER

PT J
AU Iriyama, A
   Obata, R
   Inoue, Y
   Takahashi, H
   Tamaki, Y
   Yanagi, Y
AF Iriyama, Aya
   Obata, Ryo
   Inoue, Yuji
   Takahashi, Hidenori
   Tamaki, Yasuhiro
   Yanagi, Yasuo
TI Effect of posterior juxtascleral triamcinolone acetonide on the efficacy
   and choriocapillaris hypoperfusion of photodynamic therapy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; triamcinolone acetonide; combination
   therapy; choroidal circulation
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL TRIAMCINOLONE;
   MACULAR DEGENERATION; VERTEPORFIN; COMBINATION; INJECTION; EXPRESSION;
   VEGF
AB Purpose To evaluate the effect of posterior juxtascleral triamcinolone acetonide (TA) injection combined with photodynamic therapy with verteporfin (PDT) for treating exudative age-related macular degeneration (AMD), the best-corrected visual acuity (BCVA), the retreatment rates and the rate of choroidal hypoperfusion were investigated.
   Methods A total of 67 eyes with subfoveal choroidal neovascularization (CNV) due to AMD were included. Forty-four eyes underwent PDT alone (PDT-alone group), and 23 eyes underwent PDT with the posterior juxtascleral injection of TA (PDT+TA group). Every 3 months after the PDT, the eyes were evaluated with regard to BCVA and requirement for retreatment by fluorescein angiography (FA) with the aid of optical coherence tomography (OCT). Choroiocapillaris hypoperfusion was assessed by indocyanine green angiography (ICGA) at 3 and 12 months. All patients completed a 1-year follow-up.
   Results At the baseline, there was no difference in lesion type, size or visual acuity between the two groups. At 1 year, the change in BCVA was -0.0811 logarithm of the minimum angle of resolution (LogMAR) in the PDT-alone group, compared with -0.0432 logMAR in the PDT+TA group. There was no significant difference in the change in BCVA between the two groups (P=0.6910). The PDT+TA group required a lower mean number of treatments (1.64 compared with 2.34 [P=0.0223]) and showed a higher rate of choriocapillaris occlusion at 3 months, but no significant difference at 1 year (P=0.9243)
   Conclusions Fewer retreatments were required in the TA+PDT group. There was no significant difference in the change in BCVA between the two groups. Adjacent TA may promote short-term choriocapillaris hypoperfusion.
C1 [Iriyama, Aya; Obata, Ryo; Inoue, Yuji; Takahashi, Hidenori; Tamaki, Yasuhiro; Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
C3 University of Tokyo
RP Yanagi, Y (通讯作者)，Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM yanagi-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022; Takahashi, Hidenori/H-2945-2019; Yanagi,
   Yasuo/AAF-2670-2020
OI Takahashi, Hidenori/0000-0001-5331-4730; Yanagi,
   Yasuo/0000-0002-0362-7285; Obata, Ryo/0000-0002-1762-0797
CR Arias L, 2006, OPHTHALMOLOGY, V113, P2243, DOI 10.1016/j.ophtha.2006.04.039
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Augustin AJ, 2006, EUR J OPHTHALMOL, V16, P824, DOI 10.1177/112067210601600607
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Obata R, 2007, BRIT J OPHTHALMOL, V91, P100, DOI 10.1136/bjo.2006.098004
   Parodi MB, 2003, BRIT J OPHTHALMOL, V87, P177, DOI 10.1136/bjo.87.2.177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Tano Y, 2003, AM J OPHTHALMOL, V136, P1049, DOI 10.1016/S0002-9394(03)00576-2
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
NR 19
TC 13
Z9 15
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2008
VL 246
IS 3
BP 339
EP 344
DI 10.1007/s00417-007-0667-5
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 260DW
UT WOS:000252992000003
PM 17805556
DA 2022-11-30
ER

PT J
AU Kalariya, NM
   Ramana, KV
   Srivastava, SK
   van Kuijk, FJGM
AF Kalariya, Nilesh M.
   Ramana, Kota V.
   Srivastava, Satish K.
   van Kuijk, Frederik J. G. M.
TI Carotenoid derived aldehydes-induced oxidative stress causes apoptotic
   cell death in human retinal pigment epithelial cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
ID BETA-CAROTENE; ALDOSE REDUCTASE; CLEAVAGE PRODUCTS; HYPOCHLOROUS ACID;
   DNA-DAMAGE; ZEAXANTHIN; LUTEIN; IDENTIFICATION; INVOLVEMENT; LEUKEMIA
AB Carotenoids have been advocated as potential therapeutic agents in treating age-related macular degeneration (AMD). In ocular tissues carotenoids may undergo oxidation and form carotenoid-derived aldehydes (CDA), which would be toxic to tissues. We have investigated the cytotoxic effects of CDA from P-carotene, Lutein and Zeaxanthin on human retinal pigment epithelial cells (ARPE-19). The serum-starved ARPE-19 cells were treated with CDA without or with antioxidant, N-acetylcysteine (NAC) and cell viability, apoptosis, reactive oxygen species (ROS) levels, nuclear chromatin condensation as well as fragmentation, change in mitochondrial membrane potential (MMP) and activation of transcription factors NF-kappa B and AP-1 were determined. We observed a dose and time-dependent decline in cell viability upon incubation of ARPE-19 cells with CDA. The CDA treatment also led to elevation in ROS levels in a dose-dependent manner. Upon CDA treatment a significant number of apoptotic cells were observed. Also early apoptotic changes in ARPE-19 cells induced by CDA were associated with change in MMP. Increased nuclear chromatin condensation and fragmentation were also observed in cells treated with CDA. The cytotoxicity of CDA in ARPE-19 cells was significantly ameliorated by the antioxidant, NAC. Furthermore, CDA induced the activation of NF-kappa B and AP-1 which was significantly inhibited by NAC. Thus our results demonstrate that CDA could increase the oxidative stress in ARPE-19 cells by elevating ROS levels that would cause imbalance in cellular redox status, which could lead to cell death. This would suggest that high carotenoid supplementation for treatment of AMD should be used cautiously. (C) 2007 Elsevier Ltd. All rights reserved.
C1 [Kalariya, Nilesh M.; van Kuijk, Frederik J. G. M.] Univ Texas Galveston, Med Branch, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
   [Ramana, Kota V.; Srivastava, Satish K.] Univ Texas Galveston, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
C3 University of Texas System; University of Texas Medical Branch
   Galveston; University of Texas System; University of Texas Medical
   Branch Galveston
RP van Kuijk, FJGM (通讯作者)，Univ Texas Galveston, Med Branch, Dept Ophthalmol & Visual Sci, Room 2-100,700 Univ Blvd, Galveston, TX 77555 USA.
EM fjvankui@utmb.edu
RI Ramana, Kota/C-5460-2012
OI Ramana, Kota/0000-0001-6502-7800
FU Intramural NIH HHS [Z01 DK036118] Funding Source: Medline; NIDDK NIH HHS
   [R01 DK036118, R37 DK036118, R37 DK036118-20] Funding Source: Medline;
   NIGMS NIH HHS [GM71036, R01 GM071036, R01 GM071036-05] Funding Source:
   Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [Z01DK036118, R37DK036118, R01DK036118] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071036]
   Funding Source: NIH RePORTER
CR Alija AJ, 2006, CARCINOGENESIS, V27, P1128, DOI 10.1093/carcin/bgi342
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2005, ANAL BIOCHEM, V345, P296, DOI 10.1016/j.ab.2005.07.006
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   BOK D, 1993, J CELL SCI, P189
   Chichili GR, 2006, BRIT J NUTR, V96, P643, DOI 10.1079/BJN20061843
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   HANDELMAN GJ, 1991, FREE RADICAL BIO MED, V10, P427, DOI 10.1016/0891-5849(91)90051-4
   HARRISON JE, 1976, J BIOL CHEM, V251, P1371
   Ho CC, 2007, AM J CLIN NUTR, V85, P770, DOI 10.1093/ajcn/85.3.770
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hurst JS, 2005, EXP EYE RES, V81, P239, DOI 10.1016/j.exer.2005.04.002
   Hurst JS, 2004, BIOFACTORS, V20, P23, DOI 10.1002/biof.5520200103
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5476, DOI 10.1167/iovs.06-0194
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Krasowska A, 2004, BRAIN RES, V997, P176, DOI 10.1016/j.brainres.2003.09.080
   Lee CS, 2002, PHARMACOL TOXICOL, V91, P140, DOI 10.1034/j.1600-0773.2002.910309.x
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   Leung IYF, 2005, EXP EYE RES, V81, P513, DOI 10.1016/j.exer.2005.03.009
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu C, 2004, J NUTR, V134, P426, DOI 10.1093/jn/134.2.426
   Muriach M, 2006, FREE RADICAL BIO MED, V41, P979, DOI 10.1016/j.freeradbiomed.2006.06.023
   Nagao A, 2004, J NUTR, V134, p237S, DOI 10.1093/jn/134.1.237S
   Nara E, 2001, NUTR CANCER, V39, P273, DOI 10.1207/S15327914nc392_18
   OTTONELLO L, 1994, EUR J CLIN INVEST, V24, P42, DOI 10.1111/j.1365-2362.1994.tb02058.x
   Palozza P, 2003, J NUTR, V133, P381, DOI 10.1093/jn/133.2.381
   Palozza P, 2002, INT J CANCER, V97, P593, DOI 10.1002/ijc.10094
   Palozza P, 2003, MOL ASPECTS MED, V24, P353, DOI 10.1016/S0098-2997(03)00031-1
   Prasain JK, 2005, J MASS SPECTROM, V40, P916, DOI 10.1002/jms.868
   Ramana KV, 2004, FASEB J, V18, P1209, DOI 10.1096/fj.04-1650com
   Ramana KV, 2002, J BIOL CHEM, V277, P32063, DOI 10.1074/jbc.M202126200
   Salgo MG, 1999, FREE RADICAL BIO MED, V26, P162, DOI 10.1016/S0891-5849(98)00172-5
   Siems W, 2002, FASEB J, V16, P1289, DOI 10.1096/fj.01-0765fje
   Sommerburg O, 2003, FREE RADICAL BIO MED, V35, P1480, DOI 10.1016/j.freeradbiomed.2003.08.020
   Srivastava SK, 2005, ENDOCR REV, V26, P380, DOI 10.1210/er.2004-0028
   Takeyama N, 2002, EXP CELL RES, V274, P16, DOI 10.1006/excr.2001.5447
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6
   van Kuijk F J, 1985, J Free Radic Biol Med, V1, P215, DOI 10.1016/0748-5514(85)90121-7
   Vissers MCM, 2001, J BIOL CHEM, V276, P46835, DOI 10.1074/jbc.M107664200
   VU HT, 2006, VIS SCI, V47, P3783
   Vu HTV, 2006, BRIT J OPHTHALMOL, V90, P389, DOI 10.1136/bjo.2005.078055
   Wang L., 2007, J BURNS WOUNDS, V6, P65
   Whiteman M, 2005, FREE RADICAL BIO MED, V38, P1571, DOI 10.1016/j.freeradbiomed.2005.02.030
   Winkler BS, 1999, MOL VIS, V5
   Yeh SL, 2006, CHEM-BIOL INTERACT, V163, P199, DOI 10.1016/j.cbi.2006.08.002
   ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367
   Zhang W, 2001, FREE RADICAL BIO MED, V30, P699, DOI 10.1016/S0891-5849(01)00465-8
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 57
TC 64
Z9 68
U1 0
U2 15
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2008
VL 86
IS 1
BP 70
EP 80
DI 10.1016/j.exer.2007.09.010
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 249ED
UT WOS:000252209100009
PM 17977529
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Clarke, FR
   Clarke, JM
   McCaig, TN
   Knox, RE
   DePauw, RM
AF Clarke, F. R.
   Clarke, J. M.
   McCaig, T. N.
   Knox, R. E.
   DePauw, R. M.
TI Inheritance of yellow pigment concentration in seven durum wheat crosses
SO CANADIAN JOURNAL OF PLANT SCIENCE
LA English
DT Article
DE durum wheat (Triticum turgidum L. var. durum); pigment concentration;
   inheritance; environment
ID LIPOXYGENASE ACTIVITY; QUALITY; IDENTIFICATION; CHARACTERS; TESTS; COLOR
AB Yellow pigment concentration of the endosperm due to the presence of xanthophyll and other related compounds is an important processing quality characteristic in durum wheat (Triticum turgidum L. var. durum). There is also interest in plant pigments for health reasons because lutein, a major component of durum grain pigment, may. play a role in prevention of age-related macular degeneration. Selection for pigment concentration of durum wheat is thus an important breeding objective. Clarification of environmental effects and the mode of inheritance would aid planning of crosses and selection strategies to improve pigment concentration. This study evaluated seven durum wheat crosses of high by low pigment concentration parents in five field trials grown at two or more locations for 2 or more years in western Canada. Pigment concentration varied with environment. A portion of the variability could be ascribed to environmental effects on kernel weight, which tended to be negatively correlated with pigment concentration in some crosses and years (r = 0.08 to -0.49), but was not consistent. Inheritance of pigment concentration was multigenic as evidenced by bi-directional transgressive segregation and estimates of the number of effective factors controlling the trait. The number of effective factors varied with cross and environment, ranging from 3 to 27. Heritability of pigment concentration was high when measured in replicated, multi-location, multi-year trials, and ranged from 0.88 to 0.95, but lower (0.34) in an unreplicated segregating cross. The complex inheritance of pigment concentration means that other genetic tools, such as DNA markers, will be required to improve choice of parents for crossing and selection strategies in breeding programs.
C1 Agr & Agri Food Canada, Semiarid Prairie Agr Res Ctr, Swift Current, SK S9H 3X2, Canada.
C3 Agriculture & Agri Food Canada
RP Clarke, FR (通讯作者)，Agr & Agri Food Canada, Semiarid Prairie Agr Res Ctr, Box 1030,Swift Current, Swift Current, SK S9H 3X2, Canada.
EM clarkef@agr.gc.ca
OI Knox, Ron/0000-0002-2030-3899
CR Alvarez JB, 1999, PLANT BREEDING, V118, P187, DOI 10.1046/j.1439-0523.1999.118002187.x
   *AM ASS CER CHEM, 1983, 1450 AM ASS CER CHEM
   AZZALINI A, 1984, J ROY STAT SOC B MET, V46, P335
   Baker R.J., 1986, SELECTION INDICES PL, DOI [10.1201/9780429280498, DOI 10.1201/9780429280498]
   BAKER RJ, 1988, CAN J PLANT SCI, V68, P405, DOI 10.4141/cjps88-051
   BAKER RJ, 1988, CAN J PLANT SCI, V68, P1258
   BAKER RJ, 1983, WHEAT PROT MAN WORKS, P1
   Borrelli GM, 1999, CEREAL CHEM, V76, P335, DOI 10.1094/CCHEM.1999.76.3.335
   BRAATEN M. O., 1962, CROP SCI, V2, P277, DOI 10.2135/cropsci1962.0011183X000200040003x
   CHOO TM, 1982, CAN J GENET CYTOL, V24, P337, DOI 10.1139/g82-035
   CLARK J. ALLEN, 1928, JOUR AMER SOC AGRON, V20, P1297
   Clarke FR, 1998, CROP SCI, V38, P62, DOI 10.2135/cropsci1998.0011183X003800010011x
   CORNELIUS PL, 1992, THEOR APPL GENET, V84, P161, DOI 10.1007/BF00223996
   DEXTER JE, 2001, C I NATL RECHERCHE A, V99, P139
   Elouafi I, 2001, HEREDITAS, V135, P255, DOI 10.1111/j.1601-5223.2001.t01-1-00255.x
   Falconer D. S., 1997, INTRO QUANTITATIVE G
   Graham Robin D., 2000, Food and Nutrition Bulletin, V21, P404
   Guler M, 2003, CAN J PLANT SCI, V83, P327
   Hessler TG, 2002, CROP SCI, V42, P1695, DOI 10.2135/cropsci2002.1695
   HURD EA, 1972, CAN J PLANT SCI, V52, P687, DOI 10.4141/cjps72-112
   IRVINE GN, 1950, CEREAL CHEM, V27, P205
   JOHNSTON RA, 1983, CROP SCI, V23, P607, DOI 10.2135/cropsci1983.0011183X002300040001x
   KNAPP SJ, 1985, CROP SCI, V25, P192, DOI 10.2135/cropsci1985.0011183X002500010046x
   Knox RE, 2000, PLANT BREEDING, V119, P289, DOI 10.1046/j.1439-0523.2000.00498.x
   LEBSOCK KL, 1965, CROP SCI, V5, P605, DOI DOI 10.2135/CROPSCI1965.0011183X000500060048X
   LEE J, 1976, THEOR APPL GENET, V47, P243, DOI 10.1007/BF00284394
   LEPAGE M, 1968, CEREAL CHEM, V45, P600
   Littell R.C., 1996, SASR SYSTEM MIXED MO
   Lynch Michael, 1998
   MANGELS CE, 1932, CEREAL CHEM, V9, P485
   MARKLEY M. C., 1937, Cereal Chemistry, V14, P400
   MATSUO RR, 1980, CAN J PLANT SCI, V60, P49, DOI 10.4141/cjps80-007
   Matuz J, 1996, CEREAL RES COMMUN, V24, P203
   MCCAIG TN, 1992, CEREAL CHEM, V69, P671
   MCLEOD JG, 1991, CROP SCI, V31, P1717, DOI 10.2135/cropsci1991.0011183X003100060095x
   Miller NJ, 1996, FEBS LETT, V384, P240, DOI 10.1016/0014-5793(96)00323-7
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   PORTER JW, 1984, ISOPENTENOIDS PLANTS, P161
   Rawlings O., 1998, APPL REGRESSION ANAL, P372, DOI [DOI 10.1007/B98890, 10.1007/b98890]
   Sacks EJ, 2001, J AM SOC HORTIC SCI, V126, P221, DOI 10.21273/JASHS.126.2.221
   SNAPE JW, 1984, THEOR APPL GENET, V67, P143, DOI 10.1007/BF00317020
   Steel R.G., 1997, PRINCIPLES PROCEDURE
   TOWNLEYSMITH TF, 1987, CAN J PLANT SCI, V67, P225, DOI 10.4141/cjps87-026
   van den Berg H, 2000, J SCI FOOD AGR, V80, P880, DOI 10.1002/(SICI)1097-0010(20000515)80:7&lt;880::AID-JSFA646&gt;3.0.CO;2-1
   WHITESIDE A. G. O., 1934, CEREAL CHEM, V11, P615
   WONG LSL, 1986, CROP SCI, V26, P1171, DOI 10.2135/cropsci1986.0011183X002600060020x
   Worzella WW, 1942, J AGRIC RES, V65, P0501
   Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303
NR 48
TC 50
Z9 53
U1 0
U2 6
PU CANADIAN SCIENCE PUBLISHING
PI OTTAWA
PA 65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA
SN 0008-4220
EI 1918-1833
J9 CAN J PLANT SCI
JI Can. J. Plant Sci.
PD JAN
PY 2006
VL 86
IS 1
BP 133
EP 141
DI 10.4141/P05-083
PG 9
WC Agronomy; Plant Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Plant Sciences
GA 077SU
UT WOS:000240051300012
DA 2022-11-30
ER

PT J
AU Costa, RA
   Calucci, D
   Paccola, L
   Jorge, R
   Cardillo, JA
   Castro, JC
   Scott, IU
AF Costa, RA
   Calucci, D
   Paccola, L
   Jorge, R
   Cardillo, JA
   Castro, JC
   Scott, IU
TI Occult chorioretinal anastomosis in AgeRelated macular degeneration: A
   prospective study by optical coherence tomography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; CHOROIDAL NEOVASCULARIZATION;
   CLASSIFICATION; DETACHMENTS; DRUSEN
AB PURPOSE: To investigate macular optical coherence tomography (OCT) features in patients with chorioretinal anastomosis (CRA) and drusen, as well as their correlation with the Gass occult,CRA hypothesis.
   DESIGN: Prospective observational case series.
   METHODS: SETTING: Tertiary ophthalmic referral center. STUDY POPULATION: All patients with biomicroscopic evidence of CRA and drusen consecutively evaluated between February 2003 and March 2004. OBSERVATION PROCEDURES: Third,generation OCT evaluation and stereoscopic angiographic studies. MAIN OUTCOME MEASURES: Macular morphologic features at baseline and at 12 weeks.
   RESULTS: Twenty eyes with CRA and drusen were identified in 11 patients, seven women (63.6%) and four men (36.4%) ranging in age from 69 to 82 years (median, 79 years). Focal elevation of the retinal pigment epithelium was seen in eyes with stage 1 (pre-clinical) CRA. Small hyperreflective signals at the level of the elevated retinal pigment epithelium were seen in stage 2 CRA. In stage 3 CRA, a hyperreflective "mound" at the level of the elevated retinal pigment epithelium was seen in association with a thickened retina. In stage 4 CRA sub-retinal pigment epithelium fluid accumulation was present, and complete disorganization of the macular region was observed in stage 5 CRA. Macular changes were observed in eight eyes (40%) at follow-up, with all but one CRA lesion progressing one stage.
   CONCLUSION: Morphologic features and changes demonstrated by OCT suggest that fibrovascular detachment of the retinal pigment epithelium followed by development of occult CRA are the initial events occurring in eyes with CRA in age,related macular degeneration. Our findings may support the evolutionary CRA staging system proposed by Gass.
C1 Hosp Olhos Araraquara, UDAT, Retina Diagnost & Treatment Div, BR-14801310 Araraquara, SP, Brazil.
   Univ Sao Paulo, Ribeirao Preto Sch Med, Retina & Citreous Sect, BR-14049 Ribeirao Preto, SP, Brazil.
   Univ Sao Paulo, Inst Fis Sao Carlos, Sao Carlos, SP, Brazil.
   Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL USA.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Bascom Palmer Eye
   Institute; University of Miami
RP Costa, RA (通讯作者)，Hosp Olhos Araraquara, UDAT, Retina Diagnost & Treatment Div, Rua Padre Duarte 989,Apto 172, BR-14801310 Araraquara, SP, Brazil.
EM roger.retina@globo.com
RI Neto, Jarbas C Castro/G-2915-2014; Jorge, Rodrigo/H-3930-2012; Costa,
   Rogerio A/E-6930-2013; Jorge, Rodrigo/AAK-7615-2021
OI Jorge, Rodrigo/0000-0002-2652-0720; Costa, Rogerio
   A/0000-0002-0800-2233; Jorge, Rodrigo/0000-0002-2652-0720; Cardillo,
   Jose Augusto/0000-0002-5791-3201; Scott, Ingrid/0000-0002-3908-7153
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brancato R, 2002, EUR J OPHTHALMOL, V12, P467, DOI 10.5301/EJO.2008.2283
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   GREEN WR, 1971, ARCH OPHTHALMOL-CHIC, V86, P487, DOI 10.1001/archopht.1971.01000010489001
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   OELLER JN, 2004, ATLAS RARE OPHTHAL C
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 12
TC 17
Z9 18
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2005
VL 140
IS 1
BP 107
EP 116
DI 10.1016/j.ajo.2005.02.042
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 949IN
UT WOS:000230778700016
PM 15963937
DA 2022-11-30
ER

PT J
AU Melecchi, A
   Amato, R
   Lapi, D
   Dal Monte, M
   Rusciano, D
   Bagnoli, P
   Cammalleri, M
AF Melecchi, Alberto
   Amato, Rosario
   Lapi, Dominga
   Dal Monte, Massimo
   Rusciano, Dario
   Bagnoli, Paola
   Cammalleri, Maurizio
TI Increased efficacy of dietary supplement containing wax ester-rich
   marine oil and xanthophylls in a mouse model of dry macular degeneration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE calanus oil; omega-3 fatty acids; carotenoids; oxidative stress;
   inflammation; gliosis; retinal thickness
ID OXIDATIVE STRESS; CALANUS-FINMARCHICUS; AGE; INFLAMMATION; CELLS;
   OMEGA-3-FATTY-ACIDS; GLIA; EPA; DHA
AB Age-related macular degeneration (AMD) is nowadays considered among the retinal diseases whose clinical management lacks established treatment approaches, mainly for its atrophic (dry) form. In this respect, the use of dietary patterns enriched in omega-3 and antioxidant xanthophylls has emerged as a promising approach to counteract dry AMD progression although the prophylactic potential of omega-3 of fish origin has been discussed. Whether enriched availability of omega-3 and xanthophylls may increase the effectiveness of diet supplementation in preventing dry AMD remains to be fully established. The present study aims at comparing the efficacy of an existing orally administered formulation based on lutein and fish oil, as a source of omega-3, with a novel formulation providing the combination of lutein and astaxanthin with Calanus oil (COil), which contains omega-3 together with their precursors policosanols. Using a mouse model of dry AMD based on subretinal injection of polyethylene glycol (PEG)-400, we assessed the comparative efficacy of both formulations on PEG-induced major hallmarks including oxidative stress, inflammation, glial reactivity and outer retinal thickness. Dietary supplementation with both mixtures has been found to exert a significant antioxidant and anti-inflammatory activity as reflected by the overall amelioration of the PEG-induced pathological hallmarks. Noteworthy, the formulation based on COil appeared to be more protective than the one based on fish oil, presumably because of the higher bioavailability of omega-3 in COil. These results support the use of dietary supplements combining omega-3 and xanthophylls in the prevention and treatment of AMD and suggest that the source of omega-3 might contribute to treatment efficacy.
C1 [Melecchi, Alberto; Amato, Rosario; Lapi, Dominga; Dal Monte, Massimo; Bagnoli, Paola; Cammalleri, Maurizio] Univ Pisa, Dept Biol, Pisa, Italy.
   [Dal Monte, Massimo; Cammalleri, Maurizio] Univ Pisa, Interdept Res Ctr Nutrafood Nutraceut & Food Hlth, Pisa, Italy.
   [Rusciano, Dario] Fidia Farmaceut SpA, Res Ctr, Catania, Italy.
C3 University of Pisa; University of Pisa
RP Amato, R; Cammalleri, M (通讯作者)，Univ Pisa, Dept Biol, Pisa, Italy.; Cammalleri, M (通讯作者)，Univ Pisa, Interdept Res Ctr Nutrafood Nutraceut & Food Hlth, Pisa, Italy.
EM maurizio.cammalleri@unipi.it; rosario.amato@unipi.it
FU Fidia Farmaceutici SpA (Abano Terme, PD, Italy)
FX This research was funded by grants from Fidia Farmaceutici SpA (Abano
   Terme, PD, Italy) to MC.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   Burhop M, 2022, NUTRIENTS, V14, DOI 10.3390/nu14020396
   Cammalleri M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101079
   Campochiaro PA, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.14.26
   Cao YQ, 2022, CURR MED CHEM, V29, P6141, DOI 10.2174/0929867329666220511142817
   Chakravarthy U, 2022, EYE, V36, P2232, DOI 10.1038/s41433-022-02153-9
   Chew EY, 2022, JAMA OPHTHALMOL, V140, P692, DOI 10.1001/jamaophthalmol.2022.1640
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Cook CM, 2016, LIPIDS, V51, P1137, DOI 10.1007/s11745-016-4189-y
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de Almeida Torres R.J., 2022, FRONT DRUG CHEM CLIN, V5, P1, DOI [10.15761/FDCCR.1000157, DOI 10.15761/FDCCR.1000157]
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   Eastlake K, 2016, GLIA, V64, P495, DOI 10.1002/glia.22942
   Elmasry K, 2019, BRIT J PHARMACOL, V176, P93, DOI 10.1111/bph.14507
   Gasmi A, 2020, APPL MICROBIOL BIOT, V104, P967, DOI 10.1007/s00253-019-10293-4
   Giannaccare G, 2020, MAR DRUGS, V18, DOI 10.3390/md18050239
   Jansen KM, 2019, AM J PHYSIOL-HEART C, V317, pH290, DOI 10.1152/ajpheart.00191.2019
   Jiang H, 2021, CLIN NUTR, V40, P5662, DOI 10.1016/j.clnu.2021.10.005
   Kang QZ, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101799
   Kaspar JW, 2010, J BIOL CHEM, V285, P21349, DOI 10.1074/jbc.M110.121863
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SY, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108391
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Lombardo M, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.887104
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Lyzogubov VV, 2014, EXP EYE RES, V127, P143, DOI 10.1016/j.exer.2014.07.021
   Lyzogubov VV, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.204701
   Naguib YMA, 2000, J AGR FOOD CHEM, V48, P1150, DOI 10.1021/jf991106k
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Pedersen AM, 2014, J AQUAT FOOD PROD T, V23, P633, DOI 10.1080/10498850.2012.741662
   Prokopiou E, 2017, BMJ OPEN OPHTHALMOL, V2, DOI [10.1136/bmjophth-2016-000056corr1, 10.1136/bmjophth-2016-000056]
   Rabin DM, 2013, AGING-US, V5, P51
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Rossino MG, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10081296
   Rudolf X.V., 2018, J CELL MOL PHARM, V1, P101
   Salma W, 2016, PROSTAG LEUKOTR ESS, V108, P13, DOI 10.1016/j.plefa.2016.03.006
   Sarkar A, 2022, DRUG DISCOV TODAY, V27, P2322, DOI [10.1016/j.drudis.2022.04.013, 10.1016/j.drudis.2022.04.013This]
   Schots PC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00961
   Schweighofer B, 2009, THROMB HAEMOSTASIS, V102, P544, DOI 10.1160/TH08-12-0830
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Souied EH, 2016, OPHTHALMIC RES, V55, P62, DOI 10.1159/000441359
   Stepan M, 2022, NUTRIENTS, V14, DOI 10.3390/nu14010149
   Swanson D, 2012, ADV NUTR, V3, P1, DOI 10.3945/an.111.000893
   Tan CS, 2022, CLIN OPHTHALMOL, V16, P917, DOI 10.2147/OPTH.S231913
   Telegina DV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1009, DOI 10.1134/S000629791809002X
   Turpaev KT, 2013, BIOCHEMISTRY-MOSCOW+, V78, P111, DOI 10.1134/S0006297913020016
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Wasserfurth P, 2021, BRIT J NUTR, V125, P432, DOI 10.1017/S0007114520002809
NR 55
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 13
PY 2022
VL 13
AR 1038730
DI 10.3389/fphar.2022.1038730
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 5U3ZE
UT WOS:000876488300001
PM 36313376
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sacconi, R
   Battista, M
   Borrelli, E
   Senni, C
   Tombolini, B
   Grosso, D
   Querques, L
   Bandello, F
   Querques, G
AF Sacconi, Riccardo
   Battista, Marco
   Borrelli, Enrico
   Senni, Carlotta
   Tombolini, Beatrice
   Grosso, Domenico
   Querques, Lea
   Bandello, Francesco
   Querques, Giuseppe
TI CHOROIDAL VASCULARITY INDEX IS ASSOCIATED WITH GEOGRAPHIC ATROPHY
   PROGRESSION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; CVI; geographic atrophy; macular
   atrophy
ID OPTICAL COHERENCE TOMOGRAPHY; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; EYE DISEASE; CHORIOCAPILLARIS; CLASSIFICATION;
   VASCULATURE; ENLARGEMENT; THICKNESS; RATES
AB Purpose: To investigate the correlation between choroidal vascularity index and the enlargement of geographic atrophy (GA) lesion secondary to age-related macular degeneration during the 2-year follow-up. Methods: In this longitudinal observational study, 26 eyes (26 patients, mean age 75.7 +/- 8.8 years) affected by GA were included. Choroidal vascularity index was calculated in the subfoveal 3000-mu m area. The main outcome measure included correlation analysis between baseline choroidal vascularity index and the rate of GA enlargement. Results: During the 2-year follow-up, the mean GA area increased from 6.99 +/- 5.28 mm(2) to 10.69 +/- 6.61 mm(2)(P < 0.001), accounting for a growth rate of 0.35 +/- 0.20 and 0.31 +/- 0.17 mm/year after the square root transformation in the first and second year of follow-up, respectively. Stromal choroidal area significantly decreased during the 2-year follow-up (P = 0.002). Interestingly, there was a significant correlation between the baseline choroidal vascularity index and the rate of GA enlargement (r=-0.432, P = 0.027) and between stromal choroidal area and the rate of GA enlargement (r = 0.422, P = 0.032). No other significant relationship was disclosed among choroidal parameters with the rate of GA enlargement. Conclusion: Choroidal vascularity index impairment is strictly related to the rate of GA enlargement during the 1-year and 2-year follow-up in patients affected by GA. For this reason, choroidal vascularity index could be considered a predictor of GA progression in the clinical setting, and it could be considered as a new potential biomarker in the efficacy evaluation of new GA interventions.
C1 [Sacconi, Riccardo; Battista, Marco; Borrelli, Enrico; Senni, Carlotta; Tombolini, Beatrice; Grosso, Domenico; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Sacconi, Riccardo; Battista, Marco; Borrelli, Enrico; Senni, Carlotta; Tombolini, Beatrice; Grosso, Domenico; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM querques.giuseppe@unisr.it
OI bandello, francesco/0000-0003-3238-9682; Sacconi,
   Riccardo/0000-0003-2891-2012; Querques, Giuseppe/0000-0002-3292-9581
CR Anger EM, 2004, EXP EYE RES, V78, P1117, DOI 10.1016/j.exer.2004.01.011
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Iovino C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020595
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Sacconi R, 2020, GRAEF ARCH CLIN EXP, V258, P2163, DOI 10.1007/s00417-020-04769-7
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P97, DOI 10.1136/bjophthalmol-2019-315800
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
   Zhou H, 2020, OPHTHALMOL RETINA, V4, P204, DOI 10.1016/j.oret.2019.09.012
NR 31
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2022
VL 42
IS 2
BP 381
EP 387
DI 10.1097/IAE.0000000000003305
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YJ6CJ
UT WOS:000744618600021
PM 34561405
DA 2022-11-30
ER

PT J
AU Borkenstein, AF
   Borkenstein, EM
AF Borkenstein, Andreas F.
   Borkenstein, Eva-Maria
TI A case report detailing use of a new intraocular lens with advanced
   technology, designed specifically for patients with center-involving
   macular disorders
SO MEDICINE
LA English
DT Article
DE AMD; EyeMax Mono; IOL; phacoemulsification; visual acuity
ID CATARACT-SURGERY; VISUAL-ACUITY; VISION
AB Rationale: Many studies have shown that cataract surgery can be performed safely and improve visual acuity, without increasing the risk of progression of existing age-related macular degeneration (AMD). Data are emerging for an intraocular lens (IOL) that utilizes an advanced optical design to optimize the image supplied to all areas of the macula and not just the foveal center, which may benefit patients with center-involving macular disorders.
   Patient concerns: An 83-year-old Caucasian female presented with poor contrast sensitivity and color perception with increasing glare over the preceding year.
   Diagnosis: She had a progressive cortical cataract and stable dry AMD in the left eye, and wet AMD in the right eye. In the left eye, preoperative best-corrected distance visual acuity (BCDVA) was 0.2 (decimal) and best-corrected near visual acuity (BCNVA) was 0.05 (decimal).
   Interventions: Standard small-incision phacoemulsification was performed in the left eye, with capsular bag implantation of EyeMax Mono (LEH Pharma, London, UK), a single-piece, soft, hydrophobic, acrylic IOL designed to optimize image quality across the macula, rather than a standard monofocal lens.
   Outcomes: At 6 months postoperation, visual acuity in the left eye had markedly improved, with a BCDVA of 0.5 (decimal) and a BCNVA of 0.2 (decimal).
   Conclusion: In this first case undertaken at our center (and the first in Austria), cataract extraction and EyeMax Mono implantation were performed safely, with good subjective and objective outcome measures consistent with the effects of image optimization across the macula. Further studies of this IOL in patients with center-involving macular disorders, such as AMD, are warranted.
C1 [Borkenstein, Andreas F.; Borkenstein, Eva-Maria] Privatklin Kreuzschwestern Graz, Kreuzgasse 35, A-8010 Graz, Austria.
RP Borkenstein, AF (通讯作者)，Privatklin Kreuzschwestern Graz, Kreuzgasse 35, A-8010 Graz, Austria.
EM crustalith@gmx.at
CR Casparis H, 2017, COCHRANE DB SYST REV, V2
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Dunbar HMP, 2018, OPHTHALMOL THER, V7, P33, DOI 10.1007/s40123-018-0129-7
   Ehmann DS, 2017, CURR OPIN OPHTHALMOL, V28, P58, DOI 10.1097/ICU.0000000000000331
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Grzybowski A, 2017, GRAEF ARCH CLIN EXP, V255, P1687, DOI 10.1007/s00417-017-3740-8
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Kessel L, 2016, ACTA OPHTHALMOL, V94, P755, DOI 10.1111/aos.13120
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Qureshi MA, 2018, EUR J OPHTHALMOL, V28, P198, DOI 10.5301/ejo.5001052
   Robbie SJ, 2018, J REFRACT SURG, V34, P718, DOI 10.3928/1081597X-20180831-01
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
NR 14
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUL
PY 2019
VL 98
IS 30
AR e16583
DI 10.1097/MD.0000000000016583
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA IQ4UV
UT WOS:000480747400070
PM 31348295
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Delgado, ABG
   de la Cerda, B
   Amador, JA
   Sanchez, MLV
   Fernandez-Munoz, B
   Lopez, IR
   de la Rua, ER
   Lloret, AD
   Calado, SM
   Pernaute, RS
   Bhattacharya, SS
   Corrales, FJD
AF Garcia Delgado, Ana B.
   de la Cerda, Berta
   Alba Amador, Julia
   Valdes Sanchez, Maria Lourdes
   Fernandez-Munoz, Beatriz
   Relimpio Lopez, Isabel
   Rodriguez de la Rua, Enrique
   Diez Lloret, Andrea
   Calado, Sofia M.
   Sanchez Pernaute, Rosario
   Bhattacharya, Shom S.
   Diaz Corrales, Francisco J.
TI Subretinal Transplant of Induced Pluripotent Stem Cell-Derived Retinal
   Pigment Epithelium on Nanostructured Fibrin-Agarose
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE macular degeneration; retinal pigment epithelium; induced pluripotent
   stem cells; subretinal implant; fibrin-agarose hydrogel
ID MACULAR DEGENERATION; REGENERATION; SUBSTITUTE; THERAPIES
AB Damage to the retinal pigment epithelium (RPE) in age-related macular degeneration and other diseases results in photoreceptor cell death and blindness. Replacement of RPE is therefore being explored as a therapy for several retinal diseases. To move toward a future personalized autologous transplant approach, we have prepared a biocompatible implant using RPE derived from induced pluripotent stem cells (iPSCs) reprogrammed from a healthy donor's monocytes. The correct positioning of the polarized RPE is essential to fulfill its role and protect photoreceptors from degeneration. Hence, we have used a biocompatible hydrogel matrix of fibrin and agarose that allows the surgical placement of an RPE sheet in the subretinal space, keeping its functional orientation. Our aim was to demonstrate safety and viability of the transplant in preclinical models. Pigs were used to test the feasibility of a regular vitreoretinal surgery. Our results show that this implant is suitable for subretinal transplantation allowing human RPE cells to survive and maintain their phenotype and orientation without any local or systemic adverse events. The ability to transplant the iPSC-derived RPE sheet in its natural orientation will surely increase the chance to obtain a therapeutic effect in future translational studies.
   Impact Statement In the promising field of cellular therapy for retinal degenerative diseases, a new biomaterial is proposed as a scaffold to grow and surgically introduce a monolayer of retinal pigment epithelial cells into the subretinal space, keeping the orientation of the cells for a proper functional integration of the transplant. The use of induced pluripotent stem cells as the starting material for retinal pigment epithelial cells is intended to advance toward a personalized medicine approach.
C1 [Garcia Delgado, Ana B.; de la Cerda, Berta; Valdes Sanchez, Maria Lourdes; Diez Lloret, Andrea; Calado, Sofia M.; Bhattacharya, Shom S.; Diaz Corrales, Francisco J.] Andalusian Ctr Mol Biol & Regenerat Med CABIMER, Regenerat & Cell Therapy Dept, Seville 41092, Spain.
   [Alba Amador, Julia; Fernandez-Munoz, Beatriz; Sanchez Pernaute, Rosario] Iniciat Andaluza Terapias Avanzadas, Unidad Prod & Reprogramac Celular, Seville, Spain.
   [Relimpio Lopez, Isabel; Rodriguez de la Rua, Enrique] Univ Hosp Virgen Macarena, Seville, Spain.
   [Relimpio Lopez, Isabel; Rodriguez de la Rua, Enrique] Carlos III Inst Hlth Spain, RETICS Oftared, Minist Hlth, RD16-0008-0010, Seville, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); Universidad
   Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de
   Biologia Molecular y Medicina Regenerativa (CABIMER); Hospital
   Universitario Virgen Macarena
RP de la Cerda, B; Corrales, FJD (通讯作者)，Andalusian Ctr Mol Biol & Regenerat Med CABIMER, Regenerat & Cell Therapy Dept, Seville 41092, Spain.
EM berta.delacerda@cabimer.es; francisco.diaz@cabimer.es
RI Relimpio-López, Isabel/ABG-5718-2021; Calado, Sofia M./K-2202-2016;
   Sanchez-Pernaute, Rosario/AAZ-9566-2021; Sanchez-Pernaute,
   Rosario/ABD-8661-2021; Diaz-Corrales, Francisco J./L-7559-2014
OI Relimpio-López, Isabel/0000-0002-2872-2940; Calado, Sofia
   M./0000-0001-5509-4145; Sanchez-Pernaute, Rosario/0000-0003-1144-9025;
   Diaz-Corrales, Francisco J./0000-0002-5752-0205; Garcia Delgado, Ana
   Belen/0000-0002-9818-9336; Fernandez-Munoz, Beatriz/0000-0003-4238-9598;
   Rodriguez de la Rua, Enrique/0000-0001-7630-4252
FU Andalusian Government; patients association Macula Retina; Consejeria de
   Salud, Junta de Andalucia; ISCIII (Miguel Servet-I) - European Regional
   Development Fund (ERDF) [CP/00071]
FX Authors are grateful to the patients association Macula Retina for the
   constant support along this project and to the Andalusian Government for
   funding. We thank IAVANTE for surgical help and excellent animal care
   and Prof. Miguel Alaminos, Prof. Antonio Campos, Fernando Campos, and
   Blanca Arribas for technical advice and Baush+Lomb for lending the
   surgical equipment for pigs. Funding: Study supported by Consejeria de
   Salud, Junta de Andalucia and by ISCIII (Miguel Servet-I, 2015)
   cofinanced by European Regional Development Fund (ERDF) (CP/00071).
CR Alaminos M, 2006, INVEST OPHTH VIS SCI, V47, P3311, DOI 10.1167/iovs.05-1647
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Calado SM, 2018, STEM CELL RES, V33, P251, DOI 10.1016/j.scr.2018.11.002
   Campos-Cuerva R, 2019, J TISSUE ENG REGEN M, V13, P664, DOI 10.1002/term.2831
   Carriel V, 2017, J TISSUE ENG REGEN M, V11, P553, DOI 10.1002/term.1949
   Carriel V, 2017, J TISSUE ENG REGEN M, V11, P1412, DOI 10.1002/term.2039
   Carriel V, 2012, CELLS TISSUES ORGANS, V196, P1, DOI 10.1159/000330682
   Chato-Astrain J, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00501
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Garzon I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051961
   Gonzalez-Andrades M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016487
   Hong SG, 2014, CELL REP, V7, P1298, DOI 10.1016/j.celrep.2014.04.019
   Jha BS, 2015, CURR STEM CELL REP, V1, P79, DOI 10.1007/s40778-015-0014-4
   Liu Y, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0053-y
   Lukovic D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12910
   Luo MY, 2018, INT J OPHTHALMOL-CHI, V11, P150, DOI 10.18240/ijo.2018.01.23
   Mandai Michiko, 2017, N Engl J Med, V377, P792, DOI 10.1056/NEJMc1706274
   Martin-Piedra MA, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700078
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Rodriguez IA, 2012, J TISSUE ENG REGEN M, V6, P636, DOI 10.1002/term.466
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Scionti G, 2014, J BIOMED MATER RES A, V102, P2573, DOI 10.1002/jbm.a.34929
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Valdes-Sanchez L, 2013, HUM MOL GENET, V22, P1507, DOI 10.1093/hmg/dds563
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 31
TC 9
Z9 9
U1 4
U2 19
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
EI 1937-335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD MAY
PY 2019
VL 25
IS 9-10
BP 799
EP 808
DI 10.1089/ten.tea.2019.0007
PG 10
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA HY8ZW
UT WOS:000468430000012
PM 30963803
DA 2022-11-30
ER

PT J
AU Gao, XR
   Huang, H
   Kim, H
AF Gao, X. Raymond
   Huang, Hua
   Kim, Heejin
TI Genome-wide association analyses identify 139 loci associated with
   macular thickness in the UK Biobank cohort
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; GENETIC INFLUENCES; HEALTHY EYES;
   DEGENERATION; PLEIOTROPY; SCHIZOPHRENIA; MUTATIONS; PROLINE; CALIBER
AB The macula, located near the center of the retina in the human eye, is responsible for providing critical functions, such as central, sharp vision. Structural changes in the macula are associated with many ocular diseases, including age-related macular degeneration (AMD) and glaucoma. Although macular thickness is a highly heritable trait, there are no prior reported genome-wide association studies (GWASs) of it. Here we describe the first GWAS of macular thickness, which was measured by spectral-domain optical coherence tomography using 68 423 participants from the UK Biobank cohort. We identified 139 genetic loci associated with macular thickness at genome-wide significance (P < 5 x 10(-8)). The most significant loci were LINC00461 (P = 5.1 x 10(-120)) TSPAN10 (P = 1.2 x 10(-118)), RDH5 (P = 9.2 x 10(-105)) and SLC6A20 (P = 1.4 x 10(-71)). Results from gene expression demonstrated that these genes are highly expressed in the retina. Other hits included many previously reported AMD genes, such as NPLOC4 (P = 1.7 x 10(-103)), RAD51B (P = 9.1 x 10(-14)) and SLC16A8 (P = 1.7 x 10(-8)), further providing functional significance of the identified loci. Through cross-phenotype analysis, these genetic loci also exhibited pleiotropic effects with myopia, neurodegenerative diseases (e.g. Parkinson's disease, schizophrenia and Alzheimer's disease), cancer (e.g. breast, ovarian and lung cancers) and metabolic traits (e.g. body mass index, waist circumference and type 2 diabetes). Our findings provide the first insight into the genetic architecture of macular thickness and may further elucidate the pathogenesis of related ocular diseases, such as AMD.
C1 [Gao, X. Raymond; Huang, Hua; Kim, Heejin] Ohio State Univ, Div Human Genet, Dept Ophthalmol & Visual Sci, Columbus, OH 43212 USA.
   [Gao, X. Raymond; Huang, Hua; Kim, Heejin] Ohio State Univ, Div Human Genet, Dept Biomed Informat, Columbus, OH 43212 USA.
C3 University System of Ohio; Ohio State University; University System of
   Ohio; Ohio State University
RP Gao, XR (通讯作者)，Ohio State Univ, Div Human Genet, Dept Ophthalmol & Visual Sci, Columbus, OH 43212 USA.; Gao, XR (通讯作者)，Ohio State Univ, Div Human Genet, Dept Biomed Informat, Columbus, OH 43212 USA.
EM ray.x.gao@gmail.com
FU National Institutes of Health (NIH; Bethesda, MD, USA) [R01EY022651,
   R01EY027315, RF1AG060472, P30EY001792]; NATIONAL EYE INSTITUTE
   [R01EY022651, P30EY001792, R01EY027315] Funding Source: NIH RePORTER
FX This work was supported in part by the National Institutes of Health
   (NIH; Bethesda, MD, USA) [R01EY022651, R01EY027315, RF1AG060472 and
   P30EY001792 (departmental core grant)]. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the NIH.
CR Allen NE, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008601
   Broer S, 2008, J CLIN INVEST, V118, P3881, DOI 10.1172/JCI36625
   Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Chamberlain MD, 2006, INVEST OPHTH VIS SCI, V47, P336, DOI 10.1167/iovs.05-0599
   Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8
   Chao JR, 2017, J BIOL CHEM, V292, P12895, DOI 10.1074/jbc.M117.788422
   Charrin S, 2014, J CELL SCI, V127, P3641, DOI 10.1242/jcs.154906
   Chen XX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085716, 10.1371/journal.pone.0091809, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0087752, 10.1371/journal.pone.0091830]
   Chesmore K, 2018, HUM GENET, V137, P39, DOI 10.1007/s00439-017-1854-z
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   den Haan Jurre, 2017, Alzheimers Dement (Amst), V6, P162, DOI 10.1016/j.dadm.2016.12.014
   Fan Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11008
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gao XR, 2018, HUM MOL GENET, V27, P2205, DOI 10.1093/hmg/ddy111
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Greenfield DS, 2003, ARCH OPHTHALMOL-CHIC, V121, P41
   Gupta P, 2013, INVEST OPHTH VIS SCI, V54, P7968, DOI 10.1167/iovs.13-12436
   Hajee ME, 2009, ARCH OPHTHALMOL-CHIC, V127, P737, DOI 10.1001/archophthalmol.2009.106
   Ikram MK, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001184
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Kelty PJ, 2008, INVEST OPHTH VIS SCI, V49, P2668, DOI 10.1167/iovs.07-1000
   Khawaja AP, 2018, NAT GENET, V50, P778, DOI 10.1038/s41588-018-0126-8
   Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z
   Kim JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110292
   Kiser PD, 2012, BBA-MOL CELL BIOL L, V1821, P137, DOI 10.1016/j.bbalip.2011.03.005
   Lee WW, 2013, INVEST OPHTH VIS SCI, V54, P7785, DOI 10.1167/iovs.13-12534
   Loh PR, 2015, NAT GENET, V47, P1385, DOI 10.1038/ng.3431
   Loh PR, 2015, NAT GENET, V47, P284, DOI 10.1038/ng.3190
   MacGregor S, 2018, NAT GENET, V50, P1067, DOI 10.1038/s41588-018-0176-y
   Manichaikul A, 2010, BIOINFORMATICS, V26, P2867, DOI 10.1093/bioinformatics/btq559
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Moore SW, 2006, PEDIATR SURG INT, V22, P305, DOI 10.1007/s00383-006-1655-2
   Moschos MM, 2016, CUTAN OCUL TOXICOL, V35, P13, DOI 10.3109/15569527.2014.1003267
   Mustafi D, 2013, HUM MOL GENET, V22, P2992, DOI 10.1093/hmg/ddt156
   Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P3925
   O'Connell J, 2016, NAT GENET, V48, P817, DOI 10.1038/ng.3583
   Patel PJ, 2016, OPHTHALMOLOGY, V123, P829, DOI 10.1016/j.ophtha.2015.11.009
   Pickrell JK, 2016, NAT GENET, V48, P709, DOI 10.1038/ng.3570
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Raffler J, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005487
   Rastegar-Mojarad M, 2015, NAT BIOTECHNOL, V33, DOI 10.1038/nbt.3183
   Robinson JR, 2018, CTS-CLIN TRANSL SCI, V11, P112, DOI 10.1111/cts.12522
   Scerri TS, 2017, NAT GENET, V49, P559, DOI 10.1038/ng.3799
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Shin SY, 2014, NAT GENET, V46, P543, DOI 10.1038/ng.2982
   Stearns FW, 2010, GENETICS, V186, P767, DOI 10.1534/genetics.110.122549
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779
   Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005
   Visscher PM, 2016, NAT GENET, V48, P707, DOI 10.1038/ng.3604
   Wang J, 2017, NUCLEIC ACIDS RES, V45, pW130, DOI 10.1093/nar/gkx356
   Wistow G, 2002, MOL VIS, V8, P205
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
NR 55
TC 37
Z9 37
U1 3
U2 23
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 1
PY 2019
VL 28
IS 7
BP 1162
EP 1172
DI 10.1093/hmg/ddy422
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA HR6FL
UT WOS:000463244700009
PM 30535121
OA Green Published
DA 2022-11-30
ER

PT J
AU Russakoff, DB
   Lamin, A
   Oakley, JD
   Dubis, AM
   Sivaprasad, S
AF Russakoff, Daniel B.
   Lamin, Ali
   Oakley, Jonathan D.
   Dubis, Adam M.
   Sivaprasad, Sobha
TI Deep Learning for Prediction of AMD Progression: A Pilot Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography; image
   analysis; deep learning; choroidal neovascularization
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; NEOVASCULARIZATION;
   ANGIOGRAPHY; DRUSEN
AB PURPOSE. To develop and assess a method for predicting the likelihood of converting from early/intermediate to advanced wet age-related macular degeneration (AMD) using optical coherence tomography (OCT) imaging and methods of deep learning.
   METHODS. Seventy-one eyes of 71 patients with confirmed early/intermediate AMD with contralateral wet AMD were imaged with OCT three times over 2 years (baseline, year 1, year 2). These eyes were divided into two groups: eyes that had not converted to wet AMD (n = 40) at year 2 and those that had (n = 31). Two deep convolutional neural networks (CNN) were evaluated using 5-fold cross validation on the OCT data at baseline to attempt to predict which eyes would convert to advanced AMD at year 2: (1) VGG16, a popular CNN for image recognition was fine-tuned, and (2) a novel, simplified CNN architecture was trained from scratch. Preprocessing was added in the form of a segmentation-based normalization to reduce variance in the data and improve performance.
   RESULTS. Our new architecture, AMDnet, with preprocessing, achieved an area under the receiver operating characteristic (ROC) curve (AUC) of 0.89 at the B-scan level and 0.91 for volumes. Results for VGG16, an established CNN architecture, with preprocessing were 0.82 for B-scans/0.87 for volumes versus 0.66 for B-scans/0.69 for volumes without preprocessing.
   CONCLUSIONS. A CNN with layer segmentation-based preprocessing shows strong predictive power for the progression of early/intermediate AMD to advanced AMD. Use of the preprocessing was shown to improve performance regardless of the network architecture.
C1 [Russakoff, Daniel B.; Oakley, Jonathan D.] Voxeleron LLC, 4695 Chabot Dr,Suite 200, Pleasanton, CA 94588 USA.
   [Lamin, Ali; Dubis, Adam M.; Sivaprasad, Sobha] NIHR Moorfields Biomed Res Ctr, London, England.
   [Lamin, Ali; Dubis, Adam M.; Sivaprasad, Sobha] UCL Inst Ophthalmol, London, England.
C3 University of London; University College London
RP Russakoff, DB (通讯作者)，Voxeleron LLC, 4695 Chabot Dr,Suite 200, Pleasanton, CA 94588 USA.
EM daniel@voxeleron.com
RI Sivaprasad, S./D-6876-2015; Dubis, Adam/AAB-1366-2021
OI Sivaprasad, S./0000-0001-8952-0659; 
FU NIHR Biomedical Research Centre at Moorfields Eye Hospital; UCL
   Institute of Ophthalmology
FX The authors thank Utkarsh Sharma for his expert input on the physics of
   OCTA and OCT in general. The authors thank the NIHR Biomedical Research
   Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology for
   supporting some of the investigators (AMD, SS, AL) in this study. The
   authors also thank the reviewers for their insightful commentary.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Boser B. E., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P144, DOI 10.1145/130385.130401
   Chung CY, 2018, INT OPHTHALMOL, V38, P1119, DOI 10.1007/s10792-017-0570-y
   Cruz-Herranz A, 2016, NEUROLOGY, V86, P2303, DOI 10.1212/WNL.0000000000002774
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Gossage KW, 2003, J BIOMED OPT, V8, P570, DOI 10.1117/1.1577575
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Hinton G. E., ARXIV201212070580
   Hirano T, 2018, BRIT J OPHTHALMOL, V102, P1199, DOI 10.1136/bjophthalmol-2017-311358
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Mukkamala SK, 2012, ARCH OPHTHALMOL-CHIC, V130, P1547, DOI 10.1001/archophthalmol.2012.2491
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   Rattani A, 2017, 2017 IEEE INTERNATIONAL JOINT CONFERENCE ON BIOMETRICS (IJCB), P762, DOI 10.1109/BTAS.2017.8272767
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Simonyan K, ARXIV201414091556
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zeiler M.D., ARXIV201313112901
NR 27
TC 42
Z9 42
U1 1
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2019
VL 60
IS 2
BP 712
EP 722
DI 10.1167/iovs.18-25325
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HN0LZ
UT WOS:000459881100025
PM 30786275
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU von der Burchard, C
   Treumer, F
   Ehlken, C
   Koinzer, S
   Purtskhvanidze, K
   Tode, J
   Roider, J
AF von der Burchard, Claus
   Treumer, Felix
   Ehlken, Christoph
   Koinzer, Stefan
   Purtskhvanidze, Konstantine
   Tode, Jan
   Roider, Johann
TI Retinal volume change is a reliable OCT biomarker for disease activity
   in neovascular AMD
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; OCT; Biomarker; VEGF; PRN; Macula; Retina
ID MACULAR DEGENERATION; RANIBIZUMAB; TUBULATION
AB Purpose Current algorithms for automated computer interpretation of optical coherence tomography (OCT) imaging of patients suffering from neovascular age-related macular degeneration (AMD) mostly rely on fluid detection. However, fluid detection itself and correct interpretation of the fluid currently limits diagnostic accuracy. We therefore performed a detailed analysis of the requirements that would have to be met for fluid detection approaches. We further investigated if monitoring retinal volume would be a viable alternative to detect disease activity.
   Methods Retrospective analysis and manual grading of 764 OCT volume scans of 44 patients with exudative AMD treated with intravitreal anti-VEGF injections at a pro-re-nata (PRN) treatment regimen for at least 24 months.
   Results Detection of subretinal fluid (SRF) or intraretinal fluid (IRF) alone is not sufficient for disease detection. A combination of SRF and IRF can detect disease activity with a sensitivity of 98.6% and a specificity of 82%. With further characterization of IRF into exudative and degenerative cysts, specificity can be increased to 100%. However, correct characterization is currently not achieved by published fluid detection approaches. Change of macular retinal volume (MRV) can depict disease activity with sensitivity of 88.4% and specificity of 89.6%. Combination with the detection of SRF can further improve diagnostic accuracy to a specificity of 93.3% and sensitivity of 93.9% without relying on IRF or IRF characterization.
   Conclusion Fluid detection without further characterization is not sufficient for AMD monitoring. Either further distinction between exudative and degenerative cysts is necessary, or other activity markers have to be taken into account. MRV offers good potential to fill this diagnostic gap and might become an important monitoring marker.
C1 [von der Burchard, Claus; Treumer, Felix; Ehlken, Christoph; Koinzer, Stefan; Purtskhvanidze, Konstantine; Tode, Jan; Roider, Johann] Christian Albrechts Univ Kiel, Dept Ophthalmol, Univ Med Ctr, Arnold Heller Str 3, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP von der Burchard, C (通讯作者)，Christian Albrechts Univ Kiel, Dept Ophthalmol, Univ Med Ctr, Arnold Heller Str 3, D-24105 Kiel, Germany.
EM claus.vonderburchard@uksh.de
RI von der Burchard, Claus/GZG-4104-2022
FU German Federal Ministry of Education and Research (BMBF) [13N13766]
FX The German Federal Ministry of Education and Research (BMBF) provided
   financial support in the form of a research grand (Grant No. 13N13766).
CR Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Espina M, 2016, BRIT J OPHTHALMOL, V100, P819, DOI 10.1136/bjophthalmol-2015-307141
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Pauleikhoff D, 2013, KLIN MONATSBL AUGENH, V230, P170, DOI 10.1055/s-0032-1328113
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sabouri Mohammad Rasoul, 2016, Med Hypothesis Discov Innov Ophthalmol, V5, P104
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623
   Wang C., 2017, MATH PROBL ENG, V2017, P1, DOI DOI 10.HTTPS://D0I.0RG/10.1155/2017/3405619
   Xu X, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/380218
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 18
TC 6
Z9 8
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2018
VL 256
IS 9
BP 1623
EP 1629
DI 10.1007/s00417-018-4040-7
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GQ7OL
UT WOS:000441932500008
PM 29915918
DA 2022-11-30
ER

PT J
AU Koh, JEW
   Ng, EYK
   Bhandary, SV
   Laude, A
   Acharya, UR
AF Koh, Joel E. W.
   Ng, Eddie Y. K.
   Bhandary, Sulatha V.
   Laude, Augustinus
   Acharya, U. Rajendra
TI Automated detection of retinal health using PHOG and SURF features
   extracted from fundus images
SO APPLIED INTELLIGENCE
LA English
DT Article
DE Fundus; Eye; PHOG; SURF; Classifier; PSO; Glaucoma; AMD; Diabetes
   retinopathy
ID DECISION-SUPPORT-SYSTEM; CONFIGURATION PATTERN FEATURES;
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; DIAGNOSIS; IDENTIFICATION;
   SEGMENTATION; TRANSFORM; ALGORITHM; DWT
AB Many health-related problems arise with aging. One of the diseases that is prevalent among the elderly is the loss of sight. Various eye diseases, namely age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma are the prime causes of vision loss as we grow old. Nevertheless, early detection of such eye diseases can impede the progression of this problem. Therefore, the elderly are encouraged to attend regular eye checkups for early detection of eye diseases. However, it is time-consuming and laborious to conduct a mass eye screening session frequently. Hence, we proposed a novel approach to develop an automated retinal health screening system in this work. This paper discusses a retinal screening system to automatically differentiate normal image from abnormal (AMD, DR, and glaucoma) fundus images. The fundus images are subjected to the pyramid histogram of oriented gradients (PHOG) and speeded up robust features (SURF) techniques. Then, the extracted data are subjected to adaptive synthetic sampling to balance the number of data in the two classes (normal and abnormal). Subsequently, we employed the canonical correlation analysis approach to fuse the highly-correlated features extracted from the two (PHOG and SURF) descriptors. We have achieved 96.21% accuracy, 95.00% sensitivity, and 97.42% specificity with ten-fold cross-validation strategy using k-nearest neighbor (kNN) classifier. This novel algorithm has high potential in the diagnosis of normal eyes during the mass eye screening session or in polyclinics quickly and reliably. Hence, the patients having abnormal eyes can be sent to the main hospitals which will reduce the workload for the ophthalmologists.
C1 [Koh, Joel E. W.; Acharya, U. Rajendra] Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.
   [Koh, Joel E. W.; Ng, Eddie Y. K.] Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore 639798, Singapore.
   [Bhandary, Sulatha V.] Kasturba Med Coll & Hosp, Dept Ophthalmol, Manipal 576104, Karnataka, India.
   [Laude, Augustinus] Tan Tock Seng Hosp, Natl Healthcare Grp Eye Inst, Singapore 308433, Singapore.
   [Acharya, U. Rajendra] SUSS Univ, Sch Sci & Technol, Dept Biomed Engn, Singapore 599491, Singapore.
   [Acharya, U. Rajendra] Univ Malaya, Dept Biomed Engn, Fac Engn, Kuala Lumpur, Malaysia.
C3 Nanyang Technological University & National Institute of Education (NIE)
   Singapore; Nanyang Technological University; Manipal Academy of Higher
   Education (MAHE); Kasturba Medical College, Manipal; Tan Tock Seng
   Hospital; Singapore University of Social Sciences (SUSS); Universiti
   Malaya
RP Koh, JEW (通讯作者)，Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore 599489, Singapore.; Koh, JEW (通讯作者)，Nanyang Technol Univ, Sch Mech & Aerosp Engn, Singapore 639798, Singapore.
EM falco_peregrinus14@yahoo.co.uk
RI Ng, E Y K/A-1375-2011; Acharya, Rajendra U/E-3791-2010
OI Ng, E Y K/0000-0002-5701-1080; Acharya, Rajendra U/0000-0003-2689-8552;
   Bhandary, Sulatha/0000-0002-3150-707X
FU Social Innovation Research Fund (Project Title: Automated Eye Screening:
   A Direct Approach for Referral), Singapore
FX Authors would like to thank the Social Innovation Research Fund (Project
   Title: Automated Eye Screening: A Direct Approach for Referral),
   Singapore for providing us a grant for this research. We would also like
   to express our sincere thanks to Manipal University, Manipal, India for
   providing us the images for this study.
CR Abramoff MD, 2005, TELEMED J E-HEALTH, V11, P668, DOI 10.1089/tmj.2005.11.668
   Abramoff MD, 2010, OPHTHALMOLOGY, V117, P1147, DOI 10.1016/j.ophtha.2010.03.046
   Acharya R, 2008, ARTECH HSE BIOINF BI, P1
   Acharya UR, 2009, P I MECH ENG H, V223, P545, DOI 10.1243/09544119JEIM486
   Acharya UR, 2017, COMPUT BIOL MED, V88, P72, DOI 10.1016/j.compbiomed.2017.06.022
   Acharya UR, 2017, J COMPUT SCI-NETH, V20, P41, DOI 10.1016/j.jocs.2017.03.005
   Acharya UR, 2017, COMPUT BIOL MED, V84, P59, DOI 10.1016/j.compbiomed.2017.03.016
   Acharya UR, 2016, COMPUT BIOL MED, V75, P54, DOI 10.1016/j.compbiomed.2016.04.015
   Acharya UR, 2016, COMPUT BIOL MED, V73, P131, DOI 10.1016/j.compbiomed.2016.04.009
   Acharya UR, 2015, BIOMED SIGNAL PROCES, V15, P18, DOI 10.1016/j.bspc.2014.09.004
   Acharya UR, 2011, IEEE T INF TECHNOL B, V15, P449, DOI 10.1109/TITB.2011.2119322
   Acharya UR, 2012, J MED SYST, V36, P2011, DOI 10.1007/s10916-011-9663-8
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Agurto C, 2010, IEEE T MED IMAGING, V29, P502, DOI 10.1109/TMI.2009.2037146
   [Anonymous], 1991, Ophthalmology, V98, P786
   [Anonymous], 1989, FUND PHOT HLTH TECHN
   Antal B, 2012, IEEE T BIO-MED ENG, V59, P1720, DOI 10.1109/TBME.2012.2193126
   Bay H, 2008, COMPUT VIS IMAGE UND, V110, P346, DOI 10.1016/j.cviu.2007.09.014
   Bock R, 2010, MED IMAGE ANAL, V14, P471, DOI 10.1016/j.media.2009.12.006
   Bosch A, 2007, P 6 ACM INT C IM VID, P410
   Boyd K., 2017, WHAT IS GLAUCOMA
   COVER TM, 1967, IEEE T INFORM THEORY, V13, P21, DOI 10.1109/TIT.1967.1053964
   Dua S, 2012, IEEE T INF TECHNOL B, V16, P80, DOI 10.1109/TITB.2011.2176540
   Duda R.O., 2006, PATTERN CLASSIFICATI
   Faust O, 2012, J MED SYST, V36, P145, DOI 10.1007/s10916-010-9454-7
   Fraser CE, 2017, DIABETIC RETINOPATHY
   Ganesan K, 2014, MED BIOL ENG COMPUT, V52, P663, DOI 10.1007/s11517-014-1167-5
   Garcia V, 2012, KNOWL-BASED SYST, V25, P13, DOI 10.1016/j.knosys.2011.06.013
   Gardner GG, 1996, BRIT J OPHTHALMOL, V80, P940, DOI 10.1136/bjo.80.11.940
   Haddrill M, ALL VISION WHAT IS A
   He HB, 2008, IEEE IJCNN, P1322, DOI 10.1109/IJCNN.2008.4633969
   Hijazi MHA, 2014, INT J SIMUL SYST SCI, V15, P57
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1942, DOI 10.1109/icnn.1995.488968
   Kennedy J, 2001, KAUFMANN PUBLISHERS
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   Koh JEW, 2017, COMPUT BIOL MED, V84, P89, DOI 10.1016/j.compbiomed.2017.03.008
   Kolar R, 2008, RADIOENGINEERING, V17, P109
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Lim TH, 2007, ANN ACAD MED SINGAP, V36, pS15
   Maheshwari S, 2017, ITERATIVE VARIATIONA
   Maheshwari S, 2017, IEEE J BIOMED HEALTH, V21, P803, DOI 10.1109/JBHI.2016.2544961
   Mookiah MRK, 2013, KNOWL-BASED SYST, V39, P9, DOI 10.1016/j.knosys.2012.09.008
   Mookiah MRK, 2015, KNOWL-BASED SYST, V89, P654, DOI 10.1016/j.knosys.2015.09.012
   Mookiah MRK, 2015, COMPUT BIOL MED, V63, P208, DOI 10.1016/j.compbiomed.2015.05.019
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Mookiah MRK, 2012, KNOWL-BASED SYST, V33, P73, DOI 10.1016/j.knosys.2012.02.010
   Nayak J, 2008, J MED SYST, V32, P107, DOI 10.1007/s10916-007-9113-9
   Nayak J, 2009, J MED SYST, V33, P337, DOI 10.1007/s10916-008-9195-z
   Niemeijer M, 2010, IEEE T MED IMAGING, V29, P185, DOI 10.1109/TMI.2009.2033909
   Noronha K, 2013, P I MECH ENG H, V227, P251, DOI 10.1177/0954411912470240
   Noronha KP, 2014, BIOMED SIGNAL PROCES, V10, P174, DOI 10.1016/j.bspc.2013.11.006
   Piramuthu S, 2004, EUR J OPER RES, V156, P483, DOI 10.1016/s0377-2217(02)00911-6
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   Reza AM, 2004, J VLSI SIG PROC SYST, V38, P35, DOI 10.1023/B:VLSI.0000028532.53893.82
   Ryan S, 2012, RETINA
   Sun QS, 2005, PATTERN RECOGN, V38, P2437, DOI 10.1016/j.patcog.2004.12.013
   Tan JH, 2017, J COMPUT SCI-NETH, V20, P70, DOI 10.1016/j.jocs.2017.02.006
   U RA, 2008, J MED SYST, V32, P481, DOI 10.1007/s10916-008-9154-8
   Usher D, 2004, DIABETIC MED, V21, P84, DOI 10.1046/j.1464-5491.2003.01085.x
   Wang X, 2005, P SOC PHOTO-OPT INS, V5852, P462, DOI 10.1117/12.621707
   WHO, 2018, AGEING HLTH
   World Health Organization, 2016, GLOBAL REPORT DIABET
   Yun WL, 2008, INFORM SCIENCES, V178, P106, DOI 10.1016/j.ins.2007.07.020
   Zhang Z, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-80
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
NR 67
TC 21
Z9 22
U1 1
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0924-669X
EI 1573-7497
J9 APPL INTELL
JI Appl. Intell.
PD MAY
PY 2018
VL 48
IS 5
SI SI
BP 1379
EP 1393
DI 10.1007/s10489-017-1048-3
PG 15
WC Computer Science, Artificial Intelligence
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA GB9NS
UT WOS:000429401100021
DA 2022-11-30
ER

PT J
AU Biesemeier, A
   Eibl, O
   Eswara, S
   Audinot, JN
   Wirtz, T
   Schraermeyer, U
AF Biesemeier, Antje
   Eibl, Oliver
   Eswara, Santhana
   Audinot, Jean-Nicolas
   Wirtz, Tom
   Schraermeyer, Ulrich
TI Transition metals and trace elements in the retinal pigment epithelium
   and choroid: correlative ultrastructural and chemical analysis by
   analytical electron microscopy and nano-secondary ion mass spectrometry
SO METALLOMICS
LA English
DT Article
ID OCULAR MELANIN; LIQUID-CHROMATOGRAPHY; MACULAR DEGENERATION;
   SUBSTANTIA-NIGRA; HUMAN RPE; IRON; MELANOSOMES; AGE; DISEASE; COPPER
AB Understanding the localisation and abundance of structural elements, trace elements and especially transition metals like Cu and Zn in ocular tissue sections is important for physiology, and also for the characterisation of diseases related to oxidative stress like age-related macular degeneration. Transition metal abundances were investigated in an aged donor eye by nano-secondary ion mass spectrometry (nano-SIMS) elemental mapping using Cs+ and O- primary ions, respectively, and correlated to their respective mole fractions investigated by analytical electron microscopy (AEM). The ultrastructure of the tissue and the elemental composition of melanosomes of the choroid and RPE, and RPE lipofuscin and melanolipofuscin granules can adequately be investigated by nano-SIMS using the secondary ion maps. Melanosomes, 0.5-1 mu m in size, yield sulphur maps and maps of stored metals like calcium, sodium and copper. Lipofuscin shows especially high phosphorus signals. Elements with mole fractions of about 0.1 at%, e.g. for P and Cu, as investigated by AEM before, can be validated using simultaneous SIMS maps with an estimated lateral resolution of 66 nm with typical acquisition times of 30 minutes for each area of interest. However, Zn (0.19 at%) was not detected by SIMS. Nano-SIMS imaging of CN-, PO2-, S-, Cu+, Ca+, Fe+ and Na+ ions provides excellent detection limits demonstrating the possibilities for chemical mapping with high-sensitivity trace element detection and reduced acquisition times. Quantification of nanoSIMS data was achieved by correlating mole fractions obtained by AEM to secondary ions per pixel obtained by nano-SIMS. Both methods yield the melanin type in melanosomes and trace metal storage.
C1 [Biesemeier, Antje; Schraermeyer, Ulrich] Ctr Ophthalmol, Div Expt Vitreoretinal Surg, Schleichstr 12-1, D-72076 Tubingen, Germany.
   [Eibl, Oliver] Univ Tubingen, Inst Appl Phys, Morgenstelle 10, D-72076 Tubingen, Germany.
   [Eswara, Santhana; Audinot, Jean-Nicolas; Wirtz, Tom] Luxembourg Inst Sci & Technol, Mat Res & Technol Dept, Adv Instrumentat Ion Nanoanalyt AINA, 41 Rue Brill, L-4422 Belvaux, Luxembourg.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Luxembourg Institute of
   Science & Technology
RP Biesemeier, A (通讯作者)，Ctr Ophthalmol, Div Expt Vitreoretinal Surg, Schleichstr 12-1, D-72076 Tubingen, Germany.
EM antje.biesemeier@med.uni-tuebingen.de
RI Eswara, Santhana/E-9143-2010; Audinot, Jean-Nicolas/I-5114-2013
OI Eswara, Santhana/0000-0003-4151-2304; Audinot,
   Jean-Nicolas/0000-0002-4966-7653; Wirtz, Tom/0000-0002-7912-5193;
   Biesemeier, Antje/0000-0002-3462-8803
FU DFG [BI1551/2-1]; National Research Fund Luxembourg (FNR)
   [INTER/MERA/14/9822270]
FX This work (AB) was cofunded by the DFG (BI1551/2-1) and the National
   Research Fund Luxembourg (FNR) within the framework of the C4HEALTH
   project through grant INTER/MERA/14/9822270. Special thanks to the
   tissue donor and her family and the Center for Ophthalmology Tuebingen
   for providing eye tissue samples. We thank Sigrid Schultheiss for
   technical assistance and Judith Birch for proof reading.
CR Audinot JN, 2011, SURF INTERFACE ANAL, V43, P302, DOI 10.1002/sia.3550
   Barzegar-Befroei N., 2011, BIOMEDICAL HLTH RES, V76, P460
   Behrends J., 2012, PHYSIOLOGIE
   Bellono NW, 2016, SCI REP-UK, V6, DOI 10.1038/srep26570
   Biesemeier A, 2016, J NEUROCHEM, V138, P339, DOI 10.1111/jnc.13648
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Biesemeier A, 2012, METALLOMICS, V4, P323, DOI 10.1039/c2mt00187j
   Biesemeier A, 2011, EXP EYE RES, V93, P29, DOI 10.1016/j.exer.2011.04.004
   Biesemeier A, 2011, MICRON, V42, P461, DOI 10.1016/j.micron.2011.01.004
   Bourassa MW, 2012, METALLOMICS, V4, P721, DOI 10.1039/c2mt20052j
   Braidy N, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00138
   d'Ischia M, 2015, PIGM CELL MELANOMA R, V28, P520, DOI 10.1111/pcmr.12393
   da Cunha MML, 2016, MICRON, V84, P23, DOI 10.1016/j.micron.2016.02.005
   Desbenoit N, 2013, ANAL BIOANAL CHEM, V405, P4039, DOI 10.1007/s00216-013-6811-7
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Eibl O, 2006, MICRON, V37, P262, DOI 10.1016/j.micron.2005.08.006
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   INCA, 1998, MICR SUIT ISS 18B VE
   ITO S, 1985, ANAL BIOCHEM, V144, P527, DOI 10.1016/0003-2697(85)90150-2
   JIMBOW K, 1984, CANCER RES, V44, P1128
   Julien S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029245
   Lamason RL, 2005, SCIENCE, V310, P1782, DOI 10.1126/science.1116238
   Marin J, 1999, EXP GERONTOL, V34, P503, DOI 10.1016/S0531-5565(99)00029-7
   McRae R, 2009, CHEM REV, V109, P4780, DOI 10.1021/cr900223a
   Mueller CW, 2013, ADV AGRON, V121, P1, DOI 10.1016/B978-0-12-407685-3.00001-3
   Oakley AE, 2007, NEUROLOGY, V68, P1820, DOI 10.1212/01.wnl.0000262033.01945.9a
   Phan NTN, 2014, SURF INTERFACE ANAL, V46, P123, DOI 10.1002/sia.5547
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Quintana C, 2007, MICROSC RES TECHNIQ, V70, P281, DOI 10.1002/jemt.20403
   SAMUELSON DA, 1993, EXP EYE RES, V56, P63, DOI 10.1006/exer.1993.1009
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Sulzer D, 2008, J NEUROCHEM, V106, P24, DOI 10.1111/j.1471-4159.2008.05385.x
   Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   ULSHAFER RJ, 1990, ARCH OPHTHALMOL-CHIC, V108, P113, DOI 10.1001/archopht.1990.01070030119041
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   Wirtz T, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/43/434001
   Wolkow N, 2011, ARCH OPHTHALMOL-CHIC, V129, P1466, DOI 10.1001/archophthalmol.2011.309
   Zecca L, 2004, P NATL ACAD SCI USA, V101, P9843, DOI 10.1073/pnas.0403495101
   Zecca L, 2008, P NATL ACAD SCI USA, V105, P17567, DOI 10.1073/pnas.0808768105
   Zucca FA, 2017, PROG NEUROBIOL, V155, P96, DOI 10.1016/j.pneurobio.2015.09.012
NR 44
TC 7
Z9 7
U1 1
U2 16
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1756-5901
EI 1756-591X
J9 METALLOMICS
JI Metallomics
PD FEB
PY 2018
VL 10
IS 2
BP 296
EP 308
DI 10.1039/c7mt00259a
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GE6DD
UT WOS:000431313500008
PM 29327028
DA 2022-11-30
ER

PT J
AU Best, AL
   Fajnkuchen, F
   Nghiem-Buffet, S
   Grenet, T
   Quentel, G
   Delahaye-Mazza, C
   Cohen, SY
   Giocanti-Auregan, A
AF Best, Anne-Laurence
   Fajnkuchen, Franck
   Nghiem-Buffet, Sylvia
   Grenet, Typhaine
   Quentel, Gabriel
   Delahaye-Mazza, Corinne
   Cohen, Salomon Y.
   Giocanti-Auregan, Audrey
TI Treatment Efficacy and Compliance in Patients with Diabetic Macular
   Edema Treated with Ranibizumab in a Real-Life Setting
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL TRIAMCINOLONE; DEFERRED LASER; TRIAL; OUTCOMES;
   PHOTOCOAGULATION; DEXAMETHASONE; SAFETY; PROMPT
AB Purpose. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods. A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. Results. Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 mu m. At M12, the mean VA was 63.4 letters (p < 0 0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 mu m (p = 0 0001) after a mean number of 5.33 intravitreal injections. In patients who received = 7 injections, the VA gain and final VA were significantly higher than in patients who received < 7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n = 55). Discussion/Conclusion. Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients.
C1 [Best, Anne-Laurence; Fajnkuchen, Franck; Nghiem-Buffet, Sylvia; Grenet, Typhaine; Giocanti-Auregan, Audrey] Paris 13 Univ, DHU Vis & Handicaps, Avicenne Hosp, AP HP,Ophthalmol Dept, Bobigny, France.
   [Fajnkuchen, Franck; Nghiem-Buffet, Sylvia; Grenet, Typhaine; Quentel, Gabriel; Delahaye-Mazza, Corinne; Cohen, Salomon Y.] Ctr Imagerie & Laser, Paris, France.
   [Cohen, Salomon Y.] Paris Est Univ, Ctr Hosp Intercommunal Creteil, Ophthalmol Dept, Creteil, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Avicenne - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI
   Creteil
RP Giocanti-Auregan, A (通讯作者)，Paris 13 Univ, DHU Vis & Handicaps, Avicenne Hosp, AP HP,Ophthalmol Dept, Bobigny, France.
EM audreygiocanti@yahoo.fr
FU AVOPH (Bobigny, France), an association for research and education;
   CIL-ASSOC (association for research-Centre d'Imagerie et de Laser,
   Paris, France)
FX This work was supported by an unrestricted grant from AVOPH (Bobigny,
   France), an association for research and education, and CIL-ASSOC
   (association for research-Centre d'Imagerie et de Laser, Paris, France).
CR Autorite deSante Haute, 2015, COMMISSION TRANSPARE
   Bandello F, 2012, EYE, V26, P485, DOI 10.1038/eye.2011.337
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Delcourt C, 2009, DIABETES METAB, V35, P431, DOI 10.1016/j.diabet.2009.06.002
   Dugel PU, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S100764
   Elman MJ, 2015, OPHTHALMOLOGY, V122, P375, DOI 10.1016/j.ophtha.2014.08.047
   Elman MJ, 2011, OPHTHALMOLOGY, V118, P609, DOI 10.1016/j.ophtha.2010.12.033
   Ghanchi F, 2016, EYE, V30, P133, DOI 10.1038/eye.2015.209
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P2473, DOI 10.1016/j.ophtha.2014.07.002
   Gillies MC, 2011, OPHTHALMOLOGY, V118, P866, DOI 10.1016/j.ophtha.2010.09.029
   Gillies MC, 2009, OPHTHALMOLOGY, V116, P2182, DOI 10.1016/j.ophtha.2009.04.049
   Granstrom T, 2016, DIABETES RES CLIN PR, V121, P157, DOI 10.1016/j.diabres.2016.09.015
   Haller JA, 2010, ARCH OPHTHALMOL-CHIC, V128, P289, DOI 10.1001/archophthalmol.2010.21
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Hrarat L, 2016, OPHTHALMOLOGICA, V236, P207, DOI 10.1159/000453006
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Mitchell P, 2015, CURR MED RES OPIN, V31, P1967, DOI 10.1185/03007995.2015.1081880
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Prunte C, 2016, BRIT J OPHTHALMOL, V100, P787, DOI 10.1136/bjophthalmol-2015-307249
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 24
TC 25
Z9 25
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2018
VL 2018
AR 4610129
DI 10.1155/2018/4610129
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GE4PQ
UT WOS:000431198700001
PM 29850205
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Sulzbacher, F
   Pollreisz, A
   Kaider, A
   Kickinger, S
   Sacu, S
   Schmidt-Erfurth, U
AF Sulzbacher, Florian
   Pollreisz, Andreas
   Kaider, Alexandra
   Kickinger, Stefan
   Sacu, Stefan
   Schmidt-Erfurth, Ursula
CA Vienna Eye Study Ctr
TI Identification and clinical role of choroidal neovascularization
   characteristics based on optical coherence tomography angiography
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age related macular degeneration; angiogenesis; optical coherence
   tomography; optical coherence tomography angiography
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; THERAPY; CAPILLARIES;
   FLOW
AB PurposeTo suggest a novel classification of neovascular age-related macular degeneration (AMD) based on optical coherence tomography angiography (OCTA) and to correlate morphological characteristics based on optical coherence tomography (OCT)/OCTA with clinical criteria of disease activity.
   MethodsA total of 88 eyes with neovascular AMD (14 treatment-naive, 74 eyes following anti-vascular endothelial growth factor treatment (VEGF)) were examined using the AngioVue OCTA system (Optovue, Inc., Fremont, CA, USA) and evaluated based on vascular morphology. Choroidal neovascularization (CNV)-vessel morphology based on OCTA and associations with retinal layers were described and correlated with clinical markers of disease activity.
   ResultsIn treatment-naive CNV, CNV-vessel morphology based on OCTA showed a dense-net configuration (DN) in 12 of 14 eyes, a loose-net configuration (LN) in one of 14 eyes and an unidentifiable CNV pattern in one of 14 eyes, whereas in treated CNV, DN was registered in 43.2% (32/74), LN in 27% (20/74), DN with additional LN (mixed type) in 14.9% (11/74) and an unidentifiable CNV pattern in 14.9% (11/74). Clinical correlations revealed a significantly longer disease duration for LN with a median value of 4.3years compared to DN with 2.0years (p=0.009) and for CNV involving the outer retina with 3.1years compared to CNV not involving the outer retina with 1.9years (p=0.051).
   ConclusionOptical coherence tomography angiography (OCTA) allows identification of distinct CNV-specific vascular patterns at the level of the outer retinal layer and choriocapillaris. Correlation with clinical and functional parameters may be useful to better understand pathophysiological mechanisms and guide efficient therapeutic strategies.
C1 [Sulzbacher, Florian; Pollreisz, Andreas; Kickinger, Stefan; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   [Kaider, Alexandra] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Sect Clin Biometr, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna
RP Sacu, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM stefan.sacu@meduniwien.ac.at
RI Pollreisz, Andreas/AAJ-1538-2021
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR Adamis AP, 2009, RETINA, V29, P42
   Coscas G, 2016, ACTA OPHTHALMOL
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Fernandes LHS, 2002, RETINA-J RET VIT DIS, V22, P557, DOI 10.1097/00006982-200210000-00005
   Flower R, 2008, INVEST OPHTH VIS SCI, V49, P5510, DOI 10.1167/iovs.07-1504
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Freund KB, 2011, RETINA, V30, P1333
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Parravano M, 2016, ACTA OPHTHALMOL
   Pauleikhoff D, 2011, GRAEF ARCH CLIN EXP, V249, P631, DOI 10.1007/s00417-011-1639-3
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tam J, 2011, BIOMED OPT EXPRESS, V2, P781, DOI 10.1364/BOE.2.000781
   Wang Q, 2016, ACTA OPHTHALMOL, V94, P415, DOI 10.1111/aos.12841
NR 25
TC 55
Z9 58
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2017
VL 95
IS 4
BP 414
EP 420
DI 10.1111/aos.13364
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX6OJ
UT WOS:000403361300038
PM 28133946
OA Bronze
DA 2022-11-30
ER

PT J
AU Leinonen, H
   Rossi, M
   Salo, AM
   Tiainen, P
   Hyvarinen, J
   Pitkanen, M
   Sormunen, R
   Miinalainen, I
   Zhang, C
   Soininen, R
   Kivirikko, KI
   Koskelainen, A
   Tanila, H
   Myllyharju, J
   Koivunen, P
AF Leinonen, Henri
   Rossi, Maarit
   Salo, Antti M.
   Tiainen, Paivi
   Hyvarinen, Jaana
   Pitkanen, Marja
   Sormunen, Raija
   Miinalainen, Ilkka
   Zhang, Chi
   Soininen, Raija
   Kivirikko, Kari I.
   Koskelainen, Ari
   Tanila, Heikki
   Myllyharju, Johanna
   Koivunen, Peppi
TI Lack of P4H-TM in mice results in age-related retinal and renal
   alterations
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID TRANSMEMBRANE PROLYL 4-HYDROXYLASE; MACULAR DEGENERATION; MOUSE MODELS;
   HYPOXIA; ROD; MECHANISMS; LIGHT; CONE; ELECTRORETINOGRAPHY;
   PHOTORESPONSES
AB Age-related macular degeneration (AMD), affecting the retinal pigment epithelium (RPE), is the leading cause of blindness in middle-aged and older people in developed countries. Genetic and environmental risk factors have been identified, but no effective cure exists. Using a mouse model we show that a transmembrane prolyl 4-hydroxylase (P4H-TM), which participates in the oxygen-dependent regulation of the hypoxia-inducible factor (HIF), is a potential novel candidate gene for AMD. We show that P4h-tm had its highest expression levels in the mouse RPE and brain, heart, lung, skeletal muscle and kidney. P4h-tm(-/-) mice were fertile and had a normal life span. Lack of P4h-tm stabilized HIF-1a in cortical neurons under normoxia, while in hypoxia it increased the expression of certain HIF target genes in tissues with high endogenous P4h-tm expression levels more than in wild-type mice. Renal erythropoietin levels increased in P4h-tm(-/-) mice with aging, but the resulting similar to 2-fold increase in erythropoietin serum levels did not lead to erythrocytosis. Instead, accumulation of lipid-containing lamellar bodies in renal tubuli was detected in P4h-tm(-/-) mice with aging, resulting in inflammation and fibrosis, and later glomerular sclerosis and albuminuria. Lack of P4h-tm was associated with retinal thinning, rosette-like infoldings and drusen-like structure accumulation in RPE with aging, as is characteristic of AMD. Photoreceptor recycling was compromised, and electroretinograms revealed functional impairment of the cone pathway in adult P4h-tm(-/-) mice and cone and rod deficiency in middle-aged mice. P4H-TM is therefore imperative for normal vision, and potentially a novel candidate for age-induced diseases, such as AMD.
C1 [Leinonen, Henri; Tanila, Heikki] Univ Eastern Finland, AI Virtanen Inst, Dept Neurobiol, Kuopio, Finland.
   [Rossi, Maarit; Salo, Antti M.; Tiainen, Paivi; Hyvarinen, Jaana; Zhang, Chi; Kivirikko, Kari I.; Myllyharju, Johanna; Koivunen, Peppi] Univ Oulu, Bioctr Oulu, Oulu Ctr Cell Matrix Res, FIN-90014 Oulu, Finland.
   [Rossi, Maarit; Salo, Antti M.; Tiainen, Paivi; Hyvarinen, Jaana; Zhang, Chi; Kivirikko, Kari I.; Myllyharju, Johanna; Koivunen, Peppi] Univ Oulu, Fac Biochem & Mol Med, FIN-90014 Oulu, Finland.
   [Pitkanen, Marja; Koskelainen, Ari] Aalto Univ, Sch Sci, Dept Neurosci & Biomed Engn, FI-00076 Aalto, Finland.
   [Sormunen, Raija; Miinalainen, Ilkka; Soininen, Raija] Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland.
   [Sormunen, Raija] Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland.
   [Sormunen, Raija] Oulu Univ Hosp, FIN-90014 Oulu, Finland.
C3 University of Eastern Finland; University of Oulu; University of Oulu;
   Aalto University; University of Oulu; University of Oulu; University of
   Oulu
RP Koivunen, P (通讯作者)，Univ Oulu, Fac Biochem & Mol Med, Bioctr Oulu, Oulu Ctr Cell Matrix Res, Aapistie 7,POB 5400, FIN-90014 Oulu, Finland.
EM peppi.koivunen@oulu.fi
RI Leinonen, Henri/V-2684-2019
OI Leinonen, Henri/0000-0002-0388-832X; Miinalainen,
   Ilkka/0000-0002-3922-3442; Pitkanen, Marja/0000-0002-6054-8380
FU Academy of Finland [120156, 140765, 218129, 200471, 202469]; Center of
   Excellence Grant [251314]; S. Juselius Foundation; Emil Aaltonen
   Foundation; Jane and Aatos Erkko Foundation; FibroGen, Inc.
FX This study was supported by Academy of Finland through Grants 120156,
   140765 and 218129 (P.K.), 200471, 202469 and Center of Excellence
   2012-2017 Grant 251314 (J.M.), and by the S. Juselius Foundation (P.K.,
   J.M.), the Emil Aaltonen Foundation (P.K.), the Jane and Aatos Erkko
   Foundation (P.K., J.M.) and FibroGen, Inc. (J.M.).
CR Aleman TS, 2011, INVEST OPHTH VIS SCI, V52, P6898, DOI 10.1167/iovs.11-7701
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009
   DONNER K, 1988, ACTA PHYSIOL SCAND, V134, P535, DOI 10.1111/j.1365-201X.1988.tb10632.x
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Flynn E, 2014, INVEST OPHTH VIS SCI, V55, P5643, DOI 10.1167/iovs.14-14136
   Ghosh KK, 2004, J COMP NEUROL, V469, P70, DOI 10.1002/cne.10985
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   Gundersen H. J., 1986, THOMPSON J MICROSC 1, V143, P3, DOI DOI 10.1111/J.1365-2818.1986.TB02764.X
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hartnett ME, 2012, NEW ENGL J MED, V367, P2515, DOI 10.1056/NEJMra1208129
   Heikkinen H, 2008, VISION RES, V48, P264, DOI 10.1016/j.visres.2007.11.005
   Hyvarinen J, 2010, J BIOL CHEM, V285, P42023, DOI 10.1074/jbc.M110.145904
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kaasinen E, 2014, EUR J MED GENET, V57, P543, DOI 10.1016/j.ejmg.2014.07.002
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Koivunen P, 2007, J BIOL CHEM, V282, P30544, DOI 10.1074/jbc.M704988200
   Kolesnikov AV, 2010, J NEUROSCI, V30, P11222, DOI 10.1523/JNEUROSCI.4239-09.2010
   Laitala A, 2012, BLOOD, V120, P3336, DOI 10.1182/blood-2012-07-441824
   Lange C, 2011, INVEST OPHTH VIS SCI, V52, P5872, DOI 10.1167/iovs.11-7204
   Lavoie J, 2014, BIOL PSYCHIAT, V75, P479, DOI 10.1016/j.biopsych.2012.11.024
   Leinonen H, 2016, J ALZHEIMERS DIS, V51, P21, DOI 10.3233/JAD-150798
   MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2
   Myllyharju J, 2008, ANN MED, V40, P402, DOI 10.1080/07853890801986594
   Myllyharju J, 2013, BIOL CHEM, V394, P435, DOI 10.1515/hsz-2012-0328
   Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8
   Okano K, 2012, J NEUROCHEM, V121, P146, DOI 10.1111/j.1471-4159.2012.07647.x
   Ozer A, 2007, NAT CHEM BIOL, V3, P144, DOI 10.1038/nchembio863
   PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0
   Ragauskas S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113317
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   Rautavuoma K, 2004, P NATL ACAD SCI USA, V101, P14120, DOI 10.1073/pnas.0404966101
   Sears JE, 2008, P NATL ACAD SCI USA, V105, P19898, DOI 10.1073/pnas.0805817105
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Tulvatana W, 1999, ARCH OPHTHALMOL-CHIC, V117, P399, DOI 10.1001/archopht.117.3.399
   Vinberg F, 2015, J GEN PHYSIOL, V146, P307, DOI 10.1085/jgp.201511412
   Weymouth AE, 2008, PROG RETIN EYE RES, V27, P1, DOI 10.1016/j.preteyeres.2007.09.003
NR 42
TC 11
Z9 11
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD SEP 1
PY 2016
VL 25
IS 17
BP 3810
EP 3823
DI 10.1093/hmg/ddw228
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EJ4IW
UT WOS:000393181300013
PM 27466183
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Niu, SJ
   de Sisternes, L
   Chen, Q
   Leng, T
   Rubin, DL
AF Niu, Sijie
   de Sisternes, Luis
   Chen, Qiang
   Leng, Theodore
   Rubin, Daniel L.
TI Automated geographic atrophy segmentation for SD-OCT images using
   region-based C-V model via local similarity factor
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; AGE-RELATED MACULOPATHY; ACTIVE CONTOURS
   DRIVEN; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE; PROGRESSION;
   DRUSEN; AREA
AB Age-related macular degeneration (AMD) is the leading cause of blindness among elderly individuals. Geographic atrophy (GA) is a phenotypic manifestation of the advanced stages of non-exudative AMD. Determination of GA extent in SD-OCT scans allows the quantification of GA-related features, such as radius or area, which could be of important value to monitor AMD progression and possibly identify regions of future GA involvement. The purpose of this work is to develop an automated algorithm to segment GA regions in SD-OCT images. An en face GA fundus image is generated by averaging the axial intensity within an automatically detected sub-volume of the three dimensional SD-OCT data, where an initial coarse GA region is estimated by an iterative threshold segmentation method and an intensity profile set, and subsequently refined by a region-based Chan-Vese model with a local similarity factor. Two image data sets, consisting on 55 SD-OCT scans from twelve eyes in eight patients with GA and 56 SD-OCT scans from 56 eyes in 56 patients with GA, respectively, were utilized to quantitatively evaluate the automated segmentation algorithm. We compared results obtained by the proposed algorithm, manual segmentation by graders, a previously proposed method, and experimental commercial software. When compared to a manually determined gold standard, our algorithm presented a mean overlap ratio (OR) of 81.86% and 70% for the first and second data sets, respectively, while the previously proposed method OR was 72.60% and 65.88% for the first and second data sets, respectively, and the experimental commercial software OR was 62.40% for the second data set. (C) 2016 Optical Society of America
C1 [Niu, Sijie; Chen, Qiang] Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, Nanjing 210094, Jiangsu, Peoples R China.
   [Niu, Sijie; de Sisternes, Luis; Rubin, Daniel L.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA.
   Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA USA.
   [Leng, Theodore; Rubin, Daniel L.] Stanford Univ, Sch Med, Dept Med Biomed Informat Res, Stanford, CA 94305 USA.
C3 Nanjing University of Science & Technology; Stanford University;
   Stanford University; Stanford University
RP Chen, Q (通讯作者)，Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, Nanjing 210094, Jiangsu, Peoples R China.; Rubin, DL (通讯作者)，Stanford Univ, Dept Radiol, Stanford, CA 94305 USA.; Leng, T; Rubin, DL (通讯作者)，Stanford Univ, Sch Med, Dept Med Biomed Informat Res, Stanford, CA 94305 USA.
EM chen2qiang@njust.edu.cn; tedleng@stanford.edu; dlrubin@stanford.edu
RI chen, qiang/GWZ-7308-2022; Leng, Theodore/AAQ-7459-2020
OI Leng, Theodore/0000-0002-8461-3562
FU China Scholarship Council [201406840031]; six talent peaks project in
   Jiangsu Province [2014-SWXY-024]; fundamental research funds for the
   Central Universities [30920140111004]; Qing Lan project [D040201];
   Spectrum-SPADA innovation grant of Stanford University, part of the
   Clinical and Translational Science Award (CTSA) program - National
   Center for Advancing Translational Sciences at the National Institutes
   of Health (NIH) [UL1 TR001085]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [UL1TR001085] Funding Source: NIH RePORTER
FX This work was supported by China Scholarship Council, 201406840031; the
   six talent peaks project in Jiangsu Province (2014-SWXY-024); the
   fundamental research funds for the Central Universities under Grant No.
   30920140111004, Qing Lan project under Grant No. D040201; and a
   Spectrum-SPADA innovation grant of Stanford University, part of the
   Clinical and Translational Science Award (CTSA) program, funded by the
   National Center for Advancing Translational Sciences (Grant: UL1
   TR001085) at the National Institutes of Health (NIH).
CR Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Chan TF, 2001, IEEE T IMAGE PROCESS, V10, P266, DOI 10.1109/83.902291
   Chen Q, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.2
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   de Sisternes L, 2015, INVEST OPHTH VIS SCI, V56, P3415, DOI 10.1167/iovs.14-16345
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Gonzales R., 1992, DIGITAL IMAGE PROCES
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Ji ZX, 2015, INFORM SCIENCES, V301, P285, DOI 10.1016/j.ins.2015.01.006
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li C.M., 2007, P IEEE C COMP VIS PA, P1, DOI DOI 10.1109/CVPR.2007.383014
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Liu SG, 2012, PATTERN RECOGN, V45, P2769, DOI 10.1016/j.patcog.2011.11.019
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   OSHER S, 1988, J COMPUT PHYS, V79, P12, DOI 10.1016/0021-9991(88)90002-2
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Sonka M., 1993, IMAGE PROCESSING ANA
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Tsechpenakis G, 2008, LECT NOTES COMPUT SC, V5241, P883, DOI 10.1007/978-3-540-85988-8_105
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zhang KH, 2010, PATTERN RECOGN, V43, P1199, DOI 10.1016/j.patcog.2009.10.010
NR 33
TC 46
Z9 49
U1 0
U2 16
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD FEB 1
PY 2016
VL 7
IS 2
BP 581
EP 600
DI 10.1364/BOE.7.000581
PG 20
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA DC5FN
UT WOS:000369247000029
PM 26977364
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Fields, MA
   Cai, H
   Bowrey, HE
   Moreira, EF
   Gooz, MB
   Kunchithapautham, K
   Gong, J
   Vought, E
   Del Priore, LV
AF Fields, Mark A.
   Cai, Hui
   Bowrey, Hannah E.
   Moreira, Ernesto F.
   Gooz, Monika Beck
   Kunchithapautham, Kannan
   Gong, Jie
   Vought, Emma
   Del Priore, Lucian V.
TI Nitrite Modification of Extracellular Matrix Alters CD46 Expression and
   VEGF Release in Human Retinal Pigment Epithelium
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium; CD46;
   vascular endothelial growth factor; Bruch's membrane
ID MEMBRANE COFACTOR PROTEIN; COMPLEMENT REGULATORY PROTEIN; BRUCHS
   MEMBRANE; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; OXIDATIVE
   STRESS; DRUSEN FORMATION; ACTIVATION; GROWTH; CELLS
AB PURPOSE. Loss of CD46 has recently been implicated in choroidal neovascularization in mice. Herein we investigated the effect of nitrite modification of the extracellular matrix (ECM) as an in vitro model of "aging" and its effect on CD46 expression and vascular endothelial growth factor (VEGF) release in cocultured human retinal pigment epithelium (RPE).
   METHODS. ARPE-19 cells were plated onto RPE-derived ECM conditions (untreated; nitrite modified; nitrite modified followed by washing with Triton X-100; or nitrite modified followed by washing with Triton X-100 and coated with extracellular matrix ligands). Cells were cultured for 7 days and CD46 expression was analyzed by immunohistochemistry and Western blot. Additionally, CD46 short interfering RNA (siRNA) was transfected into ARPE-19 cells, and VEGF levels were determined by ELISA. Finally, in the same ECM conditions, ARPE-19 cells were challenged with normal human serum and VEGF levels determined by ELISA.
   RESULTS. CD46 is expressed on the basolateral surface of ARPE-19 cells on RPE-derived ECM. Nitrite modification of ECM reduced the expression of CD46 on ARPE-19 cells by 0.5-fold (P = 0.003) and increased VEGF release in ARPE-19 cells by 1.7-fold (P < 0.001). CD46 knockdown also increased release of VEGF on the apical and basal sides of ARPE-19 cells in culture by 1.3- (P = 0.012) and 1.2-fold (P = 0.017), respectively.
   CONCLUSIONS. Nitrite modification of the ECM decreased CD46 expression and increased the release of VEGF from ARPE-19 cells. Changes in CD46 expression may lead to changes in VEGF and play a pathologic role in the development of age-related macular degeneration.
C1 [Fields, Mark A.; Bowrey, Hannah E.; Moreira, Ernesto F.; Kunchithapautham, Kannan; Gong, Jie; Del Priore, Lucian V.] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   [Fields, Mark A.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
   [Cai, Hui] Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA.
   [Gooz, Monika Beck] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
   [Vought, Emma] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Columbia University; Medical University of South Carolina;
   Medical University of South Carolina
RP Del Priore, LV (通讯作者)，Med Univ S Carolina, Storm Eye Inst, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM delprior@musc.edu
OI Bowrey, Hannah/0000-0002-3774-4201
FU NCI NIH HHS [P30 CA138313, P30CA138313] Funding Source: Medline;
   NATIONAL CANCER INSTITUTE [P30CA138313] Funding Source: NIH RePORTER
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   Barilla-LaBarca ML, 2002, J IMMUNOL, V168, P6298, DOI 10.4049/jimmunol.168.12.6298
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2010, J BIOL CHEM, V285, P33826, DOI 10.1074/jbc.M110.153130
   BORLAND C, 1987, INT J EPIDEMIOL, V16, P31, DOI 10.1093/ije/16.1.31
   Capuron L, 2011, BIOL PSYCHIAT, V70, P175, DOI 10.1016/j.biopsych.2010.12.006
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dixelius J, 2004, J BIOL CHEM, V279, P23766, DOI 10.1074/jbc.M311675200
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Fett AL, 2012, HISTOL HISTOPATHOL, V27, P357, DOI 10.14670/HH-27.357
   Fremeaux-Bacchi V, 2007, AM J KIDNEY DIS, V49, P323, DOI 10.1053/j.ajkd.2006.10.022
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Liszewski MK, 1996, ADV IMMUNOL, V61, P201
   LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243
   Lyzogubov V, 2014, AM J PATHOL, V184, P2537, DOI 10.1016/j.ajpath.2014.06.001
   Maisner A, 1997, J BIOL CHEM, V272, P20793, DOI 10.1074/jbc.272.33.20793
   Maisner A, 1996, J BIOL CHEM, V271, P18853, DOI 10.1074/jbc.271.31.18853
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Paik DC, 2001, CONNECT TISSUE RES, V42, P111, DOI 10.3109/03008200109014253
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Richards A, 2007, MOL IMMUNOL, V44, P111, DOI 10.1016/j.molimm.2006.07.004
   Rohrer B, 2010, ADV EXP MED BIOL, V703, P137, DOI 10.1007/978-1-4419-5635-4_10
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   SEYA T, 1989, BIOCHEM J, V264, P581, DOI 10.1042/bj2640581
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Sun K, 2007, MOL VIS, V13, P2310
   Sweigard JH, 2011, GENE THER, V18, P613, DOI 10.1038/gt.2011.6
   Teuchert M, 1999, J BIOL CHEM, V274, P19979, DOI 10.1074/jbc.274.28.19979
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Tsou R, 2001, MOL CELL BIOCHEM, V224, P81, DOI 10.1023/A:1011947301849
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang Z, 2005, CURR EYE RES, V30, P691, DOI 10.1080/02713680590968259
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P416
NR 53
TC 11
Z9 11
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2015
VL 56
IS 8
BP 4231
EP 4238
DI 10.1167/iovs.15-16438
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT5WV
UT WOS:000362882700007
PM 26161984
OA Green Published
DA 2022-11-30
ER

PT J
AU Park, H
   Lee, DS
   Yim, MJ
   Choi, YH
   Park, S
   Seo, SK
   Choi, JS
   Jang, WH
   Yea, SS
   Park, WS
   Lee, CM
   Jung, WK
   Choi, IW
AF Park, Hongzoo
   Lee, Dae-Sung
   Yim, Mi-Jin
   Choi, Yung Hyun
   Park, Saegwang
   Seo, Su-Kil
   Choi, Jung Sik
   Jang, Won Hee
   Yea, Sung Su
   Park, Won Sun
   Lee, Chang-Min
   Jung, Won-Kyo
   Choi, Il-Whan
TI 3,3-Diindolylmethane inhibits VEGF expression through the HIF-1 and NF-B
   pathways in human retinal pigment epithelial cells under chemical
   hypoxic conditions
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE 3; 3-diindolylmethane; hypoxia; vascular endothelial growth factor;
   retinal pigment epithelial cells; choroidal neovas-cularization;
   age-related macular degeneration
ID INDUCIBLE FACTOR-I; HIF-1-ALPHA; GROWTH
AB Oxidative stress in the retinal pigment epithelium (RPE) can lead to the pathological causes of age-related macular degeneration (AMD). Hypoxia induces oxidative damage in retinal pigment epithelial cells (RPE cells). In this study, we investigated the capacity of 3,3-diindolyl-methane (DIM) to reduce the expression of vascular endothelial growth factor (VEGF) under hypoxic conditions, as well as the molecular mechanisms involved. Human RPE cells (ARPE-19 cells) were treated with cobalt chloride (CoCl2, 200 mu M) and/or DIM (10 and 20 mu M). The production of VEGF was measured by enzyme-linked immunosorbent assay. The trans-location of hypoxia-inducible factor-1 (HIF-1) and nuclear factor-B (NF-B) was determined by western blot analysis. The binding activity of HIF-1 and NF-B was analyzed by electrophoretic mobility shift assay. The phosphorylation levels of mitogen-activated protein kinases (MAPKs) were measured by western blot analysis. The levels of mitochondrial reactive oxygen species (ROS) were detected by fluorescence microplate assay. The results revealed that DIM significantly attenuated the CoCl2-induced expression of VEGF in the ARPE-19 cells. The CoCl2-induced translocation and activation of HIF-1 and NF-B were also attenuated by treatment with DIM. In addition, DIM inhibited the CoCl2-induced activation of p38 MAPK in the ARPE-19 cells. Pre-treatment with YCG063, a mitochondrial ROS inhibitor, led to the downregulation of the CoCl2-induced production of VEGF by suppressing HIF-1 and NF-B activity. Taken together, the findings of our study demonstrate that DIM inhibits the CoCl2-induced production of VEGF by suppressing mitochondrial ROS production, thus attenuating the activation of HIF-1 and p38 MAPK/NF-B.
C1 [Park, Hongzoo] Kangwon Natl Univ, Kangwon Natl Univ Hosp, Dept Urol, Chunchon, Gangwon Do, South Korea.
   [Lee, Dae-Sung; Yim, Mi-Jin] Marine Biodivers Inst Korea, Seocheon, Chungcheongnam, South Korea.
   [Choi, Yung Hyun] Dong Eui Univ, Dept Biochem, Coll Oriental Med, Busan, South Korea.
   [Park, Saegwang; Seo, Su-Kil; Choi, Il-Whan] Inje Univ, Dept Microbiol, Coll Med, Busan, South Korea.
   [Choi, Jung Sik] Inje Univ, Busan Paik Hosp, Dept Internal Med, Coll Med, Busan, South Korea.
   [Jang, Won Hee; Yea, Sung Su] Inje Univ, Dept Biochem, Coll Med, Busan, South Korea.
   [Park, Won Sun] Kangwon Natl Univ, Sch Med, Dept Physiol, Chunchon, Gangwon Do, South Korea.
   [Lee, Chang-Min] Warren Alpert Sch Med, Dept Mol Microbiol & Immunol, Providence, RI USA.
   [Jung, Won-Kyo] Pukyong Natl Univ, Dept Biomed Engn, Busan, South Korea.
   [Jung, Won-Kyo] Pukyong Natl Univ, Ctr Marine Integrated Biomed Technol Plus BK21, Busan, South Korea.
C3 Kangwon National University; Kangwon National University Hospital;
   Marine Biodiversity Institute of Korea (MABIK); Dong-Eui University;
   Inje University; Inje University; Inje University; Kangwon National
   University; Pukyong National University; Pukyong National University
RP Choi, IW (通讯作者)，Inje Univ, Coll Med, Dept Microbiol, 75 Bokji Ro, Busan 614735, South Korea.
EM wkjungng@pknu.ac.kr; cihima@inje.ac.kr
RI Jung, Won-Kyo/D-6824-2016
OI Jung, Won-Kyo/0000-0002-1615-750X; Choi, Jung Sik/0000-0002-4235-0522
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science and Technology [2013-R1A1A4A01011649]; Kangwon National
   University
FX This study was supported the Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education, Science and Technology (2013-R1A1A4A01011649). This study was
   also supported by the 2011 Research Grant from Kangwon National
   University.
CR Banerjee S, 2011, MUTAT RES-REV MUTAT, V728, P47, DOI 10.1016/j.mrrev.2011.06.001
   Brignall M S, 2001, Altern Med Rev, V6, P580
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cervellati F, 2014, FREE RADICAL RES, V48, P303, DOI 10.3109/10715762.2013.867484
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Fay J, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2102
   Guo M, 2006, APOPTOSIS, V11, P67, DOI 10.1007/s10495-005-3085-3
   Gupta B, 2013, FOOD CHEM, V141, P1841, DOI 10.1016/j.foodchem.2013.05.006
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029
   Kiriakidis S, 2003, J CELL SCI, V116, P665, DOI 10.1242/jcs.00286
   Kunimasa K, 2010, J NUTR, V140, P1, DOI 10.3945/jn.109.112359
   Lee SH, 2005, BIOCHEM BIOPH RES CO, V328, P63, DOI 10.1016/j.bbrc.2004.12.138
   Ratcliffe PJ, 2000, NAT MED, V6, P1315, DOI 10.1038/82113
   Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153
   Shertzer H G, 2000, Drug Metabol Drug Interact, V17, P159
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532
   Vadlapatla RK, 2014, EYE, V28, P93, DOI 10.1038/eye.2013.240
   Xia C, 2007, CANCER RES, V67, P10823, DOI 10.1158/0008-5472.CAN-07-0783
   Yang XM, 2009, INVEST OPHTH VIS SCI, V50, P1873, DOI 10.1167/iovs.08-2591
   Yu BC, 2013, LIFE SCI, V92, P282, DOI 10.1016/j.lfs.2012.12.011
NR 21
TC 22
Z9 22
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JUL
PY 2015
VL 36
IS 1
BP 301
EP 308
DI 10.3892/ijmm.2015.2202
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CN0WO
UT WOS:000358134900034
PM 25955241
OA Bronze
DA 2022-11-30
ER

PT J
AU Vertes, AA
AF Vertes, Alain A.
TI Deciphering the therapeutic stem cell strategies of large and midsize
   pharmaceutical firms
SO REGENERATIVE MEDICINE
LA English
DT Article
DE big pharma; cytotherapeutics; disruptive innovation; licensing and
   partnerships; midsize pharmaceutical firms; radical innovation; stem
   cells; technology adoption; technology deployment
ID CORD BLOOD ENGRAFTMENT; RADICAL INNOVATION; GERM-CELLS; TRANSPLANTATION;
   BUSINESS; HISTORY; LANDSCAPE; APPROVAL; SUCCESS; DISEASE
AB The slow adoption of cytotherapeutics remains a vexing hurdle given clinical progress achieved to date with a variety of stem cell lineages. Big and midsize pharmaceutical companies as an asset class still delay large-scale investments in this arena until technological and market risks will have been further reduced. Nonetheless, a handful of stem cell strategic alliance and licensing transactions have already been implemented, indicating that progress is actively monitored, although most of these involve midsize firms. The greatest difficulty is, perhaps, that the regenerative medicine industry is currently only approaching the point of inflexion of the technology development S-curve, as many more clinical trials read out. A path to accelerating technology adoption is to focus on innovation outliers among healthcare actors. These can be identified by analyzing systemic factors (e. g., national science policies and industry fragmentation) and intrinsic factors (corporate culture, e. g., nimble decision-making structures; corporate finance, e. g., opportunity costs and ownership structure; and operations, e. g., portfolio management strategies, threats on existing businesses and patent expirations). Another path is to accelerate the full clinical translation and commercialization of an allogeneic cytotherapeutic product in any indication to demonstrate the disease-modifying potential of the new products for treatment and prophylaxis, ideally for a large unmet medical need such as dry age-related macular degeneration, or for an orphan disease such as biologics-refractory acute graft-versus-host disease. In times of decreased industry average research productivities, regenerative medicine products provide important prospects for creating new franchises with a market potential that could very well mirror that achieved with the technology of monoclonal antibodies.
C1 [Vertes, Alain A.] London Business Sch, London, England.
   [Vertes, Alain A.] NxR Biotechnol GmbH, Basel, Switzerland.
C3 University of London; London Business School
RP Vertes, AA (通讯作者)，London Business Sch, London, England.
EM info@nxrbiotech.com
OI VERTES, Alain/0000-0003-0903-4082
FU Mesoblast; Targazyme; New Jersey-based Saint-Peter's University
FX AA Vertes discloses that, at the time of writing this manuscript, he
   held professional positions at Eli Lilly, Pfizer and, particularly,
   Roche, where he managed the strategic alliance between Roche and
   Alnylam, and initiated in 2007 and led until 2010 Roche's global
   therapeutic stem cell initiative. He holds active consultancies
   including in regenerative medicine and/or has financial involvement with
   Mesoblast, Targazyme (formerly America Stem Cell) and New Jersey-based
   Saint-Peter's University; he is also a member of CellCure's scientific
   and medical advisory board. The author has no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Aggarwal SR, 2014, NAT BIOTECHNOL, V32, P32, DOI 10.1038/nbt.2794
   Aldridge S, 2010, PHARMAFILE      0816
   Alsberg E, 2009, TISSUE ENG PT A, V15, P203, DOI 10.1089/ten.tea.2008.0633
   [Anonymous], 2010, NOVO NORDISK ANN REP
   [Anonymous], 2011, BIOJERUSALEM    0403
   [Anonymous], 2009, FUTURE MONOCLONAL AN
   [Anonymous], 2010, 2010 CEPHALON ANN RE
   [Anonymous], 2010, FIERCE BIOTECH  0409
   [Anonymous], 2012, MEDTRONIC ANN REPORT
   Anonymous, 2011, CELGENE ANN REPORT
   [Anonymous], 2000, CELL REPLACEMENT THE
   [Anonymous], 2013, BIOSPECTRUM     0401
   [Anonymous], 2009, FIERCE BIOTECH  1111
   [Anonymous], 2012, GENET ENG NEWS  0328
   [Anonymous], 2005, NOVO NORDISK ANN REP
   Assink M, 2006, EUR J INNOV MANAG, V9, P215, DOI 10.1108/14601060610663587
   Baron F, 2004, SPRINGER SEMIN IMMUN, V26, P71, DOI 10.1007/s00281-004-0165-3
   Baron F, 2010, BIOL BLOOD MARROW TR, V16, P838, DOI 10.1016/j.bbmt.2010.01.011
   Barton-Burke Margaret, 2008, Oncology (Williston Park), V22, P31
   Bayon Y, 2014, TISSUE ENG PART B-RE, V20, P243, DOI [10.1089/ten.teb.2012.0683, 10.1089/ten.TEB.2012.0683]
   Ben-David U, 2013, CELL STEM CELL, V12, P167, DOI 10.1016/j.stem.2012.11.015
   Bergman K, 2007, NAT BIOTECHNOL, V25, P419, DOI 10.1038/nbt0407-419
   Berkrot B, 2011, REUTERS
   Bird J, 2012, JAPAN PHARM PEER SET
   Bonner-Weir S, 2005, NAT BIOTECHNOL, V23, P857, DOI 10.1038/nbt1115
   Boregowda SV, 2013, MESENCHYMAL STROMAL, P145
   Bruneel J, 2012, TECHNOL ANAL STRATEG, V24, P951, DOI 10.1080/09537325.2012.718667
   Bull ND, 2011, STEM CELLS, V29, P1170, DOI 10.1002/stem.676
   Bushell-Embling D, 2013, AUSSIE STEM CELL FIR
   CAMBROSIO A, 1992, J HIST BIOL, V25, P175, DOI 10.1007/BF00162840
   Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0
   Carroll J, 2014, FIERCE BIOTECH  0106
   Castiaux A, 2007, J ENG TECHNOL MANAGE, V24, P36, DOI 10.1016/j.jengtecman.2007.01.003
   Christensen C.M., 1997, INNOVATORS DILEMMA N
   Christensen CM, 2008, HARVARD BUS REV, V86, P98
   Christopherson KW, 2007, STEM CELLS DEV, V16, P355, DOI 10.1089/scd.2007.9996
   Coffey P, 2009, REGEN MED, V4, P505, DOI 10.2217/RME.09.33
   Coutu DL, 2012, STEM CELLS BIOL REG, P35, DOI 10.1007/978-1-61779-471-1_4
   Crunkhorn S, 2012, NAT REV DRUG DISCOV, V11, P11, DOI 10.1038/nrd3633
   Culme-Seymour EJ, 2012, REGEN MED, V7, P455, DOI [10.2217/RME.12.45, 10.2217/rme.12.45]
   Cyranoski D, 2013, NAT MED, V19, P510, DOI 10.1038/nm0513-510
   Danneels E, 2004, J PROD INNOVAT MANAG, V21, P246, DOI 10.1111/j.0737-6782.2004.00076.x
   ETTLIE JE, 1984, MANAGE SCI, V30, P682, DOI 10.1287/mnsc.30.6.682
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Ewing Reese., 2011, REUTERS
   Gardner TA, 2012, HUM VACC IMMUNOTHER, V8, P534, DOI 10.4161/hv.19795
   Glassman RH, 2004, NAT REV DRUG DISCOV, V3, P177, DOI 10.1038/nrd1309
   Gluckman E, 2009, BONE MARROW TRANSPL, V44, P621, DOI 10.1038/bmt.2009.280
   Gratwohl A, 2012, CURR PROBL DERMATOL, V43, P81, DOI 10.1159/000335266
   Guo TX, 2009, ENDOCR REV, V30, P214, DOI 10.1210/er.2009-0004
   HAMEL G, 1991, HARVARD BUS REV, V69, P81
   Hamel G, 2010, GHOST POLITBURO
   Harding R., 2013, FINANCIAL TIMES
   Harrison C, 2011, NAT REV DRUG DISCOV, V10, P12, DOI 10.1038/nrd3356
   Haussecker D, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2011.9
   HENDERSON R, 1993, RAND J ECON, V24, P248, DOI 10.2307/2555761
   Herper M., 2011, FORBES
   Imamura M, 2010, MOL REPROD DEV, V77, P802, DOI 10.1002/mrd.21223
   Jack A, 2013, FINANCIAL TIMES
   Jenq RR, 2010, NAT REV CANCER, V10, P213, DOI 10.1038/nrc2804
   Jimenez J, 2012, HARVARD BUS REV, V90, P39
   Kessel M, 2011, NAT BIOTECHNOL, V29, P27, DOI 10.1038/nbt.1748
   Kobayashi A, 2008, DIS MANAG HEALTH OUT, V16, P217, DOI 10.2165/00115677-200816040-00003
   Konski AF, 2009, NAT BIOTECHNOL, V27, P722, DOI 10.1038/nbt0809-722
   Kresge N, 2011, BLOOMBERG
   Kunisato A, 2010, STEM CELLS DEV, V19, P229, DOI 10.1089/scd.2009.0149
   Lane J, 2013, BIOFUELS DIGEST 0313
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7
   Leifer R, 2001, ACAD MANAGE EXEC, V15, P102, DOI 10.5465/AME.2001.5229646
   Licata P, 2009, EL MUNDO        0424
   Linton JD, 2013, CREAT INNOV MANAG, V22, P10, DOI 10.1111/caim.12013
   Lou K-J, 2013, SCI BUS EXCH, V6, P1
   Mason C, 2011, REGEN MED, V6, P265, DOI [10.2217/RME.11.28, 10.2217/rme.11.28]
   Mason C, 2008, REGEN MED, V3, P1, DOI 10.2217/17460751.3.1.1
   Mason C, 2012, CELL STEM CELL, V11, P735, DOI 10.1016/j.stem.2012.11.013
   McGlynn M, 2013, FIERCE BIOTECH  0715
   McKernan R, 2010, CELL STEM CELL, V6, P517, DOI 10.1016/j.stem.2010.05.012
   Mimeault M, 2006, STEM CELLS, V24, P2319, DOI 10.1634/stemcells.2006-0066
   Mullin E, 2013, FIERCE BIOTECH  0710
   Mullin E, 2013, FIERCE BIOTECH  1118
   Nelson AL, 2010, NAT REV DRUG DISCOV, V9, P767, DOI 10.1038/nrd3229
   Netterwald J, 2009, GENET ENG BIOTECHN N, V29, P1
   Nuzzi R, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/946090
   O'Connor GC, 2004, J ENG TECHNOL MANAGE, V21, P11, DOI 10.1016/j.jengtecman.2003.12.002
   Palmer E, 2014, FIERCEPHARMA    0117
   Robinson SN, 2012, EXP HEMATOL, V40, P445, DOI 10.1016/j.exphem.2012.01.015
   Rossbach M, 2011, STEM CELLS BIOL REG, P91, DOI 10.1007/978-1-60761-959-8_9
   Sackstein R, 2012, EXP HEMATOL, V40, P518, DOI 10.1016/j.exphem.2012.03.004
   Schulze U, 2013, NAT REV DRUG DISCOV, V12, P419, DOI 10.1038/nrd4035
   Senior M, 2014, NAT BIOTECHNOL, V32, P501, DOI 10.1038/nbt0614-501
   Sheridan C, 2011, NAT BIOTECHNOL, V29, P121, DOI 10.1038/nbt.1769
   Staton T., 2013, FIERCE PHARMA   0509
   Stern JH, 2011, NEUROTHERAPEUTICS, V8, P736, DOI 10.1007/s13311-011-0077-6
   Stringer R, 2000, CALIF MANAGE REV, V42, P70, DOI 10.2307/41166054
   Taupin P, 2006, CURR OPIN INVEST DR, V7, P473
   Thomas ED, 1999, SEMIN HEMATOL, V36, P95
   Thompson K, 2013, CELL THERAPY CATAPUL
   Tirrell M, 2011, BUSINESS WEEK
   Toyooka Y, 2003, P NATL ACAD SCI USA, V100, P11457, DOI 10.1073/pnas.1932826100
   Tozer D, 2011, FUTURE MED, V6, P157
   Vanek PG, 2008, FUTURE MED, V3, P237
   Vertes AA, 2012, MEDNOUS          APR
   Vertes AA, 2009, CREATING EFFECTIVE C
   Vertes AA, 2010, MEDNOUS          JUL
   Vertes AA, 2012, REUTERS
   Vertes AA., 2012, CHALLENGES, V3, P70, DOI DOI 10.3390/CHALLE3020070
   Vertes AA, 2010, DELIVERY REGENERATIV, P153
   Vertes AA, 2009, PHAC CELL GEN THER F
   Vertes AA, 2011, REUTERS
   Vertes AA, 2006, NAT BIOTECHNOL, V24, P761, DOI 10.1038/nbt0706-761
   Villiger R, 2009, MABS-AUSTIN, V1, P172, DOI 10.4161/mabs.1.2.7638
   Vinas T, 2005, MEDTRONIC STAKES POS
   von Bonin M, 2009, BONE MARROW TRANSPL, V43, P245, DOI 10.1038/bmt.2008.316
   Yla-Herttuala S, 2012, MOL THER, V20, P1831, DOI 10.1038/mt.2012.194
NR 114
TC 8
Z9 8
U1 0
U2 25
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1746-0751
EI 1746-076X
J9 REGEN MED
JI Regen. Med.
PD JUL
PY 2014
VL 9
IS 4
BP 479
EP 495
DI 10.2217/RME.14.16
PG 17
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Cell Biology; Engineering
GA AO2XC
UT WOS:000341189500013
PM 25159065
DA 2022-11-30
ER

PT J
AU Huang, OS
   Zheng, YF
   Tay, WT
   Chiang, PPC
   Lamoureux, EL
   Wong, TY
AF Huang, Olivia S.
   Zheng, Yingfeng
   Tay, Wan Ting
   Chiang, Peggy Pei-Chia
   Lamoureux, Ecosse L.
   Wong, Tien Y.
TI Lack of Awareness of Common Eye Conditions in the Community
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Asia; awareness; epidemiology; eye diseases; public health
ID SINGAPORE MALAY EYE; OPEN-ANGLE GLAUCOMA; BLUE MOUNTAINS EYE;
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; SOUTHERN INDIA;
   VISUAL-ACUITY; POPULATION; PREVALENCE; DISEASES
AB Purpose: Awareness of eye conditions aids health promotion activities and leads to better outcomes. We examined factors influencing the lack of awareness of common eye conditions in a population.
   Methods: The Singapore Malay Eye Study examined 3280 (78.7% response) Malays aged 40-80 years. We included 2112 (64.4%) participants with at least one of five eye conditions: 1504 (71.2%) with cataract, 1013 (47.8%) with myopia, 270 (12.8%) with diabetic retinopathy, 181 (8.6%) with age-related macular degeneration and 150 (7.1%) with glaucoma. Lack of awareness was defined in the questionnaire as not answering "yes" to previously being told by a doctor of having the eye condition.
   Results: Among 2112 participants, 83.2% were unaware of at least one of their eye conditions. After controlling for age, sex and socioeconomic factors, participants unaware of their eye condition were older (odds ratio, OR, 1.03, per 1 year, p < 0.001), had better visual acuity (OR 1.32, p = 0.04), lower education (OR 1.89, p < 0.001), poorer literacy (OR 1.44, p = 0.02), lower income (OR 1.73, p = 0.009), higher blood glucose (OR 1.08, per 1 mmol/L, p < 0.001), higher serum cholesterol (OR 1.20, per 1 mmol/L, p = 0.003), lower annual eye examination attendance (OR 2.08, p < 0.001) and were less likely to wear glasses (OR 2.90, p < 0.001) than those who were aware of their condition.
   Conclusions: In this community-based population, 80% of those with common eye conditions were unaware of their condition.
C1 [Huang, Olivia S.; Zheng, Yingfeng; Tay, Wan Ting; Chiang, Peggy Pei-Chia; Lamoureux, Ecosse L.; Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Zheng, Yingfeng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China.
   [Lamoureux, Ecosse L.; Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
C3 National University of Singapore; Singapore National Eye Center; Sun Yat
   Sen University; Centre for Eye Research Australia; University of
   Melbourne; National University of Singapore
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore, Singapore.
EM ophwty@nus.edu.sg
RI Zheng, Yingfeng/AAE-2983-2022; Lamoureux, Ecosse/Z-5482-2019; Wong, Tien
   Yin/AAC-9724-2020; Zheng, Yingfeng/CAE-9225-2022
OI Wong, Tien Yin/0000-0002-8448-1264; Zheng, Yingfeng/0000-0002-0914-7864
FU Biomedical Research Council (BMRC), Singapore [08/1/35/19/550]; National
   Medical Research Council (NMRC), Singapore [StaR/0003/2008]
FX This study was funded by Biomedical Research Council (BMRC),
   08/1/35/19/550 & National Medical Research Council (NMRC),
   StaR/0003/2008, Singapore.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Attebo K, 1997, AUST NZ J OPHTHALMOL, V25, P283, DOI 10.1111/j.1442-9071.1997.tb01516.x
   Baker RS, 1998, OPHTHALMOLOGY, V105, P1373, DOI 10.1016/S0161-6420(98)98015-0
   Bylsma GW, 2004, CLIN EXP OPHTHALMOL, V32, P573, DOI 10.1111/j.1442-9071.2004.00905.x
   Dandona L, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-6
   Dandona R, 2001, B WORLD HEALTH ORGAN, V79, P96
   Foong AWP, 2008, OPHTHALMOLOGY, V115, P802, DOI 10.1016/j.ophtha.2007.04.066
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Hennis A, 2007, OPHTHALMOLOGY, V114, P1816, DOI 10.1016/j.ophtha.2007.06.013
   Huang OS, 2009, ANN ACAD MED SINGAP, V38, P1048
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Landers JA, 2002, CLIN EXP OPHTHALMOL, V30, P104, DOI 10.1046/j.1442-6404.2002.00493.x
   Lavanya R, 2009, BRIT J OPHTHALMOL, V93, P299, DOI 10.1136/bjo.2008.148650
   Lim LS, 2010, OPHTHALMOLOGY, V117, P524, DOI 10.1016/j.ophtha.2009.07.044
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   Muller A, 2006, CLIN EXP OPHTHALMOL, V34, P445, DOI 10.1111/j.1442-9071.2006.01234.x
   Ramakrishnan R, 2003, OPHTHALMOLOGY, V110, P1484, DOI 10.1016/S0161-6420(03)00564-5
   Sathyamangalam RV, 2009, INDIAN J OPHTHALMOL, V57, P355, DOI 10.4103/0301-4738.55073
   Shen SY, 2008, INVEST OPHTH VIS SCI, V49, P3846, DOI 10.1167/iovs.08-1759
   Topouzis F, 2008, AM J OPHTHALMOL, V145, P327, DOI 10.1016/j.ajo.2007.09.013
   Varma R, 2011, AM J OPHTHALMOL, V152, P515, DOI 10.1016/j.ajo.2011.06.004
   Weir E, 2004, CAN MED ASSOC J, V170, P463
   Wong TY, 2008, OPHTHALMOLOGY, V115, P1869, DOI 10.1016/j.ophtha.2008.05.014
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
NR 24
TC 27
Z9 28
U1 0
U2 11
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD FEB
PY 2013
VL 20
IS 1
BP 52
EP 60
DI 10.3109/09286586.2012.751429
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 077ZN
UT WOS:000314068000008
PM 23350556
DA 2022-11-30
ER

PT J
AU Popescu, ML
   Boisjoly, H
   Schmaltz, H
   Kergoat, MJ
   Rousseau, J
   Moghadaszadeh, S
   Djafari, F
   Freeman, EE
AF Popescu, Mihaela L.
   Boisjoly, Helene
   Schmaltz, Heidi
   Kergoat, Marie-Jeanne
   Rousseau, Jacqueline
   Moghadaszadeh, Solmaz
   Djafari, Fawzia
   Freeman, Ellen E.
TI Age-Related Eye Disease and Mobility Limitations in Older Adults
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID GERIATRIC DEPRESSION SCALE; OPEN-ANGLE GLAUCOMA; BLUE MOUNTAINS EYE;
   VISUAL-FIELD LOSS; BEAVER DAM EYE; MACULAR DEGENERATION; POSTURAL
   STABILITY; BENZODIAZEPINE USE; DRIVING CESSATION; SEE PROJECT
AB PURPOSE. To examine the extent of mobility limitations in patients with age-related macular degeneration (AMD), glaucoma, or Fuchs' corneal dystrophy compared with that in a control group of older adults with good vision.
   METHODS. Two hundred seventy-two patients (68 with AMD, 49 with Fuchs' dystrophy, 82 with glaucoma, and 73 controls) from the ophthalmology clinics of Maisonneuve-Rosemont Hospital (Montreal, Canada) participated in a cross-sectional study from September 2009 until February 2011. Control patients who had normal visual acuity and visual fields were recruited from the same clinics. Questionnaire (life space, falls, and driving) and performance-based (one-legged balance test, Timed Up and Go [TUG] test) mobility data were collected; visual acuity, contrast sensitivity, and visual field were measured; and the medical record was reviewed.
   RESULTS. The three eye diseases were associated with different patterns of mobility limitations. Patients with glaucoma had the most types of mobility limitations, as they had reduced life-space scores, had worse TUG scores, were less likely to drive, and were more likely to have poor balance than the control group (P < 0.05). Compared with the controls, patients with AMD and Fuchs' corneal dystrophy had reduced life-space scores and were less likely to drive (P < 0.05).
   CONCLUSIONS. The results suggest that eye diseases, especially glaucoma, restrain the mobility of older people in many different ways. It is important to further explore the impact of eye disease on mobility in this population, to develop interventions that could help affected older adults maintain their independence. (Invest Ophthalmol Vis Sci. 2011;52:7168-7174) DOI:10.1167/iovs.11-7564
C1 [Freeman, Ellen E.] Hop Maison Neuve Rosemont, CSA, RC, Ctr Rech, Montreal, PQ H1T 2M4, Canada.
   [Boisjoly, Helene; Djafari, Fawzia; Freeman, Ellen E.] Univ Montreal, Dept Ophthalmol, Quebec City, PQ, Canada.
   [Schmaltz, Heidi] Univ Calgary, Dept Geriatr Med, Calgary, AB, Canada.
   [Kergoat, Marie-Jeanne; Rousseau, Jacqueline] Inst Univ Geriatrie Montreal, Ctr Rech, Montreal, PQ, Canada.
C3 Universite de Montreal; Universite de Montreal; University of Calgary;
   Universite de Montreal
RP Freeman, EE (通讯作者)，Hop Maison Neuve Rosemont, CSA, RC, Ctr Rech, F131,5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.
EM eefreeman@gmail.com
OI Freeman, Ellen/0000-0002-1403-8427
FU CNIB, Toronto, ONT, Canada; Canadian Institutes of Health Research,
   Ottawa, ONT, Canada [IAP-98996]; Fonds de Recherche en Sante du Quebec;
   Fonds de recherche en ophtalmologie de l'Universite de Montreal
FX Supported by a CNIB New Investigator Grant, Toronto, ONT, Canada;
   Canadian Institutes of Health Research Grant IAP-98996, Ottawa, ONT,
   Canada; Fonds de Recherche en Sante du Quebec salary award (EEF); and a
   Fonds de recherche en ophtalmologie de l'Universite de Montreal salary
   award (MLP).
CR Almeida OP, 1999, INT J GERIATR PSYCH, V14, P858, DOI 10.1002/(SICI)1099-1166(199910)14:10<858::AID-GPS35>3.0.CO;2-8
   Anderson Andrew J, 2003, Ophthalmol Clin North Am, V16, P213, DOI 10.1016/S0896-1549(03)00011-7
   Auger C, 2009, DISABIL REHABIL-ASSI, V4, P31, DOI 10.1080/17483100802543064
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Baker PS, 2003, J AM GERIATR SOC, V51, P1610, DOI 10.1046/j.1532-5415.2003.51512.x
   Black Alex, 2005, Clin Exp Optom, V88, P212
   Black AA, 2008, OPTOMETRY VISION SCI, V85, P489, DOI 10.1097/OPX.0b013e31817882db
   BOURQUE P, 1990, CAN J AGING, V9, P348, DOI 10.1017/S0714980800007467
   Burke W J, 1991, J Geriatr Psychiatry Neurol, V4, P173, DOI 10.1177/089198879100400310
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   CAMPBELL MK, 1993, J GERONTOL, V48, pS230, DOI 10.1093/geronj/48.4.S230
   Cello KE, 2000, AM J OPHTHALMOL, V129, P314, DOI 10.1016/S0002-9394(99)00414-6
   Coleman AL, 2004, OPHTHALMOLOGY, V111, P857, DOI 10.1016/j.ophtha.2003.09.033
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   CUMMINGS SR, 1988, J AM GERIATR SOC, V36, P613, DOI 10.1111/j.1532-5415.1988.tb06155.x
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326
   Freeman EE, 2008, INVEST OPHTH VIS SCI, V49, P5257, DOI 10.1167/iovs.07-1106
   Friedman DS, 2007, OPHTHALMOLOGY, V114, P2232, DOI 10.1016/j.ophtha.2007.02.001
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gilhotra JS, 2001, CLIN EXP OPHTHALMOL, V29, P104, DOI 10.1046/j.1442-9071.2001.00411.x
   GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902
   Hassan SE, 2002, OPTOMETRY VISION SCI, V79, P697, DOI 10.1097/00006324-200211000-00007
   Haymes SA, 2007, INVEST OPHTH VIS SCI, V48, P1149, DOI 10.1167/iovs.06-0886
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Klein R, 2005, AM J OPHTHALMOL, V140, P129, DOI 10.1016/j.ajo.2004.12.049
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x
   Leveille SG, 2000, J GERONTOL B-PSYCHOL, V55, pS41
   Lord SR, 2000, GERONTOLOGY, V46, P306, DOI 10.1159/000022182
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Maxwell CJ, 1997, PHARMACOEPIDEM DR S, V6, P27, DOI 10.1002/(SICI)1099-1557(199701)6:1<27::AID-PDS240>3.0.CO;2-S
   McGwin G, 2004, INVEST OPHTH VIS SCI, V45, P3934, DOI 10.1167/iovs.04-0524
   Neutel CI, 1996, AGE AGEING, V25, P273, DOI 10.1093/ageing/25.4.273
   Newman AB, 2006, JAMA-J AM MED ASSOC, V295, P2018, DOI 10.1001/jama.295.17.2018
   PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x
   Ramulu PY, 2009, OPHTHALMOLOGY, V116, P1846, DOI 10.1016/j.ophtha.2009.03.033
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Shabana N, 2005, CLIN EXP OPHTHALMOL, V33, P264, DOI 10.1111/j.1442-9071.2005.01003.x
   SOROCK GS, 1988, ARCH INTERN MED, V148, P2441, DOI 10.1001/archinte.148.11.2441
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   SPAULDING SJ, 1994, OPTOMETRY VISION SCI, V71, P770, DOI 10.1097/00006324-199412000-00007
   SZLYK JP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1033, DOI 10.1001/archopht.1995.01100080085033
   Vellas BJ, 1997, J AM GERIATR SOC, V45, P735, DOI 10.1111/j.1532-5415.1997.tb01479.x
   WILTON K, 2010, MONTREAL GAZETT 0922
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   World Health Organization (WHO), OB OV
NR 50
TC 70
Z9 70
U1 1
U2 34
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2011
VL 52
IS 10
BP 7168
EP 7174
DI 10.1167/iovs.11-7564
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 827YU
UT WOS:000295467200017
PM 21862652
DA 2022-11-30
ER

PT J
AU Schmidt, CQ
   Slingsby, FC
   Richards, A
   Barlow, PN
AF Schmidt, Christoph Q.
   Slingsby, Fern C.
   Richards, Anna
   Barlow, Paul N.
TI Production of biologically active complement factor H in therapeutically
   useful quantities
SO PROTEIN EXPRESSION AND PURIFICATION
LA English
DT Article
DE Protein therapeutic; Age-related macular degeneration; Atypical
   haemolytic uraemic syndrome; Dense deposit disease; Synthetic gene
ID HEMOLYTIC-UREMIC SYNDROME; GLOMERULONEPHRITIS TYPE-II; POLYANION
   BINDING-SITE; DENSE DEPOSIT DISEASE; MACULAR DEGENERATION;
   MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; ALTERNATIVE PATHWAY;
   PICHIA-PASTORIS; PROTEIN BETA-1H; HETEROLOGOUS PROTEINS
AB Human complement factor H (FH), an abundant 155-kDa plasma glycoprotein with 40 disulphide bonds, regulates the alternative-pathway complement cascade. Mutations and single nucleotide polymorphisms in the FH gene predispose to development of age-related macular degeneration, atypical haemolytic uraemic syndrome and dense deposit disease. Supplementation with FH variants protective against disease is an enticing therapeutic prospect. Current sources of therapeutic FH are restricted to human blood plasma highlighting a need for recombinant material. Previously FH expression in cultured plant, mammalian or insect cells yielded protein amounts inadequate for full characterisation, and orders of magnitude below therapeutic usefulness. Here, the V62,Y402 variant of FH has been produced recombinantly (rFH) in Pichia pastoris cells. Codon-optimisation proved essential whilst exploitation of the yeast mating alpha-factor peptide ensured secretion. We thereby produced multiple 10s-of-milligram of rFH. Following endoglycosidase H digestion of N-linked glycans, rFH (with eight residual N-acetylglucosamine moieties) was purified on heparin-affinity resin and anion-exchange chromatography. Full-length rFH was verified by mass spectrometry and Western blot using monoclonal antibodies to the C-terminus. Recombinant FH is a single non-aggregated species (by dynamic light scattering) and fully functional in biochemical and biological assays. An additional version of rFH was produced in which eight N-glycosylation sequons were ablated by Asn-Gln substitutions resulting in a glycan-devoid product. Successful production of rFH in this potentially very highly expressing system makes production of therapeutically useful quantities economically viable. Furthermore, ease of genetic manipulation in P. pastoris would allow production of engineered FH versions with enhanced pharmacokinetic and pharmacodynamic properties. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Schmidt, Christoph Q.; Slingsby, Fern C.; Barlow, Paul N.] Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland.
   [Schmidt, Christoph Q.; Slingsby, Fern C.; Barlow, Paul N.] Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JJ, Midlothian, Scotland.
   [Richards, Anna] Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland.
C3 University of Edinburgh; University of Edinburgh; University of
   Edinburgh
RP Schmidt, CQ (通讯作者)，Joseph Black Chem Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.
EM cschmidt@staffmail.ed.ac.uk; Paul.Barlow@ed.ac.uk
RI Richards, Anna/E-8337-2013; Barlow, Paul N/G-2853-2011
FU Wellcome Trust [081179]; Chief Scientist's Office; Chief Scientist
   Office [CZB/4/763] Funding Source: researchfish
FX We thank Dr John White, Dr Bruce Ward and Ms Pamela Beattie and the
   staff of the Edinburgh Protein Production Facility for assistance with
   protein production and purification. We thank Dr Henry March of Celldex
   Therapeutics for the gift of sCR1. PNB, CQS and FCS are supported by
   grants from the Wellcome Trust (081179), and the Chief Scientist's
   Office; AR is a Wellcome Trust Intermediate Clinical Fellow.
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Buttner-Mainik A., 2010, PLANT BIOTE IN PRESS
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Carbone J, 2007, CURR DRUG SAF, V2, P9, DOI 10.2174/157488607779315480
   Cereghino GPL, 1999, CURR OPIN BIOTECH, V10, P422, DOI 10.1016/S0958-1669(99)00004-X
   d'Anjou MC, 2001, BIOTECHNOL BIOENG, V72, P1, DOI 10.1002/1097-0290(20010105)72:1<1::AID-BIT1>3.0.CO;2-T
   Daly R, 2005, J MOL RECOGNIT, V18, P119, DOI 10.1002/jmr.687
   Dragon-Durey MA, 2005, SPRINGER SEMIN IMMUN, V27, P359, DOI 10.1007/s00281-005-0003-2
   Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Eckart MR, 1996, CURR OPIN BIOTECH, V7, P525, DOI 10.1016/S0958-1669(96)80056-5
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fenaille F, 2007, GLYCOBIOLOGY, V17, P932, DOI 10.1093/glycob/cwm060
   Ferreira VP, 2006, J IMMUNOL, V177, P6308, DOI 10.4049/jimmunol.177.9.6308
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Fremeaux-Bacchi V, 2005, J MED GENET, V42, P852, DOI 10.1136/jmg.2005.030783
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Harris CL, 2005, J BIOL CHEM, V280, P2569, DOI 10.1074/jbc.M410179200
   Hartner FS, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-39
   Hocking HG, 2008, J BIOL CHEM, V283, P9475, DOI 10.1074/jbc.M709587200
   Hoots WK, 2001, TRANSFUS MED REV, V15, P3, DOI 10.1053/tm.2001.25377
   Huo XD, 2007, PROTEIN EXPRES PURIF, V54, P234, DOI 10.1016/j.pep.2007.03.016
   JANSEN JH, 1995, VET REC, V137, P240, DOI 10.1136/vr.137.10.240
   Jokiranta TS, 2006, EMBO J, V25, P1784, DOI 10.1038/sj.emboj.7601052
   Jokiranta TS, 2001, INT IMMUNOPHARMACOL, V1, P495, DOI 10.1016/S1567-5769(00)00042-4
   JOUVIN MH, 1984, J IMMUNOL, V133, P3250
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Kavanagh D, 2007, MOL IMMUNOL, V44, P3162, DOI 10.1016/j.molimm.2007.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KRISTENSEN T, 1986, P NATL ACAD SCI USA, V83, P3963, DOI 10.1073/pnas.83.11.3963
   KUHN S, 1995, J IMMUNOL, V155, P5663
   Lachmann P.J., 2010, ADV IMMUNOL, V104, P115
   Licht C, 2006, KIDNEY INT, V70, P42, DOI 10.1038/sj.ki.5000269
   Lorimer D, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-36
   MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982
   MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Moore I, 2010, BLOOD, V115, P379, DOI 10.1182/blood-2009-05-221549
   Murasugi Akira, 2010, Recent Pat Biotechnol, V4, P153
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Ramon R, 2007, J BIOTECHNOL, V130, P39, DOI 10.1016/j.jbiotec.2007.02.025
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6
   RIPOCHE J, 1986, BIOSCIENCE REP, V6, P65, DOI 10.1007/BF01145180
   Sahu A, 1998, J IMMUNOL, V160, P5596
   Sanchez-Corral P, 2004, MOL IMMUNOL, V41, P81, DOI 10.1016/j.molimm.2004.01.003
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Schmidt CQ, 2008, CLIN EXP IMMUNOL, V151, P14, DOI 10.1111/j.1365-2249.2007.03553.x
   Schmidt CQ, 2008, J IMMUNOL, V181, P2610, DOI 10.4049/jimmunol.181.4.2610
   Schmidt CQ, 2010, J MOL BIOL, V395, P105, DOI 10.1016/j.jmb.2009.10.010
   SHARMA AK, 1994, GENE, V143, P301, DOI 10.1016/0378-1119(94)90116-3
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285
   Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4
   Soares DC, 2005, STRUCTURAL BIOLOGY OF THE COMPLEMENT SYSTEM, P19
   Vervecken Wouter, 2007, V389, P119
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   Waters AM, 2011, PEDIATR NEPHROL, V26, P41, DOI 10.1007/s00467-010-1556-4
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Young TS, 2009, BIOCHEMISTRY-US, V48, P2643, DOI 10.1021/bi802178k
NR 73
TC 50
Z9 53
U1 0
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-5928
EI 1096-0279
J9 PROTEIN EXPRES PURIF
JI Protein Expr. Purif.
PD APR
PY 2011
VL 76
IS 2
BP 254
EP 263
DI 10.1016/j.pep.2010.12.002
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 716ID
UT WOS:000286961400014
PM 21146613
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kaiser, PK
AF Kaiser, Peter K.
CA Visudyne Occult CNV VIO Study Grp
TI Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a
   randomized trial
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization; Occult;
   Verteporfin
ID REPORT NO. 3; MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   PHOTODYNAMIC THERAPY; CLINICAL-TRIAL; TAP; COMBINATION; GUIDELINES;
   LESIONS
AB Objective: To determine whether verteporfin photodynamic therapy (PDT) can safely reduce the risk of vision loss in patients with subfoveal occult with no classic choroidal neovascularization (CNV) due to age-related macular degeneration.
   Research design and methods: Eligible patients were >= 50 years of age with lesion size <= 6 disc areas and best-corrected vision 20/40-20/200. A total of 364 patients with occult with no classic CNV were randomly assigned 2 : 1 to verteporfin PDT (n = 244) or placebo ( n 120). The primary outcome measures were loss of >= 15 and >= 30 letters of visual acuity (VA) from baseline at 12 and 24 months.
   Clinical trial registration: This study was registered with ClinicalTrials.gov on 20 July 2005. ClinicalTrials.gov identifier: NCT00121407.
   Results: A total of 37% and 47% of verteporfin-treated patients versus 45% and 53% of placebo recipients lost >= 15 letters of VA at month 12 and month 24, respectively; 16% and 23% of verteporfin-treated patients versus 17% and 25% of placebo recipients lost >= 30 letters at month 12 and month 24, respectively. These differences were not statistically significant. Four (1.6%) verteporfin-treated patients and one placebo patient (who received verteporfin in error) experienced an acute severe VA decrease; all five patients recovered some degree of vision. No unexpected ocular or systemic adverse events were identified.
   Conclusions: Verteporfin PDT in the treatment of occult with no classic CNV was safe and well-tolerated. The differences between the two groups in the primary efficacy variables were not significant. Baseline characteristics and patient selection methods may have contributed to the small treatment effect.
C1 [Kaiser, Peter K.; Visudyne Occult CNV VIO Study Grp] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,Desk I3, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Novartis Pharma AG and QLT Inc
FX This study was funded by Novartis Pharma AG and QLT Inc.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   Kaiser PK, 2005, CURR MED RES OPIN, V21, P705, DOI 10.1185/030079905X43659
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   *TAP VIP STUD GROU, 2004, RETINA, V24, P1
NR 12
TC 22
Z9 22
U1 0
U2 6
PU LIBRAPHARM/INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4 LQ, ENGLAND
SN 0300-7995
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD AUG
PY 2009
VL 25
IS 8
BP 1853
EP 1860
DI 10.1185/03007990903038616
PG 8
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 495YD
UT WOS:000269930800004
PM 19530976
DA 2022-11-30
ER

PT J
AU Hu, YT
   Zhang, TR
   Wu, JG
   Li, Y
   Lu, XR
   Qian, F
   Yin, ZQ
   Ma, ZZ
AF Hu, Yuntao
   Zhang, Taoran
   Wu, Jianguo
   Li, Ying
   Lu, Xinrong
   Qian, Fang
   Yin, Zhengqin
   Ma, Zhizhong
TI Autologous transplantation of RPE with partial-thickness choroid after
   mechanical debridement of Bruch membrane in the rabbit
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR TRANSLOCATION SURGERY;
   FIBROBLAST-GROWTH-FACTOR; ANTERIOR LENS CAPSULE; PHOTODYNAMIC THERAPY;
   SURGICAL REMOVAL; SHORT-TERM; PERIPHERAL RETINECTOMY; INTRAVITREAL
   INJECTION; BEVACIZUMAB AVASTIN
AB PURPOSE. An improved translocation technique for autologous retinal pigment epithelium ( RPE) transplantation is presented. The graft consists of a sheet of a partial-thickness choroid with RPE attached.
   METHODS. Twenty-seven pigmented rabbits were used in this study. After mechanical debridement of Bruch membrane,partialthickness RPE- choroid sheets were transplanted onto the subretinal space in 25 rabbits. The animals were examined by fundus photographs and fluorescein angiographs and were killed postoperatively at 1, 2, 4, 12, and 24 weeks. Eyecups containing the grafts were examined by light microscopy and immunohistochemistry. In addition, two partial-thickness RPE-choroid sheets were analyzed by transmission electron microscopy ( TEM).
   RESULTS. TEM revealed that the partial-thickness RPE- choroid graft consisted of retinal pigment epithelial cells, Bruch membrane, choriocapillaris, and ruptured middle vessels. The thickness of the graft was approximately 50 to 60 mu m. Fluorescein angiography revealed neither fluorescein leakage nor staining in the graft at early or late phase. Light microscopy revealed that in 17 experiments in which the graft survived, the neural retina remained intact; however, in eight experiments with unsuccessful grafts, the neural retina degenerated. The surviving graft showed revascularization and monolayered retinal pigment epithelial cells. Furthermore, in sections in which the neural retina over the graft remained intact, all retinal pigment epithelial cells in the graft and rhodopsin in photoreceptor outer segments were positively labeled with anticellular retinaldehy-debinding protein antibodies and anti-opsin antibodies, respectively.
   CONCLUSIONS. A partial-thickness RPE- choroid graft showed improved integration with the host choroid and photoreceptors. This technique has the potential to be a treatment for age-related macular degeneration.
C1 [Hu, Yuntao; Zhang, Taoran; Wu, Jianguo; Li, Ying; Lu, Xinrong; Qian, Fang; Ma, Zhizhong] Peking Univ, Ctr Eye, Hosp 3, Beijing 100083, Peoples R China.
   [Yin, Zhengqin] Third Mil Med Univ, SW Eye Hosp, Chongqing, Peoples R China.
C3 Peking University; Army Medical University
RP Ma, ZZ (通讯作者)，Peking Univ, Ctr Eye, Hosp 3, 49 N Garden Rd, Beijing 100083, Peoples R China.
EM puh3_yk@bjmu.edu.cn
RI Wu, Jian/AAU-5221-2020
OI Wu, Jian/0000-0001-9933-7364; hu, yuntao/0000-0003-2708-2547
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Aramant RB, 2002, EXP EYE RES, V75, P115, DOI 10.1006/exer.2002.2001
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BERGSTROM A, 1994, EXP EYE RES, V58, P301, DOI 10.1006/exer.1994.1021
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Buffenn AN, 2001, J AAPOS, V5, P388, DOI 10.1067/mpa.2001.120173
   BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   CAMPOCHIARO PA, 1993, EXP EYE RES, V57, P539, DOI 10.1006/exer.1993.1158
   COSCAS G, 1991, ARCH OPHTHALMOL-CHIC, V109, P1258, DOI 10.1001/archopht.1991.01080090082028
   Crafoord S, 2002, ACTA OPHTHALMOL SCAN, V80, P387, DOI 10.1034/j.1600-0420.2002.800408.x
   DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3
   Davis FA., 1929, T AM OPHTHAL SOC, V27, P401
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   Dintelmann TS, 1999, GRAEF ARCH CLIN EXP, V237, P830, DOI 10.1007/s004170050320
   Eckstein M, 1998, EYE, V12, P775, DOI 10.1038/eye.1998.201
   Fraunfelder FW, 2005, DRUG TODAY, V41, P703, DOI 10.1358/dot.2005.41.11.917340
   Freedman SF, 2003, AM J OPHTHALMOL, V136, P640, DOI 10.1016/S0002-9394(03)00334-9
   Fujii GY, 2000, AM J OPHTHALMOL, V130, P751, DOI 10.1016/S0002-9394(00)00771-6
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Geng LJ, 1999, EXP EYE RES, V69, P539, DOI 10.1006/exer.1999.0735
   GRIGNOLO A, 1966, EXP EYE RES, V5, P86, DOI 10.1016/S0014-4835(66)80024-6
   Grisanti S, 1997, INVEST OPHTH VIS SCI, V38, P1619
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   GUPTA BD, 1978, BIOPHYS STRUCT MECH, V4, P129, DOI 10.1007/BF00539227
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   HAGINS WA, 1972, ANNU REV BIOPHYS BIO, V1, P131, DOI 10.1146/annurev.bb.01.060172.001023
   Harding S, 2001, EYE, V15, P407, DOI 10.1038/eye.2001.145
   Harris A, 1999, PROG RETIN EYE RES, V18, P669
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   HEITZMANN H, 1972, NATURE-NEW BIOL, V235, P114, DOI 10.1038/newbio235114a0
   Holz FG, 2003, BIOMED TECH, V48, P82
   Ivert L, 2003, GRAEF ARCH CLIN EXP, V241, P656, DOI 10.1007/s00417-003-0653-5
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   KONDERDING MA, 2004, EXPER OPIN THER TAR, V8, P255
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lu LC, 2001, BIOMATERIALS, V22, P3345, DOI 10.1016/S0142-9612(01)00172-7
   Maaijwee KJM, 2007, BRIT J OPHTHALMOL, V91, P546, DOI 10.1136/bjo.2006.103259
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   MCKEEVER PJ, 1978, AM J VET RES, V39, P1706
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Ohno-Matsui K, 2005, MOL VIS, V11, P1
   OSTROY SE, 1977, BIOCHIM BIOPHYS ACTA, V463, P91, DOI 10.1016/0304-4173(77)90004-0
   Park CH, 2003, AM J OPHTHALMOL, V136, P830, DOI 10.1016/S0002-9394(03)00723-2
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Rechtman Ehud, 2002, Expert Opin Pharmacother, V3, P931, DOI 10.1517/14656566.3.7.931
   RIPPS H, 1969, J PHYSIOL-LONDON, V200, P151, DOI 10.1113/jphysiol.1969.sp008686
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3
   SAARI JC, 1982, J BIOL CHEM, V257, P13329
   Sakuragi M, 2001, CURR EYE RES, V23, P185, DOI 10.1076/ceyr.23.3.185.5465
   Schraermeyer U, 1999, INVEST OPHTH VIS SCI, V40, P1545
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Stanga Paulo E., 2001, International Ophthalmology, V23, P297, DOI 10.1023/A:1014482025960
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Stanzel BV, 2005, EXP EYE RES, V80, P103, DOI 10.1016/j.exer.2004.06.032
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   Thomson RC, 1996, BIOMATERIALS, V17, P321, DOI 10.1016/0142-9612(96)85570-0
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Wang H, 2004, EXP EYE RES, V78, P53, DOI 10.1016/j.exer.2003.09.024
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Wygnanski-Jaffe T, 2006, OPHTHAL SURG LAS IM, V37, P358, DOI 10.3928/15428877-20060901-01
   Yepez JB, 2003, OPHTHALMOLOGY, V110, P2262, DOI 10.1016/j.ophtha.2003.08.008
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
NR 92
TC 12
Z9 14
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2008
VL 49
IS 7
BP 3185
EP 3192
DI 10.1167/iovs.07-1299
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318WR
UT WOS:000257124000053
PM 18390637
DA 2022-11-30
ER

PT J
AU Gamm, DM
   Melvan, JN
   Shearer, RL
   Pinilla, I
   Sabat, G
   Svendsen, CN
   Wright, LS
AF Gamm, David M.
   Melvan, J. Nicholas
   Shearer, Rebecca L.
   Pinilla, Isabel
   Sabat, Grzegorz
   Svendsen, Clive N.
   Wright, Lynda S.
TI A novel serum-free method for culturing human prenatal retinal pigment
   epithelial cells
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HUMAN RPE CELLS; MACULAR DEGENERATION; CYSTATIN-C; BINDING-PROTEIN;
   GROWTH-FACTOR; AMYLOID-BETA; IN-VITRO; SUPPLEMENTED MEDIUM; PRECURSOR
   CELLS; TIGHT JUNCTIONS
AB PURPOSE. Established techniques for culturing primary human retinal pigment epithelial (RPE) cells have facilitated the laboratory investigation of this multipurpose retinal cell layer. However, most culture methods involve the use of animal serum to establish and maintain RPE monolayers, which can complicate efforts to define and study factors involved in the maturation and function of these cells. Therefore, this study was conducted to develop a simple, serum-free system to propagate and sustain human RPE in vitro.
   METHODS. RPE was dissected from human prenatal donor eyes and cultured in serum-free defined medium containing the commercially formulated supplement B27 or N2. Cultures were grown initially as adherent tissue sections or suspended spherical aggregates and later expanded and maintained as monolayers. PCR, Western blot analysis, and immunocytochemistry were used to monitor gene and protein expression in established cultures, followed by examination of secretory products in RPE conditioned medium by ELISA and mass spectrometric analysis.
   RESULTS. In medium supplemented with B27, but not N2, RPE could be expanded up to 40,000-fold over six passages and maintained in culture for more than 1 year. In long-term cultures, typical cellular morphology and pigmentation were observed, along with expression of characteristic RPE markers. RPE monolayers also retained proper apical-basal orientation and secreted multiple factors implicated in the maintenance of photoreceptor health and the pathogenesis of age-related macular degeneration.
   CONCLUSIONS. Monolayer cultures of human prenatal RPE can be grown and maintained long term in the total absence of serum and still retain the phenotype, gene and protein expression profile, and secretory capacity exhibited by mature RPE cells.
C1 [Gamm, David M.; Melvan, J. Nicholas; Shearer, Rebecca L.; Svendsen, Clive N.; Wright, Lynda S.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Waisman Ctr T607, Madison, WI 53705 USA.
   [Svendsen, Clive N.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Anat & Neurol, Madison, WI 53705 USA.
   [Sabat, Grzegorz] Univ Wisconsin, Sch Med & Publ Hlth, Genet Biotechnol Ctr, Madison, WI 53705 USA.
   [Pinilla, Isabel] Aragon Ciencias Salud, Zaragoza, Spain.
   [Pinilla, Isabel] Miguel Servet Univ Hosp, Dept Ophthalmol, Zaragoza, Spain.
   [Gamm, David M.; Melvan, J. Nicholas; Shearer, Rebecca L.; Svendsen, Clive N.; Wright, Lynda S.] Univ Wisconsin, Sch Med & Publ Hlth, Waisman Ctr, Madison, WI 53705 USA.
   [Gamm, David M.; Melvan, J. Nicholas; Shearer, Rebecca L.; Svendsen, Clive N.; Wright, Lynda S.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53705 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Miguel
   Servet University Hospital; University of Wisconsin System; University
   of Wisconsin Madison; University of Wisconsin System; University of
   Wisconsin Madison
RP Gamm, DM (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Waisman Ctr T607, 1500 Highland Ave, Madison, WI 53705 USA.
EM dgamm@wisc.edu
OI Pinilla, Isabel/0000-0003-0349-9997; Sabat, Grzegorz/0000-0001-7668-7767
FU NEI NIH HHS [K08 EY015138, K08 EY 015138] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [K08EY015138] Funding Source: NIH RePORTER
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Araki Y, 2004, J BIOL CHEM, V279, P24343, DOI 10.1074/jbc.M401925200
   Araki Y, 2003, J BIOL CHEM, V278, P49448, DOI 10.1074/jbc.M306024200
   Arndt CF, 2001, INVEST OPHTH VIS SCI, V42, P472
   ARONSON JF, 1983, IN VITRO CELL DEV B, V19, P642
   ARRINDELL EL, 1992, EXP CELL RES, V203, P192, DOI 10.1016/0014-4827(92)90055-D
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Behling KC, 2002, MOL VIS, V8, P449
   Beuckmann CT, 1996, J NEUROSCI, V16, P6119
   BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514
   BOULTON ME, 1982, BIRTH DEFECTS-ORIG, V18, P101
   BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513
   CAMPOCHIARO PA, 1991, INVEST OPHTH VIS SCI, V32, P65
   Chang CW, 1997, INVEST OPHTH VIS SCI, V38, P1082
   Chen L, 2003, MOL VIS, V9, P151
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DEPOMERAI DI, 1981, J EMBRYOL EXP MORPH, V62, P291
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   EDWARDS RB, 1982, METHOD ENZYMOL, V81, P39
   Engelmann K, 2004, GRAEF ARCH CLIN EXP, V242, P65, DOI 10.1007/s00417-003-0811-9
   Gabrielian K, 1999, GRAEF ARCH CLIN EXP, V237, P241, DOI 10.1007/s004170050225
   Gamm DM, 2005, ANN NY ACAD SCI, V1049, P107, DOI 10.1196/annals.1334.011
   GAUR VP, 1992, EXP EYE RES, V54, P645, DOI 10.1016/0014-4835(92)90020-S
   GOLDBERG AM, 1980, TOXICOLOGY, V17, P201, DOI 10.1016/0300-483X(80)90095-5
   Griffiths J B, 1987, Dev Biol Stand, V66, P155
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2004, MOL VIS, V10, P598
   HETH CA, 1987, CURR EYE RES, V6, P1007, DOI 10.3109/02713688709034872
   Hirase T, 1997, J CELL SCI, V110, P1603
   Hoppe G, 2004, BBA-MOL BASIS DIS, V1689, P33, DOI 10.1016/j.bbadis.2004.01.004
   Hu J, 2001, MOL VIS, V7, P14
   Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4
   Ishida K, 1997, CURR EYE RES, V16, P96, DOI 10.1076/ceyr.16.2.96.5093
   Ishida M, 1998, CURR EYE RES, V17, P392, DOI 10.1080/02713689808951220
   JAWOROWSKI A, 1995, BBA-GEN SUBJECTS, V1245, P121, DOI 10.1016/0304-4165(95)00079-Q
   Kanuga N, 2002, INVEST OPHTH VIS SCI, V43, P546
   Kaven C, 2000, CURR EYE RES, V20, P480, DOI 10.1076/0271-3683(200006)20:6;1-Y;FT480
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   KURIYAMA S, 1991, INVEST OPHTH VIS SCI, V32, P2882
   LAUBER JK, 1983, CURR EYE RES, V2, P863, DOI 10.3109/02713688209020023
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   McFarlane S, 2005, BRIT J OPHTHALMOL, V89, P107, DOI 10.1136/bjo.2004.045914
   MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   OKA MS, 1984, EXP CELL RES, V154, P537, DOI 10.1016/0014-4827(84)90178-2
   ONG DE, 1994, BIOCHEMISTRY-US, V33, P1835, DOI 10.1021/bi00173a029
   Paraoan L, 2003, EXP EYE RES, V76, P753, DOI 10.1016/S0014-4835(03)00061-7
   Paraoan L, 2000, INT J BIOCHEM CELL B, V32, P417, DOI 10.1016/S1357-2725(99)00143-0
   Pearson RA, 2005, NEURON, V46, P731, DOI 10.1016/j.neuron.2005.04.024
   Peng SM, 2003, INVEST OPHTH VIS SCI, V44, P808, DOI 10.1167/iovs.02-0473
   Pfeffer B, 2004, MOL VIS, V10, P23
   PFEFFER BA, 1986, INVEST OPHTH VIS SCI, V27, P1031
   Rahner C, 2004, J CELL SCI, V117, P3307, DOI 10.1242/jcs.01181
   Rakoczy PE, 1999, EXP EYE RES, V69, P367, DOI 10.1006/exer.1999.0700
   Rambhatla L, 2002, INVEST OPHTH VIS SCI, V43, P1622
   RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7
   Rezai KA, 1999, INVEST OPHTH VIS SCI, V40, P1223
   Rizzolo LJ, 2007, INT REV CYTOL, V258, P195, DOI 10.1016/S0074-7696(07)58004-6
   Schwegler J S, 1997, Mol Vis, V3, P10
   Shah G, 1999, Dev Biol Stand, V99, P17
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5
   SVENDSEN CN, 1995, EXP BRAIN RES, V102, P407
   Tezel TH, 1998, EXP EYE RES, V66, P807, DOI 10.1006/exer.1998.0492
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tian J, 2005, BRIT J OPHTHALMOL, V89, P1510, DOI 10.1136/bjo.2005.072108
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Topp KS, 1996, NEUROSCIENCE, V71, P1133, DOI 10.1016/0306-4522(95)00497-1
   TURKSEN K, 1989, OPHTHALMIC RES, V21, P56, DOI 10.1159/000266768
   VANDENBERG JJM, 1995, LIPIDS, V30, P599, DOI 10.1007/BF02536996
   Vassiliev V, 2005, BRAIN RES REV, V49, P633, DOI 10.1016/j.brainresrev.2005.03.003
   Wachs FP, 2003, LAB INVEST, V83, P949, DOI 10.1097/01.LAB.0000075556.74231.A5
   Wakasugi K, 2004, BIOCHEMISTRY-US, V43, P5119, DOI 10.1021/bi0495782
   Wasselius J, 2001, INVEST OPHTH VIS SCI, V42, P1901
   Williams CD, 1997, ANAT RECORD, V249, P380, DOI 10.1002/(SICI)1097-0185(199711)249:3<380::AID-AR9>3.0.CO;2-Y
   WONG HC, 1988, ARCH OPHTHALMOL-CHIC, V106, P1439
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zheng J, 1999, Yan Ke Xue Bao, V15, P187
   Zurdel J, 2002, BRIT J OPHTHALMOL, V86, P214, DOI 10.1136/bjo.86.2.214
NR 85
TC 56
Z9 62
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2008
VL 49
IS 2
BP 788
EP 799
DI 10.1167/iovs.07-0777
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 256RK
UT WOS:000252747100042
PM 18235029
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Yoshida, S
   Yashar, BM
   Hiriyanna, S
   Swaroop, A
AF Yoshida, S
   Yashar, BM
   Hiriyanna, S
   Swaroop, A
TI Microarray analysis of gene expression in the aging human retina
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ADULT HUMAN RETINA; CALORIC RESTRICTION; CDNA CLONES; PROFILE; ARRAYS;
   DISCOVERY; LIBRARY; NETWORK; BRAIN; MICE
AB PURPOSE. To develop gene expression profiles Of Noting and elderly human retinas and identify candidate genes for aging-associated retinal diseases.
   METHODS. Gene microarray slides containing 2400 human genes (primarily neuronal) were hybridized to biotin or dinitrophenyl (DNP)-labeled target cDNAs that were synthesized using total RNAs from young (13-14 years) and elderly (62-74 years) human retinas. Hybridization signals were visualized with cyanine (Cy)-5 or Cy-3 fluorescent reporter molecules. and the fluorescence intensities of the images were analyzed by computer. Northern blot analysis and real-time quantitative reverse transcription PCR (qRT-PCR) were performed to validate the microarray results.
   RESULTS. Of the 2400 genes represented on the microarray slides, more than 50% hybridized to the retinal cDNA targets. Expression of a majority of these genes was not altered during aging; nonetheless, changes in the expression of 24 genes were detected between young and elderly retinas. These genes could be clustered into four categories: energy metabolism, stress response, cell growth, and neuronal transmission/signaling. Northern blot analysis and qRT-PCR results confirmed the changes in expression of 8 of 10 genes examined.
   CONCLUSIONS. Using commercially available slide microarrays, the authors show that aging of the human retina is associated with changes in patterns of gene expression. This analysis suggests that pathways involved in stress response and energy metabolism play key roles in retinal aging. These studies demonstrate the utility of gene microarrays in identifying global patterns of retinal gene expression and lay the foundation for future studies defining the genetic basis of aging-associated retinal diseases, such as age-related macular degeneration.
C1 Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   Univ Michigan, WK Kellogg Eye Ctr, Dept Human Genet, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Swaroop, A (通讯作者)，Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
OI Swaroop, Anand/0000-0002-1975-1141; Yoshida, Shigeo/0000-0003-1049-8909;
   Yashar, Beverly M./0000-0003-0807-3258
FU NEI NIH HHS [EY07003, EY11115] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY011115] Funding Source: NIH RePORTER
CR Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Bernstein SL, 2000, INVEST OPHTH VIS SCI, V41, P2857
   Bortoluzzi S, 2000, INVEST OPHTH VIS SCI, V41, P3305
   Buraczynska M, 2002, INVEST OPHTH VIS SCI, V43, P603
   Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598
   Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Farjo R, 2002, VISION RES, V42, P463, DOI 10.1016/S0042-6989(01)00219-X
   GIESER L, 1992, GENOMICS, V13, P873, DOI 10.1016/0888-7543(92)90173-P
   Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700
   Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5
   Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/ng0501-21
   Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390
   Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046
   Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834
   Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447
   Livesey FJ, 2000, CURR BIOL, V10, P301, DOI 10.1016/S0960-9822(00)00379-1
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   Sandberg R, 2000, P NATL ACAD SCI USA, V97, P11038, DOI 10.1073/pnas.97.20.11038
   Schena M, 2000, MICROARRAY BIOCHIP TECHNOLOGY, P1
   Sinha S, 2000, INVEST OPHTH VIS SCI, V41, P24
   SISTERMANS EA, 1995, CELL TISSUE RES, V280, P435, DOI 10.1007/s004410050372
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tirschwell DL, 1997, NEUROLOGY, V48, P352, DOI 10.1212/WNL.48.2.352
   Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a
   Wang WH, 2001, MOL VIS, V7, P89
   Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2
   Yu JD, 2002, MOL VIS, V8, P130
   Zarrinkar PP, 2001, GENOME RES, V11, P1256, DOI 10.1101/gr.GR-1748R
NR 31
TC 88
Z9 99
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2002
VL 43
IS 8
BP 2554
EP 2560
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 577ZZ
UT WOS:000177094100007
PM 12147584
DA 2022-11-30
ER

PT J
AU Cousins, SW
   Machemer, R
   Kokame, GT
   Mettu, PS
   Waheed, NK
   Landa, G
AF Cousins, Scott W.
   Machemer, Robert
   Kokame, Gregg T.
   Mettu, Priyatham (Prithu) S.
   Waheed, Nadia Khalida
   Landa, Gennady
TI MANAGING ANTI-VEGF-RESISTANT NEOVASCULAR AMD: IS IT POLYPOIDAL CHOROIDAL
   VASCULOPATHY?
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
ID VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; RANIBIZUMAB;
   ASSOCIATION; COMBINATION; EFFICACY; SAFETY
C1 [Cousins, Scott W.] Duke Univ, Sch Med, Durham, NC 27708 USA.
   [Machemer, Robert] Duke Univ, Sch Med, Ophthalmol & Immunol, Durham, NC USA.
   [Machemer, Robert] Duke Univ, Sch Med, Res, Durham, NC USA.
   [Machemer, Robert] Duke Eye Ctr, Duke Ctr Macular Dis, Durham, NC USA.
   [Kokame, Gregg T.] Univ Hawaii Manoa, John A Burns Sch Med, Honolulu, HI 96822 USA.
   [Kokame, Gregg T.] Retina Ctr Pali Momi, Aiea, HI USA.
   [Mettu, Priyatham (Prithu) S.] Duke Univ, Sch Med, Duke Ctr Macular Dis, Duke Eye Ctr,Ophthalmol, Durham, NC USA.
   [Waheed, Nadia Khalida] Tufts Univ, Sch Med, Ophthalmol, Boston, MA 02111 USA.
   [Waheed, Nadia Khalida] Boston Image Reading Ctr, Boston, MA USA.
   [Landa, Gennady] Icahn Sch Med Mt Sinai, Ophthalmol, New York, NY 10029 USA.
   [Landa, Gennady] New York Eye & Ear Infirm Mt Sinai, Dept Ophthalmol, New York, NY USA.
   [Landa, Gennady] New York Eye & Ear Infirm Mt Sinai, Tribeca Off, New York, NY USA.
   [Landa, Gennady] New York Eye & Ear Infirm Mt Sinai, Williamsburg Off, New York, NY USA.
C3 Duke University; Duke University; Duke University; Duke University;
   University of Hawaii System; University of Hawaii Manoa; Duke
   University; Tufts University; Icahn School of Medicine at Mount Sinai;
   New York Eye & Ear Infirmary of Mount Sinai; New York Eye & Ear
   Infirmary of Mount Sinai; New York Eye & Ear Infirmary of Mount Sinai
RP Cousins, SW (通讯作者)，Duke Univ, Sch Med, Durham, NC 27708 USA.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   de Carlo TE, 2019, RETINA-J RET VIT DIS, V39, P1343, DOI 10.1097/IAE.0000000000002139
   Gallemore RP, 2017, CLIN OPHTHALMOL, V11, P223, DOI 10.2147/OPTH.S119510
   Hatz K, 2014, BRIT J OPHTHALMOL, V98, P188, DOI 10.1136/bjophthalmol-2013-303444
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame G., 2017, 50 ANN M RET SOC OCT
   Kokame GT, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0305-2
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2013, OPEN OPHTHALMOL J, V7, P79, DOI 10.2174/1874364101307010082
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nakata I, 2012, INVEST OPHTH VIS SCI, V53, P6576, DOI 10.1167/iovs.12-10219
   Nicholas, 2016, INVEST OPHTHALMOL VI, V57
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Qian TW, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12840
   Rebhun CB, 2018, OPHTHALMOL RETINA, V2, P306, DOI 10.1016/j.oret.2017.08.013
   Sarraf David, 2014, Trans Am Ophthalmol Soc, V112, P142
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Tso Mark O M, 2018, Am J Ophthalmol Case Rep, V11, P176, DOI 10.1016/j.ajoc.2017.10.012
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 1982, MAC SOC M FEBR 5 MIA
NR 31
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2019
VL 39
SU 1
BP 3
EP 11
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4ST
UT WOS:000480741500001
DA 2022-11-30
ER

PT J
AU Masahara, H
   Nakazawa, M
   Kawamura, E
   Eguchi, S
AF Masahara, Hidetaka
   Nakazawa, Mitsuru
   Kawamura, Eiji
   Eguchi, Shuichiro
TI Exclusion of Influences of ARMS2 Polymorphisms on the Central Visual
   Field in Retinitis Pigmentosa
SO OPHTHALMOLOGICA
LA English
DT Article
DE A69S; ARMS2 gene; Mean deviation slope; Polymorphism; Retinitis
   pigmentosa; Visual field
ID COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   MESSENGER-RNA; ONE FORM; RCS RAT; GENE; MUTATIONS; ASSOCIATION;
   LOC387715
AB Purpose: To investigate the effects of polymorphisms of the age-related maculopathy susceptibility 2 (ARMS2) gene on the central visual field defects in retinitis pigmentosa (RP). Subjects and Methods: The visual field was evaluated using the 10-2 Swedish Interactive Threshold Algorithm Fast Program and mean deviation (MD) slope, and regression coefficients of average sensitivity of the central 4 points (Cent4) were compared between each genetic subgroup. Results: The MD slope (right/left) was as follows: GG, -1.37 +/- 2.18/-0.89 +/- 1.15; GT, -0.56 +/- 1.40/-0.77 +/- 1.04; TT, -0.75 +/- 0.64/-0.38 +/- 0.92 dB/year. The Cent4 was as follows: GG, -1.34 +/- 2.37/-1.60 +/- 3.21; GT, -1.15 +/- 2.08/1.07 +/- 1.80; Ti, -1.20 +/- 0.91/-0.65 +/- 1.37 dB/year. No significant differences in the degree of progression were observed when comparing groups. Conclusions: These data suggest that polymorphisms of the ARMS2 do not modify the progression of the central field of vision in RP patients. (C) 2013 S. Karger AG, Basel
C1 [Masahara, Hidetaka; Nakazawa, Mitsuru; Kawamura, Eiji] Hirosaki Univ, Grad Sch Med, Dept Ophthalmol, Hirosaki, Aomori 0368562, Japan.
   [Masahara, Hidetaka; Eguchi, Shuichiro] Eguchi Eye Hosp, Hakodate, Hokkaido, Japan.
C3 Hirosaki University
RP Nakazawa, M (通讯作者)，Hirosaki Univ, Grad Sch Med, Dept Ophthalmol, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.
EM mitsuru@cc.hirosaki-u.ac.jp
RI Nakazawa, Mitsuru/ABI-7897-2020
OI Nakazawa, Mitsuru/0000-0001-6095-5712
FU Japan Society for the Promotion of Science [C-24592616]
FX We wish to thank Mr. Naoya Yamamoto and Miss Yukari Chiba for technical
   assistance. This study was supported by a Grant-in-Aid for Scientific
   Research (C-24592616) from the Japan Society for the Promotion of
   Science (to M.N.).
CR Abrera-Abeleda MA, 2006, J MED GENET, V43, P582, DOI 10.1136/jmg.2005.038315
   Bowne SJ, 2002, HUM MOL GENET, V11, P559, DOI 10.1093/hmg/11.5.559
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chakarova CF, 2002, HUM MOL GENET, V11, P87, DOI 10.1093/hmg/11.1.87
   CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dryja TP, 1999, INVEST OPHTH VIS SCI, V40, P1859
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0
   Ferrara DC, 2008, ARCH OPHTHALMOL-CHIC, V126, P1562, DOI 10.1001/archopht.126.11.1562
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fuse N, 2011, AM J OPHTHALMOL, V151, P550, DOI 10.1016/j.ajo.2010.08.048
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Grover S, 1997, OPHTHALMOLOGY, V104, P460, DOI 10.1016/S0161-6420(97)30291-7
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Heinen S, 2007, J AM SOC NEPHROL, V18, P506, DOI 10.1681/ASN.2006091069
   Hirakawa H, 1999, AM J OPHTHALMOL, V127, P436, DOI 10.1016/S0002-9394(98)00408-5
   Iijima H, 2012, JPN J OPHTHALMOL, V56, P224, DOI 10.1007/s10384-012-0135-6
   Jonsen A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3539
   KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   McKie AB, 2001, HUM MOL GENET, V10, P1555, DOI 10.1093/hmg/10.15.1555
   MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130
   Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35
   Nakazawa M, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/292040
   Oishi A, 2009, EYE, V23, P299, DOI 10.1038/sj.eye.6703077
   Oksjoki R, 2003, ARTERIOSCL THROM VAS, V23, P630, DOI 10.1161/01.ATV.0000057808.91263.A4
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Terasaki H, 2001, INVEST OPHTH VIS SCI, V42, P229
   Thompson IA, 2013, AM J OPHTHALMOL, V155, P1068, DOI 10.1016/j.ajo.2013.01.019
   Venturini G, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003040
   Vithana EN, 2001, MOL CELL, V8, P375, DOI 10.1016/S1097-2765(01)00305-7
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 42
TC 0
Z9 0
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 231
IS 1
BP 51
EP 57
DI 10.1159/000355093
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 278UJ
UT WOS:000328915100008
PM 24217333
OA Green Published
DA 2022-11-30
ER

PT J
AU Reeves, BC
   Harding, SP
   Langham, J
   Grieve, R
   Tomlin, K
   Walker, J
   Guerriero, C
   Carpenter, J
   Patton, WP
   Muldrew, KA
   Peto, T
   Chakravarthy, U
AF Reeves, B. C.
   Harding, S. P.
   Langham, J.
   Grieve, R.
   Tomlin, K.
   Walker, J.
   Guerriero, C.
   Carpenter, J.
   Patton, W. P.
   Muldrew, K. A.
   Peto, T.
   Chakravarthy, U.
TI Verteporfin photodynamic therapy for neovascular age-elated macular
   degeneration: cohort study for the UK
SO HEALTH TECHNOLOGY ASSESSMENT
LA English
DT Article
ID QUALITY-OF-LIFE; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VISUAL FUNCTION
   QUESTIONNAIRE; RANDOMIZED CLINICAL-TRIALS; LOW-VISION AIDS;
   COST-EFFECTIVENESS; CONTRAST SENSITIVITY; HEALTH-STATUS; UTILITY; TAP
AB Objectives: The verteporfin photodynamic therapy(VPDT) cohort study aimed to answer five questions: (a) Is VPDT in the NHS provided as in randomised trials?: (b) Is 'outcome' the same in the NHS as in randomised trials?: (c) Is 'utcome' the same for patients ineligible for randomised trials?: (d) Is VPDT safe when provided in the NHS?; and (e) How effective and cost-effective is VPDT?
   Design: Treatment register.
   Setting: All hospitals providing VPDT in the NHS.
   Participants: All patients attending VPDT clinics.
   Interventions: Infusion of verteporfin followed by infrared laser exposure is called VPDT, and is used to treat neovascular age-related macular degeneration (nAMD). The VPDT cohort study advised clinicians to follow patients every 3 months during treatment or active observation, retreating based on criteria used in the previous commercial 'TAP' (Treatment of Age-related macular degeneration with Photodynamic therapy) trials of VPDT.
   Main outcome measures: The primary outcome was logarithm of the minimum angle of resolution monocular best-corrected distance visual acuity (BCVA). Secondary outcomes were adverse reactions and events; morphological changes in treated nAMD (wet) lesions; and for a subset of patients, 6-monthly contrast sensitivity, generic and visual health-related quality of life (HRQoL) and resource use. Treated eyes were classified as eligible for the TAP trials (EFT), ineligible (IFT) or unclassifiable (UNC).
   Results: Forty-seven hospitals submitted data for 8323 treated eyes in 7748 patients; 4919 eyes in 4566 patients were treated more than 1 year before the last data submission or had completed treatment. Of 4043 eyes with nAMD in 4043 patients, 1227 were classified as EFT, 1187 as IFT and 1629 as UNC. HRQoL and resource use data were available for about 2000 patients. The mean number of treatments in years 1 and 2 was 2.3 and 0.4 respectively. About 50% of eyes completed treatment within 1 year. BCVA deterioration in year 1 did not differ between eligibility groups. EFT eyes lost 11.6 letters (95% confidence interval 10.1 to 13.0 letters) compared with 9.9 letters in VPDT-treated eyes in the TAP trials. EFT eyes had poorer BCVA at baseline than IFT and UNC eyes. Adverse reactions and events were reported for 1.4% of first visits - less frequently than those reported in the TAP trials. Associations between BCVA in the best-seeing eye with HRQoL and community health and social care resource use showed that the 11-letter difference in BCVA between VPDT and sham treatment in the TAP trials corresponded to differences in utility of 0.012 and health and social service costs of (sic)60 and (sic)92 in years 1 and 2, respectively. VPDT provided an incremental cost per quality-adjusted life-year (QALY) of (sic)170,000 over 2 years.
   Conclusions: VPDT was administered less frequently than in the TAP trials, with less than half of those treated followed up for >1 year in routine clinical practice. Deterioration in BCVA over time in EFT eyes was similar to that in the TAP trials. The similar falls in BCVA after VPDT across the pre-defined TAP eligibility groups do not mean that the treatment is equally effective in these groups because deterioration in BCVA can be influenced by the parameters that determined group membership. Safety was no worse than in the TAP trials. The estimated cost per QALY was similar to the highest previous estimate. Although VPDT is no longer in use as monotherapy for neovascular AMD, its role as adjunctive treatment has not been fully explored. VPDT also has potential as monotherapy in the management of vascular malformations of the retina and choroid and with trials underway in neovascularisation due to myopia and polypoidal choroidopathy.
C1 [Chakravarthy, U.] Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Reeves, B. C.; Langham, J.; Grieve, R.; Tomlin, K.; Walker, J.; Guerriero, C.; Carpenter, J.] London Sch Hyg & Trop Med, London WC1, England.
   [Harding, S. P.] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool, Merseyside, England.
   [Patton, W. P.; Muldrew, K. A.; Peto, T.] Moorfields Eye Hosp NHS Trust, London, England.
C3 Queens University Belfast; University of London; London School of
   Hygiene & Tropical Medicine; Royal Liverpool & Broadgreen University
   Hospitals NHS Trust; Royal Liverpool University Hospital; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Belfast, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381; Harding, Simon/0000-0003-4676-1158;
   Chakravarthy, Usha/0000-0002-2606-3734; Carpenter,
   James/0000-0003-3890-6206; Grieve, Richard/0000-0001-8899-1301
FU National Institute for Health Research Health Technology Assessment;
   National Institute for Health Research [03/36/01] Funding Source:
   researchfish
FX The National Institute for Health Research Health Technology Assessment
   programme.
CR Ali F, 2004, ARCH OPHTHALMOL-CHIC, V122, P710, DOI 10.1001/archopht.122.5.710
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Azab M, 2004, RETINA-J RET VIT DIS, V24, P1
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BARNES RM, 2004, OUTCOMES VERTEPORFIN
   Birchall W, 1999, BMJ-BRIT MED J, V319, P707
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bradley C, 2001, LANCET, V357, P7, DOI 10.1016/S0140-6736(00)03562-5
   Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8
   Brazier J, 2004, HEALTH ECON, V13, P873, DOI 10.1002/hec.866
   BRAZIER J, 2007, MEASURING VALUING HL, P7
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   [British Medical Association Royal Pharmaceutical Society of Great Britain], 2009, BRIT NAT FORM
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Browne J, 2007, PATIENT REPORTED OUT
   Browne JP, 2006, LARYNGOSCOPE, V116, P297, DOI 10.1097/01.mlg.0000198338.05826.18
   Buggage RR, 1999, ARCH OPHTHALMOL-CHIC, V117, P1239
   Chakravarthy Usha, 2005, Curr Opin Ophthalmol, V16, P179, DOI 10.1097/01.icu.0000163035.37957.c2
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Colquitt JL, 2008, HLTH TECHNOL ASSESS, V12
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   CURTIS L, 2008, UNIT COSTS HLTH SOCI, P35
   Deeks JJ, 2003, HLTH TECHNOL ASSESS, V7
   *DEP HLTH, 2002, NHS REF COSTS 2002 A, P136
   DepartmentofHealth(UK), 2009, GUID ROUT COLL PAT R
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205
   El Mallah MK, 2000, BRIT J OPHTHALMOL, V84, P952, DOI 10.1136/bjo.84.9.952
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   EuroQol Group, 1990, HLTH POLICY, V16, P119
   Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006
   Fletcher EC, 2008, OPHTHALMOLOGY, V115, P2192, DOI 10.1016/j.ophtha.2008.07.018
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   Gold M.R., 1996, COST EFFECTIVENESS H, P82
   Greiner R A, 2001, Semin Ophthalmol, V16, P218, DOI 10.1076/soph.16.4.218.10302
   Grieve R, 2009, OPHTHALMOLOGY, V116, P2471, DOI 10.1016/j.ophtha.2009.10.023
   Griffin SC, 2007, BMJ-BRIT MED J, V334, P624, DOI 10.1136/bmj.39129.442164.55
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Harding S, 2001, EYE, V15, P407, DOI 10.1038/eye.2001.145
   Harding Simon P, 2009, Ophthalmology, V116, pe1, DOI 10.1016/j.ophtha.2009.10.022
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hendy J, 2007, BRIT MED J, V334, P1360, DOI 10.1136/bmj.39195.598461.551
   *HLTH UT INC, 2008, HLTH UT IND MARK 3
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Keam SJ, 2004, DRUG AGING, V21, P203, DOI 10.2165/00002512-200421030-00005
   Keam SJ, 2003, DRUGS, V63, P2521, DOI 10.2165/00003495-200363220-00016
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Langham J, 2009, STROKE, V40, P111, DOI 10.1161/STROKEAHA.108.517805
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Machin D, 1997, SAMPLE SIZE TABLES C
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MANGIONE CM, 2001, ARCH OPHTHA IN PRESS
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Margrain TH, 1999, BRIT MED J, V318, P1504, DOI 10.1136/bmj.318.7197.1504
   Meads C, 2004, BRIT J OPHTHALMOL, V88, P212, DOI 10.1136/bjo.2003.019471
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   MEADS C, 2003, HLTH TECHNOL ASSESS, V7
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Mullahy J, 1998, J HEALTH ECON, V17, P247, DOI 10.1016/S0167-6296(98)00030-7
   *NAT I CLIN EXC, 2008, UPD GUID METH TECHN
   *NAT I CLIN EXC, 2003, CLIN EFF COST EFF PH
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Reeves BC, 2009, OPHTHALMOLOGY, V116, P2463, DOI 10.1016/j.ophtha.2009.10.031
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32
   Sharma S, 2001, CAN J OPHTHALMOL, V36, P332, DOI 10.1016/S0008-4182(01)80120-4
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smiddy WE, 2007, OPHTHALMOLOGY, V114, P847, DOI 10.1016/j.ophtha.2006.10.038
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stelmack J, 2001, OPTOMETRY VISION SCI, V78, P335, DOI 10.1097/00006324-200105000-00017
   Stevens KJ, 2006, HEALTH ECON, V15, P527, DOI 10.1002/hec.1076
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   STIRLING B, 2009, HLTH EC POL LAW, V4, P425
   SWETS JA, 1961, PSYCHOL REV, V68, P301, DOI 10.1037/h0040547
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1016/j.jclinepi.2008.12.011, 10.1503/cmaj.090523]
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   WHO World Health Organization, 2006, CONST WHO BAS DOC S
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Wright SE, 2000, CLIN EXP OPHTHALMOL, V28, P140, DOI 10.1046/j.1442-9071.2000.00296.x
   [No title captured]
NR 103
TC 11
Z9 12
U1 0
U2 12
PU NIHR JOURNALS LIBRARY
PI SOUTHAMPTON
PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE,
   ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND
SN 1366-5278
EI 2046-4924
J9 HEALTH TECHNOL ASSES
JI Health Technol. Assess.
PD FEB
PY 2012
VL 16
IS 6
BP 1
EP +
DI 10.3310/hta16060
PG 187
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA 920WL
UT WOS:000302439300001
PM 22348600
OA gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Nordestgaard, LT
   Christoffersen, M
   Lauridsen, BK
   Afzal, S
   Nordestgaard, BG
   Frikke-Schmidt, R
   Tybjorg-Hansen, A
AF Nordestgaard, Liv Tybjaerg
   Christoffersen, Mette
   Lauridsen, Bo Kobbero
   Afzal, Shoaib
   Nordestgaard, Borge Gronne
   Frikke-Schmidt, Ruth
   Tybjorg-Hansen, Anne
TI Long-term Benefits and Harms Associated With Genetic Cholesteryl Ester
   Transfer Protein Deficiency in the General Population
SO JAMA CARDIOLOGY
LA English
DT Article
ID ISCHEMIC VASCULAR-DISEASE; MACULAR DEGENERATION; HDL-CHOLESTEROL;
   HIGH-RISK; CETP; VARIANTS; INHIBITION; RARE; MORTALITY; NPC1L1
AB This cohort study assesses the relative benefits and harms associated with genetic cholesteryl ester transfer protein deficiency.
   Question What is the balance between the long-term clinical benefits and harms associated with genetic cholesteryl ester transfer protein (CETP) deficiency?
   Findings This cohort study of the Danish general population found that genetic CETP deficiency was associated with lower risk of cardiovascular morbidity and mortality but higher risk of age-related macular degeneration (AMD). The lower risk of cardiovascular end points was associated with genetically lower levels of non-high density lipoprotein (HDL) cholesterol, while the higher risk of AMD was associated with genetically higher levels of HDL cholesterol.
   Meaning Despite a beneficial association between genetic CETP deficiency and cardiovascular outcomes, the increased risk of AMD may call into question the use of pharmacologic CETP inhibitors.
   IMPORTANCE The balance between the potential long-term clinical benefits and harms associated with genetic cholesteryl ester transfer protein (CETP) deficiency, mimicking pharmacologic CETP inhibition, is unknown.
   OBJECTIVE To assess the relative benefits and harms associated with genetic CETP deficiency.
   DESIGN, SETTING, AND PARTICIPANTS This study examined 2 similar prospective cohorts of the Danish general population, with data on a total of 102 607 participants collected from October 10, 1991, through December 7, 2018.
   EXPOSURES Weighted CETP allele scores.
   MAIN OUTCOMES AND MEASURES Incident cardiovascular mortality, ischemic heart disease, myocardial infarction, ischemic stroke, peripheral arterial disease, vascular dementia, Alzheimer disease, all-cause mortality, and age-related macular degeneration (AMD). The study first tested whether a CETP allele score was associated with morbidity and mortality, when scaled to genetically lower levels of non-high-density lipoprotein (HDL) cholesterol (ie, 17 mg/dL), corresponding to the reduction observed for anacetrapib vs placebo in the Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification (REVEAL) trial. Second, the study assessed how much of the change in morbidity and mortality was associated with genetically lower levels of non-HDL cholesterol. Finally, the balance between the potential long-term clinical benefits and harms associated with genetic CETP deficiency was quantified. For AMD, the analyses also included higher levels of HDL cholesterol associated with genetic CETP deficiency.
   RESULTS Of 102 607 individuals in the study, 56 559 (55%) were women (median age, 58 years [IQR, 47-67 years]). Multivariable adjusted hazard ratios showed that a genetically lower level of non-HDL cholesterol (ie, 17 mg/dL) was associated with a lower risk of cardiovascular mortality (hazard ratio [HR], 0.77 [95% CI, 0.62-0.95]), ischemic heart disease (HR, 0.80 [95% CI, 0.68-0.95]), myocardial infarction (HR, 0.72 [95% CI, 0.55-0.93]), peripheral arterial disease (HR, 0.80 [95% CI, 0.63-1.02]), and vascular dementia (HR, 0.38 [95% CI, 0.18-0.80]) and an increased risk of AMD (HR, 2.33 [95% CI, 1.63-3.30]) but was not associated with all-cause mortality (HR, 0.91 [95% CI, 0.81-1.02]), ischemic stroke (HR, 1.05 [95% CI, 0.81-1.36]), or Alzheimer disease (HR, 1.25 [95% CI, 0.89-1.76]). When scaled to a higher level of HDL cholesterol, the increased risk of AMD was even larger. A considerable fraction of the lower risk of cardiovascular end points was associated with genetically lower levels of non-HDL cholesterol, while the higher risk of AMD was associated with genetically higher levels of HDL cholesterol. Per 1 million person-years, the projected 1916 more AMD events associated with genetically higher levels of HDL cholesterol was similar to the 1962 fewer events of cardiovascular mortality and myocardial infarction combined associated with genetically lower levels of non-HDL cholesterol.
   CONCLUSIONS AND RELEVANCE This study suggests that genetic CETP deficiency, mimicking pharmacologic CETP inhibition, was associated with a lower risk of cardiovascular morbidity and mortality, but with a markedly higher risk of AMD.
C1 [Nordestgaard, Liv Tybjaerg; Christoffersen, Mette; Lauridsen, Bo Kobbero; Frikke-Schmidt, Ruth; Tybjorg-Hansen, Anne] Copenhagen Univ Hosp, Rigshosp, Dept Clin Biochem, Copenhagen, Denmark.
   [Nordestgaard, Liv Tybjaerg; Afzal, Shoaib; Nordestgaard, Borge Gronne; Frikke-Schmidt, Ruth; Tybjorg-Hansen, Anne] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark.
   [Lauridsen, Bo Kobbero] Copenhagen Univ Hosp, Rigshosp, Dept Cardiol, Copenhagen, Denmark.
   [Afzal, Shoaib; Nordestgaard, Borge Gronne] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Dept Clin Biochem, Copenhagen, Denmark.
   [Afzal, Shoaib; Nordestgaard, Borge Gronne; Frikke-Schmidt, Ruth; Tybjorg-Hansen, Anne] Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Dept Clin Biochem, Copenhagen Gen Populat Study, Copenhagen, Denmark.
   [Nordestgaard, Borge Gronne; Tybjorg-Hansen, Anne] Copenhagen Univ Hosp, Bispebjerg & Frederiksberg Hosp, Copenhagen City Heart Study, Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   Rigshospitalet; University of Copenhagen; University of Copenhagen;
   University of Copenhagen; University of Copenhagen; Bispebjerg Hospital
RP Tybjorg-Hansen, A (通讯作者)，Rigshosp, Dept Clin Biochem, Sect Mol Genet, Blegdamsvej 9, DK-2100 Copenhagen C, Denmark.
EM anne.tybjaerg.hansen@regionh.dk
RI Christoffersen, Mette/AFE-8953-2022; Afzal, Shoaib/B-6763-2012
OI Afzal, Shoaib/0000-0002-1442-4694; Tybjaerg Nordestgaard,
   Liv/0000-0002-5490-0034; Nordestgaard, Borge/0000-0002-1954-7220
FU Research Council at Rigshospitalet
FX Funded by the Research Council at Rigshospitalet.
CR Armitage J, 2019, J AM COLL CARDIOL, V73, P477, DOI 10.1016/j.jacc.2018.10.072
   Bandesh K, 2019, J HUM GENET, V64, P573, DOI 10.1038/s10038-019-0591-7
   Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628
   Barter PJ, 2003, ARTERIOSCL THROM VAS, V23, P160, DOI 10.1161/01.ATV.0000054658.91146.64
   Benn M, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1648
   Blauw LL, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.117.002034
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cohen JC, 2006, P NATL ACAD SCI USA, V103, P1810, DOI 10.1073/pnas.0508483103
   Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   EU Clinical Trials Register, CLIN TRIALS TA 8995
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Ference BA, 2017, JAMA-J AM MED ASSOC, V318, P947, DOI 10.1001/jama.2017.11467
   Frikke-Schmidt R, 2004, J CLIN INVEST, V114, P1343, DOI 10.1172/JCI200420361
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gotto AM, 2014, J CARDIOVASC PHARM T, V19, P543, DOI 10.1177/1074248414529621
   Haase CL, 2011, J INTERN MED, V270, P136, DOI 10.1111/j.1365-2796.2011.02381.x
   Haase CL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003063
   Haase CL, 2010, J CLIN ENDOCR METAB, V95, pE500, DOI 10.1210/jc.2010-0450
   Harrison SC, 2018, JAMA CARDIOL, V3, P26, DOI 10.1001/jamacardio.2017.4293
   Hovingh GK, 2015, LANCET, V386, P452, DOI 10.1016/S0140-6736(15)60158-1
   HPS3 TIMI55-REVEAl Collaborative, 2017, NEW ENGL J MED, V377, P1217, DOI 10.1056/NEJMoa1706444
   Johannsen TH, 2012, J AM COLL CARDIOL, V60, P2041, DOI 10.1016/j.jacc.2012.07.045
   Lauridsen BK, 2015, EUR HEART J, V36, P1601, DOI 10.1093/eurheartj/ehv108
   Lincoff AM, 2017, NEW ENGL J MED, V376, P1933, DOI 10.1056/NEJMoa1609581
   Liutkeviciene R, 2017, GENE, V636, P30, DOI 10.1016/j.gene.2017.09.022
   Millwood IY, 2018, JAMA CARDIOL, V3, P34, DOI 10.1001/jamacardio.2017.4177
   Momozawa Y, 2016, HUM MOL GENET, V25, P5027, DOI 10.1093/hmg/ddw335
   Nicholls SJ, 2020, EXPERT REV CARDIOVAS, V18, P127, DOI 10.1080/14779072.2020.1745633
   Nomura A, 2017, CIRC RES, V121, P81, DOI 10.1161/CIRCRESAHA.117.311145
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797
   Tall AR, 2018, CIRC RES, V122, P106, DOI 10.1161/CIRCRESAHA.117.311978
   Tang CS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10206
   Thompson A, 2008, JAMA-J AM MED ASSOC, V299, P2777, DOI 10.1001/jama.299.23.2777
   Wang YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep15711
   Winkler TW, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-00760-7
   [Anonymous], 2000, JAMA, V284, P3043, DOI 10.1001/jama.2013.281053
NR 40
TC 12
Z9 12
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2380-6583
EI 2380-6591
J9 JAMA CARDIOL
JI JAMA Cardiol.
PD JAN
PY 2022
VL 7
IS 1
BP 55
EP 64
DI 10.1001/jamacardio.2021.3728
EA OCT 2021
PG 10
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA YG3TP
UT WOS:000704806300008
PM 34613338
OA Green Published
DA 2022-11-30
ER

PT J
AU Qu, JF
   Velaga, SB
   Hariri, AH
   Nittala, MG
   Sadda, S
AF Qu, Jinfeng
   Velaga, Swetha Bindu
   Hariri, Amir H.
   Nittala, Muneeswar Gupta
   Sadda, Srinivas
TI CLASSIFICATION AND QUANTITATIVE ANALYSIS OF GEOGRAPHIC ATROPHY
   JUNCTIONAL ZONE USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE geographic atrophy; spectral domain optical coherence tomography;
   retinal pigment epithelium; nonneovascular AMD; photoreceptors; Bruch
   membrane ellipsoid zone
ID FUNDUS AUTOFLUORESCENCE PATTERNS; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; PROGRESSION; DENSITY; IMPACT; EYES
AB Purpose: The junctional zone at the border of areas of geographic atrophy (GA) in eyes with nonneovascular age-related macular degeneration is an important target region for future therapeutic strategies. The goal of this study was to perform a detailed classification and quantitative characterization of the junctional zone using spectral domain optical coherence tomography.
   Methods: Spectral domain optical coherence tomography volume cube scans (Spectralis OCT, 1024 x 37, Automatic Real Time. 9) were obtained from 15 eyes of 11 patients with GA because of nonneovascular age-related macular degeneration. Volume optical coherence tomography data were imported into previously described validated grading software (3D-OCTOR), and manual segmentation of the retinal pigment epithelium (RPE) and photoreceptor layers was performed on all B-scans (total of 555). Retinal pigment epithelium and photoreceptor defect maps were produced for each case. The borders of the photoreceptor defect area and RPE defect area were delineated individually on separate annotation layers. The two outlines were then superimposed to compare the areas of overlap and nonoverlap. The perimeter of the RPE defect area was calculated by the software in pixels. The superimposed outline of the photoreceptor defect area and the RPE defect area was scrutinized to classify the overlap configuration of the junctional zone into one of three categories: Type 0, exact correspondence between the edge of the RPE defect and photoreceptor defect; Type 1, loss of photoreceptors outside and beyond the edge of the RPE defect; Type 2, preservation of photoreceptors beyond the edge of the RPE defect. The relative proportion of the various border configurations was expressed as a percentage of the perimeter of the RPE defect. Each configuration was then classified into four subgroups according to irregularity of the RPE band and the presence of debris.
   Results: Fifteen eyes of 11 patients (mean age: 79.3 +/- 4.3 years; range: 79-94 years) were included in this study. Seventeen GA lesions were analyzed. Two hundred and thirty-two Bscans were found to pass through the GA lesions, yielding 612 individual GA borders which were separately analyzed and classified. The mean area of the RPE defect was 4.0 +/- 4.4 mm(2), which was significantly smaller than that of the photoreceptor defect which measured 4.4 +/- 4.1 mm(2) (paired t test, P = 0.037). On average, 18.0 +/- 9.6% (range, 2.3-36.6%) of the junctional zone was of the Type 0 configuration, 57.3 +/- 19.0% (range, 21.3-96.8%) was Type 1, and 24.7 +/- 18.0% (range, 0.9-64.4%) was Type 2. Type 1 was more prevalent than Type 0 and 2 (analysis of variance, P = 0.000). Debris was present at the margin of the defect in 24.3% (149 of 612) of all assessed junctional zones; 20.0% (14 of 70) of Type 0 junctions, 28.7% (120 of 418) of Type 1, and 12.1% (15 of 124) of Type 2. Debris was more common in Type 1 than Type 2 junctions (P, 0.001). Retinal pigment epithelial irregularity was present at the margin of the defect in 34.8% (213 of 612) of all assessed junctional zones; 52.9% (37 of 70) of Type 0 junctions, 38.0% (159 of 418) of Type 1, and 13.7% (17 of 124) of Type 2. Retinal pigment epithelial irregularity was present more often at Type 0 and Type 1 than at Type 2 junctions (P < 0.001 for both).
   Conclusion: The size of the optical coherence tomography-visible RPE and photoreceptor defect in GA lesions differ significantly. There were significant areas where the photoreceptor outer segments were preserved despite the absence of visible RPE cells, and also areas of photoreceptor outer segment loss despite apparent RPE preservation. These findings have implications for development of therapeutic strategies, particularly cell-replacement approaches.
C1 [Qu, Jinfeng; Velaga, Swetha Bindu; Hariri, Amir H.; Nittala, Muneeswar Gupta; Sadda, Srinivas] Doheny Eye Inst, Doheny Image Reading Ctr, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Qu, Jinfeng] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Hariri, Amir H.; Sadda, Srinivas] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; Peking University; University of California
   System; University of California Los Angeles; University of California
   Los Angeles Medical Center; David Geffen School of Medicine at UCLA
RP Sadda, S (通讯作者)，Doheny Eye Inst, DVRC 211,1355 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Nittala, Muneeswar/AAT-7533-2020
FU Optos; Carl Zeiss Meditec
FX S. Sadda is a consultant for and receives research support from Optos
   and Carl Zeiss Meditec, serves as a consultant for Center-Vue, and has
   access to research instruments provided by Heidelberg Engineering,
   Topcon Medical Systems, Optos, Carl Zeiss Meditec, Nidek, and CenterVue.
   The remaining authors have no conflict of interest to disclose.
CR Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Book B, 2017, OPHTHALMOLOGE, V114, P49, DOI 10.1007/s00347-016-0308-7
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Caramoy A, 2010, BRIT J OPHTHALMOL, V94, P1040, DOI 10.1136/bjo.2009.161299
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Gamulescu MA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/851648
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kwon Yoon Hyung, 2014, Korean J Ophthalmol, V28, P386, DOI 10.3341/kjo.2014.28.5.386
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Mones J, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.026
   Nittala MG, 2011, EYE, V25, P1347, DOI 10.1038/eye.2011.173
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Sunness JS, 2007, RETINA-J RET VIT DIS, V27, P204, DOI 10.1097/01.iae.0000248148.56560.b1
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 37
TC 6
Z9 6
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2018
VL 38
IS 8
BP 1456
EP 1463
DI 10.1097/IAE.0000000000001824
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VJ
UT WOS:000454002400013
PM 28834947
DA 2022-11-30
ER

PT J
AU Robert, G
   Monika, E
   Illes, K
   Andras, P
   Miklos, R
   Zsuzsa, R
   Antal, S
   Zsolt, NZ
AF Robert, Gergely
   Monika, Ecsedy
   Illes, Kovacs
   Andras, Papp
   Miklos, Resch
   Zsuzsa, Recsan
   Antal, Szabo
   Zsolt, Nagy Zoltan
TI Pachychoroid diseases
SO ORVOSI HETILAP
LA English
DT Review
DE pachychoroid disease; eplerenone; micropulse laser; anti-VEGF; PDT
ID CENTRAL SEROUS CHORIORETINOPATHY; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   VERTEPORFIN PHOTODYNAMIC THERAPY; RECEPTOR ANTAGONIST TREATMENT;
   MINERALOCORTICOID RECEPTOR; AQUEOUS-HUMOR; THICKNESS; RANIBIZUMAB;
   EFFICACY; SPECTRUM
AB The aim of this study is to present our knowledge about pachychoroid diseases using case reports, literature review and our own clinical experiences. A summary flow chart of treatment options for the subgroups was prepared, too. Pachychoroid diseases include the following: central serous chorioretinopathy (CSCR), pachychoroid pigment epitheliopathy (PPE), pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy (PCV), peripapillary pachychoroid syndrome (PPS), focal choroidal excavation (FCE). A common feature of pachychoroid diseases is the quantitative or qualitative abnormality of the choroidea, which is often associated with subretinal fluid accumulation. The disease group does not currently have a standard treatment protocol; some of the multiple treatments prove to be more effective, however, there are significant differences between the subgroups. We summarize which subgroup benefits from eplerenone tablet therapy, micropulse laser therapy, verteporfin photodynamic therapy or intravitreal anti-VEGF injection therapy.
C1 [Robert, Gergely; Monika, Ecsedy; Illes, Kovacs; Andras, Papp; Miklos, Resch; Zsuzsa, Recsan; Antal, Szabo; Zsolt, Nagy Zoltan] Semmelweis Egyet, Altalanos Orvostud Kar, Szemeszeti Klin, Budapest, Hungary.
C3 Semmelweis University
RP Robert, G (通讯作者)，Ulloi U 26, H-1085 Budapest, Hungary.
EM dr.robertgergely@gmail.com
CR Alonso-Martin B, 2020, ARCH SOC ESP OFTALMO, V95
   Azuma K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65346-w
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bousquet E, 2013, RETINA-J RET VIT DIS, V33, P2096, DOI 10.1097/IAE.0b013e318297a07a
   Carvalho-Recchia CA, 2002, OPHTHALMOLOGY, V109, P1834, DOI 10.1016/S0161-6420(02)01117-X
   Cebeci Z, 2016, TURK OFTALMOL DERG, V46, P296, DOI 10.4274/tjo.24445
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Ecsedy M., 2018, SZEMESZET, V155, P11
   Ecsedy M, OPTICAL COHERENCE TO
   Freund KB, 2020, OSLI RETINA, V51, P206, DOI 10.3928/23258160-20200326-01
   Gergely R., NAVILAS MICROPULSE L
   Gergely R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73959-4
   Gergely R, 2017, RETINA-J RET VIT DIS, V37, P1084, DOI 10.1097/IAE.0000000000001303
   Ghadiali Q, 2016, RETINA-J RET VIT DIS, V36, P611, DOI 10.1097/IAE.0000000000000748
   Honda S, 2014, OPHTHALMOLOGICA, V232, P92, DOI 10.1159/000360308
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Kitajima Y, 2020, GRAEF ARCH CLIN EXP, V258, P1279, DOI 10.1007/s00417-020-04661-4
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kovacs KD, 2020, OSLI RETINA, V51, P54, DOI 10.3928/23258160-20191211-08
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim JW, 2011, GRAEF ARCH CLIN EXP, V249, P969, DOI 10.1007/s00417-010-1581-9
   Ma JL, 2014, ACTA OPHTHALMOL, V92, pe594, DOI 10.1111/aos.12482
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Miyamoto N, 2019, BRIT J OPHTHALMOL, V103, P844, DOI 10.1136/bjophthalmol-2018-312419
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ntomoka CG, 2018, EYE, V32, P1079, DOI 10.1038/s41433-018-0029-z
   Pang CE, 2014, INVEST OPHTH VIS SCI, V55, P5252, DOI 10.1167/iovs.14-14959
   Park W, 2019, GRAEF ARCH CLIN EXP, V257, P2155, DOI 10.1007/s00417-019-04426-8
   Pautler SE, 2015, CLIN OPHTHALMOL, V9, P43, DOI 10.2147/OPTH.S75448
   Perkins SL, 2002, OPHTHALMOLOGY, V109, P262, DOI 10.1016/S0161-6420(01)00951-4
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Recsan Zs, 2019, SZEMESZET, V156, P48
   Roca JA, 2018, BRIT J OPHTHALMOL, V102, P1696, DOI 10.1136/bjophthalmol-2017-311291
   Sanchez-Cano A, 2014, AM J OPHTHALMOL, V158, P574, DOI 10.1016/j.ajo.2014.05.035
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Shin MC, 2011, RETINA-J RET VIT DIS, V31, P1937, DOI 10.1097/IAE.0b013e31820a6a17
   Stepanov A, 2018, CES SLOV OFTALMOL, V74, P3, DOI [10.31348/2018/1/1-1-2018, DOI 10.31348/2018/1/1-1-2018]
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Van Rijssen TJ, 2019, AM J OPHTHALMOL, V205, P1, DOI 10.1016/j.ajo.2019.03.025
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wu CY, 2018, RETINA-J RET VIT DIS, V38, P1642, DOI 10.1097/IAE.0000000000002117
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
   Zhao M, 2010, FASEB J, V24, P3405, DOI 10.1096/fj.09-154344
NR 50
TC 0
Z9 0
U1 1
U2 5
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 0030-6002
EI 1788-6120
J9 ORVOSI HETILAP
JI Orvosi Hetilap
PD MAY
PY 2021
VL 162
IS 20
BP 770
EP 781
DI 10.1556/650.2021.32062
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SF9WQ
UT WOS:000653098200001
PM 33999854
OA Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Quin, G
   Liew, G
   Ho, IV
   Gillies, M
   Fraser-Bell, S
AF Quin, Godfrey
   Liew, Gerald
   I-Van Ho
   Gillies, Mark
   Fraser-Bell, Samantha
TI Diagnosis and interventions for central serous chorioretinopathy: review
   and update
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE central serous chorioretinopathy; indocyanine green angiography; laser
   photocoagulation; retina
ID INDOCYANINE GREEN VIDEOANGIOGRAPHY; HALF-DOSE VERTEPORFIN;
   TERM-FOLLOW-UP; ARGON-LASER PHOTOCOAGULATION; OPTICAL COHERENCE
   TOMOGRAPHY; GUIDED PHOTODYNAMIC THERAPY; ENDOTHELIAL GROWTH-FACTOR;
   INTRAVITREAL BEVACIZUMAB; FUNDUS AUTOFLUORESCENCE; CHOROIDAL
   NEOVASCULARIZATION
AB Most acute cases of central serous chorioretinopathy resolve spontaneously with minimal visual impairment. The small percentage of eyes developing chronic or recurrent disease that do warrant treatment is often difficult to control. Emergent investigations and treatments have added to the established options available to manage these cases. Optical coherence tomography has proved valuable for both imaging subtle fundoscopic findings and monitoring disease progression. Fluorescein angiography aids identification of pigment epithelial leaks and targets the use of argon laser treatment if outside the fovea. Fluorescein angiography also assists differentiation from other choroidal pathologies such as choroidal neovascularization and polypoidal choroidal vasculopathy. Where the diagnosis is uncertain, indocyanine green angiography can demonstrate classic midphase hyperpermeability. This is also useful to guide the application of photodynamic therapy. Newer treatments such as intravitreal anti-vascular endothelial growth factor are as yet unproven.
C1 [Quin, Godfrey; Liew, Gerald; I-Van Ho; Gillies, Mark; Fraser-Bell, Samantha] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Liew, Gerald] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Quin, Godfrey; I-Van Ho] Macquarie Univ, Australian Sch Adv Med, Sydney, NSW 2109, Australia.
C3 University of Sydney; University of Sydney; Macquarie University
RP Fraser-Bell, S (通讯作者)，Univ Sydney, Sydney Eye Hosp C09, Sydney, NSW 2006, Australia.
EM sfraserbell@gmail.com
RI Fraser-Bell, Samantha/ABE-8574-2020; Liew, Gerald/AAB-6870-2022
OI Fraser-Bell, Samantha/0000-0001-5646-9359; Ho, I-Van/0000-0002-7215-1233
CR Alomran Mohamed Shaker, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100325-07
   Annesley W H Jr, 1981, Trans Am Ophthalmol Soc, V79, P335
   Artunay O, 2010, CURR EYE RES, V35, P91, DOI 10.3109/02713680903428306
   AVVAD FK, 1995, OPHTHALMOLOGY, V102, P401
   Ayata A, 2009, BRIT J OPHTHALMOL, V93, P79, DOI 10.1136/bjo.2008.141564
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   BRANCATO R, 1987, GRAEF ARCH CLIN EXP, V225, P166, DOI 10.1007/BF02175443
   BRANCATO R, 1989, INVEST OPHTH VIS SCI, V30, P1504
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Canakis C, 2003, AM J OPHTHALMOL, V136, P750, DOI 10.1016/S0002-9394(03)00397-0
   CASTROCORREIA J, 1992, DOC OPHTHALMOL, V81, P379
   Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Chappelow AV, 2000, ARCH OPHTHALMOL-CHIC, V118, P1211
   Chen SN, 2008, OPHTHALMOLOGY, V115, P2229, DOI 10.1016/j.ophtha.2008.08.026
   Chhablani JK, 2010, RETINA-J RET VIT DIS, V30, P1323, DOI 10.1097/IAE.0b013e3181e46b09
   Chrapek O, 2002, Cesk Slov Oftalmol, V58, P382
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dinc UA, 2011, CLIN EXP OPTOM, V94, P452, DOI 10.1111/j.1444-0938.2011.00598.x
   Dohrmann J, 2001, OPHTHALMOLOGE, V98, P1069, DOI 10.1007/s003470170027
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P989, DOI 10.1097/00006982-200512000-00006
   Ehrlich R, 2012, CLIN EXP OPHTHALMOL, V40, pE32, DOI 10.1111/j.1442-9071.2011.02654.x
   Fabianova J, 1998, Cesk Slov Oftalmol, V54, P401
   Arevalo JF, 2011, GRAEF ARCH CLIN EXP, V249, P1159, DOI 10.1007/s00417-011-1651-7
   FICKER L, 1988, BRIT J OPHTHALMOL, V72, P829, DOI 10.1136/bjo.72.11.829
   Framme C, 2005, ACTA OPHTHALMOL SCAN, V83, P161, DOI 10.1111/j.1600-0420.2005.00442.x
   Fujimoto H, 2008, OPHTHALMOLOGY, V115, P1494, DOI 10.1016/j.ophtha.2008.01.021
   Gass JD, 1977, AM ACAD OPHTHALMOL 1, V83, P456
   GELBER GS, 1987, AM J PSYCHIAT, V144, P46
   GILBERT CM, 1984, BRIT J OPHTHALMOL, V68, P815, DOI 10.1136/bjo.68.11.815
   Golshahi A, 2010, ACTA OPHTHALMOL, V88, P576, DOI 10.1111/j.1755-3768.2008.01467.x
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Guyer DRGE, 1994, PRINCIPLES PRACTICE, V2, P1818
   Ho I-Van, 2008, Retin Cases Brief Rep, V2, P1, DOI 10.1097/ICB.0b013e318074bc8c
   Huang WC, 2009, EYE, V23, P488, DOI 10.1038/eye.2008.55
   Hussain N, 2006, CLIN EXP OPHTHALMOL, V34, P137, DOI 10.1111/j.1442-9071.2006.01171.x
   Ibrahim MA, 2011, EYE, V2, P293
   IE D, 1993, BRIT J OPHTHALMOL, V77, P349, DOI 10.1136/bjo.77.6.349
   Imamura Y, 2011, RETINA, V29, P1469
   Inoue M, 2011, OPHTHALMOLOGICA, V225, P37, DOI 10.1159/000314709
   Inoue R, 2010, AM J OPHTHALMOL, V149, P441, DOI 10.1016/j.ajo.2009.10.011
   Kanagawa M, 1970, Nihon Ganka Kiyo, V21, P451
   Kim SW, 2012, BRIT J OPHTHALMOL, V96, P350, DOI 10.1136/bjo.2011.204503
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Lai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282
   LANDERS MB, 1977, ANN OPHTHALMOL, V9, P1567
   Lanzetta P, 2008, EUR J OPHTHALMOL, V18, P934, DOI 10.1177/112067210801800613
   LEAVER P, 1979, BRIT J OPHTHALMOL, V63, P674, DOI 10.1136/bjo.63.10.674
   Lee JY, 2011, ACTA OPHTHALMOL, V89, pE293, DOI 10.1111/j.1755-3768.2009.01835.x
   Lee PY, 2009, JPN J OPHTHALMOL, V53, P52, DOI 10.1007/s10384-008-0613-z
   Lee ST, 2011, J OCUL PHARMACOL TH, V27, P611, DOI 10.1089/jop.2011.0045
   Leng T, 2011, OPEN OPHTHALMOL J, V5, P6, DOI 10.2174/1874364101105010006
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Lim JW, 2011, BRIT J OPHTHALMOL, V95, P514, DOI 10.1136/bjo.2010.182121
   Lim JW, 2011, GRAEF ARCH CLIN EXP, V249, P969, DOI 10.1007/s00417-010-1581-9
   Lim JW, 2010, RETINA-J RET VIT DIS, V30, P1465, DOI 10.1097/IAE.0b013e3181d8e7fe
   Lim Ji Won, 2010, Korean J Ophthalmol, V24, P155, DOI 10.3341/kjo.2010.24.3.155
   Lim SJ, 2010, RETINA-J RET VIT DIS, V30, P100, DOI 10.1097/IAE.0b013e3181bcf0b4
   Marmor MF, 1999, ARCH OPHTHALMOL-CHIC, V117, P184
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Menchini U, 1997, INT OPHTHALMOL, V21, P57, DOI 10.1023/A:1005880129005
   Minckler D, 2000, OPHTHALMOLOGY, V107, P9, DOI 10.1016/S0161-6420(99)00085-8
   Mitarai K, 2006, GRAEF ARCH CLIN EXP, V244, P1415, DOI 10.1007/s00417-006-0277-7
   Montero JA, 2005, BRIT J OPHTHALMOL, V89, P562, DOI 10.1136/bjo.2004.049403
   Nielsen JS, 2007, RETINA-J RET VIT DIS, V27, P119, DOI 10.1097/IAE.0b013e3180316fd8
   Nielsen JS, 2011, RETINA-J RET VIT DIS, V31, P1928, DOI 10.1097/IAE.0b013e31821c3ef6
   Ojima Y, 2008, AM J OPHTHALMOL, V146, P77, DOI 10.1016/j.ajo.2008.02.016
   Piccolino FC, 2003, RETINA-J RET VIT DIS, V23, P752, DOI 10.1097/00006982-200312000-00002
   PICCOLINO FC, 1992, RETINA-J RET VIT DIS, V12, P96, DOI 10.1097/00006982-199212020-00004
   Pryds A, 2011, ACTA OPHTHALMOL, V17, P211
   Reibaldi M, 2010, AM J OPHTHALMOL, V149, P307, DOI 10.1016/j.ajo.2009.08.026
   Ricci F, 2004, EUR J OPHTHALMOL, V14, P74, DOI 10.1177/112067210401400115
   ROBERTSON DM, 1983, AM J OPHTHALMOL, V95, P457, DOI 10.1016/0002-9394(83)90265-9
   ROBERTSON DM, 1986, OPHTHALMOLOGY, V93, P972
   Rouvas A, 2012, EUR J OPHTHALMOL, V22, P417, DOI 10.5301/ejo.5000051
   Schaal KB, 2009, EUR J OPHTHALMOL, V19, P613, DOI 10.1177/112067210901900415
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Sekiryu T, 2010, INVEST OPHTH VIS SCI, V51, P4956, DOI 10.1167/iovs.09-5009
   Senturk F, 2011, AM J OPHTHALMOL, V151, P303, DOI 10.1016/j.ajo.2010.08.019
   Sharma T, 2004, OPHTHALMOLOGY, V111, P1708, DOI 10.1016/j.ophtha.2004.03.025
   Sharma Tarun, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100215-23
   Shin JY, 2011, RETINA-J RET VIT DIS, V31, P119, DOI 10.1097/IAE.0b013e3181e378f2
   Shukla D, 2008, EYE, V22, P100, DOI 10.1038/sj.eye.6702449
   SLUSHER MM, 1986, RETINA-J RET VIT DIS, V6, P81, DOI 10.1097/00006982-198600620-00003
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   SPALTER HF, 1968, ARCH OPHTHALMOL-CHIC, V79, P247, DOI 10.1001/archopht.1968.03850040249005
   SPITZNAS M, 1987, GRAEF ARCH CLIN EXP, V225, P437, DOI 10.1007/BF02334172
   SPITZNAS M, 1986, GRAEF ARCH CLIN EXP, V224, P321, DOI 10.1007/BF02150023
   Spitznas M, 1989, RETINA, P217
   Suzuki K, 2002, JPN J OPHTHALMOL, V46, P308, DOI 10.1016/S0021-5155(02)00477-X
   Taban M, 2004, AM J OPHTHALMOL, V137, P1073, DOI 10.1016/j.ajo.2004.01.043
   Tatham A, 2006, J OCUL PHARMACOL TH, V22, P145, DOI 10.1089/jop.2006.22.145
   Tobari I, 1971, Nippon Ganka Gakkai Zasshi, V75, P596
   Torres-Soriano ME, 2008, GRAEF ARCH CLIN EXP, V246, P1235, DOI 10.1007/s00417-008-0856-x
   Verma Lalit, 2004, BMC Ophthalmol, V4, P15, DOI 10.1186/1471-2415-4-15
   Wang GH, 2011, MED PRIN PRACT, V20, P283, DOI 10.1159/000323594
   Wei SY, 2005, OPHTHAL SURG LAS IM, V36, P412, DOI 10.3928/1542-8877-20050901-11
   Wu ZHY, 2011, RETINA-J RET VIT DIS, V31, P1378, DOI 10.1097/FTD.0b013e31820beb02
   YAMADA K, 1992, OPHTHALMOLOGICA, V205, P69, DOI 10.1159/000310315
   Yaman A, 2007, Bull Soc Belge Ophtalmol, P69
   Yannuzzi L A, 1992, Eur J Ophthalmol, V2, P103
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   Yannuzzi LA, 2010, AM J OPHTHALMOL, V149, P361, DOI 10.1016/j.ajo.2009.11.017
   Yap EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P689, DOI 10.1001/archopht.1996.01100130681007
   Zhao MW, 2009, RETINA-J RET VIT DIS, V29, P1155, DOI 10.1097/IAE.0b013e3181a6c028
NR 108
TC 59
Z9 61
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAR
PY 2013
VL 41
IS 2
BP 187
EP 200
DI 10.1111/j.1442-9071.2012.02847.x
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 115JL
UT WOS:000316808300013
PM 22788713
DA 2022-11-30
ER

PT J
AU Rozanowska, MB
   Czuba-Pelech, B
   Rozanowski, B
AF Rozanowska, Malgorzata B.
   Czuba-Pelech, Barbara
   Rozanowski, Bartosz
TI Is There an Optimal Combination of AREDS2 Antioxidants Zeaxanthin,
   Vitamin E and Vitamin C on Light-Induced Toxicity of Vitamin A Aldehyde
   to the Retina?
SO ANTIOXIDANTS
LA English
DT Article
DE carotenoid; xanthophyll; zeaxanthin; alpha-tocopherol; ascorbate;
   retina; retinal pigment epithelium; photosensitized oxidation;
   phototoxicity; age-related macular degeneration
ID CAROTENOID RADICAL CATIONS; ASCORBIC-ACID; MACULAR DEGENERATION; PIGMENT
   EPITHELIUM; OXIDATIVE STRESS; SINGLET OXYGEN; ARPE-19 CELLS; EYE
   DISEASE; FATTY-ACIDS; DONOR EYES
AB Vitamins C and E and zeaxanthin are components of a supplement tested in a large clinical trial-Age-Related Eye Disease Study 2 (AREDS2)-and it has been demonstrated that they can inhibit the progression of age-related macular degeneration. The aim of this study was to determine the optimal combinations of these antioxidants to prevent the phototoxicity mediated by vitamin A aldehyde (ATR), which can accumulate in photoreceptor outer segments (POS) upon exposure to light. We used cultured retinal pigment epithelial cells ARPE-19 and liposomes containing unsaturated lipids and ATR as a model of POS. Cells and/or liposomes were enriched with lipophilic antioxidants, whereas ascorbate was added just before the exposure to light. Supplementing the cells and/or liposomes with single lipophilic antioxidants had only a minor effect on phototoxicity, but the protection substantially increased in the presence of both ways of supplementation. Combinations of zeaxanthin with alpha-tocopherol in liposomes and cells provided substantial protection, enhancing cell viability from similar to 26% in the absence of antioxidants to similar to 63% in the presence of 4 mu M zeaxanthin and 80 mu M alpha-tocopherol, and this protective effect was further increased to similar to 69% in the presence of 0.5 mM ascorbate. The protective effect of ascorbate disappeared at a concentration of 1 mM, whereas 2 mM of ascorbate exacerbated the phototoxicity. Zeaxanthin or alpha-tocopherol partly ameliorated the cytotoxic effects. Altogether, our results suggest that the optimal combination includes upper levels of zeaxanthin and oc-tocopherol achievable by diet and/or supplementations, whereas ascorbate needs to be at a four-fold smaller concentration than that in the vitreous. The physiological relevance of the results is discussed.
C1 [Rozanowska, Malgorzata B.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4HQ, Wales.
   [Rozanowska, Malgorzata B.] Cardiff Univ, Cardiff Inst Tissue Engn & Repair CITER, Cardiff CF24 4HQ, Wales.
   [Czuba-Pelech, Barbara] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Biophys, PL-30387 Krakow, Poland.
   [Rozanowski, Bartosz] Pedagogical Univ, Inst Biol, PL-30084 Krakow, Poland.
C3 Cardiff University; Cardiff University; Jagiellonian University
RP Rozanowska, MB (通讯作者)，Cardiff Univ, Sch Optometry & Vis Sci, Cardiff CF24 4HQ, Wales.; Rozanowska, MB (通讯作者)，Cardiff Univ, Cardiff Inst Tissue Engn & Repair CITER, Cardiff CF24 4HQ, Wales.
EM rozanowskamb@cardiff.ac.uk; barbara.czuba-pelech@uj.edu.pl;
   bartosz.rozanowski@up.krakow.pl
FU Ministry of Science and Higher Education/State Committee for Scientific
   Research, Poland [PB 6PO4A 06217, 3P04A 044 23]
FX This research was funded by grants from the Ministry of Science and
   Higher Education/State Committee for Scientific Research, Poland PB
   6PO4A 06217 and 3P04A 044 23; the TravellingWellcome Trust Fellowships
   to M.B.R. and B.R. This research was funded in part by theWellcome
   Trust. For the purpose of Open Access, the author has applied a CC BY
   public copyright license to any Author Accepted Manuscript version
   arising from this submission.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Arunkumar R, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158617
   Bandara S, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2200068119
   Bazan H.E., 1990, COMP ROD OUTER SEGM, V31, P1433
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Bisby RH, 1999, J PHYS CHEM A, V103, P7454, DOI 10.1021/jp990838c
   Black HS, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9030264
   BLANKS JC, 1992, INVEST OPHTH VIS SCI, V33, P2814
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Burke M, 2001, J PHOTOCH PHOTOBIO B, V60, P1, DOI 10.1016/S1011-1344(01)00111-7
   Burke M, 2001, FEBS LETT, V500, P132, DOI 10.1016/S0014-5793(01)02601-1
   Chen Y, 2012, J BIOL CHEM, V287, P5059, DOI 10.1074/jbc.M111.315432
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Potilinski MC, 2021, NEUROPHARMACOLOGY, V188, DOI 10.1016/j.neuropharm.2021.108513
   Dillon J, 1996, PHOTOCHEM PHOTOBIOL, V63, P680, DOI 10.1111/j.1751-1097.1996.tb05673.x
   Edge R, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010005
   Fiedor J, 2005, BBA-BIOENERGETICS, V1709, P1, DOI 10.1016/j.bbabio.2005.05.008
   Fiedor J, 2014, NUTRIENTS, V6, P466, DOI 10.3390/nu6020466
   Firsov AM, 2022, J PHOTOCH PHOTOBIO B, V229, DOI 10.1016/j.jphotobiol.2022.112425
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   Gosbell AD, 2006, INVEST OPHTH VIS SCI, V47, P2613, DOI 10.1167/iovs.05-0962
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Halliwell B., 2015, Free radicals in biology and medicine
   Jadeja RN, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050790
   Jiang Q, 2014, FREE RADICAL BIO MED, V72, P76, DOI 10.1016/j.freeradbiomed.2014.03.035
   Jungert A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102944
   KAISER S, 1990, ARCH BIOCHEM BIOPHYS, V277, P101, DOI 10.1016/0003-9861(90)90556-E
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   Kiser PD, 2016, ANNU REV VIS SCI, V2, P197, DOI 10.1146/annurev-vision-111815-114407
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Lamberson CR, 2014, J AM CHEM SOC, V136, P838, DOI 10.1021/ja410569g
   Levine M, 2011, ADV NUTR, V2, P78, DOI 10.3945/an.110.000109
   LI ZY, 1985, INVEST OPHTH VIS SCI, V26, P1589
   Lykkesfeldt J, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102412
   Ma N, 2016, INVEST OPHTH VIS SCI, V57, P3440, DOI 10.1167/iovs.16-19162
   Maeda Akiko, 2013, Drug Discov Today Dis Models, V10, pe163
   Maeda A, 2014, P NATL ACAD SCI USA, V111, pE1428, DOI 10.1073/pnas.1317986111
   Maeda A, 2012, NAT CHEM BIOL, V8, P170, DOI 10.1038/nchembio.759
   Maeda T, 2012, PHOTOCHEM PHOTOBIOL, V88, P1309, DOI 10.1111/j.1751-1097.2012.01143.x
   Maeda T, 2009, INVEST OPHTH VIS SCI, V50, P4917, DOI 10.1167/iovs.09-3581
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P181, DOI 10.1136/bjo.63.3.181
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Molday RS, 2022, PROG RETIN EYE RES, V89, DOI 10.1016/j.preteyeres.2021.101036
   Moran NE, 2018, ADV NUTR, V9, P465, DOI 10.1093/advances/nmy025
   NAASH MI, 1989, EXP EYE RES, V48, P309, DOI 10.1016/S0014-4835(89)80080-6
   Nagra M, 2017, J ANAT, V231, P319, DOI 10.1111/joa.12641
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Noell W K, 1987, Prog Clin Biol Res, V247, P469
   Ohira A, 2003, INVEST OPHTH VIS SCI, V44, P1230, DOI 10.1167/iovs.02-0191
   Olchawa MM, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111044
   Olchawa MM, 2021, PIGM CELL MELANOMA R, V34, P670, DOI 10.1111/pcmr.12914
   Olchawa MM, 2017, FREE RADICAL RES, V51, P799, DOI 10.1080/10715762.2017.1380307
   Organisciak D T, 1987, Prog Clin Biol Res, V247, P455
   ORGANISCIAK DT, 1990, INVEST OPHTH VIS SCI, V31, P1195
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   ORGANISCIAK DT, 1984, CURR EYE RES, V3, P257, DOI 10.3109/02713688408997208
   ORGANISCIAK DT, 1992, CURR EYE RES, V11, P231, DOI 10.3109/02713689209001774
   ORGANISCIAK DT, 1987, CURR EYE RES, V6, P1051, DOI 10.3109/02713688709034876
   Prasain JK, 2005, J MASS SPECTROM, V40, P916, DOI 10.1002/jms.868
   Puntel A, 2015, BIOMATERIALS, V44, P103, DOI 10.1016/j.biomaterials.2014.12.019
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Ratnayake K, 2020, CELL SIGNAL, V69, DOI 10.1016/j.cellsig.2020.109547
   Ratnayake K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28254-8
   Rice ME, 1998, NEUROSCIENCE, V82, P1213
   Roanowska M., 2008, OPHTHALMOLOGY RES VI, P405
   ROBISON WG, 1982, RETINA-J RET VIT DIS, V2, P263, DOI 10.1097/00006982-198202040-00012
   Rodieck R.W., 1998, 1 STEPS SEEING
   Romero-Vazquez S, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070763
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Rozanowska M, 1997, PHOTOCHEM PHOTOBIOL, V65, P472, DOI 10.1111/j.1751-1097.1997.tb08593.x
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Rozanowska M, 2005, FREE RADICAL BIO MED, V39, P1399, DOI 10.1016/j.freeradbiomed.2005.07.018
   Rozanowska M, 2002, INVEST OPHTH VIS SCI, V43, P2088
   Rozanowska M., 2009, PHOTOBIOLOGICAL SCI
   Rozanowska M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112799
   Rozanowska M, 2010, CAROTENOIDS: PHYSICAL, CHEMICAL, AND BIOLOGICAL FUNCTIONS AND PROPERTIES, P309
   Rozanowska M, 2012, PHOTOCHEM PHOTOBIOL, V88, P1408, DOI 10.1111/j.1751-1097.2012.01228.x
   Rozanowska M, 2012, PHOTOCHEM PHOTOBIOL, V88, P1362, DOI 10.1111/j.1751-1097.2012.01161.x
   Rozanowska MB, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050753
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P658, DOI 10.1111/j.1751-1097.2007.00291.x
   Ruan Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031296
   Rychlicka M, 2018, MOLECULES, V23, DOI 10.3390/molecules23020314
   Sahu B, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110746
   Sandhu J, 2018, CELL, V175, P514, DOI 10.1016/j.cell.2018.08.033
   Sawada O, 2014, EXP EYE RES, V123, P27, DOI 10.1016/j.exer.2014.04.003
   Schalch W, 2010, CAROTENOIDS: PHYSICAL, CHEMICAL, AND BIOLOGICAL FUNCTIONS AND PROPERTIES, P257
   Shui YB, 2009, ARCH OPHTHALMOL-CHIC, V127, P475, DOI 10.1001/archophthalmol.2008.621
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   STOYANOVSKY DA, 1995, CURR EYE RES, V14, P181, DOI 10.3109/02713689509033513
   Stuetz W, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100614
   Toma C, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050653
   Traber MG, 2019, AM J CLIN NUTR, V110, P1148, DOI 10.1093/ajcn/nqz172
   von Lintig J, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100864
   Widomska J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051333
   WOODFORD BJ, 1983, INVEST OPHTH VIS SCI, V24, P862
   Wrona M, 2004, FREE RADICAL BIO MED, V36, P1094, DOI 10.1016/j.freeradbiomed.2004.02.005
   Wrona M, 2003, FREE RADICAL BIO MED, V35, P1319, DOI 10.1016/j.freeradbiomed.2003.07.005
   Yu GP, 2021, BIOCONJUGATE CHEM, V32, P572, DOI 10.1021/acs.bioconjchem.1c00043
   Yu GP, 2014, BIOMACROMOLECULES, V15, P4570, DOI 10.1021/bm501352s
   Zaffarin ASM, 2020, INT J NANOMED, V15, P9961, DOI 10.2147/IJN.S276355
NR 105
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD JUN
PY 2022
VL 11
IS 6
AR 1132
DI 10.3390/antiox11061132
PG 26
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA 2K4HJ
UT WOS:000816298800001
PM 35740030
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Loukovaara, S
   Haukka, J
AF Loukovaara, Sirpa
   Haukka, Jari
TI Intravitreal anti-VEGF therapy is not associated with a higher risk of
   all-cause mortality in patients with macular oedema caused by posterior
   segment vascular diseases
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE all&#8208; cause mortality; anti&#8208; VEGF; diabetic macular oedema;
   retinal vein occlusion; wet age&#8208; related macular degeneration
ID DEGENERATION
AB Purpose To examine whether real-world clinical patients with macular oedema (MO) receiving intravitreal antivascular endothelial growth factor (VEGF) therapy have a higher mortality compared with a matched reference population.
   Methods A population-based, retrospective cohort study of 26 386 patients from Finland, from January 1, 2001, to December 31, 2017. Index patients were identified through the Caring Epidemiology Project database, receiving at least one intravitreal anti-VEGF injection for wet age-related macular degeneration (AMD, n = 2243, 48.61%), diabetic MO (n = 744, 16.12%), MO due to retinal vascular occlusion (n = 589, 12.77%), or other MO (n = 1038, 22.5%). For each individual treated with intravitreal injection (n = 4614), five age- , sex- , calendar year- and hospital district- matched control individuals (n = 21 772) were chosen. Baseline data of chronic conditions were available. All-cause and cause-specific mortality was analysed using Cox ' s proportional hazards model.
   Results In general, the anti-VEGF treated patients had a higher prevalence of systemic conditions, including diabetes (60.1% vs. 46.8%, p < 0.001), chronic hypertension (38.4% vs. 34.6%, p < 0.001), in hospital-treated ischaemic heart disease (23.1% vs. 21.5%, p = 0.014), and glaucoma (11.1% vs. 6.3%, p < 0.001) than controls. There was no difference in all-cause mortality between the anti-VEGF treated patients and matched controls (p = 0.62). In unadjusted Kaplan-Meier analysis of wet AMD subgroup, all-cause mortality was lower in anti-VEGF treated patients than matched controls (p = 0.015), but adjusted Cox ' s proportional hazards model showed no difference in the risk of all-cause mortality (HR 0.85, 95% CI 0.66-1.09).
   Conclusions Intravitreal anti-VEGF therapy was not associated with an increase in the risk of mortality in patients with MO compared with age- and sex-matched controls.
C1 [Loukovaara, Sirpa] Univ Helsinki, Unit Vitreoretinal Surg, Dept Ophthalmol, Helsinki Univ Hosp, Helsinki, Finland.
   [Loukovaara, Sirpa] Univ Helsinki, Individualized Drug Therapy Res Program, Helsinki, Finland.
   [Haukka, Jari] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland.
   [Haukka, Jari] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; University of Helsinki; Tampere University
RP Loukovaara, S (通讯作者)，Univ Helsinki, Unit Vitreoretinal Surg, Dept Ophthalmol, Haartmaninkatu 4 C, Helsinki 00290, Finland.; Loukovaara, S (通讯作者)，Helsinki Univ Hosp, Haartmaninkatu 4 C, Helsinki 00290, Finland.
EM sirpa.loukovaara@hus.fi
RI Haukka, Jari/G-1484-2014
OI Haukka, Jari/0000-0003-1450-6208
FU University of Helsinki, Finland [Y1014SI004]
FX This study was supported by Y1014SI004 grant (SL), and funded by
   University of Helsinki, Finland (JH).
CR Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Baillif S, 2018, J FR OPHTALMOL, V41, P271, DOI 10.1016/j.jfo.2017.11.006
   Campa C, 2016, CURR DRUG TARGETS, V17, P328, DOI 10.2174/1573399811666150615151324
   Cheung CMG, 2014, J INTERN MED, V276, P140, DOI 10.1111/joim.12227
   Costagliola C, 2019, EXPERT OPIN DRUG SAF, V18, P803, DOI 10.1080/14740338.2019.1643838
   Dalvin LA, 2019, JAMA OPHTHALMOL, V137, P483, DOI 10.1001/jamaophthalmol.2018.6891
   GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
   Maloney MH, 2021, OPHTHALMOLOGY, V128, P417, DOI 10.1016/j.ophtha.2020.07.062
   Nguyen CL, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0785-3
   Niskanen L, 2020, J EPIDEMIOL COMMUN H, V74, P950, DOI 10.1136/jech-2019-213602
   Nordisk Medicinal-Statistisk Komite, 2010, NOMESCO CLASS SURG P
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scott LJ, 2015, EXPERT OPIN DRUG SAF, V14, P379, DOI 10.1517/14740338.2015.991712
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   Virgili G, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub5
NR 16
TC 2
Z9 2
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2021
VL 99
IS 6
BP E893
EP E898
DI 10.1111/aos.14717
EA JAN 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UO6TY
UT WOS:000604099100001
PM 33389820
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lemmens, S
   Breda, JB
   Van Keer, K
   Jacobs, T
   Van Landeghem, R
   De Boever, P
   Stalmans, I
AF Lemmens, Sophie
   Barbosa Breda, Joao
   Van Keer, Karel
   Jacobs, Tine
   Van Landeghem, Ruben
   De Boever, Patrick
   Stalmans, Ingeborg
TI The Prevalence of Undiagnosed Age-Related Sight-Threatening Diseases in
   Self-Proclaimed Healthy Individuals
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; VISUAL IMPAIRMENT; GLOBAL PREVALENCE; VISION
   IMPAIRMENT; MACULAR DEGENERATION; 5-YEAR INCIDENCE; UNITED-STATES;
   RISK-FACTORS; EYE CARE; POPULATION
AB Background. Age-related conditions such as glaucoma, age-related macular degeneration, diabetic retinopathy, and cataract have become the major cause of visual impairment and blindness in high-income countries. The aim of the current study is to investigate the prevalence of these eye diseases in a cohort of self-proclaimed healthy elderly and thus get a rough estimation of the prevalence of undiagnosed age-related eye conditions in the Belgian population. Methods. Individuals aged 55 and older without ophthalmological complaints were asked to fill in a general medical questionnaire and underwent an ophthalmological examination, which included a biomicroscopic examination, intraocular pressure measurement, axial length measurement, and acquisition of fundus pictures and optical coherence tomography scans. Information regarding follow-up was collected in those who received the advice of referral to an ophthalmologist or the advice to have more frequent follow-up visits, based on their study evaluation. Results. The cohort included 102 people and comprised 46% men (median age 70 years, range 57-85 years). Referral for additional examinations was made in 26 participants (25%). The advice to have more regular follow-up ophthalmologist visits was given to nine additional participants (9%). No significant correlations between baseline characteristics and the need for referral could be identified. Follow-up information was available for 25 out of 26 referred volunteers. Out of these, four underwent a therapeutic intervention based on study referral, up until 18 months after study participation. All four interventions took place in the age group 65-74 years. Conclusions. This study shows that, even in an elderly population with self-proclaimed healthy eyes and good general health, a significant proportion of subjects showed ocular findings that need regular follow-up and/or intervention. The frequency of prior ophthalmological examinations does not seem to be relevant to this proportion, meaning that everyone above 55 years old needs a routine ophthalmological evaluation.
C1 [Lemmens, Sophie; Van Keer, Karel; Jacobs, Tine; Van Landeghem, Ruben; Stalmans, Ingeborg] Univ Hosp UZ Leuven, Dept Ophthalmol, Herestr 49, B-3000 Louvain, Belgium.
   [Lemmens, Sophie; Barbosa Breda, Joao; Van Keer, Karel; Stalmans, Ingeborg] Katholieke Univ Leuven, Dept Neurosci, Res Grp Ophthalmol, Herestr 49, B-3000 Leuven, Belgium.
   [Lemmens, Sophie; De Boever, Patrick] VITO Flemish Inst Technol Res, Hlth Unit, Boeretang 200, B-2400 Mol, Belgium.
   [Barbosa Breda, Joao] Ctr Hosp Sao Joao, Dept Ophthalmol, Porto, Portugal.
   [De Boever, Patrick] Hasselt Univ, Ctr Environm Sci, Agoralaan, B-3590 Diepenbeek, Belgium.
   [De Boever, Patrick] Univ Antwerp, Dept Biol, Univ Pl, B-12610 Antwerp, Belgium.
C3 KU Leuven; VITO; Sao Joao Hospital; Hasselt University; University of
   Antwerp
RP Lemmens, S (通讯作者)，Univ Hosp UZ Leuven, Dept Ophthalmol, Herestr 49, B-3000 Louvain, Belgium.; Lemmens, S (通讯作者)，Katholieke Univ Leuven, Dept Neurosci, Res Grp Ophthalmol, Herestr 49, B-3000 Leuven, Belgium.; Lemmens, S (通讯作者)，VITO Flemish Inst Technol Res, Hlth Unit, Boeretang 200, B-2400 Mol, Belgium.
EM sophie.1.lemmens@uzleuven.be; joao_breda@hotmail.com;
   karel.vankeer@uzleuven.be; tine.1.jacobs@uzleuven.be;
   ruben.vanlandeghem@uzleuven.be; pdboever@gmail.com;
   ingeborg.stalmans@uzleuven.be
RI De Boever, Patrick/AAA-8387-2019; Lemmens, Sophie/L-1661-2019
OI De Boever, Patrick/0000-0002-5197-8215; Stalmans,
   Ingeborg/0000-0001-7507-4512; Barbosa-Breda, Joao/0000-0001-7816-816X;
   Lemmens, Sophie/0000-0002-6842-1747
FU VITO-UZ Leuven PhD grant
FX The authors would like to thank Professor Emeritus Alfons Verbruggen for
   the recruitment support and Ms. Sien Boons, Ms. Freya Cachet, and Ms.
   Sarah Spileers for the administrative support to this study. Sophie
   Lemmens is holder of a joint VITO-UZ Leuven PhD grant.
CR American Academy of Ophthalmology, 2015, POL STAT FREQ OC EX
   Anstey KJ, 2001, GERONTOLOGY, V47, P289, DOI 10.1159/000052814
   Cassard SD, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.032
   Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dhital A, 2010, EYE, V24, P1437, DOI 10.1038/eye.2010.60
   DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851
   Dimitrov PN, 2003, INVEST OPHTH VIS SCI, V44, P5075, DOI 10.1167/iovs.02-0457
   Evans JR, 2007, OPHTHALMOLOGY, V114, P283, DOI 10.1016/j.ophtha.2006.10.006
   Federation International Diabetes, 2017, FEDERATION INT DIABE
   Fernández M.J., 2010, Arch Soc Esp Oftalmol, V85, P174, DOI 10.1016/S0365-6691(10)55003-2
   Finger RP, 2007, OPHTHALMOLOGE, V104, P839, DOI 10.1007/s00347-007-1600-3
   Finger R. P., 2013, OPHTHALMOLOGY AGEING, P19
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P4381, DOI 10.1167/iovs.10-6987
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fleming C, 2005, ANN FAM MED, V3, P167, DOI 10.1370/afm.293
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Founti P, 2018, ACTA OPHTHALMOL, V96, pE859, DOI 10.1111/aos.13758
   Gonzalez-Martin-Moro J, 2016, Arch Soc Esp Oftalmol, V91, P526, DOI 10.1016/j.oftal.2016.03.014
   Grodum K, 2002, ACTA OPHTHALMOL SCAN, V80, P627, DOI 10.1034/j.1600-0420.2002.800613.x
   Huang SS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1362, DOI 10.1001/archophthalmol.2009.138
   Jacob J, 2016, OPHTHALMOLOGICA, V236, P81, DOI 10.1159/000446585
   Keunen Jan E E, 2011, Ned Tijdschr Geneeskd, V155, pA3461
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Li JPO, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100900
   Lin MY, 2004, J AM GERIATR SOC, V52, P1996, DOI 10.1111/j.1532-5415.2004.52554.x
   Lord SR, 2006, AGE AGEING, V35, P55, DOI 10.1093/ageing/afl088
   Maberley DAL, 2007, EYE, V21, P528, DOI 10.1038/sj.eye.6702257
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   Mukesh BN, 2002, OPHTHALMOLOGY, V109, P1047, DOI 10.1016/S0161-6420(02)01040-0
   O'Neill EC, 2014, JAMA OPHTHALMOL, V132, P560, DOI 10.1001/jamaophthalmol.2014.96
   Orr P, 1999, OPHTHALMOLOGY, V106, P904, DOI 10.1016/S0161-6420(99)00508-4
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Prokofyeva E, 2013, ACTA OPHTHALMOL, V91, P395, DOI 10.1111/j.1755-3768.2012.02444.x
   Puent BD, 2005, OPTOMETRY VISION SCI, V82, P612, DOI 10.1097/01.opx.0000171334.54708.89
   Rabi DM, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-124
   Reyes-Ortiz CA, 2005, J AM GERIATR SOC, V53, P681, DOI 10.1111/j.1532-5415.2005.53219.x
   Schuster AK, 2017, AGING-US, V9, P1030, DOI 10.18632/aging.101208
   Senra H, 2015, OPHTHALMOLOGY, V122, P851, DOI 10.1016/j.ophtha.2014.10.022
   Shaikh Y, 2014, AM J OPHTHALMOL, V158, P1121, DOI 10.1016/j.ajo.2014.08.023
   Siu AL, 2016, JAMA-J AM MED ASSOC, V315, P908, DOI 10.1001/jama.2016.0763
   Sloan FA, 2005, J AM GERIATR SOC, V53, P1867, DOI 10.1111/j.1532-5415.2005.53560.x
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Topouzis F, 2008, AM J OPHTHALMOL, V145, P327, DOI 10.1016/j.ajo.2007.09.013
   Tuulonen A, 2011, INDIAN J OPHTHALMOL, V59, pS24, DOI 10.4103/0301-4738.73684
   van Nispen R, 2019, ACTA OPHTHALMOL, V97, P401, DOI 10.1111/aos.13956
   Weih LM, 2001, OPHTHALMOLOGY, V108, P1966, DOI 10.1016/S0161-6420(01)00799-0
   Weinreb R. N., 2008, GLAUCOMA SCREENING
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Wong EYH, 2004, OPHTHALMOLOGY, V111, P1508, DOI 10.1016/j.ophtha.2004.01.029
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yonekawa Y, 2011, OPHTHALMOLOGY, V118, P1790, DOI 10.1016/j.ophtha.2011.02.002
   Zemba M, 2008, Oftalmologia, V52, P81
   Zhang XZ, 2007, ARCH OPHTHALMOL-CHIC, V125, P411, DOI 10.1001/archopht.125.3.411
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 59
TC 1
Z9 1
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD NOV 7
PY 2020
VL 2020
AR 3709793
DI 10.1155/2020/3709793
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA OY5IJ
UT WOS:000594280000002
PM 33489327
OA Green Submitted, Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Ansari, WH
   Han, MM
   Haq, S
   Conti, FF
   Silva, FQ
   Singh, RP
AF Ansari, Waseem H.
   Han, Michael M.
   Haq, Siraj
   Conti, Felipe F.
   Silva, Fabiana Q.
   Singh, Rishi P.
TI Baseline Ocular Characteristics of Patients Undergoing Initiation of
   Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular
   Edema
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID VISUAL-ACUITY; RETINAL THICKNESS; PREVALENCE; RANIBIZUMAB; ASSOCIATION;
   BEVACIZUMAB; AFLIBERCEPT; VITRECTOMY; OUTCOMES
AB BACKGROUND AND OBJECTIVES: Patients with diabetic macular edema (DME) have variable anatomic and visual responses to anti-vascular endothelial growth (VEGF) treatments based on their presenting visual acuity (VA). The aim of study is to report the baseline ocular and imaging characteristics of patients presenting with DME who were treatment-naive and who initiated anti-VECF in routine clinical practice.
   PATIENTS AND METHODS: Single-center, cross-sectional study of 638 patients. Subjects were divided into two VA groups: Early Treatment Diabetic Retinopathy Study (ETDRS) less than 70 and ETDRS greater than 70 and ocular variables were compared between groups.
   RESULTS: Average central subfield thickness (CST) was 363.5 mu m, cube volume was 11.7 mm(3), and cube average thickness (CAT) was 326.1 mu m. Additionally, 21.5% had subretinal fluid (SRF), and 50.5% had hard exudates on presentation. Eyes with ETDRS less than 70 had greater CAT (338.5 mu m(3) vs. 313.2 mu m(3) ; P < .001), greater cube volume (12.2 mm(3) vs. 11.3 mm(3) ; P < .001), greater CST (383.5 mu m vs. 350.0 mu m; P < .001), and SRF (25.5% vs. 17.3%; P = .012). Furthermore, 7.64% had glaucoma, 1.3% had dry age-related macular degeneration, 4.5% of patients were vitrectomized, and 28.7% were pseudophakic. Regarding diabetic stage, 37% had proliferative diabetic retinopathy (PDR) and 63% presented with non-proliferative diabetic retinopathy. Patients presenting with ETDRS less than 70 were more likely to have a history of vitrectomy (7.1% vs. 1.9%, P = .002) and presence of PDR (42.3% vs. 31.4%, P = .004).
   CONCLUSION: The results describe a population of patients from a routine clinical practice not entirely represented in clinical trials, with key differences in ocular characteristics seen between VA groups.
C1 [Ansari, Waseem H.; Conti, Felipe F.; Silva, Fabiana Q.; Singh, Rishi P.] Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,Mail Code I-32, Cleveland, OH 44195 USA.
   [Han, Michael M.; Haq, Siraj; Singh, Rishi P.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Conti, Felipe F.; Singh, Rishi P.] Cleveland Clin Fdn, Ctr Ophthalm Bioinformat, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Conti, Felipe F.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
C3 Cleveland Clinic Foundation; Case Western Reserve University; Cleveland
   Clinic Foundation; Universidade Federal de Sao Paulo (UNIFESP)
RP Singh, RP (通讯作者)，Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave,Mail Code I-32, Cleveland, OH 44195 USA.
EM singhr@ccf.org
RI Silva, Fabiana/GWU-9143-2022
FU Regeneron Pharmaceuticals
FX Portions of the study were funded by an unrestricted research grant from
   Regeneron Pharmaceuticals.
CR Al Faran A, 2014, RETINA-J RET VIT DIS, V34, P1208, DOI 10.1097/IAE.0000000000000059
   Alasil T, 2010, OPHTHALMOLOGY, V117, P2379, DOI 10.1016/j.ophtha.2010.03.051
   [Anonymous], 1995, ARCH OPHTHALMOL-CHIC, V113, P1144
   Antonetti DA, 2012, NEW ENGL J MED, V366, P1227, DOI 10.1056/NEJMra1005073
   Baker CW, 2013, JAMA OPHTHALMOL, V131, P870, DOI 10.1001/jamaophthalmol.2013.2313
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Byeon SH, 2009, OPHTHALMOLOGY, V116, P1949, DOI 10.1016/j.ophtha.2009.06.066
   Channa R, 2014, EYE, V28, P269, DOI 10.1038/eye.2013.245
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danis RP, 2010, RETINA-J RET VIT DIS, V30, P1627, DOI 10.1097/IAE.0b013e3181dde5f5
   Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Flaxel CJ, 2010, RETINA-J RET VIT DIS, V30, P1488, DOI 10.1097/IAE.0b013e3181e7974f
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gupta P, 2016, INVEST OPHTH VIS SCI, V57, P2905, DOI 10.1167/iovs.15-18469
   Kim BY, 2006, AM J OPHTHALMOL, V142, P405, DOI 10.1016/j.ajo.2006.04.023
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Kralinger MT, 2006, OPHTHALMOLOGICA, V220, P147, DOI 10.1159/000091756
   Sim DA, 2013, INVEST OPHTH VIS SCI, V54, P2353, DOI 10.1167/iovs.12-11103
   Vujosevic S, 2017, AM J OPHTHALMOL, V181, P149, DOI 10.1016/j.ajo.2017.06.026
   Wells JA, 2016, JAMA OPHTHALMOL, V134, P127, DOI 10.1001/jamaophthalmol.2015.4599
   Zhou MW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102972
NR 23
TC 4
Z9 4
U1 0
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2019
VL 50
IS 2
BP 69
EP 75
DI 10.3928/23258160-20190129-02
PG 7
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA HL6KP
UT WOS:000458843200011
PM 30768213
DA 2022-11-30
ER

PT J
AU Windsor, MA
   Sun, SJJ
   Frick, KD
   Swanson, EA
   Rosenfeld, PJ
   Huang, D
AF Windsor, Matthew A.
   Sun, Sissi J. J.
   Frick, Kevin D.
   Swanson, Eric A.
   Rosenfeld, Philip J.
   Huang, David
TI Estimating Public and Patient Savings From Basic Research-A Study of
   Optical Coherence Tomography in Managing Antiangiogenic Therapy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TREAT-AND-EXTEND; MACULAR DEGENERATION; UNITED-STATES; RANIBIZUMAB;
   BEVACIZUMAB; EFFICACY; TRIAL
AB PURPOSE: To compare patient and Medicare savings from the use of optical coherence tomography (OCT) in guiding therapy for neovascular age-related macular degeneration (nvAMD) to the research investments made in developing OCT by the National Institutes of Health (NIH) and the National Science Foundation (NSF).
   DESIGN: Observational cohort study.
   METHODS: Main outcome measures were spending by Medicare as tracked by Current Procedural Terminology codes on intravitreal injections (67028), retinal OCT imaging (92134), and anti-vascular endothelial growth factor (anti-VEGF) treatment-specific J-codes (J0178, J2778, J9035, J3490, and J3590). These claims were identified from the Medicare Provider Utilization and Payment Data from the Centers for Medicare and Medicaid Services among fee-for-service (FFS) Medicare beneficiaries from 2012 to 2015; 2008 claims were acquired from the 100% FFS Part B Medicare Claims File. OCT research costs were determined by searching for grants awarded by NIH and NSF from inception to 2015. All costs and savings were discounted by 3% annually and adjusted for inflation to 2015 dollars.
   RESULTS: From 2008 to 2015, the United States government and nvAMD patients have accrued an estimated savings of $9.0 billion and $2.2 billion, respectively, from the use of OCT to guide personalized anti-VEGF treatment. The $9.0 billion represents a 21-fold return on government investment into developing the technology through NIH and NSF grants.
   CONCLUSIONS: Although an overall cost-benefit ratio of government-sponsored research is difficult to estimate because the benefit may be diffuse and delayed, the investment in OCT over 2 decades has been recouped many times over in just a few years through better personalized therapy. (C) 2017 The Authors. Published by Elsevier Inc.
C1 [Windsor, Matthew A.] Assoc Res Vis & Ophthalmol, Rockville, MD USA.
   [Sun, Sissi J. J.; Frick, Kevin D.] Johns Hopkins Carey Business Sch, Baltimore, MD USA.
   [Swanson, Eric A.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Huang, David] Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
C3 Johns Hopkins University; Massachusetts Institute of Technology (MIT);
   Bascom Palmer Eye Institute; University of Miami; Oregon Health &
   Science University
RP Huang, D (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM davidhuang@alum.mit.edu
OI Frick, Kevin/0000-0002-0178-5319; Windsor, Matthew
   A./0000-0002-0014-6101
FU RESEARCH TO PREVENT BLINDNESS (New York, NY); National Institutes of
   Health (Bethesda, MD) [P30 EY010572]; Champalimaud Foundation (Lisbon,
   Portugal); NATIONAL EYE INSTITUTE [P30EY010572] Funding Source: NIH
   RePORTER
FX DAVID HUANG WAS SUPPORTED BY AN UNRESTRICTED GRANT FROM RESEARCH TO
   PREVENT BLINDNESS (New York, NY), National Institutes of Health
   (Bethesda, MD) P30 EY010572, and the Champalimaud Foundation (Lisbon,
   Portugal).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2017, PART B NAT SUMM DAT
   [Anonymous], 2017, NSF AW SEARCH 2017
   [Anonymous], 2016, WHATS MED SUPPL INS
   [Anonymous], 2017, MED PART B DRUG AV S
   [Anonymous], 2015, JUN 2015 DAT HLTH CA
   [Anonymous], 2017, MED PHYS FEE SCHED S
   [Anonymous], 2017, NIH RES PORTF ONL RE
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bezerra HG, 2009, JACC-CARDIOVASC INTE, V2, P1035, DOI 10.1016/j.jcin.2009.06.019
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Calabresi PA, 2015, OPTICAL COHERENCE TO
   Centers for Medicare and Medicaid Services, 2016, MED 2016 COSTS GLANC
   Centers for Medicare and Medicaid Services, 2017, MED PROV UT PAYM DAT
   Cheung N, 2014, DIABETES CARE, V37, P900, DOI 10.2337/dc13-1990
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   Food and Drug Administration, 2012, FED REGISTER, V77, P2012
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gold M, 2017, MEDICARE ADVANTAGE 2
   Gold MR., 1996, COST EFFECTIVENESS H
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Izatt JA, 2008, BIOL MED PHYS BIOMED, P47, DOI 10.1007/978-3-540-77550-8_2
   Jumper JM, 2012, ASRS 2012 PREFERENCE
   Kantarjian H, 2015, MAYO CLIN PROC, V90, P500, DOI 10.1016/j.mayocp.2015.01.014
   Leitner M, 2013, OPTICAL COHERENCE TO, P163, DOI 10.5772/53960.
   Liang H, 2005, OPT EXPRESS, V13, P6133, DOI 10.1364/OPEX.13.006133
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mittra RA, 2008, ASRS 2008 PREFERENCE
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smiddy WE, 2009, OPHTHALMOLOGY, V116, P481, DOI 10.1016/j.ophtha.2008.10.029
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stone T, 2015, ASRS 2015 PREFERENCE
   Swanson E. A., 2012, ESTIMATES OPHTHALMIC
   Tsai TH, 2014, DIAGNOSTICS, V4, P57, DOI 10.3390/diagnostics4020057
   US Bureau of Labor Statistics, 2017, CONS PRIC IND
   Welzel J, 2001, SKIN RES TECHNOL, V7, P1, DOI 10.1034/j.1600-0846.2001.007001001.x
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Ying G, 2015, OPHTHALMOLOGY, V122
NR 45
TC 23
Z9 24
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2018
VL 185
BP 115
EP 122
DI 10.1016/j.ajo.2017.09.027
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FQ8TL
UT WOS:000418636000018
PM 29224686
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Liu, C
   Chang, DX
   Zhang, XH
   Sui, H
   Kong, YD
   Zhu, RY
   Wang, WP
AF Liu, Chen
   Chang, Daoxiao
   Zhang, Xinhui
   Sui, Hong
   Kong, Yindi
   Zhu, Rongyue
   Wang, Wenping
TI Oral fast-dissolving films containing lutein nanocrystals for improved
   bioavailability: formulation development, in vitro and in vivo
   evaluation
SO AAPS PHARMSCITECH
LA English
DT Article
DE bioavailability; Box-Behnken Design; lutein; nanocrystals; oral
   fast-dissolving films
ID HIGH-PRESSURE HOMOGENIZATION; DRUG-DELIVERY SYSTEM; HOT-MELT EXTRUSION;
   BOX-BEHNKEN DESIGN; MACULAR DEGENERATION; NANOPARTICLES; OPTIMIZATION
AB Lutein is widely used as diet supplement for prevention of age-related macular degeneration. However, the application and efficacy of lutein in food and nutritional products has been hampered due to its poor solubility and low oral bioavailability. This study aimed to develop and evaluate the formulation of oral fast-dissolving film (OFDF) containing lutein nanocrystals for enhanced bioavailability and compliance. Lutein nanocrystals were prepared by anti-solvent precipitation method and then encapsulated into the films by solvent casting method. The formulation of OFDF was optimized by Box-Behnken Design (BBD) as follows: HPMC 2.05% (w/v), PEG 400 1.03% (w/v), Cremophor EL 0.43% (w/v). The obtained films exhibited uniform thickness of 35.64 +/- 1.64 mu m and drug content of 0.230 +/- 0.003 mg/cm(2) and disintegrated rapidly in 29 +/- 8 s. The nanocrystal-loaded films with reconstituted particle size of 377.9 nm showed better folding endurance and faster release rate in vitro than the conventional OFDFs with raw lutein. The microscope images, thermograms, and diffractograms indicated that lutein nanocrystals were highly dispersed into the films. After administrated to SD rats, t(max) was decreased from 3 h for oral solution formulation to less than 0.8 h for OFDF formulations, and C-max increased from 150 ng/mL for solution to 350 ng/mL for conventional OFDF or 830 ng/mL for nanocrystal OFDF. The AUC(0-24h) of conventional or nanocrystal OFDF was 1.37 or 2.08-fold higher than that of the oral solution, respectively. These results suggested that drug nanocrystal-loaded OFDF can be applied as a promising approach for enhanced bioavailability of poor soluble drugs like lutein.
C1 [Liu, Chen] Ningxia Med Univ, Pharmaceut Preparat Ctr, Gen Hosp, Ningxia 750004, Peoples R China.
   [Chang, Daoxiao; Zhang, Xinhui; Sui, Hong; Kong, Yindi; Zhu, Rongyue; Wang, Wenping] Ningxia Med Univ, Sch Pharm, Dept Pharmaceut, 1160 Shengli St, Ningxia 750004, Peoples R China.
   [Wang, Wenping] Minist Educ, Ningxia Engn & Technol Res Ctr Modernizat Hui Med, Ningxia 750004, Peoples R China.
   [Wang, Wenping] Minist Educ, Key Lab Hui Ethn Med Modernizat, Ningxia 750004, Peoples R China.
C3 Ningxia Medical University; Ningxia Medical University
RP Wang, WP (通讯作者)，Ningxia Med Univ, Sch Pharm, Dept Pharmaceut, 1160 Shengli St, Ningxia 750004, Peoples R China.; Wang, WP (通讯作者)，Minist Educ, Ningxia Engn & Technol Res Ctr Modernizat Hui Med, Ningxia 750004, Peoples R China.; Wang, WP (通讯作者)，Minist Educ, Key Lab Hui Ethn Med Modernizat, Ningxia 750004, Peoples R China.
EM wpwang2015@163.com
FU National Natural Science Foundation of China [81660665]
FX This work was financially supported from the National Natural Science
   Foundation of China (81660665).
CR Abdelbary A, 2014, AAPS PHARMSCITECH, V15, P1603, DOI 10.1208/s12249-014-0186-8
   Alshetaili AS, 2016, DRUG DEV IND PHARM, V42, P1833, DOI 10.1080/03639045.2016.1178769
   Apte RS, 2016, EBIOMEDICINE, V5, P26, DOI 10.1016/j.ebiom.2016.02.003
   Aslam M, 2016, J MOL LIQ, V219, P897, DOI 10.1016/j.molliq.2016.03.069
   Bin Liew K, 2012, AAPS PHARMSCITECH, V13, P134, DOI 10.1208/s12249-011-9729-4
   Croy SR, 2005, J PHARM SCI-US, V94, P2345, DOI 10.1002/jps.20301
   Davidov-Pardo G, 2016, FOOD CHEM, V196, P821, DOI 10.1016/j.foodchem.2015.10.018
   Garsuch V, 2010, J PHARM PHARMACOL, V62, P539, DOI 10.1211/jpp.62.04.0018
   Gleize B, 2013, BRIT J NUTR, V110, P1, DOI 10.1017/S0007114512004813
   Kapoor R, 2014, INNOV FOOD SCI EMERG, V26, P490, DOI 10.1016/j.ifset.2014.05.015
   Khan S, 2015, AAPS PHARMSCITECH, V16, P800, DOI 10.1208/s12249-014-0268-7
   Lai F, 2015, CARBOHYD POLYM, V121, P217, DOI 10.1016/j.carbpol.2014.11.070
   Lei YY, 2016, DRUG DELIV TRANSL RE, V6, P519, DOI 10.1007/s13346-016-0300-4
   Montenegro-Nicolini M, 2017, AAPS PHARMSCITECH, V18, P3, DOI 10.1208/s12249-016-0525-z
   Pandey GS, 2014, IJAPBC, V3, P199
   Preis M, 2015, AAPS PHARMSCITECH, V16, P234, DOI 10.1208/s12249-015-0313-1
   Querques G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149219
   Read AM, 2011, INFLUENCE DIGESTION
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Shanmugam S, 2011, EUR J PHARM BIOPHARM, V79, P250, DOI 10.1016/j.ejpb.2011.04.012
   Shen BD, 2013, EUR J PHARM BIOPHARM, V85, P1348, DOI 10.1016/j.ejpb.2013.09.019
   Shen CY, 2014, DRUG DEV IND PHARM, V40, P649, DOI 10.3109/03639045.2014.884116
   Stancanelli R, 2012, J PHARMACEUT BIOMED, V71, P214, DOI 10.1016/j.jpba.2012.07.034
   Sushma M, 2014, CURR DRUG DELIV, V11, P172, DOI 10.2174/15672018113109990045
   Tian Y, 2015, ARCH BIOCHEM BIOPHYS, V572, P49, DOI 10.1016/j.abb.2015.01.019
   Alvarez MV, 2015, PHYTOCHEM REV, V14, P891, DOI 10.1007/s11101-015-9434-0
   Xia YR, 2015, PHARM DEV TECHNOL, V20, P375, DOI 10.3109/10837450.2014.882936
   Yanagi M, 2008, BIOL PHARM BULL, V31, P278, DOI 10.1248/bpb.31.278
   Ye XY, 2016, AAPS PHARMSCITECH, V17, P78, DOI 10.1208/s12249-015-0389-7
   Yoo J, 2013, BIOMOL THER, V21, P173, DOI 10.4062/biomolther.2013.011
NR 30
TC 31
Z9 31
U1 7
U2 36
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-9932
J9 AAPS PHARMSCITECH
JI AAPS PharmSciTech
PD NOV
PY 2017
VL 18
IS 8
BP 2957
EP 2964
DI 10.1208/s12249-017-0777-2
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FK7BP
UT WOS:000413659200012
PM 28462465
DA 2022-11-30
ER

PT J
AU Pratt, JD
   Stevenson, SB
   Bedell, HE
AF Pratt, Joshua D.
   Stevenson, Scott B.
   Bedell, Harold E.
TI Scotoma Visibility and Reading Rate with Bilateral Central Scotomas
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE macular degeneration; scotoma; perceptual filling-in; eccentric viewing;
   low vision rehabilitation; reading speed; reading eye movements; gaze
   contingent display
ID SCANNING LASER OPHTHALMOSCOPE; PREFERRED RETINAL LOCUS; LOW-VISION;
   MACULAR DEGENERATION; CORTICAL MAPS; BLIND SPOT; FILLING-IN;
   REORGANIZATION; PSYCHOPHYSICS; LOCATION
AB Purpose In this experiment, we tested whether perceptually delineating the scotoma location and border with a gaze contingent polygon overlay improves reading speed and reading eye movements in patients with bilateral central scotomas.
   Methods Eight patients with age-related macular degeneration and bilateral central scotomas read aloud MNRead style sentences with their preferred eye. Eye movement signals from an EyeLink II eyetracker were used to create a gaze contingent display in which a polygon overlay delineating the area of the patient's scotoma was superimposed on the text during 18 of the 42 trials. Blocks of six trials with the superimposed polygon were alternated with blocks of six trials without the polygon. Reading speed and reading eye movements were assessed before and after the subjects practiced reading with the polygon overlay.
   Results All of the subjects but one showed an increase in reading speed. A paired-samples t-test for the group as a whole revealed a statistically significant increase in reading speed of 0.075 0.060 (SD) log wpm after reading with the superimposed polygon. Individual subjects demonstrated significant changes in reading eye movements, with the greatest number of subjects demonstrating a shift in the average vertical fixation locus. Across subjects, there was no significant difference between the initial and final reading eye movements in terms of saccades per second, average fixation duration, average amplitude of saccades, or proportion of non-horizontal saccades.
   Conclusions The improvement in reading speed (0.075 log wpm or 19%) over the short experimental session for the majority of subjects indicates that making the scotoma location more visible is potentially beneficial for improving reading speed in patients with bilateral central scotomas. Additional research to examine the efficacy of more extended training with this paradigm is warranted.
C1 [Pratt, Joshua D.; Stevenson, Scott B.; Bedell, Harold E.] Univ Houston, Coll Optometry, Houston, TX USA.
C3 University of Houston System; University of Houston
RP Pratt, JD (通讯作者)，Twin Harbors Eye Ctr, Aberdeen, WA 98520 USA.
EM jdpratt07@gmail.com
FU National Eye Institute [P30 EY 07551]; NATIONAL EYE INSTITUTE
   [P30EY007551] Funding Source: NIH RePORTER
FX This research was supported in part by core grant P30 EY 07551 from the
   National Eye Institute. The authors thank Chris Kuether, Swati Modi, OD,
   Nicole Hooper, OD, Ana Perez, OD, and Danny Zander, OTR for their
   assistance with the study, and Drs. J. Steven Mansfield and Gordon E.
   Legge for providing MNRead sentences.
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   Aguilar C, 2011, VISION RES, V51, P997, DOI 10.1016/j.visres.2011.02.010
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   CHINO YM, 1992, VISION RES, V32, P789, DOI 10.1016/0042-6989(92)90021-A
   Deruaz Anouk, 2006, BMC Ophthalmol, V6, P35, DOI 10.1186/1471-2415-6-35
   Dilks DD, 2009, J NEUROSCI, V29, P2768, DOI 10.1523/JNEUROSCI.5258-08.2009
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fletcher Donald C, 2012, Optom Vis Sci, V89, P1395, DOI 10.1097/OPX.0b013e318264cc77
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Holocomb J G, 1976, J Am Optom Assoc, V47, P1438
   KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637
   Mansfield J.S., 1993, OPT SOC AM TECHNOL D, V3, P232
   Mansfield JS, 1996, INVEST OPHTH VIS SCI, V37, P1492
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Pratt JD, 2014, OPTOMETRY VISION SCI, V91, P312, DOI 10.1097/OPX.0000000000000167
   RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0
   RAMACHANDRAN VS, 1992, NATURE, V356, P115, DOI 10.1038/356115a0
   RAYNER K, 1981, J EXP PSYCHOL HUMAN, V7, P167, DOI 10.1037/0096-1523.7.1.167
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   SCHUCHARD RA, 1995, AM J OCCUP THER, V49, P870, DOI 10.5014/ajot.49.9.870
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Seiple W, 2011, INVEST OPHTH VIS SCI, V52, P2938, DOI 10.1167/iovs.10-6137
   Spillmann L, 2006, VISION RES, V46, P4252, DOI 10.1016/j.visres.2006.08.033
   Stelmack JA, 2004, J REHABIL RES DEV, V41, P729, DOI 10.1682/JRRD.2003.08.0136
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   van der Geest JN, 2002, J NEUROSCI METH, V114, P185, DOI 10.1016/S0165-0270(01)00527-1
   Verezen CA, 2011, OPTOMETRY VISION SCI, V88, P1164, DOI 10.1097/OPX.0b013e31822891e0
   Watson GR, 2006, J REHABIL RES DEV, V43, P761, DOI 10.1682/JRRD.2005.07.0120
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   Zur D, 2003, VISION RES, V43, P971, DOI 10.1016/S0042-6989(03)00038-5
NR 34
TC 3
Z9 3
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAR
PY 2017
VL 94
IS 3
BP 279
EP 289
DI 10.1097/OPX.0000000000001042
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EM9KU
UT WOS:000395631200002
PM 28030516
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Vennedey, V
   Danner, M
   Evers, SMAA
   Fauser, S
   Stock, S
   Dirksen, CD
   Hiligsmann, M
AF Vennedey, Vera
   Danner, Marion
   Evers, Silvia M. A. A.
   Fauser, Sascha
   Stock, Stephanie
   Dirksen, Carmen D.
   Hiligsmann, Mickael
TI Using qualitative research to facilitate the interpretation of
   quantitative results from a discrete choice experiment: insights from a
   survey in elderly ophthalmologic patients
SO PATIENT PREFERENCE AND ADHERENCE
LA English
DT Article
DE discrete choice experiment; patient preferences; qualitative research;
   age related macular degeneration; intravitreal injection
ID MACULAR DEGENERATION; PREFERENCE
AB Background: Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in industrialized countries. Currently, mainly three treatment options are available, which are all intravitreal injections, but differ with regard to the frequency of injections needed, their approval status, and cost. This study aims to estimate patients' preferences for characteristics of treatment options for neovascular AMD.
   Methods: An interviewer-assisted discrete choice experiment was conducted among patients suffering from AMD treated with intravitreal injections. A Bayesian efficient design was used for the development of 12 choice tasks. In each task patients indicated their preference for one out of two treatment scenarios described by the attributes: side effects, approval status, effect on visual function, injection and monitoring frequency. While answering the choice tasks, patients were asked to think aloud and explain the reasons for choosing or rejecting specific characteristics. Quantitative data were analyzed with a mixed multinomial logit model.
   Results: Eighty-six patients completed the questionnaire. Patients significantly preferred treatments that improve visual function, are approved, are administered in a pro re nata regimen (as needed), and are accompanied by bimonthly monitoring. Patients significantly disliked less frequent monitoring visits (every 4 months) and explained this was due to fear of deterioration being left unnoticed, and in turn experiencing disease deterioration. Significant preference heterogeneity was found for all levels except for bimonthly monitoring visits and severe, rare eye-related side effects. Patients gave clear explanations of their individual preferences during the interviews.
   Conclusion: Significant preference trends were discernible for the overall sample, despite the preference heterogeneity for most treatment characteristics. Patients like to be monitored and treated regularly, but not too frequently or infrequently. The results of our qualitative research facilitated the interpretation of the quantitative data collected in this study.
C1 [Vennedey, Vera; Danner, Marion; Stock, Stephanie] Cologne Univ Hosp, Inst Hlth Econ & Clin Epidemiol, Cologne, Germany.
   [Evers, Silvia M. A. A.; Hiligsmann, Mickael] Maastricht Univ, Sch Primary Care & Publ Hlth CAPHRI, Dept Hlth Serv Res, NL-6200 MD Maastricht, Netherlands.
   [Evers, Silvia M. A. A.] Netherlands Inst Mental Hlth & Addict, Trimbos Inst, Dept Publ Mental Hlth, Utrecht, Netherlands.
   [Fauser, Sascha] Cologne Univ Hosp, Dept Vitreo Retinal Surg, Ctr Ophthalmol, Cologne, Germany.
   [Dirksen, Carmen D.] Univ Hosp Maastricht, Dept Clin Epidemiol & Med Technol Assessment, CAPHRI, Maastricht, Netherlands.
C3 University of Cologne; Maastricht University; Trimbos Institute;
   University of Cologne; Maastricht University
RP Vennedey, V (通讯作者)，Inst Hlth Econ & Clin Epidemiol, Gleueler Str 176-178, D-50935 Cologne, Germany.
EM vera.vennedey@uk-koeln.de
RI Evers, Silvia MAA/K-9720-2015; Evers, Silvia/ABG-2128-2020
OI Evers, Silvia MAA/0000-0003-1026-570X; Evers, Silvia/0000-0003-1026-570X
FU Bayer Vital GmbH, Germany
FX The authors thank Dr Dirk Muller, Dr Philipp Muther, and Fabian Julich
   for their input during the study preparation; Sabrina Liebner and
   Fatjana Bylo for their support during patient recruitment. Furthermore,
   the authors would like to thank all patients for their participation.
   This investigator-initiated study was financially supported by Bayer
   Vital GmbH, Germany (which markets the product aflibercept). The sponsor
   had no role in the study design, data collection, data analysis or
   writing and publishing of the report.
CR Altman DG, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d2304
   Bech M, 2005, HEALTH ECON, V14, P1079, DOI 10.1002/hec.984
   Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013
   Coast Joanna, 2007, J Health Serv Res Policy, V12, P25, DOI 10.1258/135581907779497602
   Coast J, 2012, HEALTH ECON, V21, P730, DOI 10.1002/hec.1739
   Danner M, 2016, PATIENT, V9, P47, DOI 10.1007/s40271-015-0122-3
   de Bekker-Grob EW, 2015, PATIENT, V8, P373, DOI 10.1007/s40271-015-0118-z
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   European Medicines Agency, 2012, SUMM EUR PUBL ASS RE
   European Medicines Agency, 2008, SUMM EUR PUBL ASS RE
   Feller William, 1968, INTRO PROBABILITY TH, V1
   Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223
   Lancsar E, 2006, HEALTH ECON, V15, P797, DOI 10.1002/hec.1104
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Orme B.K., 2006, GETTING STARTED CONJ
   Real JP, 2015, GRAEF ARCH CLIN EXP, V253, P1859, DOI 10.1007/s00417-014-2885-y
   Ryan M, 2008, ECON NON-MARK GOOD, V11, P1, DOI 10.1007/978-1-4020-5753-3
   Ryan M, 2009, HEALTH ECON, V18, P321, DOI 10.1002/hec.1369
   Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71
   Wenzel M, 2014, OPHTHALMO CHIRURGIE, V26, P171
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 23
TC 16
Z9 16
U1 0
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-889X
J9 PATIENT PREFER ADHER
JI Patient Prefer. Adherence
PY 2016
VL 10
BP 993
EP 1002
DI 10.2147/PPA.S101584
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DN8VK
UT WOS:000377357700001
PM 27350743
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lee, SH
   Colosi, P
   Lee, H
   Ohn, YH
   Kim, SW
   Kwak, HW
   Park, TK
AF Lee, Si Hyung
   Colosi, Peter
   Lee, Heuiran
   Ohn, Young-Hoon
   Kim, Sung-Woon
   Kwak, Hyung Woo
   Park, Tae Kwann
TI Laser Photocoagulation Enhances Adeno-Associated Viral Vector
   Transduction of Mouse Retina
SO HUMAN GENE THERAPY METHODS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; FIBRILLARY ACIDIC PROTEIN; PIGMENT
   EPITHELIAL-CELLS; FIBROBLAST-GROWTH-FACTOR; UP-REGULATION; VISUAL-LOSS;
   RANIBIZUMAB; EXPRESSION; RAT; MANAGEMENT
AB Laser photocoagulation is a well-established treatment modality for retinal disease. Discrete laser burns can be placed anywhere in the retina, singly or multiply, and the burn intensity is controllable. This study investigates the effect of prior laser photocoagulation on the retinal transduction properties of intravitreally administered adeno-associated viral (AAV) vectors. C57BL/6J mice were subjected to unilateral laser photocoagulation 48 hr before bilateral intravitreal injection of self-complementary cytomegaloviral enhanced green fluorescent protein (EGFP) vectors packaged in AAV type 2, 5, and 8 capsids. The eyes were enucleated 4 weeks after injection and examined by histochemistry and quantitative image analysis. Laser pretreatment resulted in substantially increased localized transduction around the burn site for all AAV capsid types. Without laser pretreatment, the vectors transduced only ganglion cells (AAV2) or sporadic cells around the optic nerve head (AAV5 and AAV8). Laser pretreatment increased AAV2 vector expression throughout the entire retina and focally at the burn site. Transduced cells at the burn site included retinal pigment epithelium (RPE), photoreceptors, Muller cells, inner nuclear layer cells, and retinal ganglion cells. The AAV5 vector showed increased RPE transduction at the burn site only. The AAV8 vector showed augmented expression in RPE, photoreceptors, and Muller cells around the burn site. Migrating RPE cells, present in the neural retina near the burn site, were also transduced by all three capsid types as evidenced by colocalization of EGFP and cytokeratin. Laser photocoagulation can be used to precisely direct AAV vector transduction to discrete locations in the retina. A combination of laser and AAV-mediated gene expression may allow the development of improved therapies for diabetic retinopathy, branch and central vein occlusion, and age-related macular degeneration.
C1 [Lee, Si Hyung; Ohn, Young-Hoon; Park, Tae Kwann] Soonchunhyang Univ, Dept Ophthalmol, Coll Med, Puchon 420767, South Korea.
   [Colosi, Peter] BioMarin Pharmaceut, Novato, CA 94901 USA.
   [Lee, Heuiran] Univ Ulsan, Dept Microbiol, Coll Med, Seoul 138736, South Korea.
   [Kim, Sung-Woon] Kyung Hee Univ, Sch Med, Dept Endocrinol & Metab, Seoul 130872, South Korea.
   [Kwak, Hyung Woo] Kyung Hee Univ, Sch Med, Dept Ophthalmol, Seoul 138872, South Korea.
C3 Soonchunhyang University; BioMarin Pharmaceutical Inc.; University of
   Ulsan; Kyung Hee University; Kyung Hee University
RP Park, TK (通讯作者)，Soonchunhyang Univ, Dept Ophthalmol, Coll Med, Bucheon Hosp, 1174 Jung Dong, Puchon 420767, South Korea.
EM tkpark@schmc.ac.kr
RI Lee, Si Hyung/ABH-1408-2020
OI Park, Tae Kwann/0000-0001-9689-4384
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science, and Technology [2011-0014354]
FX This work was supported by a Basic Science Research Program through the
   National Research Foundation of Korea (NRF), funded by the Ministry of
   Education, Science, and Technology (grant 2011-0014354).
CR [Anonymous], 1978, Ophthalmology, V85, P82
   [Anonymous], 1976, AM J OPHTHALMOL, V81, P383
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CLARKSON JG, 1995, OPHTHALMOLOGY, V102, P1425
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Dalkara D, 2009, MOL THER, V17, P2096, DOI 10.1038/mt.2009.181
   ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1
   Fong DS, 2002, SURV OPHTHALMOL, V47, pS238, DOI 10.1016/S0039-6257(02)00389-2
   Gee MS, 2003, AM J PATHOL, V162, P183, DOI 10.1016/S0002-9440(10)63809-6
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HISCOTT PS, 1984, BRIT J OPHTHALMOL, V68, P708, DOI 10.1136/bjo.68.10.708
   IE D, 1994, CURR EYE RES, V13, P743, DOI 10.3109/02713689409047009
   Ishida K, 1998, INVEST OPHTH VIS SCI, V39, P801
   KASPER M, 1988, HISTOCHEMISTRY, V89, P369, DOI 10.1007/BF00500639
   KLEINER RC, 1988, AM J OPHTHALMOL, V106, P298, DOI 10.1016/0002-9394(88)90365-0
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lewis GP, 2003, INT REV CYTOL, V230, P263, DOI 10.1016/S0074-7696(03)30005-1
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   MCDONALD HR, 1985, OPHTHALMOLOGY, V92, P388
   McIntosh RL, 2007, OPHTHALMOLOGY, V114, P835, DOI 10.1016/j.ophtha.2007.01.010
   Nagineni CN, 2005, J CELL PHYSIOL, V203, P35, DOI 10.1002/jcp.20213
   OWARIBE K, 1988, CELL TISSUE RES, V254, P301
   Ozaki S, 2000, INVEST OPHTH VIS SCI, V41, P568
   Paulus YM, 2008, INVEST OPHTH VIS SCI, V49, P5540, DOI 10.1167/iovs.08-1928
   ROSENBERG N, 1986, ARCH OPHTHALMOL-CHIC, V104, P34
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shin O, 2008, J GENE MED, V10, P762, DOI 10.1002/jgm.1204
   Song JH, 2009, OPHTHALMOLOGICA, V223, P85, DOI 10.1159/000175312
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tackenberg MA, 2009, MOL VIS, V15, P1886
   TUCCARI G, 1986, BASIC APPL HISTOCHEM, V30, P425
   TURKSEN K, 1989, OPHTHALMIC RES, V21, P56, DOI 10.1159/000266768
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Virgili G., 2005, COCHRANE DB SYST REV, V4
   Weber M, 2003, MOL THER, V7, P774, DOI 10.1016/S1525-0016(03)00098-4
   Yamamoto C, 1996, JPN J OPHTHALMOL, V40, P480
   Yin L, 2011, INVEST OPHTH VIS SCI, V52, P2775, DOI 10.1167/iovs.10-6250
NR 47
TC 22
Z9 24
U1 0
U2 9
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1946-6536
EI 1946-6544
J9 HUM GENE THER METHOD
JI Hum. Gene Ther. Methods
PD FEB
PY 2014
VL 25
IS 1
BP 83
EP 91
DI 10.1089/hgtb.2013.089
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA AI5MN
UT WOS:000336911600008
PM 24191872
OA Green Published
DA 2022-11-30
ER

PT J
AU Wang, MY
   Rousseau, J
   Boisjoly, H
   Schmaltz, H
   Kergoat, MJ
   Moghadaszadeh, S
   Djafari, F
   Freeman, EE
AF Wang, Meng Ying
   Rousseau, Jacqueline
   Boisjoly, Helene
   Schmaltz, Heidi
   Kergoat, Marie-Jeanne
   Moghadaszadeh, Solmaz
   Djafari, Fawzia
   Freeman, Ellen E.
TI Activity Limitation due to a Fear of Falling in Older Adults with Eye
   Disease
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VISUAL-FIELD LOSS; ACTIVITY RESTRICTION; CONTRAST SENSITIVITY; MACULAR
   DEGENERATION; MOBILITY; PERFORMANCE; GLAUCOMA; RISK; POPULATION;
   IMPAIRMENT
AB PURPOSE. To examine whether patients with age-related macular degeneration (AMD), glaucoma, or Fuchs corneal dystrophy report limiting their activity due to a fear of falling as compared with a control group of older adults with good vision.
   METHODS. We recruited 345 patients (93 with AMD, 57 with Fuchs, 98 with glaucoma, and 97 controls) from the ophthalmology clinics of Maisonneuve-Rosemont Hospital (Montreal, Canada) to participate in a cross-sectional study from September 2009 until July 2012. Control patients who had normal visual acuity and visual field were recruited from the same clinics. Participants were asked if they limited their activity due to a fear of falling. Visual acuity, contrast sensitivity, and visual field were measured and the medical record was reviewed.
   RESULTS. Between 40% and 50% of patients with eye disease reported activity limitation due to a fear of falling compared with only 16% of controls with normal vision. After adjustment for age, sex, race, number of comorbidities, cognition, and lens opacity, the Fuchs groups was most likely to report activity limitation due to a fear of falling (odds ratio [OR] = 3.07; 95% confidence interval [CI], 1.33-7.06) followed by the glaucoma group (OR = 2.84; 95% CI, 1.36-5.96) and the AMD group (OR = 2.42; 95% CI, 1.09-5.35). Contrast sensitivity best explained these associations.
   CONCLUSIONS. Activity limitation due to a fear of falling is very common in older adults with visually impairing eye disease. Although this compensatory strategy may protect against falls, it may also put people at risk for social isolation and disability. (Invest Ophthalmol Vis Sci. 2012;53:7967-7972) DOI: 10.1167/iovs.12-10701
C1 [Wang, Meng Ying; Boisjoly, Helene; Moghadaszadeh, Solmaz; Djafari, Fawzia; Freeman, Ellen E.] Hop Maison Neuve Rosemont, Ctr Rech, Montreal, PQ H1T 2M4, Canada.
   [Rousseau, Jacqueline; Kergoat, Marie-Jeanne] Inst Univ Geriatrie Montreal, Ctr Rech, Montreal, PQ, Canada.
   [Boisjoly, Helene; Djafari, Fawzia; Freeman, Ellen E.] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Schmaltz, Heidi] Univ Calgary, Dept Geriatr Med, Calgary, AB, Canada.
C3 Universite de Montreal; Universite de Montreal; Universite de Montreal;
   University of Calgary
RP Freeman, EE (通讯作者)，Hop Maisonneuve Rosemont Rech Ophtalmol, CSA, RC, F131 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.
EM eefreeman@gmail.com
OI Freeman, Ellen/0000-0002-1403-8427
FU Canadian National Institute for the Blind New Investigator grant
   (Toronto, Canada); Canadian Institutes of Health Research (Ottawa,
   Canada) [IAP-98996]; Fonds de Recherche en Sante du Quebec
FX Supported by Canadian National Institute for the Blind New Investigator
   grant (Toronto, Canada), Canadian Institutes of Health Research Grant
   IAP-98996 (Ottawa, Canada), and a Fonds de Recherche en Sante du Quebec
   salary award (EEF).
CR Alamgir H, 2012, INJURY, V43, P2065, DOI 10.1016/j.injury.2011.12.001
   Almeida OP, 1999, INT J GERIATR PSYCH, V14, P858, DOI 10.1002/(SICI)1099-1166(199910)14:10<858::AID-GPS35>3.0.CO;2-8
   Anderson Andrew J, 2003, Ophthalmol Clin North Am, V16, P213, DOI 10.1016/S0896-1549(03)00011-7
   Auger C, 2009, DISABIL REHABIL-ASSI, V4, P31, DOI 10.1080/17483100802543064
   Austin N, 2007, J AM GERIATR SOC, V55, P1598, DOI 10.1111/j.1532-5415.2007.01317.x
   BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422
   Baker PS, 2003, J AM GERIATR SOC, V51, P1610, DOI 10.1046/j.1532-5415.2003.51512.x
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Black AA, 2008, OPTOMETRY VISION SCI, V85, P489, DOI 10.1097/OPX.0b013e31817882db
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Burke W J, 1991, J Geriatr Psychiatry Neurol, V4, P173, DOI 10.1177/089198879100400310
   Busse A, 2002, J CLIN EPIDEMIOL, V55, P909, DOI 10.1016/S0895-4356(02)00449-3
   Delbaere K, 2004, AGE AGEING, V33, P368, DOI 10.1093/ageing/afh106
   Deshpande N, 2008, AM J PHYS MED REHAB, V87, P354, DOI 10.1097/PHM.0b013e31815e6e9b
   Deshpande N, 2008, J AM GERIATR SOC, V56, P615, DOI 10.1111/j.1532-5415.2007.01639.x
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P21, DOI 10.1111/j.1475-1313.1990.tb01100.x
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fletcher PC, 2004, AGE AGEING, V33, P273, DOI 10.1093/ageing/afh077
   Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326
   Friedman DS, 2007, OPHTHALMOLOGY, V114, P2232, DOI 10.1016/j.ophtha.2007.02.001
   Friedman SM, 2002, J AM GERIATR SOC, V50, P1329, DOI 10.1046/j.1532-5415.2002.50352.x
   Hoenig H, 2006, J AM GERIATR SOC, V54, P262, DOI 10.1111/j.1532-5415.2005.00588.x
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Lachman ME, 1998, J GERONTOL B-PSYCHOL, V53, pP43, DOI 10.1093/geronb/53B.1.P43
   Lamb SE, 2005, J AM GERIATR SOC, V53, P1618, DOI 10.1111/j.1532-5415.2005.53455.x
   LORD SR, 1991, AGE AGEING, V20, P175, DOI 10.1093/ageing/20.3.175
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Murphy SL, 2002, J AM GERIATR SOC, V50, P516, DOI 10.1046/j.1532-5415.2002.50119.x
   Newman AB, 2006, JAMA-J AM MED ASSOC, V295, P2018, DOI 10.1001/jama.295.17.2018
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.037
   Rovner BW, 2008, AM J GERIAT PSYCHIAT, V16, P454, DOI 10.1097/JGP.0b013e31816b7342
   Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806
   Vellas BJ, 1997, J AM GERIATR SOC, V45, P735, DOI 10.1111/j.1532-5415.1997.tb01479.x
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
NR 36
TC 58
Z9 59
U1 2
U2 30
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2012
VL 53
IS 13
BP 7967
EP 7972
DI 10.1167/iovs.12-10701
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 064EX
UT WOS:000313056000008
PM 23132799
DA 2022-11-30
ER

PT J
AU Fernandes, RAB
   Diniz, B
   Ribeiro, R
   Humayun, M
AF Brant Fernandes, Rodrigo A.
   Diniz, Bruno
   Ribeiro, Ramiro
   Humayun, Mark
TI Artificial vision through neuronal stimulation
SO NEUROSCIENCE LETTERS
LA English
DT Review
DE Artificial vision; Blindness; Visual prosthesis; Retinal prosthesis
ID SUPRACHOROIDAL-TRANSRETINAL STIMULATION; ELECTRICAL-STIMULATION;
   MULTICHANNEL ELECTRODE; VISUAL PROSTHESIS; BLIND; NERVE; FEASIBILITY;
   CUFF; RETINA; ARRAY
AB Introduction: The term visual prosthesis refers to any device capable of eliciting visual percepts in an individual through electrical stimulation of any part of the visual system.
   Background: Blindness can be due to eye pathology or due to damage of the lateral geniculate or visual cortex. Eye pathology other than diseases that affect the cornea and lens are numerous and some of the leading causes are diabetic retinopathy, age-related macular degeneration, retinal detachment, glaucoma, and retinal vascular occlusions.
   The visual prosthesis can be divided into non-retinal and retinal approaches. Non-retinal approaches include cortical and optic nerve prosthesis. Retinal approaches are aimed at eye pathologies in which at least part of the optic nerve remains intact whereas when the optic nerve is nearly completely damaged and/or the eye itself is disfigured or degenerated then a non-retinal approach is warranted. The retinal prosthesis can be placed on the surface of the retina, in the subretinal space or in the suprachoroidal space.
   Results: Several independent groups related variable degrees of success in promoting visual sensations through electrical stimulation of the visual system.
   Every technique, equipment and anatomical target has its advantages and disadvantages, and the biological/electrical-mechanical interface is still the aspect of the research towards a chronic, long term, reliable biomimetic implant.
   Conclusions: The visual prostheses have achieved significant developments in recent years. We see continued improvement in visual acuity with increasing number and density of electrodes. Even though the visual acuity is still poor relative to normal vision, these subjects can read letters using their implants. Perhaps more importantly, blind patients can use these devices for mobility and orientation. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Brant Fernandes, Rodrigo A.; Diniz, Bruno; Ribeiro, Ramiro; Humayun, Mark] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Brant Fernandes, Rodrigo A.; Diniz, Bruno] Univ Fed Sao Paulo, Unifesp, EPM, Sao Paulo, Brazil.
   [Diniz, Bruno] CAPES Fdn, Brasilia, DF, Brazil.
   [Ribeiro, Ramiro] FEMPAR, Hosp Evangel Curitiba, Curitiba, Parana, Brazil.
C3 Doheny Eye Institute; University of Southern California; Universidade
   Federal de Sao Paulo (UNIFESP); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)
RP Fernandes, RAB (通讯作者)，1355 San Pablo St,Suite 102, Los Angeles, CA 90033 USA.
EM rbrant@doheny.org; bdiniz@doheny.org; rribeiro@doheny.org;
   humayun@usc.edu
RI Brant, Rodrigo/CAE-3286-2022; Brant, Rodrigo/AAR-1878-2021; Fernandes,
   Rodrigo/GWV-4158-2022
OI Brant, Rodrigo/0000-0002-0274-0315; Brant, Rodrigo/0000-0002-0274-0315; 
CR AGNEW WF, 1986, EXP NEUROL, V92, P162, DOI 10.1016/0014-4886(86)90132-9
   Besch D, 2008, BRIT J OPHTHALMOL, V92, P1361, DOI 10.1136/bjo.2007.131961
   Branner A, 2000, BRAIN RES BULL, V51, P293, DOI 10.1016/S0361-9230(99)00231-2
   Brelen ME, 2010, INVEST OPHTH VIS SCI, V51, P5351, DOI 10.1167/iovs.09-4346
   BRINDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479, DOI 10.1113/jphysiol.1968.sp008519
   BRINDLEY GS, 1974, T AM ACAD OPHTHALMOL, V78, pO741
   Brindley GS., 1964, J PHYSL, V177, P44
   Caspi A, 2009, ARCH OPHTHALMOL-CHIC, V127, P398, DOI 10.1001/archophthalmol.2009.20
   CHA K, 1992, VISION RES, V32, P1367, DOI 10.1016/0042-6989(92)90229-C
   CHA K, 1992, J OPT SOC AM A, V9, P673, DOI 10.1364/JOSAA.9.000673
   CHA KH, 1992, ANN BIOMED ENG, V20, P439, DOI 10.1007/BF02368135
   Chow AY, 2004, ARCH OPHTHALMOL-CHIC, V122, P460, DOI 10.1001/archopht.122.4.460
   Ciavatta VT, 2009, INVEST OPHTH VIS SCI, V50, P4523, DOI 10.1167/iovs.08-2072
   Cornsweet T., 1970, VISUAL PERCEPTION
   Cuoco FA, 2000, IEEE T REHABIL ENG, V8, P35, DOI 10.1109/86.830947
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DOBELLE WH, 1974, J PHYSIOL-LONDON, V243, P553, DOI 10.1113/jphysiol.1974.sp010766
   DOBELLE WH, 1976, NATURE, V259, P111, DOI 10.1038/259111a0
   Dobelle WH, 2000, ASAIO J, V46, P3, DOI 10.1097/00002480-200001000-00002
   DOBELLE WH, 1979, NEUROSURGERY, V5, P521, DOI 10.1227/00006123-197910000-00022
   Foerster O., 1929, J PSYCHOL NEUROL, V39, P435
   Fujikado T., 2011, IOVS PAPERS IN PRESS
   Fujikado T., 2003, JAPAN EXPERIENCE EPI
   GREENBERG R, 1998, THESIS J HOPKINS U B
   Greenberg RJ, 1999, IEEE T BIO-MED ENG, V46, P505, DOI 10.1109/10.759051
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Humayun MS, 1998, EYE, V12, P605, DOI 10.1038/eye.1998.151
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Kanda H, 2004, INVEST OPHTH VIS SCI, V45, P560, DOI 10.1167/iovs.02-1268
   Klauke S., 2011, IOVS, V52
   Lakhanpal Rohit R, 2003, Curr Opin Ophthalmol, V14, P122, DOI 10.1097/00055735-200306000-00002
   Levine M., 1985, VISION MAN MACHINE
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Margalit E, 2002, SURV OPHTHALMOL, V47, P335, DOI 10.1016/S0039-6257(02)00311-9
   Maynard EM, 2001, ANNU REV BIOMED ENG, V3, P145, DOI 10.1146/annurev.bioeng.3.1.145
   Maynard EM, 1997, ELECTROEN CLIN NEURO, V102, P228, DOI 10.1016/S0013-4694(96)95176-0
   McCreery DB, 1997, IEEE T BIO-MED ENG, V44, P931, DOI 10.1109/10.634645
   McCreery D, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/3/036005
   Morimoto T, 2002, NEUROREPORT, V13, P227, DOI 10.1097/00001756-200202110-00011
   Nakauchi K, 2005, GRAEF ARCH CLIN EXP, V243, P169, DOI 10.1007/s00417-004-1060-2
   Nakauchi K, 2007, J NEURAL ENG, V4, pS50, DOI 10.1088/1741-2560/4/1/S07
   NAPLES GG, 1988, IEEE T BIO-MED ENG, V35, P905, DOI 10.1109/10.8670
   POLLEN DA, 1977, BRAIN BEHAV EVOLUT, V14, P67, DOI 10.1159/000125576
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Richard G., 2009, INVEST OPHTHALMOL VI
   Sakaguchi H, 2004, JPN J OPHTHALMOL, V48, P256, DOI 10.1007/s10384-004-0055-1
   Schmidt EM, 1996, BRAIN, V119, P507, DOI 10.1093/brain/119.2.507
   Shandurina A. N., 1995, Fiziologiya Cheloveka, V21, P25
   Shandurina A N, 1996, Neurosci Behav Physiol, V26, P137, DOI 10.1007/BF02359417
   Shivdasani MN, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/3/036008
   SWEENEY JD, 1986, IEEE T BIO-MED ENG, V33, P541, DOI 10.1109/TBME.1986.325818
   Torab K, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/3/035001
   UNGAR IJ, 1986, ANN BIOMED ENG, V14, P437, DOI 10.1007/BF02367364
   Varela C, 2003, VISION RES, V43, P879, DOI 10.1016/S0042-6989(02)00493-5
   Veraart C, 2003, ARTIF ORGANS, V27, P996, DOI 10.1046/j.1525-1594.2003.07305.x
   Veraart C, 1998, BRAIN RES, V813, P181, DOI 10.1016/S0006-8993(98)00977-9
   Weiland JD, 2000, IEEE T BIO-MED ENG, V47, P911, DOI 10.1109/10.846685
   Wilson BS, 2008, J REHABIL RES DEV, V45, P695, DOI 10.1682/JRRD.2007.10.0173
   Wong YT, 2008, IEEE ENG MED BIO, P1789, DOI 10.1109/IEMBS.2008.4649525
   Wong YT, 2009, VISION RES, V49, P825, DOI 10.1016/j.visres.2009.02.018
   Zrenner E, 1997, OPHTHALMIC RES, V29, P269, DOI 10.1159/000268025
   Zrenner E, 2011, P ROY SOC B-BIOL SCI, V278, P1489, DOI 10.1098/rspb.2010.1747
NR 64
TC 49
Z9 54
U1 2
U2 66
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD JUN 25
PY 2012
VL 519
IS 2
SI SI
BP 122
EP 128
DI 10.1016/j.neulet.2012.01.063
PG 7
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 970QG
UT WOS:000306146800006
PM 22342306
DA 2022-11-30
ER

PT J
AU Knecht, PB
   Bosch, MM
   Michels, S
   Mannhardt, S
   Schmid, U
   Bosch, MA
   Menke, MN
AF Knecht, Pascal Bruno
   Bosch, Martina Monika
   Michels, Stephan
   Mannhardt, Soenke
   Schmid, Ursina
   Bosch, Martin Albert
   Menke, Marcel Nico
TI The ocular pulse amplitude at different intraocular pressure: a
   prospective study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE dynamic contour tonometry; intraocular pressure; intravitreal injection;
   ocular pulse amplitude
ID CHOROIDAL BLOOD-FLOW; DYNAMIC CONTOUR TONOMETRY; MACULAR DEGENERATION;
   INTRAVITREAL INJECTIONS; VOLUME; RIGIDITY; GLAUCOMA; EYES; PARAMETERS;
   LENGTH
AB Purpose: To investigate changes in ocular pulse amplitude (OPA) during a short-term increase in intraocular pressure (IOP) and to assess possible influences of biometrical properties of the eye, including central corneal thickness (CCT) and axial length.
   Methods: In a prospective, single centre study, OPA and IOP as measured by dynamic contour tonometry (DCT) were taken before baseline-and post-OPA (delta) intravitreal injection of 0.05 ml anti-vascular endothelial growth factor agents. Analysis was performed employing linear regression with baseline-and post (delta)-OPA differences as the dependent and post-IOP as well as delta IOP as the independent variable. A multilinear regression analysis with delta OPA as the dependent variable and baseline IOP, post-IOP, CCT and axial length as independent variables was conducted.
   Results: Forty eyes of 40 patients were included. IOP and OPA increased significantly after injection (IOP mean increase +/- SD: 17.83 +/- 9.83 mmHg, p < 0.001; OPA mean increase +/- SD: 1.39 +/- 1.16 mmHg, p < 0.001). For every mmHg increase in IOP, the OPA showed a linear increase of 0.05 mmHg (slope 0.05, 95% CI: 0.02-0.09, p = 0.003, r(2) = 0.20). Multiple regression analysis with delta OPA as the dependent variable revealed a partial correlation coefficient of 0.47 (p = 0.003) for post-IOP as the only significant contribution.
   Conclusion: A clear positive relationship between OPA measurements and IOP levels was shown in a clinical routine setting using DCT focusing on baseline and postinterventional comparisons of OPA values after intravitreal injections in patients with exudative age related macular degeneration. When considering the OPA for diagnostic purposes, we recommend indication of corresponding IOP values.
C1 [Knecht, Pascal Bruno; Bosch, Martina Monika; Michels, Stephan; Mannhardt, Soenke; Schmid, Ursina; Bosch, Martin Albert; Menke, Marcel Nico] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Michels, Stephan] Triemli Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital; Triemli Hospital
RP Knecht, PB (通讯作者)，Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM pascal.knecht@usz.ch
OI Menke, Marcel/0000-0002-6561-6178
CR Bayerle-Eder M, 2005, BRIT J OPHTHALMOL, V89, P704, DOI 10.1136/bjo.2004.062661
   Benz MS, 2006, OPHTHALMOLOGY, V113, P1174, DOI 10.1016/j.ophtha.2005.10.061
   Berisha F, 2010, ACTA OPHTHALMOL, V88, P766, DOI 10.1111/j.1755-3768.2009.01577.x
   BIENFANG DC, 1989, ACTA OPHTHALMOL, V67, P35
   BYNKE HG, 1968, ACTA OPHTHALMOL, V46, P1135
   BYNKE HG, 1967, OPHTHALMOLOGICA, V153, P29, DOI 10.1159/000305034
   Dastiridou AI, 2009, INVEST OPHTH VIS SCI, V50, P5718, DOI 10.1167/iovs.09-3760
   DOLLERY CT, 1968, INVEST OPHTH VISUAL, V7, P191
   FRIEDMAN E, 1989, OPHTHALMOLOGY, V96, P104
   Grieshaber MC, 2009, ACTA OPHTHALMOL, V87, P329, DOI 10.1111/j.1755-3768.2008.01217.x
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   JAMES CB, 1991, GRAEF ARCH CLIN EXP, V229, P341, DOI 10.1007/BF00170692
   Kanngiesser HE, 2005, J GLAUCOMA, V14, P344, DOI 10.1097/01.ijg.0000176936.16015.4e
   Kaufmann C, 2004, INVEST OPHTH VIS SCI, V45, P3118, DOI 10.1167/iovs.04-0018
   Kaufmann C, 2006, ARCH OPHTHALMOL-CHIC, V124, P1104, DOI 10.1001/archopht.124.8.1104
   KIEL JW, 1995, EXP EYE RES, V60, P267, DOI 10.1016/S0014-4835(05)80109-5
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Knecht PB, 2009, RETINA-J RET VIT DIS, V29, P1175, DOI 10.1097/IAE.0b013e3181aade74
   Kniestedt C, 2006, J GLAUCOMA, V15, P91, DOI 10.1097/00061198-200604000-00003
   Kniestedt C, 2004, ARCH OPHTHALMOL-CHIC, V122, P1287, DOI 10.1001/archopht.122.9.1287
   Kotliar K, 2007, ACTA OPHTHALMOL SCAN, V85, P777, DOI 10.1111/j.1600-0420.2007.00939.x
   LANGHAM ME, 1989, ACTA OPHTHALMOL, V67, P9
   LAWRENCE C, 1996, INVEST OPHTHALMOL, V5, P515
   Metelitsina TI, 2010, BRIT J OPHTHALMOL, V94, P1629, DOI 10.1136/bjo.2009.176859
   Mori F, 2001, BRIT J OPHTHALMOL, V85, P531, DOI 10.1136/bjo.85.5.531
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   PERKINS ES, 1981, CURR EYE RES, V1, P19, DOI 10.3109/02713688109019968
   PERKINS ES, 1985, BRIT J OPHTHALMOL, V69, P676, DOI 10.1136/bjo.69.9.676
   Polak K, 2003, EYE, V17, P84, DOI 10.1038/sj.eye.6700246
   Polska E, 2007, INVEST OPHTH VIS SCI, V48, P3768, DOI 10.1167/iovs.07-0307
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Romppainen T, 2007, OPHTHALMOLOGE, V104, P230, DOI 10.1007/s00347-006-1467-8
   Schilder P, 1994, Surv Ophthalmol, V38 Suppl, pS52, DOI 10.1016/0039-6257(94)90046-9
   Schmidt KG, 1998, KLIN MONATSBL AUGENH, V213, P241, DOI 10.1055/s-2008-1034980
   Schmidt KG, 2001, BRIT J OPHTHALMOL, V85, P678, DOI 10.1136/bjo.85.6.678
   SILVER DM, 1989, ACTA OPHTHALMOL, V67, P25
   Silver DM, 2000, CURR EYE RES, V20, P115, DOI 10.1076/0271-3683(200002)20:2;1-D;FT115
   Stalmans I, 2008, J GLAUCOMA, V17, P403, DOI 10.1097/IJG.0b013e31815c5f2c
   THIEL R, 1928, BER DTSCH OPHTHAL GE, V47, P198
   TOMEY KF, 1981, ANN OPHTHALMOL, V13, P569
   TREW DR, 1991, GRAEF ARCH CLIN EXP, V229, P553, DOI 10.1007/BF00203321
   Tsai CC, 2005, EYE, V19, P159, DOI 10.1038/sj.eye.6701434
   Wegner W, 1930, ARCH AUGENHEILKD, V102, P1
NR 43
TC 12
Z9 12
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2011
VL 89
IS 5
BP E466
EP E471
DI 10.1111/j.1755-3768.2011.02141.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 792KH
UT WOS:000292742800013
PM 21401909
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Kennedy, RD
   Spafford, MM
   Schultz, ASH
   Iley, MD
   Zawada, V
AF Kennedy, Ryan David
   Spafford, Marlee M.
   Schultz, Annette S. H.
   Iley, Matthew D.
   Zawada, Violet
TI Smoking Cessation Referrals in Optometric Practice: A Canadian Pilot
   Study
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE public health; smoking; age-related macular degeneration; tobacco-use
   cessation
ID CIGARETTE-SMOKING; MACULAR DEGENERATION; ASSOCIATION; CATARACT; RISK;
   ATTITUDES; MEN
AB Purpose. The current pilot study sought to understand optometrists' attitudes toward addressing tobacco use within the scope of their practice, and to identify opportunities within Canada to integrate optometrists as health care partners into the national tobacco cessation network.
   Methods. A descriptive qualitative design was used to conduct this pilot study. Five focus groups were conducted with 29 informants, including 11 practicing community optometrists and 18 senior Doctor of Optometry students from the University of Waterloo. Rationales, barriers, and opportunities to practice patterns were identified.
   Results. Optometrists and optometry students knew the association of smoking with eye diseases such as age-related macular degeneration and cataract; however, some informants selectively asked patients about smoking behavior based on patient age or visit type. Most informants indicated that they did inform their patients who smoke of their increased risk of developing certain eye diseases; however, very few informants assessed whether their patients wanted to stop smoking and no informants reported that they had ever provided a patient with explicit support for tobacco cessation. This limited role in smoking cessation support for patients due, in part, to insufficient: financial incentives, training and educational tools and materials, knowledge of community resources for cessation treatments, and time during appointments. Several opportunities were identified to better integrate optometry into tobacco control efforts such as optometrists' access to patients, patients' fear of blindness as a tool to motivate behavior changes, and practitioners' openness to change.
   Conclusions. Optometrists can be a helpful addition to a smoking cessation healthcare network that already involves more than a dozen health care professions including medicine, nursing, pharmacy, dentistry, and dental hygiene. The findings of this study will be used to develop a national survey of Canadian optometrists' practice patterns regarding tobacco use prevention efforts and cessation supports for their patients. (Optom Vis Sci 2011; 88:766-771)
C1 [Kennedy, Ryan David] Univ Waterloo, Propel Ctr Populat Hlth Impact, Fac Appl Hlth Sci, Waterloo, ON N2L 3G1, Canada.
   [Kennedy, Ryan David] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Ctr Global Tobacco Control, Boston, MA 02115 USA.
   [Spafford, Marlee M.; Iley, Matthew D.; Zawada, Violet] Univ Waterloo, Sch Optometry, Waterloo, ON N2L 3G1, Canada.
   [Schultz, Annette S. H.] Univ Manitoba, Fac Nursing, Winnipeg, MB, Canada.
C3 University of Waterloo; Harvard University; Harvard T.H. Chan School of
   Public Health; University of Waterloo; University of Manitoba
RP Kennedy, RD (通讯作者)，Univ Waterloo, Propel Ctr Populat Hlth Impact, Fac Appl Hlth Sci, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.
EM rdkenned@uwaterloo.ca
RI Kennedy, Ryan David/U-3794-2017; Spafford, Marlee/A-1386-2010
OI Kennedy, Ryan David/0000-0002-9448-5234; Schultz,
   Annette/0000-0002-7944-2180
CR American Medical Association, 1993, GUID AD PREV HLTH SE
   Christen WG, 2000, JAMA-J AM MED ASSOC, V284, P713, DOI 10.1001/jama.284.6.713
   Cockburn David M, 2005, Clin Exp Optom, V88, P2
   Fiore M C, 2000, Respir Care, V45, P1200
   Gordon JS, 2002, TOB CONTROL, V11, P84
   Gorin SS, 2004, CANCER EPIDEM BIOMAR, V13, P2012
   Gurwood AS, 2006, OPTOMETRY, V77, P206
   Hoppe E., 1998, OPTOM ED, V24, P21
   Kelly SP, 2005, J CATARACT REFR SURG, V31, P2395, DOI 10.1016/j.jcrs.2005.06.039
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Loo DLS, 2009, CLIN EXP OPTOM, V92, P42, DOI 10.1111/j.1444-0938.2008.00283.x
   Maurice E., 2006, Morbidity and Mortality Weekly Report, V55, P1148
   ODELL LE, 2008, OPTOMETRY, V79, P293
   Passut J, 2008, PRIM CARE OPTOM NEWS, V13, P118
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ritchie J., 1994, ANAL QUALITATIVE DAT, P173, DOI DOI 10.4324/9780203413081_CHAPTER_9
   Schultz ASH, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015388
   Sheck LHN, 2009, CLIN EXP OPTOM, V92, P75, DOI 10.1111/j.1444-0938.2009.00348.x
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Spafford MM, 2010, OPTOM ED, V36, P38
   Thompson C, 2007, OPHTHAL PHYSL OPT, V27, P389, DOI 10.1111/j.1475-1313.2007.00483.x
   VICKERS M, 2005, REV OPTOM, V142, P23
   Weintraub JM, 2002, AM J EPIDEMIOL, V155, P72, DOI 10.1093/aje/155.1.72
   WINCH P, 2006, HARVARD INT REV 0506
   2009, SERVICE CANADA 3121
NR 26
TC 16
Z9 16
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-5488
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JUN
PY 2011
VL 88
IS 6
BP 766
EP 771
DI 10.1097/OPX.0b013e318216b203
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 766ON
UT WOS:000290794200014
PM 21460753
DA 2022-11-30
ER

PT J
AU Dugas, B
   Charbonnier, S
   Baarine, M
   Ragot, K
   Delmas, D
   Menetrier, F
   Lherminier, J
   Malvitte, L
   Khalfaoui, T
   Bron, A
   Creuzot-Garcher, C
   Latruffe, N
   Lizard, G
AF Dugas, B.
   Charbonnier, S.
   Baarine, M.
   Ragot, K.
   Delmas, D.
   Menetrier, F.
   Lherminier, J.
   Malvitte, L.
   Khalfaoui, T.
   Bron, A.
   Creuzot-Garcher, C.
   Latruffe, N.
   Lizard, Gerard
TI Effects of oxysterols on cell viability, inflammatory cytokines, VEGF,
   and reactive oxygen species production on human retinal cells:
   cytoprotective effects and prevention of VEGF secretion by resveratrol
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE ARPE-19 cells; Caspase-independent cell death; Inflammatory cytokines;
   Oxysterols; Phospholipidosis; Resveratrol; Reactive oxygen species; VEGF
ID PIGMENT EPITHELIAL-CELLS; AGE-RELATED MACULOPATHY; ENDOTHELIAL
   GROWTH-FACTOR; LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; MACULAR
   DEGENERATION; CULTURED RPE; OXIDIZED LDL; 7-KETOCHOLESTEROL; APOPTOSIS
AB Oxysterols are assumed to play important roles in age-related macular degeneration, a major cause of blindness. So we characterized the cytotoxic, oxidative, inflammatory, and angiogenic activities of oxysterols (7 beta-hydroxycholesterol (7 beta-OH), 7-ketocholesterol (7KC), 25-hydroxycholesterol (25-OH)) in human retinal ARPE-19 cells, and evaluated the protective effects of resveratrol (Rsv: 1 mu M), a polyphenol from red wine.
   ARPE-19 cells were treated with 7 beta-OH, 7KC, or 25-OH (5-40 mu g/mL; 24-48 h) without or with Rsv. Cell viability was determined using trypan blue and the MTT assay. Cell death was characterized by electron microscopy and in situ detection of activated caspases with fluorochrome-labeled inhibitors of caspases. Reactive oxygen species (ROS) production was measured with hydroethidine. ELISA methods and a cytometric bead assay were used to quantify cytokines involved in inflammation (IL-8, IL-1 beta, IL-6, IL-10, IL-12p70, TNF-alpha, MCP-1) and VEGF.
   7 beta-OH and 7KC triggered a caspase-independent cell death process associated with the presence of multilamellar cytoplasmic structures evocating phospholipidosis, increased ROS production, and IL-8 secretion. 7 beta-OH enhanced VEGF secretion. No cytotoxic effects were identified with 25-OH, which highly stimulated ROS production, MCP-1, and VEGF secretion. With oxysterols, no IL-10, TNF-alpha, and IL-12p70 secretion were detected. 25-OH induced IL-8 secretion through the MEK/ERKA1/2 signaling pathway, and Rsv showed cytoprotective activities and inhibited VEGF secretion.
   7 beta-OH, 7KC, and 25-OH have cytotoxic, oxidative, inflammatory, and/or angiogenic activities on ARPE-19 cells. As Rsv has some protective effects against oxysterol-induced cell death and VEGF secretion it could be valuable in ARMD treatment.
C1 [Dugas, B.; Charbonnier, S.; Ragot, K.; Delmas, D.; Malvitte, L.; Khalfaoui, T.; Latruffe, N.; Lizard, Gerard] Fac Sci Gabriel, INSERM 866, F-21000 Dijon, France.
   [Menetrier, F.] UMR FLAVIC, INRA U 1129, F-21000 Dijon, France.
   [Lherminier, J.] INRA, Serv Commun Microscopie Elect, F-21065 Dijon, France.
   [Bron, A.; Creuzot-Garcher, C.] INRA, Grp Rech Eil & Nutr, UMR FLAVIC 1129, F-21000 Dijon, France.
   [Dugas, B.; Malvitte, L.; Bron, A.; Creuzot-Garcher, C.] CHU Hop Gen, Serv Ophtalmol, F-21000 Dijon, France.
   [Baarine, M.] Univ Bourgogne, CNRS,Ctr Rech, GDR 2583, INSERM Lipides Nutr Canc Equipe Biochim Metab & N, F-21000 Dijon, France.
C3 Institut Agro; AgroSup Dijon; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Bourgogne; INRAE; INRAE;
   INRAE; CHU Dijon Bourgogne; Centre National de la Recherche Scientifique
   (CNRS); Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Bourgogne
RP Lizard, G (通讯作者)，Fac Sci Gabriel, INSERM 866, 6 Bd Gabriel, F-21000 Dijon, France.
EM Gerard.Lizard@u-bourgogne.fr
RI Lizard, Gerard/B-2439-2012; Charbonnier, Soëli/H-7003-2017; Bron,
   Alain/AAP-8010-2020; Delmas, Dominique/AAD-9749-2019
OI Charbonnier, Soëli/0000-0002-3185-635X; Bron, Alain/0000-0002-7265-931X;
   Delmas, Dominique/0000-0003-3576-0248; Delmas,
   Dominique/0000-0002-8911-8499
FU INSERM; University Hospital of Dijon (CHU de Dijon)
FX This work was supported by grants from the INSERM, and the University
   Hospital of Dijon (CHU de Dijon). The authors are indebted to Ms. Linda
   Northrup for reviewing the English version of the manuscript.
CR Anderson N, 2006, FEBS LETT, V580, P5533, DOI 10.1016/j.febslet.2006.08.061
   Brown AJ, 2009, MOL ASPECTS MED, V30, P111, DOI 10.1016/j.mam.2009.02.005
   Chang JY, 1998, CURR EYE RES, V17, P95, DOI 10.1076/ceyr.17.1.95.5252
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Dann JM, 2009, GYNECOL ONCOL, V113, P374, DOI 10.1016/j.ygyno.2009.02.014
   de Kok TM, 2008, EUR J NUTR, V47, P51, DOI 10.1007/s00394-008-2006-y
   Delmas D, 2005, MOL NUTR FOOD RES, V49, P377, DOI 10.1002/mnfr.200400098
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Elner Susan G, 2008, Trans Am Ophthalmol Soc, V106, P215
   Goldberg DA, 2003, CLIN BIOCHEM, V36, P79, DOI 10.1016/S0009-9120(02)00397-1
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kimura Y, 2008, CANCER SCI, V99, P2083, DOI 10.1111/j.1349-7006.2008.00948.x
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3
   Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2
   Lemaire-Ewing S, 2009, CELL BIOL TOXICOL, V25, P127, DOI 10.1007/s10565-008-9063-0
   Lizard G, 1999, ARTERIOSCL THROM VAS, V19, P1190, DOI 10.1161/01.ATV.19.5.1190
   Lizard G, 2000, FREE RADICAL BIO MED, V28, P743, DOI 10.1016/S0891-5849(00)00163-5
   Luna C, 2009, FOOD CHEM TOXICOL, V47, P198, DOI 10.1016/j.fct.2008.10.029
   Luthra S, 2006, INVEST OPHTH VIS SCI, V47, P5569, DOI 10.1167/iovs.06-0333
   Malvitte L, 2006, J FR OPHTALMOL, V29, P570, DOI 10.1016/S0181-5512(06)73815-3
   Malvitte L, 2008, CURR EYE RES, V33, P769, DOI 10.1080/02713680802337397
   Marel AK, 2008, MOL NUTR FOOD RES, V52, P538, DOI 10.1002/mnfr.200700185
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   O'Callaghan YC, 2001, CELL BIOL TOXICOL, V17, P127, DOI 10.1023/A:1010914306375
   Okawara M, 2007, BIOCHEM PHARMACOL, V73, P550, DOI 10.1016/j.bcp.2006.11.003
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   Pedruzzi E, 2004, MOL CELL BIOL, V24, P10703, DOI 10.1128/MCB.24.24.10703-10717.2004
   Prunet C, 2006, CYTOM PART A, V69A, P359, DOI 10.1002/cyto.a.20272
   Rahman I, 2006, BIOCHEM PHARMACOL, V72, P1439, DOI 10.1016/j.bcp.2006.07.004
   Ramos MA, 1998, ARTERIOSCL THROM VAS, V18, P1188, DOI 10.1161/01.ATV.18.7.1188
   Rodriguez IR, 2009, PHOTOCHEM PHOTOBIOL, V85, P1116, DOI 10.1111/j.1751-1097.2009.00568.x
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Scherle PA, 1998, J IMMUNOL, V161, P5681
   Schmitz G, 2009, BBA-MOL CELL BIOL L, V1791, P524, DOI 10.1016/j.bbalip.2008.12.007
   Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005
   Sheu SJ, 2008, J OCUL PHARMACOL TH, V24, P551, DOI 10.1089/jop.2008.0013
   Sung SC, 2009, J VASC RES, V46, P36, DOI 10.1159/000135663
   Tang ZH, 2007, J HUAZHONG U SCI-MED, V27, P508, DOI 10.1007/s11596-007-0508-0
   Vejux A, 2008, BRAZ J MED BIOL RES, V41, P545, DOI 10.1590/S0100-879X2008000700001
   Vejux A, 2007, HISTOCHEM CELL BIOL, V127, P609, DOI 10.1007/s00418-006-0268-0
   Yoshida A, 1998, INVEST OPHTH VIS SCI, V39, P1097
   Ziegler CC, 2004, J NUTR, V134, P5, DOI 10.1093/jn/134.1.5
NR 50
TC 80
Z9 81
U1 0
U2 6
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
J9 EUR J NUTR
JI Eur. J. Nutr.
PD OCT
PY 2010
VL 49
IS 7
BP 435
EP 446
DI 10.1007/s00394-010-0102-2
PG 12
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 654ON
UT WOS:000282177900007
PM 20339855
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Magnussen, AL
   Rennel, ES
   Hua, J
   Bevan, HS
   Beazley Long, N
   Lehrling, C
   Gammons, M
   Floege, J
   Harper, SJ
   Agostini, HT
   Bates, DO
   Churchill, AJ
AF Magnussen, Anette L.
   Rennel, Emma S.
   Hua, Jing
   Bevan, Heather S.
   Beazley Long, Nicholas
   Lehrling, Christina
   Gammons, Melissa
   Floege, Juergen
   Harper, Steven J.
   Agostini, Hansjuergen T.
   Bates, David O.
   Churchill, Amanda J.
TI VEGF-A(165)b Is Cytoprotective and Antiangiogenic in the Retina
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SPLICE VARIANT; DIABETIC-RETINOPATHY;
   ANGIOGENIC ISOFORMS; TUMOR-GROWTH; VEGF; VEGF(165)B; BEVACIZUMAB; CELLS;
   NEOVASCULARIZATION
AB PURPOSE. A number of key ocular diseases, including diabetic retinopathy and age-related macular degeneration, are characterized by localized areas of epithelial or endothelial damage, which can ultimately result in the growth of fragile new blood vessels, vitreous hemorrhage, and retinal detachment. VEGF-A(165), the principal neovascular agent in ocular angiogenic conditions, is formed by proximal splice site selection in its terminal exon 8. Alternative splicing of this exon results in an antiangiogenic isoform, VEGF-A(165)b, which is downregulated in diabetic retinopathy. Here the authors investigate the antiangiogenic activity of VEGF(165)b and its effect on retinal epithelial and endothelial cell survival.
   METHODS. VEGF-A(165)b was injected intraocularly in a mouse model of retinal neovascularization (oxygen-induced retinopathy [OIR]). Cytotoxicity and cell migration assays were used to determine the effect of VEGF-A(165)b.
   RESULTS. VEGF-A(165)b dose dependently inhibited angiogenesis (IC50, 12.6 pg/eye) and retinal endothelial migration induced by 1 nM VEGF-A(165) across monolayers in culture (IC50, 1 nM). However, it also acts as a survival factor for endothelial cells and retinal epithelial cells through VEGFR2 and can stimulate downstream signaling. Furthermore, VEGF-A(165)b injection, while inhibiting neovascular proliferation in the eye, reduced the ischemic insult in OIR (IC50, 2.6 pg/eye). Unlike bevacizumab, pegaptanib did not interact directly with VEGF-A(165)b. CONCLUSIONS. The survival effects of VEGF-A(165)b signaling can protect the retina from ischemic damage. These results suggest that VEGF-A(165)b may be a useful therapeutic agent in ischemia-induced angiogenesis and a cytoprotective agent for retinal pigment epithelial cells. (Invest Ophthalmol Vis Sci. 2010; 51:4273-4281) DOI:10.1167/iovs.09-4296
C1 [Magnussen, Anette L.; Rennel, Emma S.; Hua, Jing; Bevan, Heather S.; Beazley Long, Nicholas; Gammons, Melissa; Harper, Steven J.; Bates, David O.] Univ Bristol, Sch Vet Sci, Dept Physiol & Pharmacol, Microvasc Res Labs,Bristol Heart Inst, Bristol BS2 8EJ, Avon, England.
   [Lehrling, Christina; Agostini, Hansjuergen T.] Univ Freiburg, Univ Eye Hosp, Freiburg, Germany.
   [Floege, Juergen] Rhein Westfal TH Aachen, Univ Hosp, Div Nephrol & Clin Immunol, Achen, Germany.
   [Churchill, Amanda J.] Univ Bristol, Bristol Eye Hosp, Unit Ophthalmol, Bristol BS1 2LX, Avon, England.
C3 University of Bristol; University of Freiburg; RWTH Aachen University;
   Bristol Eye Hospital; University of Bristol
RP Bates, DO (通讯作者)，Univ Bristol, Sch Vet Sci, Dept Physiol & Pharmacol, Microvasc Res Labs,Bristol Heart Inst, Southwell St, Bristol BS2 8EJ, Avon, England.
EM dave.bates@bris.ac.uk; a.j.churchill@bristol.ac.uk
RI Beazley-long, Nicholas/I-7131-2019
OI Beazley-long, Nicholas/0000-0001-7342-2771; Bates,
   David/0000-0003-4850-2360; gammons, melissa/0000-0001-9661-9331
FU Fight for Sight; National Eye Research Centre; Richard Bright VEGF
   Research Trust; North Bristol NHS Trust Adrian Wright Bequest into
   Disability in the Elderly; Skin Cancer Research Fund; Wellcome Trust
   [79736, 69029]; British Heart Foundation [BS/06/005]
FX Supported by Fight for Sight (ER), the National Eye Research Centre, the
   Richard Bright VEGF Research Trust and the North Bristol NHS Trust
   Adrian Wright Bequest into Disability in the Elderly (AM), the Skin
   Cancer Research Fund (MG), Wellcome Trust Grants 79736 (JH, NBL) and
   69029 (HSB), and British Heart Foundation Grant BS/06/005 (DOB).
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Anderson HR, 1995, BRIT J OPHTHALMOL, V79, P1120, DOI 10.1136/bjo.79.12.1120
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH547, DOI 10.1152/ajpheart.00616.2005
   Bates DO, 2002, CANCER RES, V62, P4123
   Benest AV, 2009, NATURE, V458, P41, DOI 10.1038/458041a
   Bevan HS, 2008, NEPHRON PHYSIOL, V110, P57, DOI 10.1159/000177614
   Bogaert E, 2006, MUSCLE NERVE, V34, P391, DOI 10.1002/mus.20609
   ChanLing T, 1997, MICROSC RES TECHNIQ, V36, P1
   Eremina V, 2008, NEW ENGL J MED, V358, P1129, DOI 10.1056/NEJMoa0707330
   Ergorul C, 2008, MOL VIS, V14, P1517
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Hamdollah Zadeh MA, 2008, MICROCIRCULATION, V15, P605, DOI 10.1080/10739680802220323
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hua J, 2010, INVEST OPHTH VIS SCI, V51, P4282, DOI 10.1167/iovs.09-4360
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   JAUREGUI HO, 1981, IN VITRO CELL DEV B, V17, P1100
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577
   Kinose F, 2005, MOL VIS, V11, P366
   Konopatskaya O, 2006, MOL VIS, V12, P626
   Krohne TU, 2009, BRIT J OPHTHALMOL, V93, P91, DOI 10.1136/bjo.2008.145102
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410
   Nowak DG, 2010, J BIOL CHEM, V285, P5532, DOI 10.1074/jbc.M109.074930
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842
   Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Qiu Y, 2008, FASEB J, V22, P1104, DOI 10.1096/fj.07-9718com
   Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309
   Rennel ES, 2009, BRIT J CANCER, V101, P1183, DOI 10.1038/sj.bjc.6605249
   Rennel ES, 2008, EUR J CANCER, V44, P1883, DOI 10.1016/j.ejca.2008.05.027
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   STITT AW, 1995, BRIT J OPHTHALMOL, V79, P362, DOI 10.1136/bjo.79.4.362
   Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9
   Sun HW, 2007, BIOCHEM BIOPH RES CO, V353, P152, DOI 10.1016/j.bbrc.2006.12.002
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolosa L, 2008, J NEUROCHEM, V105, P1080, DOI 10.1111/j.1471-4159.2007.05206.x
   Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308
   Whittles CE, 2002, MICROCIRCULATION, V9, P513, DOI 10.1038/sj.mn.7800164
   Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934
NR 54
TC 59
Z9 66
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2010
VL 51
IS 8
BP 4273
EP 4281
DI 10.1167/iovs.09-4296
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 629JT
UT WOS:000280194100061
PM 20237249
OA Green Published
DA 2022-11-30
ER

PT J
AU Giani, A
   Cigada, M
   Esmaili, DD
   Salvetti, P
   Luccarelli, S
   Marziani, E
   Luiselli, C
   Sabella, P
   Cereda, M
   Eandi, C
   Staurenghi, G
AF Giani, Andrea
   Cigada, Mario
   Esmaili, Daniel D.
   Salvetti, Paola
   Luccarelli, Saverio
   Marziani, Ermengarda
   Luiselli, Cristiano
   Sabella, Pierfilippo
   Cereda, Matteo
   Eandi, Chiara
   Staurenghi, Giovanni
TI ARTIFACTS IN AUTOMATIC RETINAL SEGMENTATION USING DIFFERENT OPTICAL
   COHERENCE TOMOGRAPHY INSTRUMENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE artifacts; comparison; optical coherence tomography; retinal boundaries;
   retinal segmentation; spectral domain
ID DIABETIC MACULAR EDEMA; THICKNESS; DIAGNOSIS; DISEASES
AB Purpose: The purpose of this study was to compare and evaluate artifact errors in automatic inner and outer retinal boundary detection produced by different time-domain and spectral-domain optical coherence tomography (OCT) instruments.
   Methods: Normal and pathologic eyes were imaged by six different OCT devices. For each instrument, standard analysis protocols were used for macular thickness evaluation. Error frequencies, defined as the percentage of examinations affected by at least one error in retinal segmentation (EF-exam) and the percentage of total errors per total B-scans, were assessed for each instrument. In addition, inner versus outer retinal boundary delimitation and central (1,000 mu m) versus noncentral location of errors were studied.
   Results: The study population of the EF-exam for all instruments was 25.8%. The EF-exam of normal eyes was 6.9%, whereas in all pathologic eyes, it was 32.7% (P < 0.0001). The EF-exam was highest in eyes with macular holes, 83.3%, followed by epiretinal membrane with cystoid macular edema, 66.6%, and neovascular age-related macular degeneration, 50.3%. The different OCT instruments produced different EF-exam values (P < 0.0001). The Zeiss Stratus produced the highest percentage of total errors per total B-scans compared with the other OCT systems, and this was statistically significant for all devices (P <= 0.005) except the Optovue RTvue-100 (P = 0.165).
   Conclusion: Spectral-domain OCT instruments reduce, but do not eliminate, errors in retinal segmentation. Moreover, accurate segmentation is lower in pathologic eyes compared with normal eyes for all instruments. The important differences in EF among the instruments studied are probably attributable to analysis algorithms used to set retinal inner and outer boundaries. Manual adjustments of retinal segmentations could reduce errors, but it will be important to evaluate interoperator variability. RETINA 30: 607-616, 2010
C1 [Giani, Andrea] IRCCS, GB Bietti Eye Fdn, Rome, Italy.
   [Cigada, Mario; Salvetti, Paola; Luccarelli, Saverio; Marziani, Ermengarda; Luiselli, Cristiano; Sabella, Pierfilippo; Staurenghi, Giovanni] Univ Milan, Sacco Hosp, Dept Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Esmaili, Daniel D.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv, Boston, MA USA.
   [Cereda, Matteo] Sacro Cuore Hosp Negrar, Dept Ophthalmol, Verona, Italy.
   [Eandi, Chiara] Univ Turin, Dept Clin Physiopathol, Eye Clin, Turin, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; University of Milan; Luigi Sacco Hospital; Harvard
   University; Harvard Medical School; Massachusetts Eye & Ear Infirmary;
   IRCCS Sacro Cuore Don Calabria; University of Turin
RP Giani, A (通讯作者)，Univ Milan Italy, Sacco Hosp, Eye Clin,Sch Ophthalmol 2, Dept Clin Sci Luigi Sacco, W Via GB Grassi 74, I-20100 Milan, Italy.
EM andreagiani@gmail.com
RI Luccarelli, Saverio/ABF-5408-2020; Giani, Andrea/L-5926-2017;
   Staurenghi, Giovanni/K-4388-2017
OI Salvetti, Anna Paola/0000-0002-5513-2241; Luccarelli, Saverio
   Vincenzo/0000-0003-0908-9067; Giani, Andrea/0000-0003-0682-1945; Eandi,
   Chiara Maria/0000-0003-3656-1689; Staurenghi,
   Giovanni/0000-0002-2299-5251
CR Apushkin MA, 2004, OPHTHALMOLOGY, V111, P1899, DOI 10.1016/j.ophtha.2004.04.019
   Browning DJ, 2004, OPHTHALMOLOGY, V111, P712, DOI 10.1016/j.ophtha.2003.06.028
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Karam EZ, 2007, BRIT J OPHTHALMOL, V91, P1139, DOI 10.1136/bjo.2007.114074
   Larsson J, 2005, AM J OPHTHALMOL, V139, P802, DOI 10.1016/j.ajo.2004.12.054
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Muscat S, 2001, OPHTHALMIC SURG LAS, V32, P474
   Pons ME, 2005, OPHTHALMOLOGY, V112, P1079, DOI 10.1016/j.ophtha.2004.11.061
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   R Development Core Team, 2005, R LANG ENV STAT COMP
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
   Thomas D, 2004, EYE, V18, P561, DOI 10.1038/sj.eye.6700729
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
NR 17
TC 45
Z9 45
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2010
VL 30
IS 4
BP 607
EP 616
DI 10.1097/IAE.0b013e3181c2e09d
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608AE
UT WOS:000278548900010
PM 20094011
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Lo Giudice, G
   Gismondi, M
   de Belvis, V
   Cian, R
   Tavolato, M
   Galan, A
AF Lo Giudice, Giuseppe
   Gismondi, Maurizio
   de Belvis, Valentina
   Cian, Roberto
   Tavolato, Marco
   Galan, Alessandro
TI SINGLE-SESSION PHOTODYNAMIC THERAPY COMBINED WITH INTRAVITREAL
   BEVACIZUMAB FOR RETINAL ANGIOMATOUS PROLIFERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; photodynamic therapy; retinal angiomatous proliferation;
   age-related macular degeneration
ID OCCULT CHOROIDAL NEOVASCULARIZATION; MACULAR DEGENERATION; AVASTIN
   TREATMENT; TRIAMCINOLONE; ANASTOMOSES; COMBINATION; ABLATION
AB Purpose: To evaluate the efficacy of single-session photodynamic therapy (PDT) combined with intravitreal bevacizumab (IVB) in the treatment of retinal angiomatous proliferation (RAP) in age-related macular degeneration.
   Methods: In this pilot study, eight patients with RAP underwent indocyanine green angiography (ICGA)-guided single-session verteporfin PDT followed by intravitreal bevacizumab (1.25 mg) within a 0-day +/- 1-day interval. All patients were naive to treatment. Best-corrected visual acuity (BCVA), fluorescein angiography, ICGA, and optical coherence tomography (OCT) were performed at baseline and at each follow-up visit. All patients received three consecutive monthly IVB injections; thereafter, retreatment with bevacizumab was performed in the case of worsening BCVA or a deterioration of angiographic or OCT findings.
   Results: All patients had 9 months of follow-up. Complete resolution of angiographic leakage was achieved in all eyes at 9 months. A significant improvement in the mean BCVA was observed at 1 month, 3 months, 6 months, and 9 months after combined treatment (P = 0.004). Visual acuity improved in 62.5% and was stable in 37.5% of cases. No patients had a decrease in BCVA of three or more lines during follow-up. Mean central macular thickness was significantly reduced in all patients (P < 0.0001) as controlled at 1-month, 3-month, 6-month, and 9-month intervals from initial treatment. The mean number of injections for the 9 months were 3.2 +/- 0.4. No ocular complications or systemic events developed.
   Conclusion: Sequenced combined treatment with single-session PDT and IVB injections may be useful in treating RAP, reducing or eliminating retinal edema, and improving or stabilizing visual acuity. Further investigations are warranted to outline the appropriate treatment paradigm for combination therapy.
C1 [Lo Giudice, Giuseppe; Cian, Roberto; Tavolato, Marco; Galan, Alessandro] St Antoino Hosp, Dept Ophthalmol, I-35100 Padua, Italy.
   [Gismondi, Maurizio] Santa Maria Misericordia Hosp, Dept Ophthalmol, Udine, Italy.
   [de Belvis, Valentina] Univ Padua, Dept Pediat, Pediat Ophthalmol Unit, Padua, Italy.
C3 Hospital Santa Maria della Misericordia; University of Padua
RP Lo Giudice, G (通讯作者)，St Antoino Hosp, Dept Ophthalmol, Via Facciolati 71, I-35100 Padua, Italy.
EM gvofta@libero.it
RI LO GIUDICE, GIUSEPPE/GQB-0418-2022
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Axer-Siegel R, 2002, OPHTHALMOLOGY, V109, P1726, DOI 10.1016/S0161-6420(02)01149-1
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Bressler NM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1741, DOI 10.1001/archopht.123.12.1741
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2005, AM J OPHTHALMOL, V140, P107, DOI 10.1016/j.ajo.2005.02.042
   Costagliola C, 2007, AM J OPHTHALMOL, V144, P449, DOI 10.1016/j.ajo.2007.05.025
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Ghazi NG, 2008, RETINA-J RET VIT DIS, V28, P689, DOI 10.1097/IAE.0b013e318162d982
   Joeres S, 2007, GRAEF ARCH CLIN EXP, V245, P1597, DOI 10.1007/s00417-007-0580-y
   Johnson TM, 2006, RETINA-J RET VIT DIS, V26, P765, DOI 10.1097/01.iae.0000244264.98642.af
   Kang Jae Hoon, 2007, Korean J Ophthalmol, V21, P213, DOI 10.3341/kjo.2007.21.4.213
   Klais CM, 2006, RETINA-J RET VIT DIS, V26, P773, DOI 10.1097/01.iae.0000244261.52901.67
   Krieglstein TR, 2006, BRIT J OPHTHALMOL, V90, P1357, DOI 10.1136/bjo.2006.092536
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Mantel I, 2006, EUR J OPHTHALMOL, V16, P705, DOI 10.1177/112067210601600507
   Matsumoto Y, 2007, RETINA-J RET VIT DIS, V27, P426, DOI 10.1097/IAE.0b013e31804a7af2
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Nakata M, 2006, AM J OPHTHALMOL, V141, P968, DOI 10.1016/j.ajo.2005.12.029
   Nicolo M, 2006, GRAEF ARCH CLIN EXP, V244, P1336, DOI 10.1007/s00417-006-0306-6
   Panagiotidis D, 2006, EUR J OPHTHALMOL, V16, P326, DOI 10.1177/112067210601600221
   Rouvas AA, 2008, GRAEF ARCH CLIN EXP, V246, P315, DOI 10.1007/s00417-007-0669-3
   Saito M, 2008, AM J OPHTHALMOL, V146, P935, DOI 10.1016/j.ajo.2008.06.033
   SAS Institute Inc, 2007, SAS STAT US GUID VER
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   Yang JC, 2004, CLIN CANCER RES, V10, p6367S, DOI 10.1158/1078-0432.CCR-050006
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 30
TC 16
Z9 16
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL-AUG
PY 2009
VL 29
IS 7
BP 949
EP 955
DI 10.1097/IAE.0b013e3181af106d
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 470DT
UT WOS:000267955400007
PM 19584653
DA 2022-11-30
ER

PT J
CA German Soc Ophthalmology
   German Retina Soc
   Retinologische Gesell EV RG
   German Ophthalmologists
   Berufsverband Augenarzte Deutsch
   BVA
TI Statement of the German Ophthalmological Society (DOG), the German
   Retina Society (GRS), and the Professional Association of German
   Ophthalmologists (BVA) on anti-VEGF treatment in neovascular age-related
   macular degeneration Status February 2020
SO OPHTHALMOLOGE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB TREATMENT; CLINICAL BURDEN;
   VISUAL-ACUITY; PLAN REGIMEN; OUTCOMES; THERAPY; EFFICACY; VERTEPORFIN;
   BEVACIZUMAB
C1 [German Soc Ophthalmology] Deutsch Ophthalmol Gesell, Platenstr 1, D-80336 Munich, Germany.
   [German Retina Soc; Retinologische Gesell EV RG] Retinolog Gesell eV, German Retina Soc, Freiburg, Germany.
   [German Ophthalmologists; Berufsverband Augenarzte Deutsch; BVA] Berufsverband Augenarzte Deutschlands eV, Profess Assoc German Ophthalmologists, Dusseldorf, Germany.
RP Deutsch Ophthalmol Gesell, Platenstr 1, D-80336 Munich, Germany.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Augsburger M, 2019, GRAEF ARCH CLIN EXP, V257, P1889, DOI 10.1007/s00417-019-04404-0
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Baumal CR., 2020, OPHTHALMOLOGY
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BVA DOG RG, 2017, OPHTHALMOLOGE, V114, P220
   BVA DOG RG, 2017, KLIN MONATSBL AUGENH, V234, P650
   BVA DOG RG, 2018, AUGENARZT, V2, P83
   BVA DOG RG, 2017, OPHTHALMOLOGE, V114, P432
   BVA DOG RG, 2017, KLIN MONATSBL AUGENH, V234, P829
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hoerster R, 2011, BRIT J OPHTHALMOL, V95, P1424, DOI 10.1136/bjo.2010.201129
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   RG DOG BVA, 2011, OPHTHALMOLOGE, V108, P86
   RG DOG BVA, 2015, OPHTHALMOLOGE, V112, P237
   RG DOG BVA, 2013, KLIN MONBL AUGENHEIL, V230, P170
   RG DOG BVA, 2011, KLIN MONBL AUGENHEIL, V228, P138
   RG DOG BVA, 2013, OPHTHALMOLOGE, V110, P405
   RG DOG BVA., 2009, KLIN MONBL AUGENHEIL, V226, P388
   RG DOG BVA, 2012, OPHTHALMOLOGE, V109, P405
   RG DOG BVA, 2012, KLIN MONATSBL AUGENH, V229, P541
   RG DOG BVA, 2007, KLIN MONBL AUGENHEIL, V224, P559
   RG DOG BVA, 2009, OPHTHALMOLOGE, V106, P457
   RG DOG BVA, 2007, OPHTHALMOLOGE, V104, P628
   RG DOG BVA, 2015, KLIN MONATSBL AUGENH, V232, P202
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stasch-Bouws J, 2020, OPHTHALMOLOGE, V117, P336, DOI 10.1007/s00347-019-01030-3
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
NR 54
TC 3
Z9 4
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0941-293X
EI 1433-0423
J9 OPHTHALMOLOGE
JI Ophthalmologe
PD JAN
PY 2021
VL 118
IS SUPPL 1
SU 1
BP 31
EP 39
DI 10.1007/s00347-020-01188-1
EA JUL 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PU7IM
UT WOS:000553748100002
PM 32728806
DA 2022-11-30
ER

PT J
AU Armento, A
   Murali, A
   Marzi, J
   Almansa-Garcia, AC
   Arango-Gonzalez, B
   Kilger, E
   Clark, SJ
   Schenke-Layland, K
   Ramlogan-Steel, CA
   Steel, JC
   Ueffing, M
AF Armento, Angela
   Murali, Aparna
   Marzi, Julia
   Almansa-Garcia, Ana C.
   Arango-Gonzalez, Blanca
   Kilger, Ellen
   Clark, Simon J.
   Schenke-Layland, Katja
   Ramlogan-Steel, Charmaine A.
   Steel, Jason C.
   Ueffing, Marius
TI Complement Factor H Loss in RPE Cells Causes Retinal Degeneration in a
   Human RPE-Porcine Retinal Explant Co-Culture Model
SO BIOMOLECULES
LA English
DT Article
DE age-related macular degeneration (AMD); complement factor H (CFH);
   retinal pigment epithelium (RPE) cells; retinal degeneration;
   co-culture; porcine retinal explants; Raman; mitochondria; oxidized
   lipids
ID MACULAR DEGENERATION; RAMAN-SPECTROSCOPY; DNA STRUCTURES; POLYMORPHISM;
   CONE; CYTOCHROME
AB Age-related Macular degeneration (AMD) is a degenerative disease of the macula affecting the elderly population. Treatment options are limited, partly due to the lack of understanding of AMD pathology and the lack of suitable research models that replicate the complexity of the human macula and the intricate interplay of the genetic, aging and lifestyle risk factors contributing to AMD. One of the main genetic risks associated with AMD is located on the Complement Factor H (CFH) gene, leading to an amino acid substitution in the Factor H (FH) protein (Y402H). However, the mechanism of how this FH variant promotes the onset of AMD remains unclear. Previously, we have shown that FH deprivation in RPE cells, via CFH silencing, leads to increased inflammation, metabolic impairment and vulnerability toward oxidative stress. In this study, we established a novel co-culture model comprising CFH silenced RPE cells and porcine retinal explants derived from the visual streak of porcine eyes, which closely resemble the human macula. We show that retinae exposed to FH-deprived RPE cells show signs of retinal degeneration, with rod cells being the first cells to undergo degeneration. Moreover, via Raman analyses, we observed changes involving the mitochondria and lipid composition of the co-cultured retinae upon FH loss. Interestingly, the detrimental effects of FH loss in RPE cells on the neuroretina were independent of glial cell activation and external complement sources. Moreover, we show that the co-culture model is also suitable for human retinal explants, and we observed a similar trend when RPE cells deprived of FH were co-cultured with human retinal explants from a single donor eye. Our findings highlight the importance of RPE-derived FH for retinal homeostasis and provide a valuable model for AMD research.
C1 [Armento, Angela; Murali, Aparna; Almansa-Garcia, Ana C.; Arango-Gonzalez, Blanca; Kilger, Ellen; Clark, Simon J.; Ueffing, Marius] Eberhard Karls Univ Tubingen, Inst Ophthalm Res, Dept Ophthalmol, D-72076 Tubingen, Germany.
   [Murali, Aparna; Ramlogan-Steel, Charmaine A.; Steel, Jason C.] Univ Queensland, Fac Med, Herston, Qld 4006, Australia.
   [Marzi, Julia; Schenke-Layland, Katja] Eberhard Karls Univ Tubingen, Inst Biomed Engn, Dept Med Technol & Regenerat Med, D-72076 Tubingen, Germany.
   [Marzi, Julia; Schenke-Layland, Katja] Univ Tubingen, NMI Nat & Med Sci Inst, D-72770 Reutlingen, Germany.
   [Marzi, Julia; Schenke-Layland, Katja] Eberhard Karls Univ Tubingen, Cluster Excellence iFIT EXC 2180 Image Guided & F, D-72076 Tubingen, Germany.
   [Clark, Simon J.] Univ Manchester, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Manchester M13 9PL, Lancs, England.
   [Schenke-Layland, Katja] Univ Calif Los Angeles, Dept Med Cardiol, Cardiovasc Res Labs, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Ramlogan-Steel, Charmaine A.; Steel, Jason C.] Cent Queensland Univ, Sch Hlth Med & Appl Sci, Brisbane, Qld 4000, Australia.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; University of Queensland; Eberhard Karls University of
   Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls
   University of Tubingen; University of Manchester; University of
   California System; University of California Los Angeles; University of
   California Los Angeles Medical Center; David Geffen School of Medicine
   at UCLA; Central Queensland University
RP Armento, A; Ueffing, M (通讯作者)，Eberhard Karls Univ Tubingen, Inst Ophthalm Res, Dept Ophthalmol, D-72076 Tubingen, Germany.
EM angela.armento@uni-tuebingen.de; aparnamuralib@gmail.com;
   julia.marzi@uni-tuebingen.de;
   ana-cristina.almansa-garcia@uni-tuebingen.de;
   blanca.arango-gonzalez@klinikum.uni-tuebingen.de;
   ellen.kilger@uni-tuebingen.de; simon.clark@uni-tuebingen.de;
   katja.schenke-layland@uni-tuebingen.de; c.ramlogan-steel@cqu.edu.au;
   j.steel2@uq.edu.au; marius.ueffing@uni-tuebingen.de
OI Murali, Aparna/0000-0002-1567-3430; Marzi, Julia/0000-0003-1545-5430;
   Clark, Simon/0000-0001-8394-8355; Arango-Gonzalez,
   Blanca/0000-0002-9045-182X; Armento, Angela/0000-0002-6357-1500;
   Ueffing, Marius/0000-0003-2209-2113
FU fortune-Programm [2640-0-0]; EU [863203]; Kerstan Foundation; Helmut
   Ecker Foundation; University of Tubingen
FX Angela Armento is supported by the fortune-Programm (project number
   2640-0-0). This work was supported by the EU Horizons 2020 program,
   Grant Agreement number: 863203-Dynamic adaptive microscopy for
   label-free multi-parametric imaging in biology and medicine (DynAMic) to
   Marius Ueffing, donations from Jutta Emilie Paula Henny Granier and the
   Kerstan Foundation to Marius Ueffing and the Helmut Ecker Foundation to
   Simon J Clark. We acknowledge support by Open Access Publishing Fund of
   University of Tubingen.
CR Armento A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168727
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Beltran-Heredia E, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0471-x
   BENEVIDES JM, 1983, NUCLEIC ACIDS RES, V11, P5747, DOI 10.1093/nar/11.16.5747
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Brazhe NA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041990
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004
   Catala Angel, 2011, Front Biosci (Schol Ed), V3, P52, DOI 10.2741/s131
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Czamara K, 2015, J RAMAN SPECTROSC, V46, P4, DOI 10.1002/jrs.4607
   Daugan MV, 2021, CANCER IMMUNOL RES, V9, P909, DOI 10.1158/2326-6066.CIR-20-0787
   DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ebeling MC, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040789
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Harvey H, 2014, EXP BRAIN RES, V232, P3363, DOI 10.1007/s00221-014-4078-7
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hurst J, 2020, J CELL MOL MED, V24, P4312, DOI 10.1111/jcmm.15091
   Hurst J, 2017, ATLA-ALTERN LAB ANIM, V45, P11, DOI 10.1177/026119291704500105
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kostic C, 2016, J PATHOL, V238, P300, DOI 10.1002/path.4641
   Li Y, 2014, FOOD RES INT, V58, P1, DOI 10.1016/j.foodres.2014.01.056
   Machado NFL, 2012, J RAMAN SPECTROSC, V43, P1991, DOI 10.1002/jrs.4121
   Marzi J, 2019, ACTA BIOMATER, V89, P193, DOI 10.1016/j.actbio.2019.03.026
   Mohlin C, 2018, UPSALA J MED SCI, V123, P28, DOI 10.1080/03009734.2018.1431744
   Molins B, 2016, SCI REP-UK, V6, DOI 10.1038/srep22889
   Murali A, 2019, CLIN EXP OPHTHALMOL, V47, P274, DOI 10.1111/ceo.13434
   Okada M, 2012, P NATL ACAD SCI USA, V109, P28, DOI 10.1073/pnas.1107524108
   Okano K, 2012, J NEUROCHEM, V121, P146, DOI 10.1111/j.1471-4159.2012.07647.x
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Pfeiffer RL, 2016, EXP EYE RES, V150, P62, DOI 10.1016/j.exer.2016.04.022
   PRESCOTT B, 1984, BIOPOLYMERS, V23, P235, DOI 10.1002/bip.360230206
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Rashid K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01975
   Rasoulinejad SA, 2015, CASP J INTERN MED, V6, P141
   Ren MD, 2014, PROG LIPID RES, V55, P1, DOI 10.1016/j.plipres.2014.04.001
   Schnichels S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100880
   Schnichels S, 2019, ATLA-ALTERN LAB ANIM, V47, P19, DOI 10.1177/0261192919840092
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Shindou H, 2017, J BIOL CHEM, V292, P12054, DOI [10.1074/jbc.M117.790568, 10.1074/jbc.m117.790568]
   Spiers RM, 2019, ACTA BIOMATER, V99, P269, DOI 10.1016/j.actbio.2019.09.013
   SPIRO TG, 1972, P NATL ACAD SCI USA, V69, P2622, DOI 10.1073/pnas.69.9.2622
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun GY, 2018, PROSTAG LEUKOTR ESS, V136, P3, DOI 10.1016/j.plefa.2017.03.006
   Swinkels M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18395-7
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Todd L, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1505-5
   Wagner N, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.556700
   Williams JAE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068616
NR 57
TC 2
Z9 2
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD NOV
PY 2021
VL 11
IS 11
AR 1621
DI 10.3390/biom11111621
PG 19
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 3C5SZ
UT WOS:000828684100001
PM 34827622
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Schustak, J
   Twarog, M
   Wu, XQ
   Wu, HY
   Huang, Q
   Bao, Y
AF Schustak, Joshua
   Twarog, Michael
   Wu, Xiaoqiu
   Wu, Henry Y.
   Huang, Qian
   Bao, Yi
TI Mechanism of Nucleic Acid Sensing in Retinal Pigment Epithelium (RPE):
   RIG-I Mediates Type I Interferon Response in Human RPE
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID NF-KAPPA-B; TOLL-LIKE RECEPTOR-3; MACULAR DEGENERATION; GENES; CELLS;
   BETA; DNA; IDENTIFICATION; INDUCTION; PROTECTS
AB Age-related macular degeneration (AMD), a degenerative disease of the outer retina, is the leading cause of blindness among the elderly. A hallmark of geographic atrophy (GA), an advanced type of nonneovascular AMD (dry AMD), is photoreceptor and retinal pigment epithelium (RPE) cell death. Currently, there are no FDA-approved therapies for GA due to a lack of understanding of the disease-causing mechanisms. Increasing evidence suggests that chronic inflammation plays a predominant role in the pathogenesis of dry AMD. Dead or stressed cells release danger signals and inflammatory factors, which causes further damage to neighboring cells. It has been reported that type I interferon (IFN) response is activated in RPE cells in patients with AMD. However, how RPE cells sense stress to initiate IFN response and cause further damage to the retina are still unknown. Although it has been reported that RPE can respond to extracellularly added dsRNA, it is unknown whether and how RPE detects and senses internally generated or internalized nucleic acids. Here, we elucidated the molecular mechanism by which RPE cells sense intracellular nucleic acids. Our data demonstrate that RPE cells can respond to intracellular RNA and induce type I IFN responses via the RIG-I (DExD/H-box helicase 58, DDX58) RNA helicase. In contrast, we showed that RPE cells were unable to directly sense and respond to DNA through the cGAS-STING pathway. We demonstrated that this was due to the absence of the cyclic GMP-AMP synthase (cGAS) DNA sensor in these cells. The activation of IFN response via RIG-I induced expression of cell death effectors and caused barrier function loss in RPE cells. These data suggested that RPE-intrinsic pathways of nucleic acid sensing are biased toward RNA sensing.
C1 [Schustak, Joshua; Twarog, Michael; Wu, Xiaoqiu; Wu, Henry Y.; Huang, Qian; Bao, Yi] Novartis Inst BioMed Res, Dept Ophthalmol, 22 Windsor St, Cambridge, MA 02139 USA.
C3 Novartis
RP Huang, Q; Bao, Y (通讯作者)，Novartis Inst BioMed Res, Dept Ophthalmol, 22 Windsor St, Cambridge, MA 02139 USA.
EM qian.huang@dragonflytx.com; yi.bao@novartis.com
OI Bao, Yi/0000-0003-0748-1575
CR Ablasser A, 2009, NAT IMMUNOL, V10, P1065, DOI 10.1038/ni.1779
   Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100
   Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553
   Bianchi E, 2013, INT J MOL MED, V31, P232, DOI 10.3892/ijmm.2012.1164
   Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976
   Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040
   Chiu YH, 2009, CELL, V138, P576, DOI 10.1016/j.cell.2009.06.015
   DeJesus R, 2016, ELIFE, V5, DOI [10.7554/elife.17290, 10.7554/eLife.17290]
   Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623
   Dhir A, 2018, NATURE, V560, P238, DOI 10.1038/s41586-018-0363-0
   Du M, 2019, THERANOSTICS, V9, P4688, DOI 10.7150/thno.36862
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Farkas D, 2019, AM J RESP CRIT CARE, V199, P199, DOI 10.1164/rccm.201707-1370OC
   Gaetani L, 2016, J NEUROL, V263, P422, DOI 10.1007/s00415-015-7879-0
   Honda K, 2006, IMMUNITY, V25, P349, DOI 10.1016/j.immuni.2006.08.009
   Hooks JJ, 2008, J IMMUNOL, V180, P3789, DOI 10.4049/jimmunol.180.6.3789
   Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581
   Iwanaszko M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1511-7
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kerur N, 2018, NAT MED, V24, P50, DOI 10.1038/nm.4450
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Li H, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00290
   Li Y, 2018, CELL DEATH DIFFER, V25, P1304, DOI 10.1038/s41418-017-0041-z
   LOEB KR, 1992, J BIOL CHEM, V267, P7806
   Ma F, 2015, J IMMUNOL, V194, P1545, DOI 10.4049/jimmunol.1402066
   Mavragani CP, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00238
   Medhat E, 2016, HEPATOL SURG NUTR, V5, P209, DOI 10.21037/hbsn.2015.12.14
   Mustafi D, 2012, J CLIN INVEST, V122, P2989, DOI 10.1172/JCI64427
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Patel AK, 2013, MOL IMMUNOL, V54, P122, DOI 10.1016/j.molimm.2012.11.005
   Perng YC, 2018, NAT REV MICROBIOL, V16, P423, DOI 10.1038/s41579-018-0020-5
   Reder AT, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00281
   Sarhan J, 2019, CELL DEATH DIFFER, V26, P332, DOI 10.1038/s41418-018-0122-7
   Schlee M, 2016, NAT REV IMMUNOL, V16, P566, DOI 10.1038/nri.2016.78
   Semenova N, 2019, NUCLEIC ACIDS RES, V47, P10235, DOI 10.1093/nar/gkz768
   Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012
   Shaw AE, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2004086
   Stawowczyk M, 2011, J BIOL CHEM, V286, P7257, DOI 10.1074/jbc.M110.207068
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tamura T, 2008, ANNU REV IMMUNOL, V26, P535, DOI 10.1146/annurev.immunol.26.021607.090400
   Taylor JM, 2014, NEUROBIOL AGING, V35, P1012, DOI 10.1016/j.neurobiolaging.2013.10.089
   Thapa RJ, 2013, P NATL ACAD SCI USA, V110, pE3109, DOI 10.1073/pnas.1301218110
   Volkman HE, 2019, ELIFE, V8, DOI 10.7554/eLife.47491
   West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156
   Wornle M, 2011, INVEST OPHTH VIS SCI, V52, P6536, DOI 10.1167/iovs.10-6993
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xiong MG, 2018, VIROL SIN, V33, P117, DOI 10.1007/s12250-018-0005-6
   Xiong WJ, 2019, P NATL ACAD SCI USA, V116, P5785, DOI 10.1073/pnas.1821000116
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Zhang HX, 2013, P NATL ACAD SCI USA, V110, P6459, DOI 10.1073/pnas.1304432110
NR 52
TC 3
Z9 4
U1 1
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PD JUN 19
PY 2021
VL 2021
AR 9975628
DI 10.1155/2021/9975628
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA TF1UH
UT WOS:000670497900001
PM 34239945
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Swaminathan, SS
   Kunkler, AL
   Quan, AV
   Medert, CM
   Vanner, EA
   Feuer, W
   Chang, TC
AF Swaminathan, Swarup S.
   Kunkler, Anne L.
   Quan, Ann, V
   Medert, Charles M.
   Vanner, Elizabeth A.
   Feuer, William
   Chang, Ta Chen
TI Rates of RNFL Thinning in Patients with Suspected or Confirmed Glaucoma
   Receiving Unilateral Intravitreal Injections for Exudative AMD
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NERVE-FIBER LAYER; ENDOTHELIAL GROWTH-FACTOR; GANGLION-CELL COMPLEX;
   ANTERIOR-CHAMBER PARACENTESIS; INNER PLEXIFORM LAYER; MACULAR
   DEGENERATION; INTRAOCULAR-PRESSURE; ANTI-VEGF; OCULAR HYPERTENSION;
   THICKNESS CHANGES
AB PURPOSE: This study evaluated whether the rate of retinal nerve fiber layer (RNFL) thinning is faster in eyes receiving intravitreal injections than in fellow uninjected eyes among patients suspected of having or confirmed to have glaucoma and exudative age-related macular degeneration (AMD).
   DESIGN: Retrospective comparative cohort study.
   METHODS: Patients with a diagnosis of unilateral exudative AMD and confirmed to have or suspected of having glaucoma in both eyes receiving unilateral intravitreal injections were identified. Those with >= 3 RNFL optical coherence tomography scans and >= 6 injections were included in the study. Rates of RNFL thinning in the injected eye versus the uninjected eye were estimated using linear mixed models. The main outcome measurement was the differences in rates of RNFL thinning in the injected versus the fellow uninjected eye. The effects of postinjection elevation of intraocular pressure (IOP), injection frequency, and number of injections were also evaluated.
   RESULTS: A total of 53 patients met the inclusion criteria, receiving 26.4 +/- 15.9 intravitreal injections. The average rate of RNFL thinning in uninjected eyes was -0.620 mu m/year (P = .029). Injected eyes had an additional incremental loss of -0.385 mm/year, but this value was not statistically significant (95% confidence interval [CI]:-1.147 to 0.379 mm/year; P = .324). Subgroup analysis with only glaucoma patients (n = 33) also demonstrated a nonsignificant effect of injections (-0.568 mm/year; 95% CI:-1.454 to 0.319 mm/year; P = .212). Postinjection IOP elevation, injection frequency, and total number of injections were not associated with faster RNFL loss.
   CONCLUSIONS: Among exudative AMD patients with glaucoma or suspected of having glaucoma, the rate of RNFL thinning in eyes receiving intravitreal injections did not significantly differ from that of fellow uninjected eyes. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Swaminathan, Swarup S.; Kunkler, Anne L.; Quan, Ann, V; Medert, Charles M.; Vanner, Elizabeth A.; Feuer, William; Chang, Ta Chen] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Swaminathan, SS (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM sswaminathan@miami.edu
OI Vanner, Elizabeth/0000-0003-1875-4524; Chang, Ta
   Chen/0000-0003-4827-5014
FU US National Institutes of Health Center Core grant [P30EY014801];
   Research to Prevent Blindness; University of Miami Institute for
   Advanced Study of the Americas Pilot grant; Intelligent Research in
   Sight (IRIS) Registry-American Glaucoma Society (AGS) Research
   Initiative grant; Miami Clinical and Translational Science Institute
   [UL1TR002736]; National Center for Advancing Translational Sciences;
   National Institute on Minority Health and Health Disparities
FX Publication of this article was supported by US National Institutes of
   Health Center Core grant P30EY014801; an unrestricted grant from
   Research to Prevent Blindness; a 2019 University of Miami Institute for
   Advanced Study of the Americas Pilot grant; a 2018 Intelligent Research
   in Sight (IRIS) Registry-American Glaucoma Society (AGS) Research
   Initiative grant; Miami Clinical and Translational Science Institute
   grant UL1TR002736; and support from the National Center for Advancing
   Translational Sciences and the National Institute on Minority Health and
   Health Disparities. The funding organizations had no role in the design
   or conduct of this research.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Chauhan BC, 2020, OPHTHALMOLOGY, V127, P177, DOI 10.1016/j.ophtha.2019.09.013
   Crowther MJ, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-146
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Du J, 2019, J GLAUCOMA, V28, P1035, DOI 10.1097/IJG.0000000000001382
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gabrielle PH, 2020, OPHTHALMOL RETINA, V4, P861, DOI 10.1016/j.oret.2020.06.020
   Gomez-Mariscal M, 2019, GRAEF ARCH CLIN EXP, V257, P2221, DOI 10.1007/s00417-019-04354-7
   Hoddap E, 1993, CLIN DECISIONS GLAUC
   Hoguet A, 2019, OPHTHALMOLOGY, V126, P611, DOI 10.1016/j.ophtha.2018.11.019
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Hwang DJ, 2014, INVEST OPHTH VIS SCI, V55, P4213, DOI 10.1167/iovs.13-13776
   Jo Young-Joon, 2016, Korean J Ophthalmol, V30, P114, DOI 10.3341/kjo.2016.30.2.114
   Kitsu K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.10
   Kopic A, 2017, ACTA CLIN CROAT, V56, P406, DOI 10.20471/acc.2017.56.03.07
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee HJ, 2016, AM J OPHTHALMOL, V161, P214, DOI 10.1016/j.ajo.2015.09.020
   Lee JW, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0255-8
   Lee WJ, 2017, J GLAUCOMA, V26, P980, DOI 10.1097/IJG.0000000000000776
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Medeiros FA, 2011, INVEST OPHTH VIS SCI, V52, P5794, DOI 10.1167/iovs.10-7111
   Medeiros FA, 2010, AM J OPHTHALMOL, V149, P908, DOI 10.1016/j.ajo.2010.01.010
   Michalska-Malecka K, 2016, CLIN INTERV AGING, V11, P357, DOI 10.2147/CIA.S93820
   Mwanza JC, 2015, INVEST OPHTH VIS SCI, V56, P6344, DOI 10.1167/iovs.15-17248
   Nuesi R, 2020, CURR OPHTHALMOL REP, V8, P111, DOI 10.1007/s40135-020-00235-z
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7
   Rouvas A, 2009, OPHTHALMOLOGICA, V223, P383, DOI 10.1159/000228590
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Saleh R, 2017, GRAEF ARCH CLIN EXP, V255, P817, DOI 10.1007/s00417-017-3590-4
   Saxena S, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0157-z
   Sengul EA, 2016, J OCUL PHARMACOL TH, V32, P665, DOI 10.1089/jop.2016.0014
   Shin HJ, 2016, INVEST OPHTH VIS SCI, V57, P1798, DOI 10.1167/iovs.15-18404
   Shin HJ, 2014, INVEST OPHTH VIS SCI, V55, P2403, DOI 10.1167/iovs.13-13769
   Sobaci G, 2013, INT J OPHTHALMOL-CHI, V6, P211, DOI 10.3980/j.issn.2222-3959.2013.02.20
   Soheilian M, 2017, GRAEF ARCH CLIN EXP, V255, P1705, DOI 10.1007/s00417-017-3702-1
   Song S, 2016, INDIAN J OPHTHALMOL, V64, P762, DOI 10.4103/0301-4738.195006
   Tah V, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/627674
   Tseng JJ, 2012, J GLAUCOMA, V21, P241, DOI 10.1097/IJG.0b013e31820d7d19
   Valverde-Megias A, 2019, GRAEF ARCH CLIN EXP, V257, P1459, DOI 10.1007/s00417-019-04325-y
   Wingard JB, 2019, CLIN OPHTHALMOL, V13, P2563, DOI 10.2147/OPTH.S232548
   Wu ZC, 2017, AM J OPHTHALMOL, V181, P106, DOI 10.1016/j.ajo.2017.06.017
   Yang J., 2020, OPHTHALMOL RETINA
   Zhang ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep38326
   Zucchiatti I, 2017, RETINA-J RET VIT DIS, V37, P1314, DOI 10.1097/IAE.0000000000001360
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 49
TC 4
Z9 4
U1 3
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2021
VL 226
BP 206
EP 216
DI 10.1016/j.ajo.2020.12.016
EA APR 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TL1CP
UT WOS:000674592100023
PM 33359714
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Corbelli, E
   Borrelli, E
   Parravano, M
   Sacconi, R
   Gilardi, M
   Costanzo, E
   Cavalleri, M
   Querques, L
   Bandello, F
   Querques, G
AF Corbelli, Eleonora
   Borrelli, Enrico
   Parravano, Mariacristina
   Sacconi, Riccardo
   Gilardi, Marta
   Costanzo, Eliana
   Cavalleri, Michele
   Querques, Lea
   Bandello, Francesco
   Querques, Giuseppe
TI Multimodal imaging characterization of peripheral drusen
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Drusen; Peripheral retina; Multimodal imaging; Ultra-widefield;
   Age-related macular degeneration
ID AGE; CHOLESTEROL; DEPOSITS; OPTOMAP
AB Purpose To provide an integrate multimodal imaging characterization of peripheral drusen in the eyes with and without macular signs of age-related macular degeneration (AMD) and to analyze their association with macular findings. Methods In this retrospective, cross-sectional study, subjects with peripheral drusen were imaged with the Optos (Optos PLC, Dunfermline, Scotland, UK) and Spectralis devices to obtain referenced spectral domain optical coherence tomography (SD-OCT) images. Two experienced graders independently graded the ultra-widefield (UWF) pseudocolor and fundus autofluorescence (FAF) images for the presence of peripheral drusen and analyzed peripheral druse features using OCT. Main outcome measures included quantitative and qualitative assessment of peripheral drusen. Results Fifty-seven eyes (30 subjects) were included in the analysis. Mean +/- SD age was 77.6 +/- 9.2 years (range 54-97 years). On pseudocolor images, graders identified the presence of drusen in all the enrolled eyes (Cohen's kappa was 1.0). On FAF images, Cohen's kappa was 0.71. In the topographical assessment, peripheral drusen were detected in 23 cases in the temporal region, in 40 cases in the nasal region, in 40 cases in the inferior region, and in 42 cases in the superior region. On SD-OCT images, peripheral drusen had a high reflective core in 97.1% of cases, while remaining drusen were characterized by a low reflective core. The macula was affected by early/intermediate AMD in 23 eyes (43.5%) and late AMD in 6 eyes (10.5%). Conclusions We provided an integrate multimodal imaging assessment of peripheral drusen in the eyes with and without AMD. Peripheral drusen were characterized by distinguished features that may suggest that these lesions constitute a distinct disease, rather than representing an expansion of AMD.
C1 [Corbelli, Eleonora; Borrelli, Enrico; Sacconi, Riccardo; Cavalleri, Michele; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] Univ V, Dept Ophthalmol, Salute Raffaele, Via Olgettina 60, Milan, Italy.
   [Parravano, Mariacristina; Gilardi, Marta; Costanzo, Eliana] Fondaz Bietti, IRCCS, Rome, Italy.
RP Querques, G (通讯作者)，Univ V, Dept Ophthalmol, Salute Raffaele, Via Olgettina 60, Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Cavalleri, Michele/AAS-2701-2020
OI Cavalleri, Michele/0000-0001-5308-1201; Sacconi,
   Riccardo/0000-0003-2891-2012; Querques, Giuseppe/0000-0002-3292-9581;
   Borrelli, Enrico/0000-0003-2815-5031; bandello,
   francesco/0000-0003-3238-9682
CR Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Borrelli E, 2019, OPHTHALMOL RETIN
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Csincsik L, 2018, OPHTHALMIC RES, V59, P182, DOI 10.1159/000487053
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Forrester JV, 2008, ELSEVIER, V568, DOI [10.1038/nrg1202.J, DOI 10.1038/NRG1202.J]
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Khan KN, 2016, PROG RETIN EYE RES
   Khandhadia S, 2009, BRIT J OPHTHALMOL, V93, P52, DOI 10.1136/bjo.2008.148072
   Kumar V, 2016, INDIAN J OPHTHALMOL, V64, P930, DOI 10.4103/0301-4738.198842
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   Mackenzie PJ, 2007, RETINA-J RET VIT DIS, V27, P1119, DOI 10.1097/IAE.0b013e3180592b5c
   McCarter RV, 2018, BRIT J OPHTHALMOL, V102, P483, DOI 10.1136/bjophthalmol-2017-310526
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J
   Nagiel A, 2016, RETINA-J RET VIT DIS, V36, P660, DOI 10.1097/IAE.0000000000000937
   Oishi M, 2014, INVEST OPHTH VIS SCI, V55, P3572, DOI 10.1167/iovs.14-13912
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Rosa N, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3120941
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Veerappan M, 2016, OPHTHALMOLOGY, V123, P2554, DOI 10.1016/j.ophtha.2016.08.047
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
NR 26
TC 3
Z9 3
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2020
VL 258
IS 3
BP 543
EP 549
DI 10.1007/s00417-019-04586-7
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KN4JG
UT WOS:000514804400009
PM 31900644
DA 2022-11-30
ER

PT J
AU Lene, P
   Ouerfelli-Ethier, J
   Fournet, R
   Laurin, AS
   Gosselin, F
   Khan, AZ
AF Lene, Paul
   Ouerfelli-Ethier, Julie
   Fournet, Romain
   Laurin, Anne-Sophie
   Gosselin, Frederic
   Khan, Aarlenne Zein
TI Changes in eye movement parameters in the presence of an artificial
   central scotoma
SO RESTORATIVE NEUROLOGY AND NEUROSCIENCE
LA English
DT Article
DE Age macular degeneration; preferred retinal locus; attentional shift;
   central vision loss; vision loss adaptation
ID PREFERRED RETINAL LOCI; BILATERAL FOVEAL LESIONS; SPATIAL-RESOLUTION;
   COVERT ATTENTION; ADULT CAT; FIXATION CHARACTERISTICS; CONTRAST
   SENSITIVITY; MACULAR DEGENERATION; ECCENTRIC FIXATION; VISUAL-ATTENTION
AB Background: Central vision loss, such as in the case of age-related macular degeneration (AMD), has a a major negative impact on patients' quality of life. However, some patients have shown spontaneous adaptive strategies development, mostly relying on their peripheral vision.
   Objective: This study assesses eye movement and eccentric visual function adaptive behaviors of a healthy population in the presence of simulated central vision loss. We wished to determine how central vision loss affects eye movements, specifically the foveal-target alignment.
   Methods: Fifteen healthy participants (7 females, M = 21.69, SD = 2.13) discriminated the orientation of a Gabor relative to the vertical located at 12 deg of eccentricity to the right of fixation, in the presence of a gaze-contingent artificial central scotoma either visible or invisible. The artificial central scotoma was 4 degrees diameter in order to simulate an earlier stage of degenerative disease while still impairing foveal vision. The target's orientation varied between 10 degrees counter-clockwise and 10. clockwise. Each participant performed four blocks of 75 trials each per day over 10 days, the first day being a baseline without scotoma.
   Results: We found changes in the endpoints of the 1st saccade over the practice days. The most common pattern was a gradual upward shift. We also observed a significant increase in discrimination performance over the 9 days of practice. We did not find any difference linked to the scotoma types.
   Conclusions: These findings suggest that the presence of an artificial central scotoma combined with a challenging discrimination task induces both changes in saccade planning mechanisms, resulting in a new eccentric-target alignment, and improvements in eccentric visual functions. This demonstrates the potential of this research paradigm to understand and potentially improve visual function in patients with central vision loss.
C1 [Lene, Paul; Ouerfelli-Ethier, Julie; Fournet, Romain; Laurin, Anne-Sophie; Khan, Aarlenne Zein] Univ Montreal, Ecole Optometrie, Lab Vis Attent & Act, Montreal, PQ, Canada.
   [Lene, Paul; Gosselin, Frederic] Univ Montreal, Dept Psychol, Montreal, PQ, Canada.
   [Gosselin, Frederic; Khan, Aarlenne Zein] Univ Montreal, Ctr Interdisciplinaire Rech Cerveau & Apprentissa, Montreal, PQ, Canada.
C3 Universite de Montreal; Universite de Montreal; Universite de Montreal
RP Khan, AZ (通讯作者)，Ecole Optometrie, 2nd Floor,3744 Rue Jean Brillant, Montreal, PQ H3T 1P1, Canada.
EM aarlenne.khan@umontreal.ca
FU Vision Health Research Network National and International Networking
   Grant; Foundation Antoine-Turmel, Quebec
FX Funding was provided for by the Vision Health Research Network National
   and International Networking Grant and the Foundation Antoine-Turmel,
   Quebec.
CR Agaoglu MN, 2019, INVEST OPHTH VIS SCI, V60
   Alahyane N, 2016, J VISION, V16, DOI 10.1167/16.1.6
   Anton-Erxleben K, 2013, NAT REV NEUROSCI, V14, P188, DOI 10.1038/nrn3443
   Bahcall DO, 1999, NATURE, V400, P864, DOI 10.1038/23693
   Bahcall DO, 2000, VISION RES, V40, P2779, DOI 10.1016/S0042-6989(00)00117-6
   Barraza-Bernal MJ, 2017, VISION RES, V140, P1, DOI 10.1016/j.visres.2017.07.009
   Barraza-Bernal MJ, 2017, J VISION, V17, DOI 10.1167/17.2.11
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Brandt C.T., 2011, SUBCORTICAL CONTROL
   Calford MB, 2000, J PHYSIOL-LONDON, V524, P587, DOI 10.1111/j.1469-7793.2000.t01-1-00587.x
   Carrasco M, 2001, SPATIAL VISION, V15, P61, DOI 10.1163/15685680152692015
   Carrasco M, 2000, VISION RES, V40, P1203, DOI 10.1016/S0042-6989(00)00024-9
   Carrasco M, 1997, VISION RES, V37, P63, DOI 10.1016/S0042-6989(96)00102-2
   Carrasco M., 2018, CURRENT OPINION PSYC
   Carrasco M, 2014, COLD SH Q B, V79, P149, DOI 10.1101/sqb.2014.79.024687
   Carrasco M, 2011, VISION RES, V51, P1484, DOI 10.1016/j.visres.2011.04.012
   Carrasco M, 2009, PROG BRAIN RES, V176, P65, DOI 10.1016/S0079-6123(09)17605-7
   Castet E, 2012, SEEING PERCEIVING, V25, P449, DOI 10.1163/187847611X620955
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   CHINO YM, 1992, VISION RES, V32, P789, DOI 10.1016/0042-6989(92)90021-A
   Chino YM, 1995, CAN J PHYSIOL PHARM, V73, P1323, DOI 10.1139/y95-187
   Chung S, 2013, INVEST OPHTH VIS SCI, V54
   Chung STL, 2011, INVEST OPHTH VIS SCI, V52, P1164, DOI 10.1167/iovs.10-6034
   Collins CE, 2003, J NEUROSCI, V23, P2251
   Cornelissen FW, 2002, BEHAV RES METH INS C, V34, P613, DOI 10.3758/BF03195489
   Crossland MD, 2002, OPTOMETRY VISION SCI, V79, P735, DOI 10.1097/00006324-200211000-00011
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995
   DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0
   De Bie J., 1987, EYE MOVEMENTS PHYSL, P85
   Denison R., 2018, J VISION, V18, P1032
   Deruaz A, 2004, BRIT J OPHTHALMOL, V88, P461, DOI 10.1136/bjo.2003.025601
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   DEUBEL H, 1986, HUM NEUROBIOL, V5, P245
   Dupuis-Roy N, 2007, VISION RES, V47, P349, DOI 10.1016/j.visres.2006.10.016
   EDGAR GK, 1990, PERCEPTION, V19, P759, DOI 10.1068/p190759
   ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460
   ERKELENS CJ, 1993, EXP BRAIN RES, V93, P157
   FISCHER B, 1986, BIOL CYBERN, V55, P253, DOI 10.1007/BF00355600
   FISCHER B, 1990, PERCEPTION, V19, P805, DOI 10.1068/p190805
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Fletcher Donald C, 2012, Optom Vis Sci, V89, P1395, DOI 10.1097/OPX.0b013e318264cc77
   Foulsham T, 2011, ATTEN PERCEPT PSYCHO, V73, P266, DOI 10.3758/s13414-010-0014-5
   Fuchs A.F., 1967, TARA, P161
   GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0
   Gilbert CD, 2009, J PHYSIOL-LONDON, V587, P2743, DOI 10.1113/jphysiol.2009.171488
   Gordon P, 1997, J AM PLANN ASSOC, V63, P95, DOI 10.1080/01944369708975727
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   HALLETT PE, 1976, VISION RES, V16, P99, DOI 10.1016/0042-6989(76)90083-3
   HEINEN SJ, 1992, VISION RES, V32, P365, DOI 10.1016/0042-6989(92)90145-9
   HEINEN SJ, 1991, EXP BRAIN RES, V83, P670
   Intriligator J, 2001, COGNITIVE PSYCHOL, V43, P171, DOI 10.1006/cogp.2001.0755
   Johnson Addie, 2004, ATTENTION THEORY PRA
   KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637
   Kaas Jon H, 2003, Adv Neurol, V93, P87
   KAPOULA Z, 1986, VISION RES, V26, P735, DOI 10.1016/0042-6989(86)90087-8
   Kirchner H, 2006, VISION RES, V46, P1762, DOI 10.1016/j.visres.2005.10.002
   Klein SA, 2001, PERCEPT PSYCHOPHYS, V63, P1421, DOI 10.3758/BF03194552
   Kline D.W., 1985, VISION AGING
   Krauzlis RJ, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0205
   KROSE BJA, 1989, VISION RES, V29, P1607, DOI 10.1016/0042-6989(89)90142-9
   Kwon MY, 2013, CURR BIOL, V23, P1663, DOI 10.1016/j.cub.2013.06.056
   LABERGE D, 1973, MEM COGNITION, V1, P268, DOI 10.3758/BF03198108
   Laubrock J, 2013, J VISION, V13, DOI 10.1167/13.12.11
   Lee KK, 2010, CAN J OPHTHALMOL, V45, P393, DOI 10.3129/i10-021
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Liu R, 2016, J VISION, V16, DOI 10.1167/16.6.10
   Loschky LC, 2005, VIS COGN, V12, P1057, DOI 10.1080/13506280444000652
   Loschky LC, 2002, J EXP PSYCHOL-APPL, V8, P99, DOI 10.1037/1076-898X.8.2.99
   Mackeben M, 1999, SPATIAL VISION, V12, P51, DOI 10.1163/156856899X00030
   Maniglia M, 2016, RESTOR NEUROL NEUROS, V34, P697, DOI 10.3233/RNN-150575
   Markowitz SN, 2010, CAN J OPHTHALMOL, V45, P58, DOI 10.3129/i09-244
   Masson GS, 2000, VISUAL NEUROSCI, V17, P753, DOI 10.1017/S0952523800175091
   MCLAUGHLIN SC, 1967, PERCEPT PSYCHOPHYS, V2, P359, DOI 10.3758/BF03210071
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   MEIENBERG O, 1981, ANN NEUROL, V9, P537, DOI 10.1002/ana.410090605
   Merabet LB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003046
   Messias EL, 2007, PSYCHIAT CLIN N AM, V30, P323, DOI 10.1016/j.psc.2007.04.007
   MILLODOT M, 1974, J OPT SOC AM, V64, P110, DOI 10.1364/JOSA.64.000110
   Moore T, 2006, CURR OPIN NEUROBIOL, V16, P159, DOI 10.1016/j.conb.2006.03.009
   Moore T, 2001, P NATL ACAD SCI USA, V98, P1273, DOI 10.1073/pnas.021549498
   NAZIR TA, 1992, VISION RES, V32, P771, DOI 10.1016/0042-6989(92)90192-L
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Nuthmann A, 2016, J VISION, V16, DOI 10.1167/16.2.3
   Nuthmann A, 2014, J EXP PSYCHOL HUMAN, V40, P342, DOI 10.1037/a0033854
   Nuthmann A, 2013, VIS COGN, V21, P803, DOI 10.1080/13506285.2013.832449
   Owsley C, 2016, ANNU REV VIS SCI, V2, P255, DOI 10.1146/annurev-vision-111815-114550
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231
   PRABLANC C, 1978, VISION RES, V18, P557, DOI 10.1016/0042-6989(78)90202-X
   PREVIC FH, 1990, BEHAV BRAIN SCI, V13, P519, DOI 10.1017/S0140525X00080018
   Reingold EM, 2002, BEHAV RES METH INS C, V34, P491, DOI 10.3758/BF03195478
   Renninger Laura Walker, 2005, Adv Neural Inf Process Syst, V17, P1121
   Renninger LW, 2007, J VISION, V7, DOI 10.1167/7.3.6
   RIJSDIJK JP, 1980, VISION RES, V20, P235, DOI 10.1016/0042-6989(80)90108-X
   Roelfsema PR, 2010, TRENDS COGN SCI, V14, P64, DOI 10.1016/j.tics.2009.11.005
   Rolfs M, 2018, VISION RES, V152, P126, DOI 10.1016/j.visres.2017.11.009
   Rosen S, 2014, J VISION, V14, DOI 10.1167/14.6.10
   ROVAMO J, 1979, EXP BRAIN RES, V37, P495, DOI 10.1007/bf00236819
   Sasaki Y, 2010, NAT REV NEUROSCI, V11, P53, DOI 10.1038/nrn2737
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   Seitz A, 2005, TRENDS COGN SCI, V9, P329, DOI 10.1016/j.tics.2005.05.010
   SHIOIRI S, 1989, PERCEPTION, V18, P347, DOI 10.1068/p180347
   SPEAR PD, 1993, VISION RES, V33, P2589, DOI 10.1016/0042-6989(93)90218-L
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 1999, MOL VIS, V5
   Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   van Diepen P. M. J., 1998, EYE GUIDANCE READING, P337, DOI [10.1016/B978-008043361-5/50016-X, DOI 10.1016/B978-008043361-5/50016-X]
   Varsori M, 2004, VISION RES, V44, P2691, DOI 10.1016/j.visres.2004.05.027
   Vernet M., 2017, NEUROPSYCHOLOGIA
   Wallman J, 1998, J NEUROPHYSIOL, V80, P2405, DOI 10.1152/jn.1998.80.5.2405
   Walsh DV, 2014, VISION RES, V96, P75, DOI 10.1016/j.visres.2014.01.005
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   Womelsdorf T, 2006, NAT NEUROSCI, V9, P1156, DOI 10.1038/nn1748
   Wright R.D, 2008, ORIENTING ATTENTION
   Yeshurun Y, 1999, VISION RES, V39, P293, DOI 10.1016/S0042-6989(98)00114-X
   Yu DY, 2010, VISION RES, V50, P860, DOI 10.1016/j.visres.2010.02.006
NR 123
TC 1
Z9 1
U1 3
U2 4
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 0922-6028
EI 1878-3627
J9 RESTOR NEUROL NEUROS
JI Restor. Neurol. Neurosci.
PY 2020
VL 38
IS 3
BP 203
EP 222
DI 10.3233/RNN-190957
PG 20
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA NF7RV
UT WOS:000563492600002
PM 32675431
DA 2022-11-30
ER

PT J
AU Tsolaki, E
   Bertazzo, S
AF Tsolaki, Elena
   Bertazzo, Sergio
TI Pathological Mineralization: The Potential of Mineralomics
SO MATERIALS
LA English
DT Review
DE mineralomics; calcification; pathological mineralization; ectopic
   calcification; minerals
ID SCANNING-ELECTRON-MICROSCOPY; TRANSFORM INFRARED-SPECTROSCOPY; AMORPHOUS
   CALCIUM-PHOSPHATE; CHRONIC KIDNEY-DISEASE; BONE-MATRIX PROTEINS;
   VASCULAR CALCIFICATION; PLACENTAL CALCIFICATION; BREAST-CANCER; ARTERIAL
   CALCIFICATION; CORNEAL CALCIFICATION
AB Pathological mineralization has been reported countless times in the literature and is a well-known phenomenon in the medical field for its connections to a wide range of diseases, including cancer, cardiovascular, and neurodegenerative diseases. The minerals involved in calcification, however, have not been directly studied as extensively as the organic components of each of the pathologies. These have been studied in isolation and, for most of them, physicochemical properties are hitherto not fully known. In a parallel development, materials science methods such as electron microscopy, spectroscopy, thermal analysis, and others have been used in biology mainly for the study of hard tissues and biomaterials and have only recently been incorporated in the study of other biological systems. This review connects a range of soft tissue diseases, including breast cancer, age-related macular degeneration, aortic valve stenosis, kidney stone diseases, and Fahr's syndrome, all of which have been associated with mineralization processes. Furthermore, it describes how physicochemical material characterization methods have been used to provide new information on such pathologies. Here, we focus on diseases that are associated with calcium-composed minerals to discuss how understanding the properties of these minerals can provide new insights on their origins, considering that different conditions and biological features are required for each type of mineral to be formed. We show that mineralomics, or the study of the properties and roles of minerals, can provide information which will help to improve prevention methods against pathological mineral build-up, which in the cases of most of the diseases mentioned in this review, will ultimately lead to new prevention or treatment methods for the diseases. Importantly, this review aims to highlight that chemical composition alone cannot fully support conclusions drawn on the nature of these minerals.
C1 [Tsolaki, Elena; Bertazzo, Sergio] UCL, Dept Med Phys & Biomed Engn, London WC1E 6BT, England.
C3 University of London; University College London
RP Bertazzo, S (通讯作者)，UCL, Dept Med Phys & Biomed Engn, London WC1E 6BT, England.
EM elena.tsolaki.15@ucl.ac.uk; s.bertazzo@ucl.ac.uk
RI ; Bertazzo, Sergio/J-7357-2016
OI Tsolaki, Elena/0000-0003-1436-7834; Bertazzo, Sergio/0000-0003-4889-8190
FU National Institute for Health Research
FX We would like to thank Matt Pilgrim, Imre Lengyel and the University
   College London Institute of Ophthalmology and Moorfields Eye Hospital
   Eye Tissue Repository (supported by National Institute for Health
   Research funding) for providing the eye tissue samples.
CR Aggarwal KP, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/292953
   Alarmo EL, 2010, ENDOCR-RELAT CANCER, V17, pR123, DOI 10.1677/ERC-09-0273
   Alelign T, 2018, ADV UROL, V2018, DOI 10.1155/2018/3068365
   Alexander RT, 2014, CLIN J AM SOC NEPHRO, V9, P506, DOI 10.2215/CJN.04960513
   ALZUHAIR AGH, 1984, ARCH GYNECOL, V234, P167, DOI 10.1007/BF00570752
   Anderson SB, 2003, BRIT J OPHTHALMOL, V87, P587, DOI 10.1136/bjo.87.5.587
   Auw-Haedrich C, 2002, SURV OPHTHALMOL, V47, P515, DOI 10.1016/S0039-6257(02)00357-0
   Azpiazu D, 2018, NEFROLOGIA, V38, P250, DOI 10.1016/j.nefro.2017.07.005
   Baker R, 2010, BRIT J CANCER, V103, P1034, DOI 10.1038/sj.bjc.6605873
   Baker RN, 2007, PROC SPIE, V6628, DOI 10.1117/12.728240
   Barrett HE, 2015, BIOMED ENG ONLINE, V14, DOI 10.1186/1475-925X-14-S1-S5
   Basiri A, 2012, UROL J, V9, P445
   Bawari S, 2017, INDIAN J PHARM SCI, V79, P164, DOI 10.4172/pharmaceutical-sciences.1000214
   Bazin D, 2012, CHEM REV, V112, P5092, DOI 10.1021/cr200068d
   Bazin D, 2016, CR CHIM, V19, P1439, DOI 10.1016/j.crci.2015.03.001
   BEALL SS, 1989, ANN NEUROL, V26, P569, DOI 10.1002/ana.410260412
   BELLAHCENE A, 1995, AM J PATHOL, V146, P95
   Beres F, 2018, CONNECT TISSUE RES, V59, P46, DOI 10.1080/03008207.2018.1435644
   Bertazzo S, 2014, LANCET, V384, P1294, DOI 10.1016/S0140-6736(13)62369-7
   Bertazzo S, 2013, NAT MATER, V12, P576, DOI [10.1038/NMAT3627, 10.1038/nmat3627]
   BIGI A, 1981, INORG CHIM A-BIOINOR, V55, P81, DOI 10.1016/S0020-1693(00)90786-2
   Bigi A, 1997, J INORG BIOCHEM, V68, P45, DOI 10.1016/S0162-0134(97)00007-X
   Bihl G, 2001, LANCET, V358, P651, DOI 10.1016/S0140-6736(01)05782-8
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Blair HC, 2017, TISSUE ENG PART B-RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Blanco P, 1999, J NEUROL NEUROSUR PS, V67, P697
   Blaser MC, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00187
   Bonfiglio R, 2018, FUTURE ONCOL, V14, P3097, DOI 10.2217/fon-2018-0624
   Boskey Adele L, 2006, Curr Osteoporos Rep, V4, P71, DOI 10.1007/s11914-006-0005-6
   Boskey Adele L, 2013, Bonekey Rep, V2, P447, DOI 10.1038/bonekey.2013.181
   Boskey AL, 2005, VIB SPECTROSC, V38, P107, DOI 10.1016/j.vibspec.2005.02.015
   BOSKEY AL, 1989, BONE MINER, V6, P111, DOI 10.1016/0169-6009(89)90044-5
   Bugnicourt JM, 2009, CLIN J AM SOC NEPHRO, V4, P284, DOI 10.2215/CJN.02140508
   BUSING CM, 1981, VIRCHOWS ARCH A, V393, P307, DOI 10.1007/BF00430830
   Carapetis JR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2015.84
   Casanova MF, 2003, PSYCHIAT RES, V121, P59, DOI 10.1016/S0165-1781(03)00202-6
   Castellanos MR, 2008, NAT CLIN PRACT NEPHR, V4, P337, DOI 10.1038/ncpneph0804
   Chan ED, 2002, AM J RESP CRIT CARE, V165, P1654, DOI 10.1164/rccm.2108054
   Chen IH, 2014, MAT SCI ENG C-MATER, V35, P441, DOI 10.1016/j.msec.2013.11.024
   Chen KH, 2011, ULTRASOUND OBST GYN, V37, P328, DOI 10.1002/uog.7733
   Chen YY, 2019, MINERALS-BASEL, V9, DOI 10.3390/min9020068
   Childs MA, 2013, J UROLOGY, V189, P1347, DOI 10.1016/j.juro.2012.11.079
   Chiou HJ, 2010, RHEUMATOLOGY, V49, P548, DOI 10.1093/rheumatology/kep359
   Cloutier J, 2015, WORLD J UROL, V33, P157, DOI 10.1007/s00345-014-1444-9
   Coe FL, 2005, J CLIN INVEST, V115, P2598, DOI 10.1172/JCI26662
   Cottignoli Valentina, 2015, Patholog Res Int, V2015, P342984, DOI 10.1155/2015/342984
   Cox RF, 2012, BRIT J CANCER, V106, P525, DOI 10.1038/bjc.2011.583
   Cox RF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041679
   Cozzolino M, 2008, AM J NEPHROL, V28, P339, DOI 10.1159/000111827
   Cros J, 2016, CR CHIM, V19, P1642, DOI 10.1016/j.crci.2015.06.015
   Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161
   Demer LL, 2014, ARTERIOSCL THROM VAS, V34, P715, DOI 10.1161/ATVBAHA.113.302070
   Demetri-Lewis A, 2012, AM J ROENTGENOL, V198, pW325, DOI 10.2214/AJR.10.5732
   Dessombz A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051691
   Domingos F, 2011, NEPHROL DIAL TRANSPL, V26, P864, DOI 10.1093/ndt/gfq501
   Dorozhkin SV, 2007, J MATER SCI, V42, P1061, DOI 10.1007/s10853-006-1467-8
   DUCKETT S, 1977, ACTA NEUROPATHOL, V38, P7, DOI 10.1007/BF00691269
   Durgawale P, 2010, BIOMED RES-INDIA, V21, P305
   Durham AL, 2018, CARDIOVASC RES, V114, P590, DOI 10.1093/cvr/cvy010
   Dyer RB, 1998, RADIOGRAPHICS, V18, P1405, DOI 10.1148/radiographics.18.6.9821191
   Eanes E.D., 1998, CALCIUM PHOSPHATES B, P21
   Fakhoury MQ, 2019, WORLD J UROL, V37, P1723, DOI 10.1007/s00345-018-2562-6
   Farlay D, 2010, J BONE MINER METAB, V28, P433, DOI 10.1007/s00774-009-0146-7
   FERENCZY A, 1977, CANCER, V39, P2451, DOI 10.1002/1097-0142(197706)39:6<2451::AID-CNCR2820390623>3.0.CO;2-7
   Florencio-Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   FORSTL H, 1992, BEHAV NEUROL, V5, P53, DOI 10.3233/BEN-1992-5110
   FRANKLIN RE, 1953, NATURE, V171, P740, DOI 10.1038/171740a0
   FRAPPART L, 1984, HUM PATHOL, V15, P880, DOI 10.1016/S0046-8177(84)80150-1
   Gadaleta SJ, 1996, CALCIFIED TISSUE INT, V58, P9, DOI 10.1007/BF02509540
   Global Burden of Disease Cancer Collaboration, 2017, JAMA Oncol, V3, P524, DOI 10.1001/jamaoncol.2016.5688
   Gohr CM, 2007, CONNECT TISSUE RES, V48, P286, DOI 10.1080/03008200701692362
   Goldsmith CS, 2009, CLIN MICROBIOL REV, V22, P552, DOI 10.1128/CMR.00027-09
   Gorski JP, 2011, FRONT BIOSCI-LANDMRK, V16, P2598, DOI 10.2741/3875
   GRANNUM PAT, 1979, AM J OBSTET GYNECOL, V133, P915, DOI 10.1016/0002-9378(79)90312-0
   Haka AS, 2002, CANCER RES, V62, P5375
   Halverson Paul B, 2003, Curr Rheumatol Rep, V5, P244, DOI 10.1007/s11926-003-0074-9
   Harder SL, 2008, AM J NEURORADIOL, V29, P176, DOI 10.3174/ajnr.A0770
   Hess B, 1997, NEPHROL DIAL TRANSPL, V12, P1362, DOI 10.1093/ndt/12.7.1362
   Higgins CL, 2005, ARTERIOSCL THROM VAS, V25, P1567, DOI 10.1161/01.ATV.0000172017.79441.73
   Ho CY, 2016, ARTERIOSCL THROM VAS, V36, P1475, DOI 10.1161/ATVBAHA.116.306717
   Hsu JJ, 2016, HEART, V102, P1710, DOI 10.1136/heartjnl-2016-309667
   Hsu THS, 2011, UROL RES, V39, P165, DOI 10.1007/s00240-010-0316-z
   Hutcheson JD, 2016, NAT MATER, V15, P335, DOI 10.1038/nmat4519
   HUTCHINSON WB, 1980, J NATL CANCER I, V65, P13
   Hyun JS, 2018, WORLD J MENS HEALTH, V36, P15, DOI 10.5534/wjmh.17018
   Ibsen CJS, 2016, CHEM-EUR J, V22, P12347, DOI 10.1002/chem.201601280
   Imbert L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202833
   Jamal A, 2017, J OBSTET GYNAECOL, V37, P605, DOI 10.1080/01443615.2017.1285871
   Javadi S, 2017, AM J ROENTGENOL, V209, P77, DOI 10.2214/AJR.17.17862
   Jaworski K, 2017, POL J RADIOL, V82, P490, DOI 10.12659/PJR.902024
   Jha V, 2018, KIDNEY INT, V94, P462, DOI 10.1016/j.kint.2018.05.009
   Kamoun A, 1999, PEDIATR NEPHROL, V13, P920, DOI 10.1007/s004670050728
   Kapustin AN, 2015, CIRC RES, V116, P1312, DOI 10.1161/CIRCRESAHA.116.305012
   Khan SR, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.8
   Klesges LM, 1998, AM J EPIDEMIOL, V147, P127
   Kompa S, 2006, BURNS, V32, P744, DOI 10.1016/j.burns.2006.01.003
   Kostyunin AE, 2019, J MOL CELL CARDIOL, V132, P189, DOI 10.1016/j.yjmcc.2019.05.016
   Kraaij S, 2018, MED ORAL PATOL ORAL, V23, pE540, DOI 10.4317/medoral.22533
   Kunitake JAMR, 2018, J STRUCT BIOL, V202, P25, DOI 10.1016/j.jsb.2017.12.002
   Kwon YS, 2004, J KOREAN MED SCI, V19, P611, DOI 10.3346/jkms.2004.19.4.611
   LAVID FJ, 1995, CORNEA, V14, P97
   LeBedis CA, 2008, RADIOGRAPHICS, V28, P1741, DOI 10.1148/rg.286085515
   LEGROS R, 1987, CALCIFIED TISSUE INT, V41, P137, DOI 10.1007/BF02563793
   Leventouri T, 2009, INT J BIOMATER, V2009, DOI 10.1155/2009/698547
   Lieske JC, 2006, AM J KIDNEY DIS, V48, P897, DOI 10.1053/j.ajkd.2006.09.002
   LIM J J, 1975, Journal of Biological Physics, V3, P111, DOI 10.1007/BF02308895
   Liu C, 2015, SCI REP-UK, V5, DOI 10.1038/srep17269
   Livingston JH, 2014, DEV MED CHILD NEUROL, V56, P612, DOI 10.1111/dmcn.12359
   Lotsari A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06570-x
   Louvet L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115342
   Lu H, 2012, ULTRASTRUCT PATHOL, V36, P160, DOI 10.3109/01913123.2011.653710
   Maki M, 2000, PATHOL INT, V50, P531, DOI 10.1046/j.1440-1827.2000.01075.x
   Malmqvist L, 2017, ACTA OPHTHALMOL, V95, P352, DOI 10.1111/aos.13315
   Mathonnet M, 2016, CR CHIM, V19, P1672, DOI 10.1016/j.crci.2015.02.008
   MCCARTY DJ, 1966, ARTHRITIS RHEUM, V9, P804, DOI 10.1002/art.1780090608
   McKenna D, 2005, ACTA OBSTET GYN SCAN, V84, P7, DOI 10.1111/j.0001-6349.2005.00563.x
   McNally EA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029258
   Meadowcroft MD, 2009, J MAGN RESON IMAGING, V29, P997, DOI 10.1002/jmri.21731
   Mejdoubi M, 2006, J NEUROL NEUROSUR PS, V77, P1328, DOI 10.1136/jnnp.2006.098590
   Mendes EM, 2018, CLINICS PRACT, V8, P5, DOI 10.4081/cp.2018.1007
   Mercimek Mehmet Necmettin, 2015, World J Nephrol, V4, P271, DOI 10.5527/wjn.v4.i2.271
   MILLER JM, 1988, AM J PERINAT, V5, P19, DOI 10.1055/s-2007-999645
   Mirza FG, 2018, J MATERN-FETAL NEO M, V31, P797, DOI 10.1080/14767058.2017.1295443
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692
   Moe SM, 2004, CIRC RES, V95, P560, DOI 10.1161/01.RES.0000141775.67189.98
   MOHAN H, 1969, BRIT J OPHTHALMOL, V53, P195, DOI 10.1136/bjo.53.3.195
   Moran M, 2013, ULTRASOUND OBST GYN, V41, P545, DOI 10.1002/uog.12278
   Morgan EF, 2018, ANNU REV BIOMED ENG, V20, P119, DOI [10.1146/annurev-bioeng-062117121139, 10.1146/annurev-bioeng-062117-121139]
   Morgan MP, 2001, MOL CARCINOGEN, V32, P111, DOI 10.1002/mc.1070
   Mulay SR, 2014, NEPHROL DIAL TRANSPL, V29, P507, DOI 10.1093/ndt/gft248
   Nalawade Yojana V, 2009, Indian J Radiol Imaging, V19, P282, DOI 10.4103/0971-3026.57208
   Nicholson BP, 2011, BRIT J OPHTHALMOL, V95, P290, DOI 10.1136/bjo.2008.157032
   Nirumand MC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030765
   O'Connor G R, 1972, Trans Am Ophthalmol Soc, V70, P58
   O'Grady S, 2018, BBA-REV CANCER, V1869, P310, DOI 10.1016/j.bbcan.2018.04.006
   Oh EM, 2014, ANN SURG TREAT RES, V86, P115, DOI 10.4174/astr.2014.86.3.115
   Oliva F, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-95
   Oliveira JRM, 2016, SCI REP-UK, V6, DOI 10.1038/srep22961
   Omelon S, 2013, CALCIFIED TISSUE INT, V93, P382, DOI 10.1007/s00223-013-9784-9
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Peeters FECM, 2018, EUR HEART J, V39, P2618, DOI 10.1093/eurheartj/ehx653
   Poggi SH, 2001, PLACENTA, V22, P591, DOI 10.1053/plac.2001.0688
   Qi XM, 2017, ONCOL LETT, V14, P79, DOI 10.3892/ol.2017.6112
   RADI MJ, 1989, ARCH PATHOL LAB MED, V113, P1367
   Reynolds TM, 2005, J CLIN PATHOL, V58, P134, DOI 10.1136/jcp.2004.019588
   Rockhill J., 2007, NEUROSURG FOCUS, V23, pE1
   Roingeard P, 2008, BIOL CELL, V100, P491, DOI 10.1042/BC20070173
   Rostron P., 2016, INT J ENG TECHNOL RE, V6, P50
   Saleem S, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-156
   Salmani Deepalaxmi, 2014, J Nat Sci Biol Med, V5, P352, DOI 10.4103/0976-9668.136182
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Scales CD, 2016, CLIN J AM SOC NEPHRO, V11, P1305, DOI 10.2215/CJN.13251215
   SCHMID K, 1980, ATHEROSCLEROSIS, V37, P199, DOI 10.1016/0021-9150(80)90005-2
   Schrage NF, 2005, GRAEF ARCH CLIN EXP, V243, P780, DOI 10.1007/s00417-004-1089-2
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Scimeca M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-286
   Scott R, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2016.29
   Scott R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00183-y
   Shah FA, 2019, BONE RES, V7, DOI 10.1038/s41413-019-0053-z
   Singh Vivek K, 2014, Biophys Rev, V6, P291, DOI 10.1007/s12551-014-0144-4
   Smolski M, 2015, UROLOGY, V85, P178, DOI 10.1016/j.urology.2014.09.026
   SPIRT BA, 1982, RADIOLOGY, V142, P707, DOI 10.1148/radiology.142.3.7063688
   Sroga GE, 2012, CURR OSTEOPOROS REP, V10, P141, DOI 10.1007/s11914-012-0103-6
   Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI 10.1016/S1474-4422(18)30499-X
   Suh JH, 2008, ANN DIAGN PATHOL, V12, P165, DOI 10.1016/j.anndiagpath.2007.07.001
   Sun XY, 2017, ACS OMEGA, V2, P6039, DOI 10.1021/acsomega.7b00510
   SUTOR DJ, 1974, BRIT J UROL, V46, P533, DOI 10.1111/j.1464-410X.1974.tb03852.x
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Tabar L, 2000, LANCET, V355, P429
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Taylor EN, 2005, JAMA-J AM MED ASSOC, V293, P455, DOI 10.1001/jama.293.4.455
   Taylor EN, 2005, KIDNEY INT, V68, P1230, DOI 10.1111/j.1523-1755.2005.00516.x
   TERMINE JD, 1972, CLIN ORTHOP RELAT R, P207, DOI 10.1097/00003086-197206000-00036
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   TINDALL V R, 1965, J Obstet Gynaecol Br Commonw, V72, P356
   Tintut Y, 2018, FRONT CARDIOVASC MED, V5, DOI 10.3389/fcvm.2018.00172
   Tolle M, 2015, EUR J CLIN INVEST, V45, P976, DOI 10.1111/eci.12493
   Tokuyama T, 2002, AM J KIDNEY DIS, V39, P291, DOI 10.1053/ajkd.2002.30548
   Tomazic B B, 2001, Z Kardiol, V90 Suppl 3, P68
   TOMAZIC BB, 1988, ATHEROSCLEROSIS, V69, P5, DOI 10.1016/0021-9150(88)90284-5
   ULSHAFER RJ, 1987, INVEST OPHTH VIS SCI, V28, P683
   URABE H, 1983, J CHEM PHYS, V78, P5937, DOI 10.1063/1.444600
   Valenzuela A., 2016, CURR TREAT OPT RHEUM, V2, P85, DOI DOI 10.1007/S40674-016-0035-X
   VARMA VA, 1985, SCAN ELECTRON MICROS, V1985, P1567
   Viegas CSB, 2018, ARTERIOSCL THROM VAS, V38, P575, DOI 10.1161/ATVBAHA.117.310578
   VIRTANEN I, 1976, CANCER, V38, P824, DOI 10.1002/1097-0142(197608)38:2<824::AID-CNCR2820380227>3.0.CO;2-6
   Wang LL, 2017, J VIROL, V91, DOI 10.1128/JVI.01605-16
   Ward R, 2014, LANCET NEUROL, V13, P1045, DOI 10.1016/S1474-4422(14)70117-6
   Watkins DA, 2017, NEW ENGL J MED, V377, P713, DOI 10.1056/NEJMoa1603693
   WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0
   White RJ, 2018, CASE REP OPHTHALM, V9, P82, DOI 10.1159/000485963
   Wilkinson L, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160594
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wopenka B, 2005, MAT SCI ENG C-BIO S, V25, P131, DOI 10.1016/j.msec.2005.01.008
   Xie CM, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/2875189
   Xu HS, 2013, EXPERT OPIN PHARMACO, V14, P435, DOI 10.1517/14656566.2013.775250
   Yildiz S, 2014, CLINICS, V69, P841, DOI 10.6061/clinics/2014(12)09
   Yu JK, 2013, ASIAN J SURG, V36, P26, DOI 10.1016/j.asjsur.2012.06.001
   Zazzeroni L, 2018, EUR J VASC ENDOVASC, V55, P425, DOI 10.1016/j.ejvs.2017.12.009
   Zisman AL, 2017, CLIN J AM SOC NEPHRO, V12, P1699, DOI 10.2215/CJN.11201016
NR 200
TC 20
Z9 22
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1996-1944
J9 MATERIALS
JI Materials
PD OCT
PY 2019
VL 12
IS 19
AR 3126
DI 10.3390/ma12193126
PG 22
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA JI2QG
UT WOS:000493308500075
PM 31557841
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Maruyama-Inoue, M
   Sato, S
   Yamane, S
   Kadonosono, K
AF Maruyama-Inoue, Maiko
   Sato, Shimpei
   Yamane, Shin
   Kadonosono, Kazuaki
TI Variable response of subretinal hyperreflective material to
   anti-vascular endothelial growth factor classified with optical
   coherence tomography angiography
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Anti-vascular endothelial growth factor; Subretinal hyperreflective
   material; Subretinal hyperreflective exudation; Optical coherence
   tomography angiography
ID DEGENERATION TREATMENTS TRIALS; MACULAR DEGENERATION; VISUAL-ACUITY;
   ASSOCIATION; OUTCOMES
AB PurposeTo evaluate the prognosis and response of neovascular age-related macular degeneration (AMD) to anti-vascular endothelial growth factor (VEGF), according to the components of subretinal hyperreflective material (SHRM) classified using optical coherence tomography angiography (OCTA), is the aim of this study.MethodsWe retrospectively studied 39 eyes of 39 consecutive patients with SHRM associated with exudative AMD, who underwent standard examination and multimodal imaging, including fundus photography, optical coherence tomography (OCT), and OCTA. We classified SHRM into type 2 neovascularization (NV), fibrosis, subretinal hyperreflective exudation (SHE), and hemorrhage using OCTA. If compound SHRM was found, components in the foveal center were considered. All patients except one with fibrosis received anti-VEGF treatment for more than 12months. The best-corrected visual acuity (BCVA) values measured before treatment and at 3, 6, and 12months after the first injection were compared according to the components of SHRM.ResultsUsing OCTA, 11 eyes with type 2 NV showed abnormal blood flow and 1 eye with fibrosis showed strong surface projection. Both SHE and hemorrhage components showed projection artifact with no intrinsic flow. However, OCTA enabled eyes with SHE (17 eyes) to be distinguished from those with hemorrhage (10 eyes) because hemorrhage showed masking of choriocapillaris flow. Eyes with SHE showed a significant improvement in the mean logMAR BCVA as compared with the value at the baseline, which was sustained throughout the 12-month follow-up period (p<0.05). In eyes with type 2 NV and hemorrhage, no significant difference in the mean BCVA values was observed at any follow-up time-point (all, p>0.05).ConclusionOCTA was useful to noninvasively distinguish SHRM components. It may be important to consider the components of SHRM to predict the visual acuity in patients with AMD.
C1 [Maruyama-Inoue, Maiko; Sato, Shimpei; Yamane, Shin; Kadonosono, Kazuaki] Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa, Japan.
C3 Yokohama City University
RP Maruyama-Inoue, M (通讯作者)，Yokohama City Univ, Med Ctr, Dept Ophthalmol, Yokohama, Kanagawa, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   Kawashima Y, 2017, AM J OPHTHALMOL, V181, P61, DOI 10.1016/j.ajo.2017.06.015
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 13
TC 6
Z9 6
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2018
VL 256
IS 11
BP 2089
EP 2096
DI 10.1007/s00417-018-4121-7
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GX8NF
UT WOS:000448042400010
PM 30173338
DA 2022-11-30
ER

PT J
AU Jiang, J
   Xu, K
   Wang, L
   Xin, W
   Zhao, GR
   Huang, M
   Li, SJ
   Luan, XJ
   Fang, JM
AF Jiang, Jing
   Xu, Ke
   Wang, Ling
   Xin, Wei
   Zhao, Guorui
   Huang, Min
   Li, Shenjun
   Luan, Xuejing
   Fang, Jianmin
TI Pharmacology study of a chimeric decoy receptor trap fusion protein on
   retina neovascularization by dual blockage of VEGF and FGF-2
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Retina neovascularization; Dual blockage; VEGF; FGF-2
ID GROWTH-FACTOR VEGF; MACULAR DEGENERATION; ANGIOGENESIS; EXPRESSION
AB Background: Clinical anti-vascular epithelial growth factor (VEGF) therapy trials faced a major challenge due to upregulated expression of other pro-angiogenic factors, such as fibroblast growth factor-2 (FGF-2). RC28, a novel recombinant dual decoy receptor IgG1 Fc-fusion protein, can block VEGFA and FGF-2 simultaneously. It is designed for the treatment of neovascular age-related macular degeneration and other pathological ocular neovascularization. The present study investigated the prevention efficacy of RC28 on choroidal neovascularization (CNV) in a monkey model and compared to the other mono VEGF antagonists; biodistribution and pharmacokinetics performance were also investigated.
   Methods: ELISA and endothelial cell proliferation, migration, and tubule formation assay evaluated the bioactivity of RC28 in vitro, and an initial comparison was made among the mono target antagonists, Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (EYLEA), Conbercept (KH902), and Ranibizumab (Lucentis). Laser-induced CNV in monkeys, and both VEGF and FGF-2 serum levels were detected in animals before and after the CNV model were induced. RC28 prevention efficacy was compared to other VEGF antagonists on CNV with respect to the incidence of CNV and several ophthalmic examinations. Ocular and systemic levels of RC28 were analyzed by Zr-89-labeled RC28 after single intravitreal administration for the biodistribution and pharmacokinetic profiles.
   Results: RC28 is a unique fusion protein with high affinity to both VEGF and FGF-2, and beneficial to in vitro and in vivo bioactivity. The in vivo pharmacological studies demonstrated that the incidence of CNV formation was largely reduced in RC28 treatment groups with a low dosage as compared to other VEGF antagonist control groups. Furthermore, traces of RC28 were detected as dispersing from eyeballs to the liver after 20 days, and a prolonged half-time pharmacokinetic profile was exhibited.
C1 [Jiang, Jing] Binzhou Med Univ, Dept Pharmacol, Yantai 256603, Shandong, Peoples R China.
   [Xu, Ke] Beijing Inst Radiat Med, Dept Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   [Wang, Ling; Xin, Wei; Zhao, Guorui; Huang, Min; Li, Shenjun; Luan, Xuejing] RemeGen Ltd, Yantai 264000, Shandong, Peoples R China.
   [Fang, Jianmin] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.
C3 Binzhou Medical University; Academy of Military Medical Sciences -
   China; Tongji University
RP Jiang, J (通讯作者)，Binzhou Med Univ, Dept Pharmacol, Yantai 256603, Shandong, Peoples R China.; Fang, JM (通讯作者)，Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.
EM jing_jiang1974@sina.com
FU National Science and Technology Major. Project of China
   [2013ZX09102040]; Taishan Scholars of. Shandong Province
FX This work was supported by a grant from National Science and Technology
   Major. Project of China (No. 2013ZX09102040), the funding of Taishan
   Scholars of. Shandong Province to Binzhou Medical University.
CR Abdullah SE, 2012, CANCER-AM CANCER SOC, V118, P3455, DOI 10.1002/cncr.26540
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019
   Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176
   Kasai N, 2016, PHARM RES-DORDR, V33, P476, DOI 10.1007/s11095-015-1803-2
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Li D, 2014, BRIT J CANCER, V111, P68, DOI 10.1038/bjc.2014.282
   Li D, 2016, CANCER LETT, V377, P164, DOI 10.1016/j.canlet.2016.04.036
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Murakami M, 2011, J CLIN INVEST, V121, P2668, DOI 10.1172/JCI44762
   Oladipupo SS, 2014, P NATL ACAD SCI USA, V111, P13379, DOI 10.1073/pnas.1324235111
   Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659
   Su L, 2016, RETINA-J RET VIT DIS, V36, P938, DOI 10.1097/IAE.0000000000000900
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 18
TC 10
Z9 10
U1 2
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD AUG 30
PY 2018
VL 121
BP 251
EP 259
DI 10.1016/j.ejps.2018.04.043
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GL5QM
UT WOS:000437223600026
PM 29715501
DA 2022-11-30
ER

PT J
AU Due, WW
   An, YL
   He, XD
   Zhang, DL
   He, W
AF Due, Weiwei
   An, Yuanlong
   He, Xiangdong
   Zhang, Donglei
   He, Wei
TI Protection of Kaempferol on Oxidative Stress-Induced Retinal Pigment
   Epithelial Cell Damage
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID SODIUM IODATE; EXPRESSION; FLAVONOIDS; VEGF; RPE; DYSFUNCTION; RECEPTOR;
   MODEL
AB The protection of retinal pigment epithelium (RPE) injury plays an important role in the prevention of or in delaying the pathological progress of retinal degeneration diseases, like age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa. Oxidative stress has been identified as a major inducer of RPE injury, which eventually could lead to a loss of vision. Kaempferol is a natural flavonoid widely distributed in many edible plants, fruits, and traditional medicines and has been reported to have antioxidant, anti-inflammatory, anticancer, and antimicrobial activities. The present study demonstrates that the total antioxidant capacity of kaempferol is approximately two times stronger than that of lutein which is also a natural antioxidant that is widely used in the prevention or treatment of AMD. Our data indicates that kaempferol protects human RPE cells (ARPE-19) from hydrogen peroxide- (H2O2-) induced oxidative cell damage and apoptosis through the signaling pathways involving Bax/Bcl-2 and caspase-3 molecules proofed by real-time PCR and Western blot results. Kaempferol also inhibits the upregulated vascular endothelial growth factor (VEGF) mRNA expression levels induced by H2O2 in ARPE-19 cells and affects the oxidation and antioxidant imbalanced system in ARPE-19 cells treated by H2O2 through the regulations of both the activities of reactive oxygen species (ROS) and superoxide dismutase (SOD). Furthermore, our in vivo experimental results show that in sodium iodate-induced retinal degeneration rat model, kaempferol could protect sodium iodate-induced pathological changes of retina tissue and retinal cells apoptosis as well as the upregulated VEGF protein expression in RPE cells. In summary, these novel fmdings demonstrate that kaempferol could protect oxidative stressed-human RPE cell damage through its antioxidant activity and antiapoptosis function, suggesting that kaempferol has a potential role in the prevention and therapeutic treatment of AMD or other retinal diseases mediated by oxidative stress.
C1 [Due, Weiwei; An, Yuanlong; He, Xiangdong; Zhang, Donglei; He, Wei] He Univ, Sch Pharm, Shenyang 110163, Liaoning, Peoples R China.
   [He, Wei] Shenyang Ind Technol Inst Ophthalmol, Shenyang 110163, Liaoning, Peoples R China.
RP Zhang, DL; He, W (通讯作者)，He Univ, Sch Pharm, Shenyang 110163, Liaoning, Peoples R China.; He, W (通讯作者)，Shenyang Ind Technol Inst Ophthalmol, Shenyang 110163, Liaoning, Peoples R China.
EM zhangdonglei@huh.edu.cn; hewei@huh.edu.cn
OI Zhang, Donglei/0000-0003-1962-5257
FU Natural Science Foundation of Technology Department of Liaoning Province
   of China [2015020681]; Foundation of Shenyang Municipal Science and
   Technology Bureau of China [F16-205-1-36]
FX This work was supported by grants from the Natural Science Foundation of
   Technology Department of Liaoning Province of China (2015020681) and the
   Foundation of Shenyang Municipal Science and Technology Bureau of China
   (F16-205-1-36).
CR Amano S, 2005, MICROVASC RES, V69, P45, DOI 10.1016/j.mvr.2004.11.001
   Barker FM, 2010, CURR MED RES OPIN, V26, P2011, DOI 10.1185/03007995.2010.494549
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benzie IFF, 2014, ADV FOOD NUTR RES, V71, P1, DOI 10.1016/B978-0-12-800270-4.00001-8
   Calderon-Montano JM, 2011, MINI-REV MED CHEM, V11, P298, DOI 10.2174/138955711795305335
   Chen AY, 2013, FOOD CHEM, V138, P2099, DOI 10.1016/j.foodchem.2012.11.139
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Devi KP, 2015, PHARMACOL RES, V99, P1, DOI 10.1016/j.phrs.2015.05.002
   Dinc E, 2017, CURR EYE RES, V42, P1659, DOI 10.1080/02713683.2017.1368085
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Haque R, 2017, J RECEPT SIG TRANSD, V37, P560, DOI 10.1080/10799893.2017.1369120
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   Hu QQ, 2015, MOL MED REP, V12, P6577, DOI 10.3892/mmr.2015.4287
   Huang WY, 2018, J AGR FOOD CHEM, V66, P1638, DOI 10.1021/acs.jafc.7b06135
   Hung TW, 2017, INT J MED SCI, V14, P984, DOI 10.7150/ijms.20336
   Jager AK, 2011, MOLECULES, V16, P1471, DOI 10.3390/molecules16021471
   Kadioglu O, 2015, ANTICANCER RES, V35, P2645
   Kampkotter A, 2007, ARCH TOXICOL, V81, P849, DOI 10.1007/s00204-007-0215-4
   Khan M., 2014, ISRN OPHTHALMOL, V2014, DOI DOI 10.1155/2014/608390
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   King RE, 2005, CHEM-BIOL INTERACT, V151, P143, DOI 10.1016/j.cbi.2004.11.003
   Kiuchi K., 2009, CURRENT EYE RES, V25, P373
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu HJ, 2017, MOL MED REP, V16, P2069, DOI 10.3892/mmr.2017.6838
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Marie M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0331-5
   Maugeri A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072118
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moriguchi M, 2018, INVEST OPHTH VIS SCI, V59, P3476, DOI 10.1167/iovs.17-23532
   Osakabe N, 2004, EXP BIOL MED, V229, P33, DOI 10.1177/153537020422900104
   Pan HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096190
   Pintea A, 2011, J FOOD COMPOS ANAL, V24, P830, DOI 10.1016/j.jfca.2011.03.007
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011
   Sant DW, 2018, INVEST OPHTH VIS SCI, V59, P3608, DOI 10.1167/iovs.18-24101
   Scott FL, 2009, NATURE, V457, P1019, DOI 10.1038/nature07606
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suzuki R, 2014, J OCUL PHARMACOL TH, V30, P419, DOI 10.1089/jop.2013.0100
   Szewczyk K, 2014, NAT PROD RES, V28, P1655, DOI 10.1080/14786419.2014.938335
   Tatsimo Simplice Joel Ndendoung, 2012, BMC Res Notes, V5, P158, DOI 10.1186/1756-0500-5-158
   Xu XH, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414-431X20165396, 10.1590/1414-431x20165396]
   Yan YT, 2018, INT J BIOL MACROMOL, V115, P600, DOI 10.1016/j.ijbiomac.2018.04.011
   Yang YP, 2014, INVEST OPHTH VIS SCI, V55, P1696, DOI 10.1167/iovs.13-12477
   Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200
   Zhang DL, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00176
NR 47
TC 69
Z9 74
U1 3
U2 26
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2018
VL 2018
AR 1610751
DI 10.1155/2018/1610751
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HC5QL
UT WOS:000451857400001
PM 30584457
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lee, AY
   Lee, CS
   Egan, CA
   Bailey, C
   Johnston, RL
   Natha, S
   Hamilton, R
   Khan, R
   Al-Husainy, S
   Brand, C
   Akerele, T
   Mckibbin, M
   Downey, L
   Tufail, A
AF Lee, Aaron Y.
   Lee, Cecilia S.
   Egan, Catherine A.
   Bailey, Clare
   Johnston, Robert L.
   Natha, Salim
   Hamilton, Robin
   Khan, Rehna
   Al-Husainy, Sahar
   Brand, Christopher
   Akerele, Toks
   Mckibbin, Martin
   Downey, Louise
   Tufail, Adnan
TI UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as
   needed (PRN) ranibizumab versus continuous aflibercept in UK clinical
   practice
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; VEGF-TRAP; OUTCOMES; EXTEND; TREAT
AB Aims To compare the effectiveness of continuous aflibercept versus pro re nata (PRN) ranibizumab therapy for neovascular age-related macular degeneration (nAMD).
   Methods Multicentre, national electronic medical record (EMR) study on treatment naive nAMD eyes undergoing PRN ranibizumab or continuous (fixed or treat and extend (F/TE)) aflibercept from 21 UK hospitals. Anonymised data were extracted, and eyes were matched on age, gender, starting visual acuity (VA) and year of starting treatment. Primary outcome was change in vision at 1 year.
   Results 1884 eyes (942 eyes in each group) were included. At year 1, patients on PRN ranibizumab gained 1.6 ETDRS (Early Treatment Diabetic Retinopathy Study) letters (95% CI 0.5 to 2.7, p=0.004), while patients on F/TE aflibercept gained 6.1 letters (95% CI 5.1 to 7.1, p=2.2e-16). Change in vision at 1 year of the F/TE aflibercept group was 4.1 letters higher (95% CI 2.5 to 5.8, p=1.3e-06) compared with the PRN ranibizumab group after adjusting for age, starting VA, gender and year of starting therapy. The F/TE aflibercept group had significantly more injections compared with the PRN ranibizumab group (7.0 vs 5.8, p<2.2e-16), but required less clinic visits than the PRN ranibizumab group (10.8 vs 9.0, p<2.2e-16). Cost-effectiveness analysis showed an incremental cost-effectiveness ratio of 58 047.14 GBP/quality-adjusted life year for continuous aflibercept over PRN ranibizumab.
   Conclusion Aflibercept achieved greater VA gains at 1 year than ranibizumab. The observed VA differences are small and likely to be related to more frequent treatment with aflibercept, suggesting that ranibizumab should also be delivered by F/TE posology.
C1 [Lee, Aaron Y.; Lee, Cecilia S.] Univ Washington, Dept Ophthalmol, Box 359608,325 Ninth Ave, Seattle, WA 98104 USA.
   [Lee, Aaron Y.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Egan, Catherine A.; Hamilton, Robin; Tufail, Adnan] UCL Inst Ophthalmol, London, England.
   [Egan, Catherine A.; Tufail, Adnan] Moorfields Eye Hosp NHS Fdn TrustLondonUK, NIHR Biomed Res Ctr, London, England.
   [Bailey, Clare] Bristol Eye Hosp, Bristol, Avon, England.
   [Johnston, Robert L.] Gloucestershire Hosp NHS Fdn Trust, Cheltenham, Glos, England.
   [Natha, Salim] Wrightington Wigan & Leigh NHS Fdn Trust, Wigan, Lancs, England.
   [Khan, Rehna] Calderdale & Huddersfield NHS Fdn Trust, Huddersfield, W Yorkshire, England.
   [Al-Husainy, Sahar] Heart England NHS Fdn Trust, Solihull, W Midlands, England.
   [Brand, Christopher] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England.
   [Akerele, Toks] Hinchingbrooke Hlth Care NHS Trust, Huntingdon, England.
   [Mckibbin, Martin] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England.
   [Downey, Louise] Hull & East Yorkshire Hosp NHS Fdn Trust, Kingston Upon Hull, N Humberside, England.
C3 University of Washington; University of Washington Seattle; University
   of London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London;
   Bristol Eye Hospital; Gloucestershire Hospitals NHS Foundation Trust;
   Heart of England NHS Foundation Trust; University of Sheffield;
   University of Leeds
RP Lee, CS (通讯作者)，Univ Washington, Dept Ophthalmol, Box 359608,325 Ninth Ave, Seattle, WA 98104 USA.
EM leecs2@uw.edu
RI Lee, Aaron/AAT-2839-2020; Lee, Cecilia/K-2569-2014
OI Lee, Cecilia/0000-0003-1994-7213; Tufail, Adnan/0000-0001-6131-7640;
   Egan, Catherine/0000-0001-5593-1169; Lee, Aaron/0000-0002-7452-1648
FU National Eye Institute (NEI) [K23EY024921]; National Institute for
   Health Research (NIHR) Biomedical Research Centre based at Moorfields
   Eye Hospital NHS Foundation Trust; UCL Institute of Ophthalmology;
   NATIONAL EYE INSTITUTE [K23EY024921] Funding Source: NIH RePORTER
FX CSL was supported by the National Eye Institute (NEI) (K23EY024921). RH,
   CAE and AT were supported by the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology.
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   National Institute for Health and Care Excellence (NICE), RAN PEG TREATM AG RE
   National Institute for Health Excellence C, AFL SOL INJ TREAT WE
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 18
TC 29
Z9 30
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2017
VL 101
IS 12
BP 1683
EP 1688
DI 10.1136/bjophthalmol-2016-309818
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FN7OC
UT WOS:000416206600017
PM 28478396
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Xie, XB
   Feng, J
   Kang, ZF
   Zhang, SK
   Zhang, LX
   Zhang, Y
   Li, XF
   Tang, YZ
AF Xie, Xiaobin
   Feng, Jun
   Kang, Zefeng
   Zhang, Shoukang
   Zhang, Lixia
   Zhang, Yan
   Li, Xuefei
   Tang, Youzhi
TI Taxifolin protects RPE cells against oxidative stress-induced apoptosis
SO MOLECULAR VISION
LA English
DT Article
ID MACULAR DEGENERATION; DIABETIC CARDIOMYOPATHY; MOLECULAR-MECHANISMS;
   IN-VIVO; NRF2; ACTIVATION; FLAVONOIDS; CANCER; 3H-1,2-DITHIOLE-3-THIONE;
   CARCINOGENESIS
AB Purpose: Oxidative stress-induced damage to RPE cells has been suggested to be an important factor in the pathogenesis of age-related macular degeneration. Taxifolin, a flavonol, has been shown to exhibit significant antioxidant properties. The purpose of this study was to investigate the potential protective effects of taxifolin on RPE cells cultured under oxidative stress conditions and to elucidate the underlying mechanisms.
   Methods: Human RPE (ARPE-19) cells were treated with different concentrations of taxifolin and 0.4 mM of H2O2 for 24 h. Cell viability was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Apoptosis was quantitatively measured by annexin V/propidium iodide double staining, and the expression levels of poly (ADP-ribose) polymerase (PARP) were evaluated by western blotting. Reactive oxygen species (ROS) were measured using a commercially available ROS detection system. The expressions of phase II enzymes, including NAD(P)H quinine oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), and glutamate-cysteine ligase modifier (GCLM) and catalytic (GCLC) subunits, were examined using real-time PCR and western blotting. The nuclear localization of the nuclear factor (erythroid-derived 2)-like 2 (NRF2) protein was detected by western blotting.
   Results: Taxifolin clearly inhibited the decrease in H2O2-induced cell viability, cell apoptosis, and intracellular ROS generation. In addition, taxifolin inhibited the H2O2-induced PARP cleavage. Moreover, treatment with taxifolin activated mRNA and the protein expression of NRF2 by inducing the translocation of NRF2 to the nucleus. Consequently, the mRNA and protein levels of the phase II enzymes NQO1, HO-1, GCLM, and GCLC increased.
   Conclusions: Taxifolin was shown to protect RPE cells against oxidative stress-induced apoptosis. The potential mechanism appears to involve the activation of NRF2 and the phase II antioxidant enzyme system.
C1 [Xie, Xiaobin; Feng, Jun; Kang, Zefeng; Zhang, Shoukang; Zhang, Lixia; Zhang, Yan; Li, Xuefei; Tang, Youzhi] China Acad Chinese Med Sci, Eye Hosp, Beijing, Peoples R China.
   [Xie, Xiaobin; Feng, Jun; Tang, Youzhi] Chinese Acad Chinese Med Sci, Postdoctoral Res Stn, 33 Lugu Rd, Beijing 100040, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Eye Hospital, CACMS; China
   Academy of Chinese Medical Sciences
RP Tang, YZ (通讯作者)，China Acad Chinese Med Sci, Eye Hosp, Beijing, Peoples R China.; Tang, YZ (通讯作者)，Chinese Acad Chinese Med Sci, Postdoctoral Res Stn, 33 Lugu Rd, Beijing 100040, Peoples R China.
EM lulizhu2001@126.com
OI Xie, Xiaobin/0000-0001-6874-8339
FU China Postdoctoral Science Foundation [2015M571241]
FX This study was supported by a grant from China Postdoctoral Science
   Foundation (2015M571241). The authors confirm that there are no known
   conflicts of interest associated with this publication and there has
   been no significant financial support for this work that could have
   influenced its outcome.
CR Baird L, 2011, ARCH TOXICOL, V85, P241, DOI 10.1007/s00204-011-0674-5
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Dok-Go H, 2003, BRAIN RES, V965, P130, DOI 10.1016/S0006-8993(02)04150-1
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Fang Y, 2012, J BIOL CHEM, V287, P35234, DOI 10.1074/jbc.M112.389494
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gocer H, 2016, J ENZYM INHIB MED CH, V31, P441, DOI 10.3109/14756366.2015.1036051
   Guo HP, 2015, TOXICOL APPL PHARM, V287, P168, DOI 10.1016/j.taap.2015.06.002
   GUPTA MB, 1971, JPN J PHARMACOL, V21, P377, DOI 10.1254/jjp.21.377
   Hanus J, 2015, INVEST OPHTH VIS SCI, V56, P5048, DOI 10.1167/iovs.15-16401
   Jung YH, 2010, LIFE SCI, V86, P351, DOI 10.1016/j.lfs.2010.01.008
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   Khullar M, 2010, CAN J PHYSIOL PHARM, V88, P233, DOI 10.1139/Y10-016
   Kim KC, 2010, INT J BIOCHEM CELL B, V42, P297, DOI 10.1016/j.biocel.2009.11.009
   Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947
   Li KR, 2016, SCI REP-UK, V6, DOI 10.1038/srep25525
   Li WG, 2009, MOL CARCINOGEN, V48, P91, DOI 10.1002/mc.20465
   Ma Q, 2012, PHARMACOL REV, V64, P1055, DOI 10.1124/pr.110.004333
   Manigandan K, 2015, BIOCHIMIE, V119, P103, DOI 10.1016/j.biochi.2015.10.014
   Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033
   Oi N, 2012, CANCER PREV RES, V5, P1103, DOI 10.1158/1940-6207.CAPR-11-0397
   Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Schauss AG, 2015, INT J TOXICOL
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Slimestad R, 2007, J AGR FOOD CHEM, V55, P10067, DOI 10.1021/jf0712503
   Su Jian, 2014, Zhong Yao Cai, V37, P243
   Sun X, 2014, FOOD CHEM TOXICOL, V63, P221, DOI 10.1016/j.fct.2013.11.013
   Topal F, 2015, J ENZYM INHIB MED CH, V6, P1
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Vladimirov YA, 2009, BIOCHEMISTRY-MOSCOW+, V74, P301, DOI 10.1134/S0006297909030092
   Voulgari C, 2010, VASC HEALTH RISK MAN, V6, P883, DOI 10.2147/VHRM.S11681
   Wang YH, 2006, J BIOMED SCI, V13, P127, DOI 10.1007/s11373-005-9031-0
   Woo JM, 2012, MOL VIS, V18, P901
   Yildirim Z, 2011, CLINICS, V66, P743, DOI 10.1590/S1807-59322011000500006
   Zhao MY, 2015, INT IMMUNOPHARMACOL, V28, P938, DOI 10.1016/j.intimp.2015.04.032
NR 39
TC 48
Z9 52
U1 1
U2 11
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 27
PY 2017
VL 23
BP 520
EP 528
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA FB9XM
UT WOS:000406492700001
PM 28761325
DA 2022-11-30
ER

PT J
AU Omay, E
   Elgin, U
   Sen, E
   Yilmazbas, P
AF Omay, Esra
   Elgin, Ufuk
   Sen, Emine
   Yilmazbas, Pelin
TI The early effects of intravitreal anti vascular endothelial growth
   factor agents on intraocular pressure and central corneal thickness
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; Ranibizumab; Anti-VEGF; Intravitreal injection; Intraocular
   pressure; Central corneal thickness
ID MACULAR DEGENERATION; FACTOR INJECTIONS; ADVERSE EVENTS; BEVACIZUMAB;
   RANIBIZUMAB; VEGF
AB To investigate the early effects of two intravitreal (IV) anti vascular endothelial growth factor agents (anti-VEGF), bevacizumab and ranibizumab, on intraocular pressure (IOP) and central corneal thickness (CCT) within the first post-injection month. This prospective study comprised 109 eyes of 109 adult cases who had IV bevacizumab or ranibizumab injections because of age-related macular degeneration (ARMD), retinal venous occlusion (RVO), diabetic retinopathy, and macular edema or central serous chorioretinopathy (CSCR). None of the cases had medical histories of any kinds of glaucoma or increased IOP and IV injection before and all of them underwent a detailed ocular examination including measurements of IOP by non-contact tonometer and CCT by ultrasonic pachymeter pre-injection. IOP measurements were repeated at 30 min and 1st, 7th, and 30th day after the injection. CCT measurements were repeated at the 7th and 30th post-injection day. Paired sample t tests were used for the statistical analysis in order to evaluate the significance of changes in IOP and CCT. The mean age of 56 male and 53 female cases was 63.58 +/- 11.04 years. Fifty-six cases (51.4 %) had diabetic retinopathy, 33 cases (30.3 %) had ARMD, 11 cases (10.1 %) had RVO, and 9 cases (8.3 %) had CSCR. Bevacizumab was used in 97 (89 %) cases and ranibizumab was used in 12 (11 %) cases. The IOP increased significantly 30 min after the injection (p < 0.001) but significant decreases were observed at the 1st, 7th, and 30th day post-injection (p < 0.001). No significant differences were observed in CCT between pre-injection and 7th and 30th post-injection day values (p = 0.924 and p = 0.589, respectively). Intravitreal bevacizumab and ranibizumab injections can cause hyper acute increase in IOP because of vitreal expansion but this effect is generally reversible in non-glaucomatous cases.
C1 [Omay, Esra; Elgin, Ufuk; Sen, Emine; Yilmazbas, Pelin] Ulucanlar Eye Res Hosp, Ulucanlar Caddesi 59, TR-06240 Ankara, Turkey.
C3 Ankara Ulucanlar Eye Training & Research Hospital
RP Omay, E (通讯作者)，Ulucanlar Eye Res Hosp, Ulucanlar Caddesi 59, TR-06240 Ankara, Turkey.
EM aesrakaraagac@gmail.com
CR Abedi G, 2013, SEMIN OPHTHALMOL, V28, P126, DOI 10.3109/08820538.2013.771195
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Cacciamani A, 2013, JPN J OPHTHALMOL, V57, P63, DOI 10.1007/s10384-012-0194-8
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Guler M, 2014, CURR EYE RES, V39, P989, DOI 10.3109/02713683.2014.888452
   Kodjikian L, 2014, GRAEF ARCH CLIN EXP, V252, P1529, DOI 10.1007/s00417-014-2764-6
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Kucukerdonmez C, 2015, EUR J OPHTHALMOL, V25, P51, DOI 10.5301/ejo.5000480
   Lemos-Reis R, 2014, CLIN OPHTHALMOL, V8, P1383, DOI 10.2147/OPTH.S64721
   Morshedi RG, 2014, J GLAUCOMA
   Perez-Rico C, 2010, CORNEA, V29, P849, DOI 10.1097/ICO.0b013e3181ca33d2
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Segal O, 2013, IMAJ, V15, P420
   Shikari H, 2014, SEMIN OPHTHALMOL, V29, P276, DOI 10.3109/08820538.2014.962167
   Simo R, 2014, DIABETES CARE, V37, P893, DOI 10.2337/dc13-2002
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   SooHoo JR, 2014, CURR OPIN OPHTHALMOL, V25, P127, DOI 10.1097/ICU.0000000000000036
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Yeh S, 2015, OPHTHALMOLOGY, V122, P769, DOI 10.1016/j.ophtha.2014.10.013
NR 20
TC 10
Z9 10
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2016
VL 36
IS 5
BP 665
EP 670
DI 10.1007/s10792-016-0171-1
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW4GT
UT WOS:000383601800010
PM 26780098
DA 2022-11-30
ER

PT J
AU Mednick, ZD
   Cao, K
   Braga-Mele, R
AF Mednick, Zale D.
   Cao, Kathy
   Braga-Mele, Rosa
TI A survey for the need of translational aids among Canadian
   ophthalmologists
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID HEALTH LITERACY
AB Objective: To conduct a needs assessment survey of Canadian ophthalmologists to determine whether there is a requirement for translational aids in ophthalmology, and if so, the content, format, and languages to include.
   Design: Anonymous voluntary online needs assessment questionnaire.
   Participants: A total of 139 ophthalmologists completed the online needs assessment questionnaire.
   Methods: An anonymous voluntary online survey in English and French was distributed to 700 active members (practicing Canadian ophthalmologists) of the Canadian Ophthalmological Society. Data were collected regarding the potential utility of translational aids, as well as the contents and languages that should be included if such aids were to be created. Level of support for translational aids, as well as the contents and languages of potential translational aids, was assessed.
   Results: The survey response rate was 19.9% (139/700). The majority of the respondents (130/139, 93.5%) have encountered difficulty in communicating with patients because of language barrier, and 88.5% (123/139) would benefit from having a list of ophthalmologic terms translated into several of Canada's most popular languages. The top 10 languages that the respondents indicated would be most beneficial are (in descending order): Chinese, Hindi, Spanish, Punjabi, Italian, Portuguese, Arabic, Greek, Cree, and Vietnamese. The survey responses provided a comprehensive list of the most useful ophthalmologic symptoms, instructions to patients, and diagnoses to be translated. Most respondents (120/139, 86.3%) believed that having basic information pamphlets on specific ocular conditions translated into several languages would benefit their practice: the top 3 conditions were cataract, glaucoma, and age-related macular degeneration. Producing the translational aids in both paper and electronic format was found to be the most favoured (89/139, 64.0%).
   Conclusions: Canadian ophthalmologists believe they would benefit from translational aids. The results of this survey provide a framework for the creation of such aids.
C1 [Mednick, Zale D.] Queens Univ, Dept Ophthalmol, Toronto, ON M4K 1N2, Canada.
   [Cao, Kathy; Braga-Mele, Rosa] Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada.
   [Cao, Kathy; Braga-Mele, Rosa] Kensington Eye Inst, Toronto, ON, Canada.
C3 Queens University - Canada; University of Toronto
RP Mednick, ZD (通讯作者)，Queens Univ, Dept Ophthalmol, 245 Danforth Ave, Toronto, ON M4K 1N2, Canada.
FU Kensington Eye Institute, Toronto, Ont
FX This work was supported by the Kensington Eye Institute, Toronto, Ont.
   The sponsor or funding organization had no role in the design or conduct
   of this research.
CR Crane J A, 1997, J Emerg Med, V15, P1, DOI 10.1016/S0736-4679(96)00261-2
   Misra-Hebert AD, 2012, CLEV CLIN J MED, V79, P127, DOI 10.3949/ccjm.79a.11006
   Perera KYS, 2012, J HEALTH COMMUN, V17, P141, DOI 10.1080/10810730.2011.585926
   Shaw SJ, 2009, J IMMIGR MINOR HEALT, V11, P460, DOI 10.1007/s10903-008-9135-5
   Shin H. B. R., 2003, LANGUAGE USE ENGLISH
   Statistics Canada, POP LANG SPOK MOST O
   Statistics Canada, POP MOTH TONG AG GRO
   Statistics Canada, DET MOTH TONG 186 KN
   Visscher KL, 2012, CAN J OPHTHALMOL, V47, P72, DOI 10.1016/j.jcjo.2011.12.016
   Yip MP, 2012, CONTEMP NURSE, V40, P160, DOI 10.5172/conu.2012.40.2.160
NR 10
TC 0
Z9 0
U1 0
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2015
VL 50
IS 5
BP 388
EP 392
DI 10.1016/j.jcjo.2015.05.018
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CW0UN
UT WOS:000364705100025
PM 26455976
DA 2022-11-30
ER

PT J
AU Lee, IT
   Liu, SW
   Chi, PL
   Lin, CC
   Hsiao, LD
   Yang, CM
AF Lee, I-Ta
   Liu, Shiau-Wen
   Chi, Pei-Ling
   Lin, Chih-Chung
   Hsiao, Li-Der
   Yang, Chuen-Mao
TI TNF-alpha Mediates PKC delta/JNK1/2/c-Jun-Dependent Monocyte Adhesion
   via ICAM-1 Induction in Human Retinal Pigment Epithelial Cells
SO PLOS ONE
LA English
DT Article
ID SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; SIGNALING PATHWAYS; EXPRESSION;
   INFLAMMATION; MOLECULE-1; ACTIVATION; MOTILITY; DISEASES; STRESS
AB Retinal inflammatory diseases induced by cytokines, such as tumor necrosis factor-alpha (TNF-alpha) are associated with an up-regulation of intercellular adhesion molecule-1 (ICAM-1) in the retinal pigment epithelial cells (RPECs). Retinal pigment epithelium (RPE) is a monolayer of epithelial cells that forms the outer blood-retinal barrier in the posterior segment of the eye, and is also implicated in the pathology of, such as neovascularization in age-related macular degeneration (AMD). However, the detailed mechanisms of TNF-alpha-induced ICAM-1 expression are largely unclear in human RPECs. We demonstrated that in RPECs, TNF-alpha could induce ICAM-1 protein and mRNA expression and promoter activity, and monocyte adhesion. TNF-alpha-mediated responses were attenuated by pretreatment with the inhibitor of PKCs (Ro318220), PKC delta (Rottlerin), MEK1/2 (U0126), JNK1/2 (SP600125), or AP-1 (Tanshinone IIA) and transfection with siRNA of TNFR1, TRAF2, JNK2, p42, or c-Jun. We showed that TNF-alpha could stimulate the TNFR1 and TRAF2 complex formation. TNF-alpha stimulated JNK1/2 was also reduced by Rottlerin or SP600125. However, Rottlerin had no effect on TNF-alpha-induced p42/p44 MAPK phosphorylation. We observed that TNF-alpha induced c-Jun phosphorylation which was inhibited by Rottlerin or SP600125. On the other hand, TNF-alpha-stimulated ICAM-1 promoter activity was prominently lost in RPECs transfected with the point-mutated AP-1 ICAM-1 promoter plasmid. These results suggest that TNF-alpha-induced ICAM-1 expression and monocyte adhesion is mediated through a TNFR1/TRAF2/PKC delta/JNK1/2/c-Jun pathway in RPECs. These findings concerning TNF-alpha induced ICAM-1 expression in RPECs imply that TNF-alpha might play an important role in ocular inflammation and diseases.
C1 [Lee, I-Ta; Liu, Shiau-Wen; Chi, Pei-Ling; Hsiao, Li-Der; Yang, Chuen-Mao] Chang Gung Univ, Coll Med, Dept Physiol & Pharmacol, Taoyuan, Taiwan.
   [Lee, I-Ta; Liu, Shiau-Wen; Chi, Pei-Ling; Hsiao, Li-Der; Yang, Chuen-Mao] Chang Gung Univ, Coll Med, Hlth Ageing Res Ctr, Taoyuan, Taiwan.
   [Lin, Chih-Chung] Chang Gung Univ, Chang Gung Mem Hosp Lin Kou, Dept Anesthet, Taoyuan, Taiwan.
   [Lin, Chih-Chung] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
C3 Chang Gung University; Chang Gung University; Chang Gung Memorial
   Hospital; Chang Gung University; Chang Gung University
RP Yang, CM (通讯作者)，Chang Gung Univ, Coll Med, Dept Physiol & Pharmacol, Taoyuan, Taiwan.
EM chuenmao@mail.cgu.edu.tw
OI Lee, I-Te/0000-0003-2665-3635; Chi, Belinda/0000-0003-0332-6682; Yang,
   Chuen-Mao/0000-0002-3208-5438
FU National Science Council, Taiwan [NSC101-2321-B-182-013,
   NSC101-2320-B-182-039-MY3, NSC101-2314-B-182-182A-112]; Ministry of
   Education, Taiwan [EMRPD1C0261, EMRPD1C0271]; Chang Gung Medical
   Research Foundation, Taiwan [CMRPD1C0102, CMRPD1B0382, CMRPD1C0561,
   CMRPG3B1092, CMRPG3C1301]
FX This work was supported by NSC101-2321-B-182-013,
   NSC101-2320-B-182-039-MY3, and NSC101-2314-B-182-182A-112 from National
   Science Council, Taiwan; EMRPD1C0261 and EMRPD1C0271 from Ministry of
   Education, Taiwan; and CMRPD1C0102, CMRPD1B0382, CMRPD1C0561,
   CMRPG3B1092 and CMRPG3C1301 from Chang Gung Medical Research Foundation,
   Taiwan. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Alam R, 2011, CLIN EXP ALLERGY, V41, P149, DOI 10.1111/j.1365-2222.2010.03658.x
   bdala-Valencia H, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041054, DOI 10.1371/JOURNAL.PONE.0041054]
   Ding RQ, 2011, J CARDIOVASC PHARM T, V16, P160, DOI 10.1177/1074248410382106
   Giansanti V, 2013, J CELL MOL MED, V17, P103, DOI 10.1111/j.1582-4934.2012.01652.x
   Huang XB, 2012, PHARM BIOL, V50, P1111, DOI 10.3109/13880209.2012.658476
   Lan WW, 2012, OCUL SURF, V10, P137, DOI 10.1016/j.jtos.2012.04.001
   Lee CW, 2007, AM J PHYSIOL-LUNG C, V292, pL799, DOI 10.1152/ajplung.00311.2006
   Lee CW, 2011, J CELL PHYSIOL, V226, P2103, DOI 10.1002/jcp.22537
   Lee IT, 2008, J IMMUNOL, V181, P5098, DOI 10.4049/jimmunol.181.7.5098
   Lee IT, 2013, J NUTR BIOCHEM, V24, P124, DOI 10.1016/j.jnutbio.2012.03.009
   Lee IT, 2012, BIOCHEM PHARMACOL, V84, P581, DOI 10.1016/j.bcp.2012.05.005
   Lee IT, 2010, J CELL PHYSIOL, V224, P454, DOI 10.1002/jcp.22142
   Lee IT, 2009, AM J PATHOL, V175, P519, DOI 10.2353/ajpath.2009.090016
   Lin YM, 2013, CANCER LETT, V328, P135, DOI 10.1016/j.canlet.2012.08.029
   Mullins RF, 2006, MOL VIS, V12, P224
   Phalitakul S, 2011, PHARMACOL RES, V64, P493, DOI 10.1016/j.phrs.2011.06.001
   Yang CM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-12
   Yang CM, 2010, J CELL PHYSIOL, V224, P516, DOI 10.1002/jcp.22153
   Yang SF, 2010, J BIOL CHEM, V285, P29808, DOI 10.1074/jbc.M110.108183
   Zhu L, 2009, LUPUS, V18, P116, DOI 10.1177/0961203308094764
NR 20
TC 26
Z9 28
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 12
PY 2015
VL 10
IS 2
AR e0117911
DI 10.1371/journal.pone.0117911
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CB8WX
UT WOS:000349914000037
PM 25675437
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Abu-Yaghi, NE
   Shokry, AN
   Abu-Sbeit, RH
AF Abu-Yaghi, Nakhleh E.
   Shokry, Ahmed N.
   Abu-Sbeit, Rami H.
TI Bilateral same-session intravitreal injections of anti-vascular
   endothelial growth factors
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE anti-vascular endothelial growth factor; diabetic macular edema;
   age-related macular degeneration; endophthalmitis; visual acuity
ID RANIBIZUMAB LUCENTIS; BEVACIZUMAB; ENDOPHTHALMITIS; SAFETY
AB AIM: To document the indications, safety and possible complications of bilateral same-session intravitreal anti-vascular endothelial growth factor (VEGF) injections performed in the ophthalmic operating room.
   METHODS: A retrospective case series study. Consecutive records of seventy four patients receiving simultaneous bilateral intravitreal injections of either ranibizumab or bevacizumab, between September 2010 and September 2013, were reviewed and the outcomes were assessed. Data collected included number of injections, indications for injections, pre -injection and post-injection visual acuity (VA), pre-injection and post-injection intraocular pressure and ocular and systemic complications/complaints after each injection.
   RESULTS: A total of 342 injections were administered to 74 patients, with a mean of 4.62 injections per patient. Seventy -three patients received bevacizumab (Avastin; Genentech Inc., South San Francisco, California, USA) alone, and only one patient received both bevacizumab and ranibizumab (Lucentis; Genentech Inc.) distributed between the injections. Pre - and post -injection VA follow-up measurements were available for 65 patients. Mean follow up period was 22mo. The indications for initiating therapy were choroidal neovascular membrane from age-related macular degeneration (3 patients) and diabetic macular edema (71 patients). The mean Snellen VA before each injection was 6/22. The next post injection follow -up mean Snellen VA was 6/20. One patient had a painful, culture-positive endophthalmitis in one eye 3d after bilateral bevacizumab. Another patient had a painless subconjunctival hemorrhage in one eye. No other ocular or systemic adverse side effects/complaints have been registered in this study group.
   CONCLUSION: Bilateral same -session intravitreal injections using a separate povidone-iodine preparation, speculum, needle, and syringe for each eye are well tolerated. None of the subjects in this study requested to switch to alternating unilateral injections. Proper patient counseling as to the risk of complications with this procedure is necessary.
C1 [Abu-Yaghi, Nakhleh E.; Shokry, Ahmed N.; Abu-Sbeit, Rami H.] Univ Jordan, Fac Med, Dept Ophthalmol, Amman 11118, Jordan.
C3 University of Jordan
RP Abu-Yaghi, NE (通讯作者)，Univ Jordan, Fac Med, Dept Ophthalmol, Queen Rania St POB 7599, Amman 11118, Jordan.
EM nakhlehabuyaghi@yahoo.com
RI Abu-Yaghi, Nakhleh E./N-5922-2015
OI Abu Sbeit, Rami/0000-0003-1609-629X; Abu-Yaghi,
   Nakhleh/0000-0002-6509-4082
CR Abu-Yaghi NE, 2012, MIDDLE EAST AFR J OP, V19, P83, DOI 10.4103/0974-9233.92120
   Bakri SJ, 2009, AM J OPHTHALMOL, V148, P66, DOI 10.1016/j.ajo.2009.02.013
   Davis RP, 2010, CLIN OPHTHALMOL, V4, P703
   Diago T, 2009, RETINA-J RET VIT DIS, V29, P601, DOI 10.1097/IAE.0b013e31819d2591
   Fintak DR, 2008, RETINA-J RET VIT DIS, V28, P1395, DOI 10.1097/IAE.0b013e3181884fd2
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Fung AE, 2009, OPHTHALMOLOGY, V116, P286, DOI 10.1016/j.ophtha.2008.09.014
   Gismondi M, 2009, J GLAUCOMA, V18, P658, DOI 10.1097/IJG.0b013e31819c4893
   Green-Simms AE, 2011, AM J OPHTHALMOL, V151, P329, DOI 10.1016/j.ajo.2010.08.039
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Huang PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082454
   Krispel C, 2013, WORLD J DIABETES, V4, P310, DOI 10.4239/wjd.v4.i6.310
   Lima LH, 2009, RETINA-J RET VIT DIS, V29, P1213, DOI 10.1097/IAE.0b013e3181b32d27
   Mahajan VB, 2011, RETINA-J RET VIT DIS, V31, P31, DOI 10.1097/IAE.0b013e3181ed8c80
   Marticorena J, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/928123
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matsuyama K, 2011, J OCUL PHARMACOL TH, V27, P379, DOI 10.1089/jop.2010.0194
   NUZZI R, 2013, SEMIN OPHTHALMOL
   Pershing S, 2013, OPHTHAL SURG LAS IM, V44, P460, DOI 10.3928/23258160-20130909-07
   Roth DB, 2008, AM J OPHTHALMOL, V146, P346, DOI 10.1016/j.ajo.2008.04.037
   Semoun O, 2009, J FR OPHTALMOL, V32, P58, DOI 10.1016/j.jfo.2008.11.002
   Stewart MW, 2013, CLIN OPHTHALMOL, V7, P1257, DOI 10.2147/OPTH.S36443
   Tan MH, 2014, AM J OPHTHALMOL, V157, P237, DOI 10.1016/j.ajo.2013.08.013
   Wang Donghyun, 2014, Korean J Ophthalmol, V28, P32, DOI 10.3341/kjo.2014.28.1.32
   Woo SJ, 2012, RETINA-J RET VIT DIS, V32, P667, DOI 10.1097/IAE.0b013e31822c296b
NR 25
TC 13
Z9 14
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD DEC 18
PY 2014
VL 7
IS 6
BP 1017
EP 1021
DI 10.3980/j.issn.2222-3959.2014.06.20
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AW9AY
UT WOS:000346551300020
PM 25540758
DA 2022-11-30
ER

PT J
AU Pang, CE
   Freund, KB
AF Pang, Claudine E.
   Freund, K. Bailey
TI Ghost Maculopathy: An Artifact on Near-Infrared Reflectance and Multi
   Color Imaging Masquerading as Chorioretinal Pathology
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; OCULAR FUNDUS
AB PURPOSE: To describe the features of an artifact on near-infrared reflectance and Multi Color imaging, termed "ghost maculopathy," and to illustrate how it may masquerade as true chorioretinal pathology.
   DESIGN: This was a retrospective, observational case series. "
   METHODS: The authors studied 144 eyes of 72 consecutive patients in a vitreoretinal clinical practice, reviewing multimodal imaging including color and red-free fundus photography, fundus autofluorescence (FAF), near-infrared reflectance, Multi Color imaging, and spectral-domain optical coherence tomography (SD OCT).
   RESULTS: In 36 of 144 eyes (25%), there was an appearance of a hyper-reflective spot on near-infrared reflectance and Multi Color imaging, located at the macula, nasal or superonasal to the fovea, which did not correspond to any apparent lesion on color and red-free fundus photography, FAF, or SD OCT. This spot was termed the "ghost image" in this phenomenon of "ghost maculopathy." The ghost image was present consistently on near-infrared reflectance and Multi Color imaging in all 36 eyes at every imaging encounter, showing minimal and subtle variability in its shape and location within each eye; however, it showed large interindividual variability in size, shape, location, and reflectivity between different eyes. Nine eyes were found to have a similar hyperreflective spot resembling that in ghost maculopathy, but corresponding SD OCT images were consistent with diagnoses of choroidal nevus, age-related macular degeneration, and multifocal choroiditis. All eyes with ghost maculopathy were found to be pseudophakic with a posterior chamber intraocular lens.
   CONCLUSION: Ghost maculopathy is the phenomenon of an imaging artifact appearing at the macula on near-infrared reflectance and Multi Color imaging that occurs predominantly in pseudophakic patients and may be mistaken for true chorioretinal pathology. Awareness of this artifact is prudent to avoid misinterpretation of clinical findings and possible unnecessary overinvestigation. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Pang, Claudine E.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Pang, Claudine E.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Sch Med, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; New York University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat
   Hospital, New York; Macula Foundation, Inc, New York, New York
FX BOTH AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF Interest. K. Bailey Freund is a consultant for
   Genentech, Regeneron, Heidelberg Engineering, and Bayer. Claudine E.
   Pang has no proprietary or commercial interest in any of the materials
   discussed in this article. Funding/support: LuEsther T. Mertz Retinal
   Research Center, Manhattan Eye, Ear and Throat Hospital, New York and
   The Macula Foundation, Inc, New York, New York. The funding organization
   had no role in the design or conduct of this research. Author
   contributions: design and conduct of the study (C.E.P., K.B.F.);
   collection (C.E.P., K.B.F.), management, analysis, and interpretation of
   the data (C.E.P., K.B.F.); preparation, review, and approval of the
   manuscript (C.E.P., K.B.F.).
CR DALLOW RL, 1974, ARCH OPHTHALMOL-CHIC, V92, P254
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Gorrand JM, 1999, J OPT SOC AM A, V16, P1229, DOI 10.1364/JOSAA.16.001229
   GORRAND JM, 1984, VISION RES, V24, P1097, DOI 10.1016/0042-6989(84)90088-9
   Murphy R, 2012, RETINAL PHYS, V9, P77
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Theelen T, 2010, ESSENT OPHTHALMOL, P77, DOI 10.1007/978-3-540-85540-8_8
   Theelen T, 2009, GRAEF ARCH CLIN EXP, V247, P1625, DOI 10.1007/s00417-009-1148-9
NR 9
TC 34
Z9 41
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2014
VL 158
IS 1
BP 171
EP 178
DI 10.1016/j.ajo.2014.03.003
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK0IY
UT WOS:000338097300023
PM 24631479
DA 2022-11-30
ER

PT J
AU Lam, M
   Dimaano, ML
   Oyetakin-White, P
   Retuerto, MA
   Chandra, J
   Mukherjee, PK
   Ghannoum, MA
   Cooper, KD
   Baron, ED
AF Lam, Minh
   Dimaano, Matthew L.
   Oyetakin-White, Patricia
   Retuerto, Mauricio A.
   Chandra, Jyotsna
   Mukherjee, Pranab K.
   Ghannoum, Mahmoud A.
   Cooper, Kevin D.
   Baron, Elma D.
TI Silicon Phthalocyanine 4 Phototoxicity in Trichophyton rubrum
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID THERAPY-INDUCED APOPTOSIS; PHOTODYNAMIC THERAPY; TOENAIL ONYCHOMYCOSIS;
   CELLS; SUSCEPTIBILITY; TERBINAFINE; RESISTANCE; PDT; PHARMACOKINETICS;
   INHIBITION
AB Trichophyton rubrum is the leading pathogen that causes long-lasting skin and nail dermatophyte infections. Currently, topical treatment consists of terbinafine for the skin and ciclopirox for the nails, whereas systemic agents, such as oral terbinafine and itraconazole, are also prescribed. These systemic drugs have severe side effects, including liver toxicity. Topical therapies, however, are sometimes ineffective. This led us to investigate alternative treatment options, such as photodynamic therapy (PDT). Although PDT is traditionally recognized as a therapeutic option for treating a wide range of medical conditions, including age-related macular degeneration and malignant cancers, its antimicrobial properties have also received considerable attention. However, the mechanism(s) underlying the susceptibility of dermatophytic fungi to PDT is relatively unknown. As a noninvasive treatment, PDT uses a photosensitizing drug and light, which, in the presence of oxygen, results in cellular destruction. In this study, we investigated the mechanism of cytotoxicity of PDT in vitro using the silicon phthalocyanine (Pc) 4 [SiPc(OSi(CH3)(2)(CH2)(3)N(CH3)(2))(OH)] in T. rubrum. Confocal microscopy revealed that Pc 4 binds to cytoplasmic organelles, and upon irradiation, reactive oxygen species (ROS) are generated. The impairment of fungal metabolic activities as measured by an XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt) assay indicated that 1.0 mu M Pc 4 followed by 670 to 675 nm light at 2.0 J/cm(2) reduced the overall cell survival rate, which was substantiated by a dry weight assay. In addition, we found that this therapeutic approach is effective against terbinafine-sensitive (24602) and terbinafine-resistant (MRL666) strains. These data suggest that Pc 4-PDT may have utility as a treatment for dermatophytosis.
C1 [Lam, Minh; Dimaano, Matthew L.; Oyetakin-White, Patricia; Cooper, Kevin D.; Baron, Elma D.] Case Western Reserve Univ, Dept Dermatol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
   [Lam, Minh; Cooper, Kevin D.; Baron, Elma D.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Case Skin Dis Res Ctr, Cleveland, OH 44106 USA.
   [Retuerto, Mauricio A.; Chandra, Jyotsna; Mukherjee, Pranab K.; Ghannoum, Mahmoud A.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Ctr Med Mycol, Cleveland, OH 44106 USA.
   [Cooper, Kevin D.; Baron, Elma D.] Louis Stokes VA Med Ctr, Cleveland, OH USA.
C3 Case Western Reserve University; Case Western Reserve University
   Hospital; Case Western Reserve University; Case Western Reserve
   University Hospital; Case Western Reserve University; Case Western
   Reserve University Hospital; US Department of Veterans Affairs; Veterans
   Health Administration (VHA); Case Western Reserve University; Louis
   Stokes Cleveland Veterans Affairs Medical Center
RP Baron, ED (通讯作者)，Case Western Reserve Univ, Dept Dermatol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA.
EM elma.baron@case.edu
OI Cooper, Kevin/0000-0002-1986-3602
FU National Institutes of Health via Skin Diseases Research Center (SDRC)
   [5P30AR039750]; Ohio Department of Development, Center for Innovative
   Immunosuppressive Therapeutics [TECH 09-023]; NIDCR [R01DE17846]; Oral
   HIV AIDS Research Alliance (OHARA) [BRS-ACURE-S-11-000049-110229];
   NIAID/NEI [NEI/R21EY021303, NIAID/R21AI074077]; Infectious Diseases Drug
   Development Center (IDDDC, Case); NATIONAL EYE INSTITUTE [R21EY021303]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASES [R21AI074077] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
   [P30AR039750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL
   &CRANIOFACIAL RESEARCH [R43DE017846, R44DE017846] Funding Source: NIH
   RePORTER
FX This study has been supported in part by the National Institutes of
   Health (grant 5P30AR039750) via the Skin Diseases Research Center (SDRC)
   and the Ohio Department of Development, Center for Innovative
   Immunosuppressive Therapeutics (grant TECH 09-023). Funding support was
   also provided by the NIDCR to M. A. G. (R01DE17846), the Oral HIV AIDS
   Research Alliance (OHARA; grant no. BRS-ACURE-S-11-000049-110229),
   NIAID/NEI to P. K. M. (NEI/R21EY021303 and NIAID/R21AI074077), and the
   Infectious Diseases Drug Development Center (IDDDC, Case) to P.K.M.
CR Baltazar LD, 2013, J ANTIMICROB CHEMOTH, V68, P354, DOI 10.1093/jac/dks414
   Baran TM, 2010, LASER SURG MED, V42, P728, DOI 10.1002/lsm.20962
   Bliss JM, 2004, ANTIMICROB AGENTS CH, V48, P2000, DOI 10.1128/AAC.48.6.2000-2006.2004
   Chabrier-Rosello Y, 2010, J PHOTOCH PHOTOBIO B, V99, P117, DOI 10.1016/j.jphotobiol.2010.03.005
   Chandra J, 2008, NAT PROTOC, V3, P1909, DOI 10.1038/nprot.2008.192
   DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961
   De Rosa FS, 2000, PHARM RES-DORDR, V17, P1447, DOI 10.1023/A:1007612905378
   Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931
   Egorin MJ, 1999, CANCER CHEMOTH PHARM, V44, P283, DOI 10.1007/s002800050979
   Elewski BE, 1997, INT J DERMATOL, V36, P754, DOI 10.1046/j.1365-4362.1997.00163.x
   Amorim JCF, 2012, AN BRAS DERMATOL, V87, P250, DOI 10.1590/S0365-05962012000200009
   Ghannoum MA, 2004, J CLIN MICROBIOL, V42, P2977, DOI 10.1128/JCM.42.7.2977-2979.2004
   GOMER GJ, 1988, LASER SURG MED, V8, P450, DOI 10.1002/lsm.1900080503
   Gulcan A, 2011, J AM PODIAT MED ASSN, V101, P49, DOI 10.7547/1010049
   Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a
   He J, 1997, PHOTOCHEM PHOTOBIOL, V65, P581
   Kamp H, 2005, MYCOSES, V48, P101, DOI 10.1111/j.1439-0507.2004.01070.x
   Kumar S, 2009, EXPERT OPIN INV DRUG, V18, P727, DOI [10.1517/13543780902810352, 10.1517/13543780902810352 ]
   Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200
   Lam M, 2011, PHOTOCHEM PHOTOBIOL, V87, P904, DOI 10.1111/j.1751-1097.2011.00938.x
   Leber R, 2003, ANTIMICROB AGENTS CH, V47, P3890, DOI 10.1128/AAC.47.12.3890-3900.2003
   Leyden J, 1998, J AM ACAD DERMATOL, V38, pS42, DOI 10.1016/S0190-9622(98)70483-9
   Lupetti A, 2002, TRENDS MOL MED, V8, P76, DOI 10.1016/S1471-4914(02)02280-3
   Maisch T, 2009, MINI-REV MED CHEM, V9, P974, DOI 10.2174/138955709788681582
   MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x
   MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x
   Monfrecola G, 2004, PHOTOCH PHOTOBIO SCI, V3, P419, DOI 10.1039/b315629j
   Mukherjee PK, 2003, ANTIMICROB AGENTS CH, V47, P82, DOI 10.1128/AAC.47.1.82-86.2003
   Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286
   Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816
   OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x
   Osborne CS, 2006, ANTIMICROB AGENTS CH, V50, P2234, DOI 10.1128/AAC.01600-05
   Piraccini BM, 2008, J AM ACAD DERMATOL, V59, pS75, DOI 10.1016/j.jaad.2008.06.015
   Plaetzer K, 2005, CURR PHARM DESIGN, V11, P1151, DOI 10.2174/1381612053507648
   Plaetzer K, 2009, LASER MED SCI, V24, P259, DOI 10.1007/s10103-008-0539-1
   Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3
   Robertson CA, 2009, J PHOTOCH PHOTOBIO B, V96, P1, DOI 10.1016/j.jphotobiol.2009.04.001
   RYDER NS, 1992, BRIT J DERMATOL, V126, P2, DOI 10.1111/j.1365-2133.1992.tb00001.x
   Smijs TGM, 2004, PHOTOCHEM PHOTOBIOL, V80, P197, DOI 10.1562/2004-04-22-RA-146.1
   Smijs TGM, 2003, PHOTOCHEM PHOTOBIOL, V77, P556, DOI 10.1562/0031-8655(2003)077&lt;0556:PIOTDT&gt;2.0.CO;2
   Smijs TGM, 2007, J ANTIMICROB CHEMOTH, V60, P750, DOI 10.1093/jac/dkm304
   Smijs TGM, 2011, PHOTOCHEM PHOTOBIOL, V87, P2, DOI 10.1111/j.1751-1097.2010.00848.x
   Taguchi H, 1996, INVEST OPHTH VIS SCI, V37, P1444
   Thomas J, 2010, J CLIN PHARM THER, V35, P497, DOI 10.1111/j.1365-2710.2009.01107.x
   Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2
   Varnes ME, 1999, BIOCHEM BIOPH RES CO, V255, P673, DOI 10.1006/bbrc.1999.0261
NR 46
TC 13
Z9 15
U1 1
U2 20
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2014
VL 58
IS 6
BP 3029
EP 3034
DI 10.1128/AAC.01448-13
PG 6
WC Microbiology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microbiology; Pharmacology & Pharmacy
GA AK9VP
UT WOS:000338776900005
PM 24614382
OA Green Published
DA 2022-11-30
ER

PT J
AU Wang, YZ
   He, YG
   Mitzel, G
   Zhang, S
   Bartlett, M
AF Wang, Yi-Zhong
   He, Yu-Guang
   Mitzel, Gina
   Zhang, Song
   Bartlett, Mike
TI Handheld Shape Discrimination Hyperacuity Test on a Mobile Device for
   Remote Monitoring of Visual Function in Maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; diabetic retinopathy; shape
   discrimination; visual acuity; remote vision self-testing
ID DIABETIC-RETINOPATHY; MACULAR DEGENERATION; RANIBIZUMAB; ADAPTATION;
   FREQUENCY; CARE
AB PURPOSE. Frequency monitoring of age-related macular degeneration (AMD) and diabetic retinopathy (DR) is crucial for timely intervention. This study evaluated a handheld shape discrimination hyperacuity (hSDH) test iPhone app designed for visual function self-monitoring in patients with AMD and DR.
   METHODS. One hundred subjects (27 visually normal, 37 with AMD, and 36 with DR) were included based on clinical documentation and visual acuity of 20/100 or better. The hSDH test was implemented on the iOS platform. A cross-sectional study was conducted to compare the hSDH test with a previously established desktop SDH (dSDH) test and to assess the effect of disease severity on the hSDH test. A user survey was also conducted to assess the usability of the hSDH test on the mobile device.
   RESULTS. The hSDH test and dSDH test were highly correlated (r = 0.88, P < 0.0001). Bland-Altman analysis indicated no significant difference in hSDH and dSDH measurements. One-way ANOVA indicated that the mean hSDH measurement of the eyes with advanced AMD (n = 16) or with severe to very severe nonproliferative DR (NPDR) (n = 12) was significantly worse than that of the eyes with intermediate AMD (n = 11) or with mild to moderate NPDR (n = 11) (P < 0.0001). Ninety-eight percent of 46 patients (10 with AMD and 36 with DR) who completed the usability survey reported that the hSDH test was easy to use.
   CONCLUSIONS. This study demonstrated that the hSDH test on a mobile device is comparable to PC-based testing methods. As a mobile app, it is intuitive to use, readily accessible, and sensitive to the severity of maculopathy. It has the potential to provide patients having maculopathy with a new tool to monitor their vision at home.
C1 [Wang, Yi-Zhong; Mitzel, Gina] Retina Fdn SW, Dallas, TX 75231 USA.
   [Wang, Yi-Zhong; He, Yu-Guang] UT Southwestern Med Ctr, Dept Ophthalmol, Dallas, TX USA.
   [Zhang, Song] UT Southwestern Med Ctr, Dept Clin Sci, Dallas, TX USA.
   [Bartlett, Mike] Vital Art & Sci Inc, Richardson, TX USA.
C3 Retina Foundation of the Southwest; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas System; University of Texas Southwestern Medical Center Dallas
RP Wang, YZ (通讯作者)，Retina Fdn SW, 9600 North Cent Expressway,Suite 200, Dallas, TX 75231 USA.
EM yiwang@retinafoundation.org
FU National Institutes of Health National Eye Institute [1R43EY020016-01];
   NATIONAL EYE INSTITUTE [R43EY020016] Funding Source: NIH RePORTER
FX Supported by National Institutes of Health National Eye Institute Grant
   1R43EY020016-01.
CR [Anonymous], 1981, Dev Ophthalmol, V2, P248
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Bittner AK, 2011, OPTOMETRY VISION SCI, V88, P1496, DOI 10.1097/OPX.0b013e3182348d0b
   Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chhetri AP, 2010, P 1 ACM INT HLTH INF, P502, DOI DOI 10.1145/1882992.1883072
   Dais RM, 2006, OPHTHALMOL TIMES, V31, P6
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761
   Germain N, 2011, DIABETES CARE, V34, P580, DOI 10.2337/dc10-1373
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guyer DR, 1999, RETINA VITREOUS MACU
   Hartnett ME, 2005, ARCH OPHTHALMOL-CHIC, V123, P387, DOI 10.1001/archopht.123.3.387
   Hazin R, 2011, CURR OPIN OPHTHALMOL, V22, P174, DOI 10.1097/ICU.0b013e32834595e8
   Hess RF, 1999, VISION RES, V39, P4354, DOI 10.1016/S0042-6989(99)00153-4
   Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Jeffrey BG, 2002, VISION RES, V42, P2773, DOI 10.1016/S0042-6989(02)00332-2
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Loffler G, 2003, VISION RES, V43, P519, DOI 10.1016/S0042-6989(02)00686-7
   LOSADA MA, 1993, VISION RES, V33, P2321, DOI 10.1016/0042-6989(93)90109-A
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   NACHMIAS J, 1981, VISION RES, V21, P215, DOI 10.1016/0042-6989(81)90115-2
   Nagi DK, 2009, DIABETIC MED, V26, P1301, DOI 10.1111/j.1464-5491.2009.02838.x
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Romero-Aroca P, 2010, CLIN OPHTHALMOL, V4, P1481, DOI 10.2147/OPTH.S14521
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SLOANE ME, 1988, J OPT SOC AM A, V5, P2181, DOI 10.1364/JOSAA.5.002181
   SWANSON WH, 1992, PERCEPT PSYCHOPHYS, V51, P409, DOI 10.3758/BF03211637
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vijan S, 2000, JAMA-J AM MED ASSOC, V283, P889, DOI 10.1001/jama.283.7.889
   Wang YZ, 2005, VISION RES, V45, P1375, DOI 10.1016/j.visres.2004.12.003
   Wang YZ, 2000, OSA TRENDS OPT PHOTO, V35, P77
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Wang YZ, 2001, OPTOMETRY VISION SCI, V78, P447, DOI 10.1097/00006324-200106000-00019
   WEIBULL W, 1951, J APPL MECH-T ASME, V18, P293
   Wilkinson F, 1998, VISION RES, V38, P3555, DOI 10.1016/S0042-6989(98)00039-X
   Yogesan K, 2000, J TELEMED TELECARE, V6, P96, DOI 10.1258/1357633001934302
   Zeimer R, 2002, INVEST OPHTH VIS SCI, V43, P1581
NR 44
TC 42
Z9 43
U1 0
U2 20
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2013
VL 54
IS 8
BP 5497
EP 5504
DI 10.1167/iovs.13-12037
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 228EA
UT WOS:000325167200044
PM 23860761
OA Green Published
DA 2022-11-30
ER

PT J
AU Askou, AL
   Pournaras, JAC
   Pihlmann, M
   Svalgaard, JD
   Arsenijevic, Y
   Kostic, C
   Bek, T
   Dagnaes-Hansen, F
   Mikkelsen, JG
   Jensen, TG
   Corydon, TJ
AF Askou, Anne Louise
   Pournaras, Jean-Antoine C.
   Pihlmann, Maria
   Svalgaard, Jesper D.
   Arsenijevic, Yvan
   Kostic, Corinne
   Bek, Toke
   Dagnaes-Hansen, Frederik
   Mikkelsen, Jacob Giehm
   Jensen, Thomas Gryesten
   Corydon, Thomas J.
TI Reduction of choroidal neovascularization in mice by adeno-associated
   virus-delivered anti-vascular endothelial growth factor short hairpin
   RNA
SO JOURNAL OF GENE MEDICINE
LA English
DT Article
DE adeno-associated virus; AMD; angiogenesis; anti-VEGF gene therapy;
   choroidal neovascularization; short hairpin RNA
ID GENE-THERAPY; MOUSE MODEL; OCULAR NEOVASCULARIZATION; TARGETING VEGF;
   CONGENITAL AMAUROSIS; RETINAL FUNCTION; VECTOR; SUPPRESSION; EXPRESSION;
   KNOCKDOWN
AB Background Strategies leading to the long-term suppression of inappropriate ocular angiogenesis are required to avoid the need for repetitive monthly injections for treatment of diseases of the eye, such as age-related macular degeneration (AMD). The present study aimed to develop a strategy for the sustained repression of vascular endothelial growth factor (VEGF), which is identified as the key player in exudative AMD. Methods We have employed short hairpin (sh)RNAs combined with adeno-associated virus (AAV) delivery to obtain the targeted expression of potent gene-regulatory molecules. Anti-VEGF shRNAs were analyzed in human retinal pigment epithelial (RPE) cells using Renilla luciferase screening. For in vivo delivery of the most potent shRNA, self-complementary AAV vectors were packaged in serotype 8 capsids (scAAV2/8-hU6-sh9). In vivo efficacy was evaluated either by injection of scAAV2/8-hU6-sh9 into murine hind limb muscles or in a laser-induced murine model of choroidal neovascularization (CNV) following scAAV2/8-hU6-sh9 subretinal delivery. Results Plasmids encoding anti-VEGF shRNAs showed efficient knockdown of human VEGF in RPEs. Intramuscular administration led to localized expression and 91% knockdown of endogenous murine (m)VEGF. Subsequently, the ability of AAV2/8-encoded shRNAs to impair vessel formation was evaluated in the murine model of CNV. In this model, the sizes of the CNV were significantly reduced (up to 48%) following scAAV2/8-hU6-sh9 subretinal delivery. Conclusions Using anti-VEGF vectors, we have demonstrated efficient silencing of endogenous mVEGF and showed that subretinal administration of scAAV2/8-hU6-sh9 has the ability to impair vessel formation in an AMD animal model. Thus, AAV-encoded shRNA can be used for the inhibition of neovascularization, leading to the development of sustained anti-VEGF therapy. Copyright (c) 2012 John Wiley & Sons, Ltd.
C1 [Askou, Anne Louise; Pihlmann, Maria; Svalgaard, Jesper D.; Dagnaes-Hansen, Frederik; Mikkelsen, Jacob Giehm; Jensen, Thomas Gryesten; Corydon, Thomas J.] Aarhus Univ, Dept Biomed, DK-8000 Aarhus C, Denmark.
   [Pournaras, Jean-Antoine C.] Univ Lausanne, Jules Gonin Eye Hosp, Vitreoretinal Surg Unit, Lausanne, Switzerland.
   [Arsenijevic, Yvan; Kostic, Corinne] Univ Lausanne, Jules Gonin Eye Hosp, Unit Gene Therapy & Stem Cell Biol, Lausanne, Switzerland.
   [Bek, Toke] Aarhus Univ Hosp, Dept Ophthalmol, DK-8000 Aarhus, Denmark.
C3 Aarhus University; University of Lausanne; University of Lausanne;
   Aarhus University
RP Corydon, TJ (通讯作者)，Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 4, DK-8000 Aarhus C, Denmark.
EM tjc@hum-gen.au.dk
RI Askou, Anne/AGW-2995-2022; Core, Vector/CAF-4832-2022
OI Mikkelsen, Jacob Giehm/0000-0002-1322-3209; Pihlmann Kristensen,
   Maria/0000-0003-3270-9607; Askou, Anne Louise/0000-0002-5512-1796; Bek,
   Toke/0000-0002-0409-2534; Dagnaes-Hansen, Frederik/0000-0002-6622-0853;
   Kostic, Corinne/0000-0003-1006-9733; Arsenijevic,
   Yvan/0000-0001-6960-1291; Corydon, Thomas Juhl/0000-0003-3588-6350
FU Lundbeck Foundation [R44-A4289]; Danish Eye Foundation AP; Moller og
   Hustru Chastine Mc-Kinney Mollers Fond til almene Formaal; Aase og Ejnar
   Danielsens Fond; Civilingenior Lars Andersens Fond; Provisu Foundation
FX We thank Tina F. Hindkjaer (Department of Biomedicine), Christian
   Knudsen (Department of Biomedicine), Meriem Tekaya (Unit of Gene Therapy
   and Stem Cell Biology) and Verene Pignat (Unit of Gene Therapy and Stem
   Cell Biology) for their excellent technical assistance. This work was
   supported by The Lundbeck Foundation (Grant No. R44-A4289), The Danish
   Eye Foundation AP. Moller og Hustru Chastine Mc-Kinney Mollers Fond til
   almene Formaal, Aase og Ejnar Danielsens Fond, Civilingenior Lars
   Andersens Fond, and the Provisu Foundation. The authors declare that
   there are no conflicts of interest.
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Allocca M, 2007, J VIROL, V81, P11372, DOI 10.1128/JVI.01327-07
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bemelmans AP, 2006, PLOS MED, V3, P1892, DOI 10.1371/journal.pmed.0030347
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Chadderton N, 2009, MOL THER, V17, P593, DOI 10.1038/mt.2008.301
   Clark ML, 2008, ANIMAL MODELS CHOROI
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Dinculescu A, 2005, HUM GENE THER, V16, P649, DOI 10.1089/hum.2005.16.649
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jakobsen M, 2009, MOL THER, V17, P1743, DOI 10.1038/mt.2009.141
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kostic C, 2003, GENE THER, V10, P818, DOI 10.1038/sj.gt.3301948
   Kostic C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016588
   Lai CM, 2009, INVEST OPHTH VIS SCI, V50, P4279, DOI 10.1167/iovs.08-3253
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   MacLachlan TK, 2011, MOL THER, V19, P326, DOI 10.1038/mt.2010.258
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Mao YX, 2011, HUM GENE THER, V22, P1525, DOI 10.1089/hum.2011.090
   Min SH, 2005, MOL THER, V12, P644, DOI 10.1016/j.ymthe.2005.06.002
   Mussolino C, 2011, GENE THER, V18, P637, DOI 10.1038/gt.2011.3
   Natkunarajah M, 2008, GENE THER, V15, P463, DOI 10.1038/sj.gt.3303074
   Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D
   Paskowitz DM, 2007, HUM GENE THER, V18, P871, DOI 10.1089/hum.2007.065
   Pihlmann M, 2012, J GENE MED, V14, P328, DOI 10.1002/jgm.2623
   Reich S, 2003, MOL VIS, V9, P210
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Singerman L, 2009, RETINA-J RET VIT DIS, V29, pS49, DOI 10.1097/IAE.0b013e3181ad2341
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stieger K, 2008, MOL THER, V16, P916, DOI 10.1038/mt.2008.41
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tschernutter M, 2005, GENE THER, V12, P694, DOI 10.1038/sj.gt.3302460
   Vandenberghe LH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002103
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Xiao X, 1998, J VIROL, V72, P2224, DOI 10.1128/JVI.72.3.2224-2232.1998
   Yokoi K, 2007, INVEST OPHTH VIS SCI, V48, P3324, DOI 10.1167/iovs.06-1306
   Yuan MK, 2010, MOL VIS, V16, P1743
NR 47
TC 40
Z9 43
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1099-498X
EI 1521-2254
J9 J GENE MED
JI J. Gene. Med.
PD NOV
PY 2012
VL 14
IS 11
BP 632
EP 641
DI 10.1002/jgm.2678
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 041OI
UT WOS:000311410700003
PM 23080553
DA 2022-11-30
ER

PT J
AU Tsuruma, K
   Shimazaki, H
   Ohno, Y
   Inoue, Y
   Honda, A
   Imai, S
   Lee, J
   Shimazawa, M
   Satoh, M
   Hara, H
AF Tsuruma, Kazuhiro
   Shimazaki, Hiroki
   Ohno, Yuta
   Inoue, Yuki
   Honda, Akiko
   Imai, Shunsuke
   Lee, Jinyong
   Shimazawa, Masamitsu
   Satoh, Masahiko
   Hara, Hideaki
TI Metallothionein-III Deficiency Exacerbates Light-Induced Retinal
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; OXYGEN FREE-RADICALS; OXIDATIVE STRESS;
   MACULAR DEGENERATION; KAPPA-B; DAMAGE; EXPRESSION; MICE; APOPTOSIS; GENE
AB PURPOSE. Retinal photoreceptor damage is a common feature of ophthalmic disorders, such as age-related macular degeneration and retinitis pigmentosa. Oxidative stress has a key role in these diseases. Metallothioneins (MTs) are a family of cysteine-rich proteins, and various physiologic functions have been reported, including protection against metal toxicity and antioxidative potency. We investigated the functional role of MT-III in light-induced retinal damage.
   METHODS. The expression of retinal MT-I, -II, and -III mRNA was evaluated by real-time reverse-transcription PCR in retina exposed to light. Retinal damage in MT-deficient mice was induced by exposure to white light at 16,000 lux for 3 hours after dark adaptation. Photoreceptor damage was evaluated histologically by measuring the thickness of the outer nuclear layer (ONL) 5 days after light exposure and by electroretinogram recording. In an in vitro experiment, the MT-III siRNAs were tested for their effects on light-induced mouse photoreceptor cell (661W) damage.
   RESULTS. The mRNAs of the MTs were increased significantly in murine retina after light exposure. The ONL in the MT-III-deficient mice was remarkably thinner compared to light-exposed wild-type (WT) mice, and a- and b-wave amplitudes were decreased; the damage induced in MT-I/-II-deficient mice was comparable to that observed in WT mice. MT-III knockdown by siRNA in 661W exacerbated the cell damage and increased the production of reactive oxygen species in response to light exposure.
   CONCLUSIONS. These findings suggested that MT-III can help protect against light-induced retinal damage compared to MT-I/II. Some of these effects may be exerted by its antioxidative potency. (Invest Ophthalmol Vis Sci. 2012;53:7896-7903) DOI:10.1167/iovs.12-10165
C1 [Tsuruma, Kazuhiro; Shimazaki, Hiroki; Ohno, Yuta; Inoue, Yuki; Imai, Shunsuke; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Gifu 5011196, Japan.
   [Honda, Akiko; Lee, Jinyong; Satoh, Masahiko] Aichi Gakuin Univ, Sch Pharm, Lab Pharmaceut Hlth Sci, Nisshin, Aichi, Japan.
C3 Gifu Pharmaceutical University; Aichi Gakuin University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu-pu.ac.jp
RI Ohno, Yuta/AIE-4047-2022
OI Ohno, Yuta/0000-0002-8182-3150; Honda, Akiko/0000-0002-7358-4372
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BLANKS JC, 1992, INVEST OPHTH VIS SCI, V33, P2814
   Chen L, 2004, EXP EYE RES, V79, P287, DOI 10.1016/j.exer.2004.05.004
   Chen WH, 1999, INVEST OPHTH VIS SCI, V40, P744
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421
   Dong A, 2006, J CELL PHYSIOL, V208, P516, DOI 10.1002/jcp.20683
   El Ghazi I., 2010, INT J ALZHEIMERS DIS, DOI DOI 10.4061/2011/20863421234102
   Erickson JC, 1997, J NEUROSCI, V17, P1271
   Glickman RD, 2002, INT J TOXICOL, V21, P473, DOI 10.1080/10915810290169909
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   HIDALGO J, 1989, REV ESP FISIOL, V45, P255
   Hozumi I, 2008, NEUROSCI LETT, V438, P54, DOI 10.1016/j.neulet.2008.04.047
   KAEGI JH, 1961, J BIOL CHEM, V236, P2435
   KLAASSEN CD, 1989, BIOL TRACE ELEM RES, V21, P119, DOI 10.1007/BF02917244
   Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734
   LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727
   Lu HS, 2002, EXP EYE RES, V74, P83, DOI 10.1006/exer.2001.1101
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584
   Matsunaga N, 2009, MOL NUTR FOOD RES, V53, P869, DOI 10.1002/mnfr.200800394
   Mittag TW, 1999, EXP EYE RES, V69, P677, DOI 10.1006/exer.1999.0748
   MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659
   Nachman-Clewner M, 2008, INVEST OPHTH VIS SCI, V49, P3207, DOI 10.1167/iovs.07-1039
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   NISHIMURA H, 1991, HISTOCHEMISTRY, V95, P535, DOI 10.1007/BF00266738
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580
   Organisciak DT, 1999, PHOTOCHEM PHOTOBIOL, V70, P261, DOI 10.1111/j.1751-1097.1999.tb07998.x
   PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333
   Samson SLA, 1998, PROG NUCLEIC ACID RE, V59, P257, DOI 10.1016/S0079-6603(08)61034-X
   SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T
   SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x
   SHAHINFAR S, 1991, CURR EYE RES, V10, P47, DOI 10.3109/02713689109007610
   Suemori S, 2006, INVEST OPHTH VIS SCI, V47, P3975, DOI 10.1167/iovs.06-0275
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Tate DJ, 2002, CURR EYE RES, V24, P12, DOI 10.1076/ceyr.24.1.12.5426
   THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6
   Tsuruma K, 2012, INVEST OPHTH VIS SCI, V53, P6729, DOI 10.1167/iovs.11-9378
   Vasak M, 2005, J TRACE ELEM MED BIO, V19, P13, DOI 10.1016/j.jtemb.2005.03.003
   Wells PG, 2009, TOXICOL SCI, V108, P4, DOI 10.1093/toxsci/kfn263
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Winkler BS, 1999, MOL VIS, V5
   Wunderlich KA, 2010, INVEST OPHTH VIS SCI, V51, P4809, DOI 10.1167/iovs.09-5073
   Yamamoto M, 1999, HISTOCHEM J, V31, P81, DOI 10.1023/A:1003510719302
   You HJ, 2002, BBA-GEN SUBJECTS, V1573, P33, DOI 10.1016/S0304-4165(02)00325-2
NR 46
TC 14
Z9 14
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2012
VL 53
IS 12
BP 7896
EP 7903
DI 10.1167/iovs.12-10165
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064EE
UT WOS:000313053500065
PM 23132798
DA 2022-11-30
ER

PT J
AU Jones, BW
   Kondo, M
   Terasaki, H
   Lin, Y
   McCall, M
   Marc, RE
AF Jones, B. W.
   Kondo, M.
   Terasaki, H.
   Lin, Y.
   McCall, M.
   Marc, R. E.
TI Retinal remodeling
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Retinal remodeling; Retina; Retinal degeneration; Retinitis pigmentosa;
   Macular degeneration
ID RECESSIVE RETINITIS-PIGMENTOSA; GTPASE ACCELERATING PROTEIN;
   GANGLION-CELLS; TRANSGENIC RAT; MOUSE MODEL; PHOTORECEPTOR DEGENERATION;
   ROD PHOSPHODIESTERASE; MACULAR DEGENERATION; CONE PHOTORECEPTORS;
   NEURITE OUTGROWTH
AB Retinal photoreceptor degeneration takes many forms. Mutations in rhodopsin genes or disorders of the retinal pigment epithelium, defects in the adenosine triphosphate binding cassette transporter, ABCR gene defects, receptor tyrosine kinase defects, ciliopathies and transport defects, defects in both transducin and arrestin, defects in rod cyclic guanosine 3',5'-monophosphate phosphodiesterase, peripherin defects, defects in metabotropic glutamate receptors, synthetic enzymatic defects, defects in genes associated with signaling, and many more can all result in retinal degenerative disease like retinitis pigmentosa (RP) or RP-like disorders. Age-related macular degeneration (AMD) and AMD-like disorders are possibly due to a constellation of potential gene targets and gene/gene interactions, while other defects result in diabetic retinopathy or glaucoma. However, all of these insults as well as traumatic insults to the retina result in retinal remodeling. Retinal remodeling is a universal finding subsequent to retinal degenerative disease that results in deafferentation of the neural retina from photoreceptor input as downstream neuronal elements respond to loss of input with negative plasticity. This negative plasticity is not passive in the face of photoreceptor degeneration, with a phased revision of retinal structure and function found at the molecular, synaptic, cell, and tissue levels involving all cell classes in the retina, including neurons and glia. Retinal remodeling has direct implications for the rescue of vision loss through bionic or biological approaches, as circuit revision in the retina corrupts any potential surrogate photoreceptor input to a remnant neural retina. However, there are a number of potential opportunities for intervention that are revealed through the study of retinal remodeling, including therapies that are designed to slow down photoreceptor loss, interventions that are designed to limit or arrest remodeling events, and optogenetic approaches that target appropriate classes of neurons in the remnant neural retina.
C1 [Jones, B. W.; Lin, Y.; Marc, R. E.] Univ Utah, Dept Ophthalmol, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
   [Kondo, M.; Terasaki, H.] Nagoya Univ, Dept Ophthalmol, Grad Sch Med, Nagoya, Aichi 4648601, Japan.
   [McCall, M.] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
C3 Utah System of Higher Education; University of Utah; Nagoya University;
   University of Louisville
RP Jones, BW (通讯作者)，Univ Utah, Dept Ophthalmol, Moran Eye Ctr, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM bryan.jones@m.cc.utah.edu
RI Terasaki, Hiroko/M-5054-2014
OI Jones, Bryan/0000-0001-5527-6643; McCall, Maureen/0000-0002-9781-315X
FU NIH [EY015128, EY02576]; Research to Prevent Blindness [EYO14800];
   Edward N. and Della L. Thome Memorial Foundation; Moran Eye Center Tiger
   Team Translational Medicine Award; Ministry of Health, Labor and
   Welfare, Japan [H16-sensory-001]; Grants-in-Aid for Scientific Research
   [23592603] Funding Source: KAKEN; NATIONAL CENTER FOR RESEARCH RESOURCES
   [P41RR000592] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [P30EY014800, R01EY015128, R01EY002576] Funding Source: NIH RePORTER
FX We would like to thank Carl B. Watt for his work in electron microscopy,
   imaging, and manuscript review. William Drew Ferrell was invaluable in
   data preparation and in reviewing the manuscript. Kevin Rapp assisted
   with confocal microscopy, which resulted in figure construction. Maggie
   Shaw and Jia-Hui Yang assisted with data acquisition, tissue
   preparation, immunocytochemistry, and ultramicrotomy. James R. Anderson
   assisted in ultrastructural data assembly. Monica Vetter and Alejandra
   Bosco helped provide the DBA/2J mouse tissues, provided guidance, and
   helped to review the manuscript. Support: NIH EY015128 (RM), NIH EY02576
   (RM), EYO14800 Vision Core, an unrestricted grant from Research to
   Prevent Blindness to the Moran Eye Center; Edward N. and Della L. Thome
   Memorial Foundation grant for Age-Related Macular Degeneration Research
   (BWJ), a Research to Prevent Blindness Career Development Award (BWJ),
   Moran Eye Center Tiger Team Translational Medicine Award (BWJ), Sciences
   Research Grant H16-sensory-001 from the Ministry of Health, Labor and
   Welfare, Japan (MK).
CR Aguirre G D, 1998, Mol Vis, V4, P23
   Aleman TS, 2007, INVEST OPHTH VIS SCI, V48, P4759, DOI 10.1167/iovs.07-0453
   Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anderson JR, 2011, MOL VIS, V17
   Anderson JR, 2009, PLOS BIOL, V7, P493, DOI 10.1371/journal.pbio.1000074
   Baehr W, 2009, VISION RES, V49, P2636, DOI 10.1016/j.visres.2009.04.008
   Baloyannis SJ, 2009, J NEUROL SCI, V283, P153, DOI 10.1016/j.jns.2009.02.370
   Beltran WA, 2006, INVEST OPHTH VIS SCI, V47, P1669, DOI 10.1167/iovs.05-0845
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Bull ND, 2008, INVEST OPHTH VIS SCI, V49, P3449, DOI 10.1167/iovs.08-1770
   Busskamp V, 2010, SCIENCE, V329, P413, DOI 10.1126/science.1190897
   Bywood PT, 2000, EXP NEUROL, V161, P306, DOI 10.1006/exnr.1999.7259
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Canola K, 2007, INVEST OPHTH VIS SCI, V48, P446, DOI 10.1167/iovs.06-0190
   CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489
   CHANG CJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P880, DOI 10.1001/archopht.1995.01100070054025
   Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Choi SS, 2011, BRIT J OPHTHALMOL, V95, P131, DOI 10.1136/bjo.2010.183756
   Chua J, 2009, J COMP NEUROL, V514, P473, DOI 10.1002/cne.22029
   Clagett-Dame M, 2006, J NEUROBIOL, V66, P739, DOI 10.1002/neu.20241
   Clarke G, 2000, NAT GENET, V25, P67, DOI 10.1038/75621
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   Cuenca N, 2004, NEUROSCIENCE, V127, P301, DOI 10.1016/j.neuroscience.2004.04.042
   Cuenca N, 2005, EUR J NEUROSCI, V22, P1057, DOI 10.1111/j.1460-9568.2005.04300.x
   Cuenca N, 2010, EXP EYE RES, V91, P273, DOI 10.1016/j.exer.2010.05.020
   Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   deRaad S, 1996, OPHTHALMIC RES, V28, P99, DOI 10.1159/000267881
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Doroudchi MM, 2011, MOL THER, V19, P1220, DOI 10.1038/mt.2011.69
   Dryja TP, 2005, P NATL ACAD SCI USA, V102, P4884, DOI 10.1073/pnas.0501233102
   DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280
   Duncan JL, 2003, ADV EXP MED BIOL, V533, P165
   Duncan T, 2006, PHOTOCHEM PHOTOBIOL, V82, P741, DOI 10.1562/2005-10-05-RA-712
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   Feigenspan A, 1998, J NEUROSCI, V18, P6776
   Firth SI, 2006, VISUAL NEUROSCI, V23, P807, DOI 10.1017/S095252380623013X
   Fletcher EL, 1996, J COMP NEUROL, V376, P343
   Frederick JM, 2001, INVEST OPHTH VIS SCI, V42, P826
   Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hu G, 2003, J BIOL CHEM, V278, P14550, DOI 10.1074/jbc.M212046200
   Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799
   HUANG SH, 1995, NAT GENET, V11, P468, DOI 10.1038/ng1295-468
   Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216
   Iandiev I, 2006, INVEST OPHTH VIS SCI, V47, P2161, DOI 10.1167/iovs.05-0595
   Ivanova E, 2009, MOL VIS, V15, P1680
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jiang L, 2011, INVEST OPHTH VIS SCI, V51, P4488
   Jones Bryan W, 2005, Clin Exp Optom, V88, P282
   Jones BW, 2011, J COMP NEUROL, V519, P2713, DOI 10.1002/cne.22703
   Jones BW, 2006, ADV EXP MED BIOL, V572, P405
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Jones BW, 2003, J COMP NEUROL, V464, P1, DOI 10.1002/cne.10703
   Jones BW, 2004, INVEST OPHTHALMOL VI, V45, pE
   KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308
   Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174
   KOLB H, 1974, INVEST OPHTH VISUAL, V13, P487
   KOLB H, 1991, J COMP NEUROL, V310, P267, DOI 10.1002/cne.903100210
   Kondo M, 2009, INVEST OPHTH VIS SCI, V50, P1371, DOI 10.1167/iovs.08-2863
   Kremer H, 2006, HUM MOL GENET, V15, pR262, DOI 10.1093/hmg/ddl205
   Lagali PS, 2008, NAT NEUROSCI, V11, P667, DOI 10.1038/nn.2117
   Lewis GP, 1998, INVEST OPHTH VIS SCI, V39, P424
   Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7
   LI ZY, 1995, J NEUROSCI, V15, P5429
   LI ZY, 1995, OPHTHALMOLOGY, V102, P805, DOI 10.1016/S0161-6420(95)30953-0
   Lin Y, 2011, FASEB J, V81-92
   Lin Y, 2011, ARVO M, V52, P1846
   Lin Y, 2010, ARVO M, V51
   Linberg KA, 2006, MOL VIS, V12, P1674
   Machida S, 2000, INVEST OPHTH VIS SCI, V41, P3200
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Marc R, 2009, ENCY EYE
   Marc RE, 2003, MOL NEUROBIOL, V28, P139, DOI 10.1385/MN:28:2:139
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Marc RE, 2002, J NEUROSCI, V22, P413, DOI 10.1523/JNEUROSCI.22-02-00413.2002
   Marc RE, 2000, J COMP NEUROL, V425, P560, DOI 10.1002/1096-9861(20001002)425:4<560::AID-CNE7>3.0.CO;2-D
   Marc Robert E., 2006, P33, DOI 10.1007/0-387-28190-8_3
   Marc RE, 2008, MOL VIS, V14, P782
   Marc RE, 2007, INVEST OPHTH VIS SCI, V48, P3364, DOI 10.1167/iovs.07-0032
   Margolis DJ, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/507037
   MCLAUGHLIN ME, 1995, P NATL ACAD SCI USA, V92, P3249, DOI 10.1073/pnas.92.8.3249
   MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088
   Park SJ, 2001, CELL TISSUE RES, V306, P341, DOI 10.1007/s004410100453
   Peng YW, 2000, NAT NEUROSCI, V3, P1121, DOI 10.1038/80639
   Phipps JA, 2006, INVEST OPHTH VIS SCI, V47, P3187, DOI 10.1167/iovs.05-1493
   Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x
   Pu ML, 2006, INVEST OPHTH VIS SCI, V47, P3579, DOI 10.1167/iovs.05-1450
   Ray A, 2010, CELL TISSUE RES, V339, P481, DOI 10.1007/s00441-009-0916-5
   Ross JW, 2012, INVEST OPHTH VIS SCI, V53, P501, DOI 10.1167/iovs.11-8784
   Seiler MJ, 2010, EUR J NEUROSCI, V31, P508, DOI 10.1111/j.1460-9568.2010.07085.x
   Sekirnjak C, 2009, J NEUROPHYSIOL, V102, P3260, DOI 10.1152/jn.00663.2009
   Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922
   Sommer ME, 2006, VISION RES, V46, P4532, DOI 10.1016/j.visres.2006.08.031
   Sommer ME, 2006, J BIOL CHEM, V281, P9407, DOI 10.1074/jbc.M510037200
   Specht D, 2007, EUR J NEUROSCI, V26, P2506, DOI 10.1111/j.1460-9568.2007.05886.x
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stasheff SF, 2008, J NEUROPHYSIOL, V99, P1408, DOI 10.1152/jn.00144.2007
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Strettoi E, 2000, P NATL ACAD SCI USA, V97, P11020, DOI 10.1073/pnas.190291097
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   Strettoi E, 2003, VISION RES, V43, P867, DOI 10.1016/S0042-6989(02)00594-1
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730
   Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8
   VanLeeuwen JE, 2010, J NEUROSCI RES, V88, P650, DOI 10.1002/jnr.22216
   Varela C, 2003, VISION RES, V43, P879, DOI 10.1016/S0042-6989(02)00493-5
   Vasireddy V, 2007, HUM MOL GENET, V16, P471, DOI 10.1093/hmg/ddl480
   VOIGT T, 1987, J NEUROSCI, V7, P4115
   Wensel TG, 2008, VISION RES, V48, P2052, DOI 10.1016/j.visres.2008.03.010
   WONG ROL, 1991, J NEUROBIOL, V22, P685, DOI 10.1002/neu.480220704
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yefimova MG, 2010, NEUROBIOL DIS, V40, P311, DOI 10.1016/j.nbd.2010.06.005
   Yen HJ, 2006, HUM MOL GENET, V15, P667, DOI 10.1093/hmg/ddi468
   Zeitz C, 2005, INVEST OPHTH VIS SCI, V46, P4328, DOI 10.1167/iovs.05-0526
   Zeitz C, 2008, INVEST OPHTH VIS SCI, V49, P4105, DOI 10.1167/iovs.08-1717
   Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817
NR 127
TC 121
Z9 125
U1 0
U2 49
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2012
VL 56
IS 4
BP 289
EP 306
DI 10.1007/s10384-012-0147-2
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 974JT
UT WOS:000306431700001
PM 22644448
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Shastry, BS
AF Shastry, Barkur S.
TI Pharmacogenomics in Ophthalmology
SO DISCOVERY MEDICINE
LA English
DT Article
ID COMPLEMENT FACTOR-H; ADVERSE DRUG-REACTIONS; OPEN-ANGLE GLAUCOMA;
   MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; PERSONALIZED MEDICINE; GENE
   POLYMORPHISM; GLUCOCORTICOID-RECEPTOR; LOC387715 GENOTYPES; PREDICTIVE
   ROLE
AB Inter-individual variation in drug response and adverse drug reactions (ADRs) are well known in medicine. This individual variation in drug response could be at least, in part, due to genetic diversity among individuals. Although substantial studies that connect genetic variants to inter-individual variation in drug response have been documented in several diseases such as cancer and heart diseases, such studies are slowly progressing in ophthalmology. In recent years, advancement in technologies has led to the identification of genes associated with several eye disorders. At the same time, some small-scale studies have demonstrated the association of various genotypes or haplotypes with response to drug therapies. However, its integration into clinical practice in ophthalmology is not possible at present. This is because there are many challenging questions that remain to be addressed. For instance, in the case of complex disorders a single gene study is not enough. Multiple genes, environmental factors, multiple single nucleotide polymorphisms (SNPs), and rare or low frequency variants may contribute to the disease and they must be considered. The functional aspects of many genetic variants are not known. This raises questions of their biological importance and their clinical usefulness. In addition, there are legal, ethical, and social issues that need to be regulated. Moreover, physicians and patients must be educated about the limitation and sensitivity of genetic testing. At present pharmacogenetic studies in ophthalmology are still in their infancy and do not suggest that a pharmacogenetic basis of drug development in ophthalmology is a concept that can yield immediate results, but can become a reality in the future. In this article an attempt has been made to summarize some of the recent small-scale pharmacogenetic studies on two major eye disorders, age-related macular degeneration (AMD) and glaucoma. [Discovery Medicine 12(63):159-167, August 2011]
C1 Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.
C3 Oakland University
RP Shastry, BS (通讯作者)，Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.
EM shastry@oakland.edu
CR Badcott David, 2006, Med Health Care Philos, V9, P307, DOI 10.1007/s11019-006-9008-4
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2009, CLIN EXP OPHTHALMOL, V37, P814, DOI 10.1111/j.1442-9071.2009.02136.x
   Bhutto IA, 2011, BR J OPHTHA IN PRESS
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown D.M., 2009, OPHTHALMOLOGY, V116, pe5
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carlquist JF, 2011, DISCOV MED, V11, P469
   Chowers I, 2008, MOL VIS, V14, P2263
   Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Doney ASF, 2009, DIABETIC MED, V26, P460, DOI 10.1111/j.1464-5491.2009.02719.x
   Evans WE, 2001, ANNU REV GENOM HUM G, V2, P9, DOI 10.1146/annurev.genom.2.1.9
   Feng X, 2009, OPHTHALMOLOGY, V116, pe1
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Frueh FW, 2004, PHARMACOGENOMICS, V5, P571, DOI 10.1517/14622416.5.5.571
   Gerzenstein SM, 2008, OPHTHALMIC GENET, V29, P166, DOI 10.1080/13816810802320217
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Khandhadia S, 2011, EYE, V25, P921, DOI 10.1038/eye.2011.91
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Koenekoop RK, 2007, CLIN EXP OPHTHALMOL, V35, P473, DOI 10.1111/j.1442-9071.2007.01534.x
   Kuehn BM, 2008, JAMA-J AM MED ASSOC, V300, P2715, DOI 10.1001/jama.2008.823
   Lai TYY, 2010, PERS MED, V7, P371, DOI [10.2217/pme.10.25, 10.2217/PME.10.25]
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   Li JP, 2008, DRUG SAFETY, V31, P127, DOI 10.2165/00002018-200831020-00003
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Macdonald Ian M, 2009, Open Ophthalmol J, V3, P46, DOI 10.2174/1874364100903020046
   Maeda M, 2006, CURR DIABETES REV, V2, P467, DOI 10.2174/1573399810602040467
   MARMION VJ, 1971, P ROY SOC MED, V64, P628, DOI 10.1177/003591577106400614
   McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344
   McCarty CA, 2004, CLIN EXP OPHTHALMOL, V32, P236, DOI 10.1111/j.1442-9071.2004.00833.x
   McCarty CA, 2008, ARCH OPHTHALMOL-CHIC, V126, P959, DOI 10.1001/archopht.126.7.959
   McKibbin M, 2011, BR J OPHTHA IN PRESS
   McLaren NC, 2003, PHARMACOGENOMICS J, V3, P197, DOI 10.1038/sj.tpj.6500181
   McLeod HL, 2001, ANNU REV PHARMACOL, V41, P101, DOI 10.1146/annurev.pharmtox.41.1.101
   Mezer E, 2009, CURR OPIN OPHTHALMOL, V20, P382, DOI 10.1097/ICU.0b013e32832f7feb
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Moroi SE, 2008, OPHTHALMOLOGY, V115, P925, DOI 10.1016/j.ophtha.2008.04.020
   Nakata I, 2011, OPHTHALMOLOGY, V118, P1408, DOI 10.1016/j.ophtha.2010.12.011
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani F, 2011, CURR DRUG TARGETS, V12, P138, DOI 10.2174/138945011794182773
   Parmeggiani Francesco, 2009, Recent Pat DNA Gene Seq, V3, P114
   Parmeggiani F, 2010, OPHTHALMOLOGY, V117, P517, DOI 10.1016/j.ophtha.2009.08.028
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Penha FM, 2011, EXPERT OPIN DRUG MET, V7, P1021, DOI 10.1517/17425255.2011.585970
   Razeghinejad MR, 2011, EYE, V25, P971, DOI 10.1038/eye.2011.128
   Razeghinejad MR, 2011, AM J MED, V124, P20, DOI 10.1016/j.amjmed.2010.08.011
   Richa S, 2010, CNS DRUGS, V24, P501, DOI 10.2165/11533180-000000000-00000
   Richmond TD, 2008, BIOTECHNOL ANN REV, V14, P411, DOI 10.1016/S1387-2656(08)00015-X
   Romero-Aroca P, 2009, EYE VIS RES DEV, P191
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Santaella RM, 2007, DRUGS, V67, P75, DOI 10.2165/00003495-200767010-00006
   Schork NJ, 2010, J BIOPHARM STAT, V20, P315, DOI 10.1080/10543400903572779
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Semeraro F, 2011, CURR VASC PHARMACOL, V9, P629, DOI 10.2174/157016111796642670
   Shastry BS, 2007, J HUM GENET, V52, P871, DOI 10.1007/s10038-007-0200-z
   Shastry B, 2010, GRAEF ARCH CLIN EXP, V248, P1057, DOI 10.1007/s00417-010-1333-x
   Shastry BS, 2004, DRUG DEVELOP RES, V62, P143, DOI 10.1002/ddr.10377
   Shastry BS, 2006, PHARMACOGENOMICS J, V6, P16, DOI 10.1038/sj.tpj.6500338
   Shastry BS, 2011, ADV MED BIOL, V26
   Sheybani A, 2009, RETINA-J RET VIT DIS, V29, P1404, DOI 10.1097/IAE.0b013e3181b32d13
   Szabo V, 2007, MOL VIS, V13, P659
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Volotinen M, 2011, BASIC CLIN PHARMACOL, V108, P297, DOI 10.1111/j.1742-7843.2011.00694.x
   Wiggs JL, 2008, ARCH OPHTHALMOL-CHIC, V126, P422, DOI 10.1001/archopht.126.3.422
   Yang YF, 2009, J OCUL PHARMACOL TH, V25, P163, DOI 10.1089/jop.2008.0028
   Yuan HZ, 2010, J OCUL PHARMACOL TH, V26, P497, DOI 10.1089/jop.2010.0013
NR 79
TC 10
Z9 10
U1 0
U2 2
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD AUG
PY 2011
VL 12
IS 63
BP 159
EP 167
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA V27VD
UT WOS:000208639800008
PM 21878193
DA 2022-11-30
ER

PT J
AU Yin, JG
   Thomas, F
   Lang, JC
   Chaum, E
AF Yin, Jinggang
   Thomas, Fridtjof
   Lang, John C.
   Chaum, Edward
TI Modulation of Oxidative Stress Responses in the Human Retinal Pigment
   Epithelium Following Treatment With Vitamin C
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID EARLY GENE-EXPRESSION; DNA-BINDING ACTIVITY; ACTIVATOR PROTEIN-1; AP-1
   ACTIVITY; CELLS; FOS; TRANSPORTER; INDUCTION; ANTIOXIDANT; PROMOTER
AB Oxidative stress (OS) in the retina plays an important role in the development and progression of age-related macular degeneration (AMD). Our previous work has shown that OS can quantitatively regulate the expression of AP-1 family genes in the retinal pigment epithelium (RPE). In this study, we sought to determine whether AP-1 genes can be used as cellular biomarkers of OS to evaluate the efficacy of ascorbate, the major aqueous-phase antioxidant in the blood, in reducing OS in RPE cells in vitro. Human ARPE19 cells were pretreated with increasing levels of ascorbate (0-500 mu M) for 3 days which was then removed from the medium. OS was induced 24 h later by the addition of hydrogen peroxide for 1-4 h, to bring the final media concentration of H2O2 to 500 mu M. FosB, c-Fos, and ATF3 gene expression was examined from 0 to 24 h after OS. Pretreatment with 200 mu M ascorbate maximally reduced the transcriptional OS response of AP-1 genes by up to 87% after 1 and 4 h, compared to controls. One hundred micromolar of ascorbate provided a statistically significant, but far more modest effect. Ascorbate supplementation of 100-200 mu M appears to strongly inhibit OS-induced activation of AP-1 in vitro, but pretreatment with higher levels of ascorbate conferred no additional advantage. These studies suggest that there are optimal levels of antioxidant supplementation to the RPE in vitro. Laboratory assays based upon transcription factor biomarkers may be useful to define beneficial molecular responses to new antioxidants, alternative dosing regimens, and to explore therapeutic efficacy in OS models in vitro. J. Cell. Physiol. 226: 2025-2032, 2011. (C) 2010 Wiley-Liss, Inc.
C1 [Yin, Jinggang; Chaum, Edward] Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA.
   [Thomas, Fridtjof] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA.
   [Lang, John C.] Alcon Res Ltd, Ft Worth, TX USA.
   [Chaum, Edward] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center; University of Tennessee System; University of Tennessee Health
   Science Center; Novartis; Alcon; University of Tennessee System;
   University of Tennessee Health Science Center
RP Chaum, E (通讯作者)，Hamilton Eye Inst, 930 Madison Ave,Suite 731, Memphis, TN 38163 USA.
EM echaum@uthsc.edu
RI Chaum, Edward/AAR-1512-2021
OI Chaum, Edward/0000-0003-3542-8376; Thomas, Fridtjof/0000-0003-1325-4870
FU Alcon Research Inc., Ft. Worth, TX; Research to Prevent Blindness, New
   York, NY; Plough Foundation, Memphis, TN; Lions of Arkansas Foundation
   Inc.; UTHSC Hamilton Eye Institute [P30 EY013080]; NATIONAL EYE
   INSTITUTE [P30EY013080] Funding Source: NIH RePORTER
FX Contract grant sponsor: Alcon Research Inc., Ft. Worth, TX.; Contract
   grant sponsor: Research to Prevent Blindness, New York, NY.; Contract
   grant sponsor: Plough Foundation, Memphis, TN.; Contract grant sponsor:
   The Lions of Arkansas Foundation Inc.; Contract grant sponsor: UTHSC
   Hamilton Eye Institute NEI Core Grant for Vision Research;; Contract
   grant number: P30 EY013080.; This study was supported in part by a
   research grant from Alcon Research Inc., Ft. Worth, TX, an unrestricted
   UTHSC departmental grant from Research to Prevent Blindness, New York,
   NY, The Lions of Arkansas Foundation Inc., and the Plough Foundation,
   Memphis, TN. Dr. Lang is an employee of Alcon Research Ltd., Ft. Worth,
   TX. Dr. Chaum is the recipient of an RPB Senior Scientist Award and
   participates in the AREDS2 clinical trial (Clinical Trials. gov
   Identifier: NCT00345176) as the site PI at UTHSC. The authors would like
   to thank Ms. Weihong Huo for her technical assistance in performing the
   studies, Dr. Christina Winborn for her review of the manuscript, and the
   UTHSC Hamilton Eye Institute Core Grant for Vision Research, supported
   by the National Eye Institute (P30 EY013080).
CR ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682
   AMSTAD PA, 1992, CANCER RES, V52, P3952
   Arkan MC, 2001, FREE RADICAL BIO MED, V31, P374, DOI 10.1016/S0891-5849(01)00601-3
   Biondi C, 2007, MOL HUM REPROD, V13, P77, DOI 10.1093/molehr/gal092
   Caprile T, 2009, J NEUROCHEM, V108, P563, DOI 10.1111/j.1471-4159.2008.05788.x
   Catani MV, 2005, NUTR REV, V63, P81, DOI 10.1111/j.1753-4887.2005.tb00125.x
   Catani MV, 2001, BIOCHEM J, V356, P77, DOI 10.1042/0264-6021:3560077
   Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x
   Chang HJ, 2009, TOXICOL IN VITRO, V23, P622, DOI 10.1016/j.tiv.2009.02.008
   Chaum E, 2009, J CELL BIOCHEM, V108, P1280, DOI 10.1002/jcb.22358
   Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385
   CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X
   DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804
   Duarte TL, 2005, FREE RADICAL RES, V39, P671, DOI 10.1080/10715760500104025
   ESPOSITO F, 1995, BBA-GENE STRUCT EXPR, V1260, P308, DOI 10.1016/0167-4781(94)00209-L
   Geller SF, 2003, ADV EXP MED BIOL, V533, P249
   Giddabasappa A, 2010, INVEST OPHTH VIS SCI, V51, P5278, DOI 10.1167/iovs.10-5316
   Gonzales M, 2002, GENE, V293, P169, DOI 10.1016/S0378-1119(02)00723-0
   HALLIWELL B, 1992, FEBS LETT, V313, P62, DOI 10.1016/0014-5793(92)81185-O
   Harman D, 2006, ANN NY ACAD SCI, V1067, P454, DOI 10.1196/annals.1354.065
   HOLM S, 1979, SCAND J STAT, V6, P65
   Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425
   KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kutner M.H., 2005, APPL LINEAR STAT MOD
   Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901
   Loke WM, 2006, BIOCHEM BIOPH RES CO, V345, P1039, DOI 10.1016/j.bbrc.2006.04.174
   Lu D, 2007, BIOCHEM J, V401, P559, DOI 10.1042/BJ20061081
   Manfredini S, 2004, BIOORGAN MED CHEM, V12, P5453, DOI 10.1016/j.bmc.2004.07.043
   MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136
   MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225
   MORRIS BJ, 1995, J BIOL CHEM, V270, P24740
   Olson ER, 2010, CANCER PREV RES, V3, P876, DOI 10.1158/1940-6207.CAPR-09-0220
   Portugal CC, 2009, J NEUROCHEM, V108, P507, DOI 10.1111/j.1471-4159.2008.05786.x
   Reddy SPM, 2002, AM J PHYSIOL-LUNG C, V283, pL1161, DOI 10.1152/ajplung.00140.2002
   Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383
   Takeda M, 2000, INVEST OPHTH VIS SCI, V41, P2412
   Wang YX, 2000, BIOCHEM BIOPH RES CO, V267, P488, DOI 10.1006/bbrc.1999.1929
   Winkler BS, 1999, MOL VIS, V5
   XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x
   Yang HT, 2006, J CELL BIOCHEM, V98, P1560, DOI 10.1002/jcb.20877
NR 41
TC 21
Z9 22
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2011
VL 226
IS 8
BP 2025
EP 2032
DI 10.1002/jcp.22532
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 762ZJ
UT WOS:000290520900008
PM 21520054
DA 2022-11-30
ER

PT J
AU Barker, FM
   Snodderly, DM
   Johnson, EJ
   Schalch, W
   Koepcke, W
   Gerss, J
   Neuringer, M
AF Barker, Felix M., II
   Snodderly, D. Max
   Johnson, Elizabeth J.
   Schalch, Wolfgang
   Koepcke, Wolfgang
   Gerss, Joachim
   Neuringer, Martha
TI Nutritional Manipulation of Primate Retinas, V: Effects of Lutein,
   Zeaxanthin, and n-3 Fatty Acids on Retinal Sensitivity to
   Blue-Light-Induced Damage
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR PIGMENT DENSITY; DOCOSAHEXAENOIC ACID; OXIDATIVE STRESS;
   OPTICAL-DENSITY; EYE DISEASE; VITAMIN-C; AGE; DEGENERATION; CAROTENOIDS;
   PROTECTION
AB PURPOSE. Blue-light photooxidative damage has been implicated in the etiology of age-related macular degeneration (AMD). The macular pigment xanthophylls lutein (L) and zeaxanthin (Z) and n-3 fatty acids may reduce this damage and lower the risk of AMD. This study investigated the effects of the lifelong absence of xanthophylls followed by L or Z supplementation, combined with the effects of n-3 fatty acid deficiency, on acute blue-light photochemical damage.
   METHODS. Subjects included eight rhesus monkeys with no lifelong intake of xanthophylls and no detectable macular pigment. Of these, four had low n-3 fatty acid intake and four had adequate intakes. Control subjects had typical L, Z, and n-3 fatty acid intake. Retinas received 150-mu m-diameter exposures of low-power 476-nm laser light at 0.5 mm (similar to 2 degrees) eccentricity, which is adjacent to the macular pigment peak, and parafoveally at 1.5 mm (similar to 6 degrees). Exposures of xanthophyll-free animals were repeated after supplementation with pure L or Z for 22 to 28 weeks. Ophthalmoscopically visible lesion areas were plotted as a function of exposure energy, with greater slopes of the regression lines indicating greater sensitivity to damage.
   RESULTS. In control animals, the fovea was less sensitive to blue-light-induced damage than the parafovea. Foveal protection was absent in xanthophyll-free animals but was evident after supplementation. In the parafovea, animals low in n-3 fatty acids showed greater sensitivity to damage than animals with adequate levels.
   CONCLUSIONS. After long-term xanthophyll deficiency, L or Z supplementation protected the fovea from blue light-induced damage, whereas adequate n-3 fatty acid levels reduced the damage in the parafovea. (Invest Ophthalmol Vis Sci. 2011;52: 3934-3942) DOI:10.1167/iovs.10-5898
C1 [Neuringer, Martha] Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA.
   [Neuringer, Martha] Oregon Hlth & Sci Univ, Casey Eye Inst, Beaverton, OR USA.
   [Barker, Felix M., II] Salus Univ, Penn Coll Optometry, Elkins Pk, PA USA.
   [Snodderly, D. Max] Schepens Eye Res Inst, Boston, MA USA.
   [Johnson, Elizabeth J.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Schalch, Wolfgang] DSM Nutr Prod Ltd, Kaiseraugst, Switzerland.
   [Koepcke, Wolfgang; Gerss, Joachim] Univ Munster, Dept Med Informat & Bioinformat, Munster, Germany.
C3 Oregon Health & Science University; Oregon National Primate Research
   Center; Oregon Health & Science University; Harvard University; Schepens
   Eye Research Institute; Tufts University; United States Department of
   Agriculture (USDA); DSM NV; University of Munster
RP Neuringer, M (通讯作者)，Oregon Reg Primate Res Ctr, 505 NW 185th Ave, Beaverton, OR 97006 USA.
EM neuringe@ohsu.edu
RI Gerß, Joachim WO/B-5702-2013
OI Snodderly, Donald/0000-0002-3428-609X
FU DSM Nutritional Products Ltd., Kaiseraugst, Switzerland; Institute of
   Diabetes, Digestive and Kidney Diseases [DK29930]; National Center for
   Research Resources [RR00163]; U.S. Department of Agriculture
   [581950-9-001]; National Eye Institute [P30 EY03790]; Foundation
   Fighting Blindness; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000163,
   P51RR000163] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [P30EY003790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029930] Funding Source:
   NIH RePORTER
FX Supported by DSM Nutritional Products Ltd., Kaiseraugst, Switzerland;
   Grant DK29930 from the Institute of Diabetes, Digestive and Kidney
   Diseases; Grant RR00163 from the National Center for Research Resources;
   Grant 581950-9-001 from the U.S. Department of Agriculture; Grant P30
   EY03790 from the National Eye Institute; and a grant from The Foundation
   Fighting Blindness.
CR Bazan NG, 2007, INVEST OPHTH VIS SCI, V48, P4866, DOI 10.1167/iovs.07-0918
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BUSH RA, 1991, EXP EYE RES, V53, P741, DOI 10.1016/0014-4835(91)90109-R
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   DAYHAWBARKER P, 1987, PHOTOCHEM PHOTOBIOL, V46, P1051, DOI 10.1111/j.1751-1097.1987.tb04892.x
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   German OL, 2006, J NEUROCHEM, V98, P1507, DOI 10.1111/j.1471-4159.2006.04061.x
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   HAM WT, 1986, OPTICAL RAD VISUAL H, P43
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   HANDELMAN GJ, 1991, INVEST OPHTH VIS SCI, V32, P257
   HARWERTH RS, 1975, VISION RES, V15, P1193, DOI 10.1016/0042-6989(75)90162-5
   HARWERTH RS, 1971, SCIENCE, V174, P520, DOI 10.1126/science.174.4008.520
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   HUPP SL, 1987, ARCH OPHTHALMOL-CHIC, V105, P1022
   JAFFE GJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P445
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Leung IYF, 2005, EXP EYE RES, V81, P513, DOI 10.1016/j.exer.2005.03.009
   Leung IYF, 2004, INVEST OPHTH VIS SCI, V45, P3244, DOI 10.1167/iovs.02-1233
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   MAINSTER MA, 1993, LASERS LIGHT OPHTHAL, V5, P117
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Organisciak DT, 1996, INVEST OPHTH VIS SCI, V37, P2243
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SCHALCH W, 1992, FREE RADICALS AGING, P280
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7
   SMITH HE, 1944, US NAVAL B, P675
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1992, J NEUROSCI, V12, P1169
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   SPERLING HG, 1980, VISION RES, V20, P1117, DOI 10.1016/0042-6989(80)90049-8
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
   Winkler BS, 1999, MOL VIS, V5
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 71
TC 120
Z9 123
U1 2
U2 22
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2011
VL 52
IS 7
BP 3934
EP 3942
DI 10.1167/iovs.10-5898
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800BP
UT WOS:000293332500003
PM 21245404
OA Green Published
DA 2022-11-30
ER

PT J
AU Dunavoelgyi, R
   Sacu, S
   Simader, C
   Pruente, C
   Schmidt-Erfurth, U
AF Dunavoelgyi, Roman
   Sacu, Stefan
   Simader, Christian
   Pruente, Christian
   Schmidt-Erfurth, Ursula
TI Changes in macular sensitivity after reduced fluence photodynamic
   therapy combined with intravitreal triamcinolone
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; microperimetry; photodynamic therapy;
   reduced fluence; triamcinolone acetonide
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN THERAPY; FUNDUS
   PERIMETRY; VISUAL FUNCTION; DEGENERATION; MICROPERIMETRY; ACETONIDE;
   DISEASE; SCOTOMA
AB Purpose: This study aimed to evaluate the course of macular sensitivity (MS) following treatment with reduced fluence photodynamic therapy (RPDT) versus standard photodynamic therapy (SPDT) in combination with intravitreal triamcinolone acetonide (IVTA) in patients with neovascular age-related macular degeneration, and to investigate the correlation between MS and angiographic outcomes.
   Methods: Forty eyes in 40 patients were included in this prospective, randomized clinical study. Group 1 patients received RPDT (n = 20, light dose of 25 J/cm(2) at 300 mW/cm(2)); group 2 patients received SPDT (n = 20, light dose of 50 J/cm(2) at 600 mW/cm(2)). All patients received 4 mg IVTA administered on the same day as RPDT or SPDT. Microperimetry, visual acuity testing (ETDRS) and fluorescein angiography (FA) were performed at baseline, and at months 3, 6, 9 and 12. Main outcome parameters were mean differential light threshold (DLT), and absolute and relative scotoma size.
   Results: Mean DLT decreased from 4.71 dB at baseline to 3.45 dB after 12 months in the SPDT + IVTA group (mean decrease 1.26 dB; p > 0.05) and from 5.42 dB to 4.92 dB in the RPDT + IVTA group (mean decrease 0.5 dB; p > 0.05). Absolute and relative scotoma sizes remained stable in both groups at 12 months (mean change 0 and -0.6 test-points; p > 0.05). Mean DLT values and absolute scotoma sizes correlated well with early and late leakage areas in FA (r = -0.45 to -0.80, p < 0.02).
   Conclusions: With regard to MS, RPDT + IVTA did not show significant benefits over SPDT + IVTA at 12 months. Macular sensitivity correlated well with angiographic outcomes.
C1 [Dunavoelgyi, Roman; Sacu, Stefan; Simader, Christian; Pruente, Christian; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Sacu, S (通讯作者)，Med Univ Vienna, Allgemeines Krankenhaus AKH Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM stefan.sacu@meduniwien.ac.at
OI Dunavoelgyi, Roman/0000-0002-1842-240X; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Simader, Christian/0000-0002-1784-2883
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bunse A, 2000, KLIN MONATSBL AUGENH, V216, P158, DOI 10.1055/s-2000-10537
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Frimpong-Boateng A, 2009, ACTA OPHTHALMOL, V87, P183, DOI 10.1111/j.1755-3768.2008.01213.x
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   LIE S, 2008, ACTA OPHTHALMOL
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Parodi MB, 2007, ACTA OPHTHALMOL SCAN, V85, P50, DOI 10.1111/j.1600-0420.2006.00738.x
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Richter-Mueksch S, 2007, AM J OPHTHALMOL, V144, P23, DOI 10.1016/j.ajo.2007.03.045
   ROHRSCHNEIDER K, 1995, GRAEF ARCH CLIN EXP, V233, P743, DOI 10.1007/BF00184084
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   Sawa M, 2006, JPN J OPHTHALMOL, V50, P111, DOI 10.1007/s10384-005-0292-y
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   SCHNEIDER U, 1993, KLIN MONATSBL AUGENH, V203, P212, DOI 10.1055/s-2008-1045670
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Yodoi Y, 2007, AM J OPHTHALMOL, V143, P984, DOI 10.1016/j.ajo.2007.01.026
NR 29
TC 5
Z9 6
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2011
VL 89
IS 2
BP 166
EP 171
DI 10.1111/j.1755-3768.2009.01646.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 725RV
UT WOS:000287664700037
PM 19860783
DA 2022-11-30
ER

PT J
AU Al-Atabany, WI
   Memon, MA
   Downes, SM
   Degenaar, PA
AF Al-Atabany, Walid I.
   Memon, Muhammad A.
   Downes, Susan M.
   Degenaar, Patrick A.
TI Designing and testing scene enhancement algorithms for patients with
   retina degenerative disorders
SO BIOMEDICAL ENGINEERING ONLINE
LA English
DT Article
ID RECEPTIVE-FIELDS; EDGE-DETECTION; VISION; RECOGNITION; TELEVISION;
   FRAMEWORK; PEOPLE; IMAGES; SPACE
AB Background: Retina degenerative disorders represent the primary cause of blindness in UK and in the developed world. In particular, Age Related Macular Degeneration (AMD) and Retina Pigmentosa (RP) diseases are of interest to this study. We have therefore created new image processing algorithms for enhancing the visual scenes for them.
   Methods: In this paper we present three novel image enhancement techniques aimed at enhancing the remaining visual information for patients suffering from retina dystrophies. Currently, the only effective way to test novel technology for visual enhancement is to undergo testing on large numbers of patients. To test our techniques, we have therefore built a retinal image processing model and compared the results to data from patient testing. In particular we focus on the ability of our image processing techniques to achieve improved face detection and enhanced edge perception.
   Results: Results from our model are compared to actual data obtained from testing the performance of these algorithms on 27 patients with an average visual acuity of 0.63 and an average contrast sensitivity of 1.22. Results show that Tinted Reduced Outlined Nature (TRON) and Edge Overlaying algorithms are most beneficial for dynamic scenes such as motion detection. Image Cartoonization was most beneficial for spatial feature detection such as face detection. Patient's stated that they would most like to see Cartoonized images for use in daily life.
   Conclusions: Results obtained from our retinal model and from patients show that there is potential for these image processing techniques to improve visual function amongst the visually impaired community. In addition our methodology using face detection and efficiency of perceived edges in determining potential benefit derived from different image enhancement algorithms could also prove to be useful in quantitatively assessing algorithms in future studies.
C1 [Al-Atabany, Walid I.; Memon, Muhammad A.; Degenaar, Patrick A.] Univ London Imperial Coll Sci Technol & Med, Inst Biomed Engn, London SW7 1LU, England.
   [Degenaar, Patrick A.] Univ London Imperial Coll Sci Technol & Med, Dept Neurosci, London SW7 1LU, England.
   [Downes, Susan M.] Oxford Eye Hosp, Oxford OX3 9DU, England.
   [Al-Atabany, Walid I.] Helwan Univ, Dept Biomed Engn, Cairo 11421, Egypt.
C3 Imperial College London; Imperial College London; Egyptian Knowledge
   Bank (EKB); Helwan University
RP Al-Atabany, WI (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Inst Biomed Engn, London SW7 1LU, England.
EM walid.atbany06@imperial.ac.uk
RI Degenaar, Patrick/B-4006-2010; al-atabany, walid/U-3720-2019
OI Degenaar, Patrick/0000-0002-5984-6698; al-atabany,
   walid/0000-0002-8141-2511
FU Royal Society; EPSRC [F029241]; Egyptian government
FX We would like to acknowledge and thank the Royal Society Research fund,
   and the EPSRC (F029241) for supporting this research. Also Mr. Walid
   Al-Atabany would like to thank the Egyptian government, who are
   sponsoring him for his PhD. We would also like to thank Anna Rudenko,
   the research nurse and Bushra Mushtaq, the medical retinal Fellow for
   helping with the patients in this study and the patients for taking part
   in the study.
CR Apfelbaum HL, 2008, OPHTHAL PHYSL OPT, V28, P204, DOI 10.1111/j.1475-1313.2008.00537.x
   Atabany W, 2008, IEEE INT SYMP CIRC S, P1476, DOI 10.1109/ISCAS.2008.4541708
   Atabany W, 2008, CAIRO INT BIOM ENG, P80
   Banks DJ, 2007, ELECTRON LETT, V43, P704, DOI 10.1049/el:20071440
   Bovik A, 2005, HANDBOOK OF IMAGE AND VIDEO PROCESSING, 2ND EDITION, pV, DOI 10.1016/B978-012119792-6/50062-0
   BRABYN JA, 1982, IEEE T BIO-MED ENG, V29, P285, DOI 10.1109/TBME.1982.324945
   CANNY J, 1986, IEEE T PATTERN ANAL, V8, P679, DOI 10.1109/TPAMI.1986.4767851
   Chang EC, 2000, APPL COMPUT HARMON A, V9, P312, DOI 10.1006/acha.2000.0324
   CHANG PR, 1991, VISUAL COMMUNICA 1 2, V1606, P456
   Comaniciu D, 2002, IEEE T PATTERN ANAL, V24, P603, DOI 10.1109/34.1000236
   DeCarlo D, 2002, ACM T GRAPHIC, V21, P769
   Degenaar P, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/3/035007
   DOWLING JE, 1990, RETINA APPROACHABLE
   Elliott DB, 1997, INVEST OPHTH VIS SCI, V38, P2566
   Everingham MR, 1999, INT J VIRTUAL REALIT, V3, P3
   Field GD, 2007, ANNU REV NEUROSCI, V30, P1, DOI 10.1146/annurev.neuro.30.051606.094252
   FLECK MM, 1992, IEEE T PATTERN ANAL, V14, P337, DOI 10.1109/34.120328
   Foster A, 2005, EYE, V19, P1133, DOI 10.1038/sj.eye.6701973
   Fullerton M, 2006, J SOC INF DISPLAY, V14, P15, DOI 10.1889/1.2166829
   Geisler WS, 1998, P SOC PHOTO-OPT INS, V3299, P294, DOI 10.1117/12.320120
   Grau V, 2004, IEEE T MED IMAGING, V23, P447, DOI 10.1109/TMI.2004.824224
   Han SD, 2009, IEEE T IMAGE PROCESS, V18, P2289, DOI 10.1109/TIP.2009.2025560
   Hubel DH, 2009, J PHYSIOL-LONDON, V587, P2722
   HUBEL DH, 1959, J PHYSIOL-LONDON, V148, P574, DOI 10.1113/jphysiol.1959.sp006308
   Jobson DJ, 1997, IEEE T IMAGE PROCESS, V6, P965, DOI 10.1109/83.597272
   KIENZLE W, 2005, ADV NEURAL INFORM PR, V17, P673
   KOLB H, 2010, WEB VISION
   MAHOWALD MA, 1991, SILICON RETINA ADAPT, V1473, P52
   MASSOF RW, 1992, OPTOMETRY VISION SCI, V69, P32, DOI 10.1097/00006324-199201000-00005
   Morillas CA, 2007, BIOSYSTEMS, V87, P156, DOI 10.1016/j.biosystems.2006.09.009
   Moscovitch M, 1997, J COGNITIVE NEUROSCI, V9, P555, DOI 10.1162/jocn.1997.9.5.555
   Osuna E, 1997, PROC CVPR IEEE, P130, DOI 10.1109/CVPR.1997.609310
   Peli E, 2005, OPHTHAL PHYSL OPT, V25, P543, DOI 10.1111/j.1475-1313.2005.00340.x
   Peli E, 2004, J OPT SOC AM A, V21, P937, DOI 10.1364/JOSAA.21.000937
   Peli E, 2007, SID INT SYMP DIG TEC, V38, P1074, DOI 10.1889/1.2785492
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   PERONA P, 1990, IEEE T PATTERN ANAL, V12, P629, DOI 10.1109/34.56205
   PROTHERO JD, 1993, TREATMENT AKINESIA U
   Raskar R, 2004, ACM T GRAPHIC, V23, P679, DOI 10.1145/1015706.1015779
   Shah S, 1996, IEEE T SYST MAN CY B, V26, P259, DOI 10.1109/3477.485837
   Shen JB, 2007, COMPUT GRAPH-UK, V31, P119, DOI 10.1016/j.cag.2006.10.004
   Tate R, 2005, PREVALENCE VISUAL IM
   Teng QZ, 2000, P SOC PHOTO-OPT INS, V4224, P109, DOI 10.1117/12.403953
   Tsao DY, 2008, ANNU REV NEUROSCI, V31, P411, DOI 10.1146/annurev.neuro.30.051606.094238
   VARGASMARTIN F, 2005, INT C SERIES, V1282, P1075
   Veraart C, 2004, EXPERT REV MED DEVIC, V1, P139, DOI 10.1586/17434440.1.1.139
   Viola P., 2001, ROBUST REAL TIME OBJ
   Wang HC, 2006, IEEE IMAGE PROC, P2893, DOI 10.1109/ICIP.2006.313034
   Winnemoller H, 2006, ACM T GRAPHIC, V25, P1221, DOI 10.1145/1141911.1142018
   Wolffsohn JS, 2007, AM J OPHTHALMOL, V144, P436, DOI 10.1016/j.ajo.2007.05.031
NR 50
TC 20
Z9 20
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-925X
J9 BIOMED ENG ONLINE
JI Biomed. Eng. Online
PD JUN 18
PY 2010
VL 9
AR 27
DI 10.1186/1475-925X-9-27
PG 25
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 645DQ
UT WOS:000281431500001
PM 20565870
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ma, H
   Tochigi, A
   Shearer, TR
   Azuma, M
AF Ma, Hong
   Tochigi, Ayumi
   Shearer, Thomas R.
   Azuma, Mitsuyoshi
TI Calpain Inhibitor SNJ-1945 Attenuates Events Prior to Angiogenesis in
   Cultured Human Retinal Endothelial Cells
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID GROWTH-FACTOR; CALPASTATIN; LP82; LENS; IDENTIFICATION; INVOLVEMENT;
   PROTEOLYSIS; ACTIVATION; RATS; VEGF
AB Purpose: Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis and microvascular permeability. VEGF-induced cytoskeletal reorganization plays a crucial role in angiogenesis. Cytoskeletal organization in endothelial cells is regulated by calpain proteases (EC 3.4.22.17). Calpains are a family of 14 calcium-regulated, intracellular cysteine proteases, which modulate cellular functions by limited, specific proteolysis. Calpain 1 (mu-calpain) and calpain 2 (m-calpain) are the 2 major typical calpain isoforms and are responsible for most calpain activity in endothelial cells. The purpose of the present study was to determine if an orally available form of calpain inhibitor, SNJ-1945, prevented angiogenesis induced by VEGF in cultured retinal endothelial cells.
   Methods: Human retinal microvascular endothelial cells (HRMEC) were incubated with VEGF (60-100 ng/mL) for 24 h. Calcium uptake was measured with Fluo8. Total calpain activity was measured using fluorescent-labeled casein substrate, and separate activities for calpains 1 and 2 were assessed by casein zymography. Proteolysis of endogenous calpain substrate alpha-spectrin in situ was analyzed by immunoblotting. Angiogenesis in vitro was evaluated by measuring cell migration and tube formation into Matrigel.
   Results: Incubation of HRMEC with VEGF resulted in calcium uptake, increased activity of mainly calpain 2, and increased calpain proteolysis of alpha-spectrin. Treatment of endothelial cells with calpain inhibitor SNJ-1945 reversed VEGF-mediated tube formation and cell motility.
   Conclusions: Inhibition of angiogenesis by specific calpain inhibitor in the presence of VEGF supported our hypothesis that calpains may be involved in VEGF-mediated angiogenesis in retinal endothelial cells. Therefore, manipulating calpain activity by calpain inhibitor SNJ-1945 might provide a promising therapy for management of pathological angiogenesis, such as that occurring in proliferative retinopathy and age-related macular degeneration with neovascularization.
C1 [Ma, Hong; Shearer, Thomas R.; Azuma, Mitsuyoshi] Oregon Hlth & Sci Univ, Dept Integrat Biosci, Portland, OR 97239 USA.
   [Tochigi, Ayumi; Azuma, Mitsuyoshi] Senju Pharmaceut Co Ltd, Senju Lab Ocular Sci, Beaverton, OR USA.
C3 Oregon Health & Science University; Senju Pharmaceutical Co. Ltd.
RP Shearer, TR (通讯作者)，Oregon Hlth & Sci Univ, Dept Integrat Biosci, 611 SW Campus Dr, Portland, OR 97239 USA.
EM shearert@ohsu.edu
CR Azuma M, 2000, CURR EYE RES, V21, P710, DOI 10.1076/0271-3683(200009)21:3;1-R;FT710
   Azuma M, 2008, SURV OPHTHALMOL, V53, P150, DOI 10.1016/j.survophthal.2007.12.006
   Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9
   Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002
   Cuerrier D, 2006, BIOCHEMISTRY-US, V45, P7446, DOI 10.1021/bi060425j
   Dedieu S, 2004, EXP CELL RES, V292, P187, DOI 10.1016/j.yexcr.2003.08.014
   Deroanne CF, 2001, CARDIOVASC RES, V49, P647, DOI 10.1016/S0008-6363(00)00233-9
   Ferrara N, 2001, ACTA HAEMATOL-BASEL, V106, P148, DOI 10.1159/000046610
   Franco S, 2004, EXP CELL RES, V299, P179, DOI 10.1016/j.yexcr.2004.05.021
   Fujitani K, 1997, J CELL BIOCHEM, V66, P197, DOI 10.1002/(SICI)1097-4644(19970801)66:2<197::AID-JCB7>3.0.CO;2-L
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   Khorchid A, 2002, NAT STRUCT BIOL, V9, P239, DOI 10.1038/nsb0402-239
   Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Nakajima T, 2001, BBA-GENE STRUCT EXPR, V1519, P55, DOI 10.1016/S0167-4781(01)00212-3
   Nakamura Y, 1999, EXP EYE RES, V69, P155, DOI 10.1006/exer.1998.0686
   Nakamura Y, 2000, INVEST OPHTH VIS SCI, V41, P1460
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Newcomb JK, 2000, METH MOL B, V144, P219
   Oka T, 2006, NEUROSCIENCE, V141, P2139, DOI 10.1016/j.neuroscience.2006.05.060
   Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647
   RASER KJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P211, DOI 10.1006/abbi.1995.1284
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Shearer TR, 1998, CURR EYE RES, V17, P1037, DOI 10.1076/ceyr.17.11.1037.5232
   Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002
   Shirasaki Y, 2006, J OCUL PHARMACOL TH, V22, P417, DOI 10.1089/jop.2006.22.417
   Su YC, 2006, FASEB J, V20, P1443, DOI 10.1096/fj.05-5354com
   Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12
   Tamada Y, 2000, J OCUL PHARMACOL TH, V16, P271, DOI 10.1089/jop.2000.16.271
   Ueda Y, 2001, EXP EYE RES, V73, P625, DOI 10.1006/exer.2001.1071
NR 30
TC 22
Z9 22
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD OCT
PY 2009
VL 25
IS 5
BP 409
EP 414
DI 10.1089/jop.2009.0030
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 511DB
UT WOS:000271143000004
PM 19857102
OA Green Published
DA 2022-11-30
ER

PT J
AU Sacca, SC
   Bolognesi, C
   Battistella, A
   Bagnis, A
   Izzotti, A
AF Sacca, S. C.
   Bolognesi, C.
   Battistella, A.
   Bagnis, A.
   Izzotti, A.
TI Gene-environment interactions in ocular diseases
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Review
DE Cataract; Glaucoma; Age-related macular degeneration; DNA damage;
   Oxidative stress; Individual susceptibility
ID OPEN-ANGLE GLAUCOMA; AGE-RELATED MACULOPATHY; HUMAN TRABECULAR MESHWORK;
   COMPLEMENT FACTOR-H; S-TRANSFERASE M1; CENTRAL CORNEAL THICKNESS;
   AQUEOUS-HUMOR OUTFLOW; LONG-TERM INCIDENCE; BODY-MASS INDEX;
   LIPID-PEROXIDATION PRODUCTS
AB Degenerative ocular diseases are widespread in the population and represent a major cause of reversible and irreversible blindness. Scientific evidences have been accumulating supporting the role of genotoxic damage and gene environment interactions in the pathogenesis of these diseases mainly including glaucoma, age-related macular degeneration, and cataract.
   Glaucoma, in its degenerative form, is characterized by the degeneration of the trabecular meshwork, the tissue of the anterior chamber of the eye devoted to aqueous-humour outflow. Such a degenerative process results in intra-ocular pressure increase and progressive damage of optic nerve head. Oxidative stress and DNA damage play an important role in inducing the degeneration of these well differentiated target tissues in which DNA damage results in a progressive cell loss.
   Macular degeneration is a common age-related disease affecting the central regions of the retina inducing progressive accumulation of oxidized lipoproteins and neovascularization. Environmental genotoxic risk factors include diet, light, and cigarette smoke paralleled by individual susceptibility as determined by adverse genetic assets.
   Cataract is a progressive opacity of the crystalline lens resulting from molecular damages induced by various risk factors including UV-containing light. This disease has been related to a failure in antioxidant defences. Experimental study provides evidence that cataract patients possess higher basal level of DNA damage, as evaluated by Comet test, in lymphocytes than controls. This finding is paralleled by the higher susceptibility to oxidative stress observed in the same patients. These novel experimental data further support the role of DNA damage as a main factor contributing to cataract onset.
   In conclusion, the examined degenerative ocular diseases recognise environmental risk factors often displaying genotoxic attitudes. Whenever these factors target individuals who are susceptible due their genetic assets the results is the onset of a specific eye disease depending on the affected ocular tissue. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Sacca, S. C.; Bagnis, A.] St Martino Hosp, Div Ophthalmol, Genoa, Italy.
   [Bolognesi, C.] Canc Res Inst IST, Genoa, Italy.
   [Battistella, A.; Izzotti, A.] Univ Genoa, Dept Hlth Sci, Genoa, Italy.
C3 University of Genoa
RP Bolognesi, C (通讯作者)，Natl Inst Canc Res IST, Environm Carcinogenesis Unit, Largo R Benzi 10, I-16132 Genoa, Italy.
EM claudia.bolognesi@istge.it
RI Sacca, Sergio/D-5118-2018; Saccà, Sergio/AAG-3335-2019
OI Sacca, Sergio/0000-0001-6973-5978; Saccà, Sergio/0000-0001-6973-5978;
   izzotti, alberto/0000-0002-8588-0347
CR Abu-Amero KK, 2008, MOL VIS, V14, P425
   Abu-Amero KK, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-38
   Adam MF, 1997, HUM MOL GENET, V6, P2091, DOI 10.1093/hmg/6.12.2091
   ALLINGHAM RR, 1992, INVEST OPHTH VIS SCI, V33, P1661
   ALVARADO J, 1981, INVEST OPHTH VIS SCI, V21, P714
   ALVARADO J, 1984, OPHTHALMOLOGY, V91, P564
   Alvarado J, 1984, RECENT ADV GLAUCOMA, P3
   Alvarado JA, 2005, BRIT J OPHTHALMOL, V89, P1500, DOI 10.1136/bjo.2005.081307
   Alvarado JA, 2004, AM J PHYSIOL-CELL PH, V286, pC621, DOI 10.1152/ajpcell.00108.2003
   Alvarado Jorge A, 2005, Trans Am Ophthalmol Soc, V103, P148
   Alward WLM, 1998, NEW ENGL J MED, V338, P1022, DOI 10.1056/NEJM199804093381503
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Aragon-Martin JA, 2008, MOL VIS, V14, P533
   BABIZHAYEV MA, 1989, ACTA OPHTHALMOL, V67, P371
   BABIZHAYEV MA, 1989, ACTA OPHTHALMOL, V67, P281
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459
   BENGTSSON B, 1981, BRIT J OPHTHALMOL, V65, P46, DOI 10.1136/bjo.65.1.46
   BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bruttini M, 2003, ARCH OPHTHALMOL-CHIC, V121, P1034, DOI 10.1001/archopht.121.7.1034
   Caballero M, 2003, BIOCHEM BIOPH RES CO, V308, P346, DOI 10.1016/S0006-291X(03)01385-8
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cakir Y, 2007, FREE RADICAL BIO MED, V43, P1279, DOI 10.1016/j.freeradbiomed.2007.07.015
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   CHATTERJEE A, 1982, BRIT J OPHTHALMOL, V66, P35, DOI 10.1136/bjo.66.1.35
   Chen YN, 2007, BRAIN RES, V1148, P28, DOI 10.1016/j.brainres.2007.02.027
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Choudhary S, 2005, TOXICOL APPL PHARM, V204, P122, DOI 10.1016/j.taap.2004.08.023
   CHOW CK, 1986, J AM COLL NUTR, V5, P305
   Chow J, 2007, MOL VIS, V13, P1926
   Christen WG, 2008, ARCH OPHTHALMOL-CHIC, V126, P102, DOI 10.1001/archopht.126.1.102
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Craig J E, 1999, Curr Opin Ophthalmol, V10, P126, DOI 10.1097/00055735-199904000-00009
   CRAIG WY, 1989, BMJ-BRIT MED J, V298, P784, DOI 10.1136/bmj.298.6676.784
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Cumming RG, 1997, ARCH OPHTHALMOL-CHIC, V115, P1296, DOI 10.1001/archopht.1997.01100160466015
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dandekar SS, 2006, BRIT J OPHTHALMOL, V90, P724, DOI 10.1136/bjo.2005.086355
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DelaPaz MA, 1996, INVEST OPHTH VIS SCI, V37, P1849
   Delcourt C, 2000, AM J EPIDEMIOL, V151, P497
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   DEVOOGD S, 2008, ACH OPTHALMOL, V1, P110
   Erden-Inal M, 2002, CELL BIOCHEM FUNCT, V20, P61, DOI 10.1002/cbf.937
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Fingert JH, 2002, SURV OPHTHALMOL, V47, P547, DOI 10.1016/S0039-6257(02)00353-3
   Fingert JH, 1998, GENOME RES, V8, P377, DOI 10.1101/gr.8.4.377
   Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Flammer J, 2002, PROG RETIN EYE RES, V21, P359, DOI 10.1016/S1350-9462(02)00008-3
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gabelt BT, 2003, INVEST OPHTH VIS SCI, V44, P2118, DOI 10.1167/iovs.02-0569
   Gabelt BT, 2005, PROG RETIN EYE RES, V24, P612, DOI 10.1016/j.preteyeres.2004.10.003
   Galambos P, 2006, OPHTHALMOLOGY, V113, P1832, DOI 10.1016/j.ophtha.2006.05.030
   Gherghel D, 2005, INVEST OPHTH VIS SCI, V46, P877, DOI 10.1167/iovs.04-0777
   Gherghel D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1359, DOI 10.1001/archopht.117.10.1359
   Gherghel D, 2000, AM J OPHTHALMOL, V130, P597, DOI 10.1016/S0002-9394(00)00766-2
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Gohdes DM, 2005, PREVENT CHRONIC DIS, V2, P1
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gong G, 2007, J NATL MED ASSOC, V99, P559
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   GREEN K, 1995, OPHTHALMIC RES, V27, P143, DOI 10.1159/000267860
   GRIERSON I, 1987, EYE, V1, P204, DOI 10.1038/eye.1987.38
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Habdous M, 2004, ANN BIOL CLIN-PARIS, V62, P15
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Hejtmancik JF, 2004, EXP EYE RES, V79, P3, DOI 10.1016/j.exer.2004.03.014
   Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255
   Hogg P, 2000, INVEST OPHTH VIS SCI, V41, P1091
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hong S, 2007, ARCH OPHTHALMOL-CHIC, V125, P1010, DOI 10.1001/archopht.125.8.1010
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   IZZOTTI A, 2007, EYE, V2, P1
   JANTER JA, 2008, PLOS ONE, V3, P2091
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson M, 2002, INVEST OPHTH VIS SCI, V43, P2950
   Johnson M, 2006, EXP EYE RES, V82, P545, DOI 10.1016/j.exer.2005.10.011
   Johnstone MA, 2004, J GLAUCOMA, V13, P421, DOI 10.1097/01.ijg.0000131757.63542.24
   JONASSON F, 2004, ACTA OPHTHALMOL SCAN, V82, P342
   JONES CA, 1987, RADIAT RES, V110, P244, DOI 10.2307/3576902
   Juronen E, 2000, EXP EYE RES, V71, P447, DOI 10.1006/exer.2000.0899
   KAHN MG, 1983, INVEST OPHTH VIS SCI, V24, P1283
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kelly SP, 2005, J CATARACT REFR SURG, V31, P2395, DOI 10.1016/j.jcrs.2005.06.039
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kirwan RP, 2005, MOL VIS, V11, P798
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIMAN NJ, 1993, CURR EYE RES, V12, P423, DOI 10.3109/02713689309024624
   KLEIMAN NJ, 1990, CURR EYE RES, V9, P1185, DOI 10.3109/02713689009003475
   KLEIMAN NJ, 1990, MUTAT RES, V240, P35, DOI 10.1016/0165-1218(90)90006-N
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   Klein BEK, 2003, AM J OPHTHALMOL, V136, P506, DOI 10.1016/S0002-9394(03)00290-3
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN BEK, 1992, INVEST OPHTH VIS SCI, V33, P2224
   KLEIN BEK, 1993, OPHTHALMOLOGY, V100, P1609
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Knudtson MD, 2006, BRIT J OPHTHALMOL, V90, P1461, DOI 10.1136/bjo.2006.103796
   Kubota R, 1998, BIOCHEM BIOPH RES CO, V242, P396, DOI 10.1006/bbrc.1997.7972
   Kumar A, 2007, MOL VIS, V13, P667
   La Rosa FA, 2001, ARCH OPHTHALMOL-CHIC, V119, P23
   Leske M C, 1996, Ophthalmic Epidemiol, V3, P85, DOI 10.3109/09286589609080113
   LESKE MC, 1995, ARCH OPHTHALMOL-CHIC, V113, P918, DOI 10.1001/archopht.1995.01100070092031
   Leske MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P48
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   Leske MC, 1997, ARCH OPHTHALMOL-CHIC, V115, P1051, DOI 10.1001/archopht.1997.01100160221012
   Li GR, 2007, MOL VIS, V13, P2282
   Li WG, 2001, J BIOL CHEM, V276, P29251, DOI 10.1074/jbc.M102124200
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lichter PR, 2001, J GLAUCOMA, V10, pS13, DOI 10.1097/00061198-200110001-00006
   Lindblad BE, 2007, OPHTHALMOLOGY, V114, P680, DOI 10.1016/j.ophtha.2006.07.046
   Liu Q, 2007, INVEST OPHTH VIS SCI, V48, P4580, DOI 10.1167/iovs.07-0170
   Liu YH, 2004, HUM MOL GENET, V13, P1193, DOI 10.1093/hmg/ddh128
   MAEPEA O, 1992, EXP EYE RES, V54, P879, DOI 10.1016/0014-4835(92)90151-H
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MARAINI G, 1991, AM J EPIDEMIOL, V133, P541
   MARAINI G, 1994, AM J OPHTHALMOL, V118, P623
   Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058
   Matsui H, 2003, INVEST OPHTH VIS SCI, V44, P3467, DOI 10.1167/iovs.02-0830
   McCarty CA, 2001, INVEST OPHTH VIS SCI, V42, P1677
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   McNaught AI, 2000, ARCH OPHTHALMOL-CHIC, V118, P900
   MEHRA K S, 1976, Annals of Ophthalmology, V8, P462
   Meister A., 1989, GLUTATHIONE CHEM BIO, P361
   MELROSE MA, 1985, OPHTHALMIC SURG LAS, V16, P648
   MIBU H, 1994, EXP EYE RES, V58, P85, DOI 10.1006/exer.1994.1197
   Miglior S, 2007, OPHTHALMOLOGY, V114, P3, DOI 10.1016/j.ophtha.2006.05.075
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Minamino T, 2002, CIRCULATION, V105, P1541, DOI 10.1161/01.CIR.0000013836.85741.17
   Mitchell CH, 2002, AM J PHYSIOL-CELL PH, V283, pC315, DOI 10.1152/ajpcell.00544.2001
   Mitchell P, 2004, J GLAUCOMA, V13, P319, DOI 10.1097/00061198-200408000-00010
   Mozaffarieh M, 2008, MOL VIS, V14, P1584
   Mozaffarieh M, 2008, MOL VIS, V14, P224
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nucci C, 2007, INT REV NEUROBIOL, V82, P397, DOI 10.1016/S0074-7742(07)82022-8
   O'Brien ET, 2000, INVEST OPHTH VIS SCI, V41, P3842
   Odrich S, 1988, Lens Res, V5, P203
   Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Oz O, 2006, EUR J OPHTHALMOL, V16, P105
   Park BC, 2007, GENES CELLS, V12, P969, DOI 10.1111/j.1365-2443.2007.01102.x
   PARK JW, 1992, FREE RADICAL BIO MED, V12, P245, DOI 10.1016/0891-5849(92)90111-S
   Pastor-Valero Maria, 2007, BMC Ophthalmol, V7, P18, DOI 10.1186/1471-2415-7-18
   Pasutto F, 2008, INVEST OPHTH VIS SCI, V49, P270, DOI 10.1167/iovs.07-0500
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Pompella A, 2003, BIOCHEM PHARMACOL, V66, P1499, DOI 10.1016/S0006-2952(03)00504-5
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quigley HA, 1999, PROG RETIN EYE RES, V18, P39, DOI 10.1016/S1350-9462(98)00014-7
   Racette L, 2003, SURV OPHTHALMOL, V48, P295, DOI 10.1016/S0039-6257(03)00028-6
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Reddy VN, 2004, EXP EYE RES, V79, P859, DOI 10.1016/j.exer.2004.04.005
   Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901
   RITTER LL, 1993, ARCH OPHTHALMOL-CHIC, V111, P113, DOI 10.1001/archopht.1993.01090010117037
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Ronkko S, 2007, MOL VIS, V13, P408
   Sacca SC, 1998, OPHTHALMOLOGICA, V212, P115, DOI 10.1159/000027290
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Sacca SC, 2007, EXP EYE RES, V84, P389, DOI 10.1016/j.exer.2006.10.008
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Sarfarazi Mansoor, 2003, Ophthalmol Clin North Am, V16, P529
   Schmidt S, 2005, MOL VIS, V11, P941
   Scholl HPN, 2007, MOL VIS, V13, P196
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Scott WK, 2007, OPHTHALMOLOGY, V114, P1151, DOI 10.1016/j.ophtha.2006.08.054
   Seddom JM, 2007, JAMA-J AM MED ASSOC, V297, P2585
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293
   SEKINE Y, 1995, EXP EYE RES, V60, P159, DOI 10.1016/S0014-4835(95)80006-9
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   SHIBUYA E, 2008, INVEST OPHTHALMOL VI
   Shiels A, 2007, ARCH OPHTHALMOL-CHIC, V125, P165, DOI 10.1001/archopht.125.2.165
   Shimizu S, 2000, AM J OPHTHALMOL, V130, P165, DOI 10.1016/S0002-9394(00)00536-5
   SIDJANIN D, 1993, CURR EYE RES, V12, P773, DOI 10.3109/02713689309020382
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Singh RP, 2001, J GLAUCOMA, V10, P206, DOI 10.1097/00061198-200106000-00011
   Sit AJ, 1997, INVEST OPHTH VIS SCI, V38, P1517
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Soto D, 2004, INVEST OPHTH VIS SCI, V45, P3650, DOI 10.1167/iovs.04-0060
   SPECTOR A, 1995, EXP EYE RES, V60, P471, DOI 10.1016/S0014-4835(05)80062-4
   SPECTOR A, 1995, EXP EYE RES, V60, P483, DOI 10.1016/S0014-4835(05)80063-6
   SPERDUTO RD, 1994, AM J EPIDEMIOL, V140, P555
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Tan J, 2007, AM J CLIN NUTR, V86, P1502
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   TARWADI VK, 2008, CLIN NUTR
   TAYLOR A, 1995, AM J CLIN NUTR, V62, P1439, DOI 10.1093/ajcn/62.6.1439S
   TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201
   Tezel G, 2007, INVEST OPHTH VIS SCI, V48, P705, DOI 10.1167/iovs.06-0810
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   Toda N, 2007, PROG RETIN EYE RES, V26, P205, DOI 10.1016/j.preteyeres.2007.01.004
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Townsend DM, 2003, BIOMED PHARMACOTHER, V57, P145, DOI 10.1016/S0753-3322(03)00043-X
   Tsai SY, 2003, OPHTHALMOLOGY, V110, P1089, DOI 10.1016/S0161-6420(03)00243-4
   Ueda J, 2000, J HISTOCHEM CYTOCHEM, V48, P1321, DOI 10.1177/002215540004801003
   Unal M, 2007, EXP EYE RES, V85, P328, DOI 10.1016/j.exer.2007.06.003
   Unal M, 2007, BRIT J OPHTHALMOL, V91, P527, DOI 10.1136/bjo.2006.102418
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Ventura ACS, 2001, BRIT J OPHTHALMOL, V85, P792, DOI 10.1136/bjo.85.7.792
   Voghel G, 2007, MECH AGEING DEV, V128, P662, DOI 10.1016/j.mad.2007.09.006
   WANG GM, 1990, CHINESE MED J-PEKING, V103, P945
   Wang J, 2007, J CENT SOUTH UNIV T, V14, P19, DOI 10.1007/s11771-007-0004-5
   Wang N, 2001, NAT MED, V7, P304, DOI 10.1038/85446
   Weber AJ, 2005, INVEST OPHTH VIS SCI, V46, P3197, DOI 10.1167/iovs.04-0834
   Weih LM, 2001, ARCH OPHTHALMOL-CHIC, V119, P875
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   Wentz-Hunter K, 2004, J CELL PHYSIOL, V200, P45, DOI 10.1002/jcp.10478
   WHITFIELD R, 1990, BRIT J OPHTHALMOL, V74, P333, DOI 10.1136/bjo.74.6.333
   Wiggs JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P30, DOI 10.1001/archopht.125.1.30
   WILSON MR, 1987, ARCH OPHTHALMOL-CHIC, V105, P1066
   Wilson RM., 1996, GLAUCOMAS, P753
   Wolfs RCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1640, DOI 10.1001/archopht.116.12.1640
   WORGUL BV, 1991, MUTAGENESIS, V6, P495, DOI 10.1093/mutage/6.6.495
   Wu SY, 1997, ARCH OPHTHALMOL-CHIC, V115, P1572, DOI 10.1001/archopht.1997.01100160742012
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yam GHT, 2007, INVEST OPHTH VIS SCI, V48, P1683, DOI 10.1167/iovs.06-0943
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Yildirim O, 2005, GRAEF ARCH CLIN EXP, V243, P327, DOI 10.1007/s00417-004-1013-9
   Younan C, 2002, AM J EPIDEMIOL, V155, P997, DOI 10.1093/aje/155.11.997
   Yucel YH, 2000, ARCH OPHTHALMOL-CHIC, V118, P378
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeitz O, 2007, GRAEF ARCH CLIN EXP, V245, P1327, DOI 10.1007/s00417-006-0526-9
   Zhou LL, 1999, J CELL PHYSIOL, V180, P182, DOI 10.1002/(SICI)1097-4652(199908)180:2<182::AID-JCP6>3.0.CO;2-X
NR 260
TC 58
Z9 59
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-1964
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD JUL 10
PY 2009
VL 667
IS 1-2
SI SI
BP 98
EP 117
DI 10.1016/j.mrfmmm.2008.11.002
PG 20
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA 475NI
UT WOS:000268366200011
PM 19046976
DA 2022-11-30
ER

PT J
AU Churchill, AJ
   Carter, JG
   Ramsden, C
   Turner, SJ
   Yeung, A
   Brenchley, PEC
   Ray, DW
AF Churchill, Amanda J.
   Carter, James G.
   Ramsden, Conor
   Turner, Steven J.
   Yeung, Anna
   Brenchley, Paul E. C.
   Ray, David W.
TI VEGF polymorphisms are associated with severity of diabetic retinopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL-GROWTH-FACTOR; EXONIC SPLICING ENHANCERS; HAPLOTYPE
   RECONSTRUCTION; MACULAR DEGENERATION; GENE; POPULATION; RISK; VARIANTS;
   DNA
AB PURPOSE. To determine whether single nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor (VEGF) gene are associated with severity of diabetic retinopathy.
   METHODS. A case-control study was conducted in which 45 individuals with type 1 or 2 diabetes with proliferative diabetic retinopathy (PDR) and 61 individuals with type 1 or 2 diabetes without retinopathy (DWR) were genotyped for 14 SNPs in the VEGF promoter and gene.
   RESULTS. Three of the promoter SNP genotypes, -160C, -152A (rs13207351), and -116A (rs1570360), showed significant independent associations with PDR, as well as the mini-haplotype CAA (P = 0.00017). Two promoter haplotypes were associated with severity of retinopathy: -460C, -417T, -172C, -165C, -160C, -152A, -141A, -116A, +405C was associated with PDR (OR [95% CI] = 29.92 [3.91, 228.78], P = 1.62 x 10(-5)) and -460C, -2417T, -172C, -165C, -160C, -152A, -141A, -116G, -405G was associated with DWR (OR = 0.05 [0.01, 0.35], P = 0.000373). Furthermore, two haplotype-tagged (ht) SNPs, +4618 (rs735286) and +5092 (rs2146323), and five htSNP haplotypes were associated with severity of retinopathy. When the nine promoter/5' untranslated region [UTR] and five htSNP genotypes were combined into a 14-SNP haplotype, a single haplotype, -460C, -417T, -172C, -165C, -160C, -152A, -141A, -116A, -405C, -674T, -4618C, -5092A, -9162C, -9512C was found to be significantly associated with the PDR group (OR = 18.45 [2.35, 144.67], P = 0.00622).
   CONCLUSIONS. A clear association was demonstrated between VEGF SNPs and severity of diabetic retinopathy. Furthermore, two of the htSNP haplotypes appear to be more generalized markers for angiogenesis, in that these have been found in prior work to be associated with neovascular age-related macular degeneration.
C1 [Churchill, Amanda J.; Carter, James G.; Ramsden, Conor; Turner, Steven J.; Yeung, Anna] Univ Bristol, Bristol Eye Hosp, Unit Ophthalmol, Bristol BS1 2LX, Avon, England.
   [Brenchley, Paul E. C.; Ray, David W.] Univ Manchester, Sch Clin & Lab Med, Manchester, Lancs, England.
C3 Bristol Eye Hospital; University of Bristol; University of Manchester
RP Churchill, AJ (通讯作者)，Univ Bristol, Bristol Eye Hosp, Unit Ophthalmol, Lower Maudlin St, Bristol BS1 2LX, Avon, England.
EM a.j.churchill@bristol.ac.uk
OI Carter, James/0000-0003-1860-9677; Ray, David/0000-0002-4739-6773;
   Brenchley, Paul/0000-0003-1290-9919
CR Al-Kateb H, 2007, DIABETES, V56, P2161, DOI 10.2337/db07-0376
   Awata T, 2005, BIOCHEM BIOPH RES CO, V333, P679, DOI 10.1016/j.bbrc.2005.05.167
   Awata T, 2002, DIABETES, V51, P1635, DOI 10.2337/diabetes.51.5.1635
   Bates DO, 2002, CANCER RES, V62, P4123
   *BIOBASE, 2004, TRANSPL VERS 1 4
   Box NF, 1998, MAMM GENOME, V9, P50, DOI 10.1007/s003359900678
   Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616
   CHO Y, 2006, Patent No. 2006135117
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Del Bo R, 2006, IMMUNOGENETICS, V58, P107, DOI 10.1007/s00251-006-0089-2
   Errera FIV, 2007, DIABETES CARE, V30, P275, DOI 10.2337/dc06-1399
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Ke XY, 2003, BIOINFORMATICS, V19, P287, DOI 10.1093/bioinformatics/19.2.287
   Lambrechts D, 2003, NAT GENET, V34, P383, DOI 10.1038/ng1211
   LIINAMAA MJ, 2007, EUR ASS VIS EY RES A
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786
   Ng EWM, 2006, ANN NY ACAD SCI, V1082, P151, DOI 10.1196/annals.1348.062
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Powell B, 2003, MOL VIS, V9, P460
   Ray D, 2004, DIABETES, V53, P861, DOI 10.2337/diabetes.53.3.861
   Rueda B, 2005, HUM IMMUNOL, V66, P864, DOI 10.1016/j.humimm.2005.05.004
   RUNNEBAUM IB, 1995, LANCET, V345, P994, DOI 10.1016/S0140-6736(95)90745-9
   *SEATTLESNPS, 2005, NHLBI PROGR GEN APPL
   Smith PJ, 2006, HUM MOL GENET, V15, P2490, DOI 10.1093/hmg/ddl171
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Stevens A, 2003, CANCER RES, V63, P812
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Uitenbroek DG., 1997, SISA BINOMIAL
   Vannay A, 2005, PEDIATR RES, V57, P396, DOI 10.1203/01.PDR.0000153867.80238.E0
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
NR 34
TC 86
Z9 90
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2008
VL 49
IS 8
BP 3611
EP 3616
DI 10.1167/iovs.07-1383
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 330NW
UT WOS:000257951100047
PM 18441306
DA 2022-11-30
ER

PT J
AU Bhosale, P
   Serban, B
   Zhao, DY
   Bernstein, PS
AF Bhosale, Prakash
   Serban, Bogdan
   Zhao, Da You
   Bernstein, Paul S.
TI Identification and metabolic transformations of carotenoids in ocular
   tissues of the japanese quail Coturnix japonica
SO BIOCHEMISTRY
LA English
DT Article
ID MACULAR PIGMENT; NUTRITIONAL MANIPULATION; LUTEIN SUPPLEMENTATION;
   PRIMATE RETINAS; PROTECTIVE ROLE; ZEAXANTHIN; 3'-OXOLUTEIN; RAMAN; HPLC
AB As in humans and monkeys, lutein [(3R,3'R,6'R)-beta,epsilon-carotene-3,3'-diol] and zeaxanthin [a mixture of (3R,3'R)-beta,beta-carotene-3,3'diol and (3R,3'S-meso)-beta,beta-carotene-3,3'-diol] are found in substantial amounts in the retina of the Japanese quail Coturnix japonica. This makes the quail retina an excellent nonprimate small animal model for studying the metabolic transformations of these important macular carotenoids that are thought to play an integral role in protection against light-induced oxidative damage such as that found in age-related macular degeneration (AMD). In this study, we first identified the array of carotenoids present in the quail retina using C30 HPLC coupled with in-line mass spectral and photodiode array detectors. In addition to dietary lutein (2.1%) and zeaxanthin (11.8%), we identified adonirubin (5.4%), 3'-oxolutein (3.8%), meso-zeaxanthin (3.0%), astaxanthin (28.2%), galloxanthin (12.2%), epsilon,epsilon-carotene (18.5%), and beta-apo-2'-carotenol (9.5%) as major ocular carotenoids. We next used deuterium-labeled lutein and zeaxanthin as dietary supplements to study the pharmacokinetics and metabolic transformations of these two ocular pigments in serum and ocular tissues. We then detected and quantitated labeled carotenoids in ocular tissue using both HPLC-coupled mass spectrometry and noninvasive resonance Raman spectroscopy. Results indicated that dietary zeaxanthin is the precursor of 3'-oxolutein, beta-apo-2'-carotenol, adonirubin, astaxanthin, galloxanthin, and epsilon,epsilon-carotene, whereas dietary lutein is the precursor for meso-zeaxanthin. Studies also revealed that the pharmacokinetic patterns of uptake, carotenoid absorption, and transport from serum into ocular tissues were similar to results observed in most human clinical studies.
C1 Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah
RP Bernstein, PS (通讯作者)，Univ Utah, Sch Med, Dept Ophthalmol & Visual Sci, Moran Eye Ctr, 65 Med Dr, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
FU NATIONAL EYE INSTITUTE [R01EY011600, R29EY011600] Funding Source: NIH
   RePORTER; NEI NIH HHS [R29 EY011600, R01 EY011600-09, R01 EY011600,
   EY-11600] Funding Source: Medline
CR Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2005, BIOTECHNOL LETT, V27, P1719, DOI 10.1007/s10529-005-2737-2
   Bhosale P, 2005, ANAL BIOCHEM, V345, P296, DOI 10.1016/j.ab.2005.07.006
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P1435, DOI 10.1167/iovs.06-1046
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Bhosale P, 2006, BIOTECHNOL LETT, V28, P1371, DOI 10.1007/s10529-006-9105-8
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Britton G., 1995, CAROTENOIDS B, V1B, P13
   FITE KV, 1993, EXP EYE RES, V57, P449, DOI 10.1006/exer.1993.1147
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   GOLDSMITH TH, 1984, VISION RES, V24, P1661, DOI 10.1016/0042-6989(84)90324-9
   GOODWIN TW, 1986, ANNU REV NUTR, V6, P273, DOI 10.1146/annurev.nu.06.070186.001421
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Karadas F, 2006, BRIT POULTRY SCI, V47, P200, DOI 10.1080/00071660600611003
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5476, DOI 10.1167/iovs.06-0194
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   McGraw KJ, 2002, COMP BIOCHEM PHYS B, V132, P811, DOI 10.1016/S1096-4959(02)00100-8
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   PFANDER H, 1992, METHOD ENZYMOL, V213, P3
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   STRANSKY H, 1977, J COMP PHYSIOL, V115, P265, DOI 10.1007/BF00692536
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Toyoda Y, 2002, INVEST OPHTH VIS SCI, V43, P1210
   TYCZKOWSKI JK, 1986, POULTRY SCI, V65, P2135, DOI 10.3382/ps.0652135
   Wang YM, 2007, EXP EYE RES, V84, P591, DOI 10.1016/j.exer.2006.11.013
NR 39
TC 46
Z9 50
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD AUG 7
PY 2007
VL 46
IS 31
BP 9050
EP 9057
DI 10.1021/bi700558f
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 195VA
UT WOS:000248439000015
PM 17630780
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kandel, H
   Nguyen, V
   Piermarocchi, S
   Ceklic, L
   Teo, K
   Arnalich-Montiel, F
   Miotto, S
   Daien, V
   Gillies, MC
   Watson, SL
AF Kandel, Himal
   Nguyen, Vuong
   Piermarocchi, Stefano
   Ceklic, Lala
   Teo, Kelvin
   Arnalich-Montiel, Francisco
   Miotto, Stefania
   Daien, Vincent
   Gillies, Mark C.
   Watson, Stephanie L.
TI Quality of life impact of eye diseases: a Save Sight Registries study
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; diabetic macular edema; emotional;
   keratoconus; patient-reported outcomes; Quality of life; Questionnaire;
   Rasch analysis; Retinal vein occlusion; Visual function
ID VISION IMPAIRMENT; VISUAL IMPAIRMENT; MACULAR DEGENERATION; REFRACTIVE
   ERROR; HEALTH; QUESTIONNAIRES; GUIDANCE; OUTCOMES; SELF; CARE
AB Background The objectives of this study were to evaluate the quality-of-life (QoL) impact of eye diseases (keratoconus; neovascular age-related macular degeneration, AMD; retinal vein occlusion, RVO; and diabetic macular edema, DME) using the Impact of Vision Impairment (IVI) questionnaire, and to determine the relationship between the IVI scores and visual acuity. Methods This cross-sectional, multicentre, real-world study utilised the prospective, web-based Save Sight Registries. The IVI was completed by 1557 patients: 307 with keratoconus, 1049 with AMD, 148 with RVO and 53 with DME. Statistical analysis included Rasch analysis, Welch t-test, one-way ANOVA, Tukey's test, Pearson correlation, and multiple regression. Results The IVI scales (Overall; Visual Function, VF; Emotional, EM) had robust psychometric properties. The keratoconus patients had the worst Overall (adjusted mean: 48.2 vs. DME 58.8, RVO 64.6, AMD 67.6 units), VF (47.7 vs. DME 59.4, RVO 65.9, AMD 68.9 units) and EM (50.8 vs. DME 63.1, RVO 69.2, AMD 71.8 units) scores (all p < 0.05). The IVI scales scores weakly correlated with better and worse eye visual acuity (Pearson's r 0.24-0.39, all p < 0.05). The correlations were similar in the better eye (Overall 0.35, VF 0.39, EM 0.24) and the worse eye (Overall 0.31, VF 0.33, EM 0.25) visual acuity. Correlations with visual acuity were stronger for VF than for the EM scores. Conclusions The IVI was a psychometrically robust QoL questionnaire. Keratoconus patients had worse IVI scores than patients with retinal diseases. The low strength of correlations between visual acuity and QoL scores, although statistically significant, suggested that a complex relationship exists.
C1 [Kandel, Himal; Nguyen, Vuong; Gillies, Mark C.; Watson, Stephanie L.] Univ Sydney, Fac Med & Hlth, Save Sight Inst, South Block,Level 1,8 Macquarie St, Sydney, NSW 2000, Australia.
   [Piermarocchi, Stefano; Miotto, Stefania] Padua Camposampiero Hosp, Dept Ophthalmol, Padua, Italy.
   [Ceklic, Lala] Ctr Zastitu Vida Pale, Eastern Sarajevo, Bosnia & Herceg.
   [Teo, Kelvin] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
   [Arnalich-Montiel, Francisco] IRYCIS, Hosp Univ Ramon y Cajal, Cornea & External Eye Dis, Madrid, Spain.
   [Daien, Vincent] Univ Hosp Montpellier, Ophthalmol, Montpellier, France.
C3 University of Sydney; National University of Singapore; Singapore
   National Eye Center; Hospital Universitario Ramon y Cajal; Universite de
   Montpellier; CHU de Montpellier
RP Kandel, H (通讯作者)，Univ Sydney, Fac Med & Hlth, Save Sight Inst, South Block,Level 1,8 Macquarie St, Sydney, NSW 2000, Australia.
EM himal.kandel@sydney.edu.au
RI Arnalich, Francisco/K-7723-2014; Watson, Stephanie/ABE-5488-2020;
   Kandel, Himal/Q-1031-2018; Daien, Vincent/Z-5516-2019
OI Watson, Stephanie/0000-0001-6699-1765; Kandel,
   Himal/0000-0002-6745-6411; Gillies, mark/0000-0001-8580-0274; Daien,
   Vincent/0000-0001-5675-0861; Arnalich-Montiel,
   Francisco/0000-0002-1229-2018; Nguyen, Vuong/0000-0001-9070-9803
FU Claffy Foundation; Keratoconus Australia; Ophthalmic Research Institute
   of Australia; Sydney Medical School Foundation; Royal Australian and New
   Zealand College of Ophthalmologists Eye Foundation; National Health and
   Medical Research Council; Mr Larry Kornhauser, OAM
FX Claffy Foundation; Keratoconus Australia; Mr Larry Kornhauser, OAM;
   Ophthalmic Research Institute of Australia; Sydney Medical School
   Foundation; Royal Australian and New Zealand College of Ophthalmologists
   Eye Foundation; National Health and Medical Research Council
CR Akoglu H, 2018, TURK J EMERG MED, V18, P91, DOI 10.1016/j.tjem.2018.08.001
   Aryadoust V, 2021, LANG TEST, V38, P6, DOI 10.1177/0265532220927487
   Atkinson TM, 2012, QUAL LIFE RES, V21, P1159, DOI 10.1007/s11136-011-0031-4
   Boone WJ, 2016, CBE-LIFE SCI EDUC, V15, DOI 10.1187/cbe.16-04-0148
   Bottomley A, 2016, LANCET ONCOL, V17, pE510, DOI 10.1016/S1470-2045(16)30510-1
   Broman AT, 2002, INVEST OPHTH VIS SCI, V43, P3393
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Chiang PPC, 2013, OPHTHALMOLOGY, V120, P415, DOI 10.1016/j.ophtha.2012.07.077
   Clayton JA, 2015, CURR EYE RES, V40, P102, DOI 10.3109/02713683.2014.986333
   Fehnel S, 2013, EXPERT REV PHARM OUT, V13, P441, DOI 10.1586/14737167.2013.814957
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P686, DOI 10.1136/bjophthalmol-2016-308701
   Fenwick EK, 2016, JAMA OPHTHALMOL, V134, P1087, DOI 10.1001/jamaophthalmol.2016.2394
   Ferdi A, 2022, BRIT J OPHTHALMOL, V106, P1206, DOI 10.1136/bjophthalmol-2020-317547
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032
   Finger RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081042
   Finger RP, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-113
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P3613, DOI 10.1167/iovs.10-7127
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Kandel H, 2021, INVEST OPHTH VIS SCI, V62
   Kandel H, 2022, CLIN EXP OPTOM, V105, P96, DOI 10.1080/08164622.2021.1924626
   Kandel H, 2021, CORNEA, V40, P1581, DOI 10.1097/ICO.0000000000002747
   Kandel H, 2021, OPHTHAL PHYSL OPT, V41, P591, DOI 10.1111/opo.12792
   Kandel H, 2021, J ALLER CL IMM-PRACT, V9, P595, DOI 10.1016/j.jaip.2020.09.067
   Kandel H, 2020, CORNEA, V39, P303, DOI 10.1097/ICO.0000000000002169
   Kandel H, 2020, CORNEA, V39, P386, DOI 10.1097/ICO.0000000000002170
   Kandel H, 2017, OPTOMETRY VISION SCI, V94, P1102, DOI 10.1097/OPX.0000000000001143
   Kandel H, 2017, NEW ENGL J MED, V377, P2096, DOI 10.1056/NEJMc1712573
   Kandel H, 2017, CLIN EXP OPHTHALMOL, V45, P677, DOI 10.1111/ceo.12954
   Kandel H, 2017, J REFRACT SURG, V33, P416, DOI 10.3928/1081597X-20170310-01
   Khadka J, 2013, OPTOMETRY VISION SCI, V90, P720, DOI 10.1097/OPX.0000000000000001
   Kymes SM, 2004, AM J OPHTHALMOL, V138, P527, DOI 10.1016/j.ajo.2004.04.031
   Lamoureux E, 2010, GRAEF ARCH CLIN EXP, V248, P527, DOI 10.1007/s00417-009-1260-x
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Massof RW, 2002, OPTOMETRY VISION SCI, V79, P516, DOI 10.1097/00006324-200208000-00015
   McLeod LD, 2011, EXPERT REV PHARM OUT, V11, P163, DOI [10.1586/erp.11.12, 10.1586/ERP.11.12]
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Nutheti R, 2007, OPHTHALMOLOGY, V114, P1552, DOI 10.1016/j.ophtha.2006.11.012
   Pearson AR, 2000, EYE, V14, P625, DOI 10.1038/eye.2000.154
   Pesudovs K., 2006, BMC OPHTHALMOLOGY, V6, P1, DOI DOI 10.1186/1471-2415-6-25
   Piemarocchi S, 2011, EUR J OPHTHALMOL, V21, P55, DOI 10.5301/EJO.2010.1519
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Scott AW, 2016, JAMA OPHTHALMOL, V134, P1111, DOI 10.1001/jamaophthalmol.2016.2627
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Unden AL, 2008, GENDER MED, V5, P162, DOI 10.1016/j.genm.2008.05.003
   Wysong A, 2009, ARCH OPHTHALMOL-CHIC, V127, P320, DOI 10.1001/archophthalmol.2008.613
   Zwick R, 1999, J EDUC MEAS, V36, P1, DOI 10.1111/j.1745-3984.1999.tb00543.x
NR 49
TC 1
Z9 1
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAY
PY 2022
VL 50
IS 4
BP 386
EP 397
DI 10.1111/ceo.14050
EA FEB 2022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2D8NZ
UT WOS:000751989500001
PM 35080803
OA Green Published
DA 2022-11-30
ER

PT J
AU Li, X
   Cai, SC
   He, ZM
   Reilly, J
   Zeng, ZH
   Strang, N
   Shu, XH
AF Li, Xing
   Cai, Shichang
   He, Zhiming
   Reilly, James
   Zeng, Zhihong
   Strang, Niall
   Shu, Xinhua
TI Metabolomics in Retinal Diseases: An Update
SO BIOLOGY-BASEL
LA English
DT Review
DE metabolomics; retinopathy; age-related macular degeneration; diabetic
   retinopathy; retinitis pigmentosa; retinopathy of premature; glaucoma
ID SPECTROMETRY-BASED METABOLOMICS; AQUEOUS-HUMOR; MASS-SPECTROMETRY;
   MACULAR DEGENERATION; DIABETIC-RETINOPATHY; MITOCHONDRIAL DYSFUNCTION;
   GLOBAL PREVALENCE; OXIDATIVE STRESS; GLAUCOMA; PLASMA
AB Simple Summary</p>
   Visual loss and blindness caused by retinal disease has a significant negative effect on the quality of life of many adults and children, and as a result has become a global public health concern. In the early stage, the majority of retinal diseases have no obvious symptoms and, during disease progression, current therapeutic options, such as surgery, laser photocoagulation, and anti-VEGF agents, all have significant limitations. Furthermore, the pathophysiological mechanisms underlying retinal disease have not been fully delineated. These issues highlight the importance of developing more effective screening strategies and/or diagnostic biomarkers to improve retinal disease outcomes. Metabolomics are a promising tool for discovering various biomarkers that improve understanding of the pathogenesis of retinal disease. Here, we will review the impact of metabolomics in addressing the above challenges.</p>
   Retinal diseases are a leading cause of visual loss and blindness, affecting a significant proportion of the population worldwide and having a detrimental impact on quality of life, with consequent economic burden. The retina is highly metabolically active, and a number of retinal diseases are associated with metabolic dysfunction. To better understand the pathogenesis underlying such retinopathies, new technology has been developed to elucidate the mechanism behind retinal diseases. Metabolomics is a relatively new "omics " technology, which has developed subsequent to genomics, transcriptomics, and proteomics. This new technology can provide qualitative and quantitative information about low-molecular-weight metabolites (M.W. < 1500 Da) in a given biological system, which shed light on the physiological or pathological state of a cell or tissue sample at a particular time point. In this article we provide an extensive review of the application of metabolomics to retinal diseases, with focus on age-related macular degeneration (AMD), diabetic retinopathy (DR), retinopathy of prematurity (ROP), glaucoma, and retinitis pigmentosa (RP).</p>
C1 [Li, Xing; He, Zhiming; Shu, Xinhua] Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Peoples R China.
   [Cai, Shichang] Hunan Univ Med, Sch Med, Dept Human Anat, Huaihua 418000, Peoples R China.
   [Reilly, James; Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Zeng, Zhihong] Changsha Univ, Coll Biol & Environm Engn, Changsha 410022, Peoples R China.
   [Strang, Niall; Shu, Xinhua] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
C3 Shaoyang University; Glasgow Caledonian University; Changsha University;
   Glasgow Caledonian University
RP Shu, XH (通讯作者)，Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Peoples R China.; Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.; Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
EM lixing3971@hnsyu.edu.cn; caishichang2008@163.com; 40003@hnsyu.edu.cn;
   J.Reilly@gcu.ac.uk; z20181201@ccsu.edu.cn; N.Strang@gcu.ac.uk;
   Xinhua.Shu@gcu.ac.uk
RI Zeng, Zhihong/HEV-8703-2022
OI Cai, Shichang/0000-0002-6320-6423; Shu, Xinhua/0000-0003-3760-3019
FU Shaoyang University; Rosetrees Trust [M160, M160-F1, M160-F2]; Sight
   Research UK [SAC037]; Lotus Scholarship Program of Hunan Province (2019)
FX X.L. was supported by a Startup Fund of Shaoyang University. X.S. was
   supported by the Rosetrees Trust (M160, M160-F1, M160-F2), Sight
   Research UK (SAC037), and the Lotus Scholarship Program of Hunan
   Province (2019).
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Adams GGW, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013366
   Aderemi AV, 2021, METABOLITES, V11, DOI 10.3390/metabo11070418
   Agnifili L, 2012, ACTA OPHTHALMOL, V90, pe132, DOI 10.1111/j.1755-3768.2011.02255.x
   Alamri A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061387
   Alseekh S, 2021, NAT METHODS, V18, P747, DOI 10.1038/s41592-021-01197-1
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P823
   Antonetti DA, 2021, NAT REV ENDOCRINOL, V17, P195, DOI 10.1038/s41574-020-00451-4
   Arroba AI, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00203
   Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Barba I, 2010, INVEST OPHTH VIS SCI, V51, P4416, DOI 10.1167/iovs.10-5348
   Barbosa-Breda J, 2018, OPHTHALMIC RES, V59, P1, DOI 10.1159/000479158
   Bjerkhaug AU, 2021, ACTA PAEDIATR, V110, P2316, DOI 10.1111/apa.15874
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Breda JB, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108268
   Buisset A, 2019, J PROTEOME RES, V18, P1307, DOI 10.1021/acs.jproteome.8b00915
   Burgess LG, 2015, INVEST OPHTH VIS SCI, V56, P5020, DOI 10.1167/iovs.15-16702
   Cabrerizo J, 2017, J GLAUCOMA, V26, P349, DOI 10.1097/IJG.0000000000000603
   Chaleckis R, 2019, CURR OPIN BIOTECH, V55, P44, DOI 10.1016/j.copbio.2018.07.010
   Chao JR, 2017, J BIOL CHEM, V292, P12895, DOI 10.1074/jbc.M117.788422
   Chen LY, 2016, DIABETES, V65, P1099, DOI 10.2337/db15-0661
   Chen XL, 2019, MOL VIS, V25, P489
   Civan MM, 2004, EXP EYE RES, V78, P625, DOI 10.1016/j.exer.2003.09.021
   Curovic VR, 2020, DIABETES, V69, P2217, DOI 10.2337/db20-0104
   D'Alessandro A, 2014, MOL BIOSYST, V10, P1290, DOI 10.1039/c3mb70362b
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   de la Barca JMC, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030631
   Delvaux A, 2022, MASS SPECTROM REV, V41, P695, DOI 10.1002/mas.21685
   Deng P, 2019, REV ENVIRON HEALTH, V34, P251, DOI 10.1515/reveh-2019-0030
   DiCarlo JE, 2018, J CLIN INVEST, V128, P2177, DOI 10.1172/JCI120429
   Donato L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073484
   Donato L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010070
   Early Treatment Diab, 2020, OPHTHALMOLOGY, V127, pS99, DOI 10.1016/j.ophtha.2020.01.030
   Edison AS, 2019, METHODS MOL BIOL, V2037, P69, DOI 10.1007/978-1-4939-9690-2_5
   Eid S, 2019, DIABETOLOGIA, V62, P1539, DOI 10.1007/s00125-019-4959-1
   Gallenga CE, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10060848
   Gao Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58346-3
   Gargallo-Garriga A, 2020, MOLECULES, V25, DOI 10.3390/molecules25173960
   Ge N, 2021, RSC ADV, V11, P5491, DOI 10.1039/d0ra00343c
   Geier B, 2020, NAT MICROBIOL, V5, P498, DOI 10.1038/s41564-019-0664-6
   Georgakopoulou I, 2020, METABOLOMICS, V16, DOI 10.1007/s11306-020-01680-4
   Go YM, 2020, FASEB J, V34, P12502, DOI 10.1096/fj.202000612R
   Gong HJ, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2020.107921
   Haines NR, 2018, J PROTEOME RES, V17, P2421, DOI 10.1021/acs.jproteome.8b00169
   Hamel C, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-40
   Han GG, 2020, J PROTEOME RES, V19, P2358, DOI 10.1021/acs.jproteome.0c00036
   Harder JM, 2020, P NATL ACAD SCI USA, V117, P33619, DOI 10.1073/pnas.2014213117
   Heberle H, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0611-3
   Heiles S, 2021, ANAL BIOANAL CHEM, V413, P5927, DOI 10.1007/s00216-021-03425-1
   Homma K, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101921
   Hou XW, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.13
   Hu KF, 2011, J AM CHEM SOC, V133, P1662, DOI 10.1021/ja1095304
   Hussain RM, 2021, DRUG DES DEV THER, V15, P2653, DOI 10.2147/DDDT.S295223
   Hysi PG, 2019, REDOX BIOL, V20, P349, DOI 10.1016/j.redox.2018.10.004
   Jin HY, 2019, J PHARMACEUT BIOMED, V174, P414, DOI 10.1016/j.jpba.2019.06.013
   Karnovsky A, 2020, METHODS MOL BIOL, V2104, P387, DOI 10.1007/978-1-0716-0239-3_19
   Karu N, 2018, ANAL CHIM ACTA, V1030, P1, DOI 10.1016/j.aca.2018.05.031
   Kersten E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218457
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Kim SJ, 2018, SURV OPHTHALMOL, V63, P618, DOI 10.1016/j.survophthal.2018.04.002
   Kumarasamy NA, 2006, EUR J INFLAMM, V4, P129, DOI [10.1177/1721727X0600400301, DOI 10.1177/1721727X0600400301, 10.1177/1721727x0600400301]
   Kunikata H, 2017, SCI REP-UK, V7, DOI 10.1038/srep41984
   Kutsyr O, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86052-1
   Lains I, 2019, METABOLITES, V9, DOI 10.3390/metabo9070127
   Lains I, 2019, J PROTEOME RES, V18, P1278, DOI 10.1021/acs.jproteome.8b00877
   Lains I, 2019, PROG RETIN EYE RES, V69, P57, DOI 10.1016/j.preteyeres.2018.11.002
   Lains I, 2018, OPHTHALMOLOGY, V125, P245, DOI 10.1016/j.ophtha.2017.08.008
   Lains I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177749
   Lambert V, 2020, J MOL MED, V98, P1737, DOI 10.1007/s00109-020-01994-9
   Lefevere E, 2017, MITOCHONDRION, V36, P66, DOI 10.1016/j.mito.2017.03.006
   Leruez S, 2018, INVEST OPHTH VIS SCI, V59, P4355, DOI 10.1167/iovs.18-24938
   Li DP, 2021, ANNU REV PLANT BIOL, V72, P867, DOI 10.1146/annurev-arplant-071720-114836
   Li ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep38342
   Li SB, 2021, CRIT REV FOOD SCI, V61, P1448, DOI 10.1080/10408398.2020.1761287
   Li X, 2011, MOL BIOSYST, V7, P2228, DOI 10.1039/c0mb00341g
   Lin AL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207451
   Liu K, 2020, J PROTEOME RES, V19, P699, DOI 10.1021/acs.jproteome.9b00574
   Lu F, 2020, EXP EYE RES, V190, DOI 10.1016/j.exer.2019.107855
   Luo D, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0555-7
   Makela V, 2016, J MAGN RESON, V271, P34, DOI 10.1016/j.jmr.2016.08.003
   Marchand J, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-018-1360-x
   Marchetti V, 2011, SCI REP-UK, V1, DOI 10.1038/srep00076
   Marcovecchio ML, 2020, MOL DIAGN THER, V24, P507, DOI 10.1007/s40291-020-00483-6
   Martineau E, 2020, MAGN RESON CHEM, V58, P390, DOI 10.1002/mrc.4899
   Mazumder AG, 2017, CLIN OPHTHALMOL, V11, P2073, DOI 10.2147/OPTH.S140110
   Mendez KM, 2021, METABOLITES, V11, DOI 10.3390/metabo11030183
   Micera A, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.601647
   Midena E, 2021, GRAEF ARCH CLIN EXP, V259, P3549, DOI 10.1007/s00417-021-05285-y
   Mitchell SL, 2018, INVEST OPHTH VIS SCI, V59, P4978, DOI 10.1167/iovs.18-25137
   Mussap M, 2013, CLIN CHIM ACTA, V426, P127, DOI 10.1016/j.cca.2013.08.020
   Myer C, 2020, MOL OMICS, V16, P425, DOI 10.1039/c9mo00192a
   Myer C, 2020, EXP EYE RES, V194, DOI 10.1016/j.exer.2020.108024
   Nazifova-Tasinova N, 2020, BIOMED PAP, V164, P236, DOI 10.5507/bp.2020.028
   Nzoughet JK, 2020, METABOLITES, V10, DOI 10.3390/metabo10020049
   Olesti E, 2021, ANALYST, V146, P1820, DOI 10.1039/d0an02212h
   Osada H, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03741-5
   Osborn MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072737
   Pan CW, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01452-7
   Pang ZQ, 2021, NUCLEIC ACIDS RES, V49, pW388, DOI 10.1093/nar/gkab382
   Pareek V, 2020, SCIENCE, V368, P283, DOI 10.1126/science.aaz6465
   Paris LP, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-015-0877-5
   Park KS, 2018, CELL MOL LIFE SCI, V75, P1559, DOI 10.1007/s00018-018-2744-9
   Patrick AT, 2020, J DIABETES METAB DIS, V19, P829, DOI 10.1007/s40200-020-00570-9
   Peng LY, 2018, BIOCHEM BIOPH RES CO, V496, P1276, DOI 10.1016/j.bbrc.2018.01.188
   Pereiro X, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77087-x
   Peterson DJ, 2007, MAGN RESON CHEM, V45, P937, DOI 10.1002/mrc.2073
   Petras D, 2017, CURR OPIN CHEM BIOL, V36, P24, DOI 10.1016/j.cbpa.2016.12.018
   Pinu FR, 2019, METABOLITES, V9, DOI 10.3390/metabo9060108
   Pulukool SK, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89137-z
   Qin YT, 2022, ACTA OPHTHALMOL, V100, pE204, DOI 10.1111/aos.14874
   Rhee SY, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-018-1383-3
   Rong SZ, 2017, BIOMED CHROMATOGR, V31, DOI 10.1002/bmc.3963
   Rosell M, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8100447
   Rossi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20164029
   Sabanayagam C, 2019, LANCET DIABETES ENDO, V7, P140, DOI 10.1016/S2213-8587(18)30128-1
   Sas KM, 2018, J LIPID RES, V59, P173, DOI 10.1194/jlr.M077222
   Schwartzman ML, 2010, DIABETES, V59, P1780, DOI 10.2337/db10-0110
   Scimone C, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108641
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sen P, 2020, EYE, V34, P632, DOI 10.1038/s41433-019-0643-4
   Singh C, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129398
   Sissler M, 2017, TRENDS MOL MED, V23, P693, DOI 10.1016/j.molmed.2017.06.002
   Smith LEH, 2004, GROWTH HORM IGF RES, V14, pS140, DOI 10.1016/j.ghir.2004.03.030
   Stein JD, 2021, JAMA-J AM MED ASSOC, V325, P164, DOI 10.1001/jama.2020.21899
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Sumarriva K, 2019, INVEST OPHTH VIS SCI, V60, P3119, DOI 10.1167/iovs.19-27321
   Szabados L, 2010, TRENDS PLANT SCI, V15, P89, DOI 10.1016/j.tplants.2009.11.009
   Takayanagi Y, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121305
   Tang YZ, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.621146
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Ting DSW, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0812-9
   Tomita Y, 2021, DIABETOLOGIA, V64, P70, DOI 10.1007/s00125-020-05309-y
   Tribble JR, 2021, REDOX BIOL, V43, DOI 10.1016/j.redox.2021.101988
   Wang HY, 2020, ACTA DIABETOL, V57, P41, DOI 10.1007/s00592-019-01363-0
   Wang JH, 2016, PHILOS T R SOC A, V374, DOI 10.1098/rsta.2015.0376
   Wang RH, 2019, ANAL BIOANAL CHEM, V411, P4349, DOI 10.1007/s00216-019-01709-1
   Wang X, 2020, BIOMED CHROMATOGR, V34, DOI 10.1002/bmc.4792
   Wang Y, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.6.9
   Weiss ER, 2019, EXP EYE RES, V184, P135, DOI 10.1016/j.exer.2019.03.007
   Wert KJ, 2020, EBIOMEDICINE, V52, DOI 10.1016/j.ebiom.2020.102636
   Wiggenhauser LM, 2020, DIABETES, V69, P1020, DOI 10.2337/db19-0873
   Wishart DS, 2019, PHYSIOL REV, V99, P1819, DOI 10.1152/physrev.00035.2018
   Wishart DS, 2019, J MAGN RESON, V306, P155, DOI 10.1016/j.jmr.2019.07.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xuan QH, 2020, ADV SCI, V7, DOI 10.1002/advs.202001714
   Xuan QH, 2020, ANAL BIOANAL CHEM, V412, P3585, DOI 10.1007/s00216-020-02632-6
   Yam M, 2019, J BIOL CHEM, V294, P10278, DOI 10.1074/jbc.RA119.007983
   Yang YH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.12
   Yun JH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241365
   Zhang E, 2020, MAMM GENOME, V31, P77, DOI 10.1007/s00335-020-09837-1
   Zhang LJ, 2016, HUM MOL GENET, V25, P4244, DOI 10.1093/hmg/ddw256
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zhang R, 2021, J PROTEOME RES, V20, P909, DOI 10.1021/acs.jproteome.0c00690
   Zhang R, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03103-7
   Zhang XW, 2020, RSC ADV, V10, P3092, DOI 10.1039/c9ra08985c
   Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073197
   Zhou YD, 2020, EXP EYE RES, V199, DOI 10.1016/j.exer.2020.108198
   Zhu XR, 2019, NUTR METAB, V16, DOI 10.1186/s12986-019-0358-3
   Zuo JJ, 2021, BMJ OPEN DIAB RES CA, V9, DOI 10.1136/bmjdrc-2020-001443
NR 159
TC 2
Z9 2
U1 11
U2 25
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-7737
J9 BIOLOGY-BASEL
JI Biology-Basel
PD OCT
PY 2021
VL 10
IS 10
AR 944
DI 10.3390/biology10100944
PG 25
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA WN4LN
UT WOS:000711741400001
PM 34681043
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhao, XH
   Gao, M
   Liang, J
   Chen, YH
   Wang, YM
   Wang, YW
   Xiao, YS
   Zhao, ZZ
   Wan, XL
   Jiang, M
   Luo, XT
   Wang, F
   Sun, XD
AF Zhao, Xiaohuan
   Gao, Min
   Liang, Jian
   Chen, Yuhong
   Wang, Yimin
   Wang, Yuwei
   Xiao, Yushu
   Zhao, Zhenzhen
   Wan, Xiaoling
   Jiang, Mei
   Luo, Xueting
   Wang, Feng
   Sun, Xiaodong
TI SLC7A11 Reduces Laser-Induced Choroidal Neovascularization by Inhibiting
   RPE Ferroptosis and VEGF Production
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE RPE; ferroptosis; VEGF; CNV
ID MACULAR DEGENERATION; OXIDATIVE STRESS; LIPID-PEROXIDATION; CELL-DEATH;
   SECRETION; MECHANISM; INJURY; RISK
AB In age-related macular degeneration (AMD), one of the principal sources of vascular endothelial growth factor (VEGF) is retinal pigment epithelium (RPE) cells under hypoxia or oxidative stress. Solute carrier family 7 member 11 (SLC7A11), a key component of cystine/glutamate transporter, regulates the level of cellular lipid peroxidation, and restrains ferroptosis. In our study, we assessed the role of SLC7A11 in laser-induced choroidal neovascularization (CNV) and explored the underlying mechanism. We established a mouse model of CNV to detect the expression level of SLC7A11 and VEGF during disease progression. We found the expression of the SLC7A11 protein in RPE cells peaked at 3 days after laser treatment, which was correlated with the expression of VEGF. Intraperitoneal injection of SLC7A11 inhibitor expanded the area of CNV. We examined functional proteins related to oxidative stress and Fe2+ and found laser-induced ferroptosis accompanied by increased Fe2+ content and GPX4 expression in the RPE-choroidal complex after laser treatment. We verified the expression of SLC7A11 in the ARPE19 cell line and the effects of its inhibitors on cell viability and lipid peroxidation in vitro. Application of SLC7A11 inhibitor and SLC7A11 knockdown increased the level of lipid peroxidation and reduced the cell viability of ARPE19 which can be rescued by ferroptosis inhibitors ferrostatin-1 (Fer-1) and liproxstatin-1 (Lip-1). Conversely, SLC7A11 overexpression induced resistance to erastin or RSL3-induced ferroptosis. Moreover, we tested the possible regulatory transcription factor NF-E2-related factor 2 (NRF2) of SLC7A11 by Western blot. Knock-down of NRF2 decreased the expression of SLC7A11. Our study suggests that SLC7A11 plays a key role in the laser-induced CNV model by protecting RPE cells from ferroptosis. SLC7A11 provides a new therapeutic target for neovascular AMD patients.
C1 [Zhao, Xiaohuan; Gao, Min; Liang, Jian; Chen, Yuhong; Wang, Yimin; Wang, Yuwei; Xiao, Yushu; Zhao, Zhenzhen; Wan, Xiaoling; Jiang, Mei; Luo, Xueting; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
   [Zhao, Xiaohuan; Gao, Min; Liang, Jian; Chen, Yuhong; Wang, Yimin; Wang, Yuwei; Xiao, Yushu; Zhao, Zhenzhen; Wan, Xiaoling; Jiang, Mei; Luo, Xueting; Sun, Xiaodong] Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.
   [Zhao, Xiaohuan; Gao, Min; Liang, Jian; Chen, Yuhong; Wang, Yimin; Wang, Yuwei; Xiao, Yushu; Zhao, Zhenzhen; Wan, Xiaoling; Jiang, Mei; Luo, Xueting; Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
   [Zhao, Xiaohuan; Gao, Min; Liang, Jian; Chen, Yuhong; Wang, Yimin; Wang, Yuwei; Xiao, Yushu; Zhao, Zhenzhen; Wan, Xiaoling; Jiang, Mei; Luo, Xueting; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Wang, Feng] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Ctr Microbiota & Immunol Dis, Shanghai Inst Immunol,Dept Immunol & Microbiol, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Jiao Tong University
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.; Sun, XD (通讯作者)，Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.; Wang, F (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Ctr Microbiota & Immunol Dis, Shanghai Inst Immunol,Dept Immunol & Microbiol, Shanghai, Peoples R China.
EM wangfeng16@sjtu.edu.cn; xdsun@sjtu.edu.cn
OI Sun, Xiaodong/0000-0001-5015-0945
FU National Natural Science Foundation of China [81730026]; National Key RD
   Program [2017YFA0105301]; National Major Scientific and Technological
   Special Project for "Significant New Drugs Development"
   [2019ZX09301113]; Science and Technology Commission of Shanghai
   Municipality [17411953000, 19495800700]; Shanghai Collaborative
   Innovation Center for Translational Medicine [TM201917]; Shanghai
   Institutions of Higher Learning; Top Young Talent Program of Shanghai
FX This study was supported by grants from the National Natural Science
   Foundation of China (81730026), the National Key R&D Program
   (2017YFA0105301), the National Major Scientific and Technological
   Special Project for "Significant New Drugs Development" during the
   Thirtieth Five-year Plan Period (2019ZX09301113), the Science and
   Technology Commission of Shanghai Municipality (17411953000 and
   19495800700), Shanghai Collaborative Innovation Center for Translational
   Medicine (TM201917) to XS, the Program for Professor of Special
   Appointments (Eastern Scholar) at Shanghai Institutions of Higher
   Learning, and the Top Young Talent Program of Shanghai to FW.
CR Al Gwairi O., 2016, J OPHTHALMOL, V2016
   Al-Latayfeh M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006411
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arjamaa O, 2017, GRAEF ARCH CLIN EXP, V255, P1757, DOI 10.1007/s00417-017-3711-0
   Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Christova Y, 2004, MOL REPROD DEV, V68, P365, DOI 10.1002/mrd.20084
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344
   Kannan R, 2006, MOL VIS, V12, P1649
   Koppula P, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0288-x
   Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338
   Lee JJ, 2020, BIOCHEM BIOPH RES CO, V521, P414, DOI 10.1016/j.bbrc.2019.10.138
   Li YC, 2020, TOXICOL LETT, V321, P12, DOI 10.1016/j.toxlet.2019.12.011
   Linares V, 2011, EXPERT OPIN DRUG SAF, V10, P253, DOI 10.1517/14740338.2011.529898
   Liu D.S., 2017, NAT COMMUN, V8
   Nasca C, 2017, NEURON, V96, P402, DOI 10.1016/j.neuron.2017.09.020
   Nazari M, 2014, BMC BIOTECHNOL, V14, DOI 10.1186/s12896-014-0087-7
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   Paeng SH, 2015, INT J MOL MED, V35, P1419, DOI 10.3892/ijmm.2015.2116
   Rosenberg M., 2019, SCI REP-UK, V9
   Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Shin C.S., 2017, NAT COMMUN, V8
   Sun Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0794-4
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019
   Wong W.L., 2014, LANCET GLOB HEALTH, V2, P106
   Xiao M, 2019, FASEB J, V33, P13920, DOI DOI 10.1096/FJ.201901283RR
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Yu HT, 2017, J CELL MOL MED, V21, P648, DOI 10.1111/jcmm.13008
   Zheng Z., 2020, CELL ONCOL, V43, P95, DOI [10.1007/s13402-019-00474-8, DOI 10.1007/S13402-019-00474-8]
   Zilka O, 2017, ACS CENTRAL SCI, V3, P232, DOI 10.1021/acscentsci.7b00028
NR 38
TC 6
Z9 7
U1 4
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD FEB 18
PY 2021
VL 9
AR 639851
DI 10.3389/fcell.2021.639851
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA QR4DP
UT WOS:000625161400001
PM 33681224
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Orhan, C
   Tuzcu, M
   Gencoglu, H
   Sahin, E
   Sahin, N
   Ozercan, IH
   Namjoshi, T
   Srivastava, V
   Morde, A
   Rai, D
   Padigaru, M
   Sahin, K
AF Orhan, Cemal
   Tuzcu, Mehmet
   Gencoglu, Hasan
   Sahin, Emre
   Sahin, Nurhan
   Ozercan, Ibrahim Hanifi
   Namjoshi, Tejas
   Srivastava, Vandita
   Morde, Abhijeet
   Rai, Deshanie
   Padigaru, Muralidhara
   Sahin, Kazim
TI Different Doses of beta-Cryptoxanthin May Secure the Retina from
   Photooxidative Injury Resulted from Common LED Sources
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
AB Retinal damage associated with loss of photoreceptors is a hallmark of eye diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. Potent nutritional antioxidants were previously shown to abate the degenerative process in AMD. beta-Cryptoxanthin (BCX) is an essential dietary carotenoid with antioxidant, anti-inflammatory, and provitamin A activity. It is a potential candidate for developing intervention strategies to delay the development/progression of AMD. In the current study, the effect of a novel, highly purified BCX oral formulation on the rat retinal damage model was evaluated. Rats were fed with BCX for four weeks at the doses of 2 and 4 mg/kg body weight in the form of highly bioavailable oil suspension, followed by retinal damage by exposing to the bright light-emitting diode (LED) light (750 lux) for 48 hrs. Animals were sacrificed after 48 hours, and eyes and blood samples were collected and analyzed. BCX supplementations (2 and 4 mg/kg) showed improvements in the visual condition as demonstrated by histopathology of the retina and measured parameters such as total retinal thickness and outer nuclear layer thickness. BCX supplementation helped reduce the burden of oxidative stress as seen by decreased serum and retinal tissue levels of malondialdehyde (MDA) and restored the antioxidant enzyme activities in BCX groups. Further, BCX supplementation modulated inflammatory markers (IL-1 beta, IL-6, and NF-kappa B), apoptotic proteins (Bax, Bcl-2, caspase 3), growth proteins and factors (GAP43, VEGF), glial and neuronal proteins (GFAP, NCAM), and heme oxygenase-1 (HO-1), along with the mitochondrial stress markers (ATF4, ATF6, Grp78, Grp94) in the rat retinal tissue. This study indicates that oral supplementation of BCX exerts a protective effect on light-induced retinal damage in the rats via reducing oxidative stress and inflammation, also protected against mitochondrial DNA damage and cellular death.
C1 [Orhan, Cemal; Sahin, Emre; Sahin, Nurhan; Sahin, Kazim] Firat Univ, Fac Vet Sci, Dept Anim Nutr, TR-23119 Elazig, Turkey.
   [Tuzcu, Mehmet; Gencoglu, Hasan] Firat Univ, Fac Sci, Div Biol, TR-23119 Elazig, Turkey.
   [Ozercan, Ibrahim Hanifi] Firat Univ, Fac Med, Dept Pathol, TR-23119 Elazig, Turkey.
   [Namjoshi, Tejas; Srivastava, Vandita] OmniAct Hlth Technol, Biotechnol Pk, Pune 411057, Maharashtra, India.
   [Morde, Abhijeet; Padigaru, Muralidhara] OmniAct Hlth Technol, Wagle Estate, Thana 400604, India.
   [Rai, Deshanie] OmniAct Hlth Technol Inc, Morristown, NJ 07960 USA.
C3 Firat University; Firat University; Firat University
RP Sahin, K (通讯作者)，Firat Univ, Fac Vet Sci, Dept Anim Nutr, TR-23119 Elazig, Turkey.
EM nsahinkm@yahoo.com
RI Orhan, Cemal/Q-2086-2015; GENCOGLU, HASAN/Q-2668-2015; Sahin,
   Kazim/D-5625-2009; ÖZERCAN, ibrahim Hanifi/W-7883-2018; Sahin,
   Emre/B-1871-2018; Tuzcu, Mehmet/H-2953-2018
OI Orhan, Cemal/0000-0003-4138-7689; GENCOGLU, HASAN/0000-0002-7716-552X;
   Sahin, Kazim/0000-0001-9542-5244; ÖZERCAN, ibrahim
   Hanifi/0000-0002-8781-8838; Sahin, Emre/0000-0001-7625-1883; Tuzcu,
   Mehmet/0000-0002-1329-3143
FU OmniActive Health Technologies (Morristown, NJ, USA); Turkish Academy of
   Science (Turkey); OmniActive Health Technologies (Thane, India)
FX The authors thank OmniActive Health Technologies (Morristown, NJ, USA
   and Thane, India) and the Turkish Academy of Science (in part, KS,
   Turkey). This work was supported by OmniActive Health Technologies
   (Morristown, NJ, USA, and Thane, India) and in part by the Turkish
   Academy of Science (Turkey). The funders had no role in the project
   design, data collection, data analyses, and interpretation.
CR Ali D, 2011, TOXICOL LETT, V204, P199, DOI 10.1016/j.toxlet.2011.04.033
   Ali D, 2010, TOXICOL LETT, V199, P193, DOI 10.1016/j.toxlet.2010.08.023
   Amengual J, 2013, J BIOL CHEM, V288, P34081, DOI 10.1074/jbc.M113.501049
   Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020
   Arantes-Rodrigues R, 2012, LAB ANIMAL, V41, P129, DOI 10.1038/laban0512-129
   Aydin B, 2014, CUTAN OCUL TOXICOL, V33, P192, DOI 10.3109/15569527.2013.832282
   Baksheeva VE, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8010003
   Barim O, 2010, ECOTOX ENVIRON SAFE, V73, P138, DOI 10.1016/j.ecoenv.2009.08.002
   Bejarano-Escobar R, 2012, J EXP BIOL, V215, P3799, DOI 10.1242/jeb.072124
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Benedetto MM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00417
   Bressler S.B., 2013, RETINA 5 EDITION, P1150, DOI [10.1016/B978-1-4557-0737-9.00065-5, DOI 10.1016/B978-1-4557-0737-9.00065-5]
   Burri BJ, 2016, NUTR REV, V74, P69, DOI 10.1093/nutrit/nuv064
   Burri BJ, 2015, J SCI FOOD AGR, V95, P1786, DOI 10.1002/jsfa.6942
   Carrara M, 2013, INT J MOL SCI, V14, P6454, DOI 10.3390/ijms14036454
   Cervia D, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081146
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Coronel J, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040842
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   deRaad S, 1996, OPHTHALMIC RES, V28, P99, DOI 10.1159/000267881
   Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621
   Eggersdorfer M, 2018, ARCH BIOCHEM BIOPHYS, V652, P18, DOI 10.1016/j.abb.2018.06.001
   Erisgin Z, 2019, INT J EXP PATHOL, V100, P330, DOI 10.1111/iep.12334
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fusakio ME, 2016, MOL BIOL CELL, V27, P1536, DOI 10.1091/mbc.E16-01-0039
   Fuster JJ, 2014, EMBO J, V33, P1425, DOI 10.15252/embj.201488856
   Gardner BM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013169
   Gong XM, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040100
   Gupta CL, 2020, PHOTOCHEM PHOTOBIOL, V96, P1061, DOI 10.1111/php.13244
   Hachana S, 2020, CURR EYE RES, V45, P965, DOI 10.1080/02713683.2020.1712730
   He MS, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/5376439
   Hillary RF, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0453-1
   Hyduke D.R, 2010, HDB CELL SIGNALING 2, P2107, DOI [10.1016/B978-0-12-374145-5.00257-6, DOI 10.1016/B978-0-12-374145-5.00257-6]
   Iandiev I, 2008, INVEST OPHTH VIS SCI, V49, P3559, DOI 10.1167/iovs.08-1723
   Jaadane I, 2017, J CELL MOL MED, V21, P3453, DOI 10.1111/jcmm.13255
   Jha KA, 2015, NEUROCHEM RES, V40, P2153, DOI 10.1007/s11064-015-1698-7
   Jun I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68565-3
   Jung E, 2018, MOLECULES, V23, DOI 10.3390/molecules23112806
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Karatepe M, 2004, LC GC N AM, V22, P362
   Kobylewski SE, 2017, BIOL TRACE ELEM RES, V176, P278, DOI 10.1007/s12011-016-0824-y
   Kowluru RA, 2003, FREE RADICAL RES, V37, P1169, DOI 10.1080/10715760310001604189
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Li C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9702820
   Lin CH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071799
   Llopis S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020232
   Luo BQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020364
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   McClinton KJ, 2020, NUTR NEUROSCI, V23, P838, DOI 10.1080/1028415X.2018.1563664
   NRC (US), 1995, NUTRIENT REQUIREMENT
   Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034
   Okamoto T, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.20
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Orhan C, 2016, J OCUL PHARMACOL TH, V32, P631, DOI 10.1089/jop.2015.0154
   Pawlowska E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9682318
   Peach CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041264
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Sahin K, 2019, BIOCHEM BIOPH RES CO, V516, P163, DOI 10.1016/j.bbrc.2019.06.032
   Sahin K, 2019, CUTAN OCUL TOXICOL, V38, P161, DOI 10.1080/15569527.2018.1554667
   Shang YM, 2017, INT J OPHTHALMOL-CHI, V10, P191, DOI 10.18240/ijo.2017.02.03
   Stahl W, 2005, DEV OPHTHALMOL, V38, P70, DOI 10.1159/000082768
   Thomas CN, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.32
   Ulas M, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0537-3
   Wei QQ, 2018, DRUG DES DEV THER, V12, P2715, DOI 10.2147/DDDT.S176349
   Widomska J, 2016, FOODS, V5, DOI 10.3390/foods5010007
   Wong P, 2017, MOL VIS, V23, P718
   Wong-Riley M, 2010, EYE BRAIN, V2, P99
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
   Zhang SX, 2014, EXP EYE RES, V125, P30, DOI 10.1016/j.exer.2014.04.015
   Zhang Y, 2005, INVEST OPHTH VIS SCI, V46, P2133, DOI 10.1167/iovs.04-1235
NR 71
TC 3
Z9 3
U1 3
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD FEB 10
PY 2021
VL 2021
AR 6672525
DI 10.1155/2021/6672525
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA QM5ZM
UT WOS:000621857200004
PM 33628377
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Anteby, R
   Barzelay, A
   Barak, A
AF Anteby, Roi
   Barzelay, Aya
   Barak, Adiel
TI Vitrectomy in patients 85 years of age and older: surgical outcomes and
   visual prognosis
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE PPV; visual acuity; age-related macular degeneration; retinal detachment
ID PARS-PLANA VITRECTOMY; RHEGMATOGENOUS RETINAL-DETACHMENT; SUBMACULAR
   HEMORRHAGE; SURGERY
AB Purpose: To evaluate visual and surgical outcomes in very elderly patients (above 85 years of age) undergoing pars plana vitrectomy (PPV).
   Patients and methods: A single-center, retrospective study was carried out on the medical records of 82 patients aged 85 years and older who had undergone PPV from 2006 to 2013. Patients ranged in age from 86 to 99 years, with a mean age of 88.9 years (+/- 2.88). Visual results and intraoperative and postoperative complications were the main outcome measures. Visual improvement/worsening was defined as at least +/- 0.1 logMAR change.
   Results: Mean follow-up was 7.25 months (+/- 5.35), with a range of 1-28 months. General anesthesia was used in 63% of the operations. The most common indication was retinal detachment (27%). The ocular condition necessitating PPV was secondary to trauma (most commonly after a fall) in 10 eyes (12%). Mean visual acuity (VA) improved from 1/58 preoperatively to 1/29 at the final evaluation (p=0.014). Mean improvement in VA in eyes of patients with the comorbidity of age-related macular degeneration (n=34) was 41% lower compared to eyes of patients without the disease (n=48, p=0.013). In the subgroup of patients operated on for retinal detachment, 45.4% did not reach primary anatomic success and 45.4% needed additional retina-affecting surgery. One or more major ocular complications were reported in 24 eyes (29%), while 19 eyes (23%) had minor ocular complications.
   Conclusion: Improved VA was documented in more than half of the older adults aged 85-99 undergoing vitrectomy. Despite the rate of complications in the very elderly, the possibility of optimizing visual function may positively affect quality of life in this subgroup.
C1 [Anteby, Roi; Barzelay, Aya; Barak, Adiel] Tel Aviv Univ, Sackler Fac Med, POB 39040, IL-6997801 Tel Aviv, Israel.
   [Barzelay, Aya; Barak, Adiel] Tel Aviv Sourasky Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center
RP Anteby, R (通讯作者)，Tel Aviv Univ, Sackler Fac Med, POB 39040, IL-6997801 Tel Aviv, Israel.
EM roianteby@mail.tau.ac.il
OI Anteby, Roi/0000-0003-0567-0655
CR Abunajma MA, 2016, CLIN OPHTHALMOL, V10, P1653, DOI 10.2147/OPTH.S98555
   Andreoli MT, 2011, OPHTHALMOLOGY, V118, P156, DOI 10.1016/j.ophtha.2010.04.034
   Chandra A, 2014, OPHTHALMOLOGY, V121, P311, DOI 10.1016/j.ophtha.2013.06.021
   Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4
   dell'Omo R, 2013, GRAEF ARCH CLIN EXP, V251, P485, DOI 10.1007/s00417-012-2059-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Heimann H, 2007, OPHTHALMOLOGY, V114, P2142, DOI 10.1016/j.ophtha.2007.09.013
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Huang Y, 2016, RETINA, V37, P1049
   Jackson TL, 2014, OPHTHALMOLOGY, V121, P643, DOI 10.1016/j.ophtha.2013.07.015
   Lim LS, 2014, OPHTHALMOLOGY, V121, P305, DOI 10.1016/j.ophtha.2013.08.033
   Ma YY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110256
   Mohamed YH, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2193518
   Moisseiev E, 2012, CURR EYE RES, V37, P50, DOI 10.3109/02713683.2011.614373
   Muto T, 2016, CLIN OPHTHALMOL, V10, P239, DOI 10.2147/OPTH.S95622
   Raczynska D, 2016, CLIN INTERV AGING, V11, P407, DOI 10.2147/CIA.S101835
   Rau CS, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/s13049-014-0063-1
   Salvi SM, 2006, POSTGRAD MED J, V82, P581, DOI 10.1136/pgmj.2005.040857
   Song SJ, 2015, RETINA-J RET VIT DIS, V35, P866, DOI 10.1097/IAE.0000000000000406
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Stein JD, 2009, ARCH OPHTHALMOL-CHIC, V127, P1656, DOI 10.1001/archophthalmol.2009.300
   Wubben TJ, 2016, OPHTHALMOLOGY, V123, P590, DOI 10.1016/j.ophtha.2015.11.001
NR 22
TC 6
Z9 6
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2018
VL 13
BP 243
EP 249
DI 10.2147/CIA.S154425
PG 7
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA FW5BO
UT WOS:000425331300001
PM 29467571
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gonzalez, EG
   Tarita-Nistor, L
   Mandelcorn, E
   Mandelcorn, M
   Steinbach, MJ
AF Gonzalez, Esther G.
   Tarita-Nistor, Luminita
   Mandelcorn, Efrem
   Mandelcorn, Mark
   Steinbach, Martin J.
TI Mechanisms of Image Stabilization in Central Vision Loss: Smooth Pursuit
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
ID PREFERRED RETINAL LOCI; MACULAR DEGENERATION; EYE-MOVEMENTS; FIXATION
   STABILITY; CENTRAL SCOTOMAS; READING SPEED; DISEASE; LOCATION; FOVEA;
   AMD
AB SIGNIFICANCE In addition to understanding the adaptive mechanisms of eccentric viewing during smooth pursuit, the ocular motor adaptations of patients with central vision loss give us a better understanding of the basic mechanisms of smooth pursuit in the healthy visual system.
   PURPOSE For patients with age-related macular degeneration and controls with normal vision, we examined the closed-loop gain of horizontal and vertical smooth pursuit eye movements as a function of stimulus speed and direction. We hypothesized that pursuit gain functions would be affected by stimulus speed and the location of the preferred retinal locus (PRL) in relation to the scotoma as determined by a fixation stability task using a microperimeter. Specifically, that a PRL on the left of the scotoma in the visual field would decrease the rightward gain relative to the leftward gain and a PRL below the scotoma in the visual field would decrease the upward gain.
   METHODS Ten patients and 15 controls were tested in a step-ramp procedure with direction (left/right for horizontal motion; up/down for vertical motion), speed (5, 10, 15, 20, and 30 deg/s), and five replication conditions randomized and blocked by orientation (horizontal vs. vertical).
   RESULTS Horizontal pursuit had a higher gain than vertical pursuit. The two eyes of the patients moved conjugately with similar smooth pursuit gains. For horizontal pursuit, all patients, regardless of PRL location, showed significantly better pursuit of leftward motion. For vertical pursuit, downward pursuit had a higher gain than upward pursuit for most patients.
   CONCLUSIONS PRL location was not predictive of the directional preponderance of pursuit performance. These results imply that patients may not use the PRL that was initially found during a static fixation task; they may adapt to the task by using a PRL that appears more suitable.
C1 [Gonzalez, Esther G.; Tarita-Nistor, Luminita; Steinbach, Martin J.] Toronto Western Hosp, Krembil Res Inst, Toronto, ON, Canada.
   [Gonzalez, Esther G.; Mandelcorn, Efrem; Mandelcorn, Mark; Steinbach, Martin J.] Univ Toronto, Dept Optometry & Vis Sci, Toronto, ON, Canada.
   [Gonzalez, Esther G.; Steinbach, Martin J.] York Univ, Ctr Vis Res, Toronto, ON, Canada.
C3 Krembil Research Institute; University of Toronto; University Toronto
   Affiliates; University Health Network Toronto; University of Toronto;
   York University - Canada
RP Gonzalez, EG (通讯作者)，Toronto Western Hosp, Krembil Res Inst, Toronto, ON, Canada.; Gonzalez, EG (通讯作者)，Univ Toronto, Dept Optometry & Vis Sci, Toronto, ON, Canada.; Gonzalez, EG (通讯作者)，York Univ, Ctr Vis Res, Toronto, ON, Canada.
EM esther.gonzalez@utoronto.ca
CR Amore FM, 2013, OPHTHAL PHYSL OPT, V33, P611, DOI 10.1111/opo.12048
   BALOH RW, 1988, AVIAT SPACE ENVIR MD, V59, P121
   Cheung SH, 2005, VISUAL NEUROSCI, V22, P187, DOI 10.1017/S0952523805222071
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   COLLEWIJN H, 1984, J PHYSIOL-LONDON, V351, P217, DOI 10.1113/jphysiol.1984.sp015242
   Crossland MD, 2002, OPTOMETRY VISION SCI, V79, P735, DOI 10.1097/00006324-200211000-00011
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DISCENNA AO, 1995, J NEUROSCI METH, V58, P89, DOI 10.1016/0165-0270(94)00162-A
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P932, DOI 10.1097/OPX.0000000000000246
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Gonzalez EG, 2006, CAN J OPHTHALMOL, V41, P333, DOI 10.1139/I06-019
   Gonzalez EG, 2014, VISION RES, V101, P151, DOI 10.1016/j.visres.2014.06.014
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Irving EL, 2011, INVEST OPHTH VIS SCI, V52, P658, DOI 10.1167/iovs.10-5480
   Kerber KA, 2006, NEUROBIOL AGING, V27, P1346, DOI 10.1016/j.neurobiolaging.2005.07.009
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   LISBERGER SG, 1981, J NEUROPHYSIOL, V46, P229, DOI 10.1152/jn.1981.46.2.229
   Lisberger SG, 2015, ANNU REV VIS SCI, V1, P447, DOI 10.1146/annurev-vision-082114-035349
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Macedo AF, 2011, INVEST OPHTH VIS SCI, V52, P1275, DOI 10.1167/iovs.09-4334
   Mach E., 1886, ANAL SENSATIONS
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   Mones J, 2005, EYE, V19, P1142, DOI 10.1038/sj.eye.6701717
   MOSCHNER C, 1994, J GERONTOL, V49, pM235, DOI 10.1093/geronj/49.5.M235
   NOORDEN GKV, 1962, AM J OPHTHALMOL, V53, P642, DOI 10.1016/0002-9394(62)91987-6
   O'Neill-Biba M, 2010, OPHTHAL PHYSL OPT, V30, P705, DOI 10.1111/j.1475-1313.2010.00775.x
   PAIGE GD, 1994, EXP BRAIN RES, V98, P355
   Pidcoe PE, 2006, INVEST OPHTH VIS SCI, V47, P169, DOI 10.1167/iovs.04-0564
   RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P326, DOI 10.1113/jphysiol.1961.sp006811
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   Rottach KG, 1996, VISION RES, V36, P2189, DOI 10.1016/0042-6989(95)00302-9
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   Seiple W, 2013, OPTOMETRY VISION SCI, V90, P45, DOI 10.1097/OPX.0b013e3182794775
   Shanidze N, 2016, J VISION, V16, DOI 10.1167/16.15.23
   Shanidze N, 2016, J VISION, V16, DOI 10.1167/16.3.1
   Tarita-Nistor L, 2006, CAN J OPHTHALMOL, V41, P327, DOI 10.1139/I06-029
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tarita-Nistor L, 2006, VISION RES, V46, P2487, DOI 10.1016/j.visres.2006.01.035
   Tarita-Nistor L, 2017, OPTOMETRY VISION SCI, V94, P239, DOI 10.1097/OPX.0000000000001018
   Tarita-Nistor L, 2015, OPTOMETRY VISION SCI, V92, P863, DOI 10.1097/OPX.0000000000000641
   Tarita-Nistor L, 2013, CAN J OPHTHALMOL, V48, P443, DOI 10.1016/j.jcjo.2013.04.005
   Tarita-Nistor L, 2011, INVEST OPHTH VIS SCI, V52, P1887, DOI 10.1167/iovs.10-6059
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   Thier P, 2005, CURR OPIN NEUROBIOL, V15, P645, DOI 10.1016/j.conb.2005.10.013
   Timberlake GT, 2008, OPTOMETRY VISION SCI, V85, P270, DOI 10.1097/OPX.0b013e31816928b9
   Timberlake GT, 2011, INVEST OPHTH VIS SCI, V52, P2540, DOI 10.1167/iovs.10-6062
   UKWADE MT, 1993, OPTOMETRY VISION SCI, V70, P123, DOI 10.1097/00006324-199302000-00007
   Valmaggia C, 2001, BRIT J OPHTHALMOL, V85, P169, DOI 10.1136/bjo.85.2.169
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   WINTERSON BJ, 1978, VISION RES, V18, P1165, DOI 10.1016/0042-6989(78)90100-1
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   ZACKON DH, 1987, ACTA OTO-LARYNGOL, V104, P290, DOI 10.3109/00016488709107331
NR 62
TC 4
Z9 4
U1 0
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JAN
PY 2018
VL 95
IS 1
BP 60
EP 69
DI 10.1097/OPX.0000000000001161
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FS0JA
UT WOS:000419459000009
PM 29252901
DA 2022-11-30
ER

PT J
AU Inoue, Y
   Shimazawa, M
   Nakamura, S
   Takata, S
   Hashimoto, Y
   Izawa, H
   Masuda, T
   Tsuruma, K
   Sakaue, T
   Nakayama, H
   Higashiyama, S
   Hara, H
AF Inoue, Yuki
   Shimazawa, Masamitsu
   Nakamura, Shinsuke
   Takata, Shinsuke
   Hashimoto, Yuhei
   Izawa, Hiroshi
   Masuda, Tomomi
   Tsuruma, Kazuhiro
   Sakaue, Tomohisa
   Nakayama, Hironao
   Higashiyama, Shigeki
   Hara, Hideaki
TI Both Autocrine Signaling and Paracrine Signaling of HB-EGF Enhance
   Ocular Neovascularization
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE endothelial cell; heparin-binding EGF-like growth factor; macular
   degeneration; mice; retina; vascular diseases
ID EPIDERMAL-GROWTH-FACTOR; PROTEIN-COUPLED RECEPTORS; PROLIFERATIVE
   DIABETIC-RETINOPATHY; FACTOR KNOCKOUT MICE; MACULAR DEGENERATION;
   ENDOTHELIAL-CELLS; CHOROIDAL NEOVASCULARIZATION; EPITHELIAL-CELLS; VEGF;
   TRANSACTIVATION
AB Objective The incidence of blindness is increasing because of the increase in abnormal ocular neovascularization. Anti-VEGF (vascular endothelial growth factor) therapies have led to good results, although they are not a cure for the blindness. The purpose of this study was to determine what role HB-EGF (heparin-binding epidermal growth factor-like growth factor) plays in ocular angiogenesis.
   Approach and Results We examined the role played by HB-EGF in ocular neovascularization in 2 animal models of neovascularization: laser-induced choroidal neovascularization (CNV) and oxygen-induced retinopathy. We also studied human retinal microvascular endothelial cells in culture. Our results showed that the neovascularization was decreased in both the CNV and oxygen-induced retinopathy models in HB-EGF conditional knockout mice compared with that in wild-type mice. Moreover, the expressions of HB-EGF and VEGF were increased after laser-induced CNV and oxygen-induced retinopathy, and their expression sites were located around the neovascular areas. Exposure of human retinal microvascular endothelial cells to HB-EGF and VEGF increased their proliferation and migration, and CRM-197 (cross-reactive material-197), an HB-EGF inhibitor, decreased the HB-EGF-induced and VEGF-induced cell proliferation and migration. VEGF increased the expression of HB-EGF mRNA. VEGF-dependent activation of EGFR (epidermal growth factor receptor)/ERK1/2 (extracellular signal-regulated kinase 1/2) signaling and cell proliferation of endothelial cells required stimulation of the ADAM17 (a disintegrin and metalloprotease) and ADAM12. CRM-197 decreased the grades of the fluorescein angiograms and size of the CNV areas in marmoset monkeys.
   Conclusions These findings suggest that HB-EGF plays an important role in the development of CNV. Therefore, further investigations of HB-EGF are needed as a potential therapeutic target in the treatment of exudative age-related macular degeneration.
C1 [Inoue, Yuki; Shimazawa, Masamitsu; Nakamura, Shinsuke; Takata, Shinsuke; Hashimoto, Yuhei; Izawa, Hiroshi; Masuda, Tomomi; Tsuruma, Kazuhiro; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
   [Masuda, Tomomi; Nakayama, Hironao; Higashiyama, Shigeki] Ehime Univ Shitsukawa, Div Cell Growth & Tumor Regulat, Proteosci Ctr, Toon, Japan.
   [Sakaue, Tomohisa; Higashiyama, Shigeki] Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Shitsukawa, Toon, Japan.
C3 Gifu Pharmaceutical University; Ehime University; Ehime University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu-pu.ac.jp
OI Hara, Hideaki/0000-0003-2046-9001
FU JSPS (Japan Society for the Promotion of Science) KAKENHI Grant
   [15J07670]
FX This work was supported by JSPS (Japan Society for the Promotion of
   Science) KAKENHI Grant Number 15J07670.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Arkonac BM, 1998, J BIOL CHEM, V273, P4400, DOI 10.1074/jbc.273.8.4400
   Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Ciamporcero E, 2015, MOL CANCER THER, V14, P101, DOI 10.1158/1535-7163.MCT-14-0094
   Cole CL, 2014, J BIOL CHEM, V289, P10488, DOI 10.1074/jbc.M113.534263
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cui D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12796
   Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Frohlich C, 2013, BIOCHEM J, V452, P97, DOI 10.1042/BJ20121558
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2
   Hayase Y, 1998, BRAIN RES, V784, P163, DOI 10.1016/S0006-8993(97)01325-5
   HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698
   Hollborn M, 2005, MOL VIS, V11, P397
   Hollborn M, 2006, CURR EYE RES, V31, P863, DOI 10.1080/02713680600888807
   Inoue Y, 2013, INVEST OPHTH VIS SCI, V54, P3815, DOI 10.1167/iovs.12-11236
   Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260
   Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3
   Kovacs K, 2015, INVEST OPHTH VIS SCI, V56, P6523, DOI 10.1167/iovs.15-16793
   Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   Maretzky T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1232
   MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015
   Mori S, 2003, J BIOL CHEM, V278, P46029, DOI 10.1074/jbc.M306393200
   Nakai K, 2009, J DERMATOL SCI, V55, P170, DOI 10.1016/j.jdermsci.2009.06.002
   Nakamura S, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14545
   Nakamura S, 2011, ARTERIOSCL THROM VAS, V31, P1041, DOI 10.1161/ATVBAHA.111.223594
   Oliveira-Cunha Melissa, 2011, Cancers (Basel), V3, P1513, DOI 10.3390/cancers3021513
   Oyagi A, 2011, NEUROSCIENCE, V185, P116, DOI 10.1016/j.neuroscience.2011.04.034
   Oyagi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007461
   Papa A, 2015, EXPERT OPIN THER TAR, V19, P55, DOI 10.1517/14728222.2014.970176
   PEER J, 1995, LAB INVEST, V72, P638
   Peterson JL, 2014, INVEST OPHTH VIS SCI, V55, P2870, DOI 10.1167/iovs.13-12943
   Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260
   Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3
   Reynolds CM, 2002, HYPERTENSION, V39, P525, DOI 10.1161/hy0202.103076
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sears JE, 2008, P NATL ACAD SCI USA, V105, P19898, DOI 10.1073/pnas.0805817105
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Singh AB, 2004, J CELL SCI, V117, P1365, DOI 10.1242/jcs.01037
   Stratman AN, 2010, BLOOD, V116, P4720, DOI 10.1182/blood-2010-05-286872
   Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200
   Takata S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09898
   Wan J, 2012, DEV CELL, V22, P334, DOI 10.1016/j.devcel.2011.11.020
   Wang XM, 2013, NATURE, V499, P306, DOI 10.1038/nature12345
   Weskamp G, 2010, CIRC RES, V106, P932, DOI 10.1161/CIRCRESAHA.109.207415
   Wykoff CC, 2014, BRIT J OPHTHALMOL, V98, P951, DOI 10.1136/bjophthalmol-2013-304736
   Xu KP, 2007, INVEST OPHTH VIS SCI, V48, P2242, DOI 10.1167/iovs.06-0560
   Yamazaki S, 2003, J CELL BIOL, V163, P469, DOI 10.1083/jcb.200307035
   Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026
   Zhou Y, 2010, NEUROSIGNALS, V18, P141, DOI 10.1159/000319823
NR 62
TC 15
Z9 16
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD JAN
PY 2018
VL 38
IS 1
BP 174
EP 185
DI 10.1161/ATVBAHA.117.310337
PG 12
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA FR1XS
UT WOS:000418861700023
PM 29191924
OA Bronze
DA 2022-11-30
ER

PT J
AU Espina, M
   Arcinue, CA
   Ma, FY
   Camacho, N
   Barteselli, G
   Mendoza, N
   Ferrara, N
   Freeman, WR
AF Espina, Mark
   Arcinue, Cheryl A.
   Ma, Feiyan
   Camacho, Natalia
   Barteselli, Giulio
   Mendoza, Nadia
   Ferrara, Napoleone
   Freeman, William R.
TI Outer retinal tubulations response to anti-VEGF treatment
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; SCAN
AB Aim To review the longitudinal changes of outer retinal tubulations (ORTs) in wet age-related macular degeneration (AMD) and their response to anti-vascular endothelial growth factor (VEGF) therapy by spectral-domain optical coherence tomography (SD-OCT), and to correlate these observations with disease activity, presence or absence of fluid, and patients' demographics.
   Methods Retrospective study of wet AMD eyes treated with anti-VEGF agents and showing ORTs on SD-OCT, and the patients' fellow eye with wet AMD but without ORTs.
   Results Fifty-one wet AMD eyes from 31 patients diagnosed and treated for wet AMD were included in the review and analysis of data; 33 eyes showed ORTs at baseline, while 18 fellow eyes had no ORTs. During a median follow-up treatment period of 11 months, 23 eyes had stable ORTs and 10 eyes had ORT changes. Among the 10 eyes with ORTs changes, ORTs collapsed during anti-VEGF treatment in 5 eyes but then reappeared within 12 months after stopping treatment. In two eyes, ORTs increased in size during anti-VEGF treatment, while in two other eyes ORTs collapsed without any treatment. In a single eye, ORTs collapsed within 10 months of no treatment and did not reappear upon recurrence of fluid. Eyes with ORTs tended to have lower visual acuity than eyes with no ORTs due to greater disruption of the external limiting membrane in the fovea.
   Conclusions ORTs documented by SD-OCT may exhibit multiple types of longitudinal changes, such as collapse, recurrence or enlargement, which could be associated with anti-VEGF treatment or spontaneous. Some ORTs may have a vascular component or may be vascular in nature, considering their response to anti-VEGF treatment, while other ORTs are likely composed only of degenerating photoreceptor cells and may collapse independently from anti-VEGF treatments.
C1 [Espina, Mark; Arcinue, Cheryl A.; Ma, Feiyan; Camacho, Natalia; Barteselli, Giulio; Mendoza, Nadia; Freeman, William R.] Univ Calif San Diego, Shiley Eye Inst, Jacobs Retina Ctr, Dept Ophthalmol, La Jolla, CA 92093 USA.
   [Barteselli, Giulio] Genentech Inc, Dept Ophthalmol, San Francisco, CA 94080 USA.
   [Ferrara, Napoleone] Univ Calif San Diego, Moores Canc Ctr, Shiley Eye Inst, La Jolla, CA 92093 USA.
   [Ferrara, Napoleone] Sch Med, La Jolla, CA USA.
C3 University of California System; University of California San Diego;
   Roche Holding; Genentech; University of California System; University of
   California San Diego
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Inst, 0946,9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM freeman@eyecenter.ucsd.edu
FU NIH [R01EY016323]; NEI vision core grant [P30EY022589]; Research to
   Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY018589, R01EY007366,
   P30EY022589] Funding Source: NIH RePORTER
FX This study was supported by NIH grant R01EY016323, NEI vision core grant
   P30EY022589, and an unrestricted fund from the Research to Prevent
   Blindness to the Department of Ophthalmology, University of California
   San Diego. The funding organisations had no role in the design or
   conduct of this research.
CR [Anonymous], 1997, DIAGNOSIS TREATMENT
   Barteselli G, 2013, AM J OPHTHALMOL, V156, P588, DOI 10.1016/j.ajo.2013.04.030
   Chhablani J, 2013, INT J OPHTHALMOL-CHI, V6, P62, DOI 10.3980/j.issn.2222-3959.2013.01.13
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Gamulescu MA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/851648
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P7637, DOI 10.1167/iovs.12-10047
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 11
TC 10
Z9 11
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2016
VL 100
IS 6
BP 819
EP 823
DI 10.1136/bjophthalmol-2015-307141
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DN3WL
UT WOS:000376994700019
PM 26423451
OA Green Published
DA 2022-11-30
ER

PT J
AU Zhang, SJ
   Yu, N
   Zhang, R
   Zhang, SH
   Wu, JH
AF Zhang, Shujie
   Yu, Ning
   Zhang, Rong
   Zhang, Shenghai
   Wu, Jihong
TI Interleukin-17A Induces IL-1 beta Secretion From RPE Cells Via the NLRP3
   Inflammasome
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE RPE cells; IL-17A; inflammasome; AMD
ID PIGMENT EPITHELIAL-CELLS; DELTA-T-CELLS; MACULAR DEGENERATION; INNATE
   IMMUNITY; ACTIVATION; IL-17A; GAMMA; PROMOTER; DISEASE; SYSTEM
AB PURPOSE. Inflammasome activation and IL-1 beta production have been proposed to have an important role in age-related macular degeneration (AMD). Growing evidence is emerging for involvement of interleukin-17A (IL-17A) in AMD pathogenesis. We investigated the effects of IL-17A on the activation of inflammasome and production of IL-1 beta in primary human RPE cells.
   METHODS. Primary human RPE cells were isolated and cultured for the following experiments. Expression patterns of IL-17 receptor A (IL-17RA), IL-17 receptor C (IL-17RC), and ACT1 were analyzed by RT-PCR, flow cytometry, and immunofluorescence. IL-17A was added to the cell cultures, and cytokine expression, signaling pathways, and inflammasome machinery were investigated using real-time RT-PCR, ELISA, Western blot, flow cytometry, and small interfering RNA.
   RESULTS. Retinal pigment epithelial cells constitutively expressed IL-17RA, IL-17RC, and ACT1. IL-17A upregulated the mRNA levels of pro-IL-1 beta, IL-8, CCL2, and CCL20, as well as the protein level of IL-1 beta. IL-17A induced the phosphorylation of Akt, Erk1/2, p38 MAPK, and NF-kappa B p65 in RPE cells. Blocking NF-kappa B attenuated IL-17A-induced expression of pro-IL-1 beta mRNA. IL-17A enhanced pro-caspase-1 and NLRP3 mRNA expression. Inhibiting caspase-1 activity and silencing NLRP3 decreased IL-1 beta secretion, confirming NLRP3 as the IL-17A-responsive inflammasome on the posttranscriptional level. The mechanism of IL-17A-triggered NLRP3 activation and subsequent IL-1 beta secretion was found to involve the generation of reactive oxygen species.
   CONCLUSIONS. Our results suggest that IL-17A triggers a key inflammatory mediator, IL-1 beta, from RPE cells, via NLRP3 inflammasome activation, holding therapeutic potential for AMD.
C1 [Zhang, Shujie; Zhang, Rong; Zhang, Shenghai; Wu, Jihong] Fudan Univ, Eye & ENT Hosp, Res Ctr, Shanghai 200031, Peoples R China.
   [Zhang, Shujie; Zhang, Rong; Zhang, Shenghai; Wu, Jihong] Fudan Univ, Minist Hlth, Key Lab Myopia, Shanghai 200031, Peoples R China.
   [Zhang, Shujie; Zhang, Rong; Zhang, Shenghai; Wu, Jihong] Fudan Univ, Shanghai Key Lab Visual Impairment & Restorat, Shanghai 200031, Peoples R China.
   [Yu, Ning] Shanghai Skin Dis Hosp, Dept Dermatol, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Zhang, SH; Wu, JH (通讯作者)，Fudan Univ, Shanghai Med Coll, Eye & ENT Hosp, Res Ctr, 83 Fenyang Rd, Shanghai 200031, Peoples R China.
EM zsheent@gmail.com; jihongwu@fudan.edu.cn
OI wu, Ji-Hong/0000-0003-3892-5757
FU National Natural Science Foundations of China [81200675, 81470624];
   Fundamental Research Funds for the Central Universities
FX Supported by the National Natural Science Foundations of China
   (81200675, 81470624) and the Fundamental Research Funds for the Central
   Universities. The authors alone are responsible for the content and
   writing of the paper.
CR Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Ardeljan D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095900
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Chen Y, 2011, MOL VIS, V17, P3072
   Chen Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018139
   Cho KA, 2012, INT IMMUNOL, V24, P147, DOI 10.1093/intimm/dxr110
   Davis BK, 2011, ANNU REV IMMUNOL, P29707
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Gu CF, 2013, CYTOKINE, V64, P477, DOI 10.1016/j.cyto.2013.07.022
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hamada S, 2008, J IMMUNOL, V181, P3456, DOI 10.4049/jimmunol.181.5.3456
   HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hu SJ, 2015, J NEUROSCI, V35, P6987, DOI 10.1523/JNEUROSCI.3955-14.2015
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Martinon F, 2010, EUR J IMMUNOL, V40, P616, DOI 10.1002/eji.200940168
   Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449
   Nowak JZ, 2014, ACTA POL PHARM, V71, P900
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Song CW, 2008, J IMMUNOL, V181, P6117, DOI 10.4049/jimmunol.181.9.6117
   Sutterwala FS, 2014, ANN NY ACAD SCI, V1319, P82, DOI 10.1111/nyas.12458
   Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Werner JL, 2011, INFECT IMMUN, V79, P3966, DOI 10.1128/IAI.05493-11
   Zhao ZY, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15166
   Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957
NR 37
TC 30
Z9 35
U1 0
U2 17
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2016
VL 57
IS 2
BP 312
EP 319
DI 10.1167/iovs.15-17578
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI6EF
UT WOS:000373591300003
PM 26830368
OA gold
DA 2022-11-30
ER

PT J
AU Park, YG
   Roh, YJ
AF Park, Young Gun
   Roh, Young-Jung
TI One year results of intravitreal ranibizumab monotherapy for retinal
   angiomatous proliferation: a comparative analysis based on disease
   stages
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Ranibizumab; Retinal angiomatous proliferation; Stages; Recurrence rate
ID MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; BEVACIZUMAB;
   NEOVASCULARIZATION; TRIAMCINOLONE; LUCENTIS; RAP
AB Background: Retinal angiomatous proliferation (RAP) has been known as a variant of exudative age-related macular degeneration (AMD) with a unfavorable prognosis. To evaluate the effect of ranibizumab administered initially as three loading doses for patients with various stages of RAP.
   Methods: A retrospective chart review of 40 patients (41 eyes) with RAP was conducted. The study divided patients into three groups of Group I (8 eyes in stage I), Group II (17eyes in stage II), and Group III (16 eyes in stage III). All patients received three initial monthly intravitreal injections (0.5 mg) of ranibizumab and were monitored monthly for 12 months. Reinjection of ranibizumab after three initial monthly doses was administered on as-needed basis. The main outcome measures were the change in the mean of best-corrected Snellen visual acuity (BCVA) and central macular thickness (CMT), and the total number of injections received during the 12 months.
   Results: The mean change in BCVA at 12 months was-0.286,-0.165, and-0.151 (logMAR) in Group I, II, and III, respectively. CMT was also reduced by a mean of 32.72 +/- 56.75, 57.45 +/- 56.48 and 148.37 +/- 98.59 mu m. The mean number of injections in Group I was significant lower than those in Group II and III (P < 0.001, P < 0.001, and P = 0.15 for Group I versus Group II, Group I versus Group III, and Group II versus Group III, respectively).
   Conclusions: The 12-month follow-up outcomes suggest that three consecutive loading doses of intravitreal ranibizumab is an effective treatment on early stage (stage I) of RAP. Patients in stage I showed a significantly lower recurrence rate than patients in later stages.
C1 [Park, Young Gun; Roh, Young-Jung] Catholic Univ Korea, Coll Med, Yeouido St Marys Hosp, Dept Ophthalmol, Seoul 150713, South Korea.
C3 Catholic University of Korea
RP Roh, YJ (通讯作者)，Catholic Univ Korea, Coll Med, Yeouido St Marys Hosp, Dept Ophthalmol, 62 Yeouido Dong, Seoul 150713, South Korea.
EM cuteyg2000@catholic.ac.kr
FU Yeouido St. Mary's Hospital, College of Medicine, The Catholic
   University of Korea
FX The authors acknowledge with gratitude funding from Yeouido St. Mary's
   Hospital, College of Medicine, The Catholic University of Korea.
CR Atmani K, 2010, EYE, V24, P1193, DOI 10.1038/eye.2010.9
   Boscia F, 2004, AM J OPHTHALMOL, V138, P1077, DOI 10.1016/j.ajo.2004.06.072
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Bressler NM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1741, DOI 10.1001/archopht.123.12.1741
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P1165, DOI 10.1007/s00417-009-1089-3
   Kramann CA, 2012, ACTA OPHTHALMOL, V90, P487, DOI 10.1111/j.1755-3768.2010.01952.x
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee MY, 2011, RETINA-J RET VIT DIS, V31, P65, DOI 10.1097/IAE.0b013e3181e586e3
   Maier M, 2013, OPHTHALMOLOGE, V110, P1171, DOI 10.1007/s00347-012-2732-7
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Meyerle CB, 2007, RETINA-J RET VIT DIS, V27, P451, DOI 10.1097/IAE.0b013e318030ea80
   Montero JA, 2009, EUR J OPHTHALMOL, V19, P448, DOI 10.1177/112067210901900320
   Nakano S, 2012, CLIN OPHTHALMOL, V6, P277, DOI 10.2147/OPTH.S29718
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Parodi MB, 2011, ACTA OPHTHALMOL, DOI 1111/j.1755-3768.2011.02265.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   Rouvas AA, 2010, EYE LOND, V24, P1643
   Rouvas A, 2009, GRAEF ARCH CLIN EXP, V247, P1609, DOI 10.1007/s00417-009-1138-y
   Rouvas AA, 2008, GRAEF ARCH CLIN EXP, V246, P315, DOI 10.1007/s00417-007-0669-3
   Rouvas AA, 2012, RETINA-J RET VIT DIS, V32, P1181, DOI 10.1097/IAE.0b013e318235d8ce
   Rouvas AA, 2009, RETINA-J RET VIT DIS, V29, P536, DOI 10.1097/IAE.0b013e318196b1de
   Sahu AK, 2010, RETINA-J RET VIT DIS, V30, P981, DOI 10.1097/IAE.0b013e3181dde596
   Saito M, 2012, AM J OPHTHALMOL, V153, P504, DOI 10.1016/j.ajo.2011.08.038
   Sakimoto S, 2005, AM J OPHTHALMOL, V139, P917, DOI 10.1016/j.ajo.2004.10.046
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 34
TC 8
Z9 8
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 21
PY 2015
VL 15
AR 182
DI 10.1186/s12886-015-0172-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ2ZI
UT WOS:000366973300001
PM 26691185
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Westenskow, PD
   Kurihara, T
   Bravo, S
   Feitelberg, D
   Sedillo, ZA
   Aguilar, E
   Friedlander, M
AF Westenskow, Peter D.
   Kurihara, Toshihide
   Bravo, Stephen
   Feitelberg, Daniel
   Sedillo, Zack A.
   Aguilar, Edith
   Friedlander, Martin
TI Performing Subretinal Injections in Rodents to Deliver Retinal Pigment
   Epithelium Cells in Suspension
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 95; Retinal pigment epithelium; subretinal injections;
   translational medicine; age-related macular degeneration; cell-based
   delivery
ID EMBRYONIC STEM-CELLS; LONG-TERM SAFETY; MACULAR DEGENERATION;
   TRANSPLANTATION; RPE; DIFFERENTIATION; TRANSLOCATION; PHAGOCYTOSIS;
   IMPLANTATION; GENERATION
AB The conversion of light into electrical impulses occurs in the outer retina and is accomplished largely by rod and cone photoreceptors and retinal pigment epithelium (RPE) cells. RPE provide critical support for photoreceptors and death or dysfunction of RPE cells is characteristic of age-related macular degeneration (AMD), the leading cause of permanent vision loss in people age 55 and older. While no cure for AMD has been identified, implantation of healthy RPE in diseased eyes may prove to be an effective treatment, and large numbers of RPE cells can be readily generated from pluripotent stem cells. Several interesting questions regarding the safety and efficacy of RPE cell delivery can still be examined in animal models, and well-accepted protocols used to inject RPE have been developed. The technique described here has been used by multiple groups in various studies and involves first creating a hole in the eye with a sharp needle. Then a syringe with a blunt needle loaded with cells is inserted through the hole and passed through the vitreous until it gently touches the RPE. Using this injection method, which is relatively simple and requires minimal equipment, we achieve consistent and efficient integration of stem cell-derived RPE cells in between the host RPE that prevents significant amount of photoreceptor degeneration in animal models. While not part of the actual protocol, we also describe how to determine the extent of the trauma induced by the injection, and how to verify that the cells were injected into the subretinal space using in vivo imaging modalities. Finally, the use of this protocol is not limited to RPE cells; it may be used to inject any compound or cell into the subretinal space.
C1 [Westenskow, Peter D.; Kurihara, Toshihide; Bravo, Stephen; Feitelberg, Daniel; Aguilar, Edith; Friedlander, Martin] Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA.
   [Westenskow, Peter D.; Sedillo, Zack A.; Friedlander, Martin] Lowy Med Res Inst, San Diego, CA USA.
C3 Scripps Research Institute
RP Westenskow, PD (通讯作者)，Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA.
EM petewest@scripps.edu; friedlan@scripps.edu
RI Kurihara, Toshihide/ABA-7058-2020
OI Kurihara, Toshihide/0000-0002-5457-2720; Westenskow,
   Peter/0000-0001-9841-6220
FU National Eye Institute (NEI) [EY11254, EY021416]; California Institute
   for Regenerative Medicine (CIRM) [TR1-01219]; Lowy Medical Research
   Institute (LMRI); NATIONAL EYE INSTITUTE [F32EY021416, R01EY011254]
   Funding Source: NIH RePORTER
FX We wish to thank Alison Dorsey for helping to develop the subretinal
   injection technique. We also acknowledge the National Eye Institute (NEI
   grants EY11254 and EY021416), California Institute for Regenerative
   Medicine (CIRM grant TR1-01219), and the Lowy Medical Research Institute
   (LMRI) for very generous funding for this project.
CR Abe T, 2000, TOHOKU J EXP MED, V191, P7, DOI 10.1620/tjem.191.7
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJ, 2009, MOL VIS, V15, P283
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Eberle D, 2014, JOVE-J VIS EXP, DOI 10.3791/50932
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Fisher SK, 2005, PROG RETIN EYE RES, V24, P395, DOI 10.1016/j.preteyeres.2004.10.004
   Fuhrmann S, 2000, DEVELOPMENT, V127, P4599
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hu YT, 2012, OPHTHALMIC RES, V48, P186, DOI 10.1159/000338749
   Huber G, 2009, INVEST OPHTH VIS SCI, V50, P5888, DOI 10.1167/iovs.09-3724
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Joussen AM, 2003, GRAEF ARCH CLIN EXP, V241, P966, DOI 10.1007/s00417-003-0792-8
   Kim KH, 2008, J VISION, V8, DOI 10.1167/8.1.17
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Krohne TU, 2012, STEM CELL TRANSL MED, V1, P96, DOI 10.5966/sctm.2011-0057
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Pennesi ME, 2012, INVEST OPHTH VIS SCI, V53, P4644, DOI 10.1167/iovs.12-9611
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   Westenskow P., J VIS EXP IN PRESS
   Westenskow PD, 2014, NEW VISUAL NEUROSCIENCES, P1611
   Westenskow PD, 2012, INVEST OPHTH VIS SCI, V53, P6282, DOI 10.1167/iovs.12-9721
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135
NR 44
TC 26
Z9 26
U1 0
U2 4
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JAN
PY 2015
IS 95
AR e52247
DI 10.3791/52247
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CR7MA
UT WOS:000361532900038
PM 25651341
OA Green Published
DA 2022-11-30
ER

PT J
AU Chasan, JE
   Delaune, B
   Maa, AY
   Lynch, MG
AF Chasan, Joel E.
   Delaune, Bill
   Maa, April Y.
   Lynch, Mary G.
TI Effect of a Teleretinal Screening Program on Eye Care Use and Resources
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC-RETINOPATHY; TELEOPHTHALMOLOGY
AB IMPORTANCE Telemedicine is a useful clinical method to extend health care to patients with limited access. Minimal information exists on the subsequent effect of telemedicine activities on eye care resources.
   OBJECTIVE To evaluate the effect of a community-based diabetic teleretinal screening program on eye care use and resources.
   DESIGN, SETTING, AND PARTICIPANTS The current study was a retrospective medical record review of patients who underwent diabetic teleretinal screening in the community-based clinics of the Atlanta Veterans Affairs Medical Center from October 1, 2008, through March 31, 2009, and who were referred for an ophthalmic examination in the eye clinic.
   EXPOSURES Clinical medical records were reviewed for a 2-year period after patients were referred from teleretinal screening. The following information was collected for analysis: patient demographics, referral and confirmatory diagnoses, ophthalmology clinic visits, diagnostic procedures, surgical procedures, medications, and spectacle prescriptions.
   MAIN OUTCOMES AND MEASURES The accuracy between referring and final diagnoses and the eye care resources that were used in the care of referred patients.
   RESULTS The most common referral diagnoses were nonmacular diabetic retinopathy (43.2%), nerve-related disease (30.8%), lens or media opacity (19.1%), age-related macular degeneration (12.9%), and diabetic macular edema (5.6%). The percentage of agreement among these 5 visually significant diagnoses was 90.4%, with a total sensitivity of 73.6%. Diabetic macular edema required the greatest number of ophthalmology clinic visits, diagnostic tests, and surgical procedures. Using Medicare cost data estimates, the mean cost incurred during a 2-year period per patient seen in the eye clinic was approximately $1000.
   CONCLUSIONS AND RELEVANCE Although a teleretinal screening program can be accurate and sensitive for multiple visually significant diagnoses, measurable resource burdens should be anticipated to adequately prepare for the associated increase in clinical care.
C1 [Chasan, Joel E.; Maa, April Y.; Lynch, Mary G.] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Delaune, Bill] Ctr Visual & Neurocognit Rehabil, Atlanta, GA USA.
   [Maa, April Y.; Lynch, Mary G.] Atlanta VA Med Ctr, Ophthalmol Sect, Decatur, GA 30033 USA.
C3 Emory University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical
   Center
RP Lynch, MG (通讯作者)，Atlanta VA Med Ctr, Ophthalmol Sect 112, 1670 Clairmont Rd, Decatur, GA 30033 USA.
EM mary.lynch4@va.gov
CR Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143
   American Academy of Ophthalmology Retina Panel, 2008, PREF PRACT PATT GUID
   Bragge P, 2011, ARCH OPHTHALMOL-CHIC, V129, P435, DOI 10.1001/archophthalmol.2010.319
   Cavallerano AA, 2003, RETINA-J RET VIT DIS, V23, P215, DOI 10.1097/00006982-200304000-00013
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Gomez-Ulla F, 2002, DIABETES CARE, V25, P1384, DOI 10.2337/diacare.25.8.1384
   HUNT RJ, 1986, J DENT RES, V65, P128, DOI 10.1177/00220345860650020701
   IBM Corp, 2013, IBM SPSS STAT WINDOW
   JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909
   Jones S, 2010, DIABETIC MED, V27, P249, DOI 10.1111/j.1464-5491.2009.02870.x
   Kerr D, 1998, DIABETIC MED, V15, P878, DOI 10.1002/(SICI)1096-9136(199810)15:10<878::AID-DIA686>3.0.CO;2-3
   Orcutt J, 2004, DIABETES CARE, V27, pB50, DOI 10.2337/diacare.27.suppl_2.B50
   Whited JD, 2005, TELEMED J E-HEALTH, V11, P641, DOI 10.1089/tmj.2005.11.641
NR 13
TC 48
Z9 50
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD SEP
PY 2014
VL 132
IS 9
BP 1045
EP 1051
DI 10.1001/jamaophthalmol.2014.1051
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ8FL
UT WOS:000343059600003
PM 24875731
DA 2022-11-30
ER

PT J
AU Westrup, VMZ
   Dietzel, M
   Pauleikhoff, D
   Hense, HW
AF Westrup, Verena Meyer Zu
   Dietzel, Martha
   Pauleikhoff, Daniel
   Hense, Hans-Werner
TI The Association of Retinal Structure and Macular Pigment Distribution
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE optical coherence tomography; retinal morphology; macular pigment; MPOD;
   epidemiology; MARS
ID OPTICAL COHERENCE TOMOGRAPHY; AGE-RELATED MACULOPATHY; FOVEAL PIT
   MORPHOLOGY; SPATIAL PROFILE; HEALTHY EYES; THICKNESS; DEGENERATION;
   DENSITY; PROGRESSION; ZEAXANTHIN
AB PURPOSE. Macular pigment optical density (MPOD) and age-related macular degeneration (AMD) are thought to be associated; however, the details are not yet understood clearly. This study aimed at investigating how retinal anatomic structures relate with the spatial MPOD distribution in single eyes.
   HODS. In a subgroup of the third follow-up examination of the Munster Aging and Retina Study (MARS) cohort (mean age, 78.4 years), 124 single eyes of 79 participants with early AMD were examined. The MPOD was assessed using 2-wavelength autofluorescence (AF). Retinal thickness (RT) and fovea pit profile slopes were measured using optical coherence tomography (OCT). The results were analyzed for interocular correlation in 58 pairs of eyes, and for the association of MPOD distribution patterns with RT using uni-and multivariate statistical methods.
   RESULTS. The interocular correlations for several measures of RT and RT layers were high (P < 0.001). The RT was inversely and significantly related to MPOD at 1.08 and at 2.08 from the foveal center, but not to central MPOD. After controlling for sex, age, smoking, and spherical equivalent, RT was significantly thinner (- 39.7 mu m, P < 0.001) in eyes with ring-like compared to normal MPOD distribution. In particular, a thinner layer between internal and external limiting membrane showed strong associations with ring-like structures.
   CONCLUSIONS. Higher values of MPOD at 1 degrees and 2 degrees, as well as a ring-like distribution of MPOD were associated significantly with thinner maculae, due to thinner inner retinal layers. The MPOD distribution was unrelated to the slope of the foveal pit or the choroidal thickness. Our results suggest that the retinal section between the internal and external limiting membrane is involved in the spatial distribution of MPOD.
C1 [Westrup, Verena Meyer Zu; Hense, Hans-Werner] Univ Munster, Fac Med, Inst Epidemiol & Social Med, D-48129 Munster, Germany.
   [Dietzel, Martha; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
C3 University of Munster; St. Franziskus-Hospital
RP Hense, HW (通讯作者)，Univ Munster, Fac Med, Inst Epidemiol & Social Med, Albert Schweitzer Campus 1,D 3, D-48129 Munster, Germany.
EM hense@uni-muenster.de
FU Deutsche Forschungsgesellschaft [HE 2293/5-1, HE 2293/5-2, HE 2293/5-3,
   PA 357/7-1]; Intramural International Monetary Fund of the University of
   Muenster; Pro Retina Foundation; Jackstaedt Foundation
FX Supported in part by Deutsche Forschungsgesellschaft Grants HE 2293/5-1,
   5-2, 5-3, and PA 357/7-1; the Intramural International Monetary Fund of
   the University of Muenster; the Pro Retina Foundation; and the
   Jackstaedt Foundation.
CR Alamouti B, 2003, BRIT J OPHTHALMOL, V87, P899, DOI 10.1136/bjo.87.7.899
   Asefzadeh B, 2007, OPTOMETRY VISION SCI, V84, P941
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Costa RA, 2005, AM J OPHTHALMOL, V140, P349, DOI 10.1016/j.ajo.2005.03.027
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P8016, DOI 10.1167/iovs.11-7610
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Dubis AM, 2009, BRIT J OPHTHALMOL, V93, P1223, DOI 10.1136/bjo.2008.150110
   Dubis AM, 2012, INVEST OPHTH VIS SCI, V53, P1628, DOI 10.1167/iovs.11-8488
   Farwick A, 2009, EYE, V23, P2238, DOI 10.1038/eye.2008.426
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Gass JDM, 1999, ARCH OPHTHALMOL-CHIC, V117, P821
   Kashani AH, 2010, AM J OPHTHALMOL, V149, P496, DOI 10.1016/j.ajo.2009.09.025
   Kelty PJ, 2008, INVEST OPHTH VIS SCI, V49, P2668, DOI 10.1167/iovs.07-1000
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Kirby ML, 2009, INVEST OPHTH VIS SCI, V50, P1383, DOI 10.1167/iovs.08-2494
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Liew SHM, 2006, EXP EYE RES, V82, P915, DOI 10.1016/j.exer.2005.10.014
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Powner MB, 2010, OPHTHALMOLOGY, V117, P2407, DOI 10.1016/j.ophtha.2010.04.001
   Ray R, 2005, AM J OPHTHALMOL, V140, P351, DOI 10.1016/j.ajo.2005.03.039
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477
   Rii T, 2012, AM J OPHTHALMOL, V153, P524, DOI 10.1016/j.ajo.2011.08.021
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Song WK, 2010, INVEST OPHTH VIS SCI, V51, P3913, DOI 10.1167/iovs.09-4189
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Tick S, 2011, INVEST OPHTH VIS SCI, V52, P5105, DOI 10.1167/iovs.10-7005
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Wagner-Schuman M, 2011, INVEST OPHTH VIS SCI, V52, P625, DOI 10.1167/iovs.10-5886
   Zeimer M, 2012, INVEST OPHTH VIS SCI, V53, P4852, DOI 10.1167/iovs.12-9713
NR 34
TC 18
Z9 18
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2014
VL 55
IS 2
BP 1169
EP 1175
DI 10.1167/iovs.13-12903
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB6IU
UT WOS:000331891700065
PM 24474270
DA 2022-11-30
ER

PT J
AU Butt, T
   Dunbar, HMP
   Morris, S
   Orr, S
   Rubin, GS
AF Butt, Thomas
   Dunbar, Hannah M. P.
   Morris, Stephen
   Orr, Shepley
   Rubin, Gary S.
TI Patient and Public Preferences for Health States Associated with AMD
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; QALYs; health-related quality of life;
   EQ-5D; SF-6D; time trade-off; visual acuity
ID QUALITY-OF-LIFE; MACULAR DEGENERATION; UTILITY VALUES; IMPACT
AB Purpose. Health utility values suitable for calculating quality-adjusted life-years are increasingly used to assess the cost-effectiveness of treatments for age-related macular degeneration (AMD). In the United States, health utilities are usually derived from the patients' own valuation or modeled using visual acuity as a surrogate outcome. In the United Kingdom and throughout Europe, health utilities are derived from public valuations. Our aim was to test if utility values for health states associated with AMD elicited directly from patients were different from those calculated from public tariffs for health-related quality of life (HRQoL) questionnaires.
   Methods. Generic preference-based HRQoL questionnaires (EQ-5D and SF-6D) and the time trade-off (TTO) and visual analog scale (VAS) valuation techniques were administered to a sample of UK patients with AMD (N = 60). Health utilities were calculated using standard general population tariffs for the patient EQ-5D and SF-6D health states and directly from patient TTO and VAS scores.
   Results. Mean utilities derived from the public tariffs were significantly higher than from patients' valuation (mean [TSD], 0.613 (+/- 0.275) for the EQ-5D and 0.628 (+/- 0.114) for the SF-6D compared with 0.481 [+/- 0.411] for the TTO and 56.7 [+/- 21.8] for the VAS score; p < 0.001). The EQ-5D was not significantly different from the SF-6D (p > 0.6). Visual acuity in the better seeing eye was not associated with any utility measure (all r < 0.08; p > 0.2).
   Conclusions. Patient and public preferences for health states associated with AMD are different, with patients valuing their health state more severely than the public tariffs of commonly used HRQoL questionnaires. Visual acuity did not predict health utility using any measure, and therefore, care should be taken when using visual acuity as a surrogate measure for utility in health economic analyses.
C1 [Butt, Thomas; Dunbar, Hannah M. P.; Rubin, Gary S.] UCL, Inst Ophthalmol, London WC1E 6BT, England.
   [Morris, Stephen] UCL, Dept Appl Hlth Res, London WC1E 6BT, England.
   [Orr, Shepley] UCL, Dept Civil & Environm Engn, London WC1E 6BT, England.
   [Rubin, Gary S.] NIHR Moorfields Biomed Res Ctr, London, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London
RP Butt, T (通讯作者)，UCL Inst Ophthalmol, Dept Visual Neurosci, 11-43 Bath St, London EC1V 9EL, England.
EM thomas.butt.10@ucl.ac.uk
RI Butt, Thomas/AAH-7882-2019
OI Butt, Thomas/0000-0002-0387-4550; Morris, Stephen/0000-0002-5828-3563
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Moorfields Eye Hospital NHS Foundation Trust; National
   Institute for Health Research (NIHR) Biomedical Research Centre based at
   UCL Institute of Ophthalmology; EPSRC [EP/I033270/1] Funding Source:
   UKRI; Engineering and Physical Sciences Research Council [EP/I033270/1]
   Funding Source: researchfish; Fight for Sight [1777/78] Funding Source:
   researchfish
FX The research was supported by the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology. The views expressed
   are those of the author(s) and not necessarily those of the NHS, the
   NIHR, or the Department of Health.
CR Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0
   Baker R, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14270
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8
   Brazier J, 2004, HEALTH ECON, V13, P873, DOI 10.1002/hec.866
   Brazier J., 2016, MEASURING VALUING HL, V2, DOI 10.1093/med/9780198725923.001.0001
   Brazier J, 2005, APPL HEALTH ECON HEA, V4, P201, DOI 10.2165/00148365-200504040-00002
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
   Drummond MF, 2005, METHODS EC EVALUATIO
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Gold MR., 1996, COST EFFECTIVENESS H
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Mitchell J, 2005, INT C SER, V1282, P654
   MVH Group, 1995, MEAS VAL HLTH
   NICE, 2008, GUID METH TECHN APPR
   NORD E, 1993, HEALTH POLICY, V24, P227, DOI 10.1016/0168-8510(93)90042-N
   Peacock S, 2008, OPHTHAL EPIDEMIOL, V15, P218, DOI 10.1080/09286580801979417
   Rowen D, 2012, MED DECIS MAKING, V32, P31, DOI 10.1177/0272989X11408435
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   Torrance G W, 1972, Health Serv Res, V7, P118
   TORRANCE GW, 1976, SOCIO ECON PLAN SCI, V10, P129, DOI 10.1016/0038-0121(76)90036-7
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
NR 26
TC 16
Z9 16
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2013
VL 90
IS 8
BP 855
EP 860
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 298SP
UT WOS:000330345000017
PM 23811607
DA 2022-11-30
ER

PT J
AU Terasaki, H
   Kase, S
   Shirasawa, M
   Otsuka, H
   Hisatomi, T
   Sonoda, S
   Ishida, S
   Ishibashi, T
   Sakamoto, T
AF Terasaki, Hiroto
   Kase, Satoru
   Shirasawa, Makoto
   Otsuka, Hiroki
   Hisatomi, Toshio
   Sonoda, Shozo
   Ishida, Susumu
   Ishibashi, Tatsuro
   Sakamoto, Taiji
TI TNF-alpha Decreases VEGF Secretion in Highly Polarized RPE Cells but
   Increases It in Non-Polarized RPE Cells Related to Crosstalk between JNK
   and NF-kappa B Pathways
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL-CELLS; CHOROIDAL
   NEOVASCULAR MEMBRANES; ACTIVATED PROTEIN-KINASES; MACULAR DEGENERATION;
   OXIDATIVE-STRESS; EXPRESSION; INHIBITION; CHORIOCAPILLARIS; MACROPHAGES
AB Asymmetrical secretion of vascular endothelial growth factor (VEGF) by retinal pigment epithelial (RPE) cells in situ is critical for maintaining the homeostasis of the retina and choroid. VEGF is also involved in the development and progression of age-related macular degeneration (AMD). We studied the effect of tumor necrosis factor-alpha (TNF-alpha) on the secretion of VEGF in polarized and non-polarized RPE cells (P-RPE cells and N-RPE cells, respectively) in culture and in situ in rats. A subretinal injection of TNF-alpha caused a decrease in VEGF expression and choroidal atrophy. Porcine RPE cells were seeded on Transwell (TM) filters, and their maturation and polarization were confirmed by the asymmetrical VEGF secretion and trans electrical resistance. Exposure to TNF-alpha decreased the VEGF secretion in P-RPE cells but increased it in N-RPE cells in culture. TNF-alpha inactivated JNK in P-RPE cells but activated it in N-RPE cells, and TNF-alpha activated NF-kappa B in P-RPE cells but not in N-RPE cells. Inhibition of NF-kappa B activated JNK in both types of RPE cells indicating crosstalk between JNK and NF-kappa B. TNF-alpha induced the inhibitory effects of NF-kappa B on JNK in P-RPE cells because NF-kappa B is continuously inactivated. In N-RPE cells, however, it was not evident because NF-kappa B was already activated. The basic activation pattern of JNK and NF-kappa B and their crosstalk led to opposing responses of RPE cells to TNF-alpha. These results suggest that VEGF secretion under inflammatory conditions depends on cellular polarization, and the TNF-alpha-induced VEGF down-regulation may result in choroidal atrophy in polarized physiological RPE cells. TNF-alpha-induced VEGF up-regulation may cause neovascularization by non-polarized or non-physiological RPE cells.
C1 [Terasaki, Hiroto; Shirasawa, Makoto; Otsuka, Hiroki; Sonoda, Shozo; Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 890, Japan.
   [Kase, Satoru; Ishida, Susumu] Hokkaido Univ, Dept Ophthalmol, Sapporo, Hokkaido, Japan.
   [Hisatomi, Toshio; Ishibashi, Tatsuro] Kyushu Univ, Dept Ophthalmol, Fukuoka 812, Japan.
C3 Kagoshima University; Hokkaido University; Kyushu University
RP Sakamoto, T (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 890, Japan.
EM tsakamot@m3.kufm.kagoshima-u.ac.jp
OI Hisatomi, Toshio/0000-0003-2552-9595
FU Research Committee on 18 Chorioretinal Degeneration and Optic Atrophy,
   Ministry of Health, Labor, and Welfare; Ministry of Education, Science,
   and Culture of the Japanese Government [20390450]
FX Supported in part by a grant from the Research Committee on 18
   Chorioretinal Degeneration and Optic Atrophy, Ministry of Health, Labor,
   and Welfare (to TS), and by a Grant-in-Aid for Scientific Research (No
   20390450) from the Ministry of Education, Science, and Culture of the
   Japanese Government. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467
   Baffert F, 2006, AM J PHYSIOL-HEART C, V290, pH547, DOI 10.1152/ajpheart.00616.2005
   Bian ZM, 2007, INVEST OPHTH VIS SCI, V48, P2738, DOI 10.1167/iovs.06-1023
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BOK D, 1993, J CELL SCI, P189
   Burke JM, 2008, PROG RETIN EYE RES, V27, P579, DOI 10.1016/j.preteyeres.2008.08.002
   De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Guma M, 2009, P NATL ACAD SCI USA, V106, P8760, DOI 10.1073/pnas.0902659106
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Honorati MC, 2004, OSTEOARTHR CARTILAGE, V12, P683, DOI 10.1016/j.joca.2004.05.009
   Josko J, 2004, MED SCI MONITOR, V10, pRA89
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P893
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martelli A, 2009, REPRODUCTION, V137, P45, DOI 10.1530/REP-08-0117
   MILLER SS, 1982, P NATL ACAD SCI-BIOL, V79, P2111, DOI 10.1073/pnas.79.6.2111
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Otsuka H, 2010, AM J PATHOL, V177, P2268, DOI 10.2353/ajpath.2010.100134
   Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200
   Papa S, 2009, BIOL CHEM, V390, P965, DOI 10.1515/BC.2009.111
   Rizzolo LJ, 1997, HISTOL HISTOPATHOL, V12, P1057
   RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523
   Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568
   Woo JM, 2012, MOL VIS, V18, P901
   Yin YM, 2009, BIOMED PHARMACOTHER, V63, P429, DOI 10.1016/j.biopha.2009.04.045
   Yoshinaga N, 2011, LAB INVEST, V91, P1277, DOI 10.1038/labinvest.2011.101
   Yoshino Y, 2006, INT J ONCOL, V29, P981
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 42
TC 32
Z9 34
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 29
PY 2013
VL 8
IS 7
AR e69994
DI 10.1371/journal.pone.0069994
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 204MP
UT WOS:000323369700115
PM 23922887
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Sato, Y
   Kondo, Y
   Sumi, M
   Takekuma, Y
   Sugawara, M
AF Sato, Yuki
   Kondo, Yu
   Sumi, Masato
   Takekuma, Yoh
   Sugawara, Mitsuru
TI Intracellular Uptake Mechanism of Lutein in Retinal Pigment Epithelial
   Cells
SO JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
LA English
DT Article
ID SERUM CONCENTRATIONS; BINDING PROTEIN; SR-BI; ZEAXANTHIN; CAROTENOIDS;
   TRANSPORT; ARPE-19; INVOLVEMENT; EXPRESSION; DENSITY
AB Purpose. Lutein is a carotenoid mainly found in green leafy vegetables and is located in the macula lutea in the human eye. It has received much attention recently due to its preventive effect on age-related macular degeneration, and it has been consumed as a supplement. However, little information about the pharmacokinetic properties of lutein is available. Detailed knowledge of pharmacokinetic properties of lutein is needed for the development of pharmaceutics. In this study, we focused on the macular accumulation of lutein and investigated the uptake mechanism into human retinal pigment epithelial cells. Methods. ARPE-19 cells were used for the study on the accumulation mechanism of lutein. The concentration of lutein was determined using an HPLC system. Involvement of scavenger class B type 1 (SR-B1) in the accumulation of lutein in ARPE-19 cells was suggested from the results of an inhibition study using block lipid transport 1 (BLT-1), a selective inhibitor of SR-B1. To investigate the involvement of SR-B1 in more detail, small interfering RNA (siRNA) was transfected and the mRNA and protein expression levels of SR-B1 were assessed by quantitative real-time reverse transcription polymerase chain reaction and Western blotting, respectively. Results. We confirmed a sufficient siRNA knockdown effect in both mRNA and protein expression levels of SR-B1. We then found that lutein uptake was significantly decreased by siRNA knockdown of SR-B1. Conclusion. The uptake of lutein was significantly decreased by 40% compared with the control uptake level. This suggested that active transport of lutein into ARPE-19 cells is mainly via SR-B1, given the result that lutein uptake at 4 degrees C was about 40% less that that at 37 degrees C.
C1 [Sato, Yuki; Kondo, Yu; Sumi, Masato; Takekuma, Yoh; Sugawara, Mitsuru] Hokkaido Univ, Fac Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 060, Japan.
C3 Hokkaido University
RP Sugawara, M (通讯作者)，Hokkaido Univ, Fac Pharmaceut Sci, Kita Ku, Kita 12 Jo,Nishi 6 Chome, Sapporo, Hokkaido 060, Japan.
EM msuga@pharm.hokudai.ac.jp
RI Sugawara, Mitsuru/A-5274-2012; Takekuma, Yoh/F-9723-2012
OI Sugawara, Mitsuru/0000-0001-5350-2950; Takekuma, Yoh/0000-0002-4325-0785
FU Northern Advancement Center for Science & Technology of Hokkaido; Japan
   Society for the Promotion of Science (JSPS) [24790140]
FX We thank JARD Inc. and Koyo Mercantile Co., Ltd. for providing lutein.
   This work was supported in part by Grants-in-Aid for Regional R&D
   Proposal-Based Program from Northern Advancement Center for Science &
   Technology of Hokkaido and Grants-in-Aid for Young Scientists (B) (Grant
   number 24790140) from the Japan Society for the Promotion of Science
   (JSPS).
CR Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485
   Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131
   Betters JL, 2010, FEBS LETT, V584, P2740, DOI 10.1016/j.febslet.2010.03.030
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Chisaki I, 2009, BBA-BIOMEMBRANES, V1788, P2396, DOI 10.1016/j.bbamem.2009.08.014
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Duong M, 2006, ARTERIOSCL THROM VAS, V26, P541, DOI 10.1161/01.ATV.0000203515.25574.19
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   During A, 2005, J NUTR, V135, P2305, DOI 10.1093/jn/135.10.2305
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Granado F, 2003, BRIT J NUTR, V90, P487, DOI 10.1079/BJN2003927
   Granado F., 1996, European Journal of Clinical Nutrition, V50, P246
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Landrum JT, 1999, PURE APPL CHEM, V71, P2237, DOI 10.1351/pac199971122237
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Lornejad-Schafer MR, 2007, EUR J NUTR, V46, P79, DOI 10.1007/s00394-006-0635-6
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Olmedilla B, 2001, BRIT J NUTR, V85, P227, DOI 10.1079/BJN2000248
   Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554
   Sato Y, 2012, J PHARM PHARM SCI, V15, P256, DOI 10.18433/J38K56
   Sato Y, 2011, BIOPHARM DRUG DISPOS, V32, P151, DOI 10.1002/bdd.746
   Vachali P, 2012, ARCH BIOCHEM BIOPHYS, V519, P32, DOI 10.1016/j.abb.2012.01.006
   Yamamoto A, 2010, J PHARM SCI-US, V99, P2475, DOI 10.1002/jps.21991
   [No title captured]
NR 31
TC 14
Z9 14
U1 1
U2 8
PU CANADIAN SOC PHARMACEUTICAL SCIENCES
PI EDMONTON
PA 3118 DENTISTRY-PHARMACY CENTRE UNIV ALBERTA CAMPUS, EDMONTON, ALBERTA
   T6G2N8, CANADA
EI 1482-1826
J9 J PHARM PHARM SCI
JI J. Pharm. Pharm. Sci.
PY 2013
VL 16
IS 3
BP 494
EP 501
DI 10.18433/J33K61
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 206SC
UT WOS:000323541700010
PM 24021296
OA gold
DA 2022-11-30
ER

PT J
AU Klein, R
   Meuer, SM
   Knudtson, MD
   Iyengar, SK
   Klein, BEK
AF Klein, Ronald
   Meuer, Stacy M.
   Knudtson, Michael D.
   Iyengar, Sudha K.
   Klein, Barbara E. K.
TI The epidemiology of retinal reticular drusen
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER-DAM EYE; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   VISUAL-ACUITY; 10-YEAR PERIOD; HIGH-RISK; POPULATION; AUTOFLUORESCENCE;
   PROGRESSION; PREVALENCE
AB PURPOSE: To describe the prevalence and 15-year cumulative incidence of and risk factors for reticular drusen.
   DESIGN: Population-based prospective study.
   METHODS: Four thousand nine hundred and twenty-six persons, 43 to 86 years of age, were included between 1988 and 1990, of whom 3 684, 2,764, and 2,119 participated in five-, 10-, and 15-year follow-up examinations, respectively, in Beaver Dam, Wisconsin. Main outcome measures included prevalence and 15-year incidence of reticular drusen determined by grading stereoscopic color fundus photographs.
   RESULTS: The prevalence at baseline and the 15-year cumulative incidence in either eye of reticular drusen was 0.7% and 3.0%, respectively. The 15-year incidence of reticular drusen varied with. age from 0.4% in those 43 to 54 years of age to 6.6% in those 75 years or older at baseline (P <.001). In a multivariate model, while controlling for age, risk factors statistically significantly associated with increased risk of incident reticular drusen included: being female (odds ratio [OR], 2.8), current smoking (OR vs never, 1.9), less education (OR per category, 1.7), B-vitamin complex use (OR vs none, 2.5), single vitamin B (OR vs none, 2.9), history of steroid eye drops use (OR, 5.9), glaucoma (OR, 2.8), and more severe drusen type (e.g., soft indistinct drusen; OR, 1.4), whereas diabetes (OR, 0.1) at baseline was associated with decreased risk. Right eyes with reticular drusen at baseline had higher cumulative incidence of geographic atrophy (21% vs 9%) and exudative age-related macular degeneration [AMD] (20% vs 10%) compared with eyes with soft indistinct drusen.
   CONCLUSIONS: This population based study documents the long-term cumulative incidence of reticular drusen and its risk factors and shows its association with a high risk of incident late AMD.
C1 [Klein, Ronald; Meuer, Stacy M.; Knudtson, Michael D.; Klein, Barbara E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   [Iyengar, Sudha K.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Case
   Western Reserve University
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, 610 N Walnut St,417 WARF, Madison, WI 53726 USA.
EM kteinr@epi.ophth.wisc.edu
RI /S-1190-2019
OI /0000-0001-7488-250X; Klein, Ronald/0000-0002-4428-6237
FU NATIONAL EYE INSTITUTE [U10EY006594] Funding Source: NIH RePORTER; NEI
   NIH HHS [U10 EY006594, U10 EY006594-20, EY 06594] Funding Source:
   Medline
CR [Anonymous], [No title captured]
   Arnold J, 1996, RETINA-J RET VIT DIS, V16, P168, DOI 10.1097/00006982-199616020-00020
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Fleiss JL, 1973, STATISTICAL METHODS, P162
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   GASS JD, 1987, STEREOSCOPIC ATLAS M, P662
   Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hosmer DW, 1989, APPL LOGISTIC REGRES, P238
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, BEAVER DAM EYE STUDY, V2
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Knudtson MD, 2004, INVEST OPHTH VIS SCI, V45, P2135, DOI 10.1167/iovs.03-1085
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   SAITO Y, 1990, BRIT J OPHTHALMOL, V74, P702, DOI 10.1136/bjo.74.11.702
   Sliney D. H., 1999, J EPIDEMIOL, V9, P22, DOI DOI 10.2188/JEA.9.6SUP_22
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
NR 33
TC 166
Z9 171
U1 0
U2 46
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2008
VL 145
IS 2
BP 317
EP 326
DI 10.1016/j.ajo.2007.09.008
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 263GG
UT WOS:000253205000021
PM 18045568
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Thornblad, TA
   Elliott, KS
   Jowett, J
   Visscher, PM
AF Thornblad, Tobias A.
   Elliott, Kate S.
   Jowett, Jeremy
   Visscher, Peter M.
TI Prioritization of positional candidate genes using multiple web-based
   software tools
SO TWIN RESEARCH AND HUMAN GENETICS
LA English
DT Article
ID ASSOCIATION; SCHIZOPHRENIA; DATABASE; NEUREGULIN-1
AB The prioritization of genes within a candidate genomic region is an important step in the identification of causal gene variants affecting complex traits. Surprisingly, there have been very few reports of bioinformatics tools to perform such prioritization. The purpose of this article is to investigate the performance of 3 positional candidate gene software tools available, PosMed, GeneSniffer and SUSPECTS. The comparison was made for 40, 20 and 10 Mb regions in the human genome centred around known susceptibility genes for the common diseases breast cancer, Crohn's disease, age-related macular degeneration and schizophrenia. The known susceptibility gene was not always ranked highly, or not ranked at all, by 1 or more of the software tools. There was a large variation between the 3 tools regarding which genes were prioritized, and their rank order. PosMed and GeneSniffer were most similar in their prioritization gene list, whereas SUSPECTS identified the same candidate genes only for the narrowest (10 Mb) regions. Combining 2 or all of the candidate gene finding tools was superior in terms of ranking positional candidates. It is possible to reduce the number of candidate genes from a starting set in a region of interest by combining a variety of candidate gene finding tools. Conversely, we recommend caution in relying solely on single positional candidate gene prioritization tools. Our results confirm the obvious, that is, that starting with a narrower positional region gives a higher likelihood that the true susceptibility gene is selected, and that it is ranked highly. A narrow confidence interval for the mapping of complex trait genes by linkage can be achieved by maximizing marker informativeness and by having large samples. Our results suggest that the best approach to classify a minimum set of candidate genes is to take those genes that are prioritized by multiple prioritization tools.
C1 [Thornblad, Tobias A.; Visscher, Peter M.] Queensland Inst Med Res, Brisbane, Qld 4029, Australia.
   [Elliott, Kate S.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England.
   [Jowett, Jeremy] Int Diabet Inst, Caulfield, Vic, Australia.
C3 QIMR Berghofer Medical Research Institute; University of Oxford;
   Wellcome Centre for Human Genetics
RP Thornblad, TA (通讯作者)，Queensland Inst Med Res, 300 Herston Rd, Brisbane, Qld 4029, Australia.
EM tobias.thornblad@gmail.com
RI Visscher, Peter/ABB-6151-2020; Jowett, Jeremy/A-3809-2009
OI Visscher, Peter/0000-0002-2143-8760; Thornblad,
   Tobias/0000-0001-8171-2429
CR Abecasis GR, 2000, AM J HUM GENET, V66, P279, DOI 10.1086/302698
   Adie EA, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-55
   Aerts S, 2006, NAT BIOTECHNOL, V24, P719, DOI 10.1038/nbt0606-719d
   Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504-431
   Blake JA, 2006, NUCLEIC ACIDS RES, V34, pD562, DOI 10.1093/nar/gkj085
   Blaveri E, 2001, EUR J HUM GENET, V9, P469, DOI 10.1038/sj.ejhg.5200646
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Faraone SV, 2004, HUM HERED, V57, P59, DOI 10.1159/000077543
   Franke L, 2006, AM J HUM GENET, V78, P1011, DOI 10.1086/504300
   Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641
   Jensen LJ, 2006, NAT REV GENET, V7, P119, DOI 10.1038/nrg1768
   Katiyar Pragati, 2006, Nucl Recept Signal, V4, pe006
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kossakowska AE, 1999, ANN NY ACAD SCI, V878, P578, DOI 10.1111/j.1749-6632.1999.tb07732.x
   LORD P, 2003, PAC S BIOCOMPUT, V8, P601
   *MCKUSICK NATH I G, 2006, GENESNIFFER ACC DAT
   Mendoza JL, 2005, REV ESP ENFERM DIG, V97, P46
   Morton NE, 2003, PHILOS T ROY SOC B, V358, P1701, DOI 10.1098/rstb.2003.1357
   Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046
   *NCBI, 2006, ACC US POSMED
   *OMIM, 2006, ACC US POSMED
   Pruitt KD, 2000, TRENDS GENET, V16, P44, DOI 10.1016/S0168-9525(99)01882-X
   Sourvinos G, 1997, TUMOR BIOL, V18, P157, DOI 10.1159/000218026
   Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734
   Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212
   Tiffin N, 2005, NUCLEIC ACIDS RES, V33, P1544, DOI 10.1093/nar/gki296
   Tiffin N, 2006, NUCLEIC ACIDS RES, V34, P3067, DOI 10.1093/nar/gkl381
   Tosato S, 2005, SCHIZOPHRENIA BULL, V31, P613, DOI 10.1093/schbul/sbi043
   Visscher PM, 2004, BEHAV GENET, V34, P477, DOI 10.1023/B:BEGE.0000023652.93162.e8
   Wei J, 2004, NEUROSCI LETT, V366, P336, DOI 10.1016/j.neulet.2004.05.063
   Zhang YB, 2004, AM J MED GENET B, V129B, P16, DOI 10.1002/ajmg.b.30076
NR 31
TC 27
Z9 28
U1 0
U2 2
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1832-4274
EI 1839-2628
J9 TWIN RES HUM GENET
JI Twin Res. Hum. Genet.
PD DEC
PY 2007
VL 10
IS 6
BP 861
EP 870
DI 10.1375/twin.10.6.861
PG 10
WC Genetics & Heredity; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Obstetrics & Gynecology
GA 242LW
UT WOS:000251727600010
PM 18179399
DA 2022-11-30
ER

PT J
AU Cai, WB
   Ma, JF
   Li, CY
   Yang, ZH
   Yang, X
   Liu, W
   Liu, ZG
   Li, MT
   Gao, GQ
AF Cai, WB
   Ma, JF
   Li, CY
   Yang, ZH
   Yang, X
   Liu, W
   Liu, ZG
   Li, MT
   Gao, GQ
TI Enhanced anti-angiogenic effect of a deletion mutant plasminogen kringle
   5 on of neovascularization
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE plasminogen kringle 5; angiogenic inhibitors; mutation; pathologic
   neovascularization
ID EPITHELIUM-DERIVED FACTOR; ENDOTHELIAL GROWTH-FACTOR; RETINAL
   NEOVASCULARIZATION; VASCULAR LEAKAGE; TUMOR-GROWTH; INHIBITOR;
   ANGIOSTATIN; CELLS; RATS; APOPTOSIS
AB Kringle 5 (K5), a proteolytic fragment of plasminogen, has been proved to be an angiogenic inhibitor. Previously, we have evaluated the effect of K5 on the vascular leakage and neovascularization in a rat model of oxygen-induced retinopathy. In this study, we expressed K5 and a deletion mutant of K5 (K5 mutant) in a prokaryocyte expression system and purified them by affinity chromatography. K5 mutant was generated by deleting 11 amino acids from K5 while retaining the three disulfide bonds. The anti-angiogenic activity of intact K5 and K5 mutant were compared in endothelial cells and retinal neovascularization rat model. K5 mutant inhibited the proliferation of primary human retinal capillary endothelial cells (HRCEC) in a concentration-dependent manner, with an apparent EC50 of approximate 35 nmol/L,which is twofold more potent than intact K5. In the even higher concentration range, K5 mutant did not inhibit pericytes from the same origin of HRCEC, which suggested an endothelial cell-specific inhibition. K5 mutant had no effect on normal liver cells and Bel7402 hepatoma cells even at high concentration range either. Intravitreal injection of the K5 and mutant in the oxygen-induced retinopathy rat model both resulted in significantly fewer neovascular tufts and nonperfusion area than controls with PBS injection, as shown by fluorescein angiography. Furthermore, K5 mutant exhibited more strong inhibition effect on neovascularization than intact K5 by quantification of vascular cells. These results suggest that this K5 deletion mutant is a more potent angiogenic inhibitor than intact K5 and may have therapeutic potential in the treatment of those disorders with neovascularization, such as solid tumor, diabetic retinopathy, age-related macular degeneration, rheumatoid arthritis, and hyperplasia of prostate. J. Cell. Biochem. 96: 1254-1261, 2005. (c) 2005 Wiley-Liss, Inc.
C1 Sun Yat Sen Univ, Zhongshan Med Sch, Dept Biochem, Guangzhou 510089, Guangdong, Peoples R China.
   476 Hosp PLA, Dept Internal Med, Fuzhou 350002, Fujian Province, Peoples R China.
   Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510089, Guangdong, Peoples R China.
   Sun Yat Sen Univ, Zhongshan Med Sch, Proteom Lab, Guangzhou 510089, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University
RP Gao, GQ (通讯作者)，Sun Yat Sen Univ, Zhongshan Med Sch, Dept Biochem, Guangzhou 510089, Guangdong, Peoples R China.
EM gaog@gzsums.edu.cn
CR Cai Wei-Bin, 2004, Sheng Li Ke Xue Jin Zhan, V35, P159
   Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924
   Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461
   Castellino FJ, 1997, CIBA F SYMP, V212, P46
   CASTELLINO FJ, 1997, CIBA F SYMP, V212, P60
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Franck-Lissbrant I, 1998, ENDOCRINOLOGY, V139, P451, DOI 10.1210/en.139.2.451
   Gao G, 2003, DIABETOLOGIA, V46, P689, DOI 10.1007/s00125-003-1085-9
   Gao GQ, 2002, DIABETES, V51, P1218, DOI 10.2337/diabetes.51.4.1218
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   GRANT MB, 1991, INVEST OPHTH VIS SCI, V32, P53
   Hamanaka T, 2001, AM J OPHTHALMOL, V132, P648, DOI 10.1016/S0002-9394(01)01108-4
   Ji WR, 1998, BIOCHEM BIOPH RES CO, V247, P414, DOI 10.1006/bbrc.1998.8825
   Jimenez B, 2001, J MOL MED-JMM, V78, P663, DOI 10.1007/s001090000178
   Koch AE, 2003, ANN RHEUM DIS, V62, P60, DOI 10.1136/ard.62.suppl_2.ii60
   Kontogeorgos G, 2003, MICROSC RES TECHNIQ, V60, P59, DOI 10.1002/jemt.10243
   Lu H, 1999, BIOCHEM BIOPH RES CO, V258, P668, DOI 10.1006/bbrc.1999.0612
   Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200
   O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926
   OREILLY MS, 1994, COLD SPRING HARB SYM, V59, P471, DOI 10.1101/SQB.1994.059.01.052
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   Zhang D, 2001, DIABETOLOGIA, V44, P757, DOI 10.1007/s001250051685
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhang SX, 2004, DIABETOLOGIA, V47, P124, DOI 10.1007/s00125-003-1276-4
NR 27
TC 10
Z9 19
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD DEC 15
PY 2005
VL 96
IS 6
BP 1254
EP 1261
DI 10.1002/jcb.20601
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 985CF
UT WOS:000233353000015
PM 16167344
DA 2022-11-30
ER

PT J
AU Jonas, JB
   Kreissig, I
   Degenring, R
AF Jonas, JB
   Kreissig, I
   Degenring, R
TI Intraocular pressure after intravitreal injection of triamcinolone
   acetonide
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID EXPERIMENTAL PROLIFERATIVE VITREORETINOPATHY; EXUDATIVE MACULAR
   DEGENERATION; OPTIC-NERVE HEAD; CRYSTALLINE CORTISONE; ADJUNCTIVE
   TREATMENT; RETINAL TOXICITY; DELIVERY DEVICE; RAT MODEL;
   NEOVASCULARIZATION; EDEMA
AB Aim: To investigate the intraocular pressure (IOP) response after intravitreal injections of triamcinolone acetonide as treatment of intraocular neovascular or oedematous diseases.
   Methods: The prospective consecutive non-comparative interventional case series study included 71 patients (75 eyes) with progressive exudative age related macular degeneration (n=64 eyes) or diffuse diabetic macular oedema (n=11 eyes), who received an intravitreal injection of 25 mg triamcinolone acetonide. Mean follow up time was 6.86 (SD 2.52) months (range 3.1-14.47 months).
   Results: IOP increased significantly (p<0.001) from 15.43 (3.26) mm Hg preoperatively to a mean maximum of 23.38 (8.37) mm Hq (range 13-64 mm Hg) postoperatively. An IOP rise to values higher than 21 mm Hg was observed in 39 (52%) eyes. Elevation of IOP occurred about 2 months after the injection. Preoperative predictive factor for the rise in IOP was younger age (p=0.013). It was statistically independent of refractive error, presence of diabetes mellitus, and indication for the injection. In all but one eye, IOP could be lowered to the normal range with topical medication, without development of glaucomatous optic nerve head changes. In the eyes with an elevation of IOP, IOP normalised about 6 months after the injection, without further medication. Eyes undergoing repeatedly intravitreal injections of triamcinolone acetonide showed only an elevation of IOP, if after the first injection a rise of IOP had occurred.
   Conclusions: After intravitreal injections of 25 mg of triamcinolone acetonide, an IOP elevation can develop in about 50% of eyes, starting about 1-2 months after the injection. In the vast majority, IOP can be normalised by topical medication, and returns to normal values without further medication about 6 months after the injection.
C1 Univ Heidelberg, Augenklin, Fac Clin Med Mannheim, Dept Ophthalmol, D-68167 Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf
RP Jonas, JB (通讯作者)，Univ Heidelberg, Augenklin, Fac Clin Med Mannheim, Dept Ophthalmol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
RI CLIHON, Residencia Medica/K-4896-2013
OI CLIHON, Residencia Medica/0000-0001-6734-2513
CR Antcliff RJ, 2001, OPHTHALMOLOGY, V108, P765, DOI 10.1016/S0161-6420(00)00658-8
   ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   BECKER B, 1965, ARCH OPHTHALMOL-CHIC, V74, P621
   BECKER B, 1966, ARCH OPHTHALMOL-CHIC, V76, P477
   Berger AS, 1996, INVEST OPHTH VIS SCI, V37, P2318
   BIGGER JF, 1972, NEW ENGL J MED, V287, P992
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Giles C L, 1974, Am J Ophthalmol, V77, P438
   GRAHAM RO, 1974, ARCH OPHTHALMOL-CHIC, V92, P149, DOI 10.1001/archopht.1974.01010010155016
   Greenberg PB, 2002, BRIT J OPHTHALMOL, V86, P247, DOI 10.1136/bjo.86.2.247
   HIDA T, 1986, AM J OPHTHALMOL, V101, P190, DOI 10.1016/0002-9394(86)90593-3
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jaffe GJ, 2000, OPHTHALMOLOGY, V107, P2024, DOI 10.1016/S0161-6420(00)00466-8
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Jonas JB, 2001, AM J OPHTHALMOL, V132, P425, DOI 10.1016/S0002-9394(01)01010-8
   Jonas JB, 2000, BRIT J OPHTHALMOL, V84, P1064, DOI 10.1136/bjo.84.9.1064
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Jonas JB, 2001, J GLAUCOMA, V10, P284, DOI 10.1097/00061198-200108000-00007
   Jonas JB, 2001, GRAEF ARCH CLIN EXP, V239, P464, DOI 10.1007/s004170100293
   Jonas JB, 2001, AM J OPHTHALMOL, V131, P468, DOI 10.1016/S0002-9394(00)00882-5
   Kivilcim M, 2000, OPHTHALMIC SURG LAS, V31, P474
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
   Machemer R, 1996, RETINA-J RET VIT DIS, V16, P166, DOI 10.1097/00006982-199616020-00017
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   McCullough DG, 1998, J ECON ENTOMOL, V91, P785, DOI 10.1093/jee/91.4.785
   MCLEAN EB, 1975, AM J OPHTHALMOL, V80, P835, DOI 10.1016/0002-9394(75)90280-9
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Reinhard T, 2002, TRANSPLANT INT, V15, P81, DOI 10.1007/s00147-002-0381-5
   SCHINDLER RH, 1982, AM J OPHTHALMOL, V93, P415, DOI 10.1016/0002-9394(82)90130-1
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   TANO Y, 1980, AM J OPHTHALMOL, V90, P810, DOI 10.1016/S0002-9394(14)75196-7
   Wingate RJB, 1999, AUST NZ J OPHTHALMOL, V27, P431
   Yang CS, 1998, ARCH OPHTHALMOL-CHIC, V116, P69, DOI 10.1001/archopht.116.1.69
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
NR 42
TC 294
Z9 331
U1 0
U2 2
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2003
VL 87
IS 1
BP 24
EP 27
DI 10.1136/bjo.87.1.24
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 631RN
UT WOS:000180180700008
PM 12488256
OA Green Submitted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Kahiel, Z
   Grant, A
   Aubin, MJ
   Buhrmann, R
   Kergoat, MJ
   Freeman, EE
AF Kahiel, Zaina
   Grant, Alyssa
   Aubin, Marie-Josee
   Buhrmann, Ralf
   Kergoat, Marie-Jeanne
   Freeman, Ellen E.
TI Vision, Eye Disease, and the Onset of Balance Problems: The Canadian
   Longitudinal Study on Aging
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CATARACT-SURGERY; POSTURAL STABILITY; VISUAL IMPAIRMENT; INJURIOUS
   FALLS; OLDER-ADULTS; MOBILITY; VALIDITY; 1ST
AB PURPOSE: To understand the relationship between visual impairment, self-reported eye disease, and the onset of balance problems.
   DESIGN: Population-based prospective cohort study.
   METHODS: Baseline and 3-year follow-up data were used from the Canadian Longitudinal Study on Aging. The Comprehensive Cohort included 30,097 adults aged 45 to 85 years recruited from 11 sites across 7 provinces. Balance was measured using the 1-leg balance test. Those who could not stand on 1 leg for at least 60 seconds failed the balance test. Presenting visual acuity was measured using the Early Treatment of Diabetic Retinopathy Study chart. Participants were asked about a previous diagnosis of cataract, macular degeneration, or glaucoma. Logistic regression was used.
   RESULTS: Of the 12,158 people who could stand for 60 seconds on 1 leg at baseline, 18% were unable to do the same 3 years later. For each line worse of visual acuity, there was a 15% higher odds of failing the balance test at follow-up (odds ratio [OR] = 1.15, 95% confidence interval [CI] 1.10, 1.20) after adjustment. Those with a report of a former (OR = 1.59, 95% CI 1.17, 2.16) or current cataract (OR = 1.31, 95% CI 1.01, 1.68) were more likely to fail the test at follow-up. Age-related macular degeneration and glaucoma were not associated with failure on the balance test.
   CONCLUSION: These data provide longitudinal evidence that vision loss increases the odds of balance problems over a 3-year period. Efforts to prevent avoidable vision loss are needed, as are efforts to improve the balance of visually impaired people. (C) 2021 The Author(s). Published by Elsevier Inc.
C1 [Kahiel, Zaina; Freeman, Ellen E.] Univ Ottawa, Sch Epidemiol & Publ Hlth, 600 Peter Morand Crescent, Ottawa, ON K1G 5Z3, Canada.
   [Aubin, Marie-Josee] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Aubin, Marie-Josee] Maisonneuve Rosemont Hosp, Montreal, PQ, Canada.
   [Aubin, Marie-Josee] Univ Montreal, Ecole Sante Publ, Montreal, PQ, Canada.
   [Buhrmann, Ralf; Freeman, Ellen E.] Univ Ottawa, Inst Eye, Ottawa, ON, Canada.
   [Aubin, Marie-Josee] Inst Univ Geriatrie Montreal, Montreal, PQ, Canada.
   [Buhrmann, Ralf; Freeman, Ellen E.] Ottawa Hosp, Res Inst, Ottawa, ON, Canada.
C3 University of Ottawa; Universite de Montreal; Universite de Montreal;
   Universite de Montreal; University of Ottawa; Ottawa Hospital Research
   Institute; Universite de Montreal; University of Ottawa; Ottawa Hospital
   Research Institute
RP Freeman, EE (通讯作者)，Univ Ottawa, Sch Epidemiol & Publ Hlth, 600 Peter Morand Crescent, Ottawa, ON K1G 5Z3, Canada.
EM eefreeman@gmail.com
OI Aubin, Marie-Josee/0000-0003-0392-3110; Kergoat,
   Marie-Jeanne/0000-0002-0981-1008
FU Government of Canada through the Canadian Institutes of Health Research
   (CIHR) [LSA 94473, ACD 170303]; Canada Foundation for Innovation
FX This research was made possible using the data collected by the Canadian
   Longitudinal Study on Aging (CLSA). Funding for the Canadian
   Longitudinal Study on Aging (CLSA) is provided by the Government of
   Canada through the Canadian Institutes of Health Research (CIHR) under
   grants LSA 94473 and ACD 170303 and also by the Canada Foundation for
   Innovation. The funders had no role in the analysis or the
   interpretation of results. Financial Disclosures: No financial
   disclosures. All authors attest that they meet the current ICMJE
   criteria for authorship.
CR Aljied R, 2018, CAN J OPHTHALMOL, V53, P291, DOI 10.1016/j.jcjo.2018.01.027
   Alshammari FS, 2014, DIABETES TECHNOL THE, V16, P822, DOI 10.1089/dia.2014.0183
   Anand V, 2003, INVEST OPHTH VIS SCI, V44, P4670, DOI 10.1167/iovs.03-0455
   Baloh RW, 2003, ARCH NEUROL-CHICAGO, V60, P835, DOI 10.1001/archneur.60.6.835
   Brannan S, 2003, BRIT J OPHTHALMOL, V87, P560, DOI 10.1136/bjo.87.5.560
   Chatard H, 2017, FRONT HUM NEUROSCI, V11, DOI 10.3389/fnhum.2017.00158
   de Luna RA, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.8
   Farhoudi DB, 2018, ACTA OPHTHALMOL, V96, P283, DOI 10.1111/aos.13554
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Franz JR, 2015, HUM MOVEMENT SCI, V40, P381, DOI 10.1016/j.humov.2015.01.012
   Freeman EE, 2008, INVEST OPHTH VIS SCI, V49, P5257, DOI 10.1167/iovs.07-1106
   Giorgetti M M, 1998, Physiother Res Int, V3, P274, DOI 10.1002/pri.150
   Harwood RH, 2005, BRIT J OPHTHALMOL, V89, P53, DOI 10.1136/bjo.2004.049478
   Jorgensen MG, 2013, J GERONTOL A-BIOL, V68, P845, DOI 10.1093/gerona/gls222
   Kotecha A, 2012, INVEST OPHTH VIS SCI, V53, P7795, DOI 10.1167/iovs.12-10866
   Kulmala J, 2012, AGING CLIN EXP RES, V24, P461, DOI 10.3275/8185
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Lord SR, 2000, GERONTOLOGY, V46, P306, DOI 10.1159/000022182
   Lundstrom M, 2018, J CATARACT REFR SURG, V44, P447, DOI 10.1016/j.jcrs.2018.01.031
   McGwin G, 2006, J AM GERIATR SOC, V54, P1089, DOI 10.1111/j.1532-5415.2006.00770.x
   Meuleners LB, 2014, AGE AGEING, V43, P341, DOI 10.1093/ageing/aft177
   Michikawa T, 2009, J ORTHOP SCI, V14, P675, DOI 10.1007/s00776-009-1371-6
   Mihailovic A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.30
   Patty L, 2012, OPHTHALMOLOGY, V119, P1725, DOI 10.1016/j.ophtha.2012.02.029
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x
   Satariano WA, 1996, J AGING HEALTH, V8, P334, DOI 10.1177/089826439600800303
   Schwartz S, 2005, INVEST OPHTH VIS SCI, V46, P920, DOI 10.1167/iovs.04-0543
   Sorbello S, 2020, J AGING PHYS ACTIV, V28, P756, DOI 10.1123/japa.2019-0057
   Sourdet S, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2011.11.003
   Sundermier L, 1996, J GERONTOL A-BIOL, V51, pM45, DOI 10.1093/gerona/51A.2.M45
   Thomas JC, 2014, EXP GERONTOL, V57, P218, DOI 10.1016/j.exger.2014.06.012
   Vellas BJ, 1997, J AM GERIATR SOC, V45, P735, DOI 10.1111/j.1532-5415.1997.tb01479.x
   West CG, 2002, J AM GERIATR SOC, V50, P136, DOI 10.1046/j.1532-5415.2002.50019.x
   Willis JR, 2013, JAMA OPHTHALMOL, V131, P1049, DOI 10.1001/jamaophthalmol.2013.316
   Wilson SJ, 2016, PREV MED, V87, P41, DOI 10.1016/j.ypmed.2016.02.023
NR 36
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2021
VL 231
BP 170
EP 178
DI 10.1016/i.aio.2021.06.008
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA WG0VE
UT WOS:000706716500017
PM 34157278
DA 2022-11-30
ER

PT J
AU Li, T
   Zhou, XD
AF Li, Tao
   Zhou, Xiaodong
TI Causes and Five-Year Proportion of New Irreversible Visual Impairment in
   Jinshan District, Shanghai, from 2009-2018
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISION LOSS; BLINDNESS; PREVALENCE; ADULTS; POPULATION; TRENDS; URBAN
AB Purpose. To describe the age distribution and main causes of new registered irreversible visual impairment (VI) and to compare the five-year proportion of VI in Jinshan district, Shanghai, from 2009 to 2018. Methods. The new irreversible VI data were collected in the registry system from the Disabled Persons' Federation in Jinshan district from January 1, 2009, to December 31, 2018. Age, gender, and causes of VI were included, and the 5-year proportion of VI was calculated. Results. The peak occurrence of blindness occurred in the 50-59 yrs group in 2009-2013 and in the >= 70 yrs group in 2014-2018. The peak occurrence of low vision occurred in the 40-49 yrs group in 2009-2013 and in the 50-59 yrs group in 2014-2018. Myopic macular degeneration (MMD, 15.5%), diabetic retinopathy (DR, 14.3%), and other optic nerve atrophy (ONA, 14.3%) were the three leading causes of blindness in 2009-2013, whereas MMD (21.3%), age-related macular degeneration (AMD, 19.6%), ONA (14.9%) were the three leading causes of blindness in 2014-2018. MMD (39.2%), DR (9.6%), ONA (8.8%) were the three leading causes of low vision in 2009-2013, whereas MMD (38.7%), AMD (23.3%), ONA (7.4%) were the three leading causes of low vision in 2014-2018. The proportions of blindness and low vision caused by AMD were higher in 2014-2018 than those in 2009-2013 (P=0.034 and P<0.001, respectively). Conclusion. The present study demonstrated an increasing trend in the number of irreversibly visually impaired individuals from 2009 to 2018. More attention should be paid to people with high myopia and old age.
C1 [Li, Tao; Zhou, Xiaodong] Fudan Univ, Dept Ophthalmol, Jinshan Hosp, Shanghai, Peoples R China.
   [Li, Tao] Fudan Univ, Dept Ophthalmol, Eye & ENT Hosp, Shanghai, Peoples R China.
C3 Fudan University; Fudan University
RP Zhou, XD (通讯作者)，Fudan Univ, Dept Ophthalmol, Jinshan Hosp, Shanghai, Peoples R China.
EM xdzhou2005@163.com
CR [Anonymous], 2012, TOTAL NUMBER DISABIL
   [Anonymous], 2012, TABULATION 2010 POPU
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Campbell M, 2019, BIOCHEM PHARMACOL, V164, P321, DOI 10.1016/j.bcp.2019.04.029
   Cheng CY, 2020, BRIT J OPHTHALMOL, V104, P616, DOI 10.1136/bjophthalmol-2018-313308
   Chun BY, 2016, CURR OPIN OPHTHALMOL, V27, P475, DOI 10.1097/ICU.0000000000000314
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Figueroa AG, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040910
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Kepa Beata, 2007, Med Wieku Rozwoj, V11, P217
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Mirza E, 2019, EURASIAN J MED, V51, P242, DOI 10.5152/eurasianjmed.2019.18312
   Polack S, 2008, BRIT J OPHTHALMOL, V92, P1026, DOI 10.1136/bjo.2007.134791
   Sainz-Gomez C, 2010, EUR J OPHTHALMOL, V20, P442, DOI 10.1177/112067211002000228
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   Varma R, 2016, JAMA OPHTHALMOL, V134, P785, DOI 10.1001/jamaophthalmol.2016.1261
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wang LH, 2013, INVEST OPHTH VIS SCI, V54, P4117, DOI 10.1167/iovs.13-11911
   Wang W, 2017, JAMA OPHTHALMOL, V135, P1295, DOI 10.1001/jamaophthalmol.2017.3449
   Wu LC, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-10
   Xia F, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0603-3
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
NR 27
TC 4
Z9 4
U1 1
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD JUL 28
PY 2021
VL 2021
AR 8873283
DI 10.1155/2021/8873283
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UA0FZ
UT WOS:000684842700002
PM 34367689
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Choudhury, R
   Bayatti, N
   Scharff, R
   Szula, E
   Tilakaratna, V
   Udsen, MS
   McHarg, S
   Askari, JA
   Humphries, MJ
   Bishop, PN
   Clark, SJ
AF Choudhury, Rawshan
   Bayatti, Nadhim
   Scharff, Richard
   Szula, Ewa
   Tilakaratna, Viranga
   Udsen, Maja Soberg
   McHarg, Selina
   Askari, Janet A.
   Humphries, Martin J.
   Bishop, Paul N.
   Clark, Simon J.
TI FHL-1 interacts with human RPE cells through the alpha 5 beta 1 integrin
   and confers protection against oxidative stress
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMPLEMENT FACTOR-H; BRUCHS MEMBRANE IMPLICATIONS; RETINAL-PIGMENT
   EPITHELIUM; MACULAR DEGENERATION; ATTACHMENT; INHIBITION; MIGRATION;
   BINDING; DAMAGE; INFLAMMATION
AB Retinal pigment epithelial (RPE) cells that underlie the neurosensory retina are essential for the maintenance of photoreceptor cells and hence vision. Interactions between the RPE and their basement membrane, i.e. the inner layer of Bruch's membrane, are essential for RPE cell health and function, but the signals induced by Bruch's membrane engagement, and their contributions to RPE cell fate determination remain poorly defined. Here, we studied the functional role of the soluble complement regulator and component of Bruch's membrane, Factor H-like protein 1 (FHL-1). Human primary RPE cells adhered to FHL-1 in a manner that was eliminated by either mutagenesis of the integrin-binding RGD motif in FHL-1 or by using competing antibodies directed against the alpha 5 and beta 1 integrin subunits. These short-term experiments reveal an immediate protein-integrin interaction that were obtained from primary RPE cells and replicated using the hTERT-RPE1 cell line. Separate, longer term experiments utilising RNAseq analysis of hTERT-RPE1 cells bound to FHL-1, showed an increased expression of the heat-shock protein genes HSPA6, CRYAB, HSPA1A and HSPA1B when compared to cells bound to fibronectin (FN) or laminin (LA). Pathway analysis implicated changes in EIF2 signalling, the unfolded protein response, and mineralocorticoid receptor signalling as putative pathways. Subsequent cell survival assays using H2O2 to induce oxidative stress-induced cell death suggest hTERT-RPE1 cells had significantly greater protection when bound to FHL-1 or LA compared to plastic or FN. These data show a non-canonical role of FHL-1 in protecting RPE cells against oxidative stress and identifies a novel interaction that has implications for ocular diseases such as age-related macular degeneration.
C1 [Choudhury, Rawshan; Bayatti, Nadhim; Scharff, Richard; Szula, Ewa; Tilakaratna, Viranga; McHarg, Selina; Bishop, Paul N.; Clark, Simon J.] Univ Manchester, Div Evolut & Genom Sci, Sch Biol Sci, Fac Biol Med & Hlth, Oxford, England.
   [Udsen, Maja Soberg] Univ Copenhagen, Panum Inst, Dept Immunol & Microbiol, Copenhagen, Denmark.
   [Askari, Janet A.; Humphries, Martin J.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth,Wellcome Ctr Cell Matrix Res, Sch Biol Sci,Div Cell Matrix Biol & Regenerat Med, Oxford, England.
   [Bishop, Paul N.] Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Clark, Simon J.] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Fac Biol Med & Hlth, Oxford, England.
   [Clark, Simon J.] Eberhard Karls Univ Tubingen, Inst Ophthalm Res, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.
   [Clark, Simon J.] Univ Tubingen, Univ Eye Clin, Dept Ophthalmol, Tubingen, Germany.
C3 University of Manchester; University of Copenhagen; University of
   Manchester; Manchester Royal Eye Hospital; University of Manchester;
   University of Manchester; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital
RP Clark, SJ (通讯作者)，Univ Manchester, Div Evolut & Genom Sci, Sch Biol Sci, Fac Biol Med & Hlth, Oxford, England.; Clark, SJ (通讯作者)，Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Fac Biol Med & Hlth, Oxford, England.; Clark, SJ (通讯作者)，Eberhard Karls Univ Tubingen, Inst Ophthalm Res, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.; Clark, SJ (通讯作者)，Univ Tubingen, Univ Eye Clin, Dept Ophthalmol, Tubingen, Germany.
EM simon.clark@uni-tuebingen.de
OI Udsen, Maja Soberg/0000-0003-4822-2764
FU Fight for Sight research grant [1852/53]; Macular Society UK research
   grant; MRC Career development Fellowship [MR/K024418/1]; Helmut Ecker
   Foundation, Germany
FX We thank Leo Zeef and Andy Hayes of the Bioinformatics and Genomic
   Technologies Core Facilities at the University of Manchester for
   providing support with regard to RNA-seq. This work was funded by a
   Fight for Sight research grant (1852/53), a Macular Society UK research
   grant, and an MRC Career development Fellowship (MR/K024418/1). SJC is
   funded by the Helmut Ecker Foundation, Germany.
CR Afshari FT, 2009, EYE, V23, P1890, DOI 10.1038/eye.2008.411
   Alge-Priglinger CS, 2009, MOL VIS, V15, P2162
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Black JRM, 2016, GENET MED, V18, P283, DOI 10.1038/gim.2015.70
   Blanco-Mezquita JT, 2011, INVEST OPHTH VIS SCI, V52, P8505, DOI 10.1167/iovs.11-8194
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Briones A.M., 2019, ALDOSTERONE MINERALO, DOI [10.5772/intechopen.87225, DOI 10.5772/INTECHOPEN.87225]
   Bruner KL, 1997, RECEPT SIGNAL TRANS, V7, P85
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Cho MJ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0327-y
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Clark SJ., 2017, REF MODUL NEUROSCI B, DOI [10.1016/B978-0-12-809324-5.01520-0, DOI 10.1016/B978-0-12-809324-5.01520-0]
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Deane CAS, 2018, J ALZHEIMERS DIS, V66, P1295, DOI 10.3233/JAD-180536
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Eamegdool SS, 2020, FREE RADICAL BIO MED, V146, P357, DOI 10.1016/j.freeradbiomed.2019.11.018
   Eibl KH, 2006, INVEST OPHTH VIS SCI, V47, P364, DOI 10.1167/iovs.05-0657
   Elfrink HL, 2013, MOL CELLS, V35, P291, DOI 10.1007/s10059-013-2286-9
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   FONTAINE M, 1989, BIOCHEM J, V258, P927, DOI 10.1042/bj2580927
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Hajieva Parvana, 2015, J Neurochem, V133, P352, DOI 10.1111/jnc.12987
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321
   Horton ER, 2016, J CELL SCI, V129, P4159, DOI 10.1242/jcs.192054
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Idrees Sana, 2019, Int Ophthalmol Clin, V59, P221, DOI 10.1097/IIO.0000000000000258
   Keenan TDL, 2015, INVEST OPHTH VIS SCI, V56, P4870, DOI 10.1167/iovs.15-17009
   Keenan TDL, 2014, INVEST OPHTH VIS SCI, V55, P5370, DOI 10.1167/iovs.14-14126
   Koivisto L, 2014, ADV WOUND CARE, V3, P762, DOI 10.1089/wound.2013.0436
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Langford-Smith A, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00025
   Lee SH, 2019, BMB REP, V52, P24, DOI 10.5483/BMBRep.2019.52.1.290
   Li R, 2009, INVEST OPHTH VIS SCI, V50, P5988, DOI 10.1167/iovs.09-3591
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Michael M, 2020, CURR OPIN CELL BIOL, V63, P31, DOI 10.1016/j.ceb.2019.12.008
   Nagasaki H, 1998, PROG RETIN EYE RES, V17, P77, DOI 10.1016/S1350-9462(97)00007-4
   Nandrot EF, 2008, ADV EXP MED BIOL, V613, P369, DOI 10.1007/978-0-387-74904-4_43
   Noonan EJ, 2007, CELL STRESS CHAPERON, V12, P393, DOI 10.1379/CSC-278e.1
   Penke B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010325
   Pijuan J, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00107
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Proulx S, 2003, MOL VIS, V9, P473
   Randles MJ, 2020, MATRIX BIOL, V90, P61, DOI 10.1016/j.matbio.2020.02.005
   RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593
   Roggia MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134870
   Schnittert J, 2018, ADV DRUG DELIVER REV, V129, P37, DOI 10.1016/j.addr.2018.01.020
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Sivapathasuntharam C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37673-6
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Swinkels M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18395-7
   Tababat-Khani P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070465
   Taylor RL, 2019, OPHTHALMOLOGY, V126, P1410, DOI 10.1016/j.ophtha.2019.03.013
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Yu C., 2019, J CELL SCI, V132
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
   Zhao M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08125-6
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zheng B, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001059
NR 74
TC 4
Z9 4
U1 3
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 8
PY 2021
VL 11
IS 1
AR 14175
DI 10.1038/s41598-021-93708-5
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TK9ZD
UT WOS:000674513600093
PM 34239032
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Mukai, A
   Otsuki, Y
   Ito, E
   Fujita, T
   Ueno, M
   Maeda, T
   Kinoshita, S
   Sotozono, C
   Hamuro, J
AF Mukai, Atsushi
   Otsuki, Yohei
   Ito, Eiko
   Fujita, Tomoko
   Ueno, Morio
   Maeda, Tadao
   Kinoshita, Shigeru
   Sotozono, Chie
   Hamuro, Junji
TI Mitochondrial miRNA494-3p in extracellular vesicles participates in
   cellular interplay of iPS-Derived human retinal pigment epithelium with
   macrophages
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE iPS derived RPE; Macrophage; EV miRNA; Innate cross talk; AMD
ID TNF-ALPHA; MACULAR DEGENERATION; IMMUNE-RESPONSES; EXOSOME RELEASE;
   CELLS; POLARIZATION; INFLAMMATION; NEOVASCULARIZATION; INHIBITION;
   ACTIVATION
AB To explore new molecular targets for therapy in human model systems by discerning the role of extracellular vesicle (EV) microRNAs (miRs) secreted by human retinal pigment epithelium (hRPE) cells and their cellular interplay with macrophages (Mps). Human Mps differentiated from THP-1 cells stimulated by phorbol myristate acetate were co-cultured with induced pluripotent stem cell-derived differentiated hRPE (iPS-hRPE) cells in Transwell (R) system separated by 0.40 mu m or 0.03 mu m filters. EV-associated CD63+ proteins (CD63+ EV) were detected by western blotting, and secreted EVs were analyzed by Nanosight tracking. The miR profiles of the secreted EVs were determined using 3D-gene human microRNA chips (Toray Industries, Inc.). Levels of CD63+ EV were increased in co-cultures concomitantly with the increased production of EV particles (50-150 nm). The increased production of EVs was associated with higher production of MCP-1, IL-6, IL-8 from hRPE cells, and VEGF and repressed production of TNF-alpha from Mps and pigment epithelium-derived factor (PEDF) from RPE cells. Ultracentrifugation of semi-purified EVs increased the secretion of these pro-inflammatory cytokines and EV particles from hRPE cells, but this effect was eliminated in transwells equipped with 0.03 mu m filters, whereas no repression of PEDF and TNF-alpha secretion occurred. 3D-gene miR analysis revealed a selective increase in secretion of miR494-3p in EVs from iPS-hRPE cells during the interplay with Mps. The miRs in EVs secreted by hRPE cells may have a critical role in the vicious inflammatory cycle, whereas repression of TNF-alpha and PEDF require cell-to-cell contact that is independent of EVs or exosomes. MiR494-3p may be a candidate molecular target of diagnosis and therapy for age-related macular degeneration.
C1 [Mukai, Atsushi; Otsuki, Yohei; Ito, Eiko; Fujita, Tomoko; Ueno, Morio; Sotozono, Chie; Hamuro, Junji] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020841, Japan.
   [Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Frontier Med Sci & Technol Ophthalmol, Kyoto, Japan.
   [Maeda, Tadao] Kobe Eye Ctr Hosp, Chuo Ku, 2-1-8 Minatojima Minami Cho, Kobe, Hyogo 6500047, Japan.
C3 Kyoto Prefectural University of Medicine; Kyoto Prefectural University
   of Medicine
RP Hamuro, J (通讯作者)，Kyoto Prefectural Univ Med, Dept Ophthalmol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6020841, Japan.
EM jshimo@koto.kpu-m.ac.jp
FU JSPS KAKENHI [JP20K09807]
FX This work was supported by JSPS KAKENHI Grant Number JP20K09807.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   An EY, 2008, MOL VIS, V14, P2292
   Atienzar-Aroca S, 2018, J CELL MOL MED, V22, P5244, DOI 10.1111/jcmm.13730
   Atienzar-Aroca S, 2016, J CELL MOL MED, V20, P1457, DOI 10.1111/jcmm.12834
   Baig MS, 2020, INFLAMM RES, V69, P435, DOI 10.1007/s00011-020-01318-0
   Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353
   Bruunsgaard H, 2000, CLIN EXP IMMUNOL, V121, P255, DOI 10.1046/j.1365-2249.2000.01281.x
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Chakraborty C, 2020, MOL THER-NUCL ACIDS, V20, P606, DOI 10.1016/j.omtn.2020.04.002
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD182, DOI 10.1167/iovs.18-24883
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Devarajan G, 2016, CURR EYE RES, V41, P1235, DOI 10.3109/02713683.2015.1109129
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hageman GS, 1999, MOL VIS, V5
   Harrell CR, 2018, ADV EXP MED BIOL, V1089, P47, DOI 10.1007/5584_2018_219
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   HOOKS JJ, 1988, INVEST OPHTH VIS SCI, V29, P1444
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kataoka K, 2011, INVEST OPHTH VIS SCI, V52, P1431, DOI 10.1167/iovs.10-5798
   Klingeborn M, 2018, ADV EXP MED BIOL, V1074, P539, DOI 10.1007/978-3-319-75402-4_65
   Klingeborn M, 2017, PROG RETIN EYE RES, V59, P158, DOI 10.1016/j.preteyeres.2017.04.004
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   Knickelbein JE, 2016, INVEST OPHTH VIS SCI, V57, P4101, DOI 10.1167/iovs.15-18353
   Korthagen NM, 2015, BRIT J OPHTHALMOL, V99, P700, DOI 10.1136/bjophthalmol-2014-306309
   Lee H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00924
   Li N, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1372-0
   Li W, 2013, AGEING RES REV, V12, P1005, DOI 10.1016/j.arr.2013.05.006
   Locke CJ, 2014, EXP EYE RES, V129, P1, DOI 10.1016/j.exer.2014.10.010
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luo C, 2018, AGING-US, V10, P1380, DOI 10.18632/aging.101474
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Momen-Heravi F, 2018, J LEUKOCYTE BIOL, V103, P1205, DOI 10.1002/JLB.3MIR1117-459R
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Otsuki Y, 2021, EXP EYE RES, V205, DOI 10.1016/j.exer.2021.108496
   Reyes NJ, 2017, NAT REV IMMUNOL, V17, P322, DOI 10.1038/nri.2017.13
   Shah N, 2018, BBA-MOL BASIS DIS, V1864, P2610, DOI 10.1016/j.bbadis.2018.04.016
   Shao GH, 2020, J INFLAMM-LOND, V17, DOI 10.1186/s12950-020-00247-3
   Shirasawa M, 2013, EXP EYE RES, V110, P59, DOI 10.1016/j.exer.2013.02.012
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sugita S, 2016, STEM CELL REP, V7, P619, DOI 10.1016/j.stemcr.2016.08.011
   Sugita S, 2015, INVEST OPHTH VIS SCI, V56, P1051, DOI 10.1167/iovs.14-15619
   Tong Y, 2016, MED HYPOTHESES, V97, P98, DOI 10.1016/j.mehy.2016.10.027
   Touhami S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1106-8
   Ueno M, 2016, INVEST OPHTH VIS SCI, V57, P5509, DOI 10.1167/iovs.16-19804
   van Ingen E, 2019, MOL THER-NUCL ACIDS, V18, P638, DOI 10.1016/j.omtn.2019.09.021
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang HB, 2016, MOL VIS, V22, P116
   Wei YY, 2018, CIRCULATION, V138, P2007, DOI 10.1161/CIRCULATIONAHA.117.031589
   Welten SMJ, 2014, CIRC RES, V115, P696, DOI 10.1161/CIRCRESAHA.114.304747
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yamawaki T, 2016, INVEST OPHTH VIS SCI, V57, P5945, DOI 10.1167/iovs.16-20604
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
NR 62
TC 3
Z9 3
U1 1
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2021
VL 208
AR 108621
DI 10.1016/j.exer.2021.108621
EA MAY 2021
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SV3VG
UT WOS:000663749400005
PM 34000275
DA 2022-11-30
ER

PT J
AU Ausayakhun, S
   Snyder, BM
   Ausayakhun, S
   Nanegrungsunk, O
   Apivatthakakul, A
   Narongchai, C
   Melo, JS
   Keenan, JD
AF Ausayakhun, Somanguan
   Snyder, Blake M.
   Ausayakhun, Sakarin
   Nanegrungsunk, Onnisa
   Apivatthakakul, Atitaya
   Narongchai, Chanusnun
   Melo, Jason S.
   Keenan, Jeremy D.
TI Clinic-Based Eye Disease Screening Using Non-Expert Fundus Photo Graders
   at the Point of Screening: Diagnostic Validity and Yield
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; DIABETIC-RETINOPATHY; CYTOMEGALOVIRUS RETINITIS;
   TELEMEDICINE; CARE; PROGRAM
AB center dot PURPOSE: The intent of this study was to deter-mine the diagnostic accuracy of several diagnostic tests for age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, and cataract, as well as the proportions of patients with eye disease from each of 3 enrolling clinics.
   center dot DESIGN: Diagnostic accuracy study.
   center dot METHODS: Patients >= 50 years old in a diabetes, thyroid, and general medicine clinic were screened us-ing visual acuity, tonometry, and fundus photography. Photographs were graded at the point-of-screening by non-ophthalmic personnel. Participants with positive screening test results in either eye and a 10% random sample with negative results in both eyes were referred for an in-person, reference-standard ophthalmology examination.
   center dot RESULTS: Of 889 participants enrolled, 229 partici-pants failed at least 1 test in either eye, of which 189 presented for an ophthalmic examination. An additional 76 participants with completely normal screening test results were referred for examination, of which 50 at-tended. Fundus photography screening had the highest yield for DR (sensitivity: 67%; 95% confidence inter -val [CI]: 39%-87%), visual acuity screening for cataract (sensitivity: 89%; 95% CI: 86%-92%), and intraocular pressure screening for glaucoma or suspected glaucoma(sensitivity: 25%; 95% CI: 14%-40%). The burden of disease was relatively high in all 3 clinics, with at least 1 of the diseases of interest (ie, AMD, DR, glaucoma or suspected glaucoma, or cataract) detected in 25% of par-ticipants (95% CI: 17-35%) from the diabeteses clinic, 34% (95% CI: 22%-49%) from the thyroid clinic, and 21% (95% CI: 13%-32%) from the general clinic.
   center dot CONCLUSIONS: Non-expert eye disease screening in health clinics may be a useful model for detection of eye disease in resource-limited settings. (Am J Ophthalmol 2021;227: 245-253. (c) 2021 Elsevier Inc. All rights re-served.)
C1 [Ausayakhun, Somanguan; Nanegrungsunk, Onnisa; Apivatthakakul, Atitaya; Narongchai, Chanusnun] Chiang Mai Univ, Fac Med, Dept Ophthalmol, Chiang Mai, Thailand.
   [Ausayakhun, Somanguan] Chiang Mai Univ, Mai Univ Lasik Ctr, Fac Med, Chiang Mai, Thailand.
   [Snyder, Blake M.] Univ Colorado, Denver Sch Med, Aurora, CO USA.
   [Snyder, Blake M.; Melo, Jason S.; Keenan, Jeremy D.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA.
   [Ausayakhun, Sakarin] Chiang Mai Univ, Sriphat Med Ctr, Fac Med, Chiang Mai, Thailand.
   [Keenan, Jeremy D.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
C3 Chiang Mai University; Chiang Mai University; University of Colorado
   System; University of Colorado Anschutz Medical Campus; University of
   California System; University of California San Francisco; Chiang Mai
   University; University of California System; University of California
   San Francisco
RP Keenan, JD (通讯作者)，Med Sci Bldg S334,Box 0412,513 Parnassus Ave, San Francisco, CA 94143 USA.
EM jeremy.keenan@ucsf.edu
RI Snyder, Blake/GRN-9747-2022
OI Melo, Jason/0000-0003-2116-4656; Keenan, Jeremy/0000-0002-7118-1457
FU Doris Duke Charitable Foundation through an International Clinical
   Research Fellowship; Peierls Foundation; JaMel and Tom Perkins Family
   Foundation; Fortisure Foundation; That Man May See; Research to Prevent
   Blindness
FX The study was supported by the Doris Duke Charitable Foundation through
   an International Clinical Research Fellowship, the Peierls Foundation,
   the JaMel and Tom Perkins Family Foundation, the Fortisure Foundation,
   That Man May See, and Research to Prevent Blindness.
CR [Anonymous], 2021, LANCET GLOB HEALTH, V9, pE144
   [Anonymous], 2021, LANCET GLOB HEALTH, pE130
   Balyen L, 2019, ASIA-PAC J OPHTHALMO, V8, P264, DOI 10.22608/APO.2018479
   Bolme S, 2020, ACTA OPHTHALMOL, V98, P139, DOI 10.1111/aos.14184
   Brady CJ, 2014, J MED INTERNET RES, V16, P175, DOI 10.2196/jmir.3807
   Burlina P, 2018, JAMA OPHTHALMOL, V136, P1305, DOI 10.1001/jamaophthalmol.2018.3799
   Burr J, 2007, HEALTH TECHNOL ASSES, V11, P1, DOI 10.3310/hta11410
   Capewell N., 2019, BMJ OPEN, V9
   Chasan JE, 2014, JAMA OPHTHALMOL, V132, P1045, DOI 10.1001/jamaophthalmol.2014.1051
   Cheng CY, 2020, BRIT J OPHTHALMOL, V104, P616, DOI 10.1136/bjophthalmol-2018-313308
   Daskivich LP, 2017, JAMA INTERN MED, V177, P642, DOI 10.1001/jamainternmed.2017.0204
   DEsposito F., SYST REV-LONDON, V10, P4
   Estopinal CB, 2013, OPHTHAL EPIDEMIOL, V20, P267, DOI 10.3109/09286586.2013.821498
   Frcophth AT, 2017, OPHTHALMOLOGY, V124, P343, DOI 10.1016/j.ophtha.2016.11.014
   Gichangi M, 2015, OPHTHAL EPIDEMIOL, V22, P226, DOI 10.3109/09286586.2015.1040924
   Hark LA, 2017, AM J OPHTHALMOL, V181, P114, DOI 10.1016/j.ajo.2017.06.024
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Islam MM, 2020, COMPUT METH PROG BIO, V191, DOI 10.1016/j.cmpb.2020.105320
   Jirawison C, 2015, JAMA OPHTHALMOL, V133, P198, DOI 10.1001/jamaophthalmol.2014.4766
   Joseph S, 2019, JAMA OPHTHALMOL, V137, P786, DOI 10.1001/jamaophthalmol.2019.1070
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Keeffe JE, 2019, BRIT J OPHTHALMOL, V103, P878, DOI 10.1136/bjophthalmol-2018-311946
   Kita Y, 2020, J GLAUCOMA, V29, P572, DOI 10.1097/IJG.0000000000001509
   Maa AY, 2020, OPHTHALMOLOGY, V127, P38, DOI 10.1016/j.ophtha.2019.07.026
   Malvankar-Mehta MS., 2014, PLOS ONE, V9
   Mansberger SL, 2015, JAMA OPHTHALMOL, V133, P518, DOI 10.1001/jamaophthalmol.2015.1
   Mowatt G, 2008, INVEST OPHTH VIS SCI, V49, P5373, DOI 10.1167/iovs.07-1501
   Murchison AP, 2017, CURR EYE RES, V42, P963, DOI 10.1080/02713683.2017.1297463
   Nangia V, 2019, BRIT J OPHTHALMOL, V103, P871, DOI 10.1136/bjophthalmol-2018-312292
   Pareja-Rios A, 2017, Arch Soc Esp Oftalmol, V92, P63, DOI 10.1016/j.oftal.2016.08.006
   Piyasena MMPN, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0846-y
   Rajalakshmi R, 2021, EYE, V35, P162, DOI 10.1038/s41433-020-01262-7
   Rathi S, 2017, OPHTHALMOLOGY, V124, P1729, DOI 10.1016/j.ophtha.2017.05.026
   Rono HK, 2018, LANCET GLOB HEALTH, V6, pE924, DOI [10.1016/S2214-109X(18)30244-4, 10.1016/s2214-109x(18)30244-4]
   Salam AA, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3175-4
   Shah M, 2018, INT J HEALTH PLAN M, V33, P627, DOI 10.1002/hpm.2508
   Ting DSW, 2016, CLIN EXP OPHTHALMOL, V44, P260, DOI 10.1111/ceo.12696
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Yen M, 2014, JAMA OPHTHALMOL, V132, P1052, DOI 10.1001/jamaophthalmol.2014.1108
NR 39
TC 1
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2021
VL 227
BP 245
EP 253
DI 10.1016/j.ajo.2021.03.029
EA MAY 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SP2EZ
UT WOS:000659487300027
PM 33823160
DA 2022-11-30
ER

PT J
AU Abdullah, YI
   Schuman, JS
   Shabsigh, R
   Caplan, A
   Al-Aswad, LA
AF Abdullah, Yasser Ibraheem
   Schuman, Joel S.
   Shabsigh, Ridwan
   Caplan, Arthur
   Al-Aswad, Lama A.
TI Ethics of Artificial Intelligence in Medicine and Ophthalmology
SO ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE algorithms; artificial intelligence; bioethics; deep learning; machine
   learning
ID BIG DATA; INTERNATIONAL COMMITTEE; CARE; PERFORMANCE; RETINOPATHY;
   OWNERSHIP; PRIVACY; EMPATHY; ERA
AB Background: This review explores the bioethical implementation of artificial intelligence (AI) in medicine and in ophthalmology. AI, which was first introduced in the 1950s, is defined as "the machine simulation of human mental reasoning, decision making, and behavior". The increased power of computing, expansion of storage capacity, and compilation of medical big data helped the AI implementation surge in medical practice and research. Ophthalmology is a leading medical specialty in applying AI in screening, diagnosis, and treatment. The first Food and Drug Administration approved autonomous diagnostic system served to diagnose and classify diabetic retinopathy. Other ophthalmic conditions such as age-related macular degeneration, glaucoma, retinopathy of prematurity, and congenital cataract, among others, implemented AI too.
   Purpose: To review the contemporary literature of the bioethical issues of AI in medicine and ophthalmology, classify ethical issues in medical AI, and suggest possible standardizations of ethical frameworks for AI implementation.
   Methods: Keywords were searched on Google Scholar and PubMed between October 2019 and April 2020. The results were reviewed, cross-referenced, and summarized. A total of 284 references including articles, books, book chapters, and regulatory reports and statements were reviewed, and those that were relevant were cited in the paper.
   Results: Most sources that studied the use of AI in medicine explored the ethical aspects. Bioethical challenges of AI implementation in medicine were categorized into 6 main categories. These include machine training ethics, machine accuracy ethics, patient-related ethics, physician-related ethics, shared ethics, and roles of regulators.
   Conclusions: There are multiple stakeholders in the ethical issues surrounding AI in medicine and ophthalmology. Attention to the various aspects of ethics related to AI is important especially with the expanding use of AI. Solutions of ethical problems are envisioned to be multifactorial.
C1 [Abdullah, Yasser Ibraheem; Schuman, Joel S.; Al-Aswad, Lama A.] NYU, Grossman Sch Med, NYU Langone Hlth, Dept Ophthalmol, New York, NY 10017 USA.
   [Schuman, Joel S.] NYU, Tandon Sch Engn, Dept Biomed Engn, Brooklyn, NY USA.
   [Schuman, Joel S.] NYU, Tandon Sch Engn, Dept Elect & Comp Engn, Brooklyn, NY USA.
   [Schuman, Joel S.] NYU, Grossman Sch Med, NYU Langone Hlth, Dept Physiol & Neurosci, New York, NY 10017 USA.
   [Schuman, Joel S.] NYU, Renter Neural Sci, Coll Arts & Sci, New York, NY 10017 USA.
   [Shabsigh, Ridwan] SBH Hlth Syst, New York, NY USA.
   [Shabsigh, Ridwan] Weill Cornell Med Coll, New York, NY USA.
   [Caplan, Arthur; Al-Aswad, Lama A.] NYU, Dept Populat Hlth, NYU Langone Hlth, Grossman Sch Med, New York, NY 10017 USA.
C3 New York University; NYU Langone Medical Center; New York University;
   New York University Tandon School of Engineering; New York University;
   New York University Tandon School of Engineering; New York University;
   NYU Langone Medical Center; New York University; Cornell University; New
   York University; NYU Langone Medical Center
RP Al-Aswad, LA (通讯作者)，NYU, Langone Eye Ctr, 222 E 41st,Suite 4-092, New York, NY 10017 USA.
EM Lama.al-aswad@nyulangone.org
RI Schuman, Joel/K-7304-2012
OI Schuman, Joel/0000-0002-8885-3766
FU Research to Prevent Blindness, New York, NY
FX Supported by Research to Prevent Blindness, New York, NY.
CR Allain J.S., 2012, LA LAW REV, V73, P1049
   Amato F., 2013, APPLYING ARTIFICIAL
   Anderson Michael, 2019, AMA J ETHICS, V21, P125, DOI DOI 10.1001/amajethics.2019.125
   [Anonymous], 2018, BIG DATA SECURITY PR
   [Anonymous], 2017, BBC NEWS
   Antonopoulos P., 2011, SECONDARY USE HLTH D
   Asada M., 2019, AAAI SPRING S CONSC
   Baird S., 2017, GDPR MATCH HLTH INSU
   Balthazar P, 2018, J AM COLL RADIOL, V15, P580, DOI 10.1016/j.jacr.2017.11.035
   Barrett L., 2018, SEATTLE UL REV, V42, P1057
   Bauchner H, 2019, JAMA-J AM MED ASSOC, V322, P2290, DOI 10.1001/jama.2019.19786
   Beauchamp T.L., 2012, PRINCIPLES BIOMEDICA
   Beebe J., 2019, YOU CAN NOW MAKE MON
   Bertino E, 2005, PROC INT CONF DATA, P521
   Bolon-Canedo V, 2015, COMPUT METH PROG BIO, V122, P1, DOI 10.1016/j.cmpb.2015.06.004
   Braun M, 2020, PRIMER ETHICS BASED, DOI [10.1136/medethics-2019-105860, DOI 10.1136/MEDETHICS-2019-105860]
   Brodie F, 2019, JAMA OPHTHALMOL, V137, P1349, DOI 10.1001/jamaophthalmol.2019.3708
   Cabitza F, 2017, JAMA-J AM MED ASSOC, V318, P517, DOI 10.1001/jama.2017.7797
   Caruana R, 2015, KDD'15: PROCEEDINGS OF THE 21ST ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P1721, DOI 10.1145/2783258.2788613
   Cassel C, 2019, JAMA-J AM MED ASSOC, V322, P105, DOI 10.1001/jama.2019.9523
   Cavoukian A., 2012, PRIVACY DESIGN AGE B
   Char DS, 2018, NEW ENGL J MED, V378, P981, DOI 10.1056/NEJMp1714229
   Cios KJ, 2002, ARTIF INTELL MED, V26, P1, DOI 10.1016/S0933-3657(02)00049-0
   Combs C Donald, 2019, AMA J Ethics, V21, pE153, DOI 10.1001/amajethics.2019.153
   Dilsizian SE, 2014, CURR CARDIOL REP, V16, DOI 10.1007/s11886-013-0441-8
   Doshi-Velez F, 2019, JAMA-J AM MED ASSOC, V322, P1777, DOI 10.1001/jama.2019.17304
   Evans BJ., 2011, HARV JL TECH, V25, P69
   Fairwarning.com, 2018, GDPR HIPAA WHAT AR D
   Feldman B., 2012, BIG DATA HEALTHCARE, V360, P122
   Fogel AL, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-017-0012-2
   Froomkin AM, 2019, ARIZ L REV, V61, P33, DOI DOI 10.2139/SSRN.3114347
   Galeon D., 2017, DRUGS RAPE MASSACRES
   Geis JR, 2019, RADIOLOGY, V293, P436, DOI 10.1148/radiol.2019191586
   Grewal PS, 2018, CAN J OPHTHALMOL, V53, P309, DOI 10.1016/j.jcjo.2018.04.019
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Gutwirth S, 2016, DATA PROTECTION MOVE
   Hall MA, 2009, JAMA-J AM MED ASSOC, V301, P1282, DOI 10.1001/jama.2009.389
   Hart RD., 2018, QUARTZ PRESCRIPTION
   He JX, 2019, NAT MED, V25, P30, DOI 10.1038/s41591-018-0307-0
   Hoff T, 2011, HEALTH CARE MANAGE R, V36, P338, DOI 10.1097/HMR.0b013e31821826a1
   Hsu J., 2019, UNDARK MAGAZINE
   Hwang TJ, 2019, JAMA-J AM MED ASSOC, V322, P2285, DOI 10.1001/jama.2019.16842
   Ienca M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204937
   Jha S, 2016, JAMA-J AM MED ASSOC, V316, P2353, DOI 10.1001/jama.2016.17438
   Kapoor R, 2019, SURV OPHTHALMOL, V64, P233, DOI 10.1016/j.survophthal.2018.09.002
   Keane PA, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0048-y
   Kels CG, 2020, JAMA-J AM MED ASSOC, V323, P476, DOI 10.1001/jama.2019.19645
   Khanna S, 2010, INT DENT J, V60, P269, DOI 10.1922/IDJ_2422Khanna04
   Kish LJ, 2015, NAT BIOTECHNOL, V33, P921, DOI 10.1038/nbt.3340
   Kleinsmith A, 2015, COMPUT HUM BEHAV, V52, P151, DOI 10.1016/j.chb.2015.05.033
   Kohli A, 2019, AM J ROENTGENOL, V213, P886, DOI 10.2214/AJR.18.20410
   Kostkova P, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00007
   Laessig M., 2019, PALGRAVE HDB GLOBAL, P451, DOI [DOI 10.1057/978-1-137-54984-6_23, 10.1057/978-1-137-54984-6_23]
   Loftus TJ, 2020, JAMA SURG, V155, P148, DOI 10.1001/jamasurg.2019.4917
   Loh E., 2018, BMJ LEAD, V2, P59, DOI [10.1136/leader-2018-000071, DOI 10.1136/leader-2018-000071]
   Luxton David D, 2019, AMA J Ethics, V21, pE131, DOI 10.1001/amajethics.2019.131
   Luxton DD, 2014, PROF PSYCHOL-RES PR, V45, P332, DOI 10.1037/a0034559
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Maddox TM, 2019, JAMA-J AM MED ASSOC, V321, P31, DOI 10.1001/jama.2018.18932
   Matheny ME, 2020, JAMA-J AM MED ASSOC, V323, P509, DOI 10.1001/jama.2019.21579
   Mathias J., 2018, THESIS BOSTON U
   McCoy MS, 2020, JAMA-J AM MED ASSOC, V323, P505, DOI 10.1001/jama.2019.22354
   McMillan R., 2015, WALL STR J
   Mintz Y, 2019, MINIM INVASIV THER, V28, P73, DOI 10.1080/13645706.2019.1575882
   National Science and Technology Council (US), 2016, NAT ART INT RES DEV
   Nebeker C, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1377-7
   NHSX, 2019, ARTIFICIAL INTELLIGE
   Noga M., 2017, SAP SE NEWS IND
   Nuffield Council on Bioethics, 2018, ART INT HEALTHC RES, P1
   Nuffield Council on Bioethics, ARTIFICIAL INTELLIGE
   Nundy S, 2019, JAMA-J AM MED ASSOC, V322, P497, DOI 10.1001/jama.2018.20563
   Panch T, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0155-4
   Parikh RB, 2019, JAMA-J AM MED ASSOC, V322, P2377, DOI 10.1001/jama.2019.18058
   Park SH, 2018, RADIOLOGY, V286, P800, DOI 10.1148/radiol.2017171920
   Pesapane F, 2018, INSIGHTS IMAGING, V9, P745, DOI 10.1007/s13244-018-0645-y
   Povyakalo AA, 2013, MED DECIS MAKING, V33, P98, DOI 10.1177/0272989X12465490
   Price W., 2015, CARDOZO L REV, V37, P1401
   Price WN, 2019, NAT MED, V25, P37, DOI 10.1038/s41591-018-0272-7
   Price WN, 2019, JAMA-J AM MED ASSOC, V322, P1765, DOI 10.1001/jama.2019.15064
   Price WN., 2017, BIG DATA HLTH LAW BI
   Puaschunder JM., 2018, ARTIFICIAL INTELLIGE
   Ranscombe P., 2019, SCOTSMAN
   Rault R, 2018, STUD COMPUT INTELL, V762, P1, DOI 10.1007/978-3-319-73751-5_1
   Rodwin MA, 2010, AM J LAW MED, V36, P586, DOI 10.1177/009885881003600403
   Rodwin MA, 2009, JAMA-J AM MED ASSOC, V302, P86, DOI 10.1001/jama.2009.965
   Rumbold JMM, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7108
   Rysewyk SPV., 2015, MACHINE MED ETHICS
   Schiff Daniel, 2019, AMA J Ethics, V21, pE138, DOI 10.1001/amajethics.2019.138
   Sloan Robert H., 2014, J HIGH TECHNOLOGY LA, V14, P372
   Sullivan Hannah R, 2019, AMA J Ethics, V21, pE160, DOI 10.1001/amajethics.2019.160
   Taichman DB, 2017, JAMA-J AM MED ASSOC, V317, P2491, DOI 10.1001/jama.2017.6514
   Taichman DB, 2016, ANN INTERN MED, V164, P505, DOI 10.7326/M15-2928
   Tan Z, 2019, ASIA-PAC J OPHTHALMO, V8, P197, DOI 10.22608/APO.2019122
   Ting DSW, 2019, OPHTHALMOLOGY, V126, P1475, DOI 10.1016/j.ophtha.2019.09.014
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7
   Tsai TL, 2003, J AM MED INFORM ASSN, V10, P478, DOI 10.1197/jamia.M1279
   Vallverdu J, 2015, INTEL SYST CONTR AUT, V74, P341, DOI 10.1007/978-3-319-08108-3_20
   Vayena E, 2017, J BIOETHIC INQ, V14, P501, DOI 10.1007/s11673-017-9809-6
   Vladeck DC, 2014, WASH LAW REV, V89, P116
   Wachter RM, 2020, JAMA-J AM MED ASSOC, V323, P507, DOI 10.1001/jama.2019.21215
   Wahl B, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000798
   Wallach W, 2008, AI SOC, V22, P463, DOI 10.1007/s00146-007-0093-6
   Wallach Wendell, 2009, MORAL MACHINES TEACH
   Wartman Steven A, 2019, AMA J Ethics, V21, pE146, DOI 10.1001/amajethics.2019.146
   Weld D.S., 2018, INTELLIGIBLE ARTIFIC
   Williams AM, 2018, PHYSIOL GENOMICS, V50, P237, DOI 10.1152/physiolgenomics.00119.2017
   Winfield AF, 2019, P IEEE, V107, P509, DOI 10.1109/JPROC.2019.2900622
   Yampolskiy R.V., 2016, WORKSH 30 AAAI C ART
   Yarnell CJ, 2017, JAMA-J AM MED ASSOC, V318, P1479, DOI 10.1001/jama.2017.14418
   Zhang AY, 2018, 2018 IEEE/ACM 5TH INTERNATIONAL CONFERENCE ON BIG DATA COMPUTING APPLICATIONS AND TECHNOLOGIES (BDCAT), P107, DOI 10.1109/BDCAT.2018.00021
NR 112
TC 4
Z9 4
U1 12
U2 28
PU ASIA-PACIFIC ACAD OPHTHALMOLOGY-APAO
PI KOWLOON
PA 4-F, HONG KONG EYE HOSP, 147K ARGYLE ST, KOWLOON, KOWLOON, HONG KONG
   00000, PEOPLES R CHINA
EI 2162-0989
J9 ASIA-PAC J OPHTHALMO
JI Asia-Pac. J. Ophthalmol.
PD MAY-JUN
PY 2021
VL 10
IS 3
BP 289
EP 298
DI 10.1097/APO.0000000000000397
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA TP4SV
UT WOS:000677586300008
PM 34383720
OA gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Reichenbach, A
   Bringmann, A
AF Reichenbach, Andreas
   Bringmann, Andreas
TI Purinergic signaling in retinal degeneration and regeneration
SO NEUROPHARMACOLOGY
LA English
DT Review
DE ATP; Adenosine; Neurodegeneration; Edema; Cell proliferation; Retina
ID MULLER GLIAL-CELLS; P2X(7) RECEPTOR ACTIVATION; PERICYTE-CONTAINING
   MICROVASCULATURE; P2X(7)-INDUCED PORE FORMATION; OSMOTIC VOLUME
   REGULATION; ISCHEMIC RAT RETINA; ADENOSINE RECEPTOR; GANGLION-CELLS; P2Y
   RECEPTORS; INTRAOCULAR-PRESSURE
AB Purinergic signaling is centrally involved in mediating the degeneration of the injured and diseased retina, the induction of retinal gliosis, and the protection of the retinal tissue from degeneration. Dysregulated calcium signaling triggered by overactivation of P2X(7) receptors is a crucial step in the induction of neuronal and microvascular cell death under pathogenic conditions like ischemia-hypoxia, elevated intraocular pressure, and diabetes, respectively. Overactivation of P2X(7) plays also a pathogenic role in inherited and age-related photoreceptor cell death and in the age-related dysfunction and degeneration of the retinal pigment epithelium. Gliosis of micro- and macroglial cells, which is induced and/or modulated by purinergic signaling and associated with an impaired homeostatic support to neurons, and the ATP-mediated propagation of retinal gliosis from a focal injury into the surrounding noninjured tissue are involved in inducing secondary cell death in the retina. On the other hand, alterations in the glial metabolism of extracellular nucleotides, resulting in a decreased level of ATP and an increased level of adenosine, may be neuroprotective in the diseased retina. Purinergic signals stimulate the proliferation of retinal glial cells which contributes to glial scarring which has protective effects on retinal degeneration and adverse effects on retinal regeneration. Pharmacological modulation of purinergic receptors, e.g., inhibition of P2X and activation of adenosine receptors, may have clinical importance for the prevention of photoreceptor, neuronal, and microvascular cell death in diabetic retinopathy, retinitis pigmentosa, age-related macular degeneration, and glaucoma, respectively, for the clearance of retinal edema, and the inhibition of dysregulated cell proliferation in proliferative retinopathies.
   This article is part of a Special Issue entitled 'Purines in Neurodegeneration and Neuroregeneration'. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Reichenbach, Andreas] Univ Leipzig, Paul Flechsig Inst Brain Res, D-04109 Leipzig, Germany.
   [Bringmann, Andreas] Univ Leipzig, Dept Ophthalmol, D-04109 Leipzig, Germany.
   [Bringmann, Andreas] Univ Leipzig, Hosp Eye, D-04109 Leipzig, Germany.
C3 Leipzig University; Leipzig University; Leipzig University
RP Reichenbach, A (通讯作者)，Univ Leipzig, Fac Med, Paul Flechsig Inst Brain Res, Liebigstr 19, D-04103 Leipzig, Germany.
EM reia@medizin.uni-leipzig.de
RI Reichenbach, Andreas/B-2510-2017
FU Deutsche Forschungsgemeinschaft [GRK 1097/1, RE 849/16-1]
FX Some of the work presented in this review was conducted with grants from
   the Deutsche Forschungsgemeinschaft (GRK 1097/1, RE 849/16-1).
CR Abu Khamidakh AE, 2013, EXP EYE RES, V108, P129, DOI 10.1016/j.exer.2013.01.009
   Ahmad S, 2013, J NEUROIMMUNOL, V264, P54, DOI 10.1016/j.jneuroim.2013.09.015
   Anccasi RM, 2013, PURINERG SIGNAL, V9, P15, DOI 10.1007/s11302-012-9324-5
   Andrews A, 1999, INVEST OPHTH VIS SCI, V40, P2683
   Arroba AI, 2014, ADV EXP MED BIOL, V801, P373, DOI 10.1007/978-1-4614-3209-8_47
   Azuma M, 2008, SURV OPHTHALMOL, V53, P150, DOI 10.1016/j.survophthal.2007.12.006
   Battista AG, 2009, J NEUROCHEM, V111, P600, DOI 10.1111/j.1471-4159.2009.06352.x
   Berler D K, 1989, Trans Am Ophthalmol Soc, V87, P515
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   BLAZYNSKI C, 1992, J NEUROCHEM, V58, P761, DOI 10.1111/j.1471-4159.1992.tb09783.x
   Brandle U, 1998, MOL BRAIN RES, V62, P106, DOI 10.1016/S0169-328X(98)00254-X
   BRESNICK GH, 1983, OPHTHALMOLOGY, V90, P1301
   Bringmann A, 1999, INVEST OPHTH VIS SCI, V40, P3316
   Bringmann A, 2000, INVEST OPHTH VIS SCI, V41, P2791
   Bringmann A, 2005, ACTA OPHTHALMOL SCAN, V83, P528, DOI 10.1111/j.1600-0420.2005.00565.x
   Bringmann A, 2000, GLIA, V29, P35, DOI 10.1002/(SICI)1098-1136(20000101)29:1<35::AID-GLIA4>3.0.CO;2-A
   Bringmann A., 2003, Biomedical Research (Aligarh), V14, P38
   Bringmann A, 2004, OPHTHALMIC RES, V36, P241, DOI 10.1159/000081203
   Bringmann A, 2002, GLIA, V37, P139, DOI 10.1002/glia.10025
   Bringmann A, 2001, INVEST OPHTH VIS SCI, V42, P860
   Bringmann A, 2007, CURR EYE RES, V32, P143, DOI 10.1080/02713680601139333
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Bringmann Andreas, 2013, Front Endocrinol (Lausanne), V4, P48, DOI 10.3389/fendo.2013.00048
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Bringmann A, 2009, GRAEF ARCH CLIN EXP, V247, P865, DOI 10.1007/s00417-009-1082-x
   Bruckner E, 2012, NEUROCHEM RES, V37, P268, DOI 10.1007/s11064-011-0606-z
   CHEBABO SR, 1995, BRAIN RES, V695, P203, DOI 10.1016/0006-8993(95)00778-O
   Chung H, 2007, INVEST OPHTH VIS SCI, V48, P5742, DOI 10.1167/iovs.07-0566
   Costa G, 2009, J NEUROSCI RES, V87, P1375, DOI 10.1002/jnr.21956
   Costenla AR, 1999, EXP EYE RES, V68, P367, DOI 10.1006/exer.1998.0645
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   deKozak Y, 1997, OCUL IMMUNOL INFLAMM, V5, P85, DOI 10.3109/09273949709085056
   Delyfer MN, 2005, MOL VIS, V11, P688
   Dilip R, 2013, J MOL HISTOL, V44, P639, DOI 10.1007/s10735-013-9525-4
   Dmitriev AV, 1999, VISUAL NEUROSCI, V16, P1157, DOI 10.1017/S095252389916615X
   Doonan F, 2005, INVEST OPHTH VIS SCI, V46, P3530, DOI 10.1167/iovs.05-0248
   DUDEK FE, 1990, NEUROSCI LETT, V120, P267, DOI 10.1016/0304-3940(90)90056-F
   Elsherbiny NM, 2013, BIOCHEM BIOPH RES CO, V436, P355, DOI 10.1016/j.bbrc.2013.05.023
   Faude F, 2001, J NEUROCYTOL, V30, P379
   FEIGENSPAN A, 1994, P NATL ACAD SCI USA, V91, P10893, DOI 10.1073/pnas.91.23.10893
   Fontainhas AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015973
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Francke M, 2005, VISION RES, V45, P2256, DOI 10.1016/j.visres.2004.08.028
   Francke M, 2002, INVEST OPHTH VIS SCI, V43, P870
   Francke M, 2001, INVEST OPHTH VIS SCI, V42, P1072
   Francke M, 1997, GLIA, V20, P210, DOI 10.1002/(SICI)1098-1136(199707)20:3<210::AID-GLIA5>3.0.CO;2-B
   Franke H, 2005, NEUROCHEM INT, V47, P235, DOI 10.1016/j.neuint.2005.04.022
   Franke H, 2006, PFLUG ARCH EUR J PHY, V452, P622, DOI 10.1007/s00424-006-0071-8
   Fraser-Bell S, 2008, CURR OPIN OPHTHALMOL, V19, P185, DOI 10.1097/ICU.0b013e3282fb7c45
   Fries JE, 2005, INVEST OPHTH VIS SCI, V46, P3000, DOI 10.1167/iovs.05-0043
   Fries JE, 2004, MOL BRAIN RES, V130, P1, DOI 10.1016/j.molbrainres.2004.06.041
   Fries JE, 2004, INVEST OPHTH VIS SCI, V45, P3410, DOI 10.1167/iovs.04-0141
   Garcia TB, 2014, J NEUROCHEM, V131, P303, DOI 10.1111/jnc.12822
   Garhofer G, 2004, BRIT J OPHTHALMOL, V88, P887, DOI 10.1136/bjo.2003.033548
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ghiardi GJ, 1999, VISION RES, V39, P2519, DOI 10.1016/S0042-6989(99)00038-3
   GREEN WR, 1991, AM J OPHTHALMOL, V112, P520, DOI 10.1016/S0002-9394(14)76852-7
   Grosche A, 2012, INVEST OPHTH VIS SCI, V53, P4170, DOI 10.1167/iovs.12-9746
   Guha S, 2013, FASEB J, V27, P4500, DOI 10.1096/fj.13-236166
   Hartwick ATE, 2004, INVEST OPHTH VIS SCI, V45, P3740, DOI 10.1167/iovs.04-0214
   Hernandez C, 2006, DIABETES CARE, V29, P2028, DOI 10.2337/dc06-0556
   Hirano Y, 2014, NAT MED, V20, P1372, DOI 10.1038/nm.3671
   Housley GD, 2009, TRENDS NEUROSCI, V32, P128, DOI 10.1016/j.tins.2009.01.001
   Hu HL, 2010, EXP EYE RES, V91, P425, DOI 10.1016/j.exer.2010.06.017
   Huang W, 2011, EXP EYE RES, V93, P700, DOI 10.1016/j.exer.2011.09.001
   Iandiev I, 2007, PURINERG SIGNAL, V3, P423, DOI 10.1007/s11302-007-9061-3
   Iandiev I, 2008, INVEST OPHTH VIS SCI, V49, P3559, DOI 10.1167/iovs.08-1723
   Iandiev I, 2006, INVEST OPHTH VIS SCI, V47, P2161, DOI 10.1167/iovs.05-0595
   Ikuno Y, 2002, INVEST OPHTH VIS SCI, V43, P483
   Innocenti B, 2004, J NEUROSCI, V24, P8577, DOI 10.1523/JNEUROSCI.2812-04.2004
   Ishii K, 2003, J COMP NEUROL, V459, P267, DOI 10.1002/cne.10608
   Ji M, 2012, J NEUROSCI, V32, P12744, DOI 10.1523/JNEUROSCI.1291-12.2012
   Ju KR, 2006, BRAIN RES, V1122, P209, DOI 10.1016/j.brainres.2006.09.022
   Kakurai K, 2013, NEUROSCI LETT, V534, P237, DOI 10.1016/j.neulet.2012.11.060
   Kalisch F, 2006, EXP EYE RES, V83, P962, DOI 10.1016/j.exer.2006.05.003
   Kaur C, 2007, J PATHOL, V212, P429, DOI 10.1002/path.2195
   Kawamura H, 2003, J PHYSIOL-LONDON, V551, P787, DOI 10.1113/jphsiol.2003.047977
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886
   Kim KY, 2004, NEUROBIOL AGING, V25, P491, DOI 10.1016/j.neurobiolaging.2003.07.005
   Krugel K, 2010, NEUROSCIENCE, V165, P1147, DOI 10.1016/j.neuroscience.2009.11.035
   Krugel K, 2011, EXP EYE RES, V92, P87, DOI 10.1016/j.exer.2010.11.007
   Kumar B, 2014, EXP EYE RES, V125, P193, DOI 10.1016/j.exer.2014.06.009
   Kumar B, 2013, MICROVASC RES, V87, P65, DOI 10.1016/j.mvr.2013.01.002
   Kur J, 2014, J PHYSIOL-LONDON, V592, P491, DOI 10.1113/jphysiol.2013.267294
   Kurth-Nelson ZL, 2009, J NEUROSCI, V29, P11339, DOI 10.1523/JNEUROSCI.2493-09.2009
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Larsen AK, 1996, INVEST OPHTH VIS SCI, V37, P2603
   Larsen M, 2005, INVEST OPHTH VIS SCI, V46, P2313, DOI 10.1167/iovs.04-0893
   Li B, 2000, EXP EYE RES, V70, P755, DOI 10.1006/exer.2000.0843
   Li Q, 2001, BRAIN RES, V907, P93, DOI 10.1016/S0006-8993(01)02607-5
   Li Y, 2001, J NEUROPHYSIOL, V85, P986, DOI 10.1152/jn.2001.85.2.986
   Liao SD, 2006, INVEST OPHTH VIS SCI, V47, P5032, DOI 10.1167/iovs.06-0422
   Lindqvist N, 2010, INVEST OPHTH VIS SCI, V51, P1683, DOI 10.1167/iovs.09-4159
   Linsenmeier RA, 1998, INVEST OPHTH VIS SCI, V39, P1647
   Liou GI, 2008, INVEST OPHTH VIS SCI, V49, P5526, DOI 10.1167/iovs.08-2196
   Liu YL, 2012, MOL MED, V18, P1387, DOI 10.2119/molmed.2012.00008
   LUTTY GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P267, DOI 10.1001/archopht.1992.01080140123039
   Lutty GA, 2003, PROG RETIN EYE RES, V22, P95, DOI 10.1016/S1350-9462(02)00058-7
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   Makarenkova HP, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00063
   Maminishkis A, 2002, INVEST OPHTH VIS SCI, V43, P3555
   Mandecka A, 2007, DIABETES CARE, V30, P3048, DOI 10.2337/dc07-0927
   Martin KRG, 2002, INVEST OPHTH VIS SCI, V43, P2236
   McKernan DP, 2007, INVEST OPHTH VIS SCI, V48, P5420, DOI 10.1167/iovs.07-0287
   Metea MR, 2006, J NEUROSCI, V26, P2862, DOI 10.1523/JNEUROSCI.4048-05.2006
   Meyer CH, 2002, INVEST OPHTH VIS SCI, V43, P3567
   Milenkovic I, 2003, INVEST OPHTH VIS SCI, V44, P1211, DOI 10.1167/iovs.02-0260
   Mino RP, 2001, INVEST OPHTH VIS SCI, V42, P3320
   Mishra A, 2011, P NATL ACAD SCI USA, V108, P17827, DOI 10.1073/pnas.1110533108
   Mishra A, 2010, GLIA, V58, P1996, DOI 10.1002/glia.21068
   Mitchell CH, 2001, J PHYSIOL-LONDON, V534, P193, DOI 10.1111/j.1469-7793.2001.00193.x
   Mitchell CH, 2008, PURINERG SIGNAL, V4, P101, DOI 10.1007/s11302-007-9054-2
   Mitchell CH, 2009, PURINERG SIGNAL, V5, P241, DOI 10.1007/s11302-009-9142-6
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172
   Moll V, 2002, INVEST OPHTH VIS SCI, V43, P766
   Morigiwa K, 2000, NEUROSCI LETT, V282, P153, DOI 10.1016/S0304-3940(00)00887-9
   Morigiwa K, 2000, Nihon Yakurigaku Zasshi, V115, P185
   Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5
   NEAL M, 1994, BRIT J PHARMACOL, V113, P1085, DOI 10.1111/j.1476-5381.1994.tb17106.x
   Neumann F, 2010, NEUROCHEM RES, V35, P522, DOI 10.1007/s11064-009-0092-8
   Newman E A, 2001, Prog Brain Res, V132, P241
   Newman EA, 2005, J NEUROSCI, V25, P5502, DOI 10.1523/JNEUROSCI.1354-05.2005
   Newman EA, 2004, GLIA, V47, P268, DOI 10.1002/glia.20030
   Newman EA, 2003, J NEUROSCI, V23, P1659, DOI 10.1523/jneurosci.23-05-01659.2003
   Newman EA, 2001, J NEUROSCI, V21, P2215, DOI 10.1523/JNEUROSCI.21-07-02215.2001
   Newman EA, 1998, J NEUROSCI, V18, P4022
   Newman EA, 1997, SCIENCE, V275, P844, DOI 10.1126/science.275.5301.844
   Newman EA, 2004, NEURON GLIA BIOL, V1, P245, DOI 10.1017/S1740925X0500013X
   Newman EA, 2013, J CEREBR BLOOD F MET, V33, P1685, DOI 10.1038/jcbfm.2013.145
   Niyadurupola N, 2013, INVEST OPHTH VIS SCI, V54, P2163, DOI 10.1167/iovs.12-10968
   Notomi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053338
   Notomi S, 2011, AM J PATHOL, V179, P2798, DOI 10.1016/j.ajpath.2011.08.035
   Ola MS, 2013, INT J MOL SCI, V14, P2559, DOI 10.3390/ijms14022559
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Ostwald P, 1997, VISION RES, V37, P3453, DOI 10.1016/S0042-6989(96)00222-2
   Pannicke T, 2006, DIABETES, V55, P633, DOI 10.2337/diabetes.55.03.06.db05-1349
   Pannicke T, 2005, VISION RES, V45, P1781, DOI 10.1016/j.visres.2005.01.016
   Pannicke T, 2005, J NEUROIMMUNOL, V161, P145, DOI 10.1016/j.jneuroim.2005.01.003
   Pannicke T, 2004, MOL CELL NEUROSCI, V26, P493, DOI 10.1016/j.mcn.2004.04.005
   Pannicke T, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.317
   Pannicke T, 2001, GLIA, V35, P213, DOI 10.1002/glia.1086
   Pannicke T, 2000, J NEUROSCI, V20, P5965, DOI 10.1523/JNEUROSCI.20-16-05965.2000
   Pearson R, 2002, J NEUROSCI, V22, P7569
   Pearson RA, 2005, NEURON, V46, P731, DOI 10.1016/j.neuron.2005.04.024
   Peng B, 2014, J NEUROSCI, V34, P8139, DOI 10.1523/JNEUROSCI.5200-13.2014
   Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193
   PEREZ MTR, 1986, BRAIN RES, V398, P106, DOI 10.1016/0006-8993(86)91255-2
   Peterson WM, 1997, J NEUROSCI, V17, P2324
   Plithussery T, 2007, NEUROSCIENCE, V146, P403, DOI 10.1016/j.neuroscience.2007.01.055
   Preissler J, 2015, GLIA, V63, P206, DOI 10.1002/glia.22744
   Puthussery T, 2004, J COMP NEUROL, V472, P13, DOI 10.1002/cne.20045
   Puthussery T, 2006, EUR J NEUROSCI, V24, P7, DOI 10.1111/j.1460-9568.2006.04895.x
   Puthussery T, 2009, J COMP NEUROL, V513, P430, DOI 10.1002/cne.21964
   Rehak M, 2009, INVEST OPHTH VIS SCI, V50, P2359, DOI 10.1167/iovs.08-2332
   Reichenbach A, 2007, GRAEF ARCH CLIN EXP, V245, P627, DOI 10.1007/s00417-006-0516-y
   Reigada D, 2008, NEUROSCIENCE, V157, P396, DOI 10.1016/j.neuroscience.2008.08.036
   Reigada D, 2006, J PHYSIOL-LONDON, V575, P707, DOI 10.1113/jphysiol.2006.114439
   Relvas LJM, 2009, INVEST OPHTH VIS SCI, V50, P1241, DOI 10.1167/iovs.08-1902
   Resta V, 2007, EUR J NEUROSCI, V25, P2741, DOI 10.1111/j.1460-9568.2007.05528.x
   Ribelayga C, 2005, J NEUROSCI, V25, P215, DOI 10.1523/JNEUROSCI.3138-04.2005
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Roh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040065
   Roth S, 1997, EXP EYE RES, V65, P771, DOI 10.1006/exer.1997.0391
   Ryan JS, 1999, J PHYSIOL-LONDON, V520, P745, DOI 10.1111/j.1469-7793.1999.00745.x
   Sakamoto K, 2001, EUR J PHARMACOL, V418, P89, DOI 10.1016/S0014-2999(01)00938-4
   Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009
   Santos PF, 2000, BRAIN RES, V852, P10, DOI 10.1016/S0006-8993(99)02155-1
   Santos PF, 1999, J NEUROBIOL, V41, P340, DOI 10.1002/(SICI)1097-4695(19991115)41:3<340::AID-NEU3>3.3.CO;2-#
   Sarman S, 2008, CURR EYE RES, V33, P285, DOI 10.1080/02713680701885470
   Pereira TDS, 2010, BRAIN RES, V1316, P129, DOI 10.1016/j.brainres.2009.12.034
   Sivakumar V, 2011, J PATHOL, V224, P245, DOI 10.1002/path.2858
   Skatchkov SN, 2006, GLIA, V53, P266, DOI 10.1002/glia.20280
   Stella SL, 2003, J NEUROPHYSIOL, V90, P165, DOI 10.1152/jn.00671.2002
   Stepinac TK, 2005, INVEST OPHTH VIS SCI, V46, P956, DOI 10.1167/iovs.04-0500
   Sugiyama T, 2005, AM J PHYSIOL-CELL PH, V288, pC568, DOI 10.1152/ajpcell.00380.2004
   Sugiyama T, 2004, INVEST OPHTH VIS SCI, V45, P1026, DOI 10.1167/iovs.03-1062
   Sugiyama T, 2006, ARCH OPHTHALMOL-CHIC, V124, P1143, DOI 10.1001/archopht.124.8.1143
   Sugiyama T, 2014, WORLD J DIABETES, V5, P141, DOI 10.4239/wjd.v5.i2.141
   Sugiyama T, 2013, MOL VIS, V19, P2080
   Sugiyama T, 2010, INVEST OPHTH VIS SCI, V51, P3236, DOI 10.1167/iovs.09-4192
   Sun XL, 2002, J NEUROCHEM, V81, P550, DOI 10.1046/j.1471-4159.2002.00832.x
   Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735
   Taomoto M, 2000, INVEST OPHTH VIS SCI, V41, P230
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Taschenberger H, 1999, J NEUROSCI, V19, P3353
   Tovell VE, 2008, INVEST OPHTH VIS SCI, V49, P350, DOI 10.1167/iovs.07-1040
   Trueblood KE, 2011, AM J PHYSIOL-CELL PH, V301, pC1213, DOI 10.1152/ajpcell.00265.2011
   Uckermann O, 2006, J NEUROSCI RES, V83, P538, DOI 10.1002/jnr.20760
   Uckermann O, 2005, J PHARMACOL EXP THER, V315, P1036, DOI 10.1124/jpet.105.092353
   Uckermann O, 2005, INVEST OPHTH VIS SCI, V46, P2592, DOI 10.1167/iovs.04-1402
   Uckermann O, 2004, J NEUROSCI, V24, P10149, DOI 10.1523/JNEUROSCI.3203-04.2004
   Uckermann O, 2002, J NEUROSCI RES, V70, P209, DOI 10.1002/jnr.10406
   Uckermann Ortrud, 2005, Purinergic Signal, V1, P383, DOI 10.1007/s11302-005-0779-5
   Uhlmann S, 2003, INVEST OPHTH VIS SCI, V44, P4114, DOI 10.1167/iovs.03-0183
   Vessey KA, 2012, PLOS ONE, V7, P290, DOI 10.1371/journal.pone.0029990
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   Vindeirinho J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067499
   Vitanova LA, 2014, ACTA HISTOCHEM, V116, P694, DOI 10.1016/j.acthis.2013.12.008
   Vogler S, 2013, J NEUROCHEM, V126, P372, DOI 10.1111/jnc.12307
   Voigt J, 2015, NEUROCHEM RES, V40, P651, DOI 10.1007/s11064-014-1511-z
   Wahl V, 2013, NEUROSCIENCE, V246, P59, DOI 10.1016/j.neuroscience.2013.04.045
   Wang MH, 2014, ADV EXP MED BIOL, V801, P333, DOI 10.1007/978-1-4614-3209-8_42
   Warburg O, 1927, BIOCHEM Z, V184, P484
   Ward MM, 2009, NEUROSCIENCE, V160, P555, DOI 10.1016/j.neuroscience.2009.02.022
   Ward MM, 2010, ADV EXP MED BIOL, V664, P385, DOI 10.1007/978-1-4419-1399-9_44
   Weick M, 2005, INVEST OPHTH VIS SCI, V46, P1525, DOI 10.1167/iovs.04-0417
   Weuste M, 2006, BIOCHEM BIOPH RES CO, V347, P310, DOI 10.1016/j.bbrc.2006.06.077
   Wurm A, 2008, EXP EYE RES, V87, P385, DOI 10.1016/j.exer.2008.07.004
   Wurm A, 2008, J NEUROCHEM, V104, P386, DOI 10.1111/j.1471-4159.2007.04992.x
   Wurm A, 2006, AM J PATHOL, V169, P1990, DOI 10.2353/ajpath.2006.060628
   Wurm A, 2011, PROG RETIN EYE RES, V30, P324, DOI 10.1016/j.preteyeres.2011.06.001
   Wurm A, 2011, INVEST OPHTH VIS SCI, V52, P3360, DOI 10.1167/iovs.10-6901
   Wurm A, 2010, J NEUROCHEM, V112, P1261, DOI 10.1111/j.1471-4159.2009.06541.x
   Wurm A, 2009, MOL VIS, V15, P1858
   Wurm A, 2009, GLIA, V57, P1680, DOI 10.1002/glia.20883
   Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P1522, DOI 10.1167/iovs.10-6172
   Yoon HZ, 2002, CLIN EXP OPHTHALMOL, V30, P424, DOI 10.1046/j.1442-9071.2002.00573.x
   Yu J, 2012, EXP THER MED, V3, P617, DOI 10.3892/etm.2012.457
   Yu J, 2012, ONCOL REP, V27, P748, DOI 10.3892/or.2011.1565
   Zeng H, 2014, NEUROSCIENCE, V275, P54, DOI 10.1016/j.neuroscience.2014.05.065
   Zhang M, 2006, MOL VIS, V12, P937
   Zhang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035446
   Zhang X, 2007, EXP EYE RES, V85, P637, DOI 10.1016/j.exer.2007.07.016
   Zhang XL, 2006, J NEUROCHEM, V98, P566, DOI 10.1111/j.1471-4159.2006.03900.x
   Zhang XL, 2005, INVEST OPHTH VIS SCI, V46, P2183, DOI 10.1167/iovs.05-0052
NR 228
TC 48
Z9 50
U1 1
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD MAY
PY 2016
VL 104
SI SI
BP 194
EP 211
DI 10.1016/j.neuropharm.2015.05.005
PG 18
WC Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA DN8HR
UT WOS:000377320300017
PM 25998275
DA 2022-11-30
ER

PT J
AU Gerding, H
AF Gerding, H.
TI Long-term Results of Intravitreal Anti-VEGF Injections in Wet AMD: A
   Meta-Analysis
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Review
DE age related macular degeneration; AMD; wAMD, nAMD; anti-VEGF;
   ranibizumab; aflibercept; bevacizumab; retina; macula; meta-analysis;
   review
ID MACULAR-DEGENERATION; RANIBIZUMAB TREATMENT; VISUAL OUTCOMES; EXUDATIVE
   AMD; FOLLOW-UP; IMPACT; 5-YEAR; EYES
AB Background: Although intravitreal anti-VEGF medications are widely used in age-related macular degeneration, no systematic data analysis is available on the long-term prognosis of this relatively new therapeutic approach.
   Material and Methods: A meta-analysis was performed on available Medline literature. 13 relevant clinical studies (14 case series) could be identified, covering 10 247 treated eyes. The majority of available reports originate from single centre retrospective real-life environments.
   Results: The mean improvement in average visual gain was 0.9 +/- 0.5 (mean +/- 1 standard deviation, median; 0.8 lines) at year 1, 1.2 +/- 1.1 (median: 1.1) letters at year 2, 0.7 +/- 1.0 (median: 0.7) letters at year 3, and 0.2 +/- 0.8 (median: 0.5), 0.4 +/- 0.4 (median: 0.5) at years 4 and 5. The drop-out rates in these studies was relatively high. At the end of year 3, the average percentage of observed eyes was 44.3 +/- 18.4% (mean +/- 1 standard deviation), at the end of year 4 23.5 +/- 23.9% and after years 6 and 7 below 10% (8.2 and 7.9%). The mean treatment frequency of injections in all available studies was highest in year 1 (6.4 +/- 1.2, 6.1 - mean +/- SD; median), followed by relatively consistent mean values of 4.1 and 5.1 (year (Y)2: 4.4, Y3: 4.3, Y4: 4.7, Y5: 4.1, Y6: 5.1, Y7: 4.7) injections per year.
   Conclusions: The results of this meta-analysis clearly indicate that intravitreal anti-VEGF injection therapy is capable of maintaining visual acuity on a long-term basis of at least 4-5 years.
C1 [Gerding, H.] Augenzentrum Klin Pallas, Olten, Switzerland.
   [Gerding, H.] Univ Munster, Dept Ophthalmol, D-48149 Munster, Germany.
C3 University of Munster
RP Gerding, H (通讯作者)，Klin Pallas, Dept Retinol, Louis Giroud Str 20, CH-4600 Olten, Switzerland.
EM hgerding@klinik-pallas.ch
RI Gerding, Heinrich/M-2363-2019
OI Gerding, Heinrich/0000-0003-3968-5601
FU Novartis; Bayer; Allergan; Heidelberg Engineering
FX H. G. received consulting fees, travelling reimbursement and lecture
   honoraria from Novartis, Bayer, Allergan and Heidelberg Engineering.
   This project is investigator initiated and was not sponsored.
CR Amstutz CA, 2015, KLIN MONATSBL AUGENH, V232, P533, DOI 10.1055/s-0035-1545673
   Beykin G, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0019-x
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Buckle M, 2016, BRIT J OPHTHALMOL, V100, P240, DOI 10.1136/bjophthalmol-2014-306423
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Gerding H, 2014, KLIN MONATSBL AUGENH, V231, P427, DOI 10.1055/s-0034-1368241
   Gerding H, 2010, KLIN MONATSBL AUGENH, V227, P294, DOI 10.1055/s-0029-1245209
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Zhu MD, 2015, GRAEF ARCH CLIN EXP, V253, P1217, DOI 10.1007/s00417-014-2799-8
NR 19
TC 16
Z9 16
U1 0
U2 6
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2016
VL 233
IS 4
BP 471
EP 474
DI 10.1055/s-0041-111835
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DK6ON
UT WOS:000375043500040
PM 27116511
DA 2022-11-30
ER

PT J
AU Hoeg, TB
   Ellervik, C
   Buch, H
   La Cour, M
   Klemp, K
   Kvetny, J
   Erngaard, D
   Moldow, B
AF Hoeg, Tracy Beth
   Ellervik, Christina
   Buch, Helena
   La Cour, Morten
   Klemp, Kristian
   Kvetny, Jan
   Erngaard, Ditte
   Moldow, Birgitte
TI Danish Rural Eye Study: Epidemiology of Adult Visual Impairment
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE visual impairment; Blindness; population-based; Denmark
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; BLINDNESS; VISION;
   ACUITY; PREVALENCE; POPULATION; AUSTRALIA; CATARACT; DESIGN
AB Purpose: To examine the frequency and causes of visual impairment (VI) in a select population of Danish adults.
   Methods: A total of 3843 adults aged 20-94 years from the Danish General Suburban Population Study (GESUS) were included in the population-based, cross-sectional ophthalmological study, Danish Rural Eye Study (DRES). All DRES participants received a comprehensive general health examination preceding their eye examination, including measurement of best-corrected visual acuity (BCVA) for each eye, bilateral 45 degrees retinal fundus photographs and further ophthalmological examination where indicated.
   Results: Overall, 3826 of 3843 participants (99.6%) had bilateral visual acuity measurements. The overall frequency of VI (BCVA <20/40 in the better-seeing eye) was 0.4% (95% confidence interval, CI, 0.2-0.7%; n = 15) among all DRES participants, 0.6% (95% CI 0.3-1.0%; n = 15) among participants >50 years and 3.7% (95% CI 2.1-6.5%; n = 11) in participants >80 years. The primary causes of VI in the better-seeing eye were age-related macular degeneration (AMD) in 46.7% (7/15) and cataract in 26.7% (4/15). A total of 43.3% (n = 115) of participants >80 years were pseudophakic in one or both eyes. The frequency of diabetes (HbA(1c) >= 48 mmol/mol or self-reported diagnosis) was 5.9% (n = 227), including 1.3% (n = 51) newly diagnosed in the GESUS. Of participants determined to have VI due to exudative AMD, 50% had received anti-vascular endothelial growth factor (VEGF) treatment.
   Conclusion: We report a relatively low frequency of VI among Danish adults over 59 years of age compared with that observed 10-15 years ago, which is both consistent with other recent Scandinavian studies and reflective of our relatively healthy and mobile population sample.
C1 [Hoeg, Tracy Beth; Erngaard, Ditte; Moldow, Birgitte] Univ Copenhagen, Naestved Hosp, Dept Ophthalmol, Ringstedgade 61, DK-4700 Naestved, Denmark.
   [Hoeg, Tracy Beth; Ellervik, Christina; La Cour, Morten] Univ Copenhagen, Fac Hlth Sci, DK-4700 Naestved, Denmark.
   [Ellervik, Christina] Nykobing Falster Hosp, Dept Gen Populat Study, Nykobing, Denmark.
   [Buch, Helena; La Cour, Morten] Capital Reg Eye Clin, Dept Ophthalmol, Glostrup, Denmark.
   [Buch, Helena; Klemp, Kristian] Natl Univ Hosp, Dept Ophthalmol, Rigshosp, Copenhagen, Denmark.
   [Buch, Helena] Copenhagen Private Hosp, Copenhagen Eye & Strabismus Clin, Copenhagen, Denmark.
   [Kvetny, Jan] Naestved Hosp, Dept Internal Med, Naestved, Denmark.
   [Kvetny, Jan] Univ Southern Denmark, Inst Reg Hlth Serv, Odense, Denmark.
C3 Naestved Hospital; University of Copenhagen; University of Copenhagen;
   Rigshospitalet; University of Copenhagen; Naestved Hospital; University
   of Southern Denmark
RP Hoeg, TB (通讯作者)，Univ Copenhagen, Naestved Hosp, Dept Ophthalmol, Ringstedgade 61, DK-4700 Naestved, Denmark.
EM exophoria@gmail.com
RI Hesgaard, Helena Buch/E-8226-2011; Ellervik, Christina/H-2977-2019; la
   Cour, Morten/L-1600-2013
OI Hesgaard, Helena Buch/0000-0002-2097-0202; Ellervik,
   Christina/0000-0002-3088-4375; Dornonville de la Cour,
   Morten/0000-0002-7712-9772; Hoeg, Tracy/0000-0002-2341-6573
FU Region Zealand Foundation; Naestved Hospital Foundation; Fight for Sight
   Denmark; Alcon/Novartis; Eva and Hans Carl Adolf Holms Memorial
   Scholarship; Ulla and Mogens Folmer Andersen's Fund; Mr. and Mrs. Johs
   M. Klein Memorial Scholarship; Edith and Henrik Henriksen's Memorial
   Scholarship
FX Dr. Hoeg's work has been funded by Region Zealand Foundation, Naestved
   Hospital Foundation and Fight for Sight Denmark. Dr. La Cour has
   received fees for talks about ocriplasmin from Alcon/Novartis. Dr.
   Ellervik has been funded by Region Zealand Foundation and is a
   consultant for Area9. Dr. Moldow is a consultant for Region Zealand.
   Drs. Buch, Klemp, Kvetny and Erngaard report no conflicts of interest.;
   The authors would like to acknowledge the financial support of Region
   Zealand Foundation; Naestved Hospital Foundation, Fight for Sight
   Denmark, Eva and Hans Carl Adolf Holms Memorial Scholarship, Ulla and
   Mogens Folmer Andersen's Fund, Mr. and Mrs. Johs M. Klein Memorial
   Scholarship, and Edith and Henrik Henriksen's Memorial Scholarship. The
   funding sources had no role in the study design, conduct, data
   collection, management, analysis, interpretation of the data,
   preparation, review, approval of the manuscript or decision to submit
   the manuscript for publication.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Behndig A, 2011, J CATARACT REFR SURG, V37, P1539, DOI 10.1016/j.jcrs.2011.05.021
   Bergholdt HKM, 2013, DAN MED J, V60
   Bertelsen G, 2013, ACTA OPHTHALMOL, V91, P635, DOI 10.1111/j.1755-3768.2012.02511.x
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Chiang PPC, 2013, DIABETIC MED, V30, pE32, DOI 10.1111/dme.12053
   Cole BL, 2007, CLIN EXP OPTOM, V90, P157, DOI 10.1111/j.1444-0938.2007.00135.x
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danermark B, 2012, SCAND J PUBLIC HEALT, V40, P287, DOI 10.1177/1403494812459621
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Gunnlaugsdottir E, 2010, ACTA OPHTHALMOL, V88, P358, DOI 10.1111/j.1755-3768.2008.01445.x
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Ko F, 2012, JAMA-J AM MED ASSOC, V308, P361
   Lohmann E., 2014, VAERN SYNET MEDLEMSB, V4, P14
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   Sun JK, 2012, ARCH OPHTHALMOL-CHIC, V130, P470, DOI 10.1001/archophthalmol.2011.377
   Tan JSL, 2008, OPHTHAL EPIDEMIOL, V15, P317, DOI 10.1080/09286580802105806
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Wolfram C, 2012, OPHTHAL EPIDEMIOL, V19, P3, DOI 10.3109/09286586.2011.628136
NR 23
TC 7
Z9 7
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD JAN 2
PY 2016
VL 23
IS 1
BP 53
EP 62
DI 10.3109/09286586.2015.1066396
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DF3LF
UT WOS:000371244800009
PM 26825126
DA 2022-11-30
ER

PT J
AU Luttrull, JK
   Margolis, BWL
AF Luttrull, Jeffrey K.
   Margolis, Benjamin W. L.
TI Functionally Guided Retinal Protective Therapy for Dry Age-Related
   Macular and Inherited Retinal Degenerations: A Pilot Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE laser; macula; pattern electroretinogram; microperimetry; age-related
   macular degeneration; retinitis pigmentosa; prophylaxis; retinal
   protection; retinal function testing; functionally guided disease
   management; prevention; central vision analyzer; contrast sensitivity
ID MICROPULSE DIODE-LASER; GANGLION-CELL FUNCTION; PROLIFERATIVE
   DIABETIC-RETINOPATHY; CENTRAL SEROUS CHORIORETINOPATHY; PROGRESSIVE
   LOSS; EARLY GLAUCOMA; VISUAL-ACUITY; PHOTOCOAGULATION; EDEMA; PATTERN
AB PURPOSE. To review the results of retinal function testing in eyes undergoing panmacular subthreshold diode micropulse laser (SDM) prophylaxis for chronic progressive retinal disease.
   METHODS. The records of all patients undergoing prophylactic panmacular SDM for high-risk age-related macular degeneration (AMD) and inherited photoreceptor degenerations (IRDs) examined by pattern electroretinography (PERG), automated microperimetry (AMP), and Central Vision Analyzer (CVA) testing before and after treatment were reviewed.
   RESULTS. A total of 158 consecutive eyes of 108 patients with AMD and 10 consecutive eyes of 8 patients with IRDs, evaluated both before and after SDM by PERG, were eligible for study. The IRD diagnoses included rod-cone degeneration (four eyes), cone-rod degeneration (three eyes), and Stargardt's disease (three eyes). In AMD, AMP was performed in 40 consecutive eyes, and CVA in the subsequent 73 consecutive eyes concurrent with PERG. The SDM treatment consisted of 1800 to 3000 confluent spots throughout the retina circumscribed by the major vascular arcades, including the fovea ("panmacular''). Testing was performed 1 week before and by 1 month after treatment. Results indicated that 149/168 eyes were improved by primary PERG measures: 139/158 eyes with AMD by PERG low-contrast scan Magnitude D (MagD)(mu V)/Magnitude (Mag)(mu V) ratios (P = 0.0001) and 10/10 eyes with IRDs by 24(0) concentric ring scan MagD(mu V)/Mag(mu V) ratios (P = 0.002). Snellen visual acuity (VA) was unchanged, but macular sensitivity by AMP (P = 0.0439) and mesopic contrast VA by CVA (P = 0.006) were improved. There were no adverse treatment effects.
   CONCLUSIONS. Our findings suggest a role for SDM as retinal protective therapy in chronic progressive retinal diseases. Pattern electroretinography enables (early, preventive) functionally guided, rather than (late, therapeutic) image-guided, disease management.
C1 [Luttrull, Jeffrey K.; Margolis, Benjamin W. L.] Ojai Retinal Technol LLC, Ojai, CA USA.
   [Luttrull, Jeffrey K.; Margolis, Benjamin W. L.] EyEngineering Inc, Ojai, CA USA.
   [Margolis, Benjamin W. L.] Santa Clara Univ, Dynam & Control Syst Lab, Santa Clara, CA 95053 USA.
C3 Santa Clara University
RP Luttrull, JK (通讯作者)，3160 Telegraph Rd,Suite 230, Ventura, CA 93003 USA.
EM jkluttrull@gmail.com
OI Margolis, Benjamin/0000-0001-5602-1888
CR ARDEN GB, 1982, ANN NY ACAD SCI, V388, P580, DOI 10.1111/j.1749-6632.1982.tb50818.x
   Banitt MR, 2013, INVEST OPHTH VIS SCI, V54, P2346, DOI 10.1167/iovs.12-11026
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bowd C, 2009, J GLAUCOMA, V18, P437, DOI 10.1097/IJG.0b013e31818c6f44
   ELLENBERG SS, 1993, BRIT J CANCER, V68, P457, DOI 10.1038/bjc.1993.369
   Faria BM, 2015, RETINA-J RET VIT DIS, V35, P1465, DOI 10.1097/IAE.0000000000000474
   Garrison FH, 1966, INTRO HIST MED
   Gutstein W, 2015, J COMPUT SCI SYST BI, V8, P225
   Koss MJ, 2012, EYE, V26, P307, DOI 10.1038/eye.2011.282
   Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001
   Luttrull JK, 2008, EYE, V22, P607, DOI 10.1038/sj.eye.6702725
   Luttrull JK, 2015, RETINA-J RET VIT DIS, V35, P1184, DOI 10.1097/IAE.0000000000000458
   Luttrull JK, 2014, RETINA-J RET VIT DIS, V34, P2010, DOI 10.1097/IAE.0000000000000177
   Luttrull JK, 2012, CURR DIABETES REV, V8, P274, DOI 10.2174/157339912800840523
   Luttrull JK, 2012, RETINA-J RET VIT DIS, V32, P375, DOI 10.1097/IAE.0b013e3182206f6c
   Luttrull JK, 2005, BRIT J OPHTHALMOL, V89, P74, DOI 10.1136/bjo.2004.051540
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Neveu MM, 2006, DOC OPHTHALMOL, V113, P71, DOI 10.1007/s10633-006-9016-y
   ODOM JV, 1992, CLIN VISION SCI, V7, P263
   Porciatti V, 2004, OPHTHALMOLOGY, V111, P161, DOI 10.1016/j.ophtha.2003.04.007
   RIGGS LA, 1986, VISION RES, V26, P1443, DOI 10.1016/0042-6989(86)90167-7
   Roisman L, 2013, OSLI RETINA, V44, P465, DOI 10.3928/23258160-20130909-08
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3rd ed.
   Schachat AP, 2015, OPHTHALMOLOGY, V122, P222, DOI 10.1016/j.ophtha.2014.09.015
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P1045, DOI 10.1016/j.ophtha.2013.11.041
   Scott IU, 2014, JAMA OPHTHALMOL, V132, P535, DOI 10.1001/jamaophthalmol.2014.93
   Sivaprasad S, 2007, CLIN EXP OPHTHALMOL, V35, P640, DOI 10.1111/j.1442-9071.2007.01566.x
   Sramek C, 2011, INVEST OPHTH VIS SCI, V52, P1780, DOI 10.1167/iovs.10-5917
   van Teijlingen ER, 2001, J ADV NURS, V34, P289, DOI 10.1046/j.1365-2648.2001.01757.x
   Ventura LM, 2005, OPHTHALMOLOGY, V112, P20, DOI 10.1016/j.ophtha.2004.09.002
   Ventura LM, 2012, INVEST OPHTH VIS SCI, V53, P659, DOI 10.1167/iovs.11-8525
   Vujosevic S, 2010, RETINA-J RET VIT DIS, V30, P908, DOI 10.1097/IAE.0b013e3181c96986
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
NR 33
TC 27
Z9 38
U1 1
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2016
VL 57
IS 1
BP 265
EP 275
DI 10.1167/iovs.15-18163
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DI6DN
UT WOS:000373589500030
PM 26818793
OA gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Lee, YM
   Kim, CS
   Jo, K
   Sohn, EJ
   Kim, JS
   Kim, J
AF Lee, Yun Mi
   Kim, Chan-Sik
   Jo, Kyuhyung
   Sohn, Eun Jin
   Kim, Jin Sook
   Kim, Junghyun
TI Inhibitory effect of Samul-tang on retinal neovascularization in
   oxygen-induced retinopathy
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Retinal neovascularization; Stromal cell-derived factor 1; Chemokine
   (C-X-C motif) receptor 4; Vascular endothelial growth factor;
   Oxygen-induced retinopathy
ID ENDOTHELIAL GROWTH-FACTOR; IN-VIVO; ANGIOGENESIS; CELLS; SDF-1/CXCR4;
   CXCR4; SUPPRESSION; MECHANISMS; EXPRESSION; RECEPTOR
AB Background: Retinal neovascularization is a common cause of vision loss in proliferative diabetic retinopathy, retinopathy of prematurity and age-related macular degeneration. Samul-tang (SMT) is a widely used traditional herbal medicine in East Asia and is also known as Shimotsu-to in Japanese and Si-Wu decoction in Chinese. This study was designed to evaluate the inhibitory effect of SMT on retinal pathogenic angiogenesis in a mouse model of oxygen-induced retinopathy (OIR).
   Method: The mice were exposed to a 75 % concentration of oxygen for five days, starting on postnatal day 7 (P7-P12). The mice were then exposed to room air and were intraperitoneally injected with SMT (10 mg/kg or 50 mg/kg) once per day for five days (P12-P16). On P17, we measured retinal neovascularization and evaluated both the expression of angiogenesis-related proteins and changes in the gene expression level in the mRNA.
   Results: SMT reduced the area of the central retina and reduced retinal neovascularization in OIR mice. The protein array revealed that SMT reduced the level of SDF-1 protein expression. Quantitative real-time PCR revealed that the HIF-1 alpha, SDF-1, CXCR4 and VEGF mRNA levels in the retinas of OIR mice were elevated compared with those of normal control mice. However, SMT decreased the levels of HIF-1 alpha, SDF-1, CXCR4 and VEGF mRNA in OIR mice.
   Conclusion: We are the first to elucidate that SMT inhibits the retinal pathogenic angiogenesis induced by ischemic retinopathy in OIR mice. SMT significantly inhibited retinal neovascularization by downregulating HIF-1 alpha, SDF-1, CXCR4 and VEGF. Based on the results of our study, SMT could be a useful herbal medicine for treating ischemic retinopathy.
C1 [Lee, Yun Mi; Kim, Chan-Sik; Jo, Kyuhyung; Sohn, Eun Jin; Kim, Jin Sook; Kim, Junghyun] KIOM, Herbal Med Res Div, Korean Med Based Herbal Drug Dev Grp, Taejon 305811, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Kim, J (通讯作者)，KIOM, Herbal Med Res Div, Korean Med Based Herbal Drug Dev Grp, 1672 Yuseongdaero, Taejon 305811, South Korea.
EM dvmhyun@kiom.re.kr
FU Korea Institute of Oriental Medicine (KIOM) [K14302]
FX This research was supported by a grant [K14302] from the Korea Institute
   of Oriental Medicine (KIOM).
CR Abu El-Asrar AM, 2013, ACTA DIABETOL, V50, P545, DOI 10.1007/s00592-011-0330-9
   Agrawal S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/943409
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Al-Shabrawey M, 2013, EXPERT REV OPHTHALMO, V8, P267, DOI 10.1586/EOP.13.17
   Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182
   Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869
   Cai XX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088176
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Connor KM, 2009, NAT PROTOC, V4, P1565, DOI 10.1038/nprot.2009.187
   Deng H, 2010, J ETHNOPHARMACOL, V127, P781, DOI 10.1016/j.jep.2009.09.053
   Fong GH, 2008, ANGIOGENESIS, V11, P121, DOI 10.1007/s10456-008-9107-3
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   유새롬, 2014, [Journal of Korean Medicine, 대한한의학회지], V35, P28
   Jung MH, 2009, CARCINOGENESIS, V30, P655, DOI 10.1093/carcin/bgp039
   Kojima S, 1996, BIOL PHARM BULL, V19, P47, DOI 10.1248/bpb.19.47
   Kwak DH, 2002, J ETHNOPHARMACOL, V81, P373, DOI 10.1016/S0378-8741(02)00122-8
   Lee HJ, 2009, AM J CHINESE MED, V37, P127, DOI 10.1142/S0192415X09006722
   Lee Y, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/245271
   Liekens S, 2010, CURR PHARM DESIGN, V16, P3903, DOI 10.2174/138161210794455003
   Nishigaki A, 2013, GYNECOL ENDOCRINOL, V29, P230, DOI 10.3109/09513590.2012.736551
   Nishigaki A, 2011, FERTIL STERIL, V95, P742, DOI 10.1016/j.fertnstert.2010.10.028
   Park SW, 2014, J CELL MOL MED, V18, P875, DOI 10.1111/jcmm.12235
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5
   Salcedo R, 2003, MICROCIRCULATION, V10, P359, DOI 10.1038/sj.mn.7800200
   Seo Chang-b, 2011, [Journal of Korean Medicine, 대한한의학회지], V32, P25
   Sierra MD, 2004, BLOOD, V103, P2452
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   Simpson DAC, 1999, BIOCHEM BIOPH RES CO, V262, P333, DOI 10.1006/bbrc.1999.1201
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Sonmez K, 2008, OPHTHALMOLOGY, V115, P1065, DOI 10.1016/j.ophtha.2007.08.050
   Tomao F, 2014, ONCOTARGETS THER, V7, DOI 10.2147/OTT.S68286
   Unoki N, 2010, INVEST OPHTH VIS SCI, V51, P3362, DOI 10.1167/iovs.09-4978
   Villalvilla A, 2012, LIFE SCI, V91, P264, DOI 10.1016/j.lfs.2012.07.019
   Wang W, 2012, INT J MOL SCI, V13, P15373, DOI 10.3390/ijms131115373
   Wang Y, 2013, ADV CIV ENG, V2013, DOI 10.1155/2013/189105
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yi Zhong, 1997, MODERN STUDY MED FOR
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   마진열, 2008, [Journal of Physiology & Pathology in Korean Medicine, 동의생리병리학회지], V22, P137
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 43
TC 9
Z9 10
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD AUG 12
PY 2015
VL 15
AR 271
DI 10.1186/s12906-015-0800-7
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA CO6RV
UT WOS:000359284800004
PM 26264147
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Inoue, Y
   Tsuruma, K
   Nakanishi, T
   Oyagi, A
   Ohno, Y
   Otsuka, T
   Shimazawa, M
   Hara, H
AF Inoue, Yuki
   Tsuruma, Kazuhiro
   Nakanishi, Tomohiro
   Oyagi, Atsushi
   Ohno, Yuta
   Otsuka, Tomohiro
   Shimazawa, Masamitsu
   Hara, Hideaki
TI Role of Heparin-Binding Epidermal Growth Factor-Like Growth Factor in
   Light-Induced Photoreceptor Degeneration in Mouse Retina
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; heparin-binding epidermal growth
   factor-like growth factor (HB-EGF); light-induced retinal degeneration;
   neuroprotection; photoreceptor
ID FACTOR HB-EGF; DIPHTHERIA-TOXIN RECEPTOR; PROTEIN-COUPLED RECEPTORS;
   CENTRAL-NERVOUS-SYSTEM; FACTOR KNOCKOUT MICE; NEUROTROPHIC FACTOR; RAT
   RETINA; INTRAVITREAL INJECTION; MESSENGER-RNA; POSTNATAL RAT
AB PURPOSE. Although heparin-binding epidermal growth factor-like growth factor (HB-EGF) has been reported to have protective effects against various neuronal cell damage, its role in the retina has not been elucidated. Here, we investigated its role in light-induced photoreceptor degeneration using retinas and ventral forebrain-specific Hb-egf knockout (KO) mice.
   METHODS. Disruption of Hb-egf was confirmed by beta-galactosidase (LacZ) staining and RT-PCR. Time-dependent changes in retinal HB-EGF were measured using quantitative RT-PCR and Western blotting. Retinal damage was induced by exposure to light. Recombinant human HB-EGF was injected intravitreally. Electroretinogram (ERG) and histological analyses were performed. To evaluate the effect of HB-EGF against light irradiation-induced cell death, 661W cells, a transformed mouse cone cell line, were used.
   RESULTS. LacZ-positive cells were observed and Hb-egf deletion was confirmed in the retinas of Hb-egf KO mice. Hb-egf and pro-HB-EGF levels were increased after light exposure in wild-type (WT) mice. Exposure to light reduced the a- and b-wave amplitudes of the dark-adapted ERG, and also outer nuclear layer (ONL) thickness, in Hb-egf KO mice versus WT mice. Treatment with HB-EGF improved both the a- and b-wave amplitudes and the thickness of the ONL. The 661W cell death induced by light irradiation was exacerbated by Hb-egf knockdown. HB-EGF also protected against light-induced cell death and reduced reactive oxygen species (ROS) production in 661W cells. HB-EGF treatment improved the a-wave amplitudes and the thickness of the ONL in Hb-egf KO mice.
   CONCLUSIONS. These data suggest that HB-EGF plays a pivotal role in light-induced photoreceptor degeneration. It therefore warrants investigation as a potential therapeutic target for such light-induced retinal diseases as age-related macular degeneration.
C1 [Inoue, Yuki; Tsuruma, Kazuhiro; Nakanishi, Tomohiro; Oyagi, Atsushi; Ohno, Yuta; Otsuka, Tomohiro; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Gifu 5011196, Japan.
C3 Gifu Pharmaceutical University
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM hidehara@gifu-pu.ac.jp
RI Ohno, Yuta/AIE-4047-2022
OI Ohno, Yuta/0000-0002-8182-3150
CR Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35
   Close JL, 2006, GLIA, V54, P94, DOI 10.1002/glia.20361
   DLUZ SM, 1993, J BIOL CHEM, V268, P18330
   Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268
   Farkas LM, 2002, J NEURAL TRANSM, V109, P267, DOI 10.1007/s007020200022
   Furuta Y, 2000, GENESIS, V26, P130, DOI 10.1002/(SICI)1526-968X(200002)26:2<130::AID-GENE9>3.3.CO;2-9
   Harada T, 2002, J NEUROSCI, V22, P9228, DOI 10.1523/jneurosci.22-21-09228.2002
   HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698
   Hollborn M, 2005, MOL VIS, V11, P397
   Imai S, 2010, J PHARMACOL EXP THER, V335, P645, DOI 10.1124/jpet.110.171298
   Imai S, 2010, EUR J PHARMACOL, V642, P77, DOI 10.1016/j.ejphar.2010.05.057
   IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x
   Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100
   Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin KL, 2004, J CEREBR BLOOD F MET, V24, P399, DOI 10.1097/00004647-200404000-00005
   Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x
   Kuhn MA, 2002, ANTIOXID REDOX SIGN, V4, P639, DOI 10.1089/15230860260220148
   Kyhn MV, 2009, EXP EYE RES, V89, P1012, DOI 10.1016/j.exer.2009.08.014
   Lambiase A, 2005, INVEST OPHTH VIS SCI, V46, P3800, DOI 10.1167/iovs.05-0301
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Lee KS, 2007, BBA-MOL CELL RES, V1773, P1637, DOI 10.1016/j.bbamcr.2007.07.001
   Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41
   Li GY, 2007, J NEUROSCI, V27, P203, DOI 10.1523/JNEUROSCI.0445-06.2007
   LI ZY, 1985, INVEST OPHTH VIS SCI, V26, P1589
   Liu Y, 2010, MOL VIS, V16, P2903
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Mishima K, 1996, NEUROSCI LETT, V213, P153
   NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K
   Nakagawa T, 1998, DEV BRAIN RES, V108, P263, DOI 10.1016/S0165-3806(98)00057-1
   Nakazawa T, 2002, INVEST OPHTH VIS SCI, V43, P3319
   Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Oyagi A, 2011, NEUROSCIENCE, V185, P116, DOI 10.1016/j.neuroscience.2011.04.034
   Oyagi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007461
   Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260
   Shimazaki H, 2011, INVEST OPHTH VIS SCI, V52, P7289, DOI 10.1167/iovs.11-7983
   Sun XD, 2007, CURR EYE RES, V32, P765, DOI 10.1080/02713680701531082
   Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200
   Tanaka H, 2009, MOL VIS, V15, P662
   Tanaka J, 2011, J AGR FOOD CHEM, V59, P528, DOI 10.1021/jf103186a
   Tsuruma K, 2012, INVEST OPHTH VIS SCI, V53, P7896, DOI 10.1167/iovs.12-10165
   Wan J, 2012, DEV CELL, V22, P334, DOI 10.1016/j.devcel.2011.11.020
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Weuste M, 2006, BIOCHEM BIOPH RES CO, V347, P310, DOI 10.1016/j.bbrc.2006.06.077
   Xia GL, 2001, ANTIOXID REDOX SIGN, V3, P919, DOI 10.1089/15230860152665073
   Yamauchi M, 2011, EUR J PHARMACOL, V650, P110, DOI 10.1016/j.ejphar.2010.09.081
   Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026
   Yang JH, 2003, INVEST OPHTH VIS SCI, V44, P1312, DOI 10.1167/iovs.02-0768
   Zhu CQC, 2002, DEVELOPMENT, V129, P2835
NR 50
TC 11
Z9 12
U1 1
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2013
VL 54
IS 6
BP 3815
EP 3829
DI 10.1167/iovs.12-11236
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 173YW
UT WOS:000321120700001
PM 23640042
DA 2022-11-30
ER

PT J
AU Schweizer, J
   Hollmach, J
   Steiner, G
   Knels, L
   Funk, RHW
   Koch, E
AF Schweizer, Julia
   Hollmach, Julia
   Steiner, Gerald
   Knels, Lilla
   Funk, Richard H. W.
   Koch, Edmund
TI Hyperspectral imaging - A new modality for eye diagnostics
SO BIOMEDICAL ENGINEERING-BIOMEDIZINISCHE TECHNIK
LA English
DT Article
AB Age-related-macular-degeneration (AMD) is the leading cause of blindness in people over 65 years in the western society. The prevalence of AMD arises during old age, due to the generally increased oxidative cell stress. In case of AMD, the symptoms include irreversible degenerative cell processes, like apoptosis, and morphological changes in the eye-background. Currently, there are no effective treatments to regenerate the visual function of patients with this disease. Therefore, it is essential to develop methods for an early detection of AMD in order to stop the degeneration processes. The cell protein cytochrome-c (cyt-c) has been identified as a key signalling molecule in degeneration processes and apoptosis. In its oxidized state, the protein exhibits several strong absorbance bands in the spectral range between 400 nm and 700 nm. Using hyperspectral imaging spectroscopy, the oxidative state of cyt-c can be detected in real time, without the need for additional biochemical markers, in cell cultures in vitro. Initial studies were performed with two systems. The first system is a high performance uv/vis imaging spectrometer coupled to a microscope. The second system is a model representing the optical properties of a human eye. Reflected light from the eye background was collected in an optical fibre and transferred into a highly sensitive linear photodiode spectrometer. The collected spectroscopic data provide information about the oxidative state of cyt-c during oxidative stress. By using these spectral signals, we will be able to draw conclusions about the biochemical status and degeneration process in cells. The results demonstrate that reflection spectroscopy has a high potential for developing a fast, non-invasive spectroscopic system to detect the early state of AMD.
C1 [Schweizer, Julia; Hollmach, Julia; Steiner, Gerald; Koch, Edmund] Tech Univ Dresden, Fac Carl Gustav Carus Med, Clin Sensoring & Monitoring, Dresden, Germany.
   [Knels, Lilla; Funk, Richard H. W.] Tech Univ Dresden, Fac Carl Gustav Carus Med, Inst Anat, Dresden, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden
RP Schweizer, J (通讯作者)，Tech Univ Dresden, Fac Carl Gustav Carus Med, Clin Sensoring & Monitoring, Dresden, Germany.
EM julia.schweizer@tu-dresden.de
OI Koch, Edmund/0000-0003-0554-2178
CR Bressler NM, 2000, BRIT MED J, V321, P1425, DOI 10.1136/bmj.321.7274.1425
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Fedurco M, 2004, BBA-PROTEINS PROTEOM, V1703, P31, DOI 10.1016/j.bbapap.2004.09.013
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Johnson EJ, 2010, CURR OPIN CLIN NUTR, V13, P28, DOI 10.1097/MCO.0b013e32833308ff
   Kerr J.F.R., 1987, P93
   Knels L, 2008, J NEUROCHEM, V106, P1876, DOI 10.1111/j.1471-4159.2008.05540.x
   Knels L, 2011, EUR J NEUROSCI, V34, P548, DOI 10.1111/j.1460-9568.2011.07790.x
   Seigel GM, 2004, CURR EYE RES, V28, P257, DOI 10.1076/ceyr.28.4.257.27831
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wyllie A H, 1980, Int Rev Cytol, V68, P251
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 12
TC 18
Z9 20
U1 0
U2 7
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0013-5585
EI 1862-278X
J9 BIOMED ENG-BIOMED TE
JI Biomed. Eng.-Biomed. Tech.
PD SEP
PY 2012
VL 57
SU 1
BP 293
EP 296
DI 10.1515/bmt-2012-4375
PG 4
WC Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Medical Informatics
GA VI5WH
UT WOS:000497706300147
DA 2022-11-30
ER

PT J
AU VanNasdale, DA
   Elsner, AE
   Kohne, KD
   Peabody, TD
   Malinovsky, VE
   Haggerty, BP
   Weber, A
   Clark, CA
AF VanNasdale, Dean A.
   Elsner, Ann E.
   Kohne, Kimberly D.
   Peabody, Todd D.
   Malinovsky, Victor E.
   Haggerty, Bryan P.
   Weber, Anke
   Clark, Christopher A.
TI Foveal Localization in Non-Exudative AMD Using Scanning Laser
   Polarimetry
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE fovea; polarimetry; birefringence; phase retardation; age-related
   macular degeneration; retina
ID OPTICAL COHERENCE TOMOGRAPHY; PREFERRED RETINAL LOCUS; AGE-RELATED
   MACULOPATHY; NERVE-FIBER LAYER; IMAGING POLARIMETRY; SUBRETINAL
   STRUCTURES; CORNEAL POLARIZATION; MACULAR DEGENERATION; GEOGRAPHIC
   ATROPHY; PHASE RETARDATION
AB Purpose. To determine whether custom scanning laser polarimetry (SLP) images, differing in polarization content, can be used to accurately localize the fovea in the presence of non-exudative age-related macular degeneration (AMD). To determine whether alterations to the foveal structure in non-exudative AMD significantly disrupts the birefringent Henle fiber layer, responsible for the macular cross pattern in some SLP images. To determine whether phase retardation information, specifically color-coded information representing its magnitude and axis, allow better foveal localization than images including retardation amplitude only.
   Methods. SLP images were acquired in 25 AMD subjects and 25 age-matched controls. Raw data were used to generate five custom image types differing in polarization content. The foveal location was marked by three graders in each image type for each subject. The difference in variability was compared between the AMD subjects and matched controls. We further determined whether the orientation of Henle fiber layer phase retardation improved localization in 10 subjects with the highest variability in images including only phase retardation amplitude.
   Results. Images that differed in polarization content led to strikingly different visualizations of AMD pathology. The Henle fiber layer remained sufficiently intact to assist in fovea localization in all subjects but with more variability in the AMD group. For both the AMD and matched control group, images containing birefringence amplitude and orientation information reduced the amount of intragrader, intergrader, and interimage variability for estimating foveal location.
   Conclusions. The disruption in Henle fiber birefringence was evident in the eyes with AMD but nevertheless was sufficient to help in foveal localization despite macular pathology. Phase retardation amplitude and axis of orientation can be a useful tool in foveal localization in patients with AMD. (Optom Vis Sci 2012;89:667-677)
C1 [VanNasdale, Dean A.; Elsner, Ann E.; Kohne, Kimberly D.; Peabody, Todd D.; Malinovsky, Victor E.; Haggerty, Bryan P.; Clark, Christopher A.] Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
   [Weber, Anke] Aachen Univ Hosp, Aachen, Germany.
C3 Indiana University System; Indiana University Bloomington; RWTH Aachen
   University; RWTH Aachen University Hospital
RP VanNasdale, DA (通讯作者)，Indiana Univ, Sch Optometry, 800 E Atwater Ave, Bloomington, IN 47405 USA.
EM dvannasd@indiana.edu
FU National Eye Institute, National Institute of Health [K23 EY017886,
   RO1-EY007624, RO1-EB002346, P30-EY019008]; NATIONAL EYE INSTITUTE
   [R01EY007624, P30EY019008, K23EY017886] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
   [R01EB002346] Funding Source: NIH RePORTER
FX This project was supported by grant numbers K23 EY017886 (DAV),
   RO1-EY007624 (AEE), RO1-EB002346 (AEE), and P30-EY019008 (SAB) from the
   National Eye Institute, National Institute of Health.
CR Bagga H, 2005, AM J OPHTHALMOL, V139, P437, DOI 10.1016/j.ajo.2004.10.019
   Bueno JM, 2007, J OPT SOC AM A, V24, P1337, DOI 10.1364/JOSAA.24.001337
   Burns SA, 2003, INVEST OPHTH VIS SCI, V44, P4061, DOI 10.1167/iovs.03-0124
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Davis MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P289
   DREHER AW, 1992, APPL OPTICS, V31, P3730, DOI 10.1364/AO.31.003730
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Elsner AE, 2002, J OPT SOC AM A, V19, P215, DOI 10.1364/JOSAA.19.000215
   Elsner AE, 2007, J OPT SOC AM A, V24, P1468, DOI 10.1364/JOSAA.24.001468
   Elsner AE, 2008, VISION RES, V48, P2578, DOI 10.1016/j.visres.2008.04.031
   Emerson GG, 2007, RETINA-J RET VIT DIS, V27, P724, DOI 10.1097/IAE.0b013e318042b3c8
   Gotzinger E, 2008, INVEST OPHTH VIS SCI, V49, P5366, DOI 10.1167/iovs.08-2081
   Greenfield DS, 2001, OPHTHALMOLOGY, V108, P1065, DOI 10.1016/S0161-6420(01)00569-3
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leydolt C, 2010, ACTA OPHTHALMOL, V88, P594, DOI 10.1111/j.1755-3768.2008.01485.x
   Mellem-Kairala MB, 2005, INVEST OPHTH VIS SCI, V46, P1099, DOI 10.1167/iovs.04-0574
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miura M, 2005, AM J OPHTHALMOL, V140, P1014, DOI 10.1016/j.ajo.2005.06.033
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Miura M, 2007, J OPT SOC AM A, V24, P1431, DOI 10.1364/JOSAA.24.001431
   Miura M, 2009, OPHTHAL SURG LAS IM, V40, P607, DOI 10.3928/15428877-20091030-15
   Miyazawa A, 2009, OPT EXPRESS, V17, P17426, DOI 10.1364/OE.17.017426
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   VanNasdale DA, 2011, VISION RES, V51, P2263, DOI 10.1016/j.visres.2011.08.017
   VanNasdale DA, 2009, J VISION, V9, DOI 10.1167/9.3.21
   Weber A, 2007, EYE, V21, P353, DOI 10.1038/sj.eye.6702203
   Weber A, 2004, OPT EXPRESS, V12, P5178, DOI 10.1364/OPEX.12.005178
   WEINREB RN, 1995, AM J OPHTHALMOL, V119, P627, DOI 10.1016/S0002-9394(14)70221-1
   Weinreb RN, 2002, ARCH OPHTHALMOL-CHIC, V120, P901, DOI 10.1001/archopht.120.7.901
   Yamanari M, 2009, OPT EXPRESS, V17, P12385, DOI 10.1364/OE.17.012385
   Zhou QY, 2002, INVEST OPHTH VIS SCI, V43, P2221
   Zhou QY, 1997, APPL OPTICS, V36, P2273, DOI 10.1364/AO.36.002273
NR 41
TC 8
Z9 8
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD MAY
PY 2012
VL 89
IS 5
BP 667
EP 677
DI 10.1097/OPX.0b013e31824eeb25
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 937JM
UT WOS:000303654800025
PM 22466102
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kuo, IC
   Broman, AT
   Massof, RW
   Park, W
AF Kuo, Irene C.
   Broman, Aimee T.
   Massof, Robert W.
   Park, William
TI The impact of cataract surgery on patients from a low-vision clinic
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; VISUAL FUNCTION;
   SYSTEMS-MODEL; POPULATION; EYE; REHABILITATION; PROGRESSION; IMPAIRMENT;
   WORKFORCE
AB Objective: To evaluate the effects of cataract extraction with intraocular lens implantation (CE-IOL) in low-vision patients.
   Design: Prospective, interventional case series.
   Participants: Twenty low-vision patients (30 eyes) underwent CE-IOL by 1 surgeon at an academic institution.
   Methods: Pre- and post-CE-IOL visual acuities and responses to a 23-page survey (self-reported functioning in general vision, mobility, illumination, and ability to see faces) were compared.
   Results: Sixteen patients had age-related macular degeneration (AMD); 1 patient each had rod-cone dystrophy, oculocutaneous albinism, retinitis pigmentosa, or cerebrovascular accident. The average age was 78 years (range: 53-96 years). Preoperative best-corrected visual acuity (BCVA) ranged from 20/70 to count fingers; postoperative BCVA at 8 weeks was 20/40 to 20/400, with improvement in 25 (83%) eyes of 15 patients, and no change in the rest. The average change in logMAR of BCVA in the 1 eye or in the eye with better preoperative vision in bilateral surgery was an improvement of 0.6 logMAR units (p = 0.0001). Seventeen (85%) patients noted an improvement in visual function and would consent to CE-IOL again. Twelve patients completed the survey pre- and post-CE-IOL at 3 months. More patients could read with a magnifier after surgery. On average, self-reported functioning was improved.
   Conclusions: In this small study, CE-IOL offered subjective and objective benefits to patients from a low vision clinic, many of whom may have been dissuaded from CE-IOL. Most patients had moderately dense cataracts and moderate to advanced AMD, and these features may help form clinical recommendations. Expectations are important to elicit preoperatively. Postoperatively, patients may be more receptive to low-vision services and devices when the prognosis for visual rehabilitation is better.
C1 [Kuo, Irene C.; Broman, Aimee T.; Massof, Robert W.; Park, William] Wilmer Eye Inst, Baltimore, MD 21236 USA.
   [Kuo, Irene C.; Broman, Aimee T.; Massof, Robert W.; Park, William] Dept Ophthalmol, Baltimore, MD USA.
   [Broman, Aimee T.] Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21205 USA.
   [Massof, Robert W.] Johns Hopkins Univ, Sch Med, Lions Vis Res & Rehabil Ctr, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Johns Hopkins University
RP Kuo, IC (通讯作者)，Wilmer Eye Inst, 4924 Campbell Blvd 100, Baltimore, MD 21236 USA.
EM ickuo@jhmi.edu
FU National Eye Institute; Lions Vision Research; Research to Prevent
   Blindness, New York, New York; National Eye Institute Core [P30
   EY001765-29]; NATIONAL EYE INSTITUTE [P30EY001765] Funding Source: NIH
   RePORTER
FX The authors have made the following disclosures: Alcon Research
   Institute (R.W.M.); consulting fee or paid advisory board), National Eye
   Institute (R.W.M.), National Eye Institute (R.W.M.), Lions Vision
   Research (R.W.M.). The remaining authors have no proprietary or
   commercial interest in any materials discussed in this article.;
   Research was supported by an unrestricted grant from Research to Prevent
   Blindness, New York, New York, and National Eye Institute Core (P30
   EY001765-29).
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Erie JC, 2007, J CATARACT REFR SURG, V33, P1273, DOI 10.1016/j.jcrs.2007.03.053
   Etzioni DA, 2003, ANN SURG, V238, P170, DOI 10.1097/01.SLA.0000081085.98792.3d
   Hawkins BS, 2001, OPHTHALMOLOGY, V108, P1900, DOI 10.1016/S0161-6420(01)00755-2
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   KLEIN B, 2009, ARCH OPHTHALMOL-CHIC, V11, P528
   Lee PP, 2007, ARCH OPHTHALMOL-CHIC, V125, P406, DOI 10.1001/archopht.125.3.406
   Lee PP, 2006, ARCH OPHTHALMOL-CHIC, V124, P12, DOI 10.1001/archopht.124.1.12
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P763, DOI 10.1097/OPX.0b013e3181339efd
   MASSOF RW, 1995, OPTOMETRY VISION SCI, V72, P725, DOI 10.1097/00006324-199510000-00005
   Massof RW, 1998, OPTOMETRY VISION SCI, V75, P349, DOI 10.1097/00006324-199805000-00025
   Monestam E, 1997, ACTA OPHTHALMOL SCAN, V75, P569
   Monestam EI, 2008, CLIN OPHTHALMOL, V2, P187
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
NR 25
TC 4
Z9 4
U1 0
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2011
VL 46
IS 5
BP 391
EP U120
DI 10.1016/j.jcjo.2011.07.008
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 839RB
UT WOS:000296385200005
PM 21995980
DA 2022-11-30
ER

PT J
AU Cordeiro, S
   Seyler, S
   Stindl, J
   Milenkovic, VM
   Strauss, O
AF Cordeiro, Soenke
   Seyler, Sebastian
   Stindl, Julia
   Milenkovic, Vladimir M.
   Strauss, Olaf
TI Heat-Sensitive TRPV Channels in Retinal Pigment Epithelial Cells:
   Regulation of VEGF-A Secretion
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; AGE-RELATED MACULOPATHY; CHOROIDAL
   BLOOD-FLOW; MACULAR DEGENERATION; FACTOR-I; TRANSPUPILLARY
   THERMOTHERAPY; IGFBP-3 SECRETION; UP-REGULATION; ION CHANNELS;
   FACTOR-BETA
AB PURPOSE. Choroidal neovascularization in age-related macular degeneration is caused, to a large extent, by increased secretion of vascular endothelial growth factor (VEGF)-A by the retinal pigment epithelium (RPE). The purpose of the study was to identify pathways that lead to increased VEGF secretion by the RPE.
   METHODS. Ca2(+) signaling was studied in ARPE-19 and human RPE cells in primary culture by means of Ca2(+) imaging. Membrane conductance was measured in the whole-cell configuration of the patch-clamp technique. VEGF-A secretion was measured by using ELISA.
   RESULTS. Freshly isolated RPE cells or ARPE-19 cells were shown to express TRPV1, -2, -3, and -4 channels. Increasing the temperature or stimulation by IGF-1 increased the VEGF-A secretion rate in both cell types. These effects were both sensitive to the TRPV channel blocker ruthenium red (20 mu M). The heat-inducible Ca2(+) signals were blocked by the TRPV channel blockers La3(+) and ruthenium red by 68% and 52%, respectively. In contrast, high concentrations of 2-APB (3 mM) increased [Ca2(+)](i), whereas the TRPV1 channel opener capsaicin and the TRPV3 channel opener camphor had no effect. Reduction of TRPV2 expression by siRNA attenuated the heat-evoked Ca2(+) response. In addition, a heat-activated inwardly rectifying current was measured that was completely blocked by ruthenium red. IGF-1 also increased whole-cell current with a corresponding increase in [Ca2(+)](i), which was blocked by the PI3-kinase blocker LY294002.
   CONCLUSIONS. The data strongly suggest that TRPV2 channels expressed by the RPE are involved in the Ca2(+) signaling that mediates both heat-dependent and IGF-1 (via PI3-kinase activation)-induced VEGF secretion. (Invest Ophthalmol Vis Sci.2010;51:6001-6008) DOI:10.1167/iovs.09-4720
C1 [Stindl, Julia; Milenkovic, Vladimir M.; Strauss, Olaf] Univ Hlth Ctr Regensburg, Klin & Poliklin Augenheilkunde, Regensburg, Germany.
   [Cordeiro, Soenke; Seyler, Sebastian; Strauss, Olaf] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Augenheilkunde, Hamburg, Germany.
   [Cordeiro, Soenke] Hannover Med Sch, Inst Neurophysiol, D-30623 Hannover, Germany.
C3 University of Regensburg; University of Hamburg; University Medical
   Center Hamburg-Eppendorf; Hannover Medical School
RP Strauss, O (通讯作者)，Klinikum Univ Regensburg, Klin & Poliklin Augenheilkunde, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM strauss@eye-regensburg.de
RI Strauss, Olaf/AAA-6485-2019; Cordeiro, Soenke/A-1782-2012; Cordeiro,
   Soenke/H-9002-2012
OI Cordeiro, Soenke/0000-0002-1049-8303; Strauss, Olaf/0000-0002-6272-8596
FU Deutsche Forschungsgemeinschaft (DFG) [STR480/8-1, STR480/8-2]
FX Supported by the Deutsche Forschungsgemeinschaft (DFG) Grants STR480/8-1
   and 8-2.
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Bian ZM, 2007, INVEST OPHTH VIS SCI, V48, P2738, DOI 10.1167/iovs.06-1023
   Boels K, 2001, J CELL SCI, V114, P3599
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Flaxel C, 2007, RETINA-J RET VIT DIS, V27, P629, DOI 10.1097/01.iae.0000249561.02567.fd
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   Hattenbach LO, 2005, OPHTHALMIC RES, V37, P341, DOI 10.1159/000088263
   Ibarra MS, 2004, INVEST OPHTH VIS SCI, V45, P3678, DOI 10.1167/iovs.04-0436
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Ishida K, 1998, INVEST OPHTH VIS SCI, V39, P801
   Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   Lee H, 2005, PFLUG ARCH EUR J PHY, V451, P160, DOI 10.1007/s00424-005-1438-y
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morimura Y, 2004, ARCH OPHTHALMOL-CHIC, V122, P1510, DOI 10.1001/archopht.122.10.1510
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Ogata N, 2001, GRAEF ARCH CLIN EXP, V239, P87, DOI 10.1007/s004170000235
   PARVER LM, 1980, AM J OPHTHALMOL, V89, P641, DOI 10.1016/0002-9394(80)90280-9
   Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619
   Rosenthal R, 2005, BIOCHEM BIOPH RES CO, V337, P241, DOI 10.1016/j.bbrc.2005.09.028
   Rosenthal R, 2004, BIOCHEM BIOPH RES CO, V323, P1203, DOI 10.1016/j.bbrc.2004.08.219
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Sherkheli MA, 2009, J PHARM PHARM SCI, V12, P116, DOI 10.18433/J37C7K
   Slomiany MG, 2006, J PHARMACOL EXP THER, V318, P666, DOI 10.1124/jpet.106.104158
   Slomiany MG, 2004, INVEST OPHTH VIS SCI, V45, P2838, DOI 10.1167/iovs.03-0565
   Slomiany MG, 2004, AM J PHYSIOL-CELL PH, V287, pC746, DOI 10.1152/ajpcell.00568.2003
   Smith LEH, 1999, NAT MED, V5, P1390, DOI 10.1038/70963
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strauss O, 2007, EXPERT REV OPHTHALMO, V2, P551, DOI 10.1586/17469899.2.4.551
   Tanihara H, 1997, PROG RETIN EYE RES, V16, P271, DOI 10.1016/S1350-9462(96)00028-6
   Van Buren JJ, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-17
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Vriens J, 2009, MOL PHARMACOL, V75, P1262, DOI 10.1124/mol.109.055624
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   Xiao M, 1999, BRIT J OPHTHALMOL, V83, P728, DOI 10.1136/bjo.83.6.728
NR 44
TC 47
Z9 48
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2010
VL 51
IS 11
BP 6001
EP 6008
DI 10.1167/iovs.09-4720
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672BQ
UT WOS:000283558400076
PM 20539001
DA 2022-11-30
ER

PT J
AU Sofat, R
   Casas, JP
   Kumari, M
   Talmud, PJ
   Ireland, H
   Kivimaki, M
   Marmot, M
   Hughes, AD
   Thom, S
   Ebrahim, S
   Whittaker, JC
   Smeeth, L
   Lawlor, DA
   Humphries, SE
   Hingorani, AD
AF Sofat, Reecha
   Casas, Juan P.
   Kumari, Meena
   Talmud, Philippa J.
   Ireland, Helen
   Kivimaki, Mika
   Marmot, Michael
   Hughes, Alun D.
   Thom, Simon
   Ebrahim, Shah
   Whittaker, John C.
   Smeeth, Liam
   Lawlor, Debbie A.
   Humphries, Steve E.
   Hingorani, Aroon D.
TI Genetic variation in complement factor H and risk of coronary heart
   disease: Eight new studies and a meta-analysis of around 48,000
   individuals
SO ATHEROSCLEROSIS
LA English
DT Article
DE Complement factor H; Coronary heart disease; Genetic epidemiology
ID C-REACTIVE PROTEIN; GENOME-WIDE ASSOCIATION; BLUE-MOUNTAINS-EYE; MACULAR
   DEGENERATION; MYOCARDIAL-INFARCTION; ARTERY-DISEASE; Y402H POLYMORPHISM;
   AGE; VARIANT; ATHEROSCLEROSIS
AB Objectives: To investigate the association of polymorphisms in complement factor H (CFH) and coronary heart disease (CHD) using meta-analysis.
   Background: Age-related macular degeneration (AMD) and CHD may share partially overlapping pathogenesis. A non-synonymous SNP (rs1061170/Y402H) in CFH encoding complement factor H (fH) is robustly associated with increased AMD risk but associations with CHD risk have been inconsistent.
   Methods: We conducted de novo genotyping and genetic association analyses of incident and prevalent CHD in four studies, and in silico analysis of the same association in a further four cohorts. We pooled these data with information from all published studies using random effects meta-analysis, including a total of 48,646 participants of which 9097 were CHD cases. We also evaluated the association of Y402H with known risk factors for CHD by pooling results from new and in silico studies providing relevant data. Results: CFH genotype was not associated with CHD. Compared to the reference TT homozygote group the pooled odds ratio (OR) for individuals homozygous for the C allele was 1.02, 95% CI (0.91, 1.13) and that for heterozygote TC individuals was 1.04 (0.98, 1.10). There was no association of CFH with systolic and diastolic blood pressure, total-, LDL- and HDL-cholesterol, or body mass index. Individuals who were CC compared to TT had higher triglyceride levels: pooled mean difference 0.06 (0.02, 0.10) mmol/L, p = 0.005.
   Conclusions: The AMD-associated CFH genotype is not associated with CHD. With the possible exception of triglycerides, this CFH SNP was not associated with a wide range of other CHD risk factors. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
C1 [Sofat, Reecha; Hingorani, Aroon D.] UCL, Ctr Clin Pharmacol, Div Med, London WC1E 6JF, England.
   [Casas, Juan P.; Kumari, Meena; Kivimaki, Mika; Marmot, Michael; Hingorani, Aroon D.] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England.
   [Casas, Juan P.; Ebrahim, Shah; Smeeth, Liam] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Talmud, Philippa J.; Ireland, Helen] UCL, Ctr Cardiovasc Genet, Div Med, London WC1E 6JF, England.
   [Hughes, Alun D.; Thom, Simon] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Healthcare NHS Trust, Natl Heart & Lung Inst, Int Ctr Circulatory Hlth, London W2 1LA, England.
   [Whittaker, John C.] NFSP, GlaxoSmithKline, Res & Dev, Div Genet, Harlow CM19 5AW, Essex, England.
   [Lawlor, Debbie A.] Univ Bristol, Dept Social Med, MRC Ctr Causal Anal Translat Epidemiol, Bristol BS8 1TH, Avon, England.
C3 University of London; University College London; University of London;
   University College London; University of London; London School of
   Hygiene & Tropical Medicine; University of London; University College
   London; Imperial College London; GlaxoSmithKline; University of Bristol
RP Sofat, R (通讯作者)，UCL, Ctr Clin Pharmacol, Div Med, Rayne Bldg,5 Univ St, London WC1E 6JF, England.
EM r.sofat@ucl.ac.uk
RI Whittaker, John C/B-8609-2012; Hughes, Alun David/N-3781-2013; Ireland,
   Helen A/B-9868-2008; Kivimaki, Mika/B-3607-2012; Marmot, M
   G/Y-3920-2019; Smeeth, Liam/X-5862-2018
OI Whittaker, John C/0000-0002-3529-2379; Hughes, Alun
   David/0000-0001-5432-5271; Ireland, Helen A/0000-0002-7980-548X;
   Kivimaki, Mika/0000-0002-4699-5627; Marmot, M G/0000-0002-2431-6419;
   Kumari, Meena/0000-0001-9716-1035; Lawlor, Debbie A/0000-0002-6793-2262;
   Sofat, Reecha/0000-0002-0242-6115; Smeeth, Liam/0000-0002-9168-6022;
   Talmud, Philippa/0000-0002-5560-1933; Humphries, Stephen
   E/0000-0002-8221-6547; Hingorani, Aroon/0000-0001-8365-0081; Thom,
   Simon/0000-0002-3020-1351
FU MRC [G0601354]; Pfizer; British Heart Foundation (Schillingford)
   [FS/07/011]; British Heart Foundation [FS 05/125, RG/08/008]; Wellcome
   Trust [076113/B/04/Z]; British Heart Foundation Chair in Cardiovascular
   Genetics; UK Medical Research Council [MRC G0600705]; NIHR Biomedical
   Research Centre; European Commission [BMH4-CT96-0272]; Swedish Medical
   Research Council; Swedish heart-lung Foundation; INSERM; Universite de
   la Mediterranee [U626]; Foundation pour la Recherche Medicale (FRM);
   Medical Research Council; Economic and Social Research Council; British
   Heart Foundation Health and Safety Executive; Department of Health;
   National Heart Lung and Blood Institute, US [HL36310]; NIH: National
   Institute on Aging, US [AG13196]; NIH; Agency for Health Care Policy
   Research [HS06516]; John D and Catherine T. MacArthur Foundation
   Research Networks on Successful Midlife Development and Socioeconomic
   Status and Health; National Institute on Aging (NIA) [AG1764406S1];
   Department of Health Policy Research Programme; Coronary Thrombosis
   Trust; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG017644, R01AG013196, R37AG013196] Funding Source: NIH RePORTER;
   MRC [G0902037, G0600705] Funding Source: UKRI; British Heart Foundation
   [RG/07/008/23674] Funding Source: researchfish; Medical Research Council
   [G0902037, G19/35, G0600705, G0601354, G0100222, G8802774] Funding
   Source: researchfish
FX This work was supported by an MRC Biomarkers Award is G0601354, which is
   co-sponsored by Pfizer. Reecha Sofat is supported by a British Heart
   Foundation (Schillingford) Clinical Training Fellowship (FS/07/011).
   Aroon Hingorani holds a British Heart Foundation Senior Fellowship (FS
   05/125). Liam Smeeth holds a Wellcome Trust Senior Research Fellowship.
   Steve Humphries holds a British Heart Foundation Chair in Cardiovascular
   Genetics and both he and Philippa Talmud are supported by the British
   Heart Foundation (RG/08/008). Debbie A. Lawlor works in an MRC Centre
   that receives support from the UK Medical Research Council (MRC
   G0600705). Alun Hughes and Simon Thom receive support from the NIHR
   Biomedical Research Centre Funding Scheme. The HIFMECH study was
   supported by the European Commission (BMH4-CT96-0272), the Swedish
   Medical Research Council, the Swedish heart-lung Foundation, INSERM, and
   Universite de la Mediterranee (INSERM U626), Foundation pour la
   Recherche Medicale (FRM) and Programme Hospitalier de Recherche Clinique
   (PHRC 1996). The Whitehall II study has been supported by grants from
   the Medical Research Council; Economic and Social Research Council;
   British Heart Foundation; Health and Safety Executive; Department of
   Health; National Heart Lung and Blood Institute (HL36310), US, NIH:
   National Institute on Aging (AG13196), US, NIH; Agency for Health Care
   Policy Research (HS06516); and the John D and Catherine T. MacArthur
   Foundation Research Networks on Successful Midlife Development and
   Socioeconomic Status and Health. Samples from the English Longitudinal
   Study of Ageing (ELSA) DNA Repository (EDNAR), received support under a
   grant (AG1764406S1) awarded by the National Institute on Aging (NIA).
   ELSA was developed by a team of researchers based at the National Centre
   for Social Research, University College London and the Institute of
   Fiscal Studies. The data were collected by the National Centre for
   Social Research. The developers and funders of ELSA and the Archive do
   not bear any responsibility for the analyses or interpretations
   presented here. The British Women's Heart and Health Study is funded by
   the Department of Health Policy Research Programme and the British Heart
   Foundation. The views expressed in the publication are those of the
   authors and not necessarily those of any funding bodies. Recruitment for
   the Ealing Diabetes Study was supported by the Coronary Thrombosis
   Trust. The Wellcome Trust Case Control Consortium was funded by the
   Wellcome Trust (076113/B/04/Z).
CR Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2006, ATHEROSCLEROSIS, V188, P213, DOI 10.1016/j.atherosclerosis.2006.04.013
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hakobyan S, 2008, J BIOL CHEM, V283, P30451, DOI 10.1074/jbc.M803648200
   Haskard DO, 2008, CURR OPIN LIPIDOL, V19, P478, DOI 10.1097/MOL.0b013e32830f4a06
   Iltumur K, 2005, APMIS, V113, P167, DOI 10.1111/j.1600-0463.2005.apm1130303.x
   Ireland H, 2005, ATHEROSCLEROSIS, V183, P283, DOI 10.1016/j.atherosclerosis.2005.02.028
   Juhan-Vague I, 2003, J THROMB HAEMOST, V1, P2322, DOI 10.1046/j.1538-7836.2003.00458.x
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lagrand WK, 1997, CIRCULATION, V95, P97, DOI 10.1161/01.CIR.95.1.97
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lawlor DA, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-17
   Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   Marmot M, 2005, INT J EPIDEMIOL, V34, P251, DOI 10.1093/ije/dyh372
   Marmot M., 2003, HLTH WEALTH LIFESTYL
   Meng WH, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-62
   Miller GJ, 1996, THROMB HAEMOSTASIS, V75, P767
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Muscari A, 1998, ACTA CARDIOL, V53, P345
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nicaud V, 2007, J MOL MED-JMM, V85, P771, DOI 10.1007/s00109-007-0185-2
   Oksjoki R, 2003, ARTERIOSCL THROM VAS, V23, P630, DOI 10.1161/01.ATV.0000057808.91263.A4
   Pai JK, 2007, EUR HEART J, V28, P1297, DOI 10.1093/eurheartj/ehm090
   PINCKARD RN, 1980, J CLIN INVEST, V66, P1050, DOI 10.1172/JCI109933
   Pulido JS, 2007, MAYO CLIN PROC, V82, P301, DOI 10.4065/82.3.301
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Sjoberg AP, 2007, J BIOL CHEM, V282, P10894, DOI 10.1074/jbc.M610256200
   Speidl WS, 2005, EUR HEART J, V26, P2294, DOI 10.1093/eurheartj/ehi339
   Stark K, 2007, CLIN SCI, V113, P213, DOI 10.1042/CS20070028
   Stephens JW, 2004, CARDIOVASC DIABETOL, V3, DOI 10.1186/1475-2840-3-2
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   YASUDA M, 1990, CIRCULATION, V81, P156, DOI 10.1161/01.CIR.81.1.156
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
   Zhang HF, 2011, MOL BIOL REP, V38, P2933, DOI 10.1007/s11033-010-9956-x
NR 50
TC 23
Z9 25
U1 0
U2 8
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0021-9150
EI 1879-1484
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD NOV
PY 2010
VL 213
IS 1
BP 184
EP 190
DI 10.1016/j.atherosclerosis.2010.07.021
PG 7
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 669NB
UT WOS:000283356400078
PM 20708732
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Gensler, G
   Rosner, B
AF Seddon, Johanna M.
   Gensler, Gary
   Rosner, Bernard
TI C-Reactive Protein and CFH, ARMS2/HTRA1 Gene Variants Are Independently
   Associated with Risk of Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; BODY-MASS INDEX; ENVIRONMENTAL ASSOCIATIONS;
   VITAMIN-C; POLYMORPHISM; DIETARY; SUSCEPTIBILITY; SMOKING; Y402H; HTRA1
AB Purpose: Genetic variants CFH and ARMS2/HTRA1 gene regions as well as high-sensitivity C-reactive protein (CRP) levels are related to age-related macular degeneration (AMD). We evaluated their independent and combined effects on risk of AMD, as well as their interactions.
   Design: Case-control study.
   Participants: Subjects with AMD (n = 244) or no or minimal maculopathy (n = 209) in the Age Related Eye Disease Ancillary Study.
   Methods: Risk factors, genotypes, and biomarkers were assessed by questionnaire, direct measurement, and analyses of blood specimens. The independent and joint effects of serum CRP and CFH (rs1061170) and ARMS2/HTRA1 (rs10490924) genotypes were assessed using logistic regression analyses, adjusting for age, gender, education, smoking, body mass index, and vitamin/mineral supplementation.
   Main Outcome Measures: We defined AMD as large drusen, geographic atrophy, or neovascular disease.
   Results: Higher CRP levels were associated with a higher risk of AMD, controlling for genotype and demographic and behavioral risk factors, with odds ratio 2.6 for levels of 3.0 mg/L and above versus below 1.0 mg/L (95% confidence interval, 1.01-6.7). Single nucleotide polymorphisms (SNPs) in both genes were also independently associated with risk of AMD, controlling for the level of CRP and other factors. Presence of both highest level of CRP together with risk genotypes for both SNPs, conferred the highest risk of AMD (OR 5.4, 95% CI 1.4-21.1).
   Conclusions: High-sensitivity CRP and polymorphisms in the CFH and ARMS2/HTRA1 genes are independently associated with risk of AMD. Higher CRP level tends to confer a higher risk of AMD within most genotype groups.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2010; 117: 1560-1566 (C) 2010 by the American Academy of Ophthalmology.
C1 [Seddon, Johanna M.] Tufts Univ, Sch Med, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol,Tufts Med Ctr,New England Eye Ctr, Boston, MA 02111 USA.
   [Gensler, Gary] EMMES Corp, Rockville, MD USA.
   [Rosner, Bernard] Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA.
C3 Tufts Medical Center; Tufts University; Emmes Corporation; Harvard
   University; Harvard Medical School
RP Seddon, JM (通讯作者)，Tufts Univ, Sch Med, Ophthalm Epidemiol & Genet Serv, Dept Ophthalmol,Tufts Med Ctr,New England Eye Ctr, 800 Washington St,450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
FU National Institutes of Health (NIH) National Eye Institute
   [R01-EY11309]; Massachusetts Lions Eye Research Fund, Inc, Northboro,
   MA; Genentech, Inc.; New England Eye Center, Tufts Medical Center, Tufts
   University School of Medicine; NATIONAL EYE INSTITUTE [R01EY011309]
   Funding Source: NIH RePORTER
FX Supported by grants from the National Institutes of Health (NIH)
   National Eye Institute R01-EY11309; Massachusetts Lions Eye Research
   Fund, Inc, Northboro, MA; Individual Research Grant from Genentech,
   Inc.; and the Macular Degeneration Research Fund, New England Eye
   Center, Tufts Medical Center, Tufts University School of Medicine.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ridker PM, 2004, CIRCULATION, V109, P1955, DOI 10.1161/01.CIR.0000125690.80303.A8
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2008, ALBERT JAKOBIECS PRI, V1, P413
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 39
TC 54
Z9 55
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2010
VL 117
IS 8
BP 1560
EP 1566
DI 10.1016/j.ophtha.2009.11.020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 634QU
UT WOS:000280598900016
PM 20346514
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yang, DL
   Elner, SG
   Lin, LR
   Reddy, VN
   Petty, HR
   Elner, VM
AF Yang, Dongli
   Elner, Susan G.
   Lin, Li-Ren
   Reddy, Venkat N.
   Petty, Howard R.
   Elner, Victor M.
TI Association of Superoxide Anions with Retinal Pigment Epithelial Cell
   Apoptosis Induced by Mononuclear Phagocytes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SENILE MACULAR DEGENERATION; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   MITOCHONDRIAL-DNA DAMAGE; FOCAL CEREBRAL-ISCHEMIA; OXIDATIVE STRESS;
   ACTIVATED MACROPHAGES; MUTANT MICE; RPE CELLS; HYDROGEN-PEROXIDE; BRUCHS
   MEMBRANE
AB PURPOSE. Oxidative stress of the retinal pigment epithelium by reactive oxygen species and monocytic infiltration have been implicated in age-related macular degeneration. The purpose of this study was to determine the role of superoxide anions (O-2(-)) in mononuclear phagocyte-induced RPE apoptosis.
   METHODS. Mouse RPE cell cultures were established from wildtype and heterozygous superoxide dismutase 2-knockout (Sod2(+/-)) mice. The intracellular reactive oxygen species, O-2(-) and hydrogen peroxide, were measured by using dihydroethidium assay and 5-(and 6)-chloromethyl-2',7'-dichlorodihydrofluorescence diacetate, acetyl ester assay, respectively. RPE apoptosis was evaluated by Hoechst staining and terminal deoxynucleotidyltransferase dUTP nick-end labeling assay. Changes in mitochondrial membrane potential were detected by 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide dye. Activated caspases and caspase-3 were detected in situ by FITC-VAD-fmk staining and caspase-3 substrate, respectively.
   RESULTS. Mononuclear phagocytes and interferon-gamma-activated mononuclear phagocytes induced the production of intracellular RPE O-2(-), a decrease in RPE mitochondrial membrane potential, caspase activation, and apoptosis of mouse RPE cells. All theses changes were significantly enhanced in the Sod2(+/-) RPE cells. Activated mononuclear phagocytes induced more of these oxidative and apoptotic changes in RPE cells than did unstimulated mononuclear phagocytes.
   CONCLUSIONS. The authors have shown that the decreased expression of SOD2 and increased superoxide production correlate with RPE apoptosis induced by unstimulated and activated mononuclear phagocytes. The authors suggest that elevated O-2(-) levels due to genetic abnormalities of SOD2 or immunologic activation of mononuclear phagocytes lead to greater levels of RPE apoptosis. The present study could serve as a useful model to characterize RPE/phagocyte interaction in AMD and other retinal diseases. (Invest Ophthalmol Vis Sci. 2009; 50: 4998-5005) DOI: 10.1167/iovs.09-3620
C1 [Yang, Dongli; Elner, Susan G.; Lin, Li-Ren; Reddy, Venkat N.; Petty, Howard R.; Elner, Victor M.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   [Petty, Howard R.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48105 USA.
   [Elner, Victor M.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan
RP Elner, VM (通讯作者)，Univ Michigan, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM velner@umich.edu
OI Elner, Victor/0000-0001-7708-1898; , Howard/0000-0001-8516-3666
FU National Institutes of Health [EY09441, EY00484, CA74120, EY07003];
   NATIONAL CANCER INSTITUTE [R01CA074120] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY000484, R37EY000484, R01EY009441] Funding
   Source: NIH RePORTER
FX Supported by the National Institutes of Health Grants EY09441 (VME),
   EY00484 (VNR), CA74120 (HRP), and EY07003 (core). VME is a recipient of
   a Senior Scientific Investigator Award from Research to Prevent
   Blindness.
CR Aliprantis AO, 1996, IMMUNOL TODAY, V17, P573, DOI 10.1016/S0167-5699(96)10071-2
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Arantes RME, 2000, NEUROREPORT, V11, P177
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Barak A, 2001, INVEST OPHTH VIS SCI, V42, P247
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Davies AM, 2003, EMBO J, V22, P2537, DOI 10.1093/emboj/cdg254
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DiezRoux G, 1997, DEVELOPMENT, V124, P3633
   Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240
   Duffield JS, 2005, AM J PATHOL, V167, P1207, DOI 10.1016/S0002-9440(10)61209-6
   Duffield JS, 2000, J IMMUNOL, V164, P2110, DOI 10.4049/jimmunol.164.4.2110
   Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675
   Duffield JS, 2001, AM J PATHOL, V159, P1397, DOI 10.1016/S0002-9440(10)62526-6
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Ferrington DA, 2006, EXP EYE RES, V83, P638, DOI 10.1016/j.exer.2006.03.003
   Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8
   Fujimura M, 1999, J NEUROSCI, V19, P3414
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Hirano S, 1998, IMMUNOLOGY, V93, P102
   HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0
   Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Karbowski M, 1999, FREE RADICAL BIO MED, V26, P396, DOI 10.1016/S0891-5849(98)00209-3
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kitamura M, 1998, J IMMUNOL, V160, P5163
   Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   LANG RA, 1993, CELL, V74, P453, DOI 10.1016/0092-8674(93)80047-I
   Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu L, 2000, BIOL REPROD, V62, P1745, DOI 10.1095/biolreprod62.6.1745
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Mallat M, 2005, CURR OPIN NEUROBIOL, V15, P101, DOI 10.1016/j.conb.2005.01.006
   Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8
   Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846
   Meszaros AJ, 2000, J IMMUNOL, V165, P435, DOI 10.4049/jimmunol.165.1.435
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Murakami K, 1998, J NEUROSCI, V18, P205
   Nakayama M, 2000, J EXP MED, V192, P1373, DOI 10.1084/jem.192.9.1373
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   Pardo M, 2006, FREE RADICAL BIO MED, V41, P1795, DOI 10.1016/j.freeradbiomed.2006.08.027
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ramachandran A, 2002, BIOL CHEM, V383, P693, DOI 10.1515/BC.2002.071
   Rao S, 2007, DEVELOPMENT, V134, P4449, DOI 10.1242/dev.012187
   Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   Reddy VN, 2004, EXP EYE RES, V79, P859, DOI 10.1016/j.exer.2004.04.005
   Sakaguchi N, 1998, BIOCHEM PHARMACOL, V55, P1973, DOI 10.1016/S0006-2952(98)00041-0
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503
   Song EW, 2000, CELL IMMUNOL, V204, P19, DOI 10.1006/cimm.2000.1687
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   YANG J, 1997, SCIENCE, V275, P1132
   Yang JH, 2005, INVEST OPHTH VIS SCI, V46, P1039, DOI 10.1167/iovs.04-0325
   Yoshida A, 2003, LAB INVEST, V83, P1117, DOI 10.1097/01.LAB.0000082393.02727.B5
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zhang F, 2008, CELL SIGNAL, V20, P637, DOI 10.1016/j.cellsig.2007.11.013
   Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4
NR 81
TC 16
Z9 16
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2009
VL 50
IS 10
BP 4998
EP 5005
DI 10.1167/iovs.09-3620
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 497XE
UT WOS:000270097200062
PM 19458341
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Fujihara, M
   Bartels, E
   Nielsen, LB
   Handa, JT
AF Fujihara, Masashi
   Bartels, Emil
   Nielsen, Lars B.
   Handa, James T.
TI A human apoB100 transgenic mouse expresses human apoB100 in the RPE and
   develops features of early AMD
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; basal laminar deposit; basal linear
   deposit; apolipoprotein B; lipoproteins; retinal pigmented epithelium
ID RETINAL-PIGMENT EPITHELIUM; TRIGLYCERIDE TRANSFER PROTEIN; AGE-RELATED
   MACULOPATHY; BRUCHS MEMBRANE; APOLIPOPROTEIN-B; MACULAR DEGENERATION;
   DIETARY-FAT; MORPHOMETRIC-ANALYSIS; BASAL DEPOSITS; ANIMAL-MODEL
AB apoB100 lipoprotein particles have been found to accumulate in Bruch membrane prior to the development of age-related macular degeneration (AMD). This work was performed to determine whether mice that overexpress apoB100 in the RPE/choroid and liver develop landmarks of early AMD over time. Mice transgenic for a human genomic fragment encoding the full length human apoB ("apoB100" mice) and litter-mate control mice were given a normal chow or high-fat diet for 12 months. Mice were evaluated for human apoB mRNA expression in the RPE/choroid and liver by RT-qPCR. Phenotypic changes associated with early AMD were evaluated by ultrastructural analysis using transmission electron microscopy. Changes were semi-quantified using linear regression analysis. Both the RPE/choroid and liver of apoB100 mice expressed both human and mouse apoB mRNA. Transmission electron microscopy showed ultrastructural changes consistent with early human AMD including loss of basal infoldings and accumulation of cytoplasmic vacuoles in the RPE, and basal laminar deposits containing long-spacing collagen and heterogeneous debris in Bruch membrane of apoB100 mice. In apoB100 mice given a high-fat diet, basal linear-like deposits were identified in 12-month-old mice. Linear regression analysis showed that the genotype (human apoB transgene) was a stronger influencing factor than high-fat diet in producing AMD-like lesions used in this study. Human apoB100 transgenic mice overexpress apoB in RPE and, with time, develop validated phenotypic changes that are seen in early human AMD. The phenotypic changes were aggravated by feeding a high-fat diet. The apoB100 mouse model could be valuable in determining the role of apoB-containing lipoproteins in triggering the onset of early AMD. (C) 2009 Published by Elsevier Ltd.
C1 [Fujihara, Masashi; Handa, James T.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
   [Bartels, Emil; Nielsen, Lars B.] Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark.
   [Nielsen, Lars B.] Univ Copenhagen, Dept Biomed Sci, Copenhagen, Denmark.
C3 Johns Hopkins University; Johns Hopkins Medicine; Rigshospitalet;
   University of Copenhagen; University of Copenhagen
RP Handa, JT (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, 1550 Orleans St,Room 144, Baltimore, MD 21287 USA.
EM jthanda@jhmi.edu
RI Bartels, Emil/AAY-3268-2020
FU Lincy Foundation [EY14005, EY74005]; Rigshospitalet, Copenhagen; The
   Novo Nordisk Foundation; Boserup's Foundation; Gerda and Aage Haensch
   Foundation; The Danish Diabetes Foundation; The AP Moller Foundation for
   the Advancement of Medical Science; NATIONAL EYE INSTITUTE [R01EY014005,
   R01EY019904] Funding Source: NIH RePORTER
FX EY14005 (JTH), Lincy Foundation (JTH), EY74005 (JTH), RPB unrestricted
   grant (Wilmer), and generous gifts from Ric and Sandy Forsythe, the Kwok
   family, the Merlau family, and Aleda Wright. Institutional grants from
   Rigshospitalet, Copenhagen (LN), The Novo Nordisk Foundation (LN),
   Boserup's Foundation (LN), Gerda and Aage Haensch Foundation (LN), The
   Danish Diabetes Foundation (LN), and The AP Moller Foundation for the
   Advancement of Medical Science (LN).
CR *AG REL EYE DIS ST, 2001, 8 AREDS, V119, P1417
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dashti N, 2006, BRIT J OPHTHALMOL, V90, P1028, DOI 10.1136/bjo.2006.093856
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Dougan SK, 2007, J EXP MED, V204, P533, DOI 10.1084/jem.20062006
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Ershov AV, 2000, J NEUROSCI RES, V60, P328, DOI 10.1002/(SICI)1097-4547(20000501)60:3<328::AID-JNR7>3.0.CO;2-5
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GULCAN HG, 1993, INVEST OPHTH VIS SCI, V34, P3187
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hofker MH, 1998, ATHEROSCLEROSIS, V137, P1, DOI 10.1016/S0021-9150(97)00266-9
   Ida H, 2004, INVEST OPHTH VIS SCI, V45, P2348, DOI 10.1167/iovs.03-1337
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   LI CM, 2005, J LIPID RES
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Mohler PJ, 2007, J BIOL CHEM, V282, P26981, DOI 10.1074/jbc.M700500200
   Nielsen LB, 2002, J BIOL CHEM, V277, P27014, DOI 10.1074/jbc.M203458200
   Nielsen LB, 1998, CIRCULATION, V98, P13, DOI 10.1161/01.CIR.98.1.13
   Nielsen LB, 2002, ARTERIOSCL THROM VAS, V22, P1489, DOI 10.1161/01.ATV.0000030199.06252.26
   Patel S, 2008, INT J BIOCHEM CELL B, V40, P576, DOI 10.1016/j.biocel.2007.11.017
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2004, OPHTHALMOLOGE, V101, P715, DOI 10.1007/s00347-003-0942-8
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Unger RH, 2002, BBA-MOL CELL BIOL L, V1585, P202, DOI 10.1016/S1388-1981(02)00342-6
   Yokoyama M, 2004, J BIOL CHEM, V279, P4204, DOI 10.1074/jbc.M311995200
NR 47
TC 46
Z9 48
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2009
VL 88
IS 6
BP 1115
EP 1123
DI 10.1016/j.exer.2009.01.017
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 449EC
UT WOS:000266312600014
PM 19450445
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zetterberg, M
   Landgren, S
   Andersson, ME
   Palmer, MS
   Gustafson, DR
   Skoog, I
   Minthon, L
   Thelle, DS
   Wallin, A
   Bogdanovic, N
   Andreasen, N
   Blennow, K
   Zetterberg, H
AF Zetterberg, Madeleine
   Landgren, Sara
   Andersson, Malin E.
   Palmer, Mona Seibt
   Gustafson, Deborah R.
   Skoog, Ingmar
   Minthon, Lennart
   Thelle, Dag S.
   Wallin, Anders
   Bogdanovic, Nenad
   Andreasen, Niels
   Blennow, Kaj
   Zetterberg, Henrik
TI Association of complement factor HY402H gene polymorphism with
   Alzheimer's disease
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE age-related macular degreneration (AMD); complement system; dementia;
   genetics; inflammation
ID FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN; MACULAR DEGENERATION;
   ALTERNATIVE PATHWAY; CEREBROSPINAL-FLUID; INFLAMMATORY PROCESSES; DRUSEN
   FORMATION; APOLIPOPROTEIN-E; POTENTIAL ROLE; MESSENGER-RNA
AB Alzheimer's disease (AD) and age-related macular degeneration (AMD) share several epidemiological and biochemical features. The present study aimed to assess the possible influence of the AMD-associated complement factor H (CFH) Y402H (1277T > C) polymorphism on the risk of AD. Caucasian subjects (n=800) meeting the criteria for probable (n = 717) or definite (n = 83) AD and Caucasian non-demented controls (n 1265) were included in this multi-center case-control study, in which genotype and allele frequencies of the CFH 1277T > C polymorphism were determined and related to diagnosis, APOE genotype, Mini-Mental State Examination score (MMSE) and the cerebrospinal fluid (CSF) biomarkers total-tau (T-tau), phospho-tau(181), (P-tau(181)), and beta-amyloid(1-42) (A beta(1-42)). The AMD-associated CFH genotypes (1277CC and 1277TC) were overrepresented in subjects with AD as compared to control individuals (P = 0.029). Positive C carrier status was associated with an odds ratio (OR) for AD of 1.24 (95% confidence interval [CI] 1.02-1.50). When APOE 4 carrier status was included in the regression model, this association was even stronger (OR 1.34, 95% CI: 1.08-1.65, P=0.007). Subgroup analysis showed that the association between CFH C allele positivity and AD was only evident for individuals carrying the APOE epsilon 4 allele. Positive C carrier status was also associated with lower levels of CSF A beta(1-42) selectively in the control group in an APOE epsilon 4-independent manner (P=0.003). In conclusion, the CFH 1277T > C polymorphism seems to influence the risk of AD and there appears to be an interaction between CFH 1277C and APOE epsilon 4 alleles. The CFH 1277C allele may predispose patients for co-morbidity in AD and AMD. (c) 2007 Wiley-Liss, Inc.
C1 [Zetterberg, Madeleine] Gothenburg Univ, Sahlgrenska Acad,Sahlgrenska Univ Hosp Molndal, Sect Ophthalmol,Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, S-43180 Molndal, Sweden.
   [Zetterberg, Madeleine] Gothenburg Univ, Sahlgrenska Acad, Inst Biomed, Dept Med Chem & Cell Biol, Gothenburg, Sweden.
   [Landgren, Sara] Gothenburg Univ, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Pharmacol, Gothenburg, Sweden.
   [Andersson, Malin E.; Gustafson, Deborah R.; Skoog, Ingmar; Wallin, Anders; Blennow, Kaj; Zetterberg, Henrik] Gothenburg Univ, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden.
   [Palmer, Mona Seibt; Blennow, Kaj; Zetterberg, Henrik] Gothenburg Univ, Sahlgrenska Acad, Inst Biomed, Dept Clin Chem & Transfus Med, Gothenburg, Sweden.
   [Minthon, Lennart] Lund Univ, Clin Memory Res Unit, Dept Clin Sci Malmo, Lund, Sweden.
   [Minthon, Lennart] Malmo Univ Hosp, Neuropsychiat Clin, Malmo, Sweden.
   [Thelle, Dag S.] Gothenburg Univ, Sahlgrenska Acad, Dept Community Med & Publ Hlth, Gothenburg, Sweden.
   [Thelle, Dag S.] Univ Oslo, Inst Basic Med Sci, Dept Biostat, Oslo, Norway.
   [Bogdanovic, Nenad] Karolinska Univ Hosp Huddinge, Karolinska Inst, Sect Clin Geriatr, Neurotec Dept, Stockholm, Sweden.
   [Andreasen, Niels] Karolinska Univ Hosp Huddinge, Memory Clin, Dept Geriatr Med, Stockholm, Sweden.
C3 Sahlgrenska University Hospital; University of Gothenburg; University of
   Gothenburg; University of Gothenburg; University of Gothenburg;
   University of Gothenburg; Lund University; Lund University; Skane
   University Hospital; University of Gothenburg; University of Oslo;
   Karolinska Institutet; Karolinska University Hospital; Karolinska
   Institutet; Karolinska University Hospital
RP Zetterberg, M (通讯作者)，Gothenburg Univ, Sahlgrenska Acad,Sahlgrenska Univ Hosp Molndal, Sect Ophthalmol,Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, S-43180 Molndal, Sweden.
EM madeleine.zetterberg@gu.se
RI Thelle, Dag Steinar/ABD-1867-2020
OI Thelle, Dag Steinar/0000-0002-4417-5967
FU Swedish Research Council [K2007-63X-20402-01-4, 14002, 09946]; Swedish
   Council for Working Life and Social Research; Swedish Society for
   Medical Research; Kronprinsessan Margaretas Arbetsnamnd for Svnskadade;
   Sahlgrenska University Hospital; Goteborg Medical Society; Swedish Brain
   Power; Hjalmar Svenssons forskningsfond
FX Grant sponsor: Swedish Research Council; Grant numbers:
   K2007-63X-20402-01-4, 14002, 09946; Grant sponsor: Swedish Council for
   Working Life and Social Research; Grant sponsor: Swedish Society for
   Medical Research; Grant sponsor: Kronprinsessan Margaretas Arbetsnamnd
   for Svnskadade; Grant sponsor: Sahlgrenska University Hospital; Grant
   sponsor: Goteborg Medical Society; Grant sponsor: Swedish Brain Power;
   Grant sponsor: Hjalmar Svenssons forskningsfond, Stiftelsen for Gamla
   Tjanarinnor and Alzheimerfonden.
CR Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   BENGTSSON C, 1973, ACTA MED SCAND, P311
   Bertram L, 2004, HUM MOL GENET, V13, pR135, DOI 10.1093/hmg/ddh077
   Bertram L, 2007, NAT GENET, V39, P17, DOI 10.1038/ng1934
   Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998
   Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1
   Blennow K, 2000, J NEURAL TRANSM, V107, P1065, DOI 10.1007/s007020070052
   Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349
   FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971
   Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Griffin WST, 1998, BRAIN PATHOL, V8, P65
   Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Hulstaert F, 1999, NEUROLOGY, V52, P1555, DOI 10.1212/WNL.52.8.1555
   Hye A, 2006, BRAIN, V129, P3042, DOI 10.1093/brain/awl279
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee JH, 2007, ARCH NEUROL-CHICAGO, V64, P501, DOI 10.1001/archneur.64.4.501
   McGeer EG, 2003, PROG NEURO-PSYCHOPH, V27, P741, DOI 10.1016/S0278-5846(03)00124-6
   McGeer PL, 2007, NEUROBIOL AGING, V28, P639, DOI 10.1016/j.neurobiolaging.2006.03.013
   MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863
   MCGEER PL, 1989, NEUROSCI LETT, V107, P341, DOI 10.1016/0304-3940(89)90843-4
   McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   MOLD C, 1984, J IMMUNOL, V133, P882
   POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2
   Prince JA, 2004, NEUROLOGY, V62, P2116, DOI 10.1212/01.WNL.0000128088.08695.05
   Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301
   Souied EH, 2005, MOL VIS, V11, P1135
   Steen B, 2004, ARCH GERONTOL GERIAT, P413
   Strohmeyer R, 2002, J NEUROIMMUNOL, V131, P135, DOI 10.1016/S0165-5728(02)00272-2
   Strohmeyer R, 2000, MOL BRAIN RES, V81, P7, DOI 10.1016/S0169-328X(00)00149-2
   Vanmechelen E, 2000, NEUROSCI LETT, V285, P49, DOI 10.1016/S0304-3940(00)01036-3
   Watson MD, 1997, AMYLOID, V4, P147, DOI 10.3109/13506129709014379
   Webster S, 1997, NEUROBIOL AGING, V18, P415, DOI 10.1016/S0197-4580(97)00042-0
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zetterberg H, 2003, NEUROSCI LETT, V352, P67, DOI 10.1016/j.neulet.2003.08.011
NR 56
TC 59
Z9 61
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD SEP 5
PY 2008
VL 147B
IS 6
BP 720
EP 726
DI 10.1002/ajmg.b.30668
PG 7
WC Genetics & Heredity; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Psychiatry
GA 346EB
UT WOS:000259050100008
PM 18163432
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   Walsh, AC
   Muldrew, A
   Updike, PG
   Barbour, T
   Sadda, SR
AF Chakravarthy, Usha
   Walsh, Alexander C.
   Muldrew, Alyson
   Updike, Paul G.
   Barbour, Tara
   Sadda, SriniVas R.
TI Quantitative fluorescein angiographic analysis of choroidal neovascular
   membranes: Validation and correlation with visual function
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR DEGENERATION; PEGAPTANIB SODIUM; RADIOTHERAPY
AB PURPOSE. To compare computerized analysis with traditional grading methods in the analysis of fluorescein angiograms from patients with choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) and to examine the clinical relevance of parameters generated by computerized analysis by testing their relationships with clinical measures of vision.
   METHODS. Custom quantitative fluorescein analysis (QFA) software was used to analyze 62 angiograms from patients with CNV for whom distance visual acuity (DVA) data were available. On applying QFA, we obtained three mathematical parameters for each lesion component: pixel area (PA), integrated intensity (II), and positive fluorescence (PF). Quotients (Q) were derived for the latter two parameters by correcting against background (b) or optic nerve (o) fluorescence (IIQ(b), IIQ(o), PFQ(b), and PFQ(o)). The new metrics were compared with traditional grading parameters of classic CNV and lesion area. The relationships of both sets of angiographic data with measures of vision were explored by regression analyses.
   RESULTS. Weighted kappa between QFA and traditional grading for lesion subtype assessment was high (kappa = 0.7). Regression analyses with PA, IIQb, IIQo, PFQb, and PFQo for each lesion descriptor (leakage, classic CNV, occult CNV, total lesion) as independent variables and DVA as the dependent variable showed that in every case PFQb exhibited the most significant relationship with vision (adjusted r(2) = 0.26). Parameter estimates showed that for a change of 30 units on the PFQb for classic CNV, a loss of 20 letters of DVA may be expected. No parameters from traditional grading methods showed statistically significant relationships with DVA.
   CONCLUSIONS. The markers of dynamic change in area and intensity of fluorescence exhibited stronger relationships with visual function than did area measurements alone.
C1 Calif State Univ Los Angeles, Keck Sch Med, Doheny Eye Inst,Adv Macular Diagnost Lab, Doheny Image Reading Ctr,Doheny Retina Inst, Los Angeles, CA 90032 USA.
   Queens Univ, Dept Ophthalmol, Royal Grp Hosp, Belfast, Antrim, North Ireland.
C3 California State University System; California State University Los
   Angeles; Doheny Eye Institute; Queens University Belfast
RP Sadda, SR (通讯作者)，Doheny Retina Inst, DEI 3610,1450 San Pablo St, Los Angeles, CA 90033 USA.
EM sadda@usc.edu
OI Chakravarthy, Usha/0000-0002-2606-3734
FU NEI NIH HHS [EY015914, EY03040] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R21EY015914, P30EY003040] Funding Source: NIH RePORTER
CR [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Berger JW, 2000, INVEST OPHTH VIS SCI, V41, P2286
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2005, RETINA-J RET VIT DIS, V25, P253
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hipwell JH, 1998, PHYSIOL MEAS, V19, P165, DOI 10.1088/0967-3334/19/2/004
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   Jaakkola A, 2001, EUR J OPHTHALMOL, V11, P269, DOI 10.1177/112067210101100310
   Kaiser RS, 2002, RETINA-J RET VIT DIS, V22, P683, DOI 10.1097/00006982-200212000-00001
   Kourlas H, 2006, CLIN THER, V28, P36, DOI 10.1016/j.clinthera.2006.01.009
   Sadda SR, 2004, RETINA-J RET VIT DIS, V24, P888, DOI 10.1097/00006982-200412000-00008
   SAITO J, 1995, EYE, V9, P70, DOI 10.1038/eye.1995.11
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 16
TC 19
Z9 19
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2007
VL 48
IS 1
BP 349
EP 354
DI 10.1167/iovs.06-0493
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 124GC
UT WOS:000243355100046
PM 17197553
DA 2022-11-30
ER

PT J
AU Sharma, S
   Bakal, J
   Sharma, SM
   Covert, D
   Shah, GK
AF Sharma, S
   Bakal, J
   Sharma, SM
   Covert, D
   Shah, GK
TI Drug pricing for a novel treatment for wet macular degeneration: using
   incremental cost-effectiveness ratios to ensure societal value
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; anecortave acetate; cost-effectiveness analysis; macular
   degeneration; medical economics; photodynamic therapy; quality of life;
   utilities; verteporfin
ID QUALITY-OF-LIFE; TIME TRADE-OFF; UTILITY-ASSESSMENT; VISION; DEPRESSION
AB Objective: Health economic models can assist policy-makers in determining the value of novel treatments from the viewpoint of society. In this context, value is defined as the benefit of treatment, given its cost. A new treatment for wet age-related macular degeneration (AMD), juxtascleral administration of anecortave acetate, IS mg for depot suspension (Retaane), is now in a late-phase clinical trial. In a theoretical analysis, we sought to determine the cost at which this treatment might offer economic value to society, using incremental cost-effectiveness ratios (ICERs).
   Methods: A series of I -year cost-utility models was created for the investigational treatment and standard treatment (photodynamic therapy [PDT] with verteporfin [Visudyne]). Value to society was defined in terms of theoretical associated ICERs (in US dollars): $ 100 000 per quality-adjusted life-year (QALY), $50 000/QALY, $20 000/QALY and $0/QALY, the point of economic indifference. Models were created from the societal perspective and included a patient-derived utility assessment involving regression equations to estimate time trade-off preferences, event probabilities derived from a randomized clinical trial comparing the safety and efficacy of anecortave administration and PDT with verteporfin, decision analysis and relevant costing information.
   Results: An ICER of $ 100 000/QALY would be associated with an anecortave cost of $3022/vial, an ICER of $50 000/QALY with an anecortave cost of $2986/vial and an ICER of $20 000/QALY with an anecortave cost of $2964/vial. The point of economic indifference between anecortave administration and standard therapy would occur with an anecortave cost of $2950/vial.
   Interpretation: In theory, an anecortave cost of $2986/vial is associated with an ICER of $50 000/QALY, the threshold by many health technology assessment and reimbursement agencies.
C1 Queens Univ, Cost Effective Ocular Hlth Policy Unit, Kingston, ON, Canada.
   Queens Univ, Dept Ophthalmol & Community Hlth & Epidemiol, Kingston, ON, Canada.
   Alcon Res Ltd, Ft Worth, TX USA.
   Washington Univ, Barnes Retina Inst, St Louis, MO USA.
C3 Queens University - Canada; Queens University - Canada; Novartis; Alcon;
   Washington University (WUSTL)
RP Sharma, S (通讯作者)，Queens Univ, Hop Hotel Dieu, Cost Effective Ocular Hlth Policy Unit, Brock 2-224B,166 Brock St, Kingston, ON K7L 5G2, Canada.
RI Bakal, Jeff/ABE-4051-2021
OI Bakal, Jeffrey/0000-0002-3658-2554
CR Academy of Managed Care Pharmacy, 2000, PRINC SOUND DRUG FOR
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   BLAIR J, 2004, INVEST OPHTHALMOL VI, V45
   Blazer DG, 2003, J GERONTOL A-BIOL, V58, P249
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRAITHWAITE RS, 50 000 QALY INERTIA
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   *CANT COMM, CLEAR VIS SOL CAN VI
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   CHUMNEY ECG, SURVEY ACCEPTABLE VA
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Devlin N, 2004, HEALTH ECON, V13, P437, DOI 10.1002/hec.864
   FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x
   Garis Robert I, 2002, Manag Care, V11, P43
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hirth RA, 2000, MED DECIS MAKING, V20, P332, DOI 10.1177/0272989X0002000310
   Hollands H, 2001, CAN J OPHTHALMOL, V36, P202, DOI 10.1016/S0008-4182(01)80041-7
   KOCHERA A, 2002, 56 PUBL POL I AM ASS, P1
   LAUFER FN, 2004, SOC MED DECIS MAKING, V16, P4
   LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   *ONT MIN HLTH LONG, ONT GUID EC AN PHARM
   *PR NEWSW, ALC PRES MOR RET CLI
   *PRACT MAN INF COR, 2005, MED FEES US 2005
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Saaddine JB, 2003, OPHTHALMOLOGY, V110, P253, DOI 10.1016/S0161-6420(02)01839-0
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Sharma S, 2003, BRIT J OPHTHALMOL, V87, P259, DOI 10.1136/bjo.87.3.259
   Sharma S, 2002, BRIT J OPHTHALMOL, V86, P493, DOI 10.1136/bjo.86.5.493
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Taylor H R, 2000, Trans Am Ophthalmol Soc, V98, P91
   *TREATM AG REL MAC, 1999, ARCH OPHTHALMOL-CHIC, V118, P488
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
NR 37
TC 19
Z9 20
U1 0
U2 2
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 369
EP 377
DI 10.1016/S0008-4182(05)80079-1
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400012
PM 15947806
DA 2022-11-30
ER

PT J
AU Gupta, P
   Fenwick, EK
   Man, REK
   Gan, ATL
   Sabanayagam, C
   Quek, D
   Qian, CX
   Cheung, CMG
   Cheng, CY
   Lamoureux, EL
AF Gupta, Preeti
   Fenwick, Eva K.
   Man, Ryan E. K.
   Gan, Alfred T. L.
   Sabanayagam, Charumathi
   Quek, Debra
   Qian, Chaoxu
   Cheung, Chui Ming Gemmy
   Cheng, Ching-Yu
   Lamoureux, Ecosse L.
TI Different impact of early and late stages irreversible eye diseases on
   vision-specific quality of life domains
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SINGAPORE MALAY EYE; MACULAR DEGENERATION; VISUAL IMPAIRMENT;
   DIABETIC-RETINOPATHY; GLOBAL PREVALENCE; RISK-FACTORS; PSYCHOMETRIC
   PROPERTIES; METHODOLOGY; POPULATION; QUESTIONNAIRE
AB To determine the differential impact of the irreversible eye diseases on vision-related quality of life (VRQoL) in a multi-ethnic Asian population. 2652 participants from the Singapore Epidemiology of Eye Disease Study, with any of the following early and late-stage eye conditions including age-related macular degeneration (AMD, n = 158), diabetic retinopathy (DR, n = 105; non vision threatening [non-VTDR]; VTDR), glaucoma (n = 57) and myopic macular degeneration (MMD, n = 106), or none of the above (controls, 2226 [83.9%]) were included. Rasch-scaled scores of the Emotional well-being Mobility and Reading subscales of the Impact of Vision Impairment (IVI) questionnaire, collectively referred to as "VRQoL" were assessed. Multivariable linear regression analyses and pairwise comparisons adjusting for age, gender, ethnicity, socio-economic status, BMI, smoking, alcohol use, presence of systemic diseases and presenting VI were performed to assess and compare the impact of the presence and severity of each eye condition on the three IVI domains. Multivariable adjusted pairwise comparisons of VRQoL between early stages of the four eye diseases showed no significant differences (all P > 0.05). For late stage diseases, individuals with VTDR had significantly larger decrements in Emotional well-being compared to glaucoma (beta - 0.81; 95% CI - 1.47 to - 0.16) and MMD (beta - 1.17; 95% CI - 2.16 to - 0.18); and Reading decrements compared to glaucoma (beta - 0.66; 95% CI - 1.22 to - 0.11). When compared to late glaucoma, individuals with late AMD (beta - 0.76; 95% CI - 1.50 to - 0.01) had significantly larger IVI Mobility subscale decrements. VTDR and late AMD, appear to have the greatest impact on VRQoL, compared to late glaucoma and MMD, suggesting a differential impact of late-stage eye disease categorization on VRQoL.
C1 [Gupta, Preeti; Fenwick, Eva K.; Man, Ryan E. K.; Gan, Alfred T. L.; Sabanayagam, Charumathi; Qian, Chaoxu; Cheung, Chui Ming Gemmy; Cheng, Ching-Yu; Lamoureux, Ecosse L.] Singapore Eye Res Inst SERI, 20 Coll Rd,Discovery Tower Level 6, Singapore 169856, Singapore.
   [Gupta, Preeti; Fenwick, Eva K.; Man, Ryan E. K.; Gan, Alfred T. L.; Sabanayagam, Charumathi; Quek, Debra; Qian, Chaoxu; Cheung, Chui Ming Gemmy; Cheng, Ching-Yu; Lamoureux, Ecosse L.] Populat Hlth, Singapore Natl Eye Ctr, 20 Coll Rd,Discovery Tower Level 6, Singapore 169856, Singapore.
   [Gupta, Preeti; Man, Ryan E. K.; Sabanayagam, Charumathi; Cheung, Chui Ming Gemmy; Cheng, Ching-Yu; Lamoureux, Ecosse L.] Duke NUS Med Sch, Singapore, Singapore.
   [Sabanayagam, Charumathi; Cheung, Chui Ming Gemmy; Cheng, Ching-Yu; Lamoureux, Ecosse L.] Natl Univ Singapore, Singapore, Singapore.
C3 Singapore National Eye Center; National University of Singapore;
   National University of Singapore
RP Lamoureux, EL (通讯作者)，Singapore Eye Res Inst SERI, 20 Coll Rd,Discovery Tower Level 6, Singapore 169856, Singapore.; Lamoureux, EL (通讯作者)，Populat Hlth, Singapore Natl Eye Ctr, 20 Coll Rd,Discovery Tower Level 6, Singapore 169856, Singapore.; Lamoureux, EL (通讯作者)，Duke NUS Med Sch, Singapore, Singapore.; Lamoureux, EL (通讯作者)，Natl Univ Singapore, Singapore, Singapore.
EM ecosse.lamoureux@seri.com.sg
RI Cheng, Ching-Yu/Y-2229-2019
OI Cheng, Ching-Yu/0000-0003-0655-885X; Man, Ryan/0000-0001-5028-605X;
   Sabanayagam, Charumathi/0000-0002-4042-4719
FU Singapore Ministry of Health's National Medical Research Council (NMRC)
   [NMRC/STaR/0003/2008]; Biomedical Research Council (BMRC), Singapore
   [08/1/35/19/550]
FX Singapore Ministry of Health's National Medical Research Council (NMRC)
   under its Talent Development Scheme NMRC/STaR/0003/2008 and Biomedical
   Research Council (BMRC), Singapore 08/1/35/19/550. The Grant body had no
   roles in design, conduct or data analysis of the study, nor in
   manuscript preparation and approval. The funding sources had no role in
   design and conduct of the study; collection, management, analysis, and
   interpretation of the data; preparation, review, or approval of the
   manuscript; or in the decision to submit the manuscript for publication.
CR Ang M, 2018, BRIT J OPHTHALMOL, V102, P878, DOI 10.1136/bjophthalmol-2017-310745
   [Anonymous], 2007, Community Eye Health, V20, P37
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Broman AT, 2002, INVEST OPHTH VIS SCI, V43, P3393
   Chan EW, 2013, INVEST OPHTH VIS SCI, V54, P1169, DOI 10.1167/iovs.12-10258
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Fenwick EK, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.3
   Fenwick EK, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100801
   Fenwick EK, 2019, BRIT J OPHTHALMOL, V103, P1314, DOI 10.1136/bjophthalmol-2018-313082
   Fenwick EK, 2017, INVEST OPHTH VIS SCI, V58, P6379, DOI 10.1167/iovs.16-20950
   Fenwick EK, 2017, JAMA OPHTHALMOL, V135, P469, DOI 10.1001/jamaophthalmol.2017.0266
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P686, DOI 10.1136/bjophthalmol-2016-308701
   Fenwick EK, 2017, BRIT J OPHTHALMOL, V101, P591, DOI 10.1136/bjophthalmol-2016-308541
   Fenwick EK, 2016, JAMA OPHTHALMOL, V134, P1087, DOI 10.1001/jamaophthalmol.2016.2394
   Fenwick EK, 2016, QUAL LIFE RES, V25, P871, DOI 10.1007/s11136-015-1141-1
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Garamendi E, 2006, VISION RES, V46, P1375, DOI 10.1016/j.visres.2005.07.007
   Gupta P, 2018, OPHTHALMOLOGY, V125, P1401, DOI 10.1016/j.ophtha.2018.02.011
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jonas JB, 2017, LANCET, V390, P2183, DOI 10.1016/S0140-6736(17)31469-1
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Khadka J, 2016, OPTOMETRY VISION SCI, V93, P1502, DOI 10.1097/OPX.0000000000000958
   Khadka J, 2015, J GLAUCOMA, V24, P12, DOI 10.1097/IJG.0b013e318287ac11
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P789, DOI 10.1097/OPX.0b013e3181334b83
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Lamoureux EL, 2010, OPHTHALMOLOGY, V117, P757, DOI 10.1016/j.ophtha.2009.09.035
   Lamoureux EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P84, DOI 10.1001/archopht.122.1.84
   Lansingh VC, 2007, OPHTHALMOLOGY, V114, P1670, DOI 10.1016/j.ophtha.2006.12.013
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Linacre J. M., 2017, USERS GUIDE WINSTEPS
   Majithia S, 2021, INT J EPIDEMIOL, V50, P41, DOI 10.1093/ije/dyaa238
   Mallinson T, 2007, OPTOMETRY VISION SCI, V84, P675, DOI 10.1097/OPX.0b013e3181339f44
   Man REK, 2020, OPHTHALMOLOGY, V127, P1145, DOI 10.1016/j.ophtha.2020.01.056
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Nirmalan PK, 2005, INVEST OPHTH VIS SCI, V46, P2308, DOI 10.1167/iovs.04-0830
   Nordmann Jean-Philippe, 2003, Health Qual Life Outcomes, V1, P75, DOI 10.1186/1477-7525-1-75
   Nutheti R, 2007, OPHTHALMOLOGY, V114, P1552, DOI 10.1016/j.ophtha.2006.11.012
   Ohno-Matsui K, 2017, RETINA-J RET VIT DIS, V37, P1043, DOI 10.1097/IAE.0000000000001348
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Patel PJ, 2020, CLIN OPHTHALMOL, V14, P15, DOI 10.2147/OPTH.S226425
   Rees G, 2013, INVEST OPHTH VIS SCI, V54, P7431, DOI 10.1167/iovs.13-12153
   Rosman M, 2012, CLIN EXP OPHTHALMOL, V40, P557, DOI 10.1111/j.1442-9071.2012.02763.x
   Sabanayagam C, 2017, CLIN EXP OPHTHALMOL, V45, P779, DOI 10.1111/ceo.12974
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   Wong MYZ, 2017, AM J OPHTHALMOL, V183, P99, DOI 10.1016/j.ajo.2017.09.002
   Wong TY, 2019, AM J OPHTHALMOL, V206, P48, DOI 10.1016/j.ajo.2019.05.006
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wong YL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.14
   Wong YL, 2018, INVEST OPHTH VIS SCI, V59, P4603, DOI 10.1167/iovs.18-24032
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zhang XM, 2019, EYE CONTACT LENS, V45, P11, DOI 10.1097/ICL.0000000000000544
   Zou MJ, 2020, BRIT J OPHTHALMOL, V104, P1748, DOI 10.1136/bjophthalmol-2019-315298
NR 65
TC 0
Z9 0
U1 2
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 19
PY 2022
VL 12
IS 1
AR 8465
DI 10.1038/s41598-022-12425-9
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 1J6ZE
UT WOS:000798064600090
PM 35589884
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Barth, T
   Helbig, H
AF Barth, Teresa
   Helbig, Horst
TI Ischemic Choroidal Diseases
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE choroid; angiography; choroidal infarction; vascular occlusion; ischemia
ID VASCULAR OCCLUSION; MALIGNANT HYPERTENSION; INDOCYANINE GREEN; FUNDUS
   LESIONS; CHOROIDOPATHY; INJECTION; ANGIOGRAPHY; ATROPHY
AB Introduction Ischemic choroidal diseases are an underdiagnosed entity. The clinical pattern varies according to the size and the localisation of the affected vascular structure.
   Clinical Presentation In eyes with occlusion of the long posterior ciliary arteries, characteristic triangular patches of choroidal ischemia (Amalric sign) are seen, which in the course of time merge into well-defined areas of atrophy of the retinal pigment epithelium. Above the non-perfused choroidal areas, hyperpigmented, grouped lines appear (Siegrist streaks). Circumscribed ischemia of smaller choroidal arterioles and capillary vessels appears as multifocal, yellowish lesions in the posterior fundus (Elschnig spots). Vortex vein occlusion becomes manifest as exudative haemorrhagic choroidal swelling in the periphery.
   Causes of Choroidal Ischemia Apart from arterial hypertension as a major risk factor, some immunological disorders such as giant cell arteritis and systemic lupus erythematosus and haematological pathologies also affect choroidal perfusion. Furthermore, choroidal ischemia occurs due to local inflammation, as found in eyes with acute multifocal posterior placoid pigment epitheliopathy (APMPPE). Rarely, choroidal infarction is of iatrogenic origin or drug-induced. Recent advances in imaging, such as the introduction of enhanced depth imaging optical coherence tomography (EDI-OCT) and OCT angiography (OCT-A), have improved the visualisation of the choroidal vasculature and complement the classical angiographic procedures. In patients with age-related macular degeneration (AMD) and diabetes, some changes in choroidal blood flow and vascular structure have also been noted. While in AMD the choroidal pathologies correlate with the disease progression and the functional prognosis, the pathophysiological relationship between diabetic choroidopathy and retinopathy is currently unclear.
   Management and Conclusion With regard to the limited therapeutic options for choroidal ischemia, optimisation of the cardiovascular risk profile and the management of accompanying ocular and systemic diseases are essential.
C1 [Barth, Teresa; Helbig, Horst] Univ Klinikum Rogensburg, Klin & Poliklin Augenheilkunde, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
C3 University of Regensburg
RP Barth, T (通讯作者)，Univ Klinikum Rogensburg, Klin & Poliklin Augenheilkunde, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.
EM teresa.barth@ukr.de
CR AlTalbishi A, 2015, EUR J OPHTHALMOL, V25, pE84, DOI 10.5301/ejo.5000586
   Amalric P, 1971, Trans Ophthalmol Soc U K, V91, P305
   AMALRIC P, 1991, Eye (London), V5, P519
   Berufsverband der Augenarzte Deutschlands, 2001, GES BER AUG DEUTSCHL
   Berufsverband der Augenarzte Deutschlands, 2017, OPHTHALMOLOGE, V114, P120, DOI [10.1007/s00347-016-0435-1, DOI 10.1007/S00347-016-0435-1]
   Biousse V, 2018, OPHTHALMOLOGY, V125, P1597, DOI 10.1016/j.ophtha.2018.03.054
   Bird AC, 2006, RETINA-J RET VIT DIS, P971, DOI DOI 10.1016/B978-0-323-02598-0.50060-4
   Carle MV, 2014, JAMA OPHTHALMOL, V132, P637, DOI 10.1001/jamaophthalmol.2014.498
   COGAN DG, 1975, ARCH OPHTHALMOL-CHIC, V93, P1
   Cohen S, 2006, ARCH OPHTHALMOL-CHIC, V124, P922, DOI 10.1001/archopht.124.6.922
   Dattilo Michael, 2018, Ann Eye Sci, V3, DOI 10.21037/aes.2018.05.04
   Ebrahimiadib N, 2021, SURV OPHTHALMOL, V66, P653, DOI 10.1016/j.survophthal.2020.12.006
   Elschnig A., 1904, WIEN MED WOCHENSCHR, V54, P446
   Farazdaghi MK, 2019, J OPHTHAL VIS RES, V14, P78, DOI 10.4103/jovr.jovr_125_18
   GOLDBAUM MH, 1976, ARCH OPHTHALMOL-CHIC, V94, P1025
   Hande P, 2017, INDIAN J OPHTHALMOL, V65, P1033, DOI 10.4103/ijo.IJO_42_17
   Hay-Smith G, 2006, EYE, V20, P982, DOI 10.1038/sj.eye.6702100
   HAYREH SS, 1986, OPHTHALMOLOGY, V93, P1383
   Heiferman MJ, 2017, RETINA-J RET VIT DIS, V37, P2084, DOI 10.1097/IAE.0000000000001487
   Hirata A, 2008, JPN J OPHTHALMOL, V52, P510, DOI 10.1007/s10384-008-0596-9
   Hsu CT, 2001, RETINA-J RET VIT DIS, V21, P348, DOI 10.1097/00006982-200108000-00009
   JAMPOL LM, 1975, AM J OPHTHALMOL, V79, P452, DOI 10.1016/0002-9394(75)90622-4
   Kang HM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224210
   KISHI S, 1985, ARCH OPHTHALMOL-CHIC, V103, P1189, DOI 10.1001/archopht.1985.01050080101029
   Kotoula M, 2018, INT J OPHTHALMOL-CHI, V11, P528, DOI 10.18240/ijo.2018.03.28
   Lim Soojin, 2018, Am J Ophthalmol Case Rep, V11, P149, DOI 10.1016/j.ajoc.2018.06.007
   Marker DA, 2011, OPHTHALMOLOGE, V108, P64, DOI 10.1007/s00347-010-2218-4
   Mantel I, 2014, GRAEF ARCH CLIN EXP, V252, P753, DOI 10.1007/s00417-013-2543-9
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Melancia D, 2016, GRAEF ARCH CLIN EXP, V254, P1453, DOI 10.1007/s00417-016-3360-8
   Moshfeghi DM, 2002, AM J OPHTHALMOL, V134, P132, DOI 10.1016/S0002-9394(02)01426-5
   Nemiroff Julia, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS113, DOI 10.1097/ICB.0000000000000442
   Nguyen QD, 2000, LUPUS, V9, P288, DOI 10.1191/096120300680199024
   Park D, 1995, OPHTHALMOLOGY, V102, P1877, DOI 10.1016/S0161-6420(95)30780-4
   Park SH, 2008, CLIN OPHTHALMOL, V2, P679
   Peyman GA, 2000, OPHTHALMOLOGY, V107, P29, DOI 10.1016/S0161-6420(99)00012-3
   Reddy Shantan, 2011, Retin Cases Brief Rep, V5, P91, DOI 10.1097/ICB.0b013e3181e2506f
   Rezkallah Amina, 2019, Am J Ophthalmol Case Rep, V13, P131, DOI 10.1016/j.ajoc.2019.01.001
   Sakai Daiki, 2020, Am J Ophthalmol Case Rep, V18, P100710, DOI 10.1016/j.ajoc.2020.100710
   Siegrist A, 1899, Z AUGENHEILKUNDE, V2, pS36
   Song Y, 2013, GRAEF ARCH CLIN EXP, V251, P2647, DOI 10.1007/s00417-013-2462-9
   THOMAS EL, 1986, OPHTHALMOLOGY, V93, P405
   TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132
   Tsukikawa M, 2020, CLIN OPTOM, V12, P67, DOI 10.2147/OPTO.S183492
   Valmaggia C, 1999, RETINA-J RET VIT DIS, V19, P131, DOI 10.1097/00006982-199902000-00008
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P518, DOI 10.1007/s00417-003-0650-8
NR 47
TC 2
Z9 2
U1 1
U2 7
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD SEP
PY 2021
VL 238
IS 9
BP 962
EP 969
DI 10.1055/a-1402-7592
EA AUG 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YR5SL
UT WOS:000692781900003
PM 34416787
DA 2022-11-30
ER

PT J
AU Kuzma, E
   Littlejohns, TJ
   Khawaja, AP
   Llewellyn, DJ
   Ukoumunne, OC
   Thiem, U
AF Kuzma, Elzbieta
   Littlejohns, Thomas J.
   Khawaja, Anthony P.
   Llewellyn, David J.
   Ukoumunne, Obioha C.
   Thiem, Ulrich
TI Visual Impairment, Eye Diseases, and Dementia Risk: A Systematic Review
   and Meta-Analysis
SO JOURNAL OF ALZHEIMERS DISEASE
LA English
DT Review
DE Alzheimer's disease; dementia; eye diseases; prospective studies; vision
   disorders
ID OPEN-ANGLE GLAUCOMA; ALZHEIMERS-DISEASE; MACULAR DEGENERATION; VISION
   IMPAIRMENT; ASSOCIATIONS; PREVENTION
AB Background: Visual impairment and eye diseases have been associated with dementia, though with mixed findings and often in cross-sectional studies.
   Objective: To identify prospective studies investigating associations between visual impairment or common eye diseases and risk of all-cause dementia or key dementia subtypes.
   Methods: We searched Medline, PsycINFO, and Embase from inception to January 2020. We also conducted backward and forward citation searches of included studies and set up alerts to identify studies published after the search date. Random-effects meta-analysis was used to combine adjusted estimates across studies.
   Results: Thirty studies met our eligibility criteria. For visual impairment, pooled estimates indicated an increased risk of all-cause dementia (37,705 participants, 3,415 cases, risk ratio [RR] = 1.38, 95% confidence interval [CI]: 1.19-1.59, I-2 = 28.6%). Pooled estimates also suggested an increased dementia risk associated with cataract (6,659 participants, 1,312 cases, hazard ratio [HR] = 1.17, 95% CI: 1.00-1.38, I-2 = 0.0%) and diabetic retinopathy (43,658 participants, 7,060 cases, HR =1.34, 95% CI: 1.11-1.61, I-2 = 63.9%), respectively. There was no evidence of an association between glaucoma (175,357 participants, 44,144 cases, HR = 0.97, 95% CI: 0.90-1.04, I-2 = 51.5%) or age-related macular degeneration (7,800,692 participants, > 2,559 cases, HR = 1.15, 95% CI: 0.88-1.50, I-2 = 91.0%) and risk of dementia, respectively.
   Conclusion: As visual impairment, cataract, and diabetic retinopathy are associated with an increased likelihood of developing dementia, early diagnosis may help identify those at risk of dementia. Given most causes of visual impairment are treatable or preventable, the potential for dementia prevention warrants further investigation.
C1 [Kuzma, Elzbieta; Thiem, Ulrich] Univ Hamburg, Albertinen Haus Ctr Geriatr & Gerontol, Hamburg, Germany.
   [Littlejohns, Thomas J.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England.
   [Khawaja, Anthony P.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Khawaja, Anthony P.] UCL Inst Ophthalmol, London, England.
   [Llewellyn, David J.] Univ Exeter, Coll Med & Hlth, Exeter, Devon, England.
   [Llewellyn, David J.] Alan Turing Inst, London, England.
   [Ukoumunne, Obioha C.] Univ Exeter, Med Sch, NIHR ARC South West Peninsula PenARC, Exeter, Devon, England.
   [Thiem, Ulrich] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany.
C3 University of Hamburg; University of Oxford; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London; University of Exeter;
   University of Exeter; University of Hamburg; University Medical Center
   Hamburg-Eppendorf
RP Kuzma, E (通讯作者)，Albertinen Haus Ctr Geriatr & Gerontol, Sellhopsweg 18-22, D-22459 Hamburg, Germany.
EM elzbieta.kuzma@immanuelalbertinen.de
RI Littlejohns, Thomas/GMY-4044-2022
OI Llewellyn, David/0000-0002-2441-4246
FU Nicolaus and Margrit Langbehn Foundation; Moorfields Eye Charity Career
   Development Fellowship; UK Research and Innovation Future Leaders
   Fellowship; National Institute for Health Research (NIHR) Applied
   Research Collaboration (ARC) South West Peninsula; Alzheimer's Research
   UK; National Health and Medical Research Council (NHMRC), JP Moulton
   Foundation; National Institute on Aging/National Institutes of Health
   [RF1AG055654]; Alan Turing Institute/Engineering and Physical Sciences
   Research Council [EP/N510129/1]; Federal Ministry of Education and
   Research (BMBF); Federal Joint Committee (G-BA) Innovation Fund
FX We thank all authors of original studies who supported our work by
   providing additional data and/or clarifications. This study was
   supported by the Nicolaus and Margrit Langbehn Foundation (to E.K. and
   U.T.), a Moorfields Eye Charity Career Development Fellowship and a UK
   Research and Innovation Future Leaders Fellowship (to A.P.K.), the
   National Institute for Health Research (NIHR) Applied Research
   Collaboration (ARC) South West Peninsula (to D.J.L. and O.C.U.),
   Alzheimer's Research UK, National Health and Medical Research Council
   (NHMRC), JP Moulton Foundation, National Institute on Aging/National
   Institutes of Health (RF1AG055654), Alan Turing Institute/Engineering
   and Physical Sciences Research Council (EP/N510129/1; to D.J.L.), the
   Federal Ministry of Education and Research (BMBF) and the Federal Joint
   Committee (G-BA) Innovation Fund (to U.T). The views expressed are those
   of the author(s) and not necessarily those of the National Health
   Service, the National Institute for Health Research, or the Department
   of Health and Social Care or other funders.
CR Albers MW, 2015, ALZHEIMERS DEMENT, V11, P70, DOI 10.1016/j.jalz.2014.04.514
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Brenowitz WD, 2019, J GERONTOL A-BIOL, V74, P890, DOI 10.1093/gerona/gly264
   Burton MJ, 2021, LANCET GLOB HEALTH, V9, pE489, DOI 10.1016/S2214-109X(20)30488-5
   Carriere I, 2013, J AFFECT DISORDERS, V151, P164, DOI 10.1016/j.jad.2013.05.071
   Chen YY, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022987
   Cheung CY, 2019, CURR OPIN NEUROL, V32, P82, DOI 10.1097/WCO.0000000000000645
   Choi S, 2020, AM J OPHTHALMOL, V210, P41, DOI 10.1016/j.ajo.2019.11.001
   Chou R, 2009, 0905135EF1 AG HEALTH
   Davies-Kershaw HR, 2018, J AM GERIATR SOC, V66, P1823, DOI 10.1111/jgs.15456
   Ekstrom C, 2014, ACTA OPHTHALMOL, V92, P355, DOI 10.1111/aos.12184
   Exalto LG, 2014, J ALZHEIMERS DIS, V42, pS109, DOI 10.3233/JAD-132570
   Fischer ME, 2016, J AM GERIATR SOC, V64, P1981, DOI 10.1111/jgs.14308
   Griffiths TD, 2020, NEURON, V108, P401, DOI 10.1016/j.neuron.2020.08.003
   Hamalainen A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55696-5
   Harris RJ, 2008, STATA J, V8, P3, DOI 10.1177/1536867X0800800102
   Helmer C, 2013, ANN NEUROL, V74, P171, DOI 10.1002/ana.23926
   Heringa SM, 2013, J CEREBR BLOOD F MET, V33, P983, DOI 10.1038/jcbfm.2013.58
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hwang PH, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12054
   Jefferis JM, 2011, BRIT J OPHTHALMOL, V95, P17, DOI 10.1136/bjo.2009.165902
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Keenan TDL, 2015, BRIT J OPHTHALMOL, V99, P524, DOI 10.1136/bjophthalmol-2014-305863
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Kuo FH, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072426
   Kuzma E, 2018, ALZHEIMERS DEMENT, V14, P1416, DOI 10.1016/j.jalz.2018.06.3061
   Lai SW, 2014, EUR J EPIDEMIOL, V29, P57, DOI [10.1007/s10654-014-9878-3, 10.1007/s10654-014-9903-6]
   Lee ATC, 2020, J GERONTOL A-BIOL, V75, P2162, DOI 10.1093/gerona/glaa036
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Lin IC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108938
   Livingston G, 2020, LANCET, V396, P413, DOI 10.1016/S0140-6736(20)30367-6
   Livingston G, 2017, LANCET, V390, P2673, DOI 10.1016/S0140-6736(17)31363-6
   Mancino R, 2018, CURR NEUROPHARMACOL, V16, P971, DOI 10.2174/1570159X16666171206144045
   Maruta M, 2020, PSYCHOGERIATRICS, V20, P262, DOI 10.1111/psyg.12494
   Moon JY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29557-6
   Nael V, 2019, EUR J EPIDEMIOL, V34, P141, DOI 10.1007/s10654-018-00478-y
   Nam GE, 2021, AM J OPHTHALMOL, V221, P181, DOI 10.1016/j.ajo.2020.07.050
   NHS Centre for Reviews and Dissemination,, 2009, SYSTEMATIC REV CRDS
   Ong SR, 2018, EYE, V32, P1296, DOI 10.1038/s41433-018-0081-8
   Ou Y, 2012, OPHTHAL EPIDEMIOL, V19, P285, DOI 10.3109/09286586.2011.649228
   Paik JS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66002-z
   Pellegrini M, 2020, CLIN EXP OPHTHALMOL, V48, P593, DOI 10.1111/ceo.13754
   Rodill LG, 2018, ALZ DIS ASSOC DIS, V32, P125, DOI 10.1097/WAD.0000000000000230
   Rogers MAM, 2010, AM J EPIDEMIOL, V171, P728, DOI 10.1093/aje/kwp453
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   Schrijvers EMC, 2012, NEUROLOGY, V79, P365, DOI 10.1212/WNL.0b013e318260cd7e
   Shang XW, 2021, OPHTHALMOLOGY, V128, P1135, DOI 10.1016/j.ophtha.2020.12.029
   Sperling R, 2014, NEURON, V84, P608, DOI 10.1016/j.neuron.2014.10.038
   Su CW, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002833
   Thomas B H, 2004, Worldviews Evid Based Nurs, V1, P176, DOI 10.1111/j.1524-475X.2004.04006.x
   Tran EM, 2020, JAMA OPHTHALMOL, V138, P624, DOI 10.1001/jamaophthalmol.2020.0959
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   van der Aa HPA, 2015, INVEST OPHTH VIS SCI, V56, P849, DOI 10.1167/iovs.14-15848
   World Health Organisation, 2013, UN EYE HLTH GLOB ACT
   Xiao ZX, 2020, J ALZHEIMERS DIS, V76, P529, DOI 10.3233/JAD-200295
   Xu XH, 2019, ACTA OPHTHALMOL, V97, P665, DOI 10.1111/aos.14114
   Xue M, 2019, AGEING RES REV, V55, DOI 10.1016/j.arr.2019.100944
NR 59
TC 5
Z9 5
U1 6
U2 6
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1387-2877
EI 1875-8908
J9 J ALZHEIMERS DIS
JI J. Alzheimers Dis.
PY 2021
VL 83
IS 3
BP 1073
EP 1087
DI 10.3233/JAD-210250
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Neurosciences & Neurology
GA WB2LV
UT WOS:000703410000012
PM 34397414
OA Green Published, Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Bascuas, T
   Kropp, M
   Harmening, N
   Asrih, M
   Izsvak, Z
   Thumann, G
AF Bascuas, Thais
   Kropp, Martina
   Harmening, Nina
   Asrih, Mohammed
   Izsvak, Zsuzsanna
   Thumann, Gabriele
TI Induction and Analysis of Oxidative Stress in Sleeping Beauty
   Transposon-Transfected Human Retinal Pigment Epithelial Cells
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
ID MACULAR DEGENERATION; HYDROGEN-PEROXIDE; GENE-EXPRESSION; H2O2; DAMAGE;
   IRIS
AB Oxidative stress plays a critical role in several degenerative diseases, including age-related macular degeneration (AMD), a pathology that affects similar to 30 million patients worldwide. It leads to a decrease in retinal pigment epithelium (RPE)synthesized neuroprotective factors, e.g., pigment epithelium-derived factor (PEDF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), followed by the loss of RPE cells, and eventually photoreceptor and retinal ganglion cell (RGC) death. We hypothesize that the reconstitution of the neuroprotective and neurogenic retinal environment by the subretinal transplantation of transfected RPE cells overexpressing PEDF and GM-CSF has the potential to prevent retinal degeneration by mitigating the effects of oxidative stress, inhibiting inflammation, and supporting cell survival. Using the Sleeping Beauty transposon system (SB100X) human RPE cells have been transfected with the PEDF and GM-CSF genes and shown stable gene integration, long-term gene expression, and protein secretion using qPCR, western blot, ELISA, and immunofluorescence. To confirm the functionality and the potency of the PEDF and GM-CSF secreted by the transfected RPE cells, we have developed an in vitro assay to quantify the reduction of H2O2-induced oxidative stress on RPE cells in culture. Cell protection was evaluated by analyzing cell morphology, density, intracellular level of glutathione, UCP2 gene expression, and cell viability. Both, transfected RPE cells overexpressing PEDF and/or GM-CSF and cells non-transfected but pretreated with PEDF and/or GM-CSF (commercially available or purified from transfected cells) showed significant antioxidant cell protection compared to non-treated controls. The present H2O2-model is a simple and effective approach to evaluate the antioxidant effect of factors that may be effective to treat AMD or similar neurodegenerative diseases.
C1 [Bascuas, Thais; Kropp, Martina; Harmening, Nina; Asrih, Mohammed; Thumann, Gabriele] Univ Geneva, Expt Ophthalmol, Geneva, Switzerland.
   [Bascuas, Thais; Kropp, Martina; Harmening, Nina; Thumann, Gabriele] Univ Hosp Geneva, Dept Ophthalmol, Geneva, Switzerland.
   [Izsvak, Zsuzsanna] Max Delbruck Ctr Mol Med, Geneva, Switzerland.
C3 University of Geneva; University of Geneva
RP Bascuas, T (通讯作者)，Univ Geneva, Expt Ophthalmol, Geneva, Switzerland.; Bascuas, T (通讯作者)，Univ Hosp Geneva, Dept Ophthalmol, Geneva, Switzerland.
EM thais.bascuascastillo@unige.ch
FU Swiss National Sciences Foundation; European Commission; European
   Research Council, ERC [294742]
FX The authors would like to thank Gregg Sealy and Alain Conti for
   excellent technical assistance and Prof. Zsuzsanna Izsvak from the
   Max-Delbruck Center in Berlin for kindly providing the pSB100X and
   pT2-CAGGS-Venus plasmids. This work was supported by the Swiss National
   Sciences Foundation and the European Commission in the context of the
   Seventh Framework Programme. Z.I was funded by European Research
   Council, ERC Advanced [ERC-2011-ADG 294742].
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alhasani RH, 2018, FOOD CHEM TOXICOL, V112, P76, DOI 10.1016/j.fct.2017.12.037
   Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Bascuas T, 2019, HUM GENE THER, V30, pA112
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Campochiaro PA, 2017, HUM GENE THER, V28, P99, DOI 10.1089/hum.2016.117
   Cao SJ, 2013, MOL VIS, V19, P718
   Chen XD, 2017, INT J OPHTHALMOL-CHI, V10, P507, DOI 10.18240/ijo.2017.04.02
   Donadelli M, 2014, CELL MOL LIFE SCI, V71, P1171, DOI 10.1007/s00018-013-1407-0
   Electron Microscopy Sciences, Neubauer Haemocytometry
   Farnoodian M, 2018, AM J PHYSIOL-CELL PH, V314, pC456, DOI 10.1152/ajpcell.00259.2017
   Garcia-Garcia L, 2017, MOL THER-NUCL ACIDS, V9, P1, DOI 10.1016/j.omtn.2017.08.001
   Geiger RC, 2005, INVEST OPHTH VIS SCI, V46, P3435, DOI 10.1167/iovs.04-1487
   GIBLIN FJ, 1984, EXP EYE RES, V38, P87, DOI 10.1016/0014-4835(84)90142-8
   Gong XM, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040100
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9
   Hao Y., 2019, NUTRIENTS, V11, P1
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   Johnen S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/863845
   Johnen S, 2012, INVEST OPHTH VIS SCI, V53, P4787, DOI 10.1167/iovs.12-9951
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma ST, 2014, AM J HYPERTENS, V27, P345, DOI 10.1093/ajh/hpt225
   Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Polato F, 2016, ADV EXP MED BIOL, V854, P699, DOI 10.1007/978-3-319-17121-0_93
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Schallenberg M, 2012, GRAEF ARCH CLIN EXP, V250, P699, DOI 10.1007/s00417-012-1932-9
   Schallenberg M, 2009, EXP EYE RES, V89, P665, DOI 10.1016/j.exer.2009.06.008
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Thumann G, 2017, MOL THER-NUCL ACIDS, V6, P302, DOI 10.1016/j.omtn.2017.02.002
   Tu G, 2016, MOL MED REP, V13, P2320, DOI 10.3892/mmr.2016.4797
   Ung L, 2017, CLIN SCI, V131, P2865, DOI 10.1042/CS20171246
   Wang X, 2019, MOL MED REP, V19, P59, DOI 10.3892/mmr.2018.9645
   Weigel AL, 2002, FREE RADICAL BIO MED, V33, P1419, DOI 10.1016/S0891-5849(02)01082-1
   Zareba M, 2006, FREE RADICAL BIO MED, V40, P87, DOI 10.1016/j.freeradbiomed.2005.08.015
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
NR 40
TC 1
Z9 1
U1 0
U2 2
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD DEC
PY 2020
IS 166
AR e61957
DI 10.3791/61957
PG 25
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA RV9TE
UT WOS:000646166900042
PM 33369607
DA 2022-11-30
ER

PT J
AU Kabedi, NN
   Kayembe, DL
   Mwanza, JC
AF Kabedi, Nelly N.
   Kayembe, David L.
   Mwanza, Jean-Claude
TI Profile of retinal diseases in adult patients attending two major eye
   clinics in Kinshasa, the Democratic Republic of Congo
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE retinal disorders; Kinshasa; Democratic Republic of Congo; sub-Saharan
   Africa; pattern
ID MACULAR DEGENERATION; PATTERN; PREVALENCE; IBADAN
AB AIM: To determine the frequency and types of retinal diseases and the extend of the related visual loss in adult patients attending two public eye clinics of Kinshasa, Democratic Republic of Congo.
   METHODS: Review of medical records of patients with retinal diseases seen in the major eye clinics in Kinshasa, the University Hospital of Kinshasa (UHK) and Saint Joseph Hospital (SJH), from January 2012 to December 2014. Demographics and diagnoses were retrieved and analyzed. Outcome measures were frequency and prevalence of retinal diseases, blindness and low vision.
   RESULTS: A total of 40 965 patients aged 40y or older were examined during this period in both clinics. Of these, 1208 had retinal disease, giving a 3-year and an annual prevalence of 3% and 1%, respectively. Mean age was 61.7 +/- 10.7y, and 55.8% of the patients were males. Arterial hypertension (68.1%) and diabetes (43.3%) were the most common systemic comorbidities. Hypertensive retinopathy (41.8%), diabetic retinopathy (37.9%), age-related macular degeneration (AMD; 14.6%), and chorioretinitis and retinal vein occlusion (7.3% each) were the most common retinal diseases, with 3-year prevalence rates of 1.3%, 1.0%, 0.43%, and 0.21% respectively. Bilateral low vision and blindness were present in 26.8% and 8.4% of the patients at presentation. Major causes of low vision and blindness were diabetic retinopathy (14.8%), AMD (4.9%), retinal detachment (2.8%), and retinal vein occlusion (2.5%). The prevalence was significantly higher among males than females, and at the UHK than SJH.
   CONCLUSION: Retinal diseases are common among Congolese adult patients attending eye clinics in Kinshasa. They cause a significant proportion of low vision and blindness.
C1 [Kabedi, Nelly N.; Kayembe, David L.; Mwanza, Jean-Claude] Univ Kinshasa, Dept Ophthalmol, Sch Med, Kinshasa, DEM REP CONGO.
   [Mwanza, Jean-Claude] Univ N Carolina, Dept Ophthalmol, Sch Med, Chapel Hill, NC 27599 USA.
C3 Universite de Kinshasa; University of North Carolina; University of
   North Carolina Chapel Hill; University of North Carolina School of
   Medicine
RP Mwanza, JC (通讯作者)，Univ N Carolina, Dept Ophthalmol, 130 Mason Farm Rd,5151 Bioinformat Bldg,CB 7040, Chapel Hill, NC 27599 USA.
EM jcmwanza@med.unc.edu
RI Mwanza, Jean-Claude/L-4235-2017
CR ABIOSE A, 1979, ANN OPHTHALMOL, V11, P1067
   Ajayi IA, 2016, PAK J OPHTHALMOL, V32, P152
   Bastawrous A, 2017, JAMA OPHTHALMOL, V135, P631, DOI 10.1001/jamaophthalmol.2017.1109
   Bastawrous A, 2014, TROP MED INT HEALTH, V19, P600, DOI 10.1111/tmi.12276
   Bayauli MP, 2018, J EPIDEMIOLOGICAL RE, V4, P33
   Bogunjoko TJ, 2018, INT J COMMUNITY MED, V6, P8
   BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32
   Chan WM, 2009, RETINA TODAY, P30
   Cho NH, 2018, DIABETES RES CLIN PR, V138, P271, DOI 10.1016/j.diabres.2018.02.023
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   Eze BI, 2010, MIDDLE EAST AFR J OP, V17, P246, DOI 10.4103/0974-9233.65491
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Hatef E, 2008, RETINA-J RET VIT DIS, V28, P755, DOI 10.1097/IAE.0b013e3181613463
   Kabedi NN, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4103871
   Kabedi NN, 2014, CARDIOVASC J AFR, V25, P228, DOI 10.5830/CVJA-2014-045
   Katchunga PB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219377
   Khan A., 2011, PAK J OPHTHALMOL, V27, P155
   Kim Joon-Bom, 2017, Curr Ophthalmol Rep, V5, P176, DOI 10.1007/s40135-017-0137-0
   Li JH, 2017, IEEE IMAGE PROC, P1, DOI 10.1109/ICIP.2017.8296231
   Malerbi FK, 2015, EINSTEIN-SAO PAULO, V13, P530, DOI 10.1590/S1679-45082015AO3538
   Mathenge W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001393
   Nwosu S N, 2000, Ophthalmic Epidemiol, V7, P41, DOI 10.1076/0928-6586(200003)7:1;1-2;FT041
   Oluleye ST, 2016, INT J GEN MED, V9, P285, DOI 10.2147/IJGM.S107241
   Oluleye TS, 2013, CLIN OPHTHALMOL, V7, P1373, DOI 10.2147/OPTH.S47511
   Oluleye TS, 2006, EYE, V20, P1461, DOI 10.1038/sj.eye.6702343
   Oluleye TS, 2012, CLIN OPHTHALMOL, V6, P561, DOI 10.2147/OPTH.S27470
   Omotoso A B, 2016, Clin Hypertens, V22, P19, DOI 10.1186/s40885-016-0053-x
   Onakpoya OH, 2008, J NATL MED ASSOC, V100, P1286, DOI 10.1016/S0027-9684(15)31506-6
   Phanzu BK, 2015, GLOBAL J MED RES, V14
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Teshome T, 2004, ETHIOPIAN MED J, V42, P185
   Uhumwangho O M, 2015, J West Afr Coll Surg, V5, P1
NR 35
TC 1
Z9 1
U1 0
U2 0
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD OCT 18
PY 2020
VL 13
IS 10
BP 1652
EP 1659
DI 10.18240/ijo.2020.10.21
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NX2EZ
UT WOS:000575529300021
PM 33078118
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Do, JY
   Kim, J
   Kim, MJ
   Lee, JY
   Park, SY
   Yanai, R
   Lee, IK
   Park, S
   Park, DH
AF Do, Ji Yeon
   Kim, Juhee
   Kim, Mi-Jin
   Lee, Jung Yi
   Park, So-Young
   Yanai, Ryoji
   Lee, In-Kyu
   Park, Sungmi
   Park, Dong Ho
TI Fursultiamine Alleviates Choroidal Neovascularization by Suppressing
   Inflammation and Metabolic Reprogramming
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE choroidal neovascularization; inflammation; metabolic reprogramming;
   mitochondria; fursultiamine
ID RETINAL-PIGMENT EPITHELIUM; BIOAVAILABILITY ASSESSMENT; GENE-EXPRESSION;
   RPE; THIAMINE; BENFOTIAMINE; HIF-1-ALPHA; IL-8; DEGENERATION;
   MACROPHAGES
AB PURPOSE. To assess the therapeutic effects of fursultiamine on choroidal neovascularization (CNV) through its modulation of inflammation and metabolic reprogramming in the retinal pigment epithelium (RPE).
   METHODS. The anti-angiogenic effects of fursultiamine were assessed by measuring vascular leakage and CNV lesion size in the laser-induced CNV mouse model. Inflammatory responses were evaluated by quantitative polymerase chain reaction, western blot, and ELISA in both CNV eye tissues and in vitro cell cultures using ARPE-19 cells or primary human RPE (hRPE) cells under lipopolysaccharide (LPS) treatment or hypoxia. Mitochondrial respiration was assessed by measuring oxygen consumption in ARPE-19 cells treated with LPS with or without fursultiamine, and lactate production was measured in ARPE-19 cells subjected to hypoxia with or without fursultiamine.
   RESULTS. In laser-induced CNV, fursultiamine significantly decreased vascular leakage and lesion size, as well as the numbers of both choroidal and retinal inflammatory cytokines, including IL-1 beta, IL-6, IL-8, and TNF-alpha. In LPS-treated ARPE-19 cells, fursultiamine decreased proinflammatory cytokine secretion and nuclear factor kappa B phosphorylation. Furthermore, fursultiamine suppressed LPS-induced upregulation of IL-6, IL-8, and monocyte chemoattractant protein-1 in a dose-dependent and time-dependent manner in primary hRPE cells. Interestingly, fursultiamine significantly enhanced mitochondrial respiration in the LPS-treated ARPE-19 cells. Additionally, fursultiamine attenuated hypoxia-induced aberrations, including lactate production and inhibitory phosphorylation of pyruvate dehydrogenase. Furthermore, fursultiamine attenuated hypoxia-induced VEGF secretion and mitochondrial fission in primary hRPE cells that were replicated in ARPE-19 cells.
   CONCLUSIONS. Our findings show that fursultiamine is a viable putative therapeutic for neovascular age-related macular degeneration by modulating the inflammatory response and metabolic reprogramming by enhancing mitochondrial respiration in the RPE.
C1 [Do, Ji Yeon; Kim, Juhee; Kim, Mi-Jin; Lee, Jung Yi; Lee, In-Kyu; Park, Sungmi; Park, Dong Ho] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Leading Edge Res Ctr Drug Discovery & Dev Diabet, 807 Hoguk Ro, Daegu 41404, South Korea.
   [Lee, Jung Yi] JD Biosci Inc, R&D Ctr, Gwangju, South Korea.
   [Park, So-Young] Kyungpook Natl Univ, Coll Pharm, Daegu, South Korea.
   [Park, So-Young] Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Daegu, South Korea.
   [Yanai, Ryoji] Yamaguchi Univ, Dept Ophthalmol, Grad Sch Med, Ube, Yamaguchi, Japan.
   [Lee, In-Kyu] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea.
   [Park, Dong Ho] Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Ophthalmol, 130 Dongdeok Ro, Daegu 41944, South Korea.
C3 Kyungpook National University; Kyungpook National University Hospital;
   Kyungpook National University; Kyungpook National University; Yamaguchi
   University; Kyungpook National University; Kyungpook National University
   Hospital; Kyungpook National University; Kyungpook National University
   Hospital
RP Park, S (通讯作者)，Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Leading Edge Res Ctr Drug Discovery & Dev Diabet, 807 Hoguk Ro, Daegu 41404, South Korea.; Park, DH (通讯作者)，Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Ophthalmol, 130 Dongdeok Ro, Daegu 41944, South Korea.
EM smpark93@gmail.com; dongho_park@knu.ac.kr
RI Kim, Mi Jin/GXH-9639-2022; Lee, In-Kyu/AAR-6374-2021
FU Basic Science Research Program of the National Research Foundation of
   Korea - Ministry of Science and ICT, Republic of Korea
   [2019R1A2C1084371]; Korea Health Technology R&D Project of the Korea
   Health Industry Development Institute - Ministry of Health & Welfare,
   Republic of Korea [HI16C1501]
FX DHP is financially supported by the Basic Science Research Program of
   the National Research Foundation of Korea, funded by the Ministry of
   Science and ICT, Republic of Korea (2019R1A2C1084371), and by the Korea
   Health Technology R&D Project of the Korea Health Industry Development
   Institute, funded by the Ministry of Health & Welfare, Republic of Korea
   (HI16C1501).
CR Adijanto J, 2014, EXP EYE RES, V126, P77, DOI 10.1016/j.exer.2014.01.015
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Andre H, 2015, INVEST OPHTH VIS SCI, V56, P6591, DOI 10.1167/iovs.15-16476
   Bian ZM, 2001, INVEST OPHTH VIS SCI, V42, P1660
   BITSCH R, 1991, ANN NUTR METAB, V35, P292, DOI 10.1159/000177659
   Bozic I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118372
   Bretz CA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20520-z
   Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016
   Cui HS, 2018, INT OPHTHALMOL, V38, P2053, DOI 10.1007/s10792-017-0697-x
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   ELNER VM, 1990, AM J PATHOL, V136, P745
   Gangolf M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013616
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hasegawa E, 2017, P NATL ACAD SCI USA, V114, pE7545, DOI 10.1073/pnas.1620898114
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Iacovelli J, 2016, INVEST OPHTH VIS SCI, V57, P1038, DOI 10.1167/iovs.15-17758
   Imtiyaz HZ, 2010, CURR TOP MICROBIOL, V345, P105, DOI 10.1007/82_2010_74
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   KITAMORI N, 1993, J NUTR SCI VITAMINOL, V39, P465, DOI 10.3177/jnsv.39.465
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Lonsdale D, 2006, EVID-BASED COMPL ALT, V3, P49, DOI 10.1093/ecam/nek009
   MICELI MV, 1990, INVEST OPHTH VIS SCI, V31, P277
   Min BK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00944
   Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Pacal L, 2014, WORLD J DIABETES, V5, P288, DOI 10.4239/wjd.v5.i3.288
   Palsson-McDermott EM, 2015, CELL METAB, V21, P65, DOI [10.1016/j.cmet.2014.12.005, 10.1016/j.cmet.2015.01.017]
   Park WS, 2016, CLIN THER, V38, P2277, DOI 10.1016/j.clinthera.2016.08.009
   Pearce EL, 2013, IMMUNITY, V38, P633, DOI 10.1016/j.immuni.2013.04.005
   Rodriguez-Prados JC, 2010, J IMMUNOL, V185, P605, DOI 10.4049/jimmunol.0901698
   Satish S, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9248640
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Van den Bossche J, 2017, TRENDS IMMUNOL, V38, P395, DOI 10.1016/j.it.2017.03.001
   Wang XC, 1999, INVEST OPHTH VIS SCI, V40, P477
   Xie FF, 2014, J CLIN PHARMACOL, V54, P688, DOI 10.1002/jcph.261
   Yadav UCS, 2010, FREE RADICAL BIO MED, V48, P1423, DOI 10.1016/j.freeradbiomed.2010.02.031
   Yanai R, 2014, P NATL ACAD SCI USA, V111, P9603, DOI 10.1073/pnas.1401191111
   Zera K, 2016, GENE, V595, P212, DOI 10.1016/j.gene.2016.10.013
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
NR 45
TC 5
Z9 5
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2020
VL 61
IS 12
AR 24
DI 10.1167/iovs.61.12.24
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OR2IJ
UT WOS:000589298400017
PM 33107903
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Singh, SR
   Fung, AT
   Fraser-Bell, S
   Lupidi, M
   Mohan, S
   Gabrielle, PH
   Zur, D
   Iglicki, M
   Lopez-Corell, PM
   Gallego-Pinazo, R
   Farinha, C
   Lima, LH
   Mansour, AM
   Casella, AM
   Wu, LT
   Silva, R
   Uwaydat, SH
   Govindahari, V
   Arevalo, JF
   Chhablani, J
AF Singh, Sumit Randhir
   Fung, Adrian T.
   Fraser-Bell, Samantha
   Lupidi, Marco
   Mohan, Sashwanthi
   Gabrielle, Pierre-Henry
   Zur, Dinah
   Iglicki, Matias
   Lopez-Corell, Paula
   Gallego-Pinazo, Roberto
   Farinha, Claudia
   Lima, Luiz H.
   Mansour, Ahmad M.
   Casella, Antonio Marcello
   Wu, Lihteh
   Silva, Rufino
   Uwaydat, Sami H.
   Govindahari, Vishal
   Arevalo, Jose Fernando
   Chhablani, Jay
TI One-year outcomes of anti-vascular endothelial growth factor therapy in
   peripapillary choroidal neovascularisation
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE peripapillary choroidal neovascularisation (CNV); age-related macular
   degeneration (AMD); inflammatory cnv; angioid streaks; optic nerve head
   drusen; idiopathic intracranial hypertension (IIH); anti-vascular
   endothelial growth factors (VEGF)
ID INTRAVITREAL ZIV-AFLIBERCEPT; PHOTODYNAMIC THERAPY; SUBRETINAL
   NEOVASCULARIZATION; MACULAR DEGENERATION; BEVACIZUMAB; MEMBRANES;
   VERTEPORFIN
AB Purpose
   To report the visual and anatomical outcomes in eyes with peripapillary choroidal neovascularisation (CNV) through 12 months.
   Methods
   This was a multicentre, retrospective, interventional case series which included treatment-naive cases of peripapillary choroidal neovascular membrane (CNVM) with a minimum follow-up of 12 months. Multimodal imaging which comprised optical coherence tomography (OCT), fluorescein angiography and/or indocyanine green angiography was performed at baseline and follow-up visits. OCT parameters included central macular thickness (CMT), subfoveal choroidal thickness (SFCT) and retinal and choroidal thickness at site of CNV. Patients were treated with anti-vascular endothelial growth factors (VEGF) on pro re nata protocol, photodynamic therapy, laser photocoagulation or a combination. Main outcome measures were change in best corrected visual acuity (BCVA) and OCT parameters.
   Results
   A total of 77 eyes (74 patients; mean age: 61.9 +/- 21.8 years) with a mean disease duration of 9.2 +/- 14.1 months were included. BCVA improved significantly from 0.55 +/- 0.54 logMAR (20/70) at baseline to 0.29 +/- 0.39 logMAR (20/40) at 12 months (p<0.001) with a mean of 4.9 +/- 2.9 anti-VEGF injections. CMT, SFCT and retinal thickness at site of CNVM reduced significantly (p<0.001, <0.001 and 0.02, respectively) through 12 months. The most common disease aetiologies were neovascular age-related macular degeneration, and idiopathic, inflammatory and angioid streaks. Age (p=0.04) and baseline BCVA (p<0.001) were significant predictors of change in BCVA at 12 months.
   Conclusion
   Peripapillary CNVM, though uncommon, is associated with diverse aetiologies. Anti-VEGF agents lead to significant visual acuity and anatomical improvement in these eyes over long term irrespective of the aetiology.
C1 [Singh, Sumit Randhir; Govindahari, Vishal; Chhablani, Jay] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad, Andhra Pradesh, India.
   [Singh, Sumit Randhir] LV Prasad Eye Inst, Retina & Uveitis Dept, GMR Varalakshmi Campus, Visakhapatnam, Andhra Pradesh, India.
   [Fung, Adrian T.] Westmead Hosp, Dept Ophthalmol, Sydney, NSW, Australia.
   [Fung, Adrian T.] Univ Sydney, Sydney Eye Hosp, Save Sight Inst, Sydney, NSW, Australia.
   [Fung, Adrian T.] Macquarie Univ, Fac Med & Hlth Sci, Sydney, NSW, Australia.
   [Fraser-Bell, Samantha] Univ Sydney, Dept Ophthalmol, Sydney, NSW, Australia.
   [Lupidi, Marco] Univ Perugia, Dept Ophthalmol, Perugia, Italy.
   [Mohan, Sashwanthi] LV Prasad Eye Inst, Acad Eye Care Educ, Hyderabad, Telangana, India.
   [Gabrielle, Pierre-Henry] Ctr Hosp Univ Dijon, Ophthalmol, Dijon, France.
   [Gabrielle, Pierre-Henry] INRA Ctr Dijon, Ctr Sci Gout & Alimentat, Eye & Nutr Res Grp, Dijon, France.
   [Zur, Dinah] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
   [Iglicki, Matias] Univ Buenos Aires, Private Retina Serv, Buenos Aires, DF, Argentina.
   [Lopez-Corell, Paula] Univ & Polytech Hosp La Fe, Dept Ophthalmol, Valencia, Spain.
   [Gallego-Pinazo, Roberto] Hosp Univ & Politecn La Fe, Valencia, Spain.
   [Farinha, Claudia; Silva, Rufino] Coimbra Univ Hosp Ctr, Ophthalmol Dept, Coimbra, Portugal.
   [Farinha, Claudia; Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Lima, Luiz H.] Univ Fed Sao Paulo, Ophthalmol, Sao Paulo, Brazil.
   [Mansour, Ahmad M.] Amer Univ Beirut, Dept Ophthalmol, Beirut, Lebanon.
   [Casella, Antonio Marcello] Univ Estadual Londrina, Ophthalmol, Londrina, Parana, Brazil.
   [Wu, Lihteh] Inst Cirugia Ocular, Vitreoretinal Dept, San Jose, Costa Rica.
   [Uwaydat, Sami H.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
   [Govindahari, Vishal] LV Prasad Eye Inst, Retina & Uveitis Serv, MTC Campus, Bhubaneswar, Odisha, India.
   [Arevalo, Jose Fernando] Johns Hopkins Univ, Sch Med, Wilmer Inst, Retina Div, Baltimore, MD 21205 USA.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; University of
   Sydney; University of Sydney; Macquarie University; University of
   Sydney; University of Perugia; L. V. Prasad Eye Institute; CHU Dijon
   Bourgogne; INRAE; Institut Agro; AgroSup Dijon; Centre National de la
   Recherche Scientifique (CNRS); Universite de Bourgogne; Tel Aviv
   University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical
   Center; University of Buenos Aires; Hospital Universitari i Politecnic
   La Fe; Universidade de Coimbra; Centro Hospitalar e Universitario de
   Coimbra (CHUC); Universidade de Coimbra; Universidade Federal de Sao
   Paulo (UNIFESP); American University of Beirut; Universidade Estadual de
   Londrina; University of Arkansas System; University of Arkansas Medical
   Sciences; L. V. Prasad Eye Institute; Johns Hopkins University
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad, Andhra Pradesh, India.
EM jay.chhablani@gmail.com
RI Zur, Dinah/AAX-7620-2020; Silva, Rufino M/J-2817-2012; GABRIELLE,
   Pierre-Henry/Y-4971-2018; Fraser-Bell, Samantha/ABE-8574-2020; Farinha,
   Claudia/R-1392-2017
OI Silva, Rufino M/0000-0001-8676-0833; GABRIELLE,
   Pierre-Henry/0000-0002-9688-4845; Fraser-Bell,
   Samantha/0000-0001-5646-9359; Arevalo Suarez, Fernando
   Antonio/0000-0002-4114-5949; Mohan, Sashwanthi/0000-0002-2239-5440;
   Farinha, Claudia/0000-0003-4596-0913; M Lopez-Corell,
   Paula/0000-0003-3354-367X; Chhablani, Jay/0000-0003-1772-3558; Lupidi,
   Marco/0000-0002-6817-2488; Iglicki, Matias/0000-0003-2257-9108
CR Adrean SD, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/4802690
   Al-Gharbi N, 2015, MIDDLE EAST AFR J OP, V22, P245, DOI 10.4103/0974-9233.150639
   Ament CS, 2006, ARCH OPHTHALMOL-CHIC, V124, P957, DOI 10.1001/archopht.124.7.957
   [Anonymous], 1987, Arch Ophthalmol, V105, P1499
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Braimah IZ, 2017, BRIT J OPHTHALMOL, V101, P1201, DOI 10.1136/bjophthalmol-2016-309994
   Browning DJ, 2005, OPHTHALMOLOGY, V112, P1054, DOI 10.1016/j.ophtha.2004.11.062
   D'Souza P, 2018, RETINA-J RET VIT DIS, V38, P1307, DOI 10.1097/IAE.0000000000001710
   Farah ME, 2004, BRIT J OPHTHALMOL, V88, P1055, DOI 10.1136/bjo.2003.035808
   Figueroa MS, 2008, BRIT J OPHTHALMOL, V92, P1244, DOI 10.1136/bjo.2008.144196
   Giacomelli G, 2017, OPHTHALMOLOGICA, V238, P44, DOI 10.1159/000477498
   Hamoudi H, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/602729
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Hoeh AE, 2009, EUR J OPHTHALMOL, V19, P163, DOI 10.1177/112067210901900128
   Hoye VJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1287
   Jutley G, 2011, EYE, V25, P675, DOI 10.1038/eye.2011.24
   KIES JC, 1988, AM J OPHTHALMOL, V105, P11, DOI 10.1016/0002-9394(88)90114-6
   Lin TZ, 2019, RETINA-J RET VIT DIS, V39, P1936, DOI 10.1097/IAE.0000000000002272
   LOPEZ PF, 1992, RETINA-J RET VIT DIS, V12, P147, DOI 10.1097/00006982-199212020-00012
   Mansour AM, 2008, AM J OPHTHALMOL, V146, P410, DOI 10.1016/j.ajo.2008.05.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Neri P, 2009, MIDDLE EAST AFR J OP, V16, P245, DOI 10.4103/0974-9233.58422
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenblatt BJ, 2005, RETINA-J RET VIT DIS, V25, P33, DOI 10.1097/00006982-200501000-00004
   Roy R, 2017, INDIAN J OPHTHALMOL, V65, P295, DOI 10.4103/ijo.IJO_262_16
   RUBEN S, 1994, ACTA OPHTHALMOL, V72, P118
   Sachdev Nishant, 2007, Indian J Ophthalmol, V55, P457
   SILVESTRI G, 1993, EYE, V7, P398, DOI 10.1038/eye.1993.78
   Singh SR, 2017, ASIA-PAC J OPHTHALMO, V6, P561, DOI 10.22608/APO.2017263
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Wilde C, 2019, EYE, V33, P451, DOI 10.1038/s41433-018-0232-y
NR 31
TC 5
Z9 5
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2020
VL 104
IS 5
BP 678
EP 683
DI 10.1136/bjophthalmol-2019-314542
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LL2KF
UT WOS:000531384100015
PM 31401554
DA 2022-11-30
ER

PT J
AU Zhang, LW
   Liu, SH
   Wang, JH
   Zou, JL
   Zeng, HL
   Zhao, H
   Zhang, BX
   He, Y
   Shi, JM
   Yoshida, S
   Zhou, YD
AF Zhang, Liwei
   Liu, Shaohua
   Wang, Jiang-Hui
   Zou, Jingling
   Zeng, Huilan
   Zhao, Han
   Zhang, Boxiang
   He, Yan
   Shi, Jingming
   Yoshida, Shigeo
   Zhou, Yedi
TI Differential Expressions of microRNAs and Transfer RNA-derived Small
   RNAs: Potential Targets of Choroidal Neovascularization
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Microrna; transfer RNA-derived small RNA; choroidal neovascularization;
   angiogenesis; age-related macular degeneration
ID MACULAR DEGENERATION; NONCODING RNAS; FRAGMENTS; ANGIOGENESIS
AB Purpose: Choroidal neovascularization (CNV) is one of the major clinical characteristics of neovascular age-related macular degeneration (AMD). Small non-coding RNAs, such as microRNAs (miRNAs) and transfer RNA-derived small RNAs (tsRNAs) play key roles in diverse biological functions. The purpose of the study was to investigate the roles and possible functions of the miRNAs and tsRNAs in CNV. Methods: The mouse model of laser-induced CNV was conducted by laser photocoagulation. The expression profiles of miRNAs and tsRNAs were accessed by small RNA sequencing (RNA-Seq) in RPE-choroid-sclera complexes of mice in CNV group and control group. Selected altered miRNAs and tsRNAs were validated by qRT-PCR. Target genes were predicted by informatics analysis and intersected with the previous microarray study of altered mRNAs. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted to reveal the biological functions and signaling pathways with which these target genes are most enriched. Results: The results revealed that 79 miRNAs and 72 tsRNAs in total were significantly altered in the RPE-choroid-sclera complexes of CNV mice. GO analysis revealed that the altered target genes of the selected miRNAs most enriched in immune response, integral component of membrane and peptide binding, while the altered target genes of tsRNAs most enriched in regulation of immune system process, extracellular region, and core promoter binding. Moreover, KEGG pathway analysis demonstrated that altered target genes of miRNAs and tsRNAs most enriched in hematopoietic cell lineage and nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway, respectively. Conclusions: Our study identified differential expressions of miRNAs and tsRNAs in CNV model, and these altered miRNAs and tsRNAs might be novel potential targets in treating CNVs in patients with neovascular AMD.
C1 [Zhang, Liwei; Liu, Shaohua; Zou, Jingling; Zeng, Huilan; Zhao, Han; Zhang, Boxiang; He, Yan; Shi, Jingming; Zhou, Yedi] Cent S Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Zhang, Liwei; Liu, Shaohua; Zou, Jingling; Zeng, Huilan; Zhao, Han; Zhang, Boxiang; He, Yan; Shi, Jingming; Zhou, Yedi] Hunan Clin Res Ctr Ophthalm Dis, Changsha, Hunan, Peoples R China.
   [Wang, Jiang-Hui] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Wang, Jiang-Hui] Univ Melbourne, Dept Surg, Ophthalmol, East Melbourne, Vic, Australia.
   [Yoshida, Shigeo] Kurume Univ, Sch Med, Dept Ophthalmol, Kurume, Fukuoka, Japan.
C3 Central South University; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; Kurume University
RP Zhou, YD (通讯作者)，Cent S Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
EM zhouyedi@csu.edu.cn
RI He, Yan/AAF-4204-2021
OI He, Yan/0000-0003-4357-4082; Zhao, Han/0000-0002-5803-505X; zhang,
   liwei/0000-0002-4349-5360; Zhou, Yedi/0000-0002-8948-1108
FU National Natural Science Foundation of China [81500746, 81600714,
   81800855]; Department of Science and Technology, Hunan [2015TP2007];
   Natural Science Foundation of Hunan Province [2018JJ3765]
FX This work was supported by the National Natural Science Foundation of
   China [81500746, 81600714, 81800855]; Department of Science and
   Technology, Hunan [2015TP2007]; Natural Science Foundation of Hunan
   Province [2018JJ3765].
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Askou AL, 2019, MOL THER-NUCL ACIDS, V16, P38, DOI 10.1016/j.omtn.2019.01.012
   Berber P, 2017, MOL DIAGN THER, V21, P31, DOI 10.1007/s40291-016-0234-z
   Chan JJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051310
   Cole C, 2009, RNA, V15, P2147, DOI 10.1261/rna.1738409
   Cui YY, 2019, J CELL PHYSIOL, V234, P8740, DOI 10.1002/jcp.27533
   Deng YP, 2017, CELL PHYSIOL BIOCHEM, V42, P2255, DOI 10.1159/000479999
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Ehlken C, 2019, OPHTHALMIC RES, V61, P174, DOI 10.1159/000481260
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Feng YF, 2018, FASEB J, V32, P1626, DOI 10.1096/fj.201700640R
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Goodarzi H, 2015, CELL, V161, P790, DOI 10.1016/j.cell.2015.02.053
   Kim HK, 2017, NATURE, V552, P57, DOI 10.1038/nature25005
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Kuscu C, 2018, RNA, V24, P1093, DOI 10.1261/rna.066126.118
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Li Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep20850
   Li SQ, 2018, GENES-BASEL, V9, DOI 10.3390/genes9050246
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luther KM, 2018, J MOL CELL CARDIOL, V119, P125, DOI 10.1016/j.yjmcc.2018.04.012
   Magee RG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22488-2
   Martinez G, 2017, NUCLEIC ACIDS RES, V45, P5142, DOI 10.1093/nar/gkx103
   Nakama T, 2015, GENE THER, V22, P127, DOI 10.1038/gt.2014.112
   Olvedy M, 2016, ONCOTARGET, V7, P24766, DOI 10.18632/oncotarget.8293
   Park YG, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/637316
   Ragusa M, 2013, MOL VIS, V19, P430
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Schirbel A, 2013, GASTROENTEROLOGY, V144, P613, DOI 10.1053/j.gastro.2012.11.005
   Sharma U, 2016, SCIENCE, V351, P391, DOI 10.1126/science.aad6780
   Shen JK, 2008, MOL THER, V16, P1208, DOI 10.1038/mt.2008.104
   Shen LY, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8030054
   Shen YJ, 2018, J MOL MED, V96, P1167, DOI 10.1007/s00109-018-1693-y
   Shigematsu M, 2015, GENE REGUL SYST BIO, V9, P27, DOI 10.4137/GRSB.S29411
   Sun CX, 2018, CELL PHYSIOL BIOCHEM, V49, P419, DOI 10.1159/000492977
   Wang L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060895
   Wang WZ, 2018, EXP CELL RES, V370, P24, DOI 10.1016/j.yexcr.2018.06.002
   Weinheimer-Haus EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119106
   Xu TY, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4029-3
   Yang C, 2018, CARDIOVASC THER, V36, DOI 10.1111/1755-5922.12329
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068173
   Zhang XP, 2018, EXP EYE RES, V167, P122, DOI 10.1016/j.exer.2017.12.001
   Zhang Y, 2018, INT J RHEUM DIS, V21, P1659, DOI 10.1111/1756-185X.13346
   Zhang Y, 2017, THERANOSTICS, V7, P3155, DOI 10.7150/thno.19646
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
   Zhuang Z, 2015, MOL VIS, V21, P1173
NR 47
TC 18
Z9 19
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD NOV 2
PY 2019
VL 44
IS 11
BP 1226
EP 1235
DI 10.1080/02713683.2019.1625407
EA JUN 2019
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JJ1IG
UT WOS:000471807000001
PM 31136199
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Velez, G
   Machlab, DA
   Tang, PH
   Sun, Y
   Tsang, SH
   Bassuk, AG
   Mahajan, VB
AF Velez, Gabriel
   Machlab, Daniel A.
   Tang, Peter H.
   Sun, Yang
   Tsang, Stephen H.
   Bassuk, Alexander G.
   Mahajan, Vinit B.
TI Proteomic analysis of the human retina reveals region-specific
   susceptibilities to metabolic-and oxidative stress-related diseases
SO PLOS ONE
LA English
DT Article
ID SUPEROXIDE-DISMUTASE; VASCULAR INJURY; GENE; MUTATION; CELL;
   PATHOPHYSIOLOGY; DEGENERATION; EXPRESSION; GLAUCOMA; EBSELEN
AB Differences in regional protein expression within the human retina may explain molecular predisposition of specific regions to ophthalmic diseases like age-related macular degeneration, cystoid macular edema, retinitis pigmentosa, and diabetic retinopathy. To quantify protein levels in the human retina and identify patterns of differentially-expressed proteins, we collected foveomacular, juxta-macular, and peripheral retina punch biopsies from healthy donor eyes and analyzed protein content by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Protein expression was analyzed with 1-way ANOVA, gene ontology, pathway representation, and network analysis. We identified a mean of 1,974 proteins in the foveomacular retina, 1,999 in the juxta-macular retina, and 1,779 in the peripheral retina. Six hundred ninety-seven differentially-expressed proteins included those unique to and abundant in each anatomic region. Proteins with higher expression in each region include: heat-shock protein 90-alpha (HSP90AA1), and pyruvate kinase (PKM) in the foveomacular retina; vimentin (VIM) and fructose-bisphosphate aldolase C (ALDOC); and guanine nucleotide-binding protein subunit beta-1 (GNB1) and guanine nucleotide-binding protein subunit alpha-1 (GNAT1) in the peripheral retina. Pathway analysis identified downstream mediators of the integrin signaling pathway to be highly represented in the foveomacular region (P = 6.48 e-06). Metabolic pathways were differentially expressed among all retinal regions. Gene ontology analysis showed that proteins related to antioxidant activity were higher in the juxta-macular and the peripheral retina, but present in lower amounts in the foveomacular retina. Our proteomic analysis suggests that certain retinal regions are susceptible to different forms of metabolic and oxidative stress. The findings give mechanistic insight into retina function, reveal important molecular processes, and prioritize new pathways for therapeutic targeting.
C1 [Velez, Gabriel; Machlab, Daniel A.; Tang, Peter H.; Mahajan, Vinit B.] Stanford Univ, Om Lab, Palo Alto, CA 94304 USA.
   [Velez, Gabriel; Tang, Peter H.; Sun, Yang; Mahajan, Vinit B.] Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Palo Alto, CA 94304 USA.
   [Velez, Gabriel] Univ Iowa, Med Scientist Training Program, Iowa City, IA USA.
   [Tang, Peter H.; Sun, Yang; Mahajan, Vinit B.] Palo Alto Vet Adm, Palo Alto, CA 94304 USA.
   [Tsang, Stephen H.] Columbia Univ, Jonas Childrens Vis Care, New York, NY USA.
   [Tsang, Stephen H.] Columbia Univ, Dept Ophthalmol, Bernard & Shirlee Brown Glaucoma Lab, Columbia Stem Cell Initiat,Inst Human Nutr, New York, NY 10027 USA.
   [Tsang, Stephen H.] Columbia Univ, Dept Pathol, Bernard & Shirlee Brown Glaucoma Lab, Columbia Stem Cell Initiat,Inst Human Nutr, New York, NY USA.
   [Tsang, Stephen H.] Columbia Univ, Dept Cell Biol, Bernard & Shirlee Brown Glaucoma Lab, Columbia Stem Cell Initiat,Inst Human Nutr, New York, NY USA.
   [Tsang, Stephen H.] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY USA.
   [Bassuk, Alexander G.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
C3 Stanford University; Stanford University; University of Iowa; Columbia
   University; Columbia University; Columbia University; Columbia
   University; Columbia University; University of Iowa
RP Mahajan, VB (通讯作者)，Stanford Univ, Om Lab, Palo Alto, CA 94304 USA.; Mahajan, VB (通讯作者)，Stanford Univ, Byers Eye Inst, Dept Ophthalmol, Palo Alto, CA 94304 USA.; Mahajan, VB (通讯作者)，Palo Alto Vet Adm, Palo Alto, CA 94304 USA.
EM vinit.mahajan@stanford.edu
OI Bassuk, Alexander/0000-0002-4067-2157; Velez,
   Gabriel/0000-0003-0819-5933; Mahajan, Vinit/0000-0003-1886-1741
FU NIH [R01EY026682, R01EY024665, R01EY025225, R01EY024698, R21AG050437,
   F30EYE027986, T32GM007337, K08-EY022058, R01-EY025295]; Doris Duke
   Charitable Foundation [2013103]; Research to Prevent Blindness; National
   Institutes of Health [R01EY024698, R21AG050437, 5P30EY019007,
   R01EY018213]; National Cancer Institute Core [5P30CA013696]; Research to
   Prevent Blindness (RPB) Physician-Scientist Award, unrestricted funds
   from RPB, New York, NY, USA; Tistou and Charlotte Kerstan Foundation,
   New York State [C029572]; Foundation Fighting Blindness New York
   Regional Research Center Grant [C-NY05-0705-0312]; Joel Hoffman Fund;
   Professor Gertrude Rothschild Stem Cell Foundation; Gebroe Family
   Foundation; VA merit [CX001298]; Ziegler Foundation for the Blind; Lowe
   syndrome association; Alcon Research Institute; NATIONAL EYE INSTITUTE
   [R01EY025295, K08EY022058] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH
   RePORTER; Veterans Affairs [I01CX001481] Funding Source: NIH RePORTER
FX VBM and AGB are supported by NIH grants [R01EY026682, R01EY024665,
   R01EY025225, R01EY024698 and R21AG050437; https://www.nih.gov], The
   Doris Duke Charitable Foundation [grant# 2013103; http://www.ddcf.org],
   and Research to Prevent Blindness [https://www.rpbusa.org/rpb]. GV is
   supported by NIH [F30EYE027986 and T32GM007337; https://www.nih.gov].
   The Barbara & Donald Jonas Laboratory of Regenerative Medicine and
   Bernard & Shirlee Brown Glaucoma Laboratory are supported by the
   National Institutes of Health [5P30EY019007, R01EY018213, R01EY024698,
   R21AG050437; https://www.nih.gov], National Cancer Institute Core
   [5P30CA013696], the Research to Prevent Blindness (RPB)
   Physician-Scientist Award, unrestricted funds from RPB
   [https://www.rpbusa.org], New York, NY, USA. SHT is a member of the
   RD-CURE Consortium and is supported by the Tistou and Charlotte Kerstan
   Foundation [http://www.kerstanstiftung.org], New York State [C029572],
   the Foundation Fighting Blindness New York Regional Research Center
   Grant [C-NY05-0705-0312; http://www.blindness.org], the Joel Hoffman
   Fund, the Professor Gertrude Rothschild Stem Cell Foundation, and the
   Gebroe Family Foundation. YS is supported by NIH grant [K08-EY022058,
   R01-EY025295; https://www.nih.gov], VA merit CX001298
   [https://www.va.gov], Ziegler Foundation for the Blind
   [http://emzfoundation.com], Lowe syndrome association
   [http://lowesyndrome.org], and Alcon Research Institute
   [www.myalcon.com/research-development/alcon-research-institute/].; VBM
   and AGB are supported by NIH grants [R01EY026682, R01EY024665,
   R01EY025225, R01EY024698, R21AG050437], The Doris Duke Charitable
   Foundation Grant #2013103, and Research to Prevent Blindness (RPB), New
   York, NY. GV is supported by NIH grants [F30EYE027986 and T32GM007337].
   The Barbara & Donald Jonas Laboratory of Regenerative Medicine and
   Bernard & Shirlee Brown Glaucoma Laboratory are supported by the
   National Institute of Health [5P30EY019007, R01EY018213, R01EY024698,
   R21AG050437], National Cancer Institute Core [5P30CA013696], the
   Research to Prevent Blindness (RPB) Physician-Scientist Award,
   unrestricted funds from RPB, New York, NY, USA. SHT is a member of the
   RD-CURE Consortium and is supported by the Tistou and Charlotte Kerstan
   Foundation, the Schneeweiss Stem Cell Fund, New York State [C029572],
   the Foundation Fighting Blindness New York Regional Research Center
   Grant [C-NY05-0705-0312], the Joel Hoffman Fund, the Professor Gertrude
   Rothschild Stem Cell Foundation, and the Gebroe Family Foundation. YS is
   supported by NIH grants [K08EY022058 and R01EY025295] and the U.S.
   Department of Veterans Affairs Grant CX001298.
CR Bareil C, 2001, HUM GENET, V108, P328, DOI 10.1007/s004390100496
   Bjornson RD, 2008, J PROTEOME RES, V7, P293, DOI 10.1021/pr0701198
   Coppey LJ, 2001, BRIT J PHARMACOL, V134, P21, DOI 10.1038/sj.bjp.0704216
   DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0
   Dryja TP, 1996, NAT GENET, V13, P358, DOI 10.1038/ng0796-358
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751
   Duncan JL, 2011, INVEST OPHTH VIS SCI, V52, P9614, DOI 10.1167/iovs.11-8600
   Farkas MH, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-486
   Gabryel B, 2006, PHARMACOL REP, V58, P381
   Geer LY, 2004, J PROTEOME RES, V3, P958, DOI 10.1021/pr0499491
   Giordano CR, 2015, INVEST OPHTH VIS SCI, V56, P3095, DOI 10.1167/iovs.14-16194
   Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   HAYDEN DW, 1992, J VET DIAGN INVEST, V4, P209, DOI 10.1177/104063879200400222
   Hipp S, 2015, ACTA OPHTHALMOL, V93, pE281, DOI 10.1111/aos.12573
   Hoang QQ, 2014, P NATL ACAD SCI USA, V111, P2402, DOI 10.1073/pnas.1324284111
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jung CW, 2001, NEUROSCI LETT, V304, P157, DOI 10.1016/S0304-3940(01)01784-0
   Kang DH, 2013, CIRCULATION, V128, P834, DOI 10.1161/CIRCULATIONAHA.113.001725
   La Spada AR, 2011, NEUROBIOLOGY HUNTING
   Li MY, 2014, HUM MOL GENET, V23, P4001, DOI 10.1093/hmg/ddu114
   Liebmann JM, 2017, NEW ENGL J MED, V376, P2079, DOI 10.1056/NEJMcibr1702486
   Lin JB, 2016, NPJ AGING MECH DIS, V2, DOI 10.1038/npjamd.2016.3
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Mahajan VB, 2014, PROTEOM CLIN APPL, V8, P204, DOI 10.1002/prca.201300062
   Malukiewicz-Wisniewska Grazyna, 2005, Klin Oczna, V107, P70
   Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198
   McFadden SL, 2003, TOXICOL APPL PHARM, V186, P46, DOI 10.1016/S0041-008X(02)00017-0
   Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092
   Morimura H, 1999, NAT GENET, V23, P393, DOI 10.1038/70496
   Nita Malgorzata, 2016, Oxid Med Cell Longev, V2016, P3164734, DOI 10.1155/2016/3164734
   Punzo C, 2012, J BIOL CHEM, V287, P1642, DOI 10.1074/jbc.R111.304428
   Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897
   Skeie JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127567
   Skeie JM, 2014, JAMA OPHTHALMOL, V132, P1271, DOI 10.1001/jamaophthalmol.2014.2065
   Skeie JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082140
   Sorrentino FS, 2016, EYE, V30, P1542, DOI 10.1038/eye.2016.197
   Sun LL, 2013, RAPID COMMUN MASS SP, V27, P157, DOI 10.1002/rcm.6437
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tan SM, 2015, EXP EYE RES, V136, P1, DOI 10.1016/j.exer.2015.04.015
   Thiadens AAHJ, 2009, AM J HUM GENET, V85, P240, DOI 10.1016/j.ajhg.2009.06.016
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Tsai CY, 2017, EYE LOND
   Velez G, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.97818
   Velez Gabriel, 2017, Am J Ophthalmol Case Rep, V5, P107, DOI 10.1016/j.ajoc.2016.12.023
   Velez G, 2016, JAMA OPHTHALMOL, V134, P444, DOI 10.1001/jamaophthalmol.2015.5934
   Vizcaino JA, 2014, NAT BIOTECHNOL, V32, P223, DOI 10.1038/nbt.2839
   Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145
   Wallez Y, 2008, BBA-BIOMEMBRANES, V1778, P794, DOI 10.1016/j.bbamem.2007.09.003
   Wang R, 2012, NAT BIOTECHNOL, V30, P135, DOI 10.1038/nbt.2112
   Williams PA, 2017, SCIENCE, V355, P756, DOI 10.1126/science.aal0092
   Wolfensberger TJ, 2017, DEV OPHTHALMOL, V58, P74, DOI 10.1159/000455275
   Xu JY, 2014, BBA-MOL BASIS DIS, V1842, P2106, DOI 10.1016/j.bbadis.2014.07.008
   Yen CY, 2009, MOL CELL PROTEOMICS, V8, P857, DOI 10.1074/mcp.M800384-MCP200
   Yousif LF, 2013, CELL ADHES MIGR, V7, P101, DOI 10.4161/cam.22680
   Zhang PB, 2015, PROTEOMICS, V15, P836, DOI 10.1002/pmic.201400397
NR 57
TC 26
Z9 27
U1 3
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2018
VL 13
IS 2
AR e0193250
DI 10.1371/journal.pone.0193250
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FW8RO
UT WOS:000425604300103
PM 29466423
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ezati, R
   Etemadzadeh, A
   Soheili, ZS
   Samiei, S
   Pirmardan, ER
   Davari, M
   Najafabadi, HS
AF Ezati, Razie
   Etemadzadeh, Azadeh
   Soheili, Zahra-Soheila
   Samiei, Shahram
   Pirmardan, Ehsan Ranaei
   Davari, Malihe
   Najafabadi, Hoda Shams
TI The influence of rAAV2-mediated SOX2 delivery into neonatal and adult
   human RPE cells; a comparative study
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE neural progenitor cells; retinal pigmented epithelial cells (RPE);
   retinal progenitor cells (RPC); SOX2 gene
ID RETINAL-PIGMENT EPITHELIUM; PLURIPOTENT STEM-CELLS; NESTIN EXPRESSION;
   PROGENITOR CELLS; NEURONS; GENERATION; DIFFERENTIATE; EFFICIENT; GENE;
   PAX6
AB Cell replacement is a promising therapy for degenerative diseases like age-related macular degeneration (AMD). Since the human retina lacks regeneration capacity, much attention has been directed toward persuading for cells that can differentiate into retinal neurons. In this report, we have investigated reprogramming of the human RPE cells and concerned the effect of donor age on the cellular fate as a critical determinant in reprogramming competence. We evaluated the effect of SOX2 over-expression in human neonatal and adult RPE cells in cultures. The coding region of human SOX2 gene was cloned into adeno-associated virus (AAV2) and primary culture of human neonatal/adult RPE cells were infected by recombinant virus. De-differentiation of RPE to neural/retinal progenitor cells was investigated by quantitative real-time PCR and ICC for neural/retinal progenitor cells' markers. Gene expression analysis showed 80-fold and 12-fold over-expression for SOX2 gene in infected neonatal and adult hRPE cells, respectively. The fold of increase for Nestin in neonatal and adult hRPE cells was 3.8-fold and 2.5-fold, respectively. PAX6 expression was increased threefold and 2.5-fold in neonatal/adult treated cultures. Howbeit, we could not detect rhodopsin, and CHX10 expression in neonatal hRPE cultures and expression of rhodopsin in adult hRPE cells. Results showed SOX2 induced human neonatal/adult RPE cells to de-differentiate toward retinal progenitor cells. However, the increased number of PAX6, CHX10, Thy1, and rhodopsin positive cells in adult hRPE treated cultures clearly indicated the considerable generation of neuro-retinal terminally differentiated cells.
   Since the human retina lacks regeneration capacity, finding cells which can differentiate into retinal neurons will provide promising therapy for eye degenerative diseases. We used SOX2 gene to induce human neonatal/adult RPE cells to dedifferentiate toward retinal progenitor cells.
C1 [Ezati, Razie; Etemadzadeh, Azadeh; Soheili, Zahra-Soheila; Davari, Malihe; Najafabadi, Hoda Shams] Natl Inst Genet Engn & Biotechnol, Inst Med Biotechnol, Tehran, Iran.
   [Samiei, Shahram] High Inst Res & Educ Transfus Med, Blood Transfus Res Ctr, Tehran, Iran.
   [Pirmardan, Ehsan Ranaei] Tarbiat Modares Univ, Fac Basic Sci, Tehran, Iran.
C3 Tarbiat Modares University
RP Soheili, ZS (通讯作者)，Natl Inst Genet Engn & Biotechnol, Minist Sci Res & Technol, POB 14965-161,Pajoohesh Blvd,17th Kilometers, Tehran, Iran.
EM soheili@nigeb.ac.ir
RI Pirmardan, Ehsan Ranaei/AAG-3914-2021; Soheili,
   Zahra-Soheila/W-8316-2018
OI Soheili, Zahra-Soheila/0000-0003-1292-465X; Ranaei Pirmardan,
   Ehsan/0000-0002-6848-5839
CR Aasen T, 2008, NAT BIOTECHNOL, V26, P1276, DOI 10.1038/nbt.1503
   Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609
   Bibb LC, 2001, HUM MOL GENET, V10, P1571, DOI 10.1093/hmg/10.15.1571
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Cepko C, 2014, NAT REV NEUROSCI, V15, P615, DOI 10.1038/nrn3767
   Chen MF, 2010, INVEST OPHTH VIS SCI, V51, P5970, DOI 10.1167/iovs.09-4504
   Davari M, 2013, MOL VIS, V19, P2330
   Dhomen NS, 2006, INVEST OPHTH VIS SCI, V47, P386, DOI 10.1167/iovs.05-0428
   Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Gill KP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.2
   Giorgetti A, 2009, CELL STEM CELL, V5, P353, DOI 10.1016/j.stem.2009.09.008
   Grigoryan EN, 2016, BIOMEDICINES, V4, DOI 10.3390/biomedicines4040028
   Herzog RW, 2010, DISCOV MED, V9, P105
   Hsieh YW, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-32
   Hu CH, 2010, J GENE MED, V12, P766, DOI 10.1002/jgm.1496
   Hu QR, 2014, STEM CELL TRANSL MED, V3, P1526, DOI 10.5966/sctm.2014-0038
   John S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/465169
   Kallas A, 2014, STEM CELLS INT, V2014, DOI 10.1155/2014/298163
   Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311
   Kim K, 2010, NATURE, V467, P285, DOI 10.1038/nature09342
   Lamba D, 2008, CELL STEM CELL, V2, P538, DOI 10.1016/j.stem.2008.05.002
   Lee JH, 2012, ANAT CELL BIOL, V45, P38, DOI 10.5115/acb.2012.45.1.38
   Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290
   Li XM, 2010, INVEST OPHTH VIS SCI, V51, P516, DOI 10.1167/iovs.09-3822
   Luz-Madrigal A, 2014, BMC BIOL, V12, DOI 10.1186/1741-7007-12-28
   Ma WX, 2009, STEM CELLS, V27, P1376, DOI 10.1002/stem.48
   MacLaren RE, 2007, EYE, V21, P1352, DOI 10.1038/sj.eye.6702842
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Matsushima D, 2011, DEVELOPMENT, V138, P443, DOI 10.1242/dev.055178
   Miao CH, 1998, NAT GENET, V19, P13, DOI 10.1038/ng0598-13
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Philips GT, 2005, DEV BIOL, V279, P308, DOI 10.1016/j.ydbio.2004.12.018
   Qiu GT, 2007, EXP EYE RES, V84, P1047, DOI 10.1016/j.exer.2007.01.014
   Raisler B. J., 2005, LAB TECHNIQUES BIOCH, V31, P103
   Saini JS, 2016, ADV EXP MED BIOL, V854, P557, DOI 10.1007/978-3-319-17121-0_74
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shih AH, 2006, NEOPLASIA, V8, P1072, DOI 10.1593/neo.06526
   Shin DH, 2003, ACTA HISTOCHEM, V105, P267, DOI 10.1078/0065-1281-00709
   Somers A, 2010, STEM CELLS, V28, P1728, DOI 10.1002/stem.495
   Tanaka S, 2004, MOL CELL BIOL, V24, P8834, DOI 10.1128/MCB.24.20.8834-8846.2004
   Taranova OV, 2006, GENE DEV, V20, P1187, DOI 10.1101/gad.1407906
   Thomas CE, 2004, J VIROL, V78, P3110, DOI 10.1128/JVI.78.6.3110-3122.2004
   Wang B, 2011, PLOS CURR-TREE LIFE, DOI 10.1371/currents.RRN1274
   Wang SZ, 2010, EXPERT OPIN BIOL TH, V10, P1227, DOI 10.1517/14712598.2010.495218
   Wiese C, 2004, CELL MOL LIFE SCI, V61, P2510, DOI 10.1007/s00018-004-4144-6
   Yan RT, 2013, INVEST OPHTH VIS SCI, V54, P4766, DOI 10.1167/iovs.13-11936
   Yan RT, 2010, J COMP NEUROL, V518, P526, DOI 10.1002/cne.22236
NR 51
TC 4
Z9 6
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2018
VL 233
IS 2
BP 1222
EP 1235
DI 10.1002/jcp.25991
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA FL9RB
UT WOS:000414593500045
PM 28480968
DA 2022-11-30
ER

PT J
AU Kashani, AH
   Chen, CL
   Gahm, JK
   Zheng, F
   Richter, GM
   Rosenfeld, PJ
   Shi, YG
   Wang, RKK
AF Kashani, Amir H.
   Chen, Chieh-Li
   Gahm, Jin K.
   Zheng, Fang
   Richter, Grace M.
   Rosenfeld, Philip J.
   Shi, Yonggang
   Wang, Ruikang K.
TI Optical coherence tomography angiography: A comprehensive review of
   current methods and clinical applications
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Optical coherence tomography angiography; Retina; Glaucoma; Physiology;
   Vascular disease; Macular degeneration
ID FOVEAL AVASCULAR ZONE; SWEPT-SOURCE OCT; INDOCYANINE GREEN ANGIOGRAPHY;
   BLOOD-FLOW-VELOCITY; DIABETIC MACULAR EDEMA; RETINAL VEIN OCCLUSION;
   AMPLITUDE-DECORRELATION ANGIOGRAPHY; RADIAL PERIPAPILLARY CAPILLARIES;
   SUBRETINAL HYPERREFLECTIVE MATERIAL; SPECTRAL-DOMAIN
AB OCT has revolutionized the practice of ophthalmology over the past 10-20 years. Advances in OCT technology have allowed for the creation of novel OCT-based methods. OCT-Angiography (OCTA) is one such method that has rapidly gained clinical acceptance since it was approved by the FDA in late 2016. OCTA images are based on the variable backscattering of light from the vascular and neurosensory tissue in the retina. Since the intensity and phase of backscattered light from retinal tissue varies based on the intrinsic movement of the tissue (e.g. red blood cells are moving, but neurosensory tissue is static), OCTA images are essentially motion-contrast images. This motion-contrast imaging provides reliable, high resolution, and non-invasive images of the retinal vasculature in an efficient manner. In many cases, these images are approaching histology level resolution. This unprecedented resolution coupled with the simple, fast and non-invasive imaging platform have allowed a host of basic and clinical research applications. OCTA demonstrates many important clinical findings including areas of macular telangiectasia, impaired perfusion, microaneurysms, capillary remodeling, some types of intraretinal fluid, and neovascularization among many others. More importantly, OCTA provides depth-resolved information that has never before been available. Correspondingly, OCTA has been used to evaluate a spectrum of retinal vascular diseases including diabetic retinopathy (DR), retinal venous occlusion (RVO), uveitis, retinal arterial occlusion, and age-related macular degeneration among others. In this review, we will discuss the methods used to create OCTA images, the practical applications of OCTA in light of invasive dye-imaging studies (e.g. fluorescein angiography) and review clinical studies demonstrating the utility of OCTA for research and clinical practice. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Kashani, Amir H.; Richter, Grace M.] Univ Southern Calif, USC Roski Eye Inst, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Chen, Chieh-Li; Wang, Ruikang K.] Univ Washington Seattle, Dept Biomed Engn, Seattle, WA 98195 USA.
   [Gahm, Jin K.; Shi, Yonggang] Univ Southern Calif, Lab Neuro Imaging LONI, USC Stevens Neuroimaging & Informat Inst, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Zheng, Fang; Rosenfeld, Philip J.] Univ Miami, Bascom Palmer Eye Inst, Dept Ophthalmol, Miller Sch Med, Miami, FL 33136 USA.
C3 University of Southern California; University of Washington; University
   of Washington Seattle; University of Southern California; Bascom Palmer
   Eye Institute; University of Miami
RP Kashani, AH (通讯作者)，USC, USC Roski Eye Inst, Keck Sch Med, 1450 San Pablo St,Suite 4700, Los Angeles, CA 90033 USA.
EM ahkashan@usc.edu
RI Gahm, Jin Kyu/AAA-4624-2021; Wang, Ruikang/L-3889-2019
OI Wang, Ruikang/0000-0001-5169-8822; Gahm, Jin Kyu/0000-0001-8827-402X
FU NEI NIH HHS [R21 EY027879, K08 EY027006] Funding Source: Medline; NIBIB
   NIH HHS [P41 EB015922] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [R21EY027879, K08EY027006] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015922] Funding
   Source: NIH RePORTER
CR Adhi M, 2016, INVEST OPHTH VIS SCI, V57, pOCT486, DOI 10.1167/iovs.15-18907
   Agemy SA, 2015, RETINA-J RET VIT DIS, V35, P2353, DOI 10.1097/IAE.0000000000000862
   Akagi T, 2016, AM J OPHTHALMOL, V168, P237, DOI 10.1016/j.ajo.2016.06.009
   Al-Sheikh M, 2016, INVEST OPHTH VIS SCI, V57, P3907, DOI 10.1167/iovs.16-19570
   Alnawaiseh M, 2017, RETINA-J RET VIT DIS, V37, P1642, DOI 10.1097/IAE.0000000000001419
   ALTERMAN M, 1968, BRIT J OPHTHALMOL, V52, P26, DOI 10.1136/bjo.52.1.26
   An L, 2008, OPT EXPRESS, V16, P11438, DOI 10.1364/OE.16.011438
   An L, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.11.116018
   An L, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3642638
   An L, 2010, OPT EXPRESS, V18, P8220, DOI 10.1364/OE.18.008220
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P807
   Antcliff RJ, 2000, OPHTHALMOLOGY, V107, P593, DOI 10.1016/S0161-6420(99)00087-1
   AREND O, 1995, GRAEF ARCH CLIN EXP, V233, P244, DOI 10.1007/BF00183599
   AREND O, 1995, ARCH OPHTHALMOL-CHIC, V113, P610, DOI 10.1001/archopht.1995.01100050078034
   Avila CP, 1998, AM J OPHTHALMOL, V126, P683, DOI 10.1016/S0002-9394(98)00114-7
   Barton JK, 2005, OPT EXPRESS, V13, P5234, DOI 10.1364/OPEX.13.005234
   Bedggood Phillip, 2012, Biomed Opt Express, V3, P3264, DOI 10.1364/BOE.3.003264
   BENNETT AG, 1994, GRAEF ARCH CLIN EXP, V232, P361, DOI 10.1007/BF00175988
   BENYA R, 1989, CATHETER CARDIO DIAG, V17, P231, DOI 10.1002/ccd.1810170410
   Bhanushali D, 2016, INVEST OPHTH VIS SCI, V57, pOCT519, DOI 10.1167/iovs.15-18901
   Bojikian KD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154691
   Bolz M, 2010, OPHTHALMOLOGY, V117, P538, DOI 10.1016/j.ophtha.2009.07.035
   Bonini MA, 2015, RETINA-J RET VIT DIS, V35, P2339, DOI 10.1097/IAE.0000000000000850
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   BRESNICK GH, 1984, ARCH OPHTHALMOL-CHIC, V102, P1286
   Burgansky-Eliash Z, 2013, OSLI RETINA, V44, P51, DOI 10.3928/23258160-20121221-13
   Burgoyne CF, 2011, EXP EYE RES, V93, P120, DOI 10.1016/j.exer.2010.09.005
   Bursell SE, 1996, INVEST OPHTH VIS SCI, V37, P886
   Camino A, 2016, BIOMED OPT EXPRESS, V7, P3905, DOI 10.1364/BOE.7.003905
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P1783, DOI 10.1016/j.ophtha.2014.03.021
   Caprioli J, 2016, OPHTHALMOLOGY, V123, P117, DOI 10.1016/j.ophtha.2015.09.027
   Cardoso JN, 2016, AM J OPHTHALMOL, V163, P93, DOI 10.1016/j.ajo.2015.11.025
   Carpineto P, 2016, BRIT J OPHTHALMOL, V100, P671, DOI 10.1136/bjophthalmol-2015-307330
   Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   Chalam K V, 2016, J Ophthalmic Vis Res, V11, P84, DOI 10.4103/2008-322X.180709
   Chalam KV, 2012, INVEST OPHTH VIS SCI, V53, P8154, DOI 10.1167/iovs.12-10290
   Chen C., 2016, OPTIC DISC PERFUSION
   Chen C B.K., 2016, REPEATABILITY REPROD
   Chen CL, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.11.116009
   Chen CL, 2017, BIOMED OPT EXPRESS, V8, P1056, DOI 10.1364/BOE.8.001056
   Chen CL, 2016, INVEST OPHTH VIS SCI, V57, pOCT475, DOI 10.1167/iovs.15-18909
   Chen ZP, 1997, OPT LETT, V22, P1119, DOI 10.1364/OL.22.001119
   Cheung N, 2008, INVEST OPHTH VIS SCI, V49, P2403, DOI 10.1167/iovs.07-1313
   Choi WJ, 2016, BIOMED OPT EXPRESS, V7, P2709, DOI 10.1364/BOE.7.002709
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Cicinelli MV, 2017, RETINA-J RET VIT DIS, V37, P436, DOI 10.1097/IAE.0000000000001199
   Cole ED, 2016, INVEST OPHTH VIS SCI, V57, pOCT356, DOI 10.1167/iovs.15-18473
   Conrath J, 2005, EYE, V19, P322, DOI 10.1038/sj.eye.6701456
   Coscas F, 2016, AM J OPHTHALMOL, V161, P160, DOI 10.1016/j.ajo.2015.10.008
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Couturier A, 2015, RETINA-J RET VIT DIS, V35, P2384, DOI 10.1097/IAE.0000000000000859
   Dalimier E, 2012, DERMATOLOGY, V224, P84, DOI 10.1159/000337423
   Danis RP, 2010, RETINA-J RET VIT DIS, V30, P1627, DOI 10.1097/IAE.0b013e3181dde5f5
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   de Carlo TE, 2016, OSLI RETINA, V47, P115, DOI 10.3928/23258160-20160126-03
   De Carlo TE, 2015, RETINA-J RET VIT DIS, V35, P2364, DOI 10.1097/IAE.0000000000000882
   De Carlo TE, 2015, RETINA-J RET VIT DIS, V35, P2392, DOI 10.1097/IAE.0000000000000744
   De Rojas JO, 2016, NEUROLOGY, V87, P2065, DOI 10.1212/WNL.0000000000003313
   de Salles MC, 2016, INVEST OPHTH VIS SCI, V57, pOCT242, DOI 10.1167/iovs.15-18819
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Dubis AM, 2012, INVEST OPHTH VIS SCI, V53, P1628, DOI 10.1167/iovs.11-8488
   Dubois A, 2002, APPL OPTICS, V41, P805, DOI 10.1364/AO.41.000805
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Enfield J, 2011, BIOMED OPT EXPRESS, V2, P1184, DOI 10.1364/BOE.2.001184
   Falavarjani KG, 2017, INVEST OPHTH VIS SCI, V58, P30, DOI 10.1167/iovs.16-20579
   Falavarjani KG, 2016, RETINA-J RET VIT DIS, V36, pS168, DOI 10.1097/IAE.0000000000001259
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Filho CADG, 2013, OPHTHAL SURG LAS IM, V44, P204, DOI 10.3928/23258160-20130313-12
   Fingler J, 2008, INVEST OPHTH VIS SCI, V49, P5055, DOI 10.1167/iovs.07-1627
   Fingler J, 2007, OPT EXPRESS, V15, P12636, DOI 10.1364/OE.15.012636
   Fingler J, 2009, OPT EXPRESS, V17, P22190, DOI 10.1364/OE.17.022190
   Freeman C, 2001, EYE, V15, P12, DOI 10.1038/eye.2001.5
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gabriele ML, 2010, PROG RETIN EYE RES, V29, P556, DOI 10.1016/j.preteyeres.2010.05.005
   GANDOLFI SA, 1995, OPHTHALMIC SURG LAS, V26, P121
   Gao S.S., 2016, INVEST OPHTHALMOL VI, V57, DOI DOI 10.OCT27
   Gao SS, 2016, OPT LETT, V41, P496, DOI 10.1364/OL.41.000496
   Gao SS, 2015, OPT LETT, V40, P2305, DOI 10.1364/OL.40.002305
   Garcia CR, 1999, OPHTHALMOLOGY, V106, P1114, DOI 10.1016/S0161-6420(99)90264-6
   GASS JDM, 1993, OPHTHALMOLOGY, V100, P1536
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   GOMEZULLA F, 1991, AM J OPHTHALMOL, V112, P94, DOI 10.1016/S0002-9394(14)76222-1
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   GREEN WR, 1980, T OPHTHAL SOC UK, V100, P162
   Grulkowski I, 2012, BIOMED OPT EXPRESS, V3, P2733, DOI 10.1364/BOE.3.002733
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Hara T, 1998, AM J OPHTHALMOL, V126, P560, DOI 10.1016/S0002-9394(98)00112-3
   Hasegawa N, 2016, INVEST OPHTH VIS SCI, V57, pOCT348, DOI 10.1167/iovs.15-18782
   Hassan Muhammad, 2016, Int Ophthalmol Clin, V56, P1, DOI 10.1097/IIO.0000000000000130
   HENKIND P, 1967, BRIT J OPHTHALMOL, V51, P115, DOI 10.1136/bjo.51.2.115
   Hirooka K, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-73
   HO AC, 1994, OPHTHALMOLOGY, V101, P534
   Hong BK, 2013, CAN J OPHTHALMOL, V48, P489, DOI 10.1016/j.jcjo.2013.05.009
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   Horii T, 2015, RETINA-J RET VIT DIS, V35, P264, DOI 10.1097/IAE.0000000000000282
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Huang YP, 2014, OSLI RETINA, V45, P382, DOI 10.3928/23258160-20140909-08
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P1411, DOI 10.1001/jamaophthalmol.2016.4272
   Hwang TS, 2015, RETINA-J RET VIT DIS, V35, P2371, DOI 10.1097/IAE.0000000000000716
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Issa PC, 2013, PROG RETIN EYE RES, V34, P49, DOI 10.1016/j.preteyeres.2012.11.002
   Izatt JA, 1997, OPT LETT, V22, P1439, DOI 10.1364/OL.22.001439
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jian ZP, 2010, OPT EXPRESS, V18, P1024, DOI 10.1364/OE.18.001024
   Jonathan E, 2011, J BIOPHOTONICS, V4, P583, DOI 10.1002/jbio.201000103
   Kashani AH, 2015, RETINA-J RET VIT DIS, V35, P2323, DOI 10.1097/IAE.0000000000000811
   Kashani AH, 2010, AM J OPHTHALMOL, V149, P496, DOI 10.1016/j.ajo.2009.09.025
   Kim AY, 2016, AM J OPHTHALMOL, V171, P101, DOI 10.1016/j.ajo.2016.08.035
   Kim AY, 2016, INVEST OPHTH VIS SCI, V57, pOCT362, DOI 10.1167/iovs.15-18904
   Kim DY, 2012, INVEST OPHTH VIS SCI, V53, P85, DOI 10.1167/iovs.11-8249
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   Kim J, 2015, PHYS MED BIOL, V60, pR211, DOI 10.1088/0031-9155/60/10/R211
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   Koulisis N., 2016, QUANTITATIVE MICROVA
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kuehlewein L, 2015, INVEST OPHTH VIS SCI, V56, P3984, DOI 10.1167/iovs.15-16510
   Kumar RS, 2016, INVEST OPHTH VIS SCI, V57, P6079, DOI 10.1167/iovs.16-19984
   Kurokawa K, 2012, OPT EXPRESS, V20, P22796, DOI 10.1364/OE.20.022796
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Landa Gennady, 2012, International Ophthalmology, V32, P211, DOI 10.1007/s10792-012-9547-z
   Lang SJ, 2016, OSLI RETINA, V47, P935, DOI 10.3928/23258160-20161004-07
   Lavik EB, 2013, DRUG DELIV, V1, P734
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Leitgeb R, 2003, OPT EXPRESS, V11, P889, DOI 10.1364/OE.11.000889
   Leitgeb RA, 2003, OPT EXPRESS, V11, P3116, DOI 10.1364/OE.11.003116
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Leung CKS, 2014, CURR OPIN OPHTHALMOL, V25, P104, DOI 10.1097/ICU.0000000000000024
   Leveque PM, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/6956717
   Levison AL, 2017, BRIT J OPHTHALMOL, V101, P616, DOI 10.1136/bjophthalmol-2016-308806
   Li M, 2017, AM J OPHTHALMOL, V174, P56, DOI 10.1016/j.ajo.2016.10.018
   Liu L, 2015, BIOMED OPT EXPRESS, V6, P3564, DOI 10.1364/BOE.6.003564
   Liu L, 2015, JAMA OPHTHALMOL, V133, P1045, DOI 10.1001/jamaophthalmol.2015.2225
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Lupidi M, 2016, AM J OPHTHALMOL, V169, P9, DOI 10.1016/j.ajo.2016.06.008
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Makita S, 2011, OPT EXPRESS, V19, P1271, DOI 10.1364/OE.19.001271
   Mammo Z, 2016, AM J OPHTHALMOL, V170, P41, DOI 10.1016/j.ajo.2016.07.015
   Mammo Z, 2015, INVEST OPHTH VIS SCI, V56, P5074, DOI 10.1167/iovs.15-16773
   MANSOUR AM, 1993, RETINA-J RET VIT DIS, V13, P125, DOI 10.1097/00006982-199313020-00006
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   Mariampillai A, 2010, OPT LETT, V35, P1257, DOI 10.1364/OL.35.001257
   Marmor MF, 2008, ARCH OPHTHALMOL-CHIC, V126, P907, DOI 10.1001/archopht.126.7.907
   Marschall S, 2011, ANAL BIOANAL CHEM, V400, P2699, DOI 10.1007/s00216-011-5008-1
   Mase T, 2016, INVEST OPHTH VIS SCI, V57, pOCT504, DOI 10.1167/iovs.15-18877
   Matsunaga D, 2014, OSLI RETINA, V45, P510, DOI 10.3928/23258160-20141118-04
   Matsunaga DR, 2015, OSLI RETINA, V46, P796, DOI 10.3928/23258160-20150909-03
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McNamara PM, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.126008
   Mendis KR, 2010, INVEST OPHTH VIS SCI, V51, P5864, DOI 10.1167/iovs.10-5333
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Mo S, 2016, INVEST OPHTH VIS SCI, V57, pOCT130, DOI 10.1167/iovs.15-18932
   Moghimi S, 2012, INVEST OPHTH VIS SCI, V53, P4519, DOI 10.1167/iovs.11-8362
   Moore J, 1999, J ANAT, V194, P89, DOI 10.1046/j.1469-7580.1999.19410089.x
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Moysidis Stavros N, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS18, DOI 10.1097/ICB.0000000000000391
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Nemiroff J, 2016, AM J OPHTHALMOL, V162, P121, DOI 10.1016/j.ajo.2015.10.026
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Nunes RP, 2015, OSLI RETINA, V46, P162, DOI 10.3928/23258160-20150213-17
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   PARODI MB, 1995, INT OPHTHALMOL, V19, P25, DOI 10.1007/BF00156415
   Pece A, 2005, EUR J OPHTHALMOL, V15, P759, DOI 10.1177/112067210501500616
   Pechauer AD, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/121973
   PEDERSON JE, 1982, ARCH OPHTHALMOL-CHIC, V100, P426
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Ploner SB, 2016, RETINA-J RET VIT DIS, V36, pS118, DOI 10.1097/IAE.0000000000001328
   Proskurin SG, 2003, OPT LETT, V28, P1227, DOI 10.1364/OL.28.001227
   Querques G, 2016, BRIT J OPHTHALMOL, V100, P1724, DOI 10.1136/bjophthalmol-2016-308370
   Rainer L, 2002, PROC SPIE, V4619, P16, DOI 10.1117/12.470477
   Rao HL, 2017, BRIT J OPHTHALMOL, V101, P1066, DOI 10.1136/bjophthalmol-2016-309377
   Reichel E, 1995, OPHTHALMIC SURG LAS, V26, P513
   Reichel E, 1995, OPHTHALMOLOGY, V102, P1871, DOI 10.1016/S0161-6420(95)30781-6
   Remky A, 1997, OPHTHALMOLOGY, V104, P33, DOI 10.1016/S0161-6420(97)30365-0
   Rispoli M, 2015, RETINA-J RET VIT DIS, V35, P2332, DOI 10.1097/IAE.0000000000000845
   RIVA CE, 1983, INVEST OPHTH VIS SCI, V24, P47
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P608
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Roisman L, 2016, DEV OPHTHALMOL, V56, P146, DOI 10.1159/000442807
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Samara WA, 2015, RETINA-J RET VIT DIS, V35, P2188, DOI 10.1097/IAE.0000000000000847
   Schmitt JM, 1999, J BIOMED OPT, V4, P95, DOI 10.1117/1.429925
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Scoles D, 2009, BMC OPHTHALMOL, V9, DOI 10.1186/1471-2415-9-9
   Scripsema Nicole K, 2016, Invest Ophthalmol Vis Sci, V57, pOCT611, DOI 10.1167/iovs.15-18945
   Shi Y., 2017, CURVELET BASED VESSE
   SNODDERLY DM, 1992, J NEUROSCI, V12, P1169
   Son T, 2016, BIOMED OPT EXPRESS, V7, P3151, DOI 10.1364/BOE.7.003151
   Sophie R, 2013, AM J OPHTHALMOL, V156, P693, DOI 10.1016/j.ajo.2013.05.039
   Spaide R.F, 2015, OPHTHALMOLOGY, P1
   Spaide R.F., 2015, RETINA, V35, P1
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P1200, DOI 10.1016/j.ajo.2015.09.010
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, OPHTHALMOLOGY, V122, P2261, DOI 10.1016/j.ophtha.2015.07.025
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Squirrell DM, 2001, EYE, V15, P261, DOI 10.1038/eye.2001.91
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   STITT AW, 1995, BRIT J OPHTHALMOL, V79, P362, DOI 10.1136/bjo.79.4.362
   Suh MH, 2016, OPHTHALMOLOGY, V123, P2509, DOI 10.1016/j.ophtha.2016.09.002
   Suh MH, 2016, OPHTHALMOLOGY, V123, P2309, DOI 10.1016/j.ophtha.2016.07.023
   Szkulmowska A, 2009, OPT EXPRESS, V17, P10584, DOI 10.1364/OE.17.010584
   Takase N, 2015, RETINA-J RET VIT DIS, V35, P2377, DOI 10.1097/IAE.0000000000000849
   Takayama K, 2017, ACTA OPHTHALMOL, V95, pE344, DOI 10.1111/aos.13244
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Tan CS, 2016, INVEST OPHTH VIS SCI, V57, pOCT224, DOI 10.1167/iovs.15-18869
   Tan PEZ, 2015, INVEST OPHTH VIS SCI, V56, P3989, DOI 10.1167/iovs.14-15879
   Tao YK, 2009, OPT EXPRESS, V17, P4177, DOI 10.1364/OE.17.004177
   Thorell MR, 2014, OSLI RETINA, V45, P526, DOI 10.3928/23258160-20141118-07
   Thorell MR, 2014, OSLI RETINA, V45, P369, DOI 10.3928/23258160-20140909-06
   Tick S, 2011, INVEST OPHTH VIS SCI, V52, P5105, DOI 10.1167/iovs.10-7005
   Tokayer J, 2013, BIOMED OPT EXPRESS, V4, P1909, DOI 10.1364/BOE.4.001909
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Tomic L, 2005, ACTA OPHTHALMOL SCAN, V83, P705, DOI 10.1111/j.1600-0420.2005.00522.x
   Toto L, 2016, INVEST OPHTH VIS SCI, V57, pOCT268, DOI 10.1167/iovs.15-18872
   TSAI CS, 1991, OPHTHALMOLOGY, V98, P1412
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Waisbourd M, 2016, GRAEF ARCH CLIN EXP, V254, P1159, DOI 10.1007/s00417-016-3321-2
   Wang Q, 2016, AM J OPHTHALMOL, V168, P95, DOI 10.1016/j.ajo.2016.05.005
   Wang RKK, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2724920
   Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083
   Wang RKK, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2357854
   Wang RKK, 2016, OPT LETT, V41, P2330, DOI 10.1364/OL.41.002330
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Wang RKK, 2010, IEEE J SEL TOP QUANT, V16, P545, DOI 10.1109/JSTQE.2009.2033609
   Wang RKK, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3353958
   Wang XG, 2014, BRIT J OPHTHALMOL, V98, P1368, DOI 10.1136/bjophthalmol-2013-304547
   Wang XL, 2015, GRAEF ARCH CLIN EXP, V253, P1557, DOI 10.1007/s00417-015-3095-y
   WEINHAUS RS, 1995, EXP EYE RES, V61, P1, DOI 10.1016/S0014-4835(95)80053-0
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   WILSON DJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P100, DOI 10.1001/archopht.1988.01060130106038
   Wittstrom E, 2010, GRAEF ARCH CLIN EXP, V248, P485, DOI 10.1007/s00417-009-1220-5
   Wojtkowski M, 2004, OPT EXPRESS, V12, P2404, DOI 10.1364/OPEX.12.002404
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu H, 2016, INVEST OPHTH VIS SCI, V57, P4464, DOI 10.1167/iovs.16-19603
   Xu J, 2015, BRIT J OPHTHALMOL, V99, P1315, DOI 10.1136/bjophthalmol-2014-306010
   Yang Y, 2016, INVEST OPHTH VIS SCI, V57, P6020, DOI 10.1167/iovs.16-19542
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
   Yarmohammadi A, 2016, OPHTHALMOLOGY, V123, P2498, DOI 10.1016/j.ophtha.2016.08.041
   Yarmohammadi A, 2016, INVEST OPHTH VIS SCI, V57, pOCT451, DOI 10.1167/iovs.15-18944
   Yeung L, 2009, OPHTHALMOLOGY, V116, P1158, DOI 10.1016/j.ophtha.2008.12.063
   Yousefi S, 2014, PHYS MED BIOL, V59, P6693, DOI 10.1088/0031-9155/59/22/6693
   Yousefi S, 2011, IEEE T BIO-MED ENG, V58, DOI 10.1109/TBME.2011.2152839
   Yu J, 2016, INVEST OPHTH VIS SCI, V57, pOCT204, DOI 10.1167/iovs.15-18630
   Yu PK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135151
   Zahid S, 2016, INVEST OPHTH VIS SCI, V57, P4940, DOI 10.1167/iovs.16-19656
   Zhang AQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.10.100901
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang GL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0080969, 10.1371/journal.pone.0063486, 10.1371/journal.pone.0059428, 10.1371/journal.pone.0064689, 10.1371/journal.pone.0059254]
   Zhang M, 2016, INVEST OPHTH VIS SCI, V57, P5101, DOI 10.1167/iovs.16-19776
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
   Zhang QQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22017
   Zhang QQ, 2015, RETINA-J RET VIT DIS, V35, P2285, DOI 10.1097/IAE.0000000000000840
   Zotter S, 2011, OPT EXPRESS, V19, P1217, DOI 10.1364/OE.19.001217
NR 279
TC 447
Z9 465
U1 31
U2 205
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2017
VL 60
BP 66
EP 100
DI 10.1016/j.preteyeres.2017.07.002
PG 35
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ3HN
UT WOS:000412621500004
PM 28760677
OA Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Lindner, M
   Nadal, J
   Mauschitz, MM
   Luning, A
   Czauderna, J
   Pfau, M
   Schmitz-Valckenberg, S
   Holz, FG
   Schmid, M
   Fleckenstein, M
AF Lindner, Moritz
   Nadal, Jennifer
   Mauschitz, Matthias M.
   Luening, Anna
   Czauderna, Joanna
   Pfau, Maximilian
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Schmid, Matthias
   Fleckenstein, Monika
TI Combined Fundus Autofluorescence and Near Infrared Reflectance as
   Prognostic Biomarkers for Visual Acuity in Foveal-Sparing Geographic
   Atrophy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE geographic atrophy; foveal sparing; age-related macular degeneration;
   AMD; natural history; visual function
ID RETINAL-PIGMENT EPITHELIUM; SCANNING LASER OPHTHALMOSCOPE; AGE-RELATED
   MACULOPATHY; BEAVER DAM EYE; MACULAR DEGENERATION; PROGRESSION; DISEASE;
   PERIMETRY; CONE; IDENTIFICATION
AB PURPOSE. To identify predictors of best corrected visual acuity (BCVA) in eyes with fovealsparing geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
   METHODS. Best corrected visual acuity (Early Treatment Diabetic Retinopathy Study charts); serial fundus autofluorescence; and near-infrared reflectance images of patients participating in the FAM (NCT00393692) and DSGA (NCT02051998) studies were analyzed. The sizes of GA and spared fovea, and the minimal linear dimension of intact retinal pigment epithelium ("bridge'') between the residual foveal island and the surrounding retina were quantified and associations with BCVA were assessed by local regression curves and mixed effects models.
   RESULTS. A total of 65 eyes (51 patients, aged 75.68 6 8.41 years) were included. Median time between baseline and last visit with detectable foveal sparing was 18 (quartiles: 12, 33) months. Median BCVA was 0.30 (0.20, 0.52) logMAR at baseline and 0.4 (0.3, 0.7) logMAR at follow-up. Local regression curves suggested no linear association of BCVA with GA size, sparing size or bridge size. Most contrasting values for BCVA were observed for >1.5 mm(2) foveal-sparing size and for 400 lm bridge size. Employing these values as cutoff levels, mixed effects modeling revealed that both anatomic parameters, but not time, significantly impacted BCVA.
   CONCLUSIONS. During the review period eyes with foveal-sparing GA were likely to maintain the baseline BCVA. There was no linear correlation of BCVA with foveal-sparing size. Yet, BCVA was worse if the spared foveal area was <1.5 mm(2) or if the bridge was smaller than 400 lm in width. These findings add to the understanding of the natural history of foveal-sparing GA and may support future clinical trial designs.
C1 [Lindner, Moritz; Mauschitz, Matthias M.; Luening, Anna; Czauderna, Joanna; Pfau, Maximilian; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Lindner, Moritz] Univ Oxford, Nuffield Lab Ophthalmol, Sleep & Circadian Neurosci Inst, Nuffield Dept Clin Neurosci, Oxford, England.
   [Nadal, Jennifer; Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
C3 University of Bonn; University of Oxford; University of Bonn
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.; Schmid, M (通讯作者)，Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
EM matthias.schmid@imbie.uni-bonn.de; Monika.Fleckenstein@ukb.uni-bonn.de
RI Pfau, Maximilian/N-1888-2019; Lindner, Moritz/AAC-8639-2021
OI Pfau, Maximilian/0000-0001-9761-9640; Lindner,
   Moritz/0000-0002-4416-3421; Fleckenstein, Monika/0000-0001-8321-8037;
   Schmid, Matthias/0000-0002-0788-0317
FU BONFOR GEROK Program, Faculty of Medicine, University of Bonn
   [O-137.0020, O-137.0022]; DFG [Ho1926/3-1, FL 658/4-1, FL 658/4-2]
FX Supported by BONFOR GEROK Program, Faculty of Medicine, University of
   Bonn, Grant Nos. O-137.0020 (ML) and O-137.0022 (MP); DFG Grant
   Ho1926/3-1, DFG Grant FL 658/4-1, and FL 658/4-2 Genentech, Inc. (San
   Francisco, CA, USA). ML is the Knoop Junior Research Fellow at St. Cross
   College, Oxford, UK. The authors alone are responsible for the content
   and writing of the paper.
CR Allingham MJ, 2016, INVEST OPHTH VIS SCI, V57, P2283, DOI 10.1167/iovs.15-19008
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   Cellular FDA Tissue and Gene Therapies Advisory Committee, 2011, CTGTAC M 52 CELL GEN
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   de Laat P, 2013, OPHTHALMOLOGY, V120, P2684, DOI 10.1016/j.ophtha.2013.05.013
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DEMONASTERIO FM, 1985, INVEST OPHTH VIS SCI, V26, P289
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Forte R, 2013, RETINA-J RET VIT DIS, V33, P482, DOI 10.1097/IAE.0b013e318276e11e
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   GREENSTEIN VC, 1989, INVEST OPHTH VIS SCI, V30, P1732
   HART WM, 1983, OPHTHALMOLOGY, V90, P1028
   HAYREH SS, 1983, INT OPHTHALMOL, V6, P85, DOI 10.1007/BF00127636
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   International Council of Ophthalmology, 1984, VIS AC MEAS STAND
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Loader C., 2006, LOCAL REGRESSION LIK
   Okano K, 2012, J NEUROCHEM, V121, P146, DOI 10.1111/j.1471-4159.2012.07647.x
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2015, INVEST OPHTH VIS SCI, V56, P5246, DOI 10.1167/iovs.14-15114
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Snodderly DM, 2002, INVEST OPHTH VIS SCI, V43, P2815
   Sunness JS, 2008, J VISUAL IMPAIR BLIN, V102, P600
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1999, MOL VIS, V5
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   TAKAHASHI N, 1991, JPN J OPHTHALMOL, V35, P292
   van Huet RAC, 2014, INVEST OPHTH VIS SCI, V55, P7467, DOI 10.1167/iovs.13-13825
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   WEITER JJ, 1988, AM J OPHTHALMOL, V106, P286, DOI 10.1016/0002-9394(88)90363-7
NR 49
TC 23
Z9 23
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2017
VL 58
IS 6
SI SI
BP BIO61
EP BIO67
DI 10.1167/iovs.16-21210
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EZ3EI
UT WOS:000404593000008
PM 28475704
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, J
   Zheng, JS
   Wang, ZM
   Li, H
   Deng, MH
AF Wang, Jun
   Zheng, Jiashun
   Wang, Zengmiao
   Li, Hao
   Deng, Minghua
TI Inferring Gene-Disease Association by an Integrative Analysis of eQTL
   Genome-Wide Association Study and Protein-Protein Interaction Data
SO HUMAN HEREDITY
LA English
DT Article
DE Data integration; Disease-associated gene; Hidden Markov random field
AB Objectives: Genome-wide association studies (GWASs) have revealed many candidate SNPs, but the mechanisms by which these SNPs influence diseases are largely unknown. In order to decipher the underlying mechanisms, several methods have been developed to predict disease-associated genes based on the integration of GWAS and eQTL data (e.g., Sherlock and COLOC). A number of studies have also incorporated information from gene networks into GWAS analysis to reprioritize candidate genes. Methods: Motivated by these two different approaches, we have developed a statistical framework to integrate information from GWAS, eQTL, and protein-protein interaction (PPI) data to predict disease-associated genes. Our approach is based on a hidden Markov random field (HMRF) model, and we called the resulting computational algorithm GeP-HMRF (a GWAS-eQTL-PPI-based HMRF). Results: We compared the performance of GeP-HMRF with Sherlock, COLOC, and NetWAS methods on 9 GWAS datasets, using the disease-related genes in the MalaCards database as the standard, and found that GeP-HMRF significantly improves the prediction accuracy. We also applied GeP-HMRF to an age-related macular degeneration disease (AMD) dataset. Among the top 50 genes predicted by GeP-HMRF, 7 are reported by the MalaCards database to be AMD-related with an enrichment p value of 3.61 x 10(-119). Among the top 20 genes predicted by GeP-HMRF, CFHR1, CGHR3, HTRA1, and CFH are AMD-related in the MalaCards database, and another 9 genes are supported by the literature. Conclusions: We built a unified statistical model to predict disease-related genes by integrating GWAS, eQTL, and PPI data. Our approach outperforms Sherlock, COLOC, and NetWAS in simulation studies and 9 GWAS datasets. Our approach can be generalized to incorporate other molecular trait data beyond eQTL and other interaction data beyond PPI. (C) 2019 S. Karger AG, Basel
C1 [Wang, Jun; Li, Hao; Deng, Minghua] Peking Univ, Ctr Quantitat Biol, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.
   [Zheng, Jiashun; Li, Hao] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.
   [Wang, Zengmiao] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
   [Deng, Minghua] Peking Univ, Sch Math Sci, Beijing, Peoples R China.
   [Deng, Minghua] Peking Univ, Ctr Stat Sci, Beijing, Peoples R China.
C3 Peking University; University of California System; University of
   California San Francisco; University of California System; University of
   California San Diego; Peking University; Peking University
RP Li, H; Deng, MH (通讯作者)，Peking Univ, Ctr Quantitat Biol, 5 Yiheyuan Rd, Beijing 100871, Peoples R China.
EM haoli@genome.ucsf.edu; dengmh@pku.edu.cn
RI Deng, Minghua/B-1316-2012; Deng, Minghua/B-5430-2012
OI Deng, Minghua/0000-0002-9143-1898
FU National Key Basic Research project of China [2015CB910303]; National
   Key Research and Development program of China [2016YFA0502303]; National
   Natural Science Foundation of China [31471246]; China Scholarship
   Council; NIH [AG043080]; California Institute of Quantitative Biology
FX This work has been partly supported by the National Key Basic Research
   project of China (No. 2015CB910303), the National Key Research and
   Development program of China (No. 2016YFA0502303), the National Natural
   Science Foundation of China (No. 31471246), and the China Scholarship
   Council. It is also supported by NIH grant AG043080, and a grant from
   the California Institute of Quantitative Biology.
CR Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Andrieu C, 2003, MACH LEARN, V50, P5, DOI 10.1023/A:1020281327116
   Barbeira AN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03621-1
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Chen M, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001353
   Courtenay MD, 2014, THESIS
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Deng MH, 2003, J COMPUT BIOL, V10, P947, DOI 10.1089/106652703322756168
   Do R, 2013, NAT GENET, V45, P1345, DOI 10.1038/ng.2795
   Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758
   Fortune MD, 2015, NAT GENET, V47, P839, DOI 10.1038/ng.3330
   Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gamazon ER, 2015, NAT GENET, V47, P1091, DOI 10.1038/ng.3367
   Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Grassmann F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0548-0
   Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259
   Guo H, 2015, HUM MOL GENET, V24, P3305, DOI 10.1093/hmg/ddv077
   Hartwig A, 2014, INVEST OPHTH VIS SCI, V55
   He X, 2013, AM J HUM GENET, V92, P667, DOI 10.1016/j.ajhg.2013.03.022
   Hormozdiari F, 2016, AM J HUM GENET, V99, P1245, DOI 10.1016/j.ajhg.2016.10.003
   Iwayama T, 2014, J CARDIOL, V63, P344, DOI 10.1016/j.jjcc.2013.10.002
   Kang HP, 2012, DIABETOLOGIA, V55, P2205, DOI 10.1007/s00125-012-2568-3
   Kunsch H, 1995, ANN APPL PROBAB, V5, P577, DOI 10.1214/aoap/1177004696
   Lage K, 2008, P NATL ACAD SCI USA, V105, P20870, DOI 10.1073/pnas.0810772105
   Liu JZ, 2015, NAT GENET, V47, P979, DOI 10.1038/ng.3359
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Nica AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000895
   Nica AC, 2008, HUM MOL GENET, V17, pR129, DOI 10.1093/hmg/ddn285
   Oliver S, 2000, NATURE, V403, P601, DOI 10.1038/35001165
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Rappaport N., 2013, DATABASE, V12
   Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107
   Scheetz TE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058657
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Shim JE, 2017, NUCLEIC ACIDS RES, V45, pW154, DOI 10.1093/nar/gkx284
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Su Z, 2011, BIOINFORMATICS, V27, P2304, DOI 10.1093/bioinformatics/btr341
   Svendsen SG, 2014, INVEST OPHTH VIS SCI, V55
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270
   Visscher PM, 2012, AM J HUM GENET, V90, P7, DOI 10.1016/j.ajhg.2011.11.029
   Wada Y, 2001, ARCH OPHTHALMOL-CHIC, V119, P1059, DOI 10.1001/archopht.119.7.1059
   Williamson JF, 2011, GENOMICS, V98, P412, DOI 10.1016/j.ygeno.2011.08.002
   Wu MM, 2017, IEEE INT C BIOINFORM, P208, DOI 10.1109/BIBM.2017.8217651
   Wen XQ, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006646
   Yamamoto H, 2003, AM J OPHTHALMOL, V136, P572, DOI 10.1016/S0002-9394(03)00332-5
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424
NR 54
TC 6
Z9 6
U1 3
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5652
EI 1423-0062
J9 HUM HERED
JI Hum. Hered.
PY 2017
VL 83
IS 3
BP 117
EP 129
DI 10.1159/000489761
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA VH8RW
UT WOS:000456647500003
PM 30669151
OA Bronze
DA 2022-11-30
ER

PT J
AU Brandstetter, C
   Patt, J
   Holz, FG
   Krohne, TU
AF Brandstetter, Carolina
   Patt, Joshua
   Holz, Frank G.
   Krohne, Tim U.
TI Inflammasome priming increases retinal pigment epithelial cell
   susceptibility to lipofuscin phototoxicity by changing the cell death
   mechanism from apoptosis to pyroptosis
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE NLRP3 inflammasome; Age-related macular degeneration; Oxidative damage;
   Interleukin-1; C5a
ID MEDIATED PHOTOOXIDATIVE DAMAGE; NLRP3 INFLAMMASOME; MACULAR
   DEGENERATION; GROWTH-FACTOR; ALU RNA; ACTIVATION; SECRETION; IL-1-BETA;
   COMPONENT
AB Progressive death of retinal pigment epithelium (RPE) cells is a hallmark of age-related macular degeneration (AMD), the leading cause of blindness in all developed countries. Photooxidative damage and activation of the NLRP3 inflammasome have been suggested as contributing factors to this process. We investigated the effects of inflammasome activation on oxidative damage-induced RPE cell death. In primary human RPE cells and ARPE-19 cells, lipofuscin accumulated following incubation with oxidatively modified photoreceptor outer segments. Oxidative stress was induced by blue light irradiation (dominant wavelength: 448 nm, irradiance: 0.8 mW/cm(2), duration: 3 to 6 h) of lipofuscin-loaded cells and resulted in cell death by apoptosis. Prior inflammasome priming by IL-1 alpha or complement activation product C5a altered the cell death mechanism to pyroptosis and resulted in a significant increase of the phototoxic effect. Following IL-1 alpha. priming, viability 24 h after irradiation was reduced in primary RPE cells and ARPE-19 cells from 653% and 56.7% to 22.6% (p = 0.003) and 5.1% (p = 0.0002), respectively. Inflammasome-mediated IL-1 beta release occurred only in association with pyroptotic cell lysis. Inflammasome priming by conditioned media of pyroptotic cells likewise increased cell death. Suppression of inflammasome activation by inhibition of caspase-1 or cathepsins B and L significantly reduced cell death in primed cells. In summary, inflammasome priming by IL-1 alpha, C5a, or conditioned media of pyroptotic cells increases RPE cell susceptibility to photooxidative damage-mediated cell death and changes the mechanism of induced cell death from apoptosis to pyroptosis. This process may contribute to RPE degeneration in AMD and provide new targets for intervention. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Brandstetter, Carolina; Patt, Joshua; Holz, Frank G.; Krohne, Tim U.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
C3 University of Bonn
RP Krohne, TU (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM krohne@uni-bonn.de
RI Krohne, Tim/D-1497-2013; Krohne, Tim/AAG-4412-2020
OI Krohne, Tim/0000-0003-2280-925X; 
FU German Research Foundation (DFG), Bonn, Germany [KR 2863/7-1]; Pro
   Retina Foundation, Bonn, Germany [Q-037.0162]; University of Bonn, Bonn,
   Germany; BONFOR Program; SciMed Program; Bonn Graduate School of
   Neuroimmunology (BonnNI) [O-137.0014, O-137.0017, Q-611.0554]; Dr.
   Eberhard and Hilde Rudiger Foundation, Bonn, Germany [Q-037.0133]
FX The authors thank Claudine Strack, BTA, for expert technical assistance.
   The study was supported by German Research Foundation (DFG), Bonn,
   Germany, grant KR 2863/7-1; Pro Retina Foundation, Bonn, Germany, grant
   Q-037.0162; University of Bonn, Bonn, Germany, BONFOR Program, SciMed
   Program, and Bonn Graduate School of Neuroimmunology (BonnNI), grants
   O-137.0014, O-137.0017, and Q-611.0554; and Dr. Eberhard and Hilde
   Rudiger Foundation, Bonn, Germany, grant Q-037.0133 (all to TUK). The
   paper was in part presented at the 2013 annual meeting of the
   Association of Research in Vision and Ophthalmology (ARVO) in Seattle,
   Washington (Brandstetter C, Mohr LKM, Holz FG, Krohne TU. Mechanism of
   RPE cell death following activation of the NLRP3 inflammasome by
   lipofuscin photoreactivity. Invest Ophthalmol Vis Sci 2013;54:
   E-Abstract 1802).
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675
   Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891-5849(97)00007-5
   Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hornung V, 2010, EUR J IMMUNOL, V40, P620, DOI 10.1002/eji.200940185
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   Lamkanfi M, 2011, NAT REV IMMUNOL, V11, P213, DOI 10.1038/nri2936
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x
   Mohr LKM, 2015, INVEST OPHTH VIS SCI, V56, P6404, DOI 10.1167/iovs.15-16898
   OLIVER CN, 1987, J BIOL CHEM, V262, P5488
   Piccioli P, 2013, SEMIN IMMUNOL, V25, P425, DOI 10.1016/j.smim.2013.10.007
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   WARNER SJC, 1987, J IMMUNOL, V139, P1911
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150
NR 29
TC 40
Z9 42
U1 0
U2 15
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD AUG
PY 2016
VL 161
BP 177
EP 183
DI 10.1016/j.jphotobiol.2016.05.018
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DT7FZ
UT WOS:000381653800020
PM 27240191
DA 2022-11-30
ER

PT J
AU Dong, A
   Seidel, C
   Snell, D
   Ekawardhani, S
   Ahlskog, JKJ
   Baumann, M
   Shen, JK
   Iwase, T
   Tian, J
   Stevens, R
   Hackett, SF
   Stumpp, MT
   Campochiaro, PA
AF Dong, Aling
   Seidel, Christopher
   Snell, Daniel
   Ekawardhani, Savira
   Ahlskog, Julia K. J.
   Baumann, Michael
   Shen, Jikui
   Iwase, Takeshi
   Tian, Jing
   Stevens, Rebecca
   Hackett, Sean F.
   Stumpp, Michael T.
   Campochiaro, Peter A.
TI Antagonism of PDGF-BB suppresses subretinal neovascularization and
   enhances the effects of blocking VEGF-A
SO ANGIOGENESIS
LA English
DT Article
DE Age-related macular degeneration; Diabetic retinopathy; HIF-1; DARPin
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; EXPRESSION;
   MODEL; MICE; RETINOPATHY; PROTEINS; PROMOTER; DARPINS
AB Hypoxia-inducible factor-1 (HIF-1) plays an important role in retinal and subretinal neovascularization (NV). Increased levels of HIF-1 cause increased expression of vascular endothelial growth factor (VEGF-A) and current therapies for ocular NV focus on neutralizing VEGF-A, but there is mounting evidence that other HIF-1-responsive gene products may also participate. In this study, we tested the effect of a designed ankyrin repeat protein (DARPin) that selectively binds and antagonizes the hypoxia-regulated gene product PDGF-BB in three models of subretinal NV (relevant to neovascular age-related macular degeneration) and compared its effects to a DARPin that selectively antagonizes VEGF-A. Daily intraperitoneal injections of 10 mg/kg of the anti-PDGF-BB DARPin or 1 mg/kg of the anti-VEGF DARPin significantly suppressed subretinal NV from laser-induced rupture of Bruch's membrane. Injections of 1 mg/kg/day of the anti-PDGF-BB DARPin had no significant effect, but when combined with 1 mg/kg/day of the anti-VEGF-A DARPin there was greater suppression than injection of the anti-VEGF-A DARPin alone. In Vldlr (-/-) mice which spontaneously develop subretinal NV, intraocular injection of 1.85 mu g of anti-PDGF-BB or anti-VEGF-A DARPin caused significant suppression of NV and when combined there was greater suppression than with either alone. The two DARPins also showed an additive effect in Tet/opsin/VEGF double transgenic mice, a particularly severe model of subretinal NV and exudative retinal detachment. In addition, intraocular injection of 1.85 mu g of anti-PDGF-BB DARPin strongly suppressed ischemia-induced retinal NV, which is relevant to proliferative diabetic retinopathy and retinopathy of prematurity. These data demonstrate that PDGF-BB is another hypoxia-regulated gene product that along with VEGF-A contributes to ocular NV and suppression of both provides an additive effect.
C1 [Dong, Aling; Seidel, Christopher; Shen, Jikui; Iwase, Takeshi; Tian, Jing; Stevens, Rebecca; Hackett, Sean F.; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21205 USA.
   [Dong, Aling; Seidel, Christopher; Shen, Jikui; Iwase, Takeshi; Tian, Jing; Stevens, Rebecca; Hackett, Sean F.; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
   [Snell, Daniel; Ekawardhani, Savira; Ahlskog, Julia K. J.; Baumann, Michael; Stumpp, Michael T.] Mol Partners AG, Zurich, Switzerland.
   [Campochiaro, Peter A.] Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins Medicine
RP Campochiaro, PA (通讯作者)，Wilmer Eye Inst, 717 Maumenee, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
RI ekawardhani, savira/GSN-9432-2022; Iwase, Takeshi/H-8110-2015
OI Ekawardhani, Savira/0000-0002-8904-7811
FU NATIONAL EYE INSTITUTE [R01EY012609] Funding Source: NIH RePORTER; NEI
   NIH HHS [R01 EY012609, EY012609] Funding Source: Medline
CR Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962
   Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9
   Boyer DS, 2009, INVEST OPHTHALMOL VI
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Forrer P, 2003, FEBS LETT, V539, P2, DOI 10.1016/S0014-5793(03)00177-7
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kawe M, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-8
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miki K, 2009, OPHTHALMOLOGY, V116, P1748, DOI 10.1016/j.ophtha.2009.05.020
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Stahl A, 2013, ANGIOGENESIS, V16, P101, DOI 10.1007/s10456-012-9302-0
   Steiner D, 2008, J MOL BIOL, V382, P1211, DOI 10.1016/j.jmb.2008.07.085
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105
   Zimmerman T, 2006, J IMMUNOL METHODS, V314, P67, DOI 10.1016/j.jim.2006.05.012
NR 31
TC 51
Z9 58
U1 1
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0969-6970
EI 1573-7209
J9 ANGIOGENESIS
JI Angiogenesis
PD JUL
PY 2014
VL 17
IS 3
BP 553
EP 562
DI 10.1007/s10456-013-9402-5
PG 10
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA AK1XU
UT WOS:000338213400010
PM 24154861
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Cruz-Gonzalez, F
   Cieza-Borrella, C
   Valverde, GL
   Lorenzo-Perez, R
   Hernandez-Galilea, E
   Gonzalez-Sarmiento, R
AF Cruz-Gonzalez, Fernando
   Cieza-Borrella, Clara
   Lopez Valverde, Gloria
   Lorenzo-Perez, Rebeca
   Hernandez-Galilea, Emiliano
   Gonzalez-Sarmiento, Rogelio
TI CFH (rs1410996), HTRA1 (rs112000638) and ARMS2 (rs10490923) Gene
   Polymorphisms are Associated with AMD Risk in Spanish Patients
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; ARMS2; complement factor H; genetics;
   HTRA1
ID AGE-RELATED MACULOPATHY; COMPLEMENT FACTOR-H; MACULAR DEGENERATION;
   VISUAL IMPAIRMENT; FAMILIAL AGGREGATION; EXTENDED FAMILIES; CHROMOSOME
   10Q26; GENOMEWIDE-SCAN; SUSCEPTIBILITY; POPULATION
AB Purpose: Age-related macular degeneration (AMD) is the main cause of legal blindness in the western adult population. We investigated the association between SNPs located in CFH, ARMS2 and HTRA1 and AMD in Spanish patients.
   Patients and Methods: We obtained peripheral blood samples from 121 patients with a diagnosis of AMD (84 exudative and 37 atrophic) at the Department of Ophthalmology of the University Hospital of Salamanca. We took 91 subjects as a control group. We studied a single nucleotide polymorphism (SNP) in each patient for each of the genes associated with high susceptibility to developing AMD using Real-time PCR with TaqMan probes for CFH and ARMS2 polymorphisms and PCR-RFLP for HTRA1 polymorphism.
   Results: We observed a statistically significant difference between patients and controls in the distribution of CFH rs1410996 genotypes, patients homozygous for the C-allele have twice the risk of developing the disease (p = 0.010; OR = 2,176 (1.194-3.964)). The analysis of ARMS2 rs10490923 polymorphism also showed differences in allelic distribution between the case and control groups (p < 0.001). Carriers of the T-allele appear more frequently in the group of patients (p < 0.001; OR = 3.340 (1.848-6.060)). Our results also confirm significant differences in the distribution of HTRA1 rs112000638 polymorphism with an increased representation of the G-allele in the patient's group (p < 0.001; OR= 6.254(3.463-12.280)). Our study also indicates that TTGG ARMS2/HTRA1 (rs10490923/ rs112000638) haplotype increases the risk of developing AMD by 9 times.
   Conclusions: Our results show that genotypes of ARMS2 (rs10490923), HTRA1 (rs112000638) and CFH (rs1410996) polymorphisms are related to an increased risk of suffering AMD in Spanish patients.
C1 [Cruz-Gonzalez, Fernando; Lopez Valverde, Gloria; Lorenzo-Perez, Rebeca; Hernandez-Galilea, Emiliano] Univ Salamanca, Hosp Univ Salamanca, Dept Oftalmol, E-37008 Salamanca, Spain.
   [Cruz-Gonzalez, Fernando; Cieza-Borrella, Clara; Gonzalez-Sarmiento, Rogelio] Univ Salamanca, Unidad Med Mol, Dept Med, E-37008 Salamanca, Spain.
   [Gonzalez-Sarmiento, Rogelio] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, E-37008 Salamanca, Spain.
C3 University of Salamanca; University of Salamanca; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia
   Molecular y Celular del Cancer de Salamanca (IBMCC); University of
   Salamanca
RP Cruz-Gonzalez, F (通讯作者)，Complejo Hosp Salamanca, Dept Oftalmol, Paseo San Vicente 58, Salamanca 37007, Spain.
EM cruzgonzalez.fernando@gmail.com
RI Gonzalez-Sarmiento, Rogelio/V-5526-2019
OI Gonzalez-Sarmiento, Rogelio/0000-0002-2726-6795; Cieza-Borrella,
   Clara/0000-0003-2739-1040
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Assink JJM, 2005, OPHTHALMOLOGY, V112, P482, DOI 10.1016/j.ophtha.2004.10.035
   BANKS CN, 1986, AUST NZ J OPHTHALMOL, V14, P263, DOI 10.1111/j.1442-9071.1986.tb00047.x
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gorin MB, 1999, MOL VIS, V5, pU31
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Shastry BS, 2006, OPHTHALMOLOGICA, V220, P291, DOI 10.1159/000094617
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 42
TC 7
Z9 7
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD JUN
PY 2014
VL 35
IS 2
BP 68
EP 73
DI 10.3109/13816810.2013.781193
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA AH2AM
UT WOS:000335923100002
PM 23534868
DA 2022-11-30
ER

PT J
AU Querques, G
   Thi, HCT
   Forte, R
   Querques, L
   Bandello, F
   Souied, EH
AF Querques, Giuseppe
   Thi Ha Chau Tran
   Forte, Raimondo
   Querques, Lea
   Bandello, Francesco
   Souied, Eric H.
TI Anatomic response of occult choroidal neovascularization to intravitreal
   ranibizumab: a study by indocyanine green angiography
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Fluorescein angiography; Indocyanine angiography; Optical coherence
   tomography; Ranibizumab
ID MACULAR DEGENERATION; LASER PHOTOCOAGULATION; VIDEOANGIOGRAPHY; TRIAL;
   MORPHOLOGY; MEMBRANES
AB To investigate changes in indocyanine green angiography (ICGA) features of occult choroidal neovascularization (CNV) after intravitreal ranibizumab injections.
   We reviewed the charts of all consecutive patients with newly diagnosed occult CNV secondary to age-related macular degeneration (AMD) treated by intravitreal ranibizumab. In all patients, optical coherence tomography (OCT) and ICGA were performed at baseline, after 3 months and 12 months.
   Fifty-one eyes of 44 patients (ten males, 34 females, mean age 77.8 +/- 7.3 years) were included. Mean follow-up was 20.3 +/- 6.2 months. During the first 12 months, patients received 5.5 +/- 2.7 intravitreal ranibizumab injections. When compared with baseline, best-corrected visual acuity (BCVA) significantly improved at the 3-month follow-up visit (60.5 +/- 22.0 vs 50.9 +/- 20.7 letters, p = 0.04), and stabilized at 12-month visit (55.7 +/- 18.2 letters; p = 0.05). Central macular thickness (CMT) significantly improved during follow-up (229.0 +/- 54.7 mu m vs 281.0 +/- 61.3 mu m at baseline, p = 0.003). An overall stabilization was observed on ICGA in both the lesion area (5.27 +/- 3.9 mm(2) at baseline vs 4.60 +/- 3.5 mm(2) at month 12, p = 0.4), and greatest linear dimension (GLD 2.66 +/- 1.2 mm at baseline vs 2.55 +/- 1.0 mm at month 12, p = 0.3). Eight eyes (15.7%) showed CNV growth on ICGA (lesion area 3.98 +/- 3.2 mm2 at baseline vs 4.3 +/- 2.7 mm2 at month-12, p = 0.6; GLD 2.11 +/- 1.0 mm at baseline vs 2.70 +/- 0.8 mm at month-12, p = 0.05).
   ICGA suggests that functional outcomes after intravitreal ranibizumab is related to CMT reduction rather than CNV regression.
C1 [Querques, Giuseppe; Forte, Raimondo; Querques, Lea; Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, F-94000 Creteil, France.
   [Thi Ha Chau Tran] Hop St Vincent de Paul, Dept Ophthalmol, Lille, France.
   [Querques, Lea; Bandello, Francesco] Univ Vita Salute San Raffaele, Hosp San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
RI TRAN, Thi Ha Chau/AAF-2162-2020; bandello, francesco/AAH-2405-2019
OI TRAN, Thi Ha Chau/0000-0001-9066-7092; bandello,
   francesco/0000-0003-3238-9682; Querques, Giuseppe/0000-0002-3292-9581
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Costagliola C, 2009, GRAEF ARCH CLIN EXP, V247, P1031, DOI 10.1007/s00417-009-1081-y
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Flower RW, 1997, INDOCYANINE GREEN AN, P2
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P20, DOI 10.1159/000309488
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P30, DOI 10.1159/000309489
   Hermans P, 2003, OPHTHALMOLOGE, V100, P378, DOI 10.1007/s00347-002-0742-6
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   SORENSON JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P473, DOI 10.1001/archopht.1994.01090160049021
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Submacular Surgery Trials Research Group, 2006, OPHTHALMOLOGY, V113, p279e1
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 27
TC 17
Z9 17
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2012
VL 250
IS 4
BP 479
EP 484
DI 10.1007/s00417-011-1831-5
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 916AR
UT WOS:000302069400002
PM 21964851
DA 2022-11-30
ER

PT J
AU Paimela, T
   Hyttinen, JMT
   Viiri, J
   Ryhanen, T
   Karjalainen, RO
   Salminen, A
   Kaarniranta, K
AF Paimela, Tuomas
   Hyttinen, Juha M. T.
   Viiri, Johanna
   Ryhanen, Tuomas
   Karjalainen, Reijo O.
   Salminen, Antero
   Kaarniranta, Kai
TI Celastrol regulates innate immunity response via NF-kappa B and Hsp70 in
   human retinal pigment epithelial cells
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Celastrol; Hsp70; Innate immunity; Retinal pigment epithelium; NF-kappa
   B
ID NECROSIS-FACTOR-ALPHA; MACULAR DEGENERATION; P65 SUBUNIT; BRUCHS
   MEMBRANE; CULTURED RPE; IKK COMPLEX; ACTIVATION; PHOSPHORYLATION;
   KINASE; INTERLEUKIN-6
AB Elevated nuclear factor kappa B (NF-kappa B) activity and interleukin-6 (IL-6) secretion participates in the pathology of several age and inflammatory-related diseases, including age-related macular degeneration (AMD), in which retinal pigment epithelial cells are the key target. Recent findings reveal that heat shock protein 70 (Hsp70) may affect regulation of NF-kappa B. In the current study, effects of Hsp70 expression on NF-kappa B RelA/p65 activity were evaluated in human retinal pigment epithelial cells (ARPE-19) by using celastrol, a novel anti-inflammatory compound. Anti-inflammatory properties of celastrol were determined by measuring expression levels of IL-6 and endogenous NF-kappa B levels during lipopolysaccharide (LPS) exposure by using enzyme-linked immunosorbent assays (ELISA). Cell viability was measured by MTT and LDH assay, and Hsp70 expression levels were analyzed by Western blotting. ARPE-19 cells were transfected with hsp70 small interfering RNA (siRNA) in order to attenuate Hsp70 expression and activity of NF-kappa B RelA/p65 was measured using NF-kappa B consensus bound ELISA.
   Simultaneous exposures to LPS and celastrol reduced IL-6 expression levels as well as activity of phosphorylated NF-kappa B at serine 536 (Ser536) in ARPE-19 cells when compared to LPS exposure alone. In addition, inhibition of NF-kappa B RelA/p65 activity by celastrol was attenuated when Hsp70 response was silenced by siRNA. Favorable anti-inflammatory concentrations of celastrol showed no signs of cytotoxic response. Our findings reveal that celastrol is a novel plant compound which suppresses innate immunity response in human retinal pigment epithelial cells via NF-kappa B and Hsp70 regulation, and that Hsp70 is a critical regulator of NF-kappa B. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Paimela, Tuomas; Hyttinen, Juha M. T.; Viiri, Johanna; Ryhanen, Tuomas; Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Karjalainen, Reijo O.] Univ Eastern Finland, Dept Biosci, FIN-70211 Kuopio, Finland.
   [Salminen, Antero] Univ Eastern Finland, Dept Neurol, Inst Clin Med, FIN-70211 Kuopio, Finland.
   [Salminen, Antero] Univ Eastern Finland, Dept Neurol, Kuopio Univ Hosp, FIN-70211 Kuopio, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio Univ Hosp, FIN-70211 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland; Kuopio University Hospital; University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Inst Clin Med, POB 1627, FIN-70211 Kuopio, Finland.
EM kai.kaarniranta@uef.fi
OI Kaarniranta, Kai/0000-0003-2600-8679; Hyttinen, Juha/0000-0002-3414-4032
CR Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501
   Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200
   Brod SA, 2000, INFLAMM RES, V49, P561, DOI 10.1007/s000110050632
   Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705
   Bruunsgaard H, 2003, CLIN EXP IMMUNOL, V132, P24, DOI 10.1046/j.1365-2249.2003.02137.x
   Bruunsgaard H, 2001, CURR OPIN HEMATOL, V8, P131, DOI 10.1097/00062752-200105000-00001
   Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200
   Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1
   Chung HY, 2006, ANTIOXID REDOX SIGN, V8, P572, DOI 10.1089/ars.2006.8.572
   Chung HY, 2009, AGEING RES REV, V8, P18, DOI 10.1016/j.arr.2008.07.002
   Dokladny K, 2010, CELL STRESS CHAPERON, V15, P153, DOI 10.1007/s12192-009-0129-6
   Ebihara N, 2007, OPHTHAL RES, V39, P155, DOI 10.1159/000103235
   Elner SG, 2005, INVEST OPHTH VIS SCI, V46, P4627, DOI 10.1167/iovs.05-0658
   Elner VM, 2003, EXP EYE RES, V76, P321, DOI 10.1016/S0014-4835(02)00310-X
   Gill R, 2010, FREE RADICAL BIO MED, V48, P1121, DOI 10.1016/j.freeradbiomed.2010.01.006
   Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kim DH, 2009, EUR J CLIN INVEST, V39, P819, DOI 10.1111/j.1365-2362.2009.02186.x
   Kim HJ, 2002, MECH AGEING DEV, V123, P1589, DOI 10.1016/S0047-6374(02)00094-5
   Kindzelskii AL, 2004, J GEN PHYSIOL, V124, P139, DOI 10.1085/jgp.200409062
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491
   Lawrence T, 2010, INT J BIOCHEM CELL B, V42, P519, DOI 10.1016/j.biocel.2009.12.016
   Lee JH, 2006, BIOCHEM PHARMACOL, V72, P1311, DOI 10.1016/j.bcp.2006.08.014
   Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336
   Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002
   Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000
   Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Paimela T, 2007, IMMUNOL LETT, V110, P139, DOI 10.1016/j.imlet.2007.04.008
   Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353
   Salminen A, 2008, AGEING RES REV, V7, P83, DOI 10.1016/j.arr.2007.09.002
   Salminen A, 2008, IMMUNOL LETT, V117, P9, DOI 10.1016/j.imlet.2007.12.017
   Salminen A, 2009, J CLIN IMMUNOL, V29, P397, DOI 10.1007/s10875-009-9296-6
   Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shi YZ, 2006, SHOCK, V26, P277, DOI 10.1097/01.shk.0000223134.17877.ad
   Shifera AS, 2010, BIOCHEM BIOPH RES CO, V396, P585, DOI 10.1016/j.bbrc.2010.05.012
   Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Sung B, 2010, J BIOL CHEM, V285, P11498, DOI 10.1074/jbc.M109.090209
   Tanabe K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-16
   TATE DJ, 2006, INVEST OPHTH VIS SCI, V36, P1271
   Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139
   Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009
   Viiri J, 2010, MOL VIS, V16, P1399
   Weiss YG, 2007, CRIT CARE MED, V35, P2128, DOI 10.1097/01.CCM.0000278915.78030.74
   Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200
   Wu WC, 2010, MOL VIS, V16, P1864
   Yang D, 2007, EXP EYE RES, V85, P462, DOI 10.1016/j.exer.2007.06.013
   Zhang YQ, 2007, J MOL MED-JMM, V85, P1421, DOI 10.1007/s00109-007-0251-9
NR 67
TC 32
Z9 37
U1 1
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD NOV
PY 2011
VL 64
IS 5
BP 501
EP 508
DI 10.1016/j.phrs.2011.05.027
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 833VR
UT WOS:000295913600010
PM 21683142
DA 2022-11-30
ER

PT J
AU Wang, HB
   Wittchen, ES
   Jiang, YC
   Ambati, B
   Grossniklaus, HE
   Hartnett, ME
AF Wang, Haibo
   Wittchen, Erika S.
   Jiang, Yanchao
   Ambati, Balamurali
   Grossniklaus, Hans E.
   Hartnett, M. Elizabeth
TI Upregulation of CCR3 by Age-Related Stresses Promotes Choroidal
   Endothelial Cell Migration via VEGF-Dependent and -Independent Signaling
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RHO-FAMILY GTPASES; MACULAR DEGENERATION; GROWTH-FACTOR; ACTIVATION;
   RPE; TRANSMIGRATION; THERAPY; OXIDASE; RAC
AB PURPOSE. To explore the molecular mechanisms by which the C-C chemokine receptor type 3 (CCR3) and chemokine (C-C motif) ligand 11 (CCL11) regulate choroidal endothelial cell (CEC) migration and the interactions with the vascular endothelial growth factor (VEGF) signaling pathway.
   METHODS. Human retinal sections from young and aged donor normal eyes were immunolabeled. By real-time PCR, CCR3 mRNA was measured in retinal pigmented epithelium (RPE)/choroids obtained from young and aged human donor eyes and in cultured CECs exposed to hydrogen peroxide. CCR3 ligand and CCL11- or VEGF-stimulated CEC migration was also measured in the presence of the CCR3 inhibitor or control using fluorescence microscopy. Activation of Rac1, phosphorylated Akt as a readout for phosphoinositol 3-kinase signaling, and VEGFR2 activation were measured in CECs incubated with CCL11, VEGF, or combined CCL11/VEGF.
   RESULTS. CCR3 was expressed to a greater level in older compared with that in younger human retinas or RPE/choroids. Ligand-activated CCR3 increased CEC migration, which was inhibited by the CCR3 inhibitor. Rac1 activity, p-Akt, and p-VEGFR2 were significantly increased in CECs incubated with CCL11. The CCR3 inhibitor prevented VEGF-induced CEC migration and Rac1 activation in CECs. Rac1 activity was additively increased in CECs treated with CCL11 and VEGF compared with that in cells with CCL11 or VEGF treatment alone. Ligand-activated CCR3 caused VEGFR2 phosphorylation and coimmunoprecipitation of VEGFR2 and CCR3.
   CONCLUSIONS. Activated CCR3 promotes CEC migration and Rac1 activation and causes an association with and activation of VEGFR2. Cross-talk between CCR3 and VEGF signaling exists and may be important in choroidal neovascularization in human age-related macular degeneration. (Invest Ophthalmol Vis Sci. 2011;52:8271-8277) DOI: 10.1167/iovs.11-8230
C1 [Wang, Haibo; Jiang, Yanchao; Ambati, Balamurali; Hartnett, M. Elizabeth] Univ Utah, Dept Ophthalmol, John Moran Eye Ctr, Salt Lake City, UT USA.
   [Wittchen, Erika S.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC USA.
   [Grossniklaus, Hans E.] Emory Univ, Sch Med, Dept Ophthalmol, Emory Eye Ctr, Atlanta, GA 30322 USA.
C3 Utah System of Higher Education; University of Utah; University of North
   Carolina; University of North Carolina Chapel Hill; Emory University
RP Hartnett, ME (通讯作者)，65 N Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM me.hartnett@hsc.utah.edu
FU National Eye Institute [R01 EY015130, EY017011]; NATIONAL EYE INSTITUTE
   [R01EY017011, R01EY015130, P30EY014800] Funding Source: NIH RePORTER
FX Supported in part by National Eye Institute Grants R01 EY015130 (MEH)
   and EY017011 (MEH).
CR Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P2868, DOI 10.1167/iovs.10-6608
   Barth BM, 2009, MOL CELL NEUROSCI, V41, P274, DOI 10.1016/j.mcn.2009.03.007
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   DIAS JR, BR J OPHTHA IN PRESS
   EGHOJ MS, BR J OPHTHA IN PRESS
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   Li YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017106
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miyagaki T, 2011, CANCER RES, V71, P2056, DOI 10.1158/0008-5472.CAN-10-3764
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Robitaille G, 2009, ARTHRITIS RHEUM-US, V60, P2805, DOI 10.1002/art.24765
   Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Teng TS, 2009, J CELL SCI, V122, P4150, DOI 10.1242/jcs.057109
   Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
NR 31
TC 34
Z9 41
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2011
VL 52
IS 11
BP 8271
EP 8277
DI 10.1167/iovs.11-8230
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 846MN
UT WOS:000296907700005
PM 21917937
OA Green Published
DA 2022-11-30
ER

PT J
AU Malamos, P
   Sacu, S
   Georgopoulos, M
   Kiss, C
   Pruente, C
   Schmidt-Erfurth, U
AF Malamos, Panagiotis
   Sacu, Stefan
   Georgopoulos, Michael
   Kiss, Christopher
   Pruente, Christian
   Schmidt-Erfurth, Ursula
TI Correlation of High-Definition Optical Coherence Tomography and
   Fluorescein Angiography Imaging in Neovascular Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL THICKNESS ANALYSIS; ULTRAHIGH-RESOLUTION; CHOROIDAL
   NEOVASCULARIZATION
AB PURPOSE. To correlate the morphologic characteristics of choroidal neovascular lesions (CNV) in age-related macular degeneration (AMD) using raster scanning high-definition optical coherence tomography (HD-OCT) and conventional fluorescein angiography (FA).
   METHODS. In this comparative clinical study, 37 consecutive patients with classic, minimally classic, or occult CNV; 13 patients with early AMD; and 10 age-matched healthy individuals were included. HD-OCT imaging (Topcon, Tokyo, Japan) and FA (scanning retinal ophthalmoscope; HRA2; Heidelberg Engineering, Dossenheim, Germany) were performed after a complete standardized ophthalmic examination. Only one eye of each patient was included in the study. A point-to-point correlation between HD-OCT and FA images was performed. Early and late FA images at defined locations were correlated with OCT measurements, including 3D maps, 2D single scans, a thickness linear graph, and the 3D retinal pigment epithelium (RPE) segmentation.
   RESULTS. With HD-OCT imaging used to delineate the lesion morphology, early AMD was detected as having a normal foveal contour and minimal alteration in the macular area; classic CNV as a well-defined lesion with steep margins and a crater-like configuration, occult CNV as an ill-defined, flat lesion with a convex surface; and minimally classic CNV as having classic and occult components. FA-OCT overlay images provided a significant correlation between FA patterns and OCT features such as retinal thickness (RT).
   CONCLUSIONS. 3D-OCT provided realistic anatomic maps of the retina, RPE, and RT in patients with AMD. Discrimination between the predominant CNV lesion types was achieved, and their precise shape was identified, together with information about the lesion's localization and leakage activity. (Invest Ophthalmol Vis Sci. 2009; 50: 4926-4933) DOI: 10.1167/iovs.09-3610
C1 [Malamos, Panagiotis; Sacu, Stefan; Georgopoulos, Michael; Kiss, Christopher; Pruente, Christian; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Gen Hosp Vienna, A-1090 Vienna, Austria.
C3 Medical University of Vienna
RP Sacu, S (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM stefan.sacu@meduniwien.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR Ahlers C, 2006, GRAEF ARCH CLIN EXP, V244, P1233, DOI 10.1007/s00417-006-0418-z
   Asrani S, 1997, OPHTHALMOLOGY, V104, P1145, DOI 10.1016/S0161-6420(97)30170-5
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fukuchi T, 2001, GRAEF ARCH CLIN EXP, V239, P424, DOI 10.1007/s004170100296
   Hawkins BS, 1999, MOL VIS, V5
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   MUSCAT S, 2002, INVEST OPHTH VIS SCI, V41, P1486
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schmidt-Erfurth U, 2007, INVEST OPHTH VIS SCI, V48, P1751, DOI 10.1167/iovs.06-0686
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Thylefors B, 1998, AM J OPHTHALMOL, V125, P90, DOI 10.1016/S0002-9394(99)80239-6
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
NR 19
TC 35
Z9 38
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2009
VL 50
IS 10
BP 4926
EP 4933
DI 10.1167/iovs.09-3610
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 497XE
UT WOS:000270097200053
PM 19494200
DA 2022-11-30
ER

PT J
AU Farnell, DJJ
   Hatfield, FN
   Knox, P
   Reakes, M
   Spencer, S
   Parry, D
   Harding, SP
AF Farnell, D. J. J.
   Hatfield, F. N.
   Knox, P.
   Reakes, M.
   Spencer, S.
   Parry, D.
   Harding, S. P.
TI Enhancement of blood vessels in digital fundus photographs via the
   application of multiscale line operators
SO JOURNAL OF THE FRANKLIN INSTITUTE-ENGINEERING AND APPLIED MATHEMATICS
LA English
DT Article
DE blood-vessel segmentation; digital fundus photographs; multiscale line
   operators
ID RETINAL IMAGES; SEGMENTATION; TRACKING
AB We employed multiscale line operators (MSLO) in order to segment blood vessels in digital fundus images. Separately, a median filter technique was used in order to provide results that were compared to those of the MSLO. The green channel of the colour image was used, and both sets of results were further enhanced by subsequently employing a simple "randomly seeded" region-growing algorithm. We applied this approach to two sets of retinal images, namely, the ARIA (www.eyecharity.com/aria_online/) and STARE (www.ces.clemson.edu/similar to ahoover/stare/) retinal image archives. The ARIA dataset contained colour fundus images from healthy subjects, diabetic subjects, and age-related macular degeneration (AMD) subjects. Similarly, the STARE dataset contained images from both "normal'' (i.e., healthy) and "abnormal" (i.e., diseased) eyes. Manual segmentations of the blood-vessel structure for all images in the ARIA and STARE datasets were obtained by a retinal image interpretation expert. These images were then taken to be our gold standards. Receiver operator characteristic (ROC) curves were determined and the areas under the ROC curve (AZ) were obtained. A large increase in efficiency for our MSLO algorithm was observed for the entire datasets (ARIA AZ = 0.899; STARE AZ = 0.953) compared to basic thresholding alone (ARIA AZ = 0.608; STARE = AZ 0.753). Interestingly, the simple median filter algorithm followed by region growing also performed well (ARIA AZ = 0.888; STARE AZ = 0.947). Our results compared favourably to those results of previous segmentation procedures for the STARE dataset. As expected, the best results were found for the healthy control group for ARIA and for the normal subjects for STARE. (C) 2008 The Franklin Institute. Published by Elsevier Ltd. All rights reserved.
C1 [Farnell, D. J. J.] Univ Manchester, Christie Hosp NHS Fdn Trust, Fac Med & Human Sci, Acad Dept Radiat Oncol,Div Canc Studies, Manchester M20 4BX, Lancs, England.
   [Knox, P.] Univ Liverpool, Sch Hlth Sci, Div Orthopt, Liverpool L69 3GB, Merseyside, England.
   [Reakes, M.] Univ York, Dept Phys, York YO10 5DD, N Yorkshire, England.
   [Spencer, S.; Parry, D.; Harding, S. P.] Royal Liverpool Univ Hosp Trust, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.
C3 Christie NHS Foundation Trust; Christie Hospital; University of
   Manchester; University of Liverpool; University of York - UK
RP Farnell, DJJ (通讯作者)，Univ Manchester, Christie Hosp NHS Fdn Trust, Fac Med & Human Sci, Acad Dept Radiat Oncol,Div Canc Studies, Manchester M20 4BX, Lancs, England.
EM d_j_j_farnell@yahoo.co.uk
OI Farnell, Damian/0000-0003-0662-1927; Harding, Simon/0000-0003-4676-1158
FU Clinical Eye Research Centre; St. Paul's Eye Unit; Royal Liverpool and
   Broadgreen University Hospital Trust (UK) [2806, 04/Q1502/21]; Royal
   Liverpool and Broadgreen University Hospital Trust (UK);
   Interdisciplinary Bridging Award from the University of Liverpool (UK)
FX The authors gratefully acknowledge and thank the staff of the Clinical
   Eye Research Centre, St. Paul's Eye Unit, Royal Liverpool and Broadgreen
   University Hospital Trust (UK) for their hard work and advice regarding
   the ARIA project (RLBUHT Project# 2806; LREC# 04/Q1502/21). The authors
   gratefully acknowledge and thank Hoover et al. for allowing their STARE
   dataset to be publicly available. This research has been supported by a
   research and development grant from the Royal Liverpool and Broadgreen
   University Hospital Trust (UK) and by an Interdisciplinary Bridging
   Award from the University of Liverpool (UK).
CR Cao L, 2002, ELECTRON LETT, V38, P868, DOI 10.1049/el:20020594
   CHAUDHURI S, 1989, IEEE T MED IMAGING, V8, P263, DOI 10.1109/42.34715
   Chutatape O, 1998, P ANN INT IEEE EMBS, V20, P3144, DOI 10.1109/IEMBS.1998.746160
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195
   Gang L, 2002, IEEE T BIO-MED ENG, V49, P168, DOI 10.1109/10.979356
   GOATMAN KA, P MED IM UND AN 2003, P49
   Hadley EM, 2006, LECT NOTES COMPUT SC, V4046, P626
   Hoover A, 2000, IEEE T MED IMAGING, V19, P203, DOI 10.1109/42.845178
   Jiang XY, 2003, IEEE T PATTERN ANAL, V25, P131, DOI 10.1109/TPAMI.2003.1159954
   Kirbas C, 2004, ACM COMPUT SURV, V36, P81, DOI 10.1145/1031120.1031121
   Li HQ, 2005, IEEE T BIO-MED ENG, V52, P1352, DOI 10.1109/TBME.2005.847402
   Li HQ, 2000, P ANN INT IEEE EMBS, V22, P3071, DOI 10.1109/IEMBS.2000.901530
   MARTI R, 2001, LNCS, V2082, P162
   Martinez-Perez ME, 2007, MED IMAGE ANAL, V11, P47, DOI 10.1016/j.media.2006.11.004
   Martinez-Perez ME, 1999, LECT NOTES COMPUT SC, V1679, P90
   Mendonca AM, 2006, IEEE T MED IMAGING, V25, P1200, DOI 10.1109/TMI.2006.879955
   Niemeijer M, 2004, PROC SPIE, V5370, P648, DOI 10.1117/12.535349
   PAL NR, 1993, PATTERN RECOGN, V26, P1277, DOI 10.1016/0031-3203(93)90135-J
   Pinz A, 1998, IEEE T MED IMAGING, V17, P606, DOI 10.1109/42.730405
   Ricci E, 2007, IEEE T MED IMAGING, V26, P1357, DOI 10.1109/TMI.2007.898551
   Salem NM, 2007, J FRANKLIN I, V344, P243, DOI 10.1016/j.jfranklin.2006.09.001
   SALEM NM, 2006, P IEEE INT C AC SPEE, V2, P1001
   SALEM NM, 2005, P 3 IEE INT SEM MED, P23
   Satyarthi D, 2005, INDICON 2005 PROCEEDINGS, P228
   Staal J, 2004, IEEE T MED IMAGING, V23, P501, DOI 10.1109/TMI.2004.825627
   Tolias YA, 1998, IEEE T MED IMAGING, V17, P263, DOI 10.1109/42.700738
   TRIER OD, 1995, IEEE T PATTERN ANAL, V17, P312, DOI 10.1109/34.368197
   *UK NAT DIAB RET S, 2004, ESS EL DES DIAB RET
   Vermeer KA, 2004, COMPUT BIOL MED, V34, P209, DOI 10.1016/S0010-4825(03)00055-6
   WANG Y, 1997, 31 AS C SIGN SYST CO, V2, P1700
   Wu D, 2006, IEEE T BIO-MED ENG, V53, P341, DOI 10.1109/TBME.2005.862571
   YEN JC, 1995, IEEE T IMAGE PROCESS, V4, P370, DOI 10.1109/83.366472
   Yin PY, 2002, SIGNAL PROCESS, V82, P993, DOI 10.1016/S0165-1684(02)00203-7
   Zana F, 2001, IEEE T IMAGE PROCESS, V10, P1010, DOI 10.1109/83.931095
   Zwiggelaar R, 2004, IEEE T MED IMAGING, V23, P1077, DOI 10.1109/TMI.2004.828675
   ZWIGGELAAR R, P MED IM UND AN 2002, P73
   Zwiggelaar R, 1996, P 7 BRIT MACH VIS C, P715, DOI DOI 10.5244/C.10.70
NR 37
TC 56
Z9 58
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0016-0032
EI 1879-2693
J9 J FRANKLIN I
JI J. Frankl. Inst.-Eng. Appl. Math.
PD OCT 15
PY 2008
VL 345
IS 7
BP 748
EP 765
DI 10.1016/j.jfranklin.2008.04.009
PG 18
WC Automation & Control Systems; Engineering, Multidisciplinary;
   Engineering, Electrical & Electronic; Mathematics, Interdisciplinary
   Applications
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Automation & Control Systems; Engineering; Mathematics
GA 355RS
UT WOS:000259726600004
DA 2022-11-30
ER

PT J
AU da Cruz, L
   Chen, FK
   Ahmado, A
   Greenwood, J
   Coffey, P
AF da Cruz, Lyndon
   Chen, Fred K.
   Ahmado, Ahmad
   Greenwood, John
   Coffey, Pete
TI RPE transplantation and its role in retinal disease
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE retinal pigment epithelium; transplantation; review; age-related macular
   degeneration; surgery; retinal dystrophy
ID PIGMENT EPITHELIAL-CELLS; SUBFOVEAL CHOROIDAL NEOVASCULARIZATION;
   MACULAR TRANSLOCATION SURGERY; EMBRYONIC STEM-CELLS; SCANNING LASER
   OPHTHALMOSCOPE; OPTICAL COHERENCE TOMOGRAPHY; RETROVIRAL GENE-TRANSFER;
   IN-VIVO CHARACTERIZATION; THERAPY RESTORES VISION; LONG-TERM
   PRESERVATION
AB Retinal pigment epithelial (RPE) transplantation aims to restore the subretinal anatomy and re-establish the critical interaction between the RPE and the photoreceptor, which is fundamental to sight. The field has developed over the past 20 years with advances coming from a large body of animal work and more recently a considerable number of human trials. Enormous progress has been made with the potential for at least partial restoration of visual function in both animal and human clinical work. Diseases that have been treated with RPE transplantation demonstrating partial reversal of vision loss include primary RPE dystrophies such as the merTK dystrophy in the Royal College of Surgeons (RCS) rat and in humans, photoreceptor dystrophies as well as complex retinal diseases such as atrophic and neovascular age-related macular degeneration (AMD). Unfortunately, in the human trials the visual recovery has been limited at best and full visual recovery has not been demonstrated. Autologous full-thickness transplants have been used most commonly and effectively in human disease but the search for a cell source to replace autologous RPE such as embryonic stem cells, marrow-derived stem cells, umbilical cord-derived cells as well as immortalised cell lines continues. The combination of cell transplantation with other modalities of treatment such as gene transfer remains an exciting future prospect. RPE transplantation has already been shown to be capable of restoring the subretinal anatomy and improving photoreceptor function in a variety of retinal diseases. In the near future, refinements of current techniques are likely to allow RPE transplantation to enter the mainstream of retinal therapy at a time when the treatment of previously blinding retinal diseases is finally becoming a reality. (C) 2007 Elsevier Ltd. All rights reserved.
C1 Moorfields Eye Hosp, Dept Vitreoretinal Surg, London EC1V 2PD, England.
   Inst Ophthalmol, Div Cellular Therapy, London EC1V 9EL, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP da Cruz, L (通讯作者)，Moorfields Eye Hosp, Dept Vitreoretinal Surg, 162 City Rd, London EC1V 2PD, England.
EM lyndon.dacruz@moorfields.nhs.uk
RI Ahmado, Ahmad/R-5537-2019; , Fred/B-8158-2013
OI , Fred/0000-0003-2809-9930; Coffey, Peter/0000-0002-5427-2939;
   Greenwood, John/0000-0003-4496-2984
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Abe T, 2005, CELL TRANSPLANT, V14, P799, DOI 10.3727/000000005783982549
   Abe T, 1999, TOHOKU J EXP MED, V189, P179, DOI 10.1620/tjem.189.179
   Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   ANDERSON DH, 1995, J COMP NEUROL, V360, P1, DOI 10.1002/cne.903600102
   Angunawela RI, 2005, BRIT J OPHTHALMOL, V89, P386, DOI 10.1136/bjo.2004.050716
   Arditi A, 2005, INVEST OPHTH VIS SCI, V46, P2225, DOI 10.1167/iovs.04-1198
   Arnhold S, 2006, INVEST OPHTH VIS SCI, V47, P4121, DOI 10.1167/iovs.04-1501
   Asaria RHY, 2001, OPHTHALMOLOGY, V108, P1179, DOI 10.1016/S0161-6420(01)00589-9
   Atmaca-Sonmez P, 2006, EXP EYE RES, V83, P1295, DOI 10.1016/j.exer.2006.07.013
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O
   Bellmann C, 2004, INVEST OPHTH VIS SCI, V45, P2355, DOI 10.1167/iovs.03-1090
   Berglin L, 1997, GRAEF ARCH CLIN EXP, V235, P103, DOI 10.1007/BF00941738
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2004, OPHTHALMOLOGE, V101, P886, DOI 10.1007/s00347-004-1077-2
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664
   BOULTON ME, 1982, BIRTH DEFECTS-ORIG, V18, P101
   BRAUNSTEIN RA, 1979, AM J OPHTHALMOL, V88, P652, DOI 10.1016/0002-9394(79)90660-3
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   BRESSLER SB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1176
   Bressler SB, 2004, ARCH OPHTHALMOL-CHIC, V122, P325, DOI 10.1001/archopht.122.3.325
   BRITTIS M, 1987, TRANSPLANT P, V19, P1133
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burke JM, 2006, INVEST OPHTH VIS SCI, V47, P3635, DOI 10.1167/iovs.06-0104
   BUSK M, 1992, J BIOL CHEM, V267, P5790
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Cai J, 2006, J BIOL CHEM, V281, P3604, DOI 10.1074/jbc.M507401200
   Capla JM, 2006, PLAST RECONSTR SURG, V117, P836, DOI 10.1097/01.prs.0000201459.91559.7f
   Castellarin AA, 1998, EXP EYE RES, V66, P49, DOI 10.1006/exer.1997.0404
   Castellarin AA, 1998, RETINA-J RET VIT DIS, V18, P143, DOI 10.1097/00006982-199818020-00008
   Castillo BV, 1997, EXP NEUROL, V146, P1, DOI 10.1006/exnr.1997.6534
   CASTILLO BV, 1995, CURR EYE RES, V14, P677, DOI 10.3109/02713689508998495
   Chen TC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1715, DOI 10.1001/archopht.123.12.1715
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   COFFEY PJ, 2005, SOC NEUROSCIENCE
   Crafoord S, 1999, ACTA OPHTHALMOL SCAN, V77, P247, DOI 10.1034/j.1600-0420.1999.770301.x
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   CUSTER NV, 1975, EXP EYE RES, V21, P153, DOI 10.1016/0014-4835(75)90079-2
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   daCruz L, 1996, INVEST OPHTH VIS SCI, V37, P2447
   daCruz L, 1996, AUST NZ J OPHTHALMOL, V24, P78
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2004, INVEST OPHTH VIS SCI, V45, P985, DOI 10.1167/iovs.03-0662
   Del Priore LV, 2003, INVEST OPHTH VIS SCI, V44, P4044, DOI 10.1167/iovs.02-1175
   Del Priore LV, 2003, CURR EYE RES, V26, P125, DOI 10.1076/ceyr.26.2.125.14509
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   DELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939, DOI 10.1001/archopht.1995.01100070113034
   Dougherty BE, 2005, OPTOMETRY VISION SCI, V82, P970, DOI 10.1097/01.opx.0000187844.27025.ea
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   DUNAIEF JL, 1995, HUM GENE THER, V6, P1225, DOI 10.1089/hum.1995.6.9-1225
   Duncan JL, 2003, INVEST OPHTH VIS SCI, V44, P826, DOI 10.1167/iovs.02-0438
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Durlu YK, 1997, CELL TRANSPLANT, V6, P149, DOI 10.1016/S0963-6897(96)00142-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   ELDIRINI AA, 1992, GRAEF ARCH CLIN EXP, V230, P292, DOI 10.1007/BF00176307
   Enzmann V, 2000, CURR EYE RES, V21, P530, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT530
   Enzmann V, 2003, INVEST OPHTH VIS SCI, V44, P5417, DOI 10.1167/iovs.03-0468
   Enzmann V, 2001, GRAEF ARCH CLIN EXP, V239, P445, DOI 10.1007/s004170100297
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Eurell TE, 2003, VET OPHTHALMOL, V6, P237, DOI 10.1046/j.1463-5224.2003.00300.x
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   FAWZY NF, 2006, INVEST OPHTH VIS SCI, V47, P2191
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   Fine EM, 1999, VISION RES, V39, P1039, DOI 10.1016/S0042-6989(98)00208-9
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861
   FLOOD MT, 1980, INVEST OPHTH VIS SCI, V19, P1309
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Fujikado T, 2002, AM J OPHTHALMOL, V134, P849, DOI 10.1016/S0002-9394(02)01756-7
   Gabrielian K, 1999, GRAEF ARCH CLIN EXP, V237, P241, DOI 10.1007/s004170050225
   Gabrielian K, 1999, GRAEF ARCH CLIN EXP, V237, P326, DOI 10.1007/s004170050240
   Gelisken F, 2007, GRAEF ARCH CLIN EXP, V245, P1085, DOI 10.1007/s00417-006-0524-y
   Giordano GG, 1997, J BIOMED MATER RES, V34, P87, DOI 10.1002/(SICI)1097-4636(199701)34:1<87::AID-JBM12>3.0.CO;2-M
   Girman S, 2005, VISION RES, V45, P343, DOI 10.1016/j.visres.2004.08.023
   Girman SV, 2003, VISION RES, V43, P1817, DOI 10.1016/S0042-6989(03)00276-1
   Glybina IV, 2006, ARCH OPHTHALMOL-CHIC, V124, P1593, DOI 10.1001/archopht.124.11.1593
   Gouras P, 1996, VISION RES, V36, P4121, DOI 10.1016/S0042-6989(96)00180-0
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   GOURAS P, 1992, GRAEF ARCH CLIN EXP, V230, P468, DOI 10.1007/BF00175936
   GOURAS P, 1994, GRAEF ARCH CLIN EXP, V232, P599, DOI 10.1007/BF00193120
   Gouras P, 1989, Prog Clin Biol Res, V314, P659
   Gouras P., 1983, INVEST OPHTHALMOL  S, V24, P142
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 1997, INVEST OPHTH VIS SCI, V38, P1619
   Grisanti S, 2002, JPN J OPHTHALMOL, V46, P36, DOI 10.1016/S0021-5155(01)00464-6
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   GULLAPALLI VK, 2004, T AM OPHTHAL SOC, V102, P137
   Hadlock T, 1999, TISSUE ENG, V5, P187, DOI 10.1089/ten.1999.5.187
   Hansen KA, 2003, INVEST OPHTH VIS SCI, V44, P772, DOI 10.1167/iovs.02-0091
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Haruta Masathoshi, 2005, Semin Ophthalmol, V20, P17, DOI 10.1080/08820530590921846
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Haymes SA, 2006, INVEST OPHTH VIS SCI, V47, P2739, DOI 10.1167/iovs.05-1419
   HE S, 1993, GRAEF ARCH CLIN EXP, V231, P737, DOI 10.1007/BF00919290
   HEUSSEN FM, 2006, INVEST OPHTHALMOL VI, V47
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   Ho TC, 1997, EXP EYE RES, V64, P133, DOI 10.1006/exer.1996.0199
   Hoffmann Stephan, 2005, BMC Ophthalmol, V5, P16, DOI 10.1186/1471-2415-5-16
   HSU JK, 1995, RETINA-J RET VIT DIS, V15, P43, DOI 10.1097/00006982-199515010-00009
   HU DN, 1982, BIRTH DEFECTS-ORIG, V18, P67
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Imoto Y, 2003, JPN J OPHTHALMOL, V47, P444, DOI 10.1016/S0021-5155(03)00135-7
   Ishida M, 1998, CURR EYE RES, V17, P392, DOI 10.1080/02713689808951220
   JIANG LQ, 1994, EXP EYE RES, V58, P719, DOI 10.1006/exer.1994.1069
   JIANG LQ, 1994, INVEST OPHTH VIS SCI, V35, P4300
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   Kano T, 2002, INVEST OPHTH VIS SCI, V43, P3744
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   Kiilgaard JF, 2002, ACTA OPHTHALMOL SCAN, V80, P76
   KIRCHHOF B, 2006, INVEST OPHTHALMOL VI, V47
   Kitchin J.E., 1981, AUST J OPTOM, V63, P235
   Klassen H, 2006, EXPERT OPIN BIOL TH, V6, P443, DOI 10.1517/14712598.6.5.443
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kohen L, 1997, OPHTHALMIC RES, V29, P298, DOI 10.1159/000268028
   Kondo M, 1997, INVEST OPHTH VIS SCI, V38, P1049
   KRISHNA Y, 2006, J BIOMED MAT RES A
   Kumar R, 2006, TISSUE ENG, V12, P141, DOI 10.1089/ten.2006.12.141
   Kunz D, 1998, TRANSPLANT P, V30, P2398, DOI 10.1016/S0041-1345(98)00667-8
   Lai CC, 2000, INVEST OPHTH VIS SCI, V41, P3134
   Lai CC, 1999, INVEST OPHTH VIS SCI, V40, P2141
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   LANE C, 1989, EYE, V3, P27, DOI 10.1038/eye.1989.4
   LAVAIL MM, 1992, EXP EYE RES, V55, P555, DOI 10.1016/S0014-4835(05)80168-X
   Lawrence JM, 2000, INVEST OPHTH VIS SCI, V41, P518
   Lee CJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1714
   LEGGE GE, 1992, INVEST OPHTH VIS SCI, V33, P677
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   LEWIS H, 1985, OPHTHALMOLOGY, V92, P1485
   LI L, 1991, EXP EYE RES, V52, P669, DOI 10.1016/0014-4835(91)90019-B
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   LI LX, 1988, EXP EYE RES, V47, P771, DOI 10.1016/0014-4835(88)90044-9
   Lin N, 1996, CURR EYE RES, V15, P1069, DOI 10.3109/02713689609017657
   Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   LOPEZ R, 1987, INVEST OPHTH VIS SCI, V28, P1131
   LOPEZ R, 1989, INVEST OPHTH VIS SCI, V30, P586
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   LUND RD, 2006, CELLS ISOLATED UMBIL
   MAAIJWEE KJ, 2006, BR J OPHTHALMOL
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Maguire MG, 1999, AGE RELATED MACULAR, P17
   Majji AB, 2000, GRAEF ARCH CLIN EXP, V238, P779, DOI 10.1007/s004170000132
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Marmour MF, 1998, RETINAL PIGMENT EPIT
   MARMOUR MF, 1998, REINAL PIGMENT EPITH
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   MAYERSON PL, 1985, INVEST OPHTH VIS SCI, V26, P1599
   McGill TJ, 2004, VISION RES, V44, P2559, DOI 10.1016/j.visres.2004.05.025
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   Meyer JS, 2006, STEM CELLS, V24, P274, DOI 10.1634/stemcells.2005-0059
   Meyer JS, 2004, BRAIN RES, V1014, P131, DOI 10.1016/j.brainres.2004.04.019
   Michaelides M, 2005, OPHTHALMOLOGY, V112, P1592, DOI 10.1016/j.ophtha.2005.04.004
   Michels S, 2001, Semin Ophthalmol, V16, P201, DOI 10.1076/soph.16.4.201.10298
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483
   Nandrot EF, 2006, AM J PHYSIOL-CELL PH, V290, pC1256, DOI 10.1152/ajpcell.00480.2005
   Nasir MA, 1997, BRIT J OPHTHALMOL, V81, P481, DOI 10.1136/bjo.81.6.481
   Neveu MM, 2006, DOC OPHTHALMOL, V113, P71, DOI 10.1007/s10633-006-9016-y
   Nicolini J, 2000, ACTA OPHTHALMOL SCAN, V78, P527, DOI 10.1034/j.1600-0420.2000.078005527.x
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Obata R, 2006, JPN J OPHTHALMOL, V50, P479, DOI 10.1007/s10384-006-0355-8
   Oganesian A, 1999, ARCH OPHTHALMOL-CHIC, V117, P1192
   Ogata N, 1999, GRAEF ARCH CLIN EXP, V237, P678, DOI 10.1007/s004170050296
   Ohno-Matsui K, 2006, MOL VIS, V12, P1022
   OSUSKY R, 1995, GRAEF ARCH CLIN EXP, V233, P220, DOI 10.1007/BF00183595
   Oyagi T, 2004, RETINA-J RET VIT DIS, V24, P548, DOI 10.1097/00006982-200408000-00007
   Pang JJ, 2006, MOL THER, V13, P565, DOI 10.1016/j.ymthe.2005.09.001
   Patel SD, 2003, CURR OPIN STRUC BIOL, V13, P690, DOI 10.1016/j.sbi.2003.10.007
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   PEYMAN GA, 1975, INVEST OPHTH VISUAL, V14, P707
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Pinilla I, 2005, VISION RES, V45, P635, DOI 10.1016/j.visres.2004.09.014
   Plachta N, 2004, DEVELOPMENT, V131, P5449, DOI 10.1242/dev.01420
   Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200
   Poloschek CM, 2003, EYE, V17, P159, DOI 10.1038/sj.eye.6700294
   Proulx S, 2004, EXP EYE RES, V79, P157, DOI 10.1016/j.exer.2004.03.004
   PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8
   RAYNER K, 1980, PERCEPT PSYCHOPHYS, V27, P537, DOI 10.3758/BF03198682
   Rezai KA, 2000, GRAEF ARCH CLIN EXP, V238, P352, DOI 10.1007/s004170050364
   Rezai KA, 1997, INVEST OPHTH VIS SCI, V38, P2255
   Rezai KA, 1997, EXP EYE RES, V65, P23, DOI 10.1006/exer.1997.0307
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P558, DOI 10.1007/BF00947084
   RIZZOLO LJ, 1991, CELL REGUL, V2, P939, DOI 10.1091/mbc.2.11.939
   RIZZOLO LJ, 1991, EXP EYE RES, V53, P549, DOI 10.1016/0014-4835(91)90173-C
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   Rosa RH, 1996, ARCH OPHTHALMOL-CHIC, V114, P480, DOI 10.1001/archopht.1996.01100130476025
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz A, 2001, INVEST OPHTH VIS SCI, V42, P31
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Saigo Y, 2004, INVEST OPHTH VIS SCI, V45, P1996, DOI 10.1167/iovs.03-0777
   Sauve Y, 2006, VISION RES, V46, P1459, DOI 10.1016/j.visres.2005.11.009
   Sauve Y, 2004, VISION RES, V44, P9, DOI 10.1016/j.visres.2003.08.015
   Sauve Y, 1998, EXP NEUROL, V152, P243, DOI 10.1006/exnr.1998.6849
   Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   SEATON AD, 1992, INVEST OPHTH VIS SCI, V33, P83
   SEATON AD, 1994, INVEST OPHTH VIS SCI, V35, P162
   Seeliger Mathias W., 2000, Documenta Ophthalmologica, V100, P167, DOI 10.1023/A:1002731703120
   Sheedlo H J, 1989, Prog Clin Biol Res, V314, P645
   SHEEDLO HJ, 1993, EXP EYE RES, V57, P753, DOI 10.1006/exer.1993.1183
   SHEEDLO HJ, 1989, EXP EYE RES, V48, P841, DOI 10.1016/0014-4835(89)90067-5
   SHEEDLO HJ, 1993, J NEUROSCI RES, V36, P423, DOI 10.1002/jnr.490360408
   SHENG Y, 1995, INVEST OPHTH VIS SCI, V36, P381
   SILVERMAN MS, 1990, CURR EYE RES, V9, P183, DOI 10.3109/02713689008995205
   SJAARDA RN, 1993, OPHTHALMOLOGY, V100, P1513
   Springer C, 2005, OPHTHALMOLOGY, V112, P848, DOI 10.1016/j.ophtha.2004.11.051
   Stanga P. E., 2001, International Ophthalmology, V23, P309, DOI 10.1023/A:1014434110031
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999
   Sunness JS, 2005, AM J OPHTHALMOL, V140, P1085, DOI 10.1016/j.ajo.2005.07.040
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Tanihara H, 1997, PROG RETIN EYE RES, V16, P271, DOI 10.1016/S1350-9462(96)00028-6
   Terasawa Yasuo, 2006, J Artif Organs, V9, P263, DOI 10.1007/s10047-006-0352-1
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tezel TH, 1997, CURR EYE RES, V16, P802, DOI 10.1076/ceyr.16.8.802.8981
   Thayaparan K, 2007, BRIT J OPHTHALMOL, V91, P749, DOI 10.1136/bjo.2006.109280
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1991, AM J OPHTHALMOL, V111, P1, DOI 10.1016/S0002-9394(14)76888-6
   Thompson DA, 2001, NAT GENET, V28, P123, DOI 10.1038/88828
   Thomson RC, 1996, BIOMATERIALS, V17, P321, DOI 10.1016/0142-9612(96)85570-0
   Thumann G, 2006, OPHTHALMOLOGICA, V220, P170, DOI 10.1159/000091760
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   Tschernutter M, 2006, BRIT J OPHTHALMOL, V90, P718, DOI 10.1136/bjo.2005.084897
   Tschernutter M, 2005, GENE THER, V12, P694, DOI 10.1038/sj.gt.3302460
   Tsukahara I, 2002, EXP EYE RES, V74, P255, DOI 10.1006/exer.2001.1123
   Turowski P, 2004, INVEST OPHTH VIS SCI, V45, P2786, DOI 10.1167/iovs.03-0943
   VALENTINO TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P932, DOI 10.1001/archopht.1995.01100070106033
   Valtink H, 1999, GRAEF ARCH CLIN EXP, V237, P1001, DOI 10.1007/s004170050336
   Valtink M, 1999, OPHTHALMOLOGE, V96, P648, DOI 10.1007/s003470050468
   van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2005, ESSENT OPHTHALMOL, P73
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   VANMEURS JC, 2006, INVEST OPHTHALMOL MO, V47
   Verdugo ME, 2001, CELL TRANSPLANT, V10, P317, DOI 10.3727/000000001783986710
   Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Wang F, 2002, ACTA BIOCH BIOPH SIN, V34, P643
   Wang H, 2004, EXP EYE RES, V78, P53, DOI 10.1016/j.exer.2003.09.024
   Wang H, 2001, INVEST OPHTH VIS SCI, V42, P2990
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   Wang SM, 2005, J COMP NEUROL, V491, P400, DOI 10.1002/cne.20695
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Warfvinge K, 2006, CELL TRANSPLANT, V15, P603, DOI 10.3727/000000006783981594
   Warncke B, 2004, VIRCHOWS ARCH, V444, P74, DOI 10.1007/s00428-003-0891-2
   Weichel J, 2002, OPHTHALMIC SURG LAS, V33, P340
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wenkel H, 1999, INVEST OPHTH VIS SCI, V40, P3202
   Wenkel H, 1998, INVEST OPHTH VIS SCI, V39, P1823
   Whiteley SJO, 1996, EXP NEUROL, V140, P100, DOI 10.1006/exnr.1996.0120
   Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8
   Wiencke AK, 2003, ACTA OPHTHALMOL SCAN, V81, P170, DOI 10.1034/j.1600-0420.2003.00030.x
   Williams RL, 2005, J MATER SCI-MATER M, V16, P1087, DOI 10.1007/s10856-005-4710-y
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   WONGPICHEDCHAI S, 1992, INVEST OPHTH VIS SCI, V33, P3341
   YAMAGUCHI K, 1992, JPN J OPHTHALMOL, V36, P142
   YAMAMOTO S, 1993, INVEST OPHTH VIS SCI, V34, P3068
   Ye JJ, 1998, CHINESE MED J-PEKING, V111, P736
   Yepez JB, 2003, OPHTHALMOLOGY, V110, P2262, DOI 10.1016/j.ophtha.2003.08.008
   Zaghloul KA, 2006, J NEURAL ENG, V3, P257, DOI 10.1088/1741-2560/3/4/002
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   ZARBIN MA, 1999, AGE RELATED MACULAR, P363
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
   Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
   Zhao B, 2006, BRIT J OPHTHALMOL, V90, P1052, DOI 10.1136/bjo.2006.091215
NR 327
TC 181
Z9 186
U1 2
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2007
VL 26
IS 6
BP 598
EP 635
DI 10.1016/j.preteyeres.2007.07.001
PG 38
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 239EG
UT WOS:000251501000002
PM 17920328
DA 2022-11-30
ER

PT J
AU Chen, L
   Yang, PZ
   Kijlstra, A
AF Chen, L
   Yang, PZ
   Kijlstra, A
TI Distribution, markers, and functions of retinal microglia
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Review
DE retina; microglia; neurodegeneration; inflammation; AIDS; age-related
   macular degeneration; glaucoma
ID ANTIGEN-PRESENTING CELLS; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR;
   MONOCLONAL-ANTIBODIES; IMMUNOHISTOCHEMICAL LOCALIZATION; AUTOIMMUNE
   ENCEPHALOMYELITIS; MONONUCLEAR PHAGOCYTES; NEURONAL DEGENERATION; IMMUNE
   SURVEILLANCE; LEUKOCYTE ANTIGENS
AB Retinal microglia originate from hemopoietic cells and invade the retina from the retinal margin and the optic disc, most likely via the blood vessels of the ciliary body and iris, and the retinal vasculature, respectively. The microglial precursors that appear in the retina prior to vascularization are major histocompatibility complex (MHC) class I- and II-positive and express the CD45 marker, but lack specific macrophage markers. They differentiate into ramified parenchymal microglia in the adult retina. A second category of microglial precursors, which do express specific macrophage markers, migrate into the retina along with vascular precursors. They appear around blood vessels in the adult retina and are similar to macrophages or cells of the mononuclear phagocyte series (MPS). Microglia are distributed in the outer plexiform layer (OPL), outer nuclear layer (ONL), inner plexiform layer (IPL), ganglion cell layer (GCL), and nerve fiber layer (NFL) of the primate retina. The pattern of microglial distribution in the avascular retina of the quail indicates that blood vessels are not responsible for the final location of microglia in the retina. In the human retina, microglia express MHC class 1, MHC class 11, CD45, CD68, and S-22 markers. In the rat and mouse retina, OX41, OX42, OX3, OX6, OX 18, ED I, Mac-I, F4/80, 5D4 anti-keratan sulfate, and lectins are used to recognize microglia. Microglial cells play an important role in host defense against invading microorganisms, immunoregulation, and tissue repair. During neurodegeneration, activated microglial cells participate in the phagocytosis of debris and facilitate regenerative processes. In autoimmune disease, microglia have dual functions: initiating uveoretinitis,,but also limiting subsequent inflammation. Retinal microglia may be associated with vitreoretinopathy, diabetic retinopathy, glaucoma, and age-related macular degeneration. The goal of this article was to review the present knowledge about retinal microglia and the function of retinal microglia in pathological conditions.
C1 Inst Anim Sci & Hlth, NL-8200 AB Lelystad, Netherlands.
   Sun Yat Sen Univ Med Sci, Zhongshan Ophthalm Ctr, Guangzhou, Peoples R China.
   Shenzhen Ophthalm Hosp, Shenzhen, Peoples R China.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1012 WX Amsterdam, Netherlands.
   Eye Res Inst Maastricht, Maastricht, Netherlands.
C3 Sun Yat Sen University; University of Amsterdam; Academic Medical Center
   Amsterdam; Maastricht University; Maastricht University Medical Centre
   (MUMC)
RP Kijlstra, A (通讯作者)，Inst Anim Sci & Hlth, POB 65,Edelhertweg 15, NL-8200 AB Lelystad, Netherlands.
EM a.kijlstra@id.wag-ur.nl
RI Yang, Peizeng/C-6336-2013; Chen, Ling/AAM-1821-2021
CR Akaishi K, 1998, JPN J OPHTHALMOL, V42, P357, DOI 10.1016/S0021-5155(98)00035-5
   AKIYAMA H, 1990, J NEUROIMMUNOL, V30, P81, DOI 10.1016/0165-5728(90)90055-R
   ALLIOT F, 1991, P NATL ACAD SCI USA, V88, P1541, DOI 10.1073/pnas.88.4.1541
   ASHWELL K, 1989, J COMP NEUROL, V287, P286, DOI 10.1002/cne.902870303
   ASHWELL KWS, 1989, VISUAL NEUROSCI, V2, P437, DOI 10.1017/S0952523800012335
   Becher B, 1996, GLIA, V18, P1
   Bell JE, 1998, REV NEUROL-FRANCE, V154, P816
   Berman NEJ, 1999, NEUROBIOL DIS, V6, P486, DOI 10.1006/nbdi.1999.0261
   BERTOLOTTO A, 1993, J HISTOCHEM CYTOCHEM, V41, P481, DOI 10.1177/41.4.8450191
   BOYA J, 1987, ARCH HISTOL CYTOL, V50, P223, DOI 10.1679/aohc.50.223
   BOYCOTT BB, 1981, NEUROSCIENCE, V6, P679, DOI 10.1016/0306-4522(81)90151-2
   Broderick C, 2000, INVEST OPHTH VIS SCI, V41, P2613
   CHAO CC, 1994, J IMMUNOL, V152, P1246
   Cuadros MA, 1998, PROG NEUROBIOL, V56, P173, DOI 10.1016/S0301-0082(98)00035-5
   DEGROOT CJA, 1992, GLIA, V6, P301, DOI 10.1002/glia.440060408
   deKozak Y, 1997, OCUL IMMUNOL INFLAMM, V5, P85, DOI 10.3109/09273949709085056
   DESIMONE R, 1995, J NEUROPATH EXP NEUR, V54, P175
   DIAZARAYA CM, 1995, J COMP NEUROL, V363, P53, DOI 10.1002/cne.903630106
   DiazAraya CM, 1995, GLIA, V15, P458, DOI 10.1002/glia.440150409
   DIAZARAYA CM, 1994, P AUSTR NEUROSCI SOC, V5, P119
   Dick AD, 2001, INVEST OPHTH VIS SCI, V42, P170
   Domaradzka-Pytel B, 1999, J BRAIN RES, V39, P283
   Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080
   GEHRMANN J, 1993, J NEUROIMMUNOL, V48, P189, DOI 10.1016/0165-5728(93)90191-Z
   GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832
   GOODBRAND IA, 1991, ANAT EMBRYOL, V184, P71, DOI 10.1007/BF01744263
   Gullapalli VK, 2000, GRAEF ARCH CLIN EXP, V238, P319, DOI 10.1007/s004170050359
   HAO C, 1991, INT J DEV NEUROSCI, V9, P1, DOI 10.1016/0736-5748(91)90067-V
   HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004
   HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253
   HUTCHINS KD, 1990, DEV BRAIN RES, V55, P95, DOI 10.1016/0165-3806(90)90109-C
   IMAMURA K, 1990, LAB INVEST, V63, P853
   Juedes AE, 2001, J IMMUNOL, V166, P5168, DOI 10.4049/jimmunol.166.8.5168
   KITAMURA T, 1984, J COMP NEUROL, V226, P421, DOI 10.1002/cne.902260310
   KOHNO T, 1982, JPN J OPHTHALMOL, V26, P53
   LING EA, 1982, ARCH HISTOL JAPON, V45, P37, DOI 10.1679/aohc.45.37
   LING EA, 1990, ANAT EMBRYOL, V182, P481
   Luder CGK, 1999, EXP PARASITOL, V93, P23, DOI 10.1006/expr.1999.4421
   Ma NL, 1998, INVEST OPHTH VIS SCI, V39, P2384
   Madigan MC, 1996, NEUROL RES, V18, P176
   Matsubara T, 1999, INVEST OPHTH VIS SCI, V40, P3186
   MATSUMOTO Y, 1989, IMMUNOLOGY, V66, P621
   MATTIACE LA, 1990, AM J PATHOL, V136, P1101
   McGeer PL, 2000, J NEURAL TRANSM-SUPP, P53
   MCMENAMIN PG, 1992, IMMUNOLOGY, V77, P385
   MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887
   MILES JM, 1988, J NEUROPATH EXP NEUR, V47, P579, DOI 10.1097/00005072-198811000-00001
   NAVASCUES J, 1994, J COMP NEUROL, V350, P171, DOI 10.1002/cne.903500203
   Neufeld AH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1050
   Neumann H, 2001, GLIA, V36, P191, DOI 10.1002/glia.1108
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   PEARSON HE, 1993, DEV BRAIN RES, V76, P249, DOI 10.1016/0165-3806(93)90213-T
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1991, VISUAL NEUROSCI, V7, P383, DOI 10.1017/S0952523800004879
   PENFOLD PL, 1993, J NEUROIMMUNOL, V45, P183, DOI 10.1016/0165-5728(93)90179-3
   PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5
   Pouly S, 1999, GLIA, V27, P259, DOI 10.1002/(SICI)1098-1136(199909)27:3<259::AID-GLIA7>3.0.CO;2-8
   PROVIS JM, 1995, GLIA, V14, P243, DOI 10.1002/glia.440140402
   Provis JM, 1996, PERSPECT DEV NEUROBI, V3, P213
   RICHARDSON A, 1993, GLIA, V7, P25, DOI 10.1002/glia.440070107
   ROBINSON AP, 1986, IMMUNOLOGY, V57, P239
   ROQUE RS, 1993, CURR EYE RES, V12, P285, DOI 10.3109/02713689308999475
   Rungger-Brandle E, 2000, INVEST OPHTH VIS SCI, V41, P1971
   Saadati HG, 1999, CURR EYE RES, V19, P264, DOI 10.1076/ceyr.19.3.264.5319
   Satoh J, 1995, BRAIN RES, V704, P92, DOI 10.1016/0006-8993(95)01177-3
   SUZUKI H, 1988, NEUROPATH APPL NEURO, V14, P221, DOI 10.1111/j.1365-2990.1988.tb00883.x
   THANOS S, 1993, J NEUROSCI, V13, P455
   THANOS S, 1991, NEUROSCI LETT, V127, P108, DOI 10.1016/0304-3940(91)90906-A
   THANOS S, 1993, INT J DEV NEUROSCI, V11, P671, DOI 10.1016/0736-5748(93)90054-H
   THANOS S, 1992, BRAIN RES, V588, P21, DOI 10.1016/0006-8993(92)91340-K
   THANOS S, 1992, EXP EYE RES, V55, P101, DOI 10.1016/0014-4835(92)90098-D
   TOOYAMA I, 1990, BRAIN RES, V523, P273, DOI 10.1016/0006-8993(90)91496-4
   Tran CT, 1998, NEUROPATH APPL NEURO, V24, P293, DOI 10.1046/j.1365-2990.1998.00120.x
   Tumosa N, 1997, VISUAL NEUROSCI, V14, P663, DOI 10.1017/S0952523800012621
   Tumosa N, 1996, VISUAL NEUROSCI, V13, P671, DOI 10.1017/S0952523800008567
   Velasco A, 1999, NEUROSCI LETT, V263, P101, DOI 10.1016/S0304-3940(99)00117-2
   Wang X, 2000, EXP BRAIN RES, V132, P476, DOI 10.1007/s002210000360
   Weissenbock H, 2000, BRAIN PATHOL, V10, P260, DOI 10.1111/j.1750-3639.2000.tb00259.x
   WELLER M, 1990, KLIN MONATSBL AUGENH, V196, P121, DOI 10.1055/s-2008-1046141
   WELLER M, 1990, MED HYPOTHESES, V31, P157, DOI 10.1016/0306-9877(90)90012-4
   Yang PZ, 1996, INVEST OPHTH VIS SCI, V37, P77
   Yang PZ, 2002, INVEST OPHTH VIS SCI, V43, P1488
   YOSHIOKA M, 1992, ACTA NEUROPATHOL, V84, P297
   Zeng XX, 2000, J ANAT, V196, P173, DOI 10.1046/j.1469-7580.2000.19620173.x
   Zhang J, 1997, INVEST OPHTH VIS SCI, V38, P1848
NR 85
TC 153
Z9 173
U1 1
U2 29
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD MAR
PY 2002
VL 10
IS 1
BP 27
EP 39
DI 10.1076/ocii.10.1.27.10328
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 620GT
UT WOS:000179526200002
PM 12461701
DA 2022-11-30
ER

PT J
AU Youn, J
   Choi, JH
   Lee, S
   Lee, W
   Lee, SW
   Kim, W
   Song, Y
   Tumursukh, NE
   Song, JE
   Khang, G
AF Youn, Jina
   Choi, Joo Hee
   Lee, Sumi
   Lee, Wonchan
   Lee, Seong Won
   Kim, Wooyoup
   Song, Youngeun
   Tumursukh, Nomin-Erdene
   Song, Jeong Eun
   Khang, Gilson
TI Fabrication and Evaluation of Gellan Gum/Hyaluronic Acid Hydrogel for
   Retinal Tissue Engineering Biomaterial and the Influence of Substrate
   Stress Relaxation on Retinal Pigment Epithelial Cells
SO MOLECULES
LA English
DT Article
DE gellan gum; hyaluronic acid; hydrogel; substrate stress relaxation;
   retinal pigment epithelial cells
ID INJECTABLE HYDROGEL; STEM-CELLS; DELIVERY; GUM; ALGINATE;
   DIFFERENTIATION; PROLIFERATION; IMPROVES; MODULUS; DENSITY
AB Cell therapies for age-related macular degeneration (AMD) treatment have been developed by integrating hydrogel-based biomaterials. Until now, cell activity has been observed only in terms of the modulus of the hydrogel. In addition, cell behavior has only been observed in the 2D environment of the hydrogel and the 3D matrix. As time-dependent stress relaxation is considered a significant mechanical cue for the control of cellular activities, it is important to optimize hydrogels for retinal tissue engineering (TE) by applying this viewpoint. Herein, a gellan Gum (GG)/Hyaluronic acid (HA) hydrogel was fabricated using a facile physical crosslinking method. The physicochemical and mechanical properties were controlled by forming a different composition of GG and HA. The characterization was performed by conducting a mass swelling study, a sol fraction study, a weight loss test, a viscosity test, an injection force study, a compression test, and a stress relaxation analysis. The biological activity of the cells encapsulated in 3D constructs was evaluated by conducting a morphological study, a proliferation test, a live/dead analysis, histology, immunofluorescence staining, and a gene expression study to determine the most appropriate material for retinal TE biomaterial. Hydrogels with moderate amounts of HA showed improved physicochemical and mechanical properties suitable for injection into the retina. Moreover, the time-dependent stress relaxation property of the GG/HA hydrogel was enhanced when the appropriate amount of HA was loaded. In addition, the cellular compatibility of the GG/HA hydrogel in in vitro experiments was significantly improved in the fast-relaxing hydrogel. Overall, these results demonstrate the remarkable potential of GG/HA hydrogel as an injectable hydrogel for retinal TE and the importance of the stress relaxation property when designing retinal TE hydrogels. Therefore, we believe that GG/HA hydrogel is a prospective candidate for retinal TE biomaterial.
C1 [Youn, Jina; Choi, Joo Hee; Lee, Sumi; Lee, Wonchan; Lee, Seong Won; Kim, Wooyoup; Song, Youngeun; Tumursukh, Nomin-Erdene; Song, Jeong Eun; Khang, Gilson] Jeonbuk Natl Univ, Dept Bionanotechnol & Bioconvergence Engn, Jeonju Si 54896, Jeonbuk, South Korea.
   [Khang, Gilson] Dept PolymerNano Sci & Technol, Jeonju Si 54896, Jeonbuk, South Korea.
   [Khang, Gilson] Polymer Mat Fus Res Ctr, Jeonju Si 54896, Jeonbuk, South Korea.
   [Khang, Gilson] Airlangga Univ, Dept Orthopaed & Traumatol, Surabaya 60115, Jawa Timur, Indonesia.
C3 Jeonbuk National University; Airlangga University
RP Khang, G (通讯作者)，Jeonbuk Natl Univ, Dept Bionanotechnol & Bioconvergence Engn, Jeonju Si 54896, Jeonbuk, South Korea.; Khang, G (通讯作者)，Dept PolymerNano Sci & Technol, Jeonju Si 54896, Jeonbuk, South Korea.; Khang, G (通讯作者)，Polymer Mat Fus Res Ctr, Jeonju Si 54896, Jeonbuk, South Korea.; Khang, G (通讯作者)，Airlangga Univ, Dept Orthopaed & Traumatol, Surabaya 60115, Jawa Timur, Indonesia.
EM gskhang@jbnu.ac.kr
RI lee, wonchan/GWU-6005-2022
OI Khang, Gilson/0000-0002-6452-5653
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT & Future Planning
   [2020R1A2C2103089]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, ICT & Future Planning (2020R1A2C2103089).
CR Ahmed TAE, 2015, FRONT BIOENG BIOTECH, V2, DOI 10.3389/fbioe.2014.00085
   Aizawa Y, 2012, BIOMATERIALS, V33, P5198, DOI 10.1016/j.biomaterials.2012.03.062
   Akrami H, 2011, BIOCHEM GENET, V49, P313, DOI 10.1007/s10528-010-9409-1
   [Anonymous], 1996, BIOL EVALUATION MED, V26, DOI [10.1097/00149078-199604150-00011, DOI 10.1097/00149078-199604150-00011]
   Balakrishnan B, 2005, BIOMATERIALS, V26, P6335, DOI 10.1016/j.biomaterials.2005.04.012
   Ballios BG, 2015, STEM CELL REP, V4, P1031, DOI 10.1016/j.stemcr.2015.04.008
   Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004
   Barbucci R, 2002, BIOMATERIALS, V23, P4503, DOI 10.1016/S0142-9612(02)00194-1
   Bauer A, 2017, ACTA BIOMATER, V62, P82, DOI 10.1016/j.actbio.2017.08.041
   Bonilha VL, 2014, EXP EYE RES, V126, P38, DOI 10.1016/j.exer.2013.09.015
   Boochoon KS, 2014, J BIOMECH, V47, P3237, DOI 10.1016/j.jbiomech.2014.06.021
   Breuls Roel G M, 2008, Open Orthop J, V2, P103, DOI 10.2174/1874325000802010103
   Burdick JA, 2011, ADV MATER, V23, pH41, DOI 10.1002/adma.201003963
   Chaudhuri O, 2020, NATURE, V584, P535, DOI 10.1038/s41586-020-2612-2
   Chaudhuri O, 2017, BIOMATER SCI-UK, V5, P1480, DOI 10.1039/c7bm00261k
   Chaudhuri O, 2016, NAT MATER, V15, P326, DOI [10.1038/NMAT4489, 10.1038/nmat4489]
   Chen HL, 2011, INT J BIOL MACROMOL, V48, P13, DOI 10.1016/j.ijbiomac.2010.09.019
   Claybon A, 2011, JOVE-J VIS EXP, DOI 10.3791/2563
   Daly AC, 2020, NAT REV MATER, V5, P20, DOI 10.1038/s41578-019-0148-6
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Dey K, 2019, BIOMATER SCI-UK, V7, P836, DOI 10.1039/c8bm01305e
   Dromel PC, 2020, APPL MATER TODAY, V19, DOI 10.1016/j.apmt.2020.100602
   Du HW, 2012, MACROMOL BIOSCI, V12, P952, DOI 10.1002/mabi.201100422
   Gandhi JK, 2018, ACTA BIOMATER, V67, P134, DOI 10.1016/j.actbio.2017.11.058
   Delgado ABG, 2019, TISSUE ENG PT A, V25, P799, DOI [10.1089/ten.tea.2019.0007, 10.1089/ten.TEA.2019.0007]
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hayashi K, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-017-0044
   Hertz J, 2013, ACTA BIOMATER, V9, P7622, DOI 10.1016/j.actbio.2013.04.048
   Hunt NC, 2017, ACTA BIOMATER, V49, P329, DOI 10.1016/j.actbio.2016.11.016
   Hyun H, 2019, MAR DRUGS, V17, DOI 10.3390/md17010041
   Jeong YW, 2020, FRONT MATER, V7, DOI 10.3389/fmats.2020.504642
   Kaczmarek B, 2018, INT J BIOL MACROMOL, V107, P247, DOI 10.1016/j.ijbiomac.2017.08.173
   Kim HS, 2019, INT J BIOL MACROMOL, V130, P220, DOI 10.1016/j.ijbiomac.2019.01.078
   Kim SY, 2020, J IND ENG CHEM, V89, P470, DOI 10.1016/j.jiec.2020.06.025
   Kim WK, 2019, INT J BIOL MACROMOL, V141, P51, DOI 10.1016/j.ijbiomac.2019.08.176
   Lee W, 2021, ACS APPL BIO MATER, V4, P1771, DOI 10.1021/acsabm.0c01516
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Liu LL, 2019, NPG ASIA MATER, V11, DOI 10.1038/s41427-019-0185-z
   Liu Y, 2013, TISSUE ENG PT A, V19, P135, DOI [10.1089/ten.tea.2012.0209, 10.1089/ten.TEA.2012.0209]
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lou JZ, 2018, BIOMATERIALS, V154, P213, DOI 10.1016/j.biomaterials.2017.11.004
   Matricardi P, 2009, MOLECULES, V14, P3376, DOI 10.3390/molecules14093376
   Mazumder MAJ, 2012, J BIOMED MATER RES A, V100A, P1877, DOI 10.1002/jbm.a.34021
   Nam S, 2019, BIOMATERIALS, V200, P15, DOI 10.1016/j.biomaterials.2019.02.004
   Oliveira JT, 2010, J BIOMED MATER RES A, V93A, P852, DOI 10.1002/jbm.a.32574
   Park J, 2019, CELL TRANSPLANT, V28, P596, DOI 10.1177/0963689719825614
   Parker J, 2016, BIOMACROMOLECULES, V17, P476, DOI 10.1021/acs.biomac.5b01366
   Rim MA, 2020, ACS APPL BIO MATER, V3, P6079, DOI 10.1021/acsabm.0c00672
   Shin EY, 2019, MAT SCI ENG C-MATER, V103, DOI 10.1016/j.msec.2019.109787
   Soleimannejad M, 2018, ARTIF CELL NANOMED B, V46, P805, DOI 10.1080/21691401.2017.1345922
   Stergar J, 2019, BOSNIAN J BASIC MED, V19, P130, DOI 10.17305/bjbms.2019.3778
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun Y, 2016, CHEM COMMUN, V52, P5254, DOI 10.1039/c6cc01195k
   Tang ZM, 2019, BIOMATERIALS, V194, P57, DOI 10.1016/j.biomaterials.2018.12.015
   Wen B, 2016, SCI REP-UK, V6, DOI 10.1038/srep21208
   White C, 2017, J BIOMED MATER RES A, V105, P1260, DOI 10.1002/jbm.a.35992
   White CE, 2018, J BIOMED MATER RES A, V106, P2871, DOI 10.1002/jbm.a.36476
   Yoon SJ, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9121652
   Yu AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048501
   Yu BY, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3589100
   Yu XJ, 2016, COLLOID POLYM SCI, V294, P59, DOI 10.1007/s00396-015-3797-z
   Zhuo FL, 2017, MAT SCI ENG C-MATER, V81, P1, DOI 10.1016/j.msec.2017.07.029
NR 62
TC 0
Z9 0
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD SEP
PY 2022
VL 27
IS 17
AR 5512
DI 10.3390/molecules27175512
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 4K2YM
UT WOS:000851822000001
PM 36080277
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Liu, ZP
   Mao, XX
   Yang, QH
   Zhang, XY
   Xu, JA
   Ma, Q
   Zhou, YQ
   Da, QG
   Cai, YF
   Sopeyin, A
   Dong, Z
   Hong, M
   Caldwell, RB
   Sodhi, A
   Huo, YQ
AF Liu, Zhiping
   Mao, Xiaoxiao
   Yang, Qiuhua
   Zhang, Xiaoyu
   Xu, Jiean
   Ma, Qian
   Zhou, Yaqi
   Da, Qingen
   Cai, Yongfeng
   Sopeyin, Anu
   Dong, Zheng
   Hong, Mei
   Caldwell, Ruth B.
   Sodhi, Akrit
   Huo, Yuqing
TI Suppression of myeloid PFKFB3-driven glycolysis protects mice from
   choroidal neovascularization
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE glycolysis; HIF-1 alpha; HIF-2 alpha; macrophages and microglia;
   neovascular age-related macular degeneration (nAMD); NF-kappa B; PFKFB3
ID MACULAR DEGENERATION; CONCISE GUIDE; CELLS; ANGIOGENESIS; INFLAMMATION;
   RANIBIZUMAB; MACROPHAGES; METABOLISM; IL-1-BETA; PFKFB3
AB Background and Purpose: Pathological angiogenesis is a major cause of irreversible blindness in individuals with neovascular age-related macular degeneration (nAMD). Macrophages and microglia (M Phi) contribute to aberrant ocular angiogenesis. However, the role of glucose metabolism of M Phi in nAMD is still undefined. Here, we have investigated the involvement of glycolysis, driven by the kinase/phosphatase PFKFB3, in the development of choroidal neovascularization (CNV).
   Experimental Approach: CNV was induced in mice with laser photocoagulation. Choroid/retinal pigment epithelium (RPE) complexes and M Phi were isolated for analysis by qRT-PCR, western blot, flow cytometry, immunostaining, metabolic measurements and angiogenesis assays.
   Key Results: M Phi accumulated within the CNV of murine nAMD models and expressed high levels of glycolysis-related enzymes and M1/M2 polarization markers. This phenotype of hyper-glycolytic and activated M Phi was replicated in bone marrow-derived macrophages stimulated by necrotic RPE in vitro. Myeloid cell- specific knockout of PFKFB3, a key glycolytic activator, attenuated pathological neovascularization in laser-induced CNV, which was associated with decreased expression of M Phi polarization markers and pro-angiogenic factors, along with decreased sprouting of vessels in choroid/RPE complexes. Mechanistically, necrotic RPE increased PFKFB3-driven glycolysis in macrophages, leading to activation of HIF-1 alpha/HIF-2 alpha and NF-kappa B, and subsequent induction of M1/M2 markers and pro-angiogenic cytokines, finally promoting macrophage reprogramming towards an angiogenic phenotype to facilitate development of CNV. The PFKFB3 inhibitor AZ67 also inhibited activation of HIF-1 alpha/HIF-2 alpha and NF-kappa B signalling and almost completely prevented laser-induced CNV in mice.
   Conclusions and Implications: Modulation of PFKFB3-mediated macrophage glycolysis and activation is a promising strategy for the treatment of nAMD.
C1 [Liu, Zhiping; Mao, Xiaoxiao; Da, Qingen; Hong, Mei] Peking Univ Shenzhen Grad Sch, Sch Chem Biol & Biotechnol, State Key Lab Chem Oncogen, Key Lab Chem Genom, Shenzhen, Peoples R China.
   [Liu, Zhiping; Mao, Xiaoxiao; Yang, Qiuhua; Zhang, Xiaoyu; Xu, Jiean; Ma, Qian; Zhou, Yaqi; Cai, Yongfeng; Caldwell, Ruth B.; Huo, Yuqing] Augusta Univ, Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.
   [Liu, Zhiping] Jinan Univ, Coll Pharm, Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou, Peoples R China.
   [Sopeyin, Anu; Sodhi, Akrit] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
   [Dong, Zheng; Caldwell, Ruth B.; Huo, Yuqing] Augusta Univ, Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.
   [Dong, Zheng; Caldwell, Ruth B.] Charlie Norwood Vet Affairs Med Ctr, Augusta, GA USA.
   [Caldwell, Ruth B.; Huo, Yuqing] Augusta Univ, Med Coll Georgia, James & Jean Culver Vis Discovery Inst, Augusta, GA 30912 USA.
C3 University Town of Shenzhen; University System of Georgia; Augusta
   University; Jinan University; Johns Hopkins University; Johns Hopkins
   Medicine; University System of Georgia; Augusta University; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   University System of Georgia; Augusta University
RP Liu, ZP (通讯作者)，Jinan Univ, Coll Pharm, Guangzhou 510632, Peoples R China.; Huo, YQ (通讯作者)，Augusta Univ, Med Coll Georgia, Vasc Biol Ctr, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.
EM zhiping0414@163.com; yhuo@augusta.edu
RI Zhang, xiaoyu/GXA-3206-2022; Zhang, Xiaoyu/GQQ-1959-2022
OI Sopeyin, Anuoluwapo/0000-0002-6823-6154; Yang,
   Qiuhua/0000-0002-5582-3771; Zhou, Yaqi/0000-0003-0615-6631; Liu,
   Zhiping/0000-0001-7272-6917
FU National Natural Science Foundation of China [81870324]; Shenzhen
   Science and Technology Innovation Committee Grants
   [JCYJ20190808155801648]; Shenzhen Fundamental Research Program
   [GXWD20201231165807007-20200818123312001]; Shenzhen-Hong Kong Institute
   of Brain Science-Shenzhen Fundamental Research Institutions
   [2019SHIBS0004]; National Institutes of Health [R01EY030500,
   R01EY033369, R01 EY033733]; National Eye Institute of Center Core Grant
   [P30EY031631]
FX This work is supported by National Natural Science Foundation of China
   Grant 81870324 to ZL; Shenzhen Science and Technology Innovation
   Committee Grants JCYJ20190808155801648 to MH; Shenzhen Fundamental
   Research Program GXWD20201231165807007-20200818123312001 to MH;
   Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental
   Research Institutions 2019SHIBS0004 to MH; National Institutes of Health
   Grants R01EY030500 to RC and YH, R01EY033369 to RC and YH and R01
   EY033733 to YH and RC; National Eye Institute of Center Core Grant
   P30EY031631 for Vision Research to Augusta University.
CR Alexander SPH, 2021, BRIT J PHARMACOL, V178, pS412, DOI 10.1111/bph.15543
   Alexander SPH, 2021, BRIT J PHARMACOL, V178, pS313, DOI 10.1111/bph.15542
   Alexander SPH, 2018, BRIT J PHARMACOL, V175, P407, DOI 10.1111/bph.14112
   Bonello S, 2007, ARTERIOSCL THROM VAS, V27, P755, DOI 10.1161/01.ATV.0000258979.92828.bc
   Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586-019-0969-x
   Catar R, 2013, KIDNEY INT, V84, P1119, DOI 10.1038/ki.2013.217
   Chesney J, 2005, BIOCHEM BIOPH RES CO, V331, P139, DOI 10.1016/j.bbrc.2005.02.193
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490
   Cousins SW, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002671
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037
   du Sert NP, 2020, J CEREBR BLOOD F MET, V40, P1769, DOI 10.1177/0271678X20943823
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fadl BR, 2020, MOL VIS, V26, P705
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gardiner TA, 2005, AM J PATHOL, V166, P637, DOI 10.1016/S0002-9440(10)62284-5
   Gong Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132643
   Alves CH, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051217
   Hikage F, 2021, EXP CELL RES, V403, DOI 10.1016/j.yexcr.2021.112581
   Huang SCC, 2016, IMMUNITY, V45, P817, DOI 10.1016/j.immuni.2016.09.016
   Jiang H, 2016, J IMMUNOL, V197, P2880, DOI 10.4049/jimmunol.1600474
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kovacs L, 2019, AM J RESP CRIT CARE, V200, P617, DOI 10.1164/rccm.201812-2290OC
   Kowluru RA, 2004, INVEST OPHTH VIS SCI, V45, P4161, DOI 10.1167/iovs.04-0633
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Langston PK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00061
   Lilley E, 2020, BRIT J PHARMACOL, V177, P3611, DOI 10.1111/bph.15178
   Liu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0050719, 10.1371/journal.pone.0064143, 10.1371/journal.pone.0057473]
   Liu N, 2019, J CLIN INVEST, V129, P631, DOI 10.1172/JCI123027
   Liu Y, 2019, MOL THER-NUCL ACIDS, V17, P113, DOI 10.1016/j.omtn.2019.05.012
   Liu ZP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay1371
   Liu ZP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00551-2
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846
   Otsuji T, 2013, CLIN OPHTHALMOL, V7, P1487, DOI 10.2147/OPTH.S46317
   Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008
   Palsson-McDermott EM, 2015, CELL METAB, V21, P65, DOI [10.1016/j.cmet.2014.12.005, 10.1016/j.cmet.2015.01.017]
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   REDMAN RA, 2015, J CLIN ONCOL S, V33, DOI DOI 10.1200/JCO.2015.33.15_SUPPL.TPS2606
   Rogers JL, 2013, J MED CHEM, V56, P1739, DOI 10.1021/jm301847z
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Sonveaux P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033418
   Sun HL, 2007, ONCOGENE, V26, P3941, DOI 10.1038/sj.onc.1210169
   Syed BA, 2012, NAT REV DRUG DISCOV, V11, P827, DOI 10.1038/nrd3790
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191
   Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828
   Wang LN, 2021, BRIT J PHARMACOL, V178, P1055, DOI 10.1111/bph.15339
   Wang ZH, 2020, J IMMUNOL, V204, P2232, DOI 10.4049/jimmunol.1901246
   Xu JX, 2020, J PATHOL, V251, P200, DOI 10.1002/path.5447
   Xu YM, 2017, EMBO MOL MED, V9, P1263, DOI 10.15252/emmm.201607066
   Xu YM, 2014, ARTERIOSCL THROM VAS, V34, P1231, DOI 10.1161/ATVBAHA.113.303041
   Yang QH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07132-x
   Yang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep30933
   Zhang PP, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02230-y
   Zhang YK, 2021, ADV EXP MED BIOL, V1256, P121, DOI 10.1007/978-3-030-66014-7_5
NR 60
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2022
VL 179
IS 22
BP 5109
EP 5131
DI 10.1111/bph.15925
EA AUG 2022
PG 23
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 5H1VB
UT WOS:000839356300001
PM 35830274
DA 2022-11-30
ER

PT J
AU Chuan, J
   Liu, LQ
   Feng, YM
   Wang, MD
   Li, G
   Lv, Q
AF Chuan, Junlan
   Liu, Lianqiao
   Feng, Yumei
   Wang, Mengdan
   Li, Gang
   Lv, Qin
TI The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A
   Systematic Review and Meta-Analysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE neovascular age-related macular degeneration; brolucizumab; efficacy;
   safety; meta-analysis
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; PATHOGENESIS;
   RANIBIZUMAB
AB Introduction: As demonstrated in pivotal clinical trials, brolucizumab can be used to treat neovascular age-related macular degeneration (nAMD) because it antagonizes vascular endothelial growth factor (VEGF) in the vitreous. However, brolucizumab may cause retinal vasculitis obliterans in the presence of inflammation in the eyes. In the present study, a meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the efficacy and safety of brolucizumab. Methods: ., Embase, Cochrane Library, and PubMed were retrieved from inception until 31 December 2021 for RCTs assessing the efficacy and safety of brolucizumab. Changes in best corrected visual acuity (BCVA) and central sub-field thickness (CSFT) and incidence of adverse events, serious adverse events, and serious ocular adverse events were extracted from eligible RCTs. A meta-analysis was performed using RevMan 5.4.1. Results: A total of six RCTs with 3,574 participants were finally involved in this meta-analysis. The changes of best corrected visual acuity (BCVA) showed no statistically significant difference between the brolucizumab-treated group and aflibercept-treated group. Brolucizumab induced higher central sub-field thickness (CSFT) reduction than the control agent (aflibercept). The incidence of adverse events was similar between the brolucizumab group and control group (OR 0.63, 95% CI 0.37 to 1.08, p = 0.09), and brolucizumab caused fewer serious adverse events (OR 0.78, 95% CI 0.63 to 0.95, p = 0.01). However, brolucizumab could lead to more serious ocular adverse events than Lucentis and aflibercept (OR 2.15, 95% CI 1.11 to 4.16, p = 0.02). Conclusion: Brolucizumab was non-inferior to other anti-VEGF agents in improving BCVA and decreasing CSFT. But it caused more serious ocular adverse events which is worthy of special attention by ophthalmologists.
C1 [Chuan, Junlan; Liu, Lianqiao; Wang, Mengdan; Li, Gang] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Sch Med, Chengdu, Peoples R China.
   [Chuan, Junlan; Liu, Lianqiao; Wang, Mengdan; Li, Gang] Univ Elect Sci & Technol China, Sch Med, Personalized Drug Therapy Key Lab Sichuan Prov, Chengdu, Peoples R China.
   [Feng, Yumei] Mianyang Peoples Hosp, Dept Pharm, Mianyang, Peoples R China.
   [Li, Gang] Traff Hosp Sichuan Prov, Chengdu, Peoples R China.
   [Lv, Qin] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Sch Med, Chengdu, Peoples R China.
C3 Sichuan Provincial People's Hospital; University of Electronic Science &
   Technology of China; University of Electronic Science & Technology of
   China; Sichuan Provincial People's Hospital; University of Electronic
   Science & Technology of China
RP Chuan, J; Li, G (通讯作者)，Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Sch Med, Chengdu, Peoples R China.; Chuan, J; Li, G (通讯作者)，Univ Elect Sci & Technol China, Sch Med, Personalized Drug Therapy Key Lab Sichuan Prov, Chengdu, Peoples R China.; Li, G (通讯作者)，Traff Hosp Sichuan Prov, Chengdu, Peoples R China.; Lv, Q (通讯作者)，Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sichuan Acad Med Sci, Sch Med, Chengdu, Peoples R China.
EM chuanjunlan@foxmail.com; ligang7498@126.com; lvqin@126.com
FU National Natural Science Foundation of China [82101163]; Department of
   Science and Technology of Sichuan Province of China [2021YFS0388,
   2019YFS0514]; Clinical Research Foundation of Sichuan Provincial
   People's Hospital [2021LY23]; National Precision Medicine Project
   [2020YFC2005506]
FX Our work was funded by the National Natural Science Foundation of China
   (82101163), the Department of Science and Technology of Sichuan Province
   of China (2021YFS0388 and 2019YFS0514), the Clinical Research Foundation
   of Sichuan Provincial People's Hospital (2021LY23), and the National
   Precision Medicine Project (2020YFC2005506).
CR [Anonymous], 2020, AUST PRESCR, V43, P133, DOI 10.18773/austprescr.2020.045
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   ClinicalTrialsgov, 2013, EFF SAF STUD ESBA100
   ClinicalTrialsgov, 2017, STUD SAF EFF BROL 6
   ClinicalTrialsgov, 2020, EFF SAF RTH258 VERS
   ClinicalTrialsgov, 2021, EFF SAF RTH258 VERS
   ClinicalTrialsgov, 2015, SAF PHARM ETH258 SUB
   ClinicalTrialsgov, 2016, ESBA1008 SAF TOL EFF
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Desideri LF, 2021, EXPERT OPIN BIOL TH, V21, P553, DOI 10.1080/14712598.2021.1915278
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Georges A., 2014, ROM J OPHTHALMOL, V59, P74
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Hussain RM, 2021, DRUG DES DEV THER, V15, P2653, DOI 10.2147/DDDT.S295223
   Khanani AM, 2022, JAMA OPHTHALMOL, V140, P20, DOI 10.1001/jamaophthalmol.2021.4585
   Luu KT, 2022, J CLIN PHARMACOL, V62, P594, DOI 10.1002/jcph.2002
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Motevasseli T, 2021, J OPHTHAL VIS RES, V16, P670, DOI 10.18502/jovr.v16i4.9757
   Nguyen HV, 2022, EUR J OPHTHALMOL, V32, P2747, DOI 10.1177/11206721211059332
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Rahman EZ, 2020, DRUG TODAY, V56, P699, DOI 10.1358/dot.2020.56.11.3199812
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Tadayoni R, 2021, OPHTHALMOLOGICA, V244, P93, DOI 10.1159/000513048
   Tano Y, 2010, ACTA OPHTHALMOL, V88, P309, DOI 10.1111/j.1755-3768.2009.01843.x
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Yu JS, 2021, J MANAG CARE SPEC PH, V27, P743, DOI 10.18553/jmcp.2021.27.6.743
   Zhang Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.797108
NR 32
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 13
PY 2022
VL 13
AR 890732
DI 10.3389/fphar.2022.890732
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 1V5ZS
UT WOS:000806168000001
PM 35645802
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Giloyan, A
   Muradyan, D
   Khachadourian, V
AF Giloyan, Aida
   Muradyan, Diana
   Khachadourian, Vahe
TI Visual impairment and associated risk factors in patients with diabetes
   mellitus in Tavush and Armavir provinces of Armenia
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Visual impairment; Patients with diabetes; Diabetes duration; Diabetic
   retinopathy; Risk factors
ID VISION IMPAIRMENT; GLOBAL PREVALENCE; RETINOPATHY; BLINDNESS;
   PROJECTIONS; DISTANCE; TRENDS
AB Background Visual impairment (VI) and blindness remain serious public health problems among patients with diabetes. This study assessed the prevalence of VI and its associated risk factors in individuals with diabetes mellitus (DM) in Armenia. Methods This cross-sectional study recruited 1287 people with DM. All participants underwent comprehensive ophthalmic examination and responded to a structured questionnaire on sociodemographic and health characteristics, health-seeking behavior, and ocular health. The presence of eye diseases and VI was defined based on the International Classification of Diseases-11. Descriptive statistics and logistic regression were used to address the study objectives. Results The mean age of participants was 61.5 (SD = 9.6) ranging from 19.4 to 99.8 years. The mean duration of diabetes was 7.4 years. The majority of participants (70.5%) were women. The prevalence of VI and blindness was 12.1% and 0.9%, respectively. Overall, 22.4% of participants had diabetic retinopathy. In the adjusted analysis, advanced age (OR = 1.08; 95%CI: 1.06-1.11), higher education (OR = 0.37; 95%CI: 0.19-0.74), diabetes duration (OR = 1.05; 95%CI: 1.02-1.08), the presence of diabetic retinopathy (OR = 3.61; 95%CI: 2.38-5.46), age-related macular degeneration (OR = 1.88; 95%CI: 1.15-3.05), cataract (OR = 2.45; 95%CI: 1.66-3.63), and glaucoma (OR = 2.32; 95%CI: 1.25-4.30) were associated with VI. Conclusion The findings highlight the importance and need for regular eye screening and diabetes prevention programs in the country. Continuous educational programs on diabetes self-management among patients with DM can reduce complications of diabetes including vision loss due to diabetes.
C1 [Giloyan, Aida] Amer Univ Armenia, Turpanjian Sch Publ Hlth, Garo Meghrigian Inst Prevent Ophthalmol, 40 Marshal Baghramian Ave, Yerevan 0019, Armenia.
   [Muradyan, Diana; Khachadourian, Vahe] Amer Univ Armenia, Turpanjian Sch Publ Hlth, 40 Marshal Baghramian Ave, Yerevan 0019, Armenia.
RP Giloyan, A (通讯作者)，Amer Univ Armenia, Turpanjian Sch Publ Hlth, Garo Meghrigian Inst Prevent Ophthalmol, 40 Marshal Baghramian Ave, Yerevan 0019, Armenia.
EM aida@aua.am; dmuradyan@aua.am; vkhachadourian@aua.am
OI Giloyan, Aida/0000-0002-9094-9433
CR Al-Rubeaan K, 2015, ACTA OPHTHALMOL, V93, pE140, DOI 10.1111/aos.12532
   Al-Till MI, 2005, EUR J OPHTHALMOL, V15, P62, DOI 10.1177/112067210501500110
   Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS67, DOI [10.2337/dc11-S062, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc10-S062]
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   [Anonymous], EUROPEAN HLTH INFORM
   Ayukotang, 2016, INT J INNOV APPL STU, V15, P872
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32
   Cheloni R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022188
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Coyne KS, 2004, FAM PRACT, V21, P447, DOI 10.1093/fampra/cmh417
   Cui Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11365-z
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Giloyan A, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0032-0
   Harding S, 2003, DIABETIC MED, V20, P965, DOI 10.1111/j.1464-5491.2003.01077.x
   Hashemi H, 2018, J CURR OPHTHALMOL, V30, P161, DOI 10.1016/j.joco.2017.01.003
   Hayward LM, 2002, DIABETIC MED, V19, P27, DOI 10.1046/j.0742-3071.2001.00603.x
   Hosmer DW, 2013, WILEY SER PROBAB ST, P89
   International Diabetes Federation, 2017, ATL 8 GLOB FACTS
   Kahloun R, 2014, EYE, V28, P986, DOI 10.1038/eye.2014.131
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   Leasher JL, 2016, DIABETES CARE, V39, P1643, DOI 10.2337/dc15-2171
   Li JQ, 2020, EUR J EPIDEMIOL, V35, P11, DOI 10.1007/s10654-019-00560-z
   Lloyd A, 2001, Value Health, V4, P392, DOI 10.1046/j.1524-4733.2001.45029.x
   Mvitu MM, 2012, AFR HEALTH SCI, V12, P193, DOI 10.4314/ahs.v12i2.18
   Narayan KMV, 2000, DIABETES RES CLIN PR, V50, pS77
   Nutheti R, 2007, OPHTHALMOLOGY, V114, P1552, DOI 10.1016/j.ophtha.2006.11.012
   Ong SR, 2018, EYE, V32, P1296, DOI 10.1038/s41433-018-0081-8
   Rani PK, 2012, MIDDLE EAST AFR J OP, V19, P129, DOI 10.4103/0974-9233.92129
   Robinson BE, 2011, RISK FACTORS VISUAL, P52
   Ruta LM, 2013, DIABETIC MED, V30, P387, DOI 10.1111/dme.12119
   Senra H, 2015, OPHTHALMOLOGY, V122, P851, DOI 10.1016/j.ophtha.2014.10.022
   SIVAPRASAD S, 2012, PLOS ONE, V7
   Thomas RL, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107840
   Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816
   Welp A, 2016, MAKING EYE HLTH POPU
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   World Health Organization, BLINDN VIS IMP
   World Health ORGANIZATION, BLINDNESS
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yang QH, 2019, INT J OPHTHALMOL-CHI, V12, P302, DOI 10.18240/ijo.2019.02.19
   Zhang LY, 2001, DIABETES CARE, V24, P1275, DOI 10.2337/diacare.24.7.1275
   Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8
   Zoega GM, 2005, ACTA OPHTHALMOL SCAN, V83, P687, DOI 10.1111/j.1600-0420.2005.00541.x
NR 46
TC 0
Z9 0
U1 1
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD JAN
PY 2022
VL 42
IS 1
BP 47
EP 56
DI 10.1007/s10792-021-01998-5
EA AUG 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YQ0CA
UT WOS:000684077800002
PM 34379291
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Battista, M
   Vella, G
   Grosso, D
   Sacconi, R
   Querques, L
   Zucchiatti, I
   Prascina, F
   Bandello, F
   Querques, G
AF Borrelli, Enrico
   Battista, Marco
   Vella, Giovanna
   Grosso, Domenico
   Sacconi, Riccardo
   Querques, Lea
   Zucchiatti, Ilaria
   Prascina, Francesco
   Bandello, Francesco
   Querques, Giuseppe
TI The COVID-19 Pandemic Has Had Negative Effects on Baseline Clinical
   Presentation and Outcomes of Patients with Newly Diagnosed
   Treatment-Naive Exudative AMD
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; retina; neovascular AMD; outcome
ID SUBRETINAL HYPERREFLECTIVE MATERIAL; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; VISUAL OUTCOMES; RANIBIZUMAB; PREDICTORS; THERAPY; 1ST
AB Purpose: To investigate whether the coronavirus disease 2019 (COVID-19) pandemic-associated postponement in care had effects on the baseline clinical presentation of patients with newly diagnosed treatment-naive exudative neovascular age-related macular degeneration (AMD). Methods: We included the first 50 consecutive patients referred within the COVID-19 pandemic with a diagnosis of treatment-naive exudative neovascular AMD. Two groups of fifty consecutive patients with newly diagnosed neovascular exudative AMD presenting in 2018 and 2019 (control periods) were also included for comparisons. Results: Baseline visual acuity was statistically worse in patients referred during the COVID-19 pandemic period (0.87 +/- 0.51 logarithm of the minimum angle of resolution (LogMAR)) as compared with both the "2019" (0.67 +/- 0.48 LogMAR, p = 0.001) and "2018" (0.69 +/- 0.54 LogMAR, p = 0.012) control periods. Data on the visual function after a loading dose of anti-vascular endothelial growth factor (VEGF) was available in a subset of patients (43 subjects in 2020, 45 in 2019 and 46 in 2018, respectively). Mean +/- SD best corrected visual acuity (BCVA) at the 1-month follow-up visit after the third anti-VEGF injection was still worse in patients referred during the COVID-19 pandemic (0.82 +/- 0.66 LogMAR) as compared with both the "2019" (0.60 +/- 0.45 LogMAR, p = 0.021) and "2018" (0.55 +/- 0.53 LogMAR, p = 0.001) control periods. On structural optical coherence tomography (OCT), the maximum subretinal hyperreflective material (SHRM) height and width were significantly greater in the COVID-19 pandemic patients. Conclusions: We demonstrated that patients with newly diagnosed treatment-naive exudative neovascular AMD referred during the COVID-19 pandemic had worse clinical characteristics at presentation and short-term visual outcomes.
C1 [Borrelli, Enrico; Battista, Marco; Vella, Giovanna; Grosso, Domenico; Sacconi, Riccardo; Querques, Lea; Zucchiatti, Ilaria; Prascina, Francesco; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, I-20132 Milan, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, I-20132 Milan, Italy.
EM borrelli.enrico@hsr.it; battista.marco@hsr.it;
   giovanna.vella28@gmail.com; grosso.domenico@hsr.it;
   sacconi.riccardo@hsr.it; querques.lea@hsr.it; zucchiatti.ilaria@hsr.it;
   prascina.francesco@hsr.it; bandello.francesco@hsr.it;
   giuseppe.querques@unisr.it
OI Sacconi, Riccardo/0000-0003-2891-2012; Borrelli,
   Enrico/0000-0003-2815-5031; Querques, Giuseppe/0000-0002-3292-9581;
   bandello, francesco/0000-0003-3238-9682
CR Borrelli E, 2021, AM J OPHTHALMOL, V223, P129, DOI 10.1016/j.ajo.2020.10.011
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   Borrelli E, 2020, EYE, V34, P1175, DOI 10.1038/s41433-020-0880-6
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Chew JK, 2017, OPHTHALMOLOGICA, V238, P23, DOI 10.1159/000469652
   Corradetti G, 2020, OPHTHALMOL RETINA, V4, P757, DOI 10.1016/j.oret.2020.05.015
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Huang YJ, 2012, INVEST OPHTH VIS SCI, V53, P2133, DOI 10.1167/iovs.11-8755
   Iovino C, 2020, GRAEF ARCH CLIN EXP, V258, P2869, DOI 10.1007/s00417-020-04800-x
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Kumar JB, 2020, RETINA-J RET VIT DIS, V40, P845, DOI 10.1097/IAE.0000000000002552
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Martin DF, 2018, AM J OPHTHALMOL, V191, pXLI, DOI 10.1016/j.ajo.2017.12.019
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Parravano M, 2020, OPHTHALMOL THER, V9, P231, DOI 10.1007/s40123-020-00251-z
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacconi R, 2021, EUR J OPHTHALMOL, V31, P849, DOI 10.1177/1120672120963448
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Shmueli O, 2020, EYE, V34, P1165, DOI 10.1038/s41433-020-0925-x
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 41
TC 6
Z9 6
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2021
VL 10
IS 6
AR 1265
DI 10.3390/jcm10061265
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SE3CN
UT WOS:000651949000001
PM 33803808
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU De La Cruz, N
   Shabaneh, O
   Appiah, D
AF De La Cruz, Noah
   Shabaneh, Obadeh
   Appiah, Duke
TI The Association of Ideal Cardiovascular Health and Ocular Diseases Among
   US Adults
SO AMERICAN JOURNAL OF MEDICINE
LA English
DT Article
DE Cardiovascular health; Diabetic retinopathy; Life's Simple 7 (LS7);
   National Health and Nutrition Examination Survey (NHANES); Ocular
   disease
AB BACKGROUND: Globally, about 2.2 billion people have a vision impairment or blindness and approximately half of the cases could have been prevented. Several ocular diseases share common characteristics that overlap with risk factors for cardiovascular diseases. The aim of this study was to evaluate the relation between the American Heart Association's prescription for health called the Life's Simple 7 (LS7) metrics and the occurrence of ocular diseases.
   METHODS: Data were from 6118 adults ages >= 40 years who participated in the 2005-2008 National Health and Nutrition Examination Survey (NHANES). LS7 metrics consisted of information on smoking, physical activity, body mass index, diet, blood pressure, total cholesterol, and blood glucose. Scores were summed for a maximum of 14 (most ideal cardiovascular health). Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).
   RESULTS: The average age of participants was 57 years with 53% of them being women. A 1-unit increase in LS7 scores was associated with reduced odds for age-related macular degeneration (OR: 0.95, 95% CI: 0.90-0.99), diabetic retinopathy (OR: 0.68, 95% CI: 0.64-0.73), cataract (OR: 0.94, 95% CI: 0.90-0.98), and glaucoma (OR: 0.94, 95% CI: 0.88-0.99). After multivariable adjustment, the association was limited to only diabetic retinopathy (OR: 0.69, 95% CI: 0.64-0.74). This association persisted when diabetic retinopathy was limited to only diagnosis by retinal imaging.
   CONCLUSIONS: In this study, ideal cardiovascular health, which is indicative of a healthy lifestyle, was associated with lower odds for ocular diseases, especially diabetic retinopathy. These findings suggest that interventions to prevent cardiovascular diseases may also hold promise in preventing ocular diseases. (C) 2020 Elsevier Inc. All rights reserved.
C1 [De La Cruz, Noah; Shabaneh, Obadeh; Appiah, Duke] Texas Tech Univ, Dept Publ Hlth, Hlth Sci Ctr, 3601 4th St,Stop 9430, Lubbock, TX 79430 USA.
C3 Texas Tech University System; Texas Tech University; Texas Tech
   University Health Science Center
RP Appiah, D (通讯作者)，Texas Tech Univ, Dept Publ Hlth, Hlth Sci Ctr, 3601 4th St,Stop 9430, Lubbock, TX 79430 USA.
EM duke.appiah@ttuhsc.edu
RI Shabaneh, Obadeh/GON-5898-2022; Appiah/ABB-4916-2020
OI De La Cruz, Noah/0000-0002-0185-6738
CR [Anonymous], 1995, Fed Regist, V60, P7772
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Brown AF, 2018, ANN INTERN MED, V168, P541, DOI 10.7326/M17-0996
   Cheng A. C. K., 2000, Hong Kong Medical Journal, V6, P195
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Cumberland PM, 2016, JAMA OPHTHALMOL, V134, P959, DOI 10.1001/jamaophthalmol.2016.1778
   Flammer J, 2013, EUR HEART J, V34, P1270, DOI 10.1093/eurheartj/eht023
   Fraser-Bell S, 2017, CLIN EXP OPHTHALMOL, V45, P45, DOI 10.1111/ceo.12905
   Gohdes Dorothy M, 2005, Prev Chronic Dis, V2, pA17
   Gunter EW, 1988, LAB PROCEDURES USED
   King DE, 2017, J AM BOARD FAM MED, V30, P213, DOI 10.3122/jabfm.2017.02.160244
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Ko F, 2016, INVEST OPHTH VIS SCI, V57, P2152, DOI 10.1167/iovs.15-18373
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Liew G, 2011, REV ESP CARDIOL, V64, P515, DOI [10.1016/j.recesp.2011.02.014, 10.1016/j.rec.2011.02.017]
   Lloyd-Jones DM, 2010, CIRCULATION, V121, P586, DOI 10.1161/CIRCULATIONAHA.109.192703
   Loprinzi Paul D, 2015, Prev Med Rep, V2, P591, DOI 10.1016/j.pmedr.2015.07.002
   Mazidi M, 2019, ATHEROSCLEROSIS, V284, P129, DOI 10.1016/j.atherosclerosis.2018.11.012
   Ogunmoroti O, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003954
   Ostchega Y, 2012, AM J HYPERTENS, V25, P1271, DOI 10.1038/ajh.2012.120
   Qiu M, 2017, OPHTHALMOLOGY, V124, P1229, DOI 10.1016/j.ophtha.2017.03.049
   Stuart A, HEART EYE SEEING LIN
   Varma R, 2016, JAMA OPHTHALMOL, V134, P802, DOI 10.1001/jamaophthalmol.2016.1284
   Younus A, 2016, MAYO CLIN PROC, V91, P649, DOI 10.1016/j.mayocp.2016.01.019
   Zhang XZ, 2012, AM J OPHTHALMOL, V154, pS53, DOI 10.1016/j.ajo.2011.08.045
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zipf George, 2013, Vital Health Stat 1, P1
NR 27
TC 7
Z9 7
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9343
EI 1555-7162
J9 AM J MED
JI Am. J. Med.
PD FEB
PY 2021
VL 134
IS 2
BP 252
EP +
DI 10.1016/j.amjmed.2020.06.004
EA FEB 2021
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA QY0SM
UT WOS:000629755400043
PM 32828726
DA 2022-11-30
ER

PT J
AU Boyer, NP
   Thompson, DA
   Koutalos, Y
AF Boyer, Nicholas P.
   Thompson, Debra A.
   Koutalos, Yiannis
TI Relative Contributions of All-Trans and 11-Cis Retinal to Formation of
   Lipofuscin and A2E Accumulating in Mouse Retinal Pigment Epithelium
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE lipofuscin; retinaldehyde; retinol dehydrogenase
ID STARGARDTS-DISEASE; OUTER SEGMENTS; AGE PIGMENT; RPE65; FLUOROPHORE;
   DEHYDROGENASE; PROTEIN; ABCA4; ISOMEROHYDROLASE; PHOTORECEPTORS
AB PURPOSE. Bis-retinoids are a major component of lipofuscin that accumulates in the retinal pigment epithelium (RPE) in aging and age-related macular degeneration (AMD). Although bis-retinoids are known to originate from retinaldehydes required for the light response of photoreceptor cells, the relative contributions of the chromophore, 11-cis retinal, and photoisomerization product, all-trans retinal, are unknown. In photoreceptor outer segments, all-trans retinal, but not 11-cis retinal, is reduced by retinol dehydrogenase 8 (RDH8). Using Rdh8(-/-) mice, we evaluated the contribution of increased all-trans retinal to the formation and stability of RPE lipofuscin.
   METHODS. Rdh8(-/-) mice were reared in cyclic-light or darkness for up to 6 months, with selected light-reared cohorts switched to dark-rearing for the final 1 to 8 weeks. The bis-retinoid A2E was measured from chloroform-methanol extracts of RPE-choroid using HPLC-UV/VIS spectroscopy. Lipofuscin fluorescence was measured from whole flattened eyecups (excitation, 488 nm; emission, 565-725 nm).
   RESULTS. Cyclic-light-reared Rdh8(-/- )mice accumulated A2E and RPE lipofuscin approximately 1.5 times and approximately 2 times faster, respectively, than dark-reared mice. Moving Rdh8(-/-) mice from cyclic-light to darkness resulted in A2E levels less than expected to have accumulated before the move.
   CONCLUSIONS. Our findings establish that elevated levels of all-trans retinal present in cyclic-light-reared Rdh8(-/-) mice, which remain low in wild-type mice, contribute only modestly to RPE lipofuscin formation and accumulation. Furthermore, decreases in A2E levels occurring after moving cyclic-light-reared Rdh8(-/-) mice to darkness are consistent with processing of A2E within the RPE and the existence of a mechanism that could be a therapeutic target for controlling A2E cytotoxicity.
C1 [Boyer, Nicholas P.; Koutalos, Yiannis] Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
   [Thompson, Debra A.] Univ Michigan, Sch Med, Dept Ophthalmol, Ann Arbor, MI USA.
   [Thompson, Debra A.] Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.
C3 Medical University of South Carolina; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Koutalos, Y (通讯作者)，Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM koutalo@musc.edu
FU NIH [R01 EY014850, P30 EY07003]; Research to Prevent Blindness, Inc.,
   New York, NY
FX Supported by NIH Grants R01 EY014850 (to Y.K.) and P30 EY07003 (to
   D.A.T.), and Research to Prevent Blindness, Inc., New York, NY (to
   D.A.T.).
CR BATTELLE BA, 1978, EXP EYE RES, V26, P487, DOI 10.1016/0014-4835(78)90134-3
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Blakeley LR, 2011, INVEST OPHTH VIS SCI, V52, P3483, DOI 10.1167/iovs.10-6694
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Chen CH, 2017, J BIOL CHEM, V292, P19356, DOI 10.1074/jbc.M117.795187
   Chen CH, 2012, J BIOL CHEM, V287, P24662, DOI 10.1074/jbc.M112.354514
   Chen CH, 2009, INVEST OPHTH VIS SCI, V50, P3589, DOI 10.1167/iovs.08-3336
   Chrispell JD, 2009, J BIOL CHEM, V284, P21468, DOI 10.1074/jbc.M109.020966
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   FUTTERMAN S, 1970, J NEUROCHEM, V17, P149, DOI 10.1111/j.1471-4159.1970.tb02195.x
   Gutierrez DB, 2010, PHOTOCH PHOTOBIO SCI, V9, P1513, DOI 10.1039/c0pp00230e
   Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042
   KATZ ML, 1989, INVEST OPHTH VIS SCI, V30, P37
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   LAVAIL MM, 1973, J CELL BIOL, V58, P650, DOI 10.1083/jcb.58.3.650
   Lenis TL, 2018, P NATL ACAD SCI USA, V115, pE11120, DOI 10.1073/pnas.1802519115
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Maeda A, 2005, J BIOL CHEM, V280, P18822, DOI 10.1074/jbc.M501757200
   Maeda A, 2008, J BIOL CHEM, V283, P26684, DOI 10.1074/jbc.M804505200
   Maeda A, 2007, P NATL ACAD SCI USA, V104, P19565, DOI 10.1073/pnas.0707477104
   Maeda A, 2009, INVEST OPHTH VIS SCI, V50, P5435, DOI 10.1167/iovs.09-3944
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102
   OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907
   PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Quazi F, 2014, P NATL ACAD SCI USA, V111, P5024, DOI 10.1073/pnas.1400780111
   Rattner A, 2000, J BIOL CHEM, V275, P11034, DOI 10.1074/jbc.275.15.11034
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
NR 51
TC 2
Z9 2
U1 1
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2021
VL 62
IS 2
AR 1
DI 10.1167/iovs.62.2.1
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QQ5MM
UT WOS:000624567800001
PM 33523199
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Doan, S
   Zagorski, Z
   Palmares, J
   Yagmur, M
   Kaercher, T
   Benitez-Del Castillo, JM
   Van Dooren, B
   Jonckheere, P
   Jensen, PK
   Maychuk, DY
   Bezditko, P
AF Doan, Serge
   Zagorski, Zbigniew
   Palmares, Jorge
   Yagmur, Meltem
   Kaercher, Thomas
   Manuel Benitez-Del Castillo, Jose
   Van Dooren, Bart
   Jonckheere, Paul
   Jensen, Peter Koch
   Maychuk, Dmitry Yurevich
   Bezditko, Pavlo
TI Eyelid Disorders in Ophthalmology Practice: Results from a Large
   International Epidemiological Study in Eleven Countries
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Blepharitis; Dry eye; Eyelid disorders; Meibomian gland disorder; Ocular
   surface disease
ID DRY EYE; MEIBOMIAN-GLAND; OCULAR SURFACE; DYSFUNCTION REPORT; VICIOUS
   CIRCLE; RISK-FACTORS; DISEASE; PREVALENCE; SUBCOMMITTEE; WORKSHOP
AB Purpose Anecdotal evidence suggests that eyelid disorders are common, although estimates of prevalence vary. The current study determines the prevalence of eyelid disorders, meibomian gland dysfunction (MGD) and related diseases (specifically ocular surface disease) in a population of patients presenting for routine ophthalmologic consultations. Methods This cross-sectional epidemiologic survey evaluated patients presenting for routine ophthalmic visits. During the consultation an ophthalmologist completed a questionnaire, and each patient underwent an ophthalmic examination and completed a quality of life questionnaire. Results Three hundred forty-nine ophthalmologists, recruited from 11 countries, provided data on 6525 patients. Patients were predominantly females (61.6%). The mean age of the study population was 57.0 +/- 17.6 years. Eyelid disorders were diagnosed in 5109 (78.3%) patients and were statistically associated with: atopic dermatitis, seborrheic dermatitis, dry eye, age-related macular degeneration, diabetes, cataract, allergy and MGD (P < 0.05, all associations). Eyelid abnormalities were identified in 59.6% of patients; conjunctival or corneal abnormalities were observed in 64.9% and 28.1% of patients, respectively. MGD was diagnosed in 54.3% patients and was statistically significantly associated with the presence of eyelid disorders and eyelid margin abnormalities (P < 0.001, both comparisons). Dry eye was diagnosed in 61.8% of patients. Concurrent dry eye and MGD were present in 67.6% of patients. Most patients reported some degree of impaired vision and daily/work activities related to dry eye. Impact on contact lens usage, emotions and quality of sleep was also reported. The effects on daily life were associated with the presence of MGD. Conclusion In conclusion, eyelid disorders were highly prevalent in this 'real-world' population of patients from ophthalmology clinics. Routine ophthalmologic consultations provide an opportunity to improve patient quality of life and to modify topical therapy in patients who may be predisposed to eyelid disorders.
C1 [Doan, Serge] Fdn A Rothschild, Paris, France.
   [Zagorski, Zbigniew] Eye Surg Ctr, Nalenchuv, Poland.
   [Palmares, Jorge] Hosp Lusiadas, Porto, Portugal.
   [Yagmur, Meltem] Cukurova Univ, Fac Med, Balcali Hosp, Adana, Turkey.
   [Kaercher, Thomas] Augenarztpraxis, Dossenheimer Landstr, Heidelberg, Germany.
   [Manuel Benitez-Del Castillo, Jose] Hosp Clin Univ San Carlos, Inst Invest Sanitaria, Serv Oftalmol, Unidad Superficie & Inflamac Ocular, Madrid, Spain.
   [Van Dooren, Bart] Erasmus MC, Rotterdam, Netherlands.
   [Jonckheere, Paul] Oogklin Deurne, Antwerp, Belgium.
   [Jensen, Peter Koch] Univ Copenhagen, Roskilde Hosp, Copenhagen, Denmark.
   [Maychuk, Dmitry Yurevich] Svyatoslav N Fyodorov State Inst, Eye Microsurg Complex, Moscow, Russia.
   [Bezditko, Pavlo] Kharkiv Natl Med Univ, Kharkiv, Ukraine.
C3 Cukurova University; Erasmus University Rotterdam; Erasmus MC;
   University of Copenhagen; Kharkiv National Medical University
RP Doan, S (通讯作者)，Fdn A Rothschild, Paris, France.
EM serge.doan@noos.fr
RI Pavlo, Bezditko/AAG-7278-2021
CR Bartlett JD, 2015, CLIN OPHTHALMOL, V9, P1719, DOI 10.2147/OPTH.S89700
   Baudouin C, 2007, J FR OPHTALMOL, V30, P239, DOI 10.1016/S0181-5512(07)89584-2
   Baudouin C, 2016, BRIT J OPHTHALMOL, V100, P300, DOI 10.1136/bjophthalmol-2015-307415
   Baudouin C, 2013, EUR J OPHTHALMOL, V23, P47, DOI 10.5301/ejo.5000181
   Baudouin C, 2010, PROG RETIN EYE RES, V29, P312, DOI 10.1016/j.preteyeres.2010.03.001
   Borchman D, 2011, INVEST OPHTH VIS SCI, V52, P3805, DOI 10.1167/iovs.10-6514
   Butovich IA, 2009, PROG RETIN EYE RES, V28, P483, DOI 10.1016/j.preteyeres.2009.07.002
   Fechtner RD, 2010, CORNEA, V29, P618, DOI 10.1097/ICO.0b013e3181c325b2
   Giannaccare G, 2019, OCUL SURF, V17, P98, DOI 10.1016/j.jtos.2018.10.005
   HOM MM, 1990, OPTOMETRY VISION SCI, V67, P710, DOI 10.1097/00006324-199009000-00010
   Hyon JY, 2019, EYE CONTACT LENS, V45, P310, DOI 10.1097/ICL.0000000000000567
   Hyon J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40539-0
   Jaacks LM, 2019, LANCET DIABETES ENDO, V7, P231, DOI 10.1016/S2213-8587(19)30026-9
   Knop E, 2011, INVEST OPHTH VIS SCI, V52, P1938, DOI 10.1167/iovs.10-6997c
   Lemp MA, 2007, OCUL SURF, V5, P75
   Lemp MA, 2009, OCUL SURF, V7, pS1, DOI 10.1016/S1542-0124(12)70620-1
   Mastrota KM, 2008, OPTOMETRY VISION SCI, V85, P814, DOI 10.1097/OPX.0b013e3181852777
   McDonald M, 2016, OCUL SURF, V14, P144, DOI 10.1016/j.jtos.2015.11.002
   Najafi L, 2013, J DIABETES COMPLICAT, V27, P459, DOI 10.1016/j.jdiacomp.2013.04.006
   O'Brien PD, 2004, CURR ALLERGY ASTHM R, V4, P314, DOI 10.1007/s11882-004-0077-2
   Pan ZW, 2000, INDOOR AIR, V10, P237, DOI 10.1034/j.1600-0668.2000.010004237.x
   Schaumberg DA, 2011, INVEST OPHTH VIS SCI, V52, P1994, DOI 10.1167/iovs.10-6997e
   Sharma A, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/781683
   Smith JA, 2007, OCUL SURF, V5, P93
   Vaede D, 2010, J FR OPHTALMOL, V33, P505, DOI 10.1016/j.jfo.2010.06.018
   Van Went C, 2011, J FR OPHTALMOL, V34, P230, DOI 10.1016/j.jfo.2010.11.010
   Zhang XY, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/8201053
NR 29
TC 0
Z9 0
U1 0
U2 6
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD SEP
PY 2020
VL 9
IS 3
BP 597
EP 608
DI 10.1007/s40123-020-00268-4
EA JUL 2020
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MV3HE
UT WOS:000544876400001
PM 32613590
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chu, ZD
   Cheng, YX
   Zhang, QQ
   Zhou, H
   Dai, YN
   Shi, YY
   Gregori, G
   Rosenfeld, PJ
   Wang, RK
AF Chu, Zhongdi
   Cheng, Yuxuan
   Zhang, Qinqin
   Zhou, Hao
   Dai, Yining
   Shi, Yingying
   Gregori, Giovanni
   Rosenfeld, Philip J.
   Wang, Ruikang K.
TI Quantification of Choriocapillaris with Phansalkar Local Thresholding:
   Pitfalls to Avoid
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; FLOW DEFICITS; FEATURES; DEGENERATION
AB PURPOSE: To demonstrate the proper use of the Phansalkar local thresholding method (Phansalkar method) in choriocapillaris (CC) quantification with optical coherence tomography angiography (OCTA).
   DESIGN: Retrospective, observational case series.
   METHODS: Swept source OCTA imaging was performed using 3x3 mm and 6 x 6 mm scanning patterns. The CC slab was extracted after semiautomatic segmentation of the retinal pigment epithelium/Bruch membrane complex. Retinal projection artifacts were removed before further analysis, and CC OCTA images from drusen eyes were compensated using a previously published strategy. CC flow deficits (FDs) were segmented with 2 previously published algorithms: the fuzzy C-means approach (FCM method) and the Phansalkar method. With the Phansalkar method, different parameters were tested and a local window radius of 1 to 15 pixels was used. FD density, mean FD size, and FD number were calculated for comparison.
   RESULTS: Six normal eyes from 6 subjects and 6 eyes with drusen secondary to age-related macular degeneration from 6 subjects were analyzed. With both 3x3 mm and 6 x 6 mm scans from all eyes, the FD metrics were highly dependent on the selection of the local window radius when using the Phansalkar method. Larger window radii resulted in higher FD density values. FD number increased with the increase in the window radius but then decreased, with an inflection point at about 1 to 2 intercapillary distances. Mean FD size decreased then increased with increasing window radii.
   CONCLUSIONS: Multiple parameters, especially the local window radius, should be optimized before using the Phansalkar method for the quantification of CC FDs with OCTA imaging. It is recommended that the proper use of the Phansalkar method should include the selection of the window radius that is related to the expected intercapillary distance in normal eyes. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Chu, Zhongdi; Cheng, Yuxuan; Zhang, Qinqin; Zhou, Hao; Dai, Yining; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Box 355061,3720 15th Ave NE, Seattle, WA 98195 USA.
   [Shi, Yingying; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Wang, Ruikang K.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
C3 University of Washington; University of Washington Seattle; Bascom
   Palmer Eye Institute; University of Miami; University of Washington;
   University of Washington Seattle
RP Wang, RK (通讯作者)，Univ Washington, Dept Bioengn, Box 355061,3720 15th Ave NE, Seattle, WA 98195 USA.
EM wangrk@uw.edu
RI Chu, Zhongdi/F-9604-2019; Wang, Ruikang/L-3889-2019
OI Chu, Zhongdi/0000-0001-7430-5032; Wang, Ruikang/0000-0001-5169-8822;
   Rosenfeld, Philip/0000-0002-4068-6671
FU National Eye Institute, United States [R01EY024158, R01EY028753]; Salah
   Foundation; Carl Zeiss Meditec; Research to Prevent Blindness, Inc. (New
   York, NY); National Eye Institute Center Core Grant, United States
   [P30EY014801]
FX Supported by grants from the National Eye Institute, United States
   (R01EY024158 and R01EY028753), the Salah Foundation, Carl Zeiss Meditec,
   an unrestricted grant from the Research to Prevent Blindness, Inc. (New
   York, NY), and the National Eye Institute Center Core Grant, United
   States (P30EY014801) to the Department of Ophthalmology, University of
   Miami Miller School of Medicine, United States. The funding organization
   had no role in the design or conduct of this research.
CR Al-Sheikh M, 2017, OSLI RETINA, V48, P623, DOI 10.3928/23258160-20170802-04
   [Anonymous], LOCAL PHANSALKAR THR
   [Anonymous], 2018, INVEST OPHTH VIS SCI
   [Anonymous], 2012, OCULAR BLOOD FLOW
   BERNSTEIN M. H., 1965, INVEST OPHTHAL MOL, V4, P1016
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Chu ZD, 2018, QUANT IMAG MED SURG, V8, P1102, DOI 10.21037/qims.2018.12.09
   Chu ZD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34826-5
   Chu ZD, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.12.121705
   Fisher R.B., 1996, HYPERMEDIA IMAGE PRO
   Herbort CP, 1998, EYE, V12, P757, DOI 10.1038/eye.1998.198
   Huang QM, 2005, PATTERN RECOGN LETT, V26, P801, DOI 10.1016/j.patrec.2004.09.035
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Marsh-Armstrong B, 2019, BIOMED OPT EXPRESS, V10, P5337, DOI 10.1364/BOE.10.005337
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305
   Sacconi R, 2019, BRIT J OPHTHALMOL, V103, P1320, DOI 10.1136/bjophthalmol-2018-313004
   Sauvola J, 2000, PATTERN RECOGN, V33, P225, DOI 10.1016/S0031-3203(99)00055-2
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P79, DOI 10.1097/IAE.0000000000001517
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spraul CW, 2002, VISION RES, V42, P923, DOI 10.1016/S0042-6989(02)00022-6
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Yin X, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.8.086020
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang QQ, 2018, QUANT IMAG MED SURG, V8, P658, DOI 10.21037/qims.2018.08.10
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
   Zhou KH, 2019, BIOMED OPT EXPRESS, V10, P2847, DOI 10.1364/BOE.10.002847
NR 37
TC 48
Z9 50
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2020
VL 213
BP 161
EP 176
DI 10.1016/j.ajo.2020.02.003
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LK8GN
UT WOS:000531098400021
PM 32059979
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Hernandez-Moreno, L
   Senra, H
   Lewis, P
   Moreno, N
   Linhares, J
   Santana, R
   Ramos, PL
   Marques, AP
   Macedo, AF
AF Hernandez-Moreno, Laura
   Senra, Hugo
   Lewis, Peter
   Moreno, Natacha
   Linhares, Joao
   Santana, Rui
   Ramos, Pedro Lima
   Marques, Ana Patricia
   Macedo, Antonio Filipe
TI Cost-effectiveness of basic vision rehabilitation (The basic VRS-effect
   study): study protocol for a randomised controlled trial
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE cost-effectiveness; magnification; quality-of-life; vision impairment;
   vision rehabilitation; visual ability
ID QUALITY-OF-LIFE; VISUAL DISABILITY VARIABLES; MINI-MENTAL-STATE; MACULAR
   DEGENERATION; DIABETIC-RETINOPATHY; ACTIVITY INVENTORY; HOSPITAL
   ANXIETY; OLDER-ADULTS; DEPRESSION; IMPAIRMENT
AB Purpose To investigate the cost-effectiveness of a basic vision rehabilitation service (basic-VRS) in Portugal. We designed a parallel group, randomised controlled trial whose aim is to compare the effects and costs of 'usual low vision care' with a 'basic-VRS intervention' on self-reported visual ability and other psychosocial and health-related quality-of-life outcomes. Methods The trial will recruit participants that meet the following inclusion criteria: (1) visual acuity between 0.4-1.0 logMAR in the better-seeing eye, (2) cause of vision loss is diabetic retinopathy or age-related macular degeneration, (3) 18 years or older and iv) live in the community (not in nursing homes or other type of institution). Participants will be randomised to one of the study arms consisting of immediate intervention and delayed intervention. The delayed intervention group will receive 'usual care' or no intervention in the first 12 weeks. Visual acuity, contrast sensitivity and retinal structure will be assessed during the study. Results The primary outcome measure is visual ability, which will be evaluated with the Massof Activity Inventory, we expect that the intervention will raise the overall person measure or visual ability. Reading, health-related quality-of-life, anxiety and depression and social support will be also assessed. The analysis will be undertaken on an intention-to-treat basis. A cost-effectiveness analysis will be performed to provide information about the cost per unit of utility. To evaluate the cost-effectiveness of the intervention we will adopt the perspective of the healthcare system. Conclusion This study will provide additional evidence about the effects of basic-VRS on self-reported visual ability. Findings from this study should also contribute to better planning of low vision provision and, consequently, may contribute to reduce barriers to basic-VRS.
C1 [Hernandez-Moreno, Laura; Linhares, Joao; Ramos, Pedro Lima; Macedo, Antonio Filipe] Univ Minho, Dept & Ctr Phys Optometry & Vis Sci, Braga, Portugal.
   [Senra, Hugo] Univ Essex, Sch Hlth & Social Care, Colchester, Essex, England.
   [Senra, Hugo] Univ Coimbra, Fac Psychol & Educ Sci, Ctr Res Neuropsychol & Cognit Behav Intervent CIN, Coimbra, Portugal.
   [Lewis, Peter; Ramos, Pedro Lima; Macedo, Antonio Filipe] Linnaeus Univ, Dept Med & Optometry, Kalmar, Sweden.
   [Moreno, Natacha] Hosp Santa Maria Maior EPE, Barcelos, Portugal.
   [Santana, Rui; Marques, Ana Patricia] Univ NOVA, Natl Sch Publ Hlth, Publ Hlth Res Ctr, Lisbon, Portugal.
C3 Universidade do Minho; University of Essex; Universidade de Coimbra;
   Linnaeus University; Universidade Nova de Lisboa
RP Macedo, AF (通讯作者)，Univ Minho, Dept & Ctr Phys Optometry & Vis Sci, Braga, Portugal.; Macedo, AF (通讯作者)，Linnaeus Univ, Dept Med & Optometry, Kalmar, Sweden.
EM antonio.macedo@lnu.se
RI Marques, Ana Patricia R S S/V-9571-2017; Marques, Ana
   Patricia/AAY-3342-2020; Linhares, João/M-7020-2013; Macedo,
   Antonio/I-8108-2013; Santana, Rui/I-3294-2017
OI Marques, Ana Patricia R S S/0000-0001-8242-7021; Marques, Ana
   Patricia/0000-0001-8242-7021; Linhares, João/0000-0001-9197-5134;
   Macedo, Antonio/0000-0003-3436-2010; Lewis, Peter/0000-0002-8365-0601;
   Santana, Rui/0000-0003-1370-3242; Lima Ramos, Pedro/0000-0003-1280-9854;
   Senra, Hugo/0000-0001-8054-6473
FU Essilor Portugal
FX We would like to acknowledge the hospital where the study takes place
   for the availability of the space and information. We also would like to
   acknowledge staff from the department of ophthalmology for their
   collaboration in the recruitment process. The ophthalmic lenses and part
   of the magnifiers are supported by Essilor Portugal.
CR Acton JH, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1235-2
   American Optometric Association, 2009, INTR VIS REH RES GUI
   ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814
   Barker L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010987.pub2
   Baskaran K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216775
   Binns AM, 2012, SURV OPHTHALMOL, V57, P34, DOI 10.1016/j.survophthal.2011.06.006
   Black Alex, 2005, Clin Exp Optom, V88, P212
   Bookwala J, 2011, GERONTOLOGIST, V51, P798, DOI 10.1093/geront/gnr051
   Bray N, 2017, ACTA OPHTHALMOL, V95, pE415, DOI 10.1111/aos.13255
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Brown JC, 2014, OPHTHALMOLOGY, V121, P1655, DOI 10.1016/j.ophtha.2014.02.030
   Burggraaff MC, 2012, INVEST OPHTH VIS SCI, V53, P3645, DOI 10.1167/iovs.11-9226
   Callahan CM, 2002, MED CARE, V40, P771, DOI 10.1097/00005650-200209000-00007
   Castro Celina Tamaki Monteiro de, 2005, Arq Bras Oftalmol, V68, P777
   Cheong Allen C Y, 2002, Clin Exp Optom, V85, P229
   Chiang PPC, 2011, OPHTHAL EPIDEMIOL, V18, P109, DOI 10.3109/09286586.2011.560745
   Coyne KS, 2004, FAM PRACT, V21, P447, DOI 10.1093/fampra/cmh417
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P617, DOI 10.1097/01.opx.0000171336.40273.3f
   Crossland MD, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-015939
   Cruess AF, 2011, CAN J OPHTHALMOL, V46, P315, DOI 10.1016/j.jcjo.2011.06.006
   CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386
   Drummond MF, 2015, INTRO EC EVALUATION
   Drumond M F, 1985, World Health Stat Q, V38, P355
   Dunbar HMP, 2012, OPHTHAL PHYSL OPT, V32, P282, DOI 10.1111/j.1475-1313.2012.00914.x
   Dunbar HMP, 2013, THESIS
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M
   Eilertsen G, 2016, J HOUS ELDER, V30, P199, DOI 10.1080/02763893.2016.1162256
   Eklund K, 2005, DISABIL REHABIL, V27, P1203, DOI 10.1080/09638280500052716
   Ferreira LN, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0491-x
   Ferreira M, 2017, MULT SCLER RELAT DIS, V14, P16, DOI 10.1016/j.msard.2017.01.014
   Ferreira MB, 2018, PEERJ, V6, DOI 10.7717/peerj.5737
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Freeman, 2007, CARE PATIENT VISUAL
   Frick KD, 2010, INVEST OPHTH VIS SCI, V51
   Frick KD, 2010, INVEST OPHTH VIS SCI, V51, P1801, DOI 10.1167/iovs.09-4469
   Goldstein JE, 2015, JAMA OPHTHALMOL, V133, P762, DOI 10.1001/jamaophthalmol.2015.0693
   Guerreiro M., 1994, REV PORTUGUESA NEURO, V1, P9, DOI DOI 10.1017/CB09781107415324.004
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Hernandez-Moreno L., 2018, INVEST OPHTH VIS SCI, V59, P3411
   Hong T, 2013, AM J OPHTHALMOL, V156, P393, DOI 10.1016/j.ajo.2013.04.002
   Horsman John, 2003, Health Qual Life Outcomes, V1, P54, DOI 10.1186/1477-7525-1-54
   International Statistical Classification of Diseases and Related Health Problems 10th Revision, 2016, H54 VISUAL IMPAIRMEN
   Jain R, 2011, PHARMACOECONOMICS, V29, P297, DOI 10.2165/11584630-000000000-00000
   Janssen MF, 2013, QUAL LIFE RES, V22, P1717, DOI 10.1007/s11136-012-0322-4
   Johnston Alan W, 2003, Clin Exp Optom, V86, P403
   Kay S, 2014, OPHTHAL EPIDEMIOL, V21, P66, DOI 10.3109/09286586.2014.888456
   Kempen GIJM, 2012, QUAL LIFE RES, V21, P1405, DOI 10.1007/s11136-011-0061-y
   Lam N, 2013, CAN J OPHTHALMOL, V48, P458, DOI 10.1016/j.jcjo.2013.02.014
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1476, DOI 10.1167/iovs.06-0610
   Langelaan M, 2007, OPHTHAL EPIDEMIOL, V14, P119, DOI 10.1080/09286580601139212
   Latham K, 2012, OPTOMETRY VISION SCI, V89, P1316, DOI 10.1097/OPX.0b013e31825bff1c
   LEGGE GE, 1989, OPTOMETRY VISION SCI, V66, P843, DOI 10.1097/00006324-198912000-00008
   Lovie-Kitchin Jan E, 1999, Clin Exp Optom, V82, P214
   Macedo AF, 2008, J VISION, V8, DOI 10.1167/8.14.16
   Macedo AF, 2011, INVEST OPHTH VIS SCI, V52, P1275, DOI 10.1167/iovs.09-4334
   Macedo AF, 2017, ACTA OPHTHALMOL, V95, pe783, DOI 10.1111/aos.13430
   Malkin AG, 2013, OPTOMETRY VISION SCI, V90, P799, DOI 10.1097/OPX.0000000000000005
   Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027
   Marques AP, 2019, OPHTHAL EPIDEMIOL, V26, P378, DOI 10.1080/09286586.2019.1632904
   Marques AP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198631
   Massof RW, 2007, OPTOMETRY VISION SCI, V84, P763, DOI 10.1097/OPX.0b013e3181339efd
   Massof RW, 2013, OPTOMETRY VISION SCI, V90, P788, DOI 10.1097/OPX.0000000000000011
   Massof RW, 2005, ARCH PHYS MED REHAB, V86, P946, DOI 10.1016/j.apmr.2004.09.016
   Massof RW, 2005, ARCH PHYS MED REHAB, V86, P954, DOI 10.1016/j.apmr.2004.09.017
   Matti AI, 2011, CLIN EXP OPTOM, V94, P181, DOI 10.1111/j.1444-0938.2010.00556.x
   Meyniel C, 2017, FRONT SYST NEUROSCI, V11, DOI 10.3389/fnsys.2017.00082
   Mojon-Azzi SM, 2008, OPHTHALMOLOGICA, V222, P205, DOI 10.1159/000126085
   Moreno L, 2017, 12 INT C INT SOC LOW
   National Center for Chronic Disease Prevention and Health Promotion, 2016, HLTH REL QUAL LIF HR
   NORD E, 1992, BRIT MED J, V305, P875, DOI 10.1136/bmj.305.6858.875
   O'Connor PM, 2008, CLIN EXP OPHTHALMOL, V36, P547, DOI 10.1111/j.1442-9071.2008.01830.x
   Oppe M, 2014, VALUE HEALTH, V17, P445, DOI 10.1016/j.jval.2014.04.002
   Overbury O, 2011, INVEST OPHTH VIS SCI, V52, P8933, DOI 10.1167/iovs.11-8116
   Pais-Ribeiro J, 2007, Psychol Health Med, V12, P225, DOI 10.1080/13548500500524088
   Patty NJS, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0761-y
   Pearce E, 2011, BRIT J OPHTHALMOL, V95, P105, DOI 10.1136/bjo.2009.175703
   Pereira J.M., 2011, PSYCHOLOGICA-COIMBRA, V54, P331, DOI [DOI 10.14195/1647-8606_54_13, 10.14195/1647-8606_54_13]
   Pettersson A, 2015, NORD J PSYCHIAT, V69, P497, DOI 10.3109/08039488.2015.1008568
   Poole NA, 2006, GEN HOSP PSYCHIAT, V28, P55, DOI 10.1016/j.genhosppsych.2005.08.004
   Rabiee P, VISION REHABILITATIO
   Silva MBR, 2018, INVEST OPHTH VIS SCI, V59
   Ross EL, 2016, JAMA OPHTHALMOL, V134, P888, DOI 10.1001/jamaophthalmol.2016.1669
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   Ryan B, 2014, CLIN EXP OPTOM, V97, P209, DOI 10.1111/cxo.12157
   Senn S., 2002, CONFOUNDER CONFUSION, V2nd ed.
   Senra H, 2019, AM J GERIAT PSYCHIAT, V27, P755, DOI 10.1016/j.jagp.2019.03.001
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Sharts-Hopko NC, 2010, CLIN NURSE SPEC, V24, P149, DOI 10.1097/NUR.0b013e3181d82b89
   Southall K, 2012, J VISUAL IMPAIR BLIN, V106, P261, DOI 10.1177/0145482X1210600502
   Spafford MM, 2010, J APPL GERONTOL, V29, P579, DOI 10.1177/0733464809345494
   Stelmack J, 2001, OPTOMETRY VISION SCI, V78, P335, DOI 10.1097/00006324-200105000-00017
   Stelmack JA, 2012, OPHTHAL PHYSL OPT, V32, P461, DOI 10.1111/j.1475-1313.2012.00933.x
   Sticken J, 2010, FDN LOW VISION CLIN
   Stronks HC, 2016, EXPERT REV MED DEVIC, V13, P919, DOI 10.1080/17434440.2016.1237287
   Stroupe KT, 2018, JAMA OPHTHALMOL, V136, P524, DOI 10.1001/jamaophthalmol.2018.0797
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   Taylor J, 2014, OPHTHAL PHYSL OPT, V34, P558, DOI 10.1111/opo.12149
   Tennant A, 2004, VALUE HEALTH, V7, pS22, DOI 10.1111/j.1524-4733.2004.7s106.x
   The National Institute for Health and Care Excellence, 2019, QUAL ADJ LIF YEAR QA
   TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2
   van der Aa HPA, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1437-5
   van Nispen RMA, 2016, INVEST OPHTH VIS SCI, V57
   VIRGILI G, 2018, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003303.PUB4
   Virgili G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003303.pub3
   Voss EH, 2003, MACULOPATIA OTRA FOR
   West BW., 2015, LINEAR MIXED MODELS, V2
   Wittenborn JS, 2013, OPHTHALMOLOGY, V120, P1728, DOI 10.1016/j.ophtha.2013.01.068
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
   World Health Organization, 2001, INT CLASS FUNCT DIS
   WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857
   Zheng YJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46453
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 113
TC 7
Z9 7
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAY
PY 2020
VL 40
IS 3
BP 350
EP 364
DI 10.1111/opo.12665
EA JAN 2020
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA LH4BG
UT WOS:000509491000001
PM 31989690
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Jackson, S
   Stokes, JP
AF Jackson, Shaun
   Stokes, John P.
TI Impact of out-of-pocket costs on patient initiation, adherence and
   persistence rates for patients treated with anti-vascular endothelial
   growth factor medicines
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE anti-vascular endothelial growth factor; expense; macular degeneration;
   out-of-pocket
ID MACULAR DEGENERATION
AB Importance Out-of-pocket costs are a key driver of patient decisions to access, adhere and persist with anti-vascular endothelial growth factor (VEGF) therapy. The Medicare Benefits Schedule Review Taskforce proposes a 69% reduction in the scheduled fee for intravitreal injections (item 42 738) which risks increasing out-of-pocket costs for patients and worsening visual outcomes. Background To determine the impact of out-of-pocket costs on current anti-VEGF utilization rates in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). Design This is a retrospective cohort drug-utilization analysis. Participants This study involved 11 592 patients in Australia diagnosed with nAMD or DMO. Methods A retrospective analysis of electronic, de-identified dispensing records of patients diagnosed with nAMD or DMO who initiated anti-VEGF therapy between January 1, 2016 and December 2018 across Australia. Patients were categorized by treatment facility type: bulk-billing clinics (BBCs) and "rest of market" clinics (ROMCs). Main Outcome Measures Dispensing quantities, intervals and persistence rates. Results For patients with nAMD who initiated therapy between 2016 and 2018 the mean number of medicines dispensed up to September 30, 2019 was 17.0 for BBC and 13.8 for ROMC patients. For patients with DMO, the mean number of medicines dispensed was 16.5 for BBC patients and 12.5 for ROMC patients. Patients treated at BBCs had higher persistence rates than those treated at ROMCs. DMO patients had higher initiation rates BBCs (46%) vs ROMCs (25%). Conclusions and Relevance Lower out-of-pocket costs are associated with higher adherence and persistence rates for anti-VEGF therapy in patients with AMD and DMO and higher initiation rates for DMO patients.
C1 [Jackson, Shaun; Stokes, John P.] Inservio, Sydney, NSW 2103, Australia.
   [Stokes, John P.] Charles Sturt Univ, Dept Biomed Sci, Orange, NSW, Australia.
C3 Charles Sturt University
RP Stokes, JP (通讯作者)，Inservio, Sydney, NSW 2103, Australia.
EM john.stokes@inservio.com.au
OI Stokes, John/0000-0002-7707-0360
FU Inservio
FX This study was funded entirely by Inservio.
CR [Anonymous], 2019, OPHTH REP
   Australian Institute of Health and Welfare, 2018, PAT OUT OF POCK SPEN
   Callander EJ, 2017, AUST J PRIM HEALTH, V23, P15, DOI 10.1071/PY16005
   Callander EJ, 2016, DIABETES-METAB RES, V32, P581, DOI 10.1002/dmrr.2771
   Carter H, 2018, AUSTR DIAB ED ASS AD
   Department of Health, MBS ONL IT 18240 427
   Gillies M, 2015, CLIN EXP OPHTHALMOL, V43, P108
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Medicare Australia Statistics, 42738 MED AUSTR STAT
   Medicare Australia Statistics, PHARM BEN SCH IT REP
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   National Seniors, 2018, OUT POCK HLTH CAR CO
   Schofield D, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-220
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 18
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAY
PY 2020
VL 48
IS 4
BP 477
EP 485
DI 10.1111/ceo.13706
EA JAN 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LT4BR
UT WOS:000506730500001
PM 31872517
DA 2022-11-30
ER

PT J
AU Mrejen, S
   Giocanti-Auregan, A
   Tabary, S
   Cohen, SY
AF Mrejen, Sarah
   Giocanti-Auregan, Audrey
   Tabary, Sandrine
   Cohen, Salomon Y.
TI SENSITIVITY OF 840-nm SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY
   ANGIOGRAPHY IN DETECTING TYPE 1 NEOVASCULARIZATION ACCORDING TO THE
   HEIGHT OF THE ASSOCIATED PIGMENT EPITHELIAL DETACHMENT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascularization; pigment; epithelial detachment; optical
   coherence tomography angiography
ID OCCULT CHOROIDAL NEOVASCULARIZATION; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   MACULAR DEGENERATION; TREATMENT RESPONSE; SECONDARY; RANIBIZUMAB;
   ANASTOMOSES; SYSTEM
AB Purpose: To evaluate the ability of optical coherence tomography angiography (OCTA) to detect abnormal vascular blood flow in Type 1 neovascularization (NV) with or without significant pigment epithelial detachment (PED).
   Methods: Consecutive age-related macular degeneration patients with either treatment-naive or anti-vascular endothelial growth factor-treated Type 1 NV were divided into 2 groups based on the PED height on structural OCT: greater than 250 mm (Group 1) versus less than 250 mm (Group 2). Two independent senior retina specialists analyzed the OCTA images (Zeiss Angioplex OCT, Carl Zeiss AG, Jena, Germany) using the automatic slabs alone (first reader) versus automatic and manual segmentation slabs (second reader).
   Results: In Group 1, 15 men and 42 women, aged from 51 years to 97 years (mean: 87.5), were included. Optical coherence tomography angiography was able to show an abnormal blood flow suggestive of Type 1 NV in 23 (40.3%) of 57 eyes for the first reader and in 32 (56.1%) of 57 eyes for the second reader. In Group 2, 7 men and 30 women, aged from 60 years to 96 years (mean: 80.2), were included. The first and second readers were able to observe an image suggestive of Type 1 NV in 33/37 (89.2%) and 37/37 (100%) of eyes, respectively.
   Conclusion: The ability of OCTA to detect an abnormal blood flow in Type 1 NV was found to highly depend on the height of the associated PED and the use of manual segmentation slabs. Our results suggest that automatic slabs of OCTA should be interpreted with caution for the diagnosis of vascularized PED. The diagnosis of Type 1 NV using OCTA requires the use of manual segmentation and a multimodal imaging approach, especially when the height of the associated PED is >250 mu m.
C1 [Mrejen, Sarah; Tabary, Sandrine; Cohen, Salomon Y.] Ophthalm Ctr Imaging & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
   [Mrejen, Sarah] XV XX Natl Ophthalm Ctr, Dept Ophthalmol, Paris, France.
   [Giocanti-Auregan, Audrey] Avicenne Hosp, AP HP, Dept Ophthalmol, Bobigny, France.
   [Cohen, Salomon Y.] Univ Paris Est, Interc Hosp, Dept Ophthalmol, Creteil, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Avicenne - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI
   Creteil
RP Cohen, SY (通讯作者)，Ophthalm Ctr Imaging & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycsyc75@gmail.com
FU CIL-ASSOC (Paris, France), an association for research and education
FX Supported by an unrestricted grant from CIL-ASSOC (Paris, France), an
   association for research and education.
CR BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cohen SY, 2017, RETINA-J RET VIT DIS, V37, P1625, DOI 10.1097/IAE.0000000000001695
   Cohen SY, 2011, RETINA-J RET VIT DIS, V31, P209, DOI 10.1097/IAE.0b013e31820a69db
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   El Ameen A, 2015, RETINA-J RET VIT DIS, V35, P2212, DOI 10.1097/IAE.0000000000000773
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Iafe NA, 2016, DEV OPHTHALMOL, V56, P45, DOI 10.1159/000442776
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Liang MC, 2016, DEV OPHTHALMOL, V56, P62, DOI 10.1159/000442780
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Miere A, 2017, RETINA-J RET VIT DIS, V37, P1873, DOI 10.1097/IAE.0000000000001447
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Rebhun CB, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.6.4
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P234, DOI 10.1097/IAE.0000000000001343
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
NR 44
TC 7
Z9 7
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2019
VL 39
IS 10
BP 1973
EP 1984
DI 10.1097/IAE.0000000000002244
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KC9EX
UT WOS:000507475300018
PM 30015765
DA 2022-11-30
ER

PT J
AU Chan, CK
   Sarraf, D
   Abraham, P
AF Chan, Clement K.
   Sarraf, David
   Abraham, Prema
TI Treatment outcomes of conventional or high-dose ranibizumab for
   vascularized pigment epithelial detachment based on lesion subtypes
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Fibrovascular pigment epithelial detachment; retinal pigment epithelial
   tears; vascularized pigment epithelial detachment; vascularized serous
   pigment epithelial detachment
ID SINGLE INTRAVITREAL INJECTION; MACULAR DEGENERATION; INTRAOCULAR
   PHARMACOKINETICS; BEVACIZUMAB; HUMANS; TEARS; CLASSIFICATION; THERAPY
AB Introduction: A post hoc study was conducted to compare visual and anatomic outcomes of vascularized serous pigment epithelial detachment (Group 1) with fibrovascular pigment epithelial detachment (Group 2) due to age-related macular degeneration treated with either 0.5 or 2.0 mg ranibizumab injections. Methods: A prospective, randomized trial was performed with the following regimens for 12 months: (1) 0.5 mg monthly, (2) 0.5 mg monthly for 4 months followed by pro re nata injections, (3) 2.0 mg monthly, and (4) 2.0 mg monthly for 4 months followed by pro re nata injections. Primary measure was best-corrected standardized vision. Secondary measures included central subfield, thickness surface area A(2), greatest linear diameter, heights of pigment epithelial detachment and choroidal neovascularization (CNV), subretinal fluid, cystoid macular edema, and adverse events. Results: For 36 eyes (8 in Group 1 and 28 in Group 2), follow-up time was 12 months. There were no differences in baseline features between groups except for pigment epithelial detachment A(2) (Group 2 > Group 1). Two-way analysis of variance showed comparable improvements in anatomic and vision outcomes. Three-way analysis of variance also showed similar responses for both lesion subtypes with high-dose treatment. There was a trend toward greater pigment epithelial detachment resolution in Group 1 eyes. There were no differences in retinochoroidal angiomatous proliferation (Type-3 CNV) and cataracts between groups, although greater percentages of eyes in Group 1 developed retinal pigment epithelial tears (25% vs 10.7%). Conclusion: There were no differences in vision and anatomic outcomes between lesion subtypes, and similarly, more rapid responses to high-dose than conventional-dose ranibizumab occurred for eyes with both lesion subtypes. More retinal pigment epithelial tears may develop in eyes with vascularized serous pigment epithelial detachment.
C1 [Chan, Clement K.] Southern Calif Desert Retina Consultants, Palm Desert, CA USA.
   [Chan, Clement K.] Inland Retina Consultants, Riverside, CA USA.
   [Chan, Clement K.] Loma Linda Univ, Dept Ophthalmol, Loma Linda, CA 92350 USA.
   [Sarraf, David] UCLA, Jules Stein Eye Inst, Los Angeles, CA 90024 USA.
   [Abraham, Prema] Black Hills Reg Eye Inst, Rapid City, SD USA.
C3 Loma Linda University; University of California System; University of
   California Los Angeles
RP Chan, CK (通讯作者)，Southern Calif Desert Retina Consultants, POB 2467, Palm Springs, CA 92263 USA.
EM CChan@desertretina.com
FU Roche-Genentech Inc.; Owen Locke Foundation; Kirchgessner Foundation
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   investigator-initiated study has received grant supports from
   Roche-Genentech Inc., Owen Locke Foundation, and Kirchgessner
   Foundation.
CR Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Lommatzsch A, 2009, EYE, V23, P2163, DOI 10.1038/eye.2008.425
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Sarraf D, 2013, RETINA-J RET VIT DIS, V33, P1551, DOI 10.1097/IAE.0b013e31828992f5
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 18
TC 2
Z9 4
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2018
VL 28
IS 6
BP 677
EP 683
DI 10.1177/1120672117747034
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ9QD
UT WOS:000449834800010
PM 29575941
DA 2022-11-30
ER

PT J
AU McFadyen, JD
   Kiefer, J
   Braig, D
   Loseff-Silver, J
   Potempa, LA
   Eisenhardt, SU
   Peter, K
AF McFadyen, James D.
   Kiefer, Jurij
   Braig, David
   Loseff-Silver, Julia
   Potempa, Lawrence A.
   Eisenhardt, Steffen Ulrich
   Peter, Karlheinz
TI Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation:
   Evidence for a Direct Biological Role of C-Reactive Protein and Its
   Conformational Changes
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE inflammation; C-reactive protein; cardiovascular diseases;
   ischemia/reperfusion; Alzheimer disease
ID ACUTE-PHASE PROTEINS; COMPLEMENT ACTIVATION; MACULAR DEGENERATION;
   PENTAMERIC SYMMETRY; CARDIOVASCULAR-DISEASE; ALZHEIMERS-DISEASE; ACUTE
   REJECTION; UP-REGULATION; BURN WOUNDS; C/EBP-BETA
AB C-reactive protein (CRP) is a member of the pentraxin superfamily that is widely recognized as a marker of inflammatory reactions and cardiovascular risk in humans. Recently, a growing body of data is emerging, which demonstrates that CRP is not only a marker of inflammation but also acts as a direct mediator of inflammatory reactions and the innate immune response. Here, we critically review the various lines of evidence supporting the concept of a pro-inflammatory "CRP system." The CRP system consists of a functionally inert circulating pentameric form (pCRP), which is transformed to its highly pro-inflammatory structural isoforms, pCRP* and ultimately to monomeric CRP (mCRP). While retaining an overall pentameric structure, pCRP* is structurally more relaxed than pCRP, thus exposing neoepitopes important for immune activation and complement fixation. Thereby, pCRP* shares its pro-inflammatory properties with the fully dissociated structural isoform mCRP. The dissociation of pCRP into its pro-inflammatory structural isoforms and thus activation of the CRP system occur on necrotic, apoptotic, and ischemic cells, regular beta-sheet structures such as beta-amyloid, the membranes of activated cells (e.g., platelets, monocytes, and endothelial cells), and/or the surface of micro-particles, the latter by binding to phosphocholine. Both pCRP* and mCRP can cause activation of platelets, leukocytes, endothelial cells, and complement. The localization and deposition of these pro-inflammatory structural isoforms of CRP in inflamed tissue appear to be important mediators for a range of clinical conditions, including ischemia/reperfusion (I/R) injury of various organs, cardiovascular disease, transplant rejection, Alzheimer's disease, and age-related macular degeneration. These findings provide the impetus to tackle the vexing problem of innate immunity response by targeting CRP. Understanding the "activation process" of CRP will also likely allow the development of novel anti-inflammatory drugs, thereby providing potential new immunomodulatory therapeutics in a broad range of inflammatory diseases.
C1 [McFadyen, James D.; Loseff-Silver, Julia; Peter, Karlheinz] Baker Heart & Diabet Inst, Atherothrombosis & Vasc Biol Lab, Melbourne, Vic, Australia.
   [McFadyen, James D.] Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia.
   [McFadyen, James D.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia.
   [Kiefer, Jurij; Braig, David; Eisenhardt, Steffen Ulrich] Univ Freiburg, Med Fac, Med Ctr, Dept Plast & Hand Surg, Freiburg, Germany.
   [Potempa, Lawrence A.] Roosevelt Univ, Coll Pharm, Schaumburg, IL USA.
   [Peter, Karlheinz] Alfred Hosp, Ctr Heart, Melbourne, Vic, Australia.
   [Peter, Karlheinz] Monash Univ, Dept Immunol, Melbourne, Vic, Australia.
C3 Florey Institute of Neuroscience & Mental Health; Monash University;
   University of Freiburg; Florey Institute of Neuroscience & Mental
   Health; Monash University
RP Peter, K (通讯作者)，Baker Heart & Diabet Inst, Atherothrombosis & Vasc Biol Lab, Melbourne, Vic, Australia.; Peter, K (通讯作者)，Alfred Hosp, Ctr Heart, Melbourne, Vic, Australia.; Peter, K (通讯作者)，Monash Univ, Dept Immunol, Melbourne, Vic, Australia.
EM karlheinz.peter@baker.edu.au
RI /S-2765-2019; Eisenhardt, Steffen/AAF-8033-2021
OI /0000-0002-8040-2258; Eisenhardt, Steffen Ulrich/0000-0003-4471-3160
FU National Health and Medical Research Council of Australia (NHMRC);
   German Research Foundation (DFG) [EI 866/1-1, EI 866/2-1, EI 866/5-1];
   Heisenberg fellowship of the German Research Foundation (DFG) [EI
   866/4-1]; Charles and Sylvia Clinical Investigator Fellowship
FX This work was supported by a grant from the National Health and Medical
   Research Council of Australia (NHMRC) to KP and grants from the German
   Research Foundation (DFG) to SE (EI 866/1-1, EI 866/2-1, and EI
   866/5-1), KP is a NHMRC Principal Research Fellow, SE holds a Heisenberg
   fellowship of the German Research Foundation (DFG) (EI 866/4-1), JM
   holds a Charles and Sylvia Clinical Investigator Fellowship.
CR Abernethy TJ, 1941, J EXP MED, V73, P173, DOI 10.1084/jem.73.2.173
   Agrawal A, 2003, MOL IMMUNOL, V40, P373, DOI 10.1016/S0161-5890(03)00148-2
   Agrawal A, 2003, IMMUNOLOGY, V108, P539, DOI 10.1046/j.1365-2567.2003.01608.x
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64
   Aurora P, 2010, J HEART LUNG TRANSPL, V29, P1129, DOI 10.1016/j.healun.2010.08.008
   Bang R, 2005, J BIOL CHEM, V280, P25095, DOI 10.1074/jbc.M504782200
   Braig D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14188
   Braig D, 2014, INT IMMUNOL, V26, P467, DOI 10.1093/intimm/dxu056
   Calabro P, 2005, J AM COLL CARDIOL, V46, P1112, DOI 10.1016/j.jacc.2005.06.017
   CECKA JM, 1991, TRANSPLANT P, V23, P1263
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   De La Torre R, 2013, J THROMB HAEMOST, V11, P2048, DOI 10.1111/jth.12415
   DEBEER FC, 1982, IMMUNOLOGY, V45, P55
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W
   Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507
   Enocsson H, 2009, ARTHRITIS RHEUM, V60, P3755, DOI 10.1002/art.25042
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200
   Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353
   Griselli M, 1999, J EXP MED, V190, P1733, DOI 10.1084/jem.190.12.1733
   GULANIKAR AC, 1992, TRANSPLANTATION, V53, P323, DOI 10.1097/00007890-199202010-00013
   Habersberger J, 2012, CARDIOVASC RES, V96, P64, DOI 10.1093/cvr/cvs237
   Halloran PF, 1997, TRANSPL P, V29, P79, DOI 10.1016/S0041-1345(96)00015-2
   Hart A, 2018, AM J TRANSPLANT, V18, P18, DOI 10.1111/ajt.14557
   Hausenloy DJ, 2013, J CLIN INVEST, V123, P92, DOI 10.1172/JCI62874
   HURLIMANN J, 1966, J EXP MED, V123, P365, DOI 10.1084/jem.123.2.365
   Inoue T, 2005, J AM COLL CARDIOL, V46, P239, DOI 10.1016/j.jacc.2005.04.029
   IWAMOTO N, 1994, NEUROSCI LETT, V177, P23, DOI 10.1016/0304-3940(94)90035-3
   Jabs WJ, 2003, EUR J IMMUNOL, V33, P152, DOI 10.1002/immu.200390018
   Ji SR, 2007, FASEB J, V21, P284, DOI 10.1096/fj.06-6722com
   Ji SR, 2009, FASEB J, V23, P1806, DOI 10.1096/fj.08-116962
   Ji SR, 2006, ARTERIOSCL THROM VAS, V26, P935, DOI 10.1161/01.ATV.0000206211.21895.73
   Khreiss T, 2005, CIRC RES, V97, P690, DOI 10.1161/01.RES.0000183881.11739.CB
   Khreiss T, 2004, CIRCULATION, V109, P2016, DOI 10.1161/01.CIR.0000125527.41598.68
   Kresl JJ, 1998, INT J BIOCHEM CELL B, V30, P1415, DOI 10.1016/S1357-2725(98)00078-8
   KUSHNER I, 1961, J EXP MED, V114, P961, DOI 10.1084/jem.114.6.961
   KUTA AE, 1986, J EXP MED, V164, P321, DOI 10.1084/jem.164.1.321
   Lagrand WK, 1997, CIRCULATION, V95, P97, DOI 10.1161/01.CIR.95.1.97
   Li HY, 2014, J BIOL CHEM, V289, P14283, DOI 10.1074/jbc.M114.555318
   Libby Peter, 2004, Am J Med, V116 Suppl 6A, p9S
   Lu JH, 2008, NATURE, V456, P989, DOI 10.1038/nature07468
   MacLeod CM, 1941, J EXP MED, V73, P191, DOI 10.1084/jem.73.2.191
   Massberg S, 1999, BLOOD, V94, P3829, DOI 10.1182/blood.V94.11.3829.423k35_3829_3838
   Masters CL, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.56
   MATAS AJ, 1994, TRANSPLANTATION, V57, P857, DOI 10.1097/00007890-199403270-00015
   MCCARTY M, 1947, J EXP MED, V85, P491, DOI 10.1084/jem.85.5.491
   Meuwissen M, 2006, J CLIN PATHOL, V59, P196, DOI 10.1136/jcp.2005.027235
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Mihlan M, 2011, FASEB J, V25, P4198, DOI 10.1096/fj.11-186460
   Molins B, 2011, CARDIOVASC RES, V92, P328, DOI 10.1093/cvr/cvr226
   O'Flynn J, 2016, AM J PHYSIOL-RENAL, V310, pF1308, DOI 10.1152/ajprenal.00645.2014
   Oberbarnscheidt MH, 2014, J CLIN INVEST, V124, P3579, DOI 10.1172/JCI74370
   OPELZ G, 1994, NEW ENGL J MED, V330, P816, DOI 10.1056/NEJM199403243301203
   OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739
   Pegues MA, 2013, AM J PHYSIOL-RENAL, V304, pF1358, DOI 10.1152/ajprenal.00476.2012
   Pepys MB, 2006, NATURE, V440, P1217, DOI 10.1038/nature04672
   PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X
   POTEMPA LA, 1983, MOL IMMUNOL, V20, P1165, DOI 10.1016/0161-5890(83)90140-2
   Povoa P, 2002, INTENS CARE MED, V28, P235, DOI 10.1007/s00134-002-1209-6
   Ramage L, 2004, INHAL TOXICOL, V16, P607, DOI 10.1080/08958370490464599
   Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646
   Ridker PM, 2018, LANCET, V391, P319, DOI 10.1016/S0140-6736(17)32814-3
   Ridker PM, 2009, CLIN CHEM, V55, P209, DOI 10.1373/clinchem.2008.119214
   Ridker PM, 2004, AM HEART J, V148, pS19, DOI 10.1016/j.ahj.2004.04.028
   Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731
   Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Salahudeen AK, 2004, KIDNEY INT, V65, P713, DOI 10.1111/j.1523-1755.2004.00416.x
   Sano T, 2003, CIRCULATION, V108, P282, DOI 10.1161/01.CIR.0000079173.84669.4F
   Santonocito C, 2014, ANESTH ANALG, V119, P624, DOI 10.1213/ANE.0000000000000263
   Scheltens P, 2016, LANCET, V388, P505, DOI 10.1016/S0140-6736(15)01124-1
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Semple JW, 2011, NAT REV IMMUNOL, V11, P264, DOI 10.1038/nri2956
   Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Slevin M, 2015, SCI REP-UK, V5, DOI 10.1038/srep13281
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
   Strang F, 2012, BRAIN PATHOL, V22, P337, DOI 10.1111/j.1750-3639.2011.00539.x
   Szalai AJ, 2002, IMMUNOL RES, V26, P279, DOI 10.1385/IR:26:1-3:279
   Thiele JR, 2014, CIRCULATION, V130, P35, DOI 10.1161/CIRCULATIONAHA.113.007124
   Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9
   TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561
   TISHLER M, 1985, CLIN RHEUMATOL, V4, P321, DOI 10.1007/BF02031616
   Tullius SG, 2000, J AM SOC NEPHROL, V11, P1317, DOI 10.1681/ASN.V1171317
   Valenzuela NM, 2017, J CLIN INVEST, V127, P2492, DOI 10.1172/JCI90597
   van de Goot F, 2009, J BURN CARE RES, V30, P274, DOI 10.1097/BCR.0b013e318198a252
   VIGUSHIN DM, 1993, J CLIN INVEST, V91, P1351, DOI 10.1172/JCI116336
   VOLANAKIS JE, 1974, J IMMUNOL, V113, P9
   VOLANAKIS JE, 1979, NATURE, V281, P155, DOI 10.1038/281155a0
   Voleti B, 2006, MOL IMMUNOL, V43, P891, DOI 10.1016/j.molimm.2005.06.045
   Wang J, 2017, NAT REV NEUROL, V13, P612, DOI 10.1038/nrneurol.2017.111
   WOOD JA, 1993, BRAIN RES, V629, P245, DOI 10.1016/0006-8993(93)91327-O
   Yasojima K, 2000, BRAIN RES, V887, P80, DOI 10.1016/S0006-8993(00)02970-X
   Yousuf O, 2013, J AM COLL CARDIOL, V62, P397, DOI 10.1016/j.jacc.2013.05.016
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503
   Zouki C, 2001, J IMMUNOL, V167, P5355, DOI 10.4049/jimmunol.167.9.5355
NR 101
TC 71
Z9 75
U1 0
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUN 12
PY 2018
VL 9
AR 1351
DI 10.3389/fimmu.2018.01351
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA GJ0XE
UT WOS:000434977000001
PM 29946323
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bian, ZM
   Field, MG
   Elner, SG
   Kahlenberg, JM
   Elner, VM
AF Bian, Zong-Mei
   Field, Matthew G.
   Elner, Susan G.
   Kahlenberg, J. Michelle
   Elner, Victor M.
TI Distinct CD40L receptors mediate inflammasome activation and secretion
   of IL-1 beta and MCP-1 in cultured human retinal pigment epithelial
   cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE CD40L; Inflammasome; IL-1 beta; MCP-1; Retinal pigment epithelium; RPE;
   Age-related macular degeneration; AMD
ID KAPPA-B ACTIVATION; MACULAR DEGENERATION; GENE-EXPRESSION; INTEGRIN
   ALPHA-5-BETA-1; ORBITAL FIBROBLASTS; CYTOKINE EXPRESSION; NLRP3
   INFLAMMASOME; ENDOTHELIAL-CELLS; BRUCHS MEMBRANE; SMOOTH-MUSCLE
AB CD40L signaling occurs in several diseases with inflammatory components, including ocular and retinal diseases. However, it has never been evaluated as a pathogenic mechanism in age-related macular degeneration (AMD) or as an inducer of inflammasome formation in any cell type. mRNA and protein levels of CD40, IL-1 beta, NALP1, NALP3, caspase-1, and caspase-5 were determined by RT-PCR, qPCR, and Western blot. CD40L receptor (CD40, alpha 5 beta 1, and CD11b) expression was determined by Western and immunofluorescent staining. IL-1 beta, IL-18, and MCP-1 secretions were determined by ELISA. NALP1 and NALP3 inflammasome formation were determined by Co-IP. Experiments were conducted on primary human retinal pigment epithelial (hRPE) cells from four different donors. Human umbilical vein endothelial (HUVEC) and monocytic leukemia (THP-1) cells demonstrated the general applicability of our findings. In hRPE cells, CD40L-induced NALP1 and NALP3 inflammasome activation, cleavage of caspase-1 and caspase-5, and IL-1 beta and IL-18 secretion. Interestingly, neutralizing CD11b and alpha 5 beta 1 antibodies, but not CD40, reduced CD40L-induced IL-1 beta secretion in hRPE cells. Similarly, CD40L treatment also induced HUVEC and THP-1 cells to secret IL-1 beta through CD11b and alpha 5 beta 1. Additionally, the CD40L-induced IL-1 beta secretion acted in an autocrine/paracrine manner to feed back and induce hRPE cells to secrete MCP-1. This study is the first to show that CD40L induces inflammasome activation in any cell type, including hRPE cells, and that this induction is through CD11b and alpha 5 beta 1 cell-surface receptors. These mechanisms likely play an important role in many retinal and non-retinal diseases and provide compelling drug targets that may help reduce pro-inflammatory processes.
C1 [Bian, Zong-Mei; Field, Matthew G.; Elner, Susan G.; Elner, Victor M.] Univ Michigan, Dept Ophthalmol, Ann Arbor, MI 48105 USA.
   [Kahlenberg, J. Michelle] Univ Michigan, Dept Internal Med Rheumatol, Ann Arbor, MI 48105 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan
RP Field, MG (通讯作者)，Univ Michigan, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM mgfield@umich.edu
OI Elner, Victor/0000-0001-7708-1898; Kahlenberg, J.
   Michelle/0000-0002-4006-8945
FU NIH [EY-09441, N007361, EY007003]; Research to Prevent Blindness-Senior
   Scientific Award; NATIONAL EYE INSTITUTE [R01EY009441, F31EY007003,
   P30EY007003] Funding Source: NIH RePORTER
FX This study was supported by NIH Grants EY-09441, N007361, EY007003, and
   Research to Prevent Blindness-Senior Scientific Award (VME).
CR Andre P, 2002, CIRCULATION, V106, P896, DOI 10.1161/01.CIR.0000028962.04520.01
   Bagenstose LM, 2005, J IMMUNOL, V175, P124, DOI 10.4049/jimmunol.175.1.124
   Bian ZM, 2004, INVEST OPHTH VIS SCI, V45, P1887, DOI 10.1167/iovs.03-0608
   Bian ZM, 2003, EXP EYE RES, V76, P573, DOI 10.1016/S0014-4835(03)00029-0
   Bian ZM, 2011, INVEST OPHTH VIS SCI, V52, P8646, DOI 10.1167/iovs.11-7570
   Brignole F, 2000, INVEST OPHTH VIS SCI, V41, P1356
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chaurasia P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004617
   Chen YJ, 2018, AM J PATHOL, V188, P1031, DOI 10.1016/j.ajpath.2017.12.014
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cummins TD, 2018, METHODS MOL BIOL, V1788, P43, DOI 10.1007/7651_2017_85
   D'Aversa TG, 2002, AM J PATHOL, V160, P559, DOI 10.1016/S0002-9440(10)64875-4
   DESCHENES J, 1988, BRIT J OPHTHALMOL, V72, P83, DOI 10.1136/bjo.72.2.83
   DEVOS AF, 1992, CURR EYE RES, V11, P581, DOI 10.3109/02713689209001814
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x
   ELNER SG, 1991, LAB INVEST, V64, P819
   Elner SG, 2003, EXP EYE RES, V76, P585, DOI 10.1016/S0014-4835(03)00028-9
   Elner SG, 1996, INVEST OPHTH VIS SCI, V37, P696
   ELNER SG, 1992, LAB INVEST, V66, P200
   Elner VM, 1997, EXP EYE RES, V65, P781, DOI 10.1006/exer.1997.0380
   ELNER VM, 1990, AM J PATHOL, V136, P745
   ELNER VM, 1981, SCIENCE, V211, P74, DOI 10.1126/science.7444450
   FRANK RN, 1984, OPHTHALMOLOGY, V91, P626
   FRANKS WA, 1992, CURR EYE RES, V11, P187, DOI 10.3109/02713689208999531
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Gelbmann CM, 2003, GUT, V52, P1448, DOI 10.1136/gut.52.10.1448
   Greene JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144133
   Guarda G, 2009, NATURE, V460, P269, DOI 10.1038/nature08100
   Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2
   Hassan GS, 2012, IMMUNOBIOLOGY, V217, P521, DOI 10.1016/j.imbio.2011.03.010
   HAYREH SS, 1986, OPHTHALMOLOGY, V93, P1383
   Heeschen C, 2003, NEW ENGL J MED, V348, P1104, DOI 10.1056/NEJMoa022600
   Hirakawa M, 2006, FASEB J, V20, P1992, DOI 10.1096/fj.05-5580com
   Huang B., 2013, INT J ADV MANUF TECH, P1, DOI DOI 10.1177/0954405413497474
   Hwang CJ, 2009, INVEST OPHTH VIS SCI, V50, P2262, DOI 10.1167/iovs.08-2328
   Jadhav S, 2001, J IMMUNOL, V167, P5986, DOI 10.4049/jimmunol.167.10.5986
   JAFFE GJ, 1992, EXP EYE RES, V55, P325, DOI 10.1016/0014-4835(92)90197-Z
   Kanneganti TD, 2007, IMMUNITY, V26, P433, DOI 10.1016/j.immuni.2007.03.008
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251
   Khare S, 2016, METHODS MOL BIOL, V1417, P131, DOI 10.1007/978-1-4939-3566-6_8
   Kilmon MA, 2007, BLOOD, V110, P1595, DOI 10.1182/blood-2007-06-061648
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Koumas L, 2001, AM J PATHOL, V159, P925, DOI 10.1016/S0002-9440(10)61768-3
   KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x
   Lamkanfi M, 2012, ANNU REV CELL DEV BI, V28, P137, DOI 10.1146/annurev-cellbio-101011-155745
   Lee VWS, 2010, NEPHROL DIAL TRANSPL, V25, P717, DOI 10.1093/ndt/gfp569
   Leveille C, 2007, J BIOL CHEM, V282, P5143, DOI 10.1074/jbc.M608342200
   Li R, 2009, INVEST OPHTH VIS SCI, V50, P5988, DOI 10.1167/iovs.09-3591
   LIMB G A, 1991, Eye (London), V5, P686
   Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200
   Mach F, 1997, CIRCULATION, V96, P396
   Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Michel NA, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00040
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   NAKAMORI S, 1993, CANCER RES, V53, P3632
   Pietravalle F, 1996, J BIOL CHEM, V271, P5965, DOI 10.1074/jbc.271.11.5965
   PLANCK SR, 1993, CURR EYE RES, V12, P205, DOI 10.3109/02713689308999465
   POLLACK A, 1986, ARCH OPHTHALMOL-CHIC, V104, P1377, DOI 10.1001/archopht.1986.01050210131040
   Portillo JAC, 2017, DIABETES, V66, P483, DOI 10.2337/db16-0051
   Portillo JAC, 2008, J IMMUNOL, V181, P8719, DOI 10.4049/jimmunol.181.12.8719
   ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3475
   Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776
   Schonbeck U, 1997, J BIOL CHEM, V272, P19569, DOI 10.1074/jbc.272.31.19569
   Sugiura T, 2000, J IMMUNOL, V164, P6593, DOI 10.4049/jimmunol.164.12.6593
   SYMONS JA, 1987, CLIN EXP IMMUNOL, V68, P648
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Togo T, 2000, BRAIN RES, V885, P117, DOI 10.1016/S0006-8993(00)02984-X
   Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Verma VK, 2016, J HEPATOL, V64, P651, DOI 10.1016/j.jhep.2015.11.020
   Vyleta ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036044
   WAKEFIELD D, 1992, CYTOKINE, V4, P1, DOI 10.1016/1043-4666(92)90028-P
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/724648
   Willermain F, 2000, INVEST OPHTH VIS SCI, V41, P3485
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zhao LQ, 2010, INVEST OPHTH VIS SCI, V51, P4652, DOI 10.1167/iovs.09-3789
   Zirlik A, 2007, CIRCULATION, V115, P1571, DOI 10.1161/CIRCULATIONAHA.106.683201
NR 84
TC 12
Z9 12
U1 0
U2 15
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2018
VL 170
BP 29
EP 39
DI 10.1016/j.exer.2018.02.014
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GG4CB
UT WOS:000432638900005
PM 29454857
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ying, GS
   Maguire, MG
   Glynn, R
   Rosner, B
AF Ying, Gui-shuang
   Maguire, Maureen G.
   Glynn, Robert
   Rosner, Bernard
TI Tutorial on Biostatistics: Statistical Analysis for Correlated Binary
   Eye Data
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Correlated binary data; generalized estimating equations; generalized
   linear mixed effects model; inter-eye correlation; marginal model
ID MACULAR DEGENERATION; REGRESSION-ANALYSIS; RETINOPATHY; MODELS; TRIAL;
   AREDS
AB Purpose: To describe and demonstrate methods for analyzing correlated binary eye data.
   Methods: We describe non-model based (McNemar's test, Cochran-Mantel-Haenszel test) and model-based methods (generalized linear mixed effects model, marginal model) for analyses involving both eyes. These methods were applied to: (1) CAPT (Complications of Age-related Macular Degeneration Prevention Trial) where one eye was treated and the other observed (paired design); (2) ETROP (Early Treatment for Retinopathy of Prematurity) where bilaterally affected infants had one eye treated conventionally and the other treated early and unilaterally affected infants had treatment assigned randomly; and (3) AREDS (Age-Related Eye Disease Study) where treatment was systemic and outcome was eye-specific (both eyes in the same treatment group).
   Results: In the CAPT (n = 80), treatment group (30% vision loss in treated vs. 44% in observed eyes) was not statistically significant (p = 0.07) when inter-eye correlation was ignored, but was significant (p = 0.01) with McNemar's test and the marginal model. Using standard logistic regression for unfavorable vision in ETROP, standard errors and p-values were larger for person-level covariates and were smaller for ocular covariates than using models accounting for inter-eye correlation. For risk factors of geographic atrophy in AREDS, two-eye analyses accounting for inter-eye correlation yielded more power than one-eye analyses and provided larger standard errors and p-values than invalid two-eye analyses ignoring inter-eye correlation.
   Conclusion: Ignoring inter-eye correlation can lead to larger p-values for paired designs and smaller p-values when both eyes are in the same group. Marginal models or mixed effects models using the eye as the unit of analysis provide valid inference.
C1 [Ying, Gui-shuang; Maguire, Maureen G.] Univ Penn, Dept Ophthalmol, Perelman Sch Med, Ctr Prevent Ophthalmol & Biostat, Philadelphia, PA 19104 USA.
   [Glynn, Robert; Rosner, Bernard] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA.
   [Glynn, Robert; Rosner, Bernard] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Harvard University;
   Brigham & Women's Hospital; Harvard University; Brigham & Women's
   Hospital
RP Ying, GS (通讯作者)，Univ Penn, Dept Ophthalmol, Perelman Sch Med, Ctr Prevent Ophthalmol & Biostat, Philadelphia, PA 19104 USA.
EM gsying@mail.med.upenn.edu
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services [R01EY022445, P30 EY01583-26]; Research to
   Prevent Blindness to the University of Pennsylvania; NATIONAL EYE
   INSTITUTE [R01EY022445, P30EY001583] Funding Source: NIH RePORTER
FX This study was supported by grants R01EY022445 and P30 EY01583-26 from
   the National Eye Institute, National Institutes of Health, Department of
   Health and Human Services and an unrestricted grant from Research to
   Prevent Blindness to the University of Pennsylvania.
CR Armstrong RA, 2013, OPHTHAL PHYSL OPT, V33, P7, DOI 10.1111/opo.12009
   BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   DUFFY SW, 1989, AM J EPIDEMIOL, V130, P371, DOI 10.1093/oxfordjournals.aje.a115343
   Good William V, 2004, Trans Am Ophthalmol Soc, V102, P233
   Good WV, 2001, OPHTHALMOLOGY, V108, P1013, DOI 10.1016/S0161-6420(01)00540-1
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355
   McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996
   Murdoch IE, 1998, BRIT J OPHTHALMOL, V82, P971, DOI 10.1136/bjo.82.8.971
   Neuhaus J M, 1992, Stat Methods Med Res, V1, P249, DOI 10.1177/096228029200100303
   NEUHAUS JM, 1991, INT STAT REV, V59, P25, DOI 10.2307/1403572
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   SELF SG, 1987, J AM STAT ASSOC, V82, P605, DOI 10.2307/2289471
   Ten Have TR, 1999, STAT MED, V18, P947, DOI 10.1002/(SICI)1097-0258(19990430)18:8<947::AID-SIM95>3.0.CO;2-B
   WALLENSTEIN S, 1993, BIOMETRICS, V49, P1077, DOI 10.2307/2532249
   Ying GS, 2017, OPHTHAL EPIDEMIOL, V24, P130, DOI 10.1080/09286586.2016.1259636
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 19
TC 48
Z9 48
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2018
VL 25
IS 1
BP 1
EP 12
DI 10.1080/09286586.2017.1320413
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ6WT
UT WOS:000427741700001
PM 28532207
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Heller, JP
   Kwok, JCF
   Vecino, E
   Martin, KR
   Fawcett, JW
AF Heller, Janosch P.
   Kwok, Jessica C. F.
   Vecino, Elena
   Martin, Keith R.
   Fawcett, James W.
TI A Method for the Isolation and Culture of Adult Rat Retinal Pigment
   Epithelial (RPE) Cells to Study Retinal Diseases
SO FRONTIERS IN CELLULAR NEUROSCIENCE
LA English
DT Article
DE retinal pigment epithelium; rat; papain; isolation; culture; adult;
   age-related macular degeneration; retina
ID PLURIPOTENT STEM-CELLS; HUMAN BRUCHS MEMBRANE; MACULAR DEGENERATION;
   EXTRACELLULAR-MATRIX; DIRECTED DIFFERENTIATION; PHOTORECEPTOR RESCUE;
   VISUAL FUNCTION; SHORT-TERM; IN-VITRO; TRANSPLANTATION
AB Diseases such as age-related macular degeneration (AMD) affect the retinal pigment epithelium (RPE) and lead to the death of the epithelial cells and ultimately blindness. RPE transplantation is currently a major focus of eye research and clinical trials using human stem cell-derived RPE cells are ongoing. However, it remains to be established to which extent the source of RPE cells for transplantation affects their therapeutic efficacy and this needs to be explored in animal models. Autotransplantation of RPE cells has attractions as a therapy, but existing protocols to isolate adult RPE cells from rodents are technically difficult, time-consuming, have a low yield and are not optimized for long-term cell culturing. Here, we report a newly devised protocol which facilitates reliable and simple isolation and culture of RPE cells from adult rats. Incubation of a whole rat eyeball in 20 U/ml papain solution for 50 min yielded 4 x 10(4) viable RPE cells. These cells were hexagonal and pigmented upon culture. Using immunostaining, we demonstrated that the cells expressed RPE cell specific marker proteins including cytokeratin 18 and RPE65, similar to RPE cells in vivo. Additionally, the cells were able to produce and secrete Bruch's membrane matrix components similar to in vivo situation. Similarly, the cultured RPE cells adhered to isolated Bruch's membrane as has previously been reported. Therefore, the protocol described in this article provides an efficient method for the rapid and easy isolation of high quantities of adult rat RPE cells. This provides a reliable platform for studying the therapeutic targets, testing the effects of drugs in a preclinical setup and to perform in vitro and in vivo transplantation experiments to study retinal diseases.
C1 [Heller, Janosch P.; Kwok, Jessica C. F.; Vecino, Elena; Martin, Keith R.; Fawcett, James W.] Univ Cambridge, John van Geest Ctr Brain Repair, Dept Clin Neurosci, Cambridge, England.
   [Heller, Janosch P.] UCL, Inst Neurol, Dept Clin & Expt Epilepsy, London, England.
   [Vecino, Elena] Univ Basque Country, Dept Cellular Biol, Leioa, Spain.
   [Vecino, Elena] Univ Basque Country, Bizkaia, Spain.
   [Martin, Keith R.] Univ Cambridge, Dept Ophthalmol, NIHR Biomed Res Ctr, Cambridge, England.
   [Martin, Keith R.] Univ Cambridge, Wellcome Tust Med Res Council Cambridge Stem Cell, Cambridge, England.
C3 University of Cambridge; University of London; University College
   London; University of Basque Country; University of Basque Country;
   University of Cambridge; University of Cambridge
RP Martin, KR (通讯作者)，Univ Cambridge, John van Geest Ctr Brain Repair, Dept Clin Neurosci, Cambridge, England.
EM krgm2@cam.ac.uk
RI Heller, Janosch/J-7509-2019; Vecino, Elena/AAO-3462-2021; Heller,
   Janosch/GVT-5921-2022
OI Heller, Janosch/0000-0002-8825-3787; Vecino, Elena/0000-0002-1672-5132;
   Fawcett, James/0000-0002-7990-4568
FU Medical Research Council [G10000864]; Christopher and Dana Reeves
   Foundation; Wellcome Trust MRC Cambridge Stem Cell Institute and Fight
   for Sight; Grupos Consolidados Gobierno Vasco [1T437-10]; MRC [G1000864]
   Funding Source: UKRI; Medical Research Council [G1000864] Funding
   Source: researchfish
FX This work was funded by the following grants: Medical Research Council
   (G10000864) (JH, JK and JF), Christopher and Dana Reeves Foundation
   (JF), the Wellcome Trust MRC Cambridge Stem Cell Institute and Fight for
   Sight (KM), and Grupos Consolidados Gobierno Vasco (1T437-10) (EV).
CR Afshari FT, 2010, GLIA, V58, P857, DOI 10.1002/glia.20970
   Afshari FT, 2010, BRAIN, V133, P448, DOI 10.1093/brain/awp319
   Agulhon C, 2007, J PHYSIOL-LONDON, V583, P945, DOI 10.1113/jphysiol.2007.135715
   Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Solinis MA, 2015, EUR J PHARM BIOPHARM, V95, P331, DOI 10.1016/j.ejpb.2014.12.022
   BAUMGARTNER I, 1989, GRAEF ARCH CLIN EXP, V227, P541, DOI 10.1007/BF02169449
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   Bertolotti E, 2014, PROG RETIN EYE RES, V42, P130, DOI 10.1016/j.preteyeres.2014.06.002
   Bian ZM, 2007, INVEST OPHTH VIS SCI, V48, P2738, DOI 10.1167/iovs.06-1023
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8
   Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   Campbell Matthew, 2012, Adv Exp Med Biol, V763, P70
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Castellarin AA, 1998, BRIT J OPHTHALMOL, V82, P480, DOI 10.1136/bjo.82.5.480
   Castillo BV, 1997, EXP NEUROL, V146, P1, DOI 10.1006/exnr.1997.6534
   CASTILLO BV, 1995, CURR EYE RES, V14, P677, DOI 10.3109/02713689508998495
   CHANG CW, 1991, CURR EYE RES, V10, P1081, DOI 10.3109/02713689109020348
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Cong LD, 2008, INVEST OPHTH VIS SCI, V49, P4115, DOI 10.1167/iovs.08-1976
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x
   EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301
   EDWARDS RB, 1981, VISION RES, V21, P147, DOI 10.1016/0042-6989(81)90149-8
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200
   Gibbs D, 2003, ADV EXP MED BIOL, V533, P347
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009
   Heller JP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.4
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Housset M, 2013, J NEUROSCI, V33, P9890, DOI 10.1523/JNEUROSCI.1099-13.2013
   Hu J, 2010, METHODS MOL BIOL, V652, P55, DOI 10.1007/978-1-60327-325-1_2
   Huang J, 2009, MOL VIS, V15, P223
   HUNT RC, 1989, J CELL SCI, V92, P655
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Johansson UE, 2010, J HISTOCHEM CYTOCHEM, V58, P377, DOI 10.1369/jhc.2009.954933
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   KONARI K, 1995, EXP EYE RES, V61, P99, DOI 10.1016/S0014-4835(95)80063-8
   Kreppel F., 2002, INVEST OPHTH VIS SCI, V43, P1965
   Lane A, 2014, STEM CELL TRANSL MED, V3, P1295, DOI 10.5966/sctm.2014-0094
   Langenfeld A, 2015, GRAEF ARCH CLIN EXP, V253, P1493, DOI 10.1007/s00417-015-3011-5
   LI LX, 1988, EXP EYE RES, V47, P771, DOI 10.1016/0014-4835(88)90044-9
   Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200
   MAYERSON PL, 1985, INVEST OPHTH VIS SCI, V26, P1599
   NABI IR, 1993, J CELL SCI, V104, P37
   NAN W, 1993, INVEST OPHTH VIS SCI, V34, P101
   Nandrot EF, 2012, BIOL CELL, V104, P326, DOI 10.1111/boc.201100076
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Pfeffer BA, 2014, EXP EYE RES, V126, P1, DOI 10.1016/j.exer.2014.07.010
   Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1716, DOI 10.1167/iovs.02-0287
   Pierce EA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017285
   Pinzon-Duarte G, 2000, VISION RES, V40, P3455, DOI 10.1016/S0042-6989(00)00185-1
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sahel JA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017111
   SAKAGAMI K, 1995, OPHTHALMIC RES, V27, P262, DOI 10.1159/000267735
   Sato R, 2013, INVEST OPHTH VIS SCI, V54, P1740, DOI 10.1167/iovs.12-10068
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   SHEEDLO HJ, 1993, EXP EYE RES, V57, P753, DOI 10.1006/exer.1993.1183
   Sheridan C, 2004, GRAEF ARCH CLIN EXP, V242, P68, DOI 10.1007/s00417-003-0800-z
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   TAMAI M, 1979, INVEST OPHTH VIS SCI, V18, P913
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P767
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   VINORES SA, 1995, EXP EYE RES, V60, P385, DOI 10.1016/S0014-4835(05)80095-8
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Wang H, 2006, J REHABIL RES DEV, V43, P713, DOI 10.1682/JRRD.2005.06.0114
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   WEN R, 1994, J PHYSIOL-LONDON, V476, P187, DOI 10.1113/jphysiol.1994.sp020122
NR 97
TC 13
Z9 13
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-5102
J9 FRONT CELL NEUROSCI
JI Front. Cell. Neurosci.
PD NOV 20
PY 2015
VL 9
AR 449
DI 10.3389/fncel.2015.00449
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CW5AQ
UT WOS:000365008200001
PM 26635529
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sulaiman, RS
   Basavarajappa, HD
   Corson, TW
AF Sulaiman, Rania S.
   Basavarajappa, Halesha D.
   Corson, Timothy W.
TI Natural product inhibitors of ocular angiogenesis
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Angiogenesis; Natural compounds; Blinding diseases; Small molecules;
   Choroidal neovascularization; Retinal neovascularization; Polyphenols
ID ENDOTHELIAL GROWTH-FACTOR; OXYGEN-INDUCED RETINOPATHY; INDUCED CHOROIDAL
   NEOVASCULARIZATION; UBIQUITIN-PROTEASOME PATHWAY; RETINAL OXIDATIVE
   STRESS; CELL-CYCLE PROGRESSION; NF-KAPPA-B; IN-VITRO; MACULAR
   DEGENERATION; DIABETIC-RETINOPATHY
AB Natural products are characterized by high chemical diversity and biochemical specificity; therefore, they are appealing as lead compounds for drug discovery. Given the importance of angiogenesis to many pathologies, numerous natural products have been explored as potential anti-angiogenic drugs. Ocular angiogenesis underlies blinding eye diseases such as retinopathy of prematurity (ROP) in children, proliferative diabetic retinopathy (DR) in adults of working age, and age-related macular degeneration (AMD) in the elderly. Despite the presence of effective therapy in many cases, these diseases are still a significant health burden. Anti-VEGF biologics are the standard of care, but may cause ocular or systemic side effects after intraocular administration and patients may be refractory. Many anti-angiogenic compounds inhibit tumor growth and metastasis alone or in combination therapy, but a more select subset of them has been tested in the context of ocular neovascular diseases. Here, we review the promise of natural products as anti-angiogenic agents, with a specific focus on retinal and choroidal neovascularization. The multifunctional curcumin and the chalcone isoliquiritigenin have demonstrated promising anti-angiogenic effects in mouse models of DR and choroidal neovascularization (CNV) respectively. The homoisoflavanone cremastranone and the flavonoid deguelin have been shown to inhibit ocular neovascularization in more than one disease model. The isoflavone genistein and the flavone apigenin on the other hand are showing potential in the prevention of retinal and choroidal angiogenesis with long-term administration. Many other products with anti-angiogenic potential in vitro such as the lactone withaferin A, the flavonol quercetin, and the stilbenoid combretastatin A4 are awaiting investigation in different ocular disease-relevant animal models. These natural products may serve as lead compounds for the design of more specific, efficacious, and affordable drugs with minimal side effects. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Sulaiman, Rania S.; Basavarajappa, Halesha D.; Corson, Timothy W.] Indiana Univ Sch Med, Eugene & Marilyn Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Sulaiman, Rania S.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA.
   [Basavarajappa, Halesha D.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Corson, Timothy W.] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA.
   [Sulaiman, Rania S.] Cairo Univ, Fac Pharm, Dept Biochem, Cairo, Egypt.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Egyptian Knowledge Bank (EKB); Cairo
   University
RP Corson, TW (通讯作者)，1160 West Michigan St, Indianapolis, IN 46202 USA.
EM tcorson@iupui.edu
RI Corson, Timothy W./B-6851-2009; Basavarajappa, Halesha
   Dhurvigere/V-2038-2019
OI Corson, Timothy W./0000-0002-1402-7875; Basavarajappa, Halesha
   Dhurvigere/0000-0002-2840-5937
FU International Retinal Research Foundation; Showalter Research Trust;
   Retina Research Foundation; Carl Marshall and Mildred Almen Reeves
   Foundation; IUPUI FORCES grant; Research to Prevent Blindness, Inc.;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR001106,
   UL1TR001108, UL1TR002529] Funding Source: NIH RePORTER
FX We thank Drs. Michael Boulton and Dulcie Mulholland for critical
   comments on the manuscript. Related work in the authors' laboratory is
   supported by the International Retinal Research Foundation, the
   Showalter Research Trust, the Retina Research Foundation, the Carl
   Marshall and Mildred Almen Reeves Foundation, and an IUPUI FORCES grant.
   This publication was supported in part by an unrestricted grant from
   Research to Prevent Blindness, Inc. HDB is a Kemin Health Ausich
   Graduate Scholar and TWC is an Indiana CTSI KL2 Scholar (NIH/NCATS
   KL2TR001106).
CR Ahmed B, 2003, INT J CANCER, V105, P20, DOI 10.1002/ijc.11010
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   ASHTON N, 1954, BRIT J OPHTHALMOL, V38, P397, DOI 10.1136/bjo.38.7.397
   Bagli E, 2004, CANCER RES, V64, P7936, DOI 10.1158/0008-5472.CAN-03-3104
   Bai XH, 2003, J BIOL CHEM, V278, P35501, DOI 10.1074/jbc.M302967200
   Bargagna-Mohan P, 2007, CHEM BIOL, V14, P623, DOI 10.1016/j.chembiol.2007.04.010
   Bargagna-Mohan P, 2006, INVEST OPHTH VIS SCI, V47, P4138, DOI 10.1167/iovs.05-1452
   Bargagna-Mohan P, 2010, J BIOL CHEM, V285, P7657, DOI 10.1074/jbc.M109.093765
   Basavarajappa H.D., 2013, INVEST OPHTHALMOL VI, V54
   Basavarajappa H.D., 2014, INVEST OPHTHALMOL VI, V55
   Basavarajappa HD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095694
   Benny O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012515
   Brakenhielm E, 2001, FASEB J, V15, P1798, DOI 10.1096/fj.01-0028fje
   Buck SB, 2008, BIOTECHNIQUES, V44, P927, DOI 10.2144/000112812
   Cao LM, 2010, INVEST OPHTH VIS SCI, V51, P6658, DOI 10.1167/iovs.10-5524
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chen Y, 2008, GRAEF ARCH CLIN EXP, V246, P373, DOI 10.1007/s00417-007-0728-9
   Coats David K, 2005, Trans Am Ophthalmol Soc, V103, P281
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Corson TW, 2007, CELL, V130, P769, DOI 10.1016/j.cell.2007.08.021
   DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Folkman J, 1992, Semin Cancer Biol, V3, P89
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1
   FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690
   Fraisl P, 2009, DEV CELL, V16, P167, DOI 10.1016/j.devcel.2009.01.003
   FUGNER A, 1973, ARZNEIMITTEL-FORSCH, V23, P932
   Gerhauser C, 1997, CANCER RES, V57, P3429
   Griggs J, 2002, AM J PATHOL, V160, P1097, DOI 10.1016/S0002-9440(10)64930-9
   GRILLI M, 1993, INT REV CYTOL, V143, P1
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Horinaka M, 2006, MOL CANCER THER, V5, P945, DOI 10.1158/1535-7163.MCT-05-0431
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Jackson SJT, 2006, J NUTR, V136, P1178, DOI 10.1093/jn/136.5.1178
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JAVITT J, 1993, PEDIATRICS, V91, P859
   Jhanji V, 2011, BRIT J OPHTHALMOL, V95, P1309, DOI 10.1136/bjophthalmol-2011-300110
   Ji HF, 2009, EMBO REP, V10, P194, DOI 10.1038/embor.2009.12
   Jo DH, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-38
   Jung MH, 2009, CARCINOGENESIS, V30, P655, DOI 10.1093/carcin/bgp039
   Kador PF, 2007, J OCUL PHARMACOL TH, V23, P132, DOI 10.1089/jop.2006.0103
   Kang SW, 2010, J NUTR BIOCHEM, V21, P55, DOI 10.1016/j.jnutbio.2008.10.004
   Kawaii S, 1999, J AGR FOOD CHEM, V47, P3565, DOI 10.1021/jf990153+
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Kim JH, 2008, J CELL MOL MED, V12, P2407, DOI 10.1111/j.1582-4934.2008.00243.x
   Kim JH, 2008, MOL VIS, V14, P556
   Kim JH, 2008, J PHARMACOL EXP THER, V324, P643, DOI 10.1124/jpet.107.132720
   Kim JH, 2007, BIOCHEM BIOPH RES CO, V362, P848, DOI 10.1016/j.bbrc.2007.08.100
   Kim JH, 2009, MOL VIS, V15, P1868
   Kim MH, 2003, J CELL BIOCHEM, V89, P529, DOI 10.1002/jcb.10543
   Kim Woo Taek, 2010, Korean J Ophthalmol, V24, P108, DOI 10.3341/kjo.2010.24.2.108
   Kim WY, 2008, CANCER PREV RES, V1, P577, DOI 10.1158/1940-6207.CAPR-08-0184
   Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657
   KONOSHIMA M, 1968, CHEM PHARM BULL, V16, P1139
   KOROMA BM, 1994, BIOCHEM PHARMACOL, V48, P809, DOI 10.1016/0006-2952(94)90060-4
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Kumar B, 2013, MICROVASC RES, V87, P65, DOI 10.1016/j.mvr.2013.01.002
   KUTTAN R, 1987, TUMORI, V73, P29, DOI 10.1177/030089168707300105
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai AKW, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/106594
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lee B, 2014, ORG BIOMOL CHEM, V12, P7673, DOI 10.1039/c4ob01604a
   Lee YJ, 2011, PHARMACOL THERAPEUT, V130, P157, DOI 10.1016/j.pharmthera.2011.01.010
   Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Macha S, 2003, OPHTHALMIC DRUG DELI
   MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375
   Majumdar S, 2010, J PHARM PHARMACOL, V62, P951, DOI 10.1211/jpp.62.08.0001
   Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727
   Matsumoto H, 2006, EXP EYE RES, V83, P348, DOI 10.1016/j.exer.2005.12.019
   Miean KH, 2001, J AGR FOOD CHEM, V49, P3106, DOI 10.1021/jf000892m
   Mishra BB, 2011, EUR J MED CHEM, V46, P4769, DOI 10.1016/j.ejmech.2011.07.057
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405
   Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3
   Nakajima M, 2001, INVEST OPHTH VIS SCI, V42, P2110
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nyberg P, 2005, CANCER RES, V65, P3967, DOI 10.1158/0008-5472.CAN-04-2427
   PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0
   Paranthan RR, 2011, MOL VIS, V17, P1901
   Park SW, 2012, INVEST OPHTH VIS SCI, V53, P7718, DOI 10.1167/iovs.11-8790
   Premanand C, 2006, INVEST OPHTH VIS SCI, V47, P2179, DOI 10.1167/iovs.05-0580
   Qazi Y, 2009, J GENET, V88, P495, DOI 10.1007/s12041-009-0068-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sagar S M, 2006, Curr Oncol, V13, P99
   Sagar S M, 2006, Curr Oncol, V13, P14
   Sapieha P, 2010, J CLIN INVEST, V120, P3022, DOI 10.1172/JCI42142
   Schmidt BM, 2007, NAT CHEM BIOL, V3, P360, DOI 10.1038/nchembio0707-360
   Sheu ML, 2008, FREE RADICAL BIO MED, V44, P2043, DOI 10.1016/j.freeradbiomed.2008.03.014
   Shim JS, 2004, PLANTA MED, V70, P171, DOI 10.1055/s-2004-815496
   Singh AK, 1996, CANCER LETT, V107, P109, DOI 10.1016/0304-3835(96)04357-1
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Smith LEH, 2002, ACTA PAEDIATR, V91, P26, DOI 10.1080/08035250260095771
   Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5
   Soufi FG, 2012, PHARMACOL REP, V64, P1505, DOI 10.1016/S1734-1140(12)70948-9
   Srirangam R, 2012, J PHARM SCI-US, V101, P1631, DOI 10.1002/jps.23047
   Stewart MW, 2012, BRIT J OPHTHALMOL, V96, P1157, DOI 10.1136/bjophthalmol-2011-300654
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Vavilala DT, 2013, BIOCHEM BIOPH RES CO, V438, P697, DOI 10.1016/j.bbrc.2013.07.118
   Vaya J, 1997, FREE RADICAL BIO MED, V23, P302, DOI 10.1016/S0891-5849(97)00089-0
   Wang B, 2005, J OCUL PHARMACOL TH, V21, P107, DOI 10.1089/jop.2005.21.107
   Yang SJ, 2014, CURR EYE RES, V39, P745, DOI 10.3109/02713683.2013.868908
   Yang Y, 2013, MOL CELL ENDOCRINOL, V378, P46, DOI 10.1016/j.mce.2013.04.021
   Young SL, 2004, EXPERT OPIN INV DRUG, V13, P1171, DOI 10.1517/13543784.13.9.1171
   Zhang L, 2009, CURR EYE RES, V34, P257, DOI 10.1080/02713680902725962
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zhuang Pei, 2011, Eye Sci, V26, P23, DOI 10.3969/j.issn.1000-4432.2011.01.006
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P425, DOI 10.1089/jop.2006.22.425
NR 119
TC 65
Z9 70
U1 1
U2 53
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2014
VL 129
BP 161
EP 171
DI 10.1016/j.exer.2014.10.002
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX4HJ
UT WOS:000346893800019
PM 25304218
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Shen, DF
   Cao, XG
   Zhao, L
   Tuo, JS
   Wong, WT
   Chan, CC
AF Shen, Defen
   Cao, Xiaoguang
   Zhao, Lian
   Tuo, Jingsheng
   Wong, Wai T.
   Chan, Chi-Chao
TI Naloxone Ameliorates Retinal Lesions in Ccl2/Cx3cr1 Double-Deficient
   Mice via Modulation of Microglia
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID INDUCED PHOTORECEPTOR DEGENERATION; MACULAR DEGENERATION; NITRIC-OXIDE;
   NEURODEGENERATIVE DISEASES; THERAPEUTIC INTERVENTION;
   INTRAOCULAR-PRESSURE; SUBRETINAL MICROGLIA; ACTIVATED MICROGLIA;
   PARKINSONS-DISEASE; OPIOID RECEPTOR
AB PURPOSE. The role of naloxone, an opioid receptor antagonist, on microglial inhibition and neuroprotective effects has been reported in lipopolysaccharide (LPS)-induced neurodegeneration and light-induced photoreceptor degeneration. The authors evaluated the effects of naloxone on Ccl2(-/-)/Cx3cr1(-/-) (DKO) mice, a murine model of age-related macular degeneration (AMD).
   METHODS. Two-month-old DKO and wild-type controls were given daily intraperitoneal injections of naloxone or PBS for 2 months. Animals were examined monthly by funduscopy. Ocular tissue was analyzed histologically and in retinal flat mount preparations. Ocular A2E was measured using HPLC. Quantitative RT-PCR analyzed TNF-alpha, IL-1 beta, IL-10 and TLR4 transcripts in the DKO eyes and LPS activated culture microglial cells. Serum nitrite was measured using Griess colorimetric reaction.
   RESULTS. Naloxone ameliorated the clinical progression and severity of retinal lesions in the DKO mice compared with those of untreated controls. Histopathology also showed less focal retinal degeneration in the treated DKO mice than in controls. The aggregation of microglia in the outer retina in DKO mice was significantly reduced in naloxone-treated animals compared with control untreated DKO. Ocular TNF-alpha, IL-1 beta, and TLR4 transcripts and A2E were significantly lower in naloxone-treated DKO animals and cultured microglial cells than in controls, as were serum nitrite levels.
   CONCLUSIONS. Naloxone significantly reduces the progress of retinal lesions in DKO mice. Naloxone modulates microglia accumulation and activation at the site of retinal degeneration, which may be mediated by inhibition of the proinflammatory molecules of NO, TNF-alpha, and IL-beta. The potential therapeutic effects of naloxone on retinal degeneration, including AMD, warrants further investigation. (Invest Ophthalmol Vis Sci. 2011;52:2897-2904) DOI:10.1167/iovs.10-6114
C1 [Shen, Defen; Cao, Xiaoguang; Tuo, Jingsheng; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Zhao, Lian; Wong, Wai T.] NEI, Unit Neuronal & Glial Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
   [Cao, Xiaoguang] Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100871, Peoples R China.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Peking University
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, Bldg 10,Room 10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Tuo, Jingsheng/0000-0002-1372-7810
FU National Eye Institute; NATIONAL EYE INSTITUTE [ZIAEY000418,
   ZIAEY000463, ZIAEY000222, ZICEY000461] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute Intramural Research Program.
CR Ahmed F, 2004, INVEST OPHTH VIS SCI, V45, P1247, DOI 10.1167/iovs.03-1123
   Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Beutler B, 2002, CURR TOP MICROBIOL, V270, P109
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   Bonfiglio V, 2006, EUR J PHARMACOL, V534, P227, DOI 10.1016/j.ejphar.2006.01.045
   Carter DA, 2003, BRIT J OPHTHALMOL, V87, P481, DOI 10.1136/bjo.87.4.481
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen L, 2004, EXP EYE RES, V79, P239, DOI 10.1016/j.exer.2004.05.002
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Dick AD, 2009, EYE, V23, P1939, DOI 10.1038/eye.2008.380
   DING AH, 1988, J IMMUNOL, V141, P2407
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Gehrig A, 2007, INVEST OPHTH VIS SCI, V48, P891, DOI 10.1167/iovs.06-0641
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Gwak MS, 2010, NEUROSCIENCE, V167, P256, DOI 10.1016/j.neuroscience.2010.02.017
   IIJIMA I, 1978, J MED CHEM, V21, P398, DOI 10.1021/jm00202a018
   Jeohn GH, 2002, NEUROSCIENCE, V114, P689, DOI 10.1016/S0306-4522(02)00356-1
   Kang JH, 2001, NEUROREPORT, V12, P1449, DOI 10.1097/00001756-200105250-00030
   Kercher L, 2007, J VIROL, V81, P10340, DOI 10.1128/JVI.00865-07
   Kong LY, 1997, J PHARMACOL EXP THER, V280, P61
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100
   Lin SL, 2010, BEHAV BRAIN RES, V207, P30, DOI 10.1016/j.bbr.2009.09.034
   Liu B, 2000, J PHARMACOL EXP THER, V293, P607
   Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048
   Lu X, 2000, NEUROSCIENCE, V97, P285, DOI 10.1016/S0306-4522(00)00033-6
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   MARCOLI M, 1989, INT J IMMUNOPHARMACO, V11, P57, DOI 10.1016/0192-0561(89)90099-4
   Naskar R, 2002, INVEST OPHTH VIS SCI, V43, P2962
   Ni YQ, 2008, INVEST OPHTH VIS SCI, V49, P2589, DOI 10.1167/iovs.07-1173
   Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17
   Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Santos AM, 2010, J COMP NEUROL, V518, P477, DOI 10.1002/cne.22227
   Sasahara M, 2008, AM J PATHOL, V172, P1693, DOI 10.2353/ajpath.2008.080024
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   SIMPKINS CO, 1985, LIFE SCI, V37, P1381, DOI 10.1016/0024-3205(85)90076-1
   Stagni E, 2010, J OCUL PHARMACOL TH, V26, P31, DOI 10.1089/jop.2009.0081
   Streit WJ, 2005, BRAIN RES REV, V48, P234, DOI 10.1016/j.brainresrev.2004.12.013
   Sugama Shuei, 2009, Inflammation & Allergy Drug Targets, V8, P277
   Tansey MG, 2007, EXP NEUROL, V208, P1, DOI 10.1016/j.expneurol.2007.07.004
   THANOS S, 1993, J NEUROSCI, V13, P455
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Wang XJ, 2007, J NEUROIMMUNE PHARM, V2, P259, DOI 10.1007/s11481-007-9075-1
   Wax MB, 2008, J NEUROSCI, V28, P12085, DOI 10.1523/JNEUROSCI.3200-08.2008
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Zhang JH, 2006, STROKE, V37, P1094, DOI 10.1161/01.STR.0000206444.29930.18
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
   Zhang P, 2010, J NEUROCHEM, V112, P434, DOI 10.1111/j.1471-4159.2009.06477.x
   Zhao L, 2009, EXP EYE RES, V88, P1004, DOI 10.1016/j.exer.2008.12.013
   Zheng HH, 2010, NEUROIMMUNOMODULAT, V17, P31, DOI 10.1159/000243083
NR 55
TC 24
Z9 27
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 2897
EP 2904
DI 10.1167/iovs.10-6114
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 770PN
UT WOS:000291100800005
PM 21245403
OA Green Published
DA 2022-11-30
ER

PT J
AU Akens, MK
   Hardisty, MR
   Wilson, BC
   Schwock, J
   Whyne, CM
   Burch, S
   Yee, AJM
AF Akens, Margarete K.
   Hardisty, Michael R.
   Wilson, Brian C.
   Schwock, Joerg
   Whyne, Cari M.
   Burch, Shane
   Yee, Albert J. M.
TI Defining the therapeutic window of vertebral photodynamic therapy in a
   murine pre-clinical model of breast cancer metastasis using the
   photosensitizer BPD-MA (Verteporfin)
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Spine; Breast cancer; Bone metastasis; Photodynamic therapy
ID PROSTATE; LESIONS; RATES; BONE
AB Breast cancer is known to cause metastatic lesions in the bone, which can lead to skeletal-related events. Currently, radiation therapy and surgery are the treatment of choice, but the success rate varies and additional adjuncts are desirable. Photodynamic therapy (PDT) has been applied successfully as a non-radiative treatment for numerous cancers. Earlier work has shown that the athymic rat model is suitable to investigate the effect of PDT on bone metastasis and benzoporphyrin-derivative monoacid ring A (BPD-MA; verteporfin) has been shown to be a selective photosensitizer. The aim of this study was to define the therapeutic window of photosensitizer with regard to drug and light dose. Human breast carcinoma cells (MT-1)-stable transfected with the luciferase gene-were injected intra-cardiacally into athymic rats. At 14 days, the largest vertebral lesion by bioluminescence imaging was targeted for single treatment PDT. A drug escalating-de-escalating scheme was used (starting drug dose and light energy of 0.2 mg/kg and 50 J, respectively). Outcomes included 48 h post-treatment bioluminescence of remaining viable tumour, histomorphometric assessment of tumour burden, and neurologic evaluation. The region of effect by bioluminescence and histology increased with increasing drug dose and light energy. A safe and effective drug-light dose combination in this model appears to be 0.5 mg/kg BPD-MA and applied light energy of less than 50 J for the thoracic spine and 1.0 mg/kg and 75 J for the lumbar spine. For translation to clinical use, it is an advantage that BPD-MA (verteporfin), a second-generation photosensitizer, is already approved to treat age-related macular degeneration. Overall, PDT represents an exciting potential new minimally-invasive local, safe and effective therapy in the management of patients with spinal metastases.
C1 [Akens, Margarete K.; Hardisty, Michael R.; Whyne, Cari M.; Yee, Albert J. M.] Sunnybrook Hlth Sci Ctr, Div Orthopaed Surg, Toronto, ON M4N 3M5, Canada.
   [Wilson, Brian C.; Schwock, Joerg] Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.
   [Burch, Shane] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA.
C3 University of Toronto; Sunnybrook Research Institute; University Toronto
   Affiliates; Sunnybrook Health Science Center; University of Toronto;
   University Toronto Affiliates; University Health Network Toronto;
   University of California System; University of California San Francisco
RP Akens, MK (通讯作者)，Sunnybrook Hlth Sci Ctr, Div Orthopaed Surg, Room E2-44,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM makens@sri.utoronto.ca
RI Akens, Margarete/K-5502-2013
OI Akens, Margarete/0000-0003-3523-2381; Schwock,
   Joerg/0000-0001-8889-5600; Wilson, Brian C./0000-0001-5543-666X
FU National Cancer Institute of Canada
FX Funding for this study was generously provided by the Canadian Breast
   Cancer Foundation, Ontario Chapter through a grant from the National
   Cancer Institute of Canada. The human breast cancer MT-1 cells were
   kindly provided by Dr. O. Engebraaten, Norwegian Radium Hospital, Oslo,
   Norway.
CR Akens MK, 2007, PHOTOCHEM PHOTOBIOL, V83, P1034, DOI 10.1111/j.1751-1097.2007.00172.x
   Allison R, 2001, CANCER, V91, P1, DOI 10.1002/1097-0142(20010101)91:1<1::AID-CNCR1>3.0.CO;2-P
   BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1
   Bendszus M, 2008, BRAIN, V131, P2341, DOI 10.1093/brain/awn156
   Biel MA, 2007, PHOTOCHEM PHOTOBIOL, V83, P1063, DOI 10.1111/j.1751-1097.2007.00153.x
   Bisland SK, 2004, PHOTOCHEM PHOTOBIOL, V80, P22, DOI 10.1562/2004-03-05-RA-100.1
   Burch S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1921887
   Burch S, 2005, CANC DRUG DISC DEV, P243
   Burch S, 2005, J ORTHOP RES, V23, P995, DOI 10.1016/j.orthres.2004.12.014
   Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001
   Clemons M, 2006, ONCOLOGIST, V11, P227, DOI 10.1634/theoncologist.11-3-227
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   Dole KC, 2005, PHOTOMED LASER SURG, V23, P172, DOI 10.1089/pho.2005.23.172
   Ecker RD, 2005, MAYO CLIN PROC, V80, P1177, DOI 10.4065/80.9.1177
   FINGAR VH, 1987, PHOTOCHEM PHOTOBIOL, V45, P643, DOI 10.1111/j.1751-1097.1987.tb07392.x
   Grossweiner LI, 1997, J PHOTOCH PHOTOBIO B, V38, P258, DOI 10.1016/S1011-1344(96)07469-6
   Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483
   Hebel R., 1986, ANATOMY EMBRYOLOGY L
   Henderson BW, 2006, LASER SURG MED, V38, P489, DOI 10.1002/lsm.20327
   Henderson BW, 2004, CANCER RES, V64, P2120, DOI 10.1158/0008-5472.CAN-03-3513
   Katagiri H, 1998, INT J RADIAT ONCOL, V42, P1127, DOI 10.1016/S0360-3016(98)00288-0
   LAM S, 1994, SEMIN ONCOL, V21, P15
   Li J, 2008, PHYS MED BIOL, V53, P2103, DOI 10.1088/0031-9155/53/8/007
   Lipton Allan, 2003, Curr Treat Options Oncol, V4, P151, DOI 10.1007/s11864-003-0016-9
   MARCON NE, 1994, SEMIN ONCOL, V21, P20
   Niedre M, 2002, PHOTOCHEM PHOTOBIOL, V75, P382, DOI 10.1562/0031-8655(2002)075<0382:DNILDO>2.0.CO;2
   Parekh SG, 1999, LASER SURG MED, V24, P375, DOI 10.1002/(SICI)1096-9101(1999)24:5<375::AID-LSM8>3.0.CO;2-B
   POWERS SK, 1991, NEUROSURGERY, V29, P688, DOI 10.1227/00006123-199111000-00008
   RICHTER AM, 1990, J PHOTOCH PHOTOBIO B, V5, P231, DOI 10.1016/1011-1344(90)80008-L
   Tatsui H, 1996, SPINE, V21, P2143, DOI 10.1097/00007632-199609150-00017
   Verma S, 2007, PHOTOCHEM PHOTOBIOL, V83, P996, DOI 10.1111/j.1751-1097.2007.00166.x
   Wai EK, 2003, SPINE, V28, P508, DOI 10.1097/00007632-200303010-00018
   Zhou XD, 2004, PHOTOCHEM PHOTOBIOL, V79, P323, DOI 10.1562/MU-03-31.1
NR 33
TC 34
Z9 34
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JAN
PY 2010
VL 119
IS 2
BP 325
EP 333
DI 10.1007/s10549-009-0356-7
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 534MQ
UT WOS:000272902200007
PM 19263216
DA 2022-11-30
ER

PT J
AU Bhosale, P
   Li, BX
   Sharifzadeh, M
   Gellermann, W
   Frederick, JM
   Tsuchida, K
   Bernstein, PS
AF Bhosale, Prakash
   Li, Binxing
   Sharifzadeh, Mohsen
   Gellermann, Werner
   Frederick, Jeanne M.
   Tsuchida, Kozo
   Bernstein, Paul S.
TI Purification and Partial Characterization of a Lutein-Binding Protein
   from Human Retina
SO BIOCHEMISTRY
LA English
DT Article
ID MACULAR PIGMENT; PRIMATE RETINAS; OCULAR-TISSUES; JAPANESE-QUAIL;
   RHESUS-MONKEYS; BETA-CAROTENE; BOMBYX-MORI; HUMAN EYE; ZEAXANTHIN;
   IDENTIFICATION
AB Dietary intake of lutein and zeaxanthin appears to be advantageous for protecting human retinal and macular tissues from degenerative disorders such as age-related macular degeneration. Selective concentration of just two of the many dietary carotenoids suggests that uptake and transport of these xanthophyll carotenoids into the human foveal region are mediated by specific xanthophyll-binding proteins such as GSTP1 which has previously been identified as the zeaxanthin-binding protein of the primate macula. Here, a membrane-associated human retinal lutein-binding protein (HR-LBP) was purified from human peripheral retina using ion-exchange chromatography followed by size-exclusion chromatography. After attaining 83-fold enrichment of HR-LBP, this protein exhibited a significant bathochromic shift of similar to 90 nm in association with lutein, and equilibrium binding studies demonstrated saturable, specific binding toward lutein with a K-D of 0.45 mu M. Examination for cross-reactivity with antibodies raised against known lutein-binding proteins from other organisms revealed consistent labeling of a major protein band of purified HR-LBP at similar to 29 kDa with an antibody raised against silkworm (Bombyx mori) carotenoid-binding protein (CBP), a member of steroidogenic acute regulatory (StAR) protein family with significant homology to many human StAR proteins. Immunolocalization with antibodies directed against either CBP or GSTP1 showed specific labeling of rod and cone inner segments, especially in the mitochondria-rich ellipsoid region. There was also strong labeling of the outer plexiform (Henle fiber) layer with anti-GSTP1. Such localizations compare favorably with the distribution of macular carotenoids as revealed by resonance Raman microscopy. Our results suggest that HR-LBP may facilitate lutein's localization to a region of the cell subject to considerable oxidative stress.
C1 [Bhosale, Prakash; Li, Binxing; Frederick, Jeanne M.; Bernstein, Paul S.] Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Sharifzadeh, Mohsen; Gellermann, Werner] Univ Utah, Dept Phys, Salt Lake City, UT 84112 USA.
   [Tsuchida, Kozo] Natl Inst Infect Dis, Div Radiol Protect & Biol, Tokyo, Japan.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; National Institute of Infectious
   Diseases (NIID)
RP Bernstein, PS (通讯作者)，Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
RI Li, Binxing/C-9153-2012; Li, Binxing/ABB-7775-2020
OI Li, Binxing/0000-0002-0715-7495
FU National Institutes of Health [EY-11600, EY-014800-039003]; Foundation
   Fighting Blindness, Inc.; Research to Prevent Blindness (RPB, New York,
   NY); Kemin Health (Des Moines, IA); Teimei Empress; Futaba Memorial
   Foundations; NATIONAL EYE INSTITUTE [R01EY011600, P30EY014800,
   R29EY011600] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health Grants EY-11600
   and EY-014800-039003 (NEI core grant), by center grants of the
   Foundation Fighting Blindness, Inc., to the University of Utah, by an
   unrestricted grant to the Department of Ophthalmology at the University
   of Utah from Research to Prevent Blindness (RPB, New York, NY), and by
   Kemin Health (Des Moines, IA). K.T. was supported by the Teimei Empress
   and Futaba Memorial Foundations.
CR ADLER R, 1999, MOL VIS, V3, P31
   Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x
   Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2007, BIOCHEMISTRY-US, V46, P9050, DOI 10.1021/bi700558f
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P1435, DOI 10.1167/iovs.06-1046
   Bhosale P, 2007, ARCH BIOCHEM BIOPHYS, V458, P121, DOI 10.1016/j.abb.2006.10.005
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   BONE RA, 1984, VISION RES, V24, P103, DOI 10.1016/0042-6989(84)90094-4
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Czeczuga-Semeniuk E, 2005, ONCOL REP, V14, P1385
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   ELIZABETH RP, 2006, EXP EYE RES, V82, P741, DOI DOI 10.1016/J.EXER.2005.10.012
   ENGEL HM, 1988, OPHTHALMOLOGICA, V196, P143, DOI 10.1159/000309891
   Gass JDM, 1999, ARCH OPHTHALMOL-CHIC, V117, P821
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hendrickson A, 2006, EXP EYE RES, V83, P920, DOI 10.1016/j.exer.2006.04.017
   Kakitani Y, 2007, BIOCHEMISTRY-US, V46, P7302, DOI 10.1021/bi602485x
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   LAKSHMAN MR, 1993, METHOD ENZYMOL, V214, P256
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Leeson S, 2004, POULTRY SCI, V83, P1709, DOI 10.1093/ps/83.10.1709
   Matthews SJ, 2006, COMP BIOCHEM PHYS B, V144, P206, DOI 10.1016/j.cbpb.2006.02.007
   McGraw KJ, 2003, COMP BIOCHEM PHYS B, V135, P689, DOI 10.1016/S1096-4959(03)00164-7
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Nussbaum J J, 1981, Retina, V1, P296, DOI 10.1097/00006982-198101040-00007
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Sakudoh T, 2005, BIOCHEM BIOPH RES CO, V336, P1125, DOI 10.1016/j.bbrc.2005.08.241
   Sakudoh T, 2007, P NATL ACAD SCI USA, V104, P8941, DOI 10.1073/pnas.0702860104
   Sharifzadeh M, 2008, J OPT SOC AM A, V25, P947, DOI 10.1364/JOSAA.25.000947
   Sierra A, 2004, J NEUROENDOCRINOL, V16, P787, DOI 10.1111/j.1365-2826.2004.01226.x
   Sierralta WD, 2005, MOL CELL ENDOCRINOL, V242, P103, DOI 10.1016/j.mce.2005.08.003
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V6, P660
   Tabunoki H, 2002, J BIOL CHEM, V277, P32133, DOI 10.1074/jbc.M204507200
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915
   WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   Zagalsky PF, 2003, ACTA CRYSTALLOGR D, V59, P1529, DOI 10.1107/S0907444903013416
NR 51
TC 77
Z9 78
U1 0
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JUN 9
PY 2009
VL 48
IS 22
BP 4798
EP 4807
DI 10.1021/bi9004478
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 453HM
UT WOS:000266601500016
PM 19402606
DA 2022-11-30
ER

PT J
AU An, EY
   Gordish-Dressman, H
   Hathout, Y
AF An, Eunkyung
   Gordish-Dressman, Heather
   Hathout, Yetrib
TI Effect of TNF-alpha on human ARPE-19-secreted proteins
SO MOLECULAR VISION
LA English
DT Article
ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; NECROSIS-FACTOR-ALPHA; SUBRETINAL
   NEOVASCULAR MEMBRANES; FACTOR-H POLYMORPHISM; GROWTH-FACTOR-BETA;
   I-KAPPA-B; EPITHELIAL-CELLS; GENE-EXPRESSION; AMINO-ACIDS; MACULAR
   DEGENERATION
AB Purpose: To identify cytokine-induced changes in the secretome of human retinal pigment epithelial (RPE) cells and their potential implication in age-related macular degeneration pathogenesis.
   Methods: Stable isotope labeling by amino in cell culture (SILAC) was used in combination with liquid chromatography tandem mass spectrometry (LC-MS/MS) to measure differential protein secretion from tumor necrosis factor-alpha (TNF-alpha) treated ARPE-19 versus untreated ARPE-19 cells. Typically, one set of cells was subcultured in a medium in which Arg and Lys were replaced by C-13(6)-Arg and N-15(2), C-13(6)-Lys while the other set of cells was grown in unlabeled medium. The fully labeled cells were then treated with TNF-alpha, while unlabeled cells were left untreated. Spent media from both treated and untreated cells were collected, mixed at 1:1 ratio, and processed for LC-MS/MS analysis. Labeled and unlabeled peptide pairs were identified and their intensities were used to determine protein ratios in TNF-alpha treated cells versus untreated cells. To validate the data, we performed a reverse experiment in which unlabeled cells were treated with TNF-alpha while labeled cells were kept untreated.
   Results: A total of 146 proteins were identified as putatively secreted proteins in the spent medium of ARPE-19 cells and only six among these were differentially secreted following TNF-a treatment. Secretion of complement 3 and sulfhydryl oxidase-1 was increased by twofold, fibronectin by 1.7 fold, plasminogen activator inhibitor 1 by 1.9 fold and syndecan-4 by 4.35 fold while secretion of trans-golgi network protein-2 was decreased by twofold.
   Conclusions: TNF-v modulates secretion of specific proteins in ARPE-19 cells. These proteins are involved in pathways relevant to AMD pathogenesis (e.g., extracellular matrix remodeling, complement pathway, and angiogenesis).
C1 [An, Eunkyung; Gordish-Dressman, Heather; Hathout, Yetrib] Childrens Natl Med Ctr, Ctr Genet Med, Washington, DC 20010 USA.
   [An, Eunkyung] George Washington Univ, Inst Biomed Sci, Program Biochem & Mol Genet, Washington, DC USA.
C3 Children's National Health System; George Washington University
RP Hathout, Y (通讯作者)，Childrens Natl Med Ctr, Ctr Genet Med, 111 Michigan Ave,NW, Washington, DC 20010 USA.
EM yhathout@cnmcresearch.org
FU NIH/NEI [5R21EY01672302]; NATIONAL EYE INSTITUTE [R21EY016723] Funding
   Source: NIH RePORTER
FX This work was supported by NIH/NEI grant 5R21EY01672302. Eunkyung An is
   a predoctoral student in the Biochemistry and Molecular Genetics program
   of the Institute for Biomedical Sciences at the George Washington
   University. This work is from a dissertation to be presented to the
   above program in partial fulfillment of the requirements for the Ph.D
   degree. We thank Dr. Kristy Brown for her help with mass spectrometry
   maintenance and Dr. Zhangzhi Hu for Bioinformatics support.
CR Amanchy R, 2005, J PROTEOME RES, V4, P1661, DOI 10.1021/pr050134h
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923
   Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353
   Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790
   BRADLEY JR, 1993, J IMMUNOL, V150, P5544
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Chen CC, 2007, EMBO J, V26, P1257, DOI 10.1038/sj.emboj.7601596
   Chen YQ, 2001, THROMB HAEMOSTASIS, V86, P1563, DOI 10.1055/s-0037-1616763
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493
   Dobreva I, 2008, J PROTEOME RES, V7, P1740, DOI 10.1021/pr700852r
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELNER SG, 1991, LAB INVEST, V64, P819
   Elner Susan G, 2002, Trans Am Ophthalmol Soc, V100, P273
   Elner VM, 1997, EXP EYE RES, V65, P781, DOI 10.1006/exer.1997.0380
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Gronborg M, 2006, MOL CELL PROTEOMICS, V5, P157, DOI 10.1074/mcp.M500178-MCP200
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Gruhler A, 2005, MOL CELL PROTEOMICS, V4, P310, DOI 10.1074/mcp.M400219-MCP200
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halligan BD, 2005, J AM SOC MASS SPECTR, V16, P302, DOI 10.1016/j.jasms.2004.11.014
   HIGUCHI M, 1994, J IMMUNOL, V152, P3550
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   JAFFE GJ, 1993, INVEST OPHTH VIS SCI, V34, P2776
   Janeway Jr CA, 2001, IMMUNOBIOLOGY
   Jones SJ, 1999, J IMMUNOL, V162, P1042
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Kruger M, 2008, P NATL ACAD SCI USA, V105, P2451, DOI 10.1073/pnas.0711713105
   Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179
   Liu J, 2008, J PROTEOME RES, V7, P2033, DOI 10.1021/pr7007779
   Liu RM, 2008, ANTIOXID REDOX SIGN, V10, P303, DOI 10.1089/ars.2007.1903
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Macfelda K, 2002, J MOL CELL CARDIOL, V34, P1681, DOI 10.1006/jmcc.2002.2117
   Marmor M. F., 1998, RETINAL PIGMENT EPIT, DOI [10.1098/rsif.2015.0563, DOI 10.1098/RSIF.2015.0563]
   Moon MR, 1999, J SURG RES, V82, P48, DOI 10.1006/jsre.1998.5503
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Narayan S, 2003, INVEST OPHTH VIS SCI, V44, P4885, DOI 10.1167/iovs.03-0387
   Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200
   Pandey M, 2005, FASEB J, V19, P1317, DOI 10.1096/fj.04-3459fje
   Penn JS, 2003, INVEST OPHTH VIS SCI, V44, P5423, DOI 10.1167/iovs.02-0804
   Portes KF, 2008, J MOL HISTOL, V39, P217, DOI 10.1007/s10735-007-9156-8
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   Sheerin NS, 1997, KIDNEY INT, V51, P703, DOI 10.1038/ki.1997.101
   SHI GJS, 2006, ARVO ANN M APR 30 MA
   SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989
   SIREN V, 1992, OPHTHALMIC RES, V24, P203, DOI 10.1159/000267169
   Stokes MP, 2007, P NATL ACAD SCI USA, V104, P19855, DOI 10.1073/pnas.0707579104
   Takeshita Y, 2006, METABOLISM, V55, P1464, DOI 10.1016/j.metabol.2006.06.016
   Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5
   VANDERSCHAFT TL, 1993, GRAEF ARCH CLIN EXP, V231, P470, DOI 10.1007/BF02044234
   WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yan CH, 2004, FASEB J, V18, P540, DOI 10.1096/fj.03-0960fje
   Yang P, 2005, INVEST OPHTH VIS SCI, V46, P1755, DOI 10.1167/iovs.04-1039
   Yang P, 2004, INVEST OPHTH VIS SCI, V45, P2438, DOI 10.1167/iovs.03-0805
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhang GA, 2006, J PROTEOME RES, V5, P581, DOI 10.1021/pr050362b
   Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786
NR 64
TC 29
Z9 29
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 11
PY 2008
VL 14
IS 263-65
BP 2292
EP 2303
PG 12
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 413VZ
UT WOS:000263822000003
PM 19093006
DA 2022-11-30
ER

PT J
AU Johnson, MA
   Lutty, GA
   McLeod, DS
   Otsuji, T
   Flower, RW
   Sandagar, G
   Alexander, T
   Steidl, SM
   Hansen, BC
AF Johnson, MA
   Lutty, GA
   McLeod, DS
   Otsuji, T
   Flower, RW
   Sandagar, G
   Alexander, T
   Steidl, SM
   Hansen, BC
TI Ocular structure and function in an aged monkey with spontaneous
   diabetes mellitus
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE retina; diabetes; diabetic retinopathy; animal model; choroid; primate
ID OPEN-ANGLE GLAUCOMA; VASCULATURE; PRESSURE
AB Diabetes mellitus develops spontaneously in middle-aged, obese rhesus monkeys, thus making them a good model for examining the effects of co-morbid factors on the development of end-organ damage. Changes in structure and function in the eyes of one monkey who spontaneously developed type 2 diabetes are reported here. This animal had concomitant hypertension, high levels of triglycerides and serum cholesterol, and a low fraction of high-density lipoprotein. The eyes showed intraretinal hemorrhages and large areas of retinal capillary nonperfusion. Indo-cyanin green (ICG) angiography revealed a large area of non- or poorly perfused choriocapillaris in one eye, and immunohistochemistry showed loss of viable choriocapillaries in this region. Both basal laminar deposits and hard drusen were present on areas of Bruch's membrane adjacent to nonviable choriocapillaris. Blood flow via the nasal posterior ciliary arteries to this section of choroid was not detectable by color duplex Doppler ultrasound, indicating contribution of extraocular vascular disease to ischemia in this eye. There was a severe decline in number of photoreceptor inner and outer segments, and corresponding reductions in the multifocal electroretinogram (ERG), in the areas of choriocapillaris loss. The ganzfeld ERG indicated loss in both inner and outer retinal function. Much of the ganglion cell layer was absent throughout the retina, possibly reflecting the effect of diabetes as well as chronic open angle glaucoma; the latter diagnosis supported by elevated intraocular pressures and excavated optic disks.
   In summary, high resolution, enzyme histochemical and histopathological analyses of a diabetic hypertensive monkey retina and choroid after serial functional in vivo analyses have demonstrated the relationship between vascular dysfunction and visual function loss. Choroidal vascular dysfunction in both large and small vessels was associated with age-related macular degeneration-like changes in Bruch's membrane and photoreceptor degeneration. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Univ Maryland, Dept Ophthalmol, Sch Med, Baltimore, MD 21201 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD USA.
   Univ Maryland, Dept Surg, Sch Med, Baltimore, MD 21201 USA.
   Univ Maryland, Dept Physiol, Sch Med, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore; Johns
   Hopkins University; Johns Hopkins Medicine; University System of
   Maryland; University of Maryland Baltimore; University System of
   Maryland; University of Maryland Baltimore
RP Johnson, MA (通讯作者)，Univ Maryland, Dept Ophthalmol, Sch Med, 419 W Redwood St,Suite 420, Baltimore, MD 21201 USA.
EM mjohnson@umaryland.edu
RI Hansen, Barbara C/J-8723-2012
OI Hansen, Barbara C/0000-0001-9646-3525
FU NIA NIH HHS [N01-AG-3-1012] Funding Source: Medline
CR Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Dielemans I, 1996, OPHTHALMOLOGY, V103, P1271, DOI 10.1016/S0161-6420(96)30511-3
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   HOOD DC, 1993, VISION RES, V33, P1605, DOI 10.1016/0042-6989(93)90027-T
   Johnson MA, 1996, J OPT SOC AM A, V13, P572, DOI 10.1364/JOSAA.13.000572
   KIM SY, 2004, IN PRESS INVEST OPHT
   LUTTY GA, 1992, ARCH OPHTHALMOL-CHIC, V110, P267, DOI 10.1001/archopht.1992.01080140123039
   Otsuji T, 2002, EXP EYE RES, V75, P201, DOI 10.1006/exer.2002.2020
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
NR 10
TC 49
Z9 52
U1 0
U2 9
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2005
VL 80
IS 1
BP 37
EP 42
DI 10.1016/j.exer.2004.08.006
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 899EG
UT WOS:000227127100005
PM 15652524
DA 2022-11-30
ER

PT J
AU Murray, IJ
   Rodrigo-Diaz, E
   Kelly, JMF
   Aslam, TM
   Tahir, HJ
   Carden, D
   Patryas, L
   Parry, NRA
AF Murray, Ian J.
   Rodrigo-Diaz, Elena
   Kelly, Jeremiah M. F.
   Aslam, Tariq M.
   Tahir, Humza J.
   Carden, David
   Patryas, Laura
   Parry, Neil R. A.
TI The role of dark adaptation in understanding early AMD
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Rhodopsin regeneration; Sensitivity control; Dark adaptation; Drusen;
   Early; intermediate AMD; Structure versus function
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; BRUCHS MEMBRANE; VISUAL-PIGMENT; PSYCHOPHYSICAL EVIDENCE;
   BINDING PROTEINS; OPTICAL-DENSITY; AGING RETINA; VITAMIN-A
AB The main aim of the paper is to discuss current knowledge on how Age Related Macular Degeneration (AMD) affects Dark Adaptation (DA). The paper is divided into three parts. Firstly, we outline some of the molecular mechanisms that control DA. Secondly, we review the psychophysical issues and the corresponding analytical techniques. Finally, we characterise the link between slowed DA and the morphological abnormalities in early AMD.Historically, DA has been regarded as too cumbersome for widespread clinical application. Yet the technique is extremely useful; it is widely accepted that the psychophysically obtained slope of the second rod-mediated phase of the dark adaptation function is an accurate assay of photoreceptor pigment regeneration kinetics. Technological developments have prompted new ways of generating the DA curve, but analytical problems remain. A simple potential solution to these, based on the application of a novel fast mathematical algorithm, is presented. This allows the calculation of the parameters of the DA curve in real time.Improving current management of AMD will depend on identifying a satisfactory endpoint for evaluating future therapeutic strategies. This must be implemented before the onset of severe disease. Morphological changes progress too slowly to act as a satisfactory endpoint for new therapies whereas functional changes, such as those seen in DA, may have more potential in this regard. It is important to recognise, however, that the functional changes are not confined to rods and that building a mathematical model of the DA curve enables the separation of rod and cone dysfunction and allows more versatility in terms of the range of disease severity that can be monitored. Examples are presented that show how analysing the DA curve into its constituent components can improve our understanding of the morphological changes in early AMD.
C1 [Murray, Ian J.; Rodrigo-Diaz, Elena; Kelly, Jeremiah M. F.; Aslam, Tariq M.; Tahir, Humza J.; Carden, David; Patryas, Laura; Parry, Neil R. A.] Univ Manchester, Fac Biol, Vis Sci Lab, Med & Hlth, Manchester, England.
   [Parry, Neil R. A.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Royal Eye Hosp, Vis Sci Ctr, Manchester Acad Hlth Sci Ctr, Manchester, England.
C3 University of Manchester; Manchester Royal Eye Hospital; University of
   Manchester
RP Murray, IJ (通讯作者)，Univ Manchester, Fac Biol, Vis Sci Lab, Med & Hlth, Manchester, England.
EM ian.j.murray@manchester.ac.uk
OI Kelly, Jeremiah/0000-0002-7336-7132
FU Manchester Biomedical Research Centre; Greater Manchester Comprehensive
   Local Research Network; Newtricious RD B.V.; National Eye Research
   Centre (ERD); NIHR Invention for Innovation (i4i) Programme
FX NRAP and TA are supported by Manchester Biomedical Research Centre and
   the Greater Manchester Comprehensive Local Research Network. Some of
   this work was supported by Newtricious R&D B.V. (HJT and ERD) and by The
   National Eye Research Centre (ERD) . The NIHR Invention for Innovation
   (i4i) Programme funded the clinical trial and JK. IJM, DC and JK are
   directors of MuMac Research who developed the RapiDA technique. We
   sincerely thank the reviewers for carefully reading the paper and for
   their many insightful comments.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   Arnold Jennifer J, 2007, BMJ Clin Evid, V2007
   Arshavsky VY, 2002, NEURON, V36, P1, DOI 10.1016/S0896-6273(02)00937-6
   Barlow H.B., 1972, HDB SENSORY PHYSIOLO, VVIII, P1
   Bates D., 1988, NONLINEAR REGRESSION
   BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   BESHARSE JC, 1977, SCIENCE, V196, P536, DOI 10.1126/science.300504
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Binns AM, 2018, INVEST OPHTH VIS SCI, V59, pAMD114, DOI 10.1167/iovs.18-24211
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOK D, 1993, J CELL SCI, P189
   Bone RA, 2004, ARCH BIOCHEM BIOPHYS, V430, P137, DOI 10.1016/j.abb.2004.04.003
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BOYNTON RM, 1970, SCIENCE, V170, P1423, DOI 10.1126/science.170.3965.1423
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BROWN B, 1986, OPHTHAL PHYSL OPT, V6, P81, DOI 10.1111/j.1475-1313.1986.tb00704.x
   BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703
   Chen KG, 2019, OPHTHALMOLOGY, V126, P856, DOI 10.1016/j.ophtha.2018.09.039
   Chichan H, 2021, CLIN OPHTHALMOL, V15, P1887, DOI 10.2147/OPTH.S307671
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Choi EH, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000850
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Christoforidis J, 2011, GRAEF ARCH CLIN EXP, V249, P1345, DOI 10.1007/s00417-011-1706-9
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   COILE DC, 1992, VISUAL NEUROSCI, V8, P27, DOI 10.1017/S0952523800006465
   Cox C., 2005, ENCY BIOSTATISTICS, DOI [10.1002/0470011815.b2a15029, DOI 10.1002/0470011815.B2A15029]
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   DAS SR, 1992, BIOCHEM J, V285, P907, DOI 10.1042/bj2850907
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Dimitrov PN, 2012, INVEST OPHTH VIS SCI, V53, P5213, DOI 10.1167/iovs.11-8958
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Gaffney AJ, 2013, DOC OPHTHALMOL, V127, P191, DOI 10.1007/s10633-013-9400-3
   Gaffney AJ, 2011, OPTOMETRY VISION SCI, V88, P1080, DOI 10.1097/OPX.0b013e3182223697
   GOLDSTEIN EB, 1973, VISION RES, V13, P527
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hammond BR, 2014, INVEST OPHTH VIS SCI, V55, P8583, DOI 10.1167/iovs.14-15573
   Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3
   Hecht S, 1937, PHYSIOL REV, V17, P239, DOI 10.1152/physrev.1937.17.2.239
   Higgins BE, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86193-3
   Higgins BE, 2021, OPHTHALMOL THER, V10, P21, DOI 10.1007/s40123-020-00323-0
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   HURVICH LM, 1955, J OPT SOC AM, V45, P602, DOI 10.1364/JOSA.45.000602
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   INGLING CR, 1977, VISION RES, V17, P1083, DOI 10.1016/0042-6989(77)90014-1
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   JONES GJ, 1989, P NATL ACAD SCI USA, V86, P9606, DOI 10.1073/pnas.86.23.9606
   Kelly P.F., 2012, LANDSCAPES GLOBALIZA
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lamb TD, 2016, EYE, V30, P179, DOI 10.1038/eye.2015.236
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   LAMB TD, 1981, VISION RES, V21, P1773, DOI 10.1016/0042-6989(81)90211-X
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Lamb TD, 2015, VISION RES, V110, P23, DOI 10.1016/j.visres.2015.02.014
   Lee Y., 2020, RECENT ADV NEW PERSP
   Lee Y, 2015, INVEST OPHTH VIS SCI, V56, P8403, DOI 10.1167/iovs.15-16936
   Li BX, 2020, P NATL ACAD SCI USA, V117, P12352, DOI 10.1073/pnas.1922793117
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Mahroo OAR, 2004, J PHYSIOL-LONDON, V554, P417, DOI 10.1113/jphysiol.2003.051250
   Mahroo OAR, 2012, DOC OPHTHALMOL, V125, P137, DOI 10.1007/s10633-012-9344-z
   Margrain TH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60660-9
   MARSHALL J, 1979, BRIT J OPHTHALMOL, V63, P181, DOI 10.1136/bjo.63.3.181
   Mata NL, 2002, NEURON, V36, P69, DOI 10.1016/S0896-6273(02)00912-1
   McFarland RA, 1955, J GERONTOL, V10, P424, DOI 10.1093/geronj/10.4.424
   McGwin G, 1999, BEHAV RES METH INS C, V31, P712, DOI 10.3758/BF03200752
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Mustafi D, 2009, PROG RETIN EYE RES, V28, P289, DOI 10.1016/j.preteyeres.2009.05.003
   NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308
   Osterberg G, 1935, TOPOGRAPHY LAYER ROD
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   Palczewski K, 2020, P NATL ACAD SCI USA, V117, P19629, DOI 10.1073/pnas.2008211117
   PandaJonas S, 1995, OPHTHALMOLOGY, V102, P1853, DOI 10.1016/S0161-6420(95)30784-1
   Parry NRA, 2006, J OPT SOC AM A, V23, P1586, DOI 10.1364/JOSAA.23.001586
   Patryas L, 2013, GRAEF ARCH CLIN EXP, V251, P1821, DOI 10.1007/s00417-013-2324-5
   PEPPERBERG DR, 1978, J GEN PHYSIOL, V71, P369, DOI 10.1085/jgp.71.4.369
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   PLANTNER JJ, 1991, EXP EYE RES, V53, P269, DOI 10.1016/0014-4835(91)90083-Q
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P413, DOI 10.1113/jphysiol.1975.sp010982
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reuter T, 2011, VISION RES, V51, P2243, DOI 10.1016/j.visres.2011.08.021
   Robinson DG, 2019, INVEST OPHTH VIS SCI, V60, P580, DOI 10.1167/iovs.18-25092
   Robson AG, 2008, VISUAL NEUROSCI, V25, P575, DOI 10.1017/S0952523808080681
   Robson JG, 1998, DOC OPHTHALMOL, V95, P187, DOI 10.1023/A:1001891904176
   Rodrigo-Diaz E, 2017, MECH DARK ADAPTATION
   Rodrigo-Diaz E, 2019, INVEST OPHTH VIS SCI, V60, P5070, DOI 10.1167/iovs.19-27971
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   RUSHTON WAH, 1968, VISION RES, V8, P617, DOI 10.1016/0042-6989(68)90040-0
   RUSHTON WAH, 1972, VISION RES, V12, P1073, DOI 10.1016/0042-6989(72)90098-3
   Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3
   SAARI JC, 1982, J BIOL CHEM, V257, P13329
   Saari JC, 2012, ANNU REV NUTR, V32, P125, DOI 10.1146/annurev-nutr-071811-150748
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Shevell SK, 2017, J OPT SOC AM A, V34, P1099, DOI 10.1364/JOSAA.34.001099
   SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNYDER AW, 1977, J OPT SOC AM, V67, P696, DOI 10.1364/JOSA.67.000696
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Stiles W.S., 1932, EQUIVALENT ADAPTATIO, P194
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sturr JF, 1997, VISION RES, V37, P475, DOI 10.1016/S0042-6989(96)00196-4
   Tahir Humza J, 2018, Invest Ophthalmol Vis Sci, V59, pAMD202, DOI 10.1167/iovs.18-24227
   Tahir HJ, 2017, EXP EYE RES, V155, P47, DOI 10.1016/j.exer.2016.11.016
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59, P289, DOI 10.1167/iovs.17-22528
   Tikidji-Hamburyan A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01816-6
   TREUTWEIN B, 1995, VISION RES, V35, P2503, DOI 10.1016/0042-6989(95)00016-X
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   van Hateren JH, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-34
   Wang JS, 2011, PROG RETIN EYE RES, V30, P115, DOI 10.1016/j.preteyeres.2010.11.001
   Weber E. H., 1834, PULSU RESORPTIONE AU
   Weiss Ellen, 2020, Biochem (Lond), V42, P44, DOI 10.1042/BIO20200067
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu QQ, 2007, BIOCHEMISTRY-US, V46, P8669, DOI 10.1021/bi7004619
   Wyszecki G., 2000, COLOR SCI CONCEPTS M, Vsecond
NR 145
TC 0
Z9 0
U1 3
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2022
VL 88
AR 101015
DI 10.1016/j.preteyeres.2021.101015
PG 31
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1W4LD
UT WOS:000806745600002
PM 34626782
DA 2022-11-30
ER

PT J
AU Zicarelli, F
   Azzolini, C
   Cornish, E
   Agarwal, A
   Khochtali, S
   Airaldi, M
   Khairallah, M
   Viola, F
   Staurenghi, G
   McCluskey, P
   Invernizzi, A
AF Zicarelli, Federico
   Azzolini, Claudia
   Cornish, Elisa
   Agarwal, Aniruddha
   Khochtali, Sana
   Airaldi, Matteo
   Khairallah, Moncef
   Viola, Francesco
   Staurenghi, Giovanni
   McCluskey, Peter
   Invernizzi, Alessandro
TI OPTICAL COHERENCE TOMOGRAPHY FEATURES OF CHOROIDAL NEOVASCULARIZATION
   AND THEIR CORRELATION WITH AGE, GENDER, AND UNDERLYING DISEASE
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE uveitis; inflammatory choroidal neovascularization; pitchfork sign;
   optical coherence tomography; iCNV; myopia; myopic CNV; choroidal
   neovascularization; exudative age-related macular degeneration
ID SECONDARY
AB Purpose: To investigate the influence of age, gender, and underlying disease on the optical coherence tomography (OCT) features of choroidal neovascularization (CNV) secondary to inflammation, myopia (mCNV), and age-related macular degeneration (AMD-CNV). Methods: Demographic and clinical data of eyes with treatment-naive inflammatory CNV, mCNV, and Type 2 AMD-CNV were collected. Optical coherence tomography images were reviewed to determine the presence of pitchfork sign, pigment epithelial detachment, subretinal fluid (SRF), intraretinal cysts, subretinal hyperreflective material, atrophy, and outer retinal disruption graded 1 to 4. The influence of demographics and underlying etiology on OCT signs was investigated. Results: One hundred and eighty-five eyes from 179 patients were enrolled. The mean [SD] age was 36 [+/- 14.4], 62 [+/- 18], and 77 [+/- 8] for the inflammatory CNV, mCNV, and AMD-CNV, respectively (P < 0.001). Multiple linear regression showed that the presence of pitchfork sign was negatively associated with age (P < 0.0001), regardless of underlying disease. By contrast, the SRF, pigment epithelial detachment, intraretinal cysts, and the outer retinal disruption were all positively influenced by age, regardless of gender and underlying disease (all P < 0.01). Logistic regression showed that none of the OCT signs increased the likelihood for diagnosis of inflammatory CNV. By contrast, the absence of SRF was suggestive for mCNVs, and the presence of pigment epithelial detachment and SRF was suggestive for AMD-CNVs. Conclusion: The age of the patient had a significant effect on the OCT appearance of the CNV, particularly the presence of a pitchfork sign, regardless of the underlying etiology. The absence of SRF was suggestive for a diagnosis of mCNVs. The presence of SRF and pigment epithelial detachment was suggestive for AMD-CNVs.
C1 [Zicarelli, Federico; Airaldi, Matteo; Staurenghi, Giovanni; Invernizzi, Alessandro] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Azzolini, Claudia; Viola, Francesco] Univ Milan, Ca Granda Fdn Osped Maggiore Policlin, Dept Clin Sci & Community Hlth, Ophthalmol Unit, Milan, Italy.
   [Cornish, Elisa; McCluskey, Peter; Invernizzi, Alessandro] Univ Sydney, Sydney Med Sch, Save Sight Inst, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Agarwal, Aniruddha] Postgrad Inst Med Educ & Res PGIMER, Adv Eye Ctr, Chandigarh, India.
   [Khochtali, Sana; Khairallah, Moncef] Univ Monastir, Fattouma Bourguiba Univ Hosp, Fac Med, Dept Ophthalmol, Monastir, Tunisia.
C3 University of Milan; Luigi Sacco Hospital; IRCCS Ca Granda Ospedale
   Maggiore Policlinico; University of Milan; University of Sydney; Post
   Graduate Institute of Medical Education & Research (PGIMER), Chandigarh;
   Universite de Monastir; Hopital Fattouma Bourguiba
RP Invernizzi, A (通讯作者)，Univ Milan, Eye Clin, Luigi Sacco Hosp, Via GB Grassi 74, I-20157 Milan, Italy.
EM alessandro.invernizzi@gmail.com
OI Airaldi, Matteo/0000-0001-9010-1208
CR Agarwal A, 2018, J OPHTHALMIC INFLAMM, V8, DOI 10.1186/s12348-018-0155-6
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cheung CMG, 2013, LANCET, V382, P1230, DOI 10.1016/S0140-6736(13)61580-9
   Cunningham ET, 2020, OCUL IMMUNOL INFLAMM, V28, P2, DOI 10.1080/09273948.2019.1704153
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   Falavarjani KG, 2019, OSLI RETINA, V50, P719, DOI 10.3928/23258160-20191031-07
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fuerst NM, 2016, OPHTHALMIC GENET, V37, P445, DOI 10.3109/13816810.2015.1126616
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P1049, DOI 10.1097/IAE.0b013e31827e25b8
   Ikuno Y, 2015, OPHTHALMOLOGY, V122, P1220, DOI 10.1016/j.ophtha.2015.01.025
   Invernizzi A, 2020, BRIT J OPHTHALMOL, V104, P1052, DOI 10.1136/bjophthalmol-2019-315257
   Invernizzi A, 2018, EUR J OPHTHALMOL, V28, P216, DOI 10.5301/ejo.5001047
   Lin D., 2016, PLOS ONE, V11, P1
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   Marano F, 2000, GRAEF ARCH CLIN EXP, V238, P760, DOI 10.1007/s004170000186
   Neri P, 2009, BRIT J OPHTHALMOL, V93, P155, DOI 10.1136/bjo.2008.145896
   Parfitt A, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000276
   Pellegrini M, 2018, RETINA-J RET VIT DIS, V38, P1338, DOI 10.1097/IAE.0000000000001730
   Rajabian F, 2021, EUR J OPHTHALMOL, V31, pNP67, DOI 10.1177/1120672119892802
   Ramtohul P, 2019, OPHTHALMOL RETINA, V3, P615, DOI 10.1016/j.oret.2019.04.009
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shin HJ, 2012, GRAEF ARCH CLIN EXP, V250, P61, DOI 10.1007/s00417-011-1774-x
   Tarau IS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143578
   Wilkerson JL, 2019, MOL NEUROBIOL, V56, P7188, DOI 10.1007/s12035-019-1599-x
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Zafar Sidra, 2016, Am J Ophthalmol Case Rep, V4, P7, DOI 10.1016/j.ajoc.2016.06.009
NR 30
TC 6
Z9 6
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2021
VL 41
IS 5
BP 1076
EP 1083
DI 10.1097/IAE.0000000000002984
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2UF
UT WOS:000658831500026
PM 33079791
DA 2022-11-30
ER

PT J
AU Singh, RK
   Winkler, PA
   Binette, F
   Petersen-Jones, SM
   Nasonkin, IO
AF Singh, Ratnesh K.
   Winkler, Paige A.
   Binette, Francois
   Petersen-Jones, Simon M.
   Nasonkin, Igor O.
TI Comparison of Developmental Dynamics in Human Fetal Retina and Human
   Pluripotent Stem Cell-Derived Retinal Tissue
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
DE retina; retinal organoid; human fetal retina; human pluripotent stem
   cell; retinal differentiation; photoreceptors
ID FALSE DISCOVERY RATE; PIGMENT EPITHELIUM; VISUAL IMPAIRMENT;
   BIOCONDUCTOR PACKAGE; EXPRESSION ANALYSIS; SURFACE ANTIGEN; INTACT
   SHEETS; NEURAL RETINA; PHOTORECEPTOR; TRANSPLANTATION
AB Progressive vision loss, caused by retinal degenerative (RD) diseases such as age-related macular degeneration, retinitis pigmentosa, and Leber congenital amaurosis, severely impacts quality of life and affects millions of people. Finding efficient treatment for blinding diseases is among the greatest unmet clinical needs. The evagination of optic vesicles from developing pluripotent stem cell-derived neuroepithelium and self-organization, lamination, and differentiation of retinal tissue in a dish generated considerable optimism for developing innovative approaches for treating RD diseases, which previously were not feasible. Retinal organoids may be a limitless source of multipotential retinal progenitors, photoreceptors (PRs), and the whole retinal tissue, which are productive approaches for developing RD disease therapies. In this study we compared the distribution and expression level of molecular markers (genetic and epigenetic) in human fetal retina (age 8-16 weeks) and human embryonic stem cell (hESC)-derived retinal tissue (organoids) by immunohistochemistry, RNA-seq, flow cytometry, and mass-spectrometry (to measure methylated and hydroxymethylated cytosine level), with a focus on PRs to evaluate the clinical application of hESC-retinal tissue for vision restoration. Our results revealed high correlation in gene expression profiles and histological profiles between human fetal retina (age 8-13 weeks) and hESC-derived retinal tissue (10-12 weeks). The transcriptome signature of hESC-derived retinal tissue from retinal organoids maintained for 24 weeks in culture resembled the transcriptome of human fetal retina of more advanced developmental stages. The histological profiles of 24 week-old hESC-derived retinal tissue displayed mature PR immunophenotypes and presence of developing inner and outer segments. Collectively, our work highlights the similarity of hESC-derived retinal tissue at early stages of development (10 weeks), and human fetal retina (age 8-13 weeks) and it supports the development of regenerative medicine therapies aimed at using tissue from hESC-derived retinal organoids (hESC-retinal implants) for mitigating vision loss.
C1 [Singh, Ratnesh K.; Binette, Francois; Nasonkin, Igor O.] Lineage Cell Therapeut Inc, 1010 Atlantic Ave, Alameda, CA 94501 USA.
   [Winkler, Paige A.; Petersen-Jones, Simon M.] Michigan State Univ, Coll Vet Med, Dept Small Anim Clin Sci, E Lansing, MI 48824 USA.
C3 Michigan State University
RP Singh, RK; Nasonkin, IO (通讯作者)，Lineage Cell Therapeut Inc, 1010 Atlantic Ave, Alameda, CA 94501 USA.
EM rsingh@lineagecell.com; inasonkin@lineagecell.com
CR Aldiri I, 2017, NEURON, V94, P550, DOI 10.1016/j.neuron.2017.04.022
   [Anonymous], 2010, GLOBAL EC COST VISUA
   Aramant RB, 2002, PROG RETIN EYE RES, V21, P57, DOI 10.1016/S1350-9462(01)00020-9
   Aronesty E., 2013, OPEN BIOINFORMATICS, V7, P1, DOI [DOI 10.2174/1875036201307010001, 10.2174/1875036201307010001]
   Baghbaderani BA, 2016, STEM CELL REV REP, V12, P394, DOI 10.1007/s12015-016-9662-8
   Baghbaderani BA, 2015, STEM CELL REP, V5, P647, DOI 10.1016/j.stemcr.2015.08.015
   Banin E, 2006, STEM CELLS, V24, P246, DOI 10.1634/stemcells.2005-0009
   Bardy C, 2015, P NATL ACAD SCI USA, V112, pE2725, DOI 10.1073/pnas.1504393112
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Brandt N, 2013, INT J DEV BIOL, V57, P351, DOI 10.1387/ijdb.120217gr
   Brown J, 2017, BIOINFORMATICS, V33, P3137, DOI 10.1093/bioinformatics/btx373
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Christensen R, 2013, CURR OPIN NEUROBIOL, V23, P1018, DOI 10.1016/j.conb.2013.07.004
   Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082
   Crook JM, 2007, CELL STEM CELL, V1, P490, DOI 10.1016/j.stem.2007.10.004
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Ferris FL, 2004, ARCH OPHTHALMOL-CHIC, V122, P451, DOI 10.1001/archopht.122.4.451
   Frick KD, 2010, INVEST OPHTH VIS SCI, V51, P1801, DOI 10.1167/iovs.09-4469
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003
   Funk WD, 2012, STEM CELL RES, V8, P154, DOI 10.1016/j.scr.2011.10.001
   Gamm DM, 2019, AM J OPHTHALMOL, V206, P113, DOI 10.1016/j.ajo.2019.04.033
   Garber K, 2015, NAT BIOTECHNOL, V33, P890, DOI 10.1038/nbt0915-890
   Hambright D, 2012, MOL VIS, V18, P920
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hendrickson A, 2008, EXP EYE RES, V87, P415, DOI 10.1016/j.exer.2008.07.016
   Hendrickson A, 2016, AM J OPHTHALMOL, V161, P29, DOI 10.1016/j.ajo.2015.09.023
   Hirano M, 2003, DEV DYNAM, V228, P664, DOI 10.1002/dvdy.10425
   Hoshino A, 2017, DEV CELL, V43, P763, DOI 10.1016/j.devcel.2017.10.029
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Koso H, 2009, INVEST OPHTH VIS SCI, V50, P5411, DOI 10.1167/iovs.08-3246
   Kuwahara A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7286
   Lakowski J, 2011, STEM CELLS, V29, P1391, DOI 10.1002/stem.694
   Lakowski J, 2018, STEM CELLS, V36, P709, DOI 10.1002/stem.2775
   Lakowski J, 2015, STEM CELLS, V33, P2469, DOI 10.1002/stem.2051
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lancaster MA, 2014, SCIENCE, V345, DOI 10.1126/science.1247125
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Ludwig Tenneille, 2007, Curr Protoc Stem Cell Biol, VChapter 1, DOI 10.1002/9780470151808.sc01c02s2
   Mathieson K, 2012, NAT PHOTONICS, V6, P391, DOI [10.1038/nphoton.2012.104, 10.1038/NPHOTON.2012.104]
   McLelland BT, 2018, INVEST OPHTH VIS SCI, V59, P2586, DOI 10.1167/iovs.17-23646
   Meyer JS, 2011, STEM CELLS, V29, P1206, DOI 10.1002/stem.674
   Molday RS, 2015, J CELL SCI, V128, P4039, DOI 10.1242/jcs.175687
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nasonkin IO, 2013, DEVELOPMENT, V140, P1330, DOI 10.1242/dev.086603
   Palanker D, 2020, OPHTHALMOLOGY, V127, P1097, DOI 10.1016/j.ophtha.2020.02.024
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Perera A, 2015, CELL REP, V11, P283, DOI 10.1016/j.celrep.2015.03.020
   Radke ND, 2004, ARCH OPHTHALMOL-CHIC, V122, P1159, DOI 10.1001/archopht.122.8.1159
   Radtke ND, 2002, AM J OPHTHALMOL, V133, P544, DOI 10.1016/S0002-9394(02)01322-3
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Regent F, 2020, MOL VIS, V26, P97
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Schmitz F, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00003
   Seiler MJ, 2010, EUR J NEUROSCI, V31, P508, DOI 10.1111/j.1460-9568.2010.07085.x
   Seiler MJ, 2008, EUR J NEUROSCI, V28, P208, DOI 10.1111/j.1460-9568.2008.06279.x
   Seiler MJ, 1998, INVEST OPHTH VIS SCI, V39, P2121
   Shi Y, 2017, NAT REV DRUG DISCOV, V16, P115, DOI 10.1038/nrd.2016.245
   Singh R, 2018, STEM CELL REV REP, V14, P463, DOI 10.1007/s12015-018-9802-4
   Singh RK, 2021, J OCUL PHARMACOL TH, V37, P147, DOI 10.1089/jop.2020.0016
   Singh RK, 2020, J TISSUE ENG REGEN M, V14, P388, DOI 10.1002/term.2997
   Singh RK, 2019, STEM CELLS DEV, V28, P1151, DOI 10.1089/scd.2019.0090
   Singh RK, 2018, JOVE-J VIS EXP, DOI 10.3791/58274
   Singh RK, 2017, EXP EYE RES, V159, P132, DOI 10.1016/j.exer.2016.11.014
   Singh RK, 2015, STEM CELLS DEV, V24, P2778, DOI 10.1089/scd.2015.0144
   Singh RK, 2014, INVEST OPHTH VIS SCI, V55, P3081, DOI 10.1167/iovs.13-13728
   SOLBERG T, 1986, ACTA OPHTHALMOL, V64, P26
   Solovei I, 2009, CELL, V137, P356, DOI 10.1016/j.cell.2009.01.052
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Tu HY, 2019, EBIOMEDICINE, V39, P562, DOI 10.1016/j.ebiom.2018.11.028
   Volland S, 2015, P NATL ACAD SCI USA, V112, P14870, DOI 10.1073/pnas.1516309112
   Wahlin KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00774-9
   Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356
   Ward CM, 2020, BIOINFORMATICS, V36, P2587, DOI 10.1093/bioinformatics/btz937
   Welby E, 2017, STEM CELL REP, V9, P1898, DOI 10.1016/j.stemcr.2017.10.018
   Woch G, 2001, INVEST OPHTH VIS SCI, V42, P1669
   Yoav Benjamini, 2001, Behavioural Brain Research, V125, P279, DOI 10.1016/S0166-4328(01)00297-2
   Zhao SL, 2001, DEVELOPMENT, V128, P5051
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
   1969, J ULTRA MOL STRUCT R, V26, P31
NR 83
TC 6
Z9 6
U1 1
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
EI 1557-8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD APR 15
PY 2021
VL 30
IS 8
BP 399
EP 417
DI 10.1089/scd.2020.0085
PG 19
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA RM9QE
UT WOS:000639990900001
PM 33677999
OA Green Published
DA 2022-11-30
ER

PT J
AU Li, JQ
   Yin, X
   Zhang, BY
   Li, C
   Lu, PR
AF Li, Jianqing
   Yin, Xue
   Zhang, Bingyu
   Li, Chen
   Lu, Peirong
TI Bioinformatical Analysis of miRNA-mRNA Interaction Network Underlying
   Macrophage Aging and Cholesterol-Responsive Difference between Young and
   Aged Macrophages
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID MACULAR DEGENERATION; INFLAMMATION; TARGET; IDENTIFICATION; HOMEOSTASIS;
   TISSUE; SITES
AB Purpose.Macrophage aging is involved with the occurrence and progression of age-related macular degeneration (AMD). The purpose of this study was to identify the specific microRNAs (miRNA), mRNAs, and their interactions underlying macrophage aging and response to cholesterol through bioinformatical analysis in order to get a better understanding of the mechanism of AMD.Methods.The microarray data were obtained from Gene Expression Omnibus (accession GSE111304 and GSE111382). The age-related differentially expressed genes in macrophages were identified using R software. Further miRNA-mRNA interactions were analyzed through miRWalk, mirTarBase, starBase, and then produced by Cytoscape. The functional annotations including Gene Ontology and KEGG pathways of the miRNA target genes were performed by the DAVID and the STRING database. In addition, protein-protein interaction network was constructed to identify the key genes in response to exogenous cholesterol.Results. When comparing aged and young macrophages, a total of 14 miRNAs and 101 mRNAs were detected as differentially expressed. Besides, 19 validated and 544 predicted miRNA-mRNA interactions were detected. Lipid metabolic process was found to be associated with macrophage aging through functional annotations of the miRNA targets. After being treated with oxidized and acetylated low-density lipoprotein, miR-714 and 16 mRNAs differentially expressed in response to both kinds of cholesterol between aged and young macrophages. Among them, 6 miRNA-mRNA predicted pairs were detected. The functional annotations were mainly related to lipid metabolism process and farnesyl diphosphate farnesyl transferase 1 (FDFT1) was identified to be the key gene in the difference of response to cholesterol between aged and young macrophages.Conclusions.Lipid metabolic process was critical in both macrophage aging and response to cholesterol thus was regarded to be associated with the occurrence and progression of AMD. Moreover, miR-714-FDFT1 may modulate cholesterol homeostasis in aged macrophages and have the potential to be a novel therapeutic target for AMD.
C1 [Li, Jianqing; Yin, Xue; Zhang, Bingyu; Li, Chen; Lu, Peirong] Soochow Univ, Affiliated Hosp 1, Dept Ophthalmol, 188 Shizi St, Suzhou 215006, Peoples R China.
C3 Soochow University - China
RP Lu, PR (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Ophthalmol, 188 Shizi St, Suzhou 215006, Peoples R China.
EM li_jianqing@foxmail.com; yinxuescu@163.com; 20174032023@stu.suda.edu.cn;
   kristy0902@126.com; lupeirong@suda.edu.cn
OI Li, Jianqing/0000-0001-7868-8421
FU National Natural Science Foundation of China [81671641]; Jiangsu
   Provincial Medical Innovation Team [CXTDA2017039]; Jiangsu Provincial
   Natural Science Foundation [BK20151208]; Postgraduate Research &
   Practice Innovation Program of Jiangsu Province [KYCX18_2528]; Soochow
   Scholar Project of Soochow University [R5122001]
FX The authors report receiving funding from the National Natural Science
   Foundation of China (NSFC no. 81671641), Jiangsu Provincial Medical
   Innovation Team (no. CXTDA2017039), Jiangsu Provincial Natural Science
   Foundation (no. BK20151208), Postgraduate Research & Practice Innovation
   Program of Jiangsu Province (KYCX18_2528), and the Soochow Scholar
   Project of Soochow University (no. R5122001).
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Apryatin SA, 2019, BIOCHEMISTRY-MOSCOW+, V84, P1093, DOI 10.1134/S0006297919090128
   Bellinger MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093297
   Chen J, 2013, CELL METAB, V17, P471, DOI 10.1016/j.cmet.2013.03.010
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Demirci MDS, 2019, METHODS MOL BIOL, V1912, P175, DOI 10.1007/978-1-4939-8982-9_7
   Ding JZ, 2015, DIABETES, V64, P3464, DOI 10.2337/db14-1314
   Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Gao F, 2015, INT J BIOL SCI, V11, P109, DOI 10.7150/ijbs.10276
   GERRITY RG, 1981, AM J PATHOL, V103, P181
   Gui T, 2012, LAB INVEST, V92, P1250, DOI 10.1038/labinvest.2012.85
   Hagbi-Levi S, 2017, NEUROBIOL AGING, V51, P71, DOI 10.1016/j.neurobiolaging.2016.11.018
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Leon LE, 2017, METHODS MOL BIOL, V1509, P209, DOI 10.1007/978-1-4939-6524-3_19
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JB, 2018, EBIOMEDICINE, V32, P9, DOI 10.1016/j.ebiom.2018.05.035
   Lin JB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120157
   Lu QY, 2019, CAN J OPHTHALMOL, V54, P291, DOI 10.1016/j.jcjo.2018.06.010
   Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   NESS GC, 1994, ARCH BIOCHEM BIOPHYS, V311, P277, DOI 10.1006/abbi.1994.1238
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Sene A, 2015, TRENDS MOL MED, V21, P43, DOI 10.1016/j.molmed.2014.10.005
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Shin KU, 2017, OPHTHALMIC RES, V57, P32, DOI 10.1159/000449168
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Wong CK, 2017, J IMMUNOL, V199, P1060, DOI 10.4049/jimmunol.1700397
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056
   Zhao B, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0498-z
NR 44
TC 1
Z9 1
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD JUN 13
PY 2020
VL 2020
AR 9267475
DI 10.1155/2020/9267475
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA MC7ZL
UT WOS:000543499900003
PM 32626771
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lutski, M
   Shohat, T
   Mery, N
   Zucker, I
AF Lutski, Miri
   Shohat, Tamy
   Mery, Nisim
   Zucker, Inbar
TI Incidence and Risk Factors for Blindness in Adults With Diabetes: The
   Israeli National Diabetes Registry (INDR)
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INCIDENCE RATES; RETINOPATHY; EPIDEMIOLOGY; PROGRESSION; PREVALENCE;
   GLAUCOMA; VISION; TRENDS; POPULATION; PREVENTION
AB PURPOSE: To estimate the 3-year incidence of blindness among diabetes patients aged >= 18 years; to compare blindness incidence rates of persons with and without diabetes; and to investigate risk factors associated with diabetic retinopathy (DR), age-related macular degeneration (ARMD), glaucoma, and cataract-related blindness.
   DESIGN: Cohort study.
   METHODS: The Israeli National Diabetes Registry for 2012 was cross-linked with the database of blindness certifications obtained from the National Registry of the Blind. Blindness was defined as the receipt of an official certificate of blindness (a visual acuity of 3/60 or worse, or a visual field loss of < 20 degrees in the better eye.) Incidence rates of blindness, overall and by main cause of blindness, were calculated for the years 2013-2015. Standardized morbidity ratios (SMRs) for 2013 were calculated, using the nondiabetic population as a reference. A multinomial logistic model was used to identify covariates associated with the incidence of blindness by main cause of blindness.
   RESULTS: The 3-year incidence rates were 31.0 and 8.4 per 10 000 for overall and DR-related blindness, respectively. The SMR for overall blindness in people with diabetes was significantly higher than in the general nondiabetic population (1.39; 95% confidence interval: 1.27-1.53); however, the SMRs for ARMD, glaucoma, and cataract were not statistically significant. Poor metabolic control, insulin treatment, long diabetes duration, and chronic kidney disease were associated with DR-related blindness. Low socioeconomic status (SES) was associated with both cataract and DR-related blindness.
   CONCLUSIONS: Optimum metabolic control of diabetes is important for prevention of DR-related blindness. SES-related disparities in blindness risk should be explored and reduced by directing efforts to provide appropriate treatment for all diabetic patients in order to prevent unnecessary blindness. (C) 2018 Published by Elsevier Inc.
C1 [Lutski, Miri; Shohat, Tamy; Mery, Nisim; Zucker, Inbar] Minist Hlth, Israel Ctr Dis Control, Ramat Gan, Israel.
   [Shohat, Tamy; Zucker, Inbar] Tel Aviv Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth, Sackler Fac Med, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine
RP Lutski, M (通讯作者)，Minist Hlth, Israel Ctr Dis Control, Ramat Gan, Israel.
EM Miri.Lutski@moh.gov.il
OI Lutski, Miri/0000-0002-0290-3081
CR AGARDH E, 1993, DIABETIC MED, V10, P555, DOI 10.1111/j.1464-5491.1993.tb00120.x
   [Anonymous], 1991, Ophthalmology, V98, P786
   [Anonymous], 2008, 2008 CENS POP HOUS H
   Avisar R, 2006, ISRAEL MED ASSOC J, V8, P880
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Breslow N E, 1987, IARC Sci Publ, P1
   Brosius FC, 2006, CIRCULATION, V114, P1083, DOI 10.1161/CIRCULATIONAHA.106.177321
   Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Farber MD, 2003, OPHTHAL EPIDEMIOL, V10, P267, DOI 10.1076/opep.10.4.267.15910
   Hall HN, 2013, DIABETIC MED, V30, P1349, DOI 10.1111/dme.12223
   Hemmingsen B, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6898
   Hippisley-Cox J, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5441
   Huang OS, 2009, ANN ACAD MED SINGAP, V38, P1048
   Islam FMA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133043
   Jeganathan VSE, 2008, DIABETES CARE, V31, P1905, DOI 10.2337/dc08-0342
   Klein BEK, 2007, OPHTHAL EPIDEMIOL, V14, P179, DOI 10.1080/09286580701396720
   Klein R, 2008, OPHTHALMOLOGY, V115, P1859, DOI 10.1016/j.ophtha.2008.08.023
   Lin SY, 2017, ACTA OPHTHALMOL, V95, pe756, DOI 10.1111/aos.13400
   Manor O, 2012, NATL PROGRAM QUALITY
   Matthews DR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1631
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Mukesh BN, 2006, ARCH OPHTHALMOL-CHIC, V124, P79, DOI 10.1001/archopht.124.1.79
   Negahban Kambiz, 2002, Curr Opin Ophthalmol, V13, P419, DOI 10.1097/00055735-200212000-00013
   Omae T, 2016, INVEST OPHTH VIS SCI, V57, P1345, DOI 10.1167/iovs.15-18813
   PIRIE A., 1965, INVEST OPHTHALMOL, V4, P629
   Saaddine JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P1740, DOI 10.1001/archopht.126.12.1740
   Sabanayagam C, 2016, OPHTHAL EPIDEMIOL, V23, P209, DOI 10.1080/09286586.2016.1193618
   Salinero-Fort MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076417
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Stefannson E, 2006, BRIT J OPHTHALMOL, V90, P2, DOI 10.1136/bjo.082065
   Stratton IM, 2001, DIABETOLOGIA, V44, P156, DOI 10.1007/s001250051594
   Tomic M, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/818671
   Topouzis F, 2011, AM J OPHTHALMOL, V152, P219, DOI 10.1016/j.ajo.2011.01.032
   Tracey ML, 2016, DIABETES RES CLIN PR, V121, P1, DOI 10.1016/j.diabres.2016.08.016
   Trautner C, 2003, INVEST OPHTH VIS SCI, V44, P1031, DOI 10.1167/iovs.02-0304
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6
   van Leiden HA, 2003, ARCH OPHTHALMOL-CHIC, V121, P245, DOI 10.1001/archopht.121.2.245
   Wang W, 2017, JAMA OPHTHALMOL, V135, P1295, DOI 10.1001/jamaophthalmol.2017.3449
   World Health Organization, 2005, PREV BLINDN DIAB MEL
   Yanagi M, 2011, CLIN EXP OPHTHALMOL, V39, P252, DOI 10.1111/j.1442-9071.2010.02455.x
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yong VK, 2006, OPHTHAL EPIDEMIOL, V13, P35, DOI 10.1080/09286580500473779
NR 43
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2019
VL 200
BP 57
EP 64
DI 10.1016/j.ajo.2018.12.008
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HT5TG
UT WOS:000464625600007
PM 30578785
DA 2022-11-30
ER

PT J
AU Inan, S
   Cetinkaya, E
   Duman, R
   Dogan, I
   Inan, UU
AF Inan, Sibel
   Cetinkaya, Ersan
   Duman, Resat
   Dogan, Ismet
   Inan, Umit Ubeyt
TI Quality of life among patients with age-related severe macular
   degeneration assessed using the NEI-VFQ, HADS-A, HADS-D and SF-36 tests.
   A cross-sectional study
SO SAO PAULO MEDICAL JOURNAL
LA English
DT Article
DE Quality of life; Macular degeneration; VFQ-25; HAD-A; SF-36
ID DEPRESSIVE SYMPTOMS; RESOURCE UTILIZATION; GLAUCOMA; ANXIETY; PEOPLE;
   BURDEN; IMPACT
AB BACKGROUND: Exudative age-related macular degeneration (e-AMD) may cause severe central vision loss. Patients with e-AMD can experience difficulties in daily basic activities and suffer from psychological problems. Our aim was to assess quality of life (QoL) and anxiety and depression status among patients with e-AMD.
   DESIGN AND SETTING: Cross-sectional study in a state university.
   METHODS: We included 200 e-AMD patients and 120 age and gender-matched controls. We assessed QoL using the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) and the Short Form (SF)-36 test; and anxiety and depression status using the Hospital Anxiety Depression Scales A and D (HADS-A and HADS-D).
   RESULTS: The mean ages in the e-AMD and control groups were 68.40 +/- 9.8 and 66.31 +/- 8.98, respectively. Visual acuity among e-AMD patients was 0.37 +/- 0.31 and 0.39 +/- 0.32 in the right and left eyes, respectively. The e-AMD patients performed significantly worse than the controls in NEI-VFQ-25 (P < 0.05 for all items). The proportions of e-AMD patients scoring higher than the cutoffs in HADS-A and HADS-D were significantly higher than among the controls (41.5% versus 12.5% and 63.5% versus 27.5%; P < 0.001). The e-AMD patients had significantly lower mean scores than the controls for each of the SF-36 QoL items (P < 0.001). The NEI-VFQ-25 scores were significantly lower among patients with bilateral e-AMD than among those with unilateral disease (P < 0.05 for all). The HADS scores were positively correlated with duration of e-AMD and patient age, but negatively with vision levels (P < 0.05 for all items).
   CONCLUSION: The e-AMD patients had higher depression and anxiety scores and lower QoL scores.
C1 [Inan, Sibel; Cetinkaya, Ersan; Duman, Resat; Dogan, Ismet; Inan, Umit Ubeyt] AKU, Dept Ophthalmol, Tip Fak, TR-03200 Afyon, Turkey.
C3 Afyon Kocatepe University
RP Inan, S (通讯作者)，AKU, Dept Ophthalmol, Tip Fak, TR-03200 Afyon, Turkey.
EM drinan33@gmail.com
RI Duman, Reşat/ABD-6350-2021; Inan, sibel/AAB-7691-2021
CR Akyuz G, 2006, TURKISH J PHYS MED R, V52, pA57
   Aydemir O., 1997, TURK PSIKIYATRI DERG, V8, P280
   Berman K, 2006, INT PSYCHOGERIATR, V18, P415, DOI 10.1017/S1041610205002905
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Casten RJ, 2002, J VISUAL IMPAIR BLIN, V96, P399, DOI 10.1177/0145482X0209600603
   Casten R, 2010, ARCH OPHTHALMOL-CHIC, V128, P506, DOI 10.1001/archophthalmol.2010.24
   Cumurcu BE, 2010, TURK KLIN TIP BILIM, V30, P698
   Cypel Marcela C., 2004, International Ophthalmology, V25, P267, DOI 10.1007/s10792-005-0077-9
   GLYNN RJ, 1991, ARCH OPHTHALMOL-CHIC, V109, P205, DOI 10.1001/archopht.1991.01080020051041
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KLEINSCHMIDT JJ, 1995, J HLTH ED, V26, P26, DOI DOI 10.1080/10556699.1995.10603073
   Kocak N, 2014, TURK OFTALMOL DERG, V44, P83, DOI 10.4274/tjo.13471
   Kocyigit H., 1999, J DRUG THER, V12, P102
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Matamoros E, 2015, OPHTHALMOLOGICA, V234, P151, DOI 10.1159/000433448
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   McGwin G, 2003, OPHTHAL EPIDEMIOL, V10, P303, DOI 10.1076/opep.10.5.303.17323
   Orr P, 2011, INVEST OPHTH VIS SCI, V52, P3354, DOI 10.1167/iovs.10-5645
   Popescu ML, 2012, INVEST OPHTH VIS SCI, V53, P2308, DOI 10.1167/iovs.11-9330
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Sun C, 2007, OPHTHAL EPIDEMIOL, V14, P127, DOI 10.1080/09286580601186742
   Toprak AB, 2005, TURK OFTALMOL DERG, V35, P453
   WATSON D, 1995, J ABNORM PSYCHOL, V104, P3, DOI 10.1037/0021-843X.104.1.3
   Wilson MR, 1998, OPHTHALMOLOGY, V105, P2112, DOI 10.1016/S0161-6420(98)91135-6
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 27
TC 8
Z9 8
U1 0
U2 0
PU ASSOCIACAO PAULISTA MEDICINA
PI SAO PAULO
PA AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL
SN 1516-3180
J9 SAO PAULO MED J
JI Sao Paulo Med. J.
PD JAN-FEB
PY 2019
VL 137
IS 1
BP 25
EP 32
DI 10.1590/1516-3180.2018.0195071218
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HZ4AI
UT WOS:000468789100005
PM 31116266
OA gold
DA 2022-11-30
ER

PT J
AU El-Darzi, N
   Astafev, A
   Mast, N
   Saadane, A
   Lam, M
   Pikuleva, IA
AF El-Darzi, Nicole
   Astafev, Artem
   Mast, Natalia
   Saadane, Aicha
   Lam, Morrie
   Pikuleva, Irina A.
TI N,N-Dimethyl-3 beta-hydroxycholenamide Reduces Retinal Cholesterol via
   Partial Inhibition of Retinal Cholesterol Biosynthesis Rather Than its
   Liver X Receptor Transcriptional Activity
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE N,N-dimethyl-3 beta-hydroxycholenamide; retina; cholesterol; Delta
   24-dehydrocholesterol; CYP27A1; CYP46A1; liver X receptor
ID LXR-ALPHA; CYTOCHROME-P450 27A1; LIPID-METABOLISM; DIRECT EXPRESSION;
   ESCHERICHIA-COLI; MARKETED DRUGS; MOUSE RETINA; IN-VITRO; MICE;
   DESMOSTEROLOSIS
AB N,N-dimethyl-3 beta-hydroxycholenamide (DMHCA) is an experimental pharmaceutical and a steroidal liver X receptor (LXR) agonist, which does not induce undesired hepatic lipogenesis. Herein, DMHCA was evaluated for its retinal effects on normal C57BL/6J and Cyp27a1(-/-) Cyp46a1(-/-) mice; the latter having higher retinal total and esterified cholesterol in addition to retinal vascular abnormalities. Different doses and two formulations were used for DMHCA delivery either via drinking water (C57BL/6J mice) or by oral gavage (Cyp27a1(-/-) Cyp46a1(-/-) mice). The duration of treatment was 1 week for C57BL/6J mice and 2 or 4 weeks for Cyp27a1(-/-) Cyp46a1(-/-) mice. In both genotypes, the higher DMHCA doses (37-80 mg/kg of body weight/day) neither increased serum triglycerides nor serum cholesterol but altered the levels of retinal sterols. Total retinal cholesterol was decreased in the DMHCA-treated mice, mainly due to a decrease in retinal unesterified cholesterol. In addition, retinal levels of cholesterol precursors lanosterol, zymosterol, desmosterol, and lathosterol were changed in Cyp27a1(-/-) Cyp46a1(-/-) mice. In both genotypes, DMHCA effect on retinal expression of the LXR target genes was only moderate and gender-specific. Collectively, the data obtained provide evidence for a decrease in retinal cholesterol as a result of DMHCA acting in the retina as an enzyme inhibitor of cholesterol biosynthesis rather than a LXR transcriptional activator. Specifically, DMHCA appears to partially inhibit the cholesterol biosynthetic enzyme Delta 24-dehydrocholesterol reductase rather than upregulate the expression of LXR target genes involved in reverse cholesterol transport. The identified DMHCA dosages, formulations, and routes of delivery as well as the observed effects on the retina should be considered in future studies using DMHCA as a potential therapeutic for age-related macular degeneration and diabetic retinopathy.
C1 [El-Darzi, Nicole; Astafev, Artem; Mast, Natalia; Saadane, Aicha; Lam, Morrie; Pikuleva, Irina A.] Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
C3 Case Western Reserve University
RP Pikuleva, IA (通讯作者)，Case Western Reserve Univ, Dept Ophthalmol & Visual Sci, Cleveland, OH 44106 USA.
EM iap8@case.edu
OI Lam, Morrie/0000-0001-6580-2459; Pikuleva, Irina/0000-0001-9742-6232;
   Saadane, Aicha/0000-0001-9985-2147
FU National Institutes of Health [EY018383, EY011373, EY025383]; NATIONAL
   EYE INSTITUTE [P30EY011373, R01EY018383] Funding Source: NIH RePORTER
FX This work was supported in part by National Institutes of Health Grant
   EY018383 and EY011373 to (IP) and EY025383. IP is a Carl F. Asseff
   Professor of Ophthalmology.
CR Alberti S, 2000, GENE, V243, P93, DOI 10.1016/S0378-1119(99)00555-7
   Andersson HC, 2002, AM J MED GENET, V113, P315, DOI 10.1002/ajmg.b.10873
   Bachmanov AA, 2002, BEHAV GENET, V32, P435, DOI 10.1023/A:1020884312053
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   Brown MS, 2009, J LIPID RES, V50, pS15, DOI 10.1194/jlr.R800054-JLR200
   Caldas YA, 2011, KIDNEY INT, V80, P535, DOI 10.1038/ki.2011.159
   Calkin AC, 2012, NAT REV MOL CELL BIO, V13, P213, DOI 10.1038/nrm3312
   Chang TY, 2006, ANNU REV CELL DEV BI, V22, P129, DOI 10.1146/annurev.cellbio.22.010305.104656
   Chen WL, 2007, CELL METAB, V5, P73, DOI 10.1016/j.cmet.2006.11.012
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   FitzPatrick DR, 1998, AM J MED GENET, V75, P145, DOI 10.1002/(SICI)1096-8628(19980113)75:2<145::AID-AJMG5>3.3.CO;2-1
   Fliesler SJ, 2010, J LIPID RES, V51, P3399, DOI 10.1194/jlr.R010538
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Ghosh S, 2012, CURR OPIN ENDOCRINOL, V19, P136, DOI 10.1097/MED.0b013e3283507836
   Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748
   Hanna IH, 1998, ARCH BIOCHEM BIOPHYS, V350, P324, DOI 10.1006/abbi.1997.0534
   Hazra S, 2012, DIABETES, V61, P3270, DOI 10.2337/db11-1596
   Hong C, 2014, NAT REV DRUG DISCOV, V13, P433, DOI 10.1038/nrd4280
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Kalaany NY, 2006, ANNU REV PHYSIOL, V68, P159, DOI 10.1146/annurev.physiol.68.033104.152158
   Kratzer A, 2009, J LIPID RES, V50, P312, DOI 10.1194/jlr.M800376-JLR200
   Lam M, 2018, MOL PHARMACOL, V93, P101, DOI 10.1124/mol.117.110742
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Liu J, 2005, BIOCHEM J, V391, P389, DOI 10.1042/BJ20050428
   Mast N, 2006, BIOCHEMISTRY-US, V45, P4396, DOI 10.1021/bi052654w
   Mast N, 2008, P NATL ACAD SCI USA, V105, P9546, DOI 10.1073/pnas.0803717105
   Mast N, 2015, MOL PHARMACOL, V88, P428, DOI 10.1124/mol.115.099598
   Mast N, 2012, MOL PHARMACOL, V82, P824, DOI 10.1124/mol.112.080424
   Mast N, 2011, INVEST OPHTH VIS SCI, V52, P594, DOI 10.1167/iovs.10-6021
   Mast N, 2010, BBA-MOL CELL BIOL L, V1801, P674, DOI 10.1016/j.bbalip.2010.03.005
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitsche MA, 2015, ELIFE, V4, DOI 10.7554/eLife.07999
   Muller C, 2017, EUR J MED CHEM, V140, P305, DOI 10.1016/j.ejmech.2017.08.011
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Omarova S, 2012, J CLIN INVEST, V122, P3012, DOI 10.1172/JCI63816
   PANDAJONAS S, 1994, OPHTHALMOLOGY, V101, P519
   Patel M, 2014, DIABETOLOGIA, V57, P435, DOI 10.1007/s00125-013-3095-6
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pfeifer T, 2011, CURR PHARM BIOTECHNO, V12, P285, DOI 10.2174/138920111794295774
   Pfrieger FW, 2011, PROG LIPID RES, V50, P357, DOI 10.1016/j.plipres.2011.06.002
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Quinet EM, 2004, J LIPID RES, V45, P1929, DOI 10.1194/jlr.M400257-JLR200
   REMTULLA S, 1985, VISION RES, V25, P21, DOI 10.1016/0042-6989(85)90076-8
   Saadane A, 2016, J BIOL CHEM, V291, P20427, DOI 10.1074/jbc.M116.744656
   Saadane A, 2014, AM J PATHOL, V184, P2403, DOI 10.1016/j.ajpath.2014.05.024
   SAGARA Y, 1992, FEBS LETT, V300, P208, DOI 10.1016/0014-5793(92)80847-A
   SAGARA Y, 1993, BIOL PHARM BULL, V16, P627
   Spann NJ, 2012, CELL, V151, P138, DOI 10.1016/j.cell.2012.06.054
   Spencer TA, 2001, J MED CHEM, V44, P886, DOI 10.1021/jm0004749
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Yu S, 2016, FASEB J, V30, P2570, DOI 10.1096/fj.201600244R
   Zelcer N, 2006, J CLIN INVEST, V116, P607, DOI 10.1172/JCI27883
   Zerenturk EJ, 2013, PROG LIPID RES, V52, P666, DOI 10.1016/j.plipres.2013.09.002
   Zerenturk EJ, 2012, BBA-MOL CELL BIOL L, V1821, P1350, DOI 10.1016/j.bbalip.2012.07.006
   Zhang Y, 2003, J BIOL CHEM, V278, P11642, DOI 10.1074/jbc.M211559200
   Zheng WC, 2015, J LIPID RES, V56, P81, DOI 10.1194/jlr.M053439
   Zolotushko J, 2011, EUR J HUM GENET, V19, P942, DOI 10.1038/ejhg.2011.74
NR 62
TC 5
Z9 5
U1 0
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 25
PY 2018
VL 9
AR 827
DI 10.3389/fphar.2018.00827
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GO1YY
UT WOS:000439759700001
PM 30090064
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ambrosio, L
   Ambrosio, G
   Nicoletti, G
   de Crecchio, G
   Falsini, B
AF Ambrosio, L.
   Ambrosio, G.
   Nicoletti, G.
   de Crecchio, G.
   Falsini, B.
TI The value of multifocal electroretinography to predict progressive
   visual acuity loss in early AMD
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Multifocal electroretinography;
   Progressive retinal degeneration; Visual acuity
ID AGE-RELATED MACULOPATHY; FOVEAL FLICKER SENSITIVITY; RETINAL FUNCTION;
   MACULAR DEGENERATION; DRUSEN; DYSFUNCTION; ADAPTATION; ERG
AB Background To investigate, in a prospective study, the role of multifocal electroretinography (mfERG) for predicting visual acuity decline in early age-related macular degeneration (AMD) with time.
   Methods Twenty-six early AMD patients (12 males and 14 females, mean age 66.9 +/- A 9.8; range 46-82 years) were included in the study. A complete ophthalmic examination and mfERG (Retiscan, Roland Germany, ISCEV standard protocol) were performed at the study entry (baseline), after 20 and 24 months. The first-order kernel mfERG responses were analyzed by ring analysis. The amplitude density (AD) of the first positive peak (P1, nV/deg(2)), the P1 amplitude (A mu V) and P1 implicit time (ms) for Rings 1 (central) to 6 (most peripheral) were evaluated. Data were statistically analyzed by analysis of variance and receiver operating characteristic (ROC) curves.
   Results The loss in the mfERG Ring 1 AD from normal control values, recorded at baseline, was correlated with the decrease in ETDRS visual acuity with time (P = 0.004). ROC analysis showed that, after 24 months, the average decline in visual acuity was greater (3 letters vs 0.4 letters, P = 0.0021) in patients whose Ring 1 P1 AD at baseline was equal to or less than 65.9 nV/deg(2), compared to those with higher AD values. Both P1 amplitude and AD of Ring 1 had an area under the curve of 0.702 (95 % confidence interval 0.50-0.92) with a sensitivity of 64.3 % (35.14-87.24 %) and a specificity of 91.7 % (61.52-99.79 %).
   Conclusions The present results indicate that mfERG P1 amplitude and AD of Ring 1 may be highly specific to predict visual acuity decline in early AMD.
C1 [Ambrosio, L.; Ambrosio, G.; Nicoletti, G.; de Crecchio, G.] Univ Naples Federico II, Dept Neurosci, Naples, Italy.
   [Falsini, B.] Catholic Univ, Dept Ophthalmol, Rome, Italy.
C3 University of Naples Federico II; Catholic University of the Sacred
   Heart; IRCCS Policlinico Gemelli
RP Ambrosio, L (通讯作者)，Univ Naples Federico II, Dept Neurosci, Via Pansini, Naples, Italy.
EM lucyambro@yahoo.it
RI Falsini, Benedetto/V-1070-2019; Ambrosio, Lucia/F-2345-2018; Falsini,
   Benedetto/AAC-5907-2022
OI Falsini, Benedetto/0000-0002-1694-1062; Ambrosio,
   Lucia/0000-0001-5488-8429; Falsini, Benedetto/0000-0002-3569-4968
CR Binns AM, 2007, INVEST OPHTH VIS SCI, V48, P2806, DOI 10.1167/iovs.06-0392
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Feigl B, 2005, INVEST OPHTH VIS SCI, V46, P4722, DOI 10.1167/iovs.05-0795
   Garcia-Garcia JG, 2013, CLIN OPHTHALMOL, V7, P1303, DOI 10.2147/OPTH.S39258
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   Gerth C, 2009, DOC OPHTHALMOL, V118, P63, DOI 10.1007/s10633-008-9133-x
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3150
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3143
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Piccardi M, 2009, OPHTHALMIC RES, V41, P194, DOI 10.1159/000217723
   Takiura K, 2001, INVEST OPHTH VIS SCI, V42, pS73
   Wood A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096742
   Yavas GF, 2014, DOC OPHTHALMOL, V129, P167, DOI 10.1007/s10633-014-9460-z
NR 27
TC 1
Z9 2
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD OCT
PY 2015
VL 131
IS 2
BP 125
EP 135
DI 10.1007/s10633-015-9507-9
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR4ZP
UT WOS:000361348900005
PM 26135127
DA 2022-11-30
ER

PT J
AU Asmus, LR
   Grimshaw, JPA
   Richle, P
   Eicher, B
   Urech, DM
   Gurny, R
   Moller, M
AF Asmus, Lutz R.
   Grimshaw, John P. A.
   Richle, Philipp
   Eicher, Barbara
   Urech, David M.
   Gurny, Robert
   Moeller, Michael
TI Injectable formulations for an intravitreal sustained-release
   application of a novel single-chain VEGF antibody fragment
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Age-related macular degeneration (AMD); Intravitreal application;
   Polyester; Single-chain antibody fragment (scFv); Sustained-release;
   VEGF antibody
ID SEMISOLID POLY(ORTHO ESTER); MACULAR DEGENERATION; DRUG-DELIVERY;
   BIODEGRADABLE POLYMERS; GANCICLOVIR IMPLANT; BEVACIZUMAB; INJECTIONS;
   LIQUID; SYSTEM
AB Sustained-release formulations of a single-chain anti-VEGF-A antibody fragment were investigated in vitro toward their potential use for intravitreal applications. The hydrophobic polyester hexylsubstituted poly(lactic acid) (hexPLA) was selected as the sustained-release excipient for its biodegradability and semi-solid aggregate state, allowing an easy and mild formulation procedure. The lyophilized antibody fragment ESBA903 was micronized and incorporated into the liquid polymer matrix by cryo-milling, forming homogeneous and injectable suspensions. The protein showed excellent compatibility with the hexPLA polymer and storage stability at 4 degrees C for 10 weeks. Additionally, hexPLA shielded the incorporated active substance from the surrounding medium, resulting in a better stability of ESBA903 inside the polymer than after its release in the buffer solution. Formulations of ESBA903 with hexPLA having drug loadings between 1.25% and 5.0% and polymer molecular weights of 1500 g/mol, 2500 g/mol, 3500 g/mol and 5000 g/mol were investigated regarding their in vitro release. All formulations except with the highest molecular weight formed spherical depots in aqueous buffer solutions and released the antibody fragment for at least 6-14 weeks. The polymer viscosity derived from the molecular weight strongly influenced the release rate, while the drug loading had minor influence, allowing customization of the release profile and the daily drug release. Size exclusion chromatography and SDS-PAGE revealed that the antibody fragment structure was kept intact during incorporation and release from the liquid matrix. Furthermore, the released protein monomer maintained its high affinity to human VEGF-A, as measured by surface plasmon resonance analysis. Formulations of ESBA903 in hexPLA meet the basic needs to be used for intravitreal sustained-release applications in age-related macular degeneration treatment. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Asmus, Lutz R.; Gurny, Robert; Moeller, Michael] Univ Geneva, Sch Pharmaceut Sci, Univ Lausanne, CH-1211 Geneva, Switzerland.
   [Grimshaw, John P. A.; Richle, Philipp; Eicher, Barbara; Urech, David M.] ESBATech, CH-8952 Zurich, Switzerland.
C3 University of Geneva; University of Lausanne
RP Moller, M (通讯作者)，Univ Geneva, Sch Pharmaceut Sci, Quai Ernest Ansermet 30, CH-1211 Geneva, Switzerland.
EM lutz.asmus@gmx.net; john.grimshaw@novartis.com;
   philipp.richle@esbatech.com; barbara.eicher@esbatech.com;
   david.urech@hotmail.com; robert.gurny@unige.ch; Michael.Moeller@unige.ch
CR American Academy of Ophthalmology Retina Panel, 2008, PREF PRACT PATT GUID
   Amsden BG, 2010, MACROMOL BIOSCI, V10, P825, DOI 10.1002/mabi.200900465
   Amsden BG, 2010, J CONTROL RELEASE, V145, P109, DOI 10.1016/j.jconrel.2010.03.029
   Asmus LR, 2012, EUR J PHARM BIOPHARM, V81, P591, DOI 10.1016/j.ejpb.2012.04.015
   Asmus LR, 2011, EUR J PHARM BIOPHARM, V79, P584, DOI 10.1016/j.ejpb.2011.07.007
   Behar-Cohen F., 2006, ADV DRUG DELIV REV, V58, P1182
   Borras L, 2010, J BIOL CHEM, V285, P9054, DOI 10.1074/jbc.M109.072876
   Boyer DS, 1999, AM J OPHTHALMOL, V127, P349, DOI 10.1016/S0002-9394(98)00176-7
   Einmahl S, 2000, J BIOMED MATER RES, V50, P566, DOI 10.1002/(SICI)1097-4636(20000615)50:4<566::AID-JBM12>3.0.CO;2-M
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hassan AS, 2009, EUR J PHARM BIOPHARM, V73, P337, DOI 10.1016/j.ejpb.2009.07.009
   Jaffe GJ, 2005, OPHTHALMOLOGY, V112, P1192, DOI 10.1016/j.ophtha.2005.03.013
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Katsamba PS, 2006, ANAL BIOCHEM, V352, P208, DOI 10.1016/j.ab.2006.01.034
   Kimura H, 2001, OPHTHALMOLOGICA, V215, P143, DOI 10.1159/000050849
   Kotliar K, 2007, ACTA OPHTHALMOL SCAN, V85, P777, DOI 10.1111/j.1600-0420.2007.00939.x
   Kraeling MEK, 1997, J SOC COSMET CHEM, V48, P187
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   Martin DF, 1997, ARCH OPHTHALMOL-CHIC, V115, P1389, DOI 10.1001/archopht.1997.01100160559005
   Maur AAD, 2004, METHODS, V34, P215, DOI 10.1016/j.ymeth.2004.04.004
   Merkli A, 1996, BIOMATERIALS, V17, P897, DOI 10.1016/0142-9612(96)83285-6
   Meyer CH, 2010, J OCUL PHARMACOL TH, V26, P491, DOI 10.1089/jop.2010.0045
   Musch DC, 1997, NEW ENGL J MED, V337, P83, DOI 10.1056/NEJM199707103370203
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Rungseevijitprapa W, 2009, EUR J PHARM SCI, V36, P524, DOI 10.1016/j.ejps.2008.12.003
   Schlingemann RO, 2009, PROG BRAIN RES, V175, P253, DOI 10.1016/S0079-6123(09)17517-9
   Sintzel MB, 1998, BIOMATERIALS, V19, P791, DOI 10.1016/S0142-9612(97)00229-9
   Sintzel MB, 1998, INT J PHARM, V175, P165, DOI 10.1016/S0378-5173(98)00274-9
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Trimaille T, 2004, J POLYM SCI POL CHEM, V42, P4379, DOI 10.1002/pola.20251
   Veurink M, 2014, J OCUL PHARMACOL TH, V30, P517, DOI 10.1089/jop.2013.0117
   Veurink M, 2013, EUR J PHARM SCI, V49, P233, DOI 10.1016/j.ejps.2013.02.021
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
NR 34
TC 10
Z9 11
U1 1
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 2015
VL 95
BP 250
EP 260
DI 10.1016/j.ejpb.2015.02.007
PN B
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CU8WH
UT WOS:000363824300010
PM 25779352
DA 2022-11-30
ER

PT J
AU Zhang, Y
   Huang, Q
   Tang, M
   Zhang, JJ
   Fan, W
AF Zhang, Yi
   Huang, Qing
   Tang, Min
   Zhang, Junjun
   Fan, Wei
TI Complement Factor H Expressed by Retinal Pigment Epithelium Cells Can
   Suppress Neovascularization of Human Umbilical Vein Endothelial Cells:
   An in vitro Study
SO PLOS ONE
LA English
DT Article
ID MACULAR DEGENERATION; OXIDATIVE STRESS; GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; ACTIVATION; DRUSEN; PROTEINS; PATHOGENESIS;
   INFLAMMATION; POLYMORPHISM
AB Complement factor H (CFH) is one of the most important soluble complement regulatory proteins and is closely associated with age-related macular degeneration (AMD), the leading cause of irreversible central vision loss in the elderly population in developed countries. Our study searches to investigate whether CFH expression is changed in oxidative damaged retinal pigment epithelium (RPE) cells and the role of CFH in the in vitro neovascularization. First, it was confirmed by immunofluorescence staining that CFH was expressed by ARPE-19 cells. CFH mRNA and protein in oxidative (H2O2) damaged ARPE-19 cells were both reduced, as determined by Real-time PCR and Western blotting analysis. Enzyme-linked immunosorbent assay (ELISA) also showed that ARPE-19 cells treated with H2O2 caused an increase in C3a content, which indicates complement activation. Then, wound assays were performed to show that CFH expression suppression promoted human umbilical vein endothelial cell (HUVECs) migration. Thereafter, ARPE-19 cells were transfected with CFH-specific siRNA and CFH knockdown was confirmed with the aid of Real-time PCR, immunofluorescence staining and Western blotting. The ELISA results showed that specific CFH knockdown in ARPE-19 cells activated the complement system. Finally, in vitro matrigel tube formation assay was performed to determine whether change of CFH expression in RPE would affect tube formation by HUVECs. More tubes were formed by HUVECs co-cultured with ARPE-19 cells transfected with CFH specific-siRNA when compared with controls. Our results suggested that RPE cells might be the local CFH source, and RPE cell injuries (such as oxidative stress) may cause CFH expression suppression, which in turn may lead to complement activation and promotion of tube formation by HUVECs. This finding is of importance in elucidating the role of complement in the pathogenesis of ocular neovascularization including choroidal neovascularization.
C1 [Zhang, Yi; Huang, Qing; Tang, Min; Zhang, Junjun; Fan, Wei] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
C3 Sichuan University
RP Fan, W (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Sichuan, Peoples R China.
EM fanwei55@yahoo.com
FU National Natural Science Foundation of China [8107042]
FX WF is supported by the National Natural Science Foundation of China (No.
   8107042). The funder had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   BROOIMANS RA, 1992, EUR J IMMUNOL, V22, P791, DOI 10.1002/eji.1830220324
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Denker SP, 2002, J CELL BIOL, V159, P1087, DOI 10.1083/jcb.200208050
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fan W, 2002, INVEST OPHTH VIS SCI, V43, pU656
   Fan W, 2002, IN VITRO CELL DEV-AN, V38, P228
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Flierman R, 2007, IMMUNOBIOLOGY, V212, P363, DOI 10.1016/j.imbio.2006.11.005
   Fosbrink M, 2006, J BIOL CHEM, V281, P19009, DOI 10.1074/jbc.M602055200
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Honda S, 2001, MOL VIS, V7, P63
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kurihara R, 2010, INFLAMM RES, V59, P659, DOI 10.1007/s00011-010-0178-4
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   McLaughlin BJ, 2003, INVEST OPHTH VIS SCI, V44, P3669, DOI 10.1167/iovs.02-0813
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Salvador-Morales C, 2006, MOL IMMUNOL, V43, P193, DOI 10.1016/j.molimm.2005.02.006
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Smailhodzic D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112682
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Wu ZH, 2007, J BIOL CHEM, V282, P22414, DOI 10.1074/jbc.M702321200
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 50
TC 9
Z9 9
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 19
PY 2015
VL 10
IS 6
AR e0129945
DI 10.1371/journal.pone.0129945
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CL3FE
UT WOS:000356835000075
PM 26091360
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU de Carvalho, JER
   Klaassen, I
   Vogels, IMC
   Schipper-Krom, S
   van Noorden, CJF
   Reits, E
   Gorgels, TGMF
   Bergen, AAB
   Schlingemann, RO
AF de Carvalho, J. Emanuel Ramos
   Klaassen, Ingeborg
   Vogels, Ilse M. C.
   Schipper-Krom, Sabine
   van Noorden, Cornelis J. F.
   Reits, Eric
   Gorgels, Theo G. M. F.
   Bergen, Arthur A. B.
   Schlingemann, Reinier O.
TI Complement Factor C3a Alters Proteasome Function in Human RPE Cells and
   in an Animal Model of Age-Related RPE Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE proteasome; retina; age-related macular degeneration; complement; C3a;
   gamma-interferon; ophthalmology; CCL2(-/-)
ID RETINAL-PIGMENT EPITHELIUM; FACTOR-H POLYMORPHISM; KNOCK-OUT MICE;
   MACULAR DEGENERATION; PHOTORECEPTOR APOPTOSIS; OXIDATIVE DAMAGE;
   GAMMA-INTERFERON; DRUSEN; ACTIVATION; LIPOFUSCIN
AB PURPOSE. Complement activation plays an unequivocal role in the pathogenesis of age-related macular degeneration (AMD). More recent evidence suggests an additional role in AMD for the ubiquitin proteasome pathway (UPP), a protein-degradation nanomachinery present in all types of eukaryotic cells. The purpose of this study was to elaborate on these findings and investigate whether the complement system directly contributes to derangements in the UPP through the activated complement components C3a and C5a.
   METHODS. In the retinal pigment epithelial cells (RPE) of monocyte chemoattractant protein-1-deficient CCL2(-/-) mice, a mouse model that may serve as a model for age-related atrophic degeneration of the RPE, proteasome function was investigated by immunohistochemistry of household (beta 5) and immuno (beta 5i) subunit expression. Subsequently, proteasome overall activity was determined using the BodipyFl-Ahx(3)L(3)VS probe in primary-cultured human retinal pigment epithelial cells (HRPE) cells that were exposed to different stimuli including C3a and C5a, using confocal laser scanning microscopy and flow cytometry. Gene expression and protein levels of proteasome subunits alpha 7, PA28 alpha, beta 5, and beta 5i were also studied in RPE cells after exposure to IFN-gamma, C3a, and C5a by real-time PCR and Western blotting.
   RESULTS. Retinal pigment epithelial cells of CCL2(-/-) mice showed immunoproteasome upregulation. C3a, but not C5a supplementation, induced a decreased proteasome overall activity in HRPE cells, whereas mRNA and protein levels of household proteasome and immunoproteasome subunits were unaffected.
   CONCLUSIONS. In HRPE cells, C3a induces decreased proteasome-mediated proteolytic activity, whereas in a mouse model of age-related RPE atrophy, the immunoproteasome was upregulated, indicating a possible role for complement-driven posttranslational alterations in proteasome activity in the cascade of pathologic events that result in AMD.
C1 [de Carvalho, J. Emanuel Ramos; Klaassen, Ingeborg; Vogels, Ilse M. C.; van Noorden, Cornelis J. F.; Schlingemann, Reinier O.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Ocular Angiogenesis Grp, NL-1105 AZ Amsterdam, Netherlands.
   [de Carvalho, J. Emanuel Ramos; Klaassen, Ingeborg; Vogels, Ilse M. C.; van Noorden, Cornelis J. F.; Schlingemann, Reinier O.] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, Ocular Angiogenesis Grp, NL-1105 AZ Amsterdam, Netherlands.
   [Schipper-Krom, Sabine; van Noorden, Cornelis J. F.; Reits, Eric] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands.
   [Gorgels, Theo G. M. F.; Bergen, Arthur A. B.; Schlingemann, Reinier O.] Royal Acad Sci KNAW, NIN, Amsterdam, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; University
   of Amsterdam; Academic Medical Center Amsterdam; University of
   Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands Academy
   of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)
RP Schlingemann, RO (通讯作者)，Acad Med Ctr, Dept Ophthalmol, Med Retina Unit, Room A2-122,POB 22660, NL-1100 DD Amsterdam, Netherlands.
EM r.schlingemann@amc.uva.nl
RI Klaassen, Ingeborg/F-7333-2015
OI Klaassen, Ingeborg/0000-0003-1695-9403; Bergen,
   Arthur/0000-0002-6333-9576
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Berkers CR, 2007, MOL PHARM, V4, P739, DOI 10.1021/mp0700256
   Bora NS, 2008, SEMIN IMMUNOPATHOL, V30, P85, DOI 10.1007/s00281-008-0110-y
   Bose S, 2001, BIOCHEM J, V353, P291, DOI 10.1042/0264-6021:3530291
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   Burke JM, 1998, INVEST OPHTH VIS SCI, V39, P1478
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dahlmann B, 2000, J MOL BIOL, V303, P643, DOI 10.1006/jmbi.2000.4185
   Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ding QX, 2006, ANTIOXID REDOX SIGN, V8, P130, DOI 10.1089/ars.2006.8.130
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Dudek EJ, 2005, FASEB J, V19, P1707, DOI 10.1096/fj.05-4049fje
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fernandes AF, 2006, EXP EYE RES, V83, P1472, DOI 10.1016/j.exer.2006.07.024
   Ferrington DA, 2008, J NEUROCHEM, V106, P158, DOI 10.1111/j.1471-4159.2008.05345.x
   Florea BI, 2010, CHEM BIOL, V17, P795, DOI 10.1016/j.chembiol.2010.05.027
   Goldberg AL, 2002, MOL IMMUNOL, V39, P147, DOI 10.1016/S0161-5890(02)00098-6
   Grimm C, 2001, CELL DEATH DIFFER, V8, P859, DOI 10.1038/sj.cdd.4400871
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hayashi T, 1999, MOL CELL BIOL, V19, P8646
   Hayashi T, 2001, J APPL PHYSIOL, V91, P2804, DOI 10.1152/jappl.2001.91.6.2804
   Hohn A, 2011, FREE RADICAL BIO MED, V50, P585, DOI 10.1016/j.freeradbiomed.2010.12.011
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hope AD, 2003, J NEUROCHEM, V86, P394, DOI 10.1046/j.1471-4159.2003.01844.x
   Iuvone PM, 2002, INVEST OPHTH VIS SCI, V43, P564
   JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kapphahn RJ, 2007, EXP EYE RES, V84, P646, DOI 10.1016/j.exer.2006.12.002
   KATZ ML, 1989, INVEST OPHTH VIS SCI, V30, P37
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   KATZ ML, 1989, MECH AGEING DEV, V49, P23, DOI 10.1016/0047-6374(89)90065-1
   KATZ ML, 1985, ARCH BIOL, V96, P360
   KATZ ML, 1992, INVEST OPHTH VIS SCI, V33, P2612
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Klare N, 2007, J MOL BIOL, V373, P1, DOI 10.1016/j.jmb.2007.07.038
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li ZM, 2004, J NEUROCHEM, V90, P19, DOI 10.1111/j.1471-4159.2004.02456.x
   Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Murata S, 2009, NAT REV MOL CELL BIO, V10, P104, DOI 10.1038/nrm2630
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48
   Rivett AJ, 2001, BIOCHIMIE, V83, P363
   ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6
   SAMBROOK J, 1989, NATURE, V342, P224, DOI 10.1038/342224a0
   Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Tanaka K, 1997, ADV IMMUNOL, V64, P1, DOI 10.1016/S0065-2776(08)60885-8
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Verdoes M, 2006, CHEM BIOL, V13, P1217, DOI 10.1016/j.chembiol.2006.09.013
   Vessey K, 2012, CLIN EXP OPHTHALMOL, V40, P131
   Wassell J, 1998, INVEST OPHTH VIS SCI, V39, P1487
   Wenzel A, 2001, INVEST OPHTH VIS SCI, V42, P1653
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P3622, DOI 10.1167/iovs.07-1559
NR 72
TC 23
Z9 24
U1 1
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2013
VL 54
IS 10
BP 6489
EP 6501
DI 10.1167/iovs.13-12374
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 246VI
UT WOS:000326567700005
PM 23982842
DA 2022-11-30
ER

PT J
AU Morales, MU
   Saker, S
   Mehta, RL
   Rubinstein, M
   Amoaku, WM
AF Morales, Marco Ulises
   Saker, Saker
   Mehta, Rajnikant L.
   Rubinstein, Martin
   Amoaku, Winfried M.
TI Preferred retinal locus profile during prolonged fixation attempts
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID STABILITY; SCOTOMA
AB Objective: The retinal area or location used during any fixation attempt defines the preferred retinal locus (PRL). It is presumed that during prolonged fixation attempts there may be various representative reference points within the PRL area. This study aims to clarify this presumption.
   Design: Prospective, nonrandomized, observational case series.
   Participants: Sixty-five eyes of 41 patients from the University of Nottingham, Queen's Medical Centre Retina and Low Vision Clinics.
   Methods: A total of 65 eyes of 41 patients from the University of Nottingham, Queen's Medical Centre Retina and Low Vision Clinics were assessed for PRL using the Macular Integrity Assessment (MAIA) microperimetry equipment (CenterVue, Padova, Italy). The MAIA allows automatic calculation for 2 points named PRL initial (FRU), which is calculated after the first 10 seconds of fixation, and PRL final (PRLf), which is calculated after the completion of all fixation attempts during the microperimetry test.
   Results: Estimates of PRLi and PRLf were produced for all patients. Forty-six (71%) eyes were classified as having stable fixation; 40 of the 46 eyes (87%) had both PRLs location over the fovea centralis. Nineteen of 65 eyes (29%) were classified as having unstable or relatively unstable fixation; different PRLi and PRLf locations were found in 18 (95%) of the 19 eyes, including 13 (68%) with central geographic atrophy secondary to dry age-related macular degeneration. The mean rate of change was 5.3 units in fixation per unit change in distance in both PRLi and PRLf.
   Conclusions: The representative points during prolonged fixation attempts may vary at different stages of fixation. This is reflected in the characteristics of fixation stability of the patients and presents a possible association with main pathology responsible for low vision.
C1 [Morales, Marco Ulises; Saker, Saker] Univ Nottingham, Queens Med Ctr, Div Ophthalmol & Visual Sci, Nottingham NG7 2UH, England.
   [Mehta, Rajnikant L.; Rubinstein, Martin; Amoaku, Winfried M.] Univ Nottingham, Queens Med Ctr, Natl Inst Hlth Res Design Serv East Midlands, Nottingham NG7 2UH, England.
C3 University of Nottingham; University of Nottingham
RP Morales, MU (通讯作者)，Univ Nottingham, Queens Med Ctr, Div Ophthalmol & Visual Sci, B Floor,East Block,Derby Rd, Nottingham NG7 2UH, England.
EM msxmum@nottingham.ac.uk
RI saker, samir H/A-5499-2008; Saker, Samir H/Y-4774-2018
OI Saker, Samir H/0000-0003-2793-0972; Morales, Marco
   U./0000-0002-1508-2753; Amoaku, Winfried/0000-0001-5028-7984; Mehta,
   Rajnikant/0000-0002-5341-5598
FU School of Clinical Sciences (Division of Ophthalmology and Visual
   Sciences) of the University of Nottingham
FX This study was supported by the School of Clinical Sciences (Division of
   Ophthalmology and Visual Sciences) of the University of Nottingham as
   part of the postgraduate research PhD program.
CR Crossland MD, 2011, INVEST OPHTH VIS SCI, V52, P411, DOI 10.1167/iovs.10-5473
   Deruaz A, 2002, VISION RES, V42, P2947, DOI 10.1016/S0042-6989(02)00354-1
   Dunbar HMP, 2010, INVEST OPHTH VIS SCI, V51, P4346, DOI 10.1167/iovs.09-4556
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Greenstein VC, 2008, RETINA-J RET VIT DIS, V28, P1234, DOI 10.1097/IAE.0b013e31817c1b47
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P347, DOI 10.1016/j.jcjo.2013.07.010
   Markowitz SN, 2011, INVEST OPHTH VIS SCI, V52, P1191, DOI 10.1167/iovs.11-7197
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   Safran AB, 1999, BRIT J OPHTHALMOL, V83, P1341, DOI 10.1136/bjo.83.12.1341
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   Seiple WH., 2012, OPTOM REP, V2, P11
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Tarita-Nistor L, 2009, INVEST OPHTH VIS SCI, V50, P84, DOI 10.1167/iovs.08-2342
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
NR 17
TC 16
Z9 18
U1 0
U2 7
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2013
VL 48
IS 5
BP 368
EP 374
DI 10.1016/j.jcjo.2013.05.022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5OM
UT WOS:000331149300020
PM 24093182
DA 2022-11-30
ER

PT J
AU Patel, AK
   Hackam, AS
AF Patel, Amit K.
   Hackam, Abigail S.
TI Toll-like receptor 3 (TLR3) protects retinal pigmented epithelium (RPE)
   cells from oxidative stress through a STAT3-dependent mechanism
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Toll-like receptor 3; Retinal pigmented epithelium; Oxidative stress;
   STAT3
ID MACULAR DEGENERATION; MESSENGER-RNA; CANCER-CELLS; DISEASE; DAMAGE;
   NEURODEGENERATION; INFLAMMATION; ACTIVATION; EXPRESSION; PATHWAY
AB Toll-like receptors (TLRs) are essential receptors of the innate immune system and are first responders for protection against bacterial and viral pathogens. Recently, several TLRs have also been implicated in regulating cell death and survival in non-pathogen injuries such as stroke and oxidative stress. Investigating the role of TLRs during central nervous system damage is an important focus of research that may reveal new mechanisms underlying the cellular response to injury and survival. Retinal pigmented epithelium (RPE) cells form an epithelial layer underneath the neural retina that maintains the function of photoreceptors and are the primary cell type affected in the retinal disease age-related macular degeneration (AMD). Predicted loss of function polymorphisms in the TLR3 gene are associated with protection from AMD but the role of TLR3 in regulating RPE survival during AMD-like injury, such as high oxidative stress, is not known. Therefore the purpose of this study is to evaluate the effect of TLR3 signaling on RPE viability during oxidative stress. We demonstrated that TLR3 activation in the presence of oxidative stress injury significantly increased RPE cell viability, in contrast to TLR3 reducing cell viability in the absence of cellular injury. Furthermore, we show signal transducer and activator of transcription 3 (STAT3) signaling as an essential mediator of TLR3-regulated protection of RPE cells. STAT3 signaling was increased by TLR3 activation and knockdown of STAT3 transcripts using siRNA abolished the protective effect of TLR3 during oxidative stress. Together, these results demonstrate a novel pro-survival role for TLR3 signaling within the RPE during injury. These findings support the concept that dysregulation of TLR3 activity may contribute to the development of AMD, suggesting that precise regulation of the TLR3 pathway during AMD-associated injury could be of therapeutic interest. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Patel, Amit K.; Hackam, Abigail S.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Hackam, AS (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, McKnight Bldg,Room 407,1638 NW 10th Ave, Miami, FL 33136 USA.
EM ahackam@med.miami.edu
FU Research to Prevent Blindness Ernest & Elizabeth Althouse Special
   Scholar Award; Karl Kirchgessner Foundation; NIH [RO1 EY017837]; Fight
   for Sight Student Fellowship; Research to Prevent Blindness; NEI Center
   Core Grant [P30EY014801]; NATIONAL EYE INSTITUTE [R01EY017837,
   P30EY014801] Funding Source: NIH RePORTER
FX This study was supported by a Research to Prevent Blindness Ernest &
   Elizabeth Althouse Special Scholar Award, the Karl Kirchgessner
   Foundation, NIH grant RO1 EY017837, and a Fight for Sight Student
   Fellowship. Institutional support to BPEI was from a Research to Prevent
   Blindness Unrestricted Grant and an NEI Center Core Grant P30EY014801.
CR Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Barry SP, 2009, BIOCHEM BIOPH RES CO, V385, P324, DOI 10.1016/j.bbrc.2009.05.051
   Bernard JJ, 2012, NATURE MED
   Bsibsi M, 2006, GLIA, V53, P688, DOI 10.1002/glia.20328
   Bsibsi M, 2010, J IMMUNOL, V184, P6929, DOI 10.4049/jimmunol.0902419
   BUS JS, 1984, ENVIRON HEALTH PERSP, V55, P37, DOI 10.2307/3429690
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061
   Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431
   Cavassani KA, 2008, J EXP MED, V205, P2609, DOI 10.1084/jem.20081370
   Chen M, 2008, INVEST OPHTH VIS SCI, V49, P3699, DOI 10.1167/iovs.07-1522
   Chen R, 2008, ONCOGENE, V27, P225, DOI 10.1038/sj.onc.1210907
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cingolani C, 2006, FREE RADICAL BIO MED, V40, P660, DOI 10.1016/j.freeradbiomed.2005.09.032
   Cole JE, 2011, P NATL ACAD SCI USA, V108, P2372, DOI 10.1073/pnas.1018515108
   Dai XJ, 2006, J INVEST DERMATOL, V126, P1574, DOI 10.1038/sj.jid.5700294
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Drouin-Ouellet J, 2012, TRENDS PHARMACOL SCI, V33, P542, DOI 10.1016/j.tips.2012.07.002
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Dvoriantchikova G, 2010, MOL VIS, V16, P1907
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Ehlers M, 2007, TRENDS IMMUNOL, V28, P74, DOI 10.1016/j.it.2006.12.006
   Estornes Y, 2012, CELL DEATH DIFFER, V19, P1482, DOI 10.1038/cdd.2012.22
   Fragoso MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046892
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Hackam AS, 2004, INVEST OPHTH VIS SCI, V45, P2929, DOI 10.1167/iovs.03-1184
   Jin YH, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-178
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200
   Kilic U, 2008, NEUROBIOL DIS, V31, P33, DOI 10.1016/j.nbd.2008.03.002
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Komori H, 2012, J BIOL CHEM, V287, P30688, DOI 10.1074/jbc.M112.353771
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Leung PY, 2012, STROKE, V43, P1383, DOI 10.1161/STROKEAHA.111.641522
   Liu Y, 2010, J BIOL CHEM, V285, P27429, DOI 10.1074/jbc.M110.142752
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Luo W, 2011, ATHEROSCLEROSIS, V214, P81, DOI 10.1016/j.atherosclerosis.2010.10.009
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Nakamura REI, 2010, GROWTH FACTORS, V28, P232, DOI 10.3109/08977191003738832
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   Sarafian TA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009532
   Sharma S, 2011, BRAIN RES, V1373, P189, DOI 10.1016/j.brainres.2010.11.096
   Shiose S, 2011, J BIOL CHEM, V286, P15543, DOI 10.1074/jbc.M111.228551
   Silva AK, 2010, MOL VIS, V16, P36
   Slater L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001178
   Stevens SL, 2011, J NEUROSCI, V31, P8456, DOI 10.1523/JNEUROSCI.0821-11.2011
   Strauss O., 1995, SOURCEWEBVISION ORG
   Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003
   Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47
   van Noort JM, 2009, PROG BRAIN RES, V175, P139, DOI 10.1016/S0079-6123(09)17509-X
   Walter S, 2007, CELL PHYSIOL BIOCHEM, V20, P947, DOI 10.1159/000110455
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yi H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036560
   Zhang SSM, 2003, EXP EYE RES, V76, P421, DOI 10.1016/S0014-4835(03)00002-2
NR 56
TC 34
Z9 38
U1 1
U2 82
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD JUN
PY 2013
VL 54
IS 2
BP 122
EP 131
DI 10.1016/j.molimm.2012.11.005
PG 10
WC Biochemistry & Molecular Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Immunology
GA 094HP
UT WOS:000315253900003
PM 23267850
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zweifel, SA
   Maygar, I
   Berger, W
   Tschuor, P
   Becker, M
   Michels, S
AF Zweifel, S. A.
   Maygar, I.
   Berger, W.
   Tschuor, P.
   Becker, M.
   Michels, S.
TI Multimodal Imaging of Autosomal Dominant Drusen
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE Malattia Leventinese; Doyne honeycomb retinal dystrophy; autosomal
   dominant drusen; familial drusen; early onset drusen; subretinal
   drusenoid deposits; reticular pseudodrusen; spectral domain optical
   coherence tomography; multimodal imaging
ID MALATTIA LEVENTINESE; RETICULAR PSEUDODRUSEN; TOMOGRAPHY; DEPOSITS
AB Background: Malattia Leventinese (ML) is a dominantly inherited macular dystrophy characterized by a radial pattern of drusen in the macular area and on the nasal edge of the optic disc. This case series describes the morphological features of drusen associated with ML using multimodal imaging.
   History and Signs: Three patients (two of the same family but only one with the ML phenotype) were analyzed by multimodal imaging including spectral domain optical coherence tomography (SD OCT) and genetic testing. In two patients multiple drusen in the macular region and around the optic nerve head were observed bilaterally. A radial pattern was only seen in one patient. These drusenoid deposits showed early hyperfluorescence in fluorescein angiography (FA) and intense staining in indocyanine green angiography similar to cuticular drusen (basal laminar drusen). The corresponding SD OCT scan revealed two types of deposits. The first, more prominent type, were focal nodular sub-retinal pigment epithelium (RPE) deposits. The second type of deposit appears to be localized on the anterior part of the RPE comparable to subretinal drusenoid deposits (SDD; reticular pseudodrusen).
   Therapy and Outcome: A single nucleotide variation c.1033C>T (p.R345W) in the EFEMP1 gene was found in case 1 (classic ML), but could not be detected in case 2 and 3. So far our patients have not suffered from any visual complaints and have not developed choroidal neovascularization. They will be followed up regularly.
   Discussion: Multimodal imaging including SD OCT provided new information about the appearance of drusen in eyes with ML/early onset drusen. In addition to the sub-RPE deposits some deposits appear above the RPE, however have different characteristic findings on FA/ICG, auto-fluorescence, near infrared reflectance and blue light imaging than SDD observed in patients with age-related macular degeneration. SD OCT alone might not be sufficient to characterize these type of drusen in ML.
C1 [Zweifel, S. A.] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Tschuor, P.; Becker, M.; Michels, S.] Univ Zurich, Div Med Mol Genet, Inst Med Genet, CH-8603 Schwerzenbach, Switzerland.
   [Maygar, I.; Berger, W.] Triemli Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   Triemli Hospital
RP Zweifel, SA (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM sandrine.zweifel@usz.ch
RI Zweifel, Sandrine/AAX-5045-2020; Becker, Matthias/A-8733-2014
CR Doyne R., 1899, T OPHTHAL SOC UK, V19, P71
   Gaillard MC, 2005, KLIN MONATSBL AUGENH, V222, P180, DOI 10.1055/s-2005-857972
   Marmorstein Lihua, 2004, Ophthalmic Genet, V25, P219, DOI 10.1080/13816810490498305
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Saemisch T, 1925, HDB GESAMMTEN AUGENH, P1
   Souied EH, 2006, AM J OPHTHALMOL, V141, P404, DOI 10.1016/j.ajo.2005.09.001
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1163, DOI 10.1097/IAE.0b013e3181ed8d05
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 10
TC 9
Z9 10
U1 0
U2 4
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2012
VL 229
IS 4
BP 399
EP 402
DI 10.1055/s-0031-1299404
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 925VC
UT WOS:000302788900022
PM 22496012
DA 2022-11-30
ER

PT J
AU Carter, JG
   Cherry, J
   Williams, K
   Turner, S
   Bates, DO
   Churchill, AJ
AF Carter, J. G.
   Cherry, J.
   Williams, K.
   Turner, S.
   Bates, D. O.
   Churchill, A. J.
TI Splicing Factor Polymorphisms, the Control of VEGF Isoforms and
   Association with Angiogenic Eye Disease
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Angiogenesis; Diabetes; Macular degeneration; Polymorphism; Retinopathy
ID ENDOTHELIAL GROWTH-FACTOR; SR FAMILY; IDENTIFICATION; DOMAINS; GENE
AB Purpose: Alternative splicing of the last exon (exon 8) of vascular endothelial growth factor (VEGF) pre-mRNA is a key element in the balance of pro- and anti-angiogenic VEGF isoforms in exudative age-related macular degeneration (exAMD) and proliferative diabetic retinopathy (PDR). Three splicing factors, SRp40, ASF/SF2, and SRp55 are predicted to control alternative splicing by binding to exonic splice enhancers (ESE) in VEGF exon 8. This pilot study examines whether there is an association between angiogenic eye disease and splicing factor polymorphisms, and whether there are sequence variations in the alternative splice sites of the VEGF gene.
   Materials and Methods: A case: control pilot study comparing 163 individuals with angiogenic eye disease (94 exAMD and 69 PDR patients) with 95 age-matched controls. Splicing factor polymorphisms were genotyped by Restriction Fragment Length Polymorphism (RFLP) and sequencing, and the VEGF alternatively spliced region was assessed by denaturing High Performance Liquid Chromatography (dHPLC) using a transgenomic WAVE heteroduplex analyzer.
   Results: No variations were observed in the alternatively spliced region of VEGF exon 8. ASF/SF2 polymorphisms showed no association with exAMD or PDR. For PDR, we observed a trend in SRp40 (rs6573908) where the 5136CC genotype was more frequent in controls (p = 0.0517) and a significant association of the SRp55 (rs2235611), where the 2994C allele was more common in the PDR group (p = 0.03). This remained strong, but not significant, after logistic regression for age, sex, disease type, and duration (p = 0.06).
   Conclusions: The lack of variation in the VEGF alternatively spliced region suggests the importance of sequence conservation in this area in maintaining the balance of pro-and anti-angiogenic VEGF isoforms. The link between PDR and the SRp55 2994 polymorphism suggests a disease-specific association between factors controlling VEGF splicing and ocular angiogenesis.
C1 [Churchill, A. J.] Univ Bristol, Bristol Eye Hosp, Unit Ophthalmol, Bristol BS1 2LX, Avon, England.
   [Bates, D. O.] Univ Bristol, Sch Vet Sci, Dept Physiol & Pharmacol, Microvasc Res Labs, Bristol BS1 2LX, Avon, England.
C3 Bristol Eye Hospital; University of Bristol; University of Bristol
RP Churchill, AJ (通讯作者)，Univ Bristol, Bristol Eye Hosp, Unit Ophthalmol, Lower Maudlin St, Bristol BS1 2LX, Avon, England.
EM a.j.churchill@bristol.ac.uk
OI Carter, James/0000-0003-1860-9677; Cherry, Jocelyn/0000-0002-4950-1792;
   Bates, David/0000-0003-4850-2360; Williams, Katie M/0000-0003-4596-3938
CR Bates DO, 2002, CANCER RES, V62, P4123
   Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9
   CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x
   Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225
   Chiu YL, 2006, BIOCHEM BIOPH RES CO, V341, P663, DOI 10.1016/j.bbrc.2005.12.218
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362
   Kaiser PK, 2007, INT J CLIN PRACT, V61, P501, DOI 10.1111/j.1742-1241.2007.01299.x
   Ng YS, 2006, EXP CELL RES, V312, P527, DOI 10.1016/j.yexcr.2005.11.008
   PENG XB, 1995, MOL CELL BIOL, V15, P6273
   Perrin RM, 2005, DIABETOLOGIA, V48, P2422, DOI 10.1007/s00125-005-1951-8
   Powell B, 2003, MOL VIS, V9, P460
   SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692
   Woolard J, 2006, FASEB J, V20, pA539
   Zhang B, 2009, INVEST OPHTH VIS SCI, V50, P3943, DOI 10.1167/iovs.08-2954
NR 17
TC 14
Z9 15
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD APR
PY 2011
VL 36
IS 4
BP 328
EP 335
DI 10.3109/02713683.2010.548892
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 735BW
UT WOS:000288389400006
PM 21309690
DA 2022-11-30
ER

PT J
AU Yau, GL
   Jackman, CS
   Hooper, PL
   Sheidow, TG
AF Yau, Gary L.
   Jackman, Christopher S.
   Hooper, Philip L.
   Sheidow, Tom G.
TI Intravitreal Injection Anesthesia-Comparison of Different Topical
   Agents: A Prospective Randomized Controlled Trial
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; CATARACT-SURGERY; PEDIATRIC PAIN; SCALE;
   LIDOCAINE; VALIDATION; PARENTS; RATINGS; SCORES; GEL
AB PURPOSE: To compare the anesthetic effectiveness of 3 topical agents used for intravitreal injections.
   DESIGN: Randomized, triple-armed, double-blinded, prospective, single-centered trial in patients receiving intravitreal ranibizumab for neovascular age-related macular degeneration.
   METHODS: Patients were randomized 1:1:1 to receive 0.5% tetracaine hydrochloride drops and a 4% lidocaine pledget (n = 31), 0.5% tetracaine hydrochloride drops alone (n = 31), or 4% cocaine (+ epinephrine 1/100 000) drops alone (n = 31). Patients were asked to score their pain experience using a visual analogue scale (VAS) immediately following and 15 minutes after their injection. The average of these scores was used as the primary outcome. The physician performing the procedure separately scored his perception of the patients' pain using the Wong-Baker FACES scale.
   RESULTS: Means of the averaged VAS pain score for Groups 1, 2, and 3 were: 19 (95% confidence interval [CI] 12-26), 21 (95% CI 13-29), and 21 (95% Cl 16-27) respectively. Mean Wong-Baker pain scores for Groups 1, 2, and 3 were 1.9 (95% CI 1.3-2.6), 2.1 (95% CI 1.4-2.7), and 2.3 (95% Cl 1.6-3.1) respectively. There was no significant difference (P = .549) between groups for average VAS pain score. Similarly, there was no significant difference (P = .790) for the physician-perceived pain score between groups.
   CONCLUSIONS: There was no clinical difference in patient pain experience between the 3 anesthetic options tested. The addition of a 4% lidocaine pledget offered no clinical advantage in pain relief compared to 0.5% tetracaine or 4% cocaine (+ epinephrine 1/100 000) drops alone. (Am J Ophthalmol 2011;151:333-337. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Yau, Gary L.; Jackman, Christopher S.; Hooper, Philip L.; Sheidow, Tom G.] Univ Western Ontario, Ivey Eye Inst, London, ON N6A 4V2, Canada.
C3 Western University (University of Western Ontario)
RP Sheidow, TG (通讯作者)，Univ Western Ontario, Ivey Eye Inst, 268 Grosvenor St E, London, ON N6A 4V2, Canada.
EM sheidowt@rogers.com
OI Sheidow, Tom/0000-0001-6370-1857
FU Novartis; QLT; Pfizer
FX THE AUTHORS INDICATE NO FINANCIAL CONFLICT OR PROPRIETARY INTEREST IN
   ANY MATERIAL OR METHOD MENTIONED. No direct government or
   nongovernmental financial support was used to fund this study. Dr
   Sheidow is a member of advisory boards for Novartis, QLT, and Pfizer and
   has research study grants from each, none of which were used to support
   the current study. Dr Hooper is a consultant for Alcon Inc. Dr Jackman
   has received lecture fees from Novartis. The remaining author reports no
   financial disclosures. Involved in conception and design of study (TO.,
   C.J., G.Y., P.H.); analysis and interpretation (T.S., C.J., G.Y.);
   writing of manuscript (G.Y.); critical revision of manuscript (T.S.,
   C.J., G.Y., P.H.); final approval of the manuscript (TO., C.J., P.H.);
   data collection (T.S., C.J., P.H.); and provision of materials,
   patients, or resources (T.S., C.J., P.H.). We would like to thank our
   research assistants, AnneMarie Powell and Teresa Jantzi (A.M.P., T.J.),
   for their assistance with this study. The study and data accumulation
   were carried out with approval from the University of Western Ontario
   Health Sciences Research Ethics Board. Informed consent for the research
   was obtained from all participating patients.
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Chambers CT, 1999, PAIN, V83, P25, DOI 10.1016/S0304-3959(99)00086-X
   Cintra LP, 2009, OPHTHAL SURG LAS IM, V40, P13, DOI 10.3928/15428877-20090101-05
   Crandall AS, 1999, OPHTHALMOLOGY, V106, P60, DOI 10.1016/S0161-6420(99)90007-6
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman SM, 2006, AM J OPHTHALMOL, V142, P887, DOI 10.1016/j.ajo.2006.06.033
   Garra G, 2010, ACAD EMERG MED, V17, P50, DOI 10.1111/j.1553-2712.2009.00620.x
   HEIMANN H, MED RETINA ESSENTIAL
   Jacobi PC, 2000, ARCH OPHTHALMOL-CHIC, V118, P1037, DOI 10.1001/archopht.118.8.1037
   Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8
   Kaderli B, 2006, EUR J OPHTHALMOL, V16, P718, DOI 10.1177/112067210601600509
   Kelly AM, 2001, EMERG MED J, V18, P205, DOI 10.1136/emj.18.3.205
   Kozak I, 2005, RETINA-J RET VIT DIS, V25, P994, DOI 10.1097/00006982-200512000-00007
   Morris B, 2009, BRIT J OPHTHALMOL, V93, P329, DOI 10.1136/bjo.2008.145268
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Salo D, 2003, AM J EMERG MED, V21, P515, DOI 10.1016/S0735-6757(03)00210-9
   SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5
   Wilson GAM, 1996, ANAESTHESIA, V51, P1005, DOI 10.1111/j.1365-2044.1996.tb14991.x
   Zakrzewski PA, 2009, OPHTHALMOLOGY, V116, P1168, DOI 10.1016/j.ophtha.2009.01.022
NR 19
TC 33
Z9 34
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2011
VL 151
IS 2
BP 333
EP 337
DI 10.1016/j.ajo.2010.08.031
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 712ZX
UT WOS:000286705900022
PM 21168822
DA 2022-11-30
ER

PT J
AU DeMarco, SC
   Lazzi, G
   Liu, WT
   Weiland, JD
   Humayun, MS
AF DeMarco, SC
   Lazzi, G
   Liu, WT
   Weiland, JD
   Humayun, MS
TI Computed SAR and thermal elevation in a 0.25-mm 2-D model of the human
   eye and head in response to an implanted retinal stimulator - Part I:
   Models and methods
SO IEEE TRANSACTIONS ON ANTENNAS AND PROPAGATION
LA English
DT Article
DE age-related macular degeneration; finite-difference time domain (FDTD);
   retina prosthesis; retinitis pigmentosa; specific absorption rate (SAR);
   stimulator IC; temperature; thermal simulation
ID DIELECTRIC-PROPERTIES; BIOLOGICAL TISSUES; ELECTRICAL-STIMULATION;
   MORPHOMETRIC ANALYSIS; RETINITIS-PIGMENTOSA; TEMPERATURE RISES;
   COMPUTATION; TELEPHONES; ABSORPTION; FIELDS
AB Retinitis pigmentosa and age-related macular degeneration lead to blindness through progressive loss of retinal photoreceptors. Attempts are under way to construct a visual prosthesis to recover a limited sense of vision for these patients with the aid of implantable electronic devices. The function of these microchips is to provide electrical stimulation to existing viable retinal tissues-living ganglion and bipolar cells-using an array of on-chip stimulus circuits, while the dominant mechanism for power and data. communication for these implanted devices has been wireless inductive telemetry using coils. This paper describes methods and models used to estimate the heating induced in the human eye and surrounding head tissues subject to the operation of this retinal prosthesis. A two-dimensional 0.25-mm high-resolution human head model has been developed with the aid of a new semiautomatic graphical segmentation algorithm. Finite-difference-based numerical methods for both electromagnetic and thermal modeling have been used to determine the influence of the specific absorption rate (associated with 2-MHz inductive coupling to the implant) and of stimulator integrated circuit (IC) power on tissue heating under different operational conditions and different hypothesis on choroidal blood flow and properties of the complex implanted circuitry. Results, provided in Part 11 of this paper, show that temperature increases of approximately 0.6 and 0.4degreesC are induced in the midvitreous of the human eye in the absence and presence of choroidal blood flow, respectively, for a 60-electrode retinal prosthesis chip. Correspondent temperature rises of approximately 0.19 and 0.004degreesC on the retina are obtained for these cases. Comparison with in vivo experimental measurements on intraocular heating in dog eyes shows good agreement.
C1 N Carolina State Univ, Dept Elect & Comp Engn, Raleigh, NC 27695 USA.
   Univ So Calif, Doheny Eye Inst, Los Angeles, CA 90089 USA.
C3 University of North Carolina; North Carolina State University; Doheny
   Eye Institute; University of Southern California
RP DeMarco, SC (通讯作者)，N Carolina State Univ, Dept Elect & Comp Engn, Raleigh, NC 27695 USA.
OI Weiland, James/0000-0003-3453-9074
CR BARD P, 1961, MED PHYSIOL, P240
   BARDATI F, 1980, ALTA FREQ, V49, P61
   Bernardi P, 2000, IEEE T MICROW THEORY, V48, P1118, DOI 10.1109/22.848494
   Bernardi P, 1998, IEEE T MICROW THEORY, V46, P2074, DOI 10.1109/22.739285
   DEMARCO SC, UNPUB 60 CHANNEL IMP
   Dowling J.E., 1987, RETINA APPROACHABLE
   DUCK FA, 1990, PHYSICAL PROPERTIES
   ESSELLE KP, 1992, IEEE T BIO-MED ENG, V39, P693, DOI 10.1109/10.142644
   Forrester JV., 1996, EYE BASIC SCI PRACTI
   Gabriel C, 1996, PHYS MED BIOL, V41, P2231, DOI 10.1088/0031-9155/41/11/001
   Gabriel C, 1996, NALOETR19960037 RAD
   Gabriel C., COMPILATION DIELECTR
   Gabriel S, 1996, PHYS MED BIOL, V41, P2251, DOI 10.1088/0031-9155/41/11/002
   Gabriel S, 1996, PHYS MED BIOL, V41, P2271, DOI 10.1088/0031-9155/41/11/003
   Gandhi OP, 1996, IEEE T MICROW THEORY, V44, P1884, DOI 10.1109/22.539947
   HARDY J, 1970, PHYSL BEHAV TEMPERAT, P281
   Hirata A, 2000, IEEE T ELECTROMAGN C, V42, P386, DOI 10.1109/15.902308
   HIRATA A, 1999, P AS PAC MICR C, V2, P477
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Hymen L., 1987, EYE, V1, P330
   KRITIKOS HN, 1981, J MICROWAVE POWER EE, V16, P327, DOI 10.1080/16070658.1981.11689256
   LAGENDIJK JJW, 1982, PHYS MED BIOL, V27, P1301, DOI 10.1088/0031-9155/27/11/001
   Lazzi G, 2000, IEEE T MICROW THEORY, V48, P2033, DOI 10.1109/22.884192
   LI Q, 1999, THERMAL MODEL HUMAN
   Majji AB, 1999, INVEST OPHTH VIS SCI, V40, P2073
   SALZMANN M, 1912, ANATOMY PHYSL HUMAN
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   SAUDE T, 1993, OCULAR ANTOMY PHYSL
   Schwartz S. H., 1994, VISUAL PERCEPTION CL
   SCOTT JA, 1988, PHYS MED BIOL, V33, P243, DOI 10.1088/0031-9155/33/2/004
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   STUCHLY MA, 1980, J MICROWAVE POWER EE, V15, P19
   Sullivan D. M., 2013, ELECTROMAGNETIC SIMU
   TAFLOVE A, 1975, IEEE T MICROW THEORY, V23, P888, DOI 10.1109/TMTT.1975.1128708
   *USAF SCH AER MED, 1986, RAD RAD DOS HDB
   Wang JQ, 1999, IEEE T MICROW THEORY, V47, P1528, DOI 10.1109/22.780405
   1993, RES PREVENT BLINDNES
   1993, EYE CARE STAT
NR 39
TC 75
Z9 77
U1 0
U2 8
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-926X
EI 1558-2221
J9 IEEE T ANTENN PROPAG
JI IEEE Trans. Antennas Propag.
PD SEP
PY 2003
VL 51
IS 9
BP 2274
EP 2285
DI 10.1109/TAP.2003.816395
PG 12
WC Engineering, Electrical & Electronic; Telecommunications
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Telecommunications
GA 721UU
UT WOS:000185337500015
DA 2022-11-30
ER

PT J
AU Zhang, YH
   Li, MC
   Yuan, ST
   Liu, QH
   Chen, Q
AF Zhang, Yuhan
   Li, Mingchao
   Yuan, Songtao
   Liu, Qinghuai
   Chen, Qiang
TI Robust region encoding and layer attribute protection for the
   segmentation of retina with multifarious abnormalities
SO MEDICAL PHYSICS
LA English
DT Article
DE layer segmentation; multifarious retinal abnormalities; optical
   coherence tomography angiography (OCTA); spectral-domain optical
   coherence tomography (SD-OCT)
ID COHERENCE TOMOGRAPHY IMAGES; AUTOMATIC SEGMENTATION; OCT IMAGES; FLUID
   SEGMENTATION; BOUNDARIES; CLASSIFICATION
AB Purpose To robustly segment retinal layers that are affected by complex variety of retinal diseases for optical coherence tomography angiography (OCTA) en face projection generation. Methods In this paper, we propose a robust retinal layer segmentation model to reduce the impact of multifarious abnormalities on model performance. OCTA vascular distribution that is regarded as the supplements of spectral domain optical coherence tomography (SD-OCT) structural information is introduced to improve the robustness of layer region encoding. To further reduce the sensitivity of region encoding to retinal abnormalities, we propose a multitask layer-wise refinement (MLR) module that can refine the initial layer region segmentation results layer-by-layer. Finally, we design a region-to-surface transformation (RtST) module without additional training parameters to convert the encoding layer regions to their corresponding layer surfaces. This transformation from layer regions to layer surfaces can remove the inaccurate segmentation regions, and the layer surfaces are easier to be used to protect the retinal layer natures than layer regions. Results Experimental data includes 273 eyes, where 95 eyes are normal and 178 eyes contain complex retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), central serous chorioretinopathy (CSC), choroidal neovascularization (CNV), and so forth. The dice similarity coefficient (DSC: %) of superficial, deep and outer retina achieves 98.92, 97.48, and 98.87 on normal eyes and 98.35, 95.33, and 98.17 on abnormal eyes. Compared with other commonly used layer segmentation models, our model achieves the state-of-the-art layer segmentation performance. Conclusions The final results prove that our proposed model obtains outstanding performance and has enough ability to resist retinal abnormalities. Besides, OCTA modality is helpful for retinal layer segmentation.
C1 [Zhang, Yuhan; Li, Mingchao; Chen, Qiang] Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, 200 Xiao LingWei, Nanjing 210094, Jiangsu, Peoples R China.
   [Yuan, Songtao; Liu, Qinghuai] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing University of Science & Technology; Nanjing Medical University
RP Chen, Q (通讯作者)，Nanjing Univ Sci & Technol, Sch Comp Sci & Engn, 200 Xiao LingWei, Nanjing 210094, Jiangsu, Peoples R China.; Yuan, ST (通讯作者)，Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM yuansongtao@vip.sina.com; chen2giang@njust.edu.cn
RI chen, qiang/GWZ-7308-2022
FU National Natural Science Foundation of China [62172223, 61671242]; Key
   R&D Program of Jiangsu Science and Technology Department [BE2018131];
   Fundamental Research Funds for the Central Universities [30921013105];
   Natural Science Foundation of Jiangsu Province [BK20180069]; Six talent
   peaks project in Jiangsu Province [SWYY-056]
FX National Natural Science Foundation of China, Grant/Award Numbers:
   62172223, 61671242; Key R&D Program of Jiangsu Science and Technology
   Department, Grant/Award Number: BE2018131; Fundamental Research Funds
   for the Central Universities, Grant/Award Number: 30921013105; Natural
   Science Foundation of Jiangsu Province, Grant/Award Number: BK20180069;
   Six talent peaks project in Jiangsu Province, Grant/Award Number:
   SWYY-056
CR Abhishek AM, 2014, 2014 IEEE CONFERENCE ON BIOMEDICAL ENGINEERING AND SCIENCES (IECBES), P204, DOI 10.1109/IECBES.2014.7047486
   Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Apostolopoulos S., 2017, INT C MED IM COMP CO, P177
   Chen L.C., 2018, P EUROPEAN C COMPUTE
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Cicek Ozgun, 2016, Medical Image Computing and Computer-Assisted Intervention - MICCAI 2016. 19th International Conference. Proceedings: LNCS 9901, P424, DOI 10.1007/978-3-319-46723-8_49
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   FERCHER AF, 1995, OPT COMMUN, V117, P43, DOI 10.1016/0030-4018(95)00119-S
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jin QG, 2019, KNOWL-BASED SYST, V178, P149, DOI 10.1016/j.knosys.2019.04.025
   Keller B, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.7.076015
   Kiaee F, 2018, IEEE IMAGE PROC, P2795, DOI 10.1109/ICIP.2018.8451025
   Kugelman J, 2018, BIOMED OPT EXPRESS, V9, P5759, DOI 10.1364/BOE.9.005759
   Liu X., 2020, IEEE T INSTRUMENT ME, V99, P1
   Liu XM, 2019, IEEE ACCESS, V7, P3046, DOI 10.1109/ACCESS.2018.2889321
   Liu XM, 2019, IEEE J BIOMED HEALTH, V23, P1404, DOI 10.1109/JBHI.2018.2856276
   Liu YH, 2019, BIOMED OPT EXPRESS, V10, P1064, DOI 10.1364/BOE.10.001064
   Montuoro A, 2017, BIOMED OPT EXPRESS, V8, P1874, DOI 10.1364/BOE.8.001874
   Novosel J, 2017, IEEE T MED IMAGING, V36, P1276, DOI 10.1109/TMI.2017.2666045
   Oliveira J, 2017, BIOMED OPT EXPRESS, V8, P281, DOI 10.1364/BOE.8.000281
   Rathke Fabian, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10433, P177, DOI 10.1007/978-3-319-66182-7_21
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Shah A, 2018, BIOMED OPT EXPRESS, V9, P4509, DOI 10.1364/BOE.9.004509
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Song Q, 2013, IEEE T MED IMAGING, V32, P376, DOI 10.1109/TMI.2012.2227120
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P348, DOI 10.1364/BOE.5.000348
   Sui XD, 2017, NEUROCOMPUTING, V237, P332, DOI 10.1016/j.neucom.2017.01.023
   Vermeer KA, 2011, BIOMED OPT EXPRESS, V2, P1743, DOI 10.1364/BOE.2.001743
   Wang B, 2021, IEEE J BIOMED HEALTH, V25, P3029, DOI 10.1109/JBHI.2021.3066208
   Wang C, 2017, IEEE J BIOMED HEALTH, V21, P1694, DOI 10.1109/JBHI.2017.2675382
   Wang J, 2019, BIOMED OPT EXPRESS, V10, P2639, DOI 10.1364/BOE.10.002639
   Weber ML, 2016, DEV OPHTHALMOL, V55, P167, DOI 10.1159/000431194
   Xiang DH, 2018, IEEE T IMAGE PROCESS, V27, P5880, DOI 10.1109/TIP.2018.2860255
   Yazdanpanah A, 2009, LECT NOTES COMPUT SC, V5762, P649, DOI 10.1007/978-3-642-04271-3_79
   Yuhan Zhang, 2020, Medical Image Computing and Computer Assisted Intervention - MICCAI 2020. 23rd International Conference. Proceedings. Lecture Notes in Computer Science (LNCS 12265), P647, DOI 10.1007/978-3-030-59722-1_62
   Zang PX, 2017, BIOMED OPT EXPRESS, V8, P1306, DOI 10.1364/BOE.8.001306
   Zhou ZW, 2019, LECT NOTES COMPUT SC, V11767, P384, DOI 10.1007/978-3-030-32251-9_42
   Zhou ZW, 2018, LECT NOTES COMPUT SC, V11045, P3, DOI 10.1007/978-3-030-00889-5_1
NR 41
TC 0
Z9 0
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0094-2405
EI 2473-4209
J9 MED PHYS
JI Med. Phys.
PD DEC
PY 2021
VL 48
IS 12
BP 7773
EP 7789
DI 10.1002/mp.15315
EA NOV 2021
PG 17
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA YA5OQ
UT WOS:000716564200001
PM 34716932
DA 2022-11-30
ER

PT J
AU Priyanka, P
   Rathore, AS
AF Priyanka, Priyanka
   Rathore, Anurag S.
TI A novel strategy for efficient expression of an antibody fragment in
   Escherichia coli: ranibizumab as a case study
SO JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE ranibizumab; antibody engineering; E; coli BL21 (DE3); RP-HPLC; LC-MS;
   native PAGE; SPR
ID CELL-DENSITY CULTIVATION; INITIATION; BIOLOGY; CODON
AB BACKGROUND Complex biotherapeutics such as non-glycosylated antibody fragments can be easily manufactured in Escherichia coli due to advancements in recombinant DNA technology. Ranibizumab is one such example of a complex, non-glycosylated protein used to treat age-related macular degeneration and macular oedema. Ranibizumab, a humanized monoclonal antibody fragment, is often expressed as inclusion bodies using the E. coli expression system. In this study, we propose a novel strategy for achieving efficient expression of antibody fragments in E. coli BL21 (DE3). Here, the whole antibody fragment (heavy chain + light chain of ranibizumab) has been engineered and cloned in a pET series vector under single promoter belonging to a prokaryotic host along with an extra ribosome binding site to allow equal expression of the light and heavy chains. RESULTS We demonstrate heterologous expression of ranibizumab with a protein concentration of 0.4 +/- 0.019 mg mL(-1), confirmed using reversed-phase high-performance liquid chromatography with the double copy clone. The reduced and refolded antibody fragment have been analytically characterized using liquid chromatography-mass spectrometry, where masses of the in-house clone were in correspondence with marketed product. Native polyacrylamide gel electrophoresis and surface plasmon resonance (SPR) analyses were performed to confirm the formation of purified and active recombinant product. Binding kinetics to the target analyte vascular endothelial growth factor of refolded in-house product was found to be similar to the marketed product as per SPR (12.7 nmol L-1 vs. 10.4 nmol L-1). CONCLUSION Cloning and process optimization have been performed to enhance expression yield. The proposed strategy offers an efficient approach for enhanced production of antibody fragments in microbial hosts. (c) 2021 Society of Chemical Industry (SCI).
C1 [Priyanka, Priyanka; Rathore, Anurag S.] Indian Inst Technol, Dept Chem Engn, New Delhi, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Delhi
RP Rathore, AS (通讯作者)，Indian Inst Technol Delhi, Dept Chem Engn, New Delhi, India.
EM asrathore@biotechcmz.com
OI Rathore, Anurag/0000-0002-5913-4244
FU Department of Biotechnology, Ministry of Science and Technology
   [BT/COE/34/SP15097/2015]; Biotechnology Industry Research Assistance
   Council [BT/NBM0159/04/2019]
FX This work was funded by the Department of Biotechnology, Ministry of
   Science and Technology (number BT/COE/34/SP15097/2015) and the
   Biotechnology Industry Research Assistance Council (number
   BT/NBM0159/04/2019). The authors would like to acknowledge help from Dr
   Jaya Gupta in reviewing and editing of the final manuscript.
CR Ahmad ZA, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/980250
   [Anonymous], 2021, T7 PROMOTOR CATALOGU
   [Anonymous], 2021, RANIBIZUMAB 10MG ML
   [Anonymous], 2021, FIERCE PHARMA
   Arie JP, 2006, MOL MICROBIOL, V62, P427, DOI 10.1111/j.1365-2958.2006.05394.x
   Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476-5381.2009.00190.x
   CHEN HY, 1994, NUCLEIC ACIDS RES, V22, P4953, DOI 10.1093/nar/22.23.4953
   Cook KM, 2010, CA-CANCER J CLIN, V60, P222, DOI 10.3322/caac.20075
   Dangi AK, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00630
   Erdag B, 2011, BIOTECHNOL APPL BIOC, V58, P412, DOI 10.1002/bab.61
   Farkade, 2014, CLONING EXPRESSION P
   FDA, 2016, REC MICR VECT US GEN
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Froger Alexandrine, 2007, J Vis Exp, P253, DOI 10.3791/253
   Gani, 2018, METHOD PRODUCING REF
   Goemans C, 2014, BBA-MOL CELL RES, V1843, P1517, DOI 10.1016/j.bbamcr.2013.10.014
   Gupta SK, 2016, CRIT REV BIOTECHNOL, V36, P1089, DOI 10.3109/07388551.2015.1084264
   Gupta SK, 2017, CRIT REV MICROBIOL, V43, P31, DOI 10.3109/1040841X.2016.1150959
   Humphreys DP, 2000, PROTEIN EXPRES PURIF, V20, P252, DOI 10.1006/prep.2000.1286
   James WS., 1997, HDB MICROBIOLOGICAL
   Jozala AF, 2016, BRAZ J MICROBIOL, V47, P51, DOI 10.1016/j.bjm.2016.10.007
   KORZ DJ, 1995, J BIOTECHNOL, V39, P59, DOI 10.1016/0168-1656(94)00143-Z
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Kumar D, 2019, BIOENGINEERING-BASEL, V6, DOI 10.3390/bioengineering6020029
   Laursen BS, 2005, MICROBIOL MOL BIOL R, V69, P101, DOI 10.1128/MMBR.69.1.101-123.2005
   Lim HK, 2000, APPL MICROBIOL BIOT, V53, P201, DOI 10.1007/s002530050009
   Manderson D, 2006, J IND MICROBIOL BIOT, V33, P173, DOI 10.1007/s10295-005-0046-3
   Nguyen MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089038
   Miot M, 2004, MICROB CELL FACT, V3, DOI 10.1186/1475-2859-3-4
   Muhlmann M, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0832-4
   Nelson AL, 2010, MABS-AUSTIN, V2, P77, DOI 10.4161/mabs.2.1.10786
   Raab David, 2010, Syst Synth Biol, V4, P215, DOI 10.1007/s11693-010-9062-3
   Rahmen N, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0191-y
   RIESENBERG D, 1991, J BIOTECHNOL, V20, P17, DOI 10.1016/0168-1656(91)90032-Q
   Rosano GL, 2019, PROTEIN SCI, V28, P1412, DOI 10.1002/pro.3668
   Rosano GL, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00172
   Schofield DM, 2016, BIOTECHNOL PROGR, V32, P840, DOI 10.1002/btpr.2273
   Singh A, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0222-8
   Walsh G, 2018, NAT BIOTECHNOL, V36, P1136, DOI 10.1038/nbt.4305
   Walsh G, 2014, NAT BIOTECHNOL, V32, P992, DOI 10.1038/nbt.3040
   Zou LH, 2011, THERANOSTICS, V1, P395, DOI 10.7150/thno/v01p0395
NR 42
TC 2
Z9 2
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0268-2575
EI 1097-4660
J9 J CHEM TECHNOL BIOT
JI J. Chem. Technol. Biotechnol.
PD JAN
PY 2022
VL 97
IS 1
BP 42
EP 54
DI 10.1002/jctb.6883
EA AUG 2021
PG 13
WC Biotechnology & Applied Microbiology; Chemistry, Multidisciplinary;
   Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Chemistry; Engineering
GA XH5GS
UT WOS:000687775000001
DA 2022-11-30
ER

PT J
AU Annamalai, B
   Parsons, N
   Nicholson, C
   Joseph, K
   Coughlin, B
   Yang, XF
   Jones, BW
   Tomlinson, S
   Rohrer, B
AF Annamalai, Balasubramaniam
   Parsons, Nathaniel
   Nicholson, Crystal
   Joseph, Kusumam
   Coughlin, Beth
   Yang, Xiaofeng
   Jones, Bryan W.
   Tomlinson, Stephen
   Rohrer, Barbel
TI Natural immunoglobulin M-based delivery of a complement alternative
   pathway inhibitor in mouse models of retinal degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Complement system; Choroidal neovascularization; Smoke-induced ocular
   pathology; Natural antibody-mediated targeting; Alternative pathway
   inhibitor; Encapsulated ARPE-19 cells
ID EPSTEIN-BARR-VIRUS; MACULAR-DEGENERATION; CHOROIDAL NEOVASCULARIZATION;
   OXIDATIVE STRESS; TARGETED INHIBITOR; PIGMENT EPITHELIUM; ANTIBODIES;
   SYSTEM; INJURY; MEMBRANE
AB Purpose: Age-related macular degeneration is a slowly progressing disease. Studies have tied disease risk to an overactive complement system. We have previously demonstrated that pathology in two mouse models, the choroidal neovascularization (CNV) model and the smoke-induced ocular pathology (SIOP) model, can be reduced by specifically inhibiting the alternative complement pathway (AP). Here we report on the development of a novel injury-site targeted inhibitor of the alternative pathway, and its characterization in models of retinal degeneration.
   Methods: Expression of the danger associated molecular pattern, a modified annexin IV, in injured ARPE-19 cells was confirmed by immunohistochemistry and complementation assays using B4 IgM mAb. Subsequently, a construct was prepared consisting of B4 single chain antibody (scFv) linked to a fragment of the alternative pathway inhibitor, fH (B4-scFv-fH). ARPE-19 cells stably expressing B4-scFv-fH were microencapsulated and administered intravitreally or subcutaneously into C57BL/6 J mice, followed by CNV induction or smoke exposure. Progression of CNV was analyzed using optical coherence tomography, and SIOP using structurefunction analyses. B4-scFv-fH targeting and AP specificity was assessed by Western blot and binding experiments.
   Results: B4-scFv-fH was secreted from encapsulated RPE and inhibited complement in RPE monolayers. B4-scFvfH capsules reduced CNV and SIOP, and western blotting for breakdown products of C3 alpha, IgM and IgG confirmed a reduction in complement activation and antibody binding in RPE/choroid.
   Conclusions: Data supports a role for natural antibodies and neoepitope expression in ocular disease, and describes a novel strategy to target AP-specific complement inhibition to diseased tissue in the eye. Precis: AMD risk is tied to an overactive complement system, and ocular injury is reduced by alternative pathway (AP) inhibition in experimental models. We developed a novel inhibitor of the AP that targets an injury-specific danger associated molecular pattern, and characterized it in disease models.
C1 [Annamalai, Balasubramaniam; Parsons, Nathaniel; Nicholson, Crystal; Joseph, Kusumam; Coughlin, Beth; Rohrer, Barbel] Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
   [Yang, Xiaofeng; Tomlinson, Stephen] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
   [Jones, Bryan W.] Univ Utah, Dept Ophthalmol, Salt Lake City, UT USA.
   [Tomlinson, Stephen; Rohrer, Barbel] Ralph H Johnson VA Med Ctr, Div Res, Charleston, SC USA.
   [Rohrer, Barbel] Med Univ South Carolina, Dept Neurosci, Charleston, SC 29425 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; Utah System of Higher Education; University of Utah; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Ralph H Johnson VA Medical Center; Medical University of South Carolina
RP Rohrer, B (通讯作者)，Med Univ South Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
OI Jones, Bryan/0000-0001-5527-6643; Coughlin, Beth/0000-0002-4031-4595
FU National Institutes of Health [R01EY019320, R01EY024581]; Department of
   Veterans Affairs [IK6BX004858, RX000444, BX003050, IK6BX005235,
   RX001141, BX004256]; South Carolina SmartState Endowment; Moran Eye
   Center Core [R01 EY015128, R01 EY028927, P30 EY014800]; Research to
   Prevent Blindness (New York) Unrestricted Grant
FX At MUSC, the study was supported by the National Institutes of Health
   (R01EY019320, R01EY024581) (BR) , the Department of Veterans Affairs
   (IK6BX004858, RX000444 and BX003050) (BR) , (IK6BX005235, RX001141 and
   BX004256) (ST) , and the South Carolina SmartState Endowment (BR) . In
   Utah, the following grants are acknowledged: R01 EY015128 (BWJ, R01
   EY028927 to BWJ, P30 EY014800 to Moran Eye Center Core, and Research to
   Prevent Blindness (New York) Unrestricted Grant to the Department of
   Ophthalmology & Visual Sciences, University of Utah.
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Alawieh A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao6459
   Alawieh A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0464-8
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Anderson JR, 2009, PLOS BIOL, V7, P493, DOI 10.1371/journal.pbio.1000074
   Annamalai B., MOL VIS
   Annamalai B, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.45
   Annamalai B, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.2.3
   Atkinson C, 2005, J CLIN INVEST, V115, P2444, DOI 10.1172/JCI25208
   Atkinson C, 2015, CIRCULATION, V131, P1171, DOI 10.1161/CIRCULATIONAHA.114.010482
   AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0
   Bandyopadhyay M, 2012, INVEST OPHTH VIS SCI, V53, P1953, DOI 10.1167/iovs.11-8638
   Baumgarth N, 2005, SPRINGER SEMIN IMMUN, V26, P347, DOI 10.1007/s00281-004-0182-2
   Belhaj M., 2020, JOVE
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Chen YF, 2009, J IMMUNOL, V182, P6031, DOI 10.4049/jimmunol.0804191
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DELCAYRE AX, 1991, EMBO J, V10, P919, DOI 10.1002/j.1460-2075.1991.tb08025.x
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ding JW, 2008, J IMMUNOL, V180, P261, DOI 10.4049/jimmunol.180.1.261
   Elkon K, 2008, NAT CLIN PRACT RHEUM, V4, P491, DOI 10.1038/ncprheum0895
   Elvington A, 2012, J IMMUNOL, V188, P1460, DOI 10.4049/jimmunol.1102132
   Fearon DT, 1998, SEMIN IMMUNOL, V10, P355, DOI 10.1006/smim.1998.0137
   Fischer N, 2007, PATHOBIOLOGY, V74, P3, DOI 10.1159/000101046
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Holers VM, 2007, MOL IMMUNOL, V44, P64, DOI 10.1016/j.molimm.2006.07.003
   Holers VM, 2013, ADV EXP MED BIOL, V735, P137, DOI 10.1007/978-1-4614-4118-2_9
   Holers VM, 2003, CLIN IMMUNOL, V107, P140, DOI 10.1016/S1521-6616(03)00034-2
   Holers VM, 2000, IMMUNOPHARMACOLOGY, V49, P125, DOI 10.1016/S0162-3109(00)80298-2
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Husain B, 2018, BIODRUGS, V32, P441, DOI 10.1007/s40259-018-0299-9
   Joachim SC, 2007, GRAEF ARCH CLIN EXP, V245, P619, DOI 10.1007/s00417-006-0429-9
   Joseph K, 2013, J BIOL CHEM, V288, P12753, DOI 10.1074/jbc.M112.421891
   Kulik L, 2009, J IMMUNOL, V182, P5363, DOI 10.4049/jimmunol.0803980
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Li YM, 2009, INVEST OPHTH VIS SCI, V50, P1336, DOI 10.1167/iovs.08-2589
   LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931
   Marshall K, 2018, HEPATOLOGY, V67, P721, DOI 10.1002/hep.29512
   Michaelsen TE, 2004, SCAND J IMMUNOL, V59, P34, DOI 10.1111/j.0300-9475.2004.01362.x
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ozkan B, 2012, CAN J OPHTHALMOL, V47, P264, DOI 10.1016/j.jcjo.2012.03.016
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   Rayborn ME, 2006, ADV EXP MED BIOL, V572, P75
   Reuter, 2011, BIOPROTOC, pE166
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rohrer B, 2012, J OCUL PHARMACOL TH, V28, P402, DOI 10.1089/jop.2011.0212
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Saeed AFUH, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00495
   Schnabolk G, 2015, INVEST OPHTH VIS SCI, V56, P1850, DOI 10.1167/iovs.14-15910
   Schnabolk G, 2014, EXP EYE RES, V129, P18, DOI 10.1016/j.exer.2014.10.005
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sieving P.A., 2005, NIH VIDEOCAST 0614
   Silverman Gregg J, 2009, Discov Med, V8, P151
   Stoppelkamp S, 2010, J NEUROSCI METH, V194, P132, DOI 10.1016/j.jneumeth.2010.10.008
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Thurman JM, 2013, J CLIN INVEST, V123, P2218, DOI 10.1172/JCI65861
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Woodell A, 2016, INVEST OPHTH VIS SCI, V57, P1728, DOI 10.1167/iovs.15-18471
   Woodell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067894
NR 70
TC 1
Z9 1
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2021
VL 207
AR 108583
DI 10.1016/j.exer.2021.108583
EA MAY 2021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SQ8BK
UT WOS:000660574800004
PM 33878326
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lin, AC
   Lee, CS
   Blazes, M
   Lee, AY
   Gorin, MB
AF Lin, Andrew C.
   Lee, Cecilia S.
   Blazes, Marian
   Lee, Aaron Y.
   Gorin, Michael B.
TI Assessing the Clinical Utility of Expanded Macular OCTs Using Machine
   Learning
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE machine learning; primary open-angle glaucoma; optical coherence
   tomography; age-related macular degeneration; diabetic macular edema
ID OPTICAL COHERENCE TOMOGRAPHY; DIABETIC-RETINOPATHY; GLAUCOMATOUS DAMAGE;
   DEGENERATION; AMD; EDEMA
AB Purpose: Optical coherence tomography (OCT) is widely used in the management of retinal pathologies, including age-related macular degeneration (AMD), diabetic macular edema (DME), and primary open-angle glaucoma (POAG). We used machine learning techniques to understand diagnostic performance gains from expanding macular OCT B-scans compared with foveal-only OCT B-scans for these conditions.
   Methods: Electronic medical records were extracted to obtain 61 B-scans per eye from patients with AMD, diabetic retinopathy, or POAG. We constructed deep neural networks and random forest ensembles and generated area under the receiver operating characteristic (AUROC) and area under the precision recall (AUPR) curves.
   Results: After extracting 630,000 OCT images, we achieved improved AUROC and AUPR curves when comparing the central image (one B-scan) to all images (61 B-scans). The AUROC and AUPR points of diminishing return for diagnostic accuracy for macular OCT coverage were found to be within 2.75 to 4.00 mm (14-19 B-scans), 4.25 to 4.50 mm (20-21 B-scans), and 4.50 to 6.25 mm (21-28 B-scans) for AMD, DME, and POAG, respectively. All models with >0.25 mm of coverage had statistically significantly improved AUROC/AUPR curves for all diseases (P < 0.05).
   Conclusions: Systematically expanded macular coverage models demonstrated significant differences in total macular coverage required for improved diagnostic accuracy, with the largest macular area being relevant in POAG followed by DME and then AMD. These findings support our hypothesis that the extent of macular coverage by OCT imaging in the clinical setting, for any of the three major disorders, has a measurable impact on the functionality of artificial intelligence decision support.
   Translational Relevance: We used machine learning techniques to improve OCT imaging standards for common retinal disease diagnoses.
C1 [Lin, Andrew C.; Lee, Cecilia S.; Blazes, Marian; Lee, Aaron Y.] Univ Washington, Sch Med, Dept Ophthalmol, Seattle, WA 98104 USA.
   [Lin, Andrew C.] NYU, Dept Ophthalmol, 550 1St Ave, New York, NY 10016 USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA USA.
C3 University of Washington; University of Washington Seattle; New York
   University; University of California System; University of California
   Los Angeles
RP Lee, AY (通讯作者)，Univ Washington, 325 Ninth Ave,Box 359608, Seattle, WA 98104 USA.
EM leeay@uw.edu
OI Lee, Aaron/0000-0002-7452-1648
FU National Institutes of Health-National Eye Institute [K23EY029246,
   R01AG060942]; Research to Prevent Blindness
FX Supported by grants from the National Institutes of Health-National Eye
   Institute (K23EY029246 and R01AG060942) and by an unrestricted grant
   from Research to Prevent Blindness. The sponsors or funding
   organizations had no role in the design or conduct of this research.
CR Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Abramoff MD, 2013, JAMA OPHTHALMOL, V131, P351, DOI 10.1001/jamaophthalmol.2013.1743
   An GZ, 2019, J HEALTHC ENG, V2019, DOI 10.1155/2019/4061313
   Asaoka R, 2019, AM J OPHTHALMOL, V198, P136, DOI 10.1016/j.ajo.2018.10.007
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Bhagat N, 2009, SURV OPHTHALMOL, V54, P1, DOI 10.1016/j.survophthal.2008.10.001
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848
   Domalpally A, 2017, OPHTHALMOLOGY, V124, P479, DOI 10.1016/j.ophtha.2016.12.004
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gupta Divakar, 2016, Taiwan J Ophthalmol, V6, P3, DOI 10.1016/j.tjo.2016.01.003
   Hood DC, 2017, PROG RETIN EYE RES, V57, P46, DOI 10.1016/j.preteyeres.2016.12.002
   Hood DC, 2014, INVEST OPHTH VIS SCI, V55, P632, DOI 10.1167/iovs.13-13130
   Hood DC, 2013, PROG RETIN EYE RES, V32, P1, DOI 10.1016/j.preteyeres.2012.08.003
   Hood DC, 2012, TRANSL VIS SCI TECHN, V1, DOI 10.1167/tvst.1.1.3
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kihara Y, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.8029
   Lee CS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42042-y
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lee SY, 2021, STATPEARLS
   Maa AY, 2020, OPHTHALMOLOGY, V127, P544, DOI 10.1016/j.ophtha.2019.10.025
   Maetschke S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219126
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Murakami T, 2013, OPHTHALMOLOGY, V120, P2596, DOI 10.1016/j.ophtha.2013.06.014
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Philip S, 2007, BRIT J OPHTHALMOL, V91, P1512, DOI 10.1136/bjo.2007.119453
   Prahs P, 2018, GRAEF ARCH CLIN EXP, V256, P91, DOI 10.1007/s00417-017-3839-y
   Ran AR, 2019, LANCET DIGIT HEALTH, V1, pE172, DOI 10.1016/S2589-7500(19)30085-8
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Takahashi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179790
   Tan GS, 2017, LANCET DIABETES ENDO, V5, P143, DOI 10.1016/S2213-8587(16)30052-3
   Ung C, 2019, INVEST OPHTHALMOL VI, V60, P3465
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008081.pub3
   Wang DL, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.6.4
   Wen JC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214875
   Wessel MM, 2012, BRIT J OPHTHALMOL, V96, P694, DOI 10.1136/bjophthalmol-2011-300774
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
NR 44
TC 6
Z9 6
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAY
PY 2021
VL 10
IS 6
AR 32
DI 10.1167/tvst.10.6.32
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL4SY
UT WOS:000656910500005
PM 34038502
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Miere, A
   Capuano, V
   Kessler, A
   Zambrowski, O
   Jung, C
   Colantuono, D
   Pallone, C
   Semoun, O
   Petit, E
   Souied, E
AF Miere, Alexandra
   Capuano, Vittorio
   Kessler, Arthur
   Zambrowski, Olivia
   Jung, Camille
   Colantuono, Donato
   Pallone, Carlotta
   Semoun, Oudy
   Petit, Eric
   Souied, Eric
TI Deep learning-based classification of retinal atrophy using fundus
   autofluorescence imaging
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Retinal imaging; Deep learning; Convolutional neural network; Inherited
   retinal disease; Geographic atrophy
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; MACULAR DEGENERATION;
   AUTOMATED DETECTION
AB Purpose: To automatically classify retinal atrophy according to its etiology, using fundus autofluorescence (FAF) images, using a deep learning model.
   Methods: In this study, FAF images of patients with advanced dry age-related macular degeneration (AMD), also called geographic atrophy (GA), and genetically confirmed inherited retinal diseases (IRDs) in late atrophic stages [Stargardt disease (STGD1) and Pseudo-Stargardt Pattern Dystrophy (PSPD)] were included. The FAF images were used to train a multi-layer deep convolutional neural network (CNN) to differentiate on FAF between atrophy in the context of AMD (GA) and atrophy secondary to IRDs. Three-hundred fourteen FAF images were included, of which 110 images were of GA eyes and 204 were eyes with genetically confirmed STGD1 or PSPD. In the first approach, the CNN was trained and validated with 251 FAF images. Established augmentation techniques were used and an Adam optimizer was used for training. For the subsequent testing, the built classifiers were then tested with 63 untrained FAF images. The visualization method was integrated gradient visualization. In the second approach, 10-fold cross-validation was used to determine the model's performance. Results: In the first approach, the best performance of the model was obtained using 10 epochs, with an accuracy of 0.92 and an area under the curve for Receiver Operating Characteristic (AUC-ROC) of 0.981. Mean accuracy was 87.30 +/- 2.96. In the second approach, a mean accuracy of 0.79 +/- 0.06 was obtained.
   Conclusion: This study describes the use of a deep learning-based algorithm to automatically classify atrophy on FAF imaging according to its etiology. Accurate differential diagnosis between GA and late-onset IRDs masquerading as GA on FAF can be performed with good accuracy and AUC-ROC values.
C1 [Miere, Alexandra; Capuano, Vittorio; Zambrowski, Olivia; Colantuono, Donato; Pallone, Carlotta; Semoun, Oudy; Souied, Eric] Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Miere, Alexandra; Petit, Eric] Univ Paris Est, Lab Images Signals & Intelligent Syst LISSI, EA 3956, Creteil, France.
   [Kessler, Arthur] Univ Paris Est, EPISEN ISBS, Creteil, France.
   [Jung, Camille] Ctr Hosp Intercommunal Creteil, Clin Res Ctr, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Miere, A (通讯作者)，Univ Paris Est Creteil, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94010 Creteil, France.
EM alexandra.miere@chicreteil.fr
RI 于, 于增臣/AAH-4657-2021; Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Colantuono,
   Donato/0000-0001-8193-2739
CR Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   ASTM D5298-16, 2016, STANDARD TEST METHOD, DOI DOI 10.1520/D5298-16
   [白桦 Bai Hua], 2010, [水土保持研究, Research of Soil and Water Conservation], V17, P40
   dos Santos C. N., 2018, INT COMMUN HEAT MASS, DOI DOI 10.1016/0735-1933(85)90003-X
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Holder G.E., 2014, INHERITED CHORIORETI, P213, DOI [10.1007/978-3-540-69466-3_19., DOI 10.1007/978-3-540-69466-3_19]
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hu Z., 2018, JINGDEZHEN TIANBAO L
   Hu ZH, 2015, J MED IMAGING, V2, DOI 10.1117/1.JMI.2.1.014501
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Hu ZJ, 2019, ELS MIC SOC BOOK SER, P353, DOI 10.1016/B978-0-08-102816-2.00018-6
   Kim JH, 2009, COMPUT STAT DATA AN, V53, P3735, DOI 10.1016/j.csda.2009.04.009
   Kingma J., 2014, ARXIV
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20980
   Ometto G, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.38
   Schmitz-Valckenberg S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100893
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Sparrow JR, 2016, ADV EXP MED BIOL, V854, P285, DOI 10.1007/978-3-319-17121-0_38
   Sundararajan M, ARXIV170301365CS
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P2053, DOI 10.1007/s00417-018-4098-2
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Vanwinckelen G., 2012, BENELEARN 2012 P 21, P39
   Yao C, THESIS U TROMSO NORW
NR 24
TC 4
Z9 4
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD MAR
PY 2021
VL 130
AR 104198
DI 10.1016/j.compbiomed.2020.104198
PG 7
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA QP6AW
UT WOS:000623918600005
PM 33383315
OA Bronze
DA 2022-11-30
ER

PT J
AU Sartini, F
   Figus, M
   Casini, G
   Nardi, M
   Posarelli, C
AF Sartini, Francesco
   Figus, Michele
   Casini, Giamberto
   Nardi, Marco
   Posarelli, Chiara
TI Pachychoroid neovasculopathy: a type-1 choroidal neovascularization
   belonging to the pachychoroid spectrum-pathogenesis, imaging and
   available treatment options
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Review
DE Pachychoroid neovasculopathy; Pachychoroid disease; Intravitreal
   anti-VEGF; Photodynamic therapy
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY;
   ENDOTHELIAL GROWTH-FACTOR; PHOTODYNAMIC THERAPY; MICROPULSE LASER;
   TRANSPUPILLARY THERMOTHERAPY; AFLIBERCEPT THERAPY; ANGIOGRAPHY;
   THICKNESS; FEATURES
AB Purpose The purpose of this paper is to provide a meaningful literature review about the epidemiology, pathogenesis, imaging and treatment of pachychoroid neovasculopathy (PNV). Methods A computerized search from inception up to December 2019 of the online electronic database PubMed was performed using the following search string: "pachychoroid neovasculopathy". The reference list in each article was scanned for additional relevant publications. Results PNV is a type-1 choroidal neovascularization, overlying focal areas of choroidal thickening and dilated choroidal vessels. It can develop in patients affected by pachychoroid pigment epitheliopathy or chronic central serous chorioretinopathy. The absence of drusen, the presence of pachydrusen, younger age of onset and choroidal thickening distinguish it from neovascular age-related macular degeneration (AMD). PNV incidence and prevalence data are lacking. Its pathophysiology is not fully understood, but angiogenic mechanisms involved in neovascular AMD may be different from those in PNV. Due to optical coherence tomography (OCT) improvements, PNV can be diagnosed more easily than before. In particular, PNV shows a shallow pigment epithelium detachment with an undulating retinal pigment epithelium over a subfoveal choroidal thickening, associated with vein enlargement in Haller's layer (named pachyvessels) and choriocapillaris thinning. On OCT angiography, PNV reveals tangled hyper-reflective filamentous neovessels in the choriocapillaris itself. The current first-line PNV treatment is intravitreal anti-VEGF (vascular endothelial growth factor) injections with a treat-and-extend regimen. In particular, aflibercept shows a higher rate of fluid absorption than others. In the case of fluid recurrence or persistence, photodynamic therapy is a valid alternative. Conclusion Ongoing research into pathophysiology and imaging improvements may be helpful in defining prognostic criteria and stratifying patient risk, allowing responsible monitoring and management of PNV.
C1 [Sartini, Francesco; Figus, Michele; Casini, Giamberto; Nardi, Marco; Posarelli, Chiara] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Ophthalmol, Via Savi 10, I-56126 Pisa, Italy.
C3 University of Pisa
RP Figus, M (通讯作者)，Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Ophthalmol, Via Savi 10, I-56126 Pisa, Italy.
EM figusmichele@gmail.com
RI Posarelli, Chiara/AAW-9528-2020
OI Figus, Michele/0000-0003-2243-9033
CR Akkaya S, 2018, INT OPHTHALMOL, V38, P2239, DOI 10.1007/s10792-017-0666-4
   [Anonymous], 1995, Arch Ophthalmol, V113, P190
   Arf S, 2020, JPN J OPHTHALMOL, V64, P257, DOI 10.1007/s10384-020-00730-7
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Azar G, 2017, ACTA OPHTHALMOL, V95, P421, DOI 10.1111/aos.13221
   Azuma K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212055
   Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bicer O, 2018, TURK OFTALMOL DERG, V48, P262, DOI 10.4274/tjo.89166
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chhablani J, 2019, INDIAN J OPHTHALMOL, V67, P171, DOI 10.4103/ijo.IJO_1456_18
   Cho HJ, 2019, J OCUL PHARMACOL TH, V35, P174, DOI 10.1089/jop.2018.0107
   Dansingani KK, 2016, OPHTHALMOLOGY, V123, P2628, DOI 10.1016/j.ophtha.2016.06.060
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   De Cilia S, 2019, ACTA OPHTHALMOL, V97, pE559, DOI 10.1111/aos.13995
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P1668, DOI 10.1097/IAE.0000000000001773
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Gawecki M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020242
   Gupta MP, 2016, CLIN OPHTHALMOL, V10, P1275, DOI 10.2147/OPTH.S105080
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   HAYREH SS, 1973, BRIT J OPHTHALMOL, V57, P217, DOI 10.1136/bjo.57.4.217
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Hussain N, 2006, GRAEF ARCH CLIN EXP, V244, P1045, DOI 10.1007/s00417-005-0175-4
   Hwang H, 2020, RETINA-J RET VIT DIS, V40, P1724, DOI 10.1097/IAE.0000000000002662
   Inhoffen W, 2012, KLIN MONATSBL AUGENH, V229, P889, DOI 10.1055/s-0032-1315077
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Kitaya N, 2003, BRIT J OPHTHALMOL, V87, P709, DOI 10.1136/bjo.87.6.709
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Lee JH, 2016, RETINA-J RET VIT DIS, V36, P889, DOI 10.1097/IAE.0000000000000809
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Li ZY, 2015, CELL BIOCHEM BIOPHYS, V73, P545, DOI 10.1007/s12013-015-0675-8
   Manayath GJ, 2017, OSLI RETINA, V48, P334, DOI 10.3928/23258160-20170329-08
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Midena E, 2020, RETINA-J RET VIT DIS, V40, P126, DOI 10.1097/IAE.0000000000002356
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, INVEST OPHTH VIS SCI, V55, P5252, DOI 10.1167/iovs.14-14959
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Roca JA, 2018, BRIT J OPHTHALMOL, V102, P1696, DOI 10.1136/bjophthalmol-2017-311291
   Roy R, 2019, INDIAN J OPHTHALMOL, V67, P1678, DOI 10.4103/ijo.IJO_1481_18
   Sartini F, 2019, EYE, V33, P1035, DOI 10.1038/s41433-019-0381-7
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Scholz P, 2017, ADV THER, V34, P1528, DOI 10.1007/s12325-017-0559-y
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Takahashi K, 1998, AM J OPHTHALMOL, V125, P367, DOI 10.1016/S0002-9394(99)80148-2
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   van Dijk EHC, 2018, OPHTHALMOLOGY, V125, P1547, DOI 10.1016/j.ophtha.2018.04.021
NR 58
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD DEC
PY 2020
VL 40
IS 12
BP 3577
EP 3589
DI 10.1007/s10792-020-01522-1
EA JUL 2020
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PB5UO
UT WOS:000553730500001
PM 32729062
DA 2022-11-30
ER

PT J
AU Kadkhodaeian, HA
   Tiraihi, T
   Ahmadieh, H
   Ziaei, H
   Daftarian, N
   Taheri, T
AF Kadkhodaeian, Hamid Aboutaleb
   Tiraihi, Taki
   Ahmadieh, Hamid
   Ziaei, Hossein
   Daftarian, Narsis
   Taheri, Taher
TI Generation of Retinal Pigmented Epithelium-Like Cells from Pigmented
   Spheres Differentiated from Bone Marrow Stromal Cell-Derived
   Neurospheres
SO TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE Bone marrow stromal stem cells; Neurosphere; Retinal pigment epithelium;
   Transdifferentiation
ID IN-VITRO DIFFERENTIATION; EMBRYONIC STEM-CELLS; EFFICIENT GENERATION;
   MACULAR DEGENERATION; RPE; EXPRESSION; PHAGOCYTOSIS; DERIVATION;
   PHENOTYPE
AB BACKGROUND: Retinal degeneration causes blindness, and cell replacement is a potential therapy. The purpose of this study is to formation of pigmented neurospheres in a simple medium, low-cost, high-performance manner over a short period of time while expressing markers of RPE cells and the activation of specific genes of the pigment cells. Also, these neurospheres have the ability to produce a monolayer of retinal pigment epithelium-like cells (RPELC) with the ability of photoreceptor outer segment phagocytosis.
   METHODS: BMSC were isolated from pigmented hooded male rats and were immunoreactive to BMSC markers, then converted into neurospheres, differentiated into pigmented spheres (PS), and characterized using Retinal pigment epithelium-specific 65 kDa protein (RPE65), Retinaldehyde-binding protein 1 (CRALBP) and orthodenticle homeobox 2 (OTX2) markers by immunocytochemistry, RT-PCR and RT-qPCR. The PS were harvested into RPELC. The functionality of RPELC was evaluated by phagocytosis of fluorescein-labeled photoreceptor outer segment.
   RESULTS: The BMSC immunophenotype was confirmed by immunostained for fibronectin, CD90, CD166 and CD44. These cells differentiated into osteogenic and lipogenic cells. The generated neurospheres were immunoreactive to nestin and stemness genes. The PS after 7-14 days were positive for RPE65 (92.76-100%), CRALBP (95.21-100%) and OTX2 (94.88-100%), and after 30 days RT-PCR, qPCR revealed increasing in gene expression. The PS formed a single layer of RPELC after cultivation and phagocyte photoreceptor outer segments.
   CONCLUSION: Bone marrow stromal stem cells can differentiate into functional retinal pigmented epithelium cells in a simple, low-cost, high-performance manner over a short period of time. These cells due to expressing the RPELC genes and markers can be used in cell replacement therapy for degenerative diseases including age-related macular degeneration as well as retinitis pigmentosa.
C1 [Kadkhodaeian, Hamid Aboutaleb; Tiraihi, Taki] Tarbiat Modares Univ, Fac Med Sci, Dept Anat Sci, POB 3519899951, Tehran 3514799422, Iran.
   [Kadkhodaeian, Hamid Aboutaleb] Semnan Univ Med Sci, Fac Med, Nervous Syst Stem Cells, Basij Blvd, Semnan 3519899951, Iran.
   [Ahmadieh, Hamid; Ziaei, Hossein; Daftarian, Narsis] Shahid Beheshti Univ Med Sci, Labbafinezhad Hosp, Ophthalm Res Ctr, Dist 4,9th Boostan St, Tehran 1983963113, Iran.
   [Taheri, Taher] Khatam Alanbia Hosp, Shefa Neurosci Res Ctr, Rashid Yasemi St,Upper Mirdamad St,Vali Asr St, Tehran 1996816747, Iran.
C3 Tarbiat Modares University; Semnan University of Medical Sciences;
   Shahid Beheshti University Medical Sciences
RP Tiraihi, T (通讯作者)，Tarbiat Modares Univ, Fac Med Sci, Dept Anat Sci, POB 3519899951, Tehran 3514799422, Iran.
EM takialtr@modares.ac.ir
RI kadkhodaeian, Hamid Aboutaleb/K-7997-2017; Daftarian,
   Narsis/AAW-5803-2020; Ahmadieh, Hamid/M-4853-2017
OI kadkhodaeian, Hamid Aboutaleb/0000-0002-9736-9722; Daftarian,
   Narsis/0000-0001-5846-8739; Ahmadieh, Hamid/0000-0002-8139-2661
FU Shefa Neuroscience Research Center at Khatam Alanbia Hospital, Tehran,
   Iran [86-N-105]; Faculty of Medical Sciences, Tarbiat Modares
   University, Tehran, Iran
FX This project was funded by Shefa Neuroscience Research Center at Khatam
   Alanbia Hospital, Tehran, Iran (Grant # 86-N-105). The authors are also
   grateful for the support of the Faculty of Medical Sciences, Tarbiat
   Modares University, Tehran, Iran.
CR Aruta C, 2011, PIGM CELL MELANOMA R, V24, P233, DOI 10.1111/j.1755-148X.2010.00793.x
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Chiou SH, 2005, BIOCHEM BIOPH RES CO, V326, P578, DOI 10.1016/j.bbrc.2004.11.061
   Darabi S, 2013, IN VITRO CELL DEV-AN, V49, P638, DOI 10.1007/s11626-013-9628-y
   Duan P, 2013, CELL PHYSIOL BIOCHEM, V31, P601, DOI 10.1159/000350080
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Fuhrmann S, 2010, CURR TOP DEV BIOL, V93, P61, DOI [10.1016/S0070-2153(10)93003-2, 10.1016/B978-0-12-385044-7.00003-5]
   Garg A, 2017, CELLS-BASEL, V6, DOI 10.3390/cells6010004
   Grinnemo KH, 2008, CELL TISSUE RES, V331, P67, DOI 10.1007/s00441-007-0486-3
   Grinnemo KH, 2006, REPROD BIOMED ONLINE, V13, P712, DOI 10.1016/S1472-6483(10)60663-3
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Huang JH, 2012, LANCET, V379, P2050, DOI 10.1016/S0140-6736(12)60891-5
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Li Y, 2007, INVEST OPHTH VIS SCI, V48, P4321, DOI 10.1167/iovs.06-1015
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Machalinska A, 2009, CURR EYE RES, V34, P748, DOI 10.1080/02713680903050592
   Marshall Leisa L, 2013, Consult Pharm, V28, P723, DOI 10.4140/TCP.n.2013.723
   Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Mathivanan I, 2015, EXP CELL RES, V333, P11, DOI 10.1016/j.yexcr.2015.02.001
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Mekala SR, 2013, J BIOSCIENCES, V38, P123, DOI 10.1007/s12038-012-9296-1
   Moviglia GA, 2012, OPHTHALMIC RES, V48, P1, DOI 10.1159/000339839
   Mu YL, 2014, INT J CLIN EXP MED, V7, P3843
   Naghdi Majid, 2009, Iranian Biomedical Journal, V13, P117
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Paek HJ, 2014, WORLD J DIABETES, V5, P235, DOI 10.4239/wjd.v5.i3.235
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Rezanejad H, 2014, CELL TISSUE RES, V356, P65, DOI 10.1007/s00441-014-1795-y
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Simerman AA, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-12
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Stern JH, 2011, NEUROTHERAPEUTICS, V8, P736, DOI 10.1007/s13311-011-0077-6
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tang ZM, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1183-y
   Vossmerbaeumer U, 2009, CYTOTHERAPY, V11, P177, DOI 10.1080/14653240802714819
   Westenskow P, 2015, JOVE-J VIS EXP, DOI 10.3791/52214
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang GY, 2015, LANCET, V386, P29, DOI 10.1016/S0140-6736(15)61202-8
   Zhang KJ, 2014, PROTEIN CELL, V5, P48, DOI 10.1007/s13238-013-0011-2
NR 49
TC 5
Z9 5
U1 1
U2 5
PU KOREAN TISSUE ENGINEERING REGENERATIVE MEDICINE SOC
PI SEOCHO-GU
PA 1414 SEOCHO WORLD OFFICETEL 19, SEOUN-RO, SEOCHO-GU, SEOUL 06732, SOUTH
   KOREA
SN 1738-2696
EI 2212-5469
J9 TISSUE ENG REGEN MED
JI Tissue Eng. Regen. Med.
PD JUN
PY 2019
VL 16
IS 3
BP 253
EP 263
DI 10.1007/s13770-019-00183-1
PG 11
WC Cell & Tissue Engineering; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Engineering
GA IA8DJ
UT WOS:000469787800004
PM 31205854
OA Green Published
DA 2022-11-30
ER

PT J
AU Chan, CM
   Huang, DY
   Sekar, P
   Hsu, SH
   Lin, WW
AF Chan, Chi-Ming
   Huang, Duen-Yi
   Sekar, Ponarulselvam
   Hsu, Shu-Hao
   Lin, Wan-Wan
TI Reactive oxygen species-dependent mitochondrial dynamics and autophagy
   confer protective effects in retinal pigment epithelial cells against
   sodium iodate-induced cell death
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE Retinal epithelium; Reactive oxygen species; Sodium iodate;
   Mitochondrial dynamics; Autophagy; Age-related macular degeneration
ID OXIDATIVE STRESS
AB Background: Oxidative stress is a major factor in retinal pigment epithelium (RPE) cells injury that contributes to age-related macular degeneration (AMD). NaIO3 is an oxidative toxic agent and its selective RPE cell damage makes it as a reproducible model of AMD. Although NaIO3 is an oxidative stress inducer, the roles of ROS in NaIO3-elicited signaling pathways and cell viability have not been elucidated, and the effect of NaIO3 on autophagy in RPE cells remains elusive.
   Methods: In human ARPE-19 cells, we used Annexin V/PI staining to determine cell viability, immunoblotting to determine protein expression and signaling cascades, confocal microscopy to determine mitochondrial dynamics and mitophagy, and Seahorse analysis to determine mitochondrial oxidative phosphorylation.
   Results: We found that NaIO3 can dramatically induce cytosolic but not mitochondrial ROS production. NaIO3 can also activate ERK, p38, JNK and Akt, increase LC3II expression, induce Drp-1 phosphorylation and mitochondrial fission, but inhibit mitochondrial respiration. Confocal microscopic data indicated a synergism of NaIO3 and bafilomycin A1 on LC3 punctate formation, indicating the induction of autophagy. Using cytosolic ROS antioxidant NAC, we found that p38 and JNK are downstream signals of ROS and involve in NaIO3-induced cytotoxicity but not in mitochondrial dynamics, while ROS is also involved in LC3II expression. Unexpectedly NAC treatment upon NaIO3 stimulation leads to an enhancement of mitochondrial fragmentation and cell death. Moreover, inhibition of autophagy and Akt further enhances cell susceptibility to NaIO3.
   Conclusions: We conclude that NaIO3-induced oxidative stress and cytosolic ROS production exert multiple signaling pathways that coordinate to control cell death in RPE cells. ROS-dependent p38 and JNK activation lead to cytotoxicity, while ROS-mediated autophagy and mitochondrial dynamic balance counteract the cell death mechanisms induced by NaIO3 in RPE cells.
C1 [Chan, Chi-Ming; Huang, Duen-Yi; Sekar, Ponarulselvam; Lin, Wan-Wan] Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei, Taiwan.
   [Chan, Chi-Ming; Hsu, Shu-Hao] Cardinal Tien Hosp, Dept Ophthalmol, New Taipei, Taiwan.
   [Chan, Chi-Ming] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan.
   [Huang, Duen-Yi; Sekar, Ponarulselvam; Lin, Wan-Wan] Taipei Med Univ, Grad Inst Med Sci, Taipei, Taiwan.
C3 National Taiwan University; Fu Jen Catholic University; Taipei Medical
   University
RP Lin, WW (通讯作者)，Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei, Taiwan.; Lin, WW (通讯作者)，Taipei Med Univ, Grad Inst Med Sci, Taipei, Taiwan.
EM wwllaura1119@ntu.edu.tw
RI Chan, Chi-Ming/GWZ-3612-2022
OI Sekar, Ponarulselvam/0000-0003-4282-2865; Lin, Wan
   Wan/0000-0002-3207-734X
FU MOST [107-2320-B-002-036 -MY3, IBMS-CRC106-P03, CTH-104-1-2A2,
   CTH-105A-224]
FX We like to thank the research funding from MOST 107-2320-B-002-036 -MY3,
   IBMS-CRC106-P03, CTH-104-1-2A2 and CTH-105A-224.
CR Bai L, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-77
   Balmer J, 2015, INT J MOL SCI, V16, P15086, DOI 10.3390/ijms160715086
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   BOK D, 1993, J CELL SCI, P189
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Chang CC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9015765
   Chen L, 2018, INT J MOL MED, V42, P1096, DOI 10.3892/ijmm.2018.3675
   Cid-Castro C, 2018, CELL MOL NEUROBIOL, V38, P995, DOI 10.1007/s10571-018-0584-7
   Dhingra A, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00351
   Due WW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1610751
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Hariri S, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.2.026017
   Hyttinen JMT, 2018, CELL MOL LIFE SCI, V75, P2991, DOI 10.1007/s00018-018-2843-7
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jezek J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010013
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Keeling E, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7020016
   Koinzer S, 2015, CURR EYE RES, V40, P853, DOI 10.3109/02713683.2014.961613
   Kolosova NG, 2018, AGING-US, V10, P2136, DOI 10.18632/aging.101537
   Lin YC, 2018, J OCUL PHARMACOL TH, V34, P500, DOI 10.1089/jop.2017.0073
   Mao XY, 2018, BIOMED PHARMACOTHER, V103, P517, DOI 10.1016/j.biopha.2018.04.038
   Nadal-Nicolas FM, 2018, ADV EXP MED BIOL, V1074, P457, DOI 10.1007/978-3-319-75402-4_56
   Sahani MH, 2014, AUTOPHAGY, V10, P431, DOI 10.4161/auto.27344
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   Sekar P, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0293-3
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Zhang W, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0864-5
   Zhang YY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4596746
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
NR 30
TC 31
Z9 32
U1 4
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1021-7770
EI 1423-0127
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD MAY 22
PY 2019
VL 26
AR 40
DI 10.1186/s12929-019-0531-z
PG 11
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA HZ3XI
UT WOS:000468781300002
PM 31118030
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zhao, HL
   Wang, RQ
   Ye, MX
   Zhang, L
AF Zhao, Hailan
   Wang, Ruiqing
   Ye, Mingxia
   Zhang, Lan
TI Genipin protects against H2O2-induced oxidative damage in retinal
   pigment epithelial cells by promoting Nrf2 signaling
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; oxidative stress; genipin; nuclear
   factor-erythroid 2-related factor-2 signaling
ID RPE CELLS; STRESS; ANTIOXIDANT; APOPTOSIS; PATHWAY; SURVIVAL;
   ACTIVATION; INHIBITION; INJURY; ROLES
AB Oxidative stress serves a vital function in the pathogenesis of age-related macular degeneration (AMD); genipin (GP) possesses antioxidative properties. The present study aimed to investigate the effects of GP on retinal pigment epithelial (RPE) cells induced by H2O2 and the underlying mechanism. ARPE-19 cells were subjected to H2O2 treatment to induce oxidative damage. Cell viability was determined via an MTT assay. Reactive oxygen species (ROS) levels and cell apoptosis were detected by flow cytometry. Nuclear factor-erythroid 2-related factor-2 (Nrf2) signaling-associated and the expression of apoptosis-associated factors were measured using reverse transcription-quantitative polymerase chain reaction assay and western blotting. The results revealed that 200 mu M H2O2 and 30 mu M GP were determined to be the optimal concentrations for subsequent experimentation. GP reversed the inhibitory effects of H2O2 by promoting cell viability, attenuating ROS accumulation and cell apoptosis, and increased the expression of Nrf2, heme oxygenase-1 (HO-1) and NAD(P)H: Quinine oxidoreductase 1 (NQO1); Nrf2 silencing inhibited HO-1 and NQO1 expression. In addition, Nrf2 silencing enhanced the effects of H2O2 by promoting ROS production and cell apoptosis. Compared with H2O2, Nrf2 silencing further decreased the expression levels of B-cell lymphoma-2 (Bcl-2), but increased that of Bcl-2-associated X protein and cleaved-caspase-3. The results of the present study revealed that Nrf2 silencing attenuated the protective effects of GP on H2O2-induced injury in ARPE-19 cells by promoting apoptosis and oxidation. Collectively, GP attenuated oxidative damage induced by H2O2 in ARPE-19 cells. Furthermore, the molecular mechanism may be associated with the Nrf2 signaling pathway. The findings of the present study nay provide insight into a potential therapeutic agent for the treatment of AMD.
C1 [Zhao, Hailan; Ye, Mingxia; Zhang, Lan] Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Ophthalmol, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China.
   [Wang, Ruiqing] Jilin Univ, Hosp 2, Dept Ophthalmol, Changchun 130041, Jilin, Peoples R China.
C3 Hangzhou Medical College; Zhejiang Provincial People's Hospital; Jilin
   University
RP Zhang, L (通讯作者)，Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Ophthalmol, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China.
EM lanz_zhangla@163.com
CR Areti A, 2014, REDOX BIOL, V2, P289, DOI 10.1016/j.redox.2014.01.006
   Ayyasamy V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024792
   Chen SC, 2017, MOL MED REP, V15, P4360, DOI 10.3892/mmr.2017.6542
   Chen XD, 2017, INT J OPHTHALMOL-CHI, V10, P507, DOI 10.18240/ijo.2017.04.02
   Chen XL, 2014, RENAL FAILURE, V36, P1298, DOI 10.3109/0886022X.2014.930650
   Dando I, 2013, BBA-MOL CELL RES, V1833, P672, DOI 10.1016/j.bbamcr.2012.10.028
   Dias HKI, 2012, FREE RADICAL BIO MED, V53, pS49, DOI 10.1016/j.freeradbiomed.2012.08.523
   Du L, 2017, BIOMED PHARMACOTHER, V85, P136, DOI 10.1016/j.biopha.2016.11.108
   Dun Y, 2013, FREE RADICAL BIO MED, V65, P1340, DOI 10.1016/j.freeradbiomed.2013.10.006
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Hoshovs'ka Iu V, 2009, Fiziol Zh, V55, P28
   Hu HT, 2018, BIOCHEM BIOPH RES CO, V495, P2171, DOI 10.1016/j.bbrc.2017.12.078
   Hu YY, 2015, BRAIN RES, V1605, P39, DOI 10.1016/j.brainres.2015.02.015
   Huang Y, 2015, J NUTR BIOCHEM, V26, P1401, DOI 10.1016/j.jnutbio.2015.08.001
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang H, 2017, J NEUROCHEM, V140, P307, DOI 10.1111/jnc.13900
   Kang KA, 2010, INT J MOL SCI, V11, P4348, DOI 10.3390/ijms11114348
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kim ES, 2012, ONCOL REP, V27, P567, DOI 10.3892/or.2011.1508
   Lee CH, 2014, J PHARMACOL SCI, V124, P344, DOI 10.1254/jphs.13174FP
   Lim W, 2010, PHARM BIOL, V48, P1354, DOI 10.3109/13880209.2010.483246
   Lin YH, 2013, BIOMATERIALS, V34, P4466, DOI 10.1016/j.biomaterials.2013.02.028
   Liu HJ, 2017, MOL MED REP, V16, P2069, DOI 10.3892/mmr.2017.6838
   Liu LB, 2018, J BIOCHEM MOL TOXIC, V32, DOI 10.1002/jbt.22052
   LIU X, 2017, PEERJ, V5, DOI DOI 10.7717/PEERJ.3642
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Machida K, 2000, CHEM PHARM BULL, V48, P746
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Patel AK, 2013, MOL IMMUNOL, V54, P122, DOI 10.1016/j.molimm.2012.11.005
   Radi E, 2014, J ALZHEIMERS DIS, V42, pS125, DOI 10.3233/JAD-132738
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Shin JK, 2017, TOXICOL APPL PHARM, V328, P25, DOI 10.1016/j.taap.2017.05.002
   Sies H, 2014, J BIOL CHEM, V289, P8735, DOI 10.1074/jbc.R113.544635
   Slimen IB, 2014, INT J HYPERTHER, V30, P513, DOI 10.3109/02656736.2014.971446
   Su Jian, 2014, Zhong Yao Cai, V37, P243
   Vurusaner B, 2016, FREE RADICAL BIO MED, V91, P93, DOI 10.1016/j.freeradbiomed.2015.12.007
   Wang KJ, 2015, BIOCHEM BIOPH RES CO, V468, P541, DOI 10.1016/j.bbrc.2015.10.117
   Wang Y, 2017, EXP EYE RES, V160, P45, DOI 10.1016/j.exer.2017.04.010
   Xie XB, 2017, MOL VIS, V23, P520
   Yu DW, 2016, FITOTERAPIA, V112, P244, DOI 10.1016/j.fitote.2016.06.010
   Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003
   Zhu C, 2017, BIOMED PHARMACOTHER, V88, P124, DOI 10.1016/j.biopha.2016.11.089
   Zhu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26322
   Zuo T, 2017, CELL PHYSIOL BIOCHEM, V43, P1855, DOI 10.1159/000484074
NR 47
TC 30
Z9 31
U1 1
U2 26
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD FEB
PY 2019
VL 43
IS 2
BP 936
EP 944
DI 10.3892/ijmm.2018.4027
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA HG4CX
UT WOS:000454923000028
PM 30569096
OA Green Published, hybrid, Green Submitted
DA 2022-11-30
ER

PT J
AU Song, Y
   Tian, X
   Wang, XH
   Feng, H
AF Song, Yu
   Tian, Xia
   Wang, Xuehong
   Feng, Hui
TI Vascular protection of salicin on IL-1 beta-induced endothelial
   inflammatory response and damages in retinal endothelial cells
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Retinal endothelial cell (RECs); salicin; IL-1 beta; reactive oxygen
   species (ROS); inflammation; NF-kappa B
ID WILLOW BARK; ANTIOXIDANT ENZYMES; EXPRESSION; EXTRACT
AB Retinal endothelial cells (RECs) are involved in many ocular diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. Salicin is the major ingredient of willow bark extract, and it has been shown to be a potent anti-inflammatory agent. We aim to explore whether salicin has a vascular protective effect in RECs. Our data indicate that the presence of salicin in RECs culture media ameliorates interleukin-1 beta (IL-1 beta)-induced cellular reactive oxygen species (ROS) production and NADPH oxidase 4 (NOX-4) expression. At the cellular level, salicin attenuates IL-1 beta-induced mitochondrial injury as revealed by its preservation on mitochondrial membrane potential (MMP). Furthermore, salicin inhibits IL-1 beta-induced production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1), vascular adhesion molecules such as intercellular cell adhesion molecule-1 (iCAM-1) and vascular cell adhesion molecule 1 (VCAM-1), and high-mobility group protein 1 (HMGB-1). On the other hand, salicin recovers IL-1 beta-induced reduction of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) release. The presence of salicin significantly reduces the IL-1 beta-induced release of lactate dehydrogenase (LDH), indicating that it mitigates cytokine caused cytotoxicity. Mechanistically, we show that salicin suppresses IL-1 beta-induced activation of the nuclear factor-kappa B (NF-kappa B) signaling as revealed by its suppression on nuclear p65 protein and transfected NF-kappa B promoter. Collectively, our study demonstrates by multiple facets of its mechanisms that salicin is a protective agent in retinal endothelial cells. These results imply its potential use in therapeutic usage of retinal disease.
C1 [Song, Yu; Tian, Xia; Wang, Xuehong; Feng, Hui] Weihai Cent Hosp, Dept Ophthalmol, 3 Mishan East Rd, Weihai 264400, Shangdong, Peoples R China.
RP Feng, H (通讯作者)，Weihai Cent Hosp, Dept Ophthalmol, 3 Mishan East Rd, Weihai 264400, Shangdong, Peoples R China.
EM hfeng0102@163.com
CR Ago T, 2004, CIRCULATION, V109, P227, DOI 10.1161/01.CIR.0000105680.92873.70
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Fiebich BL, 2003, CLIN PHARMACOL THER, V74, P96, DOI 10.1016/S0009-9236(03)00116-4
   Freischmidt A, 2012, PHYTOMEDICINE, V19, P245, DOI 10.1016/j.phymed.2011.08.065
   Hormozi M, 2019, ARTIF CELL NANOMED B, V47, P891, DOI 10.1080/21691401.2019.1580286
   Ishikado A, 2013, FREE RADICAL BIO MED, V65, P1506, DOI 10.1016/j.freeradbiomed.2012.12.006
   Kaufeld AM, 2014, J NAT PROD, V77, P1607, DOI 10.1021/np500177u
   Knuth S, 2011, PLANTA MED, V77, P1024, DOI 10.1055/s-0030-1270722
   Kong CS, 2014, PHYTOTHER RES, V28, P1246, DOI 10.1002/ptr.5126
   Li Y, 2015, INT IMMUNOPHARMACOL, V26, P286, DOI 10.1016/j.intimp.2015.04.016
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Phillips B. E., 2007, RETINAL VASCULAR DIS, P139
   Relhan N, 2017, CURR OPIN OPHTHALMOL, V28, P205, DOI 10.1097/ICU.0000000000000362
   Rubsam A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040942
   Tang DL, 2014, MOL MED, V20, P359, DOI 10.2119/molmed.2014.00063
   Verma N, 2014, INFLAMM RES, V63, P161, DOI 10.1007/s00011-013-0685-1
   Vlachojannis JE, 2009, PHYTOTHER RES, V23, P897, DOI 10.1002/ptr.2747
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Zhang JZ, 2019, ARTIF CELL NANOMED B, V47, P1207, DOI 10.1080/21691401.2019.1593857
   Zou L, 2017, CELL STRESS CHAPERON, V22, P5, DOI 10.1007/s12192-016-0735-z
NR 21
TC 19
Z9 20
U1 0
U2 13
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2019
VL 47
IS 1
BP 1995
EP 2002
DI 10.1080/21691401.2019.1608220
PG 8
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA HZ0PL
UT WOS:000468543600001
PM 31106593
OA gold
DA 2022-11-30
ER

PT J
AU Lee, WJ
   Kim, YK
   Kim, YW
   Jeoung, JW
   Kim, SH
   Heo, JW
   Yu, HG
   Park, KH
AF Lee, Won June
   Kim, Young Kook
   Kim, Yong Woo
   Jeoung, Jin Wook
   Kim, Seok Hwan
   Heo, Jang Won
   Yu, Hyeong Gon
   Park, Ki Ho
TI Rate of Macular Ganglion Cell-inner Plexiform Layer Thinning in
   Glaucomatous Eyes With Vascular Endothelial Growth Factor Inhibition
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE ganglion cell-inner plexiform layer; glaucoma; age-related macular
   degeneration; vascular endothelial growth factor
ID AGE-RELATED MACULOPATHY; ZONE PARAPAPILLARY ATROPHY; OPEN-ANGLE
   GLAUCOMA; INTRAVITREAL RANIBIZUMAB; INTRAOCULAR-PRESSURE; 10-YEAR
   INCIDENCE; RISK-FACTORS; DEGENERATION; THICKNESS; PREVALENCE
AB Purpose: To evaluate the rate of progressive macular ganglion cell-inner plexiform layer (GCIPL) thinning in patients with open-angle glaucoma (OAG) who had been treated with intravitreal antivascular endothelial growth factor (VEGF) injection for wet age-related macular degeneration (AMD).
   Methods: This study was a retrospective modified case control study with fellow eye comparison. We enrolled bilateral OAG patients who had been treated with repeated anti-VEGF injections for unilateral wet AMD and followed-up on for a minimum of 24 months by Cirrus high-definition optical coherence tomography. The rate of macular GCIPL thinning was determined by linear regression of serial optical coherence tomography GCIPL thickness measurements over time. We compared the rate of macular GCIPL thinning between anti-VEGF-treated eyes and fellow untreated dry AMD eyes.
   Results: This study involved 32 OAG eyes of 16 subjects. The total follow-up period was 58.4 +/- 25.5 (24 to 98) months, and the mean number of anti-VEGF injections was 10.6 +/- 10.4 (3 to 40). The eyes with repeated anti-VEGF treatment differed significantly from their fellow eyes in the rate of GCIPL thinning (-2.95 +/- 3.58 vs. -0.77 +/- 0.95 mu m/y, P= 0.015). Also, multivariable regression analyses showed that anti-VEGF injection was significantly associated with the rate of GCIPL thinning (P= 0.025).
   Conclusions: In subjects with bilateral OAG, the rate of GCIPL thinning is significantly faster in eyes treated with anti-VEGF injection for wet AMD than in untreated dry AMD fellow eyes. This finding suggests that in glaucomatous eyes, VEGF inhibition could play a role, at least in part, in progressive change of inner retinal layers.
C1 [Lee, Won June; Kim, Young Kook; Jeoung, Jin Wook; Heo, Jang Won; Yu, Hyeong Gon; Park, Ki Ho] Seoul Natl Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
   [Lee, Won June; Kim, Young Kook; Jeoung, Jin Wook; Kim, Seok Hwan; Heo, Jang Won; Yu, Hyeong Gon; Park, Ki Ho] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Kim, Seok Hwan] Seoul Natl Univ, Dept Ophthalmol, Boramae Hosp, Seoul, South Korea.
   [Kim, Yong Woo] Armed Forces Capital Hosp, Dept Ophthalmol, Seongnam, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital
RP Park, KH (通讯作者)，Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Ophthalmol, Coll Med, 101 Daehak Ro, Seoul 110744, South Korea.
EM kihopark@snu.ac.kr
RI Lee, Won June/Y-8207-2018
OI Lee, Won June/0000-0002-3506-7139; Kim, Young Kook/0000-0002-6037-8449
CR Alshareef RA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155319
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Hwang YH, 2016, OPHTHALMOLOGY, V123, P950, DOI 10.1016/j.ophtha.2015.12.032
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kim YW, 2014, OPHTHALMOLOGY, V121, P1341, DOI 10.1016/j.ophtha.2014.01.008
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Lee EJ, 2015, OPHTHALMOLOGY, V122, P2234, DOI 10.1016/j.ophtha.2015.07.020
   Lee EJ, 2015, OPHTHALMOLOGY, V122, P721, DOI 10.1016/j.ophtha.2014.10.007
   Lee EJ, 2011, INVEST OPHTH VIS SCI, V52, P4422, DOI 10.1167/iovs.10-6818
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Murdoch IE, 1998, BRIT J OPHTHALMOL, V82, P971, DOI 10.1136/bjo.82.8.971
   Park HYL, 2014, AM J PATHOL, V184, P1752, DOI 10.1016/j.ajpath.2014.02.016
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Resnikoff S, 2002, B WORLD HEALTH ORGAN, V82, P844
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Romano MR, 2012, BRAIN RES, V1478, P55, DOI 10.1016/j.brainres.2012.08.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudnicka AR, 2006, INVEST OPHTH VIS SCI, V47, P4254, DOI 10.1167/iovs.06-0299
   Saleh R, 2017, GRAEF ARCH CLIN EXP, V255, P817, DOI 10.1007/s00417-017-3590-4
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Shin HJ, 2016, INVEST OPHTH VIS SCI, V57, P1798, DOI 10.1167/iovs.15-18404
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang YM, 2007, J NEUROSCI, V27, P304, DOI 10.1523/JNEUROSCI.4433-06.2007
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Zinkernagel MS, 2015, INVEST OPHTH VIS SCI, V56, P1894, DOI 10.1167/iovs.14-16204
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 35
TC 14
Z9 14
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-0829
EI 1536-481X
J9 J GLAUCOMA
JI J. Glaucoma
PD NOV
PY 2017
VL 26
IS 11
BP 980
EP 986
DI 10.1097/IJG.0000000000000776
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP0MY
UT WOS:000417297000013
PM 28930884
DA 2022-11-30
ER

PT J
AU Hutton-Smith, LA
   Gaffney, EA
   Byrne, HM
   Maini, PK
   Gadkar, K
   Mazer, NA
AF Hutton-Smith, Laurence A.
   Gaffney, Eamonn A.
   Byrne, Helen M.
   Maini, Philip K.
   Gadkar, Kapil
   Mazer, Norman A.
TI Ocular Pharmacokinetics of Therapeutic Antibodies Given by Intravitreal
   Injection: Estimation of Retinal Permeabilities Using a 3-Compartment
   Semi-Mechanistic Model
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE retina; permeability; intravitreal; pharmacokinetics; mechanistic
   modeling
ID RANIBIZUMAB; MEMBRANE; GROWTH; RABBIT
AB Intravitreally (IVT) injected macromolecules for the treatment of age-related macular degeneration must permeate through the inner limiting membrane (ILM) into the retina and through the retinal pigment epithelium (RPE) to enter the choroid. A quantitative understanding of intraocular transport mechanisms, elimination pathways, and the effect of molecular size is currently incomplete. We present a semimechanistic, 3-compartment (retina, vitreous, and aqueous) pharmacokinetic (PK) model, expressed using linear ordinary differential equations (ODEs), to describe the molecular concentrations following a single IVT injection. The model was fit to experimental rabbit data, with Fab, Fc, IgG, and IgG null antibodies and antibody fragments, to estimate key ocular pharmacokinetic parameters. The model predicts an ocular half-life, t(1/2), which is the same for all compartments and dependent on the hydrodynamic radius (Rh) of the respective molecules, consistent with observations from the experimental data. Estimates of the permeabilities of the RPE and ILM are derived for Rh values ranging from 2.5 to 4.9 nm, and are found to be in good agreement with ex-vivo measurements from bovine eyes. We show that the ratio of these permeabilities largely determines the ratio of the molecular concentrations in the retina and vitreal compartments and their dependence on R-h. The model further provides estimates for the ratio of fluxes corresponding to the elimination pathways from the eye, i.e., aqueous humor to retina/choroid, which increase from 5:1 to 7:1 as Rh decreases. Our semimechanistic model provides a quantitative framework for interpreting ocular PK and the effects of molecule size on rate-determining parameters. We have shown that intraocular permeabilities can be reasonably estimated from 3-compartment ocular PK data and can determine how these parameters influence the half-life, retinal permeation, and elimination of intravitreally injected molecules from the eye.
C1 [Hutton-Smith, Laurence A.; Gaffney, Eamonn A.; Byrne, Helen M.; Maini, Philip K.] Univ Oxford, Wolfson Ctr Math Biol, Math Inst, Radcliffe Observ Quarter, Andrew Wiles Bldg,Woodstock Rd, Oxford OX2 6GG, England.
   [Gadkar, Kapil] Genentech Inc, Dept Preclin & Translat Pharmacokinet, San Francisco, CA 94080 USA.
   [Mazer, Norman A.] Roche Innovat Ctr Basel, Roche Pharma Res Early Dev, Clin Pharmacol, Bldg 663-2130-12,Hochstr 16, CH-4070 Basel, Switzerland.
C3 University of Oxford; Roche Holding; Genentech; Roche Holding
RP Hutton-Smith, LA (通讯作者)，Univ Oxford, Wolfson Ctr Math Biol, Math Inst, Radcliffe Observ Quarter, Andrew Wiles Bldg,Woodstock Rd, Oxford OX2 6GG, England.; Mazer, NA (通讯作者)，Roche Innovat Ctr Basel, Roche Pharma Res Early Dev, Clin Pharmacol, Bldg 663-2130-12,Hochstr 16, CH-4070 Basel, Switzerland.
EM laurence.hutton-smith@pmb.ox.ac.uk; norman.mazer@roche.com
OI Gaffney, Eamonn/0000-0002-6888-4362; Byrne, Helen/0000-0003-1771-5910
FU EPSRC [EP/L016044/1]; MRC [EP/L016044/1]; Roche Pharma Research and
   Early Development
FX Funding provided to Wolfson Centre of Mathematical Biology by EPSRC and
   MRC (Grant No. EP/L016044/1). Additional funding provided by Roche
   Pharma Research and Early Development.
CR [Anonymous], 2015, MATLAB USER GUIDE R2
   BARANY E, 1949, AM J OPHTHALMOL, V32, P177, DOI 10.1016/S0002-9394(14)78371-0
   Boye SE, 2013, MOL THER, V21, P509, DOI 10.1038/mt.2012.280
   del Amo E. M., 2017, PROG RETIN EYE RES
   Efron B., 1994, INTRO BOOTSTRAP
   Gadkar K, 2015, INVEST OPHTH VIS SCI, V56, P5390, DOI 10.1167/iovs.15-17108
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Halfter W, 2008, EYE, V22, P1207, DOI 10.1038/eye.2008.19
   Hutton-Smith LA, 2016, MOL PHARMACEUT, V13, P2941, DOI 10.1021/acs.molpharmaceut.5b00849
   MAURICE DM, 1959, AM J OPHTHALMOL, V47, P361, DOI 10.1016/S0002-9394(14)78042-0
   Missel PJ, 2012, PHARM RES-DORDR, V29, P3251, DOI 10.1007/s11095-012-0721-9
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   Saunders DJ, 2015, BRIT J OPHTHALMOL, V99, P1554, DOI 10.1136/bjophthalmol-2015-306771
   Shatz W, 2016, MOL PHARMACEUT, V13, P2996, DOI 10.1021/acs.molpharmaceut.6b00345
   Terasaki H, 2015, RETINA-J RET VIT DIS, V35, P1007, DOI 10.1097/IAE.0000000000000428
   Tervonen A, 2014, PHARM RES-DORDR, V31, P2297, DOI 10.1007/s11095-014-1325-3
   Vacca O, 2014, GLIA, V62, P468, DOI 10.1002/glia.22617
   Vllasaliu D, 2014, EXP CELL RES, V323, P218, DOI 10.1016/j.yexcr.2014.02.022
   Wright JF, 2005, MOL THER, V12, P171, DOI 10.1016/j.ymthe.2005.02.021
   Yanez JA, 2011, THER DELIV, V2, P643, DOI [10.4155/tde.11.19, 10.4155/TDE.11.19]
NR 22
TC 38
Z9 38
U1 1
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD AUG
PY 2017
VL 14
IS 8
BP 2690
EP 2696
DI 10.1021/acs.molpharmaceut.7b00164
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FD3AG
UT WOS:000407405300023
PM 28631484
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Katibeh, M
   Behboudi, H
   Moradian, S
   Alizadeh, Y
   Beiranvand, R
   Sabbaghi, H
   Ahmadieh, H
AF Katibeh, Marzieh
   Behboudi, Hassan
   Moradian, Siamak
   Alizadeh, Yousef
   Beiranvand, Ramin
   Sabbaghi, Hamideh
   Ahmadieh, Hamid
TI Rapid Assessment of Avoidable Blindness and Diabetic Retinopathy in
   Gilan Province, Iran
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Diabetic retinopathy; Gilan Province; Iran; Rapid Assessment of
   Avoidable Blindness
ID VA-BALUCHESTAN PROVINCE; VISUAL IMPAIRMENT; RISK-FACTORS; PREVALENCE;
   POPULATION; YAZD
AB Purpose: To conduct an assessment of avoidable blindness and diabetic retinopathy (DR) in Gilan, 2014.
   Methods: A cross-sectional population-based survey was performed on a representative sample of urban and rural individuals aged <= 50 years of the province. Blindness was defined as presenting visual acuity (PVA) <3/60 in the better eye. Moderate visual impairment (MVI) and severe visual impairment (SVI) were defined as 6/60 <= PVA <6/18 and 3/60 <= PVA <6/60 in the better eye, respectively. Diabetes mellitus (DM) was determined based on random blood sugar (RBS) levels 200 mg/dL or a previous diagnosis. We used the Scottish grading system to grade DR.
   Results: We invited 2975 individuals from 85 clusters. Age- and sex-adjusted prevalence and 95% confidence interval (CI) of blindness, SVI, MVI, and DM in 2587 participants (response rate: 86.9%) were 1.5% (95% CI: 1.1-2.0), 1.5% (95% CI: 0.9-2.0), 11.3% (95% CI: 9.9-12.7) and 21.4% (95% CI: 19.2-23.7), respectively. The leading causes of blindness were cataract (47.1%), age-related macular degeneration (14.7%) and DR (8.8%). Cataract surgery (CS) coverage was 69.3%. The main challenges for CS were cost and unawareness. The outcome of CS was good in 66.9% of operated eyes. Any DR and/or maculopathy were observed in 25.3% (95% CI: 21.0-29.5) of subjects including 12.6% (95% CI: 9.7-15.6) sight-threatening DR. In previously known DM cases, 215 (41.7%) had never undergone an eye examination for DR.
   Conclusion: The proportion of avoidable blindness and DR is considerable in Gilan Province.
C1 [Katibeh, Marzieh] Aarhus Univ, Dept Publ Hlth, Ctr Global Hlth, Aarhus, Denmark.
   [Katibeh, Marzieh; Beiranvand, Ramin] Shahid Beheshti Univ Med Sci, Ophthalm Epidemiol Res Ctr, Tehran, Iran.
   [Behboudi, Hassan; Alizadeh, Yousef] Guilan Univ Med Sci, Amiralmomenin Hosp, Eye Res Ctr, Rasht, Iran.
   [Moradian, Siamak; Sabbaghi, Hamideh; Ahmadieh, Hamid] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran.
C3 Aarhus University; Shahid Beheshti University Medical Sciences; Shahid
   Beheshti University Medical Sciences
RP Katibeh, M (通讯作者)，Shahid Beheshti Univ Med Sci, Ophthalm Epidemiol Res Ctr, Tehran, Iran.
EM m.k@ph.au.dk
RI Sabbaghi, Hamideh/AAT-2398-2021; beiranvand, ramin/T-8150-2017;
   Ahmadieh, Hamid/M-4853-2017; moradian, siamak/AAW-6294-2020; behboudi,
   hasan/I-1543-2017; alizadeh, yousef/I-5027-2017
OI beiranvand, ramin/0000-0003-2799-1169; Ahmadieh,
   Hamid/0000-0002-8139-2661; behboudi, hasan/0000-0001-7309-1503; ,
   maryam/0000-0002-2214-8976; alizadeh, yousef/0000-0001-5196-4166;
   Moradian, Siamak/0000-0002-5328-7565; Katibeh,
   Marzieh/0000-0002-1542-7117
FU Shahid Beheshti University of Medical Sciences, Tehran, Iran; Guilan
   University of Medical Sciences, Rasht, Iran
FX Financial support for this study was received from (1) Shahid Beheshti
   University of Medical Sciences, Tehran, Iran, and (2) Guilan University
   of Medical Sciences, Rasht, Iran.
CR Adeghate E, 2006, ANN NY ACAD SCI, V1084, P1, DOI 10.1196/annals.1372.029
   Al Ghamdi AH, 2012, BRIT J OPHTHALMOL, V96, P1168, DOI 10.1136/bjophthalmol-2012-301874
   [Anonymous], 2002, Community Eye Health, V15, P49
   Azimi-Nezhad M, 2008, SINGAP MED J, V49, P571
   Dehghan MH, 2015, J DIABETES, V7, P139, DOI 10.1111/1753-0407.12205
   Fotouhi A, 2004, BRIT J OPHTHALMOL, V88, P740, DOI 10.1136/bjo.2003.031153
   Haghdoost A. A., 2009, Eastern Mediterranean Health Journal, V15, P591
   Hajar S, 2015, SAUDI MED J, V36, P449, DOI 10.15537/smj.2015.4.10371
   Hall V, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-564
   Hashemi H, 2012, EYE, V26, P1071, DOI 10.1038/eye.2012.94
   Hashemi H., 2013, J CURR OPHTHALMOL, V25, P262
   Hashemi H, 2015, IRAN J PUBLIC HEALTH, V44, P855
   Iran SCo, 2011, POP HOUS CENS
   Isipradit S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114245
   Javadi MA, 2009, BMC OPHTHALMOL, V9, DOI 10.1186/1471-2415-9-12
   Katibeh Marzieh, 2015, J Ophthalmic Vis Res, V10, P279, DOI 10.4103/2008-322X.170362
   Katibeh M, 2015, OPHTHAL EPIDEMIOL, V22, P208, DOI 10.3109/09286586.2015.1037400
   Katibeh M, 2013, OPHTHAL EPIDEMIOL, V20, P61, DOI 10.3109/09286586.2012.744844
   Kuper Hannah, 2006, Community Eye Health, V19, P68
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Polack S, 2012, OPHTHALMOLOGY, V119, P1033, DOI 10.1016/j.ophtha.2011.11.002
   Rabiu MM, 2015, EUR J OPHTHALMOL, V25, P320, DOI 10.5301/ejo.5000557
   Rajavi Z, 2011, OPHTHALMOLOGY, V118, P1812, DOI 10.1016/j.ophtha.2011.01.049
   Shahriari HA, 2007, BRIT J OPHTHALMOL, V91, P579, DOI 10.1136/bjo.2006.105734
   World Health Organization, 2007, VIS 2020 RIGHT SIGHT
   Zatic T, 2015, BRIT J OPHTHALMOL, V99, P832, DOI 10.1136/bjophthalmol-2014-305824
NR 26
TC 12
Z9 14
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2017
VL 24
IS 6
BP 381
EP 387
DI 10.1080/09286586.2017.1307993
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FN4AG
UT WOS:000415944200004
PM 28422552
DA 2022-11-30
ER

PT J
AU Kanan, Y
   Brobst, D
   Han, ZC
   Naash, MI
   Al-Ubaidi, MR
AF Kanan, Yogita
   Brobst, Daniel
   Han, Zongchao
   Naash, Muna I.
   Al-Ubaidi, Muayyad R.
TI Fibulin 2, a Tyrosine O-Sulfated Protein, Is Up-regulated Following
   Retinal Detachment
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Extracellular Matrix; Fibronectin; Post-translational Modification;
   Retinal Degeneration; Tyrosine Sulfation; Retinal Detachment; Retinal
   Pigment Epithelium
ID EPITHELIAL-MESENCHYMAL TRANSITION; MACULAR DEGENERATION;
   BASEMENT-MEMBRANE; CELL MIGRATION; PROLIFERATIVE VITREORETINOPATHY;
   TRANSGENIC MICE; PLASMID DNA; P-SELECTIN; CUTIS LAXA; T-ANTIGEN
AB Background: Fibulin 2 is an ECM protein of basement membranes and elastic tissues. Results: Fibulin 2 is up-regulated during retinal detachment. Conclusion: Up-regulation of fibulin 2 following detachment points to its role in the adhesion of the RPE to the Bruch membrane and prevention of RPE migration. Significance: This is the first study addressing the role of fibulin 2 in retinal detachment.
   Retinal detachment is the physical separation of the retina from the retinal pigment epithelium. It occurs during aging, trauma, or during a variety of retinal disorders such as age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, or as a complication following cataract surgery. This report investigates the role of fibulin 2, an extracellular component, in retinal detachment. A major mechanism for detachment resolution is enhancement of cellular adhesion between the retina and the retinal pigment epithelium and prevention of its cellular migration. This report shows that fibulin 2 is mainly present in the retinal pigment epithelium, Bruch membrane, choriocapillary, and to a lesser degree in the retina. In vitro studies revealed the presence of two isoforms for fibulin 2. The small isoform is located inside the cell, and the large isoform is present inside and outside the cells. Furthermore, fibulin 2 is post-translationally modified by tyrosine sulfation, and the sulfated isoform is present outside the cell, whereas the unsulfated pool is internally located. Interestingly, sulfated fibulin 2 significantly reduced the rate of cellular growth and migration. Finally, levels of fibulin 2 dramatically increased in the retinal pigment epithelium following retinal detachment, suggesting a direct role for fibulin 2 in the re-attachment of the retina to the retinal pigment epithelium. Understanding the role of fibulin 2 in enhancing retinal attachment is likely to help improve the current therapies or allow the development of new strategies for the treatment of this sight-threatening condition.
C1 [Kanan, Yogita; Brobst, Daniel; Han, Zongchao; Naash, Muna I.; Al-Ubaidi, Muayyad R.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center
RP Kanan, Y (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, BMSB 781,940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.
EM ykanan@ouhsc.edu; muayyad-al-ubaidi@ouhsc.edu
OI Han, Zongchao/0000-0002-2019-395X
FU National Institutes of Health [R01EY10609, R01EY018137]; NEI
   [P30EY12190]; Oklahoma Center for the Advancement of Science and
   Technology; Foundation Fighting Blindness; NATIONAL EYE INSTITUTE
   [P30EY012190, R01EY018656, R01EY018137, R01EY010609] Funding Source: NIH
   RePORTER
FX This work was supported, in whole or in part, by National Institutes of
   Health Grants R01EY10609 (to M. I. N.) and R01EY018137 (to M. R. A.) and
   Grant P30EY12190 from NEI. This work was also supported by the Oklahoma
   Center for the Advancement of Science and Technology (to Y. K.) and the
   Foundation Fighting Blindness (to M. R. A.).
CR Alcendor DJ, 2011, AM J PATHOL, V179, P1443, DOI 10.1016/j.ajpath.2011.05.024
   AlUbaidi MR, 1997, EXP EYE RES, V64, P573, DOI 10.1006/exer.1996.0240
   ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681
   ANDERSON DH, 1981, INVEST OPHTH VIS SCI, V21, P10
   Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Chapman SL, 2010, ARTERIOSCL THROM VAS, V30, P68, DOI 10.1161/ATVBAHA.109.196725
   CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745
   CHEN CA, 1988, BIOTECHNIQUES, V6, P632
   de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6
   Debeer P, 2002, J MED GENET, V39, P98, DOI 10.1136/jmg.39.2.98
   Dietrich-Ntoukas T, 2012, CORNEA, V31, P564, DOI 10.1097/ICO.0b013e3182254b78
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Dunwell TL, 2009, EPIGENETICS-US, V4, P185, DOI 10.4161/epi.4.3.8752
   Farjo R, 2008, INVEST OPHTH VIS SCI, V49, P511, DOI 10.1167/iovs.07-1013
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   FRIEDERICH E, 1988, J CELL BIOL, V107, P1655, DOI 10.1083/jcb.107.5.1655
   Garcia S, 2008, J CELL BIOCHEM, V104, P377, DOI 10.1002/jcb.21633
   Go SL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1237, DOI 10.1001/archopht.123.9.1237
   HACKETT SF, 1989, ARCH OPHTHALMOL-CHIC, V107, P391, DOI 10.1001/archopht.1989.01070010401033
   Hill VK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-51
   Hoffhines AJ, 2006, J BIOL CHEM, V281, P37877, DOI 10.1074/jbc.M609398200
   Hoffhines AJ, 2009, J BIOL CHEM, V284, P3096, DOI 10.1074/jbc.M808434200
   Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x
   Hucthagowder V, 2006, AM J HUM GENET, V78, P1075, DOI 10.1086/504304
   Hunzelmann N, 2001, BRIT J DERMATOL, V145, P217, DOI 10.1046/j.1365-2133.2001.04337.x
   HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200
   IMMEL J, 1986, INVEST OPHTH VIS SCI, V27, P1770
   Ivert L, 2002, GRAEF ARCH CLIN EXP, V240, P232, DOI 10.1007/s00417-001-0392-4
   Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282
   Kanan Y, 2009, EXP EYE RES, V89, P559, DOI 10.1016/j.exer.2009.05.010
   Kang HK, 2008, BMJ-BRIT MED J, V336, P1235, DOI 10.1136/bmj.39581.525532.47
   Kim TH, 2010, MOL CELLS, V29, P413, DOI 10.1007/s10059-010-0049-4
   Kusubata M, 1999, J INVEST DERMATOL, V113, P906, DOI 10.1046/j.1523-1747.1999.00802.x
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Law EWL, 2012, ONCOGENE, V31, P728, DOI 10.1038/onc.2011.272
   LEE KP, 1990, ARCH TOXICOL, V64, P135, DOI 10.1007/BF01974399
   LEYTE A, 1991, J BIOL CHEM, V266, P740
   Lim JJ, 2013, BIOMATERIALS, V34, P5007, DOI 10.1016/j.biomaterials.2013.03.037
   LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125
   Lotery AJ, 2006, HUM MUTAT, V27, P568, DOI 10.1002/humu.20344
   Loveland K, 1998, BIOL REPROD, V58, P1123, DOI 10.1095/biolreprod58.5.1123
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   Martin F, 2003, OPHTHALMIC RES, V35, P232, DOI 10.1159/000071175
   Miosge N, 1996, HISTOCHEM J, V28, P109, DOI 10.1007/BF02331415
   Monigatti F, 2002, BIOINFORMATICS, V18, P769, DOI 10.1093/bioinformatics/18.5.769
   Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200
   Muthana SM, 2012, ACS CHEM BIOL, V7, P31, DOI 10.1021/cb2004466
   Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a
   Nour M, 2003, INVEST OPHTH VIS SCI, V44, P4505, DOI 10.1167/iovs.03-0453
   Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200
   PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269
   Perkumas KM, 2012, EXP EYE RES, V96, P82, DOI 10.1016/j.exer.2011.12.017
   PFAFF M, 1995, EXP CELL RES, V219, P87, DOI 10.1006/excr.1995.1208
   Piscaglia F, 2009, CELL TISSUE RES, V337, P449, DOI 10.1007/s00441-009-0823-9
   Polkinghorne PJ, 2004, CLIN EXP OPHTHALMOL, V32, P159, DOI 10.1111/j.1442-9071.2004.00003.x
   Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771
   Rider CC, 2006, BIOCHEM SOC T, V34, P458, DOI 10.1042/BST0340458
   Rodgers SD, 2001, BIOPHYS J, V81, P2001, DOI 10.1016/S0006-3495(01)75850-X
   Saika Shizuya, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P69, DOI 10.2174/187153008783928343
   Salmivirta K, 2002, EXP CELL RES, V279, P188, DOI 10.1006/excr.2002.5611
   Sasaki T, 1996, J CELL SCI, V109, P2895
   SASAKI T, 1995, J MOL BIOL, V254, P892, DOI 10.1006/jmbi.1995.0664
   Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5
   Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje
   Sherry DM, 2010, EUR J NEUROSCI, V32, P1461, DOI 10.1111/j.1460-9568.2010.07431.x
   Sicot FX, 2008, MOL CELL BIOL, V28, P1061, DOI 10.1128/MCB.01876-07
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Strom A, 2006, CARDIOVASC RES, V69, P755, DOI 10.1016/j.cardiores.2005.12.001
   Tan E, 2004, INVEST OPHTH VIS SCI, V45, P764, DOI 10.1167/iovs.03-1114
   Tsuda T, 2012, J MOL CELL CARDIOL, V52, P273, DOI 10.1016/j.yjmcc.2011.11.001
   Utani A, 1997, J BIOL CHEM, V272, P2814, DOI 10.1074/jbc.272.5.2814
   Westmuckett AD, 2008, GEN COMP ENDOCR, V156, P145, DOI 10.1016/j.ygcen.2007.12.006
   Yanagisawa H, 2009, J CELL COMMUN SIGNAL, V3, P337, DOI 10.1007/s12079-009-0065-3
   Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478
   Zafiropoulos A, 2008, CONNECT TISSUE RES, V49, P153, DOI 10.1080/03008200802148702
   Zeng R, 2012, INVEST OPHTH VIS SCI, V53, P1685, DOI 10.1167/iovs.11-8241
   Zhu JZ, 2011, BIOCHEMISTRY-US, V50, P1524, DOI 10.1021/bi101240v
NR 79
TC 7
Z9 7
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 9
PY 2014
VL 289
IS 19
BP 13419
EP 13433
DI 10.1074/jbc.M114.562157
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AG6IR
UT WOS:000335522800040
PM 24692557
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Ouyang, YL
   Pleyer, U
   Shao, Q
   Keane, PA
   Stubiger, N
   Joussen, AM
   Sadda, SR
   Heussen, FM
AF Ouyang, Yanling
   Pleyer, Uwe
   Shao, Qing
   Keane, Pearse A.
   Stuebiger, Nicole
   Joussen, Antonia M.
   Sadda, Srinivas R.
   Heussen, Florian M.
TI Evaluation of Cystoid Change Phenotypes in Ocular Toxoplasmosis Using
   Optical Coherence Tomography
SO PLOS ONE
LA English
DT Article
ID CONGENITAL TOXOPLASMOSIS; MACULAR DEGENERATION; RETINOCHOROIDITIS;
   PATHOGENESIS; FEATURES; GONDII
AB Purpose: To present unique cystoid changes occurring in patients with ocular toxoplasmosis observed in spectral domain optical coherence tomography (OCT).
   Methods: Forty-six patients (80 eyes) with a diagnosis of ocular toxoplasmosis, who underwent volume OCT examination between January 2005 and October 2012, were retrospectively collected. Review of clinical examination findings, fundus photographs, fluorescein angiograms (FA) and OCT image sets obtained at initial visits and follow-up. Qualitative and quantitative analyses of cystoid space phenotypes visualized using OCT.
   Results: Of the 80 eyes included, 17 eyes (15 patients) demonstrated cystoid changes in the macula on OCT. Six eyes (7.5%) had cystoid macular edema (CME), 2 eyes (2.5%) had huge outer retinal cystoid space (HORC), 12 eyes (15%) had cystoid degeneration and additional 3 eyes (3.75%) had outer retinal tubulation due to age related macular degeneration. In one eye with HORC, the lesion was seen in the photoreceptor outer segment, accompanied by photoreceptor elongation and splitting. Three eyes presented with paravascular cystoid degeneration in the inner retina without other macular OCT abnormality.
   Conclusions: In this study, different phenotypes of cystoid spaces seen in eyes with ocular toxoplasmosis using spectral domain OCT (SD-OCT) were demonstrated. CME presented as an uncommon feature, consistently with previous findings. Identification of rare morphological cystoid features (HORC with/without photoreceptor enlongation or splitting) on clinical examination had provided evidence to previous experimental models, which may also expand the clinical spectrum of the disease. Cystoid degeneration in the inner retina next to the retinal vessels in otherwise "normal" looking macula was observed, which may suggest more often clinical evaluation for those patients. Further studies are needed to verify the relevance of cystoid features seen on SD-OCT in assisting with the diagnosis and management of ocular toxoplasmosis.
C1 [Ouyang, Yanling; Pleyer, Uwe; Shao, Qing; Stuebiger, Nicole; Joussen, Antonia M.; Heussen, Florian M.] Univ Med Berlin, Charite, Dept Ophthalmol, Berlin, Germany.
   [Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Keane, Pearse A.] UCL Inst Ophthalmol, London, England.
   [Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust; University of
   London; University College London; Doheny Eye Institute; University of
   Southern California; University of Southern California
RP Heussen, FM (通讯作者)，Univ Med Berlin, Charite, Dept Ophthalmol, Berlin, Germany.
EM florian.heussen@gmail.com
RI Joussen, Antonia/AAA-6901-2022; Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X; Heussen, Florian
   Moritz/0000-0003-0536-9870
FU Department of Health's NIHR Biomedical Research Centre for Ophthalmology
   at Moorfields Eye Hospital; UCL Institute of Ophthalmology; Allergan
   European Retina Panel; Novartis; Allergan Inc.; Bayer AG; federal
   ministry of education and research of Germany (BMBF) through the Toxonet
   02 research collaboration; Carl Zeiss Meditec; Optos; Optovue, Inc.;
   Academy of Medical Sciences (AMS) [AMS-SGCL6-Keane] Funding Source:
   researchfish; National Institute for Health Research [CL-2010-18-004]
   Funding Source: researchfish
FX Dr. Keane has received a proportion of his funding from the Department
   of Health's NIHR Biomedical Research Centre for Ophthalmology at
   Moorfields Eye Hospital and UCL Institute of Ophthalmology. The views
   expressed in the publication are those of the author and not necessarily
   those of the Department of Health. Drs. Keane and Heussen have received
   travel grants from the Allergan European Retina Panel. Dr. Joussen
   received financial compensation for lectures from Novartis, Allergan
   Inc. and Bayer AG. Dr. Pleyer received funding from the federal ministry
   of education and research of Germany (BMBF) through the Toxonet 02
   research collaboration and has been the Principal
   Investigator/Consultant for Abbott, Alcon, Allergan, Amgen, Bausch and
   Lomb, Bayer/Schering, Centocor, Esba Tech, Novartis but no commercial
   interests or financial relationships to any agent, device, or technique.
   Dr. Sadda is a co-inventor of Doheny intellectual property related to
   optical coherence tomography that has been licensed by Topcon Medical
   Systems, and is a member of the scientific advisory board for Heidelberg
   Engineering. Dr Sadda also receives research support from Carl Zeiss
   Meditec, Optos, and Optovue, Inc. The authors have no commercial
   interests for the manuscript. This work was partially supported by the
   funding from the federal ministry of education and research of Germany
   (BMBF) through the Toxonet 02 research collaboration and the Department
   of Health's NIHR Biomedical Research Centre for Ophthalmology at
   Moorfields Eye Hospital and UCL Institute of Ophthalmology. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bonfioli Adriana A, 2005, Semin Ophthalmol, V20, P129, DOI 10.1080/08820530500231961
   Bosch-Driessen LEH, 2002, OPHTHALMOLOGY, V109, P869, DOI 10.1016/S0161-6420(02)00990-9
   CASSADY J V, 1960, Trans Am Ophthalmol Soc, V58, P392
   Diniz B, 2011, CLIN OPHTHALMOL, V5, P645, DOI 10.2147/OPTH.S20033
   Dodds EM, 2008, AM J OPHTHALMOL, V146, P856, DOI 10.1016/j.ajo.2008.09.006
   FRENKEL J K, 1961, Surv Ophthalmol, V6, P799
   Gallagher MJ, 2007, BRIT J OPHTHALMOL, V91, P1680, DOI 10.1136/bjo.2007.124099
   Garg S, 2009, RETINA-J RET VIT DIS, V29, P631, DOI 10.1097/IAE.0b013e318198d8de
   GAZZINELLI RT, 1994, EXP PARASITOL, V78, P217, DOI 10.1006/expr.1994.1022
   GROSSNIKLAUS HE, 1990, OPHTHALMOLOGY, V97, P1342, DOI 10.1016/S0161-6420(90)32412-0
   Heussen FM, 2011, INVEST OPHTH VIS SCI, V52, P7792, DOI 10.1167/iovs.11-8023
   Holland GN, 1999, AM J OPHTHALMOL, V128, P502, DOI 10.1016/S0002-9394(99)00263-9
   Ishihara K, 2009, OPHTHALMOLOGY, V116, P1799, DOI 10.1016/j.ophtha.2009.04.002
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kianersi F, 2012, INT OPHTHALMOLOGY
   Kovacevic-Pavicevic D, 2012, EYE, V26, P723, DOI 10.1038/eye.2012.20
   Ouyang Y, 2013, RETINA PHILADELPHIA
   Ouyang YL, 2013, INVEST OPHTH VIS SCI, V54, P1460, DOI 10.1167/iovs.12-10727
   Ouyang YL, 2011, INVEST OPHTH VIS SCI, V52, P7019, DOI 10.1167/iovs.11-8046
   Ouyang YL, 2010, INVEST OPHTH VIS SCI, V51, P5213, DOI 10.1167/iovs.09-4635
   Remington JSDG, 1976, TOXOPLASMOSIS INFECT, P191
   Roberts F, 1999, PARASITOL TODAY, V15, P51, DOI 10.1016/S0169-4758(98)01377-5
   ROBERTS T, 1990, J AM VET MED ASSOC, V196, P249
   Saxena Sandeep, 2010, J Ocul Biol Dis Infor, V3, P109, DOI 10.1007/s12177-011-9062-x
   SCHLAEGEL TF, 1984, ARCH OPHTHALMOL-CHIC, V102, P697, DOI 10.1001/archopht.1984.01040030553014
   Tedesco RC, 2004, PARASITOL RES, V92, P467, DOI 10.1007/s00436-003-1031-2
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 27
TC 15
Z9 15
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 5
PY 2014
VL 9
IS 2
AR e86626
DI 10.1371/journal.pone.0086626
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AA1AT
UT WOS:000330829200021
PM 24505261
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Burggraaff, MC
   Trieu, J
   de Vries-Knoppert, WAEJ
   Balk, L
   Petzold, A
AF Burggraaff, Marloes C.
   Trieu, Jennifer
   de Vries-Knoppert, Willemien A. E. J.
   Balk, Lisanne
   Petzold, Axel
TI The Clinical Spectrum of Microcystic Macular Edema
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE MME; microcysts; pseudocysts; optical coherence tomography; inner
   nuclear layer thickness; microcystic macular changes
ID OPTICAL COHERENCE TOMOGRAPHY; POTASSIUM CHANNEL KIR4.1; INNER NUCLEAR
   LAYER; MULTIPLE-SCLEROSIS; RETINAL TELANGIECTASIS; NEUROMYELITIS-OPTICA;
   WATERSHED ZONES; MULLER CELLS; DEGENERATION; NEUROPATHY
AB PURPOSE. Microcystic macular edema (MME), originally described in British literature as microcystic macular oedema (MMO), defines microcysts in the inner nuclear layer (INL) of the retina. Microcystic macular edema was described in multiple sclerosis (MS), but can be found in numerous disorders. The presence of MME has important prognostic and therapeutic implications; however, the differential diagnosis is unknown. This study aimed to describe the clinical spectrum of MME.
   METHODS. A single-center, retrospective cohort study. A bootstrap analysis was performed to reduce the 5865 patients (22,376 scans), who had undergone OCT imaging between January 2010 and February 2013, to a representative dataset. The presence of MME was rated by independent observers.
   RESULTS. The dataset consisted of 1368 patients (mean age 62, range, 4-101 years), 2589 eyes and 6449 scans. Microcystic macular edema was present in 133/1303 (10%) of patients and 0/65 (0%) of healthy controls. The interrater agreement for detecting MME was substantial (kappa 0.6) and could be further improved after refining the criteria (kappa 0.8). The clinical spectrum included age-related macular degeneration, epiretinal membranes, postoperative lesions, diabetic retinopathy, vascular occlusion, MS (with/without optic neuritis), optic neuropathy, central serous chorioretinopathy, medication, and miscellaneous causes. The longitudinal pattern of MME was transient (84%) or static. Microcystic macular edema could be associated with an increase or decrease in INL thickness and was predominantly located nasally (48%) and/or temporally (50%).
   CONCLUSIONS. This study substantially widened the clinical spectrum of MME. Diagnostic criteria were refined and validated. The associated phenotype may imply Muller cell dysfunction within the watershed zone. The longitudinal data and evidence from previous studies suggest follow-up of these patients and their visual function.
C1 [Burggraaff, Marloes C.; Trieu, Jennifer; de Vries-Knoppert, Willemien A. E. J.] VU Univ Med Ctr Amsterdam, Dept Ophthalmol, NL-1007 MB Amsterdam, Netherlands.
   [Balk, Lisanne; Petzold, Axel] VU Univ Med Ctr Amsterdam, Dept Neurol, NL-1007 MB Amsterdam, Netherlands.
C3 Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije
   Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER
RP Burggraaff, MC (通讯作者)，VU Univ Med Ctr Amsterdam, Dept Ophthalmol, De Boelelaan 1117,POB 7057, NL-1007 MB Amsterdam, Netherlands.
EM m.burggraaff@vumc.nl
RI Petzold, Axel/C-1090-2009
OI Petzold, Axel/0000-0002-0344-9749
CR Abegg M, 2014, OPHTHALMOLOGY, V121, P142, DOI 10.1016/j.ophtha.2013.08.045
   Abegg M, 2012, BRAIN, V135, DOI 10.1093/brain/aws215
   Balk LJ, 2012, BRAIN, V135, DOI 10.1093/brain/aws216
   Barboni P, 2013, BRAIN 7, V136, pe329
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Brar M, 2010, RETINA-J RET VIT DIS, V30, P383, DOI 10.1097/IAE.0b013e3181cd4803
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Cohen SM, 2007, RETINA-J RET VIT DIS, V27, P59, DOI 10.1097/01.iae.0000256663.94734.e1
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Gaudric A, 2006, ARCH OPHTHALMOL-CHIC, V124, P1410, DOI 10.1001/archopht.124.10.1410
   Gelfand JM, 2013, JAMA NEUROL, V70, P629, DOI 10.1001/jamaneurol.2013.1832
   Gelfand JM, 2012, BRAIN, V135, P1786, DOI 10.1093/brain/aws098
   GIUFFRE G, 1989, DOC OPHTHALMOL, V72, P175, DOI 10.1007/BF00156707
   Gocho K, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/676803
   Gualino V, 2005, AM J OPHTHALMOL, V140, P757, DOI 10.1016/j.ajo.2005.04.042
   Hayreh SS, 2010, AM J OPHTHALMOL, V150, P940, DOI 10.1016/j.ajo.2010.08.011
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Kisimbi J, 2013, BRAIN, V136, P3418, DOI 10.1093/brain/awt221
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lujan B, 2013, BRAIN, V136, P1
   Mayer MA, 2010, BIOMED OPT EXPRESS, V1, P1358, DOI 10.1364/BOE.1.001358
   Park Susanna S, 2009, Retin Cases Brief Rep, V3, P33, DOI 10.1097/ICB.0b013e31815e93cf
   Petzold A, 2014, J NEUROL, V261, P17, DOI 10.1007/s00415-013-6957-4
   Petzold A, 2012, LANCET NEUROL, V11, P933, DOI 10.1016/S1474-4422(12)70231-4
   Querques G, 2011, AM J OPHTHALMOL, V152, P100, DOI 10.1016/j.ajo.2011.01.027
   Reichenbach A, 2007, GRAEF ARCH CLIN EXP, V245, P627, DOI 10.1007/s00417-006-0516-y
   Saidha S, 2012, LANCET NEUROL, V11, P963, DOI 10.1016/S1474-4422(12)70213-2
   Sotirchos ES, 2013, NEUROLOGY, V80, P1406, DOI 10.1212/WNL.0b013e31828c2f7a
   Srivastava R, 2012, NEW ENGL J MED, V367, P115, DOI 10.1056/NEJMoa1110740
   Tewarie P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034823
   Traber G, 2013, N AM NEUR SOC NANOS
   Udagawa T, 2012, NEUROSCIENCE, V215, P209, DOI 10.1016/j.neuroscience.2012.04.037
NR 34
TC 68
Z9 71
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2014
VL 55
IS 2
BP 952
EP 961
DI 10.1167/iovs.13-12912
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB6IU
UT WOS:000331891700040
PM 24398089
DA 2022-11-30
ER

PT J
AU Mizutani, T
   Ashikari, M
   Tokoro, M
   Nozaki, M
   Ogura, Y
AF Mizutani, Takeshi
   Ashikari, Masayuki
   Tokoro, Mayumi
   Nozaki, Miho
   Ogura, Yuichiro
TI Suppression of Laser-Induced Choroidal Neovascularization by a CCR3
   Antagonist
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; CELL PROLIFERATION;
   UP-REGULATION; VEGF; RANIBIZUMAB; INHIBITION; ACTIVATION; EXPRESSION
AB PURPOSE. To evaluate the efficacy of a novel CCR3 antagonist for laser injury-induced choroidal neovascularization (CNV) inmice.
   METHODS. We evaluated YM-344031, a novel and selective small-molecule CCR3 antagonist. CNV was induced by laser injury in C57BL/6J mice, and its volume was measured after 7 days by confocal microscopy. Leakage from the CNV was also measured after 7 days by fluorescein angiography. The CCR3 antagonist was administered by gavage at 1 hour before and 1 day after the laser injury, or intravitreous injection immediately after the laser injury. After the laser injury, ELISA, Western blot analysis, and real-time RT-PCR for VEGF-A expression in the RPE/choroid, and immunohistochemistry for CCR3, CCL11, Ki67, and Rac1 was performed.
   RESULTS. Both oral administration and intravitreous injection of YM-344031 significantly suppressed the CNV volume (P < 0.0001 and P < 0.01, respectively). Pathologically significant leakage was significantly less common in YM-344031-injected mice (P < 0.0001). The mean VEGF protein level was significantly increased in vehicle-injected eyes after the laser injury (P < 0.05). Although the YM-344031-injected eyes did not show VEGF-A suppression after the laser injury, VEGF164 mRNA upregulation was significantly suppressed in YM-344031-injected mice (P < 0.05), and intravitreous injection of YM-344031 appeared to suppress CCR3, CCL11 (eotaxin), Ki67, and Rac1 expression after the laser injury.
   CONCLUSIONS. The present data suggest that the CCR3 antagonist YM-344031 can suppress CNV, via suppression of the upregulation of VEGF164 mRNA in VEGF isoform after the laser injury. Although our findings may warrant further investigation, YM-344031 may have potential as a new therapy for age-related macular degeneration. (Invest Ophthalmol Vis Sci. 2013; 54: 1564-1572) DOI:10.1167/iovs.11-9095
C1 [Mizutani, Takeshi; Ashikari, Masayuki; Tokoro, Mayumi; Nozaki, Miho; Ogura, Yuichiro] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi 4678601, Japan.
C3 Nagoya City University
RP Nozaki, M (通讯作者)，Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.
EM nozakim@med.nagoya-cu.ac.jp
FU Ministry of Health, Labour and Welfare of Japan; Japan Society for the
   Promotion of Science
FX Supported by a Grant-in-Aid for Scientific Research (C) from the Japan
   Society for the Promotion of Science and a Grant-in-Aid for Scientific
   Research from the Ministry of Health, Labour and Welfare of Japan.
CR Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P2868, DOI 10.1167/iovs.10-6608
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ashikari M, 2010, INVEST OPHTH VIS SCI, V51, P3820, DOI 10.1167/iovs.09-5121
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chakravarthi S., 2009, INDIAN J SCI TECHNOL, V2, P1
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   GERDES J, 1984, J IMMUNOL, V133, P1710
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Itaya M, 2007, INVEST OPHTH VIS SCI, V48, P5677, DOI 10.1167/iovs.07-0156
   Jamaluddin MS, 2009, ARTERIOSCL THROM VAS, V29, P2146, DOI 10.1161/ATVBAHA.109.194134
   Li Y, 2010, PLOS ONE, V6
   Liclican EL, 2010, INVEST OPHTH VIS SCI, V51, P6311, DOI 10.1167/iovs.10-5455
   Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571
   Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582
   Suzuki K, 2006, BIOCHEM BIOPH RES CO, V339, P1217, DOI 10.1016/j.bbrc.2005.11.141
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tan WF, 2008, FASEB J, V22, P1829, DOI 10.1096/fj.07-096438
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Zhang L, 2002, BIOCHEM BIOPH RES CO, V292, P860, DOI 10.1006/bbrc.2002.6710
NR 34
TC 20
Z9 22
U1 0
U2 11
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2013
VL 54
IS 2
BP 1564
EP 1572
DI 10.1167/iovs.11-9095
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100BS
UT WOS:000315670300085
PM 23404125
DA 2022-11-30
ER

PT J
AU Zheng, YL
   Sahni, J
   Campa, C
   Stangos, AN
   Raj, A
   Harding, SP
AF Zheng, Yalin
   Sahni, Jayashree
   Campa, Claudio
   Stangos, Alexandros N.
   Raj, Ankur
   Harding, Simon P.
TI Computerized Assessment of Intraretinal and Subretinal Fluid Regions in
   Spectral-Domain Optical Coherence Tomography Images of the Retina
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; QUANTITATIVE SUBANALYSIS; THICKNESS
   MEASUREMENTS; MACULAR DEGENERATION; RANIBIZUMAB; SEGMENTATION; EDEMA
AB PURPOSE: To evaluate a new computerized segmentation technique for the quantification of intraretinal and subretinal fluid in spectral-domain optical coherence tomography (SD OCT) images of the retina.
   DESIGN: Prospective, cross-sectional study.
   METHODS: Thirty-seven B-scan images of 37 patients with exudative age-related macular degeneration were chosen randomly from SD OCT volume scans (1 per volume scan). All hyporeflective areas in the image first were segmented automatically as candidate regions by the program. Researchers who were masked to the candidate region information selected each fluid region from the original image using a single mouse click. The program then delineated the boundary of each region selected and calculated quantitative parameters, including total area of fluid regions if multiple regions were selected. The performance of our technique was validated by comparing the results with the measurements obtained from boundaries manually delineated by 2 masked observers. Time efficiency, agreement with manual delineation, and intraobserver and interobserver agreement of using the program were evaluated.
   RESULTS: The proposed technique reduced the average processing time per image approximately 6-fold (15 seconds for computerized segmentation vs 90 seconds for manual delineation). There was good agreement between computerized segmentation and manual delineation measured by intraclass correlation coefficient (range, 0.897 to 0.979) and the Dice coefficient (range, 0.721 to 0.785). The proposed technique has excellent intraobserver and interobserver agreement (intraclass correlation coefficient range, 0.998 to 0.999; Dice coefficient range. 0.959 to 0.981).
   CONCLUSIONS: This computerized segmentation method allows for accurate and fast quantification of fluid in retinal SD OCT images and could assist in monitoring disease progression and evaluating therapeutic intervention. (Am J Ophthalmol 2013;155:277-286. (c) 2013 by Elsevier Inc. All rights reserved.)
C1 [Zheng, Yalin; Sahni, Jayashree; Campa, Claudio; Raj, Ankur; Harding, Simon P.] Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, Liverpool L69 3GA, Merseyside, England.
   [Zheng, Yalin; Sahni, Jayashree; Campa, Claudio; Stangos, Alexandros N.; Raj, Ankur; Harding, Simon P.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
C3 University of Liverpool; Royal Liverpool & Broadgreen University
   Hospitals NHS Trust; Royal Liverpool University Hospital; University of
   Liverpool
RP Zheng, YL (通讯作者)，Univ Liverpool, Dept Eye & Vis Sci, Inst Ageing & Chron Dis, 3rd Floor,UCD Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.
EM yalin.zheng@liv.ac.uk
RI Zheng, Yalin/N-6432-2017
OI Zheng, Yalin/0000-0002-7873-0922; Harding, Simon/0000-0003-4676-1158
FU Pfizer; Novartis; Allergan
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and the following were reported. Drs
   Sahni and Harding have received fees for lectures; advisory boards; and
   travel, accommodation, or meeting expenses unrelated to this publication
   from Pfizer, Novartis, and Allergan. The remaining authors have no
   financial support or financial conflict of interests to disclose.
   Involved in Conception and design of study (Y.Z., J.S., C.C., A.N.S.,
   A.R., S.P.H.); Collection of data (J.S., C.C., A.N.S.); Analysis and
   interpretation of data (Y.Z., J.S., A.N.S., C.C.); Writing the article
   (Y.Z.); and Critical revision and final approval of article (J.S.,
   A.N.S., C.C., A.R., S.P.H.).
CR Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Ahlers C, 2009, INVEST OPHTH VIS SCI, V50, P3417, DOI 10.1167/iovs.08-2759
   Barthelmes D, 2008, INVEST OPHTH VIS SCI, V49, P3529, DOI 10.1167/iovs.07-1320
   Benson SE, 2006, EYE, V20, P1030, DOI 10.1038/sj.eye.6702073
   Bresson X, 2007, J MATH IMAGING VIS, V28, P151, DOI 10.1007/s10851-007-0002-0
   Brown DM, 2010, OPHTHALMOLOGY, V117
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen J, 2007, CLIN EXP OPTOM, V90, P317, DOI 10.1111/j.1444-0938.2007.00151.x
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P1
   Diabetic Retinopathy Clinical Research Network, 2007, OPHTHALMOLOGY, V114, P526
   Diabetic Retinopathy Clinical Research Network, 2010, OPHTHALMOLOGY, V117
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Goldstein T, 2010, J SCI COMPUT, V45, P272, DOI 10.1007/s10915-009-9331-z
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P802, DOI 10.1016/j.ophtha.2011.12.005
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Sahni J, 2007, CLIN EXP OPHTHALMOL, V35, P13, DOI 10.1111/j.1442-9071.2006.01385.x
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Zheng YL, 2010, INVEST OPHTH VIS SCI, V51, P3653, DOI 10.1167/iovs.09-4935
   ZIJDENBOS AP, 1994, IEEE T MED IMAGING, V13, P716, DOI 10.1109/42.363096
NR 31
TC 46
Z9 49
U1 0
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2013
VL 155
IS 2
BP 277
EP 286
DI 10.1016/j.ajo.2012.07.030
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 078YQ
UT WOS:000314137400011
PM 23111180
DA 2022-11-30
ER

PT J
AU Tseng, VL
   Greenberg, PB
   Wu, WC
   Jiang, L
   Li, E
   Kang, JM
   Scott, IU
   Friedmann, PD
AF Tseng, Victoria L.
   Greenberg, Paul B.
   Wu, Wen-Chih
   Jiang, Lan
   Li, Emily
   Kang, Jessica M.
   Scott, Ingrid U.
   Friedmann, Peter D.
TI Cataract Surgery Complications in Nonagenarians
SO OPHTHALMOLOGY
LA English
DT Article
ID OUTCOMES
AB Purpose: To investigate whether nonagenarians relative to octogenarians are at increased risk of ocular complications from cataract surgery in the US Veterans Health Administration (VHA).
   Design: A retrospective cohort study.
   Participants: A total of 554 nonagenarians and 11 407 octogenarians who received cataract surgery in the VHA.
   Methods: Nonagenarians and octogenarians who received 1 cataract surgery without a second surgery within 90 days between October 1, 2005, and September 30, 2007, were identified using the National Patient Care Database (NPCD). Data collected include demographics, preoperative systemic and ocular comorbidities, intraoperative complications, and 90-day postoperative complications. The adjusted odds ratio (OR) of complications in nonagenarians using octogenarians as a reference group was calculated using logistic regression modeling.
   Main Outcome Measures: Intraoperative and postoperative ocular complications within 90 days of cataract surgery in nonagenarians versus octogenarians.
   Results: The most common systemic comorbidity for both age groups was diabetes mellitus (DM), and the most common ocular comorbidity for both age groups was age-related macular degeneration (AMD). Octogenarians had a higher prevalence of most systemic comorbidities, and nonagenarians had a higher prevalence of most ocular comorbidities. The most common intraoperative and postoperative complications for both age groups were vitreous loss or posterior capsular tear and posterior capsular opacification. The risk of having any intraoperative or postoperative complication was 13.5% for octogenarians and 13.4% for nonagenarians (P = 0.9001). The OR of having any intraoperative or postoperative complication in nonagenarians with octogenarians as a reference group was 0.94 (95% confidence interval, 0.73-1.22).
   Conclusions: Nonagenarians relative to octogenarians are not at increased risk of ocular complications from cataract surgery in the VHA. Further studies are needed to evaluate other outcome parameters, such as visual function and quality of life, in nonagenarians undergoing cataract surgery.
C1 [Tseng, Victoria L.; Greenberg, Paul B.; Li, Emily; Kang, Jessica M.] VA Med Ctr, Sect Ophthalmol, Providence, RI 02908 USA.
   [Tseng, Victoria L.; Greenberg, Paul B.; Li, Emily; Kang, Jessica M.] Brown Univ, Div Ophthalmol, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Tseng, Victoria L.; Greenberg, Paul B.; Wu, Wen-Chih; Jiang, Lan; Friedmann, Peter D.] VA Med Ctr, Res Enhancement Award Program, Providence, RI 02908 USA.
   [Wu, Wen-Chih; Friedmann, Peter D.] VA Med Ctr, Med Serv, Providence, RI 02908 USA.
   [Wu, Wen-Chih; Friedmann, Peter D.] Brown Univ, Dept Med, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Scott, Ingrid U.] Penn State Coll Med, Dept Ophthalmol, Hershey, PA USA.
   [Scott, Ingrid U.] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Providence VA Medical Center; Brown University; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Providence VA
   Medical Center; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Providence VA Medical Center; Brown University;
   Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health
RP Greenberg, PB (通讯作者)，VA Med Ctr, Sect Ophthalmol, 830 Chalkstone Ave, Providence, RI 02908 USA.
EM paul_greenberg@brown.edu
RI Kang, Jessica/GZA-6384-2022
OI Scott, Ingrid/0000-0002-3908-7153
FU Center on Systems, Outcomes, and Quality in Chronic Disease and
   Rehabilitation; Health Service Research and Development Service
   [REA08-263]; Department of Veterans Affairs
FX Supported by the Center on Systems, Outcomes, and Quality in Chronic
   Disease and Rehabilitation, Research Enhancement Award Program, Health
   Service Research and Development Service Grant number REA08-263,
   Department of Veterans Affairs.
CR *AM AC OPHTH CAT A, 2006, PREF PRACT PATT CAT, P20
   [Anonymous], 2007, INT CLASSIFICATION D
   [Anonymous], NAT PAT CAR DAT NPCD
   Arias Elizabeth, 2007, Natl Vital Stat Rep, V56, P1
   Beebe M, 2007, CURRENT PROCEDURAL T, P282
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Daley J, 2001, ANNU REV MED, V52, P275, DOI 10.1146/annurev.med.52.1.275
   GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008
   Greenberg PB, 2011, OPHTHALMOLOGY, V118, P507, DOI 10.1016/j.ophtha.2010.07.023
   Greenberg PB, 2010, OPHTHALMOLOGY, V117, P1894, DOI 10.1016/j.ophtha.2010.02.009
   Kaplan GG, 2010, AM J GASTROENTEROL, V105, P1808, DOI 10.1038/ajg.2010.232
   Lee P, 2007, OPHTHALMOLOGY, V114, P403, DOI 10.1016/j.ophtha.2006.11.021
   MEHMET B, 2009, J OPTOM, V2, P138
   Monestam E, 2004, AM J OPHTHALMOL, V137, P145, DOI 10.1016/S0002-9394(03)00900-0
   Rosen E, 2009, EYE, V23, P1120, DOI 10.1038/eye.2008.203
   Syam PP, 2004, EYE, V18, P59, DOI 10.1038/sj.eye.6700521
   *US BUR CENS, 65 YEARS POP 2000 CE
   *US BUR CENS, PROJ TOT RES POP 5 Y
   *US DEP VET AFF, VA INF RES CTR BEN I
NR 19
TC 13
Z9 13
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2011
VL 118
IS 7
BP 1229
EP 1235
DI 10.1016/j.ophtha.2010.11.023
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 786JL
UT WOS:000292303000002
PM 21388686
DA 2022-11-30
ER

PT J
AU Zhu, DH
   Deng, XM
   Spee, C
   Sonoda, S
   Hsieh, CL
   Barron, E
   Pera, M
   Hinton, DR
AF Zhu, Danhong
   Deng, Xuemei
   Spee, Christine
   Sonoda, Shozo
   Hsieh, Chih-Lin
   Barron, Ernesto
   Pera, Martin
   Hinton, David R.
TI Polarized Secretion of PEDF from Human Embryonic Stem Cell-Derived RPE
   Promotes Retinal Progenitor Cell Survival
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; CHOROIDAL NEOVASCULARIZATION; RETINOBLASTOMA CELLS;
   SPEMANN ORGANIZER; HEAD INDUCTION; ROYAL-COLLEGE; IN-VITRO; RCS RATS
AB PURPOSE. Human embryonic stem cell- derived RPE (hES-RPE) transplantation is a promising therapy for atrophic age-related macular degeneration (AMD); however, future therapeutic approaches may consider co-transplantation of hES-RPE with retinal progenitor cells (RPCs) as a replacement source for lost photoreceptors. The purpose of this study was to determine the effect of polarization of hES-RPE monolayers on their ability to promote survival of RPCs.
   METHODS. The hES-3 cell line was used for derivation of RPE. Polarization of hES-RPE was achieved by prolonged growth on permeable inserts. RPCs were isolated from 16- to 18-week-gestation human fetal eyes. ELISA was performed to measure pigment epithelium-derived factor (PEDF) levels front conditioned media.
   RESULTS. Pigmented RPE-like cells appeared as early as 4 weeks in culture and were subcultured at 8 weeks. Differentiated hES-RPE had a normal chromosomal karyotype. Phenotypically polarized hES-RPE cells showed expression of RPE-specific genes. Polarized hES-RPE showed prominent expression of PEDF in apical cytoplasm and a marked increase in secretion of PEDE into the medium compared with nonpolarized culture. RPCs grown in the presence of supernatants from polarized hES-RPE showed enhanced survival, which was ablated by the presence of anti-PEDE antibody.
   CONCLUSIONS. hES-3 cells can be differentiated into functionally polarized hES-RPE cells that exhibit characteristics similar to those of native RPE. On polarization, hES-RPE cells secrete high levels of PEDF that can support RPC survival. These experiments suggest that polarization of hES-RPE would be an important feature for promotion of RPC survival in future cell therapy for atrophic AMD. (Invest Ophthalmol Vis Sci, 2011;52: 1585) DOI:10.1167/iovs.10-6413
C1 [Zhu, Danhong; Deng, Xuemei; Hinton, David R.] Univ So Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90089 USA.
   [Spee, Christine; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA.
   [Hsieh, Chih-Lin] Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA 90089 USA.
   [Pera, Martin] Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA.
   [Zhu, Danhong; Deng, Xuemei; Spee, Christine; Sonoda, Shozo; Barron, Ernesto; Hinton, David R.] Univ So Calif, Doheny Eye Inst, Los Angeles, CA 90089 USA.
   [Sonoda, Shozo] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 890, Japan.
C3 University of Southern California; University of Southern California;
   University of Southern California; University of Southern California;
   Doheny Eye Institute; University of Southern California; Kagoshima
   University
RP Hinton, DR (通讯作者)，Univ So Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90089 USA.
EM dhinton@usc.edu
RI PERA, MARTIN/A-9812-2012
OI PERA, MARTIN/0000-0001-6239-0428
FU California Institute for Regenerative Medicine [RS 1-00222-1,
   DR1-01444]; Arnold and Mabel Beckman Foundation
FX Supported in part by Grants RS 1-00222-1 and DR1-01444 from the
   California Institute for Regenerative Medicine and by the Arnold and
   Mabel Beckman Foundation.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Aramant RB, 2002, EXP EYE RES, V75, P115, DOI 10.1006/exer.2002.2001
   Aramant RB, 1999, INVEST OPHTH VIS SCI, V40, pS598
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bilak MM, 1999, J NEUROPATH EXP NEUR, V58, P719, DOI 10.1097/00005072-199907000-00006
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703
   Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.0.CO;2-M
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   da Cruz L, 2007, PROG RETIN EYE RES, V26, P598, DOI 10.1016/j.preteyeres.2007.07.001
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   De Marzo A, 2010, ADV EXP MED BIOL, V664, P621, DOI 10.1007/978-1-4419-1399-9_71
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dottori Mirella, 2008, V438, P19, DOI 10.1007/978-1-59745-133-8_3
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   ERIKSON J, 1982, P NATL ACAD SCI-BIOL, V79, P5611, DOI 10.1073/pnas.79.18.5611
   Gamm DM, 2008, STEM CELLS, V26, P3182, DOI 10.1634/stemcells.2008-0300
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Ikeda H, 2005, P NATL ACAD SCI USA, V102, P11331, DOI 10.1073/pnas.0500010102
   Jiang CH, 2010, MOL VIS, V16, P983
   Katz ML, 2005, MECH AGEING DEV, V126, P513, DOI 10.1016/j.mad.2004.11.004
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kojima T, 2006, MOL CELL BIOCHEM, V293, P63, DOI 10.1007/s11010-006-2680-0
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   KRILL AE, 1966, AM J OPHTHALMOL, V61, P1405, DOI 10.1016/0002-9394(66)90478-8
   LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   LEE E, BR J OPHTHALMOL
   Li H, 2006, EXP EYE RES, V83, P824, DOI 10.1016/j.exer.2006.04.014
   Libby RT, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-108
   Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Lund RD, 2001, PROG RETIN EYE RES, V20, P415, DOI 10.1016/S1350-9462(01)00003-9
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   MCCONNELL DG, 1965, J CELL BIOL, V27, P459, DOI 10.1083/jcb.27.3.459
   Meyer JS, 2009, P NATL ACAD SCI USA, V106, P16698, DOI 10.1073/pnas.0905245106
   Miyazaki M, 2003, GENE THER, V10, P1503, DOI 10.1038/sj.gt.3302028
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7
   Nistor G, 2010, J NEUROSCI METH, V190, P63, DOI 10.1016/j.jneumeth.2010.04.025
   Palmieri D, 1999, EXP CELL RES, V247, P142, DOI 10.1006/excr.1998.4341
   Pang JJ, 2005, MOL VIS, V11, P152
   PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Raisler BJ, 2002, P NATL ACAD SCI USA, V99, P8909, DOI 10.1073/pnas.122247299
   Ramirez-Castillejo C, 2006, NAT NEUROSCI, V9, P331, DOI 10.1038/nn1657
   Reh TA, 2010, METHODS MOL BIOL, V636, P139, DOI 10.1007/978-1-60761-691-7_9
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sauve Y, 2002, NEUROSCIENCE, V114, P389, DOI 10.1016/S0306-4522(02)00271-3
   SCHATZ H, 1975, International Ophthalmology Clinics, V15, P169, DOI 10.1097/00004397-197501510-00014
   SEIGEL GM, 1994, GROWTH FACTORS, V10, P289, DOI 10.3109/08977199409010995
   Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1
   SHEEDLO H J, 1991, Journal of Neural Transplantation and Plasticity, V2, P55
   Sheedlo H J, 1989, Prog Clin Biol Res, V314, P645
   Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598
   SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0
   SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2008, INVEST OPHTH VIS SCI, V49, P1210, DOI 10.1167/iovs.07-0667
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   West EL, 2009, PROG BRAIN RES, V175, P3, DOI 10.1016/S0079-6123(09)17501-5
   West EL, 2010, STEM CELLS, V28, P1997, DOI 10.1002/stem.520
   Zhou JM, 2008, CELL BIOL INT, V32, P80, DOI 10.1016/j.cellbi.2007.08.015
   Zhu DH, 2010, VISION RES, V50, P643, DOI 10.1016/j.visres.2009.09.002
NR 76
TC 64
Z9 66
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2011
VL 52
IS 3
BP 1573
EP 1585
DI 10.1167/iovs.10-6413
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 742SR
UT WOS:000288965300045
OA Green Published
DA 2022-11-30
ER

PT J
AU Viiri, J
   Hyttinen, JMT
   Ryhanen, T
   Rilla, K
   Paimela, T
   Kuusisto, E
   Siitonen, A
   Urtti, A
   Salminen, A
   Kaarniranta, K
AF Viiri, Johanna
   Hyttinen, Juha M. T.
   Ryhanen, Tuomas
   Rilla, Kirsi
   Paimela, Tuomas
   Kuusisto, Erkki
   Siitonen, Ari
   Urtti, Arto
   Salminen, Antero
   Kaarniranta, Kai
TI p62/sequestosome 1 as a regulator of proteasome inhibitor-induced
   autophagy in human retinal pigment epithelial cells
SO MOLECULAR VISION
LA English
DT Article
ID INNATE IMMUNITY SYSTEM; BINDING PROTEIN P62; HEAT-SHOCK PROTEINS;
   OXIDATIVE STRESS; SEQUESTOSOME 1/P62; DRUSEN FORMATION; UBIQUITIN;
   HSP70; DEGRADATION; ACTIVATION
AB Purpose: The pathogenesis of age-related macular degeneration involves impaired protein degradation in retinal pigment epithelial (RPE) cells. The ubiquitin-proteasome pathway and the lysosomal pathway including autophagy are the major proteolytic systems in eukaryotic cells. Prior to proteolysis, heat shock proteins (HSPs) attempt to refold stress-induced misfolded proteins and thus prevent the accumulation of cytoplasmic protein aggregates. Recently, p62/sequestosome 1 (p62) has been shown to be a key player linking the proteasomal and lysosomal clearance systems. In the present study, the functional roles of p62 and HSP70 were evaluated in conjunction with proteasome inhibitor-induced autophagy in human RPE cells (ARPE-19).
   Methods: The p62, HSP70, and ubiquitin protein levels and localization were analyzed by western blotting and immunofluorescense. Confocal and transmission electron microscopy were used to detect cellular organelles and to evaluate the morphological changes. The p62 and HSP70 levels were modulated using RNA interference and overexpression techniques. Cell viability was measured by colorimetric assay.
   Results: Proteasome inhibition evoked the accumulation of perinuclear aggregates that strongly colocalized with p62 and HSP70. The p62 perinuclear accumulation was time-and concentration-dependent after MG-132 proteasome inhibitor loading. The silencing of p62, rather than Hsp70, evoked suppression of autophagy, when related to decreased LC3-II levels after bafilomycin treatment. In addition, the p62 silencing decreased the ubiquitination level of the perinuclear aggregates. Recently, we showed that hsp70 mRNA depletion increased cell death in ARPE-19 cells. Here, we demonstrate that p62 mRNA silencing has similar effects on cellular viability.
   Conclusions: Our findings open new avenues for understanding the mechanisms of proteolytic processes in retinal cells, and could be useful in the development of novel therapies targeting p62 and HSP70.
C1 [Viiri, Johanna; Hyttinen, Juha M. T.; Ryhanen, Tuomas; Paimela, Tuomas; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Rilla, Kirsi] Univ Eastern Finland, Inst Biomed, Dept Anat, Kuopio, Finland.
   [Kuusisto, Erkki; Siitonen, Ari; Salminen, Antero] Univ Eastern Finland, Inst Clin Med, Dept Neurol, Kuopio, Finland.
   [Urtti, Arto] Univ Helsinki, Fac Pharm, Ctr Drug Res, Helsinki, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Eastern Finland; University of Helsinki; Kuopio University Hospital;
   University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Kuopio, Dept Ophthalmol, POB 1627, FIN-70211 Kuopio, Finland.
EM Kai.Kaarniranta@uef.fi
OI Hyttinen, Juha/0000-0002-3414-4032; Kaarniranta,
   Kai/0000-0003-2600-8679; Rilla, Kirsi/0000-0002-7862-5727
FU Academy of Finland; Emil Aaltonen Foundation; Finnish Cultural
   Foundation; Finnish Eye Foundation; Finnish Eye and Tissue Bank
   Foundation; Finnish Funding Agency for Technology and Innovation;
   Paivikki and Sakari Sohlberg Foundation
FX This work was supported by the Academy of Finland, the Emil Aaltonen
   Foundation, the Finnish Cultural Foundation and its North Savo Fund, the
   Finnish Eye Foundation, the Finnish Eye and Tissue Bank Foundation, the
   Finnish Funding Agency for Technology and Innovation and the Paivikki
   and Sakari Sohlberg Foundation. The authors thank Anne Kontkanen, Sunna
   Lappalainen and Tapio Nuutinen for technical assistance and Dr. Ewen
   MacDonald for checking the language.
CR Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   Amadio M, 2008, CURR PHARM DESIGN, V14, P2651, DOI 10.2174/138161208786264052
   Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Calderwood SK, 2009, GERONTOLOGY, V55, P550, DOI 10.1159/000225957
   Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552
   Daugaard M, 2007, CANCER RES, V67, P2559, DOI 10.1158/0008-5472.CAN-06-4121
   Ding WX, 2008, AUTOPHAGY, V4, P141, DOI 10.4161/auto.5190
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9
   Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0
   Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200
   INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P
   Kaarniranta K, 2005, NEUROSCI LETT, V382, P185, DOI 10.1016/j.neulet.2005.03.009
   Kaarniranta K, 1998, P NATL ACAD SCI USA, V95, P2319, DOI 10.1073/pnas.95.5.2319
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Klettner A, 2004, DRUG NEWS PERSPECT, V17, P299, DOI 10.1358/dnp.2004.17.5.829033
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Kurz T, 2009, AUTOPHAGY, V5, P93, DOI 10.4161/auto.5.1.7248
   Kuusisto E, 2002, NEUROPATH APPL NEURO, V28, P228, DOI 10.1046/j.1365-2990.2002.00394.x
   Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009
   Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Moseley PL, 1997, J APPL PHYSIOL, V83, P1413, DOI 10.1152/jappl.1997.83.5.1413
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Paul S, 2008, BIOESSAYS, V30, P1172, DOI 10.1002/bies.20852
   Petrovski G, 2007, AUTOPHAGY, V3, P509
   Rajawat YS, 2009, AGEING RES REV, V8, P199, DOI 10.1016/j.arr.2009.05.001
   Rusten TE, 2010, NAT CELL BIOL, V12, P207, DOI 10.1038/ncb0310-207
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Ryhanen T, 2008, EUR J PHARMACOL, V584, P229, DOI 10.1016/j.ejphar.2008.02.010
   Salminen A, 2008, AGEING RES REV, V7, P83, DOI 10.1016/j.arr.2007.09.002
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Sambrook J, 1989, MOL CLONING LABORATO, p1 25
   Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8
   Seibenhener ML, 2007, FEBS LETT, V581, P175, DOI 10.1016/j.febslet.2006.12.027
   Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6
NR 53
TC 63
Z9 65
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 27
PY 2010
VL 16
IS 154
BP 1399
EP 1414
PG 16
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 643GQ
UT WOS:000281284000001
PM 20680098
DA 2022-11-30
ER

PT J
AU Xu, XR
   Zou, YH
   Chiou, GCY
AF Xu, Xin-Rong
   Zou, Yan-Hong
   Chiou, George C. Y.
TI Effect of D-Timolol and L-Timolol on rat experimental choroidal
   neovascularization in vivo and endothelial cells in vitro
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE D-Timolol; L-Timolol; choroidal neovascularization; rat
ID AGE-RELATED MACULOPATHY; BLOOD-FLOW; PREVALENCE
AB AIM: Impairment of choroidal perfusion was found in age-related macular degeneration(AMD) patients. We postulated that vasoactive agents, which can reduce choroidal blood flow resistance, might prevent the development of choroidal neovascularization (CNV). D-Timolol and L-Timolol are hypotensive agents used in cardiovascular and glaucoma therapy. Their effects on laser-induced experimental CNV rat model and human umbilical vein endothelial cells (HUVEC) were thus evaluated.
   METHODS: Male Brown Norway rats were anesthetized to receive Nd:YAG laser to break the Bruch's membrane. D-Timolol and L-Timolol were given once daily through intraperitoneal injection after laser treatment for 4 weeks. Fluorescein angiography(FA) was performed on 2 weeks and 4 weeks. HUVEC were tested by proliferation assay and adhesion assay with D-Timolol and L-Timolol at different concentrations.
   RESULTS: D-Timolol reduced the fluorescein leakage to 83% of the control group in laser-induced rat's CNV model at a dosage of 15mg/ (kg .d). L-Timolol had no effect on CNV formation even at a higher dosage of 20mg/ (kg .d). D-Timolol inhibited the endothelial cells proliferation significantly by 300mg/L. L-Timolol also significantly inhibited the cell proliferation at 1 000mg/L. But at a lower dose such as 300mg/L, no significant inhibitory effect was found. Both drugs showed no effect on cell adhesion function in cell culture experiments.
   CONCLUSION: D-Timolol was found to prevent CNV development in laser-induced model in vivo and inhibit vascular endothelial cells proliferation in vitro. L-Timolol had no effect on cell proliferation at the same dose, and neither on rat CNV model. The results indicate these two isomers have different functions on rat's CNV prevention and on HUVEC cell proliferation.
C1 [Chiou, George C. Y.] Texas A&M Univ, Inst Ocular Pharmacol, Syst Hlth Sci Ctr, College Stn, TX 77843 USA.
   Texas A&M Univ, Dept Med Pharmacol & Toxicol, Coll Med, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center; Texas A&M University System; Texas A&M
   University College Station
RP Chiou, GCY (通讯作者)，Texas A&M Univ, Inst Ocular Pharmacol, Syst Hlth Sci Ctr, College Stn, TX 77843 USA.
EM chiou@medicine.tamhsc.edu
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   CHIOU GCY, 1983, CURR EYE RES, V2, P507
   CHIOU GCY, 1992, J OCUL PHARMACOL, V8, P183, DOI 10.1089/jop.1992.8.183
   CHIOU GCY, 1986, OPHTHALMIC RES, V18, P265, DOI 10.1159/000265445
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   HACKETT SF, 1987, CELL BIOL INT REP, V11, P279, DOI 10.1016/0309-1651(87)90089-0
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LIU JHK, 1983, INVEST OPHTH VIS SCI, V24, P1276
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   YAN HY, 1987, OPHTHALMIC RES, V19, P45, DOI 10.1159/000265470
NR 10
TC 0
Z9 0
U1 0
U2 3
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2008
VL 1
IS 3
BP 208
EP 211
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V13QY
UT WOS:000207682500005
DA 2022-11-30
ER

PT J
AU Rohrer, B
   Demos, C
   Frigg, R
   Grimm, C
AF Rohrer, Barbel
   Demos, Christina
   Frigg, Rico
   Grimm, Christian
TI Classical complement activation and acquired immune response pathways
   are not essential for retinal degeneration in the rdl mouse
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE retinal degeneration; immune response; rd1; SCID; Rag1(-/-); complement
   system
ID PHOTORECEPTOR CELL-DEATH; FACTOR-H POLYMORPHISM; MICROGLIA; GENE; MICE;
   C1Q; EXPRESSION; MULTIPLE; IDENTIFICATION; AUTOIMMUNITY
AB Misregulation of the innate immune response and other immune-related processes have been suggested to play a critical role in the pathogenesis of a number of different neurodegenerative diseases, including age related macular degeneration. In an animal model for photoreceptor degeneration, several genes of the innate and acquired immune system were found to be differentially regulated in the retina during the degenerative process. In addition to this differential regulation of individual genes, we found that in the rd1 retina a significantly higher number of genes involved in immune-related responses were expressed at any given time during the degenerative period. The peak of immune-related gene expression was at postnatal day 14, coinciding with the peak of photoreceptor apoptosis in the rd1 mouse. We directly tested the potential involvement of acquired and innate immune responses in initiation and progression of photoreceptor degeneration by analyzing double mutant animals. Retinal morphology and photoreceptor apoptosis of rd1 mice on a SCID genetic background (no mature T- and B-cells) or in combination with a RAG1 (no functional B- and T-cells) or a Clq alpha (no functional classical complement activation pathway) knockout was followed during the degenerative process using light microscopy or TUNEL staining, respectively. Although complement factor Clq alpha was highly up-regulated in the rd1 retina concomitantly with the degenerative process, lack of this protein did not protect the rd1 retina. Similarly, retinal degeneration and photoreceptor apoptosis appeared to proceed normally in the rd1 mouse lacking functional B- and T-cells. Our results suggest that both, the classical complement system of innate immunity and a functional acquired immune response are not essential for the degenerative process in the rd1 mouse retina. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
   Med Univ S Carolina, Dept Neurosci, Div Res, Charleston, SC 29425 USA.
   Univ Zurich, Ctr Integrat Human Physiol, Univ Eye Clin Zurich, Lab Retinal Cell Biol, CH-8091 Zurich, Switzerland.
   Univ Zurich, Ctr Neurosci, CH-8091 Zurich, Switzerland.
C3 Medical University of South Carolina; Medical University of South
   Carolina; University of Zurich; Zurich Center Integrative Human
   Physiology (ZIHP); University of Zurich
RP Rohrer, B (通讯作者)，Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave,SEI 511, Charleston, SC 29425 USA.
EM rohrer@musc.edu
OI Grimm, Christian/0000-0001-9318-4352
FU NEI NIH HHS [EY014793, R01 EY013520, R24 EY014793, EY013520] Funding
   Source: Medline; NATIONAL EYE INSTITUTE [R01EY013520, R24EY014793]
   Funding Source: NIH RePORTER
CR Acosta ML, 2005, MOL VIS, V11, P717
   Adler R, 1999, MOL VIS, V5
   Andrieu-Soler C, 2005, MOL VIS, V11
   BARNUM SR, 1995, CRIT REV ORAL BIOL M, V6, P132, DOI 10.1177/10454411950060020301
   Barnum SR, 2002, IMMUNOL RES, V26, P7, DOI 10.1385/IR:26:1-3:007
   Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004
   Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56
   Botto M, 2002, IMMUNOBIOLOGY, V205, P395, DOI 10.1078/0171-2985-00141
   Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327
   Crusio WE, 1996, TRENDS NEUROSCI, V19, P186, DOI 10.1016/S0166-2236(96)20023-2
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Egensperger R, 1996, DEV BRAIN RES, V97, P1, DOI 10.1016/S0165-3806(96)00119-8
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   FARBER DB, 1995, INVEST OPHTH VIS SCI, V36, P263
   Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4
   Fox DA, 1999, ANN NY ACAD SCI, V893, P282, DOI 10.1111/j.1749-6632.1999.tb07837.x
   Gass P, 1998, LEARN MEMORY, V5, P274
   Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hafezi F, 2000, BRIT J OPHTHALMOL, V84, P922, DOI 10.1136/bjo.84.8.922
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holers VM, 2000, IMMUNOPHARMACOLOGY, V49, P125, DOI 10.1016/S0162-3109(00)80298-2
   Hughes EH, 2004, EXP EYE RES, V78, P1077, DOI 10.1016/j.exer.2004.02.002
   Hughes EH, 2003, INVEST OPHTH VIS SCI, V44, P2229, DOI 10.1167/iovs.02-0824
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuehn MH, 2006, EXP EYE RES, V83, P620, DOI 10.1016/j.exer.2006.03.002
   Lathe R, 1996, TRENDS NEUROSCI, V19, P183, DOI 10.1016/S0166-2236(96)20022-0
   Leveillard T, 2004, NAT GENET, V36, P755, DOI 10.1038/ng1386
   Lohr HR, 2006, EXP EYE RES, V83, P380, DOI 10.1016/j.exer.2006.01.014
   LOLLEY RN, 1974, J NEUROCHEM, V22, P701, DOI 10.1111/j.1471-4159.1974.tb04283.x
   MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G
   Nally JE, 2005, INFECT IMMUN, V73, P7014, DOI 10.1128/IAI.73.10.7014-7017.2005
   NONOYAMA S, 1993, J IMMUNOL, V150, P3817
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   PROVIS JM, 1995, GLIA, V14, P243, DOI 10.1002/glia.440140402
   Provis JM, 1996, PERSPECT DEV NEUROBI, V3, P213
   Reme CE, 2003, DOC OPHTHALMOL, V106, P25, DOI 10.1023/A:1022423724376
   Rohrer B, 2004, J BIOL CHEM, V279, P41903, DOI 10.1074/jbc.M405085200
   Roque RS, 1996, INVEST OPHTH VIS SCI, V37, P196
   Sahel Jose-Alain, 2005, Retina, V25, pS38, DOI 10.1097/00006982-200512001-00015
   Schafer MKH, 2000, J IMMUNOL, V164, P5446, DOI 10.4049/jimmunol.164.10.5446
   SHEEDLO HJ, 1995, DEV BRAIN RES, V85, P171, DOI 10.1016/0165-3806(94)00203-C
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Streit WJ, 2005, NEUROL RES, V27, P685, DOI 10.1179/016164105X49463
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Zeiss CJ, 2004, INVEST OPHTH VIS SCI, V45, P971, DOI 10.1167/iovs.03-0301
   Zeng HY, 2005, INVEST OPHTH VIS SCI, V46, P2992, DOI 10.1167/iovs.05-0118
NR 55
TC 20
Z9 20
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2007
VL 84
IS 1
BP 82
EP 91
DI 10.1016/j.exer.2006.08.017
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123JP
UT WOS:000243292500011
PM 17069800
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wu, KHC
   Madigan, MC
   Billson, FA
   Penfold, PL
AF Wu, KHC
   Madigan, MC
   Billson, FA
   Penfold, PL
TI Differential expression of GFAP in early v late AMD: a quantitative
   analysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FIBRILLARY ACIDIC PROTEIN; EPITHELIUM-DERIVED FACTOR; AGE-RELATED
   MACULOPATHY; INTERMEDIATE-FILAMENT EXPRESSION; RETINAL-PIGMENT
   EPITHELIUM; MULLER CELL CHANGES; GENE-EXPRESSION; GROWTH-FACTORS;
   ASTROCYTES; PROLIFERATION
AB Background/aims: Glial fibrillary acidic protein (GFAP) is an established indicator of retinal stress; its expression in retinal astrocytes and Muller cells has been demonstrated to be modulated by cytokines and retinal pathology, including age related macular degeneration (AMD). This study aims to quantify the modulation of GFAP expression in retinas with drusen and atrophic AMD versus normal age matched controls.
   Methods: Following a histopathological survey, 17 donor retinas were classified into four groups: drusen (n=5), geographic atrophy (GA) (n=6), aged normal (n=3), and young normal (n=3). Paramacular cryosections were immunolabelled with GFAP antibody, examined by confocal microscopy, and quantified by NIH digital image analysis. Groups were matched for potential confounding factors including age, sex, and postmortem delay.
   Results: A significant increase in GFAP immunolabelling of macroglia was noted in aged normal compared with young normal retinas (p<0.04). Upregulation of GFAP immunoreactivity involving astrocytes was observed in drusen retinas compared with control retinas (p<0.03). GFAP was also upregulated in retinas with GA compared with controls (p<0.05) and in retinas with GA compared with drusen (p<0.04), both involving Muller cells. Discrete regions of GFAP upregulation in Muller cells were associated with drusen formation. In GA specimens atrophied retinal pigment epithelium (RPE) was substituted by GFAP immunoreactive Muller cell processes (gliosis).
   Conclusion: This study provides a quantitative assessment of GFAP modulation in ageing and AMD affected retinas. Morphological observations were consistent with quantitative analyses indicating differential modulation of GFAP immunoreactivity in inner and outer retina. Upmodulation of GFAP in inner retina and astroglial processes was predominantly associated with drusen, while in outer retina Muller glia upmodulation of GFAP was associated with disruption of the RPE and blood-retinal barrier.
C1 Univ Sydney, Dept Clin Ophthalmol, Save Sight Inst, Sydney, NSW 2006, Australia.
C3 University of Sydney
RP Penfold, PL (通讯作者)，Sydney Eye Hosp, Dept Clin Ophthalmol, Save Sight Inst, GPO Box 4337, Sydney, NSW 2001, Australia.
EM ppenfold@eye.usyd.edu.au
CR Adler R, 1999, MOL VIS, V5
   BENVENISTE EN, 1992, CHEM IMMUNOL, V52, P106
   BIGNAMI A, 1979, EXP EYE RES, V28, P63
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Campochiaro P.A., 1999, MOL VIS, V5, P24
   Cao W, 2001, EXP EYE RES, V72, P591, DOI 10.1006/exer.2001.0990
   CHAKRABARTI S, 1997, DIABETES S1, V46, pA71
   Cotrina ML, 2002, J NEUROSCI RES, V67, P1
   DILORETO DA, 1995, BRAIN RES, V698, P1, DOI 10.1016/0006-8993(95)00647-9
   DREHER Z, 1992, J COMP NEUROL, V323, P59, DOI 10.1002/cne.903230106
   Dyer MA, 2000, NAT NEUROSCI, V3, P873, DOI 10.1038/78774
   EISENFELD AJ, 1984, INVEST OPHTH VIS SCI, V25, P1321
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gomes FCA, 1999, BRAZ J MED BIOL RES, V32, P619, DOI 10.1590/S0100-879X1999000500016
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   HOLLANDER H, 1991, J COMP NEUROL, V313, P587, DOI 10.1002/cne.903130405
   HUMPHREY MF, 1993, J COMP NEUROL, V334, P545, DOI 10.1002/cne.903340404
   Jablonski MM, 2000, GLIA, V32, P192, DOI 10.1002/1098-1136(200011)32:2<192::AID-GLIA80>3.0.CO;2-6
   Jablonski MM, 2000, J NEUROSCI, V20, P7149
   Jablonski MM, 2001, GLIA, V35, P14, DOI 10.1002/glia.1066
   JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   LAPING NJ, 1994, BRAIN PATHOL, V4, P259, DOI 10.1111/j.1750-3639.1994.tb00841.x
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046
   LEWIS GP, 1992, J NEUROSCI, V12, P3968
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   Mizutani M, 1998, DIABETES, V47, P445, DOI 10.2337/diabetes.47.3.445
   Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0
   Nishiyama T, 2000, TOHOKU J EXP MED, V191, P221, DOI 10.1620/tjem.191.221
   NORK TM, 1986, ARCH OPHTHALMOL-CHIC, V104, P1383, DOI 10.1001/archopht.1986.01050210137041
   OKADA M, 1990, GRAEF ARCH CLIN EXP, V228, P467, DOI 10.1007/BF00927264
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pure DG, 1995, PROG RETIN EYE RES, V15, P89
   RAMIREZ JM, 1994, VISION RES, V34, P1935, DOI 10.1016/0042-6989(94)90024-8
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Reilly JF, 1998, GLIA, V22, P202, DOI 10.1002/(SICI)1098-1136(199802)22:2<202::AID-GLIA11>3.0.CO;2-1
   Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARTHY PV, 1998, INVEST OPHTH VIS SCI, V39, pS452
   SHAW G, 1984, EUR J CELL BIOL, V33, P95
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   TOUT S, 1993, NEUROSCIENCE, V55, P291, DOI 10.1016/0306-4522(93)90473-S
   VERNADAKIS A, 1986, ASTROCYTES PHYSL BIO, P377
   Vilaplana J, 1999, J NEUROSCI METH, V88, P181, DOI 10.1016/S0165-0270(99)00016-3
   Wang X, 2000, EXP BRAIN RES, V132, P476, DOI 10.1007/s002210000360
   Wu KHC, 2002, CLIN EXP OPHTHALMOL, V30, P200, DOI 10.1046/j.1442-9071.2002.00515.x
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 52
TC 95
Z9 97
U1 1
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2003
VL 87
IS 9
BP 1159
EP 1166
DI 10.1136/bjo.87.9.1159
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 713EB
UT WOS:000184842500024
PM 12928288
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Shen, WY
   Garrett, KL
   Wang, CG
   Zhang, K
   Ma, ZZ
   Constable, IJ
   Rakoczy, PE
AF Shen, WY
   Garrett, KL
   Wang, CG
   Zhang, K
   Ma, ZZ
   Constable, IJ
   Rakoczy, PE
TI Preclinical evaluation of a phosphorothioate oligonucleotide in the
   retina of rhesus monkey
SO LABORATORY INVESTIGATION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   INTERNAL RIBOSOME ENTRY; FACTOR MESSENGER-RNA; MACULAR DEGENERATION;
   ANTISENSE OLIGONUCLEOTIDE; PROLIFERATIVE RETINOPATHY; INTRAVITREAL
   INJECTION; HUMAN CYTOMEGALOVIRUS; PHOTODYNAMIC THERAPY
AB Overexpression of vascular endothelial growth factor (VEGF) has been strongly implicated in the development of choroidal neovascularization (CNV) in patients with age-related macular degeneration. In this study, a phosphorothioate oligonucleotide (PS-oligo) targeting both human and rat VEGF(165) genes upstream of the translation initiation code, named DS135 in this study, was evaluated for its uptake dynamics and retinal tolerance after intravitreal (IV) and subretinal (SR) injections in the rhesus monkey. Intravitreal and SR injections of a fluorescent-labeled DS135 (FL-DS135) resulted in both dose- and time-dependent uptake and persistence, and FL-DS135 remained detectable in the retina for at least 3 weeks after injection. Ophthalmic examination showed transient vitreous haze after IV delivery of a high dose but not with a low dose of FL-DS135. Histologic examination showed no evidence of retinal degeneration with respect to IV delivery. After SIR delivery, however, dose-related cellular infiltration, transient residual fluid, and slight distortion of the neuroretina were observed. The biologic efficacy of DS135 was further assessed in a laser-induced CNV model, and development of CNV was determined by fluorescein angiography and histologic examination. Incomplete inhibition of CNV formation was observed after IV and SR injection of DS135, but no statistically significant difference was achieved when compared with dose-matched control of PS-oligo. Analysis of fluorescein angiogram and histologic examination showed less than 30% incidence of CNV development in this monkey model. Our study demonstrated that PS-oligos can be successfully introduced into the retina, although with potential limitations, after SR delivery. DS135, a PS-oligo targeting the VEGF gene upstream of the translation initiation code, partially inhibited CNV formation. An improved CNV model is necessary for further confirmation of the full therapeutic potency of DS135 before clinical application.
C1 Univ Western Australia, Ctr Ophthalmol & Visual Sci, Perth, WA 6009, Australia.
   Lions Eye Inst, Dept Mol Ophthalmol, Perth, WA 6009, Australia.
   Gen Hosp, Chinese Peoples Liberat Army, Dept Ophthalmol, Beijing, Peoples R China.
C3 University of Western Australia; Lions Eye Institute; University of
   Western Australia; Chinese People's Liberation Army General Hospital
RP Rakoczy, PE (通讯作者)，Lions Eye Inst, Dept Mol Ophthalmol, 2 Verdun St, Nedlands, WA 6009, Australia.
OI constable, ian/0000-0002-2140-6478
CR Bass E, 2000, AM J OPHTHALMOL, V130, P408
   BLACK LE, 1994, ANTISENSE RES DEV, V4, P299, DOI 10.1089/ard.1994.4.299
   Bressler NM, 2000, AM J OPHTHALMOL, V130, P387
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Detrick B, 2001, INVEST OPHTH VIS SCI, V42, P163
   Dvorchik BH, 2000, DRUG METAB DISPOS, V28, P1255
   FloresAguilar M, 1997, J INFECT DIS, V175, P1308, DOI 10.1086/516461
   Fong DS, 2000, OPHTHALMOLOGY, V107, P2314
   Garrett KL, 2001, J GENE MED, V3, P373, DOI 10.1002/jgm.197
   Hangai M, 1998, ARCH OPHTHALMOL-CHIC, V116, P342, DOI 10.1001/archopht.116.3.342
   Ho SP, 1998, MOL BRAIN RES, V62, P1
   Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Leeds JM, 1997, DRUG METAB DISPOS, V25, P921
   Leeds JM, 1998, DRUG METAB DISPOS, V26, P670
   Lip PL, 2000, INVEST OPHTH VIS SCI, V41, P2115
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Mendoza JL, 2001, EDUC PSYCHOL MEAS, V61, P650, DOI 10.1177/00131640121971419
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Ogata N, 1999, CURR EYE RES, V18, P261, DOI 10.1076/ceyr.18.4.261.5358
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Rakoczy PE, 1996, ANTISENSE NUCLEIC A, V6, P207, DOI 10.1089/oli.1.1996.6.207
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shen WY, 1999, BRIT J OPHTHALMOL, V83, P852, DOI 10.1136/bjo.83.7.852
   Shen WY, 2000, GRAEF ARCH CLIN EXP, V238, P273, DOI 10.1007/s004170050353
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Shiraga F, 1998, Semin Ophthalmol, V13, P31, DOI 10.3109/08820539809066080
   Sone H, 1999, LIFE SCI, V65, P2573, DOI 10.1016/S0024-3205(99)00526-3
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515
   Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112
   Stone TW, 2000, AM J OPHTHALMOL, V130, P242, DOI 10.1016/S0002-9394(00)00495-5
   Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   ZHANG NL, 1993, INVEST OPHTH VIS SCI, V34, P2412
NR 45
TC 28
Z9 35
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2002
VL 82
IS 2
BP 167
EP 182
DI 10.1038/labinvest.3780409
PG 16
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 525AW
UT WOS:000174045900006
PM 11850530
OA Bronze
DA 2022-11-30
ER

PT J
AU Marquez-Tirado, B
   Gutierrez-Tenorio, J
   Tortajada, A
   Continente, LL
   Caravaca-Fontaan, F
   Malik, TH
   Montero, RR
   Elias, S
   Gonzalez, AS
   Fernandez-Juarez, G
   Sanchez-Corral, P
   Pickering, MC
   Praga, M
   de Cordoba, SR
   de Jorge, EG
AF Marquez-Tirado, Barbara
   Gutierrez-Tenorio, Josue
   Tortajada, Agustin
   Continente, Laura Lucientes
   Caravaca-Fontaan, Fernando
   Malik, Talat H.
   Montero, Raquel Roldan
   Elias, Sandra
   Gonzalez, Ana Saiz
   Fernandez-Juarez, Gema
   Sanchez-Corral, Pilar
   Pickering, Matthew C.
   Praga, Manuel
   Rodriguez de Cordoba, Santiago
   Goicoechea de Jorge, Elena
TI Factor H-Related Protein 1 Drives Disease Susceptibility and Prognosis
   in C3 Glomerulopathy
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
DE C3 glomerulopathy; complement; factor H-related protein 1; glomerular
   disease; disease susceptibility; prognosis; genetic renal disease
ID NEPHRITIC FACTORS; COMPLEMENT C3; PATHWAY; GLOMERULONEPHRITIS;
   DYSREGULATION; CONVERTASE; MUTATION; BETA-1H; CFHR1
AB Background C3 glomerulopathy (C3G) is a heterogeneous group of chronic renal diseases characterized predominantly by glomerular C3 deposition and complement dysregulation. Mutations in factor H-related (FHR) proteins resulting in duplicated dimerization domains are prototypical of C3G, although the underlying pathogenic mechanism is unclear.& nbsp;Methods Using in vitro and in vivo assays, we performed extensive characterization of an FHR-1 mutant with a duplicated dimerization domain. To assess the FHR-1 mutant's association with disease susceptibility and renal prognosis, we also analyzed CFHR1 copy number variations and FHR-1 plasma levels in two Spanish C3G cohorts and in a control population.& nbsp;Results Duplication of the dimerization domain conferred FHR-1 with an increased capacity to interact with C3-opsonized surfaces, which resulted in an excessive activation of the alternative pathway. This activation does not involve C3b binding competition with factor H. These findings support a scenario in which mutant FHR-1 binds to C3-activated fragments and recruits native C3 and C3b; this leads to formation of alternative pathway C3 convertases, which increases deposition of C3b molecules, overcoming FH regulation. This suggests that a balanced FHR-1/FH ratio is crucial to control complement amplification on opsonized surfaces. Consistent with this conceptual framework, we show that the genetic deficiency of FHR-1 or decreased FHR-1 in plasma confers protection against developing C3G and associates with better renal outcome.& nbsp;Conclusions Our findings explain how FHR-1 mutants with duplicated dimerization domains result in predisposition to C3G. They also provide a pathogenic mechanism that may be shared by other diseases, such as IgA nephropathy or age-related macular degeneration, and identify FHR-1 as a potential novel therapeutic target in C3G.
C1 [Caravaca-Fontaan, Fernando; Praga, Manuel] Univ Complutense Madrid, Res Inst Hosp Octubre 12 imas12, Dept Immunol, Madrid, Spain.
   [Malik, Talat H.] Res Inst Hosp 12 Octubre imas12, Madrid, Spain.
   [Montero, Raquel Roldan] Fdn Jimenez Diaz, Inst Invest Sanitaria, Madrid, Spain.
   [Elias, Sandra] Hosp Univ Ramon & Cajal, Nephrol Dept, Inst Ramon & Cajal Invest Sanitaria IRYCIS, Madrid, Spain.
   [Gonzalez, Ana Saiz] Imperial Coll London, Ctr Inflammatory Dis, London, England.
   [Fernandez-Juarez, Gema] Hosp Univ Ramon & Cajal, Pathol Anat, Madrid, Spain.
   [Sanchez-Corral, Pilar] Hosp Univ Fdn, Nephrol Dept, Alcorcon, Spain.
   [Praga, Manuel] Paz Univ Hosp, Hosp Paz Inst Hlth Res IdiPAZ, Ctr Biomed Network Res Rare Dis CIBERER, Madrid, Spain.
   [Rodriguez de Cordoba, Santiago] Univ Complutense Madrid, Dept Med, Madrid, Spain.
   [Goicoechea de Jorge, Elena] Ctr Biol Res, Rare Dis Networking Biomed Res Ctr, Madrid, Spain.
   [Goicoechea de Jorge, Elena] Univ Complutense Madrid, Dept Med, Ave Complutense S-N, Madrid 28040, Spain.
C3 Complutense University of Madrid; Fundacion Jimenez Diaz; Hospital
   Universitario Ramon y Cajal; Imperial College London; Hospital
   Universitario Ramon y Cajal; Alcorcon Foundation University Hospital;
   CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Complutense
   University of Madrid; Consejo Superior de Investigaciones Cientificas
   (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Complutense
   University of Madrid
RP de Jorge, EG (通讯作者)，Ctr Biol Res, Rare Dis Networking Biomed Res Ctr, Madrid, Spain.; de Jorge, EG (通讯作者)，Univ Complutense Madrid, Dept Med, Ave Complutense S-N, Madrid 28040, Spain.
EM egoicoec@ucm.es
RI Sánchez-Corral, Pilar/GLR-0387-2022
OI Saiz Gonzalez, Ana/0000-0001-7110-450X; LUCIENTES CONTINENTE,
   LAURA/0000-0001-5596-370X
FU Ministerio de Ciencia e Innovacion [RTI2018-095955-B-100,
   BES-2015-073833]; European Union [899163]; Autonomous Region of Madrid
   [S2017/BMD-3673]; Instituto de Salud Carlos III; European Union's
   European Regional Development Fund [PI19/01695, PI19/00970, PI19/01624];
   Wellcome Trust [212252/Z/18/Z]; Ministerio de Economia y Competitividad
   [PID2019-104912RB-100]
FX E. Goicoechea de Jorge is supported by Ministerio de Ciencia e
   Innovacion grant RTI2018-095955-B-100 and the European Union's Horizon
   2020 Framework Programme grant 899163. J. Gutierrez-Tenorio is supported
   by Ministerio de Ciencia e Innovacion grant BES-2015-073833. L.
   Lucientes Continente is supported by the Autonomous Region of Madrid
   grant S2017/BMD-3673. G. Fernandez-Juarez, P. Sanchez-Corral, B.
   Marquez-Tirado, and M. Praga are supported by the Instituto de Salud
   Carlos III and the European Union's European Regional Development Fund
   grants PI19/01695, PI19/00970, and PI19/01624, respectively. M.C.
   Pickering is a Wellcome Trust Senior Fellow in Clinical Science
   (212252/Z/18/Z). S. Rodriguez de Cordoba is supported by the Ministerio
   de Economia y Competitividad grant PID2019-104912RB-100 and Autonomous
   Region of Madrid grant S2017/BMD-3673.
CR Blaum BS, 2015, NAT CHEM BIOL, V11, P77, DOI [10.1038/NCHEMBIO.1696, 10.1038/nchembio.1696]
   Caravaca-Fontan F, 2020, CLIN J AM SOC NEPHRO, V15, P1287, DOI 10.2215/CJN.15241219
   Chen Q, 2014, J CLIN INVEST, V124, P145, DOI 10.1172/JCI71866
   Corvillo F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00886
   Csincsi AI, 2017, J IMMUNOL, V199, P292, DOI 10.4049/jimmunol.1600483
   Csincsi AI, 2015, J IMMUNOL, V194, P4963, DOI 10.4049/jimmunol.1403121
   de Jorge EG, 2018, J AM SOC NEPHROL, V29, P240, DOI 10.1681/ASN.2017050518
   de Jorge EG, 2013, P NATL ACAD SCI USA, V110, P4685, DOI 10.1073/pnas.1219260110
   Donadelli R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02329
   Dopler A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.615748
   Gale DP, 2010, LANCET, V376, P794, DOI 10.1016/S0140-6736(10)60670-8
   Gharavi AG, 2011, NAT GENET, V43, P321, DOI 10.1038/ng.787
   Hebecker M, 2012, J BIOL CHEM, V287, P19528, DOI 10.1074/jbc.M112.364471
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hou J, 2014, KIDNEY INT, V85, P450, DOI 10.1038/ki.2013.340
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jozsi M, 2015, TRENDS IMMUNOL, V36, P374, DOI 10.1016/j.it.2015.04.008
   Loeven MA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.676662
   Lores-Motta L, 2021, AM J HUM GENET, V108, P1367, DOI 10.1016/j.ajhg.2021.06.002
   Merinero HM, 2021, BLOOD, V138, P2185, DOI 10.1182/blood.2021012037
   Merinero HM, 2021, BLOOD, V137, P3484, DOI 10.1182/blood.2020010069
   Medjeral-Thomas NR, 2017, KIDNEY INT, V92, P942, DOI 10.1016/j.kint.2017.03.043
   PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257
   Pickering MC, 2013, KIDNEY INT, V84, P1079, DOI 10.1038/ki.2013.377
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Piras R, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.670727
   Sanchez-Corral P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01607
   Schramm EC, 2015, BLOOD, V125, P2359, DOI 10.1182/blood-2014-10-609073
   Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959
   Smith RJH, 2019, NAT REV NEPHROL, V15, P129, DOI 10.1038/s41581-018-0107-2
   Hidalgo MS, 2017, EUR J IMMUNOL, V47, P504, DOI 10.1002/eji.201646758
   Tortajada A, 2017, KIDNEY INT, V92, P953, DOI 10.1016/j.kint.2017.03.041
   Tortajada A, 2013, J CLIN INVEST, V123, P2434, DOI 10.1172/JCI68280
   WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268
   WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147
   Xiao X, 2016, MOL IMMUNOL, V77, P89, DOI 10.1016/j.molimm.2016.07.007
   Zhang YZ, 2012, CLIN J AM SOC NEPHRO, V7, P265, DOI 10.2215/CJN.07900811
   Zhao J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002079
NR 38
TC 5
Z9 5
U1 3
U2 4
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1401 H Street NW, Suite 900, WASHINGTON, DC 20005, UNITED STATES
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD JUN
PY 2022
VL 33
IS 6
BP 1137
EP 1153
DI 10.1681/ASN.2021101318
EA MAY 2022
PG 17
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA 1Y4RX
UT WOS:000795742900001
PM 35545301
OA Bronze
DA 2022-11-30
ER

PT J
AU Richert, E
   Papenkort, J
   von der Burchard, C
   Klettner, A
   Arnold, P
   Lucius, R
   Brinkmann, R
   Framme, C
   Roider, J
   Tode, J
AF Richert, Elisabeth
   Papenkort, Julia
   von der Burchard, Claus
   Klettner, Alexa
   Arnold, Philipp
   Lucius, Ralph
   Brinkmann, Ralf
   Framme, Carsten
   Roider, Johann
   Tode, Jan
TI Selective retina therapy and thermal stimulation of the retina:
   different regenerative properties-implications for AMD therapy
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Selective retina therapy (SRT); Thermal stimulation of the retina (TSR);
   Age- related macular degeneration (AMD); Regeneration; Rejuvenation
ID CENTRAL SEROUS CHORIORETINOPATHY; RPE-CHOROID EXPLANTS; MACULAR
   DEGENERATION; PIGMENT EPITHELIUM; MICROPULSE LASER; BRUCHS MEMBRANE;
   EXPRESSION; CELLS; VEGF; METALLOPROTEINASES
AB Background Selective Retina Therapy (SRT), a photodisruptive micropulsed laser modality that selectively destroys RPE cells followed by regeneration, and Thermal Stimulation of the Retina (TSR), a stimulative photothermal continuous wave laser modality that leads to an instant sublethal temperature increase in RPE cells, have shown therapeutic effects on Age-related Macular Degeneration (AMD) in mice. We investigate the differences between both laser modalities concerning RPE regeneration. Methods For PCR array, 6 eyes of murine AMD models, apolipoprotein E and nuclear factor erythroid-derived 2- like 2 knock out mice respectively, were treated by neuroretina-sparing TSR or SRT. Untreated litter mates were controls. Eyes were enucleated either 1 or 7 days after laser treatment. For morphological analysis, porcine RPE/choroid organ cultures underwent the same laser treatment and were examined by calcein vitality staining 1 h and 1, 3 or 5 days after irradiation. Results TSR did not induce the expression of cell-mediators connected to cell death. SRT induced necrosis associated cytokines as well as inflammation 1 but not 7 days after treatment. Morphologically, 1 h after TSR, there was no cell damage. One and 3 days after TSR, dense chromatin and cell destruction of single cells was seen. Five days after TSR, there were signs of migration and proliferation. In contrast, 1 h after SRT a defined necrotic area within the laser spot was seen. This lesion was closed over days by migration and proliferation of adjacent cells. Conclusions SRT induces RPE cell death, followed by regeneration within a few days. It is accompanied by necrosis induced inflammation, RPE proliferation and migration. TSR does not induce immediate RPE cell death; however, migration and mitosis can be seen a few days after laser irradiation, not accompanied by necrosis-associated inflammation. Both might be a therapeutic option for the treatment of AMD.
C1 [Richert, Elisabeth; Papenkort, Julia; von der Burchard, Claus; Klettner, Alexa; Roider, Johann; Tode, Jan] Christian Albrechts Univ Kiel, Dept Ophthalmol, Univ Med Ctr, Kiel, Germany.
   [Arnold, Philipp] Friedrich Alexander Univ Erlangen Nurnberg, Nurnberg, Germany.
   [Lucius, Ralph] Christian Albrechts Univ Kiel, Inst Anat, Kiel, Germany.
   [Brinkmann, Ralf] Med Laser Ctr Lubeck, Lubeck, Germany.
   [Brinkmann, Ralf] Univ Lubeck, Inst Biomed Opt, Lubeck, Germany.
   [Framme, Carsten; Tode, Jan] Hannover Med Sch, Dept Ophthalmol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Erlangen Nuremberg; University of Kiel; University of Lubeck;
   Hannover Medical School
RP Tode, J (通讯作者)，Christian Albrechts Univ Kiel, Dept Ophthalmol, Univ Med Ctr, Kiel, Germany.; Tode, J (通讯作者)，Hannover Med Sch, Dept Ophthalmol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM tode.jan@mh-hannover.de
RI von der Burchard, Claus/GZG-4104-2022; Brinkmann, Ralf/E-6701-2012;
   Brinkmann, Ralf/HDL-7611-2022
OI Brinkmann, Ralf/0000-0002-0445-8102; Klettner, Alexa/0000-0002-2709-1059
FU Projekt DEAL; Helmut Ecker Stiftung, Germany
FX Open Access funding enabled and organized by Projekt DEAL. Research
   presented here was funded by Helmut Ecker Stiftung, Germany.
CR Ahir A, 2002, INVEST OPHTH VIS SCI, V43, P458
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baade A, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.11.118001
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Boehme MWJ, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2188-1
   Brinkmann R, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.061219
   Buttner M, 2021, GRAEF ARCH CLIN EXP, V259, P1401, DOI 10.1007/s00417-020-04999-9
   Chang DB, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.5.23
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Frizziero L, 2021, J PERS MED, V11, DOI 10.3390/jpm11050405
   Guymer RH, 2018, OPHTHALMOLOGY
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Jun S, 2018, EXP EYE RES
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kern K, 2018, EXP EYE RES, V170, P117, DOI 10.1016/j.exer.2018.02.013
   Kim M, 2021, LASER SURG MED, V53, P499, DOI 10.1002/lsm.23305
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klettner A, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108214
   Klettner A, 2019, METHODS MOL BIOL, V1834, P109, DOI 10.1007/978-1-4939-8669-9_8
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Lavinsky D, 2014, RETINA-J RET VIT DIS, V34, P87, DOI 10.1097/IAE.0b013e3182993edc
   Luttrull JK, 2020, CLIN OPHTHALMOL, V14, P2983, DOI 10.2147/OPTH.S268322
   Luttrull JK, 2014, RETINA-J RET VIT DIS, V34, P2010, DOI 10.1097/IAE.0000000000000177
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Neri S, 2001, CLIN DIAGN LAB IMMUN, V8, P1131, DOI 10.1128/CDLI.8.6.1131-1135.2001
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Park YG, 2017, GRAEF ARCH CLIN EXP, V255, P1375, DOI 10.1007/s00417-017-3672-3
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Povaay B., 2019, HIGH RESOLUTION IMAG
   Prasuhn M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112418
   Richert E, 2020, CYTOKINE X
   Richert E, 2021, LASER SURG MED, V53, P359, DOI 10.1002/lsm.23288
   Richert E, 2020, ADV MED SCI-POLAND, V65, P71, DOI 10.1016/j.advms.2019.11.003
   Richert E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23163
   Richert E, 2016, INVEST OPHTH VIS SCI, V57
   Roider J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1028
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   Roider J, 2010, GRAEF ARCH CLIN EXP, V248, P1263, DOI 10.1007/s00417-010-1356-3
   Schrader WF, 2006, OPHTHALMOLOGE, V103, P742, DOI 10.1007/s00347-006-1418-4
   Sramek C, 2011, INVEST OPHTH VIS SCI, V52, P1780, DOI 10.1167/iovs.10-5917
   Tode J, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.11
   Tode J, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.3.2
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011
   Verdina T, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041066
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yamamoto Manabu, 2020, Am J Ophthalmol Case Rep, V19, P100794, DOI 10.1016/j.ajoc.2020.100794
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhou LJ, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.682264
NR 57
TC 0
Z9 0
U1 2
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 30
PY 2021
VL 21
IS 1
AR 412
DI 10.1186/s12886-021-02188-8
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XF3RC
UT WOS:000723990400001
PM 34847865
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Liu, YV
   Konar, G
   Aziz, K
   Tun, SBB
   Hua, CHE
   Tan, BY
   Tian, J
   Luu, CD
   Barathi, VA
   Singh, MS
AF Liu, Ying, V
   Konar, Gregory
   Aziz, Kanza
   Tun, Sai Bo Bo
   Hua, Candice Ho Ee
   Tan, Bingyao
   Tian, Jing
   Luu, Chi D.
   Barathi, Veluchamy A.
   Singh, Mandeep S.
TI Localized Structural and Functional Deficits in a Nonhuman Primate Model
   of Outer Retinal Atrophy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; macular laser photocoagulation;
   nonhuman primate model; retinal atrophy; retinal transplantation
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; MACULAR DEGENERATION;
   BRUCHS MEMBRANE; CHOROIDAL NEOVASCULARIZATION; DARK ATROPHY; CELLS;
   EYES; RPE; LASER
AB PURPOSE. Cell-based therapy development for geographic atrophy (GA) in age-related macular degeneration (AMD) is hampered by the paucity of models of localized photore-ceptor and retinal pigment epithelium (RPE) degeneration. We aimed to characterize the structural and functional deficits in a laser-induced nonhuman primate model, including an analysis of the choroid.
   METHODS. Macular laser photocoagulation was applied in four macaques. Fundus photog-raphy, optical coherence tomography (OCT), dye angiography, and OCT-angiography were conducted over 4.5 months, with histological correlation. Longitudinal changes in spatially resolved macular dysfunction were measured using multifocal electroretinogra-phy (MFERG).
   RESULTS. Lesion features, depending on laser settings, included photoreceptor layer degeneration, inner retinal sparing, skip lesions, RPE elevation, and neovascularization. The intralesional choroid was degenerated. The normalized mean MFERG amplitude within lesions was consistently lower than control regions (0.94 +/- 0.35 vs. 1.10 +/- 0.27, P = 0.032 at month 1, 0.67 +/- 0.22 vs. 0.83 +/- 0.15, P = 0.0002 at month 2, and 0.97 +/- 0.31 vs. 1.20 +/- 0.21, P < 0.0001 at month 3.5). The intertest variation of mean MFERG amplitudes in rings 1 to 5 ranged from 13.0% to 26.0% in normal eyes.
   CONCLUSIONS. Laser application in this model caused localized outer retinal, RPE, and choriocapillaris loss. Localized dysfunction was apparent by MFERG in the first month after lesion induction. Correlative structure-function testing may be useful for research on the functional effects of stem cell-based therapy for GA. MFERG amplitude data should be interpreted in the context of relatively high intertest variability of the rings that correspond to the central macula. Sustained choroidal insufficiency may limit long-term subretinal graft viability in this model.
C1 [Liu, Ying, V; Konar, Gregory; Aziz, Kanza; Singh, Mandeep S.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
   [Tun, Sai Bo Bo; Hua, Candice Ho Ee; Tan, Bingyao; Barathi, Veluchamy A.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Tan, Bingyao] SERI NTU Adv Ocular Engn Stance, Singapore, Singapore.
   [Tian, Jing] Johns Hopkins Univ, Dept Biostat, Sch Publ Hlth, Baltimore, MD USA.
   [Luu, Chi D.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic, Australia.
   [Luu, Chi D.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Barathi, Veluchamy A.] Duke NUS Grad Med Sch, Acad Clin Program Ophthalmol, Singapore, Singapore.
   [Barathi, Veluchamy A.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
C3 Johns Hopkins University; Johns Hopkins Medicine; National University of
   Singapore; Singapore National Eye Center; Johns Hopkins University;
   Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; National University of Singapore; National
   University of Singapore
RP Singh, MS (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM singhcorrespauth@gmail.com
RI TUN, SAI BO BO/O-1085-2018; Tun, Sai Bo Bo/GRF-2470-2022
OI TUN, SAI BO BO/0000-0002-2013-8379; 
FU NIH [R01 EY033103-01]; Foundation Fighting Blindness
   [CD-RM-09180749-JHU]; Shulsky Foundation; Juliette RP Vision Foundation;
   NEI Core Grant [EY001765]; Joseph Albert Hekimian Fund; Singapore NMRC
   Centre Grant [NMRC/CG/M010/2017/PreClinical]
FX Supported by NIH R01 EY033103-01, the Foundation Fighting Blindness
   (Career Development Award CD-RM-09180749-JHU to MSS), The Shulsky
   Foundation, Juliette RP Vision Foundation, NEI Core Grant (EY001765),
   Joseph Albert Hekimian Fund, and Singapore NMRC Centre Grant
   (NMRC/CG/M010/2017/PreClinical).
CR Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Alabduljalil T, 2019, AM J OPHTHALMOL, V202, P79, DOI 10.1016/j.ajo.2019.02.007
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anger EM, 2004, EXP EYE RES, V78, P1117, DOI 10.1016/j.exer.2004.01.011
   Arrigo A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091425
   Augsburger AS, 2012, VET OPHTHALMOL, V15, P84, DOI 10.1111/j.1463-5224.2012.01052.x
   Ben M, 2017, SCI TRANSL MED, V9
   Ben M'Barek K, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119603
   Berger JW, 1997, LASER SURG MED, V20, P409, DOI 10.1002/(SICI)1096-9101(1997)20:4<409::AID-LSM6>3.0.CO;2-U
   Bhutto Imran A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD143, DOI 10.1167/iovs.18-24245
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bonilha VL, 2016, OPHTHALMIC GENET, V37, P150, DOI 10.3109/13816810.2014.958861
   Bouskila J, 2018, EXP EYE RES, V177, P55, DOI 10.1016/j.exer.2018.07.027
   Capuano V, 2016, BRIT J OPHTHALMOL, V100, P677, DOI 10.1136/bjophthalmol-2015-307169
   Chidlow G, 2013, INVEST OPHTH VIS SCI, V54, P2319, DOI 10.1167/iovs.12-11204
   Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1
   Coupland S, 2019, ACTA OPHTHALMOL, V97, DOI 10.1111/j.1755-3768.2019.5370
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   Dawson WW, 2008, VISION RES, V48, P360, DOI 10.1016/j.visres.2007.08.006
   Ding Y, 2017, EXP EYE RES, V159, P58, DOI 10.1016/j.exer.2017.03.009
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57, pOCT299, DOI 10.1167/iovs.15-18865
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   ELMOFTY A, 1978, EXP EYE RES, V27, P499, DOI 10.1016/0014-4835(78)90027-1
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fischer MD, 2012, DOC OPHTHALMOL, V125, P179, DOI 10.1007/s10633-012-9340-3
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Ghosn C, 2017, INVEST OPHTH VIS SCI, V58
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Grebe R, 2019, EXP EYE RES, V181, P252, DOI 10.1016/j.exer.2019.02.018
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Hadziahmetovic M, 2012, INVEST OPHTH VIS SCI, V53, P5231, DOI 10.1167/iovs.12-10204
   Ibbett P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43906-z
   Idelson M, 2018, STEM CELL REP, V11, P681, DOI 10.1016/j.stemcr.2018.07.009
   Ikeda Y, 2018, INVEST OPHTH VIS SCI, V59, P826, DOI 10.1167/iovs.17-22958
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Kim SY, 2014, INVEST OPHTH VIS SCI, V55, P6031, DOI 10.1167/iovs.14-15091
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   KORTE GE, 1989, INVEST OPHTH VIS SCI, V30, P1938
   Kwan ASL, 1999, EXP NEUROL, V159, P21, DOI 10.1006/exnr.1999.7157
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lin XY, 2019, EXP EYE RES, V184, P1, DOI 10.1016/j.exer.2019.03.020
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Lorach H, 2015, INVEST OPHTH VIS SCI, V56, P4644, DOI 10.1167/iovs.14-16011
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Mandai M, 2017, STEM CELL REP, V8, P69, DOI 10.1016/j.stemcr.2016.12.008
   Mattison JA, 2017, EXP GERONTOL, V94, P41, DOI 10.1016/j.exger.2016.12.005
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Moshiri A, 2019, J CLIN INVEST, V129, P863, DOI 10.1172/JCI123980
   Muller PL, 2018, INVEST OPHTH VIS SCI, V59, pAMD122, DOI 10.1167/iovs.18-23819
   Odergren A, 2006, CURR EYE RES, V31, P765, DOI 10.1080/02713680600865045
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Picaud S, 2019, P NATL ACAD SCI USA, V116, P26280, DOI 10.1073/pnas.1902292116
   Pilotto E, 2019, GRAEF ARCH CLIN EXP, V257, P1159, DOI 10.1007/s00417-019-04289-z
   POLLACK A, 1992, EXPERIENTIA, V48, P219, DOI 10.1007/BF01930458
   Ratra D, 2018, RETINA-J RET VIT DIS, V38, P2395, DOI 10.1097/IAE.0000000000001879
   ROIDER J, 1993, P NATL ACAD SCI USA, V90, P8643, DOI 10.1073/pnas.90.18.8643
   Ronan Shawn, 2006, Trans Am Ophthalmol Soc, V104, P232
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shiragami C, 1998, BRIT J OPHTHALMOL, V82, P1056, DOI 10.1136/bjo.82.9.1056
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh MS, 2018, INVEST OPHTH VIS SCI, V59, pAMD78, DOI 10.1167/iovs.18-24426
   Singh MS, 2013, P NATL ACAD SCI USA, V110, P1101, DOI 10.1073/pnas.1119416110
   Sodi A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190780
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Song Q, 2008, OPT EXPRESS, V16, P10518, DOI 10.1364/OE.16.010518
   Stanzel BV, 2014, STEM CELL REP, V2, P64, DOI 10.1016/j.stemcr.2013.11.005
   Tan BY, 2019, BIOMED OPT EXPRESS, V10, P356, DOI 10.1364/BOE.10.000356
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terrell D, 2019, SEMIN OPHTHALMOL, V34, P287, DOI 10.1080/08820538.2019.1620808
   Tran TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.16
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Wei X, 2019, ACTA OPHTHALMOL, V97, pE116, DOI 10.1111/aos.13836
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wright CB, 2020, P NATL ACAD SCI USA, V117, P2579, DOI 10.1073/pnas.1909761117
   Yang Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013469
   Yiu G, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.32
   Yiu G, 2018, EXP EYE RES, V168, P69, DOI 10.1016/j.exer.2018.01.012
   Yiu G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14715-z
NR 93
TC 1
Z9 1
U1 1
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2021
VL 62
IS 13
AR 8
DI 10.1167/iovs.62.13.8
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WS1QB
UT WOS:000714963000004
PM 34643661
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Uppal, S
   Dergunov, SA
   Zhang, WY
   Gentleman, S
   Redmond, TM
   Pinkhassik, E
   Poliakov, E
AF Uppal, Sheetal
   Dergunov, Sergey A.
   Zhang, Weiyu
   Gentleman, Susan
   Redmond, T. Michael
   Pinkhassik, Eugene
   Poliakov, Eugenia
TI Xanthophylls Modulate Palmitoylation of Mammalian beta-Carotene
   Oxygenase 2
SO ANTIOXIDANTS
LA English
DT Article
DE BCO2; palmitoylation; xanthophylls; large unilamellar vesicles; &#946;
   -carotene
AB An extensive body of work has documented the antioxidant role of xanthophylls (lutein and zeaxanthin) in human health and specifically how they provide photoprotection in human vision. More recently, evidence is emerging for the transcriptional regulation of antioxidant response by lutein/lutein cleavage products, similar to the role of beta-carotene cleavage products in the modulation of retinoic acid receptors. Supplementation with xanthophylls also provides additional benefits for the prevention of age-related macular degeneration (AMD) and attenuation of Alzheimer's disease symptoms. Mammalian beta-carotene oxygenase 2 (BCO2) asymmetrically cleaves xanthophylls as well as beta-carotene in vitro. We recently demonstrated that mouse BCO2 (mBCO2) is a functionally palmitoylated enzyme and that it loses palmitoylation when cells are treated with beta-carotene. The mouse enzyme is the easiest model to study mammalian BCO2 because it has only one isoform, unlike human BCO2 with several major isoforms with various properties. Here, we used the same acyl-RAC methodology and confocal microscopy to elucidate palmitoylation and localization status of mBCO2 in the presence of xanthophylls. We created large unilamellar vesicle-based nanocarriers for the successful delivery of xanthophylls into cells. We demonstrate here that, upon treatment with low micromolar concentration of lutein (0.15 mu M), mBCO2 is depalmitoylated and shows partial nuclear localization (38.00 +/- 0.04%), while treatment with zeaxanthin (0.45 mu M) and violaxanthin (0.6 mu M) induces depalmitoylation and protein translocation from mitochondria to a lesser degree (20.00 +/- 0.01% and 35.00 +/- 0.02%, respectively). Such a difference in the behavior of mBCO2 toward various xanthophylls and its translocation into the nucleus in the presence of various xanthophylls suggests a possible mechanism for transport of lutein/lutein cleavage products to the nucleus to affect transcriptional regulation.
C1 [Uppal, Sheetal; Gentleman, Susan; Redmond, T. Michael; Poliakov, Eugenia] NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.
   [Dergunov, Sergey A.; Zhang, Weiyu; Pinkhassik, Eugene] Univ Connecticut, Dept Chem, Storrs, CT 06269 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Connecticut
RP Redmond, TM; Poliakov, E (通讯作者)，NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.; Pinkhassik, E (通讯作者)，Univ Connecticut, Dept Chem, Storrs, CT 06269 USA.
EM sheetal.uppal2@nih.gov; sergey.dergunov@uconn.edu;
   weiyu.zhang@uconn.edu; sbgman@verizon.net; redmondd@nei.nih.gov;
   eugene.pinkhassik@uconn.edu; poliakove@nei.nih.gov
OI Redmond, T. Michael/0000-0002-1813-5291; Uppal,
   Sheetal/0000-0002-3685-8602
FU Intramural Research Program of the National Eye Institute, NIH; National
   Science Foundation [CHE-1709921]
FX This research was funded by the Intramural Research Program of the
   National Eye Institute, NIH (T.M. Redmond) and by the National Science
   Foundation (CHE-1709921; E. Pinkhassik).
CR Amengual J, 2011, FASEB J, V25, P948, DOI 10.1096/fj.10-173906
   Babino D, 2016, ACS CHEM BIOL, V11, P1049, DOI 10.1021/acschembio.5b00967
   Babino D, 2015, J BIOL CHEM, V290, P24844, DOI 10.1074/jbc.M115.668822
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Berry SD, 2009, GENETICS, V182, P923, DOI 10.1534/genetics.109.101741
   Boesch-Saadatmandi C, 2011, CYTOTECHNOLOGY, V63, P89, DOI 10.1007/s10616-010-9324-7
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Chakraborty S, 2020, P NATL ACAD SCI USA, V117, P21896, DOI 10.1073/pnas.2004807117
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Czeczuga-Semeniuk E, 2005, ONCOL REP, V14, P1385
   dela Sena C, 2016, J BIOL CHEM, V291, P14609, DOI 10.1074/jbc.M116.723684
   DELMELLE M, 1978, PHOTOCHEM PHOTOBIOL, V27, P731, DOI 10.1111/j.1751-1097.1978.tb07671.x
   Demmig-Adams B, 2020, MOLECULES, V25, DOI 10.3390/molecules25163607
   Dergunov Sergey A, 2015, Biochem Biophys Rep, V2, P137, DOI 10.1016/j.bbrep.2015.05.011
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Eriksson J, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000010
   Eroglu A, 2012, J BIOL CHEM, V287, P15886, DOI 10.1074/jbc.M111.325142
   Eroglu A, 2010, ARCH BIOCHEM BIOPHYS, V504, P11, DOI 10.1016/j.abb.2010.07.025
   Frede K, 2017, J AGR FOOD CHEM, V65, P5944, DOI 10.1021/acs.jafc.7b01929
   Grudzinski W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10183-7
   Gruszecki WI, 2005, BBA-MOL BASIS DIS, V1740, P108, DOI 10.1016/j.bbadis.2004.11.015
   Guo X, 2017, J NUTR BIOCHEM, V46, P74, DOI 10.1016/j.jnutbio.2017.02.019
   Johnson Elizabeth J, 2013, J Aging Res, V2013, P951786, DOI 10.1155/2013/951786
   Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   LAZRAK T, 1987, BIOCHIM BIOPHYS ACTA, V903, P132, DOI 10.1016/0005-2736(87)90163-5
   Li BX, 2014, P NATL ACAD SCI USA, V111, P10173, DOI 10.1073/pnas.1402526111
   Li BX, 2011, BIOCHEMISTRY-US, V50, P2541, DOI 10.1021/bi101906y
   Li Rasia, 2015, Biochem Biophys Rep, V4, P52, DOI 10.1016/j.bbrep.2015.08.012
   Lindqvist A, 2005, J HISTOCHEM CYTOCHEM, V53, P1403, DOI 10.1369/jhc.5A6705.2005
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Lobo GP, 2012, DEVELOPMENT, V139, P2966, DOI 10.1242/dev.079632
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   MILON A, 1986, HELV CHIM ACTA, V69, P12, DOI 10.1002/hlca.19860690104
   Mortensen A, 1997, FREE RADICAL RES, V26, P549, DOI 10.3109/10715769709097826
   Nacke C, 2011, J MOL CATAL B-ENZYM, V71, P133, DOI 10.1016/j.molcatb.2011.04.009
   Nolan JM, 2018, J ALZHEIMERS DIS, V64, P367, DOI [10.3233/jad-180160, 10.3233/JAD-180160]
   Palczewski G, 2014, FASEB J, V28, P4457, DOI 10.1096/fj.14-252411
   Poliakov E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13521-x
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102
   Roy A, 2012, NUCLEIC ACIDS RES, V40, pW471, DOI 10.1093/nar/gks372
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Scott HL, 2019, BIOPHYS J, V117, P1381, DOI 10.1016/j.bpj.2019.09.006
   Shivarudrappa AH, 2020, J CELL COMMUN SIGNAL, V14, P207, DOI 10.1007/s12079-019-00539-1
   Socaciu C, 2000, SPECTROCHIM ACTA A, V56, P2799, DOI 10.1016/S1386-1425(00)00375-9
   STRZALKA K, 1994, BBA-BIOMEMBRANES, V1194, P138, DOI 10.1016/0005-2736(94)90212-7
   Thomas LD, 2020, J BIOL CHEM, V295, P15553, DOI 10.1074/jbc.RA120.015515
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Uppal S, 2020, MOLECULES, V25, DOI 10.3390/molecules25081942
   Uppal S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41501-w
   Vage DI, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-10
   Wang CX, 2015, ARCH BIOCHEM BIOPHYS, V572, P2, DOI 10.1016/j.abb.2015.01.009
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Widomska J, 2019, EXP EYE RES, V178, P238, DOI 10.1016/j.exer.2018.06.012
   Widomska J, 2016, FOODS, V5, DOI 10.3390/foods5010007
   Wu L, 2016, EXP BIOL MED, V241, P1879, DOI 10.1177/1535370216657900
   Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40
   Ziouzenkova O, 2007, MOL ENDOCRINOL, V21, P77, DOI 10.1210/me.2006-0225
NR 60
TC 1
Z9 2
U1 4
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD MAR
PY 2021
VL 10
IS 3
AR 413
DI 10.3390/antiox10030413
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA RD2IB
UT WOS:000633307500001
PM 33803144
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Granstam, E
   Aurell, S
   Sjovall, K
   Paul, A
AF Granstam, Elisabet
   Aurell, Sandra
   Sjovall, Kersti
   Paul, Anna
TI Switching anti-VEGF agent for wet AMD: evaluation of impact on visual
   acuity, treatment frequency and retinal morphology in a real-world
   clinical setting
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Wet AMD; Anti-VEGF agent; Treatment; Switch; Visual acuity
ID MACULAR DEGENERATION; INTRAVITREAL AFLIBERCEPT; VISION LOSS;
   RANIBIZUMAB; OUTCOMES
AB Purpose The aim of the present cross-sectional real-world study is to evaluate the impact of switch of anti-VEGF agent from ranibizumab to aflibercept on visual acuity, treatment frequency and retinal morphology after 12 months in eyes with ongoing chronic treatment for wet age-related macular degeneration (AMD) compared to eyes not subjected to switch of anti-VEGF agent. Methods Data was obtained retrospectively from the Swedish Macular Register, spectral-domain optical coherence tomography (OCT) images and electronic patient charts. All eyes included were treated in the same clinical setting at the Department of Ophthalmology at the county hospital of Vastmanland in Vasteras, Sweden. Results In total, 282 and 359 eyes were included in the non-switch and switch cohorts, respectively. The cohorts were well balanced. Visual acuity remained stable during the observation period in both cohorts of eyes. The number of anti-VEGF treatments slowly declined over time in both cohorts of eyes and, consequently, the treatment intervals increased during the observation period. In eyes subjected to switch of anti-VEGF agent, planned treatment interval at 12 months was 7.6 (mean; SD 2.9) weeks compared to 6.8 (mean; SD 2.7) in the non-switch cohort (P = 0.001). OCT images demonstrated lower prevalence of intraretinal and subretinal fluid as well as pigment epithelial detachment at 12 months in eyes subjected to switch of anti-VEGF agent compared to non-switch eyes. Conclusion Switch of anti-VEGF agent from ranibizumab to aflibercept did not affect visual function whereas improvement in retinal morphology was observed. These findings suggest a beneficial effect of switching from ranibizumab to aflibercept in eyes with ongoing chronic anti-VEGF treatment irrespective of previous response to ranibizumab. Longer follow-up is required to further evaluate the potential clinical significance of this finding.
C1 [Granstam, Elisabet; Aurell, Sandra] Uppsala Univ Reg Vastmanland, Ctr Clin Res, Vasteras, Region Vastmanl, Sweden.
   [Granstam, Elisabet; Aurell, Sandra; Sjovall, Kersti; Paul, Anna] Dept Ophthalmol, S-72189 Vasteras, Region Vastmanl, Sweden.
RP Granstam, E (通讯作者)，Uppsala Univ Reg Vastmanland, Ctr Clin Res, Vasteras, Region Vastmanl, Sweden.; Granstam, E (通讯作者)，Dept Ophthalmol, S-72189 Vasteras, Region Vastmanl, Sweden.
EM elisabet.granstam@regionvastmanland.se
OI Granstam, Elisabet/0000-0003-3164-547X
FU Uppsala University
FX Open Access funding provided by Uppsala University.
CR Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Ashraf M, 2018, OSLI RETINA, V49, P166, DOI 10.3928/23258160-20180221-03
   Aurell S, 2019, ACTA OPHTHALMOL, V97, P519, DOI 10.1111/aos.13989
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hara C, 2019, GRAEF ARCH CLIN EXP, V257, P2559, DOI 10.1007/s00417-019-04456-2
   Hatz K, 2017, RETINA-J RET VIT DIS, V37, P1185, DOI 10.1097/IAE.0000000000001318
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2016, RETINA-J RET VIT DIS, V36, P53, DOI 10.1097/IAE.0000000000000664
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma S, 2013, OPHTHALMOLOGY, V123, P865, DOI [10.1016/j.ophtha.2013.01.073, DOI 10.1016/J.OPHTHA.2013.01.073]
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Turksever C, 2017, OPHTHALMOLOGICA, V238, P172, DOI 10.1159/000477856
   Westborg I, 2017, ACTA OPHTHALMOL, V95, P787, DOI 10.1111/aos.13539
NR 23
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2021
VL 259
IS 8
BP 2085
EP 2093
DI 10.1007/s00417-020-05059-y
EA JAN 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TX9FL
UT WOS:000605917300003
PM 33415353
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Weiner, C
   Hecht, I
   Rotenstreich, Y
   Guttman, S
   Or, L
   Morad, Y
   Shapira, G
   Shomron, N
   Pras, E
AF Weiner, Chen
   Hecht, Idan
   Rotenstreich, Ygal
   Guttman, Sharon
   Or, Lior
   Morad, Yair
   Shapira, Guy
   Shomron, Noam
   Pras, Eran
TI The pathogenicity of SLC38A8 in five families with foveal hypoplasia and
   congenital nystagmus
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Foveal hypoplasia; FVH2; SLC38A8; FHONDA syndrome; Karaite jews
ID MUTATIONS
AB Purpose: A recently described subtype of foveal hypoplasia with congenital nystagmus and optic-nerve-decussation defects was found to be associated with mutations in the SLC38A8 gene. The aim of this study is to advance the clinical and molecular knowledge of SLC38A8 gene mutations.
   Methods: Five Israeli families with congenital foveal hypoplasia were studied, two of Karait Jewish origins and three of Indian Jewish origins. Subjects underwent a comprehensive ophthalmic examination including retinal photography and ocular coherence tomography. Molecular analysis including whole exome sequencing and screening of the SLC38A8 gene for specific disease-causing variants was performed.
   Results: Eight affected individuals were identified, all had congenital nystagmus and all but one had hypoplastic foveal pits. Anterior segment dysgenesis was observed in only one patient, one had evidence of developmental delay and another displayed early age-related macular degeneration (AMD). Molecular analysis revealed a recently described homozygous mutation, c.95T > G; p.Ile32Ser, in two families of Jewish Indian descent, and the same mutation in two families of Karaite Jewish descent. In a patient with only one pathogenic mutation (c.95T > G; p.Ile32Ser), a possible partial clinical expression of the disorder was seen. One patient of Jewish Indian descent was found to be compound heterozygous for c.95T > G; p.Ile32Ser and a novel mutation c.490_491delCT; p.L164Vfs*41.
   Conclusions: In five unrelated families with congenital nystagmus and foveal hypoplasia, mutations in the SLC38A8 gene were identified. Possible partial expression in a heterozygous patient was observed and novel potential disease-related phenotypes were identified including early-onset AMD and developmental delay. A novel mutation was also identified and a similar mutation in both Indian and Karaite Jewish ethnicities could be suggestive for common ancestry.
C1 [Weiner, Chen; Pras, Eran] Shamir Med Ctr, Dept Ophthalmol, Mallows Ophthalmogenet Lab, Assaf Harofeh Med Ctr, Zenfin, Israel.
   [Weiner, Chen; Hecht, Idan; Rotenstreich, Ygal; Guttman, Sharon; Or, Lior; Morad, Yair; Shapira, Guy; Shomron, Noam; Pras, Eran] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Hecht, Idan; Guttman, Sharon; Or, Lior; Morad, Yair; Pras, Eran] Shamir Med Ctr, Assaf Harofeh Med Ctr, Dept Ophthalmol, Zerifin, Israel.
   [Rotenstreich, Ygal] Sheba Med Ctr, Goldschleger Eye Inst, Electrophysiol Clin & Retinal Res Lab, Ramat Gan, Israel.
   [Shomron, Noam] Tel Aviv Univ, Sago Sch Neurosci, Tel Aviv, Israel.
   [Shomron, Noam] Tel Aviv Univ, Edmond J Safra Ctr Bioinformat, Tel Aviv, Israel.
C3 Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv
   University; Sackler Faculty of Medicine; Shamir Medical Center (Assaf
   Harofeh); Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv
   University; Tel Aviv University
RP Weiner, C (通讯作者)，Shamir Med Ctr, Dept Ophthalmol, IL-70300 Beer Yaagov, Israel.
EM w24369@gmail.com
OI Or, Lior/0000-0003-3734-7545; Shapira, Guy/0000-0001-9376-4955; Hecht,
   Idan/0000-0001-5634-0432
FU Claire and Amedee Maratier Institute for the Study of Blindness and
   Visual Disorders [TAU: 32003197000, 32003125000]; Sackler Faculty of
   Medicine, Tel-Aviv University, Tel-Aviv, Israel [7205]; Chief Scientist
   Office of the Ministry of Health, Israel; Consortium for Mapping Retinal
   Degeneration Disorders in Israel [BR-GE-0214-0639-TECH,
   BR-GE-0518-0734-TECH]; Foundation Fighting Blindness [3-12583]; Israeli
   Ministry of Health
FX Funding of this study was supported by the Claire and Amedee Maratier
   Institute for the Study of Blindness and Visual Disorders (TAU#:
   32003197000); The Ernest And Nusia Gothelf research funds (TAU#:
   32003125000), Sackler Faculty of Medicine, Tel-Aviv University,
   Tel-Aviv, Israel. This work was also supported in part by grant no. 7205
   from the Chief Scientist Office of the Ministry of Health, Israel;
   'Lira' Association and the Consortium for Mapping Retinal Degeneration
   Disorders in Israel, and by Grants BR-GE-0214-0639-TECH and
   BR-GE-0518-0734-TECH from the Foundation Fighting Blindness, Grant
   3-12583 from the Israeli Ministry of Health.
CR Al-Araimi M, 2013, MOL VIS, V19, P2165
   Astren Fred., 2004, KARAITE JUDAISM HIST
   Azuma N, 1996, NAT GENET, V13, P141, DOI 10.1038/ng0696-141
   Campbell J, 2019, CHILD LIT ASSN SER, P9
   Dorey SE, 2003, BRIT J OPHTHALMOL, V87, P767, DOI 10.1136/bjo.87.6.767
   Hagglund MGA, 2015, J MOL BIOL, V427, P1495, DOI 10.1016/j.jmb.2014.10.016
   Jiang YC, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1578-y
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Livneh A, 2001, EUR J HUM GENET, V9, P191, DOI 10.1038/sj.ejhg.5200608
   Matsushita I, 2017, OPHTHALMOLOGY, V124, P896, DOI 10.1016/j.ophtha.2017.01.046
   Myerowitz R, 1997, HUM MUTAT, V9, P195, DOI 10.1002/(SICI)1098-1004(1997)9:3<195::AID-HUMU1>3.3.CO;2-J
   OLIVER MD, 1987, BRIT J OPHTHALMOL, V71, P926, DOI 10.1136/bjo.71.12.926
   Olszowy-Schlanger Judith, 2003, KARAITE JUDAISM GUID, V73
   Parfitt Tudor, 2002, LOST TRIBES ISRAEL H
   Perez Y, 2014, EUR J HUM GENET, V22, P703, DOI 10.1038/ejhg.2013.212
   Pochini L, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00061
   Poulter JA, 2013, AM J HUM GENET, V93, P1143, DOI 10.1016/j.ajhg.2013.11.002
   Pras E, 1998, AM J MED GENET, V80, P173, DOI 10.1002/(SICI)1096-8628(19981102)80:2<173::AID-AJMG16>3.3.CO;2-J
   Pras E, 2015, J MED GENET, V52, P484, DOI 10.1136/jmedgenet-2015-103130
   Procopio V, 2018, GENE, V641, P279, DOI 10.1016/j.gene.2017.10.068
   Shields RA, 2015, CLIN CASE REP, V3, P676, DOI 10.1002/ccr3.319
   Toral MA, 2017, MOL GENET GENOM MED, V5, P202, DOI 10.1002/mgg3.266
   Tsaras G, 2009, AM J MED, V122, P507, DOI 10.1016/j.amjmed.2008.12.020
NR 23
TC 9
Z9 9
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2020
VL 193
AR 107958
DI 10.1016/j.exer.2020.107958
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KZ8MD
UT WOS:000523511400006
PM 32032626
DA 2022-11-30
ER

PT J
AU Chu, ZD
   Gregori, G
   Rosenfeld, PJ
   Wang, RKK
AF Chu, Zhongdi
   Gregori, Giovanni
   Rosenfeld, Philip J.
   Wang, Ruikang K.
TI Quantification of Choriocapillaris with Optical Coherence Tomography
   Angiography: A Comparison Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FEATURES; EYES; DEGENERATION
AB PURPOSE: To demonstrate the variation in quantitative choriocapillaris (CC) metrics with various binarization approaches using optical coherence tomography angiography (OCTA).
   DESIGN: Retrospective, observational, cross-sectional case series.
   METHODS: Macular OCTA scans, 3- x 3-mm and 6- x 6-mm, were obtained from normal eyes and from eyes with drusen secondary to age-related macular degeneration (AMD). The CC slab was extracted, and the CC flow deficits (FDs) were segmented with 2 previously published algorithms: the fuzzy C-means approach (FCM method) and Phansalkar's local thresholding (Phansalkar method). Four different values for the radius were used in order to investigate the effect on the FD segmentation when using the Phansalkar method. FD density (FDD), mean FD size (MFDS), FD number (FDN), FD area (FDA) and intercapillary distance (ICD) were calculated for comparison. Repeatability was assessed as coefficient of variation (CV), and Pearson's correlation analysis was conducted.
   RESULTS: Six eyes from 6 subjects with normal eyes and 6 eyes from 6 subjects with drusen secondary to AMD were scanned. The 3- x 3-mm scans resulted in higher repeatability than the 6- x 6-mm scans. For the Phansalkar method, larger values of the radius resulted in higher repeatability. ANOVA tests resulted in significant differences (P < 0.001) among the FCM method and the Phansalkar method with different radius options for all CC metrics and scan sizes investigated. In 3- x 3-mm scans, significant correlation was found between the FCM method and the Phansalkar method for all quantitative CC metrics other than FDN (all P < 0.001; 0.90 < r < 0.99).
   CONCLUSIONS: Quantitative CC analysis with commercially available OCTA is complicated and researchers need to pay close attention to how they conduct such analyses. ((C) 2019 Elsevier Inc. All rights reserved.)
C1 [Chu, Zhongdi; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Wang, Ruikang K.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
C3 University of Washington; University of Washington Seattle; Bascom
   Palmer Eye Institute; University of Miami; University of Washington;
   University of Washington Seattle
RP Wang, RKK (通讯作者)，Univ Washington, Box 355061,3720 15th Ave North East, Seattle, WA 98195 USA.
EM wangrk@uw.edu
RI Wang, Ruikang/L-3889-2019; Chu, Zhongdi/F-9604-2019
OI Wang, Ruikang/0000-0001-5169-8822; Chu, Zhongdi/0000-0001-7430-5032
FU US National Eye Institute [R01EY024158, R01EY028753]; National Eye
   Institute Center [P30EY014801]; Salah Foundation; Carl Zeiss Meditec;
   Research to Prevent Blindness, Inc.; Department of Ophthalmology,
   University of Miami Miller School of Medicine; NATIONAL EYE INSTITUTE
   [P30EY014801, R01EY028753] Funding Source: NIH RePORTER
FX Research has been supported by US National Eye Institute grants
   R01EY024158 and R01EY028753, National Eye Institute Center core grant
   P30EY014801, the Salah Foundation, Carl Zeiss Meditec, an unrestricted
   grant from the Research to Prevent Blindness, Inc., and the Department
   of Ophthalmology, University of Miami Miller School of Medicine. The
   funding organization had no role in the design or conduct of this
   research.
CR Al-Sheikh M, 2017, OSLI RETINA, V48, P623, DOI 10.3928/23258160-20170802-04
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Borrelli E, 2018, INVEST OPHTH VIS SCI, V59
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Cao JT, 1998, ARCH OPHTHALMOL-CHIC, V116, P589, DOI 10.1001/archopht.116.5.589
   Carnevali A, 2017, ACTA DIABETOL, V54, P695, DOI 10.1007/s00592-017-0996-8
   Chan G, 2015, MICROVASC RES, V100, P32, DOI 10.1016/j.mvr.2015.04.006
   Chen CL, 2017, BIOMED OPT EXPRESS, V8, P1056, DOI 10.1364/BOE.8.001056
   Chen CL, 2016, QUANT IMAG MED SURG, V6, P125, DOI 10.21037/qims.2016.03.05
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Chu ZD, 2018, QUANT IMAG MED SURG, V8, P1102, DOI 10.21037/qims.2018.12.09
   Chu ZD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34826-5
   Chu ZD, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.12.121705
   Chu ZD, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066008
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   Gorczynska I, 2017, PROC SPIE, V10045, DOI 10.1117/12.2251704
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Kashani AH, 2017, PROG RETIN EYE RES, V60, P66, DOI 10.1016/j.preteyeres.2017.07.002
   Kim AY, 2016, AM J OPHTHALMOL, V171, P101, DOI 10.1016/j.ajo.2016.08.035
   Kim AY, 2016, INVEST OPHTH VIS SCI, V57, pOCT362, DOI 10.1167/iovs.15-18904
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Koulisis N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176404
   Kurokawa K, 2017, BIOMED OPT EXPRESS, V8, P1803, DOI 10.1364/BOE.8.001803
   Lutty G, 1999, MOL VIS, V5
   Meditec CZ, 2016, CZ MEDITEC PLEX ELIT
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nazari H, 2014, J OPHTHALMIC INFLAMM, V4, DOI 10.1186/1869-5760-4-9
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pepple KL, 2018, JAMA OPHTHALMOL, V136, P1288, DOI 10.1001/jamaophthalmol.2018.3474
   Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305
   Richter GM, 2018, J GLAUCOMA, V27, P281, DOI 10.1097/IJG.0000000000000888
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Samara WA, 2016, AM J OPHTHALMOL, V166, P76, DOI 10.1016/j.ajo.2016.03.033
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P79, DOI 10.1097/IAE.0000000000001517
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Sugano Y, 2018, CLIN OPHTHALMOL, V12, P2267, DOI 10.2147/OPTH.S179634
   TORCZYNSKI E, 1976, AM J OPHTHALMOL, V81, P428, DOI 10.1016/0002-9394(76)90298-1
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Xu JJ, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.11.116007
   Yin X, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.8.086020
   YONEYA S, 1983, INT OPHTHALMOL, V6, P95, DOI 10.1007/BF00127637
   Zhang AQ, 2015, BIOMED OPT EXPRESS, V6, P4130, DOI 10.1364/BOE.6.004130
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 50
TC 46
Z9 46
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2019
VL 208
BP 111
EP 123
DI 10.1016/j.ajo.2019.07.003
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JZ0OI
UT WOS:000504803400014
PM 31323202
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yi, QY
   Wang, YY
   Chen, LS
   Li, WD
   Shen, Y
   Jin, YH
   Yang, J
   Wang, YW
   Yuan, JS
   Cheng, LY
AF Yi, Quan-Yong
   Wang, Yan-Yan
   Chen, Li-Shuang
   Li, Wen-Die
   Shen, Yu
   Jin, Yuanhui
   Yang, Jie
   Wang, Yuwen
   Yuan, Jianshu
   Cheng, Lingyun
TI Implication of inflammatory cytokines in the aqueous humour for
   management of macular diseases
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE anti-inflammation; anti-VEGF; aqueous humour; ICAM-1; IL-6; macular
   disease management; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY;
   PRO-PERMEABILITY FACTORS; VISUAL-ACUITY; INTRAVITREAL AFLIBERCEPT;
   EDEMA; RANIBIZUMAB; TRIAL; PREVALENCE; THICKNESS
AB Purpose To characterize profile of cytokines in aqueous humour of common macular diseases during intravitreal anti-VEGF therapy. Methods Aqueous humour from eyes with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular oedema (DME), neovascular age-related macular degeneration (nAMD) or pathologic myopia associated choroidal neovascularization (pmCNV) was sampled prior to 1st (n = 144) and 2nd (n = 48) intravitreal anti-VEGF therapy. Cytokines including vascular endothelium growth factor (VEGF), intercellular adhesion molecule 1 (ICAM-1) and interleukin 6 (IL-6) were quantitated and analysed along with retinal thickness data by optical coherence tomography (OCT) across two intravitreal injections and five macular disease types. Results ICAM-1, IL-6 and VEGF are positively associated in the aqueous humour of naive eyes (r = 0.39-0.77, p = 0.018 to <0.0001). ICAM-1, VEGF and IL-6 were significantly higher in CRVO and DME while lowest in pmCNV (p < 0.0001). Reduction of central retinal thickness (CRT) as a favourable response to anti-VEGF therapy was in the order of CRVO, BRVO, DME and nAMD/pmCNV (p < 0.0001). The strongest predictor for favourable CRT reduction was baseline CRT (p < 0.0001) followed by baseline ICAM-1 (p = 0.04). After the 1st intravitreal anti-VEGF therapy, VEGF in aqueous humour lowered significantly but ICAM-1 and IL-6 levels remained unchanged. ICAM-1 was not predictive for CRT reduction following 2nd anti-VEGF therapy. Conclusion Rate of cytokine production is disease-dependent and higher in CRVO and DME. Anatomical response to intravitreal anti-VEGF therapy is disease-specific and best in RVO patients. A combination therapy using both anti-VEGF and anti-inflammatory therapeutics may be superior to single anti-VEGF therapy, at least for RVO and DME.
C1 [Yi, Quan-Yong; Wang, Yan-Yan; Chen, Li-Shuang; Li, Wen-Die; Wang, Yuwen; Yuan, Jianshu] Ningbo Eye Hosp, Ningbo, Zhejiang, Peoples R China.
   [Shen, Yu; Jin, Yuanhui; Yang, Jie] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Inst Ocular Pharmacol, Wenzhou, Peoples R China.
   [Cheng, Lingyun] Univ Calif San Diego, Dept Ophthalmol, Jacobs Retina Ctr, Shiley Eye Inst, La Jolla, CA 92093 USA.
C3 Wenzhou Medical University; University of California System; University
   of California San Diego
RP Cheng, LY (通讯作者)，Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Inst, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM l1cheng@ucsd.edu
OI Cheng, Lingyun/0000-0002-0748-5173
FU Ningbo Natural Science Funding [2017A610237]; Zhejiang Province
   Medicinal & Health Science Development Plan [2017KY619, 2018KY735]
FX This work was supported by the Ningbo Natural Science Funding
   [2017A610237]; the Zhejiang Province Medicinal & Health Science
   Development Plan [2017KY619; 2018KY735]. We thank Stephanie Landeros for
   English proofreading of the manuscript.
CR Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bressler SB, 2012, ARCH OPHTHALMOL-CHIC, V130, P1153, DOI 10.1001/archophthalmol.2012.1107
   Browning DJ, 2007, OPHTHALMOLOGY, V114, P525, DOI 10.1016/j.ophtha.2006.06.052
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   Campochiaro PA, 2016, AM J OPHTHALMOL, V170, P245, DOI 10.1016/j.ajo.2016.07.014
   Campochiaro PA, 2016, AM J OPHTHALMOL, V168, P13, DOI 10.1016/j.ajo.2016.04.017
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P538, DOI 10.1016/j.ophtha.2014.08.031
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1690, DOI 10.1016/j.ophtha.2017.04.028
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Funatsu H, 2003, OPHTHALMOLOGY, V110, P1690, DOI 10.1016/S0161-6420(03)00568-2
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032
   Hutton-Smith LA, 2018, MOL PHARMACEUT, V15, P2770, DOI 10.1021/acs.molpharmaceut.8b00280
   Kotake O, 2019, OPHTHALMIC RES, V61, P210, DOI 10.1159/000488494
   Lazic R, 2014, RETINA-J RET VIT DIS, V34, P719, DOI 10.1097/IAE.0b013e3182a48958
   Li JQ, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/1425707
   Li YB, 2008, AM J OPHTHALMOL, V146, P329, DOI 10.1016/j.ajo.2008.04.015
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Moon J, 2016, EYE, V30, P1084, DOI 10.1038/eye.2016.96
   Noma H, 2010, GRAEF ARCH CLIN EXP, V248, P1515, DOI 10.1007/s00417-010-1350-9
   Oh IK, 2010, CURR EYE RES, V35, P1116, DOI 10.3109/02713683.2010.510257
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Qian TW, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022700
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Roh MI, 2008, YONSEI MED J, V49, P931, DOI 10.3349/ymj.2008.49.6.931
   Shah Ankoor R, 2017, J Vitreoretin Dis, V1, P169, DOI 10.1177/2474126416682569
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Urias EA, 2017, VISION RES, V139, P221, DOI 10.1016/j.visres.2017.06.015
   Wong TY, 2017, ANTIVEGFS EFFICACIOU
   Zhang ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep38326
NR 32
TC 11
Z9 11
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2020
VL 98
IS 3
BP E309
EP E315
DI 10.1111/aos.14248
EA SEP 2019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LH4QT
UT WOS:000486960200001
PM 31531945
OA Bronze
DA 2022-11-30
ER

PT J
AU Ting, DSW
   Peng, L
   Varadarajan, AV
   Keane, PA
   Burlina, PM
   Chiang, MF
   Schmetterer, L
   Pasquale, LR
   Bressler, NM
   Webster, DR
   Abramoff, M
   Wong, TY
AF Ting, Daniel S. W.
   Peng, Lily
   Varadarajan, Avinash V.
   Keane, Pearse A.
   Burlina, Philippe M.
   Chiang, Michael F.
   Schmetterer, Leopold
   Pasquale, Louis R.
   Bressler, Neil M.
   Webster, Dale R.
   Abramoff, Michael
   Wong, Tien Y.
TI Deep learning in ophthalmology: The technical and clinical
   considerations
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
ID OPTICAL COHERENCE TOMOGRAPHY; PLUS DISEASE DIAGNOSIS; MACULAR
   DEGENERATION; DIABETIC-RETINOPATHY; CARDIOVASCULAR RISK; GLOBAL
   PREVALENCE; HEART-DISEASE; AUTOMATED DETECTION; VISION IMPAIRMENT;
   IMAGE-ANALYSIS
AB The advent of computer graphic processing units, improvement in mathematical models and availability of big data has allowed artificial intelligence (AI) using machine learning (ML) and deep learning (DL) techniques to achieve robust performance for broad applications in social-media, the intemet of things, the automotive industry and healthcare. DL systems in particular provide improved capability in image, speech and motion recognition as well as in natural language processing. In medicine, significant progress of AI and DL systems has been demonstrated in image-centric specialties such as radiology, dermatology, pathology and ophthalmology. New studies, including pre-registered prospective clinical trials, have shown DL systems are accurate and effective in detecting diabetic retinopathy (DR), glaucoma, age-related macular degeneration (AMD), retinopathy of prematurity, refractive error and in identifying cardiovascular risk factors and diseases, from digital fundus photographs. There is also increasing attention on the use of AI and DL systems in identifying disease features, progression and treatment response for retinal diseases such as neovascular AMD and diabetic macular edema using optical coherence tomography (OCT). Additionally, the application of ML to visual fields may be useful in detecting glaucoma progression. There are limited studies that incorporate clinical data including electronic health records, in AL and DL algorithms, and no prospective studies to demonstrate that AI and DL algorithms can predict the development of clinical eye disease. This article describes global eye disease burden, unmet needs and common conditions of public health importance for which AI and DL systems may be applicable. Technical and clinical aspects to build a DL system to address those needs, and the potential challenges for clinical adoption are discussed. AI, ML and DL will likely play a crucial role in clinical ophthalmology practice, with implications for screening, diagnosis and follow up of the major causes of vision impairment in the setting of ageing populations globally.
C1 [Ting, Daniel S. W.; Schmetterer, Leopold; Wong, Tien Y.] Natl Univ Singapore, Duke NUS Med Sch, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Peng, Lily; Varadarajan, Avinash V.; Webster, Dale R.] Google AI Healthcare, Mountain View, CA USA.
   [Keane, Pearse A.] Moorfields Eye Hosp, London, England.
   [Burlina, Philippe M.; Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Burlina, Philippe M.] Johns Hopkins Univ, Appl Phys Lab, Baltimore, MD 21218 USA.
   [Burlina, Philippe M.] Johns Hopkins Univ, Malone Ctr Engn Healthcare, Baltimore, MD USA.
   [Chiang, Michael F.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol & Med Informat, Portland, OR 97201 USA.
   [Chiang, Michael F.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
   [Schmetterer, Leopold] Nanyang Technol Univ, Lee Kong Chian Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Schmetterer, Leopold] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.
   [Schmetterer, Leopold] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria.
   [Pasquale, Louis R.] Icahn Sch Med Mt Sinai, Dept Ophthalmol, New York, NY 10029 USA.
   [Abramoff, Michael] Univ Iowa Hlth Care, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
C3 National University of Singapore; Singapore National Eye Center;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Johns Hopkins University; Johns Hopkins Medicine;
   Johns Hopkins University; Johns Hopkins University Applied Physics
   Laboratory; Johns Hopkins University; Oregon Health & Science
   University; Oregon Health & Science University; Nanyang Technological
   University & National Institute of Education (NIE) Singapore; Nanyang
   Technological University; Medical University of Vienna; Medical
   University of Vienna; Icahn School of Medicine at Mount Sinai;
   University of Iowa
RP Ting, DSW (通讯作者)，Duke NUS Med Sch, Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM daniel.ting.s.w@singhealth.com.sg
RI Keane, Pearse/AAE-5709-2019; Wong, Tien Yin/AAC-9724-2020; Abramoff,
   Michael/A-5836-2009
OI Keane, Pearse/0000-0002-9239-745X; Wong, Tien Yin/0000-0002-8448-1264;
   Schmetterer, Leopold/0000-0002-7189-1707; Bidwai, Pooja
   Vishal/0000-0002-3077-4395; Abramoff, Michael/0000-0002-3490-0037
FU National Medical Research Council (NMRC), Ministry of Health (MOH),
   Singapore National Health Innovation Center, Innovation to Develop Grant
   [NHIC-I2D-1409022]; SingHealth Foundation Research Grant
   [SHF/FG648S/2015]; Tanoto Foundation; NMRC, MOH [0796/2003, IRGO7nov013,
   IRGO9nov014, STaR/0003/2008, STaR/2013, CG/SERI/2010]; Biomedical
   Research Council [08/1/35/19/550, 09/1/35/19/616]; MOH, Singapore
   [AIC/RPDD/SIDRP/SERI/FY2013/0018, AIC/HPD/FY2016/0912]
FX This project received funding from National Medical Research Council
   (NMRC) Health Service Research Grant and Large Collaborative Grant
   (DYNAMO), Ministry of Health (MOH), Singapore National Health Innovation
   Center, Innovation to Develop Grant (NHIC-I2D-1409022); SingHealth
   Foundation Research Grant (SHF/FG648S/2015), and the Tanoto Foundation;
   unrestricted donations to the Retina Division, Johns Hopkins University
   School of Medicine. For Singapore Epidemiology of Eye Diseases (SEED)
   study, we received funding from NMRC, MOH (grants 0796/2003,
   IRGO7nov013, IRGO9nov014, STaR/0003/2008 & STaR/2013; CG/SERI/2010) and
   Biomedical Research Council (grants 08/1/35/19/550, 09/1/35/19/616). The
   Singapore Diabetic Retinopathy Program (SiDRP) received funding from the
   MOH, Singapore (grants AIC/RPDD/SIDRP/SERI/FY2013/0018 &
   AIC/HPD/FY2016/0912).
CR Abbey AM, 2016, OPHTHALMOLOGY, V123, P385, DOI 10.1016/j.ophtha.2015.09.048
   Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Anwar SM, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1088-1
   Asaoka R, 2019, AM J OPHTHALMOL, V198, P136, DOI 10.1016/j.ajo.2018.10.007
   Ataer-Cansizoglu E, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.6.5
   Baeza M, 2009, INT J CLIN PRACT, V63, P433, DOI 10.1111/j.1742-1241.2008.01921.x
   Blencowe H, 2013, PEDIATR RES, V74, P4, DOI 10.1038/pr.2013.203
   Bonaldi L, 2016, PROCEDIA COMPUT SCI, V90, P54, DOI 10.1016/j.procs.2016.07.010
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Bunce C, 2009, AM J OPHTHALMOL, V148, P4, DOI 10.1016/j.ajo.2008.09.032
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Cai S, 2017, CURR EYE RES, V42, P568, DOI 10.1080/02713683.2016.1205630
   Campbell JP, 2016, OPHTHALMOLOGY, V123, P1795, DOI 10.1016/j.ophtha.2016.04.035
   Campbell JP, 2016, OPHTHALMOLOGY, V123, P2338, DOI 10.1016/j.ophtha.2016.07.026
   Campbell JP, 2016, JAMA OPHTHALMOL, V134, P651, DOI 10.1001/jamaophthalmol.2016.0611
   Carin L, 2018, JAMA-J AM MED ASSOC, V320, P1192, DOI 10.1001/jama.2018.13316
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chan RVP, 2010, RETINA-J RET VIT DIS, V30, P958, DOI 10.1097/IAE.0b013e3181c9696a
   Chang RT, 2016, ASIA-PAC J OPHTHALMO, V5, P32, DOI 10.1097/APO.0000000000000173
   Char DS, 2018, NEW ENGL J MED, V378, P981, DOI 10.1056/NEJMp1714229
   Chauhan BC, 2015, OPHTHALMOLOGY, V122, P1786, DOI 10.1016/j.ophtha.2015.06.001
   Chauhan BC, 2013, AM J OPHTHALMOL, V156, P218, DOI 10.1016/j.ajo.2013.04.016
   Cheung CYL, 2013, STROKE, V44, P2402, DOI 10.1161/STROKEAHA.113.001738
   Chiang MF, 2007, ARCH OPHTHALMOL-CHIC, V125, P875, DOI 10.1001/archopht.125.7.875
   Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3
   Cooney MT, 2009, EUR J CARDIOV PREV R, V16, P304, DOI 10.1097/HJR.0b013e3283213140
   Crowston JG, 2004, BRIT J OPHTHALMOL, V88, P766, DOI 10.1136/bjo.2003.028548
   D'Agostino RB, 2008, CIRCULATION, V117, P743, DOI 10.1161/CIRCULATIONAHA.107.699579
   Daniel E, 2015, JAMA OPHTHALMOL, V133, P675, DOI 10.1001/jamaophthalmol.2015.0460
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   Divo MJ, 2014, EUR RESPIR J, V44, P1055, DOI 10.1183/09031936.00059814
   Doblhoff-Dier V, 2014, BIOMED OPT EXPRESS, V5, P630, DOI 10.1364/BOE.5.000630
   Dudina A, 2011, EUR J CARDIOV PREV R, V18, P731, DOI 10.1177/1741826711412039
   Elze T, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2014.1118
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fleck BW, 2018, EYE, V32, P74, DOI 10.1038/eye.2017.150
   FLECK BW, 1994, BRIT J OPHTHALMOL, V78, P421, DOI 10.1136/bjo.78.5.421-a
   Fledelius HC, 2010, ACTA OPHTHALMOL, V88, P514, DOI 10.1111/j.1755-3768.2009.01660.x
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Garcia GGP, 2019, AM J OPHTHALMOL, V199, P111, DOI 10.1016/j.ajo.2018.10.012
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gelman SK, 2010, ARCH OPHTHALMOL-CHIC, V128, P1217, DOI 10.1001/archophthalmol.2010.186
   Gilbert C, 1997, LANCET, V350, P12, DOI 10.1016/S0140-6736(97)01107-0
   Goff DC, 2014, CIRCULATION, V129, pS49, DOI 10.1161/01.cir.0000437741.48606.98
   Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991, DOI 10.1001/archopht.123.7.991
   Gomes L, 2014, IEEE SPECTRUM
   Good WV, 2010, ARCH OPHTHALMOL-CHIC, V128, P663, DOI 10.1001/archophthalmol.2010.72
   Graham I, 2007, EUR HEART J, V28, P2375, DOI 10.1093/eurheartj/ehm316
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Gschliesser A, 2015, AM J OPHTHALMOL, V160, P553, DOI 10.1016/j.ajo.2015.05.016
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hewing NJ, 2013, JAMA OPHTHALMOL, V131, P1026, DOI 10.1001/jamaophthalmol.2013.135
   Hira Ravi S, 2015, J Am Coll Cardiol, V65, P111, DOI 10.1016/j.jacc.2014.10.035
   Hong SW, 2018, AM J OPHTHALMOL, V192, P65, DOI 10.1016/j.ajo.2018.04.022
   HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455
   Hwang EJ, 2019, CLIN INFECT DIS, V69, P739, DOI 10.1093/cid/ciy967
   Joshi Neil, 2018, JAMA OPHTHALMOL
   Kalpathy-Cramer J, 2016, OPHTHALMOLOGY, V123, P2345, DOI 10.1016/j.ophtha.2016.07.020
   Keane PA, 2014, OPHTHALMOLOGY, V121, P2489, DOI 10.1016/j.ophtha.2014.07.054
   Keck KM, 2013, RETINA-J RET VIT DIS, V33, P1700, DOI 10.1097/IAE.0b013e3182845c39
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Kim S. J., 2018, J AM ASS PEDIAT OPHT, V22, pe78
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Koreen Susan, 2007, Ophthalmology, V114, pe59, DOI 10.1016/j.ophtha.2007.10.006
   Krause J, 2018, OPHTHALMOLOGY, V125, P1264, DOI 10.1016/j.ophtha.2018.01.034
   Krizhevsky A., 2012, ADV NEURAL INF PROCE, P1097, DOI DOI 10.1145/3065386
   Kwon J, 2017, BRIT J OPHTHALMOL, V101, P1618, DOI 10.1136/bjophthalmol-2016-309914
   Lakhani P, 2017, RADIOLOGY, V284, P574, DOI 10.1148/radiol.2017162326
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Li F, 2018, BMC MED IMAGING, V18, DOI 10.1186/s12880-018-0273-5
   Li ZX, 2018, DIABETES CARE, V41, P2509, DOI 10.2337/dc18-0147
   Ludwig CA, 2017, OSLI RETINA, V48, P553, DOI 10.3928/23258160-20170630-06
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Masumoto H, 2018, J GLAUCOMA, V27, P647, DOI 10.1097/IJG.0000000000000988
   McCarthy J., 1955, PROPOSAL DARTMOUTH S, V31, P1955
   Menti E., 2016, AUTOMATIC GENERATION
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Moleta C, 2017, AM J OPHTHALMOL, V176, P70, DOI 10.1016/j.ajo.2016.12.025
   Muhammad H, 2017, J GLAUCOMA, V26, P1086, DOI 10.1097/IJG.0000000000000765
   Myung JS, 2011, J AAPOS, V15, P573, DOI 10.1016/j.jaapos.2011.06.011
   Nagiel A, 2012, OPHTHALMOLOGY, V119, P2644, DOI 10.1016/j.ophtha.2012.07.015
   Peters D, 2014, ACTA OPHTHALMOL, V92, P421, DOI 10.1111/aos.12203
   Phelps DL, 2000, PEDIATRICS, V105, P295
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Quellec G, 2014, IEEE ENG MED BIO, P154, DOI 10.1109/EMBC.2014.6943552
   Quinn GE, 2016, EYE BRAIN, V8, P31, DOI 10.2147/EB.S94436
   Rao R, 2012, RETINA-J RET VIT DIS, V32, P1148, DOI 10.1097/IAE.0b013e31823ac3c3
   Raumviboonsuk P, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0099-8
   Reynolds JD, 2002, ARCH OPHTHALMOL-CHIC, V120, P1470, DOI 10.1001/archopht.120.11.1470
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Roth GA, 2017, J AM COLL CARDIOL, V70, P1, DOI 10.1016/j.jacc.2017.04.052
   SAMUEL AL, 1959, IBM J RES DEV, V3, P211, DOI 10.1147/rd.33.0210
   Savini G, 2011, CURR OPIN OPHTHALMOL, V22, P115, DOI 10.1097/ICU.0b013e3283437222
   Schell GJ, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-137
   Schmidl D, 2015, J OCUL PHARMACOL TH, V31, P63, DOI 10.1089/jop.2014.0067
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Seidelmann SB, 2016, CIRCULATION, V134, P1328, DOI 10.1161/CIRCULATIONAHA.116.023425
   Shibata N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33013-w
   Simonyan K. V. A., 2017, COMPUT VISION PATTER
   Slidsborg C, 2012, BRIT J OPHTHALMOL, V96, P549, DOI 10.1136/bjophthalmol-2011-300573
   Stone NJ, 2014, CIRCULATION, V129, pS1, DOI 10.1161/01.cir.0000437738.63853.7a
   TASMAN W, 1988, ARCH OPHTHALMOL-CHIC, V106, P463
   Tham Yih-Chung, 2014, Ophthalmology, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   Ting DSW, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0097-x
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2018, NAT BIOMED ENG, V2, P140, DOI 10.1038/s41551-018-0210-5
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Varadarajan AV, 2018, INVEST OPHTH VIS SCI, V59, P2861, DOI 10.1167/iovs.18-23887
   Vayena E, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002689
   Wallace DK, 2008, J AAPOS, V12, P352, DOI 10.1016/j.jaapos.2007.11.022
   Wallace DK, 2011, ARCH OPHTHALMOL-CHIC, V129, P591, DOI 10.1001/archophthalmol.2011.63
   Wallace DK, 2000, J AAPOS, V4, P224, DOI 10.1067/mpa.2000.105273
   Wang JJ, 2006, HEART, V92, P1583, DOI 10.1136/hrt.2006.090522
   Wang MY, 2018, OPHTHALMOLOGY, V125, P352, DOI 10.1016/j.ophtha.2017.09.021
   Wheatley CM, 2002, ARCH DIS CHILD-FETAL, V87, pF78, DOI 10.1136/fn.87.2.F78
   Wicherts JM, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01832
   Wilson CM, 2012, J AAPOS, V16, P223, DOI 10.1016/j.jaapos.2011.11.015
   Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837
   Windsor MA, 2018, AM J OPHTHALMOL, V185, P115, DOI 10.1016/j.ajo.2017.09.027
   Witt N, 2006, HYPERTENSION, V47, P975, DOI 10.1161/01.HYP.0000216717.72048.6c
   Wittenberg LA, 2012, J PEDIAT OPHTH STRAB, V49, P11, DOI 10.3928/01913913-20110222-01
   Wong RK, 2012, J AAPOS, V16, P177, DOI 10.1016/j.jaapos.2011.12.154
   Wong TY, 2006, ARCH INTERN MED, V166, P2388, DOI 10.1001/archinte.166.21.2388
   Wong TY, 2016, JAMA-J AM MED ASSOC, V316, P2366, DOI 10.1001/jama.2016.17563
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Worrall DE, 2016, LECT NOTES COMPUT SC, V10008, P68, DOI 10.1007/978-3-319-46976-8_8
   Xu YP, 2017, BIOMED OPT EXPRESS, V8, P4061, DOI 10.1364/BOE.8.004061
   Yeboah J, 2012, JAMA-J AM MED ASSOC, V308, P788, DOI 10.1001/jama.2012.9624
   Yip WF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09204-2
   Yousefi S, 2014, IEEE T BIO-MED ENG, V61, P2112, DOI 10.1109/TBME.2014.2314714
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 147
TC 167
Z9 176
U1 22
U2 203
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2019
VL 72
AR 100759
DI 10.1016/j.preteyeres.2019.04.003
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JB1HL
UT WOS:000488311400001
PM 31048019
OA Green Submitted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Keeffe, JE
   Casson, RJ
   Pesudovs, K
   Taylor, HR
   Cicinelli, MV
   Das, A
   Flaxman, SR
   Jonas, JB
   Kempen, JH
   Leasher, J
   Limburg, H
   Naidoo, K
   Silvester, AJ
   Stevens, GA
   Tahhan, N
   Wong, TY
   Resnikoff, S
   Bourne, RRA
AF Keeffe, Jill Elizabeth
   Casson, Robert J.
   Pesudovs, Konrad
   Taylor, Hugh R.
   Cicinelli, Maria Vittoria
   Das, Aditi
   Flaxman, Seth R.
   Jonas, Jost B.
   Kempen, John H.
   Leasher, Janet
   Limburg, Hans
   Naidoo, Kovin
   Silvester, Alexander J.
   Stevens, Gretchen A.
   Tahhan, Nina
   Wong, Tien Yin
   Resnikoff, Serge
   Bourne, Rupert R. A.
CA Vision Loss Expert Grp Global
TI Prevalence and causes of vision loss in South-east Asia and Oceania in
   2015: magnitude, temporal trends and projections
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE global burden of disease study; vision loss expert group; blindness;
   vision impairment; epidemiology
ID VISUAL IMPAIRMENT; REFRACTIVE ERROR; GLOBAL PREVALENCE; BLINDNESS;
   WORLDWIDE; POPULATION; PRESBYOPIA; DISTANCE; ADULTS
AB Background To assess prevalence and causes of vision impairment in South-east Asia and Oceania regions from 1990 to 2015 and to forecast the figures for 2020. Methods Based on a systematic review of medical literature, prevalence of blindness (presenting visual acuity (PVA) <3/60 in the better eye), moderate and severe vision impairment (MSVI; PVA <6/18 but >= 3/60), mild vision impairment (PVA <6/12 but >= 6/18) and near vision impairment (>N5 or N8 in the presence of normal vision) were estimated for 1990, 2010, 2015 and 2020. Results The age-standardised prevalence of blindness for all ages and both genders was higher in the Oceania region but lower for MSVI when comparing the subregions. The prevalence of near vision impairment in people >= 50 years was 41% (uncertainty interval (UI) 18.8 to 65.9). Comparison of the data for 2015 with 2020 predicts a small increase in the numbers of people affected by blindness, MSVI and mild VI in both subregions. The numbers predicted for near VI in South-east Asia are from 90.68 million in 2015 to 102.88 million in 2020. The main causes of blindness and MSVI in both subregions in 2015 were cataract, uncorrected refractive error, glaucoma, corneal disease and age-related macular degeneration. There was no trachoma in Oceania from 1990 and decreasing prevalence in South-east Asia with elimination predicted by 2020. Conclusions In both regions, the main challenges for eye care come from cataract which remains the main cause of blindness with uncorrected refractive error the main cause of MSVI. The trend between 1990 and 2015 is for a lower prevalence of blindness and MSVI in both regions.
C1 [Keeffe, Jill Elizabeth] LV Prasad Eye Inst, Hyderabad 500034, Telangana, India.
   [Casson, Robert J.] Univ Adelaide, Adelaide, SA, Australia.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat Hlth, Melbourne, Vic, Australia.
   [Cicinelli, Maria Vittoria] Ist Sci San Raffaele, Milan, Italy.
   [Das, Aditi] Hlth Educ Yorkshire, London, England.
   [Flaxman, Seth R.] Imperial Coll London, Dept Math & Data Sci Inst, London, England.
   [Jonas, Jost B.] Heidelberg Univ, Univ Med Mannheim, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
   [Kempen, John H.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Immunol & Uveitis Serv, Boston, MA 02114 USA.
   [Kempen, John H.] Discovery Eye Ctr, Leawood, KS USA.
   [Kempen, John H.] MyungSung Christian Med Ctr, Addis Ababa, Ethiopia.
   [Leasher, Janet] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA.
   [Limburg, Hans] Hlth Informat Serv, Grootebroek, Netherlands.
   [Naidoo, Kovin] Univ Kwazulu Natal, African Vis Res Inst, Durban, South Africa.
   [Naidoo, Kovin; Tahhan, Nina; Resnikoff, Serge] Brien Holden Vis Inst, Sydney, NSW, Australia.
   [Silvester, Alexander J.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Prescot St, Liverpool, Merseyside, England.
   [Stevens, Gretchen A.] WHO, Dept Informat Evidence & Res, Geneva, Switzerland.
   [Tahhan, Nina; Resnikoff, Serge] Univ New South Wales, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Wong, Tien Yin] Natl Univ Singapore, Duke NUS Grad Med Sch, Singapore Eye Res Inst, Singapore, Singapore.
   [Bourne, Rupert R. A.] Anglia Ruskin Univ, Vis & Eye Res Unit, Cambridge, England.
C3 L. V. Prasad Eye Institute; University of Adelaide; University of
   Melbourne; Vita-Salute San Raffaele University; IRCCS Ospedale San
   Raffaele; Imperial College London; Ruprecht Karls University Heidelberg;
   Harvard University; Massachusetts Eye & Ear Infirmary; Nova Southeastern
   University; University of Kwazulu Natal; Brien Holden Vision Institute;
   Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; World Health
   Organization; University of New South Wales Sydney; National University
   of Singapore; Singapore National Eye Center; Anglia Ruskin University
RP Keeffe, JE (通讯作者)，LV Prasad Eye Inst, Hyderabad 500034, Telangana, India.
EM jillkeeffe@lvpei.org
RI cicinelli, maria vittoria/M-1611-2019; Naidoo, Kovin
   Shunmugam/AAF-5914-2020; Wong, Tien Yin/AAC-9724-2020; Tejedor,
   Jaime/G-7728-2015; Leasher, Janet/B-8889-2016
OI cicinelli, maria vittoria/0000-0003-2938-0409; Wong, Tien
   Yin/0000-0002-8448-1264; Tejedor Fraile, Jaime/0000-0001-5507-5622;
   Battaglia Parodi, Maurizio/0000-0002-0385-7961; Kempen,
   John/0000-0002-2967-4792; Jonas, Jost/0000-0003-2972-5227; Leasher,
   Janet/0000-0002-8779-5162; Pesudovs, Konrad/0000-0002-6322-9369
FU Brien Holden Vision Institute
FX This study was funded by the Brien Holden Vision Institute. The results
   in this paper are prepared independently of the final estimates of the
   Global Burden of Diseases, Injuries, and Risk Factors study. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bourne R, 2013, OPHTHAL EPIDEMIOL, V20, P33, DOI 10.3109/09286586.2012.741279
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brian G, 2011, OPHTHAL EPIDEMIOL, V18, P75, DOI 10.3109/09286586.2010.551576
   Brian G, 2010, NEW ZEAL MED J, V123, P68
   Casson RJ, 2007, OPHTHALMOLOGY, V114, P2302, DOI 10.1016/j.ophtha.2007.02.004
   Casson RJ, 2012, OPHTHALMOLOGY, V119, P2021, DOI 10.1016/j.ophtha.2012.03.049
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Keeffe J, 2014, BRIT J OPHTHALMOL, V98, P586, DOI 10.1136/bjophthalmol-2013-304050
   Ramke J, 2012, PUBLIC HEALTH NUTR, V15, P2118, DOI 10.1017/S1368980011003491
   Ramke J, 2012, CLIN EXP OPHTHALMOL, V40, P490, DOI 10.1111/j.1442-9071.2011.02749.x
   Ramke J, 2012, OPHTHAL EPIDEMIOL, V19, P52, DOI 10.3109/09286586.2011.645108
   Ramke J, 2012, INVEST OPHTH VIS SCI, V53, P434, DOI 10.1167/iovs.11-8161
   Resnikoff S, 2012, BRIT J OPHTHALMOL, V96, P783, DOI 10.1136/bjophthalmol-2011-301378
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]
   WHO, AGE STANDARDIZATION
   World Health Organization, UN EYE HLTH GLOB ACT
   Zainal M, 2002, BRIT J OPHTHALMOL, V86, P951, DOI 10.1136/bjo.86.9.951
   Zhou B, 2016, LANCET, V387, P1513, DOI 10.1016/S0140-6736(16)00618-8
NR 20
TC 13
Z9 13
U1 0
U2 15
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2019
VL 103
IS 7
BP 878
EP 884
DI 10.1136/bjophthalmol-2018-311946
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IF4HJ
UT WOS:000473042100003
PM 30209084
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Zhou, JQ
   Wang, YX
   Xu, L
   Zhao, L
   Wang, S
   Xu, J
   You, QS
   Yang, H
   Wei, WB
   Jonas, JB
AF Zhou, Jin Qiong
   Wang, Ya Xing
   Xu, Liang
   Zhao, Liang
   Wang, Shuang
   Xu, Jie
   You, Qi Sheng
   Yang, Hua
   Wei, Wen Bin
   Jonas, Jost B.
TI POSTERIOR FUNDUS HEMORRHAGES Frequency and Associated Factors: The
   Beijing Eye Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retinal hemorrhages; arterial hypertension; diabetes mellitus; diabetic
   retinopathy; retinal vein occlusion; glaucoma
ID RISK-FACTORS; OLDER PERSONS; RETINOPATHY; PREVALENCE; GLAUCOMA; LESIONS;
   CHINA
AB Purpose: To examine frequency and associations of retinal hemorrhages.
   Methods: The population-based Beijing Eye Study included 3,468 individuals. Monoscopic fundus photographs were examined for hemorrhages.
   Results: Retinal hemorrhages were detected in 515 eyes (429 individuals) (prevalence: 7.6%; 95% confidence interval [CI]: 7.0-8.0 per eye; 12.7%; 95% CI: 11.7-13.7 per person). Higher prevalence of retinal hemorrhages was correlated (multivariate analysis) with higher systolic blood pressure (P < 0.001; odds ratio: 1.02; 95% CI: 1.01-1.03), higher prevalence of diabetic retinopathy (P < 0.001; odds ratio: 121; 95% CI: 61-240), and higher prevalence of retinal vein occlusions (P < 0.001; odds ratio: 27; 95% CI: 17-42). Retinal hemorrhages were due to diabetic retinopathy (189 [36.7%] eyes), retinal vein occlusions (n = 65 [12.6%]), posterior vitreous detachment (n = 23 [4.5%]), glaucoma (n = 14 [2.7%]), exudative age-related macular degeneration (n = 8 [1.6%]), hypertensive retinopathy (n = 10 [1.9%]), and exudative myopic maculopathy (n = 1 [0.2%]). Retinal hemorrhages without evident ocular cause ("NOH") were detected in 204 (3.0%) eyes (or 39.6% of all retinal hemorrhages). Higher prevalence of NOHs was correlated with higher systolic blood pressure (P < 0.001; odds ratio: 1.02; 95% CI: 1.01-1.03) after adjusting for blood glucose concentration and prevalence of cortical cataract.
   Conclusion: In a population-based recruited cohort of individuals aged 50+ years, prevalence of any fundus hemorrhage was about 8% per eye and 13% per individual. Approximately 60% of the hemorrhages were due to ocular reasons, mainly diabetic retinopathy, retinal vein occlusions, and posterior vitreous detachment, whereas 40% of the bleedings were not evidently associated with ophthalmologic causes but strongly with elevated systolic blood pressure.
C1 [Zhou, Jin Qiong; Wei, Wen Bin] Capital Med Univ, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Eye Ctr,Beijing Tongren Hosp, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
   [Wang, Ya Xing; Xu, Liang; Zhao, Liang; Wang, Shuang; Xu, Jie; You, Qi Sheng; Yang, Hua] Capital Med Univ, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Fac Clin Med Mannheim, Mannheim, Germany.
C3 Capital Medical University; Capital Medical University; Ruprecht Karls
   University Heidelberg
RP Wei, WB (通讯作者)，Capital Med Univ, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing Ophthalmol & Visual Sci Key Lab, Beijing Tongren Eye Ctr,Beijing Tongren Hosp, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China.
EM tr_weiwenbin@163.com
RI Xu, Jie/AIE-0524-2022; xu, jie/GQR-1913-2022; wang, YA XING/K-9671-2016;
   You, Qisheng/AAG-7153-2020
OI xu, jie/0000-0002-2039-7055; wang, YA XING/0000-0003-2749-7793; You,
   Qisheng/0000-0003-0743-7320
FU National Natural Science Foundation of China [81770890]
FX Supported by National Natural Science Foundation of China (Grant
   #81770890).
CR Bertelsen G, 2014, ACTA OPHTHALMOL, V92, P316, DOI 10.1111/aos.12199
   Bhargava M, 2014, ACTA OPHTHALMOL, V92, pe602, DOI 10.1111/aos.12446
   Cugati S, 2006, EYE, V20, P1239, DOI 10.1038/sj.eye.6702085
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Kawasaki R, 2006, OPHTHALMOLOGY, V113, P1378, DOI 10.1016/j.ophtha.2006.02.052
   Keenan JD, 2009, AM J OPHTHALMOL, V147, P934, DOI 10.1016/j.ajo.2008.12.009
   Klein Ronald, 2006, Trans Am Ophthalmol Soc, V104, P98
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P1568, DOI 10.1001/archophthalmol.2010.298
   Liew G, 2011, OPHTHALMOLOGY, V118, P1612, DOI 10.1016/j.ophtha.2011.01.003
   Liu L, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008855
   Munch IC, 2012, ACTA OPHTHALMOL, V90, P613, DOI 10.1111/j.1755-3768.2011.2148.x
   Peng XY, 2010, OPHTHALMOLOGY, V117, P531, DOI 10.1016/j.ophtha.2009.07.045
   Schrijvers EMC, 2012, NEUROLOGY, V79, P365, DOI 10.1212/WNL.0b013e318260cd7e
   Shi Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175966
   Wang S, 2009, OPHTHALMOLOGY, V116, P2373, DOI 10.1016/j.ophtha.2009.05.041
   Wang YX, 2010, AM J OPHTHALMOL, V150, P917, DOI 10.1016/j.ajo.2010.06.037
   Wang Y, 2006, AM J OPHTHALMOL, V142, P241, DOI 10.1016/j.ajo.2006.02.032
   Wong TY, 2002, JAMA-J AM MED ASSOC, V288, P67, DOI 10.1001/jama.288.1.67
   Wong TY, 2005, JAMA-J AM MED ASSOC, V293, P63, DOI 10.1001/jama.293.1.63
   Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0
   Xu J, 2013, OPHTHALMOLOGY, V120, P2023, DOI 10.1016/j.ophtha.2013.03.009
   Yu T, 1998, ARCH OPHTHALMOL-CHIC, V116, P83, DOI 10.1001/archopht.116.1.83
   Zhou JQ, 2013, OPHTHALMOLOGY, V120, P803, DOI 10.1016/j.ophtha.2012.09.033
   ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P3
NR 24
TC 1
Z9 1
U1 1
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2019
VL 39
IS 6
BP 1206
EP 1215
DI 10.1097/IAE.0000000000002122
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4WW
UT WOS:000480753300034
PM 29533284
DA 2022-11-30
ER

PT J
AU Zhang, JY
   Zhou, KW
   Zhang, XY
   Zhou, YQ
   Li, Z
   Shang, F
AF Zhang, Jingyue
   Zhou, Kewen
   Zhang, Xinyu
   Zhou, Yeqi
   Li, Zhen
   Shang, Fu
TI Celastrol Ameliorates Inflammation in Human Retinal Pigment Epithelial
   Cells by Suppressing NF-kappa B Signaling
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE celastrol; retinal pigment epithelial cell; inflammation; NF-kappa B
   signaling; age-related macular degeneration
ID OXIDATIVE STRESS; MACULAR DEGENERATION; INSULIN-RESISTANCE; INHIBITION;
   ACTIVATION; RESPONSES; PROTECTS
AB Purpose: Celastrol is a triterpenoid quinine methide that exerts important biological effects on a variety of disease models. In this study, we aim to assess the ability of celastrol to inhibit lipopolysaccharide (LPS)-induced inflammation in retinal pigment epithelial (RPE) cells. Methods: Primary cultures of human RPE (HRPE) cells and ARPE-19 cell lines were treated with celastrol alone or in combination with LPS. The cytotoxic effect of celastrol on RPE cells was determined by the CCK-8 assay. Protein and mRNA levels of inflammatory cytokines, including IL-6, IL-8, and MCP-1, were detected by flow cytometry or by real-time fluorescent quantitative PCR, respectively. The levels of phosphorylated intermediates in the NF-kappa B signaling pathway (such as I kappa B alpha/beta and p65) and MAPK signaling pathway (p38MAPK, SAPK/JNK, and p42/p44MAPK) were detected by western blotting. Results: Celastrol significantly inhibited LPS-induced expression of protein and mRNA expression levels encoding the proinflammatory cytokines, IL-6, IL-8, and MCP-1, in both HRPE and ARPE-19 cells. Cell viability and apoptosis assays revealed that celastrol had no apparent cytotoxic effect and it inhibited apoptosis of RPE cells at concentrations of less than 1 mu M. Mechanistically, RPE cells that were pretreated with celastrol exhibited a substantial decrease in phosphorylation of the NF-kappa B pathway regulators, IKK alpha/beta and I kappa B alpha, and subsequently inactivated P65, suggesting that celastrol ameliorates LPS-induced inflammation by suppressing the NF-kappa B signaling pathway. Conclusion: Our results provide evidence that celastrol is a potent anti-inflammatory agent in RPE cells and it may have potential applications in prevention and treatment of age-related macular degeneration.
C1 [Zhang, Jingyue; Zhou, Kewen; Zhang, Xinyu; Zhou, Yeqi; Li, Zhen; Shang, Fu] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Shang, F (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 54 Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM shangfumax@sina.com
CR Abu Bakar MH, 2017, EUR J PHARMACOL, V799, P73, DOI 10.1016/j.ejphar.2017.01.043
   Abu Bakar MH, 2015, MOLECULES, V20, P8242, DOI 10.3390/molecules20058242
   An SY, 2017, BMB REP, V50, P25, DOI 10.5483/BMBRep.2017.50.1.114
   Arjamaa O, 2017, GRAEF ARCH CLIN EXP, V255, P1757, DOI 10.1007/s00417-017-3711-0
   Bian MJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0516-8
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hu MJ, 2017, MOL CELL, V66, P141, DOI 10.1016/j.molcel.2017.03.008
   Jung HW, 2007, EXP MOL MED, V39, P715, DOI 10.1038/emm.2007.78
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kannaiyan R, 2011, CANCER LETT, V303, P9, DOI 10.1016/j.canlet.2010.10.025
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim DH, 2009, EUR J CLIN INVEST, V39, P819, DOI 10.1111/j.1365-2362.2009.02186.x
   Kyung H, 2015, BRAIN RES, V1609, P21, DOI 10.1016/j.brainres.2015.03.032
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Lee JH, 2006, BIOCHEM PHARMACOL, V72, P1311, DOI 10.1016/j.bcp.2006.08.014
   Li YH, 2012, BRAIN RES, V1464, P8, DOI 10.1016/j.brainres.2012.04.054
   Ni HW, 2014, ACTA HAEMATOL-BASEL, V131, P102, DOI 10.1159/000354770
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083
   Pinna GF, 2004, BIOCHEM BIOPH RES CO, V322, P778, DOI 10.1016/j.bbrc.2004.07.186
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Roy A, 2016, INT IMMUNOPHARMACOL, V40, P79, DOI 10.1016/j.intimp.2016.08.026
   Seo WY, 2011, BIOCHEM BIOPH RES CO, V407, P535, DOI 10.1016/j.bbrc.2011.03.053
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Tao LF, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0489-7
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Venkatesha SH, 2012, BIOORGAN MED CHEM, V20, P5229, DOI 10.1016/j.bmc.2012.06.050
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Youn GS, 2014, TOXICOL APPL PHARM, V280, P42, DOI 10.1016/j.taap.2014.07.010
   Zhang HL, 2018, CELL PHYSIOL BIOCHEM, V49, P1918, DOI 10.1159/000493653
   Zhao J, 2015, INT IMMUNOPHARMACOL, V26, P221, DOI 10.1016/j.intimp.2015.03.033
NR 33
TC 11
Z9 11
U1 2
U2 17
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD MAR 1
PY 2019
VL 35
IS 2
BP 116
EP 123
DI 10.1089/jop.2018.0092
PG 8
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA HU5DC
UT WOS:000465295200005
PM 30596540
DA 2022-11-30
ER

PT J
AU Juncal, VR
   Hanout, M
   Altomare, F
   Chow, DR
   Giavedoni, LR
   Muni, RH
   Wong, DT
   Berger, AR
AF Juncal, Verena R.
   Hanout, Mostafa
   Altomare, Filiberto
   Chow, David R.
   Giavedoni, Louis R.
   Muni, Rajeev H.
   Wong, David T.
   Berger, Alan R.
TI Surgical management of submacular hemorrhage: experience at an academic
   Canadian centre
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   PARS-PLANA VITRECTOMY; MACULAR DEGENERATION; SUBRETINAL HEMORRHAGE;
   PNEUMATIC DISPLACEMENT; GAS INJECTION; INTRAVITREAL; RANIBIZUMAB;
   SECONDARY
AB Objective: To report the anatomical and visual outcomes of patients with thick submacular hemorrhage (SMH) treated with pars plane vitrectomy (PPV), subretinal tissue plasminogen activator (t-PA), and pneumatic displacement.
   Design: Single-centre, retrospective case series.
   Participants: A total of 99 eyes of 99 consecutive patients with thick SMH secondary to any underlying etiology treated with PPV with subretinal t-PA and pneumatic displacement by 6 vitreoretinal surgeons at St. Michael's Hospital, Toronto, between July 2004 and August 2016.
   Methods: All medical records and colour fundus photographs were reviewed for data collection. Blood displacement was evaluated at follow-up visits and classified as complete, partial, or none. Main outcome measures included blood displacement at final follow-up, postoperative Snellen best-corrected visual acuities (BCVA), and complication and recurrence rates.
   Results: Patients had a mean age of 77.7 +/- 12.3 years and were followed up for an average of 18.4 +/- 22.3 months. Wet age-related macular degeneration was the most common etiology associated with thick SMH (80.8%). Complete blood displacement was observed by final follow-up in 85.9% of the cases, partial displacement in 12.1%, and none in 2.0%. Mean logMAR BCVA improved from 2.03 +/- 0.81 (Snellen 20/2143) at baseline to 1.80 +/- 1.00 (Snellen 20/1262; p = 0.009) at final follow-up, and baseline BCVA was a significant predictor of final BCVA (p < 0.001). Early postoperative complications included vitreous hemorrhage in 13 eyes and rhegmatogenous retinal detachment in 8. Recurrent SMH was observed in 12 cases.
   Conclusions: Vitrectomy with subretinal t-PA and pneumatic displacement seems to be an effective treatment for SMH in terms of blood displacement and visual outcomes.
C1 [Juncal, Verena R.; Hanout, Mostafa; Altomare, Filiberto; Chow, David R.; Giavedoni, Louis R.; Muni, Rajeev H.; Wong, David T.; Berger, Alan R.] Univ Toronto, St Michaels Hosp, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Chow, David R.; Berger, Alan R.] Toronto Retina Inst, Toronto, ON, Canada.
C3 University of Toronto; University Toronto Affiliates; Saint Michaels
   Hospital Toronto
RP Berger, AR (通讯作者)，Univ Toronto, Dept Ophthalmol & Vis Sci, Suite 801-61 Queen St East, Toronto, ON M5C 2T2, Canada.
EM bergera@smh.ca
OI Wong, David/0000-0003-1376-845X
CR Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   Fujikawa M, 2013, RETINA-J RET VIT DIS, V33, P1908, DOI 10.1097/IAE.0b013e318287d99d
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Gonzalez-Lopez JJ, 2016, EYE, V30, P929, DOI 10.1038/eye.2016.65
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Kitagawa Y, 2016, OPHTHALMOLOGY, V123, P1278, DOI 10.1016/j.ophtha.2016.01.035
   Klettner A, 2015, BRIT J OPHTHALMOL, V99, P864, DOI 10.1136/bjophthalmol-2014-306454
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Moisseiev E, 2014, EUR J OPHTHALMOL, V24, P925, DOI 10.5301/ejo.5000500
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
   Woo J. John, 2004, International Ophthalmology Clinics, V44, P43, DOI 10.1097/00004397-200404410-00006
NR 32
TC 8
Z9 8
U1 0
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2018
VL 53
IS 4
BP 408
EP 414
DI 10.1016/j.jcjo.2017.10.010
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GQ3DR
UT WOS:000441541300033
PM 30119797
DA 2022-11-30
ER

PT J
AU Park, SS
   Moisseiev, E
   Bauer, G
   Anderson, JD
   Grant, MB
   Zam, A
   Zawadzki, RJ
   Werner, JS
   Nolta, JA
AF Park, Susanna S.
   Moisseiev, Elad
   Bauer, Gerhard
   Anderson, Johnathon D.
   Grant, Maria B.
   Zam, Azhar
   Zawadzki, Robert J.
   Werner, John S.
   Nolta, Jan A.
TI Advances in bone marrow stem cell therapy for retinal dysfunction
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Bone marrow; CD34; Hematopoietic; Mesenchymal; Retina; Stem cells
ID ENDOTHELIAL PROGENITOR CELLS; MESENCHYMAL STROMAL CELLS; OPTICAL
   COHERENCE TOMOGRAPHY; HUMAN NEURAL PROGENITORS; EXTRACELLULAR VESICLES;
   PIGMENT EPITHELIUM; RAT MODEL; TISSUE-REPAIR; MACULAR EDEMA; CD34(+)
   CELLS
AB The most common cause of untreatable vision loss is dysfunction of the retina. Conditions, such as age related macular degeneration, diabetic retinopathy and glaucoma remain leading causes of untreatable blindness worldwide. Various stem cell approaches are being explored for treatment of retinal regeneration. The rationale for using bone marrow stem cells to treat retinal dysfunction is based on preclinical evidence showing that bone marrow stem cells can rescue degenerating and ischemic retina. These stem cells have primarily paracrine trophic effects although some cells can directly incorporate into damaged tissue. Since the paracrine trophic effects can have regenerative effects on multiple cells in the retina, the use of this cell therapy is not limited to a particular retinal condition. Autologous bone marrow-derived stem cells are being explored in early clinical trials as therapy for various retinal conditions. These bone marrow stem cells include mesenchymal stem cells, mononuclear cells and CD34(+) cells. Autologous therapy requires no systemic immunosuppression or donor matching. Intravitreal delivery of CD34(+) cells and mononuclear cells appears to be tolerated and is being explored since some of these cells can home into the damaged retina after intravitreal administration. The safety of intravitreal delivery of mesenchymal stem cells has not been well established. This review provides an update of the current evidence in support of the use of bone marrow stem cells as treatment for retinal dysfunction. The potential limitations and complications of using certain forms of bone marrow stem cells as therapy are discussed. Future directions of research include methods to optimize the therapeutic potential of these stem cells, non-cellular alternatives using extracellular vesicles, and in vivo high-resolution retinal imaging to detect cellular changes in the retina following cell therapy. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Park, Susanna S.; Moisseiev, Elad; Zawadzki, Robert J.; Werner, John S.] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Bauer, Gerhard; Anderson, Johnathon D.; Nolta, Jan A.] Univ Calif Davis, Inst Regenerat Cures, Stem Cell Program, Sacramento, CA 95817 USA.
   [Grant, Maria B.] Indiana Univ, Glick Eye Inst, Dept Ophthalmol, Indianapolis, IN 46204 USA.
   [Zam, Azhar; Zawadzki, Robert J.] Univ Calif Davis, Dept Cell Biol & Human Anat, UC Davis RISE Eye Pod Small Anim Imaging Lab, Davis, CA 95616 USA.
   [Moisseiev, Elad] Tel Aviv Univ, Sackler Sch Med, Tel Aviv Med Ctr, Dept Ophthalmol, Tel Aviv, Israel.
   [Zam, Azhar] Univ Basel, Dept Biomed Engn, Allschwil, Switzerland.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis; Indiana
   University System; Indiana University-Purdue University Indianapolis;
   University of California System; University of California Davis; Tel
   Aviv University; Sackler Faculty of Medicine; University of Basel
RP Park, SS (通讯作者)，Univ Calif Davis, Ctr Eye, Dept Ophthalmol & Vis Sci, 4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
EM sscpark@ucdavis.edu; emoisseiev@ucdavis.edu; gbauer@ucdavis.edu;
   joanderson@ucdavis.edu; mabgrant@iupui.edu; azam@ucdavis.edu;
   rjzawadzki@ucdavis.edu; jswerner@ucdavis.edu; janolta@ucdavis.edu
RI Anderson, Johnathon D./H-5997-2019; Zam, Azhar/K-1772-2019; Yiu,
   Glenn/AAF-2858-2020; Zam, Azhar/ABE-2827-2021; Anderson,
   Johnathon/AAA-1647-2019; Zawadzki, Robert J./S-3236-2019; Zam,
   Azhar/K-8248-2012
OI Zam, Azhar/0000-0001-7789-5680; Zam, Azhar/0000-0001-7789-5680;
   Anderson, Johnathon/0000-0001-5404-2298; Zawadzki, Robert
   J./0000-0002-9574-156X; Nolta, Jan/0000-0003-4576-8542
FU Allergan, Inc.; Genentech, Inc.; Roche/Novartis; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCES [UL1TR001860] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [P30EY012576, R01EY026556, R01EY024239]
   Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [T32HL086350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCES [R01GM099688] Funding Source: NIH RePORTER
FX SSP has received research support to conduct contracted research from
   Allergan, Inc., Genentech, Inc., Roche/Novartis to study the effect of
   intravitreal anti-VEGF therapy and other drugs for treatment of retinal
   dysfunction. SSP has received honoraria from Genenetech, Inc., and
   Healthnet for consulting. JA and JAN hold provisional intellectual
   property rights for a method of exosome isolation from mesenchymal stem
   cells. A provisional intellectual property right application has been
   filed regarding intravitreal application of exosomes for ophthalmic
   applications (JA,JAN,EL,SSP).
CR Anderson JD, 2016, STEM CELLS, V34, P601, DOI 10.1002/stem.2298
   Arnhold S, 2007, GRAEF ARCH CLIN EXP, V245, P414, DOI 10.1007/s00417-006-0382-7
   Arslan F, 2013, STEM CELL RES, V10, P301, DOI 10.1016/j.scr.2013.01.002
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Bahlmann FH, 2005, HYPERTENSION, V45, P526, DOI 10.1161/01.HYP.0000159191.98140.89
   Bara JJ, 2014, STEM CELLS, V32, P1713, DOI 10.1002/stem.1649
   BERENSON RJ, 1988, J CLIN INVEST, V81, P951, DOI 10.1172/JCI113409
   Bernardo ME, 2013, CELL STEM CELL, V13, P392, DOI 10.1016/j.stem.2013.09.006
   Bhatwadekar AD, 2010, DIABETES, V59, P2010, DOI 10.2337/db10-0287
   Boudreault K, 2016, JAMA OPHTHALMOL, V134, P711, DOI 10.1001/jamaophthalmol.2016.0803
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Bunce C, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-58
   Busik JV, 2009, J EXP MED, V206, P2897, DOI 10.1084/jem.20090889
   Caballero S, 2007, DIABETES, V56, P960, DOI 10.2337/db06-1254
   Caballero S, 2013, INVEST OPHTH VIS SCI, V54, P3000, DOI 10.1167/iovs.12-10280
   Calzi SL, 2008, DIABETES, V57, P2488, DOI 10.2337/db08-0381
   Calzi SL, 2009, MICROVASC RES, V78, P132, DOI 10.1016/j.mvr.2009.03.007
   Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886
   Cappellari R, 2016, ATHEROSCLEROSIS, V251, P373, DOI 10.1016/j.atherosclerosis.2016.05.028
   Cerman E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156495
   Chakravarthy H, 2016, STEM CELLS, V34, P972, DOI 10.1002/stem.2259
   Chakravarthy H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146829
   Chaput N, 2011, SEMIN IMMUNOPATHOL, V33, P419, DOI 10.1007/s00281-010-0233-9
   Chen MF, 2010, INVEST OPHTH VIS SCI, V51, P5970, DOI 10.1167/iovs.09-4504
   Cheng M, 2015, J MOL CELL CARDIOL, V81, P49, DOI 10.1016/j.yjmcc.2015.01.024
   Chiba M, 2012, ONCOL REP, V28, P1551, DOI 10.3892/or.2012.1967
   Choi SS, 2011, BRIT J OPHTHALMOL, V95, P131, DOI 10.1136/bjo.2010.183756
   Chui TYP, 2013, INVEST OPHTH VIS SCI, V54, P7115, DOI 10.1167/iovs.13-13027
   Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003
   Critser PJ, 2010, CURR OPIN ORGAN TRAN, V15, P68, DOI 10.1097/MOT.0b013e32833454b5
   De Becker A, 2007, HAEMATOLOGICA, V92, P440, DOI 10.3324/haematol.10475
   de Jong OG, 2012, J EXTRACELL VESICLES, V1, DOI 10.3402/jev.v1i0.18396
   Desrochers LM, 2016, DEV CELL, V37, P301, DOI 10.1016/j.devcel.2016.04.019
   Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152
   Doeppner TR, 2015, STEM CELL TRANSL MED, V4, P1131, DOI 10.5966/sctm.2015-0078
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Douglas JY, 2012, PROG RETIN EYE RES, V31, P481, DOI 10.1016/j.preteyeres.2012.04.005
   Drago D, 2013, BIOCHIMIE, V95, P2271, DOI 10.1016/j.biochi.2013.06.020
   Dreixler JC, 2014, INVEST OPHTH VIS SCI, V55, P3785, DOI 10.1167/iovs.13-11683
   Duan P, 2013, CELL PHYSIOL BIOCHEM, V31, P601, DOI 10.1159/000350080
   Edelberg JM, 2002, CIRC RES, V90, pE89, DOI 10.1161/01.RES.0000020861.20064.7E
   EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978
   Enzmann V, 2009, ARCH OPHTHALMOL-CHIC, V127, P563, DOI 10.1001/archophthalmol.2009.65
   Fadini GP, 2015, DIABETES, V64, P2969, DOI 10.2337/db15-0077
   Fiorina P, 2011, J IMMUNOL, V186, P121, DOI 10.4049/jimmunol.1000799
   Foster A, 2005, EYE, V19, P1133, DOI 10.1038/sj.eye.6701973
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890-196803000-00009
   Fukuda S, 2013, STEM CELLS, V31, P2149, DOI 10.1002/stem.1469
   Galderisi U, 2014, MED RES REV, V34, P1100, DOI 10.1002/med.21322
   Gamm DM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000338
   Ge JF, 2014, STEM CELL REV REP, V10, P295, DOI 10.1007/s12015-013-9492-x
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Gong LH, 2008, CLIN EXP OPHTHALMOL, V36, P666, DOI 10.1111/j.1442-9071.2008.01857.x
   Goodell MA, 2015, NAT REV MOL CELL BIO, V16, P299, DOI 10.1038/nrm3980
   Gorczynska I, 2016, BIOMED OPT EXPRESS, V7, P911, DOI 10.1364/BOE.7.000911
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Harris JR, 2006, INVEST OPHTH VIS SCI, V47, P2108, DOI 10.1167/iovs.05-0928
   Hazra S, 2013, DIABETOLOGIA, V56, P644, DOI 10.1007/s00125-012-2781-0
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Hofling AA, 2003, BLOOD, V101, P2054, DOI 10.1182/blood-2002-08-2597
   Hu GW, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt546
   Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Johnson TV, 2014, BRAIN, V137, P503, DOI 10.1093/brain/awt292
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe131, DOI 10.1111/j.1755-3768.2009.01564.x
   Jorgensen MM, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26048
   Katsman D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050417
   Kawai H, 2010, J CEREBR BLOOD F MET, V30, P1487, DOI 10.1038/jcbfm.2010.32
   Kholia S, 2016, VASC PHARMACOL, VS1537-1891, P30105
   Kim DY, 2012, INVEST OPHTH VIS SCI, V53, P85, DOI 10.1167/iovs.11-8249
   Kim Hyongbum, 2012, Endocrine Metabolic & Immune Disorders-Drug Targets, V12, P168
   Kim J. Y., 2016, RETIN CASES BRIEF RE
   Kingman S, 2004, B WORLD HEALTH ORGAN, V82, P887
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Kramer-Albers EM, 2016, CURR OPIN NEUROBIOL, V39, P101, DOI 10.1016/j.conb.2016.04.016
   Kramerov AA, 2016, EXP BIOL MED, V241, P559, DOI 10.1177/1535370215609692
   Kriechbaum K, 2014, EYE, V28, P9, DOI 10.1038/eye.2013.242
   Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003
   Le Blanc K, 2006, CYTOTHERAPY, V8, P559, DOI 10.1080/14653240601045399
   Leeper NJ, 2010, CIRCULATION, V122, P517, DOI 10.1161/CIRCULATIONAHA.109.881441
   Leow SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128973
   Leung EH, 2016, OSLI RETINA, V47, P600, DOI 10.3928/23258160-20160601-16
   Levkovitch-Verbin H, 2010, INVEST OPHTH VIS SCI, V51, P6394, DOI 10.1167/iovs.09-4310
   Li H, 2012, MED HYPOTHESES, V78, P286, DOI 10.1016/j.mehy.2011.11.003
   Li N, 2009, GRAEF ARCH CLIN EXP, V247, P503, DOI 10.1007/s00417-008-1009-y
   Li Y, 2006, INVEST OPHTH VIS SCI, V47, P1646, DOI 10.1167/iovs.05-1092
   Lu B, 2010, EXP EYE RES, V91, P449, DOI 10.1016/j.exer.2010.06.024
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu SJ, 2007, NAT METHODS, V4, P501, DOI 10.1038/nmeth1041
   Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713
   Machalinska A, 2009, CURR EYE RES, V34, P748, DOI 10.1080/02713680903050592
   Mackie AR, 2011, TEX HEART I J, V38, P474
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Medina RJ, 2010, INVEST OPHTH VIS SCI, V51, P5906, DOI 10.1167/iovs.09-4951
   Medina RJ, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-18
   Mesentier-Louro LA, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5078619
   Moisseiev E, 2016, INVEST OPHTH VIS SCI, V57, P4125, DOI 10.1167/iovs.16-19252
   Muller-Sieburg CE, 2002, BLOOD, V100, P1302, DOI 10.1182/blood.V100.4.1302.h81602001302_1302_1309
   Murasawa S, 2002, CIRCULATION, V106, P1133, DOI 10.1161/01.CIR.0000027584.85865.B4
   Neuss S, 2004, STEM CELLS, V22, P405, DOI 10.1634/stemcells.22-3-405
   Otani A, 2004, J CLIN INVEST, V114, P765, DOI 10.1172/JCI200421686
   Pang WW, 2011, P NATL ACAD SCI USA, V108, P20012, DOI 10.1073/pnas.1116110108
   Parameswaran S, 2015, STEM CELLS, V33, P1743, DOI 10.1002/stem.1987
   Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200
   Park S. S., 2016, INVEST OPHTH VIS SCI, V57
   Park S. S., 2004, DUANES FDN CLIN OPHT, VI, P1
   Park SS, 2015, INVEST OPHTH VIS SCI, V56, P81, DOI 10.1167/iovs.14-15415
   Park SS, 2012, INVEST OPHTH VIS SCI, V53, P986, DOI 10.1167/iovs.11-8833
   Park TS, 2014, CIRCULATION, V129, P359, DOI 10.1161/CIRCULATIONAHA.113.003000
   Perry TE, 2009, CARDIOVASC RES, V84, P317, DOI 10.1093/cvr/cvp215
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Poddar R, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.12.126010
   Posel C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050293
   Radtke ND, 2002, AM J OPHTHALMOL, V133, P544, DOI 10.1016/S0002-9394(02)01322-3
   Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702
   Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132
   Rehman J, 2004, J AM COLL CARDIOL, V43, P2314, DOI 10.1016/j.jacc.2004.02.049
   Ruster B, 2006, BLOOD, V108, P3938, DOI 10.1182/blood-2006-05-025098
   Ryan Jennifer M, 2005, J Inflamm (Lond), V2, P8, DOI 10.1186/1476-9255-2-8
   Salz DA, 2016, JAMA OPHTHALMOL, V134, P644, DOI 10.1001/jamaophthalmol.2016.0600
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Sengupta N, 2003, INVEST OPHTH VIS SCI, V44, P4908, DOI 10.1167/iovs.03-0342
   Sengupta N, 2009, MOL THER, V17, P1594, DOI 10.1038/mt.2009.145
   Shah SU, 2013, CAN J OPHTHALMOL, V48, P204, DOI 10.1016/j.jcjo.2013.01.013
   Shantsila E, 2007, J AM COLL CARDIOL, V49, P741, DOI 10.1016/j.jacc.2006.09.050
   Shaw JE, 2010, DIABETES RES CLIN PR, V87, P4, DOI 10.1016/j.diabres.2009.10.007
   Shi MX, 2007, HAEMATOLOGICA, V92, P897, DOI 10.3324/haematol.10669
   Siqueira RC, 2013, BONE MARROW TRANSPL, V48, P612, DOI 10.1038/bmt.2012.185
   Siqueira RC, 2015, ACTA OPHTHALMOL, V93, pE174, DOI 10.1111/aos.12473
   Siqueira RC, 2011, RETINA-J RET VIT DIS, V31, P1207, DOI 10.1097/IAE.0b013e3181f9c242
   Siqueira RC, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt91
   Soliman MK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152788
   Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271
   Squillaro T, 2016, CELL TRANSPLANT, V25, P829, DOI 10.3727/096368915X689622
   STELLA CC, 1995, HAEMATOLOGICA, V80, P367
   Sun JN, 2015, STEM CELLS, V33, P1543, DOI 10.1002/stem.1960
   Sun XR, 2011, CYTOTHERAPY, V13, P294, DOI 10.3109/14653249.2010.523075
   Tassoni A, 2015, STEM CELLS, V33, P3006, DOI 10.1002/stem.2095
   Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730
   Thinda S., 2015, HDB VITREORETINAL DI, P119
   Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043
   Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279
   Turner L, 2016, CELL STEM CELL, V19, P154, DOI 10.1016/j.stem.2016.06.007
   Tzameret A, 2014, EXP EYE RES, V118, P135, DOI 10.1016/j.exer.2013.10.023
   Tzekov R, 1999, SURV OPHTHALMOL, V44, P53, DOI 10.1016/S0039-6257(99)00063-6
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Vaughan Erin E, 2012, Methods Mol Biol, V916, P351, DOI 10.1007/978-1-61779-980-8_25
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Wang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009200
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan JL, 2013, STEM CELL REV REP, V9, P360, DOI 10.1007/s12015-013-9433-8
   Yau G., 2015, HDB VITREORETINAL DI, P33
   Yodoi Y, 2007, INVEST OPHTH VIS SCI, V48, P5464, DOI 10.1167/iovs.07-0093
   Yu B, 2014, INT J MOL SCI, V15, P4142, DOI 10.3390/ijms15034142
   Zhang YQ, 2003, INVEST OPHTH VIS SCI, V44, P324, DOI 10.1167/iovs.02-0132
   Zohlnhofer D, 2006, JAMA-J AM MED ASSOC, V295, P1003, DOI 10.1001/jama.295.9.1003
   Zou H, 2010, BIOCHEM BIOPH RES CO, V391, P1268, DOI 10.1016/j.bbrc.2009.12.057
NR 162
TC 68
Z9 72
U1 1
U2 37
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2017
VL 56
BP 148
EP 165
DI 10.1016/j.preteyeres.2016.10.002
PG 18
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ1YY
UT WOS:000393007700007
PM 27784628
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Wimmer, T
   Lorenz, B
   Stieger, K
AF Wimmer, T.
   Lorenz, B.
   Stieger, K.
TI Quantification of the vascular endothelial growth factor with a
   bioluminescence resonance energy transfer (BRET) based single molecule
   biosensor
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Vascular endothelial growth factor (VEGF); Bioluminescence resonance
   energy transfer (BRET); Single chain variable fragment (scFv);
   Ranibizumab
ID PROTEIN-PROTEIN INTERACTIONS; ANTI-VEGF ANTIBODY; LIVING SUBJECTS;
   MACULAR DEGENERATION; REAL-TIME; BINDING; ANGIOGENESIS; RANIBIZUMAB;
   LUCIFERASE; VARIANTS
AB Neovascular pathologies in the eye like age-related macular degeneration (AMD), the diabetic retinopathie (DR), retinopathie of prematurity (ROP) or the retinal vein occlusion (RVO) are caused through a hypoxia induced upregulation of the vascular endothelial growth factor (VEGF). So far a correlation of intraocular VEGF concentrations to the impact of the pathologies is limited because of invasive sampling. Therefore, a minimally invasive, repeatable quantification of VEGF levels in the eye is needed to correlate the stage of VEGF induced pathologies as well as the efficacy of anti-VEGF treatment. Here we describe the development of three variants of enhanced BRET2 (eBRET2) based, single molecule biosensors by fusing a Renilla luciferase mutant with enhanced light output (RLuc8) to the N-terminus and a suitable eBRET2 acceptor fluorophore (GFP2) to the C-terminus of a VEGF binding domain, directly fused or separated with two different peptide linkers for the quantification of VEGF in vitro. The VEGF binding domain consists of a single chain variable fragment (scFv) based on ranibizumab in which the light- and the heavy-Flab) chains were connected with a peptide linker to generate one open reading frame (orf). All three variants generate measureable eBRET2 ratios by transferring energy from the luciferase donor to the GFP2 acceptor, whereas only the directly fused and the proline variant permit VEGF quantification. The directly fused biosensor variant allows the quantification of VEGF with higher sensitivity, compared to the widely used ELISA systems and a wide dynamic quantification range in vitro. Our system demonstrates not only an additional in vitro application on VEGF quantification but also a promising step towards an applicable biosensor in an implantable device able to quantify VEGF reliably after implantation in vivo. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Wimmer, T.; Lorenz, B.; Stieger, K.] Univ Giessen, Dept Ophthalmol, Giessen, Germany.
C3 Justus Liebig University Giessen
RP Stieger, K (通讯作者)，Univ Giessen, Dept Ophthalmol, Giessen, Germany.
EM knut.stieger@uniklinikum-giessen.de
RI Stieger, Knut/A-1600-2012
OI Stieger, Knut/0000-0002-8298-5629
FU research prize from Novartis Germany (EYE-novative research prize)
FX The authors gratefully acknowledge S. Gambhir (Stanford University, CA,
   USA) for providing RLc8 cDNA constructs. This work was supported by a
   research prize from Novartis Germany (EYE-novative research prize 2014).
CR Borroto-Escuela DO, 2013, METHOD CELL BIOL, V117, P141, DOI 10.1016/B978-0-12-408143-7.00008-6
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Dacres H, 2012, BIOCHEM BIOPH RES CO, V425, P625, DOI 10.1016/j.bbrc.2012.07.133
   De A, 2007, CANCER RES, V67, P7175, DOI 10.1158/0008-5472.CAN-06-4623
   Dragulescu-Andrasi A, 2011, P NATL ACAD SCI USA, V108, P12060, DOI 10.1073/pnas.1100923108
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Foerster T., 1948, ANN PHYS, V2, P55
   Geretti E, 2008, ANGIOGENESIS, V11, P31, DOI 10.1007/s10456-008-9097-1
   Goel HL, 2013, NAT REV CANCER, V13, P871, DOI 10.1038/nrc3627
   Hang HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104133
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kowanetz M, 2006, CLIN CANCER RES, V12, P5018, DOI 10.1158/1078-0432.CCR-06-1520
   Le NCH, 2014, BIOSENS BIOELECTRON, V62, P177, DOI 10.1016/j.bios.2014.06.032
   Loening AM, 2007, NAT METHODS, V4, P641, DOI 10.1038/NMETH1070
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Pfleger KDG, 2006, NAT PROTOC, V1, P337, DOI 10.1038/nprot.2006.52
   Rea I, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3626008
   Schaarschmidt J., 2016, J BIOCH CHEM
   Sela-Culang I, 2012, J IMMUNOL, V189, P4890, DOI 10.4049/jimmunol.1201493
   Siddiqui S., 2013, FRONT ENDOCRINOL, V4, P1
   Turner APF, 2013, CHEM SOC REV, V42, P3184, DOI 10.1039/c3cs35528d
   Wimmer T, 2015, J OCUL PHARMACOL TH, V31, P269, DOI 10.1089/jop.2014.0125
NR 25
TC 15
Z9 15
U1 4
U2 67
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD DEC 15
PY 2016
VL 86
BP 609
EP 615
DI 10.1016/j.bios.2016.07.058
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA DY1KG
UT WOS:000384853300084
PM 27459244
DA 2022-11-30
ER

PT J
AU Cacciamani, A
   Parravano, M
   Scarinci, F
   Esposito, G
   Varano, M
   Micera, A
AF Cacciamani, Andrea
   Parravano, Mariacristina
   Scarinci, Fabio
   Esposito, Graziana
   Varano, Monica
   Micera, Alessandra
TI A Simple Spontaneous Vitreal Reflux Collecting Procedure During
   Intravitreal Injection: Set-Up and Validation Studies
SO CURRENT EYE RESEARCH
LA English
DT Article
DE IL13; micropipettes; nAMD; tears; VEGF; vitreal reflux
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; CYTOKINES;
   IDENTIFICATION; DEGENERATION; PATHOGENESIS
AB Aim: To set-up a simple technique for collecting spontaneous vitreal reflux (VR) in patients undergoing intravitreal injection. Both total protein concentration and vascular endothelial growth factor (VEGF)/Interleukin 13 (IL13) levels were used to validate the technique.Methods: Sixty consecutive patients with neovascular age-related macular degeneration (nAMD, vitreal reflux drop, VR) and 10 patients underwent vitrectomy for macular hole (whole vitreous removal) were enrolled for the study as controls. Thirty-three out of 60 patients were also subjected to tear sampling. VR sampling was performed after the intravitreal injection. Four sampling tools (10 Schirmer strips, 10 microsponges, 20 millipore filters; 20 micropipettes) were tested. Analysis of protein concentration/composition was performed between VR samples and vitreous samples to analyze the difference. The concentration of VEGF and IL 13 levels between cases and control samples were compared.Results: Millipore and micropipette techniques allowed the collection of higher protein concentrations in VR samples, comparison of both protein concentrations revealed no significant difference in the protein profile. However, the micropipette sampling was found easier to perform and did not require additional protein extraction from a solid support (membrane). Indeed, tear proteins and drug contaminants were not detected in micropipette samples. Increased VEGF levels were detected in naive VR group and to a less extend in VR group of nAMD patients undergoing intravitreal injection, with respect to the controls (macular holes). No significant differences in IL13 levels were quantified in nAMD sub-groups, as compared to naive and controls.Conclusions: Overall, we provide evidence for a safe method for sampling VR at the end of intravitreal injection. This procedure might represent an interesting approach either for the prognosis of disease or monitoring the efficacy of intravitreal therapy.
C1 [Cacciamani, Andrea; Parravano, Mariacristina; Scarinci, Fabio; Esposito, Graziana; Varano, Monica; Micera, Alessandra] GB Bietti Fdn, IRCCS, Via Livenza 3, I-00198 Rome, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia
RP Cacciamani, A (通讯作者)，GB Bietti Fdn, IRCCS, Via Livenza 3, I-00198 Rome, Italy.
EM andrea_cacciamani@hotmail.com
RI Cacciamani, Andrea/AAB-2154-2021; Varano, Monica/K-8573-2016; Scarinci,
   Fabio/AAB-5126-2020; Micera, Alessandra/J-3373-2013
OI Cacciamani, Andrea/0000-0003-1793-9842; Scarinci,
   Fabio/0000-0001-5444-4377; micera, alessandra/0000-0002-9375-6071;
   esposito, graziana/0000-0002-8777-197X; Varano,
   Monica/0000-0002-6530-1563
FU Italian Ministry of Health
FX The authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the paper. The study was
   partially supported by the Italian Ministry of Health and by an
   intramural sustain from Fondazione Roma (Italy).
CR Aiello LP, 2005, NEW ENGL J MED, V353, P839, DOI 10.1056/NEJMe058142
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Brodie FL, 2014, RETINA-J RET VIT DIS, V34, P1473, DOI 10.1097/IAE.0000000000000098
   Brodie FL, 2014, CURR EYE RES, V39, P752, DOI 10.3109/02713683.2013.864774
   Bromberg-White JL, 2013, INVEST OPHTH VIS SCI, V54, P6472, DOI 10.1167/iovs.13-12518
   BROWN D, 1994, CURR EYE RES, V13, P639, DOI 10.3109/02713689408999899
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Davuluri G, 2009, ARCH OPHTHALMOL-CHIC, V127, P613, DOI 10.1001/archophthalmol.2009.88
   Ehlers JP, 2011, SURV OPHTHALMOL, V56, P281, DOI 10.1016/j.survophthal.2010.11.006
   Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005
   Funatsu H, 2005, OPHTHALMOLOGY, V112, P806, DOI 10.1016/j.ophtha.2004.11.045
   Funatsu H, 2006, ADV CLIN CHEM, V42, P111, DOI 10.1016/S0065-2423(06)42004-7
   Giansanti F, 2009, INVEST OPHTH VIS SCI, V50, P5328, DOI 10.1167/iovs.09-3569
   Hohenstein-Blaul NVU, 2013, EXP EYE RES, V117, P126, DOI 10.1016/j.exer.2013.07.015
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Koss MJ, 2012, ACTA OPHTHALMOL, V90, pe98, DOI 10.1111/j.1755-3768.2011.02292.x
   Lee WJ, 2012, BRIT J OPHTHALMOL, V96, P1426, DOI 10.1136/bjophthalmol-2012-301913
   Mitry D, 2013, COCHRANE DB SYST REV, V1
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Noma H, 2005, AM J OPHTHALMOL, V140, P256, DOI 10.1016/j.ajo.2005.03.003
   Noma H, 2012, RETINA-J RET VIT DIS, V32, P86, DOI 10.1097/IAE.0b013e31821801de
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pfahler SM, 2009, RETINA-J RET VIT DIS, V29, P1032, DOI 10.1097/IAE.0b013e3181a2c1eb
   Romero-Aroca P, 2013, WORLD J DIABETES, V4, P165, DOI 10.4239/wjd.v4.i5.165
   Saeed MU, 2011, SEMIN OPHTHALMOL, V26, P357, DOI 10.3109/08820538.2011.588648
   SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119
   Virgili G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub3
   Wu CW, 2004, AM J OPHTHALMOL, V137, P655, DOI 10.1016/j.ajo.2003.11.009
NR 28
TC 8
Z9 8
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUL
PY 2016
VL 41
IS 7
BP 971
EP 976
DI 10.3109/02713683.2015.1080282
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR6KL
UT WOS:000380010700016
PM 26470652
DA 2022-11-30
ER

PT J
AU de Silva, SR
   Bindra, MS
AF de Silva, S. R.
   Bindra, M. S.
TI Early treatment of acute submacular haemorrhage secondary to wet AMD
   using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF
   agent
SO EYE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; SUBRETINAL HEMORRHAGE;
   NATURAL-HISTORY; EXPANSILE GAS; MANAGEMENT; INJECTION
AB Purpose Acute submacular haemorrhage secondary to wet age-related macular degeneration (AMD) has a poor prognosis for which there is currently no 'gold standard' treatment. We evaluated the efficacy of early treatment using intravitreal triple therapy of tissue plasminogen activator (tPA), expansile gas, and an anti-VEGF agent.
   Methods This retrospective case series included eight patients presenting with acute submacular haemorrhage involving the fovea. All patients received treatment with 50 mu g (0.05 ml) tPA, 0.3 ml 100% perfluoropropane (C3F8), and an anti-VEGF agent (0.05 mg Ranibizumab or 1.25 mg Bevacizumab in 0.05 ml) administered via intravitreal injection. An anterior chamber paracentesis post injection or vitreous tap was performed before injection to prevent retinal vascular occlusion secondary to raised intra-ocular pressure. Outcomes assessed were visual acuity, change in macular morphology, and complications.
   Results Patients presented promptly with delay between symptom onset and clinic review being 1.9 +/- 0.6 days (mean +/- SD). Treatment was delivered quickly with interval from presentation to treatment being 1.1 +/- 1.2 days. Symptom onset to treatment was 3.0 +/- 1.0 days. Subfoveal haemorrhage was effectively displaced in all patients. LogMAR visual acuity improved from 1.67 +/- 0.47 at presentation to 0.63 +/- 0.33 at final follow-up (P<0.0001), a mean of 7.9 +/- 4.8 months after treatment. Central retinal thickness improved from 658.1 +/- 174.2 mu m at presentation to 316.6 +/- 142.4 mu m at final follow-up (P = 0.0028).
   Conclusions Early treatment of submacular haemorrhage using intravitreal tPA, C3F8, and anti-VEGF was effective in significantly improving visual acuity in this series of patients who presented soon after symptom onset. Treatment was well tolerated in this group of elderly and potentially frail patients.
C1 [de Silva, S. R.; Bindra, M. S.] Stoke Mandeville Hosp, Aylesbury, Bucks, England.
RP Bindra, MS (通讯作者)，Stoke Mandeville Hosp, Dept Ophthalmol, Mandeville Rd, Aylesbury, Bucks, England.
EM mandeep.bindra@buckshealthcare.nhs.uk
OI De Silva, Samantha/0000-0002-4455-2814
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Buhl M, 1999, OPHTHALMOLOGE, V96, P792, DOI 10.1007/s003470050498
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Heriot W, 1996, VAIL VITR M VAIL CO
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Sandhu SS, 2010, CLIN OPHTHALMOL, V4, P637
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
NR 18
TC 11
Z9 11
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2016
VL 30
IS 7
BP 952
EP 957
DI 10.1038/eye.2016.67
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR0GS
UT WOS:000379586600008
PM 27080482
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Clemens, CR
   Alten, F
   Heiduschka, P
   Eter, N
AF Clemens, Christoph R.
   Alten, Florian
   Heiduschka, Peter
   Eter, Nicole
TI MORPHOLOGY SCORE AS A MARKER OF RETINAL FUNCTION IN DRUSENOID PIGMENT
   EPITHELIAL DETACHMENT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; multifocal electroretinography;
   microperimetry; drusenoid pigment epithelial detachment; scanning laser
   ophthalmoscopy; spectral domain optical coherence tomography; morphology
   score
ID OPTICAL COHERENCE TOMOGRAPHY; SCANNING LASER OPHTHALMOSCOPE; MACULAR
   DEGENERATION; MULTIFOCAL ELECTRORETINOGRAM; MICROPERIMETRY;
   CLASSIFICATION; SENSITIVITY; FEATURES; LESION; EYES
AB Purpose:To evaluate a morphology score for drusenoid pigment epithelial detachment (dPED) regarding predictability of a decline in retinal function beyond best-corrected visual acuity.Methods:Thirteen eyes of 10 patients with dPED due to age-related macular degeneration (AMD) were included (age 72.8 4.2 years). All underwent volume spectral domain optical coherence tomography, fluorescence angiography, and confocal scanning laser ophthalmoscopy infrared imaging as well as multifocal electroretinography and microperimetry. The dPED morphology score suggested consists of five parameters: hyperreflective spots in infrared, lesion diameter, lesion height, presence of vitelliform-like material in the subretinal space or subretinal fluid, and integrity of the ellipsoid zone in spectral domain optical coherence tomography. Subsequently, a score value between 0 and 1 according to the extent of morphologic changes was correlated to foveal multifocal electroretinography and microperimetry measurements.Results:The mean best-corrected visual acuity was 20/40. The mean height and mean diameter of dPED were 312.2 +/- 111 m and 2,535 +/- 805 m. Two dPED showed no hyperreflective spots in confocal scanning laser ophthalmoscopy infrared images, three displayed a moderate stage of hyperreflective spots, and eight had severe hyperreflective spots. Two eyes showed subretinal fluid, and five patients showed vitelliform-like material in the subretinal space. Eight eyes revealed a severe disruption of the ellipsoid zone. Although no correlation was found between dPED morphology score and best-corrected visual acuity, eyes with a dPED morphology score >0.5 revealed distinctly decreased values in functional measurements compared with those with a score 0.5.Conclusion:The dPED morphology score aggregates all currently known morphologic changes in dPED and represents a valuable tool for clinical lesion evaluation. Furthermore, it allows for assessing an estimate of functional decline beyond best-corrected visual acuity.
C1 [Clemens, Christoph R.; Alten, Florian; Heiduschka, Peter; Eter, Nicole] Univ Munster, Med Ctr, Dept Ophthalmol, D-48149 Munster, Germany.
C3 University of Munster
RP Clemens, CR (通讯作者)，Univ Munster, Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM christoph.clemens@ukmuenster.de
RI Heiduschka, Peter/AAX-3882-2021
CR Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Garcia CAD, 2013, RETINA-J RET VIT DIS, V33, P1558, DOI 10.1097/IAE.0b013e318285cbd2
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Gabor GD, 2010, INVEST OPHTH VIS SCI, V51, P6710, DOI 10.1167/iovs.09-5064
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Gundogan FC, 2008, DOC OPHTHALMOL, V117, P175, DOI 10.1007/s10633-008-9119-8
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Iwama D, 2010, CLIN EXP OPHTHALMOL, V38, P483, DOI 10.1111/j.1442-9071.2010.02294.x
   Jurklies B, 2002, GRAEF ARCH CLIN EXP, V240, P244, DOI 10.1007/s00417-002-0439-1
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P647, DOI 10.1097/IAE.0b013e31823fb847
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Ogino K, 2014, JPN J OPHTHALMOL, V58, P155, DOI 10.1007/s10384-013-0295-z
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Schatz P, 2010, INVEST OPHTH VIS SCI, V51, P4754, DOI 10.1167/iovs.10-5152
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   SUTTER EE, 1991, SIAM J COMPUT, V20, P686, DOI 10.1137/0220043
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Yip YWY, 2010, DOC OPHTHALMOL, V120, P193, DOI 10.1007/s10633-010-9213-6
NR 31
TC 3
Z9 3
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2015
VL 35
IS 7
BP 1351
EP 1359
DI 10.1097/IAE.0000000000000473
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM2AA
UT WOS:000357480600008
PM 25658174
DA 2022-11-30
ER

PT J
AU Liu, CQ
   Cao, LN
   Yang, S
   Xu, LXY
   Liu, P
   Wang, F
   Xu, D
AF Liu, Chaoqi
   Cao, Lining
   Yang, Shuai
   Xu, Linxinyu
   Liu, Pei
   Wang, Fang
   Xu, Ding
TI Subretinal injection of amyloid-beta peptide accelerates RPE cell
   senescence and retinal degeneration
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE age-related macular degeneration; inflammation; senescence; retinal
   pigment epithelium
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; OXIDATIVE STRESS;
   GEOGRAPHIC ATROPHY; IN-VIVO; DRUSEN; INFLAMMATION; EXPRESSION; RECEPTOR;
   PATTERNS
AB Drusen are considered a hallmark characteristic of age-related macular degeneration (AMD). In our previous study, we found that amyloid- (A) peptide, a component of drusen, induced the cells of the retinal pigment epithelium (RPE; RPE cells) to enter senescence; however, its effects in vivo remain unknown. Thus, the present study was carried out to explore the in vivo effects of A peptide on RPE cell senescence and senescence-associated inflammation in C57BL/6 mice. C57BL/6 mice received a subretinal injection of A(1-42) peptide; on day 7 post-injection, the mice were anesthetized and subjected to whole-body perfusion with 4% paraformaldehyde (PFA) in PBS and the whole eyes were then enucleated. Retinal function was assessed by electroretinography (ERG), and the morphological characteristics of the retina were examined by light and electron microscopy. Fundus autofluorescence (FAF) was examined by confocal scanning laser ophthalmoscopy (cSLO). The expression of p16(INK4a), a marker of cellular senescence, was examined by immunofluorescence staining and western blot analysis. The RPE-choroid was analyzed for cytokine expression by RT-PCR. In A(1-42)-injected mice, scotopic ERG responses declined. Degenerative alterations, including the disruption of the inner segment (IS)/outer segment (OS) junction and extensive vacuolation and thickness of Bruch's membrane (BrM) were observed under a a light microscope. The accumulation of vacuoles and the loss of basal infoldings in the RPE were identified using an electron microscope. FAF and p16(INK4a) expression increased in A(1-42)-injected mice. In addition, A(1-42) upregulated interleukin (IL)-6 and IL-8 gene expression in the RPE-choroid. In conclusion, our results confirm the effects of A(1-42) peptide on RPE senescence in vivo. The A-injected mice developed AMD-like ocular pathology. It is thus suggested that RPE cell senescence is a potential mechanistic link between inflammation and retinal degeneration.
C1 [Liu, Chaoqi; Cao, Lining; Yang, Shuai; Xu, Linxinyu; Liu, Pei; Wang, Fang; Xu, Ding] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China.
C3 Tongji University
RP Wang, F (通讯作者)，Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Ophthalmol, 301 Middle Yan Chang Rd, Shanghai 200072, Peoples R China.
EM 18917683335@163.com; daisyxu70@hotmail.com
FU Outstanding Youths Program of Shanghai Tongji University [1501219084];
   Science and Technology Commission of Shanghai [11JC1409900]; National
   High Technology Research and Development Program of China (863 program)
   [S2010GR0002]
FX We would like to thank the Biochemistry and Molecular Biology Institute
   of Shanghai Tenth People's Hospital and are grateful for their
   technological support. This study was supported by grants from the
   Outstanding Youths Program of Shanghai Tongji University (No.
   1501219084), the Science and Technology Commission of Shanghai (No.
   11JC1409900) and the National High Technology Research and Development
   Program of China (863 program, No. S2010GR0002).
CR Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013
   Bhat R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045069
   Bressler Neil M, 2005, Retina, V25, P130, DOI 10.1097/00006982-200507001-00016
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Butterfield DA, 2004, BRAIN PATHOL, V14, P426
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Cao L, 2013, BRAZ J MED BIOL RES, V46, P659, DOI 10.1590/1414-431X20132903
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Cho YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057172
   Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Dagouassat M, 2013, AM J RESP CRIT CARE, V187, P703, DOI 10.1164/rccm.201208-1361OC
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Donnini S, 2010, FASEB J, V24, P2385, DOI 10.1096/fj.09-146456
   DRUEKE T, 1990, KIDNEY INT, V37, P1438, DOI 10.1038/ki.1990.134
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Freund A, 2010, TRENDS MOL MED, V16, P238, DOI 10.1016/j.molmed.2010.03.003
   Golde TE, 2009, ALZHEIMERS RES THER, V1, DOI 10.1186/alzrt5
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hanitzsch R, 1997, DOC OPHTHALMOL, V94, P275, DOI 10.1007/BF02582985
   He N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.437
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999
   HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468
   Jeyapalan JC, 2008, MECH AGEING DEV, V129, P467, DOI 10.1016/j.mad.2008.04.001
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Katz ML, 2005, MECH AGEING DEV, V126, P513, DOI 10.1016/j.mad.2004.11.004
   KATZ ML, 1984, EXP EYE RES, V38, P137, DOI 10.1016/0014-4835(84)90098-8
   Ksiazek K, 2009, AM J PHYSIOL-REG I, V296, pR374, DOI 10.1152/ajpregu.90451.2008
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI [10.1167/iovs.12-10849234627523947398, DOI 10.1167/IOVS.12-10849234627523947398]
   Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   PENN RD, 1969, NATURE, V223, P201, DOI 10.1038/223201a0
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   Rawes V, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1291
   Rayess H, 2012, INT J CANCER, V130, P1715, DOI 10.1002/ijc.27316
   Robson JG, 2004, VISION RES, V44, P3253, DOI 10.1016/j.visres.2004.09.002
   ROBSON JG, 1995, VISUAL NEUROSCI, V12, P837, DOI 10.1017/S0952523800009408
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com
   Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   TIAN N, 1995, VISION RES, V35, P1359, DOI 10.1016/0042-6989(95)98715-L
   Timmers A, 2001, MOL VIS, V7, P131
   Tsuji T, 2010, RESPIRATION, V80, P59, DOI 10.1159/000268287
   Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
NR 59
TC 42
Z9 47
U1 0
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JAN
PY 2015
VL 35
IS 1
BP 169
EP 176
DI 10.3892/ijmm.2014.1993
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AX0MW
UT WOS:000346647300020
PM 25385658
OA Bronze
DA 2022-11-30
ER

PT J
AU Cai, JJ
   Sun, L
   Lin, B
   Wu, MA
   Qu, J
   Snider, BJ
   Wu, SZ
AF Cai, Jingjing
   Sun, Lin
   Lin, Bing
   Wu, Meng'ai
   Qu, Jia
   Snider, B. Joy
   Wu, Shengzhou
TI Pretreatment with Proteasome Inhibitors Protects against Oxidative
   Injuries via PPAR alpha-Dependent and -Independent Pathways in ARPE-19
   Cells
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; ACTIVATION; DISEASE;
   STRESS; RPE; APOPTOSIS; DAMAGE; BRAIN; DEATH
AB PURPOSES. Oxidative processes may play important roles in age-related macular degeneration. Previous studies have suggested that enhancing proteasome activity by pretreatment with low doses of proteasome inhibitors reduces injury from oxidative damage in neuronal cultures. The objective of the current study was to determine whether proteasome inhibitors could ameliorate the toxicity from oxidative stresses in ARPE-19 cells and to dissect the pathways that may mediate these protective effects.
   METHODS. The toxicity of oxidative stressors menadione (VK3) and 4-hydroxynonenal (4-HNE) and the protective effects of proteasome inhibitors, including MG-132 and clasto-lactacystin-beta-lactone (LA), were studied in ARPE-19 cells. Binding and activation of the peroxisome proliferator-activated receptors (PPARs) family of transcription factors were studied using electrophoretic mobility shift assay (EMSA) and a peroxisome proliferator-activated response element (PPRE)-driven dualluciferase reporter gene.
   RESULTS. An 18-hour pretreatment with 30 to 300 nM MG-132 or 300 to 1000 nM LA reduced the toxicity of menadione or 4-HNE in ARPE-19 cells. The protective effects of MG-132 pretreatment were partially reversed by the PPAR alpha antagonist GW6471 but not by the PPAR gamma antagonist GW9662; in contrast, neither agent reduced the protective effects of LA. MG-132 but not LA induced increased expression of a PPRE-driven luciferase reporter gene in a dose-dependent manner. Nuclear proteins isolated from ARPE-19 cells treated by MG-132 had increased binding to PPRE sequences as measured by EMSA.
   CONCLUSIONS. Our data suggest that pretreatment with proteasome inhibitors reduces oxidative injury in ARPE-19 cells and that the underlying mechanisms are different for different proteasome inhibitors, with PPAR alpha-dependent effects for MG-132 and PPAR-independent effects for LA. (Invest Ophthalmol Vis Sci. 2012; 53: 5967-5974) DOI:10.1167/iovs.12-10048
C1 [Wu, Shengzhou] Wenzhou Med Coll, Sch Optometry & Ophthalmol, Natl Minist Hlth, Key Lab Visual Sci, Wenzhou 325027, Zhejiang, Peoples R China.
   [Cai, Jingjing; Sun, Lin; Lin, Bing; Wu, Meng'ai; Qu, Jia; Wu, Shengzhou] Hosp Eye, Wenzhou Med Coll, Hangzhou 325027, Zhejiang, Peoples R China.
   [Cai, Jingjing; Sun, Lin; Lin, Bing; Wu, Meng'ai; Qu, Jia; Wu, Shengzhou] State Key Lab Cultivat Base, Hangzhou, Zhejiang, Peoples R China.
   [Cai, Jingjing; Sun, Lin; Lin, Bing; Wu, Meng'ai; Qu, Jia; Wu, Shengzhou] Zhejiang Prov Key Lab Ophthalmol & Optometry, Hangzhou, Zhejiang, Peoples R China.
   [Snider, B. Joy] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
C3 Wenzhou Medical University; Wenzhou Medical University; Washington
   University (WUSTL)
RP Wu, SZ (通讯作者)，Wenzhou Med Coll, Sch Optometry & Ophthalmol, Natl Minist Hlth, Key Lab Visual Sci, Wenzhou 325027, Zhejiang, Peoples R China.
EM wszlab@mail.eye.ac.cn
RI wu, shengzhou/ABG-8579-2021; Lin, Binshan/A-9772-2009
OI wu, shengzhou/0000-0003-1154-2369; Lin, Binshan/0000-0002-8481-302X;
   Cai, Jingjing/0000-0003-0708-3809
FU Zhejiang Province Natural Science Foundation [Y2110086]; Scientific
   Research Foundation for the Returned Overseas Chinese Scholars, State
   Education Ministry of China; Wenzhou Medical College [89210001];
   Talented College Students of Zhejiang Province [2011R413007]
FX Supported in part by Zhejiang Province Natural Science Foundation Grant
   Y2110086, by Scientific Research Foundation for the Returned Overseas
   Chinese Scholars, State Education Ministry of China, by Start-up Funding
   Grant 89210001 from Wenzhou Medical College (SW), and the Talented
   College Students of Zhejiang Province Grant 2011R413007.
CR Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812
   Chang JY, 2008, PPAR RES, V2008, DOI 10.1155/2008/720163
   Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q
   Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Field-Smith Antonia, 2006, Ther Clin Risk Manag, V2, P271, DOI 10.2147/tcrm.2006.2.3.271
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Ha KN, 2006, INVEST OPHTH VIS SCI, V47, P2709, DOI 10.1167/iovs.05-1322
   Hawkins BS, 1999, MOL VIS, V5
   Jeong S, 2011, ACTA PHARMACOL SIN, V32, P230, DOI 10.1038/aps.2010.198
   Kapphahn RJ, 2007, EXP EYE RES, V84, P646, DOI 10.1016/j.exer.2006.12.002
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221
   Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x
   Kraft DC, 2006, ANN NY ACAD SCI, V1067, P420, DOI 10.1196/annals.1354.060
   Lee CS, 2004, J NEUROCHEM, V91, P996, DOI 10.1111/j.1471-4159.2004.02813.x
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204
   Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353
   McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050
   MICELI MV, 1994, EXP CELL RES, V214, P242, DOI 10.1006/excr.1994.1254
   Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5
   Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tsao WC, 2005, EXP CELL RES, V304, P234, DOI 10.1016/j.yexcr.2004.11.004
   TSUKAHARA T, 1988, EUR J BIOCHEM, V177, P261, DOI 10.1111/j.1432-1033.1988.tb14371.x
   Ueda T, 1996, OPHTHALMIC RES, V28, P184, DOI 10.1159/000267901
   Wang ZY, 2009, FREE RADICAL BIO MED, V46, P1032, DOI 10.1016/j.freeradbiomed.2008.11.027
   Wegener S, 2004, STROKE, V35, P616, DOI 10.1161/01.STR.0000115767.17923.6A
   Wu SZ, 2004, ANN NY ACAD SCI, V1035, P133, DOI 10.1196/annals.1332.009
   Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074
   Yin KJ, 2002, J NEUROSCI, V22, P9764
NR 37
TC 7
Z9 7
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2012
VL 53
IS 9
BP 5967
EP 5974
DI 10.1167/iovs.12-10048
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004QE
UT WOS:000308695400112
PM 22879419
DA 2022-11-30
ER

PT J
AU Patel, H
   Gilmartin, B
   Cubbidge, RP
   Logan, NS
AF Patel, Hetal
   Gilmartin, Bernard
   Cubbidge, Robert P.
   Logan, Nicola S.
TI In vivo measurement of regional variation in anterior scleral resistance
   to Schiotz indentation
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE ocular rigidity; Schiotz tonometry; sclera; tissue resistance
ID OCULAR PULSE AMPLITUDE; INTRAOCULAR-PRESSURE; COLLAGEN ARCHITECTURE;
   BLOOD-FLOW; RIGIDITY; SEM; AGE; EYE
AB Purpose: Recent studies indicate that ocular and scleral rigidity is pertinent to our understanding of glaucoma, age related macular degeneration and the development and pathogenesis of myopia. The principal method of measuring ocular rigidity is by extrapolation of data from corneal indentation tonometry (K-o) using Friedenwald's transformation algorithms. Using scleral indentation (Schiotz tonometry) we assess whether regional variations in resistance to indentation occur in vivo across the human anterior globe directly, with reference to the deflection of Schiotz scale readings.
   Methods: Data were collected from both eyes of 26 normal young adult subjects with a range of refractive error (mean spherical equivalent +/- S. D. of -1.77 D +/- 3.28 D, range -10.56 to +4.38 D). Schiotz tonometry (5.5 g & 7.5 g) was performed on the cornea and four scleral quadrants; supero-temporal (ST) and -nasal (SN), infero-temporal (IT) and -nasal (IN) approximately 8 mm posterior to the limbus.
   Results: Values of K-o (mm(3))(-1) were consistent with those previously reported (mean 0.0101 +/- 0.0082, range 0.0019-0.0304). In regards to the sclera, significant differences (p < 0.001) were found across quadrants with indentation readings for both loads between means for the cornea and ST; ST and SN; ST and IT, ST and IN. Mean (+/- S. D.) scale readings for 5.5 g were: cornea 5.93 +/- 1.14, ST 8.05 +/- 1.58, IT 7.03 +/- 1.86, SN 6.25 +/- 1.10, IN 6.02 +/- 1.49; and 7.5 g: cornea 9.26 +/- 1.27, ST 11.56 +/- 1.65, IT 10.31 +/- 1.74, SN 9.91 +/- 1.20, IN 9.50 +/- 1.56.
   Conclusions: Significant regional variation was found in the resistance of the anterior sclera to indentation produced by the Schiotz tonometer.
C1 [Patel, Hetal; Gilmartin, Bernard; Cubbidge, Robert P.; Logan, Nicola S.] Aston Univ, Ophthalm Res Grp, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
C3 Aston University
RP Patel, H (通讯作者)，Aston Univ, Ophthalm Res Grp, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.
EM h.d.patel1@aston.ac.uk
RI Logan, Nicola/ABC-9102-2020
OI Cubbidge, Robert P/0000-0002-7851-1375; Logan, Nicola
   S/0000-0002-0538-9516
FU College of Optometrist
FX College of Optometrist's Summer Scholarship ( 2008) for Larissa
   Dorochtchak- Technical Assistant in the above study.
CR ALLEN M J, 1964, Am J Optom Arch Am Acad Optom, V41, P476
   Allen MJ, 1963, J AM OPTOM ASSN, V34, P616
   Allen MJ, 1963, J AM OPTOM ASSOC, V34, P956
   Asejczyk-Widlicka M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2907453
   Bayerle-Eder M, 2005, BRIT J OPHTHALMOL, V89, P704, DOI 10.1136/bjo.2004.062661
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Curtin B J, 1969, Trans Am Ophthalmol Soc, V67, P417
   Dastiridou AI, 2009, INVEST OPHTH VIS SCI, V50, P5718, DOI 10.1167/iovs.09-3760
   Ebneter A, 2009, EYE, V23, P606, DOI 10.1038/eye.2008.47
   Elsheikh A, 2010, EXP EYE RES, V90, P624, DOI 10.1016/j.exer.2010.02.010
   FISHMAN DR, 1991, J CLIN NEURO-OPHTHAL, V11, P162
   FRIBERG TR, 1988, EXP EYE RES, V47, P429, DOI 10.1016/0014-4835(88)90053-X
   Friedenwald J.S., 1937, AM J OPHTHALMOL, V20, P985, DOI [10.1016/s0002-9394(37)90425-2, DOI 10.1016/S0002-9394(37)90425-2, 10.1016/S0002-9394(37)90425-2]
   Friedenwald JS, 1957, T AM ACAD OPHTHALMOL, V61, P108
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Gomi CF, 2007, AM J OPHTHALMOL, V144, P654, DOI 10.1016/j.ajo.2007.07.026
   GREENE PR, 1980, AM J OPTOM PHYS OPT, V57, P902
   Herzog D, 2008, GRAEF ARCH CLIN EXP, V246, P1737, DOI 10.1007/s00417-008-0922-4
   Hommer A, 2008, INVEST OPHTH VIS SCI, V49, P4046, DOI 10.1167/iovs.07-1342
   KAISERKUPFER MI, 1985, T OPHTHAL SOC UK, V104, P191
   KOKOTT W, 1938, A VONGRAEFES ARCH OP, V138, P424
   Lam AKC, 2003, OPTOMETRY VISION SCI, V80, P305, DOI 10.1097/00006324-200304000-00008
   MOSES RA, 1982, INVEST OPHTH VIS SCI, V22, P551
   Norman RE, 2010, EXP EYE RES, V90, P277, DOI 10.1016/j.exer.2009.11.001
   Pallikaris IG, 2006, AM J OPHTHALMOL, V141, P611, DOI 10.1016/j.ajo.2005.11.010
   Pallikaris IG, 2005, INVEST OPHTH VIS SCI, V46, P409, DOI 10.1167/iovs.04-0162
   Rada JAS, 2006, EXP EYE RES, V82, P185, DOI 10.1016/j.exer.2005.08.009
   READER AL, 1982, OPHTHALMOLOGY, V89, P1084
   Schmid KL, 2003, CURR EYE RES, V26, P65, DOI 10.1076/ceyr.26.2.65.14513
   Schubert HD, 1996, SURV OPHTHALMOL, V41, P97, DOI 10.1016/S0039-6257(96)80001-4
   SHULMAN P F, 1963, Am J Optom Arch Am Acad Optom, V40, P133
   Singh KD, 2006, INVEST OPHTH VIS SCI, V47, P2272, DOI 10.1167/iovs.05-0856
   SMOLEK M, 1988, AM J OPTOM PHYS OPT, V65, P653
   SPITZNAS M, 1971, AM J OPHTHALMOL, V71, P68, DOI 10.1016/0002-9394(71)91095-6
   Taban M, 2010, OCUL IMMUNOL INFLAMM, V18, P305, DOI 10.3109/09273941003658292
   THALE A, 1993, ANN ANAT, V175, P215, DOI 10.1016/S0940-9602(11)80004-X
   Thale A, 1996, OPHTHALMOLOGICA, V210, P137, DOI 10.1159/000310693
   Thale A, 1996, OPHTHALMOLOGICA, V210, P142, DOI 10.1159/000310694
NR 38
TC 20
Z9 21
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD SEP
PY 2011
VL 31
IS 5
BP 437
EP 443
DI 10.1111/j.1475-1313.2011.00840.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 806GD
UT WOS:000293793400002
PM 21504438
DA 2022-11-30
ER

PT J
AU Wornle, M
   Merkle, M
   Wolf, A
   Ribeiro, A
   Himmelein, S
   Kernt, M
   Kampik, A
   Eibl-Lindner, KH
AF Woernle, Markus
   Merkle, Monika
   Wolf, Armin
   Ribeiro, Andrea
   Himmelein, Susanne
   Kernt, Marcus
   Kampik, Anselm
   Eibl-Lindner, Kirsten H.
TI Inhibition of TLR3-Mediated Proinflammatory Effects by
   Alkylphosphocholines in Human Retinal Pigment Epithelial Cells
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID TOLL-LIKE RECEPTOR-3; COMPLEMENT FACTOR-H; MACULAR DEGENERATION; RISK;
   PROLIFERATION; RECOGNITION; MILTEFOSINE; EXPRESSION
AB PURPOSE. To elucidate the role of Toll-like receptor 3 (TLR3) in the pathogenesis of age-related macular degeneration (AMD) and to investigate the effect of alkylphosphocholines (APCs) on the TLR3-mediated expression of cytokines and growth factors in human retinal pigment epithelial (RPE) cells.
   METHODS. Confluent cultures of human RPE cells (ARPE-19) were stimulated with poly (I:C) RNA as a well-established ligand for TLR3. Cytokine profiles were determined by RT-PCR on the activation of TLR3. RPE cells were transfected with siRNA specific for TLR3 and RIG-1 to determine the receptors involved. The effect of preincubation of RPE cells with APCs on the expression level of target genes was assessed.
   RESULTS. Poly (I:C) RNA stimulation led to a dose-dependent increase in the expression of TLR3 and RIG-I. A significant increase in expression levels of IL-6, TNF-alpha, IL-8, MCP-1, ICAM-1, and BFGF was observed after poly (I:C) RNA stimulation (P < 0.05). This effect was time and dose dependent. No effect on PEDG or VEGF expression was seen. Transfection of RPE cells with siRNA specific for TLR3 reduced poly (I:C) RNA-induced mRNA expression of the genes (P < 0.05). Preincubation of RPE cells with APCs significantly reduced the poly (I:C) RNA-induced expression of the target genes (P < 0.05).
   CONCLUSIONS. The authors demonstrate that the expression of proinflammatory cytokines and chemokines in RPE cells depends on the activation of TLR3. The induction of downstream gene expression is blocked by siRNA specific for TLR3 and alkylphosphocholines. Therefore, TLR3 should be considered a novel target in AMD therapy. (Invest Ophthalmol Vis Sci. 2011; 52:6536-6544) DOI:10.1167/iovs.10-6993
C1 [Wolf, Armin; Kernt, Marcus; Kampik, Anselm; Eibl-Lindner, Kirsten H.] Univ Munich, Dept Ophthalmol, Klinikum Univ Munchen, D-80336 Munich, Germany.
   [Woernle, Markus; Ribeiro, Andrea; Himmelein, Susanne] Univ Munich, Med Policlin, Dept Internal Med, D-80336 Munich, Germany.
   [Merkle, Monika] Klinikum Traunstein, Dept Internal Med, Traunstein, Germany.
C3 University of Munich; University of Munich
RP Eibl-Lindner, KH (通讯作者)，Univ Munich, Dept Ophthalmol, Klinikum Univ Munchen, Campus Innenstadt,Mathildenstr 8, D-80336 Munich, Germany.
EM kirsten.eibl@med.uni-muenchen.de
FU Freunde und Forderer der Augenklinik der Ludwig-Maximilians-Universitat
   Munchen; Else Kroner-Fresenius-Stiftung; Fritz-Bender-Stiftung; Deutsche
   Vereinigung zur Bekampfung von Viruskrankheiten
FX Supported by Freunde und Forderer der Augenklinik der
   Ludwig-Maximilians-Universitat Munchen (KE); Else
   Kroner-Fresenius-Stiftung, Fritz-Bender-Stiftung, Deutsche Vereinigung
   zur Bekampfung von Viruskrankheiten (MW).
CR Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Botos I, 2009, BBA-GENE REGUL MECH, V1789, P667, DOI 10.1016/j.bbagrm.2009.06.005
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Eibl KH, 2006, INVEST OPHTH VIS SCI, V47, P364, DOI 10.1167/iovs.05-0657
   Eibl KH, 2004, INVEST OPHTH VIS SCI, V45, P2619, DOI 10.1167/iovs.03-1351
   Eibl KH, 2003, INVEST OPHTH VIS SCI, V44, P3556, DOI 10.1167/iovs.02-1172
   Eibl KH, 2007, INVEST OPHTH VIS SCI, V48, P1305, DOI 10.1167/iovs.06-0591
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Leonard R, 2001, J CLIN ONCOL, V19, P4150, DOI 10.1200/JCO.2001.19.21.4150
   Marshall-Clarke S, 2007, J BIOL CHEM, V282, P24759, DOI 10.1074/jbc.M700188200
   Matsukura S, 2007, INT ARCH ALLERGY IMM, V143, P80, DOI 10.1159/000101411
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556
   Vitour D, 2007, SCI STKE, V384, P20
   Wornle M, 2006, AM J PATHOL, V168, P370, DOI 10.2353/ajpath.2006.050491
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood-2006-12-063636
NR 26
TC 20
Z9 21
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2011
VL 52
IS 9
BP 6536
EP 6544
DI 10.1167/iovs.10-6993
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 815SI
UT WOS:000294548300024
PM 21715345
DA 2022-11-30
ER

PT J
AU Saunders, RE
   Goodship, THJ
   Zipfel, PF
   Perkins, SJ
AF Saunders, RE
   Goodship, THJ
   Zipfel, PF
   Perkins, SJ
TI An interactive web database of factor H-associated hemolytic uremic
   syndrome mutations: Insights into the structural consequences of
   disease-associated mutations
SO HUMAN MUTATION
LA English
DT Article
DE factor H; complement; HUS; CFH; mutation database; immunodeficiency
   diseases; membranoproliferative glomerulonephritis; age-related macular
   degeneration
ID COMPLEMENT FACTOR-H; HEPARIN-BINDING DOMAIN; STREPTOCOCCAL-M PROTEIN;
   MACULAR DEGENERATION; ANALYTICAL ULTRACENTRIFUGATION; ALTERNATIVE
   PATHWAY; NEUTRON-SCATTERING; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; X-RAY
AB Factor H (FH) is a central complement regulator comprised of 20 short complement repeat (SCR) domains. Nucleotide changes within this gene (CFH) have been observed in patients with hemolytic uremic syndrome (HUS), and also membranoproliferative glomerulonephritis and age-related macular degeneration. All parts of FH are affected, but many mutations are clustered in the C-terminal part of FH. Up to now, structural analyses of HUS have been based on SCR-20, a domain that is involved in FH interactions with C3b, heparin, and endothelial cells. In order to identify the structural and functional consequence of HUS mutations, further disease, associated mutations were analyzed in terms of homology and nuclear magnetic resonance (NMR) models for factor H SCR domains. An interactive web database of 54 human HUS-associated mutations and others was created from the literature (www.FH,HUS.org). This has comprehensive search and analysis tools, integrating phenotypic and genetic data with structural analysis. Each mutation can be highlighted on the SCR structure to.-ether with the patient FH and C3 levels where available. Two new insights were obtained from our collection of data. First, phenotypic data on FH clarify our previously proposed classification of Type I and Type II disorders that both lead to HUS, where Type I affects FH secretion and folding, and Type II leads to expressed protein in plasma that is functionally defective. Second, the new mutations show more clearly that SCR domains from SCR,16 to SCR,19 are important for the ligand binding activities of FH as well as SCR-20. This FH web database will facilitate the interpretation of new mutations and polymorphisms when these are identified in patients, and it will clarify the functional role of FH.
C1 UCL, Dept Biochem & Mol Biol, Royal Free & Univ Coll, Sch Med, London WC1E 6BT, England.
   Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Hans Knoll Inst Nat Prod Res, Dept Infect Biol, Jena, Germany.
C3 University of London; University College London; UCL Medical School;
   Newcastle University - UK; Hans Knoll Institute (HKI)
RP Perkins, SJ (通讯作者)，UCL, Dept Biochem & Mol Biol, Royal Free & Univ Coll, Sch Med, Darwin Bldg,Gower St, London WC1E 6BT, England.
EM s.perkins@medsch.ucl.ac.uk
FU Wellcome Trust Funding Source: Medline
CR Altschul SF, 1998, TRENDS BIOCHEM SCI, V23, P444, DOI 10.1016/S0968-0004(98)01298-5
   Aslam M, 2003, J MOL BIOL, V329, P525, DOI 10.1016/S0022-2836(03)00492-3
   Aslam M, 2001, J MOL BIOL, V309, P1117, DOI 10.1006/jmbi.2001.4720
   Ault BH, 2000, PEDIATR NEPHROL, V14, P1045, DOI 10.1007/s004670050069
   Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168
   Ballermann BJ, 1998, KIDNEY INT, V53, P1810, DOI 10.1046/j.1523-1755.1998.00943.x
   BARLOW PN, 1992, BIOCHEMISTRY-US, V31, P3626, DOI 10.1021/bi00129a011
   BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Blackmore TK, 1996, J IMMUNOL, V157, P5422
   Blackmore TK, 1998, J IMMUNOL, V160, P3342
   Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166
   Buddles MRH, 2000, AM J HUM GENET, V66, P1721, DOI 10.1086/302877
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Caprioli J, 2001, J AM SOC NEPHROL, V12, P297, DOI 10.1681/ASN.V122297
   Claustres M, 2002, GENOME RES, V12, P680, DOI 10.1101/gr.217702
   Creighton TE, 1993, PROTEINS STRUCTURES
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hegasy GA, 2002, AM J PATHOL, V161, P2027, DOI 10.1016/S0002-9440(10)64481-1
   Hellwage J, 2002, J IMMUNOL, V169, P6935, DOI 10.4049/jimmunol.169.12.6935
   HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657
   Jokiranta TS, 2000, J BIOL CHEM, V275, P27657
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KOISTINEN V, 1992, BIOCHEM J, V283, P317, DOI 10.1042/bj2830317
   KOISTINEN V, 1993, MOL IMMUNOL, V30, P113, DOI 10.1016/0161-5890(93)90082-M
   Kraiczy P, 2004, J BIOL CHEM, V279, P2421, DOI 10.1074/jbc.M308343200
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Law SKA, 1995, COMPLEMENT
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396
   Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Ormsby RJ, 2004, MOL IMMUNOL, V41, P289
   PANGBURN MK, 1991, J BIOL CHEM, V266, P16847
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   Perez-Caballero D, 2001, AM J HUM GENET, V68, P478, DOI 10.1086/318201
   Perkins SJ, 2002, BIOCHEM SOC T, V30, P996, DOI 10.1042/bst0300996
   PERKINS SJ, 1986, EUR J BIOCHEM, V157, P155, DOI 10.1111/j.1432-1033.1986.tb09652.x
   Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337
   Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743
   Remuzzi G, 2002, LANCET, V359, P1671, DOI 10.1016/S0140-6736(02)08560-4
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   Sanchez-Corral P, 2000, IMMUNOGENETICS, V51, P366, DOI 10.1007/s002510050631
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6
NR 57
TC 75
Z9 78
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD JAN
PY 2006
VL 27
IS 1
BP 21
EP 30
DI 10.1002/humu.20268
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 997LD
UT WOS:000234245900003
PM 16281287
DA 2022-11-30
ER

PT J
AU Breithaupt, DE
   Weller, P
   Wolters, M
   Hahn, A
AF Breithaupt, DE
   Weller, P
   Wolters, M
   Hahn, A
TI Comparison of plasma responses in human subjects after the ingestion of
   3R,3R '-zeaxanthin dipalmitate from wolfberry (Lycium barbarum) and
   non-esterified 3R,3R '-zeaxanthin using chiral high-performance liquid
   chromatography
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE 3R,3 ' R-zeaxanthin; zeaxanthin esters; plasma carotenoid response;
   chiral analysis; liquid chromatography-atmospheric pressure chemical
   ionisation-mass spectrometry
ID BETA-CRYPTOXANTHIN ESTERS; GOU-QI-ZI; INTESTINAL-ABSORPTION; HUMAN
   CHYLOMICRONS; MASS-SPECTROMETRY; MACULAR PIGMENT; CAROTENOIDS;
   ZEAXANTHIN; LUTEIN; IDENTIFICATION
AB Age-related macular degeneration (AMD) is one of the most common eye diseases of elderly individuals. It has been suggested that lutein and zeaxanthin may reduce the risk for AMD. Information concerning the absorption of non-esterified or esterified zeaxanthin is rather scarce. Furthermore, the formation pathway of meso (3R,3'S)-zeaxanthin, which does not occur in plants but is found in the macula, has not yet been identified. Thus, the present study was designed to assess the concentration of 3R,3R'-zeaxanthin reached in plasma after the consumption of a. single dose of native 3R,3'R-zeaxanthin palmitate from wolfberry (Lycium barbarum) or non-esterified 3R,3'R-zeaxanthin in equal amounts. In a randomised, single-blind cross-over study, twelve volunteers were administered non-esterified or esterified 3R,3'R-zeaxanthin (5 mg) suspended in yoghurt together with a balanced breakfast. Between the two intervention days, a 3-week depletion period was inserted. After fasting overnight, blood was collected before the dose (0 h), and at 3, 6, 9, 12, and 24 h after the dose. The concentration of non-esterified 3R,3'R-zeaxanthin was determined by chiral HPLC. For the first time, chiral liquid chromatography-atmospheric pressure chemical ionisation-MS was used to confirm the appearance of 3R,3'R-zeaxanthin in pooled plasma samples. Independent of the consumed diet, plasma 3R,3'R-zeaxanthin concentrations increased significantly (P=0.05) and peaked after 9-24 h. Although the concentration curves were not distinguishable, the respective areas under the curve were distinguishable according to a two-sided F and t test (P=0.05). Thus, the study indicates an enhanced bioavailability of 3R, 3'R-zeaxathin dipalmitate compared with the non-esterified form. The formation of meso-zeaxanthin was not observed during the time period studied.
C1 Univ Hohenheim, Inst Food Chem, D-70593 Stuttgart, Germany.
   Univ Hannover, Inst Food Sci, D-30453 Hannover, Germany.
C3 University Hohenheim; Leibniz University Hannover
RP Breithaupt, DE (通讯作者)，Univ Hohenheim, Inst Food Chem, Garbenstr 28, D-70593 Stuttgart, Germany.
EM breithau@uni-hohenheim.de
OI Hahn, Andreas/0000-0001-8459-6582
CR Barua AB, 2001, J CHROMATOGR A, V936, P71, DOI 10.1016/S0021-9673(01)01145-1
   Barua AB, 1999, BIOCHEM J, V339, P359, DOI 10.1042/0264-6021:3390359
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bohm V, 1999, EUR J NUTR, V38, P118, DOI 10.1007/s003940050052
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bowen PE, 2002, J NUTR, V132, P3668, DOI 10.1093/jn/132.12.3668
   Breithaupt DE, 2000, EUR FOOD RES TECHNOL, V211, P52, DOI 10.1007/s002170050588
   Breithaupt DE, 2003, BRIT J NUTR, V90, P795, DOI 10.1079/BJN2003962
   Breithaupt DE, 2001, J AGR FOOD CHEM, V49, P2064, DOI 10.1021/jf001276t
   Grobusch KK, 2000, ATHEROSCLEROSIS, V148, P49, DOI DOI 10.1016/S0021-9150(99)00221-X
   JORDAN P, 1995, CLIN CHEM, V41, P924
   Khachik F, 1997, ANAL CHEM, V69, P1873, DOI 10.1021/ac961085i
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   KHACHIK F, 1992, ANAL CHEM, V64, P2111, DOI 10.1021/ac00042a016
   Lam KW, 1999, FOOD CHEM, V67, P173, DOI 10.1016/S0308-8146(99)00119-3
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Leung IYF, 2001, INVEST OPHTH VIS SCI, V42, P466
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   MURKOVIC M, 2000, J FOOD COMPOS ANAL, V13, P455
   OLSON JA, 1994, PURE APPL CHEM, V66, P1011, DOI 10.1351/pac199466051011
   Perez-Galvez A, 2003, BRIT J NUTR, V89, P787, DOI 10.1079/BJN2003842
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Weller P, 2003, J AGR FOOD CHEM, V51, P7044, DOI 10.1021/jf034803s
   Wingerath T, 1995, ARCH BIOCHEM BIOPHYS, V324, P385, DOI 10.1006/abbi.1995.0052
   Yao LH, 2000, LIPIDS, V35, P339, DOI 10.1007/s11745-000-0531-0
   Zhou L, 1999, J OCUL PHARMACOL TH, V15, P557, DOI 10.1089/jop.1999.15.557
NR 27
TC 66
Z9 76
U1 1
U2 27
PU C A B I PUBLISHING
PI WALLINGFORD
PA C/O PUBLISHING DIVISION, WALLINGFORD OX10 8DE, OXON, ENGLAND
SN 0007-1145
J9 BRIT J NUTR
JI Br. J. Nutr.
PD MAY
PY 2004
VL 91
IS 5
BP 707
EP 713
DI 10.1079/BJN20041105
PG 7
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 824EL
UT WOS:000221668600007
PM 15137922
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Evans, JR
   Fletcher, AE
   Wormald, RPL
AF Evans, JR
   Fletcher, AE
   Wormald, RPL
TI Causes of visual impairment in people aged 75 years and older in
   Britain: an add-on study to the MRC Trial of Assessment and Management
   of Older People in the Community
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NURSING-HOME RESIDENTS; BLUE MOUNTAINS EYE; POPULATION; PREVALENCE;
   ACUITY; BLINDNESS
AB Background: Visual impairment and blindness are common in older people in Britain. It is important to know the causes of visual impairment to develop health service and research priorities. The authors aimed to identify the causes of visual impairment in people aged 75 years and older in Britain.
   Methods: In the MRC Trial of the Assessment and Management of Older People in the Community, trial nurses tested visual acuity in everyone aged 75 years and older in 53 general practices. For all visually impaired patients in 49 of the 53 medical practices, data regarding the cause of vision loss were extracted from the general practice medical notes. Additional follow up questionnaires were also sent to the hospital ophthalmologist to confirm the cause of vision loss. Visual impairment was defined as a binocular acuity of less than 6/18.
   Results: There were 1742 (12.5%) people visually impaired in the 49 participating practices. Of these, 450 (26%) achieved a pinhole visual acuity in either eye of 6/18 or better. In these people, the principal reason for visual loss was considered to be refractive error. The cause of visual loss was available for 976 (76%) of the remaining 1292 visually impaired people identified. The main cause of visual loss was age related macular degeneration (AMD); 52.9% (95% confidence interval 49.2 to 56.5) of people had AMD as a main or contributory cause. This was followed by cataract (35.9%), glaucoma (11.6%), myopic degeneration (4.2%), and diabetic eye disease (3.4%).
   Conclusions: A substantial proportion of visual impairment in our sample of older people in Britain can be attributed to remediable causes - refractive error and cataract. There is considerable potential for visual rehabilitation in this age group. For the large proportion with macular degeneration, low vision services will be important.
C1 Inst Ophthalmol, Dept Epidemiol & Int Eye Hlth, London, England.
   London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, London WC1, England.
C3 University of London; University College London; University of London;
   London School of Hygiene & Tropical Medicine
RP Evans, JR (通讯作者)，Inst Ophthalmol, Dept Epidemiol & Int Eye Hlth, London, England.
EM jennifer.evans@lshtm.ac.uk
RI Evans, Jennifer/F-4672-2012
OI Evans, Jennifer/0000-0002-6137-2030
CR Desai P, 1999, BRIT J OPHTHALMOL, V83, P1336, DOI 10.1136/bjo.83.12.1336
   EDERER F, 1986, AM J PUBLIC HEALTH, V76, P160, DOI 10.2105/AJPH.76.2.160
   Evans J., 1995, STUDIES MED POPULATI, V57
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   Fletcher AE, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-21
   Foran S, 2002, AM J OPHTHALMOL, V134, P712, DOI 10.1016/S0002-9394(02)01673-2
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   MCGRAW PV, 1993, OPHTHAL PHYSL OPT, V13, P400, DOI 10.1111/j.1475-1313.1993.tb00499.x
   Mitchell P, 1997, MED J AUSTRALIA, V166, P73, DOI 10.5694/j.1326-5377.1997.tb138724.x
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   van der Pols JC, 2000, BRIT J OPHTHALMOL, V84, P165, DOI 10.1136/bjo.84.2.165
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P2203, DOI 10.1016/S0161-6420(00)00459-0
   WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226
NR 14
TC 92
Z9 94
U1 0
U2 16
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR 1
PY 2004
VL 88
IS 3
BP 365
EP 370
DI 10.1136/bjo.2003.019927
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 776EY
UT WOS:000189104800014
PM 14977771
OA Bronze, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Avraham, D
   Yitzhaky, Y
AF Avraham, David
   Yitzhaky, Yitzhak
TI Simulating the perceptual effects of electrode-retina distance in
   prosthetic vision
SO JOURNAL OF NEURAL ENGINEERING
LA English
DT Article
DE retina; electrode; distance; prosthesis; vision; phosphene; persistence
ID ELECTRICAL-STIMULATION; VISUAL-PERCEPTION; GANGLION-CELLS; STRUCTURAL
   SIMILARITY; SPATIAL-RESOLUTION; THRESHOLDS; ACTIVATION; PERFORMANCE;
   DESIGN
AB Objective. Retinal prostheses aim to restore some vision in retinitis pigmentosa and age-related macular degeneration blind patients. Many spatial and temporal aspects have been found to affect prosthetic vision. Our objective is to study the impact of the space-variant distance between the stimulating electrodes and the surface of the retina on prosthetic vision and how to mitigate this impact. Approach. A prosthetic vision simulation was built to demonstrate the perceptual effects of the electrode-retina distance (ERD) with different random spatial variations, such as size, brightness, shape, dropout, and spatial shifts. Three approaches for reducing the ERD effects are demonstrated: electrode grouping (quads), ERD-based input-image enhancement, and object scanning with and without phosphene persistence. A quantitative assessment for the first two approaches was done based on experiments with 20 subjects and three vision-based computational image similarity metrics. Main results. The effects of various ERDs on phosphenes' size, brightness, and shape were simulated. Quads, chosen according to the ERDs, effectively elicit phosphenes without exceeding the safe charge density limit, whereas single electrodes with large ERD cannot do so. Input-image enhancement reduced the ERD effects effectively. These two approaches significantly improved ERD-affected prosthetic vision according to the experiment and image similarity metrics. A further reduction of the ERD effects was achieved by scanning an object while moving the head. Significance. ERD has multiple effects on perception with retinal prostheses. One of them is vision loss caused by the incapability of electrodes with large ERD to evoke phosphenes. The three approaches presented in this study can be used separately or together to mitigate the impact of ERD. A consideration of our approaches in reducing the perceptual effects of the ERD may help improve the perception with current prosthetic technology and influence the design of future prostheses.
C1 [Avraham, David; Yitzhaky, Yitzhak] Ben Gurion Univ Negev, Sch Elect & Comp Engn, Dept Electroopt Engn, IL-84105 Beer Sheva, Israel.
C3 Ben Gurion University
RP Avraham, D (通讯作者)，Ben Gurion Univ Negev, Sch Elect & Comp Engn, Dept Electroopt Engn, IL-84105 Beer Sheva, Israel.
EM Davav@post.bgu.ac.il
OI /0000-0002-3910-8911
FU Israel Science Foundation [1519/20]
FX This research was supported by the Israel Science Foundation (Grant No.
   1519/20).
CR Ahuja AK, 2013, PROG RETIN EYE RES, V36, P1, DOI 10.1016/j.preteyeres.2013.01.002
   Avraham D, 2021, SYMMETRY-BASEL, V13, DOI 10.3390/sym13101763
   Avraham D, 2021, J NEURAL ENG, V18, DOI 10.1088/1741-2552/ac1b6c
   Ayton LN, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.25
   Ayton LN, 2020, CLIN NEUROPHYSIOL, V131, P1383, DOI 10.1016/j.clinph.2019.11.029
   Ayton LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115239
   Beyeler M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45416-4
   Biswas S, 2014, PROCEEDINGS OF THE 20TH ANNUAL INTERNATIONAL CONFERENCE ON MOBILE COMPUTING AND NETWORKING (MOBICOM '14), P1, DOI 10.1145/2639108.2639416
   BRUMMER SB, 1977, IEEE T BIO-MED ENG, V24, P440, DOI 10.1109/TBME.1977.326179
   Caspi A, 2009, ARCH OPHTHALMOL-CHIC, V127, P398, DOI 10.1001/archophthalmol.2009.20
   Cohen E, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/5/056017
   Dagnelie G, 2006, INVEST OPHTH VIS SCI, V47, P1241, DOI 10.1167/iovs.05-0157
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   Dorn JD, 2013, JAMA OPHTHALMOL, V131, P183, DOI 10.1001/2013.jamaophthalmol.221
   Dowling J, 2006, FRONT ARTIF INTEL AP, V138, P138
   Erickson-Davis C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0229189
   Flores T, 2018, J NEURAL ENG, V15, DOI 10.1088/1741-2552/aaac39
   Fornos AP, 2012, INVEST OPHTH VIS SCI, V53, P2720, DOI 10.1167/iovs.11-9344
   Fornos AP, 2005, INVEST OPHTH VIS SCI, V46, P3906, DOI 10.1167/iovs.04-1173
   Ghodasra DH, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0225-1
   Greenberg RJ, 1999, IEEE T BIO-MED ENG, V46, P505, DOI 10.1109/10.759051
   Gregori NZ, 2018, AM J OPHTHALMOL, V193, P87, DOI 10.1016/j.ajo.2018.06.012
   Grosberg LE, 2017, J NEUROPHYSIOL, V118, P1457, DOI 10.1152/jn.00750.2016
   Hao Wu, 2014, 2014 International Conference on Information Science, Electronics and Electrical Engineering (ISEEE), P425, DOI 10.1109/InfoSEEE.2014.6948145
   Ho AC, 2015, OPHTHALMOLOGY, V122, P1547, DOI 10.1016/j.ophtha.2015.04.032
   Hornig R, 2007, ARTIFICIAL SIGHT BAS, P111, DOI [10.1007/978-0-387-49331-2_6, DOI 10.1007/978-0-387-49331-2_6]
   Horsager A, 2010, INVEST OPHTH VIS SCI, V51, P1223, DOI 10.1167/iovs.09-3746
   Horsager A, 2009, INVEST OPHTH VIS SCI, V50, P1483, DOI 10.1167/iovs.08-2595
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Humayun MS, 2012, OPHTHALMOLOGY, V119, P779, DOI 10.1016/j.ophtha.2011.09.028
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Jensen RJ, 2005, INVEST OPHTH VIS SCI, V46, P1486, DOI 10.1167/iovs.04-1018
   Jensen RJ, 2003, INVEST OPHTH VIS SCI, V44, P3533, DOI 10.1167/iovs.02-1041
   Jung JH, 2015, VISION RES, V111, P182, DOI 10.1016/j.visres.2014.10.023
   Kasi H, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-44
   Kasi H, 2011, MED ENG PHYS, V33, P755, DOI 10.1016/j.medengphy.2011.01.015
   Keseru M, 2012, ACTA OPHTHALMOL, V90, pE1, DOI 10.1111/j.1755-3768.2011.02288.x
   Klauke S, 2011, INVEST OPHTH VIS SCI, V52, P449, DOI 10.1167/iovs.09-4410
   Loudin JD, 2007, J NEURAL ENG, V4, pS72, DOI 10.1088/1741-2560/4/1/S09
   Luo YHL, 2016, AM J OPHTHALMOL, V170, P100, DOI 10.1016/j.ajo.2016.07.021
   Luo YHL, 2016, PROG RETIN EYE RES, V50, P89, DOI 10.1016/j.preteyeres.2015.09.003
   Mahadevappa M, 2005, IEEE T NEUR SYS REH, V13, P201, DOI 10.1109/TNSRE.2005.848687
   Margalit E, 2002, SURV OPHTHALMOL, V47, P335, DOI 10.1016/S0039-6257(02)00311-9
   Muqit MMK, 2019, OPHTHALMOLOGY, V126, P637, DOI 10.1016/j.ophtha.2018.11.010
   Naidu A, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01631-6
   Nanduri D, 2008, IEEE ENG MED BIO, P1785, DOI 10.1109/IEMBS.2008.4649524
   Nanduri D, 2012, INVEST OPHTH VIS SCI, V53, P205, DOI 10.1167/iovs.11-8401
   Niketeghad S, 2020, J NEUROSURG, V132, P2000, DOI 10.3171/2019.3.JNS182774
   Palanker D, 2005, J NEURAL ENG, V2, pS105, DOI 10.1088/1741-2560/2/1/012
   Palanker D, 2020, OPHTHALMOLOGY, V127, P1097, DOI 10.1016/j.ophtha.2020.02.024
   Parmeggiani F, 2017, EUR J OPHTHALMOL, V27, pE16, DOI 10.5301/ejo.5000852
   Pham P, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/4/046002
   Ponomarenko N., 2007, PROC 3 INT WORKSHOP, P1
   Rachitskaya AV, 2016, OSLI RETINA, V47, P999, DOI 10.3928/23258160-20161031-03
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5355, DOI 10.1167/iovs.02-0819
   Sampat MP, 2009, IEEE T IMAGE PROCESS, V18, P2385, DOI 10.1109/TIP.2009.2025923
   Sanchez-Garcia M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227677
   Second Sight, 2013, ARG 2 RET PROSTH SYS
   Second Sight, 2013, ARG 2 RET PROSTH SYS
   Seider MI, 2015, CLIN OPHTHALMOL, V9, P2213, DOI 10.2147/OPTH.S96570
   Sekirnjak C, 2008, J NEUROSCI, V28, P4446, DOI 10.1523/JNEUROSCI.5138-07.2008
   Shivdasani MN, 2014, INVEST OPHTH VIS SCI, V55, P6467, DOI 10.1167/iovs.14-14396
   Sinclair NC, 2016, INVEST OPHTH VIS SCI, V57, P4948, DOI 10.1167/iovs.15-18991
   Stronks HC, 2014, EXPERT REV MED DEVIC, V11, P23, DOI 10.1586/17434440.2014.862494
   Sui XH, 2015, INT J ARTIF ORGANS, V38, P277, DOI 10.5301/ijao.5000412
   Thorn JT, 2022, J NEURAL ENG, V19, DOI 10.1088/1741-2552/ac5a5c
   van Steveninck JD, 2022, J VISION, V22, DOI 10.1167/jov.22.2.1
   Wang Z, 2003, CONF REC ASILOMAR C, P1398
   Weiland JD, 2003, P ANN INT IEEE EMBS, V25, P2021, DOI 10.1109/IEMBS.2003.1280131
   Weitz AC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4877
   Wilke R, 2011, INVEST OPHTH VIS SCI, V52, P5995, DOI 10.1167/iovs.10-6946
   Xia P, 2015, ARTIF ORGANS, V39, P1038, DOI 10.1111/aor.12504
   Xu LT, 2021, EUR J OPHTHALMOL, V31, P194, DOI 10.1177/1120672119885799
   Yanai D, 2007, AM J OPHTHALMOL, V143, P820, DOI 10.1016/j.ajo.2007.01.027
NR 76
TC 0
Z9 0
U1 1
U2 1
PU IOP Publishing Ltd
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1741-2560
EI 1741-2552
J9 J NEURAL ENG
JI J. Neural Eng.
PD JUN 1
PY 2022
VL 19
IS 3
AR 035001
DI 10.1088/1741-2552/ac6f82
PG 17
WC Engineering, Biomedical; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Neurosciences & Neurology
GA 1W1LE
UT WOS:000806540400001
PM 35561665
DA 2022-11-30
ER

PT J
AU Midena, E
   Torresin, T
   Velotta, E
   Pilotto, E
   Parrozzani, R
   Frizziero, L
AF Midena, Edoardo
   Torresin, Tommaso
   Velotta, Erika
   Pilotto, Elisabetta
   Parrozzani, Raffaele
   Frizziero, Luisa
TI OCT Hyperreflective Retinal Foci in Diabetic Retinopathy: A
   Semi-Automatic Detection Comparative Study
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE inflammation; OCT; hyperreflective retinal foci; diabetic retinopathy;
   automatic detection; biomarker
AB Optical coherence tomography (OCT) allows us to identify, into retinal layers, new morphological entities, which can be considered clinical biomarkers of retinal diseases. According to the literature, solitary, small (<30 mu m), medium level hyperreflective (similar to retinal fiber layer) retinal foci (HRF) may represent aggregates of activated microglial cells and an in vivo biomarker of retinal inflammation. The identification and quantification of this imaging biomarker allows for estimating the level and possibly the amount of intraretinal inflammation in major degenerative retinal disorders, whose inflammatory component has already been demonstrated (diabetic retinopathy, age-related macular degeneration, radiation retinopathy). Currently, diabetic retinopathy (DR) probably represents the best clinical model to apply this analysis in the definition of this clinical biomarker. However, the main limitation to the clinical use of HRF is related to the technical difficulty of counting them: a time-consuming methodology, which also needs trained examiners. To contribute to solve this limitation, we developed and validated a new method for the semi-automatic detection of HRF in OCT scans. OCT scans of patients affected by DR, were analyzed. HRF were manually counted in High Resolution spectral domain OCT images. Then, the same OCT scans underwent semi-automatic HRF counting, using an ImageJ software with four different settings profiles. Statistical analysis showed an excellent intraclass correlation coefficient (ICC) between the manual count and each of the four semi-automated methods. The use of the second setting profile allows to obtain at the Bland-Altman graph a bias of -0.2 foci and a limit of agreement of +/- 16.3 foci. This validation approach opens the way not only to the reliable and daily clinical applicable quantification of HRF, but also to a better knowledge of the inflammatory component-including its progression and regression changes-of diabetic retinopathy.
C1 [Midena, Edoardo; Torresin, Tommaso; Velotta, Erika; Pilotto, Elisabetta; Parrozzani, Raffaele] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [Midena, Edoardo; Frizziero, Luisa] IRCCS Fdn Bietti, Rome, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Midena, E (通讯作者)，Univ Padua, Dept Ophthalmol, Padua, Italy.; Midena, E (通讯作者)，IRCCS Fdn Bietti, Rome, Italy.
EM edoardo.midena@unipd.it
OI Torresin, Tommaso/0000-0001-5535-9350
FU Ministry of Health; Fondazione Roma
FX The contribution of the Fondazione Bietti in this paper was supported by
   Ministry of Health and Fondazione Roma.
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Boss JD, 2017, INVEST OPHTH VIS SCI, V58, P5594, DOI 10.1167/iovs.17-21973
   Chatziralli IP, 2016, RETINA-J RET VIT DIS, V36, P2319, DOI 10.1097/IAE.0000000000001070
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Coscas G, 2010, OPTICAL COHERENCE TOMOGRAPHY IN AGE-RELATED MACULAR DEGENERATION: OCT IN AMD, SECOND EDITION, P171
   De Benedetto U, 2015, RETINA-J RET VIT DIS, V35, P449, DOI 10.1097/IAE.0000000000000336
   Demircan N, 2006, EYE, V20, P1366, DOI 10.1038/sj.eye.6702138
   Framme C, 2012, INVEST OPHTH VIS SCI, V53, P5814, DOI 10.1167/iovs.12-9950
   Frizziero L, 2016, RETINA-J RET VIT DIS, V36, P1664, DOI 10.1097/IAE.0000000000000986
   Funatsu H, 2009, OPHTHALMOLOGY, V116, P73, DOI 10.1016/j.ophtha.2008.09.037
   Lee H, 2018, INVEST OPHTH VIS SCI, V59, P715, DOI 10.1167/iovs.17-23042
   Milne R, 2013, AMINO ACIDS, V44, P1397, DOI 10.1007/s00726-011-1071-3
   Mokhtari M, 2017, IEEE ENG MED BIO, P1497, DOI 10.1109/EMBC.2017.8037119
   Ogino K, 2012, RETINA-J RET VIT DIS, V32, P77, DOI 10.1097/IAE.0b013e318217ffc7
   Parrozzani R, 2019, RETINA-J RET VIT DIS, V39, pE45, DOI 10.1097/IAE.0000000000002647
   Pilotto E, 2020, OPHTHALMOLOGY, V127, P1774, DOI 10.1016/j.ophtha.2020.03.024
   Pilotto E, 2019, BRIT J OPHTHALMOL, V103, P1001, DOI 10.1136/bjophthalmol-2018-312461
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Sonoda S, 2014, RETINA-J RET VIT DIS, V34, P741, DOI 10.1097/IAE.0b013e3182a48917
   Strimbu K, 2010, CURR OPIN HIV AIDS, V5, P463, DOI 10.1097/COH.0b013e32833ed177
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
   Varga L, 2019, COMPUT METH PROG BIO, V178, P91, DOI 10.1016/j.cmpb.2019.06.019
   Vujosevic S, 2017, AM J OPHTHALMOL, V181, P149, DOI 10.1016/j.ajo.2017.06.026
   Vujosevic S, 2017, ACTA OPHTHALMOL, V95, P464, DOI 10.1111/aos.13294
   Vujosevic S, 2017, RETINA-J RET VIT DIS, V37, P1092, DOI 10.1097/IAE.0000000000001304
   Vujosevic S, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/491835
   Vujosevic S, 2016, RETINA-J RET VIT DIS, V36, P1298, DOI 10.1097/IAE.0000000000000912
   Yu CC, 2019, MED PHYS, V46, P4502, DOI 10.1002/mp.13728
   Zong HL, 2011, CURR DIABETES REP, V11, P244, DOI 10.1007/s11892-011-0198-7
   Zur D, 2018, OPHTHALMOLOGY, V125, P267, DOI 10.1016/j.ophtha.2017.08.031
NR 31
TC 9
Z9 9
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD APR 22
PY 2021
VL 12
AR 613051
DI 10.3389/fimmu.2021.613051
PG 8
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA RX5VO
UT WOS:000647291500001
PM 33968016
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wilde, C
   Awad, M
   Giannouladis, K
   Lakshmanan, A
   Yeung, AMH
   Dua, H
   Amoaku, WMK
AF Wilde, Craig
   Awad, Mary
   Giannouladis, Konstantinos
   Lakshmanan, Arun
   Yeung, Aaron Ming-Hon
   Dua, Harminder
   Amoaku, Winfried M. K.
TI Natural course of adult-onset vitelliform lesions in eyes with and
   without comorbid subretinal drusenoid deposits
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Adult-onset vitelliform lesions; Subretinal drusenoid deposits;
   Reticular drusen; Pseudodrusen; Prognosis; Adult-onset foveomacular
   vitelliform dystrophy
ID RETICULAR PSEUDODRUSEN; MACULAR DEGENERATION; ASSESSMENT PROJECT;
   PREVALENCE; DYSTROPHY; PROGRESSION
AB Purpose Adult vitelliform lesions (AVL) are associated with age related macular degeneration (AMD) and subretinal drusenoid deposits (SRDD). We evaluated the natural course of AVL, assessing the influence of SRDD on disease progression, visual function and incidence of macular atrophy (MA) and choroidal neovascular membranes (CNVM). Methods A retrospective cohort study was conducted between January 2011 and March 2016. Demographic, clinical and imaging data from 26 consecutive AVL patients were analysed following case note review. Optical coherence tomography images were graded for SRDD and patients divided into those with/without SRDD. Outcomes included presenting/changes in best corrected visual acuity (BCVA) and incidence of MA/CNVM. Results Mean age was 78.6 +/- 7.6 years. Mean follow-up was 51.5 +/- 25.6 months. Twelve patients (46.2%) had SRDD at presentation with 3 more (11.5%) developing them. Subjects with SRDD were older (mean 81.7 +/- 6.1 years vs 74.3 +/- 7.6 years, p = 0.010). Mean presenting BCVA was worse in SRDD eyes (0.39 +/- 0.31 logMAR vs 0.19 +/- 0.18 logMAR, p = 0.017). Eight of 15 patients with SRDD (53.3%) developed incident MA or CNVM; higher than those with no SRDD (1/11, 9.1%; p = 0.036). Two patients (7.7%) developed full thickness macular holes. Conclusions Patients with AVL and SRDD likely represent an advanced pathological stage or phenotype with worse visual outcome and higher risk of MA/CNVM. Possible overlap with AMD exists. Follow-up, counselling and provisions for early detection/treatment of complications should be made. Better classification including improved understanding of phenotypic and genetic variations with reference to comorbid diseases including AMD is required. Presence of SRDD in AVL offers a dichotomous classification, indicating risk of future MA/CNVM formation.
C1 [Wilde, Craig; Dua, Harminder; Amoaku, Winfried M. K.] Univ Nottingham, EENT Ctr, Queens Med Ctr, Ophthalmol & Vis Sci,Div Clin Neurosci, B Floor, Nottingham, England.
   [Awad, Mary; Giannouladis, Konstantinos; Lakshmanan, Arun; Yeung, Aaron Ming-Hon] Nottingham Univ Hosp NHS Trust, Nottingham, England.
C3 University of Nottingham; Nottingham University Hospital NHS Trust
RP Wilde, C (通讯作者)，Univ Nottingham, EENT Ctr, Queens Med Ctr, Ophthalmol & Vis Sci,Div Clin Neurosci, B Floor, Nottingham, England.
EM craig_wilde@hotmail.com
OI Giannouladis, Konstantinos/0000-0003-4819-234X; Amoaku,
   Winfried/0000-0001-5028-7984
CR Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   BURGESS DB, 1987, OPHTHALMOLOGY, V94, P362
   Gass J D, 1974, Trans Am Ophthalmol Soc, V72, P139
   GLACETBERNARD A, 1990, J FR OPHTALMOL, V13, P407
   Goldberg N, 2012, ARCH OPHTHALMOL-CHIC, V130, P1221, DOI 10.1001/archophthalmol.2012.407
   GREAVES AH, 1990, AUST NZ J OPHTHALMOL, V18, P171, DOI 10.1111/j.1442-9071.1990.tb00610.x
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Querques G, 2008, AM J OPHTHALMOL, V146, P135, DOI 10.1016/j.ajo.2008.02.017
   Querques G, 2011, AM J OPHTHALMOL, V152, P304, DOI 10.1016/j.ajo.2011.01.047
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Tewari R, 2018, INDIAN J OPHTHALMOL, V66, P708, DOI 10.4103/ijo.IJO_1046_17
   Tiosano L, 2016, BRIT J OPHTHALMOL, V100, P1476, DOI 10.1136/bjophthalmol-2015-307658
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wilde C, 2016, EYE, V30, P817, DOI 10.1038/eye.2016.46
   Wilde C, 2018, OPHTHALMOL RETINA, V2, P1218, DOI 10.1016/j.oret.2018.06.009
   Wilde C, 2018, EYE, V32, P1130, DOI 10.1038/s41433-018-0049-8
NR 16
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD JUN
PY 2020
VL 40
IS 6
BP 1501
EP 1508
DI 10.1007/s10792-020-01319-2
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LQ2CJ
UT WOS:000534816600020
PM 32130624
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Szmacinski, H
   Hegde, K
   Zeng, HH
   Eslami, K
   Puche, AC
   Lengyel, I
   Thompson, RB
AF Szmacinski, Henryk
   Hegde, Kavita
   Zeng, Hui-Hui
   Eslami, Katayoun
   Puche, Adam C.
   Lengyel, Imre
   Thompson, Richard B.
TI Imaging hydroxyapatite in sub-retinal pigment epithelial deposits by
   fluorescence lifetime imaging microscopy with tetracycline staining
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE fluorescence lifetime imaging microscopy; age-related macular
   degeneration; drusen; tetracyclines; fluorescence ophthalmoscopy;
   hydroxyapatite; sub-retinal pigment epithelium deposits; retina
AB Significance: Recent evidence suggests that hydroxyapatite (HAP) in sub-retinal pigment epithelial (sub-RPE) deposits in aged human eyes may act to nucleate and contribute to their growth to clinically detectable size. Sub-RPE deposits such as drusen are clinical hallmarks of age-related macular degeneration (AMD), therefore enhanced and earlier detection is a clinical need. We found that tetracycline-family antibiotics, long known to stain HAP in teeth and bones, can also label the HAP in sub-RPE deposits. However, HAP-bound tetracycline fluorescence excitation and emission spectra overlap with the well-known autofluorescence of outer retinal tissues, making them difficult to resolve.
   Aim: In this initial study, we sought to determine if the HAP-bound tetracyclines also exhibit enhanced fluorescence lifetimes, providing a useful difference in lifetime compared with the short lifetimes observed in vivo in the human retina by the pioneering work of Schweitzer, Zinkernagel, Hammer, and their colleagues, and thus a large enough effect size to resolve the HAP from background by fluorescence lifetime imaging.
   Approach: We stained authentic HAP with tetracyclines and measured the lifetime(s) by phase fluorometry, and stained aged, fixed human cadaver retinas with drusen with selected tetracyclines and imaged them by fluorescence lifetime imaging microscopy (FLIM).
   Results: We found that chlortetracycline and doxycycline exhibited substantial increase in fluorescence lifetime compared to the free antibiotics and the retinal background, and the drusen were easily resolvable from the retinal background in these specimens by FLIM.
   Conclusions: These findings suggest that FLIM imaging of tetracycline (and potentially other molecules) binding to HAP could become a diagnostic tool for the development and progression of AMD. (C) The Authors. Published by SPIE under a Creative Commons Attribution 4.0 Unported License.
C1 [Szmacinski, Henryk; Zeng, Hui-Hui; Eslami, Katayoun; Thompson, Richard B.] Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 20742 USA.
   [Hegde, Kavita] Coppin State Univ, Dept Nat Sci, Baltimore, MD USA.
   [Puche, Adam C.] Univ Maryland, Sch Med Anat & Neurosci, Baltimore, MD USA.
   [Lengyel, Imre] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
RP Thompson, RB (通讯作者)，Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 20742 USA.
EM Richard.thompson@som.umaryland.edu
FU Mercer fund for the Fight for Sight; Wilson H. Elkins Professorship;
   Belfast Association for the Blind; Optos, PLC; PRISM Program
FX The authors wish to thank the reviewers and editors for their thoughtful
   comments and suggestions. The authors also wish to thank Professor
   Lakowicz for the use of his FLIM, the Bright Focus Foundation (I.L. and
   RBT); the Bill Brown Charitable Trust, the Mercer fund for the Fight for
   Sight, and the Eye Charity of Moorfields Eye Hospital (I.L.); and the
   PRISM Program (K.E.). K.H. is the recipient of the Wilson H. Elkins
   Professorship, and I.L. acknowledges a research grant from the YBelfast
   Association for the Blind and unrestricted support from Optos, PLC.
CR Agwuh KN, 2006, J ANTIMICROB CHEMOTH, V58, P256, DOI 10.1093/jac/dkl224
   ANDERSON HH, 1950, AM J TROP MED, V30, P193
   [Anonymous], INVEST OPHTH VIS SCI
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Gaviola E., 1927, Zeitschrift fur Physik, V42, P853, DOI 10.1007/BF01776683
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   KELLY DJ, 1992, J INFECT DIS, V166, P1184, DOI 10.1093/infdis/166.5.1184
   Kovar JL, 2011, ANAL BIOCHEM, V416, P167, DOI 10.1016/j.ab.2011.05.011
   Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, V2nd
   LAKOWICZ JR, 1992, ANAL BIOCHEM, V202, P316, DOI 10.1016/0003-2697(92)90112-K
   Liu ZL, 2018, BIOMED OPT EXPRESS, V9, P4246, DOI 10.1364/BOE.9.004246
   McCranor BJ, 2014, METALLOMICS, V6, P1034, DOI 10.1039/c3mt00305a
   Nelson M. L., 2007, COMPREHENSIVE MED 2, V7, P597
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   PINSKY BG, 1993, CYTOMETRY, V14, P123, DOI 10.1002/cyto.990140204
   Redford GI, 2005, J FLUORESC, V15, P805, DOI 10.1007/s10895-005-2990-8
   Renner L., 2013, INVEST OPHTH VIS SCI, V54, P4110
   Riviere J. E., 2001, Veterinary pharmacology and therapeutics, P828
   Schweitzer D, 2009, OPHTHALMOLOGE, V106, P714, DOI 10.1007/s00347-009-1975-4
   SKINNER HCW, 1975, YALE J BIOL MED, V48, P377
   Szmacinski H., 2018, PROC SPIE, V10484
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   THOMPSON RB, 1988, ANAL CHEM, V60, P670, DOI 10.1021/ac00158a014
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Zaheer A, 2001, NAT BIOTECHNOL, V19, P1148, DOI 10.1038/nbt1201-1148
NR 29
TC 2
Z9 2
U1 1
U2 4
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD APR
PY 2020
VL 25
IS 4
AR 047001
DI 10.1117/1.JBO.25.4.047001
PG 11
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA VL3IR
UT WOS:000831140500002
PM 32319262
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Saito, Y
   Kuse, Y
   Inoue, Y
   Nakamura, S
   Hara, H
   Shimazawa, M
AF Saito, Yuichi
   Kuse, Yoshiki
   Inoue, Yuki
   Nakamura, Shinsuke
   Hara, Hideaki
   Shimazawa, Masamitsu
TI Transient acceleration of autophagic degradation by pharmacological Nrf2
   activation is important for retinal pigment epithelium cell survival
SO REDOX BIOLOGY
LA English
DT Article
DE NF-E2-related factor 2; Sequestosome 1; Autophagy; Retinal pigment
   epithelium; Non-exudative age-related macular degeneration
ID ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS; DEGENERATION; INJURY;
   MICE; RPE; GLUTATHIONE; PROTECTION; LIPOFUSCIN; DISEASES
AB Non-exudative age-related macular degeneration (AMD) is mainly caused by the accumulation of lipofuscin and drusen on the retinal pigment epithelium (RPE). Both oxidative stress and autophagic dysfunction accelerate the deposition of lipofuscin at the RPE. One of the key regulators in the response against oxidative stress is the NF-E2-Related Factor 2 (Nrf2)-kelch like ECH associated protein 1 (Keap1) axis, which is also closely associated with the autophagy pathway. Nrf2 activation upregulates the expression levels of certain anti-oxidative enzymes [e.g. Heme oxygenase-1 (HO-1)], which attenuates oxidative damage. However, until now, the relationship between cytoprotective effects of Nrf2 activation and autophagic degradation remain unclear. To address these questions, we investigated the effects of a novel Nrf2 activator, RS9, on RPE damage. We found that RS9 protected ARPE-19 cells against NaIO3 -induced oxidative damage, and that the protective effects of RS9 were inhibited by co-treatment with zinc protoporphyrin, an HO-1 inhibitor. Next, we examined the involvement of autophagic degradation in the protective effects of RS9. Co-treatment with RS9 and chloroquine, a lysosomal acidification inhibitor, inhibited the protective effect. Furthermore, western blotting and immunostaining showed that RS9 accelerated autophagy flux and induced transient upregulation of p62 [also known as sequestosome 1 (SQSTM1)]. Co-treatment with chloroquine and RS9 also inhibited the degradation of autophagosomes. Transient upregulation of SQSTM1 by RS9 was unaltered by HO-1 knockdown using siRNA. RS9 and chloroquine had the same actions in light damaged adult zebrafish retina as those in vitro. In conclusion, we clarified the relationship between acceleration of the autophagy pathway and the cytoprotective effects of Nrf2 activation in RPE cells and zebrafish retina. These findings indicated that Nrf2 activation could be a promising therapeutic approach for non-exudative AMD by supporting RPE maintenance.
C1 [Saito, Yuichi; Kuse, Yoshiki; Inoue, Yuki; Nakamura, Shinsuke; Hara, Hideaki; Shimazawa, Masamitsu] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigakunishi, Gifu 5011196, Japan.
C3 Gifu Pharmaceutical University
RP Shimazawa, M (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigakunishi, Gifu 5011196, Japan.
EM nakamuras@gifu-pu.ac.jp; hidehara@gifu-pu.ac.jp; shimazawa@gifu-pu.ac.jp
RI Kuse, Yoshiki/AAB-7445-2021
OI Hara, Hideaki/0000-0003-2046-9001; Saito, Yuichi/0000-0002-7738-276X
FU JSPS KAKENHI [JP17J10301]
FX This work was supported by JSPS KAKENHI Grant Number JP17J10301. We
   would like to thank Dr. Yasuhiro Nakagami (Daiichi Sankyo Co., Ltd.) for
   encouraging this work.
CR Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Cai Y, 2016, AUTOPHAGY, V12, P225, DOI 10.1080/15548627.2015.1121360
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   de Zeeuw D, 2013, NEW ENGL J MED, V369, P2492, DOI 10.1056/NEJMoa1306033
   Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899
   Girmens JF, 2012, INTRACTABLE RARE DIS, V1, P103, DOI 10.5582/irdr.2012.v1.3.103
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Houghton CA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7857186
   Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003
   Inoue Y, 2017, J NEUROCHEM, V141, P750, DOI 10.1111/jnc.14029
   Jang J, 2016, CELL, V165, P410, DOI 10.1016/j.cell.2016.02.014
   Jang KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.437
   Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kolko M, 2014, MOL VIS, V20, P511
   Kumar H, 2014, NAT PROD REP, V31, P109, DOI 10.1039/c3np70065h
   Labbe RF, 1999, CLIN CHEM, V45, P2060
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   lejima D., 2015, J BIOL CHEM, V290, P2784, DOI [10.1074/jbc.M114.593384, DOI 10.1074/JBC.M114.593384]
   Liu XB, 2016, REDOX BIOL, V8, P98, DOI 10.1016/j.redox.2015.12.005
   Liu Z., 2015, ALZHEIMERS DIS, DOI [10.1155/2015/352723, DOI 10.1155/2015/352723]
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mokhtari V, 2017, CELL J, V19, P11
   Mukaigasa K, 2012, MOL CELL BIOL, V32, P4455, DOI 10.1128/MCB.00481-12
   Nakagami Y, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7469326
   Nakagami Y, 2015, BRIT J PHARMACOL, V172, P1237, DOI 10.1111/bph.12999
   Nakanishi T, 2013, J NEUROCHEM, V125, P111, DOI 10.1111/jnc.12116
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889
   Park Ji Young, 2013, J Cancer Prev, V18, P249
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Qin SF, 2014, EXP EYE RES, V118, P100, DOI 10.1016/j.exer.2013.11.010
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   Saito Y, 2016, J PHARMACOL SCI, V131, P215, DOI 10.1016/j.jphs.2016.05.009
   Steele ML, 2013, REDOX BIOL, V1, P441, DOI 10.1016/j.redox.2013.08.006
   Tan CC, 2014, NEUROBIOL AGING, V35, P941, DOI 10.1016/j.neurobiolaging.2013.11.019
   Uddin MJ, 2013, FREE RADICAL BIO MED, V65, P1331, DOI 10.1016/j.freeradbiomed.2013.09.027
   Westerfield M., 2007, ZEBRAFISH BOOK GUIDE
   Yadav A, 2013, J MOL MODEL, V19, P767, DOI 10.1007/s00894-012-1601-2
   Yamauchi K, 2016, NEUROSCIENCE, V333, P302, DOI 10.1016/j.neuroscience.2016.07.035
   Zare-shahabadi A, 2015, REV NEUROSCIENCE, V26, P385, DOI 10.1515/revneuro-2014-0076
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zhang JL, 2015, INT J MOL SCI, V16, P1644, DOI 10.3390/ijms16011644
   Zhang XD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19361
NR 47
TC 27
Z9 27
U1 0
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD OCT
PY 2018
VL 19
BP 354
EP 363
DI 10.1016/j.redox.2018.09.004
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GZ8FF
UT WOS:000449722100034
PM 30216854
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bartnik, SE
   Copeland, SP
   Aicken, AJ
   Turner, AW
AF Bartnik, Stephen E.
   Copeland, Stephen P.
   Aicken, Angela J.
   Turner, Angus W.
TI Optometry-facilitated teleophthalmology: an audit of the first year in
   Western Australia
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE ophthalmology; optometry; telehealth; telemedicine; teleophthalmology
ID EYE CARE; TELEMEDICINE; RETINOPATHY
AB Background: Lions Outback Vision has run a state-wide teleophthalmology service since 2011. In September 2015 the Australian federal government introduced a Medicare reimbursement for optometry-facilitated teleophthalmology consultations under specific circumstances. This audit demonstrates the first 12 months experience with this scheme. We aim to provide practical insights for others looking to embed a telemedicine program as part of delivering outreach clinical services.
   Methods: A 12-month retrospective audit was performed between September 2015 and August 2016, inclusive. A research officer used a specifically designed data extraction tool to record information from all teleophthalmology consultations performed in the time period. The primary outcome was the diagnosis at the end of the teleophthalmology consultation. Secondary outcome measures included the number of teleconsultations, cataract surgery rate, remoteness area of patients referred and imaging accompanying the referral.
   Results: In the 12-month period, 709 patients were referred resulting in 683 teleophthalmology teleconsultations. Cataract was the most frequent diagnosis (n = 287, 42.7 per cent), followed by glaucoma (n = 77, 11 per cent), age-related macular degeneration (n = 30, 4.4 per cent) and diabetic retinopathy (n = 26, 3.8 per cent). Of those who had teleconsultations, 98.6 per cent were from Outer Regional, Remote or Very Remote Australia. One or more accompanying images or investigations were part of 349 (49 per cent) teleconsultations, most commonly optical coherence tomography (215, 30 per cent) and fundus photography (148, 21 per cent). Face-to-face consultations were undertaken at an outreach clinic in 23 (3.4 per cent) cases, to determine the diagnosis. There were no statistically significant factors associated with attendance at teleophthalmology consultation, or for successfully undergoing cataract surgery.
   Conclusion: Teleophthalmology is a valuable adjunct to regional outreach ophthalmology services, providing patients with increased access to specialist care for a wide range of ophthalmic conditions, and more efficient access to surgical care.
C1 [Bartnik, Stephen E.; Copeland, Stephen P.; Aicken, Angela J.; Turner, Angus W.] Lions Eye Inst, Lions Outback Vis, Perth, WA, Australia.
   [Turner, Angus W.] Univ Western Australia, Ctr Vis & Ophthalm Sci, Perth, WA, Australia.
C3 Lions Eye Institute; University of Western Australia
RP Bartnik, SE (通讯作者)，Lions Eye Inst, Lions Outback Vis, Perth, WA, Australia.
EM stevebartnik@gmail.com
CR Australian Bureau of Statistics, 2011, 1270 0 55 005 AUSTR, V5
   Bai VT, 2007, TELEMED J E-HEALTH, V13, P313, DOI 10.1089/tmj.2006.0048
   Bar-Sela SM, 2007, J TELEMED TELECARE, V13, P119, DOI 10.1258/135763307780677640
   Cheng J, 2014, OPHTHALMOLOGY, V121, P126, DOI 10.1016/j.ophtha.2013.08.027
   Foreman J, 2018, CLIN EXP OPHTHALMOL, V46, P213, DOI 10.1111/ceo.13035
   John S, 2012, TELEMED E-HEALTH, V18, P382, DOI 10.1089/tmj.2011.0190
   Johnson KA, 2015, AUST J RURAL HEALTH, V23, P142, DOI 10.1111/ajr.12150
   Keenan J, 2015, CLIN EXP OPHTHALMOL, V43, P221, DOI 10.1111/ceo.12398
   Khan S, 2012, OPHTHAL PHYSL OPT, V32, P472, DOI 10.1111/j.1475-1313.2012.00943.x
   Li HK, 1999, SURV OPHTHALMOL, V44, P61, DOI 10.1016/S0039-6257(99)00059-4
   Moffatt JJ, 2010, AUST HEALTH REV, V34, P276, DOI 10.1071/AH09794
   O'day R, 2016, CLIN EXP OPTOM, V99, P163, DOI 10.1111/cxo.12334
   Royal Australian and New Zealand College of Ophthalmologists, 2016, RANZCO REF PATHW GLA
   Shi LL, 2015, BRIT J OPHTHALMOL, V99, P823, DOI 10.1136/bjophthalmol-2014-305631
   Sim Dawn A, 2016, J Diabetes Sci Technol, V10, P308, DOI 10.1177/1932296816629983
   Sood S, 2007, TELEMED J E-HEALTH, V13, P573, DOI 10.1089/tmj.2006.0073
   Thomas SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113779
   Weaver DT, 2013, CURR OPIN OPHTHALMOL, V24, P425, DOI 10.1097/ICU.0b013e3283645b41
NR 18
TC 19
Z9 19
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD SEP
PY 2018
VL 101
IS 5
BP 700
EP 703
DI 10.1111/cxo.12658
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR8PG
UT WOS:000442986200013
PM 29444552
DA 2022-11-30
ER

PT J
AU Hsieh, FC
   Hung, CT
   Cheng, KC
   Wu, CY
   Chen, YC
   Wu, YJ
   Liu, WT
   Chiu, CC
AF Hsieh, Feng-Chi
   Hung, Chun-Tzu
   Cheng, Kai-Chun
   Wu, Chang-Yi
   Chen, Yen-Chun
   Wu, Yu-Jen
   Liu, Wangta
   Chiu, Chien-Chih
TI Protective Effects of Lycium barbarism Extracts on UVB-Induced Damage in
   Human Retinal Pigment Epithelial Cells Accompanied by Attenuating ROS
   and DNA Damage
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID TOLL-LIKE RECEPTOR-3; ENDOTHELIAL GROWTH-FACTOR; OCULAR HYPERTENSION
   MODEL; MACULAR DEGENERATION; DIABETIC-RETINOPATHY; INNATE IMMUNITY;
   GANGLION-CELLS; PHOTORECEPTOR DEGENERATION; NEURONAL SURVIVAL; PATHWAY
AB The medicinal herb Lycium barbarum fruit has been widely used for improving and maintaining the health of the eyes in the Far East for many centuries. This study is aimed at investigating whether protective effects generated from the aqueous (LBA) and ethanol (LBE) extracts of the L. barbarum fruit existed against oxidative stress-induced apoptosis in human retinal pigment epithelial cells. L. barbarum extracts LBA and LBE exerted the activity of ROS scavenging and rescued UVB irradiation-induced growth inhibition in retinal pigment epithelial ARPE-19 cells. Compared to LBA, the ethanol extract LBE exerted a superior protective activity on UVB-induced growth arrest in ARPE-19 cells. Both L. barbarum extracts significantly reduced cell cycle G(2)-arrest population in ARPE-19 cells. Furthermore, the cytometer-based Annexin V/propidium iodide staining assay further showed that both L. barbarum extracts protected ARPE-19 cells from UVB-induced apoptosis. L. barbarum extracts also reduced the activation of gamma H2AX, a sensor of DNA damage in ARPE-19 cells in a dose-responsive manner. By using Ingenuity Pathway Analysis (IPA), the bioinformatics revealed that the protective effects of both LBA and LBE extracts might be involved in three signaling pathways, especially the Toll-like receptor (TLR) pathway associated with cellular proliferation. Our study suggests that both ethanol and aqueous extracts of L. barbarum exhibit antioxidant activity and rescue UVB-induced apoptosis of ARPE-19 cells. Collectively, the ethanol extract exerts a superior effect on rescuing UVB-induced growth arrest of ARPE-19 compared to the aqueous extract, which might be associated with the activation of TLR signaling. Our present work will benefit the preventive strategy of herbal medicine-based vision protection for treating eye diseases such as age-related macular degeneration in the future.
C1 [Hsieh, Feng-Chi; Hung, Chun-Tzu] Yuans Gen Hosp, Dept Radiol, Kaohsiung 802, Taiwan.
   [Hung, Chun-Tzu] Yuans Gen Hosp, Dept Ophthalmol, Kaohsiung 802, Taiwan.
   [Cheng, Kai-Chun] Kaohsiung Municipal Hsiaokang Hosp, Dept Ophthalmol, Kaohsiung 812, Taiwan.
   [Cheng, Kai-Chun] Kaohsiung Med Univ Hosp, Dept Ophthalmol, Kaohsiung 807, Taiwan.
   [Cheng, Kai-Chun] Shu Zen Jr Coll Med & Management, Dept Optometry, Kaohsiung 821, Taiwan.
   [Wu, Chang-Yi; Chen, Yen-Chun; Liu, Wangta; Chiu, Chien-Chih] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung 807, Taiwan.
   [Wu, Chang-Yi; Chiu, Chien-Chih] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 804, Taiwan.
   [Wu, Yu-Jen] Meiho Univ, Dept Nursing, Pingtung 912, Taiwan.
   [Liu, Wangta] Kaohsiung Med Univ, Lipid Sci & Aging Res Ctr, Kaohsiung 807, Taiwan.
   [Chiu, Chien-Chih] Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung 807, Taiwan.
   [Chiu, Chien-Chih] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Translat Res Ctr, Canc Ctr, Kaohsiung 807, Taiwan.
   [Chiu, Chien-Chih] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Municipal Siao-Gang Hospital;
   Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   Kaohsiung Medical University; National Sun Yat Sen University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; Kaohsiung Medical
   University
RP Liu, WT; Chiu, CC (通讯作者)，Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung 807, Taiwan.; Chiu, CC (通讯作者)，Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 804, Taiwan.; Liu, WT (通讯作者)，Kaohsiung Med Univ, Lipid Sci & Aging Res Ctr, Kaohsiung 807, Taiwan.; Chiu, CC (通讯作者)，Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung 807, Taiwan.; Chiu, CC (通讯作者)，Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Translat Res Ctr, Canc Ctr, Kaohsiung 807, Taiwan.; Chiu, CC (通讯作者)，Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan.
EM liuwangta@kmu.edu.tw; cchiu@kmu.edu.tw
RI Chiu, Chien-Chih/AAW-9861-2020
OI Chiu, Chien-Chih/0000-0001-7307-2468; Chen, Yen-Chun/0000-0003-2991-7536
FU Ministry of Science and Technology, Taiwan [MOST106-2320-B-037-012,
   MOST107-2320-B-037-023, MOST 107-2311-B-037-001]; National Sun Yat-sen
   University-KMU Joint Research Project, Taiwan [NSYSU-KMU106-P019,
   NSYSU-KMU107-P002]; Yuan's General Hospital, Kaohsiung [RG15-002];
   Kaohsiung Medical University, Taiwan [KMU-SH000151, KMU-M104008,
   KMU-TP105A07]; Kaohsiung Municipal Hsiaokang Hospital, Taiwan
   [kmhk-105-018, kmhk-106-022]
FX The study was supported financially by the grants
   MOST106-2320-B-037-012, MOST107-2320-B-037-023, and MOST
   107-2311-B-037-001 from the Ministry of Science and Technology, Taiwan;
   by the grants NSYSU-KMU106-P019 and NSYSU-KMU107-P002 from the National
   Sun Yat-sen University-KMU Joint Research Project, Taiwan; by the grant
   from Yuan's General Hospital, Kaohsiung (RG15-002); by the grants
   KMU-SH000151, KMU-M104008, and KMU-TP105A07 from the Kaohsiung Medical
   University, Taiwan; and by the grants kmhk-105-018 and kmhk-106-022 from
   the Kaohsiung Municipal Hsiaokang Hospital, Taiwan. We are also grateful
   for the Center for Research Resources and Development (Kaohsiung Medical
   University) for the instrumental support of IPA analysis, flow
   cytometer, and confocal microscopy.
CR Agarwal S, 2017, BIOCHEM BIOPH RES CO, V483, P1166, DOI 10.1016/j.bbrc.2016.08.043
   Bharadwaj AS, 2013, PROG RETIN EYE RES, V32, P102, DOI 10.1016/j.preteyeres.2012.08.004
   Broadhead ML, 2010, GROWTH FACTORS, V28, P280, DOI 10.3109/08977191003604513
   Bsibsi M, 2006, GLIA, V53, P688, DOI 10.1002/glia.20328
   CAPETANDES A, 1990, INVEST OPHTH VIS SCI, V31, P1738
   Chabane N, 2008, OSTEOARTHR CARTILAGE, V16, P1267, DOI 10.1016/j.joca.2008.03.009
   Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chintala SK, 2015, INVEST OPHTH VIS SCI, V56, P505, DOI 10.1167/iovs.14-15539
   Chiu CC, 2011, J AGR FOOD CHEM, V59, P4288, DOI 10.1021/jf200566a
   Chiu K, 2010, J CELL BIOCHEM, V110, P311, DOI 10.1002/jcb.22539
   Chiu Kin, 2009, J Ocul Biol Dis Infor, V2, P47
   Chou WW, 2013, TOXICOL IN VITRO, V27, P1728, DOI 10.1016/j.tiv.2013.05.002
   Clerkin JS, 2008, CANCER LETT, V266, P30, DOI 10.1016/j.canlet.2008.02.029
   Cui BK, 2011, MOLECULES, V16, P9116, DOI 10.3390/molecules16119116
   D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256
   Dupont C, 2009, SEMIN REPROD MED, V27, P351, DOI 10.1055/s-0029-1237423
   Dvoriantchikova G, 2010, MOL VIS, V16, P1907
   ELNER VM, 1992, EXP EYE RES, V54, P361, DOI 10.1016/0014-4835(92)90048-W
   Fawcett JW, 2017, EYE, V31, P206, DOI 10.1038/eye.2016.293
   Gao GQ, 2002, DIABETES, V51, P1218, DOI 10.2337/diabetes.51.4.1218
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gao ML, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20692
   Geest CR, 2009, BLOOD, V114, P3402, DOI 10.1182/blood-2008-08-175141
   Hanisch UK, 2008, TRENDS NEUROSCI, V31, P176, DOI 10.1016/j.tins.2008.01.005
   Ho YS, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-15
   Jeong SY, 2016, J NEUROCHEM, V136, P851, DOI 10.1111/jnc.13441
   Kan JY, 2016, ONCOTARGET, V7, P31336, DOI 10.18632/oncotarget.9140
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lau TL, 2009, EMBO J, V28, P1351, DOI 10.1038/emboj.2009.63
   Lee C., 2017, OXIDATIVE MED CELLUL, V2017
   Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100
   Li HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068881
   Li HH, 2013, MAR DRUGS, V11, P2625, DOI 10.3390/md11072625
   Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380
   Li XY, 2010, CYTOKINE, V49, P1, DOI 10.1016/j.cyto.2009.08.010
   Li YJ, 2017, MOL CELL NEUROSCI, V85, P45, DOI 10.1016/j.mcn.2017.08.006
   Lim T. K., 2013, EDIBLE MED NONMEDICI, V6, P240
   Lin NC, 2011, J AGR FOOD CHEM, V59, P10088, DOI 10.1021/jf2021754
   Liu F, 2018, INVEST OPHTH VIS SCI, V59, P597, DOI 10.1167/iovs.17-22881
   Liu X, 2013, INT J OPHTHALMOL-CHI, V6, P221, DOI [10.3980/J.ISSN.2222-3959.2013.02.22, 10.3980/j.issn.2222-3959.2013.02.22]
   Luo Q, 2004, LIFE SCI, V76, P137, DOI 10.1016/j.lfs.2004.04.056
   Ma M, 2009, FOOD CHEM, V113, P872, DOI 10.1016/j.foodchem.2008.03.064
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Miller-Kasprzak E, 2008, BIOMED PHARMACOTHER, V62, P158, DOI 10.1016/j.biopha.2007.07.015
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Patel AK, 2014, MOL CELL NEUROSCI, V63, P38, DOI 10.1016/j.mcn.2014.09.004
   Pons M, 2011, INVEST OPHTH VIS SCI, V52, P3842, DOI 10.1167/iovs.10-6254
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Sivak JM, 2002, PROG RETIN EYE RES, V21, P1, DOI 10.1016/S1350-9462(01)00015-5
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Tang LJ, 2018, BIOMED PHARMACOTHER, V103, P829, DOI 10.1016/j.biopha.2018.04.104
   Ushio-Fukai M, 2008, CANCER LETT, V266, P37, DOI 10.1016/j.canlet.2008.02.044
   Valdiglesias V, 2013, MUTAT RES-REV MUTAT, V753, P24, DOI 10.1016/j.mrrev.2013.02.001
   Wu X., 2014, CANCER BIOL THER, V6, P646
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yen CY, 2012, MUTAT RES-GEN TOX EN, V747, P253, DOI 10.1016/j.mrgentox.2012.06.003
   YUE BYJT, 1991, CELL BIOL INT REP, V15, P365, DOI 10.1016/0309-1651(91)90125-3
   Zheng Z, 2009, DIABETES, V58, P954, DOI 10.2337/db07-1524
NR 64
TC 14
Z9 15
U1 5
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2018
VL 2018
AR 4814928
DI 10.1155/2018/4814928
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HB0RL
UT WOS:000450724900001
PM 30524656
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Mao, XB
   You, ZP
   Wu, C
   Huang, J
AF Mao, Xin-Bang
   You, Zhi-Peng
   Wu, Chen
   Huang, Jun
TI Potential suppression of the high glucose and insulin-induced retinal
   neovascularization by Sirtuin 3 in the human retinal endothelial cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Sirtuin 3; Neovascularization; Retinal endothelial cells; Migration;
   Autophagy
ID TUMOR-GROWTH; ANGIOGENESIS; METABOLISM; VEGF
AB Retinal neovascularization generally play roles in the formation of various severe eye diseases, such as age-related macular degeneration and diabetic retinopathy. The regulation of neovascularization-related pathways by Sirtuin 3 (Sirt3), a major mitochondrial NAD(+)-dependent deacetylase, give us a cue that Sirt3 may participate in the retinal neovascularization. However, the mechanism remains unclear. Here, we established a retinal neovascularization model by using human retinal endothelial cells (HRECs) under the induction of high glucose and insulin (HGI). With this model, Sirt3-expressing lentivirus was constructed and then used to investigate the effect of Sirt3 overexpression on the expression of migration-, neovascularization- and autophagy-related genes. After the treatment of HGI on HRECs, the mRNA and protein levels of migration-related genes, including matrix metalloproteinase-2 (MMP-2) and MMP-9, were significantly upregulated. Meanwhile, angiogenesis-related genes, including vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1 alpha (HIF-1 alpha), and insulin-like growth factor-1 (IGF-1) were promoted at both mRNA and protein levels. However, HGI had no clear effect on the mRNA and protein levels of microtubule associated protein 1 light chain 3 (LC3), an autophagy-related gene. When Sirt3 was overexpressed by lentivirus infection after HGI, the upregulation of MMP-2, MMP-9, VEGF, HIF-1 alpha, and IGF-1 were suppressed at both transcription and translation levels. At the same time, LC3 mRNA and LC3-II protein increased. These results suggest that Sirt3 may inhibit retinal neovascularization by regulating the migration-, neovascularization- and autophagy-related factors expression. Thus we argue that Sirt3 may be a potential candidate drug for curing various eye diseases induced by retinal neovascularization. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Mao, Xin-Bang; You, Zhi-Peng; Wu, Chen; Huang, Jun] Nanchang Univ, Affiliated Hosp 2, Dept Ophthalmol, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University
RP You, ZP (通讯作者)，Nanchang Univ, Affiliated Hosp 2, Dept Ophthalmol, Nanchang 330006, Jiangxi, Peoples R China.
EM yzpengy@163.com
FU Second Affiliated Hospital of Nanchang University
FX This work was supported by the Second Affiliated Hospital of Nanchang
   University.
CR Aksoy H, 2000, CLIN BIOCHEM, V33, P47, DOI 10.1016/S0009-9120(99)00085-5
   Bansode RR, 2011, INT J BIOL SCI, V7, P629, DOI 10.7150/ijbs.7.629
   Barnett JM, 2007, INVEST OPHTH VIS SCI, V48, P907, DOI 10.1167/iovs.06-0082
   Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Cattaneo M, 2016, INT J CARDIOL, V223, P917, DOI 10.1016/j.ijcard.2016.08.261
   Di Y, 2016, INT J OPHTHALMOL-CHI, V9, P804, DOI 10.18240/ijo.2016.06.02
   Du JH, 2012, AM J PHYSIOL-CELL PH, V302, pC383, DOI 10.1152/ajpcell.00164.2011
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   Jing EX, 2011, P NATL ACAD SCI USA, V108, P14608, DOI 10.1073/pnas.1111308108
   Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000
   Le Gat L, 2003, GENE THER, V10, P2098, DOI 10.1038/sj.gt.3302122
   Li G, 2015, J ENERGY INST, V1, P1, DOI DOI 10.1016/J.ATHER0SCLER0SIS.2015.09.020
   Li HQ, 2013, INT J ONCOL, V43, P1420, DOI 10.3892/ijo.2013.2103
   Li RR, 2016, CHIN LIT CULT WORLD, P1
   Lim S, 2016, ONCOTARGET, V7, P38282, DOI 10.18632/oncotarget.9436
   Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160
   Nagy JA, 2008, ANGIOGENESIS, V11, P109, DOI 10.1007/s10456-008-9099-z
   Ohno-Matsui K, 2003, INVEST OPHTH VIS SCI, V44, P5370, DOI 10.1167/iovs.03-0249
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Paradowska-Gorycka A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160769
   Parfyonova YV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P119, DOI 10.1023/A:1013964517211
   Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x
   Simo R, 2006, CURR DIABETES REV, V2, P71, DOI 10.2174/157339906775473671
   Sun HL, 2014, STEM CELLS, V32, P1943, DOI 10.1002/stem.1671
   Tafani M, 2008, AUTOPHAGY, V4, P1042, DOI 10.4161/auto.7070
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Vaz-Pereira S., 2016, RETINA
NR 33
TC 25
Z9 26
U1 1
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 8
PY 2017
VL 482
IS 2
BP 341
EP 345
DI 10.1016/j.bbrc.2016.11.065
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EI7PJ
UT WOS:000392690100025
PM 27856259
DA 2022-11-30
ER

PT J
AU McCloud, C
   Khadka, J
   Gilhotra, JS
   Pesudovs, K
AF McCloud, Christine
   Khadka, Jyoti
   Gilhotra, Jagjit Singh
   Pesudovs, Konrad
TI Divergence in the Lived Experience of People with Macular Degeneration
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE age-related macular degeneration; qualitative; quality of life;
   anti-VEGF; intravitreal injection
ID AGE-RELATED MACULOPATHY; QUALITY-OF-LIFE; OLDER-ADULTS; READING
   REHABILITATION; RISK-FACTORS; BLINDNESS; VISION; RANIBIZUMAB;
   POPULATION; IMPACT
AB Purpose. The aim of this study was to understand people's experience with age-related macular degeneration (AMD) in light of new treatment successes.
   Methods. An interpretive qualitative methodology was used to facilitate understanding of the experience of people with AMD. Rich in-depth data were collected using focus groups and individual interviews. Thematic analysis of the data occurred through the processes of line-by-line coding, aggregation, and theme development using the NVivo 10 software.
   Results. A total of 4 focus groups and 16 individual interviews were conducted with 34 people (median age = 81 years; range = 56 to 102 years; 19 females) with AMD. Four major themes arose from the narratives of the participants: cautious optimism, enduring, adaptation, and profound loss. Cautious optimism resonated for participants who had received successful treatment and stabilization of AMD. Enduring emerged as participants with exudative AMD described an ongoing need for invasive and frequent treatments (anti-vascular endothelial growth factor injections) that maintained their vision. Adaptation was evident in the narratives of all participants and was directly related to the physical and psychological limitations that were a consequence of visual disability. Profound loss encompassed both physical and emotional aspects of deteriorating vision and was most evident in patients for whom treatment had failed or had not been considered appropriate for their disease.
   Conclusions. The findings of this study shed new light on the influence of underlying pathology, disease trajectory, and success of new treatments on quality of life of people living with AMD. Optimism toward maintaining vision in the presence of exudative AMD was described by participants, moderated by ongoing caution and a need for endurance of frequent and often problematic intravitreal treatments. These findings add a deeper understanding of this complex and life-changing experience.
C1 [McCloud, Christine] Flinders Univ S Australia, Sch Nursing & Midwifery, Bedford Pk, SA 5042, Australia.
   [Khadka, Jyoti; Pesudovs, Konrad] Flinders Univ S Australia, Discipline Optometry & Vis Sci, NH&MRC Ctr Clin Eye Res, Bedford Pk, SA 5042, Australia.
   [Gilhotra, Jagjit Singh] Univ Adelaide, South Australian Inst Ophthalmol, Royal Adelaide Hosp, Adelaide, SA, Australia.
   [Gilhotra, Jagjit Singh] Univ Adelaide, Discipline Ophthalmol & Visual Sci, Royal Adelaide Hosp, Adelaide, SA, Australia.
   [Gilhotra, Jagjit Singh] Queen Elizabeth Hosp, Ophthalmol Network, Adelaide, SA, Australia.
C3 Flinders University South Australia; Flinders University South
   Australia; Royal Adelaide Hospital; University of Adelaide; Royal
   Adelaide Hospital; University of Adelaide
RP Khadka, J (通讯作者)，NH&MRC Ctr Clin Eye Res, Discipline Optometry & Vis Sci, Bedford Pk, SA 5042, Australia.
EM Jyoti.Khadka@flinders.edu.au
RI Khadka, Jyoti/P-3935-2018; Pesudovs, Konrad/T-9403-2019
OI Khadka, Jyoti/0000-0003-1012-2119; Pesudovs, Konrad/0000-0002-6322-9369
FU National Health and Medical Research Council [1031838]
FX This study is funded by National Health and Medical Research Council
   (grant no. 1031838).
CR Bennion AE, 2012, SOC SCI MED, V75, P976, DOI 10.1016/j.socscimed.2012.04.023
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Burton AE, 2013, BR J VIS IMPAIR, V31
   Cheung N, 2012, AM J OPHTHALMOL, V153, P193, DOI 10.1016/j.ajo.2011.11.022
   Coco-Martin MB, 2013, OPHTHALMOLOGY, V120, P151, DOI 10.1016/j.ophtha.2012.07.035
   *CTR EYE RES AUSTR, 2004, CLEAR INS EC IMP COS
   Feely M, 2007, J VISUAL IMPAIR BLIN, V101, P44, DOI 10.1177/0145482X0710100106
   Fenwick EK, 2013, QUAL LIFE RES, V22, P1851, DOI 10.1007/s11136-012-0307-3
   Fenwick EK, 2012, QUAL LIFE RES, V21, P1771, DOI 10.1007/s11136-012-0110-1
   Geirsdottir A, 2012, BRIT J OPHTHALMOL, V96, P444, DOI 10.1136/bjophthalmol-2011-300304
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Holloway I., 2009, QUALITATIVE RES NURS
   Khadka J, 2015, J GLAUCOMA, V24, P12, DOI 10.1097/IJG.0b013e318287ac11
   Khadka J, 2013, OPTOMETRY VISION SCI, V90, P720, DOI 10.1097/OPX.0000000000000001
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lee L, 2008, AUSTRALAS J AGEING, V27, P170, DOI 10.1111/j.1741-6612.2008.00298.x
   Liu CJ, 2013, AM J OCCUP THER, V67, P279, DOI 10.5014/ajot.2013.005512
   Mogk M, 2008, J VISUAL IMPAIR BLIN, V102
   Mogk M, 2008, J VISUAL IMPAIR BLIN, V102, P581, DOI 10.1177/0145482X0810201002
   Moore LW, 2005, APPL NURS RES, V18, P110, DOI 10.1016/j.apnr.2004.06.014
   Morse, 2012, QUALITATIVE HLTH RES
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Nguyen NX, 2009, ACTA OPHTHALMOL, V87, P849, DOI 10.1111/j.1755-3768.2008.01423.x
   Owsley C, 2006, REHABIL PSYCHOL, V51, P23, DOI 10.1037/0090-5550.51.1.23
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Pesudovs K, 2010, OPTOMETRY VISION SCI, V87, P285, DOI 10.1097/OPX.0b013e3181d408d7
   Polder JJ, 2002, EUR J PUBLIC HEALTH, V12, P57, DOI 10.1093/eurpub/12.1.57
   Polit D.F., 2020, NURSING RES GENERATI
   Polit DF., 2004, NURSING RES GENERATI
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Richer S, 2012, NUTRIENTS, V4, P1812, DOI 10.3390/nu4121812
   Robine JM, 2004, J GERONTOL A-BIOL, V59, P590, DOI 10.1093/gerona/59.6.M590
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Routasalo PE, 2009, J ADV NURS, V65, P297, DOI 10.1111/j.1365-2648.2008.04837.x
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Saldana J., 2011, UNDERSTANDING QUALIT
   Shaw ME, 2010, OPHTHALMIC NURSING
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Slakter JS, 2005, SURV OPHTHALMOL, V50, P263, DOI 10.1016/j.survophthal.2005.02.007
   Stanford P, 2009, BR J VIS IMPAIR, V27
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Thetford C, 2013, BR J VIS IMPAIR, V31
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wahl HW, 2004, PSYCHOL AGING, V19, P235, DOI 10.1037/0882-7974.19.1.235
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Whitehead D, 2013, NURSING MIDWIFERY RE, P263
   Willis E., 2012, UNDERSTANDING AUSTR, V2nd
   Wong EYH, 2004, J VISUAL IMPAIR BLIN, V98
NR 51
TC 37
Z9 39
U1 0
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD AUG
PY 2014
VL 91
IS 8
BP 966
EP 974
DI 10.1097/OPX.0000000000000320
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA AN4KL
UT WOS:000340556500021
PM 24978869
DA 2022-11-30
ER

PT J
AU Fleckenstein, M
   Schmitz-Valckenberg, S
   Lindner, M
   Bezatis, A
   Becker, E
   Fimmers, R
   Holz, FG
AF Fleckenstein, Monika
   Schmitz-Valckenberg, Steffen
   Lindner, Moritz
   Bezatis, Athanasios
   Becker, Eva
   Fimmers, Rolf
   Holz, Frank G.
CA Fundus Autoflourescence Age-Relate
TI The "Diffuse-Trickling'' Fundus Autofluorescence Phenotype in Geographic
   Atrophy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE phenotyping; pathogenesis; geographic atrophy; retinal imaging
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; RETICULAR PSEUDODRUSEN;
   CARDIOVASCULAR-DISEASE; MALIGNANT HYPERTENSION; RISK-FACTORS;
   PROGRESSION; PREVALENCE; PATTERNS; CHORIOCAPILLARIS
AB PURPOSE. To further characterize a subgroup of patients exhibiting the fundus autofluorescence (FAF) "diffuse-trickling'' phenotype associated with geographic atrophy (GA).
   METHODS. In the context of the Fundus Autofluorescence in Age-Related Macular Degeneration (FAM) Study, patients with diffuse-trickling GA were examined and characterized by FAF and spectral-domain optical coherence tomography imaging. Age, sex distribution, and medical history were compared with FAM study patients (n = 288, 60.1% female) with other GA phenotypes (non-diffuse-trickling). In a subset of patients, subfoveal choroidal thickness (SCT) was analyzed.
   RESULTS. Patients with diffuse-trickling (n = 61), compared with patients with non-diffuse-trickling GA, had a significantly younger age at first presentation (68.2 +/- 11.6 vs. 75.4 +/- 8.1 years, P < 0.001), a shift in the proportion of men from 55% in the age group younger than 65 to 19% in the age group older than or equal to 65, and a significantly higher rate of myocardial infarction (MI) in the age group younger than 65 (24% vs. 0%, P = 0.011); all but one patient with MI were male. Further evaluation revealed that in the age group younger than 65, 54% of patients with diffuse-trickling had been hospitalized due to cardiovascular diseases including hypertensive crisis, angina, and MI. Analysis of choroidal thickness revealed a significantly thinner SCT in diffuse-trickling compared with non-diffuse-trickling GA (135.2 +/- 56.4 vs. 191.4 +/- 77.8 mu m, P < 0.001).
   CONCLUSIONS. The results indicate an association of diffuse-trickling GA with systemic cardiovascular disorders in the younger study population. Together with the ocular morphologic characteristics including a lobular appearance and a thin choroid, a vascular insufficiency at the level of the choroid may play a pathogenetic role in this distinct GA phenotype.
C1 [Fleckenstein, Monika; Schmitz-Valckenberg, Steffen; Lindner, Moritz; Bezatis, Athanasios; Becker, Eva; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Fimmers, Rolf] Univ Bonn, Inst Biostat, D-53127 Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Monika.Fleckenstein@ukb.uni-bonn.de
RI Lindner, Moritz/AAC-8639-2021; Walter, Peter/L-5982-2018
OI Lindner, Moritz/0000-0002-4416-3421; Fleckenstein,
   Monika/0000-0001-8321-8037; Weber, Bernhard H.F./0000-0002-8808-7723;
   Walter, Peter/0000-0001-8745-6593
FU Deutsche Forschungsgemeinschaft [German Research Council Ho1926/1-3, FL
   658/4-1]; BONFOR [0-137-0012]
FX Supported by grants from the Deutsche Forschungsgemeinschaft (German
   Research Council Ho1926/1-3, FL 658/4-1), and BONFOR 0-137-0012 (MF).
CR Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 1992, Arch Ophthalmol, V110, P1701
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Ayyagari R, 2005, INVEST OPHTH VIS SCI, V46, P3363, DOI 10.1167/iovs.05-0159
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Boon CJF, 2008, VISION RES, V48, P2569, DOI 10.1016/j.visres.2008.01.010
   Borooah S, 2009, BRIT J OPHTHALMOL, V93, P284, DOI 10.1136/bjo.2008.150151
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P6552, DOI 10.1167/iovs.11-7298
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P637, DOI 10.1167/iovs.09-3547
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   HAYREH SS, 1986, OPHTHALMOLOGY, V93, P1383
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   KISHI S, 1985, ARCH OPHTHALMOL-CHIC, V103, P1189, DOI 10.1001/archopht.1985.01050080101029
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Soumplis V, 2013, ACTA OPHTHALMOL, V91, pE191, DOI 10.1111/aos.12010
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   TORCZYNSKI E, 1976, AM J OPHTHALMOL, V81, P428, DOI 10.1016/0002-9394(76)90298-1
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   WEITER J, 1977, AM J OPHTHALMOL, V83, P741, DOI 10.1016/0002-9394(77)90143-X
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 66
TC 37
Z9 39
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2014
VL 55
IS 5
BP 2911
EP 2920
DI 10.1167/iovs.13-13409
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL9TP
UT WOS:000339484800013
PM 24699379
DA 2022-11-30
ER

PT J
AU Zhang, L
   Sonka, M
   Folk, JC
   Russell, SR
   Abramoff, MD
AF Zhang, Li
   Sonka, Milan
   Folk, James C.
   Russell, Stephen R.
   Abramoff, Michael D.
TI Quantifying Disrupted Outer Retinal-Subretinal Layer in SD-OCT Images in
   Choroidal Neovascularization
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE retina; AMD; choroidal neovascularization; imaging; OCT
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; GRAPH-SEARCH;
   SEGMENTATION; FLUID
AB PURPOSE. We reported a fully automated method to identify and quantify the thickness of the outer retinal-subretinal (ORSR) layer from clinical spectral-domain optical coherence tomography (SD-OCT) scans of choroidal neovascularization (CNV) due to exudative age-related macular degeneration (eAMD).
   METHODS. A total of 23 subjects with CNV met eligibility. Volumetric SD-OCT scans of 23 eyes were obtained (Zeiss Cirrus, 200 x 200 x 1024 voxels). In a subset of eyes, scans were repeated. The OCT volumes were analyzed using our standard parameters and using a 3-dimensional (3D) graph-search approach with an adaptive cost function. A retinal specialist graded the segmentation as generally accurate, local segmentation inaccuracies, or failure. Reproducibility on repeat scans was analyzed using root mean square coefficient of variation (RMS CV) of the average ORSR thickness.
   RESULTS. Using a standard segmentation approach, 1/23 OCT segmentations was graded generally accurate and 22/23 were failure(s). With the adaptive method 21/23 segmentations were graded generally accurate; 2/23 were local segmentation inaccuracies and none was a failure. The intermethod quality of segmentation was significantly different (P << 0.001). The average ORSR thickness measured on CNV patients (78.0 mu m; 95% confidence interval [CI], 72.5-83.4 mu m) is significantly larger (P << 0.001) than normal average ORSR layer thickness (51.5 +/- 3.3 mu m). The RMS CV was 8.1%.
   CONCLUSIONS. We have developed a fully automated 3D method for segmenting the ORSR layer in SD-OCT of patients with CNV from eAMD. Our method can quantify the ORSR layer thickness in the presence of fluid, which has the potential to augment management accuracy and efficiency of anti-VEGF treatment.
C1 [Zhang, Li; Sonka, Milan; Abramoff, Michael D.] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
   [Sonka, Milan; Folk, James C.; Russell, Stephen R.; Abramoff, Michael D.] Univ Iowa Hosp & Clin, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Russell, Stephen R.; Abramoff, Michael D.] Univ Iowa, Div Inst Vis Res, Carver Family Ctr Macular Degenerat, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] Univ Iowa, Inst Vis Res, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] Iowa City VA Med Ctr, Dept Vet Affairs, Iowa City, IA USA.
   [Abramoff, Michael D.] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Iowa; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Iowa City VA Health Care System; University of
   Iowa
RP Abramoff, MD (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM michael-abramoff@uiowa.edu
RI Abramoff, Michael D/A-5836-2009
OI Abramoff, Michael D/0000-0002-3490-0037; Folk,
   James/0000-0002-6271-2906; Russell, Stephen/0000-0003-3776-1367
FU [R01-EY017066];  [R01-EY018853];  [R01-EB004640]; NATIONAL EYE INSTITUTE
   [R01EY018853, R01EY017066, R01EY019112] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING
   [R01EB004640] Funding Source: NIH RePORTER
FX Supported by Grants R01-EY017066 and R01-EY018853 (MDA, MS), and
   R01-EB004640 (MS).
CR Abramoff MD, 2013, INVEST OPHTH VIS SCI, V54, P3721, DOI 10.1167/iovs.13-11812
   Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Ahlers C, 2009, INVEST OPHTH VIS SCI, V50, P3417, DOI 10.1167/iovs.08-2759
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Folk JC, 2010, NEW ENGL J MED, V363, P1648, DOI 10.1056/NEJMct1000495
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Kiernan DF, 2010, AM J OPHTHALMOL, V149, P18, DOI 10.1016/j.ajo.2009.08.037
   Lee K, 2010, IEEE T MED IMAGING, V29, P159, DOI 10.1109/TMI.2009.2031324
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Smretschnig E, 2010, GRAEF ARCH CLIN EXP, V248, P1693, DOI 10.1007/s00417-010-1415-9
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
NR 17
TC 20
Z9 20
U1 0
U2 9
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2014
VL 55
IS 4
BP 2329
EP 2335
DI 10.1167/iovs.13-13048
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AH1WS
UT WOS:000335913100043
PM 24569576
OA Green Published
DA 2022-11-30
ER

PT J
AU Jamous, KF
   Jalbert, I
   Kalloniatis, M
   Boon, MY
AF Jamous, Khalid F.
   Jalbert, Isabelle
   Kalloniatis, Michael
   Boon, Mei Ying
TI Australian general medical practitioner referral pathways for people
   with different ocular conditions
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related maculopathy; diabetic retinopathy; glaucoma; GP referral
   pathways; low vision rehabilitation
ID DIABETIC-RETINOPATHY; POSTAL QUESTIONNAIRE; VISUAL-ACUITY; NO TIME;
   GLAUCOMA; OPTOMETRISTS; IMPACT; IMPAIRMENT; PREVALENCE; SERVICES
AB BackgroundThe aim was to obtain an overview of general medical practitioner (GP) referral pathways to ocular health care and allied services for people identified with age-related macular degeneration (AMD), diabetic retinopathy (DR) or glaucoma (GL).
   MethodsA questionnaire was developed to survey GPs in Australia. Questions included demographic information and referral patterns to ocular and health service providers. The survey was posted to 1,050 randomly selected GPs across Australia.
   ResultsFifty-eight GPs participated in this study amounting to a 6.5 per cent response rate. Nearly all GPs referred patients to ophthalmologists (AMD: 98 per cent; DR: 98 per cent; GL: 95 per cent). A smaller proportion of GPs also referred to low vision rehabilitation (LVR) services (AMD: 34 per cent; DR: 33 per cent; GL: 22 per cent), optometrists (AMD: 26 per cent; DR: 34 per cent; GL: 31 per cent), or support services (AMD: 17 per cent; DR: 40 per cent; GL: 19 per cent). For the three tested conditions, there were no statistically significant differences in the proportions of GPs, who referred to ophthalmologists (p = 0.43), optometrists (p = 0.48) or to low vision rehabilitation services (p = 0.31). The proportion of GPs who referred to support services was significantly higher for patients diagnosed with DR than AMD or GL (p < 0.05).
   ConclusionThe majority of GPs referred patients with AMD, DR or GL to ophthalmologists. Fewer GPs considered referrals to optometrists, low vision rehabilitation or support services. General practitioners may need to be more aware about the central role of optometrists in the delivery of primary eye health care. In the interest of optimising eye care, closer working relationships between GPs and optometrists should be fostered.
C1 [Jamous, Khalid F.; Jalbert, Isabelle; Kalloniatis, Michael; Boon, Mei Ying] Univ New S Wales, Sch Optometry & Vis Sci, Kensington, NSW 2033, Australia.
   [Jamous, Khalid F.] King Saud Univ, Fac Med, Dept Ophthalmol, Riyadh, Saudi Arabia.
   [Kalloniatis, Michael] Univ New S Wales, Ctr Eye Hlth, Kensington, NSW 2033, Australia.
C3 University of New South Wales Sydney; King Saud University; University
   of New South Wales Sydney
RP Boon, MY (通讯作者)，Univ New S Wales, Sch Optometry & Vis Sci, POB 1, Kensington, NSW 2033, Australia.
EM m.boon@unsw.edu.au
RI Boon, Mei Ying/F-2194-2016; Jalbert, Isabelle/T-5888-2017
OI Boon, Mei Ying/0000-0002-9759-8402; Jalbert,
   Isabelle/0000-0002-1351-0072; Kalloniatis, Michael/0000-0002-5264-4639
FU King Saud University at Riyadh, Saudi Arabia
FX Khalid F Jamous was supported by a scholarship from King Saud University
   at Riyadh, Saudi Arabia. We thank Dr Lisa Nivison-Smith and Dr Barbara
   Zangerl for their valuable contributions in reviewing the manuscript.
CR AAO. American Academy of Ophthalmology Retina/Vitreous Panel, 2008, PREF PRACT PATT GUID
   AIHW, 2005, VIS PROBL OLD AUSTR
   [Anonymous], 2010, NHMRC GUIDELINES SCR
   Armstrong D, 2000, BRIT J GEN PRACT, V50, P479
   Barclay S, 2002, FAM PRACT, V19, P105, DOI 10.1093/fampra/19.1.105
   Bell RWD, 1997, OPHTHAL PHYSL OPT, V17, P7
   Britt H, 2010, MED J AUSTRALIA, V173, P63
   Britt H, 2002, GEN PRACTICE SERIES
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Carnicelli A, 2003, AUSTRALAS J AGEING, V22, P179, DOI 10.1111/j.1741-6612.2003.tb00494.x
   Churchill R, 1999, BRIT J GEN PRACT, V49, P738
   Coyne KS, 2004, FAM PRACT, V21, P447, DOI 10.1093/fampra/cmh417
   Creative Research Systems, SAMPL SIZ CALC
   Davies M, 2011, HIGH EDUC, V62, P279, DOI 10.1007/s10734-010-9387-6
   FEATHERSTONE PI, 1992, BRIT J GEN PRACT, V42, P21
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162
   Health Workforce Australia, 2012, AUSTR HLTH WORKF SER
   Henson DB, 2003, EYE, V17, P21, DOI 10.1038/sj.eye.6700261
   Hill K, 2001, Aust Health Rev, V24, P163
   Hummers-Pradier E, 2008, FAM PRACT, V25, P105, DOI 10.1093/fampra/cmn015
   Ibraheim A, 1 STOP JOURNEY OPHTH
   Johnson RB, 2007, J MIX METHOD RES, V1, P112, DOI 10.1177/1558689806298224
   Junghans B, DELIVERING OPTOMETRI
   Kaner EF, 1998, BRIT J GEN PRACT, V48, P1067
   Keeffe JE, 1998, AUST NZ J OPHTHALMOL, V26, pS16, DOI 10.1111/j.1442-9071.1998.tb01360.x
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   KHAN A, 2004, AUST J PRIM HEALTH, V10, P76
   Kiely PM, 2009, CLIN EXP OPTOM, V92, P362, DOI 10.1111/j.1444-0938.2009.00383.x
   Kleinstein R N, 1987, J Am Optom Assoc, V58, P879
   Leung Ivan Y-F, 2008, Optometry, V79, P266, DOI 10.1016/j.optm.2007.03.017
   Lim HY, 2008, CLIN EXP OPTOM, V91, P177, DOI 10.1111/j.1444-0938.2007.00214.x
   LONG CA, 1991, AGE AGEING, V20, P392, DOI 10.1093/ageing/20.6.392
   Lovie-Kitchin Jan E, 1999, Clin Exp Optom, V82, P214
   Lovie-Kitchin JE., 1996, CLIN EXP OPTOM, V79, P227
   MD Foundation, PROJ VIS 2 MAC DEG F
   Miles M.B., 1994, QUALITATIVE DATA ANA
   National Health and Medical Research Council, 2008, GUIDELINES MANAGEMEN
   NOVAK JD, 1990, J RES SCI TEACH, V27, P937, DOI 10.1002/tea.3660271003
   Optometry Board Of Australia, 2010, GUID US SCHED MED
   Optometry Board of Australia, REV GUID US SCHED ME
   Ozerov I, 2001, EINSTEIN Q J BIOL ME, V18, P164
   Perfetti S, 1998, ACTA OPHTHALMOL SCAN, V76, P52
   Pick ZS, 2008, CLIN EXP OPHTHALMOL, V36, P762, DOI 10.1111/j.1442-9071.2008.01874.x
   Piterman L, 2005, INTERN MED J, V35, P491, DOI 10.1111/j.1445-5994.2005.00860.x
   Pomeroy SEM, 2010, AUST J PRIM HEALTH, V16, P147, DOI 10.1071/PY09024
   Pooley JE, 1996, REFERRALS COMMUNITY
   RACGP, 2011, DIAB MAN GEN PRACT
   Resnikoff S, 2012, BRIT J OPHTHALMOL, V96, P783, DOI 10.1136/bjophthalmol-2011-301378
   Rowe S, 2004, JAMA-J AM MED ASSOC, V291, P1487, DOI 10.1001/jama.291.12.1487
   Schmid Katrina L, 2002, Clin Exp Optom, V85, P221
   Steele C, 2008, OPTOM PRACT, V9, P5
   STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193
   STRONG NP, 1992, OPHTHAL PHYSL OPT, V12, P3, DOI 10.1016/0275-5408(92)90003-F
   Sudman S., 1996, THINKING ANSWERS APP, V1
   Taylor P., 2020, CLEAR FOCUS EC IMPAC
   The Primary Health Care Research and Information Service, 2011, SUMM DAT REP 2008 20
   The Royal Australian College of General Practitioners, 2009, GUID PREV ACT GEN PR
   The Royal Victorian Eye and Ear Hospital, 2011, REF GUID REF GUID GP
   Ting D, 2011, AUST FAM PHYSICIAN, V40, P233
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
NR 63
TC 6
Z9 6
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD MAR
PY 2014
VL 97
IS 2
BP 152
EP 159
DI 10.1111/cxo.12102
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB3NT
UT WOS:000331698200008
PM 23944239
DA 2022-11-30
ER

PT J
AU Li, ZR
   Dong, X
   Liu, HL
   Chen, X
   Shi, HQ
   Fan, YS
   Hou, DS
   Zhang, XM
AF Li, Zhongrui
   Dong, Xin
   Liu, Hongling
   Chen, Xi
   Shi, Huanqi
   Fan, Yan
   Hou, Dingshan
   Zhang, Xiaomei
TI Astaxanthin protects ARPE-19 cells from oxidative stress via
   upregulation of Nrf2-regulated phase II enzymes through activation of
   PI3K/Akt
SO MOLECULAR VISION
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; NF-KAPPA-B; IN-VITRO; CAROTENOID ASTAXANTHIN;
   MACULAR DEGENERATION; SH-SY5Y CELLS; DNA-DAMAGE; PC12 CELLS; RPE;
   EXPRESSION
AB Purpose: Oxidative stress on retinal pigment epithelial (RPE) cells is thought to play a crucial role in the development and progression of age-related macular degeneration. Astaxanthin (AST) is a carotenoid that shows significant antioxidant properties. This study was designed to investigate the protective effect of AST on ARPE-19 cells against oxidative stress and the possible underlying mechanism.
   Methods: ARPE-19 cells exposed to different doses of H2O2 were incubated with various concentrations of AST and cell viability subsequently detected with the (4-[3-[4-iodophenyl]-2-4(4-nitrophenyl)-2H-5-tetrazolio-1,3-benzene disulfonate]; WST-1) assay. The apoptosis rate and intracellular levels of reactive oxygen species (ROS) were measured with flow cytometry. NAD(P)H quinine oxidoreductase 1 (NQO1), hemeoxygenase-1 (HO-1), glutamate-cysteine ligase modifier subunit (GCLM), and glutamate-cysteine ligase catalytic subunit (GCLC) expression were examined with real-time PCR and western blotting. The nuclear localization of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) protein and the expression levels of cleaved caspase-3 and protein kinase B proteins were evaluated with western blotting.
   Results: AST clearly reduced H2O2-induced cell viability loss, cell apoptosis, and intracellular generation of ROS. Furthermore, treatment with AST activated the Nrf2-ARE pathway by inducing Nrf2 nuclear localization. Consequently, Phase II enzymes NQO1, HO-1, GCLM, and GCLC mRNA and proteins were increased. AST inhibited expression of H2O2-induced cleaved caspase-3 protein. Activation of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway was involved in the protective effect of AST on the ARPE-19 cells.
   Conclusions: AST protected ARPE-19 cells against H2O2-induced oxidative stress via Nrf2-mediated upregulation of the expression of Phase II enzymes involving the PI3K/Akt pathway.
C1 [Li, Zhongrui; Dong, Xin; Liu, Hongling; Shi, Huanqi; Fan, Yan; Hou, Dingshan; Zhang, Xiaomei] Harbin Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Harbin 150001, Heilongjiang Pr, Peoples R China.
   [Chen, Xi] Harbin Med Univ, Affiliated Hosp 1, Dept Pharm, Harbin 150001, Heilongjiang Pr, Peoples R China.
C3 Harbin Medical University; Harbin Medical University
RP Zhang, XM (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 23 Youzheng St, Harbin 150001, Heilongjiang Pr, Peoples R China.
EM zhangxm667@163.com
FU National Natural Science Foundation [NSFC: 30,970,749]; Natural Science
   Foundation of Heilongjiang Province [D200924]
FX This study was supported by a grant from the National Natural Science
   Foundation (NSFC: 30,970,749) and partly supported by Natural Science
   Foundation of Heilongjiang Province (D200924). The authors confirm that
   there are no known conflicts of interest associated with this
   publication and there has been no significant financial support for this
   work that could have influenced its outcome.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben-Dor A, 2005, MOL CANCER THER, V4, P177
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campoio TR, 2011, TOXICOL IN VITRO, V25, P1448, DOI 10.1016/j.tiv.2011.04.018
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Coral-Hinostroza GN, 2004, COMP BIOCHEM PHYS C, V139, P99, DOI 10.1016/j.cca.2004.09.011
   Dong X, 2011, MOL VIS, V17, P2040
   Fassett RG, 2011, MAR DRUGS, V9, P447, DOI 10.3390/md9030447
   Feng ZH, 2010, J NUTR BIOCHEM, V21, P1222, DOI 10.1016/j.jnutbio.2009.10.010
   Geiger RC, 2005, INVEST OPHTH VIS SCI, V46, P3435, DOI 10.1167/iovs.04-1487
   Ha KN, 2006, INVEST OPHTH VIS SCI, V47, P2709, DOI 10.1167/iovs.05-1322
   Han XZ, 2008, FOOD CHEM TOXICOL, V46, P3140, DOI 10.1016/j.fct.2008.06.086
   Higuera-Ciapara I, 2006, CRIT REV FOOD SCI, V46, P185, DOI 10.1080/10408690590957188
   Hussein G, 2005, BIOL PHARM BULL, V28, P47, DOI 10.1248/bpb.28.47
   Ikeda Y, 2008, J NEUROCHEM, V107, P1730, DOI 10.1111/j.1471-4159.2008.05743.x
   Ikeuchi M, 2007, BIOSCI BIOTECH BIOCH, V71, P893, DOI 10.1271/bbb.60521
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Jia ZY, 2011, MOL VIS, V17, P210
   Kaczara P, 2010, FREE RADICAL BIO MED, V48, P1064, DOI 10.1016/j.freeradbiomed.2010.01.022
   Kim JH, 2010, INT J MOL SCI, V11, P5110, DOI 10.3390/ijms11125109
   Kim KC, 2010, INT J BIOCHEM CELL B, V42, P297, DOI 10.1016/j.biocel.2009.11.009
   Kim YH, 2010, INT IMMUNOPHARMACOL, V10, P1560, DOI 10.1016/j.intimp.2010.09.007
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Lee DH, 2011, FOOD CHEM TOXICOL, V49, P271, DOI 10.1016/j.fct.2010.10.029
   Lee DH, 2010, J CLIN BIOCHEM NUTR, V47, P121, DOI 10.3164/jcbn.10-29
   Li YB, 2006, PHARMACOL RES, V53, P6, DOI 10.1016/j.phrs.2005.08.002
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Naguib YMA, 2000, J AGR FOOD CHEM, V48, P1150, DOI 10.1021/jf991106k
   Naito Y, 2004, BIOFACTORS, V20, P49, DOI 10.1002/biof.5520200105
   Nakajima Y, 2008, J PHARM PHARMACOL, V60, P1365, DOI 10.1211/jpp/60.10.0013
   Ohgami K, 2003, INVEST OPHTH VIS SCI, V44, P2694, DOI 10.1167/iovs.02-0822
   Park SH, 2010, TOXICOLOGY, V278, P131, DOI 10.1016/j.tox.2010.04.003
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Rojo AI, 2008, J NEUROCHEM, V105, P192, DOI 10.1111/j.1471-4159.2007.05124.x
   Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X
   Saito M, 2012, GRAEF ARCH CLIN EXP, V250, P239, DOI 10.1007/s00417-011-1843-1
   Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281
   Song XD, 2011, BIOL PHARM BULL, V34, P839, DOI 10.1248/bpb.34.839
   Tripathi DN, 2010, MUTAT RES-GEN TOX EN, V696, P69, DOI 10.1016/j.mrgentox.2009.12.014
   Wang L, 2008, INVEST OPHTH VIS SCI, V49, P1671, DOI 10.1167/iovs.07-1099
   Wang ZY, 2009, FREE RADICAL BIO MED, V46, P1032, DOI 10.1016/j.freeradbiomed.2008.11.027
   Wolf AM, 2010, J NUTR BIOCHEM, V21, P381, DOI 10.1016/j.jnutbio.2009.01.011
   Xiao HB, 2011, TOXICOLOGY, V290, P286, DOI 10.1016/j.tox.2011.10.007
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Zareba M, 2006, FREE RADICAL BIO MED, V40, P87, DOI 10.1016/j.freeradbiomed.2005.08.015
   Zheng Y, 2010, MOL VIS, V16, P1467
NR 46
TC 110
Z9 117
U1 0
U2 29
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 25
PY 2013
VL 19
BP 1656
EP 1666
PG 11
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 189HS
UT WOS:000322258700005
PM 23901249
DA 2022-11-30
ER

PT J
AU Zaitlen, N
   Lindstrom, S
   Pasaniuc, B
   Cornelis, M
   Genovese, G
   Pollack, S
   Barton, A
   Bickeboller, H
   Bowden, DW
   Eyre, S
   Freedman, BI
   Friedman, DJ
   Field, JK
   Groop, L
   Haugen, A
   Heinrich, J
   Henderson, BE
   Hicks, PJ
   Hocking, LJ
   Kolonel, LN
   Landi, MT
   Langefeld, CD
   Le Marchand, L
   Meister, M
   Morgan, AW
   Raji, OY
   Risch, A
   Rosenberger, A
   Scherf, D
   Steer, S
   Walshaw, M
   Waters, KM
   Wilson, AG
   Wordsworth, P
   Zienolddiny, S
   Tchetgen, ET
   Haiman, C
   Hunter, DJ
   Plenge, RM
   Worthington, J
   Christiani, DC
   Schaumberg, DA
   Chasman, DI
   Altshuler, D
   Voight, B
   Kraft, P
   Patterson, N
   Price, AL
AF Zaitlen, Noah
   Lindstroem, Sara
   Pasaniuc, Bogdan
   Cornelis, Marilyn
   Genovese, Giulio
   Pollack, Samuela
   Barton, Anne
   Bickeboeller, Heike
   Bowden, Donald W.
   Eyre, Steve
   Freedman, Barry I.
   Friedman, David J.
   Field, John K.
   Groop, Leif
   Haugen, Aage
   Heinrich, Joachim
   Henderson, Brian E.
   Hicks, Pamela J.
   Hocking, Lynne J.
   Kolonel, Laurence N.
   Landi, Maria Teresa
   Langefeld, Carl D.
   Le Marchand, Loic
   Meister, Michael
   Morgan, Ann W.
   Raji, Olaide Y.
   Risch, Angela
   Rosenberger, Albert
   Scherf, David
   Steer, Sophia
   Walshaw, Martin
   Waters, Kevin M.
   Wilson, Anthony G.
   Wordsworth, Paul
   Zienolddiny, Shanbeh
   Tchetgen, Eric Tchetgen
   Haiman, Christopher
   Hunter, David J.
   Plenge, Robert M.
   Worthington, Jane
   Christiani, David C.
   Schaumberg, Debra A.
   Chasman, Daniel I.
   Altshuler, David
   Voight, Benjamin
   Kraft, Peter
   Patterson, Nick
   Price, Alkes L.
TI Informed Conditioning on Clinical Covariates Increases Power in
   Case-Control Association Studies
SO PLOS GENETICS
LA English
DT Article
ID QUANTITATIVE-TRAIT LOCI; GENOME-WIDE ASSOCIATION; CANCER SUSCEPTIBILITY
   LOCI; DISCORDANT SIB PAIRS; AGE-OF-ONSET; GENETIC-VARIANTS; LUNG-CANCER;
   COMMON VARIANT; HIGH-RISK; SMOKING
AB Genetic case-control association studies often include data on clinical covariates, such as body mass index (BMI), smoking status, or age, that may modify the underlying genetic risk of case or control samples. For example, in type 2 diabetes, odds ratios for established variants estimated from low-BMI cases are larger than those estimated from high-BMI cases. An unanswered question is how to use this information to maximize statistical power in case-control studies that ascertain individuals on the basis of phenotype (case-control ascertainment) or phenotype and clinical covariates (case-controlcovariate ascertainment). While current approaches improve power in studies with random ascertainment, they often lose power under case-control ascertainment and fail to capture available power increases under case-control-covariate ascertainment. We show that an informed conditioning approach, based on the liability threshold model with parameters informed by external epidemiological information, fully accounts for disease prevalence and non-random ascertainment of phenotype as well as covariates and provides a substantial increase in power while maintaining a properly controlled falsepositive rate. Our method outperforms standard case-control association tests with or without covariates, tests of gene x covariate interaction, and previously proposed tests for dealing with covariates in ascertained data, with especially large improvements in the case of case-control-covariate ascertainment. We investigate empirical case-control studies of type 2 diabetes, prostate cancer, lung cancer, breast cancer, rheumatoid arthritis, age-related macular degeneration, and end-stage kidney disease over a total of 89,726 samples. In these datasets, informed conditioning outperforms logistic regression for 115 of the 157 known associated variants investigated (P-value = 1x10(-9)). The improvement varied across diseases with a 16% median increase in chi(2) test statistics and a commensurate increase in power. This suggests that applying our method to existing and future association studies of these diseases may identify novel disease loci.
C1 [Zaitlen, Noah; Lindstroem, Sara; Pasaniuc, Bogdan; Pollack, Samuela; Tchetgen, Eric Tchetgen; Hunter, David J.; Christiani, David C.; Schaumberg, Debra A.; Kraft, Peter; Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Zaitlen, Noah; Pasaniuc, Bogdan; Pollack, Samuela; Tchetgen, Eric Tchetgen; Kraft, Peter; Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
   [Zaitlen, Noah; Pasaniuc, Bogdan; Pollack, Samuela; Hunter, David J.; Plenge, Robert M.; Altshuler, David; Voight, Benjamin; Kraft, Peter; Patterson, Nick; Price, Alkes L.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA USA.
   [Zaitlen, Noah; Lindstroem, Sara; Pasaniuc, Bogdan; Pollack, Samuela; Hunter, David J.; Kraft, Peter; Price, Alkes L.] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA.
   [Cornelis, Marilyn; Hunter, David J.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
   [Schaumberg, Debra A.; Chasman, Daniel I.] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA USA.
   [Genovese, Giulio; Friedman, David J.] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA.
   [Barton, Anne; Eyre, Steve; Worthington, Jane] Univ Manchester, Manchester Acad Hlth Sci Ctr, Arthrit Res UK Epidemiol Unit, Manchester, Lancs, England.
   [Bickeboeller, Heike; Rosenberger, Albert] Univ Gottingen, Univ Med Ctr, Dept Genet Epidemiol, Gottingen, Germany.
   [Bowden, Donald W.] Wake Forest Sch Med, Ctr Human Genom, Winston Salem, NC USA.
   [Freedman, Barry I.] Wake Forest Sch Med, Nephrol Sect, Dept Internal Med, Winston Salem, NC USA.
   [Field, John K.; Raji, Olaide Y.] Univ Liverpool, Roy Castle Lung Canc Res Programme, Liverpool L69 3BX, Merseyside, England.
   [Groop, Leif] Lund Univ, Scania Univ Hosp, Diabet & Endocrinol Res Unit, Dept Clin Sci, Malmo, Sweden.
   [Haugen, Aage; Zienolddiny, Shanbeh] Natl Inst Occupat Hlth, Sect Toxicol, Oslo, Norway.
   [Heinrich, Joachim] German Res Ctr Environm Hlth, Inst Epidemiol, Neuherberg, Germany.
   [Henderson, Brian E.; Waters, Kevin M.; Haiman, Christopher] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
   [Hicks, Pamela J.] Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27103 USA.
   [Hocking, Lynne J.] Univ Aberdeen, Div Appl Med, Musculoskeletal Res Programme, Aberdeen, Scotland.
   [Kolonel, Laurence N.; Le Marchand, Loic] Univ Hawaii, Canc Res Ctr, Program Epidemiol, Honolulu, HI 96813 USA.
   [Landi, Maria Teresa] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
   [Langefeld, Carl D.] Wake Forest Univ, Bowman Gray Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA.
   [Meister, Michael] Univ Klinikum, Thoraxklin, Heidelberg, Germany.
   [Meister, Michael; Risch, Angela] German Ctr Lung Res, Translat Lung Res Ctr Heidelberg, Heidelberg, Germany.
   [Morgan, Ann W.] NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England.
   [Risch, Angela; Scherf, David] DKFZ German Canc Res Ctr, Heidelberg, Germany.
   [Steer, Sophia] Kings Coll Hosp London, Natl Hlth Serv Fdn Trust, London, England.
   [Walshaw, Martin] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England.
   [Wilson, Anthony G.] Univ Sheffield, Deptartment Infect & Immun, Sheffield, S Yorkshire, England.
   [Wordsworth, Paul] Nuffield Orthopaed Ctr, NIHR Oxford Musculoskeletal Biomed Res Unit, Oxford OX3 7LD, England.
   [Plenge, Robert M.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
   [Plenge, Robert M.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA.
   [Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
   [Schaumberg, Debra A.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
   [Altshuler, David; Voight, Benjamin] Massachusetts Gen Hosp, Dept Mol Biol, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Altshuler, David; Voight, Benjamin] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
   [Altshuler, David; Voight, Benjamin] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
   [Altshuler, David; Voight, Benjamin] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Harvard University; Harvard T.H. Chan School of Public
   Health; Harvard University; Brigham & Women's Hospital; Harvard
   University; Harvard Medical School; Schepens Eye Research Institute;
   Harvard University; Beth Israel Deaconess Medical Center; University of
   Manchester; University of Gottingen; Wake Forest University; Wake Forest
   University; University of Liverpool; Lund University; Helmholtz
   Association; Helmholtz-Center Munich - German Research Center for
   Environmental Health; University of Southern California; Wake Forest
   University; Wake Forest Baptist Medical Center; University of Aberdeen;
   Cancer Research Center of Hawaii; University of Hawaii System; National
   Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI);
   Wake Forest University; Wake Forest Baptist Medical Center; Ruprecht
   Karls University Heidelberg; Leeds Biomedical Research Centre; Helmholtz
   Association; German Cancer Research Center (DKFZ); King's College
   Hospital NHS Foundation Trust; King's College Hospital; Liverpool Heart
   & Chest Hospital; University of Sheffield; Nuffield Orthopaedic Centre;
   University of Oxford; Harvard University; Brigham & Women's Hospital;
   Harvard University; Brigham & Women's Hospital; Harvard University;
   Harvard T.H. Chan School of Public Health; Harvard University; Brigham &
   Women's Hospital; Harvard University; Massachusetts General Hospital;
   Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard Medical School; Harvard University; Harvard Medical School
RP Zaitlen, N (通讯作者)，Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
EM nzaitlen@hsph.harvard.edu; aprice@hsph.harvard.edu
RI Altshuler, David M/A-4476-2009; Tchetgen, Eric Tchetgen/AAF-6160-2021;
   Bickeböller, Heike/V-2318-2018; eyre, stephen/K-3776-2017; Heinrich,
   Joachim/N-1720-2013; Field, John K./AAD-5674-2020; Zienolddiny,
   Shanbeh/O-7392-2015; Risch, Angela/H-2669-2013; Barton,
   Anne/N-2053-2014; Worthington, Jane/M-9770-2014
OI Altshuler, David M/0000-0002-7250-4107; Bickeböller,
   Heike/0000-0002-3361-5488; eyre, stephen/0000-0002-1251-6974; Heinrich,
   Joachim/0000-0002-9620-1629; Field, John K./0000-0003-3951-6365; Risch,
   Angela/0000-0002-8026-5505; Barton, Anne/0000-0003-3316-2527;
   Worthington, Jane/0000-0003-0544-042X; Friedman,
   David/0000-0002-0301-9298; Zienolddiny, Shan/0000-0001-9747-9625;
   Hocking, Lynne J/0000-0002-2414-2826; Pasaniuc,
   Bogdan/0000-0002-0227-2056; Morgan, Ann/0000-0003-1109-624X
FU National Heart, Lung, and Blood Institute [HL043851, HL69757]; National
   Cancer Institute [CA 047988]; Donald W. Reynolds Foundation; Fondation
   Leducq; Amgen; NIH [R01 HG006399, R21 ES020754, 5T32ES007142-27]; U.S.
   National Institutes of Health, National Cancer Institute
   [U01-CA98233-07, U01-CA98710-06, U01-CA98216-06, U01-CA98758-07];
   Manchester Biomedical Research Centre; Arthritis Research Campaign;
   NATIONAL CANCER INSTITUTE [U01CA098710, U01CA098216, U01CA098233,
   U01CA098758, U19CA148127, R01CA092824, R01CA047988] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043851,
   U01HL069757, U19HL069757] Funding Source: NIH RePORTER; NATIONAL HUMAN
   GENOME RESEARCH INSTITUTE [R01HG006399] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES020754,
   T32ES007142, R01ES020337] Funding Source: NIH RePORTER
FX The WGHS is supported by HL043851 and HL69757 from the National Heart,
   Lung, and Blood Institute and CA 047988 from the National Cancer
   Institute, the Donald W. Reynolds Foundation and the Fondation Leducq,
   with collaborative scientific support and funding for genotyping
   provided by Amgen. This work was funded by NIH grants R01 HG006399 (B
   Pasaniuc, S Pollack, N Patterson, AL Price) and R21 ES020754 (N Zaitlen,
   M Cornelis, N Patterson, AL Price) and NIH fellowship 5T32ES007142-27 (N
   Zaitlen). This work was supported by the U.S. National Institutes of
   Health, National Cancer Institute [cooperative agreements U01-CA98233-07
   to DJ Hunter, U01-CA98710-06 to S Gapstur, U01-CA98216-06 to E Riboli
   and R Kaaks, and U01-CA98758-07 to BE Henderson, and Intramural Research
   Program of NIH/National Cancer Institute, Division of Cancer
   Epidemiology and Genetics]. A Barton, S Eyre, and J Worthington were
   supported by Manchester Biomedical Research Centre and the Arthritis
   Research Campaign. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amos CI, 2010, NAT GENET, V42, P366, DOI 10.1038/ng0510-366
   ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775
   Campa D, 2011, JNCI-J NATL CANCER I, V103, P1252, DOI 10.1093/jnci/djr265
   Chanock SJ, 2008, NATURE, V452, P537, DOI 10.1038/452537a
   Chatterjee N, 2005, BIOMETRIKA, V92, P399, DOI 10.1093/biomet/92.2.399
   Clayton D, 2012, GENET EPIDEMIOL, V36, P409, DOI 10.1002/gepi.21635
   Cox DR., 1974, THEORETICAL STAT
   Dong J, 2012, NAT GENET, V44, P895, DOI 10.1038/ng.2351
   Ellis KL, 2010, CIRC-CARDIOVASC GENE, V3, P286, DOI 10.1161/CIRCGENETICS.109.917443
   FALCONER DS, 1967, ANN HUM GENET, V31, P1
   Field JK, 2005, INT J ONCOL, V27, P1633
   Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634
   Freedman ML, 2006, P NATL ACAD SCI USA, V103, P14068, DOI 10.1073/pnas.0605832103
   Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032
   Guey LT, 2011, GENET EPIDEMIOL
   Hamza TH, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002237
   Holm H, 2011, NAT GENET, V43, P316, DOI 10.1038/ng.781
   Hunter DJ, 2005, NAT REV CANCER, V5, P977, DOI 10.1038/nrc1754
   Imielinski M, 2009, NAT GENET, V41, P1335, DOI 10.1038/ng.489
   Jewell N. P., 2004, STAT EPIDEMIOLOGY
   Jewell NP, 2004, STAT EPIDEMIOLOGY, DOI DOI 10.1371/J0URNAL.P0NE.0017142
   Jin GF, 2009, CARCINOGENESIS, V30, P987, DOI 10.1093/carcin/bgp090
   Kathiresan S, 2009, NAT GENET, V41, P334, DOI 10.1038/ng.327
   Kote-Jarai Z, 2011, NAT GENET, V43, P785, DOI 10.1038/ng.882
   Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183
   Kryukov GV, 2009, P NATL ACAD SCI USA, V106, P3871, DOI 10.1073/pnas.0812824106
   Kuo CL, 2010, GENET EPIDEMIOL, V34, P246, DOI 10.1002/gepi.20455
   LANDER ES, 1989, GENETICS, V121, P185
   Lee SH, 2011, AM J HUM GENET, V88, P294, DOI 10.1016/j.ajhg.2011.02.002
   Lindstrom S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017142
   Lumley T, 2002, ANNU REV PUBL HEALTH, V23, P151, DOI 10.1146/annurev.publhealth.23.100901.140546
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   Monsees GM, 2009, GENET EPIDEMIOL, V33, P717, DOI 10.1002/gepi.20424
   Neuhaus JM, 1998, J AM STAT ASSOC, V93
   Perry JRB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002741
   PIEGORSCH WW, 1994, STAT MED, V13, P153, DOI 10.1002/sim.4780130206
   Pirinen M, 2012, NAT GENET, V44, P848, DOI 10.1038/ng.2346
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Price AL, 2010, NAT REV GENET, V11, P459, DOI 10.1038/nrg2813
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ridker PM, 2008, CLIN CHEM, V54, P249, DOI 10.1373/clinchem.2007.099366
   RISCH N, 1995, SCIENCE, V268, P1584, DOI 10.1126/science.7777857
   Risch NJ, 1996, AM J HUM GENET, V58, P836
   ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444
   Rose S, 2008, INT J BIOSTATISTICS, V4
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   So HC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001230
   Sulem P, 2011, NAT GENET, V43, P1127, DOI 10.1038/ng.972
   Thomas D, 2010, NAT REV GENET, V11, P259, DOI 10.1038/nrg2764
   Thomson W, 2007, NAT GENET, V39, P1431, DOI 10.1038/ng.2007.32
   Van Gestel S, 2000, BEHAV GENET, V30, P141, DOI 10.1023/A:1001907321955
   VanderWeele TJ, 2012, AM J EPIDEMIOL, V175, P1013, DOI 10.1093/aje/kwr467
   Voight BF, 2010, NAT GENET, V42, P579, DOI 10.1038/ng.609
   Wald NJ, 1996, BRIT MED BULL, V52, P3, DOI 10.1093/oxfordjournals.bmb.a011530
   Wallace C, 2006, AM J HUM GENET, V78, P498, DOI 10.1086/500562
   Wasserman L., 2005, ALL STAT
   Waters KM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001078
   Wray NR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000864
   Zaitlen N, 2012, BIOINFORMATICS, V38, P904
   Zaitlen N, 2012, BIOINFORMATICS, V28, P1729, DOI 10.1093/bioinformatics/bts259
   Zienolddiny S, 2008, CARCINOGENESIS, V29, P1164, DOI 10.1093/carcin/bgn020
NR 61
TC 50
Z9 51
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD NOV
PY 2012
VL 8
IS 11
AR e1003032
DI 10.1371/journal.pgen.1003032
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 048DY
UT WOS:000311891600020
PM 23144628
OA Green Published, gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Kumar, A
   Gogia, V
   Shah, VM
   Nag, TC
AF Kumar, Atul
   Gogia, Varun
   Shah, Vinit M.
   Nag, Tapas C.
TI Comparative evaluation of anatomical and functional outcomes using
   brilliant blue G versus triamcinolone assisted ILM peeling in macular
   hole surgery in Indian population
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Brilliant blue G; ILM peeling; Triamcinolone acetonide; Macular hole
   surgery
ID INTERNAL-LIMITING MEMBRANE; PARS-PLANA VITRECTOMY; PIGMENT
   EPITHELIAL-CELLS; TRYPAN BLUE; VITREOUS SURGERY; VITREORETINAL SURGERY;
   EPIRETINAL MEMBRANE; ACETONIDE; REMOVAL; MANAGEMENT
AB To compare anatomical and functional outcomes using brilliant blue G (BBG) vs triamcinolone acetonide (TA)-assisted ILM peeling in macular hole surgery (MHS).
   Simple, comparative, retrospective, non-randomised, interventional single-centre study.
   Ninety-four eyes of 94 patients with idiopathic macular holes (a parts per thousand yen stage 2) who underwent MHS at our centre were included. Patients with failed macular holes, post-traumatic macular holes, history of previous vitreoretinal surgery, high myopia (6 dioptres or more) or any other macular pathology potentially limiting visual acuity, such as diabetic retinopathy or age-related macular degeneration, were excluded. An OCT evaluation of hole status was followed by pars plana vitrectomy for each of these eyes. Those who underwent TA-assisted ILM peeling were considered as group 1 and those with BBG-assisted ILM peeling were considered as group 2. Primary outcome measures included anatomical hole closure and functional success in terms of change in visual acuity of a parts per thousand yen2 LogMAR lines. Various preoperative factors were also evaluated.
   Anatomical hole closure was achieved in 85 eyes (90.43%) and visual gain in 78 eyes (82.9%). Mean postoperative follow-up duration was 16.14 +/- 1.95 months. No significant difference was found in anatomical and functional success between the two groups. Group 1 had a significantly higher incidence of postoperative glaucoma. Duration of symptoms of < 12 months (p = 0.004) and preoperative visual acuity a parts per thousand currency sign1.0 LogMAR were related to anatomical success. However, greater visual gain was found in patients with chronic holes (a parts per thousand yen12 months) (p = 0.046) and poor preoperative visual acuity (> 1.0 LogMAR) (p = 0.001).
   BBG-assisted ILM peeling offers an effective alternative to triamcinolone, with the added advantage of marked enhancement of vitreoretinal interface contrast with comparable hole closure rates and visual outcomes.
C1 [Kumar, Atul; Gogia, Varun; Shah, Vinit M.] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
   [Nag, Tapas C.] All India Inst Med Sci, Dept Anat, New Delhi 110029, India.
C3 All India Institute of Medical Sciences (AIIMS) New Delhi; Dr. Rajendra
   Prasad Centre for Ophthalmic Sciences; All India Institute of Medical
   Sciences (AIIMS) New Delhi
RP Kumar, A (通讯作者)，All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, New Delhi 110029, India.
EM atul56kumar@yahoo.com
RI NAG, TAPAS CHANDRA/R-6285-2019
OI NAG, TAPAS CHANDRA/0000-0002-6962-0844
CR Abdelkader E, 2008, SURV OPHTHALMOL, V53, P368, DOI 10.1016/j.survophthal.2008.04.006
   Ando F, 2004, AM J OPHTHALMOL, V137, P609, DOI 10.1016/j.ajo.2003.08.038
   Brooks HL, 2000, OPHTHALMOLOGY, V107, P1939, DOI 10.1016/S0161-6420(00)00331-6
   Da Mata AP, 2001, OPHTHALMOLOGY, V108, P1187, DOI 10.1016/S0161-6420(01)00593-0
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P623, DOI 10.1097/00006982-200607000-00006
   Enaida H, 2006, RETINA-J RET VIT DIS, V26, P631, DOI 10.1097/00006982-200607000-00007
   Freeman WR, 1997, ARCH OPHTHALMOL-CHIC, V115, P11, DOI 10.1001/archopht.1997.01100150013002
   Fukukita M, 2007, RETINA-J RET VIT DIS, V27, P122, DOI 10.1097/01.iae.0000258270.98012.62
   FUNATA M, 1992, RETINA-J RET VIT DIS, V12, P289, DOI 10.1097/00006982-199212040-00001
   Haritoglou C, 2002, AM J OPHTHALMOL, V134, P661, DOI 10.1016/S0002-9394(02)01751-8
   Horio N, 2005, ARCH OPHTHALMOL-CHIC, V123, P96, DOI 10.1001/archopht.123.1.96
   Jin Y, 2005, EXP EYE RES, V81, P395, DOI 10.1016/j.exer.2005.02.010
   KELLY NE, 1991, ARCH OPHTHALMOL-CHIC, V109, P654, DOI 10.1001/archopht.1991.01080050068031
   Kumagai K, 2004, RETINA-J RET VIT DIS, V24, P721, DOI 10.1097/00006982-200410000-00006
   Kumar Atul, 2002, Indian Journal of Ophthalmology, V50, P123
   Kumar A, 2010, INDIAN J OPHTHALMOL, V58, P232, DOI 10.4103/0301-4738.62650
   Kumar Atut, 2005, Indian Journal of Ophthalmology, V53, P159
   Kwok A. K. H., 2005, Hong Kong Medical Journal, V11, P259
   Kwok AKH, 2003, BRIT J OPHTHALMOL, V87, P71, DOI 10.1136/bjo.87.1.71
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P178, DOI 10.1016/S0002-9394(01)00976-X
   Li K, 2003, BRIT J OPHTHALMOL, V87, P216, DOI 10.1136/bjo.87.2.216
   Liesenhoff Ontje, 1996, Ophthalmologe, V93, P655, DOI 10.1007/s003470050053
   Margherio RR, 2000, ARCH OPHTHALMOL-CHIC, V118, P495
   Mester V, 2000, AM J OPHTHALMOL, V129, P769, DOI 10.1016/S0002-9394(00)00358-5
   MEYER CH, 2008, DEV OPHTHALMOL, V42, P115
   MEYER CH, 2008, DEV OPHTHALMOL, V42, P91
   MEYER CH, 2008, DEV OPHTHALMOL, V42, P69
   MORRIS R, 1994, OPHTHALMOLOGY, V101, P1
   Nomoto H, 2008, RETINA-J RET VIT DIS, V28, P427, DOI 10.1097/IAE.0b013e31815ec2f1
   ORELLANA J, 1993, BRIT J OPHTHALMOL, V77, P555, DOI 10.1136/bjo.77.9.555
   Park DW, 1999, OPHTHALMOLOGY, V106, P1392, DOI 10.1016/S0161-6420(99)00730-7
   Perrier M, 2003, AM J OPHTHALMOL, V135, P909, DOI 10.1016/S0002-9394(02)02256-0
   Peyman GA, 2000, RETINA-J RET VIT DIS, V20, P554, DOI 10.1097/00006982-200005000-00024
   Rezai KA, 2004, AM J OPHTHALMOL, V138, P492, DOI 10.1016/j.ajo.2004.03.033
   Rezai KA, 2004, AM J OPHTHALMOL, V137, P931, DOI 10.1016/j.ajo.2003.11.016
   Rodrigues EB, 2005, GRAEF ARCH CLIN EXP, V243, P291, DOI 10.1007/s00417-004-0992-x
   Rodrigues EB, 2010, AM J OPHTHALMOL, V149, P265, DOI 10.1016/j.ajo.2009.08.020
   Rodrigues EB, 2009, SURV OPHTHALMOL, V54, P576, DOI 10.1016/j.survophthal.2009.04.011
   RUBY AJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P359, DOI 10.1001/archopht.1994.01090150089029
   RYAN EH, 1994, ARCH OPHTHALMOL-CHIC, V112, P1545, DOI 10.1001/archopht.1994.01090240051025
   Shah GK, 2005, RETINA-J RET VIT DIS, V25, P972, DOI 10.1097/00006982-200512000-00003
   Shah GK, 2004, AM J OPHTHALMOL, V138, P656, DOI 10.1016/j.ajo.2004.04.025
   Smiddy WE, 2001, OPHTHALMOLOGY, V108, P1471, DOI 10.1016/S0161-6420(00)00645-X
   Smiddy WE, 2004, AM J OPHTHALMOL, V137, P525, DOI 10.1016/j.ajo.2003.12.011
   Teba FA, 2003, OPHTHALMOLOGY, V110, P2409, DOI 10.1016/S0161-6420(03)00716-4
   Tornambe PE, 1998, RETINA-J RET VIT DIS, V18, P286, DOI 10.1097/00006982-199803000-00021
   Uemoto R, 2002, BRIT J OPHTHALMOL, V86, P1240, DOI 10.1136/bjo.86.11.1240
   Veckeneer M, 2001, GRAEF ARCH CLIN EXP, V239, P698, DOI 10.1007/s004170100341
   WENDEL RT, 1993, OPHTHALMOLOGY, V100, P1671
   Yoon HS, 1996, AM J OPHTHALMOL, V122, P67, DOI 10.1016/S0002-9394(14)71965-8
NR 50
TC 25
Z9 28
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2011
VL 249
IS 7
BP 987
EP 995
DI 10.1007/s00417-010-1609-1
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 784NG
UT WOS:000292163400006
PM 21234585
DA 2022-11-30
ER

PT J
AU Dugel, PU
   Bianchini, K
AF Dugel, Pravin U.
   Bianchini, Kuo
TI Development of an Activity-based Costing Model to Evaluate Physician
   Office Practice Profitability
SO OPHTHALMOLOGY
LA English
DT Article
AB Objective: Newer treatment regimens for age-related macular degeneration have significantly affected traditional and non-traditional retinal services across all types of practice settings around the country as they seek to find a balance among delivering best patient care, keeping operating costs under control, and maintaining profitability.
   Design: A systematic retrospective review of a multi-city, multi-physician retinal practice's accounting system to obtain data on revenues, expenses, and profit. Data reviewed were from practice management systems to obtain claims level data on clinical procedures across 7 primary activity centers: non-laser surgery, laser surgery, office visits, optical coherence tomography (OCT), non-OCT diagnostics, drugs and drug injections, and research.
   Participants: All treated patients from a retina practice from January 1, 2005, to December 31, 2007.
   Methods: Retrospective claims data review from a multi-physician retina practice detailing Current Procedural Terminology and Healthcare Common Procedure Coding System procedures performed and billed, submitted charges, allowed charges, and net collections. Analyses were performed by an outside firm and verified by a risk advisory firm.
   Main Outcome Measures: Identifying practice efficiencies/inefficiencies as they relate to patient care.
   Results: An elaborate analysis using activity-based costing (ABC) showed that increased office visits and OCT and non-OCT diagnostics had a significant negative impact on the practice's profit margins, whereas surgical procedures contributed to the majority of the practice's profit margins because of the lower operating costs associated with surgery.
   Conclusions: The practice was able to accommodate the demand in patient volume, medical retina services, and medical imaging with the advent of anti-vascular endothelial growth factor therapy and realized a seismic shift in operating costs. The practice attempted to deliver state-of-the-art patient care in a cost-effective manner, yet underwent a significant decline in its financial health.
C1 [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ 85014 USA.
RP Dugel, PU (通讯作者)，Retinal Consultants Arizona, 1101 E Missouri Ave, Phoenix, AZ 85014 USA.
EM pdugel@gmail.com
FU NeoVista, Inc., Newark, California
FX This analysis was supported by an unrestricted educational grant from
   NeoVista, Inc., Newark, California.
CR Berlin Mark F, 2004, J Med Pract Manage, V19, P219
   Centers for Medicare and Medicaid Services, 2009, ANN PHYS FEE SCHED P
   Coa P, 2006, METHOD INFORM MED, V45, P462
   Emmett Dennis, 2005, J Hosp Mark Public Relations, V15, P79
   Fabrizio NA, 2005, UROL CLIN N AM, V32, P291, DOI 10.1016/j.ucl.2005.03.010
   Grandlich Cheryl, 2004, AORN J, V79, P189, DOI 10.1016/S0001-2092(06)61152-6
   Lievens Y, 2003, INT J RADIAT ONCOL, V57, P522, DOI 10.1016/S0360-3016(03)00579-0
   LOOP FD, 1995, ANN THORAC SURG, V60, P1509, DOI 10.1016/0003-4975(95)00684-D
   Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339
NR 9
TC 9
Z9 9
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2011
VL 118
IS 1
BP 203
EP U231
DI 10.1016/j.ophtha.2010.04.035
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 701PF
UT WOS:000285832500030
PM 20709400
DA 2022-11-30
ER

PT J
AU Soheilian, M
   Karimi, S
   Ramezani, A
   Peyman, GA
AF Soheilian, Masoud
   Karimi, Saeed
   Ramezani, Alireza
   Peyman, Gholam A.
TI PILOT STUDY OF INTRAVITREAL INJECTION OF DICLOFENAC FOR TREATMENT OF
   MACULAR EDEMA OF VARIOUS ETIOLOGIES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE intravitreal injection; macular edema; NSAID
ID ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR-PRESSURE; DIABETIC-RETINOPATHY;
   CATARACT-SURGERY; IN-VITRO; INHIBITION; HYALURONAN; EXPRESSION; CELLS;
   ANGIOGENESIS
AB Purpose: The purpose of this study was to evaluate the effect of a single dose of intravitreal diclofenac, a potent nonsteroidal antiinflammatory drug, on visual acuity and central macular thickness in patients with macular edema of various etiologies.
   Methods: In this prospective noncomparative case series, 10 eyes of 10 patients with clinically significant diabetic macular edema (n = 5), neovascular age-related macular degeneration (n = 2), pseudophakic cystoid macular edema (n = 1), macular edema secondary to old branch retinal vein occlusion (n = 1), and cystoid macular edema secondary to chronic intermediate uveitis (n = 1) received 500 mu g/0.1 mL of intravitreal diclofenac. The primary outcome measure was change in visual acuity.
   Results: After 2 weeks, visual acuity improved in 3 (30%) eyes (P = 0.78), did not change in 3 (30%) eyes, and decreased in 3 (30%) eyes. After 4 weeks, improvement of best-corrected visual acuity occurred in 5 (50%) eyes (P = 0.07), but in 3 eyes (30%), best-corrected visual acuity did not change, and in 1 eye (10%), visual acuity decreased. After 8 weeks, visual acuity improved in 7 (70%) eyes (P = 0.019), got worse in 1 eye (10%), and did not change in 2 eyes (20%). Central macular thickness did not decrease significantly at 8 weeks. On the basis of electroretinography, no significant changes in the amplitude of a-wave or b-wave in relation to baseline were noticed in any eye.
   Conclusion: Up to 8 weeks, intravitreal diclofenac treatment of eyes with macular edema of various etiologies yielded prominent improvement in visual acuity but was not associated with a significant decrease in central macular thickness. No toxic effect of intravitreal diclofenac was observed. RETINA 30: 509-515, 2010
C1 [Soheilian, Masoud; Karimi, Saeed; Ramezani, Alireza] Shahid Beheshti Univ MC, Labbafinejad Med Ctr, Dept Ophthalmol, Tehran, Iran.
   [Soheilian, Masoud; Ramezani, Alireza] Negah Eye Ctr, Tehran, Iran.
   [Peyman, Gholam A.] Univ Arizona, Dept Ophthalmol, Tucson, AZ USA.
   [Peyman, Gholam A.] Arizona State Univ, Phoenix, AZ USA.
   [Peyman, Gholam A.] Maricopa Hosp, Phoenix, AZ USA.
C3 Shahid Beheshti University Medical Sciences; University of Arizona;
   Arizona State University; Arizona State University-Downtown Phoenix
RP Soheilian, M (通讯作者)，Shahid Beheshti Univ MC, Labbafinejad Med Ctr, Dept Ophthalmol, Pasdaran Ave,Boostan 9 St, Tehran, Iran.
EM masoud_soheilian@yahoo.com
RI Soheilian, Masoud/AAW-4743-2020; Ramezani, Alireza/AAF-4834-2020;
   Karimi, Saeed/AAW-4905-2020; Ramezani, Alireza/AAZ-2606-2020
OI Ramezani, Alireza/0000-0002-1925-1251; Soheilian,
   Masoud/0000-0001-7508-426X
CR ALAM CAS, 1995, J PHARM PHARMACOL, V47, P407, DOI 10.1111/j.2042-7158.1995.tb05820.x
   Audren F, 2006, ACTA OPHTHALMOL SCAN, V84, P624, DOI 10.1111/j.1600-0420.2006.00700.x
   BenEzra D, 1997, GRAEF ARCH CLIN EXP, V235, P200, DOI 10.1007/BF00941759
   BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T
   Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581
   Costagliola C, 2005, EXP EYE RES, V81, P610, DOI 10.1016/j.exer.2005.03.020
   FLYNN JT, 1990, TREATMENT RETINOPATH, P81
   Gillies MC, 2005, OPHTHALMOLOGY, V112, P139, DOI 10.1016/j.ophtha.2004.07.017
   GOA KL, 1992, DRUG AGING, V2, P473, DOI 10.2165/00002512-199202060-00004
   Joussen AM, 2002, FASEB J, V16, P438, DOI 10.1096/fj.01-0707fje
   Kim SJ, 2008, RETINA-J RET VIT DIS, V28, P595, DOI 10.1097/IAE.0b013e31815e98a5
   KOTHARI HV, 1987, BIOCHIM BIOPHYS ACTA, V921, P502, DOI 10.1016/0005-2760(87)90078-6
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   NAVEH N, 1990, OPHTHALMIC RES, V22, P3, DOI 10.1159/000266995
   NAVEH N, 1991, PROSTAGLANDINS, V41, P143, DOI 10.1016/0090-6980(91)90027-D
   PATZ A, 1982, AM J OPHTHALMOL, V94, P715, DOI 10.1016/0002-9394(82)90297-5
   PEER J, 1995, LAB INVEST, V72, P638
   PREUDHOMME Y, 1985, INVEST OPHTH VIS SCI, V26, P1336
   Schmid KE, 2006, GRAEF ARCH CLIN EXP, V244, P1446, DOI 10.1007/s00417-006-0322-6
   Seed MP, 1997, ADV EXP MED BIOL, V433, P339
   Shen WY, 2000, GRAEF ARCH CLIN EXP, V238, P273, DOI 10.1007/s004170050353
   Snyder RW, 2000, J CATARACT REFR SURG, V26, P1225, DOI 10.1016/S0886-3350(00)00439-9
   Starita Carla, 2007, Dev Ophthalmol, V39, P122, DOI 10.1159/000098504
   STJERNSCHANTZ J, 1984, HDB EXPT PHARM, V69, P311
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   WEINREB RN, 1988, INVEST OPHTH VIS SCI, V29, P1708
   Wilkinson-Berka JL, 2004, CURR PHARM DESIGN, V10, P3331, DOI 10.2174/1381612043383142
NR 27
TC 44
Z9 57
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2010
VL 30
IS 3
BP 509
EP 515
DI 10.1097/IAE.0b013e3181bdfa43
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608AD
UT WOS:000278548800020
PM 19952986
DA 2022-11-30
ER

PT J
AU Rutland, CS
   Jiang, KY
   Soff, GA
   Mitchell, CA
AF Rutland, Catrin S.
   Jiang, Keyi
   Soff, Gerald A.
   Mitchell, Christopher A.
TI Maternal administration of anti-angiogenic agents, TNP-470 and
   Angiostatin(4.5), induces fetal microphthalmia
SO MOLECULAR VISION
LA English
DT Article
ID CHRONIC PLACENTAL INSUFFICIENCY; ENDOTHELIAL GROWTH-FACTOR; ALCOHOL
   SYNDROME; TUMOR-GROWTH; RETINAL VASCULATURE; VEGF EXPRESSION;
   BINDING-PROTEIN; CELL-MIGRATION; OPTIC-NERVE; IN-VITRO
AB Purpose: Agents specifically targeting the vasculature as a mode of therapy are finding increasing use in the clinic, primarily in the treatment of colon cancer (Avastin(TM)) and age-related macular degeneration (Lucentis(TM)). We have previously shown that maternal administration of angiogenic inhibitors (TNP-470 [O-[chloroacetylcarbamoyl] fumagillol, initially called AGM-1470], the first angiogenic inhibitor to undergo clinical trials, and Angiostatin(4.5), currently in phase I-III clinical trials) cause fetal growth restriction and/or placental abnormalities. During a rapid growth phase of ocular development in the mouse (embryonic days 12 to 19 [E12-E19]), the placenta mediates the metabolic requirements of the fetus and consequently may impact upon the growth of the highly oxygen sensitive fetal eye.
   Methods: We injected pregnant dams (between E10.5 - E18.5) with anti-angiogenic agents, which caused either a placental insufficiency type of IUGR (intrauterine growth restriction; i.e., TNP-470) or frank placental pathology (Angiostatin(4.5) [AS(4.5)]), and assessed changes in absolute ocular dimensions, tissue types, and vascular profiles using stereological techniques.
   Results: The experiments showed that ocular volumes were significantly reduced in fetal mice where dams were treated with either TNP-470 or AS4.5. Furthermore, TNP-470 specifically caused a reduction in hyaloid blood vessel length and volume, the only intraocular vascular circulation in fetal mice.
   Conclusions: These experiments support the hypothesis that the angiogenic inhibitors (specifically TNP-470 and AS4.5) induce microphthalmia either indirectly by their known effects on placental morphology (and/or function) or directly via altering microvascular growth in the fetus. These results also warrant further investigation of a new experimental paradigm linking placental pathology-related fetal growth restriction and microphthalmia.
C1 [Mitchell, Christopher A.] Univ Ulster, Ctr Mol Biosci, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland.
   [Rutland, Catrin S.] Univ Nottingham, City Hosp Nottingham, Acad Div Obstet & Gynaecol, Nottingham NG7 2RD, England.
   [Jiang, Keyi; Soff, Gerald A.] Northwestern Univ, Feinberg Med Sch, Chicago, IL 60611 USA.
C3 Ulster University; Nottingham University Hospital NHS Trust; Nottingham
   City Hospital; University of Nottingham; Northwestern University;
   Feinberg School of Medicine
RP Mitchell, CA (通讯作者)，Univ Ulster, Ctr Mol Biosci, Sch Biomed Sci, Cromore Rd, Coleraine BT52 1SA, Londonderry, North Ireland.
EM ca.mitchell@ulster.ac.uk
RI Mitchell, Christopher/ABH-1426-2020; Rutland, Catrin/A-7508-2010
OI Mitchell, Christopher/0000-0002-4422-7499; Rutland,
   Catrin/0000-0002-2009-4898
CR Ahmed MH, 1996, J SURG RES, V64, P35, DOI 10.1006/jsre.1996.0303
   Albini A, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-5
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Ash JD, 2000, DEV BIOL, V223, P383, DOI 10.1006/dbio.2000.9755
   ATKINSON SD, 2007, BRIT MICR SOC M APR
   Cain CC, 2007, PRENATAL DIAG, V27, P373, DOI 10.1002/pd.1674
   CHAN T, 1991, BRIT J OPHTHALMOL, V75, P524, DOI 10.1136/bjo.75.9.524
   Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579
   Cook C S, 1988, J Pediatr Ophthalmol Strabismus, V25, P60
   COOK CS, 1987, ARCH OPHTHALMOL-CHIC, V105, P1576, DOI 10.1001/archopht.1987.01060110122045
   CrettonScott E, 1996, CANCER CHEMOTH PHARM, V38, P117, DOI 10.1007/s002800050458
   De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102
   Drixler TA, 2001, INVEST OPHTH VIS SCI, V42, P3325
   ELHIFNAWI E, 1994, ANN ANAT, V176, P143
   Emoto M, 2000, ANTICANCER RES, V20, P601
   Gately S, 1996, CANCER RES, V56, P4887
   Gedeon C, 2006, PLACENTA, V27, P861, DOI 10.1016/j.placenta.2005.09.001
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gervaz P, 1998, INT J EXP PATHOL, V79, P359
   Gogat K, 2004, INVEST OPHTH VIS SCI, V45, P7, DOI 10.1167/iovs.02-1096
   Goldberg MF, 1997, AM J OPHTHALMOL, V124, P587, DOI 10.1016/S0002-9394(14)70899-2
   Golzio C, 2007, AM J HUM GENET, V80, P1179, DOI 10.1086/518177
   Goretzki L, 2000, J BIOL CHEM, V275, P28625, DOI 10.1074/jbc.M002290200
   GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x
   Hallene KL, 2006, NEUROSCIENCE, V142, P267, DOI 10.1016/j.neuroscience.2006.06.017
   HANDE MP, 1993, TERATOGEN CARCIN MUT, V13, P145, DOI 10.1002/tcm.1770130305
   Hanford HA, 2003, CANCER RES, V63, P4275
   Hellstrom A, 1999, J CLIN ENDOCR METAB, V84, P795, DOI 10.1210/jc.84.2.795
   Hellstrom A, 2002, J CLIN ENDOCR METAB, V87, P3413, DOI 10.1210/jc.87.7.3413
   Hellstrom A, 2000, EYE, V14, P324, DOI 10.1038/eye.2000.81
   HINZPETER EN, 1992, KLIN MONATSBL AUGENH, V200, P33, DOI 10.1055/s-2008-1045711
   HITTNER H M, 1981, Journal of Pediatric Ophthalmology and Strabismus, V18, P55
   HITTNER H M, 1981, Journal of Pediatric Ophthalmology and Strabismus, V18, P52
   HITTNER HM, 1977, J PEDIATR-US, V91, P455, DOI 10.1016/S0022-3476(77)81324-3
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0
   Joussen AM, 2001, INVEST OPHTH VIS SCI, V42, P2510
   Kang HT, 2004, J BIOCHEM MOL BIOL, V37, P159
   Klauber N, 1997, NAT MED, V3, P443, DOI 10.1038/nm0497-443
   Klein SA, 1999, J SURG RES, V82, P268, DOI 10.1006/jsre.1998.5551
   Koyanagi S, 2003, J PHARMACOL EXP THER, V304, P669, DOI 10.1124/jpet.102.043562
   LEUNG CCK, 1983, PEDIATR RES, V17, P313, DOI 10.1203/00006450-198305000-00002
   Loeliger M, 2005, INVEST OPHTH VIS SCI, V46, P3300, DOI 10.1167/iovs.04-1357
   Loeliger M, 2004, INVEST OPHTH VIS SCI, V45, P2361, DOI 10.1167/iovs.03-1349
   Loeliger M, 2003, CLIN EXP OPHTHALMOL, V31, P250, DOI 10.1046/j.1442-9071.2003.00639.x
   Lucas R, 1998, BLOOD, V92, P4730
   Male A, 2002, EUR J HUM GENET, V10, P807, DOI 10.1038/sj.ejhg.5200890
   Matsunaga T, 2002, CIRCULATION, V105, P2185, DOI 10.1161/01.CIR.0000015856.84385.E9
   Mauceri HJ, 1998, NATURE, V394, P287, DOI 10.1038/28412
   MAYHEW TM, 1988, PLACENTA, V9, P565, DOI 10.1016/0143-4004(88)90001-X
   Mitchell Christopher A., 2006, Angiogenesis, V9, P209, DOI 10.1007/s10456-006-9056-7
   Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811
   Newton HB, 2007, CURR OPIN INVEST DR, V8, P1009
   Parentin F, 2004, CURR EYE RES, V28, P11, DOI 10.1076/ceyr.28.1.11.23491
   Pinazo-Duran M D, 1997, Eur J Ophthalmol, V7, P262
   PINAZODURAN MD, 1993, TERATOLOGY, V48, P305, DOI 10.1002/tera.1420480404
   RENZ BE, 1977, ANN OPHTHALMOL, V9, P179
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rout UK, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-44
   Rutland CS, 2007, MOL VIS, V13, P47
   Rutland CS, 2005, BIOL REPROD, V73, P1164, DOI 10.1095/biolreprod.105.043893
   Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms
   Satchi-Fainaro R, 2005, CANCER CELL, V7, P251, DOI 10.1016/j.ccr.2005.02.007
   Sathornsumetee S, 2006, ANTI-CANCER DRUG, V17, P1003, DOI 10.1097/01.cad.0000231473.00030.1f
   Scapini P, 2002, J IMMUNOL, V168, P5798, DOI 10.4049/jimmunol.168.11.5798
   Sharma MR, 2006, EXP MOL PATHOL, V81, P136, DOI 10.1016/j.yexmp.2006.03.002
   Shusterman S, 2001, CLIN CANCER RES, V7, P977
   Sima J, 2004, FEBS LETT, V564, P19, DOI 10.1016/S0014-5793(04)00297-2
   Sima Jing, 2006, Yan Ke Xue Bao, V22, P252
   Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099
   Skapinker R, 1987, J Perinatol, V7, P279
   Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   STROMLAND K, 1985, ACTA OPHTHALMOL, V63, P1
   Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200
   Tozer GM, 2005, NAT REV CANCER, V5, P423, DOI 10.1038/nrc1628
   Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247
   Velde EAT, 2003, EXP MOL PATHOL, V75, P119, DOI 10.1016/S0014-4800(03)00049-2
   Wahl ML, 2005, J CELL BIOCHEM, V96, P242, DOI 10.1002/jcb.20480
   Wajih N, 2003, BLOOD, V101, P1857, DOI 10.1182/blood-2002-02-0582
   Wang YQ, 2006, BIOCHEM BIOPH RES CO, V341, P239, DOI 10.1016/j.bbrc.2005.12.175
   Wong JCY, 2003, HUM MOL GENET, V12, P2063, DOI 10.1093/hmg/ddg219
   Yang H, 2006, MOL VIS, V12, P511
   Yoshio Y, 2004, KIDNEY INT, V66, P1677, DOI 10.1111/j.1523-1755.2004.00935.x
   Youn MR, 2006, BIOCHEM BIOPH RES CO, V343, P917, DOI 10.1016/j.bbrc.2006.03.043
   Zhang P, 2002, J BIOMED SCI, V9, P34, DOI 10.1007/BF02256576
   Zhang W, 2003, INVEST OPHTH VIS SCI, V44, P3551, DOI 10.1167/iovs.03-0008
NR 87
TC 7
Z9 9
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUN 26
PY 2009
VL 15
IS 134
BP 1260
EP 1269
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 470PB
UT WOS:000267986800001
PM 19572040
DA 2022-11-30
ER

PT J
AU Liggett, TE
   Griffiths, TD
   Gaillard, ER
AF Liggett, Thomas E.
   Griffiths, T. Daniel
   Gaillard, Elizabeth R.
TI Isolation and characterization of a spontaneously immortalized bovine
   retinal pigmented epithelial cell line
SO BMC CELL BIOLOGY
LA English
DT Article
ID FIBROBLAST-GROWTH-FACTOR; EXTRACELLULAR-MATRIX; TELOMERASE EXPRESSION;
   VIMENTIN EXPRESSION; GENE-EXPRESSION; TIGHT JUNCTION; RPE65; ACID;
   DIFFERENTIATION; MEMBRANE
AB Background: The Retinal Pigmented Epithelium (RPE) is juxtaposed with the photoreceptor outer segments of the eye. The proximity of the photoreceptor cells is a prerequisite for their survival, as they depend on the RPE to remove the outer segments and are also influenced by RPE cell paracrine factors. RPE cell death can cause a progressive loss of photoreceptor function, which can diminish vision and, over time, blindness ensues. Degeneration of the retina has been shown to induce a variety of retinopathies, such as Stargardt's disease, Cone-Rod Dystrophy (CRD), Retinitis Pigmentosa (RP), Fundus Flavimaculatus (FFM), Best's disease and Age-related Macular Degeneration (AMD). We have cultured primary bovine RPE cells to gain a further understanding of the mechanisms of RPE cell death. One of the cultures, named tRPE, surpassed senescence and was further characterized to determine its viability as a model for retinal diseases.
   Results: The tRPE cell line has been passaged up to 150 population doublings and was shown to be morphologically similar to primary cells. They have been characterized to be of RPE origin by reverse transcriptase PCR and immunocytochemistry using the RPE-specific genes RPE65 and CRALBP and RPE-specific proteins RPE65 and Bestrophin. The tRPE cells are also immunoreactive to vimentin, cytokeratin and zonula occludens-1 antibodies. Chromosome analysis indicates a normal diploid number. The tRPE cells do not grow in suspension or in soft agar. After H-3 thymidine incorporation, the cells do not appear to divide appreciably after confluency.
   Conclusion: The tRPE cells are immortal, but still exhibit contact inhibition, serum dependence, monolayer growth and secrete an extra-cellular matrix. They retain the in-vivo morphology, gene expression and cell polarity. Additionally, the cells endocytose exogenous melanin, A2E and purified lipofuscin granules. This cell line may be a useful in-vitro research model for retinal maculopathies.
C1 [Liggett, Thomas E.; Gaillard, Elizabeth R.] No Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA.
   [Griffiths, T. Daniel] Marquette Univ, Dept Biol Sci, Milwaukee, WI 53233 USA.
   [Gaillard, Elizabeth R.] No Illinois Univ, Dept Chem & Biochem, De Kalb, IL 60115 USA.
C3 Northern Illinois University; Marquette University; Northern Illinois
   University
RP Gaillard, ER (通讯作者)，No Illinois Univ, Dept Biol Sci, De Kalb, IL 60115 USA.
EM Thomas_E_Liggett@rush.edu; gaillard@niu.edu
RI Gaillard, Elizabeth/M-2627-2019
FU National Institutes of Health [RO1 EY12344]; Midwest Eye Bank and
   Transplantation Centers; NATIONAL EYE INSTITUTE [R01EY012344] Funding
   Source: NIH RePORTER
FX This study was supported in part by National Institutes of Health Grant
   (RO1 EY12344) and the Midwest Eye Bank and Transplantation Centers.
CR Adler R, 1999, MOL VIS, V5
   Alge CS, 2003, INVEST OPHTH VIS SCI, V44, P3629, DOI 10.1167/iovs.02-1225
   Alizadeh M, 2001, INVEST OPHTH VIS SCI, V42, P2706
   ANDREOLI JM, 1995, CELL MOTIL CYTOSKEL, V32, P10, DOI 10.1002/cm.970320103
   BAN Y, 1997, MOL VIS, V3, P1
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   Bonnet A, 2001, CHROMOSOME RES, V9, P673, DOI 10.1023/A:1012908508488
   BOULTON M, 1985, EXP EYE RES, V41, P209, DOI 10.1016/0014-4835(85)90026-0
   BREATHNA.AS, 1966, J ULTRA MOL STRUCT R, V16, P584, DOI 10.1016/S0022-5320(66)80008-4
   BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703
   CAMPOCHIARO PA, 1993, EXP EYE RES, V57, P539, DOI 10.1006/exer.1993.1158
   CAMPOCHIARO PA, 1991, INVEST OPHTH VIS SCI, V32, P65
   CHADER GJ, 1991, INVEST OPHTHALMOL, V10, P1081
   CHANG CW, 1991, CURR EYE RES, V10, P1081, DOI 10.3109/02713689109020348
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   DENHARDT DT, 1991, EXP CELL RES, V192, P128, DOI 10.1016/0014-4827(91)90167-S
   Denton ML, 2006, INVEST OPHTH VIS SCI, V47, P3065, DOI 10.1167/iovs.05-1066
   DIPAOLO JA, 1983, J NATL CANCER I, V70, P3
   DISINGER M, 1982, P NATL ACAD SCI USA, V79, P2018
   DOCHERTY RJ, 1984, J CELL SCI, V71, P61
   DUTT K, 1989, CURR EYE RES, V8, P435, DOI 10.3109/02713688909000023
   FARBOUND B, 1999, MOL VIS, V5, P1
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891
   FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617
   Fusenig N E, 1985, Carcinog Compr Surv, V9, P293
   FUSENIG NE, 1992, CANC FORUM, V6, P209
   GEREBEN B, 1995, NEUROBIOLOGY-BUDAPES, V3, P151
   Gollapalli DR, 2004, P NATL ACAD SCI USA, V101, P10030, DOI 10.1073/pnas.0401936101
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRIFFITHS TD, 1979, RADIAT RES, V79, P87
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611
   HAMEL CP, 1993, J BIOL CHEM, V268, P15751
   Hamel CP, 2001, BRIT J OPHTHALMOL, V85, P424, DOI 10.1136/bjo.85.4.424
   Heckelen A, 2004, ACTA OPHTHALMOL SCAN, V82, P564, DOI 10.1111/j.1600-0420.2004.00317.x
   Ho TC, 1997, EXP EYE RES, V64, P133, DOI 10.1006/exer.1996.0199
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2419
   HOPWOOD LE, 1971, RADIAT RES, V46, P70, DOI 10.2307/3573103
   HUNT RC, 1990, J CELL PHYSIOL, V145, P187, DOI 10.1002/jcp.1041450202
   HUOTARI V, 1995, DIFFERENTIATION, V58, P205, DOI 10.1046/j.1432-0436.1995.5830205.x
   Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056
   Kaida M, 2000, INVEST OPHTH VIS SCI, V41, P3215
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3
   Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023
   Kigasawa Kazuteru, 1998, Tokai Journal of Experimental and Clinical Medicine, V23, P147
   Kim KS, 1998, CURR EYE RES, V17, P962, DOI 10.1076/ceyr.17.10.962.5243
   Ma JX, 2001, INVEST OPHTH VIS SCI, V42, P1429
   MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   MCCORMICK JJ, 1989, ENVIRON MOL MUTAGEN, V14, P105, DOI 10.1002/em.2850140619
   MCLAREN MJ, 1993, EXP CELL RES, V204, P311, DOI 10.1006/excr.1993.1038
   NABI IR, 1993, J CELL SCI, V104, P37
   NICOLETTI A, 1995, HUM MOL GENET, V4, P641, DOI 10.1093/hmg/4.4.641
   Nicoletti A, 1998, INVEST OPHTH VIS SCI, V39, P637
   OSBORN M, 1989, CURRENT COMMUNICATIO, P79
   OSTROVSKY MA, 1987, VISION RES, V27, P893, DOI 10.1016/0042-6989(87)90005-8
   Park JK, 2002, EXP MOL MED, V34, P107, DOI 10.1038/emm.2002.16
   Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915
   Pihan G, 2003, CANCER CELL, V4, P89, DOI 10.1016/S1535-6108(03)00195-8
   RABB MF, 1986, OPHTHALMOLOGY, V93, P1443
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   RIZZOLO LJ, 1990, EXP EYE RES, V51, P435, DOI 10.1016/0014-4835(90)90156-O
   Rose MT, 2002, J DAIRY RES, V69, P345, DOI 10.1017/S0022029902005551
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Seshadri R, 1996, INT J CANCER, V67, P353
   SHEEDLO HJ, 1995, IN VITRO CELL DEV-AN, V31, P330
   STANFORD KK, 1982, J NATL CANCER I, V68, P895
   STOKER MGP, 1967, NATURE, V215, P171, DOI 10.1038/215171a0
   Tezel TH, 1998, EXP EYE RES, V66, P807, DOI 10.1006/exer.1998.0492
   Tombran-Tink J, 2004, EXP EYE RES, V78, P945, DOI 10.1016/j.exer.2003.12.013
   Torcynznski E., 1982, OCULAR ANATOMY EMBRY, P553
   TURKSEN K, 1989, OPHTHALMIC RES, V21, P56, DOI 10.1159/000266768
   Valtink H, 1999, GRAEF ARCH CLIN EXP, V237, P1001, DOI 10.1007/s004170050336
   VANDERVELDEN LA, 1993, HEAD NECK-J SCI SPEC, V15, P133, DOI 10.1002/hed.2880150209
   Velicescu M, 2003, CANCER RES, V63, P5813
   Wang H, 2006, J REHABIL RES DEV, V43, P713, DOI 10.1682/JRRD.2005.06.0114
   Ward DA, 1997, IN VITRO CELL DEV-AN, V33, P588, DOI 10.1007/s11626-997-0104-4
   WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108
   Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179
   Zeiss CJ, 2004, VET OPHTHALMOL, V7, P239, DOI 10.1111/j.1463-5224.2004.04033.x
   [No title captured]
NR 84
TC 8
Z9 8
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2121
J9 BMC CELL BIOL
JI BMC Cell Biol.
PD MAY 4
PY 2009
VL 10
AR 33
DI 10.1186/1471-2121-10-33
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 453RC
UT WOS:000266627600001
PM 19413901
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sharma, A
   Neekhra, A
   Gramajo, AL
   Patil, J
   Chwa, M
   Kuppermann, BD
   Kenney, MC
AF Sharma, Ashish
   Neekhra, Aneesh
   Gramajo, Ana L.
   Patil, Jayaprakash
   Chwa, Marilyn
   Kuppermann, Baruch D.
   Kenney, M. Cristina
TI Effects of Benzo(e) Pyrene, a Toxic Component of Cigarette Smoke, on
   Human Retinal Pigment Epithelial Cells In Vitro
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID POLYCYCLIC AROMATIC-HYDROCARBONS; AGE-RELATED MACULOPATHY; DNA ADDUCT
   FORMATION; MACULAR DEGENERATION; CASPASE ACTIVATION; POOLED FINDINGS;
   RISK-FACTORS; APOPTOSIS; DEATH; INDUCTION
AB PURPOSE. To better understand the cellular and molecular basis for the epidemiologic association between cigarette smoke and age-related macular degeneration (AMD), the authors examined the effects of Benzo(e) Pyrene (B(e) P), a toxic element in cigarette smoke, on human retinal pigment epithelial cells (ARPE-19).
   METHODS. ARPE-19 cells were cultured in Dulbecco modified Eagle medium containing 10% fetal bovine serum. Cells were treated for 24 hours with 1000 mu M, 400 mu M, 200 mu M, and 100 mu M B(e) P. Cell viability was determined by a trypan blue dye-exclusion assay. Activities of caspase-3/ 7, caspase-8, caspase-9, and caspase-12 were measured by a fluorescence image scanner, and DNA laddering was evaluated by electrophoresis on 3% agarose gel.
   RESULTS. The mean percentage of cell viabilities of ARPE-19 cells was decreased in a dose-dependent manner after exposure to B(e) P at the higher concentrations of 1000 mu M (20.0 +/- 0.4; P < 0.001), 400 mu M (35.6 +/- 6.4; P < 0.001), and 200 mu M (58.7 +/- 2.3; P < 0.001) but not at 100 mu M (95.9 +/- 0.7; P > 0.05) compared with the equivalent dimethyl sulfoxide (DMSO)-treated control cultures. There were significant increases in caspase-3/ 7, -8, -9, and -12 activities compared with the DMSO-treated controls (P < 0.001). DNA laddering revealed bands at 200-bp intervals.
   CONCLUSIONS. These results show that B(e) P is a toxicant to human retinal pigment epithelial cells in vitro. It causes cell death and induces apoptosis by the involvement of multiple caspase pathways. (Invest Ophthalmol Vis Sci. 2008; 49: 5111-5117) DOI: 10.1167/iovs.08-2060
C1 [Kenney, M. Cristina] Univ Calif Irvine, Med Ctr, Dept Ophthalmol, Sch Med, Orange, CA 92868 USA.
   [Neekhra, Aneesh] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Gramajo, Ana L.] Fdn VER, Dept Oftalmol, Cordoba, Argentina.
C3 University of California System; University of California Irvine;
   University of Wisconsin System; University of Wisconsin Madison
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Med Ctr, Dept Ophthalmol, Sch Med, 101 City Dr, Orange, CA 92868 USA.
EM mkenney@uci.edu
OI Sharma, Ashish/0000-0002-8550-9791
FU Discovery Eye Foundation; Iris and B. Gerald Cantor Foundation; Gilbert
   Foundation; Ko Family Foundation; Skirball Molecular Ophthalmology
   Program; Research to Prevent Blindness Foundation; Henry L. Guenther
   Foundation
FX Supported by the Discovery Eye Foundation, Iris and B. Gerald Cantor
   Foundation, Gilbert Foundation, Ko Family Foundation, the Skirball
   Molecular Ophthalmology Program, the Research to Prevent Blindness
   Foundation, and Henry L. Guenther Foundation.
CR Arroyo JG, 2005, AM J OPHTHALMOL, V139, P605, DOI 10.1016/j.ajo.2004.11.046
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   BARNEA ER, 1991, GYNECOL OBSTET INVES, V32, P4, DOI 10.1159/000292981
   Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8
   CHANG SW, 1995, OPHTHALMIC RES, V27, P74, DOI 10.1159/000267600
   Chiou SH, 2002, OPHTHALMIC RES, V34, P77, DOI 10.1159/000048332
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christoph R, 1998, RESTOR NEUROL NEUROS, V12, P59
   DAS ND, 1981, EXP EYE RES, V33, P525, DOI 10.1016/S0014-4835(81)80127-3
   Delhalle S, 2003, ANN NY ACAD SCI, V1010, P1, DOI 10.1196/annals.1299.001
   Ding J, 2007, CANCER SCI, V98, P1323, DOI 10.1111/j.1349-7006.2007.00530.x
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383
   El Ghrably I, 2004, INVEST OPHTH VIS SCI, V45, P1473, DOI 10.1167/iovs.03-0060
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Falahatpisheh MH, 2004, J Carcinog, V3, P12, DOI 10.1186/1477-3163-3-12
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9
   Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200
   Heidel SM, 2000, CANCER RES, V60, P3454
   Hockley SL, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-260
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Jiang SN, 2000, INVEST OPHTH VIS SCI, V41, P645
   Kalariya NM, 2008, EXP EYE RES, V86, P70, DOI 10.1016/j.exer.2007.09.010
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Kowluru RA, 2002, FREE RADICAL RES, V36, P993, DOI 10.1080/1071576021000006572
   Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833
   Luthra S, 2006, INVEST OPHTH VIS SCI, V47, P5569, DOI 10.1167/iovs.06-0333
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887
   Narayanan R, 2006, INVEST OPHTH VIS SCI, V47, P722, DOI 10.1167/iovs.05-0772
   Narayanan R, 2005, INVEST OPHTH VIS SCI, V46, P304, DOI 10.1167/iovs.04-0703
   Neekhra A, 2007, INVEST OPHTH VIS SCI, V48, P1362, DOI 10.1167/iovs.06-0900
   Park SY, 2006, TOXICOL LETT, V167, P27, DOI 10.1016/j.toxlet.2006.08.011
   Patton WP, 2002, EXP EYE RES, V74, P513, DOI 10.1006/exer.2001.1160
   RAMOS KS, 1994, J TOXICOL ENV HEALTH, V43, P419, DOI 10.1080/15287399409531932
   ROGGEBAND R, 1994, CARCINOGENESIS, V15, P661, DOI 10.1093/carcin/15.4.661
   Saleh M, 2006, NATURE, V440, P1064, DOI 10.1038/nature04656
   Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451
   Sanyal MK, 2007, BIRTH DEFECTS RES B, V80, P49, DOI 10.1002/bdrb.20102
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SHICHI H, 1976, EXP EYE RES, V23, P165, DOI 10.1016/0014-4835(76)90200-1
   Shiraga S, 2002, J NEUROIMMUNOL, V132, P72, DOI 10.1016/S0165-5728(02)00314-4
   Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sugihara N, 2007, TOXICOL IN VITRO, V21, P827, DOI 10.1016/j.tiv.2007.02.005
   Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032
   Szurman P, 2006, EXP EYE RES, V83, P584, DOI 10.1016/j.exer.2006.02.012
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topinka J, 1998, MUTAT RES-GEN TOX EN, V419, P91, DOI 10.1016/S1383-5718(98)00127-2
   Trisnawaty A, 2000, MUTAT RES-GEN TOX EN, V468, P227, DOI 10.1016/S1383-5718(00)00052-8
   Uhl M, 2000, MUTAT RES-GEN TOX EN, V468, P213, DOI 10.1016/S1383-5718(00)00051-6
   Vakharia DD, 2001, DRUG METAB DISPOS, V29, P999
   Valamanesh F, 2007, MOL VIS, V13, P1746
   van Grevenynghe J, 2005, J PHARMACOL EXP THER, V314, P693, DOI 10.1124/jpet.105.084780
   Vayssier-Taussat M, 2001, AM J PHYSIOL-HEART C, V280, pH1293, DOI 10.1152/ajpheart.2001.280.3.H1293
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Yang JH, 2005, INVEST OPHTH VIS SCI, V46, P1039, DOI 10.1167/iovs.04-0325
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yeung CK, 2003, INVEST OPHTH VIS SCI, V44, P5293, DOI 10.1167/iovs.03-0490
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zacks DN, 2003, INVEST OPHTH VIS SCI, V44, P1262, DOI 10.1167/iovs.02-0492
   ZEDECK MS, 1980, J ENVIRON PATHOL TOX, V3, P537
NR 72
TC 43
Z9 45
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2008
VL 49
IS 11
BP 5111
EP 5117
DI 10.1167/iovs.08-2060
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 366RX
UT WOS:000260502200057
PM 18586875
DA 2022-11-30
ER

PT J
AU Uppal, G
   Milliken, A
   Lee, J
   Acheson, J
   Hykin, P
   Tufail, A
   da Cruz, L
AF Uppal, Gurmit
   Milliken, Andrew
   Lee, John
   Acheson, James
   Hykin, Phil
   Tufail, Adnan
   da Cruz, Lyndon
TI New algorithm for assessing patient suitability for macular
   translocation surgery
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; case selection; translocation surgery
ID VISUAL FUNCTION; 360-DEGREE RETINOTOMY; RETINAL SEPARATION;
   DEGENERATION; RETINECTOMY; RELOCATION
AB Purpose: We propose a case selection algorithm to assess suitability for macular translocation for subfoveal neovascular membrane (CNV) secondary to age-related macular degeneration. The algorithm is based on preoperative assessment of residual foveal function, as assessed by a slit-lamp fixation task and duration of visual loss, in patients with poor acuity. We validate our slit-lamp fixation task against an objective analysis (Nidek MP-1 Microperimetry) and proceed to examine surgical outcomes as selected by the algorithm.
   Methods: A prospective series of 27 consecutive patients with CNV underwent translocation at Moorfields Eye Hospital, London between May 2003 and May 2006.
   Results: Validation of the slit-lamp fixation task revealed 100% concordance in classification of fixation between the slit-lamp task and the microperimeter. At an average follow up of 12.2 months, the mean Early Treatment of Diabetic Retinopathy Study distance acuity improved from logMAR 0.88 to 0.68 (P < 0.03). Sixty-six per cent of patients achieved an acuity of <= logMAR 0.8 (6/30), 22% an acuity of <= logMAR 0.3 (6/12) and 33% gained three lines of acuity. The mean MN Read reading acuity improved from logMAR 1.23 to 0.91 (P < 0.01). Forty-four per cent of patients achieved an acuity of >= logMAR 0.7 (N10), 15% an acuity of >= logMAR 0.4 (N5) and 44% gained three lines of acuity.
   Discussion: We have demonstrated a simple case selection algorithm that is based on residual foveal function and suggests good outcomes. The strongest indicators of foveal function are fixation characteristics and duration of visual loss. In contrast to previous studies, our algorithm suggests good outcomes independently of preoperative visual acuity and CNV characteristics.
C1 Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust
RP Uppal, G (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EC1V 2PD, England.
EM gurmit@orange.net
OI Tufail, Adnan/0000-0001-6131-7640
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P11
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   Fujikado T, 2001, AM J OPHTHALMOL, V131, P101, DOI 10.1016/S0002-9394(00)00770-4
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   *MAC PHOT STUD GRO, 1991, ARCH OPHTHALMOL-CHIC, V111, P1220
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P629, DOI 10.1007/BF00921956
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Oyagi T, 2004, RETINA-J RET VIT DIS, V24, P548, DOI 10.1097/00006982-200408000-00007
   Pertile G, 2002, AM J OPHTHALMOL, V134, P560, DOI 10.1016/S0002-9394(02)01641-0
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Seaber JH, 1997, GRAEF ARCH CLIN EXP, V235, P76, DOI 10.1007/BF00941733
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Toth CA, 2004, GRAEF ARCH CLIN EXP, V242, P541, DOI 10.1007/s00417-004-0867-1
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   WHITTAKER SG, 1993, OPTOMETRY VISION SCI, V70, P54, DOI 10.1097/00006324-199301000-00010
NR 27
TC 13
Z9 13
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUL
PY 2007
VL 35
IS 5
BP 448
EP 457
DI 10.1111/j.1442-9071.2007.01528.x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 197BY
UT WOS:000248529600010
PM 17651250
DA 2022-11-30
ER

PT J
AU Maines, LW
   French, KJ
   Wolpert, EB
   Antonetti, DA
   Smith, CD
AF Maines, Lynn W.
   French, Kevin J.
   Wolpert, Ellen B.
   Antonetti, David A.
   Smith, Charles D.
TI Pharmacologic manipulation of sphingosine kinase in retinal endothelial
   cells: Implications for angiogenic ocular diseases
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID NF-KAPPA-B; FACTOR-INDUCED ACTIVATION; GROWTH-FACTOR;
   VASCULAR-PERMEABILITY; DIABETIC-RETINOPATHY; BARRIER FUNCTION; TUBE
   FORMATION; VEGF RECEPTOR; UP-REGULATION; TNF-ALPHA
AB PURPOSE. The increased vascular permeability and pathogenic angiogenesis observed in diabetic retinopathy are induced, at least in part, by local inflammation and vascular endothelial growth factor (VEGF). Therefore, inhibition of signaling from VEGF and tumor necrosis factor-alpha (TNF alpha) is a promising approach to the treatment of this disease, as well as ocular diseases with similar etiologies, including age-related macular degeneration. A growing body of evidence demonstrates that sphingosine kinase (SK) plays an important role in cellular proliferation and angiogenesis. This study was undertaken to examine the effects of SK inhibitors on the responses of retinal endothelial cells (RECs) to VEGF and TNF alpha and their therapeutic efficacy in a diabetic retinopathy model.
   METHODS. The expression and function of SK in bovine and human RECs were examined by immunoblot analysis. The involvement of SK in mediating responses to VEGF and TNF alpha was examined by using pharmacologic inhibitors of SK in cellular and in vivo assays, including a 3-month streptozotocin-induced diabetic retinopathy model in rats.
   RESULTS. SK was present and active in human and bovine RECs, and SK activity in these cells was stimulated by VEGF. Inhibitors of SK blocked VEGF-induced production of sphingosine 1-phosphate and markedly attenuated VEGF-induced proliferation and migration of RECs. In addition, SK inhibitors were shown to block TNF alpha-induced expression of adhesion proteins, suppress VEGF-induced vascular leakage in an in vivo mouse model, and reduce retinal vascular leakage in the rat diabetic retinopathy model.
   CONCLUSIONS. Overall, these studies demonstrate that inhibitors of SK attenuate the effects of proliferative and inflammatory stimuli on RECs both in vitro and in vivo, and so could be significant therapeutics in the treatment of diabetic retinopathy.
C1 Med Univ S Carolina, Dept Pharmaceut Sci, Charleston, SC 29425 USA.
   Apogee Biotechnol Corp, Hershey, PA USA.
   Penn State Coll Med, Dept Cellular & Mol Physiol, Hershey, PA USA.
   Penn State Coll Med, Dept Ophthalmol, Hershey, PA USA.
C3 Medical University of South Carolina; Pennsylvania Commonwealth System
   of Higher Education (PCSHE); Pennsylvania State University; Penn State
   Health; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health
RP Smith, CD (通讯作者)，Med Univ S Carolina, Dept Pharmaceut Sci, 280 Calhoun St,Box 250140, Charleston, SC 29425 USA.
EM smithchd@musc.edu
OI antonetti, david/0000-0003-1130-6577
FU NATIONAL EYE INSTITUTE [R43EY016608] Funding Source: NIH RePORTER; NEI
   NIH HHS [1R43 EY 016608, R43 EY016608-01, R43 EY016608] Funding Source:
   Medline
CR Adamis A P, 1999, Angiogenesis, V3, P9, DOI 10.1023/A:1009071601454
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200
   Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Barber AJ, 2005, INVEST OPHTH VIS SCI, V46, P2210, DOI 10.1167/iovs.04-1340
   BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2
   Boland MP, 1996, BIOCHEM SOC T, V24, pS1, DOI 10.1042/bst024001s
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   CAMUSSI G, 1991, INT ARCH ALLER A IMM, V96, P84, DOI 10.1159/000235539
   Chen XL, 2004, AM J PHYSIOL-HEART C, V287, pH1452, DOI 10.1152/ajpheart.01101.2003
   Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200
   English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795
   FEISTRITZER C, 2005, BLOOD, V5, P78
   Frank RN, 1997, ARCH OPHTHALMOL-CHIC, V115, P1036, DOI 10.1001/archopht.1997.01100160206011
   French KJ, 2003, CANCER RES, V63, P5962
   FRENCH KJ, 2006, J PHARMACOL EXP THER, V47, P1412
   Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450
   Gardner T W, 1995, Trans Am Ophthalmol Soc, V93, P583
   Grant MB, 2004, EXPERT OPIN INV DRUG, V13, P1275, DOI 10.1517/13543784.13.10.1275
   HAMMES HP, 1998, DIABETES, P1
   Igarashi J, 2003, P NATL ACAD SCI USA, V100, P10664, DOI 10.1073/pnas.1934494100
   Kelly JJ, 1998, AM J PHYSIOL-LUNG C, V274, pL810, DOI 10.1152/ajplung.1998.274.5.L810
   KIM I, J BIOL CHEM, V6, P14
   Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756-3282(96)00181-0
   Lee SJ, 2004, CANCER LETT, V208, P89, DOI 10.1016/j.canlet.2003.11.008
   Linz-McGillem LA, 2004, STEM CELLS DEV, V13, P496, DOI 10.1089/1547328042417282
   Maines LW, 2005, NEUROPHARMACOLOGY, V49, P610, DOI 10.1016/j.neuropharm.2005.04.028
   MAINES LW, IN PRESS DIG DIS SCI
   Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644
   Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297
   McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088
   MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789
   Murata T, 1996, LAB INVEST, V74, P819
   Newton R, 2000, BIOCHEM BIOPH RES CO, V277, P675, DOI 10.1006/bbrc.2000.3722
   Oshima Y, 2004, J CELL PHYSIOL, V199, P399, DOI 10.1002/jcp.10441
   Parker JC, 2000, J APPL PHYSIOL, V89, P2241, DOI 10.1152/jappl.2000.89.6.2241
   PEER J, 1995, LAB INVEST, V72, P638
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650
   Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200
   Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   SCHNITZER JE, 1994, BIOCHEM BIOPH RES CO, V199, P11, DOI 10.1006/bbrc.1994.1185
   Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   SONE H, 1997, DIABETOLOGIA, P6
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   TAHA TA, 2004, BIOCHIM BIOPHYS ACTA, V82, P55
   Wu DY, 2003, J BIOL CHEM, V278, P10983, DOI 10.1074/jbc.M207470200
   Wu WC, 2003, ONCOGENE, V22, P3361, DOI 10.1038/sj.onc.1206285
   Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196
   Yin F, 2005, INVEST OPHTH VIS SCI, V46, P1927, DOI 10.1167/iovs.04-1256
NR 55
TC 48
Z9 55
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2006
VL 47
IS 11
BP 5022
EP 5031
DI 10.1167/iovs.05-1236
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 098XS
UT WOS:000241557500055
PM 17065523
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Thurmann, PA
   Schalch, W
   Aebischer, JC
   Tenter, U
   Cohn, W
AF Thurmann, PA
   Schalch, W
   Aebischer, JC
   Tenter, U
   Cohn, W
TI Plasma kinetics of lutein, zeaxanthin, and 3 '-dehydro-lutein after
   multiple oral doses of a lutein supplement
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE xanthophylls; carotenoids; lutein; zeaxanthin; all-E-3 '-dehydro-lutein;
   multiple oral dose kinetics; macular pigment; age-related macular
   degeneration
ID BETA-CAROTENE; CATARACT-EXTRACTION; BIOAVAILABILITY; ABSORPTION;
   DEPLETION; LYCOPENE; SPINACH; RISK
AB Background: Adequate intake of lutein is postulated to reduce the risk of age-related macular degeneration, but kinetic information for developing a dosing regimen is sparse.
   Objective: The objective was to characterize lutein plasma kinetics in a multiple dosing design and to assess the effects of lutein intake on concentrations of other plasma carotenoids.
   Design: After a run-in period of 7 d, 19 healthy volunteers were assigned to receive daily oral doses of 4.1 mg lutein (n = 8; group 1) or 20.5 mg lutein (n = 8; group 2) for 42 d or no lutein (n = 3; control group). The supplement contained 8.3% zeaxanthin relative to lutein (100%). The time profiles of plasma xanthophyll concentrations were monitored over the dosing phase, and samples were collected frequently on day 42 and for 24 d after dosing.
   Results: Average plasma all-E-lutein concentrations increased from 0.14 to 0.52 +/- 0.13 and 1.45 +/- 0.69 mu mol/L in groups 1 and 2. respectively. Dose-normalized lutein bioavailability in group 2 was approximate to 60% of that in group 1. Kinetic disposition half-life did not differ significantly between groups. On average, dosing for 18 d was required to reach a > 90% fraction of the steady state concentration, which is consistent with an effective half-life for accumulation of approximate to 5.6 d. Plasma kinetics of all-E-lutein were paralleled by those of all-E-3'-dehydro-lutein. Kinetic analysis indicated formation of allE-3'-dehydro-lutein from lutein. Lutein was well tolerated and did not affect the concentrations of other carotenoids.
   Conclusion: Long-term supplementation with 4.1 and 20.5 mg lutein as beadlets increased plasma lutein concentrations approximate to 3.5- and 10-fold, respectively.
C1 DSM Nutr Prod Ltd, Dept Human Nutr & Hlth, CH-4002 Basel, Switzerland.
   Univ Witten Herdecke, HELIOS Klinikum Wuppertal, Inst Clin Pharmacol, Wuppertal, Germany.
C3 DSM NV; Helios Kliniken; Witten Herdecke University
RP Cohn, W (通讯作者)，DSM Nutr Prod Ltd, Dept Human Nutr & Hlth, POB 3255, CH-4002 Basel, Switzerland.
EM willy.cohn@dsm.com
OI Thurmann, Petra/0000-0001-9724-1422
CR Aebischer CP, 1999, METHOD ENZYMOL, V299, P348
   Bowen PE, 2002, J NUTR, V132, P3668, DOI 10.1093/jn/132.12.3668
   BOXENBAU.HG, 1974, J PHARMACOKINET BIOP, V2, P123, DOI 10.1007/BF01061504
   BOXENBAUM H, 1995, J CLIN PHARMACOL, V35, P763, DOI 10.1002/j.1552-4604.1995.tb04117.x
   Brown L, 1999, AM J CLIN NUTR, V70, P517
   Burri BJ, 2001, J NUTR, V131, P2096, DOI 10.1093/jn/131.8.2096
   Castenmiller JJM, 1999, J NUTR, V129, P349, DOI 10.1093/jn/129.2.349
   Chasan-Taber L, 1999, AM J CLIN NUTR, V70, P509
   CHUGAHUJA JK, 1993, J AM DIET ASSOC, V93, P318, DOI 10.1016/0002-8223(93)91559-9
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   DARKO S, 2003, METBOLISM, V52, P1153
   Davies NP, 2004, PROG RETIN EYE RES, V23, P533, DOI 10.1016/j.preteyeres.2004.05.004
   DIMITROV NV, 1988, AM J CLIN NUTR, V48, P298, DOI 10.1093/ajcn/48.2.298
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   FOSSATI P, 1982, CLIN CHEM, V28, P2077
   Furr HC, 1997, J NUTR BIOCHEM, V8, P364, DOI 10.1016/S0955-2863(97)00060-0
   GIBALDI M, 1982, PHAMACOKINETICS
   Granado F, 2002, EUR J NUTR, V41, P47, DOI 10.1007/s003940200007
   Hartmann D, 2004, AM J CLIN NUTR, V79, P410
   HETHOF V, 1999, AM J CLIN NUTR, V70, P261
   KHACHIK F, 1995, J CELL BIOCHEM, P236
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   LANDAW EM, 1984, AM J PHYSIOL, V246, pR665, DOI 10.1152/ajpregu.1984.246.5.R665
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   LEMARCHAND L, 1995, INT J CANCER, V63, P18, DOI 10.1002/ijc.2910630105
   Mares-Perlman JA, 1999, AM J CLIN NUTR, V70, P431
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   MCGOWAN MW, 1983, CLIN CHEM, V29, P538
   Mohamedshah FY, 1999, FASEB J, V13, pA554
   Nebeling LC, 1997, J AM DIET ASSOC, V97, P991, DOI 10.1016/S0002-8223(97)00239-3
   Olmedilla B, 1997, CANCER LETT, V114, P179, DOI 10.1016/S0304-3835(97)04656-9
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   RICHMOND W, 1973, CLIN CHEM, V19, P1350
   Rowland M, 2011, CLIN PHARMACOKINET
   SCHALCH W, 1992, FREE RADICALS AGING, V62, P280
   SCHULZ HU, 1991, INT J CLIN PHARM TH, V29, P293
   SEDDON JM, 1995, JAMA-J AM MED ASSOC, V273, P622
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   van den Berg H, 1998, INT J VITAM NUTR RES, V68, P360
   van den Berg H, 1999, NUTR REV, V57, P1, DOI 10.1111/j.1753-4887.1999.tb01769.x
   van den Berg H, 1998, AM J CLIN NUTR, V68, P82, DOI 10.1093/ajcn/68.1.82
NR 41
TC 52
Z9 57
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD JUL
PY 2005
VL 82
IS 1
BP 88
EP 97
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 945BC
UT WOS:000230474400015
PM 16002805
DA 2022-11-30
ER

PT J
AU Rosenblatt, BJ
   Shah, GK
   Blinder, K
AF Rosenblatt, BJ
   Shah, GK
   Blinder, K
TI Photodynamic therapy with verteporfin for peripapillary choroidal
   neovascularizaltion
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal neovascular membrane; photodynamic therapy; peripapillary
ID OCULAR HISTOPLASMOSIS SYNDROME; RANDOMIZED CLINICAL-TRIALS; MACULAR
   DEGENERATION; LESIONS; PHOTOCOAGULATION; SECONDARY
AB Purpose: To evaluate the efficacy of photodynamic therapy with verteporfin in the management of symptomatic extrafoveal peripapillary choroidal neovascularization (CNV).
   Methods: Seven eyes of seven patients with symptomatic peripapillary CNV underwent visual acuity testing, ophthalmic examination, color photography, and fluorescein angiography to evaluate the results of photodynamic therapy with verteporfin. Patients were offered treatment following the development of hemorrhage, subretinal fluid, or lipid if it was associated with visual symptoms. A standard nomogram was used to dose Visudyne, application was performed in three separate 30-second zones confluent over the extent of the lesion. The light dose per unit area applied to the retina was approximately 18 J/cm(2).
   Results: Five of the seven had CNV limited to the peripapillary area associated with age-related macular degeneration; the remaining two eyes had presumed ocular histoplasmosis syndrome. In five of the seven eyes, two treatments were needed and in two eyes only one treatment was necessary to elicit resolution of active leakage. Retreatment was performed at an average of 76 days after initial treatment. Baseline best-corrected visual acuity (BCVA) ranged from 20/20 to 20/150. Final BCVA ranged from 20/20 to 20/80. In all eyes except for one, which had a pretreatment vision of 20/20, at least two lines of Snellen visual acuity improvement were achieved. Resolution of submacular fluid, hemorrhage, or exudates was noted in six eyes; in the remaining eye there was persistence of subretinal lipid. There were no complications including optic neuropathy in any of the treated eyes. Follow-up ranged from 6 to 13.5 months following last treatment (mean, 10 months).
   Conclusion: Photodynamic therapy with verteporfin for extrafoveal symptomatic peripapillary CNV appears to be effective in improving vision and promoting the resolution of subfoveal exudates, hemorrhage, or fluid. A randomized controlled study with longer follow-up is justified.
C1 Barnes Retina Inst, St Louis, MO 63144 USA.
   Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Shah, GK (通讯作者)，Barnes Retina Inst, 1600 S Brentwood Blvd,8th Floor, St Louis, MO 63144 USA.
EM gkshah@sbcglobal.net
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BLOOM SM, 1990, RETINA-J RET VIT DIS, V10, P261, DOI 10.1097/00006982-199010000-00006
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Busquets MA, 2003, RETINA-J RET VIT DIS, V23, P299, DOI 10.1097/00006982-200306000-00003
   Karacorlu M, 2002, AM J OPHTHALMOL, V134, P360, DOI 10.1016/S0002-9394(02)01626-4
   MARSH MJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P56
   Robertson DM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1155
   Ruiz-Oliva F, 2002, OPHTHALMOLOGY, V109, P1043, DOI 10.1016/S0161-6420(02)00972-7
   Saperstein DA, 2002, OPHTHALMOLOGY, V109, P1499, DOI 10.1016/S0161-6420(02)01103-X
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P1256, DOI 10.1016/S0161-6420(02)01059-X
   Spaide RF, 2002, AM J OPHTHALMOL, V134, P62, DOI 10.1016/S0002-9394(02)01452-6
   SWARTZ M, 1983, BRIT J OPHTHALMOL, V67, P517, DOI 10.1136/bjo.67.8.517
NR 14
TC 25
Z9 26
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2005
VL 25
IS 1
BP 33
EP 37
DI 10.1097/00006982-200501000-00004
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 891OG
UT WOS:000226589800004
PM 15655438
DA 2022-11-30
ER

PT J
AU Sadda, SR
   Pieramici, DJ
   Marsh, MJ
   Bressler, NM
   Bressler, SB
AF Sadda, SR
   Pieramici, DJ
   Marsh, MJ
   Bressler, NM
   Bressler, SB
TI Changes in lesion size after submacular surgery for subfoveal choroidal
   neovascularization in the submacular surgery trials pilot study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE submacular surgery; choroidal neovascularization; lesion size
ID RANDOMIZED CLINICAL-TRIALS; MACULAR DEGENERATION; LASER
   PHOTOCOAGULATION; PHOTODYNAMIC THERAPY; SURGICAL REMOVAL; HEMORRHAGE;
   VERTEPORFIN; MEMBRANES
AB Purpose: To compare the size of subfoveal lesions based on photographic documentation before and after submacular surgery of choroidal neovascularization (CNV) lesions.
   Methods: Subfoveal lesion sizes at baseline and month 3 follow-up visits for patients assigned to surgery in the Submacular Surgery Trials (SST) Pilot Study were assessed categorically using Macular Photocoagulation Study (MPS) disc area (DA) circles. The Submacular Surgery Trials Pilot Study groups reviewed were as follows: Group N (age-related macular degeneration [AMD]; lesion <50% blood; classic CNV present; size less than or equal to9 MPS DAs); Group R (AMD; prior nonfoveal laser; classic CNV present; size less than or equal to9 MPS DAs); Group B (AMD; lesion greater than or equal to50% blood); and Group H (ocular histoplasmosis syndrome or idiopathic; classic CNV present; size less than or equal to9 MPS DAs).
   Results: Postoperative month 3 lesion size was at least 1 size category smaller than the preoperative lesion size in 6% (4/66) of Group N, 0 (0/31) of Group R, 66% (2/34) of Group H, and 45% (18/40) of Group B eyes. In Group H eyes, there was no size change in 50% (17/34), and enlargement was found in 44% (15/34). For eyes in Groups N and R, approximately one third remained stable (20/66, 30% and 12/31, 39%, respectively), whereas two thirds enlarged by at least 1 category (42/66, 64% and 19/31, 61%, respectively).
   Conclusions: The change in lesion size after submacular surgery was variable, with a tendency for Group H lesions to remain the same size or larger, Group B lesions to measure smaller, and Group N and Group R lesions to be larger.
C1 Johns Hopkins Med Inst, Baltimore, MD 21205 USA.
   Doheny Eye Inst, Doheny Retina Inst, Los Angeles, CA 90033 USA.
   Calif Retina Res Fdn, Santa Barbara, CA USA.
   Wilmer Ophthalmol Inst, Clin Trials & Biometry Ctr, Baltimore, MD USA.
   Wilmer Ophthalmol Inst, Retinal Vasc Ctr, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Doheny Eye Institute;
   Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine
RP Bressler, NM (通讯作者)，Johns Hopkins Med Inst, 550 N Broadway,Suite 115, Baltimore, MD 21205 USA.
EM nmboffice@jhmi.edu
FU NATIONAL EYE INSTITUTE [U10EY011547, R21EY010823] Funding Source: NIH
   RePORTER; NEI NIH HHS [U10 EY11547, R21 EY10823] Funding Source: Medline
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bass E, 2000, AM J OPHTHALMOL, V130, P408
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P969
   BERGER AS, 1992, OPHTHALMOLOGY, V99, P975
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   CAPONE A, 1994, INDIAN J OPHTHALMOL, V118, P659
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Giovannini A, 1999, OPHTHALMOLOGICA, V213, P139, DOI 10.1159/000027408
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Kaplan H, 1996, BRIT J OPHTHALMOL, V80, P101, DOI 10.1136/bjo.80.2.101
   Maas S, 1995, Eur J Ophthalmol, V5, P48
   Melberg NS, 1996, OPHTHALMOLOGY, V103, P1064, DOI 10.1016/S0161-6420(96)30566-6
   MELBERG NS, 1996, DISCUSSION, V103, P1067
   Rao P K, 2000, Curr Opin Ophthalmol, V11, P180, DOI 10.1097/00055735-200006000-00005
   Roth DB, 1997, OPHTHALMIC SURG LAS, V28, P920
   Saxena Sandeep, 1997, Indian Journal of Ophthalmology, V45, P77
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shiraga F, 1999, AM J OPHTHALMOL, V128, P147, DOI 10.1016/S0002-9394(99)00078-1
   Sternberg P, 2000, ARCH OPHTHALMOL-CHIC, V118, P1428
   THOMAS MA, 1992, INT OPHTHALMOL CLIN, V32, P173, DOI 10.1097/00004397-199203220-00016
   THOMAS MA, 1992, CURR OPIN OPHTHALMOL, V3, P349, DOI 10.1097/00055735-199206000-00009
   2000, AMJ OPHTHALMOL, V130, P387
NR 30
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2004
VL 24
IS 6
BP 888
EP 899
DI 10.1097/00006982-200412000-00008
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 881EL
UT WOS:000225846100008
PM 15579986
DA 2022-11-30
ER

PT J
AU Buch, H
   Vinding, T
   la Cour, M
   Appleyard, M
   Jensen, GB
   Nielsen, NV
AF Buch, H
   Vinding, T
   la Cour, M
   Appleyard, M
   Jensen, GB
   Nielsen, NV
TI Prevalence and causes of visual impairment and blindness among 9980
   Scandinavian adults - The Copenhagen City Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; BEAVER-DAM EYE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; AGE-SPECIFIC PREVALENCE; DIABETIC-RETINOPATHY;
   MACULAR DEGENERATION; URBAN-POPULATION; QUESTIONNAIRE INFORMATION;
   PHOTODYNAMIC THERAPY; OLDER AMERICANS
AB Purpose: To investigate the age-specific prevalence and causes of visual impairment and blindness in an epidemiologic study of an adult Scandinavian population.
   Design: Population-based, cross-sectional study.
   Participants: The study population was composed of 9980 persons, ages 20 to 84, from the general population of Copenhagen, Denmark.
   Methods: This study is based on the third Copenhagen City Heart Study (CCHS III). Participants who reported visual impairment or blindness or had difficulty reading newspaper type and used prescribed eye medications were contacted from 1999 through 2000 and asked to complete a standardized interview concerning their ophthalmologic history. Verification of objective ophthalmologic data was done with a validated questionnaire response method.
   Main Outcome Measures: Best-corrected visual acuity in the better eye and primary causes of visual impairment and blindness. Visual impairment was defined as visual acuity worse than 20/40 but better than 20/200, and blindness was defined as visual acuity of 20/200 or worse.
   Results: The age-standardized prevalence rates of visual impairment and blindness were 0.66% and 0.20%, respectively, and rose significantly with age (P<0.001). For persons 20 to 64 years, myopia-related retinal disorders, diabetic retinopathy, optic neuropathy, and retinitis pigmentosa were the most common causes of impaired vision. For persons 65 to 84 years, cataract was the most common cause of visual impairment, whereas age-related macular degeneration was the major cause of blindness.
   Conclusions: Visual impairment and blindness are strongly associated with increasing age, and the causes are determined by age. Among persons aged 20 to 64 years, an intervention for the predominating eye diseases might have some effect. Among those aged 65 to 84 years, cataract surgery could reduce visual impairment by one third.
C1 Natl Univ Hosp, Rigshosp, Dept Ophthalmol E 2061, DK-2100 Copenhagen O, Denmark.
   Bispebjerg Hosp, Epidemiol Res Unit, Copenhagen, Denmark.
   Hvidovre Univ Hosp, Dept Cardiol, Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; Bispebjerg Hospital;
   University of Copenhagen
RP Buch, H (通讯作者)，Natl Univ Hosp, Rigshosp, Dept Ophthalmol E 2061, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.
EM hbh@dadlnet.dk
RI la Cour, Morten/L-1600-2013; Hesgaard, Helena Buch/E-8226-2011
OI Hesgaard, Helena Buch/0000-0002-2097-0202; Dornonville de la Cour,
   Morten/0000-0002-7712-9772
CR [Anonymous], 1992, INT STAT CLASS DIS R, V1-3
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Casson R, 1996, AUST NZ J OPHTHALMOL, V24, P239, DOI 10.1111/j.1442-9071.1996.tb01586.x
   COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319
   DANA MR, 1990, JAMA-J AM MED ASSOC, V264, P2400, DOI 10.1001/jama.264.18.2400
   Dandona R, 2002, OPHTHALMOLOGY, V109, P1871, DOI 10.1016/S0161-6420(02)01183-1
   *DANM STAT, STATB DENM
   *EUROSTAT, 1999, DEM STAT 1960 99
   Foran S, 2000, CLIN EXP OPHTHALMOL, V28, P143, DOI 10.1046/j.1442-9071.2000.00292.x
   HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129
   HILLER R, 1983, AM J PUBLIC HEALTH, V73, P93, DOI 10.2105/AJPH.73.1.93
   HIRVELA H, 1995, ACTA OPHTHALMOL SCAN, V73, P99
   Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017
   Katz J, 1996, J VISUAL IMPAIR BLIN, V90, P367
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1992, DIABETES CARE, V15, P1875, DOI 10.2337/diacare.15.12.1875
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   KRUEGER DE, 1957, AM J PUBLIC HEALTH N, V47, P953, DOI 10.2105/AJPH.47.8.953
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   MCCARTY DJ, 1996, RISE RISE DIABETES A, V1, P60
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Munoz B, 2002, INVEST OPHTH VIS SCI, V43, P608
   Newland H S, 1996, Ophthalmic Epidemiol, V3, P97, DOI 10.3109/09286589609080114
   Norregaard JC, 1996, ACTA OPHTHALMOL SCAN, V74, P604
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   PONTE F, 1994, GRAEF ARCH CLIN EXP, V232, P469, DOI 10.1007/BF00195355
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P395
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   SCHIOLER G, 1993, KLASSIFIKATION SYGDO
   Schnohr P, 1977, Ugeskr Laeger, V139, P1921
   SCHNOHR P, 2001, EUR HEART J SUPPL, V3, P15
   Schulzer M, 1998, AM J OPHTHALMOL, V126, P487
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   TIELSCH JM, 1991, ARCH OPHTHALMOL-CHIC, V109, P637, DOI 10.1001/archopht.1991.01080050051027
   TRETLI S, 1982, J EPIDEMIOL COMMUN H, V36, P269, DOI 10.1136/jech.36.4.269
   VALSANIA P, 1993, ARCH OPHTHALMOL-CHIC, V111, P202, DOI 10.1001/archopht.1993.01090020056023
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
NR 53
TC 265
Z9 278
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2004
VL 111
IS 1
BP 53
EP 61
DI 10.1016/j.ophtha.2003.05.010
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 760JA
UT WOS:000187806800010
PM 14711714
DA 2022-11-30
ER

PT J
AU Yuan, Y
   Kong, W
   Liu, XM
   Shi, GH
AF Yuan, Yun
   Kong, Wen
   Liu, Xiao-Mei
   Shi, Guo-Hua
TI A Hypoxia-Regulated Retinal Pigment Epithelium-Specific Gene Therapy
   Vector Reduces Choroidal Neovascularization in a Mouse Model
SO CURRENT GENE THERAPY
LA English
DT Article
DE Age-related macular degeneration; choroidal neovascularization; hypoxia
   responsive elements; soluble fms-like tyrosine kinase-1;
   adeno-associated virus vector; gene therapy
ID INTRAVITREAL BEVACIZUMAB INJECTION; ANTI-VEGF AGENTS; MACULAR
   DEGENERATION; OCULAR NEOVASCULARIZATION; RANIBIZUMAB; INHIBITION;
   ANGIOGENESIS; TRANSDUCTION; HIF-1-ALPHA; EXPRESSION
AB Background: Wet age-related macular degeneration (wAMD) is characterized by the presence of choroidal neovascularization (CNV). Although there are some clinical drugs targeting vascular endothelial growth factor (VEGF) and inhibiting CNV, two major side effects limit their application, including the excessive activity of anti-VEGF and frequent intraocular injections. To explore better treatment strategies, researchers developed a hypoxic modulator retinal pigment epithelium (RPE)-specific adeno-associated virus (AAV) vector expressing endostatin to inhibit CNV. However, the mechanism of endostatin is complex. Instead, soluble fms-like tyrosine kinase-1 (sFlt-1) can inhibit VEGF-induced angiogenesis through two simple and clear mechanisms, giving rise to sequestration of VEGF and forming an inactive heterodimer with the membrane-spanning isoforms of the VEGF receptor Flt-1 and kinase insert domain-containing receptor. Objective: In this study, we chose sFlt-1 as a safer substitute to treat wAMD by inhibiting VEGF-induced angiogenesis. Methods: The AAV2/8-Y733F-REG-RPE-sFlt-1 vector was delivered by intravitreal injection to the eyes of mice. AAV2/8-Y733F vector is a mutant of the AAV2/8 vector, and the REG-RPE promoter is a hypoxia-regulated RPE-specific promoter. Two animal models were used to evaluate the function of the vector. Results: In the cobalt chloride-induced hypoxia model, the results demonstrated that the AAV2/8-Y733F-REG-RPE-sFlt-1 vector induced the expression of the sFlt-1 gene in RPE cells through hypoxia. In the laser-induced CNV model, the results demonstrated that the AAV2/8-Y733F-REG-RPE-sFlt-1 vector reduced laser-induced CNV. Conclusion: Hypoxia regulated, RPE-specific AAV vector-mediated sFlt-1 gene is a hypoxia-regulated antiangiogenic vector for wAMD.
C1 [Yuan, Yun; Kong, Wen; Liu, Xiao-Mei; Shi, Guo-Hua] Univ Sci & Technol China, Sch Biomed Engn Suzhou, Div Life Sci & Med, Suzhou, Peoples R China.
   [Yuan, Yun; Kong, Wen; Liu, Xiao-Mei; Shi, Guo-Hua] Chinese Acad Sci, Suzhou Inst Biomed Engn & Technol, Suzhou, Peoples R China.
C3 Chinese Academy of Sciences; University of Science & Technology of
   China, CAS; Chinese Academy of Sciences; Suzhou Institute of Biomedical
   Engineering & Technology, CAS
RP Yuan, Y (通讯作者)，Chinese Acad Sci, Suzhou Inst Biomed Engn & Technol, Dept Inspect, Suzhou, Peoples R China.
EM kwt3231@163.com
OI Yuan, Yun/0000-0002-4293-4069
FU National Natural Science Foundation of China [61675226]
FX This study was supported by grants from the National Natural Science
   Foundation of China (61675226).
CR Alegria-Schaffer A, 2009, METHOD ENZYMOL, V463, P573, DOI 10.1016/S0076-6879(09)63033-0
   Altiok EI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155990
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Askou AL, 2021, GENE THER, V28, P209, DOI 10.1038/s41434-020-0168-2
   Aslanzadeh V, 2018, GENOME RES, V28, P606, DOI 10.1101/gr.236265.118
   Bainbridge JWB, 2003, GENE THER, V10, P1049, DOI 10.1038/sj.gt.3301945
   Biswal MR, 2018, J MOL MED, V96, P1107, DOI 10.1007/s00109-018-1683-0
   Boast K, 1999, HUM GENE THER, V10, P2197, DOI 10.1089/10430349950017185
   Caglar C, 2016, CUTAN OCUL TOXICOL, V35, P248, DOI 10.3109/15569527.2015.1075998
   Chen H, 2008, MOL THER, V16, P924, DOI 10.1038/mt.2008.35
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Cimmino F, 2019, BMC MED GENET, V20, DOI 10.1186/s12881-019-0767-1
   Claybon A, 2011, JOVE-J VIS EXP, DOI 10.3791/2563
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Dougherty CJ, 2008, MOL VIS, V14, P471
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Georgiadis A, 2016, GENE THER, V23, P857, DOI 10.1038/gt.2016.66
   Grieger JC, 2006, NAT PROTOC, V1, P1412, DOI 10.1038/nprot.2006.207
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   He Y, 2013, CHIN OPT LETT, V11, DOI 10.3788/COL201311.021101
   Hickmott JW, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.51
   Huang Shaofen, 2015, Eye Sci, V30, P70
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Lai YKY, 2002, GENE THER, V9, P804, DOI 10.1038/sj.gt.3301695
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Madrakhimov SB, 2020, MOL THER-METH CLIN D, V17, P647, DOI 10.1016/j.omtm.2020.03.018
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Mozayan A, 2013, OPHTHAL SURG LAS IM, V44, P25, DOI 10.3928/23258160-20121221-08
   Nevo O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081176
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   Ozsutcu M, 2013, CASE REP OPHTHALM, V4, P7, DOI 10.1159/000342873
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Schor Ignacio E, 2013, Cancer Treat Res, V158, P1, DOI 10.1007/978-3-642-31659-3_1
   Shah RS, 2015, JOVE-J VIS EXP, DOI 10.3791/53502
   Shin JY, 2015, GRAEF ARCH CLIN EXP, V253, P2151, DOI 10.1007/s00417-015-2977-3
   Sorbera LA, 2003, DRUG FUTURE, V28, P541, DOI 10.1358/dof.2003.028.06.738510
   Tabatabaii Ali, 2013, Middle East Afr J Ophthalmol, V20, P87, DOI 10.4103/0974-9233.106402
   Takahashi K, 2017, MOL THER, V25, P296, DOI 10.1016/j.ymthe.2016.10.008
   Tanaka K, 2018, PLACENTA, V74, P20, DOI 10.1016/j.placenta.2018.12.009
   Tufan HA, 2014, CLIN EXP OPTOM, V97, P178, DOI 10.1111/cxo.12009
   Walia A, 2015, BBA-GEN SUBJECTS, V1850, P2422, DOI 10.1016/j.bbagen.2015.09.007
   Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573-019-0012-9
   Wang F, 2013, MED SCI MONIT BASIC, V19, P187, DOI 10.12659/MSMBR.883968
   Williams PD, 2016, RETINA-J RET VIT DIS, V36, P909, DOI 10.1097/IAE.0000000000000801
   Xi L, 2004, AM J PHYSIOL-HEART C, V287, pH2369, DOI 10.1152/ajpheart.00422.2004
   Xu D, 2013, ONCOL LETT, V6, P445, DOI 10.3892/ol.2013.1382
   Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200
   Zhong L, 2008, P NATL ACAD SCI USA, V105, P7827, DOI 10.1073/pnas.0802866105
NR 54
TC 0
Z9 0
U1 4
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5232
EI 1875-5631
J9 CURR GENE THER
JI Curr. Gene Ther.
PY 2022
VL 22
IS 5
BP 417
EP 426
DI 10.2174/1566523222666220405135135
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 5D0PV
UT WOS:000864654100006
PM 35382718
DA 2022-11-30
ER

PT J
AU Bhattarai, N
   Korhonen, E
   Mysore, Y
   Kaarniranta, K
   Kauppinen, A
AF Bhattarai, Niina
   Korhonen, Eveliina
   Mysore, Yashavanthi
   Kaarniranta, Kai
   Kauppinen, Anu
TI Hydroquinone Induces NLRP3-Independent IL-18 Release from ARPE-19 Cells
SO CELLS
LA English
DT Article
DE hydroquinone; oxidative stress; IL-1 beta; IL-18; NLRP3; RPE cell; PARP;
   DNA damage; NAC; APDC
ID PIGMENT EPITHELIUM-CELLS; NLRP3 INFLAMMASOME ACTIVATION; MACULAR
   DEGENERATION AMD; INDUCED DNA-DAMAGE; PROTECTIVE IMMUNITY; INDUCED
   APOPTOSIS; OXIDATIVE STRESS; RESPONSES; RECEPTOR; ATP
AB Age-related macular degeneration (AMD) is a retinal disease leading to impaired vision. Cigarette smoke increases the risk for developing AMD by causing increased reactive oxygen species (ROS) production and damage in the retinal pigment epithelium (RPE). We have previously shown that the cigarette tar component hydroquinone causes oxidative stress in human RPE cells. In the present study, we investigated the propensity of hydroquinone to induce the secretion of interleukin (IL)-1 beta and IL-18. The activation of these cytokines is usually regulated by the Nucleotide-binding domain, Leucine-rich repeat, and Pyrin domain 3 (NLRP3) inflammasome. ARPE-19 cells were exposed to hydroquinone, and cell viability was monitored using the lactate dehydrogenase (LDH) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salt (MTT) assays. Enzyme-linked immunosorbent assays (ELISAs) were used to measure the levels of proinflammatory cytokines IL-1 beta and IL-18 as well as NLRP3, caspase-1, and poly (ADP-ribose) polymerase (PARP). Hydroquinone did not change IL-1 beta release but significantly increased the secretion of IL-18. Cytoplasmic NLRP3 levels increased after the hydroquinone treatment of IL-1 alpha-primed RPE cells, but IL-18 was equally released from primed and nonprimed cells. Hydroquinone reduced the intracellular levels of PARP, which were restored by treatment with the ROS scavenger N-acetyl-cysteine (NAC). NAC concurrently reduced the NLRP3 levels but had no effect on IL-18 release. In contrast, the NADPH oxidase inhibitor ammonium pyrrolidinedithiocarbamate (APDC) reduced the release of IL-18 but had no effect on the NLRP3 levels. Collectively, hydroquinone caused DNA damage seen as reduced intracellular PARP levels and induced NLRP3-independent IL-18 secretion in human RPE cells.
C1 [Bhattarai, Niina; Korhonen, Eveliina; Mysore, Yashavanthi; Kauppinen, Anu] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70210, Finland.
   [Korhonen, Eveliina] Univ Helsinki, Helsinki Univ Hosp, Dept Clin Chem, Helsinki 00290, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70210, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70210, Finland.
C3 University of Eastern Finland; University of Helsinki; Helsinki
   University Central Hospital; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland
RP Bhattarai, N; Kauppinen, A (通讯作者)，Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70210, Finland.
EM niina.bhattarai@uef.fi; eveliina.korhonen@uef.fi;
   yashavanthi.mysore@uef.fi; kai.kaarniranta@uef.fi; anu.kauppinen@uef.fi
RI Harju, Niina/ABA-7085-2020; Mysore, Yashavanthi/O-2190-2016
OI Harju, Niina/0000-0001-9031-5353; Mysore,
   Yashavanthi/0000-0001-8279-0998; Korhonen, Eveliina/0000-0002-5360-7258
FU Academy of Finland [297267, 307341, 328443, 296840, 333302]; Emil
   Aaltonen Foundation; Paivikki and Sakari Sohlberg Foundation; Kuopio
   University Hospital [5503743]; Finnish Eye Foundation; Sigrid Juselius
   Foundation; Sokeain Ystavat ry; Silma-ja Kudospankkisaatio
FX This research was funded by the Academy of Finland (297267, 307341,
   328443, 296840 and 333302), the Emil Aaltonen Foundation, the Paivikki
   and Sakari Sohlberg Foundation, the Kuopio University Hospital
   (5503743), the Finnish Eye Foundation, The Sigrid Juselius Foundation,
   Sokeain Ystavat ry, and Silma-ja Kudospankkisaatio. The APC was funded
   by the Academy of Finland (328443).
CR Aho J, 2016, PURINERG SIGNAL, V12, P575, DOI 10.1007/s11302-016-9508-5
   Amores-Iniesta J, 2017, CELL REP, V21, P3414, DOI 10.1016/j.celrep.2017.11.079
   Bando K, 2017, J INVEST DERMATOL, V137, P1082, DOI 10.1016/j.jid.2016.12.018
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bhattarai N, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010067
   Bhattarai N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062066
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cho JY, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/298010
   Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020
   Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S
   Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Ghose P, 2011, J IMMUNOL, V187, P1333, DOI 10.4049/jimmunol.1100092
   Hasegawa T, 2016, BIOCHEM BIOPH RES CO, V477, P329, DOI 10.1016/j.bbrc.2016.06.106
   Huang CX, 2015, J BIOL CHEM, V290, P5367, DOI 10.1074/jbc.M114.603738
   Jha S, 2009, J IMMUNOL, V183, P7623, DOI 10.4049/jimmunol.0902425
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kauppinen A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00384
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Knodler LA, 2014, CELL HOST MICROBE, V16, P249, DOI 10.1016/j.chom.2014.07.002
   Korhonen E, 2020, FASEB J, V34, P6437, DOI 10.1096/fj.201902355RR
   Lee H, 2018, BIOMOL THER, V26, P417, DOI 10.4062/biomolther.2017.167
   Lee JS, 2012, MOL BIOL REP, V39, P6737, DOI 10.1007/s11033-012-1498-y
   Ling XX, 2016, BIOMED ENVIRON SCI, V29, P80, DOI 10.3967/bes2016.008
   Liu JX, 2017, MOL MED REP, V16, P8076, DOI 10.3892/mmr.2017.7643
   Luo LH, 2008, CHEM-BIOL INTERACT, V173, P1, DOI 10.1016/j.cbi.2008.02.002
   McKee CM, 2020, J LEUKOCYTE BIOL, V108, P937, DOI 10.1002/JLB.3MR0720-513R
   Moustafa MT, 2017, J OCUL PHARMACOL TH, V33, P610, DOI 10.1089/jop.2016.0129
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Piippo N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25123-2
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Qin S, 2008, J INFLAMM RES, V1, P49
   Ramirez C, 2016, J OCUL PHARMACOL TH, V32, P102, DOI 10.1089/jop.2015.0083
   Roberts JS, 2015, INT J MOL SCI, V16, P23337, DOI 10.3390/ijms161023337
   Satoh E, 2011, J TOXICOL SCI, V36, P741, DOI 10.2131/jts.36.741
   Schneider BE, 2010, EUR J IMMUNOL, V40, P396, DOI 10.1002/eji.200939583
   Schwarz A, 2006, J IMMUNOL, V176, P2896, DOI 10.4049/jimmunol.176.5.2896
   Schwarz T, 2009, J INVEST DERM SYMP P, V14, P63, DOI 10.1038/jidsymp.2009.3
   Sousa FG, 2012, CARCINOGENESIS, V33, P1433, DOI 10.1093/carcin/bgs132
   Sutterwala FS, 2014, ANN NY ACAD SCI, V1319, P82, DOI 10.1111/nyas.12458
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1413-8
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zhu QF, 2017, J IMMUNOL, V198, P4210, DOI 10.4049/jimmunol.1700352
NR 56
TC 3
Z9 3
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUN
PY 2021
VL 10
IS 6
AR 1405
DI 10.3390/cells10061405
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA SX6GE
UT WOS:000665300200001
PM 34204067
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ekinci, C
   Guler, EM
   Kocyigit, A
   Kirik, F
   Ozdemir, H
AF Ekinci, Cansu
   Guler, Eray Metin
   Kocyigit, Abdurrahim
   Kirik, Furkan
   Ozdemir, Hakan
TI Effects of 1,25 Dihydroxyvitamin D-3 on Human Retinal Pigment Epithelial
   Cell Lines
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE ARPE-19 cells; Age-related macular degeneration; Vitamin D; Oxidative
   stress
ID VITAMIN-D; OXIDATIVE STRESS; MACULAR DEGENERATION; DNA-DAMAGE; CANCER
   MORTALITY
AB Purpose To assess the effects of 1,25 dihydroxyvitamin D-3 (vitamin D-3) either alone or under oxidative damage on human retinal pigment epithelium cell lines. Methods The human retinal pigment epithelial cell lines were pretreated with hydrogen peroxide with different concentrations (100-1000 mu M) and durations (4, 12 and 24 h) to determine the appropriate dose. A group of cells were treated with vitamin D-3 alone, and another group of cells were co-treated with different concentrations of (10-100 nM) vitamin D-3 and hydrogen peroxide. Anti-cytotoxic, anti-apoptotic and anti-genotoxic effects of vitamin D-3 on the hydrogen peroxide treated cell line were evaluated. In addition, mitochondrial membrane potentials of treated cell lines were measured. Results Vitamin D-3 showed statistically significant anti-cytotoxic effects and increased cell viability in all concentrations (p < 0.001). It has also significantly decreased the intracellular ROS generation at concentrations between 10-60 nM and increased intracellular reactive oxygen species in high doses over 90 nM (p < 0.01). When apoptosis was evaluated, vitamin D-3 caused statistically significant decrease in a dose-dependent manner (p < 0.001). In terms of DNA damage which was caused by oxidative stress, it was observed that vitamin D-3 significantly reduced the damage in a dose-dependent manner (p < 0.001). At the doses of 10-50 nM, vitamin D-3 significantly decreased the mitochondrial membrane potential (p < 0.01). Conclusion Our study suggests that 1,25 (OH)(2) D3 is capable for alleviating the oxidative damage in ARPE cell lines. With these results, vitamin D is thought to be a therapeutic alternative for the prevention of age-related macular degeneration. This warrants further investigations.
C1 [Ekinci, Cansu; Guler, Eray Metin; Kirik, Furkan; Ozdemir, Hakan] Bezmialem Vakif Univ, Dept Ophthalmol, Fac Med, Adnan Menderes Vatan Ave, TR-34093 Istanbul, Turkey.
   [Kocyigit, Abdurrahim] Bezmialem Vakif Univ, Sch Med, Dept Med Biochem, Istanbul, Turkey.
C3 Bezmialem Vakif University; Bezmialem Vakif University
RP Ozdemir, H (通讯作者)，Bezmialem Vakif Univ, Dept Ophthalmol, Fac Med, Adnan Menderes Vatan Ave, TR-34093 Istanbul, Turkey.
EM MOzdemir@bezmialem.edu.tr
RI Guler, Eray Metin/T-6699-2017
OI Guler, Eray Metin/0000-0003-4351-1719; Ozdemir,
   Hakan/0000-0002-1719-4265; Kirik, Furkan/0000-0001-5846-8536; Kocyigit,
   Abdurrahim/0000-0003-2335-412X
FU Bezmialem Vakif University Scientific Research Projects Unit
   [11.2018/20]
FX This work was supported by the Bezmialem Vakif University Scientific
   Research Projects Unit under Grant, Project number: 11.2018/20.
CR Albert Daniel M, 2002, Ophthalmic Genet, V23, P137, DOI 10.1076/opge.23.3.137.7883
   Alsalem JA, 2014, INVEST OPHTH VIS SCI, V55, P2140, DOI 10.1167/iovs.13-13019
   Annweiler C, 2016, MATURITAS, V88, P101, DOI 10.1016/j.maturitas.2016.04.002
   Arunasree KM, 2010, PHYTOMEDICINE, V17, P581, DOI 10.1016/j.phymed.2009.12.008
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Coscas G, 1991, Rev Prat, V41, P2320
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Egan KM, 2009, ANN EPIDEMIOL, V19, P455, DOI 10.1016/j.annepidem.2009.01.005
   GARLAND FC, 1990, PREV MED, V19, P614, DOI 10.1016/0091-7435(90)90058-R
   Gunes-Bayir A, 2017, ANTI-CANCER DRUG, V28, P522, DOI 10.1097/CAD.0000000000000491
   Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193
   Kocyigit A., 2019, American Journal of Plant Sciences, V10, P1933
   Kocyigit A, 2018, MUTAT RES-GEN TOX EN, V829, P50, DOI [10.1016/j.mrgentox.2018.64.002, 10.1016/j.mrgentox.2018.04.002]
   Kocyigit A, 2017, CELL MOL BIOL, V63, P97, DOI 10.14715/cmb/2017.63.11.17
   LEFKOWITZ ES, 1994, INT J EPIDEMIOL, V23, P1133, DOI 10.1093/ije/23.6.1133
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Nair-Shalliker V, 2012, MUTAT RES-FUND MOL M, V733, P50, DOI 10.1016/j.mrfmmm.2012.02.005
   Nunez-Alvarez C, 2019, ACTA OPHTHALMOL, V97, pE103, DOI 10.1111/aos.13812
   Pittas AG, 2007, J CLIN ENDOCR METAB, V92, P2017, DOI 10.1210/jc.2007-0298
   Reins RY, 2015, EXP EYE RES, V134, P101, DOI 10.1016/j.exer.2015.02.019
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richer SP, 2013, J OPTOM, V6, P124, DOI [10.1016/j.optom.2012.11.001, DOI 10.1016/J.OPTOM.2012.11.001]
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Tao JX, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6435364
   Tohari AM, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090341
   Tohari AM, 2016, CELL BIOCHEM FUNCT, V34, P82, DOI 10.1002/cbf.3167
   Wimalawansa SJ, 2019, BIOLOGY-BASEL, V8, DOI 10.3390/biology8020030
NR 32
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2021
VL 41
IS 10
BP 3333
EP 3340
DI 10.1007/s10792-021-01895-x
EA MAY 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA US1GW
UT WOS:000652902200002
PM 34021828
DA 2022-11-30
ER

PT J
AU Gomel, N
   Azem, N
   Baruch, T
   Hollander, N
   Rachmiel, R
   Kurtz, S
   Waisbourd, M
AF Gomel, Nir
   Azem, Nur
   Baruch, Tzidkiyahu
   Hollander, Nadine
   Rachmiel, Rony
   Kurtz, Shimon
   Waisbourd, Michael
TI Teleophthalmology Screening for Early Detection of Ocular Diseases in
   Underserved Populations in Israel
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article
DE e-Health; telemedicine; telehealth; ophthalmology; global health
ID PHILADELPHIA GLAUCOMA DETECTION; DIABETIC-RETINOPATHY; EYE CARE;
   PROGRAM; CAMERA
AB Background: The purpose of this study was to investigate the feasibility and effectiveness of an innovative telemedicine community-based intervention to increase detection of previously undiagnosed ocular diseases in high-risk populations in Israel.
   Methods: A team comprising an ocular technician, a project manager, and a driver was sent to underserved areas in Israel. Patient demographics, ocular, and medical information were recorded. Visual acuity (VA), intraocular pressure and fundus photographs were obtained. The data were transferred to the Ophthalmology Reading Center in Tel-Aviv Medical Center, where it was interpreted by an ophthalmologist. A letter was sent to the patients indicating examination results. It instructed them to return for a follow-up examination if indicated.
   Results: A total of 124 individuals underwent telemedicine remote screening examinations in 10 locations. The mean age was 79.9 +/- 7.2 years, with female predominance of 67%. The major pathologies detected were (1) reduction in VA >6/12 in at least one eye (n = 48, 38.7%); (2) glaucoma suspicion in the optic disk (n = 18, 14.5%); (3) ocular hypertension >21 mmHg (n = 15, 12.1%); (4) age-related macular degeneration (AMD; n = 15, 12.1%); (5) diabetic retinopathy (n = 6, 4.8%); (6) visually significant cataract (n = 6, 4.8%); and (7) other pathologies (n = 11, 8.9%); 97.7% of the patients reported high satisfaction rates (they were satisfied or very satisfied from the project model).
   Conclusions: Our pilot telemedicine screening project effectively detected ocular diseases in underserved areas in Israel and helped improve access to eye care. This project has the potential of reaching a national level, allow for early diagnosis, and prevent vision loss and blindness in underserved areas.
C1 [Gomel, Nir; Azem, Nur; Rachmiel, Rony; Kurtz, Shimon; Waisbourd, Michael] Tel Aviv Med Ctr & Sch Med, Div Ophthalmol, 6 Weizmann St, IL-64239 Tel Aviv, Israel.
   [Gomel, Nir; Azem, Nur; Rachmiel, Rony; Kurtz, Shimon; Waisbourd, Michael] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Baruch, Tzidkiyahu; Hollander, Nadine] Lirot Assoc, Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine
RP Waisbourd, M (通讯作者)，Tel Aviv Med Ctr & Sch Med, Div Ophthalmol, 6 Weizmann St, IL-64239 Tel Aviv, Israel.
EM michaelwa@tlvmc.gov.il
OI Gomel, Nir/0000-0002-4771-1374
FU Novartis Israel Ltd.
FX The project was supported by Novartis Israel Ltd.
CR Christopher M, 2020, OPHTHALMOLOGY, V127, P346, DOI 10.1016/j.ophtha.2019.09.036
   Christopher M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35044-9
   Govindaiah A., 2018, ANN INT C IEEE ENG M, pS702
   Hark L, 2016, OPHTHAL EPIDEMIOL, V23, P122, DOI 10.3109/09286586.2015.1099683
   Hark LA, 2017, AM J OPHTHALMOL, V181, P114, DOI 10.1016/j.ajo.2017.06.024
   Hark LA, 2017, J GLAUCOMA, V26, P697, DOI 10.1097/IJG.0000000000000716
   Levy J, 2011, ISR MED ASSOC J, V13, P137
   Li Zhijian, 2012, Conn Med, V76, P85
   Maa AY, 2017, TELEMED E-HEALTH, V23, P42, DOI 10.1089/tmj.2016.0039
   Mizrachi Y, 2014, INT OPHTHALMOL, V34, P831, DOI 10.1007/s10792-013-9887-3
   Natarajan S, 2019, JAMA OPHTHALMOL, V137, P1182, DOI 10.1001/jamaophthalmol.2019.2923
   Nguyen HV, 2016, OPHTHALMOLOGY, V123, P2571, DOI 10.1016/j.ophtha.2016.08.021
   Pizzi LT, 2018, BRIT J OPHTHALMOL, V102, P225, DOI 10.1136/bjophthalmol-2016-310078
   Rathi S, 2017, OPHTHALMOLOGY, V124, P1729, DOI 10.1016/j.ophtha.2017.05.026
   Sim Dawn A, 2016, J Diabetes Sci Technol, V10, P308, DOI 10.1177/1932296816629983
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Stanimirovic A, 2020, CAN J OPHTHALMOL, V55, P8, DOI 10.1016/j.jcjo.2019.06.008
   Waisbourd M, 2016, OPHTHALMOLOGY, V123, P1667, DOI 10.1016/j.ophtha.2016.04.031
   Yip JLY, 2014, J EPIDEMIOL COMMUN H, V68, P204, DOI 10.1136/jech-2013-203265
   Zheng CX, 2016, J COMMUN HEALTH, V41, P359, DOI 10.1007/s10900-015-0104-3
NR 20
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
EI 1556-3669
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD FEB 1
PY 2022
VL 28
IS 2
BP 233
EP 239
DI 10.1089/tmj.2021.0098
EA MAY 2021
PG 7
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA YW5IK
UT WOS:000651173900001
PM 33999746
DA 2022-11-30
ER

PT J
AU Wilde, C
   Poostchi, A
   Narendran, R
   MacNab, HK
   Hillman, JG
   Alexander, P
   Amoaku, WM
   Vernon, SA
AF Wilde, Craig
   Poostchi, Ali
   Narendran, Rajesh
   MacNab, Hamish K.
   Hillman, Jonathan G.
   Alexander, Phillip
   Amoaku, Winfried M.
   Vernon, Stephen A.
TI Prevalence of optic disc haemorrhages in an elderly UK Caucasian
   population and possible association with reticular pseudodrusen-the
   Bridlington Eye Assessment Project (BEAP): a cross-sectional study
   (2002-2006)
SO EYE
LA English
DT Article
ID NORMAL-TENSION GLAUCOMA; OPEN-ANGLE GLAUCOMA; NERVE-FIBER LAYER;
   RISK-FACTORS; PERIPAPILLARY ATROPHY; OCULAR HYPERTENSION; CHOROIDAL
   THICKNESS; BLOOD-PRESSURE; PROGRESSION; DIFFUSE
AB Aims To determine disc haemorrhage (DH) prevalence in an elderly UK population-the Bridlington Eye Assessment Project (BEAP).
   Methods Thirty-degree fundus photographs (3549 participants >= 65 years) were graded for DH/macula changes. Glaucoma evaluation included Goldmann tonometry, 26-point suprathreshold visual-fields and mydriatic slit-lamp assessment for glaucomatous optic neuropathy.
   Results In all, 3548 participants with photographs in at least one eye. DHs were present in 53 subjects (1.49%), increasing from 1.17% (65- to 69-year age group) to 2.19% (80- to 84-year age group), p = 0.06. DH was found in 9/96 (9.38%) right eyes (RE) with open-angle glaucoma (OAG). Two of twelve RE (16.67%) with normal-tension glaucoma (NTG) had DH. Prevalence in eyes without glaucoma was lower (32/3452, [0.93%]). Reticular pseudodrusen (RPD) occurred in 170/3212 (5.29%) subjects without DH, and 8/131 subjects (6.11%) with OAG. Twenty eyes had NTG, two of whom had RPD (10%) (p = 0 .264) . Within a logistic regression model, DH was associated with glaucoma (OR 10.2, 95% CI 5.32-19.72) and increasing age (OR 1.05, 95% CI 1.00-1.10, p = 0.03). DH was associated with RPD (p = 0.05) with univariate analysis but this was not statistically significant in the final adjusted model. There was no significant association with gender, diabetes mellitus (DM), hypertension treatment or Age-related Macular Degeneration (AMD) grade.
   Conclusion DH prevalence is 1.5% in those over 65 years old and significantly associated with glaucoma and increasing age. There appears to be increased RPD prevalence in eyes with DH and NTG with age acting as a confounding factor. Larger studies are required to fully assess the relationship and investigate a possible shared aetiology of choroidal ischaemia.
C1 [Wilde, Craig; Poostchi, Ali; Amoaku, Winfried M.] Univ Nottingham, Queens Med Ctr, EENT Ctr, Div Clin Neurosci,Ophthalmol & Vis Sci, B Floor, Nottingham, England.
   [Narendran, Rajesh] York Teaching Hosp NHS Fdn Trust, Scarborough Hosp, Dept Ophthalmol, York, N Yorkshire, England.
   [MacNab, Hamish K.; Hillman, Jonathan G.] Med Ctr, Stn Ave, Bridlington YO16 4LZ, England.
   [Alexander, Phillip] Cambridge Univ Hosp, Dept Vitreoretinal Surg, Cambridge, England.
   [Vernon, Stephen A.] BMI Pk Hosp, Nottingham, England.
C3 University of Nottingham; University of Cambridge
RP Vernon, SA (通讯作者)，BMI Pk Hosp, Nottingham, England.
EM profsavernon@doctors.org.uk
OI Amoaku, Winfried/0000-0001-5028-7984
FU Macular Society UK, Andover, Hants; Guide Dogs for the Blind, Reading,
   Berkshire, UK; Pfizer; Pharmacia; Yorkshire Wolds and Coast Primary Care
   Trust; Lords Feoffees of Bridlington; Bridlington Hospital League of
   Friends; Hull and East Riding Charitable Trust; National Eye Research
   Centre (Yorkshire); Rotary Club of Bridlington; Alexander Pigott Wernher
   Memorial Trust; Bridlington Lions Club; Inner Wheel Club of Bridlington;
   Soroptimist International of Bridlington; Patricia and Donald Shepherd
   Charitable Trust
FX This research was funded in part by a Research Grant from the Macular
   Society UK, Andover, Hants and an unrestricted grant from Guide Dogs for
   the Blind, Reading, Berkshire, UK. The Bridlington Eye Assessment
   Project was funded by an unrestricted grant from Pfizer. We would also
   like to thank the following organisations for financial support of the
   Project: Pharmacia, Yorkshire Wolds and Coast Primary Care Trust, The
   Lords Feoffees of Bridlington, Bridlington Hospital League of Friends,
   The Hull and East Riding Charitable Trust, The National Eye Research
   Centre (Yorkshire), The Rotary Club of Bridlington, The Alexander Pigott
   Wernher Memorial Trust, Bridlington Lions Club, The Inner Wheel Club of
   Bridlington, Soroptimist International of Bridlington and The Patricia
   and Donald Shepherd Charitable Trust.
CR AIRAKSINEN PJ, 1981, ARCH OPHTHALMOL-CHIC, V99, P1795, DOI 10.1001/archopht.1981.03930020669009
   AIRAKSINEN PJ, 1981, ACTA OPHTHALMOL, V59, P231
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BENGTSSON B, 1981, ACTA OPHTHALMOL, V59, P1
   Bengtsson B, 2007, OPHTHALMOLOGY, V114, P205, DOI 10.1016/j.ophtha.2006.07.060
   Bjerrum J, 1889, NORD OPHTHALMOL TIDS, V2, P141
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Budenz DL, 2006, OPHTHALMOLOGY, V113, P2137, DOI 10.1016/j.ophtha.2006.06.022
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chung HS, 1999, BRIT J OPHTHALMOL, V83, P466, DOI 10.1136/bjo.83.4.466
   Clarke PM, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e8308
   CORBETT JJ, 1985, INVEST OPHTH VIS SCI, V26, P1101
   DIEHL DLC, 1990, ARCH OPHTHALMOL-CHIC, V108, P545, DOI 10.1001/archopht.1990.01070060093056
   Drance S, 2001, AM J OPHTHALMOL, V131, P699, DOI 10.1016/S0002-9394(01)00964-3
   DRANCE SM, 1977, ARCH OPHTHALMOL-CHIC, V95, P226
   DRANCE SM, 1970, CAN J OPHTHALMOLOGY, V5, P137
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Furlanetto RL, 2014, AM J OPHTHALMOL, V157, P945, DOI 10.1016/j.ajo.2014.02.009
   Garg A, 2017, INVEST OPHTH VIS SCI, V58, P2810, DOI 10.1167/iovs.16-20343
   GLOSTER J, 1981, BRIT J OPHTHALMOL, V65, P452, DOI 10.1136/bjo.65.7.452
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Healey PR, 1998, OPHTHALMOLOGY, V105, P216, DOI 10.1016/S0161-6420(98)92704-X
   HEIJL A, 1986, ACTA OPHTHALMOL, V64, P274
   HENDRICKX KH, 1994, OPHTHALMOLOGY, V101, P1165
   Hirooka K, 2012, CLIN EXP OPHTHALMOL, V40, P576, DOI 10.1111/j.1442-9071.2012.02762.x
   Ishida K, 2000, AM J OPHTHALMOL, V129, P707, DOI 10.1016/S0002-9394(00)00441-4
   JONAS JB, 1994, AM J OPHTHALMOL, V118, P1
   JONAS JB, 1988, INVEST OPHTH VIS SCI, V29, P1151
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   Jonas JB, 2002, INVEST OPHTH VIS SCI, V43, P2956
   Kim DW, 2015, INVEST OPHTH VIS SCI, V56, P3666, DOI 10.1167/iovs.14-16319
   Kim YD, 2010, EYE, V24, P567, DOI 10.1038/eye.2009.163
   KITAZAWA Y, 1986, OPHTHALMOLOGY, V93, P853
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lane D, 2002, J HYPERTENS, V20, P1089, DOI 10.1097/00004872-200206000-00019
   Lee KM, 2016, ACTA OPHTHALMOL, V94, pE697, DOI 10.1111/aos.13086
   Park HS, 2015, OPTOMETRY VISION SCI, V92, P700, DOI 10.1097/OPX.0000000000000591
   Park KH, 1996, OPHTHALMOLOGY, V103, P1899, DOI 10.1016/S0161-6420(96)30409-0
   Pesola GR, 2001, AM J EMERG MED, V19, P43, DOI 10.1053/ajem.2001.20021
   PHELPS CD, 1985, INVEST OPHTH VIS SCI, V26, P1105
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Ramulu P, 2009, CURR OPIN OPHTHALMOL, V20, P92, DOI 10.1097/ICU.0b013e32832401a9
   Roberts KF, 2012, ARCH OPHTHALMOL-CHIC, V130, P980, DOI 10.1001/archophthalmol.2012.371
   Siegner SW, 1996, OPHTHALMOLOGY, V103, P1014, DOI 10.1016/S0161-6420(96)30572-1
   Skalicky SE, 2016, CLIN EXP OPHTHALMOL, V44, P377, DOI 10.1111/ceo.12672
   Soares AS, 2004, OPHTHALMOLOGY, V111, P1653, DOI 10.1016/j.ophtha.2004.03.023
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Sugiyama K, 1999, ACTA OPHTHALMOL SCAN, V77, P139, DOI 10.1034/j.1600-0420.1999.770204.x
   Sugiyama K, 1999, OPHTHALMOLOGY, V106, P1762, DOI 10.1016/S0161-6420(99)90347-0
   Sugiyama K, 1997, OPHTHALMOLOGY, V104, P1926, DOI 10.1016/S0161-6420(97)30005-0
   Sugiyama T, 2000, OPHTHALMIC RES, V32, P79, DOI 10.1159/000055594
   Suh MH, 2011, CLIN EXP OPHTHALMOL, V39, P513, DOI 10.1111/j.1442-9071.2010.02482.x
   Tomidokoro A, 2009, EYE, V23, P1032, DOI 10.1038/eye.2008.247
   Uhler TA, 2008, CURR OPIN OPHTHALMOL, V19, P89, DOI 10.1097/ICU.0b013e3282f3e6bc
   Varma R, 2004, OPHTHALMOLOGY, V111, P1439, DOI 10.1016/j.ophtha.2004.01.025
   Wang Y, 2006, AM J OPHTHALMOL, V142, P241, DOI 10.1016/j.ajo.2006.02.032
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Yamamoto T, 2004, J GLAUCOMA, V13, P356, DOI 10.1097/01.ijg.0000137436.68060.d2
   Zheng YF, 2010, INVEST OPHTH VIS SCI, V51, P3399, DOI 10.1167/iovs.09-4867
NR 61
TC 0
Z9 0
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD APR
PY 2019
VL 33
IS 4
BP 580
EP 586
DI 10.1038/s41433-018-0263-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HS8ME
UT WOS:000464123000011
PM 30385878
OA Green Accepted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Bruender, MC
   Benjamin, N
   Agostini, HT
   Stahl, A
   Ehlken, C
AF Bruender, Marie-Christine
   Benjamin, Nicola
   Agostini, Hansjuergen Thomas
   Stahl, Andreas
   Ehlken, Christoph
TI Subjective evaluation of visual acuity is not reliable to detect disease
   activity in different exudative maculopathies
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Sensitivity; Specificity; Maculopathy; Macular edema; Diagnosis;
   Diagnostic accuracy
ID MACULAR DEGENERATION; DIAGNOSTIC-ACCURACY; MONITORING DEVICE;
   RANIBIZUMAB; HOME; THERAPY
AB Background Patients with exudative maculopathies (neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)) are faced with a high burden of examinations and treatments. This study was conceived to analyze the accuracy of a subjective evaluation of visual acuity (VA) and metamorphopsia to detect disease reactivation, compared to morphological signs of reactivation assessed by means of SD-OCT.
   Methods Retrospective study of 888 patients treated for nAMD (n = 638), DME (84), BRVO (110), and CRVO (56) was conducted. Subjective evaluation of the patient at an examination (i.e., change of VA and/or metamorphopsia) was compared to clinical evaluation of disease activity as assessed by SD-OCT. Sensitivity and specificity, negative and positive predictive values (PPV/NPV) for detection of active disease were calculated. Factors associated with false-negative subjective evaluation were analyzed by regression analysis.
   Results The sensitivity of the subjective evaluation to detect disease reactivation was < 0.50 in all exudative maculopathies. Sensitivity was increased to >= 0.60 by combining subjective worsening with loss of 1 line in the VA test in RVO, but not in DME and nAMD. The specificity was > 0.85 in all patients. PPV was > 0.85 in patients with RVO. Regression analysis did not reveal any factors that could reliably identify patient subgroups in which OCT could be omitted, though CRVO patients with a visual acuity of < 0.3 logMAR had an odds ratio of 0.20 for false-negative subjective evaluation (p = 0.009).
   Conclusion The accuracy of subjective evaluation to discriminate disease activity in patients with different exudative maculopathies was low and cannot substitute for frequent SD-OCT exams. Routinely assessed clinical parameters such as age, visual acuity, or treatment experience were of no use to predict the validity of subjective evaluation of disease activity.
C1 [Bruender, Marie-Christine; Agostini, Hansjuergen Thomas; Stahl, Andreas; Ehlken, Christoph] Albert Ludwigs Univ, Ctr Eye, Med Ctr, Fac Med, Killianstr 5, D-79106 Freiburg, Germany.
   [Benjamin, Nicola] Univ Hosp Heidelberg, Thoraxclin, Ctr Pulm Hypertens, Rontgenstr 1, D-69126 Heidelberg, Germany.
   [Ehlken, Christoph] Univ Kiel, Dept Ophthalmol, Fac Med, Arnold Heller Str 3, D-24105 Kiel, Germany.
C3 University of Freiburg; Ruprecht Karls University Heidelberg; University
   of Kiel
RP Ehlken, C (通讯作者)，Albert Ludwigs Univ, Ctr Eye, Med Ctr, Fac Med, Killianstr 5, D-79106 Freiburg, Germany.; Ehlken, C (通讯作者)，Univ Kiel, Dept Ophthalmol, Fac Med, Arnold Heller Str 3, D-24105 Kiel, Germany.
EM christoph.ehlken@uksh.de
RI Benjamin, Nicola/AAJ-4360-2021
CR Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1136/bmj.h5527, 10.1373/clinchem.2015.246280, 10.1148/radiol.2015151516]
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Ehlken C, 2017, TREATMENT NEOVASCULA, DOI [10.1097/IAE, DOI 10.1097/IAE]
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Hessellund A, 2012, ACTA OPHTHALMOL, V90, P471, DOI 10.1111/j.1755-3768.2010.02074.x
   Hoerster R, 2011, BRIT J OPHTHALMOL, V95, P1424, DOI 10.1136/bjo.2010.201129
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Larsen M, 2016, OPHTHALMOLOGY, V123, P1101, DOI 10.1016/j.ophtha.2016.01.011
   Markun S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143085
   Mathew R, 2012, EYE, V26, P389, DOI 10.1038/eye.2011.326
   McKibbin M, 2015, GRAEF ARCH CLIN EXP, V253, P1479, DOI 10.1007/s00417-014-2839-4
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   Thomas M, 2015, JAMA OPHTHALMOL, V133, P1425, DOI 10.1001/jamaophthalmol.2015.3684
   Ziemssen F, 2009, OPHTHALMOLOGE, V106, P465, DOI 10.1007/s00347-009-1964-7
NR 15
TC 3
Z9 3
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2018
VL 256
IS 9
BP 1565
EP 1571
DI 10.1007/s00417-018-4021-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GQ7OL
UT WOS:000441932500001
PM 29858676
DA 2022-11-30
ER

PT J
AU Lei, CY
   Lin, R
   Wang, JM
   Tao, LF
   Fu, XY
   Qiu, YG
   Lei, B
AF Lei, Chunyan
   Lin, Ru
   Wang, Jiaming
   Tao, Lifei
   Fu, Xinyu
   Qiu, Yiguo
   Lei, Bo
TI AMELIORATION OF AMYLOID beta-INDUCED RETINAL INFLAMMATORY RESPONSES BY A
   LXR AGONIST TO901317 IS ASSOCIATED WITH INHIBITION OF THE NF-kappa B
   SIGNALING AND NLRP3 INFLAMMASOME
SO NEUROSCIENCE
LA English
DT Article
DE Amyloid beta; liver x receptors; NLRP3 inflamma-some; NF-kappa B;
   retinal inflammatory response
ID LIVER X RECEPTORS; MACULAR DEGENERATION; ACTIVATION; PROTECTS; CELLS;
   MECHANISMS; EXPRESSION; INDUCTION; PATHOLOGY; DISEASES
AB Amyloid beta (A beta) is a pathogenic peptide associated with many neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The retinal inflammation in response to A beta is implicated in the pathogenesis of several ocular diseases including age-related macular degeneration, Alzheimer's-related optic neuropathy and glaucoma. In the present study, we found that a single intravitreal injection of oligomeric A beta 1-40 in mouse activated the NLRP3 inflammasome and the NF-kappa B signaling, induced the production of inflammatory cytokines including TNF-alpha and IL6. In addition, A beta 1-40 caused retinal function impairment while no noticeable morphological changes were observed under light microscope. Furthermore, immunohistochemical results showed that A beta 1-40 enhanced the number of Iba1-positive cells in the inner retina. The mRNA expressions of LXRa and LXRb decreased in the neuroretina of the A beta 1-40-injected mice. No significant difference was found on the protein expressions of LXRs and ABCA1 in both neuroretina and RPE/choroid complex between the A beta 1-40-injected group and the control group. A synthetic LXR ligand, TO901317 (TO90), enhanced the expressions of LXRa and ABCA1 at both mRNA and protein levels in the A beta 1-40-injected mice, while the LXRb expression was unchanged. TO90 preserved ERG a-and b-wave amplitudes and reduced the number of Iba1-positive cells in the A beta 1-40-treated retina. Furthermore, TO90 down-regulated the mRNA levels of TNF-alpha and IL-6, as well as the expressions of pIjBa, NLRP3, caspase-1 and IL-1 beta in the A beta-1-40-injected animals. We suggest that activation of LXRa and its target gene ABCA1 exerts potent anti-inflammatory effect on the Abtreated retina. (C) 2017 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Lei, Chunyan] Chongqing Med Univ, Dept Ophthalmol, Peoples Hosp Neijiang 1, Neijiang Affiliated Hosp, Neijiang, Peoples R China.
   [Lei, Chunyan; Lin, Ru; Wang, Jiaming; Tao, Lifei; Fu, Xinyu; Qiu, Yiguo] Chongqing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Chongqing Key Lab Ophthalmol,Chongqing Eye Inst, Chongqing, Peoples R China.
   [Lei, Bo] Zhengzhou Univ, Peoples Hosp, Henan Prov Peoples Hosp, Henan Eye Inst,Henan Eye Hosp, 7 Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Zhengzhou
   University
RP Lei, B (通讯作者)，Zhengzhou Univ, Peoples Hosp, Henan Prov Peoples Hosp, Henan Eye Inst,Henan Eye Hosp, 7 Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China.
EM 710131676@qq.com; 83243034@qq.com; 38584586@qq.com; 1057287006@qq.com;
   399925026@qq.com; vivianqiu1988@126.com; bolei99@126.com
RI Qiu, Yiguo/ACG-9526-2022
OI Qiu, Yiguo/0000-0002-9230-3206; Lei, Bo/0000-0002-5497-0905; Chunyan,
   Lei/0000-0003-4640-4601
FU National Natural Science Foundation of China [81271033, 81470621];
   National Key Clinical Specialties Construction Program of China
FX This study is supported by the National Natural Science Foundation of
   China grants (81271033, 81470621) and National Key Clinical Specialties
   Construction Program of China. The authors alone are responsible for the
   content and writing of the paper.
CR Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Bi J, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/403515
   Calkin AC, 2010, ARTERIOSCL THROM VAS, V30, P1513, DOI 10.1161/ATVBAHA.109.191197
   Chen J, 2013, CELL METAB, V17, P471, DOI 10.1016/j.cmet.2013.03.010
   Chen XS, 2010, J ALZHEIMERS DIS, V22, P1289, DOI 10.3233/JAD-2010-101323
   Cheng O, 2010, NEUROSCIENCE, V166, P1101, DOI 10.1016/j.neuroscience.2010.01.024
   Chi W, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0360-2
   Criscuolo C, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00053
   Dai BL, 2017, INFLAMM RES, V66, P523, DOI 10.1007/s00011-017-1036-4
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Devi TS, 2012, EXP DIABETES RES, DOI 10.1155/2012/438238
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Fitz NF, 2010, J NEUROSCI, V30, P6862, DOI 10.1523/JNEUROSCI.1051-10.2010
   Glabe CG, 2004, TRENDS BIOCHEM SCI, V29, P542, DOI 10.1016/j.tibs.2004.08.009
   Glabe CG, 2008, J BIOL CHEM, V283, P29639, DOI 10.1074/jbc.R800016200
   Gramlich OW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0542-6
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   He X, 2017, ONCOTARGET, V8, P32068, DOI 10.18632/oncotarget.16643
   He Y, 2013, J IMMUNOL, V190, P334, DOI 10.4049/jimmunol.1202737
   Heneka MT, 2007, J NEUROIMMUNOL, V184, P69, DOI 10.1016/j.jneuroim.2006.11.017
   HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231
   Howlett DR, 2011, EXP BRAIN RES, V214, P185, DOI 10.1007/s00221-011-2819-4
   Huang W, 2010, ARTERIOSCL THROM VAS, V30, P1542, DOI 10.1161/ATVBAHA.109.191189
   Im SS, 2011, CIRC RES, V108, P996, DOI 10.1161/CIRCRESAHA.110.226878
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ito A, 2015, ELIFE, V4, DOI 10.7554/eLife.08009
   Jen LS, 1998, NATURE, V392, P140, DOI 10.1038/32327
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lin T, 2013, MOL VIS, V19, P1769
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Masuzzo A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00127
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17
   Qiu YG, 2016, SCI REP-UK, V6, DOI 10.1038/srep31912
   Qiu YG, 2014, INVEST OPHTH VIS SCI, V55, P3809, DOI 10.1167/iovs.14-13883
   Qiu YG, 2014, CURR EYE RES, V39, P365, DOI 10.3109/02713683.2013.845224
   Rahman MM, 2011, J VIROL, V85, P12505, DOI 10.1128/JVI.00410-11
   Santos VV, 2017, J NEUROENDOCRINOL, V29, DOI 10.1111/jne.12476
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shao QH, 2017, INT IMMUNOPHARMACOL, V49, P155, DOI 10.1016/j.intimp.2017.05.027
   Shi JQ, 2013, CNS NEUROSCI THER, V19, P262, DOI 10.1111/cns.12066
   Solan PD, 2011, SHOCK, V35, P367, DOI 10.1097/SHK.0b013e3181f7d742
   Takata K., 2012, INT J ALZHEIMERS DIS, V2012, P685739, DOI [10.1155/2012/685739, DOI 10.1155/2012/685739]
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Wahrle SE, 2008, J CLIN INVEST, V118, P671, DOI 10.1172/JCI33622
   Wu SJ, 2009, CARDIOVASC RES, V84, P119, DOI 10.1093/cvr/cvp180
   Xie Z, 2002, J NEUROSCI, V22, P3484
   Yang HX, 2014, INVEST OPHTH VIS SCI, V55, P2795, DOI 10.1167/iovs.13-13323
   Yin K, 2010, MOL MED, V16, P438, DOI 10.2119/molmed.2010.00004
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
   Zheng SJ, 2015, INVEST OPHTH VIS SCI, V56, P1168, DOI 10.1167/iovs.14-15612
NR 58
TC 39
Z9 42
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD SEP 30
PY 2017
VL 360
BP 48
EP 60
DI 10.1016/j.neuroscience.2017.07.053
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FG8FW
UT WOS:000410665800006
PM 28760679
DA 2022-11-30
ER

PT J
AU Ahmad, M
   Kaszubski, PA
   Cobbs, L
   Reynolds, H
   Smith, RT
AF Ahmad, Meleha
   Kaszubski, Patrick A.
   Cobbs, Lucy
   Reynolds, Harmony
   Smith, Roland Theodore
TI Choroidal thickness in patients with coronary artery disease
SO PLOS ONE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR MACULAR DISEASE; AGE-RELATED
   MACULOPATHY; BLUE MOUNTAINS EYE; HEALTHY-SUBJECTS; MICROVASCULAR
   DYSFUNCTION; CARDIOVASCULAR-DISEASE; HEART-DISEASE; AXIAL LENGTH;
   DEGENERATION
AB Purpose
   To evaluate choroidal thickness (CTh) in patients with coronary artery disease (CAD) compared to healthy controls.
   Design
   Cross-sectional.
   Methods
   Setting: Ambulatory clinic of a large city hospital. Patient population: Thirty-four patients had documented CAD, defined as history of >50% obstruction in at least one coronary artery on cardiac catheterization, positive stress test, ST elevation myocardial infarction, or revascularization procedure. Twenty-eight age-matched controls had no self-reported history of CAD or diabetes. Patients with high myopia, dense cataracts, and retinal disease were excluded. Observation procedures: Enhanced depth imaging optical coherence tomography and questionnaire regarding medical and ocular history. Main outcome measures: Subfoveal CTh and CTh 2000 mu m superior, inferior, nasal, and temporal to the fovea in the left eye, measured by 2 readers.
   Results
   CTh was significantly lower in patients with CAD compared to controls at the subfoveal location (252 vs. 303 mu m, P = 0.002) and at all 4 cardinal macular locations. The mean difference in CTh between the 2 groups ranged from 46 to 75 mu m and was greatest in the inferior location. Within the CAD group, CTh was significantly lower temporally (P = 0.007) and nasally (P<0.001) than subfoveally, consistent with the pattern observed in controls. On multivariate analysis, CAD was negatively associated with subfoveal CTh (P = 0.006) after controlling for diabetes, hypertension, and hypercholesterolemia.
   Conclusions and relevance
   Patients with CAD have a thinner macular choroid than controls, with preservation of the normal spatial CTh pattern. Decreased CTh might predispose patients with CAD to high-risk phenotypes of age-related macular degeneration such as reticular pseudodrusen and could serve as a potential biomarker of disease in CAD.
C1 [Ahmad, Meleha; Kaszubski, Patrick A.; Cobbs, Lucy; Smith, Roland Theodore] NYU, Sch Med, Dept Ophthalmol, New York, NY 10003 USA.
   [Reynolds, Harmony] NYU, Sch Med, Leon H Charney Div Cardiol, Cardiovasc Clin Res Ctr,Dept Med, New York, NY USA.
C3 New York University; New York University
RP Smith, RT (通讯作者)，NYU, Sch Med, Dept Ophthalmol, New York, NY 10003 USA.
EM roland.smith@nyumc.org
RI Reynolds, Harmony/AAU-3154-2021
OI Reynolds, Harmony/0000-0003-0284-0655; smith,
   theodore/0000-0002-1693-943X
FU Foundation Fighting Blindness unrestricted funds from Research to
   Prevent Blindness (New York, NY); NATIONAL EYE INSTITUTE [R01EY015520]
   Funding Source: NIH RePORTER
FX This work was supported by an Individual Investigator Award from
   Foundation Fighting Blindness unrestricted funds from Research to
   Prevent Blindness (New York, NY) to the Department of Ophthalmology, New
   York University School of Medicine. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Agladioglu K, 2015, J CLIN ULTRASOUND, V43, P567, DOI 10.1002/jcu.22269
   Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P7775, DOI 10.1167/iovs.14-14915
   Akay F, 2016, EUR J OPHTHALMOL, V26, P152, DOI 10.5301/ejo.5000675
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Altinkaynak H, 2014, CURR EYE RES, V39, P1123, DOI 10.3109/02713683.2014.898310
   American Heart Association, BRINDG GAP CVD HLTH
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Bittencourt M, 2014, J OPHTHAMIC INFLAMM, V25, P258
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Camici PG, 2007, NEW ENGL J MED, V356, P830, DOI 10.1056/NEJMra061889
   COLEMAN DJ, 1979, AM J OPHTHALMOL, V88, P369
   Cymerman RM, 2016, CURR EYE RES, V41, P1482, DOI 10.3109/02713683.2015.1128552
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Esmaeelpour M, 2011, INVEST OPHTH VIS SCI, V52, P5311, DOI 10.1167/iovs.10-6875
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Ford ES, 2004, J AM COLL CARDIOL, V43, P1791, DOI 10.1016/j.jacc.2003.11.061
   Gok M, 2015, INDIAN J OPHTHALMOL, V63, P239, DOI 10.4103/0301-4738.156928
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Karapetyan A, 2016, RETINA-J RET VIT DIS, V36, P82, DOI 10.1097/IAE.0000000000000654
   KIM DY, 2015, J OPHTHALMOL, V2015, DOI DOI 10.1155/2015/620372
   KOSEKI T, 1992, Nippon Ganka Gakkai Zasshi, V96, P757
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   McClintic BR, 2010, AM J MED, V123, DOI 10.1016/j.amjmed.2009.05.030
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Novais EA, 2015, OSLI RETINA, V46, P920, DOI 10.3928/23258160-20151008-04
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Reis SE, 2001, AM HEART J, V141, P735, DOI 10.1067/mhj.2001.114198
   Sanchez-Cano A, 2014, AM J OPHTHALMOL, V158, P574, DOI 10.1016/j.ajo.2014.05.035
   Sayin N, 2015, OSLI RETINA, V46, P180, DOI 10.3928/23258160-20150213-20
   Sigler EJ, 2014, EYE, V28, P838, DOI 10.1038/eye.2014.100
   Sizmaz S, 2013, BRIT J OPHTHALMOL, V97, P601, DOI 10.1136/bjophthalmol-2012-302393
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tan KA, 2016, SURV OPHTHALMOL, V61, P566, DOI 10.1016/j.survophthal.2016.02.007
   Toyokawa N, 2012, OPHTHAL SURG LAS IM, V43, P109, DOI 10.3928/15428877-20120102-06
   Usui S, 2012, INVEST OPHTH VIS SCI, V53, P2300, DOI 10.1167/iovs.11-8383
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Wong IY, 2013, RETINA-J RET VIT DIS, V33, P423, DOI 10.1097/IAE.0b013e3182753b5a
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Xu J, 2013, OPHTHALMOLOGY, V120, P2023, DOI 10.1016/j.ophtha.2013.03.009
NR 48
TC 43
Z9 43
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2017
VL 12
IS 6
AR e0175691
DI 10.1371/journal.pone.0175691
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EY5UN
UT WOS:000404046100002
PM 28632734
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Caixinha, M
   Nunes, S
AF Caixinha, Miguel
   Nunes, Sandrina
TI Machine Learning Techniques in Clinical Vision Sciences
SO CURRENT EYE RESEARCH
LA English
DT Review
DE Automated diagnosis; clinical research; machine learning; pattern
   recognition; vision sciences
ID INDEPENDENT COMPONENT ANALYSIS; STANDARD AUTOMATED PERIMETRY; EMPIRICAL
   MODE DECOMPOSITION; ARTIFICIAL NEURAL-NETWORK; FIBER LAYER MEASUREMENTS;
   WAVELET-FOURIER ANALYSIS; DECISION-SUPPORT-SYSTEM; DIABETIC-RETINOPATHY;
   MACULAR DEGENERATION; GLAUCOMA PROGRESSION
AB This review presents and discusses the contribution of machine learning techniques for diagnosis and disease monitoring in the context of clinical vision science. Many ocular diseases leading to blindness can be halted or delayed when detected and treated at its earliest stages. With the recent developments in diagnostic devices, imaging and genomics, new sources of data for early disease detection and patients' management are now available. Machine learning techniques emerged in the biomedical sciences as clinical decision-support techniques to improve sensitivity and specificity of disease detection and monitoring, increasing objectively the clinical decision-making process. This manuscript presents a review in multimodal ocular disease diagnosis and monitoring based on machine learning approaches. In the first section, the technical issues related to the different machine learning approaches will be present. Machine learning techniques are used to automatically recognize complex patterns in a given dataset. These techniques allows creating homogeneous groups (unsupervised learning), or creating a classifier predicting group membership of new cases (supervised learning), when a group label is available for each case. To ensure a good performance of the machine learning techniques in a given dataset, all possible sources of bias should be removed or minimized. For that, the representativeness of the input dataset for the true population should be confirmed, the noise should be removed, the missing data should be treated and the data dimensionally (i.e., the number of parameters/features and the number of cases in the dataset) should be adjusted. The application of machine learning techniques in ocular disease diagnosis and monitoring will be presented and discussed in the second section of this manuscript. To show the clinical benefits of machine learning in clinical vision sciences, several examples will be presented in glaucoma, age-related macular degeneration, and diabetic retinopathy, these ocular pathologies being the major causes of irreversible visual impairment.
C1 [Caixinha, Miguel] Univ Coimbra, Fac Sci & Technol, Dept Phys, Coimbra, Portugal.
   [Caixinha, Miguel] Univ Coimbra, Fac Sci & Technol, Dept Elect & Comp Engn, Coimbra, Portugal.
   [Nunes, Sandrina] Univ Coimbra, Fac Med, Coimbra, Portugal.
   [Nunes, Sandrina] Assoc Innovat & Biomed Res Light & Image, Coimbra Coordinating Ctr Clin Res, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Universidade de
   Coimbra; Universidade de Coimbra
RP Caixinha, M (通讯作者)，Univ Coimbra, Dept Elect & Comp Engn, Polo 2, P-3030290 Coimbra, Portugal.
EM miguel.caixinha@gmail.com
OI Nunes, Sandrina/0000-0001-5401-9637; Caixinha,
   Miguel/0000-0002-4835-1980
CR Aburas A, 2007, ARISER, V3, P112
   Acharya U. R., 2007, IRBM, V28, P35
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Akram MU, 2014, COMPUT METH PROG BIO, V114, P141, DOI 10.1016/j.cmpb.2014.01.010
   Asaoka R, 2014, INVEST OPHTH VIS SCI, V55, P7814, DOI 10.1167/iovs.14-15120
   Bagheri A, 2014, MED BIOL ENG COMPUT, V52, P619, DOI 10.1007/s11517-014-1164-8
   Barton FB, 2004, AM J OPHTHALMOL, V138, P119, DOI 10.1016/j.ajo.2004.02.009
   Belghith A, 2015, ARTIF INTELL MED, V64, P105, DOI 10.1016/j.artmed.2015.04.002
   Bowd C, 2002, INVEST OPHTH VIS SCI, V43, P3444
   Bowd C, 2008, OPTOMETRY VISION SCI, V85, P396, DOI 10.1097/OPX.0b013e3181783ab6
   Bowd C, 2008, INVEST OPHTH VIS SCI, V49, P945, DOI 10.1167/iovs.07-1083
   Bowd C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085941
   Bowd C, 2012, INVEST OPHTH VIS SCI, V53, P2382, DOI 10.1167/iovs.11-7951
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Cheung CYL, 2011, INVEST OPHTH VIS SCI, V52, P1314, DOI 10.1167/iovs.10-5427
   Chiang MMT, 2010, J CLASSIF, V27, P3, DOI 10.1007/s00357-010-9049-5
   Cotter SA, 2006, OPHTHALMOLOGY, V113, P1574, DOI 10.1016/j.ophtha.2006.05.002
   DAVIES DL, 1979, IEEE T PATTERN ANAL, V1, P224, DOI 10.1109/TPAMI.1979.4766909
   Duda RO., 2001, PATTERN CLASSIFICATI
   Essock EA, 2005, INVEST OPHTH VIS SCI, V46, P2838, DOI 10.1167/iovs.04-1156
   Essock EA, 2003, ARCH OPHTHALMOL-CHIC, V121, P1238, DOI 10.1001/archopht.121.9.1238
   Essock EA, 2007, OPTOMETRY VISION SCI, V84, P380, DOI 10.1097/OPX.0b013e318058a0de
   EVERITT BS, 1995, BRIT MED J, V311, P535, DOI 10.1136/bmj.311.7004.535
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010
   Feeny AK, 2015, COMPUT BIOL MED, V65, P124, DOI 10.1016/j.compbiomed.2015.06.018
   Fraccaro P, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-10
   Ganesan K, 2014, MED BIOL ENG COMPUT, V52, P663, DOI 10.1007/s11517-014-1167-5
   Goldbaum MH, 2005, INVEST OPHTH VIS SCI, V46, P3676, DOI 10.1167/iovs.04-1167
   Goldbaum MH, 2002, INVEST OPHTH VIS SCI, V43, P162
   Goldbaum MH, 2012, INVEST OPHTH VIS SCI, V53, P6557, DOI 10.1167/iovs.11-8363
   Goldbaum Michael H, 2009, Trans Am Ophthalmol Soc, V107, P136
   Goldbaum Michael Henry, 2005, Trans Am Ophthalmol Soc, V103, P270
   Grus FH, 1999, ELECTROPHORESIS, V20, P875, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<875::AID-ELPS875>3.0.CO;2-V
   Hitzl W, 2003, J THEOR MED, V5, P161, DOI DOI 10.1080/10273360410001728011
   Huang ML, 2010, J MED SYST, V34, P1141, DOI 10.1007/s10916-009-9333-2
   Huang ML, 2010, GRAEF ARCH CLIN EXP, V248, P435, DOI 10.1007/s00417-009-1259-3
   Hung WL, 2006, LECT NOTES ARTIF INT, V3885, P340
   Isabelle G., 2003, J MACH LEARN RES, V3, P1157, DOI [10.1063/1.106515, DOI 10.1162/153244303322753616]
   IVANCIUC O, 2007, REV COMPUTATIONAL CH, V23, P291, DOI DOI 10.1002/9780470116449.CH6
   Jaccard P., 1912, NEW PHYTOL, V11, P37, DOI [DOI 10.1111/J.1469-8137.1912.TB05611.X, 10.1111/j.1469-8137.1912.tb05611.x]
   Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819
   Jiang DX, 2004, IEEE T KNOWL DATA EN, V16, P1370, DOI 10.1109/TKDE.2004.68
   Kaufman L., 1990, FINDING GROUPS DATA, P126, DOI [10.1002/9780470316801.ch3, DOI 10.1002/9780470316801.CH3]
   Kim PY, 2013, IEEE J BIOMED HEALTH, V17, P269, DOI 10.1109/TITB.2012.2218661
   Koh YW, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.8.086008
   Kononenko I, 2001, ARTIF INTELL MED, V23, P89, DOI 10.1016/S0933-3657(01)00077-X
   Krishnakumar S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125148
   Lahmiri S, 2014, BIOMED ENG-BIOMED TE, V59, P357, DOI 10.1515/bmt-2013-0082
   Langegger C, 2007, RHEUMATOL INT, V27, P699, DOI 10.1007/s00296-006-0291-4
   Mardin CY, 2003, J GLAUCOMA, V12, P340, DOI 10.1097/00061198-200308000-00008
   Marsolo K, 2007, IEEE T INF TECHNOL B, V11, P203, DOI 10.1109/TITB.2006.879591
   Mathers WD, 2004, ARCH OPHTHALMOL-CHIC, V122, P1700, DOI 10.1001/archopht.122.11.1700
   Medeiros FA, 2011, INVEST OPHTH VIS SCI, V52, P5794, DOI 10.1167/iovs.10-7111
   MILLIGAN GW, 1985, PSYCHOMETRIKA, V50, P159, DOI 10.1007/BF02294245
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Nakai M., 2011, INT J MATH ANAL, V5, P1
   Noronha K, 2013, P I MECH ENG H, V227, P251, DOI 10.1177/0954411912470240
   Nunes S, 2013, INVEST OPHTH VIS SCI, V54, P4595, DOI 10.1167/iovs.13-11895
   Oh E, 2015, INVEST OPHTH VIS SCI, V56, P3957, DOI 10.1167/iovs.15-16805
   Oh E, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-106
   Pauwels EJ, 1999, COMPUT VIS IMAGE UND, V75, P73, DOI 10.1006/cviu.1999.0763
   Poinoosawmy D, 2001, GRAEF ARCH CLIN EXP, V239, P122, DOI 10.1007/s004170100256
   Priya R., 2011, International Journal of Applied Engineering Research, V1, P844
   Quinlan JR, 1996, ACM COMPUT SURV, V28, P71, DOI 10.1145/234313.234346
   Racette L, 2010, J GLAUCOMA, V19, P167, DOI 10.1097/IJG.0b013e3181a98b85
   Raza AS, 2014, INVEST OPHTH VIS SCI, V55, P612, DOI 10.1167/iovs.13-12351
   Remeseiro B, 2012, COMPUT MATH METHOD M, V2012, DOI 10.1155/2012/207315
   Remeseiro B, 2014, IEEE J BIOMED HEALTH, V18, P1485, DOI 10.1109/JBHI.2013.2294732
   Rokach L, 2005, IEEE T SYST MAN CY C, V35, P476, DOI 10.1109/TSMCC.2004.843247
   Rosenberg D, 2004, MATERN CHILD HLTH J, V8, P19, DOI 10.1023/B:MACI.0000019845.04353.78
   Rosner B, 1997, STAT MED, V16, P357, DOI 10.1002/(SICI)1097-0258(19970228)16:4<357::AID-SIM420>3.0.CO;2-3
   Rosner B, 2007, OPHTHAL EPIDEMIOL, V14, P243, DOI 10.1080/09286580701396704
   ROUSSEEUW PJ, 1987, J COMPUT APPL MATH, V20, P53, DOI 10.1016/0377-0427(87)90125-7
   Saad A, 2014, J REFRACT SURG, V30, P542, DOI 10.3928/1081597X-20140711-07
   Sajda P, 2006, ANNU REV BIOMED ENG, V8, P537, DOI 10.1146/annurev.bioeng.8.061505.095802
   Sample PA, 2005, INVEST OPHTH VIS SCI, V46, P3684, DOI 10.1167/iovs.04-1168
   Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147
   Schmidt GW, 2008, OPHTHALMOLOGY, V115, P202, DOI 10.1016/j.ophtha.2007.04.008
   Shekar DVC, 2008, P MULTICONFERENCE EN, VI, P19
   Shin HJ, 2006, J BIOMED INFORM, V39, P227, DOI 10.1016/j.jbi.2005.04.002
   Siddiqui K., 2013, WORLD APPL SCI J, V27, P285, DOI [10.5829/idosi.wasj.2013.27.02.889, DOI 10.5829/ID0SI.WASJ.2013.27.02.889]
   Smadja D, 2013, AM J OPHTHALMOL, V156, P237, DOI 10.1016/j.ajo.2013.03.034
   Sugimoto K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003114
   Szkulmowska A, 2005, J PHYS D APPL PHYS, V38, P2606, DOI 10.1088/0022-3727/38/15/011
   Tang HYLL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066730
   Tatsuoka MM, 1989, J ED STAT, V14, P110
   Torok Z, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/623619
   Torok Z, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-40
   Trusheim MR, 2007, NAT REV DRUG DISCOV, V6, P287, DOI 10.1038/nrd2251
   Tsai CL, 2011, INVEST OPHTH VIS SCI, V52, P2767, DOI 10.1167/iovs.10-6048
   Tsien CL, 2000, J AM MED INFORM ASSN, P858
   Twa MD, 2005, OPTOMETRY VISION SCI, V82, P1038, DOI 10.1097/01.opx.0000192350.01045.6f
   Weinreb RN, 2004, AM J OPHTHALMOL, V138, P458, DOI 10.1016/j.ajo.2004.04.054
   Welikala RA, 2014, COMPUT METH PROG BIO, V114, P247, DOI 10.1016/j.cmpb.2014.02.010
   Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837
   World Health Organization, 2012, GLOB DAT VIS IMP 201
   Wu KL, 2002, PATTERN RECOGN, V35, P2267, DOI 10.1016/S0031-3203(01)00197-2
   Xu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055476
   Xu YW, 2013, LECT NOTES COMPUT SC, V8150, P468, DOI 10.1007/978-3-642-40763-5_58
   Yousefi S, 2014, IEEE T BIO-MED ENG, V61, P2112, DOI 10.1109/TBME.2014.2314714
   Yousefi S, 2014, IEEE T BIO-MED ENG, V61, P1143, DOI 10.1109/TBME.2013.2295605
NR 101
TC 41
Z9 43
U1 4
U2 41
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JAN
PY 2017
VL 42
IS 1
BP 1
EP 15
DI 10.1080/02713683.2016.1175019
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK4EY
UT WOS:000393881100001
PM 27362387
DA 2022-11-30
ER

PT J
AU Kulminski, AM
   Raghavachari, N
   Arbeev, KG
   Culminskaya, I
   Arbeeva, L
   Wu, DQ
   Ukraintseva, SV
   Christensen, K
   Yashin, AI
AF Kulminski, Alexander M.
   Raghavachari, Nalini
   Arbeev, Konstantin G.
   Culminskaya, Irina
   Arbeeva, Liubov
   Wu, Deqing
   Ukraintseva, Svetlana V.
   Christensen, Kaare
   Yashin, Anatoliy I.
TI Protective role of the apolipoprotein E2 allele in age-related disease
   traits and survival: evidence from the Long Life Family Study
SO BIOGERONTOLOGY
LA English
DT Article
DE ApoE; Health span; Life span
ID MACULAR DEGENERATION; E GENOTYPES; DIABETIC-NEPHROPATHY; RENAL-DISEASE;
   LONGEVITY; RISK; METAANALYSIS; ASSOCIATION; CANCER; PROGRESSION
AB The apolipoprotein E (apoE) is a classic example of a gene exhibiting pleiotropism. We examine potential pleiotropic associations of the apoE2 allele in three biodemographic cohorts of long-living individuals, offspring, and spouses from the Long Life Family Study, and intermediate mechanisms, which can link this allele with age-related phenotypes. We focused on age-related macular degeneration, bronchitis, asthma, pneumonia, stroke, creatinine, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol, diseases of heart (HD), cancer, and survival. Our analysis detected favorable associations of the epsilon 2 allele with lower LDL-C levels, lower risks of HD, and better survival. The epsilon 2 allele was associated with LDL-C in each gender and biodemographic cohort, including long-living individuals, offspring, and spouses, resulting in highly significant association in the entire sample (beta = -7.1, p = 6.6 x 10(-44)). This allele was significantly associated with HD in long-living individuals and offspring (relative risk [RR] = 0.60, p = 3.1 x 10(-6)) but this association was not mediated by LDL-C. The protective effect on survival was specific for long-living women but it was not explained by LDL-C and HD in the adjusted model (RR = 0.70, p = 2.1 x 10(-2)). These results show that epsilon 2 allele may favorably influence LDL-C, HD, and survival through three mechanisms. Two of them (HD- and survival-related) are pronounced in the long-living parents and their offspring; the survival-related mechanism is also sensitive to gender. The LDL-C-related mechanism appears to be independent of these factors. Insights into mechanisms linking epsilon 2 allele with age-related phenotypes given biodemographic structure of the population studied may benefit translation of genetic discoveries to health care and personalized medicine.
C1 [Kulminski, Alexander M.; Arbeev, Konstantin G.; Culminskaya, Irina; Arbeeva, Liubov; Wu, Deqing; Ukraintseva, Svetlana V.; Yashin, Anatoliy I.] Duke Univ, Social Sci Res Inst, Biodemog Aging Res Unit, Durham, NC 27708 USA.
   [Raghavachari, Nalini] NIA, 31 Ctr Dr,MSC 2292, Bethesda, MD 20892 USA.
   [Christensen, Kaare] Univ Southern Denmark, Danish Aging Res Ctr, DK-5000 Odense C, Denmark.
   [Christensen, Kaare] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense C, Denmark.
   [Christensen, Kaare] Odense Univ Hosp, Dept Clin Biochem & Pharmacol, DK-5000 Odense C, Denmark.
C3 Duke University; National Institutes of Health (NIH) - USA; NIH National
   Institute on Aging (NIA); University of Southern Denmark; University of
   Southern Denmark; Odense University Hospital; University of Southern
   Denmark; Odense University Hospital
RP Kulminski, AM (通讯作者)，Duke Univ, Social Sci Res Inst, Biodemog Aging Res Unit, Durham, NC 27708 USA.
EM Alexander.Kulminski@duke.edu
RI Arbeev, Konstantin/AAJ-4425-2020; Kulminski, Alexander/T-1290-2019;
   Christensen, Kaare/C-2360-2009
OI Arbeev, Konstantin/0000-0002-4195-7832; Christensen,
   Kaare/0000-0002-5429-5292; Kulminski, Alexander/0000-0002-0205-8228
FU National Institute on Aging [U01AG023749, U01AG023744, U01AG023712, U01
   AG023712, P01 AG043352, R01 AG047310]; NATIONAL INSTITUTE ON AGING
   [U01AG023744, R01AG047310, P30AG034424, P01AG043352, U01AG023712,
   U01AG023749] Funding Source: NIH RePORTER
FX The Long Life Family Study is funded by U01AG023749, U01AG023744 and
   U01AG023712 from the National Institute on Aging. This work was
   supported by the National Institute on Aging (Grant Numbers U01
   AG023712, P01 AG043352, R01 AG047310).
CR Anand R, 2014, J CANCER RES CLIN, V140, P1075, DOI 10.1007/s00432-014-1634-2
   Araki SI, 2003, DIABETES CARE, V26, P2416, DOI 10.2337/diacare.26.8.2416
   Burt TD, 2008, P NATL ACAD SCI USA, V105, P8718, DOI 10.1073/pnas.0803526105
   Christensen K, 2006, NAT REV GENET, V7, P436, DOI 10.1038/nrg1871
   CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Corella D, 2014, AGEING RES REV, V18, P53, DOI 10.1016/j.arr.2014.08.002
   Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038
   de Bont N, 1999, J LIPID RES, V40, P680
   De Feo E, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-494
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Eichner JE, 2002, AM J EPIDEMIOL, V155, P487, DOI 10.1093/aje/155.6.487
   Eto M, 1995, CLIN GENET, V48, P288
   Franco OH, 2009, MATURITAS, V63, P13, DOI 10.1016/j.maturitas.2009.02.006
   Govindaraju D, 2015, APPL TRANSL GENOM, V4, P23, DOI 10.1016/j.atg.2015.01.001
   Hauser PS, 2011, PROG LIPID RES, V50, P62, DOI 10.1016/j.plipres.2010.09.001
   Hunsicker LG, 1997, KIDNEY INT, V51, P1908, DOI 10.1038/ki.1997.260
   KATAN MB, 1986, LANCET, V1, P507
   Khan TA, 2013, INT J EPIDEMIOL, V42, P475, DOI 10.1093/ije/dyt034
   Kimura H, 1998, AM J KIDNEY DIS, V31, P666, DOI 10.1053/ajkd.1998.v31.pm9531184
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Kulminski AM, 2008, J AM GERIATR SOC, V56, P478, DOI 10.1111/j.1532-5415.2007.01574.x
   Kulminski AM, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004141
   Kulminski AM, 2013, REJUV RES, V16, P304, DOI 10.1089/rej.2013.1441
   Kulminski AM, 2013, AGING CELL, V12, P237, DOI 10.1111/acel.12046
   Liberopoulos E, 2004, AM J KIDNEY DIS, V43, P223, DOI 10.1053/j.ajkd.2003.10.013
   Liu H, 2015, CANCER EPIDEM BIOMAR, V24, P1632, DOI 10.1158/1055-9965.EPI-15-0367
   Mahley RW, 2009, J LIPID RES, V50, pS183, DOI 10.1194/jlr.R800069-JLR200
   Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507
   Martin GM, 2007, PLOS GENET, V3, P1121, DOI 10.1371/journal.pgen.0030125
   Matteini AM, 2010, J GERONTOL A-BIOL, V65, P1375, DOI 10.1093/gerona/glq154
   Nesse RM, 2012, J MOL MED, V90, P509, DOI 10.1007/s00109-012-0889-9
   Oda H, 1999, KIDNEY INT, V56, pS25, DOI 10.1046/j.1523-1755.1999.07107.x
   Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675
   Olshansky SJ, 2007, ANN NY ACAD SCI, V1114, P11, DOI 10.1196/annals.1396.050
   Pedersen CB, 2006, DAN MED BULL, V53, P441
   Poulain M., 2013, VIENNA YB POPUL RES, V11, P87, DOI DOI 10.1553/POPULATIONYEARBOOK2013S87
   PRENTICE RL, 1978, BIOMETRIKA, V65, P153, DOI 10.1093/biomet/65.1.153
   Rajpathak SN, 2011, J AM GERIATR SOC, V59, P1509, DOI 10.1111/j.1532-5415.2011.03498.x
   Roselaar SE, 1998, J LIPID RES, V39, P1740
   Schultz DW, 2003, ARCH OPHTHALMOL-CHIC, V121, P679, DOI 10.1001/archopht.121.5.679
   Schupf N, 2013, NEUROBIOL AGING, V34, P1287, DOI 10.1016/j.neurobiolaging.2012.08.019
   Sebastiani P, 2009, AM J EPIDEMIOL, V170, P1555, DOI 10.1093/aje/kwp309
   Seshasai RK, 2012, CLIN NEPHROL, V78, P174, DOI 10.5414/CN107427
   Sierra F, 2009, ANNU REV MED, V60, P457, DOI 10.1146/annurev.med.60.061607.220533
   Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013
   Suri S, 2013, NEUROSCI BIOBEHAV R, V37, P2878, DOI 10.1016/j.neubiorev.2013.10.010
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Vaupel JW, 2010, NATURE, V464, P536, DOI 10.1038/nature08984
   Vijg J, 2005, ANNU REV MED, V56, P193, DOI 10.1146/annurev.med.56.082103.104617
   Watson MA, 2003, CLIN SCI, V104, P537, DOI 10.1042/CS20020329
   Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250
   Yao XL, 2012, AM J PHYSIOL-LUNG C, V302, pL206, DOI 10.1152/ajplung.00110.2011
   Yashin AI, 2010, MECH AGEING DEV, V131, P215, DOI 10.1016/j.mad.2010.02.001
NR 54
TC 18
Z9 20
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1389-5729
EI 1573-6768
J9 BIOGERONTOLOGY
JI Biogerontology
PD NOV
PY 2016
VL 17
IS 5-6
BP 893
EP 905
DI 10.1007/s10522-016-9659-3
PG 13
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA EA1VX
UT WOS:000386381300009
PM 27447179
OA Green Submitted, Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Banaee, T
   Kakhki, RD
   Abrishami, M
   Mahmoudi, M
   Farzadnia, M
AF Banaee, Touka
   Kakhki, Ramin Daneshvar
   Abrishami, Mojtaba
   Mahmoudi, Mahmoud
   Farzadnia, Mehdi
TI Higher titers of anti-Chlamydia pneumoniae IgG in diabetic retinopathy:
   a cross-sectional study
SO DIABETES-METABOLISM RESEARCH AND REVIEWS
LA English
DT Article
DE Chlamydophila pneumoniae; diabetic retinopathy; diabetes mellitus;
   infection; inflammation
ID MACULAR DEGENERATION; INSULIN-RESISTANCE; INFECTION; AGE; PATHOGENESIS;
   INFLAMMATION; ASSOCIATION; ATHEROSCLEROSIS; RISK
AB BackgroundChronic inflammation has a role in the pathogenesis of diabetic retinopathy. Infection with intracellular organisms may incite chronic inflammation. This study was conducted to investigate the association between previous infection with Chlamydia pneumoniae (an intracellular microorganism) and diabetic retinopathy.
   MethodsPatients with type 2 diabetes mellitus (30-60years old) and age-matched normal controls were recruited. Patients with history of cardiovascular or cerebrovascular disease, recent pulmonary infection and the presence of age-related macular degeneration were excluded from the study. Complete ophthalmic examinations were performed. Fasting blood sugar and haemoglobin levels were measured in diabetic patients and controls, and HgbA(1c), blood urea nitrogen, creatinine and 24-h urine protein were measured in diabetic patients. Anti-C.pneumoniae IgG (enzyme-linked immunosorbent assay) was measured in the sera of all participants.
   ResultsA total of 215 type 2 diabetic patients and 243 normal healthy controls were included. Anti-C.pneumoniae IgG titers were higher in patients affected by diabetic retinopathy than participants without retinopathy (74.7833.38 vs 66.18 +/- 31.40, p=0.028). Diabetic patients with diabetic retinopathy also had higher titers than diabetic patients without diabetic retinopathy (74.78 +/- 33.38 vs 66.11 +/- 33.41, p=0.042). Of different variables including age, body mass index, haemoglobin level, glycated haemoglobin level, fasting blood sugar, mean arterial pressure and blood urea nitrogen, only age (r=0.17; p=0.001) and body mass index (r=0.15; p=0.003) were correlated with anti-C.pneumoniae IgG levels. In regression analysis, the presence of diabetic retinopathy was still a determinant of the antibody level (p=0.03).
   ConclusionAnti-C.pneumoniae IgG titers were higher in patients with diabetic retinopathy, which may indicate a role of this infection in the pathogenesis of diabetic retinopathy. Copyright (c) 2014 John Wiley & Sons, Ltd.
C1 [Banaee, Touka; Abrishami, Mojtaba] Mashhad Univ Med Sci, Retina Res Ctr, Mashhad 9195961151, Khorasan Razavi, Iran.
   [Banaee, Touka; Kakhki, Ramin Daneshvar] Mashhad Univ Med Sci, Fac Med, Khatam al Anbia Eye Hosp, Dept Ophthalmol, Mashhad 9195961151, Khorasan Razavi, Iran.
   [Kakhki, Ramin Daneshvar] Mashhad Univ Med Sci, Cornea Res Ctr, Mashhad 9195961151, Khorasan Razavi, Iran.
   [Abrishami, Mojtaba] Univ Tehran Med Sci, Farabi Eye Hosp, Eye Res Ctr, Tehran, Iran.
   [Mahmoudi, Mahmoud] Mashhad Univ Med Sci, Dept Immunol & Allergy, Immunol Res Ctr, Sch Med, Mashhad 9195961151, Khorasan Razavi, Iran.
   [Farzadnia, Mehdi] Mashhad Univ Med Sci, Sch Med, Dept Pathol, Mashhad 9195961151, Khorasan Razavi, Iran.
C3 Mashhad University Medical Science; Mashhad University Medical Science;
   Mashhad University Medical Science; Tehran University of Medical
   Sciences; Mashhad University Medical Science; Mashhad University Medical
   Science
RP Banaee, T (通讯作者)，Mashhad Univ Med Sci, Retina Res Ctr, Khatam al Anbia Eye Hosp, Ghareni Blvd, Mashhad 9195961151, Khorasan Razavi, Iran.
EM banaeet@mums.ac.ir
RI Abrishami, Mojtaba/AAH-6100-2020
OI Abrishami, Mojtaba/0000-0003-2001-7929; Daneshvar,
   Ramin/0000-0002-0884-0907
CR Adamiec-Mroczek J, 2010, CYTOKINE, V49, P269, DOI 10.1016/j.cyto.2009.11.004
   Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Black PH, 2003, BRAIN BEHAV IMMUN, V17, P350, DOI 10.1016/S0889-1591(03)00048-5
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chao JR, 2007, INVEST OPHTH VIS SCI, V48, P4019, DOI 10.1167/iovs.07-0206
   Chibber R, 2007, CURR DIABETES REV, V3, P3, DOI 10.2174/157339907779802139
   Davidson M, 1998, CIRCULATION, V98, P628, DOI 10.1161/01.CIR.98.7.628
   Frank RN, 2013, RETINA-J RET VIT DIS, V33, P899, DOI 10.1097/IAE.0b013e318287d882
   Ge Y, 2011, TRENDS CARDIOVAS MED, V21, P105, DOI 10.1016/j.tcm.2012.03.007
   Grant PJ, 2007, J INTERN MED, V262, P157, DOI 10.1111/j.1365-2796.2007.01824.x
   Guymer R, 2007, CLIN EXP OPHTHALMOL, V35, P89, DOI 10.1111/j.1442-9071.2006.01392.x
   He F, 2013, DIABETOLOGIA, V56, P457, DOI 10.1007/s00125-012-2796-6
   HOHMAN TC, 1989, EXP EYE RES, V48, P55, DOI 10.1016/0014-4835(89)90018-3
   Huang H, 2011, INVEST OPHTH VIS SCI, V52, P1336, DOI 10.1167/iovs.10-5768
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kaul K, 2010, CURR DIABETES REV, V6, P294, DOI 10.2174/157339910793360851
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011
   KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010
   Klein R, 2002, OPHTHALMOLOGY, V109, P1225, DOI 10.1016/S0161-6420(02)01074-6
   Kol A, 1998, TRENDS CARDIOVAS MED, V8, P191, DOI 10.1016/S1050-1738(98)00010-3
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Liew Gerald, 2009, Int Ophthalmol Clin, V49, P35, DOI 10.1097/IIO.0b013e31819fd5d7
   Lu QH, 2009, J HEADACHE PAIN, V10, P121, DOI 10.1007/s10194-009-0096-4
   MacIntyre A, 2002, FEMS MICROBIOL LETT, V217, P167, DOI 10.1111/j.1574-6968.2002.tb11470.x
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1
   Murea Mariana, 2012, Rev Diabet Stud, V9, P6, DOI 10.1900/RDS.2012.9.6
   Ola MS, 2012, J DIABETES COMPLICAT, V26, P56, DOI 10.1016/j.jdiacomp.2011.11.004
   Ong G, 1996, J CLIN PATHOL, V49, P102, DOI 10.1136/jcp.49.2.102
   Pai J, 1998, J PHARMACOL TOX MET, V39, P51, DOI 10.1016/S1056-8719(98)00002-1
   Ramirez JA, 1996, ANN INTERN MED, V125, P979, DOI 10.7326/0003-4819-125-12-199612150-00008
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Sahni SK, 2007, THROMB RES, V119, P531, DOI 10.1016/j.thromres.2006.06.006
   Schwartzs SG, 2006, CURR DIABETES REV, V9, P86
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Son JW, 2011, DIABETES RES CLIN PR, V91, P253, DOI 10.1016/j.diabres.2010.11.005
   Stephens RS, 2003, TRENDS MICROBIOL, V11, P44, DOI 10.1016/S0966-842X(02)00011-2
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Virok DP, 2005, INFECT IMMUN, V73, P1939, DOI 10.1128/IAI.73.4.1939-1946.2005
   Wang CM, 2009, J INFECT DIS, V200, P279, DOI 10.1086/599796
   Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X
   Yoshimura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008158
   Zong HL, 2011, CURR DIABETES REP, V11, P244, DOI 10.1007/s11892-011-0198-7
NR 45
TC 0
Z9 1
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1520-7552
EI 1520-7560
J9 DIABETES-METAB RES
JI Diabetes-Metab. Res. Rev.
PD FEB
PY 2015
VL 31
IS 2
BP 168
EP 174
DI 10.1002/dmrr.2581
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA CB9RJ
UT WOS:000349969600006
PM 25066224
DA 2022-11-30
ER

PT J
AU Klettner, A
   Recber, M
   Roider, J
AF Klettner, Alexa
   Recber, Muhammed
   Roider, Johann
TI Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab
   in an RPE/choroid organ culture
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Ranibizumab; Bevacizumab; VEGF; Efficacy
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; MACULAR
   DEGENERATION; IN-VITRO; PROLONGED BLOCKADE; GANGLION-CELLS; VEGF TRAP;
   PATHWAYS; ACTIVATION; EXPRESSION
AB Purpose Anti-VEGF treatment is the therapy of choice in age-related macular degeneration and is also applied in diabetic macular edema or retinal vein occlusion. Recently, aflibercept has been approved for therapeutic use. In this study, we investigate the efficacy of aflibercept in comparison with the VEGF-antagonists ranibizumab and bevacizumab in RPE/choroid organ cultures.
   Methods RPE/choroid organ cultures were prepared from freshly slaughtered pigs' eyes. Organ cultures were treated with 125 mu g/ml aflibercept, ranibizumab, or bevacizumab, and the VEGF content of the supernatant was evaluated over the course of 7 days. Additionally, the minimal concentration of VEGF inhibition was evaluated in organ cultures, measured after 6 h of application.
   Results Aflibercept was able to completely inhibit VEGF detection for 6 h at a minimal concentration of 0.031 mu g/ml, in contrast to bevacizumab (3.9 mu g/ml) and ranibizumab (0.244 mu g/ml). A statistically significant VEGF inhibition compared to control could be found for aflibercept and ranibizumab down to and including 0.031 mu g/ml, while bevacizumab was significantly reduced compared to control down to a concentration of 0.244 mu g/ml and again at 0.061 mu g/ml. Inhibition of VEGF after a single aflibercept application of 125 mu g/ml could be found over the course of 7 days, with some VEGF detectable at the 7th day. In contrast, VEGF was detectable after 72 h of ranibizumab treatment and some VEGF could already be found 12 h after bevacizumab treatment.
   Conclusions In conclusion, aflibercept displays a prolonged VEGF inhibition, confirming its effectiveness but also raising concerns about possible side effects of long-term usage.
C1 [Klettner, Alexa; Recber, Muhammed; Roider, Johann] Univ Kiel, Med Ctr, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel
RP Klettner, A (通讯作者)，Univ Kiel, Med Ctr, Dept Ophthalmol, Arnold Heller Str 3, D-24105 Kiel, Germany.
EM aklettner@auge.uni-kiel.de
RI Klettner, Alexa Karina/M-8344-2018
OI Klettner, Alexa/0000-0002-2709-1059
FU Novartis; Novartis Pharma
FX This research was financially supported by a Novartis research grant. AK
   has been a consultant for and received lecture fees and travel grants by
   Novartis Pharma. Parts of the data presented here have been presented at
   the DOG meeting 2013.
CR Butler JE, 2006, DEV COMP IMMUNOL, V30, P199, DOI 10.1016/j.dci.2005.06.025
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Jin J, 2013, MOL CELL BIOCHEM, V381, P267, DOI 10.1007/s11010-013-1710-y
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Klettner A., 2013, VASCULAR ENDOTHELIAL, P117
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2013, ACTA OPHTHALMOL, V91, pE211, DOI 10.1111/aos.12031
   Klettner AK, 2012, GRAEF ARCH CLIN EXP, V250, P33, DOI 10.1007/s00417-011-1776-8
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lassota N, 2008, ACTA OPHTHALMOL, V86, P495, DOI [10.1111/j.1600-0420.2007.01127.x, 10.1111/j.1755-3768.2008.01412.x]
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Middleton S, 2010, VET CLIN N AM-FOOD A, V26, P557, DOI 10.1016/j.cvfa.2010.09.002
   Miki A, 2010, J CELL PHYSIOL, V224, P262, DOI 10.1002/jcp.22129
   Minuth WW, 1996, BIOTECHNIQUES, V20, P498
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Miura Y, 2010, OPHTHAL RES, V43, P122, DOI 10.1159/000252979
   Ottino P, 2004, MOL VIS, V10, P341
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sanchez I, 2011, GRAEF ARCH CLIN EXP, V249, P475, DOI 10.1007/s00417-011-1617-9
   Shiose S, 2004, GRAEF ARCH CLIN EXP, V242, P777, DOI 10.1007/s00417-004-0910-2
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Yang PZ, 2002, INVEST OPHTH VIS SCI, V43, P1488
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
NR 33
TC 37
Z9 38
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2014
VL 252
IS 10
BP 1593
EP 1598
DI 10.1007/s00417-014-2719-y
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT0NB
UT WOS:000344631600010
PM 25047874
DA 2022-11-30
ER

PT J
AU Cooper, AE
   Ahonen, S
   Rowlan, JS
   Duncan, A
   Seppala, EH
   Vanhapelto, P
   Lohi, H
   Komaromy, AM
AF Cooper, Ann E.
   Ahonen, Saija
   Rowlan, Jessica S.
   Duncan, Alison
   Seppala, Eija H.
   Vanhapelto, Paivi
   Lohi, Hannes
   Komaromy, Andras M.
TI A Novel Form of Progressive Retinal Atrophy in Swedish Vallhund Dogs
SO PLOS ONE
LA English
DT Article
ID CANINE MULTIFOCAL RETINOPATHY; VITAMIN-E-DEFICIENCY; CONE-ROD DYSTROPHY;
   RETINITIS-PIGMENTOSA; GENE-THERAPY; NONSENSE MUTATION; ANIMAL-MODEL;
   DEGENERATION; DELETION; ACHROMATOPSIA
AB Inherited retinal degenerations, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), represent leading causes of incurable blindness in humans. This is also true in dogs, where the term progressive retinal atrophy (PRA) is used to describe inherited photoreceptor degeneration resulting in progressive vision loss. Because of the similarities in ocular anatomy, including the presence of a cone photoreceptor-rich central retinal region, and the close genotype-phenotype correlation, canine models contribute significantly to the understanding of retinal disease mechanisms and the development of new therapies. The screening of the pure-bred dog population for new forms of PRA represents an important strategy to establish new large animal models. By examining 324 dogs of the Swedish vallhund breed in seven countries and across three continents, we were able to describe a new and unique form of PRA characterized by the multifocal appearance of red and brown discoloration of the tapetal fundus followed over time by thinning of the retina. We propose three stages of the disease based on the appearance of the ocular fundus and associated visual deficits. Electroretinography revealed a gradual loss of both rod and cone photoreceptor-mediated function in Stages 2 and 3 of the disease. In the few dogs that suffered from pronounced vision loss, night-blindness occurred first in late Stage 2, followed by decreased day-vision in Stage 3. Histologic examinations confirmed the loss of photoreceptor cells at Stage 3, which was associated with the accumulation of autofluorescent material in the adjacent retinal pigment epithelium. Pedigree analysis was suggestive of an autosomal-recessive mode of inheritance. Mutations in six known canine retinal degeneration genes as well as hypovitaminosis E were excluded as causes of the disease. The observed variability in the age of disease onset and rate of progression suggest the presence of genetic and/or environmental disease modifiers.
C1 [Cooper, Ann E.; Komaromy, Andras M.] Michigan State Univ, Coll Vet Med, Dept Small Anim Clin Sci, E Lansing, MI 48824 USA.
   [Cooper, Ann E.; Rowlan, Jessica S.; Duncan, Alison; Komaromy, Andras M.] Univ Penn, Sch Vet Med, Dept Clin Studies, Philadelphia, PA 19104 USA.
   [Cooper, Ann E.] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA USA.
   [Ahonen, Saija; Seppala, Eija H.; Lohi, Hannes] Univ Helsinki, Dept Vet Biosci, Helsinki, Finland.
   [Ahonen, Saija; Seppala, Eija H.; Lohi, Hannes] Univ Helsinki, Res Programs Unit, Helsinki, Finland.
   [Ahonen, Saija; Seppala, Eija H.; Lohi, Hannes] Folkhalsan Inst Genet, Helsinki, Finland.
   [Rowlan, Jessica S.] Univ Washington, Sch Med, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Vanhapelto, Paivi] Vet Clin Vetset, Kyrkslatt, Finland.
C3 Michigan State University; University of Pennsylvania; University of
   California System; University of California Irvine; University of
   Helsinki; University of Helsinki; University of Washington; University
   of Washington Seattle
RP Komaromy, AM (通讯作者)，Michigan State Univ, Coll Vet Med, Dept Small Anim Clin Sci, E Lansing, MI 48824 USA.
EM komaromy@cvm.msu.edu
RI Lohi, Hannes/F-4596-2011
OI Lohi, Hannes/0000-0003-1087-5532; Ahonen, Saija/0000-0003-3313-784X
FU NIH [K12-EY15398, R01-EY019304, R01-EY06855]; Academy of Finland; Sigrid
   Juselius Foundation; Biocentrum Helsinki; Jane and Aatos Erkko
   Foundation; University of Helsinki Research Funds; Folkhalsan Research
   Centre; NATIONAL EYE INSTITUTE [R01EY006855, R01EY019304, K12EY015398]
   Funding Source: NIH RePORTER
FX This study was supported by NIH grants K12-EY15398, R01-EY019304,
   R01-EY06855, Academy of Finland, Sigrid Juselius Foundation, Biocentrum
   Helsinki, Jane and Aatos Erkko Foundation, University of Helsinki
   Research Funds and Folkhalsan Research Centre. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Acland GM, 2004, VET OPHTHALMOL, V7, P439
   Aguirre G D, 1998, Mol Vis, V4, P23
   AGUIRRE GD, 1988, EXP EYE RES, V46, P663, DOI 10.1016/S0014-4835(88)80055-1
   Aguirre GK, 2007, PLOS MED, V4, P1117, DOI 10.1371/journal.pmed.0040230
   American College of Veterinary Ophthalmologists, 2013, OC DIS PRES BE INH P
   Balicki I, 2013, VET OPHTHALMOL, V16, P397, DOI 10.1111/vop.12007
   Beltran WA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090390
   Beltran WA, 2012, P NATL ACAD SCI USA, V109, P2132, DOI 10.1073/pnas.1118847109
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Cideciyan AV, 2005, P NATL ACAD SCI USA, V102, P5233, DOI 10.1073/pnas.0408892102
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   CLEMENTS PJM, 1993, CURR EYE RES, V12, P861, DOI 10.3109/02713689309020391
   Daiger SP, 2013, CLIN GENET, V84, P132, DOI 10.1111/cge.12203
   Davidson MG, 1998, J AM VET MED ASSOC, V213, P645
   Ekesten B, 2013, DOC OPHTHALMOL, V127, P79, DOI 10.1007/s10633-013-9388-8
   Guyon R, 2007, MOL VIS, V13, P1094
   Guziewicz KE, 2007, INVEST OPHTH VIS SCI, V48, P1959, DOI 10.1167/iovs.06-1374
   Guziewicz KE, 2011, INVEST OPHTH VIS SCI, V52, P4497, DOI 10.1167/iovs.10-6385
   HUGHES PL, 1987, VET PATHOL, V24, P22, DOI 10.1177/030098588702400105
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Klein R, 2013, INVEST OPHTHALMOL VI, V54, pORSF5
   Komaromy AM, 2010, HUM MOL GENET, V19, P2581, DOI 10.1093/hmg/ddq136
   KOOIJMAN AC, 1980, INVEST OPHTH VIS SCI, V19, P315
   Lheriteau E, 2014, MOL THER, V22, P265, DOI 10.1038/mt.2013.232
   Miyadera K, 2012, MAMM GENOME, V23, P212, DOI 10.1007/s00335-011-9384-9
   Miyadera K, 2012, MAMM GENOME, V23, P40, DOI 10.1007/s00335-011-9361-3
   Mowat FM, 2008, MOL VIS, V14, P2518
   MuLellan GJ, 2002, VET REC, V151, P663, DOI 10.1136/vr.151.22.663
   Narfstrom KN., 2013, VET OPHTHALMOL, V5th ed., P1303
   Parker HG, 2007, GENOME RES, V17, P1562, DOI 10.1101/gr.6772807
   Petersen-Jones SM, 1999, INVEST OPHTH VIS SCI, V40, P1637
   Petit L, 2012, MOL THER, V20, P2019, DOI 10.1038/mt.2012.134
   RAY K, 1994, INVEST OPHTH VIS SCI, V35, P4291
   RIIS RC, 1981, AM J VET RES, V42, P74
   Sidjanin DJ, 2002, HUM MOL GENET, V11, P1823, DOI 10.1093/hmg/11.16.1823
   Storey ES, 2005, VET OPHTHALMOL, V8, P337, DOI 10.1111/j.1463-5224.2005.00423.x
   SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754
   Wiik AC, 2008, GENOME RES, V18, P1415, DOI 10.1101/gr.074302.107
   Yeh CY, 2013, BMC GENET, V14, DOI 10.1186/1471-2156-14-27
   Zangerl B, 2006, GENOMICS, V88, P551, DOI 10.1016/j.ygeno.2006.07.007
   Zangerl B, 2010, MOL VIS, V16, P2791
NR 43
TC 13
Z9 13
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 8
PY 2014
VL 9
IS 9
AR e106610
DI 10.1371/journal.pone.0106610
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AO4JX
UT WOS:000341304700034
PM 25198798
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Chiang, PPC
   Lamoureux, EL
   Zheng, Y
   Tay, WT
   Mitchell, P
   Wang, JJ
   Wong, TY
AF Chiang, P. P. -C.
   Lamoureux, E. L.
   Zheng, Y.
   Tay, W. T.
   Mitchell, P.
   Wang, J. J.
   Wong, T. Y.
TI Frequency and risk factors of non-retinopathy ocular conditions in
   people with diabetes: the Singapore Malay Eye Study
SO DIABETIC MEDICINE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; RETINAL VEIN OCCLUSION; BLUE MOUNTAINS EYE;
   CARDIOVASCULAR-DISEASE; EPIRETINAL MEMBRANES; VISUAL IMPAIRMENT;
   PREVALENCE; CATARACT; POPULATION; ABNORMALITIES
AB Aim To investigate the frequency and risk factors of non-retinopathy ocular conditions in persons with diabetes.
   Methods A population-based cross-sectional study of 3176 Malay persons aged between 40 and 79 years in Singapore was conducted. Cataract, glaucoma, refractive errors, age-related macular degeneration, dry eye, epiretinal membrane, ocular hypertension and retinal conditions were assessed based on standardized interviews, clinical examinations and laboratory investigations.
   Results A total of 768 participants (24.2%) had diabetes. People with diabetes were more likely to have cortical cataract (52.1 vs. 37.3%, P < 0.001), ocular hypertension (10.9 vs. 7.4%, P = 0.002) and epiretinal membrane (17.2 vs. 10.1%, P < 0.001) compared with those without diabetes. The odds of having cortical cataract (odds ratio 1.63, 95% CI 1.202.20) and epiretinal membrane (among those with previous cataract surgery: odds ratio 1.63, 95% CI 1.202.20) were significantly higher in people with diabetes compared with those without. The population attributable risks for cortical cataract and epiretinal membrane because of diabetes were 8.7 and 9.0%, respectively. In persons with diabetes, hypertension and high cholesterol were the major risk factors associated with non-retinopathy eye complications such as ocular hypertension (odds ratio 1.18, 95% CI 1.041.33) and retinal emboli (odds ratio 1.99, 95% CI 1.053.80).
   Conclusion Our results allow clinicians to better inform patients with diabetes that they are more likely to have cortical cataract and epiretinal membranes (those with previous cataract surgery) in addition to diabetic retinopathy. Two modifiable risk factorsblood pressure and cholesterol associated with ocular hypertension and retinal emboli, respectivelyare also risk factors for non-retinopathy ocular conditions in persons with diabetes.
C1 [Chiang, P. P. -C.; Lamoureux, E. L.; Zheng, Y.; Tay, W. T.; Wong, T. Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Lamoureux, E. L.; Wang, J. J.; Wong, T. Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Mitchell, P.; Wang, J. J.] Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Wong, T. Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
   [Wang, J. J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth, Singapore 117595, Singapore.
C3 National University of Singapore; Singapore National Eye Center; Centre
   for Eye Research Australia; University of Melbourne; University of
   Sydney; National University of Singapore; National University of
   Singapore
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
EM ophwty@nus.edu.sg
RI Zheng, Yingfeng/CAE-9225-2022; Mitchell, Paul/P-1498-2014; Zheng,
   Yingfeng/AAE-2983-2022; Wang, Jie Jin/P-1499-2014; Lamoureux,
   Ecosse/Z-5482-2019; wang, jie/GRS-0942-2022; Wong, Tien
   Yin/AAC-9724-2020
OI Zheng, Yingfeng/0000-0002-0914-7864; Wang, Jie Jin/0000-0001-9491-4898;
   Wong, Tien Yin/0000-0002-8448-1264
FU Biomedical Research Council (BMRC) [08/1/35/19/550]; National Medical
   Research Council (NMRC), Singapore [STaR/0003/2008]
FX This study was funded by the Biomedical Research Council (BMRC),
   08/1/35/19/550, and the National Medical Research Council (NMRC),
   STaR/0003/2008, Singapore.
CR Aksoy H, 2001, CLIN CHEM LAB MED, V39, P143, DOI 10.1515/CCLM.2001.024
   Anderson R, 2000, DIABETES, V63, P619
   Boisjoly H, 1999, AM J OPHTHALMOL, V128, P38, DOI 10.1016/S0002-9394(99)00071-9
   Cajucom-Uy H, 2010, BRIT J OPHTHALMOL, V94, P977, DOI 10.1136/bjo.2008.150847
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chiang PPC, 2011, INVEST OPHTH VIS SCI, V52, P7586, DOI 10.1167/iovs.11-7698
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Foong AWP, 2007, OPHTHAL EPIDEMIOL, V14, P25, DOI 10.1080/09286580600878844
   Jahn CE, 2001, J CATARACT REFR SURG, V27, P753, DOI 10.1016/S0886-3350(00)00686-6
   Kawasaki R, 2008, BRIT J OPHTHALMOL, V92, P1320, DOI 10.1136/bjo.2008.144626
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Leske MC, 1999, OPHTHALMOLOGY, V106, P35, DOI 10.1016/S0161-6420(99)90003-9
   McCarty CA, 1998, BRIT J OPHTHALMOL, V82, P410, DOI 10.1136/bjo.82.4.410
   Mitchell P, 1997, STROKE, V28, P63, DOI 10.1161/01.STR.28.1.63
   Mitchell P, 2005, AM J OPHTHALMOL, V140, P131, DOI 10.1016/j.ajo.2004.12.088
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P1033, DOI 10.1016/S0161-6420(97)30190-0
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Ng CH, 2011, OPHTHALMOLOGY, V118, P694, DOI 10.1016/j.ophtha.2010.08.009
   Raman R, 2010, INVEST OPHTH VIS SCI, V51, P6253, DOI 10.1167/iovs.10-5414
   Saw SM, 2008, OPHTHALMOLOGY, V115, P1713, DOI 10.1016/j.ophtha.2008.03.016
   Shahsuvaryan ML, 2003, EUR J OPHTHALMOL, V13, P445, DOI 10.1177/112067210301300505
   Sinclair AJ, 2000, AGE AGEING, V29, P335, DOI 10.1093/ageing/29.4.335
   Su DHW, 2008, OPHTHALMOLOGY, V115, P964, DOI 10.1016/j.ophtha.2007.08.021
   Tan DTH, 1997, ARCH OPHTHALMOL-CHIC, V115, P1235, DOI 10.1001/archopht.1997.01100160405001
   Tan GS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1354, DOI 10.1001/archophthalmol.2009.268
   Tan JSL, 2008, OPHTHAL EPIDEMIOL, V15, P317, DOI 10.1080/09286580802105806
   Tuomilehto J, 2003, DIABETES CARE, V26, P1770
   VINE AK, 1993, SURV OPHTHALMOL, V37, P283, DOI 10.1016/0039-6257(93)90011-U
   Wong TY, 2008, OPHTHALMOLOGY, V115, P1869, DOI 10.1016/j.ophtha.2008.05.014
   Wong Tien Yin, 2002, Curr Opin Ophthalmol, V13, P142, DOI 10.1097/00055735-200206000-00002
   Wong TY, 2005, ARCH INTERN MED, V165, P1060, DOI 10.1001/archinte.165.9.1060
   Wong TY, 2005, OPHTHALMOLOGY, V112, P540, DOI 10.1016/j.ophtha.2004.10.039
   Xu L, 2005, BR J OPHTHALMOL, V87, P1432
   Zheng YF, 2012, OPHTHALMOLOGY, V119, P2119, DOI 10.1016/j.ophtha.2012.04.027
NR 36
TC 16
Z9 17
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
EI 1464-5491
J9 DIABETIC MED
JI Diabetic Med.
PD FEB
PY 2013
VL 30
IS 2
BP E32
EP E40
DI 10.1111/dme.12053
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 075HV
UT WOS:000313876500001
PM 23074990
DA 2022-11-30
ER

PT J
AU Hogg, RE
   Ong, EL
   Chamberlain, M
   Dirani, M
   Baird, PN
   Guymer, RH
   Fitzke, F
AF Hogg, R. E.
   Ong, E. L.
   Chamberlain, M.
   Dirani, M.
   Baird, P. N.
   Guymer, R. H.
   Fitzke, F.
TI Heritability of the spatial distribution and peak density of macular
   pigment: a classical twin study
SO EYE
LA English
DT Article
DE twin study; macular pigment; lutein; zeaxanthin; heritability
ID AGE-RELATED MACULOPATHY; OPTICAL-DENSITY; HUMAN RETINA; FUNDUS
   AUTOFLUORESCENCE; BINDING PROTEIN; LUTEIN; DEGENERATION; ZEAXANTHIN;
   SAMPLE; CAROTENOIDS
AB Purpose To elucidate the heritability of peak density and spatial width of macular pigment (MP) using a Classical Twin Study.
   Methods Fundus autofluorescence images were obtained at 488 nm from 86 subjects or 43 twin pairs (21 monozygotic (MZ) and 22 dizygotic (DZ)) (27 male, 59 female) aged from 55 to 76 years (mean 62.2 +/- 5.3 years). The relative topographic distribution of MP was measured using a grey scale of intensity (0-255 units) in a 71 eccentricity around the fovea. Relative peak MP density (rPMPD) and relative spatial distribution of MP (rSDMP) were used as the main outcome measure in the statistical analysis.
   Results A significantly higher correlation was found within MZ pairs as compared with that within DZ pairs for rPMPD, (r = 0.99, 95% confidence interval (95% CI) 0.93 to 1.00) and 0.22, 95% CI -0.34 to 0.71), respectively, suggesting strong heritability of this trait. When rSDMP was compared, there was no significant difference between the correlations within MZ pairs (r = 0.48, 95% CI -0.02 to 0.83) and DZ pairs (r = 0.63, 95% CI 0.32 to 0.83), thus rSDMP is unlikely to have a considerable heritable component. In addition, there was no difference between any MP parameter when normal maculae were compared with early age-related macular degeneration (AMD) (rPMPD 0.36 vs 0.34, t = 1.18 P = 0.243, rSDMP 1.75 vs 1.75, t = 0.028 P = 0.977).
   Conclusions rPMPD is a strongly heritable trait whereas rSDMP has minimal genetic influence and a greater influence by environmental factors. The presence of macular changes associated with early AMD did not appear to influence any of these pigment parameters. Eye (2012) 26, 1217-1225; doi:10.1038/eye.2012.98; published online 29 June 2012
C1 [Hogg, R. E.] Queens Univ, Ctr Vis & Vasc Sci, Inst Clin Sci A, Belfast BT12 6BA, Antrim, North Ireland.
   [Hogg, R. E.; Ong, E. L.; Chamberlain, M.; Dirani, M.; Baird, P. N.; Guymer, R. H.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Ong, E. L.; Fitzke, F.] UCL Inst Ophthalmol, Dept Visual Neurosci, London, England.
C3 Queens University Belfast; Centre for Eye Research Australia; Royal
   Victorian Eye & Ear Hospital; University of Melbourne; University of
   London; University College London
RP Hogg, RE (通讯作者)，Queens Univ, Ctr Vis & Vasc Sci, Inst Clin Sci A, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM r.e.hogg@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Baird, Paul/0000-0002-1305-3502;
   Guymer, Robyn/0000-0002-9441-4356
FU National Health and Medical Research Council (NHMRC) Centre for Clinical
   Research Excellence [529923]; NHMRC Career Development Award; NHMRC
   practitioner fellowship; Ophthalmic Research Institute of Australia
FX We thank Dr Andrew Anderson for his help in writing the software used
   for the bootstrapping procedure. We thank the Australian Twin Registry
   for access to this national resource. This work was supported by the
   National Health and Medical Research Council (NHMRC) Centre for Clinical
   Research Excellence (#529923), NHMRC Career Development Award (RHG), and
   a NHMRC practitioner fellowship (RHG). This work was also supported by a
   grant from the Ophthalmic Research Institute of Australia. CERA receives
   Operational Infrastructure Support from the Victorian Government.
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1992, METHOD ENZYMOL, V213, P360
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Chamberlain MD, 2006, INVEST OPHTH VIS SCI, V47, P336, DOI 10.1167/iovs.05-0599
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P8016, DOI 10.1167/iovs.11-7610
   FOSTER DH, 1987, BIOL CYBERN, V57, P341, DOI 10.1007/BF00338826
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Hewitt AW, 2007, INVEST OPHTH VIS SCI, V48, P2469, DOI 10.1167/iovs.06-1470
   Hogg RE, 2009, OPHTHALMOLOGY, V116, P263, DOI 10.1016/j.ophtha.2008.09.002
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   KHACHIK F, 1992, J CHROMATOGR-BIOMED, V582, P153, DOI 10.1016/0378-4347(92)80314-G
   Kirby ML, 2009, INVEST OPHTH VIS SCI, V50, P1383, DOI 10.1167/iovs.08-2494
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   MALONEY LT, 1990, PERCEPT PSYCHOPHYS, V47, P127, DOI 10.3758/BF03205977
   MARTIN NG, 1975, ANN HUM GENET, V39, P213, DOI 10.1111/j.1469-1809.1975.tb00124.x
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Robson AG, 2005, PERCEPTION, V34, P1029, DOI 10.1068/p5196
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   Sasamoto Y, 2011, INVEST OPHTH VIS SCI, V52, P927, DOI 10.1167/iovs.10-5664
   Sharifzadeh M, 2008, J OPT SOC AM A, V25, P947, DOI 10.1364/JOSAA.25.000947
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Stockman A, 1999, VISION RES, V39, P2901, DOI 10.1016/S0042-6989(98)00225-9
   Taylor H R, 1988, Yan Ke Xue Bao, V4, P14
   TEIKARI JM, 1992, BRIT J OPHTHALMOL, V76, P218, DOI 10.1136/bjo.76.4.218
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Trieschmann M, 2003, GRAEF ARCH CLIN EXP, V241, P1006, DOI 10.1007/s00417-003-0796-4
   Wenzel AJ, 2007, OPHTHAL PHYSL OPT, V27, P329, DOI 10.1111/j.1475-1313.2007.00495.x
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
NR 54
TC 10
Z9 10
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD SEP
PY 2012
VL 26
IS 9
BP 1217
EP 1225
DI 10.1038/eye.2012.98
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004NN
UT WOS:000308688500008
PM 22744384
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Lei, L
   Tzekov, R
   Tang, SB
   Kaushal, S
AF Lei, Lei
   Tzekov, Radouil
   Tang, Shibo
   Kaushal, Shalesh
TI Accumulation and autofluorescence of phagocytized rod outer segment
   material in macrophages and microglial cells
SO MOLECULAR VISION
LA English
DT Article
ID MEDIATED PHAGOCYTOSIS; SUBRETINAL MICROGLIA; LIPOFUSCIN; PHOTORECEPTORS;
   FLUORESCENCE; BINDING
AB Purpose: To explore the ability of macrophages and microglial cells to phagocytize rod outer segments (ROSs) in a cell culture and characterize the resulting lipofuscin-like autofluorescence (LLAF).
   Methods: Either regular or modified ROSs or ROS components (11-cis-retinal, all-trans-retinal, lipids) were fed to macrophages and microglial cells for 4 days. Afterwards, autofluorescence was detected by fluorescence-activated cell sorting (FACS) at two different wavelengths (533 nm and 585 nm), and the cells were imaged by confocal and electron microscopy. Fluorescein isothiocyanate (FITC)-labeled ROSs were added to macrophage and microglial cell cultures for 1-24 h to determine the kinetics of phagocytosis in these cell lines.
   Results: Feeding with different ROSs or ROS components led to a significant increase in LLAF in both microglia and macrophages. The 4-hydroxynonenal (HNE)-modified ROSs gave rise to the highest increase in LLAF at both 533 nm and 585 nm. Application of 11-cis-retinal or all-trans-retinal resulted in higher LLAF at 585 nm, compared to application of 9-cis-retinal or liposomes. Fluorescein isothiocyanate-labeled ROSs co-localized well with lysosomes in both types of cells. HNE-modified ROSs were phagocytized more rapidly by both types of cells, compared to unmodified ROSs. Electron microscopy demonstrated inclusion bodies containing whorls of membranes in all types of cells fed with ROSs.
   Conclusions: Both macrophages and microglia have the ability to phagocytize ROSs, and this results in increased autofluorescence. Oxidation of ROSs results in faster phagocytosis, higher levels of LLAF, and the appearance of more inclusion bodies inside the cells. Results from the present study suggest that both types of cells accumulate lipofuscin-like material under physiologically relevant conditions. Such accumulation could interfere with their ability to clear cellular debris and could be part of the pathogenetic mechanism for age-related macular degeneration and other lipofuscinopathies.
C1 [Lei, Lei; Tzekov, Radouil; Kaushal, Shalesh] Univ Massachusetts, Sch Med, Dept Ophthalmol, Worcester, MA 01605 USA.
   [Lei, Lei; Tang, Shibo] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; Sun Yat Sen University
RP Kaushal, S (通讯作者)，Univ Massachusetts, Sch Med, Dept Ophthalmol, 381 Plantat St, Worcester, MA 01605 USA.
EM shalesh.kaushal@umassmemorial.org
RI TANG, Shi/GXH-5719-2022
OI Tzekov, Radouil/0000-0002-3662-9818
FU University of Massachusetts Department of Ophthalmology
FX Dr. Salesh Kaushal and Dr. Shibo Tang (tangsb@sysu.edu.cn) contributed
   equally to the conduct of this research and are to be considered
   co-corresponding authors. We thank the following people for providing
   the following cell lines or constructs used in this study: Kenneth Rock
   for murine macrophage cell line, Douglas Golenbock for the microglia
   cell line. We thank Gregory Hendricks and Lara Strittmater for help with
   electron micrographs. We thank Paul Furcinitti for help with confocal
   microscopy. This work is supported by University of Massachusetts
   Department of Ophthalmology Research and Education fund.
CR Anwar A, 2009, J LEUKOCYTE BIOL, V86, P73, DOI [10.1189/JLB.0608334, 10.1189/jlb.0608334]
   Bindewald-Wittich A, 2006, INVEST OPHTH VIS SCI, V47, P4553, DOI 10.1167/iovs.05-1562
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   BRIDGES CDB, 1984, VISION RES, V24, P1581, DOI 10.1016/0042-6989(84)90316-X
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Finnemann SC, 1999, J EXP MED, V190, P861, DOI 10.1084/jem.190.6.861
   Forrester JV, 2010, IMMUNOL REV, V234, P282, DOI 10.1111/j.0105-2896.2009.00873.x
   GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H
   GERY I, 1981, INVEST OPHTH VIS SCI, V20, P675
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100
   Hisatomi T, 2003, AM J PATHOL, V162, P1869, DOI 10.1016/S0002-9440(10)64321-0
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Jung T, 2007, ANN NY ACAD SCI, V1119, P97, DOI 10.1196/annals.1404.008
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9
   KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942
   KRINSKY NI, 1958, ARCH OPHTHALMOL-CHIC, V60, P688
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48
   Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Uehara H, 2008, J IMMUNOL, V180, P2522, DOI 10.4049/jimmunol.180.4.2522
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
NR 33
TC 23
Z9 31
U1 0
U2 9
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 17
PY 2012
VL 18
IS 12-14
BP 103
EP 113
PG 11
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 904ZF
UT WOS:000301238700002
PM 22275801
DA 2022-11-30
ER

PT J
AU Wolf-Schnurrbusch, UEK
   Wittwer, VV
   Ghanem, R
   Niederhaeuser, M
   Enzmann, V
   Framme, C
   Wolf, S
AF Wolf-Schnurrbusch, Ute E. K.
   Wittwer, Valery V.
   Ghanem, Ramzi
   Niederhaeuser, Martin
   Enzmann, Volker
   Framme, Carsten
   Wolf, Sebastian
TI Blue-Light versus Green-Light Autofluorescence: Lesion Size of Areas of
   Geographic Atrophy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR PIGMENT DENSITY; SCANNING LASER OPHTHALMOSCOPE; AGE-RELATED
   MACULOPATHY; FUNDUS AUTOFLUORESCENCE; BRUCHS MEMBRANE; HEALTHY-SUBJECTS;
   DEGENERATION; RETINA; CAROTENOIDS; EPITHELIUM
AB PURPOSE. Blue-light fundus autofluorescence (FAF) imaging is currently widely used for assessing dry age-related macular degeneration (ARMD). However, at this wavelength, the fovea appears as circular zone of marked hypofluorescence, due to the absorption of macular pigment (MP). This dark spot could be misinterpreted as an atrophic area and could lead to difficulties in identifying small, central changes. The purpose of the study was to analyze differences in image quality, FAF patterns, and lesion size, when using conventional blue-light (Lambda(1) = 488 nm) and green-light (Lambda(2) = 514 nm) FAF.
   METHODS. Patients older than 50 years with central areas of geographic atrophy (GA) secondary to ARMD were enrolled. Images were recorded with a modified confocal scanning laser ophthalmoscope (cSLO). Image quality and patterns were analyzed. The quantification of the GA was performed with customized image-analysis software.
   RESULTS. In total, 95 eyes were included. The borders of the central atrophic patches and the boundaries of the preserved foveal island were better identified in 514-nm images. In both excitation wavelengths the signal-to-noise ratio was sufficient for the identification of the FAF pattern. Significant differences were observed in the size of the GA areas detected in the 488 and 514-nm wavelength images (4.29 +/- 3.76 mm(2) vs. 3.80 +/- 3.68 mm(2); P < 0.001).
   CONCLUSIONS. The green-light FAF images (514 nm) are superior for the accurate analysis of small, central, pathologic changes, and for the determination of the central GA lesion size. Using only blue-light FAF could lead to an overinterpretation of the size of atrophic patches and the center involvement, because it suggests the presence of atrophy in the fovea. (ClinicalTrials. gov number, NCT00494325.) (Invest Ophthalmol Vis Sci. 2011;52:9497-9502) DOI:10.1167/iovs.11-8346
C1 [Wolf-Schnurrbusch, Ute E. K.] Univ Bern, Inselspital, Univ Eye Hosp, Univ Klin Augenheilkunde, CH-3010 Bern, Switzerland.
   [Wolf-Schnurrbusch, Ute E. K.; Wittwer, Valery V.; Niederhaeuser, Martin; Wolf, Sebastian] Univ Bern, Inselspital, Bern Photog Reading Ctr, CH-3010 Bern, Switzerland.
   [Ghanem, Ramzi] HELIOS Klin, Aue, Germany.
C3 University of Bern; University Hospital of Bern; University of Bern;
   University Hospital of Bern; Helios Kliniken
RP Wolf-Schnurrbusch, UEK (通讯作者)，Univ Bern, Inselspital, Univ Eye Hosp, Univ Klin Augenheilkunde, CH-3010 Bern, Switzerland.
EM ute.wolf@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Enzmann, Volker/0000-0003-4384-4855
CR BIRD AC, 1991, EYE, V5, P1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hammond BR, 1997, OPTOMETRY VISION SCI, V74, P499, DOI 10.1097/00006324-199707000-00017
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 1999, BRIT J OPHTHALMOL, V83, P276, DOI 10.1136/bjo.83.3.276
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Scholl HPN, 2004, OPHTHALMOLOGY, V111, P125, DOI 10.1016/j.ophtha.2003.05.003
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
NR 28
TC 37
Z9 37
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2011
VL 52
IS 13
BP 9497
EP 9502
DI 10.1167/iovs.11-8346
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 869WC
UT WOS:000298628200032
PM 22110076
DA 2022-11-30
ER

PT J
AU Finger, RP
   Fenwick, E
   Marella, M
   Dirani, M
   Holz, FG
   Chiang, PPC
   Lamoureux, EL
AF Finger, Robert P.
   Fenwick, Eva
   Marella, Manjula
   Dirani, Mohammed
   Holz, Frank G.
   Chiang, Peggy Pei-Chia
   Lamoureux, Ecosse L.
TI The Impact of Vision Impairment on Vision-Specific Quality of Life in
   Germany
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SINGAPORE MALAY EYE; MACULAR DEGENERATION; VISUAL IMPAIRMENT; RASCH
   ANALYSIS; OLDER-ADULTS; DEPRESSION; QUESTIONNAIRE; OUTCOMES; POPULATION;
   DISABILITY
AB PURPOSE. To validate the German-translated Impact of Vision Impairment (IVI) questionnaire, a vision-specific quality of life (QoL) scale, and determine the relationship between the severity of vision impairment, ocular conditions, and VRQoL.
   METHODS. This cross-sectional study was clinic based, with 184 patients with low vision recruited from an outpatient clinic at a German eye hospital. Participants underwent a clinical examination and completed the German IVI scale. The validity of the IVI scale was assessed using Rasch analysis. The main outcome measure was the overall functional and emotional score provided by the IVI.
   RESULTS. Overall, there were more female (n = 111, 60.3%) than male participants. Participants' mean +/- SD age and visual acuity in the better eye were 69.0 +/- 15.5 years and. 0.41 +/- 0.35 logMAR, respectively. The main cause of vision loss was age-related macular degeneration (n = 54, 29.3%). Rasch analysis demonstrated the validity of the German IVI to assess VRQoL through two subscales: vision-specific functioning and emotional well-being. In adjusted multivariate analysis models, those with mild or moderate/severe vision impairment reported significantly poorer vision-specific functioning (mean change, -6.5, P = 0.018 and -11.98, P < 0.001 for mild and moderate to severe VI, respectively) and emotional well-being (mean change, -2.35; P = 0.043 and -3.13, P = 0.004 for mild and moderate/severe VI respectively) compared with non-visually impaired patients.
   CONCLUSIONS. Using a psychometrically valid German IVI, even mild vision impairment was independently associated with poor VRQoL. These findings reinforce the importance of early preventative and rehabilitative efforts to prevent longitudinal deterioration in vision loss. (Invest Ophthalmol Vis Sci. 2011;52:3613-3619) DOI: 10.1167/iovs.10-7127
C1 [Finger, Robert P.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
   [Lamoureux, Ecosse L.] Singapore Eye Res Inst, Singapore, Singapore.
   [Finger, Robert P.; Fenwick, Eva; Marella, Manjula; Dirani, Mohammed; Chiang, Peggy Pei-Chia; Lamoureux, Ecosse L.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
C3 University of Bonn; National University of Singapore; Singapore National
   Eye Center; Centre for Eye Research Australia; Royal Victorian Eye & Ear
   Hospital
RP Finger, RP (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Dept Ophthalmol, Level 1,32 Gisborne St,E, Melbourne, Vic 3002, Australia.
EM robertfinger@gmx.net
RI Lamoureux, Ecosse/Z-5482-2019; Marella, Majula/AAN-2488-2021
OI Marella, Majula/0000-0002-1877-7956; Finger, Robert
   P/0000-0003-4253-7597
CR Ahmadian L, 2008, INVEST OPHTH VIS SCI, V49, P4051, DOI 10.1167/iovs.07-1507
   Bond TG, 2013, APPL RASCH MODEL FUN
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Broman AT, 2002, INVEST OPHTH VIS SCI, V43, P3393
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   du Toit R, 2010, OPHTHALMOLOGY, V117, P2308, DOI 10.1016/j.ophtha.2010.03.041
   Finger RP, 2008, OPHTHALMOLOGE, V105, P722, DOI 10.1007/s00347-008-1804-1
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Gothwal VK, 2010, J CATARACT REFR SURG, V36, P1181, DOI 10.1016/j.jcrs.2010.01.029
   Horowitz A, 2003, AGING MENT HEALTH, V7, P342, DOI 10.1080/1360786031000150739
   Keeffe JE, 1999, AUST NZ J OPHTHALMOL, V27, P184, DOI 10.1046/j.1440-1606.1999.00179.x
   Lamoreux EL, 2008, INVEST OPHTH VIS SCI, V49, P528, DOI 10.1167/iovs.07-1036
   Lamoureux E, 2011, AM J OPHTHALMOL, V151, P195, DOI 10.1016/j.ajo.2010.09.020
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1001, DOI 10.1167/iovs.06-0361
   Lamoureux EL, 2006, INVEST OPHTH VIS SCI, V47, P4732, DOI 10.1167/iovs.06-0220
   Lamoureux EL, 2009, INVEST OPHTH VIS SCI, V50, P2607, DOI 10.1167/iovs.08-2359
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Linacre J., 2012, USERS GUIDE WINSTEPS
   Linacre J M, 1998, J Outcome Meas, V2, P266
   Linacre J. M., 2008, RASCH MEASUREMENT CO
   Linacre JM, 1994, RASCH MEASUREMENT T, V7, P328
   Lundstrom M, 2009, J CATARACT REFR SURG, V35, P504, DOI 10.1016/j.jcrs.2008.11.038
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Mallinson T, 2004, MED CARE, V42, P17, DOI 10.1097/01.mlr.0000103522.78233.c3
   Mallinson T, 2007, OPTOMETRY VISION SCI, V84, P675, DOI 10.1097/OPX.0b013e3181339f44
   Nirmalan PK, 2005, INVEST OPHTH VIS SCI, V46, P2308, DOI 10.1167/iovs.04-0830
   Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004
   Nutheti R, 2007, OPHTHALMOLOGY, V114, P1552, DOI 10.1016/j.ophtha.2006.11.012
   Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016
   Pesudovs K, 2007, OPTOMETRY VISION SCI, V84, P663, DOI 10.1097/OPX.0b013e318141fe75
   Pesudovs Konrad, 2006, BMC Ophthalmol, V6, P25, DOI 10.1186/1471-2415-6-25
   Rasch G., 1993, PROBABILISTIC MODELS
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Rovner BW, 1998, J AM GERIATR SOC, V46, P617, DOI 10.1111/j.1532-5415.1998.tb01080.x
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Sloan Jeff A, 2005, COPD, V2, P57
   Tolman J, 2005, GERONTOLOGIST, V45, P747, DOI 10.1093/geront/45.6.747
   Varma R, 2006, OPHTHALMOLOGY, V113, P1846, DOI 10.1016/j.ophtha.2006.04.028
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857
NR 45
TC 57
Z9 57
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2011
VL 52
IS 6
BP 3613
EP 3619
DI 10.1167/iovs.10-7127
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 800CF
UT WOS:000293335400023
PM 21357395
DA 2022-11-30
ER

PT J
AU Murdaugh, LS
   Mandal, S
   Dill, AE
   Dillon, J
   Simon, JD
   Gaillard, ER
AF Murdaugh, L. S.
   Mandal, S.
   Dill, A. E.
   Dillon, J.
   Simon, J. D.
   Gaillard, E. R.
TI Compositional studies of human RPE lipofuscin: mechanisms of molecular
   modifications
SO JOURNAL OF MASS SPECTROMETRY
LA English
DT Article
DE lipofuscin; A2E; blue light damage; oxidative stress; age-related
   macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; AGE PIGMENT; A2E; ACCUMULATION; COMPONENT;
   ACYLTRANSFERASE; PHOTOCHEMISTRY; FLUOROPHORES; CHOLESTEROL; OXIDATION
AB The accumulation of lipofuscin has previously been implicated in several retinal diseases including Best's macular dystrophy, Stargardt's disease and age-related macular degeneration (AMD). Previously one of the major fluorophores of lipofuscin was identified as a bis-retinoid pyridinium salt called A2E, which is known to photochemically cause damage. In addition to A2E, there are numerous components in RPE lipofuscin that are unidentified. These compounds were determined to be structurally related to A2E by their fragmentation pattern with losses of 106, 190, 174 and/or 150 amu from the parent ion and the formation of fragments of ca 592 amu. The vast majority consists of relatively hydrophobic components corresponding to derivatized A2E with molecular weights in discrete groups of 800-900, 970-1080 and >1200 m/z regions. In order to determine the mechanism of these modifications, A2E was chemically modified by; (1) the formation of specific esters, (2) reaction with specific aldehydes and (3) spontaneous auto-oxidation. The contribution of ester formation to the naturally occurring components of lipofuscin was discounted since their fragmentation patterns were different to those found in vivo. Alternatively, reactions with specific aldehydes result in nearly identical products as those found in vivo. Artificial aging of RPE lipofuscin gives a complex mixture of structurally related components. This results from the auto- and/or photooxidation of A2E to form aldehydes, which then back react with A2E giving a series of higher molecular weight products. The majority of these modifications result in compounds that are much more hydrophobic than A2E. These higher molecular weight materials have increased values of log P compared to A2E. This increase in hydrophobicity most likely aids in the sequestering of A2E into granules with the concomitant diminution of its reactivity. Therefore, these processes may serve as protective mechanisms for the RPE. Copyright (C) 2010 John Wiley & Sons, Ltd.
C1 [Murdaugh, L. S.; Mandal, S.; Dill, A. E.; Dillon, J.; Gaillard, E. R.] No Illinois Univ, Dept Chem & Biochem, De Kalb, IL 60115 USA.
   [Dillon, J.; Gaillard, E. R.] Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
   [Simon, J. D.] Duke Univ, Dept Chem, Durham, NC 27706 USA.
C3 Northern Illinois University; Columbia University; Duke University
RP Gaillard, ER (通讯作者)，No Illinois Univ, Dept Chem & Biochem, De Kalb, IL 60115 USA.
EM gaillard@niu.edu
RI Gaillard, Elizabeth/M-2627-2019
CR Avalle LB, 2005, PHOTOCHEM PHOTOBIOL, V81, P1347, DOI 10.1562/2005-05-17-RN-531
   BARRY RJ, 1989, J BIOL CHEM, V264, P9231
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELDRED GE, 1993, NATURE, V364, P396
   Enzell CR, 1972, BIOCH APPL MASS SPEC, P375
   Ershov AV, 2000, CURR EYE RES, V21, P968, DOI 10.1076/ceyr.21.6.968.6987
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Gaillard ER, 2004, EXP EYE RES, V79, P313, DOI 10.1016/j.exer.2004.05.005
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Imanishi Y, 2004, J CELL BIOL, V166, P447, DOI 10.1083/jcb.200405110
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   LOPEZ PF, 1990, OPHTHALMOLOGY, V97, P798
   MACDONALD PN, 1988, J BIOL CHEM, V263, P12478
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   RABB MF, 1986, OPHTHALMOLOGY, V93, P1443
   Ragauskaite L, 2001, PHOTOCHEM PHOTOBIOL, V74, P483, DOI 10.1562/0031-8655(2001)074<0483:EEOTPO>2.0.CO;2
   Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c
   Reszka K, 1995, PHOTOCHEM PHOTOBIOL, V62, P1005
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   SAARI JC, 1989, J BIOL CHEM, V264, P8636
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   WALLER G, 1972, BIOCH APPL MASS SPEC, P377
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P1251, DOI 10.1562/2006-04-01-RA-864
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Winkler BS, 1999, MOL VIS, V5
NR 42
TC 20
Z9 20
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1076-5174
EI 1096-9888
J9 J MASS SPECTROM
JI J. Mass Spectrom.
PD JAN
PY 2011
VL 46
IS 1
BP 90
EP 95
DI 10.1002/jms.1865
PG 6
WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA 717RI
UT WOS:000287064700010
PM 21182214
DA 2022-11-30
ER

PT J
AU Sharei, V
   Hohn, F
   Kohler, T
   Hattenbach, LO
   Mirshahi, A
AF Sharei, Vahid
   Hoehn, Fabian
   Koehler, Thomas
   Hattenbach, Lars-Olof
   Mirshahi, Alireza
TI Course of intraocular pressure after intravitreal injection of 0.05 mL
   ranibizumab (Lucentis (R))
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Intraocular pressure; Ranibizumab; Wet age-related macular degeneration
ID TRIAMCINOLONE ACETONIDE INJECTION; MACULAR DEGENERATION; BLOOD-FLOW;
   IOP; BEVACIZUMAB; TRENDS; POPULATION; PEGAPTANIB; TONOMETRY; ELEVATION
AB PURPOSE. This prospective study examines the changes in short-term intraocular pressure (IOP) in patients with wet age-related macular degeneration (AMD) receiving intravitreal injections of 0.05 mL ranibizumab (Lucentis (R)) in a supine position.
   METHODS. A total of 45 eyes (45 patients, 16 M, 29 F, mean age: 78 y) received intravitreal ranibizumab injections for treatment of wet AMD (0.05 mL = 0.5 mg). The IOP was measured by Schiotz tonometry immediately preoperatively and postoperatively, and also after 3 and 10 minutes in a supine position. No history of glaucoma was present.
   RESULTS. The mean preoperative IOP was 22.4 +/- 5.5 mmHg in supine position. Immediately after the injection, IOP increased to 47.9 +/- 15.1 (range 23-82, p<0.001), with 32 eyes (71.1%) >40 and 19 eyes (42.2%) >50 mmHg. The mean difference between preoperative IOP and immediately after the injection was +25.5 +/- 13.6 mmHg. IOP decreased spontaneously by the first 3 minutes after operation by 12.6 +/- 6.0 mmHg and after 10 minutes by 21 +/- 9.4 mmHg. The mean difference between preoperative IOP and 10 minutes postoperatively was +4.6 +/- 7.0 mmHg (range: -9.3 to +25.9 mmHg, p<0.001). Eyes without a subconjunctival reflux had a higher increase in IOP than eyes with any reflux (p<0.001).
   CONCLUSIONS. IOP increased significantly in a considerable number of patients after intravitreal ranibizumab injections. A rapid and spontaneous decline was observed in the majority of cases. If there is no subconjunctival reflux after the injection, the increase in IOP is higher than in eyes with any backflow under the conjunctiva. (Eur J Ophthalmol 2010; 20: 174-9)
C1 [Sharei, Vahid; Hoehn, Fabian; Koehler, Thomas; Hattenbach, Lars-Olof; Mirshahi, Alireza] Ludwigshafen Hosp, Dept Ophthalmol, D-67063 Ludwigshafen, Germany.
   [Mirshahi, Alireza] Johannes Gutenberg Univ Mainz, Dept Ophthalmol, Mainz, Germany.
C3 Ludwigshafen Hospital; Johannes Gutenberg University of Mainz
RP Mirshahi, A (通讯作者)，Ludwigshafen Hosp, Dept Ophthalmol, Bremserstr 79, D-67063 Ludwigshafen, Germany.
EM Dr.Mirshahi@gmail.com
RI Hattenbach, Lars-Olof/AAC-5621-2020
OI Hattenbach, Lars-Olof/0000-0002-5275-8118
CR Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   BENGTSSON B, 1972, ACTA OPHTHALMOL, V50, P445
   Benz MS, 2006, OPHTHALMOLOGY, V113, P1174, DOI 10.1016/j.ophtha.2005.10.061
   BUCHANAN RA, 1985, AM J OPTOM PHYS OPT, V62, P59
   Chiara G F, 1989, J Am Optom Assoc, V60, P105
   Dwinger MC, 2005, KLIN MONATSBL AUGENH, V222, P638, DOI 10.1055/s-2005-858459
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Hariprasad SM, 2006, AM J OPHTHALMOL, V141, P200, DOI 10.1016/j.ajo.2005.07.053
   He Z, 2008, INVEST OPHTH VIS SCI, V49, P3026, DOI 10.1167/iovs.07-1628
   He Z, 2006, INVEST OPHTH VIS SCI, V47, P4872, DOI 10.1167/iovs.06-0590
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Lee EW, 2007, AM J OPHTHALMOL, V143, P365, DOI 10.1016/j.ajo.2006.08.033
   Lim KS, 2005, INVEST OPHTH VIS SCI, V46, P2419, DOI 10.1167/iovs.04-0610
   Longo A, 2004, INVEST OPHTH VIS SCI, V45, P546, DOI 10.1167/iovs.03-0757
   MCDERMOTT JA, 2008, ALBERT JAKOBIECS PRI, P2491
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Reche-Frutos J, 2008, EUR J OPHTHALMOL, V18, P645, DOI 10.1177/112067210801800427
   Riva CE, 1997, GRAEF ARCH CLIN EXP, V235, P618, DOI 10.1007/BF00946937
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Singh IP, 2004, AM J OPHTHALMOL, V138, P286, DOI 10.1016/j.ajo.2004.03.001
   TSUKAHARA S, 1984, BRIT J OPHTHALMOL, V68, P389, DOI 10.1136/bjo.68.6.389
   van der Jagt LH, 2005, OPHTHAL PHYSL OPT, V25, P429, DOI 10.1111/j.1475-1313.2005.00318.x
   Wingert T A, 1995, J Am Optom Assoc, V66, P670
   Ziemssen F, 2008, KLIN MONATSBL AUGENH, V225, P770, DOI 10.1055/s-2008-1027487
NR 28
TC 34
Z9 37
U1 0
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2010
VL 20
IS 1
BP 174
EP 179
DI 10.1177/112067211002000124
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 579IE
UT WOS:000276361800025
PM 19927267
DA 2022-11-30
ER

PT J
AU Vishwanathan, R
   Goodrow-Kotyla, EF
   Wooten, BR
   Wilson, TA
   Nicolosi, RJ
AF Vishwanathan, Rohini
   Goodrow-Kotyla, Elizabeth F.
   Wooten, Billy R.
   Wilson, Thomas A.
   Nicolosi, Robert J.
TI Consumption of 2 and 4 egg yolks/d for 5 wk increases macular pigment
   concentrations in older adults with low macular pigment taking
   cholesterol-lowering statins
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID HETEROCHROMATIC FLICKER PHOTOMETRY; SERUM CONCENTRATIONS;
   DIETARY-CHOLESTEROL; OPTICAL-DENSITY; ZEAXANTHIN CONCENTRATIONS;
   LIPOPROTEIN CHOLESTEROL; TISSUE CONCENTRATIONS; HDL CHOLESTEROL; LUTEIN;
   CAROTENOIDS
AB Background: Lutein and zeaxanthin may reduce the risk of dry, age-related macular degeneration because of their photo-oxidative role as macular pigment.
   Objective: The present study evaluated serum lutein, zeaxanthin, and macular pigment optical density (MPOD) responses at 0.25 degrees, 0.5 degrees, and 1 degrees retinal eccentricities to the consumption of 2 and 4 egg yolks/d by older adults taking cholesterol-lowering medications.
   Design: Subjects consumed foods containing 2 followed by 4 egg yolks/d for 5 wk each with a 4-wk egg-free period at baseline and between the 2 interventions.
   Results: Changes in MPOD (n = 37) with egg yolk consumption were inversely associated (P < 0.05) with baseline MPOD. Subjects with low-baseline MPOD (defined as MPOD <= 0.5 at 0.25 degrees, <= 0.4 at 0.5 degrees, and <= 0.35 at 1 degrees) showed increases of <= 50% (P < 0.05) with 4 egg yolks at the 3 retinal eccentricities. MPOD increased by 31% (P = 0.059) at 0.5 degrees with 2 egg yolks. Serum lutein increased by only 16% and 24% (P < 0.05) compared with increases of 36% and 82% (P < 0.001) in serum zeaxanthin (n = 52) after consumption of 2 and 4 egg yolks, respectively. Serum HDL cholesterol increased by 5% (P < 0.05) after consumption of 2 and 4 egg yolks. Serum LDL cholesterol did not change with either egg yolk treatment.
   Conclusions: Consumption of 4 egg yolks/d, and possibly of 2 egg yolks/d, for 5 wk benefited macular health in older adults with low MPOD. Serum HDL cholesterol increased without an increase in LDL cholesterol in this study population, most of whom were taking cholesterol-lowering statins. Am J Clin Nutr 2009; 90: 1272-9.
C1 [Vishwanathan, Rohini; Goodrow-Kotyla, Elizabeth F.; Wilson, Thomas A.; Nicolosi, Robert J.] Univ Massachusetts, Dept Clin Lab & Nutr Sci, Ctr Hlth & Dis Res, Lowell, MA 01854 USA.
   [Wooten, Billy R.] Brown Univ, Dept Psychol, Providence, RI 02912 USA.
C3 University of Massachusetts System; University of Massachusetts Lowell;
   Brown University
RP Nicolosi, RJ (通讯作者)，Univ Massachusetts, Dept Clin Lab & Nutr Sci, Ctr Hlth & Dis Res, 3 Solomont Way,Suite 4, Lowell, MA 01854 USA.
EM v_rohini@hotmail.com; nicolosi.robert@yahoo.com
OI Wilson, Thomas/0000-0001-8363-4356
CR *AHA, 2008, AM HEART ASS HOM
   Ahmed SS, 2005, SURV OPHTHALMOL, V50, P183, DOI 10.1016/j.survophthal.2004.12.009
   ALLAIN CC, 1974, CLIN CHEM, V20, P470
   Bone RA, 2004, ARCH BIOCHEM BIOPHYS, V430, P137, DOI 10.1016/j.abb.2004.04.003
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Goodrow EF, 2006, J NUTR, V136, P2519, DOI 10.1093/jn/136.10.2519
   Greene CM, 2005, J NUTR, V135, P2793, DOI 10.1093/jn/135.12.2793
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   Handelman GJ, 1999, AM J CLIN NUTR, V70, P247
   HANDELMAN GJ, 1992, METHOD ENZYMOL, V213, P220
   Hu FB, 1999, JAMA-J AM MED ASSOC, V281, P1387, DOI 10.1001/jama.281.15.1387
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Kaminski M S, 1993, J Am Optom Assoc, V64, P862
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   MCGOWAN MW, 1983, CLIN CHEM, V29, P538
   Mutungi G, 2008, J NUTR, V138, P272, DOI 10.1093/jn/138.2.272
   NOLAN J, 2003, AMD, P39
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Ridker PM, 2009, AM J CARDIOL, V103, P1417, DOI 10.1016/j.amjcard.2009.02.023
   Snedecor GW, 1980, STAT METHODS
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   Steghens JP, 1997, J CHROMATOGR B, V694, P71, DOI 10.1016/S0378-4347(97)00140-0
   *USDA, NUTR DAT LAB HOM
   Vertesi A, 2001, CAN FAM PHYSICIAN, V47, P2018
   Weggemans RM, 2001, AM J CLIN NUTR, V73, P885
   Wenzel AJ, 2006, J NUTR, V136, P2568, DOI 10.1093/jn/136.10.2568
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
NR 39
TC 62
Z9 66
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD NOV 1
PY 2009
VL 90
IS 5
BP 1272
EP 1279
DI 10.3945/ajcn.2009.28013
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 508TO
UT WOS:000270959500022
PM 19759170
OA Bronze
DA 2022-11-30
ER

PT J
AU Brazionis, L
   Rowley, K
   Itsiopoulos, C
   O'Dea, K
AF Brazionis, Laima
   Rowley, Kevin
   Itsiopoulos, Catherine
   O'Dea, Kerin
TI Plasma carotenoids and diabetic retinopathy
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Carotenoids; Diabetic retinopathy; Pro-vitamin A
ID SERUM CAROTENOIDS; VITAMIN-A; INSULIN-RESISTANCE; OXIDATIVE STRESS;
   CACO-2 CELLS; MELLITUS; LYCOPENE; DIETARY; RISK; TOCOPHEROLS
AB Diabetic retinopathy increases with duration of diabetes and may be associated with carotenoid status. Carotenoids alter the pro-oxidation/anti-oxidation balance, and circulating levels depend largely on dietary intake. Lower levels have been reported in diabetes and age-related macular degeneration; however, little is known of the relationship between carotenoids and diabetic complications. Consequently, the purpose of the present study was to evaluate the relationship between plasma carotenoids and diabetic retinopathy. We assessed the carotenoid-retinopathy relationship in 111 individuals with type 2 diabetes in a community-based, cross-sectional study. We photodocumented retinal status and used HPLC to measure plasma carotenoid concentrations. Data for clinical and demographic variables and risk factors for diabetic retinopathy were obtained from 24h urine and fasting blood samples, and an interviewer-assisted lifestyle questionnaire. We found that the combined lycopene and lutein/zeaxanthin (non-pro-vitamin A (non-PVA) carotenoid) concentration when compared with the pro-vitamin A (PVA) carotenoids (alpha-carotene, beta-carotene and beta-cryptoxanthin) was significantly lower in the retinopathy than non-retinopathy group (OR 1.2 (95% CI 1.0, 1.4) v. 1.6 (95% CI 1.4, 1.7), respectively; P=0.009). A higher non-PVA:PVA ratio also predicted a lower risk of diabetic retinopathy, after adjustment for potential confounders (OR 0.33 (95% CI 0.12, 0.95); P=0.039). Finally, a higher concentration of PVA carotenoids was associated with greater odds of diabetic retinopathy, after adjustment for risk factors (P=0.049). We suggest synergies between carotenoids are implicated in diabetic retinopathy, independent of established risk factors. Importantly, our observations indicate dietary modulation of retinopathy risk may be possible by increasing intakes of lutein- and lycopene-rich foods.
C1 [Brazionis, Laima; Itsiopoulos, Catherine; O'Dea, Kerin] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia.
   [Rowley, Kevin] Univ Melbourne, Sch Populat Hlth, Ctr Hlth & Soc, Onemda VicHlth Koori Hlth Unit, Melbourne, Vic 3010, Australia.
C3 St Vincent's Hospital Melbourne; University of Melbourne; University of
   Melbourne
RP Brazionis, L (通讯作者)，Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia.
EM laimab@medstv.unimelb.edu.au
RI Brazionis, Laima/G-3770-2010; O'Dea, Kerin/B-6916-2009
OI Itsiopoulos, Catherine/0000-0003-1397-4149
FU Cancer Council Victoria; National Health and Medical Research Council of
   Australia [124317]
FX The present study would not have been possible without the MCCS and the
   infrastructure support provided by the Cancer Council Victoria. The
   National Health and Medical Research Council of Australia part-funded
   the present study (project no. 124317), which represents the
   collaboration of and contribution by many.
CR Abahusain MA, 1999, EUR J CLIN NUTR, V53, P630, DOI 10.1038/sj.ejcn.1600825
   ALDINGTON SJ, 1995, DIABETOLOGIA, V38, P437, DOI 10.1007/BF00410281
   Anderson JW, 1999, J AM COLL NUTR, V18, P451, DOI 10.1080/07315724.1999.10718883
   Basu TK, 1997, NUTRITION, V13, P804, DOI 10.1016/S0899-9007(97)00192-5
   Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Chesnokova N B, 2000, Vestn Oftalmol, V116, P31
   Coyne T, 2005, AM J CLIN NUTR, V82, P685, DOI 10.1093/ajcn/82.3.685
   Coyne T, 2005, PUBLIC HEALTH NUTR, V8, P298, DOI 10.1079/PHN2004688
   During A, 2002, J LIPID RES, V43, P1086, DOI 10.1194/jlr.M200068-JLR200
   During A, 2005, J NUTR, V135, P2305, DOI 10.1093/jn/135.10.2305
   Facchini FS, 2000, AM J CLIN NUTR, V72, P776
   Ford ES, 1999, AM J EPIDEMIOL, V149, P168, DOI 10.1093/oxfordjournals.aje.a009783
   Gerster H, 1997, INT J VITAM NUTR RES, V67, P71
   Giles GG, 1990, P NUTR SOC AUST, V15, P61
   Granado F, 2004, ANN NUTR METAB, V48, P251, DOI 10.1159/000080459
   Granado F, 1998, CLIN SCI, V94, P189, DOI 10.1042/cs0940189
   Granado-Lorencio F, 2006, EUR J CLIN NUTR, V60, P1000, DOI 10.1038/sj.ejcn.1602411
   Gupta SK, 2003, NUTRITION, V19, P794, DOI 10.1016/S0899-9007(03)00140-0
   Heber D, 2002, EXP BIOL MED, V227, P920, DOI 10.1177/153537020222701013
   Hof KHV, 2000, J NUTR, V130, P503
   Hozawa A, 2006, AM J EPIDEMIOL, V163, P929, DOI 10.1093/aje/kwj136
   Ito Yoshinori, 2005, Asian Pac J Cancer Prev, V6, P10
   Khachik F, 2002, EXP BIOL MED, V227, P845, DOI 10.1177/153537020222701002
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Krill D, 1997, HUM BIOL, V69, P89
   Krinsky Norman I., 2005, Molecular Aspects of Medicine, V26, P459
   Levy Y, 2000, ANN NUTR METAB, V44, P54, DOI 10.1159/000012821
   Miranda M., 2006, Arch Soc Esp Oftalmol, V81, P27
   Muriach M, 2006, FREE RADICAL BIO MED, V41, P979, DOI 10.1016/j.freeradbiomed.2006.06.023
   Neyestani TR, 2007, J ENDOCRINOL INVEST, V30, P833, DOI 10.1007/BF03349224
   Nilsson SEG, 2003, DOC OPHTHALMOL, V106, P13, DOI 10.1023/A:1022419606629
   OBrien SF, 1996, DIABETES RES CLIN PR, V32, P81, DOI 10.1016/0168-8227(96)01252-1
   Olmedilla B, 1997, CLIN CHEM, V43, P1066
   Parker RS, 1997, EUR J CLIN NUTR, V51, pS86
   PISCATOR M, 1991, KIDNEY INT, V40, pS15
   Polidori MC, 2000, DIABETES-METAB RES, V16, P15, DOI 10.1002/(SICI)1520-7560(200001/02)16:1<15::AID-DMRR71>3.3.CO;2-2
   Quilliot D, 2005, AM J CLIN NUTR, V81, P1117
   Reunanen A, 1998, EUR J CLIN NUTR, V52, P89, DOI 10.1038/sj.ejcn.1600519
   Ribaya-Mereado JD, 2004, J AM COLL NUTR, V23, p567S, DOI 10.1080/07315724.2004.10719427
   Rissanen TH, 2003, AM J CLIN NUTR, V77, P133, DOI 10.1093/ajcn/77.1.133
   Rock CL, 1997, AM J CLIN NUTR, V65, P844, DOI 10.1093/ajcn/65.3.844
   Siegenthaler G, 1996, HORM RES, V45, P122, DOI 10.1159/000184774
   Su Q, 1999, J CHROMATOGR B, V729, P191, DOI 10.1016/S0378-4347(99)00162-0
   Sugiura M, 2006, J EPIDEMIOL, V16, P71, DOI 10.2188/jea.16.71
   Suzuki Koji, 2002, J Epidemiol, V12, P357
   Thurnham DI, 1999, P NUTR SOC, V58, P449, DOI 10.1017/S0029665199000592
   Tyssandier V, 2002, INT J VITAM NUTR RES, V72, P300, DOI 10.1024/0300-9831.72.5.300
   Upritchard JE, 2000, DIABETES CARE, V23, P733, DOI 10.2337/diacare.23.6.733
   Voutilainen S, 2006, AM J CLIN NUTR, V83, P1265
   Wang L, 2006, AM J EPIDEMIOL, V164, P576, DOI 10.1093/aje/kwj240
   Watanabe S, 2004, BIOFACTORS, V22, P213, DOI 10.1002/biof.5520220144
   *WHO, 1999, WORLD HLTH ORG DIAB
   Ylonen K, 2003, AM J CLIN NUTR, V77, P1434
NR 54
TC 63
Z9 67
U1 0
U2 14
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD JAN
PY 2009
VL 101
IS 2
BP 270
EP 277
DI 10.1017/S0007114508006545
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 398DH
UT WOS:000262712300016
PM 18554424
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Hollands, H
   Wong, J
   Bruen, R
   Campbell, RJ
   Sharma, S
   Gale, J
AF Hollands, Hussein
   Wong, Jonathan
   Bruen, Robin
   Campbell, Robert J.
   Sharma, Sanjay
   Gale, Jeffery
TI Short-term intraocular pressure changes after intravitreal injection of
   bevacizumab
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE intravitreal injection; short-term intraocular pressure; intraocular
   pressure; Avastin; bevacizumab
ID TRIAMCINOLONE ACETONIDE INJECTION; OPTIC-NERVE HEAD; CHOROIDAL
   NEOVASCULARIZATION; MACULAR DEGENERATION; ELEVATION; AVASTIN; SAFETY
AB Background: This study examines the changes in short-term intraocular pressure (IOP) in patients receiving intravitreally administered bevacizumab. A prospective series of consecutive patients undergoing injection of intravitreal bevacizumab was investigated.
   Methods: All patients received bevacizumab (0.05 cc) injected intravitreally in a standard fashion. IOP was measured at baseline, 2, 5, and 30 minutes after injection by I of 2 observers using Goldman applanation tonometry. An intraobserver study was done to assess agreement in IOP measurements.
   Results: We accrued 104 patients with a mean age of 76 years: 58% were female, and 42% were male. Most patients (85%) were being treated for neovascular age-related macular degeneration. The mean IOP? values at baseline, 2, 5, and 30 minutes after injection were 14.0 (95% confidence interval [Cl] 13.4-14.7) mm Hg, 36.1 (95% Cl 33.5-38.6) mm Hg, 25.7 (95% Cl 23.8-27.5) mm Hg, and 15.5 (95% Cl 12.4-16.5 1) mm Hg, respectively. Three patients (2.9%) had an IOP of 25 mm Hg or higher at 30 minutes. IOP normalized within 2 hours without medical therapy in 2 of these patients, and I patient required a I -week course of glaucoma medication. Regression analysis showed a trend towards phakic patients having higher IOP at 30 minutes (odds ratio = 3.2; p = 0.089).
   Interpretation: Intravitreal injection of bevacizurnab is safe with respect to short-term IOP changes, as almost all patients' IOP returned to a safe range (<25 mm Hg) within 30 minutes. Elevated IOP at 30 minutes after injection does occur, rarely, thus clinicians should consider checking IOP after injection as a precaution.Transient extreme IOP elevations occur in a significant percentage of patients, but the consequences of these events are unknown.
C1 [Hollands, Hussein; Wong, Jonathan; Campbell, Robert J.; Sharma, Sanjay; Gale, Jeffery] Hop Hotel Dieu, Dept Ophthalmol, Kingston, ON K7L5S9, Canada.
   [Bruen, Robin] Queens Univ, Hotel Dieu Hosp, Fac Med, Kingston, ON, Canada.
   [Sharma, Sanjay] Hop Hotel Dieu, Unit Cost Effective Ocular Hlth Policy, Kingston, ON, Canada.
C3 Queens University - Canada; Queens University - Canada; Queens
   University - Canada
RP Hollands, H (通讯作者)，Hop Hotel Dieu, Dept Ophthalmol, Johnson 6,166 Brock St, Kingston, ON K7L5S9, Canada.
EM 8hhl@qlink.queensu.ca
CR Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Benz MS, 2006, OPHTHALMOLOGY, V113, P1174, DOI 10.1016/j.ophtha.2005.10.061
   Dwinger MC, 2005, KLIN MONATSBL AUGENH, V222, P638, DOI 10.1055/s-2005-858459
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   Jones R, 2006, CURR OPIN OPHTHALMOL, V17, P163
   Jorge R, 2006, RETINA-J RET VIT DIS, V26, P1006, DOI 10.1097/01.iae.0000246884.76018.63
   Michelson G, 1997, GER J OPHTHALMOL, V5, P315
   QUIGLEY HA, 1977, INVEST OPHTH VIS SCI, V16, P640
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Riva CE, 1997, GRAEF ARCH CLIN EXP, V235, P618, DOI 10.1007/BF00946937
   Singh IP, 2004, AM J OPHTHALMOL, V138, P286, DOI 10.1016/j.ajo.2004.03.001
   Tewari A, 2006, RETINA-J RET VIT DIS, V26, P1093, DOI 10.1097/01.iae.0000254896.78766.74
   YAN DB, 1994, BRIT J OPHTHALMOL, V78, P643, DOI 10.1136/bjo.78.8.643
NR 14
TC 136
Z9 143
U1 0
U2 1
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD DEC
PY 2007
VL 42
IS 6
BP 807
EP 811
DI 10.3129/i07-172
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 241MJ
UT WOS:000251660200004
PM 18026202
DA 2022-11-30
ER

PT J
AU Bindewald, A
   Stuhrmann, O
   Roth, F
   Schmitz-Valckenberg, S
   Helb, HM
   Wegener, A
   Eter, N
   Holz, FG
AF Bindewald, A
   Stuhrmann, O
   Roth, F
   Schmitz-Valckenberg, S
   Helb, HM
   Wegener, A
   Eter, N
   Holz, FG
TI Lower limits of fluorescein and indocyanine green dye for digital cSLO
   fluorescence angiography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY;
   VIDEOANGIOGRAPHY; VISUALIZATION; RETINA
AB Background: With the advent of digital confocal scanning laser ophthalmoscopy it is possible to detect low levels of fluorescence. Here we used a novel confocal scanning laser ophthalmoscope (cSLO) to determine lower limits of dye required for fluorescein (FL) and indocyanine green (ICG) angiography.
   Methods: A cSLO (Heidelberg retina angiograph 2, Heidelberg Engineering, Dossenheim, Germany) with an optically pumped solid state laser (488 nm) for FL and a diode laser (790 nm) for ICG angiography (FL/ICG-A) was used. 62 FL-As were performed in 53 patients and 45 ICG-As were performed in 39 patients with neovascular age related macular degeneration. The volume and overall dye content of bolus injections was gradually tapered (FL: 500 mg, 250 mg, 200 mg, 166 mg, 100 mg; ICG: 25 mg, 20 mg, 15 mg, 10 mg, 5 mg, 2.5 mg), while dye concentrations were kept constant at 100 mg/ml for FL and at 5 mg/ml for ICG. Images were obtained 1, 5, 15, and 30 minutes after dye injection. Image quality was evaluated by two independent readers using standardised criteria.
   Results: For amounts down to 166 mg for FL and to 5 mg for ICG, sufficient image quality was achieved during all phases following injection. Only late phase images showed less contrast compared to typically used dye amounts, which was irrelevant for interpretation and clinical management.
   Conclusions: With the increased sensitivity of this novel cSLO system, amounts of injected dye during FL-A can be reduced to one third for FL and to one fifth for ICG without relevant loss of image quality or information compared to conventionally used dye levels. These amounts can be used for routine angiography and allow relevant savings for units performing FL-A.
C1 Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
OI Bindewald-Wittich, Almut/0000-0002-8151-3953
CR American National Standards Institute, 2000, Z1361 ANSI LAS I AM
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   Bindewald A, 2004, AM J OPHTHALMOL, V137, P556, DOI 10.1016/j.ajo.2003.08.004
   DITHMAR S, 1995, KLIN MONATSBL AUGENH, V207, P11, DOI 10.1055/s-2008-1035342
   FLOWER RW, 1973, INVEST OPHTH VISUAL, V12, P248
   Freeman WR, 1998, ARCH OPHTHALMOL-CHIC, V116, P455, DOI 10.1001/archopht.116.4.455
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1997, OPHTHALMOLOGE, V94, P348, DOI 10.1007/s003470050127
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   MAINSTER MA, 1982, OPHTHALMOLOGY, V89, P852, DOI 10.1016/s0161-6420(82)34714-4
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   Plesch A, 1986, Fortschr Ophthalmol, V83, P530
   RABB MF, 1978, SURV OPHTHALMOL, V22, P387, DOI 10.1016/0039-6257(78)90134-0
   SCHEIDER A, 1992, AM J OPHTHALMOL, V113, P45, DOI 10.1016/S0002-9394(14)75752-6
   SPAIDE RF, 1999, DIS RETINA VITREOUS, P29
   TITTL MK, 1999, DIS RETINA VITREOUS, P39
   WEBB RH, 1980, APPL OPTICS, V19, P2991, DOI 10.1364/AO.19.002991
   WEBB RH, 1981, IEEE T BIO-MED ENG, V28, P488, DOI 10.1109/TBME.1981.324734
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Wolf S, 1994, Ger J Ophthalmol, V3, P224
   *WORLD MED ASS, 2000, B MED ETHICS, V158, P9
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   YONEYA S, 1993, ARCH OPHTHALMOL-CHIC, V111, P1165, DOI 10.1001/archopht.1993.01090090015002
NR 30
TC 4
Z9 5
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2005
VL 89
IS 12
BP 1609
EP 1615
DI 10.1136/bjo.2005.070409
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 985HR
UT WOS:000233368700017
PM 16299141
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Nicolo, M
   Biro, A
   Cardillo-Piccolino, C
   Castellani, P
   Giovannini, A
   Mariotti, C
   Zingirian, M
   Neri, D
   Zardi, L
AF Nicolo, M
   Biro, A
   Cardillo-Piccolino, C
   Castellani, P
   Giovannini, A
   Mariotti, C
   Zingirian, M
   Neri, D
   Zardi, L
TI Expression of extradomain-B-containing fibronectin in subretinal
   choroidal neovascular membranes
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; ONCOFETAL DOMAIN; EXTRACELLULAR-MATRIX;
   HUMAN-ANTIBODY; ANGIOGENESIS; ISOFORM; GROWTH; EYE; CARCINOMA; AFFINITY
AB PURPOSE: To investigate the presence of the fibronectin isoform containing the extradomain B (B-FN), a marker,protein of angiogenesis, in surgically excised human choroidal neovascular membranes (CNVM) to evaluate whether B-FN could be used as a therapeutic target for specific antibody-photosensitizer immunoconjugates.
   DESIGN: Laboratory investigation.
   METHODS: The setting was an institutional practice. The study population consisted of 15 eyes (15 patients) with CNVM undergoing membrane excision (four eyes with age related macular degeneration, seven with pathologic myopia and four with multifocal choroiditis). The control group consisted of eight eye bank eyes (four subjects) without choroidal neovascularization. Light microscopic immunohistochemistry on cryostat sections of tissues was obtained. B-FN was detected by a human recombinant antibody, CGS-1, and compared with immunostaining for endothelial cells with factor VIII-related antigen. The main outcome measure was the presence of CGS-I positively stained cells or areas of the extracellular matrix. Staining of CGS-1 was scored on a scale from 0 to 3.
   RESULTS: Fourteen of 15 neovascular membranes stained strongly with CGS-1 (score 2 or 3). One membrane from a patient with pathologic myopia was negatively stained (score 0). CGS-1 positive staining was detected around endothelial cells and in the extracellular matrix of CNVMs. The retina of eyes without choroidal neovascularization was negative with CGS-1 in all eight donor eyes, while the choroid contained some weakly CGS-1 positive cells (score 0 and 1, respectively).
   CONCLUSIONS: The extradomain B is abundantly expressed in CNVMs, but its expression is more restricted in eyes harboring no apparent choroidal neovascularization. In the future, B-FN might serve as a target for the delivery of antibody photosensitizer immunoconjugates to newly developed vessels to enhance the selectivity of photodynamic therapy.
C1 Natl Inst Canc Res, Lab Cellular Biol, I-16132 Genoa, Italy.
   Univ Genoa, Ophthalmol Sect B, Dept Neurol & Visual Sci, Genoa, Italy.
   Ophthalmol Clin, Ancona, Italy.
   Swiss Fed Inst Technol, Dept Appl Biosci, Zurich, Switzerland.
C3 University of Genoa; IRCCS AOU San Martino IST; University of Genoa;
   Swiss Federal Institutes of Technology Domain; ETH Zurich
RP Zardi, L (通讯作者)，Natl Inst Canc Res, Cell Biol Lab, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.
RI Castellani, Patrizia/J-7333-2018; Neri, Dario/P-4368-2016
OI Castellani, Patrizia/0000-0002-6326-5853; Neri,
   Dario/0000-0001-5234-7370; Nicolo, Massimo/0000-0002-7824-3091
CR Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Birchler M, 1999, NAT BIOTECHNOL, V17, P984, DOI 10.1038/13679
   BORSI L, 1992, EXP CELL RES, V199, P98, DOI 10.1016/0014-4827(92)90466-L
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BROWN LF, 1993, AM J PATHOL, V142, P793
   CAI XX, 1993, INVEST OPHTH VIS SCI, V34, P3585
   CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139
   Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.0.CO;2-4
   CASTELLANI P, 1995, INT J CANCER, V62, P118
   CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507
   D'Ovidio MC, 1998, EUR J CANCER, V34, P1081, DOI 10.1016/S0959-8049(98)00041-0
   FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903
   Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   ISHIBASHI T, 1985, GRAEF ARCH CLIN EXP, V223, P158, DOI 10.1007/BF02148893
   Karelina TV, 1998, CANCER DETECT PREV, V22, P438, DOI 10.1046/j.1525-1500.1998.00061.x
   Kishimoto Naoko, 1993, Nippon Ganka Gakkai Zasshi, V97, P1165
   KOHNO T, 1983, JPN J OPHTHALMOL, V27, P496
   KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P506
   Madri JA, 1997, TRANSPL IMMUNOL, V5, P179, DOI 10.1016/S0966-3274(97)80035-4
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   Nickeleit V, 1996, AM J PATHOL, V149, P549
   Nicolo M, 2000, GRAEF ARCH CLIN EXP, V238, P107, DOI 10.1007/s004170050018
   Pau A, 1998, J NEUROL NEUROSUR PS, V64, P412, DOI 10.1136/jnnp.64.3.412
   Pujuguet P, 1996, AM J PATHOL, V148, P579
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4
   Scarpino S, 1999, J PATHOL, V188, P163
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Scheider A, 1999, GRAEF ARCH CLIN EXP, V237, P10, DOI 10.1007/s004170050187
   Spirin KS, 1999, CURR EYE RES, V18, P490, DOI 10.1076/ceyr.18.6.490.5267
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V211, P324, DOI 10.1055/s-2008-1035142
   SRAMEK SJ, 1987, INVEST OPHTH VIS SCI, V28, P500
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Tarli L, 1999, BLOOD, V94, P192, DOI 10.1182/blood.V94.1.192.413k22_192_198
   VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6
   Viti F, 1999, CANCER RES, V59, P347
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x
NR 43
TC 13
Z9 15
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2003
VL 135
IS 1
BP 7
EP 13
AR PII S0002-9394(02)01839-1
DI 10.1016/S0002-9394(02)01839-1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 632QG
UT WOS:000180233900002
PM 12504690
DA 2022-11-30
ER

PT J
AU Pelak, VS
   Paez, YM
   Patnaik, JL
   Holden, SK
   Subramanian, PS
   Mathias, MT
   Mandava, N
   Lynch, AM
AF Pelak, Victoria S.
   Paez, Yosbelkys Martin
   Patnaik, Jennifer L.
   Holden, Samantha K.
   Subramanian, Prem S.
   Mathias, Marc T.
   Mandava, Naresh
   Lynch, Anne M.
TI An Exploratory Study to Investigate the Utility of Clinical Screening
   for Neurodegenerative Disease in Age-Related Eye Disease Research
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; NATIONAL INSTITUTE;
   CRITERIA
AB Background: Unrecognized neurodegenerative diseases (NDD) in age-related eye disease research studies have the potential to confound vision-specific quality of life and retinal optical coherence tomography (OCT) outcome measures. The aim of this exploratory study was to investigate relationships between NDD screening tools and visual outcome measures in a small cohort of controls from the Colorado Age-Related Macular Degeneration Registry (CO-AMD), to consider the utility of future studies. Methods: Twenty-nine controls from the CO-AMD were screened using the Montreal Cognitive Assessment (MoCA), a Colorado Parkinsonian Checklist, and the Lewy Body Composite Risk Score. Univariate and multivariable linear regression modeling was used to assess associations between screening tools and the National Eye Institute Visual Function Questionnaire-25 (VFQ-25) and macular OCT outcome measures, and t tests were used to evaluate outcome measure differences between those with normal vs abnormal MoCA scores. Results: One patient withdrew. The average age was 72.8 years, and 68% were female patients. Ten participants (36%) had abnormal MoCA scores, and their VFQ-25 scores were only 1 point less and not statistically different than those with normal MoCA scores. Macular OCT volumes and thicknesses for retinal nerve fiber layer (RNFL) and retinal ganglion cell layer were consistently and moderately lower for those with abnormal MoCA scores, and a positive association between MoCA and macular RNFL volume was observed, although differences and regression were not significant. Parkinson screening tests were abnormal for only 4 participants and were not associated with OCT or VFQ-25 measures by regression modeling. Conclusions: Given the degree and direction of observed differences, further investigation is warranted regarding the relationship between cognitive screening tools and macular OCT measures in age-related eye disease research, but future investigations regarding the relationship between NDD screening tools and VFQ-25 seem unwarranted.
C1 [Pelak, Victoria S.; Paez, Yosbelkys Martin; Holden, Samantha K.; Subramanian, Prem S.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA.
   [Pelak, Victoria S.; Paez, Yosbelkys Martin; Patnaik, Jennifer L.; Subramanian, Prem S.; Mathias, Marc T.; Mandava, Naresh; Lynch, Anne M.] Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO USA.
   [Subramanian, Prem S.] Univ Colorado, Sch Med, Dept Neurosurg, Aurora, CO USA.
   [Subramanian, Prem S.] Uniformed Serv Univ Hlth Sci, Div Ophthalmol, Dept Surg, Bethesda, MD 20814 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Anschutz
   Medical Campus; University of Colorado System; University of Colorado
   Anschutz Medical Campus; Uniformed Services University of the Health
   Sciences - USA
RP Pelak, VS (通讯作者)，12631 East 17th Ave,Mail Stop B185, Aurora, CO 80045 USA.
EM Victoria.Pelak@CUAnschutz.edu
FU Frederic C. Hamilton Macular Degeneration Center; Research to Prevent
   Blindness, Inc; Colorado Clinical and Translational Sciences Institute
   [CCSTI-UL1 TR002535]; Development and Informatics Service Center (DISC)
   from NIH/NCRR
FX Fight for Sight-North American Neuro-Ophthalmology Society Research
   Award, and the AMD Registry supported by the Frederic C. Hamilton
   Macular Degeneration Center, an unrestricted grant to the Department of
   Ophthalmology from Research to Prevent Blindness, Inc, and the Colorado
   Clinical and Translational Sciences Institute (CCSTI-UL1 TR002535) with
   the Development and Informatics Service Center (DISC) from NIH/NCRR.
CR Berg D, 2015, MOVEMENT DISORD, V30, P1600, DOI 10.1002/mds.26431
   Berliner JM, 2020, PHYSIOTHER THEOR PR, V36, P701, DOI 10.1080/09593985.2018.1492055
   BLANKS JC, 1989, BRAIN RES, V501, P364, DOI 10.1016/0006-8993(89)90653-7
   den Haan Jurre, 2017, Alzheimers Dement (Amst), V6, P162, DOI 10.1016/j.dadm.2016.12.014
   Galvin James E, 2015, Alzheimers Dement (Amst), V1, P316
   Hwang PH, 2021, ALZHEIMERS DEMENT, V17, P1442, DOI 10.1002/alz.12313
   Knopman DS, 2018, ALZHEIMERS DEMENT, V14, P563, DOI 10.1016/j.jalz.2018.03.002
   Ko F, 2018, JAMA NEUROL, V75, P1198, DOI 10.1001/jamaneurol.2018.1578
   Lynch AM, 2019, RETINA-J RET VIT DIS, V39, P656, DOI 10.1097/IAE.0000000000002023
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mejia-Vergara AJ, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.578698
   Pelak VS, 2009, EXPERT REV OPHTHALMO, V4, P283, DOI 10.1586/EOP.09.18
   Perry RJ, 2000, ALZ DIS ASSOC DIS, V14, P1, DOI 10.1097/00002093-200001000-00001
   Postuma RB, 2015, MOVEMENT DISORD, V30, P1591, DOI 10.1002/mds.26424
   Prof Martin Prince D.R.B.a.D.C.F, 2011, BENEFITS EARLY DIAGN
   Roalf DR, 2013, ALZHEIMERS DEMENT, V9, P529, DOI 10.1016/j.jalz.2012.10.001
   Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003
   Vogel Sally J, 2015, Alzheimers Dement (Amst), V1, P289, DOI 10.1016/j.dadm.2015.05.002
   Ward A, 2012, ALZHEIMERS DEMENT, V8, P14, DOI 10.1016/j.jalz.2011.01.002
   Yu JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085718
NR 20
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-8022
EI 1536-5166
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD SEP
PY 2022
VL 42
IS 3
BP 346
EP 352
DI 10.1097/WNO.0000000000001550
PG 7
WC Clinical Neurology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology
GA 3V9CI
UT WOS:000841955800011
PM 35483065
DA 2022-11-30
ER

PT J
AU Cehajic-Kapetanovic, J
   Xue, KM
   Edwards, TL
   Meenink, TC
   Beelen, MJ
   Naus, GJ
   de Smet, MD
   MacLaren, RE
AF Cehajic-Kapetanovic, Jasmina
   Xue, Kanmin
   Edwards, Thomas L.
   Meenink, Thijs C.
   Beelen, Maarten J.
   Naus, Gerrit J.
   de Smet, Marc D.
   MacLaren, Robert E.
TI First-in-Human Robot-Assisted Subretinal Drug Delivery Under Local
   Anesthesia
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL GENE-THERAPY; HEMORRHAGE; INJECTION; EFFICACY; SAFETY
AB PURPOSE: To report the results of a first-in-human study using a robotic device to assist subretinal drug delivery in patients undergoing vitreoretinal surgery for macular hemorrhage.
   DESIGN: Double-armed, randomized controlled surgical trial (ClinicalTrials.gov identifier: NCT03052881).
   METHODS: The study was performed at the Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. In total, 12 participants were recruited-6 in the robot-assisted and 6 in the control manual surgery arm according to the prespecified inclusion and exclusion criteria. All subjects presented with acute loss of vision owing to a subfoveal hemorrhage secondary to neovascular age-related macular degeneration. After standard vitrectomy, intraoperative optical coherence tomography-guided subretinal injection of tissue plasminogen activator (TPA) was performed by either robot-assisted or conventional manual technique under local anesthesia. The robotic part of the procedure involved advancement of a cannula through the retina and stabilizing it during foot-controlled injection of up to 100 mu L of TPA solution. We assessed surgical success, duration of surgery, adverse events, and tolerability of surgery under local anesthesia.
   RESULTS: The procedure was well tolerated by all participants and safely performed in all cases. Total duration of surgery, time taken to complete the injection, and retinal microtrauma were similar between the groups and not clinically significant. Subretinal hemorrhage was successfully displaced at 1 month postintervention, except for 1 control subject, and the median gain in visual acuity was similar in both arms.
   CONCLUSIONS: This first-in-human study demonstrates the feasibility and safety of high-precision robotassisted subretinal drug delivery as part of the surgical management of submacular hemorrhage, simulating its potential future application in gene or cell therapy. (C) 2021 Elsevier Inc. All rights reserved.
C1 [Cehajic-Kapetanovic, Jasmina; Xue, Kanmin; Edwards, Thomas L.; MacLaren, Robert E.] Oxford Univ Hosp NHS Fdn Trust, Oxford Eye Hosp, Oxford, England.
   [Cehajic-Kapetanovic, Jasmina; Xue, Kanmin; Edwards, Thomas L.; MacLaren, Robert E.] Univ Oxford, Nuffield Lab Ophthalmol, Oxford OX3 9DU, England.
   [Meenink, Thijs C.; Beelen, Maarten J.; Naus, Gerrit J.; de Smet, Marc D.] Preceyes BV, Eindhoven, Netherlands.
C3 Oxford University Hospitals NHS Foundation Trust; University of Oxford
RP Cehajic-Kapetanovic, J (通讯作者)，Univ Oxford, Nuffield Lab Ophthalmol, Oxford OX3 9DU, England.
OI Edwards, Thomas/0000-0003-0238-7416; Cehajic-Kapetanovic,
   Jasmina/0000-0002-9956-6412; MacLaren, Robert/0000-0002-3096-4682
FU University of Oxford NIHR Biomedical Research Centre; National Institute
   for Health Research (UK) Invention for Innovation (i4i) Award; Global
   Ophthalmology Fellowship Awards Programme, Bayer, Switzerland
FX The study was sponsored by the University of Oxford NIHR Biomedical
   Research Centre and funded by the National Institute for Health Research
   (UK) Invention for Innovation (i4i) Award. J.C.K. was also funded by
   Global Ophthalmology Fellowship Awards Programme, Bayer, Switzerland.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Cehajic-Kapetanovic J, 2020, NAT MED, V26, P354, DOI 10.1038/s41591-020-0763-1
   Cukras C, 2018, MOL THER, V26, P2282, DOI 10.1016/j.ymthe.2018.05.025
   de Smet MD, 2018, CURR OPIN OPHTHALMOL, V29, P248, DOI 10.1097/ICU.0000000000000476
   de Smet MD, 2016, BRIT J OPHTHALMOL, V100, P1742, DOI 10.1136/bjophthalmol-2016-309190
   de Smet MD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162037
   Edington M, 2017, EXPERT OPIN DRUG MET, V13, P1217, DOI 10.1080/17425255.2017.1404987
   Edwards TL, 2018, NAT BIOMED ENG, V2, P649, DOI 10.1038/s41551-018-0248-4
   Jacobsen MF, 2020, RETINA-J RET VIT DIS, V40, P2091, DOI 10.1097/IAE.0000000000002720
   Gerber MJ, 2020, EYE, V34, P1554, DOI 10.1038/s41433-020-0837-9
   Gijbels A, 2014, ADV THEORY PRACTICE, P103
   Gijbels A, 2018, ANN BIOMED ENG, V46, P1676, DOI 10.1007/s10439-018-2053-3
   He XC, 2013, INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION - 2012, VOL 2: BIOMEDICAL AND BIOTECHNOLOGY, P145
   Jones BW, 2016, EXP EYE RES, V150, P149, DOI 10.1016/j.exer.2016.03.018
   Maberley DAL, 2020, GRAEF ARCH CLIN EXP, V258, P773, DOI 10.1007/s00417-020-04613-y
   MacLachlan RA, 2012, IEEE T ROBOT, V28, P195, DOI 10.1109/TRO.2011.2169634
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Meenink HCM, 2010, P EUSPEN INT C EUSPE, P3
   Meenink T, 2013, INVEST OPHTH VIS SCI, V54
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   Pfeiffer RL, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.07.004
   Roizenblatt Marina, 2018, Robot Surg, V5, P1, DOI 10.2147/RSRR.S122301
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   Singh MS, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100779
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Uneri A, 2010, P IEEE RAS-EMBS INT, P814, DOI 10.1109/BIOROB.2010.5625991
   Ueta T, 2009, OPHTHALMOLOGY, V116, P1538, DOI 10.1016/j.ophtha.2009.03.001
   Wilson JT, 2018, INT J MED ROBOT COMP, V14, DOI 10.1002/rcs.1842
   Xue K, 2017, EYE, V31, P1308, DOI 10.1038/eye.2017.158
   Xue KM, 2018, NAT MED, V24, P1507, DOI 10.1038/s41591-018-0185-5
   Yang S, 2015, IEEE-ASME T MECH, V20, P761, DOI 10.1109/TMECH.2014.2320858
NR 33
TC 8
Z9 8
U1 7
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2022
VL 237
BP 104
EP 113
DI 10.1016/j.ajo.2021.11.011
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3E8KI
UT WOS:000830227300011
PM 34788592
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Grosso, D
   Vella, G
   Sacconi, R
   Battista, M
   Querques, L
   Zucchiatti, I
   Prascina, F
   Bandello, F
   Querques, G
AF Borrelli, Enrico
   Grosso, Domenico
   Vella, Giovanna
   Sacconi, Riccardo
   Battista, Marco
   Querques, Lea
   Zucchiatti, Ilaria
   Prascina, Francesco
   Bandello, Francesco
   Querques, Giuseppe
TI Short-term outcomes of patients with neovascular exudative AMD: the
   effect of COVID-19 pandemic
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE COVID-19; Retina; Neovascular AMD; Outcome
ID TREAT-AND-EXTEND; MACULAR DEGENERATION; RANIBIZUMAB; REGIMEN
AB Purpose To estimate the impact of delayed care during the coronavirus disease 2019 (COVID-19) pandemic on the outcomes of patients with neovascular age-related macular degeneration (AMD).
   Methods Consecutive patients with diagnosis of neovascular AMD were consecutively enrolled between March 9, 2020, and June 12, 2020, (during and immediately after the Italian COVID-19 quarantine). During the inclusion (or pandemic) visit (V-0), patients received a complete ophthalmologic evaluation, including optical coherence tomography (OCT). Best-corrected visual acuity (BCVA) and OCT findings from the two preceding visits (V(-1)and V-2) were compared with data at V-0.
   Results One-hundred patients (112 eyes) were enrolled in this study. The time interval between following visits was 110.7 +/- 37.5 days within V(0)and V(-1)and 80.8 +/- 39.7 days within V(-1)and V-2, respectively (P < 0.0001). BCVA was statistically worse at the V(0)visit as compared with the immediately preceding (V-1) visit (0.50 +/- 0.43 LogMAR and 0.45 +/- 0.38 LogMAR at the V(0)and V(-1)visits, respectively;P = 0.046). On structural OCT, 91 out of 112 (81.2%) neovascular AMD eyes displayed the evidence of exudative disease activity at the V(0)visit, while 77 (68.7%) eyes exhibited signs of exudation at the V(-1)visit (P = 0.022). No differences in terms of BCVA and OCT findings were detected between the V(-1)and V(-2)visits. In multiple regression analysis, the difference in BCVA between V(0)and V(-1)visits was significantly associated with the interval time within these two visits (P = 0.026).
   Conclusion The COVID-19 pandemic-related postponement in patient care proved to be significantly associated with worse short-term outcomes in these patients.
C1 [Borrelli, Enrico; Grosso, Domenico; Vella, Giovanna; Sacconi, Riccardo; Battista, Marco; Querques, Lea; Zucchiatti, Ilaria; Prascina, Francesco; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, Milan, Italy.
   [Vella, Giovanna] Univ Pisa, Ophthalmol, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Pisa
RP Querques, G (通讯作者)，Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, Milan, Italy.
EM giuseppe.querques@unisr.it
RI Battista, Marco/AAO-3106-2021
OI Battista, Marco/0000-0001-5940-6177; Querques,
   Giuseppe/0000-0002-3292-9581; Grosso, Domenico/0000-0002-4346-3801;
   bandello, francesco/0000-0003-3238-9682; Sacconi,
   Riccardo/0000-0003-2891-2012
CR Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   Borrelli E, 2020, EYE, V34, P1175, DOI 10.1038/s41433-020-0880-6
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Corradetti G, 2020, OPHTHALMOL RETINA, V4, P757, DOI 10.1016/j.oret.2020.05.015
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Huang YJ, 2012, INVEST OPHTH VIS SCI, V53, P2133, DOI 10.1167/iovs.11-8755
   Iovino C, 2020, GRAEF ARCH CLIN EXP, V258, P2869, DOI 10.1007/s00417-020-04800-x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Martin DF, 2018, AM J OPHTHALMOL, V191, pXLI, DOI 10.1016/j.ajo.2017.12.019
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Parravano M, 2020, OPHTHALMOL THER, V9, P231, DOI 10.1007/s40123-020-00251-z
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Shmueli O, 2020, EYE, V34, P1165, DOI 10.1038/s41433-020-0925-x
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
NR 34
TC 36
Z9 36
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2020
VL 258
IS 12
BP 2621
EP 2628
DI 10.1007/s00417-020-04955-7
EA OCT 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OT7ND
UT WOS:000574791700001
PM 33009973
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Jing, RH
   Qi, TT
   Wen, C
   Yue, JQ
   Wang, GY
   Pei, C
   Ma, B
AF Jing, Ruihua
   Qi, Tiantian
   Wen, Chan
   Yue, Jiaqi
   Wang, Guangyan
   Pei, Cheng
   Ma, Bo
TI Interleukin-2 induces extracellular matrix synthesis and TGF-beta 2
   expression in retinal pigment epithelial cells
SO DEVELOPMENT GROWTH & DIFFERENTIATION
LA English
DT Article
DE age-related macular degeneration; epithelial-mesenchymal transition;
   extracellular matrix synthesis; Interleukin 2; retinal pigment
   epithelial cells
ID REGULATORY T-CELLS; TGF-BETA; IN-VITRO; MESENCHYMAL TRANSITION;
   AQUEOUS-HUMOR; GROWTH; IL-2; MIGRATION; RECEPTOR; STAT3
AB Macular fibrosis is a vital obstacle of vision acuity improvement of age-related macular degeneration patients. This study was to investigate the effects of interleukin 2 (IL-2) on epithelial-mesenchymal transition (EMT), extracellular matrix (ECM) synthesis and transforming growth factor beta 2 (TGF-beta 2) expression in retinal pigment epithelial (RPE) cells. 10 mu g/L IL-2 was used to induce fibrosis in RPE cells for various times. Western blot was used to detect the EMT marker alpha-smooth muscle actin (alpha-SMA), ECM markers fibronectin (Fn) and type 1 collagen (COL-1), TGF-beta 2, and the activation of the JAK/STAT3 and NF-kappa B signaling pathway. Furthermore, JAK/STAT3 and NF-kappa B signaling pathways were specifically blocked by WP1066 or BAY11-7082, respectively, and the expression of alpha-SMA, COL-1, Fn and TGF-beta 2 protein were detected. Wound healing and Transwell assays were used to measure cell migration ability of IL-2 with or without WP1066 or BAY11-7082. After induction of IL-2, the expressions of Fn, COL-1, TGF-beta 2 protein were significantly increased, and this effect was correlated with IL-2 treatment duration, while alpha-SMA protein expression did not change significantly. Both WP1066 and BAY11-7082 could effectively downregulate the expression of Fn, COL-1 and TGF-beta 2 induced by IL-2. What's more, both NF-kappa B and JAK/STAT3 inhibitors could suppress the activation of the other signaling pathway. Additionally, JAK/STAT3 inhibitor WP1066 and NF-kappa B inhibitor BAY 11-7082 could obviously decrease RPE cells migration capability induced by IL-2. IL-2 promotes cell migration, ECM synthesis and TGF-beta 2 expression in RPE cells via JAK/STAT3 and NF-kappa B signaling pathways, which may play an important role in proliferative vitreoretinopathy.
C1 [Jing, Ruihua; Qi, Tiantian; Wen, Chan; Yue, Jiaqi; Wang, Guangyan; Pei, Cheng; Ma, Bo] Jiaotong Univ, Affiliated Hosp Xian 1, Dept Ophthalmol, Xian 710061, Shaanxi, Peoples R China.
RP Pei, C; Ma, B (通讯作者)，Jiaotong Univ, Affiliated Hosp Xian 1, Dept Ophthalmol, Xian 710061, Shaanxi, Peoples R China.
EM peich71@163.com; mb780723@163.com
OI Jing, Ruihua/0000-0002-1915-8591
FU National Natural Science Foundation of China [81800812]; Postdoctoral
   Natural Science Foundation [2018M633528]; Natural Science Foundation of
   Shaanxi Province [2018JQ8021]; Fundamental Research Funds for the
   Central Universities [xjj2018099]; First Affiliated Hospital of Xi'an
   Jiaotong University Foundation [2016QN-04]
FX This study was supported by funding from the National Natural Science
   Foundation of China under grant (No. 81800812); the Postdoctoral Natural
   Science Foundation under grant (2018M633528); the Natural Science
   Foundation of Shaanxi Province under grant (No. 2018JQ8021); the
   Fundamental Research Funds for the Central Universities under grant
   (xjj2018099); and the First Affiliated Hospital of Xi'an Jiaotong
   University Foundation under grant (2016QN-04).
CR Anderluh M, 2019, PHARMACOL THERAPEUT, V201, P1, DOI 10.1016/j.pharmthera.2019.05.007
   Battaglia A, 2013, IMMUNOLOGY, V139, P109, DOI 10.1111/imm.12061
   Chambers ES, 2014, IMMUNOLOGY, V143, P52, DOI 10.1111/imm.12289
   Chen YZ, 2019, CELL DEATH DIFFER, V26, P1832, DOI 10.1038/s41418-018-0250-0
   Fabre T, 2014, J IMMUNOL, V193, P3925, DOI 10.4049/jimmunol.1400861
   Fasler-Kan E, 2005, OPHTHALMOLOGICA, V219, P214, DOI 10.1159/000085730
   Freudenberg K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00125
   Fujii H, 2007, BIOCHEM BIOPH RES CO, V354, P825, DOI 10.1016/j.bbrc.2007.01.067
   Hendrayani SF, 2016, ONCOTARGET, V7, P41974, DOI 10.18632/oncotarget.9633
   Hseu YC, 2019, FOOD CHEM TOXICOL, V124, P219, DOI 10.1016/j.fct.2018.12.009
   Jung KB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05450-8
   Jung KI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41790-1
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim M. S., 2019, CELL DEATH DIFFERENT, V26
   Klatzmann D, 2015, NAT REV IMMUNOL, V15, P283, DOI 10.1038/nri3823
   Kutty RK, 2018, CYTOKINE, V104, P147, DOI 10.1016/j.cyto.2017.10.009
   Li L, 2019, J CELL BIOCHEM, V120, P13372, DOI 10.1002/jcb.28612
   Li LL, 2018, THERANOSTICS, V8, P61, DOI 10.7150/thno.20893
   Li Q, 2019, EUR REV MED PHARMACO, V23, P3042, DOI 10.26355/eurrev_201904_17586
   Lin T, 2013, CYTOKINE, V62, P369, DOI 10.1016/j.cyto.2013.03.027
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Liu J, 2018, INT J MOL MED, V42, P3591, DOI 10.3892/ijmm.2018.3912
   Llavero F, 2016, CELL SIGNAL, V28, P1713, DOI 10.1016/j.cellsig.2016.07.014
   Luo J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01755
   Ma B, 2018, EXP EYE RES, V172, P94, DOI 10.1016/j.exer.2018.03.013
   Ma B, 2018, INT J BIOL SCI, V14, P437, DOI 10.7150/ijbs.23946
   Mack M, 2018, MATRIX BIOL, V68-69, P106, DOI 10.1016/j.matbio.2017.11.010
   Makarev E, 2014, AGING-US, V6, P1064, DOI 10.18632/aging.100711
   Marzec M, 2008, CANCER RES, V68, P1083, DOI 10.1158/0008-5472.CAN-07-2403
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitrokhin V, 2018, INT IMMUNOPHARMACOL, V64, P170, DOI 10.1016/j.intimp.2018.08.040
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Park JU, 2017, EUR J PHARMACOL, V799, P135, DOI 10.1016/j.ejphar.2017.02.002
   Qian YW, 2017, HEPATOLOGY, V66, P1165, DOI 10.1002/hep.29296
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Ricker LJAG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019141
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Roybal CN, 2018, AM J OPHTHALMOL, V186, P152, DOI 10.1016/j.ajo.2017.11.025
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Shelef MA, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4083
   Shen Y, 2016, EXP EYE RES, V145, P456, DOI 10.1016/j.exer.2015.09.016
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Tauriainen J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00196
   Taylor AE, 2018, HEPATOLOGY, V68, P1905, DOI 10.1002/hep.30061
   Tischner D, 2012, CELL DEATH DIFFER, V19, P1277, DOI 10.1038/cdd.2012.7
   van den Akker GG, 2017, CELL SIGNAL, V40, P190, DOI 10.1016/j.cellsig.2017.09.010
   Wang H, 2016, HYPERTENSION, V68, P114, DOI 10.1161/HYPERTENSIONAHA.116.07084
   Wang K, 2019, ACTA BIOCH BIOPH SIN, V51, P1, DOI 10.1093/abbs/gmy145
   Wang ZR, 2015, EXP THER MED, V10, P2437, DOI 10.3892/etm.2015.2809
   Wu DM, 2018, J CELL PHYSIOL, V233, P9488, DOI 10.1002/jcp.26843
   Yamamoto H, 2013, INT J BIOCHEM CELL B, V45, P2808, DOI 10.1016/j.biocel.2013.09.016
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Zhang Y, 2018, MED SCI MONITOR, V24, P7424, DOI 10.12659/MSM.910601
NR 53
TC 15
Z9 16
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1592
EI 1440-169X
J9 DEV GROWTH DIFFER
JI Dev. Growth Diff.
PD SEP
PY 2019
VL 61
IS 7-8
BP 410
EP 418
DI 10.1111/dgd.12630
EA OCT 2019
PG 9
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA JH4FG
UT WOS:000489875400001
PM 31608440
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Invernizzi, A
   Teo, K
   Nguyen, V
   Daniell, M
   Squirrell, D
   Barthelmes, D
   Gillies, MC
AF Invernizzi, Alessandro
   Teo, Kelvin
   Vuong Nguyen
   Daniell, Mark
   Squirrell, David
   Barthelmes, Daniel
   Gillies, Mark C.
TI Type 3 neovascularisation (retinal angiomatous proliferation) treated
   with antivascular endothelial growth factor: real-world outcomes at 24
   months
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE retinal angiomatous proliferation; type 3 CNV; choroidal
   neovascularisation; age-related macular degeneration; anti-VEGF; visual
   outcomes
ID MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB; FELLOW EYE; THERAPY;
   BEVACIZUMAB; RISK
AB Aims To compare 24 months outcomes of eyes with retinal angiomatous proliferations (RAPs) treated with antivascular endothelial growth factor (anti-VEGF) with a group of controls diagnosed with other neovascular age-related macular degeneration (nAMD) subtypes in a real-world setting. Methods Treatment-naive nAMD eyes that commenced anti-VEGF between January 2006 and November 2015 were identified from a registry of nAMD treatment outcomes. Cases were defined as eyes diagnosed with RAP. Three controls per case were selected among nAMD eyes with non-RAP lesions and matched on baseline visual acuity (VA), year of treatment initiation, anti-VEGF agent first injected and follow-up. Baseline VA was compared with 12 and 24 months VA. Change in VA, number of injections received, proportion of visits with active nAMD and time to first inactivation were compared between RAPs and controls. Results 157 RAPs and 469 controls were included. Baseline VA (mean (SD)) increased at 12 months (61.4 (15.5) vs 68.7 (14.7) letters, p<0.001) and remained higher (66.6 (17.3) letters) at 24 months (p<0.001) in RAPs. The change from baseline VA (mean(95% CI)) was significantly higher in RAPs than in controls at 12 months (7.3 (5.4 to 9.1) vs 4.1 (2.8 to 5.4) letters, p=0.01) and at 24 months (5.1 (2.8 to 7.3) vs 2.5 (1 to 4) letters, p=0.056). Both groups received a median of 13 injections. RAPs inactivated earlier and were less active than controls (both p<0.001). Conclusions RAPs responded well to anti-VEGF, with a significant improvement in VA persisting at 24 months. RAPs had better visual outcomes than controls at 12 and 24 months, tended to inactivate earlier and were less active throughout 2 years follow-up.
C1 [Invernizzi, Alessandro] Univ Milan, Eye Clin, Dept Biomed & Clin Sci Luigi Sacco, Luigi Sacco Hosp, I-20157 Milan, Italy.
   [Invernizzi, Alessandro; Teo, Kelvin; Vuong Nguyen; Barthelmes, Daniel; Gillies, Mark C.] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Teo, Kelvin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Daniell, Mark] Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Squirrell, David] Univ Auckland, Greenlane Clin Ctr, Auckland, New Zealand.
   [Barthelmes, Daniel] Univ Zurich, Univ Hosp Zurich, Zurich, Switzerland.
C3 University of Milan; Luigi Sacco Hospital; University of Sydney;
   National University of Singapore; Singapore National Eye Center; Centre
   for Eye Research Australia; University of Auckland; University of
   Zurich; University Zurich Hospital
RP Invernizzi, A (通讯作者)，Univ Milan, Eye Clin, Dept Biomed & Clin Sci Luigi Sacco, Luigi Sacco Hosp, I-20157 Milan, Italy.
EM alessandro.invernizzi@gmail.com
RI Daniell, Mark/AAS-1363-2020
OI Daniell, Mark/0000-0001-9528-7005; Nguyen, Vuong/0000-0001-9070-9803;
   Teo, Kelvin/0000-0002-7458-7081
FU Macular Disease Foundation Australia; Bayer; Novartis
FX The Fight Retinal Blindness! project is supported by a grant from the
   Macular Disease Foundation Australia and unrestricted educational grants
   from Bayer and Novartis.
CR [Anonymous], 2016, R LANG ENV STAT COMP
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bates D, 2013, J STAT SOFTW, V52, P1, DOI 10.18637/jss.v052.i05
   Campa C, 2010, EYE, V24, P1585, DOI 10.1038/eye.2010.88
   Cho HJ, 2016, GRAEF ARCH CLIN EXP, V254, P23, DOI 10.1007/s00417-015-2993-3
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Fang K, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/676049
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gillies MC, 2014, RETINA-J RET VIT DIS, V34, P188, DOI 10.1097/IAE.0b013e318296b271
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Gupta B, 2010, BRIT J OPHTHALMOL, V94, P672, DOI 10.1136/bjo.2009.166975
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hunter Megan A, 2004, Optometry, V75, P577, DOI 10.1016/S1529-1839(04)70190-6
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Konstantinidis L, 2009, GRAEF ARCH CLIN EXP, V247, P1165, DOI 10.1007/s00417-009-1089-3
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Montero JA, 2009, EUR J OPHTHALMOL, V19, P448, DOI 10.1177/112067210901900320
   Muggeo V.M.R., 2008, R NEWS, V8, P20, DOI DOI 10.1159/000323281
   Parodi MB, 2013, ACTA OPHTHALMOL, V91, P267, DOI 10.1111/j.1755-3768.2011.02265.x
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Scott AW, 2010, EYE, V24, P491, DOI 10.1038/eye.2009.311
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   von Elm E, 2007, PREV MED, V45, P247, DOI 10.1016/j.ypmed.2007.08.012
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
NR 33
TC 6
Z9 6
U1 1
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2019
VL 103
IS 9
BP 1337
EP 1341
DI 10.1136/bjophthalmol-2018-312944
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IT4RP
UT WOS:000482848500024
PM 30504490
DA 2022-11-30
ER

PT J
AU Abu Khamidakh, AE
   Rodriguez-Martinez, A
   Kaarniranta, K
   Kallioniemi, A
   Skottman, H
   Hyttinen, J
   Juuti-Uusitalo, K
AF Abu Khamidakh, Amna E.
   Rodriguez-Martinez, Alejandra
   Kaarniranta, Kai
   Kallioniemi, Anne
   Skottman, Heli
   Hyttinen, Jari
   Juuti-Uusitalo, Kati
TI Wound healing of human embryonic stem cell-derived retinal pigment
   epithelial cells is affected by maturation stage
SO BIOMEDICAL ENGINEERING ONLINE
LA English
DT Article
DE Image analysis; hESC-RPE; RPE; Cell maturation; Wound healing;
   Spontaneous; [Ca2+](i) increases; Mechanical stimulation; Ca2+ waves;
   Mechanically induced intercellular Ca2+ waves
ID MECHANICAL STIMULATION; MACULAR DEGENERATION; GROWTH-FACTOR; INDUCED
   CA2+; PROLIFERATION; RPE; MIGRATION; ACTIVATION; PROPAGATION; MODULATION
AB Background: Wound healing of retinal pigment epithelium (RPE) is a complex process that may take place in common age-related macular degeneration eye disease. The purpose of this study was to evaluate whether wounding and wound healing has an effect on Ca2+ dynamics in human embryonic stem cell (hESC)-RPEs cultured different periods of time.
   Methods: The 9-day-cultured or 28-day-cultured hESC-RPEs from two different cell lines were wounded and the dynamics of spontaneous and mechanically induced intracellular Ca2+ activity was measured with live-cell Ca2+ imaging either immediately or 7 days after wounding. The healing time and speed were analyzed with time-lapse bright field microscopy. The Ca2+ activity and healing speed were analysed with image analysis. In addition the extracellular matrix deposition was assessed with confocal microscopy.
   Results: The Ca2+ dynamics in hESC-RPE monolayers differed depending on the culture time: 9-day-cultured cells had higher number of cells with spontaneous Ca2+ activity close to freshly wounded edge compared to control areas, whereas in 28-day-cultured cells there was no difference in wounded and control areas. The 28-day-cultured, wounded and 7-day-healed hESC-RPEs produced wide-spreading intercellular Ca2+ waves upon mechanical stimulation, while in controls propagation was restricted. Most importantly, both wave spreading and spontaneous Ca2+ activity of cells within the healed area, as well as the cell morphology of 28-day-cultured, wounded and thereafter 7-day-healed areas resembled the 9-day-cultured hESC-RPEs.
   Conclusions: This acquired knowledge about Ca2+ dynamics of wounded hESC-RPE monolayers is important for understanding the dynamics of RPE wound healing, and could offer a reliable functionality test for RPE cells. The data presented in here suggests that assessment of Ca2+ dynamics analysed with image analysis could be used as a reliable non-invasive functionality test for RPE cells.
C1 [Abu Khamidakh, Amna E.; Hyttinen, Jari] Tampere Univ Technol, BioMediTech, Fac Biomed Sci & Engn, Arvo Ylpon Katu 34, Tampere, Finland.
   [Rodriguez-Martinez, Alejandra; Kallioniemi, Anne; Skottman, Heli; Juuti-Uusitalo, Kati] Tampere Univ Technol, BioMediTech, Fac Med & Life Sci, Arvo Ylpon Katu 34, Tampere, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio, Finland.
C3 Tampere University; Tampere University; University of Eastern Finland;
   Kuopio University Hospital; University of Eastern Finland
RP Juuti-Uusitalo, K (通讯作者)，Tampere Univ Technol, BioMediTech, Fac Med & Life Sci, Arvo Ylpon Katu 34, Tampere, Finland.
EM kati.juuti-uusitalo@staff.uta.fi
RI Hyttinen, Jari A/G-4280-2014
OI Hyttinen, Jari A/0000-0003-1850-3055; Juuti-Uusitalo,
   Kati/0000-0003-2275-5562; Skottman, Heli/0000-0002-4127-8792
FU Academy of Finland [296840, 252225, 218050, 137801]; Finnish Funding
   Agency for Technology and Innovation; Paivikki and Sakari Sohlberg
   foundation; Finnish Eye Foundation; Tampere University of Technology
FX This work was supported by the Academy of Finland [Grant Numbers 296840
   (KKa), 252225 (JHy), 218050 (HSk) and 137801 (KJ-U)], the Finnish
   Funding Agency for Technology and Innovation (JHy, HSk), Paivikki and
   Sakari Sohlberg foundation (HSk), The Finnish Eye Foundation (KKa), and
   Tampere University of Technology President's Doctoral Program (AAK). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abu Khamidakh AE, 2013, EXP EYE RES, V108, P129, DOI 10.1016/j.exer.2013.01.009
   Abu Khamidakh AE, 2016, ANN BIOMED ENG, V44, P3408, DOI 10.1007/s10439-016-1656-9
   Berra-Romani R, 2012, J VASC RES, V49, P65, DOI 10.1159/000329618
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Cordeiro JV, 2013, NAT REV MOL CELL BIO, V14, P249, DOI 10.1038/nrm3541
   Croze RH, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.6.7
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Farooqui R, 2005, J CELL SCI, V118, P51, DOI 10.1242/jcs.01577
   Gallagher-Colombo S, 2010, INVEST OPHTH VIS SCI, V51, P5343, DOI 10.1167/iovs.09-5028
   Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066
   Guo CM, 2009, CURR EYE RES, V34, P852, DOI 10.3109/02713680903128935
   HERGOTT GJ, 1993, INVEST OPHTH VIS SCI, V34, P2761
   Himpens B, 1999, FASEB J, V13, pS63
   Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643
   Kapyla E, 2014, LANGMUIR, V30, P14555, DOI 10.1021/la5023642
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Matsubayashi Y, 2004, CURR BIOL, V14, P731, DOI 10.1016/j.cub.2004.03.060
   Miura Y, 2003, JPN J OPHTHALMOL, V47, P268, DOI 10.1016/S0021-5155(03)00003-0
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Oganesian A, 1997, INT OPHTHALMOL, V21, P165, DOI 10.1023/A:1026402031902
   Pearson RA, 2005, NEURON, V46, P731, DOI 10.1016/j.neuron.2005.04.024
   Pearson RA, 2004, EUR J NEUROSCI, V19, P2435, DOI 10.1111/j.0953-816X.2004.03338.x
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Shabir S, 2008, CELL CALCIUM, V44, P453, DOI 10.1016/j.ceca.2008.02.008
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Skottman H, 2010, IN VITRO CELL DEV-AN, V46, P206, DOI 10.1007/s11626-010-9286-2
   Sorkio A, 2015, TISSUE ENG PT A, V21, P2301, DOI [10.1089/ten.tea.2014.0640, 10.1089/ten.TEA.2014.0640]
   Sorkio A, 2014, TISSUE ENG PT A, V20, P622, DOI 10.1089/ten.TEA.2013.0049
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stalmans P, 1999, CELL CALCIUM, V25, P391, DOI 10.1054/ceca.1999.0044
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Tamiya S, 2010, INVEST OPHTH VIS SCI, V51, P2755, DOI 10.1167/iovs.09-4725
   Tran POT, 1999, EXP CELL RES, V246, P319, DOI 10.1006/excr.1998.4239
   Tran POT, 1998, CELL PROLIFERAT, V31, P155
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   Woolley K, 2000, BIOESSAYS, V22, P911
   Yin J, 2007, J CELL SCI, V120, P815, DOI 10.1242/jcs.03389
NR 44
TC 3
Z9 3
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-925X
J9 BIOMED ENG ONLINE
JI Biomed. Eng. Online
PD JUL 31
PY 2018
VL 17
AR 102
DI 10.1186/s12938-018-0535-z
PG 20
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA GP0NN
UT WOS:000440507300002
PM 30064430
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Park, GB
   Kim, D
AF Park, Ga Bin
   Kim, Daejin
TI Cigarette smoke-induced EGFR activation promotes epithelial mesenchymal
   migration of human retinal pigment epithelial cells through regulation
   of the FAK-mediated Syk/Src pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE retinal pigment epithelial cell; cigarette smoke; focal adhesion kinase;
   epidermal growth factor receptor; epithelial mesenchymal transition; 12;
   15-lipooxygenase
ID FOCAL ADHESION KINASE; CONTENT SCREENING REVEALS; HUMAN BRONCHIAL CELLS;
   PROLIFERATIVE VITREORETINOPATHY; OXIDATIVE STRESS; UP-REGULATION;
   MACULAR DEGENERATION; ADJUNCTIVE TREATMENT; INHIBITOR ERLOTINIB;
   SIGNALING PATHWAYS
AB Epithelial-mesenchymal transition (EMT) of retinal pigment epithelial (RPE) cells is inevitable change of age-related macular degeneration (AMD). Smoking is a major risk factor for the development of EMT in several diseases, including lung cancer. Cigarette smoke-induced stress promotes the production of epidermal growth factor (EGF) in RPE cells. However, the underlying signaling pathways induced by aberrant EGF receptor (EGFR) expression in cigarette smoke-exposed RPE cells remain largely unknown. In the present study, the morphological transformation and production of EMT-associated cytokines were investigated to analyze the effect of smoking on the retina. Furthermore, EGF-treated or cigarette smoke-exposed RPE cells, as well as the downstream targets of EGFR, were investigated to identify the key molecules involved in EMT of cigarette smoke-stimulated RPE cells via immunoblotting. Exposure of RPE cells to cigarette smoke extract (CSE) induced secretion of VEGF and TGF-1, and increased the expression of EMT markers. CSE-mediated focal adhesion kinase (FAK) activation resulted in the phosphorylation and activation of spleen associated tyrosine kinase (Syk)/Src proto-oncogene, non-receptor tyrosine kinase (Src), leading to migration and invasion of RPE cells. Knockdown of FAK or pharmacological inhibition of Syk/Src abrogated CSE-mediated VEGF and TGF-1 production and blocked the phosphorylation of Smad2/3 in CSE-stimulated RPE cells. Erlotinib (an EGFR inhibitor) suppressed EGF and CSE-mediated switch from an epithelial to mesenchymal phenotype. Baicalein, an inhibitor of 12/15-lipooxygenase, also efficiently suppressed CSE-induced EMT processes by inhibiting EGFR-associated downstream signaling transduction. The results identified a novel signaling pathway mediated by EGFR in CSE-activated RPE cells, and suggest baicalein as a potential new therapeutic drug for CSE-associated retinopathy.
C1 [Park, Ga Bin] Kosin Univ, Coll Med, Dept Biochem, Busan 49267, South Korea.
   [Kim, Daejin] Inje Univ, Coll Med, Dept Anat, 75 Bokji Ro, Busan 47392, South Korea.
C3 Inje University
RP Kim, D (通讯作者)，Inje Univ, Coll Med, Dept Anat, 75 Bokji Ro, Busan 47392, South Korea.
EM kimdj@inje.ac.kr
FU Basic Science Research Program of Ministry of Education
   [NRF-2015R1D1A1A01056672]; Ministry of Science, ICT and Future Planning
   through the National Research Foundation of Republic of Korea
   [NRF-2015R1C1A2A01053732]
FX This study was supported by the Basic Science Research Program of
   Ministry of Education (grant no. NRF-2015R1D1A1A01056672) and Ministry
   of Science, ICT and Future Planning (grant no. NRF-2015R1C1A2A01053732)
   through the National Research Foundation of Republic of Korea. The
   sponsor had no role in the design or conduct of this research.
CR Al-Shabrawey M, 2011, DIABETES, V60, P614, DOI 10.2337/db10-0008
   Araya J, 2007, J CLIN INVEST, V117, P3551, DOI 10.1172/JCI32526
   Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007
   Buck E, 2007, MOL CANCER THER, V6, P532, DOI 10.1158/1535-7163.MCT-06-0462
   Carter CA, 2012, INT J TOXICOL, V31, P257, DOI 10.1177/1091581812440890
   Carter CA, 2009, TOXICOLOGY, V261, P89, DOI 10.1016/j.tox.2009.04.039
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chao HM, 2013, J OCUL PHARMACOL TH, V29, P539, DOI 10.1089/jop.2012.0179
   CHARTERIS DG, 1995, BRIT J OPHTHALMOL, V79, P953, DOI 10.1136/bjo.79.10.953
   Charteris DG, 2002, EYE, V16, P369, DOI 10.1038/sj.eye.6700194
   Chen Z, 2010, PATHOBIOLOGY, V77, P88, DOI 10.1159/000278290
   Cicchini C, 2008, EXP CELL RES, V314, P143, DOI 10.1016/j.yexcr.2007.09.005
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Filosto S, 2012, MOL CANCER THER, V11, P795, DOI 10.1158/1535-7163.MCT-11-0698
   Ha GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070353
   Hewing NJ, 2013, INVEST OPHTH VIS SCI, V54, P864, DOI 10.1167/iovs.12-10954
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hollborn M, 2006, CURR EYE RES, V31, P863, DOI 10.1080/02713680600888807
   Khan EM, 2008, FASEB J, V22, P910, DOI 10.1096/fj.06-7729com
   Kim J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074342
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Lee H, 2007, INVEST OPHTH VIS SCI, V48, P4291, DOI 10.1167/iovs.07-0086
   Lee MY, 2008, CLIN CANCER RES, V14, P4743, DOI 10.1158/1078-0432.CCR-08-0234
   Liu SX, 2007, MOL BIOL CELL, V18, P2169, DOI 10.1091/mbc.E06-12-1121
   Lu Q, 2011, AM J PHYSIOL-LUNG C, V301, pL847, DOI 10.1152/ajplung.00178.2011
   Morales SA, 2009, INVEST OPHTH VIS SCI, V50, P462, DOI 10.1167/iovs.07-1598
   Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S
   Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359
   Ottino P, 2003, EXP EYE RES, V76, P613, DOI 10.1016/S0014-4835(03)00003-4
   Peng HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014750
   RYAN SJ, 1993, AM J OPHTHALMOL, V115, P1
   Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2
   Seth RK, 2001, INVEST OPHTH VIS SCI, V42, P3239
   Shen Hong, 2014, J Parasitol Res, V2014, P272601, DOI 10.1155/2014/272601
   Tanaka Y, 2004, J BIOL CHEM, V279, P8567, DOI 10.1074/jbc.M309131200
   Thannickal VJ, 2003, J BIOL CHEM, V278, P12384, DOI 10.1074/jbc.M208544200
   Ueno NT, 2011, J CANCER, V2, P324, DOI 10.7150/jca.2.324
   Uttamsingh S, 2008, ONCOGENE, V27, P2626, DOI 10.1038/sj.onc.1210915
   Wertheimer C, 2013, GRAEF ARCH CLIN EXP, V251, P1529, DOI 10.1007/s00417-013-2257-z
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Zhang Q, 2005, AM J RESP CELL MOL, V32, P72, DOI 10.1165/rcmb.2004-0198OC
   Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X
NR 43
TC 20
Z9 24
U1 0
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2018
VL 17
IS 3
BP 3563
EP 3574
DI 10.3892/mmr.2017.8355
PG 12
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FV2MB
UT WOS:000424400000016
PM 29286114
OA Green Submitted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Miere, A
   Querques, G
   Semoun, O
   Amoroso, F
   Zambrowski, O
   Chapron, T
   Capuano, V
   Souied, EH
AF Miere, Alexandra
   Querques, Giuseppe
   Semoun, Oudy
   Amoroso, Francesca
   Zambrowski, Olivia
   Chapron, Thibaut
   Capuano, Vittorio
   Souied, Eric H.
TI OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES IN EARLY TYPE 3
   NEOVASCULARIZATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
   TREATMENT
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; type 3 neovascularization;
   chorioretinal anastomosis; retinal angiomatous proliferation; optical
   coherence tomography angiography
ID RETINAL ANGIOMATOUS PROLIFERATION; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; ANASTOMOSIS
AB Purpose: To investigate the morphologic changes on optical coherence tomography angiography (OCTA) of treatment-naive Type 3 neovascularization secondary to exudative age-related macular degeneration after 1 year of anti-vascular endothelial growth factor therapy.
   Methods: Consecutive patients diagnosed with treatment-naive early-stage Type 3 neovascularization were enrolled in this retrospective study. All patients underwent color fundus photographs/MultiColor (Heidelberg Engineering) imaging, fluorescein angiography, indocyanine green angiography, structural spectral domain OCT, and OCTA Optovue RTVue XR Avanti (Optovue) at baseline, and repeated OCTA and structural spectral domain OCT at Month 12. Qualitative analysis of the 3 x 3 OCTA examinations at baseline and Month 12 was then compared, to assess changes after anti-vascular endothelial growth factor therapy.
   Results: A total of 15 treatment-naive eyes of 15 consecutive patients were included in the analysis. At 12-month follow-up after pro-re-data anti-vascular endothelial growth factor therapy (5.75 +/- 1.48 injections of ranibizumab, and injections of 6.33 +/- 1.21 of aflibercept), OCTA demonstrated persistence of the deep capillary plexus abnormalities in 13/15 eyes. In the outer retina and choriocapillaris, the initial lesion became undetectable in 7/15 cases, accompanied by choriocapillaris atrophy. The abnormal vascular complex persisted in the form of a tuft-shaped lesion in the outer retinal segmentation in 9/15 eyes, which in the choriocapillaris segmentation was associated with sub-retinal pigment epithelium neovascularization in 8 cases.
   Conclusion: Optical coherence tomography angiography showed that the tuft-shaped abnormal outer retinal lesion, frequently associated with a small clew-like flow signal in the choriocapillaris, after 1 year of anti-vascular endothelial growth factor therapy, either becomes undetectable or develops sub-retinal pigment epithelium neovascularization.
C1 [Miere, Alexandra; Semoun, Oudy; Amoroso, Francesca; Zambrowski, Olivia; Chapron, Thibaut; Capuano, Vittorio; Souied, Eric H.] Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Querques, Giuseppe] Univ Vita Salute San Raffaele, IRCCS, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Querques, G (通讯作者)，Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM Giuseppe.querques@hotmail.it
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Querques,
   Giuseppe/0000-0002-3292-9581
CR Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Jackson TL, 2014, RETINA-J RET VIT DIS, V34, P568, DOI 10.1097/IAE.0b013e3182a487be
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Querques G, 2015, RETINA-J RET VIT DIS, V35, P603, DOI 10.1097/IAE.0000000000000487
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1241, DOI 10.1097/IAE.0b013e31827b639e
   Querques G, 2012, RETINA-J RET VIT DIS, V32, P458, DOI 10.1097/IAE.0b013e3182205960
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zhang M, 2015, BIOMED OPT EXPRESS, V6, P4661, DOI 10.1364/BOE.6.004661
NR 16
TC 33
Z9 35
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2017
VL 37
IS 10
BP 1873
EP 1879
DI 10.1097/IAE.0000000000001447
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FI1GH
UT WOS:000411680300019
PM 28079756
DA 2022-11-30
ER

PT J
AU Isipradit, S
   Sirimaharaj, M
   Charukamnoetkanok, P
   Thonginnetra, O
   Wongsawad, W
   Sathornsumetee, B
   Somboonthanakij, S
   Soomsawasdi, P
   Jitawatanarat, U
   Taweebanjongsin, W
   Arayangkoon, E
   Arame, P
   Kobkoonthon, C
   Pangputhipong, P
AF Isipradit, Saichin
   Sirimaharaj, Maytinee
   Charukamnoetkanok, Puwat
   Thonginnetra, Oraorn
   Wongsawad, Warapat
   Sathornsumetee, Busaba
   Somboonthanakij, Sudawadee
   Soomsawasdi, Piriya
   Jitawatanarat, Umapond
   Taweebanjongsin, Wongsiri
   Arayangkoon, Eakkachai
   Arame, Punyawee
   Kobkoonthon, Chinsuchee
   Pangputhipong, Pannet
TI The First Rapid Assessment of Avoidable Blindness (RAAB) in Thailand
SO PLOS ONE
LA English
DT Article
ID CATARACT BLINDNESS; VISUAL IMPAIRMENT; GLOBAL BLINDNESS; LOW-VISION;
   PREVALENCE; POPULATION; DISTRICT
AB Background: The majority of vision loss is preventable or treatable. Population surveys are crucial for planning, implementation, and monitoring policies and interventions to eliminate avoidable blindness and visual impairments. This is the first rapid assessment of avoidable blindness (RAAB) study in Thailand.
   Methods: A cross-sectional study of a population in Thailand age 50 years old or over aimed to assess the prevalence and causes of blindness and visual impairments. Using the Thailand National Census 2010 as the sampling frame, a stratified four-stage cluster sampling based on a probability proportional to size was conducted in 176 enumeration areas from 11 provinces. Participants received comprehensive eye examination by ophthalmologists.
   Results: The age and sex adjusted prevalence of blindness (presenting visual acuity (VA),<20/400), severe visual impairment(VA, <20/200 but >= 20/400), and moderate visual impairment (VA <20/70 but >= 20/200) were 0.6% (95% CI: 0.5-0.8), 1.3% (95% CI: 1.0-1.6), 12.6% (95% CI: 10.8-14.5). There was no significant difference among the four regions of Thailand. Cataract was the main cause of vision loss accounted for 69.7% of blindness. Cataract surgical coverage in persons was 95.1% for cut off VA of 20/400. Refractive errors, diabetic retinopathy, glaucoma, and corneal opacities were responsible for 6.0%, 5.1%, 4.0%, and 2.0% of blindness respectively.
   Conclusion: Thailand is on track to achieve the goal of VISION 2020. However, there is still much room for improvement. Policy refinements and innovative interventions are recommended to alleviate blindness and visual impairments especially regarding the backlog of blinding cataract, management of non-communicative, chronic, age-related eye diseases such as glaucoma, age-related macular degeneration, and diabetic retinopathy, prevention of childhood blindness, and establishment of a robust eye health information system.
C1 [Isipradit, Saichin; Sirimaharaj, Maytinee; Charukamnoetkanok, Puwat; Thonginnetra, Oraorn; Wongsawad, Warapat; Sathornsumetee, Busaba; Somboonthanakij, Sudawadee; Soomsawasdi, Piriya; Jitawatanarat, Umapond; Taweebanjongsin, Wongsiri; Arayangkoon, Eakkachai; Arame, Punyawee; Kobkoonthon, Chinsuchee; Pangputhipong, Pannet] Mettapracharak Wat Rai Khing Hosp, Sampran 73210, Nakornprathom, Thailand.
RP Charukamnoetkanok, P (通讯作者)，Mettapracharak Wat Rai Khing Hosp, 52 Moo 2 Rai Khing, Sampran 73210, Nakornprathom, Thailand.
EM drpuwat@yahoo.com
FU Department of Medical Services, Ministry of Public Health, Kingdom of
   Thailand
FX This work was supported by the Department of Medical Services, Ministry
   of Public Health, Kingdom of Thailand. The funder had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amansakhatov S, 2002, BRIT J OPHTHALMOL, V86, P1207, DOI 10.1136/bjo.86.11.1207
   Bachani D, 2000, Indian J Public Health, V44, P82
   Bastawrous A, 2012, OPHTHALMOLOGY, V119, P432, DOI 10.1016/j.ophtha.2011.11.014
   Beltranena F, 2007, OPHTHALMOLOGY, V114, P1558, DOI 10.1016/j.ophtha.2006.11.015
   Casson RJ, 2007, OPHTHALMOLOGY, V114, P2302, DOI 10.1016/j.ophtha.2007.02.004
   Chou R, 2009, ANN INTERN MED, V151, P44, DOI 10.7326/0003-4819-151-1-200907070-00008
   Dineen B, 2006, OPHTHAL EPIDEMIOL, V13, P31, DOI 10.1080/09286580500473787
   Duerksen R, 2003, OPHTHAL EPIDEMIOL, V10, P349, DOI 10.1076/opep.10.5.349.17326
   Foster A, 2001, BRIT J OPHTHALMOL, V85, P635, DOI 10.1136/bjo.85.6.635
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Haider S, 2003, OPHTHALMIC EPIDEMIOL, V10, P249, DOI 10.1076/opep.10.4.249.15907
   Jenchitr W, 2007, THAI J PUB HLTH OPHT, V21, P11
   Konyama K, 1998, Community Eye Health, V11, P19
   Kuper Hannah, 2006, Community Eye Health, V19, P68
   Limburg H, 1998, Ophthalmic Epidemiol, V5, P211, DOI 10.1076/opep.5.4.211.4193
   Limburg H, 1996, BRIT J OPHTHALMOL, V80, P951, DOI 10.1136/bjo.80.11.951
   Limburg H, 1997, INT J EPIDEMIOL, V26, P1049, DOI 10.1093/ije/26.5.1049
   Limburg H, 2008, BRIT J OPHTHALMOL, V92, P315, DOI 10.1136/bjo.2007.125906
   Mathenge W, 2007, PLOS MED, V4, P1187, DOI 10.1371/journal.pmed.0040217
   Mathenge W, 2007, OPHTHALMOLOGY, V114, P599, DOI 10.1016/j.ophtha.2006.06.057
   Nirmalan PK, 2005, INVEST OPHTH VIS SCI, V46, P2308, DOI 10.1167/iovs.04-0830
   Pararajasegaram R, 2011, COMMUNICATION
   Saw SM, 2003, BRIT J OPHTHALMOL, V87, P1075, DOI 10.1136/bjo.87.9.1075
   Schwab L, 2007, EYE CARE DEV NATIONS, P235
   Smith AF, 1996, BRIT J OPHTHALMOL, V80, P276, DOI 10.1136/bjo.80.4.276
   West S, 2001, B WORLD HEALTH ORGAN, V79, P244
   WHO Programme for the Prevention of Blindness, 1990, WHOPBL9018
   Wong TY, 2008, AM J OPHTHALMOL, V146, P656, DOI 10.1016/j.ajo.2008.07.048
   World Health Organization (WHO), 2013, UN EYE HLTH GLOB ACT
   Wu Min, 2007, Community Eye Health, V20, P10
   Zainal M, 2002, BRIT J OPHTHALMOL, V86, P951, DOI 10.1136/bjo.86.9.951
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
NR 32
TC 22
Z9 23
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 11
PY 2014
VL 9
IS 12
AR e114245
DI 10.1371/journal.pone.0114245
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AX8FY
UT WOS:000347146700017
PM 25502762
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Igarashi, T
   Miyake, N
   Fujimoto, C
   Yaguchi, C
   Iijima, O
   Shimada, T
   Takahashi, H
   Miyake, K
AF Igarashi, Tsutomu
   Miyake, Noriko
   Fujimoto, Chiaki
   Yaguchi, Chiemi
   Iijima, Osamu
   Shimada, Takashi
   Takahashi, Hiroshi
   Miyake, Koichi
TI Adeno-associated virus type 8 vector-mediated expression of siRNA
   targeting vascular endothelial growth factor efficiently inhibits
   neovascularization in a murine choroidal neovascularization model
SO MOLECULAR VISION
LA English
DT Article
ID SHORT HAIRPIN RNA; MACULAR DEGENERATION; GENE-THERAPY; OCULAR
   NEOVASCULARIZATION; PERMEABILITY FACTOR; MOUSE MODEL; CELLS; VEGF;
   ANGIOGENESIS; SUPPRESSION
AB siRNA-Purpose: To assess the feasibility of a gene therapeutic approach to treating choroidal neovascularization (CNV), we generated an adeno-associated virus type 8 vector (AAV2/8) encoding an siRNA targeting vascular endothelial growth factor (VEGF), and determined the AAV2/8 vector's ability to inhibit angiogenesis.
   Methods: We initially transfected 3T3 cells expressing VEGF with the AAV2/8 plasmid vector psiRNA-VEGF using the H1 promoter and found that VEGF expression was significantly diminished in the transfectants. We next injected 1 l (3 x 10(14) vg/ml) of AAV2/8 vector encoding siRNA targeting VEGF (AAV2/8/SmVEGF-2; n = 12) or control vector encoding green fluorescent protein (GFP) (AAV2/8/GFP; n = 14) into the subretinal space in C57BL/6 mice. One week later, CNV was induced by using a diode laser to make four separate choroidal burns around the optic nerve in each eye. After an additional 2 weeks, the eyes were removed for flat mount analysis of the CNV surface area.
   Results: Subretinal delivery of AAV2/8/SmVEGF-2 significantly diminished CNV at the laser lesions, compared to AAV8/GFP (1597.3 +/- 2077.2 versus 5039.5 +/- 4055.9 mu m(2); p< 0.05). Using an enzyme-linked immunosorbent assay, we found that VEGF levels were reduced by approximately half in the AAV2/8/SmVEGF-2 treated eyes.
   Conclusions: These results suggest that siRNA-VEGF can be expressed across the retina and that long-term suppression of CNV is possible through the use of stable AAV2/8-mediated siRNA-VEGF expression. In vivo gene therapy may thus be a feasible approach to the clinical management of CNV in conditions such as age-related macular degeneration.
C1 [Igarashi, Tsutomu; Fujimoto, Chiaki; Yaguchi, Chiemi; Takahashi, Hiroshi] Nippon Med Sch, Dept Ophthalmol, Tokyo 1138602, Japan.
   [Igarashi, Tsutomu; Miyake, Noriko; Iijima, Osamu; Shimada, Takashi; Miyake, Koichi] Nippon Med Sch, Res Ctr Adv Med Technol, Div Gene Therapy, Dept Biochem & Mol Biol, Tokyo 1138602, Japan.
C3 Nippon Medical School; Nippon Medical School
RP Miyake, K (通讯作者)，Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.
EM kmiyake@nms.ac.jp
OI Igarashi, Tsutomu/0000-0002-7467-6746
FU Ministry of MEXT (Ministry of Education, Culture, Sports, Science and
   Technology, Japan) [23792014]; MEXT-supported program for the strategic
   research foundation at private universities [S0801034]
FX This work was supported in part by Grant-in-Aid for Young Scientists (B)
   (23792014) from the Ministry of MEXT (Ministry of Education, Culture,
   Sports, Science and Technology, Japan) and Grant (S0801034) from
   MEXT-supported program for the strategic research foundation at private
   universities, 2008-2012. We thank Dr. James Wilson at the University of
   Pennsylvania for providing AAV packaging plasmids (pacH and p5E18-VD2/
   8). We also thank Yukihiko Hirai for making AAV viral vectors and Nagisa
   Asakawa and Maika Kobayashi for technical assistance.
CR ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Ashikari M, 2010, INVEST OPHTH VIS SCI, V51, P3820, DOI 10.1167/iovs.09-5121
   Askou AL, 2012, J GENE MED, V14, P632, DOI 10.1002/jgm.2678
   Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dinculescu A, 2005, HUM GENE THER, V16, P649, DOI 10.1089/hum.2005.16.649
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gu LP, 2010, EXP EYE RES, V91, P433, DOI 10.1016/j.exer.2010.06.019
   Hao DL, 2005, ACTA BIOCH BIOPH SIN, V37, P779, DOI 10.1111/j.1745-7270.2005.00107.x
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   HOTCHKISS ML, 1981, AM J OPHTHALMOL, V91, P177, DOI 10.1016/0002-9394(81)90170-7
   Igarashi T, 2003, GENE THER, V10, P219, DOI 10.1038/sj.gt.3301878
   Igarashi T, 2013, CURR EYE RES, V38, P569, DOI 10.3109/02713683.2013.779720
   Igarashi T, 2010, HUM GENE THER, V21, P631, DOI 10.1089/hum.2009.153
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Miyake K, 2012, J NIPPON MED SCH, V79, P394, DOI 10.1272/jnms.79.394
   Mussolino C, 2011, GENE THER, V18, P637, DOI 10.1038/gt.2011.3
   MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895
   Naito Y, 2004, NUCLEIC ACIDS RES, V32, pW124, DOI 10.1093/nar/gkh442
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Reich S, 2003, MOL VIS, V9, P210
   Ro S, 2005, BIOTECHNIQUES, V38, P625, DOI 10.2144/05384RN01
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   Singerman L, 2009, RETINA-J RET VIT DIS, V29, pS49, DOI 10.1097/IAE.0b013e3181ad2341
   Starr CE, 1998, POSTGRAD MED, V103, P153, DOI 10.3810/pgm.1998.05.480
   Stieger K, 2008, MOL THER, V16, P916, DOI 10.1038/mt.2008.41
   Takahashi H, 2005, CLIN EXP RHEUMATOL, V23, P455
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 42
TC 7
Z9 8
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 11
PY 2014
VL 20
BP 488
EP 496
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AK3HL
UT WOS:000338314000004
PM 24744609
DA 2022-11-30
ER

PT J
AU Chiu, SJ
   Izatt, JA
   O'Connell, RV
   Winter, KP
   Toth, CA
   Farsiu, S
AF Chiu, Stephanie J.
   Izatt, Joseph A.
   O'Connell, Rachelle V.
   Winter, Katrina P.
   Toth, Cynthia A.
   Farsiu, Sina
TI Validated Automatic Segmentation of AMD Pathology Including Drusen and
   Geographic Atrophy in SD-OCT Images
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; COLOR FUNDUS PHOTOGRAPHS; MACULAR
   DEGENERATION; RETINAL LAYERS; RETICULAR PSEUDODRUSEN;
   RETINITIS-PIGMENTOSA; CUTICULAR DRUSEN; DEPOSITS; THICKNESS; DIAGNOSIS
AB PURPOSE. To automatically segment retinal spectral domain optical coherence tomography (SD-OCT) images of eyes with age-related macular degeneration (AMD) and various levels of image quality to advance the study of retinal pigment epithelium (RPE)+drusen complex (RPEDC) volume changes indicative of AMD progression.
   METHODS. A general segmentation framework based on graph theory and dynamic programming was used to segment three retinal boundaries in SD-OCT images of eyes with drusen and geographic atrophy (GA). A validation study for eyes with nonneovascular AMD was conducted, forming subgroups based on scan quality and presence of GA. To test for accuracy, the layer thickness results from two certified graders were compared against automatic segmentation results for 220 B-scans across 20 patients. For reproducibility, automatic layer volumes were compared that were generated from 0 degrees versus 90 degrees scans in five volumes with drusen.
   RESULTS. The mean differences in the measured thicknesses of the total retina and RPEDC layers were 4.2 +/- 2.8 and 3.2 +/- 2.6 mu m for automatic versus manual segmentation. When the 0 degrees and 90 degrees datasets were compared, the mean differences in the calculated total retina and RPEDC volumes were 0.28% +/- 0.28% and 1.60% +/- 1.57%, respectively. The average segmentation time per image was 1.7 seconds automatically versus 3.5 minutes manually.
   CONCLUSIONS. The automatic algorithm accurately and reproducibly segmented three retinal boundaries in images containing drusen and GA. This automatic approach can reduce time and labor costs and yield objective measurements that potentially reveal quantitative RPE changes in longitudinal clinical AMD studies. (ClinicalTrials.gov number, NCT00734487.) (Invest Ophthalmol Vis Sci. 2012;53:53-61) DOI:10.1167/iovs.11-7640
C1 [Chiu, Stephanie J.; Izatt, Joseph A.; Toth, Cynthia A.; Farsiu, Sina] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
   [Izatt, Joseph A.; O'Connell, Rachelle V.; Winter, Katrina P.; Toth, Cynthia A.; Farsiu, Sina] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27708 USA.
C3 Duke University; Duke University
RP Chiu, SJ (通讯作者)，Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA.
EM stephanie.chiu@duke.edu
RI Izatt, Joseph/C-9067-2014; Toth, Cynthia/L-5534-2019; toth, cynthia
   a/F-5614-2011
OI Izatt, Joseph/0000-0003-1993-2249; Toth, Cynthia/0000-0002-2324-0854;
   Farsiu, Sina/0000-0003-4872-2902
FU American Health Assistance Foundation; Genentech [IST-4400S]
FX Supported in part by the American Health Assistance Foundation. The A2A
   SD-OCT Study was funded in part by Genentech Grant IST-4400S, with
   clinical imaging equipment support from Bioptigen and Alcon
   Laboratories.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Cormen TH., 2009, INTRO ALGORITHMS
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Dijkstra E, 1959, NUMER MATH, V1, P269, DOI DOI 10.1007/BF01386390
   Farsiu S, 2008, SPIE
   Finger RP, 2010, RETINA-J RET VIT DIS, V30, P1455, DOI 10.1097/IAE.0b013e3181e09829
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Freund DE, 2009, I S BIOMED IMAGING, P61, DOI 10.1109/ISBI.2009.5192983
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HEE MR, 1992, J OPT SOC AM B, V9, P903, DOI 10.1364/JOSAB.9.000903
   Hood DC, 2009, INVEST OPHTH VIS SCI, V50, P2328, DOI 10.1167/iovs.08-2936
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Mishra A, 2009, OPT EXPRESS, V17, P23719, DOI 10.1364/OE.17.023719
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1163, DOI 10.1097/IAE.0b013e3181ed8d05
   Szkulmowski M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771569
   Tatlipinar S, 2007, OPHTHALMOLOGICA, V221, P227, DOI 10.1159/000101923
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Yang Q, 2011, BIOMED OPT EXPRESS, V2, P2493, DOI 10.1364/BOE.2.002493
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zawadzki RJ, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2772658
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 51
TC 176
Z9 179
U1 2
U2 24
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2012
VL 53
IS 1
BP 53
EP 61
DI 10.1167/iovs.11-7640
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 924LY
UT WOS:000302694500008
PM 22039246
DA 2022-11-30
ER

PT J
AU Finger, RP
   Fimmers, R
   Holz, FG
   Scholl, HPN
AF Finger, Robert P.
   Fimmers, Rolf
   Holz, Frank G.
   Scholl, Hendrik P. N.
TI Prevalence and causes of registered blindness in the largest federal
   state of Germany
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID UNREGISTERED VISUAL IMPAIRMENT; MACULAR DEGENERATION; SOUTHERN GERMANY;
   ACUITY; POPULATION; HEALTH; MYOPIA; EYE
AB Aim As no current estimates for the prevalence and causes of blindness in Germany are available, the database of Germany's largest welfare institution (covering 9.5 million people in the federal state of Northrhine) assessing eligibility for an allowance payable to blind people was used to investigate the prevalence and the specific causes of blindness and visual impairment.
   Methods Data from a representative sample of 5100 cases out of 20 365 cases were extracted, entered into an electronic database and statistically analysed. Blindness and severe vision impairment were defined as visual acuity equal to or below 20/1000 and 20/400, respectively, in the better-seeing eye.
   Results The mean age of the overall sample was 72 +/- 22 years and the mean visual acuity of the better seeing eye was 20/800. The prevalence of blindness and severe vision impairment in Northrhine was estimated to be 47.91 per 100 000 persons. Most registered visual impairment was due to age-related macular degeneration (AMD; 41%), followed by glaucoma (15%) and diabetic eye disease (10%). Sixty-five per cent of registered blind people were women, 56% of them over the age of 80 years. Registered children and teenagers had the relative worst visual acuity (hand movement) and patients with retinal dystrophies had the relative best visual acuity (20/200) within the whole cohort (p<0.001). Standardised prevalence of blindness and severe visual impairment for Germany is estimated to be 44.4/100.000 (57.94 for women and 30.78 for men).
   Conclusions Prevalence of blindness and severe vision impairment for Germany compare well to other European countries. AMD is the most prevalent cause of registered blindness and severe vision impairment, and prevalence in women is higher. Generally, prevalence increases with age. Provision of support and welfare services need to be organised accordingly.
C1 [Finger, Robert P.; Holz, Frank G.; Scholl, Hendrik P. N.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Finger, Robert P.] Univ Melbourne, Dept Ophthalmol, Melbourne, Vic, Australia.
   [Fimmers, Rolf] Univ Bonn, Dept Biostat, D-53127 Bonn, Germany.
   [Scholl, Hendrik P. N.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
C3 University of Bonn; University of Melbourne; University of Bonn; Johns
   Hopkins University; Johns Hopkins Medicine
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM robert.finger@ukb.uni-bonn.de
OI Finger, Robert P/0000-0003-4253-7597
FU National Neurovision Research Institute (NNRI) - Foundation Fighting
   Blindness (FFB) [NNCD-CL-0310.0049-JHU-WG]; American Health Assistance
   Foundation (AHAF) [M2010042]
FX The authors thank the welfare institution Landschaftsverband Rheinland
   (LVR) for its continuing support and access to the database, and in
   particular Mr Lukas, who made this study possible. The authors are
   grateful to Reena Kunjandy and Mavus Suat, who helped with data
   collection. Supported by the Wynn-Gund Translational Research
   Acceleration Program Enhanced Research and Clinical Training Award,
   National Neurovision Research Institute (NNRI) - Foundation Fighting
   Blindness (FFB; NNCD-CL-0310.0049-JHU-WG); and the Macular Degeneration
   Research Award, American Health Assistance Foundation (AHAF; M2010042).
CR Abou-Gareeb I, 2001, Ophthalmic Epidemiol, V8, P39, DOI 10.1076/opep.8.1.39.1540
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bach M, 2007, INVEST OPHTHALMOL VI
   Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Berger W, 2010, PROG RETIN EYE RES, V29, P335, DOI 10.1016/j.preteyeres.2010.03.004
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brezin Antoine Pierre, 2005, Health Qual Life Outcomes, V3, P27, DOI 10.1186/1477-7525-3-27
   Brezin AP, 2004, BRIT J OPHTHALMOL, V88, P1330, DOI 10.1136/bjo.2003.039180
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   DOBSON AJ, 1991, STAT MED, V10, P457, DOI 10.1002/sim.4780100317
   Espinet Lawrence M, 2005, Dis Manag, V8, P86, DOI 10.1089/dis.2005.8.86
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Finger RP, 2007, OPHTHALMOLOGE, V104, P839, DOI 10.1007/s00347-007-1600-3
   Gissler M, 2003, J EPIDEMIOL COMMUN H, V57, P433, DOI 10.1136/jech.57.6.433
   Gissler M, 2002, MED INFORM INTERNET, V27, P33, DOI 10.1080/14639230110119234
   Gissler M, 2000, EUR J EPIDEMIOL, V16, P59, DOI 10.1023/A:1007639230040
   Graf M, 1999, KLIN MONATSBL AUGENH, V215, P50, DOI 10.1055/s-2008-1034669
   Jobke S, 2008, CLIN OPHTHALMOL, V2, P601
   Johnson NL, 2005, WILEY SER PROBAB ST, P1, DOI 10.1002/0471715816
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Knauer C, 2006, OPHTHALMOLOGE, V103, P735, DOI 10.1007/s00347-006-1411-y
   Lam CSY, 2004, OPTOMETRY VISION SCI, V81, P317, DOI 10.1097/01.opx.0000134905.98403.18
   Lin LLK, 2004, ANN ACAD MED SINGAP, V33, P27
   Ng HKT, 2008, COMPUT STAT DATA AN, V52, P3501, DOI 10.1016/j.csda.2007.11.004
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Resnikoff S, 2008, B WORLD HEALTH ORGAN, V86, P63, DOI 10.2471/BLT.07.041210
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Rohrschneider K, 2004, KLIN MONATSBL AUGENH, V221, P116, DOI 10.1055/s-2004-812724
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   *STAT BUND DEUTSCH, 2009, BEV NACH ALT FAM REL
   *STAT BUND DEUTSCH, 2009, BEV 31 12 NACH GESCH
   *STAT BUND DEUTSCH, 2006, DAT 2006 ZAH FAKT BU
   Trautner C, 2001, DIABETOLOGIA, V44, P147, DOI 10.1007/s001250051592
   Trautner C, 1997, DIABETES CARE, V20, P1147, DOI 10.2337/diacare.20.7.1147
   Trautner C, 2003, INVEST OPHTH VIS SCI, V44, P1031, DOI 10.1167/iovs.02-0304
   Villagra VG, 2004, HEALTH AFFAIR, V23, P255, DOI 10.1377/hlthaff.23.4.255
   World Health Organization, 1990, INT CLASS DIS
NR 40
TC 66
Z9 66
U1 0
U2 7
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2011
VL 95
IS 8
BP 1061
EP 1067
DI 10.1136/bjo.2010.194712
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 793ST
UT WOS:000292844100006
PM 21378005
DA 2022-11-30
ER

PT J
AU Barzelay, A
   Lowenstein, A
   George, J
   Barak, A
AF Barzelay, Aya
   Lowenstein, Anat
   George, Jacob
   Barak, Adiel
TI Influence of Non-Toxic Doses of Bevacizumab and Ranibizumab on
   Endothelial Functions and Inhibition of Angiogenesis
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age related macular degeneration; Angiogenesis; Anti-angiogenic therapy;
   Choroidal neovascularization; Retina
ID MACULAR DEGENERATION; IN-VITRO; INTRAVITREAL INJECTION; CELLS; GROWTH;
   VASCULOGENESIS; EXPRESSION; BINDING; VEGF; PENETRATION
AB Purpose: Ranibizumab (Lucentis) is an antibody fragment developed against all fragments of vascular endothelial growth factor (VEGF) that was approved by the FDA for treating age-related macular degeneration (AMD). Bevacizumab, a full-length anti-VEGF antibody approved for use in colon cancer, is non-FDA approved at this time but it is widely used for treating AMD. The purpose of this study was to compare the influence of Bevacizumab and Ranibizumab on angiogenesis in an in vitro model.
   Methods: A model consisting of H5V cells derived from murine hearts capillary endothelial cells (ECs) was used. The H5V cells were treated with three concentrations of Bevacizumab and Ranibizumab (0.125 mg/mL, 0.25 mg/mL, and 0.50 mg/mL) for 24 hr before all experiments. The effects of Bevacizumab and Ranibizumab on EC proliferation were compared by 3H-thymidine incorporation essay. Toxic effects and the safety of each drug in clinical concentrations were assessed by annexin 5 staining. The effects of the drugs on ECs functions were assessed by their ability to adhere to fibronectin and by evaluation of the cells' tube formation capacity on matrigel.
   Results: Both Bevacizumab and Ranibizumab equally suppressed the adhesive properties of ECs to fibronectin, and similarly inhibited ECs' proliferation capacity in a dose-dependent manner. Both Bevacizumab and Ranibizumab inhibited the ECs' tube formation capacity on matrigel, and were equally safe.
   Conclusions: Ranibizumab and Bevacizumab at low, non-toxic doses similarly inhibit several properties of the angiogenesis process. Inhibition of ECs adhesion to fibronectin and tube formation capacity does not seem to be directly related to the anti-angiogenic effects as indicated by inhibition of VEGF. Further studies for delineating the exact mechanism of action of Ranibizumab and Bevacizumab in angiogenesis are warranted.
C1 [Lowenstein, Anat; Barak, Adiel] Tel Aviv Univ, Tel Aviv Med Ctr, Dept Ophthalmol, Sackler Sch Med, IL-64239 Tel Aviv, Israel.
   [Barzelay, Aya; George, Jacob] Tel Aviv Univ, Tel Aviv Med Ctr, Vasc Biol Lab, Sackler Sch Med, IL-64239 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University;
   Sackler Faculty of Medicine
RP Barak, A (通讯作者)，Tel Aviv Univ, Tel Aviv Med Ctr, Dept Ophthalmol, Sackler Sch Med, 6 Weizman St, IL-64239 Tel Aviv, Israel.
EM omadb@post.tau.ac.il
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barzelay A, 2010, THROMB HAEMOSTASIS, V103, P188, DOI 10.1160/TH09-07-0433
   Ben-Shoshan J, 2008, STEM CELLS, V26, P2634, DOI 10.1634/stemcells.2008-0369
   Ben-Shoshan J, 2009, J VASC RES, V46, P299, DOI 10.1159/000181546
   Bischoff J, 1997, J CLIN INVEST, V99, P373, DOI 10.1172/JCI119168
   Bouhadir KH, 1998, ANN NY ACAD SCI, V842, P188, DOI 10.1111/j.1749-6632.1998.tb09647.x
   Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653
   Costa R, 2009, J CELL BIOCHEM, V108, P1410, DOI 10.1002/jcb.22378
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291
   Gien J, 2007, AM J RESP CRIT CARE, V176, P1146, DOI 10.1164/rccm.200705-750OC
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kim BS, 1998, J BIOMED MATER RES, V41, P322, DOI 10.1002/(SICI)1097-4636(199808)41:2<322::AID-JBM18>3.0.CO;2-M
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Kramer I, 2007, J CLIN PHARM THER, V32, P1, DOI 10.1111/j.1365-2710.2007.00800.x
   Kurzen H, 2003, ANTI-CANCER DRUG, V14, P515, DOI 10.1097/00001813-200308000-00003
   MARTIN DF, PRINCIPAL INVESTIGAT
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moreno SF, 2008, BRIT J OPHTHALMOL, V92, P866
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   Vacca A, 1999, BLOOD, V94, P4143, DOI 10.1182/blood.V94.12.4143.424k26_4143_4155
   Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252
   Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475
   Zhao B, 2006, BRIT J OPHTHALMOL, V90, P1052, DOI 10.1136/bjo.2006.091215
NR 31
TC 6
Z9 6
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD SEP
PY 2010
VL 35
IS 9
BP 835
EP 841
DI 10.3109/02713683.2010.489727
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664KL
UT WOS:000282958700009
PM 20795866
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Dubois, L
   Nghiem-Buffet, S
   Ayrault, S
   Fajnkuchen, F
   Guiberteau, B
   Delahaye-Mazza, C
   Quentel, G
   Tadayoni, R
AF Cohen, Salomon Y.
   Dubois, Lise
   Nghiem-Buffet, Sylvia
   Ayrault, Sandrine
   Fajnkuchen, Franck
   Guiberteau, Brigitte
   Delahaye-Mazza, Corinne
   Quentel, Gabriel
   Tadayoni, Ramin
TI Retinal Pseudocysts in Age-Related Geographic Atrophy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL-COHERENCE-TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE; MACULAR
   DEGENERATION; PATTERNS
AB PURPOSE: To report the presence of pseudocysts in retinal layers of eyes with geographic atrophy (GA) attributable to age-related macular degeneration (AMD) and to estimate their prevalence.
   DESIGN: Retrospective study.
   METHODS: SETTING: Clinical practice. PATIENTS: Consecutive patients with GA, assessed by spectral-domain optical coherence tomography (OCT). MAIN OUTCOME MEASURES: Assessment of pseudocyst prevalence in retinal layers. Statistical analysis by the chi(2) test, Fisher exact test, Mann-Whitney U test, and Cramer test, performed to explore links between the presence of pseudocysts and demographic features and/or pattern of atrophy, ie, horseshoe, homogeneous area, homogeneous area or patchy atrophy with foveal sparing, and patchy atrophy.
   RESULTS: Eighty-eight eyes of 68 GA patients aged between 61 and 94 years (mean: 79.8) were examined. In 20 patients, GA was bilateral. Twenty-four eyes (27.2%) exhibited pseudocysts corresponding to small cystoid spaces frequently located in the inner nuclear layer of the retina. There was no macular edema. Fluorescein angiography, performed in 71 eyes (80%), ruled out possible choroidal neovascularization. No correlation was found between 1) patients' age (P = .7) or gender (P > .99) and the presence of pseudocysts or 2) patterns of atrophy (Cramer test: V = 0.183) and the presence of pseudocysts.
   CONCLUSIONS: Pseudocysts seemed to be frequent in atrophic AMD. They might correspond to Muller cell degeneration, as suspected in other degenerative retinal disorders like tamoxifen retinopathy or group 2A idiopathic juxtafoveolar retinal telangiectasis. The present results indicate that pseudocysts are frequently seen on OCT in eyes with atrophic AMD and their presence should not be considered as a manifestation of neovascular AMD that requires prompt treatment. (Am J Ophthalmol 2010;150:211-217. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Cohen, Salomon Y.; Dubois, Lise; Nghiem-Buffet, Sylvia; Ayrault, Sandrine; Fajnkuchen, Franck; Guiberteau, Brigitte; Delahaye-Mazza, Corinne; Quentel, Gabriel] Ctr Ophtalmol Imagerie & Laser, F-75015 Paris, France.
   [Cohen, Salomon Y.; Tadayoni, Ramin] Univ Paris Diderot, Hop Lariboisiere, Dept Ophthalmol, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite
RP Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycsyc75@gmail.com
RI Mitchell, Paul/P-1498-2014
FU CIL-ASSOC (PARIS, FRANCE), AN ASSOCIATION FOR RESEARCH AND education
FX PUBLICATION OF THIS STUDY WAS SUPPORTED BY CIL-ASSOC (PARIS, FRANCE), AN
   ASSOCIATION FOR RESEARCH AND education. The study involved no financial
   conflict of interest. Involved in design of study (S.Y.C.); analysis and
   interpretation of data (S.Y.C., L.D., S.N.-B., R.T.), data collection
   (L.D., S.A.), preparation of the manuscript (S.Y.C., R.T.); and review
   and approval of the manuscript (S.Y.C., L.D., S.N.-B., S.A., F.F.,
   C.D.-M., B.G., G.Q., R.T.). Although French law does not require
   Institutional Review Board agreement for a retrospective study,
   agreement was nevertheless obtained from the IRB and Ethics Committee of
   the Societe Francaise d'Ophtalmologie (French Society of Ophthalmology).
   All patient records and data were stored in a secure location.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Chen YL, 2009, OPT EXPRESS, V17, P4046, DOI 10.1364/OE.17.004046
   Cohen SM, 2007, RETINA-J RET VIT DIS, V27, P59, DOI 10.1097/01.iae.0000256663.94734.e1
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gaudric A, 2008, GRAEF ARCH CLIN EXP, V246, P1071, DOI 10.1007/s00417-008-0818-3
   Gaudric A, 2006, ARCH OPHTHALMOL-CHIC, V124, P1410, DOI 10.1001/archopht.124.10.1410
   Gualino V, 2005, AM J OPHTHALMOL, V140, P757, DOI 10.1016/j.ajo.2005.04.042
   Hassenstein A, 2001, KLIN MONATSBL AUGENH, V218, P503, DOI 10.1055/s-2001-16293
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Solbach U, 1997, RETINA-J RET VIT DIS, V17, P385
   Sunness JS, 2006, RETINA-J RET VIT DIS, V26, P666, DOI 10.1097/00006982-200607000-00013
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   van Velthoven MEJ, 2007, PROG RETIN EYE RES, V26, P57, DOI 10.1016/j.preteyeres.2006.10.002
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 29
TC 55
Z9 58
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2010
VL 150
IS 2
BP 211
EP 217
DI 10.1016/j.ajo.2010.02.019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 635ZT
UT WOS:000280697800012
PM 20537310
DA 2022-11-30
ER

PT J
AU Fuchshofer, R
   Yu, AL
   Teng, HH
   Strauss, R
   Kampik, A
   Welge-Lussen, U
AF Fuchshofer, Rudolf
   Yu, Alice L.
   Teng, Hiang-Hwa
   Strauss, Rupert
   Kampik, Anselm
   Welge-Lussen, Ulrich
TI Hypoxia/reoxygenation induces CTGF and PAI-1 in cultured human retinal
   pigment epithelium cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE hypoxia; reoxygenation; age-related macular degeneration; retinal
   pigment epithelium; extracellular matrix
ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; TISSUE GROWTH-FACTOR;
   HYPOXIA-RESPONSE ELEMENT; AGE-RELATED MACULOPATHY; EXTRACELLULAR-MATRIX;
   GENE-EXPRESSION; MACULAR DEGENERATION; FREE-RADICALS; RISK-FACTORS;
   TGF-BETA
AB Early age-related macular degeneration (AMD) is characterized by thickening of Bruch's membrane due to the accumulation of extracellular matrix (ECM). This finding could be related to hypoxia of the retinal pigment epithelium (RPE). In the present study, we investigated the effects of hypoxia and reoxygenation on the expression of connective tissue growth factor (CTGF), plasminogen activator inhibitor-1 (PAI-1), collagen type IV (Col IV) and fibronectin (Fn) in cultured human RPE cells. Cultured human RPE cells were kept for 12-36 h under hypoxic conditions (1% O-2). Reoxygenation was conducted for 24 h. Hypoxia-mediated CTGF and PAI-1 expression were analyzed by using immunohistochemistry, Northern and Western blot analysis. Actinomycin D was added to examine whether hypoxia induces the transcription of CTGF and PAI-1 mRNA. Furthermore, cells were transfected with siRNA against hypoxia-inducible factor-1alpha (HIF-1 alpha) and kept under hypoxic conditions. The effects of antioxidants on hypoxia/reoxygenation-mediated CTGF and PAI-1 expression were tested by real-time PCR analysis. Production of Col IV and Fn were investigated by real-time PCR and Western blot analysis. Both hypoxia and hypoxia/reoxygenation increased the expression of CTGF, PAI-1, Col IV and Fn. Actinomycin D prevented the new transcription of CTGF and PAI-1 mRNA by hypoxia. Using siRNA against HIF-1 alpha, the hypoxia-mediated increase of CTGF and PAI-1 was inhibited. Antioxidants attenuated the reoxygenation-mediated increase of CTGF and PAI-1. The process of hypoxia/reoxygenation in the RPE may lead to an increase of ECM in the RPE and thus may contribute to the accumulation of ECM in Bruch's membrane. (C) 2008 Published by Elsevier Ltd.
C1 [Fuchshofer, Rudolf] Univ Regensburg, Dept Anat, D-93053 Regensburg, Germany.
   [Yu, Alice L.; Teng, Hiang-Hwa; Strauss, Rupert; Kampik, Anselm; Welge-Lussen, Ulrich] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
   [Welge-Lussen, Ulrich] Univ Erlangen Nurnberg, Augenklin, Dept Ophthalmol, D-91054 Erlangen, Germany.
C3 University of Regensburg; University of Munich; University of Erlangen
   Nuremberg; University of Hamburg; University Medical Center
   Hamburg-Eppendorf
RP Welge-Lussen, U (通讯作者)，Univ Erlangen Nurnberg, Augenklin, Dept Ophthalmol, Schwabachanlage 6, D-91054 Erlangen, Germany.
EM Ulrich.Welge@uk-erlangen.de
RI Fuchshofer, Rudolf/E-8221-2010; Fuchshofer, Rudolf/M-3712-2019
OI Fuchshofer, Rudolf/0000-0002-0474-6980; Fuchshofer,
   Rudolf/0000-0002-0474-6980
FU DFG [WE 2577/2-1]; DOG Research Support
FX The authors thank Angelika Pach, Jerome Moriniere and Katja Obholzer for
   excellent technical assistance.; This work was supported by DFG WE
   2577/2-1 and DOG Research Support to UWL
CR Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497
   Arden G B, 2006, J Br Menopause Soc, V12, P64, DOI 10.1258/136218006777525703
   Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Blalock TD, 2003, INVEST OPHTH VIS SCI, V44, P1879, DOI 10.1167/iovs.02-0860
   Blokhina O, 2003, ANN BOT LOND, V91, P179
   Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169
   Campbell JY, 1988, REV FINANC STUD, V1, P195, DOI 10.1093/rfs/1.3.195
   CERIELLO A, 1995, BLOOD COAGUL FIBRIN, V6, P133, DOI 10.1097/00001721-199504000-00008
   Chen CP, 2005, J CLIN ENDOCR METAB, V90, P1083, DOI 10.1210/jc.2004-0803
   Distler JHW, 2007, ARTHRITIS RHEUM-US, V56, P4203, DOI 10.1002/art.23074
   Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396
   Erichsen JT, 2001, INT J BIOCHEM CELL B, V33, P237, DOI 10.1016/S1357-2725(01)00009-7
   Fink T, 2002, BLOOD, V99, P2077, DOI 10.1182/blood.V99.6.2077
   Fogo AB, 2000, AM J KIDNEY DIS, V35, P179, DOI 10.1016/S0272-6386(00)70324-6
   Fogo AB, 1999, EXP NEPHROL, V7, P147
   Glazer-Hockstein C, 2006, RETINA-J RET VIT DIS, V26, P1, DOI 10.1097/00006982-200601000-00001
   Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Higgins DF, 2004, AM J PHYSIOL-RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004
   Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009
   Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1111/j.1523-1755.1998.00820.x
   Jiang Z, 2003, BIOCHEM BIOPH RES CO, V309, P961, DOI 10.1016/j.bbrc.2003.08.102
   Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185
   Kigasawa Kazuteru, 1998, Tokai Journal of Experimental and Clinical Medicine, V23, P147
   Kim KH, 2004, BIOCHEM BIOPH RES CO, V318, P819, DOI 10.1016/j.bbrc.2004.04.108
   Kondo S, 2006, MOL CANCER THER, V5, P129, DOI 10.1158/1535-7163.MCT-05-0097
   Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769
   Leask A, 2004, J INVEST DERMATOL, V122, P1, DOI 10.1046/j.0022-202X.2003.22133.x
   Lee HB, 2005, NEPHROLOGY, V10, pS11, DOI 10.1111/j.1440-1797.2005.00449.x
   Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1
   LESCHEY KH, 1990, INVEST OPHTH VIS SCI, V31, P839
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   LEVINSON RM, 1986, AM REV RESPIR DIS, V134, P1241
   Li C, 2002, EXP LUNG RES, V28, P373, DOI 10.1080/01902140290092001
   Li CY, 2002, AM J PHYSIOL-CELL PH, V282, pC227, DOI 10.1152/ajpcell.00112.2001
   Lijnen HR, 2005, J THROMB HAEMOST, V3, P35, DOI 10.1111/j.1538-7836.2004.00827.x
   Liu Q, 2004, BLOOD, V104, P3993, DOI 10.1182/blood-2004-03-1017
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   Marx J, 2006, SCIENCE, V311, P1704, DOI 10.1126/science.311.5768.1704
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   MCCORD JM, 1985, NEW ENGL J MED, V312, P159
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mukai Y, 2007, AM J PHYSIOL-HEART C, V292, pH1937, DOI 10.1152/ajpheart.00868.2006
   NEWSOME DA, 1988, EXP EYE RES, V46, P305, DOI 10.1016/S0014-4835(88)80022-8
   Paradis V, 1999, HEPATOLOGY, V30, P968, DOI 10.1002/hep.510300425
   Park SK, 2001, BIOCHEM BIOPH RES CO, V284, P966, DOI 10.1006/bbrc.2001.5058
   Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307
   Priglinger SG, 2003, INVEST OPHTH VIS SCI, V44, P355, DOI 10.1167/iovs.02-0224
   ROBIN ED, 1982, CHEST, V82, P659, DOI 10.1378/chest.82.6.659
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1
   Tuan TL, 1996, J INVEST DERMATOL, V106, P1007, DOI 10.1111/1523-1747.ep12338552
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   Watanabe D, 2005, RETINA-J RET VIT DIS, V25, P911, DOI 10.1097/00006982-200510000-00015
   Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12
   Welge-Lussen U, 2000, INVEST OPHTH VIS SCI, V41, P2229
   Wileman SM, 2000, BRIT J OPHTHALMOL, V84, P417, DOI 10.1136/bjo.84.4.417
   Yang Cheng, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P133
   Zhang QZ, 2003, J INVEST DERMATOL, V121, P1005, DOI 10.1046/j.1523-1747.2003.12564.x
   Zhou Z, 2005, J CELL BIOCHEM, V96, P109, DOI 10.1002/jcb.20567
NR 65
TC 18
Z9 18
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAY
PY 2009
VL 88
IS 5
BP 889
EP 899
DI 10.1016/j.exer.2008.11.036
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 443GO
UT WOS:000265898400005
PM 19118548
DA 2022-11-30
ER

PT J
AU Witmer, AN
   Vrensen, GFJM
   Van Noorden, CJF
   Schlingemann, RO
AF Witmer, AN
   Vrensen, GFJM
   Van Noorden, CJF
   Schlingemann, RO
TI Vascular endothelial growth factors and angiogenesis in eye disease
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE vascular endothelial growth factors; endothelial growth factor
   receptors; angiogenesis; vascular permeability; endothelial cells;
   pericytes; tissue distribution; eye; diabetic retinopathy; age-related
   macular degeneration
ID EPITHELIUM-DERIVED FACTOR; PROTEIN-KINASE-C; CONVERTING
   ENZYME-INHIBITION; RECEPTOR-BINDING PROPERTIES; RETINAL-PIGMENT
   EPITHELIUM; HUMAN DIABETIC-RETINOPATHY; IN-VIVO; UP-REGULATION;
   PERMEABILITY FACTOR; FACTOR VEGF
AB The vascular endothelial growth factor (VEGF) family of growth factors controls pathological angiogenesis and increased vascular permeability in important eye diseases such as diabetic retinopathy (DR) and age-related macular degeneration (AMD). The purpose of this review is to develop new insights into the cell biology of VEGFs and vascular cells in angiogenesis and vascular leakage in general, and to provide the rationale and possible pitfalls of inhibition of VEGFs as a therapy for ocular disease. From the literature it is clear that overexpression of VEGFs and their receptors VEGFR-1, VEGFR-2 and VEGFR-3 is causing increased microvascular permeability and angiogenesis in eye conditions such as DR and AMD. When we focus on the VEGF receptors, recent findings suggest a role of VEGFR-1 as a functional receptor for placenta growth factor (PIGF) and vascular endothelial growth factor-A (VEGF)-A in pericytes and vascular smooth muscle cells in vivo rather than in endothelial cells, and strongly suggest involvement of pericytes in early phases of angiogenesis. In addition, the evidence pointing to distinct functions of VEGFs in physiology in and outside the vasculature is reviewed. The cellular distribution of VEGFR-1, VEGFR-2 and VEGFR-3 suggests various specific functions of the VEGF family in normal retina, both in the retinal vasculature and in neuronal elements. Furthermore, we focus on recent findings that VEGFs secreted by epithelia, including the retinal pigment epithelium (RPE), are likely to mediate paracrine vascular survival signals for adjacent endothelia. In the choroid, derailment of this paracrine relation and overexpression of VEGF-A by RPE may explain the pathogenesis of subretinal neovascularisation in AMD. On the other hand, this paracrine relation and other physiological functions of VEGFs may be endangered by therapeutic VEGF inhibition, as is currently used in several clinical trials in DR and AMD. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Ocular Angiogenesis Grp, NL-1100 DD Amsterdam, Netherlands.
   Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Histol & Cell Biol, NL-1100 DD Amsterdam, Netherlands.
C3 University of Amsterdam; Academic Medical Center Amsterdam; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University -
   Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam
RP Schlingemann, RO (通讯作者)，Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Ocular Angiogenesis Grp, POB 22660, NL-1100 DD Amsterdam, Netherlands.
EM r.schlingemann@amc.uva.nl
CR Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   AIELLO LP, 1994, P NATL ACAD SCI USA, V91, P6231, DOI 10.1073/pnas.91.13.6231
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36
   ANDERSON S, 1993, AM J PHYSIOL, V265, pF477, DOI 10.1152/ajprenal.1993.265.4.F477
   Antonetti D A, 1999, Semin Ophthalmol, V14, P240, DOI 10.3109/08820539909069543
   Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Arden GB, 2001, BRIT J OPHTHALMOL, V85, P366, DOI 10.1136/bjo.85.3.366
   ASHTON N, 1966, AM J OPHTHALMOL, V62, P412, DOI 10.1016/0002-9394(66)91322-5
   ASHTON N, 1957, AM J OPHTHALMOL, V44, P7, DOI 10.1016/0002-9394(57)90426-9
   Aymerich MS, 2001, INVEST OPHTH VIS SCI, V42, P3287
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Bellomo D, 2000, CIRC RES, V86, pE29, DOI 10.1161/01.RES.86.2.e29
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Boulton M, 1998, BRIT J OPHTHALMOL, V82, P561, DOI 10.1136/bjo.82.5.561
   BREIER G, 1992, DEVELOPMENT, V114, P521
   Burrows JF, 1996, RES HUMAN COMP, V4, P1
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389
   Cao YH, 1996, J CLIN INVEST, V98, P2507, DOI 10.1172/JCI119069
   Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867
   Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x
   Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133
   Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Chader GJ, 2001, P NATL ACAD SCI USA, V98, P2122, DOI 10.1073/pnas.061024098
   Chakravarthy U, 1999, PROG RETIN EYE RES, V18, P511, DOI 10.1016/S1350-9462(98)00034-2
   CHARNOCKJONES DS, 1993, BIOL REPROD, V48, P1120, DOI 10.1095/biolreprod48.5.1120
   Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0
   Chua CC, 1998, BBA-MOL CELL RES, V1401, P187, DOI 10.1016/S0167-4889(97)00129-8
   Clarijs R, 2001, INVEST OPHTH VIS SCI, V42, P1422
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209
   Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9
   Crabbe MJC, 1998, PROG RETIN EYE RES, V17, P313, DOI 10.1016/S1350-9462(97)00013-X
   CROCKER DJ, 1970, EXP MOL PATHOL, V13, P51, DOI 10.1016/0014-4800(70)90084-5
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Detmar M, 2000, J DERMATOL SCI, V24, pS78, DOI 10.1016/S0923-1811(00)00145-6
   Dor Y, 1997, TRENDS CARDIOVAS MED, V7, P289, DOI 10.1016/S1050-1738(97)00091-1
   Drake CJ, 2000, DEV BIOL, V224, P178, DOI 10.1006/dbio.2000.9744
   Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946
   Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   ENGERMAN RL, 1967, LAB INVEST, V17, P738
   Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41
   Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947
   Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003
   FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341
   FAWCETT DW, 1986, TXB HISTOLOGY, V11, P913
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   Folkman J, 1997, EXS, V79, P1
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Fong TAT, 1999, CANCER RES, V59, P99
   Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197
   Gao GQ, 2002, J BIOL CHEM, V277, P9492, DOI 10.1074/jbc.M108004200
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gerhardinger C, 2001, DIABETES, V50, P175, DOI 10.2337/diabetes.50.1.175
   Gerhardinger C, 1998, AM J PATHOL, V152, P1453
   Gilbert RE, 1998, LAB INVEST, V78, P1017
   Gilbert RE, 2000, DIABETOLOGIA, V43, P1360, DOI 10.1007/s001250051539
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Grierson I, 2000, PROG RETIN EYE RES, V19, P779, DOI 10.1016/S1350-9462(00)00015-X
   Gunningham SP, 2001, J PATHOL, V193, P325, DOI 10.1002/path.814
   Hammes HP, 1998, DIABETES, V47, P401, DOI 10.2337/diabetes.47.3.401
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hellstrom A, 2001, P NATL ACAD SCI USA, V98, P5804, DOI 10.1073/pnas.101113998
   Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6
   Hofman P, 2001, ARCH OPHTHALMOL-CHIC, V119, P861
   Hofman P, 2001, OPHTHALMIC RES, V33, P156, DOI 10.1159/000055663
   Hofman P, 2000, CURR EYE RES, V21, P637, DOI 10.1076/0271-3683(200008)21:2;1-V;FT637
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hornig C, 2000, LAB INVEST, V80, P443, DOI 10.1038/labinvest.3780050
   Hughes S, 2000, INVEST OPHTH VIS SCI, V41, P1217
   Ishida S, 2000, INVEST OPHTH VIS SCI, V41, P1649
   Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242
   Joukov V, 1996, EMBO J, V15, P290
   KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077
   KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566
   Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   Khaliq A, 1998, LAB INVEST, V78, P109
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   KLEIN R, 1989, DIABETES METAB REV, V5, P559, DOI 10.1002/dmr.5610050703
   Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859
   Kozlowska U, 1998, ARCH DERMATOL RES, V290, P661, DOI 10.1007/s004030050370
   Kremer C, 1997, CANCER RES, V57, P3852
   Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729
   Kukk E, 1996, DEVELOPMENT, V122, P3829
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   La Heij E C, 2001, Ned Tijdschr Geneeskd, V145, P1390
   Lahdenranta J, 2001, P NATL ACAD SCI USA, V98, P10368, DOI 10.1073/pnas.181329198
   Laird AD, 2000, CANCER RES, V60, P4152
   LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011
   Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6
   Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671
   Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Mathews MK, 1997, INVEST OPHTH VIS SCI, V38, P2729
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621
   MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9
   Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K
   Miyamoto K, 1997, MICROVASC RES, V54, P43, DOI 10.1006/mvre.1997.2018
   Miyamoto K, 1999, Semin Ophthalmol, V14, P233, DOI 10.3109/08820539909069542
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   MONACCI WT, 1993, AM J PHYSIOL, V264, pC995, DOI 10.1152/ajpcell.1993.264.4.C995
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   MORIARTY P, 1994, BRIT J OPHTHALMOL, V78, P638, DOI 10.1136/bjo.78.8.638
   Murata T, 1996, LAB INVEST, V74, P819
   MURATA T, 1995, OPHTHALMIC RES, V27, P48, DOI 10.1159/000267567
   NEHLS V, 1994, MICROVASC RES, V48, P349, DOI 10.1006/mvre.1994.1061
   NEHLS V, 1993, HISTOCHEMISTRY, V99, P1, DOI 10.1007/BF00268014
   NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048
   NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   NOMURA M, 1995, J BIOL CHEM, V270, P28316
   Odorisio T, 2002, J CELL SCI, V115, P2559
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ogata N, 2001, CURR EYE RES, V22, P245, DOI 10.1076/ceyr.22.4.245.5506
   Ogata N, 2001, AM J OPHTHALMOL, V132, P427, DOI 10.1016/S0002-9394(01)01021-2
   Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842
   ORTEGA N, 1999, FRONT BIOSCI, V4, P141
   Ostendorf T, 1999, J CLIN INVEST, V104, P913, DOI 10.1172/JCI6740
   Otani A, 1998, CIRC RES, V82, P619, DOI 10.1161/01.RES.82.5.619
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3
   PAGANMERCADO G, 2002, INVEST OPHTH VIS SCI, V43, pS3700
   Paques M, 2000, CURR EYE RES, V21, P560, DOI 10.1076/0271-3683(200007)21:1;1-Z;FT560
   Paques M, 1997, DIABETES METAB, V23, P125
   Parenti A, 2002, CARDIOVASC RES, V55, P201, DOI 10.1016/S0008-6363(02)00326-7
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.0.CO;2-E
   Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com
   Peer J, 1996, BRIT J OPHTHALMOL, V80, P241, DOI 10.1136/bjo.80.3.241
   Persico MG, 1999, CURR TOP MICROBIOL, V237, P31
   Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Plate KH, 1997, J NEURO-ONCOL, V35, P365
   PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415
   Podesta F, 2000, AM J PATHOL, V156, P1025, DOI 10.1016/S0002-9440(10)64970-X
   Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   RAVIOLA G, 1977, EXP EYE RES, V25, P27, DOI 10.1016/S0014-4835(77)80009-2
   Regnault TRH, 2002, PLACENTA, V23, P132, DOI 10.1053/plac.2001.0757
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Ruiter D J, 1993, Behring Inst Mitt, P258
   Saaristo A, 2000, AM J PATHOL, V157, P7, DOI 10.1016/S0002-9440(10)64510-5
   SCHLINGEMANN RO, 1990, LAB INVEST, V62, P690
   SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393
   Schlingemann RO, 1996, J PATHOL, V179, P436
   Schlingemann RO, 1999, DIABETOLOGIA, V42, P596, DOI 10.1007/s001250051200
   SCHLINGEMANN RO, 1991, AM J PATHOL, V138, P1335
   SCHRODER S, 1991, AM J PATHOL, V139, P81
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057
   Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979
   Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7
   SHIFREN JL, 1994, J CLIN ENDOCR METAB, V79, P316, DOI 10.1210/jc.79.1.316
   Shinoda K, 1999, BRIT J OPHTHALMOL, V83, P834, DOI 10.1136/bjo.83.7.834
   Shinoda K, 2000, CURR EYE RES, V21, P655, DOI 10.1076/0271-3683(200008)21:2;1-V;FT655
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Simon M, 1998, J AM SOC NEPHROL, V9, P1032
   Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643
   Smith K, 1999, GREEN CHEM, V1, P83, DOI 10.1039/a901395d
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x
   Sone H, 2000, INVEST OPHTH VIS SCI, V41, P1876
   Sone H, 1997, DIABETOLOGIA, V40, P726, DOI 10.1007/s001250050740
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spranger J, 2000, DIABETOLOGIA, V43, P1404, DOI 10.1007/s001250051546
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Stitt AW, 1998, J PATHOL, V186, P306, DOI 10.1002/(SICI)1096-9896(1998110)186:3<306::AID-PATH183>3.0.CO;2-B
   Stitt AW, 1997, AM J PATHOL, V150, P523
   Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290
   Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016
   Talks KL, 2000, BRIT J HAEMATOL, V109, P477, DOI 10.1046/j.1365-2141.2000.01864.x
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Terris B, 1998, HISTOPATHOLOGY, V32, P133
   Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002
   THIEME H, 1995, DIABETES, V44, P98, DOI 10.2337/diabetes.44.1.98
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589
   TSAI JYY, 2002, INVEST OPHTH VIS SCI, V43, pS1929
   Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8
   Veikkola T, 2000, CANCER RES, V60, P203
   Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223
   Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091
   Vuorela P, 2000, OBSTET GYNECOL, V95, P353, DOI 10.1016/S0029-7844(99)00565-7
   WALDBILLIG RJ, 1988, EXP EYE RES, V47, P587, DOI 10.1016/0014-4835(88)90097-8
   Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   WILLIAMS B, 1995, HYPERTENSION, V25, P913, DOI 10.1161/01.HYP.25.5.913
   WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801
   Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603
   Witmer AN, 2002, INVEST OPHTH VIS SCI, V43, P849
   Witmer AN, 2001, J PATHOL, V195, P490, DOI 10.1002/path.969
   Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4
   Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006
   Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317
   Yi XJ, 1998, EXP BRAIN RES, V118, P155, DOI 10.1007/s002210050267
   Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6
   Ziche M, 1997, LAB INVEST, V76, P517
NR 247
TC 672
Z9 739
U1 2
U2 108
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2003
VL 22
IS 1
BP 1
EP 29
AR PII S1350-9462(02)00043-5
DI 10.1016/S1350-9462(02)00043-5
PG 29
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 652XE
UT WOS:000181405500001
PM 12597922
DA 2022-11-30
ER

PT J
AU Li, YJ
   Ou, KP
   Wang, YW
   Luo, LY
   Chen, ZZ
   Wu, JH
AF Li, Youjian
   Ou, Kepeng
   Wang, Yuwei
   Luo, Liying
   Chen, Zhongzhu
   Wu, Jiahui
TI TLR9 agonist suppresses choroidal neovascularization by restricting
   endothelial cell motility via ERK/c-Jun pathway
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE Choroidal neovascularization; CpG-ODN; TLR9 agonist; Cell proliferation
ID OXIDATIVE STRESS; IMMUNE-RESPONSE; C-JUN; ANGIOGENESIS; RECOGNITION;
   ACTIVATION; RECEPTORS; KINASE
AB Introduction: Choroidal neovascularization (CNV) is the feature of neovascular age-related macular degeneration (AMD). It has been demonstrated that inflammation plays a key role in the development of CNV. Here we aim to investigate how TLR9 agonist (CpG-ODN), one of the key regulators of inflammatory responses, suppresses CNV in vivo.
   Materials and methods: The cell viability was assessed by MTT and EdU test after CpG-ODN treatment. Endothelial cells gap assay, tube formation assay and transwell assay were practiced to observe how CpG-ODN affected the endothelial cells functions. The choroidal explants and laser-induced CNV model were built to investigate how CpG-ODN suppressed angiogenesis. The ERK and c-Jun expression were evaluated to assess if CpG-ODN affected cell proliferation. Flow cytometry and qPCR was practiced to observe how CpG-ODN regulated cell proliferation.
   Results: Our data showed that CpG-ODN not only reduced CNV area in vivo, but also decreased the RPE damage. CpG-ODN inhibited endothelial cells from migration and forming tubes, while the effect was not toxic. EdU test and MTT test suggested that CpG-ODN inhibited endothelial cells proliferation. CpG-ODN significantly increased protein expression of phosphorylated c-Jun but reduced phosphorylated ERK in HUVECs, which was confirmed in ERK transfected 293T cells. JNK inhibitor abolished the suppression of endothelial cells migration and tube formation by CpG-ODN. The findings were also in agreement with the observation in CpG-ODN treated CNV eyes in vivo. The flow cytometry and qPCR data revealed that the suppression of cell motility by CpG-ODN was achieved by arresting endothelial cells cell cycle at G0/G1 phase.
   Conclusions: Our study demonstrated that CpG-ODN suppressed endothelial cell motility by restricting the cell cycle progression at G0/G1 phase, the effect of which was achieved by interacting with ERK/c-Jun pathways.
C1 [Li, Youjian; Ou, Kepeng; Chen, Zhongzhu] Chongqing Univ Arts & Sci, Coll Pharm, Natl & Local Joint Engn Res Ctr Targeted & Innova, IATTI, Chongqing, Peoples R China.
   [Wang, Yuwei; Luo, Liying; Wu, Jiahui] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China.
   [Wang, Yuwei; Luo, Liying; Wu, Jiahui] Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai Engn Ctr Visual Sci & Photomed, Natl Clin Res Ctr Eye Dis, Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
C3 Chongqing University of Arts & Sciences; Shanghai Jiao Tong University
RP Wu, JH (通讯作者)，Shanghai Gen Hosp, Dept Ophthalmol, Shanghai, Peoples R China.
EM jianeywu628@msn.com
RI Wu, Jane/CAI-7607-2022
FU National Natural Science Foundation of China [81900868]; Chongqing
   Education Commission Project of China [KJQN202001314]; Scientific
   Research Foundation of the Chongqing University of Arts and Sciences
   [R2020FYX07]; China Postdoctoral Science Foundation [2021M693753]
FX The study was supported by National Natural Science Foundation of China
   (81900868), Chongqing Education Commission Project of China
   (KJQN202001314), the Scientific Research Foundation of the Chongqing
   University of Arts and Sciences (R2020FYX07) and China Postdoctoral
   Science Foundation (2021M693753).
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Almalki SG, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0568-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Aoki K, 2017, DEV CELL, V43, P305, DOI 10.1016/j.devcel.2017.10.016
   Aplin AC, 2014, ANGIOGENESIS, V17, P147, DOI 10.1007/s10456-013-9384-3
   Barnie PA, 2014, BIOMED REP, V2, P374, DOI 10.3892/br.2014.257
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chuang YC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040639
   Cole JE, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/393946
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   El Matri L, 2015, CLIN OPHTHALMOL, V9, P733, DOI 10.2147/OPTH.S49437
   Fitzgerald KA, 2020, CELL, V180, P1044, DOI 10.1016/j.cell.2020.02.041
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Lai CH, 2018, THERANOSTICS, V8, P1723, DOI 10.7150/thno.22056
   Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580-020-0255-7
   Liang XT, 2019, FASEB J, V33, P4559, DOI 10.1096/fj.201801690R
   Loira-Pastoriza C, 2021, INT J PHARMACEUT, V600, DOI 10.1016/j.ijpharm.2021.120504
   Marcelo KL, 2013, CIRC RES, V112, P1272, DOI 10.1161/CIRCRESAHA.113.300506
   Meng QH, 2011, PROTEIN CELL, V2, P889, DOI 10.1007/s13238-011-1113-3
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Park JY, 2016, ARCH PHARM RES, V39, P1223, DOI 10.1007/s12272-016-0776-y
   Potente M, 2017, ANNU REV PHYSIOL, V79, P43, DOI 10.1146/annurev-physiol-021115-105134
   Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039
   Pryshchep O, 2008, CIRCULATION, V118, P1276, DOI 10.1161/CIRCULATIONAHA.108.789172
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Shin EY, 2001, EXP MOL MED, V33, P276, DOI 10.1038/emm.2001.45
   Spaide R F, 1999, Curr Opin Ophthalmol, V10, P177, DOI 10.1097/00055735-199906000-00005
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tanimura S, 2017, J BIOCHEM, V162, P145, DOI 10.1093/jb/mvx048
   Tsai HC, 2019, AGING-US, V11, P9767, DOI 10.18632/aging.102423
   Tzeng HE, 2013, BIOCHEM PHARMACOL, V85, P531, DOI 10.1016/j.bcp.2012.11.021
   Valipour E, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144856
   Weber ML, 2016, DEV OPHTHALMOL, V55, P167, DOI 10.1159/000431194
   Wu JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep31873
   Wu JH, 2014, AM J PATHOL, V184, P1900, DOI 10.1016/j.ajpath.2014.03.001
   Xu FH, 2020, J CELL PHYSIOL, V235, P1374, DOI 10.1002/jcp.29056
   Zhang Y, 2016, IN VITRO CELL DEV-AN, V52, P598, DOI 10.1007/s11626-016-0003-7
   Zhang ZX, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8912961
NR 44
TC 1
Z9 1
U1 4
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD MAY
PY 2022
VL 141
AR 104338
DI 10.1016/j.mvr.2022.104338
PG 10
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA 2T8RN
UT WOS:000822735500007
PM 35150733
DA 2022-11-30
ER

PT J
AU Arunkumar, R
   Gorusupudi, A
   Li, BX
   Blount, JD
   Nwagbo, U
   Kim, HJ
   Sparrow, JR
   Bernstein, PS
AF Arunkumar, Ranganathan
   Gorusupudi, Aruna
   Li, Binxing
   Blount, J. David
   Nwagbo, Uzoamaka
   Kim, Hye Jin
   Sparrow, Janet R.
   Bernstein, Paul S.
TI Lutein and zeaxanthin reduce A2E and iso-A2E levels and improve visual
   performance in Abca4(-/-)/Bco2(-/- )double knockout mice
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Abca4; Bco2; Bisretinoids; Carotenoids; Knockout mice; Retina; RPE;
   STGD1
ID RETINAL-PIGMENT EPITHELIUM; FUNDUS AUTOFLUORESCENCE; SHORT-WAVELENGTH;
   MACULAR PIGMENT; MESO-ZEAXANTHIN; MOUSE MODELS; CELL-DEATH; LIPOFUSCIN;
   CAROTENOIDS; SUPPLEMENTATION
AB Accumulation of bisretinoids such as A2E and its isomer iso-A2E is thought to mediate blue light-induced oxidative damage associated with age-related macular degeneration (AMD) and autosomal recessive Stargardt disease (STGD1). We hypothesize that increasing dietary intake of the macular carotenoids lutein and zeaxanthin in individuals at risk of AMD and STGD1 can inhibit the formation of bisretinoids A2E and iso-A2E, which can potentially ameliorate macular degenerative diseases. To study the beneficial effect of macular carotenoids in a retinal degenerative diseases model, we used ATP-binding cassette, sub-family A member 4 (Abca4(-/-))/beta,beta-carotene-9',10'-oxygenase 2 (Bco2(-/-)) double knockout (KO) mice that accumulate elevated levels of A2E and iso-A2E in the retinal pigment epithelium (RPE) and macular carotenoids in the retina. Abca4(-/-)/Bco2(-/-)/and Abca4(-/-) mice were fed a lutein-supplemented chow, zeaxanthin-supplemented chow or placebo chow (similar to 2.6 mg of carotenoid/mouse/day) for three months. Visual function and electroretinography (ERG) were measured after one month and three months of carotenoid supplementation. The lutein and zeaxanthin supplemented Abca4(-/-)/Bco2(-/-) mice had significantly lower levels of RPE/choroid A2E and iso-A2E compared to control mice fed with placebo chow and improved visual performance. Carotenoid supplementation in Abca4(-/- )mice minimally raised retinal carotenoid levels and did not show much difference in bisretinoid levels or visual function compared to the control diet group. There was a statistically significant inverse correlation between carotenoid levels in the retina and A2E and iso-A2E levels in the RPE/choroid. Supplementation with retinal carotenoids, especially zeaxanthin, effectively inhibits bisretinoid formation in a mouse model of STGD1 genetically enhanced to accumulate carotenoids in the retina. These results provide further impetus to pursue oral carotenoids as therapeutic interventions for STGD1 and AMD.
C1 [Arunkumar, Ranganathan; Gorusupudi, Aruna; Li, Binxing; Blount, J. David; Nwagbo, Uzoamaka; Bernstein, Paul S.] Univ Utah, John A Moran Eye Ctr, Sch Med, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Kim, Hye Jin; Sparrow, Janet R.] Columbia Univ, Med Ctr, Dept Ophthalmol, New York, NY 10027 USA.
   [Kim, Hye Jin; Sparrow, Janet R.] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY USA.
C3 Utah System of Higher Education; University of Utah; Columbia
   University; Columbia University
RP Bernstein, PS (通讯作者)，Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM paul.bernstein@hsc.utah.edu
RI Blount, David/HCH-8713-2022
OI Bernstein, Paul/0000-0002-4228-7666; BLOUNT, JUDSON/0000-0003-3208-2947;
   Kim, Hye Jin/0000-0001-7363-4053
FU NIH [EY-11600, EY-14800]; Research to Prevent Blindness, New York City,
   NY
FX We would like to thank Dr. Johannes von Lintig from Case Western Reserve
   University for generously providing the Bco2-/-founder mice. This work
   was supported by NIH grants EY-11600, EY-14800, and by unrestricted
   departmental funds from Research to Prevent Blindness, New York City,
   NY.
CR Alaimo A, 2019, ARCH TOXICOL, V93, P1401, DOI 10.1007/s00204-019-02409-6
   Aleman TS, 2007, INVEST OPHTH VIS SCI, V48, P1319, DOI 10.1167/iovs.06-0764
   Barabas P, 2013, P NATL ACAD SCI USA, V110, P5181, DOI 10.1073/pnas.1214707110
   Bernstein PS, 2021, J LIPID RES, V62, DOI 10.1194/jlr.TR120000956
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Cremers FPM, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100861
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Gao Z, 2018, J BIOL CHEM, V293, P14507, DOI 10.1074/jbc.RA118.002447
   Gutierrez DB, 2010, PHOTOCH PHOTOBIO SCI, V9, P1513, DOI 10.1039/c0pp00230e
   Issa PC, 2013, INVEST OPHTH VIS SCI, V54, P5602, DOI 10.1167/iovs.13-11688
   Kane MA, 2008, ANAL BIOCHEM, V378, P71, DOI 10.1016/j.ab.2008.03.038
   Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Kim SR, 2004, P NATL ACAD SCI USA, V101, P11668, DOI 10.1073/pnas.0403499101
   Kiser PD, 2014, CHEM REV, V114, P194, DOI 10.1021/cr400107q
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Li BX, 2020, P NATL ACAD SCI USA, V117, P12352, DOI 10.1073/pnas.1922793117
   Li BX, 2018, ARCH BIOCHEM BIOPHYS, V649, P22, DOI 10.1016/j.abb.2018.05.003
   Li BX, 2017, EXP EYE RES, V159, P123, DOI 10.1016/j.exer.2017.02.016
   Li BX, 2014, P NATL ACAD SCI USA, V111, P10173, DOI 10.1073/pnas.1402526111
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   de Carvalho JRL, 2020, J BIOL CHEM, V295, P6767, DOI 10.1074/jbc.RA120.012695
   Lindshield BL, 2008, J NUTR, V138, P2367, DOI 10.3945/jn.108.099663
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Nolan JM, 2016, INVEST OPHTH VIS SCI, V57, P3429, DOI 10.1167/iovs.16-19520
   Paavo M, 2018, INVEST OPHTH VIS SCI, V59, P2459, DOI 10.1167/iovs.18-24213
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P650, DOI 10.1111/j.1751-1097.2007.00259.x
   Sears AE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.6
   Shyam R, 2017, P NATL ACAD SCI USA, V114, P10882, DOI 10.1073/pnas.1706332114
   Sparrow JR, 2016, P NATL ACAD SCI USA, V113, P4564, DOI 10.1073/pnas.1600474113
   Sparrow JR, 2015, INVEST OPHTH VIS SCI, V56, P5029, DOI 10.1167/iovs.15-16763
   Sparrow JR, 2014, ADV EXP MED BIOL, V801, P593, DOI 10.1007/978-1-4614-3209-8_75
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Stahl W, 1997, CARCINOGENESIS, V18, P89, DOI 10.1093/carcin/18.1.89
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Thomas LD, 2020, J BIOL CHEM, V295, P15553, DOI 10.1074/jbc.RA120.015515
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Ueda K, 2016, P NATL ACAD SCI USA, V113, P6904, DOI 10.1073/pnas.1524774113
   Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0200-7
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Weymouth AE, 2008, PROG RETIN EYE RES, V27, P1, DOI 10.1016/j.preteyeres.2007.09.003
   Wielgus AR, 2010, PHOTOCH PHOTOBIO SCI, V9, P1505, DOI 10.1039/c0pp00133c
   Winkler BS, 1999, MOL VIS, V5
   Wu L, 2014, INVEST OPHTH VIS SCI, V55, P1910, DOI 10.1167/iovs.14-13867
   Wu L, 2010, ADV EXP MED BIOL, V664, P533, DOI 10.1007/978-1-4419-1399-9_61
   Wu YL, 2010, P NATL ACAD SCI USA, V107, P7275, DOI 10.1073/pnas.0913112107
   Wu Y, 2009, J BIOL CHEM, V284, P20155, DOI 10.1074/jbc.M109.021345
   Yamamoto K, 2012, INVEST OPHTH VIS SCI, V53, P3536, DOI 10.1167/iovs.12-9535
   Zhao DY, 2003, ARCH OPHTHALMOL-CHIC, V121, P967, DOI 10.1001/archopht.121.7.967
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 66
TC 2
Z9 2
U1 5
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2021
VL 209
AR 108680
DI 10.1016/j.exer.2021.108680
EA JUN 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UM5UU
UT WOS:000693396400009
PM 34161819
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Lagoumtzi, SM
   Chondrogianni, N
AF Lagoumtzi, Sofia M.
   Chondrogianni, Niki
TI Senolytics and senomorphics: Natural and synthetic therapeutics in the
   treatment of aging and chronic diseases
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Senolytics; Senomorphics; Cellular senescence; Natural compounds; Aging;
   Age-related diseases; Senescence-associated secretory phenotype (SASP)
ID EXTENDS LIFE-SPAN; SENESCENCE-LIKE PHENOTYPE; MESENCHYMAL STEM-CELLS;
   DNA-DAMAGE RESPONSE; CELLULAR SENESCENCE; SECRETORY PHENOTYPE; OXIDATIVE
   STRESS; HUMAN FIBROBLASTS; BCL-2 FAMILY; TRANSCRIPTION FACTOR
AB Cellular senescence is a heterogeneous process guided by genetic, epigenetic and environmental factors, characterizing many types of somatic cells. It has been suggested as an aging hallmark that is believed to contribute to aging and chronic diseases. Senescent cells (SC) exhibit a specific senescence-associated secretory phenotype (SASP), mainly characterized by the production of proinflammatory and matrix-degrading molecules. When SC accumulate, a chronic, systemic, low-grade inflammation, known as inflammaging, is induced. In turn, this chronic immune system activation results in reduced SC clearance thus establishing a vicious circle that fuels inflammaging. SC accumulation represents a causal factor for various age-related pathologies. Targeting of several aging hallmarks has been suggested as a strategy to ameliorate healthspan and possibly lifespan. Consequently, SC and SASP are viewed as potential therapeutic targets either through the selective killing of SC or the selective SASP blockage, through natural or synthetic compounds. These compounds are members of a family of agents called senotherapeutics divided into senolytics and senomorphics. Few of them are already in clinical trials, possibly representing a future treatment of age-related pathologies including diseases such as atherosclerosis, osteoarthritis, osteoporosis, cancer, diabetes, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, hepatic steatosis, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and age-related macular degeneration. In this review, we present the already identified senolytics and senomorphics focusing on their redox-sensitive properties. We describe the studies that revealed their effects on cellular senescence and enabled their nomination as novel anti-aging agents. We refer to the senolytics that are already in clinical trials and we present various adverse effects exhibited by senotherapeutics so far. Finally, we discuss aspects of the senotherapeutics that need improvement and we suggest the design of future senotherapeutics to target specific redox-regulated signaling pathways implicated either in the regulation of SASP or in the elimination of SC.
C1 [Lagoumtzi, Sofia M.; Chondrogianni, Niki] Natl Hellen Res Fdn, Inst Chem Biol, 48 Vassileos Constantinou Ave, Athens 11635, Greece.
   Univ Western Attica, Dept Biomed Sci, 28 Ag Spyridonos Str, Athens 12243, Greece.
C3 National Hellenic Research Foundation; University of West Attica
RP Chondrogianni, N (通讯作者)，Natl Hellen Res Fdn, Inst Chem Biol, 48 Vassileos Constantinou Ave, Athens 11635, Greece.
EM slagoumtzi@eie.gr; nikichon@eie.gr
FU European Union; Greek national funds through the Operational Program
   Competitiveness, Entrepreneurship and Innovation under the Program
   "Special Actions Aquaculture - Industrial Materials - Open Innovation in
   Culture" (project ALGOSMETIC) [T6YBPi-00474]
FX We acknowledge funding by the European Union and Greek national funds
   through the Operational Program Competitiveness, Entrepreneurship and
   Innovation under the Program "Special Actions Aquaculture - Industrial
   Materials - Open Innovation in Culture" (project ALGOSMETIC, T6 Upsilon
   B Pi-00474). We would like to apologize to all the authors whose work we
   could not cite due to space limitations.
CR Ahmed SMU, 2017, BBA-MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005
   Algire C, 2012, CANCER PREV RES, V5, P536, DOI 10.1158/1940-6207.CAPR-11-0536
   Amaya-Montoya M, 2020, ADV THER, V37, P1407, DOI 10.1007/s12325-020-01287-0
   AMES BN, 1992, ANN NY ACAD SCI, V663, P85, DOI 10.1111/j.1749-6632.1992.tb38652.x
   Anisimov VN, 2008, CELL CYCLE, V7, P2769, DOI 10.4161/cc.7.17.6625
   [Anonymous], SAFETY TOLERABILITY, DOI DOI 10.1248/bpb.34.1841
   Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031
   Bae YU, 2019, J GERONTOL A-BIOL, V74, P1359, DOI 10.1093/gerona/gly208
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Ballou Lisa M, 2008, J Chem Biol, V1, P27, DOI 10.1007/s12154-008-0003-5
   Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619
   Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674
   Barzilai N.R., 2017, INNOV AGING, V1, P743, DOI 10.1093/geroni/igx004.2682
   Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011
   Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417
   Bhat R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045069
   Bitto A, 2016, ELIFE, V5, DOI 10.7554/eLife.16351
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   Borghesan M, 2020, TRENDS CELL BIOL, V30, P777, DOI 10.1016/j.tcb.2020.07.002
   Bourgeois B, 2018, FEBS LETT, V592, P2083, DOI 10.1002/1873-3468.13057
   Boyanapalli SSS, 2014, CHEM RES TOXICOL, V27, P2036, DOI 10.1021/tx500234h
   Brand MD, 2016, FREE RADICAL BIO MED, V100, P14, DOI 10.1016/j.freeradbiomed.2016.04.001
   Bussian TJ, 2018, NATURE, V562, P578, DOI 10.1038/s41586-018-0543-y
   Cabreiro F, 2013, CELL, V153, P228, DOI 10.1016/j.cell.2013.02.035
   Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5
   Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Campisi J, 2019, NATURE, V571, P183, DOI 10.1038/s41586-019-1365-2
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Montero JC, 2011, CLIN CANCER RES, V17, P5546, DOI 10.1158/1078-0432.CCR-10-2616
   Cevenini E, 2013, CURR OPIN CLIN NUTR, V16, P14, DOI 10.1097/MCO.0b013e32835ada13
   Chandrasekaran A, 2017, REDOX BIOL, V11, P91, DOI 10.1016/j.redox.2016.11.005
   Chandrashekara KT, 2014, AGE, V36, DOI 10.1007/s11357-014-9702-8
   Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010
   Chapman J, 2019, FEBS LETT, V593, P1566, DOI 10.1002/1873-3468.13498
   Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358
   Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007
   Cheng T, 2015, DRUG TODAY, V51, P491, DOI 10.1358/dot.2015.51.8.2362311
   Cherif H, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040433
   Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711
   Childs BG, 2017, NAT REV DRUG DISCOV, V16, P718, DOI 10.1038/nrd.2017.116
   Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659
   Childs BG, 2014, EMBO REP, V15, P1139, DOI 10.15252/embr.201439245
   Chondrogianni N, 2004, BIOGERONTOLOGY, V5, P55, DOI 10.1023/B:BGEN.0000017687.55667.42
   Chondrogianni N, 2003, J BIOL CHEM, V278, P28026, DOI 10.1074/jbc.M301048200
   Chondrogianni N, 2010, EXP GERONTOL, V45, P763, DOI 10.1016/j.exger.2010.07.001
   Chong MY, 2018, EMBO REP, V19, DOI 10.15252/embr.201745274
   Ciais D, 2004, ONCOGENE, V23, P8673, DOI 10.1038/sj.onc.1207939
   Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Correia-Melo C, 2019, AGING CELL, V18, DOI 10.1111/acel.12882
   Dansen TB, 2009, NAT CHEM BIOL, V5, P664, DOI 10.1038/nchembio.194
   Das L, 2018, ANTI-CANCER AGENT ME, V18, P1779, DOI 10.2174/1871520618666180604093802
   Davalli P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3565127
   De Cecco M, 2019, NATURE, V566, P73, DOI 10.1038/s41586-018-0784-9
   De Haes W, 2014, P NATL ACAD SCI USA, V111, pE2501, DOI 10.1073/pnas.1321776111
   De Martinis M, 2005, FEBS LETT, V579, P2035, DOI 10.1016/j.febslet.2005.02.055
   DEFRONZO RA, 1995, NEW ENGL J MED, V333, P541, DOI 10.1056/NEJM199508313330902
   Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dolgin E, 2020, NAT BIOTECHNOL, V38, P1371, DOI 10.1038/s41587-020-00750-1
   Doonan R, 2008, GENE DEV, V22, P3236, DOI 10.1101/gad.504808
   Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005
   Duhe Roy J, 2013, JAKSTAT, V2, pe26141, DOI 10.4161/jkst.26141
   Eggler AL, 2008, MOL NUTR FOOD RES, V52, pS84, DOI 10.1002/mnfr.200700249
   Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507
   Evangelou K, 2017, AGING CELL, V16, P192, DOI 10.1111/acel.12545
   Farkhondeh Tahereh, 2019, Current Drug Discovery Technologies, V16, P57, DOI 10.2174/1570163815666180219115453
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Fattori V, 2015, INFLAMM RES, V64, P993, DOI 10.1007/s00011-015-0885-y
   Fossel M., 2018, OBM GERIATR, V3, P1, DOI [10.21926/obm.geriatr.1901034, DOI 10.21926/OBM.GERIATR.1901034]
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6
   Freund A, 2012, MOL BIOL CELL, V23, P2066, DOI 10.1091/mbc.E11-10-0884
   Freund A, 2011, EMBO J, V30, P1536, DOI 10.1038/emboj.2011.69
   Frippiat C, 2001, J BIOL CHEM, V276, P2531, DOI 10.1074/jbc.M006809200
   Fuhrmann-Stroissnigg H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00314-z
   Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005
   Garbers C, 2013, J BIOL CHEM, V288, P4346, DOI 10.1074/jbc.M112.432955
   Gensler LS, 2013, NEUROHOSPITALIST, V3, P92, DOI 10.1177/1941874412458678
   Gines C, 2017, EXP GERONTOL, V90, P61, DOI 10.1016/j.exger.2017.01.021
   Gioran A, 2020, MECH AGEING DEV, V190, DOI 10.1016/j.mad.2020.111324
   Go J, 2018, INT J MOL MED, V42, P1875, DOI 10.3892/ijmm.2018.3782
   Gonzalez-Gualda E, 2020, AGING CELL, V19, DOI 10.1111/acel.13142
   Grosse L, 2020, CELL METAB, V32, P87, DOI 10.1016/j.cmet.2020.05.002
   Guerrero A, 2019, NAT METAB, V1, P1074, DOI 10.1038/s42255-019-0122-z
   Gutierrez-Venegas G, 2014, J ASIAN NAT PROD RES, V16, P1009, DOI 10.1080/10286020.2014.932351
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hall BM, 2017, AGING-US, V9, P1867, DOI 10.18632/aging.101268
   Hall BM, 2016, AGING-US, V8, P1294, DOI 10.18632/aging.100991
   Halvey PJ, 2007, ANTIOXID REDOX SIGN, V9, P807, DOI 10.1089/ars.2007.1526
   Han DW, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/850684
   HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Harrison CN, 2016, LEUKEMIA LYMPHOMA, V57, P2259, DOI 10.1080/10428194.2016.1195501
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Harwood M, 2007, FOOD CHEM TOXICOL, V45, P2179, DOI 10.1016/j.fct.2007.05.015
   Hashemzaei M, 2017, ONCOL REP, V38, P819, DOI 10.3892/or.2017.5766
   HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9
   HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6
   He YH, 2020, AGING CELL, V19, DOI 10.1111/acel.13117
   He YH, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00614
   Hekimi S, 2011, TRENDS CELL BIOL, V21, P569, DOI 10.1016/j.tcb.2011.06.008
   Helman A, 2016, NAT MED, V22, P412, DOI 10.1038/nm.4054
   Herbig U, 2006, SCIENCE, V311, P1257, DOI 10.1126/science.1122446
   Herbig U, 2004, MOL CELL, V14, P501, DOI 10.1016/S1097-2765(04)00256-4
   Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225
   Hickson LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/j.ebiom.2019.08.069
   Hoare M, 2016, NAT CELL BIOL, V18, P979, DOI 10.1038/ncb3397
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Hubackova S, 2019, CELL DEATH DIFFER, V26, P276, DOI 10.1038/s41418-018-0118-3
   Huggins CJ, 2013, MOL CELL BIOL, V33, P3242, DOI 10.1128/MCB.01674-12
   Ichim G, 2015, MOL CELL, V57, P860, DOI 10.1016/j.molcel.2015.01.018
   Iske J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18039-x
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324
   Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771
   Justice JN, 2019, EBIOMEDICINE, V40, P554, DOI 10.1016/j.ebiom.2018.12.052
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   Kampkotter A, 2008, COMP BIOCHEM PHYS B, V149, P314, DOI 10.1016/j.cbpb.2007.10.004
   Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612
   Kang HT, 2017, NAT CHEM BIOL, V13, P616, DOI 10.1038/nchembio.2342
   Kapeta S, 2010, J BIOL CHEM, V285, P8171, DOI 10.1074/jbc.M109.031575
   Kasai S, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020320
   Kim EC, 2019, BMB REP, V52, P47, DOI 10.5483/BMBRep.2019.52.1.293
   Kim N, 2018, J PHARMACOL SCI, V137, P195, DOI 10.1016/j.jphs.2018.06.004
   Kim SJ, 2018, AGING-US, V10, P1239, DOI 10.18632/aging.101463
   Kim TH, 2014, NEURO-ONCOLOGY, V16, P1354, DOI 10.1093/neuonc/nou088
   Kirkland JL, 2020, J INTERN MED, V288, P518, DOI 10.1111/joim.13141
   Kirkland JL, 2017, J AM GERIATR SOC, V65, P2297, DOI 10.1111/jgs.14969
   Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013
   Kirkland JL, 2015, EXP GERONTOL, V68, P19, DOI 10.1016/j.exger.2014.10.012
   Kirkland JL, 2013, EXP GERONTOL, V48, P1, DOI 10.1016/j.exger.2012.11.014
   Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027
   Klotz LO, 2017, REDOX BIOL, V13, P646, DOI 10.1016/j.redox.2017.07.015
   Kocaadam B, 2017, CRIT REV FOOD SCI, V57, P2889, DOI 10.1080/10408398.2015.1077195
   Kopp P, 1998, EUR J ENDOCRINOL, V138, P619, DOI 10.1530/eje.0.1380619
   Kovacovicova K, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00459
   Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Kumar R, 2019, BIOGERONTOLOGY, V20, P171, DOI 10.1007/s10522-018-9785-1
   Kurz DJ, 2000, J CELL SCI, V113, P3613
   Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195
   Laberge RM, 2012, AGING CELL, V11, P569, DOI 10.1111/j.1474-9726.2012.00818.x
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Lee SH, 2019, BMB REP, V52, P24, DOI 10.5483/BMBRep.2019.52.1.290
   Lee YR, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051430
   Lefaki M, 2017, REDOX BIOL, V13, P452, DOI 10.1016/j.redox.2017.07.005
   Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642
   Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001
   Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1
   Li W, 2019, AGING-US, V11, P771, DOI 10.18632/aging.101787
   Li XH, 2009, DRUG METAB DISPOS, V37, P1242, DOI 10.1124/dmd.108.025932
   Liang XR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03253-8
   Liao VHC, 2011, MECH AGEING DEV, V132, P480, DOI 10.1016/j.mad.2011.07.008
   Libby P, 2009, J AM COLL CARDIOL, V54, P2129, DOI 10.1016/j.jacc.2009.09.009
   Lilja S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4793125
   Lim H, 2015, BIOCHEM PHARMACOL, V96, P337, DOI 10.1016/j.bcp.2015.06.013
   Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934
   Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011
   Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y
   Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002
   Liu J, 2018, AUTOPHAGY, V14, P845, DOI 10.1080/15548627.2017.1390636
   Liu S, 2018, FISH SHELLFISH IMMUN, V80, P473, DOI 10.1016/j.fsi.2018.06.027
   Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lu YB, 2005, J IMMUNOL, V175, P5423, DOI 10.4049/jimmunol.175.8.5423
   Lunyak VV, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00220
   Mai S, 2010, J CELL SCI, V123, P917, DOI 10.1242/jcs.059246
   Martin N, 2021, TRENDS CELL BIOL, V31, P327, DOI 10.1016/j.tcb.2021.02.009
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   Mayorga M, 2004, J BIOL CHEM, V279, P34882, DOI 10.1074/jbc.M404616200
   McCarthy DA, 2013, J BIOL CHEM, V288, P32149, DOI 10.1074/jbc.M113.493841
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Menicacci B, 2019, J GERONTOL A-BIOL, V74, P625, DOI 10.1093/gerona/gly175
   Menicacci B, 2017, J GERONTOL A-BIOL, V72, P1187, DOI 10.1093/gerona/glw336
   Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014
   Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075
   Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08
   Moncsek A, 2018, HEPATOLOGY, V67, P247, DOI 10.1002/hep.29464
   MOODY CS, 1982, P NATL ACAD SCI-BIOL, V79, P2855, DOI 10.1073/pnas.79.9.2855
   Morand C, 1998, AM J PHYSIOL-REG I, V275, pR212, DOI 10.1152/ajpregu.1998.275.1.R212
   Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823
   Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019
   Naeimi AF, 2017, TRENDS FOOD SCI TECH, V70, P34, DOI 10.1016/j.tifs.2017.10.003
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033
   Niedernhofer LJ, 2018, NAT REV DRUG DISCOV, V17
   Niu YC, 2013, AGING CELL, V12, P1041, DOI 10.1111/acel.12133
   Oberhuber R, 2015, CIRCULATION, V132, P122, DOI 10.1161/CIRCULATIONAHA.114.014917
   Ogrodnik M, 2021, AGING CELL, V20, DOI 10.1111/acel.13296
   Ogrodnik M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15691
   Oliveira-Marques V, 2009, ANTIOXID REDOX SIGN, V11, P2223, DOI 10.1089/ARS.2009.2601
   Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579
   Onken B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008758
   Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Papaevgeniou N, 2016, ANTIOXID REDOX SIGN, V25, P855, DOI 10.1089/ars.2015.6494
   Papaevgeniou N, 2016, METHODS MOL BIOL, V1449, P1, DOI 10.1007/978-1-4939-3756-1_1
   Passos JF, 2007, PLOS BIOL, V5, P1138, DOI 10.1371/journal.pbio.0050110
   Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5
   Perrott KM, 2017, GEROSCIENCE, V39, P161, DOI 10.1007/s11357-017-9970-1
   Peters T, 2009, MECH AGEING DEV, V130, P564, DOI 10.1016/j.mad.2009.07.003
   Prata Larissa G P Langhi, 2018, Semin Immunol, V40, P101275, DOI 10.1016/j.smim.2019.04.003
   Prattichizzo F, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1810327
   Purpura M, 2018, EUR J NUTR, V57, P929, DOI 10.1007/s00394-016-1376-9
   Qian Y, 2016, CURR MOL MED, V16, P243, DOI 10.2174/1566524016666160225151647
   Rada-Iglesias A, 2007, GENOME RES, V17, P708, DOI 10.1101/gr.5540007
   Rapisarda V, 2017, CELL REP, V18, P2480, DOI 10.1016/j.celrep.2017.02.012
   Reyes-Farias M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133177
   Rha CS, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8080278
   Ristow M, 2010, EXP GERONTOL, V45, P410, DOI 10.1016/j.exger.2010.03.014
   ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339
   Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909
   Rudin CM, 2012, CLIN CANCER RES, V18, P3163, DOI 10.1158/1078-0432.CCR-11-3090
   Ryu SJ, 2007, CELL DEATH DIFFER, V14, P1020, DOI 10.1038/sj.cdd.4402091
   Saha S, 2020, MOLECULES, V25, DOI 10.3390/molecules25225474
   Salminen A, 2011, CELL MOL LIFE SCI, V68, P1021, DOI 10.1007/s00018-010-0597-y
   Samaraweera L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01964-1
   Sandireddy R, 2016, CELL MOL NEUROBIOL, V36, P883, DOI 10.1007/s10571-015-0272-9
   Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200
   Schafer MJ, 2017, MOL CELL ENDOCRINOL, V455, P93, DOI 10.1016/j.mce.2016.08.047
   Schafer MJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14532
   SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x
   Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Shao Z, 2021, OSTEOARTHR CARTILAGE, V29, P413, DOI 10.1016/j.joca.2020.11.006
   Sharma R, 2017, BIOGERONTOLOGY, V18, P367, DOI 10.1007/s10522-017-9696-6
   Shimi T, 2011, GENE DEV, V25, P2579, DOI 10.1101/gad.179515.111
   Shin JH, 2016, INT J MOL MED, V38, P1075, DOI 10.3892/ijmm.2016.2694
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3
   Song SL, 2020, ADV SCI, V7, DOI 10.1002/advs.202002611
   Stojanovic SD, 2020, EUR HEART J, V41, P2983, DOI 10.1093/eurheartj/ehz919
   Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041
   Szaniawski MA, 2020, CURR HIV-AIDS REP, V17, P219, DOI 10.1007/s11904-020-00496-0
   Taipale M, 2010, NAT REV MOL CELL BIO, V11, P515, DOI 10.1038/nrm2918
   Takano K, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101476
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Tilstra JS, 2012, J CLIN INVEST, V122, P2601, DOI 10.1172/JCI45785
   Tominaga K, 2015, PATHOBIOL AGING AGE, V5, DOI 10.3402/pba.v5.27743
   Toso A, 2014, CELL REP, V9, P75, DOI 10.1016/j.celrep.2014.08.044
   Triana-Martinez F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12888-x
   Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836
   Tullius SG, 2011, NEW ENGL J MED, V364, P1369, DOI 10.1056/NEJMc1103007
   van der Feen DE, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw4974
   Van Raamsdonk JM, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000361
   Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003
   van Vliet T, 2021, MOL CELL, V81, P2041, DOI 10.1016/j.molcel.2021.03.018
   Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285
   Vasileiou PVS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070686
   Vijg J, 2008, NATURE, V454, P1065, DOI 10.1038/nature07216
   von Kobbe C, 2019, AGING-US, V11, P12844, DOI 10.18632/aging.102557
   vonZglinicki T, 1995, GERONTOLOGY, V41, P95
   Walaszczyk A, 2019, AGING CELL, V18, DOI 10.1111/acel.12945
   Wang CF, 2009, AGING CELL, V8, P311, DOI 10.1111/j.1474-9726.2009.00481.x
   WANG E, 1995, CANCER RES, V55, P2284
   Wang P, 2014, P NATL ACAD SCI USA, V111, P7683, DOI 10.1073/pnas.1310972111
   Wang R, 2017, AGING CELL, V16, P564, DOI 10.1111/acel.12587
   Wang WY, 2016, TRENDS FOOD SCI TECH, V56, P21, DOI 10.1016/j.tifs.2016.07.004
   Wang YY, 2016, AGING-US, V8, P2915, DOI 10.18632/aging.101100
   WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3
   Wiley CD, 2021, CELL METAB, V33, P1124, DOI 10.1016/j.cmet.2021.03.008
   Wiley CD, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130056
   Wiley CD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20000-4
   Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011
   Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789
   Xu D, 2013, ADV DRUG DELIVER REV, V65, P368, DOI 10.1016/j.addr.2012.07.010
   Xu LY, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00690
   Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9
   Xu M, 2017, J GERONTOL A-BIOL, V72, P780, DOI 10.1093/gerona/glw154
   Xu M, 2015, ELIFE, V4, DOI 10.7554/eLife.12997
   Xu M, 2015, P NATL ACAD SCI USA, V112, pE6301, DOI 10.1073/pnas.1515386112
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X
   Yang H, 2020, AGING-US, V12, P12750, DOI 10.18632/aging.103177
   Yang XD, 1999, J LEUKOCYTE BIOL, V66, P401, DOI 10.1002/jlb.66.3.401
   Yosef R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11190
   Yousefzadeh MJ, 2018, EBIOMEDICINE, V36, P18, DOI 10.1016/j.ebiom.2018.09.015
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Zhang X, 2018, AGING CELL, V17, DOI 10.1111/acel.12780
   Zhu Y, 2017, AGING-US, V9, P955, DOI 10.18632/aging.101202
   Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445
NR 286
TC 33
Z9 33
U1 4
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD AUG 1
PY 2021
VL 171
BP 169
EP 190
DI 10.1016/j.freeradbiomed.2021.05.003
EA MAY 2021
PG 22
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA SV2VS
UT WOS:000663682800002
PM 33989756
DA 2022-11-30
ER

PT J
AU Wu, KL
   Liang, QH
   Huang, BT
   Ding, N
   Li, BW
   Hao, J
AF Wu, Kai-Li
   Liang, Qing-Hui
   Huang, Bin-Tao
   Ding, Na
   Li, Bo-Wei
   Hao, Jian
TI The plasma level of mCRP is linked to cardiovascular disease in
   antineutrophil cytoplasmic antibody-associated vasculitis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
DE mCRP; AAV; Cardiovascular diseases; eGFR
ID C-REACTIVE PROTEIN; GLOMERULAR ENDOTHELIAL-CELLS; COMPLEMENT ACTIVATION;
   CHINESE PATIENTS; MONOMERIC FORM; DISSOCIATION; INFLAMMATION; CORONARY;
   BINDING; RISK
AB Background C-reactive protein (CRP) has two natural isomers: C-reactive protein pentamer (pCRP) and C-reactive protein monomer (mCRP). The levels of CRP are significantly elevated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). mCRP not only activates the endothelial cells, platelets, leukocytes, and complements, but also has a proinflammatory structural subtype that can localize and deposit in inflammatory tissues. Thus, it regulates a variety of clinical diseases, such as ischemia/reperfusion (I/R) injury, Alzheimer's disease, age-related macular degeneration, and cardiovascular disease. We hypothesized that plasma mCRP levels are related to cardiovascular disease in AAV. Methods In this cross-sectional study, 37 patients with AAV were assessed. Brain natriuretic peptide (BNP) and mCRP in plasma were assessed by enzyme-linked immunosorbent assay (ELISA). The acute ST-segment elevation myocardial infarction (STEMI) was diagnosed by coronary angiography, and the Gensini score calculated. Echocardiography evaluated the ejection fraction (EF%), left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and left ventricular mass index (LVMI). Estimated glomerular filtration rate (eGFR) was calculated based on serum creatinine, age, and gender. Results The plasma level of mCRP in AAV was significantly higher than that in healthy volunteers (P < 0.001). Then, mCRP and CRP levels were compared with and without STEMI complications in AAV. The plasma level of mCRP was higher, but that of CRP was lower in STEMI. The plasma level of mCRP was correlated with Birmingham vasculitis activity score (BVAS), eGFR, BNP, EF%, LVEDV, LVESV, LVMI, and STEMI complications' Gensini score in AAV; however, CRP did not correlate with BNP, EF%, LVEDV, LVESV, LVMI, and Gensini score. Conclusions The plasma level of mCRP was related to cardiovascular diseases in AAV patients.
C1 [Wu, Kai-Li; Huang, Bin-Tao; Ding, Na; Li, Bo-Wei; Hao, Jian] Inner Mongolia Med Univ, Dept Med, Renal Div, Affiliated Hosp, Hohhot 010050, Inner Mongolia, Peoples R China.
   [Wu, Kai-Li; Liang, Qing-Hui; Ding, Na; Li, Bo-Wei] Inner Mongolia Med Univ, Hohhot 010059, Inner Mongolia, Peoples R China.
C3 Inner Mongolia Medical University; Inner Mongolia Medical University
RP Hao, J (通讯作者)，Inner Mongolia Med Univ, Dept Med, Renal Div, Affiliated Hosp, Hohhot 010050, Inner Mongolia, Peoples R China.
EM jian_hao8865@163.com
FU China Natural Science Foundation [NO81460145]; Inner Mongolia Natural
   Science Foundation [2018MS08105]
FX The two funds are the China Natural Science Foundation (NO81460145) and
   Inner Mongolia Natural Science Foundation Project Number (2018MS08105).
CR Ahn SS, 2017, CLIN RHEUMATOL, V36, P2751, DOI 10.1007/s10067-017-3868-2
   Boncler M, 2019, MOLECULES, V24, DOI 10.3390/molecules24112062
   Braig D, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14188
   Caprio V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01089
   Chen M, 2005, KIDNEY INT, V68, P2225, DOI 10.1111/j.1523-1755.2005.00679.x
   Chen SF, 2017, CLIN IMMUNOL, V175, P41, DOI 10.1016/j.clim.2016.11.013
   Coster D, 2020, INFECTION, V48, P241, DOI 10.1007/s15010-019-01383-6
   Diehl EE, 2000, AM J MED SCI, V319, P79, DOI 10.1097/00000441-200002000-00002
   Eisenhardt SU, 2009, CELL CYCLE, V8, P3885, DOI 10.4161/cc.8.23.10068
   Eisenhardt SU, 2009, CIRC RES, V105, P128, DOI 10.1161/CIRCRESAHA.108.190611
   Elias-Smale SE, 2007, ATHEROSCLEROSIS, V195, pE195, DOI 10.1016/j.atherosclerosis.2007.07.006
   Hao JA, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4604
   Hao J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038317
   Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715
   Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106
   Kalsch AI, 2010, J RHEUMATOL, V37, P2319, DOI 10.3899/jrheum.100302
   Khreiss T, 2005, CIRC RES, V97, P690, DOI 10.1161/01.RES.0000183881.11739.CB
   KOTTGEN E, 1992, J IMMUNOL, V149, P445
   Kresl JJ, 1998, INT J BIOCHEM CELL B, V30, P1415, DOI 10.1016/S1357-2725(98)00078-8
   Lee RT, 2006, GLYCOCONJUGATE J, V23, P317, DOI 10.1007/s10719-006-6173-x
   Li YW, 2017, ATHEROSCLEROSIS, V259, P75, DOI 10.1016/j.atherosclerosis.2017.02.003
   Li ZY, 2014, ARTHRITIS RHEUMATOL, V66, P1920, DOI 10.1002/art.38621
   Lin ZS, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018178
   LUQMANI RA, 1994, Q J MED, V87, P671
   Ma YC, 2006, J AM SOC NEPHROL, V17, P2937, DOI 10.1681/ASN.2006040368
   Mayo DD, 2006, J EMERG MED, V31, P201, DOI 10.1016/j.jemermed.2005.08.022
   Mihlan M, 2009, CELL DEATH DIFFER, V16, P1630, DOI 10.1038/cdd.2009.103
   Mihlan M, 2011, FASEB J, V25, P4198, DOI 10.1096/fj.11-186460
   Molins B, 2011, CARDIOVASC RES, V92, P328, DOI 10.1093/cvr/cvr226
   Mostfa SA, 2018, INDIAN HEART J, V70, pS224, DOI 10.1016/j.ihj.2018.01.012
   Nagao T, 2007, NEPHROL DIAL TRANSPL, V22, P77, DOI 10.1093/ndt/gfl555
   Nagao T, 2011, NEPHROL DIAL TRANSPL, V26, P2752, DOI 10.1093/ndt/gfr032
   Nakajima T, 2009, ODONTOLOGY, V97, P84, DOI 10.1007/s10266-009-0104-9
   O'Flynn J, 2016, AM J PHYSIOL-RENAL, V310, pF1308, DOI 10.1152/ajprenal.00645.2014
   Papathanasiou AL, 2004, ANGIOLOGY, V55, P187, DOI 10.1177/000331970405500211
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   POTEMPA LA, 1983, MOL IMMUNOL, V20, P1165, DOI 10.1016/0161-5890(83)90140-2
   Ridker PM, 2007, J AM COLL CARDIOL, V49, P2129, DOI 10.1016/j.jacc.2007.02.052
   Ridker PM, 2016, J AM COLL CARDIOL, V67, P712, DOI 10.1016/j.jacc.2015.11.037
   Ridker PM, 2003, CIRCULATION, V107, P363, DOI 10.1161/01.CIR.0000053730.47739.3C
   Rosen M, 1990, DIAG CLIN TESTING, V28, P18
   Schreiber A, 2009, J AM SOC NEPHROL, V20, P289, DOI 10.1681/ASN.2008050497
   SEGELMARK M, 1993, NEPHROL DIAL TRANSPL, V8, P696, DOI 10.1093/ndt/8.8.696
   Shrive AK, 1996, NAT STRUCT BIOL, V3, P346, DOI 10.1038/nsb0496-346
   Sun XJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00237
   Tan Y, 2011, CLIN J AM SOC NEPHRO, V6, P93, DOI 10.2215/CJN.09051209
   Tan Y, 2008, HUM IMMUNOL, V69, P840, DOI 10.1016/j.humimm.2008.09.006
   ten Oever J, 2016, J INFECTION, V72, P1, DOI 10.1016/j.jinf.2015.09.007
   Thiele JR, 2014, CIRCULATION, V130, P35, DOI 10.1161/CIRCULATIONAHA.113.007124
   Tripepi G, 2019, NEPHROL DIAL TRANSPL, P1
   Wang HW, 2001, BIOCHEM BIOPH RES CO, V288, P75, DOI 10.1006/bbrc.2001.5733
   Wang JH, 2015, ATHEROSCLEROSIS, V239, P343, DOI 10.1016/j.atherosclerosis.2015.01.024
   World Health Organization, 2002, USE ANTICOAGULANTS D, P1
   Wu Y, 2015, BIOL CHEM, V396, P1181, DOI 10.1515/hsz-2015-0149
   Xu PC, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0077-0
   Xu PC, 2014, INNATE IMMUN-LONDON, V20, P440, DOI 10.1177/1753425913508164
   Xu PC, 2012, MOL IMMUNOL, V52, P148, DOI 10.1016/j.molimm.2012.05.012
   Yeh ETH, 2005, CIRC RES, V97, P609, DOI 10.1161/01.RES.0000186188.38344.13
   Zonozi R, 2018, RHEUM DIS CLIN N AM, V44, P525, DOI 10.1016/j.rdc.2018.06.001
NR 59
TC 3
Z9 3
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478-6354
EI 1478-6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PD OCT 2
PY 2020
VL 22
IS 1
AR 228
DI 10.1186/s13075-020-02321-w
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Rheumatology
GA NZ2HP
UT WOS:000576916700001
PM 33008437
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Fatehi, F
   Jahedi, F
   Tay-Kearney, ML
   Kanagasingam, Y
AF Fatehi, Farhad
   Jahedi, Farzad
   Tay-Kearney, Mei-Ling
   Kanagasingam, Yogesan
TI Teleophthalmology for the elderly population: A review of the literature
SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS
LA English
DT Review
DE Teleophthalmology; Ocular telemedicine; Telehealth; Elderly; Aged
ID REAL-TIME TELEOPHTHALMOLOGY; DIABETIC-RETINOPATHY; MACULAR DEGENERATION;
   EYE CARE; VISUAL FUNCTION; VISION LOSS; TELEMEDICINE; IMPAIRMENT;
   PREVALENCE; TELEHEALTH
AB Background: Ophthalmology is one of the most requested medical speciality services in the elderly population. Although numerous studies have shown the potentials of telemedicine for the provision of ophthalmology services, the extent of its usability in older adults and the aged population is not clear. The aim of this study was to investigate the characteristics and usability features of teleophthalmology for the elderly population.
   Method: We searched PubMed, Embase, Scopus and CINAHL for relevant studies since 2008. Forty-five papers ma the eligibility criteria and included in this review. We used a multifaceted model to extract the data and analyze findings by cross-tabulation.
   Results: The majority of the reviewed papers included participants of 65 years of age or older. Most of the studies were conducted in the USA (38 %). Diabetic retinopathy, glaucoma, age-related macular degeneration and cataract were the most researched eye diseases, and among the imaging technologies, retinal photography had been used the most (72 %). The studies showed teleophthalmology can improve access to specialty care, reduce the number of unnecessary visits, alleviate overloads on treatment centers, and provide more comprehensive exams. It also made services cost-saving for stakeholders and cost-effective in rural areas. However, teleophthalmology was not cost-effective for patients above 80 and low-density population areas.
   Conclusion: Evidence is lacking for the usability and effectiveness of teleophthalmology for the elderly population. The findings suggest that primary care providers in collaboration with ophthalmologists could provide more effective eye care to elderly population. Appropriate training is also necessary for primary care doctors to manage and refer older patients in a timely manner. Diagnostic value and cost-effective imaging modalities which are the core of the teleophthalmology, can be enhanced by image processing techniques and artificial intelligence.
C1 [Fatehi, Farhad] Univ Queensland, Fac Med, Ctr Online Hlth, Brisbane, Qld, Australia.
   [Fatehi, Farhad; Kanagasingam, Yogesan] CSIRO, Australian E Hlth Res Ctr, Canberra, ACT, Australia.
   [Tay-Kearney, Mei-Ling] Univ Western Australia, Lions Eye Inst, Perth, WA, Australia.
   [Jahedi, Farzad] Univ Queensland, Sch Social Sci, Brisbane, Qld, Australia.
C3 University of Queensland; Commonwealth Scientific & Industrial Research
   Organisation (CSIRO); Lions Eye Institute; University of Western
   Australia; University of Queensland
RP Fatehi, F (通讯作者)，Princess Alexandra Hosp, Ground Floor,Bldg 33, Brisbane, Qld 4102, Australia.
EM f.fatehi@uq.edu.au
RI Jahedi, Farzad/A-8269-2011
OI Jahedi, Farzad/0000-0002-1265-3493
FU Queensland Government through an Advance Queensland Research Fellowship
FX FF received financial support from the Queensland Government through an
   Advance Queensland Research Fellowship (2016-2019).
CR Al Alawi E, 2012, MIDDLE EAST AFR J OP, V19, P295, DOI 10.4103/0974-9233.97928
   Andonegui J, 2016, RETINA-J RET VIT DIS, V36, P279, DOI 10.1097/IAE.0000000000000729
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   Arora S, 2014, TELEMED E-HEALTH, V20, P439, DOI 10.1089/tmj.2013.0241
   Azzolini C, 2013, J TELEMED TELECARE, V19, P437, DOI 10.1177/1357633X13501760
   Beynat J, 2009, DIABETES METAB, V35, P49, DOI 10.1016/j.diabet.2008.07.002
   Brody BL, 2012, OPHTHAL EPIDEMIOL, V19, P190, DOI 10.3109/09286586.2012.672618
   Carroll M, 2013, TELEMED E-HEALTH, V19, P377, DOI 10.1089/tmj.2012.0296
   Chabouis A, 2009, DIABETES METAB, V35, P228, DOI 10.1016/j.diabet.2008.12.001
   Chasan JE, 2014, JAMA OPHTHALMOL, V132, P1045, DOI 10.1001/jamaophthalmol.2014.1051
   Chin EK, 2014, TELEMED E-HEALTH, V20, P102, DOI 10.1089/tmj.2013.0042
   Creuzot-Garcher C, 2014, OPHTHALMIC RES, V52, P206, DOI 10.1159/000363326
   De Bats F, 2014, OPHTHALMOLOGICA, V231, P172, DOI 10.1159/000356695
   Eichenbaum JW, 2012, MT SINAI J MED, V79, P276, DOI 10.1002/msj.21303
   Eszes DJ, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/4529824
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Green C, 2014, AUST FAM PHYSICIAN, V43, P447
   Grisolia ABD, 2017, ARQ BRAS OFTALMOL, V80, P401, DOI 10.5935/0004-2749.20170099
   Hanson C, 2008, TELEMED J E-HEALTH, V14, P441, DOI [10.1089/tmj.2007.0068, 10.1089/tmj.2008.0068]
   Hark LA, 2017, AM J OPHTHALMOL, V181, P114, DOI 10.1016/j.ajo.2017.06.024
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Host BKJ, 2018, CLIN EXP OPTOM, V101, P129, DOI 10.1111/cxo.12535
   Imtiaz SA, 2017, J MED SYST, V41, DOI 10.1007/s10916-017-0695-6
   Jivraj I, 2011, TELEMED E-HEALTH, V17, P294, DOI 10.1089/tmj.2010.0155
   John S, 2015, STUD HEALTH TECHNOL, V214, P139, DOI 10.3233/978-1-61499-558-6-139
   Johnson KA, 2015, AUST J RURAL HEALTH, V23, P142, DOI 10.1111/ajr.12150
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kiage Dan, 2013, Middle East Afr J Ophthalmol, V20, P150, DOI 10.4103/0974-9233.110604
   Kirkizlar E, 2013, OPHTHALMOLOGY, V120, P2604, DOI 10.1016/j.ophtha.2013.06.029
   Klein BEK, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12782
   Kumar S, 2009, EYE, V23, P652, DOI 10.1038/eye.2008.11
   Kumar S, 2008, CLIN EXP OPTOM, V91, P545, DOI 10.1111/j.1444-0938.2008.00267.x
   Kumar S, 2006, TELEOPHTHALMOLOGY, P3, DOI 10.1007/3-540-33714-8_1
   Kurji Khaliq, 2013, Middle East Afr J Ophthalmol, V20, P56, DOI 10.4103/0974-9233.106388
   Labiris G, 2018, INT J OPHTHALMOL-CHI, V11, P314, DOI 10.18240/ijo.2018.02.22
   Li B, 2015, JAMA OPHTHALMOL, V133, P276, DOI 10.1001/jamaophthalmol.2014.5014
   Maa AY, 2017, OPHTHALMOLOGY, V124, P539, DOI 10.1016/j.ophtha.2016.11.037
   Maa AY, 2017, TELEMED E-HEALTH, V23, P42, DOI 10.1089/tmj.2016.0039
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Murchison AP, 2016, OPHTHAL EPIDEMIOL, V23, P109, DOI 10.3109/09286586.2015.1099682
   O'day R, 2016, CLIN EXP OPTOM, V99, P163, DOI 10.1111/cxo.12334
   Park DW, 2017, TELEMED E-HEALTH, V23, P113, DOI 10.1089/tmj.2016.0034
   Pasquale Louis R, 2007, Optometry, V78, P657, DOI 10.1016/j.optm.2007.04.101
   Peng JJ, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-250
   Rathi S, 2017, OPHTHALMOLOGY, V124, P1729, DOI 10.1016/j.ophtha.2017.05.026
   Rathod D, 2008, CLIN EXP OPHTHALMOL, V36, P543, DOI 10.1111/j.1442-9071.2008.01831.x
   Rodriguez Villa S, 2016, Arch Soc Esp Oftalmol, V91, P426, DOI 10.1016/j.oftal.2016.01.023
   Romero-Aroca P, 2010, CLIN OPHTHALMOL, V4, P1481, DOI 10.2147/OPTH.S14521
   Shahid K, 2012, TELEMED E-HEALTH, V18, P95, DOI 10.1089/tmj.2011.0067
   Sim Dawn A, 2016, J Diabetes Sci Technol, V10, P308, DOI 10.1177/1932296816629983
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Tan JCH, 2013, J TELEMED TELECARE, V19, P65, DOI 10.1177/1357633X13476233
   Tapp RJ, 2015, OPHTHAL EPIDEMIOL, V22, P52, DOI 10.3109/09286586.2014.988875
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   Thomas S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137913
   Tsui I, 2016, TELEMED E-HEALTH, V22, P843, DOI 10.1089/tmj.2015.0246
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wolz J, 2017, INT OPHTHALMOL, V37, P39, DOI 10.1007/s10792-016-0222-7
   Woodward MA, 2017, CORNEA, V36, P1159, DOI 10.1097/ICO.0000000000001294
   Xu L, 2012, OPHTHALMOLOGY, V119, P1167, DOI 10.1016/j.ophtha.2011.11.036
   Zapata MA, 2017, TELEMED E-HEALTH, V23, P31, DOI 10.1089/tmj.2016.0020
NR 64
TC 9
Z9 10
U1 1
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1386-5056
EI 1872-8243
J9 INT J MED INFORM
JI Int. J. Med. Inform.
PD APR
PY 2020
VL 136
AR 104089
DI 10.1016/j.ijmedinf.2020.104089
PG 8
WC Computer Science, Information Systems; Health Care Sciences & Services;
   Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Health Care Sciences & Services; Medical Informatics
GA KS6LG
UT WOS:000518418100019
PM 32044698
DA 2022-11-30
ER

PT J
AU Johansson, LH
   Skiljic, D
   Erhag, HF
   Ahlner, F
   Pernheim, C
   Sterner, TR
   Wetterberg, H
   Skoog, I
   Zetterberg, M
AF Havstam Johansson, Lena
   Skiljic, Dragana
   Falk Erhag, Hanna
   Ahlner, Felicia
   Pernheim, Christina
   Rydberg Sterner, Therese
   Wetterberg, Hanna
   Skoog, Ingmar
   Zetterberg, Madeleine
TI Vision-related quality of life and visual function in a 70-year-old
   Swedish population
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE ageing; contrast sensitivity; cross-sectional study; gender difference;
   vision-related quality of life
ID FUNCTION QUESTIONNAIRE; LENS OPACITIES; PREVALENCE; CATARACT; GENDER;
   IMPAIRMENT; BLINDNESS; GLAUCOMA; UTILITY; IMPACT
AB Purpose To investigate vision-related quality of life (VRQoL), visual function and predictors of poor vision in a population of 70-year-olds. Methods Self-reported ocular morbidity and responses to the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) in a cross-sectional population study (N = 1203) in Gothenburg, Sweden, were compared with results from ophthalmic examination (N = 560). Results The most common self-reported ophthalmic morbidities were cataract (23.4%), age-related macular degeneration (AMD; 4.7%), glaucoma (4.3%) and diabetic retinopathy (1.4%). Cataract was more prevalent in women (p = 0.001). The composite score from NEI VFQ-25 for the entire cohort was 91.4 (standard deviation: 27.5). When comparing composite score for different eye diseases, persons with cataract or AMD exhibited lower scores (p = 0.029 and 0.018, respectively). Best-corrected visual acuity (BCVA) was normal (>= 0.5 decimal) in 98.9%; two individuals had low vision (<0.3). Men exhibited better BCVA (median: -0.08 logMAR) than women (-0.06; p = 0.005). Visual field defects were observed in 16.3% and uncorrected refractive errors in 61.5%. Poor vision was reported by 7.4% of participants with presenting visual acuity (PVA) >= 0.5 (decimal), while 66.7% with PVA PVA <0.5, 55.6% obtained a BCVA of >= 1.0 with the right correction. Low contrast sensitivity was a significant predictor of experiencing poor vision (p = 0.008), while PVA and visual field defects were not. Conclusions Low contrast sensitivity is a predictor of experiencing poor vision. There is a discrepancy between subjective/objective visual function and a high prevalence of uncorrected refractive errors. Women have more cataract, and men demonstrate slightly better visual acuity.
C1 [Havstam Johansson, Lena; Skiljic, Dragana; Zetterberg, Madeleine] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, Gothenburg, Sweden.
   [Havstam Johansson, Lena; Skiljic, Dragana; Pernheim, Christina; Zetterberg, Madeleine] Sahlgrens Univ Hosp, Dept Ophthalmol, Molndal, Sweden.
   [Falk Erhag, Hanna; Ahlner, Felicia; Rydberg Sterner, Therese; Wetterberg, Hanna; Skoog, Ingmar] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Ctr Ageing & Hlth AgeCap,Dept Psychiat & Neuroche, Gothenburg, Sweden.
C3 University of Gothenburg; Sahlgrenska University Hospital; University of
   Gothenburg
RP Zetterberg, M (通讯作者)，Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci, SE-43180 Molndal, Sweden.
EM madeleine.zetterberg@gu.se
RI Wetterberg, Hanna/AAP-4071-2021
OI Wetterberg, Hanna/0000-0003-3836-825X; Rydberg Sterner,
   Therese/0000-0001-8202-8522; Skiljic, Dragana/0000-0002-9220-7767
FU Swedish government [ALF-GBG-145921, ALF-GBG-716681]; Swedish county
   councils [ALF-GBG-145921, ALF-GBG-716681]; Walter Anderson's foundation;
   De Blindas Vanner; Swedish Research Council for Health, Working Life and
   Welfare [2013-1202, AGECAP 2013-2300, 2013-2496, 2013-0475]; Konung
   Gustav och Drottning Victorias Frimurarstiftelse; Agneta PrytzFolkes och
   Gosta Folkes stiftelse; Goteborgs Lakaresallskap; Eivind och Elsa K:son
   Sylvans stiftelse
FX The study was financed by grants from the Swedish state under the ALF
   agreement between the Swedish government and the county councils
   (ALF-GBG-145921 and ALF-GBG-716681), Walter Anderson's foundation, De
   Blindas Vanner, the Swedish Research Council for Health, Working Life
   and Welfare (2013-1202, AGECAP 2013-2300, 2013-2496, 2013-0475), Konung
   Gustav och Drottning Victorias Frimurarstiftelse, Agneta PrytzFolkes och
   Gosta Folkes stiftelse, Goteborgs Lakaresallskap and Eivind och Elsa
   K:son Sylvans stiftelse.
CR Bergman B, 2002, ACTA OPHTHALMOL SCAN, V80, P598, DOI 10.1034/j.1600-0420.2002.800608.x
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Chia EM, 2006, OPHTHAL EPIDEMIOL, V13, P371, DOI 10.1080/09286580600864794
   Daga FB, 2019, BRIT J OPHTHALMOL, V103, P955, DOI 10.1136/bjophthalmol-2018-312357
   Delcourt C, 2018, OPHTHALMOLOGY, V125, P1149, DOI 10.1016/j.ophtha.2018.02.005
   Ehrlich JR, 2019, J AM GERIATR SOC, V67, P239, DOI 10.1111/jgs.15628
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Floriani I, 2016, ACTA OPHTHALMOL, V94, pe278, DOI 10.1111/aos.12890
   Fricke TR, 2018, OPHTHALMOLOGY, V125, P1492, DOI 10.1016/j.ophtha.2018.04.013
   Gabrielian A, 2010, EYE, V24, P29, DOI 10.1038/eye.2009.56
   Gerendas BS, 2018, ACTA OPHTHALMOL, V96, pE776, DOI 10.1111/aos.13665
   Hashemi H, 2017, OPHTHAL EPIDEMIOL, V24, P222, DOI 10.1080/09286586.2016.1270335
   Hyman LG, 2005, OPHTHALMOLOGY, V112, P1505, DOI 10.1016/j.ophtha.2005.03.028
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   Kallstrand-Eriksson J, 2013, SCAND J CARING SCI, V27, P433, DOI 10.1111/j.1471-6712.2012.01053.x
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Laitinen A, 2010, ACTA OPHTHALMOL, V88, P463, DOI 10.1111/j.1755-3768.2009.01566.x
   Lewallen S, 2009, BRIT J OPHTHALMOL, V93, P295, DOI 10.1136/bjo.2008.140301
   Limburg H, 2015, REV PANAM SALUD PUBL, V37, P371
   Malmusi D, 2012, EUR J PUBLIC HEALTH, V22, P781, DOI 10.1093/eurpub/ckr184
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   Nael V, 2019, JAMA OPHTHALMOL, V137, P3, DOI 10.1001/jamaophthalmol.2018.4229
   Ostberg A, 2006, OPHTHALMOLOGY, V113, P970, DOI 10.1016/j.ophtha.2006.01.067
   Owen Christopher G, 2006, BMC Ophthalmol, V6, P24, DOI 10.1186/1471-2415-6-24
   Petrillo J, 2019, J NEURO-OPHTHALMOL, V39, P153, DOI 10.1097/WNO.0000000000000697
   Roh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196481
   Smirthwaite G, 2014, ACTA OPHTHALMOL, V92, P432, DOI 10.1111/aos.12230
   Sterner TR, 2019, EUR J EPIDEMIOL, V34, P191, DOI 10.1007/s10654-018-0459-8
   Sugar EA, 2017, OPHTHALMOLOGY, V124, P1662, DOI 10.1016/j.ophtha.2017.05.015
   Thapa R, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0710-9
   Trento M, 2013, ACTA DIABETOL, V50, P873, DOI 10.1007/s00592-013-0470-1
   *UN DOEASA POP DIV, 2017, ESAPWP248 UN DOEASA
   World Health Organization, BLINDN VIS IMP
   Zebardast N, 2015, OPHTHALMOLOGY, V122, P1102, DOI 10.1016/j.ophtha.2015.02.024
   Zetterberg M, 2015, CURR EYE RES, V40, P176, DOI 10.3109/02713683.2014.898774
   Zhang SD, 2015, J GLAUCOMA, V24, P508, DOI 10.1097/IJG.0000000000000056
NR 38
TC 10
Z9 10
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2020
VL 98
IS 5
BP 521
EP 529
DI 10.1111/aos.14341
EA JAN 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA ML4LC
UT WOS:000505967700001
PM 31912642
OA Bronze
DA 2022-11-30
ER

PT J
AU Van Bergen, T
   Etienne, I
   Cunningham, F
   Moons, L
   Schlingemann, RO
   Feyen, JHM
   Stitt, AW
AF Van Bergen, Tine
   Etienne, Isabelle
   Cunningham, Fiona
   Moons, Lieve
   Schlingemann, Reinier O.
   Feyen, Jean H. M.
   Stitt, Alan W.
TI The role of placental growth factor (PlGF) and its receptor system in
   retinal vascular diseases
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Placental growth factor; VEGFR-1; Retinal diseases; Diabetic
   retinopathy; Age-related macular degeneration
ID DIABETIC MACULAR EDEMA; FACTOR GENE-EXPRESSION; HIGH-AFFINITY BINDING;
   AQUEOUS-HUMOR LEVELS; INTRAVITREAL AFLIBERCEPT; VEIN OCCLUSION; VEGF
   RECEPTORS; TYROSINE KINASE; TUMOR-CELLS; TELANGIECTASIA TYPE-1
AB Placental growth factor (PIGF) is a member of the vascular endothelial growth factor (VEGF) family. Upon binding to VEGF- and neuropilin-receptor sub-types, P1GF modulates a range of neural, glial and vascular cell responses that are distinct from VEGF-A. As P1GF expression is selectively associated with pathological angiogenesis and inflammation, its blockade does not affect the healthy vasculature. PIGF actions have been extensively described in tumor biology but more recently there has been accumulating preclinical evidence that indicates that this growth factor could have an important role in retinal diseases. High levels of P1GF have been found in aqueous humor, vitreous and/or retina of patients exhibiting retinopathies, especially those with diabetic retinopathy (DR) and, neovascular age-related macular degeneration (nvAMD). Expression of this growth factor seems to correlate closely with many of the key pathogenic features of early and late retinopathy in preclinical models. For example, studies using genetic modification and/or pharmacological treatment to block P1GF in the laser-induced choroidal neovascularization (CNV) model, oxygen-induced retinopathy model, as well as various murine diabetic models, have shown that PIGF deletion or inhibition can reduce neovascularization, retinal leakage, inflammation and gliosis, without affecting vascular development or inducing neuronal degeneration. Moreover, an inhibitory effect of P1GF blockade on retinal scarring in the mouse CNV model has also been recently demonstrated and was found to be unique for PIGF inhibition, as compared to various VEGF inhibition strategies. Together, these preclinical results suggest that anti-PlGF therapy might have advantages over anti-VEGF treatment, and that it may have clinical applications as a standalone treatment or in combination with anti-VEGF. Additional clinical studies are clearly needed to further elucidate the role of P1GF and its potential as a therapeutic target in ocular diseases.
C1 [Van Bergen, Tine; Etienne, Isabelle; Feyen, Jean H. M.] Oxurion NV, Gaston Geenslaan 1, B-3001 Leuven, Belgium.
   [Cunningham, Fiona; Stitt, Alan W.] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Moons, Lieve] Katholieke Univ Leuven, Inst Zool, Dept Biol, Neural Circuit Dev & Regenerat Res Grp, Leuven, Belgium.
   [Schlingemann, Reinier O.] Univ Amsterdam, Amsterdam UMC, Amsterdam Cardiovasc Sci,Canc Ctr Amsterdam, Ocular Angiogenesis Grp,Dept Ophthalmol, Meibergdreef 9, Amsterdam, Netherlands.
   [Schlingemann, Reinier O.] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.
C3 Queens University Belfast; KU Leuven; University of Amsterdam; Vrije
   Universiteit Amsterdam; University of Lausanne
RP Stitt, AW (通讯作者)，Queens Univ Belfast, Ctr Med Expt, Chair Expt Ophthalmol, 97 Lisburn Rd, Belfast BT9 7AE, Antrim, North Ireland.
EM a.stitt@qub.ac.uk
RI Stitt, Alan/A-9842-2009
OI Stitt, Alan/0000-0002-8647-9918; Moons, Lieve
   (Godelieve)/0000-0003-0186-1411
CR Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   Adini A, 2002, CANCER RES, V62, P2749
   Alvarez-Aznar A, 2017, CURR TOP DEV BIOL, V123, P433, DOI 10.1016/bs.ctdb.2016.10.001
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Ando R, 2014, ACTA OPHTHALMOL, V92, pE245, DOI 10.1111/aos.12251
   [Anonymous], 2013, OPHTHALMOLOGY, V120, P284, DOI [DOI 10.1016/J.OPHTHA.2013.02.034, 10.1016/j.ophtha.2012.07.065]
   Antonetti DA, 2006, DIABETES, V55, P2401, DOI 10.2337/db05-1635
   Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Ashraf M, 2017, OSLI RETINA, V48, P230, DOI 10.3928/23258160-20170301-06
   Augustin AJ, 2013, EXPERT OPIN INV DRUG, V22, P803, DOI 10.1517/13543784.2013.794782
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Bagri A, 2002, ADV EXP MED BIOL, V515, P13
   Bais C, 2010, CELL, V141, P166, DOI 10.1016/j.cell.2010.01.033
   Bates DO, 2011, BIOCHEM SOC T, V39, P1576, DOI 10.1042/BST20110671
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Bellik L, 2005, BRIT J PHARMACOL, V146, P568, DOI 10.1038/sj.bjp.0706347
   Bessho H, 2015, ANTICANCER RES, V35, P531
   Bobic S, 2012, AM J RESP CELL MOL, V46, P781, DOI 10.1165/rcmb.2011-0152OC
   Boyer DS, 2017, RETINA-J RET VIT DIS, V37, P819, DOI 10.1097/IAE.0000000000001392
   Breen EC, 2007, J CELL BIOCHEM, V102, P1358, DOI 10.1002/jcb.21579
   Brown DM, 2015, OPHTHALMOLOGY, V122, P2044, DOI 10.1016/j.ophtha.2015.06.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bu JQ, 2015, TUMOR BIOL, V36, P2695, DOI 10.1007/s13277-014-2892-y
   Busch C, 2018, ACTA DIABETOL, V55, P789, DOI 10.1007/s00592-018-1151-x
   Cai J, 2003, DIABETES, V52, P2959, DOI 10.2337/diabetes.52.12.2959
   Cai S, 2017, CURR OPIN OPHTHALMOL, V28, P636, DOI 10.1097/ICU.0000000000000424
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P538, DOI 10.1016/j.ophtha.2014.08.031
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Cao RH, 2010, P NATL ACAD SCI USA, V107, P856, DOI 10.1073/pnas.0911661107
   Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813
   Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3
   Chaballe L, 2011, GLIA, V59, P379, DOI 10.1002/glia.21108
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chau K, 2017, J HUM HYPERTENS, V31, P782, DOI 10.1038/jhh.2017.61
   Cheng SL, 2008, THORAX, V63, DOI 10.1136/thx.2007.087155
   Cheng SL, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-115
   Chichagova V, 2018, EYE, V32, P946, DOI 10.1038/s41433-018-0061-z
   Christinger HW, 2004, J BIOL CHEM, V279, P10382, DOI 10.1074/jbc.M313237200
   Cianfarani F, 2006, AM J PATHOL, V169, P1167, DOI 10.2353/ajpath.2006.051314
   Ciarnella A, 2012, CASE REP OPHTHALM, V3, P298, DOI 10.1159/000342848
   Clark WL, 2016, OPHTHALMOLOGY, V123, P330, DOI 10.1016/j.ophtha.2015.09.035
   Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629
   Clegg LE, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005445
   Constable IJ, 2016, EBIOMEDICINE, V14, P168, DOI 10.1016/j.ebiom.2016.11.016
   Couturier A, 2014, MOL VIS, V20, P908
   Crespo-Garcia Sergio, 2017, Invest Ophthalmol Vis Sci, V58, P4997, DOI 10.1167/iovs.16-21283
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Deissler HL, 2013, EXP EYE RES, V115, P162, DOI 10.1016/j.exer.2013.07.018
   Dejda A, 2016, INVEST OPHTH VIS SCI, V57, P1530, DOI 10.1167/iovs.15-18598
   DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256
   Dewerchin M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011056
   DiPalma T, 1996, MAMM GENOME, V7, P6, DOI 10.1007/s003359900003
   Djordjevic S, 2013, DRUG DISCOV TODAY, V18, P447, DOI 10.1016/j.drudis.2012.11.013
   Do DV, 2009, BRIT J OPHTHALMOL, V93, P144, DOI 10.1136/bjo.2008.138271
   Dragoni S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051378
   Eilken HM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01738-3
   Erskine L, 2011, NEURON, V70, P951, DOI 10.1016/j.neuron.2011.02.052
   Evans J. R., 2017, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD000254.PUB4
   Failla CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051306
   Feeney SA, 2003, INVEST OPHTH VIS SCI, V44, P839, DOI 10.1167/iovs.02-0040
   Filek R, 2017, INVEST OPHTHALMOL VI, V58
   Fischer C, 2007, CELL, V131, P463, DOI 10.1016/j.cell.2007.08.038
   FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fuh G, 2000, J BIOL CHEM, V275, P26690
   Gamulescu MA, 2008, GRAEF ARCH CLIN EXP, V246, P1189, DOI 10.1007/s00417-008-0795-6
   Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659
   Gerhardt H, 2004, DEV DYNAM, V231, P503, DOI 10.1002/dvdy.20148
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Green CJ, 2001, CANCER RES, V61, P2696
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Hammes HP, 1998, DIABETES, V47, P401, DOI 10.2337/diabetes.47.3.401
   He JB, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/605946
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heindryckx F, 2012, EUR J GASTROEN HEPAT, V24, P1020, DOI 10.1097/MEG.0b013e3283554219
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hollborn M, 2006, GRAEF ARCH CLIN EXP, V244, P732, DOI 10.1007/s00417-005-0154-9
   Hombrebueno JR, 2015, SCI REP-UK, V5, DOI 10.1038/srep18316
   Hou HH, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0106-1
   Hu T. T., 2017, TARGETING PLACENTAL
   Huang HZ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059482, 10.1371/journal.pone.0071808, 10.1371/journal.pone.0076982]
   Huang H, 2015, DIABETES, V64, P200, DOI 10.2337/db14-0016
   Hudson N, 2014, DEV CELL, V30, P541, DOI 10.1016/j.devcel.2014.06.027
   Huo XC, 2015, CELL PHYSIOL BIOCHEM, V35, P1787, DOI 10.1159/000373990
   Inoue Y, 2014, J NEUROSCI RES, V92, P329, DOI 10.1002/jnr.23316
   Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Ishida S, 2000, INVEST OPHTH VIS SCI, V41, P1649
   Ishihama H, 2001, INVEST OPHTH VIS SCI, V42, P1172
   Ito A, 2017, OPHTHALMOLOGICA, V238, P236, DOI 10.1159/000479937
   Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200
   Izawa H, 2015, INVEST OPHTH VIS SCI, V56, P6914, DOI 10.1167/iovs.15-16748
   Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6
   Jonas JB, 2012, RETINA-J RET VIT DIS, V32, P2150, DOI 10.1097/IAE.0b013e3182576d07
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Katz G, 2017, EUR J OPHTHALMOL, V27, P210, DOI 10.5301/ejo.5000838
   Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Khaliq A, 1998, LAB INVEST, V78, P109
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim KJ, 2012, EXP MOL MED, V44, P10, DOI 10.3858/emm.2012.44.1.023
   Klaassen I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187304
   Klaassen I, 2015, EXP EYE RES, V133, P37, DOI 10.1016/j.exer.2014.10.016
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Klein Kendra A, 2017, Int J Retina Vitreous, V3, P16, DOI 10.1186/s40942-017-0064-0
   Koay CL, 2011, EYE, V25, P1663, DOI 10.1038/eye.2011.252
   Kodjikian L, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8289253
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Kovach JL, 2016, OSLI RETINA, V47, P593, DOI 10.3928/23258160-20160601-14
   Kovacs K, 2015, INVEST OPHTH VIS SCI, V56, P6523, DOI 10.1167/iovs.15-16793
   Kowalczuk L, 2017, RETINA-J RET VIT DIS, V37, P2226, DOI 10.1097/IAE.0000000000001424
   Kowalczuk L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017462
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Lai YC, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0530-2
   Laiginhas R, 2018, GRAEF ARCH CLIN EXP, V256, P83, DOI 10.1007/s00417-017-3836-1
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Laouri M, 2011, EYE, V25, P981, DOI 10.1038/eye.2011.92
   Larcher F, 2003, MOL CARCINOGEN, V37, P83, DOI 10.1002/mc.10126
   Lassen U, 2012, BRIT J CANCER, V106, P678, DOI 10.1038/bjc.2011.609
   Lee JH, 2016, J OCUL PHARMACOL TH, V32, P659, DOI 10.1089/jop.2016.0074
   Lee R, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0026-2
   Li JK, 2015, INT J OPHTHALMOL-CHI, V8, P1202, DOI 10.3980/j.issn.2222-3959.2015.06.22
   Lieth E, 2000, CLIN EXP OPHTHALMOL, V28, P3, DOI 10.1046/j.1442-9071.2000.00222.x
   Lim JI, 2005, AM J OPHTHALMOL, V140, P1044, DOI 10.1016/j.ajo.2005.07.021
   Liu BY, 2003, MOL CELL BIOL, V23, P5269, DOI 10.1128/MCB.23.15.5269-5281.2003
   Liu H, 2013, INVEST OPHTH VIS SCI, V54, P918, DOI 10.1167/iovs.12-11291
   Loutfi M, 2014, CASE REP OPHTHALMOL, V2014, DOI 10.1155/2014/231913
   Lu M, 1999, INVEST OPHTH VIS SCI, V40, P1808
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   MAGLIONE D, 1993, ONCOGENE, V8, P925
   Makris A, 2016, HYPERTENSION, V67, P1263, DOI 10.1161/HYPERTENSIONAHA.116.07286
   Mantel I, 2018, RETINA
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Marin-Castano ME, 2013, AGE RELATED MACULAR, P39, DOI [10.5772/53958, DOI 10.5772/53958]
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Martinsson-Niskanen T, 2011, CLIN THER, V33, P1142, DOI 10.1016/j.clinthera.2011.08.007
   Matsumoto Y, 2010, JPN J OPHTHALMOL, V54, P320, DOI 10.1007/s10384-010-0810-4
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Mesquita J, 2018, CYTOKINE GROWTH F R, V39, P102, DOI 10.1016/j.cytogfr.2017.11.005
   Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com
   Mira F, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/5632634
   Mitamura Y, 2002, DIABETES CARE, V25, P2352, DOI 10.2337/diacare.25.12.2352
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Miyamoto N, 2008, OPHTHALMIC RES, V40, P203, DOI 10.1159/000119877
   Miyamoto N, 2007, DIABETOLOGIA, V50, P461, DOI 10.1007/s00125-006-0539-2
   Moon Suk J, 2010, Ophthalmic Surg Lasers Imaging, P1, DOI 10.3928/15428877-20100216-10
   Moradian S, 2008, GRAEF ARCH CLIN EXP, V246, P1699, DOI 10.1007/s00417-008-0914-4
   Motohashi R, 2017, OPHTHALMIC RES, V58, P209, DOI 10.1159/000478705
   Nakao S, 2012, INVEST OPHTH VIS SCI, V53, P4323, DOI 10.1167/iovs.11-9119
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Nguyen Q. D, 2016, ACTA OPHTHALMOL
   Niers TMH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019873
   Noma H, 2017, OPHTHALMOLOGICA, V238, P81, DOI 10.1159/000475603
   Noma H, 2015, INVEST OPHTH VIS SCI, V56, P1122, DOI 10.1167/iovs.14-15789
   Noma H, 2014, INVEST OPHTH VIS SCI, V55, P3878, DOI 10.1167/iovs.14-13961
   Nourinia Ramin, 2013, J Ophthalmic Vis Res, V8, P4
   Ogura S, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90905
   Ogura Y, 2014, AM J OPHTHALMOL, V158, P1032, DOI 10.1016/j.ajo.2014.07.027
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Oshima Y, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0021-3
   Pagani E, 2016, INT J ONCOL, V48, P1581, DOI 10.3892/ijo.2016.3362
   Papavasileiou E, 2015, HELL J NUCL MED, V18, P29
   Park HYL, 2014, AM J PATHOL, V184, P1752, DOI 10.1016/j.ajpath.2014.02.016
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Park M, 1999, BIOCHEM BIOPH RES CO, V264, P730, DOI 10.1006/bbrc.1999.1580
   Peach CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041264
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Perelman N, 2003, BLOOD, V102, P1506, DOI 10.1182/blood-2002-11-3422
   Persico MG, 1999, CURR TOP MICROBIOL, V237, P31
   Pongsachareonnont P, 2018, CLIN OPHTHALMOL, V12, P1877, DOI 10.2147/OPTH.S171636
   Nguyen QD, 2018, ACTA OPHTHALMOL, V96, pE1, DOI 10.1111/aos.13325
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Raevens S, 2017, HEPATOLOGY
   Raimondi C, 2016, PROG RETIN EYE RES, V52, P64, DOI 10.1016/j.preteyeres.2016.02.003
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rakoczy EP, 2010, AM J PATHOL, V177, P2659, DOI 10.2353/ajpath.2010.090883
   Rangasamy S, 2012, MIDDLE EAST AFR J OP, V19, P52, DOI 10.4103/0974-9233.92116
   Rhoades William, 2017, Taiwan J Ophthalmol, V7, P70, DOI 10.4103/tjo.tjo_9_17
   Ribatti D, 2008, ANGIOGENESIS, V11, P215, DOI 10.1007/s10456-008-9114-4
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P794, DOI 10.1016/j.ophtha.2018.02.027
   Rouvas A, 2013, CLIN OPHTHALMOL, V7, P1357, DOI 10.2147/OPTH.S44109
   Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sato T, 2015, OSLI RETINA, V46, P87, DOI 10.3928/23258160-20150101-16
   Sawano A, 1996, CELL GROWTH DIFFER, V7, P213
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schlingemann RO, 2013, DIABETES CARE, V36, P1629, DOI 10.2337/dc12-1951
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schultze A, 2012, CLIN EXP METASTAS, V29, P879, DOI 10.1007/s10585-012-9477-1
   Selvaraj SK, 2003, BLOOD, V102, P1515, DOI 10.1182/blood-2002-11-3423
   Shen JK, 2004, MOL MED, V10, P12, DOI 10.2119/2004-00017.Campochiaro
   Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012
   Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Shih SC, 2003, J CLIN INVEST, V112, P50, DOI 10.1172/JCI200317808
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Sivaprasad S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072755
   Smith G, 1999, BRIT J OPHTHALMOL, V83, P486, DOI 10.1136/bjo.83.4.486
   Snuderl M, 2013, CELL, V152, P1065, DOI 10.1016/j.cell.2013.01.036
   Sohn EH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1127, DOI 10.1001/archophthalmol.2012.1611
   Sohn HJ, 2011, AM J OPHTHALMOL, V152, P686, DOI 10.1016/j.ajo.2011.03.033
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Spirin KS, 1999, CURR EYE RES, V18, P490, DOI 10.1076/ceyr.18.6.490.5267
   Spradley FT, 2016, HYPERTENSION, V67, P740, DOI 10.1161/HYPERTENSIONAHA.115.06783
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Suzuki H, 2009, HYPERTENSION, V54, P1129, DOI 10.1161/HYPERTENSIONAHA.109.134668
   Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016
   Takayama K, 2010, EYE, V24, P1492, DOI 10.1038/eye.2010.61
   Taylor KL, 2002, MICROVASC RES, V64, P372, DOI 10.1006/mvre.2002.2443
   TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2
   Tjwa M, 2003, CELL TISSUE RES, V314, P5, DOI 10.1007/s00441-003-0776-3
   Tsao PN, 2004, AM J RESP CRIT CARE, V169, P505, DOI 10.1164/rccm.200306-774OC
   Usui T, 2004, INVEST OPHTH VIS SCI, V45, P368, DOI 10.1167/iovs.03-0106
   Van Bergen T, 2017, EXP EYE RES, V165, P136, DOI 10.1016/j.exer.2017.09.012
   Van Bergen T, 2013, J CELL MOL MED, V17, P1632, DOI 10.1111/jcmm.12151
   Van de Veire S, 2010, CELL, V141, P178, DOI 10.1016/j.cell.2010.02.039
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Vandewynckel YP, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-1990-6
   Voros G, 2005, ENDOCRINOLOGY, V146, P4545, DOI 10.1210/en.2005-0532
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Weed S, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.05.003
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603
   Witmer AN, 2002, INVEST OPHTH VIS SCI, V43, P849
   Witmer AN, 2001, J PATHOL, V195, P490, DOI 10.1002/path.969
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wu D, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43017
   Yamashita H, 1999, EYE, V13, P372, DOI 10.1038/eye.1999.95
   Yang W, 2003, J REPROD IMMUNOL, V60, P53, DOI 10.1016/S0165-0378(03)00082-2
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
   Yao J, 2011, P NATL ACAD SCI USA, V108, P11590, DOI 10.1073/pnas.1109029108
   Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172
   Yu Y, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0368-7
   Zachary I, 2003, BIOCHEM SOC T, V31, P1171
   Zhao B, 2004, MICROVASC RES, V68, P239, DOI 10.1016/j.mvr.2004.07.004
   Zheng Y, 2012, ACTA OPHTHALMOL, V90, pE512, DOI 10.1111/j.1755-3768.2012.02476.x
   Zhou MW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146993
   Zhou T, 2017, ONCOTARGET, V8, P4582, DOI 10.18632/oncotarget.13945
   Zhu ML, 2016, AM J PHYSIOL-REG I, V311, pR505, DOI 10.1152/ajpregu.00137.2016
   Zins K, 2013, INT J MOL SCI, V14, P17958, DOI 10.3390/ijms140917958
   2018, GRAEFES ARCH CLIN EX, V256, P325, DOI DOI 10.1007/S00417-017-3846-Z
   2017, OXID MED CELL LONGEV
   2011, OPHTHALMOLOGY, V118, P1819, DOI DOI 10.1016/J.OPHTHA.2011.02.018
   2014, CASE REP OPHTHALMOL
   2010, DIABETES CARE, V33, P2399, DOI DOI 10.2337/DC10-0493
   1999, AM J PATHOL, V155, P421
   2018, JAMA OPHTHALMOL, V136, P666, DOI DOI 10.1001/JAMAOPHTHALMOL.2018.1544
NR 271
TC 37
Z9 39
U1 1
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2019
VL 69
BP 116
EP 136
DI 10.1016/j.preteyeres.2018.10.006
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HW1OL
UT WOS:000466452100005
PM 30385175
DA 2022-11-30
ER

PT J
AU Lee, CY
   Chen, HC
   Sun, CC
   Lim, HY
   Lu, KH
   Huang, JY
   Yeh, CB
   Yang, SF
AF Lee, Chia-Yi
   Chen, Hung-Chi
   Sun, Chi-Chin
   Lim, Hung-Yu
   Lu, Ko-Hsiu
   Huang, Jing-Yang
   Yeh, Chao-Bin
   Yang, Shun-Fa
TI Gout as a Risk Factor for Dry Eye Disease: A Population-Based Cohort
   Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE gout; dry eye disease; inflammatory; population-based
ID SYSTEMIC-DISEASES; PREVALENCE; INFLAMMATION; ASSOCIATIONS; SYMPTOMS;
   UPDATE; IMPACT
AB This study evaluated the effect of gout on the risk of dry eye disease (DED) by using the National Health Insurance Research Database (NHIRD). Data for 30,192 gout patients (21,081 men and 9111 women) and 30,192 non-gout patients (21,005 men and 9187 women) were analyzed. Approximately 1 million patients were randomly sampled from the NHIRD registry. After applying exclusion criteria, patients diagnosed with gout were enrolled in the study group. Thereafter, each individual in the study group underwent the matching process via the propensity score with another non-gout individual, which constituted the control group. The main outcome was defined as the development of DED in accordance with the corresponding International Classification of Diseases, Ninth Revision. In addition to DED, other risk factors including age, sex, and urbanization, and several co-morbidities were included in the multivariate model. The incidence of DED with the adjusted hazard ratio (aHR) and cumulative probability were evaluated in the gout and non-gout patients. A total of 2913 DED events were observed in the study group, whereas 2631 DED events were observed in the control group. A higher incidence rate ratio was found in the study group after adjustment (aHR: 1.065). Moreover, the cumulative probability indicated a significantly increased risk of DED in the study group (p = 0.001). The other potential risk factors of DED according to the multivariate analysis include older age, female gender, higher degree of urbanization, keratopathy, age-related macular degeneration, glaucoma, cataract, ischemic heart disease, hyperlipidemia, peripheral vascular disease, chronic pulmonary disease, rheumatic disease, peptic ulcer disease, liver disease, and malignancy. In conclusion, gout increased the risk of DED after adjustment, and the risk is positively correlated to a longer disease period.
C1 [Lee, Chia-Yi; Lim, Hung-Yu] Show Chwan Mem Hosp, Dept Ophthalmol, Changhua 500, Taiwan.
   [Lee, Chia-Yi] Chung Hwa Univ Med Technol, Coll Med & Life Sci, Dept Optometry, Tainan 717, Taiwan.
   [Chen, Hung-Chi] Chang Gung Mem Hosp, Dept Ophthalmol, Linkou 333, Taiwan.
   [Chen, Hung-Chi] Chang Gung Univ, Dept Med, Coll Med, Taoyuan 333, Taiwan.
   [Chen, Hung-Chi] Chang Gung Mem Hosp, Ctr Tissue Engn, Linkou 333, Taiwan.
   [Sun, Chi-Chin] Chang Gung Mem Hosp, Dept Ophthalmol, Keelung 204, Taiwan.
   [Sun, Chi-Chin] Chang Gung Univ, Dept Chinese Med, Taoyuan 333, Taiwan.
   [Lim, Hung-Yu; Yang, Shun-Fa] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan.
   [Lim, Hung-Yu] Chung Chou Univ Sci & Technol, Coll Hlth, Changhua 500, Taiwan.
   [Lim, Hung-Yu] Yuanpei Univ Med Technol, Dept Optometry, Hsinchu 300, Taiwan.
   [Lu, Ko-Hsiu; Yeh, Chao-Bin] Chung Shan Med Univ, Sch Med, Taichung 402, Taiwan.
   [Lu, Ko-Hsiu] Chung Shan Med Univ Hosp, Dept Orthoped, Taichung 402, Taiwan.
   [Huang, Jing-Yang; Yang, Shun-Fa] Chung Shan Med Univ Hosp, Dept Med Res, Taichung 402, Taiwan.
   [Yeh, Chao-Bin] Chung Shan Med Univ Hosp, Dept Emergency Med, Taichung 402, Taiwan.
C3 Show Chwan Memorial Hospital; Chung Hua University; Chang Gung Memorial
   Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang
   Gung Memorial Hospital; Chang Gung University; Chung Shan Medical
   University; Chung Shan Medical University; Chung Shan Medical
   University; Chung Shan Medical University Hospital; Chung Shan Medical
   University; Chung Shan Medical University Hospital; Chung Shan Medical
   University; Chung Shan Medical University Hospital
RP Yang, SF (通讯作者)，Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan.; Yang, SF (通讯作者)，Chung Shan Med Univ Hosp, Dept Med Res, Taichung 402, Taiwan.
EM ao6u.3msn@hotmail.com; mr3756@cgmh.org.tw; arvin.sun@msa.hinet.net;
   anthonyhungyulin@hotmail.com; cshy307@csh.org.tw; wchinyang@gmail.com;
   sky5ff@gmail.com; ysf@csmu.edu.tw
RI Yang, Shun-Fa/AAN-1519-2020
OI Yang, Shun-Fa/0000-0002-0365-7927; Yeh, Chao-Bin/0000-0002-3978-5576;
   Chen, Hung-Chi/0000-0002-1117-7878; Lee, Chia-Yi/0000-0002-5719-0488;
   Sun, Chi Chini/0000-0001-9466-6986; Huang, Jing-Yang/0000-0002-0794-9388
CR Ahn JH, 2017, CLIN INTERV AGING, V12, P1331, DOI 10.2147/CIA.S140912
   Alshamrani AA, 2017, MIDDLE EAST AFR J OP, V24, P67, DOI 10.4103/meajo.MEAJO_281_16
   Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697
   Barabino S, 2016, OCUL SURF, V14, P365, DOI 10.1016/j.jtos.2016.04.005
   Baudouin C, 2018, ACTA OPHTHALMOL, V96, P111, DOI 10.1111/aos.13436
   Benedetto U, 2018, EUR J CARDIO-THORAC, V53, P1112, DOI 10.1093/ejcts/ezy167
   Chen A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05368-z
   Chen HY, 2015, OPTOMETRY VISION SCI, V92, pE227, DOI 10.1097/OPX.0000000000000667
   Chhadva P, 2017, OPHTHALMOLOGY, V124, pS20, DOI 10.1016/j.ophtha.2017.05.031
   Chia EM, 2003, CLIN EXP OPHTHALMOL, V31, P229, DOI 10.1046/j.1442-9071.2003.00634.x
   Dalbeth N, 2016, LANCET, V388, P2039, DOI 10.1016/S0140-6736(16)00346-9
   Farrand KF, 2017, AM J OPHTHALMOL, V182, P90, DOI 10.1016/j.ajo.2017.06.033
   Generali E, 2015, CLIN REV ALLERG IMMU, V49, P263, DOI 10.1007/s12016-015-8518-3
   Henrich CF, 2014, CORNEA, V33, P819, DOI 10.1097/ICO.0000000000000173
   Jiang Y, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0669-6
   Kuo CF, 2015, NAT REV RHEUMATOL, V11, P649, DOI 10.1038/nrrheum.2015.91
   Lee L, 2018, OCUL SURF, V16, P206, DOI 10.1016/j.jtos.2018.03.003
   Lee SY, 2012, OPHTHAL PHYSL OPT, V32, P518, DOI 10.1111/j.1475-1313.2012.00931.x
   Leibovitch I, 2003, RHEUMATOLOGY, V42, DOI 10.1093/rheumatology/keg261
   Miljanovic B, 2007, AM J OPHTHALMOL, V143, P409, DOI 10.1016/j.ajo.2006.11.060
   Moss SE, 2008, OPTOMETRY VISION SCI, V85, P668, DOI 10.1097/OPX.0b013e318181a947
   Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264
   Moss SE, 2004, ARCH OPHTHALMOL-CHIC, V122, P369, DOI 10.1001/archopht.122.3.369
   Pflugfelder SC, 2007, OCUL SURF, V5, P163
   Pflugfelder SC, 2017, OPHTHALMOLOGY, V124, pS4, DOI 10.1016/j.ophtha.2017.07.010
   Rhee MK, 2017, OPHTHALMOLOGY, V124, pS14, DOI 10.1016/j.ophtha.2017.08.029
   Rubin DB, 1996, BIOMETRICS, V52, P249, DOI 10.2307/2533160
   Rymal E, 2014, JAAPA-J AM ACAD PHYS, V27, P26, DOI 10.1097/01.JAA.0000453233.24754.ec
   Sharon Y, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-016-0586-8
   So AK, 2017, NAT REV RHEUMATOL, V13, P639, DOI 10.1038/nrrheum.2017.155
   Terkeltaub R, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0922-5
   Thulasi P, 2017, OPHTHALMOLOGY, V124, pS27, DOI 10.1016/j.ophtha.2017.07.022
   Titiyal JS, 2018, INDIAN J OPHTHALMOL, V66, P207, DOI 10.4103/ijo.IJO_698_17
   Tsubota K, 2017, OCUL SURF, V15, P65, DOI 10.1016/j.jtos.2016.09.003
   Uchino M, 2011, OPHTHALMOLOGY, V118, P2361, DOI 10.1016/j.ophtha.2011.05.029
   Wong ABC, 2018, OCUL SURF, V16, P289, DOI 10.1016/j.jtos.2018.03.002
   Yao W, 2011, AM J MED, V124, P1016, DOI 10.1016/j.amjmed.2011.01.030
   Yazdanyar A, 2018, CORNEA, V37, P379, DOI 10.1097/ICO.0000000000001415
   Yen JC, 2015, INT J ENV RES PUB HE, V12, P7647, DOI 10.3390/ijerph120707647
NR 39
TC 5
Z9 6
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JAN
PY 2019
VL 8
IS 1
AR 62
DI 10.3390/jcm8010062
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HJ4JU
UT WOS:000457141100061
PM 30634389
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Barben, M
   Schori, C
   Samardzija, M
   Grimm, C
AF Barben, Maya
   Schori, Christian
   Samardzija, Marijana
   Grimm, Christian
TI Targeting Hif1a rescues cone degeneration and prevents subretinal
   neovascularization in a model of chronic hypoxia
SO MOLECULAR NEURODEGENERATION
LA English
DT Article
DE Retinal degeneration; Age-related macular degeneration; Cone
   photoreceptors; Hypoxia; HIF1; VHL; Mouse model
ID RETINAL ANGIOMATOUS PROLIFERATION; ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL
   BLOOD-FLOW; MACULAR DEGENERATION; MOUSE MODEL; PDGF-B; TISSUE INHIBITOR;
   METALLOPROTEINASES-3 TIMP3; TRANSGENIC MICE; DRUSEN EXTENT
AB Background: Degeneration of cone photoreceptors leads to loss of vision in patients suffering from age-related macular degeneration (AMD) and other cone dystrophies. Evidence, such as choroidal ischemia and decreased choroidal blood flow, implicates reduced tissue oxygenation in AMD pathology and suggests a role of the cellular response to hypoxia in disease onset and progression. Such a chronic hypoxic situation may promote several cellular responses including stabilization of hypoxia-inducible factors (HIFs).
   Methods: To investigate the consequence of a chronic activation of the molecular response to hypoxia in cones, von Hippel Lindau protein (VHL) was specifically ablated in cones of the all-cone R91W; Nrl(-/-) mouse. Retinal function and morphology was evaluated by ERG and light microscopy, while differential gene expression was tested by real-time PCR. Retinal vasculature was analyzed by immunostainings and fluorescein angiography. Two-way ANOVA with Sidak's multiple comparison test was performed for statistical analysis.
   Results: Cone-specific ablation of Vhl resulted in stabilization and activation of hypoxia-inducible factor 1A (HIF1A) which led to increased expression of genes associated with hypoxia and retinal stress. Our data demonstrate severe cone degeneration and pathologic vessel growth, features that are central to AMD pathology. Subretinal neovascularization was accompanied by vascular leakage and infiltration of microglia cells. Interestingly, we observed increased expression of tissue inhibitor of metalloproteinase 3 (Timp3) during the aging process, a gene associated with AMD and Bruch's membrane integrity. Additional deletion of Hif1a protected cone cells, prevented pathological vessel growth and preserved vision.
   Conclusions: Our data provide evidence for a HIF1A-mediated mechanism leading to pathological vessel growth and cone degeneration in response to a chronic hypoxia-like situation. Consequently, our results identify HIF1A as a potential therapeutic target to rescue hypoxia-related vision loss in patients.
C1 [Barben, Maya; Schori, Christian; Samardzija, Marijana; Grimm, Christian] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, Zurich, Switzerland.
   [Barben, Maya; Grimm, Christian] Univ Zurich, Neurosci Ctr Zurich ZNZ, Zurich, Switzerland.
   [Schori, Christian; Grimm, Christian] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   University of Zurich; Zurich Center Integrative Human Physiology (ZIHP)
RP Samardzija, M (通讯作者)，Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Lab Retinal Cell Biol, Zurich, Switzerland.
EM marijana.samardzija@usz.uzh.ch
RI Samardzija, Marijana/B-9245-2008
OI Samardzija, Marijana/0000-0003-0991-4653; Grimm,
   Christian/0000-0001-9318-4352
FU Swiss National Science Foundation (SNF) [31003A_149311, 31003A_173008]
FX Supported by the Swiss National Science Foundation (SNF #31003A_149311
   and 31003A_173008).
CR Akimoto M, 2004, INVEST OPHTH VIS SCI, V45, P42, DOI 10.1167/iovs.03-0804
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   BAIRD A, 1985, BIOCHEMISTRY-US, V24, P7855, DOI 10.1021/bi00348a001
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Betsholtz C, 2004, CYTOKINE GROWTH F R, V15, P215, DOI 10.1016/j.cytogfr.2004.03.005
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Caprara C, 2011, INVEST OPHTH VIS SCI, V52, P2109, DOI 10.1167/iovs.10-6222
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Dallinger S, 1998, J AM GERIATR SOC, V46, P484, DOI 10.1111/j.1532-5415.1998.tb02471.x
   De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fruttiger M, 2002, INVEST OPHTH VIS SCI, V43, P522
   Fruttiger Marcus, 2007, Angiogenesis, V10, P77, DOI 10.1007/s10456-007-9065-1
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Geiger P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.333
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1999, Mol Vis, V5, P27
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hellstrom M, 1999, DEVELOPMENT, V126, P3047
   Heynen SR, 2011, MOL VIS, V17, P2934
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Ida H, 2003, INVEST OPHTH VIS SCI, V44, P5430, DOI 10.1167/iovs.03-0609
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Joly S, 2008, J NEUROSCI, V28, P13765, DOI 10.1523/JNEUROSCI.5114-08.2008
   Joyal JS, 2016, NAT MED, V22, P439, DOI 10.1038/nm.4059
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kast B, 2016, EXP EYE RES, V146, P60, DOI 10.1016/j.exer.2015.12.008
   Kent DL, 2014, MOL VIS, V20, P46
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kurihara T, 2010, DEVELOPMENT, V137, P1563, DOI 10.1242/dev.049015
   Lam AKC, 2003, OPTOMETRY VISION SCI, V80, P305, DOI 10.1097/00006324-200304000-00008
   Lange C, 2011, INVEST OPHTH VIS SCI, V52, P5872, DOI 10.1167/iovs.11-7204
   Lange C, 2011, NEUROBIOL DIS, V41, P119, DOI 10.1016/j.nbd.2010.08.028
   Lin RJ, 2006, AM J OPHTHALMOL, V142, P839, DOI 10.1016/j.ajo.2006.06.003
   Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242
   Lindblom P, 2003, GENE DEV, V17, P1835, DOI 10.1101/gad.266803
   Macgregor AM, 2009, J HISTOCHEM CYTOCHEM, V57, P207, DOI 10.1369/jhc.2008.952531
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Punzo C, 2012, J BIOL CHEM, V287, P1642, DOI 10.1074/jbc.R111.304428
   Punzo C, 2009, NAT NEUROSCI, V12, P44, DOI 10.1038/nn.2234
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Remsch H, 2000, GRAEF ARCH CLIN EXP, V238, P960, DOI 10.1007/s004170000202
   Roberts MR, 2006, P NATL ACAD SCI USA, V103, P6218, DOI 10.1073/pnas.0509981103
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ryan HE, 2000, CANCER RES, V60, P4010
   Samardzija M, 2008, HUM MOL GENET, V17, P281, DOI 10.1093/hmg/ddm304
   Samardzija M, 2014, INVEST OPHTH VIS SCI, V55, P5304, DOI 10.1167/iovs.14-14789
   Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004
   Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389
   Spaide RF, 2013, AGE RELATED MACULAR, P111
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Sun Y, 2017, EBIOMEDICINE, V18, P281, DOI 10.1016/j.ebiom.2017.03.026
   Swaroop A, 2010, NAT REV NEUROSCI, V11, P563, DOI 10.1038/nrn2880
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zhao L, 2011, AM J PATHOL, V179, P1265, DOI 10.1016/j.ajpath.2011.05.042
NR 82
TC 19
Z9 20
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1750-1326
J9 MOL NEURODEGENER
JI Mol. Neurodegener.
PD MAR 7
PY 2018
VL 13
AR 12
DI 10.1186/s13024-018-0243-y
PG 14
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FY7UI
UT WOS:000427068400001
PM 29514656
OA Green Accepted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Ishimaru, K
   Nakajima, T
   Namiki, Y
   Ryotokuji, K
AF Ishimaru, Keisou
   Nakajima, Takuma
   Namiki, Yoshihisa
   Ryotokuji, Kenji
TI Influences of Pinpoint Plantar Long-Wavelength Infrared Light
   Irradiation (Stress-Free Therapy) on Chorioretinal Hemodynamics,
   Atherosclerosis Factors, and Vascular Endothelial Growth Factor
SO INTEGRATIVE MEDICINE RESEARCH
LA English
DT Article
DE Pinpoint plantar long-wavelength infrared light irradiation; PP-LILI
   (stress-free therapy); Chorioretinal hemodynamics blood flow of retinal
   artery and vein; Vascular endothelial growth factor; VEGF; Laser speckle
   flowgraphy
ID DIABETES-MELLITUS; DEMENTIA
AB Background: We previously reported that pinpoint plantar long-wavelength infrared light irradiation (stress-free therapy; SFT) is useful for alleviating insulin resistance and improving intracranial blood flow in patients with type 2 diabetes mellitus. This study was undertaken to evaluate the influences of SFT on chorioretinal hemodynamics (retinal artery and vein blood flows) as well as atherosclerosis-related factors (TG, LDL-C) and VEGF in patients with dyslipidemia.
   Methods: Four patients with dyslipidemia received 15-minute irradiation with a stress-free apparatus (far-infrared wavelength, 30 mW). Using laser speckle flowgraphy, associations of chorioretinal blood flow with peripheral atherosclerosis-inducing factors/VEGF levels before and after irradiation were analyzed.
   Results: Chorioretinal blood flow increased, while TG/LDL-C levels decreased, after irradiation. VEGF tended to rise in cases with pre-irradiation baseline levels at the lower limit but tended to decrease in cases in which baseline levels had exceeded the normal range.
   Conclusion: SFT was suggested to enhance chorioretinal circulation and to normalize VEGF, thereby possibly contributing to amelioration of atherosclerosis-inducing factors. Abnormalities in chorioretinal hemodynamics are known to be highly involved in the pathophysiology of diabetic retinopathy and age-related macular degeneration, and anti-VEGF antibody has been used for treating these conditions. The necessity of risk management, involving chorioretinal blood flow, has been pointed out when dealing with central retinal vein occlusion, diabetes mellitus, ischemic cerebral/cardiac disease, dementia and so on. SFT is therefore a potential complementary medical strategy which can be expected to contribute to normalization of chorioretinal blood flow and atherosclerosis-inducing factors/VEGF levels, and thereby to the prevention of lifestyle-related chronic diseases. (c) 2018 Korea Institute of Oriental Medicine. Published by Elsevier.
C1 [Ishimaru, Keisou; Nakajima, Takuma; Namiki, Yoshihisa; Ryotokuji, Kenji] Ryotokuji Univ, Fac Hlth Sci, Urayasu, Japan.
RP Ishimaru, K (通讯作者)，Ryotokuji Univ, Fac Hlth Sci, Urayasu, Japan.
EM ishimaru@ryotokuji-u.ac.jp
OI ishimaru, keisou/0000-0001-8656-2706
CR Biessels GJ, 2006, LANCET NEUROL, V5, P64, DOI 10.1016/S1474-4422(05)70284-2
   de la Monte SM, 2006, J ALZHEIMERS DIS, V10, P89
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7
   Fukasawa R, 2014, GERIATR GERONTOL INT, V14, P229, DOI 10.1111/ggi.12140
   Fukazawa R, 2013, DEMENT GERIATR COGN, V35, P280, DOI 10.1159/000348407
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Kume K, 2011, J NEUROL, V258, P1295, DOI 10.1007/s00415-011-5927-y
   Kuo YM, 1998, BIOCHEM BIOPH RES CO, V252, P711, DOI 10.1006/bbrc.1998.9652
   Ryotokuji Kenji, 2015, Laser Ther, V24, P179, DOI 10.5978/islsm.15-OR-11
   Ryotokuji Kenji, 2015, Laser Ther, V24, P27, DOI 10.5978/islsm.15-OR-03
   Ryotokuji Kenji, 2014, Laser Ther, V23, P9, DOI 10.5978/islsm.14-OR-02
   Ryotokuji Kenji, 2013, Laser Ther, V22, P209, DOI 10.3136/islsm.22.209
   Ryotokuji Kenji, 2013, Laser Ther, V22, P93, DOI 10.3136/islsm.22.93
NR 15
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-4220
EI 2213-4239
J9 INTEGR MED RES
JI Integr. Med. Res.
PD MAR
PY 2018
VL 7
IS 1
BP 103
EP 107
DI 10.1016/j.imr.2017.12.002
PG 5
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA GA0SA
UT WOS:000428023300012
PM 29629297
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Weng, SS
   Mao, L
   Gong, YY
   Sun, T
   Gu, Q
AF Weng, Sisi
   Mao, Lei
   Gong, Yuanyuan
   Sun, Tao
   Gu, Qing
TI Role of quercetin in protecting ARPE-19 cells against H2O2-induced
   injury via nuclear factor erythroid 2 like 2 pathway activation and
   endoplasmic reticulum stress inhibition
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE quercetin; NF-E2-related factor 2; endoplasmic reticulum stress;
   apoptosis; oxidative stress; ARPE-19 cell
ID PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS; INDUCED APOPTOSIS;
   UP-REGULATION; ER STRESS; DAMAGE; RPE; EXPRESSION; HEALTH; GRP78
AB Age-related macular degeneration (AMD) is a common cause of irreversible blindness in the elderly in the western world. Research has demonstrated that degenerative and progressive conditions of retinal pigmented epithelial (RPE) cells are the key pathogenic mechanisms in AMD. Previous research has indicated the anti-apoptosis, anti-oxidant, anti-inflammatory and anti-cancer properties of quercetin. Therefore, the present study aimed to investigate the protective effects of quercetin on the ARPE-19 human retinal pigment epithelial cell line. ARPE-19 cells were pretreated with various concentrations of quercetin (0-80 mu M) before exposure to 300 mu M H2O2. Cell viability was assessed and reactive oxygen species (ROS) were determined. The importance of the NF-E2-related factor 2 (Nrf2) signaling pathway was corroborated by western blotting and immunostaining. The protein expression levels of endoplasmic reticulum-associated stress responsive genes and apoptotic markers were assessed by western blotting. The results demonstrated that in the H2O2 group, cell viability was weakened, but preserved in quercetin group in a dose-dependent manner, particularly at 20 mu M. The level of ROS decreased in the quercetin group compared with the control groups. In the quercetin group, the expression levels of Nrf2 and phase II enzymes (NQO1 and HO-1) were increased, whereas the levels of ER stress markers (binding of immunoglobulin protein, CCAAT/enhancer-binding protein homologous protein and phosphorylated eukaryotic translation initiation factor 2 alpha) were reduced. Cell apoptosis-associated protein expression levels were altered, with the increase of B-cell lymphoma 2 and reduction of Bcl-2 X-associated protein. In conclusion, quercetin protected ARPE-19 cells from H2O2-induced cytotoxicity by activating the Nrf2 pathway, inhibiting ER stress and targeting anti-apoptotic proteins.
C1 [Weng, Sisi; Mao, Lei; Gong, Yuanyuan; Sun, Tao; Gu, Qing] Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Gen Hosp, 100 Haining Rd, Shanghai 200080, Peoples R China.
C3 Shanghai Jiao Tong University
RP Gong, YY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Gen Hosp, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM gyydr@126.com
FU National Natural Science Foundation of China [81300774, 81200701];
   Natural Science Foundation of Shanghai [12ZR1424500]
FX The present study was supported by the National Natural Science
   Foundation of China (grant nos. 81300774 and 81200701) and the Natural
   Science Foundation of Shanghai (grant no. 12ZR1424500).
CR Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   D'Andrea G, 2015, FITOTERAPIA, V106, P256, DOI 10.1016/j.fitote.2015.09.018
   Dandekar A, 2015, METHODS MOL BIOL, V1292, P205, DOI 10.1007/978-1-4939-2522-3_15
   Feng JY, 2014, OPHTHALMIC RES, V52, P224, DOI 10.1159/000363387
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Hayakawa M, 2015, NEUROBIOL AGING, V36, P2509, DOI 10.1016/j.neurobiolaging.2015.05.006
   He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2
   Huang CX, 2015, J BIOL CHEM, V290, P5367, DOI 10.1074/jbc.M114.603738
   Jiang ZQ, 2015, CHIN J NAT MEDICINES, V13, P896, DOI 10.1016/S1875-5364(15)30095-9
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   Kobylinska A, 2015, POSTEP HIG MED DOSW, V69, P51, DOI 10.5604/17322693.1135423
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Li ZR, 2013, MOL VIS, V19, P1656
   Libby RT, 2010, ADV EXP MED BIOL, V664, P403, DOI 10.1007/978-1-4419-1399-9_46
   Liu K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.276
   Plafker SM, 2012, INT REV CEL MOL BIO, V298, P135, DOI 10.1016/B978-0-12-394309-5.00004-3
   Primikyri A, 2014, ACS CHEM BIOL, V2737
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Suematsu N, 2011, NEUROSCI LETT, V504, P223, DOI 10.1016/j.neulet.2011.09.028
   Tanigawa S, 2007, FREE RADICAL BIO MED, V42, P1690, DOI 10.1016/j.freeradbiomed.2007.02.017
   Wang XQ, 2011, BRAIN RES BULL, V86, P277, DOI 10.1016/j.brainresbull.2011.07.014
   Xu XR, 2016, EUR J PHARMACOL, V770, P1, DOI 10.1016/j.ejphar.2015.11.050
   Zhang Q, 2010, TOXICOL APPL PHARM, V244, P84, DOI 10.1016/j.taap.2009.08.018
   Zhao Z, 2014, FOOD CHEM TOXICOL, V74, P216, DOI 10.1016/j.fct.2014.10.001
   Zheng JH, 2016, FEBS J, V283, P2690, DOI 10.1111/febs.13527
   Zhu XB, 2017, ONCOL REP, V37, P209, DOI 10.3892/or.2016.5217
NR 28
TC 27
Z9 29
U1 1
U2 18
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2017
VL 16
IS 3
BP 3461
EP 3468
DI 10.3892/mmr.2017.6964
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FD3VX
UT WOS:000407461600141
PM 28713895
OA Bronze
DA 2022-11-30
ER

PT J
AU Ijima, R
   Kaneko, H
   Ye, FX
   Takayama, K
   Nagasaka, Y
   Kataoka, K
   Funahashi, Y
   Iwase, T
   Kachi, S
   Kato, S
   Terasaki, H
AF Ijima, Ryo
   Kaneko, Hiroki
   Ye, Fuxiang
   Takayama, Kei
   Nagasaka, Yosuke
   Kataoka, Keiko
   Funahashi, Yasuhito
   Iwase, Takeshi
   Kachi, Shu
   Kato, Seiichi
   Terasaki, Hiroko
TI Suppression of Laser-Induced Choroidal Neovascularization by the Oral
   Medicine Targeting Histamine Receptor H4 in Mice
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE histamine receptor H4; age-related macular degeneration; choroidal
   neovascularization; macrophage
ID AMD ALLERGY ITSELF; MACULAR DEGENERATION; H-4 RECEPTOR; ANTIINFLAMMATORY
   PROPERTIES; ANTIALLERGIC DRUGS; IN-VIVO; RANIBIZUMAB; MACROPHAGES;
   EXPRESSION; CELLS
AB Purpose: This study aimed to examine relationship of histamine receptor H4 (HRH4) and the pathogenesis of laser-induced choroidal neovascularization (laser-CNV) and to determine whether oral administration of HRH4 antagonists suppressed laser-CNV in mice.
   Methods: Laser photocoagulation was performed in mice to induce the laser-CNV. Histamine was administered intravitreously, and CNV volume was measured. Laser photocoagulation and intravitreous injection of HRH4 antagonist JNJ7777120 were performed after intraperitoneal injection of clodronate liposome, which depletes circulating monocyte-derived macrophages; CNV volume was compared with that in mice injected with control (dimethyl sulfoxide [DMSO]/PBS). Three days after laser-CNV, the F4/80(+)CD11b(+) macrophage population in retinal pigment epithelium (RPE)/choroid complex was quantified with flow cytometry in wild-type and Hrh4(-/-) mice. The long-acting HRH4 antagonist JNJ28307474 was then administrated periorally, and the laser-CNV volume was compared with controls.
   Results: Intravitreous injection of histamine did not affect laser-CNV volume. The laser-CNV from the eye injected with JNJ7777120 was equivalent to that injected with the DMSO/PBS in mice that had intraperitoneally received clodronate liposome. Flow cytometry after laser-CNV induction revealed a smaller F4/80(+)CD11b(+) macrophage population in the RPE/choroid complex of Hrh4(-/-) mice than in wild-type mice. Oral administration of JNJ28307474 significantly reduced laser-CNV volume in wild-type mice.
   Conclusions: Our results suggested that HRH4-positive macrophages played an important role in the pathogenesis of laser-CNV and that they require a different ligand from that of histamine. The oral administration of an HRH4 antagonist successfully reduced laser-CNV.
   Translational Relevance: Our results indicate that drugs targeting HRH4 are potentially a novel oral treatment for age-related macular degeneration.
C1 [Ijima, Ryo; Kaneko, Hiroki; Ye, Fuxiang; Takayama, Kei; Nagasaka, Yosuke; Kataoka, Keiko; Iwase, Takeshi; Kachi, Shu; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi, Japan.
   [Funahashi, Yasuhito] Nagoya Univ, Grad Sch Med, Dept Urol, Nagoya, Aichi, Japan.
   [Kato, Seiichi] Nagoya Univ Hosp, Dept Pathol & Lab Med, Nagoya, Aichi, Japan.
C3 Nagoya University; Nagoya University; Nagoya University
RP Kaneko, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI KATO, Seiichi/I-7298-2014; Kaneko, Hiroki/O-7695-2015; Kaneko,
   Hiroki/AHA-2461-2022
OI Kaneko, Hiroki/0000-0003-0731-6465; Kaneko, Hiroki/0000-0003-0731-6465;
   Ye, Fuxiang/0000-0003-2550-2173; Takayama, Kei/0000-0002-1477-9014
CR Adami M., 2014, GASTRO OPEN J, V1, P7, DOI DOI 10.17140/G0J-1-103
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coge F, 2001, BIOCHEM BIOPH RES CO, V284, P301, DOI 10.1006/bbrc.2001.4976
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Connelly WM, 2009, BRIT J PHARMACOL, V157, P55, DOI 10.1111/j.1476-5381.2009.00227.x
   Coruzzi G, 2007, EUR J PHARMACOL, V563, P240, DOI 10.1016/j.ejphar.2007.02.026
   Cowden JM, 2013, INFLAMM RES, V62, P599, DOI 10.1007/s00011-013-0612-5
   Cowden JM, 2010, J INVEST DERMATOL, V130, P1023, DOI 10.1038/jid.2009.358
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Dijkstra D, 2007, J ALLERGY CLIN IMMUN, V120, P300, DOI 10.1016/j.jaci.2007.03.024
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fukuda S, 2013, STEM CELLS, V31, P2149, DOI 10.1002/stem.1469
   Gantner F, 2002, J PHARMACOL EXP THER, V303, P300, DOI 10.1124/jpet.102.036939
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Ijima R, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15367
   Kaneko H, 2008, INVEST OPHTH VIS SCI, V49, P4162, DOI 10.1167/iovs.08-1738
   Kaneko H, 2014, BRIT J PHARMACOL, V171, P3754, DOI 10.1111/bph.12737
   Karlstedt K, 2013, BRIT J PHARMACOL, V170, P58, DOI 10.1111/bph.12173
   Kataoka K, 2011, INVEST OPHTH VIS SCI, V52, P1431, DOI 10.1167/iovs.10-5798
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Liu CL, 2001, J PHARMACOL EXP THER, V299, P121
   Morse KL, 2001, J PHARMACOL EXP THER, V296, P1058
   Nagai T, 2007, INVEST OPHTH VIS SCI, V48, P5716, DOI 10.1167/iovs.07-1023
   Nakayama T, 2004, J IMMUNOL, V173, P2078, DOI 10.4049/jimmunol.173.3.2078
   Nowroozzadeh MH, 2014, INVEST OPHTH VIS SCI, V55, P2933, DOI 10.1167/iovs.14-14415
   Oda T, 2000, J BIOL CHEM, V275, P36781, DOI 10.1074/jbc.M006480200
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P2934, DOI 10.1167/iovs.14-14500
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Strakhova MI, 2009, BRIT J PHARMACOL, V157, P44, DOI 10.1111/j.1476-5381.2009.00236.x
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Thurmond RL, 2004, J PHARMACOL EXP THER, V309, P404, DOI 10.1124/jpet.103.061754
   Ye FX, 2015, SCI REP-UK, V5, DOI 10.1038/srep07705
   Zampeli E, 2009, BRIT J PHARMACOL, V157, P24, DOI 10.1111/j.1476-5381.2009.00151.x
NR 42
TC 6
Z9 6
U1 2
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2015
VL 4
IS 2
AR 6
DI 10.1167/tvst.4.2.6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED1DF
UT WOS:000388583500006
PM 25774332
OA Green Published
DA 2022-11-30
ER

PT J
AU Zhu, D
   Yang, DY
   Guo, YY
   Zheng, YF
   Li, JL
   Wang, B
   Tao, Y
   Jonas, JB
AF Zhu, Dan
   Yang, Da-Yong
   Guo, Yuan-Yuan
   Zheng, Yan-Fei
   Li, Jun-Lian
   Wang, Bin
   Tao, Yong
   Jonas, Jost B.
TI Intracameral Interleukin 1 beta, 6, 8, 10, 12p, Tumor Necrosis Factor
   alpha and Vascular Endothelial Growth Factor and Axial Length in
   Patients with Cataract
SO PLOS ONE
LA English
DT Article
ID EPITHELIUM-DERIVED FACTOR; AGE-RELATED MACULOPATHY; AQUEOUS-HUMOR
   LEVELS; DIABETIC-RETINOPATHY; MACULAR DEGENERATION; CYTOKINE
   CONCENTRATION; EYES; PHARMACOKINETICS; PATHOGENESIS; EXPRESSION
AB Objective
   To assess associations between the aqueous humour concentration of interleukin IL-1 beta, IL-6, IL-8, IL-10 and IL-12p, tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) and axial length in eyes with cataract.
   Methods
   The hospital-based investigation included patients who underwent cataract surgery between March 2014 and April 2014. Using aqueous humour collected at the start of cataract surgery, the interleukins IL-1 beta, IL- 6, IL- 8, IL- 10 and IL- 12p, TNF-alpha and VEGF were examined using a cytometric bead array. Axial length was determined by partial coherence laser interferometry (IOL Master).
   Results
   The study included 33 patients with cataract (33 eyes) with a mean age of 69.2 +/- 10.8 years (range:50-87 years) and a mean axial length of 24.7 +/- 1.9 mm (range:22.6-31.5 mm). Lower aqueous concentration of VEGF was significantly associated with longer axial length (VEGF concentration (pg/mL) = -5.12 x Axial Length (mm) + 163; correlation coefficient r = -0.41; P<0.001) and more myopic refractive error (VEGF concentration (pg/mL) = 1.27xspherical equivalent (diopters)+44.8; r = 0.383; P = 0.002). The aqueous concentrations of all other substances were not significantly (all P>0.10) associated with axial length or refractive error.
   Conclusions Higher intravitreal concentrations of VEGF were measured in eyes with a longer axial length, while the intraocular concentrations of IL-1 beta, IL-6, IL-8, IL-10, IL-12p and TNF-alpha were not correlated with axial length. The lower concentration of VEGF in axially elongated eyes may be one of the reasons for the lower prevalence of age-related macular degeneration and diabetic retinopathy in myopic eyes.
C1 [Zhu, Dan; Yang, Da-Yong; Guo, Yuan-Yuan; Zheng, Yan-Fei; Li, Jun-Lian] Inner Mongolia Med Univ, Affiliated Hosp, Dept Ophthalmol, Hohhot, Inner Mongolia, Peoples R China.
   [Wang, Bin; Tao, Yong] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Seegartenklin Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
C3 Inner Mongolia Medical University; Peking University; Ruprecht Karls
   University Heidelberg
RP Tao, Y (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
EM drtaoyong@163.com
OI Tao, Yong/0000-0003-1443-2667
FU Program for New Century Excellent Talents in University [NCET-12-0010];
   FOK YING TONG education foundation; Deutsche Forschungsgemeinschaft;
   Ruprecht-Karls-Universitat Heidelberg within the funding programme Open
   Access Publishing
FX This study was supported by Program for New Century Excellent Talents in
   University (No: NCET-12-0010) and FOK YING TONG education foundation. We
   acknowledge financial support by Deutsche Forschungsgemeinschaft and
   Ruprecht-Karls-Universitat Heidelberg within the funding programme Open
   Access Publishing. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Carmi Y, 2013, J IMMUNOL, V190, P3500, DOI 10.4049/jimmunol.1202769
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   DEVOS AF, 1994, INVEST OPHTH VIS SCI, V35, P3873
   Funatsu H, 2009, OPHTHALMOLOGY, V116, P73, DOI 10.1016/j.ophtha.2008.09.037
   Hu Q, 2014, RETINA
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jain I S, 1965, J All India Ophthalmol Soc, V13, P88
   JAIN IS, 1967, ARCH OPHTHALMOL-CHIC, V77, P59
   Jia Y, 2014, INVEST OPHTH VIS SCI, V55, P3922, DOI 10.1167/iovs.14-13983
   Jonas JB, 2012, RETINA-J RET VIT DIS, V32, P2150, DOI 10.1097/IAE.0b013e3182576d07
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Kon CH, 1999, INVEST OPHTH VIS SCI, V40, P705
   Krohne TU, 2015, RETINA-J RET VIT DIS, V35, P69, DOI 10.1097/IAE.0000000000000265
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   Limb GA, 1999, INVEST OPHTH VIS SCI, V40, P2453
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Miao H, 2012, MOL VIS, V18, P574
   Missotten GSO, 2006, ARCH OPHTHALMOL-CHIC, V124, P1428, DOI 10.1001/archopht.124.10.1428
   MOSS SE, 1994, OPHTHALMOLOGY, V101, P77
   Noma H, 2005, AM J OPHTHALMOL, V140, P256, DOI 10.1016/j.ajo.2005.03.003
   Pierro L, 1999, RETINA-J RET VIT DIS, V19, P401, DOI 10.1097/00006982-199909000-00005
   Salom D, 2008, INVEST OPHTH VIS SCI, V49, P3499, DOI 10.1167/iovs.07-1168
   Sawada O, 2011, JPN J OPHTHALMOL, V55, P401, DOI 10.1007/s10384-011-0027-1
   Shin YJ, 2012, MOL VIS, V18, P2265
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Teichmann KD, 2002, J CATARACT REFR SURG, V28, P1886, DOI 10.1016/S0886-3350(02)01671-1
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wakabayashi T, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/257381
   Wang B, 2014, J OCUL PHARMACOL TH, V30, P587, DOI 10.1089/jop.2013.0241
   Xie XW, 2008, GRAEF ARCH CLIN EXP, V246, P1519, DOI 10.1007/s00417-008-0884-6
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 37
TC 14
Z9 16
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 13
PY 2015
VL 10
IS 2
AR e0117777
DI 10.1371/journal.pone.0117777
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CC9IO
UT WOS:000350682600086
PM 25679504
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Wang, YJ
   Subramanian, P
   Shen, DF
   Tuo, JS
   Becerra, SP
   Chan, CC
AF Wang, Yujuan
   Subramanian, Preeti
   Shen, Defen
   Tuo, Jingsheng
   Becerra, S. Patricia
   Chan, Chi-Chao
TI Pigment epithelium-derived factor reduces apoptosis and pro-inflammatory
   cytokine gene expression in a murine model of focal retinal degeneration
SO ASN NEURO
LA English
DT Article
DE age-related macular degeneration; apoptosis; inflammation;
   neuroprotection; pigment epithelium-derived factor; retina
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; FACTOR PEDF;
   CCL2/CX3CR1-DEFICIENT MICE; INTERPHOTORECEPTOR MATRIX; CELLS;
   IDENTIFICATION; LESIONS; PHOTORECEPTORS; TRANSLOCATION
AB AMD (age-related macular degeneration) is a neurodegenerative disease causing irreversible central blindness in the elderly. Apoptosis and inflammation play important roles in AMD pathogenesis. PEDF (pigment epithelium-derived factor) is a potent neurotrophic and anti-inflammatory glycoprotein that protects the retinal neurons and photoreceptors against cell death caused by pathological insults. We studied the effects of PEDF on focal retinal lesions in DKO rd8 (Ccl2(-/-)/Cx3cr1(-/-) on C57BL/6N [Crb1(rd8)]) mice, a model for progressive, focal rd (retinal degeneration). First, we found a significant decrease in PEDF transcript expression in DKO rd8 mouse retina and RPE (retinal pigment epithelium) than WT (wild-type, C57BL/6N). Next, cultured DKO rd8 RPE cells secreted lower levels of PEDF protein in the media than WT. Then the right eyes of DKO rd8 mice were injected intravitreously with recombinant human PEDF protein (1 mu g), followed by a subconjunctival injection of PEDF (3 mu g) 4 weeks later. The untreated left eyes served as controls. The effect of PEDF was assessed by fundoscopy, ocular histopathology and A2E {[2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1E, 3E,5E,7E-octatetra-enyl]-1-(2-hydroxyethyl)-4-[4-methyl-6(2,6,6-trimethyl-1-cyclohexen-1-yl) 1E,3E,5E,7E-hexatrienyl]-pyridinium} levels, as well as apoptotic and inflammatory molecules. The PEDF-treated eyes showed slower progression or attenuation of the focal retinal lesions, fewer and/or smaller photoreceptor and RPE degeneration, and significantly lower A2E, relative to the untreated eyes. In addition, lower expression of apoptotic and inflammatory molecules were detected in the PEDF-treated than untreated eyes. Our results establish that PEDF potently stabilizes photoreceptor degeneration via suppression of both apoptotic and inflammatory pathways. The multiple beneficial effects of PEDF represent a novel approach for potential AMD treatment.
C1 [Wang, Yujuan; Shen, Defen; Tuo, Jingsheng; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Wang, Yujuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510060, Guangdong, Peoples R China.
   [Subramanian, Preeti; Becerra, S. Patricia] NEI, Sect Prot Struct & Funct, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Sun Yat Sen University; National Institutes of Health (NIH) -
   USA; NIH National Eye Institute (NEI)
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI wang, yujuan/C-8428-2016
FU National Eye Institute Intramural Research Program; NATIONAL EYE
   INSTITUTE [ZIAEY000418, ZIAEY000222, ZICEY000461] Funding Source: NIH
   RePORTER
FX This work was supported by the National Eye Institute Intramural
   Research Program.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Cao W, 2001, INVEST OPHTH VIS SCI, V42, P1646
   Cao XR, 2010, DISCRETE EVENT DYN S, V20, P1, DOI 10.1007/s10626-010-0088-1
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Chu XK, 2013, BIOENGINEERED, V4, P130, DOI 10.4161/bioe.22949
   Colak E, 2012, AGING CLIN EXP RES, V24, P588, DOI 10.3275/8593
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ding XY, 2009, INVEST OPHTH VIS SCI, V50, P4957, DOI 10.1167/iovs.09-3381
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Fitzgerald DP, 2012, CANCER RES, V72, P144, DOI 10.1158/0008-5472.CAN-11-1904
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   Herzlich Alexandra A, 2009, Open Biol J, V2, P141
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Ku B, 2011, CELL RES, V21, P627, DOI 10.1038/cr.2010.149
   Libby RT, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-108
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Liu YL, 2012, MOL MED, V18, P1387, DOI 10.2119/molmed.2012.00008
   Marciniak Katarzyna, 2006, Postepy Hig Med Dosw (Online), V60, P387
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Miyazaki M, 2011, HUM GENE THER, V22, P559, DOI 10.1089/hum.2010.132
   Murakami Y, 2008, AM J PATHOL, V173, P1326, DOI 10.2353/ajpath.2008.080466
   Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Park K, 2011, AM J PATHOL, V178, P688, DOI 10.1016/j.ajpath.2010.10.014
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Ramkumar HL, 2013, J NUTR, V143, P1129, DOI 10.3945/jn.112.169649
   Reinders MEJ, 2003, J CLIN INVEST, V112, P1655, DOI 10.1172/JCI17712
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Shen DF, 2011, INVEST OPHTH VIS SCI, V52, P2897, DOI 10.1167/iovs.10-6114
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Stratikos E, 1996, PROTEIN SCI, V5, P2575, DOI 10.1002/pro.5560051220
   Subramanian P, 2012, ADV EXP MED BIOL, V723, P799, DOI 10.1007/978-1-4614-0631-0_102
   Takita H, 2003, INVEST OPHTH VIS SCI, V44, P4497, DOI 10.1167/iovs.03-0052
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-59
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Tuo JS, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.01.009
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Wang YJ, 2012, APOPTOSIS, V17, P1144, DOI 10.1007/s10495-012-0750-1
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Wolf G, 2003, NUTR REV, V61, P342, DOI 10.1301/nr.2003.oct.342-346
   WU YQ, 1995, PROTEIN EXPRES PURIF, V6, P447, DOI 10.1006/prep.1995.1060
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yabe T, 2010, CURR MOL MED, V10, P259, DOI 10.2174/156652410791065354
   Yang P, 2005, INVEST OPHTH VIS SCI, V46, P1755, DOI 10.1167/iovs.04-1039
   Zhang SX, 2006, FASEB J, V20, P323, DOI 10.1096/fj.05-4313fje
   Zhou XH, 2009, MOL VIS, V15, P438
NR 61
TC 40
Z9 40
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1759-0914
J9 ASN NEURO
JI ASN Neuro
PY 2013
VL 5
IS 5
AR e00126
DI 10.1042/AN20130028
PG 11
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 286EZ
UT WOS:000329450200002
PM 24160756
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Sasamoto, Y
   Gomi, F
   Sawa, M
   Tsujikawa, M
   Nishida, K
AF Sasamoto, Yuzuru
   Gomi, Fumi
   Sawa, Miki
   Tsujikawa, Motokazu
   Nishida, Kohji
TI Effect of 1-year lutein supplementation on macular pigment optical
   density and visual function
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Macular pigment; Fundus autofluorescence; Lutein; Contrast sensitivity;
   Microperimetry
ID AGE-RELATED MACULOPATHY; SERUM CONCENTRATIONS; PRIMATE RETINAS;
   RISK-FACTORS; VITAMIN-C; ZEAXANTHIN; CAROTENOIDS; DEGENERATION;
   PERFORMANCE; IDENTIFICATION
AB Although it is known that antioxidants including lutein can affect macular pigment optical density (MPOD) and visual function, we still have much to learn about their effect. Our aim was to assess the 1-year changes in MPOD and visual function in response to supplementation containing lutein.
   We prospectively measured the MPOD level of those who received a supplement containing 6 mg of lutein daily for 1 year. MPOD level was measured every 3 months by using autofluorescence spectrometry with the two-wavelength method. Other examinations, including contrast sensitivity and retinal sensitivity were also measured every 3 or 6 months. Stepwise regression analysis was performed to determine the factors that correlated with the changes observed in those examinations.
   Forty-three eyes of 43 Japanese subjects, including five normal eyes, five fellow eyes with central serous chorioretinopathy (CSC), and 33 fellow eyes with age-related macular degeneration (AMD) were enrolled. The higher baseline MPOD level was correlated with the eye with a clear intraocular lens (IOL). Although no time-dependent changes in the MPOD level were obtained in any area, subjects without cardiovascular diseases showed higher increase in the MPOD level. We observed significant increases in the contrast sensitivity at 1 year (p = 0.0124) and in the retinal sensitivity at 6 months (p < 0.0001) and 1 year (p < 0.0001). Stepwise regression analysis showed that nonsmokers had increased contrast sensitivity (p = 0.0173), and the fellow eye of those with CSC had less of an increase in retinal sensitivity (p = 0.0491).
   Daily supplementation with 6 mg of lutein did not affect the MPOD level for 1 year, suggesting that 6 mg of lutein may be insufficient to increase the MPOD level. However, supplementation seems to improve visual functions such as contrast sensitivity and retinal sensitivity.
C1 [Sasamoto, Yuzuru; Gomi, Fumi; Sawa, Miki; Tsujikawa, Motokazu; Nishida, Kohji] Osaka Univ, Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
C3 Osaka University
RP Gomi, F (通讯作者)，Osaka Univ, Sch Med, Dept Ophthalmol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.
EM fgomi@ophthal.med.osaka-u.ac.jp
OI Gomi, Fumi/0000-0003-0807-8817; Nishida, Kohji/0000-0001-9069-3610
FU Japan Society for the Promotion of Science, Tokyo, Japan [22591942];
   Bausch & Lomb Japan, Ltd., Tokyo, Japan
FX This clinical trial was registered at "http://www.umin.ac.jp" with study
   number of UMIN000001320 and was supported in part by Grants in Aid for
   Scientific Research from Japan Society for the Promotion of Science,
   Tokyo, Japan (No. 22591942). Bausch & Lomb Japan, Ltd., Tokyo, Japan,
   also provided partial funding for this study. The authors have full
   control of all primary data and agree to allow Graefes Archive for
   Clinical and Experimental Ophthalmology to review this data upon request
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Applegate RA, 1998, J REFRACT SURG, V14, P397, DOI 10.3928/1081-597X-19980701-05
   Bartlett HE, 2008, CLIN NUTR, V27, P218, DOI 10.1016/j.clnu.2008.01.003
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   CHAKRAVARTHY U, BMC OPHTHALMOL, V10, P31
   Christen WG, 1999, AM J EPIDEMIOL, V149, P476, DOI 10.1093/oxfordjournals.aje.a009836
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Hammond BR, 2001, ARCH BIOCHEM BIOPHYS, V385, P41, DOI 10.1006/abbi.2000.2184
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond BR, 1998, INVEST OPHTH VIS SCI, V39, P397
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   LACHENMAYR BJ, 1994, INVEST OPHTH VIS SCI, V35, P2741
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   SASAMOTO Y, 2010, INVEST OPHTH VIS SCI, V52, P927
   Sasamoto Y, 2010, INVEST OPHTH VIS SCI, V51, P5219, DOI 10.1167/iovs.09-4881
   Sawa M, 2006, JPN J OPHTHALMOL, V50, P111, DOI 10.1007/s10384-005-0292-y
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Uz E, 2003, ACTA OPHTHALMOL SCAN, V81, P161, DOI 10.1034/j.1600-0420.2003.00032.x
   Verdon W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1465, DOI 10.1001/archopht.1996.01100140663003
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
   Zeimer M, 2009, OPHTHALMOLOGE, V106, P29, DOI 10.1007/s00347-008-1773-4
NR 49
TC 30
Z9 32
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2011
VL 249
IS 12
BP 1847
EP 1854
DI 10.1007/s00417-011-1780-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 857VK
UT WOS:000297751000015
PM 21850440
DA 2022-11-30
ER

PT J
AU Goujon, N
   Brown, CM
   Xie, J
   Arnold, AL
   Dunn, RA
   Keeffe, JE
   Taylor, HR
AF Goujon, Nicolas
   Brown, Cherylee M.
   Xie, Jing
   Arnold, Anna-Lena
   Dunn, Ross A.
   Keeffe, Jill E.
   Taylor, Hugh R.
TI Self-reported vision and health of indigenous Australians
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE diabetes; eye health; indigenous Australian; population survey;
   prevention; refractive error; sun protection; vision
ID RISK-FACTORS; PREVALENCE
AB Purpose: To describe the self-reported vision, history of eye disease and general health of indigenous Australian participants in the National Indigenous Eye Health Survey.
   Methods: Using a multistage cluster sampling methodology, 30 geographic areas, stratified by remoteness, were selected to provide a representative population of indigenous Australians aged 5-15 years and 40 years and over. Before an eye examination, participants completed a questionnaire about their eye health and eye care facilities consulted, satisfaction with their vision and general health.
   Results: A total of 1694 indigenous children (49.2% female, mean age 9.5 +/- 2.9 years) and 1189 adults (61.0% female, mean age 53.1 +/- 9.7 years) participated. Three-quarters of adults (259/342) and 88.4% of children (129/146) wore the right distance glasses. Adults from remote areas were less likely to have refractive error (P = 0.002) as well as males versus females (P = 0.02). Similar results were found for children. Adults wearing appropriate distance glasses were as satisfied with their vision as people with normal vision who did not need glasses (P = 0.6). Both groups were more satisfied with their distance vision than people with poor presenting vision (P = 0.007). Self-report of cataract, diabetic retinopathy, glaucoma and age-related macular degeneration did not match with clinical findings (P < 0.001). Over 37% of adults (417/1187) and 1.3% of children (22/1691) reported having diabetes.
   Conclusion: The National Indigenous Eye Health Survey provided information to guide future planning of eye health prevention strategies for indigenous Australians. Findings indicate the importance of correcting refractive error to improve quality of life. Prevention messages should be renewed in appropriate sociocultural formats.
C1 [Goujon, Nicolas] Univ Melbourne, Ctr Eye Res Australia, WHO Collaborating Ctr Prevent Blindness, Melbourne, Vic 3002, Australia.
   [Goujon, Nicolas; Brown, Cherylee M.; Xie, Jing; Arnold, Anna-Lena; Dunn, Ross A.; Keeffe, Jill E.; Taylor, Hugh R.] Vis CRC, Sydney, NSW, Australia.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat Hlth, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Melbourne
RP Goujon, N (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, WHO Collaborating Ctr Prevent Blindness, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM ngoujon@unimelb.edu.au
RI Brown, Cherylee/R-8832-2018
OI Brown, Cherylee/0000-0002-7947-2259; /0000-0001-6694-3587; Taylor,
   Hugh/0000-0002-9437-784X
FU RANZCO Eye Foundation; Vision Cooperative Research Centre; Harold
   Mitchell Foundation
FX The authors gratefully acknowledge the NIEHS Advisory Committee and
   Steering Committee, the Aboriginal health workers, community members,
   Aboriginal liaison officers, school principals, eye health coordinators,
   the collaborating optometrists and ophthalmologists, the many volunteers
   who helped with the field work and Ms Jen Makin from the Cancer Council
   Victoria. We especially thank the 30 communities for their support and
   participation in this project. The NIEHS was supported by the RANZCO Eye
   Foundation, the Vision Cooperative Research Centre and the Harold
   Mitchell Foundation.
CR ABS, 1997, AUSTR SOC TRENDS 199
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Australian Bureau of Statistics, 2006, EXP EST AB TORR STRA
   Australian Bureau of Statistics, 2007, NAT HLTH SURV SUMM R
   Dolin P J, 1994, Ophthalmic Epidemiol, V1, P155, DOI 10.3109/09286589409047224
   FERRARO J, 2006, OPHTHAL EPIDEMIOL, V132, P137
   Gilbert CE, 2008, INVEST OPHTH VIS SCI, V49, P877, DOI 10.1167/iovs.07-0973
   GIRGIS A, 1993, HEALTH EDUC QUART, V20, P275, DOI 10.1177/109019819302000217
   Goh PP, 2005, OPHTHALMOLOGY, V112, P678, DOI 10.1016/j.ophtha.2004.10.048
   Gracey M, 2009, LANCET, V374, P65, DOI 10.1016/S0140-6736(09)60914-4
   Hassell JB, 2000, CLIN EXP OPHTHALMOL, V28, P156, DOI 10.1046/j.1442-9071.2000.00312.x
   HE M, 2004, INVEST OPHTH VIS SCI, V453, P793
   Jaross N, 2005, CLIN EXP OPHTHALMOL, V33, P26, DOI 10.1111/j.1442-9071.2005.00939.x
   Krishnaiah S, 2009, CLIN OPHTHALMOL, V3, P17
   Robaei D, 2006, OPHTHALMOLOGY, V113, P1567, DOI 10.1016/j.ophtha.2006.02.066
   TAYLOR HR, 1981, AM J EPIDEMIOL, V113, P62, DOI 10.1093/oxfordjournals.aje.a113067
   Taylor HR, 1997, EYE HLTH ABORIGINAL
   Taylor HR, 2008, AUST NZ J PUBL HEAL, V32, P489, DOI 10.1111/j.1753-6405.2008.00289.x
   TAYLOR V, 2003, REV IMPLEMENTATION N
   Tellis B, 2008, COMMUN DIS INTELL, V32, P388
   The Royal Australian College of Ophthalmologists, 1980, NAT TRACH EYE HLTH P
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Wensor M, 1999, ARCH OPHTHALMOL-CHIC, V117, P658
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
NR 24
TC 6
Z9 6
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD NOV
PY 2010
VL 38
IS 8
BP 796
EP 804
DI 10.1111/j.1442-9071.2010.02306.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 676VJ
UT WOS:000283946500010
PM 20456436
DA 2022-11-30
ER

PT J
AU Julien, S
   Kreppel, F
   Beck, S
   Heiduschka, P
   Brito, V
   Schnichels, S
   Kochanek, S
   Schraermeyer, U
AF Julien, Sylvie
   Kreppel, Florian
   Beck, Susanne
   Heiduschka, Peter
   Brito, Veronica
   Schnichels, Sven
   Kochanek, Stefan
   Schraermeyer, Ulrich
TI A reproducible and quantifiable model of choroidal neovascularization
   induced by VEGF A(165) after subretinal adenoviral gene transfer in the
   rabbit
SO MOLECULAR VISION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; RETINAL
   NEOVASCULARIZATION; INCREASED EXPRESSION; MEDIATED EXPRESSION; HELPER
   VIRUS; VECTOR; OVEREXPRESSION; MACULOPATHY; MEMBRANES
AB Purpose: To determine the effects of the vascular endothelial growth factor (VEGF)-A(165) delivered using a high capacity adenoviral vector (HC Ad. VEGF-A) on vascular growth and pathological changes in the rabbit eye. To combine different detection methods of VEGF-A(165) overexpression-induced neovascularization in the rabbit.
   Methods: HC Ad. VEGF-A(165) was constructed and injected at 5x10(6) infectious units (iu) into the subretinal space of rabbit eyes. Two and four weeks postinjection, the development of neovascularization and the expression of HC Ad-transduced VEGF-A(165) protein were followed up in vivo by scanning laser ophthalmoscopy, fluorescein and indocyanine green angiographies and ex vivo by electron microscopy and immunohistochemistry
   Results: We observed a choroidal neovascularization (CNV) with leakage in 83% of the rabbit eyes. Our findings present clear indications that there is a significant effect on the endothelial cells of the choriocapillaris after subretinal transduction of the retinal pigment epithelium (RPE) with VEGF-A(165) vector. The choroidal endothelial cells were activated, adherent junctions opened, and the fenestration was minimized, while the extracellular matrix localized between the RPE and the endothelium of the choriocapillaris was enlarged toward the lumen of the vessels, inducing a deep invagination of the endothelial cells into the vessel lumen. They also proliferated and formed pathological vessels in the subretinal space. Moreover, there was an increased expression of basic fibroblast growth factor and VEGF- A accompanied by macrophage stimulation, retinal edema, and photoreceptor loss.
   Conclusions: This is the first model of VEGF- induced CNV in the rabbit in which the pathological events following overexpression of VEGF by RPE cells have been described in detail. Many of the features of our experimental CNV resemble those observed clinically in patients having wet age-related macular degeneration.
C1 [Julien, Sylvie; Heiduschka, Peter; Schnichels, Sven; Schraermeyer, Ulrich] Univ Eye Hosp Tuebingen, Sect Expt Vitreoretinal Surg, D-72076 Tubingen, Germany.
   [Kreppel, Florian; Brito, Veronica; Kochanek, Stefan] Univ Ulm, Div Gene Therapy, D-89069 Ulm, Germany.
   [Beck, Susanne] Univ Eye Hosp Tuebingen, Retinal Diagnost Res Grp, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Ulm University; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital
RP Julien, S (通讯作者)，Univ Eye Hosp Tuebingen, Sect Expt Vitreoretinal Surg, Schleichstr 12-1, D-72076 Tubingen, Germany.
EM Sylvie.Julien@med.unituebingen.de
RI Heiduschka, Peter/AAX-3882-2021; Brito, Verónica/M-2112-2015
OI Brito, Verónica/0000-0002-4137-0708; Julien-Schraermeyer,
   Sylvie/0000-0002-2322-511X; Schnichels, Sven/0000-0002-2385-5517
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Armstrong D, 1998, Angiogenesis, V2, P93, DOI 10.1023/A:1009010628371
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   DAMATO RJ, 1995, OPHTHALMOLOGY, V102, P1261, DOI 10.1016/S0161-6420(95)30876-7
   DESTRO M, 1989, OPHTHALMOLOGY, V96, P846
   ELDIRINI AA, 1991, RETINA-J RET VIT DIS, V11, P244, DOI 10.1097/00006982-199111020-00010
   FERRARA N, 2007, RETINA, V27, P1154
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Kimura H, 1999, INVEST OPHTH VIS SCI, V40, P524
   KIMURA H, 1995, INVEST OPHTH VIS SCI, V36, P2110
   Kinnunen K, 2006, ACTA PHYSIOL, V187, P447, DOI 10.1111/j.1748-1716.2006.01588.x
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kreppel F, 2002, HUM GENE THER, V13, P1151, DOI 10.1089/104303402320138934
   Kreppel F, 2002, INVEST OPHTH VIS SCI, V43, P1965
   Lebherz C, 2005, DIABETES, V54, P1141, DOI 10.2337/diabetes.54.4.1141
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Miyamoto H, 1999, INVEST OPHTH VIS SCI, V40, P1496
   Ni M, 2005, EXP EYE RES, V81, P286, DOI 10.1016/j.exer.2005.01.027
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565
   Qiu G, 2006, EXP EYE RES, V83, P141, DOI 10.1016/j.exer.2005.11.014
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Reich S, 2003, MOL VIS, V9, P210
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Schiedner G, 1998, NAT GENET, V18, P298, DOI 10.1038/ng0398-298c
   Schiedner G, 1998, NAT GENET, V18, P180, DOI 10.1038/ng0298-180
   Seeliger Mathias W., 2000, Documenta Ophthalmologica, V100, P167, DOI 10.1023/A:1002731703120
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Shima DT, 1996, INVEST OPHTH VIS SCI, V37, P1334
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   ZHU ZR, 1989, GRAEF ARCH CLIN EXP, V227, P257, DOI 10.1007/BF02172759
NR 42
TC 23
Z9 32
U1 1
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 30
PY 2008
VL 14
IS 164
BP 1358
EP 1372
PG 15
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 336DX
UT WOS:000258345600001
PM 18682809
DA 2022-11-30
ER

PT J
AU Odergren, A
   Ming, Y
   Kvanta, A
AF Odergren, Anne
   Ming, Yue
   Kvanta, Anders
TI Photodynamic therapy of experimental choroidal neovascularization in the
   mouse
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; angiogenesis; mouse; photodynamic
   therapy
ID MACULAR DEGENERATION; GROWTH-FACTOR; VERTEPORFIN THERAPY; MEMBRANES;
   MODEL; VEGF; RETINA; MONKEY
AB Purpose: To evaluate the qualitative and quantitative effects of verteporfin photodynamic therapy (PDT) on laser-induced choroidal neovascularization (CNV) in the mouse. Methods: PDT was applied to the normal mouse fundus using light doses of 32, 64, and 83 s, and histological analysis of the treated areas was performed. CNV was induced using krypton laser photocoagulation of the fundus, and the CNV lesions were subsequently treated with PDT using light doses of 32, 64, and 83 s. Enucleated eyes were analyzed with light and transmission electron microscopies, and measurements of CNV size were done on histologic sections and on isolectin B4-stained choroidal flat mounts. Results: PDT induced a light dose-dependent damage to the surrounding neural retina in normal eyes. At a light dose of 32 s, minimal damage was detected in the neural retina, whereas higher light doses caused distortion and disruption of the outer and inner nuclear layers and of the retinal pigment epithelium. When PDT was applied over laser-induced CNV lesions, the relative height of the lesions was significantly reduced (p < 0.05) using all light doses. Transmission electron microscopy 1 day after PDT treatment revealed occlusion of many of the CNV vessels. One week after PDT treatment, the CNV lesions contained patent vessels irrespective of light dose applied. Accordingly, PDT treatment inhibited (p < 0.05) but did not halt CNV lesion growth. Conclusions: PDT treatment of laser-induced CNV may create an acute occlusion of neovessels and an inhibition of CNV lesion growth without apparent injury to the surrounding neural retina. However, PDT-treated areas will remain vascularized with continued growth of the CNV lesion, which in turn may explain the often limited effect of PDT in patients with neovascular age-related macular degeneration. Elevating the PDT light dose will not increase the treatment effect substantially but may lead to increased collateral injury.
C1 St Eriks Eye Hosp, Karolinska Inst, Sect Ophthalmol & Vis, Dept Clin Neurosci, SE-11282 Stockholm, Sweden.
   Jilin Univ, Hosp 2, Dept Ophthalmol, Changchun 130023, Peoples R China.
C3 Karolinska Institutet; Jilin University
RP Kvanta, A (通讯作者)，St Eriks Eye Hosp, Karolinska Inst, Sect Ophthalmol & Vis, Dept Clin Neurosci, Polhemsgatan 50, SE-11282 Stockholm, Sweden.
EM anders.kvanta@sankterik.ses
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Criswell MH, 2005, INVEST OPHTH VIS SCI, V46, P2168, DOI 10.1167/iovs.04-1442
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Ming Y, 2004, INVEST OPHTH VIS SCI, V45, P1969, DOI 10.1167/iovs.03-1329
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Nambu H, 2003, INVEST OPHTH VIS SCI, V44, P3650, DOI 10.1167/iovs.02-0985
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Renno RZ, 2004, ARCH OPHTHALMOL-CHIC, V122, P1002, DOI 10.1001/archopht.122.7.1002
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 22
TC 16
Z9 16
U1 2
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD SEP
PY 2006
VL 31
IS 9
BP 765
EP 774
DI 10.1080/02713680600865045
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 083DK
UT WOS:000240435900009
PM 16966149
DA 2022-11-30
ER

PT J
AU Jaakson, K
   Zernant, J
   Kulm, M
   Hutchinson, A
   Tonisson, N
   Glavac, D
   Ravnik-Glavac, M
   Hawlina, M
   Meltzer, MR
   Caruso, RC
   Testa, F
   Maugeri, A
   Hoyng, CB
   Gouras, P
   Simonelli, F
   Lewis, RA
   Lupski, JR
   Cremers, FPM
   Allikmets, R
AF Jaakson, K
   Zernant, J
   Kulm, M
   Hutchinson, A
   Tonisson, N
   Glavac, D
   Ravnik-Glavac, M
   Hawlina, M
   Meltzer, MR
   Caruso, RC
   Testa, F
   Maugeri, A
   Hoyng, CB
   Gouras, P
   Simonelli, F
   Lewis, RA
   Lupski, JR
   Cremers, FPM
   Allikmets, R
TI Genotyping microarray (gene chip) for the ABCR (ABCA4) gene
SO HUMAN MUTATION
LA English
DT Article
DE genotyping; microarray; ABCR; ABCA4; Stargardt disease; STGD1; mutation
   detection; mutation screening
ID RECESSIVE RETINITIS-PIGMENTOSA; ARRAYED PRIMER EXTENSION; CONE-ROD
   DYSTROPHY; STARGARDT-DISEASE; MACULAR DEGENERATION; TRANSPORTER GENE;
   SEQUENCE VARIATION; MUTATION DETECTION; ALLELIC VARIATION;
   CYSTIC-FIBROSIS
AB Genetic variation in the AB CR (ABCA4) gene has been associated with five distinct retinal phenotypes, including Stargardt disease/fundus flavimaculatus (STGD/FFM), cone,rod dystrophy (CRD), and age,related macular degeneration (AMD). Comparative genetic analyses of ABCR variation and diagnostics have been complicated by substantial allelic heterogeneity and by differences in screening methods. To overcome these limitations, we designed A genotyping microarray (gene chip) for ABCR that includes all similar to400 disease-associated and other variants currently described, enabling simultaneous detection of all known ABCR variants. The ABCR genotyping microarray (the ABCR400 chip) was constructed by the arrayed primer extension (APEX) technology. Each sequence change in ABCR was included on the chip by synthesis and application of sequence-specific oligonucleotides. We validated the chip by screening 136 confirmed STGD patients and 96 healthy controls, each of whom we had analyzed previously by single strand conformation polymorphism (SSCP) technology and/or wheteroduplex analysis. The microarray was >98% effective in determining the existing genetic variation and was comparable to direct sequencing in that it yielded many sequence changes undetected by SSCP In STGD patient cohorts, the efficiency of the array to detect disease associated alleles was between 54% and 78%, depending on the ethnic composition and degree of clinical and molecular characterization of a cohort. In addition, chip analysis suggested a high carrier frequency (up to 1:10) of ABCR variants in the general population. The ABCR genotyping microarray is a robust, cost-effective, and comprehensive screening tool for variation in one gene in which mutations are responsible for a substantial fraction of retinal disease. The ABCR chip is a prototype for the next generation of screening and diagnostic tools in ophthalmic genetics, bridging clinical and scientific research. (C) 2003 Wiley-Liss, Inc.
C1 Columbia Univ, Dept Ophthalmol, Eye Res Inst, New York, NY 10032 USA.
   Asper Biotech, Tartu, Estonia.
   Columbia Univ, Dept Pathol, New York, NY USA.
   Fac Med Ljubljana, Mol Genet Lab, Inst Pathol, Ljubljana, Slovenia.
   Fac Med Ljubljana, Inst Biochem, Ljubljana, Slovenia.
   Univ Ljubljana, Eye Clin, Med Ctr, Ljubljana, Slovenia.
   NEI, Ophthalm Genet & Visual Funct Branch, NIH, DHHS, Bethesda, MD 20892 USA.
   Univ Naples 2, Eye Clin, Naples, Italy.
   Univ Nijmegen, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
   Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
C3 Columbia University; Columbia University; University of Ljubljana;
   University of Ljubljana; University of Ljubljana; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); Universita della
   Campania Vanvitelli; Radboud University Nijmegen; Radboud University
   Nijmegen; Baylor College of Medicine; Baylor College of Medicine; Baylor
   College of Medicine; Baylor College of Medicine
RP Allikmets, R (通讯作者)，Columbia Univ, Dept Ophthalmol, Eye Res Inst, Rm 715,630 W 168th St, New York, NY 10032 USA.
RI Allikmets, Rando/ABD-4533-2021; Cremers, Frans/A-5625-2014; Hawlina,
   Marko/AAZ-8084-2020; Testa, Francesco/J-3185-2012; ravnik-glavac,
   metka/ABH-8339-2020; Tonisson, Neeme/H-2783-2015; Hoyng,
   C.B./H-8050-2014
OI Cremers, Frans/0000-0002-4954-5592; Testa, Francesco/0000-0002-1482-1577
FU NATIONAL EYE INSTITUTE [R01EY013255, R01EY013435] Funding Source: NIH
   RePORTER; NEI NIH HHS [EY13255, EY13435] Funding Source: Medline
CR Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   ANDERSON KL, 1995, AM J HUM GENET, V57, P1351
   Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504
   Fukui T, 2002, INVEST OPHTH VIS SCI, V43, P2819
   Fumagalli A, 2001, HUM GENET, V109, P326, DOI 10.1007/s004390100583
   Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303
   KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308
   Kurg A, 2000, GENET TEST, V4, P1, DOI 10.1089/109065700316408
   Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Maugeri A, 2000, AM J HUM GENET, V67, P960, DOI 10.1086/303079
   Maugeri A, 2002, EUR J HUM GENET, V10, P197, DOI 10.1038/sj.ejhg.5200784
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   Pastinen T, 1996, CLIN CHEM, V42, P1391
   Pastinen T, 1997, GENOME RES, V7, P606, DOI 10.1101/gr.7.6.606
   RIORDAN JR, 1989, SCIENCE, V245, P1066
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rozet JM, 1999, J MED GENET, V36, P447
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Shumaker JM, 1996, HUM MUTAT, V7, P346, DOI 10.1002/(SICI)1098-1004(1996)7:4<346::AID-HUMU9>3.3.CO;2-9
   Simonelli F, 2000, INVEST OPHTH VIS SCI, V41, P892
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Tonisson N, 2000, MICROARRAY BIOCHIP TECHNOLOGY, P247
   Tonisson N, 2002, P NATL ACAD SCI USA, V99, P5503, DOI 10.1073/pnas.082100599
   van Driel MA, 1998, OPHTHALMIC GENET, V19, P117, DOI 10.1076/opge.19.3.117.2187
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
   Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021
NR 31
TC 194
Z9 204
U1 0
U2 11
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD NOV
PY 2003
VL 22
IS 5
BP 395
EP 403
DI 10.1002/humu.10263
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 738QJ
UT WOS:000186299100007
PM 14517951
DA 2022-11-30
ER

PT J
AU Grant, MB
   Caballero, S
AF Grant, MB
   Caballero, S
TI Somatostatin analogues as drug therapies for retinopathies
SO DRUGS OF TODAY
LA English
DT Review
ID PROLIFERATIVE DIABETIC-RETINOPATHY; ENDOTHELIAL GROWTH-FACTOR; SERUM
   IGF-1 CONCENTRATION; CELL-CYCLE ARREST; RETINAL NEOVASCULARIZATION;
   IN-VIVO; RECEPTOR; OCTREOTIDE; HORMONE; ANGIOGENESIS
AB Proliferative retinopaties account for the majority of cases of vision loss throughout the world. Currently accepted therapy for retinopathy consists of retinal ablation by panretinal laser photocoagulation or cryotherapy. This technique is not without deleterious effects to patients, including diminished night vision, reduced peripheral vision and loss of precise vision, decreasing visual acuity by one to two lines in magnitude. One promising area of research into pharmacotherapeutics for retinopathies, especially proliferative diabetic retinopathy, involves the use of synthetic analogues of somatostatin. The rationale for somatostatin as a therapeutic agent for retinal neovascularization is discussed. Somatostatin analogues such as octreotide have shown promise as a safe and effective treatment for severe proliferative diabetic retinopathy by blocking the local and systemic production of growth hormone and insulin-like growth factor type 1 associated with angiogenesis and endothelial cell proliferation. There are also observations suggesting an autocrine and paracrine effect of somatostatin, perhaps directly on retinal cells, which are known to express somatostatin receptors (SSTR). SSTR2 and SSTR3 are the most important receptor subtypes mediating growth hormone secretion and endothelial cell cycle arrest, retinal endothelial cell apoptosis and release of insulin. Thus, analogues that target these receptor subtypes may prove more useful.
   Long-acting somatostatin analogues are currently being tested for treatment of diabetic retinopathy and are, in fact, the only therapeutic alternative for patients who fail panretinal photocoagulation. Whether such a therapy may also prove effective for other retinal vascular proliferative diseases such as retinopathy of prematurity and age-related macular degeneration remains an open question that deserves attention, given our new understanding of the cellular and molecular mechanisms by which somatostatin may exert its antiangiogenic effects. (C) 2002 Prous Science. All rights reserved.
C1 Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida
RP Grant, MB (通讯作者)，Univ Florida, Dept Pharmacol & Therapeut, POB 100267,1600 SW Archer Rd,Room R-5244, Gainesville, FL 32610 USA.
EM grantma@pharmacology.ufl.edu
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Aiello LP, 2000, KIDNEY INT, V58, pS113, DOI 10.1046/j.1523-1755.2000.07718.x
   Albini A, 1999, FASEB J, V13, P647, DOI 10.1096/fasebj.13.6.647
   Algvere PV, 2002, ACTA OPHTHALMOL SCAN, V80, P136, DOI 10.1034/j.1600-0420.2002.800204.x
   ALZAID AA, 1994, DIABETES CARE, V17, P531, DOI 10.2337/diacare.17.6.531
   Averbukh E, 2000, Int J Exp Diabetes Res, V1, P39, DOI 10.1155/EDR.2000.39
   Boehm BO, 2001, HORM METAB RES, V33, P300, DOI 10.1055/s-2001-15282
   Borgstrom P, 1998, PROSTATE, V35, P1
   Boulton M, 1998, BRIT J OPHTHALMOL, V82, P561, DOI 10.1136/bjo.82.5.561
   Bruns C, 1996, METABOLISM, V45, P17, DOI 10.1016/S0026-0495(96)90072-4
   Chantelau E, 1997, BRIT J OPHTHALMOL, V81, P169
   Chantelau E, 1998, BRIT J OPHTHALMOL, V82, P725, DOI 10.1136/bjo.82.7.725
   Clemens A, 1999, METABOLISM, V48, P1236, DOI 10.1016/S0026-0495(99)90261-5
   Cunha-Vaz J, 1998, DIABETIC MED, V15, pS47, DOI 10.1002/(SICI)1096-9136(1998120)15:4+<S47::AID-DIA739>3.3.CO;2-J
   Daneman D, 1981, Retina, V1, P84
   Davis MD, 1998, INVEST OPHTH VIS SCI, V39, P233
   Davis MI, 2001, HORM METAB RES, V33, P295, DOI 10.1055/s-2001-15286
   Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GRANT M, 1986, DIABETES, V35, P416, DOI 10.2337/diabetes.35.4.416
   Grant MB, 2000, DIABETES CARE, V23, P504, DOI 10.2337/diacare.23.4.504
   GRANT MB, 1993, REGUL PEPTIDES, V48, P267, DOI 10.1016/0167-0115(93)90356-D
   Higgins RD, 2002, EXP EYE RES, V74, P553, DOI 10.1006/exer.2001.1147
   HYER SL, 1989, ACTA ENDOCRINOL-COP, V120, P187, DOI 10.1530/acta.0.1200187
   HYER SL, 1988, DIABETIC MED, V5, P356, DOI 10.1111/j.1464-5491.1988.tb01005.x
   HYER SL, 1987, DIABETOLOGIA, V30, pA534
   KIRKEGAARD C, 1990, ACTA ENDOCRINOL-COP, V122, P766, DOI 10.1530/acta.0.1220766
   KOHNER EM, 1975, METABOLISM, V24, P1085, DOI 10.1016/0026-0495(75)90102-X
   Limb GA, 1996, BRIT J OPHTHALMOL, V80, P168, DOI 10.1136/bjo.80.2.168
   MALLET B, 1992, DIABETES METAB, V18, P438
   MCCOMBE M, 1991, Eye (London), V5, P569
   MERIMEE TJ, 1982, J CLIN ENDOCR METAB, V55, P999, DOI 10.1210/jcem-55-5-999
   MERIMEE TJ, 1978, NEW ENGL J MED, V298, P1217, DOI 10.1056/NEJM197806012982202
   NAVASCUES I, 1988, HORM RES, V29, P92, DOI 10.1159/000180977
   Pages P, 1999, J BIOL CHEM, V274, P15186, DOI 10.1074/jbc.274.21.15186
   Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183
   Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   POULSEN JE, 1953, DIABETES, V2, P7, DOI 10.2337/diab.2.1.7
   REISINE T, 1995, ENDOCR REV, V16, P427, DOI 10.1210/er.16.4.427
   Reynolds JD, 2001, PEDIATR DRUGS, V3, P263, DOI 10.2165/00128072-200103040-00003
   Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851
   Rohrer SP, 1998, SCIENCE, V282, P737, DOI 10.1126/science.282.5389.737
   Sharma K, 1996, MOL ENDOCRINOL, V10, P1688, DOI 10.1210/me.10.12.1688
   Shimon I, 1997, J CLIN INVEST, V100, P2386, DOI 10.1172/JCI119779
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Stone J, 1996, INVEST OPHTH VIS SCI, V37, P290
   STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995
   Wheatley CM, 2002, BRIT J OPHTHALMOL, V86, P696, DOI 10.1136/bjo.86.6.696
   Woltering EA, 1999, J PEPT RES, V53, P201, DOI 10.1111/j.1397-002X.1999.00019.x
   Yang LH, 1998, P NATL ACAD SCI USA, V95, P10836, DOI 10.1073/pnas.95.18.10836
NR 51
TC 35
Z9 37
U1 0
U2 1
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD NOV
PY 2002
VL 38
IS 11
BP 783
EP 791
DI 10.1358/dot.2002.38.11.820138
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 635EU
UT WOS:000180386200006
PM 12582462
DA 2022-11-30
ER

PT J
AU Solino, M
   Larrayoz, IM
   Lopez, EM
   Rey-Funes, M
   Bareiro, M
   Loidl, CF
   Girardi, E
   Martinez, A
   Lopez-Costa, JJ
AF Solino, Manuel
   Larrayoz, Ignacio M.
   Lopez, Ester Maria
   Rey-Funes, Manuel
   Bareiro, Mariana
   Loidl, Cesar Fabian
   Girardi, Elena
   Martinez, Alfredo
   Lopez-Costa, Juan Jose
TI Adenosine A2A Receptor: A New Neuroprotective Target in Light-Induced
   Retinal Degeneration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Adenosine; retina; degeneration; A2A receptor; CGS 21680; SCH58261
ID RAT HIPPOCAMPUS; A(2A) RECEPTORS; BINDING-SITES; CGS 21680; DYSFUNCTION;
   ACTIVATION; CAFFEINE; CELLS; A(1); LOCALIZATION
AB Continuous illumination induces the degeneration of photoreceptors. This animal model of light-induced retinal degeneration resembles many characteristics of human degenerative diseases of the outer retina, such as age-related macular degeneration. This work aimed to evaluate the potential neuroprotective effect of the modulation of adenosine A2A receptor in the model of light-induced retinal degeneration. Sprague-Dawley rats were intravitreally injected in the right eye with either CGS 21680, an adenosine A2A receptor agonist, or SCH 58261, an adenosine A2A receptor antagonist. Contralateral eyes were injected with respective vehicles as control. Then, rats were subjected to continuous illumination (12,000 lux) for 24 h. Retinas were processed by glial fibrillary acidic protein (GFAP) immunohistochemistry, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) technique, Western blotting (WB), and quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Another group of rats was subjected to functional studies by electroretinography. Animals treated with CGS21680 showed a significant increase of apoptotic nuclei in the outer nuclear layer and a significant increase of GFAP immunoreactive area of the retinas but did not alter WB nor electroretinography results. qRT-PCR showed that CGS 21680 significantly increased the expression of interleukin-1 beta. On the opposite, SCH 58261 significantly decreased apoptotic nuclei in the outer nuclear layer and GFAP immunoreactive area of the retinas. It also significantly decreased GFAP and activated caspase-3 levels as measured by WB and preserved retinal function, as treated eyes showed significantly greater amplitudes of a- and b-waves and oscillatory potentials. qRT-PCR revealed that SCH 58261 significantly decreased the expression of tumor necrosis factor-alpha. These results show that the blockade of the A2A receptor before the start of the pathogenic process is neuroprotective, as it prevents light-induced retinal damage. The use of A2A receptor antagonists deserves to be evaluated in retinal degenerative diseases.
C1 [Solino, Manuel; Lopez, Ester Maria; Rey-Funes, Manuel; Bareiro, Mariana; Loidl, Cesar Fabian; Girardi, Elena; Lopez-Costa, Juan Jose] Univ Buenos Aires, Fac Med, UBA CONICET, Inst Biol Celular & Neurociencia IBCN, Buenos Aires, Argentina.
   [Larrayoz, Ignacio M.] Ctr Biomed Res Rioja CIBIR, Biomarkers & Mol Signaling Grp, Logrono, Spain.
   [Martinez, Alfredo] Ctr Biomed Res Rioja CIBIR, Angiogenesis Study Grp, Logrono, Spain.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University of Buenos Aires
RP Lopez-Costa, JJ (通讯作者)，Univ Buenos Aires, Fac Med, UBA CONICET, Inst Biol Celular & Neurociencia IBCN, Buenos Aires, Argentina.
EM jjlopez@fmed.uba.ar
RI Larrayoz, Ignacio M/I-5613-2012; Martinez, Alfredo/GQH-5998-2022
OI Larrayoz, Ignacio M/0000-0003-1629-152X; Martinez,
   Alfredo/0000-0003-4882-4044
FU University of Buenos Aires [UBACYT 2014-17/20020130100675BA,
   2018/20020170100493BA]; Instituto de Salud Carlos III [PI19/01805,
   CP15/00198, CPII20/00029]; European Regional Development Fund (ERDF);
   Fundacion Rioja Salud (FRS)
FX This work was supported with grants of the University of Buenos Aires
   given to JL-C (UBACYT 2014-17/20020130100675BA and
   2018/20020170100493BA). JL-C was the director of the lab in BA, where
   animals were illuminated, and IHC, WB, and ERGs were carried out. This
   research was funded in part by a grant (PI19/01805) from the Instituto
   de Salud Carlos III, co-funded by European Regional Development Fund
   (ERDF) "A way to build Europe". IML was supported by Miguel Servet
   contracts (CP15/00198 and CPII20/00029) from the Instituto de Salud
   Carlos III, co-funded by European Social fund (ESF) "Investing in your
   future" and by the Fundacion Rioja Salud (FRS) given to AM. AM was the
   director of the Spanish lab where qRT-PCRs were carried out.
CR Gori MB, 2013, CELL MOL NEUROBIOL, V33, P803, DOI 10.1007/s10571-013-9947-2
   BLAZYNSKI C, 1990, J NEUROCHEM, V54, P648, DOI 10.1111/j.1471-4159.1990.tb01920.x
   BLAZYNSKI C, 1991, CELL MOL NEUROBIOL, V11, P463, DOI 10.1007/BF00734810
   Boeck CR, 2005, NEUROPHARMACOLOGY, V49, P17, DOI 10.1016/j.neuropharm.2005.01.024
   Boia R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.451
   Canas PM, 2009, J NEUROSCI, V29, P14741, DOI 10.1523/JNEUROSCI.3728-09.2009
   Ciruela F, 2006, J NEUROSCI, V26, P2080, DOI 10.1523/JNEUROSCI.3574-05.2006
   Colella M, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00605
   Cunha RA, 1999, N-S ARCH PHARMACOL, V359, P295, DOI 10.1007/PL00005355
   Cunha RA, 1996, N-S ARCH PHARMACOL, V353, P261, DOI 10.1007/BF00168627
   Cunha RA, 2016, J NEUROCHEM, V139, P1019, DOI 10.1111/jnc.13724
   Cunha RA, 2010, J ALZHEIMERS DIS, V20, pS95, DOI 10.3233/JAD-2010-1408
   dos Santos-Rodrigues A, 2015, VITAM HORM, V98, P487, DOI 10.1016/bs.vh.2014.12.014
   Dureau P, 2001, CURR EYE RES, V22, P74, DOI 10.1076/ceyr.22.1.74.6974
   Font L, 2008, PSYCHOPHARMACOLOGY, V199, P515, DOI 10.1007/s00213-008-1174-z
   Gomes CARV, 2009, J NEUROCHEM, V108, P1208, DOI 10.1111/j.1471-4159.2009.05876.x
   Grishagin IV, 2015, ANAL BIOCHEM, V473, P63, DOI 10.1016/j.ab.2014.12.007
   Gyoneva S, 2014, NEUROBIOL DIS, V67, P191, DOI 10.1016/j.nbd.2014.03.004
   HANCOCK MB, 1984, J HISTOCHEM CYTOCHEM, V32, P311, DOI 10.1177/32.3.6198359
   Housley GD, 2009, TRENDS NEUROSCI, V32, P128, DOI 10.1016/j.tins.2009.01.001
   Jenner P, 2014, INT REV NEUROBIOL, V119, P71, DOI 10.1016/B978-0-12-801022-8.00003-9
   Kaster MP, 2015, P NATL ACAD SCI USA, V112, P7833, DOI 10.1073/pnas.1423088112
   Leibovich SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002-9440(10)61170-4
   Li B, 1999, EXP EYE RES, V68, P9, DOI 10.1006/exer.1998.0573
   Li HY, 2014, VISUAL NEUROSCI, V31, P237, DOI 10.1017/S095252381300062X
   Madeira MH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20733-2
   Madeira MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27532
   Madeira MH, 2016, TRANSL RES, V169, P112, DOI 10.1016/j.trsl.2015.11.005
   MCINTOSH HH, 1994, J NEUROCHEM, V62, P992
   Nobre HV, 2010, NEUROCHEM INT, V56, P51, DOI 10.1016/j.neuint.2009.09.001
   Ongini E, 1997, DRUG DEVELOP RES, V42, P63
   Ostwald P, 1997, VISION RES, V37, P3453, DOI 10.1016/S0042-6989(96)00222-2
   Paterniti I, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-31
   Perigolo-Vicente R, 2014, BIOCHEM BIOPH RES CO, V449, P477, DOI 10.1016/j.bbrc.2014.05.036
   Rey HL, 1999, J NEUROCHEM, V72, P2345, DOI 10.1046/j.1471-4159.1999.0722345.x
   Rosim FE, 2011, EPILEPSY BEHAV, V22, P207, DOI 10.1016/j.yebeh.2011.07.004
   Roth S, 1997, EXP EYE RES, V65, P771, DOI 10.1006/exer.1997.0391
   Santiago AR, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/465694
   SEVERNS ML, 1994, DOC OPHTHALMOL, V86, P23, DOI 10.1007/BF01224625
   Solino M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198838
   Stella SL, 2002, J NEUROPHYSIOL, V87, P351, DOI 10.1152/jn.00010.2001
   Stone Trevor W, 2009, Handb Exp Pharmacol, P535, DOI 10.1007/978-3-540-89615-9_17
   Tebano MT, 2010, THESCIENTIFICWORLDJO, V10, P1768, DOI 10.1100/tsw.2010.164
   Yang ZJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11294
   ZHANG G, 1994, EUR J PHARMACOL, V255, P239, DOI 10.1016/0014-2999(94)90104-X
   Zhang SY, 2017, FASEB J, V31, P3334, DOI [10.1096/fj.201601285R, 10.1096/fj.201601285r]
NR 46
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 21
PY 2022
VL 13
AR 840134
DI 10.3389/fphar.2022.840134
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 0I8WU
UT WOS:000779695000001
PM 35387355
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gutierrez, L
   Lim, JS
   Foo, L
   Ng, WYY
   Yip, M
   Lim, GYS
   Wong, MHY
   Fong, A
   Rosman, M
   Mehta, JS
   Lin, HT
   Ting, DSJ
   Ting, DSW
AF Gutierrez, Laura
   Lim, Jane Sujuan
   Foo, Li Lian
   Ng, Wei Yan Yan
   Yip, Michelle
   Lim, Gilbert Yong San
   Wong, Melissa Hsing Yi
   Fong, Allan
   Rosman, Mohamad
   Mehta, Jodhbir Singth
   Lin, Haotian
   Ting, Darren Shu Jeng
   Ting, Daniel Shu Wei
TI Application of artificial intelligence in cataract management: current
   and future directions
SO EYE AND VISION
LA English
DT Review
DE Artificial intelligence; Telemedicine; Cataract; Cataract screening;
   Cataract surgery; IOL calculations; Biometry; Machine learning
ID INTRAOCULAR-LENS; DIABETIC-RETINOPATHY; POWER; FORMULA; BLINDNESS;
   IMAGES; VALIDATION; ACCURACY; EYES
AB The rise of artificial intelligence (AI) has brought breakthroughs in many areas of medicine. In ophthalmology, AI has delivered robust results in the screening and detection of diabetic retinopathy, age-related macular degeneration, glaucoma, and retinopathy of prematurity. Cataract management is another field that can benefit from greater AI application. Cataract is the leading cause of reversible visual impairment with a rising global clinical burden. Improved diagnosis, monitoring, and surgical management are necessary to address this challenge. In addition, patients in large developing countries often suffer from limited access to tertiary care, a problem further exacerbated by the ongoing COVID-19 pandemic. AI on the other hand, can help transform cataract management by improving automation, efficacy and overcoming geographical barriers. First, AI can be applied as a telediagnostic platform to screen and diagnose patients with cataract using slit-lamp and fundus photographs. This utilizes a deep-learning, convolutional neural network (CNN) to detect and classify referable cataracts appropriately. Second, some of the latest intraocular lens formulas have used AI to enhance prediction accuracy, achieving superior postoperative refractive results compared to traditional formulas. Third, AI can be used to augment cataract surgical skill training by identifying different phases of cataract surgery on video and to optimize operating theater workflows by accurately predicting the duration of surgical procedures. Fourth, some AI CNN models are able to effectively predict the progression of posterior capsule opacification and eventual need for YAG laser capsulotomy. These advances in AI could transform cataract management and enable delivery of efficient ophthalmic services. The key challenges include ethical management of data, ensuring data security and privacy, demonstrating clinically acceptable performance, improving the generalizability of AI models across heterogeneous populations, and improving the trust of end-users.
C1 [Gutierrez, Laura; Lim, Jane Sujuan; Foo, Li Lian; Ng, Wei Yan Yan; Yip, Michelle; Rosman, Mohamad; Mehta, Jodhbir Singth; Ting, Daniel Shu Wei] Singapore Eye Res Inst, Singapore, Singapore.
   [Lim, Jane Sujuan; Foo, Li Lian; Ng, Wei Yan Yan; Yip, Michelle; Wong, Melissa Hsing Yi; Fong, Allan; Ting, Daniel Shu Wei] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Ting, Darren Shu Jeng] Univ Nottingham, Acad Ophthalmol, Sch Med, Nottingham, England.
   [Lin, Haotian] Sun Yet Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou, Peoples R China.
C3 National University of Singapore; Singapore National Eye Center;
   Singapore National Eye Center; University of Nottingham; Sun Yat Sen
   University
RP Ting, DSW (通讯作者)，Singapore Eye Res Inst, Singapore, Singapore.
EM daniel.ting45@gmail.com
CR Acharya RU, 2010, J MED SYST, V34, P619, DOI 10.1007/s10916-009-9275-8
   Al Hajj H, 2018, MED IMAGE ANAL, V47, P203, DOI 10.1016/j.media.2018.05.001
   Al Hajj H, 2017, IEEE ENG MED BIO, P4407, DOI 10.1109/EMBC.2017.8037833
   [Anonymous], EYEWIRE NEWS
   Gonzalez DC, 2021, EYE, V35, P517, DOI 10.1038/s41433-020-0883-3
   Cheung CYL, 2011, INVEST OPHTH VIS SCI, V52, P1314, DOI 10.1167/iovs.10-5427
   Connell BJ, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000251
   Danso SO, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020322
   Debellemaniere G, 2021, AM J OPHTHALMOL, V232, P58, DOI 10.1016/j.ajo.2021.05.004
   Deng Y, 2021, BIOMED ENVIRON SCI, V34, P101, DOI 10.3967/bes2021.015
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gao X, 2012, P 11 AS C COMP VIS 2, P256, DOI DOI 10.1007/978-3-642-37444-9
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Guo LY, 2015, COMPUT IND, V69, P72, DOI 10.1016/j.compind.2014.09.005
   Hipolito-Fernandes D, 2020, CLIN OPHTHALMOL, V14, P4395, DOI 10.2147/OPTH.S290125
   Janiesch C, 2021, ELECTRON MARK, V31, P685, DOI 10.1007/s12525-021-00475-2
   Jiang JW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201142
   Jin GJC, 2007, OPHTHALMOLOGY, V114, P417, DOI 10.1016/j.ophtha.2006.07.041
   Kane JX, 2020, J CATARACT REFR SURG, V46, P1236, DOI 10.1097/j.jcrs.0000000000000235
   Kane JX, 2021, OPHTHALMOLOGY, V128, pE94, DOI 10.1016/j.ophtha.2020.08.010
   Kane JX, 2017, J CATARACT REFR SURG, V43, P333, DOI 10.1016/j.jcrs.2016.12.021
   Koch DD, 2003, J CATARACT REFR SURG, V29, P2039, DOI 10.1016/j.jcrs.2003.10.009
   Koprowski R, 2016, BIOMED ENG ONLINE, V15, DOI 10.1186/s12938-016-0243-5
   Kshetri N, 2020, IT PROF, V22, P63, DOI 10.1109/MITP.2019.2951851
   Ladas J, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.3.7
   Ladas JG, 2015, JAMA OPHTHALMOL, V133, P1431, DOI 10.1001/jamaophthalmol.2015.3832
   LaHood BR, 2018, J REFRACT SURG, V34, P331, DOI 10.3928/1081597X-20180214-02
   Lanza M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.607870
   Lecuyer G, 2020, INT J COMPUT ASS RAD, V15, P673, DOI 10.1007/s11548-019-02108-8
   Li WT, 2020, NAT BIOMED ENG, V4, P767, DOI 10.1038/s41551-020-0577-y
   Lim G, 2020, PROC INT C TOOLS ART, P1096, DOI 10.1109/ICTAI50040.2020.00167
   Lin DR, 2020, EBIOMEDICINE, V51, DOI 10.1016/j.ebiom.2019.102621
   Lin HT, 2019, ECLINICALMEDICINE, V9, P52, DOI 10.1016/j.eclinm.2019.03.001
   Liste S, VISION IMPAIRMENT BL
   Liu XX, 2019, NAT MED, V25, P1467, DOI 10.1038/s41591-019-0603-3
   Liu XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168606
   Long EP, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00319-x
   Long EP, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-016-0024
   Ma X., ARXIV PREPRINT ARXIV
   Melles RB, 2019, OPHTHALMOLOGY, V126, P1334, DOI 10.1016/j.ophtha.2019.04.011
   Menozzi M, 2020, KLIN MONATSBL AUGENH, V237, P388, DOI 10.1055/a-1119-6151
   Mirchi N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229596
   Mohammadi SF, 2012, J CATARACT REFR SURG, V38, P403, DOI 10.1016/j.jcrs.2011.09.036
   Navarrete-Welton AJ, 2020, FRONT MED-PRC, V14, P369, DOI 10.1007/s11684-020-0784-7
   Organization WH, WORLD REP VIS
   Palmer JJ, 2014, HUM RESOUR HEALTH, V12, DOI 10.1186/1478-4491-12-44
   Patel RH., 2016, INT OPHTHALMOL CLIN, V56, P171
   Ponemon I, 2020, COST DATA BREACH REP, P82
   Ramke J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172342
   Sadeghzadeh R, 2010, P MED IM UND AN, P127
   Sarma KV, 2021, J AM MED INFORM ASSN, V28, P1259, DOI 10.1093/jamia/ocaa341
   Savini G, 2020, J CATARACT REFR SURG, V46, P27, DOI 10.1016/j.jcrs.2019.08.044
   Sheeladevi S, 2016, EYE, V30, P1160, DOI 10.1038/eye.2016.156
   Singleton C., 2021, XFORCE THREAT INTELL, P43
   Sramka M, 2019, PEERJ, V7, DOI 10.7717/peerj.7202
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Sundararajan M, 2017, PR MACH LEARN RES, V70
   Thompson AM, 2004, BRIT J OPHTHALMOL, V88, P1042, DOI 10.1136/bjo.2003.032581
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Ting DSJ, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420964099
   Truong L., 2020, P IEEE CVF C COMP VI, P788
   Tsessler Maria, 2022, J Cataract Refract Surg, V48, P37, DOI 10.1097/j.jcrs.0000000000000702
   Ursell PG, 2018, EYE, V32, P1579, DOI 10.1038/s41433-018-0131-2
   Varol E, 2018, LECT NOTES COMPUT SC, V11072, P540, DOI 10.1007/978-3-030-00931-1_62
   Wan KH, 2019, AM J OPHTHALMOL, V205, P66, DOI 10.1016/j.ajo.2019.04.019
   Wang L, 2015, OPHTHALMOLOGY, V122, P2443, DOI 10.1016/j.ophtha.2015.08.037
   Warnat-Herresthal S, 2021, NATURE, V594, P265, DOI 10.1038/s41586-021-03583-3
   Wu XH, 2019, BRIT J OPHTHALMOL, V103, P1553, DOI 10.1136/bjophthalmol-2019-314729
   Xiong L, 2017, J HEALTHC ENG, V2017, DOI 10.1155/2017/5645498
   Xu X, 2020, IEEE J BIOMED HEALTH, V24, P556, DOI 10.1109/JBHI.2019.2914690
   Xu YW, 2013, LECT NOTES COMPUT SC, V8150, P468, DOI 10.1007/978-3-642-40763-5_58
   Yang JJ, 2016, COMPUT METH PROG BIO, V124, P45, DOI 10.1016/j.cmpb.2015.10.007
   Yeo TK, 2021, EYE, V35, P1705, DOI 10.1038/s41433-020-01159-5
   Yu F, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.1860
   Zhang HY, 2019, COMPUT METH PROG BIO, V182, DOI 10.1016/j.cmpb.2019.07.006
   Zhang XH, 2005, IEEE IJCNN, P2435
   Zhu, ARXIV PREPRINT ARXIV
NR 79
TC 4
Z9 4
U1 11
U2 25
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2326-0254
J9 EYE VISION
JI Eye Vis.
PD JAN 7
PY 2022
VL 9
IS 1
AR 3
DI 10.1186/s40662-021-00273-z
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YD2VY
UT WOS:000740235500001
PM 34996524
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cheng, SY
   Luo, YW
   Malachi, A
   Ko, JH
   Su, Q
   Xie, J
   Tian, B
   Lin, HJ
   Ke, X
   Zheng, Q
   Tai, PWL
   Gao, GP
   Punzo, C
AF Cheng, Shun-Yun
   Luo, Yongwen
   Malachi, Anneliese
   Ko, Jihye
   Su, Qin
   Xie, Jun
   Tian, Bo
   Lin, Haijiang
   Ke, Xiao
   Zheng, Qiang
   Tai, Phillip W. L.
   Gao, Guangping
   Punzo, Claudio
TI Low-Dose Recombinant Adeno-Associated Virus-Mediated Inhibition of
   Vascular Endothelial Growth Factor Can Treat Neovascular Pathologies
   Without Inducing Retinal Vasculitis
SO HUMAN GENE THERAPY
LA English
DT Article
DE CNV; AMD; DR; wet AMD; VEGF; anti-VEGF; conbercept; rAAV; vasculitis
ID MACULAR DEGENERATION; GENE-THERAPY; CHOROIDAL NEOVASCULARIZATION; OCULAR
   NEOVASCULARIZATION; INTRAVITREOUS INJECTION; TUMOR ANGIOGENESIS; AAV
   SEROTYPES; MOUSE MODEL; VEGF; EXPRESSION
AB The wet form of age-related macular degeneration is characterized by neovascular pathologies that, if untreated, can result in edemas followed by rapid vision loss. Inhibition of vascular endothelial growth factor (VEGF) has been used to successfully treat neovascular pathologies of the eye. Nonetheless, some patients require frequent intravitreal injections of anti-VEGF drugs, increasing the burden and risk of complications from the procedure to affected individuals. Recombinant adeno-associated virus (rAAV)-mediated expression of anti-VEGF proteins is an attractive alternative to reduce risk and burden to patients. However, controversy remains as to the safety of prolonged VEGF inhibition in the eye. Here, we show that two out of four rAAV serotypes tested by intravitreal delivery to express the anti-VEGF drug conbercept lead to a dose-dependent vascular sheathing pathology that is characterized by immune cell infiltrates, reminiscent of vasculitis in humans. We show that this pathology is accompanied by increased expression in vascular cell adhesion molecule 1 (VCAM1) and intercellular adhesion molecule 1 (ICAM1), both of which promote extravasation of immune cells from the vasculature. While formation of the vascular sheathing pathology is prevented in immunodeficient Rag-1 mice that lack B and T cells, increased expression of VACM1 and ICAM1 still occurs, indicating that inhibition of VEGF function leads to expression changes in cell adhesion molecules that promote extravasation of immune cells. Importantly, a 10-fold lower dose of one of the vectors that cause a vascular sheathing pathology is still able to reduce edemas resulting from choroidal neovascularization without causing any vascular sheathing pathology and only a minimal increase in VCAM1 expression. The data suggest that treatments of neovascular eye pathologies with rAAV-mediated expression of anti VEGF drugs can be developed safely. However, viral load needs to be adjusted to the tropisms of the serotype and the expression pattern of the promoter.
C1 [Cheng, Shun-Yun; Malachi, Anneliese; Tian, Bo; Lin, Haijiang; Punzo, Claudio] Univ Massachusetts, Med Sch, Dept Ophthalmol & Visual Sci, Worcester, MA 01655 USA.
   [Xie, Jun; Tai, Phillip W. L.; Gao, Guangping] Univ Massachusetts, Med Sch, Dept Microbiol & Physiol Syst, Worcester, MA 01605 USA.
   [Malachi, Anneliese; Ko, Jihye; Su, Qin; Xie, Jun; Tai, Phillip W. L.; Gao, Guangping; Punzo, Claudio] Univ Massachusetts, Med Sch, Horae Gene Therapy Ctr, Worcester, MA 01605 USA.
   [Luo, Yongwen] South China Agr Univ, Coll Vet Med, Guangzhou, Peoples R China.
   [Ko, Jihye; Su, Qin] Univ Massachusetts, Med Sch, Viral Vector Core, Worcester, MA 01605 USA.
   [Ke, Xiao; Zheng, Qiang] Chengdu Kanghong Pharmaceut Grp Co Ltd, Chengdu, Sichuan, Peoples R China.
   [Gao, Guangping; Punzo, Claudio] Univ Massachusetts, Med Sch, Li Weibo Inst Rare Dis Res, Worcester, MA 01605 USA.
C3 University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester; University of Massachusetts System; University
   of Massachusetts Worcester; South China Agricultural University;
   University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester
RP Punzo, C (通讯作者)，Univ Massachusetts, Med Sch, Dept Ophthalmol & Visual Sci, Worcester, MA 01655 USA.
EM claudio.punzo@umassmed.edu
FU NHLBI NIH HHS [P01 HL059407] Funding Source: Medline; NIAID NIH HHS [P01
   AI100263] Funding Source: Medline; NINDS NIH HHS [R01 NS076991] Funding
   Source: Medline
CR Amin SM, 2021, OPHTHALMIC RES, V64, P91, DOI 10.1159/000509380
   Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Auricchio A, 2001, HUM MOL GENET, V10, P3075, DOI 10.1093/hmg/10.26.3075
   Bainbridge JWB, 2002, GENE THER, V9, P320, DOI 10.1038/sj.gt.3301680
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Campochiaro PA, 2019, J CLIN INVEST, V129, P3029, DOI 10.1172/JCI129861
   Cheng SY, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11060871
   Cheng SY, 2020, P NATL ACAD SCI USA, V117, P13094, DOI 10.1073/pnas.2000339117
   Cox JT, 2021, J CLIN MED, V10, DOI 10.3390/jcm10050981
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Dalkara D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005708
   de Guimaraes TAC, 2021, BRIT J OPHTHALMOL, V105, P151, DOI 10.1136/bjophthalmol-2020-316195
   Dirkx AEM, 2003, CANCER RES, V63, P2322
   Eastlake K, 2016, GLIA, V64, P495, DOI 10.1002/glia.22942
   Favot L, 2003, THROMB HAEMOSTASIS, V90, P334, DOI 10.1160/TH03-02-0084
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Froger N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68488-z
   Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299
   Gardner TW, 1999, DOC OPHTHALMOL, V97, P229, DOI 10.1023/A:1002140812979
   Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829
   Griffioen AW, 1996, CANCER RES, V56, P1111
   Griffioen AW, 1996, BLOOD, V88, P667, DOI 10.1182/blood.V88.2.667.bloodjournal882667
   Hartnett ME, 2008, INVEST OPHTH VIS SCI, V49, P3107, DOI 10.1167/iovs.08-1780
   Hartnett ME, 2010, DOC OPHTHALMOL, V120, P25, DOI 10.1007/s10633-009-9181-x
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Heier JS, 2017, LANCET, V390, P50, DOI 10.1016/S0140-6736(17)30979-0
   Hickey DG, 2017, GENE THER, V24, P787, DOI 10.1038/gt.2017.85
   Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jin EZ, 2017, RETINA-J RET VIT DIS, V37, P971, DOI 10.1097/IAE.0000000000001274
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Koponen S, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020219
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lai CM, 2005, MOL THER, V12, P659, DOI 10.1016/j.ymthe.2005.04.022
   Liu YY, 2018, MOL THER, V26, P542, DOI 10.1016/j.ymthe.2017.12.002
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Makhoul M, 2012, EXP EYE RES, V101, P27, DOI 10.1016/j.exer.2012.05.012
   MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G
   Natkunarajah M, 2008, GENE THER, V15, P463, DOI 10.1038/sj.gt.3303074
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Petit L, 2018, CELL REP, V23, P2629, DOI 10.1016/j.celrep.2018.04.111
   Petit L, 2017, HUM GENE THER, V28, P464, DOI 10.1089/hum.2017.020
   Petit L, 2016, HUM GENE THER, V27, P563, DOI 10.1089/hum.2016.040
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Rakoczy EP, 2019, AM J OPHTHALMOL, V204, P113, DOI 10.1016/j.ajo.2019.03.006
   Rakoczy EP, 2015, LANCET, V386, P2395, DOI 10.1016/S0140-6736(15)00345-1
   Rota R, 2004, J GENE MED, V6, P992, DOI 10.1002/jgm.586
   Rutledge EA, 1998, J VIROL, V72, P309, DOI 10.1128/JVI.72.1.309-319.1998
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sena-Esteves M., 2020, COLD SPRING HARBOR P, V8
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Suzuki M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-176
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Tao Y, 2019, J INT MED RES, V47, P1202, DOI 10.1177/0300060518819613
   Tokunaga CC, 2014, INVEST OPHTH VIS SCI, V55, P1884, DOI 10.1167/iovs.13-13397
   TOUT S, 1993, NEUROSCIENCE, V55, P291, DOI 10.1016/0306-4522(93)90473-S
   Ueno S, 2008, J CELL PHYSIOL, V217, P13, DOI 10.1002/jcp.21445
   Usui V, 2015, J CLIN INVEST, V125, P2335, DOI 10.1172/JCI80297
   Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003
   Venkatesh A., 2013, CURR PROTOC MICROBIO
   Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573-019-0012-9
   Wang F, 2013, GRAEF ARCH CLIN EXP, V251, P2131, DOI 10.1007/s00417-013-2392-6
   Wang JJ, 2010, DIABETES, V59, P2297, DOI 10.2337/db09-1420
   Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070544
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00978
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Zhang M, 2008, MOL VIS, V14, P37
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
NR 71
TC 1
Z9 1
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD JUL 1
PY 2021
VL 32
IS 13-14
BP 649
EP 666
DI 10.1089/hum.2021.132
PG 18
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA TM4PG
UT WOS:000675532500005
PM 34182803
OA Green Submitted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Saito, Y
   Yako, T
   Otsu, W
   Nakamura, S
   Inoue, Y
   Muramatsu, A
   Nakagami, Y
   Shimazawa, M
   Hara, H
AF Saito, Yuichi
   Yako, Tomohiro
   Otsu, Wataru
   Nakamura, Shinsuke
   Inoue, Yuki
   Muramatsu, Aomi
   Nakagami, Yasuhiro
   Shimazawa, Masamitsu
   Hara, Hideaki
TI A triterpenoid Nrf2 activator, RS9, promotes LC3-associated phagocytosis
   of photoreceptor outer segments in a p62-independent manner
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE AMP-Activated protein kinase (AMPK); Nuclear factor erythroid 2-related
   factor 2; (Nrf2); p62; LC3-Associated phagocytosis; Retinal pigment
   epithelium (RPE); Age-related macular degeneration (AMD)
ID RETINAL-PIGMENT EPITHELIUM; TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS;
   SELECTIVE AUTOPHAGY; KEAP1-NRF2 PATHWAY; DEFENSE PATHWAYS; P62;
   DYSREGULATION; MECHANISMS; LIPOFUSCIN
AB Daily phagocytosis of shed photoreceptor outer segments (POS) by the retinal pigment epithelium (RPE) is required to sustain the visual function. Recent reports revealed that POS phagocytosis is progressed with LC3- associated manner. Patients with age -related macular degeneration (AMD) had impaired autophagic degradation in the RPE. Nrf2 is a key antioxidant transcriptional regulator that ameliorates oxidative stress which is another contributor to AMD pathogenesis. Nrf2 activation also induces the autophagy receptor protein, p62. However, the role of the Nrf2-p62 pathway in LC3-associated phagocytosis of POS is poorly understood. Here, we in- vestigated the relationships between Nrf2 activation and POS phagocytosis progression. A triterpenoid Nrf2 activator, RS9, facilitated POS uptake into phagolysosomes in RPE cells. RS9 also induced the expression of the autophagy-related proteins, LC3-II and p62, as well as phase -2 antioxidant enzymes. The e ffect of RS9 on POS phagocytosis was abolished by autophagy inhibition. Unexpectedly, p62 knockdown did not inhibit the e ffect of RS9 on POS phagocytosis, although, RS9-mediated LC3-II induction by RS9 was inhibited in p62 knockdown RPE cells. We also found that RS9 activated the AMPK ?-mTOR signaling pathway earlier than p62 induction. Knockdown of AMPK ? 1 , but not ? 2 , inhibited the RS9-mediated activation of LC3-associated phagocytosis and RS9-mediated induction of LC3-II. Furthermore, intravitreal treatment of RS9 to adult mice decreased the size of POS phagolysosomes after light exposure. Collectively, these results showed that RS9-mediated activation of POS phagocytosis was mainly ascribed to the enhancement of autophagy via AMPK ? 1 activation. Our findings reveal novel e ffects of Nrf2 and AMPK ? 1 activation that contribute to the maintenance of the RPE function via LC3- associated POS phagocytosis.
C1 [Saito, Yuichi; Yako, Tomohiro; Nakamura, Shinsuke; Inoue, Yuki; Muramatsu, Aomi; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigakunishi, Gifu 5011196, Japan.
   [Otsu, Wataru; Shimazawa, Masamitsu; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biomed Res Lab, Gifu, Japan.
   [Nakagami, Yasuhiro] Daiichi Sankyo Co Ltd, Tokyo, Japan.
C3 Gifu Pharmaceutical University; Gifu Pharmaceutical University; Daiichi
   Sankyo Company Limited
RP Hara, H (通讯作者)，Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigakunishi, Gifu 5011196, Japan.
EM saito.yakkou@gmail.com; yako.yakkou@gmail.com; otsu-wa@gifu-pu.ac.jp;
   nakamuras@gifu-pu.ac.jp; inoue.yaldsou@gmail.com;
   muramatsu.yakkou@gmail.com; nakagami.yasuhiro.y4@daiichisankyo.co.jp;
   shimazawa@gifu-pu.ac.jp; hidehara@gifu-pu.ac.jp
OI Saito, Yuichi/0000-0002-7738-276X; Nakagami,
   Yasuhiro/0000-0003-3618-1715; Hara, Hideaki/0000-0003-2046-9001
FU JSPS KAKENHI [JP17J10301]
FX This work was supported by JSPS KAKENHI Grant Number JP17J10301.
CR Atamna H, 2015, REDOX BIOL, V6, P426, DOI 10.1016/j.redox.2015.09.004
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Frost LS, 2015, MOL NEUROBIOL, V52, P1135, DOI 10.1007/s12035-014-8920-5
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Guha S, 2014, ADV EXP MED BIOL, V801, P105, DOI 10.1007/978-1-4614-3209-8_14
   Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003
   Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007
   KOCH KW, 1994, EMBO J, V13, P3312, DOI 10.1002/j.1460-2075.1994.tb06633.x
   Kolosova NG, 2018, AGING-US, V10, P2136, DOI 10.18632/aging.101537
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892
   Lambros ML, 2016, ADV EXP MED BIOL, V854, P67, DOI 10.1007/978-3-319-17121-0_10
   Liu XB, 2016, REDOX BIOL, V8, P98, DOI 10.1016/j.redox.2015.12.005
   Mao YY, 2016, ADV EXP MED BIOL, V854, P717, DOI 10.1007/978-3-319-17121-0_95
   Martinez J, 2015, NAT CELL BIOL, V17, P893, DOI 10.1038/ncb3192
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Moreno-Garcia A, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00464
   Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008
   Murase H, 2015, INVEST OPHTH VIS SCI, V56, P2511, DOI 10.1167/iovs.14-15962
   Nakagami Y, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7469326
   Nakagami Y, 2015, BRIT J PHARMACOL, V172, P1237, DOI 10.1111/bph.12999
   Parinot C., 2014, JOVE-J VIS EXP, P1, DOI 10.3791/52100
   Qin SF, 2008, J BIOL CHEM, V283, P6744, DOI 10.1074/jbc.M708848200
   Romao S, 2014, AUTOPHAGY, V10, P526, DOI 10.4161/auto.27606
   Ross FA, 2016, FEBS J, V283, P2987, DOI 10.1111/febs.13698
   Rubio N, 2014, FREE RADICAL BIO MED, V67, P292, DOI 10.1016/j.freeradbiomed.2013.11.010
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Suzuki T, 2015, FREE RADICAL BIO MED, V88, P93, DOI 10.1016/j.freeradbiomed.2015.06.006
   Tamaki N, 2014, FREE RADICAL BIO MED, V75, P222, DOI 10.1016/j.freeradbiomed.2014.07.034
   Wang YJ, 2018, ANTIOXID REDOX SIGN, V28, P141, DOI 10.1089/ars.2017.7003
   Xu DW, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.386
   Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003
NR 43
TC 11
Z9 11
U1 3
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAY 20
PY 2020
VL 152
BP 235
EP 247
DI 10.1016/j.freeradbiomed.2020.03.012
PG 13
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA MB9WV
UT WOS:000542949100003
PM 32217192
DA 2022-11-30
ER

PT J
AU Bartlett, R
   Jones, H
   Williams, G
   Farewell, D
   Acton, JH
AF Bartlett, Rebecca
   Jones, Hywel
   Williams, Gwyn
   Farewell, Daniel
   Acton, Jennifer H.
TI Agreement between ophthalmologists and optometrists in the certification
   of vision impairment
SO EYE
LA English
DT Article
ID PARTIAL SIGHT; GLAUCOMA; ENGLAND; REGISTRATION; MANAGEMENT; WALES;
   RATES; BLIND
AB Background/objectives The certification process to register patients as sight impaired or severely sight impaired is undertaken by consultant ophthalmologists, in the UK. We sought to assess the agreement between optometrists and a consensus panel, in identifying patient eligibility for certification, relative to the agreement between ophthalmologists and the consensus panel. Methods The consensus panel (4 consultant ophthalmologists and 3 optometrists with a formal accreditation in low vision), 30 consultant ophthalmologists and 99 low vision optometrists reviewed 40 randomly selected abridged cases. The eligibility outcomes from the ophthalmologists and the optometrists were compared with the consensus panel outcomes. Results For ophthalmologists and optometrists, the median (IQR) number of cases in which there was agreement with the consensus panel was 33.0 (31.0, 33.0) and 36.0 (34.0, 36.5), respectively. In severely sight impaired cases, the probabilities of agreeing on eligibility for certification were 76.0% (95% CIs 71.4%, 80.1%) for ophthalmologists and 61.8% (59.0%, 64.6%) for optometrists. In sight impaired cases, the corresponding values were 51.6% (46.7%, 56.4%) for ophthalmologists and 72.2% (69.8%, 74.5%) for optometrists. In cases of bilateral atrophic age-related macular degeneration (AMD), both groups were more likely to agree with the consensus panel and the differences between optometrists and ophthalmologists were less marked. Conclusions Optometrists demonstrated a comparable agreement relative to ophthalmologists, with the consensus panel on the eligibility of randomly selected, abridged cases for certification. The findings support the clinical decision-making ability of low vision optometrists in the certification of patients with vision impairment and provide evidence in support of policy change to allow low vision optometrists to certify individuals with atrophic AMD.
C1 [Bartlett, Rebecca; Acton, Jennifer H.] Cardiff Univ, Coll Biomed & Life Sci, Sch Optometry & Vis Sci, Cardiff, Wales.
   [Jones, Hywel; Farewell, Daniel] Cardiff Univ, Div Populat Med, Cardiff, Wales.
   [Williams, Gwyn] Singleton Hosp, Dept Ophthalmol, Swansea, W Glam, Wales.
C3 Cardiff University; Cardiff University; Singleton Hospital
RP Acton, JH (通讯作者)，Cardiff Univ, Coll Biomed & Life Sci, Sch Optometry & Vis Sci, Cardiff, Wales.
EM actonj@cardiff.ac.uk
RI Acton, Jennifer/AAU-3307-2021
OI Acton, Jennifer/0000-0002-0347-7651; Jones, Hywel/0000-0001-8308-2002
FU Sight Cymru
FX The study was funded by the charitable organisation, Sight Cymru. We are
   also grateful to the consensus panel members and to all study
   participants.
CR [Anonymous], 2019, CERT VIS IMP
   [Anonymous], 2019, SENS HLTH EYE CAR HE
   [Anonymous], 2019, CVI CERT VIS IMP
   Azuara-Blanco A, 2007, BRIT J OPHTHALMOL, V91, P1639, DOI 10.1136/bjo.2007.119628
   Baker H, 2016, OPHTHAL PHYSL OPT, V36, P545, DOI 10.1111/opo.12312
   Banes MJ, 2006, BRIT J OPHTHALMOL, V90, P579, DOI 10.1136/bjo.2005.082388
   Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01
   Boyce T, 2019, REAL PATIENTS COMING
   Bunce C, 1998, BRIT J OPHTHALMOL, V82, P72, DOI 10.1136/bjo.82.1.72
   Guerin E, 2014, EYE, V28, P808, DOI 10.1038/eye.2014.66
   Ho S, 2011, OPHTHAL PHYSL OPT, V31, P168, DOI 10.1111/j.1475-1313.2010.00813.x
   Jindal A, 2015, OPHTHAL PHYSL OPT, V35, P179, DOI 10.1111/opo.12199
   King AJW, 2000, EYE, V14, P613, DOI 10.1038/eye.2000.152
   Malik ANJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001496
   Marks JR, 2012, EYE, V26, P853, DOI 10.1038/eye.2012.58
   Mitry D, 2013, BRIT J OPHTHALMOL, V97, P1431, DOI 10.1136/bjophthalmol-2013-303578
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Rees A, 2014, EYE, V28, P832, DOI 10.1038/eye.2014.103
   Rees A, 2013, EYE, V27, P892, DOI 10.1038/eye.2013.82
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   RUMNEY NJ, 1995, OPHTHAL PHYSL OPT, V15, pS18, DOI 10.1016/0275-5408(95)98249-M
   Zapf A, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0200-9
NR 23
TC 1
Z9 1
U1 1
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2021
VL 35
IS 2
BP 433
EP 440
DI 10.1038/s41433-020-0860-x
EA APR 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PX7VQ
UT WOS:000528115600002
PM 32317794
OA Green Published, Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Little, K
   Llorian-Salvador, M
   Tang, M
   Du, X
   O'Shaughnessy, O
   McIlwaine, G
   Chen, M
   Xu, HP
AF Little, Karis
   Llorian-Salvador, Maria
   Tang, Miao
   Du, Xuan
   O'Shaughnessy, Orlaith
   McIlwaine, Gemma
   Chen, Mei
   Xu, Heping
TI A Two-Stage Laser-Induced Mouse Model of Subretinal Fibrosis Secondary
   to Choroidal Neovascularization
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE subretinal fibrosis; neovascularization; inflammation
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; MACULAR DEGENERATION; COMPLEMENT
AB Purpose: To develop a model that can recapitulate key features of macular fibrosis in neovascular age-related macular degeneration (nAMD).
   Methods: Adult C57BL/6J mice received three laser burns/eye to induce choroidal neovascularization (CNV). Seven days later, a second laser burn was directed to each of the neovascular lesions. Traditional laser-induced CNV was used as a control. Lesions were monitored at 10, 20, 30, and 40 days post-laser (p.l) treatment by fundus imaging, fundus fluorescein angiography, optical coherence tomography (OCT), and immunohistochemistry. The expression of collagen-1 (COL-1), fibronectin, alpha-smooth muscle actin, F4/80, complement factor B (CFB), Complement component 3 (C3), transforming growth factor-beta (TGF-beta), and fibroblast growth factor 2 (FGF2) in retina and retinal pigment epithelium/choroid was examined by immunofluorescence and reverse transcription polymerase chain reaction.
   Results: The two-stage laser protocol induced significantly larger lesions than the traditional laser-CNV by OCT and immunohistochemistry at all time points. Confocal microscopy detected COL-1(+) fibers and IBA1(+)/CD31(+) blood vessels in lesions from the two-stage laser protocol 30 to 40 days p.l. Lesions from traditional laser-CNV contain only COL-1(+) fibers but not blood vessels at this time point. Higher levels of proinflammatory (inducible nitric oxide synthase (iNOS), C3, CFB) and profibrotic (TGF-beta, FGF2, and vascular endothelial growth factor) genes were detected in the retinas from the two-stage laser-induced lesions compared with the traditional laser-CNV lesion. Higher number of infiltrating F4/80 macrophages was also observed in and around the two-stage laser-induced fibrotic lesion.
   Conclusions: The two-stage laser treatment induced subretinal fibrovascular membranes that persist over 40 days.
   Translational Relevance: The model is a useful tool to study the mechanism of macular fibrosis in nAMD and test antifibrotic drugs.
C1 [Little, Karis; Llorian-Salvador, Maria; Tang, Miao; Du, Xuan; O'Shaughnessy, Orlaith; McIlwaine, Gemma; Chen, Mei; Xu, Heping] Queens Univ Belfast, Welcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
C3 Queens University Belfast
RP Xu, HP (通讯作者)，Queens Univ Belfast, Welcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM heping.xu@qub.ac.uk
RI Llorian Salvador, Maria/GYV-1848-2022; Llorián-Salvador,
   Maía/HDM-6846-2022; Xu, Heping/A-4430-2008
OI Xu, Heping/0000-0003-4000-931X; Llorian-Salvador,
   Maria/0000-0002-1120-6579
FU Fight for Sight [5057/5058]; Department for the Economy (DfE) of
   Northern Ireland
FX This work is supported by Fight for Sight (5057/5058), the Department
   for the Economy (DfE) of Northern Ireland.
CR Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Chen M, 2016, AGING CELL, V15, P436, DOI 10.1111/acel.12447
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Souied EH, 2016, DEV OPHTHALMOL, V56, P86, DOI 10.1159/000442783
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang RS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146808
NR 18
TC 10
Z9 9
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2020
VL 9
IS 4
AR 3
DI 10.1167/tvst.9.4.3
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB9VX
UT WOS:000524980600003
PM 32818091
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hachana, S
   Fontaine, O
   Sapieha, P
   Lesk, M
   Couture, R
   Vaucher, E
AF Hachana, Soumaya
   Fontaine, Olivier
   Sapieha, Przemyslaw
   Lesk, Mark
   Couture, Rejean
   Vaucher, Elvire
TI The effects of anti-VEGF and kinin B-1 receptor blockade on retinal
   inflammation in laser-induced choroidal neovascularization
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTERCELLULAR-ADHESION MOLECULE-1;
   FACTOR-KAPPA-B; MACULAR DEGENERATION; PLASMA KALLIKREIN; CONCISE GUIDE;
   IN-VIVO; INTRAVITREAL INJECTION; DIABETIC-RETINOPATHY; TARGETED
   DISRUPTION
AB Background and Purpose Age-related macular degeneration (AMD) is a complex neurodegenerative disease treated by anti-VEGF intravitreal injections. As inflammation is potentially involved in retinal degeneration, the pro-inflammatory kallikrein-kinin system is a possible alternative pharmacological target. Here, we investigated the effects of anti-VEGF and anti-B-1 receptor treatments on the inflammatory mechanisms in a rat model of choroidal neovascularization (CNV).
   Experimental Approach Immediately after laser-induced CNV, Long-Evans rats were treated by eye-drop application of a B-1 receptor antagonist (R-954) or by intravitreal injection of B-1 receptor siRNA or anti-VEGF antibodies. Effects of treatments on gene expression of inflammatory mediators, CNV lesion regression and integrity of the blood-retinal barrier was measured 10 days later in the retina. B-1 receptor and VEGF-R2 cellular localization was assessed.
   Key Results The three treatments significantly inhibited the CNV-induced retinal changes. Anti-VEGF and R-954 decreased CNV-induced up-regulation of B-1 and B-2 receptors, TNF-alpha, and ICAM-1. Anti-VEGF additionally reversed up-regulation of VEGF-A, VEGF-R2, HIF-1 alpha, CCL2 and VCAM-1, whereas R-954 inhibited gene expression of IL-1 beta and COX-2. Enhanced retinal vascular permeability was abolished by anti-VEGF and reduced by R-954 and B-1 receptor siRNA treatments. Leukocyte adhesion was impaired by anti-VEGF and B-1 receptor inhibition. B-1 receptors were found on astrocytes and endothelial cells.
   Conclusion and Implications B-1 receptor and VEGF pathways were both involved in retinal inflammation and damage in laser-induced CNV. The non-invasive, self-administration of B-1 receptor antagonists on the surface of the cornea by eye drops might be an important asset for the treatment of AMD.
C1 [Hachana, Soumaya; Fontaine, Olivier; Vaucher, Elvire] Univ Montreal, Sch Optometry, CP 6128, Montreal, PQ H3C 3J7, Canada.
   [Fontaine, Olivier; Sapieha, Przemyslaw; Lesk, Mark] Maisonneuve Rosemont Hosp, Dept Ophthalmol, Res Ctr, Montreal, PQ, Canada.
   [Hachana, Soumaya; Couture, Rejean] Univ Montreal, Dept Pharmacol & Physiol, Montreal, PQ, Canada.
C3 Universite de Montreal; Universite de Montreal; Universite de Montreal
RP Vaucher, E (通讯作者)，Univ Montreal, Sch Optometry, CP 6128, Montreal, PQ H3C 3J7, Canada.
EM elvire.vaucher@umontreal.ca
OI Sapieha, Przemyslaw/0000-0002-9171-2825; Couture,
   Rejean/0000-0002-3158-8076; Vaucher, Elvire/0000-0001-7075-5263
FU Fonds de Recherche du Quebec -Sante; Groupe de recherche universitaire
   sur le medicament U. de Montreal; Canadian Institutes of Health Research
   [MOP-125962]
FX Fonds de Recherche du Quebec -Sante, Grant/Award Number: AMD/Turmel
   founds; Groupe de recherche universitaire sur le medicament U. de
   Montreal, Grant/Award Number: SH scholarship; Canadian Institutes of
   Health Research, Grant/Award Number: MOP-125962
CR Abdulaal M, 2016, SEMIN OPHTHALMOL, V31, P19, DOI 10.3109/08820538.2015.1114829
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS247, DOI 10.1111/bph.14751
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS297, DOI [10.1111/bph.14752, 10.1111/bph.14749]
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS21, DOI 10.1111/bph.14748
   Alexander SPH, 2018, BRIT J PHARMACOL, V175, P407, DOI 10.1111/bph.14112
   Aveleira CA, 2010, DIABETES, V59, P2872, DOI 10.2337/db09-1606
   Balser C, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1419-2
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bastian S, 1998, BIOCHEM BIOPH RES CO, V253, P750, DOI 10.1006/bbrc.1998.9848
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhat Menakshi, 2014, Prog Drug Res, V69, P111
   Brunius G, 2005, REGUL PEPTIDES, V126, P183, DOI 10.1016/j.regpep.2004.09.005
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315
   Clermont A, 2016, INVEST OPHTH VIS SCI, V57, P2390, DOI 10.1167/iovs.15-18272
   Clermont A, 2011, DIABETES, V60, P1590, DOI 10.2337/db10-1260
   Colman RW, 2006, CURR PHARM DESIGN, V12, P2599, DOI 10.2174/138161206777698710
   Couture R, 2014, CURR VASC PHARMACOL, V12, P223, DOI 10.2174/1570161112666140226121627
   Cunningham F, 2019, CURR EYE RES, V44, P813, DOI 10.1080/02713683.2019.1614197
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Emanueli C, 2002, CIRCULATION, V105, P360, DOI 10.1161/hc0302.102142
   Emanueli C, 2001, CIRCULATION, V103, P125
   Feener EP, 2010, CURR DIABETES REP, V10, P270, DOI 10.1007/s11892-010-0127-1
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   Fukuhara J, 2013, INVEST OPHTH VIS SCI, V54, P274, DOI 10.1167/iovs.12-10512
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gobeil F, 2014, PEPTIDES, V52, P82, DOI 10.1016/j.peptides.2013.12.009
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hachana S, 2018, BRIT J PHARMACOL, V175, P968, DOI 10.1111/bph.14138
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Hernandez L, 2018, J MANAG CARE SPEC PH, V24, P608, DOI 10.18553/jmcp.2018.24.7.608
   HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004
   Hillmeister P, 2011, CIRC RES, V109, P524, DOI 10.1161/CIRCRESAHA.111.240986
   Huang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071808
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]
   Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200
   Kita T, 2015, DIABETES, V64, P3588, DOI 10.2337/db15-0317
   Kuwano T, 2004, FASEB J, V18, P300, DOI 10.1096/fj.03-0473com
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Le YZ, 2017, VISION RES, V139, P108, DOI 10.1016/j.visres.2017.05.005
   Lee JE, 2008, INVEST OPHTH VIS SCI, V49, P4169, DOI 10.1167/iovs.08-2076
   Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2
   Liu F, 2016, MOL VIS, V22, P352
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Luckoff A, 2017, NAT PROTOC, V12, P1136, DOI 10.1038/nprot.2017.032
   Ma JX, 1996, EXP EYE RES, V63, P19, DOI 10.1006/exer.1996.0087
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   McGrath JC, 2015, BRIT J PHARMACOL, V172, P3189, DOI 10.1111/bph.12955
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Nagai N, 2007, INVEST OPHTH VIS SCI, V48, P2321, DOI 10.1167/iovs.06-1296
   Nakamura S, 2011, ARTERIOSCL THROM VAS, V31, P1041, DOI 10.1161/ATVBAHA.111.223594
   Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   O'Sullivan ML, 2017, GLIA, V65, P1697, DOI 10.1002/glia.23189
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Park HYL, 2014, AM J PATHOL, V184, P1752, DOI 10.1016/j.ajpath.2014.02.016
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pouliot M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033864
   Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408
   Qu Yi, 2009, Zhonghua Yan Ke Za Zhi, V45, P742
   Reibaldi M, 2018, RETINA-J RET VIT DIS, V38, P1, DOI 10.1097/IAE.0000000000001583
   Rutar M, 2016, ADV EXP MED BIOL, V854, P11, DOI 10.1007/978-3-319-17121-0_2
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Schmack I, 2009, MOL VIS, V15, P146
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Wang JJ, 2010, DIABETES, V59, P2297, DOI 10.2337/db09-1420
   Wilkinson-Berka JL, 2008, THESCIENTIFICWORLDJO, V8, P98, DOI 10.1100/tsw.2008.25
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Xie P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053329
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   Yang HD, 2011, MOL CELLS, V32, P235, DOI 10.1007/s10059-011-1026-z
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Zou YH, 2006, J OCUL PHARMACOL TH, V22, P19, DOI 10.1089/jop.2006.22.19
NR 95
TC 13
Z9 13
U1 1
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD MAY
PY 2020
VL 177
IS 9
BP 1949
EP 1966
DI 10.1111/bph.14962
EA FEB 2020
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA LD3ZY
UT WOS:000510770500001
PM 31883121
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Das, A
   Rad, P
   Choo, KKR
   Nouhi, B
   Lish, J
   Martel, J
AF Das, Arun
   Rad, Paul
   Choo, Kim-Kwang Raymond
   Nouhi, Babak
   Lish, Jonathan
   Martel, James
TI Distributed machine learning cloud teleophthalmology IoT for predicting
   AMD disease progression
SO FUTURE GENERATION COMPUTER SYSTEMS-THE INTERNATIONAL JOURNAL OF ESCIENCE
LA English
DT Article
DE Internet of Medical Things (IoMT); Deep learning; Telemedicine;
   Teleophthalmology; Macular degeneration; Mobile-cloud teleophthalmology;
   Wearable IoMT
ID ARTIFICIAL-INTELLIGENCE; SMARTPHONE OPHTHALMOSCOPY; MACULAR
   DEGENERATION; MOBILE HEALTH; RECOGNITION; RETINOPATHY; VALIDATION;
   HUMANS
AB The ability to perform screening of potential vision-impairing diseases remotely with an Ophthalmologist-in-the-loop is crucial in serving the Medically Underserved Areas/Population (MUAS/P) and in acute medical settings, such as emergency departments. With an estimated 217 million individuals affected by moderate to severe vision-impairing diseases worldwide and an increasing number of new patients with such diseases, the need for access to faster (or real-time) diagnosis on a large scale is imperative. It is evident that early diagnosis of chronic diseases such as diabetic retinopathy and age-related macular degeneration (AMD) could better prevent vision loss. In this paper, a scalable cloud based teleophthalmology architecture via the Internet of Medical Things (IoMT) for diagnosis of AMD is presented. In the proposed architecture, patients wear a head-mounted camera (OphthoAl IoMT headset) to send their retinal fundus images to their secure and private cloud drive storage for personalized disease severity detection and predictive progression analysis. A proposed AMD-ResNet convolution neural network with 152 layers will then analyze the images to identify and determine AMD disease severity. The algorithm is trained with AREDS (age related eye disease study) images from the National Institute of Health (NIH) with over 130,000 fundus images captured over 12 years, and for determining AMD severity, we achieve a sensitivity and specificity of 94.97 +/- 0.5% and 98.32 +/- 0.1% respectively. A temporal Long-Short Term Memory (LSTM) deep neural network for precision medicine and AMD predictive progression is also proposed. Patient personalization allows better targeted care, lesser side effects, and a greater likelihood of responding to treatments by tailoring healthcare on a per-patient basis. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Das, Arun; Rad, Paul; Choo, Kim-Kwang Raymond] Univ Texas San Antonio, Dept Elect & Comp Engn, San Antonio, TX 78249 USA.
   [Rad, Paul; Choo, Kim-Kwang Raymond] Univ Texas San Antonio, Dept Informat Syst & Cyber Secur, San Antonio, TX 78249 USA.
   [Nouhi, Babak; Lish, Jonathan; Martel, James] Calif Northstate Univ, Coll Med, Sacramento, CA 95757 USA.
   [Martel, James] Martel Eye Med Grp, Res Dept, Rancho Cordova, CA 95670 USA.
C3 University of Texas System; University of Texas at San Antonio (UTSA);
   University of Texas System; University of Texas at San Antonio (UTSA)
RP Choo, KKR (通讯作者)，Univ Texas San Antonio, Dept Informat Syst & Cyber Secur, San Antonio, TX 78249 USA.
EM arun.das@utsa.edu; paul.rad@utsa.edu; raymond.choo@fulbrightmail.org;
   babak.nouhi6995@cnsu.edu; jonathan.lish3474@cnsu.edu;
   james.martel@cnsu.edu
RI Choo, Kim-Kwang Raymond/A-3634-2009; Das, Arun/ABC-7045-2021
OI Choo, Kim-Kwang Raymond/0000-0001-9208-5336; Das,
   Arun/0000-0001-7512-0523
FU National Science Foundation, United States [1419165, 1445604]; National
   Eye Institute, United States [N01-EY-0-2127]
FX The authors gratefully acknowledge the use of the services of Chameleon
   cloud and Jetstream cloud, funded by National Science Foundation, United
   States awards 1419165 and 1445604 respectively. The dataset was provided
   through the Age-Related Eye Disease Study (AREDS) through dbGaP
   accession number phs000001.v3.p1. Funding support for AREDS was provided
   by the National Eye Institute, United States (N01-EY-0-2127). We would
   like to thank the AREDS participants and the AREDS Research Group for
   their valuable contribution to this research.
CR A. Group, AG REL EYE DIS STUD
   Adam MK, 2015, OSLI RETINA, V46, P631, DOI 10.3928/23258160-20150610-06
   Alaiad A, 2017, IEEE T PROF COMMUN, V60, P4, DOI 10.1109/TPC.2016.2632822
   Amodei D, 2016, PR MACH LEARN RES, V48
   [Anonymous], APPL CLOUD DEEP SEMA
   Bastawrous A, 2016, JAMA OPHTHALMOL, V134, P151, DOI 10.1001/jamaophthalmol.2015.4625
   Bengio Y., 2012, P ICML WORKSHOP UNSU, V27, P17
   Bennet J., 2017, VENTUREBEAT
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chan YFY, 2017, NAT BIOTECHNOL, V35, P354, DOI 10.1038/nbt.3826
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Cv-eye, 2013, MAC DEG
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848
   Dilsizian SE, 2014, CURR CARDIOL REP, V16, DOI 10.1007/s11886-013-0441-8
   Fogel AL, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-017-0012-2
   Gai KK, 2018, IEEE INTERNET THINGS, V5, P3059, DOI 10.1109/JIOT.2018.2830340
   Gai KK, 2018, IEEE NETWORK, V32, P34, DOI 10.1109/MNET.2018.1700407
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Glorot X, 2010, P 13 INT C ART INT S, P249, DOI DOI 10.1177/1753193409103364.
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hamet P, 2017, METABOLISM, V69, pS36, DOI 10.1016/j.metabol.2017.01.011
   Hanen Jemal, 2016, Vietnam Journal of Computer Science, V3, P267, DOI 10.1007/s40595-016-0076-y
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Hengstler M, 2016, TECHNOL FORECAST SOC, V105, P105, DOI 10.1016/j.techfore.2015.12.014
   Istepanaian RSH, 2012, IEEE T INF TECHNOL B, V16, P1, DOI 10.1109/TITB.2012.2183269
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kreitmair KV, 2017, NAT BIOTECHNOL, V35, P617, DOI 10.1038/nbt.3887
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lin J C, 1999, IEEE Eng Med Biol Mag, V18, P28, DOI 10.1109/51.775486
   Lipton Z.C, 2017, ARXIV151103677
   Ma YJ, 2017, IEEE ACCESS, V5, P7885, DOI 10.1109/ACCESS.2016.2638449
   Mesko B, 2017, EXPERT REV PRECIS ME, V2, P239, DOI 10.1080/23808993.2017.1380516
   Michalas A, 2014, 2014 IEEE 16TH INTERNATIONAL CONFERENCE ON E-HEALTH NETWORKING, APPLICATIONS AND SERVICES (HEALTHCOM), P212, DOI 10.1109/HealthCom.2014.7001843
   Miotto R, 2016, SCI REP-UK, V6, DOI 10.1038/srep26094
   Moreno E., 2017, NEW ARTIFICIAL INTEL
   National-Eye-Institute(NEI), 2015, FACTS AG REL MAC DEG
   Olczak J, 2017, ACTA ORTHOP, V88, P581, DOI 10.1080/17453674.2017.1344459
   Pacheco KD, 2016, INVEST OPHTH VIS SCI, V57
   Pan SJ, 2010, IEEE T KNOWL DATA EN, V22, P1345, DOI 10.1109/TKDE.2009.191
   PEREDNIA DA, 1995, JAMA-J AM MED ASSOC, V273, P483, DOI 10.1001/jama.273.6.483
   Petrosian AA, 2001, CLIN NEUROPHYSIOL, V112, P1378, DOI 10.1016/S1388-2457(01)00579-X
   Rad P., 2018, US Patent App, Patent No. [15/574, 935, 15574935]
   Rad P., 2015, 2015 IEEE INT C IM S, P1
   Rad P, 2018, PROCEEDINGS OF THE 51ST ANNUAL HAWAII INTERNATIONAL CONFERENCE ON SYSTEM SCIENCES (HICSS), P3
   Rivero-Garcia A, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17040733
   Russo A, 2015, AM J OPHTHALMOL, V159, P360, DOI 10.1016/j.ajo.2014.11.008
   Ryan ME, 2015, OPHTHALMOLOGY, V122, P2038, DOI 10.1016/j.ophtha.2015.06.011
   Song JC, 2018, 2018 13TH ANNUAL CONFERENCE ON SYSTEM OF SYSTEMS ENGINEERING (SOSE), P169, DOI 10.1109/SYSOSE.2018.8428720
   Strode SW, 1999, JAMA-J AM MED ASSOC, V281, P1066, DOI 10.1001/jama.281.12.1066
   Torres A.D., 2018, COMPUTATIONAL INTELL, P61
   Tulu B., 2005, HICSS P 38 ANN HAW I, p147b, DOI DOI 10.1109/HICSS.2005.56
   van Grinsven MJJP, 2013, PROC SPIE, V8670, DOI 10.1117/12.2007563
   Walton OB, 2016, JAMA OPHTHALMOL, V134, P204, DOI 10.1001/jamaophthalmol.2015.5083
   Wang XA, 2017, INT J WEB GRID SERV, V13, P246, DOI 10.1504/IJWGS.2017.085168
   Wang XA, 2017, FUTURE GENER COMP SY, V67, P242, DOI 10.1016/j.future.2016.08.008
   Wootton R., 2017, INTRO TELEMEDICINE
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 61
TC 32
Z9 32
U1 0
U2 60
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-739X
EI 1872-7115
J9 FUTURE GENER COMP SY
JI Futur. Gener. Comp. Syst.
PD APR
PY 2019
VL 93
BP 486
EP 498
DI 10.1016/j.future.2018.10.050
PG 13
WC Computer Science, Theory & Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA HM3IA
UT WOS:000459365800039
DA 2022-11-30
ER

PT J
AU Bardak, H
   Bardak, Y
   Ercalik, Y
   Erdem, B
   Arslan, G
   Timlioglu, S
AF Bardak, Handan
   Bardak, Yavuz
   Ercalik, Yesim
   Erdem, Burak
   Arslan, Gokhan
   Timlioglu, Semrin
TI Sequential tissue plasminogen activator, pneumatic displacement, and
   anti-VEGF treatment for submacular hemorrhage
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor; Neovascular age-related macular
   degeneration; Pneumatic displacement; Submacular hemorrhage; Tissue
   plasminogen activator
ID CHOROIDAL NEOVASCULAR MEMBRANE; PARS-PLANA VITRECTOMY; MACULAR
   DEGENERATION; SUBRETINAL HEMORRHAGE; INTRAVITREAL BEVACIZUMAB;
   MANAGEMENT; INJECTION; GAS; SECONDARY; COMPATIBILITY
AB Purpose: To report the results of our sequential intravitreal (IV) tissue plasminogen activator (tPA), pneumatic displacement (PD), and IV anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD)-related submacular hemorrhage (SMH).
   Methods: A total of 16 eyes of 16 patients with SMH of less than 15 days duration were included in this retrospective pilot study. The tPA was applied on the day of diagnosis, and PD was performed the following day. Patients received 3 consecutive monthly IV injections of ranibizumab starting from 15 days after PD. During the follow-ups, additional ranibizumab treatment was performed if persistent macular or recurrent subretinal or intraretinal fluid hemorrhage was observed.
   Results: The mean central retinal thickness was 489 +/- 92 mu m (311-621 mu m) at the time of diagnosis, 324 +/- 56 mu m (209-409 mu m) at the first month, 262 +/- 48 mu m (197-364 mu m) at 3 months, 248 +/- 40 mu m (190-334 mu m) at 6 months, and 253 +/- 41 mu m (192-356 mu m) at the last control (p<0.01). The mean best-corrected visual acuity was 2.08 +/- 0.79 logMAR (0.7-3.0 logMAR) at baseline, 1.41 +/- 0.70 logMAR (0.56-2.50 logMAR) at the first month, 1.21 +/- 0.66 logMAR (0.3-2.0 logMAR) at 3 months, 1.14 +/- 0.77 logMAR (0.2-2.50 logMAR) at 6 months, and 1.09 +/- 0.73 logMAR (0.3-2.50 logMAR) at the last follow-up (p<0.01).
   Conclusions: Sequential IV tPA, PD, and IV anti-VEGF treatments for SMH in patients with nAMD is effective. However, further studies are needed to establish the best treatment algorithm for SMH in patients with nAMD.
C1 [Bardak, Handan; Bardak, Yavuz; Ercalik, Yesim; Erdem, Burak; Arslan, Gokhan; Timlioglu, Semrin] Haydarpasa Numune Training & Res Hosp, Dept Ophthalmol, TR-34668 Istanbul, Turkey.
C3 Istanbul Haydarpasa Numune Training & Research Hospital; Istanbul
   Haydarpasa Sultan Abdulhamid Training & Research Hospital
RP Bardak, H (通讯作者)，Haydarpasa Numune Training & Res Hosp, Dept Ophthalmol, TR-34668 Istanbul, Turkey.
EM handanbardak@yahoo.com.tr
RI erdem, burak/AAD-7812-2021
OI Erdem, Burak/0000-0002-8889-6096
CR Agarwal M, 2010, INDIAN J OPHTHALMOL, V58, P170, DOI 10.4103/0301-4738.60078
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Chawla S, 2009, INDIAN J OPHTHALMOL, V57, P155, DOI 10.4103/0301-4738.45511
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hohn F, 2010, OPHTHALMOLOGE, V107, P328, DOI 10.1007/s00347-009-2004-3
   Isizaki E, 2016, INT OPHTHALMOL, V36, P199, DOI 10.1007/s10792-015-0102-6
   Klettner A, 2015, BRIT J OPHTHALMOL, V99, P864, DOI 10.1136/bjophthalmol-2014-306454
   Klettner A, 2012, ARCH OPHTHALMOL-CHIC, V130, P875, DOI 10.1001/archophthalmol.2012.120
   Lee Jung Pil, 2016, Korean J Ophthalmol, V30, P192, DOI 10.3341/kjo.2016.30.3.192
   Liu H, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004192
   Mahesh Gopalakrishnan, 2003, Indian Journal of Ophthalmology, V51, P349
   Mayer WJ, 2013, ACTA OPHTHALMOL, V91, P274, DOI 10.1111/j.1755-3768.2011.02264.x
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   Papavasileiou E, 2013, RETINA-J RET VIT DIS, V33, P846, DOI 10.1097/IAE.0b013e318271f278
   Sacu S, 2009, EYE, V23, P1404, DOI 10.1038/eye.2008.267
   Shah SP, 2009, OPHTHAL SURG LAS IM, V40, P308, DOI 10.3928/15428877-20090430-16
   Singh Preetam, 1999, Indian Journal of Ophthalmology, V47, P254
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Thompson John T, 2005, Trans Am Ophthalmol Soc, V103, P98
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   WADE EC, 1990, ARCH OPHTHALMOL-CHIC, V108, P973, DOI 10.1001/archopht.1990.01070090075043
NR 30
TC 7
Z9 7
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2018
VL 28
IS 3
BP 306
EP 310
DI 10.5301/ejo.5001074
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GG5BC
UT WOS:000432709000011
PM 29148027
DA 2022-11-30
ER

PT J
AU Felder, AE
   Wanek, J
   Teng, PY
   Blair, NP
   Shahidi, M
AF Felder, Anthony E.
   Wanek, Justin
   Teng, Pang-yu
   Blair, Norman P.
   Shahidi, Mahnaz
TI A method for volumetric retinal tissue oxygen tension imaging
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Rat; retina; tissue oxygen tension; three-dimensional imaging;
   phosphorescence lifetime imaging
ID OPTICAL COHERENCE TOMOGRAPHY; EXTRACTION FRACTION; VEIN OCCLUSION; LIGHT
   FLICKER; RAT; CONSUMPTION; NORMOXIA; OXIMETRY; HYPOXIA; INNER
AB Purpose: Inadequate retinal oxygenation occurs in many vision-threatening retinal diseases, including diabetic retinopathy, retinal vascular occlusions, and age-related macular degeneration. Therefore, techniques that assess retinal oxygenation are necessary to understand retinal physiology in health and disease. The purpose of the current study is to report a method for the three-dimensional (3D) imaging of retinal tissue oxygen tension (tPO(2)) in rats.
   Methods: Imaging was performed in Long Evans pigmented rats under systemic normoxia (N = 6) or hypoxia (N = 3). A vertical laser line was horizontally scanned on the retina and a series of optical section phase-delayed phosphorescence images were acquired. From these images, phosphorescence volumes at each phase delay were constructed and a 3D retinal tPO(2) volume was generated. Retinal tPO(2) volumes were quantitatively analyzed by generating retinal depth profiles of mean tPO2 (MtPO(2)) and the spatial variation of tPO(2) (SVtPO2). The effects of systemic condition (normoxia/hypoxia) and retinal depth on MtPO(2) and SVtPO2 were determined by mixed linear model.
   Results: Each 3D retinal tPO(2) volume was approximately 500 x 750 x 200 mu m (horizontal x vertical x depth) and consisted of 45 en face tPO(2) images through the retinal depth. MtPO(2) at the chorioretinal interface was significantly correlated with systemic arterial oxygen tension (P = 0.007; N = 9). There were significant effects of both systemic condition and retinal depth on MtPO(2) and SVtPO2, such that both were lower under hypoxia than normoxia and higher in the outer retina than inner retina (P < 0.001).
   Conclusion: For the first time, 3D imaging of retinal tPO(2) was demonstrated, with potential future application for assessment of physiological alterations in animal models of retinal diseases.
C1 [Felder, Anthony E.] Univ Illinois, Dept Bioengn, Chicago, IL USA.
   [Felder, Anthony E.; Wanek, Justin; Teng, Pang-yu; Blair, Norman P.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
   [Shahidi, Mahnaz] Univ Southern Calif, Dept Ophthalmol, 1450 San Pablo St, Los Angeles, CA 90033 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Southern California
RP Shahidi, M (通讯作者)，Univ Southern Calif, Dept Ophthalmol, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM mshahidi@usc.edu
FU NIH [EY017918, EY001792]; Senior Scientific Investigator award; Research
   to Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY017918, P30EY001792]
   Funding Source: NIH RePORTER
FX This study was supported by NIH grants EY017918 and EY001792, Senior
   Scientific Investigator award (MS) and an unrestricted departmental
   grant from Research to Prevent Blindness.
CR ALDER VA, 1991, DIABETOLOGIA, V34, P469, DOI 10.1007/BF00403282
   Beach JM, 1999, J APPL PHYSIOL, V86, P748, DOI 10.1152/jappl.1999.86.2.748
   BRAUN RD, 1995, INVEST OPHTH VIS SCI, V36, P542
   CHANLING TL, 1995, INVEST OPHTH VIS SCI, V36, P1201
   Cringle SJ, 2002, INVEST OPHTH VIS SCI, V43, P1922
   Dartt D., 2010, ENCY EYE
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Felder AE, 2015, INVEST OPHTH VIS SCI, V56, P6633, DOI 10.1167/iovs.15-17321
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Geirsdottir A, 2014, ACTA OPHTHALMOL, V92, P27, DOI 10.1111/aos.12294
   Hammer M, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2976032
   Hardarson SH, 2006, INVEST OPHTH VIS SCI, V47, P5011, DOI 10.1167/iovs.06-0039
   Hardarson SH, 2010, AM J OPHTHALMOL, V150, P871, DOI 10.1016/j.ajo.2010.06.020
   Kiel JW., 2010, OCULAR CIRCULATION, VChapter 4
   Lau JCM, 2012, EXP EYE RES, V102, P50, DOI 10.1016/j.exer.2012.07.004
   Linsenmeier RA, 1998, INVEST OPHTH VIS SCI, V39, P1647
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Petropoulos IK, 2013, RETINA-J RET VIT DIS, V33, P170, DOI 10.1097/IAE.0b013e318261a6b5
   POURNARAS CJ, 1989, EXP EYE RES, V49, P347, DOI 10.1016/0014-4835(89)90045-6
   Shahidi M, 2006, CURR EYE RES, V31, P357, DOI 10.1080/02713680600599446
   Shahidi M, 2009, INVEST OPHTH VIS SCI, V50, P820, DOI 10.1167/iovs.08-2343
   Shahidi M, 2010, INVEST OPHTH VIS SCI, V51, P4766, DOI 10.1167/iovs.09-4710
   Shonat RD, 2003, ANN BIOMED ENG, V31, P1084, DOI 10.1114/1.1603256
   Song W, 2014, SCI REP-UK, V4, DOI 10.1038/srep06525
   Teng PY, 2014, INVEST OPHTH VIS SCI, V55, P6055, DOI 10.1167/iovs.13-13811
   Teng PY, 2012, GRAEF ARCH CLIN EXP, V250, P361, DOI 10.1007/s00417-011-1859-6
   Traustason S, 2014, BRIT J OPHTHALMOL, V98, P1208, DOI 10.1136/bjophthalmol-2013-304580
   Trick GL, 2005, PROG RETIN EYE RES, V24, P259, DOI 10.1016/j.preteyeres.2004.08.001
   Wanek J, 2013, INVEST OPHTH VIS SCI, V54, P5012, DOI 10.1167/iovs.13-11887
   Wanek J, 2012, CURR EYE RES, V37, P132, DOI 10.3109/02713683.2011.629071
   Yi J, 2013, OPT LETT, V38, P1796, DOI 10.1364/OL.38.001796
   YU DY, 1994, AM J PHYSIOL-HEART C, V267, pH2498, DOI 10.1152/ajpheart.1994.267.6.H2498
   YU DY, 1990, INVEST OPHTH VIS SCI, V31, P2493
NR 33
TC 5
Z9 5
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2018
VL 43
IS 1
BP 122
EP 127
DI 10.1080/02713683.2017.1373823
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ1GE
UT WOS:000427324100017
PM 28956656
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Choi, JY
   Yoo, TK
   Seo, JG
   Kwak, J
   Um, TT
   Rim, TH
AF Choi, Joon Yul
   Yoo, Tae Keun
   Seo, Jeong Gi
   Kwak, Jiyong
   Um, Terry Taewoong
   Rim, Tyler Hyungtaek
TI Multi-categorical deep learning neural network to classify retinal
   images: A pilot study employing small database
SO PLOS ONE
LA English
DT Article
ID DIABETIC-RETINOPATHY; MACULAR DEGENERATION; AUTOMATED DETECTION;
   MULTICATEGORY CLASSIFICATION; PREVALENCE; GLAUCOMA; DISCRIMINATION;
   MACHINE; CANCER
AB Deep learning emerges as a powerful tool for analyzing medical images. Retinal disease detection by using computer-aided diagnosis from fundus image has emerged as a new method. We applied deep learning convolutional neural network by using MatConvNet for an automated detection of multiple retinal diseases with fundus photographs involved in STructured Analysis of the REtina (STARE) database. Dataset was built by expanding data on 10 categories, including normal retina and nine retinal diseases. The optimal outcomes were acquired by using a random forest transfer learning based on VGG-19 architecture. The classification results depended greatly on the number of categories. As the number of categories increased, the performance of deep learning models was diminished. When all 10 categories were included, we obtained results with an accuracy of 30.5%, relative classifier information (RCI) of 0.052, and Cohen's kappa of 0.224. Considering three integrated normal, background diabetic retinopathy, and dry age-related macular degeneration, the multi-categorical classifier showed accuracy of 72.8%, 0.283 RCI, and 0.577 kappa. In addition, several ensemble classifiers enhanced the multi-categorical classification performance. The transfer learning incorporated with ensemble classifier of clustering and voting approach presented the best performance with accuracy of 36.7%, 0.053 RCI, and 0.225 kappa in the 10 retinal diseases classification problem. First, due to the small size of data-sets, the deep learning techniques in this study were ineffective to be applied in clinics where numerous patients suffering from various types of retinal disorders visit for diagnosis and treatment. Second, we found that the transfer learning incorporated with ensemble classifiers can improve the classification performance in order to detect multi-categorical retinal diseases. Further studies should confirm the effectiveness of algorithms with large datasets obtained from hospitals.
C1 [Choi, Joon Yul] Seoul Natl Univ, Dept Elect & Comp Engn, Seoul, South Korea.
   [Yoo, Tae Keun; Seo, Jeong Gi; Kwak, Jiyong; Rim, Tyler Hyungtaek] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul, South Korea.
   [Um, Terry Taewoong] Univ Waterloo, Dept Elect & Comp Engn, Waterloo, ON, Canada.
C3 Seoul National University (SNU); Yonsei University; Yonsei University
   Health System; University of Waterloo
RP Yoo, TK; Rim, TH (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul, South Korea.
EM fawoo2@yuhs.ac; awaitingyourfeedback@gmail.com
RI Yoo, Tae Keun/Q-3620-2019
OI Yoo, Tae Keun/0000-0003-0890-8614; Kwak, Jay Jiyong/0000-0002-7738-9136
FU faculty research grant of Yonsei University College of Medicine
   [6-2017-0089]
FX This study was supported by a faculty research grant of Yonsei
   University College of Medicine for 2017 (6-2017-0089).
CR Abramoff MD, 2010, EXPERT REV MED DEVIC, V7, P287, DOI 10.1586/ERD.09.76
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Acharya UR, 2016, COMPUT BIOL MED, V73, P131, DOI 10.1016/j.compbiomed.2016.04.009
   Adarsh P, 2013, 2013 INTERNATIONAL CONFERENCE ON COMMUNICATIONS AND SIGNAL PROCESSING (ICCSP), P206, DOI 10.1109/iccsp.2013.6577044
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Ben-David A, 2008, EXPERT SYST APPL, V34, P825, DOI 10.1016/j.eswa.2006.10.022
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Caixinha M, 2017, CURR EYE RES, V42, P1, DOI 10.1080/02713683.2016.1175019
   Casanova R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098587
   Chan CKW, 2015, OPHTHALMOLOGY, V122, P2278, DOI 10.1016/j.ophtha.2015.06.050
   Chen XY, 2015, IEEE ENG MED BIO, P715, DOI 10.1109/EMBC.2015.7318462
   Chen XW, 2014, IEEE ACCESS, V2, P514, DOI 10.1109/ACCESS.2014.2325029
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Choi SB, 2014, IEEE ENG MED BIO, P3460, DOI 10.1109/EMBC.2014.6944367
   Deng J, 2010, LECT NOTES COMPUT SC, V6315, P71, DOI 10.1007/978-3-642-15555-0_6
   Dosovitskiy A, 2015, IEEE I CONF COMP VIS, P2758, DOI 10.1109/ICCV.2015.316
   Dudoit S, 2002, J AM STAT ASSOC, V97, P77, DOI 10.1198/016214502753479248
   Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056
   Frey BJ, 2007, SCIENCE, V315, P972, DOI 10.1126/science.1136800
   Ganesan K, 2014, MED BIOL ENG COMPUT, V52, P663, DOI 10.1007/s11517-014-1167-5
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   GOLDBAUM MH, 1990, INVEST OPHTH VIS SCI, V31, P617
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hsu CW, 2002, IEEE T NEURAL NETWOR, V13, P415, DOI 10.1109/72.991427
   Jain S, 2006, EYE, V20, P471, DOI 10.1038/sj.eye.6701916
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kijsirikul B, 2002, IEEE IJCNN, P980, DOI 10.1109/IJCNN.2002.1005608
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee CS, OPHTHALMOL RETINA
   Lin C, 2014, NEUROCOMPUTING, V123, P424, DOI 10.1016/j.neucom.2013.08.004
   Liu B, 2017, MOL THER-NUCL ACIDS, V7, P267, DOI 10.1016/j.omtn.2017.04.008
   Liu B, 2017, BIOINFORMATICS, V33, P35, DOI [10.1093/bioinformatics/btw539, 10.1093/bioinformatics/btv604]
   Liu B, 2014, BIOINFORMATICS, V30, P472, DOI 10.1093/bioinformatics/btt709
   Liu M, 2013, SENSOR ACTUAT B-CHEM, V177, P970, DOI 10.1016/j.snb.2012.11.071
   Mookiah MRK, 2013, COMPUT BIOL MED, V43, P2136, DOI 10.1016/j.compbiomed.2013.10.007
   Oh E, 2015, INVEST OPHTH VIS SCI, V56, P3957, DOI 10.1167/iovs.15-16805
   Oh E, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-106
   Oquab M, 2014, PROC CVPR IEEE, P1717, DOI 10.1109/CVPR.2014.222
   Paul R, 2016, TOMOGRAPHY, V2, P388, DOI 10.18383/j.tom.2016.00211
   Pratt H, 2016, PROCEDIA COMPUT SCI, V90, P200, DOI 10.1016/j.procs.2016.07.014
   Qi ZQ, 2016, KNOWL-BASED SYST, V107, P54, DOI 10.1016/j.knosys.2016.05.055
   Ramani RG, 2012, 2012 INTERNATIONAL CONFERENCE ON MACHINE VISION AND IMAGE PROCESSING (MVIP), P149, DOI 10.1109/MVIP.2012.6428782
   Ribeiro E, 2016, COMPUT MATH METHOD M, V2016, DOI 10.1155/2016/6584725
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Sindhwani V., 2001, SIAM, P1
   Statnikov A, 2005, BIOINFORMATICS, V21, P631, DOI 10.1093/bioinformatics/bti033
   Statnikov A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-319
   Szegedy C., 2016, 2016 IEEE C COMPUTER, P2818, DOI DOI 10.1109/CVPR.2016.308
   Phan TV, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5893601
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Welikala RA, 2014, COMPUT METH PROG BIO, V114, P247, DOI 10.1016/j.cmpb.2014.02.010
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Worrall DE, 2016, LECT NOTES COMPUT SC, V10008, P68, DOI 10.1007/978-3-319-46976-8_8
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   Zou Q, 2016, NEUROCOMPUTING, V173, P346, DOI 10.1016/j.neucom.2014.12.123
NR 59
TC 107
Z9 109
U1 1
U2 35
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 2
PY 2017
VL 12
IS 11
AR e0187336
DI 10.1371/journal.pone.0187338
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FL6FI
UT WOS:000414340200075
PM 29095872
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Kruk, J
   Kubasik-Kladna, K
   Aboul-Enein, HY
AF Kruk, Joanna
   Kubasik-Kladna, Katarzyna
   Aboul-Enein, Hassan Y.
TI The Role Oxidative Stress in the Pathogenesis of Eye Diseases: Current
   Status and a Dual Role of Physical Activity
SO MINI-REVIEWS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Antioxidants; cancer; oxidative stress; ocular disease; physical
   activity
ID NF-KAPPA-B; REACTIVE OXYGEN; FREE-RADICALS; BREAST-CANCER; IN-VITRO;
   ANTIOXIDANT ACTIVITY; DNA-DAMAGE; DRY EYE; MACULAR DEGENERATION;
   LIPID-PEROXIDATION
AB Extensive research during the past three decades has demonstrated the mechanisms by which an imbalance in the redox status of prooxidant/antioxidant reactions in cells with advantage of prooxidant reactions (oxidative stress, OS) can cause peroxidation of nucleic acids, bases, lipids, proteins and carbohydrates, thus resulting in their damage. These actions result in stimulation of signal transduction pathways and activation of transcription factors that can lead to chronic inflammation and cause tissue dysfunction. The most important oxidants are reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated by various metabolic pathways, physical, chemical and biological factors, and pathological conditions. The eye is one of the major target of the ROS/RNS attack due to exposition on several environmental factors like high pressure of oxygen, light exposure, ultraviolet rays, ionizing radiation, chemical pollutants, irritant, and pathogenic microbes, which are able to shift the redox status of a cell towards oxidizing conditions. There is increasing evidence indicating that persistent OS contributes to the development of many ocular diseases. Increases in the accumulation of hydrogen peroxide and markers of the oxidative damage to DNA, lipids, proteins observed in several eye diseases and usage of antioxidants in their treatment and prevention emphasize the involvement of OS pathways. This paper summarizes the present state of knowledge in the involvement of OS in the etiology of non-cancer ocular diseases (dry eye syndrome; corneal and conjunctive diseases; cataract; glaucoma; age-related macular degeneration; retinitis pigmentosa; diabetic retinopathy, autoimmune and inflammatory uveitis) and cancer ocular diseases (melanoma; retinoblastoma; lymphoma). The paper also discusses the potential applications of antioxidants in the prevention of eye diseases and shows a duality of physical exercise actions: protection against the ROS/RNS damage by regular-moderate physical activity and damaging effect through mediation of OS by endurance exercise without adaptable physical training.
C1 [Kruk, Joanna] Univ Szczecin, Fac Phys Culture & Hlth Promot, Dept Prevent & Occupat Therapy, PL-70453 Szczecin, Poland.
   [Kubasik-Kladna, Katarzyna] Pomeranian Med Univ, Dept Ophthalmol, Szczecin, Poland.
   [Aboul-Enein, Hassan Y.] Natl Res Ctr, Pharmaceut & Drug Ind Res Div, Natl Pharmaceut & Med Chem Dept, Giza 12622, Egypt.
C3 University of Szczecin; Pomeranian Medical University; Egyptian
   Knowledge Bank (EKB); National Research Centre (NRC)
RP Aboul-Enein, HY (通讯作者)，Natl Res Ctr, Pharmaceut & Drug Ind Res Div, Pharmaceut & Med Chem Dept, Giza 12622, Egypt.
EM haboulenein@yahoo.com
OI Kruk, Joanna/0000-0002-7551-1927
CR Adelli G.R., 2013, WJP, V2, P18, DOI [10.5497/wjp.v2.i1.18, DOI 10.5497/WJP.V2.I1.18]
   Alegre MM, 2013, ASIAN PAC J CANCER P, V14, P2207, DOI 10.7314/APJCP.2013.14.4.2207
   Alexandre J, 2006, INT J CANCER, V119, P41, DOI 10.1002/ijc.21685
   Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7
   Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   Antunes F, 1999, FREE RADICAL BIO MED, V26, P117, DOI 10.1016/S0891-5849(98)00168-3
   Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3
   Gomes ECBD, 2014, J CANCER, V5, P143, DOI 10.7150/jca.7439
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Barnett BR, 2013, GERONTOLOGY, V59, P297, DOI 10.1159/000346169
   Bartosz G., 2003, DRUGA TWARZ TLENU, P30
   Berthoud VM, 2009, ANTIOXID REDOX SIGN, V11, P339, DOI 10.1089/ars.2008.2119
   Bhinder B, 2015, ESSENT OPHTHALMOL, P73, DOI 10.1007/978-3-319-19467-7_7
   Bloomer RJ, 2004, CAN J APPL PHYSIOL, V29, P245, DOI 10.1139/h04-017
   Boscia F, 2000, INVEST OPHTH VIS SCI, V41, P2461
   Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003
   Bulua AC, 2011, J EXP MED, V208, P519, DOI 10.1084/jem.20102049
   BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3
   Cadenas E, 1997, BIOFACTORS, V6, P391, DOI 10.1002/biof.5520060404
   Campbell KL, 2007, J NUTR, V137, p161S, DOI 10.1093/jn/137.1.161S
   Cancer Research UK, 2014, EYE CANC RISK CAUS
   Cardenas E., 2000, FREE RADIC BIOL MED, V29, P222
   Cejkova J, 2004, PHYSIOL RES, V53, P1
   Cekic O, 2002, AM J OPHTHALMOL, V134, P75, DOI 10.1016/S0002-9394(02)01472-1
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chen K, 2004, J BIOL CHEM, V279, P35079, DOI 10.1074/jbc.M404859200
   Chen MH, 2014, MOL VIS, V20, P153
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Choy CKM, 2011, OPTOMETRY VISION SCI, V88, P507, DOI 10.1097/OPX.0b013e31820e9fe2
   Choy CKM, 2000, INVEST OPHTH VIS SCI, V41, P3293
   CHUNG FL, 1992, CARCINOGENESIS, V13, P1269, DOI 10.1093/carcin/13.7.1269
   Clague J, 2012, CURR ONCOL REP, V14, P550, DOI 10.1007/s11912-012-0265-5
   Cook R, 2015, CELL REP, V10, P2006, DOI 10.1016/j.celrep.2015.02.059
   Corthals SM, 2006, TOXICOL SCI, V92, P378, DOI 10.1093/toxsci/kfl007
   Craig JP, 2000, EYE, V14, P635, DOI 10.1038/eye.2000.156
   D'Orazio J, 2013, INT J MOL SCI, V14, P12222, DOI 10.3390/ijms140612222
   DAHLHAUS M, 1995, MUTAT RES-FUND MOL M, V329, P29, DOI 10.1016/0027-5107(95)00014-A
   Dalle-Donne I, 2006, CLIN CHEM, V52, P601, DOI 10.1373/clinchem.2005.061408
   Dansen TB, 2001, IUBMB LIFE, V51, P223
   Dayem Ahmed Abdal, 2010, Cancers (Basel), V2, P859, DOI 10.3390/cancers2020859
   Deepa PR, 2009, CURR EYE RES, V34, P1011, DOI 10.3109/02713680903291139
   Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567
   DIZDAROGLU M, 1994, METHOD ENZYMOL, V234, P3
   Pinazo-Duran MD, 2014, CLIN INTERV AGING, V9, P637, DOI 10.2147/CIA.S52662
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Durackova Z, 2010, PHYSIOL RES, V59, P459, DOI 10.33549/physiolres.931844
   Erdogan-Orhan I, 2010, J MED FOOD, V13, P1537, DOI 10.1089/jmf.2009.0237
   Fang YZ, 2002, NUTRITION, V18, P872, DOI 10.1016/S0899-9007(02)00916-4
   Felley-Bosco E, 1998, CANCER METAST REV, V17, P25, DOI 10.1023/A:1005948420548
   Fiedor J, 2014, NUTRIENTS, V6, P466, DOI 10.3390/nu6020466
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Fisher-Wellman Kelsey, 2009, Dyn Med, V8, P1, DOI 10.1186/1476-5918-8-1
   Forester SC, 2011, MOL NUTR FOOD RES, V55, P844, DOI 10.1002/mnfr.201000641
   Fraga CG, 2010, MOL ASPECTS MED, V31, P435, DOI 10.1016/j.mam.2010.09.006
   GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T
   Gomez-Cabrera MC, 2006, SCI SPORT, V21, P85, DOI 10.1016/j.scispo.2005.06.012
   Gomez-Cabrera MC, 2008, FREE RADICAL BIO MED, V44, P126, DOI 10.1016/j.freeradbiomed.2007.02.001
   Graue GF, 2013, EUR J OPHTHALMOL, V23, P344, DOI 10.5301/ejo.5000224
   Grossniklaus HE, 2014, AM J OPHTHALMOL, V158, P875, DOI 10.1016/j.ajo.2014.07.025
   Gul MZ, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-64
   Guo XF, 2013, J FOOD BIOCHEM, V37, P501, DOI 10.1111/j.1745-4514.2012.00655.x
   Gupta RK, 2012, ASIAN PAC J CANCER P, V13, P6295, DOI 10.7314/APJCP.2012.13.12.6295
   GUTTERIDGE JMC, 1985, CLIN CHIM ACTA, V145, P267, DOI 10.1016/0009-8981(85)90033-6
   Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341
   Halliwell B, 2009, FREE RADICAL BIO MED, V46, P531, DOI 10.1016/j.freeradbiomed.2008.11.008
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hassler M, 2007, MOL CELL, V28, P371, DOI 10.1016/j.molcel.2007.08.023
   Hatem E, 2014, FREE RADICAL BIO MED, V67, P103, DOI 10.1016/j.freeradbiomed.2013.10.807
   Health Grades Editorial Staff, WHAT IS EYE CANC
   Ho MC, 2010, J CLIN GERONTOL GERI, V1, P17, DOI 10.1016/j.jcgg.2010.10.006
   Huang PH, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1053596
   Huang PH, 2015, ONCOTARGET, V6, P20746, DOI 10.18632/oncotarget.5234
   Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046
   Hwang ES, 2007, CRIT REV FOOD SCI, V47, P27, DOI 10.1080/10408390600550299
   Ibrahim OMA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099328
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Janik-Papis Katarzyna, 2009, Klin Oczna, V111, P168
   Jensen SJK, 2003, J MOL STRUC-THEOCHEM, V666, P387, DOI 10.1016/j.theochem.2003.08.037
   Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0
   Kadekaro AL, 2012, MOL CANCER RES, V10, P778, DOI 10.1158/1541-7786.MCR-11-0436
   Kadekaro AL, 2010, FASEB J, V24, P3850, DOI 10.1096/fj.10-158485
   Kakde D., 2011, J APPL PHARM SCI, V01, DOI DOI 10.1080/1061186X.2017.1358729
   KANOFSKY JR, 1988, PHOTOCHEM PHOTOBIOL, V47, P605, DOI 10.1111/j.1751-1097.1988.tb08851.x
   Karamichos D, 2014, SCI REP-UK, V4, DOI 10.1038/srep04608
   Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6
   Kim MC, 2013, ASIAN PAC J CANCER P, V14, P3625, DOI 10.7314/APJCP.2013.14.6.3625
   Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453
   Ko ML, 2005, FREE RADICAL BIO MED, V39, P365, DOI 10.1016/j.freeradbiomed.2005.03.025
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Kruk I., 1998, REACTIONS PROCESSES, P89
   Kruk J, 2011, MED SPORTIVA, V15, P30, DOI DOI 10.2478/V10036-011-0004-2
   Kruk J, 2006, CURR CANCER THER REV, V2, P3, DOI 10.2174/157339406775471795
   Kruk J, 2014, ASIAN PAC J CANCER P, V15, P4429, DOI 10.7314/APJCP.2014.15.11.4429
   Kruk J, 2014, ASIAN PAC J CANCER P, V15, P561, DOI 10.7314/APJCP.2014.15.2.561
   Kryston TB, 2011, MUTAT RES-FUND MOL M, V711, P193, DOI 10.1016/j.mrfmmm.2010.12.016
   Kumar N, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-319
   Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953
   Lemp MA, 2007, OCUL SURF, V5, P75
   Leonarduzzi G, 2012, FREE RADICAL BIO MED, V52, P19, DOI 10.1016/j.freeradbiomed.2011.09.031
   Levin LA, 1996, INVEST OPHTH VIS SCI, V37, P2744
   Lewis LLM, 2015, INT J DEV RES, V5, P3275
   Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Liu RM, 2010, FREE RADICAL BIO MED, V48, P1, DOI 10.1016/j.freeradbiomed.2009.09.026
   Liu-Smith F, 2014, ARCH BIOCHEM BIOPHYS, V563, P51, DOI 10.1016/j.abb.2014.04.007
   Lynch BM, 2011, RECENT RESULTS CANC, V186, P13, DOI 10.1007/978-3-642-04231-7_2
   Ma LS, 2013, FOOD CHEM, V139, P503, DOI 10.1016/j.foodchem.2013.01.030
   Macri A, 2015, GRAEF ARCH CLIN EXP, V253, P425, DOI 10.1007/s00417-014-2853-6
   Magalhaes LM, 2008, ANAL CHIM ACTA, V613, P1, DOI 10.1016/j.aca.2008.02.047
   Majumdar S, 2010, J PHARM PHARMACOL, V62, P951, DOI 10.1211/jpp.62.08.0001
   Mantelli F, 2013, J CELL PHYSIOL, V228, P2253, DOI 10.1002/jcp.24398
   Margonis K, 2007, FREE RADICAL BIO MED, V43, P901, DOI 10.1016/j.freeradbiomed.2007.05.022
   Masaki H, 2010, J DERMATOL SCI, V58, P85, DOI 10.1016/j.jdermsci.2010.03.003
   Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6
   Mates JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009-9120(99)00075-2
   Mayo Clinic Staff, 2015, DIS COND RET
   McTiernan A, 2008, NAT REV CANCER, V8, P205, DOI 10.1038/nrc2325
   Mishra PK, 2011, BRIT J NUTR, V106, P1154, DOI 10.1017/S0007114511001498
   Mittler R, 2011, TRENDS PLANT SCI, V16, P300, DOI 10.1016/j.tplants.2011.03.007
   Montaruli A, 2012, SPORT SCI HLTH, V8, P1, DOI DOI 10.1007/S11332-012-0125-6
   Moore MA, 2009, ASIAN PAC J CANCER P, V10, P149
   Moreno MC, 2004, FREE RADICAL BIO MED, V37, P803, DOI 10.1016/j.freeradbiomed.2004.06.001
   Mortensen A, 2001, ARCH BIOCHEM BIOPHYS, V385, P13, DOI 10.1006/abbi.2000.2172
   Mouret S, 2012, PHOTOCH PHOTOBIO SCI, V11, P155, DOI 10.1039/c1pp05185g
   Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nakamura S, 2007, INVEST OPHTH VIS SCI, V48, P1552, DOI 10.1167/iovs.06-1027
   Neilson HK, 2009, CANCER EPIDEM BIOMAR, V18, P11, DOI 10.1158/1055-9965.EPI-08-0756
   Niki E, 2009, FREE RADICAL BIO MED, V47, P469, DOI 10.1016/j.freeradbiomed.2009.05.032
   Nogueira CR, 2013, NUTR HOSP, V28, P1666, DOI 10.3305/nh.2013.28.5.6590
   O'Connell K, 2013, CENTR EUR J SPORT SC, V1, P3
   Oduntan OA., 2011, S AFR OPTOM, V70, P191, DOI 10.4102/aveh.v70i4.116
   Ogawa Y., 2013, INFLAMM REGEN, V33, P238, DOI DOI 10.2492/inflammregen.33.238
   Oharazawa H, 2010, INVEST OPHTH VIS SCI, V51, P487, DOI 10.1167/iovs.09-4089
   Ohia SE, 2005, MUTAT RES-FUND MOL M, V579, P22, DOI 10.1016/j.mrfmmm.2005.03.025
   Ohira Akihiro, 2008, Nippon Ganka Gakkai Zasshi, V112, P22
   Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577
   Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2
   Ohta S, 2012, BBA-GEN SUBJECTS, V1820, P586, DOI 10.1016/j.bbagen.2011.05.006
   Palozza P, 2003, MOL ASPECTS MED, V24, P353, DOI 10.1016/S0098-2997(03)00031-1
   Pande V, 2005, BIOORG MED CHEM LETT, V15, P4057, DOI 10.1016/j.bmcl.2005.06.025
   Patrick Lyn, 2004, Altern Med Rev, V9, P239
   Pergoli L, 2014, MELANOMA RES, V24, P480, DOI 10.1097/CMR.0000000000000112
   Pervin I.M.N., 2011, MED TODAY, V23, P103
   Phosrithong N, 2012, CHEM BIOL DRUG DES, V79, P981, DOI 10.1111/j.1747-0285.2012.01368.x
   Picardo M, 1997, SKIN IMMUNE SYSTEM S, P207
   Quinlan CL, 2012, FREE RADICAL BIO MED, V53, P1807, DOI 10.1016/j.freeradbiomed.2012.08.015
   Rabin DM, 2013, AGING-US, V5, P51
   Rahman K, 2007, CLIN INTERV AGING, V2, P219
   Rahman T, 2012, ADV BIOSCIENCE BIOTE, V3, P997, DOI [10.4236/abb.2012.327123, DOI 10.4236/ABB.2012.327123]
   Rasmussen HM, 2013, CLIN INTERV AGING, V8, P741, DOI 10.2147/CIA.S45399
   Rasmussen PK, 2014, JAMA OPHTHALMOL, V132, P851, DOI 10.1001/jamaophthalmol.2014.376
   Reddy DB, 2009, BIOCHEM BIOPH RES CO, V381, P112, DOI 10.1016/j.bbrc.2009.02.022
   Reelfs O, 2004, J INVEST DERMATOL, V122, P1440, DOI 10.1111/j.0022-202X.2004.22620.x
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9
   Rose RC, 1998, P SOC EXP BIOL MED, V217, P397, DOI 10.3181/00379727-217-44250
   Sacca SC, 2008, PROG BRAIN RES, V173, P385, DOI 10.1016/S0079-6123(08)01127-8
   Sacca SC, 2013, MUTAT RES-REV MUTAT, V752, P153, DOI 10.1016/j.mrrev.2013.01.001
   Sacca SC, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000216
   Sachdev S, 2008, FREE RADICAL BIO MED, V44, P215, DOI 10.1016/j.freeradbiomed.2007.07.019
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Saraswathy S, 2009, INVEST OPHTH VIS SCI, V50, P5559, DOI 10.1167/iovs.08-2842
   Sareen D, 2006, INVEST OPHTH VIS SCI, V47, P3708, DOI 10.1167/iovs.06-0119
   Sasaki M, 2012, J NUTR BIOCHEM, V23, P423, DOI 10.1016/j.jnutbio.2011.01.006
   Saxena J., 2014, WORLD J PHARM RES, V3, P161
   Schneider C.D., 2004, REV BRAS MED ESPORTE, V10, P314, DOI DOI 10.1590/S1517-86922004000400008
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Serra JA, 2009, NEUROCHEM RES, V34, P2122, DOI 10.1007/s11064-009-9997-5
   Shang F, 2003, FREE RADICAL BIO MED, V34, P521, DOI 10.1016/S0891-5849(02)01304-7
   Shankar S, 2008, FRONT BIOSCI-LANDMRK, V13, P440, DOI 10.2741/2691
   Sharma D., 2014, SCH ACAD J BIOSCI, V2, P137
   Shaw PX, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/569146
   Shichi H, 2004, EXPERT OPIN INV DRUG, V13, P691, DOI 10.1517/13543784.13.6.691
   Shoham A, 2008, FREE RADICAL BIO MED, V45, P1047, DOI 10.1016/j.freeradbiomed.2008.07.021
   Sies H., 1985, OXIDATIVE STRESS, V1
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Sin HPY, 2013, ACTA OPHTHALMOL, V91, P6, DOI 10.1111/j.1755-3768.2011.02357.x
   Singh DK, 1998, ONCOLOGY-NY, V12, P1643
   Singh I, 1996, ANN NY ACAD SCI, V804, P612, DOI 10.1111/j.1749-6632.1996.tb18648.x
   Sirotkin AV, 2014, EUR J PHARMACOL, V741, P230, DOI 10.1016/j.ejphar.2014.07.057
   Smith LL, 2004, J STRENGTH COND RES, V18, P185, DOI 10.1519/00124278-200402000-00028
   Sonawane S, 2012, INVEST OPHTH VIS SCI, V53, P8253, DOI 10.1167/iovs.12-10430
   Soobrattee MA, 2005, MUTAT RES-FUND MOL M, V579, P200, DOI 10.1016/j.mrfmmm.2005.03.023
   Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004
   Stern ME, 2013, INT REV IMMUNOL, V32, P19, DOI 10.3109/08830185.2012.748052
   Stevenson W, 2012, ARCH OPHTHALMOL-CHIC, V130, P90, DOI 10.1001/archophthalmol.2011.364
   Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   Subramanyam D., 2013, Experimental Oncology, V35, P97
   Suganuma M, 2011, CANCER SCI, V102, P317, DOI 10.1111/j.1349-7006.2010.01805.x
   Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17
   Tanaka H, 2008, BRIT J CANCER, V98, P580, DOI 10.1038/sj.bjc.6604204
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   TRENAM CW, 1992, J INVEST DERMATOL, V99, P675, DOI 10.1111/1523-1747.ep12613740
   Tsuji M, 2012, CANCER CAUSE CONTROL, V23, P683, DOI 10.1007/s10552-012-9935-8
   Umapathy A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/207250
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Valluru L, 2014, OXID ANTIOXID MED SC, V13, P15, DOI [DOI 10.5455/OAMS.201113.RV.011, 10.5455/oams.201113.rv.011]
   van der Kemp PA, 2002, PHOTOCHEM PHOTOBIOL, V76, P640, DOI 10.1562/0031-8655(2002)076<0640:UBIIOH>2.0.CO;2
   Vandhana S, 2012, CURR EYE RES, V37, P830, DOI 10.3109/02713683.2012.678544
   Venza M, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/481782
   Vina J, 2000, IUBMB LIFE, V50, P271, DOI 10.1080/15216540051080994
   Wakamatsu TH, 2008, ARQ BRAS OFTALMOL, V71, P72, DOI 10.1590/S0004-27492008000700015
   WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003
   Wang YX, 2011, AM J PHYSIOL-CELL PH, V301, pC695, DOI 10.1152/ajpcell.00322.2010
   Weidinger A, 2015, BIOMOLECULES, V5, P472, DOI 10.3390/biom5020472
   Wickens AP, 2001, RESP PHYSIOL, V128, P379, DOI 10.1016/S0034-5687(01)00313-9
   Willeford KT, 2012, OPTOMETRY VISION SCI, V89, P1662, DOI 10.1097/OPX.0b013e31826c5df2
   Winzer BM, 2011, CANCER CAUSE CONTROL, V22, P811, DOI 10.1007/s10552-011-9761-4
   World Cancer Research Fund/American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P, P1
   Yamagishi SI, 2010, CURR MOL MED, V10, P284, DOI 10.2174/156652410791065264
   Yang CS, 2011, MOL NUTR FOOD RES, V55, P819, DOI 10.1002/mnfr.201100036
   Yuan JM, 2011, MOL NUTR FOOD RES, V55, P886, DOI 10.1002/mnfr.201000637
   Yue KKM, 2003, LIFE SCI, V73, P2557, DOI 10.1016/S0024-3205(03)00662-3
   Zanon-Moreno V, 2008, J GLAUCOMA, V17, P263, DOI 10.1097/IJG.0b013e31815c3a7f
   Zeng YW, 2013, ASIAN PAC J CANCER P, V14, P1585, DOI 10.7314/APJCP.2013.14.3.1585
   Zhang CX, 2011, CANCER CAUSE CONTROL, V22, P115, DOI 10.1007/s10552-010-9681-8
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhu YY, 2011, ASIAN PAC J CANCER P, V12, P2837
   Ziangirova G G, 2003, Vestn Oftalmol, V119, P54
   Zoric Lepsa, 2003, Srp Arh Celok Lek, V131, P137
NR 227
TC 92
Z9 98
U1 0
U2 75
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-5575
EI 1875-5607
J9 MINI-REV MED CHEM
JI Mini-Rev. Med. Chem.
PY 2016
VL 16
IS 3
BP 241
EP 257
DI 10.2174/1389557516666151120114605
PG 17
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CX1PS
UT WOS:000365468700011
PM 26586128
DA 2022-11-30
ER

PT J
AU Schlenker, MB
   Thiruchelvam, D
   Redelmeier, DA
AF Schlenker, Matthew B.
   Thiruchelvam, Deva
   Redelmeier, Donald A.
TI Intravitreal Anti-Vascular Endothelial Growth Factor Treatment and the
   Risk of Thromboembolism
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; FACTOR INHIBITORS; CROSSOVER DESIGN;
   CATARACT-SURGERY; ADVERSE EVENTS; UNITED-STATES; AGE; RANIBIZUMAB;
   BEVACIZUMAB; SAFETY
AB PURPOSE: To evaluate the subsequent risk of thromboembolic events in patients receiving intravitreal ranibizumab and bevacizumab for age-related macular degeneration or macular edema.
   DESIGN: Population-based crossover analysis with self-matched historical control data.
   METHODS: SETTING: Ontario, Canada, between April 1, 2006, and March 31, 2013. STUDY POPULATION: Consecutive patients 65 and older who initiated intravitreal treatment (N= 57 919). INTERVENTION: Intravitreal injection of ranibizumab or bevacizumab. MAIN OUTCOME MEASURES: Emergency visits for thromboembolic events spanning 1-4 years before treatment were compared to 1 year after treatment. Also examined were other secondary events including hip fractures, congestive heart failure, angina, falls, depression, cholecystitis, and total emergencies, as well as a control group following cataract surgery.
   RESULTS: A total of 57 919 patients were included who accounted for 1858 thromboembolic emergencies (48 per month) during the 3-year Baseline interval and 1077 thromboembolic emergencies (83 per month) during the 1-year Subsequent interval after initiating treatment. The absolute change in risk equaled an increase from 10.7 to 18.6 per 1000 patients annually after initiation of treatment (rate ratio 1.74; 95% confidence interval 1.58-1.92; P<.0001). The relative increase was particularly pronounced for ischemic stroke (rate ratio 2.18; 95% confidence interval 1.94-2.46; P<.0001). The observed increase exceeded trends due to aging, applied across patients with diverse characteristics, occurred with each medication (ranibizumab and bevacizumab), was not apparent for emergencies unrelated to thromboembolic events, and did not occur in a control group following cataract surgery.
   CONCLUSIONS: Intravitreal anti-vascular endothelial growth factor medications ranibizumab and bevacizumab may contribute to systemic thromboembolic events in patients aged 65 years or older. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Schlenker, Matthew B.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Redelmeier, Donald A.] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Thiruchelvam, Deva; Redelmeier, Donald A.] Sunnybrook Res Inst, Evaluat Clin Sci Program, Toronto, ON, Canada.
   [Thiruchelvam, Deva; Redelmeier, Donald A.] Inst Clin Evaluat Sci Ontario, Toronto, ON, Canada.
   [Redelmeier, Donald A.] Sunnybrook Hlth Sci Ctr, Div Gen Internal Med, Toronto, ON M4N 3M5, Canada.
C3 University of Toronto; University of Toronto; University of Toronto;
   Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook
   Health Science Center; University of Toronto; University of Toronto;
   Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook
   Health Science Center
RP Schlenker, MB (通讯作者)，Kensington Eye Inst, 340 Coll St,Suite 400, Toronto, ON M5T 3A9, Canada.
EM matt.schlenker@gmail.com
FU Canada Research Chair in Medical Decision Sciences; Canadian Institutes
   of Health Research; University of Toronto Postgraduate Medical Education
   Research Award
FX ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE
   OF POTENTIAL CONFLICTS OF INTEREST and none were reported.
   Funding/Support: D.A.R. is supported by a Canada Research Chair in
   Medical Decision Sciences and the Canadian Institutes of Health
   Research. M.B.S. is supported by a University of Toronto Postgraduate
   Medical Education Research Award. All authors attest that they meet the
   current ICMJE requirements to qualify as authors.
CR Al-Qureshi S, 2012, CLIN EXP OPHTHALMOL, V40, P3, DOI 10.1111/j.1442-9071.2011.02739.x
   [Anonymous], 2011, REP 2008 09 ONT STRO
   [Anonymous], HIGHL PRESCR INF US
   [Anonymous], 2003, GROWING BURDEN HEART
   [Anonymous], 2008, CIHI DAT QUAL STUD E
   Barnett AG, 2005, INT J EPIDEMIOL, V34, P215, DOI 10.1093/ije/dyh299
   Bell CM, 2009, JAMA-J AM MED ASSOC, V301, P1991, DOI 10.1001/jama.2009.683
   Box G.E.P., 2010, J TIME, V31, P303, DOI [10.1007/s11207-006-0076-7, DOI 10.1007/S11207-006-0076-7, 10.1002/9781118619193, DOI 10.1002/9781118619193]
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campbell RJ, 2012, OPHTHALMOLOGY, V119, P1604, DOI 10.1016/j.ophtha.2012.05.028
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Campbell RJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P359, DOI 10.1001/archophthalmol.2010.19
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Hoyert D. L., 2012, NATL VITAL STAT REPO, V61
   Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512
   Juurlink D., 2006, CANADIAN I HLTH INFO
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67
   Lim LS, 2011, AM J OPHTHALMOL, V152, P329, DOI 10.1016/j.ajo.2011.05.040
   MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996
   Meuleners LB, 2012, J AM GERIATR SOC, V60, P1730, DOI 10.1111/j.1532-5415.2012.04098.x
   Ng WY, 2015, AM J OPHTHALMOL, V159, P557, DOI 10.1016/j.ajo.2014.12.005
   Ontario Ministry of Finance, 2012, ONT POP PROJ UPD 201
   Rapoport MJ, 2011, AM J GERIAT PSYCHIAT, V19, P998, DOI 10.1097/JGP.0b013e31820d93f9
   Redelmeier DA, 2013, J CLIN EPIDEMIOL, V66, P955, DOI 10.1016/j.jclinepi.2013.05.003
   Redelmeier DA, 2012, NEW ENGL J MED, V367, P1228, DOI 10.1056/NEJMsa1114310
   Redelmeier DA, 2012, J CLIN EPIDEMIOL, V65, P467, DOI 10.1016/j.jclinepi.2011.09.007
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, NEW ENGL J MED, V364, P1966, DOI 10.1056/NEJMe1103334
   Schutz FAB, 2011, ANN ONCOL, V22, P1404, DOI 10.1093/annonc/mdq587
   Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tu Karen, 2007, Open Med, V1, pe18
   Ueta T, 2014, OPHTHALMOLOGY, V121, P2193, DOI 10.1016/j.ophtha.2014.05.022
   Varma R, 2012, OPHTHALMOLOGY, V119, P2108, DOI 10.1016/j.ophtha.2012.05.017
   Whyatt D, 2014, MED CARE, V52, P891, DOI 10.1097/MLR.0000000000000206
   Wilkins R., 2009, AUTOMATED GEOGRAPHIC
   Williams J., 1996, PATTERNS HLTH CARE O, P339
   Zhang XZ, 2013, JAMA OPHTHALMOL, V131, P573, DOI 10.1001/jamaophthalmol.2013.2597
NR 45
TC 23
Z9 23
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2015
VL 160
IS 3
BP 569
EP 580
DI 10.1016/j.ajo.2015.06.011
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP6AG
UT WOS:000359966100022
PM 26116264
DA 2022-11-30
ER

PT J
AU Downes, K
   Walker, LL
   Fletcher, DC
AF Downes, Ken
   Walker, Laura L.
   Fletcher, Donald C.
TI SKread predicts handwriting performance in patients with low vision
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID PREFERRED RETINAL LOCUS; MACULAR SCOTOMA; FIXATION; DISEASE
AB Objective: To assess whether performance on the Smith-Kettlewell Reading (SKread) test is a reliable predictor of handwriting performance in patients with low vision.
   Design: Cross-sectional study.
   Participants: Sixty-six patients at their initial low-vision rehabilitation evaluation.
   Methods: The patients completed all components of a routine low-vision appointment including logMAR acuity, performed the SKread test, and performed a handwriting task. Patients were timed while performing each task and their accuracy was recorded. The handwriting task was performed by having patients write 5 5-letter words into sets of boxes where each letter is separated by a box. The boxes were 15 x 15 mm, and accuracy was scored with 50 points possible from 25 letters: 1 point for each letter within the confines of a box and 1 point if the letter was legible. Correlation analysis was then performed.
   Results: Median age of participants was 84 (range 54-97) years. Fifty-seven patients (86%) had age-related macular degeneration or some other maculopathy, whereas 9 patients (14%) had visual impairment from media opacity or neurologic impairment. Median Early Treatment Diabetic Retinopathy Study acuity was 20/133 (range 20/22 to 20/1000), and median log MAR acuity was 0.82 (range 0.04-1.70). SKread errors per block correlated with logMAR acuity (r = 0.6), and SKread time per block correlated with logMAR acuity (r = 0.51). SKread errors per block correlated with handwriting task time/accuracy ratio (r = 0.61). SKread time per block correlated with handwriting task time/accuracy ratio (r = 0.7). LogMAR acuity score correlated with handwriting task time/accuracy ratio (r = 0.42). All p values were < 0.01.
   Conclusions: SKread scores predict handwriting performance in patients with low vision better than logMAR acuity.
C1 [Downes, Ken; Fletcher, Donald C.] Calif Pacific Med Ctr, Frank Stein & Paul S May Ctr Low Vis Rehabil, Dept Ophthalmol, San Francisco, CA 94115 USA.
   [Walker, Laura L.; Fletcher, Donald C.] Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA.
   [Walker, Laura L.; Fletcher, Donald C.] Envision Inc, Wichita, KS USA.
C3 California Pacific Medical Center; The Smith-Kettlewell Eye Research
   Institute
RP Fletcher, DC (通讯作者)，Calif Pacific Med Ctr, Frank Stein & Paul S May Ctr Low Vis Rehabil, 2340 Clay St,5th Floor, San Francisco, CA 94115 USA.
EM floridafletch@msn.com
FU Pacific Vision Foundation; Smith-Kettlewell Eye Research institute
FX This work was supported by The Pacific Vision Foundation and The
   Smith-Kettlewell Eye Research institute.
CR Crossland MD, 2011, RETINA-J RET VIT DIS, V31, P2109, DOI 10.1097/IAE.0b013e31820d3fba
   CUMMINGS RW, 1985, AM J OPTOM PHYS OPT, V62, P833
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   Fletcher Donald C, 2012, Optom Vis Sci, V89, P1395, DOI 10.1097/OPX.0b013e318264cc77
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   MacKeben M, OPTOM VIS S IN PRESS
   Schoessow KA, 2009, ENV C 2009 SAN ANT T
   Timberlake GT, 2013, OPTOMETRY VISION SCI, V90, P455, DOI 10.1097/OPX.0b013e31828e92eb
   Timberlake GT, 2011, INVEST OPHTH VIS SCI, V52, P2540, DOI 10.1167/iovs.10-6062
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Watson GR, 2004, J VISION IMPAIRMENT, V98, P160
   Weisser-Pike O., 2005, INT C SERIES, V1282, P331
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
NR 16
TC 0
Z9 0
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2015
VL 50
IS 3
BP 225
EP 229
DI 10.1016/j.jcjo.2015.02.002
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ5UD
UT WOS:000355555400013
PM 26040223
DA 2022-11-30
ER

PT J
AU Garcia, CAD
   Yehoshua, Z
   Gregori, G
   Farah, ME
   Feuer, W
   Rosenfeld, PJ
AF de Amorim Garcia Filho, Carlos Alexandre
   Yehoshua, Zohar
   Gregori, Giovanni
   Farah, Michel E.
   Feuer, William
   Rosenfeld, Philip J.
TI SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY IMAGING OF DRUSENOID
   PIGMENT EPITHELIAL DETACHMENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE spectral-domain optical coherence tomography; SD-OCT; age-related
   macular degeneration; AMD; retinal pigmented epithelial detachment; PED;
   drusenoid PED
ID MACULAR DEGENERATION; SEVERITY SCALE; CLASSIFICATION
AB Purpose: To evaluate drusenoid retinal pigment epithelial detachments (DPED) secondary to age-related macular degeneration (AMD) using spectral-domain optical coherence tomography imaging.
   Methods: In this prospective natural history study, eyes from patients with the diagnosis of nonexudative AMD and DPEDs were followed for at least 6 months. Eyes were scanned using the Cirrus spectral-domain optical coherence tomography instrument and the 200 x 200 A-scan raster pattern. A custom software was used to quantify volumetric changes in DPEDs and to detect the evolution and formation of geographic atrophy and choroidal neovascularization. Changes in DPED area and volume and development of the advanced forms of AMD were the main outcome.
   Results: Of the 130 patients (186 eyes) with nonadvanced AMD, 11 patients (16 eyes) presented with DPEDs during the study. Mean follow-up was 18.5 months. Most DPEDs had an area exceeding 1 disk area (14 of 16 eyes) based on color fundus images with a mean area of 4.19 mm(2) (SD = 1.35) measured by spectral-domain optical coherence tomography. The mean volume at the time the DPED was diagnosed was 0.48 mm(3) (SD = 0.28). Four different patterns of progression were observed: DPEDs remained unchanged in 8 of 16 eyes (50%), DPEDs tended to increase in volume before progressing to geographic atrophy in 5 eyes (31.25%) and choroidal neovascularization in 2 eyes (12.5%), and a DPED decreased by more than 50% without progressing to geographic atrophy or choroidal neovascularization in 1 eye (6.25%).
   Conclusion: Spectral-domain optical coherence tomography imaging is able to detect subtle changes in the area and volume of DPEDs. Quantitative spectral-domain optical coherence tomography imaging of DPEDs is useful for identifying the natural history of disease progression and as a clinical tool for monitoring eyes with AMD in clinical trials.
C1 [de Amorim Garcia Filho, Carlos Alexandre; Yehoshua, Zohar; Gregori, Giovanni; Feuer, William; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [de Amorim Garcia Filho, Carlos Alexandre; Farah, Michel E.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
C3 Bascom Palmer Eye Institute; University of Miami; Universidade Federal
   de Sao Paulo (UNIFESP)
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, Dept Ophthalmol, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Farah, Michel Eid E/F-3285-2012
OI Farah, Michel Eid E/0000-0001-5951-0193
FU Carl Zeiss Meditec, Inc, Dublin, CA; Research to Prevent Blindness, Inc;
   NEI core center [P30 EY014801]; Department of Defense (DOD)
   [W81XWH-09-1-0675]; Jerome A. Yavitz Charitable Foundation; Macula
   Vision Research Foundation; Feig Family Foundation; Gemcon Family
   Foundation; Carl and Lily Pforzheimer Foundation; Emma Clyde Hodge
   Memorial Foundation; Carl Zeiss Meditec, Inc.
FX Supported by a grant from Carl Zeiss Meditec, Inc, Dublin, CA, an
   unrestricted grant from Research to Prevent Blindness, Inc, NEI core
   center grant P30 EY014801 and Department of Defense
   (DOD-Grant#W81XWH-09-1-0675) to the University of Miami, the Jerome A.
   Yavitz Charitable Foundation, the Macula Vision Research Foundation,
   Feig Family Foundation, the Gemcon Family Foundation, the Carl and Lily
   Pforzheimer Foundation, and the Emma Clyde Hodge Memorial Foundation.;
   Drs. Garcia Filho, Yehoshua, Gregori, and Rosenfeld received research
   support from Carl Zeiss Meditec, Inc. G. Gregori coowns a patent that is
   licensed to Carl Zeiss Meditec, Inc. P. J. Rosenfeld has received
   honoraria for lectures from Carl Zeiss Meditec, Inc. W. Feuer and Dr. M.
   E. Farah has no financial or proprietary interest in the materials
   presented herein.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 14
TC 14
Z9 14
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2013
VL 33
IS 8
BP 1558
EP 1566
DI 10.1097/IAE.0b013e318285cbd2
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297CP
UT WOS:000330233200010
PM 23584692
DA 2022-11-30
ER

PT J
AU Wavre-Shapton, ST
   Tolmachova, T
   da Silva, ML
   Futter, CE
   Seabra, MC
AF Wavre-Shapton, Silene T.
   Tolmachova, Tanya
   da Silva, Mafalda Lopes
   Futter, Clare E.
   Seabra, Miguel C.
TI Conditional Ablation of the Choroideremia Gene Causes Age-Related
   Changes in Mouse Retinal Pigment Epithelium
SO PLOS ONE
LA English
DT Article
ID MACULAR DEGENERATION; RAB GTPASES; MODELS; RPE; PHAGOSOMES; PROTEOME;
   DISEASE; CELLS
AB The retinal pigment epithelium (RPE) is a pigmented monolayer of cells lying between the photoreceptors and a layer of fenestrated capillaries, the choriocapillaris. Choroideremia (CHM) is an X-linked progressive degeneration of these three layers caused by the loss of function of Rab Escort protein-1 (REP1). REP1 is involved in the prenylation of Rab proteins, key regulators of membrane trafficking. To study the pathological consequences of chronic disruption of membrane traffic in the RPE we used a cell type-specific knock-out mouse model of the disease, where the Chm/Rep1 gene is deleted only in pigmented cells (Chm(Flox), Tyr-Cre+). Transmission electron microscopy (TEM) was used to quantitate the melanosome distribution in the RPE and immunofluorescent staining of rhodopsin was used to quantitate phagocytosed rod outer segments in retinal sections. The ultrastructure of the RPE and Bruch's membrane at different ages was characterised by TEM to analyse age-related changes occurring as a result of defects in membrane traffic pathways. Chm/Rep1 gene knockout in RPE cells resulted in reduced numbers of melanosomes in the apical processes and delayed phagosome degradation. In addition, the RPE accumulated pathological changes at 5-6 months of age similar to those observed in 2-year old controls. These included the intracellular accumulation of lipofuscin-containing deposits, disorganised basal infoldings and the extracellular accumulation of basal laminar and basal linear deposits. The phenotype of the Chm(Flox), Tyr-Cre+ mice suggests that loss of the Chm/Rep1 gene causes premature accumulation of features of aging in the RPE. Furthermore, the striking similarities between the present observations and some of the phenotypes reported in age-related macular degeneration (AMD) suggest that membrane traffic defects may contribute to the pathogenesis of AMD.
C1 [Wavre-Shapton, Silene T.; Tolmachova, Tanya; da Silva, Mafalda Lopes; Seabra, Miguel C.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Mol Med Sect, London, England.
   [Wavre-Shapton, Silene T.; da Silva, Mafalda Lopes; Futter, Clare E.] UCL, UCL Inst Ophthalmol, London, England.
   [Seabra, Miguel C.] Univ Nova Lisboa, Fac Ciencias Med, CEDOC, P-1200 Lisbon, Portugal.
   [Seabra, Miguel C.] Inst Gulbenkian Ciencias, Oeiras, Portugal.
C3 Imperial College London; University of London; University College
   London; Universidade Nova de Lisboa; Instituto Gulbenkian de Ciencia
RP Futter, CE (通讯作者)，UCL, UCL Inst Ophthalmol, London, England.
EM c.futter@ucl.ac.uk; m.seabra@imperial.ac.uk
RI Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019
OI Seabra, Miguel C/0000-0002-6404-4892; Futter, Clare/0000-0001-5559-9389;
   Lopes da Silva, Mafalda/0000-0001-7651-8656; Tolmachova,
   Tanya/0000-0002-8841-0797
FU Medical Research Council; Wellcome trust; Medical Research Council
   [G0700778] Funding Source: researchfish; Fight for Sight [1936/38]
   Funding Source: researchfish; MRC [G0700778] Funding Source: UKRI
FX Funding came from the Medical Research Council (http://www.mrc.ac.uk)
   and the Wellcome trust (http://www.wellcome.ac.uk/). The authors also
   acknowledge contribution from Choroideremia Research Foundation
   Inc.(http://choroideremia.org/) and Tommy Salisbury fund
   (http://www.fightforsight.org.uk/tommysalisburyfund). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Bonilha VL, 2008, OPHTHALMIC GENET, V29, P99, DOI 10.1080/13816810802206499
   CREMERS FPM, 1994, J BIOL CHEM, V269, P2111
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Futter CE, 2004, MOL BIOL CELL, V15, P2264, DOI 10.1091/mbc.E03-10-0772
   Gibbs D, 2004, J CELL SCI, V117, P6473, DOI 10.1242/jcs.01580
   Gordiyenko NV, 2009, INVEST OPHTH VIS SCI, V51, P1143
   Guymer RH, 2004, INVEST OPHTH VIS SCI, V45, P1660, DOI 10.1167/iovs.03-0913
   Harrison RE, 2003, MOL CELL BIOL, V23, P6494, DOI 10.1128/MCB.23.18.6494-6506.2003
   Knupp C, 2002, J STRUCT BIOL, V139, P181, DOI 10.1016/S1047-8477(02)00534-8
   Knupp C, 2002, J STRUCT BIOL, V137, P31, DOI 10.1006/jsbi.2002.4449
   MISHIMA H, 1978, A GRAEF ARCH KLIN EX, V209, P1, DOI 10.1007/BF00419157
   MISHIMA H, 1981, EXP EYE RES, V33, P75, DOI 10.1016/S0014-4835(81)80083-8
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   Reale E, 2001, MATRIX BIOL, V20, P37, DOI 10.1016/S0945-053X(00)00132-3
   Roberts EA, 2006, J CELL BIOL, V174, P923, DOI 10.1083/jcb.200603026
   Rogers LD, 2007, P NATL ACAD SCI USA, V104, P18520, DOI 10.1073/pnas.0705801104
   Seabra MC, 2002, TRENDS MOL MED, V8, P23, DOI 10.1016/S1471-4914(01)02227-4
   SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420
   Smith AC, 2007, J CELL BIOL, V176, P263, DOI 10.1083/jcb.200611056
   Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728
   Strunnikova NV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008402
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tolmachova T, 2006, J CLIN INVEST, V116, P386, DOI 10.1172/JCI26617
   Tolmachova T, 2010, INVEST OPHTH VIS SCI, V51, P4913, DOI 10.1167/iovs.09-4892
   Vieira OV, 2003, MOL CELL BIOL, V23, P2501, DOI 10.1128/MCB.23.7.2501-2514.2003
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
NR 28
TC 40
Z9 40
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2013
VL 8
IS 2
AR e57769
DI 10.1371/journal.pone.0057769
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 098BN
UT WOS:000315519000159
PM 23460904
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Keenan, TDL
   Wotton, CJ
   Goldacre, MJ
AF Keenan, Tiarnan D. L.
   Wotton, Clare J.
   Goldacre, Michael J.
TI Trends over time and geographical variation in rates of intravitreal
   injections in England
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; VISUAL IMPAIRMENT; BEVACIZUMAB; RANIBIZUMAB;
   POPULATION; PREVALENCE; VISION; ADULTS; IMPACT; DRUG
AB Aims The recent emergence of antivascular endothelial growth factor (anti-VEGF) drugs has led to increased numbers of patients undergoing intravitreal injection for age-related macular degeneration (AMD). The aims of this study were to report on trends over time and geographical variation in intravitreal injection rates in England, and consider the implications for publicly funded health services of introducing new and expensive treatments.
   Methods Hospital episode statistics were analysed for annual treatment rates of intravitreal injection between the NHS financial years of 1989/1990 and 2008/1999.
   Results Annual injection rates increased from 0.4 episodes (95% CI 0.37 to 0.49) per 100 000 population in 1989/1990 to 10.7 (10.4-11.0) in 2006/2007. Rates then rose exponentially to 59.5 (58.8-60.2) in 2008/2009, with increasing use of multiple injections per person. The largest growth in injection rates was found in older people, and for AMD. Numbers of treatment episodes increased from 203 (1989/1990) to 30 458 (2008/2009). Geographical analysis showed a very wide variation across local authority areas in injection rates, from 0.9 (0.2-2.2) to 42.2 (38.9-45.7) people per 100 000 population in 2005-2008.
   Conclusion Rates of intravitreal injection increased exponentially from 2006/2007. This followed the US Food and Drug Association licensing of ranibizumab for the treatment of neovascular AMD (2006), and its recommendation by National Institute for Health and Clinical Excellence (2008). This study demonstrates some of the major issues which arise with the emergence of expensive new treatments, including speed and cost of adoption, geographical variation in access, and implications for licensing, commissioning and health financing in an ageing society.
C1 [Keenan, Tiarnan D. L.] Manchester Royal Eye Hosp, Manchester M13 9WL, Lancs, England.
   [Keenan, Tiarnan D. L.] Univ Manchester, Fac Med & Human Sci, Sch Biomed, Manchester, Lancs, England.
   [Wotton, Clare J.; Goldacre, Michael J.] Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford, England.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Oxford
RP Keenan, TDL (通讯作者)，Manchester Royal Eye Hosp, Oxford Rd, Manchester M13 9WL, Lancs, England.
EM tiarnan.keenan@doctors.org.uk
RI Wotton, Clare J/L-8863-2018; Wotton, Clare/L-8863-2018
OI Wotton, Clare J/0000-0002-7173-1009; Wotton, Clare/0000-0002-5753-907X
FU Fight For Sight; English National Institute for Health Research; Fight
   for Sight [1865/66] Funding Source: researchfish
FX Geographical atlases of surgical rates were produced using data provided
   through EDINA UKBORDERS with the support of the Economic and Social
   Research Council and the Joint Information Systemic Committee, together
   with boundary material which is copyright of the Crown. Record linkage
   was undertaken on the English national dataset by the Oxford Record
   Linkage Study team.; TDLK is funded by Fight For Sight through a
   Clinical Fellowship. The Unit of HealthCare Epidemiology is funded to
   undertake research on the regional and national hospital databases by
   the English National Institute for Health Research.
CR Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Campbell RJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P359, DOI 10.1001/archophthalmol.2010.19
   Clinical Trials and Evaluation Unit (CTEU), 2009, ALT TREATM INH VEGF
   Coleman AL, 2010, AM J OPHTHALMOL, V150, P683, DOI 10.1016/j.ajo.2010.05.030
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Fletcher A, 2001, LOW VISION SERVICES
   Hawkes N, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d62
   IDEM, 2006, AV OPHTH GLOB PHEN C, V1
   Keenan TDL, 2009, EYE, V23, P1141, DOI 10.1038/eye.2008.195
   Keenan TDL, 2011, BRIT J OPHTHALMOL, V95, P468, DOI 10.1136/bjo.2010.182329
   Kernt M, 2010, CLIN OPHTHALMOL, V4, P121
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   National Institute for Health and Clinical Excellence, 2010, BEV EYE COND PRESC W
   National Institute for Health and Clinical Excellence, 2008, RAN PEG TREATM AG RE
   Noble M, 2004, INDEX MULTIPLE DEPRI
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Ramulu PY, 2010, ARCH OPHTHALMOL-CHIC, V128, P1335, DOI 10.1001/archophthalmol.2010.224
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Royal College of Ophthalmology statement, 2009, MAX CAP AMD SERV
   Shelsta HN, 2011, RETINA-J RET VIT DIS, V31, P4, DOI 10.1097/IAE.0b013e3181fd9740
   Smith AF, 2010, BRIT J OPHTHALMOL, V94, P1116, DOI 10.1136/bjo.2010.179945
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   The Royal College of Ophthalmologists, 2007, COMM CONT AMD SERV G
   The Royal College of Ophthalmologists, 2010, INT GUID MAN RET VEI
   The Royal College of Ophthalmologists, 2009, US BEV AV AG REL MAC
   Tufail A, 2010, BMJ-BRIT MED J, V340, pc2459
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Ziemssen F, 2009, DRUG AGING, V26, P295, DOI 10.2165/00002512-200926040-00002
NR 33
TC 39
Z9 39
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2012
VL 96
IS 3
BP 413
EP 418
DI 10.1136/bjophthalmol-2011-300338
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 896XO
UT WOS:000300604900023
PM 21875871
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Vidro-Kotchan, E
   Yendluri, BB
   Le-Thai, T
   Tsin, A
AF Vidro-Kotchan, Eileen
   Yendluri, Bharat Bhushan
   Le-Thai, Terrie
   Tsin, Andrew
TI NBHA Reduces Acrolein-Induced Changes in ARPE-19 Cells: Possible
   Involvement of TGF beta
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Acrolein; Age-related macular degeneration; Retinal pigment epithelium;
   TGF beta; VEGF
ID PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; MILD COGNITIVE
   IMPAIRMENT; INDUCED-OXIDATIVE STRESS; T-BUTYL HYDROXYLAMINE;
   LIPID-PEROXIDATION; MACULAR DEGENERATION; PROTEIN MODIFICATIONS;
   CIGARETTE-SMOKE; EXPRESSION
AB Purpose: Acrolein, a toxic, reactive aldehyde formed metabolically and environmentally, has been implicated in the damage to and dysfunction of the retinal pigment epithelium (RPE) that accompanies age-related macular degeneration (AMD). Our purpose was to investigate the potential of acrolein to influence the release of transforming growth factor beta-2 (TGF beta 2) and vascular endothelial growth factor (VEGF), to assess the ability of N-benzylhydroxylamine (NBHA) to prevent the effect of acrolein on cytokine release and reduction of viable cells, and to explore the pathway by which acrolein might be causing the increase of VEGF.
   Materials and Methods: Confluent ARPE-19 cells were treated with acrolein and/or NBHA. They were also pretreated with SIS3, a specific inhibitor of SMAD 3, and ZM39923, a JAK3 inhibitor, before being treated with acrolein. Viable cells were counted; ELISA was used to measure the TGF beta 2 and/or VEGF in the conditioned media.
   Results: Acrolein was shown to reduce the number of viable ARPE-19 cells and to upregulate the release of the proangiogenic cytokines TGF beta 2 and VEGF. Co-treatment with 200 mu M NBHA significantly reduced the effects of acrolein on viable cell number and TGF beta 2 release. Pretreatment of the cells with SIS3 partially blocked the action of acrolein on decreased viable cell number and VEGF upregulation, suggesting that part of the effects of acrolein are mediated by the increased levels of TGF beta and its signaling.
   Conclusions: Our results suggest that the action of acrolein on the reduction of viability and VEGF increase by ARPE-19 cells is partially mediated by TGF beta 2. By reducing the effects of acrolein, NBHA and SIS3 could be potential pharmacological agents in the prevention and progression of acrolein-induced damage to the RPE that relates to AMD.
C1 [Vidro-Kotchan, Eileen; Yendluri, Bharat Bhushan; Le-Thai, Terrie; Tsin, Andrew] Univ Texas San Antonio, San Antonio, TX 78249 USA.
C3 University of Texas System; University of Texas at San Antonio (UTSA)
RP Tsin, A (通讯作者)，Univ Texas San Antonio, 1 UTSA Circle, San Antonio, TX 78249 USA.
EM Andrew.tsin@utsa.edu
FU Kronkosky Charitable Foundation; San Antonio Neuroscience Alliance, San
   Antonio Life Sciences Institute; Semp Russ Foundation of the San Antonio
   Area Foundation; NEI; NIH [GM08194]; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCES [S06GM008194] Funding Source: NIH RePORTER
FX The authors wish to thank the Kronkosky Charitable Foundation, the San
   Antonio Neuroscience Alliance, San Antonio Life Sciences Institute, the
   Semp Russ Foundation of the San Antonio Area Foundation, STTM and CRSGP
   grants, the NEI, and the NIH Score Grant (GM08194) for their generous
   support of our work. We also wish to thank Brandi Betts, Ruby Ortiz, and
   Thomas Barron for their technical assistance; Brian Yust and Drs. Terri
   Krakower, Will Haskins, and Jeff Grigsby for their critical review of
   this manuscript.
CR Atamna H, 2000, J BIOL CHEM, V275, P6741, DOI 10.1074/jbc.275.10.6741
   Ayalasomayajula SP, 2002, EUR J PHARMACOL, V449, P213, DOI 10.1016/S0014-2999(02)02043-5
   Batista CKLP, 2006, BRAZ J MED BIOL RES, V39, P1475
   Bazan NG, 2006, ADV EXP MED BIOL, V572, P531
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Bondi CD, 2010, J AM SOC NEPHROL, V21, P93, DOI 10.1681/ASN.2009020146
   Burcham PC, 2002, TOXICOLOGY, V181, P229, DOI 10.1016/S0300-483X(02)00287-1
   Carmella SG, 2007, CHEM RES TOXICOL, V20, P986, DOI 10.1021/tx700075y
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Cong GH, 2010, CHEM-BIOL INTERACT, V184, P366, DOI 10.1016/j.cbi.2010.02.005
   CROSS CE, 1993, ANN NY ACAD SCI, V686, P72, DOI 10.1111/j.1749-6632.1993.tb39157.x
   Cross CE, 1993, ANN NY ACAD SCI, V686, P89
   Ferrara N, 2000, RECENT PROG HORM RES, V55, P15
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Frippiat C, 2002, FREE RADICAL BIO MED, V33, P1334, DOI 10.1016/S0891-5849(02)01044-4
   Frippiat C, 2001, J BIOL CHEM, V276, P2531, DOI 10.1074/jbc.M006809200
   Heimsath EG, 2006, CURR EYE RES, V31, P1073, DOI 10.1080/02713680601052320
   Hipkiss AR, 2001, MECH AGEING DEV, V122, P169, DOI 10.1016/S0047-6374(00)00231-1
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483
   Joshi-Barve S, 2009, FREE RADICAL BIO MED, V47, P47, DOI 10.1016/j.freeradbiomed.2009.03.021
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kapphahn RJ, 2006, EXP EYE RES, V83, P165, DOI 10.1016/j.exer.2005.11.017
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kopitz J, 2004, BIOCHIMIE, V86, P825, DOI 10.1016/j.biochi.2004.09.029
   Krejsgaard T, 2006, LEUKEMIA, V20, P1759, DOI 10.1038/sj.leu.2404350
   Kuksa V, 2003, VISION RES, V43, P2959, DOI 10.1016/S0042-6989(03)00482-6
   Kwolek-Mirek M, 2009, CELL BIOL TOXICOL, V25, P363, DOI 10.1007/s10565-008-9090-x
   Lange C, 2010, ADV EXP MED BIOL, V664, P601, DOI 10.1007/978-1-4419-1399-9_69
   Lee JH, 2004, CARCINOGENESIS, V25, P1435, DOI 10.1093/carcin/bgh139
   Lee S C, 1999, Korean J Ophthalmol, V13, P16
   Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483
   Liu ZB, 2007, J NEUROCHEM, V103, P2690, DOI 10.1111/j.1471-4159.2007.04954.x
   Lovell MA, 2007, NUCLEIC ACIDS RES, V35, P7497, DOI 10.1093/nar/gkm821
   Luna JD, 1997, J NEUROSCI RES, V49, P268, DOI 10.1002/(SICI)1097-4547(19970801)49:3<268::AID-JNR2>3.0.CO;2-A
   Lykkesfeldt J, 2000, AM J CLIN NUTR, V71, P530
   MUETHER PS, 2010, GRAEFES ARCH CLIN EX
   Nagineni CN, 2007, J CELL PHYSIOL, V210, P192, DOI 10.1002/jcp.20839
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nguyen E, 2003, BBA-MOL BASIS DIS, V1637, P107, DOI 10.1016/S0925-4439(02)00220-X
   ONEILL CA, 1994, J LAB CLIN MED, V124, P359
   Pan J, 2002, CHEM RES TOXICOL, V15, P367, DOI 10.1021/tx010136q
   Pan J, 2009, CHEM RES TOXICOL, V22, P798, DOI 10.1021/tx800355k
   Park YS, 2008, ANN NY ACAD SCI, V1126, P185, DOI 10.1196/annals.1433.034
   PFEFFER BA, 1994, EXP EYE RES, V59, P323, DOI 10.1006/exer.1994.1114
   RADU RA, 2010, COMPLEMENT SYSTEM DY
   Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156
   Saiki R, 2009, STROKE, V40, P3356, DOI 10.1161/STROKEAHA.109.553248
   Sakata K, 2003, BIOCHEM BIOPH RES CO, V305, P143, DOI 10.1016/S0006-291X(03)00716-2
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Sheu SJ, 2010, J OCUL PHARMACOL TH, V26, P231, DOI 10.1089/jop.2009.0137
   Stevens JF, 2008, MOL NUTR FOOD RES, V52, P7, DOI 10.1002/mnfr.200700412
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tomitori H, 2005, STROKE, V36, P2609, DOI 10.1161/01.STR.0000190004.36793.2d
   UNDA R, 2003, UNPUB
   Vidro EK, 2008, CURR EYE RES, V33, P984, DOI 10.1080/02713680802450976
   Vogt RR, 2006, J CELL BIOCHEM, V98, P1196, DOI 10.1002/jcb.20831
   Voloboueva LA, 2005, INVEST OPHTH VIS SCI, V46, P4302, DOI 10.1167/iovs.04-1098
   Williams TI, 2006, NEUROBIOL AGING, V27, P1094, DOI 10.1016/j.neurobiolaging.2005.06.004
   Wood PL, 2006, BRAIN RES, V1095, P190, DOI 10.1016/j.brainres.2006.04.038
   Woodruff TJ, 2007, ENVIRON HEALTH PERSP, V115, P410, DOI 10.1289/ehp.9467
   Yoshida M, 2009, BIOCHEM BIOPH RES CO, V378, P313, DOI 10.1016/j.bbrc.2008.11.054
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 71
TC 8
Z9 8
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD APR
PY 2011
VL 36
IS 4
BP 370
EP 378
DI 10.3109/02713683.2010.549601
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 735BW
UT WOS:000288389400012
PM 21309688
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Rohrschneider, K
   Bultmann, S
   Springer, C
AF Rohrschneider, Klaus
   Bueltmann, Stefan
   Springer, Christina
TI Use of fundus perimetry (microperimetry) to quantify macular sensitivity
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPE; DIFFERENTIAL LIGHT THRESHOLD; PREFERRED
   RETINAL LOCI; GEOGRAPHIC ATROPHY; VISUAL FUNCTION; FIXATION STABILITY;
   HOLE SURGERY; SCOTOMAS; VISION; AMD
AB The advances in retinal imaging technologies have led to enormous innovation towards diagnostic in current ophthalmology, enabling the practitioner to detect early retinal changes and to document treatment effects. While, in the past, retinoscopy, visual acuity testing and perimetry played the major role in functional diagnostics, today, laser-based systems like laser scanning imaging systems especially for fluorescein-angiography, optical coherence tomography, electrodiagnostic systems and the analysis of retinal vessels may be used as well. However, the challenge to correlate subjective alterations or clinical changes with visual function, still remains. Micro- or fundus perimetry offers the option to test retinal sensitivity while directly observing the fundus.
   In this paper, we review the literature encompassing the results of more than 25 years of fundus perimetry, i.e. perimetry under simultaneous visualization of the fundus. During this time, results on known diseases and reproducibility of the technique were published, but a lot of work was also performed on the combination of different examination methods, allowing a synopsis of long-term results and new approaches by combining different methods and improving each of them.
   The first part of this review attends to improvements of the method. The second part addresses the clinical and diagnostic values. The final part is dedicated to diagnostic and long-term observation of fundus perimetric results beginning with common and rare diseases like age-related macular degeneration, macular holes and diabetic retinopathy, various types of macular dystrophies ending with challenges in conventional perimetry like glaucoma and malingering.
   Due to the experience and progress in the field of fundus perimetry and retinal imaging, the method has long passed its role of observing and has all the potential for prediction, early detection and treatment-monitoring of macular diseases. (c) 2008 Elsevier Ltd. All rights reserved.
C1 [Rohrschneider, Klaus; Bueltmann, Stefan; Springer, Christina] Heidelberg Univ, Dept Ophthalmol, D-69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP Rohrschneider, K (通讯作者)，Heidelberg Univ, Dept Ophthalmol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
EM kr@uni-hd.de
OI Rohrschneider, Klaus/0000-0003-1996-7935
FU Deutsche Forschungsgemeinschaft [DFG Ro 973/11-1, Ro 973/11-2]
FX Supported in part by Deutsche Forschungsgemeinschaft DFG Ro 973/11-1 and
   Ro 973/11-2.
CR ACOSTA F, 1991, OPHTHALMOLOGY, V98, P1820
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   *AM NAT STAND I, 2000, AM NAT STAND SAF US
   Andersen IVN, 1996, ACTA OPHTHALMOL SCAN, V74, P135
   Anderson D.R., 1987, PERIMETRY AUTOMATION
   [Anonymous], 1995, Arch Ophthalmol, V113, P1144
   BULTMANN S, 1998, OPHTHALMIC RES, V30, P79
   CHEN FK, 2008, INVESTIG OPHTHALMOL
   Convento E, 2006, PERIMETRY FUNDUS INT, P229
   CRONE RA, 1975, OPHTHALMOLOGICA, V171, P51, DOI 10.1159/000307429
   CULHAM LE, 1992, OPHTHAL PHYSL OPT, V12, P281, DOI 10.1111/j.1475-1313.1992.tb00398.x
   Deruaz Anouk, 2006, BMC Ophthalmol, V6, P35, DOI 10.1186/1471-2415-6-35
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   ENOCH JM, 1978, INVEST OPHTH VIS SCI, V17, P208
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   FLECKENSTEIN M, 2008, EYE
   Fletcher D. C., 1994, OPHTHALMOLOGY CLIN N, V7, P257
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   GOODRICH GL, 1986, AM J OPTOM PHYS OPT, V63, P119
   GRAEFE AV, 1856, ARCH OPHTHALMOL-CHIC, P258
   Guez JE, 1998, OPHTHALMOLOGY, V105, P694, DOI 10.1016/S0161-6420(98)94026-X
   HAEFLIGER IO, 1989, AM J OPHTHALMOL, V107, P417, DOI 10.1016/0002-9394(89)90667-3
   HAEFLIGER IO, 1991, OPHTHALMOLOGY, V98, P1529
   Haritoglou C, 2002, AM J OPHTHALMOL, V134, P661, DOI 10.1016/S0002-9394(02)01751-8
   Haritoglou C, 2001, BRIT J OPHTHALMOL, V85, P231, DOI 10.1136/bjo.85.2.231
   Hikichi T, 2000, ARCH OPHTHALMOL-CHIC, V118, P193
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Ishiko S, 1998, OPHTHALMIC SURG LAS, V29, P95
   Jarc-Vidmar M, 2006, EYE, V20, P688, DOI 10.1038/sj.eye.6701949
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   KANI K, 1978, DOC OPHTHALMOL P SER, V19, P341
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P84, DOI 10.1136/bjo.2007.124016
   Kristin N, 2001, OPHTHALMOLOGE, V98, P1060, DOI 10.1007/s003470170025
   Kube T, 2005, OPHTHALMOLOGICA, V219, P16, DOI 10.1159/000081777
   Meyer JH, 1997, BRIT J OPHTHALMOL, V81, P355, DOI 10.1136/bjo.81.5.355
   Midena E, 2007, EUR J OPHTHALMOL, V17, P63, DOI 10.1177/112067210701700109
   MIDENA E, 2006, INVESTIG OPHTHALMOL, V47
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Muller S, 2000, OPHTHALMOLOGE, V97, P142, DOI 10.1007/s003470050024
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   NOBLE KG, 1979, ARCH OPHTHALMOL-CHIC, V97, P1281
   Okada K, 2006, EYE, V20, P805, DOI 10.1038/sj.eye.6702014
   Orzalesi N, 1998, VISION RES, V38, P763, DOI 10.1016/S0042-6989(97)00171-5
   Oshima Y, 1998, RETINA-J RET VIT DIS, V18, P109, DOI 10.1097/00006982-199818020-00003
   Ozdemir H, 2008, EYE, V22, P204, DOI 10.1038/sj.eye.6702563
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Richter-Mueksch S, 2007, AM J OPHTHALMOL, V144, P23, DOI 10.1016/j.ajo.2007.03.045
   Riss-Jayle M, 2008, J FR OPHTALMOL, V31, P379, DOI 10.1016/S0181-5512(08)71432-3
   Rohrschneider K, 1998, AM J OPHTHALMOL, V126, P52, DOI 10.1016/S0002-9394(98)00065-8
   Rohrschneider K, 1997, BRIT J OPHTHALMOL, V81, P568, DOI 10.1136/bjo.81.7.568
   Rohrschneider K, 2005, AM J OPHTHALMOL, V139, P125, DOI 10.1016/j.ajo.2004.08.060
   ROHRSCHNEIDER K, 1995, GRAEF ARCH CLIN EXP, V233, P743, DOI 10.1007/BF00184084
   ROHRSCHNEIDER K, 1995, INVEST OPHTH VIS SCI, V36, pS232
   Rohrschneider K, 1997, OPHTHALMOLOGE, V94, P624, DOI 10.1007/s003470050171
   Rohrschneider K, 2001, OPHTHALMOLOGE, V98, P3, DOI 10.1007/s003470170193
   Rohrschneider K, 1998, RETINA-J RET VIT DIS, V18, P453
   ROHRSCHNEIDER K, 1995, KLIN MONATSBL AUGENH, V207, P102, DOI 10.1055/s-2008-1035356
   Rohrschneider K, 1995, Ger J Ophthalmol, V4, P197
   Rohrschneider K, 2000, AM J OPHTHALMOL, V129, P27, DOI 10.1016/S0002-9394(99)00270-6
   ROHRSCHNEIDER K, 2006, PERIMETRY FUNDUS INT, P215
   Rohrschneider K, 1999, PERIMETRY UPDATE 199, P453
   Rohrschneider Klaus, 2001, International Ophthalmology, V24, P177, DOI 10.1023/A:1022536322766
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Schuchard RA, 1999, J REHABIL RES DEV, V36, P294
   SCHUCHARD RA, 1994, OPHTHALMOLOGY CLIN N, V7, P243
   SJAARDA RN, 1993, OPHTHALMOLOGY, V100, P1513
   SJAARDA RN, 1993, AM J OPHTHALMOL, V116, P129, DOI 10.1016/S0002-9394(14)71276-0
   Small KW, 1999, MOL VIS, V5
   Springer C, 2007, OPHTHALMOLOGE, V104, P474, DOI 10.1007/s00347-007-1538-5
   Springer C, 2006, OPHTHALMOLOGE, V103, P791, DOI 10.1007/s00347-006-1396-6
   SPRINGER C, 2008, INVESTIG OPHTHALMOL, V49
   SPRINGER C, 2005, INVESTIG OPHTHALMOL, V46
   SPRINGER C, 2006, PERIMETRY FUNDUS INT, P27
   STEIGER R M, 1955, Ophthalmologica, V129, P240
   SUNNESS JS, 1995, AM J OPHTHALMOL, V119, P143, DOI 10.1016/S0002-9394(14)73866-8
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, pS232
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Szlyk JP, 2005, RETINA-J RET VIT DIS, V25, P489, DOI 10.1097/00006982-200506000-00015
   TIMBERLAKE GT, 1982, INVEST OPHTH VIS SCI, V22, P91
   Toonen F., 1996, Investigative Ophthalmology and Visual Science, V37, pS974
   TREUMER F, 2006, BR J OPHTHALMOL
   Varano M, 1998, Semin Ophthalmol, V13, P203, DOI 10.3109/08820539809056054
   VONNOORDEN GK, 1959, AM J OPHTHALMOL, V48, P511, DOI 10.1016/0002-9394(59)90887-6
   Vujosevic S, 2006, INVEST OPHTH VIS SCI, V47, P3044, DOI 10.1167/iovs.05-1141
   Watson GR, 2006, J REHABIL RES DEV, V43, P761, DOI 10.1682/JRRD.2005.07.0120
   WEBB RH, 1981, IEEE T BIO-MED ENG, V28, P488, DOI 10.1109/TBME.1981.324734
   Wirbelauer C, 2001, OPHTHALMOLOGE, V98, P151, DOI 10.1007/s003470170176
   WOLF S, 1994, INVEST OPHTH VIS SCI, V35, P1504
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
NR 95
TC 154
Z9 161
U1 0
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2008
VL 27
IS 5
BP 536
EP 548
DI 10.1016/j.preteyeres.2008.07.003
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 373AF
UT WOS:000260942700003
PM 18723109
DA 2022-11-30
ER

PT J
AU Houssier, M
   Raoul, W
   Lavalette, S
   Keller, N
   Guillonneau, X
   Baragatti, B
   Jonet, L
   Jeanny, JC
   Behar-Cohen, F
   Coceani, F
   Scherman, D
   Lachapelle, P
   Ong, H
   Chemtob, S
   Sennlaub, F
AF Houssier, Marianne
   Raoul, William
   Lavalette, Sophie
   Keller, Nicole
   Guillonneau, Xavier
   Baragatti, Barbara
   Jonet, Laurent
   Jeanny, Jean-Claude
   Behar-Cohen, Francine
   Coceani, Flavio
   Scherman, Daniel
   Lachapelle, Pierre
   Ong, Huy
   Chemtob, Sylvain
   Sennlaub, Florian
TI CD36 deficiency leads to choroidal involution via COX2 down-regulation
   in rodents
SO PLOS MEDICINE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ROD OUTER SEGMENTS; CYCLOOXYGENASE-2
   GENE-EXPRESSION; MACULAR DEGENERATION; HYPERTENSIVE-RATS; FATTY-ACID;
   RCS RAT; PHAGOCYTOSIS; CELLS; NEOVASCULARIZATION
AB Background
   In the Western world, a major cause of blindness is age-related macular degeneration (AMD). Recent research in angiogenesis has furthered the understanding of choroidal neovascularization, which occurs in the ''wet'' form of AMD. In contrast, very little is known about the mechanisms of the predominant, ''dry'' form of AMD, which is characterized by retinal atrophy and choroidal involution. The aim of this study is to elucidate the possible implication of the scavenger receptor CD36 in retinal degeneration and choroidal involution, the cardinal features of the dry form of AMD.
   Methods and Findings
   We here show that deficiency of CD36, which participates in outer segment ( OS) phagocytosis by the retinal pigment epithelium (RPE) in vitro, leads to significant progressive age-related photoreceptor degeneration evaluated histologically at different ages in two rodent models of CD36 invalidation in vivo ( Spontaneous hypertensive rats (SHR) and CD36(-/-) mice). Furthermore, these animals developed significant age related choroidal involution reflected in a 100%-300% increase in the avascular area of the choriocapillaries measured on vascular corrosion casts of aged animals. We also show that proangiogenic COX2 expression in RPE is stimulated by CD36 activating antibody and that CD36-deficient RPE cells from SHR rats fail to induce COX2 and subsequent vascular endothelial growth factor ( VEGF) expression upon OS or antibody stimulation in vitro. CD36(-/-) mice express reduced levels of COX2 and VEGF in vivo, and COX2(-/-) mice develop progressive choroidal degeneration similar to what is seen in CD36 deficiency.
   Conclusions
   CD36 deficiency leads to choroidal involution via COX2 down-regulation in the RPE. These results show a novel molecular mechanism of choroidal degeneration, a key feature of dry AMD. These findings unveil a pathogenic process, to our knowledge previously undescribed, with important implications for the development of new therapies.
C1 [Houssier, Marianne; Raoul, William; Lavalette, Sophie; Keller, Nicole; Jonet, Laurent; Jeanny, Jean-Claude; Behar-Cohen, Francine; Sennlaub, Florian] Inst Natl Sante & Rech Med, U872, Paris, France.
   [Houssier, Marianne; Raoul, William; Lavalette, Sophie; Keller, Nicole; Jonet, Laurent; Jeanny, Jean-Claude; Behar-Cohen, Francine; Sennlaub, Florian] Univ Paris 06, Ctr Rech Cordeliers, Paris, France.
   [Houssier, Marianne; Raoul, William; Lavalette, Sophie; Keller, Nicole; Jonet, Laurent; Jeanny, Jean-Claude; Behar-Cohen, Francine; Sennlaub, Florian] Univ Paris 05, UMR S 872, Paris, France.
   [Guillonneau, Xavier] Inst Natl Sante & Rech Med, U592, Paris, France.
   [Guillonneau, Xavier] Univ Paris 06, UMR 592, Paris, France.
   [Baragatti, Barbara; Coceani, Flavio] Scuola Super Sant Anna, Pisa, Italy.
   [Baragatti, Barbara; Coceani, Flavio] CNR, Inst Clin Physiol, I-56100 Pisa, Italy.
   [Behar-Cohen, Francine; Scherman, Daniel] Univ Paris 05, Ctr Natl Rech Sci, Inst Natl Sante Rech Med, U640,UMR 8151, Paris, France.
   [Lachapelle, Pierre; Chemtob, Sylvain] Hop Ste Justine, Dept Pediat Ophthalmol & Pharmacol, Res Ctr, Montreal, PQ, Canada.
   [Ong, Huy] Univ Montreal, Fac Pharm, Montreal, PQ, Canada.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite; Universite Paris Cite;
   UDICE-French Research Universities; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Sorbonne Universite; Scuola Superiore Sant'Anna;
   Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica
   (IFC-CNR); Centre National de la Recherche Scientifique (CNRS); Institut
   National de la Sante et de la Recherche Medicale (Inserm); UDICE-French
   Research Universities; Universite Paris Cite; Universite de Montreal;
   Universite de Montreal
RP Sennlaub, F (通讯作者)，Inst Natl Sante & Rech Med, U872, Paris, France.
EM sennlaub@idf.inserm.fr
RI Guillonneau, xavier/E-3995-2017; Raoul, William/H-2118-2018; Sennlaub,
   Florian/F-2756-2017; guillonneau, xavier/AAF-9495-2021
OI Guillonneau, xavier/0000-0001-7379-3935; Raoul,
   William/0000-0002-5040-3372; Sennlaub, Florian/0000-0003-4412-1341;
   guillonneau, xavier/0000-0001-7379-3935; Scherman,
   Daniel/0000-0003-1207-1298; Lachapelle, Pierre/0000-0002-7792-1102;
   Houssier, Marianne/0000-0002-5329-4597
CR Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013
   Chowers I, 2004, INVEST OPHTH VIS SCI, V45, P2098, DOI 10.1167/iovs.03-0863
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718
   ENDEMANN G, 1993, J BIOL CHEM, V268, P11811
   Ershov AV, 1999, J NEUROSCI RES, V58, P254, DOI 10.1002/(SICI)1097-4547(19991015)58:2<254::AID-JNR5>3.0.CO;2-U
   Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055
   Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FUNK R, 1985, EXP EYE RES, V40, P191, DOI 10.1016/0014-4835(85)90004-1
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Janabi M, 2000, ARTERIOSCL THROM VAS, V20, P1953, DOI 10.1161/01.ATV.20.8.1953
   Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517
   Kanayama M, 2007, J BIOL CHEM, V282, P24166, DOI 10.1074/jbc.M703212200
   Kargman S, 1996, BIOCHEM PHARMACOL, V52, P1113, DOI 10.1016/0006-2952(96)00462-5
   Kincer JF, 2002, J BIOL CHEM, V277, P23525, DOI 10.1074/jbc.M202465200
   Lee P, 1998, SURV OPHTHALMOL, V43, P245, DOI 10.1016/S0039-6257(98)00035-6
   LI S, 1995, ARCH OPHTHALMOL-CHIC, V113, P521, DOI 10.1001/archopht.1995.01100040143041
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50
   MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6
   Nandrot E, 2000, NEUROBIOL DIS, V7, P586, DOI 10.1006/nbdi.2000.0328
   ROGERS LJ, 1993, PHYSIOL BEHAV, V54, P903, DOI 10.1016/0031-9384(93)90300-5
   Ryeom SW, 1996, J CELL SCI, V109, P387
   SAHAGUN G, 1989, AM J PATHOL, V134, P1227
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sennlaub F, 2003, CIRCULATION, V108, P198, DOI 10.1161/01.CIR.0000080735.93327.00
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6
   Wu DY, 2003, J BIOL CHEM, V278, P10983, DOI 10.1074/jbc.M207470200
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
NR 33
TC 47
Z9 51
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1676
J9 PLOS MED
JI PLos Med.
PD FEB
PY 2008
VL 5
IS 2
BP 323
EP 330
AR e39
DI 10.1371/journal.pmed.0050039
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 287PK
UT WOS:000254928800022
PM 18288886
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Grassi, MA
   Fingert, JH
   Scheetz, TE
   Roos, BR
   Ritch, R
   West, SK
   Kawase, K
   Shire, AM
   Mullins, RE
   Stone, EM
AF Grassi, Michael A.
   Fingert, John H.
   Scheetz, Todd E.
   Roos, Benjamin R.
   Ritch, Robert
   West, Sheila K.
   Kawase, Kazuhide
   Shire, Abdirashid M.
   Mullins, Robert E.
   Stone, Edwin M.
TI Ethnic variation in AMD-associated complement factor H polymorphism
   p.Tyr402His
SO HUMAN MUTATION
LA English
DT Article
DE age-related macular degeneration; AMD; complement factor H; CFH; ethnic
   variation
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; FAMILIAL AGGREGATION;
   JAPANESE POPULATION; RACIAL-DIFFERENCES; UNITED-STATES; PREVALENCE; EYE;
   RISK; BALTIMORE
AB Age-related macular degeneration (AMD) is the most common cause of irreversible visual loss in the developed world. Previous studies have demonstrated that the c. 1204T > C, p.Tyr402His allelic variant in the complement factor H (CFH) gene is associated with an approximately three-fold increased risk for AMD in Caucasians of predominantly European descent. Both the prevalence as well as the phenotypic spectrum of AMD varies widely among persons of different ethnicities. We hypothesized that populations with a lower prevalence of AMD might also have a lower prevalence of the CFH risk allele. In this study we sought to determine the frequency of this sequence variant in control populations of Caucasians, African Americans, Hispanics, Somalis, and Japanese. Normal control populations were assembled for each ethnic group: Caucasian (n = 148), Somali (n = 128), African American (n = 75), Hispanic (n = 81), and Japanese (n = 82). Individuals were genotyped using a restriction digest assay and the frequency of the C allele at nucleotide position 1204 of the CFH gene was determined. A bioinformatic approach was used to identify SNPs in linkage disequilibrium with rs1061170 (c. 1204T > C, p.Tyr402His) from the human haplotype map project database (HapMap) in order to validate the findings. We found widely discordant frequencies of the risk allele between some of the different ethnic groups: Japanese 0.07 +/- 0.02, Hispanics 0.17 +/- 0.03, African-Americans 0.35 +/- 0.04, Caucasians 0.34 +/- 0.03, and Somalis 0.34 0.03. Allele frequencies generated by analysis of the HapMap database were consistent with these findings. This study suggests that there are other yet unidentified genetic factors important in the pathogenesis of AMD that may mitigate the effects of c.1204T > C, p.Tyr402His variant.
C1 Univ Iowa, Coll Med, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   Heed Ophthalm Fdn, Cleveland, OH USA.
   Ctr Bioinformat & Computat Biol, Iowa City, IA USA.
   Howard Hughes Med Inst, Chevy Chase, MD USA.
   New York Eye & Ear Infirm, New York, NY 10003 USA.
   New York Med Coll, Valhalla, NY 10595 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   Gifu Univ, Dept Ophthalmol, Grad Sch Med, Gifu, Japan.
   Mayo Clin, Coll Med, Dept Gastroenterol & Hepatol, Rochester, MN USA.
C3 University of Iowa; Howard Hughes Medical Institute; New York Eye & Ear
   Infirmary of Mount Sinai; New York Medical College; Johns Hopkins
   University; Johns Hopkins Medicine; Gifu University; Mayo Clinic
RP Stone, EM (通讯作者)，Univ Iowa, Coll Med, Ctr Macular Degenerat, Dept Ophthalmol & Visual Sci, 20 Hawkins Dr, Iowa City, IA 52242 USA.
EM edwin-stone@uiowa.edu
RI Fingert, John/AAX-4750-2021; Fingert, John/F-8787-2012
OI Fingert, John/0000-0002-0377-0479; Fingert, John/0000-0002-0377-0479;
   Stone, Edwin M./0000-0003-3343-4414; Mullins,
   Robert/0000-0002-5006-0891; Scheetz, Todd/0000-0002-1965-5811
CR Andersen Nis, 2004, Int J Circumpolar Health, V63 Suppl 2, P320
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BUFFONE GJ, 1985, CLIN CHEM, V31, P164
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Freeman B, 1997, BEHAV GENET, V27, P251, DOI 10.1023/A:1025614231190
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ishiko S, 2002, OPHTHALMOLOGY, V109, P2165, DOI 10.1016/S0161-6420(02)01227-7
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KUBO N, 1989, ANN ESTIMATED NUMBER, P136
   Kubo N, 1990, REPORT NATIONWIDE CL, P121
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   MARUO T, 1991, JPN J OPHTHALMOL, V35, P268
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   PIERAMICI DJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1043, DOI 10.1001/archopht.1994.01090200049020
   Quigley HA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1819, DOI 10.1001/archopht.119.12.1819
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Uyama M, 2000, BRIT J OPHTHALMOL, V84, P1018, DOI 10.1136/bjo.84.9.1018
   UYAMA M, 1992, EXCEPTA MED, V2, P947
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
   YUZAWA M, 1991, JPN J OPHTHALMOL, V35, P87
NR 35
TC 59
Z9 60
U1 0
U2 5
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD SEP
PY 2006
VL 27
IS 9
BP 921
EP 925
DI 10.1002/humu.20359
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 076PK
UT WOS:000239970000009
PM 16865697
DA 2022-11-30
ER

PT J
AU Somani, R
   Tennant, M
   Rudnisky, C
   Weis, E
   Ting, A
   Eppler, J
   Greve, M
   Hinz, B
AF Somani, R
   Tennant, M
   Rudnisky, C
   Weis, E
   Ting, A
   Eppler, J
   Greve, M
   Hinz, B
TI Comparison of stereoscopic digital imaging and slide film photography in
   the identification of macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; diagnostic imaging; macular degeneration; photography;
   teleophthalmology
ID AGE-RELATED MACULOPATHY; DIABETIC-RETINOPATHY; FUNDUS PHOTOGRAPHY;
   VISUAL IMPAIRMENT; ESTIMATING KAPPA; PREVALENCE; BLINDNESS
AB Background: This study compared the sensitivity and specificity of stereoscopic digital photography of the retina through a dilated pupil with a 45 degrees nonmydriatic camera and joint Photographic Experts Group (JPEG) compression of the images with the sensitivity and specificity of 35-mm slide film photography in the identification of age-related macular degeneration (AMD).
   Methods: Consecutive patients with a diagnosis of AMD were enrolled. Stereoscopic retinal images of the disc, macula and temporal macula were captured with a digital 45 degrees nonmydriatic camera (then compressed into JPEG format) and with a standard fundus camera and slide film. A single retinal specialist graded both image formats in masked fashion, at least I month apart, using a modified Age-Related Eye Disease Study (AREDS) severity scale. The digital images were displayed on a monitor and viewed with the use of liquid crystal display shutter glasses and stereo imaging software. The film images were mounted on a light box and graded with the use of a stereoviewer. Primary outcome measures included the presence or absence of AMD pathological features. Positive and negative predictive values (PPVs and NPVs), sensitivity, specificity and weighted kappa(W) statistics were calculated.
   Results: We photographed 203 eyes (of 103 patients) with both digital and slide film cameras. Correlation of the 2 image formats was substantial in identifying AREDS level 3a or greater (kappa(W) = 0.64, standard error = 0.08, PPV = 0.95, NPV = 0.66, sensitivity = 0.93, specificity = 0.74) and excellent in identifying level 4b or greater (kappa(W) = 0.83, standard error = 0.05, PPV = 0.81, NPV = 0.98, sensitivity = 0.94, specificity = 0.94).
   Interpretation: High-resolution stereoscopic, mydriatic, 45 degrees digital images captured with a nonmydriatic camera and JPEG compressed correlate well with stereoscopic slide film photographs in the identification of moderate to advanced AMD (AREDS level 3a or greater).
C1 Univ Alberta, Royal Alexandra Hosp, Dept Ophthalmol, Edmonton, AB T5H 3V9, Canada.
   Secure Diagnost Imaging Inc, Edmonton, AB, Canada.
   Univ Calgary, Dept Math & Stat, Calgary, AB T2N 1N4, Canada.
C3 Royal Alexandra Hospital; University of Alberta; University of Calgary
RP Tennant, M (通讯作者)，Univ Alberta, Royal Alexandra Hosp, Dept Ophthalmol, 10240 Kingsway Ave, Edmonton, AB T5H 3V9, Canada.
EM mtennant@ualberta.ca
RI Weis, Ezekiel/A-7246-2008
OI Weis, Ezekiel/0000-0002-6862-0850
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Agresti A, 1990, CATEGORICAL DATA ANA, P365
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bursell SE, 2001, OPHTHALMOLOGY, V108, P572, DOI 10.1016/S0161-6420(00)00604-7
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   FLEISS JL, 1969, PSYCHOL BULL, V72, P323, DOI 10.1037/h0028106
   Fransen SR, 2002, OPHTHALMOLOGY, V109, P595, DOI 10.1016/S0161-6420(01)00990-3
   GART JJ, 1990, BIOMETRICS, V46, P637, DOI 10.2307/2532084
   Henricsson M, 1996, ACTA OPHTHALMOL SCAN, V74, P533
   Ho T., 1997, SMJ, V38, P149
   KALM H, 1989, ACTA OPHTHALMOL, V67, P546
   KALM H, 1992, ACTA OPHTHALMOL, V70, P228
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LANDIS JR, 1977, BIOMETRICS, V33, P363, DOI 10.2307/2529786
   Liesenfeld B, 2000, DIABETES CARE, V23, P345, DOI 10.2337/diacare.23.3.345
   Lim JI, 2000, OPHTHALMOLOGY, V107, P866, DOI 10.1016/S0161-6420(00)00057-9
   Lim JI, 2002, RETINA-J RET VIT DIS, V22, P59, DOI 10.1097/00006982-200202000-00011
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   ODEN NL, 1991, STAT MED, V10, P1303, DOI 10.1002/sim.4780100813
   Penman AD, 1998, DIABETIC MED, V15, P783, DOI 10.1002/(SICI)1096-9136(199809)15:9<783::AID-DIA634>3.0.CO;2-5
   Rudnisky CJ, 2002, OPHTHALMOLOGY, V109, P267, DOI 10.1016/S0161-6420(01)00933-2
   SACKETT DL, 1983, CAN MED ASSOC J, V129, P429
   SCHOUTEN HJA, 1993, STAT MED, V12, P2207, DOI 10.1002/sim.4780122306
   Shanit D, 1998, J TELEMED TELECARE, V4, P1, DOI 10.1258/1357633981931317
   Tennant M T, 2000, Diabetes Technol Ther, V2, P583, DOI 10.1089/15209150050502005
   Tennant MTS, 2001, CAN J OPHTHALMOL, V36, P187, DOI 10.1016/S0008-4182(01)80039-9
   Tikellis G, 2000, CLIN EXP OPHTHALMOL, V28, P367, DOI 10.1046/j.1442-9071.2000.00336.x
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Villalpando CG, 1997, ARCH MED RES, V28, P129
   Younis N, 2003, LANCET, V361, P195, DOI 10.1016/S0140-6736(03)12267-2
NR 31
TC 15
Z9 15
U1 0
U2 4
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 293
EP 302
DI 10.1016/S0008-4182(05)80072-9
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400005
PM 15947799
DA 2022-11-30
ER

PT J
AU Ciulla, T
   Pollack, JS
   Williams, DF
AF Ciulla, Thomas
   Pollack, John S.
   Williams, David F.
TI Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema
   due to retinal vein occlusion: a real-world analysis of 15 613 patient
   eyes
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Treatment Medical; Retina; Macula
ID INTRAVITREAL AFLIBERCEPT INJECTION; GROWTH-FACTOR THERAPY; SUSTAINED
   BENEFITS; 12-MONTH OUTCOMES; RANIBIZUMAB; BEVACIZUMAB; PHARMACOKINETICS;
   DEGENERATION
AB Background/Aims To assess visual acuity (VA) outcomes and antivascular endothelial growth factor (anti-VEGF) therapy intensity in retinal vein occlusion (RVO)-related macular oedema (ME). Methods A retrospective study was completed in treatment-naive patients with RVO-related ME from 2013 to 2019, using the Vestrum Health Retina Database. Results Mean baseline age was 72.4 years and 54% were women. In 6 months, in 8876 eyes with branch retinal vein occlusion (BRVO)-related ME, after a mean of 4.5 anti-VEGF injections, VA increased by 9.4 letters (95% confidence interval (CI) for change in VA +8.94 to +9.78, p<0.001) from a baseline of 55.1 letters. In 6737 eyes with central retinal vein occlusion (CRVO)-related ME, after a mean of 4.6 anti-VEGF injections over 6 months, VA improved by 9.2 letters (95% CI +8.50 to +9.87, p<0.001) from a baseline of 37.2 letters. In 1 year, VA gain was similar (BRVO: 7.4 injections, +8.1 letters, 95% CI +7.55 to +8.57, p<0.001; CRVO: 7.6 injections, +7.1 letters, 95% CI +6.31 to +7.95, p<0.001). In 6 months and 1 year, mean letters gain increased with number of anti-VEGF injections. Patient eyes with baseline VA of 20/40 or better tended to lose VA in 1 year. Conclusion Mean change in VA correlates with treatment intensity, but patients with better VA at presentation are susceptible to vision loss, reflecting a ceiling effect. Assessed with the same database, VA gains compare favourably with 1-year VA gains in neovascular age-related macular degeneration and diabetic ME, but exhibit a larger gap when compared with corresponding randomised controlled trials.
C1 [Ciulla, Thomas] Midwest Eye Inst, Retina Serv, Indianapolis, IN USA.
   [Ciulla, Thomas] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Pollack, John S.] Rush Univ, Chicago, IL 60612 USA.
   [Williams, David F.] Univ Minnesota, Minneapolis, MN USA.
C3 Indiana University System; Indiana University Bloomington; Rush
   University; University of Minnesota System; University of Minnesota Twin
   Cities
RP Ciulla, T (通讯作者)，10300 North Illinois St, Indianapolis, IN 46290 USA.
EM thomasciulla@gmail.com
OI Ciulla, Thomas/0000-0001-5557-6777
CR ASRS, 2017, PREF TRENDS MEMB SUR
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P538, DOI 10.1016/j.ophtha.2014.08.031
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Ciulla TA, 2021, BRIT J OPHTHALMOL, V105, P216, DOI 10.1136/bjophthalmol-2020-315933
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P1179, DOI 10.1016/j.oret.2018.06.004
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Clark WL, 2016, OPHTHALMOLOGY, V123, P330, DOI 10.1016/j.ophtha.2015.09.035
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Gale R, 2021, BRIT J OPHTHALMOL, V105, P549, DOI 10.1136/bjophthalmol-2020-315836
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P202, DOI 10.1016/j.ophtha.2013.08.012
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scott IU, 2017, JAMA-J AM MED ASSOC, V317, P2072, DOI 10.1001/jama.2017.4568
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
NR 28
TC 9
Z9 9
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2021
VL 105
IS 12
BP 1696
EP 1704
DI 10.1136/bjophthalmol-2020-317337
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XJ6PS
UT WOS:000726907900016
PM 33055088
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Silpa-archa, S
   Limwattanayingyong, J
   Tadarati, M
   Amphornphruet, A
   Ruamviboonsuk, P
AF Silpa-archa, Sukhum
   Limwattanayingyong, Jirawut
   Tadarati, Mongkol
   Amphornphruet, Atchara
   Ruamviboonsuk, Paisan
TI Capacity building in screening and treatment of diabetic retinopathy in
   Asia-Pacific region
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Capacity building; diabetic retinopathy screening; diabetic retinopathy
   treatment; health workforce; nurse-led intravitreal injection
ID INTRAVITREAL INJECTIONS; RANIBIZUMAB; MODEL; OPTOMETRISTS; POPULATIONS;
   VALIDATION; PHYSICIANS; NURSES; SAFETY; IMAGES
AB The focus of capacity building for screening and treatment of diabetic retinopathy (DR) is on health professionals who are nonophthalmologists. Both physicians and nonphysicians are recruited for screening DR. Although there is no standardization of the course syllabus for the capacity building, it is generally accepted to keep their sensitivity >80%, specificity >95%, and clinical failure rate <5% for the nonophthalmologists, if possible. A systematic literature search was performed using the PubMed database and the following search terms: diabetic retinopathy, diabetic retinopathy screening, Asia, diabetic retinopathy treatment, age-related macular degeneration, capacity building, deep learning, artificial intelligence (AI), nurse-led clinic, and intravitreal injection (IVI). AI may be a tool for improving their capacity. Capacity building on IVIs of antivascular endothelial growth factors for DR is focused on nurses. There is evidence that, after a supervision of an average of 100 initial injections, the trained nurses can do the injections effectively and safely, the rate of endophthalmitis ranges from 0.03 to 0.07%, comparable to ophthalmologists. However, laws and regulations, which are different among countries, are challenges and barriers for nonophthalmologists, particularly for nonphysicians, for both screening and treatment of DR. Even if nonphysicians or physicians who are nonophthalmologists are legally approved for these tasks, sustainability of the capacity is another important challenge, this may be achieved if the capacity building can be part of their career development. Patient acceptability is another important barrier for initiating care provided by nonophthalmologists, particularly in Asia. There are also collaborations between national eye institutes of high-income countries, nongovernment organizations, and local eye institutes to improve both the quality and quantity of ophthalmologists and retinal specialists in low-income countries in Asia. This approach may require more labor, cost, and time consuming than training nonophthalmologists.
C1 [Silpa-archa, Sukhum; Limwattanayingyong, Jirawut; Tadarati, Mongkol; Amphornphruet, Atchara; Ruamviboonsuk, Paisan] Rangsit Univ, Dept Ophthalmol, Rajavithi Hosp, Coll Med, Bangkok 10400, Thailand.
C3 Rajavithi Hospital; Rangsit University
RP Ruamviboonsuk, P (通讯作者)，Rangsit Univ, Dept Ophthalmol, Rajavithi Hosp, Coll Med, Bangkok 10400, Thailand.
EM paisan.trs@gmail.com
RI Silpa-archa, Sukhum/AAE-6396-2022
OI Silpa-archa, Sukhum/0000-0002-3903-1889
CR American Academy of Ophthalmology, INTR INJ GUID TECHN
   American Diabetes Association, 2010, Diabetes Care, V33 Suppl 1, pS11, DOI 10.2337/dc10-S011
   Askew D, 2009, AUST FAM PHYSICIAN, V38, P650
   Austeng D, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0348-4
   Beede E, 2020, PROCEEDINGS OF THE 2020 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI'20), DOI 10.1145/3313831.3376718
   Bhalla S, 2020, INDIAN J OPHTHALMOL, V68, pS67, DOI 10.4103/ijo.IJO_1859_19
   Bhargava M, 2012, SINGAP MED J, V53, P715
   Blyth M, 2020, CLIN OPHTHALMOL, V14, P2507, DOI 10.2147/OPTH.S238529
   Bolme S, 2020, ACTA OPHTHALMOL, V98, P139, DOI 10.1111/aos.14184
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   DaCosta J, 2015, EYE, V29, P290, DOI 10.1038/eye.2014.249
   DaCosta J, 2014, EYE, V28, P734, DOI 10.1038/eye.2014.69
   Devalla SK, 2020, BRIT J OPHTHALMOL, V104, P301, DOI 10.1136/bjophthalmol-2019-315016
   Gallagher Mary-Josephine, 2017, Br J Nurs, V26, P800, DOI 10.12968/bjon.2017.26.14.800
   Gulshan V, 2019, JAMA OPHTHALMOL, V137, P987, DOI 10.1001/jamaophthalmol.2019.2004
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hasler PW, 2015, ACTA OPHTHALMOL, V93, P122, DOI 10.1111/aos.12589
   Heydon P, 2021, BRIT J OPHTHALMOL, V105, P723, DOI 10.1136/bjophthalmol-2020-316594
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee K, 2009, GLOB INST, P1
   Li E, 2015, GRAEF ARCH CLIN EXP, V253, P1619, DOI 10.1007/s00417-014-2921-y
   Li ZX, 2018, DIABETES CARE, V41, P2509, DOI 10.2337/dc18-0147
   Mall SP, 2015, EYE, V29, P290, DOI 10.1038/eye.2014.234
   Michelotti MM, 2014, CLIN OPHTHALMOL, V8, P755, DOI 10.2147/OPTH.S59982
   Mohamed R, 2018, EYE, V32, P1148, DOI 10.1038/s41433-017-0008-9
   Mwangi N, 2017, HUM RESOUR HEALTH, V15, DOI 10.1186/s12960-017-0196-1
   National Eye Institute, 2019, AGE RELATED MACULAR
   Perez-de-Arcelus M, 2013, CURR DIABETES REV, V9, P2, DOI 10.2174/157339913804143180
   Raman V, 2021, EYE, V35, P388, DOI 10.1038/s41433-020-1114-7
   Ramasamy K, 2021, INDIAN J OPHTHALMOL, V69, P482, DOI 10.4103/ijo.IJO_3716_20
   Rani PK, 2021, INDIAN J OPHTHALMOL, V69, P655, DOI 10.4103/ijo.IJO_1944_20
   Ratnarajan G, 2013, BRIT J OPHTHALMOL, V97, P395, DOI 10.1136/bjophthalmol-2012-302155
   Resnikoff S, 2020, BRIT J OPHTHALMOL, V104, P588, DOI 10.1136/bjophthalmol-2019-314336
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal College of Ophthalmologists, 2013, COLL STAT INTR INJ N
   Ruamviboonsuk P, 2006, OPHTHALMOLOGY, V113, P826, DOI 10.1016/j.ophtha.2005.11.021
   Ruamviboonsuk P, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0146-5
   Samalia P, 2016, NEW ZEAL MED J, V129, P32
   Scruggs BA, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.5
   Silpa-archa Sukhum, 2017, Journal of the Medical Association of Thailand, V100, pS136
   Simcock P, 2014, EYE, V28, P1161, DOI 10.1038/eye.2014.153
   Soh YQ, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.28
   Stanley S., 2013, INT J OPHTHALM PRACT, V4, P68, DOI DOI 10.12968/IJ0P.2013.4.2.686
   Teo AWJ, 2020, EYE, V34, P2151, DOI 10.1038/s41433-020-1077-8
   Teo AWJ, 2020, EYE, V34, P2123, DOI 10.1038/s41433-020-0920-2
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Wong TY, 2019, ASIA-PAC J OPHTHALMO, V8, P448, DOI 10.1097/APO.0000000000000267
   World Health Organization, WORLD HLTH REPORT 20
   Wu XH, 2019, BRIT J OPHTHALMOL, V103, P1553, DOI 10.1136/bjophthalmol-2019-314729
   Xie YC, 2020, LANCET DIGIT HEALTH, V2, pE240, DOI 10.1016/S2589-7500(20)30060-1
   Zheng YF, 2013, INVEST OPHTH VIS SCI, V54, P2171, DOI 10.1167/iovs.12-11393
   Zondervan M, 2013, EYE NEWS, V19, P34
NR 52
TC 0
Z9 0
U1 1
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD NOV
PY 2021
VL 69
IS 11
BP 2959
EP 2967
DI 10.4103/ijo.IJO_1075_21
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YY0RM
UT WOS:000754501000010
PM 34708730
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yang, P
   Neal, SE
   Buehne, KL
   Tewkesbury, GM
   Klingeborn, M
   Yang, YY
   Baciu, P
   Jaffe, GJ
AF Yang, Ping
   Neal, Samantha E.
   Buehne, Kristen L.
   Tewkesbury, Grace M.
   Klingeborn, Mikael
   Yang, Yae-Young
   Baciu, Peter
   Jaffe, Glenn J.
TI Complement-mediated release of fibroblast growth factor 2 from human RPE
   cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Retinal pigment epithelial;
   Complement; Fibroblast growth factor 2
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; RECEPTOR ANTAGONIST;
   EXPRESSION; ACTIVATION; MEMBRANE; PROTEINS; FGF-2; MICE;
   NEOVASCULARIZATION
AB Purpose: Complement activation is associated with choroidal neovascularization (CNV) in age-related macular degeneration (AMD). Fibroblast growth factor 2 (FGF2) and membrane attack complex (MAC) are present in eyes of patients with CNV. Herein, we investigated the effect of complement activation on FGF2 release in human retinal pigment epithelial (RPE) cells.
   Methods: Cultured human RPE cells were primed with an anti-RPE antibody and then treated with C1q-depleted human serum in the presence or absence of Tec kinases inhibitor (LFM-A13). 38 cytokines/chemokines levels were measured by Luminex technology. Secretion of FGF2 and interleukin (IL)-6 was assessed by ELISA. Tec protein was measured by Western blot. mRNA expression of FGF2, chemokine (C-X-C motif) ligand 1 (CXCL-1), and family members of Tec kinases was evaluated by qPCR. Cell viability and MAC deposition were determined by WST-1 assay and flow cytometry, respectively. Results: Complement activation caused increased FGF2 and IL-6 release. FGF2 was released when C6-depleted human serum was reconstituted with C6. Anti-C5 antibody significantly attenuated complement-mediated FGF2 release, but not IL-6. FGF2 mRNA levels were not affected, while CXCL-1 mRNA levels were increased by complement activation. FGF2-containing extracellular vesicles were detected in response to complement challenge. Tec mRNA and protein were expressed in RPE cells. In the presence of LFM-A13, secretion of FGF2, but not IL-6, and MAC deposition were significantly decreased and cell viability was significantly increased in complement-treated cells when compared to controls.
   Conclusions: Complement plays an important role to release FGF2 from RPE cells. Tec kinase is involved in MAC formation and complement-mediated FGF2 release. This information suggests a role for complement activation to mediate neovascularization in conditions such as AMD, and may elucidate potential therapeutic targets.
C1 [Yang, Ping; Neal, Samantha E.; Buehne, Kristen L.; Tewkesbury, Grace M.; Klingeborn, Mikael; Jaffe, Glenn J.] Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd, Durham, NC 27710 USA.
   [Yang, Yae-Young; Baciu, Peter] Allergan Pharmaceut Inc, Dept Biol, Irvine, CA 92612 USA.
C3 Duke University; AbbVie; Allergan
RP Jaffe, GJ (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd, Durham, NC 27710 USA.
EM jaffe001@mc.duke.edu
OI Klingeborn, Mikael/0000-0003-2907-0371; Neal,
   Samantha/0000-0002-0173-6752; Tewkesbury, Grace/0000-0001-7519-7731
FU Research to Prevent Blindness; NIH [P30EY005722]
FX This work was supported, in part, by Unrestricted Research to Prevent
   Blindness Grant and the NIH Core Grant [P30EY005722] .
CR Acosta JA, 1996, MOL MED, V2, P755, DOI 10.1007/BF03401659
   Andres G, 2009, J CELL MOL MED, V13, P2083, DOI 10.1111/j.1582-4934.2008.00415.x
   BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Browning AC, 2008, BRIT J OPHTHALMOL, V92, P1003, DOI 10.1136/bjo.2007.127670
   Calippe B, 2014, CR BIOL, V337, P178, DOI 10.1016/j.crvi.2013.12.003
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   CARNEY DF, 1985, J IMMUNOL, V134, P1804
   Ceccarelli S, 2007, INT J CANCER, V121, P1494, DOI 10.1002/ijc.22844
   Chen QS, 2013, MEDIAT INFLAMM, V2013, DOI [10.1155/2013/928315, 10.1155/2013/434010]
   Choudhary M, 2019, ADV EXP MED BIOL, V1185, P9, DOI 10.1007/978-3-030-27378-1_2
   Cybulsky AV, 1999, AM J PATHOL, V155, P1701, DOI 10.1016/S0002-9440(10)65485-5
   Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3
   Dong ZY, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107775
   Ebert AD, 2010, TRAFFIC, V11, P813, DOI 10.1111/j.1600-0854.2010.01059.x
   Eichler W, 2008, EXP EYE RES, V87, P342, DOI 10.1016/j.exer.2008.06.017
   Engling A, 2002, J CELL SCI, V115, P3619, DOI 10.1242/jcs.00036
   FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311
   FOLKMAN J, 1988, AM J PATHOL, V130, P393
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hollborn M, 2004, GRAEF ARCH CLIN EXP, V242, P414, DOI 10.1007/s00417-004-0879-x
   Holtkamp GM, 1999, EUR J IMMUNOL, V29, P215, DOI 10.1002/(SICI)1521-4141(199901)29:01<215::AID-IMMU215>3.0.CO;2-#
   Ida H, 2003, INVEST OPHTH VIS SCI, V44, P5430, DOI 10.1167/iovs.03-0609
   JAFFE GJ, 1992, EXP EYE RES, V55, P325, DOI 10.1016/0014-4835(92)90197-Z
   KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   La Venuta G, 2016, J BIOL CHEM, V291, P17787, DOI 10.1074/jbc.M116.729384
   La Venuta G, 2015, J BIOL CHEM, V290, P27015, DOI 10.1074/jbc.R115.689257
   Lee SJ, 2007, J MICROBIOL BIOTECHN, V17, P1024
   Lueck K, 2015, OPHTHALMIC RES, V54, P195, DOI 10.1159/000439596
   Luo C, 2011, MOL VIS, V17, P1588
   Malhotra V, 2013, EMBO J, V32, P1660, DOI 10.1038/emboj.2013.104
   MANO H, 1990, ONCOGENE, V5, P1781
   Matsuda Y, 2019, MOL THER-NUCL ACIDS, V17, P819, DOI 10.1016/j.omtn.2019.07.018
   MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113
   Monsinjon T, 2003, FASEB J, V17, P1003, DOI 10.1096/fj.02-0737com
   Monti M, 2013, J MOL CELL CARDIOL, V63, P107, DOI 10.1016/j.yjmcc.2013.07.006
   Moskovich O, 2007, J BIOL CHEM, V282, P29977, DOI 10.1074/jbc.M703742200
   Nahavandipour A, 2020, ACTA OPHTHALMOL, V98, P434, DOI 10.1111/aos.14402
   NGUYEN M, 1993, J NATL CANCER I, V85, P241, DOI 10.1093/jnci/85.3.241
   Nickel W, 2005, TRAFFIC, V6, P607, DOI 10.1111/j.1600-0854.2005.00302.x
   Ozaki H, 1998, AM J PATHOL, V153, P757, DOI 10.1016/S0002-9440(10)65619-2
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Pilzer D, 2005, SPRINGER SEMIN IMMUN, V27, P375, DOI 10.1007/s00281-005-0004-1
   Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004
   Proia P, 2008, INT J MOL MED, V21, P63
   Schafer T, 2004, J BIOL CHEM, V279, P6244, DOI 10.1074/jbc.M310500200
   Schiera G, 2007, J CELL MOL MED, V11, P1384, DOI 10.1111/j.1582-4934.2007.00100.x
   Silverman SM, 2019, ADV EXP MED BIOL, V1185, P33, DOI 10.1007/978-3-030-27378-1_6
   Stahl A, 2009, GRAEF ARCH CLIN EXP, V247, P767, DOI 10.1007/s00417-009-1058-x
   Steringer JP, 2018, SEMIN CELL DEV BIOL, V83, P3, DOI 10.1016/j.semcdb.2018.02.010
   Steringer JP, 2015, J MOL BIOL, V427, P1202, DOI 10.1016/j.jmb.2014.07.012
   Szade A, 2015, IUBMB LIFE, V67, P145, DOI 10.1002/iub.1358
   Takesono A, 2002, J CELL SCI, V115, P3039
   Taverna S, 2003, J BIOL CHEM, V278, P51911, DOI 10.1074/jbc.M304192200
   Tegla CA, 2011, IMMUNOL RES, V51, P45, DOI 10.1007/s12026-011-8239-5
   Trudel C, 2000, J CELL PHYSIOL, V185, P260, DOI 10.1002/1097-4652(200011)185:2<260::AID-JCP11>3.0.CO;2-X
   Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y
   Yang P, 2005, INVEST OPHTH VIS SCI, V46, P1755, DOI 10.1167/iovs.04-1039
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
   Yang P, 2017, INVEST OPHTH VIS SCI, V58, P3073, DOI 10.1167/iovs.16-20083
   Yang P, 2014, INVEST OPHTH VIS SCI, V55, P3012, DOI 10.1167/iovs.13-13554
   Zhang M, 2013, SCIENCE, V340, P559, DOI 10.1126/science.1234740
   Zittermann SI, 2006, AM J PATHOL, V168, P835, DOI 10.2353/ajpath.2006.050479
NR 69
TC 0
Z9 0
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD MAR
PY 2021
VL 204
AR 108471
DI 10.1016/j.exer.2021.108471
EA JAN 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QT5HA
UT WOS:000626617300001
PM 33516764
DA 2022-11-30
ER

PT J
AU Fletcher, EL
AF Fletcher, Erica L.
TI Advances in understanding the mechanisms of retinal degenerations
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related macular degeneration; P2X receptors; photoreceptors;
   photoswitches; retinal degeneration; retinal prosthesis
ID INDUCED PHOTORECEPTOR DEATH; RESTORING VISUAL FUNCTION; P2X(7)
   RECEPTORS; GANGLION-CELLS; INNATE PHAGOCYTOSIS; SCAVENGER ACTIVITY;
   GABA(C) RECEPTORS; IMPROVES RECOVERY; APOPTOTIC CELLS; BIPOLAR CELLS
AB Photoreceptor death is an important contributor to irreversible vision loss worldwide. In this review, I outline our work examining the role that purines, such as adenosine triphosphate (ATP), have in normal retinal function and in retinal disease. Our work shows that the actions of ATP, mediated by P2X receptors, are expressed in various retinal layers including photoreceptor terminals, and when stimulated by excessive levels of ATP is associated with rapid death of neurons. Treatment with a compound that blocks the action of P2X and some P2Y receptors reduces photoreceptor death in a mouse model of retinal degeneration. Our observations not only provide a means for developing a potential treatment for reducing photoreceptor death, but also provides a novel way of studying the neural plasticity effects that develop in the inner retina following photoreceptor death. There are a range of inner retinal changes that could influence the effectiveness of retinal prostheses. Indeed, using an ATP-induced degeneration model, we established that the amount of electrical stimulation required to elicit a response in the visual cortex was affected by the level of glial scarring. However, changes in P2X7 receptor expression by OFF ganglion cells during retinal degeneration can also be exploited by photoswitches to restore light sensitivity to degenerated retinae. Finally, our work has also considered how P2X7 expression by innate immune cells, and its role as a scavenger receptor, contributes to age-related macular degeneration (AMD). Our results show that loss of P2X7 function is associated with thickening of Bruch's membrane as well as increased risk of advanced disease in people with AMD. Overall, our work over the last 20 years highlights the importance of purinergic signalling in normal retinal function and retinal disease and suggest that developing therapies that target P2X7 function could be of benefit for these diseases.
C1 [Fletcher, Erica L.] Univ Melbourne, Dept Anat & Neurosci, Melbourne, Vic, Australia.
C3 University of Melbourne
RP Fletcher, EL (通讯作者)，Univ Melbourne, Dept Anat & Neurosci, Melbourne, Vic, Australia.
EM elf@unimelb.edu.au
FU National Health and Medical Research Council; Australian Research
   Council; Macular Diseases Foundation of Australia
FX I am deeply humbled and grateful to have received the H Barry Collin
   Medal and would like to thank Optometry Australia for this honour. I am
   also very grateful to the many students and staff I have had the
   privilege to work with over the years. Although I cannot name all the
   students and postdoctoral scientists I have had the privilege to work
   with, Dr Theresa Puthussery, Dr Joanna Phipps, Dr Laura Downie, Dr
   Kirstan Vessey, Dr Andrew Jobling and Dr Una Greferath deserve special
   mention. They have undertaken many tireless hours in the laboratory and
   made my research endeavours particularly rewarding over many years. I
   thank them all from the bottom of my heart. I would also like to pay
   tribute to my collaborators and mentors Prof Robyn Guymer, Prof Heinz
   Wassle, Prof Michael Kalloniatis and Prof Suzi Fleiszig who taught me
   the art of being a research scientist -they showed that research can be
   fun, that one needs to focus on the important questions, and then
   communicate it in a way that could be embraced by the wider research
   community. I thank them for the many hours of discussion, guidance and
   advice over many years (and for the countless margaritas that were
   consumed along the way). Finally, I would like to thank my family - to
   my husband, Richard Lindsay and children Paul, Charlotte and Hanna -
   thank you sincerely for your endless support and understanding. I wish
   to acknowledge my funding sources - the National Health and Medical
   Research Council, the Australian Research Council and the Macular
   Diseases Foundation of Australia - without whose funding, none of our
   work would be possible. I am extremely grateful for this support.
CR Aghaizu ND, 2017, PROG BRAIN RES, V231, P191, DOI 10.1016/bs.pbr.2017.01.001
   Ait-Ali N, 2015, CELL, V161, P817, DOI 10.1016/j.cell.2015.03.023
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anderson EE, 2016, CELL TISSUE RES, V364, P263, DOI 10.1007/s00441-015-2337-y
   Aplin FP, 2016, INVEST OPHTH VIS SCI, V57, P5216, DOI 10.1167/iovs.16-19926
   Aplin FP, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00046
   Aplin FP, 2014, INVEST OPHTH VIS SCI, V55, P8319, DOI 10.1167/iovs.14-15732
   Ayton LN, 2020, CLIN NEUROPHYSIOL, V131, P1383, DOI 10.1016/j.clinph.2019.11.029
   Ayton LN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115239
   Burnstock Geoffrey, 2018, Brain Neurosci Adv, V2, p2398212818817494, DOI 10.1177/2398212818817494
   Chua J, 2009, J COMP NEUROL, V514, P473, DOI 10.1002/cne.22029
   Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472
   Euler T, 1998, J NEUROPHYSIOL, V79, P1384, DOI 10.1152/jn.1998.79.3.1384
   Fletcher EL, 1999, J COMP NEUROL, V413, P155, DOI 10.1002/(SICI)1096-9861(19991011)413:1<155::AID-CNE11>3.0.CO;2-6
   Fletcher EL, 1998, J COMP NEUROL, V396, P351, DOI 10.1002/(SICI)1096-9861(19980706)396:3<351::AID-CNE6>3.0.CO;2-1
   Fletcher EL, 1996, J COMP NEUROL, V376, P343
   Greferath U, 2004, NEUROIMAGE, V23, P1027, DOI 10.1016/j.neuroimage.2004.06.044
   Greferath U, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00293
   Gu BJ, 2018, BRIT J PHARMACOL, V175, P4195, DOI 10.1111/bph.14470
   Gu BJ, 2016, ACTA NEUROPATHOL, V132, P377, DOI 10.1007/s00401-016-1596-3
   Gu BJ, 2015, HUM MOL GENET, V24, P5644, DOI 10.1093/hmg/ddv278
   Gu BJ, 2013, FASEB J, V27, P1479, DOI 10.1096/fj.12-215368
   Gu BJ, 2012, J BIOL CHEM, V287, P17318, DOI 10.1074/jbc.M112.340885
   Gu BJ, 2011, J IMMUNOL, V187, P2365, DOI 10.4049/jimmunol.1101178
   Gu BJ, 2009, AM J PHYSIOL-CELL PH, V297, pC430, DOI 10.1152/ajpcell.00079.2009
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Hack I, 2001, EUR J NEUROSCI, V13, P15, DOI 10.1046/j.1460-9568.2001.01357.x
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   He JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00912
   Ho T, 2014, NEUROSCIENCE, V277, P55, DOI 10.1016/j.neuroscience.2014.06.055
   Ho T, 2016, J OCUL PHARMACOL TH, V32, P509, DOI 10.1089/jop.2015.0158
   Ho T, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00389
   Housley GD, 2009, TRENDS NEUROSCI, V32, P128, DOI 10.1016/j.tins.2009.01.001
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Kalloniatis M, 1999, PROG RETIN EYE RES, V18, P811, DOI 10.1016/S1350-9462(98)00036-6
   Kalloniatis M, 2016, EXP EYE RES, V150, P106, DOI 10.1016/j.exer.2015.10.019
   KALLONIATIS M, 1993, J COMP NEUROL, V336, P174, DOI 10.1002/cne.903360203
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130
   North RA, 2006, PFLUG ARCH EUR J PHY, V452, P479, DOI 10.1007/s00424-006-0060-y
   O'Brien EE, 2014, J COMP NEUROL, V522, P1155, DOI 10.1002/cne.23487
   Oesch NW, 2019, VISUAL NEUROSCI, V36, DOI 10.1017/S095252381900004X
   Pan ZH, 2015, ANNU REV VIS SCI, V1, P185, DOI 10.1146/annurev-vision-082114-035532
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106
   Petoe MA, 2017, INVEST OPHTH VIS SCI, V58, P3231, DOI 10.1167/iovs.16-21041
   Pfeiffer RL, 2020, PROG RETIN EYE RES, V74, DOI 10.1016/j.preteyeres.2019.07.004
   Plithussery T, 2007, NEUROSCIENCE, V146, P403, DOI 10.1016/j.neuroscience.2007.01.055
   Puthussery T, 2006, J COMP NEUROL, V496, P595, DOI 10.1002/cne.20889
   Puthussery T, 2004, J COMP NEUROL, V472, P13, DOI 10.1002/cne.20045
   Puthussery T, 2006, EUR J NEUROSCI, V24, P7, DOI 10.1111/j.1460-9568.2006.04895.x
   Puthussery T, 2009, J COMP NEUROL, V513, P430, DOI 10.1002/cne.21964
   Reigada D, 2008, NEUROSCIENCE, V157, P396, DOI 10.1016/j.neuroscience.2008.08.036
   Saha S, 2016, NEUROSCIENCE, V329, P1, DOI 10.1016/j.neuroscience.2016.04.032
   Sanderson J, 2014, EXP EYE RES, V127, P270, DOI 10.1016/j.exer.2014.08.009
   Stasheff SF, 2011, J NEUROPHYSIOL, V105, P3002, DOI 10.1152/jn.00704.2010
   Tochitsky I, 2018, CHEM REV, V118, P10748, DOI 10.1021/acs.chemrev.7b00723
   Tochitsky I, 2017, SCI REP-UK, V7, DOI 10.1038/srep45487
   Tochitsky I, 2016, NEURON, V92, P100, DOI 10.1016/j.neuron.2016.08.038
   Tochitsky I, 2015, CURR OPIN NEUROBIOL, V34, P74, DOI 10.1016/j.conb.2015.01.018
   Tochitsky I, 2014, NEURON, V81, P800, DOI 10.1016/j.neuron.2014.01.003
   Vessey KA, 2020, METHODS MOL BIOL, V2041, P209, DOI 10.1007/978-1-4939-9717-6_15
   Vessey KA, 2017, AM J PATHOL, V187, P1670, DOI 10.1016/j.ajpath.2017.04.016
   Vessey KA, 2014, J COMP NEUROL, V522, P2928, DOI 10.1002/cne.23558
   Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082
   Ward MM, 2008, NEUROSCIENCE, V155, P1262, DOI 10.1016/j.neuroscience.2008.06.035
   WASSLE H, 1991, VISUAL NEUROSCI, V7, P99, DOI 10.1017/S095252380001097X
   Wassle H, 2004, NAT REV NEUROSCI, V5, P747, DOI 10.1038/nrn1497
   Wassle H, 1998, VISION RES, V38, P1411, DOI 10.1016/s0042-6989(97)00300-3
   Wilson Y, 2002, P NATL ACAD SCI USA, V99, P3252, DOI 10.1073/pnas.042701199
   Zhang XL, 2006, J NEUROCHEM, V98, P566, DOI 10.1111/j.1471-4159.2006.03900.x
   Zhang XL, 2005, INVEST OPHTH VIS SCI, V46, P2183, DOI 10.1167/iovs.05-0052
NR 74
TC 4
Z9 4
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD NOV
PY 2020
VL 103
IS 6
BP 723
EP 732
DI 10.1111/cxo.13146
EA OCT 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH3IB
UT WOS:000576598300001
PM 33090561
DA 2022-11-30
ER

PT J
AU Aziz, E
   Batool, R
   Akhtar, W
   Rehman, S
   Shahzad, T
   Malik, A
   Shariati, MA
   Laishevtcev, A
   Plygun, S
   Heydari, M
   Rauf, A
   Arif, SA
AF Aziz, Ejaz
   Batool, Riffat
   Akhtar, Wasim
   Rehman, Shazia
   Shahzad, Tasmeena
   Malik, Ayesha
   Shariati, Mohammad Ali
   Laishevtcev, Alexey
   Plygun, Sergey
   Heydari, Mojtaba
   Rauf, Abdur
   Arif, Shaheer Ahmed
TI Xanthophyll: Health benefits and therapeutic insights
SO LIFE SCIENCES
LA English
DT Article
DE Xanthophyll; Lutein; Zeaxanthin; Supplement
ID INDUCED OXIDATIVE STRESS; BETA-CRYPTOXANTHIN; MACULAR PIGMENT; IN-VITRO;
   DIETARY LUTEIN; HUMAN SKIN; SUBARACHNOID HEMORRHAGE;
   ISCHEMIA-REPERFUSION; INDUCED CYTOTOXICITY; CONTACT-DERMATITIS
AB Xanthophylls constitute a major part of carotenoids in nature. They are an oxidized version of carotenoid. Xanthophyll has widely drawn scientists' attentions in terms of its functionality, bioavailability and diversity. An assortment of xanthophyll varieties includes lutein, zeaxanthin, beta-cryptoxanthin, capsanthin, astaxanthin, and fucoxanthin. Chemically, lutein and zeaxanthin are dipolar carotenoids with hydroxyl groups at both ends of their molecules that bestow hydrophilic properties to them. Hydrophilic affinity in lutein and zeaxanthin makes better bioavailability in reaction with singlet oxygen in water phase, whereas non-polar carotenoids have shown to have less efficiency in scavenging free radicals. Xanthophylls have been studied for their effects in a wide variety of diseases including neurologic, ophthalmologic, oral, allergic and immune diseases. This review highlights pharmaco-pharmaceutical applications of xanthophylls as well asits drug interactions with beta-carotene.
   Different types of xanthophylls have been shown to have neuroprotective effects. Fucoxanthin demonstrated potent antiplasmodial activity. Lutein and zeaxanthin prevent the progression of age related macular degeneration. They have also demonstrated promising effects on uveitis, retinitis pigmentosa, scleritis, cataracts, glaucoma, retinal ischemia and choroideremia. Astaxanthin showed to have skin protecting effects against ultraviolet light injury. Astaxanthin have anti-allergic activity against the contact dermatitis especially to treat the patients having adverse reactions induced by steroids. Astaxanthin has been reported to exert beneficial effects in preventing oral lichen planus and early stage cancers. beta-cryptoxanthin has been considered a good candidate for prevention of bone loss via osteoblastic bone formation and inhibiting osteoclastic bone resorption. There is also some concern that higher dose of xanthophylls may be linked to increased risk of skin cancer and gastric adenocarcinoma. However this increased risk was not statistically significant when adjusted for confounding factors. Further researches including clinical studies are needed to better evaluate the efficacy and safety of xanthophylls in prevention and treatment of different diseases.
C1 [Aziz, Ejaz] GDC Khanpur, Dept Bot, Haripur, Pakistan.
   [Batool, Riffat] PMAS UAAR, Univ Inst Biochem & Biotechnol, Rawalpindi, Pakistan.
   [Akhtar, Wasim] Univ Azad Jammu & Kashmir, Dept Bot, Muzaffarabad, Pakistan.
   [Rehman, Shazia; Shahzad, Tasmeena; Malik, Ayesha] Quaid I Azam Univ Islamabad, Dept Plant Sci, Islamabad, Pakistan.
   [Shariati, Mohammad Ali; Laishevtcev, Alexey; Plygun, Sergey] Orel State Univ, Lab Biocontrol & Antimicrobial Resistance, Oryol 302026, Russia.
   [Laishevtcev, Alexey] Russian Acad Sci, All Russian Sci Res Inst Expt Vet Med, Fed Res Ctr, Moscow 109428, Russia.
   [Plygun, Sergey] European Soc Clin Microbiol & Infect Dis, CH-4051 Basel, Switzerland.
   [Plygun, Sergey] All Russian Res Inst Phytopathol, B Vyazyomy 143050, Moscow Region, Russia.
   [Heydari, Mojtaba] Shiraz Univ Med Sci, Poostchi Ophthalmol Res Ctr, Shiraz, Iran.
   [Rauf, Abdur] Univ Swabi, Dept Chem, Anbar, Kpk, Pakistan.
   [Arif, Shaheer Ahmed] Washington State Univ Tricities, Bioprod Sci & Engn Lab, 2710 Crimson Way, Richland, WA 99354 USA.
C3 University of Azad Jammu & Kashmir; Quaid I Azam University; Orel State
   University; Federal Scientific Centre VIEV; Russian Academy of Sciences;
   Shiraz University of Medical Science; Washington State University
RP Batool, R (通讯作者)，PMAS UAAR, Univ Inst Biochem & Biotechnol, Rawalpindi, Pakistan.; Rauf, A (通讯作者)，Univ Swabi, Dept Chem, Anbar, Kpk, Pakistan.
EM ejaz.aziz.qau@gmail.com; riffatbatoolqau@gmail.com; mashaljcs@yahoo.com
RI Heydari, Mojtaba/H-9224-2013; Rauf, Abdur/G-3304-2013; Laishevtcev,
   Aleksey/S-2948-2017; Shariati, Mohammad Ali/HCI-4375-2022; Rehman,
   Shazia/HDL-6761-2022
OI Heydari, Mojtaba/0000-0001-9612-0936; Rauf, Abdur/0000-0003-2429-5491;
   Laishevtcev, Aleksey/0000-0002-5050-2274; Rehman,
   Shazia/0000-0003-1435-6166; Shariati, Mohammad Ali/0000-0001-9376-5771
CR Afolayan AF, 2008, Z NATURFORSCH C, V63, P848
   Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128
   ARIVUSELVAN N, 2011, J AGARDH INFLAMMATIO, V14, P16
   Ayano I, 2016, JPN PHARMACOL THER, V44, P1209
   Balboa EM, 2013, FOOD CHEM, V138, P1764, DOI 10.1016/j.foodchem.2012.11.026
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergman AJIW, 1998, HUM MUTAT, V12, P19, DOI 10.1002/(SICI)1098-1004(1998)12:1<19::AID-HUMU3>3.3.CO;2-V
   Bernstein PS, 2016, PROG RETIN EYE RES, V50, P34, DOI 10.1016/j.preteyeres.2015.10.003
   Berr C, 2000, J AM GERIATR SOC, V48, P1285, DOI 10.1111/j.1532-5415.2000.tb02603.x
   Zeni ALB, 2019, PHARMACOL BIOCHEM BE, V179, P63, DOI 10.1016/j.pbb.2019.02.004
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340
   Blount JD, 2003, SCIENCE, V300, P125, DOI 10.1126/science.1082142
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Braiman-Wiksman L, 2007, TOXICOL PATHOL, V35, P767, DOI 10.1080/01926230701584189
   Brown M., 2005, CLIN REFRACT OPTOM, V16, P240
   Burri BJ, 2015, J SCI FOOD AGR, V95, P1786, DOI 10.1002/jsfa.6942
   Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6
   Cavani A, 2010, CURR DRUG METAB, V11, P228, DOI 10.2174/138920010791196300
   Chew BP, 2011, VET IMMUNOL IMMUNOP, V140, P199, DOI 10.1016/j.vetimm.2010.12.004
   Chew BP, 1999, ANTICANCER RES, V19, P1849
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chong YS, 2018, CUTAN OCUL TOXICOL, V37, P52, DOI 10.1080/15569527.2017.1335748
   Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4
   Cort A, 2010, REGUL TOXICOL PHARM, V58, P121, DOI 10.1016/j.yrtph.2010.05.001
   Craft N E, 2004, J Nutr Health Aging, V8, P156
   Das BS, 1996, AM J CLIN NUTR, V64, P94, DOI 10.1093/ajcn/64.1.94
   Dias PF, 2008, MICROVASC RES, V75, P34, DOI 10.1016/j.mvr.2007.05.004
   Dilsiz N, 2006, GRAEF ARCH CLIN EXP, V244, P627, DOI 10.1007/s00417-005-0084-6
   Ekpe L., 2018, OXID ANTIOXID MED SC, P1, DOI [10.5455/oams.20180315075538, DOI 10.5455/OAMS.20180315075538, DOI 10.5455/JMP.20180627120817]
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Feart C, 2016, J GERONTOL A-BIOL, V71, P683, DOI 10.1093/gerona/glv135
   Fernandez-Garcia E, 2014, FOOD FUNCT, V5, P1994, DOI [10.1039/c4fo00280f, 10.1039/C4FO00280F]
   Fields RD, 2008, NEUROSCIENTIST, V14, P540, DOI 10.1177/1073858408320294
   Fujimura S, 2016, CLIN OPHTHALMOL, V10, P2149, DOI 10.2147/OPTH.S119251
   Garcia-de Blas E, 2013, PHYSIOL BIOCHEM ZOOL, V86, P483, DOI 10.1086/671812
   Giaconi JA, 2012, AM J OPHTHALMOL, V154, P635, DOI 10.1016/j.ajo.2012.03.048
   Gilbert PB, 2011, J INFECT DIS, V203, P969, DOI 10.1093/infdis/jiq152
   Gilchrest BA, 1996, BRIT J DERMATOL, V135, P867, DOI 10.1046/j.1365-2133.1996.d01-1088.x
   GILCHREST BA, 1992, BRIT J DERMATOL, V127, P25, DOI 10.1111/j.1365-2133.1992.tb16984.x
   Gong XM, 2018, MOLECULES, V23, DOI 10.3390/molecules23040905
   Gonzalez S, 2003, J INVEST DERMATOL, V121, P399, DOI 10.1046/j.1523-1747.2003.12355.x
   Goralczyk R, 1997, INVEST OPHTH VIS SCI, V38, P741
   GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245
   Grether-Beck S, 2017, BRIT J DERMATOL, V176, P1231, DOI 10.1111/bjd.15080
   Grether-Beck S, 2014, PHOTODERMATOL PHOTO, V30, P167, DOI 10.1111/phpp.12111
   GRUBBS CJ, 1991, ONCOLOGY, V48, P239
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hartung W, 2010, FUNCT PLANT BIOL, V37, P806, DOI 10.1071/FP10058
   He RR, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-38
   Heinrich U, 2003, J NUTR, V133, P98, DOI 10.1093/jn/133.1.98
   Hirata N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020368
   Hu LX, 2018, BIOMED PHARMACOTHER, V106, P1484, DOI 10.1016/j.biopha.2018.07.088
   Hussein G, 2005, BIOL PHARM BULL, V28, P47, DOI 10.1248/bpb.28.47
   Igras E, 2013, BRIT J OPHTHALMOL, V97, P994, DOI 10.1136/bjophthalmol-2013-303153
   Iskandar AR, 2016, CANCER PREV RES, V9, P875, DOI 10.1158/1940-6207.CAPR-16-0161
   Islam MN, 2013, FOOD CHEM TOXICOL, V55, P541, DOI 10.1016/j.fct.2013.01.054
   Ito N, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070817
   Izumi-Nagai K, 2008, INVEST OPHTH VIS SCI, V49, P1679, DOI 10.1167/iovs.07-1426
   Jahns P, 2012, BBA-BIOENERGETICS, V1817, P182, DOI 10.1016/j.bbabio.2011.04.012
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Johnson Elizabeth J, 2013, J Aging Res, V2013, P951786, DOI 10.1155/2013/951786
   Josephine Anthony, 2008, BMC Pharmacology, V8, P4, DOI 10.1186/1471-2210-8-4
   Jyonouchi H., 1995, EFFECT CAROTENOIDS I
   Katsumura N, 1996, NUTR CANCER, V26, P203, DOI 10.1080/01635589609514476
   Kavitha K., 2013, BIOCHIM BIOPHYS ACTA, V1830, P78
   Khanavi M, 2010, BIOL RES, V43, P31, DOI [10.4067/S0716-97602010000100005, /S0716-97602010000100005]
   Kim HW, 2000, VET IMMUNOL IMMUNOP, V73, P331, DOI 10.1016/S0165-2427(00)00152-5
   Kim HW, 2000, VET IMMUNOL IMMUNOP, V74, P315, DOI 10.1016/S0165-2427(00)00180-X
   Kim H, 2015, MOL MED REP, V12, P3632, DOI 10.3892/mmr.2015.3892
   Kim JY, 2009, PEDIATR GASTROENTERO, V12, P10
   Kim JH, 2016, GUT LIVER, V10, P369, DOI 10.5009/gnl15208
   Komatsu T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171178
   Kotake-Nara E, 2001, J NUTR, V131, P3303, DOI 10.1093/jn/131.12.3303
   Kotake-Nara E, 2005, CANCER LETT, V220, P75, DOI 10.1016/j.canlet.2004.07.048
   Kowshile J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109114
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lee DH, 2010, J CLIN BIOCHEM NUTR, V47, P121, DOI 10.3164/jcbn.10-29
   Lee EH, 2004, J INVEST DERMATOL, V122, P510, DOI 10.1046/j.0022-202X.2004.22227.x
   Lee JB, 2010, CARBOHYD POLYM, V81, P572, DOI 10.1016/j.carbpol.2010.03.014
   Li Rasia, 2015, Biochem Biophys Rep, V4, P52, DOI 10.1016/j.bbrep.2015.08.012
   Li SW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187810
   Liao JH, 2009, CHEM RES TOXICOL, V22, P518, DOI 10.1021/tx800378z
   Loef M, 2012, J NUTR HEALTH AGING, V16, P626, DOI 10.1007/s12603-012-0097-x
   LOYA S, 1992, ARCH BIOCHEM BIOPHYS, V293, P208, DOI 10.1016/0003-9861(92)90386-B
   Lu KW, 2011, HUM EXP TOXICOL, V30, P406, DOI 10.1177/0960327110372405
   Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661
   Lu YP, 2010, BRAIN RES, V1360, P40, DOI 10.1016/j.brainres.2010.09.016
   Lyons NM, 2002, J DERMATOL SCI, V30, P73, DOI 10.1016/S0923-1811(02)00063-4
   Maeda H, 2007, J AGR FOOD CHEM, V55, P7701, DOI 10.1021/jf071569n
   Manayi A, 2016, CRIT REV BIOTECHNOL, V36, P829, DOI 10.3109/07388551.2015.1049510
   Mares J, 2016, ANNU REV NUTR, V36, P571, DOI 10.1146/annurev-nutr-071715-051110
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Matsumoto C, 2013, BIOSCI BIOTECH BIOCH, V77, P860, DOI 10.1271/bbb.120791
   Mayeux R, 2003, ANNU REV NEUROSCI, V26, P81, DOI 10.1146/annurev.neuro.26.043002.094919
   McArdle F, 2002, FREE RADICAL BIO MED, V33, P1355, DOI 10.1016/S0891-5849(02)01042-0
   McGraw KJ, 2003, AM NAT, V162, P704, DOI 10.1086/378904
   Meephansan J, 2017, CLIN COSMET INV DERM, V10, P259, DOI 10.2147/CCID.S142795
   MICOZZI MS, 1990, JNCI-J NATL CANCER I, V82, P282, DOI 10.1093/jnci/82.4.282
   Miller E, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/572491
   Min JY, 2014, DEMENT GERIATR COGN, V37, P246, DOI 10.1159/000356486
   Miyachi M., 2015, J CLIN BIOCHEM NUTR, P14
   Motterlini R, 2002, ANTIOXID REDOX SIGN, V4, P615, DOI 10.1089/15230860260220111
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Murillo E, 2010, FOOD CHEM, V122, P167, DOI 10.1016/j.foodchem.2010.02.034
   Muthusamy A, 2014, J CEREBR BLOOD F MET, V34, P522, DOI 10.1038/jcbfm.2013.230
   Nagaki Y., 2005, J CLIN THER MED, V21, P537
   Naithani R, 2010, NUTR HEALTH SER, P421, DOI 10.1007/978-1-60761-061-8_24
   Nomura T, 1997, BIOCHEM MOL BIOL INT, V42, P361
   O'Connor I, 1998, J DERMATOL SCI, V16, P226, DOI 10.1016/S0923-1811(97)00058-3
   Ozaki K, 2015, J PHARMACOL SCI, V129, P72, DOI 10.1016/j.jphs.2015.08.003
   Palozza P, 1998, CARCINOGENESIS, V19, P373, DOI 10.1093/carcin/19.2.373
   Pang R, 2010, PHYTOTHER RES, V24, P1627, DOI 10.1002/ptr.3155
   Park BG, 2008, BIOORG MED CHEM LETT, V18, P6324, DOI 10.1016/j.bmcl.2008.10.103
   Park G, 2017, BIOL PHARM BULL, V40, P1116, DOI 10.1248/bpb.b17-00161
   Park JS, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-18
   Park JH, 2018, EXP DERMATOL, V27, P378, DOI 10.1111/exd.13437
   Pasquet V, 2011, MAR DRUGS, V9, P819, DOI 10.3390/md9050819
   Peng J, 2011, MAR DRUGS, V9, P1806, DOI 10.3390/md9101806
   Pisoschi AM, 2015, EUR J MED CHEM, V97, P55, DOI 10.1016/j.ejmech.2015.04.040
   Promphet P, 2014, BIOL RES, V47, DOI 10.1186/0717-6287-47-15
   Raghavendran HRB, 2005, MOL CELL BIOCHEM, V276, P89, DOI 10.1007/s11010-005-3194-x
   Rajput N, 2013, POULTRY SCI, V92, P1177, DOI 10.3382/ps.2012-02853
   Ribaya-Mereado JD, 2004, J AM COLL NUTR, V23, p567S, DOI 10.1080/07315724.2004.10719427
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rizwan M, 2011, BRIT J DERMATOL, V164, P154, DOI 10.1111/j.1365-2133.2010.10057.x
   Roberts RL, 2009, CLIN DERMATOL, V27, P195, DOI 10.1016/j.clindermatol.2008.01.011
   Rowe M, 2008, CONDOR, V110, P694, DOI 10.1525/cond.2008.8604
   Ruperez P, 2001, EUR FOOD RES TECHNOL, V212, P349, DOI 10.1007/s002170000264
   Saint-Mezard P, 2004, EUR J DERMATOL, V14, P284
   Saisugun J., 2017, EXTRACTION, V1
   Sakai S, 2009, J BIOL CHEM, V284, P28172, DOI 10.1074/jbc.M109.001099
   Salter-Venzon D, 2017, FOOD SCI NUTR, V5, P424, DOI 10.1002/fsn3.409
   Sarialtin S.Y., 2018, RECORDNATURAL PROD, V12
   Satia JA, 2009, AM J EPIDEMIOL, V169, P815, DOI 10.1093/aje/kwn409
   SCALLON LJ, 1988, CURR EYE RES, V7, P687, DOI 10.3109/02713688809033198
   Shao AW, 2016, MOL NEUROBIOL, V53, P18, DOI 10.1007/s12035-014-8986-0
   Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281
   Sies H, 2004, PHOTOCH PHOTOBIO SCI, V3, P749, DOI 10.1039/b316082c
   Silvan JM, 2016, FOOD FUNCT, V7, P1067, DOI [10.1039/c5fo01368b, 10.1039/C5FO01368B]
   Sinha S, 2010, PHYTOCHEMISTRY, V71, P235, DOI 10.1016/j.phytochem.2009.10.014
   Siriwardhana Nalin, 2004, Algae, V19, P59
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Stahl W, 2002, SKIN PHARMACOL APPL, V15, P291, DOI 10.1159/000064532
   STOREBAKKEN T, 1992, AQUACULTURE, V100, P209, DOI 10.1016/0044-8486(92)90372-R
   Stuetz W, 2017, FOOD CHEM, V221, P222, DOI 10.1016/j.foodchem.2016.10.065
   Sureshbabu Nagarajan, 2015, Journal of Applied Pharmaceutical Science, V5, P153
   Suzuki Y, 2006, EXP EYE RES, V82, P275, DOI 10.1016/j.exer.2005.06.023
   Swindells K, 2004, PHOTODERMATOL PHOTO, V20, P297, DOI 10.1111/j.1600-0781.2004.00121.x
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tanaka T, 1995, CARCINOGENESIS, V16, P2957, DOI 10.1093/carcin/16.12.2957
   Taylor E. J., 1998, Journal of Pharmacy and Pharmacology, V50, P78
   Terazawa S, 2012, EXP DERMATOL, V21, P11, DOI 10.1111/j.1600-0625.2012.01496.x
   Tharasena B., 2012, International Proceedings of Chemical, Biological and Environmental Engineering (IPCBEE), V39, P244
   TORRISSEN OJ, 1989, AQUACULTURE, V79, P363, DOI 10.1016/0044-8486(89)90478-X
   Tso MO, 1996, METHOD RETARDING AME
   Turrin NP, 2006, MOL NEUROBIOL, V34, P221, DOI 10.1385/MN:34:3:221
   Uchiyama S, 2005, INT J MOL MED, V15, P675
   van de Kraats J, 2008, INVEST OPHTH VIS SCI, V49, P5568, DOI 10.1167/iovs.08-1939
   Wang HQ, 2010, BRAIN RES, V1360, P159, DOI 10.1016/j.brainres.2010.08.100
   Wen X, 2015, NEUROSCIENCE, V303, P558, DOI 10.1016/j.neuroscience.2015.07.034
   Wenzel AJ, 2003, INVEST OPHTH VIS SCI, V44, P306, DOI 10.1167/iovs.01-1191
   Widomska Justyna, 2014, J Clin Exp Ophthalmol, V5, P326
   Wolf-Schnurrbusch UEK, 2015, INVEST OPHTH VIS SCI, V56, P8069, DOI 10.1167/iovs.15-17586
   Wu TH, 2006, J AGR FOOD CHEM, V54, P2418, DOI 10.1021/jf052651q
   Yamagishi R, 2014, MOL VIS, V20, P1796
   Yamaguchi M, 2004, MOL CELL BIOCHEM, V258, P137, DOI 10.1023/B:MCBI.0000012848.50541.19
   Yamaguchi M, 2003, BIOL PHARM BULL, V26, P1188, DOI 10.1248/bpb.26.1188
   Yan XJ, 1999, BIOSCI BIOTECH BIOCH, V63, P605, DOI 10.1271/bbb.63.605
   Yoshihisa Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152288
   Yoshihisa Y, 2014, EXP DERMATOL, V23, P178, DOI 10.1111/exd.12347
   Yuan JP, 2011, MOL NUTR FOOD RES, V55, P150, DOI 10.1002/mnfr.201000414
   Yuce HB, 2018, J PERIODONTAL RES, V53, P131, DOI 10.1111/jre.12497
   Zhang XS, 2014, MAR DRUGS, V12, P4291, DOI 10.3390/md12084291
NR 176
TC 19
Z9 19
U1 8
U2 31
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD JAN 1
PY 2020
VL 240
AR 117104
DI 10.1016/j.lfs.2019.117104
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA JX9LR
UT WOS:000504048800022
PM 31783054
DA 2022-11-30
ER

PT J
AU Baumann, BH
   Shu, WT
   Song, Y
   Simpson, EM
   Lakhal-Littleton, S
   Dunaief, JL
AF Baumann, Bailey H.
   Shu, Wanting
   Song, Ying
   Simpson, Elizabeth M.
   Lakhal-Littleton, Samira
   Dunaief, Joshua L.
TI Ferroportin-mediated iron export from vascular endothelial cells in
   retina and brain
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Iron; Ferroportin; Age-related macular degeneration (AMD); Retina;
   Retinal vascular endothelium; Ferritin
ID ANTITRANSFERRIN RECEPTOR ANTIBODY; TRANSFERRIN RECEPTOR;
   IMMUNOHISTOCHEMICAL LOCALIZATION; MACULAR DEGENERATION; FERROXIDASE
   ACTIVITY; MESSENGER-RNA; GAP-JUNCTIONS; EXPRESSION; FERRITIN; HEPCIDIN
AB Retinal iron accumulation has been implicated in the pathogenesis of age-related macular degeneration (AMD) and other neurodegenerative diseases. The retina and the brain are protected from the systemic circulation by the blood retinal barrier (BRB) and blood brain barrier (BBB), respectively. Iron levels within the retina and brain need to be tightly regulated to prevent oxidative injury. The method of iron entry through the retina and brain vascular endothelial cells (r&bVECs), an essential component of the BRB and BBB, is not fully understood. However, localization of the cellular iron exporter, ferroportin (Fpn), to the abluminal membrane of these cells, leads to the hypothesis that Fpn may play an important role in the import of iron across the BRB and BBB. To test this hypothesis, a mouse model with deletion of Fpn within the VECs in both the retina and the brain was developed through tail vein injection of AAV9-Ple261(CLDN5)-icre to both experimental Fpn(f/f), and control Fpn(+/+) mice at P21. Mice were aged to 9 mo and changes in retinal and brain iron distribution were observed. In vivo fundus imaging and quantitative serum iron detection were used for model validation. Eyes and brains were collected for immunofluorescence. Deletion of Fpn from the retinal and brain VECs leads to ferritin-L accumulation, an indicator of elevated iron levels, in the retinal and brain VECs. This occurred despite lower serum iron levels in the experimental mice. This result suggests that Fpn normally transfers iron from retinal and brain VECs into the retina and brain. These results help to better define the method of retina and brain iron import and will increase understanding of neurodegenerative diseases involving iron accumulation.
C1 [Baumann, Bailey H.; Shu, Wanting; Song, Ying; Dunaief, Joshua L.] Univ Penn, Perelman Sch Med, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, 305 Stellar Chance Lab,422 Curie Blvd, Philadelphia, PA 19104 USA.
   [Shu, Wanting] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Sch Med,Shanghai Key Lab Ocular Fundus Dis,Shangh, 100 Haining Rd, Shanghai 200080, Peoples R China.
   [Simpson, Elizabeth M.] Univ British Columbia, Child & Family Res Inst, Ctr Mol Med & Therapeut, 950 W 28 Ave, Vancouver, BC V5Z 4H4, Canada.
   [Simpson, Elizabeth M.] Univ British Columbia, Dept Med Genet, Vancouver, BC V6H 3N1, Canada.
   [Lakhal-Littleton, Samira] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England.
C3 University of Pennsylvania; Pennsylvania Medicine; Shanghai Jiao Tong
   University; Child & Family Research Institute; University of British
   Columbia; University of British Columbia; University of Oxford
RP Dunaief, JL (通讯作者)，Univ Penn, Perelman Sch Med, Scheie Eye Inst, FM Kirby Ctr Mol Ophthalmol, 305 Stellar Chance Lab,422 Curie Blvd, Philadelphia, PA 19104 USA.
EM bbaum@vet.upenn.edu; shuwanting@sjtu.edu.cn;
   yingsong@pennmedicine.upenn.edu; simpson@cmmt.ubc.ca;
   samira.lakhal-littleton@dpag.ox.ac.uk; jdunaief@pennmedicine.upenn.edu
OI Baumann, Bailey/0000-0002-9595-5795; Simpson,
   Elizabeth/0000-0002-0654-4303
FU NIH/NEI [EY015240]; UPenn Vision Science Training Grant
   [5T32EY007035-37]; Research to Prevent Blindness; F.M. Kirby Foundation;
   Paul and Evanina Bell Mackall Foundation Trust; Genome British Columbia
   [AGCPCanEuCre-01];  [MEYS LO1419]; NATIONAL EYE INSTITUTE [T32EY007035,
   R01EY015240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASES [T32AI070077] Funding Source: NIH RePORTER
FX Funding from NIH/NEI EY015240, the UPenn Vision Science Training Grant
   (5T32EY007035-37), Research to Prevent Blindness, the F.M. Kirby
   Foundation, a gift in memory of Lee F. Mauger, MD, the Paul and Evanina
   Bell Mackall Foundation Trust, and grant MEYS LO1419. The development of
   Ple261(CLDN5)-icre was supported by Genome British Columbia grant
   AGCPCanEuCre-01 to EMS.
CR Arosio P, 2009, BBA-GEN SUBJECTS, V1790, P589, DOI 10.1016/j.bbagen.2008.09.004
   Ayton S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7760
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Burdo JR, 2001, J NEUROSCI RES, V66, P1198, DOI 10.1002/jnr.1256
   Burdo JR, 1999, NEUROSCIENCE, V93, P1189, DOI 10.1016/S0306-4522(99)00207-9
   Cohen LA, 2010, BLOOD, V116, P1574, DOI 10.1182/blood-2009-11-253815
   DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258
   De Domenico I, 2007, EMBO J, V26, P2823, DOI 10.1038/sj.emboj.7601735
   de Leeuw CN, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0232-4
   Donovan A, 2005, CELL METAB, V1, P191, DOI 10.1016/j.cmet.2005.01.003
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   FISHMAN JB, 1987, J NEUROSCI RES, V18, P299, DOI 10.1002/jnr.490180206
   FRIDEN PM, 1991, P NATL ACAD SCI USA, V88, P4771, DOI 10.1073/pnas.88.11.4771
   Ganz T, 2004, CURR OPIN HEMATOL, V11, P251, DOI 10.1097/00062752-200407000-00004
   Gnana-Prakasam JP, 2012, BIOCHEM J, V441, P599, DOI 10.1042/BJ20111148
   Gnana-Prakasam JP, 2010, IUBMB LIFE, V62, P363, DOI 10.1002/iub.326
   Hadziahmetovic M, 2011, AM J PATHOL, V179, P335, DOI 10.1016/j.ajpath.2011.03.033
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Harford JB, 2006, P NATL ACAD SCI USA, V87, P7958, DOI DOI 10.1073/PNAS.87.20.7958
   JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0
   Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014-5793(00)01338-7
   Kissel K, 1998, HISTOCHEM CELL BIOL, V110, P63, DOI 10.1007/s004180050266
   Klaassen I, 2013, PROG RETIN EYE RES, V34, P19, DOI 10.1016/j.preteyeres.2013.02.001
   Knutson M, 2004, J NEUROSCI RES, V76, P633, DOI 10.1002/jnr.20113
   Lakhal-Littleton S, 2015, P NATL ACAD SCI USA, V112, P3164, DOI 10.1073/pnas.1422373112
   Lee DW, 2010, J NEUROCHEM, V112, P332, DOI 10.1111/j.1471-4159.2009.06470.x
   McCarthy RC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089003
   McCarthy RC, 2013, J BIOL CHEM, V288, P17932, DOI 10.1074/jbc.M113.455428
   Mendes-Jorge L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106974
   Mese G, 2007, J INVEST DERMATOL, V127, P2516, DOI 10.1038/sj.jid.5700770
   Moos T, 1996, J COMP NEUROL, V375, P675, DOI 10.1002/(SICI)1096-9861(19961125)375:4<675::AID-CNE8>3.0.CO;2-Z
   Moos T, 2004, J NEUROCHEM, V88, P233, DOI 10.1046/j.1471-4159.2003.02142.x
   Moos T, 2002, DAN MED B, DOI [10.1016/0162-0134(92)84071-T, DOI 10.1016/0162-0134(92)84071-T]
   Muckenthaler M, 1998, MOL CELL, V2, P383, DOI 10.1016/S1097-2765(00)80282-8
   Nagasawa K, 2006, J CELL PHYSIOL, V208, P123, DOI 10.1002/jcp.20647
   Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742
   PARDRIDGE WM, 1991, J PHARMACOL EXP THER, V259, P66
   Rouault Tracey A, 2006, Semin Pediatr Neurol, V13, P142, DOI 10.1016/j.spen.2006.08.002
   Sato T, 2002, DIABETES, V51, P1565, DOI 10.2337/diabetes.51.5.1565
   Shimshek DR, 2002, GENESIS, V32, P19, DOI 10.1002/gene.10023
   Smith MA, 2010, J ALZHEIMERS DIS, V19, P363, DOI 10.3233/JAD-2010-1239
   Song DL, 2016, EXP EYE RES, V151, P122, DOI 10.1016/j.exer.2016.08.008
   Song D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00024
   Steere AN, 2012, BBA-GEN SUBJECTS, V1820, P326, DOI 10.1016/j.bbagen.2011.06.003
   Syed BA, 2002, PROTEIN ENG, V15, P205, DOI 10.1093/protein/15.3.205
   Theurl M, 2016, FASEB J, V30, P813, DOI 10.1096/fj.15-276758
   Truman-Rosentsvit M, 2018, BLOOD, V131, P342, DOI 10.1182/blood-2017-02-768580
   Wolkow N, 2012, AM J PATHOL, V180, P1614, DOI 10.1016/j.ajpath.2011.12.041
   Wu LJC, 2004, BRAIN RES, V1001, P108, DOI 10.1016/j.brainres.2003.10.066
   YAMASHIRO DJ, 1984, J CELL BIOCHEM, V26, P231, DOI 10.1002/jcb.240260404
NR 52
TC 13
Z9 14
U1 0
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2019
VL 187
AR 107728
DI 10.1016/j.exer.2019.107728
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JB9FO
UT WOS:000488887100006
PM 31323276
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Leclaire, MD
   Nettels-Hackert, G
   Konig, J
   Hohn, A
   Grune, T
   Uhlig, CE
   Hansen, U
   Eter, N
   Heiduschka, P
AF Leclaire, Martin Dominik
   Nettels-Hackert, Gerburg
   Koenig, Jeannette
   Hoehn, Annika
   Grune, Tilman
   Uhlig, Constantin E.
   Hansen, Uwe
   Eter, Nicole
   Heiduschka, Peter
TI Lipofuscin-dependent stimulation of microglial cells
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Microglia; Lipofuscin; Age-related macular degeneration; Inflammation;
   VEGF; Hydrocortisone
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; AGE PIGMENT; NITRIC-OXIDE; IN-VIVO; CHOROIDAL
   NEOVASCULARIZATION; INFLAMMASOME ACTIVATION; SUBRETINAL MICROGLIA;
   MOLECULAR-MECHANISMS
AB Purpose To examine the reaction of microglial cells (MG) when incubated with lipofuscin (LP) in vitro with emphasis on the immunological reaction of the MG toward LP and the suppression of this reaction by immunomodulatory agents. MG are involved in the pathogenesis of degenerative eye disorders such as age-related macular degeneration (AMD). LP is a heterogeneous waste material that accumulates in the retinal pigment epithelium (RPE) cells with advancing age. LP is known to have toxic effects on RPE cells and therefore an elevated LP-derived fundus autofluorescence is a risk factor for AMD development. MG in the subretinal space have been reported in eyes affected by AMD. Moreover, in senescent mice, subretinal MG were found, which display an autofluorescence that may be derived from LP uptake.
   Methods In this study, we incubated MG (BV-2 cell line and primary cells from murine brain) in vitro with LP isolated from the human RPE. We observed phagocytosis, studied cell morphologies, and analyzed the cell culture supernatants. We also investigated the effect of the immunomodulatory agents hydrocortisone (HC), minocycline, and the tripeptide TKP.
   Results The MG phagocytosed the LP quickly and completely. We detected highly elevated levels of pro-inflammatory cytokines (especially of IL-6, IL-23p19, TNF-alpha, KC, RANTES, and IL-1 alpha) in the cell culture supernatants. Furthermore, levels of vascular endothelial growth factor (VEGF) were raised in BV-2 cells. Anti-inflammatory agents added to the cell cultures inhibited the inflammatory reaction, in particular hydrocortisone (HC). Minocycline and TKP had less impact on the cytokine release.
   ConclusionThe interaction of MG and LP could play a role in the development of retinal degeneration by triggering an inflammatory reaction and angiogenesis.
C1 [Leclaire, Martin Dominik; Nettels-Hackert, Gerburg; Eter, Nicole; Heiduschka, Peter] Univ Med Ctr, Dept Ophthalmol, Res Lab, Domagkstr 15, D-48149 Munster, Germany.
   [Koenig, Jeannette; Hoehn, Annika; Grune, Tilman] German Inst Human Nutr, Potsdam, Germany.
   [Uhlig, Constantin E.] Univ Med Ctr, Dept Ophthalmol, Cornea Bank Munster, Munster, Germany.
   [Hansen, Uwe] Univ Munster, Fac Med, Inst Expt Musculoskeletal Med, Munster, Germany.
C3 University of Munster; Deutsches Institut fur Ernahrungsforschung
   Potsdam-Rehbrucke (DIfE); University of Munster; University of Munster
RP Heiduschka, P (通讯作者)，Univ Med Ctr, Dept Ophthalmol, Res Lab, Domagkstr 15, D-48149 Munster, Germany.
EM peter.heiduschka@ukmuenster.de
RI Heiduschka, Peter/AAX-3882-2021
OI Grune, Tilman/0000-0003-4775-9973; Hohn, Annika/0000-0003-1306-2668;
   Konig, Jeannette/0000-0003-3217-573X
CR Ablonczy Z, 2013, ARCH BIOCHEM BIOPHYS, V539, P196, DOI 10.1016/j.abb.2013.08.005
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Adams AC, 2015, CELL MOL NEUROBIOL, V35, P961, DOI 10.1007/s10571-015-0191-9
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Bahadorani Sepehr, 2017, F1000Res, V6, P519, DOI 10.12688/f1000research.10998.1
   Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029
   Bhasin M, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-10
   BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V
   BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405
   Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011
   BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   BOULTON M, 1985, EXP EYE RES, V41, P209, DOI 10.1016/0014-4835(85)90026-0
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Burm SM, 2015, J NEUROSCI, V35, P678, DOI 10.1523/JNEUROSCI.2510-14.2015
   Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599
   Calvo P, 2015, BRIT J OPHTHALMOL, V99, P723, DOI 10.1136/bjophthalmol-2014-305684
   Chang JY, 2000, NEUROCHEM RES, V25, P903, DOI 10.1023/A:1007511221666
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05-1522
   Chen L, 2002, OCUL IMMUNOL INFLAMM, V10, P27, DOI 10.1076/ocii.10.1.27.10328
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DIAZARAYA CM, 1995, J COMP NEUROL, V363, P53, DOI 10.1002/cne.903630106
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Drew PD, 2000, BRAIN RES BULL, V52, P391, DOI 10.1016/S0361-9230(00)00275-6
   Dulla YAT, 2016, NEUROCHEM RES, V41, P2848, DOI 10.1007/s11064-016-2000-3
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELDRED GE, 1982, SCIENCE, V216, P757, DOI 10.1126/science.7079738
   Emmetsberger J, 2012, NEUROBIOL DIS, V47, P295, DOI 10.1016/j.nbd.2012.05.001
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205
   Grey AC, 2011, INVEST OPHTH VIS SCI, V52, P3926, DOI 10.1167/iovs.10-7020
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Heiduschka P, 2006, GRAEF ARCH CLIN EXP, V244, P1512, DOI 10.1007/s00417-005-0164-7
   Horvath RJ, 2008, J NEUROCHEM, V107, P557, DOI 10.1111/j.1471-4159.2008.05633.x
   Julien S, 2012, NEUROBIOL AGING, V33, P2390, DOI 10.1016/j.neurobiolaging.2011.12.009
   Kaluzny J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162869
   Karlstetter M, 2010, IMMUNOBIOLOGY, V215, P685, DOI 10.1016/j.imbio.2010.05.010
   KATZ ML, 1989, INVEST OPHTH VIS SCI, V30, P37
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krause TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094313
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253
   Lei L, 2012, MOL VIS, V18, P103
   Li L, 2017, OPHTHALMOLOGICA, V237, P29, DOI 10.1159/000453550
   Liu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0050719, 10.1371/journal.pone.0064143, 10.1371/journal.pone.0057473]
   Luheshi NM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-186
   Ma WX, 2016, ADV EXP MED BIOL, V854, P73, DOI 10.1007/978-3-319-17121-0_11
   Ma WX, 2013, NEUROBIOL AGING, V34, P943, DOI 10.1016/j.neurobiolaging.2012.06.010
   Madeira MH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/673090
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Mohr LKM, 2015, INVEST OPHTH VIS SCI, V56, P6404, DOI 10.1167/iovs.15-16898
   Moller T, 2016, GLIA, V64, P1788, DOI 10.1002/glia.23007
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139
   Ottis P, 2012, PROTEOMICS, V12, P2445, DOI 10.1002/pmic.201100668
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Peters S, 2006, OPHTHAL RES, V38, P83, DOI 10.1159/000090268
   Pozarowska D, 2016, CENT EUR J IMMUNOL, V41, P311, DOI 10.5114/ceji.2016.63132
   Raivich G, 2005, TRENDS NEUROSCI, V28, P571, DOI 10.1016/j.tins.2005.09.001
   Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7
   Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   REICHEL W, 1968, J GERONTOL, V23, P145, DOI 10.1093/geronj/23.2.145
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397
   Schindelin J, 2015, MOL REPROD DEV, V82, P518, DOI 10.1002/mrd.22489
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Smith RT, 2013, INVEST OPHTH VIS SCI, V54, P5543, DOI 10.1167/iovs.13-12798
   Sparrow JR, 2013, INVEST OPHTH VIS SCI, V54, P8325, DOI 10.1167/iovs.13-13214
   STREETEN BW, 1961, ARCH OPHTHALMOL-CHIC, V66, P391
   STREHLER BL, 1959, J GERONTOL, V14, P430, DOI 10.1093/geronj/14.4.430
   STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209
   SUZUMURA A, 1991, BRAIN RES, V545, P301, DOI 10.1016/0006-8993(91)91302-H
   Tanaka J, 1997, GLIA, V20, P23, DOI 10.1002/(SICI)1098-1136(199705)20:1<23::AID-GLIA3>3.3.CO;2-U
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terman A, 1998, APMIS, V106, P265, DOI 10.1111/j.1699-0463.1998.tb01346.x
   Terman A, 1998, MECH AGEING DEV, V100, P145, DOI 10.1016/S0047-6374(97)00129-2
   THANOS S, 1993, J NEUROSCI, V13, P455
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Toops Kimberly A, 2013, Commun Integr Biol, V6, pe24474, DOI 10.4161/cib.24474
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wake H, 2009, J NEUROSCI, V29, P3974, DOI 10.1523/JNEUROSCI.4363-08.2009
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Warburton S, 2005, MOL VIS, V11, P1122
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Winkler BS, 1999, MOL VIS, V5
   Wu L, 2010, ADV EXP MED BIOL, V664, P533, DOI 10.1007/978-1-4419-1399-9_61
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   YIN DZ, 1992, MECH AGEING DEV, V62, P35, DOI 10.1016/0047-6374(92)90142-Z
   Yoon KD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041309
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zhao MZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131429
NR 130
TC 6
Z9 6
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2019
VL 257
IS 5
BP 931
EP 952
DI 10.1007/s00417-019-04253-x
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HT9JS
UT WOS:000464886200010
PM 30693383
DA 2022-11-30
ER

PT J
AU Fang, PP
   Domdei, N
   Herrmann, P
   Schmitz-Valckenberg, S
   Holz, FG
   Harmening, WM
   Krohne, TU
AF Fang, Petra P.
   Domdei, Niklas
   Herrmann, Philipp
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Harmening, Wolf M.
   Krohne, Tim U.
TI MINIMAL OPTICAL COHERENCE TOMOGRAPHY B-SCAN DENSITY FOR RELIABLE
   DETECTION OF INTRARETINAL AND SUBRETINAL FLUID IN MACULAR DISEASES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE optical coherence tomography; retinal imaging; image analysis; OCT
   B-scan density; macular diseases; age-related macular degeneration;
   diabetic macular edema; retinal vein occlusion; intravitreal injection;
   anti-vascular endothelial growth factor therapy
ID RETINAL THICKNESS MEASUREMENTS; IMPACT
AB Purpose: To determine the minimal optical coherence tomography B-scan density for reliable detection of intraretinal and subretinal fluid.
   Methods: Spectral domain optical coherence tomography raster scanning (Spectralis; Heidelberg Engineering, Heidelberg, Germany) using a scan field of 20 degrees x 20 degrees of 97 B-scans with an interscan distance (ISD) of 60 mu m was performed in 150 eyes of 150 consecutive patients at monitoring visits for intravitreal anti-vascular endothelial growth factor therapy. Using custom software, every other B-scan was repeatedly deleted to generate additional data sets with an ISD of 120 mu m (49 B-scans), 240 mu m (25 B-scans), and 480 mu m (13 B-scans). Two independent reviewers evaluated the data sets for the presence of cystoid spaces of intraretinal fluid and subretinal fluid.
   Results: Treatment diagnoses were neovascular age-related macular degeneration (68.0%), macular edema secondary to retinal vein occlusion (20.7%), diabetic macular edema (10.7%), and other retinal diseases (4.0%). Using the source data sets with an ISD of 60 mu m, intraretinal fluid was detected in 56.0%, subretinal fluid in 19.3%, and either/both in 68.7%. Compared with these results, the sensitivity of detection of intraretinal fluid and/or subretinal fluid using an ISD of 120 mu m, 240 mu m, and 480 mu m was 99.0% (95% confidence interval, 94.7-100.0; P = 0.5), 97.1% (91.7-99.4; P = 0.1), and 87.4% (79.4-93.1; P = 0.0001), respectively.
   Conclusion: An increase of ISD up to 240 mu m does not significantly impair the detection of treatment-relevant exudative retinal changes in monitoring during intravitreal therapy of macular diseases. These findings are relevant for the choice of optical coherence tomography B-scan density in both routine clinical care and interventional clinical studies.
C1 [Fang, Petra P.; Domdei, Niklas; Herrmann, Philipp; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Harmening, Wolf M.; Krohne, Tim U.] Univ Bonn, Dept Ophthalmol, Ernst Abbe St 2, D-53127 Bonn, Germany.
C3 University of Bonn
RP Krohne, TU (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe St 2, D-53127 Bonn, Germany.
EM krohne@uni-bonn.de
RI Krohne, Tim/D-1497-2013; Krohne, Tim/AAG-4412-2020; Larsen,
   Petra/AAV-3114-2020
OI Krohne, Tim/0000-0003-2280-925X; Larsen, Petra/0000-0003-2486-632X;
   Harmening, Wolf/0000-0001-7053-1198
FU Ernst und Berta Grimmke Foundation; German Research Foundation (DFG) [HA
   5323/5-1]
FX Supported by Ernst und Berta Grimmke Foundation (to P.P.F. and T.U.K.)
   and German Research Foundation (DFG), grant HA 5323/5-1 (to W.M.H.).
CR Adam MK, 2016, BRIT J OPHTHALMOL, V100, P491, DOI 10.1136/bjophthalmol-2014-306561
   Baranano AE, 2012, ACTA OPHTHALMOL, V90, pE274, DOI 10.1111/j.1755-3768.2012.02398.x
   Chhablani J, 2013, GRAEF ARCH CLIN EXP, V251, P1303, DOI 10.1007/s00417-012-2188-0
   Courtney RJ, 2015, RETINA, V8, P583
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Ghazi NG, 2009, AM J OPHTHALMOL, V148, P90, DOI 10.1016/j.ajo.2009.02.017
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P7637, DOI 10.1167/iovs.12-10047
   Heimes B, 2016, OPHTHALMOLOGE, V113, P570, DOI 10.1007/s00347-016-0224-x
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Menke MN, 2009, AM J OPHTHALMOL, V147, P467, DOI 10.1016/j.ajo.2008.09.005
   Nittala MG, 2011, EYE, V25, P1347, DOI 10.1038/eye.2011.173
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P399, DOI 10.1167/iovs.08-1697
   Rahimy E, 2014, AM J OPHTHALMOL, V158, P345, DOI 10.1016/j.ajo.2014.05.013
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   Schmitz-Valckenberg S, 2017, OPHTHALMOLOGE, V114, P275, DOI 10.1007/s00347-017-0450-x
   Schneider EW, 2014, AM J OPHTHALMOL, V157, P978, DOI 10.1016/j.ajo.2014.01.021
   Thiele S, LONGITUDINAL A UNPUB
   Velaga SB, 2017, EYE, V31, P53, DOI 10.1038/eye.2016.260
NR 20
TC 5
Z9 5
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2019
VL 39
IS 1
BP 150
EP 156
DI 10.1097/IAE.0000000000001918
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4QS
UT WOS:000480736000027
PM 29095359
DA 2022-11-30
ER

PT J
AU Cypel, MC
   Salomao, SR
   Dantas, PEC
   Lottenberg, CL
   Kasahara, N
   Ramos, LR
   Belfort, R
AF Cypel, Marcela Colussi
   Salomao, Solange Rios
   Correa Dantas, Paulo Elias
   Lottenberg, Claudio Luiz
   Kasahara, Niro
   Ramos, Luiz Roberto
   Belfort, Rubens, Jr.
TI Vision status, ophthalmic assessment, and quality of life in the very
   old
SO ARQUIVOS BRASILEIROS DE OFTALMOLOGIA
LA English
DT Article
DE Aging; Vision disorders/diagnosis; Geriatric assessment; Blindness;
   Vision, low; Quality of life; Surveys and questionnaires; Aged; Aged, 80
   and over
ID VISUAL FUNCTION QUESTIONNAIRE; CATARACT-SURGERY; SAO-PAULO; EYE;
   IMPAIRMENT; PREVALENCE; POPULATION; BLINDNESS; AGE; DISORDERS
AB Purpose: To determine the vision status, ophthalmic findings, and quality of life among the very elderly.
   Methods: This was a cross-sectional observational study of individuals aged 80 years and above. A comprehensive ophthalmic exam was performed with mea-surement of both the presenting (PVA) and best-corrected visual acuity. The Quality of Life Short Form-36 (SF-36) and the Visual Function Questionnaire (VFQ-25) were also administered.
   Results: A total of 150 non-institutionalized participants were assigned to three age groups: 80-89 years (n = 70), 90-99 years (n = 50), and 100 years and older (n= 30). PVA and best-corrected visual acuity were normal (>= 20/30) in 20 (13.3%) and 37 participants (24.7%), respectively. Regarding PVA, mild visual impairment (<20/30 to >= 20/60) was found in in 53 (35.4%), moderate visual impairment (<20/60 to >= 20/200) in 50 (33.3%), severe visual impairment (<20/200 to >= 20/400) in 8 (5.3%), and blindness (<20/400) in 19 (12.7%) participants. Regarding best-corrected visual acuity, mild, moderate, and severe visual impairments were present in 55 (36.7%), 38 (25.3%), and 5 (3.3%) participants, respectively, and blindness was present in 15 (10%). The main causes of visual impairment/blindness were cataract (43.8%), refractive errors (21.5%), age-related macular degeneration (17.7%), and myopic degeneration (3.8%). SF-36 scores were worse in those with low visual acuity, while VFQ-25 domain scores were poorer in those with vision impairment/blindness.
   Conclusion: Vision impairment and blindness was present in three-quarters of this sample, but it was notable that adequate correction with spectacles improved visual acuity. This reinforces the need for regular ophthalmic care in elderly patients to improve their quality of life by optimizing vision.
C1 [Cypel, Marcela Colussi; Salomao, Solange Rios; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, EPM, Dept Ophthalmol & Visual Sci, UNIFESP, Sao Paulo, SP, Brazil.
   [Correa Dantas, Paulo Elias; Kasahara, Niro] Santa Casa Sao Paulo, Dept Ophthalmol, Sao Paulo, SP, Brazil.
   [Lottenberg, Claudio Luiz] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
   [Ramos, Luiz Roberto] Univ Fed Sao Paulo, UNIFESP, Dept Med Prevent, Sao Paulo, SP, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Hospital Israelita Albert
   Einstein; Universidade Federal de Sao Paulo (UNIFESP)
RP Cypel, MC (通讯作者)，Rua Simao Alvares 1-015, BR-05417030 Sao Paulo, SP, Brazil.
EM macypel@gmail.com
RI Ramos, Luiz/AAF-3871-2020; DANTAS, PAULO ELIAS CORREA/AAO-8315-2020;
   Kasahara, Niro/P-4631-2019; Salomao, Solange/AAB-3234-2021; Ramos, Luiz
   R/E-5343-2012
OI Ramos, Luiz/0000-0003-3143-8315; DANTAS, PAULO ELIAS
   CORREA/0000-0002-4363-9301; Kasahara, Niro/0000-0003-4101-0304; Salomao,
   Solange/0000-0002-3436-5599; 
FU CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) at
   Departamento de Oftalmologia, Escola Paulista de Medicina, Universidade
   Federal de Sao Paulo, Sao Paulo, SP, Brasil
FX This study was supported by CAPES (Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior) for doctoral fellowship (MCC) at Departamento
   de Oftalmologia, Escola Paulista de Medicina, Universidade Federal de
   Sao Paulo, Sao Paulo, SP, Brasil. SRS and RBJ are research scholars from
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   Brasilia, Brasil).
CR Araujo A, 2008, ARQ BRAS OFTALMOL, V71, P246, DOI 10.1590/S0004-27492008000200021
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Bergman B, 2004, ACTA OPHTHALMOL SCAN, V82, P166, DOI 10.1111/j.1600-0420.2004.00182.x
   Bledowski P, 2011, EXP GERONTOL, V46, P1003, DOI 10.1016/j.exger.2011.09.006
   Brasil. Ministerio da Saude, 2007, RED INT INF SAUD RIP
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Chia EM, 2006, ANN ACAD MED SINGAP, V35, P461
   Cypel Marcela C., 2004, International Ophthalmology, V25, P267, DOI 10.1007/s10792-005-0077-9
   Cypel Marcela Colussi, 2006, Arq. Bras. Oftalmol., V69, P665, DOI 10.1590/S0004-27492006000500008
   Cypel MC, 2008, OFTALMOGERIATRIA
   Dev MK, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-345
   EDERER F, 1973, ARCH OPHTHALMOL-CHIC, V89, P1
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Geirsdottir A, 2007, AM J OPHTHALMOL, V143, P889, DOI 10.1016/j.ajo.2006.11.057
   Glynn RJ, 2012, OPHTHAL EPIDEMIOL, V19, P159, DOI 10.3109/09286586.2012.674614
   Hennis AJ, 2009, OPHTHALMOLOGY, V116, P1461, DOI 10.1016/j.ophtha.2009.02.017
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Instituto Brasileiro de Geografia e Estatistica, 2013, TAB COMPL POP SUA PR
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lima MG, 2009, CAD SAUDE PUBLICA, V25, P2159, DOI 10.1590/S0102-311X2009001000007
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   McGwin G, 2010, CURR EYE RES, V35, P451, DOI 10.3109/02713681003664931
   Owen Christopher G, 2006, BMC Ophthalmol, V6, P24, DOI 10.1186/1471-2415-6-24
   Resnikoff S, 2008, B WORLD HEALTH ORGAN, V86, P63, DOI 10.2471/BLT.07.041210
   Salomao SR, 2008, OPHTHAL EPIDEMIOL, V15, P167, DOI 10.1080/09286580701843812
   Simao LM, 2008, ARQ BRAS OFTALMOL, V71, P540, DOI 10.1590/S0004-27492008000400014
   Veras RP, 2012, CAD SAUDE PUBLICA, V28, P1834, DOI 10.1590/S0102-311X2012001000003
   World Health Organization (WHO), 2013, AG LIF COURS
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P409, DOI 10.1016/j.ophtha.2009.11.023
NR 30
TC 9
Z9 10
U1 0
U2 5
PU CONSEL BRASIL OFTALMOLOGIA
PI SAO PAULO
PA ALAMEDA SANTOS 1343, 11 ANDAR CJ 1110, CERQUEIRA CESAR, SAO PAULO, SP
   00000, BRAZIL
SN 0004-2749
EI 1678-2925
J9 ARQ BRAS OFTALMOL
JI Arq. Bras. Oftalmol.
PD MAY-JUN
PY 2017
VL 80
IS 3
BP 159
EP 164
DI 10.5935/0004-2749.20170039
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FE5LX
UT WOS:000408254100005
PM 28832732
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Macky, TA
   Hasaballah, MAM
   Emarah, AM
   Osman, AA
   Gado, AS
AF Macky, Tamer A.
   Hasaballah, Mohamed Abdel Moniem
   Emarah, Ahmed M.
   Osman, Amr Abdellatif
   Gado, Ahmed S.
TI Predicting postoperative visual outcomes in cataract patients with
   maculopathy
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; best-corrected visual acuity; cataract
   surgery; diabetic maculopathy; potential acuity meter
ID POTENTIAL ACUITY METER; SURGERY; TESTS
AB Purpose: To assess the accuracy of the potential acuity meter (PAM) in predicting postcataract surgery visual acuity outcome in patients with healed inactive maculopathies. Study Design: Prospective interventional clinical trial. Patients and Methods: Patients scheduled for phacoemulsification had preoperative and 1 month postoperative best-corrected visual acuity (BCVA), PAM test, fluorescein angiography, and macular optical coherence tomography. Patients were grouped to following preoperative BCVA: PRE1: 0.29 and better, PRE2: 0.25-0.13, and PRE3: 0.1 or worse; age: G1 <60, G2 = 60-70, and G3 >70 years. PAM accuracy was divided into: Grade 1: Postoperative BCVA = 1 or less line error of the PAM score, Grade 2: Between 1 and 2 lines error, and Grade 3: = 3 lines or more error. Results: This study enrolled 57 patients with a mean age of 71.05 +/- 6.78 years where 34 were females. There were 21 (36.84%) patients with diabetic maculopathy and 36 (63.16%) with age-related macular degeneration. The mean preoperative BCVA was 0.198 +/- 0.12 (0.1-0.5). The mean PAM score was 0.442 +/- 0.24 (0.1-1.3). The mean postoperative BCVA was 0.4352 +/- 0.19 (0.17-1.00). The PAM score was in Grade 1, 2, and 3 in 46 (80.7%), 54 (94.7%), and 56 (98.2), respectively. There was a highly significant correlation between the PAM score and the postoperative BCVA (P < 0.001, Chi-square test). There was no correlation between the PAM test accuracy and age, gender, diagnosis, and preoperative BCVA (P = 0.661, 0.667, 0. 0.991, 0.833, Chi-square test; respectively). Conclusion: The PAM is an accurate method of predicting postoperative visual acuity for eyes with nuclear cataracts Grade I and II and inactive maculopathies.
C1 [Macky, Tamer A.; Hasaballah, Mohamed Abdel Moniem; Emarah, Ahmed M.; Osman, Amr Abdellatif; Gado, Ahmed S.] Cairo Univ, Dept Ophthalmol, Kasr El Aini Hosp, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); Cairo University
RP Macky, TA (通讯作者)，29th,13th St,Apartment 11, Cairo 11431, Egypt.
EM tamermacky@gmail.com
RI Macky, Tamer A/I-8716-2019
OI Macky, Tamer A/0000-0002-9767-8912
CR Alio J L, 1993, Eur J Ophthalmol, V3, P189
   Barrett BT, 1995, EYE, V9, P722, DOI 10.1038/eye.1995.184
   Cuzzani OE, 1998, J CATARACT REFR SURG, V24, P263, DOI 10.1016/S0886-3350(98)80209-5
   Devereux CJ, 2000, CLIN EXP OPHTHALMOL, V28, P414, DOI 10.1046/j.1442-9071.2000.00349.x
   GRANEY MJ, 1988, AM J OPHTHALMOL, V105, P460, DOI 10.1016/0002-9394(88)90235-8
   Gus PI, 2000, J CATARACT REFR SURG, V26, P1238, DOI 10.1016/S0886-3350(00)00409-0
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   LASA MSM, 1995, OPHTHALMOLOGY, V102, P1007
   MILLER ST, 1988, OPHTHALMOLOGY, V95, P1125
   MINKOWSKI JS, 1983, OPHTHALMOLOGY, V90, P1360
   SASAKI K, 1990, OPHTHALMIC RES, V22, P46, DOI 10.1159/000267064
   Tetz M R, 1992, Ger J Ophthalmol, V1, P403
   THARP A, 1994, OPHTHALMIC SURG LAS, V25, P576
   Uy HS, 2005, J CATARACT REFR SURG, V31, P548, DOI 10.1016/j.jcrs.2004.05.052
   WALTUCK MH, 1994, OPHTHALMIC SURG LAS, V25, P657
NR 15
TC 3
Z9 4
U1 0
U2 4
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD OCT
PY 2015
VL 63
IS 10
BP 775
EP 778
DI 10.4103/0301-4738.171507
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ7CE
UT WOS:000367256700006
PM 26655002
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Yang, JH
   Wang, XD
   Fuh, G
   Yu, LL
   Wakshull, E
   Khosraviani, M
   Day, ES
   Demeule, B
   Liu, J
   Shire, SJ
   Ferrara, N
   Yadav, S
AF Yang, Jihong
   Wang, Xiangdan
   Fuh, Germaine
   Yu, Lanlan
   Wakshull, Eric
   Khosraviani, Mehraban
   Day, Eric S.
   Demeule, Barthelemy
   Liu, Jun
   Shire, Steven J.
   Ferrara, Napoleone
   Yadav, Sandeep
TI Comparison of Binding Characteristics and In Vitro Activities of Three
   Inhibitors of Vascular Endothelial Growth Factor A
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE ranibizumab; aflibercept; bevacizumab; VEGF; affinity; analytical
   ultracentrifugation
ID SIZE-DISTRIBUTION ANALYSIS; VEGF-TRAP; ANALYTICAL ULTRACENTRIFUGATION;
   MACULAR DEGENERATION; RANIBIZUMAB; THERAPY; MODEL
AB The objectives of this study were to evaluate the relative binding and potencies of three inhibitors of vascular endothelial growth factor A (VEGF), used to treat neovascular age-related macular degeneration, and assess their relevance in the context of clinical outcome. Ranibizumab is a 48 kDa antigen binding fragment, which lacks a fragment crystallizable (Fc) region and is rapidly cleared from systemic circulation. Aflibercept, a 110 kDa fusion protein, and bevacizumab, a 150 kDa monoclonal antibody, each contain an Fc region. Binding affinities were determined using Biacore analysis. Competitive binding by sedimentation velocity analytical ultracentrifugation (SV-AUC) was used to support the binding affinities determined by Biacore of ranibizumab and aflibercept to VEGF. A bovine retinal microvascular endothelial cell (BREC) proliferation assay was used to measure potency. Biacore measurements were format dependent, especially for aflibercept, suggesting that biologically relevant, true affinities of recombinant VEGF (rhVEGF) and its inhibitors are yet to be determined. Despite this assay format dependency, ranibizumab appeared to be a very tight VEGF binder in all three formats. The results are also very comparable to those reported previously.(1-3) At equivalent molar ratios, ranibizumab was able to displace aflibercept from preformed aflibercept/VEGF complexes in solution as assessed by SV-AUC, whereas aflibercept was not able to significantly displace ranibizumab from preformed ranibizumab/VEGF complexes. Ranibizumab, aflibercept, and bevacizumab showed dose-dependent inhibition of BREC proliferation induced by 6 ng/mL VEGF, with average IC50 values of 0.088 +/- 0.032, 0.090 +/- 0.009, and 0.500 +/- 0.091 nM, respectively. Similar results were obtained with 3 ng/mL VEGF. In summary Biacore studies and SV-AUC solution studies show that aflibercept does not bind with higher affinity than ranibizumab to VEGF as recently reported,4 and both inhibitors appeared to be equipotent with respect to their ability to inhibit VEGF function.
C1 [Yang, Jihong; Wang, Xiangdan; Fuh, Germaine; Yu, Lanlan; Wakshull, Eric; Khosraviani, Mehraban; Day, Eric S.; Demeule, Barthelemy; Liu, Jun; Shire, Steven J.; Ferrara, Napoleone; Yadav, Sandeep] Genentech Inc, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Yadav, S (通讯作者)，Genentech Inc, 1 DNA Way,MS 56-2A, San Francisco, CA 94080 USA.
EM Yadav.sandeep@gene.com
RI Day, Eric S/C-5020-2009
FU Genentech, Inc., South San Francisco, California
FX This study was sponsored by Genentech, Inc., South San Francisco,
   California. Genentech, Inc. is a member of the Roche Group. The authors
   are employees of Genentech, Inc. Support for third-party writing
   assistance for this manuscript was provided by Genentech, Inc.
CR [Anonymous], 2007, HDB SURFACE PLASMON
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Cannon MJ, 2005, BIOTECH PHARM ASPECT, P527
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Copeland RA, 2007, NAT REV DRUG DISCOV, V6, P249
   Drake AW, 2004, ANAL BIOCHEM, V328, P35, DOI 10.1016/j.ab.2003.12.025
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gabrielson JP, 2010, ANAL BIOCHEM, V396, P231, DOI 10.1016/j.ab.2009.09.036
   Heier JS, 2013, OPHTHALMOLOGY, V120, P209
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0
   Le K., 2013, AM SOC CLIN PHARM TH
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   MacGregor IK, 2004, BIOPHYS CHEM, V108, P165, DOI 10.1016/j.bpc.2003.10.018
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Muller KM, 1998, ANAL BIOCHEM, V261, P149, DOI 10.1006/abio.1998.2725
   O'Shannessy D J, 1994, Curr Opin Biotechnol, V5, P65, DOI 10.1016/S0958-1669(05)80072-2
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Presta LG, 1997, CANCER RES, V57, P4593
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   Schuck P, 2010, EUR BIOPHYS J BIOPHY, V39, P1261, DOI 10.1007/s00249-009-0545-7
   Trilling AK, 2013, BIOSENS BIOELECTRON, V40, P219, DOI 10.1016/j.bios.2012.07.027
   Yadav Sandeep, 2013, Biophys Rev, V5, P121, DOI 10.1007/s12551-013-0109-z
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Yu YJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002230
NR 31
TC 65
Z9 72
U1 0
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD OCT
PY 2014
VL 11
IS 10
BP 3421
EP 3430
DI 10.1021/mp500160v
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AQ5NX
UT WOS:000342857000021
PM 25162961
OA Green Published
DA 2022-11-30
ER

PT J
AU Zhao, J
   Hu, J
   Lu, H
   Yang, L
AF Zhao, Jie
   Hu, Jun
   Lu, Hao
   Yang, Lei
TI A population-based study of macular choroidal neovascularization using
   optical coherence tomography in Eastern China
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; optic
   coherence tomography; population-based study; Eastern China
ID DEGENERATION; PREVALENCE
AB The aim of the present study was to investigate the pathomorphological and functional variations of choroidal neovascularization (CNV) in age-related macular degeneration (AMD) in a Chinese population using optical coherence tomography (OCT). This population-based study enrolled 59 patients (age, >45 years; eyes, 70) with early and intermediate-stage AMD from Youyi Road Community, Baoshan District, Shanghai, China. Comprehensive standardized ophthalmic examinations included visual acuity, anterior segment analysis using a slit lamp, dilated fundus evaluation by direct ophthalmoscopy, 90D handheld lens analysis, fundus photography, fundus fluorescein angiography (FFA) and fast optic disk scans using OCT. The macular CNV characteristic profiles in early and intermediate-stage AMD were determined by OCT. Data were obtained on the first visit and the follow-up period ranged between 6 and 24 months, where FFA and OCT outcomes of early and intermediate-stage AMD patients were analyzed. Three profiles of early and intermediate-stage AMD were created from the OCT and FFA results, each with a different prognosis. Firstly, drusens with unclear boundaries and evident pigment proliferation, as well as hypofluorescence around the drusens, was observed via FFA. A slight small arch field located in the retinal pigment epithelium (RPE)/choriocapillary layer (CCL) was shown on OCT scans, indicating exudative AMD. Secondly, RPE detachments of >1 pupillary distance, without CNV in the macular area, indicated geographic chorioretinitis atrophy. Finally, drusens with clear boundaries and few pigment proliferations and no certain surrounding fluorescence was observed via FFA, while a clear RPE/CCL band on the OCT scans indicated slow progress. The results of the present study demonstrated that combined OCT and FFA was the most efficient method for identifying CNV and diagnosing AMD. If the two techniques are not available concurrently, then OCT is a safer and more reliable technique to follow-up early and intermediate-stage AMD patients.
C1 [Zhao, Jie; Hu, Jun; Lu, Hao; Yang, Lei] Baoshan Cent Hosp, Dept Ophthalmol, Shanghai 201906, Peoples R China.
RP Zhao, J (通讯作者)，Baoshan Cent Hosp, Dept Ophthalmol, 181 Youyi Rd, Shanghai 201906, Peoples R China.
EM sincerjie@outlook.com
FU Shanghai Municipal Health Bureau Key Specialty Construction [ZK2012A03];
   Science and Technology Commission of Baoshan District, Shanghai
   [08-E-6]; Integrative Medicine Hospital Key Specialty Construction of
   Baoshan District, Shanghai [ZXYZK2012A03]
FX The study was supported by grants from the Projects of Shanghai
   Municipal Health Bureau Key Specialty Construction (no. ZK2012A03), the
   Science and Technology Commission of Baoshan District, Shanghai (no.
   08-E-6) and the Integrative Medicine Hospital Key Specialty Construction
   of Baoshan District, Shanghai (no. ZXYZK2012A03).
CR de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Hess DB, 2005, AM J OPHTHALMOL, V139, P509, DOI 10.1016/j.ajo.2004.10.047
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Medeiros FA, 2004, ARCH OPHTHALMOL-CHIC, V122, P827, DOI 10.1001/archopht.122.6.827
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Petrarca R, 2013, OPHTHALMOLOGY, V120, P328, DOI 10.1016/j.ophtha.2012.07.091
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Zou Haidong, 2002, Zhonghua Yan Ke Za Zhi, V38, P580
NR 18
TC 0
Z9 0
U1 1
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD AUG
PY 2014
VL 8
IS 2
BP 371
EP 376
DI 10.3892/etm.2014.1731
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AL4TK
UT WOS:000339127500004
PM 25009585
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Semkova, I
   Kociok, N
   Karagiannis, D
   Nischt, R
   Smyth, N
   Paulsson, M
   Strauss, O
   Joussen, AM
AF Semkova, Irma
   Kociok, Norbert
   Karagiannis, Dimitrios
   Nischt, Roswitha
   Smyth, Neil
   Paulsson, Mats
   Strauss, Olaf
   Joussen, Antonia M.
TI Anti-angiogenic effect of the basement membrane protein nidogen-1 in a
   mouse model of choroidal neovascularization
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE nidogen; choroidal neovascularization; basement membrane; angiogenesis
ID LEUKOCYTE RESPONSE INTEGRIN; COLLAGEN TYPE-IV; MACULAR DEGENERATION;
   BINDING; LAMININ; ENTACTIN; NETWORK; CELLS; GENE; MICE
AB In patients with age-related macular degeneration disruption of the integrity of the retinal pigment epithelium (RPE) and Bruch's membrane (BrM), precedes choroidal neovascularization (CNV). We investigated the role of the basement membrane (BM) proteins nidogen-1 and nidogen-2 for the development of experimental CNV. Laser-induced CNV was studied in Nid1(-/-) and Nid2(-/-) mice and wild type (WT) controls by fluorescein angiography, by immune histochemistry of flat-mounts or paraffin sections to analyze expression pattern of nidogen-1 and -2 and nidogen binding BM proteins, and by western blotting. The influence of VEGF and bFGF on the mRNA expression of nidogen-1 was studied in vitro. Nidogen-1 protein is present in the BM of the inner limiting membrane (ILM), the retinal capillaries, and the choroid/sclera and CNV. Nidogen-2 protein is also found in these BMs but with a weaker expression in the ILM. In the retina the absence of nidogen-1 does not influence the expression of nidogen-2 and vice versa and does not influence the expression of the BM components collagen IV, laminin gamma 1, and perlecan. In Nid(-/-) mice, CNV lesions showed increased vessel leakage during angiography and the CNV area was larger than in WT or nidogen-2 deficient mice. Laser treatment led to up-regulation of nidogen-1 protein expression in the sclera/choroid of nidogen-2 deficient or WT mice. The treatment of HUVECs with VEGF leads to a reduced expression of nidogen-1 mRNA whereas its expression remained unchanged in RPE cells. In conclusion, nidogen-1 produced by the endothelial cells acts as a factor to help stabilizing the BM, thus preventing the sprouting of new vessels or the infiltration of endothelial cells. In this sense nidogen-1 is essential to provide an anti-angiogenic environment of differentiated vessels. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Semkova, Irma; Kociok, Norbert; Karagiannis, Dimitrios; Strauss, Olaf; Joussen, Antonia M.] Charite, Dept Ophthalmol, D-13353 Berlin, Germany.
   [Nischt, Roswitha] Univ Cologne, Dept Dermatol, Cologne, Germany.
   [Smyth, Neil] Univ Southampton, Ctr Biol Sci, Southampton, Hants, England.
   [Paulsson, Mats] Univ Cologne, CMMC, Fac Med, Ctr Biochem, D-50931 Cologne, Germany.
   [Paulsson, Mats] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50931 Cologne, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; University of Cologne; University of
   Southampton; University of Cologne; University of Cologne
RP Kociok, N (通讯作者)，Charite, Dept Ophthalmol, Augustenburger Pl 1, D-13353 Berlin, Germany.
EM Norbert.Kociok@charite.de
RI Strauss, Olaf/AAA-6485-2019; Joussen, Antonia/AAA-6901-2022
OI Smyth, Neil/0000-0002-3734-2149; Strauss, Olaf/0000-0002-6272-8596
FU Foundation for Aging Research, University of Duesseldorf [324-10-1, Pa
   660/10-01, SPP 1088]
FX Funding Jo 324-10-1, Pa 660/10-01, SPP 1088, Foundation for Aging
   Research, University of Duesseldorf.
CR Abari E, 2013, GRAEF ARCH CLIN EXP, V251, P763, DOI 10.1007/s00417-012-2237-8
   Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Bader BL, 2005, MOL CELL BIOL, V25, P6846, DOI 10.1128/MCB.25.15.6846-6856.2005
   Balasubramani M, 2010, MATRIX BIOL, V29, P471, DOI 10.1016/j.matbio.2010.04.002
   Baranowsky A, 2010, MATRIX BIOL, V29, P15, DOI 10.1016/j.matbio.2009.09.004
   Bechtel M, 2012, FASEB J, V26, P3637, DOI 10.1096/fj.11-194597
   Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619
   Cordeiro S, 2010, INVEST OPHTH VIS SCI, V51, P6001, DOI 10.1167/iovs.09-4720
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001
   FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x
   Gresham HD, 1996, J BIOL CHEM, V271, P30587, DOI 10.1074/jbc.271.48.30587
   Grimpe B, 1999, GLIA, V28, P138, DOI 10.1002/(SICI)1098-1136(199911)28:2<138::AID-GLIA5>3.0.CO;2-8
   Halfter W, 2013, CELL ADHES MIGR, V7, P64, DOI 10.4161/cam.22479
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Ho MSP, 2008, MICROSC RES TECHNIQ, V71, P387, DOI 10.1002/jemt.20567
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kunze A, 2010, OPHTHALMIC RES, V43, P108, DOI 10.1159/000247595
   Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Miosge N, 2002, MATRIX BIOL, V21, P611, DOI 10.1016/S0945-053X(02)00070-7
   Murshed M, 2000, MOL CELL BIOL, V20, P7007, DOI 10.1128/MCB.20.18.7007-7012.2000
   PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x
   POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x
   REINHARDT D, 1993, J BIOL CHEM, V268, P10881
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Salmivirta K, 2002, EXP CELL RES, V279, P188, DOI 10.1006/excr.2002.5611
   Schymeinsky J, 2002, MOL CELL BIOL, V22, P6820, DOI 10.1128/MCB.22.19.6820-6830.2002
   Semkova I, 2003, INVEST OPHTH VIS SCI, V44, P5349, DOI 10.1167/iovs.02-0732
   SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111
   SIRES UI, 1993, J BIOL CHEM, V268, P2069
   SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592
   Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151
   Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5
   Timpl R, 1996, BIOESSAYS, V18, P123, DOI 10.1002/bies.950180208
   TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Willem M, 2002, DEVELOPMENT, V129, P2711
   YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang P, 2013, MATRIX BIOL, V32, P196, DOI 10.1016/j.matbio.2013.02.002
NR 43
TC 13
Z9 13
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2014
VL 118
BP 80
EP 88
DI 10.1016/j.exer.2013.11.006
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 297NI
UT WOS:000330261800011
PM 24280453
DA 2022-11-30
ER

PT J
AU Dasari, B
   Prasanthi, JRP
   Meiers, C
   Singh, BB
   Ghribi, O
AF Dasari, Bhanu
   Prasanthi, Jaya R. P.
   Meiers, Craig
   Singh, Brij B.
   Ghribi, Othman
TI Differential Effects of the Estrogen Receptor Agonist Estradiol on
   Toxicity Induced by Enzymatically-Derived or Autoxidation-Derived
   Oxysterols in Human ARPE-19 Cells
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; estrogen receptor; IL-6; liver X
   receptor; oxysterols; TNF-alpha
ID AGE-RELATED MACULOPATHY; PIGMENT EPITHELIAL-CELLS; LIVER-X-RECEPTOR;
   MACULAR DEGENERATION; BRUCHS MEMBRANE; BASAL DEPOSITS; RISK-FACTORS;
   ABROGATES APOPTOSIS; NONGENOMIC ACTIONS; OXIDATIVE STRESS
AB Purpose/aim of the study: Disturbances in cholesterol metabolism and increased levels of cholesterol oxidation products (oxysterols) in retina may contribute to age-related macular degeneration (AMD). The role of oxysterols or of their target receptors liver X receptors (LXRs) and estrogen receptors (ERs) in the pathogenesis of MD is ill-known. The purpose of this study is to determine the extent to which the oxysterols 27-hydroxycholesterol (27-OHC), 25-hydroxycholesterol (25-OHC) and 7-ketocholesterol (7-KC) affect the transcriptional activity of LXR and ER.
   Materials and methods: ARPE-19 cells, untreated or incubated with 27-OHC, 25-OHC or 7-KC for 24 h were harvested. We used Western blot analyses for detecting ERs and LXRs expression, dual luciferase assays for measuring LXRs and ERs transcriptional activity, cytotox-ONE homogeneous membrane integrity assay for measuring cytotoxicity, JC-1 method for measuring mitochondrial membrane potential changes and ELISA for measuring cytokine levels.
   Results: Both LXRs and ERs are expressed and are transcriptionally active in ARPE-19 cells. 27-OHC, 25-OHC and 7-KC inhibited ER-mediated transcriptional activity, whereas 27-OHC and 25-OHC increased LXR-mediated transcription. E2 reduced 25-OHC and 27-OHC-induced cytotoxicity, mitochondrial permeability potential decline, and cytokine secretion. The LXR agonist GW3965 or the LXR antagonist 5 alpha-6 alpha-epoxycholesterol-3-sulfate (ECHS) did not offer protection against either 27-OHC and 25-OHC or 7-KC.
   Conclusions: Increased levels of oxysterols can decrease ER and increase LXR signaling. ER agonists can offer protection against cytotoxic effects of 27-OHC and 25-OHC, two oxysterols derived by enzymatic reactions. Although they exert similar toxicity, the cellular mechanisms involved in the toxic effects of oxysterols whether derived by enzymatic or autoxidation reactions appear to be different.
C1 [Dasari, Bhanu; Prasanthi, Jaya R. P.; Meiers, Craig; Ghribi, Othman] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA.
   [Singh, Brij B.] Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58202 USA.
C3 University of North Dakota Grand Forks; University of North Dakota Grand
   Forks
RP Ghribi, O (通讯作者)，Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58202 USA.
EM othman.ghribi@med.und.edu
OI Singh, Brij/0000-0003-0535-5997
FU NIH (NIEHS) [R01ES014826]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL
   RESEARCH [R01DE017102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE
   OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014826] Funding Source: NIH
   RePORTER
FX This work was supported by a grant from the NIH (NIEHS, R01ES014826) to
   O.G.
CR Azcoitia I, 2011, TRENDS ENDOCRIN MET, V22, P467, DOI 10.1016/j.tem.2011.08.002
   Bjorkhem I, 2002, CURR OPIN LIPIDOL, V13, P247, DOI 10.1097/00041433-200206000-00003
   Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486
   Bretillon L, 2007, CURR EYE RES, V32, P361, DOI 10.1080/02713680701231857
   Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8
   Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646
   Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050
   Chen WL, 2007, CELL METAB, V5, P73, DOI 10.1016/j.cmet.2006.11.012
   Chuo JY, 2006, AM J OPHTHALMOL, V142, P931, DOI 10.1016/j.ajo.2006.08.002
   Colles SM, 2001, TRENDS CARDIOVAS MED, V11, P131, DOI 10.1016/S1050-1738(01)00106-2
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dasari B, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-22
   Dimayuga FO, 2005, J NEUROIMMUNOL, V161, P123, DOI 10.1016/j.jneuroim.2004.12.016
   Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6
   Dugas B, 2010, EUR J NUTR, V49, P435, DOI 10.1007/s00394-010-0102-2
   DuSell CD, 2008, MOL ENDOCRINOL, V22, P65, DOI 10.1210/me.2007-0383
   Dwyer MA, 2011, MOL ENDOCRINOL, V25, P360, DOI 10.1210/me.2010-0392
   Eisner A, 2009, BREAST CANCER RES TR, V117, P9, DOI 10.1007/s10549-008-0156-5
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Evans JR, 1998, EYE, V12, P256, DOI 10.1038/eye.1998.60
   Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Flynn JM, 2008, AM J PHYSIOL-ENDOC M, V295, pE637, DOI 10.1152/ajpendo.90407.2008
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200
   Giddabasappa A, 2010, INVEST OPHTH VIS SCI, V51, P5278, DOI 10.1167/iovs.10-5316
   Gramajo AL, 2010, INVEST OPHTH VIS SCI, V51, P1164, DOI 10.1167/iovs.09-3443
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Karuna R, 2011, ATHEROSCLEROSIS, V214, P448, DOI 10.1016/j.atherosclerosis.2010.10.042
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim SM, 2013, BIOCHEM BIOPH RES CO, V430, P454, DOI 10.1016/j.bbrc.2012.12.021
   Kim WS, 2009, J ALZHEIMERS DIS, V16, P121, DOI 10.3233/JAD-2009-0944
   Klein B E, 1994, Trans Am Ophthalmol Soc, V92, P289
   Kolsch H, 2001, J NEURAL TRANSM, V108, P475, DOI 10.1007/s007020170068
   Lappano R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016631
   Lee JW, 2006, EXP EYE RES, V83, P465, DOI 10.1016/j.exer.2005.11.018
   Levin ER, 2001, J APPL PHYSIOL, V91, P1860, DOI 10.1152/jappl.2001.91.4.1860
   LUND E, 1993, BIOCHIM BIOPHYS ACTA, V1166, P177, DOI 10.1016/0005-2760(93)90094-P
   Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238
   Luthra S, 2006, INVEST OPHTH VIS SCI, V47, P5569, DOI 10.1167/iovs.06-0333
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x
   Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Munaut C, 2001, BRIT J OPHTHALMOL, V85, P877, DOI 10.1136/bjo.85.7.877
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   Paimela T, 2010, EUR J PHARMACOL, V640, P219, DOI 10.1016/j.ejphar.2010.05.006
   Prasanthi RPJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026420
   Qiu QH, 2012, CHINESE MED J-PEKING, V125, P4098, DOI 10.3760/cma.j.issn.0366-6999.2012.22.034
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rodriguez IR, 2004, INVEST OPHTH VIS SCI, V45, P2830, DOI 10.1167/iovs.04-0075
   Rosklint T, 2002, EUR J CLIN INVEST, V32, P35, DOI 10.1046/j.1365-2362.2002.00931.x
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Russell DW, 2000, BBA-MOL CELL BIOL L, V1529, P126, DOI 10.1016/S1388-1981(00)00142-6
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   Simpkins JW, 2005, CNS NEUROL DISORD-DR, V4, P69, DOI 10.2174/1568007053005073
   SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Song C, 2000, ENDOCRINOLOGY, V141, P4180, DOI 10.1210/en.141.11.4180
   Sribnick EA, 2004, NEUROCHEM RES, V29, P2007, DOI 10.1007/s11064-004-6874-0
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11
   Trivino A, 2006, EXP EYE RES, V83, P357, DOI 10.1016/j.exer.2005.12.020
   Umetani M, 2007, NAT MED, V13, P1185, DOI 10.1038/nm1641
   Urata Y, 2006, J BIOL CHEM, V281, P13092, DOI 10.1074/jbc.M601984200
   Vasconsuelo A, 2008, J ENDOCRINOL, V196, P385, DOI 10.1677/JOE-07-0250
   Vejux A, 2008, BRAZ J MED BIOL RES, V41, P545, DOI 10.1590/S0100-879X2008000700001
   VINGERLING JR, 1995, BRIT MED J, V310, P1570, DOI 10.1136/bmj.310.6994.1570
NR 84
TC 7
Z9 8
U1 1
U2 12
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD NOV
PY 2013
VL 38
IS 11
BP 1159
EP 1171
DI 10.3109/02713683.2013.811257
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 227FO
UT WOS:000325096200010
PM 23841471
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Or, C
   Cui, J
   Matsubara, J
   Forooghian, F
AF Or, Chris
   Cui, Jing
   Matsubara, Joanne
   Forooghian, Farzin
TI Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human
   cultured retinal pigment epithelial cells
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Angiogenesis; Biochemistry; Retina; Macula; Pharmacology
ID FIBROBLAST-GROWTH-FACTOR; ENDOTOXIN-INDUCED UVEITIS; MACULAR
   DEGENERATION; AUTOIMMUNE UVEITIS; CYTOKINE PROFILES; GENE-EXPRESSION;
   T-CELLS; THERAPY; GAMMA; INTERLEUKIN-6
AB Aim
   Bisphosphonates have been shown to induce ocular inflammatory diseases such as uveitis and scleritis, while being protective against angiogenic diseases like neovascular age-related macular degeneration (AMD). Therefore, we studied the effects of bisphosphonates on primary culture of human fetal retinal pigment epithelium (hRPE), a cell type known to secrete both inflammatory and angiogenic factors. Alendronate and etidronate were selected for this experiment as they are members of the two structurally different classes of bisphosphonates.
   Methods
   Primary cultures of hRPE were serum-starved for 24h and then treated for 24h with alendronate (0.0001, 0.1, 100 mu M) or etidronate (0.01, 1 mu M). Cell viability was measured using the MTT assay. Investigation of secreted cytokines induced by bisphosphonates was performed using a human cytokine 29-Plex Panel (Bio-Plex) array and the results were analysed with an analysis of variance (ANOVA).
   Results
   Etidronate, at the lower concentration, significantly increased the expression of interleukin (IL)-6 (p=0.03) and IL-8 (p=0.04). At the higher concentration, etidronate significantly decreased the expression of granulocyte macrophage colony-stimulating factor (p=0.02) and basic fibroblast growth factor (bFGF) (p=0.02). Alendronate, at the highest concentration, significantly increased the expression of IL-8 (p=0.02) and decreased the expression of eotaxin (p=0.02). Alendronate also significantly decreased the expression of bFGF at all concentrations (p<0.05) and demonstrated a trend towards decreasing vascular endothelial growth factor expression at low concentration.
   Conclusions
   Alendronate and etidronate display dose dependent effects in hRPE cells. Alendronate and etidronate administration resulted in concentration dependent elevations in inflammatory cytokines. Furthermore, alendronate and etidronate administration resulted in reduced expression of a number of angiogenic factors. These findings may explain the increased incidence of ocular inflammation as well as the therapeutic effect on neovascular AMD which have been described with bisphosphonates.
C1 [Or, Chris; Cui, Jing; Matsubara, Joanne; Forooghian, Farzin] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 1M9, Canada.
C3 University of British Columbia
RP Forooghian, F (通讯作者)，St Pauls Hosp, Dept Ophthalmol, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM farzin.forooghian@gmail.com
FU Canadian Institutes of Health Research (CIHR)
FX Funding Canadian Institutes of Health Research (CIHR).
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585
   Becker MD, 2001, INVEST OPHTH VIS SCI, V42, P2563
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Curnow SJ, 2005, INVEST OPHTH VIS SCI, V46, P4251, DOI 10.1167/iovs.05-0444
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Etminan M, 2012, CAN MED ASSOC J, V184, pE431, DOI 10.1503/cmaj.111752
   Fossiez F, 1998, Int Rev Immunol, V16, P541, DOI 10.3109/08830189809043008
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Gamulescu MA, 2006, EXP EYE RES, V83, P212, DOI 10.1016/j.exer.2005.12.007
   GHOSE K, 1994, AUST NZ J MED, V24, P320, DOI 10.1111/j.1445-5994.1994.tb02186.x
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Hewitt RE, 2005, CLIN EXP IMMUNOL, V139, P101, DOI 10.1111/j.1365-2249.2005.02665.x
   Hollborn M, 2004, GRAEF ARCH CLIN EXP, V242, P414, DOI 10.1007/s00417-004-0879-x
   Honda S, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/206837
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   Jabs DA, 2000, AM J OPHTHALMOL, V130, P492, DOI 10.1016/S0002-9394(00)00659-0
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754
   McKague M, 2010, CAN FAM PHYSICIAN, V56, P1015
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Monkkonen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Nagai T, 2007, INVEST OPHTH VIS SCI, V48, P5716, DOI 10.1167/iovs.07-1023
   Nishimoto N, 2006, NAT CLIN PRACT RHEUM, V2, P619, DOI 10.1038/ncprheum0338
   NUSSENBLATT RB, 1991, INVEST OPHTH VIS SCI, V32, P3131
   Nussenblatt Robert B, 2002, Int Rev Immunol, V21, P273, DOI 10.1080/08830180212067
   Oizumi T, 2010, J ORAL MAXIL SURG, V68, P1043, DOI 10.1016/j.joms.2009.08.027
   Perez VL, 2004, OCUL IMMUNOL INFLAMM, V12, P193, DOI 10.1080/092739490500282
   Peterson JD, 2012, ORBIT, V31, P119, DOI 10.3109/01676830.2011.648818
   Qin SF, 2011, EXP EYE RES, V93, P889, DOI 10.1016/j.exer.2011.10.002
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenthal R, 2005, BIOCHEM BIOPH RES CO, V337, P241, DOI 10.1016/j.bbrc.2005.09.028
   Santos LM, 2001, ARCH SOC ESP OFTALMO, V76, P345
   SCHWEIGERER L, 1987, BIOCHEM BIOPH RES CO, V143, P934, DOI 10.1016/0006-291X(87)90340-8
   STERNFELD MD, 1989, CURR EYE RES, V8, P1029, DOI 10.3109/02713688908997395
   Susa M, 2009, ANTICANCER RES, V29, P1879
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Valentincic NV, 2011, MOL VIS, V17, P2003
   Wang XF, 2005, INVEST OPHTH VIS SCI, V46, P1508, DOI 10.1167/iovs.04-0951
   Wang Y, 2011, EYE, V25, P127, DOI 10.1038/eye.2010.196
   Yoshimura T, 2008, INT IMMUNOL, V20, P209, DOI 10.1093/intimm/dxm135
   Yoshimura T, 2009, RHEUMATOLOGY, V48, P347, DOI 10.1093/rheumatology/ken489
NR 45
TC 16
Z9 17
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2013
VL 97
IS 8
BP 1074
EP 1078
DI 10.1136/bjophthalmol-2013-303355
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 186JI
UT WOS:000322039400027
PM 23766431
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Treumer, F
   Roider, J
   Hillenkamp, J
AF Treumer, Felix
   Roider, Johann
   Hillenkamp, Jost
TI Long-term outcome of subretinal coapplication of rtPA and bevacizumab
   followed by repeated intravitreal anti-VEGF injections for neovascular
   AMD with submacular haemorrhage
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TISSUE-PLASMINOGEN ACTIVATOR; MACULAR DEGENERATION; PNEUMATIC
   DISPLACEMENT; EXUDATIVE AMD; EXPANSILE GAS; MANAGEMENT; THERAPY
AB Aim To evaluate short-term and long-term outcomes of subretinal coapplication of recombinant tissue plasminogen activator (rtPA) and bevacizumab followed by intravitreal injections of bevacizumab or ranibizumab for neovascular age-related macular degeneration with submacular haemorrhage (SMH).
   Methods Retrospective, consecutive, interventional case series of 41 eyes of 40 patients. All patients underwent pars plana vitrectomy with subretinal coapplication of rtPA and bevacizumab and intravitreal gas tamponade. Postoperatively, repeated intravitreal injections of bevacizumab or ranibizumab were applied following a flexible, predominantly visual acuity-driven re-treatment regimen.
   Results Mean diameter of SMH was 4.5 disc diameters (range 1.5-12). Complete displacement of SMH was achieved in 35 of 41 eyes. Large and prominent SMH extending beyond the vascular arcades were completely displaced in six of eight eyes. SMH recurred in eight eyes after a mean of 9.1 months (2-19). A mean of 4.5 (2-9) intravitreal anti-vascular endothelial growth factor injections were applied during 12 months postoperatively. Short-term (3 months, n=41), mean best corrected logMAR visual acuity (BCVA) improved significantly from the preoperative value 1.7 (3.0-0.5) to 0.8 (1.6-0.2). 12 eyes had reading ability (<= logMAR 0.4) and 29 eyes had gained ambulatory visual acuity (<= logMAR 1.6). Long-term (mean 17 months (12-32), n=26) BCVA was 0.9 (1.6-0.1). Compared with short-term, BCVA had decreased in 12 of 26 eyes.
   Conclusion The operation effectively displaces small and large SMHs. In the long-term, a predominantly visual acuity-driven re-treatment regimen puts the initial functional improvement at risk. More sensitive retreatment parameters may help to improve long-term functional outcome.
C1 [Treumer, Felix; Roider, Johann; Hillenkamp, Jost] Univ Med Ctr Schleswig Holstein, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Treumer, F (通讯作者)，Univ Med Ctr Schleswig Holstein, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
EM ftreumer@auge.uni-kiel.de
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Pauleikhoff D, 2011, GRAEF ARCH CLIN EXP, V249, P631, DOI 10.1007/s00417-011-1639-3
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   TAKEUCHI A, 1994, INVEST OPHTH VIS SCI, V35, P3792
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
NR 22
TC 63
Z9 65
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2012
VL 96
IS 5
BP 708
EP 713
DI 10.1136/bjophthalmol-2011-300655
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 927UX
UT WOS:000302936900021
PM 22174095
DA 2022-11-30
ER

PT J
AU Lueck, K
   Hennig, M
   Lommatzsch, A
   Pauleikhoff, D
   Wasmuth, S
AF Lueck, Katharina
   Hennig, Maren
   Lommatzsch, Albrecht
   Pauleikhoff, Daniel
   Wasmuth, Susanne
TI Complement and UV-Irradiated Photoreceptor Outer Segments Increase the
   Cytokine Secretion by Retinal Pigment Epithelial Cells
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; MACULAR DEGENERATION; HUMAN RPE;
   MEMBRANE ATTACK; GROWTH-FACTOR; AGING RETINA; AGE; LIPOFUSCIN; DRUSEN;
   SENESCENCE
AB PURPOSE. Age-related macular degeneration (AMD) is accompanied by increased complement activation, and by lipofuscin accumulation in retinal pigment epithelial (RPE) cells due to incomplete degradation of photoreceptor outer segments (POS). The influence of POS, ultraviolet (UV)-irradiated POS and human complement sera (HCS) on cytokine secretion from RPE cells was therefore examined.
   METHODS. RPE cells were incubated with POS or UV-POS every other day for 1 week. The autofluorescence (AF) was measured photometrically and by flow cytometry. Senescence-associated genes were analyzed by RT-PCR. Internalization and degradation of POS were determined using phagocytosis and degradation assays, and lysosomal function by neutral red uptake. RPE cells in polycarbonate cell culture inserts were incubated apically with POS or UV-POS and afterward basally with HCS. C7-deficient HCS was used as control. The integrity of the cell monolayer was assessed by measuring the transepithelial electrical resistance (TER) and the permeability. Interleukin (IL)-6, IL-8, monocyte chemoattractant protein-1, and vascular endothelial growth factor were quantified by ELISA.
   RESULTS. POS treatment led to an increased AF and senescence marker expression, which were further elevated in response to UV-POS. UV-POS were preferentially accumulated over POS and the lysosomal function was impaired due to UV-POS. HCS intensified the cytokine production compared with controls. POS had no effect, though UV-POS combined with HCS induced a significant increase in all cytokines.
   CONCLUSIONS. RPE cultivation with UV-POS might serve as a model to investigate the accumulation of lipofuscin-like structures. The enhanced cytokine secretion due to UV-POS with HCS may account for an increased susceptibility for lipofuscin-loaded cells to complement, inducing a proinflammatory environment as observed in AMD. (Invest Ophthalmol Vis Sci. 2012;53:1406-1413) DOI:10.1167/iovs.11-8889
C1 [Lueck, Katharina; Hennig, Maren; Pauleikhoff, Daniel; Wasmuth, Susanne] St Franziskus Hosp, Ophtha Lab, Munster, Germany.
   [Lommatzsch, Albrecht; Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
C3 St. Franziskus-Hospital; St. Franziskus-Hospital
RP Wasmuth, S (通讯作者)，Augenaerzte St Franziskus Hosp, Ophtha Lab, Hohenzollernring 74, D-48145 Munster, Germany.
EM susanne.wasmuth@makula-centrum-muenster.de
RI Kasper, Maren/AAS-1716-2021
FU Akademie des Sehens and Voltmann Foundation
FX Supported by Akademie des Sehens and Voltmann Foundation.
CR Abe T, 2003, INVEST OPHTH VIS SCI, V44, P4097, DOI 10.1167/iovs.02-0867
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BOK D, 1993, J CELL SCI, P189
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Burke JM, 1998, INVEST OPHTH VIS SCI, V39, P1478
   Chen WQ, 2008, INT J MOL MED, V21, P645
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X
   Dumont P, 2002, CELL STRESS CHAPERON, V7, P23, DOI 10.1379/1466-1268(2002)007<0023:OOAJIH>2.0.CO;2
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   GARCIADIAZ JF, 1985, BIOPHYS J, V48, P519, DOI 10.1016/S0006-3495(85)83807-8
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hollborn M, 2001, GRAEF ARCH CLIN EXP, V239, P294, DOI 10.1007/s004170100263
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, OPHTHALMOLOGE, V96, P781, DOI 10.1007/s003470050496
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Katz ML, 1996, MECH AGEING DEV, V92, P159, DOI 10.1016/S0047-6374(96)01817-9
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kilgore KS, 1996, AM J PATHOL, V149, P953
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LEE C, 1987, J UROLOGY, V138, P903, DOI 10.1016/S0022-5347(17)43413-6
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589
   MORGAN BP, 1989, BIOCHEM J, V264, P1
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Omwancha J, 2009, PROSTATE, V69, P115, DOI 10.1002/pros.20866
   Reddy SM, 2002, J IMMUNOL, V169, P702, DOI 10.4049/jimmunol.169.2.702
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   SAHLIN S, 1983, J IMMUNOL METHODS, V60, P115, DOI 10.1016/0022-1759(83)90340-X
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Strande JL, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-4
   Szweda PA, 2003, AGEING RES REV, V2, P383, DOI 10.1016/S1568-1637(03)00028-X
   Thurman JM, 2009, J BIOL CHEM, V284, P16939, DOI 10.1074/jbc.M808166200
   Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Wihlmark U, 1996, APMIS, V104, P272, DOI 10.1111/j.1699-0463.1996.tb00717.x
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 65
TC 11
Z9 11
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2012
VL 53
IS 3
BP 1406
EP 1413
DI 10.1167/iovs.11-8889
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 925VT
UT WOS:000302790700044
PM 22323489
DA 2022-11-30
ER

PT J
AU Finger, RP
   Fimmers, R
   Holz, FG
   Scholl, HPN
AF Finger, Robert P.
   Fimmers, Rolf
   Holz, Frank G.
   Scholl, Hendrik P. N.
TI Incidence of Blindness and Severe Visual Impairment in Germany:
   Projections for 2030
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BLUE MOUNTAINS EYE; DIABETIC-RETINOPATHY; SOUTHERN GERMANY; OLDER
   POPULATION; INCIDENCE RATES; REGISTER; PROGRESSION; PREVALENCE;
   INTERVAL; DISEASES
AB PURPOSE. Estimates of the incidences of severe visual impairment and blindness (SVI/B) and their causes are key to good health service planning. Thus, the database of Germany's largest state's blind registry was used to estimate current incidence rates (IR) and to project rates for Germany in 2010 and 2030.
   METHODS. The sample consisted of 3328 blind/severely visually impaired individuals newly registered between 2000 and 2008. According to German law, SVI and B were defined as visual acuity equal to or below 20/1000 and 20/400, respectively, in the better seeing eye. Data of the reference population were stratified by age and sex and were used to estimate current IRs. Standardized IRs were estimated for Germany for 2010 and 2030 using national demographic projections.
   RESULTS. Age-related macular degeneration (AMD) accounted for 50% of all incidence of SVI/B (5.56/100,000 personyears (PY), followed by glaucoma (15%; 1.65/100,000 PY) and diabetic eye disease (10%; 1.16/100,000 PY). All current IRs will rise by 2030, with the most pronounced increase in AMD. By 2030, a national AMD IR of 9.5/100,000 PY is expected, accounting for 57% of all incidence of SVI/B in Germany. The incidence of SVI/B in women will be more than twofold compared to men in 2030 (9187 vs. 3716 incident cases in 2030).
   CONCLUSIONS. There will be a dramatic increase of SVI/B by 2030 in Germany, leading to a substantial increase in the need for health and social service provision, with a focus on visually impaired elderly women. (Invest Ophthalmol Vis Sci. 2011;52:4381-4389) DOI:10.1167/iovs.10-6987
C1 [Finger, Robert P.; Holz, Frank G.; Scholl, Hendrik P. N.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Fimmers, Rolf] Univ Bonn, Dept Biostat, D-53127 Bonn, Germany.
   [Finger, Robert P.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Scholl, Hendrik P. N.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
C3 University of Bonn; University of Bonn; Centre for Eye Research
   Australia; Royal Victorian Eye & Ear Hospital; University of Melbourne;
   Johns Hopkins University; Johns Hopkins Medicine
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM robertfinger@gmx.net
OI Finger, Robert P/0000-0003-4253-7597
CR Bach M, 2007, INVEST OPHTHALMOL VI
   Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Cikamatana L, 2007, EYE, V21, P465, DOI 10.1038/sj.eye.6702771
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Farber MD, 2003, OPHTHAL EPIDEMIOL, V10, P267, DOI 10.1076/opep.10.4.267.15910
   Finger RP, 2007, OPHTHALMOLOGE, V104, P839, DOI 10.1007/s00347-007-1600-3
   FINGER RP, BR J OPHTHALMOL
   FINGER RP, INVEST OPHTHALMOL VI
   Foran S, 2000, CLIN EXP OPHTHALMOL, V28, P143, DOI 10.1046/j.1442-9071.2000.00292.x
   Gissler M, 2003, J EPIDEMIOL COMMUN H, V57, P433, DOI 10.1136/jech.57.6.433
   Gissler M, 2002, MED INFORM INTERNET, V27, P33, DOI 10.1080/14639230110119234
   Gissler M, 2000, EUR J EPIDEMIOL, V16, P59, DOI 10.1023/A:1007639230040
   Graf M, 1999, KLIN MONATSBL AUGENH, V215, P50, DOI 10.1055/s-2008-1034669
   KATALINIC A, TRANSFUS MED HEMOTHE, V37, P155
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P477, DOI 10.1016/j.ophtha.2007.11.024
   Knauer C, 2006, OPHTHALMOLOGE, V103, P735, DOI 10.1007/s00347-006-1411-y
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P176, DOI 10.1159/000027415
   Ng HKT, 2008, COMPUT STAT DATA AN, V52, P3501, DOI 10.1016/j.csda.2007.11.004
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Saaddine JB, 2008, ARCH OPHTHALMOL-CHIC, V126, P1740, DOI 10.1001/archopht.126.12.1740
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   *STAT BUND DEUTSCH, 2009, BEV 31 12 NACH GESCH
   *STAT BUND DEUTSCH, 2009, BEV NACH ALT FAM REG
   Statistisches Bundesamt Deutschland, 2006, DAT 2006 ZAHL FAKT B
   Trautner C, 2001, DIABETOLOGIA, V44, P147, DOI 10.1007/s001250051592
   Trautner C, 1997, DIABETES CARE, V20, P1147, DOI 10.2337/diacare.20.7.1147
   Trautner C, 2003, INVEST OPHTH VIS SCI, V44, P1031, DOI 10.1167/iovs.02-0304
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 31
TC 66
Z9 67
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2011
VL 52
IS 7
BP 4381
EP 4389
DI 10.1167/iovs.10-6987
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800BP
UT WOS:000293332500062
PM 21447690
DA 2022-11-30
ER

PT J
AU Dasari, B
   Prasanthi, JRP
   Marwarha, G
   Singh, BB
   Ghribi, O
AF Dasari, Bhanu
   Prasanthi, Jaya R. P.
   Marwarha, Gurdeep
   Singh, Brij B.
   Ghribi, Othman
TI The oxysterol 27-hydroxycholesterol increases beta-amyloid and oxidative
   stress in retinal pigment epithelial cells
SO BMC OPHTHALMOLOGY
LA English
DT Article
ID SMOOTH-MUSCLE-CELLS; NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS;
   AGE-RELATED MACULOPATHY; HEME OXYGENASE-1 EXPRESSION; MACULAR
   DEGENERATION; ALZHEIMERS-DISEASE; BRUCHS MEMBRANE; UNESTERIFIED
   CHOLESTEROL; APOLIPOPROTEIN-B
AB Background: Alzheimer's disease (AD) and age-related macular degeneration (AMD) share several pathological features including beta-amyloid (A beta) peptide accumulation, oxidative damage, and cell death. The causes of AD and AMD are not known but several studies suggest disturbances in cholesterol metabolism as a culprit of these diseases. We have recently shown that the cholesterol oxidation metabolite 27-hydroxycholesterol (27-OHC) causes AD-like pathology in human neuroblastoma SH-SY5Y cells and in organotypic hippocampal slices. However, the extent to which and the mechanisms by which 27-OHC may also cause pathological hallmarks related to AMD are ill-defined. In this study, the effects of 27-OHC on AMD-related pathology were determined in ARPE-19 cells. These cells have structural and functional properties relevant to retinal pigmented epithelial cells, a target in the course of AMD.
   Methods: ARPE-19 cells were treated with 0, 10 or 25 mu M 27-OHC for 24 hours. Levels of A beta peptide, mitochondrial and endoplasmic reticulum (ER) stress markers, Ca2+ homeostasis, glutathione depletion, reactive oxygen species (ROS) generation, inflammation and cell death were assessed using ELISA, Western blot, immunocytochemistry, and specific assays.
   Results: 27-OHC dose-dependently increased A beta peptide production, increased levels of ER stress specific markers caspase 12 and gadd153 (also called CHOP), reduced mitochondrial membrane potential, triggered Ca2+ dyshomeostasis, increased levels of the nuclear factor kB (NF kB) and heme-oxygenase 1 (HO-1), two proteins activated by oxidative stress. Additionally, 27-OHC caused glutathione depletion, ROS generation, inflammation and apoptotic-mediated cell death.
   Conclusions: The cholesterol metabolite 27-OHC is toxic to RPE cells. The deleterious effects of this oxysterol ranged from A beta accumulation to oxidative cell damage. Our results suggest that high levels of 27-OHC may represent a common pathogenic factor for both AMD and AD.
C1 [Dasari, Bhanu; Prasanthi, Jaya R. P.; Marwarha, Gurdeep; Ghribi, Othman] Univ N Dakota, Dept Pharmacol Physiol & Therapeut, Sch Med & Hlth Sci, Grand Forks, ND 58202 USA.
   [Singh, Brij B.] Univ N Dakota, Dept Biochem & Mol Biol, Sch Med & Hlth Sci, Grand Forks, ND 58202 USA.
C3 University of North Dakota Grand Forks; University of North Dakota Grand
   Forks
RP Ghribi, O (通讯作者)，Univ N Dakota, Dept Pharmacol Physiol & Therapeut, Sch Med & Hlth Sci, 501 N Columbia Rd, Grand Forks, ND 58202 USA.
EM oghribi@medicine.nodak.edu
OI Singh, Brij/0000-0003-0535-5997; MARWARHA, GURDEEP/0000-0001-5556-0003
FU NIEHS/NIH [5R01ES014826]; BBS [5RO1DE017102, 5P20RR017699]; NATIONAL
   CENTER FOR RESEARCH RESOURCES [P20RR017699] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH
   [R01DE017102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   ENVIRONMENTAL HEALTH SCIENCES [R01ES014826] Funding Source: NIH RePORTER
FX Supported by a grant from NIEHS/NIH to OG (5R01ES014826) and BBS
   (5RO1DE017102, and 5P20RR017699). The authors thank Dr. Byron Grove and
   Sarah Rolling (Department of Anatomy and Cell Biology, School of
   Medicine & Health Sciences, University of North Dakota) for their
   technical assistance in confocal microscopy.
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Ares MPS, 2000, ATHEROSCLEROSIS, V153, P23, DOI 10.1016/S0021-9150(00)00380-4
   Bjorkhem I, 2002, J CLIN INVEST, V110, P725, DOI 10.1172/JCI200216388
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Dentchev T, 2003, MOL VIS, V9, P184
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Frank R N, 1998, Trans Am Ophthalmol Soc, V96, P635
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Ghribi O, 2006, CURR MOL MED, V6, P119, DOI 10.2174/156652406775574514
   GHRIBI O, 2009, ALZHEIMERS DEMENT, V5, P180
   Ghribi O, 2008, J ALZHEIMERS DIS, V15, P673
   Gramajo AL, 2010, INVEST OPHTH VIS SCI, V51, P1164, DOI 10.1167/iovs.09-3443
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Hascalovici JR, 2009, J NEUROCHEM, V110, P1241, DOI 10.1111/j.1471-4159.2009.06213.x
   Heverin M, 2005, J LIPID RES, V46, P1047, DOI 10.1194/jlr.M500024-JLR200
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Javitt NB, 2008, STEROIDS, V73, P149, DOI 10.1016/j.steroids.2007.10.004
   Javitt NB, 2007, CURR OPIN LIPIDOL, V18, P283, DOI 10.1097/MOL.0b013e328133851e
   Javitt NB, 2009, CURR OPIN OPHTHALMOL, V20, P151, DOI 10.1097/ICU.0b013e32832af468
   Joffre C, 2007, CURR EYE RES, V32, P271, DOI 10.1080/02713680601187951
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kaarniranta K, 2009, EXP GERONTOL, V44, P685, DOI 10.1016/j.exger.2009.09.002
   Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642
   Kivipelto M, 2006, ACTA NEUROL SCAND, V114, P50, DOI 10.1111/j.1600-0404.2006.00685.x
   Lee JW, 2006, EXP EYE RES, V83, P465, DOI 10.1016/j.exer.2005.11.018
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li YK, 2005, J BIOL CHEM, V280, P21763, DOI 10.1074/jbc.M501759200
   Liu XM, 2005, J BIOL CHEM, V280, P872, DOI 10.1074/jbc.M410413200
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ong JM, 2003, NEUROCHEM RES, V28, P883, DOI 10.1023/A:1023223409798
   Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550
   Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9
   Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511
   Pani B, 2008, J BIOL CHEM, V283, P17333, DOI 10.1074/jbc.M800107200
   Prabhakara JPR, 2008, J NEUROCHEM, V107, P1722, DOI 10.1111/j.1471-4159.2008.05736.x
   Prasanthi JRP, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-1
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Riendeau V, 2009, FREE RADICAL RES, V43, P1019, DOI 10.1080/10715760903040610
   RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439
   Rudolf M, 2009, J HISTOCHEM CYTOCHEM, V57, P731, DOI 10.1369/jhc.2009.953448
   Sauer T, 2008, EXPERT REV OPHTHALMO, V3, P29, DOI 10.1586/17469899.3.1.29
   Schipper HM, 2006, NEUROBIOL AGING, V27, P252, DOI 10.1016/j.neurobiolaging.2005.01.016
   Selvaraj S, 2010, CNS NEUROL DISORD-DR, V9, P94, DOI 10.2174/187152710790966650
   SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X
   Setchell KDR, 1998, J CLIN INVEST, V102, P1690, DOI 10.1172/JCI2962
   Sharma S, 2008, NEUROBIOL DIS, V32, P426, DOI 10.1016/j.nbd.2008.08.002
   SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671
   Solomon A, 2009, DEMENT GERIATR COGN, V28, P75, DOI 10.1159/000231980
   Trivino A, 2006, EXP EYE RES, V83, P357, DOI 10.1016/j.exer.2005.12.020
   Vaya J, 2007, FREE RADICAL BIO MED, V42, P864, DOI 10.1016/j.freeradbiomed.2006.12.022
   Vejux A, 2008, BRAZ J MED BIOL RES, V41, P545, DOI 10.1590/S0100-879X2008000700001
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhang J, 1997, EUR J BIOCHEM, V247, P129, DOI 10.1111/j.1432-1033.1997.00129.x
   ZHOU Q, 1995, J AM COLL NUTR, V14, P169
   Zhou Q., 1997, Biomedical and Environmental Sciences, V10, P369
NR 66
TC 60
Z9 63
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD SEP 13
PY 2010
VL 10
AR 22
DI 10.1186/1471-2415-10-22
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 677TE
UT WOS:000284013900001
PM 20836858
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chan, CM
   Huang, JH
   Chiang, HS
   Wu, WB
   Lin, HH
   Hong, JY
   Hung, CF
AF Chan, Chi-Ming
   Huang, Jheng-Hua
   Chiang, Han-Sun
   Wu, Wen-Bin
   Lin, Hsin-Huang
   Hong, Jing-Yin
   Hung, Chi-Feng
TI Effects of (-)-epigallocatechin gallate on RPE cell migration and
   adhesion
SO MOLECULAR VISION
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; PROLIFERATIVE DIABETIC-RETINOPATHY;
   NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR; GREEN TEA; PDGF-BB; MACULAR
   DEGENERATION; EXPRESSION; INHIBITION; COLLAGEN
AB Purpose: In diseases such as proliferative vitreoretinopathy (PVR), proliferative diabetic retinopathy (PDR), and age-related macular degeneration (AMD), retinal pigment epithelial (RPE) cells can initiate proliferation and migration and secrete extracellular matrix (ECM) proteins. (-)-Epigallocatechin gallate (EGCG)-a natural anti-oxidant flavonoid that is abundant in green tea-has been shown to suppress the migration and adhesion of many cell types, but its effects on RPE cell migration and adhesion were unknown. Several studies have shown that platelet-derived growth factor (PDGF) enhances proliferation and migration effects on RPE cells in PVR, and that fibronectin is a major ECM component of PVR tissue. Therefore, we investigated the inhibitory effects of EGCG on RPE cell migration induced by PDGF-BB, an isoform of PDGF, and adhesion by fibronectin.
   Methods: The migration of RPE cells was detected by an electric cell-substrate impedance sensing (ECIS) migration assay and a Transwell migration assay. Cells were loaded with 2',7'-bis-(carboxyethyl)-5(6')-carboxyfluorescein acetoxymethyl ester (BCECF/AM), and their adhesion to fibronectin was examined. The interactions of EGCG with PDGF-BB were analyzed by a dot binding assay. Cytoskeletal reorganization was examined by immunofluorescence microscopy. The PDGF-BB-induced signaling pathways were detected by western blotting.
   Results: In the present study, we find that EGCG can inhibit PDGF-BB-induced human RPE cell migration and, in a dose-dependent manner, RPE cell adhesion to fibronectin. Our analysis demonstrates that EGCG does not directly bind to PDGF-BB and the inhibition of EGCG against fibronectin-induced cytoskeletal reorganization is observed. Furthermore, EGCG is shown to suppress PDGF-BB-induced PDGF-beta receptors, downstream PI3K/Akt, and MAPK phosphorylation.
   Conclusions: Our results provide the first evidence that EGCG is an effective inhibitor of RPE cell migration and adhesion to fibronectin and, therefore, may prevent epiretinal membrane formation.
C1 [Chan, Chi-Ming; Huang, Jheng-Hua; Chiang, Han-Sun; Wu, Wen-Bin; Lin, Hsin-Huang; Hung, Chi-Feng] Fu Jen Catholic Univ, Sch Med, Taipei Hsien 24205, Taiwan.
   [Chan, Chi-Ming] Cardinal Tien Hosp, Dept Ophthalmol, Taipei Hsien, Taiwan.
   [Huang, Jheng-Hua] Cathay Gen Hosp, Dept Internal Med, Taipei, Taiwan.
   [Hong, Jing-Yin] Fu Jen Catholic Univ, Dept Life Sci, Taipei Hsien 24205, Taiwan.
C3 Fu Jen Catholic University; Cathay General Hospital; Fu Jen Catholic
   University
RP Hung, CF (通讯作者)，Fu Jen Catholic Univ, Sch Med, 510 Chung Cheng Rd, Taipei Hsien 24205, Taiwan.
EM 054317@mail.fju.edu.tw
RI Chan, Chi-Ming/GWZ-3612-2022; Wu, Wen-Bin/GLT-4711-2022; Hung,
   Chi-Feng/AAL-4977-2021
OI Hung, Chi-Feng/0000-0003-3478-5451
FU Cardinal Tien Hospital; Cathay General Hospital, Taipei, Taiwan
FX This work was supported by research grants from Cardinal Tien Hospital
   and Cathay General Hospital, Taipei, Taiwan. This paper won an award for
   outstanding writing of Taiwan Medical Science Development Foundation in
   2009. We thank Dr. Leo Chan KM for checking the language.
CR Abe T, 1996, EXP EYE RES, V63, P201, DOI 10.1006/exer.1996.0109
   Alge CS, 2006, INVEST OPHTH VIS SCI, V47, P415, DOI 10.1167/iovs.05-0308
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ando A, 2000, BRIT J OPHTHALMOL, V84, P1306, DOI 10.1136/bjo.84.11.1306
   Ball SG, 2007, J CELL MOL MED, V11, P1012, DOI 10.1111/j.1582-4934.2007.00120.x
   Campochiaro PA, 1997, ARCH OPHTHALMOL-CHIC, V115, P237, DOI 10.1001/archopht.1997.01100150239014
   CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459
   CAMPOCHIARO PA, 1989, EXP EYE RES, V49, P217, DOI 10.1016/0014-4835(89)90092-4
   Carrington L, 2000, INVEST OPHTH VIS SCI, V41, P1210
   Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062
   Cassidy L, 1998, BRIT J OPHTHALMOL, V82, P181, DOI 10.1136/bjo.82.2.181
   Chae YJ, 2007, CELL PHYSIOL BIOCHEM, V20, P859, DOI 10.1159/000110446
   Chan CM, 2009, BIOCHEM BIOPH RES CO, V388, P172, DOI 10.1016/j.bbrc.2009.07.155
   Chan CM, 2008, MOL VIS, V14, P2528
   Chiang HS, 2007, LIFE SCI, V81, P1509, DOI 10.1016/j.lfs.2007.09.018
   Choudhury P, 1997, INVEST OPHTH VIS SCI, V38, P824
   Cui JZ, 2007, EYE, V21, P200, DOI 10.1038/sj.eye.6702169
   Cui J, 2009, EXP EYE RES, V88, P438, DOI 10.1016/j.exer.2008.10.020
   ELNER SG, 1995, CURR EYE RES, V14, P1045, DOI 10.3109/02713689508998529
   Esser P, 1997, EXP EYE RES, V65, P365, DOI 10.1006/exer.1997.0341
   GRISANTI S, 1995, INVEST OPHTH VIS SCI, V36, P391
   Hazgui S, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-33
   Hinton DR, 1998, EXP CELL RES, V239, P11, DOI 10.1006/excr.1997.3873
   HISCOTT P, 1994, BRIT J OPHTHALMOL, V78, P219, DOI 10.1136/bjo.78.3.219
   Hiscott P, 1999, PROG RETIN EYE RES, V18, P167, DOI 10.1016/S1350-9462(98)00024-X
   Hollborn M, 2006, BIOCHEM BIOPH RES CO, V344, P912, DOI 10.1016/j.bbrc.2006.03.185
   Hughes AD, 1996, GEN PHARMACOL-VASC S, V27, P1079, DOI 10.1016/S0306-3623(96)00060-2
   Hung CF, 2005, J CELL BIOCHEM, V96, P183, DOI 10.1002/jcb.20509
   Ikuno Y, 2002, INVEST OPHTH VIS SCI, V43, P483
   Ito S, 1999, GRAEF ARCH CLIN EXP, V237, P691, DOI 10.1007/s004170050298
   Kaufmann R, 2009, ONCOL REP, V21, P1261, DOI 10.3892/or_00000349
   Kaven C, 2000, CURR EYE RES, V20, P480, DOI 10.1076/0271-3683(200006)20:6;1-Y;FT480
   Kenarova B, 1997, Eur J Ophthalmol, V7, P64
   KIRCHHOF B, 1988, EXP EYE RES, V47, P457, DOI 10.1016/0014-4835(88)90056-5
   Krott R, 2000, OPHTHALMOLOGICA, V214, P296, DOI 10.1159/000027508
   Kushima Y, 2009, BIOL PHARM BULL, V32, P899, DOI 10.1248/bpb.32.899
   Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5
   Lei HT, 2007, INVEST OPHTH VIS SCI, V48, P2335, DOI 10.1167/iovs.06-0965
   LESCHEY KH, 1990, INVEST OPHTH VIS SCI, V31, P839
   Li R, 2007, INVEST OPHTH VIS SCI, V48, P5722, DOI 10.1167/iovs.07-0327
   Lim YC, 2008, CANCER LETT, V271, P140, DOI 10.1016/j.canlet.2008.05.048
   LIMB G A, 1991, Eye (London), V5, P686
   Lo HM, 2007, J BIOMED SCI, V14, P637, DOI 10.1007/s11373-007-9170-6
   Lo HM, 2007, BIOCHEM PHARMACOL, V74, P54, DOI 10.1016/j.bcp.2007.03.017
   Melgarejo E, 2007, CELL MOL LIFE SCI, V64, P2690, DOI 10.1007/s00018-007-7331-4
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2001
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Park G, 2008, J INVEST DERMATOL, V128, P2429, DOI 10.1038/jid.2008.103
   Peng PH, 2008, EXP EYE RES, V86, P637, DOI 10.1016/j.exer.2008.01.008
   Punathil T, 2008, BIOCHEM BIOPH RES CO, V375, P162, DOI 10.1016/j.bbrc.2008.07.157
   ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3649
   Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335
   Saika S, 2005, LAB INVEST, V85, P838, DOI 10.1038/labinvest.3700294
   Sen T, 2009, LIFE SCI, V84, P194, DOI 10.1016/j.lfs.2008.11.018
   SmithThomas L, 1996, CURR EYE RES, V15, P739, DOI 10.3109/02713689609003457
   Spraul CW, 2004, OPHTHAL RES, V36, P166, DOI 10.1159/000077330
   TINGSTROM A, 1992, J CELL SCI, V102, P315
   Troger J, 2003, BRIT J OPHTHALMOL, V87, P1403, DOI 10.1136/bjo.87.11.1403
   Yoon HS, 2000, CURR EYE RES, V20, P215, DOI 10.1076/0271-3683(200003)20:3;1-9;FT215
   Zhang YM, 2009, EUR J PHARMACOL, V606, P172, DOI 10.1016/j.ejphar.2008.12.033
   Zhu JJ, 2009, INT IMMUNOPHARMACOL, V9, P1126, DOI 10.1016/j.intimp.2009.05.002
NR 63
TC 57
Z9 60
U1 0
U2 9
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 3
PY 2010
VL 16
IS 66-69
BP 586
EP 595
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 619MB
UT WOS:000279433200002
PM 20376327
DA 2022-11-30
ER

PT J
AU Alge-Priglinger, CS
   Kreutzer, T
   Obholzer, K
   Wolf, A
   Mempel, M
   Kernt, M
   Kampik, A
   Priglinger, SG
AF Alge-Priglinger, Claudia S.
   Kreutzer, Thomas
   Obholzer, Katja
   Wolf, Armin
   Mempel, Martin
   Kernt, Marcus
   Kampik, Anselm
   Priglinger, Siegfried G.
TI Oxidative Stress-Mediated Induction of MMP-1 and MMP-3 in Human RPE
   Cells
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; ACTIVATED PROTEIN-KINASES; BRAIN-BARRIER
   DYSFUNCTION; NONLETHAL OXIDANT INJURY; MATRIX METALLOPROTEINASES;
   MACULAR DEGENERATION; BRUCHS MEMBRANE; GENE-EXPRESSION; GROWTH-FACTORS;
   MESSENGER-RNA
AB PURPOSE. In early exudative age-related macular degeneration (AMD), segmental thinning of Bruch's membrane is associated with ingrowth of choroidal neovascularization into the subretinal space. To determine whether there is a link between oxidative stress and extracellular matrix (ECM) degradation by the retinal pigment epithelium, the present study focused on the effect of oxidative stress on MMP-1 and MMP-3 expression, two enzymes with substrate specificity for components of Bruch's membrane.
   METHODS. Cultured human RPE cells were exposed to oxidative stress. To investigate the role of signal transduction proteins, cells were pretreated with the specific inhibitors SB202190 or PD98059. Secreted MMP-1 and MMP-3 were detected by ELISA, MMP-2, and MMP-9 by zymography. Expression of mRNA was determined by quantitative real-time RT-PCR. ECM degradation by retinal pigment epithelium was assessed by immunofluorescence microscopy.
   RESULTS. Oxidative stress increased MMP-1 and MMP-3 protein release but reduced MMP-2 activity. Real-time RT-PCR disclosed increases of MMP-1 and MMP-3 mRNA after oxidative stress with no modulation of TIMP-1. MMP-2 and MMP-9 mRNA was slightly enhanced. PD98059, an inhibitor of ERK1/2, markedly reduced MMP-1 expression, whereas SB202190, an inhibitor of p38 MAPK, was less effective. MMP-3 expression was attenuated by both inhibitors. Oxidative stress-stimulated type I collagen degradation by RPE cells was reduced by simultaneous treatment with a synthetic MMP-inhibitor or a neutralizing antibody against MMP-1.
   CONCLUSIONS. MMP-1 and MMP-3 in the retinal pigment epithelium are inducible by oxidative stress. The directional shift in the MMP-1,-3/TIMP-1 ratio is associated with increased type I collagen degradation. This may be an important mechanism contributing to the pathogenesis of early exudative AMD. (Invest Ophthalmol Vis Sci. 2009;50:5495-5503) DOI: 10.1167/iovs.08-3193
C1 [Alge-Priglinger, Claudia S.; Kreutzer, Thomas; Obholzer, Katja; Wolf, Armin; Kernt, Marcus; Kampik, Anselm; Priglinger, Siegfried G.] Univ Munich, Dept Ophthalmol, Munich, Germany.
   [Alge-Priglinger, Claudia S.; Priglinger, Siegfried G.] Linz Gen Hosp, Dept Ophthalmol, Linz, Austria.
   [Mempel, Martin] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany.
C3 University of Munich; Kepler University Hospital; Technical University
   of Munich
RP Priglinger, SG (通讯作者)，Linz Gen Hosp, Dept Ophthalmol, Linz, Austria.
EM siegfried.priglinger@med.uni-muenchen.de
FU Deutsche Ophthalmologische Gesellschaft Research Support 2007; DOG
   Research; Kroner Stiftung 2006
FX Supported by Deutsche Ophthalmologische Gesellschaft Research Support
   2007 (CSA), DOG Research grant support, and Kroner Stiftung 2006 (SGP).
CR Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Badger AM, 2000, OSTEOARTHR CARTILAGE, V8, P434, DOI 10.1053/joca.1999.0319
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018
   Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2
   Chung HY, 2006, ANTIOXID REDOX SIGN, V8, P572, DOI 10.1089/ars.2006.8.572
   Di Girolamo N, 2003, INVEST OPHTH VIS SCI, V44, P4705, DOI 10.1167/iovs.03-0356
   Di Girolamo N, 2004, PROG RETIN EYE RES, V23, P195, DOI 10.1016/j.preteyeres.2004.02.002
   DiGirolamo N, 1997, AM J PATHOL, V150, P653
   Dong KK, 2008, EXP DERMATOL, V17, P1037, DOI 10.1111/j.1600-0625.2008.00747.x
   Eichler W, 2002, INVEST OPHTH VIS SCI, V43, P2767
   Fleenor DL, 2003, INVEST OPHTH VIS SCI, V44, P3494, DOI 10.1167/iovs.02-0757
   Galli A, 2005, HEPATOLOGY, V41, P1074, DOI 10.1002/hep.20683
   Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010
   Gattorno M, 2002, J RHEUMATOL, V29, P1774
   Glotin AL, 2006, INVEST OPHTH VIS SCI, V47, P4614, DOI 10.1167/iovs.06-0297
   Goerge T, 2006, CANCER RES, V66, P7766, DOI 10.1158/0008-5472.CAN-05-3897
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Haorah J, 2007, J NEUROCHEM, V101, P566, DOI 10.1111/j.1471-4159.2006.04393.x
   Ho TC, 2006, APOPTOSIS, V11, P1899, DOI 10.1007/s10495-006-9403-6
   HUNT RC, 1993, INVEST OPHTH VIS SCI, V34, P3179
   Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495
   Kang KA, 2008, J TOXICOL ENV HEAL A, V71, P992, DOI 10.1080/01932690801934653
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Li DQ, 2001, ARCH OPHTHALMOL-CHIC, V119, P71
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   MARTELPELLETIER J, 1994, LAB INVEST, V70, P807
   Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075
   McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Nie L, 2006, BIOCHEM BIOPH RES CO, V339, P603, DOI 10.1016/j.bbrc.2005.11.055
   Ohbayashi H, 2002, CURR PROTEIN PEPT SC, V3, P409, DOI 10.2174/1389203023380549
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   Park CH, 2004, J INVEST DERMATOL, V123, P1012, DOI 10.1111/j.0022-202X.2004.23487.x
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137
   Sarma PK, 2008, CLIN RHEUMATOL, V27, P289, DOI 10.1007/s10067-007-0701-3
   Scherle PA, 1997, BIOCHEM BIOPH RES CO, V230, P573, DOI 10.1006/bbrc.1996.5985
   Schroeder P, 2008, J INVEST DERMATOL, V128, P2491, DOI 10.1038/jid.2008.116
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Spraul CW, 1998, OPHTHALMOLOGE, V95, P73, DOI 10.1007/s003470050240
   Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Studer RK, 2004, ARTHRITIS RES THER, V6, pR56, DOI 10.1186/ar1022
   Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Vincenti MP, 2007, J CELL PHYSIOL, V213, P355, DOI 10.1002/jcp.21208
   Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40
NR 55
TC 56
Z9 58
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2009
VL 50
IS 11
BP 5495
EP 5503
DI 10.1167/iovs.08-3193
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 514XH
UT WOS:000271429200063
PM 19516002
DA 2022-11-30
ER

PT J
AU Awan, MA
   Chavan, R
   Peh, KK
   Yang, YC
AF Awan, Muhammad Amer
   Chavan, Randhir
   Peh, Khaik K.
   Yang, Yit C.
TI The effect of the first application of verteporfin photodynamic therapy
   on lesion growth in choroidal neovascularisation and its potential
   impact on combination therapy
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
DE age-related maculopathy; choroidal neovascularisation; photodynamic
   therapy; verteporfin
ID MACULAR DEGENERATION; TRIAMCINOLONE ACETONIDE; VISUAL-ACUITY; SIZE;
   MEMBRANES; SECONDARY; INJECTION
AB Purpose: To evaluate the impact of lesion size on the observed growth of the choroidal neovascularisation (CNV) following the first application of photodynamic therapy (PDT).
   Methods: A retrospective study of consecutive patients with subfoveal classic CNV or predominantly classic CNV undergoing first verteporfin photodynamic therapy (VPDT) according to treatment of age-related macular degeneration with photodynamic therapy (TAP) protocol between June 2005 and September 2005. Patients were classified into two groups according to baseline greatest linear dimension (GLD) at the time of VPDT monotherapy. Group 1 comprised patients with lesion GLD less then 2000 mm and Group 2, patients with lesion GLD 2000 mm or larger. Difference between the mean GLD at baseline and at three months post-treatment were investigated for clinical significance using the paired t-test.
   Results: Group 1 (n = 16) showed a mean change in GLD from 1380.25 mu m to 2031.25 mu m, while Group 2 (n = 26) showed a mean change of 2909.26 mu m to 3023.07 mu m. Data of mean percentage change in GLD for Group 1 showed a 51.97 per cent increase in the lesion size [95% CI, 22.93-81.01%] in comparison to Group 2, which showed only 5.8 per cent increase in the lesion [95% CI, -9.65 -21.61%]. Comparison of the mean percentage change in GLD between the two groups showed a statistically significant difference (p = 0.003).
   Conclusions: Our study demonstrates that following the first application of VPDT, smaller lesions enlarge disproportionately more than larger lesions. As we have entered into the era of using angiostatic agents in combination with VPDT, it may be important to evaluate this effect with regards to the timing of VPDT commencement.
C1 [Awan, Muhammad Amer; Chavan, Randhir; Peh, Khaik K.; Yang, Yit C.] Wolverhampton & Midlands Cty Eye Infirm, Wolverhampton, England.
RP Awan, MA (通讯作者)，Gartnavel Royal Hosp, Tennent Inst Ophthalmol, Dept Ophthalmol, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland.
EM dramer_awan@yahoo.co.uk
RI Awan, Muhammad Amer/ABA-5651-2020
CR Arias L, 2005, BRIT J OPHTHALMOL, V89, P312, DOI 10.1136/bjo.2004.050997
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Chaudhary V, 2007, OPHTHALMOLOGY, V114, P2183, DOI 10.1016/j.ophtha.2007.02.013
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Petermeier K, 2006, BRIT J OPHTHALMOL, V90, P1034, DOI 10.1136/bjo.2006.090852
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Sivaprasad S, 2006, EYE, V20, P43, DOI 10.1038/sj.eye.6701787
NR 16
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD SEP
PY 2009
VL 92
IS 5
BP 440
EP 443
DI 10.1111/j.1444-0938.2009.00403.x
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 487YP
UT WOS:000269315900008
PM 19552669
OA Bronze
DA 2022-11-30
ER

PT J
AU Chan, CM
   Huang, JH
   Lin, HH
   Chiang, HS
   Chen, BH
   Hong, JY
   Hung, CF
AF Chan, Chi-Ming
   Huang, Jheng-Hua
   Lin, Hsin-Huang
   Chiang, Han-Sun
   Chen, Bing-Huei
   Hong, Jing-Yin
   Hung, Chi-Feng
TI Protective effects of (-)-epigallocatechin gallate on UVA-induced damage
   in ARPE19 cells
SO MOLECULAR VISION
LA English
DT Article
ID GREEN TEA POLYPHENOLS; INDUCED APOPTOSIS; CYCLOOXYGENASE-2 EXPRESSION;
   ULTRAVIOLET; MECHANISMS; GROWTH; ASSAY; P38; EPIGALLOCATECHIN-3-GALLATE;
   ANTIOXIDANT
AB Purpose: Oxidative injury to the retinal pigment epithelium (RPE) has been proposed to play a contributing role in age-related macular degeneration (AMD). Exposure to solar ultraviolet (UV) radiation is believed to cause the production of reactive oxygen species (ROS), which may cause oxidative damage to RPE cells. Studies have shown that (-)-epigallocatechin gallate (EGCG), an abundant and active component in green tea, can protect several cell types from oxidative stress. It may be useful in the prevention of early AMD.
   Methods: To determine whether EGCG protects RPE cells from UVA-induced damage, we used a cell viability assay to determine the viability of UVA-treated cells. Intracellular H2O2 levels were measured by flow cytometry. Western blotting was used to detect UVA-induced signaling pathways.
   Results: The results indicated that EGCG inhibits UVA-induced RPE cell death. In addition, intracellular H2O2 generation in RPE cells irradiated by UVA was inhibited by EGCG in a concentration-dependent manner. EGCG also inhibited UVA-induced extracullar signal-regulated kinase (ERK) and c-jun-NH2 terminal kinase (JNK) activation in RPE cells while a higher concentration of EGCG had an inhibitory effect on UVA-induced p38 activation. Finally, we investigated cyclooxygenase-2 (COX-2) expression in RPE cells exposed to UVA radiation, and EGCG was found to also have inhibited UVA-induced COX-2 expression.
   Conclusions: Taken together, our results demonstrate that EGCG inhibits UVA-induced H2O2 production, mitogen-activating protein kinase activation, and expression of COX-2. Moreover, it enhances RPE cell survival after UVA exposure. This suggests EGCG is effective in preventing UVA-induced damage in RPE cells and may be suitable for further developments as a chemoprotective factor for the primary prevention of early AMD.
C1 [Chan, Chi-Ming; Huang, Jheng-Hua; Lin, Hsin-Huang; Chiang, Han-Sun; Hung, Chi-Feng] Fu Jen Catholic Univ, Sch Med, Hsinchuang 24205, Taipei Hsien, Taiwan.
   [Chan, Chi-Ming] Cardinal Tien Hosp, Dept Ophthalmol, Taipei Hsien, Taiwan.
   [Huang, Jheng-Hua] Cathay Gen Hosp, Dept Internal Med, Taipei, Taiwan.
   [Chen, Bing-Huei] Fu Jen Catholic Univ, Grad Inst Basic Med, Taipei Hsien, Taiwan.
   [Hong, Jing-Yin] Fu Jen Catholic Univ, Dept Life Sci, Taipei Hsien, Taiwan.
C3 Fu Jen Catholic University; Cathay General Hospital; Fu Jen Catholic
   University; Fu Jen Catholic University
RP Hung, CF (通讯作者)，Fu Jen Catholic Univ, Sch Med, 510 Chung Cheng Rd, Hsinchuang 24205, Taipei Hsien, Taiwan.
EM 054317@mail.fju.edu.tw
RI Hung, Chi-Feng/AAL-4977-2021; Chan, Chi-Ming/GWZ-3612-2022
OI Hung, Chi-Feng/0000-0003-3478-5451; 
FU Cardinal Tien Hospital; Cathay General Hospital, Taipei, Taiwan; Taiwan
   Medical Science Development Foundation
FX This work was supported by research grants from Cardinal Tien Hospital
   and Cathay General Hospital, Taipei, Taiwan. This paper won an award for
   outstanding writing of Taiwan Medical Science Development Foundation in
   2008.
CR Ahmad N, 1999, NUTR REV, V57, P78, DOI 10.1111/j.1753-4887.1999.tb06927.x
   Bachelor MA, 2002, ONCOGENE, V21, P7092, DOI 10.1038/sj.onc.1205855
   Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3
   Farris P, 2007, DERMATOL THER, V20, P322, DOI 10.1111/j.1529-8019.2007.00146.x
   GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X
   Henning SA, 2005, J NUTR BIOCHEM, V16, P610, DOI 10.1016/j.jnutbio.2005.03.003
   Hirai M, 2007, LIFE SCI, V80, P1020, DOI 10.1016/j.lfs.2006.11.032
   Ho TC, 2006, APOPTOSIS, V11, P1899, DOI 10.1007/s10495-006-9403-6
   Huang CC, 2005, ARCH DERMATOL RES, V296, P473, DOI 10.1007/s00403-005-0540-5
   Itoh Y, 2005, UROL RES, V33, P261, DOI 10.1007/s00240-005-0465-7
   Kanekura T, 2001, J RHEUMATOL, V28, P1568
   Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287
   Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719
   KERR JB, 1993, SCIENCE, V262, P1032, DOI 10.1126/science.262.5136.1032
   Lambert JD, 2006, DRUG METAB DISPOS, V34, P8, DOI 10.1124/dmd.104.003434
   Laube T, 2004, OPHTHALMOLOGY, V111, P880, DOI 10.1016/j.ophtha.2003.08.031
   MAINSTER MA, 1986, AM J OPHTHALMOL, V102, P727, DOI 10.1016/0002-9394(86)90400-9
   McCarty CA, 1996, INVEST OPHTH VIS SCI, V37, P1720
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nanjo F, 1996, FREE RADICAL BIO MED, V21, P895, DOI 10.1016/0891-5849(96)00237-7
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Patton WP, 1999, INVEST OPHTH VIS SCI, V40, P3268
   Peus D, 1999, J INVEST DERMATOL, V112, P751, DOI 10.1046/j.1523-1747.1999.00584.x
   Peus D, 1999, FREE RADICAL BIO MED, V27, P1197, DOI 10.1016/S0891-5849(99)00198-7
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Studer RK, 2005, J ORTHOP RES, V23, P454, DOI 10.1016/j.orthres.2004.08.012
   Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2
   Tipoe George L., 2007, Cardiovascular & Hematological Disorders - Drug Targets, V7, P135
   Tobi SE, 2002, INT J CANCER, V102, P439, DOI 10.1002/ijc.10730
   Tratsk KS, 2003, GRAEF ARCH CLIN EXP, V241, P852, DOI 10.1007/s00417-003-0747-0
   Ulivi V, 2008, J CELL BIOCHEM, V104, P1393, DOI 10.1002/jcb.21717
   van het Hof KH, 1999, P SOC EXP BIOL MED, V220, P203, DOI 10.1046/j.1525-1373.1999.d01-34.x
   Winkler BS, 1999, MOL VIS, V5
   YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038
   Yang GY, 2000, CARCINOGENESIS, V21, P2035, DOI 10.1093/carcin/21.11.2035
   Yao K, 2008, MOL VIS, V14, P217
   Youn HY, 2007, J PHOTOCH PHOTOBIO B, V88, P21, DOI 10.1016/j.jphotobiol.2007.04.012
NR 44
TC 45
Z9 49
U1 1
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 30
PY 2008
VL 14
IS 291-95
BP 2528
EP 2534
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 414IX
UT WOS:000263858200001
PM 19119326
DA 2022-11-30
ER

PT J
AU Barbazetto, IA
   Room, M
   Yannuzzi, NA
   Barile, GR
   Merriam, JE
   Bardal, AMC
   Freund, KB
   Yannuzzi, LA
   Allikmets, R
AF Barbazetto, Irene A.
   Room, Miia
   Yannuzzi, Nicholas A.
   Barile, Gaetano R.
   Merriam, Joanna E.
   Bardal, Anne M. C.
   Freund, K. Bailey
   Yannuzzi, Lawrence A.
   Allikmets, Rando
TI ATM gene variants in patients with idiopathic perifoveal telangiectasia
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID JUXTAFOVEOLAR RETINAL TELANGIECTASIS; FACTOR-H POLYMORPHISM; MUTATIONS;
   RISK; DNA; MISSENSE; SPECTRUM; LOCUS; MODEL; CREB
AB PURPOSE. To investigate the prevalence of sequence variants in the ATM gene and to determine the frequency of major age-related macular degeneration (AMD)-associated variants in CFH, CFB, and 10q26 loci in patients with idiopathic perifoveal telangiectasia (IPT).
   METHODS. Thirty patients with diagnoses of IPT underwent standard ophthalmologic evaluation that included visual acuity testing, fundus photography, and fluorescein angiography. DNA was screened for variations in the ATM gene by a combination of denaturing high-performance liquid chromatography and direct sequencing. Major AMD-associated alleles in CFH, CFB, and 10q loci were screened by PCR-restriction fragment-length polymorphism.
   RESULTS. Nineteen female and 11 male patients (average age, 59 years) with a median visual acuity of 20/50 were evaluated. Six patients were of Asian-Indian origin, one was Hispanic, and 23 were of European-American ancestry. Nine of 30 (30%) patients had diabetes mellitus, 18 of 30 (60%) patients had hypertension, and 12 of 30 (40%) patients had a history of smoking. Screening of the ATM gene revealed a null allele in 2 of 23 (8.7%) patients of European ancestry, previously disease-associated missense alleles in 4 of 23 (17.4%) patients, and common missense alleles in 7 of 23 (30.4%) patients. No variants were identified in the ATM gene in patients of Asian or Hispanic origin. Frequencies of major AMD-associated alleles in CFH, CFB, and 10q loci in the IPT cohort were similar to those in the ethnically matched general population.
   CONCLUSIONS. At least 26%, and maybe up to 57%, of IPT patients of European-American descent carried possibly disease-associated ATM alleles. Vascular risk factors such as hypertension, diabetes, and smoking may be associated with the pathogenesis of the disease.
C1 [Allikmets, Rando] Columbia Univ, Eye Res Inst, Dept Ophthalmol, New York, NY 10032 USA.
   [Allikmets, Rando] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Barbazetto, Irene A.; Bardal, Anne M. C.; Freund, K. Bailey; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, New York, NY USA.
C3 Columbia University; Columbia University; Vitreous Retina Macula
   Consultants of New York
RP Allikmets, R (通讯作者)，Columbia Univ, Eye Res Inst, Dept Ophthalmol, Room 715,630 W 168th St, New York, NY 10032 USA.
EM rla22@columbia.edu
RI Allikmets, Rando/ABD-4533-2021; Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU National Institutes of Health [EY13435]; The Macula Foundation, Inc.;
   Research to Prevent Blindness, Inc.; NATIONAL EYE INSTITUTE
   [R01EY013435] Funding Source: NIH RePORTER
FX Supported by National Institutes of Health Grant EY13435, The Macula
   Foundation, Inc., and an unrestricted grant from Research to Prevent
   Blindness, Inc. to the Department of Ophthalmology, Columbia University.
CR Bonnen PE, 2000, AM J HUM GENET, V67, P1437, DOI 10.1086/316908
   Broeks A, 2000, AM J HUM GENET, V66, P494, DOI 10.1086/302746
   Broeks A, 2008, BREAST CANCER RES TR, V107, P243, DOI 10.1007/s10549-007-9543-6
   Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205
   CHEW EY, 1986, ARCH OPHTHALMOL-CHIC, V104, P71
   Dodson GE, 2006, J BIOL CHEM, V281, P1692, DOI 10.1074/jbc.M509577200
   Dork T, 2001, CANCER RES, V61, P7608
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   GASS JDM, 1993, OPHTHALMOLOGY, V100, P1536
   Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942
   GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kuljis RO, 1999, BRAIN RES, V842, P351, DOI 10.1016/S0006-8993(99)01813-2
   Larson GP, 1997, GENET TEST, V1, P165, DOI 10.1089/gte.1997.1.165
   Lavin MF, 2005, MUTAT RES-FUND MOL M, V569, P123, DOI 10.1016/j.mrfmmm.2004.04.020
   Leys A, 2000, RETINA-J RET VIT DIS, V20, P184, DOI 10.1097/00006982-200003000-00011
   Maberley DAL, 1999, OPHTHALMOLOGY, V106, P2248, DOI 10.1016/S0161-6420(99)90523-7
   Maillet P, 2002, J MED GENET, V39, P751, DOI 10.1136/jmg.39.10.751
   Maillet P, 2000, INT J CANCER, V88, P928, DOI 10.1002/1097-0215(20001215)88:6<928::AID-IJC14>3.0.CO;2-P
   Mauget-Faysse M, 2003, INVEST OPHTH VIS SCI, V44, P3257, DOI 10.1167/iovs.02-1269
   Miles PD, 2007, AM J PHYSIOL-ENDOC M, V293, pE70, DOI 10.1152/ajpendo.00259.2006
   Platzer M, 1997, GENOME RES, V7, P592, DOI 10.1101/gr.7.6.592
   Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821
   Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101
   Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011
   Shiloh Y, 2003, CELL CYCLE, V2, P116, DOI 10.4161/cc.2.2.342
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P709, DOI 10.1016/S0002-9394(02)01331-4
   Takao N, 2000, FEBS LETT, V472, P133, DOI 10.1016/S0014-5793(00)01422-8
   Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
NR 34
TC 12
Z9 13
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2008
VL 49
IS 9
BP 3806
EP 3811
DI 10.1167/iovs.07-1357
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 344AB
UT WOS:000258896500008
PM 18502988
DA 2022-11-30
ER

PT J
AU Muller, A
   Vu, HT
   Ferraro, JG
   Keeffe, JE
   Taylor, HR
AF Muller, Andreas
   Vu, Hien T.
   Ferraro, John G.
   Keeffe, Jill E.
   Taylor, Hugh R.
TI Rapid and cost-effective method to assess vision disorders in a
   population
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE ageing; eye disease; eye health; visual impairment
ID FREQUENCY-DOUBLING TECHNOLOGY; BILATERAL VISUAL IMPAIRMENT; AGE-RELATED
   MACULOPATHY; FUNDUS CAMERA; FIELD LOSS; PERIMETRY; GLAUCOMA; PREVALENCE
AB The aim was to develop a means of rapidly assessing eye health in a cost- and time-effective way to monitor changes over time.
   Key features of the five main eye diseases that cause vision loss in Australia were assessed. Participation was volunteer-based from randomly selected Melbourne suburbs. Recruitment was by mail. Anterior segments and fundi were photographed with a digital non-mydriatic fundus camera. Visual fields were tested with Frequency Doubling Technology. A questionnaire collected information about demographics, general health and lifestyle. Findings from this rapid assessment were compared with those from a population-based study.
   A total of 1695 people, aged between 70 and 79 years (mean 74), were recruited. The rates and causes of visual impairment were similar between the rapid assessment method and the population-based study. Among the 134 people (8%) with visual impairment at presentation, 98 (73%) had undercorrected refractive error, 17 (13%) had age-related macular degeneration, 11 (8%) had cataract, 2 (2%) had diabetic retinopathy and 2 (2%) had glaucoma. Screening costs per participant were only about AU$145, compared with AU$433 in the Melbourne Visual Impairment Project (VIP). The application of Frequency Doubling Technology as well as the use of a non-mydriatic digital camera for fundus and lens photography resulted in an average examination time of less than half the time needed in the VIP. Data collection took 3 months rather than 4 years in the VIP.
   The rapid assessment method was efficient in time and cost and produced results comparable to a normal population-based survey. Repeating the study design for a similarly sampled group every 2 years would allow the assessment of changes in the prevalence of undiagnosed eye disease.
C1 Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Univ New S Wales, Vis Cooperat Res Ctr, Sydney, NSW, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of New South Wales Sydney; Visa Inc
RP Muller, A (通讯作者)，Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM mullera@unimelb.edu.au
OI Taylor, Hugh/0000-0002-9437-784X
CR Alward WLM, 2000, AM J OPHTHALMOL, V129, P376, DOI 10.1016/S0002-9394(00)00352-4
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Burnstein Y, 2000, AM J OPHTHALMOL, V129, P328, DOI 10.1016/S0002-9394(99)00364-5
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dimock J, 1999, AUST NZ J OPHTHALMOL, V27, P208, DOI 10.1046/j.1440-1606.1999.00207.x
   Ferraro JG, 2006, OPHTHAL EPIDEMIOL, V13, P127, DOI 10.1080/09286580500545717
   Ferraro JG, 2005, AM J OPHTHALMOL, V139, P725, DOI 10.1016/j.ajo.2004.09.083
   Ferris FL, 2004, ARCH OPHTHALMOL-CHIC, V122, P451, DOI 10.1001/archopht.122.4.451
   GOLDBERG MF, 1968, S TREATMENT DIABETIC
   Johnson CA, 1997, INVEST OPHTH VIS SCI, V38, P413
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   Palacios MJS, 2003, MED CLIN-BARCELONA, V121, P446, DOI 10.1157/13052791
   Quigley HA, 1998, AM J OPHTHALMOL, V125, P819, DOI 10.1016/S0002-9394(98)00046-4
   ROBIN TA, 2005, OPHTHAL EPIDEMIOL, V12, P205
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   Yogesan K, 1999, J GLAUCOMA, V8, P297
NR 18
TC 12
Z9 13
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2006
VL 34
IS 6
BP 521
EP 525
DI 10.1111/j.1442-9071.2006.1275.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 074FO
UT WOS:000239798300005
PM 16925698
DA 2022-11-30
ER

PT J
AU Fujii, GY
   de Juan, E
   Sunness, J
   Humayun, MS
   Pieramici, DJ
   Chang, TS
AF Fujii, GY
   de Juan, E
   Sunness, J
   Humayun, MS
   Pieramici, DJ
   Chang, TS
TI Patient selection for macular translocation surgery using the scanning
   laser ophthalmoscope
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; FUNDUS PERIMETRY; DEGENERATION;
   MICROPERIMETRY; MACULOPATHY; RETINOTOMY
AB Objectives. To evaluate the use of the scanning laser ophthalmoscope (SLO) as a predictor for potential visual improvement in eyes with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) undergoing limited macular translocation.
   Design: Retrospective noncomparative case series.
   Participants: Consecutive series of 71 eyes of 70 patients with subfoveal CNV secondary to AMD that underwent effective and uncomplicated limited macular translocation at the Wilmer Ophthalmological Institute.
   Methods: Evaluation of the fundus microperimetry and fixation pattern was conducted on all patients using the Rodenstock scanning laser ophthalmoscope (G. Rodenstock Instrument GmbH, Munich, Germany) within 72 hours before surgery.
   Main Outcome Measures: Sensitivity and specificity in addition to positive and negative predictive values of SLO findings for visual outcome after macular translocation.
   Results: Stable fixation presented the highest positive predictive value for visual acuity equal to or better than 201100 (30 of 33 = 0.91), and predominantly eccentric fixation had the highest negative predictive value for visual acuity worse than 20/100 (7 of 9 = 0.78). Sensitivity was higher for the presence of predominantly central fixation (42 of 48 = 0.87), and specificity was higher for relatively unstable/unstable fixation (20 of 23 = 0.87).
   Conclusions: Eyes with stable and central fixation (without dense central scotoma) good preoperative visual acuity, and short length of symptoms are those with the greatest chance to achieve good vision after macular translocation. The knowledge of the fixation and microperimetry pattern enables better understanding of the macular function in eyes with AMD and may be useful for evaluation of baseline retinal cell viability. Incorporation of these testing modalities may help to optimize patient selection for macular translocation or other future techniques aimed at rescuing photoreceptors.
C1 Univ So Calif, Doheny Retina Inst, Keck Sch Med, Doheny Eye Ctr, Los Angeles, CA 90033 USA.
   Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Baltimore, MD 21287 USA.
C3 Doheny Eye Institute; University of Southern California; Johns Hopkins
   University; Johns Hopkins Medicine
RP de Juan, E (通讯作者)，Univ So Calif, Doheny Eye Inst, Keck Sch Med, 1450 San Pablo St,Room 3620, Los Angeles, CA 90033 USA.
OI Sunness, Janet/0000-0001-8823-0780
CR *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   CULHAM LE, 1992, OPHTHAL PHYSL OPT, V12, P281, DOI 10.1111/j.1475-1313.1992.tb00398.x
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fujikado T, 1998, AM J OPHTHALMOL, V126, P839, DOI 10.1016/S0002-9394(98)00201-3
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lewis H, 1999, AM J OPHTHALMOL, V128, P135, DOI 10.1016/S0002-9394(99)00207-X
   Loewenstein A, 1998, AM J OPHTHALMOL, V125, P657, DOI 10.1016/S0002-9394(98)00014-2
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Rohrschneider K, 1998, AM J OPHTHALMOL, V126, P52, DOI 10.1016/S0002-9394(98)00065-8
   Rohrschneider K, 1997, BRIT J OPHTHALMOL, V81, P568, DOI 10.1136/bjo.81.7.568
   ROHRSCHNEIDER K, 1995, GRAEF ARCH CLIN EXP, V233, P743, DOI 10.1007/BF00184084
   ROHRSCHNEIDER K, 1995, KLIN MONATSBL AUGENH, V207, P102, DOI 10.1055/s-2008-1035356
   Rohrschneider K, 1995, Ger J Ophthalmol, V4, P197
   Schneider U, 1996, Klin Monbl Augenheilkd, V209, P8
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   SCHNEIDER U, 1993, KLIN MONATSBL AUGENH, V203, P212, DOI 10.1055/s-2008-1045670
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Tornow RP, 1998, ACTA ANAT, V162, P163
   Van de Velde F J, 1990, Ophtalmologie, V4, P291
   Varano M, 1998, Semin Ophthalmol, V13, P203, DOI 10.3109/08820539809056054
NR 26
TC 128
Z9 137
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2002
VL 109
IS 9
BP 1737
EP 1744
AR PII S0161-6420(02)01120-X
DI 10.1016/S0161-6420(02)01120-X
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 592CT
UT WOS:000177919700036
PM 12208725
DA 2022-11-30
ER

PT J
AU Andresen, J
   Kepp, T
   Ehrhardt, J
   von Der Burchard, C
   Roider, J
   Handels, H
AF Andresen, Julia
   Kepp, Timo
   Ehrhardt, Jan
   von Der Burchard, Claus
   Roider, Johann
   Handels, Heinz
TI Deep learning-based simultaneous registration and unsupervised
   non-correspondence segmentation of medical images with pathologies
SO INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY
LA English
DT Article
DE Image registration; Non-correspondence detection; Pathology
   segmentation; Convolutional neural network; Optical coherence tomography
ID BRAIN; NORMALIZATION; ALGORITHMS; ATLAS
AB Purpose The registration of medical images often suffers from missing correspondences due to inter-patient variations, pathologies and their progression leading to implausible deformations that cause misregistrations and might eliminate valuable information. Detecting non-corresponding regions simultaneously with the registration process helps generating better deformations and has been investigated thoroughly with classical iterative frameworks but rarely with deep learning-based methods. Methods We present the joint non-correspondence segmentation and image registration network (NCR-Net), a convolutional neural network (CNN) trained on a Mumford-Shah-like functional, transferring the classical approach to the field of deep learning. NCR-Net consists of one encoding and two decoding parts allowing the network to simultaneously generate diffeomorphic deformations and segment non-correspondences. The loss function is composed of a masked image distance measure and regularization of deformation field and segmentation output. Additionally, anatomical labels are used for weak supervision of the registration task. No manual segmentations of non-correspondences are required. Results The proposed network is evaluated on the publicly available LPBA40 dataset with artificially added stroke lesions and a longitudinal optical coherence tomography (OCT) dataset of patients with age-related macular degeneration. The LPBA40 data are used to quantitatively assess the segmentation performance of the network, and it is shown qualitatively that NCR-Net can be used for the unsupervised segmentation of pathologies in OCT images. Furthermore, NCR-Net is compared to a registration-only network and state-of-the-art registration algorithms showing that NCR-Net achieves competitive performance and superior robustness to non-correspondences. Conclusion NCR-Net, a CNN for simultaneous image registration and unsupervised non-correspondence segmentation, is presented. Experimental results show the network's ability to segment non-correspondence regions in an unsupervised manner and its robust registration performance even in the presence of large pathologies.
C1 [Andresen, Julia; Kepp, Timo; Ehrhardt, Jan; Handels, Heinz] Univ Lubeck, Inst Med Informat, Ratzeburger Allee 160, D-23562 Lubeck, Germany.
   [Ehrhardt, Jan; Handels, Heinz] German Res Ctr Artificial Intelligence, Lubeck, Germany.
   [von Der Burchard, Claus; Roider, Johann] Christian Albrechts Univ Kiel, Dept Ophthalmol, Kiel, Germany.
C3 University of Lubeck; University of Kiel
RP Andresen, J (通讯作者)，Univ Lubeck, Inst Med Informat, Ratzeburger Allee 160, D-23562 Lubeck, Germany.
EM j.andresen@uni-luebeck.de
RI von der Burchard, Claus/GZG-4104-2022
OI Andresen, Julia/0000-0002-9113-3954
FU Projekt DEAL; Federal Ministry of Education and Research (Project:
   KI-Lab Lubeck)
FX Open Access funding enabled and organized by Projekt DEAL. This work was
   in part funded by the Federal Ministry of Education and Research
   (Project: KI-Lab Lubeck).
CR Balakrishnan G, 2019, IEEE T MED IMAGING, V38, P1788, DOI 10.1109/TMI.2019.2897538
   Boveiri HR, 2020, COMPUT ELECTR ENG, V87, DOI 10.1016/j.compeleceng.2020.106767
   Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845
   Chen X, 2021, PROG BIOMED ENG, V3, DOI 10.1088/2516-1091/abd37c
   Chitphakdithai N, 2010, LECT NOTES COMPUT SC, V6361, P367
   Dalca AV, 2018, LECT NOTES COMPUT SC, V11070, P729, DOI 10.1007/978-3-030-00928-1_82
   de Vos BD, 2017, LECT NOTES COMPUT SC, V10553, P204, DOI 10.1007/978-3-319-67558-9_24
   Dosovitskiy A, 2015, IEEE I CONF COMP VIS, P2758, DOI 10.1109/ICCV.2015.316
   Ehrhardt J, 2015, BILDVERARBEITUNG FUR DIE MEDIZIN 2015: ALGORITHMEN - SYSTEME - ANWENDUNGEN, P209, DOI 10.1007/978-3-662-46224-9_37
   Gooya A, 2012, IEEE T MED IMAGING, V31, P1941, DOI 10.1109/TMI.2012.2210558
   Han X, 2017, I S BIOMED IMAGING, P10, DOI 10.1109/ISBI.2017.7950456
   Haskins G, 2020, MACH VISION APPL, V31, DOI 10.1007/s00138-020-01060-x
   Hering A., 2019, BILDVERARBEITUNG F R, P309, DOI DOI 10.1007/978-3-658-25326-4_69
   Hu YP, 2018, LECT NOTES COMPUT SC, V11070, P774, DOI 10.1007/978-3-030-00928-1_87
   Kanglin Chen, 2015, Scale Space and Variational Methods in Computer Vision. 5th International Conference, SSVM 2015. Proceedings: LNCS 9087, P360, DOI 10.1007/978-3-319-18461-6_29
   Klein A, 2009, NEUROIMAGE, V46, P786, DOI 10.1016/j.neuroimage.2008.12.037
   Krebs J, 2018, ARXIV180609907
   Kruger J, 2020, COMPUT VIS IMAGE UND, V190, DOI 10.1016/j.cviu.2019.102839
   Kruger J, 2019, PROC SPIE, V10949, DOI 10.1117/12.2511121
   Kurmann T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49740-7
   Li HY, 2019, IEEE T CYBERNETICS, V49, P4388, DOI 10.1109/TCYB.2018.2864776
   Liu XX, 2015, IEEE T MED IMAGING, V34, P2583, DOI 10.1109/TMI.2015.2448556
   Maier O, 2017, MED IMAGE ANAL, V35, P250, DOI 10.1016/j.media.2016.07.009
   Miao S, 2016, I S BIOMED IMAGING, P1430, DOI 10.1109/ISBI.2016.7493536
   Nachev P, 2008, NEUROIMAGE, V39, P1215, DOI 10.1016/j.neuroimage.2007.10.002
   Niethammer M, 2011, LECT NOTES COMPUT SC, V6892, P639, DOI 10.1007/978-3-642-23629-7_78
   Ou YM, 2014, IEEE T MED IMAGING, V33, P2039, DOI 10.1109/TMI.2014.2330355
   Ou YM, 2011, MED IMAGE ANAL, V15, P622, DOI 10.1016/j.media.2010.07.002
   Periaswamy S, 2006, MED IMAGE ANAL, V10, P452, DOI 10.1016/j.media.2005.03.006
   Rekik Islem, 2015, Patch Based Tech Med Imaging (2015), V9467, P197, DOI 10.1007/978-3-319-28194-0_24
   Rekik I, 2014, NEUROIMAGE-CLIN, V5, P332, DOI 10.1016/j.nicl.2014.07.009
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Sandkuhler R., 2018, ARXIV PREPRINT ARXIV
   Sedghi A, 2019, LECT NOTES COMPUT SC, V11840, P12, DOI 10.1007/978-3-030-32689-0_2
   Sentker T, 2018, LECT NOTES COMPUT SC, V11070, P765, DOI 10.1007/978-3-030-00928-1_86
   Shattuck DW, 2008, NEUROIMAGE, V39, P1064, DOI 10.1016/j.neuroimage.2007.09.031
   Sokooti Hessam, 2017, Medical Image Computing and Computer Assisted Intervention - MICCAI 2017. 20th International Conference. Proceedings: LNCS 10433, P232, DOI 10.1007/978-3-319-66182-7_27
   Trouve A, 2005, FOUND COMPUT MATH, V5, P173, DOI 10.1007/s10208-004-0128-z
   Yang X, 2017, NEUROIMAGE, V158, P378, DOI 10.1016/j.neuroimage.2017.07.008
   Zhou TH, 2016, PROC CVPR IEEE, P117, DOI 10.1109/CVPR.2016.20
NR 40
TC 2
Z9 2
U1 1
U2 10
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1861-6410
EI 1861-6429
J9 INT J COMPUT ASS RAD
JI Int. J. Comput. Assist. Radiol. Surg.
PD APR
PY 2022
VL 17
IS 4
BP 699
EP 710
DI 10.1007/s11548-022-02577-4
EA MAR 2022
PG 12
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging;
   Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging; Surgery
GA 0J7UZ
UT WOS:000763848600001
PM 35239133
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Busch, M
   Pfeil, JM
   Dahmcke, M
   Brauckmann, T
   Grossjohann, R
   Chisci, V
   Hunfeld, E
   Eilts, S
   Omran, W
   Morawiec-Kisiel, E
   Schulz, D
   Paul, S
   Tayar, A
   Brunder, MC
   Grundel, B
   Kustner, M
   Stahl, A
AF Busch, Martin
   Pfeil, Johanna M.
   Daehmcke, Merlin
   Brauckmann, Tara
   Grossjohann, Rico
   Chisci, Viola
   Hunfeld, Elisabeth
   Eilts, Sonja
   Omran, Wael
   Morawiec-Kisiel, Ewa
   Schulz, Daniel
   Paul, Sebastian
   Tayar, Allam
   Bruender, Marie-Christine
   Grundel, Bastian
   Kuestner, Martin
   Stahl, Andreas
TI Anti-drug antibodies to brolucizumab and ranibizumab in serum and
   vitreous of patients with ocular disease
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE ADA; anti-drug antibodies; brolucizumab; intraocular inflammation;
   intravitreal; occlusive vasculitis; ranibizumab; retinal vasculitis;
   VEGF inhibitors
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL INJECTION;
   VEGF; EYE; BEVACIZUMAB; PREVALENCE
AB PurposePostapproval reports of intraocular inflammation (IOI) and occlusive retinal vasculitis following intravitreal brolucizumab are accumulating. A role of anti-drug antibodies (ADAs) to brolucizumab is under current scientific discussion. The purpose of the present study was to measure brolucizumab ADAs in a cross-sectional ophthalmic patient population and to compare the occurrence of brolucizumab ADAs with that of ranibizumab ADAs.
   MethodsOne hundred and ninety-two serum samples and 54 vitreous samples were collected from patients with a range of eye diseases including neovascular age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, cataract, glaucoma, dry eye disease, macular hole, epiretinal membranes and intraocular lens (IOL) dislocation. Serum and vitreous samples were analysed for immune globuline (Ig) G ADAs to brolucizumab and ranibizumab using indirect enzyme-linked immunosorbent assay (ELISA). Optical Density (OD) was read at 450nm (wavelength correction at 550nm) for ADA level measurements.
   ResultsPresence of brolucizumab ADAs was observed in patients with and without prior brolucizumab exposure. Both the frequency of notable ADA signals (OD>0.1) and the mean ADA signal in serum samples were higher for brolucizumab than for ranibizumab. Two patients who experienced severe IOI and occlusive retinal vasculitis following intravitreal brolucizumab had high brolucizumab ADA serum levels. In one of these two patients, high brolucizumab ADA levels were also found in vitreous. Another patient developed moderate IOI without retinal vasculitis in the presence of low brolucizumab ADA serum levels. Overall, notable brolucizumab ADA levels were less frequent in vitreous than in the corresponding serum samples but with a tendency for higher prevalence in vitreous from patients with diabetic retinopathy.
   ConclusionBrolucizumab ADAs occur with significant prevalence in a typical ophthalmic patient population and may represent a risk factor for IOI and occlusive retinal vasculitis following brolucizumab.
C1 [Busch, Martin; Pfeil, Johanna M.; Daehmcke, Merlin; Brauckmann, Tara; Grossjohann, Rico; Chisci, Viola; Hunfeld, Elisabeth; Eilts, Sonja; Omran, Wael; Morawiec-Kisiel, Ewa; Schulz, Daniel; Paul, Sebastian; Tayar, Allam; Bruender, Marie-Christine; Grundel, Bastian; Stahl, Andreas] Univ Med Ctr Greifswald, Dept Ophthalmol, Ferdinand Sauerbruch Str, D-17475 Greifswald, Germany.
   [Kuestner, Martin] Augenarzte Pappelallee, Greifswald, Germany.
C3 Greifswald Medical School
RP Busch, M (通讯作者)，Univ Med Ctr Greifswald, Dept Ophthalmol, Ferdinand Sauerbruch Str, D-17475 Greifswald, Germany.
EM martin.busch@med.uni-greifswald.de
OI Pfeil, Johanna Madeleine/0000-0002-2731-6094; Hunfeld,
   Elisabeth/0000-0001-6273-2993
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson WJ, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00307-7
   Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54
   Baldo BA, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26333
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cox JT, 2021, J CLIN MED, V10, DOI 10.3390/jcm10050981
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   Jawa V, 2013, CLIN IMMUNOL, V149, P534, DOI 10.1016/j.clim.2013.09.006
   Klein R, 2020, OPHTHALMOLOGY, V127, pS122, DOI 10.1016/j.ophtha.2020.01.033
   Knickelbein JE, 2016, OPHTHAL EPIDEMIOL, V23, P69, DOI 10.3109/09286586.2015.1122067
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pham B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022031
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Sharma A, 2022, OCUL IMMUNOL INFLAMM, V30, P1508, DOI 10.1080/09273948.2021.1897628
   Sharma A, 2020, EYE, V34, P1726, DOI 10.1038/s41433-020-0853-9
   Sharma A, 2020, EYE, V34, P614, DOI 10.1038/s41433-019-0636-3
   Sharma A, 2019, EYE, V33, P1359, DOI 10.1038/s41433-019-0434-y
   Sigford DK, 2015, CLIN OPHTHALMOL, V9, P773, DOI 10.2147/OPTH.S77067
   Souied EH, 2016, OPHTHAL EPIDEMIOL, V23, P71, DOI 10.3109/09286586.2015.1090004
   Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574
   Wessels U, 2018, BIOANALYSIS, V10, P803, DOI 10.4155/bio-2018-0047
   Williams PD, 2016, RETINA-J RET VIT DIS, V36, P909, DOI 10.1097/IAE.0000000000000801
   Witkin Andre J, 2020, J Vitreoretin Dis, V4, P269, DOI 10.1177/2474126420930863
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 39
TC 1
Z9 1
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2022
VL 100
IS 8
BP 903
EP 910
DI 10.1111/aos.15124
EA FEB 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6D4SX
UT WOS:000761675300001
PM 35225432
DA 2022-11-30
ER

PT J
AU Montesel, A
   Bucolo, C
   Sallo, FB
   Eandi, CM
AF Montesel, Andrea
   Bucolo, Claudio
   Sallo, Ferenc B.
   Eandi, Chiara M.
TI Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life
   Clinical Practice
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE brolucizumab; anti-vascular endothelial growth factor; intravitreal
   route; neovascular age-related macular degeneration; retina; choroid
ID TREAT-AND-EXTEND; MACULAR DEGENERATION; GEOGRAPHIC ATROPHY;
   STANDARDIZATION; REGIMEN; GROWTH
AB To report the early efficacy and safety outcomes of treatment with intravitreal injections of brolucizumab (IVT-B) in patients presenting neovascular age-related macular degeneration (nAMD) in a tertiary clinical setting. A retrospective case series of patients that received IVT-B with a minimum of two injections performed and at least 4 weeks of follow-up after last injection. Nineteen eyes of 19 patients were included. The number of IVT-B performed for the whole cohort was 58 injections; the mean number of IVT-B per patient was 3.0 +/- 1.0 (range 2-6); the mean follow-up time was 14.4 +/- 9.0 weeks. Mean baseline best-corrected visual acuity was 0.4 +/- 0.4 logMAR and at the last follow-up was 0.4 +/- 0.6 logMAR (p = 0.778). All eyes showed a reduction in retinal thickness, with the central macular thickness being 470 +/- 151 mu m at baseline and 360 +/- 144 mu m at the last follow-up (p = 0.001). Intra-retinal fluid was present at baseline in 12 eyes (63%) and in three eyes (16%) at the last follow-up (p = 0.065). Sub-retinal fluid was present at baseline in 17 eyes (89%) and at the last follow-up in three eyes (16%, p = 0.011). Pigment epithelium detachment was apparent in the 16 eyes (84%) at baseline and was still present in 14 eyes (73%, p = 0.811). One adverse event of intraocular inflammation was reported. In conclusion, our short-term experience showed that brolucizumab was highly effective in restoring the anatomy and in stabilizing the visual acuity of eyes with nAMD. Its safety profile should be evaluated carefully and needs further investigations.
C1 [Montesel, Andrea; Sallo, Ferenc B.; Eandi, Chiara M.] Univ Lausanne, Dept Ophthalmol, Fdn Asile Aveugles, Jules Gonin Eye Hosp, Lausanne, Switzerland.
   [Bucolo, Claudio] Univ Catania, Sch Med, Dept Biomed & Biotechnol Sci, Catania, Italy.
C3 University of Lausanne; University of Catania
RP Eandi, CM (通讯作者)，Univ Lausanne, Dept Ophthalmol, Fdn Asile Aveugles, Jules Gonin Eye Hosp, Lausanne, Switzerland.
EM chiara.eandi@unito.it
CR Avaylon J, 2020, INT MED CASE REP J, V13, P145, DOI 10.2147/IMCRJ.S252260
   Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Conti B, 1997, EUR J PHARM SCI, V5, P287, DOI 10.1016/S0928-0987(97)00023-7
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Enriquez AB, 2021, JAMA OPHTHALMOL, V139, P441, DOI 10.1001/jamaophthalmol.2020.7085
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Haensli C, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122666
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kondapalli SSA, 2020, JAMA OPHTHALMOL, V138, P1103, DOI 10.1001/jamaophthalmol.2020.2810
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Maruko I, 2021, GRAEF ARCH CLIN EXP, V259, P2857, DOI 10.1007/s00417-021-05136-w
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   NUSSENBLATT RB, 1985, OPHTHALMOLOGY, V92, P467
   Reibaldi M, 2016, AM J OPHTHALMOL, V161, P78, DOI 10.1016/j.ajo.2015.09.031
   Ricci F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218242
   Rosenfeld PJ, 2021, AM J OPHTHALMOL, V223, P446, DOI 10.1016/j.ajo.2020.06.034
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma A, 2020, BRIT J OPHTHALMOL, V104, P1631, DOI 10.1136/bjophthalmol-2020-317528
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Sharma A, 2020, EYE, V34, P1726, DOI 10.1038/s41433-020-0853-9
   Sharma A, 2020, EYE, V34, P1318, DOI 10.1038/s41433-020-0842-z
   Sharma A, 2020, EYE, V34, P1310, DOI 10.1038/s41433-020-0831-2
   Siedlecki J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64901-9
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
NR 35
TC 4
Z9 4
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 4
PY 2021
VL 12
AR 720345
DI 10.3389/fphar.2021.720345
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA WZ9WS
UT WOS:000720310500001
PM 34803674
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Celebi, ARC
   Celebi, OO
AF Celebi, Ali Riza Cenk
   Celebi, Ozlem Onerci
TI The effect of topical ocular moxifloxacin on conjunctival and nasal
   mucosal flora
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STAPHYLOCOCCUS-AUREUS; BACTERIAL-FLORA; ENDOPHTHALMITIS; LEVOFLOXACIN;
   COLONIZATION; PROPHYLAXIS; INJECTION; CARRIAGE
AB To determine the short-term effect of topically administered ocular moxifloxacin on conjunctival and nasal bacterial mucosal flora. The study included 20 patients with newly diagnosed age-related macular degeneration. Each patient's diseased eye was selected as the treatment eye and the fellow eye was selected as the control eye. All treatment eyes constituted the treatment group and all controls eyes constituted the control group. All patients received intravitreal injection of ranibizumab. Cultures were obtained from the inferior conjunctival fornix and the nostrils in all patients. Patients were instructed to administer moxifloxacin eye drops to the treatment eye 4 times daily for 1 week. The patients were instructed to come for a follow-up exam 1 week post intravitreal injection. The bacterial culture positivity rate and the bacteria isolated from the conjunctiva and nostrils were recorded in the 2 groups before and after use of topical ocular moxifloxacin. Mean age of the patients (12 female and 8 male) was 64.9 years. Before use of topical ocular moxifloxacin the conjunctival and nasal culture positivity rates in the treatment group were both 100%, versus 90% and 95%, respectively, in the control group. At the follow-up exam the conjunctival and nasal mucosa culture positivity rates in the treatment group decreased to 20% (4/20) and 30% (6/20), respectively (P<0.001), versus 85% (17/20) and 80% (16/20), respectively, in the control group (P=0.68 and P=0.72 for conjunctival and nasal). This is the first study to show that moxifloxacin applied to the ocular surface topically has a significant effect on nasal flora. Daily administration of topical ocular moxifloxacin for 1 week significantly reduces the nasal bacterial flora in addition to conjunctival flora.
C1 [Celebi, Ali Riza Cenk] Acibadem Univ, Sch Med, Atakent Educ & Res Hosp, Dept Ophthalmol, Turgut Ozal Blvd 16, TR-34303 Istanbul, Turkey.
   [Celebi, Ozlem Onerci] Eregli State Hosp, Dept Otorhinolaryngol, Toros Mah Yurt Cad 13, TR-42000 Eregli, Konya, Turkey.
C3 Acibadem University; Karadeniz Eregli State Hospital
RP Celebi, ARC (通讯作者)，Acibadem Univ, Sch Med, Atakent Educ & Res Hosp, Dept Ophthalmol, Turgut Ozal Blvd 16, TR-34303 Istanbul, Turkey.
EM arcenkcelebi@gmail.com
RI Celebi, Ali Riza Cenk/I-3906-2013
CR Alabiad CR, 2011, AM J OPHTHALMOL, V152, P999, DOI 10.1016/j.ajo.2011.05.026
   Alexandrou Terry J, 2006, Trans Am Ophthalmol Soc, V104, P196
   Aoki T, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9020254
   Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304
   Callaway T. R., 2008, Animal Health Research Reviews, V9, P217, DOI 10.1017/S1466252308001540
   Chen HW, 2016, SCI REP-UK, V6, DOI 10.1038/srep27870
   Dave SB, 2013, OPHTHALMOLOGY, V120, P937, DOI 10.1016/j.ophtha.2012.11.005
   De Kaspar HM, 2008, AM J OPHTHALMOL, V145, P136, DOI 10.1016/j.ajo.2007.08.031
   Deguchi H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203705
   Durmaz E, 2011, J OTOLARYNGOL-HEAD N, V40, P493, DOI 10.2310/7070.2011.110155
   Han DP, 1996, AM J OPHTHALMOL, V122, P1
   Hoshi S, 2020, CORNEA, V39, P1401, DOI 10.1097/ICO.0000000000002445
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   JOUSIMIESSOMER HR, 1989, J CLIN MICROBIOL, V27, P2736, DOI 10.1128/JCM.27.12.2736-2743.1989
   Kawata T, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0413-7
   Kim SJ, 2010, OPHTHALMOLOGY, V117, P2372, DOI 10.1016/j.ophtha.2010.03.034
   Kimura Naoko, 2007, Nippon Ganka Gakkai Zasshi, V111, P504
   Kluytmans JAJW, 1996, INFECT CONT HOSP EP, V17, P780
   Lina G, 2003, APPL ENVIRON MICROB, V69, P18, DOI 10.1128/AEM.69.1.18-23.2003
   Mah Francis S, 2004, Curr Opin Ophthalmol, V15, P316, DOI 10.1097/00055735-200408000-00007
   McClellan KA, 1997, SURV OPHTHALMOL, V42, P233, DOI 10.1016/S0039-6257(97)00090-8
   Moss JM, 2008, OPHTHALMOLOGY, V115, P2013, DOI 10.1016/j.ophtha.2008.06.024
   Moss JM, 2009, OPHTHALMOLOGY, V116, P1498, DOI 10.1016/j.ophtha.2009.02.024
   Nejima R, 2017, J CATARACT REFR SURG, V43, P42, DOI 10.1016/j.jcrs.2016.10.024
   Park B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025880
   Pleyer U, 1997, OPHTHALMOLOGICA, V211, P2, DOI 10.1159/000310878
   SAVOLAINEN S, 1986, Rhinology (Utrecht), V24, P249
   SHELL JW, 1982, SURV OPHTHALMOL, V26, P207, DOI 10.1016/0039-6257(82)90081-9
   SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P639
   Storey P, 2014, OPHTHALMOLOGY, V121, P283, DOI 10.1016/j.ophtha.2013.08.037
   Ta CN, 2003, OPHTHALMOLOGY, V110, P1946, DOI 10.1016/S0161-6420(03)00735-8
   Wang JJ, 2020, EUR J CLIN MICROBIOL, V39, P711, DOI 10.1007/s10096-019-03775-w
   Wertheim HFL, 2005, LANCET INFECT DIS, V5, P751, DOI 10.1016/S1473-3099(05)70295-4
NR 33
TC 2
Z9 2
U1 1
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 2
PY 2021
VL 11
IS 1
AR 13782
DI 10.1038/s41598-021-93233-5
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TH5XU
UT WOS:000672163500015
PM 34215812
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Spooner, KL
   Fraser-Bell, S
   Hong, T
   Wong, JG
   Chang, AA
AF Spooner, Kimberly L.
   Fraser-Bell, Samantha
   Hong, Thomas
   Wong, James G.
   Chang, Andrew A.
TI Long-term outcomes of anti-VEGF treatment of retinal vein occlusion
SO EYE
LA English
DT Article
ID MACULAR EDEMA; NATURAL-HISTORY; FOLLOW-UP; RANIBIZUMAB; AFLIBERCEPT
AB Background/objectives To analyze the long-term outcomes of eyes with retinal vein occlusion (RVO) 8 years after commencing treatment with anti-vascular endothelial growth factor (VEGF) agents. Subjects/methods Retrospective, multicentre study of 221 eyes diagnosed with RVO, which were commenced on anti-VEGF therapy between 2009 and 2011. VA and CRT were recorded at baseline and at subsequent annual time points. The mean number of injections administered each year and the incidence of adverse events were recorded. Results Of a total of 221 eyes which commenced treatment with anti-VEGF agents for RVO, 95 were diagnosed with BRVO and 126 with CRVO. 8-year data were available for 94 eyes (43%). The mean age of patients was 65.1 +/- 12.0 years. Mean VA improved from baseline by 16.9 letters, (57.8-74.7 letters), (P < 0.001). For BRVO eyes, mean VA improved from 60.5 to 74.8 letters (p < 0.001) and for CRVO eyes from 52.0 to 66.4 letters (p < 0.001). In all RVO eyes, there was a reduction in mean CRT from 501.0 to 249.1 mu m; in BRVO eyes from 472.4 to 284.7 mu m and in CRVO eyes from 533.9 to 267.5 mu m. In the 8th year after starting treatment, eyes with RVO were receiving a mean of four injections. Conclusion Good long-term outcomes of VEGF inhibition for eyes with RVO were found in this study. Patients maintained a gain of 3-lines of vision 8-years after the commencing therapy. This encouraging result contrasts with long-term studies of patients with neovascular age-related macular degeneration, where initial gains are lost over time.
C1 [Spooner, Kimberly L.; Fraser-Bell, Samantha; Hong, Thomas; Wong, James G.; Chang, Andrew A.] Sydney Retina Clin, Sydney, NSW, Australia.
   [Fraser-Bell, Samantha; Wong, James G.; Chang, Andrew A.] Univ Sydney, Sydney Med Sch, Save Sight Inst, Discipline Ophthalmol, Sydney, NSW, Australia.
   [Fraser-Bell, Samantha] Retina Associates, Sydney, NSW, Australia.
   [Wong, James G.] Strathfield Retina Clin, Strathfield, NSW, Australia.
C3 University of Sydney
RP Chang, AA (通讯作者)，Sydney Retina Clin, Sydney, NSW, Australia.; Chang, AA (通讯作者)，Univ Sydney, Sydney Med Sch, Save Sight Inst, Discipline Ophthalmol, Sydney, NSW, Australia.
EM achang@sydneyretina.com.au
OI Fraser-Bell, Samantha/0000-0001-5646-9359
CR Bilgic A, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/7462098
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P209, DOI 10.1016/j.ophtha.2013.08.038
   Chatziralli I, 2018, RETINA-J RET VIT DIS, V38, P559, DOI 10.1097/IAE.0000000000001579
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hayreh SS, 2011, OPHTHALMOLOGY, V118, P119, DOI 10.1016/j.ophtha.2010.04.019
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Heier JS, 2012, OPHTHALMOLOGY, V119, P802, DOI 10.1016/j.ophtha.2011.12.005
   Khurana RN, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0159-x
   Kung FF, 2020, OPHTHALMOL RETINA, V4, P1047, DOI 10.1016/j.oret.2020.05.005
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Ogura Y, 2014, AM J OPHTHALMOL, V158, P1032, DOI 10.1016/j.ajo.2014.07.027
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Rogers SL, 2010, OPHTHALMOLOGY, V117, P1094, DOI 10.1016/j.ophtha.2010.01.058
   Singh SR, 2020, SEMIN OPHTHALMOL, V35, P2, DOI 10.1080/08820538.2019.1686528
   Song PG, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010427
   Spooner K, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2018-000249
   Varma R, 2012, OPHTHALMOLOGY, V119, P2108, DOI 10.1016/j.ophtha.2012.05.017
NR 19
TC 4
Z9 4
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2022
VL 36
IS 6
BP 1194
EP 1201
DI 10.1038/s41433-021-01620-z
EA JUN 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1U7PW
UT WOS:000660493900007
PM 34117379
DA 2022-11-30
ER

PT J
AU Aziz, K
   Swenor, BK
   Canner, JK
   Singh, MS
AF Aziz, Kanza
   Swenor, Bonnielin K.
   Canner, Joseph K.
   Singh, Mandeep S.
TI The Direct Healthcare Cost of Stargardt Disease: A Claims-Based Analysis
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Inherited retinal diseases; Visual rehabilitation; Macular degeneration;
   Orphan disease; Low vision
AB Purpose: Stargardt disease (SD) is the most common juvenile macular degeneration and a leading cause of uncorrectable childhood blindness. The progressive and incurable nature of this chronic condition entails a long-term financial burden on affected individuals. The economic costs of SD have not been characterized in detail, so we aimed to estimate the direct healthcare cost of SD.
   Methods: Outpatient administrative claims data (2010-2014) for patients with SD were analyzed from the IBM (R) MarketScan (R) Commercial Claims and Encounters Database. Two comparison groups were selected: nonexudative age-related macular degeneration (AMD) and bilateral sensorineural hearing loss (SHL). Gross median payments per year of insurance coverage were calculated.
   Results: A total of 472,428 patients were analyzed (5,015 SD, 369,750 SHL and 97,663 AMD patients respectively). The payment per year of insurance coverage for SD (median: 105.58 USD, IQR: 50.53 USD-218.71 USD) was higher than that of SHL (median: 51.01 USD, IQR: 25.66 USD-121.66 USD, p < .001) and AMD (median: 76.20 USD, IQR: 38.00 USD-164.86 USD, p < .001). When adjusted for age, sex, year of first service, and type of benefit plan, the annual payment for SD was 47.83 USD higher than SHL (p < .001) and 17.34 USD higher than AMD (p < .001).
   Conclusions: There is a significant direct healthcare cost associated with SD. The annual per-patient cost of SD was higher than SHL, another condition that causes sensory impairment in people of all ages, and nonexudative AMD which causes a similar pattern of visual loss that typically begins later in life. The total lifetime per-patient cost of SD may exceed that of nonexudative AMD.
C1 [Aziz, Kanza; Swenor, Bonnielin K.; Singh, Mandeep S.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
   [Swenor, Bonnielin K.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Canner, Joseph K.] Johns Hopkins Univ, Sch Med, Johns Hopkins Surg Ctr Outcomes Res, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Bloomberg School of Public Health; Johns
   Hopkins University
RP Singh, MS (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.
EM mandeep@jhmi.edu
RI Singh, Mandeep/AAS-8842-2021; Swenor, Bonnie/ABH-1542-2021
OI Singh, Mandeep/0000-0003-1749-0088; Swenor, Bonnie/0000-0002-6044-0951
FU Foundation Fighting Blindness [CD-RM-0918-0749-JHU]; Joseph Albert
   Hekimian Fund; National Institute on Aging [K01AG052640]; Research to
   Prevent Blindness
FX Foundation Fighting Blindness CD-RM-0918-0749-JHU (MSS), Joseph Albert
   Hekimian Fund (MSS), National Institute on Aging K01AG052640 (BKS),
   Research to Prevent Blindness (unrestricted grant to the Wilmer Eye
   Institute)
CR Abdollahi SH, 2013, SEMIN OPHTHALMOL, V28, P372, DOI 10.3109/08820538.2013.825286
   Armstrong JD, 1998, OPHTHALMOLOGY, V105, P448, DOI 10.1016/S0161-6420(98)93026-3
   Auricchio A, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017301
   Bertakis KD, 2000, J FAM PRACTICE, V49, P147
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   De Silva S, 2016, GENE THER, V23, P767, DOI 10.1038/gt.2016.54
   Frick KD, 2012, ARCH OPHTHALMOL-CHIC, V130, P629, DOI 10.1001/archophthalmol.2011.2820
   Halpern MT, 2006, HEALTH CARE FINANC R, V27, P37
   Hansen L, 2018, IBM MARKETSCAN RES D
   Hussain RM, 2018, EXPERT OPIN BIOL TH, V18, P1049, DOI 10.1080/14712598.2018.1513486
   Lu LJ, 2017, GRAEF ARCH CLIN EXP, V255, P1057, DOI 10.1007/s00417-017-3619-8
   McClements ME, 2019, HUM GENE THER, V30, P590, DOI 10.1089/hum.2018.156
   SCHMIER J, 2006, PHARMACOECONOMICS, V24
   Schroeder L, 2006, PEDIATRICS, V117, P1101, DOI 10.1542/peds.2005-1335
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Tanna P, 2017, BRIT J OPHTHALMOL, V101, P25, DOI 10.1136/bjophthalmol-2016-308823
   Walia S, 2009, OPHTHALMIC GENET, V30, P63, DOI 10.1080/13816810802695550
   Weiter, 1985, OPHTHALMOLOGY, V92, DOI [10.1016/S0161-6420(85)34086-1, DOI 10.1016/S0161-6420(85)34086-1]
   Welp A, 2016, MAKING EYE HLTH POPU, DOI [10.17226/23471, DOI 10.17226/23471]
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Wittenborn JS, 2013, OPHTHALMOLOGY, V120, P1728, DOI 10.1016/j.ophtha.2013.01.068
   World Health Organization, 2017, GLOB COSTS UN HEAR L
   Zahid S, 2013, AM J OPHTHALMOL, V155, P465, DOI 10.1016/j.ajo.2012.09.011
NR 26
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD NOV 2
PY 2021
VL 28
IS 6
BP 533
EP 539
DI 10.1080/09286586.2021.1883675
EA FEB 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XW1CM
UT WOS:000620465300001
PM 33615979
OA hybrid
DA 2022-11-30
ER

PT J
AU Du, YY
   You, LT
   Ni, BR
   Sai, N
   Wang, WP
   Sun, MY
   Xu, R
   Yao, Y
   Zhang, ZQ
   Qu, CH
   Yin, XB
   Ni, J
AF Du, Yuanyuan
   You, Longtai
   Ni, Boran
   Sai, Na
   Wang, Wenping
   Sun, Mingyi
   Xu, Rui
   Yao, Yu
   Zhang, Zhiqin
   Qu, Changhai
   Yin, Xingbin
   Ni, Jian
TI Phillyrin Mitigates Apoptosis and Oxidative Stress in Hydrogen
   Peroxide-Treated RPE Cells through Activation of the Nrf2 Signaling
   Pathway
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID CYTOCHROME-C; MACULAR DEGENERATION; CYCLE ARREST; MITOCHONDRIAL; ROS;
   BINDING; ANTIOXIDANTS; RELEASE; CANCER; INJURY
AB Oxidative stress-induced dysfunction or apoptosis in retinal pigment epithelial (RPE) cells is an important cause of dry age-related macular degeneration (AMD). Although phillyrin has been shown to exert significant antioxidant effects, the underlying mechanism of action remains unclear. The purpose of this study was to investigate the protective effect of phillyrin on hydrogen peroxide- (H2O2-) induced oxidative stress damage in RPE cells and the potential mechanism involved. It was found that phillyrin significantly protected RPE cells from H2O2 cytotoxicity. Furthermore, phillyrin alleviated oxidative stress-induced apoptosis via inhibition of endogenous and exogenous apoptotic pathways. Compared with the H2O2-treated group, the expressions of cleaved caspase-3, cleaved caspase-9, cleaved polymerase (PARP), death receptor Fas, and cleaved caspase-8, as well as Bax/Bcl-2 ratio were decreased in RPE cells after the phillyrin intervention. In addition, phillyrin reversed the oxidative stress-induced reductions in superoxide dismutase (SOD) and glutathione (GSH) levels and annulled the elevations in reactive oxygen species (ROS) and malondialdehyde (MDA), thereby restoring oxidant-antioxidant homeostasis. Phillyrin treatment upregulated the expressions of cyclin E, cyclin-dependent kinase 2 (CDK2), and cyclin A and downregulated the expressions of p21 and p-p53, thereby reversing the G0/G1 cell cycle arrest in H2O2-treated RPE cells. Pretreatment with phillyrin also increased the expressions of nuclear factor-erythroid 2-related factor 2 (Nrf2), total Nrf2, heme oxygenase-1 (HO-1), and NAD(P)H: quinone oxidoreductases-1 (NQO-1) in RPE cells and inhibited the formation of Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 protein complex. Thus, phillyrin effectively protected RPE cells from oxidative stress through activation of the Nrf2 signaling pathway and inhibition of the mitochondria-dependent apoptosis pathway.
C1 [Du, Yuanyuan; You, Longtai; Sai, Na; Wang, Wenping; Sun, Mingyi; Xu, Rui; Yao, Yu; Zhang, Zhiqin; Qu, Changhai; Yin, Xingbin] Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing 100029, Peoples R China.
   [Ni, Boran] Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing 100029, Peoples R China.
   [Sai, Na] Inner Mongolia Med Univ, Sch Pharm, Hohhot 010110, Peoples R China.
   [Ni, Jian] Beijing Univ Chinese Med, Beijing Res Inst Chinese Med, Beijing 100029, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese
   Medicine; Inner Mongolia Medical University; Beijing University of
   Chinese Medicine
RP Qu, CH; Yin, XB (通讯作者)，Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing 100029, Peoples R China.; Ni, J (通讯作者)，Beijing Univ Chinese Med, Beijing Res Inst Chinese Med, Beijing 100029, Peoples R China.
EM dyy94012@163.com; ylt_svip@163.com; niboran@foxmail.com;
   yxsaina@126.com; wangwenp6@163.com; smyyy008@163.com;
   poppyrui0805@163.com; 20190935142@bucm.edu.cn; zzq1417355@163.com;
   quchanghai@bucm.edu.cn; yxbtcm@163.com; njtcm@263.net
OI Wang, Wenping/0000-0002-9488-9474; Xu, Rui/0000-0002-6631-9386;
   Changhai, QU/0000-0001-6617-1476
FU Training Programme of the Beijing Municipal Excellent Talents Foundation
   [2017000020124G295]
FX This study was generously supported by the Training Programme of the
   Beijing Municipal Excellent Talents Foundation (No. 2017000020124G295).
CR Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2
   Amar SAA, 2019, AGING MALE, V22, P198, DOI 10.1080/13685538.2018.1488955
   Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Barker FM, 2011, INVEST OPHTH VIS SCI, V52, P3934, DOI 10.1167/iovs.10-5898
   Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040
   Bhardwaj M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154525
   Binet MT, 2014, J EXP MAR BIOL ECOL, V452, P91, DOI 10.1016/j.jembe.2013.12.008
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chen H, 2017, PHYTOMEDICINE, V27, P52, DOI 10.1016/j.phymed.2017.02.004
   Chen JQ, 2009, BBA-MOL CELL RES, V1793, P1540, DOI 10.1016/j.bbamcr.2009.06.001
   Chen LQ, 2019, NEUROCHEM INT, V125, P57, DOI 10.1016/j.neuint.2019.02.008
   Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022
   Claro S, 2014, INT J RADIAT BIOL, V90, P914, DOI 10.3109/09553002.2014.911988
   De Jong PTVM, 2018, EYE, V32, P904, DOI 10.1038/eye.2017.298
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hu Q., 2017, J FUNCTIONAL FOODS, V37, P569
   Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X
   Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1
   Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011
   Liu SM, 2017, J ZHEJIANG UNIV-SC B, V18, P89, DOI [10.1631/jzus.B1600022, 10.1631/jzus.b1600022]
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   Menshikova EB, 2010, MOL BIOL+, V44, P343, DOI 10.1134/S0026893310030015
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pan XL, 2014, INFLAMM RES, V63, P597, DOI 10.1007/s00011-014-0731-7
   Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   Schonhoff CM, 2003, J BIOL CHEM, V278, P18265, DOI 10.1074/jbc.M212459200
   Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2
   Shih CM, 2004, J CELL BIOCHEM, V91, P384, DOI 10.1002/jcb.10761
   Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959
   Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337
   Sripathi SR, 2016, PROTEIN J, V35, P1, DOI 10.1007/s10930-015-9641-y
   Sriram N, 2009, PULM PHARMACOL THER, V22, P221, DOI 10.1016/j.pupt.2008.12.010
   Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun YL, 2019, BMC CANCER, V20, DOI 10.1186/s12885-019-6169-0
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Wei T, 2014, CELL MOL NEUROBIOL, V34, P1165, DOI 10.1007/s10571-014-0091-4
   Wysokinski D, 2011, TOHOKU J EXP MED, V223, P253, DOI 10.1620/tjem.223.253
   Zhang D, 2020, INFLAMMATION, V43, P540, DOI 10.1007/s10753-019-01136-5
   Zhang F, 2019, J CELL BIOCHEM, V120, P19902, DOI 10.1002/jcb.29298
   Zhang Y, 2018, J ETHNOPHARMACOL, V218, P27, DOI 10.1016/j.jep.2018.02.033
   Zhao F, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1898213
   Zheng B, 2020, ACTA PHARMACEUT, V70, P191, DOI 10.2478/acph-2020-0017
NR 59
TC 17
Z9 18
U1 8
U2 23
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD OCT 12
PY 2020
VL 2020
AR 2684672
DI 10.1155/2020/2684672
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OP9YR
UT WOS:000588450000004
PM 33101585
OA Green Published, gold
DA 2022-11-30
ER

EF